<SEC-DOCUMENT>0001411690-22-000007.txt : 20220301
<SEC-HEADER>0001411690-22-000007.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220301161839
ACCESSION NUMBER:		0001411690-22-000007
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		130
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bionano Genomics, Inc.
		CENTRAL INDEX KEY:			0001411690
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				261756290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38613
		FILM NUMBER:		22698299

	BUSINESS ADDRESS:	
		STREET 1:		9540 TOWNE CENTRE DRIVE
		STREET 2:		SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 888-7600

	MAIL ADDRESS:	
		STREET 1:		9540 TOWNE CENTRE DRIVE
		STREET 2:		SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bionano Genomics, Inc
		DATE OF NAME CHANGE:	20190308

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioNano Genomics, Inc
		DATE OF NAME CHANGE:	20120703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioNanomatrix Inc
		DATE OF NAME CHANGE:	20070906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bngo-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e3db6ed1-8b4e-4b22-9c48-82142796368a,g:231d39e4-2c00-4236-9c0c-64cfa873dbdc,d:43bade00237b4e8cb3c24c30ea1cd6d3--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bngo="http://bionanogenomics.com/20211231" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bngo-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM180L2ZyYWc6OTE3ZGRmMGY2Mjk5NGViYTg1MTZkYzgxNjliMGIwOTAvdGFibGU6OGE3OTM4MzYzY2FhNGFjOTk0MzFhNWViNjM3OWVmYzAvdGFibGVyYW5nZTo4YTc5MzgzNjNjYWE0YWM5OTQzMWE1ZWI2Mzc5ZWZjMF8zLTEtMS0xLTE_4f9dd4aa-e955-4259-acbb-5c49b7f142c3">0001411690</ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM180L2ZyYWc6OTE3ZGRmMGY2Mjk5NGViYTg1MTZkYzgxNjliMGIwOTAvdGFibGU6OGE3OTM4MzYzY2FhNGFjOTk0MzFhNWViNjM3OWVmYzAvdGFibGVyYW5nZTo4YTc5MzgzNjNjYWE0YWM5OTQzMWE1ZWI2Mzc5ZWZjMF80LTEtMS0xLTE_f6cdbb06-88cb-4b6f-9207-2a7fe370baac">2021</ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM180L2ZyYWc6OTE3ZGRmMGY2Mjk5NGViYTg1MTZkYzgxNjliMGIwOTAvdGFibGU6OGE3OTM4MzYzY2FhNGFjOTk0MzFhNWViNjM3OWVmYzAvdGFibGVyYW5nZTo4YTc5MzgzNjNjYWE0YWM5OTQzMWE1ZWI2Mzc5ZWZjMF81LTEtMS0xLTE_31e3ad2d-b236-4048-bb8a-765acfb0132d">FY</ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM180L2ZyYWc6OTE3ZGRmMGY2Mjk5NGViYTg1MTZkYzgxNjliMGIwOTAvdGFibGU6OGE3OTM4MzYzY2FhNGFjOTk0MzFhNWViNjM3OWVmYzAvdGFibGVyYW5nZTo4YTc5MzgzNjNjYWE0YWM5OTQzMWE1ZWI2Mzc5ZWZjMF82LTEtMS0xLTE_0dec9f45-4b4e-42e8-aaee-3ab861924d62">false</ix:nonNumeric><ix:nonNumeric contextRef="i371c9488f9534e7b9b874201105a3f58_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc4OTc_81782cd1-ff67-4bc0-b19a-d3f9ef09300e">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ibec93384d0cb4cd38ec922514c5a2307_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTk0L2ZyYWc6MjkwMzg1NjBmMzU2NGFmMWExZjU4NDg3N2I2OGQ5YTcvdGFibGU6NGNhMzFiMjBhMThhNDE1MmFjY2FmMTcxNTk5ZWU2MzUvdGFibGVyYW5nZTo0Y2EzMWIyMGExOGE0MTUyYWNjYWYxNzE1OTllZTYzNV8wLTEtMS0xLTQzNDky_52a18f3b-7164-40b0-ad75-d6cf0ae2f8d1">1</ix:nonNumeric><ix:nonNumeric contextRef="ic9a9995ad77a4d72a6747277f6afc40f_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTk0L2ZyYWc6MjkwMzg1NjBmMzU2NGFmMWExZjU4NDg3N2I2OGQ5YTcvdGFibGU6NGNhMzFiMjBhMThhNDE1MmFjY2FmMTcxNTk5ZWU2MzUvdGFibGVyYW5nZTo0Y2EzMWIyMGExOGE0MTUyYWNjYWYxNzE1OTllZTYzNV8xLTEtMS0xLTQzNDky_68ab19d9-bfc9-4e7a-ad16-617459f61768">1</ix:nonNumeric><ix:nonNumeric contextRef="i7901fe27277a43038341f30e9235fb33_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTk0L2ZyYWc6MjkwMzg1NjBmMzU2NGFmMWExZjU4NDg3N2I2OGQ5YTcvdGFibGU6NGNhMzFiMjBhMThhNDE1MmFjY2FmMTcxNTk5ZWU2MzUvdGFibGVyYW5nZTo0Y2EzMWIyMGExOGE0MTUyYWNjYWYxNzE1OTllZTYzNV8yLTEtMS0xLTQzNDky_6b2e5881-8944-400c-9963-5b044129efb2">1</ix:nonNumeric><ix:nonNumeric contextRef="i72760e7d4c4d4bc29225a99c2b52e6a4_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTk0L2ZyYWc6MjkwMzg1NjBmMzU2NGFmMWExZjU4NDg3N2I2OGQ5YTcvdGFibGU6NGNhMzFiMjBhMThhNDE1MmFjY2FmMTcxNTk5ZWU2MzUvdGFibGVyYW5nZTo0Y2EzMWIyMGExOGE0MTUyYWNjYWYxNzE1OTllZTYzNV8zLTEtMS0xLTQzNTA1_1a2e84f2-b001-4795-a1e3-db33fae07cd2">1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bngo-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie425f0ffddbe4e4dacd9db92085c4d0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0f3d7dc69bc4efbb36a792b9284b7a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc7366eda1d47268de3bcdd81337d41_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie2dd45992746482e9f54504e09c41346_I20220224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ifedeab9392574bbf9284ae95544b0969_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef8a112a8af49b29859c89619c7063f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cb6eb48fccd436d82f456c60a03129e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab96b4f9d91c40b3bcff03e74ce07d85_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15621385cea8481886f364ad4a851311_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17c82a645e374a6bb89950a49d16c0b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0efd9aa753ee49239268311cb402902f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c0ff63e4b1469dae81b41f649a9a94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd11d2c4283b40818c2322674b6ee110_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic96f54a37ef346c38c3fce9c1e707621_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2232560f854d898b520b0322a5df9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c7362828a64a8eb87f775b1491fd99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45ae24785a44441a4802ef1030f892b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3634a0ee07e4c1fb4cb0dc6914a2405_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaa462baf9fc4f2680655d14713bccaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida156f9281c3453e97c6d3eb9345fa03_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515aa68d30164045bab97fec3cd86d29_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0418bf1522234b33bd7a72931d18580f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib40de96003224a488c14b76a879a457e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:TwoCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i371c9488f9534e7b9b874201105a3f58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03e386398bdb44b3addd41e681970261_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec93384d0cb4cd38ec922514c5a2307_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a9995ad77a4d72a6747277f6afc40f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7901fe27277a43038341f30e9235fb33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72760e7d4c4d4bc29225a99c2b52e6a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia421179e929849a0811736046100d29a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a66891cd81408b94c3dcf095dd9aa1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>bngo:segment</xbrli:measure></xbrli:unit><xbrli:context id="i9b2ff0a385ec4419bd63ad02cc162c4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie803dd47b1c54023ad328f5a634b77a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0bf1763a264af2afecbaaa10564f18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7b1ff8dff57441e9939f8789ca2e6c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55aca94255b45f7ba3ade3bbb054941_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ac604fde724aebbc7ddc5ec7989381_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc32dda88c8491493b3a97900889e74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65481e6e2e34f818b1abd233bbcb586_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9baa4e36abe6400f9c053d7f3434b31f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9377784747ef4e6792d946ece3659fdb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd45b65fd98e44ee92578a3812d0ebdf_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796761a85df6417896123b60211dc456_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4cd58ed3c4a43c7accda85e938edcc0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3054d21f6f4798b007ef1b3abea827_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac08b5e748c44125918877c58eeb2adc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c68a12eca334a838f030a41e51a46b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff8553873fd49468f9f75a5c165e98f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c615c6f945420e93b92d85cf0b8c01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0873412be8547959d4aa0e904da5fca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89f08d0b9d254e4cb81421c9274acb67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763f202ae44a40c09fe53b95d9006d97_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b47aea725d34079a308232d226a3001_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4169c1867a245108d470229bac5dbac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f8f8c29630a401a88a5285f57e55166_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76c0e564fd0c4699af8abe0b4a4a8f5b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639735ace7a54defa242bf743d278ad3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede1a65bd15f4596838c10a96b56c281_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86bea6db7f4248ed94253fad6c47e824_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029ea0650fb04082a13c21022c54f216_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60395f370984c03913b1237f78f5f74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie85c1983cea24f5fbb6e90a2a347fd4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie758ad97885e40af865734d6d0735fbd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64252642d88c4f9a8cdb7a3c4abb6daa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fd395e693f843f68c015a3fb16e63e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b6072efea34c43a77e7e2a8d672e57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd8b99cec464ca2a5fbc78e6d86bd6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21077c1aab5d457cb1cdf940f451908e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfba7f0bab47499d9d16e7fcfea7c8e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66e1e879fb554dcaa245d830024b147c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad7080a2ac2845729f17c608390c3daf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678854c029c5451f9cf24fe07efbf514_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0ee927463d486baa5cba33982c2569_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic609659d259845b3a37a1bf8b59de543_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1a6733a3f14bf2972c366549628e23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i219dd660a26b49beb67b572a81c81389_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3289f5383254228be7158bd06d11bfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a26c057095f4a36a0b30546701c58f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i467ef72acc6840729feb7f12f3a6e516_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93e575b671b4188b8e1e04eb90b0d27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9bc63b1b5444dea0111bbe4ec8f8bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1484c4dbff544b29b2781e84672dded_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe2bac092bd4c778f47ddbc97f1d0c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf405044e174ea88a98016ca955831d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id637a744712b44988d29a346fc913709_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ba840538fd4b0791ae9c324539369e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>bngo:lease</xbrli:measure></xbrli:unit><xbrli:context id="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5544954547a5409f8662da2a285cdb1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i970b26562f48462b986160dadd23e2e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9431acbfefa14bc1a8c51e9791630133_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e966a20a2d94bd6ac86960b0db2e83b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7c44f25d40c4d78a5d9623e10febeb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib110b6c1e25a43b190344fed192d23fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ServiceEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cdf5494bbd9490295ca735e1ec45cfd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ServiceEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386f22e822f8474daca8ae8933acbb26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa83cb53f8d446e58b64dd7b82b48311_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba22332706445abbde9bbbbbea71f04_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ReagentRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2d20d9c1274e4e8d7386137b4f34ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ReagentRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e2dc0ae87648a58b8afa4c80a78bce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ReagentRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a480bc32add481ea931915f5e4e20a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af5f30224ff436d833405ae9d5be9ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6981036f191b41ae8e646c1a85e17819_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79aff88d479e4c73bf896e7479d3d66f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45196371119428bb263f59a387de373_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33d1be42b47486b97d23a00612757c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb5ee1e4c6bd48d2be372e02f845f9f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bngo:CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ac9d5e475ba4422a72f931d6569a467_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bngo:CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187f2e41e0e647169625953a97e7c680_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:LoanUnderPaycheckProtectionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i885cb3edb89544758da163ee290c2716_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:TermA1LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8fefc0da0874a5b9ef1c40c3768d9b2_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:TermA2LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9113153c66234219aee4b2506362eeb2_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusTerm3LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc845bca945a4f5fa755dc944afdc43d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd4ec7b849b4fdfb36d13c56714da97_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e120690c77f416090e340927b324ea8_I20210514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifada802da30d4375a5c5a06d5d2c5ddf_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d74e091a5294082809d17f5146d70ad_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d3bb253582446b9f1f1ac8c1549355_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e07068caf640e88b8e67d05b03a126_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e87945aa7f410299777da79c66a83f_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:RevolverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb921d59feb74c7e9883ca143d13a63e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e9fefb7a034edb966f004c59f7d49c_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i807cfb44a24d46fe8574bed9d3d3fa46_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3751fdde71464399810902ffa867ecde_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12947374461e4e6b9a6e0e872431a338_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ec81e424f424534aa64d4e480141a53_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4795567b94164ea29b5699dc096d6ebf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5821d7ac4676425ba01bdcd20c6d2f91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:RevolverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d06a7344f2e49ab9598f04154df56cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:LoanUnderPaycheckProtectionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i938f91bd8c3946d395a47bb4a55c4f39_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id95371e1105d406580e1d89a5e055efa_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i842467c3c99147a9899c7166293dd2df_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0733c5c486d840aa90f9b967fc4b62a4_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96948543913400fa1d1b0b719ebabf1_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad11bf28fea04b8aba14929027d8fa54_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia66ac253e88644c8815ddb6f83187e4d_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473f14c3b9164deeb0b53c014f09915c_D20210112-20210112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-12</xbrli:startDate><xbrli:endDate>2021-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2623ef25413a4354ac9f72e113c78e64_D20210112-20210112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-12</xbrli:startDate><xbrli:endDate>2021-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01445096e010443d97b89ad87ab3c883_I20210112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5df53405a8de4826bff81815bde4ed6c_I20210112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i411e62885bec4fb3beab2f000e27b94f_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id608a0c5267f429cb8c9e21ce9a996e7_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49d68891599499b9fcf7774b2002c46_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96499813715849179f8f5b094e5056d1_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6ccdf4c05242a6877437f969ff350d_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d0542f51814417b825a21ad6a71dd4c_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6b16906f9c47c490d636cc5dc3cd1b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04fb2be1f6bc4a1ea3a4950d33413347_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9dfa5830e684b5b9aeb0425d2971c55_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie90abf42c0fa483585e7c0ddbc44d00c_D20210323-20210323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3baa8f239ec74369b0750b2c579131a4_D20210801-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6575ee0a35434402aebe8d5e012a1d85_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50bbecaae644414b92db4dfed11dc7e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a4af39e9424b53a07681fa1a5d8f50_D20200302-20200302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-02</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1a664a51c194792a34d9f22fad31cac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonStockWarrantsOriginalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f822c4990b1439daba5becfbc85c5aa_I20200302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93c22029995e4f6384a607093272bbfa_D20200302-20200302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonStockWarrantsAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-02</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab207f0b1ddf422e9fdb826c96fbbae0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonStockWarrantsAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2aef460467747f28861ce3854e7c187_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c415e70a6a948e8b2be43920872a619_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9ca65a64a4549f589630eadc720acf0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4b74c4fd9d4e7094439d2d2c7562e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bngo:AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea7966b68f743518a7b346891b8cfa1_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandAndTwentyInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c21833ff0041eaad1473112a77f0a7_D20211006-20211006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandAndTwentyInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-06</xbrli:startDate><xbrli:endDate>2021-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ad50c757a9743e791dd8f5af71e8e31_I20211006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandAndTwentyInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e25fe9fc0eb46c29dddcb5c5cfde31d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandAndTwentyInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bngo:AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f676ebcb6964b0db783a5db2a081ffa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8eacd11ad8142c39a3d70452a09fdda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab4219a77977404ba46cadf9c1e2d9e1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7265080c4d794589a09bd0e17f4e4a2d_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96e920c0320b47feb8ecdd4d667557e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86da882447604a1e9e8017d09d518536_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1180bacce9964e6ab67c6cf06acfbbde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1112f0645024f47bfb4ccd3ed88f2ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a68a48ad08c4a4a90ebcf1971894c02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f80b7d6b8944158bd9c8a9940a3b414_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6166e9bcdaf64523922f223a68f2ae8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f329ca85c24dc6ac16f2cf9b3ac9b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe3e09f6a3945efabf706cebdf47304_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48d32570b3e4421289d391c0f57b1c05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc3a87e87bc437b84ce90bf5c661e8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd34a35d15694242a41144a942e3bbd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i729c6da2107844e28908f101e5b69b18_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e08bcf17c014092be59db6343e02b9d_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2390b4b66da344ecb775181baacb32dc_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ddb1728db3a49f8abb7b5af01e8a6e3_D20220215-20220215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-15</xbrli:startDate><xbrli:endDate>2022-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5183cf0cdf481fb13cb77e135891e9_D20220215-20220215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-15</xbrli:startDate><xbrli:endDate>2022-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826d7a082f1c44b7bf787aecb9e7c3ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ieb6d3ff5dfb74f5e9b0306ff18734baa_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320f1643428144d38fdcf459b451c4a6_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i470e708352854bb7934441171219601e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:SaltLakeCityUtahMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ea6c5e3b632418db86e6b334229c600_I20211021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:ElSegundoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idebec6bf5580446897b029f768bd15cf_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44b75fe239a4b60b494433a3f77f70d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99a808d515494cdbadb3da6e47f4e15c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29f75a2dd05a4220bc087386e5a5149b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4c282464a94473ba123371ddc89314a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3624ecef1ddd4361a818dfb9464218ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8898d29f877f4495ab155612c9339010_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37f97c4ea0a4f4bb16de8adcef347a3_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bngo:EscrowedSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132f0f05159f47b79fd74e910694340d_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a669e6254fb41a7804a698577b0161a_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i257cbc434ff74964959fc60f88c37154_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5462c3bde0c4f4b91de75d0b7ce8831_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294164fc14f446a2b2e24cbae2459436_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c4019bf43a47b28bc8cfe7f136b957_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bdd4786bb848d3aab8623ac0910407_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974ac13511bd4accb073439efd2968a7_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1804c21be1e41dc94b90988721c64f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001411690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.138%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6MDE5NmUwMDk3NTFkNGI4MTg1YmEyYzQxNTlkNWMyYzYvdGFibGVyYW5nZTowMTk2ZTAwOTc1MWQ0YjgxODViYTJjNDE1OWQ1YzJjNl8wLTAtMS0xLTEvdGV4dHJlZ2lvbjplMDkyNDNjZGMzYzk0NzBiOTdhMzY4OWQ3ZmIzYjA0ZV85_47e23ca0-79d6-4347-a539-fe971f102978">10-K</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark&#160;One) </span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV81NDk3NTU4MTQzMzc5_c40fe8ab-26e0-4e08-bc12-16e9d6fa45b1">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV81NDk3NTU4MTQyNzc1_0b22c2cb-7b91-4ea7-bd66-b19cfa9702e8"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV81NDk3NTU4MTQyNzc1_f6d8b9e9-c8f9-49a5-adfc-ed45212ba188">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR </span></div><div style="margin-top:4pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDA3_921c0877-17e4-4ecc-8fed-a9358acf9315">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#160;<ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDEw_3f6e0396-5c7b-4b6d-8310-3430b91c497e">001-38613</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.305%"><tr><td style="width:1.0%"></td><td style="width:26.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.174%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6NTIzMTYyN2EyNzA2NDg1N2JiMzI3YzMzNDhkNWZhMDYvdGFibGVyYW5nZTo1MjMxNjI3YTI3MDY0ODU3YmIzMjdjMzM0OGQ1ZmEwNl8xLTAtMS0xLTE_779f0e7d-c20e-46e7-94a5-820cbb16887c">Bionano Genomics, Inc.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of Registrant as specified in its Charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.138%"><tr><td style="width:1.0%"></td><td style="width:46.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8wLTAtMS0xLTE_b69aad8e-a372-4817-aa42-94e36eaca2d9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8wLTItMS0xLTE_a2d25b87-e88e-488e-8ebf-c2a5b17990e5">26-1756290</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(I.R.S. Employer <br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjozN2JkYzA4MGNkMjc0MWM4OWQ3MmNhNzY5MzZlN2RjN180_23ecc9f0-c859-43a9-a6ac-760adcae2402">9540 Towne Centre Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjozN2JkYzA4MGNkMjc0MWM4OWQ3MmNhNzY5MzZlN2RjN184_7077bee8-d7cb-460e-8587-02763dee547b">Suite 100</ix:nonNumeric>, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjozN2JkYzA4MGNkMjc0MWM4OWQ3MmNhNzY5MzZlN2RjN18xMw_500bbd29-b87b-41a7-9128-06528a85d3f9">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjozN2JkYzA4MGNkMjc0MWM4OWQ3MmNhNzY5MzZlN2RjN18xNw_d94444e6-68ec-477d-8b5b-d07741c99f7c">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTItMS0xLTE_cbf503f9-5e82-4c8e-ae6c-17dc1206a144">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF80LTAtMS0xLTEvdGV4dHJlZ2lvbjozZDk0Y2MzNWZkZTg0M2ExOGMyYzk0ZTg3Mzk2Mzg2M181Nw_5ba322fb-0c7d-4090-9875-f1f1dbc7f62a">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF80LTAtMS0xLTEvdGV4dHJlZ2lvbjozZDk0Y2MzNWZkZTg0M2ExOGMyYzk0ZTg3Mzk2Mzg2M182MQ_decdee30-c390-4791-b5a5-dcbc9d005d9f">888-7600</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.777%"><tr><td style="width:1.0%"></td><td style="width:43.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie425f0ffddbe4e4dacd9db92085c4d0d_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8xLTAtMS0xLTE_cfe78cb6-e9b3-40c9-a70f-7932f28e60fa">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie425f0ffddbe4e4dacd9db92085c4d0d_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8xLTEtMS0xLTE_7598bc44-4b93-4107-8480-c6f2e3d5394d">BNGO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie425f0ffddbe4e4dacd9db92085c4d0d_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8xLTItMS0xLTE_6571f48b-cc8b-40c9-8a12-f30a9177080d">The Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic0f3d7dc69bc4efbb36a792b9284b7a8_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8yLTAtMS0xLTE_c44036a6-3689-4df0-a4f7-bb24b87fcd5b">Warrants to purchase Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic0f3d7dc69bc4efbb36a792b9284b7a8_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8yLTEtMS0xLTE_a472f58e-d174-4f76-842c-7fc4484ff754">BNGOW</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic0f3d7dc69bc4efbb36a792b9284b7a8_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8yLTItMS0xLTE_fb3b250e-15c9-4022-8274-b2452fb15373">The Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDEy_ec03460a-2ae3-4f5a-ad59-efa522b12a4c">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDA4_a9a1a61c-6e1d-4743-951a-bea446f2a1c1">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDAx_128f9add-a183-4735-8c5f-39b6ddd076a3">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDEx_636de7dd-0421-4897-b7c8-79cb634573b4">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6MjcyNmY2NTdlYzBiNDhiZjg5YzBhNWEwYTA3ZmIyNzAvdGFibGVyYW5nZToyNzI2ZjY1N2VjMGI0OGJmODljMGE1YTBhMDdmYjI3MF8wLTAtMS0xLTMxMTU2_99dde3c9-f69e-45d8-983a-18dd56db51ce">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:4pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6MjcyNmY2NTdlYzBiNDhiZjg5YzBhNWEwYTA3ZmIyNzAvdGFibGVyYW5nZToyNzI2ZjY1N2VjMGI0OGJmODljMGE1YTBhMDdmYjI3MF8xLTMtMS0xLTE_16ff21f8-d5bd-441f-92b3-184bcff9e934">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6MjcyNmY2NTdlYzBiNDhiZjg5YzBhNWEwYTA3ZmIyNzAvdGFibGVyYW5nZToyNzI2ZjY1N2VjMGI0OGJmODljMGE1YTBhMDdmYjI3MF8yLTEtMS0xLTE_9db930ee-d840-440f-a317-4fa5278af2fc">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDEz_f2553d24-cba7-4445-9aa0-b72110abce35">&#9746;</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;YES&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDA5_fcbd0def-e7df-4544-8e28-db6f5f9c2a32">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;NO&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2021 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $<ix:nonFraction unitRef="usd" contextRef="ibbc7366eda1d47268de3bcdd81337d41_I20210630" decimals="-3" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zODQ4MjkwNzAxMjI1_9337cf9f-0c54-4009-b5bc-656f5cf44fbd">2,045,466,000</ix:nonFraction> based on the closing price of the registrant&#8217;s common stock on June 30, 2021 of $7.33 per share, as reported by the Nasdaq Capital Market.</span></div><div style="margin-top:4pt;text-align:justify"><span><br/></span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of February&#160;24, 2022, the Registrant had <ix:nonFraction unitRef="shares" contextRef="ie2dd45992746482e9f54504e09c41346_I20220224" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zODQ4MjkwNzAxMTE3_0adc21ac-f11f-412e-bfe2-6fb8fc0bdd24">289,612,949</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDA0_f428d142-f3c0-40db-a6ea-c50f7d92a965" escape="true">Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#8217;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#8217;s fiscal year ended December&#160;31, 2021.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_22">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_1868">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_1868">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_79">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_79">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_82">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_82">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_85">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_85">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_88">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_88">62</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_94">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_94">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_97">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_97">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_100">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_100">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_124">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_127">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_127">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_196">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_196">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_199">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_199">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_202">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_202">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_2560">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_2560">108</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_208">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_208">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_211">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_211">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_214">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_214">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_217">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_217">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_220">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_220">108</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;IV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_226">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_226">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_232">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_232">111</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_235">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_235">111</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As used in this Form 10-K, &#8220;Bionano,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer to Bionano Genomics, Inc. and its subsidiaries or, as the context may require, Bionano Genomics, Inc. only. "Lineagen" and "BioDiscovery" refer to our wholly owned subsidiaries, Lineagen, Inc. and BioDiscovery, LLC.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note Regarding Forward-Looking Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements and information within the meaning of the safe harbor provisions for the U.S. Private Securities Litigation Reform Act of 1955. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or &#8220;would&#8221; or the negative of these words or other similar terms or expressions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report, regarding, among other things: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our products, and our ability to serve those markets; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our products; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the growth of our business and integrate acquired businesses;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to expand our commercial organization to address effectively existing and new markets that we intend to target; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully execute our strategy and meet anticipated goals and milestones </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete effectively in a competitive industry; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of competitive technologies or improvements in existing technologies and the success of any such technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance of our third-party contract sales organizations, suppliers and manufacturers; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenues, reimbursement rates, capital requirements and needs for additional financing; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business and our expectations with respect to the duration of such impacts and the resulting effects on our business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not realize the anticipated benefits and synergies of our recent and any future acquisitions or other strategic transactions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain funding for our operations; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract collaborators and strategic partnerships; </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely on forward-looking statements as predictions of future events. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in Part I, Item 1A Risk Factors and elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties may emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report. And while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements made in this Annual Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Annual Report to reflect events or circumstances after the date of this Annual Report or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_2819"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">address</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> all of the risks that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, and other risks and uncertainties that we face, are set forth below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Annual Report and our other filings with the SEC before making investment decisions regarding our securities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are an early-commercial-stage company and have a limited commercial history, which may make it difficult to evaluate our current business and predict our future performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred recurring net losses since we were formed and expect to incur losses in the future. We cannot be certain that we will achieve or sustain profitability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, which makes our future operating results difficult to predict and could cause the market price of our securities to decline substantially;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, and that of our customers, has been adversely affected by the effects of public health crises, including the COVID-19 pandemic. In particular, the COVID-19 pandemic has materially affected our operations globally, including at our headquarters in San Diego, California, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business. As a result, in some cases we have had to delay instrument installations or service-related visits. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future capital needs are uncertain and we may require additional funding in the future to advance the commercialization of Saphyr, NxClinical and our other products, technologies, and services, as well as continue our research and development efforts. If we fail to obtain additional funding, we will be forced to delay, reduce or eliminate our commercialization and development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisitions, joint ventures and other strategic transactions could disrupt or otherwise harm our business and may cause dilution to our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our products or technologies fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success is dependent upon our ability to further penetrate our existing customer base and attract new customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently limited to &#8220;research use only&#8221; with respect to many of the materials and components used in our consumable products including our assays;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the near term, sales of our Saphyr system, the NxClinical software, our consumables and genome analysis services will depend on levels of research and development spending by clinical research laboratories, academic and governmental research institutions and biopharmaceutical companies, a reduction in which could limit demand for our technologies, products and adversely affect our business and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not successfully manage the development and launch of new products and technologies, our financial results could be adversely affected;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the FDA determines that our RUO products are medical devices or if we seek to market our RUO products for clinical diagnostic or health screening use, we will be required to obtain regulatory clearance(s) or approval(s), and may be required to cease or limit sales of our then marketed products, which could materially and adversely affect our business, financial condition and results of operations. Any such regulatory process would be expensive, time-consuming and uncertain both in timing and in outcome;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, it may reduce our ability to maintain any technological or competitive advantage over our competitors and potential competitors, and our business may be harmed; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our securities may be volatile or may decline regardless of our operating performance, and you could lose all or part of your investment.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_22"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global genomics company focused on elevating the health and wellness of all people.  We are pioneers of optical genome mapping, or OGM, for genome analysis and provide a suite of genome analysis solutions designed to enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through OGM solutions, clinical testing and laboratory services and software. We offer OGM and software solutions for applications across applied, translational and clinical research and we offer diagnostic services to physicians specializing in medical management for individuals with genetic conditions such as pediatric neurodevelopmental disorders, or NDDs, including autism spectrum disorders, or ASDs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell the Saphyr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. The Saphyr system is used in clinical and discovery research  to streamline the identification of structural changes in chromosomes, known as cytogenetics, and to accelerate the search for answers in genetic disease and cancer applications. The Saphyr system is comprised of an instrument, chip consumables, reagents and software containing a suite of data analysis and visualization tools. In addition to our Saphyr system and software products, we offer laboratory services to provide data generated by the Saphyr system to researchers seeking access to OGM data. The Saphyr system has been shown to outperform the current gold standard methods for cytogenetics and molecular genetics including karyotyping, fluorescence in-situ hybridization (FISH), Southern blot and chromosomal microarray. The Saphyr system has also been shown to identify structural changes in chromosomes that cannot be identified using current commercially available solutions for gene sequencing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide proprietary molecular genetic clinical testing services for individuals demonstrating clinical presentations consistent with NDDs, including ASDs and other disorders of childhood development. Our comprehensive genetic testing services include reporting for known NDD-causing genome variations, including testing for proprietary variations, and combines testing with our Proprietary Variant Index (PRISM) which uses a proprietary database of over 35,000 individuals with NDDs tested with over 60,000 tests that provides additional evidence for candidate genes associated with NDDs.  This testing is a CLIA-certified diagnostic testing service, and we have expertise in selling cytogenetic assays to physicians, providing genetic counseling services to individuals undergoing testing and their families, and contracting with third-party payors for reimbursement.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide laboratory services to clinicians, scientists, pharmaceutical companies, and others who are seeking to incorporate OGM into their genomics research without the need to bring our Saphyr system in house. Laboratory services for OGM are performed in our laboratory facilities in San Diego and at partner laboratories in the United States and Europe, and serve as solutions for researchers and clinicians who would like to use OGM for various applications in genomics but have yet to acquire the Saphyr.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software solutions deliver genomic data interpretation solutions tailored for research use in cytogenomics and molecular pathology labs in genetic disease and cancer research markets, with an emphasis on structural variation. We offer an industry-leading, platform-agnostic software solution that can integrate OGM with next-generation sequencing, or NGS, and microarray data.  This software solution is designed to provide analysis, visualization, interpretation and reporting of structural variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Our software currently enables analysis of NGS and microarray data, and we are developing a version that we expect to be able to incorporate OGM data to make our software a more comprehensive offering for analysis of genomic data.  We believe the integration of OGM with data types common in the industry, such as Variant Call Format (VCF), and Binary Alignment Map (BAM), should accelerate and broaden our position in digital cytogenetics and comprehensive genome analysis by enabling us to simplify the assessment of clinically relevant variants in cytogenomics applications, potentially reducing interpretation time per sample and expanding our reach into the discovery and translational research markets through the combination of OGM and NGS data.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past year, we believe we have transformed our business from an instrument company to a provider of a full suite of genomics solutions. We expanded into molecular genetic clinical testing services through our August 2020 acquisition of Lineagen Inc. Our recent expansion into software solutions was made possible by our October 2021 acquisition of BioDiscovery, LLC. We believe that these acquisitions, along with internal investments in research and development and the build out of our commercial teams, have positioned us well to make OGM standard of care for many constitutional genetic disorders and cancers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Highlights</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Adoption of Offerings for Saphyr</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano executed on its commercialization strategy, expanded the utilization of its Saphyr system and increased the amount of Bionano data generated across the globe, driving scientific momentum.  </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grew our installed base to 164 as of December&#160;31, 2021, an increase of approximately 69% from a total installed base of 97 as of December&#160;31, 2020. Installed base represents the global number of Saphyr instruments installed at end-customer locations and therefore ready to process optical genome mapping.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sold 3,204 flowcells in the fourth quarter of 2021, an increase of approximately 29% over the 2,484 flowcells sold during the fourth quarter of 2020. For the year ended December&#160;31, 2021, total flowcells sold reached 12,518, an increase of approximately 98% over the 6,311 flowcells sold during the year ended December&#160;31, 2020. The Saphyr chip is the consumable that packages nanochannel arrays for DNA linearization. In its current form, each Saphyr chip has three flowcells. Flowcells sold refers to the units of genome mapping consumables used for analyzing one genome, purchased by customers to process optical genome mapping.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Validated the Utility of OGM for Applications in Clinical Research with Benchmarking, Scientific Publication and Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigorous and extensive benchmarking of Saphyr was conducted against traditional cytogenetic methods and long read sequencing and these results were published and validated in several key publications, presentations and announcements including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">OGM demonstrated 100% concordance with karyotyping, FISH, and chromosomal microarray in constitutional disorders in two studies appearing in the August 2021 issue of the American Journal of Human Genetics; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The authors in these back-to-back AJHG publications describe OGM as a better alternative to traditional cytogenetics assays for both inherited genetic disease and hematologic malignancy applications since it consolidates multiple antiquated methods requiring manual integration for interpretation into a single workflow with higher resolution for detection of all classes of structural variants.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">University Hospitals Leuven in Belgium, received its accreditation from the Belgian Accreditation Body (BELAC) for using OGM in analysis of acute lymphoblastic leukemia (ALL) and showed significant improvements in cost and turnaround time relative to traditional techniques of FISH and MLPA.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Published study by Johns Hopkins University in the Journal of Clinical &amp; Anatomic Pathology outlining a stepwise approach to adoption of OGM for cancer analysis in their cytogenetics lab.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A team from the University of Iowa published the largest clinical research study to date evaluating OGM for facioscapulohumeral muscular dystrophy (FSHD). The study, published in the Journal of Molecular Diagnostics, concluded that OGM can be performed quicker, more accurately, and more reproducibly than the current gold standard method of Southern blot analysis.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Publication of a study and of 76 subjects by authors at The University of Texas MD Anderson Cancer Center, which evaluated the utility of OGM as an alternative to traditional cytogenomic methods for the characterization of structural variation (SV) in myelodysplastic syndrome (MDS). The study was published in Blood, the journal of the American Society of Hematology (ASH) and presented at the 2021 ASH annual conference.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Publication of a study from the International COVID-19 Host Genome Structural Variation Consortium, which is a global open host genome structural variation consortium for COVID-19 response. The consortium is comprised of over 30 researchers from leading institutions who are using OGM to assess structural variations in the human genome that could be contributing to COVID-19 susceptibility or progression. In this study, OGM was conducted on samples from 52 severely ill COVID-19 subjects to investigate structural variations as decisive predisposition factors associated with COVID-19. The researchers identified 7 structural variations in 9 subjects (17% of subjects analyzed) involving genes implicated in two key host-viral interaction pathways: innate immunity and inflammatory response, and viral replication and spread. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Researchers from leading institutions in the US published in medRxiv the first readout from the ongoing multi-site clinical research study designed to support OGM as an alternative to traditional workflows in cytogenetics for postnatal inherited genetic disease. The IRB-approved clinical study evaluated 331 individual sample runs from 202 unique samples across five sites for interim measures of key endpoints:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Concordance with traditional techniques &#8211; 97.7% (214 out of 219 samples)</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Partially concordant with traditional techniques &#8211; 2.3% (5 out of 219 samples)</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Concordance with traditional techniques for pathogenic variant calls &#8211; 100% (219 out of 219 samples)</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Concordance with chromosomal microarray (CMA) &#8211; 100% (103 out of 103 samples)</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">First-pass success rate for OGM &#8211; 94% (311 out of 331 samples)</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Reproducibility of analytical QC from site-to-site &#8211; 98.8% (171 out of 173 replicates)</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Reproducibility of pathogenic variant calls from site-to-site &#8211; 100% (173 out of 173 replicates)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Researchers from the Medical College of Georgia/Augusta University published a study that evaluated the performance and utility of combining OGM and a 523-gene NGS panel for comprehensive evaluation of myeloid tumors and compared it to standard cytogenetic methods (karyotyping and fluorescence in situ hybridization (FISH) and a 54-gene NGS panel. The combination of OGM and a 523-gene NGS panel is superior to standard methods and more cost effective than whole genome sequencing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, and the measures imposed to contain this pandemic in areas where we operate our business and elsewhere have disrupted and are expected to continue to impact our business. COVID-19 related disruptions to the global supply chain created and may continue to create challenges in our getting sufficient components and raw materials for production of our OGM systems and consumables. At various times throughout the pandemic, we have been unable to visit certain customer sites to support installation or service our OGM systems.  In addition, study enrollment for clinical studies generally has been affected by COVID-19. While we have not experienced adverse effects on study enrollment, we may begin to as we continue to pursue clinical studies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more detailed discussion of the impacts of the COVID-19 pandemic on our business, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - COVID-19.&#8221;</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_25"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Industry Background </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genome analysis is the process of extracting and interpreting biological information from DNA and RNA. DNA is the code that is found in all living cells and determines the characteristics and health of all living organisms. Although each organism&#8217;s DNA order is unique, all DNA is composed of the same four nucleotides that come in pairs, which are referred to as base pairs. The human genome is composed of six billion of these base pairs (three billion of which are the maternal copy and three billion of which are the paternal copy of the genome), distributed across 23 pairs of chromosomes ranging in size from approximately 50&#160;million to approximately 250&#160;million base pairs. Genome variation is defined as at least one base pair differing in a comparison of sequence against a reference standard and can be as large as tens of millions of base pairs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genome structure refers to the way in which the various functional elements of the genome such as genes, reading frames, promoters and others are ordered, oriented and organized across the 23 pairs of chromosomes. Structural variations represent differences in the amount or location of genomic DNA from one individual compared to a reference genome. Structural variation is one of the most biologically important aspects of the human genome and is a major factor for the cause of genetic disorders and cancer. Each structural variation involves the rearrangement or repetition of as few as several hundred base pairs to as many as tens of millions of base pairs. Structural variations may be inherited or arise spontaneously. Structural variations are well-known to cause diseases such as constitutional genetic disorders and cancer. Many researchers and clinicians now agree that despite major advances in the speed and cost-effectiveness of DNA sequencing, it fails to reliably detect structural variations. OGM enables the detection of all classes of structural variants, and we believe no methodology exists that can detect structural variations more comprehensively or cost efficiently than OGM with the Saphyr system.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the traditional cytogenomic methods of detecting structural variations for research and clinical applications, karyotyping, CMA, and fluorescent in situ hybridization, or FISH, are antiquated and cumbersome and can only detect a small proportion of the structural variations across an entire genome. OGM is designed to offer cytogeneticists the ability to fully digitize and replace these traditional methods with one simplified, cost effective and scalable workflow using the Saphyr system.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that software is necessary for genome analysis and should be the primary interface for how cytogeneticists interact with the data and report their findings. We believe the software&#8217;s ease of use, core analysis functionality and the time necessary to obtain a reportable result are the most important factors to customers when considering a platform adoption decision and that data interpretation is typically a critical bottleneck in methods of genome analysis and therefore software is a key component in the entire workflow. The majority of software solutions on the market today have been developed with NGS as the primary application with the focus on the interpretation and reporting of single nucleotide variants (SNVs) instead of SVs. Our software solution, NxClinical, was developed with copy number variation as the core focus and has become established as an industry leading solution for interpretation and reporting of CNVs for CMA and NGS.  To the extent we are successful in integrating OGM into NxClinical, we anticipate that our software will be the first software solution delivering a fully integrated interpretation capability for SVs from OGM as well as seamless integration with NGS, with the potential to enable complementary OGM and NGS workflows through one software solution.   </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_2756"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Solutions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OGM Systems</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OGM is our proprietary approach to measuring genome structure and structural variation. The OGM workflow is novel, comprehensive, scalable, cost effective and highly differentiated. OGM data are currently generated using the Saphyr system, which directly measures sequence specific patterns (SSPs) along extremely long DNA molecules in an unbiased approach without any amplification. Using the SSPs, software constructs detailed physical map of the genome that accurately assigns the chromosomal location, order, orientation and quantity of sequence and in-turn, all the genome&#8217;s functional elements. We believe OGM is capable of comprehensive, cost effective and efficient detection of all classes of SVs and CNVs. Today, these structural variations cannot be reliably detected by genome sequencing. High throughput sequencers, of which there are approximately 16,000 currently installed worldwide, are reliable for detecting genomic differences involving a few base pairs or SNVs, which Saphyr does not identify. Sequencing, including NGS, cannot reliably detect the larger structural variations that our Saphyr system is designed to detect. Therefore, Saphyr may be adopted alongside this installed base of sequencers as a complement that is designed to give users the ability to see a much wider scope of genome variation from single bases of DNA to full chromosomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OGM was built upon four key elements: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Extremely long molecules for analysis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Saphyr system is capable of analyzing single molecules that are on average approximately 250,000 base pairs in length and can be as long as millions of base pairs. These lengths are over 1,000 times longer than the average read length with Illumina sequencing systems and approximately 10-20 times longer than the average read lengths with Pacific Biosciences of California, or PacBio, and Oxford Nanopore systems. We believe these long read lengths overcome the inherent challenges of genome complexity and are the key to Saphyr&#8217;s unprecedented sensitivity and specificity.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Proprietary nanotechnology for massively parallel linearization and analysis of long molecules with single molecule imaging. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analyzing these extremely long chromosomal fragments required invention. We invented, patented, developed and commercialized nanochannel arrays to capture long single molecules of DNA from solution and unwind and linearize them for structural variation analysis. Each molecule is imaged separately, making it possible to deconvolute complex mixtures including haplotypes and heterogeneous tumors.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">DNA labeling chemistry specifically for physical mapping. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detailed analysis of SSPs we use is also highly unique and novel. Instead of identifying the sequence of every base pair in these long fragments, we label and detect SSPs or motifs that occur universally across every genome with an average frequency of approximately one site for every few thousand base pairs. The key to our method entails introducing fluorescent tags at the sequence-specific site using highly specific and robust enzymatic chemistry along the extremely long fragments. These fragments, stretched out in nanochannels, are then directly imaged allowing us to measure the distance between labels with high accuracy. The pattern of labels detected on all these fragments can then be related to the pattern of sequence motif sites in a reference genome for comparison. Changes in the pattern indicate structural variation. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bioinformatic tools for structural variation analysis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our approach includes a novel bioinformatics platform that we developed from the ground-up to take advantage of the unique benefits of our solution. It comprises proprietary algorithms for the construction of a structurally accurate physical map of the genome to assign structure. Physical maps of a test subject are then compared to a reference or other subjects in cross-mapping analysis that allows our system to detect genome wide structural variation, including the most complex balanced events. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Saphyr system provides a solution for comprehensive structural variation analysis at a higher resolution than traditional techniques allowing for more answers that matter to be obtained in genetic disease and cancer applications. We believe that Saphyr is the only product capable of detecting structural variations at high sensitivity and specificity with a workflow that is cost-effective and time efficient. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include researchers and clinicians who seek to identify and understand the biological implications of genome variation.  We believe that Saphyr can replace more traditional cytogenetic tools which are expensive, slow and labor-intense, with an advanced solution designed to simplify workflow, reduce cost, and increase assay success rates.  We believe Saphyr has the potential to significantly increase success rates and provide more answers across a wide range of applications in genomics.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Testing and Laboratory Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer tests that use CMA for evaluation of patients suspected of having certain genetic diseases, which is recommended by the American College of Medical Genetics and Genomics (ACMG), the American Academy of Pediatrics (AAP), and the American Academy of Neurology (AAN), among other renowned societies. We are actively performing research to determine whether OGM with the Saphyr system can replace CMA as the front-line test for children with developmental disorders. As the scientific, peer-reviewed literature supports this claim, the coding entities such as CMS and the AMA would need to adopt the proper procedural codes to allow for insurance reimbursement of new testing methodologies before they become mainstream clinical diagnostic instruments. Importantly, OGM is expected to be able to detect full mutations consistent with fragile X syndrome, which is another front-line test for children, especially males, with autism spectrum disorder and intellectual disability. Studies are ongoing to determine the sensitivity and specificity for OGM as it relates to fragile X syndrome. We also </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employ Whole Exome Sequencing (WES), which aims to detect genome SNVs that are different from genome structural variations and are not detectable by OGM. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are uniquely positioned to develop LDT&#8217;s that can improve upon the existing standards of care for diagnostic testing for NDDs. We have an established channel to work with payers to secure reimbursement alternatives for Saphyr-based testing. If reimbursements can be established, we intend to share our strategies with our customers to drive demand for the Saphyr system. We plan to expand our testing menu with inclusion of OGM to demonstrate workflow implementation in a clinical setting in order to drive adoption as well as serve as a conduit for enabling access for those customers unable to make a capital equipment expenditure. Our goal is to enable access, demonstrate excellence of the OGM workflow as a model within a CLIA setting for educational purposes, drive advancements in product development for clinical grade testing of OGM at scale.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Software Solutions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer industry leading genome analysis software that enables genomics labs to analyze and interpret data across a wide range of platforms to generate highly informative data visualizations for streamlined and simple reporting of causal variants. Today, NxClinical software is among the most comprehensive solutions for analysis and interpretation of any microarray or NGS generated data integrating copy number variants (CNVs), absence of heterozygosity (AOH) and loss of heterozygosity (LOH), as well as SNVs from sequencing data into a single well integrated interface that is used across the globe by renowned academic and commercial clinical laboratories. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition of BioDiscovery has expanded our portfolio into providing data analysis and interpretation solutions across NGS, CMA and OGM. These software solutions are expected to allow us to leverage and expand our network of Bionano customers and to potentially enable future adoption of OGM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe integrating OGM data into NxClinical should substantially improve the analysis and reporting capabilities of our current Saphyr system, making OGM easier to adopt and use by our customers. Through BioDiscovery, we can now serve the NGS and array markets directly though software with an industry leading data interpretation solution for revealing more answers with delivery of copy number variants across the genome. Our software monetization strategy is predicated on a pay-per-sample model where customers running NGS and/or array today can adopt, which sets the stage for future OGM adoptions. Software is a way for us to participate directly in the NGS market while also enabling OGM data to be seamlessly integrated with NGS in one view for a comprehensive analysis, which is unique to Bionano.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_31"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Offerings </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Saphyr System and Consumables</span></div><div style="margin-top:6pt;text-align:center"><img src="bngo-20211231_g1.jpg" alt="bngo-20211231_g1.jpg" style="height:123px;margin-bottom:5pt;vertical-align:text-bottom;width:313px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop and market the Saphyr system, a complete sample-to-result solution for structural variation analysis by OGM that empowers comprehensive genome analysis and facilitates a deeper understanding of genetic variation and function. We believe the Saphyr system is capable of addressing the needs for structural variation analysis because it is:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Highly sensitive. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Saphyr is the most sensitive detector of structural variations larger than 500 base pairs currently on the market.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cost effective. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consumables cost per genome, at an average of approximately $500, can be less than the combination of standard techniques and well below both short-read and long-read WGS at a depth of 160x coverage. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Scalable and fast. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relative to traditional techniques, Saphyr has demonstrated up to a 75% reduction in turnaround time for analysis of acute lymphoblastic leukemia (ALL) subjects when used instead of karyotyping, FISH and MLPA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Saphyr Instrument </span></div><div style="margin-top:6pt;text-align:center"><img src="bngo-20211231_g2.jpg" alt="bngo-20211231_g2.jpg" style="height:67px;margin-bottom:5pt;vertical-align:text-bottom;width:147px"/></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Saphyr instrument is a single-molecule imager that includes high performance optics, automated sample loading based on machine learning algorithms and computational hardware and control software. The instrument&#8217;s high-performance optics simultaneously image DNA linearized in hundreds of thousands of nanochannels. The instrument&#8217;s control interface is the user&#8217;s primary control center to design and monitor experiments as they occur in real time. The computational hardware is responsible for the secondary processing of the image data being produced on the Saphyr. The Saphyr instrument is currently capable of analyzing up to 5,000 human genomes per year at 30x coverage. At the end of 2021 we announced the completion of a prototype currently in development that is expected to significantly increase the throughput. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Saphyr Chip </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Saphyr Chip&#174; is the consumable that packages the nanochannel arrays for DNA linearization. In its current form, each Saphyr chip has three flow cells containing approximately 120,000 nanochannels that are roughly 30 nanometers wide, and each flowcell can hold one unique sample. To manufacture the arrays, we use photolithography in a semiconductor fabrication facility to print hundreds of thousands of tiny grooves on silicon wafers and then dice the wafers into individual chips. Our chips are inexpensive to manufacture and highly scalable. The fluidic environment in each channel allows individual molecules to move swiftly utilizing only the charge of DNA. Hundreds of thousands of molecules can move through hundreds of thousands of parallel nanochannels simultaneously, enabling extremely high-throughput processing on a single-molecule basis. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Saphyr Sample Prep and Labeling Kits </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bionano Prep Kits&#8482; and DNA labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight, or UHMW, DNA for use with the Saphyr system. These kits are optimized for performing our genome mapping applications on a variety of sample types.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our workflow begins with the isolation of ultra-high molecular weight DNA. Our sample prep kits are optimized for isolating and purifying ultra-high molecular weight DNA in a process that is gentler than existing DNA extraction methods. The resulting purified DNA is millions of base pairs long and optimal for use with our systems. Each Bionano Prep Kit allows customers to perform five to 10 HMW DNA preps. Our kits and protocols enable the extraction of HMW DNA from a variety of sample types including human or animal tissue and tumors, plant tissue, cell lines, bone marrow aspirates and human blood. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our labeling reagents are optimized for applications on our genome mapping systems. Starting with HMW DNA purified using the appropriate Bionano Prep Kit, fluorescent labels are attached to specific sequence motifs. The result is uniquely identifiable genome-specific label patterns that enable de novo map assembly, anchoring sequencing contigs and discovery of structural variations as small as 500 base pairs to up to chromosome arm lengths. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our kit for DNA labeling, the Direct Label and Stain (DLS) kit, is a proprietary, nondestructive chemistry for sequence motif labeling of genomic DNA that improves every aspect of our genome mapping. DLS uses a single direct-labeling enzymatic reaction to attach a fluorophore to the DNA at a specific 6-base pair sequence motif, yielding approximately 16 labels per 100,000 base pairs in the human genome. After labeling, the molecules are linearized in the Saphyr chip on the Saphyr instrument and imaged. Through the isolation, labeling and linearization steps, the molecules maintain an average length of around 250,000 base pairs. The label patterns on each molecule allow them to be uniquely identified and aligned in a pair-wise comparison against all other molecules imaged from the same sample.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software Solutions </span></div><div style="margin-top:6pt;text-align:justify"><img src="bngo-20211231_g3.jpg" alt="bngo-20211231_g3.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data solutions offering includes a complete suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps and algorithms and databases for bioinformatics processing, all of which is driven through convenient web-based management and monitoring tools. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a suite of proprietary algorithms and databases that fully enable our proprietary bioinformatic and structural variation analysis pipelines. Using pairwise alignment of the single molecule images, consensus genome maps are constructed, refined, extended and merged. Molecules are then clustered into two alleles, and a diploid assembly is created to allow for heterozygous </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">structural variation detection. Genome maps typically span entire chromosome arms in single, contiguous maps. Comparative analysis of maps reveals structural variation. Our customers use our variant annotation workflow to specifically uncover rare and sample-specific mutations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hardware solution includes the Saphyr Compute Server, which provides cluster-like performance in an affordable, compact solution and the Bionano Compute Server, which expands the analytical capacity of the suite of tools. With these solutions, our customers are capable of performing multiple simultaneous analyses and sustaining continuous throughput, which allows them to spend less time waiting for data, so they can focus on investigating results. We also offer a cloud-based solution for data analysis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NxClinical is among the most comprehensive and up-to-date solutions for cytogenetics and molecular genetics, providing one system for analysis and interpretation of all genomic variants from microarray and NGS data. We are developing a version of NxClinical to incorporate OGM data, which is expected to become our software solution once completed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Testing and Laboratory Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through Bionano Labs, we offer OGM data to researchers seeking access to OGM data. We intend to build a menu of LDT&#8217;s on Saphyr to demonstrate the capabilities of OGM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FirstStepDx PLUS is a CMA designed to identify an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fragile X syndrome (FXS) testing is designed to detect individuals (both males and females) with FXS, as well as carriers of the condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NextStepDx PLUS is a whole exome sequencing test designed to identify genetic variants that are associated with disorders of childhood development. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EpiPanelDx PLUS is a genetic testing panel designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PGx test identifies over 60 alleles in 11 genes. PGx testing is one aspect of personalized medicine and is used to aid health care providers with medications and dosage.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_34"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Opportunity </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to Markets and Markets, the worldwide market for genomics products and services is expected to reach approximately $54.4 billion by 2025, up from approximately $22.7 billion in 2020, representing a compound annual growth rate of 19%. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the two areas of the genomics market that are driving demand for the Saphyr System are: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Consolidation of traditional cytogenetics techniques in constitutional and cancer applications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To provide a robust clinical analysis, cytogenetic assays detect known structural variations that are linked to specific diseases or therapeutic responses. The technologies used for detecting structural variations are expensive and involve cumbersome workflows with relatively limited ability to scale to higher volumes or more complex testing panels. Sequencers tend not to be used for cytogenetics due to their inability to reliably detect structural variations. Cytogenetics laboratories are beginning to adopt Saphyr as a more effective, scalable and efficient approach to finding the structural variations causative to genetic diseases and cancer. For this segment, Saphyr is used alone tool for providing comprehensive and accurate detection of all classes of structural variations and enable clinically relevant calls without the need for any sequencing or legacy cytogenetic technology. We estimate that approximately 2,500 cytogenetics labs exist worldwide.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Combining OGM with sequencing for molecular genetics and discovery research applications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In discovery research across patient cohorts, sequencing is primarily used to find SNVs responsible for disease or therapeutic response. Sequencing alone, however, is significantly limited due to its inability to reveal structural variations. Our Saphyr system has been expanding this market segment by complementing sequencing to expand the scope of genome variation that can be analyzed in studies to achieve a more comprehensive view of the genome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that the current worldwide discovery research and cytogenetics segments together comprise an addressable opportunity for us to sell up to an aggregate of approximately 10,000 OGM-based instruments, representing a total instrument market opportunity of approximately $2.1 billion. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the instrument sales opportunity, our OGM-based instruments generate recurring revenue from chip consumables and reagents that are used on a per-sample basis. We believe estimate that each of our OGM-based instruments has the potential to create recurring revenue from chip consumable sales in a range of between $70,000 to approximately $175,000 per year, suggesting a potential annual recurring revenue from chip consumable sales opportunity between approximately $0.7 billion to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $1.7 billion. We have based this estimated annual recurring revenue opportunity for chip consumable sales on anticipated customer and an assumed price of $500 per chip consumable and sample prep and labeling kit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that if our OGM-based instruments can successfully penetrate these addressable market opportunities, this should spur additional basic and translational research creating new areas where Saphyr (or successor instruments) and OGM data can be used to improve the standard of care and patient management. These may include preconception, products of conception and prenatal genetic applications, uses to advance gene editing techniques and precision medicine.  In the long term, we anticipate potential opportunities in population screening, newborn screening, biopharma applications in cell quality control and oncology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current market opportunity estimates for total OGM-based instrument sales and annual recurring revenue from chip consumable sales are forward-looking statements and are subject to significant risks and uncertainties. While these were prepared in good faith, we cannot provide assurances as to future results or events. These estimates are based on third-party market research data and our future outlook, which is dependent in principal part on anticipated demand for OGM instruments, complementary capabilities of OGM and NGS, expected consumption of chips and sample prep and labeling kits. In particular, these estimates are based on current and projected selling prices for instruments and consumables, each of which is subject to change over time. These estimates and assumptions underlying our addressable market opportunities involve significant judgments with respect to, among other things, future economic, competitive, regulatory, market and financial conditions, as well as future customer demand, business decisions and corporate opportunities that may not be realized, and that are inherently subject to significant business, economic, competitive and regulatory risks and uncertainties, all of which are difficult to predict and many of which are outside of our control. Our underlying assumptions and estimates may prove to be inaccurate and our financial objectives may not be realized, and therefore our actual results may differ materially from these estimated addressable market opportunities. In addition, these addressable opportunities should not be construed as financial guidance and should not otherwise be relied upon as being necessarily indicative of future results, and you are cautioned not to place undue reliance on these estimated addressable opportunities. In preparing these estimated addressable opportunities, we have relied upon and assumed, without independent verification, the accuracy and completeness of certain industry and market information provided to us by third parties or through publicly available sources, which information involves assumptions and limitations, and you should not give undue weight to such information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established relationships with key opinion leaders in genomics research and clinical applications, including rare diseases and oncology, including some of the world&#8217;s most prominent clinical, translational research, basic research, academic and government institutions as well as leading pharmaceutical and diagnostic companies. Examples include Quest Diagnostics, Brigham and Women&#8217;s Hospital, Harvard Medical School, MD Anderson Cancer Center, Children&#8217;s Hospital Los Angeles, Columbia University Medical Center, Children&#8217;s Hospital of Philadelphia, Medical College of Georgia at Augusta University, Children&#8217;s National Health System, Boston Children&#8217;s Hospital, PerkinElmer, Praxis Genomics, Garvan Institute of Medical Research, McDonnell Genome Institute at Washington University, National Institutes of Health, Pennsylvania State University, Radboud University Medical Center and Salk Institute for Biological Studies. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_37"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are primarily focused on driving adoption of OGM through the Saphyr system. Our goal is to streamline structural variant identification and enable new research in genomics to allow greater insight into their role in human health in ways that have not been possible with any other current research and diagnostic technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy to achieve this includes: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Demonstrate that Saphyr is a superior alternative to traditional techniques in constitutional genetic disorders and hematologic malignancy applications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Optical genome mapping has demonstrated superior detection sensitivity for all classes of structural variants relative to karyotyping, FISH and CMA in numerous peer-reviewed publications over the last year and offers benefits of improved assay success rates, faster time to result and a lower total cost.  The value proposition and competitive differentiation for OGM in cytogenetics market is exceptionally strong with an immediate opportunity to digitize legacy microscope techniques (karyotyping) with a superior approach using Saphyr. Since the cytogenetics market understands the importance of structural variants and these genomic variants are the basis of this medical discipline, we believe the cytogenetics market is well poised as the entry point for global expansion.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Complement NGS with OGM in translational, applied and discovery research markets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We believe the combination of NGS and OGM can provide the most comprehensive and cost-effective analysis of genome variants from SNVs to whole chromosomes. NGS is an accurate technique for measuring genome variants below 500 bp while OGM bridges the gap by enabling detection of all structural variants above 500 bp to reveal more answers and resolve previously unresolved cases from using NGS alone. There are over 15,000 NGS instruments installed globally and for each of these sequencers our vision is to complement with a mapper in Saphyr to provide a more comprehensive picture of the genome for more discoveries, publications and translation into molecular genetics. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Accelerate broad reimbursement for OGM and establish it as the standard of care in guidelines by professional medical societies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are investing in four multi-center clinical studies for postnatal, prenatal, hematologic malignancies and solid tumor analyses relative to standard of care. Each study is designed with an expectation for recruitment of 1,000 subjects and will assess sensitivity, specificity, reproducibility, concordance and incremental clinically relevant findings relative to standard of care. We are investing in these programs to build the necessary evidence to establish reimbursement and to pave the way for inclusion in professional society guidelines to advance standard of care. The first preliminary readout from the multicenter postnatal study was published in December 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Support the publication of findings with OGM by our customers beyond the more than 340 papers published to date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual number of publications featuring data generated by Saphyr and its predecessor system has steadily increased since 2010 when the first publication appeared. Recently, the overall number of these publications has grown significantly. For example, of the 340 peer-reviewed and pre-print papers published since 2019, 161 were published in 2021 alone. We intend to continue to support and foster our customer base to help grow the number of publications featuring our systems&#8217; data. We believe that these publications are impactful as our customers&#8217; studies cover structural variations in areas of high unmet medical need, such as rare and undiagnosed pediatric diseases, neurological and muscular diseases, developmental delays and disorders, prostate cancer and leukemia. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Continue to innovate our products and technologies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designed Saphyr to accommodate performance enhancements without the need for replacement of the entire instrument. For example, hardware upgrades and new consumables are made available to purchase by customers. We intend for these performance enhancements to be delivered on a regular basis. In addition, we periodically make available software upgrades to customers through download at no charge. We expect to continue developing and refining our technologies to improve the ease of use of our Saphyr system and enable our existing installed systems to meaningfully increase sample throughput and sensitivity and specificity of structural variation detection. A high throughput version is currently in development that is expected to significantly increase the throughput and lower the cost per sample. Compared to the Saphyr system, which images DNA at a rate of approximately 205 Gbp per hour, the new system is expected to image nearly 820 Gbp per hour and we announced the completion of this protype at the end of 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Partner with industry-leading companies and laboratories to expand adoption in clinical markets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establish additional collaborations with customers to help drive validating studies. Expand partnership efforts with clinical diagnostic companies to commercialize LDTs in the U.S. as well as LDTs and approved tests outside the U.S. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_40"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, our commercial team consisted of 152 individuals in sales, sales support and marketing. Our sales support personnel include individuals in customer solutions, field service engineers and field application specialists. This commercial staff is primarily located in North America, Europe, and China. Most of our sales support team is located at our headquarters in San Diego and some work remotely throughout the U.S., Europe, and China. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products through a direct sales force based in North America and Europe. Our sales strategy involves the use of a combination of sales managers and sales representatives. We expect to increase our sales force as we expand our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products through a network of distributors in the Asia-Pacific region and select other markets outside of North America and Europe. Specifically, we distribute our instruments and reagents via third-party distributors in markets such as China, Japan, South Korea, Singapore, Australia, India and South Africa. Three of our distributors are in China, one in Australia, one in Italy, one in Sweden, one in Japan and one in South Korea. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The role of our sales managers and sales representatives is to educate customers on the advantages of Saphyr and the applications that our system makes possible. The role of our field application specialists is to provide on-site training and scientific technical support to prospective and existing customers. Our field application specialists are technical experts with advanced degrees, including seven with PhDs., and generally have extensive experience in academic research and core sequencing lab experience. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we maintain an applications lab team in San Diego, California composed of scientific experts who can transfer knowledge from the research and development team to the field application specialists. The applications lab team also runs foundational scientific collaborations and proof of principle studies, which help demonstrate the value of our product offering to prospective customers. This team also provides commercial services by running samples on Saphyr for researchers who do not have a Saphyr system of their own.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to expand our sales, support, and marketing efforts in the future by expanding our direct footprint in North America and Europe as well as developing a more comprehensive support network in China where significant market opportunities exist. Additionally, we believe that there is significant opportunity in other European, South American, Asia-Pacific and Middle Eastern regions. We plan to expand into these regions via initial penetration with distributors. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systems are relatively new to the life science marketplace and require a capital investment by our customers. The sales process typically involves numerous interactions and demonstrations with multiple people within an organization. Some potential customers conduct in-depth evaluations of the system including having us run experiments on in-house Saphyr systems. In addition, in most countries, sales to academic or governmental institutions require participation in a tender process involving preparation of extensive documentation and a lengthy review process. Because of these factors and the budget cycles of our customers, our sales cycle, the time from initial contact with a customer to our receipt of a purchase order, can often be nine to 12 months. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily sell our suite of LDTs to pediatric physicians through a physician-directed &#8220;in-person&#8221; sales model. This commercial staff is located in North America, and the sales personnel primarily work remotely in U.S. states where we have obtained insurance reimbursement. Our sales and marketing efforts are targeted primarily on specialty pediatricians, including pediatric neurologists, medical geneticists, and developmental and behavioral pediatricians. We also target general pediatricians with large numbers of patients. Our managed care efforts are directed to establishing contracts and/or credentialing with private and governmental insurance carriers that provide coverage for patients with ASD and other forms of NDDs.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_43"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instruments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments are manufactured by a third-party medical device manufacturer. Nearly complete instruments are shipped by the manufacturer to us for final assembly and quality control testing. Upon completion, we ship directly to our customers&#8217; locations globally, or distributors&#8217; locations in the case of certain systems sold in the Asia-Pacific region. Installation of, and training on, our products is provided by our employees in the markets where we conduct direct sales, and by distributors in those markets where we operate with distributors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe this manufacturing strategy is efficient and conserves capital. However, in the event it becomes necessary to utilize a different contract manufacturer, we would experience additional costs, delays and difficulties in doing so, and our business could be harmed. This manufacturer actively manages obsolescence of all components in our system. This is done through their supply management process where we get notified of any parts that will become obsolete with enough lead time to identify alternatives. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumables </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our chip consumables are produced by a third-party manufacturer at its facility; however, we have established procedures for a replacement manufacturer if required. We complete final assembly and quality control assessments of our chips at our headquarters in San Diego. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reagents are sourced from a limited number of suppliers, including certain single source suppliers. Reagents include all components required to run a sample on OGM, such as capture and detector reagents, enzyme reagents and enzyme substrate. Although we believe that alternatives would be available, it would take time to identify and validate replacement reagents for our assay kits, which could negatively affect our ability to supply assay kits on a timely basis. Reagents are supplied through a single source supplier. This supplier requires a sufficient notification period to allow for supply continuity and the identification and technology transfer to a new supplier in the event either party wishes to terminate the relationship. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage component obsolescence by subscribing to our vendors&#8217; end-of-life notifications. If a vendor is unable to provide sufficient notification, we keep safety stock of the component to minimize disruption to operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing and Supply </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing strategy is to outsource instrument and chip manufacturing and internally develop and assemble reagent kits in our own facility. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fundamental long-term software strategy is based on our goal of making OGM ubiquitous with increased utilization through simplified data interpretation and a seamless integration with NGS and array data to provide the most compressive genome analysis.  In addition, we can participate directly in the NGS and array markets for genetic disease and cancer applications independent of OGM using a monetization model with a pay-per-sample NxClinical software offering. In this manner we can expand our network of Bionano customers into our software ecosystem with among the most comprehensive platform-agnostic genome interpretation solution where our proprietary original content in OGM can be adopted when needed to obtain a more comprehensive view of the genome by revealing all classes of structural variants. We plan on continuing to enable OGM users with the full solution with software at no additional charge while we monetize the per sample utilization for NGS.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Testing and Laboratory Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Labs OGM testing is performed at our lab in San Diego, or at our partner labs in the United States and Europe. We intend to increase our testing capacity, expand our menu of testing, and pursue CLIA certification for the San Diego lab. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For diagnostic testing currently through our Lineagen subsidiary, we maintain contracts with a network of laboratories to perform the wet work on our various LDT tests in order to conserve capital and maintain flexibility of adjusting contract lab based on the best-in-class/most updated technology and customer service. As of December 31, 2021, we have established contracts with two primary laboratories to perform wet lab services. All third-party laboratories have met stringent criteria, including passing a site visit from our management, and being CAP and CLIA-certified. We obtain raw data from laboratories for interpretation and reporting. Our short-term strategy is to augment our existing test menu with OGM based LDT&#8217;s.  Eventually, we intend to convert these tests to OGM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Agreements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Princeton University </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2004, we entered into a license agreement, or the License Agreement, with Princeton University, or Princeton. Pursuant to the License Agreement, we received a worldwide, exclusive right and license to, among other things, manufacture and market products or services utilizing patents and inventions related to our sample preparation, DNA imaging and genomic data analysis platform and other key technology. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to pay Princeton an annual license maintenance fee in the mid-four digits, which can be reduced by royalties paid to Princeton during the preceding 12 month period. We are also obligated to make royalty payments to Princeton equal to (i) a percentage in the mid-single digits of our and any of our sub-licensees&#8217; net sales of products covered by the License Agreement and (ii) a percentage in the low-single digits of our and any of our sub-licensees&#8217; revenue from services covered by the License Agreement. Our royalty obligations continue on a licensed product-by-licensed product and licensed service-by-licensed service basis, in every country of the world, until the later of the last sale of a licensed product or service or the expiration of all Princeton patent rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the License Agreement will continue until all of our royalty payment obligations have expired, unless terminated earlier. Princeton may terminate the License Agreement upon written notice in the event of our material breach of the License Agreement if such breach remains uncured for 60 days. We may terminate the License Agreement without cause upon 60 days&#8217; advance written notice to Princeton. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement for the Manufacture of Our Instruments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged a single third-party manufacturer to produce and test our instruments on an as-ordered basis. The manufacturer of our instruments has no obligation to manufacture our instruments without a purchase order. In addition, this manufacturer has no obligation to maintain inventory in excess of any open purchase orders or materials in excess of the amount it reasonably determines will be consumed within 90 days. We are obligated to purchase any material deemed in excess pursuant to the agreement. The price we pay is determined according to a mutually agreed-upon pricing formula. We may terminate a purchase order by giving the manufacturer at least 30 days&#8217; written notice. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement for the Manufacture of Our Chip Consumables </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged a single third-party manufacturer to manufacture our chip consumables used in our Saphyr system and provide engineering services to us. This third-party has no obligation to manufacture our chip consumables without a purchase order. The prices and fees we pay are established in our agreement with this manufacturer or determined by the manufacturer pursuant if supported by appropriate information. Our agreement with this manufacturer automatically renews for successive one year terms unless a party notifies the other party in writing at least 30 days prior to the expiration of the then-current term. We may terminate an order of the agreement at any time upon 30 days&#8217; written notice. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_46"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genome Analysis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core technology for nucleic acid research is related to methods and devices for non-sequencing based analysis of macromolecules such as nucleic acids. Using this technology, long (high-molecular weight) nucleic acids can be suitably labeled and elongated in order to ascertain structural information such as scaffold organization, copy number, and genomic repeats that is not readily obtained with current sequencing-based approaches. We have secured and continue to pursue intellectual property rights globally, including rights related to analysis of nucleic acid molecules, as well as innovations in the molecular biology and bioinformatics spaces. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a global patent portfolio that includes 101 issued patents or allowed applications across 26 patent families and an exclusively licensed portfolio of patents and applications from Princeton University, which includes 35 patents across two families. The global patent portfolio owned and licensed by us has effective filing dates ranging from 2001 to 2018. The owned and licensed patent families contain issued patents and pending applications that relate to devices, systems, and methods for macromolecular analysis, genetic testing, computer software systems and reflect our active and ongoing research programs.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to pursuing patents, we have taken steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, as applicable, advisors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diagnostic Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lineagen, Inc. has registered trademarks to certain of its genetic testing services and a patent portfolio of patent applications that relate to diagnostic tests and methods to diagnose or predict disease by detecting one or more of ASD-associated CNVs, methods for assessing the presence or absence of a chromosomal deletion or duplication syndrome and methods of selecting patients for treatment based on such assessments, probe compositions, and related PCR-based methods of diagnosis by detecting ASD-associated SNPs and / or CNVs, methods for treating Wolf-Hirschhorn syndrome (4P- syndrome) seizures with cannabidiol or with vitamin B6 combination in patients with deletion of particular seizure susceptibility region, and has exclusively licensed a method of identifying a genome sequence mutation that is linked to causality of a disease using computer program product from The Hospital for Sick Children (SickKids) in in Toronto, Canada.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioDiscovery has over 25 years of experience in development of software and algorithms for analysis, visualization, and interpretation of genomic data. It has amassed a large base of commercial grade code along with expertise in multi-modal data integration with specific methods for copy number analysis. In addition to patents for microarray array data and image analysis, it has developed CNV segmentation algorithms called SNP-Rank and Fast Adaptive State Segmentation Technology (FASST). Additionally, the company BioDiscovery invented the Multi-Scale Reference (MSR) algorithm for CNV detection from NGS data.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_49"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to and impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and internationally. These include laws and regulations particular to our business and laws and regulations relating to conducting business generally (e.g., export controls laws, U.S. Foreign Corrupt Practices Act and similar laws of other jurisdictions). We also are subject to inspections and audits by governmental agencies. Set forth below are highlights of certain key regulatory schemes applicable to our business. Below are discussions concerning government regulation of our Optical Genome Mapping, or OGM, products and services and, separately, our Diagnostic Services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Optical Genome Mapping</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our OGM products are currently intended for research use only, or RUO, applications, although our customers may use our products to develop their own products that are subject to regulation by the FDA. Although most products intended for RUO are not currently subject to clearance or approval by the FDA, RUO products fall under the FDA&#8217;s jurisdiction if they are used for clinical rather than research purposes. Consequently, our products are labeled &#8220;For Research Use Only.&#8221; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s 2013 Guidance for Industry and Food and Drug Administration Staff on &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only,&#8221; or, the RUO/IUO Guidance, provides the FDA&#8217;s thinking on when IVD products are properly labeled for RUO or for IUO. The RUO/IUO Guidance explains that the FDA will review the totality of the circumstances when evaluating whether equipment and testing components are properly labeled as RUO. Merely including a labeling statement that a product is intended for research use only will not necessarily exempt the device from the FDA&#8217;s 510(k) clearance, premarket approval, or other requirements, if the circumstances surrounding the distribution of the product indicate that the manufacturer intends its product to be used for clinical diagnostic use. These circumstances may include written or verbal marketing claims or links to articles regarding a product&#8217;s performance in clinical applications, a manufacturer&#8217;s provision of technical support for clinical validation or clinical applications, or solicitation of business from clinical laboratories, all of which could be considered evidence of intended uses that conflict with RUO labeling. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When marketed for clinical diagnostic use, our products will be regulated by the FDA as medical devices. The FDA defines a medical device in part as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article which is intended for the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease in man. FDA regulates the development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of medical devices. The FDA also requires the device to be registered by the medical device manufacturer and listed as a marketed product. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA classifies medical devices into one of three classes on the basis of the intended use of the device, the risk associated with the use of the device for that indication, as determined by the FDA, and on the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. Class I devices, which have the lowest level of risk associated with them, are subject to general controls. Class II devices are subject to general controls and special controls, including performance standards. Class III devices, which have the highest level of risk associated with them, are subject to general controls and premarket approval. Most Class I devices and some Class II devices are exempt from a requirement that the manufacturer submit a premarket notification, or 510(k), and receive clearance from the FDA which is otherwise a </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">premarketing requirement for a Class II device. Class III devices may not be commercialized until a premarket approval application, or PMA, is submitted to and approved by the FDA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">510(k) Clearance Pathway </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain 510(k) clearance, a sponsor must submit to the FDA a premarket notification demonstrating that the device is substantially equivalent, or SE, to a device legally marketed in the U.S. for which a PMA was not required. The FDA is supposed to make a SE determination within 90 days of FDA&#8217;s receipt of the 510(k), but it often takes longer if the FDA requests additional information. Most 510(k)s do not require supporting data from clinical trials, but the FDA may request such data. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premarket Approval Pathway </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A PMA must be submitted if a new device cannot be cleared through the 510(k) process. The PMA process is generally more complex, costly and time consuming than the 510(k) process. A PMA must be supported by extensive data including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device for its intended use. After a PMA is sufficiently complete, the FDA will accept the application for filing and begin an in-depth review of the submitted information. By statute, the FDA has 180 days to review the accepted application, although, review of the application generally can take between one and three years. During this review period, the FDA may request additional information or clarification of information already provided. Also during the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will conduct a preapproval inspection of the manufacturing facility to ensure compliance with its quality system regulations, or QSRs. New premarket approval applications or premarket approval application supplements are also required for product modifications that affect the safety and efficacy of the device. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are usually required to support a PMA and are sometimes required for a 510(k). In the U.S., if the device is determined to present a &#8220;significant risk,&#8221; the manufacturer may not begin a clinical trial until it submits an investigational device exemption application, or IDE, and obtains approval of the IDE from the FDA. These clinical trials are also subject to the review, approval and oversight of an institutional review board, or IRB, at each clinical trial site. The clinical trials must be conducted in accordance with the FDA&#8217;s IDE regulations and good clinical practices. A clinical trial may be suspended by the FDA, the sponsor or an IRB at its institution at any time for various reasons, including a belief that the risks to the study participants outweigh the benefits of participation in the trial. Even if a clinical trial is completed, the results may not demonstrate the safety and efficacy of a device to the satisfaction of the FDA, or may be equivocal or otherwise not be sufficient to obtain approval of a device. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a medical device is placed on the market, numerous regulatory requirements apply. These include among other things: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with QSRs, which require manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reporting of device malfunctions, serious injuries or deaths;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Registration of the establishments where the devices are produced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Labeling regulations, which prohibit the promotion of products for uncleared or unapproved uses; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical device reporting obligations, which require that manufacturers investigate and report to the FDA adverse events, including deaths, or serious injuries that may have been or were caused by a medical device and malfunctions in the device that would likely cause or contribute to a death or serious injury if it were to recur. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions, including but not limited to, warning letters; fines, injunctions, and civil penalties; recall or seizure of the device; operating restrictions, partial suspension or total shutdown of production; refusal to grant 510(k) clearance or PMA approvals of new devices; withdrawal of 510(k) clearance or PMA approvals; and civil or criminal prosecution. To ensure compliance with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced inspections by the FDA. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laboratory Developed Tests (LDTs)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agencies involved in the regulation of LDTs include CMS and the FDA. CMS regulates the quality of clinical laboratories and the clinical testing process pursuant to the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and the FDA regulates the safety and effectiveness of the diagnostic test pursuant to authorities in the Federal, Food, Drug, and Cosmetic Act (FDCA). Although the FDA has statutory authority to regulate medical devices, the FDA has historically exercised its enforcement discretion and not enforced applicable provisions of the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDCA and FDA regulations with respect to LDTs, which are a subset of in vitro diagnostic tests that are intended for clinical use and designed, manufactured and used entirely within a single laboratory. The FDA does not consider devices to be LDTs if they are designed or manufactured completely, or partly, outside of the laboratory that offers and uses them. We sell our Saphyr system on an RUO basis to CLIA certified cytogenetic laboratories, which may use the system to develop LDTs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At various times since 2006, the FDA has issued documents outlining its intent to require varying levels of FDA oversight of many types of LDTs.  Congress has also considered legislation that would change how LDTs are regulated. It is unclear at this time if or when the FDA will finalize its plans to end enforcement discretion for LDTs, and even then, whether the new regulatory requirements are expected to be phased-in over time. However, the FDA may decide to regulate certain LDTs on a case-by-case basis at any time. A significant change in the way that the FDA regulates any LDTs that we, our collaborators, or our customers develop using our technology could affect our business. If the FDA requires laboratories to undergo premarket review and comply with other applicable FDA requirements in the future, the cost and time required to commercialize an LDT will increase substantially and may reduce the financial incentive for laboratories to develop LDTs, which could reduce demand for our instruments and our other products. In addition, if the FDA were to change the way that it regulates LDTs to require that we undergo pre-market review or comply with other applicable FDA requirements before we can sell our instruments or our other products to clinical cytogenetics laboratories, our ability to sell our instruments and other products to this addressable market would be delayed, thereby impeding our ability to penetrate this market and generate revenue from sales of our instruments and our other products. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Europe/Rest of World Government Regulation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the commencement of clinical trials or marketing of our product for clinical diagnostic use in those countries. The regulations in other jurisdictions vary from those in the U.S. and may be easier or more difficult to satisfy and are subject to change. For example, the European Union recently published new regulations that will result in greater regulation of medical devices and IVDs. The IVD Regulation is significantly different from the IVD Directive that it replaces in that it will ensure that the new requirements apply uniformly and on the same schedule across the member states, including a risk-based classification system and increasing the requirements for conformity assessment. The conformity assessment process results in the receipt of a CE designation which has been sufficient to begin marketing many types of IVDs. That process will become more difficult and costly to complete.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Governmental Regulation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations related to the protection of the environment, the health and safety of employees and the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials. For example, the U.S. Occupational Safety and Health Administration has established extensive requirements relating specifically to workplace safety for healthcare employers in the U.S. This includes requirements to develop and implement multi-faceted programs to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries. For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject to regulation by one or more of the following agencies: the U.S. Department of Transportation, the U.S. Public Health Service, the U.S. Postal Service and the International Air Transport Association. We generally use third-party vendors to dispose of regulated medical waste, hazardous waste and radioactive materials that we may use during our research.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratories that purchase certain of our OGM products and perform clinical diagnostic testing are also subject to extensive regulation under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, requiring clinical laboratories to meet specified standards in areas such as personnel qualifications, administration, participation in proficiency testing, patient test management, quality control, quality assurance and inspections. Adverse interpretations of current CLIA regulations or future changes in CLIA regulations could have an adverse effect on sales of any affected products. Moreover, if we decide to operate our own clinical testing laboratory with respect to our OGM products, such clinical testing would require compliance with CLIA. If, in the future, we operate our own clinical laboratory to perform clinical diagnostic testing with respect to our OGM products, such activities would become subject to the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and its corresponding regulations, as well as additional federal and state laws that impose a variety of fraud and abuse prohibitions on healthcare providers, including clinical laboratories. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our OGM product, Saphyr, is for research use only, but clinical laboratories may acquire our instrumentation through a capital purchase or capital lease and use the Saphyr and direct label stain chemistry to create their own potentially reimbursable products, such as laboratory developed tests for in vitro diagnostics. Our customers may generate revenue for these testing services by seeking the necessary approval of their product from the FDA or CMS, along with coverage and reimbursement from third-party payors, including government health programs and private health plans. The ability of our customers to commercialize diagnostic tests based on our technology will depend in part on the extent to which coverage and reimbursement for these tests will be available from such third-party payors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., molecular testing laboratories have multiple options for reimbursement coding, but we expect that the primary codes used will be the genomic sequencing procedure codes, or GSPs. The American Medical Association, or AMA, added GSPs to its clinical laboratory fee schedule in 2015. In addition, CMS recently issued a coverage determination providing for the reimbursement of next-generation sequencing for certain cancer diagnostics using an FDA-approved in vitro diagnostic test. Private health plans often follow CMS coverage and reimbursement guidelines to a substantial degree, and it is difficult to predict what CMS will decide with respect to the coverage and reimbursement of any products or services our customers try to commercialize. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, coverage for molecular diagnostic testing is varied. Countries with statutory health insurance (e.g., Germany, France, The Netherlands) tend to be more progressive in technology adoption with favorable reimbursement for molecular diagnostic testing. In countries such as the United Kingdom with tax-based insurance, adoption and reimbursement for molecular diagnostic testing is not uniform and is influenced by local budgets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, coverage and reimbursement of new products and services is uncertain, and whether laboratories that use our instruments to develop their own products or services will attain coverage and adequate reimbursement is unknown. In the U.S., there is no uniform policy for determining coverage and reimbursement. Coverage can differ from payor to payor, and the process for determining whether a payor will provide coverage may be separate from the process for setting the reimbursement rate. In addition, the U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls and restrictions on reimbursement.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diagnostic Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Laboratory Improvement Amendments of 1988 and State Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical laboratory, we are required to hold certain federal and state licenses, certifications and permits to conduct our business. As to federal certifications, in 1988, Congress passed the CLIA, establishing more rigorous quality standards for all commercial laboratories that perform testing on human specimens for the purpose of providing information for the diagnosis, prevention, or treatment of disease or the assessment of the health or impairment of human beings. CLIA requires such laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure the accuracy, reliability and timeliness of patient test results. CLIA certification is also a prerequisite to be eligible to bill state and federal healthcare programs, as well as many commercial third-party payers, for laboratory testing services. Our laboratory located in Salt Lake City, Utah is CLIA certified. This laboratory must comply with all applicable CLIA requirements. If a clinical laboratory is found to be out of compliance with CLIA standards, CMS may impose sanctions, limit or revoke the laboratory&#8217;s CLIA certificate (and prohibit the owner, operator or laboratory director from owning, operating, or directing a laboratory for two years following license revocation), a directed plan of correction, on-site monitoring, civil monetary penalties, civil actions for injunctive relief, criminal penalties, or suspension or exclusion from the Medicare and Medicaid programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIA provides that a state may adopt laboratory licensure requirements and regulations that are more stringent than those under federal law and requires compliance with such laws and regulations. The State of Utah follows all CLIA regulations for laboratory facility and personnel requirements. Utah does not have any additional licensure and regulations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratory in Salt Lake City, Utah has also been accredited by the College of American Pathologists, or CAP, which means that our laboratory has been certified as following CAP standards and guidelines in operating the laboratory facility and in performing tests that ensure the quality of our test results. Further, certain states require clinical laboratories to obtain licenses to test specimens from patients, or to receive orders from physicians, within those states. We hold such out-of-state laboratory licenses in California, Pennsylvania, and Maryland</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HIPAA and other Privacy Laws </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), established comprehensive federal standards for the privacy and security of health information. The HIPAA standards apply to three types of organizations: health plans, healthcare clearing houses, and healthcare providers that conduct certain healthcare transactions electronically (&#8220;Covered Entities&#8221;). Title II of HIPAA, the Administrative Simplification Act, contains provisions that address the privacy of health data, the security of health data, the standardization of identifying numbers used in the healthcare system and the standardization of certain healthcare transactions. The privacy regulations protect medical records and other protected health information by, among other things, limiting their use and release, giving patients the right to access their medical records and limiting most disclosures of health information to the minimum amount necessary to accomplish an intended purpose. The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security policies and procedures. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act, or HITECH, provisions of the American Recovery and Reinvestment Act of 2009. HITECH expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance and established new breach notification requirements for Covered Entities. Regulations implementing major provisions of HITECH were finalized on January 25, 2013 through publication of the HIPAA Omnibus Rule (the &#8220;Omnibus Rule&#8221;). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under HITECH's breach notification requirements, Covered Entities must report breaches of protected health information that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of the U.S. Department of Health and Human Services (the &#8220;Secretary&#8221;). Required breach notices must be made as soon as is reasonably practicable, but no later than 60 days following discovery of the breach. Reports must be made to affected individuals and to the Secretary and, in some cases depending on the size of the breach, they must be reported through local and national media. Breach reports can lead to investigation, enforcement and civil litigation, including class action lawsuits. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our clinical diagnostic services, we are currently subject to HIPAA and maintain an active compliance program that is designed to identify security incidents and other issues in a timely fashion and enable us to remediate, mitigate harm or report if required by law. We are subject to prosecution and/or administrative enforcement and increased civil and criminal penalties for non-compliance, including a new, four-tiered system of monetary penalties adopted under HITECH. We are also subject to enforcement by state attorneys general who were given authority to enforce HIPAA under HITECH. To mitigate penalties under the HITECH breach notification provisions, we must ensure that breaches of protected health information are promptly detected and reported within the company, so that we can make all required notifications on a timely basis. However, even if we make required reports on a timely basis, we may still be subject to penalties for the underlying breach. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the federal privacy and security regulations, there are a number of state laws regarding the privacy and security of health information and personal data that are applicable to our clinical laboratories. Many states have also implemented genetic testing and privacy laws imposing specific patient consent requirements and protecting test results by strictly limiting the disclosure of those results. State requirements are particularly stringent regarding predictive genetic tests, due to the risk of genetic discrimination against healthy patients identified through testing as being at a high risk for disease. We believe that we have taken the steps required of us to comply with health information privacy and security statutes and regulations, including genetic testing and genetic information privacy laws in all jurisdictions, both state and federal. However, these laws constantly change, and we may not be able to maintain compliance in all jurisdictions where we do business. Failure to maintain compliance, or changes in state or federal laws regarding privacy or security could result in civil and/or criminal penalties, significant reputational damage and could have a material adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The General Data Protection Regulation (&#8220;GDPR&#8221;), which applies to all EU member states from May 25, 2018, also applies to some of our operations. The GDPR is discussed in more detail elsewhere in this report. The GDPR applies not only to organizations within the EU, but also applies to organizations outside of the EU that offer goods or services to EU data subjects or that process or hold personal data of EU data subjects. The regulation specifies higher potential liabilities for certain data protection violations, and we anticipate that it will result in a greater compliance burden for us as we conduct our business in the European Union. Fines for non-compliance can range from the greater of 2% of annual global revenues or &#8364;10 million, up to the greater of 4% of annual global revenues or &#8364;20 million. The GDPR is discussed in more detail under the heading &#8220;International Regulations&#8221; below.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transparency Laws and Regulations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A federal law known as the Physician Payments Sunshine Act (the &#8220;Sunshine Act&#8221;) requires certain medical device manufacturers to track and report to the federal government certain payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals and ownership or investment interests held by physicians and their immediate family members. Manufacturers must report data for the previous calendar year by the 90th day of the then-current calendar year. CMS then publishes the data on a publicly available website no later than June 30th. There are also state &#8220;sunshine&#8221; laws that require manufacturers to provide reports to state governments on pricing and marketing information. Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing activities, and such laws may also prohibit or limit certain other sales and marketing practices. These laws may adversely affect our sales, marketing, and other activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or to otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement and Billing </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement and billing for diagnostic services is highly complex. Laboratories must bill various payors, such as private third-party payors, including managed care organizations (&#8220;MCO&#8221;), and state and federal health care programs, such as Medicare and Medicaid, and each may have different billing requirements. Additionally, the audit requirements we must meet to ensure compliance with applicable laws and regulations, as well as our internal compliance policies and procedures, add further complexity to the billing process. Other factors that complicate billing include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variability in coverage and information requirements among various payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient financial assistance programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">missing, incomplete or inaccurate billing information provided by ordering physicians; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">billings to payors with whom we do not have contracts; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes with payors as to which party is responsible for payment; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes with payors as to the appropriate level of reimbursement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the reimbursement arrangement and applicable law, the party that reimburses us for our services may be: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third-party who provides coverage to the patient, such as an insurance company or MCO; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a state or federal healthcare program; or </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presently, approximately 90% of our diagnostic service revenue is paid by private third-party payors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Fraud and Abuse Laws </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of state and federal laws prohibit fraud and abuse involving state and federal health care programs, such as Medicare and Medicaid. These laws are interpreted broadly and enforced aggressively by various state and federal agencies, including CMS, the Department of Justice, the Office of Inspector General for the Department of Health and Human Services (&#8220;OIG&#8221;), and various state agencies. In addition, the Medicare and Medicaid programs increasingly use a variety of contractors to review claims data and to identify improper payments as well as fraud and abuse. Any overpayments must be repaid within 60 days of identification unless a favorable decision is obtained on appeal. In some cases, these overpayments can be used as the basis for an extrapolation, by which the error rate is applied to a larger set of claims, and which can result in even higher repayments. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback Laws </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program. &#8220;Remuneration&#8221; is broadly defined to include anything of monetary value, such as, for example, cash payments, gifts or gift certificates, discounts, or the furnishing of services, supplies or equipment. The Anti-Kickback Statute can be interpreted broadly to prohibit many arrangements and practices that are lawful in businesses outside of the health care industry. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognizing the potential breadth of interpretation of the Anti-Kickback Statute and the fact that it may technically prohibit many otherwise innocuous or beneficial arrangements within the health care industry, the OIG has issued a series of regulations, or safe harbors intended to protect such arrangements. Compliance with all requirements of a safe harbor immunizes the parties to the business arrangement from prosecution under the Anti-Kickback Statute. The failure of a business arrangement to fit within a safe harbor does not necessarily mean that the arrangement is illegal or that the OIG will pursue prosecution but would be evaluated on a case-by-case basis. Still, in the absence of an applicable safe harbor, a violation of the Anti-Kickback Statute may occur even if only one purpose of an arrangement is to induce referrals. The penalties for violating the Anti-Kickback Statute can be severe. These sanctions include criminal, civil and administrative penalties, imprisonment and possible exclusion from the federal health care programs. Many states have adopted laws similar to the Anti-Kickback Statute, and some apply to items and services reimbursable by any payor, including private third-party payors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, prohibits payments for referrals to recovery homes, clinical treatment facilities, and laboratories. EKRA&#8217;s reach extends beyond federal health care programs to include private insurance (i.e., it is an &#8220;all payor&#8221; statute). For purposes of EKRA, the term &#8220;laboratory&#8221; is defined broadly and without reference to any connection to substance use disorder treatment. The law includes a limited number of exceptions, some of which closely align with corresponding federal Anti-Kickback Statute exceptions and safe harbors, and others that materially differ. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Self-Referral Bans </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal ban on physician self-referrals, commonly known as the Stark Law, prohibits, subject to certain exceptions, physician referrals of Medicare patients to an entity providing certain designated health services, which include laboratory services, if the physician or an immediate family member of the physician has any financial relationship with the entity. Several Stark Law exceptions are relevant to arrangements involving clinical laboratories, including but not limited to: (1) fair market value compensation for the provision of items or services; (2) payments by physicians to a laboratory for clinical laboratory services; (3) certain space and equipment rental arrangements that satisfy certain requirements; and (4) personal services arrangements. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties and possible exclusion from federal health care programs. In addition to the Stark Law, many states have their own self-referral bans, which may extend to all self-referrals, regardless of the payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State and Federal Prohibitions on False Claims </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government. Under the False Claims Act, a person acts knowingly if he or she has actual knowledge of the information or acts in deliberate ignorance or in reckless disregard of the truth or falsity of the information. Specific intent to defraud is not required. The qui tam provisions of the False Claims Act allow a private individual to bring an action on behalf of the federal government and to share in any amounts paid by the defendant to the government in connection with the action. Penalties include payment of up to three times the actual damages sustained by the government, plus significant civil penalties, as well as possible exclusion from federal health care programs. In addition, various states have enacted similar laws modeled after the False Claims Act that apply to items and services reimbursed under Medicaid and other state health care programs, and, in several states, such laws apply to claims submitted to any payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Civil Monetary Penalties Law </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Civil Monetary Penalties Law, or the CMP Law, prohibits, among other things, (1) the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies; (2) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal health care program; (3) billing for services requested by an unlicensed physician or an excluded provider; and (4) billing for medically unnecessary services. The penalties for violating the CMP Law include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Penalties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the aforementioned fraud and abuse laws could result in significant penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, additional integrity oversight and reporting obligations, imprisonment, contractual damages, and reputational harm. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market some of our tests outside of the United States and are subject to foreign regulatory requirements governing laboratory licensure, human clinical testing, use of tissue, privacy and data security, and marketing approval for our tests. These requirements vary by jurisdiction, differ from those in the United States and may require us to implement additional compliance measures or perform additional pre-clinical or clinical testing. For example, the In Vitro Diagnostic Medical Devices (2017/746/EU) (&#8220;IVDR&#8221;) will replace the existing In Vitro Diagnostic Medical Devices Directive (98/79/EC) (&#8220;IVDD&#8221;) in the European Union (&#8220;EU&#8221;). The IVDR was published in May 2017, marking the start of a five-year period of transition from the IVDD. During the transitional period the IVDR will come into force gradually, starting with the provisions related to the designation of Notified Bodies and the ability of manufacturers to apply for new certificates under the IVDR. The transitional period will end on 26 May 2022, the &#8220;Date of Application&#8221; (&#8220;DoA&#8221;) of the Regulation. From that point the IVDR will apply fully. The EU has also implemented the General Data Protection Regulation, or GDPR, which requires us to meet new and more stringent requirements regarding the handling of personal data about European Union residents. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required. We are also required to maintain accurate information on and control over sales and distributors&#8217; activities that may fall within the purview of the Foreign Corrupt Practices Act, its books and records provisions and its anti-bribery provisions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratory is subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemical, biological agents and compounds, blood and bone marrow samples and other human tissue. Typically, we use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations related to the protection of the environment, the health and safety of employees and the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials. For example, the U.S. Occupational Safety and Health Administration (&#8220;OSHA&#8221;) has established extensive requirements relating specifically to workplace safety for healthcare employers in the U.S. This includes requirements to develop and implement multi-faceted programs to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries. For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject to regulation by one or more of the following agencies: the U.S. Department of Transportation, the U.S. Public Health Service, the United States Postal Service, the Office of Foreign Assets Control, and the International Air Transport Association. We generally use third-party vendors to dispose of regulated medical waste, hazardous waste and radioactive materials and contractually require them to comply with applicable laws and regulations.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and abroad, there have been and continue to be a number of legislative initiatives to contain healthcare costs and change the way healthcare is financed. By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, President Trump signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA, such as removing penalties, effective January 1, 2019, for not complying with the ACA's individual mandate to carry health insurance. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form.  Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on April 1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things, significantly altered the payment methodology under the Medicare Clinical Laboratory Fee Schedule, or CLFS. PAMA requires certain laboratories performing clinical diagnostic laboratory tests to report to CMS the amounts paid by private payors for laboratory tests. Beginning on January 1, 2018, CMS has begun using reported private payor pricing to periodically revise payment rates under the CLFS. Based on current law, between January 1, 2023 and March 31, 2023, applicable laboratories will be required to report on data collected during January 1, 2019 and June 30, 2019. This data will be utilized to determine 2024 to 2026 CLFS rates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services. For example, Congress is considering additional health reform measures. In addition, sales of our tests outside of the U.S. will subject us to foreign regulatory requirements, which may also change over time. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are directly or indirectly, through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal and state anti-kickback statutes and false claims laws. These laws may impact, among other things, our sales and marketing and education programs, and our financial and business relationships with researchers who use our instruments to develop marketed products or services. By way of example: the federal Anti-Kickback Statute prohibits, among other things, any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, to induce, or in return for, purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item, or service reimbursable, in whole or in part, under a federal healthcare program; and the federal false claims laws, including, without limitation the federal civil False Claims Act, prohibit, among other things, anyone from knowingly and willingly presenting, or causing to be presented for payment, to the federal government (including Medicare and Medicaid) claims for reimbursement for, among other things, drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. The ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute to clarify that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a crime. In addition, the ACA clarifies that the government may assert that a claim that includes items or service resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, prohibits payments for referrals to recovery homes, clinical treatment facilities, and laboratories. EKRA&#8217;s reach extends beyond federal health care programs to include private insurance (i.e., it is an &#8220;all payor&#8221; statute). For purposes of EKRA, the term &#8220;laboratory&#8221; is defined broadly and without reference to any connection to substance use disorder treatment. The law includes a limited number of exceptions, some of which closely align with corresponding federal Anti-Kickback Statute exceptions and safe harbors, and others that materially differ. Additionally, the Stark Law, which prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any non-governmental third-party payors, including private insurers. In addition, we may be subject to HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers and their business associates who create, use or disclose individually identifiable health information on their behalf. We may also be subject to state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of these laws, we may be subject to significant penalties, including, without limitation, civil, criminal, and administrative penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, additional integrity oversight and reporting obligations, imprisonment, contractual damages, and reputational harm. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 299 employees, of which 152 work in sales, sales support and marketing, 80 work in research and development, 34 work in operations and 33&#160;work in general and administrative. As of December&#160;31, 2021, of our 299 employees, 251 were located in the U.S. and 48 were employed outside the U.S. None of our employees are represented by a labor union or are subject to a collective bargaining agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of stock-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_55"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were formed in January 2003 as BioNanomatrix LLC, a Delaware limited liability company. In August 2007, we became BioNanomatrix Inc., a Delaware corporation. In October 2011, we changed our name to BioNano Genomics, Inc., and in July 2018, we changed our name to Bionano Genomics, Inc. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 9540 Towne Centre Drive, Suite 100, San Diego, California 92121, and our telephone number is (858) 888-7600. Our website address is www.bionanogenomics.com. Information contained in, or that can be accessed through, our website is not incorporated by reference into this Annual Report, and you should not consider information on our website to be part of this Annual Report. Our design logo, &#8220;Bionano,&#8221; and our other registered and common law trade names, trademarks and service marks are the property of Bionano Genomics, Inc. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access to our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to these reports filed with or furnished to the SEC, may be obtained through the investor section of our website at http://www.bionanogenomics.com. We do not charge for access to and viewing of these reports. Information in the investor section and on our website is not part of this Annual Report on Form 10-K or any of our other securities filings. Our filings with the SEC may be accessed through the SEC&#8217;s website at www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included unless otherwise specified, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1868"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this Annual Report, including our financial statements and related notes appearing below. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition or results of operations. In such case, the trading price of our securities could decline. This Annual Report also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1881"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our financial condition and need for additional capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early commercial-stage company and have a limited commercial-history, which may make it difficult to evaluate our current business and predict our future performance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an early commercial-stage company and have a limited commercial history. Our limited commercial history may make it difficult to evaluate our current business and, especially when combined with the other risk factors listed in this section, makes predictions about our future success or viability subject to significant uncertainty. In particular, we have significantly increased our headcount through recent acquisitions of other businesses and the expansion of our sales, marketing and research and development teams, which has increased our operating costs in a manner not historically reflected in our consolidated financial statements, and plan to further increase headcount as we expand our operations. Our business model has evolved over time, and combined with our recent acquisitions, this has impacted the composition and concentration of our revenues, which we expect to continue to change with any future acquisitions and further expansion of our operations. These changes, among others, may make it difficult to evaluate our current business, assess our future performance relative to prior performance and accurately predict our future performance. We have encountered in the past, and will continue to encounter in the future, risks and difficulties frequently experienced by early commercial-stage companies, including those associated with scaling up our infrastructure, increasing the size of our organization and integrating acquired businesses. If we do not address these risks </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successfully, or if our assumptions regarding these risks and uncertainties are incorrect or change over time, our results of operations could differ materially from our expectations and our business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred recurring net losses since we were formed and expect to incur losses in the future. We cannot be certain that we will achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred recurring net losses. We incurred net losses of $72.4&#160;million and $41.1&#160;million, and used cash in operations of $71.9&#160;million and $38.3&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $216.1&#160;million. We cannot predict if we will be profitable in the near future or at all. We expect that our losses will continue for the foreseeable future as we plan to invest significant additional funds toward the expansion of our commercial organization, research and development efforts and capital expenditures, among other things. Our recent acquisitions have increased our expenses and we expect that any future acquisitions of businesses, assets, products or technologies will further increase our expenses, which may result in additional losses. We also expect significant increases in our stock-based compensation expense in future periods, reflecting higher stock option valuations as a public company and the issuance of additional equity awards due to increased headcount. In addition, we incur significant legal, accounting and other expenses as a result of being a public company, especially as we no longer qualify as an emerging growth company or a smaller reporting company and are therefore required to comply with additional disclosure and compliance requirements, subject to a transition period. These factors, among others, will make it hard for us to achieve and sustain profitability. We may also incur significant losses in the future for a number of other reasons, many of which are beyond our control, including the level of market acceptance of our products, the introduction of competitive products and technologies, our future product development efforts, our market penetration and our margins, as well as the other risks described below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, which makes our future operating results difficult to predict and could cause the market price of our securities to decline substantially.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous factors, many of which are outside our control, may cause or contribute to significant fluctuations in our quarterly and annual operating results. These fluctuations may make financial planning and forecasting uncertain and may result in unanticipated decreases in our available cash, which could negatively affect our business and prospects. In addition, one or more of such factors may cause our revenue or operating expenses in one period to be disproportionately higher or lower relative to the other periods. As a result, comparing our operating results on a period-to-period basis might not be meaningful. You should not rely on our past results as indicative of our future performance. Moreover, our stock price might be based on expectations of future performance that are unrealistic or that we might not meet and, if our revenue or operating results fall below the expectations of investors or securities analysts, the price of our securities could decline substantially. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results have varied in the past. In addition to other risk factors listed in this section, some of the important factors that, alone or together, may cause fluctuations in our quarterly and annual operating results include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adoption of our optical genome mapping solutions on our Saphyr system or successor systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the successful integration of our Lineagen and BioDiscovery businesses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">execution on our commercial and reimbursement strategy involving Lineagen;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer demand for current BioDiscovery software solutions, including NxClinical, and future software solutions developed through BioDiscovery&#8217;s platform; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of customer orders and payments and our ability to recognize revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of utilization of consumables by our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reductions in or other difficulties relating to staffing, capacity, shutdowns or slowdowns of laboratories and other institutions in our customer base, as well as other impacts stemming from the COVID-19 pandemic or other similar factors, such as reduced or delayed investment in new technologies or spending on products, technologies or consumables; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in purchasing patterns across our customer base, including potential differences in consumables spending between earlier adopters of our technologies and more recent customers and variances in rates of increase of consumables spending following new technology purchases, some of which may be compounded by impacts of the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate new personnel, technology and other assets that we may acquire into our company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of the introduction of new systems, products, technologies, system and product enhancements and services; </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in governmental funding of life sciences research and development or other changes that impact budgets, budget cycles or seasonal or other spending patterns of our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any current or future litigation or governmental investigations involving us or other third parties with whom we do business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a significant portion of our operating expenses are relatively fixed in nature, and planned expenditures are based in part on expectations regarding future revenue. Accordingly, unexpected revenue shortfalls could decrease our gross margins and cause significant changes in our operating results from quarter to quarter. If this occurs, the trading price of our securities could fall substantially.  This variability and unpredictability caused by factors such as those described above and elsewhere in this section could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our securities could decline substantially. Such a stock price decline could occur even when we have met or exceeded any previously publicly stated guidance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain adequate revenue growth or do not successfully manage such growth, our business and growth prospects will be harmed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not achieve substantial growth rates in future periods. Investors should not rely on our operating results for any prior periods as an indication of our future operating performance. To effectively manage our anticipated future growth, we must continue to maintain and enhance our financial, accounting, manufacturing, customer support and sales administration systems, processes and controls. Failure to effectively manage our anticipated growth could lead us to over-invest or under-invest in development, operational and administrative infrastructure; result in weaknesses in our infrastructure, systems, or controls; give rise to operational mistakes, losses, loss of customers, productivity or business opportunities; and result in loss of employees and reduced productivity of remaining employees. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued growth could require significant capital expenditures and might divert financial resources from other projects such as the development of new products, technologies and services. As additional products and technologies are commercialized, we may need to incorporate new equipment, implement new technology systems, or hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and technologies, and could damage our reputation and the prospects for our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our management is unable to effectively manage our anticipated growth, our expenses may increase more than expected, our revenue could decline or grow more slowly than expected and we may be unable to implement our business strategy. The quality of our products, technologies and services may suffer, which could negatively affect our reputation and harm our ability to retain and attract customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future capital needs are uncertain and we will require additional funding in the future to advance the commercialization of Saphyr, NxClinical and our other products, technologies and services, as well as continue our research and development efforts. If we fail to obtain additional funding, we will be forced to delay, reduce or eliminate our commercialization and development efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts of cash in order to continue the commercialization of our products and technologies, fund our research and development programs, expand headcount and execute potential strategic transactions. Although we raised  $384.7 million of gross proceeds during 2021, we may need to raise additional funding, or we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. Such funding may mean the sale of common or preferred equity or convertible debt securities, entry into one or more credit facilities or another form of third-party funding, or seeking other debt financing. We may also consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities, or for other reasons, including to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our sales and marketing efforts to further commercialize our products, technologies and services and address competitive developments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our research and development efforts to improve our existing products, technologies and services and develop and launch new products, technologies and services, particularly if any of our products, technologies and services are deemed by the U.S. Food and Drug Administration, or FDA, to be medical devices or otherwise subject to additional regulation by the FDA;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek FDA approval to market our existing RUO products or new products utilized for diagnostic purposes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lease additional facilities or build out existing facilities as we continue to grow our employee headcount, inventory and research and development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further expand our operations outside the United States;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into collaboration arrangements, if any, or in-license products and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or invest in complimentary businesses or assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cover increased costs incurred as a result of continued operation as a public company, including costs resulting from our no longer qualifying as an emerging growth company and a smaller reporting company and becoming a large accelerated filer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will be influenced by many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our products, technologies and services, and the variability in costs to achieve such acceptance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing additional sales, marketing and distribution capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of our research and development activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy any outstanding or future debt obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our existing distribution and marketing arrangements and our ability to enter into additional arrangements in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of the COVID-19 pandemic; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various ways we could raise additional capital carry potential risks. We cannot assure you that we will be able to obtain additional funds on acceptable terms, or at all. If we raise additional funds by issuing equity or equity-linked securities, our stockholders may experience dilution. Any equity or debt securities we issue could provide for rights, preferences, or privileges senior to those of holders of our common stock. Future debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt or equity financing may contain terms that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or commercialization of our technologies and products. We also may have to reduce marketing, customer support or other resources devoted to our products or technologies or cease operations. Any of these factors could have a material adverse effect on our financial condition, operating results and business. Any of the foregoing could significantly harm our business, prospects, financial condition and results of operation and could cause the price of our securities to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, and that of our customers, has been adversely affected by the effects of public health crises, including the COVID-19 pandemic. In particular, the COVID-19 pandemic has materially affected our operations globally, including at our headquarters in San Diego, California, as well as the business or operations of our research partners, customers and other third parties with whom we conduct business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by health crises in regions where we have operations, concentrations of sales and marketing teams, distributors or other business operations. Such health crises could also affect the business or operations of our research partners, customers and other third parties with whom we conduct business. In particular, the evolving effects of the COVID-19 pandemic and government measures taken in response have had significant impacts, both direct and indirect, on businesses and commerce, as significant reductions in business-related activities have occurred, supply chains have been disrupted, and manufacturing and clinical development activities have been curtailed or suspended. Continued remote work policies, quarantines, shelter-in-place and similar government orders, shutdowns or other restrictions on the conduct of business operations related to the effects of the COVID-19 pandemic have materially affected and may continue to materially affect how we, our customers, and our suppliers are operating our businesses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to public health directives and orders implemented in response to the COVID-19 pandemic, we have implemented work-from-home policies for certain employees. We have also modified certain business practices, including those related to employee travel and cancellation of physical participation in meetings, events and conferences, and implemented new protocols to promote social distancing and enhance sanitary measures in our offices and facilities. The quarantine of our personnel and the inability to access our facilities or customer sites has adversely affected, and is expected to continue adversely affecting, our operations, namely in sales and marketing and product delivery. For example, we experienced at various times during the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pandemic the inability to visit certain customer sites to support installation or service our OGM systems. In addition, certain members of our workforce are now performing their duties remotely and these employees have not been able to maintain the same level of productivity and efficiency due a lack of resources that would otherwise be available to them in our offices and additional demands on their time, such as increased responsibilities resulting from school closures or the illness of family members. Furthermore, our remote workforce poses increased risks to our information technology systems and data as more of our personnel leverage resources not necessarily within our control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of these public health directives and orders and our related adjustments in our business have negatively impacted productivity, disrupted our business and delayed our timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. The spread of COVID-19 has resulted in a widespread health crisis that is also adversely affecting economies and financial markets globally, which  may negatively affect demand for our products, technologies and services and materially affect us financially. For example, customers who have committed to order minimum quantities of consumables or to purchase our Saphyr instrument have delayed these commitments. Further, restrictions on our ability to travel, stay-at-home orders and other similar restrictions on our business have limited our ability to support our global and domestic operations, including providing installation and training and customer service, resulting in disruptions in our sales and marketing efforts and negative impacts on our commercial strategy. In addition, while many of our employees have been vaccinated, we do not know if vaccination will remain effective against further COVID-19 variants such as the Delta and Omicron variants. To the extent our employees are exposed to or become ill with COVID-19, our ability to conduct our operations may be impaired from time to time.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disruption of global financial markets as a result of COVID-19 may limit our ability to access capital, which could negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could also materially affect our business and the value of our securities even after the outbreak of COVID-19 has subsided due to, among other things, unforeseen adverse impacts on us or our third-party manufacturers, vendors and customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in connection with our Lineagen diagnostic services, COVID-19 poses the risk that we or our employees, contractors, suppliers, courier delivery services and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. The continued spread of COVID-19 and the measures taken by the governments of countries affected could disrupt the supply chain of materials needed for our diagnostic tests, interrupt our ability to receive specimens, impair our ability to perform or deliver the results from our tests, impede patient movement or interrupt healthcare services causing a decrease in test volumes, delay coverage decisions from Medicare and third-party payors, delay ongoing and planned clinical trials involving our tests and have a material adverse effect on our business, financial condition and results of operations. For example, COVID-19 related disruptions to the global supply chain created challenges in our getting sufficient components and raw materials for production of our OGM systems and consumables. If the pandemic persists, these disruptions could reoccur or persist.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. In addition, quarantines, stay-at-home, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, have disrupted our supply chain and affected customer decision-making. For example, any actual or perceived disruption in our product distribution channel could alter customer buying decisions, prompting customers to delay or cancel their orders, which would negatively impact our sales revenue and could harm our reputation. In addition, we anticipate that ongoing disruptions in our supply chain will cause shortages in the materials required to operate our instruments, therefore limiting our ability to process customer samples and the ability of users of our system to operate our system.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of delays or impacts on our business or the global economy as a whole, and such impacts may not be fully recoverable. In addition, the current and potential adverse impacts of the COVID-19 pandemic on our business, financial condition, results of operations and growth prospects, may also have the effect of heightening many of the other risks and uncertainties described in this Annual Report. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017 informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act or any newly enacted federal tax legislation. In </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, the Biden administration and Congress have proposed various changes to the U.S. federal tax regime. Certain of these proposals include, among other things, eliminating or modifying some of the provisions enacted in the Tax Act, a significant increase in the corporate income tax rate, a new alternative minimum tax on book income and changes in the taxation of non-U.S. income. While these proposals have not yet been enacted and it is unclear whether these proposals or similar changes will ultimately ever be enacted, the passage of any legislation as a result of these proposals or any other future changes in U.S. tax laws could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense. Moreover, should the scale of our international business activities expand, any changes in the U.S. taxation of such activities or any other changes in applicable non-U.S. tax laws could increase our worldwide effective tax rate and harm our future financial position and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and certain other tax attributes to offset future taxable income and taxes may be subject to limitations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we have federal and state tax net operating loss carryforwards of $341.1 million and $158.4 million, respectively. The federal tax loss carryforwards include $176.8 million that do not expire, but utilization of such tax loss carryforwards in taxable years beginning after December&#160;31, 2021 is limited to 80% of our taxable income. The remaining federal tax loss carryforwards of $164.3 million and state tax loss carryforwards begin to expire in 2027 and 2023, respectively, unless previously utilized. As of December&#160;31, 2021, we also have federal and California research credit carryforwards of $6.7 million and $6.1 million, respectively. The federal research credit carryforwards begin to expire in 2027 unless previously utilized. The California research credits carry forward indefinitely.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, utilization of net operating losses and research and development credit carryforwards may be subject to limitations due to ownership changes that have occurred or that could occur in the future in accordance with applicable provisions of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law. We may have experienced one or more ownership changes in the past and we may also experience additional ownership changes in the future as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss or research and development credit carryforwards is materially limited, it would harm our future operating results by increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. taxation of international business activities or the adoption of tax reform policies could materially impact our future financial position and results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Limitations on the ability of taxpayers to claim and utilize foreign tax credits and the deferral of certain tax deductions until earnings outside of the U.S. are repatriated to the U.S., as well as changes to U.S. tax laws that may be enacted in the future, could impact the tax treatment of future foreign earnings. Should the scale of our international business activities expand, any changes in the U.S. taxation of such activities could increase our worldwide effective tax rate and harm our future financial position and results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our results of operation could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions underlying our estimates and judgements relating to our critical accounting policies change or if actual circumstances differ from our assumptions, estimates or judgements, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our securities.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1886"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our business operations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, joint ventures and other strategic transactions could disrupt or otherwise harm our business and may cause dilution to our stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our growth strategy, we have acquired and may continue to acquire other businesses, products or technologies as well as pursue strategic alliances, joint ventures, technology licenses or investments in complementary businesses or assets. We may not be able to locate or make suitable acquisitions on acceptable terms, and future acquisitions may not be effectively and profitably integrated into our business. Our failure to successfully complete the integration of any business or assets that we </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquire could have an adverse effect on our prospects, business activities, cash flow, financial condition, results of operations and stock price. Integration challenges may include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in our relationships with customers, distributors or suppliers as a result of such a transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenses and liabilities related to acquired companies or assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes with the seller(s) of any acquired companies or assets or litigation resulting from acquired companies or assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired personnel, technologies, operations and legal compliance obligations into our existing business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business to acquisition integration challenges;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible write-offs or impairment charges relating to acquired businesses or assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties developing and marketing new products, technologies and services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entering markets in which we have limited or no prior experience; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordinating our efforts throughout various localities and time zones.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with any such transactions, we may also issue equity securities in a dilutive manner, incur additional debt, assume contractual obligations or liabilities or expend significant cash. Such transactions could harm our operating results and cash position, negatively affect the price of our stock and cause dilution to our current stockholders. For example, in connection with our acquisition of Lineagen, Inc., or Lineagen, a U.S.-based provider of proprietary molecular diagnostics services for individuals presenting with certain neurodevelopmental disorders, we issued 6.2 million shares of our common stock, and in our acquisition of BioDiscovery, LLC., or BioDiscovery, a U.S.-based software company with solutions for analysis, interpretation and reporting of genomics data, we paid upfront consideration consisting of a combination of approximately $52.3 million in cash and 2.7 million shares of our common stock. In connection with the acquisition of BioDiscovery, we issued an additional 5.0 million shares of our common stock subject to vesting based on continued service of a key employee. The issuances of shares in connection with the Lineagen and BioDiscovery acquisitions resulted in dilution to our existing stockholders, the payment of cash in the BioDiscovery acquisition reduced our cash by approximately $52.3 million and our headcount increased by more than 50 employees as a result of both acquisitions. Accordingly, in addition to transaction costs, these acquisitions have increased our operating expenses, further increasing our net losses. We cannot predict the number, timing or size of any future strategic transactions, or the effect that any such transactions might have on our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we conducted extensive business, financial and legal due diligence in connection with our evaluation of our recent acquisitions, our due diligence investigations may not have identified every matter that could adversely affect our business, operating results and financial condition, and such investigations may have identified matters that, in the opinion of our management based on information available at the time, bore an acceptable level of risk that they, individually or in the aggregate, might or might not adversely affect our business, operating results or financial condition. We may be unable to adequately address the financial, legal and operational risks introduced by our recent acquisitions and may have difficulty developing experience with the industries in which Lineagen and/or BioDiscovery operate. Accordingly, we cannot guarantee that our recent acquisitions will yield the results we have anticipated and unforeseen complexities and expenses may arise. In addition, we may not achieve the revenues, growth prospects and synergies expected from these recent acquisitions, and any such benefits we do achieve may not offset our increased costs, resulting in a potential impairment of goodwill or other assets that were acquired. For any future acquisitions, we may similarly be unable to achieve revenue, growth prospects and synergies in a manner consistent with our expectations. Our failure to do so could adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our products or technologies fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our ability to develop and market products and technologies that are recognized and accepted as reliable, enabling and cost-effective. Most of the potential customers for our products and technologies already use expensive research systems in their laboratories that they have used for many years and may be reluctant to replace those systems with ours. Market acceptance of our systems will depend on many factors, including our ability to demonstrate to potential customers that our technology is an attractive alternative to existing technologies. Compared to some competing technologies, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our technology is new and complex, and many potential customers have limited knowledge of, or experience with, our products and technologies. Prior to adopting our systems, some potential customers may need to devote time and effort to testing and validating our systems. Any failure of our systems to meet these customer benchmarks could result in potential customers choosing to retain their existing systems or to purchase systems other than ours. In addition, it is important that our gene mapping systems be perceived as accurate and reliable by the scientific and medical research community as a whole. The scientific community is comprised of a small number of early adopters and key opinion leaders who significantly influence the rest of the community. Historically, a significant part of our sales and marketing efforts has been directed at demonstrating the advantages of our technology to industry leaders, including those key opinion leaders, and encouraging such leaders to publish or present the results of their evaluation of our system. If we are unable to continue to motivate leading researchers to use our technology, or if such researchers are unable to achieve or unwilling to publish or present significant experimental results using our systems, acceptance and adoption of our systems will be slowed and our ability to increase our revenue would be adversely affected.  We also run the risk that researchers may produce publications or presentations with findings that are negative about our technologies or systems, and that such findings may be due to factors outside of our control, which may also slow acceptance and adoption of our systems and adversely affect our ability to increase our revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity issuances in connection with strategic transactions or raising additional capital may cause dilution to our stockholders or restrict our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we expect to finance our strategic transactions or cash needs through a combination of equity and debt financings. To the extent that we finance our strategic transactions or raise additional capital through the sale of equity or convertible debt securities, your ownership interest could be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on August 13, 2020, we entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann &amp; Co. Inc., as sales agent, or Ladenburg, under which we were eligible to offer and sell up to $40.0 million of shares of our common stock from time to time through Ladenburg. In the first half of the fiscal year ended December&#160;31, 2021, we sold approximately 6.3 million shares of common stock through Ladenburg for aggregate gross proceeds of approximately $16.9 million and exhausted our capacity under this sales agreement. In January 2021, we completed two underwritten public offerings pursuant to which we issued an aggregate of approximately 71.7 million shares of our common stock for gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $331.8 million. In March 2021, we entered into a new at-the-market facility with Cowen and Company, LLC, or Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $350.0 million through or to Cowen, acting as sales agent or principal. In August and September 2021, we sold 2.3 million shares of common stock through Cowen for gross proceeds of approximately $13.9 million before deducting offering costs. In addition, we issued shares of our common stock in connection with our recent acquisitions of Lineagen and BioDiscovery. Any future significant sales of our capital stock or strategic transactions in which we use equity as consideration would result in further dilution to our current stockholders. As a result of these issuances, our investors experienced dilution of their ownership interests.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of shares under awards granted under existing or future employee equity benefit plans may</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">cause immediate and substantial dilution to our existing stockholders. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide persons who have a responsibility for our management and/or growth with additional incentive, to increase their proprietary interest in our success, and to support and increase our ability to attract and retain individuals of exceptional talent, we maintain multiple equity incentive plans. The total number of shares of our common stock available for the grant of awards under these plans is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 million, 0.2 million and 0.7 million for our 2018 Equity Incentive Plan, as amended, 2018 Employee Stock Purchase Plan and 2020 Inducement Plan, respectively, subject to adjustment, including pursuant to automatic &#8220;evergreen&#8221; increases in certain of our plans. As of December 31, 2021, we had outstanding equity awards underlying those plans of 13.4 million.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We may also adopt one or more additional employee equity benefit plans in the future. The issuance of shares under an employee equity benefit plan may result in substantial dilution to the interests of other stockholders. For example on February 15, 2022, our Board of Directors granted our executive officers options to purchase an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of our common stock, which represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1% of our outstanding shares of common stock based on the 289.6 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock outstanding as of February&#160;24, 2022. Accordingly, the issuance of shares under current or future employee equity benefit plans will have the effect of further diluting the proportionate equity interest and voting power of holders of our common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to execute our sales and marketing strategy for our Lineagen products and services, including diagnostic assays, and are unable to gain acceptance in the market, we may be unable to generate sufficient revenue to sustain our Lineagen business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Lineagen business provides molecular diagnostics services and has engaged in only limited sales and marketing activities for the diagnostic assays currently offered through our CLIA-certified laboratory. To date, the revenue generated by our Lineagen business has been insufficient to fund operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that our current assays and our planned future assays represent a promising commercial opportunity, our products or assays may never gain significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. We will need to establish a market for our products and diagnostic assays and build that market through physician education, awareness programs and the publication of clinical trial results. Gaining acceptance in medical communities requires, among other things, publications in leading peer-reviewed journals of results from studies using our current products, assays and services and/or our planned future products, assays and services. The process of publication in leading medical journals is subject to a peer review process and peer reviewers may not consider the results of our studies sufficiently novel or worthy of publication. Failure to have our studies published in peer-reviewed journals would limit the adoption of our current products, assays and services and our planned future products, assays and services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully market the products and diagnostic assays that we have developed, and may develop in the future, will depend on numerous factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducting clinical utility studies of such assays in collaboration with key thought leaders to demonstrate their use and value in important medical decisions such as treatment selection;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our current or future partners, vigorously support our offerings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our sales force;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether healthcare providers believe such diagnostic assays provide clinical utility;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the medical community accepts that such diagnostic assays are sufficiently sensitive and specific to be meaningful in patient care and treatment decisions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continually source raw materials, shipping kits and other products that we sell or consume in our manufacturing process that are of sufficient quality and supply;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to fund planned sales and marketing activities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether private health insurers, government health programs and other third-party payors will adopt our current and future assays in their guidelines, or cover such diagnostic assays and, if so, whether they will adequately reimburse us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also increase the risk and uncertainty of the events described above and delay our development timelines. Failure to achieve widespread market acceptance of our current products, assays and services, as well as our planned future products, assays and services, would materially harm our business, financial condition and results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the near term, sales of our Saphyr system, the NxClinical software, our consumables and our genome analysis services will depend on levels of research and development spending by clinical research laboratories, academic and governmental research institutions and biopharmaceutical companies, a reduction in which could limit demand for our technologies and adversely affect our business and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near term, we expect that our revenue from sales of our Saphyr system, NxClinical software, consumables and OGM services will be derived primarily from sales to academic and governmental research institutions, as well as biopharmaceutical and contract research companies worldwide for research applications. The demand for our products and technologies will depend in part upon the research and development budgets of these customers, which are impacted by factors beyond our control, such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in government programs that provide funding to research institutions and companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">macroeconomic conditions and the political climate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the regulatory environment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientists&#8217; and customers&#8217; opinions of the utility of new products, technologies or services</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reductions in or other difficulties relating to staffing, capacity, shutdowns or slowdowns of laboratories and other institutions as well as other impacts stemming from the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in budgetary cycles; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of relatively new technologies, such as ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2017, the federal government announced the intent to cut federal biomedical research funding by as much as 18%. While there has been significant opposition to these funding cuts, the uncertainty regarding the availability of research funding for potential customers may adversely affect our operating results. Our operating results may fluctuate </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially due to reductions and delays in research and development expenditures by these customers. Any decrease in customers&#8217; budgets or expenditures, including impacts stemming from the COVID-19 pandemic, or in the size, scope or frequency of capital or operating expenditures, could materially and adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sales cycle for our systems can be lengthy and variable, which makes it difficult for us to forecast revenue and other operating results. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales process for our systems generally involves numerous interactions with multiple individuals within an organization, and often includes in-depth analysis by potential customers of our technology and products and a lengthy review process. Our customers&#8217; evaluation processes often involve a number of factors, many of which are beyond our control. As a result of these factors, the capital investment required to purchase our systems and the budget cycles of our customers, the time from initial contact with a customer to our receipt of a purchase order can vary significantly. Given the length and uncertainty of our sales cycle, we have in the past experienced, and expect to in the future experience, fluctuations in our sales on a period-to-period basis. In addition, any failure to meet customer expectations could result in customers choosing to retain their existing systems, use existing assays not requiring capital equipment or purchase systems other than ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term results depend upon our ability to improve existing products and technologies and introduce and market new products and technologies successfully. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is dependent on the continued improvement of our existing products and technologies and our development of new products and technologies utilizing our current or other potential future technology. As we introduce new products or technologies or refine, improve or upgrade versions of existing products or technologies, we cannot predict the level of market acceptance or the amount of market share these products or technologies will achieve, if any. We cannot assure you that we will not experience material delays in the introduction of new products or technologies in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our strategy of offering new products and product refinements, we expect to continue to use a substantial amount of capital for product development and refinement. We may need additional capital for product development and refinement than is available on terms favorable to us, if at all, which could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally sell our products and technologies in industries that are characterized by rapid technological changes, frequent new product and technology introductions and changing industry standards. If we do not develop new products and technologies and product and technology enhancements based on technological innovation on a timely basis, our products and technologies may become obsolete over time and our revenues, cash flow, profitability and competitive position will suffer. Our success will depend on several factors, including our ability to: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">correctly identify customer needs and preferences and predict future needs and preferences;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocate our research and development funding to products and technologies with higher growth prospects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipate and respond to our competitors&#8217; development of new products and technological innovations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">innovate and develop new technologies and applications, including software applications through our BioDiscovery subsidiary, and acquire or obtain rights to third-party technologies that may have valuable applications in the markets we serve;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully commercialize new technologies in a timely manner, price them competitively and manufacture and deliver sufficient volumes of new products of appropriate quality on time; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customers&#8217; willingness to adopt new technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest heavily in research and development of products and technologies that do not lead to significant revenue. For example, we completed the BioDiscovery Acquisition in October 2021 and will need to devote time and resources in order to further develop and integrate BioDiscovery&#8217;s software and technology solutions for our current and anticipated product offerings. We may be unsuccessful in achieving our desired results or in marketing such solutions to our future customers. Even if we successfully innovate and develop new products and technologies and product and technological enhancements, we may incur substantial costs in doing so, and our profitability may suffer. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop new products and technologies based on innovation can affect our competitive position and often requires the investment of significant resources. Difficulties or delays in research, development or production of new products, technologies and services or failure to gain market acceptance of new products and technologies may reduce future revenues and adversely affect our competitive position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not successfully manage the development and launch of new products and technologies, our financial results could be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks associated with launching new products and technologies. If we encounter development or manufacturing challenges or discover errors during our product or technology development cycle, the launch dates of new products  and technologies may be delayed. The expenses or losses associated with unsuccessful product and technology development or launch activities or lack of market acceptance of our new products and technologies could adversely affect our business or financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success is dependent upon our ability to further penetrate our existing customer base and attract new customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current customer base for our products and technologies is primarily composed of academic and governmental research institutions and biopharmaceutical and contract research companies and, for our Lineagen diagnostic services, physicians and their patients. Our success will depend upon our ability to respond to the evolving needs of, and increase our market share among, existing customers and additional potential customers, marketing new products, technologies and services as we develop them. Identifying, engaging and marketing to customers who are unfamiliar with our current products and technologies requires substantial time, expertise and expense and involves a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract, retain and manage the sales, marketing and service personnel necessary to expand market acceptance for our technology;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost of maintaining and growing a specialized sales, marketing and service force; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fact that our sales, marketing and service force may be unable to execute successful commercial activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have utilized third parties to assist with sales, distribution and customer support in certain regions of the world. There is no guarantee, when we enter into such arrangements, that we will be successful in attracting desirable sales and distribution partners. There is also no guarantee that we will be able to enter into such arrangements on favorable terms. Any failure of our sales and marketing efforts, or those of any third-party sales and distribution partners, could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently limited to &#8220;research use only&#8221; with respect to many of the materials and components used in our consumable products including our assays.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments, consumable products and assays are purchased from suppliers with a restriction that they be used for research use only, or RUO. While we have focused initially on the life sciences research market and RUO products only, part of our business strategy is to expand our product line to encompass products that are intended to be used for the diagnosis of disease and precision healthcare, either alone or in collaboration with third parties. The use of our RUO products for any such diagnostic purposes would require that we obtain regulatory clearance or approval to market our products for those purposes and also that we acquire the materials and components used in such products from suppliers without an RUO restriction. There can be no assurance that we will be able to acquire these materials and components for use in diagnostic products on acceptable terms, if at all. If we are unable to do so, we would not be able to expand our non-Lineagen product offerings beyond RUO, and our business and prospects would suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Guidance on &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only&#8221;, or, the RUO/IUO Labeling Guidance, emphasizes that the FDA will review the totality of the circumstances when evaluating whether equipment and testing components are properly labeled as RUO. It further states that merely including a labeling statement that a product is intended for research use only will not necessarily render the device exempt from the FDA&#8217;s 510(k) clearance, PMA, or other requirements, if the circumstances surrounding the distribution of the product indicate that the manufacturer intends for its product to be offered for clinical diagnostic use. These circumstances may include written or verbal marketing claims or links to articles regarding a product&#8217;s performance in clinical applications, a manufacturer&#8217;s provision of technical support for clinical validation or clinical applications, or solicitation of business from clinical laboratories, all of which could be considered evidence of intended uses that conflict with RUO labeling. If the FDA were to determine that our RUO products were intended for use in clinical investigation, diagnosis or treatment decisions, or that express or implied clinical or diagnostic claims were made for our RUO products, those products could be considered misbranded or adulterated under the Federal Food, Drug, and Cosmetic Act. If the FDA determines that our RUO products are being marketed for clinical diagnostic use without the required PMA or 510(k) clearance, we may be required to cease marketing our products as planned, recall the products from customers, revise our marketing plans, and/or suspend or delay the commercialization of our products until we obtain the required authorization. We also may be subject to a range of enforcement actions by the FDA, including warning or untitled letters, injunctions, civil monetary penalties, criminal prosecution, and recall and/or seizure of products, as well as significant adverse publicity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, in the future, we choose to commercialize our RUO products for clinical diagnostic use, we will be required to comply with the FDA&#8217;s premarket review and post-market control requirements for IVDs, as may be applicable. Complying with the FDA&#8217;s PMA and/or 510(k) clearance requirements may be expensive, time-consuming, and subject us to significant and/or unanticipated delays. Our efforts may never result in an approved PMA or 510(k) clearance for our products. Even if we obtain a PMA or 510(k) clearance, where required, such authorization may not be for the use or uses we believe are commercially attractive and/or are critical to the commercial success of our products. As a result, being subject to the FDA&#8217;s premarket </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review and/or post-market control requirements for our products could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in marketing and selling our products and technologies, and if we are unable to successfully commercialize our products and technologies, our business and operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience marketing and selling our products and technologies. We currently sell our Saphyr system for research use only, through our direct field sales and support organizations located in North America and Europe and through a combination of our own sales force and third-party distributors in additional major markets such as Australian, China, Japan and South Korea.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future sales of our products and technologies will depend in large part on our ability to effectively market and sell our products and technologies, successfully manage and expand our sales force, and increase the scope of our marketing efforts. We may also enter into additional distribution arrangements in the future. Because we have limited experience in marketing and selling our products and technologies, our ability to forecast demand, the infrastructure required to support such demand and the sales cycle to customers is unproven. If we do not build an efficient and effective sales force, our business and operating results will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a single contract manufacturer for our optical genome mapping systems and a single contract manufacturer for our chip consumables. If either of these manufacturers should fail or not perform satisfactorily, our ability to supply these products would be negatively and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a single contract manufacturer to manufacture and supply all of our OGM-based instruments. See &#8220;Business &#8212; Key Agreements&#8221; in this Annual Report. In addition, we rely on a single contract manufacturer to manufacture and supply all of our chip consumables. Since our contracts with these manufacturers do not commit them to supply quantities beyond the amounts included in our purchase orders, and do not commit them to carry inventory or make available any particular quantities, these contract manufacturers may give other customers&#8217; needs higher priority than ours, and we may not be able to obtain adequate supplies in a timely manner or on commercially reasonable terms. If either of these manufacturers were to be unable to supply instruments, our business would be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event it becomes necessary to utilize different contract manufacturers for our OGM-based instruments or chip consumables, we would experience additional costs, delays and difficulties in doing so as a result of identifying and entering into an agreement with a new supplier as well as preparing such new supplier to meet the logistical requirements associated with manufacturing our units, and our business would suffer. We may also experience additional costs and delays in the event we need access to or rights under any intellectual property of these current manufacturers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced manufacturing problems or delays that could limit the growth of our revenue or increase our losses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have encountered situations that resulted in delays or shortfalls caused by our outsourced manufacturing suppliers and by other third-party suppliers who manufacture components for our products. We have been negatively impacted by unfavorable flowcell yields in the production cycle. If we are unable to solve for the yield issue, it could lead to lower gross margins in future periods. If we are unable to keep up with demand for our products, our revenue could be impaired, market acceptance for our products could be adversely affected and our customers might instead purchase our competitors&#8217; products. Our inability to successfully manufacture our products would have a material adverse effect on our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our laboratory facilities become damaged or inoperable or we are required to vacate our existing facilities, our ability to conduct our laboratory analysis and pursue our research and development efforts may be jeopardized.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently perform all research and development activities and most of our OGM services at a single laboratory facility in San Diego, California with the remaining genome analysis services at a facility we occupy at a customer&#8217;s lab in Clermont-Ferrand, France. All of our molecular diagnostics services are processed at a single laboratory facility in Salt Lake City, Utah. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure, terrorism, burglary, public health crises (including restrictions that may be imposed on businesses by state and local governments under stay-at-home or similar orders and mandates, such as those implemented in response to the COVID-19 pandemic) or other events, which may make it difficult or impossible for us to perform our testing services for some period of time or to receive and store samples. The inability to perform tests or to reduce the backlog of sample analysis that could develop if one or both of our facilities become inoperable, for even a short period of time, may result in the loss of revenue, loss of customers or harm to our reputation, and we may be unable to regain that revenue, those customers or repair our reputation in the future. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters and man-made disasters or other sudden, unforeseen and severe adverse events.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the loss of our samples due to such events could limit or prevent our ability to conduct research and development analysis on existing tests as well as tests in development.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and the equipment we use to perform our testing and research and development could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify a new facility, replace certain pieces of equipment or license or transfer our proprietary technology to a third party, particularly in light of licensure and accreditation requirements. Even in the unlikely event that we are able to find a third party with such qualifications to enable us to resume our operations, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a limited number of suppliers or, in some cases, one supplier, for some of our materials and components used in our products, and may not be able to find replacements or immediately transition to alternative suppliers, which could have a material adverse effect on our business, financial condition, results of operations and reputation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on limited or sole suppliers for certain reagents and other materials and components that are used in our products. While we periodically forecast our needs for such materials and enter into standard purchase orders with our suppliers, we do not have long-term contracts with many of these suppliers. If we were to lose such suppliers, there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our operations, including our laboratory operations, could occur if we encounter delays or difficulties in securing these materials, or if the quality of the materials supplied do not meet our requirements, or if we cannot then obtain an acceptable substitute. The time and effort required to qualify a new supplier and ensure that the new materials provide the same or better quality results could result in significant additional costs. Any such interruption could significantly affect our business, financial condition, results of operations and reputation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of the components used in our instruments are sourced from limited or sole suppliers. If we were to lose such suppliers, there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our ability to sell and deliver instruments to customers could occur if we encounter delays or difficulties in securing these components, or if the quality of the components supplied do not meet specifications, or if we cannot then obtain an acceptable substitute. If any of these events occur, our business and operating results could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in order to mitigate these risks, we maintain inventories of certain supplies at higher levels than would be the case if multiple sources of supply were available. If our sales or testing volume decreases or we switch suppliers, we may hold excess supplies with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new products, we may experience supply issues as we ramp up our sales or test volume. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment, reagents or other materials we require for our products, our business, financial condition, results of operations and reputation could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undetected errors or defects in our products or technologies could harm our reputation, decrease market acceptance of our products or technologies or expose us to product liability claims. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products or technologies may contain undetected errors or defects when first introduced or as new versions or new products or technologies are released. Disruptions affecting the introduction or release of, or other performance problems with, our products or technologies may damage our customers&#8217; businesses and could harm their and our reputations. If that occurs, we may incur significant costs, the attention of our key personnel could be diverted, or other significant customer relations problems may arise. We may also be subject to warranty and liability claims for damages related to errors or defects in our products or technologies. In addition, if we do not meet industry or quality standards, if applicable, our products may be subject to recall. A material liability claim, recall or other occurrence that harms our reputation or decreases market acceptance of our products or technologies could harm our business and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our customers develop or use our products or assays for diagnostic purposes, someone could file a product liability claim alleging that one of our products contained a design or manufacturing defect that resulted in the failure to adequately perform, leading to death or injury. In addition, the marketing, sale and use of our current or future products and assays could lead to the filing of product liability claims against us if someone alleges that our products failed to perform as designed. We may also be subject to liability for errors in the results we provide or for a misunderstanding of, or inappropriate reliance upon, the information we provide.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business or financial condition. We cannot assure investors that our product liability insurance would adequately protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could damage our reputation, or cause current partners to terminate existing agreements and potential partners to seek other partners, any of which could impact our results of operations.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also initiate a correction to our existing products or assays, which could lead to increased costs and increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our products or services, as well as negative publicity. The occurrence of any of these events could have an adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on distributors for sales of our products outside of the United States could limit or prevent us from selling our products and could impact our revenue. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to grow our business internationally, and to do so we must attract additional distributors and retain existing distributors to maximize the commercial opportunity for our products. There is no guarantee that we will be successful in attracting or retaining desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations or may choose to favor marketing the products of our competitors. If current or future distributors do not perform adequately, or we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize long-term international revenue growth. In addition, if our distributors fail to comply with applicable laws and ethical standards, including anti-bribery laws, this could damage our reputation and could have a significant adverse effect on our business and our revenues. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to generate a substantial portion of our revenue internationally in the future and can become further subject to various risks relating to our international activities, which could adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 approximately 54% of our product revenue was generated from customers located outside of the U.S. We believe that a substantial percentage of our future revenue will come from international sources as we expand our overseas operations and develop opportunities in additional areas. We have limited experience operating internationally and engaging in international business involves a number of difficulties and risks, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required compliance with existing and changing foreign regulatory requirements and laws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties and costs of staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties protecting or procuring intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act, data privacy and security requirements, labor laws and anti-competition regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">export or import restrictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and business practices favoring local companies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, most of our revenue has been denominated in U.S. dollars. For sales made to customers outside of the U.S., we may sell our products and services in local currency outside of the U.S. As our operations in countries outside of the U.S. grow, our results of operations and cash flows may be subject to fluctuations due to changes in foreign currency exchange rates, which could harm our business in the future. For example, if the value of the U.S. dollar increases relative to foreign currencies, in the absence of a corresponding change in local currency prices, our revenue could be adversely affected as we convert revenue from local currencies to U.S. dollars. If we dedicate significant resources to our international operations and are unable to manage these risks effectively, our business, operating results and financial condition will suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, the United Kingdom Bribery Act 2010, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees and third-party intermediaries from authorizing, promising, offering, providing, soliciting, or accepting, directly or indirectly, improper payments or benefits to or from any person whether in the public or private sector for the purpose of obtaining or retaining business or securing any other improper advantage. We rely on third-party representatives, distributors, and other business partners to support sales of our products and services and our efforts to ensure regulatory compliance. In addition, as we increase our international sales and business, we may engage with additional business partners. We can be held liable for the corrupt or other illegal activities of our employees, representatives, contractors, business partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any violations of anti-corruption and anti-money laundering laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, prospects, financial condition, or results of operations. We could also incur severe penalties, including criminal and civil penalties, disgorgement, and other remedial measures. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls. Exports of our products must be made in compliance with these laws and regulations. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on us and responsible employees or managers; and, in extreme cases, the incarceration of responsible employees or managers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes in our products or changes in applicable export or import laws and regulations may create delays in the introduction and sale of our products in international markets, prevent our customers from deploying our products or, in some cases, prevent the export or import of our products to certain countries, governments or persons altogether. Any change in export or import laws and regulations, shift in the enforcement or scope of existing laws and regulations, or change in the countries, governments, persons or technologies targeted by such laws and regulations, could also result in decreased use of our products, or in our decreased ability to export or sell our products to existing or potential customers. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to recruit, train, retain, motivate and integrate key personnel, we may not achieve our goals. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success depends on our ability to recruit, train, retain, motivate and integrate key personnel, including our recently expanded senior management team, as well as our research and development, manufacturing and sales and marketing personnel. Competition for qualified personnel is intense. Our growth depends, in particular, on attracting and retaining highly-trained sales personnel with the necessary scientific background and ability to understand our systems at a technical level to effectively identify and sell to potential new customers and develop new products and technologies. Because of the complex and technical nature of our products and technologies and the dynamic market in which we compete, any failure to attract, train, retain, motivate and integrate qualified personnel could materially harm our operating results and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot provide quality technical and applications support, we could lose customers and our business and prospects will suffer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The placement of our products at new customer sites, the introduction of our technology into our customers&#8217; existing laboratory workflows and ongoing customer support can be complex. Accordingly, we need highly trained technical support personnel. Hiring technical support personnel is very competitive in our industry due to the limited number of people available with the necessary scientific and technical backgrounds and ability to understand our technology at a technical level. To effectively support potential new customers and the expanding needs of current customers, we will need to substantially expand our technical support staff. If we are unable to attract, train or retain the number of highly qualified technical services personnel that our business needs, our business and prospects will suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information systems or data or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of our business, we collect, store, use, transmit, disclose, and otherwise process sensitive, proprietary, and confidential information, including intellectual property, trade secrets, financial information, and personal data (including protected health information). We may rely upon third-party service providers and technologies to operate critical business systems to process confidential and personal data in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, encryption and authentication technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&#8217; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place. We may share or receive sensitive data with or from third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase. Moreover, these threats are becoming increasingly difficult to detect, and they come from a variety of sources. In addition to traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors now engage and are expected to continue to engage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (such as through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. Ransomware attacks, including those perpetrated by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems (including our software) or the third-party information technology systems that support us and our services. The COVID-19 pandemic and our remote workforce also poses increased risks to our information technology systems and data, as more of our personnel work from home, utilizing network connections outside our premises. Future business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to data. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products, software and services. We may expend significant resources or modify our business activities in an effort to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard, or reasonable security measures to protect our information technology systems and data.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems (including our software) because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems (including our software), our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents.  Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our software or services, deter new customers from using our software or services, and negatively impact our ability to grow and operate our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage, if any, will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruption of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we process personal data (including protected health information) and other sensitive information, including proprietary and confidential business data, trade secrets, and intellectual property. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. For example, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, impose specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Among other things, HITECH, through its implementing regulations, makes certain of HIPAA&#8217;s privacy and security standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains or transmits protected health information for or on behalf of a covered entity for a function or activity regulated by HIPAA as well as their covered subcontractors. Most healthcare providers in the United States, including clinical laboratories and institutions from which we may obtain customer data, are subject to privacy and security regulations promulgated under HIPAA, as amended by HITECH. Further, a person may be prosecuted for alleged HIPAA violations either directly or indirectly such as under aiding-and-abetting or conspiracy principles. Further, depending on the facts and circumstances, we could face substantial civil and criminal penalties and liabilities if we fail to comply with our obligations (required by law and/or contract) under HIPAA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, at the state level, the California Consumer Privacy Act of 2018, or the CCPA, imposes obligations on businesses to which it applies. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). The California Privacy Rights Act of 2020, or the CPRA, which takes effect January 1, 2023, is anticipated to expand the CCPA&#8217;s obligations on businesses. For example, the CPRA establishes a new California Privacy Protection Agency to implement and enforce relevant laws, which could increase the risk of an enforcement action. Other states have also recently enacted data privacy laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which differ from the CPRA and take effect in 2023. If we become subject to new state-level data privacy laws, the risk of enforcement action against us could increase because we may become subject to additional obligations, and the number of individuals or entities that can initiate actions against us may increase (including individuals, via a private right of action, and state actors). Data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which, if passed, could further complicate compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), and the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;) impose strict requirements for processing the personal data of individuals. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. Further, individuals may initiate litigation related to our processing of their personal data. In Canada, the Personal Information Protection and Electronic Documents Act (&#8220;PIPEDA&#8221;) and various related provincial laws, as well as Canada&#8217;s Anti-Spam Legislation (&#8220;CASL&#8221;), may apply to our operations. In addition, privacy advocates and industry groups have proposed, and may propose in the future, standards with which we are legally or contractually bound to comply.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the EEA, such as the United States, which the European Commission does not consider to provide an adequate level of data privacy and security. The European Commission released a set of &#8220;Standard Contractual Clauses&#8221; (&#8220;SCCs&#8221;) that are designed to be a valid mechanism by which entities can transfer personal data out of the EEA to jurisdictions that the European Commission has not found to provide an adequate level of protection. Currently, these SCCs are a valid mechanism to transfer personal data outside of the EEA. However, the SCCs require parties that rely on them to comply with additional obligations, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect personal data. Moreover, due to potential legal challenges, there exists some uncertainty regarding whether the SCCs will remain a valid mechanism for transfers of personal data out of the EEA. Laws in Switzerland and the UK similarly restrict transfers of personal data outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. In addition to European restrictions on cross-border transfers of personal data, other countries, such as China and Brazil, have enacted or are considering similar cross-border personal data transfer laws and local personal data residency laws, any of which could increase the cost and complexity of doing business. If we cannot implement a valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or elsewhere. The inability to import personal data to the United States could significantly and negatively impact our business operations, including by limiting our ability to collaborate with parties that are subject to European and other data privacy and security laws or by requiring us to increase our personal data processing capabilities and infrastructure in Europe and/or elsewhere at significant expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data privacy and security obligations are quickly changing, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties on which we rely. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so.  Moreover, despite our efforts, our personnel or third parties upon which we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to operate our business and proceedings against us by governmental entities or others. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to, loss of customers; interruptions or stoppages in our business operations; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The life sciences research and diagnostic markets are highly competitive. If we fail to effectively compete, our business, financial condition and operating results will suffer. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in the life sciences research and diagnostic markets. We currently compete with both established and early stage companies that design, manufacture and market systems and consumable supplies. We believe our principal competitors in the life sciences research and genome mapping markets include PacBio, Oxford Nanopore Technologies, Genomic Vision and Dovetail Genomics. In addition, there are a number of new market entrants in the process of developing novel technologies for the life sciences research, diagnostic and screening markets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current competitors are either publicly-traded, or are divisions of publicly-traded companies, and may enjoy a number of competitive advantages over us, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater name and brand recognition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantially greater financial and human resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broader product lines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger sales forces and more established distributor networks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial intellectual property portfolios;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger and more established customer bases and relationships; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">better established, larger scale, and lower cost manufacturing capabilities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the principal competitive factors in all of our target markets include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost of instruments and consumables;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accuracy, including sensitivity and specificity, and reproducibility of results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reputation among customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">innovation in product offerings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">flexibility and ease of use; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compatibility with existing laboratory processes, tools and methods. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure investors that our products or technologies will compete favorably or that we will be successful in the face of increasing competition from new products and technologies introduced by our existing competitors or new companies entering our markets. In addition, we cannot assure investors that our competitors do not have or will not develop products or technologies that currently or in the future will enable them to produce competitive products  or technologies with greater capabilities or at lower costs than ours. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged global economic downturn could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. This is particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers, possibly resulting </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the conflict between Russia and Ukraine could lead to disruption, instability and volatility in global markets and industries that could negatively impact our operations. The U.S. government and other governments in jurisdictions in which we operate have imposed severe sanctions and export controls against Russia and Russian interests and threatened additional sanctions and controls. The impact of these measures, as well as potential responses to them by Russia, is currently unknown and they could adversely affect our business, supply chain, partners or customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could adversely affect our results of operations and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and any the third parties with access to our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we contract, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. We do not have any insurance for liabilities arising from medical or hazardous materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Compliance with applicable environmental laws and regulations is expensive, and these current or future laws and regulations may impair our research, development and commercialization efforts, which could harm our business, prospects, financial condition or results of operations. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1890"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to government regulation and diagnostic product reimbursement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA determines that our RUO products are medical devices or if we seek to market our RUO products for clinical diagnostic or health screening use, we will be required to obtain regulatory clearance(s) or approval(s), and may be required to cease or limit sales of our then marketed products, which could materially and adversely affect our business, financial condition and results of operations. Any such regulatory process would be expensive, time-consuming and uncertain both in timing and in outcome.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RUO products are focused on the life sciences research market. This includes laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies. Accordingly, our products are labeled as &#8220;Research Use Only,&#8221; or RUO, and are not intended for diagnostic use. While we have focused initially on the life sciences research market and RUO products only, our strategy is to expand our product line to encompass products that are intended to be used for the diagnosis of disease, either alone or in collaboration with third parties. Such in-vitro diagnostic, or IVD, products will be subject to regulation by the FDA as medical devices, or comparable international agencies, including requirements for regulatory clearance or approval of such products before they can be marketed. If the FDA were to determine that our products are intended for clinical use or if we decided to market our products for such use, we would be required to obtain FDA 510(k) clearance or premarket approval in order to sell our products in a manner consistent with FDA laws and regulations. Such regulatory approval processes or clearances are expensive, time-consuming and uncertain; our efforts may never result in any approved premarket approval application, or PMA, or 510(k) clearance for our products; and failure by us or a collaborator to obtain or comply with such approvals and clearances could have an adverse effect on our business, financial condition or operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IVD products may be regulated as medical devices by the FDA and comparable international agencies and may require either clearance from the FDA following the 510(k) pre-market notification process or PMA from the FDA, in each case prior to marketing. If we or our collaborators are required to obtain a PMA or 510(k) clearance for products based on our technology, we or they would be subject to a substantial number of additional requirements for medical devices, including establishment registration, device listing, Quality Systems Regulations which cover the design, testing, production, control, quality assurance, labeling, packaging, servicing, sterilization (if required), and storage and shipping of medical devices (among other activities), product labeling, advertising, recordkeeping, post-market surveillance, post-approval studies, adverse event reporting, and correction and removal (recall) regulations. One or more of the products we or a collaborator may develop using our technology may also require clinical trials in order to generate the data required for PMA approval. Complying with these requirements may be time-consuming and expensive. We or our collaborators may be required to expend significant resources to ensure ongoing compliance with the FDA regulations and/or take satisfactory corrective action in response to enforcement action, which may have a material adverse effect on the ability to design, develop, and commercialize products using our technology as planned. Failure to comply with these requirements may subject us or a collaborator to a range of enforcement actions, such as warning letters, injunctions, civil monetary penalties, criminal prosecution, recall and/or seizure of products, and revocation of marketing authorization, as well as significant adverse publicity. If we or our collaborators fail to obtain, or experience significant delays in obtaining, regulatory approvals for IVD products, such products may not be able to be launched or successfully commercialized in a timely manner, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory developed tests, or LDTs, are a subset of IVD tests that are designed, manufactured and used within a single laboratory. Our Lineagen diagnostic services are provided as LDTs. The FDA maintains that LDTs are medical devices and has for the most part exercised enforcement discretion for most LDTs. A significant change in the way that the FDA regulates any LDTs that we, our collaborators or our customers market or develop using our technology could affect our business. If the FDA requires laboratories to undergo premarket review and comply with other applicable FDA requirements in the future, the cost and time required to commercialize an LDT will increase substantially, and may reduce the financial incentive for us to continue to offer our Lineagen genetic diagnostic services or for our customer laboratories to develop LDTs, which could reduce demand for our RUO instruments and our other products. In addition, if the FDA were to change the way that it regulates LDTs to require that we undergo pre-market review or comply with other applicable FDA requirements before we can sell our RUO instruments or our other products to clinical cytogenetics laboratories, our ability to sell our RUO instruments and other products to this addressable market would be delayed, thereby impeding our ability to penetrate this market and generate revenue from sales of our instruments and our other products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable FDA requirements could subject us to misbranding or adulteration allegations under the Federal Food, Drug, and Cosmetic Act. We could be subject to a range of enforcement actions, including warning letters, injunctions, civil monetary penalties, criminal prosecution, and recall and/or seizure of products, as well as significant adverse publicity. In addition, changes to the current regulatory framework, including the imposition of additional or new regulations, could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign jurisdictions have laws and regulations similar to those described above, which may adversely affect our ability to market our products as planned in such countries. The number and scope of these requirements are increasing. As in the U.S., </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the cost and time required to comply with regulatory requirements may be substantial, and there is no guarantee that we will obtain the necessary authorization(s) required to make our products commercially viable. As a result, the imposition of foreign requirements may also have a material adverse effect on the commercial viability of our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to rely on third parties in conducting any required future studies of diagnostic products that may be required by the FDA or other regulatory authorities, and those third parties may not perform satisfactorily. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct clinical trials or other studies that may be required to obtain FDA and other regulatory clearance or approval for future diagnostic products. Accordingly, we expect that we would rely on third parties, such as clinical investigators, consultants, and collaborators to conduct such studies if needed. Our reliance on these third parties for clinical and other development activities would reduce our control over these activities. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised, we may not be able to obtain regulatory clearance or approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing for our Lineagen diagnostic testing procedures is complex and requires substantial time and resources to collect payment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billing for clinical laboratory testing services in connection with our Lineagen diagnostic services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payors, including Medicare, Medicaid, private insurance companies, private healthcare institutions, and patients, all of which have different billing requirements. We generally bill third-party payors for our diagnostic testing services and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also face increased risk in our collection efforts, including potential write-offs of accounts receivable and long collection cycles, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several factors make the billing process complex, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences between the billing rates and reimbursement rates for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare, Medicaid and TRICARE;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk of government audits related to billing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes among payors as to which party is responsible for payment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in coverage and information and billing requirements among payors, including the need for prior authorization and/or advanced notification;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of patient co-payments or co-insurance and our ability to collect such payments from patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to billing codes used for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to requirements related to our current or future clinical studies, including our registry studies, which can affect eligibility for payment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing monitoring provisions of LCDs for our products, which can affect the circumstances under which a claim would be considered medically necessary;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incorrect or missing billing information; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use standard industry billing codes, known as Current Procedural Terminology, or CPT, codes, to bill for our diagnostic testing services. If these codes were to change, there is a risk of an error being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment we receive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we introduce new products, we may need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. When payors deny our claims, we may challenge the reason, low payment amount or payment denials. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the payor makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the ACA, requires providers and suppliers to report and return any overpayments received from government payors under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. These billing complexities, and the related uncertainty in obtaining payment for our products, could negatively affect our revenue and cash flow, our ability to achieve sustained profitability, and the consistency and comparability of our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our Lineagen diagnostic testing procedures are subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, our business could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Lineagen-related revenue depends on achieving and maintaining broad coverage and adequate reimbursement for our Lineagen products and diagnostic assays from third-party payors, including both government and commercial third-party payors. If third-party payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the list price of our Lineagen products and diagnostic assays, we may need to seek additional payment from the patient beyond any co-payments and deductibles, which may adversely affect demand for our Lineagen products and diagnostic assays. Coverage determinations by a third-party payor may depend on a number of factors, including, but not limited to, a third-party payor&#8217;s determination of whether our products or services are appropriate, medically necessary or cost-effective. If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our Lineagen products and diagnostic assays, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since each third-party payor makes its own decision as to whether to establish a policy to cover our Lineagen products and diagnostic assays, enter into a contract with us and set the amount it will reimburse for a product, these negotiations are a time-consuming and costly process, and they do not guarantee that the third-party payor will provide coverage or adequate reimbursement for our Lineagen products and diagnostic assays. In addition, the determinations by a third-party payor whether to cover our Lineagen products and diagnostic assays and the amount it will reimburse for them are often made on an indication-by-indication basis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the product, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our claims for reimbursement from third-party payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming and expensive, and may not result in payment. Third-party payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the third-party payors believe the funds were paid in error or determine that our Lineagen products and diagnostic assays were medically unnecessary. If a third-party payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial third-party payors for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was too much. In these situations, the third-party payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We cannot predict when, or how often, a third-party payor might engage in these reviews and we may not be able to dispute these retroactive adjustments. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future that may adversely affect the coverage and reimbursement of our Lineagen products and diagnostic assays.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If diagnostic procedures that are enabled by our Saphyr technology are subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, our business could be harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our Saphyr product is for research use only, but clinical laboratories may acquire our instrumentation through a capital purchase or capital lease and use the Saphyr and direct label stain chemistry to create their own potentially reimbursable products, such as laboratory developed tests for in vitro diagnostics. Our customers may generate revenue for these testing services by seeking the necessary approval of their product from the FDA or the Centers for Medicare &amp; Medicaid Services, or CMS, along with coverage and reimbursement from third-party payors, including government health programs and private health plans. The ability of our customers to commercialize diagnostic tests based on our technology will depend in part on the extent to which coverage and reimbursement for these tests will be available from such third-party payors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., molecular testing laboratories have multiple options for reimbursement coding, but we expect that the primary codes used will be the genomic sequencing procedure codes, or GSPs. The American Medical Association, or AMA, added </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSPs to its clinical laboratory fee schedule in 2015. In addition, CMS recently issued a coverage determination providing for the reimbursement of next-generation sequencing for certain cancer diagnostics using an FDA-approved in vitro diagnostic test. Private health plans often follow CMS coverage and reimbursement guidelines to a substantial degree, and it is difficult to predict what CMS will decide with respect to the coverage and reimbursement of any products our customers try to commercialize.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, coverage for molecular diagnostic testing is varied. Countries with statutory health insurance (e.g., Germany, France, The Netherlands) tend to be more progressive in technology adoption with favorable reimbursement for molecular diagnostic testing. In countries such as the United Kingdom with tax-based insurance, adoption and reimbursement for molecular diagnostic testing is not uniform and is influenced by local budgets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, coverage and reimbursement of new products is uncertain, and whether laboratories that use our instruments to develop their own products will attain coverage and adequate reimbursement is unknown. In the U.S., there is no uniform policy for determining coverage and reimbursement. Coverage can differ from payor to payor, and the process for determining whether a payor will provide coverage may be separate from the process for setting the reimbursement rate. In addition, the U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls and restrictions on reimbursement. We cannot be sure that coverage will be available for any diagnostic tests based on our technology, and, if coverage is available, the level of payments. Reimbursement may impact the demand for those tests. If coverage and reimbursement is not available or is available only to limited levels, our customers may not be able to successfully commercialize any tests for which they receive marketing authorization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. For example, the ACA contained a 2.3% excise tax on certain entities that manufacture or import medical devices offered for sale in the U.S., with limited exceptions, which has been permanently eliminated as part of the 2020 spending package.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, while Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA was unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on April 1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things, significantly altered the payment methodology under the Medicare Clinical Laboratory Fee Schedule, or CLFS. PAMA requires certain laboratories performing clinical diagnostic laboratory tests to report to CMS the amounts paid by private payors for laboratory tests. Such reporting has been subject to numerous delays. Beginning on January 1, 2018, CMS has begun using reported private payor pricing to periodically revise payment rates under the CLFS. Based on current law, between January 1, 2023 and March 31, 2023, applicable laboratories will be required to report on data collected during January 1, 2019 and June 30, 2019. This data will be utilized to determine 2024 to 2026 CLFS rates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we or our collaborators will receive for any cleared or approved product. Congress is considering additional health reform measures.  Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent our customers from successfully commercializing any tests for which they receive approval, which could prevent us from being able to generate revenue and attain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the Clinical Laboratory Improvement Amendment of 1988, or CLIA, which is a federal law regulating clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. Our clinical laboratory is located in Utah and must be certified under CLIA in order for us to perform testing on human specimens. CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of compliance under CLIA to perform cytogenetics. To renew this certificate, we are subject to survey and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inspection every two years. Moreover, CLIA inspectors may make periodic inspections of our clinical laboratory outside of the renewal process. The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of compliance, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for assays provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold laboratory licenses from the states of California, Pennsylvania, and Maryland, to test specimens from patients in those states or received from ordering physicians in those states. Other states may have similar requirements or may adopt similar requirements in the future. Finally, we may be subject to regulation in foreign jurisdictions if we seek to expand international distribution of our assays outside the United States. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to lose our CLIA certification or state laboratory licenses, whether as a result of a revocation, suspension or limitation, we would no longer be able to offer our assays, which would limit our revenues and harm our business. If we were to lose, or fail to obtain, a license in any other state where we are required to hold a license, we would not be able to test specimens from those states. If we were to lose our CAP accreditation, our reputation for quality, as well as our business, financial condition and results of operations, could be significantly and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal and state healthcare fraud and abuse laws and other federal and state laws applicable to our business activities, including our marketing practices. If we are unable to comply, or have not complied, with such laws, we could face substantial penalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to various federal and state fraud and abuse laws, including, without limitation, the federal and state anti-kickback statutes and false claims laws. These laws may impact, among other things, our sales and marketing and education programs, and our financial and business relationships with health care professionals. The laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, or the AKS, which prohibits, among other things, any person or entity from knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8216;&#8216;remuneration&#8217;&#8217; has been broadly interpreted to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, however these are drawn narrowly. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or the FCA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Stark Law, which prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the FCA, which can be enforced by private citizens through civil qui tam actions, prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented false, fictitious or fraudulent claims for payment or approval by the federal government, including federal health care programs, such as Medicare and Medicaid, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, prohibits payments for referrals to recovery homes, clinical treatment facilities, and laboratories. EKRA&#8217;s reach extends beyond federal health care programs to include private insurance (i.e., it is an &#8220;all payor&#8221; statute). For purposes of EKRA, the term &#8220;laboratory&#8221; is defined broadly and without reference to any connection to substance use disorder treatment. The law includes a limited number of exceptions, some of which closely align with corresponding federal Anti-Kickback Statute exceptions and safe harbors, and others that materially differ;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, in connection with the delivery of or payment for healthcare benefits, items or services. Like the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform services for them that involve individually identifiable health information as well as their covered subcontractors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that prohibit other specified practices, such as billing physicians for tests that they order or providing tests at no or discounted cost to induce physician or patient adoption; insurance fraud laws; waiving coinsurance, co-payments, deductibles, and other amounts owed by patients; billing a state Medicaid program at a price that is higher than what is charged to one or more other third-party payors employing, exercising control over or splitting professional fees with licensed professionals in violation of state laws prohibiting fee splitting or the corporate practice of medicine and other professions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any non-governmental third-party payors, including private insurers; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal data, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical laboratory, our business practices may face additional scrutiny from government regulatory agencies such as the Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General, or OIG, and CMS. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain arrangements between clinical laboratories and referring physicians have been identified in fraud alerts issued by the OIG as implicating the AKS. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory, as well as the decision to order laboratory tests, typically are made or strongly influenced by the physician, with little or no input from patients. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the Stark Law unless the arrangement meets all criteria of an applicable exception. The government has been active in enforcement of these laws as they apply to clinical laboratories.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into consulting and scientific advisory board arrangements, speaking arrangements and clinical research agreements with physicians and other healthcare providers, including some who could influence the use of our products. Although we believe that these have been structured in compliance with applicable laws, because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use of our products to be in violation of applicable laws.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations is costly. If our operations are found to be in violation of any of these laws, we may be subject to significant penalties, including, without limitation, civil, criminal, and administrative penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, additional integrity oversight and reporting obligations, imprisonment, contractual damages, and reputational harm, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, sales of our products outside of the U.S. will subject us to similar foreign regulatory requirements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1894"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, it may reduce our ability to maintain any technological or competitive advantage over our competitors and potential competitors, and our business may be harmed. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. As of March 1, 2022, we (directly or through our wholly owned subsidiaries Lineagen, Inc and BioDiscovery, LLC) were the assignee of 28 granted U.S. patents or allowed U.S. patent applications and 21 pending U.S. patent applications. We also were the assignee of approximately 96 pending patent applications and granted patents in particular jurisdictions outside the U.S. If we fail to protect and/or maintain our intellectual property, third parties may be able to compete more effectively against us, we may lose our technological or competitive advantage, and/or we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure investors that any of our currently pending or future patent applications will result in granted patents, and we cannot predict how long it will take for such patents to issue, if at all. It is possible that, for any of our patents that have issued or that may issue in the future, our competitors may design their products, technologies or services around our patented technologies. Further, we cannot assure investors that other parties will not challenge any patents granted to us, or that courts or regulatory agencies will hold our patents to be valid, enforceable, and/or infringed. We cannot guarantee investors that we will be successful in defending challenges made against our patents and patent applications. Any successful third-party challenge or challenges to our patents could result in the unenforceability or invalidity of such patents, or such patents being interpreted narrowly and/or in a manner adverse to our interests. Our ability to establish or maintain a technological or competitive advantage over our competitors and/or market entrants may be diminished because of these uncertainties. For these and other reasons, our intellectual property may not provide us with any competitive advantage. For example: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors might not have been the first to make the inventions claimed or disclosed by our pending patent applications or issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings or derivation proceedings declared by the U.S. Patent and Trademark Office, or the USPTO, which could result in substantial cost to us, and could possibly result in a loss or narrowing of patent rights. No assurance can be given that our or our licensors&#8217; patent applications or granted patents will have priority over any other patent or patent application involved in such a proceeding, or will be held valid as an outcome of the proceeding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other parties may independently develop similar or alternative products and technologies or duplicate any of our products and technologies, which can potentially impact our market share, revenue, and goodwill, regardless of whether intellectual property rights are successfully enforced against these other parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our owned or licensed pending patent applications will not result in granted patents, and even if such pending patent applications issue as patents, they may not provide intellectual property protection of commercially viable products or product features, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties, patent offices, and/or the courts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unaware of or unfamiliar with prior art and/or interpretations of prior art that could potentially impact the validity or scope of our patents or pending patent applications, or patent applications that we intend to file; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we take efforts to enter into agreements with employees, consultants, collaborators, and, as applicable, advisors to confirm ownership and chain of title in intellectual property rights. However, an inventorship or ownership dispute could arise that may permit one or more third parties to practice or enforce our intellectual property rights, including possible efforts to enforce rights against us; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may elect not to maintain or pursue intellectual property rights that, at some point in time, may be considered relevant to or enforceable against a competitor; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary products and technologies that are patentable, or we may develop additional proprietary products and technologies that are not patentable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents or other intellectual property rights of others may have an adverse effect on our business; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we apply for patents relating to our products and technologies and uses thereof, as we deem appropriate. However, we or our representatives or their agents may fail to apply for patents on important products and technologies in a timely fashion or at all, or we or our representatives or their agents may fail to apply for patents in potentially relevant jurisdictions.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct or indirect competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products, technologies or services, our competitive position could be adversely affected, as could our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, to the extent that computation methods implemented by software included in our products or technologies are not protected by our patents, our dependence on copyright and trade secret protection may not provide adequate protection. In addition, the Supreme Court&#8217;s ruling in Alice Corporation Pty. Ltd. v. CLS Bank International has narrowed the scope of patent protection available for computational methods in certain circumstances. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The measures that we use to protect the security of our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to pursuing patents on our technologies, we also rely upon trademarks, trade secrets, copyrights and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented or misappropriated. In addition, we take steps to protect our intellectual property and proprietary technologies by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets and/or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Moreover, if a party having an agreement with us has an overlapping or conflicting obligation to a third-party, our rights in and to certain intellectual property could be undermined. Monitoring unauthorized and inadvertent disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, the outcome would be unpredictable, and any remedy may be inadequate. In addition, courts outside the U.S. may be less willing to protect trade secrets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors could purchase our products  or technologies and attempt to replicate and/or improve some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design their products  or technologies around our protected technologies or develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property does not adequately protect our market share against competitors&#8217; products or technologies, services and methods, our competitive position could be adversely affected, as could our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have rights in some intellectual property that has been discovered through government funded programs and thus is subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the intellectual property rights assigned to us and/or in-licensed to us have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. For example, all of the intellectual property rights licensed to us under our license agreement with Princeton University have been generated using U.S. government funds. As a result, the U.S. government has certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third-party if the government determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail, or the applicable licensor fails, to disclose the invention to the government, elect title, and file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us, or the applicable licensor, to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that, under the circumstances, domestic manufacture is not commercially feasible. This preference for U.S. manufacturing may limit our ability to license the applicable patent rights on an exclusive basis under certain circumstances. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into future arrangements involving government funding, and we make or license inventions that result from such funding, intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh-Dole Act. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions of the Bayh-Dole Act may similarly apply. Any exercise by the government of certain of its rights could harm our competitive position, business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on technology that is licensed to us by Princeton University. Any loss of our rights to this technology could prevent us from selling our products. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some technology that relates to analysis of nucleic acids is licensed exclusively to us from Princeton University, or Princeton. We do not own the patents that underlie this license. Our rights to use this technology and employ the inventions claimed in the licensed patents are subject to the continuation of and compliance with the terms of the license. Our principal obligations under our license agreement with Princeton are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">royalty payments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual maintenance fees;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">using commercially reasonable efforts to develop and sell a product using the licensed technology and developing a market for such product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paying and/or reimbursing fees related to prosecution, maintenance and enforcement of patent rights; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing certain reports. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we breach any of these obligations, Princeton may have the right to terminate or modify the license, which could result in our being unable to develop, manufacture and sell our products or a competitor gaining access to the relevant technology. Termination or certain modifications of our license agreement with Princeton would have a material adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a party to a number of other agreements that include licenses to intellectual property, including non-exclusive licenses. We may need to enter into additional license agreements in the future. Our business could suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we have done previously, we may need or may choose to obtain licenses and/or acquire intellectual property rights from third parties to advance our research or begin commercialization of our current or future products or services, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our current or future products or services in the absence of such a license. We may fail to obtain any of these licenses or intellectual property rights on commercially reasonable terms. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected products or services, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technologies and processes infringe any intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether to take action to enforce any intellectual property rights against an allegedly infringing product or process of a third-party; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of licensed technology in relation to our development and commercialization of our products and services, and what activities satisfy those diligence obligations; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how, such as intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product or service, or the dispute may have an adverse effect on our results of operation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to agreements pursuant to which we in-license intellectual property, we may in the future grant licenses under our intellectual property, or sell certain intellectual property. Like in-licenses, out-licenses can be complex and disputes may arise </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">between us and our licensees, such as the types of disputes described above. Moreover, licensees may breach their obligations, or we may be exposed to liability due to our failure or alleged failure to satisfy our obligations. Any such occurrence could have an adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any of our partners is sued for infringing intellectual property rights of third parties, it would be costly and time consuming, and an unfavorable outcome in that litigation could have a material adverse effect on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success also depends on our ability to develop, manufacture, market and sell our products and technologies and perform our services without infringing the proprietary rights of third parties. Numerous U.S. and foreign-issued patents and pending patent applications owned by third parties exist in the fields in which we are developing manufacturing, marketing and selling products and technologies and performing services. As part of a business strategy to impede our successful commercialization and entry into new markets, competitors may allege that our products, technologies and/or services infringe their intellectual property rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could incur substantial costs and divert the attention of our management and technical personnel in defending ourselves against claims of infringement made by third parties. Any adverse ruling by a court or administrative body, or perception of an adverse ruling, may have a material adverse impact on our ability to conduct our business and our finances. Moreover, third parties making claims against us may be able to obtain injunctive relief against us, which could block our ability to offer one or more products, technologies or services and could result in a substantial award of damages against us. In addition, since we sometimes indemnify customers, collaborators or licensees, we may have additional liability in connection with any infringement or alleged infringement of third-party intellectual property. Intellectual property litigation can be very expensive, and we may not have the financial means to defend ourselves or our customers, collaborators and licensees. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, there may be pending applications, some of which are unknown to us, that may result in issued patents upon which our products, services or proprietary technologies may infringe. Moreover, we may fail to identify issued patents of relevance or incorrectly conclude that an issued patent is invalid or not infringed any of our products, services or proprietary technologies. There is a substantial amount of litigation involving patents and other intellectual property rights in our industry. If a third-party claims that we or any of our licensors, customers or collaboration partners infringe upon a third-party&#8217;s intellectual property rights, we may have to: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to obtain licenses that may not be available on commercially reasonable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">abandon any product or service alleged or held to infringe, or redesign our products or technologies or processes to avoid potential assertion of infringement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial damages including, in exceptional cases, treble damages and attorneys&#8217; fees, which we may have to pay if a court decides that the product or proprietary technology at issue infringes upon or violates the third-party&#8217;s rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial royalties or fees for, or grant cross-licenses to, our technology; or </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents we license in. In the event of infringement or unauthorized use, we may file one or more infringement lawsuits, which can be expensive and time-consuming. An adverse result in any such litigation proceedings could put one or more of our patents at risk of being invalidated, being found to be unenforceable, and/or being interpreted narrowly and could put our patent applications at risk of not issuing and/or could impact the validity or enforceability positions of our other patents or those we license. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations, continue our internal research programs, in-license needed technology, pursue, obtain or maintain intellectual property rights, or enter into development partnerships that would help us bring our products, technologies or services to market. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patent litigation can be very costly and time-consuming. An adverse outcome in such litigation or proceedings may expose us or any of our future development partners to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our issued patents could be found invalid or unenforceable if challenged in court or at the Patent Office or other administrative agency, which could have a material adverse impact on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our partners were to initiate legal proceedings against a third-party to enforce a patent related to one of our products, technologies or services, the defendant in such litigation could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are validity challenges by the defendant against the subject patent or other patents before the USPTO. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement, failure to meet the written description requirement, indefiniteness, and/or failure to disclose the best mode or to claim patent eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO, or made a misleading statement, during prosecution. Additional grounds for an unenforceability assertion include an allegation of misuse or anticompetitive use of patent rights, and an allegation of incorrect inventorship with deceptive intent. Third parties may also raise similar claims before the USPTO even outside the context of litigation. The outcome is unpredictable following legal assertions of invalidity and unenforceability. With respect to the validity question, for example, we cannot be certain that no invalidating prior art existed of which we and the patent examiner were unaware during prosecution. These assertions may also be based on information known to us or the Patent Office. If a defendant or third-party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the claims of the challenged patent. Such a loss of patent protection would or could have a material adverse impact on our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to us, and/or that their other clients or former employers allegedly have rights in our intellectual property, which could subject us to costly litigation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the life sciences industry, we engage the services of consultants and independent contractors to assist us in the development of our products, technologies and services. Many of these consultants and independent contractors were previously employed at, or may have previously or may be currently providing consulting or other services to, universities or other technology, biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may become subject to claims that our company, a consultant or an independent contractor inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. We may similarly be subject to claims stemming from similar actions of an employee, such as one who was previously employed by another company, including a competitor or potential competitor. We may become subject to claims that one or more current or former employees, consultants, advisors, or independent contractors of ours owns rights in our intellectual property and/or has assigned or is under an obligation to assign rights in our intellectual property to another party. This may include a competitor of ours. If a competitor has rights in our patents, the competitor or a licensee or related entity of the competitor may be able to make, use, sell, import, and/or export the patented technology without liability to us under our patents or the patents we license. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team. If we were not successful, we could lose valuable intellectual property rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, contractors, and, as applicable, advisors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign or may be alleged to ineffectively assign intellectual property rights to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant to which such academic advisor is required to assign any inventions developed in connection with providing services to us, such academic advisor may not have the right to assign such inventions to us, as it may conflict with his or her obligations to assign all such intellectual property to his or her employing institution. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we sometimes enter into agreements where we provide services to third parties, such as customers. Under such circumstances, our agreements may provide that certain intellectual property that we conceive in the course of providing those services is assigned to the customer. In those cases, we may not be able to use that particular intellectual property in, for example, our work for other customers without a license. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could materially and negatively affect our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, maintaining, and defending patents on current and future products, technologies and services in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, regardless of whether we are able to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevent third parties from practicing our inventions in the U.S., we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products, technologies or services, and further, may export otherwise infringing products or technologies to territories where we have patent protection, but enforcement is not as strong as it is in the U.S. These products, technologies or services may compete with our products, technologies or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents or marketing of competing products, technologies or services in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license and may adversely impact our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and our partners also face the risk that our products or components thereof are imported, reimported, or exported into markets with relatively higher prices from markets with relatively lower prices, which would result in a decrease of sales and any payments we receive from the affected market. Recent developments in U.S. patent law have made it more difficult to stop these and related practices based on theories of patent infringement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products or technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other life science industry companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents involve both technological complexity and legal complexity. Therefore, obtaining and enforcing patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act, or the AIA, became effective on March 16, 2013. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the AIA is that the U.S. transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third-party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent claiming or disclosing an invention of ours even if we had made the invention before it was made by the third-party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. Additionally, there can be a trade-off between obtaining an earlier filing date, and waiting to obtain additional data and/or further refine a patent application. In some circumstances, the effects of a decision to pursue an earlier filing or a later filing will not be known until prior art or third-party activities are subsequently discovered, such as by the USPTO or by a third-party seeking to challenge patent rights. These circumstances may apply, for example, to patent applications prepared and filed around the time of the implementation of the AIA, or with a priority application that preceded the implementation of the AIA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the AIA are changes that limit where a patent holder may file a patent infringement suit and providing additional opportunities for third parties to challenge an issued patent in the USPTO. This applies to all of our owned and in-licensed U.S. patents, even those issued before March 16, 2013. Because of a lower standard for evidence in USPTO proceedings compared to the standard for evidence in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a court action. Accordingly, a third-party may try to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third-party in court. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In addition, the contours of the laws under the AIA are subject to further judicial interpretation and/or legislative changes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years, such as Impression Products, Inc. v. Lexmark International, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., Mayo Collaborative Services v. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prometheus Laboratories, Inc. and Alice Corporation Pty. Ltd. v. CLS Bank International, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with our ability to obtain patents in the future, this combination of events has created uncertainty as to the value of patents, once obtained, including patents in the molecular biology analysis and diagnostic space in particular. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. In some cases, our licensors may be responsible for these payments, thereby decreasing our control over compliance with these requirements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use third-party open source software components in future products or technologies, and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell such products or technologies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our current products do not contain any software tools licensed by third-party authors under &#8220;open source&#8221; licenses, we may choose to use open source software in future products. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code. Some open source licenses may contain requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source licenses, be required to release the source code of our proprietary software to the public. This would allow our competitors to create similar products with less development effort and time, and ultimately could result in a loss of product sales. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to monitor any use of open source software to avoid subjecting our products to conditions, we do not intend, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that any such licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to commercialize our products. Moreover, we cannot assure investors that our processes for controlling our use of open source software in our products will be effective. If we are held to have breached the terms of an open source software license, we could be required to seek licenses from third parties to continue offering our products on terms that are not economically feasible, to re-engineer our products, to discontinue the sale of our products if re-engineering could not be accomplished on a timely basis, or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, operating results, and financial condition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use third-party software that may be difficult to replace or cause errors or failures of our products that could lead to lost customers or harm to our reputation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use software licensed from third parties in our products. In the future, this software may not be available to us on commercially reasonable terms, or at all. Any loss of the right to use any of this software could result in delays in the production of our products until equivalent technology is either developed by us, or, if available, is identified, obtained and integrated, which could harm our business. In addition, any errors or defects in third-party software or other third-party software failures could result in errors or defects or cause our products to fail, which could harm our business and be costly to correct. Many of these providers attempt to impose limitations on their liability for such errors, defects or failures, and, if enforceable, we may have additional liability to our customers or third-party providers that could harm our reputation and increase our operating costs. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to maintain our relationships with third-party software providers and to seek software from such providers that does not contain any errors or defects. Any failure to do so could adversely impact our ability to deliver reliable products to our customers and could harm our results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third-party has intellectual property rights that cover or impact our use of our technologies, we may not be able to fully use or extract value from our intellectual property rights. For example: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop and/or use technologies that are similar to our technologies or aspects of our technologies but that does not cover the claims of any our patents or patents that may issue from our patent applications or those we license;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the licensor of our licensed-in patents might not have been the first to make the inventions disclosed and/or claimed in a pending patent application that we own or license;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the licensor of our licensed-in patents might not have been the first to file patent applications disclosing and/or claiming an invention;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies without infringing our or our licensors&#8217; intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications that we own or license may not lead to issued patents or may not result in the claims that we want (for example, as to the scope of issued claims, if any);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents, if issued, that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to obtain and/or maintain necessary or useful licenses on reasonable terms or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or in-license additional proprietary technologies that are patentable; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents or other intellectual property of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business and results of operations. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1898"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Securities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our securities has been and may in the future be volatile or may decline regardless of our operating performance, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and may continue to be volatile. The daily closing market price for our common stock has varied significantly, ranging between a high price of $15.57 on February&#160;16, 2021 and a low price of $1.85 on February&#160;23, 2022. During this time, the price per share of common stock has ranged from an intra-day low of $1.63 per share to an intra-day high of $15.69 per share. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our securities is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the risk factors discussed in this section and elsewhere in our Annual Report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercial progress in marketing and selling our genome analysis systems, including sales and revenue trends;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments related to our laboratory facilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased competition in the diagnostics services industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure or funding of research at academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies, including changes that would affect their ability to purchase our products, consumables and technologies;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to obtain and/or maintain coverage and adequate reimbursement for our Lineagen products and diagnostic assays and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of our customers to obtain and/or maintain coverage and adequate reimbursement for their services using our Saphyr systems or our NxClinical software;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturers and suppliers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to establish future collaborations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new testing services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions,  dispositions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth, if any, of our targeted markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure or discontinuation of any of our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cash position;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to meet the estimates and projections of the investment community and securities analysts or that we may otherwise provide to the public;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industries or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuances of debt or equity securities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our securities by us or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our securities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffectiveness of our internal controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data breaches of our company, providers, vendors or customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including our ability to adequately protect our proprietary rights in our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political and economic conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, infectious diseases, conflict, civil unrest, epidemics or pandemics including COVID-19, outbreaks, resurgences or major catastrophic events; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for life science technology companies in particular (including companies in the diagnostic, genomic and biotechnology related sectors), have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our securities, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to comply with the applicable continued listing requirements or standards of The Nasdaq Capital Market, Nasdaq could delist our common stock.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from The Nasdaq Capital Market or if we are unable to transfer our listing to another stock market. In order to maintain this listing, we must satisfy minimum financial and other continued listing requirements and standards, including a requirement to maintain a minimum bid price of the Company's common stock of $1.00 per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in a letter dated April 22, 2020, or the Notice, we were notified by the Nasdaq Stock Market LLC, or Nasdaq, that for 30 consecutive trading days preceding the date of the Notice, the bid price of our common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2), or the Minimum Bid Price Requirement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2021, Nasdaq notified that Company that it had regained compliance with the Minimum Bid Price Requirement because the closing bid price of our common stock had been at least $1.00 per share or greater from December 29, 2020 to January 12, 2021. Although we have regained compliance with Nasdaq continued listing requirements, if we fail to satisfy another Nasdaq requirement for continued listing, Nasdaq staff could provide notice that our common stock may become subject to delisting. We cannot assure you that such an event will not happen and, if it does, that we will be able to regain compliance. Accordingly, there can be no guarantee that we will be able to maintain our Nasdaq listing. If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing. In addition, delisting of our common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, could result in a loss of current or future coverage by certain sell-side analysts and might deter certain institutions and persons from investing in our securities at all. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid dividends and we do not intend to pay dividends on our capital stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividend on our capital stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend upon results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant. Accordingly, realization of a gain on your investment will depend on the appreciation of the price of our securities, which may never occur. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and 5% stockholders and their affiliates currently beneficially own a significant percentage of our outstanding voting stock. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our securities that you may feel are in your best interest as one of our stockholders</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain effective internal control over financial reporting, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause adverse effects on our business and may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with accounting principles generally accepted in the U.S. Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, we concluded there was a material weakness in our internal control environment over financial reporting because we did not have a sufficient number of resources to support the growth and complexity of our financial reporting requirements. This material weakness contributed to a material weakness in our control activities based on the criteria set forth in the 2013 Framework. Specifically, the design of certain controls did not adequately provide appropriate segregation of duties. The failure to maintain appropriate segregation of duties had a pervasive impact and as such, this deficiency resulted in a risk that could have impacted all financial statement account balances and disclosures and was therefore considered a material weakness. The material weaknesses did not result in any identified material misstatements to our financial statements, and there were no changes to previously released financial results, and as of December 31, 2021, we concluded that </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of such date our controls and procedures were effective at a reasonable assurance level due to the implementation of remediation measures that we undertook.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we were able to remediate our prior material weakness, we cannot assure you that we will not experience future material weaknesses or that we will be able to successfully remediate any such material weakness in a timely manner or at all. If our independent registered public accounting firm is subsequently unable to conclude that our internal control over financial reporting is effective, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our securities could decline, and we could be subject to sanctions or investigations by Nasdaq, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEC or other regulatory authorities and we could be subject to shareholder litigation. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal control over financial reporting, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our internal control over financial reporting as of December 31, 2021, we concluded that, as of such date, our internal control over financial reporting was effective at a reasonable assurance level  due to our implementation of the above-mentioned measures to address material weakness discussed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive-compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas. As of June 30, 2021, the market value of our common stock held by non-affiliates exceeded $700.0 million. Consequently, we are a large accelerated filer and cease to be an emerging growth company effective December 31, 2021. As a result of this transition, we are subject to certain disclosure and compliance requirements that apply to other public companies but did not previously apply to us due to our previous status as an emerging growth company and expect to incur additional legal and financial compliance costs as a result. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies will continue to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, especially as we no longer qualify as an emerging growth company or a smaller reporting company and are therefore required to comply with additional, costly disclosure and compliance requirements, subject to a transition period. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our consolidated net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products, technologies or services. For example, these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we are required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to the restrictions and limitations described below. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. All of our outstanding shares of common stock are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act in the case of our affiliates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2021, we have filed registration statements on Form S-8 under the Securities Act registering the issuance of an aggregate of 22,104,867 shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. We also intend to file future registration statements on Form S-8 under the Securities Act registering the issuance of additional shares of common stock as the number of shares that may be issued under certain employee equity benefit plans automatically increase due to &#8220;evergreen&#8221; provisions. Shares registered under these registration statements on Form S-8 are available for sale in the public market subject to vesting arrangements and exercise of options, the lock-up agreements described above and the restrictions of Rule 144 in the case of our affiliates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our securities and may prevent or frustrate attempts by our security holders to replace or remove our current management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, the president or by a majority of the total number of authorized directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our securities to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shares of common stock began trading on The Nasdaq Capital Market on September 21, 2018. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1902"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of our securities and trading volume could decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our securities will depend in part on the research and reports that securities or industry analysts publish about us or our business. As a newly public company, we have only limited research coverage on our company by equity research analysts. If securities or industry analysts elect not to initiate or continue to provide coverage of our company, the trading price for our securities would likely be negatively impacted. If one or more of the analysts who covers us downgrades our securities or publishes inaccurate or unfavorable research about our business, the price of our securities may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our securities could decrease, which might cause the price of our securities and trading volume to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales in the public market of shares of our common stock, including shares issued upon exercise of our outstanding stock options, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities class action litigation could divert our management&#8217;s attention and harm our business and could subject us to significant liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the equity securities of life sciences and biotechnology companies. These broad market fluctuations may cause the market price of our ordinary shares to decline. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharma companies have experienced significant stock price volatility in recent years. Even if we are successful in defending claims that may be brought in the future, such litigation could result in substantial costs and may be a distraction to our management and may lead to an unfavorable outcome that could adversely impact our financial condition and prospects.</span></div><div><span><br/></span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_79"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_82"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease an aggregate of approximately 35,823 square feet of office, laboratory, and manufacturing space in two buildings at our headquarters in San Diego, California, with the lease for all rented space expiring December 31, 2025. In December 2021, we executed a new lease for approximately 11,978 additional square feet of office and laboratory space in San Diego, California that expires in January 2026. In January 2022, we executed an amendment to our headquarters lease for a new unit adding an additional 5,278 square feet of office and laboratory space in San Diego, California that expires in January 2026.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, through the acquisition of Lineagen, we obtained a lease for approximately 9,710 square feet of office space in a Salt Lake City, Utah under a non-cancelable operating lease that expires in December 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, through the acquisition of BioDiscovery, we obtained a finance lease for approximately 4,786 square feet of office space in El Segundo, California that expires in February 2041. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We feel our properties are sufficient to satisfy our current needs. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceedings against us that could reasonably be expected to have a material adverse effect on our business, financial condition or results of operations. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_88"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_91"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_94"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock began trading on The Nasdaq Capital Market on September 21, 2018 under the symbol &#8220;BNGO.&#8221; Prior to such time, there was no public market for our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Holders</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;24, 2022, there were approximately 108 holders of record of our common stock. Certain shares of our common stock are held in &#8220;street&#8221; name and thus the actual number of beneficial owners of such shares is not known or included in the foregoing number.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Holders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;24, 2022, there was one holder of record of our warrants issued in our initial public offering, which are listed on the Nasdaq Stock Market LLC under the symbol &#8220;BNGOW&#8221; (&#8220;Warrants&#8221;). Certain of our warrants are held in &#8220;street&#8221; name and thus the actual number of beneficial owners of such warrants is not known or included in the foregoing number.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings for use in the operation of our business and do not intend to declare or pay any cash dividends in the foreseeable future. Any future determination to pay dividends on our capital stock would be at the discretion of our board of directors, subject to applicable laws, and would depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors considers relevant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K, or this Annual Report. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_97"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">[RESERVED]</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_100"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our financial statements and the related notes included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and expected financial results, includes forward-looking statements that </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involve risks and uncertainties. You should review the risks described in Part I, Item 1A Risk Factors and elsewhere in this Annual Report.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_103"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping, or OGM, solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Through our Lineagen business, we provide diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through our BioDiscovery business, we offer an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses in each year since our inception. Our net losses were $72.4 million and $41.1 million for the years ended December&#160;31, 2021, and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $216.1 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our sales and marketing efforts to further commercialize our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue research and development efforts to improve our existing products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional personnel; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into collaboration arrangements, if any; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur increased costs as a result of operating as a public company. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to additional risks and uncertainties as a result of the continued spread of COVID-19 and uncertain market conditions, which could continue to have a material impact on our business and financial results. We closely monitor and comply with various applicable guidelines and legal requirements in the jurisdictions in which we operate, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. If restrictions related to COVID-19 persist, we could see additional supply chain disruptions that impact our ability to produce our products and may cause us to make strategic determinations regarding, among other things, the cost and quality of the components and supplies we acquire. At various times throughout the pandemic, we have been unable to visit certain customer sites to support installation of service our OGM systems. Our manufacturing partners, suppliers, and customers, have implemented similar operational reductions. This overall reduction in activity has contributed to a decrease in sales which negatively impacted the Company&#8217;s 2021 financial results. The future effects of COVID-19 are unknown and our financial results may continue to be negatively affected in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2021, we experienced supply chain challenges, which we largely attribute to the COVID-19 pandemic. While the COVID-19 pandemic did not prevent us from operating our business during the twelve months ended December&#160;31, 2021, we experienced substantially increased cost to secure certain component parts in our products and to produce our products at our contract manufacturers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. Further, the travel restrictions on our business have limited our ability to support our global and domestic operations, including providing installation and training and customer service, which has and may continue to slow the pace of our commercial strategy, sales and marketing efforts. These negative effects could have a material impact on our operations, business, earnings, and liquidity.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_106"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of our instruments and consumables. We currently sell our products for research use only applications and our customers are primarily laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies. In addition, we provide instruments to certain customers under our reagent rental program, under which we provide an instrument to customers at no cost and the customers agree to purchase minimum quantities of consumables. Consumable revenue consists of sales of complete assays which are developed internally by us, plus sales of kits which contain all the elements necessary to run tests. We  generate service revenue from the sale of diagnostic testing services for those with autism spectrum disorder and other neurodevelopmental disabilities </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through our wholly owned subsidiary Lineagen. We also generate service and product revenue through BioDiscovery&#8217;s NxClinical software which provides customers with solutions for analysis, interpretation and reporting of genomics data. Other revenue consists of warranty and other service-based revenue. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our revenue for the periods indicated: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,695,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,230,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service and other revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,981,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,503,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes $1.1 million of revenue generated by BioDiscovery from the date of acquisition through December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects total revenue by geography and as a percentage of total revenue, based on the billing address of our customers. North America consists of the United States and Canada. EMEIA consists of Europe, Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,329,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,489,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEIA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,604,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,981,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,503,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue for our instruments and consumables includes raw material parts costs and associated freight, shipping and handling costs, contract manufacturing costs, salaries and other personnel costs, equipment depreciation, overhead and other direct costs related to those sales recognized as product revenue in the period. Cost of service and other revenue consists of third-party laboratory costs to process the diagnostic samples, salaries of our clinical technicians who interpret and deliver the results to patients, warranty services, and other costs of servicing equipment at customer sites.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of salaries and other personnel costs, stock-based compensation, research supplies, third-party development costs for new products, materials for prototypes, equipment depreciation, and allocated overhead costs that include facility and other overhead costs. We have made substantial investments in research and development since our inception, and plan to continue to make investments in the future. Our research and development efforts have focused primarily on the tasks required to support development and commercialization of new and existing products. We believe that our continued investment in research and development is essential to our long-term competitive position. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and other personnel costs, intangibles amortization, and stock-based compensation for our sales and marketing, finance, legal, human resources and general management, as well as professional services, such as legal and accounting services. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the years ended December&#160;31, 2021 and 2020:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period-to-Period&#160;Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period-to-Period Percentage&#160;Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 to 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 to 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,695,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,230,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,465,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,273,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,013,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,981,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,503,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,478,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,524,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,810,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,714,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of service and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,583,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">920,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,663,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,107,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,730,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,377,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,485,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,256,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,229,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,490,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,068,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,422,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,975,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,324,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,651,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,101,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,551,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,550,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(927,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,519,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,592,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on forgiveness of Paycheck Protection Program loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,775,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,775,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,076,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,076,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,152,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,077,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,075,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,717,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,746,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,814)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,435,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,106,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,329,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period-to-Period&#160;Change</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period-to-Period&#160;Percentage Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 to 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 to 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instrument revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,887,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,085,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,802,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumable revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,808,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,145,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,663,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,695,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,230,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,465,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,273,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,013,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,981,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,503,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,478,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased by $9.5 million, or 111% to $18.0 million for the year ended December&#160;31, 2021, as compared to $8.5 million for the same period in 2020. The increase in product sales was driven by increased demand for our Saphyr OGM solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. We believe increased demand for our OGM systems was primarily driven by increased market awareness and additional published data demonstrating the utility of OGM. During the year ended December&#160;31, 2021, the total install base of our OGM systems increased by approximately 69%, 97 as of December&#160;31, 2020 to 164 as of December&#160;31, 2021. Additionally, for the year ended December&#160;31, 2021, total flowcells sold reached 12,518, an increase of approximately 100% from the 6,311 flowcells sold during the year ended December&#160;31, 2020. The increase in service and other revenue was primarily driven by sales generated by our Lineagen and BioDiscovery subsidiaries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $8.4 million, or 146%, to $14.1 million for the year ended December&#160;31, 2021, as compared to $5.7 million for the same period in 2020. Cost of product revenue increased primarily due to increased product sales, but was also negatively impacted by unfavorable flowcell yields in the production cycle. The yield issues led us to record a $1.2 million inventory write-off in the fourth quarter of 2021, charged to cost of product revenue. If we are unable to solve for the yield issue, it could lead to lower gross margins in future periods. Cost of service and other revenue increased primarily due to costs from Lineagen sales contributing for a full year in 2021 versus a little more than one quarter in 2020.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development, or R&amp;D expenses, increased by $12.2 million, or 119%, to $22.5 million for the year ended December&#160;31, 2021 as compared to $10.3 million for the same period in 2020. This is due to headcount additions to our development teams, resulting in a $7.2 million increase in R&amp;D compensation expense. This increase was further driven by a $5.0 million increase in product development costs, including internal materials and supply consumption costs, foundry expenses, clinical trial research, and consulting costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expenses to increase in 2022 relative to 2021 as we have added headcount in order to support our efforts to develop more scalable and efficient manufacturing workflows, expand the utility of Saphyr, and develop the next versions of OGM products &#8211; including integration of OGM data into our NxClinical software. We expect that stock based compensation will drive a significant portion of the increase in expense in 2022 as a result of the stock issued as consideration in the BioDiscovery acquisition, which primarily rolls up into research and development expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $27.4 million, or 88%, to $58.5 million for the year ended December&#160;31, 2021 as compared to $31.1 million for the same period in 2020. This increase is primarily due to a $17.0 million increase in compensation costs driven by increased headcount, and a $2.6 million increase in other headcount-related expenses. Other headcount-related expenses included the cost of recruiting, temporary employment, and facilities expenses incurred in order to support increased product demand. Headcount increased 103% from 2020 to 2021 to our global sales and back-office teams to support world-wide product distribution. In addition, we increased headcount as a result of the acquisition of BioDiscovery. Professional services &#8211; including accounting, legal, investor relations, market research, and annual meeting expenses &#8211; increased by $4.6 million. In 2021, legal costs include a total of $1.5 million in transaction-related expenses that were recorded for the BioDiscovery acquisition. The increase in accounting fees was primarily due to SOX compliance efforts and accounting for the BioDiscovery transaction while the increase in annual meeting expense is tied to the increase in the number of Bionano shareholders. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect selling, general, and administrative expenses to increase in 2022 due to our continuing investment in growing and supporting our customer base. We expect stock based compensation to drive a significant portion of the increase in expense in 2022 due to stock option awards issued to senior-level Q4 2021 hires as well as awards annual refresher grants issued to executives and non-executives in February 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased by $1.6 million, or 63%, to $0.9 million for the year ended December&#160;31, 2021, as compared to $2.5 million for the same period in 2020. In May 2021, we paid off the outstanding principal balance of the Company&#8217;s March 2019 Loan and Security Agreement (&#8220;Innovatus LSA&#8221;). The Innovatus LSA was outstanding for all of 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $0.2 million, for the year ended December&#160;31, 2021, as compared to $0.0 million for the same period in 2020 resulting from positive returns on investments. Our total available-for-sale securities balance was $226.0 million as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on forgiveness of Paycheck Protection Program loan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A gain on forgiveness of our Paycheck Protection Program loan, or PPP Loan, of $1.8 million was recognized during the year ended December&#160;31, 2021 in connection with the forgiveness of the PPP Loan, including all accrued interest in full.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on debt extinguishment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A loss on debt extinguishment of $2.1 million was recognized during the year ended December&#160;31, 2021 in connection with our payment in full of the Innovatus LSA, including all accrued interest, an end of term fee, a prepayment fee, and write-off of unamortized debt issuance costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax benefit (expense)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit increased by $5.7 million, or 19,814%, to a $5.7 million benefit for the year ended December&#160;31, 2021, as compared to a $29,000 expense for the same period in 2020, driven by the acquisition of BioDiscovery. As a result of the acquisition, we recorded a $5.8 million deferred tax liability related to customer lists, patents/trademarks, developed technology, and fixed assets as part of the business combination which reduced the Company&#8217;s valuation allowance by $5.8 million, resulting in an income tax benefit for the period.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred net losses and negative cash flows from operations. We incurred net losses of $72.4 million and $41.1 million, and used $71.9 million and $38.3 million of cash from our operating activities for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $216.1 million, cash and cash equivalents of $24.6 million and $226.0&#160;million in available-for-sale securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the years ended December&#160;31, 2021 and 2020, we have generated cash flows from sales of common stock and other equity instruments. Additionally, during the year ended December 31, 2020, we relied on debt as a source of liquidity. We anticipate that future sources of liquidity will principally come from sales of common stock and other equity instruments, borrowings from credit facilities and revenue from our commercial operations. Revenue from our commercial operations has increased due to our acquisition of revenue-positive BioDiscovery. See Note 10 to our consolidated financial statements for a discussion of our recent equity activity and Note 9 to our consolidated financial statements for a discussion of terms and provisions of our debt included in this Annual Report.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our near and longer-term liquidity requirements will consist of working capital and general corporate expenses associated with the growth of our business, including, without limitation, expenses associated with scaling up our operations and continuing to increase our manufacturing capacity, sales and marketing expense, increasing market awareness of our products and services to target customers, instrument placements with customers via the reagent rental sales strategy, additional research and development expenses associated with expanding our offerings, expenses associated with continuing to build out our corporate infrastructure and expenses associated with being a public company. Our short-term capital expenditure needs relate primarily to the ongoing build out of our manufacturing and research facilities, service lab and service-related capabilities, research and development expenses related to current and future product offerings, and enhancements to information technology. We expect such expenditures to continue throughout 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive cash flows from operations primarily from the sale of our products and services. Our cash flows from operating activities are also significantly influenced by our use of cash for operating expenses to support the growth of our business. We have historically experienced negative cash flows from operating activities as we have developed our technology, expanded our business and built our infrastructure and this may continue in the future. The following table sets forth the cash flow from operating, investing and financing activities for the periods presented: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,927,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,314,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(278,062,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,450,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336,111,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,902,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Compared to 2020</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $71.9 million during the year ended December&#160;31, 2021 as compared to $38.3 million during the year ended December&#160;31, 2020. The increase in cash used in operating activities of $33.6 million&#160;is attributed to  increased headcount of 103% across the business, increased professional fees to support ongoing business operations and increase our international presence, increased spending on materials and supplies, as well as $1.5&#160;million in acquisition-related transaction costs, including financial advisor fees, legal expenses and accounting fees during the year ended December&#160;31, 2021. We anticipate our use of cash in operating activities to increase in the next 12 to 24 months due to anticipated increases in headcount and ongoing support of our growing operations, including, R&amp;D operations. As discussed below, we anticipate our available cash balance will be sufficient to fund those increases in cash used in operating activities through at least the next 12 months, but we may consider funding those increases or increases beyond the next 12 months with the methods discussed in the section below entitled &#8220;Capital Resources.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Compared to 2020</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary investing activities have consisted of capital expenditures for the purchase of capital equipment to support our expanding infrastructure, as well as the acquisitions of Lineagen and BioDiscovery to grow our business. We </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect to continue to incur additional costs for capital expenditures related to these efforts in future periods. Net cash used in investing activities was $278.1 million during the year ended December&#160;31, 2021, compared to $2.5 million during the year ended December&#160;31, 2020.  This increase in cash used in investment activities of $275.6 million is attributed to the acquisition of BioDiscovery, our new wholly owned subsidiary, as well as purchases of available-for-sale investment securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Compared to 2020</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $336.1 million during the year ended December&#160;31, 2021 as compared to $61.9 million during the year ended December&#160;31, 2020, an increase of $274.2 million. During the year ended December&#160;31, 2021, we raised approximately $311.1 million in net proceeds from executing two follow-on offerings, $10.0 million from warrant and stock option exercises, and $29.9 million in sales under our at-the-market facilities with Landenburg Thalmann &amp; Co. Inc., or Landenburg, and Cowen and Company, LLC, or Cowen. These proceeds were offset by our repayment in full of all outstanding amounts under our Innovatus LSA of  $15.0 million, including all accrued interest, the end of term fee, and a prepayment fee.    </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_115"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Resources </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had approximately $24.6 million in cash and cash equivalents, $226.0 million of available-for-sale securities, and $250.6 million of working capital.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, we sold 27.0 million shares of our common stock under our prior at-the-market facility at an average share price of $0.82, and received gross proceeds of approximately $22.1 million before deducting offering costs of $0.6&#160;million. In January 2021, we sold an additional 6.3 million shares of our common stock under the such prior at-the-market facility at an average share price of $2.68, and received gross proceeds of approximately $16.9 million before deducting offering costs of $0.4&#160;million. This at-the-market facility  was terminated effective March 22, 2021 and replaced by an ATM with Cowen and Company, LLC, or the Cowen ATM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, we completed an underwritten public offering of 33.4 million shares of our common stock, including 4.4 million shares of our common stock sold pursuant to the underwriters' exercise in full of their option to purchase additional shares. The price to the public in the offering was $3.05 per share and the underwriters purchased the shares from us pursuant to the underwriting agreement at a price of $2.867 per share. The gross proceeds to us were&#160;approximately $101.8 million before deducting underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2021, we filed an automatically effective shelf registration statement on Form S-3 (File No. 333-252216) with the U.S. Securities and Exchange Commission, or SEC, as a &#8220;well-known seasoned issuer.&#8221; The registration statement allows us to issue an indeterminate number or amount of common stock, preferred stock, debt securities and warrants from time to time in one or more offerings. However, there can be no assurance that we will complete any future offerings of securities. Any future offerings under this registration statement will be dependent upon, among other factors, market conditions, available pricing, our financial condition, investor perception of our prospects, our capital needs and our ability to maintain status as a well-known seasoned issuer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, we completed an underwritten public offering pursuant to our shelf registration statement of 38.3 million shares of our common stock, including 5.0 million shares of our common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $6.00 per share and the underwriters purchased the shares from us pursuant to the underwriting agreement at a price of $5.64 per share. The gross proceeds to us were&#160;approximately $230.0 million before deducting underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2021, we entered into a Sales Agreement with Cowen and Company, LLC, or the Cowen ATM,  or Cowen, pursuant to which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $350.0&#160;million, through or to Cowen, acting as sales agent or principal. In the third quarter of 2021, the Company sold 2.3 million shares of common stock under the Cowen ATM at an average share price of $6.15 per share, and received gross proceeds of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$13.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before deducting offering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.6&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and available for sale securities will be sufficient to fund our planned operations, obligations as they become due, and capital investments for at least the next twelve months. This estimate is based on our current business plan. This estimate does not reflect any additional expenditures resulting from potential acquisitions or strategic transactions. We have based these estimates on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. See Note 1 to our consolidated financial statements included elsewhere in this Annual Report for more information.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_2465"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our future cash outflows for contractual obligations as of December&#160;31, 2021.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease obligations, including interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,162,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,961,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations, including interest, related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,599,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,949,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,480,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,240,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,350,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,241,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,435,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,963,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,004,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,949,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease obligations relate to our office, laboratory and manufacturing space for our corporate headquarters in San Diego, California and Lineagen operations in Salt Lake City, Utah. Finance lease obligations relate to our BioDiscovery office in El Segundo, California. See Note 11, Commitments and Contingencies to our consolidated financial statements included in this Annual Report.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase obligations primarily represent commitments for purchases of inventory from our supplier as disclosed in Note 11, Commitments and Contingencies to our consolidated financial statements included in this Annual Report.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_121"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. These accounting principles require us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We believe that the estimates, judgments and assumptions are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. Historically, revisions to our estimates have not resulted in a material change to our financial statements. While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report, the significant accounting estimates that we believe are important to aid in fully understanding and evaluating our reported financial results include the following:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for employees based on an estimated grant date fair value using the Black-Scholes option-pricing method. We have elected to account for forfeitures as they occur.&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The inputs for the Black-Scholes valuation model require management&#8217;s significant assumptions. The common share price was determined by using the quoted price on the grant date. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility was estimated based on historical volatility information of peer companies that are publicly available. Our expected dividend yield assumption is zero as we have never paid dividends and have no present intention to do so in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review goodwill annually at the reporting unit level at the same time every year or when an event occurs or circumstances change such that it is reasonably possible that an impairment may exist. We have established December 31 as the annual impairment test date. We first make a qualitative assessment as to whether goodwill is impaired and if it is more likely than not that goodwill is impaired, we perform a quantitative impairment analysis to determine if goodwill is impaired. We may also determine to skip the qualitative assessment in any year and move directly to the quantitative test. For the quantitative test, we determine the fair value of the reporting unit, then compare the fair value of the reporting unit to its carrying value. Goodwill impairment is recorded for any excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The determination of fair value requires a number of significant assumptions and judgments, including assumptions about future economic conditions, revenue growth, operating margins, and discount rates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have determined that the Company is a single reporting unit for purposes of goodwill impairment testing. As of December&#160;31, 2021, we performed a qualitative assessment of goodwill impairment which included an evaluation of changes in industry, market and macroeconomic conditions as well as consideration of our financial performance and any significant trends. Our qualitative assessment indicated that it was not more likely that not that goodwill is impaired</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> No impairments of goodwill were reported during the years ended December&#160;31, 2021 and 2020.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the provisions of ASC 805, Business Combinations, in accounting for acquisitions. It requires us to recognize separately from goodwill the identifiable assets acquired and the liabilities assumed at the acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the identifiable assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are required to be recorded to our consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for business combinations requires management to make significant estimates and assumptions, especially at the acquisition date, including estimates for intangible assets, contractual obligations assumed, pre-acquisition contingencies and any contingent consideration, where applicable. Although we believe that the assumptions and estimates we have made in the past have been reasonable and appropriate, they are based in part on historical experience and information obtained from management of the acquired company and are inherently uncertain.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally use the income approach to derive the fair value of the above identified intangible assets when accounting for business combinations. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. We selected this method because we believe the income approach most appropriately measures the value of our income producing assets. This approach requires significant management judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, appropriate discount rates, terminal values and other assumptions and estimates. The estimates and assumptions used are consistent with our business plans. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of the asset. Actual results may differ from management&#8217;s estimates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record contingent consideration resulting from a business combination at its fair value on the acquisition date. On a quarterly basis, we revalue this obligation and record any increase or decrease in fair value as an adjustment to the consolidated statement of operations. Changes to the fair value of the contingent consideration obligation may result from changes to the discount rate, the passage of time, or changes in our estimate of the likelihood or timing of achieving the criteria for payment of the contingent consideration. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent reporting period. Accordingly, changes in the assumptions described above could have a material impact on the amount of income or expense we record for contingent consideration in any given period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, &#8216;&#8216;Summary of Significant Accounting Policies,&#8217;&#8217; in the accompanying notes to our consolidated financial statements included in this Annual Report for a discussion of recent accounting pronouncements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, we were an emerging growth company within the meaning of the JOBS Act. Section 107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section 102(b) of the JOBS Act, for complying with new or revised accounting standards. However, because the market value of our common stock held by non-affiliates exceeded $700.0 million as of June 30, 2021, we are no longer an emerging growth company effective December 31, 2021. As a result, we now apply public company adoption dates for new or revised accounting standards. Further, we were required to comply with the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley regarding our internal control over financial reporting as of December&#160;31, 2021.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_124"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_127"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span><br/></span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_130"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pages</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_133">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (BDO USA, LLP; San Diego, California; PCAOB ID#<ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzAvZnJhZzphMjU3YWY4NjUzZDg0OGM2YjQwYTI3MjkwNzg4MTNhZS90YWJsZTpiZmE5YzBlODBiZDg0ODlkOWI4NWM4Nzc4NzM5MTlmOS90YWJsZXJhbmdlOmJmYTljMGU4MGJkODQ4OWQ5Yjg1Yzg3Nzg3MzkxOWY5XzEtMC0xLTEtNTMzNjYvdGV4dHJlZ2lvbjo0YjVjZGU4YmVlNTM0YjBjOWRmMjBhOTViYTJmYmJhNl81NDk3NTU4MTM4OTk3_50ea7335-af64-49c1-90f3-88be0a95acf1">243</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_133">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_136">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_136">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_139">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_139">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_1846">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_1846">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_142">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_142">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_145">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_145">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_148">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_148">80</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders and Board of Directors </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Genomics, Inc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Bionano Genomics, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) and our report dated March 1, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Accounting Principle</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2021 due to the adoption of Accounting Standards Codification Topic 842, Leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of BioDiscovery, LLC.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 14 to the Company&#8217;s consolidated financial statements, the Company acquired 100% of BioDiscovery, LLC. for a purchase price of $74.8 million. As a result of the acquisition, management was required to determine estimated fair values of the assets acquired, including certain identifiable intangible assets, and liabilities assumed.    </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the determination of fair values of the identifiable intangible assets as a critical audit matter. Management applied significant judgment in determining the unobservable inputs including revenue and expense forecasts and discount rates utilized. Auditing these elements involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters, including the extent of specialized skill or knowledge needed. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary procedures we performed to address this critical audit matter included: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing the reasonableness of the revenue and expense forecasts through: (i) evaluating historical performance of the target entity, and (ii) assessing financial projections against industry metrics and peer-group companies. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing samples of opening balance sheet amounts by tracing to supporting documentation, including evaluating that the transactions were recorded in the appropriate period. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Utilizing personnel with specialized knowledge and skill in valuation to assist in: (i) assessing the reasonableness of the discount rates incorporated into the various valuation models, and (ii) performing independent estimates to evaluate the potential effect of changes in the significant assumptions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzMvZnJhZzo0NzdjODk2ZWM3MWU0NjJhOWRjZGUyNTg3MzI3ZDEwOC90ZXh0cmVnaW9uOjQ3N2M4OTZlYzcxZTQ2MmE5ZGNkZTI1ODczMjdkMTA4XzU0OTc1NTgxNDUzOTg_dd9249e5-ddd6-45f3-9d58-9008c2d01d86">BDO USA, LLP</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzMvZnJhZzo0NzdjODk2ZWM3MWU0NjJhOWRjZGUyNTg3MzI3ZDEwOC90ZXh0cmVnaW9uOjQ3N2M4OTZlYzcxZTQ2MmE5ZGNkZTI1ODczMjdkMTA4XzU0OTc1NTgxNDU0MDA_9c91e908-fce3-4649-9e99-06818e3cf91c">San Diego, CA</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2022</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzUtMS0xLTEtMQ_1a1f02b7-f53f-4a67-b1b0-18b437b5c729">24,571,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzUtMy0xLTEtMQ_784dffad-a67b-4abb-9e37-e03d05d52224">38,449,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMS0xLTEtMjE0OTY_d3650a73-f428-4005-ab01-37e5d81d88fa">226,041,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMy0xLTEtMjE0MTY_742e3cad-bab2-4b86-b74c-6940e65490db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMC0xLTEtMS90ZXh0cmVnaW9uOmM0OTljNWUxZDNiZTRkZTc4NDYxNzNmNDA1ZDM2ZDJjXzM4NDgyOTA2OTczNTI_6d485b8b-5013-4de2-ab8b-0509aff8f3aa">690,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMC0xLTEtMS90ZXh0cmVnaW9uOmM0OTljNWUxZDNiZTRkZTc4NDYxNzNmNDA1ZDM2ZDJjXzM4NDgyOTA2OTczNDY_ed865f89-ee41-478b-b644-27093dfb5826">2,119,000</ix:nonFraction> as of December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMS0xLTEtMQ_68348e81-f649-4445-a36b-7f3bed04cddf">4,934,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMy0xLTEtMQ_6c6cf906-932c-43a5-ad1b-21e874f54cb9">2,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzctMS0xLTEtMQ_1bb63df4-5320-4f50-bcdf-4a6465fdea00">12,387,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzctMy0xLTEtMQ_f55ab2d3-98cf-47fa-a4d1-268509e02b0d">3,315,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzgtMS0xLTEtMQ_ac98ce53-25b4-4a13-833d-6c0d074d0a0c">4,481,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzgtMy0xLTEtMQ_4594ef88-2bd6-4023-bd65-5c55804228fc">2,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzktMS0xLTEtMQ_0609da75-5a60-4539-9e83-07df2150d1ce">272,414,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzktMy0xLTEtMQ_5d863386-1fe6-45c9-bc57-d30c68d39654">46,789,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEwLTEtMS0xLTE_304eb99b-7a41-47e1-acd4-b25247dd4a49">10,318,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEwLTMtMS0xLTE_03e38186-d097-4744-b3fd-7cbe67029d2e">4,910,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEyLTEtMS0xLTMzNDI0_f0d109ea-fdb0-488a-9da8-f7e55b6e0553">6,691,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEyLTMtMS0xLTMyNzcy_12e47d72-3bdf-442f-b42d-814b2587312a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets, related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEzLTEtMS0xLTMzNDI0_44bb6256-ecbd-4767-b9f2-2691469eb942">3,926,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEzLTMtMS0xLTM0ODY1_3596defc-e3fe-41c3-ab27-616e4c5b6a73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzExLTEtMS0xLTE_10eafb7d-6d4f-44cf-88cf-47a25e23ad25">26,842,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzExLTMtMS0xLTE_1a65e9bd-b389-4323-88c2-27a3c26e0650">1,475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEyLTEtMS0xLTE_e78db5b9-aa7e-4552-a14a-b71866cec2b6">56,160,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEyLTMtMS0xLTE_8b232ee1-e117-4643-a623-c00e8d72cd76">7,173,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEzLTEtMS0xLTE_5199011c-f50d-442b-9e58-0c021c8c0706">749,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEzLTMtMS0xLTE_4fb79398-f4ad-402c-85ea-b62bfc0082d5">103,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE0LTEtMS0xLTE_95411403-d06b-426f-b55f-08a40fe02454">377,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE0LTMtMS0xLTE_fa7d81d1-838f-4fb6-91cf-667da2ee12bf">60,450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE3LTEtMS0xLTE_c65fef37-8893-4cb2-aa38-b0bbb1388c2f">9,696,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE3LTMtMS0xLTE_f26bee22-0a1a-4c8c-b22e-c6a1808cf50b">2,930,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE4LTEtMS0xLTE_fccc6491-7723-4e96-a81d-07c7fd96a2c2">9,694,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE4LTMtMS0xLTE_1bdf9d11-b885-4721-9fa5-abe158f7dd7f">5,599,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE5LTEtMS0xLTE_59a97c12-276a-44e4-8558-03ba5b95e01e">684,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE5LTMtMS0xLTE_74b54746-7253-4c95-a2f9-0176c0dd31b8">416,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTEtMS0xLTMzNDM3_c0826a05-37e8-493f-82bc-a930b75666e7">1,467,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTMtMS0xLTQzMzEx_f7a3f7f9-c9fd-415f-93b3-a4654b5d6f37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liability, related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTEtMS0xLTMzMjYy_44c5d1a2-1bdf-4eb3-a8a5-98c5fd817bf1">299,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTMtMS0xLTMzMjYy_2d3df1f3-12f7-43d7-9836-7b7c34fc7d57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIxLTEtMS0xLTE_bc29b38e-6a17-4549-9adc-8c2bcf01ea7b">21,840,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIxLTMtMS0xLTE_465bd712-3ad3-41ea-8f00-6bd4ad04f00f">8,945,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTEtMS0xLTM2NTc1_e9650819-4000-497f-9202-9e138dc9e86e">5,288,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTMtMS0xLTQzMzEx_2da2c34e-d4a2-4b58-8a7e-b3a6accc8081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liability, net of current portion, related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTEtMS0xLTM2NTc1_28a47357-c503-4997-800f-ad228e8c20e0">3,642,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTMtMS0xLTQzMzEx_872949e2-a588-4b6b-9557-e588ce61333b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="bngo:ContingentConsiderationFairValueOfContingentLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTEtMS0xLTUzMjY0_6cdf920c-a47f-486e-815a-58c103b121eb">9,066,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="bngo:ContingentConsiderationFairValueOfContingentLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTMtMS0xLTUzMjY3_d897bfaa-bbca-4bcc-a9d6-6382e66a3e9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIyLTEtMS0xLTE_8073e0f5-bcea-4de6-b83b-15d1a4374213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIyLTMtMS0xLTE_15e9aca7-63f2-4561-a296-5b2ffc14f1a1">16,325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIzLTEtMS0xLTE_764651aa-ddbf-49bb-8259-05749765220a">146,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIzLTMtMS0xLTE_0d8cb8f8-5db8-4a72-962e-31ca9570be0f">98,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTEtMS0xLTE_f1d6c37c-7f02-4e21-8540-2baa9dc4283b">39,982,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTMtMS0xLTE_cffe0a7b-7b03-4bee-87d6-97bff7ee9748">25,368,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzM0LTEtMS0xLTUzMjcx_827718dc-1ec4-44f8-a552-8be2b92c0826"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzM0LTMtMS0xLTUzMjcx_8693db71-e6c5-49c1-a409-d0ddb8a71f58"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfMzg0ODI5MDY5NzMyNA_38652c6b-3873-4d6e-abd9-13f261a6ade9"><ix:nonFraction unitRef="usdPerShare" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfMzg0ODI5MDY5NzMyNA_f0eeb0ba-36c4-4a7b-9ed8-af77f1e07de9">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfMzg0ODI5MDY5NzMyOA_ebb864f2-5de9-4ba5-a813-7705e9b36bb4"><ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfMzg0ODI5MDY5NzMyOA_f4e852ab-88b0-4a3d-851a-3c0de7b6016e">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfNTQ5NzU1ODEzOTAwMQ_59d27b54-0f33-4759-b1b3-271e18d47055"><ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfNTQ5NzU1ODEzOTAwMQ_7e41969e-318e-44ce-b299-c5d76ff21a8d"><ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfNTQ5NzU1ODEzOTAwMQ_b054fc5e-f28c-498d-b3f1-1b1a747d0de1"><ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfNTQ5NzU1ODEzOTAwMQ_f271d3ed-96bd-4902-99fb-ea83e582230b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of December&#160;31, 2021 and 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTEtMS0xLTIzNTYw_8f2946c3-7cb5-46e3-af92-e5232cf52949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTMtMS0xLTIzNTYw_9f6c713e-31d9-427a-b8d7-15def6bd21d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzc0_115fae02-0270-42b3-8950-658783166a72"><ix:nonFraction unitRef="usdPerShare" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzc0_b70b67e4-a252-4c1d-8bfc-c462f7c3dc79">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzc5_4f34b870-5cc7-49d6-a4dd-87b99776e07f"><ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzc5_634437bb-68b1-4695-b8bd-eb7d54fe22d9">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzg3_71265059-c854-41d5-9225-5b305a2de873"><ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzg3_a6538da1-b693-4970-9c47-1ebce32d4b4b">289,602,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzkx_9daaeb3d-3494-4fb7-be40-3ede44023d03"><ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzkx_f7701f21-8cd0-42a9-8be7-47adc757ca6f">189,953,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTEtMS0xLTE_6293e231-46f7-4ce4-86b7-0e32c6f81fdc">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTMtMS0xLTE_0ecbc6bf-d625-499f-9897-90e1bb36feea">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMwLTEtMS0xLTE_71cef66d-2536-4fe5-aac8-880c4c2b1814">553,747,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMwLTMtMS0xLTE_f06597bf-bbac-4a9c-9520-adabba5388a7">178,747,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMxLTEtMS0xLTE_6fb933fa-1a6e-4abf-b356-9d1e3d666604">216,119,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMxLTMtMS0xLTE_08dfec40-43e6-45ef-a580-7f824cddf927">143,684,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMzLTEtMS0xLTIxNTIy_1005712c-c1b8-42d5-943b-6c9f01996461">539,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMzLTMtMS0xLTIxNDg1_04a83489-712d-4fcc-8ef3-e78f300f0cca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMyLTEtMS0xLTE_53c260f9-b431-46a9-909a-ef2acaf54b76">337,118,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMyLTMtMS0xLTE_b42ebdbd-71ad-4522-9a2d-07ae22aca43a">35,082,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMzLTEtMS0xLTE_abf5ee74-634c-4a49-acb7-bc3051d27351">377,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMzLTMtMS0xLTE_88b41bea-9e45-42f6-ab23-7ec345c9dd00">60,450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:11pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzMtMS0xLTEtMQ_d9beba78-71cc-4f04-b734-ab0046810c28">11,695,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzMtMy0xLTEtMQ_dcbbf629-6083-4ab3-93fb-c68c0f4958be">6,230,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzQtMS0xLTEtMQ_79e3525b-e535-4a63-80fa-8bebd3ee77eb">6,286,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzQtMy0xLTEtMQ_ac42e084-a8e6-4124-9a0a-273eec4dc8f7">2,273,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzUtMS0xLTEtMQ_1712abe4-b074-4db4-b0a9-540c2083e00e">17,981,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzUtMy0xLTEtMQ_9c56ea91-2ee3-4fdc-94a1-1119b9aa6cd5">8,503,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzctMS0xLTEtMQ_0fc7b170-570c-47b5-af65-2d26afb1c9c7">10,524,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzctMy0xLTEtMQ_9a8d987c-50ab-4060-8a05-8d1ee62b53fa">4,810,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of service and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzgtMS0xLTEtMQ_2e4e5235-dd53-4b82-af55-02c76617722b">3,583,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzgtMy0xLTEtMQ_03d00fe1-c0a0-4ee1-b316-9de9dff2acba">920,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzktMS0xLTEtMQ_71a73dcc-ee99-4bc2-839f-d3c0d21b4b71">14,107,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzktMy0xLTEtMQ_2265663e-f42b-46c9-8794-906d591635ba">5,730,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzExLTEtMS0xLTE_25fb1f95-a2e3-4c22-bdf3-5ffd5bc7d570">22,485,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzExLTMtMS0xLTE_d173bc65-a18e-4108-9657-4242673e4a7d">10,256,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzEyLTEtMS0xLTE_76d5966c-cbe0-4d10-9d30-e115ec705717">58,490,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzEyLTMtMS0xLTE_1e63027d-9d3b-428d-afd7-196cb7166cf6">31,068,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzEzLTEtMS0xLTE_c50b1a89-3f4f-493f-9fa5-e637b976078b">80,975,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzEzLTMtMS0xLTE_10670247-76fc-48d3-8186-ea9bc280455a">41,324,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE0LTEtMS0xLTE_14dec5b6-4bf1-4102-baae-a4f8353e519d">77,101,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE0LTMtMS0xLTE_a08f334f-3b45-46f7-b8a1-4ceb27f978ca">38,551,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE2LTEtMS0xLTIyMTI3_ba495941-1c5f-45be-aefd-822fee013045">236,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE2LTMtMS0xLTIyMTMz_510aaac5-b487-4c78-935c-a673b253867c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE2LTEtMS0xLTE_ebba1f30-dd7c-4ea3-8c4f-ad85f18078d0">927,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE2LTMtMS0xLTE_7024d21f-1ab6-4f30-a4a0-f7412e2c2d84">2,519,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on forgiveness of Paycheck Protection Program Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE4LTEtMS0xLTIxOTk0_7c77f467-d889-4401-990a-c5286f9a7683">1,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE4LTMtMS0xLTIyMDIz_e60a874f-25f0-4a25-9acb-aed803308922">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE3LTEtMS0xLTE_f0792a0f-529d-43d0-acce-f7665a66651b">2,076,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE3LTMtMS0xLTE_8f993db1-35de-4190-b43b-ab95dfa852d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE4LTEtMS0xLTE_6fc906a8-1564-4732-a522-716c2776c813">59,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE4LTMtMS0xLTE_72a064ad-0781-46f6-bbfb-e0b9e7426e9c">7,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE5LTEtMS0xLTE_31fc5b23-56bc-4d9b-8fdf-1643dac97691">1,051,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE5LTMtMS0xLTE_51c6dcc6-4b16-4c8b-80cb-b6773f10735b">2,526,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIwLTEtMS0xLTE_1f0ad0c4-3720-4dbd-872c-dea0b9d0cb2e">78,152,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIwLTMtMS0xLTE_fa099939-509c-4f76-8821-c292d1809b11">41,077,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIxLTEtMS0xLTE_c6f33af1-f542-4c03-8e6f-5b4a83cb59c9">5,717,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIxLTMtMS0xLTE_98dbbb3d-25c5-4f4f-ac73-196732b7deda">29,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIyLTEtMS0xLTE_fc547125-81b8-480d-8fe6-3390eb2712bf">72,435,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIyLTMtMS0xLTE_96d30954-9c14-4684-ac30-c16b49d763d3">41,106,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIzLTEtMS0xLTE_9a51702a-c549-4cc8-99ab-7cfe13842636">0.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIzLTMtMS0xLTE_c8f76e20-92ff-4928-a21a-9535a2ac93b8">0.39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzI0LTEtMS0xLTE_9bb6005c-3c79-4a67-b055-ca44ae359deb">276,782,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzI0LTMtMS0xLTE_5076a045-4e62-426a-b1f2-14ca1be899bd">104,251,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:11pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_1846"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.   </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Loss:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl8yLTEtMS0xLTIxNTc0_73713bc9-603b-404d-be81-3751c0772d3c">72,435,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl8yLTMtMS0xLTIxNTc0_8e18be2d-0c9b-4bfe-8377-e34e92b94618">41,106,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) on investment securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl8zLTEtMS0xLTIxNTc0_4813443b-65dc-4e08-a2ea-b3c8ab7520fd">539,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl8zLTMtMS0xLTIxNTc0_4e245e1f-3421-417d-98a1-3c26f62f946e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive Loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl80LTEtMS0xLTIxNTc0_36744b34-5054-40c3-aae0-476c18862dc4">72,974,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl80LTMtMS0xLTIxNTc0_2efd7fef-7b05-48ff-bcda-26ee035e8e95">41,106,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.   </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idef8a112a8af49b29859c89619c7063f_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTItMS0xLTE_65e65398-c048-4ffb-84a2-c8d5acd3832d">34,274,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef8a112a8af49b29859c89619c7063f_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTQtMS0xLTE_69253a04-2fad-4a95-84c9-98907ead3134">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb6eb48fccd436d82f456c60a03129e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTYtMS0xLTE_55f6d3b0-8e00-4ecb-b7a7-689308740ca6">106,188,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab96b4f9d91c40b3bcff03e74ce07d85_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTgtMS0xLTE_9d8f0593-5ade-4235-a220-f48684bc87b3">102,578,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTEwLTEtMS0x_e81a9ce2-63ef-4183-8f46-1d2dad3f0188">3,613,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE1LTItMS0xLTIyMjYw_adc8d840-a9f2-4a05-92c4-4a2839755ed0">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE1LTYtMS0xLTIyMjYw_5604ec32-c4c1-4e59-9abc-0a51a136b978">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE1LTEwLTEtMS0x_35135852-360a-4572-b84e-4c488d28e326">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE2LTYtMS0xLTE_068aa3ea-e74f-40df-8f87-5211f9c09771">1,554,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE2LTEwLTEtMS0x_1676ccdb-c2d5-44bd-a962-9d2aa4eed2ac">1,554,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE3LTItMS0xLTIyMjYw_2ea8ba4b-c7d3-4cc2-8aaa-3dc8ec47a208">43,921,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE3LTQtMS0xLTIyMjYw_9141c00f-b7b6-4bcd-a655-79b85e90a4f8">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE3LTYtMS0xLTE_e8aec500-be41-470c-af26-5e07891df5c3">37,930,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE3LTEwLTEtMS0x_e6228bdb-580c-4822-93eb-6924216baafc">37,935,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE4LTItMS0xLTE_a84bb661-cb85-45d8-8fd5-e5f5ee25d5eb">88,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE4LTYtMS0xLTE_19d08c6c-f2ba-46db-b669-6cab3d573466">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE4LTEwLTEtMS0x_912f0004-67f1-41a1-85c9-b66c93612423">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for covenant waiver</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="bngo:StockIssuedDuringPeriodSharesCovenantWaiver" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE5LTItMS0xLTE_d507a5a4-08b0-41f5-9569-4a0cdb291e09">873,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231" decimals="-3" name="bngo:StockIssuedDuringPeriodValueCovenantWaiver" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE5LTYtMS0xLTE_849f7695-df5a-4523-ae7f-49a980ba55e3">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:StockIssuedDuringPeriodValueCovenantWaiver" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE5LTEwLTEtMS0x_887687e7-5427-433b-8b0f-1891815b4105">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for warrant exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="bngo:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIwLTItMS0xLTE_f84c0730-395c-45dc-8e90-ce60a9e4baa6">104,628,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIwLTQtMS0xLTE_155ee20a-3462-49d2-b658-d7cb887fd9c6">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231" decimals="-3" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIwLTYtMS0xLTE_5453927e-978e-407a-81e8-f5230da9c70a">28,635,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIwLTEwLTEtMS0x_2cee4184-2063-4525-91ad-efc7adf1c0c9">28,645,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIxLTItMS0xLTE_4dd6ff56-c0ea-4066-a15b-de7d73aab888">6,168,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIxLTQtMS0xLTE_4f6f2daf-567f-4cc5-963d-4e081fe9322d">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIxLTYtMS0xLTE_0ac3e7a0-6541-4b12-9d8b-dbde5ead3289">4,099,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIxLTEwLTEtMS0x_e504b441-5a42-4b5a-a8a5-d7eecdfc5639">4,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17c82a645e374a6bb89950a49d16c0b8_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIyLTgtMS0xLTIyMjYw_10334d68-f25b-45f9-a999-21341885ca43">41,106,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIyLTEwLTEtMS0x_947960aa-2418-4d46-8b26-5739ea6da29b">41,106,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0efd9aa753ee49239268311cb402902f_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTItMS0xLTE_3ce6cc3e-078c-44f3-bbd9-9ad7106728ed">189,953,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efd9aa753ee49239268311cb402902f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTQtMS0xLTE_9d458d5b-bee4-4210-acf7-e3062b236ed4">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c0ff63e4b1469dae81b41f649a9a94_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTYtMS0xLTE_d73d983c-5ac1-4813-ac9c-1858eeb3e32f">178,747,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd11d2c4283b40818c2322674b6ee110_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTgtMS0xLTE_92f15afc-e689-4ab4-a295-fbbf1632f371">143,684,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTEwLTEtMS0x_b7054dc1-d7cf-4692-8618-c8e3496f2f09">35,082,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI1LTItMS0xLTIyMjYx_dad36ceb-bb8f-49ba-bf48-88589515a25d">479,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI1LTYtMS0xLTIyMjYx_4136f230-34d5-40ec-9bc3-3a1e1a09935c">602,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI1LTEwLTEtMS0yMjI2MQ_e22c1034-ea0c-4b2f-8674-dc78a970644b">602,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI2LTYtMS0xLTIyMjYx_6c9dd461-2e9a-4927-ae42-62cf6f841436">9,719,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI2LTEwLTEtMS0yMjI2MQ_1282548d-3805-4891-8555-c30ffe1a10b7">9,719,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI3LTItMS0xLTIyMjYx_6ffed0ee-67d4-49e3-b2e9-ad466a76d799">80,178,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI3LTQtMS0xLTIyMjYx_da3d93cf-d0d6-4e76-b652-2db1593fb5b1">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI3LTYtMS0xLTIyMjYx_fc81d2df-eba1-4b45-83ab-5de93922f35b">341,015,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI3LTEwLTEtMS0yMjI2MQ_bcde2c07-3af1-4a09-834e-a0587649e37c">341,023,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for warrant exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="bngo:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI4LTItMS0xLTIyMjYx_99adbdf0-3bf2-46d6-bf30-a59284cde256">10,794,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI4LTQtMS0xLTIyMjYx_b6aba601-3f3a-4af6-add9-d6676c4e0a67">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231" decimals="-3" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI4LTYtMS0xLTIyMjYx_939178b6-cdaf-47d7-8663-73166de7de1f">9,417,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI4LTEwLTEtMS0yMjI2MQ_2004e93a-0588-4a3d-b6b2-b3e0b52967c4">9,418,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI5LTItMS0xLTIyMjYx_61cda606-3e10-4f61-8809-832206d55b10">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI5LTYtMS0xLTIyMjYx_2cf947ea-3f0e-4d89-845c-5073fd324ba2">89,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI5LTEwLTEtMS0yMjI2MQ_e14e25ef-082b-4249-8bb4-382a11c0f464">89,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE4LTItMS0xLTUxOTQ4_befdf097-ba13-4ced-94c5-d6cf7bcfd71b">169,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTItMS0xLTMyOTI4_eaea050f-69f7-46ff-8fe6-f99b54962ffa">7,729,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTQtMS0xLTMyOTI4_1796eb28-0450-4d4e-a8c7-d6614d358b96">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTYtMS0xLTMyOTI4_6fc77c37-fbe8-47e4-a2d2-48d55fe10876">14,158,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTEyLTEtMS00MzM1Mw_11539adc-77a3-4ecd-93a2-b9ef316d20a3">14,159,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96f54a37ef346c38c3fce9c1e707621_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTgtMS0xLTIyMjYx_c2532f2c-1742-4ee6-8a22-b5c2dffcd6db">72,435,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTEwLTEtMS0yMjI2MQ_64936495-0fea-419b-814d-217e91173daf">72,435,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf2232560f854d898b520b0322a5df9d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMxLTEwLTEtMS0yMzQyMA_25ee301e-dc70-4151-b370-eba3a152d080">539,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMxLTEwLTEtMS0yMjI2MQ_c020f37a-5329-4cc5-8b65-708296b49d0d">539,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25c7362828a64a8eb87f775b1491fd99_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTItMS0xLTIyMjYx_aa6c52ec-2839-4e46-ba5a-c7ac8c897fa3">289,602,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c7362828a64a8eb87f775b1491fd99_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTQtMS0xLTIyMjYx_335f8d00-26bb-4e52-b0aa-5657dcaeacec">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45ae24785a44441a4802ef1030f892b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTYtMS0xLTIyMjYx_86ab5b1a-d61f-4bbe-98fd-e6bd973e3416">553,747,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3634a0ee07e4c1fb4cb0dc6914a2405_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTgtMS0xLTIyMjYx_fd2f4976-b238-4e1e-aa65-dc77996c5b19">216,119,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaa462baf9fc4f2680655d14713bccaa_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMyLTEwLTEtMS0zMTc4Mg_20b29f58-bd24-4edd-a381-f0e4a6c8451d">539,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTEwLTEtMS0yMjI2MQ_6c69b741-a0a8-422a-b484-7e12b7a650b6">337,118,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_145"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMtMS0xLTEtMQ_2ee88465-f785-4cee-852f-3835d043474e">72,435,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMtMy0xLTEtMQ_6d1579b8-6482-4214-9874-b8574e0e5928">41,106,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzUtMS0xLTEtMQ_ab2f90bc-685a-4650-8839-aed776e43d18">3,351,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzUtMy0xLTEtMQ_06c320b3-5b46-44ff-a7d6-f7b20d4cf9a6">1,479,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of financing lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYtMS0xLTEtNDE0MjQ_a8ff9970-eec6-442b-9a72-c6e6d2b20a05">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYtMy0xLTEtNDE1NTI_9d6e393a-3051-4ac4-a2ea-c4c45fb47591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of interest on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:AccretionExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzctMS0xLTEtNDYxNDY_ed2a649a-e3f6-4609-a6e4-9f641f97f0c2">329,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:AccretionExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzctMy0xLTEtNDYxNTM_7e5d3eee-2f0f-4ee4-914d-ad9c6227a57e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:NoncashInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzctMS0xLTEtMQ_de85d93f-ad41-4550-8824-6cc7737af552">205,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:NoncashInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzctMy0xLTEtMQ_9a1d794f-ad04-4510-b1c0-0418ef4cc6e9">1,264,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:NonCashLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzktMS0xLTEtNDk1OTg_d3b3a2ca-cc0a-4afa-9d25-ac24d09f1178">671,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:NonCashLeaseExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzktMy0xLTEtNDk2MDU_df0bb072-40e2-48d0-8791-a40a07e2fb06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of interest on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:SettlementOfInterestOnDebtNoncash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTEtMS0xLTUwMzgz_db928dbf-21d2-436f-a62d-fcd8156622d4">1,235,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:SettlementOfInterestOnDebtNoncash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTMtMS0xLTUwMzkx_29bd0291-7c79-4719-ad3b-36edf1c9fba5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzExLTEtMS0xLTUyMTA0_3b015c6f-911d-4907-a37f-3d097935dfaf">5,777,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzExLTMtMS0xLTUyMTE4_06b18502-a5e0-475b-899a-5c83584e1382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzgtMS0xLTEtMQ_0f639271-23ab-47ea-8d88-5c97bd929378">9,719,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzgtMy0xLTEtMQ_9b9221c4-8549-494e-a25d-9b23b3cfc1b9">1,554,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for bad debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzktMS0xLTEtMQ_70d29687-5d87-4925-a5fd-d6ab16e13019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzktMy0xLTEtMQ_34010c99-cc1d-4846-ba96-814ab54a3428">1,809,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on forgiveness of PPP Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTEtMS0xLTIyNjg2_6611ac5a-0b00-47b8-9d52-643e506af1e7">1,775,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTMtMS0xLTIyNjg2_7f68e830-4774-4533-89fe-d33600746657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTEtMS0xLTE_7fe74ffd-25f0-48eb-a25d-cf422afbf05f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTMtMS0xLTE_caac81d7-47ab-459e-a46c-ce8346406e23">126,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="bngo:GainLossOnExtinguishmentOfDebtCashExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzExLTEtMS0xLTE_32b0dfed-051c-461a-84f6-e5d090f8c022">1,480,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:GainLossOnExtinguishmentOfDebtCashExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzExLTMtMS0xLTE_76b82113-46b4-44ee-93d9-0e124bdae627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of leased equipment sold to customer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:CostOfLeasedEquipmentSoldToCustomer" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE1LTEtMS0xLTUwMTQ2_e53c64b1-a2ad-421d-8f32-69eeca116fe3">568,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:CostOfLeasedEquipmentSoldToCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE1LTMtMS0xLTUwMTYw_9e1bba24-1081-458a-b630-0164f6b2ea97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Client warranty exchange of fixed asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:ClientWarrantyExchangeOfFixedAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE2LTEtMS0xLTUwMTUz_2256454d-84aa-4868-9407-d3aae3dee714">539,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:ClientWarrantyExchangeOfFixedAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE2LTMtMS0xLTUwMTY3_6f68c82f-6260-4e09-9ac3-31e0a7fe42d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEzLTEtMS0xLTQxNDEx_108530ef-55c5-4886-9537-6dfffc748e4f">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE0LTMtMS0xLTQxNTM4_62df2a67-6ef2-471b-bff3-afa8139892a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities (net of assets acquired and liabilities assumed in acquisition)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE2LTEtMS0xLTE_dbaa89cf-85e2-4b1c-8fc4-433674e5d61c">493,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE2LTMtMS0xLTE_316de20a-9061-4ff3-a071-0091a7de5040">2,087,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE3LTEtMS0xLTE_185af922-01f0-42e8-b994-7d20d65b89c5">15,928,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE3LTMtMS0xLTE_ab4a415e-cca7-4379-9d3c-699168cdaede">4,201,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE4LTEtMS0xLTE_324751e4-5467-4dfb-9ef9-4323eb0f03bf">1,971,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE4LTMtMS0xLTE_fdcb1df8-b006-4ac7-a6f9-df3138819480">999,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE5LTEtMS0xLTE_e835079d-65c3-4e26-ad7a-0d0eceb26bbb">6,781,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE5LTMtMS0xLTE_7a13bcf6-effb-44df-8716-f82042186de0">1,810,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIwLTEtMS0xLTE_486418a9-cf3a-4390-a907-58882bb16a42">3,959,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIwLTMtMS0xLTE_072f256f-49c0-438d-8d81-3c4dfa522d7c">1,483,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIxLTEtMS0xLTE_d725d1c7-55cf-4dc6-a088-082d011c4991">71,927,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIxLTMtMS0xLTE_9db78ea9-2816-42a8-b0d3-d8d581d99344">38,314,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lineagen acquisition, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida156f9281c3453e97c6d3eb9345fa03_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIzLTEtMS0xLTE_3436a676-8f37-4000-8d9d-d30283492a54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIzLTMtMS0xLTE_cab770c5-01e9-4d3e-9888-b4272124aadf">2,450,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioDiscovery acquisition, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTEtMS0xLTQxNDMx_2057d96d-883a-457b-8b17-c59b219188c0">49,086,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI2LTMtMS0xLTQxNjM5_00cc9fc6-23d7-49b9-b14d-925d694bb7fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:PaymentsForPropertyAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI0LTEtMS0xLTE_2339d05e-db34-409d-8719-5a4e173cca27">822,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:PaymentsForPropertyAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI0LTMtMS0xLTE_168d1af5-1e5d-4417-ad7e-a5cd88ee93cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForConstructionInProcess" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMxLTEtMS0xLTQxNDQw_770ed110-76b0-49bf-959c-c0d46de534f9">638,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForConstructionInProcess" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI4LTMtMS0xLTQxNjU0_d1033740-0edf-4a64-a599-09bc820ffe1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of initial direct costs on lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:PaymentsForInitialCostsOnLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTEtMS0xLTQ5NzA4_2f67e64c-f9fd-4886-b68c-3fc621ec987b">607,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:PaymentsForInitialCostsOnLeases" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTMtMS0xLTQ5NzE1_30363296-961f-494c-a6f2-147328b4f131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of available for sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI2LTEtMS0xLTIyODA2_3e9412cc-f532-406d-bc35-4b3e27b3032c">313,392,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI2LTMtMS0xLTIyODA2_6877650c-2c98-4982-80a8-29076440f898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale and maturities of available for sale securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI3LTEtMS0xLTIyODA2_06da7171-4d71-478d-a3a2-4f6da0befea6">86,483,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI3LTMtMS0xLTIyODA2_fe4a2cf1-4e91-4b95-b18d-c2cf37b10850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI1LTEtMS0xLTE_5b8ef8d1-e02c-4f5f-bb7a-55db43e06e66">278,062,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI1LTMtMS0xLTE_1d9942f5-652c-4664-9ec6-73281a5d3f12">2,450,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of term-loan debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI4LTEtMS0xLTE_39ee0f9e-b6ab-48d3-b6b0-16680f6b8d86">15,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI4LTMtMS0xLTE_e58bd8f4-06b3-4605-95cf-16411ba3f4fd">5,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal payments of financing lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM5LTEtMS0xLTQxNDQ5_caf7f563-8274-4ce4-9e11-98f398950b62">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM5LTMtMS0xLTQxNTA2_22cc8b04-36e4-4c8c-8dc2-4f14b1e34360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from PPP Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:ProceedsFromPayrollProtectionProgramLoan" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTEtMS0xLTE_8e34f7ca-b834-4958-8b5a-f3ca4d6cd50d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:ProceedsFromPayrollProtectionProgramLoan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTMtMS0xLTE_e1e7a0bb-08ad-4d3e-aa08-5ed1e56eea05">1,774,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowing from line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMwLTEtMS0xLTE_98d334a2-6459-4121-9443-30a609c86745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMwLTMtMS0xLTE_b9d6cce7-b08c-4bfa-8a63-956e6de77b03">761,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of borrowing from line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMxLTEtMS0xLTE_a4e210f1-c96a-4ea6-8615-b324f947bd56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMxLTMtMS0xLTE_91679c5a-1105-4834-a0d8-09c872efa5e2">2,258,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMyLTEtMS0xLTE_d949b846-b9b5-416a-aba4-e9316e43f532">342,711,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMyLTMtMS0xLTE_80154ff0-e516-4912-8b43-1c0d4d8b8759">39,934,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offering expenses on sale of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMzLTEtMS0xLTE_489e6b67-6e14-46ef-903f-3dbaac16d73b">1,704,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMzLTMtMS0xLTE_610e7fba-2d09-42ab-bead-68627ad136e0">2,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:EmployeeStockPurchasePlanCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM0LTEtMS0xLTE_287163c1-01a9-4b7c-b839-faeed8947a82">89,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:EmployeeStockPurchasePlanCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM0LTMtMS0xLTE_719349bf-72fa-45ba-a073-d902cedeb4fb">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from warrant and option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM1LTEtMS0xLTE_287bb155-dd89-4fc1-8cba-a3bfcbdd5a11">10,020,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM1LTMtMS0xLTE_1de58107-ec6c-4dd4-bedf-88bd3032a38b">28,651,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM2LTEtMS0xLTE_44d9a6c4-8e53-498b-95ea-d775270f0c10">336,111,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM2LTMtMS0xLTE_ca66e273-da52-43e3-96fa-68445f472425">61,902,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease)  in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM3LTEtMS0xLTE_fdcba8fe-3159-45a2-b121-0bc594494afc">13,878,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM3LTMtMS0xLTE_54f5396f-e9e5-48cb-a330-fb9a61353446">21,138,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM4LTEtMS0xLTE_d1af1fb2-9e85-4aca-bf40-cfb5d4f1cb8b">38,449,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM4LTMtMS0xLTE_3fd55b51-e5a4-4be1-a9a8-26cbdc4cc229">17,311,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM5LTEtMS0xLTE_0197500b-f3c8-4ff2-8037-1145f601ccb1">24,571,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM5LTMtMS0xLTE_d7183ede-3388-4577-81ac-768e9d0506c5">38,449,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzQ2LTEtMS0xLTIyMzE1_9ab3917a-aaee-4f8e-ba60-a83ec6f3ea90">1,910,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzQ2LTMtMS0xLTIyMzE1_2925a967-d507-4f3b-88f5-da381da5b051">1,252,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzUwLTEtMS0xLTQzMjYw_86aa6916-6df9-48d3-840e-f37d20bcf012">447,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzUwLTMtMS0xLTQzMjY3_0593b5ae-e66e-4000-8e04-d271864ae8f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash financing and investing activity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock issued related to Lineagen acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida156f9281c3453e97c6d3eb9345fa03_D20210101-20211231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU1LTEtMS0xLTUxNzY3_2a767894-c385-4ba2-89b8-2cd0ddb97507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU1LTMtMS0xLTUxNzY3_0682c87f-e3c5-40da-9c45-5bcd161c23f1">4,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock issued related to BioDiscovery acquisition</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU2LTEtMS0xLTUxNzY3_0b5514ab-4aff-4527-9ab7-b855eeece884">14,159,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU2LTMtMS0xLTUxNzY3_93eb9e48-cc1d-481d-9c1a-267eb2fd9318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration related to BioDiscovery acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:ContingentConsiderationNoncash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU4LTEtMS0xLTUxNzY3_f1845b5c-bec6-4efb-9097-15e43651dd13">9,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:ContingentConsiderationNoncash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU4LTMtMS0xLTUxNzY3_2cecd850-1170-473d-a0a9-002bd81ed6ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities resulting from obtaining and modifying right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU5LTEtMS0xLTUxNzY3_90abbe17-850e-4d08-9954-ed444965359d">4,751,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU5LTMtMS0xLTUxNzY3_3be506e1-ce95-4221-b70a-75a03c29af13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of instruments and servers from inventory into property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="0" name="bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYwLTEtMS0xLTUxNzY3_ae8ec9b4-ce5a-45ad-9af0-d9be5b43cb93">6,857,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYwLTMtMS0xLTUxNzY3_3b11aaad-edf4-4d23-b365-ff53bf820c12">4,224,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forgiveness of PPP Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYyLTEtMS0xLTUxNzY3_6ea99887-36c3-4738-bd06-c23c0bd94edc">1,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYyLTMtMS0xLTUxNzY3_e5c309be-1811-403e-9de1-4a0521b34274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock issued for services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:StockIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYzLTEtMS0xLTUxNzY3_5de94cd9-b069-4bb3-a3ea-65fec1f3cec8">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:StockIssuedForServices" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYzLTMtMS0xLTUxNzY3_6fcd9756-25cd-49a2-afe9-cc416cde52a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue stock for covenant waiver</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:IssueCommonStockForCovenantWaiver" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzY0LTEtMS0xLTUxNzY3_b3a05efc-cc71-4aa4-b3d6-ef403eef0e07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:IssueCommonStockForCovenantWaiver" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzY0LTMtMS0xLTUxNzY3_c30fed22-0970-4647-82d5-8fabe3a40471">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant exercise pursuant to cashless exercise</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:WarrantExerciseNonCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzY1LTEtMS0xLTUxNzY3_dbc60100-13be-478d-8831-c0fe507686b6">129,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:WarrantExerciseNonCash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzY1LTMtMS0xLTUxNzY3_fbb62649-eada-4a63-bd9d-c92b4bf9038b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIONANO GENOMICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_151"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzcxMTc_8cd276d7-01eb-47bb-be2a-d06b2a5c785b" continuedAt="id2c28d47bd5646ecb2b43233633ee2ef" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="id2c28d47bd5646ecb2b43233633ee2ef"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzcxMTk_81b04708-28f7-43dd-a3c9-c5abaeaf3ddc" continuedAt="i0bbc068d9cf34edd9e3dfc537d5ceac3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#8220;Company&#8221;) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company&#8217;s mission is to transform the way the world sees the genome through optical genome mapping (&#8220;OGM&#8221;) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. (&#8220;Lineagen&#8221;) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC. (&#8220;BioDiscovery&#8221;) business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="bngo:LiquidityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzcxMjI_256fb6ef-e755-4cec-a052-02802ec22bed" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzEwOTk1MTE2NTAwNzk_5d67eb10-5e2d-4059-8d82-3cf571be3caa">24.6</ix:nonFraction>&#160;million in cash and cash equivalents, $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzEwOTk1MTE2NTAwNzM_0f2fc8af-8258-4aaf-a08b-4fba67ae0f1b">226.0</ix:nonFraction>&#160;million in short term investments, and working capital of $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-5" name="bngo:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzM4NDgyOTA3MDQ0ODk_720d2b70-5508-4036-b10e-f5f127fe767e">250.6</ix:nonFraction>&#160;million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, and September 30, 2021. In February 2021, we applied for forgiveness of our PPP Loan of approximately $<ix:nonFraction unitRef="usd" contextRef="i515aa68d30164045bab97fec3cd86d29_D20210301-20210331" decimals="-5" name="bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzM4NDgyOTA3MjY3NjM_f0742587-0f9d-457a-ae7c-789f38ddf5e1">1.8</ix:nonFraction> million, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. During the year ended December&#160;31, 2021, the outstanding term loan under the Innovatus LSA was paid in full, including all accrued interest, an end of term fee, and a prepayment fee for a total of $<ix:nonFraction unitRef="usd" contextRef="i0418bf1522234b33bd7a72931d18580f_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzM4NDgyOTA3MjY3ODQ_0ca64ae0-ae1d-447f-9c31-0e85335ae07e">17.0</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its available cash, cash equivalents and available-for-sale securities will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months. However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#8217;s business.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to additional risks and uncertainties as a result of the continued spread of COVID-19 and uncertain market conditions, which could continue to have a material impact on the Company&#8217;s business and financial results. The Company closely monitors and complies with various applicable guidelines and legal requirements in the jurisdictions in which it operates, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. If restrictions related to COVID-19 persist, the Company could see supply chain disruptions that impact its ability to produce its products and may cause the Company to make strategic determinations regarding, among other things, the cost and quality of the components and supplies it acquires. The Company&#8217;s manufacturing partners, suppliers, and customers, have implemented similar operational reductions. Despite reporting an increase in revenue for the year ended December&#160;31, 2021 when compared to the same period in 2020, the Company believes travel restrictions and overall reduced activity had a continued negative impact on the Company&#8217;s financial results. Given the continued evolution of the COVID-19 pandemic and the related complexities and uncertainties associated with the additional variants, the future effects of COVID-19 are unknown and the Company&#8217;s financial results may continue to be negatively affected in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. These negative effects could have a material impact on the Company&#8217;s operations, business, earnings, and liquidity.</span></div></ix:continuation><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_154"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzI4_1b08ffda-2b07-4084-9faa-255c5c324752" continuedAt="i99154ebc70894c5d88ccbac870b05941" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i99154ebc70894c5d88ccbac870b05941" continuedAt="i69bb9b2076bd4636b556b5adb81d1ee8"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzI5_aab490a6-375e-46d3-952f-4300349cd56a" continuedAt="ia50b3f947f91466c996132cdbc2b9173" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions used by management include estimates of selling prices for multiple performance obligation arrangements, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used in purchase accounting and to evaluate the recoverability of long-</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i69bb9b2076bd4636b556b5adb81d1ee8" continuedAt="i1d7fe2bbe9ff43abadac1b6dd4b93901"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia50b3f947f91466c996132cdbc2b9173">lived assets and goodwill, warranty reserves, certain accrued expenses, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company&#8217;s net deferred tax assets, stock-based compensation expense, and related valuation allowances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i0bbc068d9cf34edd9e3dfc537d5ceac3" continuedAt="i72d058d7e9ec4fd98d190769f61f82be">Basis of Presentation</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i72d058d7e9ec4fd98d190769f61f82be">The consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company&#8217;s 100%-owned subsidiaries.  All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzE0_499b34cd-1d72-4472-9692-ad43df961dce" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (&#8220;Lineagen Merger Sub&#8221;), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the securityholders of Lineagen, entered into an Agreement and Plan of Merger (the &#8220;Lineagen Merger Agreement&#8221;). Pursuant to the terms and conditions of the Lineagen Merger Agreement, Lineagen Merger Sub merged with and into Lineagen (the &#8220;Lineagen Merger&#8221;) whereupon the separate corporate existence of Lineagen Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Lineagen Merger as a wholly owned subsidiary of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Starship Merger Sub I, Inc., a wholly owned subsidiary of the Company (&#8220;BioDiscovery Merger Sub I&#8221;), Starship Merger Sub II, LLC, a California limited liability company (&#8220;BioDiscovery Merger Sub II&#8221;), BioDiscovery, Inc., a California corporation (&#8220;Former BioDiscovery&#8221;), and Soheil Shams, solely in his capacity as the securityholders&#8217; representative, entered into an Agreement and Plan of Merger (the &#8220;BioDiscovery Merger Agreement&#8221;), pursuant to which the Company agreed to acquire Former BioDiscovery. Pursuant to the terms and conditions of the BioDiscovery Merger Agreement, BioDiscovery Merger Sub I merged with and into Former BioDiscovery (&#8220;BioDiscovery Merger I&#8221;), whereupon the separate corporate existence of BioDiscovery Merger Sub I ceased, with Former BioDiscovery continuing as the surviving corporation of BioDiscovery Merger I and a wholly owned subsidiary of the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately after BioDiscovery Merger I, pursuant to the terms and conditions of the BioDiscovery Merger Agreement, Former BioDiscovery merged with and into BioDiscovery Merger Sub II (&#8220;BioDiscovery Merger II&#8221;), whereupon the separate corporate existence of Former BioDiscovery ceased, with BioDiscovery Merger Sub II continuing as the surviving company of BioDiscovery Merger II and a wholly owned subsidiary of the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with BioDiscovery Merger II, BioDiscovery Merger Sub II changed its name to that of our current subsidiary, BioDiscovery, LLC.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its acquisitions of Lineagen and BioDiscovery using the acquisition method of accounting pursuant to Accounting Standards Codification Topic 805, Business Combinations ("ASC 805"). Under ASC 805, the tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the acquisition date. Any excess purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of identifiable intangible assets acquired with the assistance of independent valuations that use information and assumptions provided by the Company&#8217;s management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 805, acquisition-related transaction costs (such as advisory, legal, valuation, other professional fees) are expensed in the statements of operations in the periods incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzMz_4ddf1a5f-af85-41cc-bfb5-8734d801128d" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. The Company has not experienced any losses in such accounts. The Company believes that it is not exposed to any significant credit risk on cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODA_75ea9bdd-ee18-4a92-913c-75b01e5af062" continuedAt="ic89e25a16f2b47a89c2affc5812ed59d" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221;, defines and establishes a framework for measuring fair value and expands disclosures about fair value measurements. In accordance with ASC 820, the Company has categorized its financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the company has the ability to access at the measurement date.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i1d7fe2bbe9ff43abadac1b6dd4b93901" continuedAt="i937d94b1700f4e608bd85151a9cdc4c6"><ix:continuation id="ic89e25a16f2b47a89c2affc5812ed59d"><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on quoted prices for similar attributes in active markets; quoted prices in markets where trading occurs infrequently; and inputs other than quoted prices that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODE_c8c5b94b-5a2e-4669-8f8f-3cdee25f233c" continuedAt="i8fbf7f01fef64a89aa68a66c80c5c54b" escape="true">Investment Securities</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8fbf7f01fef64a89aa68a66c80c5c54b">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income (loss). A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5Mjkz_ac659403-4fdf-4a06-b27c-b84576ec87b7" continuedAt="icd7317d0efcc4322b3597d7e65a45a1e" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company maintains deposits in federally insured major financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers are located throughout the world. The Company generally does not require collateral from its customers. More information on accounts receivable is contained in the paragraph titled &#8220;Accounts Receivable&#8221; below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources of Materials and Products</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icd7317d0efcc4322b3597d7e65a45a1e">The materials and components for the Company&#8217;s product offerings are currently obtained from single or limited sources. The Company competes with other companies for production capacity, therefore, the Company is exposed to a risk of inventory being unavailable at acceptable prices, or at all, if suppliers are unable (or decide) to provide sufficient levels of materials and components and the Company is unable to identify alternative suppliers.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzIz_76762970-4cc7-449f-859b-29165df81f5c" continuedAt="iceb549fd772a499c8d8d63b8c6ebd7e1" escape="true"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyMTU5ODI_1cadc742-5831-49b7-9f57-2707f46b814c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzItMS0xLTEtMjU5Njc_50f7baea-dea8-4f2f-b625-67fe95d5b07c">5,624,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzItNC0xLTEtMjU5Njc_35e94bbf-2cad-4d93-9410-7c1ae11b29d9">4,894,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzMtMS0xLTEtMjU5Njc_72e41804-670b-460d-a9a4-cd857dd138ce">690,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzMtNC0xLTEtMjU5Njc_6a67fed9-4546-4052-bf2a-31056ab45596">2,119,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzQtMS0xLTEtMjU5Njc_cdf89c91-a871-44ee-9c34-fbc56e631be9">4,934,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzQtNC0xLTEtMjU5Njc_24c493ba-a059-4ff7-9cf0-26a1a3ba8325">2,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For &#8220;OGM&#8221; products and services, credit is extended based upon an evaluation of each customer&#8217;s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the year ended December&#160;31, 2021, the Company recorded a recovery of bad debt expense of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA3MzIyMTg_6bb26943-1411-4181-bf5b-a5607c90d575">108,000</ix:nonFraction>, which </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i937d94b1700f4e608bd85151a9cdc4c6" continuedAt="i928175f5b19f4096ad71802195506742"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iceb549fd772a499c8d8d63b8c6ebd7e1" continuedAt="i9f4ae056f937410c8a02fd6e8054f100">is included in selling, general and administrative expenses. During the year ended December&#160;31, 2020, the Company recorded bad debt expense of $<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-5" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4MTQ4NTc_ea3e4287-ca57-4ed3-ba47-ee9b94404043">1.8</ix:nonFraction> million which was included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f4ae056f937410c8a02fd6e8054f100">Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company&#8217;s total accounts receivable balance. As of December&#160;31, 2021, no customers met or exceeded 10% of the Company&#8217;s total accounts receivable balance. As of December&#160;31, 2020, two customer balances represented <ix:nonFraction unitRef="number" contextRef="ib40de96003224a488c14b76a879a457e_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA3MzIyNTc_99a623e4-5f0c-4f7a-b389-d12f01a7713a">27.4</ix:nonFraction>%  of the Company&#8217;s total accounts receivable balance.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzE2_2b221847-7dc9-4ac1-9301-cd66270f8d64" continuedAt="idddb170191f344e998112efad00f4400" escape="true">Inventory </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idddb170191f344e998112efad00f4400">Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfUtilityInventoryTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzM0_13cf0ba2-1c3f-4e31-a4a6-f5ee42b4f5ca" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net of reserve, are as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzMtMS0xLTEtMQ_9dd3cebe-5631-42a3-9233-e3cf7aed5f79">745,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzMtMy0xLTEtMQ_1411f6a3-1e6e-4f65-834c-62ad81234d5a">2,282,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzQtMS0xLTEtMQ_147f679b-dce4-4a93-9ff3-5b3f70e79077">11,642,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzQtMy0xLTEtMQ_fc1b5a53-ce0b-4586-b6bf-270b26d4b0cf">1,033,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzUtMS0xLTEtMQ_d2d167ed-43c6-4f23-b899-3e3b6c52d366">12,387,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzUtMy0xLTEtMQ_ed9151da-0ef2-41b1-aa1a-4bbdf58f6ca7">3,315,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzI0_0afd4394-2e80-499e-bb95-7fe64a471f7c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets (including Finite-Lived Intangible Assets)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and acquired finite-lived intangible assets. The Company records property and equipment at cost, and records acquired finite-lived intangible assets based on their fair values at the date of acquisition. Property and equipment generally consist of laboratory equipment, computer and office equipment, furniture and fixtures, and leasehold improvements. Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the assets (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc4OTc_81782cd1-ff67-4bc0-b19a-d3f9ef09300e">three</span> to <ix:nonNumeric contextRef="i03e386398bdb44b3addd41e681970261_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc5MDM_39dd2f04-b153-4088-826a-a5b58c514272">five years</ix:nonNumeric>, or the remaining term of the lease for leasehold improvements, whichever is shorter). Repairs and maintenance costs are charged to expense as incurred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date. Intangible assets are amortized over the estimated useful life of the asset on a basis that approximates the pattern of economic benefit. Intangible assets are reviewed for impairment if indicators of potential impairment exist. There was no indication of impairment of intangible assets for any of the periods presented.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Lineagen and BioDiscovery acquisitions the Company recorded intangible assets, which consist of trade name intangibles, customer relationship intangibles, and a developed technology intangible, which are amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzg4MDE_f7ea3986-0330-41b7-bfd1-e0af9bc8fd1f">five years</ix:nonNumeric>. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is not recoverable when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recognized <ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzk3MTA_726decae-d317-47d8-beb5-04e9317ad45a"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzk3MTA_c2beb49c-7149-49d1-82a5-fde4e3a56be8">no</ix:nonFraction></ix:nonFraction> impairment losses on long-lived assets. Substantially all of the Company's long-lived assets are located in the U.S.</span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="bngo:ContingentConsiderationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODI_34b32e89-60c8-47ce-9830-46aee92ab719" continuedAt="i55b28274efcf4e03b4a143e0f5d35b19" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded contingent consideration resulting from a business combination at its fair value on the acquisition date. On a quarterly basis, we revalue this obligation and record any increase or decrease in fair value as an adjustment to the consolidated statement of operations. Changes to the fair value of the contingent consideration obligation may result from changes to the </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i928175f5b19f4096ad71802195506742" continuedAt="i0fa5b9b2fc834bfa98cc5465bb2fea2a"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i55b28274efcf4e03b4a143e0f5d35b19">discount rate, the passage of time, changes in our estimate of the likelihood, or timing of achieving the criteria for payment of the contingent consideration.</ix:continuation></span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzM1_b7b54a0e-df8e-4076-8a53-235f045a2bf8" continuedAt="if86bad4eb00b4df1ace7bedeb91968f4" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill arises when the purchase price of an acquired business exceeds the fair value of the identifiable net assets acquired, with such excess recorded as goodwill on the balance sheet. Goodwill is not subsequently amortized. Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indications of impairment exist. Goodwill is assigned to specific reporting units for purposes of impairment assessment. The Company has determined that it has a single operating segment and a single reporting unit. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if86bad4eb00b4df1ace7bedeb91968f4">In testing goodwill for impairment, the Company will first assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the qualitative assessment indicates that it is more likely than not that the fair value of the reporting unit is less than its carrying value, then the Company will perform a quantitative impairment analysis by comparing the fair value of the reporting unit to the carrying value of the reporting unit, including goodwill. An impairment charge for goodwill is recognized for the amount by which the carrying value of the reporting unit exceeds its fair value, not to exceed the total goodwill allocated to the reporting unit.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recognized <ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzExMjg4_444737b6-97f8-47d0-9e30-11433546cb82"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzExMjg4_8b20760e-7629-4465-81eb-02383f95ab8b">no</ix:nonFraction></ix:nonFraction> impairment losses on goodwill.</span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODM_859ee699-c9d4-46c9-b901-9414a6190ebc" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2021, the Company determines if an arrangement is, or contains, a lease at the inception of the arrangement. Right-of-use (&#8220;ROU&#8221;) assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating leases are included in operating lease right-of-use assets and operating lease liabilities in the consolidated balance sheets, while finance leases are included in finance lease right-of-use assets and finance lease liabilities.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and liabilities are recognized at commencement based on the present value of lease payments over the lease term. The Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments. The ROU assets also include any prepaid or accrued lease payments and is adjusted for lease incentives and initial direct costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease terms may include options to extend or terminate the lease which are recognized when it is reasonably certain that the Company will exercise that option. Leases with terms of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the lease terms, or in some cases, the useful life of the underlying asset. Variable lease payments are excluded from the measurement of ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. The Company accounts for the lease and non-lease components as a single lease component for all classes of underlying assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODQ_ac86089f-21f6-4f76-90e9-919a1fcbabb7" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Rent</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating leases include incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2021, the difference between rent expense and amounts paid under the lease was recorded as deferred rent in the accompanying consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzAw_357af272-93ee-4601-98c0-e9320734a041" continuedAt="idf6cb724647c4f12b80fc317cff116b8" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue primarily from the sale of products and services. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a receivable when we have an unconditional right to payment, which is generally at the time of delivery of software, consumables and instruments, including any extended warranties, or at the time services are rendered. Payment terms are typically 30 days for sales to customers in the United States but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within selling, general and administrative expenses, less any amounts reimbursed by the customer, when the corresponding revenue is recognized.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i0fa5b9b2fc834bfa98cc5465bb2fea2a" continuedAt="ie0c8e1e04eb24037950307c59a1c9ec7"><ix:continuation id="idf6cb724647c4f12b80fc317cff116b8" continuedAt="i6b8c1362c404422a9a35a471ee42c2a3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded net of discounts and sales tax. The Company&#8217;s contracts typically do not provide for product returns or refunds. In general, estimates of variable consideration and constraints are not material to the Company&#8217;s financial statements. Employee sales commissions are recorded as selling, general and administrative expenses when incurred as the amortization period for such costs, if capitalized, would have been one year or less. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenue recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue consists of sales of our Saphyr system and related consumables. These products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors. In addition, the Company provides the Saphyr system to certain customers under its reagent rental program, under which the Company provides Saphyr systems to customers at no cost and the customers agree to purchase minimum quantities of consumables.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains control of the product. As such the Company's performance obligation related to product sales is satisfied at a point in time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For transfers of instruments and consumables to customers under the Company's rental reagent program, the Company allocates the total contract consideration between the instrument and the consumables based on estimates of stand-alone selling prices, and recognizes the instrument revenue evenly over the rental period, and the consumables revenue when the consumables are delivered. Rental revenue related to the reagent rental program recognized over-time totaled $<ix:nonFraction unitRef="usd" contextRef="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231" decimals="-5" name="bngo:RentalRevenueReagentRentalProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjA0NTQ_34eb46c6-8488-4150-9530-be1c4631da21">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231" decimals="-5" name="bngo:RentalRevenueReagentRentalProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjA0NjI_9252ab49-de80-4386-a09e-285826074750">0.1</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service and other revenue recognition </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue primarily consist of revenue from diagnostic testing services, the sale of software, and license maintenance agreements, and support, repair and maintenance services and extended warranties on Saphyr systems. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the completion of diagnostic testing services is initially recorded at the estimated consideration the Company expects to receive from contractual and non-contractual payors, and is subject to adjustment based on the amount actually collected. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results, which the Company has determined is the point at which control is transferred to the customer for revenue recognition purposes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the sale of software is recognized at the point-in-time the software license is transferred to the customer, or for hosting arrangements, on a usage basis as the customer processes the number of genetic samples purchased with the software. Revenue related to license maintenance agreements is recognized over-time based on the contract term. Revenue recognized over-time related to license maintenance agreements totaled $<ix:nonFraction unitRef="usd" contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231" decimals="-5" name="bngo:LicensingRevenueAndMaintenanceAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NTQ3OTk_d0dc7c42-92ac-42fa-8e31-2fb39467a31f">0.1</ix:nonFraction> million during the year ended December&#160;31, 2021. There was no revenue recognized related to license maintenance agreements during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from support and maintenance contracts and extended warranties is recognized over time based on the contract term, which represents a faithful depiction of the transfer of goods and services given the stand-ready nature of the performance obligations. Service revenue related to repairs and customer sample evaluations is recognized as the services are performed based on the specific nature of the service. Warranty and maintenance revenue recognized over-time totaled $<ix:nonFraction unitRef="usd" contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231" decimals="-5" name="bngo:WarrantyAndMaintenanceRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjM4NDg_b0b21e5c-8abd-4d8d-bc6b-35cd3419ce35">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231" decimals="-5" name="bngo:WarrantyAndMaintenanceRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjM4NTY_3fef6ed9-b000-4944-8b86-cda30835ce9e">0.5</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in service and other revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was&#160;$<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTkxMzU_a1dc844a-c243-4c2a-8a1e-9ed0683de9f2">0.8</ix:nonFraction> million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations, as well as obligations related to software under hosting arrangements. The Company expects to recognize approximately&#160;<ix:nonFraction unitRef="number" contextRef="ibec93384d0cb4cd38ec922514c5a2307_I20211231" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTkzNzg_49b70317-3b7d-41fb-8795-0f63902db59f">82.4</ix:nonFraction>%&#160;of this amount as revenue in 2022,&#160;<ix:nonFraction unitRef="number" contextRef="ic9a9995ad77a4d72a6747277f6afc40f_I20211231" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTk0MTY_a59040a4-1aeb-42ec-8ce1-e7e765173189">13.8</ix:nonFraction>%&#160;in 2023, <ix:nonFraction unitRef="number" contextRef="i7901fe27277a43038341f30e9235fb33_I20211231" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTk0Mjg_7f08622a-dc79-457c-a654-11609105fe88">2.3</ix:nonFraction>%&#160;in 2024 and <ix:nonFraction unitRef="number" contextRef="i72760e7d4c4d4bc29225a99c2b52e6a4_I20211231" decimals="3" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTk0NDM_66e3ccbe-65bf-41ae-a657-0517c5a4e464">1.5</ix:nonFraction>% in 2025 and thereafter. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. The Company's liability for product warranties provided under its agreements with customers was $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NzcyNzM_c3f3891a-81ef-422b-8857-bc23e4dbecd2">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NzcyODE_913d98d9-2e3f-410f-bbf7-b46c3644f379">0.2</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. Warranty expense recorded in cost of goods sold totaled $<ix:nonFraction unitRef="usd" contextRef="ia421179e929849a0811736046100d29a_D20210101-20211231" decimals="-5" name="us-gaap:ProductWarrantyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NzczODM_b59a874b-4f02-4620-8ec9-9faa3f965754">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i02a66891cd81408b94c3dcf095dd9aa1_D20200101-20201231" decimals="-5" name="us-gaap:ProductWarrantyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NzczOTE_5282e3a0-67af-4bdb-822a-e3ae1e98a229">0.4</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets primarily relate to the Company&#8217;s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ie0c8e1e04eb24037950307c59a1c9ec7" continuedAt="i09cd55dde72c43f29bfc5aca808fad3b"><ix:continuation id="i6b8c1362c404422a9a35a471ee42c2a3" continuedAt="i8b27131794bd4e6c98677bced920ef5f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheets. The Company recognized revenue of&#160;$<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA3MzI5NjA_d8ef1098-8e8c-4a68-87b1-6e998eb6c6b9">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA3MzI5NjQ_f80a1948-d35b-4ca7-9f1f-af4c18c4ccaa">0.4</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor Transactions </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b27131794bd4e6c98677bced920ef5f">In certain markets, the Company sells products and provides services to customers through distributors that specialize in life sciences products. In cases where the product is delivered to a distributor, revenue recognition generally occurs when the distributors obtains control of the product. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers and do not contain return rights. Distributor sales transactions typically differ from direct customer sales as they do not require the Company&#8217;s services to install the instrument at the end customer or perform the services for the customer that are beyond the standard warranty in the first year following the sale. These transactions are accounted for in accordance with the Company&#8217;s revenue recognition policy described herein.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="bngo:CostOfGoodsAndServicesSoldPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzEw_1af49783-f4b6-4818-b208-cf7a9c863bd5" continuedAt="ia752d92128a54b5dba4fec16fb665f24" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue for products consists of the Company&#8217;s raw material parts costs and associated freight, shipping and handling costs, contract manufacturing costs, royalties due to third parties, salaries and other personnel costs, equipment depreciation, overhead and other direct costs related to those sales recognized as product revenue in the period. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia752d92128a54b5dba4fec16fb665f24">Cost of service and other revenue consists of salaries and other personnel costs, and facility costs associated with costs related to warranties and other costs of servicing equipment at customer sites, and performance of diagnostics services.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzAy_19fc06d7-836a-4e03-97d1-fac20b5450c8" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for research and product development, including acquired technology and costs incurred for technology in the development stage, are expensed as incurred.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzAz_c1887cf3-b984-4f78-8955-7f2e0736dfe6" continuedAt="i605b8204a07e4380b82b0237eeb1806a" escape="true">Patent Costs </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i605b8204a07e4380b82b0237eeb1806a">Costs related to filing and pursuing patent applications are recorded as selling, general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzE5_169152b7-5349-45b9-b478-693a1c20468f" continuedAt="i0c2e3138389f4b16b006c2fdd756e33a" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0c2e3138389f4b16b006c2fdd756e33a">The Company issues stock-based awards as compensation to employees and directors. Stock-based awards may include stock options, stock appreciation rights, vesting stock awards and performance share awards. These awards are accounted for as equity awards. To-date, the Company recognizes stock-based compensation expense net of actual forfeitures on a straight-line basis over the underlying award&#8217;s requisite service period, which is generally the vesting period, as measured using the award&#8217;s grant date fair value.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5Mjk2_71ed1c0d-2a26-49ae-91f3-82003f95dc6e" continuedAt="id942a7e98efd4e71970d688bc0e6c9bf" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id942a7e98efd4e71970d688bc0e6c9bf">The Company recognizes the impact of uncertain tax positions at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it does not have a greater than 50% likelihood of being sustained. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</ix:continuation> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i09cd55dde72c43f29bfc5aca808fad3b" continuedAt="i3547a5d03f8b43d6b11e90eb6c5aefa2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzA1_705dfed4-9b2e-4391-88eb-a8860910ef7a" continuedAt="ie889a7bbdea54c9d8289838c68d5f4bb" escape="true">Segment Reporting </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie889a7bbdea54c9d8289838c68d5f4bb">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company chief operating decision-maker, the Chief Executive Officer, views the Company&#8217;s operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI0MDcx_19114d16-c064-4b56-87a5-7a4d464fcb60">one</ix:nonFraction> operating segment.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzM2_a3ce5bd2-b1c4-453f-a45f-a6a159772244" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. Pre-funded warrants from the Company's follow-on offering have been treated as if they were common shares outstanding on the date of issuance.  The Company&#8217;s potentially dilutive securities which include outstanding warrants to purchase stock and outstanding stock options under the Company&#8217;s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzIw_46e020cf-eee3-4004-810e-2ecab8facc21" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive were as follows (in common stock equivalent shares): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b2ff0a385ec4419bd63ad02cc162c4f_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzItMS0xLTEtMQ_1ba661cd-3096-4f0e-ab58-8488f45c048d">12,765,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie803dd47b1c54023ad328f5a634b77a1_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzItMy0xLTEtMQ_84f534d9-6bbb-454d-8e5b-ede516018c63">5,290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice0bf1763a264af2afecbaaa10564f18_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzMtMS0xLTEtMQ_88765171-b14b-416d-849e-955bcf4697ce">4,356,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7b1ff8dff57441e9939f8789ca2e6c9_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzMtMy0xLTEtMQ_6721151e-6c7d-49bd-a10f-ffc687911043">15,174,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib55aca94255b45f7ba3ade3bbb054941_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMS0xLTEtNDYyMzY_b5dbd4ee-1405-49a6-9263-0244f940cdab">5,006,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03ac604fde724aebbc7ddc5ec7989381_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMy0xLTEtNDY1OTk_d1b36cb6-4573-4a90-8f7b-f352cfbdeec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfc32dda88c8491493b3a97900889e74_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMS0xLTEtMjY2Nzk_1caa88b1-5466-44a9-8dec-e1286fb292e6">361,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if65481e6e2e34f818b1abd233bbcb586_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMy0xLTEtMjY2OTA_ba0a2b5b-165a-4561-aef1-195bce26f36b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9baa4e36abe6400f9c053d7f3434b31f_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzUtMS0xLTEtMzMxMzI_46dd0284-ffb3-44f0-9b61-d1ab6383cc34">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9377784747ef4e6792d946ece3659fdb_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzUtMy0xLTEtNDM0NzY_f4bcfcf1-35b7-4329-8f24-99437a157240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMS0xLTEtMQ_c5ea2c47-d439-4cb4-b221-dabbcb243eec">22,778,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMy0xLTEtMQ_557313d4-4d51-4410-8f21-353a2c2cc5ee">20,464,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5Mjk1_4c4047a1-9e73-404f-ab32-c4087a189f2e" continuedAt="ia818a02511d74b319af712e5dca9cc53" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued But Not Yet Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuer&#8217;s Accounting for Certain Modifications or Exchanges for Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to clarify the accounting for modifications or exchanges of equity-classified warrants. The standard is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is in the process of evaluating the expected impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2021-04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on its financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The Company&#8217;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. In February 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASC 842&#8221;) which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASC 842 establishes a right-of-use model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. ASC 842 also requires disclosures to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was adopted </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i3547a5d03f8b43d6b11e90eb6c5aefa2" continuedAt="ic723d2b78dfc4c969b317d2c82d19d60"><ix:continuation id="ia818a02511d74b319af712e5dca9cc53" continuedAt="i731090fccb054c8dbb6aae0a06f55cb8"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2021, as the Company lost its status as an Emerging Growth Company effective December 31, 2021, and therefore was required to adopt the standard for the year ending December 31, 2021, using the modified retrospective method. Under this transition method, the Company recognized and measured leases that existed at the adoption date in the consolidated balance sheet as of January 1, 2021. In connection with the adoption of ASC 842, the Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company also made accounting policy elections not to apply the recognition requirements under ASC 842 to any short-term leases and to account for each separate lease and associated non-lease components as a single lease component for all the Company&#8217;s leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of ASC 842 resulted in recognition of operating lease assets and liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="ifd45b65fd98e44ee92578a3812d0ebdf_I20210101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjI2MTY_de6d6b67-6cac-4714-8efe-1279b52175c9">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd45b65fd98e44ee92578a3812d0ebdf_I20210101" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjI2MjM_7c21e2a2-80fb-4c47-acb2-ece0497821f6">2.1</ix:nonFraction> million, respectively, as of January 1, 2021, related to the lease of office and laboratory space. The comparative prior period information continues to be reported under ASC 840. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. For further details, see Note 11, Commitments and Contingencies. The adoption of the new standard did not materially impact the Company&#8217;s consolidated results of operations or cash flows.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic723d2b78dfc4c969b317d2c82d19d60"><ix:continuation id="i731090fccb054c8dbb6aae0a06f55cb8">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities From Contracts With Customers. This ASU requires an acquirer to account for revenue contracts acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. Prior to ASU 2021-08, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers and other similar contracts, at fair value on the acquisition date. The guidance is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and should be applied prospectively to business combinations occurring on or after the effective date. Early adoption is permitted. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company adopted ASU 2021-08 on October 1, 2021, and applied the ASU prospectively to its acquisition that occurred in 2021.</ix:continuation></ix:continuation> </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_2612"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF81NDk3NTU4MTU0OTE1_746b451f-182e-4472-b08e-0d13f4c4b01d" continuedAt="id8576f0cde754dcd80b523fc514c4297" escape="true">Revenue from Contracts with Customers</ix:nonNumeric></span></div><ix:continuation id="id8576f0cde754dcd80b523fc514c4297"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF81NDk3NTU4MTU0OTE2_677a0e00-49ad-491b-8a35-0c538a622f22" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue by Source</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796761a85df6417896123b60211dc456_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV8yLTEtMS0xLTQ1NTgz_ad10da36-619e-4016-a8b5-61f08bba11f1">5,887,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4cd58ed3c4a43c7accda85e938edcc0_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV8yLTMtMS0xLTQ1NTgz_6688c695-dffd-4b47-823a-b5489637c7f6">3,085,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3054d21f6f4798b007ef1b3abea827_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV8zLTEtMS0xLTQ1NTgz_125384a5-9c69-414a-a726-e5af0e711831">5,808,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac08b5e748c44125918877c58eeb2adc_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV8zLTMtMS0xLTQ1NTgz_507c7c59-6eb6-458a-8792-1a8392ff6d1b">3,145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV80LTEtMS0xLTQ1NTgz_39df2fc2-8f84-4032-be5e-a495572b75cc">11,695,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV80LTMtMS0xLTQ1NTgz_bad60275-cb7a-4801-9bf2-bdf92b2e66b4">6,230,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services and other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV81LTEtMS0xLTQ1NTgz_58e309a1-9aeb-480e-b710-46ec04f14fdc">6,286,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV81LTMtMS0xLTQ1NTgz_decb62a8-f87f-4222-b8e6-881ea44b07fd">2,273,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV82LTEtMS0xLTQ1NTgz_73970957-14c4-4c45-9dbe-38dc7258fdee">17,981,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV82LTMtMS0xLTQ1NTgz_c30bedc4-025e-4d6c-9d42-d3f4027ac293">8,503,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c68a12eca334a838f030a41e51a46b3_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV8zLTEtMS0xLTQ1NTgz_ffcc9409-8d7c-49ab-aa5c-bc6bd127c594">9,329,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ff8553873fd49468f9f75a5c165e98f_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV8zLTMtMS0xLTQ1NTgz_4951d867-7394-49f0-8dbc-8cad2347ff28">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c615c6f945420e93b92d85cf0b8c01_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV8zLTUtMS0xLTQ1NTgz_08ee92d1-aabe-46b0-a185-15ae5a34b21e">4,489,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0873412be8547959d4aa0e904da5fca_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV8zLTctMS0xLTQ1NTgz_ada2a93e-0c27-401e-875d-7ea096217d51">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEIA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f08d0b9d254e4cb81421c9274acb67_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV80LTEtMS0xLTQ1NTgz_d61873e6-6df8-4df2-97ae-2189715595ce">5,604,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i763f202ae44a40c09fe53b95d9006d97_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV80LTMtMS0xLTQ1NTgz_1086c045-b325-4d96-bbe9-da14c19487a9">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b47aea725d34079a308232d226a3001_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV80LTUtMS0xLTQ1NTgz_9fbf9f78-e6d4-4e97-bc70-d711147b0fce">3,163,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4169c1867a245108d470229bac5dbac_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV80LTctMS0xLTQ1NTgz_c47e8118-6b87-44a3-8d69-7b7ce7cfda51">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8f8c29630a401a88a5285f57e55166_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV81LTEtMS0xLTQ1NTgz_59868c7d-64f3-4cf1-86bb-b96d2f6ecddc">3,048,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76c0e564fd0c4699af8abe0b4a4a8f5b_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV81LTMtMS0xLTQ1NTgz_5a41604c-6392-4629-bf2b-5e46731a736d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639735ace7a54defa242bf743d278ad3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV81LTUtMS0xLTQ1NTgz_cc6b8b81-c84b-4c40-954b-fbad881e689b">851,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iede1a65bd15f4596838c10a96b56c281_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV81LTctMS0xLTQ1NTgz_b487c35a-ef03-44af-b0e7-e50ad87d609c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV82LTEtMS0xLTQ1NTgz_ae2130c3-eb33-4cc2-82f7-7a2677bac73c">17,981,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86bea6db7f4248ed94253fad6c47e824_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV82LTMtMS0xLTQ1NTgz_1c596456-e30c-4ff5-8156-330a1496f600">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV82LTUtMS0xLTQ1NTgz_ab86dfe5-0f52-468e-a966-844fe42d4976">8,503,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i029ea0650fb04082a13c21022c54f216_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV82LTctMS0xLTQ1NTgz_3fb05ad1-20da-450d-81ca-89cb26bf59eb">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables above provide revenue from contracts with customers by source and geographic location on a disaggregated basis. North America consists of the United States and Canada. EMEIA consists of Europe, the Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia. For the years ended December&#160;31, 2021 and 2020, sales in the United States represented <ix:nonFraction unitRef="number" contextRef="ia60395f370984c03913b1237f78f5f74_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF8zODQ4MjkwNjk4Njgw_d87b323c-fc6e-49c9-94f6-1cf16dec8277">46</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie85c1983cea24f5fbb6e90a2a347fd4f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF8zODQ4MjkwNjk4Njg1_47915f0d-8984-438a-bafa-f8cf819dab33">42</ix:nonFraction>% of revenues, respectively. During the year ended December&#160;31, 2021, sales in China accounted for <ix:nonFraction unitRef="number" contextRef="ie758ad97885e40af865734d6d0735fbd_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF8zODQ4MjkwNjk4Nzgw_c4cb9411-f66f-4536-83dc-dd62c46d7c34">11</ix:nonFraction>% of total revenue. No other countries represented greater than 10% of revenue during the years ended December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzE4NTQ_292040bf-248f-430e-80fa-c51af53e9e3c" continuedAt="if304673dd40942209ac597304e2a005f" escape="true">Investments and Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="if304673dd40942209ac597304e2a005f" continuedAt="ia6709258175444ce91b5a873276bf8a6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are not re-measured at fair value include cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s long-term debt approximates its fair value due to the market rate of interest which was determined to be a Level 2 measurement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The carrying values of these financial instruments approximate their fair values. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.</span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzU0OTc1NTgxNDM0Mzg_0b04c908-6313-4c87-8f0c-0cef41b5e022" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis in the Consolidated Balance Sheets:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64252642d88c4f9a8cdb7a3c4abb6daa_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzQtMS0xLTEtMjM5NzY_7c2bb0b2-0ddb-4593-ada0-3296d3facad4">100,860,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd395e693f843f68c015a3fb16e63e0_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzQtMy0xLTEtMjM5NzY_885a4056-5ebd-418d-af36-f17b0264380e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b6072efea34c43a77e7e2a8d672e57_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzQtNS0xLTEtMjM5NzY_91469593-abad-4787-ad7e-b7730c7e96d4">100,860,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd8b99cec464ca2a5fbc78e6d86bd6b_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzQtNy0xLTEtMjY3ODA_34c40a7e-4fa1-4fd6-9834-c36b1695ccb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21077c1aab5d457cb1cdf940f451908e_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzUtMS0xLTEtMjM5NzY_93d7450b-478e-447f-a366-5bb32517c625">125,181,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfba7f0bab47499d9d16e7fcfea7c8e8_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzUtMy0xLTEtMjM5NzY_30fceb46-f9f9-4dd5-805f-d0dd3adeddee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e1e879fb554dcaa245d830024b147c_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzUtNS0xLTEtMjM5NzY_55d7a137-55ee-4559-a719-171db9064875">125,181,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad7080a2ac2845729f17c608390c3daf_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzUtNy0xLTEtMjY3ODA_6bad2b9e-773c-4306-849e-332bce82d8a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Investments:</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678854c029c5451f9cf24fe07efbf514_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzYtMS0xLTEtMjY3Njc_07741a9a-5ae0-4aa1-8af0-18953c6c90c5">226,041,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0ee927463d486baa5cba33982c2569_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzYtMy0xLTEtMzE5NjE_1dd49086-2f0b-4e82-bf1a-032db20a08fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic609659d259845b3a37a1bf8b59de543_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzYtNS0xLTEtMjY3ODA_3b989ffa-ab90-4db2-a057-ec573b8e24f1">226,041,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1a6733a3f14bf2972c366549628e23_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzYtNy0xLTEtMzE5NjE_5df88368-9019-4418-bad2-7f7d654db0c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i219dd660a26b49beb67b572a81c81389_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzctMS0xLTEtMjM5NzY_394af263-ea30-46ab-8197-615de88ef2f6">11,126,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3289f5383254228be7158bd06d11bfb_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzctMy0xLTEtMjM5NzY_4e4c920f-0742-42f3-ab9b-95afa3841315">11,126,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a26c057095f4a36a0b30546701c58f3_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzctNS0xLTEtMjM5NzY_eb1cc238-b88e-438b-849e-d12d2d926afd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i467ef72acc6840729feb7f12f3a6e516_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzctNy0xLTEtMjY3ODA_ec72e8a4-36db-4e81-9bf0-9a6d71bedb0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93e575b671b4188b8e1e04eb90b0d27_I20201231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzktMS0xLTEtNDAwMzA_1a42b91a-ebc9-4e78-ba7b-a62daa6f9d50">9,066,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9bc63b1b5444dea0111bbe4ec8f8bb_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzktMy0xLTEtNDM4ODU_39c2a61b-9cfc-4ac9-b078-82c84ef962df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1484c4dbff544b29b2781e84672dded_I20201231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzktNS0xLTEtNDAwMzI_6a2f00bb-4630-48eb-86f3-ecf589037f40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe2bac092bd4c778f47ddbc97f1d0c3_I20201231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzktNy0xLTEtNDAwMzY_8a5d641f-b473-41ed-9211-ce418f80ae40">9,066,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds are classified as cash equivalents on the balance sheet. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration liability is reassessed on a quarterly basis using the income approach. Assumptions used to estimate the acquisition date fair value of the contingent consideration include the probability of achieving certain milestones and a discount rate of <ix:nonFraction unitRef="number" contextRef="i1cf405044e174ea88a98016ca955831d_I20211231" decimals="3" name="us-gaap:ServicingLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzM4NDgyOTA3MTk0Mzk_af5c3f55-fc63-4bff-a1fa-ea9be7c75941">3.2</ix:nonFraction>%. The fair value measurement of the contingent consideration is based on significant inputs not observed in the market (Level 3 inputs). Significant inputs used in the measurement include probabilities of achieving the remaining milestones, which depend on the milestone risk profile. The change in fair value of the contingent consideration during the year ended December&#160;31, 2021 was due to the passage of time. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzU0OTc1NTgxNjIyMDM_72e62ad1-cff4-483a-905c-ef6de3635ea7" continuedAt="i35a1f18de0f2495ca6f14c765b519315" escape="true">Changes in estimated fair value of contingent consideration liability in the year ended December&#160;31, 2021 is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ia6709258175444ce91b5a873276bf8a6"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i35a1f18de0f2495ca6f14c765b519315"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contingent</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Consideration</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Liability</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Level 3</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Measurement)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id637a744712b44988d29a346fc913709_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzEtMS0xLTEtNDQyODc_671f4ae5-0547-42b0-929b-59457656c1a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability recorded as a result of current period acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzItMS0xLTEtNDQyODc_acf3a380-3125-461e-a7e9-76e6605f46b9">9,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value, recorded in selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzMtMS0xLTEtNDQyODc_d244be2c-d00e-40c1-bf32-046f44644a3b">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzQtMS0xLTEtNDQyODc_32a483ce-5ff2-42da-abbf-810a22950e7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ba840538fd4b0791ae9c324539369e_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzUtMS0xLTEtNDQyODc_78a0fa60-997f-44b1-a56f-4dec372e4095">9,066,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not hold any investments as of December&#160;31, 2020. As of December&#160;31, 2021, the Company held <ix:nonFraction unitRef="lease" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzM4NDgyOTA3MDE3OTU_72bfbea8-746d-4344-ab9f-b9b26da6d977">57</ix:nonFraction> securities in an unrealized loss position for a period of less than 12 months resulting in an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzQzOTgwNDY1MjU0MDE_eec3cc45-55e4-487d-859e-22857b3b21c1">0.5</ix:nonFraction> million included in other comprehensive income during the year ended December&#160;31, 2021. None of the Company&#8217;s available-for-sale investment securities were in a material unrealized loss position at December&#160;31, 2021. As such, the Company has not recognized any impairment in its financial statements related to its available-for-sale investment securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzQzOTgwNDY1MTY2MDE_57a0146f-0c5a-4283-ab7b-10c682bbae34">86.5</ix:nonFraction> million relating to sales and maturities of its available for sale securities, and recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzQzOTgwNDY1MTY2MDU_64c25888-87d3-402e-8b64-513b7ed244c7">8,000</ix:nonFraction> in other income relating to the sale of these securities. Amounts are reclassified out of accumulated other comprehensive income into earnings using the specific identification method. </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzU0OTc1NTgxNDM0Mzk_1a25f6ff-c966-465e-91a7-967696b2b997" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized loss</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized loss</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzItMS0xLTEtMjM5NzY_a632546a-c9b0-48db-95be-c760facbb1e3">100,929,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzItMy0xLTEtMjM5NzY_7c1a51a3-060f-4903-9788-1f033deae98f">69,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzItNS0xLTEtMjM5NzY_cef63ab4-93d8-46ec-8e96-2e36d6453b9c">41,173,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzItNy0xLTEtMjM5NzY_58d746fd-9272-442b-99f2-467a71b4cea7">61,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzMtMS0xLTEtMjM5NzY_d271421d-4b5d-4548-ae3e-a2b0be1fddb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzMtMy0xLTEtMjM5NzY_63bf73ea-f2cb-4c1b-a015-dbd363e6bf22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzMtNS0xLTEtMjM5NzY_1183fb06-b335-41a0-a4e5-d14fd4a65a5f">84,478,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzMtNy0xLTEtMjM5NzY_0830a2fa-f1cb-4a67-868c-f33779ff6185">409,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzQtMS0xLTEtMjM5NzY_790920c6-5d3a-4e1b-9356-7822e0387334">100,929,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzQtMy0xLTEtMjM5NzY_1808398b-2e20-4835-95af-9c01c3856a3e">69,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzQtNS0xLTEtMjM5NzY_1818aff4-d99f-4372-acf3-762238a11e00">125,651,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzQtNy0xLTEtMjM5NzY_c58859d9-0f2c-46ae-b48d-59e54631e6c1">470,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in interest income for the year ended December&#160;31, 2021 was interest income related to the Company&#8217;s available for sale securities of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzM4NDgyOTA3MDE3NjI_db034ce8-9e2e-4421-9394-bafd0fa9a787">0.4</ix:nonFraction> million. All interest income related to the available for sale securities in 2021 related to year ended December&#160;31, 2021. All available-for-sale securities are classified as current assets, even if the maturity when acquired by the Company is greater than one year due to the ability to liquidate within the next 12 months.</span></div></ix:continuation><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_163"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="bngo:PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90ZXh0cmVnaW9uOjBlYTQ0MjM0MGM5NzQzZjJhZWVkNzVjNDYzZmIxN2FhXzEyMQ_f02ee080-6236-46de-9b3e-150e22b5fd28" continuedAt="ia6e01b67a853489987c1a1dd2b013ae7" escape="true">Prepaid Expenses and Other Current Assets </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia6e01b67a853489987c1a1dd2b013ae7" continuedAt="i3ada6d498f39432692437b8d85ae4f97"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90ZXh0cmVnaW9uOjBlYTQ0MjM0MGM5NzQzZjJhZWVkNzVjNDYzZmIxN2FhXzEyMw_87b01bef-0aef-44e4-8972-e0ccf64b3b75" continuedAt="i83225002ee1e4a7a9957ed4c1669fd2d" escape="true">Prepaid expenses and other current assets consist of the following: </ix:nonNumeric></ix:continuation></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i3ada6d498f39432692437b8d85ae4f97"><ix:continuation id="i83225002ee1e4a7a9957ed4c1669fd2d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepayment to supplier</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzEtMS0xLTEtMQ_9abd47ec-4d2c-44fb-b3cc-14ebf3c2d1ee">285,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzEtMy0xLTEtMjY5Mjc_82d7a32e-5eed-4655-a452-629b2c588efd">1,146,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzItMS0xLTEtMQ_301b341f-6475-49d9-b0c5-f9cd3940527d">1,461,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzItMy0xLTEtMjY5Mjc_2ee4e4b9-8f90-4a5b-9503-8214d8928a67">642,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzMtMS0xLTEtMzM0NTE_9fce8413-bdfb-40a5-bab4-51dc0e77051f">387,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:InterestReceivableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzMtMy0xLTEtMzM0NTc_47104577-7689-4086-89e6-2ea41573ec3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzMtMS0xLTEtMQ_3eba9055-2798-4c33-a689-fd222b05fd8b">2,348,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzMtMy0xLTEtMjY5Mjc_4a1a2d65-0e1c-45e7-aca5-cd75375f8cbd">462,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzQtMS0xLTEtMQ_1257045e-0d50-4730-8d5b-4553ed01b72e">4,481,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzQtMy0xLTEtMjY5Mjc_d84645ed-489e-4438-85b8-8bfc1857187c">2,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzI3MA_44bc9d87-9865-4d8e-b7a7-ba79a91390a5" continuedAt="i767d09f6646240ae9ecdb024a547bda2" escape="true">Property and Equipment, Net </ix:nonNumeric></span></div><ix:continuation id="i767d09f6646240ae9ecdb024a547bda2" continuedAt="if713c1368e984ad9abae78daa961c0ee"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzI3MQ_50bec9cf-6e9e-47a2-9cca-c4a9403eef7b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970b26562f48462b986160dadd23e2e8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzEtMS0xLTEtMQ_c2691198-ab33-474d-954b-e38f9291fe7e">819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9431acbfefa14bc1a8c51e9791630133_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzEtMy0xLTEtMQ_b7592892-89f8-4ba8-ba08-4e32c66fa079">492,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e966a20a2d94bd6ac86960b0db2e83b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzItMS0xLTEtMQ_ce5a674c-18c0-4987-a2c7-aa7b60b9c244">9,341,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7c44f25d40c4d78a5d9623e10febeb0_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzItMy0xLTEtMQ_7ca745d9-dbf8-4814-bfbf-f65cd8d949f7">6,718,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service equipment placed at customer sites</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib110b6c1e25a43b190344fed192d23fc_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzMtMS0xLTEtMQ_0c590d9e-bb93-4ce4-bce3-ae2aaa8b43bb">6,556,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdf5494bbd9490295ca735e1ec45cfd_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzMtMy0xLTEtMQ_ccfd9971-62ca-4329-8c8a-b74b60fc9cd6">3,267,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386f22e822f8474daca8ae8933acbb26_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzQtMS0xLTEtMQ_6d8a1c43-4b85-48a1-b419-1783e2dc1b60">2,674,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa83cb53f8d446e58b64dd7b82b48311_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzQtMy0xLTEtMQ_02c56cfc-f317-4765-8421-25fc3c4b623e">1,889,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzUtMS0xLTEtMQ_56768343-5b3f-4d8f-b3c8-54e6405c7970">19,390,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzUtMy0xLTEtMQ_29b367a5-46f4-42c7-b293-33fa01f72cc3">12,366,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzYtMS0xLTEtMQ_455c83b3-51be-48be-bbca-7fd6c9e220db">9,072,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzYtMy0xLTEtMQ_32cf4f4f-a33c-4925-a828-d2c178bf0df3">7,456,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzctMS0xLTEtMQ_5c1c6f39-0574-4af0-b36e-13463f861b30">10,318,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzctMy0xLTEtMQ_9d15a5df-8ca0-4493-899c-ad73231c9a66">4,910,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if713c1368e984ad9abae78daa961c0ee">For the years ended December&#160;31, 2021 and 2020, the Company recorded depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzM4NDgyOTA2OTc2MTg_d6895309-3c7d-447a-be9e-3c1a885048a1">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzM4NDgyOTA2OTc2MjI_ca2f40ce-d80d-43e6-aac8-7215d03bfa98">1.4</ix:nonFraction> million, respectively, which includes an allocation to cost of revenue of $<ix:nonFraction unitRef="usd" contextRef="iaba22332706445abbde9bbbbbea71f04_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzM4NDgyOTA2OTc1ODE_8b988bd4-c1b0-4cb5-a906-5cfb44c275e0">0.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7d2d20d9c1274e4e8d7386137b4f34ab_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzI1Mg_9f258487-af1f-4ca5-b90e-7db2b36a0fa5">0.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i81e2dc0ae87648a58b8afa4c80a78bce_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzM4NDgyOTA2OTc1NDc_899459e8-5bc8-41a5-bf83-dfeb78fd376f">41,000</ix:nonFraction> respectively.</ix:continuation> </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_169"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQ4Nw_eaf154d7-cf1c-47ef-97b5-9e809e46501b" continuedAt="i20d74f9a41954464b41f87a128d79c84" escape="true">Intangible Assets, Net </ix:nonNumeric></span></div><ix:continuation id="i20d74f9a41954464b41f87a128d79c84"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQ4OQ_a893b81f-ae70-4767-92f2-48a2bfb0a8ae" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that are subject to amortization consisted of the following at December&#160;31, 2021 and 2020:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a480bc32add481ea931915f5e4e20a7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItMi0xLTEtMjcyODM_40f463c3-3cc1-4688-ba9f-f9fa0eade8ed">1,630,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a480bc32add481ea931915f5e4e20a7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItNC0xLTEtMjcyODM_1fce2b5e-3350-4c47-9649-04a7aec8f698">210,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a480bc32add481ea931915f5e4e20a7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItNi0xLTEtMzc5MjQ_eef564ec-f408-4b4f-8bfa-448766b6b924">1,420,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6af5f30224ff436d833405ae9d5be9ad_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItOC0xLTEtMzc5NTM_9da366c9-664f-435b-8207-d641e08d022c">630,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6af5f30224ff436d833405ae9d5be9ad_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItMTAtMS0xLTM3OTUz_57fc9684-ea60-4377-8ca6-b55dc20ba09f">42,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6af5f30224ff436d833405ae9d5be9ad_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItMTItMS0xLTM3OTUz_5975e156-44c1-452b-85aa-70c47b22e30e">588,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6981036f191b41ae8e646c1a85e17819_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtMi0xLTEtMzQwNjY_b4bb254f-9df0-4bb4-abb6-8b9548ae41f8">3,950,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6981036f191b41ae8e646c1a85e17819_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtNC0xLTEtMzQwNjY_114f34d3-532e-4532-84f4-b390f5c21c47">378,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6981036f191b41ae8e646c1a85e17819_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtNi0xLTEtMzc5MjQ_f498ff85-d9da-44e3-a06c-68d7f13e1635">3,572,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79aff88d479e4c73bf896e7479d3d66f_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtOC0xLTEtMzc5NTM_299fe93a-0187-47f0-ad0f-cdffa7b511ef">950,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79aff88d479e4c73bf896e7479d3d66f_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtMTAtMS0xLTM3OTUz_858bbdf4-b703-43f9-9f92-606753ce554e">63,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79aff88d479e4c73bf896e7479d3d66f_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtMTItMS0xLTM3OTUz_f3d833eb-c7b9-45d1-8a0d-feb811c56006">887,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45196371119428bb263f59a387de373_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtMi0xLTEtMzQwNjY_fe54dc25-eabc-4123-b74c-0f7da2184311">22,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib45196371119428bb263f59a387de373_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtNC0xLTEtMzQwNjY_1bd87950-263c-4961-8904-e10090d8cf03">950,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45196371119428bb263f59a387de373_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtNi0xLTEtMzc5MjQ_5f92e00f-1362-471f-9dc8-91a857149dd9">21,850,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33d1be42b47486b97d23a00612757c8_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtOC0xLTEtMzc5NTM_13963044-feae-4191-9eae-238c2b0fb714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33d1be42b47486b97d23a00612757c8_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtMTAtMS0xLTM3OTUz_c547f26b-8428-4dd0-b58d-57c07eee7fbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33d1be42b47486b97d23a00612757c8_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtMTItMS0xLTM3OTUz_c5571e1c-99e3-447e-8cdd-580bbd889bfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtMi0xLTEtMjcyODM_23209874-4402-403e-9684-255cfa5deb30">28,380,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtNC0xLTEtMjcyODM_42bf8ade-6599-4357-a1e7-4533ed09c3ed">1,538,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzUtNi0xLTEtMzc5NTI_19840bf0-90d8-48b5-bdaf-fdc4421d151a">26,842,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzUtOC0xLTEtMzc5NTM_4e0eb9cf-b26b-40be-8d2b-ed2e91e901ac">1,580,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzUtMTAtMS0xLTM3OTUz_eecec8e4-b883-4359-a82b-75f35dfb5864">105,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzUtMTItMS0xLTM3OTUz_b16324c7-896b-47d7-82f5-f40f9c6bf8e7">1,475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense for intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQzOTgwNDY1MTE5Mjc_658d499e-c50c-4d0a-9888-2734c4f6d69f">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQzOTgwNDY1MTE5MzE_a5400a92-eca6-47a8-8699-6533dabab900">0.1</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020 respectively, in selling, general and administrative expenses. The customer relationships and trade name intangibles from the Lineagen acquisition are both being amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="icb5ee1e4c6bd48d2be372e02f845f9f7_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzM4NDgyOTA2OTg1Nzc_1f8e10f1-abd8-44fe-9d6c-298de0cf1850">5</ix:nonNumeric> years, and have remaining amortization periods of <ix:nonNumeric contextRef="icb5ee1e4c6bd48d2be372e02f845f9f7_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQzOTgwNDY1MTIwNDc_f32b670e-dcac-41f2-bb38-7f171c8cf779">3.6</ix:nonNumeric> years. The customer relationships, developed technology and trademark intangibles from the BioDiscovery acquisition are being amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="i6ac9d5e475ba4422a72f931d6569a467_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzM4NDgyOTA2OTg1NjE_9ba06e4a-50fa-4809-8492-e94d03d53b5e">5</ix:nonNumeric> years, and have remaining amortization periods of <ix:nonNumeric contextRef="i6ac9d5e475ba4422a72f931d6569a467_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQzOTgwNDY1MTIzMTA_1f0a8bff-cc3a-4fb0-976a-cd737e973132">4.8</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQ4Ng_be50df7a-a0ec-4ab7-bb4d-cfdff51ed722" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzEtMS0xLTEtMQ_0b1f3689-0af8-42fa-93c5-11c13797dd6a">5,676,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzItMS0xLTEtMQ_0ad02a6c-4241-4c7d-bad8-d29818acd8bc">5,676,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzMtMS0xLTEtMQ_785326f1-c29c-4f42-8577-238c39b41c4c">5,676,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzQtMS0xLTEtMQ_6f08c9a0-46f6-4396-bfbe-475dbc14f270">5,571,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzQtMS0xLTEtMzQyNTM_818b7a9e-e654-4240-9d16-b5e69812a56e">4,243,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzUtMS0xLTEtMQ_d466d75d-a34e-4705-b9e1-91a6620154e5">26,842,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90ZXh0cmVnaW9uOjIxOGM5MTE2NmMwZjRiOTlhZTU3NzMyZGM5OTJmMjhmXzcz_b12a722a-ae4b-4d16-b7c6-97e84689499e" continuedAt="ic1f2c49ec22148e98c7833556c3b9ad4" escape="true"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90ZXh0cmVnaW9uOjIxOGM5MTE2NmMwZjRiOTlhZTU3NzMyZGM5OTJmMjhmXzc0_e1ab2675-c843-4aaa-9763-4a8bdf444f22" continuedAt="i96d52d91040b40f1a82afdd879d16a0a" escape="true">Accrued Expenses </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ic1f2c49ec22148e98c7833556c3b9ad4"><ix:continuation id="i96d52d91040b40f1a82afdd879d16a0a"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90ZXh0cmVnaW9uOjIxOGM5MTE2NmMwZjRiOTlhZTU3NzMyZGM5OTJmMjhmXzc2_2e6ccefe-0cb5-4202-a5e6-ce6ceb189207" escape="true"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90ZXh0cmVnaW9uOjIxOGM5MTE2NmMwZjRiOTlhZTU3NzMyZGM5OTJmMjhmXzc3_4bf48228-c03a-4558-9541-3007c18489d9" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzEtMS0xLTEtMQ_51284d93-ff25-41d1-b416-78b3c863593d">4,529,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzEtMy0xLTEtMQ_393615b7-e2bf-4af4-b471-ba8b0add7430">3,251,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goods received not invoiced</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="bngo:AccruedInventoryCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzMtMS0xLTEtMQ_987942f0-e39b-4841-a1b3-4c219b20d6a2">1,073,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="bngo:AccruedInventoryCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzMtMy0xLTEtMQ_b10fdf2d-fc52-44ad-8a27-3de4af1f42d6">567,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzQtMS0xLTEtMQ_a13bac61-70af-4421-9d83-e81bb5311ba8">677,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzQtMy0xLTEtMQ_9e6aec31-2150-4dc6-b16a-84d5e7d5e86f">562,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzUtMS0xLTEtMQ_32de7254-3fd5-4929-9943-10d728121f20">1,011,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzUtMy0xLTEtMQ_8d3eb650-79c3-45c9-8117-da00eefdf6d9">358,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzYtMS0xLTEtMQ_00e84062-ac05-476b-a52e-d113f76e1432">288,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzYtMy0xLTEtMQ_ee795122-3dda-49db-bb68-e66991536486">247,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzctMS0xLTEtNDg0NDM_ea441cc3-0ab7-4af0-8c3a-f5bbad245bb4">175,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzctMy0xLTEtNDg0NDM_996e8e63-e5af-424b-9859-410dc4208c70">113,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzctMS0xLTEtMQ_efaabcd4-a109-45d3-be76-327e798b7c30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzctMy0xLTEtMQ_8398a4ad-962f-4bc1-9f55-15b13acf2f0f">98,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzgtMS0xLTEtMQ_333d5fa7-8606-4f4f-a111-9f3d70d6cee6">1,941,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzgtMy0xLTEtMQ_3102a820-7ceb-4ab1-8ade-597c8f2a0a00">403,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzktMS0xLTEtMQ_fd4eac02-3b40-454a-aa91-fdbb0181c557">9,694,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzktMy0xLTEtMQ_6198ec8c-672f-487f-a1e5-b9f5bd94cd36">5,599,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_175"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzExODIz_d5621666-6201-4c48-b8b0-fe422d673962" continuedAt="i211ea5de22974528b76974b43f466849" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="i211ea5de22974528b76974b43f466849" continuedAt="ice4e34fb637948a28b31a67a93bbbb0e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company received the PPP Loan proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i187f2e41e0e647169625953a97e7c680_D20200417-20200417" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzMjg_ea895fdf-aa2d-4600-bd02-570829ff7788">1.8</ix:nonFraction>&#160;million pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) administered by the U.S. Small Business Administration (the &#8220;SBA&#8221;).  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Loan accrued interest at a rate of 1% per annum and was subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act. In February 2021, the Company applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. A gain on forgiveness of Paycheck Protection Program loan of $<ix:nonFraction unitRef="usd" contextRef="i187f2e41e0e647169625953a97e7c680_D20200417-20200417" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzMzY_ea895fdf-aa2d-4600-bd02-570829ff7788">1.8</ix:nonFraction>&#160;million was recognized during the year ended December&#160;31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovatus LSA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company entered into a Loan and Security Agreement (the &#8220;LSA&#8221;) by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent and the lenders listed on Schedule 1.1 thereto, including East West Bank. The LSA provided a first term loan of $<ix:nonFraction unitRef="usd" contextRef="i885cb3edb89544758da163ee290c2716_I20190331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzNjA_2ea7e219-8eab-4fa6-b2db-01f7fc5e2655">17.5</ix:nonFraction> million, a second term loan of $<ix:nonFraction unitRef="usd" contextRef="if8fefc0da0874a5b9ef1c40c3768d9b2_I20190331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzNjQ_d80c1810-e1d6-4537-85e3-3748ce0fab34">2.5</ix:nonFraction> million and a third term loan of $<ix:nonFraction unitRef="usd" contextRef="i9113153c66234219aee4b2506362eeb2_I20190331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzEwOTk1MTE2NTQ0NTE_98bd4ef9-988f-4b5e-ae31-1d23edea54e3">5.0</ix:nonFraction> million (collectively, the &#8220;Term Loans&#8221;) if the Company satisfied certain funding conditions. Interest on the Term Loans is due on the first of each month at a rate of <ix:nonFraction unitRef="number" contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331" decimals="4" name="bngo:DebtInstrumentInterestRateCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzNzI_b4954d2b-46f8-4ec2-85ff-3ecfc508a9b4">10.25</ix:nonFraction>% per annum in cash or a discounted rate of <ix:nonFraction unitRef="number" contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331" decimals="4" name="bngo:DebtInstrumentInterestRateDiscountedCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzNzY_5f8f5ba3-197c-4256-b42b-8993c0bfee79">7.25</ix:nonFraction>% in cash with <ix:nonFraction unitRef="number" contextRef="icbd4ec7b849b4fdfb36d13c56714da97_I20190331" decimals="3" name="bngo:DebtInstrumentInterestRateCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzODA_82fd336f-b04e-4533-a664-b0e7c6685dbe">3.0</ix:nonFraction>% of the <ix:nonFraction unitRef="number" contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331" decimals="4" name="bngo:DebtInstrumentInterestRateCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzODQ_b4954d2b-46f8-4ec2-85ff-3ecfc508a9b4">10.25</ix:nonFraction>% per annum rate added to the principal of the loan and subject to accruing interest through the end of the interest only payment period, which ends March 1, 2022. At inception, the Company elected to pay interest in cash at a rate of <ix:nonFraction unitRef="number" contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331" decimals="4" name="bngo:DebtInstrumentInterestRateDiscountedCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzODg_5f8f5ba3-197c-4256-b42b-8993c0bfee79">7.25</ix:nonFraction>% per annum and have <ix:nonFraction unitRef="number" contextRef="icbd4ec7b849b4fdfb36d13c56714da97_I20190331" decimals="3" name="bngo:DebtInstrumentInterestRateCashRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzOTI_82fd336f-b04e-4533-a664-b0e7c6685dbe">3.0</ix:nonFraction>% per annum of the interest added back to the outstanding principal. As of May 14, 2021 (the effective date of the loan payoff), the effective interest rate, including debt issuance costs, for the Term Loans was <ix:nonFraction unitRef="number" contextRef="i5e120690c77f416090e340927b324ea8_I20210514" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MDQ_788edacd-22d7-47b1-b4c3-71555333a8ac">16.7</ix:nonFraction>%. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA provided for prepayment fees of <ix:nonFraction unitRef="number" contextRef="ifada802da30d4375a5c5a06d5d2c5ddf_D20190301-20190331" decimals="3" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MDA_a260859b-e777-4b24-a805-34c3de067a42">3.0</ix:nonFraction>% of the outstanding balance of the loan if the loan is repaid on or prior to March 14, 2020, <ix:nonFraction unitRef="number" contextRef="i4d74e091a5294082809d17f5146d70ad_D20190301-20190331" decimals="3" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MDg_3b8cbfe6-f904-455b-97c7-0119dcc393bf">2.0</ix:nonFraction>% of the amount prepaid if the prepayment occurs after March 14, 2020 but prior to March 14, 2021, <ix:nonFraction unitRef="number" contextRef="id0d3bb253582446b9f1f1ac8c1549355_D20190301-20190331" decimals="2" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MTI_297bea3d-cd9a-4689-b96c-18cc658874b5">1</ix:nonFraction>% of the amount prepaid after March 14, 2021 but prior to March 14, 2022 and <ix:nonFraction unitRef="number" contextRef="i49e07068caf640e88b8e67d05b03a126_D20190301-20190331" decimals="3" name="bngo:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MTY_d97e5fa5-12b1-4b6f-96df-be84cbbbed16">0</ix:nonFraction>% of the amount prepaid if the prepayment occurs thereafter. In addition, upon the final repayment of the total amounts borrowed, the Company is required to pay an end of term fee of $<ix:nonFraction unitRef="usd" contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MjA_e7675362-deaa-4d25-95d9-c4b5e99d0a88">0.8</ix:nonFraction> million. This end of term fee was being recognized as interest expense over the term of the LSA. As of December&#160;31, 2021, the outstanding term loan with Innovatus was paid in full, including all accrued interest, the end of term fee, and a prepayment fee for a total of $<ix:nonFraction unitRef="usd" contextRef="i0418bf1522234b33bd7a72931d18580f_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0Mjg_0ca64ae0-ae1d-447f-9c31-0e85335ae07e">17.0</ix:nonFraction> million. The Company recorded a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY4NDM_454bd8cf-a973-4fbf-a6e4-e0bfcae7484d">2.1</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA also provided for a revolving line of credit in an amount not to exceed $<ix:nonFraction unitRef="usd" contextRef="ib8e87945aa7f410299777da79c66a83f_I20190331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MzU_e6ff7173-e291-40f3-9dc9-af9d708b8026">5.0</ix:nonFraction> million (the &#8220;Revolver&#8221;), which was terminated effectively upon payment in full of the above term loan.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA was collateralized by substantially all of the Company&#8217;s assets, including its intellectual property. The LSA required the Company to comply with various affirmative and negative covenants, including: (1) a liquidity covenant requiring the Company to maintain a minimum cash balance at all times in a collateral account and (2) a revenue covenant requiring the Company to meet certain minimum revenue targets measured at the end of each calendar quarter. The LSA also included certain standard events of default, and a provision that Innovatus could declare an event of default upon the occurrence of any event that it interprets as having a material adverse impact to the Company's business, operations, or condition, a material impairment on the Company's ability to pay the secured obligations under the LSA, or upon a material adverse effect on the collateral under the agreement, thereby requiring the Company to repay the loans immediately, together with a prepayment fee and other applicable fees.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ice4e34fb637948a28b31a67a93bbbb0e" continuedAt="i6a724ce602454d6c85b8078fe00e69da"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, in connection with the receipt of $<ix:nonFraction unitRef="usd" contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODgzMTY_e48f16a2-ac6a-45f7-803f-893e0e11d6b9">20.0</ix:nonFraction>&#160;million in proceeds from the Term Loans, the Company issued to Innovatus a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="ifb921d59feb74c7e9883ca143d13a63e_I20190331" decimals="-5" name="bngo:WarrantsToPurchaseSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1MDc_1be73538-2290-45da-964c-ad0118c9f284">0.2</ix:nonFraction> million shares of its common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODgzMzE_034cb7e4-bf09-43ef-a8a9-9d1d33bb2c75">4.63</ix:nonFraction> per share, which has a term of <ix:nonNumeric contextRef="ie0e9fefb7a034edb966f004c59f7d49c_D20190301-20190331" name="bngo:ClassofWarrantorRightTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODgzNDA_a0543dd8-6e30-4627-acbd-2ce62dc29589">10</ix:nonNumeric> years. These warrants were equity classified and their respective fair value was recorded as a discount to the debt. The warrants were exercised during the year end December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the LSA was amended to among other things: (i) extend the deadline for the Company to maintain its domestic depository and operating accounts with the Bank, subject to a control agreement in favor of Innovatus, to July 31, 2019 and (ii) permit the Company to incur credit card indebtedness in an amount not to exceed $<ix:nonFraction unitRef="usd" contextRef="i807cfb44a24d46fe8574bed9d3d3fa46_I20190630" decimals="-5" name="bngo:DebtInstrumentCovenantMaximumCreditCardIndebtedness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY2NDY_3d8dee20-d2cf-474b-b665-6617e2bae963">0.2</ix:nonFraction> million. As of September 30, 2019, the Company did not achieve the revenue covenant under the Innovatus LSA. As a result, in October 2019, the Company obtained a waiver letter from Innovatus. Pursuant to the waiver letter, Innovatus agreed to allow the Company to cure its noncompliance with the revenue covenant as of September 30, 2019 so long as the Company (i) raised at least $<ix:nonFraction unitRef="usd" contextRef="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031" decimals="-6" name="bngo:DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0MTE_23240aab-27ba-49f1-8f60-227a537bb7e2">10</ix:nonFraction>&#160;million in gross proceeds from the sale of its securities in an underwritten public offering by October 31, 2019 and (ii) amended the warrant to purchase stock, issued by the Company to Innovatus in March 2019 to decrease the exercise price of the warrant from $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0MjQ_a6d71046-07ca-4798-a496-9f00876f4022">4.63</ix:nonFraction> per share to $<ix:nonFraction unitRef="usdPerShare" contextRef="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0MzE_45d0b345-d3e3-48cb-ba3b-d37bddd99f1b">0.48</ix:nonFraction> per share. Also pursuant to the waiver letter, as consideration for the prospective breach of a liquidity covenant, the Company agreed to issue to Innovatus <ix:nonFraction unitRef="shares" contextRef="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031" decimals="-5" name="bngo:WarrantsToPurchaseSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1MjI_59845969-1fdf-4c8c-b03b-9272303bc71d">0.6</ix:nonFraction> million shares of the Company's common stock. As a result of the amendment and shares issued, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1MzM_d8ba3201-5875-442a-8b39-4856e9e21ee2">0.6</ix:nonFraction> million as a debt discount, which is being amortized as interest expense over the remaining term of the LSA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company did not achieve certain financial covenants under the Innovatus LSA. As a result, in March 2020, the Company and Innovatus entered into an amendment to the Innovatus LSA (the &#8220;Second Amendment&#8221;) to, among other things: (i) waive the events of default from not achieving the specific financial covenants for the December 31, 2019 measurement date, (ii) require an immediate partial repayment of $<ix:nonFraction unitRef="usd" contextRef="i3751fdde71464399810902ffa867ecde_D20191201-20191231" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0Mzg_a971c85f-1d7f-4c13-94a0-540082ea97ef">2.1</ix:nonFraction>&#160;million, (iii) require an additional partial repayment of $<ix:nonFraction unitRef="usd" contextRef="i3751fdde71464399810902ffa867ecde_D20191201-20191231" decimals="-5" name="bngo:DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0NTI_9c4a171f-bee1-4d70-b2db-403166755409">2.9</ix:nonFraction>&#160;million on the earlier of completion of an Equity Event (as defined in the Second Amendment), or April 30, 2020, (iv) modify the liquidity covenant, such that the Company&#8217;s minimum cash balance shall vary based on outstanding borrowing capacity under the Revolver (provided, however, that the Company shall maintain a minimum cash balance of $<ix:nonFraction unitRef="usd" contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231" decimals="-5" name="bngo:DebtInstrumentCovenantLiquidityMinimumCashBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0NjY_32718490-81e8-4197-b4af-d607540f5c84">2</ix:nonFraction>&#160;million at any given time), (v) reduce the dollar amount of certain minimum revenue covenants measured as of the end of each calendar quarter (each, a &#8220;Revenue Covenant&#8221;) and (vi) modify the terms of certain events of default. For example, the Second Amendment provides for a cure period in connection with the breach of certain minimum revenue financial covenants, as long as the Company submits an updated management plan and financial projections, which are subject to Innovatus approval, and completes a Qualified Financing Event (as defined in the Second Amendment) within <ix:nonNumeric contextRef="i3751fdde71464399810902ffa867ecde_D20191201-20191231" name="bngo:DebtInstrumentCovenantWaiverFeePaymentPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0ODA_611a6104-2ddf-49d3-8dd2-d2f6cf86cbd2">45</ix:nonNumeric> days of such breach. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Second Amendment, the Company was obligated to pay Innovatus a waiver fee in the amount of $<ix:nonFraction unitRef="usd" contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231" decimals="-5" name="bngo:DebtInstrumentCovenantWaiverFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1NjM_f0c3c8bd-9c33-4913-998f-a5ac5213711e">0.2</ix:nonFraction> million and a prepayment fee of $<ix:nonFraction unitRef="usd" contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231" decimals="-5" name="bngo:DebtInstrumentCovenantPrepaymentFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1NzQ_78f95f05-e70a-439b-a1b4-78c62a3ec474">0.1</ix:nonFraction> million, payable in cash or in shares of the Company&#8217;s common stock at the Company's election, no later than following completion of the Equity Event, as defined in the Second Amendment. As described in Note 10 below, the Company completed a follow-on public offering in April 2020 that constituted an Equity Event under the Second Amendment. A portion of the proceeds from the follow-on offering were used to pay-down $<ix:nonFraction unitRef="usd" contextRef="i12947374461e4e6b9a6e0e872431a338_D20200401-20200430" decimals="-5" name="bngo:DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0OTI_41564aca-e423-4660-8fd9-1ab3c2d2831a">2.9</ix:nonFraction>&#160;million of principal balance outstanding under the Term Loans in accordance with the Second Amendment. In addition, the Company issued <ix:nonFraction unitRef="shares" contextRef="i7ec81e424f424534aa64d4e480141a53_I20200430" decimals="-5" name="bngo:WarrantsToPurchaseSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1NTA_145b467e-e0b0-4780-9abc-1100ea459438">0.9</ix:nonFraction> million shares of its common stock to Innovatus to satisfy the $<ix:nonFraction unitRef="usd" contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231" decimals="-5" name="bngo:DebtInstrumentCovenantWaiverFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1OTE_f0c3c8bd-9c33-4913-998f-a5ac5213711e">0.2</ix:nonFraction> million waiver fee and the $<ix:nonFraction unitRef="usd" contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231" decimals="-5" name="bngo:DebtInstrumentCovenantPrepaymentFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY2MDI_78f95f05-e70a-439b-a1b4-78c62a3ec474">0.1</ix:nonFraction> million prepayment fee due under the Second Amendment. As a result of the amendment and shares issued, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i7ec81e424f424534aa64d4e480141a53_I20200430" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY2MTM_48861a13-3b32-456f-b92f-a4d5b5bfa35e">0.3</ix:nonFraction> million as a debt discount, which is being amortized as interest expense over the remaining term of the LSA. Also pursuant to the Second Amendment, the Company subsequently registered such shares for resale on a registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) filed with the Securities and Exchange Commission on June 22, 2020 and declared effective on July 7, 2020. The Company has not and will not receive any of the proceeds from the offering described in the Registration Statement. In connection with the Merger, the Company and Lineagen entered into a Third Amendment (the &#8220;Third Amendment&#8221;) to the Innovatus LSA. Among other things, the Third Amendment adds Lineagen as a &#8220;Borrower&#8221; under the Innovatus LSA and updates certain financial covenants in light of Lineagen becoming a wholly owned subsidiary of the Company. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company obtained a waiver from Innovatus of its previously disclosed noncompliance, as of September 30, 2020, with the revenue covenant contained in the LSA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company was in compliance with the covenants under the Innovatus LSA. The Innovatus LSA was paid in full and terminated in 2021. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i6a724ce602454d6c85b8078fe00e69da"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Debt Obligations </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzExODI0_9c60301b-6a8d-40f4-994a-99de338163bc" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no debt as of December&#160;31, 2021. The carrying value of the Company&#8217;s debt as of December 31, 2020 was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4795567b94164ea29b5699dc096d6ebf_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzEtMy0xLTEtMQ_cf772f3b-6168-48ea-a57d-ce412508b880">15,981,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5821d7ac4676425ba01bdcd20c6d2f91_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzItMy0xLTEtMQ_8df00d84-cd7e-431e-8cfc-151f67234dac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPP Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d06a7344f2e49ab9598f04154df56cf_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzMtMy0xLTEtMQ_02580547-9805-4fcf-a15e-c733027f0d27">1,775,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total principal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzQtMy0xLTEtMQ_b8445fb7-dfd3-4c9f-b50b-f5887aa88de7">17,756,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzUtMy0xLTEtMQ_a1c6aca5-3be7-4c61-9f8e-ed6f07d194bf">1,430,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzYtMy0xLTEtMQ_738e706b-ddfc-4a10-be80-8a4b5df29ba0">16,326,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_178"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDIz_95fc2e48-0552-4f75-8534-8516dc31208f" continuedAt="i86ab7e44aabb41fb9028c4dda8cb24d0" escape="true">Stockholders&#8217; Equity and Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i86ab7e44aabb41fb9028c4dda8cb24d0" continuedAt="i5c96a2418896460b98338ce70662230d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3Mzg_4f34b870-5cc7-49d6-a4dd-87b99776e07f"><ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3Mzg_634437bb-68b1-4695-b8bd-eb7d54fe22d9">400</ix:nonFraction></ix:nonFraction> million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NDg_115fae02-0270-42b3-8950-658783166a72"><ix:nonFraction unitRef="usdPerShare" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NDg_b70b67e4-a252-4c1d-8bfc-c462f7c3dc79">0.0001</ix:nonFraction></ix:nonFraction> par value common stock. All issued shares of common stock are entitled to vote on a 1 share/1 vote basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NjE_ebb864f2-5de9-4ba5-a813-7705e9b36bb4"><ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NjE_f4e852ab-88b0-4a3d-851a-3c0de7b6016e">10</ix:nonFraction></ix:nonFraction> million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NzE_38652c6b-3873-4d6e-abd9-13f261a6ade9"><ix:nonFraction unitRef="usdPerShare" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NzE_f0eeb0ba-36c4-4a7b-9ed8-af77f1e07de9">0.0001</ix:nonFraction></ix:nonFraction> par value preferred stock. No preferred stock has been issued to date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Public Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company completed an underwritten public offering of&#160;<ix:nonFraction unitRef="shares" contextRef="i938f91bd8c3946d395a47bb4a55c4f39_D20200401-20200430" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM2NjM_148afc5c-8863-4fc4-947f-fed41ffc399f">16.9</ix:nonFraction> million&#160;shares of its common stock and, to certain investors, pre-funded warrants to purchase&#160;<ix:nonFraction unitRef="shares" contextRef="id95371e1105d406580e1d89a5e055efa_I20200430" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM3NTI_2bdc3103-ed79-4fb3-b912-8627f01b57f3">37.7</ix:nonFraction> million&#160;shares of its common stock, and accompanying common warrants to purchase up to an aggregate of&#160;<ix:nonFraction unitRef="shares" contextRef="i842467c3c99147a9899c7166293dd2df_I20200430" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NTA_e276b4b1-811f-45af-8a14-c5c4c280b006">54.5</ix:nonFraction> million&#160;shares of its common stock. Each share of common stock and pre-funded warrant to purchase&#160;<ix:nonFraction unitRef="shares" contextRef="i0733c5c486d840aa90f9b967fc4b62a4_I20200430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM5NDM_034b635c-3de7-432c-a545-b95ed1a817ab">one</ix:nonFraction>&#160;share of common stock was sold together with a common warrant to purchase&#160;<ix:nonFraction unitRef="shares" contextRef="i0733c5c486d840aa90f9b967fc4b62a4_I20200430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTYwMjM_034b635c-3de7-432c-a545-b95ed1a817ab">one</ix:nonFraction>&#160;share of common stock. The public offering price of each share of common stock and accompanying common warrant was&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="ic96948543913400fa1d1b0b719ebabf1_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQxMzg_2b938e4e-5b80-439a-9406-7d10ffeefd43">0.33</ix:nonFraction>&#160;and&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i0733c5c486d840aa90f9b967fc4b62a4_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQxNDU_2e93cc2a-a1db-4d7c-89ba-9a54af520c24">0.329</ix:nonFraction>&#160;for each pre-funded warrant. The pre-funded warrants are immediately exercisable at a price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i0733c5c486d840aa90f9b967fc4b62a4_I20200430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQyNDM_0e87c9cc-8f77-4b78-8407-67579c33160b">0.001</ix:nonFraction>&#160;per share of common stock. The common warrants are immediately exercisable at a price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="ic96948543913400fa1d1b0b719ebabf1_I20200430" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQzMzU_97970199-9d05-4e68-ae18-8af278b7414b">0.33</ix:nonFraction>&#160;per share of common stock and will expire&#160;<ix:nonNumeric contextRef="iad11bf28fea04b8aba14929027d8fa54_D20200401-20200430" name="bngo:ClassOfWarrantOrRightExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQzODA_47bb8f5a-8aa5-48f9-810e-eb8c85db18c5">five years</ix:nonNumeric> from the date of issuance. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The gross proceeds to the Company, before deducting offering costs of $<ix:nonFraction unitRef="usd" contextRef="ia66ac253e88644c8815ddb6f83187e4d_D20200401-20200430" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQ2Mzk_e758d468-1119-4dc9-88ac-5fe313564177">1.6</ix:nonFraction> million, were&#160;$<ix:nonFraction unitRef="usd" contextRef="ia66ac253e88644c8815ddb6f83187e4d_D20200401-20200430" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQ2NDg_cc9245a2-ae02-4e57-9e13-3f9e8583934b">18.0</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i473f14c3b9164deeb0b53c014f09915c_D20210112-20210112" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTQ3NzU_c3c25609-2611-4020-9374-cdebff935dfe">33.4</ix:nonFraction> million shares of common stock, including <ix:nonFraction unitRef="shares" contextRef="i2623ef25413a4354ac9f72e113c78e64_D20210112-20210112" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTQ3Nzk_68830804-4324-49c4-bde1-3d5a5e9d1b80">4.4</ix:nonFraction> million shares of common stock sold pursuant to the underwriters' exercise in full of their option to purchase additional shares. The price to the public in the offering was $<ix:nonFraction unitRef="usdPerShare" contextRef="i01445096e010443d97b89ad87ab3c883_I20210112" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQ5MzY_b8f6b884-e3cd-478c-a0fb-a1238578298f">3.05</ix:nonFraction> per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5df53405a8de4826bff81815bde4ed6c_I20210112" decimals="3" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzUwNjE_e9901374-b81c-4fb7-b5d1-9fd9a1c00c35">2.867</ix:nonFraction> per share. The gross proceeds were&#160;approximately $<ix:nonFraction unitRef="usd" contextRef="i473f14c3b9164deeb0b53c014f09915c_D20210112-20210112" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzUxMTM_c7bb397c-7c07-458d-9398-87154698e74f">101.8</ix:nonFraction> million before deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i473f14c3b9164deeb0b53c014f09915c_D20210112-20210112" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTIwNzY_d2587b91-c2db-439c-a8bf-f80a4ac78a88">0.3</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i411e62885bec4fb3beab2f000e27b94f_D20210125-20210125" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTQ3Njc_749d20da-94e1-4997-a3e4-1ee7762bda5f">38.3</ix:nonFraction> million shares of common stock, including <ix:nonFraction unitRef="shares" contextRef="id608a0c5267f429cb8c9e21ce9a996e7_D20210125-20210125" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTQ3NzE_58e2f0e8-45d4-48c9-85a4-5950f8c1dc01">5.0</ix:nonFraction> million shares of common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic49d68891599499b9fcf7774b2002c46_I20210125" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTU_0b592ebf-f1f0-4aad-939f-877647080fc6">6.00</ix:nonFraction> per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i96499813715849179f8f5b094e5056d1_I20210125" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU2MjA_d2fed8c7-48af-4b9a-b1c3-b404504f4c3f">5.64</ix:nonFraction> per share. The gross proceeds to us were&#160;approximately $<ix:nonFraction unitRef="usd" contextRef="i411e62885bec4fb3beab2f000e27b94f_D20210125-20210125" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU2Nzg_94b09ee6-5d18-442a-be25-87c2f48cafd9">230.0</ix:nonFraction> million before deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="ic49d68891599499b9fcf7774b2002c46_I20210125" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NTY3MDQ_1934c1b4-dbc5-4c46-9dd8-85a23cd8537e">0.4</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statements; Ladenburg and Cowen At-the-Market Facilities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="i1d6ccdf4c05242a6877437f969ff350d_I20200831" decimals="-6" name="bngo:SaleOfStockAuthorizedAmountToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NDM_ad6a02d2-efd9-410e-8001-7abdea4233a2">125</ix:nonFraction> million of the Company&#8217;s securities, including up to $<ix:nonFraction unitRef="usd" contextRef="i4d0542f51814417b825a21ad6a71dd4c_I20200831" decimals="-6" name="bngo:SaleOfStockAuthorizedAmountToBeIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NDc_4842bc49-9699-4003-b1fb-960c07d1dba0">40</ix:nonFraction> million of common stock pursuant to an At Market Issuance Sales Agreement, with Ladenburg Thalmann &amp; Co. Inc. acting as sales agent (the &#8220;Ladenburg ATM&#8221;). During October through December 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i8c6b16906f9c47c490d636cc5dc3cd1b_D20201001-20201231" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NTQ_b76a1a7b-eb73-4f8e-a023-f00bb611c8ab">27.0</ix:nonFraction> million shares of common stock under the Ladenburg ATM at an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NjE_a6923b59-089a-4824-9cef-a20cdc2e22d7">0.82</ix:nonFraction>, and received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i8c6b16906f9c47c490d636cc5dc3cd1b_D20201001-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NjU_22176445-2370-4ddd-a477-93baec341093">22.1</ix:nonFraction> million before deducting offering costs of $<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NzI_cfecbb2f-ff7b-4fc4-b5dc-4bca8fe8c5b6">0.6</ix:nonFraction> million. In January 2021, the Company sold an additional <ix:nonFraction unitRef="shares" contextRef="i04fb2be1f6bc4a1ea3a4950d33413347_D20210101-20210131" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1Nzk_dc40d539-c0ee-46e9-b03a-5c3cf925dd1b">6.3</ix:nonFraction> million shares of common stock under the ATM at an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie9dfa5830e684b5b9aeb0425d2971c55_I20210131" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1ODY_8eb239e8-4c41-48ed-8f52-7971b355d3c3">2.68</ix:nonFraction>, and received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i04fb2be1f6bc4a1ea3a4950d33413347_D20210101-20210131" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1OTA_7a7e71ab-c3bf-4255-842a-537788c66f9c">16.9</ix:nonFraction> million before deducting offering costs of $<ix:nonFraction unitRef="usd" contextRef="ie9dfa5830e684b5b9aeb0425d2971c55_I20210131" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTA5MDQ_a20888c7-5c28-4a32-ba40-8f61a0274913">0.4</ix:nonFraction> million. The Company terminated the Ladenburg ATM in March 2021.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i5c96a2418896460b98338ce70662230d" continuedAt="ie23fc598dad24c7ea874f5fd3398ac89"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2021, the Company filed an automatically effective shelf registration statement on Form S-3 with the SEC as a &#8220;well-known seasoned issuer,&#8221; allowing for the Company to issue an indeterminate number or amount of its securities from time to time in one or more offerings. On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) which provides for the sale, in the Company&#8217;s sole discretion, of shares of common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ie90abf42c0fa483585e7c0ddbc44d00c_D20210323-20210323" decimals="-5" name="bngo:SaleOfStockValueSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NjA2OTU_f366adba-31a7-466b-9cec-3e5335d4a5e6">350.0</ix:nonFraction> million through or to Cowen, acting as sales agent or principal (the &#8220;Cowen ATM&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company agreed to pay Cowen a commission of up to <ix:nonFraction unitRef="number" contextRef="ie90abf42c0fa483585e7c0ddbc44d00c_D20210323-20210323" decimals="3" name="bngo:CommissionFeeMaximumPercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgxNTk0NjU_0db049a9-584d-44a4-996f-a505666d80b7">3.0</ix:nonFraction>% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August and September 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i3baa8f239ec74369b0750b2c579131a4_D20210801-20210930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2MTc_5cb63bf7-b99a-45a5-a604-744e039576db">2.3</ix:nonFraction> million shares of common stock under the Cowen ATM at an average share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6575ee0a35434402aebe8d5e012a1d85_I20210930" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2MjI_65e72b56-2acc-46ec-8c23-ca14b371c50f">6.15</ix:nonFraction> per share, and received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i3baa8f239ec74369b0750b2c579131a4_D20210801-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2Mjk_7b22a412-7f90-4649-95f6-780895f3d76d">13.9</ix:nonFraction> million before deducting offering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i6575ee0a35434402aebe8d5e012a1d85_I20210930" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2NjA_b9ace35d-ec48-4d6f-8be3-602b3b855e38">0.6</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDI3_2ea9cf91-ecd1-43a1-ad48-92fe06221744" continuedAt="i8945a4d56f834064bf50ec9699b8ba3b" escape="true">A summary of the Company&#8217;s warrant activity for the year ended December 31, 2021 was as follows:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i8945a4d56f834064bf50ec9699b8ba3b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-  <br/>Average  <br/>Exercise  <br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-  <br/>Average  <br/>Remaining  <br/>Contractual  <br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate  <br/>Intrinsic  <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzUtMS0xLTEtMQ_8686dc5c-d32e-4753-85f1-71b2ae84a39b">24,406,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzUtMy0xLTEtMQ_bf28fd40-30dd-46de-9ffb-ba5ee8c5aa7c">1.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i50bbecaae644414b92db4dfed11dc7e6_D20190101-20191231" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzUtNS0xLTEtMQ_228a0666-039f-4f7f-b6ef-24c0f6dc1fe1">4.82</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231" decimals="-3" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzUtNy0xLTEtMQ_264c87ab-8f86-41ac-b8ec-1b42348899de">7,933,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzYtMS0xLTEtMQ_e7b4db8c-39e4-49e4-8b27-379320276240">95,396,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="2" name="bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzYtMy0xLTEtMQ_b2be32c3-d932-4c92-956f-1267b8e0496e">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzYtNS0xLTEtMQ_e9558ab9-ea46-4635-a5ae-4b518ac22f47">4.28</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzctMS0xLTEtMQ_7932522f-d5cf-4bb9-98ca-4db4e98e9503">104,628,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="2" name="bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzctMy0xLTEtMQ_d9fa355b-418b-4995-9849-bd999831fc09">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzctNy0xLTEtMQ_4b668a8f-d142-47e4-a29f-d2c9116fc240">56,780,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzgtMS0xLTEtMQ_fcb892b9-dc7e-46a5-957c-fcca576fba4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="2" name="bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzgtMy0xLTEtMQ_8886ce82-198a-4504-bd5c-a9617c06b88a">59.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzktMS0xLTEtMQ_6777c555-493b-4053-92dc-d3e7846510dd">15,174,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzktMy0xLTEtMQ_bfeedf16-09a3-4f9a-9984-af2ad3921aa6">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzktNS0xLTEtMQ_803761e5-08ce-4271-8f39-f9249406e0f5">3.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzktNy0xLTEtMQ_4928bbc2-2c78-4c16-97db-9d2a9e44cd2c">26,841,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEwLTEtMS0xLTI3NzAy_f0fc10e5-c9b7-4b90-9218-e882a083d222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="2" name="bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEwLTMtMS0xLTI3NzAy_45fa8ce4-c94b-4e23-b026-24f29bfe19bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzExLTEtMS0xLTI3NzAy_e3cbba43-5295-43da-8200-db05dd6788c9">10,794,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="2" name="bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzExLTMtMS0xLTI3NzAy_215b87cc-c7ed-4ccb-a8d3-dc7af0620835">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzExLTctMS0xLTI3NzAy_cf3a4e58-bd48-43b1-9903-b8c16fcade61">58,191,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEyLTEtMS0xLTI3NzAy_292dd2bd-7532-4add-8ad9-7706c8c3fede">24,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="2" name="bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEyLTMtMS0xLTI3NzAy_3ed271d1-4852-4444-98c5-44231455455c">3.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEzLTEtMS0xLTI3NzAy_d416e489-de72-4bd8-82f8-347f324bf45d">4,356,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEzLTMtMS0xLTI3NzAy_baf35909-1201-4978-a62d-4278dc2a7908">5.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEzLTUtMS0xLTI3NzAy_ee933d67-131f-4e1a-96b1-712384554524">1.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEzLTctMS0xLTI3NzAy_2de5b19f-140e-4b0b-8ba4-264c19e3ad80">785,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a Warrants Amendment and Agreement with certain holders of warrants that were exercisable for <ix:nonFraction unitRef="shares" contextRef="i44a4af39e9424b53a07681fa1a5d8f50_D20200302-20200302" decimals="-5" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDMyMjE_7f9d7547-fae2-4129-9115-f4e4f7318a55">3.2</ix:nonFraction> million shares of common stock. The agreement reduced the exercise price of existing warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1a664a51c194792a34d9f22fad31cac_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDQwNDg_c78c65af-4765-485a-af4a-4760181eac6f">0.86</ix:nonFraction> per share to $<ix:nonFraction unitRef="usdPerShare" contextRef="i6f822c4990b1439daba5becfbc85c5aa_I20200302" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDMyMzg_d2a8f9f9-b454-497f-840d-41f9ebcd8186">0.75</ix:nonFraction> per share, which were exercised following the amendment, in addition to issuing <ix:nonFraction unitRef="shares" contextRef="i93c22029995e4f6384a607093272bbfa_D20200302-20200302" decimals="-5" name="bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDMyNDU_5cd13301-9e2b-4ae4-8485-79c96e15d6f8">3.2</ix:nonFraction> million new warrants at an exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="iab207f0b1ddf422e9fdb826c96fbbae0_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDMyNTY_9c98cef1-7d18-464b-85af-db100acf08ff">1.06</ix:nonFraction> that were exercised in the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company&#8217;s board of directors (the &#8220;Board&#8221;) and its stockholders adopted the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), as a successor to and continuation of the Company&#8217;s 2006 Equity Incentive Plan (the &#8220;2006 Plan&#8221;). Under the 2018 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then its employees, directors and consultants, including employees and consultants of its affiliates. The Company has initially reserved <ix:nonFraction unitRef="shares" contextRef="ic2aef460467747f28861ce3854e7c187_I20180831" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4Xzc5MDI_04175de1-974d-4dc6-81b4-f58f2f952222">1.5</ix:nonFraction> million shares of common stock for issuance under the 2018 Plan, which is the sum of (1) <ix:nonFraction unitRef="shares" contextRef="i1c415e70a6a948e8b2be43920872a619_D20180801-20180831" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4Xzc5ODY_f85659c8-eb41-4ef6-af3f-62b9820b6679">1.0</ix:nonFraction> million new shares, plus (2) the number of shares that remained available for issuance under the 2006 Plan at the time the 2018 Plan became effective, and (3) any shares subject to outstanding stock options or other stock awards that were granted under the 2006 Plan that would have otherwise returned to the 2006 Plan. In addition, the number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2019 through January 1, 2028, in an amount equal to <ix:nonFraction unitRef="number" contextRef="ic9ca65a64a4549f589630eadc720acf0_D20210101-20211231" decimals="INF" name="bngo:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4Xzg1MzI_69519a63-9f31-4669-a786-0c536d58eaaf">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i9f4b74c4fd9d4e7094439d2d2c7562e3_I20211231" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MjEzNDY_d5707895-e48d-4c79-a0c1-678b8c4f6cbb">6.2</ix:nonFraction> million shares of common stock were authorized for future grants under the 2018 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company&#8217;s Board and its stockholders adopted the 2020 Inducement Plan and amended by the Board on October 6, 2021. Under the 2020 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then its employees, directors and consultants, including employees and consultants of its affiliates. The Company has initially reserved <ix:nonFraction unitRef="shares" contextRef="i3ea7966b68f743518a7b346891b8cfa1_I20200821" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NTgxODA_e31ba8ff-f2dd-4a4e-9965-7335f5d55d26">2.1</ix:nonFraction> million shares of common stock for issuance under the 2020 Plan. An additional <ix:nonFraction unitRef="shares" contextRef="i17c21833ff0041eaad1473112a77f0a7_D20211006-20211006" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NTg1MjA_a3df5b73-fa65-477f-8dec-fd2df6b36ea5">1.0</ix:nonFraction> million of shares of common stock was reserved for issuance under the Inducement Plan for a total of <ix:nonFraction unitRef="shares" contextRef="i4ad50c757a9743e791dd8f5af71e8e31_I20211006" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NTg2Njk_5e27371a-b5ca-4d1e-b0d2-c32c8a33e53d">3.1</ix:nonFraction> million shares pursuant to an amendment to the Inducement Plan approved by the board of directors on October 6, 2021. As of December&#160;31, 2021, there were approximately <ix:nonFraction unitRef="shares" contextRef="i5e25fe9fc0eb46c29dddcb5c5cfde31d_I20211231" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3Mjk4MDg_2fb56889-89f3-43ae-9226-337076890fd0">0.7</ix:nonFraction> million shares of common stock authorized for future grants under the 2020 Plan.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ie23fc598dad24c7ea874f5fd3398ac89" continuedAt="i47751bedcba74649b7fd7476566dbfa1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDIw_914710b0-44f0-438c-bda8-4a4f885c74af" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity is as follows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise <br/>Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Remaining <br/>Contractual <br/>Term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate <br/>Intrinsic <br/>Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzktMS0xLTEtMjgyMjg_31c5c24a-9ce1-4187-aaf3-1ee4dd9d4bdd">5,290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzktMy0xLTEtMjgyMzk_ae3fd519-5e69-49af-a21d-857ce9a53c60">1.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzktNS0xLTEtMjgyNTA_1a5acb37-a532-4390-97f8-dc196c48f76d">8.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzktNy0xLTEtMjgyNjE_055d4397-968a-496f-8af9-8e48d376d2f2">10,178,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzUtMS0xLTEtMQ_b6d70407-225f-48b8-a453-5b8e5ffb5dce">9,108,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzUtMy0xLTEtMQ_3dd93d8d-1153-4cfc-af0a-b6de6c46295e">6.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzYtMS0xLTEtMQ_a525eb11-2e56-4142-b6e0-268bfb593b8e">471,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzYtMy0xLTEtMQ_f4edc393-5a6e-4810-a686-706dbb15230c">1.30</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzYtNy0xLTEtMQ_d2a3ca36-19d1-4201-ad72-6c26cd28e7db">2,547,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzctMS0xLTEtMQ_88331313-a95e-4062-a83d-9172f62454a5">1,162,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzctMy0xLTEtMQ_d12c9177-7856-4ce1-8ea4-e79b4e0d403e">4.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzgtMS0xLTEtMQ_b8326172-d4ce-4e91-b8c6-80ba6cf0d1c5">12,765,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzgtMy0xLTEtMQ_b8d59f82-6e6b-4c4a-8124-7794172628a6">4.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzEzLTUtMS0xLTMyMDUx_c830180c-9403-4ca0-afe9-af23a7c246d7">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzgtNy0xLTEtMQ_56a640b6-fc00-4315-be36-973b36eb936d">7,891,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and exercisable at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzExLTEtMS0xLTE_ee0e345f-6ac6-4dc3-9e48-9d46769a6c98">3,389,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzExLTMtMS0xLTE_8b002701-a3d0-44b4-9a38-893a3d496604">3.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 5.5pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzExLTUtMS0xLTE_8275a453-d911-4725-a062-973db6c90884">8.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzExLTctMS0xLTE_5f07f4c7-d076-491c-96c1-2f84d3523ad5">4,428,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock option grants during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4f676ebcb6964b0db783a5db2a081ffa_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc3MDM_7589da46-bf03-4c3c-b4b1-9b1ea930a843">4.35</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ic8eacd11ad8142c39a3d70452a09fdda_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2OTk_53884071-bb6b-4bab-8ee2-b7fbb69e571a">0.44</ix:nonFraction>, respectively. The total intrinsic value of the stock options exercised during the years ended December&#160;31, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzYwNDczMTQwMDMxOTA_ffd5b27e-d63a-4234-b017-e9e9c211769f">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQzOTgwNDY1NjE0Nzg_0f93dbf4-20b2-4dea-9706-940ac4b7bb2d">7,000</ix:nonFraction>, respectively. The contractual term of stock options granted to employees was <ix:nonNumeric contextRef="i4f676ebcb6964b0db783a5db2a081ffa_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzkxMTA_dad85022-e26e-4e53-8589-563ecfbe73cb">10</ix:nonNumeric> years, which is also the maximum contractual term permitted for stock options (and stock appreciation rights) issued under the 2018 Plan. Stock options generally vest or become exercisable monthly over a <ix:nonNumeric contextRef="iab4219a77977404ba46cadf9c1e2d9e1_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDE3_151c073d-5cb3-4ca3-8394-53ca482df749">four-year</ix:nonNumeric> period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock award in the amount of <ix:nonFraction unitRef="shares" contextRef="i7265080c4d794589a09bd0e17f4e4a2d_D20211001-20211031" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3Mzc4OTQ_ad67ab99-0203-412f-8648-5b795dc59b15">5.0</ix:nonFraction> million shares with a grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7265080c4d794589a09bd0e17f4e4a2d_D20211001-20211031" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3Mzc5MDI_0e982174-922d-4781-a612-850b69949084">5.20</ix:nonFraction> a share was granted as part of the acquisition of BioDiscovery. One-third of the Restricted Shares will vest on October 18, 2022 and one-twelfth of the Restricted Shares shall vest every three months following October 18, 2022, subject to continuous service of a key employee. The weighted average remaining contractual term for the restricted stock is <ix:nonNumeric contextRef="i96e920c0320b47feb8ecdd4d667557e4_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2Nzg0Nzg_2963e44b-8863-40af-96d4-10ef04507ee4">2.8</ix:nonNumeric> years as of December&#160;31, 2021. The fair value of the restricted stock award is based on the market value of common stock as of the date of grant and is amortized to expense over the respective vesting period or the service period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues restricted stock units (RSU) and performance stock units (PSU). The Company grants restricted stock pursuant to the 2018 Stock Plan and satisfy such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. RSUs generally vest over a <ix:nonNumeric contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgxNzE4NDM_93400e7d-8217-4e1c-b9f7-604529824eda">two-year</ix:nonNumeric> period with equal vesting annually. We issue PSUs for which the number of shares issuable at the end of a <ix:nonNumeric contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgxNzk3NDI_b52c82e3-8e14-4816-af36-0699b31475ea">four-year</ix:nonNumeric> performance period is based on our performance relative to specified revenue targets and continued employment through the vesting period. </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgxNzE4MDU_32cf5a7c-1721-4d0e-b6e1-7cb7e6aecd08" continuedAt="i086f82bf83d3420980180f9beb8ab30a" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1180bacce9964e6ab67c6cf06acfbbde_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzEtMS0xLTEtMzI1MTE_a93d16ab-bb2a-4ec9-8595-5ba3d3d13fd1">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1180bacce9964e6ab67c6cf06acfbbde_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzEtMy0xLTEtNDM4NTc_bae861e8-8598-4ab0-9a5f-4e8ba7693050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzItMS0xLTEtMzI1MTE_bd6fa1a9-780b-47c8-9a5e-f32f159ca4cf">540,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1112f0645024f47bfb4ccd3ed88f2ba_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzItMy0xLTEtMzI1MjU_6b27506e-9fa3-403c-bd05-9257ce458c48">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzMtMS0xLTEtMzI1MTE_3152abe3-f650-4e5e-ae5f-acdf0c7848de">179,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1112f0645024f47bfb4ccd3ed88f2ba_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzMtMy0xLTEtMzI1MjU_c5d2ba28-b83a-414b-a87b-dd6b07598cd8">4.76</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzQtMS0xLTEtMzI1MTE_38a7744a-fa49-4e87-aae1-9462abd2c9b0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1112f0645024f47bfb4ccd3ed88f2ba_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzQtMy0xLTEtNDM4NTc_f18a7673-d684-4de5-afaa-158da9b28341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a68a48ad08c4a4a90ebcf1971894c02_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzUtMS0xLTEtMzI1MTE_27a0d617-9b27-4e44-a3d8-de28fb0ac568">361,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a68a48ad08c4a4a90ebcf1971894c02_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzUtMy0xLTEtMzI1MjU_74ac4c6d-0b5b-4aa0-931c-cc975f284051">4.74</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of the RSUs that vested was $<ix:nonFraction unitRef="usd" contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MjExNjU_49d2fad9-a031-44f0-b968-0cfb87388e36">0.9</ix:nonFraction> million during fiscal 2021, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is <ix:nonNumeric contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzAwMDA_547cd33b-45e6-40c3-915b-cbd378789897">1.4</ix:nonNumeric> years as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock activity was as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i47751bedcba74649b7fd7476566dbfa1" continuedAt="ic2305e0b4b61472fb0b7261518d0f8de"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i086f82bf83d3420980180f9beb8ab30a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f80b7d6b8944158bd9c8a9940a3b414_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzEtMS0xLTEtMzI1NDI_ffd09e62-d1c0-4b45-98e9-d38240ed09e4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f80b7d6b8944158bd9c8a9940a3b414_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzEtMy0xLTEtNDM4OTQ_2b5afdad-2509-4a72-accc-7fcb11f6e07e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzItMS0xLTEtMzI1NDI_3e3f72f4-748b-4c65-a9f5-da85246db0d9">290,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6166e9bcdaf64523922f223a68f2ae8a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzItMy0xLTEtMzI1NDg_d87e28df-769e-429e-b149-c9b69ddc780f">4.74</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzMtMS0xLTEtMzI1NDI_6f80a4a0-6129-4893-a8d7-d317a113340f">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6166e9bcdaf64523922f223a68f2ae8a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzMtMy0xLTEtNDM4OTQ_d09b1e1c-7031-4d9b-b49f-9839cd8916fb">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzQtMS0xLTEtMzI1NDI_998c1915-0568-4203-beb4-ccc29442d3f0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6166e9bcdaf64523922f223a68f2ae8a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzQtMy0xLTEtNDM4OTQ_0256b01c-2a33-4728-911d-4e9f251632c0">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33f329ca85c24dc6ac16f2cf9b3ac9b1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzUtMS0xLTEtMzI1NDI_bf239dfe-abf8-417a-8298-79a2aef71f54">290,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33f329ca85c24dc6ac16f2cf9b3ac9b1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzUtMy0xLTEtMzI1NDg_f4397ae0-ccaf-4f88-b8be-9cd453f18fc5">4.74</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual term for the PSUs is <ix:nonNumeric contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzAxMTc_56c6f067-4ff3-4804-aee6-feda599f3de1">3.4</ix:nonNumeric> years as of December&#160;31, 2021</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDI2_a663ba6c-9c17-4630-84b9-629ec79d6c76" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the years ended December&#160;31, 2021 and 2020 was as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe3e09f6a3945efabf706cebdf47304_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzItMS0xLTEtMQ_2a366ab6-72c7-41e8-8768-8bb9f6048885">3,531,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d32570b3e4421289d391c0f57b1c05_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzItMy0xLTEtMQ_879082e6-12d9-4c00-bdd1-4f01ff0f4abe">375,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc3a87e87bc437b84ce90bf5c661e8d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzMtMS0xLTEtMQ_6f8b8482-841d-4874-896f-850b5c20b52d">6,188,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd34a35d15694242a41144a942e3bbd5_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzMtMy0xLTEtMQ_592ef53d-c278-43d7-b5c7-85720e037ba8">1,179,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzQtMS0xLTEtMQ_1a36c7d8-0851-4dea-b9a9-541bf54da961">9,719,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzQtMy0xLTEtMQ_44e761a8-2efa-4bf2-b12f-bf62719eaa82">1,554,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDIy_dc9ddc85-7de6-4f78-a6ea-2b5d5293d5ae" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of the employee stock option grants were as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzMtMS0xLTEtMQ_1db27584-690a-40b2-b280-d377618fc0e8">1.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzMtMy0xLTEtMQ_387950a7-0127-4e91-9381-caf496323ee9">.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzQtMS0xLTEtMQ_88eefc49-5c52-4bb0-8924-7a19a0fa5148">76.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzQtMy0xLTEtMQ_900260cf-eb95-4420-9312-68ad7005c4ca">77.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzUtMS0xLTEtMQ_ffd2fbb8-353e-4f94-b408-771a90cee213">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzUtMy0xLTEtMQ_6cb6a0fc-140e-4044-a801-f09a45b10f7a">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzYtMS0xLTEtMQ_90047a46-4c9f-4100-8a1c-29e8f15bed27">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzYtMy0xLTEtMQ_a369c91f-71b1-4237-9f71-0244d1f96db7">0.0</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and lack of company-specific historical or implied volatility as a private company, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded. As a result, the Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forfeitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company reduces stock-based compensation expense for actual forfeitures during the period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized Stock-Based Compensation Expense </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the unrecognized compensation expense for all non-vested share-based awards was $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc3Mjk_08c1dc75-3f5d-4d63-8887-3ccc8d0a54d9">59.2</ix:nonFraction> million and is expected to be recognized as expense over a weighted-average period of <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MjEzMDg_ff691230-3111-435d-9e1c-da1ea2ec2313">3.1</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Board and the Company&#8217;s stockholders adopted the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of <ix:nonFraction unitRef="shares" contextRef="i729c6da2107844e28908f101e5b69b18_I20180831" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzExMzk1_becba571-e283-4cfb-b96e-be326adbef04">0.2</ix:nonFraction> million shares of common stock were initially reserved for issuance under the ESPP. In addition, the number shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2019, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through January&#160;1, 2028, by the lesser of (1) <ix:nonFraction unitRef="number" contextRef="i6e08bcf17c014092be59db6343e02b9d_D20180801-20180831" decimals="2" name="bngo:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzExNjk4_e5fa7d52-ab62-4067-9092-afbcd2e384b0">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of the automatic increase, (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2390b4b66da344ecb775181baacb32dc_I20180831" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzExODU4_3b06f75a-f6ab-4d6a-a951-0fe6be46f3b1">220,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares, </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ic2305e0b4b61472fb0b7261518d0f8de"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (3) a lesser number of shares as determined by the Board. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzExOTQx_b5593d14-ad03-4e7a-af50-c6c490dc07a5">0.2</ix:nonFraction> million shares of common stock were authorized for future grants under the ESPP.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Option Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2022, the compensation committee of the Company&#8217;s board of directors granted various executive officers stock options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6ddb1728db3a49f8abb7b5af01e8a6e3_D20220215-20220215" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3NDQ5MzI_e5c8ee0b-e457-4d9b-a215-9699badc717e">4.3</ix:nonFraction> million shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6ddb1728db3a49f8abb7b5af01e8a6e3_D20220215-20220215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3NDc1MjM_2cd72693-b140-4c79-ad91-3a382d41e491">2.18</ix:nonFraction> a share, in each case with an effective grant date and vesting commencement date of February 15, 2022 (the &#8220;Grant Date&#8221;). These stock option grants were issued from the 2018 Stock Plan. The shares subject to the option shall vest monthly over <ix:nonNumeric contextRef="i4d5183cf0cdf481fb13cb77e135891e9_D20220215-20220215" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzYwNDczMTQwMDMxMjI_22d5cc4a-2b2f-4baa-a694-1ce8c8a451b9">48</ix:nonNumeric> months beginning on the one-month anniversary of the Grant Date, such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.</span></div></ix:continuation><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_181"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzI4NjM_b0ddf761-67fe-494c-8b62-c0125845d29e" continuedAt="i0a5baaa7889148fd9976ef2ad2fc5e42" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i0a5baaa7889148fd9976ef2ad2fc5e42" continuedAt="ic348ae1067b44073ab93d920443401ab"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i826d7a082f1c44b7bf787aecb9e7c3ce_I20211231" decimals="0" name="bngo:LesseeOperatingLeaseAreaLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTE1Mzg_f4a8745e-26a1-4d9c-a305-2121b2a4b810">35,823</ix:nonFraction> square feet of office, laboratory, and manufacturing space in two buildings at our headquarters in San Diego, California, with the lease for all rented space expiring December 31, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, the Company executed a new lease for approximately <ix:nonFraction unitRef="sqft" contextRef="i826d7a082f1c44b7bf787aecb9e7c3ce_I20211231" decimals="0" name="bngo:LesseeOperatingLeaseAreaAdded" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1NDA0MDM_f62faffa-7f44-4c91-844b-26c53b687731">11,978</ix:nonFraction> additional square feet square feet of office and laboratory space in San Diego, California that expires in January 2026.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2022, the Company executed a new lease for an additional <ix:nonFraction unitRef="sqft" contextRef="ieb6d3ff5dfb74f5e9b0306ff18734baa_I20220131" decimals="0" name="bngo:LesseeOperatingLeaseAreaAdded" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1NDA0MTM_288ba825-bb96-4e73-86fa-a5cdbcec5ea2">5,278</ix:nonFraction> square feet of office and laboratory space in San Diego, California that expires in January 2026. Rent payments for the additional space are $<ix:nonFraction unitRef="usd" contextRef="i320f1643428144d38fdcf459b451c4a6_D20220131-20220131" decimals="-3" name="bngo:OperatingLeaseMonthlyRentPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3Mjk2ODc_b355d2ed-1784-41ba-8da1-f67bd9c4688e">16,000</ix:nonFraction> each month through December 2022, and increases annually according to the Company&#8217;s lease agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, through the acquisition of Lineagen, the Company obtained a lease for approximately <ix:nonFraction unitRef="sqft" contextRef="i470e708352854bb7934441171219601e_I20211231" decimals="0" name="bngo:LesseeOperatingLeaseAreaLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1NDEwMTg_dc3692a8-779b-4102-9c1b-2a48bd68b2fb">9,710</ix:nonFraction> square feet of office space in a Salt Lake City, Utah under a non-cancelable operating lease that expires in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance lease</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, through the acquisition of BioDiscovery, the Company obtained a finance lease of <ix:nonFraction unitRef="sqft" contextRef="i4ea6c5e3b632418db86e6b334229c600_I20211021" decimals="0" name="bngo:LesseeFinanceLeaseAreaLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTE1NjM_f769d3c3-7f46-41cc-9911-af18f50ef103">4,786</ix:nonFraction> square feet of office space in El Segundo, California that expires in February 2041.  The portion of the future payments designated as principal repayment and related interest was classified as a finance lease obligation on our consolidated balance sheets. Refer to Note 15. Related Party Transactions for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental information </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all leases, the Company has the ability to enter into renewal negotiations, prior to the lease end date, with no specific terms. At this time, it is not reasonably certain that we will extend the term of the lease and therefore the renewal period has been excluded from the aforementioned ROU asset and lease liability measurements. The leases are subject to variable charges for common area maintenance and other costs that are determined based on actual costs and includes certain lease incentives such as tenant improvement allowances. The base rent for the leases is subject to an annual increase each year. Rent expense is being recognized on a straight-line basis over the term of the lease. The Company&#8217;s estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="3" name="bngo:LesseeEstimatedIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1MzI1NzE_78f5ad52-76ef-42e1-a399-41abeb2b77e6">7.1</ix:nonFraction>% was used in its present value calculations as the operating and finance leases do not have a stated rate and the implicit rate was not readily determinable. In determining the incremental borrowing rate, the Company considered the interest rate of the Term Loans as well as publicly available data for discount rates used by peer companies.</span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzI4NjY_28aa4b51-7ab5-45b3-ad0c-ebb09605e5f6" continuedAt="id706e9f38a69406991158b4c24b0dd33" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information pertaining to the Company&#8217;s leases in which the Company is lessee for the year ended December&#160;31, 2021 is as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:OperatingLeasePaymentsModifiedAndUnmodified" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzEtNS0xLTEtMzUxOTA_9c8b25c1-1c33-4fc6-8ded-504c38c86af5">447,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzItNS0xLTEtMzUxOTA_c164a5a1-5e06-4d27-ac33-408771fbff33">47,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzMtNS0xLTEtNDA0NDE_806f07d7-c4d1-4585-8313-508e0ceacd4d">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzQtNS0xLTEtMzUxOTA_4061f5ac-ba13-45c4-842e-a52644d8426d">4.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzUtNS0xLTEtMzUxOTA_2f53d161-087e-4087-8d73-c025f5d2a2cf">19.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzItNS0xLTEtMQ_2d32badc-257a-47f2-9afc-4c5fb2dd9f7c">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzMtNS0xLTEtMQ_08e22e7d-f16f-4579-b6dd-0f2162dd7562">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash lease liabilities resulting from obtaining right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzUtNS0xLTEtMQ_395c014a-4b76-4b09-b470-6b97d150557e">4,751,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ic348ae1067b44073ab93d920443401ab" continuedAt="if77b75e058c7424db617461671d94fe8"><ix:continuation id="id706e9f38a69406991158b4c24b0dd33"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of the Company&#8217;s lease cost:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzMtMS0xLTEtMzUyNjU_97030b97-0360-4d92-8dba-6df9c8e046ec">1,118,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzMtMy0xLTEtMzUyNjU_66c4bbf7-e519-4c66-adc4-d2e1e28674ac">887,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzQtMS0xLTEtMzUyNjU_e3105880-e431-4f3a-b4d2-75ad5dffe538">386,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzQtMy0xLTEtMzUyNjU_ebef8f6f-c12c-49e7-a615-4b193b072e1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total rent expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzUtMS0xLTEtMzUyNjU_4af6243d-c5bb-4465-ad60-f19053b9ce71">1,504,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzUtMy0xLTEtMzUyNjU_2e2c8bb4-548a-41bf-b914-b0c5f311e175">887,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzctMS0xLTEtMzUyNjU_f64aa9a1-e34b-4bc6-8a24-879bf4553714">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzctMy0xLTEtMzUyNjU_4d626b16-f845-4620-84e4-498c92dda016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzgtMS0xLTEtMzUyNjU_afc4e935-4a0e-4040-ac8c-a8e7640fa228">47,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzgtMy0xLTEtMzUyNjU_4e8813b3-aebf-4a05-9b6f-56af4a49499c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:FinanceLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzktMS0xLTEtMzUyNjU_4eec1c0c-bcc7-43a8-b35a-411fe1ca2991">66,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:FinanceLeaseExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzktMy0xLTEtMzUyNjU_f450849f-edd6-42f7-af8e-d0afa89d0335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzExLTEtMS0xLTM1Mjcy_23b7dd7c-7581-49d0-9a98-b4c8d793a4d7">18,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzExLTMtMS0xLTM1Mjcy_803920ff-be22-4c76-ad6d-1b6b06452a22">422,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzEyLTEtMS0xLTQzNzQx_c1ba19d7-ce52-4c86-ad1d-ef2ce9e5a1ca">1,552,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzEyLTMtMS0xLTQzNzQx_5196c681-72a5-4723-b153-fe215319cc8f">465,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense and sublease income for the year ended December 31, 2020 reflects accounting treatment under ASC 840.</span></div></ix:continuation><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzU0OTc1NTgxNjAzMzU_7feeef88-e318-4138-9904-200f0ad1af00" escape="true"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzU0OTc1NTgxNjAzMzU_d31869d5-f7c3-4723-b6a3-cc3475e2dd4e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum payments under non-cancellable operating and finance leases as of December&#160;31, 2021, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzEtMS0xLTEtMzUzNzc_b8f00238-60aa-49b7-ac90-d82f1174b21b">1,881,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzEtMy0xLTEtMzUzOTc_09763be1-a593-4484-b2de-b75f6901d68e">314,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzItMS0xLTEtMzUzNzc_01e75dde-aafa-49c9-8800-834882e7d9bb">1,950,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzItMy0xLTEtMzUzOTc_9bf2062d-4d0b-4618-b796-6f119fc61173">322,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzMtMS0xLTEtMzUzNzc_7808020f-44df-4bb4-bb08-ac46e371cb3e">2,011,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzMtMy0xLTEtMzUzOTc_c42ede60-7c9d-40c6-b557-02e70eac4d00">330,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzQtMS0xLTEtMzUzNzc_05a04f58-afbb-4bbb-9cea-7a59b5badc4f">2,088,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzQtMy0xLTEtMzUzOTc_0ac904c0-9a0a-4caa-a1bd-de1ca12849a1">338,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzUtMS0xLTEtMzUzNzc_226a9ac6-d871-4249-b0f7-25c4d2f8acf3">232,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzUtMy0xLTEtMzUzOTc_3ff4de88-d9c6-494c-b86b-46295041d2e3">346,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzYtMS0xLTEtMzUzNzc_72be6bc3-45e3-45ba-b9c4-5c024a990340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzYtMy0xLTEtMzUzOTc_dc889080-9c85-4f89-a27d-b8abdd9003a3">5,949,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzctMS0xLTEtNDM2Mjg_39c0c893-40d6-41de-b4b9-92a1368a67fe">8,162,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzctMy0xLTEtNDM2MzE_bdaf9eba-c667-4563-b862-79fb6f4fcfe8">7,599,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzgtMS0xLTEtMzUzODg_f3562685-1585-482e-8d9c-c2a1b3839ed8">1,407,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzgtMy0xLTEtMzUzODg_78055325-01ac-41cf-b5dd-d1e95f89ada3">3,658,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzktMS0xLTEtNDM2Mjg_f925e995-ea07-4c25-87cd-c67aa6058b14">6,755,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzktMy0xLTEtNDM2MzE_61db2e83-54db-4d2c-9cd5-6849d8d933f1">3,941,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzU0OTc1NTgxNjk1NDg_0fef1046-d517-4888-b796-b55250d639c3" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASC Topic 842, future minimum rental payments under operating leases as of December&#160;31, 2020, were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ending December&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzEtNS0xLTEtNDk4OTc_d1fe34cc-28ab-4612-a477-ab0a2666f0a6">734,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzItNS0xLTEtNDk4OTc_a58feb50-6848-4971-bfe1-8c30315fa772">639,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzMtNS0xLTEtNDk4OTc_27d137f0-19c9-4a3e-b64a-dc21314c03d8">666,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzQtNS0xLTEtNDk4OTc_242dd01b-2dc1-44c5-a050-342b4f29e9f6">696,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="bngo:OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzUtNS0xLTEtNDk4OTc_acc0140a-7571-4e37-81dd-ea4e7658f838">729,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzYtNS0xLTEtNDk5Mzg_734f6c4e-c07a-40fe-96a1-d403c1a14cd7">3,464,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a contractual commitment with a supplier to purchase $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="bngo:ContractualCommitmentPurchaseOfProductsEveryQuarter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MDEzMDY_4378d9c8-8cfa-481a-bb0b-6c6f09970848">0.3</ix:nonFraction> million of products every month for an initial term of <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="bngo:PurchaseObligationInitialPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzE5NTE_d0f27164-ae08-4a4f-81ae-a9b0972e5238">two years</ix:nonNumeric> beginning in May 2021 until May 2023. The contract can be terminated with <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="bngo:PurchaseObligationContractTerminationPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzIwMTU_3e2f1d3a-cf82-4992-a7e0-57c1fe5cee70">90</ix:nonNumeric> days written notice by either party.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="if77b75e058c7424db617461671d94fe8"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of the loss can be reasonably estimated. Based on the Company&#8217;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Merger Agreement related to the acquisition of BioDiscovery, the Company agreed to pay a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-5" name="bngo:ContingentConsiderationMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTUyMTY_86f0dffe-e1c1-449e-bb78-74dddb12b8eb">10.0</ix:nonFraction> million in cash contingent on the achievement of a commercial milestone within eighteen months of the acquisition date. The Company determined the fair value of the milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The outcome of the milestone consideration is binary, meaning the milestone is either achieved or not achieved, and the only other variable factor is the timing of when the milestone is achieved. The Company determined it is highly likely that the milestone will be achieved and therefore used a 95% probability factor which is applied to the $<ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-5" name="bngo:ContingentConsiderationMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTUyMzE_86f0dffe-e1c1-449e-bb78-74dddb12b8eb">10.0</ix:nonFraction> million milestone consideration. Based on these valuation assumptions, a contingent liability of $<ix:nonFraction unitRef="usd" contextRef="idebec6bf5580446897b029f768bd15cf_I20211031" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTUyNDY_d6018568-c509-40f1-af97-be8039c22668">9.0</ix:nonFraction> million was recognized on the acquisition date. As of December&#160;31, 2021, the fair value of the milestone consideration was determined to be $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-5" name="bngo:ContingentConsiderationFairValueOfContingentLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1MzI1Nzg_52bba8db-d188-427e-a05f-7255617db5b9">9.1</ix:nonFraction> million. The change in fair value of $<ix:nonFraction unitRef="usd" contextRef="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTUyMDE_358b1c77-287a-4317-a3a1-250529fc205f">0.1</ix:nonFraction> million was recorded in selling, general and administrative expense in the consolidated statement of operations for the year ended December&#160;31, 2021.</span></div></ix:continuation><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_184"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTU_d2af6c27-6499-474c-acec-2564773ce5eb" continuedAt="i2166edb4af61475c8cc27d591b37e8f6" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i2166edb4af61475c8cc27d591b37e8f6" continuedAt="ifdc9fa8765564a1eba71945808df8b60"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTc_3c9fbd8a-86bc-4587-9dd4-8d6dfd409b7a" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of income (loss) from continuing operations are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzItMS0xLTEtMQ_23012f79-e97f-4cc1-8c2e-4dd9c2fb3e36">78,356,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzItMy0xLTEtMQ_70fc7f58-cab2-4be1-b326-e93cd2eeebab">41,191,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzMtMS0xLTEtMQ_27175a9f-fdaf-4b7d-9439-b2cf4ce2cffe">204,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzMtMy0xLTEtMQ_c684c1e4-b961-4853-ae41-0f59f139909f">114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzQtMS0xLTEtMQ_727ad42c-3f07-4cdc-839a-8c5f0a728d6a">78,152,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzQtMy0xLTEtMQ_30b25395-5684-4d02-b646-d0edd8f64000">41,077,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTE_65270edc-dc40-448b-987d-102b037afef4" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for domestic and foreign income taxes is as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzMtMS0xLTEtNDIyMTc_2db49419-1d89-4d80-a537-45907406056e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzMtMy0xLTEtNDIyMTc_f0fd505f-d546-46ae-8d34-64112646190d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzMtMS0xLTEtMQ_7c24f773-e07d-46b4-8ecb-124079040b0f">39,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzMtMy0xLTEtMQ_f37dae88-4bc0-416b-be44-d955156670e5">24,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzQtMS0xLTEtMQ_3769b693-26ee-4445-acc2-8f5a14657504">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzQtMy0xLTEtMQ_e1d5dc31-b6de-45db-93c7-c1eeae27fcd2">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current income tax provision (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzUtMS0xLTEtMQ_c9819a64-54d0-48a3-9bdd-1372db25575a">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzUtMy0xLTEtMQ_0503c990-3ab8-4106-9e48-e9417a6a339d">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzgtMS0xLTEtNDgwMzI_e58bc81e-2eb4-4e6a-8f71-3bb616d00ec9">4,055,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzgtMy0xLTEtNDgwNDA_10899e96-2dd0-467a-a6ec-b52e0c25ec15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzktMS0xLTEtNDgwNDA_1c48f5b7-4f98-4887-8f08-9a3f22a3678c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzktMy0xLTEtNDgwNDA_e458bf52-07e6-47df-97c1-3030147d70e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzEwLTEtMS0xLTQ4MDQw_b67d0109-66e8-44c8-8e38-f61ebc752dde">1,722,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzEwLTMtMS0xLTQ4MDQw_0d531fa1-d1ff-4959-8400-f21835439b27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzExLTEtMS0xLTQ4MDUw_5c562408-c1de-438d-9015-1a74fecd95a3">5,777,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzExLTMtMS0xLTQ4MDUx_d136c7b7-c212-4edd-b5cd-7a18af7f2cf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzEyLTEtMS0xLTQ4MDUw_c48138ec-8afd-43e9-a76c-e0641d72a057">5,717,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzEyLTMtMS0xLTQ4MDUx_407bd351-8c58-4138-aa6a-faf39738a254">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ifdc9fa8765564a1eba71945808df8b60" continuedAt="i5a347cbf63cb491bb522740347d1a8a1"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTg_fde17efa-a640-41a2-b973-f20543522965" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the income tax computed at the federal statutory tax rate to the expense for income taxes are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzItMS0xLTEtMQ_722c6f2d-851b-49ad-916a-b47c57a9fd41">16,413,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzItMy0xLTEtMQ_1585f368-52b1-49f7-ad5e-58f263977429">8,626,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzMtMS0xLTEtMQ_11d472af-f9d8-4f07-8399-95bfe91eea81">2,030,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzMtMy0xLTEtMQ_38a34f29-1445-4c8f-ba46-19f96284a8a5">522,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzQtMS0xLTEtMQ_ee474f93-3e2e-4e71-94f7-55a8c9329ee0">12,879,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzQtMy0xLTEtMQ_ffb9748e-0cb7-4907-9a0c-7f6e22d27d30">9,816,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 162(m)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="bngo:EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzUtMS0xLTEtNTM1ODI_36fa3645-55e2-412d-b3d0-861d115de21e">966,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="bngo:EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzUtMy0xLTEtNTM1ODk_1eac48c2-97e0-470a-964b-663e97aec9aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzUtMS0xLTEtMQ_14cc1080-a2b9-4675-9a76-093129f71468">165,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzUtMy0xLTEtMQ_12f9f20e-5766-4b30-93e3-3e34e131b4b0">67,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzYtMS0xLTEtMQ_8388ce7e-0b59-4bae-a046-a7814798fefd">938,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzYtMy0xLTEtMQ_53694a21-cf06-473d-ae5b-a9eddf4c22dc">568,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzctMS0xLTEtMQ_7a77aba8-3adf-4baa-8d2b-de174122c860"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzctMS0xLTEtMQ_ba5b443a-ba99-402e-987e-d1601bc5d0e4">16,000</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzctMy0xLTEtMQ_30509249-a5bd-48f7-986e-c2676195f327">4,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzgtMS0xLTEtMQ_503c3d8d-457f-49dd-84b3-1c9d971844cd">5,717,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzgtMy0xLTEtMQ_77e075d9-6b03-42de-a615-205abb925b05">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTk_d3d0b31b-29c5-494d-9cf8-878e10a5444c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2021 and 2020 are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzMtMS0xLTEtMQ_3de95228-cd38-4bce-8b64-44c82f55f994">81,399,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzMtMy0xLTEtMQ_d2b57344-b24b-4fde-bb68-ed8c1570a361">62,354,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzQtMS0xLTEtMQ_adbb60f8-65d6-4d38-a48f-fb845a922eb5">6,911,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzQtMy0xLTEtMQ_f16cc741-524e-4da2-bf1a-6b87cf51df9a">5,671,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzUtMS0xLTEtNDgxNzM_5b895349-9d99-47ed-b418-40b55c6a5baf">849,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzUtMy0xLTEtNDgxODU_056a9a16-ae38-49af-943a-c1a9440fe531">450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC 842 - lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="bngo:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzYtMS0xLTEtNDgxNzk_00e2ae43-a409-430c-b08f-1be709b76e5a">2,517,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="bngo:DeferredTaxAssetsLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzYtMy0xLTEtNDgxNzk_310e1ad4-7006-4bc8-995f-17c8ba4168e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzUtMS0xLTEtMQ_47982230-4847-422e-9ea7-493b73f9bc0a">1,457,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzUtMy0xLTEtMQ_a17fb5b5-7fad-45ea-8efa-accbb7411dc6">2,148,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzYtMS0xLTEtMQ_30fc090e-1be6-4dc9-a755-d9cff58e8410">93,133,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzYtMy0xLTEtMQ_ef0a9422-a287-47ab-9d50-10c53be91f8e">70,623,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="bngo:DeferredTaxLiabilitiesAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzEwLTEtMS0xLTQ4MjAx_22664231-3145-46d0-ab01-2713a5081141">7,478,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="bngo:DeferredTaxLiabilitiesAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzEwLTMtMS0xLTQ4MjAx_3a094d45-53e0-4c26-943d-8f448ca22ab6">350,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC 842 - ROU asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="bngo:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzExLTEtMS0xLTQ4MjAx_cadd0896-ceca-4735-872f-7391557a12e1">2,504,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="bngo:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzExLTMtMS0xLTQ4MjAx_d79061e3-6bc1-47de-850e-ca0755e2d4e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzEyLTEtMS0xLTQ4MjAx_95c01804-1bc4-4429-98aa-2511c401f049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzEyLTMtMS0xLTQ4MjAx_d99e4bfd-f03d-482b-9ed3-edb19e7b10f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzctMS0xLTEtMQ_569098e7-646c-43c5-8ad9-7ac02ca1ef4c">83,151,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzctMy0xLTEtMQ_caa8c856-83b7-4447-9335-03f9acaf89f4">70,273,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzgtMS0xLTEtMQ_2ff73e90-e7ad-4d94-99ce-dc201a0e615f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzgtMy0xLTEtMQ_830673b8-c2d7-4121-8927-b8c9c6a327a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has federal and state tax net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ib44b75fe239a4b60b494433a3f77f70d_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQxOTA_9a825737-946f-4c03-ab8c-a692a4d622df">341.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i99a808d515494cdbadb3da6e47f4e15c_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQzMzI_45cca2dd-6db7-4a6e-9ce8-c233ff238d82">158.4</ix:nonFraction> million, respectively. The federal tax loss carryforwards include $<ix:nonFraction unitRef="usd" contextRef="ib44b75fe239a4b60b494433a3f77f70d_I20211231" decimals="-5" name="bngo:OperatingLossCarryforwardsNotSubjecttoExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQzNDg_e6f08e95-368d-4e26-afbe-98588f08cd38">176.8</ix:nonFraction> million that do not expire but utilization is limited to 80% of the Company's taxable income in any given tax year based on current federal tax laws. The remaining federal tax loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i99a808d515494cdbadb3da6e47f4e15c_I20211231" decimals="-5" name="bngo:OperatingLossCarryforwardsSubjecttoExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQ1ODg_62eb401e-9d35-44c2-a76a-155b22deb85b">164.3</ix:nonFraction> million and state tax loss carryforwards begin to expire in 2027 and 2023, respectively, unless previously utilized. As of December&#160;31, 2021, the Company also has federal and California research credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i29f75a2dd05a4220bc087386e5a5149b_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQ3MTU_60090ac3-8dfb-46d8-ab70-b8cd8fbcfa7d">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic4c282464a94473ba123371ddc89314a_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQ3MjI_26e37b31-f1b8-4d3a-87f7-9605a194cf3e">6.1</ix:nonFraction> million, respectively. The federal research credit carryforwards begin to expire in 2027 unless previously utilized. The California research credits carry forward indefinitely. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses all available evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company has experienced net losses since inception, and the revenue and income potential of the Company&#8217;s business and market are unproven. Due to the Company&#8217;s continuing research and development ("R&amp;D") activities, the Company expects to continue to incur net losses into the foreseeable future. As such, the Company cannot conclude that it is more likely than not that its deferred tax assets will be realized. A valuation allowance of  $<ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzE3MzA_6045e6a5-86fd-4d8c-bb99-5a0e01a0ad67">83.2</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzE3Mzc_64491bce-5a88-4a6f-a26f-e0f41f4becb0">70.3</ix:nonFraction>&#160;million as of December&#160;31, 2021, and 2020, respectively, has been established to offset the deferred tax assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired BioDiscovery, LLC. an entity designated for income tax purposes as a corporation in a plan of reorganization  within the meaning of Section 368(a)(1)(A) on  October 18, 2021. Under ASC 805-740, the Company recorded deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i3624ecef1ddd4361a818dfb9464218ce_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDUzOTY_e3d3880f-2ffe-4238-a644-d15addf5c544">5.8</ix:nonFraction> million related to customer lists, patents/trademarks, developed technology, and fixed assets as part of the business combination. As the deferred tax liability recorded in the business combination constitutes a source of future taxable income, the Company recorded a decrease to its valuation allowance against its deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYwNDczMTM5NjEzMzY_4a7056bb-1327-482a-bbee-e698be7e83d9">5.8</ix:nonFraction>&#160;million as a deferred income tax benefit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating losses and R&amp;D credit carryforwards are subject to annual limitations due to ownership changes that have occurred or that could occur in the future, as required by Sections 382 and 383 of the Internal Revenue Code of 1986,as amended (the "Code"), as well as similar state and foreign provisions. These ownership changes will limit the amount of net operating losses and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change" as defined by Section 382 of the Code results from a transaction or series of </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i5a347cbf63cb491bb522740347d1a8a1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions over a three-year period resulting in an ownership change of more than 50 percentage points of outstanding stock of a company by certain stockholders. Due to the existence of the valuation allowance, limitations created by past or future ownership changes, if any, will not impact its effective tax rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company last performed a 382 study during 2013 and since this date there have been changes in ownership that will limit the Company's ability to utilize the net operating loss and R&amp;D credit carryforwards. The Company is in the process of refreshing its 382 study but the results of that analysis are unknown as of the issuance date of these consolidated financial statements. The completion of the 382 study could result in material reductions to deferred tax assets and related valuation allowance disclosed above. However, the Company had not utilized any of the net operating losses and R&amp;D credits during the years ended December 31, 2021 and 2020.          &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTM_13f01e5b-259b-4a32-943e-a449b49d5e5c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, are as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzItMS0xLTEtMQ_1dd35e20-2312-4127-b372-6acff23cdfc4">4,201,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzItMy0xLTEtMQ_d329b009-0aba-4ed0-b1f9-b56a1b143a91">3,708,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions/(reductions) for tax positions - prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzMtMS0xLTEtMQ_eb6b7764-78aa-4deb-a83a-9c60e1281238">231,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzMtMy0xLTEtMQ_b047c830-e076-4c6c-a249-99eb48d8065f">53,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzQtMS0xLTEtMQ_be9a59fc-1219-4783-88a9-5fdd7a6c015c">687,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzQtMy0xLTEtMQ_4571715f-4173-40a8-beb3-ac1acc87680c">440,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzUtMS0xLTEtMQ_3e6b9ebb-0097-4a0c-8e61-93b5e6b1cf23">5,119,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzUtMy0xLTEtMQ_906d7828-542a-40e0-90ef-c567bc324043">4,201,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the benefit of uncertain tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. Due to the valuation allowance position, none of the unrecognized tax benefits, if recognized, will impact the Company`s effective tax rate. The Company does not anticipate a significant change in the unrecognized tax benefits during the next twelve months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company had no accrual of interest and penalties on the Company&#8217;s balance sheets and has not recognized any interest and penalties in the statements of operations for the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the United States, the United Kingdom and China. The Company's tax years from 2007 (inception) are subject to examination by the United States and state authorities due to the carry forward of unutilized net operating losses and R&amp;D credits.</span></div></ix:continuation><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_187"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="bngo:DefinedContributionPlanDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODcvZnJhZzo5NGVmMDU4NDgzYWU0ZjkzODI5ZjllYTBjZGZkYzI5ZC90ZXh0cmVnaW9uOjk0ZWYwNTg0ODNhZTRmOTM4MjlmOWVhMGNkZmRjMjlkXzQ2OA_a23376a0-12af-4ea2-ac65-1eb8c1953675" continuedAt="i5c4889e4d94c4b5982f3e4db842ec8ac" escape="true">Employee Benefits </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c4889e4d94c4b5982f3e4db842ec8ac">The Company has a defined contribution 401(k) plan available to eligible employees. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. The Company expensed matching contributions of $<ix:nonFraction unitRef="usd" contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" decimals="-4" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODcvZnJhZzo5NGVmMDU4NDgzYWU0ZjkzODI5ZjllYTBjZGZkYzI5ZC90ZXh0cmVnaW9uOjk0ZWYwNTg0ODNhZTRmOTM4MjlmOWVhMGNkZmRjMjlkXzEwOTk1MTE2MjgyOTk_bf0d8cd2-8ce7-4b5a-9304-f8f8578912b8">0.83</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231" decimals="-4" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODcvZnJhZzo5NGVmMDU4NDgzYWU0ZjkzODI5ZjllYTBjZGZkYzI5ZC90ZXh0cmVnaW9uOjk0ZWYwNTg0ODNhZTRmOTM4MjlmOWVhMGNkZmRjMjlkXzEwOTk1MTE2MjgzMDY_c52e8406-bf6a-46b9-b654-ac662a35e2c8">0.46</ix:nonFraction>&#160;million for the years ended December&#160;31, 2021 and 2020, respectively.</ix:continuation></span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_190"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzczNjk_ce4ec5bf-f402-4cfb-abee-274572846aa4" continuedAt="id8e5f27bb87f4d4ea5e2cbcef67ee152" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="id8e5f27bb87f4d4ea5e2cbcef67ee152" continuedAt="ia95423225a9240ee96f43570c6144cf6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lineagen Acquisition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company, Merger Sub, Lineagen, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the security-holders of Lineagen, entered into the Lineagen Merger Agreement. Pursuant to the terms and conditions of the Lineagen Merger Agreement, Merger Sub merged with and into Lineagen whereupon the separate corporate existence of Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Merger as a wholly owned subsidiary of the Company. Lineagen&#8217;s expertise in development, commercialization and reimbursement of laboratory-developed tests provides a platform for accelerating sales growth for the Company&#8217;s Saphyr system. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Lineagen Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), the shares of capital stock of Lineagen and all options of Lineagen that were issued and outstanding immediately prior to the Effective Time were automatically cancelled and extinguished without any payment with respect thereto. Certain holders of convertible notes and other indebtedness of Lineagen at the closing of the Merger (the &#8220;Closing&#8221;) received common stock of the Company. The total number of shares of the Company&#8217;s common stock issued or reserved for issuance as consideration for the Merger was <ix:nonFraction unitRef="shares" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgyMDE5MTk_50d5410e-b5d7-441b-9a0c-470ee1e0f0ed">6,167,510</ix:nonFraction> shares, subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen (the &#8220;Merger Shares&#8221;). <ix:nonFraction unitRef="shares" contextRef="ic37f97c4ea0a4f4bb16de8adcef347a3_D20200821-20200821" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQzOTgwNDY1NzI0MzY_bba8d763-25ee-477a-b6c2-10e92283fdf8">925,126</ix:nonFraction> of the Merger Shares (the &#8220;Escrowed Shares&#8221;) were held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Lineagen Merger Agreement.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ia95423225a9240ee96f43570c6144cf6" continuedAt="ibbc4a8dacc4e4756b30f3475a68a538d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also as consideration for the Merger, pursuant to the Lineagen Merger Agreement, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgyMDE5MzA_3a76afbc-033f-44cc-b42d-fc400bb4a204">1.9</ix:nonFraction>&#160;million in cash to certain creditors and assumed certain liabilities of Lineagen totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgyMDE5NDQ_e49aa9ba-3bc3-4c3f-b620-c3c43202022f">2.9</ix:nonFraction>&#160;million, reflective of the Company's preliminary estimate of the post-closing purchase price adjustment (which adjustment is subject to finalization pursuant to the terms of the Lineagen Merger Agreement).  In addition, on August 21, 2020, concurrent with the Closing, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="-5" name="us-gaap:RepaymentsOfOtherDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgyMDE5NTg_ab36651c-1a7b-46fc-86d4-5c2e0c336ba7">1.1</ix:nonFraction>&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to that certain Promissory Note, dated April 22, 2020, by and between Lineagen and Silicon Valley Bank (the &#8220;Lineagen PPP Loan&#8221;), issued pursuant to the CARES Act administered by the SBA. The Lineagen PPP Loan was repaid by the Company prior to maturity without penalty.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its acquisition of Lineagen using the acquisition method of accounting pursuant to ASC 805.  The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non tax deductible. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. During the fourth quarter of 2020, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i132f0f05159f47b79fd74e910694340d_D20201001-20201231" decimals="-5" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQzOTgwNDY1NzI5MjM_5feba808-d493-49ed-8f21-899c376c0abe">0.2</ix:nonFraction> million adjustment to the original purchase price allocation to reduce the estimated fair value of accounts receivable, with the offsetting amount recorded to goodwill. There were no additional purchase price adjustments made during 2021. </span></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzczNjQ_4af8e24b-f03c-4473-ab0d-3e0c6e10a261" continuedAt="i21aa0cdd8c664539be1d77a00add83a1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the purchase price for the acquisition of Lineagen:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzAtMi0xLTEtMQ_fbaa27c1-e1d7-49cd-8469-6b42baebde46">1,940,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash transferred for repayment of Lineage PPP Loan (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="0" name="us-gaap:RepaymentsOfOtherDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzEtMi0xLTEtMQ_244972ec-a6ad-46e4-84dc-c4b7ae65ed40">1,105,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares common stock issued as consideration (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="0" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzItMi0xLTEtMQ_4c4b542a-2bc9-45e4-89aa-d6dec648e5e7">6,167,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares of common stock returned to the Company (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="0" name="bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzMtMi0xLTEtMQ_61ad9d01-dc5f-4a2b-99ce-751ad20ea67b">138,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price per share on closing date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzQtMi0xLTEtMQ_b5f4631a-56a1-481e-b8ce-f4aef4bb8c01">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Value of common stock consideration (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="0" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzUtMi0xLTEtMQ_3df159eb-f91a-4717-82da-d2a54d15216e">4,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total purchase price (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="0" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzYtMi0xLTEtMQ_b9d14da9-729b-4ebb-bb9f-7b85e55eaeeb">7,144,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQzMTY_366f378a-f563-43bb-9ea6-9a6e379a0356">1.9</ix:nonFraction>&#160;million in cash to certain creditors of Lineagen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="-5" name="us-gaap:RepaymentsOfOtherDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQzOTY_93bfee4b-1f07-40e6-b11b-1f82a70d35c9">1.1</ix:nonFraction>&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The total number of shares of the Company&#8217;s common stock issued as consideration for the Merger was <ix:nonFraction unitRef="shares" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQ2MzM_9d3190cd-05d3-4d5c-89d1-d78b9d63fbc0">6,167,510</ix:nonFraction> shares. The total number of Merger Shares was subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the common stock consideration and the total purchase price incorporated the return of <ix:nonFraction unitRef="shares" contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" decimals="INF" name="bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzUxMzk_ae71303c-5271-4c28-abb5-b42af709373b">138,247</ix:nonFraction> Escrowed Shares to the Company.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzczNjU_71c67f7c-1ca6-4fc9-9aa4-6ae4dc624617" continuedAt="ic7327ec1dfdc4475b75e69371d8066fa" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price was allocated to Lineagen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzAtMi0xLTEtMQ_f12b383c-d68a-41fe-ba84-de48a854bce6">596,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzEtMi0xLTEtMQ_887e7f70-2b64-464c-bc43-c1309a06eab6">337,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzItMi0xLTEtMQ_7965b304-890e-48d0-976f-96375b944c4b">209,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzMtMi0xLTEtMQ_335b9dd0-664c-44f6-b9c6-be50a04dabf4">111,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzQtMi0xLTEtMQ_08f418a7-0ac6-4f76-a100-ae589f0dc5ad">1,580,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzUtMi0xLTEtMQ_b0e27398-e2c6-4ee4-80c6-0900b1583e5a">7,173,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzYtMi0xLTEtMQ_8cd75bb0-c2c2-476e-b990-fa66c89d67c0">2,862,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzctMi0xLTEtMQ_dc7624e1-07bc-4c2e-8263-6b1724f00a2d">7,144,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzczNjY_25bc7320-d2bb-4c75-b135-2e9d68e15c9d" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i257cbc434ff74964959fc60f88c37154_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyNWUwOGExZDExNDg0YjQ0YjFlMjY1ZDdjMGY5MDRiMy90YWJsZXJhbmdlOjI1ZTA4YTFkMTE0ODRiNDRiMWUyNjVkN2MwZjkwNGIzXzAtMi0xLTEtMQ_4e50920e-2a84-415a-9ffc-f691428178a7">950,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ie5462c3bde0c4f4b91de75d0b7ce8831_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyNWUwOGExZDExNDg0YjQ0YjFlMjY1ZDdjMGY5MDRiMy90YWJsZXJhbmdlOjI1ZTA4YTFkMTE0ODRiNDRiMWUyNjVkN2MwZjkwNGIzXzEtMi0xLTEtMQ_3e7b487e-46ed-43a4-89e8-0aaeab2f1768">630,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyNWUwOGExZDExNDg0YjQ0YjFlMjY1ZDdjMGY5MDRiMy90YWJsZXJhbmdlOjI1ZTA4YTFkMTE0ODRiNDRiMWUyNjVkN2MwZjkwNGIzXzItMi0xLTEtMQ_38ec9a10-1e96-439d-86cf-017d93d9e426">1,580,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="ibbc4a8dacc4e4756b30f3475a68a538d" continuedAt="i285b9a25689c42acb573f0ce09e531c0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU3MjU_ae4f638f-eb24-43a1-8e2a-44bcdb3cb9f5">five years</ix:nonNumeric>. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU4OTY_0f326282-75a1-440c-9dbb-c7bfe250a82a">1.5</ix:nonFraction>&#160;million of acquisition-related transaction costs, including financial advisor fees, legal expenses and accounting fees during the year ended December&#160;31, 2020. These costs are included in the consolidated statement of operations in selling, general and administrative expense. Also, the Company reported approximately $<ix:nonFraction unitRef="usd" contextRef="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgxNDYzMTE_9d0ef9d0-3f7e-430e-870e-e9ae89bb0e6e">1.5</ix:nonFraction>&#160;million of service revenue generated by Lineagen in its consolidated statement of operations from the date of acquisition through December&#160;31, 2020. As the Company began integrating Lineagen&#8217;s operations with its existing operations during the fourth quarter of 2020, it is not practical or meaningful to distinguish Lineagen&#8217;s expenses or net income or loss from that of the combined operations for 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioDiscovery Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company completed the acquisition of BioDiscovery, LLC., pursuant to the BioDiscovery Merger Agreement. BioDiscovery's solutions for analysis, interpretation and reporting of genomics data is expected to accelerate and broaden Bionano&#8217;s market leadership in digital cytogenetics and comprehensive genome analysis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to BioDiscovery Merger Agreement, the Company paid upfront consideration consisting of a combination of approximately $<ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzU5NDc_7681f567-a42b-4753-a8f9-882d7941983e">52.3</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-5" name="bngo:BusinessCombinationConsiderationTransferredValueOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzYwNDQ_581c53af-f9c7-4d9a-b76b-dad9adbf7f59">40.0</ix:nonFraction>&#160;million in shares of Company common stock. Approximately $<ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-5" name="bngo:BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzYwNjE_6306306d-5792-4724-ab5f-9a0c7b46b538">26.0</ix:nonFraction>&#160;million worth of the shares of the Company&#8217;s common stock issued pursuant to the upfront consideration are subject to vesting based on continued service, subject to the terms and conditions of a stock restriction agreement. Accordingly, the restricted stock is being accounted for as compensation over the requisite service period, and is not included in the purchase price. The upfront consideration is subject to adjustment for, among other things, cash, unpaid indebtedness, unpaid transaction expenses and working capital relative to a target. Under the BioDiscovery Merger Agreement, the Company has also agreed to pay a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-5" name="bngo:BusinessAcquisitionMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzYwNzg_53093781-9fa1-4c55-a25d-7a1dbf3ca02c">10.0</ix:nonFraction>&#160;million in cash based on the achievement of certain commercial milestones. Cash of $<ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzYwOTc_0abb3a7f-ee65-4c0b-bf97-e42d576edc30">2.5</ix:nonFraction>&#160;million will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the BioDiscovery Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its acquisition of BioDiscovery using the acquisition method of accounting pursuant to ASC 805. The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non-tax deductible. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price allocation for the acquisition of BioDiscovery is preliminary and subject to revision as additional information about the fair value of assets and liabilities becomes available. As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. Per the terms of the BioDiscovery Merger Agreement, the purchase price is still subject to adjustment for the final determination of cash, unpaid indebtedness, unpaid transaction expenses and working capital, as well for deferred and current tax assets and liabilities</span></div><ix:continuation id="i21aa0cdd8c664539be1d77a00add83a1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the estimated purchase price for the acquisition of BioDiscovery:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzAtMi0xLTEtMzQzOTc_1c8a37d1-5e7c-416d-b3ac-2745375dee6d">52,291,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated fair value of milestone consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzMtMi0xLTEtMzQ0Mzg_8e093da1-4d50-4fde-818d-d682aa9455b0">9,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated return of cash to buyer from escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="bngo:BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzQtMi0xLTEtNDg4ODM_ad11e13a-d517-45a8-bff1-c58e60e6c972">694,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-3" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzQtMi0xLTEtNTM4MDU_20df15a6-c8d9-4573-a353-41e93540a819">2,723,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock price per share on closing date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzItMi0xLTEtMzQ0MTM_af491e22-7fe4-4462-a19c-8f29c6f89dfa">5.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Value of estimated common stock consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzMtMi0xLTEtMzQ0MTk_baf0e9ad-060b-4a5d-ac2b-0c56bb351d6e">14,159,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total estimated purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzYtMi0xLTEtNDM5ODY_fa723e4d-46fc-48ad-9d57-0d6693e7c5ac">74,756,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7327ec1dfdc4475b75e69371d8066fa" continuedAt="i4627e6b42fd94c11bca1d7820203de06">The total estimated purchase price was allocated to BioDiscovery&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</ix:continuation></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><ix:continuation id="i285b9a25689c42acb573f0ce09e531c0"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i4627e6b42fd94c11bca1d7820203de06"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzAtMi0xLTEtMzQ0ODI_84201405-b7eb-4710-9406-40836ea690bf">3,205,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzEtMi0xLTEtMzQ0ODI_9298b819-0a89-45d4-a65e-60b0bea1c9c9">1,782,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzItMi0xLTEtMzQ0ODI_9d566d0f-69ae-45e9-884b-7487283aa293">3,987,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzQtMi0xLTEtMzQ0ODI_c0ef3e07-73a2-40a9-83b7-6edbeba20c96">213,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzUtMi0xLTEtMzQ0ODI_3cd0f959-c1a3-46eb-8698-bd7d39be2384">26,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzYtMi0xLTEtMzQ0ODI_fb36e2be-23a0-426c-8cdc-52ba219aa8a1">48,987,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzctMi0xLTEtMzQ0ODI_557b7660-9437-43b9-b89c-26d01a4fdc02">193,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Right-of-use liabilities (short-term and long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzgtMi0xLTEtMzQ0ODI_e39787c4-58e2-4905-acf1-aa9f28269f0b">3,987,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzgtMi0xLTEtNTM0MjY_4f03fc1c-da83-4fac-b733-2410abe7fc8c">5,777,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzktMi0xLTEtMzQ0ODI_0aa6657e-ae7d-4075-b7c4-2c84c4879a09">261,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzEwLTItMS0xLTQzOTkw_627ce96e-38a7-4d11-95ef-af4f6d0c437b">74,756,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgxODcyMzk_a7263bd4-fe3c-4490-9d4d-452c4944ba80" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id7c4019bf43a47b28bc8cfe7f136b957_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo5NDgxMDc5MTI5Yjc0NDk4OWZhNTNlZDE5NDlkY2JmOC90YWJsZXJhbmdlOjk0ODEwNzkxMjliNzQ0OTg5ZmE1M2VkMTk0OWRjYmY4XzAtMi0xLTEtMzQ1MzM_01fd070c-a51d-4f27-9298-8fc2e48901ae">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i07bdd4786bb848d3aab8623ac0910407_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo5NDgxMDc5MTI5Yjc0NDk4OWZhNTNlZDE5NDlkY2JmOC90YWJsZXJhbmdlOjk0ODEwNzkxMjliNzQ0OTg5ZmE1M2VkMTk0OWRjYmY4XzEtMi0xLTEtMzQ1NDc_dcb5db06-784e-4737-8378-43cfdbcdce4c">22,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tradename</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i974ac13511bd4accb073439efd2968a7_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo5NDgxMDc5MTI5Yjc0NDk4OWZhNTNlZDE5NDlkY2JmOC90YWJsZXJhbmdlOjk0ODEwNzkxMjliNzQ0OTg5ZmE1M2VkMTk0OWRjYmY4XzItMi0xLTEtMzQ1NDA_7914cc9d-9888-4432-a260-fccb3a6e5800">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo5NDgxMDc5MTI5Yjc0NDk4OWZhNTNlZDE5NDlkY2JmOC90YWJsZXJhbmdlOjk0ODEwNzkxMjliNzQ0OTg5ZmE1M2VkMTk0OWRjYmY4XzMtMi0xLTEtNDM5NzQ_f189a7fb-f408-4498-8e94-26327781e433">26,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the income approach to derive the fair value of the identified intangible assets acquired. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed technology, customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of <ix:nonNumeric contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgxODcyMjg_3c629789-0970-4f1d-8e48-221b2be83973">five years</ix:nonNumeric>. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $-<ix:nonFraction unitRef="usd" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzM4NDgyOTA3MjM1MjE_2ba82e96-f97e-49eb-81ab-29f87a49c673">1.5</ix:nonFraction>&#160;million of acquisition-related transaction costs, including financial advisor fees, legal expenses and accounting fees during the year ended December&#160;31, 2021. These costs are included in the consolidated statement of operations in selling, general and administrative expense. The Company reported approximately $<ix:nonFraction unitRef="usd" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzM4NDgyOTA3MjM4NTE_3ae2dd90-33a6-4436-b484-a1ab5ff35ac4">1.1</ix:nonFraction>&#160;million of revenue generated by BioDiscovery in its consolidated statement of operations from the date of acquisition through December&#160;31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company began integrating BioDiscovery&#8217;s operations with its existing operations during the fourth quarter of 2021, it is not practical or meaningful to distinguish BioDiscovery&#8217;s expenses or net income or loss from that of the combine operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro forma Financial Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company, Lineagen, and BioDiscovery as if the companies had been combined as of the beginning of the year prior to the acquisition. These amounts have been calculated after applying the Company&#8217;s accounting policies and adjusting the results of Lineagen and BioDiscovery to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied at the beginning of the year prior to the acquisition. The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisitions had taken place as of January 1, 2019 and January 1, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzYwNDczMTQwMjgzNjQ_c0077ad7-f85e-4735-a905-514de0c43886" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,<br/>(Unaudited)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="0" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzItMi0xLTEtNDkyNjE_fdd938f8-2d28-4cce-95b8-d8ddd32b2a89">23,076,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231" decimals="0" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzItNC0xLTEtNDkyNjc_04b60a62-3f02-4b14-88a0-9e26de78fc2d">15,927,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="0" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzMtMi0xLTEtNDkyNjE_e290c59c-23db-486a-b09e-4e0878c64932">80,065,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231" decimals="0" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzMtNC0xLTEtNDkyNjc_1a06a8ef-299c-41f0-871b-ba45bc00e435">47,228,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzQtMi0xLTEtNDkyNjE_309a4543-9822-479c-8ef2-ad7fd8467343"><ix:nonFraction unitRef="usdPerShare" contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzQtMi0xLTEtNDkyNjE_54f7dd85-097a-4c94-a345-a4a0f8d35634">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzQtNC0xLTEtNDkyNjc_508e5633-6687-4757-903c-f17bf9c95acb"><ix:nonFraction unitRef="usdPerShare" contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzQtNC0xLTEtNDkyNjc_ca1f8a65-9ffe-4d01-8d4f-35021456a50f">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_2539"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTM5L2ZyYWc6M2ZlMjM4Zjc3NDg3NDgwMDk4MGUzYzgwYjA2ODQ1NjcvdGV4dHJlZ2lvbjozZmUyMzhmNzc0ODc0ODAwOTgwZTNjODBiMDY4NDU2N181NDk3NTU4MTQwNTQ5_cf263a1f-42cb-4df2-b241-5b1adb8b9f26" continuedAt="i9b08f0a536f0402b9009da0ec9337291" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9b08f0a536f0402b9009da0ec9337291">Through the acquisition of BioDiscovery in October 2021, the Company inherited a building lease with a landlord owned by BioDiscovery&#8217;s former Director and Chief Executive Officer, who is now the Company&#8217;s Chief Informatics Officer. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="id1804c21be1e41dc94b90988721c64f1_D20210101-20211231" decimals="-5" name="bngo:FinanceLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTM5L2ZyYWc6M2ZlMjM4Zjc3NDg3NDgwMDk4MGUzYzgwYjA2ODQ1NjcvdGV4dHJlZ2lvbjozZmUyMzhmNzc0ODc0ODAwOTgwZTNjODBiMDY4NDU2N18zODQ4MjkwNjk4ODkw_d4e26c22-00a3-4b1e-a98c-2eb0e17a7a7c">0.1</ix:nonFraction>&#160;million in finance lease costs related to this lease for the year ended December&#160;31, 2021. Refer to Note 11. Commitments and Contingencies for future commitments pertaining to this finance lease.</ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_199"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive and financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in its 2013 Internal Control &#8212; Integrated Framework. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2021. Pursuant to Section 404(c) of the Sarbanes-Oxley Act, our independent registered public accounting firm has issued an attestation report on the effectiveness of our internal control over financial reporting for the year ended December&#160;31, 2021, which is included below.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term as defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive and financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the acquisition of BioDiscovery occurred in the fourth quarter of 2021, we excluded the internal control over financial reporting of BioDiscovery from the scope of our assessment of the effectiveness of the Company&#8217;s internal controls. This exclusion is in accordance with the general guidance issued by the Staff of the SEC that an assessment of a recently-acquired business may be omitted from our scope in the year of acquisition, if specified conditions are satisfied. Goodwill and net intangibles assets acquired were not excluded from our assessment. BioDiscovery's total net assets excluded from our assessment constituted approximately 3% of the Company&#8217;s total assets as of December 31, 2021, and BioDiscovery revenues excluded from our assessment represented approximately 6% of the Company&#8217;s total revenue for the year ended December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remediation of Previously Disclosed Material Weakness</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Item 9A in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 23, 2021, our management previously identified material weaknesses in our internal control environment over financial reporting related to an insufficient number of resources to support the growth and complexity of our financial reporting requirements. Specifically, the design of certain controls did not adequately provide appropriate segregation of duties. The failure to maintain appropriate segregation of duties had a pervasive impact and as such, this deficiency resulted in a risk that could have impacted all financial statement account balances and disclosures. The material weaknesses did not result in any identified material misstatements to our financial statements, and there were no changes to previously released financial results. During 2021, our management, with the oversight of the Audit Committee of our Board of Directors, engaged in efforts to remediate the material weaknesses identified and previously disclosed. We completed these remediation measures in the quarter ended December 31, 2021, including testing of the design and concluding on the operating effectiveness of the related controls.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, remediation efforts that we implemented during 2021 include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; Management engaged external consultants to assist with our internal accounting functions and further enhance our internal controls, which increased the number of external personnel involved in financial reporting.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; We hired a new Chief Financial Officer, a Senior Manager SEC Reporting &amp; Technical Accounting, a Senior Manager of Accounting, and a Senior Accountant, which has increased the number of qualified full-time employees involved in our financial reporting and the control environment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we have determined that the material weaknesses are considered to be remediated. The financial statements and internal control over financial reporting have been audited by BDO USA LLP, an independent registered public accounting firm. BDO&#8217;s reports with respect to fairness of the presentation of the financial statements, and the effectiveness of internal control over financial reporting, are included herein.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15-d-15(f) under the Exchange Act) that occurred during the quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_2847"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders and Board of Directors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Genomics, Inc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, CA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Bionano Genomic, Inc&#8217;s. (the &#8220;Company&#8217;s&#8221;) internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (the &#8220;COSO criteria&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes and our report dated March 1, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated in the accompanying Item 9A, Management&#8217;s Annual Report on Internal Control over Financial Reporting, management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of BioDiscovery, LLC., which was acquired during the fourth quarter of 2021, and which is included in the consolidated balance sheet of the Company as of December 31, 2021, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the year then ended. BioDiscovery, LLC. constituted approximately 3% of the Company&#8217;s total assets as of December 31, 2021 and approximately 6% of revenues for the year then ended. Management did not assess the effectiveness of internal control over financial reporting of BioDiscovery, LLC. because of the timing of the acquisition. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of BioDiscovery, LLC.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ BDO USA, LLP</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, CA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 1, 2022</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_202"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. OTHER INFORMATION </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_2560"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_205"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III </span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_208"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth under the captions &#8220;Election of Directors,&#8221; &#8220;Delinquent Section 16(a) Reports,&#8221; &#8220;Information Regarding the Board of Directors and Corporate Governance,&#8221;  in our definitive proxy statement to be filed with the Securities and Exchange Commission in connection with our 2022 Annual Meeting of Stockholders, or the Proxy Statement, which is expected to be filed not later than 120 days after the end of our fiscal year ended December&#160;31, 2021, and is incorporated in this Annual Report  by reference.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of business conduct and ethics, or the Ethics Code, that applies to all our employees, officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of the Ethics Code is available on our website at www.bionanogenomics.com. If we make any substantive amendments to the Ethics Code or grant any waiver from a provision of the Ethics Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8-K. Information contained in, or that can be accessed through, our website is not incorporated by reference herein, and you should not consider information on our website to be part of this Annual Report.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_211"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth under the caption &#8220;Executive and Director Compensation&#8221; in the Proxy Statement and is incorporated in this Annual Report by reference.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_214"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in the Proxy Statement and is incorporated in this Annual Report  by reference.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_217"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth under the captions &#8220;Transaction With Related Persons and Indemnification&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in the Proxy Statement and is incorporated in this Annual Report by reference.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_220"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth under the caption &#8220;Principal Accountant Fees and Services&#8221; in the Proxy Statement and is incorporated in this Annual Report by reference.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_223"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_226"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">List the following documents filed as a part of the report: </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Financial statements</span></div><div style="margin-top:6pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this portion of Item 15 is set forth under Item 8 above. </span></div><div style="margin-top:6pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following consolidated financial statements of Bionano Genomics, Inc are included in Item 8 of this report:</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702; Reports of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702; Consolidated Balance Sheets &#8212; December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702; Consolidated Statements of Operations &#8212; Years ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702; Consolidated Statements of Comprehensive Income &#8212; Years ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702; Consolidated Statements of Cash Flows &#8212; Years ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702; Notes to Consolidated Financial Statements</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Financial statement schedule. </span></div><div style="margin-top:6pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules have been omitted because they are not required or because the required information is given in the financial statements or notes thereto set forth under Item 8 above. </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Exhibits</span></div><div style="margin-top:6pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A list of exhibits file with this Annual Report or incorporated herein by reference can be found in the Exhibit Index below.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_229"></div><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#94;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000141169020000022/bionano-ex105lineagenm.htm">Agreement and Plan of Merger, dated August 21, 2020, by and among the Company, Alta Merger Sub, Inc., Lineagen, Inc. and Michael S. Paul, Ph.D.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2&#94;&#8364; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(18)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000114036121034888/ny20001057x1_ex2-1.htm">Agreement and Plan of Merger, dated October 8, 2021, by and among the Company, Starship Merger Sub I, Inc., Starship Merger Sub II, LLC, BioDiscovery, Inc. and Soheil Shams.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000141169021000004/ex31-arcertificateofincorp.htm">Amended and Restated Certificate of Incorporation, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex32.htm">Amended and Restated Bylaws.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex41.htm">Form of Common Stock Certificate</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518217313/d782664dex48.htm">Form of Warrant to Purchase Series D-1 Preferred Stock issued to Midcap Financial Trust.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518249108/d572381dex11.htm">Form of Warrant to Purchase Common Stock Issued to Underwriters.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518332353/d635375dex41.htm">Form of Warrant Certificate (included in Exhibit 4.8).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518249108/d572381dex411.htm">Form of Warrant Agent Agreement by and between the Registrant and American Stock Transfer &amp; Trust Company LLC, as warrant agent.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518332353/d635375dex41.htm">Form of Warrant to Purchase Common Stock for Service Providers.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000119312519074842/d700738dex43.htm">Registration Rights Agreement, dated March 14, 2019, by and among the Company and the Innovatus Investors.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000114036119018566/nt10004193x4_ex1-1.htm">Form of Warrant to Purchase Common Stock issued to Investors in October 2019 Public Offering.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:100%;position:relative;top:-3.48pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120006739/nt10007734x2_ex4-16.htm">Form of Warrant to Purchase Common Stock issued to Investors in April 2020 Public Offering.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(15)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000114036121000749/nc10018580x3_ex1-1.htm">Underwriting Agreement, dated January 8, 2021, by and among Bionano Genomics, Inc. and Oppenheimer &amp; Co. Inc., as representatives of the several underwriters named therein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000114036121001667/nt10019031x5_ex1-1.htm">Underwriting Agreement, dated January 20, 2021, by and among Bionano Genomics, Inc. and Oppenheimer &amp; Co. Inc., as representatives of the several underwriters named therein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:100%;position:relative;top:-3.48pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000141169021000004/ex410-descriptionofsecurit.htm">Description of the Company&#8217;s Securities.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex102.htm">Bionano Genomics, Inc. Amended and Restated 2006 Equity Compensation Plan (the &#8220;2006 Plan&#8221;).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex103.htm">Forms of grant notice, stock option agreement and notice of exercise under the 2006 Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120018366/nt10014149x1_ex99-1.htm">Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended (the &#8220;2018 Plan&#8221;).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex105.htm">Forms of grant notice, stock option agreement and notice of exercise under the 2018 Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex106.htm">Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex107.htm">Form of Indemnification Agreement by and between the Registrant and each director and executive officer.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-ex107_bionanoxnonxemp.htm">Bionano Genomics, Inc. Non-Employee Director Compensation Policy, as amended</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1010.htm">Employment Agreement by and between the Registrant and R. Erik Holmlin, Ph.D., dated November&#160;7, 2017, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000141169020000022/bionano-ex106employmen.htm">Employment Agreement, effective as of September 1, 2020, by and between Christopher Stewart and the Company.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000141169020000022/bionano-ex107employmen.htm">Employment Agreement, effective as of August 31, 2020, by and between Alka Chaubey and the Company.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1014.htm">Employment Agreement by and between the Registrant and Mark Oldakowski, dated November&#160;7, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1020.htm">Lease by and between the Registrant and The Irvine Company LLC, dated January&#160;16, 2012.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1021.htm">First Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated September&#160;10, 2013.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1022.htm">Second Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated July&#160;1, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000141169021000004/ex1022-thirdamendmenttoirv.htm">Third Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated December 19, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000141169021000004/ex1023-fourthamendmenttoir.htm">Fourth Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated February 15, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1023.htm">Master Services Agreement by and between the Registrant and Skorpios Technologies, Inc. (f/k/a&#160;Novati Technologies, Inc. and f/k/a SVTC Technologies, LLC), dated March&#160;2, 2009, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1024.htm">Manufacturing Services Agreement by and between the Registrant and Paramit Corporation, dated February&#160;18, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1025.htm">License Agreement by and between Princeton University and the Registrant, dated January&#160;7, 2004.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1026.htm">First Amendment to the License Agreement by and between Princeton University and the Registrant, dated December&#160;17, 2004.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1027.htm">Second Amendment to the License Agreement by and between Princeton University and the Registrant, dated February&#160;25, 2010.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1028.htm">Third Amendment to the License Agreement by and between Princeton University and the Registrant, dated October&#160;17, 2011.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1029.htm">Fourth Amendment License Agreement by and between Princeton University and the Registrant, dated February&#160;9, 2012.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1032.htm">License Agreement by and between the Registrant and Q Biotechnology CV dated May&#160;1, 2014.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1033.htm">Amendment to Non-Exclusive Patent License Agreement by and between the Registrant and Q&#160;Biotechnology CV dated May&#160;1, 2014.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1034.htm">License Agreement by and between the Registrant and New York University dated November 4, 2013.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312518207855/d782664dex1035.htm">Option and Sublicense Agreement by and between the Registrant and Pacific Biosciences of California, Inc. dated February&#160;2, 2016.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1411690/000119312519074842/d700738dex103.htm">Common Stock Purchase Agreement, dated March 14, 2019, by and among the Company and the Innovatus Investors.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(20)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000114036121034291/brhc10029776_ex10-1.htm">Bionano Genomics, Inc. 2020 Inducement Plan, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120018910/brhc10014594_ex10-2.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Bionano Genomics, Inc. 2020 Inducement Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(19)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1411690/000141169021000024/bngo-20210630xexx101.htm">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Bionano Genomics, Inc. 2018 Equity Incentive Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">(17)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000114036121009777/nt10022040x3_ex1-1.htm">Sales Agreement, dated March 23, 2021, by and between the Company and Cowen and Company, LLC.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.33</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bionano-nancyridgeleasee.htm">Standard Industrial/Commercial Single-Tenant Lease, made effective as of November 23, 2021, by and between the Company and 6777 Nancy Ridge LLC.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.34&#94;+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1034_bionanoxkeyemp.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1034_bionanoxkeyemp.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1034_bionanoxkeyemp.htm"> dated October</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1034_bionanoxkeyemp.htm"> 8, 2021 and effective October 18</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1034_bionanoxkeyemp.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1034_bionanoxkeyemp.htm"> 2021, by and between the Company and Soheil Shams</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1034_bionanoxkeyemp.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.35+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1035_bionanoxstockr.htm">Stock Restriction Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1035_bionanoxstockr.htm">, dated O</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1035_bionanoxstockr.htm">c</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1035_bionanoxstockr.htm">tober 8, 2021 and effective October 18, 2021, by and between the Company and Soheil Sham</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1035_bionanoxstockr.htm">s. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-ex1036_bionanoxemploy.htm">Employment Agreement, dated June 14, 2021, by and between the Company and Richard Shippy</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:100%;position:relative;top:-3.48pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001411690/000119312519074842/d700738dex101.htm">Common Stock Purchase Agreement, dated March 14, 2019, between the Company and Aspire Capital Fund, LLC</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="bngo-1038_bionanoxcommerci.htm">Commercial Single-Tenant Lease &#8211; Net, dated February 28, 2016, by and between Tesa Beach LLC and BioDiscovery, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bngo-ex1039_bionanoxfiftha.htm">Fifth Amendment to the Lease by and between the Registrant and The Irvine Company, LLC, dated January 12, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="bngo-ex211_bionanoxsubsidi.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231-bdoauditorconse.htm">Consent of BDO USA LLP, independent registered public accounting firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney (included on signature page).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-ex311x20211231.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-ex312x20211231.htm">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-ex321x20211231.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bngo-ex322x20211231.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document&#8212;the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2018.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-225970), as amended.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 21, 2018.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 14, 2019.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-233828), as amended.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-245764).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-227073).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 8, 2019.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 10, 2020. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 14, 2020. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2020. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-237074).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 23, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(15)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 11, 2021.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 21, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(17)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 24, 2021.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(18)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on October 19, 2021.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(19)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 4, 2021.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(20)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on October 12, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#94;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted with respect to certain portions of this exhibit.  Omitted portions have been filed separately with the SEC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8364;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by &#8220;[***]&#8221;) because the Company has determined that the information is not material and is the type that the Company treats as private or confidential.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_232"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i43bade00237b4e8cb3c24c30ea1cd6d3_235"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company Name</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 1, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ R. Erik Holmlin, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">R. Erik Holmlin, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R. Erik Holmlin, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Bionano Genomics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ R. Erik Holmlin, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Stewart</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Stewart</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David L. Barker, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David L. Barker, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Albert A. Luderer, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Albert A. Luderer, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Yvonne Linney, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yvonne Linney, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Hannah Mamuszka</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hannah Mamuszka</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Aleksandar Rajkovic, M.D., Ph.D</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Aleksandar Rajkovic, M.D., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Twomey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Twomey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i43bade00237b4e8cb3c24c30ea1cd6d3_13">Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.346%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kristiina Vuori, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristiina Vuori, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Vincent Wong, J.D., M.B.A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vincent Wong, J.D., M.B.A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>bngo-ex107_bionanoxnonxemp.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7acdbf76fdfd4cfd9736de49187b427c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.7</font></div></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BIONANO&#160;GENOMICS, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NON-EMPLOYEE&#160;DIRECTOR&#160;COMPENSATION&#160;POLICY</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each member of the Board of Directors (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) who is not also serving as an employee of or consultant to Bionano Genomics, Inc. (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any of its subsidiaries (each such member, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Eligible Director</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will receive the compensation described in this policy for his or her Board service. An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Cash Compensation</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be&#160;pro-rated&#160;based on days served in the applicable fiscal year, with the&#160;pro-rated&#160;amount paid for the first fiscal quarter in which the Eligible Director provides the service and regular full quarterly payments thereafter. All annual cash fees are vested upon payment.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Board Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">a.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All Eligible Directors&#58; $40,000</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">b.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Chairman of the Board Service Retainer (in addition to Eligible Director Service Retainer)&#58; $20,000</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Committee Chair Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">a.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Chairman of the Audit Committee&#58; $20,000</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">b.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Chairman of the Compensation Committee&#58; $15,000</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">c.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Chairman of the Nominating and Corporate Governance Committee&#58; $10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">d.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Chairman of the Science and Technology Committee&#58; $10,000</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Committee Member Service Retainer (not applicable to Committee Chairs)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">a.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Member of the Audit Committee&#58; $10,000</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">b.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Member of the Compensation Committee&#58; $7,500</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">259047254 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">c.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Member of the Nominating and Corporate Governance Committee&#58; $5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">d.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Member of the Science and Technology Committee&#58; $5,000</font></td></tr></table></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity Compensation</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The equity compensation set forth below will be granted under the Company&#8217;s 2018 Equity Incentive Plan, as amended (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), subject to the approval of the Plan by the Company&#8217;s stockholders. All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock of the Company (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than for death, disability or cause, the post-termination exercise period will be 12 months from the date of termination).</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Grant</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; For each Eligible Director who is first elected or appointed to the Board following the Effective Date, on the date of such Eligible Director&#8217;s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase Common Stock with an aggregate Black-Scholes option value of $247,500 (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Initial Grant</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The shares subject to each Initial Grant will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan).</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Grant</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; On the date of each annual stockholder meeting of the Company held after the Effective Date, each Eligible Director who continues to serve as a&#160;non-employee&#160;member of the Board following such stockholder meeting will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase Common Stock with an aggregate Black-Scholes option value of $165,000 (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Annual Grant</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The shares subject to the Annual Grant will vest in equal monthly installments over the 12 months following the date of grant, provided that the Annual Grant will in any case be fully vested on the date of Company&#8217;s next annual stockholder meeting, subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended effective as of November 2, 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">259047254 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>3
<FILENAME>bionano-nancyridgeleasee.htm
<DESCRIPTION>EX-10.33
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>bionano-nancyridgeleasee</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- bionano-nancyridgeleasee001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">STANDARD INDUSTRIAL/COMMERCIAL SINGLE&#8208;TENANT LEASE &#8208; NET (DO NOT USE THIS FORM FOR MULTI&#8208;TENANT BUILDINGS) 1. Basic Provisions (&quot;Basic Provisions&quot;). 1.1    Parties. This Lease (&quot;Lease&quot;), dated for reference purposes only   November 23, 2021, is made by and between   6777 Nancy Ridge LLC (&quot;Lessor&quot;) and Bionano Genomics (&quot;Lessee&quot;), (collectively the &quot;Parties,&quot; or individually a &quot;Party&quot;). 1.2    Premises: That certain real property, including all improvements therein or to be provided by Lessor under the terms of this Lease, commonly known as (street address, city, state, zip):  6777 Nancy Ridge Drive, San Diego, CA 92121 (&quot;Premises&quot;). The Premises are located in the County of    San Diego, and are generally described as (describe briefly the nature of the property and , if applicable, the &quot;Project,&quot; if the property is located within a Project):    11,978 square feet of lab/office space.  (See also Paragraph 2) 1.3    Term:   4    years and   2  months (&quot;Original Term&quot;) commencing  December 1, 2021 (&quot;Commencement Date&quot;) and ending January 31, 2026 (&quot;Expiration Date&quot;). (See also Paragraph 3) 1.4    Early Possession: If the Premises are available Lessee may have non&#8208;exclusive possession of the Premises commencing  ________________ (&quot;Early Possession Date&quot;). (See also Paragraphs 3.2 and 3.3) 1.5      Base Rent:    $3.50 per month (&quot;Base Rent&quot;), payable on the   first (1st) day of each month commencing  January 1, 2022 . (See also Paragraph 4) &#9745; If this box is checked, there are provisions in this Lease for the Base Rent to be adjusted. The base rent shall increase annually by three percent (3%) See Paragraph                . 1.6 Base Rent and Other Monies Paid Upon Execution: (a) Base Rent:    $3.50 for the period  January 1, 2022-January 31, 2022. (b) Security Deposit:    $41,923.00 (&quot;Security Deposit&quot;).  (See also Paragraph 5) (c)Building Expenses  Association Fees: $6,947.00 for the period December 1, 2021-December 31, 2021. (d) Other:              for               . (e) Total Due Upon Execution of this Lease:    $90,793.00. 1.7      Agreed Use:    Lab/office.  (See also Paragraph 6) 1.8      Insuring Party. Lessor is the &quot;Insuring Party&quot; unless otherwise stated herein.  (See also Paragraph 8) 1.9      Real Estate Brokers. (See also Paragraph 15 and 25) (a) Representation: Each Party acknowledges receiving a Disclosure Regarding Real Estate Agency Relationship, confirms and consents to the following agency relationships in this Lease with the following real estate brokers (&quot;Broker(s)&quot;) and/or their agents (&quot;Agent(s)&quot;): Lessor's Brokerage Firm    N/A  License No.   N/A Is the broker of (check one):  &#9744;  the Lessor; or  both the Lessee and Lessor (dual agent). Lessor's Agent   N/A License No.   N/A is (check one):   &#9744;  the Lessor's Agent (salesperson or broker associate); or  &#9744;  both the Lessee's Agent and the Lessor's Agent (dual agent). Lessee's Brokerage Firm  N/A  License No.  N/A  Is the broker of (check one):   &#9744;  the Lessee; or  &#9744;  both the Lessee and Lessor (dual agent). Lessee's Agent  N/A License No.  N/A is (check one):  &#9744;  the Lessee's Agent (salesperson or broker associate); or &#9744;  both the Lessee's Agent and the Lessor's Agent (dual agent). (b) Payment to Brokers. Upon execution and delivery of this Lease by both Parties, Lessor shall pay to the Brokers the brokerage fee agreed to in a separate written agreement (or if there is no such agreement, the sum of          or          % of the total Base Rent) for the brokerage services rendered by the Brokers. 1.10   Guarantor. The obligations of the Lessee under this Lease are to be guaranteed by  N/A (&quot;Guarantor&quot;). (See also Paragraph 37) 1.11   Attachments. Attached hereto are the following, all of which constitute a part of this Lease: &#9745;     an Addendum consisting of Paragraphs      1  through    7   ; &#9745; a plot plan depicting the Premises; &#9744; a current set of the Rules and Regulations; &#9744; a Work Letter; &#9744; other (specify): . 2. Premises. 2.1    Letting. Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the Premises, for the term, at the rental, and upon all of the terms, covenants and conditions set forth in this Lease. While the approximate square footage of the Premises may have been used in the marketing of the Premises for purposes of comparison, the Base Rent stated herein is NOT tied to square footage and is not subject to adjustment should the actual size be determined to be different. NOTE: Lessee is advised to verify the actual size prior to executing this Lease. INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 1 of 16 Exhibit 10.33 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2.2    Condition. Lessor shall deliver the Premises to Lessee broom clean and free of debris on the Commencement Date or the Early Possession Date, whichever first occurs (&quot;Start Date&quot;), and, so long as the required service contracts described in Paragraph 7.1(b) below are obtained by Lessee and in effect within thirty days following the Start Date, warrants that the existing electrical, plumbing, fire sprinkler, lighting, heating, ventilating and air conditioning systems (&quot;HVAC&quot;), loading doors, sump pumps, if any, and all other such elements in the Premises, other than those constructed by Lessee, shall be in good operating condition on said date, that the structural elements of the roof, bearing walls and foundation of any buildings on the Premises (the &quot;Building&quot;) shall be free of material defects, and that the Premises do not contain hazardous levels of any mold or fungi defined as toxic under applicable state or federal law. If a non&#8208;compliance with said warranty exists as of the Start Date, or if one of such systems or elements should malfunction or fail within the appropriate warranty period, Lessor shall, as Lessor's sole obligation with respect to such matter, except as otherwise provided in this Lease, promptly after receipt of written notice from Lessee setting forth with specificity the nature and extent of such non&#8208;compliance, malfunction or failure, rectify same at Lessor's expense. The warranty periods shall be as follows: (i) 6 months as to the HVAC systems, and (ii) 30 days as to the remaining systems and other elements of the Building. If Lessee does not give Lessor the required notice within the appropriate warranty period, correction of any such non&#8208;compliance, malfunction or failure shall be the obligation of Lessee at Lessee's sole cost and expense. Lessor also warrants, that unless otherwise specified in writing, Lessor is unaware of (i) any recorded Notices of Default affecting the Premise; (ii) any delinquent amounts due under any loan secured by the Premises; and (iii) any bankruptcy proceeding affecting the Premises.   2.3    Compliance. Lessor warrants that to the best of its knowledge the improvements on the Premises comply with the building codes, applicable laws, covenants or restrictions of record, regulations, and ordinances (&quot;Applicable Requirements&quot;) that were in effect at the time that each improvement, or portion thereof, was constructed. Said warranty does not apply to the use to which Lessee will put the Premises, modifications which may be required by the Americans with Disabilities Act or any similar laws as a result of Lessee's use (see Paragraph 50), or to any Alterations or Utility Installations (as defined in Paragraph 7.3(a)) made or to be made by Lessee. NOTE: Lessee is responsible for determining whether or not the Applicable Requirements, and especially the zoning, are appropriate for Lessee's intended use, and acknowledges that past uses of the Premises may no longer be allowed. If the Premises do not comply with said warranty, Lessor shall, except as otherwise provided, promptly after receipt of written notice from Lessee setting forth with specificity the nature and extent of such non&#8208;compliance, rectify the same at Lessor's expense. If Lessee does not give Lessor written notice of a non&#8208;compliance with this warranty within 6 months following the Start Date, correction of that non&#8208;compliance shall be the obligation of Lessee at Lessee's sole cost and expense. If the Applicable Requirements are hereafter changed so as to require during the term of this Lease the construction of an addition to or an alteration of the Premises and/or Building, the remediation of any Hazardous Substance, or the reinforcement or other physical modification of the Unit, Premises and/or Building (&quot;Capital Expenditure&quot;), Lessor and Lessee shall allocate the cost of such work as follows: (a)    Subject to Paragraph 2.3(c) below, if such Capital Expenditures are required as a result of the specific and unique use of the Premises by Lessee as compared with uses by tenants in general, Lessee shall be fully responsible for the cost thereof, provided, however, that if such Capital Expenditure is required during the last 2 years of this Lease and the cost thereof exceeds 6 months' Base Rent, Lessee may instead terminate this Lease unless Lessor notifies Lessee, in writing, within 10 days after receipt of Lessee's termination notice that Lessor has elected to pay the difference between the actual cost thereof and an amount equal to 6 months' Base Rent. If Lessee elects termination, Lessee shall immediately cease the use of the Premises which requires such Capital Expenditure and deliver to Lessor written notice specifying a termination date at least 90 days thereafter. Such termination date shall, however, in no event be earlier than the last day that Lessee could legally utilize the Premises without commencing such Capital Expenditure. (b)    If such Capital Expenditure is not the result of the specific and unique use of the Premises by Lessee (such as, governmentally mandated seismic modifications), then Lessor shall pay for such Capital Expenditure and Lessee shall only be obligated to pay, each month during the remainder of the term of this Lease or any extension thereof, on the date that on which the Base Rent is due, an amount equal to 1/144th of the portion of such costs reasonably attributable to the Premises. Lessee shall pay Interest on the balance but may prepay its obligation at any time. If, however, such Capital Expenditure is required during the last 2 years of this Lease or if Lessor reasonably determines that it is not economically feasible to pay its share thereof, Lessor shall have the option to terminate this Lease upon 90 days prior written notice to Lessee unless Lessee notifies Lessor, in writing, within 10 days after receipt of Lessor's termination notice that Lessee will pay for such Capital Expenditure. If Lessor does not elect to terminate, and fails to tender its share of any such Capital Expenditure, Lessee may advance such funds and deduct same, with Interest, from Rent until Lessor's share of such costs have been fully paid. If Lessee is unable to finance Lessor's share, or if the balance of the Rent due and payable for the remainder of this Lease is not sufficient to fully reimburse Lessee on an offset basis, Lessee shall have the right to terminate this Lease upon 30 days written notice to Lessor. (c)    Notwithstanding the above, the provisions concerning Capital Expenditures are intended to apply only to non&#8208;voluntary, unexpected, and new Applicable Requirements. If the Capital Expenditures are instead triggered by Lessee as a result of an actual or proposed change in use, change in intensity of use, or modification to the Premises then, and in that event, Lessee shall either: (i) immediately cease such changed use or intensity of use and/or take such other steps as may be necessary to eliminate the requirement for such Capital Expenditure, or (ii) complete such Capital Expenditure at its own expense. Lessee shall not, however, have any right to terminate this Lease. 2.4      Acknowledgements. Lessee acknowledges that: (a) it has been given an opportunity to inspect and measure the Premises, (b) it has been advised by Lessor and/or Brokers to satisfy itself with respect to the size and condition of the Premises (including but not limited to the electrical, HVAC and fire sprinkler systems, security, environmental aspects, and compliance with Applicable Requirements and the Americans with Disabilities Act), and their suitability for Lessee's intended use, (c) Lessee has made such investigation as it deems necessary with reference to such matters and assumes all responsibility therefor as the same relate to its occupancy of the Premises, (d) it is not relying on any representation as to the size of the Premises made by Brokers or Lessor, (e) the square footage of the Premises was not material to Lessee's decision to lease the Premises and pay the Rent stated herein, and (f) neither Lessor, Lessor's agents, nor Brokers have made any oral or written representations or warranties with respect to said matters other than as set forth in this Lease. In addition, Lessor acknowledges that: (i) Brokers have made no representations, promises or warranties concerning Lessee's ability to honor the Lease or suitability to occupy the Premises, and (ii) it is Lessor's sole responsibility to investigate the financial capability and/or suitability of all proposed tenants.   2.5    Lessee as Prior Owner/Occupant. The warranties made by Lessor in Paragraph 2 shall be of no force or effect if immediately prior to the Start Date Lessee was the owner or occupant of the Premises. In such event, Lessee shall be responsible for any necessary corrective work.   3. Term. 3.1      Term. The Commencement Date, Expiration Date and Original Term of this Lease are as specified in Paragraph 1.3.   3.2    Early Possession. Any provision herein granting Lessee Early Possession of the Premises is subject to and conditioned upon the Premises being available for such possession prior to the Commencement Date. Any grant of Early Possession only conveys a non&#8208;exclusive right to occupy the Premises. If Lessee totally or partially occupies the Premises prior to the Commencement Date, the obligation to pay Base Rent shall be abated for the period of such Early Possession. All other terms of this Lease (including but not limited to the obligations to pay Real Property Taxes and insurance premiums and to maintain the Premises) shall be in effect during such period. Any such Early Possession shall not affect the Expiration Date.   3.3     Delay In Possession. Lessor agrees to use commercially reasonable efforts to deliver exclusive possession of the Premises to Lessee by the Commencement Date. If, despite said efforts, Lessor is unable to deliver possession by such date, Lessor shall not be subject to any liability therefor, nor shall such failure affect the validity of this Lease or change the Expiration Date. Lessee shall not, however, be obligated to pay Rent or perform its other obligations until Lessor delivers possession of the Premises and any period of rent abatement that Lessee would otherwise have enjoyed shall run from the date of delivery of possession and continue for a period equal to what Lessee would otherwise have enjoyed under the terms hereof, but minus any days of delay caused by the acts or omissions of Lessee. If possession is not delivered within 60 days after the Commencement Date, as the same may be extended under the terms of any Work Letter executed by Parties, Lessee may, at its option, by notice in writing within 10 days after the end of such 60 day period, cancel this Lease, in which event the Parties shall be discharged from all obligations hereunder. If such written notice is not received by Lessor within said 10 day period, Lessee's right to cancel shall terminate. If possession of the Premises is not delivered within 120 days after the Commencement Date, this Lease shall terminate unless other agreements are reached between Lessor and Lessee, in writing.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 2 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">3.4    Lessee Compliance. Lessor shall not be required to tender possession of the Premises to Lessee until Lessee complies with its obligation to provide evidence of insurance (Paragraph 8.5). Pending delivery of such evidence, Lessee shall be required to perform all of its obligations under this Lease from and after the Start Date, including the payment of Rent, notwithstanding Lessor's election to withhold possession pending receipt of such evidence of insurance. Further, if Lessee is required to perform any other conditions prior to or concurrent with the Start Date, the Start Date shall occur but Lessor may elect to withhold possession until such conditions are satisfied.   4. Rent. 4.1     Rent Defined. All monetary obligations of Lessee to Lessor under the terms of this Lease (except for the Security Deposit) are deemed to be rent (&quot;Rent&quot;).   4.2    Payment. Lessee shall cause payment of Rent to be received by Lessor in lawful money of the United States, without offset or deduction (except as specifically permitted in this Lease), on or before the day on which it is due. All monetary amounts shall be rounded to the nearest whole dollar. In the event that any invoice prepared by Lessor is inaccurate such inaccuracy shall not constitute a waiver and Lessee shall be obligated to pay the amount set forth in this Lease. Rent for any period during the term hereof which is for less than one full calendar month shall be prorated based upon the actual number of days of said month. Payment of Rent shall be made to Lessor at its address stated herein or to such other persons or place as Lessor may from time to time designate in writing. Acceptance of a payment which is less than the amount then due shall not be a waiver of Lessor's rights to the balance of such Rent, regardless of Lessor's endorsement of any check so stating. In the event that any check, draft, or other instrument of payment given by Lessee to Lessor is dishonored for any reason, Lessee agrees to pay to Lessor the sum of $25 in addition to any Late Charge and Lessor, at its option, may require all future Rent be paid by cashier's check. Payments will be applied first to accrued late charges and attorney's fees, second to accrued interest, then to Base Rent, Insurance and Real Property Taxes, and any remaining amount to any other outstanding charges or costs. 4.3     Association Fees. In addition to the Base Rent, Lessee shall pay to Lessor each month an amount equal to any owner's association or condominium fees levied or assessed against the Premises. Said monies shall be paid at the same time and in the same manner as the Base Rent.   5.         Security Deposit. Lessee shall deposit with Lessor upon execution hereof the Security Deposit as security for Lessee's faithful performance of its obligations under this Lease. If Lessee fails to pay Rent, or otherwise Defaults under this Lease, Lessor may use, apply or retain all or any portion of said Security Deposit for the payment of any amount already due Lessor, for Rents which will be due in the future, and/ or to reimburse or compensate Lessor for any liability, expense, loss or damage which Lessor may suffer or incur by reason thereof. If Lessor uses or applies all or any portion of the Security Deposit, Lessee shall within 10 days after written request therefor deposit monies with Lessor sufficient to restore said Security Deposit to the full amount required by this Lease. If the Base Rent increases during the term of this Lease, Lessee shall, upon written request from Lessor, deposit additional monies with Lessor so that the total amount of the Security Deposit shall at all times bear the same proportion to the increased Base Rent as the initial Security Deposit bore to the initial Base Rent. Should the Agreed Use be amended to accommodate a material change in the business of Lessee or to accommodate a sublessee or assignee, Lessor shall have the right to increase the Security Deposit to the extent necessary, in Lessor's reasonable judgment, to account for any increased wear and tear that the Premises may suffer as a result thereof. If a change in control of Lessee occurs during this Lease and following such change the financial condition of Lessee is, in Lessor's reasonable judgment, significantly reduced, Lessee shall deposit such additional monies with Lessor as shall be sufficient to cause the Security Deposit to be at a commercially reasonable level based on such change in financial condition. Lessor shall not be required to keep the Security Deposit separate from its general accounts. Within 90 days after the expiration or termination of this Lease, Lessor shall return that portion of the Security Deposit not used or applied by Lessor. Lessor shall upon written request provide Lessee with an accounting showing how that portion of the Security Deposit that was not returned was applied. No part of the Security Deposit shall be considered to be held in trust, to bear interest or to be prepayment for any monies to be paid by Lessee under this Lease. THE SECURITY DEPOSIT SHALL NOT BE USED BY LESSEE IN LIEU OF PAYMENT OF THE LAST MONTH'S RENT.   6.            Use. 6.1    Use. Lessee shall use and occupy the Premises only for the Agreed Use, or any other legal use which is reasonably comparable thereto, and for no other purpose. Lessee shall not use or permit the use of the Premises in a manner that is unlawful, creates damage, waste or a nuisance, or that disturbs occupants of or causes damage to neighboring premises or properties. Other than guide, signal and seeing eye dogs, Lessee shall not keep or allow in the Premises any pets, animals, birds, fish, or reptiles. Lessor shall not unreasonably withhold or delay its consent to any written request for a modification of the Agreed Use, so long as the same will not impair the structural integrity of the improvements on the Premises or the mechanical or electrical systems therein, and/or is not significantly more burdensome to the Premises. If Lessor elects to withhold consent, Lessor shall within 7 days after such request give written notification of same, which notice shall include an explanation of Lessor's objections to the change in the Agreed Use. 6.2      Hazardous Substances.   (a)     Reportable Uses Require Consent. The term &quot;Hazardous Substance&quot; as used in this Lease shall mean any product, substance, or waste whose presence, use, manufacture, disposal, transportation, or release, either by itself or in combination with other materials expected to be on the Premises, is either: (i) potentially injurious to the public health, safety or welfare, the environment or the Premises, (ii) regulated or monitored by any governmental authority, or (iii) a basis for potential liability of Lessor to any governmental agency or third party under any applicable statute or common law theory. Hazardous Substances shall include, but not be limited to, hydrocarbons, petroleum, gasoline, and/or crude oil or any products, by&#8208;products or fractions thereof. Lessee shall not engage in any activity in or on the Premises which constitutes a Reportable Use of Hazardous Substances without the express prior written consent of Lessor and timely compliance (at Lessee's expense) with all Applicable Requirements. &quot;Reportable Use&quot; shall mean (i) the installation or use of any above or below ground storage tank, (ii) the generation, possession, storage, use, transportation, or disposal of a Hazardous Substance that requires a permit from, or with respect to which a report, notice, registration or business plan is required to be filed with, any governmental authority, and/or (iii) the presence at the Premises of a Hazardous Substance with respect to which any Applicable Requirements requires that a notice be given to persons entering or occupying the Premises or neighboring properties. Notwithstanding the foregoing, Lessee may use any ordinary and customary materials reasonably required to be used in the normal course of the Agreed Use, ordinary office supplies (copier toner, liquid paper, glue, etc.) and common household cleaning materials, so long as such use is in compliance with all Applicable Requirements, is not a Reportable Use, and does not expose the Premises or neighboring property to any meaningful risk of contamination or damage or expose Lessor to any liability therefor. In addition, Lessor may condition its consent to any Reportable Use upon receiving such additional assurances as Lessor reasonably deems necessary to protect itself, the public, the Premises and/or the environment against damage, contamination, injury and/or liability, including, but not limited to, the installation (and removal on or before Lease expiration or termination) of protective modifications (such as concrete encasements) and/or increasing the Security Deposit.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 3 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">(b)    Duty to Inform Lessor. If Lessee knows, or has reasonable cause to believe, that a Hazardous Substance has come to be located in, on, under or about the Premises, other than as previously consented to by Lessor, Lessee shall immediately give written notice of such fact to Lessor, and provide Lessor with a copy of any report, notice, claim or other documentation which it has concerning the presence of such Hazardous Substance. (c)    Lessee Remediation. Lessee shall not cause or permit any Hazardous Substance to be spilled or released in, on, under, or about the Premises (including through the plumbing or sanitary sewer system) and shall promptly, at Lessee's expense, comply with all Applicable Requirements and take all investigatory and/or remedial action reasonably recommended, whether or not formally ordered or required, for the cleanup of any contamination of, and for the maintenance, security and/or monitoring of the Premises or neighboring properties, that was caused or materially contributed to by Lessee, or pertaining to or involving any Hazardous Substance brought onto the Premises during the term of this Lease, by or for Lessee, or any third party. (d)    Lessee Indemnification. Lessee shall indemnify, defend and hold Lessor, its agents, employees, lenders and ground lessor, if any, harmless from and against any and all loss of rents and/or damages, liabilities, judgments, claims, expenses, penalties, and attorneys' and consultants' fees arising out of or involving any Hazardous Substance brought onto the Premises by or for Lessee, or any third party (provided, however, that Lessee shall have no liability under this Lease with respect to underground migration of any Hazardous Substance under the Premises from adjacent properties not caused or contributed to by Lessee). Lessee's obligations shall include, but not be limited to, the effects of any contamination or injury to person, property or the environment created or suffered by Lessee, and the cost of investigation, removal, remediation, restoration and/or abatement, and shall survive the expiration or termination of this Lease. No termination, cancellation or release agreement entered into by Lessor and Lessee shall release Lessee from its obligations under this Lease with respect to Hazardous Substances, unless specifically so agreed by Lessor in writing at the time of such agreement. Notwithstanding anything to the contrary contained in Paragraph 6.2 of the Lease, Lessee shall not indemnify Lessor or be liable or responsible in any way for any Hazardous Substance brought onto the Premises or the Building by any party other than Lessee or its employees, agents or contractors. (e)     Lessor Indemnification. Except as otherwise provided in paragraph 8.7, Lessor and its successors and assigns shall indemnify, defend, reimburse and hold Lessee, its employees and lenders, harmless from and against any and all environmental damages, including the cost of remediation, which result from Hazardous Substances which existed on the Premises prior to Lessee's occupancy or which are caused by the gross negligence or willful misconduct of Lessor, its agents or employees. Lessor's obligations, as and when required by the Applicable Requirements, shall include, but not be limited to, the cost of investigation, removal, remediation, restoration and/or abatement, and shall survive the expiration or termination of this Lease. (f)    Investigations and Remediations. Lessor shall retain the responsibility and pay for any investigations or remediation measures required by governmental entities having jurisdiction with respect to the existence of Hazardous Substances on the Premises prior to Lessee's occupancy, unless such remediation measure is required as a result of Lessee's use (including &quot;Alterations&quot;, as defined in paragraph 7.3(a) below) of the Premises, in which event Lessee shall be responsible for such payment. Lessee shall cooperate fully in any such activities at the request of Lessor, including allowing Lessor and Lessor's agents to have reasonable access to the Premises at reasonable times in order to carry out Lessor's investigative and remedial responsibilities. (g)    Lessor Termination Option. If a Hazardous Substance Condition (see Paragraph 9.1(e)) occurs during the term of this Lease, unless Lessee is legally responsible therefor (in which case Lessee shall make the investigation and remediation thereof required by the Applicable Requirements and this Lease shall continue in full force and effect, but subject to Lessor's rights under Paragraph 6.2(d) and Paragraph 13), Lessor may, at Lessor's option, either (i) investigate and remediate such Hazardous Substance Condition, if required, as soon as reasonably possible at Lessor's expense, in which event this Lease shall continue in full force and effect, or (ii) if the estimated cost to remediate such condition exceeds 12 times the then monthly Base Rent or $100,000, whichever is greater, give written notice to Lessee, within 30 days after receipt by Lessor of knowledge of the occurrence of such Hazardous Substance Condition, of Lessor's desire to terminate this Lease as of the date 60 days following the date of such notice. In the event Lessor elects to give a termination notice, Lessee may, within 10 days thereafter, give written notice to Lessor of Lessee's commitment to pay the amount by which the cost of the remediation of such Hazardous Substance Condition exceeds an amount equal to 12 times the then monthly Base Rent or $100,000, whichever is greater. Lessee shall provide Lessor with said funds or satisfactory assurance thereof within 30 days following such commitment. In such event, this Lease shall continue in full force and effect, and Lessor shall proceed to make such remediation as soon as reasonably possible after the required funds are available. If Lessee does not give such notice and provide the required funds or assurance thereof within the time provided, this Lease shall terminate as of the date specified in Lessor's notice of termination. 6.3    Lessee's Compliance with Applicable Requirements. Except as otherwise provided in this Lease, Lessee shall, at Lessee's sole expense, fully, diligently and in a timely manner, materially comply with all Applicable Requirements, the requirements of any applicable fire insurance underwriter or rating bureau, and the recommendations of Lessor's engineers and/or consultants which relate in any manner to the Premises, without regard to whether said Applicable Requirements are now in effect or become effective after the Start Date. Lessee shall, within 10 days after receipt of Lessor's written request, provide Lessor with copies of all permits and other documents, and other information evidencing Lessee's compliance with any Applicable Requirements specified by Lessor, and shall immediately upon receipt, notify Lessor in writing (with copies of any documents involved) of any threatened or actual claim, notice, citation, warning, complaint or report pertaining to or involving the failure of Lessee or the Premises to comply with any Applicable Requirements. Likewise, Lessee shall immediately give written notice to Lessor of: (i) any water damage to the Premises and any suspected seepage, pooling, dampness or other condition conducive to the production of mold; or (ii) any mustiness or other odors that might indicate the presence of mold in the Premises. In addition, Lessee shall provide copies of all relevant material safety data sheets (MSDS) to Lessor within 10 days of the receipt of a written request therefor. In addition, Lessee shall provide Lessor with copies of its business license, certificate of occupancy and/or any similar document within 10 days of the receipt of a written request therefor. 6.4      Inspection; Compliance. Lessor and Lessor's &quot;Lender&quot; (as defined in Paragraph 30) and consultants authorized by Lessor shall have the right to enter into Premises at any time in the case of an emergency, and otherwise at reasonable times after reasonable notice, for the purpose of inspecting and/or testing the condition of the Premises and/or for verifying compliance by Lessee with this Lease. The cost of any such inspections shall be paid by Lessor, unless a violation of Applicable Requirements, or a Hazardous Substance Condition (see paragraph 9.1(e)) is found to exist or be imminent, or the inspection is requested or ordered by a governmental authority. In such case, Lessee shall upon request reimburse Lessor for the cost of such inspection, so long as such inspection is reasonably related to the violation or contamination. In addition, Lessee shall provide copies of all relevant material safety data sheets (MSDS) to Lessor within 10 days of the receipt of a written request therefor. Lessee acknowledges that any failure on its part to allow such inspections or testing will expose Lessor to risks and potentially cause Lessor to incur costs not contemplated by this Lease, the extent of which will be extremely difficult to ascertain. Accordingly, should the Lessee fail to allow such inspections and/or testing in a timely fashion the Base Rent shall be automatically increased, without any requirement for notice to Lessee, by an amount equal to 10% of the then existing Base Rent or $100, whichever is greater for the remainder to the Lease. The Parties agree that such increase in Base Rent represents fair and reasonable compensation for the additional risk/costs that Lessor will incur by reason of Lessee's failure to allow such inspection and/or testing. Such increase in Base Rent shall in no event constitute a waiver of Lessee's Default or Breach with respect to such failure nor prevent the exercise of any of the other rights and remedies granted hereunder.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 4 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">7.           Maintenance; Repairs; Utility Installations; Trade Fixtures and Alterations. 7.1      Lessee's Obligations.   (a)    In General. Subject to the provisions of Paragraph 2.2 (Condition), 2.3 (Compliance), 6.3 (Lessee's Compliance with Applicable Requirements), 7.2 (Lessor's Obligations), 9 (Damage or Destruction), and 14 (Condemnation), Lessee shall, at Lessee's sole expense, keep the Premises, Utility Installations (intended for Lessee's exclusive use, no matter where located), and Alterations in good order, condition and repair (whether or not the portion of the Premises requiring repairs, or the means of repairing the same, are reasonably or readily accessible to Lessee, and whether or not the need for such repairs occurs as a result of Lessee's use, any prior use, the elements or the age of such portion of the Premises), including, but not limited to, all equipment or facilities, such as plumbing, HVAC equipment, electrical, lighting facilities, boilers, pressure vessels, fire protection system, fixtures, walls (interior and exterior), foundations, ceilings, roofs, roof drainage systems, floors, windows, doors, plate glass, skylights, landscaping, driveways, parking lots, fences, retaining walls, signs, sidewalks and parkways located in, on, or adjacent to the Premises. Lessee, in keeping the Premises in good order, condition and repair, shall exercise and perform good maintenance practices, specifically including the procurement and maintenance of the service contracts required by Paragraph 7.1(b) below. Lessee's obligations shall include restorations, replacements or renewals when necessary to keep the Premises and all improvements thereon or a part thereof in good order, condition and state of repair. Lessee shall, during the term of this Lease, keep the exterior appearance of the Building in a first&#8208;class condition (including, e.g. graffiti removal) consistent with the exterior appearance of other similar facilities of comparable age and size in the vicinity, including, when necessary, the exterior repainting of the Building. (b)     Service Contracts. Lessee shall, at Lessee's sole expense, procure and maintain contracts, with copies to Lessor, in customary form and substance for, and with contractors specializing and experienced in the maintenance of the following equipment and improvements, if any, if and when installed on the Premises: (i) HVAC equipment, (ii) boiler, and pressure vessels, (iii) fire extinguishing systems, including fire alarm and/or smoke detection, (iv) landscaping and irrigation systems, (v) roof covering and drains, and (vi) clarifiers. However, Lessor reserves the right, upon notice to Lessee, to procure and maintain any or all of such service contracts, and Lessee shall reimburse Lessor, upon demand, for the cost thereof.   (c)    Failure to Perform. If Lessee fails to perform Lessee's obligations under this Paragraph 7.1, Lessor may enter upon the Premises after 10 days' prior written notice to Lessee (except in the case of an emergency, in which case no notice shall be required), perform such obligations on Lessee's behalf, and put the Premises in good order, condition and repair, and Lessee shall promptly pay to Lessor a sum equal to 115% of the cost thereof. (d)    Replacement. Subject to Lessee's indemnification of Lessor as set forth in Paragraph 8.7 below, and without relieving Lessee of liability resulting from Lessee's failure to exercise and perform good maintenance practices, if an item described in Paragraph 7.1(b) cannot be repaired other than at a cost which is in excess of 50% of the cost of replacing such item, then such item shall be replaced by Lessor, and the cost thereof shall be prorated between the Parties and Lessee shall only be obligated to pay, each month during the remainder of the term of this Lease or any extension thereof, on the date on which Base Rent is due, an amount equal to the product of multiplying the cost of such replacement by a fraction, the numerator of which is one, and the denominator of which is 144 (i.e. 1/144th of the cost per month). Lessee shall pay Interest on the unamortized balance but may prepay its obligation at any time. 7.2    Lessor's Obligations. Subject to the provisions of Paragraphs 2.2 (Condition), 2.3 (Compliance), 9 (Damage or Destruction) and 14 (Condemnation), it is intended by the Parties hereto that Lessor have no obligation, in any manner whatsoever, to repair and maintain the Premises, or the equipment therein, all of which obligations are intended to be that of the Lessee. It is the intention of the Parties that the terms of this Lease govern the respective obligations of the Parties as to maintenance and repair of the Premises. 7.3      Utility Installations; Trade Fixtures; Alterations. (a)    Definitions. The term &quot;Utility Installations&quot; refers to all floor and window coverings, air and/or vacuum lines, power panels, electrical distribution, security and fire protection systems, communication cabling, lighting fixtures, HVAC equipment, plumbing, and fencing in or on the Premises. The term &quot;Trade Fixtures&quot; shall mean Lessee's machinery and equipment that can be removed without doing material damage to the Premises. The term &quot;Alterations&quot; shall mean any modification of the improvements, other than Utility Installations or Trade Fixtures, whether by addition or deletion. &quot;Lessee Owned Alterations and/or Utility Installations&quot; are defined as Alterations and/or Utility Installations made by Lessee that are not yet owned by Lessor pursuant to Paragraph 7.4(a). (b)    Consent. Lessee shall not make any Alterations or Utility Installations to the Premises without Lessor's prior written consent. Lessee may, however, make non&#8208;structural Alterations or Utility Installations to the interior of the Premises (excluding the roof) without such consent but upon notice to Lessor, as long as they are not visible from the outside, do not involve puncturing, relocating or removing the roof or any existing walls, will not affect the electrical, plumbing, HVAC, and/or life safety systems, do not trigger the requirement for additional modifications and/or improvements to the Premises resulting from Applicable Requirements, such as compliance with Title 24, and the cumulative cost thereof during this Lease as extended does not exceed a sum equal to 3 month's Base Rent in the aggregate or a sum equal to one month's Base Rent in any one year. Notwithstanding the foregoing, Lessee shall not make or permit any roof penetrations and/or install anything on the roof without the prior written approval of Lessor. Lessor may, as a precondition to granting such approval, require Lessee to utilize a contractor chosen and/or approved by Lessor. Any Alterations or Utility Installations that Lessee shall desire to make and which require the consent of the Lessor shall be presented to Lessor in written form with detailed plans. Consent shall be deemed conditioned upon Lessee's: (i) acquiring all applicable governmental permits, (ii) furnishing Lessor with copies of both the permits and the plans and specifications prior to commencement of the work, and (iii) compliance with all conditions of said permits and other Applicable Requirements in a prompt and expeditious manner. Any Alterations or Utility Installations shall be performed in a workmanlike manner with good and sufficient materials. Lessee shall promptly upon completion furnish Lessor with as&#8208;built plans and specifications. For work which costs an amount in excess of one month's Base Rent, Lessor may condition its consent upon Lessee providing a lien and completion bond in an amount equal to 150% of the estimated cost of such Alteration or Utility Installation and/or upon Lessee's posting an additional Security Deposit with Lessor. (c)    Liens; Bonds. Lessee shall pay, when due, all claims for labor or materials furnished or alleged to have been furnished to or for Lessee at or for use on the Premises, which claims are or may be secured by any mechanic's or materialmen's lien against the Premises or any interest therein. Lessee shall give Lessor not less than 10 days notice prior to the commencement of any work in, on or about the Premises, and Lessor shall have the right to post notices of non&#8208;responsibility. If Lessee shall contest the validity of any such lien, claim or demand, then Lessee shall, at its sole expense defend and protect itself, Lessor and the Premises against the same and shall pay and satisfy any such adverse judgment that may be rendered thereon before the enforcement thereof. If Lessor shall require, Lessee shall furnish a surety bond in an amount equal to 150% of the amount of such contested lien, claim or demand, indemnifying Lessor against liability for the same. If Lessor elects to participate in any such action, Lessee shall pay Lessor's attorneys' fees and costs. 7.4      Ownership; Removal; Surrender; and Restoration. (a)    Ownership. Subject to Lessor's right to require removal or elect ownership as hereinafter provided, all Alterations and Utility Installations made by Lessee shall be the property of Lessee, but considered a part of the Premises. Lessor may, at any time, elect in writing to be the owner of all or any specified part of the Lessee Owned Alterations and Utility Installations. Unless otherwise instructed per paragraph 7.4(b) hereof, all Lessee Owned Alterations and Utility Installations shall, at the expiration or termination of this Lease, become the property of Lessor and be surrendered by Lessee with the Premises. (b)     Removal. By delivery to Lessee of written notice from Lessor not earlier than 90 and not later than 30 days prior to the end of the term of this Lease, Lessor may require that any or all Lessee Owned Alterations or Utility Installations be removed by the expiration or termination of this Lease.  Lessor may require the removal at any time of all or any part of any Lessee Owned Alterations or Utility Installations made without the required consent.         INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 5 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">(c)    Surrender; Restoration. Lessee shall surrender the Premises by the Expiration Date or any earlier termination date, with all of the improvements, parts and surfaces thereof broom clean and free of debris, and in good operating order, condition and state of repair, ordinary wear and tear excepted. &quot;Ordinary wear and tear&quot; shall not include any damage or deterioration that would have been prevented by good maintenance practice. Notwithstanding the foregoing and the provisions of Paragraph 7.1(a), if the Lessee occupies the Premises for 12 months or less, then Lessee shall surrender the Premises in the same condition as delivered to Lessee on the Start Date with NO allowance for ordinary wear and tear. Lessee shall repair any damage occasioned by the installation, maintenance or removal of Trade Fixtures, Lessee owned Alterations and/or Utility Installations, furnishings, and equipment as well as the removal of any storage tank installed by or for Lessee. Lessee shall also completely remove from the Premises any and all Hazardous Substances brought onto the Premises by or for Lessee, or any third party (except Hazardous Substances which were deposited via underground migration from areas outside of the Premises) to the level specified in Applicable Requirements. Trade Fixtures shall remain the property of Lessee and shall be removed by Lessee. Any personal property of Lessee not removed on or before the Expiration Date or any earlier termination date shall be deemed to have been abandoned by Lessee and may be disposed of or retained by Lessor as Lessor may desire. The failure by Lessee to timely vacate the Premises pursuant to this Paragraph 7.4(c) without the express written consent of Lessor shall constitute a holdover under the provisions of Paragraph 26 below.   8.            Insurance; Indemnity. 8.1    Payment For Insurance. Lessee shall pay for all insurance required under Paragraph 8 except to the extent of the cost attributable to liability insurance carried by Lessor under Paragraph 8.2(b) in excess of $2,000,000 per occurrence. Premiums for policy periods commencing prior to or extending beyond the Lease term shall be prorated to correspond to the Lease term. Payment shall be made by Lessee to Lessor within 10 days following receipt of an invoice.   8.2     Liability Insurance.   (a)    Carried by Lessee. Lessee shall obtain and keep in force a Commercial General Liability policy of insurance protecting Lessee and Lessor as an additional insured against claims for bodily injury, personal injury and property damage based upon or arising out of the ownership, use, occupancy or maintenance of the Premises and all areas appurtenant thereto. Such insurance shall be on an occurrence basis providing single limit coverage in an amount not less than $1,000,000 per occurrence with an annual aggregate of not less than $2,000,000. Lessee shall add Lessor as an additional insured by means of an endorsement at least as broad as the Insurance Service Organization's &quot;Additional Insured&#8208;Managers or Lessors of Premises&quot; Endorsement. The policy shall not contain any intra&#8208;insured exclusions as between insured persons or organizations, but shall include coverage for liability assumed under this Lease as an &quot;insured contract&quot; for the performance of Lessee's indemnity obligations under this Lease. The limits of said insurance shall not, however, limit the liability of Lessee nor relieve Lessee of any obligation hereunder. Lessee shall provide an endorsement on its liability policy(ies) which provides that its insurance shall be primary to and not contributory with any similar insurance carried by Lessor, whose insurance shall be considered excess insurance only. (b)    Carried by Lessor. Lessor shall maintain liability insurance as described in Paragraph 8.2(a), in addition to, and not in lieu of, the insurance required to be maintained by Lessee. Lessee shall not be named as an additional insured therein. 8.3      Property Insurance &#8208; Building, Improvements and Rental Value. (a)    Building and Improvements. The Insuring Party shall obtain and keep in force a policy or policies in the name of Lessor, with loss payable to Lessor, any ground&#8208;lessor, and to any Lender insuring loss or damage to the Premises. The amount of such insurance shall be equal to the full insurable replacement cost of the Premises, as the same shall exist from time to time, or the amount required by any Lender, but in no event more than the commercially reasonable and available insurable value thereof. Lessee Owned Alterations and Utility Installations, Trade Fixtures, and Lessee's personal property shall be insured by Lessee not by Lessor. If the coverage is available and commercially appropriate, such policy or policies shall insure against all risks of direct physical loss or damage (except the perils of flood and/or earthquake unless required by a Lender), including coverage for debris removal and the enforcement of any Applicable Requirements requiring the upgrading, demolition, reconstruction or replacement of any portion of the Premises as the result of a covered loss. Said policy or policies shall also contain an agreed valuation provision in lieu of any coinsurance clause, waiver of subrogation, and inflation guard protection causing an increase in the annual property insurance coverage amount by a factor of not less than the adjusted U.S. Department of Labor Consumer Price Index for All Urban Consumers for the city nearest to where the Premises are located. If such insurance coverage has a deductible clause, the deductible amount shall not exceed $5,000 per occurrence, and Lessee shall be liable for such deductible amount in the event of an Insured Loss. (b)    Rental Value. The Insuring Party shall obtain and keep in force a policy or policies in the name of Lessor with loss payable to Lessor and any Lender, insuring the loss of the full Rent for one year with an extended period of indemnity for an additional 180 days (&quot;Rental Value insurance&quot;). Said insurance shall contain an agreed valuation provision in lieu of any coinsurance clause, and the amount of coverage shall be adjusted annually to reflect the projected Rent otherwise payable by Lessee, for the next 12 month period. Lessee shall be liable for any deductible amount in the event of such loss.   (c)    Adjacent Premises. If the Premises are part of a larger building, or of a group of buildings owned by Lessor which are adjacent to the Premises, the Lessee shall pay for any increase in the premiums for the property insurance of such building or buildings if said increase is caused by Lessee's acts, omissions, use or occupancy of the Premises. 8.4      Lessee's Property; Business Interruption Insurance; Worker's Compensation Insurance.   (a)    Property Damage. Lessee shall obtain and maintain insurance coverage on all of Lessee's personal property, Trade Fixtures, and Lessee Owned Alterations and Utility Installations. Such insurance shall be full replacement cost coverage with a deductible of not to exceed $1,000 per occurrence. The proceeds from any such insurance shall be used by Lessee for the replacement of personal property, Trade Fixtures and Lessee Owned Alterations and Utility Installations.   (b)    Business Interruption. Lessee shall obtain and maintain loss of income and extra expense insurance in amounts as will reimburse Lessee for direct or indirect loss of earnings attributable to all perils commonly insured against by prudent lessees in the business of Lessee or attributable to prevention of access to the Premises as a result of such perils. (c)    Worker's Compensation Insurance. Lessee shall obtain and maintain Worker's Compensation Insurance in such amount as may be required by Applicable Requirements. Such policy shall include a 'Waiver of Subrogation' endorsement. Lessee shall provide Lessor with a copy of such endorsement along with the certificate of insurance or copy of the policy required by paragraph 8.5.   (d)    No Representation of Adequate Coverage. Lessor makes no representation that the limits or forms of coverage of insurance specified herein are adequate to cover Lessee's property, business operations or obligations under this Lease.   8.5     Insurance Policies. Insurance required herein shall be by companies maintaining during the policy term a &quot;General Policyholders Rating&quot; of at least A&#8208;, VII, as set forth in the most current issue of &quot;Best's Insurance Guide&quot;, or such other rating as may be required by a Lender. Lessee shall not do or permit to be done anything which invalidates the required insurance policies. Lessee shall, prior to the Start Date, deliver to Lessor certified copies of policies of such insurance or certificates with copies of the required endorsements evidencing the existence and amounts of the required insurance. No such policy shall be cancelable or subject to modification except after 30 days prior written notice to Lessor. Lessee shall, at least 10 days prior to the expiration of such policies, furnish Lessor with evidence of renewals or &quot;insurance binders&quot; evidencing renewal thereof, or Lessor may increase his liability insurance coverage and charge the cost thereof to Lessee, which amount shall be payable by Lessee to Lessor upon demand. Such policies shall be for a term of at least one year, or the length of the remaining term of this Lease, whichever is less. If either Party shall fail to procure and maintain the insurance required to be carried by it, the other Party may, but shall not be required to, procure and maintain the same.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 6 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">8.6    Waiver of Subrogation. Without affecting any other rights or remedies, Lessee and Lessor each hereby release and relieve the other, and waive their entire right to recover damages against the other, for loss of or damage to its property arising out of or incident to the perils required to be insured against herein. The effect of such releases and waivers is not limited by the amount of insurance carried or required, or by any deductibles applicable hereto. The Parties agree to have their respective property damage insurance carriers waive any right to subrogation that such companies may have against Lessor or Lessee, as the case may be, so long as the insurance is not invalidated thereby. 8.7    Indemnity. Except for Lessor's gross negligence or willful misconduct, Lessee shall indemnify, protect, defend and hold harmless the Premises, Lessor and its agents, Lessor's master or ground lessor, partners and Lenders, from and against any and all claims, loss of rents and/or damages, liens, judgments, penalties, attorneys' and consultants' fees, expenses and/or liabilities arising out of, involving, or in connection with, a Breach of the Lease by Lessee and/or the use and/or occupancy of the Premises and/or Project by Lessee and/or by Lessee's employees, contractors or invitees. If any action or proceeding is brought against Lessor by reason of any of the foregoing matters, Lessee shall upon notice defend the same at Lessee's expense by counsel reasonably satisfactory to Lessor and Lessor shall cooperate with Lessee in such defense. Lessor need not have first paid any such claim in order to be defended or indemnified.   8.8    Exemption of Lessor and its Agents from Liability. Notwithstanding the negligence or breach of this Lease by Lessor or its agents, neither Lessor nor its agents shall be liable under any circumstances for: (i) injury or damage to the person or goods, wares, merchandise or other property of Lessee, Lessee's employees, contractors, invitees, customers, or any other person in or about the Premises, whether such damage or injury is caused by or results from fire, steam, electricity, gas, water or rain, indoor air quality, the presence of mold or from the breakage, leakage, obstruction or other defects of pipes, fire sprinklers, wires, appliances, plumbing, HVAC or lighting fixtures, or from any other cause, whether the said injury or damage results from conditions arising upon the Premises or upon other portions of the building of which the Premises are a part, or from other sources or places, (ii) any damages arising from any act or neglect of any other tenant of Lessor or from the failure of Lessor or its agents to enforce the provisions of any other lease in the Project, or (iii) injury to Lessee's business or for any loss of income or profit therefrom. Instead, it is intended that Lessee's sole recourse in the event of such damages or injury be to file a claim on the insurance policy(ies) that Lessee is required to maintain pursuant to the provisions of paragraph 8.   8.9    Failure to Provide Insurance. Lessee acknowledges that any failure on its part to obtain or maintain the insurance required herein will expose Lessor to risks and potentially cause Lessor to incur costs not contemplated by this Lease, the extent of which will be extremely difficult to ascertain. Accordingly, for any month or portion thereof that Lessee does not maintain the required insurance and/or does not provide Lessor with the required binders or certificates evidencing the existence of the required insurance, the Base Rent shall be automatically increased, without any requirement for notice to Lessee, by an amount equal to 10% of the then existing Base Rent or $100, whichever is greater. The parties agree that such increase in Base Rent represents fair and reasonable compensation for the additional risk/costs that Lessor will incur by reason of Lessee's failure to maintain the required insurance. Such increase in Base Rent shall in no event constitute a waiver of Lessee's Default or Breach with respect to the failure to maintain such insurance, prevent the exercise of any of the other rights and remedies granted hereunder, nor relieve Lessee of its obligation to maintain the insurance specified in this Lease.   9.           Damage or Destruction. 9.1     Definitions.   (a)    &quot;Premises Partial Damage&quot; shall mean damage or destruction to the improvements on the Premises, other than Lessee Owned Alterations and Utility Installations, which can reasonably be repaired in 6 months or less from the date of the damage or destruction. Lessor shall notify Lessee in writing within 30 days from the date of the damage or destruction as to whether or not the damage is Partial or Total.   (b)   &quot;Premises Total Destruction&quot; shall mean damage or destruction to the Premises, other than Lessee Owned Alterations and Utility Installations and Trade Fixtures, which cannot reasonably be repaired in 6 months or less from the date of the damage or destruction. Lessor shall notify Lessee in writing within 30 days from the date of the damage or destruction as to whether or not the damage is Partial or Total. (c)    &quot;Insured Loss&quot; shall mean damage or destruction to improvements on the Premises, other than Lessee Owned Alterations and Utility Installations and Trade Fixtures, which was caused by an event required to be covered by the insurance described in Paragraph 8.3(a), irrespective of any deductible amounts or coverage limits involved. (d)    &quot;Replacement Cost&quot; shall mean the cost to repair or rebuild the improvements owned by Lessor at the time of the occurrence to their condition existing immediately prior thereto, including demolition, debris removal and upgrading required by the operation of Applicable Requirements, and without deduction for depreciation. (e)    &quot;Hazardous Substance Condition&quot; shall mean the occurrence or discovery of a condition involving the presence of, or a contamination by, a Hazardous Substance, in, on, or under the Premises which requires restoration. 9.2    Partial Damage &#8208; Insured Loss. If a Premises Partial Damage that is an Insured Loss occurs, then Lessor shall, at Lessor's expense, repair such damage (but not Lessee's Trade Fixtures or Lessee Owned Alterations and Utility Installations) as soon as reasonably possible and this Lease shall continue in full force and effect; provided, however, that Lessee shall, at Lessor's election, make the repair of any damage or destruction the total cost to repair of which is $10,000 or less, and, in such event, Lessor shall make any applicable insurance proceeds available to Lessee on a reasonable basis for that purpose. Notwithstanding the foregoing, if the required insurance was not in force or the insurance proceeds are not sufficient to effect such repair, the Insuring Party shall promptly contribute the shortage in proceeds (except as to the deductible which is Lessee's responsibility) as and when required to complete said repairs. In the event, however, such shortage was due to the fact that, by reason of the unique nature of the improvements, full replacement cost insurance coverage was not commercially reasonable and available, Lessor shall have no obligation to pay for the shortage in insurance proceeds or to fully restore the unique aspects of the Premises unless Lessee provides Lessor with the funds to cover same, or adequate assurance thereof, within 10 days following receipt of written notice of such shortage and request therefor. If Lessor receives said funds or adequate assurance thereof within said 10 day period, the party responsible for making the repairs shall complete them as soon as reasonably possible and this Lease shall remain in full force and effect. If such funds or assurance are not received, Lessor may nevertheless elect by written notice to Lessee within 10 days thereafter to: (i) make such restoration and repair as is commercially reasonable with Lessor paying any shortage in proceeds, in which case this Lease shall remain in full force and effect, or (ii) have this Lease terminate 30 days thereafter. Lessee shall not be entitled to reimbursement of any funds contributed by Lessee to repair any such damage or destruction. Premises Partial Damage due to flood or earthquake shall be subject to Paragraph 9.3, notwithstanding that there may be some insurance coverage, but the net proceeds of any such insurance shall be made available for the repairs if made by either Party. 9.3     Partial Damage &#8208; Uninsured Loss. If a Premises Partial Damage that is not an Insured Loss occurs, unless caused by a negligent or willful act of Lessee (in which event Lessee shall make the repairs at Lessee's expense), Lessor may either: (i) repair such damage as soon as reasonably possible at Lessor's expense, in which event this Lease shall continue in full force and effect, or (ii) terminate this Lease by giving written notice to Lessee within 30 days after receipt by Lessor of knowledge of the occurrence of such damage. Such termination shall be effective 60 days following the date of such notice. In the event Lessor elects to terminate this Lease, Lessee shall have the right within 10 days after receipt of the termination notice to give written notice to Lessor of Lessee's commitment to pay for the repair of such damage without reimbursement from Lessor. Lessee shall provide Lessor with said funds or satisfactory assurance thereof within 30 days after making such commitment. In such event this Lease shall continue in full force and effect, and Lessor shall proceed to make such repairs as soon as reasonably possible after the required funds are available. If Lessee does not make the required commitment, this Lease shall terminate as of the date specified in the termination notice.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 7 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">9.4    Total Destruction. Notwithstanding any other provision hereof, if a Premises Total Destruction occurs, this Lease shall terminate 60 days following such Destruction. If the damage or destruction was caused by the gross negligence or willful misconduct of Lessee, Lessor shall have the right to recover Lessor's damages from Lessee, except as provided in Paragraph 8.6. 9.5    Damage Near End of Term. If at any time during the last 6 months of this Lease there is damage for which the cost to repair exceeds one month's Base Rent, whether or not an Insured Loss, Lessor may terminate this Lease effective 60 days following the date of occurrence of such damage by giving a written termination notice to Lessee within 30 days after the date of occurrence of such damage. Notwithstanding the foregoing, if Lessee at that time has an exercisable option to extend this Lease or to purchase the Premises, then Lessee may preserve this Lease by, (a) exercising such option and (b) providing Lessor with any shortage in insurance proceeds (or adequate assurance thereof) needed to make the repairs on or before the earlier of (i) the date which is 10 days after Lessee's receipt of Lessor's written notice purporting to terminate this Lease, or (ii) the day prior to the date upon which such option expires. If Lessee duly exercises such option during such period and provides Lessor with funds (or adequate assurance thereof) to cover any shortage in insurance proceeds, Lessor shall, at Lessor's commercially reasonable expense, repair such damage as soon as reasonably possible and this Lease shall continue in full force and effect. If Lessee fails to exercise such option and provide such funds or assurance during such period, then this Lease shall terminate on the date specified in the termination notice and Lessee's option shall be extinguished. 9.6     Abatement of Rent; Lessee's Remedies. (a)    Abatement. In the event of Premises Partial Damage or Premises Total Destruction or a Hazardous Substance Condition for which Lessee is not responsible under this Lease, the Rent payable by Lessee for the period required for the repair, remediation or restoration of such damage shall be abated in proportion to the degree to which Lessee's use of the Premises is impaired, but not to exceed the proceeds received from the Rental Value insurance. All other obligations of Lessee hereunder shall be performed by Lessee, and Lessor shall have no liability for any such damage, destruction, remediation, repair or restoration except as provided herein. (b)    Remedies. If Lessor is obligated to repair or restore the Premises and does not commence, in a substantial and meaningful way, such repair or restoration within 90 days after such obligation shall accrue, Lessee may, at any time prior to the commencement of such repair or restoration, give written notice to Lessor and to any Lenders of which Lessee has actual notice, of Lessee's election to terminate this Lease on a date not less than 60 days following the giving of such notice. If Lessee gives such notice and such repair or restoration is not commenced within 30 days thereafter, this Lease shall terminate as of the date specified in said notice. If the repair or restoration is commenced within such 30 days, this Lease shall continue in full force and effect. &quot;Commence&quot; shall mean either the unconditional authorization of the preparation of the required plans, or the beginning of the actual work on the Premises, whichever first occurs. 9.7    Termination; Advance Payments. Upon termination of this Lease pursuant to Paragraph 6.2(g) or Paragraph 9, an equitable adjustment shall be made concerning advance Base Rent and any other advance payments made by Lessee to Lessor. Lessor shall, in addition, return to Lessee so much of Lessee's Security Deposit as has not been, or is not then required to be, used by Lessor.   10.         Real Property Taxes. 10.1   Definition. As used herein, the term &quot;Real Property Taxes&quot; shall include any form of assessment; real estate, general, special, ordinary or extraordinary, or rental levy or tax (other than inheritance, personal income or estate taxes); improvement bond; and/or license fee imposed upon or levied against any legal or equitable interest of Lessor in the Premises or the Project, Lessor's right to other income therefrom, and/or Lessor's business of leasing, by any authority having the direct or indirect power to tax and where the funds are generated with reference to the Building address. Real Property Taxes shall also include any tax, fee, levy, assessment or charge, or any increase therein: (i) imposed by reason of events occurring during the term of this Lease, including but not limited to, a change in the ownership of the Premises, and (ii) levied or assessed on machinery or equipment provided by Lessor to Lessee pursuant to this Lease.   10.2   Payment of Taxes. In addition to Base Rent, Lessee shall pay to Lessor an amount equal to the Real Property Tax installment due at least 20 days prior to the applicable delinquency date. If any such installment shall cover any period of time prior to or after the expiration or termination of this Lease, Lessee's share of such installment shall be prorated. In the event Lessee incurs a late charge on any Rent payment, Lessor may estimate the current Real Property Taxes, and require that such taxes be paid in advance to Lessor by Lessee monthly in advance with the payment of the Base Rent. Such monthly payments shall be an amount equal to the amount of the estimated installment of taxes divided by the number of months remaining before the month in which said installment becomes delinquent. When the actual amount of the applicable tax bill is known, the amount of such equal monthly advance payments shall be adjusted as required to provide the funds needed to pay the applicable taxes. If the amount collected by Lessor is insufficient to pay such Real Property Taxes when due, Lessee shall pay Lessor, upon demand, such additional sum as is necessary. Advance payments may be intermingled with other moneys of Lessor and shall not bear interest. In the event of a Breach by Lessee in the performance of its obligations under this Lease, then any such advance payments may be treated by Lessor as an additional Security Deposit. 10.3   Joint Assessment. If the Premises are not separately assessed, Lessee's liability shall be an equitable proportion of the Real Property Taxes for all of the land and improvements included within the tax parcel assessed, such proportion to be conclusively determined by Lessor from the respective valuations assigned in the assessor's work sheets or such other information as may be reasonably available. 10.4   Personal Property Taxes. Lessee shall pay, prior to delinquency, all taxes assessed against and levied upon Lessee Owned Alterations, Utility Installations, Trade Fixtures, furnishings, equipment and all personal property of Lessee. When possible, Lessee shall cause its Lessee Owned Alterations and Utility Installations, Trade Fixtures, furnishings, equipment and all other personal property to be assessed and billed separately from the real property of Lessor. If any of Lessee's said property shall be assessed with Lessor's real property, Lessee shall pay Lessor the taxes attributable to Lessee's property within 10 days after receipt of a written statement setting forth the taxes applicable to Lessee's property.   11.         Utilities and Services. 11.1   Lessee shall pay for all water, gas, heat, light, power, telephone, trash disposal and other utilities and services supplied to the Premises, together with any taxes thereon. If any such services are not separately metered or billed to Lessee, Lessee shall pay a reasonable proportion, to be determined by Lessor, of all charges jointly metered or billed. There shall be no abatement of rent and Lessor shall not be liable in any respect whatsoever for the inadequacy, stoppage, interruption or discontinuance of any utility or service due to riot, strike, labor dispute, breakdown, accident, repair or other cause beyond Lessor's reasonable control or in cooperation with governmental request or directions.   11.2   Within fifteen days of Lessor's written request, Lessee agrees to deliver to Lessor such information, documents and/or authorization as Lessor needs in order for Lessor to comply with new or existing Applicable Requirements relating to commercial building energy usage, ratings, and/or the reporting thereof.   12.         Assignment and Subletting. 12.1    Lessor's Consent Required. (a)    Lessee shall not voluntarily or by operation of law assign, transfer, mortgage or encumber (collectively, &quot;assign or assignment&quot;) or sublet all or any part of Lessee's interest in this Lease or in the Premises without Lessor's prior written consent.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 8 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">(b)    Unless Lessee is a corporation and its stock is publicly traded on a national stock exchange, a change in the control of Lessee shall constitute an assignment requiring consent. The transfer, on a cumulative basis, of 25% or more of the voting control of Lessee shall constitute a change in control for this purpose. (c)    The involvement of Lessee or its assets in any transaction, or series of transactions (by way of merger, sale, acquisition, financing, transfer, leveraged buy&#8208;out or otherwise), whether or not a formal assignment or hypothecation of this Lease or Lessee's assets occurs, which results or will result in a reduction of the Net Worth of Lessee by an amount greater than 25% of such Net Worth as it was represented at the time of the execution of this Lease or at the time of the most recent assignment to which Lessor has consented, or as it exists immediately prior to said transaction or transactions constituting such reduction, whichever was or is greater, shall be considered an assignment of this Lease to which Lessor may withhold its consent. &quot;Net Worth of Lessee&quot; shall mean the net worth of Lessee (excluding any guarantors) established under generally accepted accounting principles. (d)    An assignment or subletting without consent shall, at Lessor's option, be a Default curable after notice per Paragraph 13.1(d), or a noncurable Breach without the necessity of any notice and grace period. If Lessor elects to treat such unapproved assignment or subletting as a noncurable Breach, Lessor may either: (i) terminate this Lease, or (ii) upon 30 days written notice, increase the monthly Base Rent to 110% of the Base Rent then in effect. Further, in the event of such Breach and rental adjustment, (i) the purchase price of any option to purchase the Premises held by Lessee shall be subject to similar adjustment to 110% of the price previously in effect, and (ii) all fixed and non&#8208;fixed rental adjustments scheduled during the remainder of the Lease term shall be increased to 110% of the scheduled adjusted rent. (e)      Lessee's remedy for any breach of Paragraph 12.1 by Lessor shall be limited to compensatory damages and/or injunctive relief. (f)      Lessor may reasonably withhold consent to a proposed assignment or subletting if Lessee is in Default at the time consent is requested. (g)    Notwithstanding the foregoing, allowing a de minimis portion of the Premises, ie. 20 square feet or less, to be used by a third party vendor in connection with the installation of a vending machine or payphone shall not constitute a subletting. 12.2       Terms and Conditions Applicable to Assignment and Subletting. (a)    Regardless of Lessor's consent, no assignment or subletting shall : (i) be effective without the express written assumption by such assignee or sublessee of the obligations of Lessee under this Lease, (ii) release Lessee of any obligations hereunder, or (iii) alter the primary liability of Lessee for the payment of Rent or for the performance of any other obligations to be performed by Lessee. (b)    Lessor may accept Rent or performance of Lessee's obligations from any person other than Lessee pending approval or disapproval of an assignment. Neither a delay in the approval or disapproval of such assignment nor the acceptance of Rent or performance shall constitute a waiver or estoppel of Lessor's right to exercise its remedies for Lessee's Default or Breach. (c)      Lessor's consent to any assignment or subletting shall not constitute a consent to any subsequent assignment or subletting. (d)    In the event of any Default or Breach by Lessee, Lessor may proceed directly against Lessee, any Guarantors or anyone else responsible for the performance of Lessee's obligations under this Lease, including any assignee or sublessee, without first exhausting Lessor's remedies against any other person or entity responsible therefor to Lessor, or any security held by Lessor. (e)   Each request for consent to an assignment or subletting shall be in writing, accompanied by information relevant to Lessor's determination as to the financial and operational responsibility and appropriateness of the proposed assignee or sublessee, including but not limited to the intended use and/or required modification of the Premises, if any, together with a fee of $500 as consideration for Lessor's considering and processing said request. Lessee agrees to provide Lessor with such other or additional information and/or documentation as may be reasonably requested. (See also Paragraph 36) (f)    Any assignee of, or sublessee under, this Lease shall, by reason of accepting such assignment, entering into such sublease, or entering into possession of the Premises or any portion thereof, be deemed to have assumed and agreed to conform and comply with each and every term, covenant, condition and obligation herein to be observed or performed by Lessee during the term of said assignment or sublease, other than such obligations as are contrary to or inconsistent with provisions of an assignment or sublease to which Lessor has specifically consented to in writing.   (g)    Lessor's consent to any assignment or subletting shall not transfer to the assignee or sublessee any Option granted to the original Lessee by this Lease unless such transfer is specifically consented to by Lessor in writing. (See Paragraph 39.2)   12.3   Additional Terms and Conditions Applicable to Subletting. The following terms and conditions shall apply to any subletting by Lessee of all or any part of the Premises and shall be deemed included in all subleases under this Lease whether or not expressly incorporated therein:   (a)    Lessee hereby assigns and transfers to Lessor all of Lessee's interest in all Rent payable on any sublease, and Lessor may collect such Rent and apply same toward Lessee's obligations under this Lease; provided, however, that until a Breach shall occur in the performance of Lessee's obligations, Lessee may collect said Rent. In the event that the amount collected by Lessor exceeds Lessee's then outstanding obligations any such excess shall be refunded to Lessee. Lessor shall not, by reason of the foregoing or any assignment of such sublease, nor by reason of the collection of Rent, be deemed liable to the sublessee for any failure of Lessee to perform and comply with any of Lessee's obligations to such sublessee. Lessee hereby irrevocably authorizes and directs any such sublessee, upon receipt of a written notice from Lessor stating that a Breach exists in the performance of Lessee's obligations under this Lease, to pay to Lessor all Rent due and to become due under the sublease. Sublessee shall rely upon any such notice from Lessor and shall pay all Rents to Lessor without any obligation or right to inquire as to whether such Breach exists, notwithstanding any claim from Lessee to the contrary.   (b)    In the event of a Breach by Lessee, Lessor may, at its option, require sublessee to attorn to Lessor, in which event Lessor shall undertake the obligations of the sublessor under such sublease from the time of the exercise of said option to the expiration of such sublease; provided, however, Lessor shall not be liable for any prepaid rents or security deposit paid by such sublessee to such sublessor or for any prior Defaults or Breaches of such sublessor.   (c)      Any matter requiring the consent of the sublessor under a sublease shall also require the consent of Lessor. (d)      No sublessee shall further assign or sublet all or any part of the Premises without Lessor's prior written consent.   (e)    Lessor shall deliver a copy of any notice of Default or Breach by Lessee to the sublessee, who shall have the right to cure the Default of Lessee within the grace period, if any, specified in such notice. The sublessee shall have a right of reimbursement and offset from and against Lessee for any such Defaults cured by the sublessee.   13.         Default; Breach; Remedies.   13.1   Default; Breach. A &quot;Default&quot; is defined as a failure by the Lessee to comply with or perform any of the terms, covenants, conditions or Rules and Regulations under this Lease. A &quot;Breach&quot; is defined as the occurrence of one or more of the following Defaults, and the failure of Lessee to cure such Default within any applicable grace period: (a)    The abandonment of the Premises; the vacating of the Premises prior to the expiration or termination of this Lease without providing a commercially reasonable level of security, or where the coverage of the property insurance described in Paragraph 8.3 is jeopardized as a result thereof, or without providing reasonable assurances to minimize potential vandalism; or failure to deliver to Lessor exclusive possession of the entire Premises in accordance herewith prior to the expiration or termination of this Lease. (b)     The failure of Lessee to make any payment of Rent or any Security Deposit required to be made by Lessee hereunder, whether to Lessor or to a third party, when due, to provide reasonable evidence of insurance or surety bond, or to fulfill any obligation under this Lease which endangers or threatens life or property, where such failure continues for a period of 3 business days following written notice to Lessee. THE ACCEPTANCE BY LESSOR OF A PARTIAL PAYMENT OF RENT OR SECURITY DEPOSIT SHALL NOT CONSTITUTE A WAIVER OF ANY OF LESSOR'S RIGHTS, INCLUDING LESSOR'S RIGHT TO RECOVER POSSESSION OF THE PREMISES.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 9 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">(c)    The failure of Lessee to allow Lessor and/or its agents access to the Premises or the commission of waste, act or acts constituting public or private nuisance, and/or an illegal activity on the Premises by Lessee, where such actions continue for a period of 3 business days following written notice to Lessee. In the event that Lessee commits waste, a nuisance or an illegal activity a second time then, the Lessor may elect to treat such conduct as a non&#8208;curable Breach rather than a Default.   (d)    The failure by Lessee to provide (i) reasonable written evidence of compliance with Applicable Requirements, (ii) the service contracts, (iii) the rescission of an unauthorized assignment or subletting, (iv) an Estoppel Certificate or financial statements, (v) a requested subordination, (vi) evidence concerning any guaranty and/or Guarantor, (vii) any document requested under Paragraph 42, (viii) material safety data sheets (MSDS), or (ix) any other documentation or information which Lessor may reasonably require of Lessee under the terms of this Lease, where any such failure continues for a period of 10 days following written notice to Lessee. (e)    A Default by Lessee as to the terms, covenants, conditions or provisions of this Lease, or of the rules adopted under Paragraph 40 hereof, other than those described in subparagraphs 13.1(a), (b), (c) or (d), above, where such Default continues for a period of 30 days after written notice; provided, however, that if the nature of Lessee's Default is such that more than 30 days are reasonably required for its cure, then it shall not be deemed to be a Breach if Lessee commences such cure within said 30 day period and thereafter diligently prosecutes such cure to completion. (f)    The occurrence of any of the following events: (i) the making of any general arrangement or assignment for the benefit of creditors; (ii) becoming a &quot;debtor&quot; as defined in 11 U.S.C. &sect; 101 or any successor statute thereto (unless, in the case of a petition filed against Lessee, the same is dismissed within 60 days); (iii) the appointment of a trustee or receiver to take possession of substantially all of Lessee's assets located at the Premises or of Lessee's interest in this Lease, where possession is not restored to Lessee within 30 days; or (iv) the attachment, execution or other judicial seizure of substantially all of Lessee's assets located at the Premises or of Lessee's interest in this Lease, where such seizure is not discharged within 30 days; provided, however, in the event that any provision of this subparagraph is contrary to any applicable law, such provision shall be of no force or effect, and not affect the validity of the remaining provisions. (g)     The discovery that any financial statement of Lessee or of any Guarantor given to Lessor was materially false. (h)    If the performance of Lessee's obligations under this Lease is guaranteed: (i) the death of a Guarantor, (ii) the termination of a Guarantor's liability with respect to this Lease other than in accordance with the terms of such guaranty, (iii) a Guarantor's becoming insolvent or the subject of a bankruptcy filing, (iv) a Guarantor's refusal to honor the guaranty, or (v) a Guarantor's breach of its guaranty obligation on an anticipatory basis, and Lessee's failure, within 60 days following written notice of any such event, to provide written alternative assurance or security, which, when coupled with the then existing resources of Lessee, equals or exceeds the combined financial resources of Lessee and the Guarantors that existed at the time of execution of this Lease. 13.2  Remedies. If Lessee fails to perform any of its affirmative duties or obligations, within 10 days after written notice (or in case of an emergency, without notice), Lessor may, at its option, perform such duty or obligation on Lessee's behalf, including but not limited to the obtaining of reasonably required bonds, insurance policies, or governmental licenses, permits or approvals. Lessee shall pay to Lessor an amount equal to 115% of the costs and expenses incurred by Lessor in such performance upon receipt of an invoice therefor. In the event of a Breach, Lessor may, with or without further notice or demand, and without limiting Lessor in the exercise of any right or remedy which Lessor may have by reason of such Breach:   (a)      Terminate Lessee's right to possession of the Premises by any lawful means, in which case this Lease shall terminate and Lessee shall immediately surrender possession to Lessor. In such event Lessor shall be entitled to recover from Lessee: (i) the unpaid Rent which had been earned at the time of termination; (ii) the worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that the Lessee proves could have been reasonably avoided; (iii) the worth at the time of award of the amount by which the unpaid rent for the balance of the term after the time of award exceeds the amount of such rental loss that the Lessee proves could be reasonably avoided; and (iv) any other amount necessary to compensate Lessor for all the detriment proximately caused by the Lessee's failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including but not limited to the cost of recovering possession of the Premises, expenses of reletting, including necessary renovation and alteration of the Premises, reasonable attorneys' fees, and that portion of any leasing commission paid by Lessor in connection with this Lease applicable to the unexpired term of this Lease. The worth at the time of award of the amount referred to in provision (iii) of the immediately preceding sentence shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of the District within which the Premises are located at the time of award plus one percent. Efforts by Lessor to mitigate damages caused by Lessee's Breach of this Lease shall not waive Lessor's right to recover any damages to which Lessor is otherwise entitled. If termination of this Lease is obtained through the provisional remedy of unlawful detainer, Lessor shall have the right to recover in such proceeding any unpaid Rent and damages as are recoverable therein, or Lessor may reserve the right to recover all or any part thereof in a separate suit. If a notice and grace period required under Paragraph 13.1 was not previously given, a notice to pay rent or quit, or to perform or quit given to Lessee under the unlawful detainer statute shall also constitute the notice required by Paragraph 13.1. In such case, the applicable grace period required by Paragraph 13.1 and the unlawful detainer statute shall run concurrently, and the failure of Lessee to cure the Default within the greater of the two such grace periods shall constitute both an unlawful detainer and a Breach of this Lease entitling Lessor to the remedies provided for in this Lease and/or by said statute. (b)    Continue the Lease and Lessee's right to possession and recover the Rent as it becomes due, in which event Lessee may sublet or assign, subject only to reasonable limitations. Acts of maintenance, efforts to relet, and/or the appointment of a receiver to protect the Lessor's interests, shall not constitute a termination of the Lessee's right to possession. (c)    Pursue any other remedy now or hereafter available under the laws or judicial decisions of the state wherein the Premises are located. The expiration or termination of this Lease and/or the termination of Lessee's right to possession shall not relieve Lessee from liability under any indemnity provisions of this Lease as to matters occurring or accruing during the term hereof or by reason of Lessee's occupancy of the Premises. 13.3   Inducement Recapture. Any agreement for free or abated rent or other charges, the cost of tenant improvements for Lessee paid for or performed by Lessor, or for the giving or paying by Lessor to or for Lessee of any cash or other bonus, inducement or consideration for Lessee's entering into this Lease, all of which concessions are hereinafter referred to as &quot;Inducement Provisions,&quot; shall be deemed conditioned upon Lessee's full and faithful performance of all of the terms, covenants and conditions of this Lease. Upon Breach of this Lease by Lessee, any such Inducement Provision shall automatically be deemed deleted from this Lease and of no further force or effect, and any rent, other charge, bonus, inducement or consideration theretofore abated, given or paid by Lessor under such an Inducement Provision shall be immediately due and payable by Lessee to Lessor, notwithstanding any subsequent cure of said Breach by Lessee. The acceptance by Lessor of rent or the cure of the Breach which initiated the operation of this paragraph shall not be deemed a waiver by Lessor of the provisions of this paragraph unless specifically so stated in writing by Lessor at the time of such acceptance.   13.4    Late Charges. Lessee hereby acknowledges that late payment by Lessee of Rent will cause Lessor to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult to ascertain. Such costs include, but are not limited to, processing and accounting charges, and late charges which may be imposed upon Lessor by any Lender.  Accordingly, if any Rent shall not be received by Lessor within 5 days after such amount shall be due, then, without any requirement for notice to Lessee, Lessee shall immediately pay to Lessor a one&#8208;time late charge equal to 10% of each such overdue amount or $100, whichever is greater. The Parties hereby agree that such late charge represents a fair and reasonable estimate of the costs Lessor will incur by reason of such late payment. Acceptance of such late charge by Lessor shall in no event constitute a waiver of Lessee's Default or Breach with respect to such overdue amount, nor prevent the exercise of any of the other rights and remedies granted hereunder. In the event that a late charge is payable hereunder, whether or not collected, for 3 consecutive installments of Base Rent, then notwithstanding any provision of this Lease to the contrary, Base Rent shall, at Lessor's option, become due and payable quarterly in advance.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 10 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">13.5   Interest. Any monetary payment due Lessor hereunder, other than late charges, not received by Lessor, when due shall bear interest from the 31st day after it was due. The interest (&quot;Interest&quot;) charged shall be computed at the rate of 10% per annum but shall not exceed the maximum rate allowed by law. Interest is payable in addition to the potential late charge provided for in Paragraph 13.4. 13.6   Breach by Lessor. (a)    Notice of Breach. Lessor shall not be deemed in breach of this Lease unless Lessor fails within a reasonable time to perform an obligation required to be performed by Lessor. For purposes of this Paragraph, a reasonable time shall in no event be less than 30 days after receipt by Lessor, and any Lender whose name and address shall have been furnished to Lessee in writing for such purpose, of written notice specifying wherein such obligation of Lessor has not been performed; provided, however, that if the nature of Lessor's obligation is such that more than 30 days are reasonably required for its performance, then Lessor shall not be in breach if performance is commenced within such 30 day period and thereafter diligently pursued to completion. (b)    Performance by Lessee on Behalf of Lessor. In the event that neither Lessor nor Lender cures said breach within 30 days after receipt of said notice, or if having commenced said cure they do not diligently pursue it to completion, then Lessee may elect to cure said breach at Lessee's expense and offset from Rent the actual and reasonable cost to perform such cure, provided however, that such offset shall not exceed an amount equal to the greater of one month's Base Rent or the Security Deposit, reserving Lessee's right to seek reimbursement from Lessor for any such expense in excess of such offset. Lessee shall document the cost of said cure and supply said documentation to Lessor.   14.       Condemnation. If the Premises or any portion thereof are taken under the power of eminent domain or sold under the threat of the exercise of said power (collectively &quot;Condemnation&quot;), this Lease shall terminate as to the part taken as of the date the condemning authority takes title or possession, whichever first occurs. If more than 10% of the Building, or more than 25% of that portion of the Premises not occupied by any building, is taken by Condemnation, Lessee may, at Lessee's option, to be exercised in writing within 10 days after Lessor shall have given Lessee written notice of such taking (or in the absence of such notice, within 10 days after the condemning authority shall have taken possession) terminate this Lease as of the date the condemning authority takes such possession. If Lessee does not terminate this Lease in accordance with the foregoing, this Lease shall remain in full force and effect as to the portion of the Premises remaining, except that the Base Rent shall be reduced in proportion to the reduction in utility of the Premises caused by such Condemnation. Condemnation awards and/or payments shall be the property of Lessor, whether such award shall be made as compensation for diminution in value of the leasehold, the value of the part taken, or for severance damages; provided, however, that Lessee shall be entitled to any compensation paid by the condemnor for Lessee's relocation expenses, loss of business goodwill and/or Trade Fixtures, without regard to whether or not this Lease is terminated pursuant to the provisions of this Paragraph. All Alterations and Utility Installations made to the Premises by Lessee, for purposes of Condemnation only, shall be considered the property of the Lessee and Lessee shall be entitled to any and all compensation which is payable therefor. In the event that this Lease is not terminated by reason of the Condemnation, Lessor shall repair any damage to the Premises caused by such Condemnation.   15.         Brokerage Fees. 15.1   Additional Commission. In addition to the payments owed pursuant to Paragraph 1.9 above, Lessor agrees that: (a) if Lessee exercises any Option, (b) if Lessee or anyone affiliated with Lessee acquires any rights to the Premises or other premises owned by Lessor and located within the same Project, if any, within which the Premises is located, (c) if Lessee remains in possession of the Premises, with the consent of Lessor, after the expiration of this Lease, or (d) if Base Rent is increased, whether by agreement or operation of an escalation clause herein, then, Lessor shall pay Brokers a fee in accordance with the fee schedule of the Brokers in effect at the time the Lease was executed. The provisions of this paragraph are intended to supersede the provisions of any earlier agreement to the contrary.   15.2   Assumption of Obligations. Any buyer or transferee of Lessor's interest in this Lease shall be deemed to have assumed Lessor's obligation hereunder. Brokers shall be third party beneficiaries of the provisions of Paragraphs 1.9, 15, 22 and 31. If Lessor fails to pay to Brokers any amounts due as and for brokerage fees pertaining to this Lease when due, then such amounts shall accrue Interest. In addition, if Lessor fails to pay any amounts to Lessee's Broker when due, Lessee's Broker may send written notice to Lessor and Lessee of such failure and if Lessor fails to pay such amounts within 10 days after said notice, Lessee shall pay said monies to its Broker and offset such amounts against Rent. In addition, Lessee's Broker shall be deemed to be a third party beneficiary of any commission agreement entered into by and/or between Lessor and Lessor's Broker for the limited purpose of collecting any brokerage fee owed.   15.3   Representations and Indemnities of Broker Relationships. Lessee and Lessor each represent and warrant to the other that it has had no dealings with any person, firm, broker, agent or finder (other than the Brokers and Agents, if any) in connection with this Lease, and that no one other than said named Brokers and Agents is entitled to any commission or finder's fee in connection herewith. Lessee and Lessor do each hereby agree to indemnify, protect, defend and hold the other harmless from and against liability for compensation or charges which may be claimed by any such unnamed broker, finder or other similar party by reason of any dealings or actions of the indemnifying Party, including any costs, expenses, attorneys' fees reasonably incurred with respect thereto.   16.         Estoppel Certificates. (a)     Each Party (as &quot;Responding Party&quot;) shall within 10 days after written notice from the other Party (the &quot;Requesting Party&quot;) execute, acknowledge and deliver to the Requesting Party a statement in writing in form similar to the then most current &quot;Estoppel Certificate&quot; form published by AIR CRE, plus such additional information, confirmation and/or statements as may be reasonably requested by the Requesting Party.   (b)     If the Responding Party shall fail to execute or deliver the Estoppel Certificate within such 10 day period, the Requesting Party may execute an Estoppel Certificate stating that: (i) the Lease is in full force and effect without modification except as may be represented by the Requesting Party, (ii) there are no uncured defaults in the Requesting Party's performance, and (iii) if Lessor is the Requesting Party, not more than one month's rent has been paid in advance. Prospective purchasers and encumbrancers may rely upon the Requesting Party's Estoppel Certificate, and the Responding Party shall be estopped from denying the truth of the facts contained in said Certificate. In addition, Lessee acknowledges that any failure on its part to provide such an Estoppel Certificate will expose Lessor to risks and potentially cause Lessor to incur costs not contemplated by this Lease, the extent of which will be extremely difficult to ascertain. Accordingly, should the Lessee fail to execute and/or deliver a requested Estoppel Certificate in a timely fashion the monthly Base Rent shall be automatically increased, without any requirement for notice to Lessee, by an amount equal to 10% of the then existing Base Rent or $100, whichever is greater for remainder of the Lease. The Parties agree that such increase in Base Rent represents fair and reasonable compensation for the additional risk/costs that Lessor will incur by reason of Lessee's failure to provide the Estoppel Certificate. Such increase in Base Rent shall in no event constitute a waiver of Lessee's Default or Breach with respect to the failure to provide the Estoppel Certificate nor prevent the exercise of any of the other rights and remedies granted hereunder.   (c)       If Lessor desires to finance, refinance, or sell the Premises, or any part thereof, Lessee and all Guarantors shall within 10 days after written notice from Lessor deliver to any potential lender or purchaser designated by Lessor such financial statements as may be reasonably required by such lender or purchaser, including but not limited to Lessee's financial statements for the past 3 years. All such financial statements shall be received by Lessor and such lender or purchaser in confidence and shall be used only for the purposes herein set forth.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 11 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">17.       Definition of Lessor. The term &quot;Lessor&quot; as used herein shall mean the owner or owners at the time in question of the fee title to the Premises, or, if this is a sublease, of the Lessee's interest in the prior lease. In the event of a transfer of Lessor's title or interest in the Premises or this Lease, Lessor shall deliver to the transferee or assignee (in cash or by credit) any unused Security Deposit held by Lessor. Upon such transfer or assignment and delivery of the Security Deposit, as aforesaid, the prior Lessor shall be relieved of all liability with respect to the obligations and/or covenants under this Lease thereafter to be performed by the Lessor. Subject to the foregoing, the obligations and/or covenants in this Lease to be performed by the Lessor shall be binding only upon the Lessor as hereinabove defined.   18.       Severability. The invalidity of any provision of this Lease, as determined by a court of competent jurisdiction, shall in no way affect the validity of any other provision hereof.   19.          Days. Unless otherwise specifically indicated to the contrary, the word &quot;days&quot; as used in this Lease shall mean and refer to calendar days.   20.       Limitation on Liability. The obligations of Lessor under this Lease shall not constitute personal obligations of Lessor, or its partners, members, directors, officers or shareholders, and Lessee shall look to the Premises, and to no other assets of Lessor, for the satisfaction of any liability of Lessor with respect to this Lease, and shall not seek recourse against Lessor's partners, members, directors, officers or shareholders, or any of their personal assets for such satisfaction.   21.         Time of Essence. Time is of the essence with respect to the performance of all obligations to be performed or observed by the Parties under this Lease.   22.       No Prior or Other Agreements; Broker Disclaimer. This Lease contains all agreements between the Parties with respect to any matter mentioned herein, and no other prior or contemporaneous agreement or understanding shall be effective. Lessor and Lessee each represents and warrants to the Brokers that it has made, and is relying solely upon, its own investigation as to the nature, quality, character and financial responsibility of the other Party to this Lease and as to the use, nature, quality and character of the Premises. Brokers have no responsibility with respect thereto or with respect to any default or breach hereof by either Party.   23.         Notices.   23.1   Notice Requirements. All notices required or permitted by this Lease or applicable law shall be in writing and may be delivered in person (by hand or by courier) or may be sent by regular, certified or registered mail or U.S. Postal Service Express Mail, with postage prepaid, or by facsimile transmission, or by email, and shall be deemed sufficiently given if served in a manner specified in this Paragraph 23. The addresses noted adjacent to a Party's signature on this Lease shall be that Party's address for delivery or mailing of notices. Either Party may by written notice to the other specify a different address for notice, except that upon Lessee's taking possession of the Premises, the Premises shall constitute Lessee's address for notice. A copy of all notices to Lessor shall be concurrently transmitted to such party or parties at such addresses as Lessor may from time to time hereafter designate in writing.   23.2   Date of Notice. Any notice sent by registered or certified mail, return receipt requested, shall be deemed given on the date of delivery shown on the receipt card, or if no delivery date is shown, the postmark thereon. If sent by regular mail the notice shall be deemed given 72 hours after the same is addressed as required herein and mailed with postage prepaid. Notices delivered by United States Express Mail or overnight courier that guarantees next day delivery shall be deemed given 24 hours after delivery of the same to the Postal Service or courier. Notices delivered by hand, or transmitted by facsimile transmission or by email shall be deemed delivered upon actual receipt. If notice is received on a Saturday, Sunday or legal holiday, it shall be deemed received on the next business day. 23.3   Options. Notwithstanding the foregoing, in order to exercise any Options (see paragraph 39), the Notice must be sent by Certified Mail (return receipt requested), Express Mail (signature required), courier (signature required) or some other methodology that provides a receipt establishing the date the notice was received by the Lessor.   24.         Waivers.   (a)    No waiver by Lessor of the Default or Breach of any term, covenant or condition hereof by Lessee, shall be deemed a waiver of any other term, covenant or condition hereof, or of any subsequent Default or Breach by Lessee of the same or of any other term, covenant or condition hereof. Lessor's consent to, or approval of, any act shall not be deemed to render unnecessary the obtaining of Lessor's consent to, or approval of, any subsequent or similar act by Lessee, or be construed as the basis of an estoppel to enforce the provision or provisions of this Lease requiring such consent.   (b)    The acceptance of Rent by Lessor shall not be a waiver of any Default or Breach by Lessee. Any payment by Lessee may be accepted by Lessor on account of monies or damages due Lessor, notwithstanding any qualifying statements or conditions made by Lessee in connection therewith, which such statements and/or conditions shall be of no force or effect whatsoever unless specifically agreed to in writing by Lessor at or before the time of deposit of such payment. (c)    THE PARTIES AGREE THAT THE TERMS OF THIS LEASE SHALL GOVERN WITH REGARD TO ALL MATTERS RELATED THERETO AND HEREBY WAIVE THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE TO THE EXTENT THAT SUCH STATUTE IS INCONSISTENT WITH THIS LEASE.   25.         Disclosures Regarding The Nature of a Real Estate Agency Relationship.   (a)    When entering into a discussion with a real estate agent regarding a real estate transaction, a Lessor or Lessee should from the outset understand what type of agency relationship or representation it has with the agent or agents in the transaction. Lessor and Lessee acknowledge being advised by the Brokers in this transaction, as follows: (i)     Lessor's Agent. A Lessor's agent under a listing agreement with the Lessor acts as the agent for the Lessor only. A Lessor's agent or subagent has the following affirmative obligations: To the Lessor: A fiduciary duty of utmost care, integrity, honesty, and loyalty in dealings with the Lessor. To the Lessee and the Lessor: (a) Diligent exercise of reasonable skills and care in performance of the agent's duties. (b) A duty of honest and fair dealing and good faith. (c) A duty to disclose all facts known to the agent materially affecting the value or desirability of the property that are not known to, or within the diligent attention and observation of, the Parties. An agent is not obligated to reveal to either Party any confidential information obtained from the other Party which does not involve the affirmative duties set forth above.   (ii)     Lessee's Agent. An agent can agree to act as agent for the Lessee only. In these situations, the agent is not the Lessor's agent, even if by agreement the agent may receive compensation for services rendered, either in full or in part from the Lessor. An agent acting only for a Lessee has the following affirmative obligations. To the Lessee: A fiduciary duty of utmost care, integrity, honesty, and loyalty in dealings with the Lessee. To the Lessee and the Lessor: (a) Diligent exercise of reasonable skills and care in performance of the agent's duties.  (b) A duty of honest and fair dealing and good faith. (c) A duty to disclose all facts known to the agent materially affecting the value or desirability of the property that are not known to, or within the diligent attention and observation of, the Parties. An agent is not obligated to reveal to either Party any confidential information obtained from the other Party which does not involve the affirmative duties set forth above. (iii)      Agent Representing Both Lessor and Lessee. A real estate agent, either acting directly or through one or more associate licensees, can legally be the agent of both the Lessor and the Lessee in a transaction, but only with the knowledge and consent of both the Lessor and the Lessee. In a dual agency situation, the agent has the following affirmative obligations to both the Lessor and the Lessee: (a) A fiduciary duty of utmost care, integrity, honesty and loyalty in the dealings with either Lessor or the Lessee. (b) Other duties to the Lessor and the Lessee as stated above in subparagraphs (i) or (ii). In representing both Lessor and Lessee, the agent may not, without the express permission of the respective Party, disclose to the other Party confidential information, including, but not limited to, facts relating to either Lessee's or Lessor's financial position, motivations, bargaining position, or other personal information that may impact rent, including Lessor's willingness to accept a rent less than the listing rent or Lessee's willingness to pay rent greater than the rent offered. The above duties of the agent in a real estate transaction do not relieve a Lessor or Lessee from the responsibility to protect their own interests. Lessor and Lessee should carefully read all agreements to assure that they adequately express their understanding of the transaction.  A real estate agent is a person qualified to advise about real estate. If legal or tax advice is desired, consult a competent professional. Both Lessor and Lessee should strongly consider obtaining tax advice from a competent professional because the federal and state tax consequences of a transaction can be complex and subject to change.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 12 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee013.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee013.jpg" title="slide13" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">(b)    Brokers have no responsibility with respect to any default or breach hereof by either Party. The Parties agree that no lawsuit or other legal proceeding involving any breach of duty, error or omission relating to this Lease may be brought against Broker more than one year after the Start Date and that the liability (including court costs and attorneys' fees), of any Broker with respect to any such lawsuit and/or legal proceeding shall not exceed the fee received by such Broker pursuant to this Lease; provided, however, that the foregoing limitation on each Broker's liability shall not be applicable to any gross negligence or willful misconduct of such Broker.   (c)    Lessor and Lessee agree to identify to Brokers as &quot;Confidential&quot; any communication or information given Brokers that is considered by such Party to be confidential.   26.       No Right To Holdover. Lessee has no right to retain possession of the Premises or any part thereof beyond the expiration or termination of this Lease. At or prior to the expiration or termination of this Lease Lessee shall deliver exclusive possession of the Premises to Lessor. For purposes of this provision and Paragraph 13.1(a), exclusive possession shall mean that Lessee shall have vacated the Premises, removed all of its personal property therefrom and that the Premises have been returned in the condition specified in this Lease. In the event that Lessee does not deliver exclusive possession to Lessor as specified above, then Lessor's damages during any holdover period shall be computed at the amount of the Rent (as defined in Paragraph 4.1) due during the last full month before the expiration or termination of this Lease (disregarding any temporary abatement of Rent that may have been in effect), but with Base Rent being 150% of the Base Rent payable during such last full month. Nothing contained herein shall be construed as consent by Lessor to any holding over by Lessee.   27.       Cumulative Remedies. No remedy or election hereunder shall be deemed exclusive but shall, wherever possible, be cumulative with all other remedies at law or in equity.   28.       Covenants and Conditions; Construction of Agreement. All provisions of this Lease to be observed or performed by Lessee are both covenants and conditions. In construing this Lease, all headings and titles are for the convenience of the Parties only and shall not be considered a part of this Lease. Whenever required by the context, the singular shall include the plural and vice versa. This Lease shall not be construed as if prepared by one of the Parties, but rather according to its fair meaning as a whole, as if both Parties had prepared it.   29.      Binding Effect; Choice of Law. This Lease shall be binding upon the Parties, their personal representatives, successors and assigns and be governed by the laws of the State in which the Premises are located. Any litigation between the Parties hereto concerning this Lease shall be initiated in the county in which the Premises are located. Signatures to this Lease accomplished by means of electronic signature or similar technology shall be legal and binding.   30.         Subordination; Attornment; Non&#8208;Disturbance. 30.1   Subordination. This Lease and any Option granted hereby shall be subject and subordinate to any ground lease, mortgage, deed of trust, or other hypothecation or security device (collectively, &quot;Security Device&quot;), now or hereafter placed upon the Premises, to any and all advances made on the security thereof, and to all renewals, modifications, and extensions thereof. Lessee agrees that the holders of any such Security Devices (in this Lease together referred to as &quot;Lender&quot;) shall have no liability or obligation to perform any of the obligations of Lessor under this Lease. Any Lender may elect to have this Lease and/or any Option granted hereby superior to the lien of its Security Device by giving written notice thereof to Lessee, whereupon this Lease and such Options shall be deemed prior to such Security Device, notwithstanding the relative dates of the documentation or recordation thereof. 30.2   Attornment. In the event that Lessor transfers title to the Premises, or the Premises are acquired by another upon the foreclosure or termination of a Security Device to which this Lease is subordinated (i) Lessee shall, subject to the non&#8208;disturbance provisions of Paragraph 30.3, attorn to such new owner, and upon request, enter into a new lease, containing all of the terms and provisions of this Lease, with such new owner for the remainder of the term hereof, or, at the election of the new owner, this Lease will automatically become a new lease between Lessee and such new owner, and (ii) Lessor shall thereafter be relieved of any further obligations hereunder and such new owner shall assume all of Lessor's obligations, except that such new owner shall not: (a) be liable for any act or omission of any prior lessor or with respect to events occurring prior to acquisition of ownership; (b) be subject to any offsets or defenses which Lessee might have against any prior lessor, (c) be bound by prepayment of more than one month's rent, or (d) be liable for the return of any security deposit paid to any prior lessor which was not paid or credited to such new owner. 30.3   Non&#8208;Disturbance. With respect to Security Devices entered into by Lessor after the execution of this Lease, Lessee's subordination of this Lease shall be subject to receiving a commercially reasonable non&#8208;disturbance agreement (a &quot;Non&#8208;Disturbance Agreement&quot;) from the Lender which Non&#8208;Disturbance Agreement provides that Lessee's possession of the Premises, and this Lease, including any options to extend the term hereof, will not be disturbed so long as Lessee is not in Breach hereof and attorns to the record owner of the Premises. Further, within 60 days after the execution of this Lease, Lessor shall, if requested by Lessee, use its commercially reasonable efforts to obtain a Non&#8208;Disturbance Agreement from the holder of any pre&#8208;existing Security Device which is secured by the Premises. In the event that Lessor is unable to provide the Non&#8208;Disturbance Agreement within said 60 days, then Lessee may, at Lessee's option, directly contact Lender and attempt to negotiate for the execution and delivery of a Non&#8208;Disturbance Agreement. 30.4   Self&#8208;Executing. The agreements contained in this Paragraph 30 shall be effective without the execution of any further documents; provided, however, that, upon written request from Lessor or a Lender in connection with a sale, financing or refinancing of the Premises, Lessee and Lessor shall execute such further writings as may be reasonably required to separately document any subordination, attornment and/or Non&#8208;Disturbance Agreement provided for herein.   31.         Attorneys' Fees. If any Party or Broker brings an action or proceeding involving the Premises whether founded in tort, contract or equity, or to declare rights hereunder, the Prevailing Party (as hereafter defined) in any such proceeding, action, or appeal thereon, shall be entitled to reasonable attorneys' fees. Such fees may be awarded in the same suit or recovered in a separate suit, whether or not such action or proceeding is pursued to decision or judgment. The term, &quot;Prevailing Party&quot; shall include, without limitation, a Party or Broker who substantially obtains or defeats the relief sought, as the case may be, whether by compromise, settlement, judgment, or the abandonment by the other Party or Broker of its claim or defense. The attorneys' fees award shall not be computed in accordance with any court fee schedule, but shall be such as to fully reimburse all attorneys' fees reasonably incurred. In addition, Lessor shall be entitled to attorneys' fees, costs and expenses incurred in the preparation and service of notices of Default and consultations in connection therewith, whether or not a legal action is subsequently commenced in connection with such Default or resulting Breach ($200 is a reasonable minimum per occurrence for such services and consultation).       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 13 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee014.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee014.jpg" title="slide14" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">32.       Lessor's Access; Showing Premises; Repairs. Lessor and Lessor's agents shall have the right to enter the Premises at any time, in the case of an emergency, and otherwise at reasonable times after reasonable prior notice for the purpose of showing the same to prospective purchasers, lenders, or tenants, and making such alterations, repairs, improvements or additions to the Premises as Lessor may deem necessary or desirable and the erecting, using and maintaining of utilities, services, pipes and conduits through the Premises and/or other premises as long as there is no material adverse effect on Lessee's use of the Premises. All such activities shall be without abatement of rent or liability to Lessee.   33.       Auctions. Lessee shall not conduct, nor permit to be conducted, any auction upon the Premises without Lessor's prior written consent. Lessor shall not be obligated to exercise any standard of reasonableness in determining whether to permit an auction.   34.       Signs. Lessor may place on the Premises ordinary &quot;For Sale&quot; signs at any time and ordinary &quot;For Lease&quot; signs during the last 6 months of the term hereof. Except for ordinary &quot;for sublease&quot; signs, Lessee shall not place any sign upon the Premises without Lessor's prior written consent. All signs must comply with all Applicable Requirements.   35.       Termination; Merger. Unless specifically stated otherwise in writing by Lessor, the voluntary or other surrender of this Lease by Lessee, the mutual termination or cancellation hereof, or a termination hereof by Lessor for Breach by Lessee, shall automatically terminate any sublease or lesser estate in the Premises; provided, however, that Lessor may elect to continue any one or all existing subtenancies. Lessor's failure within 10 days following any such event to elect to the contrary by written notice to the holder of any such lesser interest, shall constitute Lessor's election to have such event constitute the termination of such interest.   36.       Consents. All requests for consent shall be in writing. Except as otherwise provided herein, wherever in this Lease the consent of a Party is required to an act by or for the other Party, such consent shall not be unreasonably withheld or delayed. Lessor's actual reasonable costs and expenses (including but not limited to architects', attorneys', engineers' and other consultants' fees) incurred in the consideration of, or response to, a request by Lessee for any Lessor consent, including but not limited to consents to an assignment, a subletting or the presence or use of a Hazardous Substance, shall be paid by Lessee upon receipt of an invoice and supporting documentation therefor. Lessor's consent to any act, assignment or subletting shall not constitute an acknowledgment that no Default or Breach by Lessee of this Lease exists, nor shall such consent be deemed a waiver of any then existing Default or Breach, except as may be otherwise specifically stated in writing by Lessor at the time of such consent. The failure to specify herein any particular condition to Lessor's consent shall not preclude the imposition by Lessor at the time of consent of such further or other conditions as are then reasonable with reference to the particular matter for which consent is being given. In the event that either Party disagrees with any determination made by the other hereunder and reasonably requests the reasons for such determination, the determining party shall furnish its reasons in writing and in reasonable detail within 10 business days following such request.   37.         Guarantor. 37.1  Execution. The Guarantors, if any, shall each execute a guaranty in the form most recently published by AIR CRE, and each such Guarantor shall have the same obligations as Lessee under this Lease. 37.2  Default. It shall constitute a Default of the Lessee if any Guarantor fails or refuses, upon request to provide: (a) evidence of the execution of the guaranty, including the authority of the party signing on Guarantor's behalf to obligate Guarantor, and in the case of a corporate Guarantor, a certified copy of a resolution of its board of directors authorizing the making of such guaranty, (b) current financial statements, (c) an Estoppel Certificate, or (d) written confirmation that the guaranty is still in effect.   38.       Quiet Possession. Subject to payment by Lessee of the Rent and performance of all of the covenants, conditions and provisions on Lessee's part to be observed and performed under this Lease, Lessee shall have quiet possession and quiet enjoyment of the Premises during the term hereof.   39.         Options. If Lessee is granted any Option, as defined below, then the following provisions shall apply. 39.1   Definition. &quot;Option&quot; shall mean: (a) the right to extend or reduce the term of or renew this Lease or to extend or reduce the term of or renew any lease that Lessee has on other property of Lessor; (b) the right of first refusal or first offer to lease either the Premises or other property of Lessor; (c) the right to purchase, the right of first offer to purchase or the right of first refusal to purchase the Premises or other property of Lessor.   39.2   Options Personal To Original Lessee. Any Option granted to Lessee in this Lease is personal to the original Lessee, and cannot be assigned or exercised by anyone other than said original Lessee and only while the original Lessee is in full possession of the Premises and, if requested by Lessor, with Lessee certifying that Lessee has no intention of thereafter assigning or subletting. 39.3   Multiple Options. In the event that Lessee has any multiple Options to extend or renew this Lease, a later Option cannot be exercised unless the prior Options have been validly exercised. 39.4    Effect of Default on Options. (a)    Lessee shall have no right to exercise an Option: (i) during the period commencing with the giving of any notice of Default and continuing until said Default is cured, (ii) during the period of time any Rent is unpaid (without regard to whether notice thereof is given Lessee), (iii) during the time Lessee is in Breach of this Lease, or (iv) in the event that Lessee has been given 3 or more notices of separate Default, whether or not the Defaults are cured, during the 12 month period immediately preceding the exercise of the Option.   (b)    The period of time within which an Option may be exercised shall not be extended or enlarged by reason of Lessee's inability to exercise an Option because of the provisions of Paragraph 39.4(a). (c)    An Option shall terminate and be of no further force or effect, notwithstanding Lessee's due and timely exercise of the Option, if, after such exercise and prior to the commencement of the extended term or completion of the purchase, (i) Lessee fails to pay Rent for a period of 30 days after such Rent becomes due (without any necessity of Lessor to give notice thereof), or (ii) if Lessee commits a Breach of this Lease.   40.       Multiple Buildings. If the Premises are a part of a group of buildings controlled by Lessor, Lessee agrees that it will abide by and conform to all reasonable rules and regulations which Lessor may make from time to time for the management, safety, and care of said properties, including the care and cleanliness of the grounds and including the parking, loading and unloading of vehicles, and to cause its employees, suppliers, shippers, customers, contractors and invitees to so abide and conform. Lessee also agrees to pay its fair share of common expenses incurred in connection with such rules and regulations.   41.       Security Measures. Lessee hereby acknowledges that the Rent payable to Lessor hereunder does not include the cost of guard service or other security measures, and that Lessor shall have no obligation whatsoever to provide same. Lessee assumes all responsibility for the protection of the Premises, Lessee, its agents and invitees and their property from the acts of third parties.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 14 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee015.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee015.jpg" title="slide15" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">42.       Reservations. Lessor reserves to itself the right, from time to time, to grant, without the consent or joinder of Lessee, such easements, rights and dedications that Lessor deems necessary, and to cause the recordation of parcel maps and restrictions, so long as such easements, rights, dedications, maps and restrictions do not unreasonably interfere with the use of the Premises by Lessee. Lessee agrees to sign any documents reasonably requested by Lessor to effectuate any such easement rights, dedication, map or restrictions.   43.       Performance Under Protest. If at any time a dispute shall arise as to any amount or sum of money to be paid by one Party to the other under the provisions hereof, the Party against whom the obligation to pay the money is asserted shall have the right to make payment &quot;under protest&quot; and such payment shall not be regarded as a voluntary payment and there shall survive the right on the part of said Party to institute suit for recovery of such sum. If it shall be adjudged that there was no legal obligation on the part of said Party to pay such sum or any part thereof, said Party shall be entitled to recover such sum or so much thereof as it was not legally required to pay. A Party who does not initiate suit for the recovery of sums paid &quot;under protest&quot; within 6 months shall be deemed to have waived its right to protest such payment.   44.         Authority; Multiple Parties; Execution.   (a)    If either Party hereto is a corporation, trust, limited liability company, partnership, or similar entity, each individual executing this Lease on behalf of such entity represents and warrants that he or she is duly authorized to execute and deliver this Lease on its behalf. Each Party shall, within 30 days after request, deliver to the other Party satisfactory evidence of such authority. (b)    If this Lease is executed by more than one person or entity as &quot;Lessee&quot;, each such person or entity shall be jointly and severally liable hereunder. It is agreed that any one of the named Lessees shall be empowered to execute any amendment to this Lease, or other document ancillary thereto and bind all of the named Lessees, and Lessor may rely on the same as if all of the named Lessees had executed such document. (c)    This Lease may be executed by the Parties in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.   45.       Conflict. Any conflict between the printed provisions of this Lease and the typewritten or handwritten provisions shall be controlled by the typewritten or handwritten provisions.   46.       Offer. Preparation of this Lease by either Party or their agent and submission of same to the other Party shall not be deemed an offer to lease to the other Party. This Lease is not intended to be binding until executed and delivered by all Parties hereto.   47.       Amendments. This Lease may be modified only in writing, signed by the Parties in interest at the time of the modification. As long as they do not materially change Lessee's obligations hereunder, Lessee agrees to make such reasonable non&#8208;monetary modifications to this Lease as may be reasonably required by a Lender in connection with the obtaining of normal financing or refinancing of the Premises.   48.       Waiver of Jury Trial. THE PARTIES HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING INVOLVING THE PROPERTY OR ARISING OUT OF THIS LEASE.   49.       Arbitration of Disputes. An Addendum requiring the Arbitration of all disputes between the Parties and/or Brokers arising out of this Lease          is           is not attached to this Lease. 50.         Accessibility; Americans with Disabilities Act. (a)      The Premises:   &#9744; have not undergone an inspection by a Certified Access Specialist (CASp). Note: A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction&#8208;related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction&#8208;related accessibility standards within the premises.   &#9744; have undergone an inspection by a Certified Access Specialist (CASp) and it was determined that the Premises met all applicable construction&#8208;related accessibility standards pursuant to California Civil Code &sect;55.51 et seq. Lessee acknowledges that it received a copy of the inspection report at least 48 hours prior to executing this Lease and agrees to keep such report confidential.   &#9744; have undergone an inspection by a Certified Access Specialist (CASp) and it was determined that the Premises did not meet all applicable construction&#8208;related accessibility standards pursuant to California Civil Code &sect;55.51 et seq. Lessee acknowledges that it received a copy of the inspection report at least 48 hours prior to executing this Lease and agrees to keep such report confidential except as necessary to complete repairs and corrections of violations of construction related accessibility standards.   In the event that the Premises have been issued an inspection report by a CASp the Lessor shall provide a copy of the disability access inspection certificate to Lessee within 7 days of the execution of this Lease.   (b)    Since compliance with the Americans with Disabilities Act (ADA) and other state and local accessibility statutes are dependent upon Lessee's specific use of the Premises, Lessor makes no warranty or representation as to whether or not the Premises comply with ADA or any similar legislation. In the event that Lessee's use of the Premises requires modifications or additions to the Premises in order to be in compliance with ADA or other accessibility statutes, Lessee agrees to make any such necessary modifications and/or additions at Lessee's expense.   LESSOR AND LESSEE HAVE CAREFULLY READ AND REVIEWED THIS LEASE AND EACH TERM AND PROVISION CONTAINED HEREIN, AND BY THE EXECUTION OF THIS LEASE SHOW THEIR INFORMED AND VOLUNTARY CONSENT THERETO. THE PARTIES HEREBY AGREE THAT, AT THE TIME THIS LEASE IS EXECUTED, THE TERMS OF THIS LEASE ARE COMMERCIALLY REASONABLE AND EFFECTUATE THE INTENT AND PURPOSE OF LESSOR AND LESSEE WITH RESPECT TO THE PREMISES.   ATTENTION: NO REPRESENTATION OR RECOMMENDATION IS MADE BY AIR CRE OR BY ANY BROKER AS TO THE LEGAL SUFFICIENCY, LEGAL EFFECT, OR TAX CONSEQUENCES OF THIS LEASE OR THE TRANSACTION TO WHICH IT RELATES. THE PARTIES ARE URGED TO:   1.     SEEK ADVICE OF COUNSEL AS TO THE LEGAL AND TAX CONSEQUENCES OF THIS LEASE. 2.     RETAIN APPROPRIATE CONSULTANTS TO REVIEW AND INVESTIGATE THE CONDITION OF THE PREMISES. SAID INVESTIGATION SHOULD INCLUDE BUT NOT BE         INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 15 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee016.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee016.jpg" title="slide16" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">LIMITED TO: THE POSSIBLE PRESENCE OF HAZARDOUS SUBSTANCES, THE ZONING OF THE PREMISES, THE STRUCTURAL INTEGRITY, THE CONDITION OF THE ROOF AND OPERATING SYSTEMS, AND THE SUITABILITY OF THE PREMISES FOR LESSEE'S INTENDED USE.   WARNING: IF THE PREMISES ARE LOCATED IN A STATE OTHER THAN CALIFORNIA, CERTAIN PROVISIONS OF THE LEASE MAY NEED TO BE REVISED TO COMPLY WITH THE LAWS OF THE STATE IN WHICH THE PREMISES ARE LOCATED.   The parties hereto have executed this Lease at the place and on the dates specified above their respective signatures. Executed at: 11:00 AM  Executed at: San Diego, CA On: 12/30/2021  On: 12/30/2021     By LESSOR:  By LESSEE: 6777 Nancy Ridge LLC  Bionano Genomics     By: /s/ David Odmark  By: /s/ Chris Stewart Name Printed: David Odmark  Name Printed: Chris Stewart Title: Managing Director  Title: CFO Phone:                   Phone: Fax:                  Fax: Email:                  Email:     By:   By:   Name Printed:                  Name Printed:                  Title:                  Title:                 Phone:                  Phone:                  Fax:                  Fax:                  Email:                  Email:                      Address:                  Address:                  Federal ID No.:                  Federal ID No.:                      BROKER  BROKER   N/A       N/A        Attn:    N/A  Attn: N/A Title:                  Title:                      Address:                  Address:                  Phone:                  Phone:                  Fax:                  Fax:                  Email:                  Email:                  Federal ID No.:                  Federal ID No.:                  Broker DRE License #: N/A  Broker DRE License #: N/A Agent DRE License #: N/A  Agent DRE License #: N/A AIR CRE * https://www.aircre.com * 213&#8208;687&#8208;8777 * contracts@aircre.com NOTICE: No part of these works may be reproduced in any form without permission in writing.       INITIALS INITIALS &copy; 2019 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM STN&#8208;27.30, Revised 10&#8208;22&#8208;2020 Page 16 of 16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee017.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee017.jpg" title="slide17" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  OPTION(S) TO EXTEND TERM   STANDARD LEASE ADDENDUM   Dated:          November 23, 2021 By and Between Lessor:          6777 Nancy Ridge LLC Lessee:          Bionano Genomics Property Address:          6777 Nancy Ridge Drive, San Diego, CA 92121 (street address, city, state, zip) Paragraph:               OPTION(S) TO EXTEND TERM. Subject to the terms, conditions and provisions of Paragraph 39, Lessor grants Lessee    1    option(s) to extend the term of the Lease (&quot;Extension Option(s)&quot;), with each Extension Option being for a term of  36 months, commencing when the prior term expires (&quot;Option Term(s)&quot;). In order to exercise an Extension Option, Lessee must give written notice of such election to Lessor and Lessor must receive such notice at least   9     but not more than    12   months prior to the date that the applicable Option Term would commence, time being of the essence. If timely and proper notification of the exercise of an Extension Option is not given by Lessee and/or received by Lessor, such Extension Option shall automatically expire. Except as specifically modified, the terms, conditions and provisions of the Lease shall apply during Option Terms but the amount of Rent during Option Terms shall be established by using the method(s) selected below (check method(s) to be used and fill in appropriately): &#9744;    I.      Consumer Price Index.   (a)    During the Option Term(s) which start(s) on                       , the monthly Base Rent shall be increased on                    and every                  months thereafter during such Option Term(s) (&quot;Option Term CPI Increase Date(s)&quot;) commensurate with the increase in the Option Term CPI (as herein defined) determined as follows: the monthly Base Rent scheduled for the month immediately preceding the first occurring Option Term CPI Increase Date shall be multiplied by a fraction the denominator of which is the Option Term Base CPI (as herein defined), and the numerator of which is the Option Term Comparison CPI (as herein defined). The amount so calculated shall constitute the new Base Rent until the next Option Term CPI Increase Date during the applicable Option Term, but in no event shall any such new Base Rent be less than the Base Rent for the month immediately preceding the applicable Option Term CPI Increase Date.   (b)      The term &quot;Option Term CPI&quot; shall mean the Consumer Price Index of the Bureau of Labor Statistics of the U.S. Department of Labor for (select one): CPI W (Urban Wage Earners and Clerical Workers) or          CPI U (All Urban Consumers), for (fill in Urban Area):          or          the area in which the Premises is located, All Items (1982&#8208;1984 = 100). The term &quot;Option Term Comparison CPI&quot; shall mean the CPI of the calendar month which is 2 full months prior to the applicable Option Term CPI Increase Date. The term &quot;Option Term Base CPI&quot; shall mean the CPI of the calendar month which is 2 full months prior to (select one): Commencement Date of the Original Term,          start of the applicable Option Term, or          (fill in month)                       . (c)       If compilation and/or publication of the CPI is transferred to another governmental department, bureau or agency or is discontinued, then instead the index most nearly the same as the CPI shall be used to calculate the Base Rent increases hereunder. If the Parties cannot agree on such alternative index, then the matter shall be submitted for decision to the American Arbitration Association in accordance with the then rules of said association and the decision of the arbitrators shall be binding upon the parties, with the cost of such arbitration being paid equally by the Parties.   &#9744;   II.     Fixed Percentage. During the Option Term(s) which start(s) on                    , the monthly Base Rent shall be increased on                      and every                      months thereafter during such Option Term(s) (&quot;Option Term Percentage Increase Date(s)&quot;) by                       percent (                        %) of the monthly Base Rent scheduled to be paid for the month immediately preceding the applicable Option Term Percentage Increase Date. &#9745;   III.   Fair Market Value. (a)     During the Option Term(s) which start(s) on February 1, 2026 , the amount of Rent shall be the amount forecasted to be the fair market rental value of the Premises during such Option Term established pursuant to the procedures, terms, assumptions and conditions set forth herein (&quot;Fair Market Value&quot;); provided, however, regardless of such Fair Market Value, Base Rent during an Option Term shall not be less than the Base Rent scheduled as of when the prior term expires. Starting as of Lessee's exercise of the applicable Extension Option (but not earlier than six (6) months before start of the applicable Option Term), the Parties shall for thirty (30) days (&quot;Negotiation Period&quot;) attempt to agree upon the Fair Market Value. If during the Negotiation Period the Parties do not agree on the Fair Market Value, then the Fair Market Value shall be established pursuant to the procedures set forth herein, which shall be binding. (b)     Each Party shall, within fifteen (15) days after the end of the Negotiation Period, in writing submit to the other Party such Party's determination of the Fair Market Value (&quot;Submitted Value(s)&quot;). If a Party fails to timely provide a Submitted Value, then the other Party's Submitted Value shall be the Fair Market Value. If both Parties timely provide Submitted Values, then each Party shall, within fifteen (15) days after both Parties have exchanged Submitted Values, in writing notify the other Party of such Party's selected arbitrator who shall meet the qualifications set forth herein (&quot;Advocate Arbitrator(s)&quot;). Lessor and Lessee may select an Advocate Arbitrator who is favorable to such Party's position and may, prior to or after appointment of an Advocate Arbitrator, consult with such Party's Advocate Arbitrator. If a Party fails to timely and properly provide notice of such Party's chosen Advocate Arbitrator, then the other Party's Submitted Value shall be the Fair Market Value. (c)       If both Parties timely and properly designate Advocate Arbitrators, then such Advocate Arbitrators shall, within fifteen (15) days after their selection, choose a third (3rd) neutral arbitrator who shall meet the qualifications set forth herein (&quot;Neutral Arbitrator&quot;). The Neutral Arbitrator shall be engaged jointly by Lessor and Lessee. If Advocate Arbitrators fail to agree upon and timely appoint a Neutral Arbitrator, then the President of AIR CRE shall appoint such Neutral Arbitrator within fifteen (15) days after request by either Party. If the President of AIR CRE does not timely appoint the Neutral Arbitrator, then either Party may file an appropriate legal action for a judge with competent jurisdiction over the Parties to appoint the Neutral Arbitrator.       INITIALS INITIALS &copy; 2017 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM OE&#8208;7.00, Revised 11&#8208;05&#8208;2021 Page 1 of 2 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee018.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee018.jpg" title="slide18" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">(d)     The Advocate Arbitrators and the Neutral Arbitrator (&quot;Arbitrator(s)&quot;) shall be duly licensed real estate brokers or salespersons in good standing in the state in which the Premises is located, shall have been active over the five (5) year period before their appointment in the leasing of properties similar to the Premises within the general real estate market of the Premises. The Neutral Arbitrator shall additionally not be related to or affiliated with either Party or Advocate Arbitrator, and shall not have previously represented in a real estate transaction a Party or anyone related to or affiliated with a Party. All matters to be determined by the Arbitrators shall be decided by a majority vote of the Arbitrators, with each Arbitrator having one (1) vote. The Arbitrators may, as the Arbitrators determine, hold hearings and require briefs, including market data and additional information.   (e)     Within thirty (30) days after selection of the Neutral Arbitrator, the three Arbitrators shall first reach a decision as to their own independent opinion of the Fair Market Value established by taking into account the terms, assumptions and conditions set forth herein (&quot;Arbitrators' Market Value&quot;), then decide which Party's Submitted Value is closer in monetary amount to the Arbitrators' Market Value (&quot;Selected Market Value&quot;), then provide the Parties a copy of the Arbitrators' Market Value and finally notify the Parties of the Selected Market Value. The Selected Market Value shall be the Fair Market Value. The Arbitrators shall have no right to decide a Selected Market Value which is a compromise to (or modification of) the Submitted Values. The decision of the Arbitrators shall be binding upon the Parties. The Party whose Submitted Value is not the Selected Market Value shall, within ten (10) days after the Arbitrators decide the Selected Market Value, pay the fees and costs of all three (3) Arbitrators. (f)     If the Fair Market Value has not been established before the start of the applicable Option Term, then Lessee shall continue to pay to Lessor rent in the amount payable for the month immediately preceding the start of such Option Term and Lessor's acceptance of such rent shall not waive, adversely affect or prejudice the Parties' right to complete establishment of the Fair Market Value or Lessor's right to collect the full amount of the Fair Market Value once the Fair Market Value is established. Lessee shall, within ten (10) days after establishment of the Fair Market Value, pay to Lessor any deficiency in rent then due for the Option Term. Following establishment of Fair Market Value, the Parties shall, within ten (10) days after request by either Party, sign an amendment to this Lease to confirm the Fair Market Value and the expiration date of this Lease, but the Parties' failure to request or to sign such an amendment shall not affect establishment of the Fair Market Value or extension of the Lease term. (g)       The Arbitrators, in deciding the Arbitrators' Market Value, shall take into account rent rates, rent abatements, periodic rent increases, real property taxes, insurance premiums and other operating expenses, tenant improvement and other applicable allowances, building services, length of lease term and other factors professional real estate brokers and/or appraisers customarily consider in determining fair market rent of property in an arm's length transaction by ready, willing and able parties for space of comparable location, size, age, condition, quality, parking, visibility, view, signage and accessibility if the Premises were marketed in a normal and customary manner for a reasonable length of time on the open market to be leased to a tenant with financial strength and credit worthiness comparable to Lessee and guarantors (if any) of this Lease (as of Lessee's exercise of the Extension Option) for a term comparable to the length of the applicable Option Term and used for the Agreed Use (or other reasonably comparable uses). The Arbitrators, in deciding the Arbitrators' Market Value, shall not consider as a comparable transaction any of the following: a sublease, lease assignment, lease renewal or extension; lease with a tenant that has equity, is related to or affiliated with the landlord; or a lease of space that was subject to a right of first refusal, right of first offer, expansion option or other encumbrances. The Arbitrators, in deciding the Arbitrators' Market Value, shall reduce the Fair Market Value on account of Alterations and improvements made by Lessee to the extent the cost thereof was paid solely by Lessee (in excess of any applicable improvement allowance, abated rent in lieu of improvement allowance or other consideration provided by Lessor for Lessee's improvement of the Premises), shall not reduce the Fair Market Value on account of any real estate brokerage commission savings by Lessor, and shall not reduce the Fair Market Value on account of deferred maintenance or repair of the Premises for which Lessee was responsible under the Lease but did not perform.   &#9744;    IV.   Fixed Rental Adjustment(s) (&quot;FRA&quot;). The monthly Base Rent shall be increased to the following amounts on the dates set forth below:   On (fill in FRA Adjustment Date(s)):  The new Base Rent shall be:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 &#9744;    V.    Continuation of Original Term Adjustments.   The monthly Base Rent during the Option Term(s) which start(s) on               shall be increased in accordance with the same formula provided in the Lease to be used to calculate increases in the Base Rent during the Original Term of the Lease.   BROKER'S FEE: For each adjustment in Base Rent specified above, the Brokers shall be paid a Brokerage Fee in accordance with paragraph 15 of the Lease or if applicable, paragraph 9 of the Sublease.   AIR CRE * https://www.aircre.com * 213&#8208;687&#8208;8777 * contracts@aircre.com NOTICE: No part of these works may be reproduced in any form without permission in writing.       INITIALS INITIALS &copy; 2017 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM OE&#8208;7.00, Revised 11&#8208;05&#8208;2021 Page 2 of 2 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- bionano-nancyridgeleasee019.jpg -->
<DIV style="padding-top:2em;">
<IMG src="bionano-nancyridgeleasee019.jpg" title="slide19" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  ADDENDUM TO LEASE   Date:      November 23, 2021 By and Between Lessor:    6777 Nancy Ridge LLC Lessee:    Bionano Genomics Property Address:   6777 Nancy Ridge Drive, San Diego, CA 92121 (street address, city, state, zip)   Paragraph:   1-5        1 . TENANT IMPROVEMENTS: Subject to the terms and condition hereof, Lessor agrees to provide $71,868.00 for interior build-out (&quot;Tenant Improvements&quot;) of the office and lab areas. Lessee has the right to use the allowance for other uses, at Lessee&#8217;s sole discretion, such as back-up generator, signage, IT and FF&amp;E.   2. BUILDING SIGNAGE/DIRECTORY BOARD: Lessee shall have the exclusive right to building top and monument signage. Lessee shall have the right to place its name and corporate logo on the signage outside the Premises and Building lobby. Lessee shall give Lessor the right to approve the design of any signage. Such approval shall not be unreasonably withheld or delayed. All costs associated with fabrication, installation, permitting, maintaining and eventual removal of said signage shall be the responsibility of Lessee. Such signage must conform to all applicable governmental rules, laws, and regulations.   3. ASSIGNMENT/SUBLEASE RIGHTS: Lessee shall have the right to sublease or assign all or any portion of the Premises to any Lessee related entity, subsidiary or successor of Lessee (&#8220;Affiliate&#8221;) without Lessor's consent, but by providing notice to Lessor. For non-affiliated companies, Lessor shall not unreasonably withhold, condition or delay the approval of any proposed sublease or assignment. Lessor shall not have a recapture right in the event of a sublease or assignment of less than sixty percent (60%) of the Premises. Any profits from a third-party sublease or assignment shall be split equally between Lessor and Lessee after Lessee's costs to sublease have been first deducted (including commissions, legal fees, tenant improvements, downtime during the marketing period, and any other concessions reasonable required to induce a subtenant). Lessor shall not have any recapture right in assignments or subleases to Lessee's Affiliates. In the event Lessee elects to sublease all or a portion of the Premises, Lessee shall not be precluded from marketing said sublease Premises to other tenants in the Building or Project. Additionally, there shall not be any floor/minimum rent that Lessee must obtain from any sublessee and/or assignee.   4. BACKUP GENERATOR: Subject to Lessor approval, which shall not be unreasonably conditioned, delayed or withheld, Lessee shall be able to install a generator in a location to be mutually agreed upon by Lessor and Lessee.   5 . HOLDING OVER: Lessee shall have the right to holdover for a period of up to three (3) months at a rental rate equal to 110% of Lessee's Base Rent during the last month of the Term. Thereafter, Lessee shall have the right to holdover on a month-to-month basis at a rental rate equal to 150% of the last month&#8217;s Base Rent.   6. HAZARDOUS SUBSTANCES: Notwithstanding anything to the contrary in this Lease, Lessee may use Hazardous Materials as reasonably necessary for the conduct of its business in the ordinary course, provided Lessee uses such Hazardous Materials in strict compliance with all Applicable Requirements.   7. PARKING: Lessee may use the parking areas adjacent to the Building during the Lease Term, at no additional cost.   In the event of any conflict between the provisions of this Addendum and the printed provisions of the Lease, this Addendum shall control.   AIR CRE * https://www.aircre.com * 213&#8208;687&#8208;8777 * contracts@aircre.com NOTICE: No part of these works may be reproduced in any form without permission in writing.         INITIALS INITIALS &copy; 2017 AIR CRE. All Rights Reserved. Last Edited: 12/20/2021 11:14 AM ADD&#8208;1.03, Revised 10&#8208;22&#8208;2020 Page 1 of 1 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>4
<FILENAME>bngo-ex1034_bionanoxkeyemp.htm
<DESCRIPTION>EX-10.34
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i14c83267444b41eea6cbb8a41eeef241_1"></div><div style="min-height:87.12pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.34</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Execution Version</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) is made and entered into by and between Bionano Genomics, Inc. (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Company&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and Soheil Shams (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Executive&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">). The Company and Executive are hereinafter collectively referred to as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Parties&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and individually referred to as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Concurrently with the execution and delivery of this Agreement, the Company&#59; Starship Merger Sub I, Inc., a California corporation and a wholly-owned subsidiary of Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Merger Sub I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; Starship Merger Sub II, LLC, a California limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Merger Sub II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; BioDiscovery, Inc., a California corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and Soheil Shams, as Securityholders&#8217; Representative, are entering into that certain Agreement and Plan of Merger (as amended, modified, or supplemented from time to time in accordance with its terms, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Merger Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Seller shall be acquired by the Company, by means of a merger of Merger Sub I with and into Seller, pursuant to which Seller will survive and become a wholly owned subsidiary of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Merger&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and, as part of the same overall transaction, promptly after Merger I, the surviving entity of Merger I will merge with and into Merger Sub II, with Merger Sub II surviving such merger (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Merger II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and, together with Merger I, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Mergers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), on the terms and subject to the conditions set forth in the Merger Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement and Executive&#8217;s employment hereunder are conditional upon the closing of the transactions contemplated in the Merger Agreement. This Agreement will become effective as of the Closing Date as defined in the Merger Agreement (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">). If the anticipated transactions contemplated in the Merger Agreement do not close, this Agreement will have no effect (even if it has been executed), will not be binding on the Company (or any of its affiliates) or on Executive, and neither Executive, the Company nor any of the Sellers (or any of their respective affiliates) shall have rights or obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company desires assurance of the association and services of Executive in order to retain Executive&#8217;s experience, skills, abilities, background and knowledge, and is willing to continue to the engagement of Executive&#8217;s services on the terms and conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive desires to be in the employ of the Company and is willing to accept employment on the terms and conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In consideration of the foregoing Recitals and mutual promises and covenants contained herein, and for other good and valuable consideration, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">EMPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive&#8217;s position shall be Chief Informatics Officer of the Company, subject to the terms and conditions set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The term of this Agreement shall begin on the Effective Date and shall continue until terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> herein (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Term&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive shall do and perform all services, acts or things necessary or advisable to manage and conduct the business of the Company and that are normally associated with the position of Chief Informatics Officer, and such other duties as may from time to time be assigned to Executive. Executive shall report to the Chief Executive Officer of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Policies and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The employment relationship between the Parties shall be governed by this Agreement and by the policies and practices established by the Company and&#47;or the Company&#8217;s Board of Directors (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Board&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), or any designated committee thereof. In the event the terms of this Agreement differ from or are in conflict with the Company&#8217;s policies and practices or the Company&#8217;s Employee Handbook, this Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Location</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless the Parties otherwise agree in writing, during the Term Executive shall perform the services Executive is required to perform pursuant to this Agreement at the Company&#8217;s offices in El Segundo, California </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Company may from time to time require Executive to travel temporarily to other locations in connection with the Company&#8217;s business.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">LOYALTY&#59; NON-COMPETITION&#59; NON-SOLICITATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Loyalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly provided herein or the Company otherwise consents in writing, during Executive&#8217;s employment by the Company, Executive shall devote Executive&#8217;s full business energies, interest, abilities and productive time to the proper and efficient performance of Executive&#8217;s duties under this Agreement. Notwithstanding the foregoing, Executive shall be permitted to continue to provide ongoing consultation, board and&#47;or advisory services to certain entities with the prior written consent of the Chief Executive Officer or Chairman of the board of directors of the Company (such consent not to be unreasonably withheld).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Agreement not to participate in Company&#8217;s Competitors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During Executive&#8217;s employment with the Company, Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its Affiliates (as defined below</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Ownership by Executive, in professionally managed funds over which Executive does not have control or discretion in investment decisions, or as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute a breach of this Section. For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such specified entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Covenant not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During Executive&#8217;s employment with the Company, Executive shall not engage in competition with the Company and&#47;or any of its Affiliates, either directly or indirectly, in any manner or capacity, as adviser, principal, agent, affiliate, promoter, partner, officer, director, employee, stockholder, owner, co-owner, consultant, or member of any association or otherwise, in any phase of the business of developing, manufacturing and marketing of products or services that are in the same field of use or which otherwise compete with the products or services of the Company except with the prior written consent of the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">COMPENSATION OF EXECUTIVE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company shall pay Executive a base salary at the annualized rate of $325,000 per year (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Base Salary&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), less payroll deductions and all required withholdings, payable in regular bi-weekly payments or otherwise in accordance with Company policy. Such Base Salary shall be prorated for any partial year of employment on the basis of a 365-day fiscal year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Discretionary Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the sole discretion of the Company, following each calendar year of employment, Executive shall be eligible to receive a discretionary cash bonus with a target amount of up to forty percent (40%) of Executive&#8217;s then-current base salary (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Bonus&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), based on Executive&#8217;s achievement relative to certain performance goals (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Performance Goals&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) to be established by the Company. The determination of whether Executive has met the Performance Goals for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any given year, and if so, the amount of any Bonus that will be paid for such year (if any), shall be determined by the Company in its sole and absolute discretion. In order to be eligible to earn or receive any Bonus, Executive must remain employed by the Company through and including the end of the year with respect to which such Bonus is earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company will reimburse Executive for all reasonable business expenses Executive incurs in conducting Executive&#8217;s duties hereunder, pursuant to the Company&#8217;s usual expense reimbursement policies&#59; provided that Executive supplies the appropriate substantiation for such expenses no later than the end of the calendar month following the month in which such expenses were incurred by Executive. For the avoidance of doubt, to the extent that any expense reimbursements payable to Executive under this Agreement are taxable income and subject to the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Code&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and the regulations and other guidance thereunder and any state law of similar effect (collectively </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Section 409A&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)&#58; (i) to be eligible to obtain reimbursement for such expenses Executive must supply the appropriate documentation substantiating such expenses no later than the end of the calendar month following the month in which such expenses were incurred by Executive, (ii) any such reimbursements will be paid by the Company as soon as administratively practicable after submission of such documentation, but in no event later than December 31 of the year following the year in which the expense was incurred, (iii) the amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (iv) the right to expense reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Changes to Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive&#8217;s compensation will be reviewed annually and may be increased from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Employment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All of Executive&#8217;s compensation and payments under this Agreement shall be subject to customary withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement which may be in effect from time to time and made available to the Company&#8217;s executive or key management employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Holidays and Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive shall be eligible for paid holiday and vacation time in accordance with Company policy as in effect from time to time and made available to Company&#8217;s senior management employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Equity. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to approval by the Board (or a committee thereof), and as an inducement material to Executive&#8217;s entering into employment with the Company, Executive shall be granted an option to purchase 400,000 shares of common stock in the Company at the fair market value on the date of grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The shares subject to the Option will vest over four years of continuous service to the Company, with twenty-five percent (25%) of the shares subject to the Option vesting on the first year anniversary of the Effective Date, and the remaining shares vesting in equal monthly installments over the subsequent thirty-six (36) months of continuous service thereafter. The Option shall be governed in all respects by the terms of the Company&#8217;s 2020 Inducement Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as amended, and option agreement between Executive and the Company. Executive shall be entitled to be considered for additional stock option grants under the Plan, as approved by the Board (or a committee thereof) in its sole discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">TERMINATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination by the Company. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive&#8217;s employment with the Company is at will and may be terminated by the Company or Executive at any time and for any reason, or for no reason, including, but not limited to, under the following conditions&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Termination by the Company for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company may terminate Executive&#8217;s employment under this Agreement for Cause by delivery of written notice to Executive. Any notice of termination given pursuant to this Section shall effect termination as of the date of the notice, or as of such other date specified in the notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Termination by the Company without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company may terminate Executive&#8217;s employment under this Agreement without Cause at any time and for any reason, or for no reason. Such termination shall be effective on the date Executive is so informed by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive may terminate Executive&#8217;s employment with the Company at any time and for any reason, or for no reason, upon 30 days&#8217; written notice to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination for Death or Complete Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive&#8217;s employment with the Company shall automatically terminate effective upon the date of Executive&#8217;s death or Complete Disability (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination by Mutual Agreement of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive&#8217;s employment with the Company may be terminated at any time upon a mutual agreement in writing of the Parties. Any such termination of employment shall have the consequences specified in such agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Compensation upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Death or Complete Disability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If Executive&#8217;s employment with the Company is terminated as a result of Executive&#8217;s death or Complete Disability, the Company shall pay to Executive, or to Executive&#8217;s heirs, Executive&#8217;s base salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, less standard deductions and withholdings (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Company shall thereafter have no further obligations to Executive and&#47;or Executive&#8217;s heirs under this Agreement, except as otherwise provided by law (and except as provided otherwise in Executive&#8217;s stock option agreements with the Company).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">With Cause or Without Good Reason. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Executive&#8217;s employment with the Company is terminated at any time either by the Company for Cause or by Executive without Good Reason, the Company shall pay the Accrued Obligations, and the Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise provided by law (and except as provided otherwise in Executive&#8217;s stock option agreements with the Company).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Without Cause or for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Executive&#8217;s employment with the Company is terminated by the Company without Cause or by Executive for Good Reason, and in either case Executive signs a separation agreement including a comprehensive waiver and release of claims in such form as the Company may require (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Release&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) on or within the time period set forth therein, but in no event later than 45 days after Executive&#8217;s termination date, and allows such Release to become effective in accordance with its terms (such latest permitted date on which the Release could become effective, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Release Deadline&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), then Executive will receive the Accrued Obligations and the following benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.75pt">Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Cash payments in the form of continuation of Executive&#8217;s Base Salary at the rate in effect at the time of termination for a period of six (6) months following the termination date (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Severance Payment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.75pt">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Provided that Executive is eligible for and timely elects continued group health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;COBRA&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) following Executive&#8217;s termination date, the Company shall pay directly to the insurance provider the premium for COBRA continuation coverage for Executive and Executive&#8217;s family for a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">period that will expire upon the earliest of (i) six (6) months following the termination date (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;COBRA Payment Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), (ii) the effective date that Executive becomes eligible for new healthcare coverage eligibility available through new employment, or (iii) the date Executive is no longer eligible for COBRA coverage, whichever comes first.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">General Severance Benefit Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">The provisions in this Section shall control and supersede anything to the contrary set forth in this Agreement. For all purposes of this Agreement, references to COBRA premiums shall not include any amounts payable by Executive under a Section 125 health care reimbursement plan under the Code. If at any time the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then regardless of whether Executive elects continued health coverage under COBRA, and in lieu of providing COBRA premiums, the Company will instead pay Executive on the last day of each remaining month of the COBRA Payment Period a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings, which payments shall continue until the earlier of expiration of the COBRA Payment Period of the date when Executive becomes eligible for health insurance coverage in connection with new employment. If Executive becomes eligible for coverage under another employer&#8217;s group health plan, Executive must immediately notify the Company of such event, and all COBRA severance benefit payments and obligations under this Agreement shall cease effective as of such date of Executive&#8217;s eligibility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">If all severance payments made under this Agreement will be subject to standard payroll deductions and withholdings and will be made on the Company&#8217;s regular payroll cycle, provided, however, that any severance payments otherwise scheduled to be made prior to the effective date of the Release shall instead accrue and be paid in the first payroll period that follows such effective date. Following provisions of any severance benefits to which Executive may be entitled under Section 4.5.3, the Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise provided by law (and except as provided otherwise in Executive&#8217;s stock option agreements with the Company).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For the purposes of this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:14pt">&#8220;Complete Disability&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall mean with respect to Executive, the inability of Executive to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined in good faith by the Board based on the basis of such reasonable medical evidence as the Board deems warranted under the circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:14pt">&#8220;Cause&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall mean the occurrence of any of the following events&#58; (i) Executive&#8217;s conviction of any felony or any crime involving fraud or dishonesty that has a material adverse effect on the Company&#59; (ii) Executive&#8217;s active participation (whether by affirmative act or material omission) in a fraud, act of dishonesty or other act of misconduct against the Company&#59; (iii) Executive&#8217;s material violation of any statutory or fiduciary duty owed to the Company&#59; (iv) Executive&#8217;s breach of any material term of any material contract between such Executive and the Company&#59; and (v) Executive&#8217;s repeated violation of any material the Company policy&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that termination by the Company due to Sections 1.5(b)(iii)&#8211;1.5(b)(vi) shall only be deemed for Cause if Executive fails to cure such conduct, violation, or breach within 30 days following Executive&#8217;s receipt of written notice from the Company, unless such conduct, violation, or breach is not capable of being cured in the good faith determination of the Company. The Executive&#8217;s Disability shall not constitute Cause as set forth herein. The determination that a termination is for Cause and whether the specified conduct, violation or breach, as applicable, has been satisfactorily cured shall be made in good faith by the Company in its sole and exclusive judgement and discretion. The term &#8220;Company&#8221; for purposes of this definition will be interpreted to include any Affiliate, as appropriate.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:14pt">&#8220;Good Reason&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall mean the occurrence of any of the following events without Executive&#8217;s consent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any resignation by Executive due to any of the following conditions shall only be deemed for Good Reason if&#58; (A) Executive gives the Company written notice of the intent to terminate for Good Reason within 90 days following the first occurrence of the condition(s) that Executive believes constitutes Good Reason, which notice shall describe such condition(s)&#59; (B) the Company fails to remedy such condition(s) within 30 days following receipt of the written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of such condition(s) from Executive&#59; and (C) Executive actually resigns Executive&#8217;s employment within the first 15 days after expiration of the Cure Period&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">material breach by the Company of any material provision in this Agreement or in any other material written agreement between the Company and Executive&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">a material reduction (which the parties agree is a reduction of at least 10%) by the Company of Executive&#8217;s base salary on the effective date hereof or as the same may be increased from time to time, unless such reduction is part of a reduction program equally applicable to other executive employees of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">a material reduction in Executive&#8217;s authority, duties or responsibilities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; in and of itself unless Executive&#8217;s new duties are materially reduced from the prior duties&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">the Company relocates the facility that is Executive&#8217;s principal place of business with the Company to a location that requires an increase in Executive&#8217;s one-way driving distance by more than 30 miles.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Survival of Certain Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Sections 2, 3.3, 3.5, and 4 through 19 of this Agreement shall survive the termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Parachute Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as otherwise provided in an agreement between Executive and the Company, if any payment or benefit Executive would receive from the Company or otherwise in connection with a change in control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then such Payment shall be equal to the Reduced Amount (as defined herein). The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Reduced Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#8217;s receipt, on an&#160;after-tax&#160;basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; is necessary so that the Payment equals the Reduced Amount, the reduction shall occur in the manner that results in the greatest economic benefit to Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section&#160;280G(b)(2)(A)(i) of the Code shall perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting such event, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within thirty (30)&#160;calendar days after the date on which Executive&#8217;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as reasonably requested by the Company or Executive. Any good faith determinations of the independent registered </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">public accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Application of Internal Revenue Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All benefits under this Agreement are intended to qualify for an exemption from application of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary set forth herein, any severance benefits that constitute &#8220;deferred compensation&#8221; within the meaning of Section 409A shall not commence in connection with Executive&#8217;s termination of employment unless and until Executive has also incurred a &#8220;separation from service&#8221; (as such term is defined in Treasury Regulation Section 1.409A-1(h)) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Separation From Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional 20% tax under Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It is intended that each installment of the severance benefit payments provided for in this Agreement is a separate &#8220;payment&#8221; for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments of the severance benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if the Company (or, if applicable, the successor entity thereto) determines that the severance benefits constitute &#8220;deferred compensation&#8221; under Section 409A and Executive is, on the termination of service, a &#8220;specified employee&#8221; of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the severance benefit payments shall be delayed until the earlier to occur of&#58; (i) the date that is six months and one day after Executive&#8217;s Separation From Service, or (ii) the date of Executive&#8217;s death. None of the severance benefits will be paid or otherwise delivered prior to the effective date of the Release. If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the calendar year in which Executive&#8217;s Separation From Service occurs, the Release will not be deemed effective any earlier than the Release Deadline. Except to the minimum extent that payments must be delayed because Executive is a &#8220;specified employee&#8221; or until the effectiveness of the Release, all amounts will be paid as soon as practicable in accordance with the Company&#8217;s normal payroll practices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The severance benefits are intended to qualify for an exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">CONFIDENTIAL AND PROPRIETARY INFORMATION&#59; NONSOLICITATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">As a condition of employment, Executive agrees to execute and abide by the Company&#8217;s Confidential Information and Inventions Assignment Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">While employed by the Company and for one year thereafter, Executive agrees that in order to protect the Company&#8217;s trade secrets and confidential and proprietary information from unauthorized use, Executive will not, either directly or through others, solicit or attempt to solicit any employee, consultant or independent contractor of the Company to terminate his or her relationship with the Company in order to become an employee, consultant or independent contractor to or for any other person or business entity.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">ASSIGNMENT AND BINDING EFFECT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be binding upon and inure to the benefit of Executive and Executive&#8217;s heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of Executive&#8217;s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be assignable by Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">NOTICES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All notices or demands of any kind required or permitted to be given by the Company or Executive under this Agreement shall be given in writing and shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail return receipt requested, postage prepaid, address as follows,</font></div><div style="padding-left:35.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Company&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bionano Genomics, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9540 Towne Centre Drive, Suite 100</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA, 92121</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; Chief Executive Officer</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">If to Executive&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Soheil Shams</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or three days after its deposit in the United States mail as specified above. Either Party may change its address for notices by giving notice to the other Party in the manner specified in this Section.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">CHOICE OF LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be construed and interpreted in accordance with the internal laws of the State of California without regard to its conflict of laws principles.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">INTEGRATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of Executive&#8217;s employment and the termination of Executive&#8217;s employment, and supersedes all prior and&#47;or contemporaneous oral and written employment agreements or arrangements between the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">AMENDMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement cannot be amended or modified except by a written agreement signed by Executive and the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">WAIVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">SEVERABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision which most accurately represents the Parties&#8217; intention with respect to the invalid or unenforceable term or provision.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">INTERPRETATION&#59; CONSTRUCTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but Executive has been encouraged to consult with, and have consulted with, Executive&#8217;s own independent counsel and tax advisors with respect to the terms of this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">REPRESENTATIONS AND WARRANTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive represents and warrants that Executive is not restricted or prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that Executive&#8217;s execution and performance of this Agreement will not violate or breach any other agreements between Executive and any other person or entity.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">COUNTERPARTS&#59; FACSIMILE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement may be executed in two counterparts, each of which shall be deemed an original, all of which together shall contribute one and the same instrument. Facsimile signatures shall be treated the same as original signatures.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">DISPUTE RESOLUTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To ensure the timely and economical resolution of disputes that may arise between Executive and the Company, both Executive and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by applicable law, Executive and the Company will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement&#59; or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Executive&#8217;s employment with the Company (including but not limited to all statutory claims)&#59; or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the termination of Executive&#8217;s employment with the Company (including but not limited to all statutory claims). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such disputes through a trial by jury or judge or through an administrative proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Arbitrator Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Individual Capacity Only</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All claims, disputes, or causes of action under this Section, whether by Executive or the Company, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences in this Section are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Arbitration Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by Judicial Arbitration and Mediation Services, Inc. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in San Diego, California, or as otherwise agreed to by Executive and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">). Executive and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&#8217;s own expense. The arbitrator shall&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> have the authority to compel adequate discovery for the resolution of the dispute&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Section shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In the event Executive intends to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Injunctive Relief and Final Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Nothing in this Section is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">TRADE SECRETS OF OTHERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It is the understanding of both the Company and Executive that Executive shall not divulge to the Company and&#47;or its subsidiaries any confidential information or trade secrets belonging to others, including Executive&#8217;s former employers, nor shall the Company and&#47;or its Affiliates seek to elicit from Executive any such information. Consistent with the foregoing, Executive shall not provide to the Company and&#47;or its Affiliates, and the Company and&#47;or its Affiliates shall not request, any documents or copies of documents containing such information.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">ADVERTISING WAIVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive agrees to permit the Company and&#47;or its affiliates, subsidiaries, or joint ventures currently existing or which shall be established during Executive&#8217;s employment by the Company (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Affiliates&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and persons or other organizations authorized by the Company and&#47;or its Affiliates, to use, publish and distribute advertising or sales promotional literature concerning the products and&#47;or services of the Company and&#47;or its Affiliates, or the machinery and equipment used in the provision thereof, in which Executive&#8217;s name and&#47;or pictures of Executive taken in the course of Executive&#8217;s provision of services to the Company and&#47;or its Affiliates, appear. Executive hereby waives and releases any claim or right Executive may otherwise have arising out of such use, publication or distribution. The Company agrees that, following termination of Executive&#8217;s employment, it will not create any new such literature containing Executive&#8217;s name and&#47;or pictures without Executive&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">INDEMNIFICATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to applicable law, Executive will be provided indemnification to the maximum extent permitted by the Company&#8217;s Bylaws and Articles of Incorporation, including coverage, if applicable, under any directors and officers insurance policies, with such indemnification determined by the Board or any of its committees in good faith based on principles consistently applied (subject to such limited </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.12pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">exceptions as the Board may approve in cases of hardship) and on terms no less favorable than provided to any other Company executive officer or director.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><div id="i14c83267444b41eea6cbb8a41eeef241_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have executed this Agreement as of the date first above written.</font></div><div style="margin-bottom:10pt;padding-left:252pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">COMPANY&#58;</font></div><div style="margin-bottom:10pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">BIONANO GENOMICS, INC.</font></div><div style="margin-bottom:10pt;padding-left:252pt"><font><br></font></div><div style="padding-left:247.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.044%"><tr><td style="width:1.0%"></td><td style="width:15.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#47;s&#47; R. Erik Holmlin, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Name&#58; R. Erik Holmlin, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Title&#58;   President and Chief Executive Officer</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Date&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">October 8, 2021</font></td></tr></table></div><div style="margin-bottom:10pt;padding-left:252pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:252pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Signature Page to Employment Agreement)</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have executed this Agreement as of the date first above written.</font></div><div style="margin-bottom:10pt;padding-left:252pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:252pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">EXECUTIVE&#58;</font></div><div style="margin-bottom:10pt;padding-left:252pt"><font><br></font></div><div style="padding-left:247.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.044%"><tr><td style="width:1.0%"></td><td style="width:13.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#47;s&#47; Soheil Shams</font></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Soheil Shams</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Date&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">October 8, 2021</font></td></tr></table></div><div style="margin-bottom:10pt;padding-left:252pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Signature Page to Employment Agreement)</font></div></div></div><div id="i14c83267444b41eea6cbb8a41eeef241_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A<br><br>CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit A-1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>5
<FILENAME>bngo-ex1035_bionanoxstockr.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i33006a09f4cc4fd6ba66f1a8ab8be6fb_1"></div><div style="min-height:92.16pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.35</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Execution Version</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STOCK RESTRICTION AGREEMENT <br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This STOCK RESTRICTION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated for reference purposes only as October 8, 2021, is made and entered into by and between Bionano Genomics, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the undersigned stockholder of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Each of Parent and the Holder are collectively referred to from time to time herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and each, individually, as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;  Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, Parent, Starship Merger Sub I, Inc., a California corporation and a wholly owned Subsidiary of Parent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Merger Sub I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Starship Merger Sub II, LLC, a California limited liability company and a wholly owned Subsidiary of Parent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Merger Sub II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with Merger Sub I, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Merger Subs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), BioDiscovery, Inc., a California corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Soheil Shams solely in its capacity as the representative of the Participating Securityholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Stockholder Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), have entered into that certain Agreement and Plan of Merger, dated as of October 8, 2021 (as such agreement may be amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Merger Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to which the Company shall be acquired by Parent, by means of a merger of Merger Sub I with and into the Company, pursuant to which the Company will survive and become a wholly owned subsidiary of Parent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Merger&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and, as part of the same overall transaction, promptly after Merger I, the surviving entity of Merger I will merge with and into Merger Sub II, with Merger Sub II surviving such merger (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Merger II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with Merger I, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Mergers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), on the terms and subject to the conditions set forth in the Merger Agreement&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, at the Closing, as part of the Merger Consideration, the Holder will receive shares of Parent Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;  and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, as a condition and inducement to Parent and the Merger Subs entering into the Merger Agreement and as a condition to the consummation of the Mergers and the other transactions contemplated by the Merger Agreement, the Holder is executing and delivering this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NOW THEREFORE, in consideration of the premises, covenants and representations set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">REVESTED STOCK CONSIDERATION</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Revesting of Certain Merger Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Holder hereby acknowledges and agrees that 5,006,479 of the Shares shall be subject to provisions set forth in this Agreement (such Shares subject to such provisions, the Holder&#8217;s &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Revested Stock Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Vesting of Revested Stock Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">The Revested Stock Consideration will be unvested as of its issuance to the Holder at the Closing. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">One-third of the Revested Stock Consideration shall vest on the first anniversary of the Closing Date and one-twelfth (1&#47;12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) of the Revested Stock Consideration shall vest every three (3) months following the first anniversary of the Closing Date (for illustrative purposes only, if the Closing Date is October 15, 2021, the first vesting will occur on October 15, 2022, the second vesting will occur on January 15, 2023 and the third vesting will occur on April 15, 2023 and so on until the final vesting date on October&#160;15,&#160;2024). The number of shares of Revested Stock Consideration that vest upon each vesting date shall be rounded down to the nearest whole share, with the balance of any shares that did not vest as a result of such rounding to vest on the final vesting date, subject to rounding.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below, the vesting of the Revested Stock Consideration on a particular vesting date shall be subject to the Holder&#8217;s continuous Service (as defined below) through and including the day of the applicable calendar month on which the vesting date occurs. The Holder shall, for purposes of this Agreement, be deemed to provide &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for so long as the Holder remains an employee of, or a consultant or advisor (pursuant to a mutually negotiated consulting or advisor agreement) to, Parent or one of Parent&#8217;s Subsidiaries. For the avoidance of doubt, termination of employment with or service to Parent or any of its Subsidiaries to take employment with or provide service to another of Parent or any of its Subsidiaries shall not be considered termination of Service. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Upon the termination of Service (i) by Parent or a Subsidiary of Parent other than for Cause, (ii) by the Holder for Good Reason or (iii) as a result of the Holder&#8217;s death or Disability, any then unvested Revested Stock Consideration shall automatically vest in full as of such date of termination of Service&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the event of termination of Service pursuant to subclauses (i) or (ii) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such Revested Stock Consideration will not vest or be released to the Holder until the Holder has executed and delivered to Parent (and not revoked) a customary release of claims arising out of the Holder&#8217;s employment (including any claims for discrimination, harassment or wrongful termination), in form and substance reasonably acceptable to Parent and subject to reasonable and customary exclusions, including exclusions for earned and unpaid compensation, unreimbursed business expenses, rights of indemnification and rights as a holder of equity securities, and such release shall have become effective.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Forfeiture of Revested Stock Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the event that the Holder&#8217;s Service terminates at any time after the Closing, then all of the Revested Stock Consideration that has not vested pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> prior to the date of such termination shall be automatically forfeited by the Holder and redeemed by Parent for no consideration, without the requirement for any further action on the part of the Holder, Parent or any other Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Right to Satisfy Claims from the Revested Stock Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Parent is expressly authorized to set off up to 100% of (i) any Damages for which it is entitled to indemnification under the Merger Agreement, or (ii) any negative Adjustment Amount determined pursuant to Section 1.17 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Post-Closing Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) of the Merger agreement for which it is entitled to indemnification under the Merger Agreement against Holder, against any Shares subject to the Revested Stock Consideration, subject to any limitations on such setoff set forth in the Merger Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Board of Directors of Parent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the Board has delegated relevant authority to the Compensation Committee of the Board, then &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall also mean the Compensation Committee.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term in the Key Employee Agreement between the Holder and Parent executed in connection with the Mergers, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Key Employee Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and, in the absence of such agreement or in the event that such agreement in effect is less favorable to the Holder, shall mean the occurrence of any of the following events&#58; (i) the Holder&#8217;s conviction of any felony or any crime involving fraud or dishonesty that has a material adverse effect on Parent&#59; (ii) the Holder&#8217;s active participation (whether by affirmative act or material omission) in a fraud, act of dishonesty or other act of misconduct against Parent&#59; (iii)  the Holder&#8217;s material violation of any statutory or fiduciary duty owed to Parent&#59; (iv) the Holder&#8217;s breach of any material term of any material contract between such Holder and Parent&#59; and (v) the Holder&#8217;s repeated violation of any material Parent policy&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that termination by Parent due to Sections 1.5(b)(iii)&#8211;1.5(b)(vi) shall only be deemed for Cause if the Holder fails to cure such conduct, violation, or breach within 30 days following the Holder&#8217;s receipt of written notice from Parent, unless such conduct, violation, or breach is not capable of being cured in the good faith determination of Parent. The Holder&#8217;s Disability shall not constitute Cause as set forth herein. The determination that a termination is for Cause and whether the specified conduct, violation or breach, as applicable, has been satisfactorily cured shall be made in good faith by Parent in its sole and exclusive judgement and discretion. The term &#8220;Parent&#8221; for purposes of this definition will be interpreted to include any Affiliate, as appropriate.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;padding-left:31.7pt;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning ascribed to such term or a similar term in the Key Employee Agreement, and, in the absence of such agreement or in the event that such agreement in effect is less favorable to the Holder, shall mean</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to the Holder, the inability of the Holder to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections&#160;22(e)(3) and 409A(a)(2)(c)(i) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and will be determined in good faith by the Board based on the basis of such reasonable medical evidence as the Board deems warranted under the circumstances.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for the Holder&#8217;s resignation shall have the meaning ascribed to such term in the Key Employee Agreement, and, in the absence of such agreement or in the event that such agreement in effect is less favorable to the Holder, shall mean the occurrence of any of the following events without the Holder&#8217;s consent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any resignation by the Holder due to any of the following conditions shall only be deemed for Good Reason if&#58; (A) the Holder gives Parent written notice of the intent to terminate for Good Reason within 90 days following the first occurrence of the condition(s) that the Holder believes constitutes Good Reason, which notice shall describe such condition(s)&#59; (B) Parent fails to remedy such condition(s) within 30 days following receipt of the written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of such condition(s) from the Holder&#59; and (C) the Holder actually resigns the Holder&#8217;s employment within the first 15 days after expiration of the Cure Period&#58;</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.19pt">material breach by Parent of any material provision in this Agreement or in any other material written agreement between Parent and the Holder&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.86pt">a material reduction (which the parties agree is a reduction of at least 10%) by Parent of the Holder&#8217;s base salary on the effective date hereof or as the same may be increased from time to time, unless such reduction is part of a reduction program equally applicable to other executive employees of Parent&#59;</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.53pt">a material reduction in the Holder&#8217;s authority, duties or responsibilities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; in and of itself unless the Holder&#8217;s new duties are materially reduced from the prior duties&#59; or</font></div><div style="margin-bottom:12pt;padding-left:67.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.19pt">Parent relocates the facility that is the Holder&#8217;s principal place of business with Parent to a location that requires an increase in the Holder&#8217;s one-way driving distance by more than 30 miles.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">The Holder will be deemed to have effected a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of Restricted Stock Consideration if the Holder, whether voluntarily or involuntarily, directly or indirectly (i) sells, pledges, encumbers, hypothecates, leases, assigns, gifts, grants an option with respect to, transfers, exchanges, tenders or disposes (by merger, by testamentary disposition, by operation of law or otherwise) all or any portion of such Restricted Stock Consideration or any interest in such Restricted Stock Consideration, (ii) creates or permits to exist any lien, pledge, charge, claim, mortgage, security interest or other encumbrance on the Restricted Stock Consideration, or (iii) agrees to take any of the actions referred to in the foregoing clauses (i) through (iii).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Dividend and Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During any period in which the Revested Stock Consideration has not fully vested pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and has not been forfeited pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Holder shall be deemed to be the legal and beneficial owner of such shares (subject to the terms of this Agreement) of Parent Common Stock and shall have the right to (i) receive any cash dividends declared thereupon (any stock dividends declared shall be deemed additional Revested Stock Consideration and shall be subject to the same vesting schedule set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and be released to the Holder or forfeited as provided herein) and (ii) vote any such shares in the Holder&#8217;s discretion with respect to each matter for which holders of shares of Parent Common Stock are entitled to vote.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Each Party agrees that the Revested Stock Consideration has been issued to the Holder as consideration in respect of the Holder&#8217;s Company Capital Stock and is not subject to wage withholding except to the extent that another treatment is required by either (i) a change in Law or (ii) a final determination within the meaning of Section 1313 of the Code&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that no Party shall be prevented from taking a tax position inconsistent with such tax treatment in settlement of a tax controversy, and no Party shall be required to litigate in order to support a tax position. The Holder agrees that the Holder shall make a protective election under Section 83(b) of the Code, with respect to the Revested Stock Consideration within 30 days after the receipt of such Revested Stock Consideration, using the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and will provide to Parent a copy of such election promptly after it is filed. Notwithstanding the foregoing, the Holder acknowledges that the Holder is relying solely on its own Tax advisors in connection with this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">The Holder agrees to submit a properly completed and executed Internal Revenue Service Form W-9 to Parent at the Closing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Guarantee of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In no event shall any provision of this Agreement or the transactions contemplated hereby give or be deemed to give the Holder any right to continued employment by Parent or any of its Subsidiaries or affect in any manner the right of the Holder&#8217;s Employer to terminate the Holder&#8217;s employment at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Equitable Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of any stock split, reverse stock split, stock dividend (including any dividend or distribution of securities convertible into capital stock), reorganization, reclassification, combination, recapitalization or other like change with respect to the Parent Common Stock occurring after the Merger I Effective Time, all references in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to specified numbers or types of shares, and all calculations provided for that are based upon numbers or types of shares affected thereby, shall be equitably adjusted to the extent necessary to provide the parties the same economic effect as contemplated by this Article I prior to such stock split, reverse stock split, stock dividend, reorganization, reclassification, combination, recapitalization or other like change.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Transfer Restrictions&#59; Additional Legend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">The Holder shall not Transfer (or cause or permit the Transfer of) any Revested Stock Consideration that has not vested in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or enter into any agreement relating thereto.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">The Holder understands that any Revested Stock Consideration that has not vested in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall bear the following restrictive legend (in addition to any other legend required by law or the Merger Agreement)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A REACQUISITION RIGHT AND OTHER RESTRICTIONS AND CONDITIONS SET FORTH IN A STOCK RESTRICTION AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER&#8217;S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE COMPANY&#8217;S PRINCIPAL CORPORATE OFFICE. ANY SALE, PLEDGE, HYPOTHECATION OR OTHER TRANSFER, OR ATTEMPT TO DO ANY OF THE FOREGOING, WITH RESPECT TO ANY SECURITIES SUBJECT TO SUCH RIGHT, RESTRICTIONS OR CONDITIONS IN CONTRAVENTION OF SUCH AGREEMENT IS NULL AND VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-right:-18pt;text-align:center;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">The Parties agree that, in the event of any breach or threatened breach by the other Party or Parties hereto of any covenant, obligation or other agreement set forth in this Agreement, (i)&#160;each Party shall be entitled, without any proof of actual damages (and in addition to any other remedy that may be available to it), to specific performance to enforce the observance and performance of such covenant, obligation or other agreement and an injunction preventing or restraining such breach or threatened breach, and (ii)&#160;no Party shall be required to provide or post any bond or other security or collateral in connection with any such decree, order or injunction or in connection with any related Legal Proceeding. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Any and all remedies expressly conferred herein upon a Party hereunder shall be deemed to be cumulative with, and not exclusive of, any other remedy conferred hereby, or by Law or in equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of Law provision or rule (whether of the State of Delaware or any other jurisdiction).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Exclusive Jurisdiction&#59; Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">ANY LEGAL PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE MERGER AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY MAY BE INSTITUTED FIRST, IN THE COURT OF CHANCERY WITHIN NEW CASTLE COUNTY IN THE STATE OF DELAWARE (AND ANY APPELLATE COURT THEREOF LOCATED WITHIN SUCH COUNTY) AND TO THE EXTENT SUCH COURT OF CHANCERY (OR APPELLATE COURT THEREOF LOCATED WITHIN SUCH COUNTY) LACKS JURISDICTION OVER THE MATTER, THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA LOCATED WITHIN NEW CASTLE COUNTY IN THE STATE OF DELAWARE (OR APPELLATE COURT THEREOF LOCATED WITHIN SUCH COUNTY), AND EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH LEGAL PROCEEDING. SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER DOCUMENT BY MAIL TO SUCH PARTY&#8217;S ADDRESS SET FORTH HEREIN SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY LEGAL PROCEEDING BROUGHT IN ANY SUCH COURT. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY LEGAL PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH LEGAL PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT OR THE MERGER AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE MERGER AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (I)&#160;NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL PROCEEDING, (II)&#160;SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III)&#160;SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV)&#160;SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SECTION 2.3(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Entire Agreement&#59; Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement, the Merger Agreement, the Non-Competition and Non-Solicitation Agreement and the Key Employee Agreement (a) constitute the entire agreement among the Parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both written and oral, among the Parties with respect to the subject matter hereof and thereof, (b) are not intended to confer upon any other Person any rights or remedies hereunder (other than in the case of the Holder&#8217;s estate or legal representative in the event of the Holder&#8217;s death or disability), and (c) shall not be assigned by the Holder by operation of law or otherwise. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and permitted assigns. Any purported assignment not permitted under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Amendment&#59; Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement can be amended, supplemented or changed, and any provision hereof can be waived, only by written instrument making specific reference to this Agreement, signed by the Parties hereto. The waiver by any Party of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. No failure on the part of any Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any notice or other communication required or permitted to be delivered to any Party under this Agreement shall be in writing and shall be deemed properly delivered, given and received (a) upon receipt when delivered by hand, (b) upon transmission, if sent by electronic mail transmission, or (c) one Business Day after being sent by courier or express delivery service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in each case the notice or other communication is sent to the address or electronic mail address as specified for such party below (or to such other address or electronic mail address as such party shall have specified in a written notice given to the other parties hereto)&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">If to Parent, then as provided for in Section 10.9 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) of the Merger Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">If to the Holder, then to the address set forth on the Holder&#8217;s signature page hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that any provision of this Agreement or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full force and effect and the application of such provision to other Persons or circumstances shall be interpreted so as reasonably to effect the intent of the Parties hereto. The Parties further agree to replace such illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other purposes of such illegal, void or unenforceable provision. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be followed by the words &#8220;without limitation.&#8221; The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;herewith&#8221; and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement. Article, section and paragraph references are to the articles, sections and paragraphs of this Agreement unless otherwise specified. The meaning assigned to each term defined herein shall be equally applicable to both the singular and the plural forms of such term, and words denoting any gender shall include all genders. The word &#8220;extent&#8221; and the phrase &#8220;to the extent&#8221; when used in this Agreement shall mean the degree to which a subject or other things extends, and such word or phrase shall not merely mean &#8220;if.&#8221; The term &#8220;or&#8221; is not exclusive, and shall be interpreted as &#8220;and&#47;or&#8221; unless the context clearly requires otherwise. A reference to any specific legislation or to any provision of any legislation shall include any amendment to, and any modification or re-enactment thereof, any legislative provision substituted therefor and all regulations and statutory instruments issued thereunder or pursuant thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall terminate upon the earlier of (a) the valid termination of the Merger Agreement in accordance with the provisions of Section 9 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) of the Merger Agreement and (b) the termination of this Agreement by mutual consent of the Parties (each individually a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Termination Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and shall be null and void in all respects after a Termination Event&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, nothing herein shall relieve any Party from liability in connection with any breach of such party&#8217;s representations, warranties or covenants contained herein occurring prior to a Termination Event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Acknowledgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each party to this Agreement acknowledges that (a) Pillsbury Winthrop Shaw Pittman LLP, counsel for the Company, represented the Company in connection with the Mergers and related transactions, (b) Cooley LLP, counsel for Parent and the Merger Subs, represented Parent and the Merger Subs in connection with this Agreement, the Mergers and related transactions, and (c) neither of the foregoing firms has represented the Holder in connection with this Agreement, the Mergers or related transactions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the date of execution of this Agreement, this Agreement shall only become effective upon the Closing, and if the Merger Agreement shall terminate in accordance with its terms prior to the Closing, this Agreement shall never become effective.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><div id="i33006a09f4cc4fd6ba66f1a8ab8be6fb_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the date first above written.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PARENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BIONANO GENOMICS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:211.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; R. Erik Holmlin, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; R. Erik Holmlin, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;   President and Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(SIGNATURE PAGE TO STOCK RESTRICTION AGREEMENT)</font></div></div></div><div id="i33006a09f4cc4fd6ba66f1a8ab8be6fb_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HOLDER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:175.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.801%"><tr><td style="width:1.0%"></td><td style="width:11.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#47;s&#47; Soheil Shams</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Name&#58; Soheil Shams</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Address&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">     &#91;***&#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                                    &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">     &#91;***&#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                                    &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">     &#91;***&#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                                    &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Email&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">     &#91;***&#93;                                                                      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   5,006,479&#160;&#160;&#160;&#160;            </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(SIGNATURE PAGE TO STOCK RESTRICTION AGREEMENT)</font></div></div></div><div id="i33006a09f4cc4fd6ba66f1a8ab8be6fb_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECTION 83(b) ELECTION</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">____________&#160;_____, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Department of the Treasury</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Internal Revenue Service</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ogden, UT 84201-0002</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Election Under Section 83(b)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income as compensation for services the excess (if any) of the fair market value of the shares described below over the amount paid for those shares. The following information is supplied in accordance with Treasury Regulation &#167; 1.83-2&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The name, social security number, address of the undersigned, and the taxable year for which this election is being made are&#58;</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Social Security Number&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Taxable year&#58;&#160;&#160;&#160;&#160;Calendar year 2021. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The property that is the subject of this election&#58;  _____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shares of common stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Bionano Genomics, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The Shares were transferred on&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> ____________&#160;_____, 2021.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">2</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;The Shares are subject to the following restrictions&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Shares are subject to forfeiture if the undersigned does not continue to provide services for Parent for a designated period of time. The risk of forfeiture lapses over a specified vesting period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The fair market value of the Shares at the time of transfer (determined without regard to any lapse restriction as defined in Treasury Regulation &#167;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.83-3(i))&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  ___________________.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">3</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">The amount paid by the undersigned for the Shares&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">___________________. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Shares were transferred as part of the consideration received by the undersigned incident to the acquisition of BioDiscovery, Inc., a California corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by Parent in a transaction qualifying as a &#8220;reorganization&#8221; within the meaning of Internal Revenue Code section 368(a). Gain or loss with respect to the undersigned&#8217;s shares of Company capital stock will be recognized to the extent provided by Internal Revenue Code section 356.  See Revenue Ruling 2007-49, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2007-2&#160;C.B. 237.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The quotient of (i)&#160;the product of (A)&#160;$30 million and (B)&#160;taxpayer&#8217;s Ownership Percentage, divided by (ii)&#160;the Parent Trading Price.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Closing Date.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;$30 million multiplied by taxpayer&#8217;s Ownership Percentage.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;$30 million multiplied by taxpayer&#8217;s Ownership Percentage.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4845-5418-2909.v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The undersigned taxpayer will file this election with the Internal Revenue Service office with which taxpayer files his annual income tax return not later than 30 days after the date of transfer of the Shares. A copy of the election also will be furnished to the person for whom the services were performed. The undersigned is the person performing the services in connection with which the Shares were transferred.</font></div><div style="margin-bottom:24pt;padding-left:234pt;padding-right:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-bottom:3pt;padding-left:234pt;padding-right:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:144pt;padding-right:144pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Name&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4845-5418-2909.v4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RETURN SERVICE REQUESTED</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Department of the Treasury</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Internal Revenue Service</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ogden, UT 84201-0002</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Election Under Section 83(b) of the Internal Revenue Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Sir or Madam&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Enclosed please find an executed election under Section 83(b) of the Internal Revenue Code of 1986, as amended, filed with respect to shares of common stock of Bionano Genomics, Inc.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Also enclosed is a copy of this letter and a stamped, self-addressed envelope. Please acknowledge receipt of these materials by marking the copy when received and returning it to the undersigned.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thank you very much for your assistance.</font></div><div style="margin-bottom:24pt;padding-left:234pt;padding-right:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-bottom:3pt;padding-left:234pt;padding-right:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:144pt;padding-right:144pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Name&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Enclosures</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4845-5418-2909.v4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>6
<FILENAME>bngo-ex1036_bionanoxemploy.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iad83ce438942430f84d05053b16a54b9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.36</font></div></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT&#160;AGREEMENT</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;(the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Agreement&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) is made and entered into effective as of June 14, 2021 (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Effective Date&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), by and between&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BIONANO&#160;GENOMICS, INC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Company&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Richard Shippy</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Executive&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">). The Company and Executive are hereinafter collectively referred to as the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Parties&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and individually referred to as a&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Party&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company desires assurance of the association and services of Executive in order to retain Executive&#8217;s experience, skills, abilities, background and knowledge, and is willing to continue to the engagement of Executive&#8217;s services on the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive desires to be in the employ of the Company, and is willing to accept employment on the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In consideration of the foregoing Recitals and mutual promises and covenants contained herein, and for other good and valuable consideration, the Parties, intending to be legally bound, agree as follows&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">1.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Title</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive&#8217;s position shall be Chief Business Officer of the Company, subject to the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The term of this Agreement shall begin on the Effective Date, and shall continue until terminated in accordance with Section&#160;4 herein (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Term&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Duties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive shall do and perform all services, acts or things necessary or advisable to manage and conduct the business of the Company and that are normally associated with the position of Chief Business Officer, and such other duties as may from time to time be assigned to Executive. Executive shall report to the Chief Executive Officer of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Policies and Procedures</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The employment relationship between the Parties shall be governed by this Agreement and by the policies and practices established by the Company and&#47;or the Company&#8217;s Board of Directors (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Board&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), or any designated committee thereof. In the event the terms of this Agreement differ from or are in conflict with the Company&#8217;s policies and practices or the Company&#8217;s Employee Handbook, this Agreement shall control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Location</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless the Parties otherwise agree in writing, during the Term Executive shall perform the services Executive is required to perform pursuant to this Agreement at the Company&#8217;s offices in San Diego, California&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Company may from time to time require Executive to travel temporarily to other locations in connection with the Company&#8217;s business.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">2.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LOYAL&#59; NON-COMPETITION&#59; NON-SOLICITATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Loyalty</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly provided herein, during Executive&#8217;s employment by the Company, Executive shall devote Executive&#8217;s full business energies, interest, abilities and productive time to the proper and efficient performance of Executive&#8217;s duties under this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement not to participate in Company&#8217;s Competitors.&#160; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During Executive&#8217;s employment with the Company, Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its Affiliates (as defined below</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Ownership by Executive, in professionally managed funds over which Executive does not have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">control or discretion in investment decisions, or as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the&#160;over-the-counter&#160;market shall not constitute a breach of this Section. For purposes of this Agreement, &#8220;Affiliate&#8221; means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls is controlled by or is under common control with such specified entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Covenant not to Compete</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During Executive&#8217;s employment with the Company, Executive shall not engage in competition with the Company and&#47;or any of its Affiliates, either directly or indirectly, in any manner or capacity, as adviser, principal, agent, affiliate, promoter, partner, officer, director, employee, stockholder, owner,&#160;co-owner,&#160;consultant, or member of any association or otherwise, in any phase of the business of developing, manufacturing and marketing of products or services that are in the same field of use or which otherwise compete with the products or services of the Company except with the prior written consent of the Company.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">3.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COMPENSATION&#160;OF&#160;EXECUTIVE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Base Salary</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company shall pay Executive a base salary at the annualized rate of $320,000 per year (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Base Salary&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), less payroll deductions and all required withholdings, payable in regular&#160;bi-weekly&#160;payments or otherwise in accordance with Company policy. Such Base Salary shall be prorated for any partial year of employment on the basis of a&#160;365-day&#160;fiscal year.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Discretionary Bonus</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At the sole discretion of the Company, following each calendar year of employment, Executive shall be eligible to receive a discretionary cash bonus with a target amount of up to forty percent (40%) of Executive&#8217;s then-current base salary (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Bonus&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), based on Executive&#8217;s achievement relative to certain performance goals (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Performance Goals&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) to be established by the Company. The determination of whether Executive has met the Performance Goals for any given year, and if so, the amount of any Bonus that will be paid for such year (if any), shall be determined by the Company in its sole and absolute discretion. In order to be eligible to earn or receive any Bonus, Executive must remain employed by the Company through and including the end of the year with respect to which such Bonus is earned.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expense Reimbursement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company will reimburse Executive for all reasonable business expenses Executive incurs in conducting Executive&#8217;s duties hereunder, pursuant to the Company&#8217;s usual expense reimbursement policies&#59; provided that Executive supplies the appropriate substantiation for such expenses no later than the end of the calendar month following the month in which such expenses were incurred by Executive. For the avoidance of doubt, to the extent that any expense reimbursements payable to Executive under this Agreement are taxable income and subject to the provisions of Section&#160;409A of the Internal Revenue Code of 1986, as amended (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Code&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and the regulations and other guidance thereunder and any state law of similar effect (collectively&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Section&#160;409A&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)&#58; (i) to be eligible to obtain reimbursement for such expenses Executive must supply the appropriate documentation substantiating such expenses no later than the end of the calendar month following the month in which such expenses were incurred by Executive, (ii)&#160;any such reimbursements will be paid by the Company as soon as administratively practicable after submission of such documentation, but in no event later than December&#160;31 of the year following the year in which the expense was incurred, (iii)&#160;the amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (iv)&#160;the right to expense reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Changes to Compensation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive&#8217;s compensation will be reviewed annually and may be increased from time to time in the Company&#8217;s sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employment Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All of Executive&#8217;s compensation and payments under this Agreement shall be subject to customary withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Benefits</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement which may be in effect from time to time and made available to the Company&#8217;s executive or key management employees.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Holidays and Vacation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive shall be eligible for paid holiday and vacation time in accordance with Company policy as in effect from time to time and made available to Company&#8217;s senior management employees.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.9&#160;&#160;&#160;&#160;Equity.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to approval by the Board (or a committee thereof), Executive shall be granted an option to purchase 400,000 shares of common stock in the Company at the fair market value on the date of grant (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Option</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The shares subject to the Option will vest over four years of continuous service to the Company, with twenty-five percent (25%) of the shares subject to the Option vesting on the first year anniversary of the Effective Date, and the remaining shares vesting in equal monthly installments over the subsequent thirty-six (36) months of continuous service thereafter.  The Option shall be governed in all respects by the terms of the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as amended, and option agreement between Executive and the Company. Executive shall be entitled to be considered for additional stock option grants under the Plan, as approved by the Board (or a committee thereof) in its sole discretion.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">4.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TERMINATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination by the Company.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive&#8217;s employment with the Company is at will and may be terminated by the Company at any time and for any reason, or for no reason, including, but not limited to, under the following conditions&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination by the Company for Cause</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company may terminate Executive&#8217;s employment under this Agreement for Cause by delivery of written notice to Executive. Any notice of termination given pursuant to this Section shall effect termination as of the date of the notice, or as of such other date specified in the notice.&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination by the Company without Cause</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company may terminate Executive&#8217;s employment under this Agreement without Cause at any time and for any reason, or for no reason. Such termination shall be effective on the date Executive is so informed by the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination by Executive</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive may terminate Executive&#8217;s employment with the Company at any time and for any reason, or for no reason, upon 30&#160;days&#8217; written notice to the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination for Death or Complete Disability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive&#8217;s employment with the Company shall automatically terminate effective upon the date of Executive&#8217;s death or Complete Disability (as defined below).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination by Mutual Agreement of the Parties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive&#8217;s employment with the Company may be terminated at any time upon a mutual agreement in writing of the Parties. Any such termination of employment shall have the consequences specified in such agreement.</font></div><div style="margin-top:18pt;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compensation upon Termination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Death or Complete Disability.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If Executive&#8217;s employment with the Company is terminated as a result of Executive&#8217;s death or Complete Disability, the Company shall pay to Executive, or to Executive&#8217;s heirs, Executive&#8217;s base salary and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, less standard deductions and withholdings. The Company shall thereafter have no further obligations to Executive and&#47;or Executive&#8217;s heirs under this Agreement, except as otherwise provided by law (and except as provided otherwise in Executive&#8217;s stock option agreements with the Company).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">With Cause or Without Good Reason.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Executive&#8217;s employment with the Company is terminated at any time either by the Company for Cause or by Executive without Good Reason, the Company shall pay the Accrued Obligations, and the Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise provided by law (and except as provided otherwise in Executive&#8217;s stock option agreements with the Company).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Without Cause or for Good Reason</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Executive&#8217;s employment with the Company is terminated by the Company without Cause or by Executive for Good Reason, and in either case Executive signs a separation agreement including a comprehensive waiver and release of claims in such form as the Company may require (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Release&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) on or within the time period set forth therein, but in no event later than 45 days after Executive&#8217;s termination date, and allows such Release to become effective in accordance with its terms (such latest permitted date on which the Release could become effective, the (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Release Deadline&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), then Executive will receive the following benefits&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:104.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.3.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severance Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Cash payments in the form of continuation of Executive&#8217;s Base Salary at the rate in effect at the time of termination for a period of six (6) months following the termination date (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Severance Payment&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:104.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.3.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Benefits</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Provided that Executive is eligible for and timely elects continued group health coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;COBRA&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) following Executive&#8217;s termination date, the Company shall pay directly to the insurance provider the premium for COBRA continuation coverage for Executive and Executive&#8217;s family for a period that will expire upon the earliest of (i)&#160;six (6) months following the termination date (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;COBRA Payment Period&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), (ii) the effective date that Executive becomes eligible for new healthcare coverage eligibility available through new employment, or (iii)&#160;the date Executive is no longer eligible for COBRA coverage, whichever comes first.</font></div><div style="margin-top:18pt;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">General Severance Benefit Terms</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:104.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.4.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;The provisions in this Section&#160;shall control and supersede anything to the contrary set forth in this Agreement. For all purposes of this Agreement, references to COBRA premiums shall not include any amounts payable by Executive under a Section 125 health care reimbursement plan under the Code. If at any time the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section&#160;2716 of the Public Health Service Act), then regardless of whether Executive elects continued health coverage under COBRA, and in lieu of providing COBRA premiums, the Company will instead pay Executive on the last day of each remaining month of the COBRA Payment Period a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings, which payments shall continue until the earlier of expiration of the COBRA Payment Period of the date when Executive becomes eligible for health insurance coverage in connection with new employment. If Executive becomes eligible for coverage under another employer&#8217;s group health plan, Executive must immediately notify the Company of such event, and all COBRA severance benefit payments and obligations under this Agreement shall cease effective as of such date of Executive&#8217;s eligibility.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:104.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.5.4.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;If all severance payments made under this Agreement will be subject to standard payroll deductions and withholdings and will be made on the Company&#8217;s regular payroll cycle, provided, however, that any severance payments otherwise scheduled to be made prior to the effective date of the Release shall instead accrue and be paid in the first payroll period that follows such effective date. Following provisions of any severance benefits to which Executive may be entitled under Section&#160;4.5.3, the Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise provided by law (and except as provided otherwise in Executive&#8217;s stock option agreements with the Company).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Definitions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For the purposes of this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Complete Disability&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall mean the inability of executive to perform Executive&#8217;s duties under this Agreement, whether with or without reasonable accommodation, because Executive has become permanently disabled within the meaning of any policy of disability income insurance covering employees of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when Executive becomes disabled, the term&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Complete Disability&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;shall mean the inability of Executive to perform Executive&#8217;s duties under this Agreement, whether with or without reasonable accommodation, by reason of any incapacity, physical or mental, which the Company, based upon medical advice or an opinion provided by a licensed physician acceptable to the Company, determines to have incapacitated Executive from satisfactorily performing all of Executive&#8217;s usual services for the Company, with or without reasonable accommodation, for a period of at least on hundred 120&#160;days during any 12-month period (whether or not consecutive). Based upon such medical advice or opinion, the determination of the Company shall be final and binding and the date such determination is made shall be the date of such Complete Disability for purposes of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Cause&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall mean the occurrence of any of the following&#58; (i)&#160;Executive&#8217;s conviction of any felony or any crime involving fraud or dishonesty that has a material adverse effect on the Company&#59; (ii)&#160;Executive&#8217;s active participation (whether by affirmative act or material omission) in a fraud, act of dishonesty or other act of misconduct against the Company and&#47;or its affiliates&#59; (iii)&#160;conduct by Executive which, based upon a good faith and reasonable factual investigation by the Company, demonstrates Executive&#8217;s gross unfitness to serve&#59; (iv)&#160;Executive&#8217;s material violation of any statutory or fiduciary duty, or duty of loyalty, owed to the Company&#59; (v)&#160;Executive&#8217;s breach of any material term of any material contract between such Executive and the Company and the failure to cure such breach within 30 days of written notice&#59; and (vi)&#160;Executive&#8217;s repeated violation of any material Company policy. Executive&#8217;s Complete Disability shall not constitute Cause as set forth herein. The determination that a termination is for Cause shall be by the Company in its sole and exclusive judgement and discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:79.55pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Good Reason</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Good Reason&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;for Executive to terminate Executive&#8217;s employment hereunder shall mean the occurrence of any of the following events without Executive&#8217;s consent&#59; provided however, that any resignation by Executive due to any of the following conditions shall only be deemed for Good Reason if&#58; (i)&#160;Executive gives the Company written notice of the intent to terminate for Good Reason within 90 days following the first occurrence of the condition(s) that Executive believes constitutes Good Reason, which notice shall describe such condition(s)&#59; (ii) the Company fails to remedy such condition(s) within 30 days following receipt of the written notice (the&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Cure Period&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) of such condition(s) from Executive&#59; and (iii)&#160;Executive actually resigns Executive&#8217;s employment within the first 15 days after expiration of the Cure Period&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:104.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;a material breach of this Agreement by the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:104.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;a material reduction (which the parties agree is a reduction of at least 10% of Executive&#8217;s Base Salary) by the Company of Executive&#8217;s Base Salary as initially set forth herein or as the same may be increased from time to time, unless such reduction is part of a reduction program equally applicable to other executive employees of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:104.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;a material reduction in Executive&#8217;s authority, duties or responsibilities, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; in and of itself unless Executive&#8217;s new duties are materially reduced from the prior duties&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:104.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.6.3.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;the Company relocates the facility that is Executive&#8217;s principal place of business with the Company to a location that requires an increase in Executive&#8217;s&#160;one-way&#160;driving distance by more than 50 miles, provided that Executive&#8217;s relocation back to the Company office from remote work will not be considered a relocation of Executive&#8217;s principal place of business for purposes of this definition.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Survival of Certain Provisions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Sections 2, 3.3, 3.5, and 4 through 19 of this Agreement shall survive the termination of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reserved</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:18pt;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application of Internal Revenue Code Section&#160;409A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All benefits under this Agreement are intended to qualify for an exemption from application of Section&#160;409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Section&#160;409A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section&#160;409A, and any ambiguities herein shall be interpreted accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary set forth herein, any severance benefits that constitute &#8220;deferred compensation&#8221; within the meaning of Section&#160;409A shall not commence in connection with Executive&#8217;s termination of employment unless and until Executive has also incurred a &#8220;separation from service&#8221; (as such term is defined in Treasury Regulation&#160;Section&#160;1.409A-1(h))&#160;(&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Separation From Service</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional 20% tax under Section&#160;409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It is intended that each installment of the severance benefit payments provided for in this Agreement is a separate &#8220;payment&#8221; for purposes of Treasury Regulation Section&#160;1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments of the severance benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section&#160;409A provided under Treasury Regulation Sections&#160;1.409A-1(b)(4),&#160;1.409A-1(b)(5)&#160;and&#160;1.409A-1(b)(9).&#160;However, if the Company (or, if applicable, the successor entity thereto) determines that the severance benefits constitute &#8220;deferred compensation&#8221; under Section&#160;409A and Executive is, on the termination of service, a &#8220;specified employee&#8221; of the Company or any successor entity thereto, as such term is defined in Section&#160;409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section&#160;409A, the timing of the severance benefit payments shall be delayed until the earlier to occur of&#58; (i)&#160;the date that is six months and one day after Executive&#8217;s Separation From Service, or (ii)&#160;the date of Executive&#8217;s death. None of the severance benefits will be paid or otherwise delivered prior to the effective date of the Release. If the severance benefits are not covered by one or more exemptions from the application of Section&#160;409A and the Release could become effective in the calendar year following the calendar year in which Executive&#8217;s Separation From Service occurs, the Release will not be deemed effective any earlier than the Release Deadline. Except to the minimum extent that payments must be delayed because Executive is a &#8220;specified employee&#8221; or until the effectiveness of the Release, all amounts will be paid as soon as practicable in accordance with the Company&#8217;s normal payroll practices.</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The severance benefits are intended to qualify for an exemption from application of Section&#160;409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section&#160;409A, and any ambiguities herein shall be interpreted accordingly.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">5.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONFIDENTIAL&#160;AND&#160;PROPRIETARY&#160;INFORMATION&#59; NONSOLICITATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;As a condition of employment, Executive agrees to execute and abide by the Company&#8217;s Confidential Information and Inventions Assignment Agreement attached hereto as&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT&#160;A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:48.95pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;While employed by the Company and for one year thereafter, Executive agrees that in order to protect the Company&#8217;s trade secrets and confidential and proprietary information from unauthorized use, Executive will not, either directly or through others, solicit or attempt to solicit any employee, consultant or independent contractor of the Company to terminate his or her relationship with the Company in order to become an employee, consultant or independent contractor to or for any other person or business entity.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">6.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ASSIGNMENT&#160;AND&#160;BINDING&#160;EFFECT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be binding upon and inure to the benefit of Executive and Executive&#8217;s heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of Executive&#8217;s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement shall be assignable by Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">7.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOTICES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All notices or demands of any kind required or permitted to be given by the Company or Executive under this Agreement shall be given in writing and shall be personally delivered (and receipted for) or faxed during normal business hours or mailed by certified mail return receipt requested, postage prepaid, address as follows,</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:0.02pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.910%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">If to the Company&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">If to Executive&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Attn&#58; Chief Executive Officer</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Richard Shippy</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Bionano Genomics, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">9540 Towne Centre Drive, Suite 100</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">San Diego, CA 92121</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or three days after its deposit in the United States mail as specified above. Either Party may change its address for notices by giving notice to the other Party in the manner specified in this Section.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">8.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CHOICE&#160;OF&#160;LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement shall be construed and interpreted in accordance with the internal laws of the State of California without regard to its conflict of laws principles.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">9.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INTEGRATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement, including&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of Executive&#8217;s employment and the termination of Executive&#8217;s employment, and supersedes all prior and&#47;or contemporaneous oral and written employment agreements or arrangements between the Parties.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">10.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement cannot be amended or modified except by a written agreement signed by Executive and the Company.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">11.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">WAIVER.</font></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">12.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SEVERABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision which most accurately represents the Parties&#8217; intention with respect to the invalid or unenforceable term or provision.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">13.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INTERPRETATION&#59; CONSTRUCTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but Executive has been encouraged to consult with, and have consulted with, Executive&#8217;s own independent counsel and tax advisors with respect to the terms of this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">14.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">REPRESENTATIONS&#160;AND&#160;WARRANTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive represents and warrants that Executive is not restricted or prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that Executive&#8217;s execution and performance of this Agreement will not violate or breach any other agreements between Executive and any other person or entity.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">15.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COUNTERPARTS&#59;&#160;FACSIMILE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement may be executed in two counterparts, each of which shall be deemed an original, all of which together shall contribute one and the same instrument. Facsimile signatures shall be treated the same as original signatures.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">16.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DISPUTE&#160;RESOLUTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To ensure the timely and economical resolution of disputes that may arise between Executive and the Company, both Executive and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by applicable law, Executive and the Company will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement&#59; or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Executive&#8217;s employment with the Company (including but not limited to all statutory claims)&#59; or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the termination of Executive&#8217;s employment with the Company (including but not limited to all statutory claims). </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such disputes through a trial by jury or judge or through an administrative proceeding.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arbitrator Authority</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition.  </font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Individual Capacity Only</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All claims, disputes, or causes of action under this Section, whether by Executive or the Company, must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.&#160;&#160; The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.&#160; To the extent that the preceding sentences in this Section are found to violate applicable law </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.&#160;&#160; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arbitration Process</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by Judicial Arbitration and Mediation Services, Inc. (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">JAMS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in San Diego, California, or as otherwise agreed to by Executive and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">).&#160;&#160;Executive and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&#8217;s own expense.&#160;&#160;The arbitrator shall&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> have the authority to compel adequate discovery for the resolution of the dispute&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award&#59; and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of law.&#160;&#160; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Section shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act  or otherwise invalid (collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excluded Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  In the event Executive intends to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Injunctive Relief and Final Orders</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Section is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">17.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRADE&#160;SECRETS&#160;OF&#160;OTHERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It is the understanding of both the Company and Executive that Executive shall not divulge to the Company and&#47;or its subsidiaries any confidential information or trade secrets belonging to others, including Executive&#8217;s former employers, nor shall the Company and&#47;or its Affiliates seek to elicit from Executive any such information. Consistent with the foregoing, Executive shall not provide to the Company and&#47;or its Affiliates, and the Company and&#47;or its Affiliates shall not request, any documents or copies of documents containing such information.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">18.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADVERTISING&#160;WAIVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive agrees to permit the Company and&#47;or its affiliates, subsidiaries, or joint ventures currently existing or which shall be established during Executive&#8217;s employment by the Company (collectively,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Affiliates&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), and persons or other organizations authorized by the Company and&#47;or its Affiliates, to use, publish and distribute advertising or sales promotional literature concerning the products and&#47;or services of the Company and&#47;or its Affiliates, or the machinery and equipment used in the provision thereof, in which Executive&#8217;s name and&#47;or pictures of Executive taken in the course of Executive&#8217;s provision of services to the Company and&#47;or its Affiliates, appear. Executive hereby waives and releases any claim or right Executive may otherwise have arising out of such use, publication or distribution. The Company agrees that, following termination of Executive&#8217;s employment, it will not create any new such literature containing Executive&#8217;s name and&#47;or pictures without Executive&#8217;s prior written consent.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">19.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INDEMNIFICATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to applicable law, Executive will be provided indemnification to the maximum extent permitted by the Company&#8217;s Bylaws and Articles of Incorporation, including coverage, if applicable, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">under any directors and officers insurance policies, with such indemnification determined by the Board or any of its committees in good faith based on principles consistently applied (subject to such limited exceptions as the Board may approve in cases of hardship) and on terms no less favorable than provided to any other Company executive officer or director.</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN&#160;WITNESS&#160;WHEREOF</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have executed this Agreement as of the date first above written.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.865%"><tr><td style="width:0.1%"></td><td style="width:1.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.370%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">BIONANO&#160;GENOMICS, INC</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.224%"><tr><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.543%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#47;s&#47; R. Erik Holmlin</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">R. Erik Holmlin, President and CEO</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.064%"><tr><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.500%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Date&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">EXECUTIVE</font></td></tr><tr style="height:9pt"><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#47;s&#47; Richard Shippy</font></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Richard Shippy</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.224%"><tr><td style="width:1.0%"></td><td style="width:11.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.558%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Date&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">May 16, 2021</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT&#160;A</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONFIDENTIAL&#160;INFORMATION&#160;AND&#160;INVENTIONS&#160;ASSIGNMENT&#160;AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>7
<FILENAME>bngo-1038_bionanoxcommerci.htm
<DESCRIPTION>EX-10.38
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i764b30bb8012429882c9d72967b0d63a_1"></div><div style="min-height:59.76pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.38</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL SINGLE-TENANT LEASE -- NET</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Basic Provisions (&#8220;Basic Provisions&#8221;).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parties&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Lease </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(&#8220;Lease&#8221;), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dated for reference purposes only, is made by and between TESA BEACH, LLC </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(&#8220;Lessor&#8221;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and BioDiscovery, Inc. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(&#8220;Lessee&#8221;), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Parties,&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or individually a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Party&#8221;).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Premises&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That certain real property, including all improvements therein or to be provided by Lessor under the terms of this Lease, and commonly known as 715 N. Douglas Avenue, El Segundo 90245 located in the County of Los Angeles, State of California, and generally described as the Office Suite (&#8220;Premises&#8221;). (See also Paragraph 2)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 years (&#8220;Original Term&#8221;) commencing March 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2016 (&#8220;Commencement Date&#8221;) and ending February 28, 2041 (&#8220;Expiration Date&#8221;). (See also Paragraph 3)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option to Renew&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided that Tenant is not in default in the performance of this Lease, Tenant shall have the option to renew the Lease for one additional term of 60 months commencing at the expiration of the initial Lease term. All of the terms and conditions of the Lease shall apply during the renewal term except that the monthly rent shall be the determined based on future market rents (subject to the restrictions of paragraph 4, below). The option shall be exercised by written notice given to Lessor not less than 90 days prior to the expiration of the prior Lease term. If notice is not given in the manner provided herein within the time specified, this option shall lapse and expire</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base Rent&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25,000 per month (&#8220;Base Rent&#8221;), payable on the day of each month commencing March 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2016. (See also Paragraph 4) </font><font style="font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If this box is checked, there are provisions in this Lease for the Base Rent to be adjusted. See Paragraph </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">51  </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base Rent and Other Monies Paid Upon Execution&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Base Rent&#58; $25,000 for the period March 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2016 to March 31</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2016. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Security Deposit&#58; $35,000 (&#8220;Security Deposit&#8221;). (See also Paragraph 5)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Association Fees&#58; $ 2013.35 for the period March 1st to March 31st, 2016.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Total Due Upon Execution of this Lease&#58; $62,013.35.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreed Use&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General office space. (See also Paragraph 6)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insuring Party&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor is the &#8220;Insuring Party&#8221; unless otherwise stated herein. (See also Paragraph 8)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Premises.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letting. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the Premises, for the term, at the rental, and upon all of the terms, covenants and conditions set forth in this Lease. While the approximate square footage of the Premises may have been used in the marketing of the Premises for purposes of comparison, the Base Rent stated herein is NOT tied to square footage and is not subject to adjustment should the actual size be determined to be different. Note&#58; Lessee is advised to verify the actual size prior to executing this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condition. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor shall deliver the Premises to Lessee broom clean and free of debris on the Commencement Date or the Early Possession Date, whichever first occurs (&#8220;Start Date&#8221;), and, so long as the required service contracts described in Paragraph 7.1(b) below are obtained by Lessee and in effect within thirty days following the Start Date, warrants that the existing electrical, plumbing, fire sprinkler, lighting, heating, ventilating and air conditioning systems (&#8220;HVAC&#8221;), loading doors, sump pumps, if any, and all other such elements in the Premises, other than those constructed by Lessee, shall be in good operating condition on said date, that the structural elements of the roof, bearing walls and foundation of any buildings on the Premises (the &#8220;Building&#8221;) shall be free of material defects, and that the Premises do not contain hazardous levels of any mold or fungi defined as toxic under applicable state or federal law. If a non-compliance with said warranty exists as of the Start Date, or if one of such systems or elements should malfunction or fail within the appropriate warranty period, Lessor shall, as Lessor&#8217;s sole obligation with respect to such matter, except as otherwise provided in this Lease, promptly after receipt of written notice from Lessee setting forth with specificity the nature and extent of such non-compliance, malfunction or failure, rectify same at Lessor&#8217;s expense. The warranty periods shall be as follows&#58; (i) 6 months as to the HVAC systems, and (ii) 30 days as to the remaining systems and other elements of the Building. If Lessee does not give Lessor the required notice within the appropriate warranty period, correction of any such noncompliance, malfunction or failure shall be the obligation of Lessee at Lessee&#8217;s sole cost and expense. Lessor also warrants, that unless otherwise specified in writing, Lessor is unaware of (i) any recorded Notices of Default affecting the Premise&#59; (ii) any delinquent amounts due under any loan secured by the Premises&#59; and (iii) any bankruptcy proceeding affecting the Premises.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compliance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor warrants that to the best of its knowledge the improvements on the Premises comply with the building codes applicable laws, covenants or restrictions of record, regulations, and ordinances (&#8220;Applicable Requirements&#8221;) that were in effect at the time that each improvement, or portion thereof, was constructed. Said warranty does not apply to the use to which Lessee will put the Premises, modifications which may be required by the Americans with Disabilities Act or any similar laws as a result of Lessee&#8217;s use (see Paragraph 50), or to any Alterations or Utility Installations (as defined in Paragraph 7.3(a)) made or to be made by Lessee. NOTE&#58; Lessee is responsible for determining whether or not the Applicable Requirements, and especially the zoning, are appropriate for Lessee&#8217;s intended use, and acknowledges that past uses of the Premises may no longer be allowed. If the Premises do not comply with said warranty, Lessor shall, except as otherwise provided, promptly after receipt of written notice from Lessee setting forth with specificity the nature and extent of such</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">non-compliance, rectify the same at Lessor&#8217;s expense. If Lessee does not give Lessor written notice of a non-compliance with this warranty within 6 months following the Start Date, correction of that non-compliance shall be the obligation of Lessee at Lessee&#8217;s sole cost and expense. If the Applicable Requirements are hereafter changed so as to require during the term of this Lease the construction of an addition to or an alteration of the Premises and&#47;or Building, the remediation of any Hazardous Substance, or the reinforcement or other physical modification of the Unit, Premises and&#47;or Building (&#8220;Capital Expenditure&#8221;), Lessor and Lessee shall allocate the cost of such work as follows&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) Subject to Paragraph 2.3(c) below, if such Capital Expenditures are required as a result of the specific and unique use of the Premises by Lessee as compared with uses by tenants in general, Lessee shall be fully responsible for the cost thereof, provided, however that if such Capital Expenditure is required during the last 2 years of this Lease and the cost thereof exceeds 6 months&#8217; Base Rent, Lessee may instead terminate this Lease unless Lessor notifies Lessee, in writing, within 10 days after receipt of Lessee&#8217;s termination notice that Lessor has elected to pay the difference between the actual cost thereof and an amount equal to 6 months&#8217; Base Rent. If Lessee elects termination, Lessee shall immediately cease the use of the Premises which requires such Capital Expenditure and deliver to Lessor written notice specifying a termination date at least 90 days thereafter. Such termination date shall, however, in no event be earlier than the last day that Lessee could legally utilize the Premises without commencing such Capital Expenditure.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) If such Capital Expenditure is not the result of the specific and unique use of the Premises by Lessee (such as, governmentally mandated seismic modifications), then Lessor shall pay for such Capital Expenditure and Lessee shall only be obligated to pay, each month during the remainder of the term of this Lease or any extension thereof, on the date that on which the Base Rent is due, an amount equal to 1&#47;144th of the portion of such costs reasonably attributable to the Premises. Lessee shall pay Interest on the balance but may prepay its obligation at any time. If, however, such Capital Expenditure is required during the last 2 years of this Lease or if Lessor reasonably determines that it is not economically feasible to pay its share thereof, Lessor shall have the option to terminate this Lease upon 90 days prior written notice to Lessee unless Lessee notifies Lessor, in writing, within 10 days after receipt of Lessor&#8217;s termination notice that Lessee will pay for such Capital Expenditure. If Lessor does not elect to terminate, and fails to tender its share of any such Capital Expenditure, Lessee may advance such funds and deduct same, with Interest, from Rent until Lessor&#8217;s share of such costs have been fully paid. If Lessee is unable to finance Lessor&#8217;s share, or if the balance of the Rent due and payable for the remainder of this Lease is not sufficient to fully reimburse Lessee on an offset basis, Lessee shall have the right to terminate this Lease upon 30 days written notice to Lessor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(c) Notwithstanding the above, the provisions concerning Capital Expenditures are intended to apply only to non-voluntary, unexpected, and new Applicable Requirements. If the Capital Expenditures are instead triggered by Lessee as a result of an actual or proposed change in use, change in intensity of use, or modification to the Premises then, and in that event, Lessee shall either&#58; (i) immediately cease such changed use or intensity of use and&#47;or take such other steps as may be necessary to eliminate the requirement for such Capital Expenditure, or (ii) complete such Capital Expenditure at its own expense. Lessee shall not, however, have any right to terminate this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Acknowledgements. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee acknowledges that&#58; (a) it has been given an opportunity to inspect and measure the Premises, (b) it has been advised by Lessor and&#47;or Brokers to satisfy itself with respect to the size and condition of the Premises (including but not limited to the electrical, HVAC and fire sprinkler systems, security, environmental aspects, and compliance with Applicable Requirements and the Americans with Disabilities Act), and their suitability for Lessee&#8217;s intended use, (c) Lessee has made such investigation as it deems necessary with reference to such matters and assumes all responsibility therefor as the same relate to its occupancy of the Premises, (d) it is not relying on any representation as to the size of the Premises made by Brokers or Lessor, (e) the square footage of the Premises was not material to Lessee&#8217;s decision to lease the Premises and pay the Rent stated herein, and (f) neither Lessor, Lessor&#8217;s agents, nor Brokers have made any oral or written representations or warranties with respect to said matters other than as set forth in this Lease. In addition, Lessor acknowledges that&#58; (i) Brokers have made no representations, promises or warranties concerning Lessee&#8217;s ability to honor the Lease or suitability to occupy the Premises, and (ii) it is Lessor&#8217;s sole responsibility to investigate the financial capability and&#47;or suitability of all proposed tenants.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Lessee as Prior Owner&#47;Occupant. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warranties made by Lessor in Paragraph 2 shall be of no force or effect if immediately prior to the Start Date Lessee was the owner or occupant of the Premises. In such event, Lessee shall be responsible for any necessary corrective work.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Term.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Term. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Commencement Date, Expiration Date and Original Term of this Lease are as specified in Paragraph 1.3.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Lessee Compliance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessor shall not be required to deliver possession of the Premises to Lessee until Lessee complies with its obligation to provide evidence of insurance (Paragraph 8.5). Pending delivery of such evidence, Lessee shall be required to perform all of its obligations under this Lease from and after the Start Date, including the payment of Rent, notwithstanding Lessor&#8217;s election to withhold possession pending receipt of such evidence of insurance. Further, if Lessee is required to perform any other conditions prior to or concurrent with the Start Date, the Start Date shall occur but Lessor may elect to withhold possession until such conditions are satisfied.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Rent.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4.1. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Rent Defined. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All monetary obligations of Lessee to Lessor under the terms of this Lease (except for the Security Deposit) are deemed to be rent </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(&#8220;Rent&#8221;).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Payment. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall cause payment of Rent to be received by Lessor in lawful money of the United States, without offset or deduction (except as specifically permitted in this Lease), on or before the day on which it is due. All monetary amounts shall be rounded to the nearest</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">whole dollar. In the event that any invoice prepared by Lessor is inaccurate such inaccuracy shall not constitute a waiver and Lessee shall be obligated to pay the amount set forth in this Lease. Rent for any period during the term hereof which is for less than one full calendar month shall be prorated based upon the actual number of days of said month. Payment of Rent shall be made to Lessor at its address stated herein or to such other persons or place as Lessor may from time to time designate in writing. Acceptance of a payment which is less than the amount then due shall not be a waiver of Lessor&#8217;s rights to the balance of such Rent, regardless of Lessor&#8217;s endorsement of any check so stating. In the event that any check, draft, or other instrument of payment given by Lessee to Lessor is dishonored for any reason, Lessee agrees to pay to Lessor the sum of $25 in addition to any Late Charge and Lessor, at its option, may require all future Rent be paid by cashier&#8217;s check. Payments will be applied first to accrued late charges and attorney&#8217;s fees, second to accrued interest, then to Base Rent, Insurance and Real Property Taxes, and any remaining amount to any other outstanding charges or costs.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Association Fees. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the Base Rent, Lessee shall pay to Lessor each month an amount equal to any owner&#8217;s association or condominium fees levied or assessed against the Premises. Said monies shall be paid at the same time and in the same manner as the Base Rent. Lessee may pay the association fee directly to the association.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Security Deposit. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall deposit with Lessor upon execution hereof the Security Deposit as security for Lessee&#8217;s faithful performance of its obligations under this Lease. If Lessee fails to pay Rent, or otherwise Defaults under this Lease, Lessor may use, apply or retain all or any portion of said Security Deposit for the payment of any amount already due Lessor, for Rents which will be due in the future, and&#47; or to reimburse or compensate Lessor for any liability, expense, loss or damage which Lessor may suffer or incur by reason thereof. If Lessor uses or applies all or any portion of the Security Deposit, Lessee shall within 10 days after written request therefor deposit monies with Lessor sufficient to restore said Security Deposit to the full amount required by this Lease. If the Base Rent increases during the term of this Lease, Lessee shall, upon written request from Lessor, deposit additional monies with Lessor so that the total amount of the Security Deposit shall at all times bear the same proportion to the increased Base Rent as the initial Security Deposit bore to the initial Base Rent. Should the Agreed Use be amended to accommodate a material change in the business of Lessee or to accommodate a sublessee or assignee, Lessor shall have the right to increase the Security Deposit to the extent necessary, in Lessor&#8217;s reasonable judgment, to account for any increased wear and tear that the Premises may suffer as a result thereof. If a change in control of Lessee occurs during this Lease and following such change the financial condition of Lessee is, in Lessor&#8217;s reasonable judgment, significantly reduced, Lessee shall deposit such additional monies with Lessor as shall be sufficient to cause the Security Deposit to be at a commercially reasonable level based on such change in financial condition. Lessor shall not be required to keep the Security Deposit separate from its general accounts. Within 30 days after the expiration or termination of this Lease, Lessor shall return that portion of the Security Deposit not used or applied by Lessor. No part of the Security Deposit shall be considered to be held in trust, to bear interest or to be prepayment for any monies to be paid by Lessee under this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Use.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Use. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall use and occupy the Premises only for the Agreed Use, or any other legal use which is reasonably comparable thereto, and for no other purpose. Lessee shall not use or permit the use of the Premises in a manner that is unlawful, creates damage, waste or a nuisance, or that disturbs occupants of or causes damage to neighboring premises or properties. Other than guide, signal and seeing eye dogs, Lessee shall not keep or allow in the Premises any pets, animals, birds, fish, or reptiles. Lessor shall not unreasonably withhold or delay its consent to any written request for a modification of the Agreed Use, so long as the same will not impair the structural integrity of the improvements on the Premises or the mechanical or electrical systems therein, and&#47;or is not significantly more burdensome to the Premises. If Lessor elects to withhold consent, Lessor shall within 7 days after such request give written notification of same, which notice shall include an explanation of Lessor&#8217;s objections to the change in the Agreed Use.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Hazardous Substances.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Reportable Uses Require Consent. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> &#8220;Hazardous Substance&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">as used in this Lease shall mean any product, substance, or waste whose presence, use, manufacture, disposal, transportation, or release, either by itself or in combination with other materials expected to be on the Premises, is either&#58; (i) potentially injurious to the public health, safety or welfare, the environment or the Premises, (ii) regulated or monitored by any governmental authority, or (iii) a basis for potential liability of Lessor to any governmental agency or third party under any applicable statute or common law theory. Hazardous Substances shall include, but not be limited to, hydrocarbons, petroleum, gasoline, and&#47;or crude oil or any products, by-products or fractions thereof. Lessee shall not engage in any activity in or on the Premises which constitutes a Reportable Use of Hazardous Substances without the express prior written consent of Lessor and timely compliance (at Lessee&#8217;s expense) with all Applicable Requirements. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Reportable Use&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean (i) the installation or use of any above or below ground storage tank, (ii) the generation, possession, storage, use, transportation, or disposal of a Hazardous Substance that requires a permit from, or with respect to which a report, notice, registration or business plan is required to be filed with, any governmental authority, and&#47;or (iii) the presence at the Premises of a Hazardous Substance with respect to which any Applicable Requirements requires that a notice be given to persons entering or occupying the Premises or neighboring properties. Notwithstanding the foregoing, Lessee may use any ordinary and customary materials reasonably required to be used in the normal course of the Agreed Use, ordinary office supplies (copier toner, liquid paper, glue, etc.) and common household cleaning materials, so long as such use is in compliance with all Applicable Requirements, is not a Reportable Use, and does not expose the Premises or neighboring property to any meaningful risk of contamination or damage or expose Lessor to any liability therefor. In addition, Lessor may condition its consent to any Reportable Use upon receiving such additional assurances as Lessor reasonably deems necessary to protect itself, the public, the Premises and&#47;or the environment against damage, contamination, injury and&#47;or liability, including, but not limited to, the installation (and removal on or before Lease expiration or termination) of protective modifications (such as concrete encasements) and&#47;or increasing the Security Deposit.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Duty to Inform Lessor. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If Lessee knows, or has reasonable cause to believe, that a Hazardous Substance has come to be located in, on, under or about the Premises, other than as previously consented to by Lessor, Lessee shall immediately give written notice of such fact to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessor, and provide Lessor with a copy of any report, notice, claim or other documentation which it has concerning the presence of such Hazardous Substance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lessee Remediation. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessee shall not cause or permit any Hazardous Substance to be spilled or released in, on, under, or about the Premises (including through the plumbing or sanitary sewer system) and shall promptly, at Lessee&#8217;s expense, comply with all Applicable Requirements and take all investigatory and&#47;or remedial action reasonably recommended, whether or not formally ordered or required, for the cleanup of any contamination of, and for the maintenance, security and&#47;or monitoring of the Premises or neighboring properties, that was caused or materially contributed to by Lessee, or pertaining to or involving any Hazardous Substance brought onto the Premises during the term of this Lease, by or for Lessee, or any third party.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lessee Indemnification. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessee shall indemnify, defend and hold Lessor, its agents, employees, lenders and ground lessor, if any, harmless from and against any and all loss of rents and&#47;or damages, liabilities, judgments, claims, expenses, penalties, and attorneys&#8217; and consultants&#8217; fees arising out of or involving any Hazardous Substance brought onto the Premises by or for Lessee, or any third </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">party (provided, however, that Lessee shall have no liability under this Lease with respect to underground migration of any Hazardous Substance under the Premises from adjacent properties not caused or contributed to by Lessee). Lessee&#8217;s obligations shall include, but not be limited to, the effects of any contamination or injury to person, property or the environment created or suffered by Lessee, and the cost of investigation, removal, remediation, restoration and&#47;or abatement, and shall survive the expiration or termination of this Lease. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">No termination, cancellation or release agreement entered into by Lessor and Lessee shall release Lessee from its obligations under this Lease with respect to Hazardous Substances, unless specifically so agreed by Lessor in writing at the time of such agreement.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lessor Indemnification. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as otherwise provided in paragraph 8.7, Lessor and its successors and assigns shall indemnify, defend, reimburse and hold Lessee, its employees and lenders, harmless from and against any and all environmental damages, including the cost of remediation, which result from Hazardous Substances which existed on the Premises prior to Lessee&#8217;s occupancy or which are caused by the gross negligence or willful misconduct of Lessor, its agents or employees. Lessor&#8217;s obligations, as and when required by the Applicable Requirements, shall include, but not be limited to, the cost of investigation, removal, remediation, restoration and&#47;or abatement, and shall survive the expiration or termination of this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investigations and Remediations. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessor shall retain the responsibility and pay for any investigations or remediation measures required by governmental entities having jurisdiction with respect to the existence of Hazardous Substances on the Premises prior to Lessee&#8217;s occupancy, unless such remediation measure is required as a result of Lessee&#8217;s use (including &#8220;Alterations&#8221;, as defined in paragraph 7.3(a) below) of the Premises, in which event Lessee shall be responsible for such payment. Lessee shall cooperate fully in any such activities at the request of Lessor, including allowing Lessor and Lessor&#8217;s agents to have reasonable access to the Premises at reasonable times in order to carry out Lessor&#8217;s investigative and remedial responsibilities.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lessor Termination Option. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If a Hazardous Substance Condition (see Paragraph 9.1(e)) occurs during the term of this Lease, unless Lessee is legally responsible therefor (in which case Lessee shall make the investigation and remediation thereof required by the Applicable Requirements and this Lease shall continue in full force and effect, but subject to Lessor&#8217;s rights under Paragraph 6.2(d) and Paragraph 13), Lessor may, at Lessor&#8217;s option, either (i) investigate and remediate such Hazardous Substance Condition, if required, as soon as reasonably possible at Lessor&#8217;s expense, in which event this Lease shall continue in full force and effect, or (ii) if the estimated cost to remediate such condition exceeds 12 times the then monthly Base Rent or $100,000, whichever is greater, give written notice to Lessee, within 30 days after receipt by Lessor of knowledge of the occurrence of such Hazardous Substance Condition, of Lessor&#8217;s desire to terminate this Lease as of the date 60 days following the date of such notice. In the event Lessor elects to give a termination notice, Lessee may, within 10 days thereafter, give written notice to Lessor of Lessee&#8217;s commitment to pay the amount by which the cost of the remediation of such Hazardous Substance Condition exceeds an amount equal to 12 times the then monthly Base Rent or $100,000, whichever is greater. Lessee shall provide Lessor with said funds or satisfactory assurance thereof within 30 days following such commitment. In such event, this Lease shall continue in full force and effect, and Lessor shall proceed to make such remediation as soon as reasonably possible after the required funds are available. If Lessee does not give such notice and provide the required funds or assurance thereof within the time provided, this Lease shall terminate as of the date specified in Lessor&#8217;s notice of termination.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lessee&#8217;s Compliance with Applicable Requirements. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as otherwise provided in this Lease, Lessee shall, at Lessee&#8217;s sole expense, fully, diligently and in a timely manner, materially comply with all Applicable Requirements, the requirements of any applicable fire insurance underwriter or rating bureau, and the recommendations of Lessor&#8217;s engineers and&#47;or consultants which relate in any manner to the such Requirements, without regard to whether such Requirements are now in effect or become effective after the Start Date. Lessee shall, within 10 days after receipt of Lessor&#8217;s written request, provide Lessor with copies of all permits and other documents, and other information evidencing Lessee&#8217;s compliance with any Applicable Requirements specified by Lessor, and shall immediately upon receipt, notify Lessor in writing (with copies of any documents involved) of any threatened or actual claim, notice, citation, warning, complaint or report pertaining to or involving the failure of Lessee or the Premises to comply with any Applicable Requirements. Likewise, Lessee shall immediately give written notice to Lessor of&#58; (i) any water damage to the Premises and any suspected seepage, pooling, dampness or other condition conducive to the production of mold&#59; or (ii) any mustiness or other odors that might indicate the presence of mold in the Premises.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Inspection&#59; Compliance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessor and Lessor&#8217;s </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;Lender&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(as defined in Paragraph 30) and consultants shall have the right to enter into Premises at any time, in the case of an emergency, and otherwise at reasonable times after reasonable notice, for the purpose of inspecting the condition of the Premises and for verifying compliance by Lessee with this Lease. The cost of any such inspections shall be paid by Lessor, unless a violation of Applicable Requirements, or a Hazardous Substance Condition (see paragraph 9.1) is found to exist or be imminent, or the inspection is requested or ordered by a governmental authority. In such case, Lessee shall upon request reimburse Lessor for the cost of such inspection, so long as such inspection is reasonably related to the violation or contamination. In addition, Lessee shall provide copies of all relevant material safety data sheets </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(MSDS) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to Lessor within 10 days of the receipt of a written request therefor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Maintenance&#59; Repairs, Utility Installations&#59; Trade Fixtures and Alterations.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Lessee&#8217;s Obligations.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">In General. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Subject to the provisions of Paragraph 2.2 (Condition), 2.3 (Compliance), 6.3 (Lessee&#8217;s Compliance with Applicable Requirements), 7.2 (Lessor&#8217;s Obligations), 9 (Damage or Destruction), and 14 (Condemnation), Lessee shall, at Lessee&#8217;s sole expense, keep the Premises, Utility Installations (intended for Lessee&#8217;s exclusive use, no matter where located), and Alterations in good order, condition and repair (whether or not the portion of the Premises requiring repairs, or the means of repairing the same, are reasonably or readily accessible to Lessee, and whether or not the need for such repairs occurs as a result of Lessee&#8217;s use, any prior use, the elements or the age of such portion of the Premises), including, but not limited to, all equipment or facilities, such as plumbing, HVAC equipment, electrical, lighting facilities, boilers, pressure vessels, fire protection system, fixtures, walls (interior and exterior), foundations, ceilings, roofs, roof drainage systems, floors, windows, doors, plate glass, skylights, landscaping, driveways, parking lots, fences, retaining walls, signs, sidewalks and parkways located in, on, or adjacent to the Premises. Lessee, in keeping the Premises in good order, condition and repair, shall exercise and perform good maintenance practices, specifically including the procurement and maintenance of the service contracts required by Paragraph 7.1(b) below. Lessee&#8217;s obligations shall include restorations, replacements or renewals when necessary to keep the Premises and all improvements thereon or a part thereof in good order, condition and state of repair. Lessee shall, during the term of this Lease, keep the exterior appearance of the Building in a first-class condition (including, e.g. graffiti removal) consistent with the exterior appearance of other similar facilities of comparable age and size in the vicinity, including, when necessary, the exterior repainting of the Building.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Service Contracts. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall, at Lessee&#8217;s sole expense, procure and maintain contracts, with copies to Lessor, in customary form and substance for, and with contractors specializing and experienced in the maintenance of the following equipment and improvements, if any, if and when installed on the Premises&#58; (i) HVAC equipment, (ii) boiler, and pressure vessels, (iii) fire extinguishing systems, including fire alarm and&#47;or smoke detection, (iv) landscaping and irrigation systems, (v) roof covering and drains, and (vi) clarifiers. However, Lessor reserves the right, upon notice to Lessee, to procure and maintain any or all of such service contracts, and Lessee shall reimburse Lessor, upon demand, for the cost thereof.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Failure to Perform. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If Lessee fails to perform Lessee&#8217;s obligations under this Paragraph 7.1, Lessor may enter upon the Premises after 10 days&#8217; prior written notice to Lessee (except in the case of an emergency, in which case no notice shall be required), perform such obligations on Lessee&#8217;s behalf, and put the Premises in good order, condition and repair, and Lessee shall promptly pay to Lessor a sum equal to 115% of the cost thereof.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Replacement. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Subject to Lessee&#8217;s indemnification of Lessor as set forth in Paragraph 8.7 below, and without relieving Lessee of liability resulting from Lessee&#8217;s failure to exercise and perform good maintenance practices, if an item described in Paragraph 7.1(b) cannot be repaired other than at a cost which is in excess of 50% of the cost of replacing such item, then such item shall be replaced by Lessor, and the cost thereof shall be prorated between the Parties and Lessee shall only be obligated to pay, each month during the remainder of the term of this Lease, on the date on which Base Rent is due, an amount equal to the product of multiplying the cost of such replacement by a fraction, the numerator of which is ne, and the denominator of which is 144 (ie. 1&#47;144th of the cost per month). Lessee shall pay Interest on the unamortized balance but may prepay its obligation at any time.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Lessor&#8217;s Obligations. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Subject to the provisions of Paragraphs 2.2 (Condition), 2.3 (Compliance), 9 (Damage or Destruction) and 14 (Condemnation), it is intended by the Parties hereto that Lessor have no obligation, in any manner whatsoever, to repair and maintain the Premises, or the equipment therein, all of which obligations are intended to be that of the Lessee. It is the intention of the Parties that the terms of this Lease govern the respective obligations of the Parties as to maintenance and repair of the Premises, and they expressly waive the benefit of any statute now or hereafter in effect to the extent it is inconsistent with the terms of this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Utility Installations&#59; Trade Fixtures&#59; Alterations.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Definitions. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The term </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Utility Installations&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">refers to all floor and window coverings, air and&#47;or vacuum lines, power panels, electrical distribution, security and fire protection systems, communication cabling, lighting fixtures, HVAC equipment, plumbing, and fencing in or on the Premises. The term </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Trade Fixtures&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean Lessee&#8217;s machinery and equipment that can be removed without doing material damage to the Premises. The term </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Alterations&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean any modification of the improvements, other than Utility Installations or Trade Fixtures, whether by addition or deletion. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Lessee Owned Alterations and&#47;or Utility Installations&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">are defined as Alterations and&#47;or Utility Installations made by Lessee that are not yet owned by Lessor pursuant to Paragraph 7.4(a).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consent. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall not make any Alterations or Utility Installations to the Premises without Lessor&#8217;s prior written consent. Lessee may, however, make non-structural Alterations or Utility Installations to the interior of the Premises (excluding the roof) without such consent but upon notice to Lessor, as long as they are not visible from the outside, do not involve puncturing, relocating or removing the roof or any existing walls, will not affect the electrical, plumbing, HVAC, and&#47;or life safety systems, and the cumulative cost thereof during this Lease as extended does not exceed a sum equal to 3 month&#8217;s Base Rent in the aggregate or a sum equal to one month&#8217;s Base Rent in any one year. Notwithstanding the foregoing, Lessee shall not make or permit any roof penetrations and&#47;or install anything on the roof without the prior written approval of Lessor. Lessor may, as a precondition to granting such approval, require Lessee to utilize a contractor chosen and&#47;or approved by Lessor. Any Alterations or Utility Installations that Lessee shall desire to make and which require the consent of the Lessor shall be presented to Lessor in written form with detailed plans. Consent shall be deemed conditioned upon Lessee&#8217;s&#58; (i) acquiring all applicable governmental permits, (ii) furnishing Lessor with copies of both the permits and the plans and specifications prior to commencement of the work, and (iii) compliance with all conditions of said permits and other Applicable Requirements in a prompt and expeditious manner. Any Alterations or Utility Installations shall be performed in a workmanlike manner with good and sufficient materials. Lessee shall promptly upon completion furnish Lessor with as-built plans and specifications. For work which costs an amount in excess of one month&#8217;s Base Rent, Lessor may condition its consent upon Lessee providing a lien and completion bond in an amount equal to 150% of the estimated cost of such Alteration or Utility Installation and&#47;or upon Lessee&#8217;s posting an additional Security Deposit with Lessor.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liens&#59; Bonds. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessee shall pay, when due, all claims for labor or materials furnished or alleged to have been furnished to or for Lessee at or for use on the Premises, which claims are or may be secured by any mechanic&#8217;s or materialmen&#8217;s lien against the Premises or any interest therein. Lessee shall give Lessor not less than 10 days notice prior to the commencement of any work in, on or about the Premises, and Lessor shall have the right to post notices of non-responsibility. If Lessee shall contest the validity of any such lien, claim or demand, then Lessee shall, at its sole expense defend and protect itself, Lessor and the Premises against the same and shall pay and satisfy any such adverse judgment that may be rendered thereon before the enforcement thereof. If Lessor shall require, Lessee shall furnish a surety bond in an amount equal to 150% of the amount of such contested lien, claim or demand, indemnifying Lessor against liability for the same. If Lessor elects to participate in any such action, Lessee shall pay Lessor&#8217;s attorneys&#8217; fees and costs.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ownership&#59; Removal&#59; Surrender&#59; and Restoration.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ownership. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subject to Lessor&#8217;s right to require removal or elect ownership as hereinafter provided, all Alterations and Utility Installations made by Lessee shall be the property of Lessee, but considered a part of the Premises. Lessor may, at any time, elect in writing to be the owner of all or any specified part of the Lessee Owned Alterations and Utility Installations. Unless otherwise instructed per paragraph 7.4(b) hereof, all Lessee Owned Alterations and Utility Installations shall, at the expiration or termination of this Lease, become the property of Lessor and be surrendered by Lessee with the Premises.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Removal. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">By delivery to Lessee of written notice from Lessor not earlier than 90 and not later than 30 days prior to the end of the term of this Lease, Lessor may require that any or all Lessee Owned Alterations or Utility Installations be removed by the expiration or termination of this Lease. Lessor may require the removal at any time of all or any part of any Lessee Owned Alterations or Utility Installations made without the required consent.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Surrender&#59; Restoration. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessee shall surrender the Premises by the Expiration Date or any earlier termination date, with all of the improvements, parts and surfaces thereof broom clean and free of debris, and in good operating order, condition and state of repair, ordinary wear and tear excepted. &#8220;Ordinary wear and tear&#8221; shall not include any damage or deterioration that would have been prevented by good maintenance practice. Notwithstanding the foregoing, if this Lease is for 12 months or less, then Lessee shall surrender the Premises in the same condition as delivered to Lessee on the Start Date with NO allowance for ordinary wear and tear. Lessee shall repair any damage occasioned by the installation, maintenance or removal of Trade Fixtures, Lessee owned Alterations and&#47;or Utility Installations, furnishings, and equipment as well as the removal of any storage tank installed by or for Lessee. Lessee shall completely remove from the Premises any and all Hazardous Substances brought onto the Premises by or for Lessee, or any third party (except Hazardous Substances which were deposited via underground migration from areas outside of the Premises) even if such removal would require Lessee to perform or pay for work that exceeds statutory requirements. Trade Fixtures shall remain the property of Lessee and shall be removed by Lessee. Any personal property of Lessee not removed on or before the Expiration Date or any earlier termination date shall be deemed to have been abandoned by Lessee and may be disposed of or retained by Lessor as Lessor may desire. The failure by Lessee to timely vacate the Premises pursuant to this Paragraph 7.4(c) without the express written consent of Lessor shall constitute a holdover under the provisions of Paragraph 26 below.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Insurance&#59; Indemnity.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Payment For Insurance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessee shall pay for all insurance required under Paragraph 8 except to the extent of the cost attributable to liability insurance carried by Lessor under Paragraph 8.2(b) in excess of $2,000,000 per occurrence. Premiums for policy periods commencing prior to or extending beyond the Lease term shall be prorated to correspond to the Lease term. Payment shall be made by Lessee to Lessor within 10 days following receipt of an invoice.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liability Insurance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carried by Lessee. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessee shall obtain and keep in force a Commercial General Liability policy of insurance protecting Lessee and Lessor as an additional insured against claims for bodily injury, personal injury and property damage based upon or arising out of the ownership, use, occupancy or maintenance of the Premises and all areas appurtenant thereto. Such insurance shall be on an occurrence basis providing single limit coverage in an amount not less than $1,000,000 per occurrence with an annual aggregate of not less than $2,000,000. Lessee shall add Lessor as an additional insured by means of an endorsement at least as broad as the Insurance Service Organization&#8217;s &#8220;Additional Insured-Managers or Lessors of Premises&#8221; Endorsement. The policy shall not contain any intra-insured exclusions as between insured persons or organizations, but shall include coverage for liability assumed under this Lease as an </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;insured contract&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for the performance of Lessee&#8217;s indemnity obligations under this Lease. The limits of said insurance shall not, however, limit the liability of Lessee nor relieve Lessee of any obligation hereunder. Lessee shall provide an endorsement on its liability policy(ies) which provides that its insurance shall be primary to and not contributory with any similar insurance carried by Lessor, whose insurance shall be considered excess insurance only.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carried by Lessor. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lessor shall maintain liability insurance as described in Paragraph 8.2(a), in addition to, and not in lieu of, the insurance required to be maintained by Lessee. Lessee shall not be named as an additional insured therein.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Property Insurance - Building, Improvements and Rental Value.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Building and Improvements. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Insuring Party shall obtain and keep in force a policy or policies in the name of Lessor, with loss payable to Lessor, any ground-lessor, and to any Lender insuring loss or damage to the Premises. The amount of such insurance shall be equal to the full insurable replacement cost of the Premises, as the same shall exist from time to time, or the amount required by any Lender, but in no event more than the commercially reasonable and available insurable value thereof. Lessee Owned Alterations and Utility Installations, Trade Fixtures, and Lessee&#8217;s personal property shall be insured by Lessee not by Lessor. If the coverage is available and commercially appropriate, such policy or policies shall insure against all risks of direct physical loss or damage (except the perils of flood and&#47;or earthquake unless required by a Lender), including coverage for debris removal and the enforcement of any Applicable Requirements requiring the upgrading, demolition, reconstruction or</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">replacement of any portion of the Premises as the result of a covered loss. Said policy or policies shall also contain an agreed valuation provision in lieu of any coinsurance clause, waiver of subrogation, and inflation guard protection causing an increase in the annual property insurance coverage amount by a factor of not less than the adjusted U.S. Department of Labor Consumer Price Index for All Urban Consumers for the city nearest to where the Premises are located. If such insurance coverage has a deductible clause, the deductible amount shall not exceed $5,000 per occurrence, and Lessee shall be liable for such deductible amount in the event of an Insured Loss.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Rental Value. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Insuring Party shall obtain and keep in force a policy or policies in the name of Lessor with loss payable to Lessor and any Lender, insuring the loss of the full Rent for one year with an extended period of indemnity for an additional 180 days (&#8220;Rental Value insurance&#8221;). Said insurance shall contain an agreed valuation provision in lieu of any coinsurance clause, and the amount of coverage shall be adjusted annually to reflect the projected Rent otherwise payable by Lessee, for the next 12 month period. Lessee shall be liable for any deductible amount in the event of such loss.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Adjacent Premises. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the Premises are part of a larger building, or of a group of buildings owned by Lessor which are adjacent to the Premises, the Lessee shall pay for any increase in the premiums for the property insurance of such building or buildings if said increase is caused by Lessee&#8217;s acts, omissions, use or occupancy of the Premises.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Lessee&#8217;s Property&#59; Business Interruption Insurance&#59; Worker&#8217;s Compensation Insurance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Property Damage. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall obtain and maintain insurance coverage on all of Lessee&#8217;s personal property, Trade Fixtures, and Lessee Owned Alterations and Utility Installations. Such insurance shall be full replacement cost coverage with a deductible of not to exceed $1,000 per occurrence. The proceeds from any such insurance shall be used by Lessee for the replacement of personal property, Trade Fixtures and Lessee Owned Alterations and Utility Installations.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Business Interruption. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall obtain and maintain loss of income and extra expense insurance in amounts as will reimburse Lessee for direct or indirect loss of earnings attributable to all perils commonly insured against by prudent lessees in the business of Lessee or attributable to prevention of access to the Premises as a result of such perils.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Worker&#8217;s Compensation Insurance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall obtain and maintain Worker&#8217;s Compensation Insurance in such amount as may be required by Applicable Requirements. Such policy shall include a &#8216;Waiver of Subrogation&#8217; endorsement. Lessee shall provide Lessor with a copy of such endorsement along with the certificate of insurance or copy of the policy required by paragraph 8.5.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">No Representation of Adequate Coverage. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessor makes no representation that the limits or forms of coverage of insurance specified herein are adequate to cover Lessee&#8217;s property, business operations or obligations under this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Insurance Policies. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Insurance required herein shall be by companies maintaining during the policy term a &#8220;General Policyholders Rating&#8221; of at least A-, VII, as set forth in the most current issue of &#8220;Best&#8217;s Insurance Guide&#8221;, or such other rating as may be required by a Lender. Lessee shall not do or permit to be done anything which invalidates the required insurance policies. Lessee shall, prior to the Start Date, deliver to Lessor certified copies of policies of such insurance or certificates with copies of the required endorsements evidencing the existence and amounts of the required insurance. No such policy shall be cancelable or subject to modification except after 30 days prior written notice to Lessor. Lessee shall, at least 10 days prior to the expiration of such policies, furnish Lessor with evidence of renewals or &#8220;insurance binders&#8221; evidencing renewal thereof, or Lessor may order such insurance and charge the cost thereof to Lessee, which amount shall be payable by Lessee to Lessor upon demand. Such policies shall be for a term of at least one year, or the length of the remaining term of this Lease, whichever is less. If either Party shall fail to procure and maintain the insurance required to be carried by it, the other Party may, but shall not be required to, procure and maintain the same.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8.6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Waiver of Subrogation. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Without affecting any other rights or remedies, Lessee and Lessor each hereby release and relieve the other, and waive their entire right to recover damages against the other, for loss of or damage to its property arising out of or incident to the perils required to be insured against herein. The effect of such releases and waivers is not limited by the amount of insurance carried or required, or by any deductibles applicable hereto. The Parties agree to have their respective property damage insurance carriers waive any right to subrogation that such companies may have against Lessor or Lessee, as the case may be, so long as the insurance is not invalidated thereby.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8.7 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Indemnity. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Except for Lessor&#8217;s gross negligence or willful misconduct, Lessee shall indemnify, protect, defend and hold harmless the Premises, Lessor and its agents, Lessor&#8217;s master or ground lessor, partners and Lenders, from and against any and all claims, loss of rents and&#47;or damages, liens, judgments, penalties, attorneys&#8217; and consultants&#8217; fees, expenses and&#47;or liabilities arising out of, involving, or in connection with, the use and&#47;or occupancy of the Premises by Lessee. If any action or proceeding is brought against Lessor by reason of any of the foregoing matters, Lessee shall upon notice defend the same at Lessee&#8217;s expense by counsel reasonably satisfactory to Lessor and Lessor shall cooperate with Lessee in such defense. Lessor need not have first paid any such claim in order to be defended or indemnified.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8.8 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exemption of Lessor and its Agents from Liability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Notwithstanding the negligence or breach of this Lease by Lessor or its agents, neither Lessor nor its agents shall be liable under any circumstances for&#58; (i) injury or damage to the person or goods, wares, merchandise or other property of Lessee, Lessee&#8217;s employees, contractors, invitees, customers, or any other person in or about the Premises, whether such damage or injury is caused by or results from fire, steam, electricity, gas, water or rain, indoor air quality, the presence of mold or from the breakage, leakage, obstruction or other defects of pipes, fire sprinklers, wires, appliances, plumbing, HVAC or lighting fixtures, or from any other cause, whether the said injury or damage results from conditions arising upon the Premises or upon other portions of the building of which the Premises are a part, or from other sources or places, (ii) any damages arising from any act or neglect of any other tenant of Lessor or from the failure of Lessor or its agents to enforce the provisions of any other lease in the Project, or (iii) injury to Lessee&#8217;s business or for any loss of income or profit therefrom. Instead, it is intended that Lessee&#8217;s sole recourse in the event of such</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">damages or injury be to file a claim on the insurance policy(ies) that Lessee is required to maintain pursuant to the provisions of paragraph 8.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8.9 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Failure to Provide Insurance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee acknowledges that any failure on its part to obtain or maintain the insurance required herein will expose Lessor to risks and potentially cause Lessor to incur costs not contemplated by this Lease, the extent of which will be extremely difficult to ascertain. Accordingly, for any month or portion thereof that Lessee does not maintain the required insurance and&#47;or does not provide Lessor with the required binders or certificates evidencing the existence of the required insurance, the Base Rent shall be automatically increased, without any requirement for notice to Lessee, by an amount equal to 10% of the then existing Base Rent or $100, whichever is greater. The parties agree that such increase in Base Rent represents fair and reasonable compensation for the additional risk&#47;costs that Lessor will incur by reason of Lessee&#8217;s failure to maintain the required insurance. Such increase in Base Rent shall in no event constitute a waiver of Lessee&#8217;s Default or Breach with respect to the failure to maintain such insurance, prevent the exercise of any of the other rights and remedies granted hereunder, nor relieve Lessee of its obligation to maintain the insurance specified in this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Damage or Destruction.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Definitions.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Premises Partial Damage&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean damage or destruction to the improvements on the Premises, other than Lessee Owned Alterations and Utility Installations, which can reasonably be repaired in 6 months or less from the date of the damage or destruction. Lessor shall notify Lessee in writing within 30 days from the date of the damage or destruction as to whether or not the damage is Partial or Total.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Premises Total Destruction&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean damage or destruction to the Premises, other than Lessee Owned Alterations and Utility Installations and Trade Fixtures, which cannot reasonably be repaired in 6 months or less from the date of the damage or destruction. Lessor shall notify Lessee in writing within 30 days from the date of the damage or destruction as to whether or not the damage is Partial or Total.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Insured Loss&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean damage or destruction to improvements on the Premises, other than Lessee Owned Alterations and Utility Installations and Trade Fixtures, which was caused by an event required to be covered by the insurance described in Paragraph 8.3(a), irrespective of any deductible amounts or coverage limits involved.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Replacement Cost&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean the cost to repair or rebuild the improvements owned by Lessor at the time of the occurrence to their condition existing immediately prior thereto, including demolition, debris removal and upgrading required by the operation of Applicable Requirements, and without deduction for depreciation.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Hazardous Substance Condition&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean the occurrence or discovery of a condition involving the presence of, or a contamination by, a Hazardous Substance, in, on, or under the Premises which requires remediation.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Partial Damage - Insured Loss. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a Premises Partial Damage that is an Insured Loss occurs, then Lessor shall, at Lessor&#8217;s expense, repair such damage (but not Lessee&#8217;s Trade Fixtures or Lessee Owned Alterations and Utility Installations) as soon as reasonably possible and this Lease shall continue in full force and effect&#59; provided, however, that Lessee shall, at Lessor&#8217;s election, make the repair of any damage or destruction the total cost to repair of which is $10,000 or less, and, in such event, Lessor shall make any applicable insurance proceeds available to Lessee on a reasonable basis for that purpose. Notwithstanding the foregoing, if the required insurance was not in force or the insurance proceeds are not sufficient to effect such repair, the Insuring Party shall promptly contribute the shortage in proceeds (except as to the deductible which is Lessee&#8217;s responsibility) as and when required to complete said repairs. In the event, however, such shortage was due to the fact that, by reason of the unique nature of the improvements, full replacement cost insurance coverage was not commercially reasonable and available, Lessor shall have no obligation to pay for the shortage in insurance proceeds or to fully restore the unique aspects of the Premises unless Lessee provides Lessor with the funds to cover same, or adequate assurance thereof, within 10 days following receipt of written notice of such shortage and request therefor. If Lessor receives said funds or adequate assurance thereof within said 10 day period, the party responsible for making the repairs shall complete them as soon as reasonably possible and this Lease shall remain in full force and effect. If such funds or assurance are not received, Lessor may nevertheless elect by written notice to Lessee within 10 days thereafter to&#58; (i) make such restoration and repair as is commercially reasonable with Lessor paying any shortage in proceeds, in which case this Lease shall remain in full force and effect, or (ii) have this Lease terminate 30 days thereafter. Lessee shall not be entitled to reimbursement of any funds contributed by Lessee to repair any such damage or destruction. Premises Partial Damage due to flood or earthquake shall be subject to Paragraph 9.3, notwithstanding that there may be some insurance coverage, but the net proceeds of any such insurance shall be made available for the repairs if made by either Party.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Partial Damage - Uninsured Loss. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a Premises Partial Damage that is not an Insured Loss occurs, unless caused by a negligent or willful act of Lessee (in which event Lessee shall make the repairs at Lessee&#8217;s expense), Lessor may either&#58; (i) repair such damage as soon as reasonably possible at Lessor&#8217;s expense, in which event this Lease shall continue in full force and effect, or (ii) terminate this Lease by giving written notice to Lessee within 30 days after receipt by Lessor of knowledge of the occurrence of such damage. Such termination shall be effective 60 days following the date of such notice. In the event Lessor elects to terminate this Lease, Lessee shall have the right within 10 days after receipt of the termination notice to give written notice to Lessor of Lessee&#8217;s commitment to pay for the repair of such damage without reimbursement from Lessor. Lessee shall provide Lessor with said funds or satisfactory assurance thereof within 30 days after making such commitment. In such event this Lease shall continue in full force and effect, and Lessor shall proceed to make such repairs as soon as reasonably possible after the required funds are available. If Lessee does not make the required commitment, this Lease shall terminate as of the date specified in the termination notice.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total Destruction. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Notwithstanding any other provision hereof, if a Premises Total Destruction occurs, this Lease shall terminate 60 days following such Destruction. If the damage or destruction was caused by the gross negligence or willful misconduct of Lessee, Lessor shall have the right to recover Lessor&#8217;s damages from Lessee, except as provided in Paragraph 8.6.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Damage Near End of Term. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If at any time during the last 6 months of this Lease there is damage for which the cost to repair exceeds one month&#8217;s Base Rent, whether or not an Insured Loss, Lessor may terminate this Lease effective 60 days following the date of occurrence of such damage by giving a written termination notice to Lessee within 30 days after the date of occurrence of such damage. Notwithstanding the foregoing, if Lessee at that time has an exercisable option to extend this Lease or to purchase the Premises, then Lessee may preserve this Lease by, (a) exercising such option and (b) providing Lessor with any shortage in insurance proceeds (or adequate assurance thereof) needed to make the repairs on or before the earlier of (i) the date which is 10 days after Lessee&#8217;s receipt of Lessor&#8217;s written notice purporting to terminate this Lease, or (ii) the day prior to the date upon which such option expires. If Lessee duly exercises such option during such period and provides Lessor with funds (or adequate assurance thereof) to cover any shortage in insurance proceeds, Lessor shall, at Lessor&#8217;s commercially reasonable expense, repair such damage as soon as reasonably possible and this Lease shall continue in full force and effect. If Lessee fails to exercise such option and provide such funds or assurance during such period, then this Lease shall terminate on the date specified in the termination notice and Lessee&#8217;s option shall be extinguished.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9.6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Abatement of Rent&#59; Lessee&#8217;s Remedies.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Abatement. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event of Premises Partial Damage or Premises Total Destruction or a Hazardous Substance Condition for which Lessee is not responsible under this Lease, the Rent payable by Lessee for the period required for the repair, remediation or restoration of such damage shall be abated in proportion to the degree to which Lessee&#8217;s use of the Premises is impaired, but not to exceed the proceeds received from the Rental Value insurance. All other obligations of Lessee hereunder shall be performed by Lessee, and Lessor shall have no liability for any such damage, destruction, remediation, repair or restoration except as provided herein.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Remedies. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If Lessor is obligated to repair or restore the Premises and does not commence, in a substantial and meaningful way, such repair or restoration within 90 days after such obligation shall accrue, Lessee may, at any time prior to the commencement of such repair or restoration, give written notice to Lessor and to any Lenders of which Lessee has actual notice, of Lessee&#8217;s election to terminate this Lease on a date not less than 60 days following the giving of such notice. If Lessee gives such notice and such repair or restoration is not commenced within 30 days thereafter, this Lease shall terminate as of the date specified in said notice. If the repair or restoration is commenced within such 30 days, this Lease shall continue in full force and effect. &#8220;Commence&#8221; shall mean either the unconditional authorization of the preparation of the required plans, or the beginning of the actual work on the Premises, whichever first occurs.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9.7 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Termination&#59; Advance Payments. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon termination of this Lease pursuant to Paragraph 6.2(g) or Paragraph 9, an equitable adjustment shall be made concerning advance Base Rent and any other advance payments made by Lessee to Lessor. Lessor shall, in addition, return to Lessee so much of Lessee&#8217;s Security Deposit as has not been, or is not then required to be, used by Lessor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">This section is left blank</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Utilities and Services. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee shall pay for all water, gas, heat, light, power, telephone, trash disposal and other utilities and services supplied to the Premises, together with any taxes thereon. If any such services are not separately metered or billed to Lessee, Lessee shall pay a reasonable proportion, to be determined by Lessor, of all charges jointly metered or billed. There shall be no abatement of rent and Lessor shall not be liable in any respect whatsoever for the inadequacy, stoppage, interruption or discontinuance of any utility or service due to riot, strike, labor dispute, breakdown, accident, repair or other cause beyond Lessor&#8217;s reasonable control or in cooperation with governmental request or directions.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Assignment and Subletting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Lessor&#8217;s Consent Required.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) Lessee shall not voluntarily or by operation of law assign, transfer, mortgage or encumber (collectively, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;assign or assignment&#8221;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">or sublet all or any part of Lessee&#8217;s interest in this Lease or in the Premises without Lessor&#8217;s prior written consent.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) Unless Lessee is a corporation and its stock is publicly traded on a national stock exchange, a change in the control of Lessee shall constitute an assignment requiring consent. The transfer, on a cumulative basis, of 25% or more of the voting control of Lessee shall constitute a change in control for this purpose.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(c) The involvement of Lessee or its assets in any transaction, or series of transactions (by way of merger, sale, acquisition, financing, transfer, leveraged buy-out or otherwise), whether or not a formal assignment or hypothecation of this Lease or Lessee&#8217;s assets occurs, which results or will result in a reduction of the Net Worth of Lessee by an amount greater than 25% of such Net Worth as it was represented at the time of the execution of this Lease or at the time of the most recent assignment to which Lessor has consented, or as it exists immediately prior to said transaction or transactions constituting such reduction, whichever was or is greater, shall be considered an assignment of this Lease to which Lessor may withhold its consent. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Net Worth of Lessee&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall mean the net worth of Lessee (excluding any guarantors) established under generally accepted accounting principles.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(d) An assignment or subletting without consent shall, at Lessor&#8217;s option, be a Default curable after notice per Paragraph 13.1(c), or a noncurable Breach without the necessity of any notice and grace period. If Lessor elects to treat such unapproved assignment or subletting as a noncurable Breach, Lessor may either&#58; (i) terminate this Lease, or (ii) upon 30 days written notice, increase the monthly Base Rent to 110% of the Base Rent then in effect. Further, in the event of such Breach and rental</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">adjustment, (i) the purchase price of any option to purchase the Premises held by Lessee shall be subject to similar adjustment to 110% of the price previously in effect, and (ii) all fixed and non-fixed rental adjustments scheduled during the remainder of the Lease term shall be increased to 110% of the scheduled adjusted rent.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(e) Lessee&#8217;s remedy for any breach of Paragraph 12.1 by Lessor shall be limited to compensatory damages and&#47;or injunctive relief.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(f) Lessor may reasonably withhold consent to a proposed assignment or subletting if Lessee is in Default at the time consent is requested.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(g) Notwithstanding the foregoing, allowing a de minimis portion of the Premises, ie. 20 square feet or less, to be used by a third party vendor in connection with the installation of a vending machine or payphone shall not constitute a subletting.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Terms and Conditions Applicable to Assignment and Subletting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Regardless of Lessor&#8217;s consent, no assignment or subletting shall&#58; (i) be effective without the express written assumption by such assignee or sublessee of the obligations of Lessee under this Lease, (ii) release Lessee of any obligations hereunder, or (iii) alter the primary liability of Lessee for the payment of Rent or for the performance of any other obligations to be performed by Lessee.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) Lessor may accept Rent or performance of Lessee&#8217;s obligations from any person other than Lessee pending approval or disapproval of an assignment. Neither a delay in the approval or disapproval of such assignment nor the acceptance of Rent or performance shall constitute a waiver or estoppel of Lessor&#8217;s right to exercise its remedies for Lessee&#8217;s Default or Breach.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) Lessor&#8217;s consent to any assignment or subletting shall not constitute a consent to any subsequent assignment or subletting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) In the event of any Default or Breach by Lessee, Lessor may proceed directly against Lessee, any Guarantors or anyone else responsible for the performance of Lessee&#8217;s obligations under this Lease, including any assignee or sublessee, without first exhausting Lessor&#8217;s remedies against any other person or entity responsible therefor to Lessor, or any security held by Lessor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(e) Each request for consent to an assignment or subletting shall be in writing, accompanied by information relevant to Lessor&#8217;s determination as to the financial and operational responsibility and appropriateness of the proposed assignee or sublessee, including but not limited to the intended use and&#47;or required modification of the Premises, if any, together with a fee of $500 as consideration for Lessor&#8217;s considering and processing said request. Lessee agrees to provide Lessor with such other or additional information and&#47;or documentation as may be reasonably requested. (See also Paragraph 36)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(f) Any assignee of, or sublessee under, this Lease shall, by reason of accepting such assignment, entering into such sublease, or entering into possession of the Premises or any portion thereof, be deemed to have assumed and agreed to conform and comply with each and every term, covenant, condition and obligation herein to be observed or performed by Lessee during the term of said assignment or sublease, other than such obligations as are contrary to or inconsistent with provisions of an assignment or sublease to which Lessor has specifically consented to in writing.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(g) Lessor&#8217;s consent to any assignment or subletting shall not transfer to the assignee or sublessee any Option granted to the original Lessee by this Lease unless such transfer is specifically consented to by Lessor in writing. (See Paragraph 39.2)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional Terms and Conditions Applicable to Subletting. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following terms and conditions shall apply to any subletting by Lessee of all or any part of the Premises and shall be deemed included in all subleases under this Lease whether or not expressly incorporated therein&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Lessee hereby assigns and transfers to Lessor all of Lessee&#8217;s interest in all Rent payable on any sublease, and Lessor may collect such Rent and apply same toward Lessee&#8217;s obligations under this Lease&#59; provided, however, that until a Breach shall occur in the performance of Lessee&#8217;s obligations, Lessee may collect said Rent. In the event that the amount collected by Lessor exceeds Lessee&#8217;s then outstanding obligations any such excess shall be refunded to Lessee. Lessor shall not, by reason of the foregoing or any assignment of such sublease, nor by reason of the collection of Rent, be deemed liable to the sublessee for any failure of Lessee to perform and comply with any of Lessee&#8217;s obligations to such sublessee. Lessee hereby irrevocably authorizes and directs any such sublessee, upon receipt of a written notice from Lessor stating that a Breach exists in the performance of Lessee&#8217;s obligations under this Lease, to pay to Lessor all Rent due and to become due under the sublease. Sublessee shall rely upon any such notice from Lessor and shall pay all Rents to Lessor without any obligation or right to inquire as to whether such Breach exists, notwithstanding any claim from Lessee to the contrary.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) In the event of a Breach by Lessee, Lessor may, at its option, require sublessee to attorn to Lessor, in which event Lessor shall undertake the obligations of the sublessor under such sublease from the time of the exercise of said option to the expiration of such sublease&#59; provided, however, Lessor shall not be liable for any prepaid rents or security deposit paid by such sublessee to such sublessor or for any prior Defaults or Breaches of such sublessor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) Any matter requiring the consent of the sublessor under a sublease shall also require the consent of Lessor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) No sublessee shall further assign or sublet all or any part of the Premises without Lessor&#8217;s prior written consent.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(e) Lessor shall deliver a copy of any notice of Default or Breach by Lessee to the sublessee, who shall have the right to cure the Default of Lessee within the grace period, if any, specified in such notice. The sublessee shall have a right of reimbursement and offset from and against Lessee for any such Defaults cured by the sublessee.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Default&#59; Breach&#59; Remedies.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Default&#59; Breach. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> &#8220;Default&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">is defined as a failure by the Lessee to comply with or perform any of the terms, covenants, conditions or Rules and Regulations under this Lease. A </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;Breach&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">is defined as the occurrence of one or more of the following Defaults, and the failure of Lessee to cure such Default within any applicable grace period&#58;</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) The abandonment of the Premises&#59; or the vacating of the Premises without providing a commercially reasonable level of security, or where the coverage of the property insurance described in Paragraph 8.3 is jeopardized as a result thereof, or without providing reasonable assurances to minimize potential vandalism.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) The failure of Lessee to make any payment of Rent or any Security Deposit required to be made by Lessee hereunder, whether to Lessor or to a third party, when due, to provide reasonable evidence of insurance or surety bond, or to fulfill any obligation under this Lease which endangers or threatens life or property, where such failure continues for a period of 3 business days following written notice to Lessee. THE ACCEPTANCE BY LESSOR OF A PARTIAL PAYMENT OF RENT OR SECURITY DEPOSIT SHALL NOT CONSTITUTE A WAIVER OF ANY OF LESSOR&#8217;S RIGHTS, INCLUDING LESSOR&#8217;S RIGHT TO RECOVER POSSESSION OF THE PREMISES.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) The failure of Lessee to allow Lessor and&#47;or its agents access to the Premises or the commission of waste, act or acts constituting public or private nuisance, and&#47;or an illegal activity on the Premises by Lessee, where such actions continue for a period of 3 business days following written notice to Lessee.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) The failure by Lessee to provide (i) reasonable written evidence of compliance with Applicable Requirements, (ii) the service contracts, (iii) the rescission of an unauthorized assignment or subletting, (iv) an Estoppel Certificate or financial statements, (v) a requested subordination, (vi) evidence concerning any guaranty and&#47;or Guarantor, (vii) any document requested under Paragraph 42, (viii) material safety data sheets (MSDS), or (ix) any other documentation or information which Lessor may reasonably require of Lessee under the terms of this Lease, where any such failure continues for a period of 10 days following written notice to Lessee.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(e) A Default by Lessee as to the terms, covenants, conditions or provisions of this Lease, or of the rules adopted under Paragraph 40 hereof, other than those described in subparagraphs 13.1(a), (b), (c) or (d), above, where such Default continues for a period of 30 days after written notice&#59; provided, however, that if the nature of Lessee&#8217;s Default is such that more than 30 days are reasonably required for its cure, then it shall not be deemed to be a Breach if Lessee commences such cure within said 30 day period and thereafter diligently prosecutes such cure to completion.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(f) The occurrence of any of the following events&#58; (i) the making of any general arrangement or assignment for the benefit of creditors&#59; (ii) becoming a &#8220;debtor&#8221; as defined in 11 U.S.C. &#167;101 or any successor statute thereto (unless, in the case of a petition filed against Lessee, the same is dismissed within 60 days)&#59; (iii) the appointment of a trustee or receiver to take possession of substantially all of Lessee&#8217;s assets located at the Premises or of Lessee&#8217;s interest in this Lease, where possession is not restored to Lessee within 30 days&#59; or (iv) the attachment, execution or other judicial seizure of substantially all of Lessee&#8217;s assets located at the Premises or of Lessee&#8217;s interest in this Lease, where such seizure is not discharged within 30 days&#59; provided, however, in the event that any provision of this subparagraph is contrary to any applicable law, such provision shall be of no force or effect, and not affect the validity of the remaining provisions.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(g) The discovery that any financial statement of Lessee or of any Guarantor given to Lessor was materially false.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(h) If the performance of Lessee&#8217;s obligations under this Lease is guaranteed&#58; (i) the death of a Guarantor, (ii) the termination of a Guarantor&#8217;s liability with respect to this Lease other than in accordance with the terms of such guaranty, (iii) a Guarantor&#8217;s becoming insolvent or the subject of a bankruptcy filing, (iv) a Guarantor&#8217;s refusal to honor the guaranty, or (v) a Guarantor&#8217;s breach of its guaranty obligation on an anticipatory basis, and Lessee&#8217;s failure, within 60 days following written notice of any such event, to provide written alternative assurance or security, which, when coupled with the then existing resources of Lessee, equals or exceeds the combined financial resources of Lessee and the Guarantors that existed at the time of execution of this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Remedies. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If Lessee fails to perform any of its affirmative duties or obligations, within 10 days after written notice (or in case of an emergency, without notice), Lessor may, at its option, perform such duty or obligation on Lessee&#8217;s behalf, including but not limited to the obtaining of reasonably required bonds, insurance policies, or governmental licenses, permits or approvals. Lessee shall pay to Lessor an amount equal to 115% of the costs and expenses incurred by Lessor in such performance upon receipt of an invoice therefor. In the event of a Breach, Lessor may, with or without further notice or demand, and without limiting Lessor in the exercise of any right or remedy which Lessor may have by reason of such Breach&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Terminate Lessee&#8217;s right to possession of the Premises by any lawful means, in which case this Lease shall terminate and Lessee shall immediately surrender possession to Lessor. In such event Lessor shall be entitled to recover from Lessee&#58; (i) the unpaid Rent which had been earned at the time of termination&#59; (ii) the worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that the Lessee proves could have been reasonably avoided&#59; (iii) the worth at the time of award of the amount by which the unpaid rent for the balance of the term after the time of award exceeds the amount of such rental loss that the Lessee proves could be reasonably avoided&#59; and (iv) any other amount necessary to compensate Lessor for all the detriment proximately caused by the Lessee&#8217;s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including but not limited to the cost of recovering possession of the Premises, expenses of reletting, including necessary renovation and alteration of the Premises, reasonable attorneys&#8217; fees, and that portion of any leasing commission paid by Lessor in connection with this Lease applicable to the unexpired term of this Lease. The worth at the time of award of the amount referred to in provision (iii) of the immediately preceding sentence shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of the District within which the Premises are located at the time of award plus one percent. Efforts by Lessor to mitigate damages caused by Lessee&#8217;s Breach of this Lease shall not waive Lessor&#8217;s right to recover any damages to which Lessor is otherwise entitled. If termination of this Lease is obtained through the provisional remedy of unlawful detainer, Lessor shall have the right to recover in such proceeding any unpaid Rent and damages as are recoverable therein, or Lessor may reserve the right to recover all or any part thereof in a separate suit. If a</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">notice and grace period required under Paragraph 13.1 was not previously given, a notice to pay rent or quit, or to perform or quit given to Lessee under the unlawful detainer statute shall also constitute the notice required by Paragraph 13.1. In such case, the applicable grace period required by Paragraph 13.1 and the unlawful detainer statute shall run concurrently, and the failure of Lessee to cure the Default within the greater of the two such grace periods shall constitute both an unlawful detainer and a Breach of this Lease entitling Lessor to the remedies provided for in this Lease and&#47;or by said statute.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) Continue the Lease and Lessee&#8217;s right to possession and recover the Rent as it becomes due, in which event Lessee may sublet or assign, subject only to reasonable limitations. Acts of maintenance, efforts to relet, and&#47;or the appointment of a receiver to protect the Lessor&#8217;s interests, shall not constitute a termination of the Lessee&#8217;s right to possession.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(c) Pursue any other remedy now or hereafter available under the laws or judicial decisions of the state wherein the Premises are located. The expiration or termination of this Lease and&#47;or the termination of Lessee&#8217;s right to possession shall not relieve Lessee from liability under any indemnity provisions of this Lease as to matters occurring or accruing during the term hereof or by reason of Lessee&#8217;s occupancy of the Premises.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Inducement Recapture. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any agreement for free or abated rent or other charges, or for the giving or paying by Lessor to or for Lessee of any cash or other bonus, inducement or consideration for Lessee&#8217;s entering into this Lease, all of which concessions are hereinafter referred to as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Inducement Provisions,&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">shall be deemed conditioned upon Lessee&#8217;s full and faithful performance of all of the terms, covenants and conditions of this Lease. Upon Breach of this Lease by Lessee, any such Inducement Provision shall automatically be deemed deleted from this Lease and of no further force or effect, and any rent, other charge, bonus, inducement or consideration theretofore abated, given or paid by Lessor under such an inducement Provision shall be immediately due and payable by Lessee to Lessor, notwithstanding any subsequent cure of said Breach by Lessee. The acceptance by Lessor of rent or the cure of the Breach which initiated the operation of this paragraph shall not be deemed a waiver by Lessor of the provisions of this paragraph unless specifically so stated in writing by Lessor at the time of such acceptance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Late Charges. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessee hereby acknowledges that late payment by Lessee of Rent will cause Lessor to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult to ascertain. Such costs include, but are not limited to, processing and accounting charges, and late charges which may be imposed upon Lessor by any Lender. Accordingly, if any Rent shall not be received by Lessor within 5 days after such amount shall be due, then, without any requirement for notice to Lessee, Lessee shall immediately pay to Lessor a one-time late charge equal to 10% of each such overdue amount or $100, whichever is greater. The Parties hereby agree that such late charge represents a fair and reasonable estimate of the costs Lessor will incur by reason of such late payment. Acceptance of such late charge by Lessor shall in no event constitute a waiver of Lessee&#8217;s Default or Breach with respect to such overdue amount, nor prevent the exercise of any of the other rights and remedies granted hereunder. In the event that a late charge is payable hereunder, whether or not collected, for 3 consecutive installments of Base Rent, then notwithstanding any provision of this Lease to the contrary, Base Rent shall, at Lessor&#8217;s option, become due and payable quarterly in advance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13.5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Interest. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any monetary payment due Lessor hereunder, other than late charges, not received by Lessor, when due shall bear interest from the 31st day after it was due. The interest </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(&#8220;Interest&#8221;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">charged shall be computed at the rate of 10% per annum but shall not exceed the maximum rate allowed by law. Interest is payable in addition to the potential late charge provided for in Paragraph 13.4.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13.6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Breach by Lessor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notice of Breach. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lessor shall not be deemed in breach of this Lease unless Lessor fails within a reasonable time to perform an obligation required to be performed by Lessor. For purposes of this Paragraph, a reasonable time shall in no event be less than 30 days after receipt by Lessor, and any Lender whose name and address shall have been furnished Lessee in writing for such purpose, of written notice specifying wherein such obligation of Lessor has not been performed&#59; provided, however, that if the nature of Lessor&#8217;s obligation is such that more than 30 days are reasonably required for its performance, then Lessor shall not be in breach if performance is commenced within such 30 day period and thereafter diligently pursued to completion.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Performance by Lessee on Behalf of Lessor. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event that neither Lessor nor Lender cures said breach within 30 days after receipt of said notice, or if having commenced said cure they do not diligently pursue it to completion, then Lessee may elect to cure said breach at Lessee&#8217;s expense and offset from Rent the actual and reasonable cost to perform such cure, provided, however, that such offset shall not exceed an amount equal to the greater of one month&#8217;s Base Rent or the Security Deposit, reserving Lessee&#8217;s right to seek reimbursement from Lessor for any such expense in excess of such offset. Lessee shall document the cost of said cure and supply said documentation to Lessor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">14. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condemnation. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the Premises or any portion thereof are taken under the power of eminent domain or sold under the threat of the exercise of said power (collectively </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8220;Condemnation&#8221;), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">this Lease shall terminate as to the part taken as of the date the condemning authority takes title or possession, whichever first occurs. If more than 10% of the Building, or more than 25% of that portion of the Premises not occupied by any building, is taken by Condemnation, Lessee may, at Lessee&#8217;s option, to be exercised in writing within 10 days after Lessor shall have given Lessee written notice of such taking (or in the absence of such notice, within 10 days after the condemning authority shall have taken possession) terminate this Lease as of the date the condemning authority takes such possession. If Lessee does not terminate this Lease in accordance with the foregoing, this Lease shall remain in full force and effect as to the portion of the Premises remaining, except that the Base Rent shall be reduced in proportion to the reduction in utility of the Premises caused by such Condemnation. Condemnation awards and&#47;or payments shall be the property of Lessor, whether such award shall be made as compensation for diminution in value of the leasehold, the value of the part taken, or for severance damages&#59; provided, however, that Lessee shall be entitled to any compensation paid by the condemnor for Lessee&#8217;s relocation expenses, loss of business goodwill and&#47;or Trade Fixtures, without regard to whether or not this Lease is terminated pursuant to the provisions of this Paragraph. All Alterations and Utility Installations made to the Premises by Lessee, for purposes of Condemnation only, shall be considered the</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property of the Lessee and Lessee shall be entitled to any and all compensation which is payable therefor. In the event that this Lease is not terminated by reason of the Condemnation, Lessor shall repair any damage to the Premises caused by such Condemnation.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This section is left blank</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estoppel Certificates.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Each Party (as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Responding Party&#8221;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall within 10 days after written notice from the other Party (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Requesting Party&#8221;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">execute, acknowledge and deliver to the Requesting Party a statement in writing in form similar to the then most current </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Estoppel Certificate&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">form published by the AIR Commercial Real Estate Association, plus such additional information, confirmation and&#47;or statements as may be reasonably requested by the Requesting Party.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) If the Responding Party shall fail to execute or deliver the Estoppel Certificate within such 10 day period, the Requesting Party may execute an Estoppel Certificate stating that&#58; (i) the Lease is in full force and effect without modification except as may be represented by the Requesting Party, (ii) there are no uncured defaults in the Requesting Party&#8217;s performance, and (iii) if Lessor is the Requesting Party, not more than one month&#8217;s rent has been paid in advance. Prospective purchasers and encumbrancers may rely upon the Requesting Party&#8217;s Estoppel Certificate, and the Responding Party shall be estopped from denying the truth of the facts contained in said Certificate. In addition, Lessee acknowledges that any failure on its part to provide such an Estoppel Certificate will expose Lessor to risks and potentially cause Lessor to incur costs not contemplated by this Lease, the extent of which will be extremely difficult to ascertain. Accordingly, should the Lessee fail to execute and&#47;or deliver a requested Estoppel Certificate in a timely fashion the monthly Base Rent shall be automatically increased, without any requirement for notice to Lessee, by an amount equal to 10% of the then existing Base Rent or $100, whichever is greater for remainder of the Lease. The Parties agree that such increase in Base Rent represents fair and reasonable compensation for the additional risk&#47;costs that Lessor will incur by reason of Lessee&#8217;s failure to provide the Estoppel Certificate. Such increase in Base Rent shall in no event constitute a waiver of Lessee&#8217;s Default or Breach with respect to the failure to provide the Estoppel Certificate nor prevent the exercise of any of the other rights and remedies granted hereunder.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) If Lessor desires to finance, refinance, or sell the Premises, or any part thereof, Lessee and all Guarantors shall within 10 days after written notice from Lessor deliver to any potential lender or purchaser designated by Lessor such financial statements as may be reasonably required by such lender or purchaser, including but not limited to Lessee&#8217;s financial statements for the past 3 years. All such financial statements shall be received by Lessor and such lender or purchaser in confidence and shall be used only for the purposes herein set forth.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition of Lessor. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Lessor&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as used herein shall mean the owner or owners at the time in question of the fee title to the Premises, or, if this is a sublease, of the Lessee&#8217;s interest in the prior lease. In the event of a transfer of Lessor&#8217;s title or interest in the Premises or this Lease, Lessor shall deliver to the transferee or assignee (in cash or by credit) any unused Security Deposit held by Lessor. Upon such transfer or assignment and delivery of the Security Deposit, as aforesaid, the prior Lessor shall be relieved of all liability with respect to the obligations and&#47;or covenants under this Lease thereafter to be performed by the Lessor. Subject to the foregoing, the obligations and&#47;or covenants in this Lease to be performed by the Lessor shall be binding only upon the Lessor as hereinabove defined.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Severability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The invalidity of any provision of this Lease, as determined by a court of competent jurisdiction, shall in no way affect the validity of any other provision hereof.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Days. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise specifically indicated to the contrary, the word &#8220;days&#8221; as used in this Lease shall mean and refer to calendar days.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation on Liability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of Lessor under this Lease shall not constitute personal obligations of Lessor or its partners, members, directors, officers or shareholders, and Lessee shall look to the Premises, and to no other assets of Lessor, for the satisfaction of any liability of Lessor with respect to this Lease, and shall not seek recourse against Lessor&#8217;s partners, members, directors, officers or shareholders, or any of their personal assets for such satisfaction.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Time of Essence. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time is of the essence with respect to the performance of all obligations to be performed or observed by the Parties under this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This section is left blank</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notices.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notice Requirements. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All notices required or permitted by this Lease or applicable law shall be in writing and may be delivered in person (by hand or by courier) or may be sent by regular, certified or registered mail or U.S. Postal Service Express Mail, with postage prepaid, or by facsimile transmission, and shall be deemed sufficiently given if served in a manner specified in this Paragraph 23. The addresses noted adjacent to a Party&#8217;s signature on this Lease shall be that Party&#8217;s address for delivery or mailing of notices. Either Party may by written notice to the other specify a different address for notice, except that upon Lessee&#8217;s taking possession of the Premises, the Premises shall constitute Lessee&#8217;s address for notice. A copy of all notices to Lessor shall be concurrently transmitted to such party or parties at such addresses as Lessor may from time to time hereafter designate in writing.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Notice. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any notice sent by registered or certified mail, return receipt requested, shall be deemed given on the date of delivery shown on the receipt card, or if no delivery date is shown, the postmark thereon. If sent by regular mail the notice shall be deemed given 72 hours after the same is addressed as required herein and mailed with postage prepaid. Notices delivered by United States Express Mail or overnight courier that guarantees next day delivery shall be deemed given 24 hours after delivery of the same to</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Postal Service or courier. Notices transmitted by facsimile transmission or similar means shall be deemed delivered upon telephone confirmation of receipt (confirmation report from fax machine is sufficient), provided a copy is also delivered via delivery or mail. If notice is received on a Saturday, Sunday or legal holiday, it shall be deemed received on the next business day.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Waivers.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) No waiver by Lessor of the Default or Breach of any term, covenant or condition hereof by Lessee, shall be deemed a waiver of any other term, covenant or condition hereof, or of any subsequent Default or Breach by Lessee of the same or of any other term, covenant or condition hereof. Lessor&#8217;s consent to, or approval of, any act shall not be deemed to render unnecessary the obtaining of Lessor&#8217;s consent to, or approval of, any subsequent or similar act by Lessee, or be construed as the basis of an estoppel to enforce the provision or provisions of this Lease requiring such consent.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The acceptance of Rent by Lessor shall not be a waiver of any Default or Breach by Lessee. Any payment by Lessee may be accepted by Lessor on account of moneys or damages due Lessor, notwithstanding any qualifying statements or conditions made by Lessee in connection therewith, which such statements and&#47;or conditions shall be of no force or effect whatsoever unless specifically agreed to in writing by Lessor at or before the time of deposit of such payment.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) THE PARTIES AGREE THAT THE TERMS OF THIS LEASE SHALL GOVERN WITH REGARD TO ALL MATTERS RELATED THERETO AND HEREBY WAIVE THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE TO THE EXTENT THAT SUCH STATUTE IS INCONSISTENT WITH THIS LEASE.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosures Regarding The Nature of a Real Estate Agency Relationship.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) When entering into a discussion with a real estate agent regarding a real estate transaction, a Lessor or Lessee should from the outset understand what type of agency relationship or representation it has with the agent or agents in the transaction. Lessor and Lessee acknowledge being advised by the Brokers in this transaction, as follows&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Lessor&#8217;s Agent. A Lessor&#8217;s agent under a listing agreement with the Lessor acts as the agent for the Lessor only. A Lessor&#8217;s agent or subagent has the following affirmative obligations&#58; To the Lessor&#58; A fiduciary duty of utmost care, integrity, honesty, and loyalty in dealings with the Lessor. To the Lessee and the Lessor&#58; a. Diligent exercise of reasonable skills and care in performance of the agent&#8217;s duties. b. A duty of honest and fair dealing and good faith. c. A duty to disclose all facts known to the agent materially affecting the value or desirability of the property that are not known to,  or within the diligent attention and observation of, the Parties. An agent is not obligated to reveal to either Party any confidential information obtained from the other Party which does not involve the affirmative duties set forth above.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Lessee&#8217;s Agent. An agent can agree to act as agent for the Lessee only. In these situations, the agent is not the Lessor&#8217;s agent, even if by agreement the agent may receive compensation for services rendered, either in full or in part from the Lessor. An agent acting only for a Lessee has the following affirmative obligations. To the Lessee&#58; A fiduciary duty of utmost care, integrity, honesty, and loyalty in dealings with the Lessee. To the Lessee and the Lessor&#58; a. Diligent exercise of reasonable skills and care in performance of the agent&#8217;s duties. b. A duty of honest and fair dealing and good faith. c. A duty to disclose all facts known to the agent materially affecting the value or desirability of the property that are not known to, or within the diligent attention and observation of, the Parties. An agent is not obligated to reveal to either Party any confidential information obtained from the other Party which does not involve the affirmative duties set forth above.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Agent Representing Both Lessor and Lessee. A real estate agent, either acting directly or through one or more associate licenses, can legally be the agent of both the Lessor and the Lessee in a transaction, but only with the knowledge and consent of both the Lessor and the Lessee. In a dual agency situation, the agent has the following affirmative obligations to both the Lessor and the Lessee&#58; a. A fiduciary duty of utmost care, integrity, honesty and loyalty in the dealings with either Lessor or the Lessee. b. Other duties to the Lessor and the Lessee as stated above in subparagraphs (i) or (ii). In representing both Lessor and Lessee, the agent may not without the express permission of the respective Party, disclose to the other Party that the Lessor will accept rent in an amount less than that indicated in the listing or that the Lessee is willing to pay a higher rent than that offered. The above duties of the agent in a real estate transaction do not relieve a Lessor or Lessee from the responsibility to protect their own interests. Lessor and Lessee should carefully read all agreements to assure that they adequately express their understanding of the transaction. A real estate agent is a person qualified to advise about real estate. If legal or tax advice is desired, consult a competent professional.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Brokers have no responsibility with respect to any default or breach hereof by either Party. The Parties agree that no lawsuit or other legal proceeding involving any breach of duty, error or omission relating to this Lease may be brought against Broker more than one year after the Start Date and that the liability (including court costs and attorneys&#8217; fees), of any Broker with respect to any such lawsuit and&#47;or legal proceeding shall not exceed the fee received by such Broker pursuant to this Lease&#59; provided, however, that the foregoing limitation on each Broker&#8217;s liability shall not be applicable to any gross negligence or willful misconduct of such Broker. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Lessor and Lessee agree to identify to Brokers as &#8220;Confidential&#8221; any communication or information given Brokers that is considered by such Party to be confidential.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Right To Holdover. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee has no right to retain possession of the Premises or any part thereof beyond the expiration or termination of this Lease. In the event that Lessee holds over, then the Base Rent shall be increased to 150% of the Base Rent applicable immediately preceding the expiration or termination. Nothing contained herein shall be construed as consent by Lessor to any holding over by Lessee.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cumulative Remedies. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No remedy or election hereunder shall be deemed exclusive but shall, wherever possible, be cumulative with all other remedies at law or in equity.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenants and Conditions&#59; Construction of Agreement. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All provisions of this Lease to be observed or performed by Lessee are both covenants and conditions. In construing this Lease, all headings and titles are for the convenience of the Parties only and shall not be considered a part of this</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease. Whenever required by the context, the singular shall include the plural and vice versa. This Lease shall not be construed as if prepared by one of the Parties, but rather according to its fair meaning as a whole, as if both Parties had prepared it.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Binding Effect&#59; Choice of Law. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Lease shall be binding upon the Parties, their personal representatives, successors and assigns and be governed by the laws of the State in which the Premises are located. Any litigation between the Parties hereto concerning this Lease shall be initiated in the county in which the Premises are located.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subordination&#59; Attornment&#59; Non-Disturbance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subordination. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Lease and any Option granted hereby shall be subject and subordinate to any ground lease, mortgage, deed of trust, or other hypothecation or security device (collectively, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Security Device&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">),</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">now or hereafter placed upon the Premises, to any and all advances made on the security thereof, and to all renewals, modifications, and extensions thereof. Lessee agrees that the holders of any such Security Devices (in this Lease together referred to as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Lender&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall have no liability or obligation to perform any of the obligations of Lessor under this Lease. Any Lender may elect to have this Lease and&#47;or any Option granted hereby superior to the lien of its Security Device by giving written notice thereof to Lessee, whereupon this Lease and such Options shall be deemed prior to such Security Device, notwithstanding the relative dates of the documentation or recordation thereof.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attornment. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that Lessor transfers title to the Premises, or the Premises are acquired by another upon the foreclosure or termination of a Security Device to which this Lease is subordinated (i) Lessee shall, subject to the non-disturbance provisions of Paragraph 30.3, attorn to such new owner, and upon request, enter into a new lease, containing all of the terms and provisions of this Lease, with such new owner for the remainder of the term hereof, or, at the election of the new owner, this Lease will automatically become a new lease between Lessee and such new owner, and (ii) Lessor shall thereafter be relieved of any further obligations hereunder and such new owner shall assume all of Lessor&#8217;s obligations, except that such new owner shall not&#58; (a) be liable for any act or omission of any prior lessor or with respect to events occurring prior to acquisition of ownership&#59; (b) be subject to any offsets or defenses which Lessee might have against any prior lessor, (c) be bound by prepayment of more than one month&#8217;s rent, or (d) be liable for the return of any security deposit paid to any prior lessor which was not paid or credited to such new owner.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Disturbance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to Security Devices entered into by Lessor after the execution of this Lease, Lessee&#8217;s subordination of this Lease shall be subject to receiving a commercially reasonable non-disturbance agreement (a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Non-Disturbance Agreement&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the Lender which Non-Disturbance Agreement provides that Lessee&#8217;s possession of the Premises, and this Lease, including any options to extend the term hereof, will not be disturbed so long as Lessee is not in Breach hereof and attorns to the record owner of the Premises. Further, within 60 days after the execution of this Lease, Lessor shall, if requested by Lessee, use its commercially reasonable efforts to obtain a Non-Disturbance Agreement from the holder of any pre-existing Security Device which is secured by the Premises. In the event that Lessor is unable to provide the Non-Disturbance Agreement within said 60 days, then Lessee may, at Lessee&#8217;s option, directly contact Lender and attempt to negotiate for the execution and delivery of a Non-Disturbance Agreement.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Executing. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements contained in this Paragraph 30 shall be effective without the execution of any further documents&#59; provided, however, that, upon written request from Lessor or a Lender in connection with a sale, financing or refinancing of the Premises, Lessee and Lessor shall execute such further writings as may be reasonably required to separately document any subordination, attornment and&#47;or Non-Disturbance Agreement provided for herein.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attorneys&#8217; Fees. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any Party or Broker brings an action or proceeding involving the Premises whether founded in tort, contract or equity, or to declare rights hereunder, the Prevailing Party (as hereafter defined) in any such proceeding, action, or appeal thereon, shall be entitled to reasonable attorneys&#8217; fees. Such fees may be awarded in the same suit or recovered in a separate suit, whether or not such action or proceeding is pursued to decision or judgment. The term, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Prevailing Party&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall include, without limitation, a Party or Broker who substantially obtains or defeats the relief sought, as the case may be, whether by compromise, settlement, judgment, or the abandonment by the other Party or Broker of its claim or defense.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The attorneys&#8217; fees award shall not be computed in accordance with any court fee schedule, but shall be such as to fully reimburse all attorneys&#8217; fees reasonably incurred. In addition, Lessor shall be entitled to attorneys&#8217; fees, costs and expenses incurred in the preparation and service of notices of Default and consultations in connection therewith, whether or not a legal action is subsequently commenced in connection with such Default or resulting Breach ($200 is a reasonable minimum per occurrence for such services and consultation).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lessor&#8217;s Access&#59; Showing Premises&#59; Repairs. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor and Lessor&#8217;s agents shall have the right to enter the Premises at any time, in the case of an emergency, and otherwise at reasonable times after reasonable prior notice for the purpose of showing the same to prospective purchasers, lenders, or tenants, and making such alterations, repairs, improvements or additions to the Premises as Lessor may deem necessary or desirable and the erecting, using and maintaining of utilities, services, pipes and conduits through the Premises and&#47;or other premises as long as there is no material adverse effect to Lessee&#8217;s use of the Premises. All such activities shall be without abatement of rent or liability to Lessee.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Auctions. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee shall not conduct, nor permit to be conducted, any auction upon the Premises without Lessor&#8217;s prior written consent. Lessor shall not be obligated to exercise any standard of reasonableness in determining whether to permit an auction.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signs. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor may place on the Premises ordinary </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;For Sale&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">signs at any time and ordinary </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;For Lease&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">signs during the last 6 months of the term hereof. Except for ordinary &#8220;for sublease&#8221; signs, Lessee shall not place any sign upon the Premises without Lessor&#8217;s prior written consent. All signs must comply with all Applicable Requirements.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Termination&#59; Merger. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless specifically stated otherwise in writing by Lessor, the voluntary or other surrender of this Lease by Lessee, the mutual termination or cancellation hereof, or a termination hereof by Lessor for Breach by Lessee, shall automatically terminate any sublease or lesser estate in the Premises&#59; provided, however, that Lessor may elect to continue any one or all existing subtenancies. Lessor&#8217;s failure within 10 days following any such event to elect to the contrary by written notice to the holder of any such lesser interest, shall constitute Lessor&#8217;s election to have such event constitute the termination of such interest.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consents. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise provided herein, wherever in this Lease the consent of a Party is required to an act by or for the other Party, such consent shall not be unreasonably withheld or delayed. Lessor&#8217;s actual reasonable costs and expenses (including but not limited to architects&#8217;, attorneys&#8217;, engineers&#8217; and other consultants&#8217; fees) incurred in the consideration of, or response to, a request by Lessee for any Lessor consent, including but not limited to consents to an assignment, a subletting or the presence or use of a Hazardous Substance, shall be paid by Lessee upon receipt of an invoice and supporting documentation therefor. Lessor&#8217;s consent to any act, assignment or subletting shall not constitute an acknowledgment that no Default or Breach by Lessee of this Lease exists, nor shall such consent be deemed a waiver of any then existing Default or Breach, except as may be otherwise specifically stated in writing by Lessor at the time of such consent. The failure to specify herein any particular condition to Lessor&#8217;s consent shall not preclude the imposition by Lessor at the time of consent of such further or other conditions as are then reasonable with reference to the particular matter for which consent is being given. In the event that either Party disagrees with any determination made by the other hereunder and reasonably requests the reasons for such determination, the determining party shall furnish its reasons in writing and in reasonable detail within 10 business days following such request.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Execution. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Guarantors, if any, shall each execute a guaranty in the form most recently published by the AIR Commercial Real Estate Association, and each such Guarantor shall have the same obligations as Lessee under this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Default. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It shall constitute a Default of the Lessee if any Guarantor fails or refuses, upon request to provide&#58; (a) evidence of the execution of the guaranty, including the authority of the party signing on Guarantor&#8217;s behalf to obligate Guarantor, and in the case of a corporate Guarantor, a certified copy of a resolution of its board of directors authorizing the making of such guaranty, (b) current financial statements, (c) an Estoppel Certificate, or (d) written confirmation that the guaranty is still in effect.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quiet Possession. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to payment by Lessee of the Rent and performance of all of the covenants, conditions and provisions on Lessee&#8217;s part to be observed and performed under this Lease, Lessee shall have quiet possession and quiet enjoyment of the Premises during the term hereof.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Lessee is granted any Option, as defined below, then the following provisions shall apply&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition. &#8220;Option&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall mean&#58; (a) the right to extend or reduce the term of or renew this Lease or to extend or reduce the term of or renew any lease that Lessee has on other property of Lessor&#59; (b) the right of first refusal or first offer to lease either the Premises or other property of Lessor&#59; (c) the right to purchase, the right of first offer to purchase or the right of first refusal to purchase the Premises or other property of Lessor.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options Personal To Original Lessee. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any Option granted to Lessee in this Lease is personal to the original Lessee, and cannot be assigned or exercised by anyone other than said original Lessee and only while the original Lessee is in full possession of the Premises and, if requested by Lessor, with Lessee certifying that Lessee has no intention of thereafter assigning or subletting.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Multiple Options. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that Lessee has any multiple Options to extend or renew this Lease, a later Option cannot be exercised unless the prior Options have been validly exercised.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect of Default on Options.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Lessee shall have no right to exercise an Option&#58; (i) during the period commencing with the giving of any notice of Default and continuing until said Default is cured, (ii) during the period of time any Rent is unpaid (without regard to whether notice thereof is given Lessee), (iii) during the time Lessee is in Breach of this Lease, or (iv) in the event that Lessee has been given 3 or more notices of separate Default, whether or not the Defaults are cured, during the 12 month period immediately preceding the exercise of the Option.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The period of time within which an Option may be exercised shall not be extended or enlarged by reason of Lessee&#8217;s inability to exercise an Option because of the provisions of Paragraph 39.4(a).</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) An Option shall terminate and be of no further force or effect, notwithstanding Lessee&#8217;s due and timely exercise of the Option, if, after such exercise and prior to the commencement of the extended term or completion of the purchase, (i) Lessee fails to pay Rent for a period of 30 days after such Rent becomes due (without any necessity of Lessor to give notice thereof), or (ii) if Lessee commits a Breach of this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Multiple Buildings. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Premises are a part of a group of buildings controlled by Lessor, Lessee agrees that it will abide by and conform to all reasonable rules and regulations which Lessor may make from time to time for the management, safety, and care of said properties, including the care and cleanliness of the grounds and including the parking, loading and unloading of vehicles, and to cause its employees, suppliers, shippers, customers, contractors and invitees to so abide and conform. Lessee also agrees to pay its fair share of common expenses incurred in connection with such rules and regulations.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Measures. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessee hereby acknowledges that the Rent payable to Lessor hereunder does not include the cost of guard service or other security measures, and that Lessor shall have no obligation whatsoever to provide same. Lessee assumes all responsibility for the protection of the Premises, Lessee, its agents and invitees and their property from the acts of third parties.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reservations. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lessor reserves to itself the right, from time to time, to grant, without the consent or joinder of Lessee, such easements, rights and dedications that Lessor deems necessary, and to cause the recordation of parcel maps and restrictions, so long as such easements, rights, dedications, maps and restrictions do not unreasonably interfere with the use of the Premises by Lessee. Lessee agrees to sign any documents reasonably requested by Lessor to effectuate any such easement rights, dedication, map or restrictions.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Under Protest. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time a dispute shall arise as to any amount or sum of money to be paid by one Party to the other under the provisions hereof, the Party against whom the obligation to pay the money is asserted shall have the right to make payment &#8220;under protest&#8221; and such payment shall not be regarded as a voluntary payment and there shall survive the right on the part of said Party to institute suit for recovery of such sum. If it shall be adjudged that there was no legal obligation on the part of said Party to pay such sum or any part thereof, said Party shall be entitled to recover such sum or so much thereof as it was not legally required to pay. A Party who does not initiate suit for the recovery of sums paid &#8220;under protest&#8221; with 6 months shall be deemed to have waived its right to protest such payment.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authority&#59; Multiple Parties&#59; Execution.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If either Party hereto is a corporation, trust, limited liability company, partnership, or similar entity, each individual executing this Lease on behalf of such entity represents and warrants that he or she is duly authorized to execute and deliver this Lease on its behalf. Each Party shall, within 30 days after request, deliver to the other Party satisfactory evidence of such authority.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) If this Lease is executed by more than one person or entity as &#8220;Lessee&#8221;, each such person or entity shall be jointly and severally liable hereunder. It is agreed that any one of the  named Lessees shall be empowered  to  execute any amendment  to  this Lease, or  other document ancillary thereto and bind all of the named Lessees, and Lessor may rely on the same as if all of the named Lessees had executed such document.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) This Lease may be executed by the Parties in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conflict. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any conflict between the printed provisions of this Lease and typewritten or handwritten provisions shall be controlled by the typewritten or handwritten provisions.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Offer. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of this Lease by either Party or their agent and submission of same to the other Party shall not be deemed an offer to lease to the other Party. This Lease is not intended to be binding until executed and delivered by all Parties hereto.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendments. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Lease may be modified only in writing, signed by the Parties in interest at the time of the modification. As long as they do not materially change Lessee&#8217;s obligations hereunder, Lessee agrees to make such reasonable non-monetary modifications to this Lease as may be reasonably required by a Lender in connection with the obtaining of normal financing or refinancing of the Premises.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Waiver of Jury Trial. THE PARTIES HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING INVOLVING THE PROPERTY OR ARISING OUT OF THIS AGREEMENT.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arbitration of Disputes. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An Addendum requiring the Arbitration of all disputes between the Parties and&#47;or Brokers arising out of this Lease</font><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">is</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">is</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">not </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attached to this Lease.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accessibility&#59; Americans with Disabilities  Act.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Premises&#58; </font><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have not undergone an inspection by a Certified Access Specialist (CASp). </font><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have undergone an inspection by a Certified Access Specialist (CASp) and it was determined that the Premises met all applicable construction-related accessibility standards pursuant to California Civil Code &#167;55.51 et seq. </font><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have undergone an inspection by a Certified Access Specialist (CASp) and it was determined that the Premises did not meet all applicable construction-related accessibility standards pursuant to California Civil Code &#167;55.51 et seq.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Since compliance with the Americans with Disabilities Act (ADA) is dependent upon Lessee&#8217;s specific use of the Premises, Lessor makes no  warranty or representation as to  whether  or  not  the Premises  comply  with ADA or  any similar  legislation. In the event that Lessee&#8217;s use of the Premises requires modifications or additions to the Premises in order to be in ADA compliance, Lessee agrees to make any such necessary modifications and&#47;or additions at Lessee&#8217;s expense.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LESSOR AND LESSEE HAVE CAREFULLY READ AND REVIEWED THIS LEASE AND EACH TERM AND PROVISION CONTAINED HEREIN, AND BY THE EXECUTION OF THIS LEASE SHOW THEIR INFORMED AND VOLUNTARY CONSENT THERETO. THE PARTIES HEREBY AGREE THAT, AT THE TIME THIS LEASE IS EXECUTED, THE TERMS OF THIS LEASE ARE COMMERCIALLY REASONABLE AND EFFECTUATE THE INTENT AND PURPOSE OF LESSOR AND LESSEE WITH RESPECT TO THE PREMISES.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ATTENTION&#58; NO REPRESENTATION OR RECOMMENDATION IS MADE BY THE AIR COMMERCIAL REAL ESTATE ASSOCIATION OR BY ANY BROKER AS TO THE LEGAL SUFFICIENCY, LEGAL EFFECT, OR TAX CONSEQUENCES OF THIS LEASE OR THE TRANSACTION TO WHICH IT RELATES. THE PARTIES ARE URGED TO&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. SEEK ADVICE OF COUNSEL AS TO THE LEGAL AND TAX CONSEQUENCES OF THIS LEASE.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. RETAIN APPROPRIATE CONSULTANTS TO REVIEW AND INVESTIGATE THE CONDITION OF THE PREMISES. SAID INVESTIGATION SHOULD INCLUDE BUT NOT BE LIMITED TO&#58; THE POSSIBLE PRESENCE OF HAZARDOUS SUBSTANCES, THE ZONING OF THE PREMISES, THE STRUCTURAL INTEGRITY, THE CONDITION OF THE ROOF AND OPERATING SYSTEMS, AND THE SUITABILITY OF THE PREMISES FOR LESSEE&#8217;S INTENDED USE.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties hereto have executed this Lease at the  place and on the dates specified above their respective signatures.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executed at&#58; Feb. 28, 2016</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executed at&#58; Feb. 28, 2016</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On&#58; &#47;s&#47; Soheil Shams</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On&#58; &#47;s&#47; Soheil Shams</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:7.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Lessor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; TESA Beach, LLC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:7.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LESSEE&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioDiscovery, Inc.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name Printed&#58; Soheil Shams, PhD</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name Printed&#58; Soheil Shams, PhD</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Owner</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; President</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:7.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address&#58; 715 N. Douglas St. El Segundo, CA 90245</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Telephone&#58;( )</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Telephone&#58;( )</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facsimile&#58;( )</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facsimile&#58;( )</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal ID No.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal ID No.</font></td></tr><tr style="height:19pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTICE&#58; These forms are often modified to meet changing requirements of law and industry needs. Always write or call to make sure you are utilizing the most current form&#58; AIR Commercial Real Estate Association, 500 N Brand Blvd, Suite 900, Glendale, CA 91203.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Telephone No. (213) 687-8777. Fax No.&#58; (213) 687-8616.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#169; Copyright 2001 - By AIR Commercial Real Estate Association. All rights reserved.</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:59.76pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rent Adjustment(s)</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Standard Lease Addendum</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dated </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 1, 2016</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">By and Between (Lessor) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tesa Beach, LLC</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Lessee) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">BioDiscovery, Inc</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Address of the Premises&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">715 N. Douglas Street, El Segundo CA 90245</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paragraph </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;Rent Adjustments&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent shall be increased yearly by 2.5% starting the March 1, 2021</font></div><div style="margin-top:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>8
<FILENAME>bngo-ex1039_bionanoxfiftha.htm
<DESCRIPTION>EX-10.39
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie8dc5e409cb3459b9ca90f6501f109d2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.39</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FIFTH AMENDMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THIS FIFTH AMENDMENT (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) is made and entered into as of<br></font><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 12, 2022, by and between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IRVINE EASTGATE OFFICE I LLC, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a Delaware limited                      liability company, hereafter called &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#34; and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BIONANO GENOMICS, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, a</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">corporation, hereafter called &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#34;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Landlord (as successor in interest to The Irvine Company LLC) and Tenant are parties to that certain lease dated January 16, 2012, which lease has been previously amended by a First Amendment to Lease dated September 10, 2013, a Second Amendment dated July 1, 2015, a Third Amendment dated December 19, 2019 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and a Fourth Amendment dated February 15, 2021 (collectively, the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;).  Pursuant to the Lease, Landlord has leased to Tenant space currently containing approximately 35,823 rentable square feet (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) described as Suites 100 and 155 on the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> floor of the building located at 9540 Towne Centre Drive, San Diego, California (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9540 Building</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and Suite 100 on the first floor of the building located at 9640 Towne Centre Drive, San Diego, California (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9640 Building</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant has requested that additional space containing approximately 5,278 rentable square feet (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Suite 150 Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) on the first floor of the 9540 Building as shown on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit&#160;A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (attached hereto) be added to the Original Premises and that the Lease be appropriately amended and Landlord is willing to do the same on the following terms and conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, in consideration of the above recitals which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:30.46pt;text-decoration:underline">Suite 150 Expansion and Effective Date.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;The Term for the Suite 150 Expansion Space shall commence on January 17, 2022 (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Suite 150 Expansion Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;).  Effective as of the Suite 150 Expansion Effective Date, the Premises, as defined in the Lease, shall be increased from 35,823 rentable square feet consisting of 19,216 rentable square feet in Suites 100 and 155 of the 9540 Building and 16,607 rentable square feet in Suite 100 of the 9640 Building to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,101</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> rentable square feet by the addition of the Suite 150 Expansion Space.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Delay in Possession</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If Landlord, for any reason whatsoever, cannot deliver possession of Suite 150 Expansion Space to Tenant on or before the Suite 150 Expansion Effective Date set forth in Section I.A above, this Amendment shall not be void or voidable nor shall Landlord be liable to Tenant for any resulting loss or damage. However, Tenant shall not be liable for any rent for the Suite 150 Expansion Space and the Suite 150 Expansion Effective Date shall not occur until Landlord delivers possession of the Suite 150 Expansion Space and the Suite 150 Expansion Space is in fact ready for occupancy as defined below, except that if Landlord&#8217;s failure to so deliver possession is attributable to any action or inaction by Tenant (including without limitation any Tenant Delay described in the Work Letter, if any, attached to this Amendment), then the Suite 150 Expansion Space shall be deemed ready for occupancy, and Landlord shall be entitled to full performance by Tenant (including the payment of rent), as of the date Landlord would have been able to deliver the Suite 150 Expansion Space to Tenant but for Tenant&#8217;s delay(s).  Subject to the foregoing, the Suite 150 Expansion Space shall be deemed ready for occupancy if and when Landlord, to the extent applicable, (a)&#160;has put into operation all building services essential for the use of the Suite 150 Expansion Space by Tenant, (b)&#160;has provided reasonable access to the Suite 150 Expansion Space for Tenant so that it may be used without unnecessary interference, and (c)&#160;Landlord and Tenant agree that Landlord shall use commercially reasonable efforts to complete all work required to be done by Landlord in this Amendment by the Suite 150 Expansion Effective Date.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.69pt;text-decoration:underline">Basic Rent.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  In addition to Tenant&#8217;s obligation to pay Basic Rent for the Original Premises, Tenant shall pay Landlord Basic Rent for the Suite 150 Expansion Space as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.410%"><tr><td style="width:1.0%"></td><td style="width:32.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Months of Term or Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Monthly Rate Per Square Foot</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Monthly Basic Rent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1 to 12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,834.00</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13 to 24</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.14</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,572.92</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25 to 36</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,311.84</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37 to 48</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,103.54</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the above schedule of Basic Rent to the contrary, as long as Tenant is not in Default (as defined in Section&#160;14.1) under the Lease, Tenant shall be entitled to an abatement of 3 full calendar months of Basic Rent in the aggregate amount of $47,502.00 (i.e. $15,834.00 per month) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Abated Basic Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for the first 3 full calendar months following the Suite 150 Expansion Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Abatement Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  In the event Tenant Defaults at any time during the Term, all Abated Basic Rent shall immediately become due and payable.  The payment by Tenant of the Abated Basic Rent in the event of a Default shall not limit or affect any of Landlord's other rights, pursuant to this Lease or at law or in equity.  Only Basic Rent shall be abated during the Abatement Period and all other additional rent and other costs and charges </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BioNano Genomics, Inc.-9540 Towne Centre Drive-STE 0150-Amendment-5A3&#160;&#160;&#160;&#160;1&#47;11&#47;2022-Opp-044372</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">specified in this Lease shall remain as due and payable pursuant to the provisions of this Lease. All such Basic Rent shall be payable by Tenant in accordance with the terms of the Lease.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Project Costs and Property Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For the period commencing on the Suite 150 Expansion Effective Date and ending on the Expiration Date, Tenant shall be obligated to pay Tenant&#8217;s Share of Project Costs and Property Taxes accruing in connection with the Suite 150 Expansion Space in accordance with the terms of the Lease.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Security Deposit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Concurrently with Tenant&#8217;s delivery of this Amendment, Tenant shall deliver the sum of $19,914.00 to Landlord, which sum shall be added to the Security Deposit presently being held by Landlord in accordance with Section 4.3 of the Lease. Accordingly, the Security Deposit is increased from $88,236.00 to $108,150.00. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Improvements to Suite 150 Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condition of Suite 150 Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Tenant has inspected the Suite 150 Expansion Space and agrees to accept the same &#34;as is&#34; without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Amendment.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant Improvements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Landlord hereby agrees to complete</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Tenant Improvements for the Suite 150 Expansion Space in accordance with the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Work Letter, attached hereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Parking</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Notwithstanding any contrary provision in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit F</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to the Lease, &#8220;Parking,&#8221; effective as of the Suite 150 Expansion Effective Date, Landlord shall lease to Tenant, and Tenant shall lease from Landlord, an additional 21 unreserved parking passes free of charge through the Expiration Date.  Thereafter, the parking charge shall be at Landlord&#8217;s scheduled parking rates from time to time.  Tenant shall have the right to designate 6 reserved parking spaces adjacent to the 9540 Building entry as reserved for Tenant and Tenant&#8217;s visitors utilizing signage approved by Landlord.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SDN List</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Tenant hereby represents and warrants that neither Tenant nor any officer, director, employee, partner, member or other principal of Tenant (collectively, &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tenant Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) is listed as a Specially Designated National and Blocked Person (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SDN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) on the list of such persons and entities issued by the U.S. Treasury Office of Foreign Assets Control (OFAC).  In the event Tenant or any Tenant Party is or becomes listed as an SDN, Tenant shall be deemed in breach of this Lease and Landlord shall have the right to terminate the Lease immediately upon written notice to Tenant.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Deleted Provisions.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Section VII.C of the Third Amendment entitled &#8220;Right of First Refusal&#8221; is hereby deleted in its entirety and of no further force or effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IX.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">GENERAL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Amendments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Lease shall remain in full force and effect except to the extent that it is modified by this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Amendment embodies the entire understanding between Landlord and Tenant and can be changed only by a writing signed by Landlord and Tenant. There have been no additional oral or written representations or agreements.  Under no circumstances shall Tenant be entitled to any rent abatement, improvement allowance, leasehold improvements, or any similar economic incentives that may have been provided Tenant in connection with entering into the Lease, unless specifically set forth in this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts&#59; Digital Signatures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If this Amendment is executed in counterparts, each is hereby declared to be an original&#59; all, however, shall constitute but one and the same amendment.  In any action or proceeding, any photographic, photostatic, or other copy of this Amendment may be introduced into evidence without foundation. The parties agree to accept a digital image (including but not limited to an image in the form of a PDF, JPEG, GIF file</font><font style="color:#1f497d;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or other e-signature) of this&#160;Amendment, if applicable, reflecting the execution of one or both of the parties, as a true and correct original.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All words commencing with initial capital letters in this Amendment and defined in the Lease shall have the same meaning in this Amendment as in the Lease, unless they are otherwise defined in this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If Tenant is a corporation, limited liability company or partnership, or is comprised of any of them, each individual executing this Amendment for the corporation, limited liability company or partnership represents that he or she is duly authorized to execute and deliver this Amendment on behalf of such entity and that this Amendment is binding upon such entity in accordance with its terms.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">California Certified Access Specialist Inspection</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Pursuant to California Civil Code &#167;&#160;1938, Landlord hereby states that the Premises have not undergone inspection by a Certified Access Specialist (CASp) (defined in California Civil Code &#167;&#160;55.52(a)(3)).  Pursuant to Section&#160;1938 of the California Civil Code, Landlord hereby provides the following notification to Tenant&#58; &#34;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law.  Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant.  The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BioNano Genomics, Inc.-9540 Towne Centre Drive-STE 0150-Amendment-5A3&#160;&#160;&#160;&#160;1&#47;11&#47;2022-Opp-044372</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">inspection, and the cost of making any repairs necessary to correct violations of construction related accessibility standards within the premises.&#34; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Attorneys' Fees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The provisions of the Lease respecting payment of attorneys' fees shall also apply to this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Article&#160;18 of the Lease is amended to provide that the parties recognize the following parties as the brokers who negotiated this Amendment, and agree that Landlord shall be responsible for payment of brokerage commissions to such brokers pursuant to its separate agreements with such brokers&#58; Irvine Management Company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Landlord&#8217;s Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is the agent of Landlord exclusively and Hughes Marino, Inc. &#47; San Diego, (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tenant&#8217;s Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is the agent of Tenant exclusively.  By the execution of this Amendment, each of Landlord and Tenant hereby acknowledge and confirm (a)&#160;receipt of a copy of a Disclosure Regarding Real Estate Agency Relationship conforming to the requirements of California Civil Code 2079.16, and (b)&#160;the agency relationships specified herein, which acknowledgement and confirmation is expressly made for the benefit of Tenant&#8217;s Broker.  If there is no Tenant&#8217;s Broker so identified herein, then such acknowledgement and confirmation is expressly made for the benefit of Landlord&#8217;s Broker.  By the execution of this Amendment, Landlord and Tenant are executing the confirmation of the agency relationships set forth herein. The warranty and indemnity provisions of Article&#160;18 of the Lease, as amended hereby, shall be binding and enforceable in connection with the negotiation of this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Execution of Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant.  Landlord shall not be bound by this Amendment until Landlord has executed and delivered the same to Tenant.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Nondisclosure of Terms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Tenant agrees that neither Tenant nor its agents or any other parties acting on behalf of Tenant shall disclose any matters set forth in this Amendment or disseminate or distribute any information concerning the terms, details or conditions hereof to any person, firm or entity without obtaining the express written consent of Landlord.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;SIGNATURES ON FOLLOWING PAGE&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BioNano Genomics, Inc.-9540 Towne Centre Drive-STE 0150-Amendment-5A3&#160;&#160;&#160;&#160;1&#47;11&#47;2022-Opp-044372</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Landlord and Tenant have duly executed this Amendment as of the day and year first above written.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LANDLORD&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRVINE EASTGATE OFFICE I LLC,</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Steven M. Case</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>Steven M. Case</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Leasing &#38; Marketing</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office Properties</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Christopher Gash</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Gash</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Operations</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office Properties</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TENANT&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIONANO GENOMICS, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a Delaware</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">corporation</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Erik Holmlin</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erik Holmlin</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEO</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Mark Oldakowski</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Oldakowski</font></div><div style="padding-left:16.25pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COO </font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BioNano Genomics, Inc.-9540 Towne Centre Drive-STE 0150-Amendment-5A3&#160;&#160;&#160;&#160;1&#47;11&#47;2022-Opp-044372</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OUTLINE AND LOCATION OF SUITE 150 EXPANSION SPACE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">9540 Towne Centre Drive</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:100%">Suite 150</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:87px;margin-bottom:5pt;vertical-align:text-bottom;width:38px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-right:-9pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="image_1.jpg" src="image_1.jpg" style="height:246px;margin-bottom:5pt;vertical-align:text-bottom;width:528px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div id="ie8dc5e409cb3459b9ca90f6501f109d2_4"></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BioNano Genomics, Inc.-9540 Towne Centre Drive-STE 0150-Amendment-5A3&#160;&#160;&#160;&#160;1&#47;11&#47;2022-Opp-044372</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5</font></div><div style="text-align:center"><font><br></font></div></div></div><div id="ie8dc5e409cb3459b9ca90f6501f109d2_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WORK LETTER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DOLLAR ALLOWANCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;SECOND GENERATION SPACE&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As used in this Work Letter, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be deemed to refer to the Suite 150 Expansion Space, as defined in the attached Amendment.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Tenant Improvement work (herein &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tenant Improvements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall consist of any work required to complete the Premises pursuant to plans and specifications approved by both Landlord and Tenant.  All of the Tenant Improvement work shall be performed by a contractor engaged by Landlord. Landlord may require that one or more designated subtrades be union contractors. The work shall be undertaken in accordance with the procedures and requirements set forth below.  </font><font style="background-color:#ffffff;color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Landlord will endeavor to diligently perform the construction of the Tenant Improvements.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ARCHITECTURAL AND CONSTRUCTION PROCEDURES</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Tenant has approved, or shall approve within the time period set forth below, a detailed space plan for the Premises, prepared by the architect engaged by Landlord for the work described herein (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Landlord&#8217;s Architect</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), which includes interior partitions, ceilings, interior finishes, interior office doors, suite entrance, floor coverings, window coverings, lighting, electrical and telephone outlets, plumbing connections, heavy floor loads and other special requirements (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preliminary Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and (ii)&#160;an estimate, prepared by the contractor engaged by Landlord for the work herein (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Landlord&#8217;s Contractor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), of the cost for which Landlord will complete or cause to be completed the Tenant Improvements (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preliminary Cost Estimate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). To the extent applicable, the Preliminary Plan shall include Landlord&#8217;s building standard tenant improvements, materials and specifications for the Project. Tenant shall approve or disapprove the Preliminary Plan by signing and delivering same to Landlord within 3 business days of its receipt by Tenant.  If Tenant disapproves any matter, Tenant shall specify in detail the reasons for disapproval and Landlord shall attempt to modify the Preliminary Plan to incorporate Tenant&#8217;s suggested revisions in a mutually satisfactory manner&#59; provided that in no event shall Tenant have the right to request changes or additions to the Preliminary Plan for the purpose of utilizing any unused portion of the Landlord Contribution (as defined below).  Notwithstanding the foregoing, however, Tenant shall approve in all respects a Preliminary Plan not later than March 21, 2022 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan Approval Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), it being understood that Tenant&#8217;s failure to do so shall constitute a &#8220;Tenant Delay&#8221; for purposes of this Amendment.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;On or before the Plan Approval Date, Tenant shall provide in writing to Landlord or Landlord&#8217;s Architect all specifications and information requested by Landlord for the preparation of final construction documents and costing, including without limitation Tenant&#8217;s final selection of wall and floor finishes, complete specifications and locations (including load and HVAC requirements) of Tenant&#8217;s equipment, and details of all other non-building standard improvements to be installed in the Premises (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Programming Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Tenant&#8217;s failure to provide the Programming Information by the Plan Approval Date shall constitute a Tenant Delay for purposes of this Amendment.  Tenant understands that final construction documents for the Tenant Improvements shall be predicated on the Programming Information, and accordingly that such information must be accurate and complete.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Upon Tenant&#8217;s approval of the Preliminary Plan and Preliminary Cost Estimate and delivery of the complete Programming Information, Landlord&#8217;s Architect and engineers shall prepare and deliver to the parties working drawings and specifications (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Working Drawings and Specifications</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and Landlord&#8217;s Contractor shall prepare a final construction cost estimate (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Final Cost Estimate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for the Tenant Improvements in conformity with the Working Drawings and Specifications.  Tenant shall have 3 business days from the receipt thereof to approve or disapprove the Working Drawings and Specifications and the Final Cost Estimate, and any disapproval or requested modification shall be limited to items not contained in the approved Preliminary Plan or Preliminary Cost Estimate&#59; provided that in no event shall Tenant have the right to request changes or additions to the Working Drawings and Specifications for the purpose of utilizing any unused portion of the Landlord Contribution. In no event shall Tenant disapprove the Final Cost Estimate if it does not exceed the approved Preliminary Cost Estimate. Should Tenant disapprove the Working Drawings and Specifications and the Final Cost Estimate, such disapproval shall be accompanied by a detailed list of revisions.  Any revision requested by Tenant and accepted by Landlord shall be incorporated by Landlord&#8217;s Architect into a revised set of Working Drawings and Specifications and Final Cost Estimate, and Tenant shall approve same in writing within 3 business days of receipt without further revision.  Tenant&#8217;s failure to comply in a timely manner with any of the requirements of this paragraph shall constitute a Tenant Delay.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;It is understood that the Preliminary Plan and the Working Drawings and Specifications, together with any Changes thereto, shall be subject to the prior approval of Landlord.  Landlord shall identify any disapproved items within 3 business days (or 2 business days in the case of Changes) after receipt of the applicable document.  Should Landlord approve work that would necessitate any ancillary Building modification or other expenditure by Landlord, then except to the extent of any remaining balance of the &#8220;Landlord Contribution&#8221; as described below, Tenant shall, in addition to its other obligations herein, promptly fund the cost thereof to Landlord.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E.&#160;&#160;&#160;&#160;In the event that Tenant requests in writing a revision in the approved Working Drawings and Specifications (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), then provided such Change is acceptable to Landlord, Landlord shall advise Tenant by written change order as soon as is practical of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BioNano Genomics, Inc.-9540 Towne Centre Drive-STE 0150-Amendment-5A3&#160;&#160;&#160;&#160;1&#47;11&#47;2022-Opp-044372</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">increase in the Completion Cost and&#47;or any Tenant Delay such Change would cause.  Tenant shall approve or disapprove such change order in writing within 2 business days following its receipt from Landlord.  Tenant&#8217;s approval of a Change shall be accompanied by Tenant&#8217;s payment of any resulting increase in the Completion Cost regardless of any unutilized portion of the Landlord Contribution.  It is understood that Landlord shall have no obligation to interrupt or modify the Tenant Improvement work pending Tenant&#8217;s approval of a change order.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F.&#160;&#160;&#160;&#160;Notwithstanding any provision in the Lease to the contrary, if Tenant fails to comply with any of the time periods specified in this Work Letter, fails otherwise to approve or reasonably disapprove any submittal within 3 business days, fails to approve in writing the Preliminary Plan by the Plan Approval Date, fails to provide all of the Programming Information requested by Landlord by the Plan Approval Date, fails to approve in writing the Working Drawings and Specifications within the time provided herein, requests any Changes, fails to make timely payment of any sum due hereunder, furnishes inaccurate or erroneous specifications or other information, or otherwise delays in any manner the completion of the Tenant Improvements (including without limitation by specifying materials that are not readily available) or the issuance of an occupancy certificate (any of the foregoing being referred to in this Amendment as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tenant Delay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), then Tenant shall bear any resulting additional construction cost or other expenses. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G.&#160;&#160;&#160;&#160;Landlord shall permit Tenant and its agents to enter the Premises prior to the Suite 150 Expansion Effective Date in order that Tenant may perform any work to be performed by Tenant hereunder through its own contractors, subject to Landlord&#8217;s prior written approval, and in a manner and upon terms and conditions and at times satisfactory to Landlord&#8217;s representative.  The foregoing license to enter the Premises prior to the Suite 150 Expansion Effective Date is, however, conditioned upon Tenant&#8217;s contractors and their subcontractors and employees working in harmony and not interfering with the work being performed by Landlord.  If at any time that entry shall cause disharmony or interfere with the work being performed by Landlord, this license may be withdrawn by Landlord upon 24 hours written notice to Tenant.  That license is further conditioned upon the compliance by Tenant&#8217;s contractors with all requirements imposed by Landlord on third party contractors and subcontractors, including without limitation the maintenance by Tenant and its contractors and subcontractors of workers&#8217; compensation and public liability and property damage insurance in amounts and with companies and on forms satisfactory to Landlord, with certificates of such insurance being furnished to Landlord prior to proceeding with any such entry.  The entry shall be deemed to be under all of the provisions of the Lease except as to the covenants to pay Rent unless Tenant commences business activities within the Premises.  Landlord shall not be liable in any way for any injury, loss or damage which may occur to any such work being performed by Tenant, the same being solely at Tenant&#8217;s risk.  In no event shall the failure of Tenant&#8217;s contractors to complete any work in the Suite 150 Suite 150 Expansion Space extend the Suite 150 Expansion Effective Date.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I.&#160;&#160;&#160;&#160;Tenant hereby designates Dave Mas, Telephone No. (610) 764-5848, as its representative, agent and attorney-in-fact for the purpose of receiving notices, approving submittals and issuing requests for Changes, and Landlord shall be entitled to rely upon authorizations and directives of such person(s) as if given directly by Tenant. Tenant may amend the designation of its construction representative(s) at any time upon delivery of written notice to Landlord.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">COST OF TENANT IMPROVEMENTS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Landlord shall complete, or cause to be completed, the Tenant Improvements, at the construction cost shown in the Final Cost Estimate (subject to the provisions of this Work Letter), in accordance with final Working Drawings and Specifications approved by both Landlord and Tenant.  Landlord shall pay towards the final construction costs (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Completion Cost</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as incurred a maximum of $142,506.00 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Landlord Contribution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), based on $27.00 per usable square foot of the Premises, and Tenant shall be fully responsible for the remainder (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tenant Contribution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If the actual cost of completion of the Tenant Improvements is less than the maximum amount provided for the Landlord Contribution, such savings shall inure to the benefit of Landlord and Tenant shall not be entitled to any credit or payment or to apply the savings toward additional work.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;The Completion Cost shall include all direct costs of Landlord in completing the Tenant Improvements, including but not limited to the following&#58;  (i)&#160;payments made to architects, engineers, contractors, subcontractors and other third party consultants in the performance of the work, (ii)&#160;permit fees and other sums paid to governmental agencies, (iii)&#160;costs of all materials incorporated into the work or used in connection with the work (excluding any furniture, fixtures and equipment relating to the Premises), and (iv) keying and signage costs. The Completion Cost shall also include an administrative&#47;supervision fee to be paid to Landlord in the amount of 3% of all such direct costs.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Prior to start of construction of the Tenant Improvements, Tenant shall pay to Landlord the amount of the Tenant Contribution set forth in the approved Final Cost Estimate.  In addition, if the actual Completion Cost of the Tenant Improvements is greater than the Final Cost Estimate because of modifications or extras requested by Tenant and not reflected on the approved working drawings, or because of Tenant Delays, then notwithstanding any unused portion of the Landlord Contribution, Tenant shall pay to Landlord, within 10 days following submission of an invoice therefor, all such additional costs, including any additional architectural fee.  If Tenant defaults in the payment of any sums due under this Work Letter, Landlord shall (in addition to all other remedies) have the same rights as in the case of Tenant&#8217;s failure to pay rent under the Lease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BioNano Genomics, Inc.-9540 Towne Centre Drive-STE 0150-Amendment-5A3&#160;&#160;&#160;&#160;1&#47;11&#47;2022-Opp-044372</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>bngo-ex211_bionanoxsubsidi.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i81c47045c6a54a64a7d66313d3fd28a9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 21.1</font></div></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subsidiaries of Bionano Genomics, Inc.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bionano Genomics UK, Ltd.,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;a private limited company organized under the laws of the United Kingdom</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bionano Genomics (Shanghai) Trading Co., Ltd.,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;a private limited company organized under the laws of the China</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioDiscovery, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a California limited liability company</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lineagen, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware corporation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>exhibit231-bdoauditorconse.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id2c56d0a4ffd4acfb1c71e94fb81616b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the Registration Statements on Form S-3 (File Nos. 333-237070,  333-239360, 333-245762, 333-251956 and 333-252216) and Form S-8 (Nos. 333-227073, 333-230589, 333-237069, 333-245764, 333-248468, 333-254654 and 333-260762) of Bionano Genomics, Inc.  (the &#8220;Company&#8221;) of our reports dated March 1, 2022, relating to the consolidated financial statements, and the effectiveness of the Company&#8217;s internal controls over financial reporting, which appear in this Annual Report on Form 10-K.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>bngo-ex311x20211231.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie67ce88b90684e4398faecf90a5363d8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, R. Erik Holmlin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Bionano Genomics, Inc., a Delaware corporation (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this&#160;&#160;report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;1, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.619%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Erik Holmlin, Ph.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>bngo-ex312x20211231.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2247436cd61b41e989e33d49d625d3c2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Stewart, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Bionano Genomics, Inc., a Delaware corporation (the &#8220;registrant&#8221;)&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:2.41pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:1.84pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;1, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.619%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher Stewart</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Stewart</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>bngo-ex321x20211231.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0148f92c0c2d498d8bfc435b2bb5a083_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, R. Erik Holmlin, Chief Executive Officer of Bionano Genomics, Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Annual Report&#8221;), and to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Erik Holmlin, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies and is being &#8220;furnished&#8221; with this Annual Report, shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Exchange Act, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>14
<FILENAME>bngo-ex322x20211231.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1aa02dc872e947a99fafffe8e7762854_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Christopher Stewart, Chief Financial Officer of Bionano Genomics, Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Annual Report&#8221;), and to which this Certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher Stewart</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Stewart</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies and is being &#8220;furnished&#8221; with this Annual Report, shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Exchange Act, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>bngo-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e3db6ed1-8b4e-4b22-9c48-82142796368a,g:231d39e4-2c00-4236-9c0c-64cfa873dbdc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bngo="http://bionanogenomics.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://bionanogenomics.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bngo-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://bionanogenomics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://bionanogenomics.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://bionanogenomics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossStatement" roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement">
        <link:definition>1004006 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Statement)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://bionanogenomics.com/role/OrganizationandOperations">
        <link:definition>2101101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperationsDetails" roleURI="http://bionanogenomics.com/role/OrganizationandOperationsDetails">
        <link:definition>2402401 - Disclosure - Organization and Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1" roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomers" roleURI="http://bionanogenomics.com/role/RevenuefromContractswithCustomers">
        <link:definition>2111103 - Disclosure - Revenue from Contracts with Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomersTables" roleURI="http://bionanogenomics.com/role/RevenuefromContractswithCustomersTables">
        <link:definition>2312302 - Disclosure - Revenue from Contracts with Customers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuefromContractswithCustomersDetails" roleURI="http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails">
        <link:definition>2413407 - Disclosure - Revenue from Contracts with Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurements" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements">
        <link:definition>2114104 - Disclosure - Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsTables" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables">
        <link:definition>2315303 - Disclosure - Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails">
        <link:definition>2416408 - Disclosure - Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2417409 - Disclosure - Investments and Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails">
        <link:definition>2418410 - Disclosure - Investments and Fair Value Measurements - Contingent Consideration Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails">
        <link:definition>2419411 - Disclosure - Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>2120105 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>2321304 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2422412 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNet">
        <link:definition>2123106 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetTables">
        <link:definition>2324305 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails" roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails">
        <link:definition>2425413 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails">
        <link:definition>2426414 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://bionanogenomics.com/role/IntangibleAssetsNet">
        <link:definition>2127107 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetTables">
        <link:definition>2328306 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetSummaryofIntangibleAssetsDetails" roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails">
        <link:definition>2429415 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>2430416 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails" roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails">
        <link:definition>2431417 - Disclosure - Intangible Assets, Net - Future Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://bionanogenomics.com/role/AccruedExpenses">
        <link:definition>2132108 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://bionanogenomics.com/role/AccruedExpensesTables">
        <link:definition>2333307 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesScheduleofAccruedExpensesDetails" roleURI="http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails">
        <link:definition>2434418 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://bionanogenomics.com/role/LongTermDebt">
        <link:definition>2135109 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://bionanogenomics.com/role/LongTermDebtTables">
        <link:definition>2336308 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>2437419 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofDebtObligationsDetails" roleURI="http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails">
        <link:definition>2438420 - Disclosure - Long-Term Debt - Schedule of Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensation" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation">
        <link:definition>2139110 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationTables" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables">
        <link:definition>2340309 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails">
        <link:definition>2441421 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationWarrantActivityDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails">
        <link:definition>2442422 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails">
        <link:definition>2443423 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Summary of Stock Option Activity Under 2018 Plan and 2006 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails">
        <link:definition>2444424 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails">
        <link:definition>2445425 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>2446426 - Disclosure - Stockholders&#8217; Equity and Stock-Based Compensation - Weighted-Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://bionanogenomics.com/role/CommitmentsandContingencies">
        <link:definition>2147111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesTables">
        <link:definition>2348310 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2449427 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSupplementalInformationDetails" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails">
        <link:definition>2450428 - Disclosure - Commitments and Contingencies - Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseCostDetails" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails">
        <link:definition>2451429 - Disclosure - Commitments and Contingencies - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails">
        <link:definition>2452430 - Disclosure - Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1">
        <link:definition>2452430 - Disclosure - Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails" roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails">
        <link:definition>2453431 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://bionanogenomics.com/role/IncomeTaxes">
        <link:definition>2154112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://bionanogenomics.com/role/IncomeTaxesTables">
        <link:definition>2355311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails" roleURI="http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails">
        <link:definition>2456432 - Disclosure - Income Taxes - Domestic and Foreign Components of Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails" roleURI="http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails">
        <link:definition>2457433 - Disclosure - Income Taxes - Provision for Domestic and Foreign Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2458434 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsDetails" roleURI="http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>2459435 - Disclosure - Income Taxes - Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2460436 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>2461437 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefits" roleURI="http://bionanogenomics.com/role/EmployeeBenefits">
        <link:definition>2162113 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/EmployeeBenefitsAdditionalInformationDetails">
        <link:definition>2463438 - Disclosure - Employee Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://bionanogenomics.com/role/Acquisitions">
        <link:definition>2164114 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://bionanogenomics.com/role/AcquisitionsTables">
        <link:definition>2365312 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAdditionalInformationDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails">
        <link:definition>2466439 - Disclosure - Acquisitions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionPurchasePriceDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails">
        <link:definition>2467440 - Disclosure - Acquisitions - Acquisition Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2468441 - Disclosure - Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsIdentifiableIntangibleAssetsDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails">
        <link:definition>2469442 - Disclosure - Acquisitions - Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsProFormaInformationDetails" roleURI="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails">
        <link:definition>2470443 - Disclosure - Acquisitions - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://bionanogenomics.com/role/RelatedPartyTransactions">
        <link:definition>2171115 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://bionanogenomics.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2472444 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bngo_PurchaseObligationContractTerminationPeriod" abstract="false" name="PurchaseObligationContractTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_ComputerAndOfficeEquipmentMember" abstract="true" name="ComputerAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember" abstract="true" name="AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClassofWarrantorRightTerm" abstract="false" name="ClassofWarrantorRightTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bngo_CommonStockWarrantsAmendedAgreementMember" abstract="true" name="CommonStockWarrantsAmendedAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightOutstandingRollForward" abstract="true" name="ClassOfWarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_PurchaseObligationInitialPurchasePeriod" abstract="false" name="PurchaseObligationInitialPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_RevolverMember" abstract="true" name="RevolverMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ElSegundoCaliforniaMember" abstract="true" name="ElSegundoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentCovenantPrepaymentFee" abstract="false" name="DebtInstrumentCovenantPrepaymentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_CorporateNotesAndBondsMember" abstract="true" name="CorporateNotesAndBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_BusinessCombinationConsiderationTransferredValueOfShares" abstract="false" name="BusinessCombinationConsiderationTransferredValueOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bngo_SaleOfStockAuthorizedAmountToBeIssued" abstract="false" name="SaleOfStockAuthorizedAmountToBeIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsPeriodTwoMember" abstract="true" name="DebtInstrumentPaymentTermsPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" abstract="false" name="AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bngo_EmployeeStockPurchasePlanCompensationExpense" abstract="false" name="EmployeeStockPurchasePlanCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod" abstract="false" name="DebtInstrumentCovenantWaiverFeePaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" abstract="false" name="TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_RentalRevenueReagentRentalProgram" abstract="false" name="RentalRevenueReagentRentalProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" abstract="false" name="OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsAxis" abstract="true" name="DebtInstrumentPaymentTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_PerformanceShareUnitsPSUsMember" abstract="true" name="PerformanceShareUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_LineagenMember" abstract="true" name="LineagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_LesseeEstimatedIncrementalBorrowingRate" abstract="false" name="LesseeEstimatedIncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bngo_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_TermA2LoanMember" abstract="true" name="TermA2LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember" abstract="true" name="CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance" abstract="false" name="DebtInstrumentCovenantLiquidityMinimumCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ReagentRentalsMember" abstract="true" name="ReagentRentalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ConsumableRevenueMember" abstract="true" name="ConsumableRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_WarrantsToPurchaseSharesIssued" abstract="false" name="WarrantsToPurchaseSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_DebtInstrumentPrepaymentFeePercent" abstract="false" name="DebtInstrumentPrepaymentFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bngo_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_OperatingLossCarryforwardsNotSubjecttoExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjecttoExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" abstract="false" name="BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" abstract="false" name="BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_CommonWarrantsMember" abstract="true" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" abstract="true" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_CommonStockWarrantsOriginalAgreementMember" abstract="true" name="CommonStockWarrantsOriginalAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_TermA1LoanMember" abstract="true" name="TermA1LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_LoanUnderPaycheckProtectionProgramMember" abstract="true" name="LoanUnderPaycheckProtectionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_CommissionFeeMaximumPercentageOfGrossProceeds" abstract="false" name="CommissionFeeMaximumPercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bngo_CostOfGoodsAndServicesSoldPolicyTextBlock" abstract="false" name="CostOfGoodsAndServicesSoldPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bngo_LesseeFinanceLeaseAreaLeased" abstract="false" name="LesseeFinanceLeaseAreaLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="bngo_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClientWarrantyExchangeOfFixedAssets" abstract="false" name="ClientWarrantyExchangeOfFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_TwoCustomersMember" abstract="true" name="TwoCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_InstrumentRevenueMember" abstract="true" name="InstrumentRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" abstract="false" name="DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bngo_PaymentsForPropertyAndEquipment" abstract="false" name="PaymentsForPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExpirationPeriod" abstract="false" name="ClassOfWarrantOrRightExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtInstrumentInterestRateDiscountedCashRate" abstract="false" name="DebtInstrumentInterestRateDiscountedCashRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsPeriodThreeMember" abstract="true" name="DebtInstrumentPaymentTermsPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_IssueCommonStockForCovenantWaiver" abstract="false" name="IssueCommonStockForCovenantWaiver" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_StockIssuedDuringPeriodValueCovenantWaiver" abstract="false" name="StockIssuedDuringPeriodValueCovenantWaiver" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_PaymentsForInitialCostsOnLeases" abstract="false" name="PaymentsForInitialCostsOnLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsPeriodOneMember" abstract="true" name="DebtInstrumentPaymentTermsPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_LesseeOperatingLeaseAreaLeased" abstract="false" name="LesseeOperatingLeaseAreaLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="bngo_ContingentConsiderationMilestonePayment" abstract="false" name="ContingentConsiderationMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_WarrantyAndMaintenanceRevenue" abstract="false" name="WarrantyAndMaintenanceRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ContingentConsiderationFairValueOfContingentLiability" abstract="false" name="ContingentConsiderationFairValueOfContingentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_InnovatusTerm3LoanMember" abstract="true" name="InnovatusTerm3LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract" abstract="true" name="OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" abstract="false" name="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtInstrumentCovenantWaiverFee" abstract="false" name="DebtInstrumentCovenantWaiverFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness" abstract="false" name="DebtInstrumentCovenantMaximumCreditCardIndebtedness" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_CowenMember" abstract="true" name="CowenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" abstract="false" name="BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_OperatingLeaseMonthlyRentPayments" abstract="false" name="OperatingLeaseMonthlyRentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_CostOfLeasedEquipmentSoldToCustomer" abstract="false" name="CostOfLeasedEquipmentSoldToCustomer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ContingentConsiderationNoncash" abstract="false" name="ContingentConsiderationNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_StockIssuedDuringPeriodSharesCovenantWaiver" abstract="false" name="StockIssuedDuringPeriodSharesCovenantWaiver" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_GainLossOnExtinguishmentOfDebtCashExpense" abstract="false" name="GainLossOnExtinguishmentOfDebtCashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_LiquidityPolicyTextBlock" abstract="false" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bngo_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_BioDiscoveryMember" abstract="true" name="BioDiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_OperatingLossCarryforwardsSubjecttoExpiration" abstract="false" name="OperatingLossCarryforwardsSubjecttoExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_AccruedInventoryCurrent" abstract="false" name="AccruedInventoryCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ProceedsFromPayrollProtectionProgramLoan" abstract="false" name="ProceedsFromPayrollProtectionProgramLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bngo_FinanceLeaseExpense" abstract="false" name="FinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_BusinessAcquisitionMilestonePayment" abstract="false" name="BusinessAcquisitionMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_WarrantExerciseNonCash" abstract="false" name="WarrantExerciseNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter" abstract="false" name="ContractualCommitmentPurchaseOfProductsEveryQuarter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_TwoThousandAndTwentyInducementPlanMember" abstract="true" name="TwoThousandAndTwentyInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="bngo_ServiceEquipmentMember" abstract="true" name="ServiceEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsPeriodFourMember" abstract="true" name="DebtInstrumentPaymentTermsPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentInterestRateCashRate" abstract="false" name="DebtInstrumentInterestRateCashRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bngo_OperatingLeasePaymentsModifiedAndUnmodified" abstract="false" name="OperatingLeasePaymentsModifiedAndUnmodified" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_LicensingRevenueAndMaintenanceAgreements" abstract="false" name="LicensingRevenueAndMaintenanceAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bngo_SaltLakeCityUtahMember" abstract="true" name="SaltLakeCityUtahMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" abstract="false" name="DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DeferredTaxLiabilitiesAmortization" abstract="false" name="DeferredTaxLiabilitiesAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_StockIssuedForServices" abstract="false" name="StockIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_DefinedContributionPlanDisclosuresTextBlock" abstract="false" name="DefinedContributionPlanDisclosuresTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bngo_SettlementOfInterestOnDebtNoncash" abstract="false" name="SettlementOfInterestOnDebtNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_NoncashInterestExpense" abstract="false" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_TwoThousandEighteenEquityIncentivePlanMember" abstract="true" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_UnvestedRestrictedStockMember" abstract="true" name="UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_EscrowedSharesMember" abstract="true" name="EscrowedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_CommonStockOptionMember" abstract="true" name="CommonStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_LesseeOperatingLeaseAreaAdded" abstract="false" name="LesseeOperatingLeaseAreaAdded" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="bngo_SaleOfStockValueSharesIssuedInTransaction" abstract="false" name="SaleOfStockValueSharesIssuedInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_InnovatusLoanAgreementMember" abstract="true" name="InnovatusLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_DebtInstrumentPaymentTermsDomain" abstract="true" name="DebtInstrumentPaymentTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bngo_ContingentConsiderationLiabilityMember" abstract="true" name="ContingentConsiderationLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>bngo-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e3db6ed1-8b4e-4b22-9c48-82142796368a,g:231d39e4-2c00-4236-9c0c-64cfa873dbdc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6906c258-d0e1-4451-bc10-3a61b2d76a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_90915936-ac08-474f-bce7-261417506ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6906c258-d0e1-4451-bc10-3a61b2d76a12" xlink:to="loc_us-gaap_CommonStockValue_90915936-ac08-474f-bce7-261417506ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_47d81d0e-c3cd-4c47-9c50-68dbb1e528d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6906c258-d0e1-4451-bc10-3a61b2d76a12" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_47d81d0e-c3cd-4c47-9c50-68dbb1e528d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_028720d9-de44-4095-96d9-fe845edcd078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6906c258-d0e1-4451-bc10-3a61b2d76a12" xlink:to="loc_us-gaap_PreferredStockValue_028720d9-de44-4095-96d9-fe845edcd078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e682448b-9419-4586-b503-3bcd487bcaca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6906c258-d0e1-4451-bc10-3a61b2d76a12" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e682448b-9419-4586-b503-3bcd487bcaca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_01e86a73-ca1e-44d0-a1cb-04494340e3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6906c258-d0e1-4451-bc10-3a61b2d76a12" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_01e86a73-ca1e-44d0-a1cb-04494340e3d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cd2af24e-7554-4347-9a87-bf2192e1d0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_692e840b-e950-425c-8540-e456ab4e6403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cd2af24e-7554-4347-9a87-bf2192e1d0f2" xlink:to="loc_us-gaap_AccountsPayableCurrent_692e840b-e950-425c-8540-e456ab4e6403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_03f98039-15f4-4756-b712-0fdaf1c83871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cd2af24e-7554-4347-9a87-bf2192e1d0f2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_03f98039-15f4-4756-b712-0fdaf1c83871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_0e755774-02f0-4f31-bf1c-882ed31f3643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cd2af24e-7554-4347-9a87-bf2192e1d0f2" xlink:to="loc_us-gaap_DeferredRevenueCurrent_0e755774-02f0-4f31-bf1c-882ed31f3643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2c6d0249-391d-4428-8fce-9e9e1a7ff745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cd2af24e-7554-4347-9a87-bf2192e1d0f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2c6d0249-391d-4428-8fce-9e9e1a7ff745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_63ad56a9-6f13-4008-9009-ea47f39e3bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cd2af24e-7554-4347-9a87-bf2192e1d0f2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_63ad56a9-6f13-4008-9009-ea47f39e3bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_27c8b7d9-9e04-46a0-bbdb-e0c930dafbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e8bce89-21b1-4de6-ac5b-2d22f54c882e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_27c8b7d9-9e04-46a0-bbdb-e0c930dafbfa" xlink:to="loc_us-gaap_StockholdersEquity_7e8bce89-21b1-4de6-ac5b-2d22f54c882e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_30a6d039-6f9c-4804-998a-e72a1d41517d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_27c8b7d9-9e04-46a0-bbdb-e0c930dafbfa" xlink:to="loc_us-gaap_Liabilities_30a6d039-6f9c-4804-998a-e72a1d41517d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_44b32591-6a17-45f9-b3f3-9e67aa9a276d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_27c8b7d9-9e04-46a0-bbdb-e0c930dafbfa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_44b32591-6a17-45f9-b3f3-9e67aa9a276d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a4475a54-6bf1-46ff-8a97-4f4010f0f702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3d5ae630-9cf1-4698-af78-dc64f6eb5f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4475a54-6bf1-46ff-8a97-4f4010f0f702" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3d5ae630-9cf1-4698-af78-dc64f6eb5f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_08d5029c-5fe8-4330-bd1f-56e8a2e20690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4475a54-6bf1-46ff-8a97-4f4010f0f702" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_08d5029c-5fe8-4330-bd1f-56e8a2e20690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_55138e57-4d48-47b2-8224-1f2f59e902da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4475a54-6bf1-46ff-8a97-4f4010f0f702" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_55138e57-4d48-47b2-8224-1f2f59e902da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_db4f295e-1f73-4417-a7f2-1d59994137c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4475a54-6bf1-46ff-8a97-4f4010f0f702" xlink:to="loc_us-gaap_Goodwill_db4f295e-1f73-4417-a7f2-1d59994137c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11c088bc-9d50-4a63-916e-87eb5d2023d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4475a54-6bf1-46ff-8a97-4f4010f0f702" xlink:to="loc_us-gaap_AssetsCurrent_11c088bc-9d50-4a63-916e-87eb5d2023d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_8315e597-c7e4-46c9-9059-36d0b2032e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4475a54-6bf1-46ff-8a97-4f4010f0f702" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_8315e597-c7e4-46c9-9059-36d0b2032e30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_167291f0-7437-4d9e-9e96-a52b7649ae53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a4475a54-6bf1-46ff-8a97-4f4010f0f702" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_167291f0-7437-4d9e-9e96-a52b7649ae53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a75e4ab3-30ae-46c2-b737-1274d5b35f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f537ae85-729b-4b9a-9ce2-087221c71301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a75e4ab3-30ae-46c2-b737-1274d5b35f58" xlink:to="loc_us-gaap_LiabilitiesCurrent_f537ae85-729b-4b9a-9ce2-087221c71301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_90a22bcd-d639-4d81-a95e-9c34f49423ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a75e4ab3-30ae-46c2-b737-1274d5b35f58" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_90a22bcd-d639-4d81-a95e-9c34f49423ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f91b6a88-dbc3-48a4-b333-6dce9824ff89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a75e4ab3-30ae-46c2-b737-1274d5b35f58" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f91b6a88-dbc3-48a4-b333-6dce9824ff89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3610a80a-c4c9-4b9d-822a-76561d22888b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a75e4ab3-30ae-46c2-b737-1274d5b35f58" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_3610a80a-c4c9-4b9d-822a-76561d22888b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a3fdbdb2-f43f-459d-9ac3-b69242856f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a75e4ab3-30ae-46c2-b737-1274d5b35f58" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a3fdbdb2-f43f-459d-9ac3-b69242856f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationFairValueOfContingentLiability_b26d2277-a881-44e9-aa3c-3e2c6144df7e" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationFairValueOfContingentLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a75e4ab3-30ae-46c2-b737-1274d5b35f58" xlink:to="loc_bngo_ContingentConsiderationFairValueOfContingentLiability_b26d2277-a881-44e9-aa3c-3e2c6144df7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0f245511-f64f-4c2d-8423-9fe543cfa8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bf96839-1677-426e-aaf8-4c9c2c38aad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f245511-f64f-4c2d-8423-9fe543cfa8f1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bf96839-1677-426e-aaf8-4c9c2c38aad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ac67194f-58f5-47b0-a5db-fc5be2840661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f245511-f64f-4c2d-8423-9fe543cfa8f1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ac67194f-58f5-47b0-a5db-fc5be2840661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_93aec615-270a-48f2-9971-ff2b1653e6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f245511-f64f-4c2d-8423-9fe543cfa8f1" xlink:to="loc_us-gaap_InventoryNet_93aec615-270a-48f2-9971-ff2b1653e6cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04316078-d3b2-4364-8d37-40a173a501d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f245511-f64f-4c2d-8423-9fe543cfa8f1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04316078-d3b2-4364-8d37-40a173a501d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f0c98377-b5a2-47fa-be70-940a4c931e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0f245511-f64f-4c2d-8423-9fe543cfa8f1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f0c98377-b5a2-47fa-be70-940a4c931e3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b59ed9af-e263-43b9-8cb1-5b5fa84309bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_daa0edd7-c64b-401b-bf12-15aafa87ce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b59ed9af-e263-43b9-8cb1-5b5fa84309bf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_daa0edd7-c64b-401b-bf12-15aafa87ce0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c21c8fdc-f84c-4b62-b401-21d5023dde13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b59ed9af-e263-43b9-8cb1-5b5fa84309bf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c21c8fdc-f84c-4b62-b401-21d5023dde13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0584b8ca-079f-4548-a75d-ac52ee75c204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_07b8bd70-d4ce-4fb5-aca3-caa7a6e8f37d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0584b8ca-079f-4548-a75d-ac52ee75c204" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_07b8bd70-d4ce-4fb5-aca3-caa7a6e8f37d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6e2f361a-db1a-48ac-856b-d95d1704ac88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0584b8ca-079f-4548-a75d-ac52ee75c204" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6e2f361a-db1a-48ac-856b-d95d1704ac88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3301c485-bf13-41e3-b333-21d06d143440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0584b8ca-079f-4548-a75d-ac52ee75c204" xlink:to="loc_us-gaap_CostsAndExpenses_3301c485-bf13-41e3-b333-21d06d143440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_517a4a91-5d34-4ebd-9aa2-91f0f6c675ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ca1e7397-41fe-45f9-82ed-e0b0eb16d483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_517a4a91-5d34-4ebd-9aa2-91f0f6c675ea" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ca1e7397-41fe-45f9-82ed-e0b0eb16d483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d6898a0a-599a-4a76-b2b4-efd817aa42c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_517a4a91-5d34-4ebd-9aa2-91f0f6c675ea" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d6898a0a-599a-4a76-b2b4-efd817aa42c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_390ea559-9377-4afc-be98-31297100ad99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_adddc3b2-8bf0-4c66-bc26-d98309b1e64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_390ea559-9377-4afc-be98-31297100ad99" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_adddc3b2-8bf0-4c66-bc26-d98309b1e64b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5819b5e8-dbcc-416c-9449-6e074caccb45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_390ea559-9377-4afc-be98-31297100ad99" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5819b5e8-dbcc-416c-9449-6e074caccb45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_45116d7b-286b-4569-96bc-0910b7f33c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_390ea559-9377-4afc-be98-31297100ad99" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_45116d7b-286b-4569-96bc-0910b7f33c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ff86ff56-0e19-4f44-9c27-06149959fb93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_390ea559-9377-4afc-be98-31297100ad99" xlink:to="loc_us-gaap_InterestExpense_ff86ff56-0e19-4f44-9c27-06149959fb93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_41c8e4f5-245d-4320-bc44-b9f238408b97" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_390ea559-9377-4afc-be98-31297100ad99" xlink:to="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_41c8e4f5-245d-4320-bc44-b9f238408b97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05b067f3-c729-4389-b04c-c83088e3120e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4ed6cbd1-c931-4a6d-85eb-8369a7dbe37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05b067f3-c729-4389-b04c-c83088e3120e" xlink:to="loc_us-gaap_OperatingIncomeLoss_4ed6cbd1-c931-4a6d-85eb-8369a7dbe37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8fe52cd8-af28-4193-b0d5-c4126668c8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05b067f3-c729-4389-b04c-c83088e3120e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8fe52cd8-af28-4193-b0d5-c4126668c8f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement" xlink:type="simple" xlink:href="bngo-20211231.xsd#CondensedConsolidatedStatementsofComprehensiveLossStatement"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_590728f1-60c4-444f-a456-d516a9d4d14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e33aebce-5b43-4695-9465-0aacf2f444c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_590728f1-60c4-444f-a456-d516a9d4d14b" xlink:to="loc_us-gaap_NetIncomeLoss_e33aebce-5b43-4695-9465-0aacf2f444c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bc013156-1bd7-4727-9f72-0cd44dd99460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_590728f1-60c4-444f-a456-d516a9d4d14b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bc013156-1bd7-4727-9f72-0cd44dd99460" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb8ff2fe-84ba-4098-97d4-9ab3fbdccac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4a764b6-ef81-481e-bfba-f7a82824e464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb8ff2fe-84ba-4098-97d4-9ab3fbdccac2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4a764b6-ef81-481e-bfba-f7a82824e464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86257acf-4ee8-42e7-bca1-e4d1c5405a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb8ff2fe-84ba-4098-97d4-9ab3fbdccac2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86257acf-4ee8-42e7-bca1-e4d1c5405a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8d5583e-3936-4cae-bc8f-4721253c1000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fb8ff2fe-84ba-4098-97d4-9ab3fbdccac2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8d5583e-3936-4cae-bc8f-4721253c1000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_564d178f-e886-4297-8ff4-d33ca64a265d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c7fc370c-21e4-4766-b977-5d7f0e8d80fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_564d178f-e886-4297-8ff4-d33ca64a265d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c7fc370c-21e4-4766-b977-5d7f0e8d80fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_4944318d-0001-4777-ac1c-9a3a998c6ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_564d178f-e886-4297-8ff4-d33ca64a265d" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_4944318d-0001-4777-ac1c-9a3a998c6ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6a7d8ef0-7e3c-4637-a336-8f00d24972c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_564d178f-e886-4297-8ff4-d33ca64a265d" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6a7d8ef0-7e3c-4637-a336-8f00d24972c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForPropertyAndEquipment_d8fbb1dd-107b-4c02-8941-c180663db35a" xlink:href="bngo-20211231.xsd#bngo_PaymentsForPropertyAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_564d178f-e886-4297-8ff4-d33ca64a265d" xlink:to="loc_bngo_PaymentsForPropertyAndEquipment_d8fbb1dd-107b-4c02-8941-c180663db35a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_90d1a00e-0133-4d6f-9e4a-7e1c47383618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_564d178f-e886-4297-8ff4-d33ca64a265d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_90d1a00e-0133-4d6f-9e4a-7e1c47383618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForInitialCostsOnLeases_e7b59568-a87d-4c79-8ab1-3aabb82386df" xlink:href="bngo-20211231.xsd#bngo_PaymentsForInitialCostsOnLeases"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_564d178f-e886-4297-8ff4-d33ca64a265d" xlink:to="loc_bngo_PaymentsForInitialCostsOnLeases_e7b59568-a87d-4c79-8ab1-3aabb82386df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_cd5a715c-01e3-4be1-840b-b7d82bfa6623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_InventoryWriteDown_cd5a715c-01e3-4be1-840b-b7d82bfa6623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e1611bc-09a9-48e5-b568-f60de62a4218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_ProfitLoss_5e1611bc-09a9-48e5-b568-f60de62a4218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1dad0c85-1535-4182-9bb9-528f1f570009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1dad0c85-1535-4182-9bb9-528f1f570009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_4bd5c15d-c5a5-4f08-b73e-3cf4a1e63396" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_4bd5c15d-c5a5-4f08-b73e-3cf4a1e63396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_6e338d3a-e9e3-45e5-a067-95ecda439eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_6e338d3a-e9e3-45e5-a067-95ecda439eda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9068ded7-5e2c-4f37-b2f1-1c15c21bfd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9068ded7-5e2c-4f37-b2f1-1c15c21bfd1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NoncashInterestExpense_7c134e1f-08a5-4548-ac29-1db8d671bed0" xlink:href="bngo-20211231.xsd#bngo_NoncashInterestExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_bngo_NoncashInterestExpense_7c134e1f-08a5-4548-ac29-1db8d671bed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eb4622cb-0198-4808-bfe3-97c7bbab3ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eb4622cb-0198-4808-bfe3-97c7bbab3ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnExtinguishmentOfDebtCashExpense_27da6417-45cd-42a8-ac3a-9b22ef2cb670" xlink:href="bngo-20211231.xsd#bngo_GainLossOnExtinguishmentOfDebtCashExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_bngo_GainLossOnExtinguishmentOfDebtCashExpense_27da6417-45cd-42a8-ac3a-9b22ef2cb670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_148c6aa9-f331-4111-a784-fe8013efe7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_148c6aa9-f331-4111-a784-fe8013efe7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_12daff18-3f4a-4cee-94d8-8ea9ae3069e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_12daff18-3f4a-4cee-94d8-8ea9ae3069e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7317635c-3c87-439d-986a-64662fb24331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7317635c-3c87-439d-986a-64662fb24331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cb7664c3-57f8-41c7-8b62-65a4ab297f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cb7664c3-57f8-41c7-8b62-65a4ab297f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1e17154d-ef6c-4c87-adf4-068760785caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1e17154d-ef6c-4c87-adf4-068760785caf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7de9ee88-02a9-4828-b836-5667819e7d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_ShareBasedCompensation_7de9ee88-02a9-4828-b836-5667819e7d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense_3b888718-f9b4-4a49-bc12-2727493eee35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_AccretionExpense_3b888718-f9b4-4a49-bc12-2727493eee35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NonCashLeaseExpense_c06da450-1f0a-4a9a-ada0-af12b2630c54" xlink:href="bngo-20211231.xsd#bngo_NonCashLeaseExpense"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_bngo_NonCashLeaseExpense_c06da450-1f0a-4a9a-ada0-af12b2630c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_d4aa6233-9fba-4432-8c6d-444cb5a4ca36" xlink:href="bngo-20211231.xsd#bngo_CostOfLeasedEquipmentSoldToCustomer"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_d4aa6233-9fba-4432-8c6d-444cb5a4ca36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClientWarrantyExchangeOfFixedAssets_a2e1c8b7-e5ed-408b-b216-5573644298fb" xlink:href="bngo-20211231.xsd#bngo_ClientWarrantyExchangeOfFixedAssets"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_bngo_ClientWarrantyExchangeOfFixedAssets_a2e1c8b7-e5ed-408b-b216-5573644298fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_434b5b3c-319f-4036-9366-d9c3b05718ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_434b5b3c-319f-4036-9366-d9c3b05718ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SettlementOfInterestOnDebtNoncash_842977b6-cdcd-4669-b520-4764750f6441" xlink:href="bngo-20211231.xsd#bngo_SettlementOfInterestOnDebtNoncash"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abcc5880-2afc-4781-af16-905e16a99ce7" xlink:to="loc_bngo_SettlementOfInterestOnDebtNoncash_842977b6-cdcd-4669-b520-4764750f6441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProceedsFromPayrollProtectionProgramLoan_aae04201-e5c7-4c5e-a527-9dcf94ada5ff" xlink:href="bngo-20211231.xsd#bngo_ProceedsFromPayrollProtectionProgramLoan"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_bngo_ProceedsFromPayrollProtectionProgramLoan_aae04201-e5c7-4c5e-a527-9dcf94ada5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_38baac1a-ff57-4a2d-ada9-e44cbf5f0b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_38baac1a-ff57-4a2d-ada9-e44cbf5f0b67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_2d03e28f-aea0-4a16-b310-4a361da6b2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_2d03e28f-aea0-4a16-b310-4a361da6b2f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ae6768c8-4bda-4776-b7d1-a4a07d764355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ae6768c8-4bda-4776-b7d1-a4a07d764355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_129dec88-c2fe-4fe9-9a47-bbb10b401267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_129dec88-c2fe-4fe9-9a47-bbb10b401267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0608a9e3-7184-4339-9637-8ce6c82d18d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0608a9e3-7184-4339-9637-8ce6c82d18d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EmployeeStockPurchasePlanCompensationExpense_720bcc88-c6fc-4f0e-abee-d7a9be171c41" xlink:href="bngo-20211231.xsd#bngo_EmployeeStockPurchasePlanCompensationExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_bngo_EmployeeStockPurchasePlanCompensationExpense_720bcc88-c6fc-4f0e-abee-d7a9be171c41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7ce05d3d-2691-4473-9838-2a8e695ac2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7ce05d3d-2691-4473-9838-2a8e695ac2a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_2cb90f3f-422b-4ecd-9c34-03e45e047717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f3629bd-8a81-48ca-9de0-cd003bae9181" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_2cb90f3f-422b-4ecd-9c34-03e45e047717" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9cc6c9ee-fac7-4fe7-a149-547f1ca7e8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_fb569893-dd7c-4531-be89-929a28cb011d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_9cc6c9ee-fac7-4fe7-a149-547f1ca7e8ac" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_fb569893-dd7c-4531-be89-929a28cb011d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_52ed9751-fd13-453b-a239-a29b6c445fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_9cc6c9ee-fac7-4fe7-a149-547f1ca7e8ac" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_52ed9751-fd13-453b-a239-a29b6c445fdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_34050805-4049-4c5b-bee6-c06af466b05a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4a065726-35b0-405d-ab71-ff853d014001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_34050805-4049-4c5b-bee6-c06af466b05a" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4a065726-35b0-405d-ab71-ff853d014001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_31277d7a-39be-449d-bb54-0e2e3378335f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_34050805-4049-4c5b-bee6-c06af466b05a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_31277d7a-39be-449d-bb54-0e2e3378335f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6eb23b56-b05f-4b5e-9927-2260ba581acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5fc1e97a-44d7-4549-9952-10b63067e32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6eb23b56-b05f-4b5e-9927-2260ba581acf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5fc1e97a-44d7-4549-9952-10b63067e32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd2b0dbe-df46-4e00-ae94-b528a7b16e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6eb23b56-b05f-4b5e-9927-2260ba581acf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd2b0dbe-df46-4e00-ae94-b528a7b16e87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3a033045-c077-4d65-b70b-0180f56d753f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_e72e7b9f-e0be-4a39-a77d-dc99da0606ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3a033045-c077-4d65-b70b-0180f56d753f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_e72e7b9f-e0be-4a39-a77d-dc99da0606ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4fd19210-0433-4248-9cb1-77aad6af68de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_3a033045-c077-4d65-b70b-0180f56d753f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4fd19210-0433-4248-9cb1-77aad6af68de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c1801c4-3205-48ef-8b2d-13b1d2e2ba3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_fec5d9a1-14c8-4be1-b8e4-207cd57cbe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Supplies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c1801c4-3205-48ef-8b2d-13b1d2e2ba3f" xlink:to="loc_us-gaap_Supplies_fec5d9a1-14c8-4be1-b8e4-207cd57cbe49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_15442f0b-d5f4-4be3-81b8-43a181c17a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c1801c4-3205-48ef-8b2d-13b1d2e2ba3f" xlink:to="loc_us-gaap_PrepaidInsurance_15442f0b-d5f4-4be3-81b8-43a181c17a53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_75c0a74c-a153-4297-8723-dd316e8f7c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c1801c4-3205-48ef-8b2d-13b1d2e2ba3f" xlink:to="loc_us-gaap_OtherAssetsCurrent_75c0a74c-a153-4297-8723-dd316e8f7c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_35c66e51-064d-465e-9642-158fe379418c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c1801c4-3205-48ef-8b2d-13b1d2e2ba3f" xlink:to="loc_us-gaap_InterestReceivableCurrent_35c66e51-064d-465e-9642-158fe379418c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d219431c-1ab7-4f98-8824-ad775c8e184d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6dcdf2b7-c990-48d5-aca7-8036b5a0061b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d219431c-1ab7-4f98-8824-ad775c8e184d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6dcdf2b7-c990-48d5-aca7-8036b5a0061b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e12ea59f-7f39-4690-a6b3-d1d127f48458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d219431c-1ab7-4f98-8824-ad775c8e184d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e12ea59f-7f39-4690-a6b3-d1d127f48458" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNetSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c94f75ab-c55c-49c7-9b02-463e09ada7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ae49f7cc-4535-45fb-b459-987f03684fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c94f75ab-c55c-49c7-9b02-463e09ada7f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ae49f7cc-4535-45fb-b459-987f03684fa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9815c18d-a9b2-417d-8f2b-3503412801d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c94f75ab-c55c-49c7-9b02-463e09ada7f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9815c18d-a9b2-417d-8f2b-3503412801d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3f8ed394-274a-4f05-bee1-9993d9627db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_995b4dfa-6a44-4271-b7b6-348972a2287c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3f8ed394-274a-4f05-bee1-9993d9627db3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_995b4dfa-6a44-4271-b7b6-348972a2287c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7494b6a7-56b0-4365-950e-3c1cacf9ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3f8ed394-274a-4f05-bee1-9993d9627db3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7494b6a7-56b0-4365-950e-3c1cacf9ff29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e77fd1af-63a2-481e-af34-94d8122071f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3f8ed394-274a-4f05-bee1-9993d9627db3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e77fd1af-63a2-481e-af34-94d8122071f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_46c5fc0d-182c-47f8-af40-809262ad53a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3f8ed394-274a-4f05-bee1-9993d9627db3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_46c5fc0d-182c-47f8-af40-809262ad53a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_993f9c6b-6de0-40d0-870d-b07e4cd4d95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3f8ed394-274a-4f05-bee1-9993d9627db3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_993f9c6b-6de0-40d0-870d-b07e4cd4d95a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AccruedExpensesScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_483e37ed-80ee-4673-bdf3-63e3d22cdd06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:to="loc_us-gaap_InterestPayableCurrent_483e37ed-80ee-4673-bdf3-63e3d22cdd06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AccruedInventoryCurrent_05d5b62e-d996-4447-a784-559c58c95a16" xlink:href="bngo-20211231.xsd#bngo_AccruedInventoryCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:to="loc_bngo_AccruedInventoryCurrent_05d5b62e-d996-4447-a784-559c58c95a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_9bdfbdd3-f4dc-49be-b902-4814a1cb9a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:to="loc_us-gaap_TaxesPayableCurrent_9bdfbdd3-f4dc-49be-b902-4814a1cb9a5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_689f916d-363e-44d9-b7ce-b78a2f439455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_689f916d-363e-44d9-b7ce-b78a2f439455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ab1ffe16-c15c-4758-838b-7c543a4a29ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ab1ffe16-c15c-4758-838b-7c543a4a29ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a7753d70-a42c-4f1c-b9fc-799ab15efe54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a7753d70-a42c-4f1c-b9fc-799ab15efe54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_2614d4a4-4bb3-4d35-bf5c-7f05f9431129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_2614d4a4-4bb3-4d35-bf5c-7f05f9431129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_fbac1b29-36f8-4b32-929d-50dac93f2c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b7604493-bb3e-47de-ac1d-0afcc1ed71ca" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_fbac1b29-36f8-4b32-929d-50dac93f2c1b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#LongTermDebtScheduleofDebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a890bdc0-4705-4838-b0df-787f35d7425d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_13a56df9-0a9b-4a5b-adf6-54840341f934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a890bdc0-4705-4838-b0df-787f35d7425d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_13a56df9-0a9b-4a5b-adf6-54840341f934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_15ab4ed0-6466-4394-a5e4-020439e74e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a890bdc0-4705-4838-b0df-787f35d7425d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_15ab4ed0-6466-4394-a5e4-020439e74e61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseExpense_b295a9e6-0c2f-4108-a630-5a91e4db6b5e" xlink:href="bngo-20211231.xsd#bngo_FinanceLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_761d14ed-64d3-43c4-be91-156f87cc6d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bngo_FinanceLeaseExpense_b295a9e6-0c2f-4108-a630-5a91e4db6b5e" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_761d14ed-64d3-43c4-be91-156f87cc6d99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fd018a09-93d0-418e-a4da-e700e7ad9ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bngo_FinanceLeaseExpense_b295a9e6-0c2f-4108-a630-5a91e4db6b5e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fd018a09-93d0-418e-a4da-e700e7ad9ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_25a2fb9e-00cc-42b3-80c3-d51221d61c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_2b0b00ae-fe0a-4e4f-ac10-e8c79f736c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseExpense_25a2fb9e-00cc-42b3-80c3-d51221d61c22" xlink:to="loc_us-gaap_VariableLeaseCost_2b0b00ae-fe0a-4e4f-ac10-e8c79f736c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2b095648-6f75-4028-976c-ade1a195e0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseExpense_25a2fb9e-00cc-42b3-80c3-d51221d61c22" xlink:to="loc_us-gaap_OperatingLeaseCost_2b095648-6f75-4028-976c-ade1a195e0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_264ede71-c0a1-4938-837c-8e8b56a6d43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseExpense_2354e809-8411-40d4-9aa3-adaee8bb6bd1" xlink:href="bngo-20211231.xsd#bngo_FinanceLeaseExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_264ede71-c0a1-4938-837c-8e8b56a6d43c" xlink:to="loc_bngo_FinanceLeaseExpense_2354e809-8411-40d4-9aa3-adaee8bb6bd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9318863d-f3bd-439e-a725-b9f236bdf8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_264ede71-c0a1-4938-837c-8e8b56a6d43c" xlink:to="loc_us-gaap_SubleaseIncome_9318863d-f3bd-439e-a725-b9f236bdf8f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_241d41c7-33f6-48d7-8af6-10e0f582a2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_264ede71-c0a1-4938-837c-8e8b56a6d43c" xlink:to="loc_us-gaap_OperatingLeaseExpense_241d41c7-33f6-48d7-8af6-10e0f582a2e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_05d607e4-ad21-4001-aa73-c05f1be686ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6b7e8831-1dad-4b08-99bb-3ab18b2071e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_05d607e4-ad21-4001-aa73-c05f1be686ec" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6b7e8831-1dad-4b08-99bb-3ab18b2071e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5096fa50-875b-4346-92de-fc62a66b5e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_05d607e4-ad21-4001-aa73-c05f1be686ec" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5096fa50-875b-4346-92de-fc62a66b5e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4b66b06b-e571-45e4-9325-70cdc248c26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_05d607e4-ad21-4001-aa73-c05f1be686ec" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4b66b06b-e571-45e4-9325-70cdc248c26c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5aa79eb8-9df7-4d9d-987c-0416eeef9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_05d607e4-ad21-4001-aa73-c05f1be686ec" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5aa79eb8-9df7-4d9d-987c-0416eeef9fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_fcd0e791-0a21-4ede-a9e1-d33e95dbd5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_05d607e4-ad21-4001-aa73-c05f1be686ec" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_fcd0e791-0a21-4ede-a9e1-d33e95dbd5e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b1c6ba58-015d-495f-9d88-4788e771bde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_05d607e4-ad21-4001-aa73-c05f1be686ec" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b1c6ba58-015d-495f-9d88-4788e771bde9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0dc0f870-3e30-4a08-af4c-59b210f71d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9585c44b-7c18-49cf-bcff-475cf2378bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0dc0f870-3e30-4a08-af4c-59b210f71d1f" xlink:to="loc_us-gaap_OperatingLeaseLiability_9585c44b-7c18-49cf-bcff-475cf2378bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f7a57440-2d30-4d69-9727-1f5cf67b5570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0dc0f870-3e30-4a08-af4c-59b210f71d1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f7a57440-2d30-4d69-9727-1f5cf67b5570" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f98dd8-c8d3-4ff9-ae49-abd76f3b0507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_865c2dc4-a93a-44bf-b9d2-2ce28dd4d846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f98dd8-c8d3-4ff9-ae49-abd76f3b0507" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_865c2dc4-a93a-44bf-b9d2-2ce28dd4d846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cae38eca-4229-4881-9b94-179621165866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f98dd8-c8d3-4ff9-ae49-abd76f3b0507" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cae38eca-4229-4881-9b94-179621165866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a1df8e69-a2c2-4a60-b203-fb1fa1a5be1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f98dd8-c8d3-4ff9-ae49-abd76f3b0507" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a1df8e69-a2c2-4a60-b203-fb1fa1a5be1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8cc18414-67d9-48c8-9282-b9b6addada8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f98dd8-c8d3-4ff9-ae49-abd76f3b0507" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8cc18414-67d9-48c8-9282-b9b6addada8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fc943698-7f80-4e36-9789-d0923cfe05c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f98dd8-c8d3-4ff9-ae49-abd76f3b0507" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fc943698-7f80-4e36-9789-d0923cfe05c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_69b3cc77-9faf-49b7-930a-92521b40aba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f98dd8-c8d3-4ff9-ae49-abd76f3b0507" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_69b3cc77-9faf-49b7-930a-92521b40aba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0300d170-3a7c-4022-82d5-8b9440bab53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_dfa187f9-4a27-4bc1-a48d-d7a4182305bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0300d170-3a7c-4022-82d5-8b9440bab53e" xlink:to="loc_us-gaap_FinanceLeaseLiability_dfa187f9-4a27-4bc1-a48d-d7a4182305bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_805ca707-9dd3-42d5-943e-2a3f9a1876fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0300d170-3a7c-4022-82d5-8b9440bab53e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_805ca707-9dd3-42d5-943e-2a3f9a1876fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_c354e1b5-df98-4c24-9a0a-6737a2403ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6a8bb007-63aa-4d89-bcf3-44d04569a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_c354e1b5-df98-4c24-9a0a-6737a2403ceb" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6a8bb007-63aa-4d89-bcf3-44d04569a98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6d8eb45a-50fa-4ac7-91a4-8a98e4ac5172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_c354e1b5-df98-4c24-9a0a-6737a2403ceb" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6d8eb45a-50fa-4ac7-91a4-8a98e4ac5172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_44c5e274-be98-45c1-ac14-a61de1a4a40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_c354e1b5-df98-4c24-9a0a-6737a2403ceb" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_44c5e274-be98-45c1-ac14-a61de1a4a40a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter_24c3f560-d32b-4b5a-a77a-13942b88f177" xlink:href="bngo-20211231.xsd#bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_c354e1b5-df98-4c24-9a0a-6737a2403ceb" xlink:to="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter_24c3f560-d32b-4b5a-a77a-13942b88f177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0bfe048b-1618-42f9-a72a-91a297cd7059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_c354e1b5-df98-4c24-9a0a-6737a2403ceb" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0bfe048b-1618-42f9-a72a-91a297cd7059" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c236761-b9bf-484c-b3ca-441f8bcd4403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_820698a8-f22f-4d0e-8344-58c97f58a2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c236761-b9bf-484c-b3ca-441f8bcd4403" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_820698a8-f22f-4d0e-8344-58c97f58a2b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_54741378-f6c9-44fe-8f1a-9f45abd10c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9c236761-b9bf-484c-b3ca-441f8bcd4403" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_54741378-f6c9-44fe-8f1a-9f45abd10c15" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8b0cbe0b-32a8-4cbe-9c9f-345ddd7f732c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_58d4f71b-35cf-4131-92a0-7c3da1c37382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8b0cbe0b-32a8-4cbe-9c9f-345ddd7f732c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_58d4f71b-35cf-4131-92a0-7c3da1c37382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_39544883-e7f6-4196-8261-ef139ac37de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8b0cbe0b-32a8-4cbe-9c9f-345ddd7f732c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_39544883-e7f6-4196-8261-ef139ac37de8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_30eb7cd6-ee90-4daa-84f5-8ad72a28d558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8b0cbe0b-32a8-4cbe-9c9f-345ddd7f732c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_30eb7cd6-ee90-4daa-84f5-8ad72a28d558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d28dfc9e-bb4d-4523-980b-ecb7317a4834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5d4f155f-9ed6-4b03-a7d4-57e3fededb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d28dfc9e-bb4d-4523-980b-ecb7317a4834" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5d4f155f-9ed6-4b03-a7d4-57e3fededb2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_59e31b1a-e74e-4461-b21e-edd87e7a9403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_d28dfc9e-bb4d-4523-980b-ecb7317a4834" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_59e31b1a-e74e-4461-b21e-edd87e7a9403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71aaee02-0914-4a83-ad20-a7c5e195930e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_dd1cf81e-6875-46aa-beb2-1ee584369f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71aaee02-0914-4a83-ad20-a7c5e195930e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_dd1cf81e-6875-46aa-beb2-1ee584369f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_0377e1fd-8600-4768-954a-453184cec004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71aaee02-0914-4a83-ad20-a7c5e195930e" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_0377e1fd-8600-4768-954a-453184cec004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ea5d569e-0adb-40ac-9b8e-74098c6bf5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71aaee02-0914-4a83-ad20-a7c5e195930e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ea5d569e-0adb-40ac-9b8e-74098c6bf5e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5c61807c-17e2-422e-8be5-8f8eb98c78b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a8e2e8ec-17a8-48fc-94f7-d8d88cb21598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5c61807c-17e2-422e-8be5-8f8eb98c78b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a8e2e8ec-17a8-48fc-94f7-d8d88cb21598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_47aea124-f938-4641-ab04-4ef8e4408603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5c61807c-17e2-422e-8be5-8f8eb98c78b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_47aea124-f938-4641-ab04-4ef8e4408603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_9c779244-a8e0-47dc-b5eb-d304462b3346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5c61807c-17e2-422e-8be5-8f8eb98c78b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_9c779244-a8e0-47dc-b5eb-d304462b3346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4bed61a1-d794-4150-a7a5-489bda87f891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5c61807c-17e2-422e-8be5-8f8eb98c78b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4bed61a1-d794-4150-a7a5-489bda87f891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_d29e9c34-c2db-4727-8d7c-2e99479bb0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5c61807c-17e2-422e-8be5-8f8eb98c78b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_d29e9c34-c2db-4727-8d7c-2e99479bb0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1eef5c6b-1dcd-455a-9498-7b11db87ba23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5c61807c-17e2-422e-8be5-8f8eb98c78b6" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1eef5c6b-1dcd-455a-9498-7b11db87ba23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount_811c8fee-8ffb-42fd-813f-5a0bc028f570" xlink:href="bngo-20211231.xsd#bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5c61807c-17e2-422e-8be5-8f8eb98c78b6" xlink:to="loc_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount_811c8fee-8ffb-42fd-813f-5a0bc028f570" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f148e670-6a2c-46e6-a6e8-920611f3c3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_18eeff58-f1f2-42a1-aa69-1f03fdff3651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f148e670-6a2c-46e6-a6e8-920611f3c3a7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_18eeff58-f1f2-42a1-aa69-1f03fdff3651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_671de41c-d0ec-40f9-9bd0-e5f2cb139b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f148e670-6a2c-46e6-a6e8-920611f3c3a7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_671de41c-d0ec-40f9-9bd0-e5f2cb139b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxLiabilitiesAmortization_b958fe0a-eaa3-4fae-8b77-f0f7ffd86213" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxLiabilitiesAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f148e670-6a2c-46e6-a6e8-920611f3c3a7" xlink:to="loc_bngo_DeferredTaxLiabilitiesAmortization_b958fe0a-eaa3-4fae-8b77-f0f7ffd86213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxLiabilitiesRightOfUseAsset_2be4c5f8-ae9f-408a-acfe-bbeb1ccec5ff" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f148e670-6a2c-46e6-a6e8-920611f3c3a7" xlink:to="loc_bngo_DeferredTaxLiabilitiesRightOfUseAsset_2be4c5f8-ae9f-408a-acfe-bbeb1ccec5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_dd707233-0fab-4138-b697-1a3f654ab495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f148e670-6a2c-46e6-a6e8-920611f3c3a7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_dd707233-0fab-4138-b697-1a3f654ab495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_430a8e20-d78e-4ec9-ac0a-faeb4dd99216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_08f6bc6e-11cc-42f8-a0fd-87490d2b1375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_430a8e20-d78e-4ec9-ac0a-faeb4dd99216" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_08f6bc6e-11cc-42f8-a0fd-87490d2b1375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a896bdcd-a96c-49ec-9c69-42f15bf613e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_430a8e20-d78e-4ec9-ac0a-faeb4dd99216" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a896bdcd-a96c-49ec-9c69-42f15bf613e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2c751e5d-6033-4d3f-bb5a-9a968a3c95fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_430a8e20-d78e-4ec9-ac0a-faeb4dd99216" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2c751e5d-6033-4d3f-bb5a-9a968a3c95fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4412e467-745b-41b0-b48b-a11995de46a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_430a8e20-d78e-4ec9-ac0a-faeb4dd99216" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4412e467-745b-41b0-b48b-a11995de46a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxAssetsLeaseLiability_a07613a4-f0f3-45ba-8d41-51a8787748f2" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_430a8e20-d78e-4ec9-ac0a-faeb4dd99216" xlink:to="loc_bngo_DeferredTaxAssetsLeaseLiability_a07613a4-f0f3-45ba-8d41-51a8787748f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_0a609d6f-6ddc-41ed-a249-ee8a8dfbd3fe" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_0a609d6f-6ddc-41ed-a249-ee8a8dfbd3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4c74f332-d1b9-46a6-a011-39201ad05cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_4c74f332-d1b9-46a6-a011-39201ad05cfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f0766244-df3e-498f-81c7-2ef890173edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_Goodwill_f0766244-df3e-498f-81c7-2ef890173edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dbcc826d-3ec9-460a-a51c-6a1c5f89b28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dbcc826d-3ec9-460a-a51c-6a1c5f89b28c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_d3e5cfc2-aefe-4920-8823-146e6e0bfd0a" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_d3e5cfc2-aefe-4920-8823-146e6e0bfd0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5be1b2eb-5ba8-4dbd-814e-7bb5bf671267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5be1b2eb-5ba8-4dbd-814e-7bb5bf671267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_fc77b608-46d8-43f6-a800-1bb600b622f4" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_fc77b608-46d8-43f6-a800-1bb600b622f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b30b0669-860d-45cd-8e7a-06d720585bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b30b0669-860d-45cd-8e7a-06d720585bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4e378ce6-b2b6-46a4-af46-646285153403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4e378ce6-b2b6-46a4-af46-646285153403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3d662a6a-a705-4412-92b5-8adf97d5af7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_3d662a6a-a705-4412-92b5-8adf97d5af7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_41074efa-b745-478e-82c3-6b0a1c713a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_41074efa-b745-478e-82c3-6b0a1c713a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b39293bc-ebfc-45c0-b567-23af315aee24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3bd21fff-dbd8-4364-b9e8-7da884d67f22" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b39293bc-ebfc-45c0-b567-23af315aee24" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>bngo-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e3db6ed1-8b4e-4b22-9c48-82142796368a,g:231d39e4-2c00-4236-9c0c-64cfa873dbdc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Cover" xlink:type="simple" xlink:href="bngo-20211231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/Cover" xlink:type="extended" id="i111d32d68f544f9ea4c94cf89794945f_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cbcd7426-e1fd-49fd-aa99-ac0f7bf3a84d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentType_cbcd7426-e1fd-49fd-aa99-ac0f7bf3a84d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_1f5ab6d6-b66e-40cd-9e35-7bed93bbe077" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentAnnualReport_1f5ab6d6-b66e-40cd-9e35-7bed93bbe077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ea16e2c5-9ae2-490f-845b-6004154c7e20" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentPeriodEndDate_ea16e2c5-9ae2-490f-845b-6004154c7e20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_78db8e8e-9a36-4f75-9293-dd23d3c70f94" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_CurrentFiscalYearEndDate_78db8e8e-9a36-4f75-9293-dd23d3c70f94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1eca04f3-2365-4912-980b-ad28e2c863aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentTransitionReport_1eca04f3-2365-4912-980b-ad28e2c863aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_41f1c5be-ef03-4a02-9d26-46bf0f643c50" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityFileNumber_41f1c5be-ef03-4a02-9d26-46bf0f643c50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e2b81e7f-79ef-41bb-b4c9-2ccd91c8e15b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityRegistrantName_e2b81e7f-79ef-41bb-b4c9-2ccd91c8e15b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4191ffe6-ad57-406a-bf67-fa62e3ef4496" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4191ffe6-ad57-406a-bf67-fa62e3ef4496" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dfa42562-8d63-4bd4-bb9d-6689bee38b39" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityTaxIdentificationNumber_dfa42562-8d63-4bd4-bb9d-6689bee38b39" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_88eedd7c-87c1-4641-96a1-53b8b04b2441" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressAddressLine1_88eedd7c-87c1-4641-96a1-53b8b04b2441" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_20924f1e-967b-4314-bc11-fe2a213236ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressAddressLine2_20924f1e-967b-4314-bc11-fe2a213236ea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4b3376fb-2b5f-4255-b3ec-e0f72ba8f4c1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressCityOrTown_4b3376fb-2b5f-4255-b3ec-e0f72ba8f4c1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_215a2418-cdf3-4cee-a734-ae66f41dc12f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressStateOrProvince_215a2418-cdf3-4cee-a734-ae66f41dc12f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_04f9f09d-aeca-4155-9a66-80a911a3ae2b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressPostalZipCode_04f9f09d-aeca-4155-9a66-80a911a3ae2b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c4b28cac-f658-43e5-bd6f-d269900290ba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_CityAreaCode_c4b28cac-f658-43e5-bd6f-d269900290ba" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e90ad7da-a41b-4e0c-9e22-d6b118e77099" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_LocalPhoneNumber_e90ad7da-a41b-4e0c-9e22-d6b118e77099" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3a2938c2-8925-41d0-a938-d5fdb21981a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_Security12bTitle_3a2938c2-8925-41d0-a938-d5fdb21981a2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c404efb8-6fdd-4f75-8403-02f045651d8f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_TradingSymbol_c404efb8-6fdd-4f75-8403-02f045651d8f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_49e10c32-e5b9-45da-ab15-69f9583e6634" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_SecurityExchangeName_49e10c32-e5b9-45da-ab15-69f9583e6634" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_3dfe9122-a8a8-474e-a2f4-a7bf82fa3663" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_3dfe9122-a8a8-474e-a2f4-a7bf82fa3663" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_2f6435f2-9fb6-4965-ae63-b166a4ee46ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityVoluntaryFilers_2f6435f2-9fb6-4965-ae63-b166a4ee46ff" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d154cd48-eee2-4531-8ec7-d9feaff0a5c1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityCurrentReportingStatus_d154cd48-eee2-4531-8ec7-d9feaff0a5c1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_abcfef81-b8b9-42d3-8247-54804ff8f184" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityInteractiveDataCurrent_abcfef81-b8b9-42d3-8247-54804ff8f184" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_81705d35-2a1e-49cc-838f-0a387e01f5be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityFilerCategory_81705d35-2a1e-49cc-838f-0a387e01f5be" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_82d2337e-f69d-4fb1-ad61-8f5661c8d047" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntitySmallBusiness_82d2337e-f69d-4fb1-ad61-8f5661c8d047" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6ee339aa-a16d-4f20-9bba-0c4b16b2d6fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityEmergingGrowthCompany_6ee339aa-a16d-4f20-9bba-0c4b16b2d6fc" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_d3eea8c4-adb7-4392-838c-6a6a0e03e96f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_IcfrAuditorAttestationFlag_d3eea8c4-adb7-4392-838c-6a6a0e03e96f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1f7bc399-9012-4a67-9bc8-8783e7dd8200" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityShellCompany_1f7bc399-9012-4a67-9bc8-8783e7dd8200" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_55d38980-3a44-48a0-ad94-f96dd2cd12a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityPublicFloat_55d38980-3a44-48a0-ad94-f96dd2cd12a4" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bf148b7b-06be-4877-85ca-82d55ba8d2bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bf148b7b-06be-4877-85ca-82d55ba8d2bc" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d7e91c84-34b2-4bf1-bd4c-935f49360316" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d7e91c84-34b2-4bf1-bd4c-935f49360316" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_05f11f27-5eb6-4cf8-8559-2ecf03439d9e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityCentralIndexKey_05f11f27-5eb6-4cf8-8559-2ecf03439d9e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4f21b17d-bb57-4f00-a90f-d71652a8a95d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentFiscalYearFocus_4f21b17d-bb57-4f00-a90f-d71652a8a95d" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_433fd701-7f39-4534-aaed-266ac54fb761" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_433fd701-7f39-4534-aaed-266ac54fb761" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_86c10ffd-eb39-4b1a-9387-c67bec4e0663" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_AmendmentFlag_86c10ffd-eb39-4b1a-9387-c67bec4e0663" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_4ae32a2a-e398-4859-a220-7db5ccacfde1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentInformationTable_4ae32a2a-e398-4859-a220-7db5ccacfde1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_4ae32a2a-e398-4859-a220-7db5ccacfde1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49" xlink:to="loc_us-gaap_ClassOfStockDomain_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d529ec44-0e10-4c7e-a40a-00dfb2617654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49" xlink:to="loc_us-gaap_ClassOfStockDomain_d529ec44-0e10-4c7e-a40a-00dfb2617654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2d128496-a1f5-45e3-bda0-3d9150a7db00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d529ec44-0e10-4c7e-a40a-00dfb2617654" xlink:to="loc_us-gaap_CommonStockMember_2d128496-a1f5-45e3-bda0-3d9150a7db00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2d0cc9de-f4fb-4f24-ba05-8896bb4c9a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d529ec44-0e10-4c7e-a40a-00dfb2617654" xlink:to="loc_us-gaap_WarrantMember_2d0cc9de-f4fb-4f24-ba05-8896bb4c9a17" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i5435be0821154fdbb97c0d0c3b82a0d3_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d421026c-284a-495d-b097-3bd61b42adeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_RevenuesAbstract_d421026c-284a-495d-b097-3bd61b42adeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3004234f-7703-4459-b058-8453a190723d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d421026c-284a-495d-b097-3bd61b42adeb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3004234f-7703-4459-b058-8453a190723d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_f4806de8-dba8-4247-b1c3-5c7a2269f176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_f4806de8-dba8-4247-b1c3-5c7a2269f176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7b302964-9ba4-4c99-af20-04ad17d40a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f4806de8-dba8-4247-b1c3-5c7a2269f176" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7b302964-9ba4-4c99-af20-04ad17d40a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0afe5902-52f8-473f-be19-992e893a20b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0afe5902-52f8-473f-be19-992e893a20b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8344ae0-519b-4c6b-9a0d-68352d4384f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8344ae0-519b-4c6b-9a0d-68352d4384f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ae621364-e7ce-4896-9d57-2b6ededa9768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:to="loc_us-gaap_CostsAndExpenses_ae621364-e7ce-4896-9d57-2b6ededa9768" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1aadd030-0d65-4d1a-a760-e972e2443181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_OperatingIncomeLoss_1aadd030-0d65-4d1a-a760-e972e2443181" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7ab97629-1974-4ddf-b3de-e3cef9621c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7ab97629-1974-4ddf-b3de-e3cef9621c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1c152114-9ea2-4f54-aeb3-6784207f6c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_InterestExpense_1c152114-9ea2-4f54-aeb3-6784207f6c18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_4a7ee486-c1a1-42c8-a589-9762bb7a54a2" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_4a7ee486-c1a1-42c8-a589-9762bb7a54a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ea95dcb1-a631-462e-9f3c-fcdb49a6df75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ea95dcb1-a631-462e-9f3c-fcdb49a6df75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9b43b845-d206-47d1-8442-740e46e0f6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9b43b845-d206-47d1-8442-740e46e0f6b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6ad5493c-267a-4c3c-bf16-34dc1da181b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6ad5493c-267a-4c3c-bf16-34dc1da181b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8e12378-50fb-4ecc-b9ae-1725e9067dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8e12378-50fb-4ecc-b9ae-1725e9067dc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b31f92b3-037e-4759-8561-acd79de9999f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b31f92b3-037e-4759-8561-acd79de9999f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cae1fa33-ce38-41d0-ac9c-3ac2b19d2a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_NetIncomeLoss_cae1fa33-ce38-41d0-ac9c-3ac2b19d2a53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_38568950-e2d2-402e-af3f-940a0980d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_38568950-e2d2-402e-af3f-940a0980d6df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7260a8c7-8436-43ce-9b12-b1fb433bb37c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7260a8c7-8436-43ce-9b12-b1fb433bb37c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_065e1247-05b7-4c66-9f80-a10a5c06b746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_StatementTable_065e1247-05b7-4c66-9f80-a10a5c06b746" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_065e1247-05b7-4c66-9f80-a10a5c06b746" xlink:to="loc_srt_ProductOrServiceAxis_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa" xlink:to="loc_srt_ProductsAndServicesDomain_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea53a2f9-a502-4199-a8b4-b9a9d5f3db94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa" xlink:to="loc_srt_ProductsAndServicesDomain_ea53a2f9-a502-4199-a8b4-b9a9d5f3db94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b7f25b5e-9a05-4617-bafd-65b1dee725b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea53a2f9-a502-4199-a8b4-b9a9d5f3db94" xlink:to="loc_us-gaap_ProductMember_b7f25b5e-9a05-4617-bafd-65b1dee725b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_811b609f-2e52-4789-9fe5-d22885f3895b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea53a2f9-a502-4199-a8b4-b9a9d5f3db94" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_811b609f-2e52-4789-9fe5-d22885f3895b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="if491ced31c644da9811c0f5674bcddab_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_826be01b-84e6-4cfa-b5ca-e68bffd24b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_826be01b-84e6-4cfa-b5ca-e68bffd24b56" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_afe40416-f6fe-447b-b658-5f7fdda7e5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_SharesOutstanding_afe40416-f6fe-447b-b658-5f7fdda7e5d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93551a91-7a8b-4613-80c3-3a302a4903b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockholdersEquity_93551a91-7a8b-4613-80c3-3a302a4903b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bcf8535-0e57-438c-971c-0c7ec693b252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bcf8535-0e57-438c-971c-0c7ec693b252" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_70d43796-9903-48c5-8eca-5d5e9cdf0163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_70d43796-9903-48c5-8eca-5d5e9cdf0163" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76f85a26-a18a-4bfe-8e6e-a5b0e85c746a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76f85a26-a18a-4bfe-8e6e-a5b0e85c746a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5926219c-b36a-477f-9aff-488f772b699d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5926219c-b36a-477f-9aff-488f772b699d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b7f0f977-52cc-4d94-a848-4f5864792dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b7f0f977-52cc-4d94-a848-4f5864792dcf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d03efc72-e559-46c6-a22c-c9030a5c6717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d03efc72-e559-46c6-a22c-c9030a5c6717" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dc55e980-a004-44c7-a501-7d97eab1a46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dc55e980-a004-44c7-a501-7d97eab1a46f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_4d511d64-8f48-44ac-b6d9-65ae2a2e983c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_4d511d64-8f48-44ac-b6d9-65ae2a2e983c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesCovenantWaiver_06afcd0b-b316-4729-a904-2f45f91886f6" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodSharesCovenantWaiver"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_bngo_StockIssuedDuringPeriodSharesCovenantWaiver_06afcd0b-b316-4729-a904-2f45f91886f6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueCovenantWaiver_d7005af6-d290-4d2d-97d4-0e3be51654b9" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodValueCovenantWaiver"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_bngo_StockIssuedDuringPeriodValueCovenantWaiver_d7005af6-d290-4d2d-97d4-0e3be51654b9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_7ceb1a94-3a59-47ec-a049-b73468db0195" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_7ceb1a94-3a59-47ec-a049-b73468db0195" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised_7dda282b-06d8-4ce6-9ed7-7fc21499f902" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised_7dda282b-06d8-4ce6-9ed7-7fc21499f902" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d67584e5-5da2-4f9e-a4d3-68ddff176369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d67584e5-5da2-4f9e-a4d3-68ddff176369" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_89e7be1f-09a2-4aa4-839e-2a3319840420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_89e7be1f-09a2-4aa4-839e-2a3319840420" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b25ced2-1f6e-41c6-b40d-3c5b11443e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_NetIncomeLoss_5b25ced2-1f6e-41c6-b40d-3c5b11443e6e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bb341e60-9135-4522-a0b2-30a8150e9c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bb341e60-9135-4522-a0b2-30a8150e9c9c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dda3e337-e1b1-4b6c-98a8-1784ab1f981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c36f9de5-fab2-495c-a7f7-b5fc700e2d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a570bf42-8c7c-4a3d-a862-4da5ec2809c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_826be01b-84e6-4cfa-b5ca-e68bffd24b56" xlink:to="loc_us-gaap_StatementTable_a570bf42-8c7c-4a3d-a862-4da5ec2809c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37651619-4c98-46e8-a2b1-700fcc6bc1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a570bf42-8c7c-4a3d-a862-4da5ec2809c6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37651619-4c98-46e8-a2b1-700fcc6bc1a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_37651619-4c98-46e8-a2b1-700fcc6bc1a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37651619-4c98-46e8-a2b1-700fcc6bc1a1" xlink:to="loc_us-gaap_EquityComponentDomain_37651619-4c98-46e8-a2b1-700fcc6bc1a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37651619-4c98-46e8-a2b1-700fcc6bc1a1" xlink:to="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f8da519-4037-4d98-aff0-e3995439e049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:to="loc_us-gaap_CommonStockMember_7f8da519-4037-4d98-aff0-e3995439e049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ef53bb67-87b6-4566-9627-88f418ca64e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ef53bb67-87b6-4566-9627-88f418ca64e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_083e4b46-1e29-4517-afc5-c50113afd892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:to="loc_us-gaap_RetainedEarningsMember_083e4b46-1e29-4517-afc5-c50113afd892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c1173535-64b2-4ea7-8fe9-64a785702d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c1173535-64b2-4ea7-8fe9-64a785702d0e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i874171b149d2414d9e5c7fb352d4337e_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bcaa4b4e-55a2-4321-9227-57ddf688214e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:to="loc_us-gaap_ProfitLoss_bcaa4b4e-55a2-4321-9227-57ddf688214e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3a4a6f5c-ccfe-4301-9504-9e127c263216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3a4a6f5c-ccfe-4301-9504-9e127c263216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_44dbcc37-7679-4d1d-89af-da9cda22c059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_44dbcc37-7679-4d1d-89af-da9cda22c059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense_429481f6-2a8b-4a68-b46a-e9ba928f078c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_AccretionExpense_429481f6-2a8b-4a68-b46a-e9ba928f078c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NoncashInterestExpense_5bd26051-aaaa-4888-822c-7b5fe84ee237" xlink:href="bngo-20211231.xsd#bngo_NoncashInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_NoncashInterestExpense_5bd26051-aaaa-4888-822c-7b5fe84ee237" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NonCashLeaseExpense_6627ca50-3445-41d6-b055-30874e0f1c8b" xlink:href="bngo-20211231.xsd#bngo_NonCashLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_NonCashLeaseExpense_6627ca50-3445-41d6-b055-30874e0f1c8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SettlementOfInterestOnDebtNoncash_725eb324-64b8-4281-b739-82d4c1a95bb8" xlink:href="bngo-20211231.xsd#bngo_SettlementOfInterestOnDebtNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_SettlementOfInterestOnDebtNoncash_725eb324-64b8-4281-b739-82d4c1a95bb8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_639a99e2-7920-4657-b173-9f5761ff8bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_639a99e2-7920-4657-b173-9f5761ff8bb2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aa9a4ec0-f048-4abc-861b-15e846682909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_ShareBasedCompensation_aa9a4ec0-f048-4abc-861b-15e846682909" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_af3a9a9d-f289-43b1-aaff-44807a469398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_af3a9a9d-f289-43b1-aaff-44807a469398" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_6aa63f06-a11a-4caa-9abf-8054adfacf45" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_6aa63f06-a11a-4caa-9abf-8054adfacf45" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_88ca8a5d-e158-49de-8c3d-f64f84c4fb32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_InventoryWriteDown_88ca8a5d-e158-49de-8c3d-f64f84c4fb32" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnExtinguishmentOfDebtCashExpense_dfc73d3a-74ca-4b8e-999f-421a0db4dc31" xlink:href="bngo-20211231.xsd#bngo_GainLossOnExtinguishmentOfDebtCashExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_GainLossOnExtinguishmentOfDebtCashExpense_dfc73d3a-74ca-4b8e-999f-421a0db4dc31" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_b53e5a7d-f0bd-4f2d-a865-65ed04c90857" xlink:href="bngo-20211231.xsd#bngo_CostOfLeasedEquipmentSoldToCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_b53e5a7d-f0bd-4f2d-a865-65ed04c90857" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClientWarrantyExchangeOfFixedAssets_7d02b10b-a6b9-4108-bfe8-fbdf7f019ee1" xlink:href="bngo-20211231.xsd#bngo_ClientWarrantyExchangeOfFixedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_ClientWarrantyExchangeOfFixedAssets_7d02b10b-a6b9-4108-bfe8-fbdf7f019ee1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_144274bc-7d24-4c14-a01d-61961439d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_144274bc-7d24-4c14-a01d-61961439d97d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0dc67d6-d724-4bef-befb-d1e889db8a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0dc67d6-d724-4bef-befb-d1e889db8a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7b110274-4f13-4cb5-b72e-555b75437948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7b110274-4f13-4cb5-b72e-555b75437948" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d9b84e2-6ba0-4af9-bc35-89018b8b94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d9b84e2-6ba0-4af9-bc35-89018b8b94aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_abdded29-3aca-4173-8017-9a5e711ef5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_abdded29-3aca-4173-8017-9a5e711ef5de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6db107f0-e757-47f8-8c00-5035ac94f07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6db107f0-e757-47f8-8c00-5035ac94f07c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54797972-e73f-4a17-be1e-61cb199859eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54797972-e73f-4a17-be1e-61cb199859eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f6e85ddc-e108-45c3-83ab-3abf335b60d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f6e85ddc-e108-45c3-83ab-3abf335b60d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForPropertyAndEquipment_3b06818f-9fdc-46c2-9f20-30e22dccc76f" xlink:href="bngo-20211231.xsd#bngo_PaymentsForPropertyAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_bngo_PaymentsForPropertyAndEquipment_3b06818f-9fdc-46c2-9f20-30e22dccc76f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_a1df67f6-41fd-464d-9000-c6afc111b364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_a1df67f6-41fd-464d-9000-c6afc111b364" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForInitialCostsOnLeases_88ce5db4-c5eb-4cb9-8682-9bda380cdfae" xlink:href="bngo-20211231.xsd#bngo_PaymentsForInitialCostsOnLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_bngo_PaymentsForInitialCostsOnLeases_88ce5db4-c5eb-4cb9-8682-9bda380cdfae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f0a0450c-b85e-4866-a726-89283e868aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f0a0450c-b85e-4866-a726-89283e868aef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ac307fe3-9665-417b-aac0-5607a36935ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ac307fe3-9665-417b-aac0-5607a36935ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3567ce93-6069-4300-ba0d-4e9040fcfa83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3567ce93-6069-4300-ba0d-4e9040fcfa83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_bac3ea55-1e70-454f-85c0-ddf7f01936af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_bac3ea55-1e70-454f-85c0-ddf7f01936af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_7f382ac5-c862-4310-9c4c-fdf1899c8445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_7f382ac5-c862-4310-9c4c-fdf1899c8445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProceedsFromPayrollProtectionProgramLoan_8a8c41d3-4598-4f03-a054-96e308dba418" xlink:href="bngo-20211231.xsd#bngo_ProceedsFromPayrollProtectionProgramLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_bngo_ProceedsFromPayrollProtectionProgramLoan_8a8c41d3-4598-4f03-a054-96e308dba418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_f60fec91-2166-4edf-8133-e6cb0055df83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_f60fec91-2166-4edf-8133-e6cb0055df83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_15a3423c-766f-437f-ae54-2cfe723ac6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_15a3423c-766f-437f-ae54-2cfe723ac6e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a136276e-c3bc-4727-95ab-be7232f87ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a136276e-c3bc-4727-95ab-be7232f87ab3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9af57e63-a32d-494e-860d-b3f0c811a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9af57e63-a32d-494e-860d-b3f0c811a4bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EmployeeStockPurchasePlanCompensationExpense_f31510ef-5ea8-4643-96c4-7ae5de5cea64" xlink:href="bngo-20211231.xsd#bngo_EmployeeStockPurchasePlanCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_bngo_EmployeeStockPurchasePlanCompensationExpense_f31510ef-5ea8-4643-96c4-7ae5de5cea64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3cd6488b-f4e9-4816-aff1-c9da3d9ddb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3cd6488b-f4e9-4816-aff1-c9da3d9ddb64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc6f0560-b749-49a2-bb12-9e263265a0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc6f0560-b749-49a2-bb12-9e263265a0d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_389517ea-3967-4c19-99eb-b0234975234e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_389517ea-3967-4c19-99eb-b0234975234e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7104e453-6082-443a-a8da-bd5421dfdc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7104e453-6082-443a-a8da-bd5421dfdc1c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9ffed5d1-fbff-48d3-8a75-c927c441cf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_afde1527-c2ab-4b6b-8813-147a70a2083d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_afde1527-c2ab-4b6b-8813-147a70a2083d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e0911443-82a3-499d-8cae-bebe374bf576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afde1527-c2ab-4b6b-8813-147a70a2083d" xlink:to="loc_us-gaap_InterestPaidNet_e0911443-82a3-499d-8cae-bebe374bf576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4d01ab5a-47f8-41d4-b602-a1001229e853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afde1527-c2ab-4b6b-8813-147a70a2083d" xlink:to="loc_us-gaap_OperatingLeasePayments_4d01ab5a-47f8-41d4-b602-a1001229e853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_bcd8e331-bdcd-4d49-ba2a-0fd1297bcd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_us-gaap_StockIssued1_bcd8e331-bdcd-4d49-ba2a-0fd1297bcd2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationNoncash_5dbfc68e-1cb3-4376-91ee-6fb34ea28e2f" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_ContingentConsiderationNoncash_5dbfc68e-1cb3-4376-91ee-6fb34ea28e2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b8464954-da8a-4857-ae13-a2c99c154503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b8464954-da8a-4857-ae13-a2c99c154503" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_fb755772-ff01-46ee-a52b-83ea92027ca7" xlink:href="bngo-20211231.xsd#bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_fb755772-ff01-46ee-a52b-83ea92027ca7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_2d7290dd-2b5c-4b9e-a9be-4efd6480d2fb" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedForServices_c28030fa-7964-43c4-82e6-d6663d041169" xlink:href="bngo-20211231.xsd#bngo_StockIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_StockIssuedForServices_c28030fa-7964-43c4-82e6-d6663d041169" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_IssueCommonStockForCovenantWaiver_05c72a2c-910d-4920-b056-f108a618e65f" xlink:href="bngo-20211231.xsd#bngo_IssueCommonStockForCovenantWaiver"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_IssueCommonStockForCovenantWaiver_05c72a2c-910d-4920-b056-f108a618e65f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantExerciseNonCash_e0796bab-f4c1-4114-828c-0057e0932d5b" xlink:href="bngo-20211231.xsd#bngo_WarrantExerciseNonCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_WarrantExerciseNonCash_e0796bab-f4c1-4114-828c-0057e0932d5b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c6dd7f1d-6edc-4338-8805-06c2fce8ab09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_StatementTable_c6dd7f1d-6edc-4338-8805-06c2fce8ab09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89ca011c-cf47-4bc0-8604-6e71b674e020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c6dd7f1d-6edc-4338-8805-06c2fce8ab09" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89ca011c-cf47-4bc0-8604-6e71b674e020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89ca011c-cf47-4bc0-8604-6e71b674e020_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89ca011c-cf47-4bc0-8604-6e71b674e020" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89ca011c-cf47-4bc0-8604-6e71b674e020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b240c7-92dc-4ab5-a023-28b70f237b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89ca011c-cf47-4bc0-8604-6e71b674e020" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b240c7-92dc-4ab5-a023-28b70f237b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_79ae529b-a677-4e46-b7c5-1d4a37fe6f05" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b240c7-92dc-4ab5-a023-28b70f237b90" xlink:to="loc_bngo_LineagenMember_79ae529b-a677-4e46-b7c5-1d4a37fe6f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_577d6994-911c-4504-9496-4846d96b87d1" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b240c7-92dc-4ab5-a023-28b70f237b90" xlink:to="loc_bngo_BioDiscoveryMember_577d6994-911c-4504-9496-4846d96b87d1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandOperationsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#OrganizationandOperationsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/OrganizationandOperationsDetails" xlink:type="extended" id="ifab1a9a04e81405da27cbad6128d0b73_OrganizationandOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_90fd91e3-7006-43d4-9968-fd52671e9fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_19e8c441-7637-41ac-88ae-2e13d1d04267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_90fd91e3-7006-43d4-9968-fd52671e9fe1" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_19e8c441-7637-41ac-88ae-2e13d1d04267" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5d351348-6b30-49f8-8012-32b448a84d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_90fd91e3-7006-43d4-9968-fd52671e9fe1" xlink:to="loc_us-gaap_DebtInstrumentTable_5d351348-6b30-49f8-8012-32b448a84d72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e78d22ba-ba8c-4330-bc09-49182e1737dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d351348-6b30-49f8-8012-32b448a84d72" xlink:to="loc_us-gaap_DebtInstrumentAxis_e78d22ba-ba8c-4330-bc09-49182e1737dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e78d22ba-ba8c-4330-bc09-49182e1737dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e78d22ba-ba8c-4330-bc09-49182e1737dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e78d22ba-ba8c-4330-bc09-49182e1737dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_01d2afa5-3dea-466d-9238-5f4f36b1aa00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e78d22ba-ba8c-4330-bc09-49182e1737dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_01d2afa5-3dea-466d-9238-5f4f36b1aa00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLoanAgreementMember_475418cc-fcda-477d-8637-eeb294566b38" xlink:href="bngo-20211231.xsd#bngo_InnovatusLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01d2afa5-3dea-466d-9238-5f4f36b1aa00" xlink:to="loc_bngo_InnovatusLoanAgreementMember_475418cc-fcda-477d-8637-eeb294566b38" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="id51c2fe9d645435ea356f708e6f66f58_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:href="bngo-20211231.xsd#bngo_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_9ff88139-6d9d-4a29-b706-bb76c9113fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_9ff88139-6d9d-4a29-b706-bb76c9113fa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fc63231e-e1c7-4d97-9aea-946a940b3456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fc63231e-e1c7-4d97-9aea-946a940b3456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bd95178f-b1e2-4135-9153-e519f09b0092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bd95178f-b1e2-4135-9153-e519f09b0092" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_470188d9-ad80-4aa1-acb2-7b2640e34684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_470188d9-ad80-4aa1-acb2-7b2640e34684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d068ba1a-f9bf-4f64-a87a-77faacbba28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d068ba1a-f9bf-4f64-a87a-77faacbba28b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_12551bac-95b3-4c9a-aff6-9f717cf3b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_12551bac-95b3-4c9a-aff6-9f717cf3b6c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_042726a8-b2db-4d6f-af65-8029bbdfb9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_042726a8-b2db-4d6f-af65-8029bbdfb9f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RentalRevenueReagentRentalProgram_903a746a-5a91-4ad8-85cd-0cd4404a0cc9" xlink:href="bngo-20211231.xsd#bngo_RentalRevenueReagentRentalProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_RentalRevenueReagentRentalProgram_903a746a-5a91-4ad8-85cd-0cd4404a0cc9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LicensingRevenueAndMaintenanceAgreements_12c72475-7ca8-4643-b5ac-275dd9903f23" xlink:href="bngo-20211231.xsd#bngo_LicensingRevenueAndMaintenanceAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_LicensingRevenueAndMaintenanceAgreements_12c72475-7ca8-4643-b5ac-275dd9903f23" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantyAndMaintenanceRevenue_adf87409-c4d9-41d8-8a5e-fd9f384d27e9" xlink:href="bngo-20211231.xsd#bngo_WarrantyAndMaintenanceRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_WarrantyAndMaintenanceRevenue_adf87409-c4d9-41d8-8a5e-fd9f384d27e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_dbb9551c-7b08-4ab5-bd92-7be6ee6bcd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_dbb9551c-7b08-4ab5-bd92-7be6ee6bcd91" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5c46c455-7714-47cb-9996-a34ec6d1a607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5c46c455-7714-47cb-9996-a34ec6d1a607" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_17e1147f-8d14-4e1c-944c-d80279640924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_17e1147f-8d14-4e1c-944c-d80279640924" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_5393ffd7-9518-4825-a1a1-2dd8ffb416a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_5393ffd7-9518-4825-a1a1-2dd8ffb416a3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyExpense_2d7cb4d0-37a3-4692-a4b8-1a9d193f7759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ProductWarrantyExpense_2d7cb4d0-37a3-4692-a4b8-1a9d193f7759" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_053a878c-36f1-4da9-b315-4fa3a2721c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_053a878c-36f1-4da9-b315-4fa3a2721c91" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_331013d6-2681-4976-a3c1-63647ed9b93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_331013d6-2681-4976-a3c1-63647ed9b93c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e78f8439-04a4-4fcd-a8ac-edb800afcada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e78f8439-04a4-4fcd-a8ac-edb800afcada" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_69a401ff-6d47-4711-9c0b-07c7b15a353b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_OperatingLeaseLiability_69a401ff-6d47-4711-9c0b-07c7b15a353b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:href="bngo-20211231.xsd#bngo_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6c115389-c268-45c4-8229-d7ce24d633ed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:to="loc_srt_NameOfMajorCustomerDomain_6c115389-c268-45c4-8229-d7ce24d633ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:to="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoCustomersMember_1a9ccc2c-a8a8-4c90-ab23-248a5d5610f5" xlink:href="bngo-20211231.xsd#bngo_TwoCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:to="loc_bngo_TwoCustomersMember_1a9ccc2c-a8a8-4c90-ab23-248a5d5610f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_611de6c7-4899-4cc1-8730-a19ebe0098bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_611de6c7-4899-4cc1-8730-a19ebe0098bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d1799b80-dfe8-4f35-9ad0-d02d53c649fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d1799b80-dfe8-4f35-9ad0-d02d53c649fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fdbdba04-baa1-476f-8dd9-0884b0281ef0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fdbdba04-baa1-476f-8dd9-0884b0281ef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5f6f29a9-1cfb-4003-8154-15056f2c2478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:to="loc_us-gaap_AccountsReceivableMember_5f6f29a9-1cfb-4003-8154-15056f2c2478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a6440df-c814-4c45-904b-b1677ad490ff_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:to="loc_srt_RangeMember_2a6440df-c814-4c45-904b-b1677ad490ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:to="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cefcb335-3d7a-4858-a6eb-85a00f2b4b2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:to="loc_srt_MinimumMember_cefcb335-3d7a-4858-a6eb-85a00f2b4b2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f22eb8a2-3f5f-421c-b75d-ca1b692484da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:to="loc_srt_MaximumMember_f22eb8a2-3f5f-421c-b75d-ca1b692484da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_e99191e2-ebf9-49a7-a389-1b02cde9324e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_e99191e2-ebf9-49a7-a389-1b02cde9324e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da8c79ac-772a-44f2-b003-82c98cd86a96_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:to="loc_srt_ProductsAndServicesDomain_da8c79ac-772a-44f2-b003-82c98cd86a96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:to="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_79a4542a-270d-46ca-8baf-84c4ba57fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_79a4542a-270d-46ca-8baf-84c4ba57fe5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b53e9737-f7cd-4037-972a-9419724eb159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:to="loc_us-gaap_ProductMember_b53e9737-f7cd-4037-972a-9419724eb159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0b2016f-c0af-47f8-b535-cd7c34d530df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0b2016f-c0af-47f8-b535-cd7c34d530df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0b66e094-cee9-4307-9bdf-5963abed89eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:to="loc_us-gaap_CostOfSalesMember_0b66e094-cee9-4307-9bdf-5963abed89eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1" xlink:type="extended" id="i04572cc7462844958dddb8071cbf5e70_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:href="bngo-20211231.xsd#bngo_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_9ff88139-6d9d-4a29-b706-bb76c9113fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_9ff88139-6d9d-4a29-b706-bb76c9113fa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fc63231e-e1c7-4d97-9aea-946a940b3456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fc63231e-e1c7-4d97-9aea-946a940b3456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bd95178f-b1e2-4135-9153-e519f09b0092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bd95178f-b1e2-4135-9153-e519f09b0092" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_470188d9-ad80-4aa1-acb2-7b2640e34684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_470188d9-ad80-4aa1-acb2-7b2640e34684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d068ba1a-f9bf-4f64-a87a-77faacbba28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d068ba1a-f9bf-4f64-a87a-77faacbba28b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_12551bac-95b3-4c9a-aff6-9f717cf3b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_12551bac-95b3-4c9a-aff6-9f717cf3b6c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_042726a8-b2db-4d6f-af65-8029bbdfb9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_042726a8-b2db-4d6f-af65-8029bbdfb9f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RentalRevenueReagentRentalProgram_903a746a-5a91-4ad8-85cd-0cd4404a0cc9" xlink:href="bngo-20211231.xsd#bngo_RentalRevenueReagentRentalProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_RentalRevenueReagentRentalProgram_903a746a-5a91-4ad8-85cd-0cd4404a0cc9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LicensingRevenueAndMaintenanceAgreements_12c72475-7ca8-4643-b5ac-275dd9903f23" xlink:href="bngo-20211231.xsd#bngo_LicensingRevenueAndMaintenanceAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_LicensingRevenueAndMaintenanceAgreements_12c72475-7ca8-4643-b5ac-275dd9903f23" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantyAndMaintenanceRevenue_adf87409-c4d9-41d8-8a5e-fd9f384d27e9" xlink:href="bngo-20211231.xsd#bngo_WarrantyAndMaintenanceRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_WarrantyAndMaintenanceRevenue_adf87409-c4d9-41d8-8a5e-fd9f384d27e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_dbb9551c-7b08-4ab5-bd92-7be6ee6bcd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_dbb9551c-7b08-4ab5-bd92-7be6ee6bcd91" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5c46c455-7714-47cb-9996-a34ec6d1a607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5c46c455-7714-47cb-9996-a34ec6d1a607" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_17e1147f-8d14-4e1c-944c-d80279640924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_17e1147f-8d14-4e1c-944c-d80279640924" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_5393ffd7-9518-4825-a1a1-2dd8ffb416a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_5393ffd7-9518-4825-a1a1-2dd8ffb416a3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyExpense_2d7cb4d0-37a3-4692-a4b8-1a9d193f7759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ProductWarrantyExpense_2d7cb4d0-37a3-4692-a4b8-1a9d193f7759" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_053a878c-36f1-4da9-b315-4fa3a2721c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_053a878c-36f1-4da9-b315-4fa3a2721c91" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_331013d6-2681-4976-a3c1-63647ed9b93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_331013d6-2681-4976-a3c1-63647ed9b93c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e78f8439-04a4-4fcd-a8ac-edb800afcada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e78f8439-04a4-4fcd-a8ac-edb800afcada" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_69a401ff-6d47-4711-9c0b-07c7b15a353b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_OperatingLeaseLiability_69a401ff-6d47-4711-9c0b-07c7b15a353b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:href="bngo-20211231.xsd#bngo_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6c115389-c268-45c4-8229-d7ce24d633ed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:to="loc_srt_NameOfMajorCustomerDomain_6c115389-c268-45c4-8229-d7ce24d633ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:to="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoCustomersMember_1a9ccc2c-a8a8-4c90-ab23-248a5d5610f5" xlink:href="bngo-20211231.xsd#bngo_TwoCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:to="loc_bngo_TwoCustomersMember_1a9ccc2c-a8a8-4c90-ab23-248a5d5610f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_611de6c7-4899-4cc1-8730-a19ebe0098bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_611de6c7-4899-4cc1-8730-a19ebe0098bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d1799b80-dfe8-4f35-9ad0-d02d53c649fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d1799b80-dfe8-4f35-9ad0-d02d53c649fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fdbdba04-baa1-476f-8dd9-0884b0281ef0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fdbdba04-baa1-476f-8dd9-0884b0281ef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5f6f29a9-1cfb-4003-8154-15056f2c2478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:to="loc_us-gaap_AccountsReceivableMember_5f6f29a9-1cfb-4003-8154-15056f2c2478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a6440df-c814-4c45-904b-b1677ad490ff_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:to="loc_srt_RangeMember_2a6440df-c814-4c45-904b-b1677ad490ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:to="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cefcb335-3d7a-4858-a6eb-85a00f2b4b2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:to="loc_srt_MinimumMember_cefcb335-3d7a-4858-a6eb-85a00f2b4b2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f22eb8a2-3f5f-421c-b75d-ca1b692484da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:to="loc_srt_MaximumMember_f22eb8a2-3f5f-421c-b75d-ca1b692484da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da8c79ac-772a-44f2-b003-82c98cd86a96_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:to="loc_srt_ProductsAndServicesDomain_da8c79ac-772a-44f2-b003-82c98cd86a96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:to="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_79a4542a-270d-46ca-8baf-84c4ba57fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_79a4542a-270d-46ca-8baf-84c4ba57fe5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b53e9737-f7cd-4037-972a-9419724eb159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:to="loc_us-gaap_ProductMember_b53e9737-f7cd-4037-972a-9419724eb159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0b2016f-c0af-47f8-b535-cd7c34d530df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0b2016f-c0af-47f8-b535-cd7c34d530df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0b66e094-cee9-4307-9bdf-5963abed89eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:to="loc_us-gaap_CostOfSalesMember_0b66e094-cee9-4307-9bdf-5963abed89eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="extended" id="i883be11f26ce4844816dd5cb797c95ed_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a0614e64-cec6-47d0-8882-8587be40b531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09fcd79a-b8e7-4ac0-ad24-7a4b10ca8224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a0614e64-cec6-47d0-8882-8587be40b531" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09fcd79a-b8e7-4ac0-ad24-7a4b10ca8224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d602d8c-d488-4b23-981d-1ad8a7bf6617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a0614e64-cec6-47d0-8882-8587be40b531" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d602d8c-d488-4b23-981d-1ad8a7bf6617" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1510d65d-4a11-4e25-aad4-4e42f7d6c83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d602d8c-d488-4b23-981d-1ad8a7bf6617" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1510d65d-4a11-4e25-aad4-4e42f7d6c83d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1510d65d-4a11-4e25-aad4-4e42f7d6c83d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1510d65d-4a11-4e25-aad4-4e42f7d6c83d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1510d65d-4a11-4e25-aad4-4e42f7d6c83d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1510d65d-4a11-4e25-aad4-4e42f7d6c83d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockOptionMember_307de868-84c9-4cd1-9192-1a92cf646a80" xlink:href="bngo-20211231.xsd#bngo_CommonStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_bngo_CommonStockOptionMember_307de868-84c9-4cd1-9192-1a92cf646a80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember_543cb3b1-d9d2-4147-8cf9-a8b94500c3e1" xlink:href="bngo-20211231.xsd#bngo_CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_bngo_CommonWarrantsMember_543cb3b1-d9d2-4147-8cf9-a8b94500c3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_UnvestedRestrictedStockMember_f1801b6e-adc2-4d33-8b3b-c8326bf9611d" xlink:href="bngo-20211231.xsd#bngo_UnvestedRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_bngo_UnvestedRestrictedStockMember_f1801b6e-adc2-4d33-8b3b-c8326bf9611d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_60ff5fa3-ff8c-43d0-9580-0f1bb2387e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_60ff5fa3-ff8c-43d0-9580-0f1bb2387e80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_cd6bc65a-7065-42ac-8413-0070d7bd5b20" xlink:href="bngo-20211231.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_cd6bc65a-7065-42ac-8413-0070d7bd5b20" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails" xlink:type="extended" id="i6da72feab23a45e2a85a94b346ec313b_SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c6d61834-32a3-422f-8b00-4d2a83ab59c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c6d61834-32a3-422f-8b00-4d2a83ab59c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_18a4da69-a206-4ee7-9efa-01a8b8774bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_18a4da69-a206-4ee7-9efa-01a8b8774bcb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="ife426e697d694d478d1903c9140ceba7_SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c6d61834-32a3-422f-8b00-4d2a83ab59c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c6d61834-32a3-422f-8b00-4d2a83ab59c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#RevenuefromContractswithCustomersDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails" xlink:type="extended" id="if33204dd65f145c8989a5b6352d68913_RevenuefromContractswithCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bf1262a6-cf4d-4d3b-924c-f2ce2c6ba7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b5e28300-93d7-47a6-85da-d6522749d5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf1262a6-cf4d-4d3b-924c-f2ce2c6ba7b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b5e28300-93d7-47a6-85da-d6522749d5bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9ffaebc4-723b-4408-b04e-6ddfbccd9bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf1262a6-cf4d-4d3b-924c-f2ce2c6ba7b4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9ffaebc4-723b-4408-b04e-6ddfbccd9bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf1262a6-cf4d-4d3b-924c-f2ce2c6ba7b4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_14f980bd-6f71-4d42-a8fb-f77f224bd40f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_srt_ProductOrServiceAxis_14f980bd-6f71-4d42-a8fb-f77f224bd40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14f980bd-6f71-4d42-a8fb-f77f224bd40f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_14f980bd-6f71-4d42-a8fb-f77f224bd40f" xlink:to="loc_srt_ProductsAndServicesDomain_14f980bd-6f71-4d42-a8fb-f77f224bd40f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_14f980bd-6f71-4d42-a8fb-f77f224bd40f" xlink:to="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember_f054a25b-f951-4d3d-9a7a-964d984c2b4e" xlink:href="bngo-20211231.xsd#bngo_InstrumentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:to="loc_bngo_InstrumentRevenueMember_f054a25b-f951-4d3d-9a7a-964d984c2b4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember_d61e9c4e-2455-4aeb-86e3-7e502368359b" xlink:href="bngo-20211231.xsd#bngo_ConsumableRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:to="loc_bngo_ConsumableRevenueMember_d61e9c4e-2455-4aeb-86e3-7e502368359b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8480c30a-6433-40ce-b6cd-0a9bb425a281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:to="loc_us-gaap_ProductMember_8480c30a-6433-40ce-b6cd-0a9bb425a281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_caee6e4a-914e-4639-a408-ed40a58ba177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_caee6e4a-914e-4639-a408-ed40a58ba177" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ac4a7525-e936-4b45-abc5-cbbbcbd15730" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_srt_StatementGeographicalAxis_ac4a7525-e936-4b45-abc5-cbbbcbd15730" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ac4a7525-e936-4b45-abc5-cbbbcbd15730_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ac4a7525-e936-4b45-abc5-cbbbcbd15730" xlink:to="loc_srt_SegmentGeographicalDomain_ac4a7525-e936-4b45-abc5-cbbbcbd15730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ac4a7525-e936-4b45-abc5-cbbbcbd15730" xlink:to="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_f7485c40-8ebe-4d48-a3d9-8a16e14ad8e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_srt_NorthAmericaMember_f7485c40-8ebe-4d48-a3d9-8a16e14ad8e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_4e1059d9-aae3-4b67-adcd-0827a034ce14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_us-gaap_EMEAMember_4e1059d9-aae3-4b67-adcd-0827a034ce14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_ba7cc646-cce3-408f-b488-e3e324b1b2ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_srt_AsiaPacificMember_ba7cc646-cce3-408f-b488-e3e324b1b2ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_e0d0d4b3-ca63-4950-abb1-0d27b105ccd9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_country_CN_e0d0d4b3-ca63-4950-abb1-0d27b105ccd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_94afd72d-cb4a-40ef-88b0-c1b05dcfa855" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_country_US_94afd72d-cb4a-40ef-88b0-c1b05dcfa855" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15149d88-2f0e-4d4f-b4d4-356037ea24f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15149d88-2f0e-4d4f-b4d4-356037ea24f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15149d88-2f0e-4d4f-b4d4-356037ea24f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15149d88-2f0e-4d4f-b4d4-356037ea24f1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15149d88-2f0e-4d4f-b4d4-356037ea24f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fd64359-0129-48dd-92ef-9e01214265fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15149d88-2f0e-4d4f-b4d4-356037ea24f1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fd64359-0129-48dd-92ef-9e01214265fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f3cc4cb3-e8b1-41fe-a648-70b29378b12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fd64359-0129-48dd-92ef-9e01214265fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f3cc4cb3-e8b1-41fe-a648-70b29378b12b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7e6b138d-d517-47de-bbd8-9d52c2c22ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fd64359-0129-48dd-92ef-9e01214265fc" xlink:to="loc_us-gaap_SalesRevenueNetMember_7e6b138d-d517-47de-bbd8-9d52c2c22ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2c42ca13-dc86-4056-ac7e-042c4554f803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2c42ca13-dc86-4056-ac7e-042c4554f803" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2c42ca13-dc86-4056-ac7e-042c4554f803_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c42ca13-dc86-4056-ac7e-042c4554f803" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2c42ca13-dc86-4056-ac7e-042c4554f803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b56d0868-3981-4548-a505-8cc6f9656fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c42ca13-dc86-4056-ac7e-042c4554f803" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b56d0868-3981-4548-a505-8cc6f9656fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_b88aa4bc-82d3-40b6-9476-dc96e14519bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b56d0868-3981-4548-a505-8cc6f9656fec" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_b88aa4bc-82d3-40b6-9476-dc96e14519bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="i9ceec533726a4a2e8ca6fe6b56f5ebe3_InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e10c10c2-5f2d-42cf-93a5-a74f73fe1647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_427222c3-1011-4358-ae31-5a01c7af8756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e10c10c2-5f2d-42cf-93a5-a74f73fe1647" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_427222c3-1011-4358-ae31-5a01c7af8756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_28e3e419-8668-46c8-abdf-ada4411549e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e10c10c2-5f2d-42cf-93a5-a74f73fe1647" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_28e3e419-8668-46c8-abdf-ada4411549e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e10c10c2-5f2d-42cf-93a5-a74f73fe1647" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_280bf7b4-9abc-4ebb-9c0e-868c018d0581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_280bf7b4-9abc-4ebb-9c0e-868c018d0581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_280bf7b4-9abc-4ebb-9c0e-868c018d0581_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_280bf7b4-9abc-4ebb-9c0e-868c018d0581" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_280bf7b4-9abc-4ebb-9c0e-868c018d0581_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_28b88d7d-ded8-47fb-ac37-ddf6efb24a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_280bf7b4-9abc-4ebb-9c0e-868c018d0581" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_28b88d7d-ded8-47fb-ac37-ddf6efb24a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_85e52825-2ebe-4b1a-b8ec-4a9b34a5cf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_28b88d7d-ded8-47fb-ac37-ddf6efb24a6f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_85e52825-2ebe-4b1a-b8ec-4a9b34a5cf4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618de55f-b0bf-4fe3-9a59-0b190ac5e398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618de55f-b0bf-4fe3-9a59-0b190ac5e398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_618de55f-b0bf-4fe3-9a59-0b190ac5e398_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618de55f-b0bf-4fe3-9a59-0b190ac5e398" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_618de55f-b0bf-4fe3-9a59-0b190ac5e398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618de55f-b0bf-4fe3-9a59-0b190ac5e398" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_af8a3d4f-15d0-4166-943d-424335af29ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_af8a3d4f-15d0-4166-943d-424335af29ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_46b7756c-59e4-4633-8a22-1b339d7f781e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_46b7756c-59e4-4633-8a22-1b339d7f781e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2c8884dd-94fc-4d36-bf26-16f29e3bffb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2c8884dd-94fc-4d36-bf26-16f29e3bffb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c419e82f-8a97-4bf1-95bc-71e60ef8c05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c419e82f-8a97-4bf1-95bc-71e60ef8c05c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c419e82f-8a97-4bf1-95bc-71e60ef8c05c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c419e82f-8a97-4bf1-95bc-71e60ef8c05c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c419e82f-8a97-4bf1-95bc-71e60ef8c05c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ad454d0-cb46-4acb-adb3-91a04f649b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c419e82f-8a97-4bf1-95bc-71e60ef8c05c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ad454d0-cb46-4acb-adb3-91a04f649b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_04a6acdb-7f89-4db6-b490-837995ffc673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ad454d0-cb46-4acb-adb3-91a04f649b5f" xlink:to="loc_us-gaap_InvestmentsMember_04a6acdb-7f89-4db6-b490-837995ffc673" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_84fdb31e-7180-4cea-9cb4-8868bc70aee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ad454d0-cb46-4acb-adb3-91a04f649b5f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_84fdb31e-7180-4cea-9cb4-8868bc70aee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_InvestmentTypeAxis_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d72bf069-06fb-4c3f-a1f5-d284be83c47a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d72bf069-06fb-4c3f-a1f5-d284be83c47a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3db797fa-43c8-4bdb-98d9-ba2e4dff72cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d72bf069-06fb-4c3f-a1f5-d284be83c47a" xlink:to="loc_us-gaap_CommercialPaperMember_3db797fa-43c8-4bdb-98d9-ba2e4dff72cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_07e51717-dd28-4e72-b369-b881f1b2831c" xlink:href="bngo-20211231.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d72bf069-06fb-4c3f-a1f5-d284be83c47a" xlink:to="loc_bngo_CorporateNotesAndBondsMember_07e51717-dd28-4e72-b369-b881f1b2831c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8c63af34-8676-4fa2-b2ab-6cec35debfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8c63af34-8676-4fa2-b2ab-6cec35debfc3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c63af34-8676-4fa2-b2ab-6cec35debfc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c63af34-8676-4fa2-b2ab-6cec35debfc3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c63af34-8676-4fa2-b2ab-6cec35debfc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d43650a2-46ff-409c-8b1c-9f9688f33988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c63af34-8676-4fa2-b2ab-6cec35debfc3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d43650a2-46ff-409c-8b1c-9f9688f33988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_72d8f843-ae10-4b0d-9161-6cb142a43d1a" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d43650a2-46ff-409c-8b1c-9f9688f33988" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_72d8f843-ae10-4b0d-9161-6cb142a43d1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="i5a5f5b9b20a842719f649453bc0789c3_InvestmentsandFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingLiabilityMeasurementInput_23bdbb35-955c-4d5c-892a-419f40a3d03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServicingLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_ServicingLiabilityMeasurementInput_23bdbb35-955c-4d5c-892a-419f40a3d03a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ce247909-c0a9-4328-acb5-fb66bc8ee2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ce247909-c0a9-4328-acb5-fb66bc8ee2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_88f4141d-edb4-4ace-bd42-551e7eb3e4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_88f4141d-edb4-4ace-bd42-551e7eb3e4cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fa6fe6a7-d27d-4029-9fef-0cdf7fa4f16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fa6fe6a7-d27d-4029-9fef-0cdf7fa4f16e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_deef0dff-eb59-45a2-9b06-6e09f8ff1203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_deef0dff-eb59-45a2-9b06-6e09f8ff1203" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5e035a96-650f-4b4c-b5d5-e8ea37f96383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5e035a96-650f-4b4c-b5d5-e8ea37f96383" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_18134308-bf90-4e21-9fa2-6b7655999094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_18134308-bf90-4e21-9fa2-6b7655999094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_18134308-bf90-4e21-9fa2-6b7655999094_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_18134308-bf90-4e21-9fa2-6b7655999094" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_18134308-bf90-4e21-9fa2-6b7655999094_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bac05c7c-efc7-469e-a770-d75a253a992c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_18134308-bf90-4e21-9fa2-6b7655999094" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bac05c7c-efc7-469e-a770-d75a253a992c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a12c7359-4a3f-410d-9354-45b3e255f750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_bac05c7c-efc7-469e-a770-d75a253a992c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a12c7359-4a3f-410d-9354-45b3e255f750" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6711bb4f-e6a2-4118-b5f9-cd5782cb3278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6711bb4f-e6a2-4118-b5f9-cd5782cb3278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_49165c1d-fb17-46bf-a95a-0e86ca334530" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6711bb4f-e6a2-4118-b5f9-cd5782cb3278" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_49165c1d-fb17-46bf-a95a-0e86ca334530" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" xlink:type="extended" id="i154d68cb87f34eb4b4d5af315c5f774a_InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ea6e293-5600-402a-b9d5-c3dde25e5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ea6e293-5600-402a-b9d5-c3dde25e5f45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89ec3e05-5cca-407c-bb5d-9658c0532400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89ec3e05-5cca-407c-bb5d-9658c0532400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b44c9278-02e8-4ab8-a53e-337664b9ef6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b44c9278-02e8-4ab8-a53e-337664b9ef6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e4352217-ffd1-4282-a8cd-00ad28331ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e4352217-ffd1-4282-a8cd-00ad28331ee4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b3549e35-f5b2-433c-a0a9-43897de31e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2ead1266-65b7-47c2-b180-4735826a323f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2ead1266-65b7-47c2-b180-4735826a323f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_85e83cfb-932f-4ba1-9d54-273f81a5f903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2ead1266-65b7-47c2-b180-4735826a323f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_85e83cfb-932f-4ba1-9d54-273f81a5f903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e83cfb-932f-4ba1-9d54-273f81a5f903_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85e83cfb-932f-4ba1-9d54-273f81a5f903" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e83cfb-932f-4ba1-9d54-273f81a5f903_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_742f5484-5d72-4350-ae43-446d6f9d30c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85e83cfb-932f-4ba1-9d54-273f81a5f903" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_742f5484-5d72-4350-ae43-446d6f9d30c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_81ad6db3-0b70-4deb-8a4d-f760e0c29873" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_742f5484-5d72-4350-ae43-446d6f9d30c1" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_81ad6db3-0b70-4deb-8a4d-f760e0c29873" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="extended" id="ic3dd144a9cf34168942796e6e0a83fa6_InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d7b1709f-585f-48de-9acc-86086f186a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d7b1709f-585f-48de-9acc-86086f186a64" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_11a13d07-f0f3-4295-9b49-eee24cc6c857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_11a13d07-f0f3-4295-9b49-eee24cc6c857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2c8a14aa-ccf8-4db9-9fef-b47f5e3ab51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2c8a14aa-ccf8-4db9-9fef-b47f5e3ab51a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a956ed62-9bf4-4e0b-8c01-4a115d819eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a956ed62-9bf4-4e0b-8c01-4a115d819eb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d7b1709f-585f-48de-9acc-86086f186a64" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b3891950-d180-42e4-b124-0358bdc64433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b3891950-d180-42e4-b124-0358bdc64433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_aea19705-d7f0-491d-8b3d-77e3dac32393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_aea19705-d7f0-491d-8b3d-77e3dac32393" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_764fef13-934b-4630-bf9b-955bbfb8deff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_764fef13-934b-4630-bf9b-955bbfb8deff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_309aed36-d111-496f-b62a-e4edf4fc41b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d7b1709f-585f-48de-9acc-86086f186a64" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_309aed36-d111-496f-b62a-e4edf4fc41b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_309aed36-d111-496f-b62a-e4edf4fc41b3" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f07ab63b-1ef3-433e-baa1-d36f96e3fdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f07ab63b-1ef3-433e-baa1-d36f96e3fdc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1026eb31-6f29-4b95-ab9d-e962180ff9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f07ab63b-1ef3-433e-baa1-d36f96e3fdc0" xlink:to="loc_us-gaap_CommercialPaperMember_1026eb31-6f29-4b95-ab9d-e962180ff9a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_652041e0-a9e1-479b-9760-8fc77220e333" xlink:href="bngo-20211231.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f07ab63b-1ef3-433e-baa1-d36f96e3fdc0" xlink:to="loc_bngo_CorporateNotesAndBondsMember_652041e0-a9e1-479b-9760-8fc77220e333" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails" xlink:type="extended" id="i5aac08276e9344f583ce8beb2716bd88_PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2a1de777-fbb5-4647-81a0-505ad2248b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2a1de777-fbb5-4647-81a0-505ad2248b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b188ae51-79e4-4e7e-acc0-c97a393980af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b188ae51-79e4-4e7e-acc0-c97a393980af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_422a498c-7a66-4fab-bdb6-600aebb83f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_422a498c-7a66-4fab-bdb6-600aebb83f91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1f343251-7531-4237-85d3-9d29bccfe391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1f343251-7531-4237-85d3-9d29bccfe391" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc60be13-ff43-48e9-91b9-13a86d2e0127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1f343251-7531-4237-85d3-9d29bccfe391" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc60be13-ff43-48e9-91b9-13a86d2e0127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc60be13-ff43-48e9-91b9-13a86d2e0127_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc60be13-ff43-48e9-91b9-13a86d2e0127" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc60be13-ff43-48e9-91b9-13a86d2e0127_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc60be13-ff43-48e9-91b9-13a86d2e0127" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ComputerAndOfficeEquipmentMember_6995c87c-aaa8-4456-a8d2-4369c4af6ea4" xlink:href="bngo-20211231.xsd#bngo_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:to="loc_bngo_ComputerAndOfficeEquipmentMember_6995c87c-aaa8-4456-a8d2-4369c4af6ea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LabEquipmentMember_5ca80e88-e74d-4ae5-be0e-9d16b9fc20df" xlink:href="bngo-20211231.xsd#bngo_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:to="loc_bngo_LabEquipmentMember_5ca80e88-e74d-4ae5-be0e-9d16b9fc20df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ServiceEquipmentMember_054c6342-7df9-4dbe-9b5d-0e89a297095d" xlink:href="bngo-20211231.xsd#bngo_ServiceEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:to="loc_bngo_ServiceEquipmentMember_054c6342-7df9-4dbe-9b5d-0e89a297095d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fed8f587-de94-47db-b2dd-529bfd324633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fed8f587-de94-47db-b2dd-529bfd324633" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#PropertyandEquipmentNetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="extended" id="i6bc20506c16d46e2bc7a26be5a3a0287_PropertyandEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4192052f-3494-4838-8184-bdfe6c913524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a567ed56-abe0-4485-8853-4270eeeab1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4192052f-3494-4838-8184-bdfe6c913524" xlink:to="loc_us-gaap_Depreciation_a567ed56-abe0-4485-8853-4270eeeab1e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb34f3a8-e620-4f43-b181-33ac7bf9e764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4192052f-3494-4838-8184-bdfe6c913524" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb34f3a8-e620-4f43-b181-33ac7bf9e764" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50d67b28-7fee-41b9-8257-919ec879eab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb34f3a8-e620-4f43-b181-33ac7bf9e764" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50d67b28-7fee-41b9-8257-919ec879eab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50d67b28-7fee-41b9-8257-919ec879eab1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50d67b28-7fee-41b9-8257-919ec879eab1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50d67b28-7fee-41b9-8257-919ec879eab1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f07c636-7f2e-4bff-81f5-b46319024a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50d67b28-7fee-41b9-8257-919ec879eab1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f07c636-7f2e-4bff-81f5-b46319024a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ReagentRentalsMember_9fb86c5d-157d-4752-975d-03c7550cdb64" xlink:href="bngo-20211231.xsd#bngo_ReagentRentalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f07c636-7f2e-4bff-81f5-b46319024a4c" xlink:to="loc_bngo_ReagentRentalsMember_9fb86c5d-157d-4752-975d-03c7550cdb64" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNetSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" xlink:type="extended" id="i577be551cf5344eea694502ffbc802d8_IntangibleAssetsNetSummaryofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6fb67006-ecc2-48e4-b7bc-2c23c06fe904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6fb67006-ecc2-48e4-b7bc-2c23c06fe904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d894a905-b99e-4cbb-9299-b3584cc69591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d894a905-b99e-4cbb-9299-b3584cc69591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cae0162-b291-4108-8bd0-d20ff051d2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cae0162-b291-4108-8bd0-d20ff051d2ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa65cb27-49fe-4071-9732-c2cd92f5060c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa65cb27-49fe-4071-9732-c2cd92f5060c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_584d3e41-b481-42c0-a21b-31b59807aea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa65cb27-49fe-4071-9732-c2cd92f5060c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_584d3e41-b481-42c0-a21b-31b59807aea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_584d3e41-b481-42c0-a21b-31b59807aea7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_584d3e41-b481-42c0-a21b-31b59807aea7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_584d3e41-b481-42c0-a21b-31b59807aea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_584d3e41-b481-42c0-a21b-31b59807aea7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_169edc26-eab4-4fd6-9f82-499e8a81148b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:to="loc_us-gaap_TradeNamesMember_169edc26-eab4-4fd6-9f82-499e8a81148b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_538d0b5b-192b-4e84-b94b-b5fa3b97c0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:to="loc_us-gaap_CustomerRelationshipsMember_538d0b5b-192b-4e84-b94b-b5fa3b97c0b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_01575713-95da-4dc6-ad34-53a7ec4f433a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_01575713-95da-4dc6-ad34-53a7ec4f433a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended" id="i828ef896a02e46fea17cb5b7b0d03aeb_IntangibleAssetsNetAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_41f759ba-e2f5-4d4d-90d0-80e44c94618d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_41f759ba-e2f5-4d4d-90d0-80e44c94618d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_63f7d973-b20a-4002-8ec4-bd5d0cdf8a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_63f7d973-b20a-4002-8ec4-bd5d0cdf8a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_87fcc343-a3d1-4042-a600-d46243f87536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_87fcc343-a3d1-4042-a600-d46243f87536" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e31a6005-01b9-4892-a6cf-c094aeb74c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e31a6005-01b9-4892-a6cf-c094aeb74c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e31a6005-01b9-4892-a6cf-c094aeb74c25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e31a6005-01b9-4892-a6cf-c094aeb74c25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e31a6005-01b9-4892-a6cf-c094aeb74c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1fd701f8-9ad1-46ad-a904-cec5c474e65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e31a6005-01b9-4892-a6cf-c094aeb74c25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1fd701f8-9ad1-46ad-a904-cec5c474e65a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember_0d18ff64-10c7-427e-804a-49df00451edd" xlink:href="bngo-20211231.xsd#bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1fd701f8-9ad1-46ad-a904-cec5c474e65a" xlink:to="loc_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember_0d18ff64-10c7-427e-804a-49df00451edd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dccf63d9-526c-4519-8576-eb72e2dc161e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dccf63d9-526c-4519-8576-eb72e2dc161e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dccf63d9-526c-4519-8576-eb72e2dc161e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dccf63d9-526c-4519-8576-eb72e2dc161e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dccf63d9-526c-4519-8576-eb72e2dc161e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ccfab7ce-6212-43fc-a2be-972b7160d286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dccf63d9-526c-4519-8576-eb72e2dc161e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ccfab7ce-6212-43fc-a2be-972b7160d286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_92157767-b900-4a94-8118-9d609c2b2ebb" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ccfab7ce-6212-43fc-a2be-972b7160d286" xlink:to="loc_bngo_LineagenMember_92157767-b900-4a94-8118-9d609c2b2ebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_469cbb83-7d4a-4d5e-af65-1971754723ce" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ccfab7ce-6212-43fc-a2be-972b7160d286" xlink:to="loc_bngo_BioDiscoveryMember_469cbb83-7d4a-4d5e-af65-1971754723ce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i4cd4e6a4d2e94b5eae309ca3a22365f1_LongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9ed54227-5044-4e1b-b09c-ca0c9fe1aa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9ed54227-5044-4e1b-b09c-ca0c9fe1aa5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5815d674-ad8e-4588-8d7e-cfb0b402d6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5815d674-ad8e-4588-8d7e-cfb0b402d6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateCashRate_3b852551-86aa-4848-9c03-aee5b50fc4c3" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentInterestRateCashRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentInterestRateCashRate_3b852551-86aa-4848-9c03-aee5b50fc4c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate_5511e3a1-0ea1-43a3-be91-5f987cf71a35" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentInterestRateDiscountedCashRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate_5511e3a1-0ea1-43a3-be91-5f987cf71a35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b38dfc26-f4f9-4e73-81d7-a0a3703f2330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b38dfc26-f4f9-4e73-81d7-a0a3703f2330" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPrepaymentFeePercent_e38b1ae1-1912-4537-9837-6349eb1f89b3" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPrepaymentFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentPrepaymentFeePercent_e38b1ae1-1912-4537-9837-6349eb1f89b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_a2ff571b-5145-49f8-883f-4d17e899d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_a2ff571b-5145-49f8-883f-4d17e899d4b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_8fc0d043-d9d2-4985-aa4a-3ec8f185025f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_8fc0d043-d9d2-4985-aa4a-3ec8f185025f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6b25cfd2-ecfd-4271-b41d-fceb4ebd1f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6b25cfd2-ecfd-4271-b41d-fceb4ebd1f6d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_99d7b194-b80d-4a58-b3c8-1d725d0ae26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_99d7b194-b80d-4a58-b3c8-1d725d0ae26e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantsToPurchaseSharesIssued_cd73ae8a-9acf-49bd-b007-02d8a4ec7767" xlink:href="bngo-20211231.xsd#bngo_WarrantsToPurchaseSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_WarrantsToPurchaseSharesIssued_cd73ae8a-9acf-49bd-b007-02d8a4ec7767" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f6630765-fbe5-456b-b3d4-1a9355c6f273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f6630765-fbe5-456b-b3d4-1a9355c6f273" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassofWarrantorRightTerm_afb13668-a44f-4ff3-96a7-55c0d0e5f903" xlink:href="bngo-20211231.xsd#bngo_ClassofWarrantorRightTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_ClassofWarrantorRightTerm_afb13668-a44f-4ff3-96a7-55c0d0e5f903" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness_88c8ebde-6a04-4e7b-bdf2-bcd6224025ba" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness_88c8ebde-6a04-4e7b-bdf2-bcd6224025ba" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross_9cb3fdb3-9b3a-401f-ba92-fec1600bd502" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross_9cb3fdb3-9b3a-401f-ba92-fec1600bd502" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_4285a78d-3012-482c-9105-38f4be6767d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_4285a78d-3012-482c-9105-38f4be6767d6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_a3235f2a-3ce5-4895-9ba2-afcfccebdf04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_RepaymentsOfDebt_a3235f2a-3ce5-4895-9ba2-afcfccebdf04" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise_d833d015-83d5-4053-9aa3-929c7677f3f5" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise_d833d015-83d5-4053-9aa3-929c7677f3f5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance_fe400e7f-0e5b-4708-b93d-6baea560e2fc" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance_fe400e7f-0e5b-4708-b93d-6baea560e2fc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod_4a2edfc8-747a-40e0-8236-54323fde8465" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod_4a2edfc8-747a-40e0-8236-54323fde8465" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantWaiverFee_4bfc20ff-8ac4-4e19-9226-a17c3960a33e" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantWaiverFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantWaiverFee_4bfc20ff-8ac4-4e19-9226-a17c3960a33e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantPrepaymentFee_d6f62da6-98f5-496c-9245-42f8924bfc42" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantPrepaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantPrepaymentFee_d6f62da6-98f5-496c-9245-42f8924bfc42" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsAxis_1cf1192d-a209-494e-bb98-d36ec7ad4a98" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:to="loc_bngo_DebtInstrumentPaymentTermsAxis_1cf1192d-a209-494e-bb98-d36ec7ad4a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsDomain_1cf1192d-a209-494e-bb98-d36ec7ad4a98_default" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bngo_DebtInstrumentPaymentTermsAxis_1cf1192d-a209-494e-bb98-d36ec7ad4a98" xlink:to="loc_bngo_DebtInstrumentPaymentTermsDomain_1cf1192d-a209-494e-bb98-d36ec7ad4a98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bngo_DebtInstrumentPaymentTermsAxis_1cf1192d-a209-494e-bb98-d36ec7ad4a98" xlink:to="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember_38404510-7a00-4974-8515-7afb12ab6304" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember_38404510-7a00-4974-8515-7afb12ab6304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_fa989691-3f6b-4c60-9057-a40da007b370" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_fa989691-3f6b-4c60-9057-a40da007b370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_e78c2bfa-8a08-4ccc-9501-7e167da5bb5d" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_e78c2bfa-8a08-4ccc-9501-7e167da5bb5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember_94518542-9fb1-4e77-ba44-cfaafd79f06b" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember_94518542-9fb1-4e77-ba44-cfaafd79f06b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:to="loc_us-gaap_DebtInstrumentAxis_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LoanUnderPaycheckProtectionProgramMember_66d4d831-84a6-49bf-96bb-50b141a28742" xlink:href="bngo-20211231.xsd#bngo_LoanUnderPaycheckProtectionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_LoanUnderPaycheckProtectionProgramMember_66d4d831-84a6-49bf-96bb-50b141a28742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA1LoanMember_9c71d5a2-cfe5-4c4b-adb7-46c8b2ea908e" xlink:href="bngo-20211231.xsd#bngo_TermA1LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_TermA1LoanMember_9c71d5a2-cfe5-4c4b-adb7-46c8b2ea908e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA2LoanMember_3ec21a63-a223-4e0b-94a3-6f72a157ab92" xlink:href="bngo-20211231.xsd#bngo_TermA2LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_TermA2LoanMember_3ec21a63-a223-4e0b-94a3-6f72a157ab92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusTerm3LoanMember_75ea1853-0573-4ec4-b34e-56ba9687447c" xlink:href="bngo-20211231.xsd#bngo_InnovatusTerm3LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_InnovatusTerm3LoanMember_75ea1853-0573-4ec4-b34e-56ba9687447c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLoanAgreementMember_e97aaa7f-dded-41c5-aa08-e38d645af2fa" xlink:href="bngo-20211231.xsd#bngo_InnovatusLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_InnovatusLoanAgreementMember_e97aaa7f-dded-41c5-aa08-e38d645af2fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RevolverMember_d9d26b1f-aaca-4ca9-9d4c-f13b65d424e3" xlink:href="bngo-20211231.xsd#bngo_RevolverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_RevolverMember_d9d26b1f-aaca-4ca9-9d4c-f13b65d424e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_79c87946-e56e-4d24-82a4-675fe4de82a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_79c87946-e56e-4d24-82a4-675fe4de82a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_79c87946-e56e-4d24-82a4-675fe4de82a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_79c87946-e56e-4d24-82a4-675fe4de82a1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_79c87946-e56e-4d24-82a4-675fe4de82a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfb2f998-3a9c-49b2-9b44-626ba38ee7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_79c87946-e56e-4d24-82a4-675fe4de82a1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfb2f998-3a9c-49b2-9b44-626ba38ee7d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c00ad9ed-5cdf-446a-918f-c14b8018d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bfb2f998-3a9c-49b2-9b44-626ba38ee7d2" xlink:to="loc_us-gaap_UnsecuredDebtMember_c00ad9ed-5cdf-446a-918f-c14b8018d3f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_8a7b9cbf-2caa-4b84-a99a-1130fa986676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bfb2f998-3a9c-49b2-9b44-626ba38ee7d2" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_8a7b9cbf-2caa-4b84-a99a-1130fa986676" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#LongTermDebtScheduleofDebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails" xlink:type="extended" id="i8627a90726094ec988d1b634c7eb1881_LongTermDebtScheduleofDebtObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ae4bca58-2eea-4640-932e-4bac6b61af80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ae4bca58-2eea-4640-932e-4bac6b61af80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d527b3e7-d13d-45a9-882a-71dae4a1b0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d527b3e7-d13d-45a9-882a-71dae4a1b0b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_22343264-6040-4078-aa3f-2ac3e312fb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:to="loc_us-gaap_LongTermDebt_22343264-6040-4078-aa3f-2ac3e312fb49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_54a845a8-a2e5-4f46-93cd-874e494a9fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:to="loc_us-gaap_DebtInstrumentTable_54a845a8-a2e5-4f46-93cd-874e494a9fb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d7ce7153-a3a5-4614-99e7-51fb49c0c64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_54a845a8-a2e5-4f46-93cd-874e494a9fb3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d7ce7153-a3a5-4614-99e7-51fb49c0c64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d7ce7153-a3a5-4614-99e7-51fb49c0c64a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d7ce7153-a3a5-4614-99e7-51fb49c0c64a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d7ce7153-a3a5-4614-99e7-51fb49c0c64a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d7ce7153-a3a5-4614-99e7-51fb49c0c64a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermLoanMember_9aab7978-a84a-4def-8507-bf4b009a9bdb" xlink:href="bngo-20211231.xsd#bngo_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:to="loc_bngo_TermLoanMember_9aab7978-a84a-4def-8507-bf4b009a9bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RevolverMember_7f735443-e825-4653-a186-4357c6d143e8" xlink:href="bngo-20211231.xsd#bngo_RevolverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:to="loc_bngo_RevolverMember_7f735443-e825-4653-a186-4357c6d143e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LoanUnderPaycheckProtectionProgramMember_350c4797-fbd4-478d-956a-401b01d1bde8" xlink:href="bngo-20211231.xsd#bngo_LoanUnderPaycheckProtectionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:to="loc_bngo_LoanUnderPaycheckProtectionProgramMember_350c4797-fbd4-478d-956a-401b01d1bde8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i492ca575545348cf99ed33696d5f24d3_StockholdersEquityandStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_684be271-a420-4308-b1d3-f8c96386149c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_684be271-a420-4308-b1d3-f8c96386149c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_dc52c546-48c7-4c84-9466-4a65008c711b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_dc52c546-48c7-4c84-9466-4a65008c711b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3caa038c-6323-43e6-a8f4-c1760a84ac64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3caa038c-6323-43e6-a8f4-c1760a84ac64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7d12209e-2e43-42f5-98b6-a3388e75a289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7d12209e-2e43-42f5-98b6-a3388e75a289" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5b23dbaa-16d5-4c85-ac11-d085db2cebdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5b23dbaa-16d5-4c85-ac11-d085db2cebdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18e9ac3a-eabb-463f-9f1b-8468675aacd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18e9ac3a-eabb-463f-9f1b-8468675aacd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6262fa51-d4fc-4ced-8bff-8937ea2a39c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6262fa51-d4fc-4ced-8bff-8937ea2a39c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bd85e0a4-ecf4-4714-9b84-0f58918f8ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bd85e0a4-ecf4-4714-9b84-0f58918f8ced" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ef99be33-e4e4-4aaa-a921-894b7ad7f400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ef99be33-e4e4-4aaa-a921-894b7ad7f400" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExpirationPeriod_3b7590cd-3861-45da-a5b6-9fdcd5cb8d42" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_ClassOfWarrantOrRightExpirationPeriod_3b7590cd-3861-45da-a5b6-9fdcd5cb8d42" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b1fa78a1-23f0-45f3-83ab-0c9c4d42c0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b1fa78a1-23f0-45f3-83ab-0c9c4d42c0ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5c2f6a7f-44b8-4bd8-9a4c-105b2212f24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5c2f6a7f-44b8-4bd8-9a4c-105b2212f24e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_145520d8-ffe2-41cd-ba33-e6a914b4a018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_145520d8-ffe2-41cd-ba33-e6a914b4a018" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e5314476-85fe-4680-a7c0-87dc92edb9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e5314476-85fe-4680-a7c0-87dc92edb9d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued_0013ec28-fcae-485b-9b13-332c6fb83485" xlink:href="bngo-20211231.xsd#bngo_SaleOfStockAuthorizedAmountToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued_0013ec28-fcae-485b-9b13-332c6fb83485" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_e57c3000-4e5b-4ea9-a1b7-ba49008025bb" xlink:href="bngo-20211231.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_e57c3000-4e5b-4ea9-a1b7-ba49008025bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_7b75fa64-fbff-484a-a3e6-b58baadebb3b" xlink:href="bngo-20211231.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_7b75fa64-fbff-484a-a3e6-b58baadebb3b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_108321b8-5401-47b9-9541-72ecf43cb1fd" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_108321b8-5401-47b9-9541-72ecf43cb1fd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_124aad6c-3995-4947-b20a-b05f33b0b5a5" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_124aad6c-3995-4947-b20a-b05f33b0b5a5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c9b36f8d-e072-48fa-9d19-efbcdec20514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c9b36f8d-e072-48fa-9d19-efbcdec20514" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c6cd0c18-f6b9-4048-b10a-e0f81d486455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c6cd0c18-f6b9-4048-b10a-e0f81d486455" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_05054f97-1cdd-4d85-b1db-3fd275c600a4" xlink:href="bngo-20211231.xsd#bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_05054f97-1cdd-4d85-b1db-3fd275c600a4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_835d6a66-0baa-4ab2-92e3-9731fdb91db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_835d6a66-0baa-4ab2-92e3-9731fdb91db6" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_43e10279-8ba4-4d04-91e2-3487bc9e5685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_43e10279-8ba4-4d04-91e2-3487bc9e5685" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_7c65c555-8e70-496e-8696-6be0a7fa49eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_7c65c555-8e70-496e-8696-6be0a7fa49eb" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_760309d1-7c42-4e6d-8545-5e70f06ef4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_760309d1-7c42-4e6d-8545-5e70f06ef4de" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7c0e8758-5912-4549-88c3-94ce1708386b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7c0e8758-5912-4549-88c3-94ce1708386b" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73f12439-1176-47cb-b8f2-6e63f4e809ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73f12439-1176-47cb-b8f2-6e63f4e809ab" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b6a88104-9f52-4444-9594-c69c7f80ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b6a88104-9f52-4444-9594-c69c7f80ab56" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_502e47e5-b6b4-496f-b5ec-19e37fb1f59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_502e47e5-b6b4-496f-b5ec-19e37fb1f59d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_82a8b332-ba10-4cee-a483-776547848e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_82a8b332-ba10-4cee-a483-776547848e65" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_222a66f0-9109-42d6-803e-74622cbcbba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_222a66f0-9109-42d6-803e-74622cbcbba3" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3c2983da-3201-48da-a0f7-4c3e5c0c4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3c2983da-3201-48da-a0f7-4c3e5c0c4d7e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_278f145a-cf52-4c60-bcd5-792e093185f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_278f145a-cf52-4c60-bcd5-792e093185f7" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e80edf7d-71c1-4ea1-b836-3e9f3820c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e80edf7d-71c1-4ea1-b836-3e9f3820c7e2" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15663b0a-0aa5-402f-865e-246df1c4b691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15663b0a-0aa5-402f-865e-246df1c4b691" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ebfc925b-df66-413f-a632-d09136e92a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ebfc925b-df66-413f-a632-d09136e92a91" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d775c9c0-50ba-44fb-a906-599069c13166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d775c9c0-50ba-44fb-a906-599069c13166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d775c9c0-50ba-44fb-a906-599069c13166_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d775c9c0-50ba-44fb-a906-599069c13166" xlink:to="loc_us-gaap_ClassOfStockDomain_d775c9c0-50ba-44fb-a906-599069c13166_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b8e680be-fd54-4c4b-a52c-7c2f2ff888d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d775c9c0-50ba-44fb-a906-599069c13166" xlink:to="loc_us-gaap_ClassOfStockDomain_b8e680be-fd54-4c4b-a52c-7c2f2ff888d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_53cf12bd-7c4f-4765-aba2-b9ac8912e15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b8e680be-fd54-4c4b-a52c-7c2f2ff888d0" xlink:to="loc_us-gaap_CommonStockMember_53cf12bd-7c4f-4765-aba2-b9ac8912e15c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember_9a23acde-e8c0-4658-a61a-cc64d452a46d" xlink:href="bngo-20211231.xsd#bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b8e680be-fd54-4c4b-a52c-7c2f2ff888d0" xlink:to="loc_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember_9a23acde-e8c0-4658-a61a-cc64d452a46d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a81d2905-4957-422b-94b4-4ef520c44b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a81d2905-4957-422b-94b4-4ef520c44b43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a81d2905-4957-422b-94b4-4ef520c44b43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a81d2905-4957-422b-94b4-4ef520c44b43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a81d2905-4957-422b-94b4-4ef520c44b43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a81d2905-4957-422b-94b4-4ef520c44b43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PreFundedWarrantMember_becb768c-d6b8-4e61-9372-970e12f9a646" xlink:href="bngo-20211231.xsd#bngo_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:to="loc_bngo_PreFundedWarrantMember_becb768c-d6b8-4e61-9372-970e12f9a646" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember_2a88a022-8a74-4c52-8f2d-7c7e4f4dfb03" xlink:href="bngo-20211231.xsd#bngo_CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:to="loc_bngo_CommonWarrantsMember_2a88a022-8a74-4c52-8f2d-7c7e4f4dfb03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockWarrantsOriginalAgreementMember_7e544fbc-2bd1-4274-88f8-15b54c2eca70" xlink:href="bngo-20211231.xsd#bngo_CommonStockWarrantsOriginalAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:to="loc_bngo_CommonStockWarrantsOriginalAgreementMember_7e544fbc-2bd1-4274-88f8-15b54c2eca70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockWarrantsAmendedAgreementMember_17cd66a1-fd89-4d6e-94fb-e348909cea47" xlink:href="bngo-20211231.xsd#bngo_CommonStockWarrantsAmendedAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:to="loc_bngo_CommonStockWarrantsAmendedAgreementMember_17cd66a1-fd89-4d6e-94fb-e348909cea47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_43cc96ac-92d8-497e-b132-caf30971a48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_43cc96ac-92d8-497e-b132-caf30971a48f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43cc96ac-92d8-497e-b132-caf30971a48f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_43cc96ac-92d8-497e-b132-caf30971a48f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43cc96ac-92d8-497e-b132-caf30971a48f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6408e62d-0254-4ee9-9495-77f2f4c67914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_43cc96ac-92d8-497e-b132-caf30971a48f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6408e62d-0254-4ee9-9495-77f2f4c67914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_28a8b35f-3ff5-4d5d-9aac-9fdf48ff2315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6408e62d-0254-4ee9-9495-77f2f4c67914" xlink:to="loc_us-gaap_EmployeeStockMember_28a8b35f-3ff5-4d5d-9aac-9fdf48ff2315" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e152921d-38e4-41d4-97b5-73305c387dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6408e62d-0254-4ee9-9495-77f2f4c67914" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e152921d-38e4-41d4-97b5-73305c387dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_29c705e8-f584-4c1e-9451-780dd4352dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_PlanNameAxis_29c705e8-f584-4c1e-9451-780dd4352dfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_29c705e8-f584-4c1e-9451-780dd4352dfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_29c705e8-f584-4c1e-9451-780dd4352dfb" xlink:to="loc_us-gaap_PlanNameDomain_29c705e8-f584-4c1e-9451-780dd4352dfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4ed26c08-2fdc-4fac-93ef-24274e78da11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_29c705e8-f584-4c1e-9451-780dd4352dfb" xlink:to="loc_us-gaap_PlanNameDomain_4ed26c08-2fdc-4fac-93ef-24274e78da11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoThousandEighteenEquityIncentivePlanMember_fc7d9369-1470-4d7d-9ddc-1b5bb3e99b6d" xlink:href="bngo-20211231.xsd#bngo_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4ed26c08-2fdc-4fac-93ef-24274e78da11" xlink:to="loc_bngo_TwoThousandEighteenEquityIncentivePlanMember_fc7d9369-1470-4d7d-9ddc-1b5bb3e99b6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoThousandAndTwentyInducementPlanMember_80d06b83-bff4-4fb1-9d94-8161db593bdc" xlink:href="bngo-20211231.xsd#bngo_TwoThousandAndTwentyInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4ed26c08-2fdc-4fac-93ef-24274e78da11" xlink:to="loc_bngo_TwoThousandAndTwentyInducementPlanMember_80d06b83-bff4-4fb1-9d94-8161db593bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b147b2c8-2869-4555-9ce7-8dde048532c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_AwardTypeAxis_b147b2c8-2869-4555-9ce7-8dde048532c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b147b2c8-2869-4555-9ce7-8dde048532c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b147b2c8-2869-4555-9ce7-8dde048532c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b147b2c8-2869-4555-9ce7-8dde048532c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b147b2c8-2869-4555-9ce7-8dde048532c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a2de7b69-7f48-4dfb-b666-75a965bd3e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a2de7b69-7f48-4dfb-b666-75a965bd3e12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_44b0c782-d7f6-440c-a4cf-d5f07c83ace2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:to="loc_us-gaap_RestrictedStockMember_44b0c782-d7f6-440c-a4cf-d5f07c83ace2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6a7b456f-5b35-41d3-ae54-5baab1a125b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6a7b456f-5b35-41d3-ae54-5baab1a125b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_e3a1393a-dfc2-46a2-ba4d-2444b98ecb73" xlink:href="bngo-20211231.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_e3a1393a-dfc2-46a2-ba4d-2444b98ecb73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d763630-3bde-4b23-9a94-8f11e37fa9bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_srt_RangeAxis_8d763630-3bde-4b23-9a94-8f11e37fa9bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d763630-3bde-4b23-9a94-8f11e37fa9bb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8d763630-3bde-4b23-9a94-8f11e37fa9bb" xlink:to="loc_srt_RangeMember_8d763630-3bde-4b23-9a94-8f11e37fa9bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5739b13a-e774-4796-bff7-748f15ca0122" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8d763630-3bde-4b23-9a94-8f11e37fa9bb" xlink:to="loc_srt_RangeMember_5739b13a-e774-4796-bff7-748f15ca0122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce6d8446-1466-43f6-88e9-5e359fdeeedc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5739b13a-e774-4796-bff7-748f15ca0122" xlink:to="loc_srt_MaximumMember_ce6d8446-1466-43f6-88e9-5e359fdeeedc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_srt_CounterpartyNameAxis_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e1010585-c6f6-4f7b-9bfd-be0921a72ebf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e1010585-c6f6-4f7b-9bfd-be0921a72ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember_9358d412-d75c-446f-a999-b72614287fd7" xlink:href="bngo-20211231.xsd#bngo_CowenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e1010585-c6f6-4f7b-9bfd-be0921a72ebf" xlink:to="loc_bngo_CowenMember_9358d412-d75c-446f-a999-b72614287fd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84dc9d36-c3dd-4623-904f-29104de09375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84dc9d36-c3dd-4623-904f-29104de09375" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84dc9d36-c3dd-4623-904f-29104de09375_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84dc9d36-c3dd-4623-904f-29104de09375" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_84dc9d36-c3dd-4623-904f-29104de09375_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1190f9e2-6818-497a-8c88-3a2d3b504f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84dc9d36-c3dd-4623-904f-29104de09375" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1190f9e2-6818-497a-8c88-3a2d3b504f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_fc7084bb-c580-434b-8a5b-8b50428938ed" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1190f9e2-6818-497a-8c88-3a2d3b504f5e" xlink:to="loc_bngo_BioDiscoveryMember_fc7084bb-c580-434b-8a5b-8b50428938ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e379a02d-fd20-49b7-8319-827ef471a7b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_srt_TitleOfIndividualAxis_e379a02d-fd20-49b7-8319-827ef471a7b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e379a02d-fd20-49b7-8319-827ef471a7b1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e379a02d-fd20-49b7-8319-827ef471a7b1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e379a02d-fd20-49b7-8319-827ef471a7b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c9bea83-46ba-463e-b4aa-8cd5fb072713" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e379a02d-fd20-49b7-8319-827ef471a7b1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c9bea83-46ba-463e-b4aa-8cd5fb072713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_bb351324-1d4f-43e0-9402-12ac956afc80" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c9bea83-46ba-463e-b4aa-8cd5fb072713" xlink:to="loc_srt_ExecutiveOfficerMember_bb351324-1d4f-43e0-9402-12ac956afc80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bb7a88f4-578d-467d-a14c-705c43c2fddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bb7a88f4-578d-467d-a14c-705c43c2fddd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bb7a88f4-578d-467d-a14c-705c43c2fddd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bb7a88f4-578d-467d-a14c-705c43c2fddd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bb7a88f4-578d-467d-a14c-705c43c2fddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8a51d32a-5e80-4079-b474-313cecd0fb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bb7a88f4-578d-467d-a14c-705c43c2fddd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8a51d32a-5e80-4079-b474-313cecd0fb67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2212c811-c786-4f78-b574-8ffc13938b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8a51d32a-5e80-4079-b474-313cecd0fb67" xlink:to="loc_us-gaap_SubsequentEventMember_2212c811-c786-4f78-b574-8ffc13938b5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" xlink:type="extended" id="i5fe8ae8e9e584839ad5e11409ba61867_StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e7976be4-8550-4af9-8da0-b930a454d7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e7976be4-8550-4af9-8da0-b930a454d7a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c28b6de6-4b19-4f55-88fc-dcbe34244e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c28b6de6-4b19-4f55-88fc-dcbe34244e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff869fac-3e47-43aa-a5a8-31781e5f4b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff869fac-3e47-43aa-a5a8-31781e5f4b90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_aeaeb370-de2a-4b53-acd7-d297b0142fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_aeaeb370-de2a-4b53-acd7-d297b0142fb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_11ae196f-3d76-4fde-bad1-026f2d967a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb29447f-426a-4be4-8e58-7c655361683f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb29447f-426a-4be4-8e58-7c655361683f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d82befa5-e8c6-4003-b852-ea484f245951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d82befa5-e8c6-4003-b852-ea484f245951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30175bde-bf8b-4057-8e1b-82f06fe3c734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30175bde-bf8b-4057-8e1b-82f06fe3c734" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_400ff465-5b9f-4951-96f1-adb2f2a06a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_400ff465-5b9f-4951-96f1-adb2f2a06a49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4688277a-8080-41ce-b4a7-826dc88728d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2b129e63-4f2d-4e94-b160-37153abd362d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2b129e63-4f2d-4e94-b160-37153abd362d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_752bc779-e987-4a7d-8827-ba91089d3ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_752bc779-e987-4a7d-8827-ba91089d3ec5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8518b76d-3478-41bc-aafc-c88ec70df7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8518b76d-3478-41bc-aafc-c88ec70df7ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8518b76d-3478-41bc-aafc-c88ec70df7ca" xlink:to="loc_us-gaap_AwardTypeAxis_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9ed6f0f-41a8-4d0c-8901-ee33913ef1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9ed6f0f-41a8-4d0c-8901-ee33913ef1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00741660-1482-4b2d-804f-81c4bf885c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9ed6f0f-41a8-4d0c-8901-ee33913ef1dc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00741660-1482-4b2d-804f-81c4bf885c27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_407cd2b3-d191-49bb-9349-90ce2b24e419" xlink:href="bngo-20211231.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9ed6f0f-41a8-4d0c-8901-ee33913ef1dc" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_407cd2b3-d191-49bb-9349-90ce2b24e419" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" id="iaa939e0b713f4c158db65f65e2f39d5d_StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f682c39c-fb55-4513-8b22-0b9e1d1d96fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8b424ceb-3416-413d-8e1b-dc6d8c0c2aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f682c39c-fb55-4513-8b22-0b9e1d1d96fc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8b424ceb-3416-413d-8e1b-dc6d8c0c2aea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a9449dba-eb34-4df0-a1b8-948291abfa75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f682c39c-fb55-4513-8b22-0b9e1d1d96fc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a9449dba-eb34-4df0-a1b8-948291abfa75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a931d097-dc47-4fdb-b912-ba64c1befb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a9449dba-eb34-4df0-a1b8-948291abfa75" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a931d097-dc47-4fdb-b912-ba64c1befb31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a931d097-dc47-4fdb-b912-ba64c1befb31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a931d097-dc47-4fdb-b912-ba64c1befb31" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a931d097-dc47-4fdb-b912-ba64c1befb31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_55628a45-f775-4a43-9140-5ed7722052c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a931d097-dc47-4fdb-b912-ba64c1befb31" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_55628a45-f775-4a43-9140-5ed7722052c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_57ed34b6-77e9-453a-953b-526d31dcd585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_55628a45-f775-4a43-9140-5ed7722052c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_57ed34b6-77e9-453a-953b-526d31dcd585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14116f54-f197-4e81-bd5b-863b92bcb4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_55628a45-f775-4a43-9140-5ed7722052c6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14116f54-f197-4e81-bd5b-863b92bcb4a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="ife5c025da6794ce0802a41690832babd_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseAreaLeased_ee6a3b59-8e51-496d-aa52-cbb4e9d38cb6" xlink:href="bngo-20211231.xsd#bngo_LesseeOperatingLeaseAreaLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_LesseeOperatingLeaseAreaLeased_ee6a3b59-8e51-496d-aa52-cbb4e9d38cb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseAreaAdded_2d0f05b1-5cc9-44a4-bf2e-670e53866469" xlink:href="bngo-20211231.xsd#bngo_LesseeOperatingLeaseAreaAdded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_LesseeOperatingLeaseAreaAdded_2d0f05b1-5cc9-44a4-bf2e-670e53866469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeaseMonthlyRentPayments_ebd5d69f-e4dc-4cd6-8269-e463a2dd78b4" xlink:href="bngo-20211231.xsd#bngo_OperatingLeaseMonthlyRentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_OperatingLeaseMonthlyRentPayments_ebd5d69f-e4dc-4cd6-8269-e463a2dd78b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeFinanceLeaseAreaLeased_3e765471-1aaf-42c7-b173-1cc69faf10e2" xlink:href="bngo-20211231.xsd#bngo_LesseeFinanceLeaseAreaLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_LesseeFinanceLeaseAreaLeased_3e765471-1aaf-42c7-b173-1cc69faf10e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeEstimatedIncrementalBorrowingRate_c5da3d36-6799-4ed4-830d-114214b37dfb" xlink:href="bngo-20211231.xsd#bngo_LesseeEstimatedIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_LesseeEstimatedIncrementalBorrowingRate_c5da3d36-6799-4ed4-830d-114214b37dfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter_a175e30e-efe1-4228-b503-e154ac521f85" xlink:href="bngo-20211231.xsd#bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter_a175e30e-efe1-4228-b503-e154ac521f85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurchaseObligationInitialPurchasePeriod_bc9cc7bd-a3a5-4ade-89dd-9aed170d3990" xlink:href="bngo-20211231.xsd#bngo_PurchaseObligationInitialPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_PurchaseObligationInitialPurchasePeriod_bc9cc7bd-a3a5-4ade-89dd-9aed170d3990" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurchaseObligationContractTerminationPeriod_fca60366-d292-40d5-b2ee-cf78198ffe8b" xlink:href="bngo-20211231.xsd#bngo_PurchaseObligationContractTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_PurchaseObligationContractTerminationPeriod_fca60366-d292-40d5-b2ee-cf78198ffe8b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationMilestonePayment_7629b371-fe05-4647-93a0-eb39a5857fa4" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_ContingentConsiderationMilestonePayment_7629b371-fe05-4647-93a0-eb39a5857fa4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ec9b5398-1411-4b60-a65f-3870437e8f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ec9b5398-1411-4b60-a65f-3870437e8f83" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationFairValueOfContingentLiability_2059b685-3677-40b2-a71e-0b6fb93c65dd" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationFairValueOfContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_ContingentConsiderationFairValueOfContingentLiability_2059b685-3677-40b2-a71e-0b6fb93c65dd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_fff7e8cc-4ca3-4eea-8234-42c2a9f2348d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_fff7e8cc-4ca3-4eea-8234-42c2a9f2348d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_srt_StatementGeographicalAxis_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8" xlink:to="loc_srt_SegmentGeographicalDomain_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8" xlink:to="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SanDiegoCaliforniaMember_c20f5659-008b-474a-90c5-960041c07da1" xlink:href="bngo-20211231.xsd#bngo_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:to="loc_bngo_SanDiegoCaliforniaMember_c20f5659-008b-474a-90c5-960041c07da1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaltLakeCityUtahMember_5eaa3b50-7518-40c1-92c8-aac4b4be542d" xlink:href="bngo-20211231.xsd#bngo_SaltLakeCityUtahMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:to="loc_bngo_SaltLakeCityUtahMember_5eaa3b50-7518-40c1-92c8-aac4b4be542d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ElSegundoCaliforniaMember_05f95761-e978-4ecf-9294-82af80245f10" xlink:href="bngo-20211231.xsd#bngo_ElSegundoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:to="loc_bngo_ElSegundoCaliforniaMember_05f95761-e978-4ecf-9294-82af80245f10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a226ab6e-ef8a-4501-8bbe-ade840789f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a226ab6e-ef8a-4501-8bbe-ade840789f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_d53be963-0e71-427c-8541-db04625d81bd" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a226ab6e-ef8a-4501-8bbe-ade840789f8e" xlink:to="loc_bngo_BioDiscoveryMember_d53be963-0e71-427c-8541-db04625d81bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5de57334-1dc8-49e8-a269-42817d90b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5de57334-1dc8-49e8-a269-42817d90b3bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5de57334-1dc8-49e8-a269-42817d90b3bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5de57334-1dc8-49e8-a269-42817d90b3bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5de57334-1dc8-49e8-a269-42817d90b3bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f3b2d135-6db8-42b0-8911-3ac701a6024a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5de57334-1dc8-49e8-a269-42817d90b3bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f3b2d135-6db8-42b0-8911-3ac701a6024a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_c7eaaa11-6c1e-4d72-89f1-d6abd56ba588" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f3b2d135-6db8-42b0-8911-3ac701a6024a" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_c7eaaa11-6c1e-4d72-89f1-d6abd56ba588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d7655f85-e8c5-437c-9d31-3f2e25ef4623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d7655f85-e8c5-437c-9d31-3f2e25ef4623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d7655f85-e8c5-437c-9d31-3f2e25ef4623_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d7655f85-e8c5-437c-9d31-3f2e25ef4623" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d7655f85-e8c5-437c-9d31-3f2e25ef4623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0f29301-a0f9-4a8a-80ae-6c25841f07e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d7655f85-e8c5-437c-9d31-3f2e25ef4623" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0f29301-a0f9-4a8a-80ae-6c25841f07e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f93df9cd-9cc1-414b-a54d-e5c7f3d95386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c0f29301-a0f9-4a8a-80ae-6c25841f07e5" xlink:to="loc_us-gaap_SubsequentEventMember_f93df9cd-9cc1-414b-a54d-e5c7f3d95386" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="ibb795f521b01491588b4f251b63655ed_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_dee772d1-e2f5-4e16-b1ad-0bc6ee3cc24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_dee772d1-e2f5-4e16-b1ad-0bc6ee3cc24f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration_d71fd556-c585-48ef-a669-e4bd2c5cd059" xlink:href="bngo-20211231.xsd#bngo_OperatingLossCarryforwardsNotSubjecttoExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration_d71fd556-c585-48ef-a669-e4bd2c5cd059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLossCarryforwardsSubjecttoExpiration_ab554b62-8fcb-44f4-abba-9c47021089d9" xlink:href="bngo-20211231.xsd#bngo_OperatingLossCarryforwardsSubjecttoExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_bngo_OperatingLossCarryforwardsSubjecttoExpiration_ab554b62-8fcb-44f4-abba-9c47021089d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1c5b7048-591d-42d1-838e-91ec2da002b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1c5b7048-591d-42d1-838e-91ec2da002b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d49baf74-8fdc-4c8e-ac96-dd35f10494c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d49baf74-8fdc-4c8e-ac96-dd35f10494c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3f4970a8-0f51-49b1-964e-cef4e33292f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3f4970a8-0f51-49b1-964e-cef4e33292f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fdf5d6f6-7f7e-4dca-9d45-f97e2dacd28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fdf5d6f6-7f7e-4dca-9d45-f97e2dacd28e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a4458fb0-a302-422c-bbf3-0ae8c9b88e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a4458fb0-a302-422c-bbf3-0ae8c9b88e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a4458fb0-a302-422c-bbf3-0ae8c9b88e61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a4458fb0-a302-422c-bbf3-0ae8c9b88e61" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a4458fb0-a302-422c-bbf3-0ae8c9b88e61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_397110f5-6b36-4ba5-b535-0062e7294598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a4458fb0-a302-422c-bbf3-0ae8c9b88e61" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_397110f5-6b36-4ba5-b535-0062e7294598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e200fe11-01ba-4937-ae45-a5525395e0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_397110f5-6b36-4ba5-b535-0062e7294598" xlink:to="loc_us-gaap_DomesticCountryMember_e200fe11-01ba-4937-ae45-a5525395e0b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_fee88d38-d997-4c37-974d-4d283ae76a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_397110f5-6b36-4ba5-b535-0062e7294598" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_fee88d38-d997-4c37-974d-4d283ae76a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_c2217f3c-212d-4639-9c5b-c4df76784ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_c2217f3c-212d-4639-9c5b-c4df76784ea8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c2217f3c-212d-4639-9c5b-c4df76784ea8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c2217f3c-212d-4639-9c5b-c4df76784ea8" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c2217f3c-212d-4639-9c5b-c4df76784ea8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d8eed451-977b-4d80-a12a-d120725ae7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c2217f3c-212d-4639-9c5b-c4df76784ea8" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d8eed451-977b-4d80-a12a-d120725ae7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_c4c26c65-cfd7-46ca-9d70-a0c3eaab8894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d8eed451-977b-4d80-a12a-d120725ae7fe" xlink:to="loc_us-gaap_ResearchMember_c4c26c65-cfd7-46ca-9d70-a0c3eaab8894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5129f33c-c71a-4344-8041-16941bdf3c85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_srt_StatementGeographicalAxis_5129f33c-c71a-4344-8041-16941bdf3c85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5129f33c-c71a-4344-8041-16941bdf3c85_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5129f33c-c71a-4344-8041-16941bdf3c85" xlink:to="loc_srt_SegmentGeographicalDomain_5129f33c-c71a-4344-8041-16941bdf3c85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a83f7a4b-76f1-4b15-8517-33e98fb5b201" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5129f33c-c71a-4344-8041-16941bdf3c85" xlink:to="loc_srt_SegmentGeographicalDomain_a83f7a4b-76f1-4b15-8517-33e98fb5b201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_fbdd57c7-706c-40cb-bd3c-8b2135b0f4a5" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a83f7a4b-76f1-4b15-8517-33e98fb5b201" xlink:to="loc_stpr_CA_fbdd57c7-706c-40cb-bd3c-8b2135b0f4a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e7268874-3256-4697-8363-da00cff648cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e7268874-3256-4697-8363-da00cff648cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7268874-3256-4697-8363-da00cff648cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e7268874-3256-4697-8363-da00cff648cd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e7268874-3256-4697-8363-da00cff648cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_094cab83-9168-4f55-bd85-4f7fc904bd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e7268874-3256-4697-8363-da00cff648cd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_094cab83-9168-4f55-bd85-4f7fc904bd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_50820a57-8870-4642-90db-7e3080e50846" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_094cab83-9168-4f55-bd85-4f7fc904bd00" xlink:to="loc_bngo_BioDiscoveryMember_50820a57-8870-4642-90db-7e3080e50846" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails" xlink:type="extended" id="i396628ff0e7f4bee950e68774a046db3_AcquisitionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5daac73f-6570-4be9-9bb1-23e19edbfe57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5daac73f-6570-4be9-9bb1-23e19edbfe57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6c4ad111-dfd6-4a3a-902e-21ea9cde6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6c4ad111-dfd6-4a3a-902e-21ea9cde6c45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_66dc0fe7-3773-47ee-90bc-2b745d131213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_66dc0fe7-3773-47ee-90bc-2b745d131213" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_38671cfd-8d1c-4d2b-96a6-abec439034cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_38671cfd-8d1c-4d2b-96a6-abec439034cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_4d3ccc8e-ee96-4179-81dd-2a57f63be996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_4d3ccc8e-ee96-4179-81dd-2a57f63be996" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_282e4b61-e68b-4de8-b349-82cf2afa0f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_282e4b61-e68b-4de8-b349-82cf2afa0f3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_51743572-94a2-4ca1-a414-468483455145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_51743572-94a2-4ca1-a414-468483455145" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f2e07e3a-f2a9-4ab1-96f5-4178a8045047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f2e07e3a-f2a9-4ab1-96f5-4178a8045047" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationConsiderationTransferredValueOfShares_bbd1d191-a34b-47f1-aa2c-ad31306f9760" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationConsiderationTransferredValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_bngo_BusinessCombinationConsiderationTransferredValueOfShares_bbd1d191-a34b-47f1-aa2c-ad31306f9760" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting_defabf47-ca36-4e0e-9ff1-b6d0d688c83b" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting_defabf47-ca36-4e0e-9ff1-b6d0d688c83b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionMilestonePayment_419ece54-349e-4110-ba0e-19ab58c812de" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_bngo_BusinessAcquisitionMilestonePayment_419ece54-349e-4110-ba0e-19ab58c812de" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_d4e8f828-c66e-4f9a-bd04-4cf4ee0eba90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_d4e8f828-c66e-4f9a-bd04-4cf4ee0eba90" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e14fc98-a17d-4b2f-a3fb-e7d75c3e9492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e14fc98-a17d-4b2f-a3fb-e7d75c3e9492" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b78c80a4-8c59-4712-a449-4c6c04b1bd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b78c80a4-8c59-4712-a449-4c6c04b1bd4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b78c80a4-8c59-4712-a449-4c6c04b1bd4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b78c80a4-8c59-4712-a449-4c6c04b1bd4d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b78c80a4-8c59-4712-a449-4c6c04b1bd4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fdf6865-2f9b-4b8c-ace6-548221d60c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b78c80a4-8c59-4712-a449-4c6c04b1bd4d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fdf6865-2f9b-4b8c-ace6-548221d60c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_c4ed7ef9-4048-405d-a27b-d8d39eed46ff" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fdf6865-2f9b-4b8c-ace6-548221d60c62" xlink:to="loc_bngo_LineagenMember_c4ed7ef9-4048-405d-a27b-d8d39eed46ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_3ad71fd6-834a-417e-8575-6f0f5bbebbfe" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fdf6865-2f9b-4b8c-ace6-548221d60c62" xlink:to="loc_bngo_BioDiscoveryMember_3ad71fd6-834a-417e-8575-6f0f5bbebbfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_66a91baa-b174-45fa-b323-632b736f15fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_66a91baa-b174-45fa-b323-632b736f15fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_66a91baa-b174-45fa-b323-632b736f15fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_66a91baa-b174-45fa-b323-632b736f15fc" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_66a91baa-b174-45fa-b323-632b736f15fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f05fe81a-3d94-4edc-9491-5d0062719cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_66a91baa-b174-45fa-b323-632b736f15fc" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f05fe81a-3d94-4edc-9491-5d0062719cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember_2e9aefdb-0ff9-42f1-b967-70959402c0ec" xlink:href="bngo-20211231.xsd#bngo_EscrowedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f05fe81a-3d94-4edc-9491-5d0062719cc6" xlink:to="loc_bngo_EscrowedSharesMember_2e9aefdb-0ff9-42f1-b967-70959402c0ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsAcquisitionPurchasePriceDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails" xlink:type="extended" id="ia5ed31bc7d4743c2ae1359566f6e1331_AcquisitionsAcquisitionPurchasePriceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cd92819-bb4b-4bc8-a49d-a3b82dac5cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cd92819-bb4b-4bc8-a49d-a3b82dac5cc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_9386c698-7109-421d-bfb9-4e926538ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_9386c698-7109-421d-bfb9-4e926538ac3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59a96614-535f-424d-b068-da93ef3459c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59a96614-535f-424d-b068-da93ef3459c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_83474ee8-02e6-4a05-9150-1be544f2a4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_83474ee8-02e6-4a05-9150-1be544f2a4c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_4a786456-8a26-4477-b185-dabed29e91c7" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_4a786456-8a26-4477-b185-dabed29e91c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_c878d363-e051-4723-9510-d5da86245503" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_c878d363-e051-4723-9510-d5da86245503" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_21c5d808-d9c8-454c-a6c9-71e2857a481e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_21c5d808-d9c8-454c-a6c9-71e2857a481e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c40d9b63-1dc0-4b5f-a5fc-e98322d3e2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c40d9b63-1dc0-4b5f-a5fc-e98322d3e2dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_36ee3160-0e78-4ec6-b443-c1b9bf7295c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_36ee3160-0e78-4ec6-b443-c1b9bf7295c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8fe7a5b-cbae-4b7b-b13c-6fb409dcf635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8fe7a5b-cbae-4b7b-b13c-6fb409dcf635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_df11280c-7e92-41e5-8b0c-65b7e0d30191" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8fe7a5b-cbae-4b7b-b13c-6fb409dcf635" xlink:to="loc_bngo_LineagenMember_df11280c-7e92-41e5-8b0c-65b7e0d30191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_ab6ba2e6-3f95-48c5-8b41-dff6b2a0897f" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8fe7a5b-cbae-4b7b-b13c-6fb409dcf635" xlink:to="loc_bngo_BioDiscoveryMember_ab6ba2e6-3f95-48c5-8b41-dff6b2a0897f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_67e9c9e2-cf3c-4335-a908-26c90b96a05b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_67e9c9e2-cf3c-4335-a908-26c90b96a05b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_67e9c9e2-cf3c-4335-a908-26c90b96a05b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_67e9c9e2-cf3c-4335-a908-26c90b96a05b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_67e9c9e2-cf3c-4335-a908-26c90b96a05b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b6991feb-87c1-45e1-abe3-48c79e52dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_67e9c9e2-cf3c-4335-a908-26c90b96a05b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b6991feb-87c1-45e1-abe3-48c79e52dd60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember_ab760d05-acab-4460-ae37-7e0df312ded5" xlink:href="bngo-20211231.xsd#bngo_EscrowedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b6991feb-87c1-45e1-abe3-48c79e52dd60" xlink:to="loc_bngo_EscrowedSharesMember_ab760d05-acab-4460-ae37-7e0df312ded5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ib8b7ab6cad1d4a78ad06d318bf07b889_AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d219d8d2-9564-4381-b14e-75d9a0c9aa44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d219d8d2-9564-4381-b14e-75d9a0c9aa44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9253f58d-8c4f-4b96-8fde-4a99b5ddaa97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9253f58d-8c4f-4b96-8fde-4a99b5ddaa97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2cc54012-7263-45f1-a6c1-8c1e48866b4a" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2cc54012-7263-45f1-a6c1-8c1e48866b4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f22e1fac-d6c1-40f2-aa95-a7dd0de48f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f22e1fac-d6c1-40f2-aa95-a7dd0de48f16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d07847e1-350a-4af5-b2bd-5f045ade6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d07847e1-350a-4af5-b2bd-5f045ade6a7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a49a2406-97ff-4950-8164-3968eb08d706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a49a2406-97ff-4950-8164-3968eb08d706" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8206c832-c35a-4c0c-b077-3f4afa3fbc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8206c832-c35a-4c0c-b077-3f4afa3fbc76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_41206614-1d67-4805-9112-49e7d3581763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_Goodwill_41206614-1d67-4805-9112-49e7d3581763" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_2824e453-e71b-4811-8386-5285963c432f" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_2824e453-e71b-4811-8386-5285963c432f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_cea1481a-c26e-4701-9b29-94ace6500bf0" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_cea1481a-c26e-4701-9b29-94ace6500bf0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e9465554-8ca8-43a6-92b4-18588aa992fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e9465554-8ca8-43a6-92b4-18588aa992fd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4d535430-3b0f-43a1-9f3e-64d5e892390f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4d535430-3b0f-43a1-9f3e-64d5e892390f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4485566d-f55a-473f-a5f0-cb788c5c4c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4485566d-f55a-473f-a5f0-cb788c5c4c10" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_53bfb226-9a4a-49e9-b1c4-9d30ab3087ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_53bfb226-9a4a-49e9-b1c4-9d30ab3087ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_53bfb226-9a4a-49e9-b1c4-9d30ab3087ed" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_231d27ca-325d-4cc5-869e-51d3b074999b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_231d27ca-325d-4cc5-869e-51d3b074999b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_a4145df5-a90e-4dee-8846-72a03ea85974" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_231d27ca-325d-4cc5-869e-51d3b074999b" xlink:to="loc_bngo_BioDiscoveryMember_a4145df5-a90e-4dee-8846-72a03ea85974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_680d1249-7fe4-433a-8b37-642f3308addb" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_231d27ca-325d-4cc5-869e-51d3b074999b" xlink:to="loc_bngo_LineagenMember_680d1249-7fe4-433a-8b37-642f3308addb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails" xlink:type="extended" id="iec7174001ec34fd3808a3270b6c19c60_AcquisitionsIdentifiableIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cf58a6b7-48c5-4d3b-a06d-f7ef402d8450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_93889daf-833d-40fb-9c16-ca85f4e0c12e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf58a6b7-48c5-4d3b-a06d-f7ef402d8450" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_93889daf-833d-40fb-9c16-ca85f4e0c12e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d7181ac3-db12-4395-873a-0e0da2d7e0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf58a6b7-48c5-4d3b-a06d-f7ef402d8450" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d7181ac3-db12-4395-873a-0e0da2d7e0fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf58a6b7-48c5-4d3b-a06d-f7ef402d8450" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0f6bcf36-5adf-4b17-a2e4-6f56391669ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0f6bcf36-5adf-4b17-a2e4-6f56391669ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f6bcf36-5adf-4b17-a2e4-6f56391669ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f6bcf36-5adf-4b17-a2e4-6f56391669ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f6bcf36-5adf-4b17-a2e4-6f56391669ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ac303f0-0c8b-45e3-82fe-7277504c1f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f6bcf36-5adf-4b17-a2e4-6f56391669ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ac303f0-0c8b-45e3-82fe-7277504c1f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_32903073-ae98-4801-8f12-3a8a2783cb17" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ac303f0-0c8b-45e3-82fe-7277504c1f93" xlink:to="loc_bngo_LineagenMember_32903073-ae98-4801-8f12-3a8a2783cb17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_2c76c5d3-a7b5-45bd-85e9-47f5f59aec27" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ac303f0-0c8b-45e3-82fe-7277504c1f93" xlink:to="loc_bngo_BioDiscoveryMember_2c76c5d3-a7b5-45bd-85e9-47f5f59aec27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_975f45eb-c1f7-433c-81eb-203b161ac069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_975f45eb-c1f7-433c-81eb-203b161ac069" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_975f45eb-c1f7-433c-81eb-203b161ac069_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_975f45eb-c1f7-433c-81eb-203b161ac069" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_975f45eb-c1f7-433c-81eb-203b161ac069_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_975f45eb-c1f7-433c-81eb-203b161ac069" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1e713d9f-94e2-4fc7-be7f-662aa72ce2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1e713d9f-94e2-4fc7-be7f-662aa72ce2bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_013950ee-ac7e-46f9-a4df-e2c25ef88d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_013950ee-ac7e-46f9-a4df-e2c25ef88d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_22f2501b-5df1-4c13-9855-ea94daa136ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:to="loc_us-gaap_TradeNamesMember_22f2501b-5df1-4c13-9855-ea94daa136ac" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="extended" id="ic579ac258e694319b6592994b72545ad_AcquisitionsProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_3a3913ff-373a-4322-bdcf-607cca16a876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_3a3913ff-373a-4322-bdcf-607cca16a876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b602ad88-5866-4a48-a1e4-9c8a4b894af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b602ad88-5866-4a48-a1e4-9c8a4b894af3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_766e9d5f-2546-4509-b5e6-4472c33e75c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_766e9d5f-2546-4509-b5e6-4472c33e75c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_cc4d8623-cd80-447d-951c-3dad09a9ecdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_cc4d8623-cd80-447d-951c-3dad09a9ecdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95cf620d-f2c2-4f6e-bea3-9c24d2719a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95cf620d-f2c2-4f6e-bea3-9c24d2719a2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_51688afb-25e3-434d-a7e9-7a6026bf6671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95cf620d-f2c2-4f6e-bea3-9c24d2719a2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_51688afb-25e3-434d-a7e9-7a6026bf6671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51688afb-25e3-434d-a7e9-7a6026bf6671_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51688afb-25e3-434d-a7e9-7a6026bf6671" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51688afb-25e3-434d-a7e9-7a6026bf6671_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e40d9eba-ea9e-49f9-9249-12a04416b2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51688afb-25e3-434d-a7e9-7a6026bf6671" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e40d9eba-ea9e-49f9-9249-12a04416b2ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_9eb78e9e-4015-47ee-aa31-a26950344a09" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e40d9eba-ea9e-49f9-9249-12a04416b2ae" xlink:to="loc_bngo_BioDiscoveryMember_9eb78e9e-4015-47ee-aa31-a26950344a09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://bionanogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i88d179e481644bc29ef3d626edf45a82_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5c04491e-96aa-4843-ade2-867e7159ae31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseExpense_b8b1d2c0-ff75-4616-945f-53e1fae15d36" xlink:href="bngo-20211231.xsd#bngo_FinanceLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c04491e-96aa-4843-ade2-867e7159ae31" xlink:to="loc_bngo_FinanceLeaseExpense_b8b1d2c0-ff75-4616-945f-53e1fae15d36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_431fbf76-fcf6-4e34-b59c-9f00f8469904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c04491e-96aa-4843-ade2-867e7159ae31" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_431fbf76-fcf6-4e34-b59c-9f00f8469904" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24938a20-ba37-4e67-98c5-34cb1d3f8895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_431fbf76-fcf6-4e34-b59c-9f00f8469904" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24938a20-ba37-4e67-98c5-34cb1d3f8895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_24938a20-ba37-4e67-98c5-34cb1d3f8895_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24938a20-ba37-4e67-98c5-34cb1d3f8895" xlink:to="loc_us-gaap_RelatedPartyDomain_24938a20-ba37-4e67-98c5-34cb1d3f8895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_269b7f1c-67df-45c8-af31-3a5d2232249c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24938a20-ba37-4e67-98c5-34cb1d3f8895" xlink:to="loc_us-gaap_RelatedPartyDomain_269b7f1c-67df-45c8-af31-3a5d2232249c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_dc5b5712-f47c-4d19-bbad-fbdc5171206a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_269b7f1c-67df-45c8-af31-3a5d2232249c" xlink:to="loc_srt_AffiliatedEntityMember_dc5b5712-f47c-4d19-bbad-fbdc5171206a" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>bngo-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e3db6ed1-8b4e-4b22-9c48-82142796368a,g:231d39e4-2c00-4236-9c0c-64cfa873dbdc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember_26fb8fcb-7cca-454a-bf93-6c33c70b7503_terseLabel_en-US" xlink:label="lab_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized for future stock awards, option grants, or employee stock purchase program</link:label>
    <link:label id="lab_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember_label_en-US" xlink:label="lab_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized For Future Stock Awards Option Grants Or Employee Stock Purchase Program [Member]</link:label>
    <link:label id="lab_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember_documentation_en-US" xlink:label="lab_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized for future stock awards, option grants, or employee stock purchase program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember" xlink:href="bngo-20211231.xsd#bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember" xlink:to="lab_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_9a79da99-4b99-42ce-98b6-23bea05b5b02_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant and option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b51abb03-c361-4dc8-a363-7059ad288d47_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_82450996-878c-4e1d-9451-25da279e136a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_AccruedInventoryCurrent_2b1df346-018f-4a4f-91f3-0ff2e8252257_terseLabel_en-US" xlink:label="lab_bngo_AccruedInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods received not invoiced</link:label>
    <link:label id="lab_bngo_AccruedInventoryCurrent_label_en-US" xlink:label="lab_bngo_AccruedInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory, Current</link:label>
    <link:label id="lab_bngo_AccruedInventoryCurrent_documentation_en-US" xlink:label="lab_bngo_AccruedInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AccruedInventoryCurrent" xlink:href="bngo-20211231.xsd#bngo_AccruedInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_AccruedInventoryCurrent" xlink:to="lab_bngo_AccruedInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5a685a3f-78b1-4d73-add4-c02a394c5cf2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b704c912-f1f8-48eb-b954-d451a9f4d5c7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0209fae2-1eae-4c93-8c7e-aff341a29f6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_e9cc54b6-cf7a-464c-80c0-7296275bfdd6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fff391f-846b-4689-86c9-ab8a060f3d96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_fc0dec31-031f-4e46-a926-078f9b106c78_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3b52646d-6ad6-454c-9737-de4a73637ed8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_9cff77f8-79c9-43f9-8177-944b5d1999bd_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod_461d5ee9-2ed6-46d3-a5b1-1e2896bab053_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (USD per share)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Canceled In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Canceled In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c956a127-7bc7-4387-bf6b-42a6ec53325b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4c5f3387-dc1e-4b01-98fe-a0587717da0c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_4013f19f-37ac-4787-821f-6703d5176e63_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:to="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_460447fc-8b10-4a40-841c-e89db4e1bc9d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_d8093bf5-c3ab-454c-9e68-8379accf1a8b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_593476a3-a06f-4f8a-97f4-80f19ab151ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e2a1853c-6466-4209-87f3-7fbea2c2aaa5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9042e7d7-f9ad-44e6-81d3-c5704e4bf10f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_31711d82-6abf-41ea-80b5-83b2a1bda064_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_1e026bf9-166b-405a-b6c8-6076b3d66c15_negatedTerseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use liabilities (short-term and long-term)</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_label_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Liability</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" xlink:to="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_794c5b9b-33e7-477d-8059-3dc9f3485100_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0f5a8fcc-7f95-440c-8141-3c57f7220021_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6fbc55e4-ee38-4eb5-834a-6dff52e21da9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_b01f5556-bc8c-40c7-a61a-2afd1c01d9e5_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter_7119cc2f-f195-4f03-9c93-b31ec7053fc5_terseLabel_en-US" xlink:label="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter_label_en-US" xlink:label="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years and Thereafter</link:label>
    <link:label id="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter_documentation_en-US" xlink:label="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years and Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" xlink:href="bngo-20211231.xsd#bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" xlink:to="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_WarrantsToPurchaseSharesIssued_9b5fdf33-1872-467e-b99c-c88ff0145592_terseLabel_en-US" xlink:label="lab_bngo_WarrantsToPurchaseSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase shares issued (shares)</link:label>
    <link:label id="lab_bngo_WarrantsToPurchaseSharesIssued_label_en-US" xlink:label="lab_bngo_WarrantsToPurchaseSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants To Purchase Shares Issued</link:label>
    <link:label id="lab_bngo_WarrantsToPurchaseSharesIssued_documentation_en-US" xlink:label="lab_bngo_WarrantsToPurchaseSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase shares issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantsToPurchaseSharesIssued" xlink:href="bngo-20211231.xsd#bngo_WarrantsToPurchaseSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_WarrantsToPurchaseSharesIssued" xlink:to="lab_bngo_WarrantsToPurchaseSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_04dc66b0-13a7-4209-8931-7b885dd62dc2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_GainLossOnExtinguishmentOfDebtCashExpense_2d4e66c3-1cf2-4b36-8057-713c34a62410_negatedLabel_en-US" xlink:label="lab_bngo_GainLossOnExtinguishmentOfDebtCashExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_bngo_GainLossOnExtinguishmentOfDebtCashExpense_label_en-US" xlink:label="lab_bngo_GainLossOnExtinguishmentOfDebtCashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Cash Expense</link:label>
    <link:label id="lab_bngo_GainLossOnExtinguishmentOfDebtCashExpense_documentation_en-US" xlink:label="lab_bngo_GainLossOnExtinguishmentOfDebtCashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Cash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnExtinguishmentOfDebtCashExpense" xlink:href="bngo-20211231.xsd#bngo_GainLossOnExtinguishmentOfDebtCashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_GainLossOnExtinguishmentOfDebtCashExpense" xlink:to="lab_bngo_GainLossOnExtinguishmentOfDebtCashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cd96966f-e18f-4e6a-817f-4bc43839e374_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ed80f26a-581a-457d-9e2c-ab0ca44c680c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_b92528fa-1cb0-4568-b897-c75627b62863_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEIA</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d11bc127-bac2-4a74-b948-c8ffe583967e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_25987a7a-b601-462d-8c9c-f715f4a3344f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f983a54c-f70d-4452-a5d7-fb409e76e8ce_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_89c7c704-4fae-47ef-9191-abbdb5be53e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3eb09175-0706-4d32-8a44-5dfe1d8b941d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dac3381-da0f-40d3-bbfe-6ba3a5084a88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bf8e1295-31ae-4e1b-bcb2-fca9a146f9ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_d2ea015a-fb48-4284-b217-0b997c93838f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5f745952-05b8-4e96-98d4-fe4ae6d5aebb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_a649e493-b976-42ab-9bac-577582835228_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_05e25573-e6c2-463c-a917-07b2ea710a26_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3b766907-7d55-4f66-8e54-3fd32cf65807_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommonStockWarrantsAmendedAgreementMember_57ad5ba9-92c9-493d-9af2-4f52b84981e4_terseLabel_en-US" xlink:label="lab_bngo_CommonStockWarrantsAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Amended Agreement</link:label>
    <link:label id="lab_bngo_CommonStockWarrantsAmendedAgreementMember_label_en-US" xlink:label="lab_bngo_CommonStockWarrantsAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Amended Agreement [Member]</link:label>
    <link:label id="lab_bngo_CommonStockWarrantsAmendedAgreementMember_documentation_en-US" xlink:label="lab_bngo_CommonStockWarrantsAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Amended Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockWarrantsAmendedAgreementMember" xlink:href="bngo-20211231.xsd#bngo_CommonStockWarrantsAmendedAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommonStockWarrantsAmendedAgreementMember" xlink:to="lab_bngo_CommonStockWarrantsAmendedAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_291ff639-bb4e-496b-9b03-43a79ae67cfa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DeferredTaxLiabilitiesAmortization_7041fac1-cfe3-49ab-ae00-f1bb800ef7d4_negatedTerseLabel_en-US" xlink:label="lab_bngo_DeferredTaxLiabilitiesAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_bngo_DeferredTaxLiabilitiesAmortization_label_en-US" xlink:label="lab_bngo_DeferredTaxLiabilitiesAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Amortization</link:label>
    <link:label id="lab_bngo_DeferredTaxLiabilitiesAmortization_documentation_en-US" xlink:label="lab_bngo_DeferredTaxLiabilitiesAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxLiabilitiesAmortization" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxLiabilitiesAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DeferredTaxLiabilitiesAmortization" xlink:to="lab_bngo_DeferredTaxLiabilitiesAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_58589a90-8c5b-49b4-bd12-63b7e2ea1568_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8ac844c0-13e8-4de0-b0c0-02ea948237b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_d0b4ea22-550b-4399-86fe-b9d79bfe5a17_negatedTerseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Canceled In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Canceled In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c2b7b599-70fb-4d1e-8970-b8d5c8d5dbf0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_514da5d6-26fb-4a09-815a-d2fb6601734b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c5809802-afb5-458d-bc62-d3d42a61a92e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_dcfdc553-d8e5-49a8-aeca-f3a2425d439e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_743b63f6-8d14-4dc8-ae87-36c58041fcb9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8425af5c-d3f4-4863-8cf3-f69868b304ff_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3e85c209-298e-4ce2-9397-e04806cf6468_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions/(reductions) for tax positions - prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_0d446171-4965-43c8-97c6-ab1bb3e0626a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_9a41e182-2770-4c42-9987-e04484e9d9da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ServiceEquipmentMember_e16ed559-ffc3-4aba-9502-dfc2fd2b36d0_terseLabel_en-US" xlink:label="lab_bngo_ServiceEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service equipment placed at customer sites</link:label>
    <link:label id="lab_bngo_ServiceEquipmentMember_label_en-US" xlink:label="lab_bngo_ServiceEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Equipment [Member]</link:label>
    <link:label id="lab_bngo_ServiceEquipmentMember_documentation_en-US" xlink:label="lab_bngo_ServiceEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service equipment placed at customer sites.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ServiceEquipmentMember" xlink:href="bngo-20211231.xsd#bngo_ServiceEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ServiceEquipmentMember" xlink:to="lab_bngo_ServiceEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServicingLiabilityMeasurementInput_81cd6cb5-686b-4f10-bf55-4ba4de6075a3_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_ServicingLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_ServicingLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servicing Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServicingLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingLiabilityMeasurementInput" xlink:to="lab_us-gaap_ServicingLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_534718b3-a5f9-470f-b4dd-2c9314f312a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e934e4ce-c47d-419c-a31c-998fa0c0a1a8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_53a5b6c1-cfc1-4815-a22b-bfe325d15084_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fb26b96f-d941-43d8-930a-620901f0c791_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_14d7875d-0a23-4d28-89a0-f0efcd6a4175_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_8dfa8ace-732a-458f-a681-4ddcf189f1bd_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_UnvestedRestrictedStockMember_29bfe30b-228c-4591-a504-5bdf2c1807c6_terseLabel_en-US" xlink:label="lab_bngo_UnvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_bngo_UnvestedRestrictedStockMember_label_en-US" xlink:label="lab_bngo_UnvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:label id="lab_bngo_UnvestedRestrictedStockMember_documentation_en-US" xlink:label="lab_bngo_UnvestedRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_UnvestedRestrictedStockMember" xlink:href="bngo-20211231.xsd#bngo_UnvestedRestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_UnvestedRestrictedStockMember" xlink:to="lab_bngo_UnvestedRestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9b8fddf4-333b-4b23-8ed6-b7aa88c31cb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a70fddab-2b1a-4de1-9316-37773a4a0ce9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_8241dd6d-1c9b-49a9-9510-df01273fe193_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_39b893f0-17e4-4100-99b4-0b6a7f58bbca_negatedTerseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Exercised In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Exercised In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_f8547e67-5011-4cd1-841e-c0bce92dfb48_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ContingentConsiderationNoncash_b479bcfc-607d-49e4-9f09-c52b18cfe3a5_terseLabel_en-US" xlink:label="lab_bngo_ContingentConsiderationNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration related to BioDiscovery acquisition</link:label>
    <link:label id="lab_bngo_ContingentConsiderationNoncash_label_en-US" xlink:label="lab_bngo_ContingentConsiderationNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Noncash</link:label>
    <link:label id="lab_bngo_ContingentConsiderationNoncash_documentation_en-US" xlink:label="lab_bngo_ContingentConsiderationNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationNoncash" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ContingentConsiderationNoncash" xlink:to="lab_bngo_ContingentConsiderationNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_881362d1-d769-46ce-a9a9-47b31bc24d8a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_723e2280-a678-4d49-97bc-43226fcb2a24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_823a3e8b-0798-434f-8a9f-54cc14bc71dc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7e9cfd86-7ba5-4052-974e-39c604e81831_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c6efdeb6-9ae5-4588-8cea-c66b39f8bb14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value &#160;</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_0637f130-cfcd-4f1d-8286-3eb8a10f3f16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyExpense_505e18ab-202a-41cc-8da3-5cb6f6de4fee_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty expense</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyExpense_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyExpense" xlink:to="lab_us-gaap_ProductWarrantyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82aece88-2e04-4bb2-a681-f1338312c5b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a4f46fe3-412e-4aa3-89a9-74b02f490f51_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_89edec65-783b-4c12-964b-ea3804962c49_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_2f2901c0-3be9-424b-84f8-5445123b5f29_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December&#160;31, 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DeferredTaxLiabilitiesRightOfUseAsset_d9c152e4-bedb-4c21-bd3a-864b5cfe0589_negatedTerseLabel_en-US" xlink:label="lab_bngo_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 842 - ROU asset</link:label>
    <link:label id="lab_bngo_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_bngo_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-Use Asset</link:label>
    <link:label id="lab_bngo_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_bngo_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_bngo_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f10e5fba-e10f-4e4c-800f-499c70fd4b44_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_983f7a44-94e2-4658-8b12-57480645df95_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_acf444ac-ebec-4045-8184-e39322432194_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per unit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_e5d04649-0e12-4bab-af6c-a98da4ad0512_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6597ed35-147c-4e51-91f7-128e3e492a31_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ContingentConsiderationMilestonePayment_d177cd4e-a465-49cb-9be3-0eadaf205eea_terseLabel_en-US" xlink:label="lab_bngo_ContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_bngo_ContingentConsiderationMilestonePayment_label_en-US" xlink:label="lab_bngo_ContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Milestone Payment</link:label>
    <link:label id="lab_bngo_ContingentConsiderationMilestonePayment_documentation_en-US" xlink:label="lab_bngo_ContingentConsiderationMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationMilestonePayment" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ContingentConsiderationMilestonePayment" xlink:to="lab_bngo_ContingentConsiderationMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e0c6ab40-be35-4a8d-9f60-82519c65d320_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_842df3f3-2c0f-48bc-973f-3867bb54c246_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_2d676c7e-239d-4df2-acb9-857f7d843892_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ContingentConsiderationPolicyTextBlock_a4fca6a6-4d8b-403f-bcd2-5c70cb6f1dee_terseLabel_en-US" xlink:label="lab_bngo_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_bngo_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_bngo_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_bngo_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_bngo_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationPolicyTextBlock" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ContingentConsiderationPolicyTextBlock" xlink:to="lab_bngo_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a709d5c9-b7ba-41b8-a6f4-cf7fd1e02ed9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CowenMember_9fd1d515-2939-4408-848d-b3f3d6f82fe2_terseLabel_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen</link:label>
    <link:label id="lab_bngo_CowenMember_label_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen [Member]</link:label>
    <link:label id="lab_bngo_CowenMember_documentation_en-US" xlink:label="lab_bngo_CowenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember" xlink:href="bngo-20211231.xsd#bngo_CowenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CowenMember" xlink:to="lab_bngo_CowenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1209dafd-3846-4a82-9539-9aa5ea8eaa3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3512054c-5112-4df8-a6d9-287bf1b217b9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_9608fdf7-9843-4a4d-a9be-21eb320e6aec_terseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_label_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:to="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0937b819-d82e-4369-b637-9b1cbe4cb4f0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_f09a754c-6b95-4596-b20f-c2c750a09c5a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to original purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4aaa3c75-e7ba-4ca9-afe1-5c948038c202_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities resulting from obtaining and modifying right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_61266fd9-cd89-4d71-9579-594d2f12bc37_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e3b66e09-7727-46b3-ab7d-d9f468d6436b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_12dfe632-c38e-416f-be56-52a537c66291_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_eb145abf-f983-4aaf-8c73-a4630b76dbb3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_502e86f3-fc09-477c-9376-8d89d203ebcb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19d45530-3c93-42ed-9dc9-d07b923a4974_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_ddd6e616-c41b-41c0-a7a7-177be4f444b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of financing lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_de737c5d-b3d2-4b3a-a45c-30a481a7ca8c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of financing lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_InnovatusTerm3LoanMember_8e19d721-c6e3-4b22-8aab-e6b0f6fb52f6_terseLabel_en-US" xlink:label="lab_bngo_InnovatusTerm3LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Term 3 Loan</link:label>
    <link:label id="lab_bngo_InnovatusTerm3LoanMember_label_en-US" xlink:label="lab_bngo_InnovatusTerm3LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Term 3 Loan [Member]</link:label>
    <link:label id="lab_bngo_InnovatusTerm3LoanMember_documentation_en-US" xlink:label="lab_bngo_InnovatusTerm3LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Term 3 Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusTerm3LoanMember" xlink:href="bngo-20211231.xsd#bngo_InnovatusTerm3LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_InnovatusTerm3LoanMember" xlink:to="lab_bngo_InnovatusTerm3LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_e2172dcd-d7fa-4107-8542-0aa9486f497f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_054ab444-2a33-4b4d-8fce-5c36d7834d4b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TwoThousandAndTwentyInducementPlanMember_e15c0bf7-872d-4cbd-b191-61711442bcee_terseLabel_en-US" xlink:label="lab_bngo_TwoThousandAndTwentyInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Inducement Plan</link:label>
    <link:label id="lab_bngo_TwoThousandAndTwentyInducementPlanMember_label_en-US" xlink:label="lab_bngo_TwoThousandAndTwentyInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand and Twenty Inducement Plan [Member]</link:label>
    <link:label id="lab_bngo_TwoThousandAndTwentyInducementPlanMember_documentation_en-US" xlink:label="lab_bngo_TwoThousandAndTwentyInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand and Twenty Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoThousandAndTwentyInducementPlanMember" xlink:href="bngo-20211231.xsd#bngo_TwoThousandAndTwentyInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TwoThousandAndTwentyInducementPlanMember" xlink:to="lab_bngo_TwoThousandAndTwentyInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_d0e6c029-6055-4300-8f47-14976d189f3b_terseLabel_en-US" xlink:label="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Payments</link:label>
    <link:label id="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_label_en-US" xlink:label="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity Net [Abstract]</link:label>
    <link:label id="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_documentation_en-US" xlink:label="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract" xlink:href="bngo-20211231.xsd#bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract" xlink:to="lab_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_79a54fb2-8d21-4d1b-9447-56f981f20e8b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f2dd0397-4c5a-4a46-a836-84dc122a3c46_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_55d85ac6-a07f-4440-90e0-cd1cf6bcee79_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contracts with Customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_8b801cfa-a1e4-419d-aebe-ca0ff8630224_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_67835fd9-5eea-4a0a-ac4f-d8ba0dab16d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock_43eb9b0f-726f-4f7a-888b-c4a4e7d64379_terseLabel_en-US" xlink:label="lab_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:label id="lab_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock_documentation_en-US" xlink:label="lab_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="bngo-20211231.xsd#bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="lab_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_84980dbd-3cbb-4784-bfd5-6614f3995ad0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c303480b-1f12-44ff-acf7-fb689c65fda7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_faffb01b-875a-4d77-9d10-8fe9510fb90b_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b19834db-de53-479b-bf66-3c3fb559fbd2_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentInterestRateCashRate_8e20b85a-a5a7-468a-8958-bc67eb4ec882_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateCashRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash rate</link:label>
    <link:label id="lab_bngo_DebtInstrumentInterestRateCashRate_label_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateCashRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Cash Rate</link:label>
    <link:label id="lab_bngo_DebtInstrumentInterestRateCashRate_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateCashRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Cash Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateCashRate" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentInterestRateCashRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentInterestRateCashRate" xlink:to="lab_bngo_DebtInstrumentInterestRateCashRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3f1b0000-5012-4946-85cd-974b424800f6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember_d9f8a8a0-418c-4876-8a93-b012cc913e11_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period One [Member]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:to="lab_bngo_DebtInstrumentPaymentTermsPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1cdf0c1a-9964-42f1-959d-017164c8921d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_560ea26d-0275-4ed8-9b11-135decbfa486_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_12a8d701-e809-42ea-9f21-7bc8564f73ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5e2e1678-0b79-46d0-abd4-b74e25f6223c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_3f609a0e-a7c1-4406-bdaa-712b2a339d1d_terseLabel_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fee</link:label>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_label_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Fee, Maximum Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission Fee, Maximum Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:href="bngo-20211231.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:to="lab_bngo_CommissionFeeMaximumPercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d0e1dbff-fcdf-4420-b75d-7337f64bea18_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9b409740-23f2-4cd7-8f58-358b96433ca4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_f53376ba-45c2-46fb-8028-69fd568c0765_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsDomain_3405be36-9ded-4cad-be59-257ac10b772e_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsDomain_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Domain]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsDomain_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Debt Instrument, Payment Terms [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsDomain" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain" xlink:to="lab_bngo_DebtInstrumentPaymentTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_496d357b-9020-405e-b970-e6503333bff8_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of bad debt expense</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_e22b90dd-3335-48a2-b49b-b2c2854e0bc8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIK</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_24ea1758-e167-466b-a429-aaffd6668964_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_92595920-0fcb-4e3e-96b2-448abc1eb607_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_9f8720cc-270f-4757-bd7d-451d55511cc8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_7bcab204-70d9-4d97-9039-04beb4f5462d_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_2a7aedb8-b97b-4d58-97aa-fde9ff452837_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommonWarrantsMember_4b4c87d5-0bec-4d83-bab8-4f2949255ca5_terseLabel_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common warrants</link:label>
    <link:label id="lab_bngo_CommonWarrantsMember_label_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Warrants [Member]</link:label>
    <link:label id="lab_bngo_CommonWarrantsMember_documentation_en-US" xlink:label="lab_bngo_CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember" xlink:href="bngo-20211231.xsd#bngo_CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommonWarrantsMember" xlink:to="lab_bngo_CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_57f7cdba-e16f-46c1-930b-7ebe99f794fb_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_IssueCommonStockForCovenantWaiver_6b93ac8e-d2c6-4e60-a373-12156cd83e52_terseLabel_en-US" xlink:label="lab_bngo_IssueCommonStockForCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for covenant waiver</link:label>
    <link:label id="lab_bngo_IssueCommonStockForCovenantWaiver_label_en-US" xlink:label="lab_bngo_IssueCommonStockForCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Common Stock For Covenant Waiver</link:label>
    <link:label id="lab_bngo_IssueCommonStockForCovenantWaiver_documentation_en-US" xlink:label="lab_bngo_IssueCommonStockForCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Common Stock For Covenant Waiver</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_IssueCommonStockForCovenantWaiver" xlink:href="bngo-20211231.xsd#bngo_IssueCommonStockForCovenantWaiver"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_IssueCommonStockForCovenantWaiver" xlink:to="lab_bngo_IssueCommonStockForCovenantWaiver" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_0474550c-4dbd-4c59-a453-b0e5ff75a63d_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1f88a5c8-d09a-4702-91bf-39324dd6fa66_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3428d1ef-f91a-4724-b1f3-d32d7539b098_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_97d54b45-aed9-4643-8ca3-6ba9b62d52d9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets, related party</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_cd5a2f48-410a-4a76-a70d-07f476c2b3d0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0d41b41c-ff84-4e52-bfd8-f3f285811a00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a564bcfd-baba-49ae-9420-096607d66e71_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0922198d-d4ac-4742-afcc-5ab4a1f05038_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_910d4a72-c63a-43bb-a812-143df2e2164c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommonStockWarrantsOriginalAgreementMember_136518d2-6a4c-4eec-a249-ae092c722c78_terseLabel_en-US" xlink:label="lab_bngo_CommonStockWarrantsOriginalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Original Agreement</link:label>
    <link:label id="lab_bngo_CommonStockWarrantsOriginalAgreementMember_label_en-US" xlink:label="lab_bngo_CommonStockWarrantsOriginalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Original Agreement [Member]</link:label>
    <link:label id="lab_bngo_CommonStockWarrantsOriginalAgreementMember_documentation_en-US" xlink:label="lab_bngo_CommonStockWarrantsOriginalAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Original Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockWarrantsOriginalAgreementMember" xlink:href="bngo-20211231.xsd#bngo_CommonStockWarrantsOriginalAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommonStockWarrantsOriginalAgreementMember" xlink:to="lab_bngo_CommonStockWarrantsOriginalAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ace5d764-983a-4810-956e-adad204df3ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0367b8eb-b7ca-40a6-906a-8e9c371b1835_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6958e8a2-269c-495e-b0db-da90f20aedb1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d9ad7e42-8f29-49c2-9f5a-c56731784487_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TermA1LoanMember_e7741501-eb07-4807-a498-463bac89f8ef_terseLabel_en-US" xlink:label="lab_bngo_TermA1LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-1 Loan</link:label>
    <link:label id="lab_bngo_TermA1LoanMember_label_en-US" xlink:label="lab_bngo_TermA1LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-1 Loan [Member]</link:label>
    <link:label id="lab_bngo_TermA1LoanMember_documentation_en-US" xlink:label="lab_bngo_TermA1LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-1 Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA1LoanMember" xlink:href="bngo-20211231.xsd#bngo_TermA1LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TermA1LoanMember" xlink:to="lab_bngo_TermA1LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ProceedsFromPayrollProtectionProgramLoan_0baf22c2-c59b-4b87-99d2-1dc0fb23b720_terseLabel_en-US" xlink:label="lab_bngo_ProceedsFromPayrollProtectionProgramLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from PPP Loan</link:label>
    <link:label id="lab_bngo_ProceedsFromPayrollProtectionProgramLoan_label_en-US" xlink:label="lab_bngo_ProceedsFromPayrollProtectionProgramLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Payroll Protection Program Loan</link:label>
    <link:label id="lab_bngo_ProceedsFromPayrollProtectionProgramLoan_documentation_en-US" xlink:label="lab_bngo_ProceedsFromPayrollProtectionProgramLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Payroll Protection Program Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProceedsFromPayrollProtectionProgramLoan" xlink:href="bngo-20211231.xsd#bngo_ProceedsFromPayrollProtectionProgramLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ProceedsFromPayrollProtectionProgramLoan" xlink:to="lab_bngo_ProceedsFromPayrollProtectionProgramLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_beaf59db-e30a-4941-a832-a4f024f4f253_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to current year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_c29cba6b-b0e7-4e15-8e19-b6d2b3a50b05_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7961eca1-c7a8-419a-af0c-5a3a94a3d8d2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_75c6c525-07c7-4a3f-a0bb-117dcdab7a05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_ab09ea1f-a724-465d-8c1c-4701f6adab17_terseLabel_en-US" xlink:label="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of Paycheck Protection Program Loan</link:label>
    <link:label id="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_f06bae28-662b-4c5c-8f45-b52d250015bc_negatedTerseLabel_en-US" xlink:label="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of PPP Loan</link:label>
    <link:label id="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_ac748b52-f292-46ab-989d-1c96a30c51a3_verboseLabel_en-US" xlink:label="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP Loan</link:label>
    <link:label id="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_label_en-US" xlink:label="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Forgiveness Of Paycheck Protection Program Loan</link:label>
    <link:label id="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_documentation_en-US" xlink:label="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Forgiveness Of Paycheck Protection Program Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:to="lab_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e3f5c186-f32b-4071-ade0-d5f0901158ad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_e36110b0-8ba8-4e58-9584-b9383a859f1f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ce40b096-f1c0-4f84-a842-9c134819cc7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesCovenantWaiver_391c0850-17f3-4400-bdeb-b211d9bc65d1_terseLabel_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for covenant waiver (in shares)</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesCovenantWaiver_label_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Covenant Waiver</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesCovenantWaiver_documentation_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Covenant Waiver</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesCovenantWaiver" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodSharesCovenantWaiver"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_StockIssuedDuringPeriodSharesCovenantWaiver" xlink:to="lab_bngo_StockIssuedDuringPeriodSharesCovenantWaiver" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82e9ac88-acbb-409f-be9f-9fb0e1c355ca_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_83142c1d-1297-45d4-8cdc-c5f69a190701_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d35ff07f-75e1-40c6-ae23-ccc55f9d622b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4712ff1c-fad1-4d66-88af-0d522627f4bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded as a result of current period acquisition</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BioDiscoveryMember_94c2b344-15b7-4066-b9d6-02237d7e5f46_terseLabel_en-US" xlink:label="lab_bngo_BioDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioDiscovery</link:label>
    <link:label id="lab_bngo_BioDiscoveryMember_label_en-US" xlink:label="lab_bngo_BioDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioDiscovery [Member]</link:label>
    <link:label id="lab_bngo_BioDiscoveryMember_documentation_en-US" xlink:label="lab_bngo_BioDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioDiscovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BioDiscoveryMember" xlink:to="lab_bngo_BioDiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ac1a3448-1eaf-4fc7-8632-4ddda7f30b3e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b93d0a68-8b2f-4083-994e-0661a02e78a2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a17e504d-1829-4741-8d38-03f055e1129e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_07643a33-9db1-40eb-915e-bb484d9f964e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0c33667d-c308-493c-b563-4111a993e0c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_455381b0-11bd-45ff-a9ef-4773479c26bd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_InstrumentRevenueMember_bcede4ff-8a6c-4371-a859-ae78b3ba9203_terseLabel_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments</link:label>
    <link:label id="lab_bngo_InstrumentRevenueMember_label_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument Revenue [Member]</link:label>
    <link:label id="lab_bngo_InstrumentRevenueMember_documentation_en-US" xlink:label="lab_bngo_InstrumentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember" xlink:href="bngo-20211231.xsd#bngo_InstrumentRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_InstrumentRevenueMember" xlink:to="lab_bngo_InstrumentRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2cf627e3-60b8-4803-a39e-20a3c5ad3a01_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c2c79f12-fe84-4544-baa7-e589f688362c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_cb3016cf-49e3-4fad-a202-3a84575e7f8c_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_57c91297-fb53-43bb-bf40-c7c0da3798fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_35dc1ad3-474f-4ab5-8ae1-8bca649413b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2aad1196-c7ed-4a37-a1b6-e4d27a8855c4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ddf2267e-16d4-4769-8d28-04b9b411ff14_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_76b76530-c311-4e8c-912e-3c52229838a1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueCovenantWaiver_81375fd6-4b79-4d92-bede-f613318a6a63_terseLabel_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for covenant waiver</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueCovenantWaiver_label_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Covenant Waiver</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueCovenantWaiver_documentation_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueCovenantWaiver" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Covenant Waiver</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueCovenantWaiver" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodValueCovenantWaiver"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_StockIssuedDuringPeriodValueCovenantWaiver" xlink:to="lab_bngo_StockIssuedDuringPeriodValueCovenantWaiver" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_eff8c513-093b-4bb0-8605-722b1bba2815_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_f0458c0a-f0ca-4ee5-bf66-b795b1a3323a_negatedTerseLabel_en-US" xlink:label="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated shares of common stock to be returned to the Company (in shares)</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_label_en-US" xlink:label="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_documentation_en-US" xlink:label="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:to="lab_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_38d79370-4724-4df3-a06f-648bfddb11fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b8d207c0-79f3-4d25-9236-2241e3f33fec_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_241dbd93-18a4-44de-bfd9-102fd76bb2a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_351ee85e-c95d-42ba-97d0-3c0bb635d4b6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_f37064b4-51e8-43a7-9054-290ec4a09662_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_dbdc812f-a25f-41fc-bb29-7ad6a6a4ce7c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c0e72f12-bfd1-43c1-9329-50ff0197c3fd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_101866d8-76dc-48dc-861b-08638de31c0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_faacc0e0-4612-479c-9903-0ed8b0cf3a1d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_31eda17c-c18a-4e94-bb99-45eea3dc0d4d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c0b3491-f1d1-4076-b9bb-2c1f57f8eca6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_969c70a2-57a6-4122-9f8f-f740cb56a20f_negatedTerseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_label_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities</link:label>
    <link:label id="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:to="lab_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4659a72b-aaa3-4c8c-9ba3-cc84a215c635_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_170ceb47-f2ae-4548-8ead-3aa24eb77a08_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_a3bf2b1f-518d-4754-ab2d-bedc0510d169_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34f93b88-4572-4a5c-871c-444a55d4780a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Domestic and Foreign Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TwoCustomersMember_a06291b4-140b-4a0c-b7d9-f197e5d14916_terseLabel_en-US" xlink:label="lab_bngo_TwoCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Customers</link:label>
    <link:label id="lab_bngo_TwoCustomersMember_label_en-US" xlink:label="lab_bngo_TwoCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Customers [Member]</link:label>
    <link:label id="lab_bngo_TwoCustomersMember_documentation_en-US" xlink:label="lab_bngo_TwoCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoCustomersMember" xlink:href="bngo-20211231.xsd#bngo_TwoCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TwoCustomersMember" xlink:to="lab_bngo_TwoCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued_a1e3d294-7f7e-43ee-98e4-f2b80e76b177_terseLabel_en-US" xlink:label="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance and sale of stock</link:label>
    <link:label id="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued_label_en-US" xlink:label="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount To Be Issued</link:label>
    <link:label id="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued_documentation_en-US" xlink:label="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount To Be Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:href="bngo-20211231.xsd#bngo_SaleOfStockAuthorizedAmountToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:to="lab_bngo_SaleOfStockAuthorizedAmountToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2f5f57f1-2f43-4169-8395-7be5a4290bb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_12b82aeb-120c-4e74-9812-c5a9ab559f5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_0f015f4a-7efa-43f2-9a06-9a32e49c8cc0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_StockIssuedForServices_fa1882eb-493d-4cdb-9b87-5afef4b9a93e_terseLabel_en-US" xlink:label="lab_bngo_StockIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for services</link:label>
    <link:label id="lab_bngo_StockIssuedForServices_label_en-US" xlink:label="lab_bngo_StockIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Services</link:label>
    <link:label id="lab_bngo_StockIssuedForServices_documentation_en-US" xlink:label="lab_bngo_StockIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued For Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedForServices" xlink:href="bngo-20211231.xsd#bngo_StockIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_StockIssuedForServices" xlink:to="lab_bngo_StockIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1fff3b01-71cf-4873-9b1d-c3b123b930a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b1b23491-e3a9-49d9-8f9b-aa53f090816c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_f8df9672-7b76-4c03-aa01-e9ddcee730d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses on sale of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_04ce35b3-fe57-4912-ac14-c0e609f09fb5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses on sale of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_63e887a7-50b2-4f60-a742-ee382ca76088_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_7547ee66-a76f-4174-8e10-e8e97104dca0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and royalties</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e6af50ec-a3e6-4d11-94bd-a6253f040ca8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_8ebc6452-d038-4383-8cfd-df55b3bde62d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6d88ff5c-34d6-46d1-a352-7ac5ab0503bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_88b15344-ed7f-45cb-9059-660e58e7856c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c3d97e1e-1dab-4d66-9db4-cbab60fd0608_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_20d251b5-312d-488c-b512-e98d9843c827_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 400,000,000 shares authorized at December&#160;31, 2021 and 2020; 289,602,000 and 189,953,000 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_1c5e03d5-177e-469d-b2ad-ff6643695ae7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_b9dd5fcb-4a5f-431b-aaee-7a35307300c3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c3a69ac0-aa9e-4f7a-b88b-b0e60044343f_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_69381829-0ea9-426b-8f35-e3b6d6b9adbe_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7e19b99c-2c09-42dd-a861-921f71e0e667_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to outstanding employee options, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5dac8922-5265-4315-8f41-274d942e6170_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8ba4fd8a-55fb-4b42-a9a6-0b5146ad36b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_e82d5f3b-0d1b-4c54-83e0-29a3c68f6f1d_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8a3f7c5e-c216-44cc-889f-c18c7565f30c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6dc06ffd-022e-42ea-bde0-544ad76592c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd7c0940-5da7-4ebc-9065-9b690d1f800b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dc04f4e3-7232-4e87-aff4-2775d624186b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_58fcfa50-e0fd-4642-ba01-73ff4744b122_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of financing lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_02241424-5a7e-4cfa-b5ff-50637cb23ac4_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2de58659-addb-4221-8436-7cf8cf1e4119_negatedLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_bbccd819-3371-4ac9-be7d-d8ef2e73d21b_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_11fbcbc1-40e2-40c9-9bb4-fb9555d4ef06_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory impairment</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_bf0965ad-0b67-46cc-a357-172bccad4088_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_bc5e9b02-fc18-435a-adb5-055aeb2a4888_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LineagenMember_223ce71f-89b3-4d62-bc4e-e9a0e39ac47e_terseLabel_en-US" xlink:label="lab_bngo_LineagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lineagen</link:label>
    <link:label id="lab_bngo_LineagenMember_label_en-US" xlink:label="lab_bngo_LineagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lineagen [Member]</link:label>
    <link:label id="lab_bngo_LineagenMember_documentation_en-US" xlink:label="lab_bngo_LineagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lineagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LineagenMember" xlink:to="lab_bngo_LineagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_a404bfdd-9de4-4da3-88ec-e10f13786d30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_b86beee7-adfa-41eb-b5c4-00aafa839187_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5a42449d-de08-4885-8d1c-2b03bdcd100b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_e044f546-ee6e-4233-b19d-5b3b1b3d2a7b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan proceeds received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised_8be46b12-e83e-4f5d-9afc-50ca9ca63377_terseLabel_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for warrant exercises</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_bngo_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_7aee7ad1-be80-4248-8279-629f1120d899_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7043fed3-e0fa-47d7-9c4f-d5f4dc64f33a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d33c05e8-be5a-416c-a2b6-8a0e7487a5b9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SettlementOfInterestOnDebtNoncash_3d7c9b8f-2d8a-4172-bc4b-f2d283968a21_negatedTerseLabel_en-US" xlink:label="lab_bngo_SettlementOfInterestOnDebtNoncash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of interest on debt</link:label>
    <link:label id="lab_bngo_SettlementOfInterestOnDebtNoncash_label_en-US" xlink:label="lab_bngo_SettlementOfInterestOnDebtNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of Interest on Debt, Noncash</link:label>
    <link:label id="lab_bngo_SettlementOfInterestOnDebtNoncash_documentation_en-US" xlink:label="lab_bngo_SettlementOfInterestOnDebtNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of Interest on Debt, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SettlementOfInterestOnDebtNoncash" xlink:href="bngo-20211231.xsd#bngo_SettlementOfInterestOnDebtNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SettlementOfInterestOnDebtNoncash" xlink:to="lab_bngo_SettlementOfInterestOnDebtNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_90c20478-ccf2-4ee2-ab30-5cab1b577f63_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_f23915ac-d4aa-4016-a2f6-6574d80c69ae_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_4dcc3af6-c9ba-499e-a982-c26317a80f60_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_d908a952-7a6d-4ce1-b3c8-b8559cce782f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount_108ded4e-9431-4659-94f4-7f50b8bba5ec_terseLabel_en-US" xlink:label="lab_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 162(m)</link:label>
    <link:label id="lab_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount_label_en-US" xlink:label="lab_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Excessive Employee Remuneration, Amount</link:label>
    <link:label id="lab_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount_documentation_en-US" xlink:label="lab_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Excessive Employee Remuneration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" xlink:href="bngo-20211231.xsd#bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" xlink:to="lab_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e43ad1e9-9971-4384-9a39-485fa2654b4a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_189cf8c6-d00a-4915-ab96-70124e72fb05_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at January 1, 2019 (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_e67557db-c90e-42cb-9dfe-e9de9df53696_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2019 (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a1aa9240-a45f-4a8d-917e-ce2f370b3d46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_InnovatusLoanAgreementMember_91bae054-f1a1-4433-87b2-74527ef4b4e7_terseLabel_en-US" xlink:label="lab_bngo_InnovatusLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus LSA</link:label>
    <link:label id="lab_bngo_InnovatusLoanAgreementMember_label_en-US" xlink:label="lab_bngo_InnovatusLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Loan Agreement [Member]</link:label>
    <link:label id="lab_bngo_InnovatusLoanAgreementMember_documentation_en-US" xlink:label="lab_bngo_InnovatusLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLoanAgreementMember" xlink:href="bngo-20211231.xsd#bngo_InnovatusLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_InnovatusLoanAgreementMember" xlink:to="lab_bngo_InnovatusLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_bcf484f6-7044-4101-b1cc-c25fe2e9171a_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_afdccf82-a1d8-45cf-adbd-7cc504bc770e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_0190be32-6de1-44fc-9cd3-7d1b2c575417_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LesseeFinanceLeaseAreaLeased_dd3d207a-ee9c-4a09-b659-f20a98b00525_terseLabel_en-US" xlink:label="lab_bngo_LesseeFinanceLeaseAreaLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, area lease (in sq ft)</link:label>
    <link:label id="lab_bngo_LesseeFinanceLeaseAreaLeased_label_en-US" xlink:label="lab_bngo_LesseeFinanceLeaseAreaLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Area Leased</link:label>
    <link:label id="lab_bngo_LesseeFinanceLeaseAreaLeased_documentation_en-US" xlink:label="lab_bngo_LesseeFinanceLeaseAreaLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Area Leased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeFinanceLeaseAreaLeased" xlink:href="bngo-20211231.xsd#bngo_LesseeFinanceLeaseAreaLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LesseeFinanceLeaseAreaLeased" xlink:to="lab_bngo_LesseeFinanceLeaseAreaLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0e5f05cb-b97c-482e-a569-af70294104ce_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_28d433d3-7c5b-42de-aaee-21c8f2009fc5_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_89b06d18-c356-41ca-8981-146b238d2765_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d8490ed7-f24b-4da9-8ca7-0beee6f7466e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ead612da-b011-4b4c-b221-9fb6304303d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_cebd93b8-d776-46e9-8b3c-7502be54b2d5_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued as consideration (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_148415f5-9bd4-4dcb-bdc5-79e976f7e4a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_77a72909-7be1-4178-950b-01442a6b15a1_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7297f409-5202-4ea5-9470-fcf91d20b947_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f178c7ed-cae1-4296-9aa4-fdbd92f5ba5d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentCovenantWaiverFee_f209547c-75cc-4e46-964f-81b287bdd39e_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantWaiverFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waiver fee</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantWaiverFee_label_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantWaiverFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Waiver Fee</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantWaiverFee_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantWaiverFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Waiver Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantWaiverFee" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantWaiverFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentCovenantWaiverFee" xlink:to="lab_bngo_DebtInstrumentCovenantWaiverFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b9081e74-ae84-440e-8254-697ffc515a84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2d687c77-a2e9-4ff6-ad1a-0c66980d81b0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by each warrant (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_86ecd660-9c68-498f-abb9-46e5a9c5d9ff_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6b918730-c280-4203-8c4b-b2e6332d0e90_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_028475f0-333c-4726-a9e6-b0d3f1246544_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness_1a31a57f-a268-4191-b362-e6793fe8e072_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum credit card indebtedness</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness_label_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Credit Card Indebtedness</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Credit Card Indebtedness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness" xlink:to="lab_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PaymentsForPropertyAndEquipment_d20d1fde-e5a3-4b83-a975-18afdc9a391b_negatedLabel_en-US" xlink:label="lab_bngo_PaymentsForPropertyAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_bngo_PaymentsForPropertyAndEquipment_label_en-US" xlink:label="lab_bngo_PaymentsForPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Property and Equipment</link:label>
    <link:label id="lab_bngo_PaymentsForPropertyAndEquipment_documentation_en-US" xlink:label="lab_bngo_PaymentsForPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForPropertyAndEquipment" xlink:href="bngo-20211231.xsd#bngo_PaymentsForPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PaymentsForPropertyAndEquipment" xlink:to="lab_bngo_PaymentsForPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_74f7f390-3578-4387-a996-7fc1ba84cf7c_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c872a0dc-3b39-4823-9820-76d5c348690f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ae28a8a-f523-4e43-aa86-521b30988fac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_62abb6cc-5c68-40ac-b2ec-d9c9d22e03c3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_5d768d7d-e583-4349-86c4-9673e78b25f6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_NoncashInterestExpense_1466b853-f867-40ec-a608-a962d890a7ae_terseLabel_en-US" xlink:label="lab_bngo_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_bngo_NoncashInterestExpense_label_en-US" xlink:label="lab_bngo_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Expense</link:label>
    <link:label id="lab_bngo_NoncashInterestExpense_documentation_en-US" xlink:label="lab_bngo_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NoncashInterestExpense" xlink:href="bngo-20211231.xsd#bngo_NoncashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_NoncashInterestExpense" xlink:to="lab_bngo_NoncashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_b164099c-c29d-4572-bc89-f4ec51e36235_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_d5f1956a-53b1-4c19-88f9-cba9f573536e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_c459f8af-bf55-46d1-8e8c-23e3be3e4f25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_1c17749f-2832-41c5-af5c-74008a07f858_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_cccb9c43-5bc8-431e-8529-41c42e517126_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0768ab6f-08e7-4b20-b6b6-7ddd56efa74a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_ee42851e-ea52-4374-9db0-5fd9d1ab2fa4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_20248b9e-26f2-4d7e-a662-cd288ede92a8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_811dccc4-3d84-4d62-b966-299e1153c06c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_8137b558-1df4-4f69-9b42-2658c559cfb9_periodStartLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_04840599-ba02-4122-97ba-b97c4b9d849a_periodEndLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d488fc6f-4556-42e4-b00b-07c55206bcd4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d35b258a-98dc-4f5d-865f-ef049849203a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3f9e3a67-4f22-474c-a44d-f40fda5fe78a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LiquidityPolicyTextBlock_7288bd36-a2d6-4a66-b337-d7a9d3c09baa_terseLabel_en-US" xlink:label="lab_bngo_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_bngo_LiquidityPolicyTextBlock_label_en-US" xlink:label="lab_bngo_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:label id="lab_bngo_LiquidityPolicyTextBlock_documentation_en-US" xlink:label="lab_bngo_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LiquidityPolicyTextBlock" xlink:href="bngo-20211231.xsd#bngo_LiquidityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LiquidityPolicyTextBlock" xlink:to="lab_bngo_LiquidityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6fe5669b-4975-4643-ba1c-3f5de7513f00_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_22a23730-ba5b-473b-9514-15cb7a152ace_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_d5f74276-cdfe-4f7a-bfd6-68544603f0ce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9e6da01e-bb6c-42b7-bedb-f5f2a64024ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b2d0b76c-8528-4b1f-9bcc-2e49517fe927_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ee21001-5bba-4958-81a4-c13f92f84ed4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_bcd53802-461f-46b4-a06c-b446a98b9db3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_fa80991a-9d37-4822-aa50-4196e173a6b5_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of outstanding term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross_77ecc056-f84c-43c6-9a99-66573a66ad66_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum proceeds</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross_label_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Proceeds From Sale Of Stock, Gross</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Proceeds From Sale Of Stock, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" xlink:to="lab_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b7fa655a-5947-4bcb-b7b9-8db9e9043add_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ecc4389f-72ff-411b-b289-2ef0d61565d3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_892be7ff-1677-4c9d-82d3-e0681a543cf1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_OperatingLeasePaymentsModifiedAndUnmodified_4ec6d7b8-a0ee-4164-81ce-fbb5a240de52_terseLabel_en-US" xlink:label="lab_bngo_OperatingLeasePaymentsModifiedAndUnmodified" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_bngo_OperatingLeasePaymentsModifiedAndUnmodified_label_en-US" xlink:label="lab_bngo_OperatingLeasePaymentsModifiedAndUnmodified" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments, Modified and Unmodified</link:label>
    <link:label id="lab_bngo_OperatingLeasePaymentsModifiedAndUnmodified_documentation_en-US" xlink:label="lab_bngo_OperatingLeasePaymentsModifiedAndUnmodified" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments, Modified and Unmodified</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeasePaymentsModifiedAndUnmodified" xlink:href="bngo-20211231.xsd#bngo_OperatingLeasePaymentsModifiedAndUnmodified"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_OperatingLeasePaymentsModifiedAndUnmodified" xlink:to="lab_bngo_OperatingLeasePaymentsModifiedAndUnmodified" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsAxis_36d4fa53-c0a9-42fa-b988-8e48467072a9_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsAxis_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Axis]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsAxis_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsAxis" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsAxis" xlink:to="lab_bngo_DebtInstrumentPaymentTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_454ad3be-f64b-4329-a94d-2f703f3cc469_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationConsiderationTransferredValueOfShares_e8673bd0-2d4c-4bae-8b14-accc2c10c9a3_terseLabel_en-US" xlink:label="lab_bngo_BusinessCombinationConsiderationTransferredValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, value of common stock</link:label>
    <link:label id="lab_bngo_BusinessCombinationConsiderationTransferredValueOfShares_label_en-US" xlink:label="lab_bngo_BusinessCombinationConsiderationTransferredValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Value Of Shares</link:label>
    <link:label id="lab_bngo_BusinessCombinationConsiderationTransferredValueOfShares_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationConsiderationTransferredValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Value Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationConsiderationTransferredValueOfShares" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationConsiderationTransferredValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationConsiderationTransferredValueOfShares" xlink:to="lab_bngo_BusinessCombinationConsiderationTransferredValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5cb3b51e-70b7-460c-be2c-84d07a92db47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_75101dc3-6d94-49d2-9f19-abc3230f4261_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f236cd53-1e8b-4cb7-8cc1-e5d820ad55af_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase shares (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8f4cd567-3bec-4cfd-ac28-b52e419ddaa3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expenses)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_1aebfbac-1f1a-4a7c-ae3e-41fc16703738_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Two [Member]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:to="lab_bngo_DebtInstrumentPaymentTermsPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_ea847e45-0fc5-459f-9403-07df2910daf8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock issued related to acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_fec5a8ba-8e79-4dd2-b1a0-cd2ad09a24f3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_95d17ded-e34e-485f-96e7-2f304289e9cb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination</link:label>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_23478cab-2431-42a0-9b69-69aed07ea5d8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_914391af-0b03-4c71-9b00-b0e545fee702_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForConstructionInProcess_e0242c15-2617-4b97-a732-f2b8bb606bc0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForConstructionInProcess" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_PaymentsForConstructionInProcess_label_en-US" xlink:label="lab_us-gaap_PaymentsForConstructionInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Construction in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForConstructionInProcess" xlink:to="lab_us-gaap_PaymentsForConstructionInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_1c13be6a-a0ea-4781-aa2f-c60a4f6f7951_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dd95e509-345a-4253-b739-3ffbcf1255ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1c6aca88-bca0-42d0-a6fd-997e60808aba_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b97a499c-628a-4118-b055-903785eaccd8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2cc44413-51d2-4c6f-9f71-1fcd6e5daa32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c870e640-0634-4adf-b571-4b443bd80ad9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a5cf9aa2-bb76-4dc9-8cc4-81d194b15d48_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dfdd2f44-4c0f-4396-9b83-6d141ba3d89d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_7ec9b6f7-8e52-4ba9-970d-e98d0fde7514_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DefinedContributionPlanDisclosuresTextBlock_6b7a12ee-adc8-42ca-ad7e-0a9d0ff6bb9e_terseLabel_en-US" xlink:label="lab_bngo_DefinedContributionPlanDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits</link:label>
    <link:label id="lab_bngo_DefinedContributionPlanDisclosuresTextBlock_label_en-US" xlink:label="lab_bngo_DefinedContributionPlanDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosures [Text Block]</link:label>
    <link:label id="lab_bngo_DefinedContributionPlanDisclosuresTextBlock_documentation_en-US" xlink:label="lab_bngo_DefinedContributionPlanDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan disclosures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DefinedContributionPlanDisclosuresTextBlock" xlink:href="bngo-20211231.xsd#bngo_DefinedContributionPlanDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DefinedContributionPlanDisclosuresTextBlock" xlink:to="lab_bngo_DefinedContributionPlanDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5b1065c6-8a61-470e-aa80-7b9896e116a3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TwoThousandEighteenEquityIncentivePlanMember_983d16bc-6101-474e-82ba-29da600320e5_terseLabel_en-US" xlink:label="lab_bngo_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:label id="lab_bngo_TwoThousandEighteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_bngo_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_bngo_TwoThousandEighteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_bngo_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoThousandEighteenEquityIncentivePlanMember" xlink:href="bngo-20211231.xsd#bngo_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="lab_bngo_TwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_3848d4ef-d793-43dd-8fc8-6d94ff6da8f7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2aa96553-f770-4fa3-be2d-21b056cc3fde_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_26e3a6e6-530a-4ead-929a-0a3c133b56fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ba525f2a-3d53-45a3-bfbf-dc9ac612090f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_a2e4c6e5-ba7f-4135-bfea-71a417faa5b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ad98fa89-d27e-4c56-a8e3-78ad0ac7c7f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Supplies_59398daa-ee4d-435e-897f-c51843f04ef5_terseLabel_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment to supplier</link:label>
    <link:label id="lab_us-gaap_Supplies_label_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Supplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8f3dfdff-33c2-479b-8909-31e23e574965_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_09d8a164-eb22-49aa-ad7a-421718bae284_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_FinanceLeaseExpense_d04d621f-1a76-4380-bb8d-8e846832e773_totalLabel_en-US" xlink:label="lab_bngo_FinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease costs</link:label>
    <link:label id="lab_bngo_FinanceLeaseExpense_87718583-2c0a-4bd7-a2f6-3093cb843cc7_terseLabel_en-US" xlink:label="lab_bngo_FinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease costs</link:label>
    <link:label id="lab_bngo_FinanceLeaseExpense_label_en-US" xlink:label="lab_bngo_FinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Expense</link:label>
    <link:label id="lab_bngo_FinanceLeaseExpense_documentation_en-US" xlink:label="lab_bngo_FinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseExpense" xlink:href="bngo-20211231.xsd#bngo_FinanceLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_FinanceLeaseExpense" xlink:to="lab_bngo_FinanceLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_220b213f-78f0-41f9-99e6-1dd63377eb32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PreFundedWarrantMember_e7fcf1b0-0427-403f-8057-f9a68622c2df_terseLabel_en-US" xlink:label="lab_bngo_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:label id="lab_bngo_PreFundedWarrantMember_label_en-US" xlink:label="lab_bngo_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:label id="lab_bngo_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_bngo_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PreFundedWarrantMember" xlink:href="bngo-20211231.xsd#bngo_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PreFundedWarrantMember" xlink:to="lab_bngo_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2efa1e07-9d9a-4496-8417-991719839e29_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_afa14733-3e58-407a-995f-7edb1f19d667_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to satisfy outstanding principal and accrued interest amounts</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3153ad5a-51ab-4225-bdfd-b8c6cec3b8e3_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ElSegundoCaliforniaMember_67d311c5-10fa-49a4-b311-825685831737_terseLabel_en-US" xlink:label="lab_bngo_ElSegundoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">El Segundo, California</link:label>
    <link:label id="lab_bngo_ElSegundoCaliforniaMember_label_en-US" xlink:label="lab_bngo_ElSegundoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">El Segundo, California [Member]</link:label>
    <link:label id="lab_bngo_ElSegundoCaliforniaMember_documentation_en-US" xlink:label="lab_bngo_ElSegundoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">El Segundo, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ElSegundoCaliforniaMember" xlink:href="bngo-20211231.xsd#bngo_ElSegundoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ElSegundoCaliforniaMember" xlink:to="lab_bngo_ElSegundoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_0db513dd-5ec9-453e-bd91-8b915c79e89f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_7e4b13e4-3934-403e-95d7-821925c68bd1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_948a789b-be32-4147-9b1a-4a38e93c35e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price per share on Effective Date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_69fdddf1-5ad2-4876-aa63-3f176b332317_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance_e60cd620-b749-402b-adee-6b6088a19f76_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum cash balance</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance_label_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Liquidity, Minimum Cash Balance</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Liquidity, Minimum Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance" xlink:to="lab_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting_39bb0fae-9938-43ef-b186-65609186db62_terseLabel_en-US" xlink:label="lab_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares subject to vesting</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting_label_en-US" xlink:label="lab_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Consideration Transferred, Value Of Shares, Subject To Vesting</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting_documentation_en-US" xlink:label="lab_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Consideration Transferred, Value Of Shares, Subject To Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" xlink:to="lab_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7d012b10-9df1-48c4-a995-4732f5c68a29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_c40ff7d1-6d87-4b6d-8b05-f14c16947f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1db66d6d-13c2-492d-b6e4-d8fea17eabe0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_022f3695-b7d1-42ad-aa65-d3af871b31fc_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_52eeafcc-a585-4586-bb48-2a3a7b5f1b21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0ec81341-5b93-4f05-82a3-bd7abb759afb_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b3a93ba7-0518-48cb-8003-9e8b95974dca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan face value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a2d1009e-c064-4dd5-94f8-6a516fa93a35_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1631ced1-51fc-4271-a64a-f07abaaed498_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b58bfd4c-d32c-4bd2-a044-a9352a10dee1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_e43f30ad-be33-45df-ac62-dd470828a90d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_WarrantExerciseNonCash_33d9fd32-0724-4501-8e66-fea078b9c77c_terseLabel_en-US" xlink:label="lab_bngo_WarrantExerciseNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise pursuant to cashless exercise</link:label>
    <link:label id="lab_bngo_WarrantExerciseNonCash_label_en-US" xlink:label="lab_bngo_WarrantExerciseNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise, Non-cash</link:label>
    <link:label id="lab_bngo_WarrantExerciseNonCash_documentation_en-US" xlink:label="lab_bngo_WarrantExerciseNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise, Non-cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantExerciseNonCash" xlink:href="bngo-20211231.xsd#bngo_WarrantExerciseNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_WarrantExerciseNonCash" xlink:to="lab_bngo_WarrantExerciseNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PurchaseObligationContractTerminationPeriod_40c33a13-187d-4aab-83ed-2e03543af064_terseLabel_en-US" xlink:label="lab_bngo_PurchaseObligationContractTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_bngo_PurchaseObligationContractTerminationPeriod_label_en-US" xlink:label="lab_bngo_PurchaseObligationContractTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Contract Termination Period</link:label>
    <link:label id="lab_bngo_PurchaseObligationContractTerminationPeriod_documentation_en-US" xlink:label="lab_bngo_PurchaseObligationContractTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Contract Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurchaseObligationContractTerminationPeriod" xlink:href="bngo-20211231.xsd#bngo_PurchaseObligationContractTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PurchaseObligationContractTerminationPeriod" xlink:to="lab_bngo_PurchaseObligationContractTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c944fadd-672f-4602-8092-f029a52c1826_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4d97f30c-4ea4-4970-8147-05edf310fc46_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SanDiegoCaliforniaMember_b5585bce-e96b-4dce-9273-e541c568f356_terseLabel_en-US" xlink:label="lab_bngo_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_bngo_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_bngo_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_bngo_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_bngo_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SanDiegoCaliforniaMember" xlink:href="bngo-20211231.xsd#bngo_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SanDiegoCaliforniaMember" xlink:to="lab_bngo_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3b43cef4-d27e-4097-85af-887ae78b84bf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5e76ab42-5844-4b61-b5bd-3280e5be748c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_27a0258a-cd56-4bb0-9312-158bbc77c440_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a57a9fe-b4c8-46b6-a174-5fdc0f0fe4f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e6465928-7d1a-4c01-b82c-09025120f8a0_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_695a4f3b-b68d-4eb4-8433-9cb9b3078518_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_6df2c9b6-e71a-4e7b-b9bd-29e50e18db9e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_3b5cec3d-b716-415e-a443-f47e4ea5d315_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod_8ebaff92-ada6-4cc3-8753-e067809e719f_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waiver fee payment period</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod_label_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Waiver Fee Payment Period</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Waiver Fee Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod" xlink:to="lab_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_47873248-ee4a-4164-ad73-4ea7795886b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_777efb82-fecb-449f-863e-cd1e3fed6509_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentCovenantPrepaymentFee_9d7cdd18-f21f-4280-9fe7-35b81c707fc1_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantPrepaymentFee_label_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Prepayment Fee</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantPrepaymentFee_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Prepayment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantPrepaymentFee" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantPrepaymentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentCovenantPrepaymentFee" xlink:to="lab_bngo_DebtInstrumentCovenantPrepaymentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7207aced-3ea5-4d60-8794-501c4c7a3eb5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_74da1ccf-bb4f-4ff4-8ca4-1022ce8e06f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_74108bde-b852-4e0e-aec6-052c42190e80_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_6632bf15-b46f-43f4-8d93-3ca712050b81_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_4d9765fb-0146-4b9c-b47e-eb1b29de8286_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowing from line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_aa7c095e-f2e6-4c0d-b72d-42f27ca85677_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_EscrowedSharesMember_6492c9c6-1ba8-42f3-b832-ac723448ce16_terseLabel_en-US" xlink:label="lab_bngo_EscrowedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrowed Shares</link:label>
    <link:label id="lab_bngo_EscrowedSharesMember_label_en-US" xlink:label="lab_bngo_EscrowedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrowed Shares [Member]</link:label>
    <link:label id="lab_bngo_EscrowedSharesMember_documentation_en-US" xlink:label="lab_bngo_EscrowedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrowed Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember" xlink:href="bngo-20211231.xsd#bngo_EscrowedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_EscrowedSharesMember" xlink:to="lab_bngo_EscrowedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_52733a51-d400-4ef8-9cc9-1ac03c22c71a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionExpense_6949d750-4d2c-4d00-abc5-7a1ec0bc476b_terseLabel_en-US" xlink:label="lab_us-gaap_AccretionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of interest on securities</link:label>
    <link:label id="lab_us-gaap_AccretionExpense_label_en-US" xlink:label="lab_us-gaap_AccretionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpense" xlink:to="lab_us-gaap_AccretionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClientWarrantyExchangeOfFixedAssets_e81f324a-587b-48d3-a054-062e2186348f_terseLabel_en-US" xlink:label="lab_bngo_ClientWarrantyExchangeOfFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client warranty exchange of fixed asset</link:label>
    <link:label id="lab_bngo_ClientWarrantyExchangeOfFixedAssets_label_en-US" xlink:label="lab_bngo_ClientWarrantyExchangeOfFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Warranty Exchange of Fixed Assets</link:label>
    <link:label id="lab_bngo_ClientWarrantyExchangeOfFixedAssets_documentation_en-US" xlink:label="lab_bngo_ClientWarrantyExchangeOfFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client Warranty Exchange of Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClientWarrantyExchangeOfFixedAssets" xlink:href="bngo-20211231.xsd#bngo_ClientWarrantyExchangeOfFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClientWarrantyExchangeOfFixedAssets" xlink:to="lab_bngo_ClientWarrantyExchangeOfFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ReagentRentalsMember_4e72cf7d-f3e5-43b6-8c1e-3b8509c78539_terseLabel_en-US" xlink:label="lab_bngo_ReagentRentalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reagent rentals</link:label>
    <link:label id="lab_bngo_ReagentRentalsMember_label_en-US" xlink:label="lab_bngo_ReagentRentalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reagent Rentals [Member]</link:label>
    <link:label id="lab_bngo_ReagentRentalsMember_documentation_en-US" xlink:label="lab_bngo_ReagentRentalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reagent Rentals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ReagentRentalsMember" xlink:href="bngo-20211231.xsd#bngo_ReagentRentalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ReagentRentalsMember" xlink:to="lab_bngo_ReagentRentalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_71f5c5e0-6d0b-4f51-82c8-945930d9a7cc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PurchaseObligationInitialPurchasePeriod_be0b5d7e-7d1d-49a5-9be2-57a065947622_terseLabel_en-US" xlink:label="lab_bngo_PurchaseObligationInitialPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial purchase period</link:label>
    <link:label id="lab_bngo_PurchaseObligationInitialPurchasePeriod_label_en-US" xlink:label="lab_bngo_PurchaseObligationInitialPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Initial Purchase Period</link:label>
    <link:label id="lab_bngo_PurchaseObligationInitialPurchasePeriod_documentation_en-US" xlink:label="lab_bngo_PurchaseObligationInitialPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Initial Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurchaseObligationInitialPurchasePeriod" xlink:href="bngo-20211231.xsd#bngo_PurchaseObligationInitialPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PurchaseObligationInitialPurchasePeriod" xlink:to="lab_bngo_PurchaseObligationInitialPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dcba0ab9-2c2d-4d11-b726-ef4a82276d35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07733323-dd23-4367-b937-bc7380eedb01_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b520139b-4e3c-4aed-964b-e9017e479bd8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_08702e0c-cd2c-4009-8510-8fcf17e81181_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_29f75829-feb8-4422-8401-0b058bfc4838_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $690,000 and $2,119,000 as of December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0bc43624-c953-49ce-bbf4-7614b4bc69df_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b10d2b2c-feee-49b6-9ba2-31abbec7ea95_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_734b6c6c-00ac-4bb4-a87e-b1834a181199_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_6b23621b-3d9d-4d08-b2af-0d313f57b9e8_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2b982cff-db64-4ef0-bf73-be3244433e59_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_01017a17-25fc-4489-9808-fbe89a6a04c7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f0c51ef7-e31b-4c04-b6e8-8cff83c6eba4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_RentalRevenueReagentRentalProgram_c4ecf29a-1cda-442d-97bc-9ee5a603779d_terseLabel_en-US" xlink:label="lab_bngo_RentalRevenueReagentRentalProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental revenue</link:label>
    <link:label id="lab_bngo_RentalRevenueReagentRentalProgram_label_en-US" xlink:label="lab_bngo_RentalRevenueReagentRentalProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Revenue, Reagent Rental Program</link:label>
    <link:label id="lab_bngo_RentalRevenueReagentRentalProgram_documentation_en-US" xlink:label="lab_bngo_RentalRevenueReagentRentalProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Revenue, Reagent Rental Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RentalRevenueReagentRentalProgram" xlink:href="bngo-20211231.xsd#bngo_RentalRevenueReagentRentalProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_RentalRevenueReagentRentalProgram" xlink:to="lab_bngo_RentalRevenueReagentRentalProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_b3d99858-51d5-4817-a937-41e38306fe2d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_559dfbf8-e241-4a4a-b03a-dedb61b1d5ff_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ed97077d-b93f-4841-90e9-367d3f4fb96d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2f6ede96-971d-42ff-91b8-4995ff7cc314_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aae9d0b3-7211-4b29-a60f-fdbdb2f4aab2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_33e0ece5-9373-499f-a439-4ebe1c98aceb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_3b793bcf-02e1-4369-880c-07a1ab512995_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_799e13f6-ed43-4e94-bea1-d83ed082168c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_91661aad-f70c-4213-9c95-c3d923730949_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4426dfa7-2b4d-4d51-885e-b451fa6da16d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9914468a-fe82-4592-979e-907af17a7077_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_de1cf279-702d-41a7-a87d-943cd239e0f0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_f566cc8f-bcce-478b-b5fd-ce36d37cd500_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_dff4266a-2224-435f-bca7-ae2110d329a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2ef760f9-a9a2-434a-8f81-efa0d460a905_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_52177244-36cf-4b79-a4cc-96df68c3fe24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e87046a7-ce6b-4ebf-92ce-9a68f77917d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2825c47b-73b5-4867-a73c-b96f1565af04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5fa6f40e-401a-432f-91b4-d94817fde675_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LesseeOperatingLeaseAreaAdded_1ae2c0c5-9ed4-4d0c-81d7-3ad6b4703d40_terseLabel_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseAreaAdded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area added (in sq ft)</link:label>
    <link:label id="lab_bngo_LesseeOperatingLeaseAreaAdded_label_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseAreaAdded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Added</link:label>
    <link:label id="lab_bngo_LesseeOperatingLeaseAreaAdded_documentation_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseAreaAdded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Added</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseAreaAdded" xlink:href="bngo-20211231.xsd#bngo_LesseeOperatingLeaseAreaAdded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LesseeOperatingLeaseAreaAdded" xlink:to="lab_bngo_LesseeOperatingLeaseAreaAdded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_7a26160e-ec9c-4e80-b4e0-f46f97479b5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TermA2LoanMember_e389bba3-2b70-4687-823d-588d9080a1fd_terseLabel_en-US" xlink:label="lab_bngo_TermA2LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-2 Loan</link:label>
    <link:label id="lab_bngo_TermA2LoanMember_label_en-US" xlink:label="lab_bngo_TermA2LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-2 Loan [Member]</link:label>
    <link:label id="lab_bngo_TermA2LoanMember_documentation_en-US" xlink:label="lab_bngo_TermA2LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A-2 Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA2LoanMember" xlink:href="bngo-20211231.xsd#bngo_TermA2LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TermA2LoanMember" xlink:to="lab_bngo_TermA2LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_481ae08d-566b-4e50-bdf6-ed7b2dd9d8b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eabbdc3c-9e20-4a0c-8fae-76642674974b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_897e1171-0f63-46d5-b71c-75ca78c2c387_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_OperatingLeaseMonthlyRentPayments_54452488-768e-4f1d-bd00-8f0723eb6dc0_terseLabel_en-US" xlink:label="lab_bngo_OperatingLeaseMonthlyRentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent payments</link:label>
    <link:label id="lab_bngo_OperatingLeaseMonthlyRentPayments_label_en-US" xlink:label="lab_bngo_OperatingLeaseMonthlyRentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent Payments</link:label>
    <link:label id="lab_bngo_OperatingLeaseMonthlyRentPayments_documentation_en-US" xlink:label="lab_bngo_OperatingLeaseMonthlyRentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeaseMonthlyRentPayments" xlink:href="bngo-20211231.xsd#bngo_OperatingLeaseMonthlyRentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_OperatingLeaseMonthlyRentPayments" xlink:to="lab_bngo_OperatingLeaseMonthlyRentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_80f599dc-9592-4327-b4f3-bc7854fe131a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b687df6c-50e8-4f8a-b8be-4ab2c22284b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_b71a5e52-0760-4987-b429-b312930db6fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_aa5a536c-bd83-4bb5-ab39-6ef4556c2cac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ComputerAndOfficeEquipmentMember_7ba3e8fc-ab22-4365-8ca8-8a5918f829aa_terseLabel_en-US" xlink:label="lab_bngo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_bngo_ComputerAndOfficeEquipmentMember_label_en-US" xlink:label="lab_bngo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer And Office Equipment [Member]</link:label>
    <link:label id="lab_bngo_ComputerAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_bngo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ComputerAndOfficeEquipmentMember" xlink:href="bngo-20211231.xsd#bngo_ComputerAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ComputerAndOfficeEquipmentMember" xlink:to="lab_bngo_ComputerAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SummaryOfSignificantAccountingPoliciesLineItems_2487f38d-0cf9-4530-b049-b3e5216da15c_terseLabel_en-US" xlink:label="lab_bngo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_bngo_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_bngo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_bngo_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_bngo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="bngo-20211231.xsd#bngo_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_bngo_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_33fea5d6-f4da-4f1e-886a-fd52c8311eda_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_8ff9867d-42b7-4622-9fb9-ed92d7342273_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_f3d3d9dd-14c0-4e1b-8983-21b18305ba76_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f39f2b1d-6f27-4cd2-9aeb-fadf84b42f4a_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b77f866d-a938-4606-bbf1-465641ce0611_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PerformanceShareUnitsPSUsMember_55e06e31-f586-4cdd-b0cd-c6abdc0d8d96_terseLabel_en-US" xlink:label="lab_bngo_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_bngo_PerformanceShareUnitsPSUsMember_label_en-US" xlink:label="lab_bngo_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSUs) [Member]</link:label>
    <link:label id="lab_bngo_PerformanceShareUnitsPSUsMember_documentation_en-US" xlink:label="lab_bngo_PerformanceShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember" xlink:href="bngo-20211231.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PerformanceShareUnitsPSUsMember" xlink:to="lab_bngo_PerformanceShareUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9af8a558-b0dc-4d9e-8796-f5245a6cd8a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_01d2a2d2-50bc-45ce-a44a-c02719855ae9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of new shares issued under plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9dee414f-50db-425c-aedc-53e5d2c3a3bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6c276997-dbbb-4b9a-addb-1472222e2075_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of estimated common stock consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_58745cd0-9672-45c3-9450-73d3fa050c2a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_PaymentsForInitialCostsOnLeases_b34353c7-3302-4a18-943a-14d2b1957a8a_negatedTerseLabel_en-US" xlink:label="lab_bngo_PaymentsForInitialCostsOnLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of initial direct costs on lease</link:label>
    <link:label id="lab_bngo_PaymentsForInitialCostsOnLeases_label_en-US" xlink:label="lab_bngo_PaymentsForInitialCostsOnLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Initial Costs on Leases</link:label>
    <link:label id="lab_bngo_PaymentsForInitialCostsOnLeases_documentation_en-US" xlink:label="lab_bngo_PaymentsForInitialCostsOnLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Initial Costs on Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForInitialCostsOnLeases" xlink:href="bngo-20211231.xsd#bngo_PaymentsForInitialCostsOnLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_PaymentsForInitialCostsOnLeases" xlink:to="lab_bngo_PaymentsForInitialCostsOnLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_38250537-bd11-466d-af89-287b2984601a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_339575b7-53d8-4659-80b2-89eadb7cf20d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b2e06d65-6b1f-4c06-b908-a3c41972b758_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_0cee5cd6-d76a-42e3-b067-225339f5413e_verboseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_26b1811e-ee8f-4b59-93bc-9401148496f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price&#160;</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_05f1f8a4-6a2d-44df-a97c-7495f5f554c5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_3ee885a5-6e3c-402c-ad7e-198be41cdc0c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CorporateNotesAndBondsMember_963e0cc3-d050-4a41-a1e4-48ff9251ef27_terseLabel_en-US" xlink:label="lab_bngo_CorporateNotesAndBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Notes/Bonds</link:label>
    <link:label id="lab_bngo_CorporateNotesAndBondsMember_label_en-US" xlink:label="lab_bngo_CorporateNotesAndBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Notes And Bonds [Member]</link:label>
    <link:label id="lab_bngo_CorporateNotesAndBondsMember_documentation_en-US" xlink:label="lab_bngo_CorporateNotesAndBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Notes And Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember" xlink:href="bngo-20211231.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CorporateNotesAndBondsMember" xlink:to="lab_bngo_CorporateNotesAndBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_ab37f1b0-392f-42ff-9ab7-c71ddbee798e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9fa9f383-6631-4fff-be84-dc8fcf4a0ffd_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_db6fad08-2935-4711-b90c-ef3fb71472e4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b919712a-db08-486c-9b5a-08787e48e622_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_bb02fdd8-68ec-43e7-a850-40dfa94e4896_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SummaryOfSignificantAccountingPoliciesTable_9e548075-4b56-49c7-80dc-f4b9874df300_terseLabel_en-US" xlink:label="lab_bngo_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_bngo_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_bngo_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_bngo_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_bngo_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SummaryOfSignificantAccountingPoliciesTable" xlink:href="bngo-20211231.xsd#bngo_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_bngo_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5a9ef106-7ba0-4a71-b375-0f59f2f4197c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_24296155-15ca-48dd-99ef-7fe2a23defa6_terseLabel_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term &#160;</link:label>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_label_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</link:label>
    <link:label id="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_documentation_en-US" xlink:label="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:href="bngo-20211231.xsd#bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:to="lab_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_fd694345-e262-470e-8f13-bf4fa4b96d10_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liability, related party</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1db72904-01b1-43bd-995a-9f24cfab8a25_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_62e2a1fe-ed5a-4e1f-b0d1-59d63fb841a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6bd016a6-eaa1-47aa-8512-e605e1a31724_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0b5b4706-803c-438a-baf1-1156ab5fc046_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b33b9519-a983-497e-a970-396dc08f2d85_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_1a0675a7-392b-410d-a5df-39ca0e8524b8_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LesseeEstimatedIncrementalBorrowingRate_bfa8f979-32a0-44a3-8990-8e6f89af14fe_terseLabel_en-US" xlink:label="lab_bngo_LesseeEstimatedIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated incremental borrowing rate</link:label>
    <link:label id="lab_bngo_LesseeEstimatedIncrementalBorrowingRate_label_en-US" xlink:label="lab_bngo_LesseeEstimatedIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Estimated Incremental Borrowing Rate</link:label>
    <link:label id="lab_bngo_LesseeEstimatedIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_bngo_LesseeEstimatedIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Estimated Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeEstimatedIncrementalBorrowingRate" xlink:href="bngo-20211231.xsd#bngo_LesseeEstimatedIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LesseeEstimatedIncrementalBorrowingRate" xlink:to="lab_bngo_LesseeEstimatedIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_WarrantyAndMaintenanceRevenue_83de5e43-18db-456f-a65f-1133441c1c44_terseLabel_en-US" xlink:label="lab_bngo_WarrantyAndMaintenanceRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and maintenance revenue</link:label>
    <link:label id="lab_bngo_WarrantyAndMaintenanceRevenue_label_en-US" xlink:label="lab_bngo_WarrantyAndMaintenanceRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and Maintenance Revenue</link:label>
    <link:label id="lab_bngo_WarrantyAndMaintenanceRevenue_documentation_en-US" xlink:label="lab_bngo_WarrantyAndMaintenanceRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and Maintenance Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantyAndMaintenanceRevenue" xlink:href="bngo-20211231.xsd#bngo_WarrantyAndMaintenanceRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_WarrantyAndMaintenanceRevenue" xlink:to="lab_bngo_WarrantyAndMaintenanceRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration_35e1e9ea-9e84-4dd5-be5e-38651bc11ef1_terseLabel_en-US" xlink:label="lab_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards that do not expire</link:label>
    <link:label id="lab_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration_label_en-US" xlink:label="lab_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label id="lab_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration_documentation_en-US" xlink:label="lab_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration" xlink:href="bngo-20211231.xsd#bngo_OperatingLossCarryforwardsNotSubjecttoExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration" xlink:to="lab_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cb33089c-fbde-426b-94d7-a8ad778a3f10_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_fc8b0c96-0e86-47d4-915f-203207729c3c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_138569d9-586e-402d-bed5-59c780280455_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8adf6a82-d4a1-4294-b46b-8500552ed62a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_1572f223-2a87-49ff-8124-9ee09bc1a2d3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a2203ea7-bc26-4cc2-941c-7a4b2f650ebf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_91669722-1f94-4479-85c6-966ac303130a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7bfbfbf-d49a-4d49-9df5-24ccee5ea209_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_5c331b9d-8d04-493b-9835-5263f6a13b96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8ef36160-a42d-4a09-b549-cfd656d123f2_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5ebba3a0-493f-48cd-a45a-a4b178a622ed_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e4dbcfbd-fc34-40f0-a7e1-4c6017e7c9a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Recognized Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_bd7a269a-58a5-4792-ae50-b6fd5d54b388_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contract liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f6276b91-2ea3-4082-8b5b-a09a5ac80320_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a78f1020-5bdd-4640-880e-67815620aedb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_968fdafe-b087-495c-9730-9db4c90b9fb1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a5dbcac7-3609-4ca9-9068-211626fbae7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_805a5c97-aaae-4ea9-be88-939e50222047_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_6848b190-0e88-40fd-9ead-065bd54b3a4a_negatedLabel_en-US" xlink:label="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated return of cash to buyer from escrow</link:label>
    <link:label id="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_label_en-US" xlink:label="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Estimated Return of Cash to Buyer from Escrow</link:label>
    <link:label id="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_documentation_en-US" xlink:label="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Estimated Return of Cash to Buyer from Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:to="lab_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_28e4ec16-65e7-42ec-a514-1ee30e2cafc7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_6ca5b83c-cf5a-443e-ad74-5ba1c8b9d526_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_91762a9c-b484-4fbf-9ab6-ef095a534d0e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_5fa8df14-fe3d-4667-b98c-323487d459c7_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term-loan debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_77d50f46-d2ec-4609-86db-c24b4a871745_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_34ad463c-508c-424a-87c0-91cc65d218c2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember_e750d336-df9a-4c00-8933-f4da56e7180f_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Four</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Four [Member]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:to="lab_bngo_DebtInstrumentPaymentTermsPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d6eee2e3-e265-4f6c-b231-c8ad49253542_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9851395a-1c7d-4d9c-8a12-a2966cdd99e0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUtilityInventoryTextBlock_0456556e-33ff-4c46-aca5-f593ff2aacc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUtilityInventoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUtilityInventoryTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUtilityInventoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Utility Inventory [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUtilityInventoryTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUtilityInventoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUtilityInventoryTextBlock" xlink:to="lab_us-gaap_ScheduleOfUtilityInventoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_43fe79c2-02ce-4bf2-8ec8-50a9be1174ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0322a371-58df-4d33-b24f-0798d980a439_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6f93f5a6-6d4a-478f-9ad0-f8ff2b8d735b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of milestone consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SaltLakeCityUtahMember_03dcb5bd-8564-4daa-a2bd-3c017cffdd64_terseLabel_en-US" xlink:label="lab_bngo_SaltLakeCityUtahMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salt Lake City, Utah</link:label>
    <link:label id="lab_bngo_SaltLakeCityUtahMember_label_en-US" xlink:label="lab_bngo_SaltLakeCityUtahMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salt Lake City, Utah [Member]</link:label>
    <link:label id="lab_bngo_SaltLakeCityUtahMember_documentation_en-US" xlink:label="lab_bngo_SaltLakeCityUtahMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salt Lake City, Utah</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaltLakeCityUtahMember" xlink:href="bngo-20211231.xsd#bngo_SaltLakeCityUtahMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SaltLakeCityUtahMember" xlink:to="lab_bngo_SaltLakeCityUtahMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73b6bf68-f8e0-42e7-b213-ee08acd8f78b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ContingentConsiderationFairValueOfContingentLiability_0e1a5fa3-374a-45bf-acf4-2866049e4760_verboseLabel_en-US" xlink:label="lab_bngo_ContingentConsiderationFairValueOfContingentLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_bngo_ContingentConsiderationFairValueOfContingentLiability_57603559-a592-42ee-a5a9-33251e6d0fb4_terseLabel_en-US" xlink:label="lab_bngo_ContingentConsiderationFairValueOfContingentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of consideration</link:label>
    <link:label id="lab_bngo_ContingentConsiderationFairValueOfContingentLiability_label_en-US" xlink:label="lab_bngo_ContingentConsiderationFairValueOfContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Fair Value of Contingent Liability</link:label>
    <link:label id="lab_bngo_ContingentConsiderationFairValueOfContingentLiability_documentation_en-US" xlink:label="lab_bngo_ContingentConsiderationFairValueOfContingentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Fair Value of Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationFairValueOfContingentLiability" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationFairValueOfContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ContingentConsiderationFairValueOfContingentLiability" xlink:to="lab_bngo_ContingentConsiderationFairValueOfContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_86bf7730-c39b-46d3-9f10-b4506cdedafb_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_063c03c9-f87c-4a84-b1f0-c4f0d6eeaf1c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ce8f570c-5376-4559-85bb-f3d2ded98831_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7891d86e-9c78-474a-a06f-ddd6a3b2e154_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_c4940551-6748-4434-b53e-468dd05cc937_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_96d92447-4d0d-42cc-9a96-8e63ffe9a9b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt and Unamortized Discount Balances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f98468f2-c34a-4d0f-ae52-097ea297c95e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6a30f6be-25a1-46d7-a869-cf6a39a933e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_2409df55-fba1-4f3b-83cc-2c138f22b214_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_327e22b9-3a96-4dc7-8d10-7e65019c54e6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8a60dea4-0d8e-4b22-bd6d-b03c46f88ee8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_26e2c6c7-d6b5-432b-9fdf-a769db2ded7b_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d9f05331-7b3a-4491-99c6-8b0d0a10746b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_77344af8-57c5-4290-b37b-2ebf96bc27d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_3b9931ed-4323-4880-86e0-312cf128fce4_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_42e3a72d-cdfe-4a08-a759-16e80de4a27f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_35d5366f-2c9a-4a24-bf2e-5dde3d00a5d3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_00f49c25-ccc3-4c28-b05f-d003a2c6449d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d15fa78f-fbd9-4f83-9f8b-6ee80e544c24_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_79e29fd8-cfef-4837-b137-61c1ed50a0c8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e0f9acde-d5a0-4bce-9ec9-e9bc62134ec8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_63809a1c-cfd3-46b9-9aff-085b9d86b5a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4b13f7d2-ba0a-45f0-8c5b-4c660b9a1c3a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_13644c5e-863d-4860-8d19-10d561d6c9ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_64eb3b68-4eb2-4ef4-8f15-0833f467e975_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_aa93db97-ae86-4daa-bdf7-363b6da00fc7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e9a3bb38-e526-4e22-9120-889bb0e13d6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock_f169e0e6-d525-400b-951b-8caf34e39886_terseLabel_en-US" xlink:label="lab_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label id="lab_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock_label_en-US" xlink:label="lab_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods And Services Sold [Policy Text Block]</link:label>
    <link:label id="lab_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock_documentation_en-US" xlink:label="lab_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods And Services Sold [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock" xlink:href="bngo-20211231.xsd#bngo_CostOfGoodsAndServicesSoldPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock" xlink:to="lab_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f4b4c4e8-1173-48ed-a83d-8199306299a5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_53e2ceaa-17ce-438a-a25f-902205d8b868_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9cabb16e-8426-4bcd-8690-06ea7b1433b9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_fe947767-2b06-4340-b66e-a03477cf90c9_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_dfa6663e-571d-44da-984f-e83580e368e0_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_eb08c55c-894c-4f11-bbee-c19397a764c5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c3bb3f5b-098e-45c7-8aae-ada559840807_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurement of Assets And Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_08c92eaa-c705-4326-ae19-4dbf51c49fa7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_2f6170dd-934f-422d-aed4-b1d2f247c2fb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowing from line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_675482c7-2277-4e3a-bcb1-434ab6fa85ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_cad9e187-97a2-48c0-9006-07a51bbc62ab_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f69ced56-2367-4064-a527-8509b9d3f745_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c2e6744-3370-4098-928b-7e510e8a8023_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_a52ff3b8-b140-43e0-8954-def3843e3a25_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held in escrow</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f3f78372-9421-4f2c-b301-ecee74225f4f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_cf0402fe-c9d8-4b6c-af8d-27f172c41ddb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_45ea9a65-0052-40a2-b628-05798ab6e6a7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_a3abc984-b5dc-4df3-a683-16812929aba8_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:to="lab_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8fda7c99-2c3d-4d25-81c2-935cc0f12dfd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter_670af567-57be-400e-88d0-5ba82f2e480a_terseLabel_en-US" xlink:label="lab_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual commitment with supplier to purchase products every quarter</link:label>
    <link:label id="lab_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter_label_en-US" xlink:label="lab_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitment, Purchase of Products, Every Quarter</link:label>
    <link:label id="lab_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter_documentation_en-US" xlink:label="lab_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitment, Purchase of Products, Every Quarter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter" xlink:href="bngo-20211231.xsd#bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter" xlink:to="lab_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LabEquipmentMember_c30a68d5-ce3c-41c4-b7ad-72439c64023d_terseLabel_en-US" xlink:label="lab_bngo_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_bngo_LabEquipmentMember_label_en-US" xlink:label="lab_bngo_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_bngo_LabEquipmentMember_documentation_en-US" xlink:label="lab_bngo_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LabEquipmentMember" xlink:href="bngo-20211231.xsd#bngo_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LabEquipmentMember" xlink:to="lab_bngo_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9c280226-4a23-459f-bf29-930f24af178c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_b0710112-32d7-4b34-8226-1df99137b87d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty liabilities</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_77141bbb-e5d4-4284-b94c-3fdf0003829f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_9db7a3e2-b62d-4162-961c-16bb52e7c428_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2df992e0-0ada-44b0-84e6-6404e8a68863_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7d3abe8c-dfd4-48ec-bcbb-c4c11bc2239c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) on investment securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0917e8b8-ac58-41c1-b213-dbf851cc9050_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_d36a92d6-6e20-4cae-9fa4-8563fbb7c9c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eacca9bb-ca52-440e-957f-d85a3dc4d485_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Stock under Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_55e16987-fadb-4e4c-94d3-edb6e05f6ccc_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2f510c23-25cc-477d-a3b4-65deef2151a2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c8693dd1-d402-4447-bdf4-22ba4fd2285f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_12455ba9-637d-4fc8-aade-2574fd7172ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CommonStockOptionMember_15e4f3f5-146b-4dea-a767-bf227a7727d9_terseLabel_en-US" xlink:label="lab_bngo_CommonStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_bngo_CommonStockOptionMember_label_en-US" xlink:label="lab_bngo_CommonStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Option [Member]</link:label>
    <link:label id="lab_bngo_CommonStockOptionMember_documentation_en-US" xlink:label="lab_bngo_CommonStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock option member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockOptionMember" xlink:href="bngo-20211231.xsd#bngo_CommonStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CommonStockOptionMember" xlink:to="lab_bngo_CommonStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8e811454-861d-45be-8e23-e5c4470a96f9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2faf1caf-e997-4945-ad9d-72cd8716a411_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash financing and investing activity</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_a2234911-dbf1-4987-871d-4191b5b0c208_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_035f7655-7b3e-4baf-bf67-8f4be1178714_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_5f9aab57-0e20-4dc8-8862-58d45f8fec6b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d4e5c7af-ba0c-4154-acf8-92b1c7ff81d0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c4c1adac-2936-470d-ab33-450df6517af1_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8ecd0975-e88a-48aa-94b7-c59b1c617845_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_4ff3b9bf-9ffa-4e78-baf9-60e59c299c49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a20d739c-efbd-4163-bdee-887c5b51e7de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d43b3131-2597-4e67-8431-92f5ae2f557b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c9f5ac02-e8da-4c63-9195-69fb4b1b2846_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LicensingRevenueAndMaintenanceAgreements_08827980-91f3-497a-866a-7c0d7c2a1cec_terseLabel_en-US" xlink:label="lab_bngo_LicensingRevenueAndMaintenanceAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue and maintenance agreements</link:label>
    <link:label id="lab_bngo_LicensingRevenueAndMaintenanceAgreements_label_en-US" xlink:label="lab_bngo_LicensingRevenueAndMaintenanceAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Revenue and Maintenance Agreements</link:label>
    <link:label id="lab_bngo_LicensingRevenueAndMaintenanceAgreements_documentation_en-US" xlink:label="lab_bngo_LicensingRevenueAndMaintenanceAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Revenue and Maintenance Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LicensingRevenueAndMaintenanceAgreements" xlink:href="bngo-20211231.xsd#bngo_LicensingRevenueAndMaintenanceAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LicensingRevenueAndMaintenanceAgreements" xlink:to="lab_bngo_LicensingRevenueAndMaintenanceAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_7cb3593b-0a30-4e10-a32f-1ab4376d227f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4431eb46-a637-4e65-8779-c712b6918f82_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_43bf9131-786a-4676-a684-646100041acc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_62ecea88-112b-4e14-bc71-481be09836c9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_1755f5ed-0fd8-4038-b084-de0380ea262d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_BusinessAcquisitionMilestonePayment_ba65cf60-e36e-4775-af49-f7b120efa8f5_terseLabel_en-US" xlink:label="lab_bngo_BusinessAcquisitionMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionMilestonePayment_label_en-US" xlink:label="lab_bngo_BusinessAcquisitionMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Milestone Payment</link:label>
    <link:label id="lab_bngo_BusinessAcquisitionMilestonePayment_documentation_en-US" xlink:label="lab_bngo_BusinessAcquisitionMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionMilestonePayment" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_BusinessAcquisitionMilestonePayment" xlink:to="lab_bngo_BusinessAcquisitionMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_14e11e5c-e84b-4103-9147-e7a81f38afe8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f46e6a2c-35ca-44ce-8338-ebbdde2b9aa6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_c724dfda-f33b-4a30-b843-89f7637329c8_terseLabel_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of instruments and servers from inventory into property and equipment, net</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_label_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Instruments And Servers To Property And Equipment From Inventory</link:label>
    <link:label id="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_documentation_en-US" xlink:label="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of instruments and servers to property and equipment from inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:href="bngo-20211231.xsd#bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:to="lab_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_751b6d28-6656-4971-8a33-2645f4ae8576_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Three</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_label_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Three [Member]</link:label>
    <link:label id="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Terms, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:to="lab_bngo_DebtInstrumentPaymentTermsPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_643cd343-ffc6-4ad5-928f-29b68d4c1411_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase, Fair value preferred stock (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fb77178a-5806-462d-b135-ff105d3b6a73_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at January 1, 2019 (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_85d11dc8-2efb-4f3c-92c3-cd33666c8b5b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2019 (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_13d4af24-6107-476f-87f0-9e997348a262_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ConsumableRevenueMember_7366a965-abec-4f4d-8bfc-fb0b407963c8_terseLabel_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumables</link:label>
    <link:label id="lab_bngo_ConsumableRevenueMember_label_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable Revenue [Member]</link:label>
    <link:label id="lab_bngo_ConsumableRevenueMember_documentation_en-US" xlink:label="lab_bngo_ConsumableRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumable Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember" xlink:href="bngo-20211231.xsd#bngo_ConsumableRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ConsumableRevenueMember" xlink:to="lab_bngo_ConsumableRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_TermLoanMember_f5dc374b-be56-4fae-a5d2-c041c895df5b_terseLabel_en-US" xlink:label="lab_bngo_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
    <link:label id="lab_bngo_TermLoanMember_label_en-US" xlink:label="lab_bngo_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_bngo_TermLoanMember_documentation_en-US" xlink:label="lab_bngo_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermLoanMember" xlink:href="bngo-20211231.xsd#bngo_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_TermLoanMember" xlink:to="lab_bngo_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4b51f282-83af-40cb-bd94-36ac91620697_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and maturities of available for sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cbe9b2d1-e494-4712-b653-d8bece1e6ba1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_35570cc3-fcef-47a8-a739-32ffe9df51a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_f3d1e9aa-0755-404c-bf10-009c583ae774_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_cef1a828-1f7b-48f8-b6ec-732788147d15_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e59e113a-ee07-4ed9-9298-00f5b0862385_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a8e4ae47-5807-41dc-9dc9-e2894821477b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_97a126ea-0dad-4ee2-a185-2843e31165c9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_bf093019-c542-4659-8dff-be1cdc9fabe8_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_06b4f556-361d-4552-8073-b5e9571e0dfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_feb41928-07f0-448a-bb5d-44e2920e1182_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed of acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3aca7b04-5203-4c86-8f60-0db85c9a0b34_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_706aef35-eb0c-4ce0-ada7-cc7e06070c4f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7929d0f7-4c37-423b-ab89-ee6c92186652_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_cde8d80c-0bc5-4823-b08e-ffcfaf48e1f5_terseLabel_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock warrant exercises (in shares)</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_bngo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f6721f32-006a-4055-bfca-0c97e5866f34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_3c582e41-6194-4c12-aabf-c9641d36dbef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_037d9296-4aea-4e1e-ba3b-39e53ea052c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_82e5f92f-f75f-477a-8681-bfe8ea797239_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_95682460-cb17-48c4-8b9c-551fe71655e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExpirationPeriod_09241334-afb6-4b38-86d4-e3fa7eb9979d_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, expiration period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExpirationPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightExpirationPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExpirationPeriod" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightExpirationPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d760e9e4-23a0-4b4b-b3a9-9a5de8a47a17_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_RevolverMember_ce31648a-e6e9-4ac2-b3d2-3161323a096b_terseLabel_en-US" xlink:label="lab_bngo_RevolverMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver</link:label>
    <link:label id="lab_bngo_RevolverMember_label_en-US" xlink:label="lab_bngo_RevolverMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver [Member]</link:label>
    <link:label id="lab_bngo_RevolverMember_documentation_en-US" xlink:label="lab_bngo_RevolverMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RevolverMember" xlink:href="bngo-20211231.xsd#bngo_RevolverMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_RevolverMember" xlink:to="lab_bngo_RevolverMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3680fe7b-75b7-428e-8fb6-ad50d2c03e91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d611a857-c46a-4e69-a0da-666470edd8f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Domestic and Foreign Components of Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_13e3d8a5-0c8e-4143-9eaf-3c66aa2e72a0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_e660fdae-bb3d-4bea-b4b7-863e874a163c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7d572b73-2ace-4ffe-ba6f-b2227337ff31_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_c397fc41-3810-4f30-ad5f-3357d08bc4bd_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2f7a7292-e180-4642-8441-d47b7a42fb59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_3c630cf2-ca83-4a78-bfd2-a8a341e4be86_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_ec09baef-6d88-48c3-8d48-ac2e3a5ccb3b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_25c57c89-9869-4243-85f6-0ec2b7052171_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_707e8d55-5716-4a17-9109-1aa1576c357b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f0ab1585-ba0c-48d5-8283-54ac8dd1bf06_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock initially reserved for future issuance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_1a726106-037d-4798-93b2-b7de72afa439_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_WorkingCapital_82314f7a-c0c4-4dc6-8d8e-152da33b731a_terseLabel_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_bngo_WorkingCapital_label_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_bngo_WorkingCapital_documentation_en-US" xlink:label="lab_bngo_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WorkingCapital" xlink:href="bngo-20211231.xsd#bngo_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_WorkingCapital" xlink:to="lab_bngo_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LoanUnderPaycheckProtectionProgramMember_157739ce-43ae-4606-b9c2-bf65eb754255_terseLabel_en-US" xlink:label="lab_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan</link:label>
    <link:label id="lab_bngo_LoanUnderPaycheckProtectionProgramMember_label_en-US" xlink:label="lab_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Under Paycheck Protection Program [Member]</link:label>
    <link:label id="lab_bngo_LoanUnderPaycheckProtectionProgramMember_documentation_en-US" xlink:label="lab_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Under Paycheck Protection Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:href="bngo-20211231.xsd#bngo_LoanUnderPaycheckProtectionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:to="lab_bngo_LoanUnderPaycheckProtectionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f5de240d-26d8-482e-b628-1d9345feabe7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_004667ad-45c6-40ad-aed6-b55c58ad0ca3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7d5f3058-7c6c-4579-8c4b-64072c61903a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_6f1c79c1-c8a3-4116-aea0-5890dbadf56c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets (including Finite-Lived Purchased Intangible Assets)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_cc699d73-0a15-42f8-ad0b-d47d5a47c9ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_83f45081-350b-4110-a562-d96e11836305_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassofWarrantorRightTerm_c565bb43-ee5b-4ced-aca1-39b0408308f1_terseLabel_en-US" xlink:label="lab_bngo_ClassofWarrantorRightTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_bngo_ClassofWarrantorRightTerm_label_en-US" xlink:label="lab_bngo_ClassofWarrantorRightTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_bngo_ClassofWarrantorRightTerm_documentation_en-US" xlink:label="lab_bngo_ClassofWarrantorRightTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassofWarrantorRightTerm" xlink:href="bngo-20211231.xsd#bngo_ClassofWarrantorRightTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassofWarrantorRightTerm" xlink:to="lab_bngo_ClassofWarrantorRightTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_e150b258-0422-47c0-b93f-94015bc58784_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_26281c9c-56f4-476a-9114-86489da4c029_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_e107853f-9873-4660-b61e-68061615850a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_d44f9f7d-c4c1-472e-983f-7099520b3038_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Granted In Period</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Granted In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:to="lab_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2bd51349-effb-4569-a42c-f98f82d87ec5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_932a63f0-75fa-478f-ac81-5205d6f491c3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d37888e6-e431-462e-90c8-e8b261c9ff12_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_62f43963-5843-4a47-9298-508a1e8b94fc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6eb6d9d6-2eea-4e26-a79c-50d9c4924ad1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b0a35f8b-0186-4c41-acdd-5c65fe730957_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a37bc3b7-550d-45ef-9683-f01638bc2404_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_3f4137be-4b2c-4c1e-9d71-ff7b0b7499f6_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_02b3e133-46f9-4c26-a3b1-2e3939246b9b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_fe869d68-3184-4aba-9b97-410cb5af6dd0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d6ce5d19-584e-4234-949d-87130f58a6a6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_72ed67ed-0e79-4fe3-ae80-c9fbfc69abb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity Under 2018 Plan and 2006 Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_592b5be2-2175-4067-b19e-fe4a871232cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity and Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0c77d9f4-288a-4740-94d5-3e91ffdce05a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of term charge</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0ea8bef6-8790-4682-8333-01df69f75087_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0d77d6ef-1276-4aa7-831f-8935636fc640_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_f3ff7537-eb6d-4f74-bab6-2451dd9bdfd0_terseLabel_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Stock under Warrants</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="lab_bngo_ClassOfWarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_71f0eb51-3860-4b63-b718-ee91007b8114_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_82a9daf9-a90c-418a-b51d-b58bf7dc15a9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_145a232c-5f77-4624-ac75-cdd21738b6cf_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_e29f62d7-1280-4985-8eda-8847ed46d402_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_bbceb927-c1b9-4593-96d8-6e414825be45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3e604a75-a4ef-46da-8171-1982bb51ab94_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2063b5bd-07cd-46e0-8c37-f3f454d85fed_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1f453f13-65ad-4db7-a926-7332ec5d6fef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_41117d17-ad0d-4038-83ab-01e3827cb504_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_f74b3787-64d6-4dbf-b862-f49bad3c970c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8ecc6d7e-18a4-432f-b06a-4594a5da2244_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities (net of assets acquired and liabilities assumed in acquisition)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember_5ee3a706-68e1-4999-88bf-9f3011a4ddbd_terseLabel_en-US" xlink:label="lab_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships, Developed Technology and Trade Names</link:label>
    <link:label id="lab_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember_label_en-US" xlink:label="lab_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships, Developed Technology and Trade Names [Member]</link:label>
    <link:label id="lab_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember_documentation_en-US" xlink:label="lab_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships, Developed Technology and Trade Names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember" xlink:href="bngo-20211231.xsd#bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember" xlink:to="lab_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ad077937-2b05-4bae-9056-3f71484b037e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1ce879c5-3c5b-468a-9184-3745548b2e80_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue stock for employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_52ffdfbf-fc38-4098-a8f8-1cf8a848aa2e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d4f0c5e9-0123-4689-943c-4d5cf836ead5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_db194e6d-a77a-4dc9-9c4e-6d3137f385d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_02605a8e-d5ac-42c4-a49b-ffd055a57de4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6469abea-a692-4ce6-aa81-e02eba6815ae_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6c52a162-4e39-4361-9c50-ca115262f957_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_275c02c6-a26a-41df-ae04-fe61883b25aa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_d13a9e0c-2b01-40e6-8edb-5885dd59e2b3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_93792540-66ef-459d-9800-c0100c6165b7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_24b24d9e-d398-4e9c-aac6-2d15a2262bb2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_acca475c-777d-4fe1-8e38-d0f6ac3c51d3_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_5a0caa29-808f-47e8-a39e-9bc0ddb2dcc8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_216f2fa4-1396-4291-925e-f622a303b38c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facility available</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_85513a2c-a035-405c-bced-1394eb29cba5_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_26504742-ae77-454f-8f8a-928e9466e277_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_5be28e27-8e66-440c-9d92-565f819da25e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_NonCashLeaseExpense_61b34801-d372-4d82-9b46-46b76bc5c480_terseLabel_en-US" xlink:label="lab_bngo_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_bngo_NonCashLeaseExpense_label_en-US" xlink:label="lab_bngo_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Lease Expense</link:label>
    <link:label id="lab_bngo_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_bngo_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NonCashLeaseExpense" xlink:href="bngo-20211231.xsd#bngo_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_NonCashLeaseExpense" xlink:to="lab_bngo_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ff53ec6c-26b5-4896-9e76-37f3e81b998b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentPrepaymentFeePercent_e6b5ee6b-49a4-49da-ba0a-dd151ba6ad54_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage</link:label>
    <link:label id="lab_bngo_DebtInstrumentPrepaymentFeePercent_label_en-US" xlink:label="lab_bngo_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percent</link:label>
    <link:label id="lab_bngo_DebtInstrumentPrepaymentFeePercent_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment fee percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPrepaymentFeePercent" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPrepaymentFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentPrepaymentFeePercent" xlink:to="lab_bngo_DebtInstrumentPrepaymentFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_CostOfLeasedEquipmentSoldToCustomer_865dc55c-e8b7-48b7-a486-d53dfb4a7130_terseLabel_en-US" xlink:label="lab_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of leased equipment sold to customer</link:label>
    <link:label id="lab_bngo_CostOfLeasedEquipmentSoldToCustomer_label_en-US" xlink:label="lab_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Leased Equipment Sold to Customer</link:label>
    <link:label id="lab_bngo_CostOfLeasedEquipmentSoldToCustomer_documentation_en-US" xlink:label="lab_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Leased Equipment Sold to Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:href="bngo-20211231.xsd#bngo_CostOfLeasedEquipmentSoldToCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:to="lab_bngo_CostOfLeasedEquipmentSoldToCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_b5757dee-637b-4cd7-acf4-f344037e5780_terseLabel_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_label_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value, Shares Issued in Transaction</link:label>
    <link:label id="lab_bngo_SaleOfStockValueSharesIssuedInTransaction_documentation_en-US" xlink:label="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Value, Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:href="bngo-20211231.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:to="lab_bngo_SaleOfStockValueSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_4e6e35a5-4e84-43fa-af53-799ca35c01c4_terseLabel_en-US" xlink:label="lab_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental rate at which the shares reserved for issuance increase</link:label>
    <link:label id="lab_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_label_en-US" xlink:label="lab_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Increase In Aggregate Number Of Shares Reserved For Future Issuance As Percentage Shares Outstanding</link:label>
    <link:label id="lab_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_documentation_en-US" xlink:label="lab_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in aggregate number of shares reserved for future issuance as percentage shares outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:href="bngo-20211231.xsd#bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:to="lab_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7f4be8d3-58cd-4656-b576-29fd206050a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_c500618f-82fe-478d-9490-6b6a2856e901_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_c42d08f1-ab89-42f6-aeae-5befd23f8ff6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e00223ea-3e8e-4d7a-8b9a-4e2eecc8881c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise_a52aaeba-586d-4a8e-af19-4b9556f1eac0_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default payment required upon completion of equity raise</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise_label_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Default Payment Required Upon Completion of Equity Raise</link:label>
    <link:label id="lab_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Default Payment Required Upon Completion of Equity Raise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" xlink:to="lab_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_faf55742-cb76-4397-b8b0-913fd4ef9b7e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued But Not Yet Adopted and Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_80f2c6a8-2399-425a-959f-6342a433e482_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_LesseeOperatingLeaseAreaLeased_2dd75332-1722-494a-a7ca-919ff34cda93_terseLabel_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseAreaLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, area leased (in sq ft)</link:label>
    <link:label id="lab_bngo_LesseeOperatingLeaseAreaLeased_label_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseAreaLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Leased</link:label>
    <link:label id="lab_bngo_LesseeOperatingLeaseAreaLeased_documentation_en-US" xlink:label="lab_bngo_LesseeOperatingLeaseAreaLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Leased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseAreaLeased" xlink:href="bngo-20211231.xsd#bngo_LesseeOperatingLeaseAreaLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_LesseeOperatingLeaseAreaLeased" xlink:to="lab_bngo_LesseeOperatingLeaseAreaLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0353586a-f9d4-4e00-8db5-5a25eec5b31e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0fd5fa84-5814-4eac-8b29-1c4a66b04e8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_99bd657b-f8b7-40ac-812f-9db08d7639ab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_a650689a-191e-46f2-a54e-dea07ac41884_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_bc17f483-3ce1-4510-a36d-2308529d167e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_97c14090-03ed-467c-b8b1-20cfe56a6044_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_EmployeeStockPurchasePlanCompensationExpense_bb3b4881-e14d-44af-877e-de2b901112ad_terseLabel_en-US" xlink:label="lab_bngo_EmployeeStockPurchasePlanCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_bngo_EmployeeStockPurchasePlanCompensationExpense_label_en-US" xlink:label="lab_bngo_EmployeeStockPurchasePlanCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Compensation Expense</link:label>
    <link:label id="lab_bngo_EmployeeStockPurchasePlanCompensationExpense_documentation_en-US" xlink:label="lab_bngo_EmployeeStockPurchasePlanCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EmployeeStockPurchasePlanCompensationExpense" xlink:href="bngo-20211231.xsd#bngo_EmployeeStockPurchasePlanCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_EmployeeStockPurchasePlanCompensationExpense" xlink:to="lab_bngo_EmployeeStockPurchasePlanCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate_fa187b92-4df7-47d5-b127-6c368b6ae395_terseLabel_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted cash rate</link:label>
    <link:label id="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate_label_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Discounted Cash Rate</link:label>
    <link:label id="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate_documentation_en-US" xlink:label="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Discounted Cash Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentInterestRateDiscountedCashRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:to="lab_bngo_DebtInstrumentInterestRateDiscountedCashRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_af6b6db2-a0a3-4069-b086-7034982a9c9a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liability, net of current portion, related party</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_OperatingLossCarryforwardsSubjecttoExpiration_3388a243-9ad8-42c7-bcd8-65067ed45978_terseLabel_en-US" xlink:label="lab_bngo_OperatingLossCarryforwardsSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_bngo_OperatingLossCarryforwardsSubjecttoExpiration_label_en-US" xlink:label="lab_bngo_OperatingLossCarryforwardsSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label id="lab_bngo_OperatingLossCarryforwardsSubjecttoExpiration_documentation_en-US" xlink:label="lab_bngo_OperatingLossCarryforwardsSubjecttoExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLossCarryforwardsSubjecttoExpiration" xlink:href="bngo-20211231.xsd#bngo_OperatingLossCarryforwardsSubjecttoExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_OperatingLossCarryforwardsSubjecttoExpiration" xlink:to="lab_bngo_OperatingLossCarryforwardsSubjecttoExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7cd859d3-8c49-4398-a676-ec8f0a0586e4_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_66fc9ec5-f8ca-4e88-a1f0-3b2e872d77bc_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_ContingentConsiderationLiabilityMember_22d89577-5a84-47b9-80fa-2c6675e8eac2_terseLabel_en-US" xlink:label="lab_bngo_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_bngo_ContingentConsiderationLiabilityMember_label_en-US" xlink:label="lab_bngo_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability [Member]</link:label>
    <link:label id="lab_bngo_ContingentConsiderationLiabilityMember_documentation_en-US" xlink:label="lab_bngo_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_ContingentConsiderationLiabilityMember" xlink:to="lab_bngo_ContingentConsiderationLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_e77fdfe1-6c17-4139-839e-3ae419219d9b_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for product warranties</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrual" xlink:to="lab_us-gaap_StandardProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_548eac1c-857b-4657-894f-2ef58b1d799a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_924eafc0-a665-4471-a4d5-59b2b28d7a5b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_DeferredTaxAssetsLeaseLiability_57cf0e12-a68f-478c-906d-07f3932183dd_terseLabel_en-US" xlink:label="lab_bngo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 842 - lease liability</link:label>
    <link:label id="lab_bngo_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_bngo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_bngo_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_bngo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxAssetsLeaseLiability" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_DeferredTaxAssetsLeaseLiability" xlink:to="lab_bngo_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_c4bfb7e9-e56a-4fd0-a274-a533794380c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ddf4fee5-1ff5-4e3e-b71d-f499e706259f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_dd7741f8-e0ae-483c-9b45-7c1120af3b27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value, recorded in selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e8cca461-17fd-4b72-b572-a9af2c63539c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b3f4c24b-adce-40f9-9822-defef9bf54a7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_7546d1d4-ad82-4127-b63d-cdecc5aab41b_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b85f5bc9-3858-4726-9d95-c7583cd39653_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_afa5cdb8-81fa-47f4-98ba-be764e628c83_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_43871e7b-f9b1-45da-a588-d7a36c7836f7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_5ae5432c-7227-4079-a289-030938fefc3a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_10d76545-846c-492d-b409-4463dcc259d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_bngo_AuditInformationAbstract_label_en-US" xlink:label="lab_bngo_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bngo_AuditInformationAbstract_documentation_en-US" xlink:label="lab_bngo_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AuditInformationAbstract" xlink:href="bngo-20211231.xsd#bngo_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bngo_AuditInformationAbstract" xlink:to="lab_bngo_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_109adf27-ee33-4787-a7ac-81c6163d8469_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6af109c-fb00-464d-ab39-f6a7ccdf84cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_fdb6a132-f48a-4703-8a94-5ac05eeb63ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_47a9d2a0-5a85-4fc7-8ca1-0ac95d62183d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_96186de5-8877-49f7-ad81-21d26e107fff_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_73a89504-4c15-4b05-a373-c5aeba120bd4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>bngo-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e3db6ed1-8b4e-4b22-9c48-82142796368a,g:231d39e4-2c00-4236-9c0c-64cfa873dbdc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://bionanogenomics.com/role/Cover" xlink:type="simple" xlink:href="bngo-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_276bf1fd-5cb3-4503-917f-c17ee25e1975" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_4ae32a2a-e398-4859-a220-7db5ccacfde1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_276bf1fd-5cb3-4503-917f-c17ee25e1975" xlink:to="loc_dei_DocumentInformationTable_4ae32a2a-e398-4859-a220-7db5ccacfde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_4ae32a2a-e398-4859-a220-7db5ccacfde1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d529ec44-0e10-4c7e-a40a-00dfb2617654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12e0b41e-9cdb-4aa0-ae37-3c9d7b3cbe49" xlink:to="loc_us-gaap_ClassOfStockDomain_d529ec44-0e10-4c7e-a40a-00dfb2617654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2d128496-a1f5-45e3-bda0-3d9150a7db00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d529ec44-0e10-4c7e-a40a-00dfb2617654" xlink:to="loc_us-gaap_CommonStockMember_2d128496-a1f5-45e3-bda0-3d9150a7db00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2d0cc9de-f4fb-4f24-ba05-8896bb4c9a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d529ec44-0e10-4c7e-a40a-00dfb2617654" xlink:to="loc_us-gaap_WarrantMember_2d0cc9de-f4fb-4f24-ba05-8896bb4c9a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_4ae32a2a-e398-4859-a220-7db5ccacfde1" xlink:to="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cbcd7426-e1fd-49fd-aa99-ac0f7bf3a84d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentType_cbcd7426-e1fd-49fd-aa99-ac0f7bf3a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_1f5ab6d6-b66e-40cd-9e35-7bed93bbe077" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentAnnualReport_1f5ab6d6-b66e-40cd-9e35-7bed93bbe077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ea16e2c5-9ae2-490f-845b-6004154c7e20" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentPeriodEndDate_ea16e2c5-9ae2-490f-845b-6004154c7e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_78db8e8e-9a36-4f75-9293-dd23d3c70f94" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_CurrentFiscalYearEndDate_78db8e8e-9a36-4f75-9293-dd23d3c70f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1eca04f3-2365-4912-980b-ad28e2c863aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentTransitionReport_1eca04f3-2365-4912-980b-ad28e2c863aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_41f1c5be-ef03-4a02-9d26-46bf0f643c50" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityFileNumber_41f1c5be-ef03-4a02-9d26-46bf0f643c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e2b81e7f-79ef-41bb-b4c9-2ccd91c8e15b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityRegistrantName_e2b81e7f-79ef-41bb-b4c9-2ccd91c8e15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4191ffe6-ad57-406a-bf67-fa62e3ef4496" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4191ffe6-ad57-406a-bf67-fa62e3ef4496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dfa42562-8d63-4bd4-bb9d-6689bee38b39" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityTaxIdentificationNumber_dfa42562-8d63-4bd4-bb9d-6689bee38b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_88eedd7c-87c1-4641-96a1-53b8b04b2441" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressAddressLine1_88eedd7c-87c1-4641-96a1-53b8b04b2441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_20924f1e-967b-4314-bc11-fe2a213236ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressAddressLine2_20924f1e-967b-4314-bc11-fe2a213236ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4b3376fb-2b5f-4255-b3ec-e0f72ba8f4c1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressCityOrTown_4b3376fb-2b5f-4255-b3ec-e0f72ba8f4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_215a2418-cdf3-4cee-a734-ae66f41dc12f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressStateOrProvince_215a2418-cdf3-4cee-a734-ae66f41dc12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_04f9f09d-aeca-4155-9a66-80a911a3ae2b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityAddressPostalZipCode_04f9f09d-aeca-4155-9a66-80a911a3ae2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c4b28cac-f658-43e5-bd6f-d269900290ba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_CityAreaCode_c4b28cac-f658-43e5-bd6f-d269900290ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e90ad7da-a41b-4e0c-9e22-d6b118e77099" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_LocalPhoneNumber_e90ad7da-a41b-4e0c-9e22-d6b118e77099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3a2938c2-8925-41d0-a938-d5fdb21981a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_Security12bTitle_3a2938c2-8925-41d0-a938-d5fdb21981a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c404efb8-6fdd-4f75-8403-02f045651d8f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_TradingSymbol_c404efb8-6fdd-4f75-8403-02f045651d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_49e10c32-e5b9-45da-ab15-69f9583e6634" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_SecurityExchangeName_49e10c32-e5b9-45da-ab15-69f9583e6634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_3dfe9122-a8a8-474e-a2f4-a7bf82fa3663" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_3dfe9122-a8a8-474e-a2f4-a7bf82fa3663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_2f6435f2-9fb6-4965-ae63-b166a4ee46ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityVoluntaryFilers_2f6435f2-9fb6-4965-ae63-b166a4ee46ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d154cd48-eee2-4531-8ec7-d9feaff0a5c1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityCurrentReportingStatus_d154cd48-eee2-4531-8ec7-d9feaff0a5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_abcfef81-b8b9-42d3-8247-54804ff8f184" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityInteractiveDataCurrent_abcfef81-b8b9-42d3-8247-54804ff8f184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_81705d35-2a1e-49cc-838f-0a387e01f5be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityFilerCategory_81705d35-2a1e-49cc-838f-0a387e01f5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_82d2337e-f69d-4fb1-ad61-8f5661c8d047" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntitySmallBusiness_82d2337e-f69d-4fb1-ad61-8f5661c8d047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6ee339aa-a16d-4f20-9bba-0c4b16b2d6fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityEmergingGrowthCompany_6ee339aa-a16d-4f20-9bba-0c4b16b2d6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_d3eea8c4-adb7-4392-838c-6a6a0e03e96f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_IcfrAuditorAttestationFlag_d3eea8c4-adb7-4392-838c-6a6a0e03e96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1f7bc399-9012-4a67-9bc8-8783e7dd8200" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityShellCompany_1f7bc399-9012-4a67-9bc8-8783e7dd8200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_55d38980-3a44-48a0-ad94-f96dd2cd12a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityPublicFloat_55d38980-3a44-48a0-ad94-f96dd2cd12a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bf148b7b-06be-4877-85ca-82d55ba8d2bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bf148b7b-06be-4877-85ca-82d55ba8d2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d7e91c84-34b2-4bf1-bd4c-935f49360316" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d7e91c84-34b2-4bf1-bd4c-935f49360316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_05f11f27-5eb6-4cf8-8559-2ecf03439d9e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_EntityCentralIndexKey_05f11f27-5eb6-4cf8-8559-2ecf03439d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4f21b17d-bb57-4f00-a90f-d71652a8a95d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentFiscalYearFocus_4f21b17d-bb57-4f00-a90f-d71652a8a95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_433fd701-7f39-4534-aaed-266ac54fb761" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_433fd701-7f39-4534-aaed-266ac54fb761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_86c10ffd-eb39-4b1a-9387-c67bec4e0663" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_858ad4c5-a742-4724-b801-b88351e9aed8" xlink:to="loc_dei_AmendmentFlag_86c10ffd-eb39-4b1a-9387-c67bec4e0663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AuditInformation" xlink:type="simple" xlink:href="bngo-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AuditInformationAbstract_9d2b6fe4-a8fa-45b3-98ae-3e5ea0a65a5e" xlink:href="bngo-20211231.xsd#bngo_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_fd0ec94f-bbf3-4cb6-925a-4d1a78ccab9d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_AuditInformationAbstract_9d2b6fe4-a8fa-45b3-98ae-3e5ea0a65a5e" xlink:to="loc_dei_AuditorName_fd0ec94f-bbf3-4cb6-925a-4d1a78ccab9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_65794ddb-888a-4c5d-a2b6-c92cbf50df84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_AuditInformationAbstract_9d2b6fe4-a8fa-45b3-98ae-3e5ea0a65a5e" xlink:to="loc_dei_AuditorLocation_65794ddb-888a-4c5d-a2b6-c92cbf50df84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_f39b3959-109e-45ca-a1c1-41808ff6d868" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_AuditInformationAbstract_9d2b6fe4-a8fa-45b3-98ae-3e5ea0a65a5e" xlink:to="loc_dei_AuditorFirmId_f39b3959-109e-45ca-a1c1-41808ff6d868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1dddc7f3-9bec-432c-a742-50eaa2f910a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1dddc7f3-9bec-432c-a742-50eaa2f910a1" xlink:to="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a7920a22-07ed-4ca2-9c8f-653b56a8870c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a7920a22-07ed-4ca2-9c8f-653b56a8870c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4192530d-364f-4928-b75d-1aec3397af2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7920a22-07ed-4ca2-9c8f-653b56a8870c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4192530d-364f-4928-b75d-1aec3397af2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9f77a7e2-049b-43b1-8af8-1842c7d13633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7920a22-07ed-4ca2-9c8f-653b56a8870c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9f77a7e2-049b-43b1-8af8-1842c7d13633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_da8dbb9d-c1de-42f2-8f88-59ef4160f906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7920a22-07ed-4ca2-9c8f-653b56a8870c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_da8dbb9d-c1de-42f2-8f88-59ef4160f906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fe759a6a-f126-467d-8336-eafdd50640c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7920a22-07ed-4ca2-9c8f-653b56a8870c" xlink:to="loc_us-gaap_InventoryNet_fe759a6a-f126-467d-8336-eafdd50640c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_713fa46b-6cd2-4468-b68e-efe23f1ce4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7920a22-07ed-4ca2-9c8f-653b56a8870c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_713fa46b-6cd2-4468-b68e-efe23f1ce4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f03b53fe-307f-4940-94ff-0f6cb7390050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7920a22-07ed-4ca2-9c8f-653b56a8870c" xlink:to="loc_us-gaap_AssetsCurrent_f03b53fe-307f-4940-94ff-0f6cb7390050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2ba7e23a-4cea-4124-8b5a-763b217b26e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2ba7e23a-4cea-4124-8b5a-763b217b26e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_54f8378f-915b-4b88-8542-f813fff71016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_54f8378f-915b-4b88-8542-f813fff71016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_6fdbf796-da4b-499a-8666-960eddaa585d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_6fdbf796-da4b-499a-8666-960eddaa585d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_41292d03-a5f2-413a-a6fb-3502bee94d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_41292d03-a5f2-413a-a6fb-3502bee94d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_71f0489b-8cf3-4705-8cab-58f76263d4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:to="loc_us-gaap_Goodwill_71f0489b-8cf3-4705-8cab-58f76263d4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2034040a-335c-46b6-8e95-b15fd22406ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2034040a-335c-46b6-8e95-b15fd22406ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_884e4425-4528-41d1-849f-188fc503601f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0335a1cc-353b-493f-a3d2-942af50b1800" xlink:to="loc_us-gaap_Assets_884e4425-4528-41d1-849f-188fc503601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1dddc7f3-9bec-432c-a742-50eaa2f910a1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_eae87b3a-f041-4074-858e-d1e624c18b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_eae87b3a-f041-4074-858e-d1e624c18b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_46fc1eb3-13d2-4ac6-9faa-957cf488b210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eae87b3a-f041-4074-858e-d1e624c18b14" xlink:to="loc_us-gaap_AccountsPayableCurrent_46fc1eb3-13d2-4ac6-9faa-957cf488b210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bed080a4-9fca-4d2f-898b-d18a91bff0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eae87b3a-f041-4074-858e-d1e624c18b14" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bed080a4-9fca-4d2f-898b-d18a91bff0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_a488902b-4e9d-41ff-a846-ee5f51c8294a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eae87b3a-f041-4074-858e-d1e624c18b14" xlink:to="loc_us-gaap_DeferredRevenueCurrent_a488902b-4e9d-41ff-a846-ee5f51c8294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b41edd18-3f89-4ba0-892f-85ed11c10081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eae87b3a-f041-4074-858e-d1e624c18b14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b41edd18-3f89-4ba0-892f-85ed11c10081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_20b6fa58-9693-4e17-9064-347e0f1705c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eae87b3a-f041-4074-858e-d1e624c18b14" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_20b6fa58-9693-4e17-9064-347e0f1705c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e724555c-843b-4a8f-b430-4992e94c8009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eae87b3a-f041-4074-858e-d1e624c18b14" xlink:to="loc_us-gaap_LiabilitiesCurrent_e724555c-843b-4a8f-b430-4992e94c8009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_569d2144-38ad-400f-ab9f-f217a10c7845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_569d2144-38ad-400f-ab9f-f217a10c7845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_79f7ebca-d881-4ae5-ae9a-80c8521f419d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_79f7ebca-d881-4ae5-ae9a-80c8521f419d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationFairValueOfContingentLiability_0b94f76b-5b0f-44e7-8d08-56e3e52a03ba" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationFairValueOfContingentLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_bngo_ContingentConsiderationFairValueOfContingentLiability_0b94f76b-5b0f-44e7-8d08-56e3e52a03ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5891f2c5-cbad-48be-b464-e5d3d09880ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5891f2c5-cbad-48be-b464-e5d3d09880ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_9337eebd-9216-41cd-ba8f-676e184a0e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_9337eebd-9216-41cd-ba8f-676e184a0e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e3238253-27ef-44b4-acd6-23f62e6aca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_Liabilities_e3238253-27ef-44b4-acd6-23f62e6aca9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8efececb-8cfa-4b66-b7a5-4d1a105d3a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8efececb-8cfa-4b66-b7a5-4d1a105d3a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1d44767f-c036-4abf-bdc5-fd0d39e03653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1d44767f-c036-4abf-bdc5-fd0d39e03653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_de724614-2b6c-4f6e-bc6f-49818844be58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1d44767f-c036-4abf-bdc5-fd0d39e03653" xlink:to="loc_us-gaap_PreferredStockValue_de724614-2b6c-4f6e-bc6f-49818844be58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4d2a081c-5261-4d2d-b547-33f7e3e586be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1d44767f-c036-4abf-bdc5-fd0d39e03653" xlink:to="loc_us-gaap_CommonStockValue_4d2a081c-5261-4d2d-b547-33f7e3e586be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ca2053be-f6e4-4af4-83c7-a2f1222b5354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1d44767f-c036-4abf-bdc5-fd0d39e03653" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ca2053be-f6e4-4af4-83c7-a2f1222b5354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74e05654-76e3-4edf-828d-dd60ddea0fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1d44767f-c036-4abf-bdc5-fd0d39e03653" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74e05654-76e3-4edf-828d-dd60ddea0fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f4be5a41-86b2-47d4-8b95-464496d8af68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1d44767f-c036-4abf-bdc5-fd0d39e03653" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f4be5a41-86b2-47d4-8b95-464496d8af68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20aa899c-98d1-4eaa-8b50-1f691a225e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1d44767f-c036-4abf-bdc5-fd0d39e03653" xlink:to="loc_us-gaap_StockholdersEquity_20aa899c-98d1-4eaa-8b50-1f691a225e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_487728a0-8801-403a-9115-53137ba1ba14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a8f318e5-6bf8-478c-83bd-a0b7510e13b8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_487728a0-8801-403a-9115-53137ba1ba14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bb7acd91-b19d-495e-a370-c0303e741a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bb7acd91-b19d-495e-a370-c0303e741a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e138e8ef-0893-4d1e-9de2-a707add4e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e138e8ef-0893-4d1e-9de2-a707add4e60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_43b83e0a-aee1-4379-8012-b1506bf9b245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_43b83e0a-aee1-4379-8012-b1506bf9b245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_41561009-cc0f-4e28-9450-7ff426c71b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_41561009-cc0f-4e28-9450-7ff426c71b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c7adebbb-d3d3-409f-9645-882d947a8937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c7adebbb-d3d3-409f-9645-882d947a8937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6e3b86ed-116e-4513-998a-d70db88b982c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6e3b86ed-116e-4513-998a-d70db88b982c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_da7238ba-66fa-44f2-9fde-3c4a5f631758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_da7238ba-66fa-44f2-9fde-3c4a5f631758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bcd7e8e4-4d55-4f79-b99e-43806cb8d633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_CommonStockSharesIssued_bcd7e8e4-4d55-4f79-b99e-43806cb8d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2aac1f88-e14c-43f7-b4a8-5c9897cb97f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68cfa558-ea04-4045-ab22-9ae4e2f574f2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2aac1f88-e14c-43f7-b4a8-5c9897cb97f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b95cc75f-8838-4547-b550-31fb118469f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_065e1247-05b7-4c66-9f80-a10a5c06b746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b95cc75f-8838-4547-b550-31fb118469f0" xlink:to="loc_us-gaap_StatementTable_065e1247-05b7-4c66-9f80-a10a5c06b746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_065e1247-05b7-4c66-9f80-a10a5c06b746" xlink:to="loc_srt_ProductOrServiceAxis_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea53a2f9-a502-4199-a8b4-b9a9d5f3db94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_478cdcd3-5fa6-4bda-84fc-0dbe71007dfa" xlink:to="loc_srt_ProductsAndServicesDomain_ea53a2f9-a502-4199-a8b4-b9a9d5f3db94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b7f25b5e-9a05-4617-bafd-65b1dee725b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea53a2f9-a502-4199-a8b4-b9a9d5f3db94" xlink:to="loc_us-gaap_ProductMember_b7f25b5e-9a05-4617-bafd-65b1dee725b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_811b609f-2e52-4789-9fe5-d22885f3895b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea53a2f9-a502-4199-a8b4-b9a9d5f3db94" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_811b609f-2e52-4789-9fe5-d22885f3895b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_065e1247-05b7-4c66-9f80-a10a5c06b746" xlink:to="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d421026c-284a-495d-b097-3bd61b42adeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_RevenuesAbstract_d421026c-284a-495d-b097-3bd61b42adeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3004234f-7703-4459-b058-8453a190723d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d421026c-284a-495d-b097-3bd61b42adeb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3004234f-7703-4459-b058-8453a190723d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_f4806de8-dba8-4247-b1c3-5c7a2269f176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_f4806de8-dba8-4247-b1c3-5c7a2269f176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7b302964-9ba4-4c99-af20-04ad17d40a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f4806de8-dba8-4247-b1c3-5c7a2269f176" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7b302964-9ba4-4c99-af20-04ad17d40a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0afe5902-52f8-473f-be19-992e893a20b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0afe5902-52f8-473f-be19-992e893a20b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8344ae0-519b-4c6b-9a0d-68352d4384f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8344ae0-519b-4c6b-9a0d-68352d4384f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ae621364-e7ce-4896-9d57-2b6ededa9768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25a7ca37-f130-4fa3-83b6-265e6eaf42ec" xlink:to="loc_us-gaap_CostsAndExpenses_ae621364-e7ce-4896-9d57-2b6ededa9768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1aadd030-0d65-4d1a-a760-e972e2443181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_OperatingIncomeLoss_1aadd030-0d65-4d1a-a760-e972e2443181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7ab97629-1974-4ddf-b3de-e3cef9621c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7ab97629-1974-4ddf-b3de-e3cef9621c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1c152114-9ea2-4f54-aeb3-6784207f6c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_InterestExpense_1c152114-9ea2-4f54-aeb3-6784207f6c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_4a7ee486-c1a1-42c8-a589-9762bb7a54a2" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_4a7ee486-c1a1-42c8-a589-9762bb7a54a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ea95dcb1-a631-462e-9f3c-fcdb49a6df75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ea95dcb1-a631-462e-9f3c-fcdb49a6df75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9b43b845-d206-47d1-8442-740e46e0f6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9b43b845-d206-47d1-8442-740e46e0f6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6ad5493c-267a-4c3c-bf16-34dc1da181b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_879c9514-bff3-4e5e-bad5-5c90dc60afb7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6ad5493c-267a-4c3c-bf16-34dc1da181b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8e12378-50fb-4ecc-b9ae-1725e9067dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8e12378-50fb-4ecc-b9ae-1725e9067dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b31f92b3-037e-4759-8561-acd79de9999f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b31f92b3-037e-4759-8561-acd79de9999f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cae1fa33-ce38-41d0-ac9c-3ac2b19d2a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_NetIncomeLoss_cae1fa33-ce38-41d0-ac9c-3ac2b19d2a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_38568950-e2d2-402e-af3f-940a0980d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_38568950-e2d2-402e-af3f-940a0980d6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7260a8c7-8436-43ce-9b12-b1fb433bb37c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9644ebc0-bd9b-4eeb-b7a8-34889a213683" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7260a8c7-8436-43ce-9b12-b1fb433bb37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement" xlink:type="simple" xlink:href="bngo-20211231.xsd#CondensedConsolidatedStatementsofComprehensiveLossStatement"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b65d4aa-7881-402a-807c-1bda37a00e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_efb6186b-659e-4995-867d-75a00fc4058e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b65d4aa-7881-402a-807c-1bda37a00e8e" xlink:to="loc_us-gaap_NetIncomeLoss_efb6186b-659e-4995-867d-75a00fc4058e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3b14ed4d-d3a7-4760-8a9c-5bd587ecc65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b65d4aa-7881-402a-807c-1bda37a00e8e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3b14ed4d-d3a7-4760-8a9c-5bd587ecc65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ca4a035-148e-4a7d-bc02-91ce48afde33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b65d4aa-7881-402a-807c-1bda37a00e8e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ca4a035-148e-4a7d-bc02-91ce48afde33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cfcce876-5721-472b-af69-8d7c78b4c14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a570bf42-8c7c-4a3d-a862-4da5ec2809c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cfcce876-5721-472b-af69-8d7c78b4c14a" xlink:to="loc_us-gaap_StatementTable_a570bf42-8c7c-4a3d-a862-4da5ec2809c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37651619-4c98-46e8-a2b1-700fcc6bc1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a570bf42-8c7c-4a3d-a862-4da5ec2809c6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37651619-4c98-46e8-a2b1-700fcc6bc1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37651619-4c98-46e8-a2b1-700fcc6bc1a1" xlink:to="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f8da519-4037-4d98-aff0-e3995439e049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:to="loc_us-gaap_CommonStockMember_7f8da519-4037-4d98-aff0-e3995439e049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ef53bb67-87b6-4566-9627-88f418ca64e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ef53bb67-87b6-4566-9627-88f418ca64e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_083e4b46-1e29-4517-afc5-c50113afd892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:to="loc_us-gaap_RetainedEarningsMember_083e4b46-1e29-4517-afc5-c50113afd892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c1173535-64b2-4ea7-8fe9-64a785702d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbfb4539-42c0-4c29-8759-57958d325a34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c1173535-64b2-4ea7-8fe9-64a785702d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_826be01b-84e6-4cfa-b5ca-e68bffd24b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a570bf42-8c7c-4a3d-a862-4da5ec2809c6" xlink:to="loc_us-gaap_StatementLineItems_826be01b-84e6-4cfa-b5ca-e68bffd24b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_826be01b-84e6-4cfa-b5ca-e68bffd24b56" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_afe40416-f6fe-447b-b658-5f7fdda7e5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_SharesOutstanding_afe40416-f6fe-447b-b658-5f7fdda7e5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93551a91-7a8b-4613-80c3-3a302a4903b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockholdersEquity_93551a91-7a8b-4613-80c3-3a302a4903b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bcf8535-0e57-438c-971c-0c7ec693b252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bcf8535-0e57-438c-971c-0c7ec693b252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_70d43796-9903-48c5-8eca-5d5e9cdf0163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_70d43796-9903-48c5-8eca-5d5e9cdf0163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76f85a26-a18a-4bfe-8e6e-a5b0e85c746a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_76f85a26-a18a-4bfe-8e6e-a5b0e85c746a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5926219c-b36a-477f-9aff-488f772b699d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5926219c-b36a-477f-9aff-488f772b699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b7f0f977-52cc-4d94-a848-4f5864792dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b7f0f977-52cc-4d94-a848-4f5864792dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d03efc72-e559-46c6-a22c-c9030a5c6717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d03efc72-e559-46c6-a22c-c9030a5c6717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dc55e980-a004-44c7-a501-7d97eab1a46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_dc55e980-a004-44c7-a501-7d97eab1a46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_4d511d64-8f48-44ac-b6d9-65ae2a2e983c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_4d511d64-8f48-44ac-b6d9-65ae2a2e983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesCovenantWaiver_06afcd0b-b316-4729-a904-2f45f91886f6" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodSharesCovenantWaiver"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_bngo_StockIssuedDuringPeriodSharesCovenantWaiver_06afcd0b-b316-4729-a904-2f45f91886f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueCovenantWaiver_d7005af6-d290-4d2d-97d4-0e3be51654b9" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodValueCovenantWaiver"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_bngo_StockIssuedDuringPeriodValueCovenantWaiver_d7005af6-d290-4d2d-97d4-0e3be51654b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_7ceb1a94-3a59-47ec-a049-b73468db0195" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_bngo_StockIssuedDuringPeriodSharesWarrantsExercised_7ceb1a94-3a59-47ec-a049-b73468db0195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised_7dda282b-06d8-4ce6-9ed7-7fc21499f902" xlink:href="bngo-20211231.xsd#bngo_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_bngo_StockIssuedDuringPeriodValueWarrantsExercised_7dda282b-06d8-4ce6-9ed7-7fc21499f902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d67584e5-5da2-4f9e-a4d3-68ddff176369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d67584e5-5da2-4f9e-a4d3-68ddff176369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_89e7be1f-09a2-4aa4-839e-2a3319840420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_89e7be1f-09a2-4aa4-839e-2a3319840420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b25ced2-1f6e-41c6-b40d-3c5b11443e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_NetIncomeLoss_5b25ced2-1f6e-41c6-b40d-3c5b11443e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bb341e60-9135-4522-a0b2-30a8150e9c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bb341e60-9135-4522-a0b2-30a8150e9c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dda3e337-e1b1-4b6c-98a8-1784ab1f981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_SharesOutstanding_dda3e337-e1b1-4b6c-98a8-1784ab1f981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c36f9de5-fab2-495c-a7f7-b5fc700e2d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8202a341-e3e0-4f26-a9db-c30c0a12485c" xlink:to="loc_us-gaap_StockholdersEquity_c36f9de5-fab2-495c-a7f7-b5fc700e2d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bngo-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8d99339c-c9f6-4ff0-8259-bff55fbd3e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c6dd7f1d-6edc-4338-8805-06c2fce8ab09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8d99339c-c9f6-4ff0-8259-bff55fbd3e5e" xlink:to="loc_us-gaap_StatementTable_c6dd7f1d-6edc-4338-8805-06c2fce8ab09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89ca011c-cf47-4bc0-8604-6e71b674e020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c6dd7f1d-6edc-4338-8805-06c2fce8ab09" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89ca011c-cf47-4bc0-8604-6e71b674e020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b240c7-92dc-4ab5-a023-28b70f237b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89ca011c-cf47-4bc0-8604-6e71b674e020" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b240c7-92dc-4ab5-a023-28b70f237b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_79ae529b-a677-4e46-b7c5-1d4a37fe6f05" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b240c7-92dc-4ab5-a023-28b70f237b90" xlink:to="loc_bngo_LineagenMember_79ae529b-a677-4e46-b7c5-1d4a37fe6f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_577d6994-911c-4504-9496-4846d96b87d1" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b240c7-92dc-4ab5-a023-28b70f237b90" xlink:to="loc_bngo_BioDiscoveryMember_577d6994-911c-4504-9496-4846d96b87d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c6dd7f1d-6edc-4338-8805-06c2fce8ab09" xlink:to="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bcaa4b4e-55a2-4321-9227-57ddf688214e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:to="loc_us-gaap_ProfitLoss_bcaa4b4e-55a2-4321-9227-57ddf688214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3a4a6f5c-ccfe-4301-9504-9e127c263216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3a4a6f5c-ccfe-4301-9504-9e127c263216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_44dbcc37-7679-4d1d-89af-da9cda22c059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_44dbcc37-7679-4d1d-89af-da9cda22c059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense_429481f6-2a8b-4a68-b46a-e9ba928f078c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_AccretionExpense_429481f6-2a8b-4a68-b46a-e9ba928f078c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NoncashInterestExpense_5bd26051-aaaa-4888-822c-7b5fe84ee237" xlink:href="bngo-20211231.xsd#bngo_NoncashInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_NoncashInterestExpense_5bd26051-aaaa-4888-822c-7b5fe84ee237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_NonCashLeaseExpense_6627ca50-3445-41d6-b055-30874e0f1c8b" xlink:href="bngo-20211231.xsd#bngo_NonCashLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_NonCashLeaseExpense_6627ca50-3445-41d6-b055-30874e0f1c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SettlementOfInterestOnDebtNoncash_725eb324-64b8-4281-b739-82d4c1a95bb8" xlink:href="bngo-20211231.xsd#bngo_SettlementOfInterestOnDebtNoncash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_SettlementOfInterestOnDebtNoncash_725eb324-64b8-4281-b739-82d4c1a95bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_639a99e2-7920-4657-b173-9f5761ff8bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_639a99e2-7920-4657-b173-9f5761ff8bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aa9a4ec0-f048-4abc-861b-15e846682909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_ShareBasedCompensation_aa9a4ec0-f048-4abc-861b-15e846682909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_af3a9a9d-f289-43b1-aaff-44807a469398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_af3a9a9d-f289-43b1-aaff-44807a469398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_6aa63f06-a11a-4caa-9abf-8054adfacf45" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_6aa63f06-a11a-4caa-9abf-8054adfacf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_88ca8a5d-e158-49de-8c3d-f64f84c4fb32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_InventoryWriteDown_88ca8a5d-e158-49de-8c3d-f64f84c4fb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnExtinguishmentOfDebtCashExpense_dfc73d3a-74ca-4b8e-999f-421a0db4dc31" xlink:href="bngo-20211231.xsd#bngo_GainLossOnExtinguishmentOfDebtCashExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_GainLossOnExtinguishmentOfDebtCashExpense_dfc73d3a-74ca-4b8e-999f-421a0db4dc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_b53e5a7d-f0bd-4f2d-a865-65ed04c90857" xlink:href="bngo-20211231.xsd#bngo_CostOfLeasedEquipmentSoldToCustomer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_CostOfLeasedEquipmentSoldToCustomer_b53e5a7d-f0bd-4f2d-a865-65ed04c90857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClientWarrantyExchangeOfFixedAssets_7d02b10b-a6b9-4108-bfe8-fbdf7f019ee1" xlink:href="bngo-20211231.xsd#bngo_ClientWarrantyExchangeOfFixedAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_bngo_ClientWarrantyExchangeOfFixedAssets_7d02b10b-a6b9-4108-bfe8-fbdf7f019ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_144274bc-7d24-4c14-a01d-61961439d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_144274bc-7d24-4c14-a01d-61961439d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf0bc8eb-e7be-4492-9795-9f29f8ff1c7e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0dc67d6-d724-4bef-befb-d1e889db8a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0dc67d6-d724-4bef-befb-d1e889db8a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7b110274-4f13-4cb5-b72e-555b75437948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7b110274-4f13-4cb5-b72e-555b75437948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d9b84e2-6ba0-4af9-bc35-89018b8b94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d9b84e2-6ba0-4af9-bc35-89018b8b94aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_abdded29-3aca-4173-8017-9a5e711ef5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_abdded29-3aca-4173-8017-9a5e711ef5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6db107f0-e757-47f8-8c00-5035ac94f07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d42fe13-49ac-4eb7-b622-ecc5dc10a562" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6db107f0-e757-47f8-8c00-5035ac94f07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54797972-e73f-4a17-be1e-61cb199859eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a688643e-366a-4b6f-a596-cfc8ee10c4f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54797972-e73f-4a17-be1e-61cb199859eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f6e85ddc-e108-45c3-83ab-3abf335b60d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f6e85ddc-e108-45c3-83ab-3abf335b60d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForPropertyAndEquipment_3b06818f-9fdc-46c2-9f20-30e22dccc76f" xlink:href="bngo-20211231.xsd#bngo_PaymentsForPropertyAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_bngo_PaymentsForPropertyAndEquipment_3b06818f-9fdc-46c2-9f20-30e22dccc76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_a1df67f6-41fd-464d-9000-c6afc111b364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_a1df67f6-41fd-464d-9000-c6afc111b364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PaymentsForInitialCostsOnLeases_88ce5db4-c5eb-4cb9-8682-9bda380cdfae" xlink:href="bngo-20211231.xsd#bngo_PaymentsForInitialCostsOnLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_bngo_PaymentsForInitialCostsOnLeases_88ce5db4-c5eb-4cb9-8682-9bda380cdfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f0a0450c-b85e-4866-a726-89283e868aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f0a0450c-b85e-4866-a726-89283e868aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ac307fe3-9665-417b-aac0-5607a36935ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ac307fe3-9665-417b-aac0-5607a36935ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3567ce93-6069-4300-ba0d-4e9040fcfa83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7dcc4bc8-2236-4ed1-bb86-60e73367cd77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3567ce93-6069-4300-ba0d-4e9040fcfa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_bac3ea55-1e70-454f-85c0-ddf7f01936af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_bac3ea55-1e70-454f-85c0-ddf7f01936af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_7f382ac5-c862-4310-9c4c-fdf1899c8445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_7f382ac5-c862-4310-9c4c-fdf1899c8445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ProceedsFromPayrollProtectionProgramLoan_8a8c41d3-4598-4f03-a054-96e308dba418" xlink:href="bngo-20211231.xsd#bngo_ProceedsFromPayrollProtectionProgramLoan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_bngo_ProceedsFromPayrollProtectionProgramLoan_8a8c41d3-4598-4f03-a054-96e308dba418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_f60fec91-2166-4edf-8133-e6cb0055df83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_f60fec91-2166-4edf-8133-e6cb0055df83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_15a3423c-766f-437f-ae54-2cfe723ac6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_15a3423c-766f-437f-ae54-2cfe723ac6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a136276e-c3bc-4727-95ab-be7232f87ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_a136276e-c3bc-4727-95ab-be7232f87ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9af57e63-a32d-494e-860d-b3f0c811a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9af57e63-a32d-494e-860d-b3f0c811a4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EmployeeStockPurchasePlanCompensationExpense_f31510ef-5ea8-4643-96c4-7ae5de5cea64" xlink:href="bngo-20211231.xsd#bngo_EmployeeStockPurchasePlanCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_bngo_EmployeeStockPurchasePlanCompensationExpense_f31510ef-5ea8-4643-96c4-7ae5de5cea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3cd6488b-f4e9-4816-aff1-c9da3d9ddb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3cd6488b-f4e9-4816-aff1-c9da3d9ddb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc6f0560-b749-49a2-bb12-9e263265a0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc6f0560-b749-49a2-bb12-9e263265a0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_389517ea-3967-4c19-99eb-b0234975234e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_389517ea-3967-4c19-99eb-b0234975234e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7104e453-6082-443a-a8da-bd5421dfdc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7104e453-6082-443a-a8da-bd5421dfdc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9ffed5d1-fbff-48d3-8a75-c927c441cf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2da8abdb-4c4f-4d9c-a4f1-23c47e494876" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9ffed5d1-fbff-48d3-8a75-c927c441cf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_afde1527-c2ab-4b6b-8813-147a70a2083d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_afde1527-c2ab-4b6b-8813-147a70a2083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e0911443-82a3-499d-8cae-bebe374bf576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afde1527-c2ab-4b6b-8813-147a70a2083d" xlink:to="loc_us-gaap_InterestPaidNet_e0911443-82a3-499d-8cae-bebe374bf576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4d01ab5a-47f8-41d4-b602-a1001229e853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_afde1527-c2ab-4b6b-8813-147a70a2083d" xlink:to="loc_us-gaap_OperatingLeasePayments_4d01ab5a-47f8-41d4-b602-a1001229e853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_562f568d-38eb-4f1e-ae67-f7497f910b27" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_bcd8e331-bdcd-4d49-ba2a-0fd1297bcd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_us-gaap_StockIssued1_bcd8e331-bdcd-4d49-ba2a-0fd1297bcd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationNoncash_5dbfc68e-1cb3-4376-91ee-6fb34ea28e2f" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationNoncash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_ContingentConsiderationNoncash_5dbfc68e-1cb3-4376-91ee-6fb34ea28e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b8464954-da8a-4857-ae13-a2c99c154503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b8464954-da8a-4857-ae13-a2c99c154503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_fb755772-ff01-46ee-a52b-83ea92027ca7" xlink:href="bngo-20211231.xsd#bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory_fb755772-ff01-46ee-a52b-83ea92027ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_2d7290dd-2b5c-4b9e-a9be-4efd6480d2fb" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_2d7290dd-2b5c-4b9e-a9be-4efd6480d2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_StockIssuedForServices_c28030fa-7964-43c4-82e6-d6663d041169" xlink:href="bngo-20211231.xsd#bngo_StockIssuedForServices"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_StockIssuedForServices_c28030fa-7964-43c4-82e6-d6663d041169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_IssueCommonStockForCovenantWaiver_05c72a2c-910d-4920-b056-f108a618e65f" xlink:href="bngo-20211231.xsd#bngo_IssueCommonStockForCovenantWaiver"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_IssueCommonStockForCovenantWaiver_05c72a2c-910d-4920-b056-f108a618e65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantExerciseNonCash_e0796bab-f4c1-4114-828c-0057e0932d5b" xlink:href="bngo-20211231.xsd#bngo_WarrantExerciseNonCash"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39d8b1d4-aebe-4daf-9172-9092dfb7847c" xlink:to="loc_bngo_WarrantExerciseNonCash_e0796bab-f4c1-4114-828c-0057e0932d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="bngo-20211231.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d72bfce9-cf01-4131-b023-f82355b741e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e0aa9eb4-aacf-4239-8462-8b2d1cef0162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d72bfce9-cf01-4131-b023-f82355b741e1" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e0aa9eb4-aacf-4239-8462-8b2d1cef0162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/OrganizationandOperationsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#OrganizationandOperationsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/OrganizationandOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b10fdc7-dd15-4d5d-85cb-ac891f281786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b6f4b40-1bb7-4948-b64e-891aa428689a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b10fdc7-dd15-4d5d-85cb-ac891f281786" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b6f4b40-1bb7-4948-b64e-891aa428689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f0b7d02c-4e2d-4779-8c49-a791eda4cee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b10fdc7-dd15-4d5d-85cb-ac891f281786" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f0b7d02c-4e2d-4779-8c49-a791eda4cee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WorkingCapital_3cf87e71-7fe9-4b7e-b4b4-394728f642db" xlink:href="bngo-20211231.xsd#bngo_WorkingCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b10fdc7-dd15-4d5d-85cb-ac891f281786" xlink:to="loc_bngo_WorkingCapital_3cf87e71-7fe9-4b7e-b4b4-394728f642db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_67593536-8d64-46b6-b9af-bbfa2cf9bfba" xlink:href="bngo-20211231.xsd#bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b10fdc7-dd15-4d5d-85cb-ac891f281786" xlink:to="loc_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_67593536-8d64-46b6-b9af-bbfa2cf9bfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5d351348-6b30-49f8-8012-32b448a84d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b10fdc7-dd15-4d5d-85cb-ac891f281786" xlink:to="loc_us-gaap_DebtInstrumentTable_5d351348-6b30-49f8-8012-32b448a84d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e78d22ba-ba8c-4330-bc09-49182e1737dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d351348-6b30-49f8-8012-32b448a84d72" xlink:to="loc_us-gaap_DebtInstrumentAxis_e78d22ba-ba8c-4330-bc09-49182e1737dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_01d2afa5-3dea-466d-9238-5f4f36b1aa00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e78d22ba-ba8c-4330-bc09-49182e1737dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_01d2afa5-3dea-466d-9238-5f4f36b1aa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLoanAgreementMember_475418cc-fcda-477d-8637-eeb294566b38" xlink:href="bngo-20211231.xsd#bngo_InnovatusLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_01d2afa5-3dea-466d-9238-5f4f36b1aa00" xlink:to="loc_bngo_InnovatusLoanAgreementMember_475418cc-fcda-477d-8637-eeb294566b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_90fd91e3-7006-43d4-9968-fd52671e9fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d351348-6b30-49f8-8012-32b448a84d72" xlink:to="loc_us-gaap_DebtInstrumentLineItems_90fd91e3-7006-43d4-9968-fd52671e9fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_19e8c441-7637-41ac-88ae-2e13d1d04267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_90fd91e3-7006-43d4-9968-fd52671e9fe1" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_19e8c441-7637-41ac-88ae-2e13d1d04267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15a717c6-3aab-49fc-b9b9-27aedf0f2e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_75611ba6-3e17-4a3b-88ef-7774fb51b416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15a717c6-3aab-49fc-b9b9-27aedf0f2e98" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_75611ba6-3e17-4a3b-88ef-7774fb51b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4e5467ac-4750-4521-8ec5-07cbb573db40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4e5467ac-4750-4521-8ec5-07cbb573db40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LiquidityPolicyTextBlock_4a4b51c7-689f-4bb0-8542-05e693a67092" xlink:href="bngo-20211231.xsd#bngo_LiquidityPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_bngo_LiquidityPolicyTextBlock_4a4b51c7-689f-4bb0-8542-05e693a67092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_789ec93a-4f05-4307-bcc0-4b2457fba8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_UseOfEstimates_789ec93a-4f05-4307-bcc0-4b2457fba8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_117917d0-55e9-4b14-935f-8af029734309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_117917d0-55e9-4b14-935f-8af029734309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1c8769cc-6978-46ac-b609-807e27ef4b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1c8769cc-6978-46ac-b609-807e27ef4b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1270fc46-3712-4455-804d-8fa85fdecde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1270fc46-3712-4455-804d-8fa85fdecde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_14355901-d32d-4823-aa1b-dbca4edc4566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_14355901-d32d-4823-aa1b-dbca4edc4566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_becd5b68-1e1d-49d1-90f0-160695a038e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_becd5b68-1e1d-49d1-90f0-160695a038e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_3310e086-8c0e-4fcf-837b-8d2cef942a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_3310e086-8c0e-4fcf-837b-8d2cef942a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_d1e9f689-e3d0-4847-a528-9e8aef3d2a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_d1e9f689-e3d0-4847-a528-9e8aef3d2a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_494676e3-0e37-459b-a54b-9313fb6f3e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_494676e3-0e37-459b-a54b-9313fb6f3e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationPolicyTextBlock_16b4e944-442d-4f01-b19c-755c6a666380" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_bngo_ContingentConsiderationPolicyTextBlock_16b4e944-442d-4f01-b19c-755c6a666380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7fa68be0-705e-4b79-804e-b86ece245bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7fa68be0-705e-4b79-804e-b86ece245bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a9854b1e-024a-4249-bef6-f6b1c60f7ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a9854b1e-024a-4249-bef6-f6b1c60f7ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_c16029a4-504b-4f59-9a6d-49e217b45eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_c16029a4-504b-4f59-9a6d-49e217b45eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c2f42060-c0ce-465a-bd38-8f5b9e166389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c2f42060-c0ce-465a-bd38-8f5b9e166389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock_ab99182c-3751-4cfa-bbd3-6d365a983a71" xlink:href="bngo-20211231.xsd#bngo_CostOfGoodsAndServicesSoldPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock_ab99182c-3751-4cfa-bbd3-6d365a983a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f7cbec2-69c1-49cb-a1dd-d472291d769e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f7cbec2-69c1-49cb-a1dd-d472291d769e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_80a2072e-dd64-4125-bccd-ecdf5f3bbcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_80a2072e-dd64-4125-bccd-ecdf5f3bbcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4eb63a8c-5193-452e-b090-335a8de056f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4eb63a8c-5193-452e-b090-335a8de056f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_b0d06699-3889-45c8-99b7-759ca01f8b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_b0d06699-3889-45c8-99b7-759ca01f8b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_f5942b24-5759-4427-850b-7ec11652e87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_f5942b24-5759-4427-850b-7ec11652e87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_74642c85-9ee0-4154-b35f-97f68a5a356a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_74642c85-9ee0-4154-b35f-97f68a5a356a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6df2dc5d-3dc7-49b2-b8ce-fd555041196a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba05eef1-be49-467c-9a7a-2fd6bcd15e0f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6df2dc5d-3dc7-49b2-b8ce-fd555041196a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad67d23b-c205-48e6-8656-9382ca34e0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7f1d2e57-6566-411d-b817-cf2f624d8680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad67d23b-c205-48e6-8656-9382ca34e0d6" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7f1d2e57-6566-411d-b817-cf2f624d8680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUtilityInventoryTextBlock_69aeab33-2052-4c15-add8-1643e5aa96e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUtilityInventoryTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad67d23b-c205-48e6-8656-9382ca34e0d6" xlink:to="loc_us-gaap_ScheduleOfUtilityInventoryTextBlock_69aeab33-2052-4c15-add8-1643e5aa96e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_19dfe329-cddb-4758-8c82-a0401058d17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad67d23b-c205-48e6-8656-9382ca34e0d6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_19dfe329-cddb-4758-8c82-a0401058d17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2152dc48-cd00-4f99-8f74-ed627f3849a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_acfaeeed-88ab-48f3-89a0-b58197c478be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2152dc48-cd00-4f99-8f74-ed627f3849a2" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_acfaeeed-88ab-48f3-89a0-b58197c478be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_64c0bab9-9484-42ca-98db-17fe35121580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2152dc48-cd00-4f99-8f74-ed627f3849a2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_64c0bab9-9484-42ca-98db-17fe35121580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f343a4f6-be15-46ef-a0d0-1b3043821558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2152dc48-cd00-4f99-8f74-ed627f3849a2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f343a4f6-be15-46ef-a0d0-1b3043821558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_db17e2c0-755e-4e7e-a120-cfca9c1ff030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:href="bngo-20211231.xsd#bngo_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db17e2c0-755e-4e7e-a120-cfca9c1ff030" xlink:to="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6c115389-c268-45c4-8229-d7ce24d633ed" xlink:to="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoCustomersMember_1a9ccc2c-a8a8-4c90-ab23-248a5d5610f5" xlink:href="bngo-20211231.xsd#bngo_TwoCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_85384647-ed19-4596-95a9-5b4d2509d2e6" xlink:to="loc_bngo_TwoCustomersMember_1a9ccc2c-a8a8-4c90-ab23-248a5d5610f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_611de6c7-4899-4cc1-8730-a19ebe0098bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d1799b80-dfe8-4f35-9ad0-d02d53c649fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac0455c6-35d7-4549-8afe-7bfc3392ebb4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d1799b80-dfe8-4f35-9ad0-d02d53c649fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fdbdba04-baa1-476f-8dd9-0884b0281ef0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5f6f29a9-1cfb-4003-8154-15056f2c2478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6528d804-4723-4454-be58-3b851fc16ef6" xlink:to="loc_us-gaap_AccountsReceivableMember_5f6f29a9-1cfb-4003-8154-15056f2c2478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2a6440df-c814-4c45-904b-b1677ad490ff" xlink:to="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cefcb335-3d7a-4858-a6eb-85a00f2b4b2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:to="loc_srt_MinimumMember_cefcb335-3d7a-4858-a6eb-85a00f2b4b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f22eb8a2-3f5f-421c-b75d-ca1b692484da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57aba9b7-6fbc-4b58-8e9f-fba1569f751a" xlink:to="loc_srt_MaximumMember_f22eb8a2-3f5f-421c-b75d-ca1b692484da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_e99191e2-ebf9-49a7-a389-1b02cde9324e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_e99191e2-ebf9-49a7-a389-1b02cde9324e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_da8c79ac-772a-44f2-b003-82c98cd86a96" xlink:to="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_79a4542a-270d-46ca-8baf-84c4ba57fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_79a4542a-270d-46ca-8baf-84c4ba57fe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_b53e9737-f7cd-4037-972a-9419724eb159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f736b2b4-b16d-4b3b-be39-faa3069b6aba" xlink:to="loc_us-gaap_ProductMember_b53e9737-f7cd-4037-972a-9419724eb159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e0b2016f-c0af-47f8-b535-cd7c34d530df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0b66e094-cee9-4307-9bdf-5963abed89eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f6f0196-4b3c-4300-b942-055d5316db83" xlink:to="loc_us-gaap_CostOfSalesMember_0b66e094-cee9-4307-9bdf-5963abed89eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:href="bngo-20211231.xsd#bngo_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesTable_57d709d4-8a02-4a88-a3a7-055ae6b23a4b" xlink:to="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_9ff88139-6d9d-4a29-b706-bb76c9113fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_9ff88139-6d9d-4a29-b706-bb76c9113fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fc63231e-e1c7-4d97-9aea-946a940b3456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fc63231e-e1c7-4d97-9aea-946a940b3456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bd95178f-b1e2-4135-9153-e519f09b0092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bd95178f-b1e2-4135-9153-e519f09b0092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_470188d9-ad80-4aa1-acb2-7b2640e34684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_470188d9-ad80-4aa1-acb2-7b2640e34684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d068ba1a-f9bf-4f64-a87a-77faacbba28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d068ba1a-f9bf-4f64-a87a-77faacbba28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_12551bac-95b3-4c9a-aff6-9f717cf3b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_12551bac-95b3-4c9a-aff6-9f717cf3b6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_042726a8-b2db-4d6f-af65-8029bbdfb9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_042726a8-b2db-4d6f-af65-8029bbdfb9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RentalRevenueReagentRentalProgram_903a746a-5a91-4ad8-85cd-0cd4404a0cc9" xlink:href="bngo-20211231.xsd#bngo_RentalRevenueReagentRentalProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_RentalRevenueReagentRentalProgram_903a746a-5a91-4ad8-85cd-0cd4404a0cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LicensingRevenueAndMaintenanceAgreements_12c72475-7ca8-4643-b5ac-275dd9903f23" xlink:href="bngo-20211231.xsd#bngo_LicensingRevenueAndMaintenanceAgreements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_LicensingRevenueAndMaintenanceAgreements_12c72475-7ca8-4643-b5ac-275dd9903f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantyAndMaintenanceRevenue_adf87409-c4d9-41d8-8a5e-fd9f384d27e9" xlink:href="bngo-20211231.xsd#bngo_WarrantyAndMaintenanceRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_bngo_WarrantyAndMaintenanceRevenue_adf87409-c4d9-41d8-8a5e-fd9f384d27e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_dbb9551c-7b08-4ab5-bd92-7be6ee6bcd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_dbb9551c-7b08-4ab5-bd92-7be6ee6bcd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5c46c455-7714-47cb-9996-a34ec6d1a607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_5c46c455-7714-47cb-9996-a34ec6d1a607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_17e1147f-8d14-4e1c-944c-d80279640924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_17e1147f-8d14-4e1c-944c-d80279640924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_5393ffd7-9518-4825-a1a1-2dd8ffb416a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_5393ffd7-9518-4825-a1a1-2dd8ffb416a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyExpense_2d7cb4d0-37a3-4692-a4b8-1a9d193f7759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ProductWarrantyExpense_2d7cb4d0-37a3-4692-a4b8-1a9d193f7759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_053a878c-36f1-4da9-b315-4fa3a2721c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_053a878c-36f1-4da9-b315-4fa3a2721c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_331013d6-2681-4976-a3c1-63647ed9b93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_331013d6-2681-4976-a3c1-63647ed9b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e78f8439-04a4-4fcd-a8ac-edb800afcada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e78f8439-04a4-4fcd-a8ac-edb800afcada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_69a401ff-6d47-4711-9c0b-07c7b15a353b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SummaryOfSignificantAccountingPoliciesLineItems_a1f4d64f-4359-47bc-87c1-cdfcc670977d" xlink:to="loc_us-gaap_OperatingLeaseLiability_69a401ff-6d47-4711-9c0b-07c7b15a353b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2c5ea173-0e11-4676-a04e-10b791fdc8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2b3efba9-0b58-47ec-a8cb-619e03ba11b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2c5ea173-0e11-4676-a04e-10b791fdc8d5" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2b3efba9-0b58-47ec-a8cb-619e03ba11b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_75f017b3-0911-49d1-8041-72c567fae64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2c5ea173-0e11-4676-a04e-10b791fdc8d5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_75f017b3-0911-49d1-8041-72c567fae64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cc2fcd77-820c-4cb0-bb1e-e6eb7f95731e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2c5ea173-0e11-4676-a04e-10b791fdc8d5" xlink:to="loc_us-gaap_InventoryNet_cc2fcd77-820c-4cb0-bb1e-e6eb7f95731e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05fe8124-ccc5-4a16-a646-9503b0630ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d602d8c-d488-4b23-981d-1ad8a7bf6617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05fe8124-ccc5-4a16-a646-9503b0630ba9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d602d8c-d488-4b23-981d-1ad8a7bf6617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1510d65d-4a11-4e25-aad4-4e42f7d6c83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d602d8c-d488-4b23-981d-1ad8a7bf6617" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1510d65d-4a11-4e25-aad4-4e42f7d6c83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1510d65d-4a11-4e25-aad4-4e42f7d6c83d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockOptionMember_307de868-84c9-4cd1-9192-1a92cf646a80" xlink:href="bngo-20211231.xsd#bngo_CommonStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_bngo_CommonStockOptionMember_307de868-84c9-4cd1-9192-1a92cf646a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember_543cb3b1-d9d2-4147-8cf9-a8b94500c3e1" xlink:href="bngo-20211231.xsd#bngo_CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_bngo_CommonWarrantsMember_543cb3b1-d9d2-4147-8cf9-a8b94500c3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_UnvestedRestrictedStockMember_f1801b6e-adc2-4d33-8b3b-c8326bf9611d" xlink:href="bngo-20211231.xsd#bngo_UnvestedRestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_bngo_UnvestedRestrictedStockMember_f1801b6e-adc2-4d33-8b3b-c8326bf9611d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_60ff5fa3-ff8c-43d0-9580-0f1bb2387e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_60ff5fa3-ff8c-43d0-9580-0f1bb2387e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_cd6bc65a-7065-42ac-8413-0070d7bd5b20" xlink:href="bngo-20211231.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6be24eff-fe58-4b3d-ba19-d26d688432b6" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_cd6bc65a-7065-42ac-8413-0070d7bd5b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a0614e64-cec6-47d0-8882-8587be40b531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d602d8c-d488-4b23-981d-1ad8a7bf6617" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a0614e64-cec6-47d0-8882-8587be40b531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09fcd79a-b8e7-4ac0-ad24-7a4b10ca8224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a0614e64-cec6-47d0-8882-8587be40b531" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09fcd79a-b8e7-4ac0-ad24-7a4b10ca8224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e77415eb-07bc-4df3-b2fd-ba72f557c011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e77415eb-07bc-4df3-b2fd-ba72f557c011" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_18a4da69-a206-4ee7-9efa-01a8b8774bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_18a4da69-a206-4ee7-9efa-01a8b8774bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_73474c0e-80a6-477d-b90b-1b4336f5dabc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c6d61834-32a3-422f-8b00-4d2a83ab59c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ad050dec-8da8-4861-a26c-0ecd826e6612" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c6d61834-32a3-422f-8b00-4d2a83ab59c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="bngo-20211231.xsd#SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenuefromContractswithCustomers" xlink:type="simple" xlink:href="bngo-20211231.xsd#RevenuefromContractswithCustomers"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenuefromContractswithCustomers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5d33f743-14b5-40b5-b6fc-395a70d7d9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_239c9e09-7fc1-427b-82ac-82ed5e708eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5d33f743-14b5-40b5-b6fc-395a70d7d9b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_239c9e09-7fc1-427b-82ac-82ed5e708eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenuefromContractswithCustomersTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#RevenuefromContractswithCustomersTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenuefromContractswithCustomersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c3af2261-ab64-4d36-8952-f7b5d08fb461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d75ecfec-c0da-46be-a4ef-e45572427633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c3af2261-ab64-4d36-8952-f7b5d08fb461" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d75ecfec-c0da-46be-a4ef-e45572427633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#RevenuefromContractswithCustomersDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9d5f15e7-0bc7-4dd3-88e9-88730e77a054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9d5f15e7-0bc7-4dd3-88e9-88730e77a054" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_14f980bd-6f71-4d42-a8fb-f77f224bd40f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_srt_ProductOrServiceAxis_14f980bd-6f71-4d42-a8fb-f77f224bd40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_14f980bd-6f71-4d42-a8fb-f77f224bd40f" xlink:to="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InstrumentRevenueMember_f054a25b-f951-4d3d-9a7a-964d984c2b4e" xlink:href="bngo-20211231.xsd#bngo_InstrumentRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:to="loc_bngo_InstrumentRevenueMember_f054a25b-f951-4d3d-9a7a-964d984c2b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ConsumableRevenueMember_d61e9c4e-2455-4aeb-86e3-7e502368359b" xlink:href="bngo-20211231.xsd#bngo_ConsumableRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:to="loc_bngo_ConsumableRevenueMember_d61e9c4e-2455-4aeb-86e3-7e502368359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8480c30a-6433-40ce-b6cd-0a9bb425a281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:to="loc_us-gaap_ProductMember_8480c30a-6433-40ce-b6cd-0a9bb425a281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_caee6e4a-914e-4639-a408-ed40a58ba177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_282073d3-2cf1-40b0-8166-f40bf674b64c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_caee6e4a-914e-4639-a408-ed40a58ba177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ac4a7525-e936-4b45-abc5-cbbbcbd15730" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_srt_StatementGeographicalAxis_ac4a7525-e936-4b45-abc5-cbbbcbd15730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ac4a7525-e936-4b45-abc5-cbbbcbd15730" xlink:to="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_f7485c40-8ebe-4d48-a3d9-8a16e14ad8e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_srt_NorthAmericaMember_f7485c40-8ebe-4d48-a3d9-8a16e14ad8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_4e1059d9-aae3-4b67-adcd-0827a034ce14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_us-gaap_EMEAMember_4e1059d9-aae3-4b67-adcd-0827a034ce14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_ba7cc646-cce3-408f-b488-e3e324b1b2ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_srt_AsiaPacificMember_ba7cc646-cce3-408f-b488-e3e324b1b2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_e0d0d4b3-ca63-4950-abb1-0d27b105ccd9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_country_CN_e0d0d4b3-ca63-4950-abb1-0d27b105ccd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_94afd72d-cb4a-40ef-88b0-c1b05dcfa855" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_891b6855-cad4-41bc-9453-c5734df38940" xlink:to="loc_country_US_94afd72d-cb4a-40ef-88b0-c1b05dcfa855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15149d88-2f0e-4d4f-b4d4-356037ea24f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15149d88-2f0e-4d4f-b4d4-356037ea24f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fd64359-0129-48dd-92ef-9e01214265fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15149d88-2f0e-4d4f-b4d4-356037ea24f1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fd64359-0129-48dd-92ef-9e01214265fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f3cc4cb3-e8b1-41fe-a648-70b29378b12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fd64359-0129-48dd-92ef-9e01214265fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f3cc4cb3-e8b1-41fe-a648-70b29378b12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7e6b138d-d517-47de-bbd8-9d52c2c22ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4fd64359-0129-48dd-92ef-9e01214265fc" xlink:to="loc_us-gaap_SalesRevenueNetMember_7e6b138d-d517-47de-bbd8-9d52c2c22ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2c42ca13-dc86-4056-ac7e-042c4554f803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2c42ca13-dc86-4056-ac7e-042c4554f803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b56d0868-3981-4548-a505-8cc6f9656fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c42ca13-dc86-4056-ac7e-042c4554f803" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b56d0868-3981-4548-a505-8cc6f9656fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_b88aa4bc-82d3-40b6-9476-dc96e14519bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b56d0868-3981-4548-a505-8cc6f9656fec" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_b88aa4bc-82d3-40b6-9476-dc96e14519bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bf1262a6-cf4d-4d3b-924c-f2ce2c6ba7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ec81d584-1926-467e-9caa-e6ba63caf742" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bf1262a6-cf4d-4d3b-924c-f2ce2c6ba7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b5e28300-93d7-47a6-85da-d6522749d5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf1262a6-cf4d-4d3b-924c-f2ce2c6ba7b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b5e28300-93d7-47a6-85da-d6522749d5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9ffaebc4-723b-4408-b04e-6ddfbccd9bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bf1262a6-cf4d-4d3b-924c-f2ce2c6ba7b4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9ffaebc4-723b-4408-b04e-6ddfbccd9bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_203d58bb-0630-4f70-9a3f-07d5263dc8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_23e1285c-c613-4929-b2e1-ef4dc794c438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_203d58bb-0630-4f70-9a3f-07d5263dc8fd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_23e1285c-c613-4929-b2e1-ef4dc794c438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e131a60f-4d97-4ed1-afe6-2f36d21335c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d4e35501-b3f6-4e7e-8ac9-0a74f8ff6e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e131a60f-4d97-4ed1-afe6-2f36d21335c9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d4e35501-b3f6-4e7e-8ac9-0a74f8ff6e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f6e62d1e-d8a9-4741-83be-8d2d5f6aaad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e131a60f-4d97-4ed1-afe6-2f36d21335c9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f6e62d1e-d8a9-4741-83be-8d2d5f6aaad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_e9dcd644-93ae-40cf-a22c-1a1bdbca3920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e131a60f-4d97-4ed1-afe6-2f36d21335c9" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_e9dcd644-93ae-40cf-a22c-1a1bdbca3920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_089ea3d7-d8df-418a-9827-f8cca588a321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_089ea3d7-d8df-418a-9827-f8cca588a321" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_280bf7b4-9abc-4ebb-9c0e-868c018d0581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_280bf7b4-9abc-4ebb-9c0e-868c018d0581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_28b88d7d-ded8-47fb-ac37-ddf6efb24a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_280bf7b4-9abc-4ebb-9c0e-868c018d0581" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_28b88d7d-ded8-47fb-ac37-ddf6efb24a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_85e52825-2ebe-4b1a-b8ec-4a9b34a5cf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_28b88d7d-ded8-47fb-ac37-ddf6efb24a6f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_85e52825-2ebe-4b1a-b8ec-4a9b34a5cf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618de55f-b0bf-4fe3-9a59-0b190ac5e398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618de55f-b0bf-4fe3-9a59-0b190ac5e398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_618de55f-b0bf-4fe3-9a59-0b190ac5e398" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_af8a3d4f-15d0-4166-943d-424335af29ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_af8a3d4f-15d0-4166-943d-424335af29ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_46b7756c-59e4-4633-8a22-1b339d7f781e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_46b7756c-59e4-4633-8a22-1b339d7f781e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2c8884dd-94fc-4d36-bf26-16f29e3bffb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9363b46d-b871-4311-bc22-07a8a378609f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2c8884dd-94fc-4d36-bf26-16f29e3bffb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c419e82f-8a97-4bf1-95bc-71e60ef8c05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c419e82f-8a97-4bf1-95bc-71e60ef8c05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ad454d0-cb46-4acb-adb3-91a04f649b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c419e82f-8a97-4bf1-95bc-71e60ef8c05c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ad454d0-cb46-4acb-adb3-91a04f649b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_04a6acdb-7f89-4db6-b490-837995ffc673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ad454d0-cb46-4acb-adb3-91a04f649b5f" xlink:to="loc_us-gaap_InvestmentsMember_04a6acdb-7f89-4db6-b490-837995ffc673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_84fdb31e-7180-4cea-9cb4-8868bc70aee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ad454d0-cb46-4acb-adb3-91a04f649b5f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_84fdb31e-7180-4cea-9cb4-8868bc70aee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_InvestmentTypeAxis_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d72bf069-06fb-4c3f-a1f5-d284be83c47a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_208ecdfd-ce9c-4aa6-90b5-4b5b688d06cb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d72bf069-06fb-4c3f-a1f5-d284be83c47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3db797fa-43c8-4bdb-98d9-ba2e4dff72cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d72bf069-06fb-4c3f-a1f5-d284be83c47a" xlink:to="loc_us-gaap_CommercialPaperMember_3db797fa-43c8-4bdb-98d9-ba2e4dff72cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_07e51717-dd28-4e72-b369-b881f1b2831c" xlink:href="bngo-20211231.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d72bf069-06fb-4c3f-a1f5-d284be83c47a" xlink:to="loc_bngo_CorporateNotesAndBondsMember_07e51717-dd28-4e72-b369-b881f1b2831c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8c63af34-8676-4fa2-b2ab-6cec35debfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8c63af34-8676-4fa2-b2ab-6cec35debfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d43650a2-46ff-409c-8b1c-9f9688f33988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c63af34-8676-4fa2-b2ab-6cec35debfc3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d43650a2-46ff-409c-8b1c-9f9688f33988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_72d8f843-ae10-4b0d-9161-6cb142a43d1a" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d43650a2-46ff-409c-8b1c-9f9688f33988" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_72d8f843-ae10-4b0d-9161-6cb142a43d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e10c10c2-5f2d-42cf-93a5-a74f73fe1647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_45652958-100c-4706-9672-4ef31982180e" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e10c10c2-5f2d-42cf-93a5-a74f73fe1647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_427222c3-1011-4358-ae31-5a01c7af8756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e10c10c2-5f2d-42cf-93a5-a74f73fe1647" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_427222c3-1011-4358-ae31-5a01c7af8756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_28e3e419-8668-46c8-abdf-ada4411549e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e10c10c2-5f2d-42cf-93a5-a74f73fe1647" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_28e3e419-8668-46c8-abdf-ada4411549e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cb865c0b-e7df-4f1a-ab60-fbc6e1160463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cb865c0b-e7df-4f1a-ab60-fbc6e1160463" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_18134308-bf90-4e21-9fa2-6b7655999094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_18134308-bf90-4e21-9fa2-6b7655999094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bac05c7c-efc7-469e-a770-d75a253a992c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_18134308-bf90-4e21-9fa2-6b7655999094" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bac05c7c-efc7-469e-a770-d75a253a992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a12c7359-4a3f-410d-9354-45b3e255f750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_bac05c7c-efc7-469e-a770-d75a253a992c" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a12c7359-4a3f-410d-9354-45b3e255f750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6711bb4f-e6a2-4118-b5f9-cd5782cb3278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a069b5b9-b6dd-44a4-b760-fe968b4b8c4c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6711bb4f-e6a2-4118-b5f9-cd5782cb3278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_49165c1d-fb17-46bf-a95a-0e86ca334530" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6711bb4f-e6a2-4118-b5f9-cd5782cb3278" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_49165c1d-fb17-46bf-a95a-0e86ca334530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_fc7f04c4-e8c9-4671-9f17-7821978116c8" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServicingLiabilityMeasurementInput_23bdbb35-955c-4d5c-892a-419f40a3d03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServicingLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_ServicingLiabilityMeasurementInput_23bdbb35-955c-4d5c-892a-419f40a3d03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ce247909-c0a9-4328-acb5-fb66bc8ee2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ce247909-c0a9-4328-acb5-fb66bc8ee2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_88f4141d-edb4-4ace-bd42-551e7eb3e4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_88f4141d-edb4-4ace-bd42-551e7eb3e4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fa6fe6a7-d27d-4029-9fef-0cdf7fa4f16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fa6fe6a7-d27d-4029-9fef-0cdf7fa4f16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_deef0dff-eb59-45a2-9b06-6e09f8ff1203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_deef0dff-eb59-45a2-9b06-6e09f8ff1203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5e035a96-650f-4b4c-b5d5-e8ea37f96383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e0775612-63e7-4994-844b-a6133f1f1f33" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5e035a96-650f-4b4c-b5d5-e8ea37f96383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_70fb02ac-accb-4474-9110-8656556308d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2ead1266-65b7-47c2-b180-4735826a323f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_70fb02ac-accb-4474-9110-8656556308d0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2ead1266-65b7-47c2-b180-4735826a323f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_85e83cfb-932f-4ba1-9d54-273f81a5f903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2ead1266-65b7-47c2-b180-4735826a323f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_85e83cfb-932f-4ba1-9d54-273f81a5f903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_742f5484-5d72-4350-ae43-446d6f9d30c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85e83cfb-932f-4ba1-9d54-273f81a5f903" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_742f5484-5d72-4350-ae43-446d6f9d30c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_81ad6db3-0b70-4deb-8a4d-f760e0c29873" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_742f5484-5d72-4350-ae43-446d6f9d30c1" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_81ad6db3-0b70-4deb-8a4d-f760e0c29873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_2ead1266-65b7-47c2-b180-4735826a323f" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ea6e293-5600-402a-b9d5-c3dde25e5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2ea6e293-5600-402a-b9d5-c3dde25e5f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89ec3e05-5cca-407c-bb5d-9658c0532400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89ec3e05-5cca-407c-bb5d-9658c0532400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b44c9278-02e8-4ab8-a53e-337664b9ef6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b44c9278-02e8-4ab8-a53e-337664b9ef6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e4352217-ffd1-4282-a8cd-00ad28331ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e4352217-ffd1-4282-a8cd-00ad28331ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b3549e35-f5b2-433c-a0a9-43897de31e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0872f5fb-6e24-48ab-8007-38b264bfeedd" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b3549e35-f5b2-433c-a0a9-43897de31e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3b15b05d-49ce-4993-ab16-1a2bbd327d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_309aed36-d111-496f-b62a-e4edf4fc41b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3b15b05d-49ce-4993-ab16-1a2bbd327d78" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_309aed36-d111-496f-b62a-e4edf4fc41b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_309aed36-d111-496f-b62a-e4edf4fc41b3" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f07ab63b-1ef3-433e-baa1-d36f96e3fdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e15f5bd7-0be0-4f57-a1fd-b9f31e4f6dc1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f07ab63b-1ef3-433e-baa1-d36f96e3fdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1026eb31-6f29-4b95-ab9d-e962180ff9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f07ab63b-1ef3-433e-baa1-d36f96e3fdc0" xlink:to="loc_us-gaap_CommercialPaperMember_1026eb31-6f29-4b95-ab9d-e962180ff9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CorporateNotesAndBondsMember_652041e0-a9e1-479b-9760-8fc77220e333" xlink:href="bngo-20211231.xsd#bngo_CorporateNotesAndBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f07ab63b-1ef3-433e-baa1-d36f96e3fdc0" xlink:to="loc_bngo_CorporateNotesAndBondsMember_652041e0-a9e1-479b-9760-8fc77220e333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d7b1709f-585f-48de-9acc-86086f186a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_309aed36-d111-496f-b62a-e4edf4fc41b3" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d7b1709f-585f-48de-9acc-86086f186a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d7b1709f-585f-48de-9acc-86086f186a64" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_11a13d07-f0f3-4295-9b49-eee24cc6c857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_11a13d07-f0f3-4295-9b49-eee24cc6c857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2c8a14aa-ccf8-4db9-9fef-b47f5e3ab51a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2c8a14aa-ccf8-4db9-9fef-b47f5e3ab51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a956ed62-9bf4-4e0b-8c01-4a115d819eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_cb4850b9-e2c2-45e9-a3e2-2b1481ca419c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a956ed62-9bf4-4e0b-8c01-4a115d819eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d7b1709f-585f-48de-9acc-86086f186a64" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b3891950-d180-42e4-b124-0358bdc64433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b3891950-d180-42e4-b124-0358bdc64433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_aea19705-d7f0-491d-8b3d-77e3dac32393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_aea19705-d7f0-491d-8b3d-77e3dac32393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_764fef13-934b-4630-bf9b-955bbfb8deff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_b750afcb-14cc-419a-9449-bb82a3b00240" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_764fef13-934b-4630-bf9b-955bbfb8deff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="bngo-20211231.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_7b18c39b-fa5d-4d37-9cb7-a0af9d125429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock_11adc087-850e-497f-b617-c9cd1ffbacb5" xlink:href="bngo-20211231.xsd#bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_7b18c39b-fa5d-4d37-9cb7-a0af9d125429" xlink:to="loc_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock_11adc087-850e-497f-b617-c9cd1ffbacb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_6b00c61d-9ed3-4ab8-9015-22d25cf6d2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_4e7bad34-9b3f-4cb8-924b-e93aca4837e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_6b00c61d-9ed3-4ab8-9015-22d25cf6d2bf" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_4e7bad34-9b3f-4cb8-924b-e93aca4837e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_63ec4275-ad5a-47c0-ad57-caf55040326a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_dd76a328-4b81-4ac0-9b7e-92e0bb2ac81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Supplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_63ec4275-ad5a-47c0-ad57-caf55040326a" xlink:to="loc_us-gaap_Supplies_dd76a328-4b81-4ac0-9b7e-92e0bb2ac81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_2f76dccf-f4e7-4271-b78f-bb3ef582dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_63ec4275-ad5a-47c0-ad57-caf55040326a" xlink:to="loc_us-gaap_PrepaidInsurance_2f76dccf-f4e7-4271-b78f-bb3ef582dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_0308ef8b-f45f-443d-bbf0-0e9696a2343e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_63ec4275-ad5a-47c0-ad57-caf55040326a" xlink:to="loc_us-gaap_InterestReceivableCurrent_0308ef8b-f45f-443d-bbf0-0e9696a2343e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8168fc72-a7b5-490f-bb55-b2b35a1b73a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_63ec4275-ad5a-47c0-ad57-caf55040326a" xlink:to="loc_us-gaap_OtherAssetsCurrent_8168fc72-a7b5-490f-bb55-b2b35a1b73a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8593b3ac-a9b6-46d3-a313-42f6560c81ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_63ec4275-ad5a-47c0-ad57-caf55040326a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8593b3ac-a9b6-46d3-a313-42f6560c81ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="bngo-20211231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84efc29e-affb-4c9f-a12f-450953f63ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_84ea683c-8b50-4e9d-bf66-80602c1799d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84efc29e-affb-4c9f-a12f-450953f63ee1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_84ea683c-8b50-4e9d-bf66-80602c1799d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6e5c6a4a-9b82-4233-9b42-bfc2df3ee506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ef93cd94-474c-4a20-b5e3-7a0b304e64a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6e5c6a4a-9b82-4233-9b42-bfc2df3ee506" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ef93cd94-474c-4a20-b5e3-7a0b304e64a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9e4b84d8-7431-4f80-a8a6-a851d4f5b40f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1f343251-7531-4237-85d3-9d29bccfe391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9e4b84d8-7431-4f80-a8a6-a851d4f5b40f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1f343251-7531-4237-85d3-9d29bccfe391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc60be13-ff43-48e9-91b9-13a86d2e0127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1f343251-7531-4237-85d3-9d29bccfe391" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc60be13-ff43-48e9-91b9-13a86d2e0127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dc60be13-ff43-48e9-91b9-13a86d2e0127" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ComputerAndOfficeEquipmentMember_6995c87c-aaa8-4456-a8d2-4369c4af6ea4" xlink:href="bngo-20211231.xsd#bngo_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:to="loc_bngo_ComputerAndOfficeEquipmentMember_6995c87c-aaa8-4456-a8d2-4369c4af6ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LabEquipmentMember_5ca80e88-e74d-4ae5-be0e-9d16b9fc20df" xlink:href="bngo-20211231.xsd#bngo_LabEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:to="loc_bngo_LabEquipmentMember_5ca80e88-e74d-4ae5-be0e-9d16b9fc20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ServiceEquipmentMember_054c6342-7df9-4dbe-9b5d-0e89a297095d" xlink:href="bngo-20211231.xsd#bngo_ServiceEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:to="loc_bngo_ServiceEquipmentMember_054c6342-7df9-4dbe-9b5d-0e89a297095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fed8f587-de94-47db-b2dd-529bfd324633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f5799071-8591-4422-9609-9bb083029d28" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fed8f587-de94-47db-b2dd-529bfd324633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1f343251-7531-4237-85d3-9d29bccfe391" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2a1de777-fbb5-4647-81a0-505ad2248b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2a1de777-fbb5-4647-81a0-505ad2248b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b188ae51-79e4-4e7e-acc0-c97a393980af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b188ae51-79e4-4e7e-acc0-c97a393980af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_422a498c-7a66-4fab-bdb6-600aebb83f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_98ae04cb-5ce3-479f-aed3-f40ffb5b25a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_422a498c-7a66-4fab-bdb6-600aebb83f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#PropertyandEquipmentNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8e52b5a2-7b72-47c7-8744-1a1de118138a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb34f3a8-e620-4f43-b181-33ac7bf9e764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8e52b5a2-7b72-47c7-8744-1a1de118138a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb34f3a8-e620-4f43-b181-33ac7bf9e764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50d67b28-7fee-41b9-8257-919ec879eab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb34f3a8-e620-4f43-b181-33ac7bf9e764" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50d67b28-7fee-41b9-8257-919ec879eab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f07c636-7f2e-4bff-81f5-b46319024a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50d67b28-7fee-41b9-8257-919ec879eab1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f07c636-7f2e-4bff-81f5-b46319024a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ReagentRentalsMember_9fb86c5d-157d-4752-975d-03c7550cdb64" xlink:href="bngo-20211231.xsd#bngo_ReagentRentalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6f07c636-7f2e-4bff-81f5-b46319024a4c" xlink:to="loc_bngo_ReagentRentalsMember_9fb86c5d-157d-4752-975d-03c7550cdb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4192052f-3494-4838-8184-bdfe6c913524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cb34f3a8-e620-4f43-b181-33ac7bf9e764" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4192052f-3494-4838-8184-bdfe6c913524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a567ed56-abe0-4485-8853-4270eeeab1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4192052f-3494-4838-8184-bdfe6c913524" xlink:to="loc_us-gaap_Depreciation_a567ed56-abe0-4485-8853-4270eeeab1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_adaa26d7-6b13-4eb1-a9da-4ba5f206bcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_16cbc9d0-d623-4685-a373-6e00f4f8181d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_adaa26d7-6b13-4eb1-a9da-4ba5f206bcbb" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_16cbc9d0-d623-4685-a373-6e00f4f8181d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_064a539f-0c14-46c7-a31a-d19fc55ef2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d31d3277-3ce0-4b14-9ffb-12c6f6e9cb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_064a539f-0c14-46c7-a31a-d19fc55ef2a1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d31d3277-3ce0-4b14-9ffb-12c6f6e9cb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_72110687-c490-485f-9f69-b1f34e813cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_064a539f-0c14-46c7-a31a-d19fc55ef2a1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_72110687-c490-485f-9f69-b1f34e813cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNetSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86fb5366-d160-4f1a-8166-c0185eedae82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa65cb27-49fe-4071-9732-c2cd92f5060c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_86fb5366-d160-4f1a-8166-c0185eedae82" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa65cb27-49fe-4071-9732-c2cd92f5060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_584d3e41-b481-42c0-a21b-31b59807aea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa65cb27-49fe-4071-9732-c2cd92f5060c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_584d3e41-b481-42c0-a21b-31b59807aea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_584d3e41-b481-42c0-a21b-31b59807aea7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_169edc26-eab4-4fd6-9f82-499e8a81148b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:to="loc_us-gaap_TradeNamesMember_169edc26-eab4-4fd6-9f82-499e8a81148b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_538d0b5b-192b-4e84-b94b-b5fa3b97c0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:to="loc_us-gaap_CustomerRelationshipsMember_538d0b5b-192b-4e84-b94b-b5fa3b97c0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_01575713-95da-4dc6-ad34-53a7ec4f433a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9e577fb-de03-4057-8856-b52c2d9c35e4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_01575713-95da-4dc6-ad34-53a7ec4f433a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa65cb27-49fe-4071-9732-c2cd92f5060c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6fb67006-ecc2-48e4-b7bc-2c23c06fe904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6fb67006-ecc2-48e4-b7bc-2c23c06fe904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d894a905-b99e-4cbb-9299-b3584cc69591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d894a905-b99e-4cbb-9299-b3584cc69591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cae0162-b291-4108-8bd0-d20ff051d2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_50f3e365-6783-4d7c-a131-41f4a11e3895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cae0162-b291-4108-8bd0-d20ff051d2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62d1d3a6-d198-4843-b4a7-776e54e6d453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_62d1d3a6-d198-4843-b4a7-776e54e6d453" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e31a6005-01b9-4892-a6cf-c094aeb74c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e31a6005-01b9-4892-a6cf-c094aeb74c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1fd701f8-9ad1-46ad-a904-cec5c474e65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e31a6005-01b9-4892-a6cf-c094aeb74c25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1fd701f8-9ad1-46ad-a904-cec5c474e65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember_0d18ff64-10c7-427e-804a-49df00451edd" xlink:href="bngo-20211231.xsd#bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1fd701f8-9ad1-46ad-a904-cec5c474e65a" xlink:to="loc_bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember_0d18ff64-10c7-427e-804a-49df00451edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dccf63d9-526c-4519-8576-eb72e2dc161e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dccf63d9-526c-4519-8576-eb72e2dc161e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ccfab7ce-6212-43fc-a2be-972b7160d286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dccf63d9-526c-4519-8576-eb72e2dc161e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ccfab7ce-6212-43fc-a2be-972b7160d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_92157767-b900-4a94-8118-9d609c2b2ebb" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ccfab7ce-6212-43fc-a2be-972b7160d286" xlink:to="loc_bngo_LineagenMember_92157767-b900-4a94-8118-9d609c2b2ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_469cbb83-7d4a-4d5e-af65-1971754723ce" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ccfab7ce-6212-43fc-a2be-972b7160d286" xlink:to="loc_bngo_BioDiscoveryMember_469cbb83-7d4a-4d5e-af65-1971754723ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4c612bd3-c584-405a-ba90-b66f6425c9cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_41f759ba-e2f5-4d4d-90d0-80e44c94618d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_41f759ba-e2f5-4d4d-90d0-80e44c94618d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_63f7d973-b20a-4002-8ec4-bd5d0cdf8a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_63f7d973-b20a-4002-8ec4-bd5d0cdf8a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_87fcc343-a3d1-4042-a600-d46243f87536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1dcf0300-d685-4f64-908a-e8f7fe099a9d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_87fcc343-a3d1-4042-a600-d46243f87536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5701f803-966a-4d37-8b0f-20cc79044cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e7f9b723-46b4-40a4-87c0-67440474a720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5701f803-966a-4d37-8b0f-20cc79044cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e7f9b723-46b4-40a4-87c0-67440474a720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c9396c08-7b8d-4f43-bf52-9849949b3c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5701f803-966a-4d37-8b0f-20cc79044cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c9396c08-7b8d-4f43-bf52-9849949b3c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9b4de71b-8399-4d63-b806-9820cb646a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5701f803-966a-4d37-8b0f-20cc79044cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9b4de71b-8399-4d63-b806-9820cb646a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0d573e28-42a2-4dd6-86bf-34f3cebd4c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5701f803-966a-4d37-8b0f-20cc79044cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0d573e28-42a2-4dd6-86bf-34f3cebd4c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fc73e069-9143-4866-a625-3b28bf912c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5701f803-966a-4d37-8b0f-20cc79044cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fc73e069-9143-4866-a625-3b28bf912c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eab0b67e-f2f8-4880-a12a-96787f3bab95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5701f803-966a-4d37-8b0f-20cc79044cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eab0b67e-f2f8-4880-a12a-96787f3bab95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AccruedExpenses" xlink:type="simple" xlink:href="bngo-20211231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_4c88643f-c47c-4593-9845-48313b97c890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e04697e0-2e54-495f-99c6-e959ffc87d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_4c88643f-c47c-4593-9845-48313b97c890" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e04697e0-2e54-495f-99c6-e959ffc87d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_053b9111-f718-4ac8-99c6-d77fd2c6018a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1ab25c81-254a-4e02-ad29-c8f3495be2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_053b9111-f718-4ac8-99c6-d77fd2c6018a" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1ab25c81-254a-4e02-ad29-c8f3495be2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AccruedExpensesScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b687907a-7c43-431e-88d5-6ea14d26e527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b687907a-7c43-431e-88d5-6ea14d26e527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AccruedInventoryCurrent_3873c61f-7c7a-408f-8a9f-c8c501d91d0f" xlink:href="bngo-20211231.xsd#bngo_AccruedInventoryCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_bngo_AccruedInventoryCurrent_3873c61f-7c7a-408f-8a9f-c8c501d91d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_bf6c9a2c-83d4-482b-9e3e-1aafdb4034b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_us-gaap_TaxesPayableCurrent_bf6c9a2c-83d4-482b-9e3e-1aafdb4034b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_31cfd52d-983f-417f-b03f-a531a28bb748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_31cfd52d-983f-417f-b03f-a531a28bb748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_de1b17eb-efb0-4fed-be13-509281b843ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_de1b17eb-efb0-4fed-be13-509281b843ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_1e592d0f-dc01-4997-8b11-01a97823caea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_1e592d0f-dc01-4997-8b11-01a97823caea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_0b75f8ad-3a5d-407e-bf3e-bd0b5e57a01c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_us-gaap_InterestPayableCurrent_0b75f8ad-3a5d-407e-bf3e-bd0b5e57a01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_368e6da2-0a1b-409e-93fd-a853ef259750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_368e6da2-0a1b-409e-93fd-a853ef259750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0553f577-a9bc-4e92-8464-1ffe0051b6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_64d547d9-c04b-41af-bee3-88535df015e2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0553f577-a9bc-4e92-8464-1ffe0051b6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/LongTermDebt" xlink:type="simple" xlink:href="bngo-20211231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d9b88903-ecbc-4788-b268-361b2d21d947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_52d32048-7029-4f8a-b957-d328730d7ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d9b88903-ecbc-4788-b268-361b2d21d947" xlink:to="loc_us-gaap_LongTermDebtTextBlock_52d32048-7029-4f8a-b957-d328730d7ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8bc3643f-5b1f-443c-b4df-b37015d643e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_da8c82af-31dd-4d10-a4bd-c5dc7e1c6f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8bc3643f-5b1f-443c-b4df-b37015d643e9" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_da8c82af-31dd-4d10-a4bd-c5dc7e1c6f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_214a9a06-8459-43d4-bd42-a3e53aa1c24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_214a9a06-8459-43d4-bd42-a3e53aa1c24a" xlink:to="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsAxis_1cf1192d-a209-494e-bb98-d36ec7ad4a98" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:to="loc_bngo_DebtInstrumentPaymentTermsAxis_1cf1192d-a209-494e-bb98-d36ec7ad4a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsAxis_1cf1192d-a209-494e-bb98-d36ec7ad4a98" xlink:to="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember_38404510-7a00-4974-8515-7afb12ab6304" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodOneMember_38404510-7a00-4974-8515-7afb12ab6304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_fa989691-3f6b-4c60-9057-a40da007b370" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodTwoMember_fa989691-3f6b-4c60-9057-a40da007b370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_e78c2bfa-8a08-4ccc-9501-7e167da5bb5d" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodThreeMember_e78c2bfa-8a08-4ccc-9501-7e167da5bb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember_94518542-9fb1-4e77-ba44-cfaafd79f06b" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPaymentTermsPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_DebtInstrumentPaymentTermsDomain_ce9536ef-4c62-47e2-966b-7cf9ee0eb0ea" xlink:to="loc_bngo_DebtInstrumentPaymentTermsPeriodFourMember_94518542-9fb1-4e77-ba44-cfaafd79f06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:to="loc_us-gaap_DebtInstrumentAxis_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1c6f0a09-40c1-4b62-9fc7-1ae5dc198374" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LoanUnderPaycheckProtectionProgramMember_66d4d831-84a6-49bf-96bb-50b141a28742" xlink:href="bngo-20211231.xsd#bngo_LoanUnderPaycheckProtectionProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_LoanUnderPaycheckProtectionProgramMember_66d4d831-84a6-49bf-96bb-50b141a28742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA1LoanMember_9c71d5a2-cfe5-4c4b-adb7-46c8b2ea908e" xlink:href="bngo-20211231.xsd#bngo_TermA1LoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_TermA1LoanMember_9c71d5a2-cfe5-4c4b-adb7-46c8b2ea908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermA2LoanMember_3ec21a63-a223-4e0b-94a3-6f72a157ab92" xlink:href="bngo-20211231.xsd#bngo_TermA2LoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_TermA2LoanMember_3ec21a63-a223-4e0b-94a3-6f72a157ab92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusTerm3LoanMember_75ea1853-0573-4ec4-b34e-56ba9687447c" xlink:href="bngo-20211231.xsd#bngo_InnovatusTerm3LoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_InnovatusTerm3LoanMember_75ea1853-0573-4ec4-b34e-56ba9687447c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_InnovatusLoanAgreementMember_e97aaa7f-dded-41c5-aa08-e38d645af2fa" xlink:href="bngo-20211231.xsd#bngo_InnovatusLoanAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_InnovatusLoanAgreementMember_e97aaa7f-dded-41c5-aa08-e38d645af2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RevolverMember_d9d26b1f-aaca-4ca9-9d4c-f13b65d424e3" xlink:href="bngo-20211231.xsd#bngo_RevolverMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b9a0b3c-c745-4ad4-9e2e-b028e16fc9a9" xlink:to="loc_bngo_RevolverMember_d9d26b1f-aaca-4ca9-9d4c-f13b65d424e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_79c87946-e56e-4d24-82a4-675fe4de82a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_79c87946-e56e-4d24-82a4-675fe4de82a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfb2f998-3a9c-49b2-9b44-626ba38ee7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_79c87946-e56e-4d24-82a4-675fe4de82a1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfb2f998-3a9c-49b2-9b44-626ba38ee7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c00ad9ed-5cdf-446a-918f-c14b8018d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bfb2f998-3a9c-49b2-9b44-626ba38ee7d2" xlink:to="loc_us-gaap_UnsecuredDebtMember_c00ad9ed-5cdf-446a-918f-c14b8018d3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_8a7b9cbf-2caa-4b84-a99a-1130fa986676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bfb2f998-3a9c-49b2-9b44-626ba38ee7d2" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_8a7b9cbf-2caa-4b84-a99a-1130fa986676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20224c8c-cc0b-4a44-9dc0-a6403fce486c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9ed54227-5044-4e1b-b09c-ca0c9fe1aa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9ed54227-5044-4e1b-b09c-ca0c9fe1aa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5815d674-ad8e-4588-8d7e-cfb0b402d6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5815d674-ad8e-4588-8d7e-cfb0b402d6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateCashRate_3b852551-86aa-4848-9c03-aee5b50fc4c3" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentInterestRateCashRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentInterestRateCashRate_3b852551-86aa-4848-9c03-aee5b50fc4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate_5511e3a1-0ea1-43a3-be91-5f987cf71a35" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentInterestRateDiscountedCashRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentInterestRateDiscountedCashRate_5511e3a1-0ea1-43a3-be91-5f987cf71a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b38dfc26-f4f9-4e73-81d7-a0a3703f2330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b38dfc26-f4f9-4e73-81d7-a0a3703f2330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentPrepaymentFeePercent_e38b1ae1-1912-4537-9837-6349eb1f89b3" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentPrepaymentFeePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentPrepaymentFeePercent_e38b1ae1-1912-4537-9837-6349eb1f89b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_a2ff571b-5145-49f8-883f-4d17e899d4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_a2ff571b-5145-49f8-883f-4d17e899d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_8fc0d043-d9d2-4985-aa4a-3ec8f185025f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_8fc0d043-d9d2-4985-aa4a-3ec8f185025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6b25cfd2-ecfd-4271-b41d-fceb4ebd1f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6b25cfd2-ecfd-4271-b41d-fceb4ebd1f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_99d7b194-b80d-4a58-b3c8-1d725d0ae26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_99d7b194-b80d-4a58-b3c8-1d725d0ae26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_WarrantsToPurchaseSharesIssued_cd73ae8a-9acf-49bd-b007-02d8a4ec7767" xlink:href="bngo-20211231.xsd#bngo_WarrantsToPurchaseSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_WarrantsToPurchaseSharesIssued_cd73ae8a-9acf-49bd-b007-02d8a4ec7767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f6630765-fbe5-456b-b3d4-1a9355c6f273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f6630765-fbe5-456b-b3d4-1a9355c6f273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassofWarrantorRightTerm_afb13668-a44f-4ff3-96a7-55c0d0e5f903" xlink:href="bngo-20211231.xsd#bngo_ClassofWarrantorRightTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_ClassofWarrantorRightTerm_afb13668-a44f-4ff3-96a7-55c0d0e5f903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness_88c8ebde-6a04-4e7b-bdf2-bcd6224025ba" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness_88c8ebde-6a04-4e7b-bdf2-bcd6224025ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross_9cb3fdb3-9b3a-401f-ba92-fec1600bd502" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross_9cb3fdb3-9b3a-401f-ba92-fec1600bd502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_4285a78d-3012-482c-9105-38f4be6767d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_4285a78d-3012-482c-9105-38f4be6767d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_a3235f2a-3ce5-4895-9ba2-afcfccebdf04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_us-gaap_RepaymentsOfDebt_a3235f2a-3ce5-4895-9ba2-afcfccebdf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise_d833d015-83d5-4053-9aa3-929c7677f3f5" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise_d833d015-83d5-4053-9aa3-929c7677f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance_fe400e7f-0e5b-4708-b93d-6baea560e2fc" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance_fe400e7f-0e5b-4708-b93d-6baea560e2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod_4a2edfc8-747a-40e0-8236-54323fde8465" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod_4a2edfc8-747a-40e0-8236-54323fde8465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantWaiverFee_4bfc20ff-8ac4-4e19-9226-a17c3960a33e" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantWaiverFee"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantWaiverFee_4bfc20ff-8ac4-4e19-9226-a17c3960a33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DebtInstrumentCovenantPrepaymentFee_d6f62da6-98f5-496c-9245-42f8924bfc42" xlink:href="bngo-20211231.xsd#bngo_DebtInstrumentCovenantPrepaymentFee"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cdd7f2e8-b8d4-496f-861b-b21925f30d2c" xlink:to="loc_bngo_DebtInstrumentCovenantPrepaymentFee_d6f62da6-98f5-496c-9245-42f8924bfc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#LongTermDebtScheduleofDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_630bbb6f-2d4d-4cb9-adb9-6302f2eb981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_54a845a8-a2e5-4f46-93cd-874e494a9fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_630bbb6f-2d4d-4cb9-adb9-6302f2eb981a" xlink:to="loc_us-gaap_DebtInstrumentTable_54a845a8-a2e5-4f46-93cd-874e494a9fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d7ce7153-a3a5-4614-99e7-51fb49c0c64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_54a845a8-a2e5-4f46-93cd-874e494a9fb3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d7ce7153-a3a5-4614-99e7-51fb49c0c64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d7ce7153-a3a5-4614-99e7-51fb49c0c64a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TermLoanMember_9aab7978-a84a-4def-8507-bf4b009a9bdb" xlink:href="bngo-20211231.xsd#bngo_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:to="loc_bngo_TermLoanMember_9aab7978-a84a-4def-8507-bf4b009a9bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_RevolverMember_7f735443-e825-4653-a186-4357c6d143e8" xlink:href="bngo-20211231.xsd#bngo_RevolverMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:to="loc_bngo_RevolverMember_7f735443-e825-4653-a186-4357c6d143e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LoanUnderPaycheckProtectionProgramMember_350c4797-fbd4-478d-956a-401b01d1bde8" xlink:href="bngo-20211231.xsd#bngo_LoanUnderPaycheckProtectionProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bbf750c1-ee8c-4f0b-90b6-ec730f1a025d" xlink:to="loc_bngo_LoanUnderPaycheckProtectionProgramMember_350c4797-fbd4-478d-956a-401b01d1bde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_54a845a8-a2e5-4f46-93cd-874e494a9fb3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ae4bca58-2eea-4640-932e-4bac6b61af80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ae4bca58-2eea-4640-932e-4bac6b61af80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d527b3e7-d13d-45a9-882a-71dae4a1b0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d527b3e7-d13d-45a9-882a-71dae4a1b0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_22343264-6040-4078-aa3f-2ac3e312fb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c0d2a4e8-f866-42c6-bc06-35ad4387d2e0" xlink:to="loc_us-gaap_LongTermDebt_22343264-6040-4078-aa3f-2ac3e312fb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensation"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ead089b1-6313-4abb-8c11-34a9e0dd397d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_02d48b97-3be8-4a94-8d47-e0c0ddc1604e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ead089b1-6313-4abb-8c11-34a9e0dd397d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_02d48b97-3be8-4a94-8d47-e0c0ddc1604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f4d87713-6f62-44cb-ace3-b67a9dee8d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c87923c1-313e-4cbc-ad3d-08c6010e55c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4d87713-6f62-44cb-ace3-b67a9dee8d67" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c87923c1-313e-4cbc-ad3d-08c6010e55c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_486472a8-42f3-44d2-89d7-3c4478e12bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4d87713-6f62-44cb-ace3-b67a9dee8d67" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_486472a8-42f3-44d2-89d7-3c4478e12bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f0b34aa7-2b68-4d9f-a36c-ea048774933c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4d87713-6f62-44cb-ace3-b67a9dee8d67" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f0b34aa7-2b68-4d9f-a36c-ea048774933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d0239416-92d1-4bed-87c7-7855a1d0523c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4d87713-6f62-44cb-ace3-b67a9dee8d67" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d0239416-92d1-4bed-87c7-7855a1d0523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ce9a32f-f925-4bef-86e9-d79ef2936d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4d87713-6f62-44cb-ace3-b67a9dee8d67" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ce9a32f-f925-4bef-86e9-d79ef2936d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9c420d37-1e50-4645-81b1-d4422cc6e4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9c420d37-1e50-4645-81b1-d4422cc6e4c9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d775c9c0-50ba-44fb-a906-599069c13166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d775c9c0-50ba-44fb-a906-599069c13166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b8e680be-fd54-4c4b-a52c-7c2f2ff888d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d775c9c0-50ba-44fb-a906-599069c13166" xlink:to="loc_us-gaap_ClassOfStockDomain_b8e680be-fd54-4c4b-a52c-7c2f2ff888d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_53cf12bd-7c4f-4765-aba2-b9ac8912e15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b8e680be-fd54-4c4b-a52c-7c2f2ff888d0" xlink:to="loc_us-gaap_CommonStockMember_53cf12bd-7c4f-4765-aba2-b9ac8912e15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember_9a23acde-e8c0-4658-a61a-cc64d452a46d" xlink:href="bngo-20211231.xsd#bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b8e680be-fd54-4c4b-a52c-7c2f2ff888d0" xlink:to="loc_bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember_9a23acde-e8c0-4658-a61a-cc64d452a46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a81d2905-4957-422b-94b4-4ef520c44b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a81d2905-4957-422b-94b4-4ef520c44b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a81d2905-4957-422b-94b4-4ef520c44b43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PreFundedWarrantMember_becb768c-d6b8-4e61-9372-970e12f9a646" xlink:href="bngo-20211231.xsd#bngo_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:to="loc_bngo_PreFundedWarrantMember_becb768c-d6b8-4e61-9372-970e12f9a646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonWarrantsMember_2a88a022-8a74-4c52-8f2d-7c7e4f4dfb03" xlink:href="bngo-20211231.xsd#bngo_CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:to="loc_bngo_CommonWarrantsMember_2a88a022-8a74-4c52-8f2d-7c7e4f4dfb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockWarrantsOriginalAgreementMember_7e544fbc-2bd1-4274-88f8-15b54c2eca70" xlink:href="bngo-20211231.xsd#bngo_CommonStockWarrantsOriginalAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:to="loc_bngo_CommonStockWarrantsOriginalAgreementMember_7e544fbc-2bd1-4274-88f8-15b54c2eca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommonStockWarrantsAmendedAgreementMember_17cd66a1-fd89-4d6e-94fb-e348909cea47" xlink:href="bngo-20211231.xsd#bngo_CommonStockWarrantsAmendedAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9d19822a-0526-4548-9c02-dfdd76358839" xlink:to="loc_bngo_CommonStockWarrantsAmendedAgreementMember_17cd66a1-fd89-4d6e-94fb-e348909cea47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_43cc96ac-92d8-497e-b132-caf30971a48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_43cc96ac-92d8-497e-b132-caf30971a48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6408e62d-0254-4ee9-9495-77f2f4c67914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_43cc96ac-92d8-497e-b132-caf30971a48f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6408e62d-0254-4ee9-9495-77f2f4c67914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_28a8b35f-3ff5-4d5d-9aac-9fdf48ff2315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6408e62d-0254-4ee9-9495-77f2f4c67914" xlink:to="loc_us-gaap_EmployeeStockMember_28a8b35f-3ff5-4d5d-9aac-9fdf48ff2315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e152921d-38e4-41d4-97b5-73305c387dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6408e62d-0254-4ee9-9495-77f2f4c67914" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e152921d-38e4-41d4-97b5-73305c387dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_29c705e8-f584-4c1e-9451-780dd4352dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_PlanNameAxis_29c705e8-f584-4c1e-9451-780dd4352dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4ed26c08-2fdc-4fac-93ef-24274e78da11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_29c705e8-f584-4c1e-9451-780dd4352dfb" xlink:to="loc_us-gaap_PlanNameDomain_4ed26c08-2fdc-4fac-93ef-24274e78da11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoThousandEighteenEquityIncentivePlanMember_fc7d9369-1470-4d7d-9ddc-1b5bb3e99b6d" xlink:href="bngo-20211231.xsd#bngo_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4ed26c08-2fdc-4fac-93ef-24274e78da11" xlink:to="loc_bngo_TwoThousandEighteenEquityIncentivePlanMember_fc7d9369-1470-4d7d-9ddc-1b5bb3e99b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_TwoThousandAndTwentyInducementPlanMember_80d06b83-bff4-4fb1-9d94-8161db593bdc" xlink:href="bngo-20211231.xsd#bngo_TwoThousandAndTwentyInducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4ed26c08-2fdc-4fac-93ef-24274e78da11" xlink:to="loc_bngo_TwoThousandAndTwentyInducementPlanMember_80d06b83-bff4-4fb1-9d94-8161db593bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b147b2c8-2869-4555-9ce7-8dde048532c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_AwardTypeAxis_b147b2c8-2869-4555-9ce7-8dde048532c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b147b2c8-2869-4555-9ce7-8dde048532c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a2de7b69-7f48-4dfb-b666-75a965bd3e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a2de7b69-7f48-4dfb-b666-75a965bd3e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_44b0c782-d7f6-440c-a4cf-d5f07c83ace2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:to="loc_us-gaap_RestrictedStockMember_44b0c782-d7f6-440c-a4cf-d5f07c83ace2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6a7b456f-5b35-41d3-ae54-5baab1a125b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6a7b456f-5b35-41d3-ae54-5baab1a125b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_e3a1393a-dfc2-46a2-ba4d-2444b98ecb73" xlink:href="bngo-20211231.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c91cb5be-6898-4877-a9dd-ed3bbd3ff829" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_e3a1393a-dfc2-46a2-ba4d-2444b98ecb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d763630-3bde-4b23-9a94-8f11e37fa9bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_srt_RangeAxis_8d763630-3bde-4b23-9a94-8f11e37fa9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5739b13a-e774-4796-bff7-748f15ca0122" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8d763630-3bde-4b23-9a94-8f11e37fa9bb" xlink:to="loc_srt_RangeMember_5739b13a-e774-4796-bff7-748f15ca0122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce6d8446-1466-43f6-88e9-5e359fdeeedc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5739b13a-e774-4796-bff7-748f15ca0122" xlink:to="loc_srt_MaximumMember_ce6d8446-1466-43f6-88e9-5e359fdeeedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_srt_CounterpartyNameAxis_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e1010585-c6f6-4f7b-9bfd-be0921a72ebf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d33f2b2b-9e60-4534-8c4e-5bb7bc83a413" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e1010585-c6f6-4f7b-9bfd-be0921a72ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CowenMember_9358d412-d75c-446f-a999-b72614287fd7" xlink:href="bngo-20211231.xsd#bngo_CowenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e1010585-c6f6-4f7b-9bfd-be0921a72ebf" xlink:to="loc_bngo_CowenMember_9358d412-d75c-446f-a999-b72614287fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_84dc9d36-c3dd-4623-904f-29104de09375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_84dc9d36-c3dd-4623-904f-29104de09375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1190f9e2-6818-497a-8c88-3a2d3b504f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_84dc9d36-c3dd-4623-904f-29104de09375" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1190f9e2-6818-497a-8c88-3a2d3b504f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_fc7084bb-c580-434b-8a5b-8b50428938ed" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1190f9e2-6818-497a-8c88-3a2d3b504f5e" xlink:to="loc_bngo_BioDiscoveryMember_fc7084bb-c580-434b-8a5b-8b50428938ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e379a02d-fd20-49b7-8319-827ef471a7b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_srt_TitleOfIndividualAxis_e379a02d-fd20-49b7-8319-827ef471a7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c9bea83-46ba-463e-b4aa-8cd5fb072713" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e379a02d-fd20-49b7-8319-827ef471a7b1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c9bea83-46ba-463e-b4aa-8cd5fb072713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_bb351324-1d4f-43e0-9402-12ac956afc80" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0c9bea83-46ba-463e-b4aa-8cd5fb072713" xlink:to="loc_srt_ExecutiveOfficerMember_bb351324-1d4f-43e0-9402-12ac956afc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bb7a88f4-578d-467d-a14c-705c43c2fddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bb7a88f4-578d-467d-a14c-705c43c2fddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8a51d32a-5e80-4079-b474-313cecd0fb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bb7a88f4-578d-467d-a14c-705c43c2fddd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8a51d32a-5e80-4079-b474-313cecd0fb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2212c811-c786-4f78-b574-8ffc13938b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8a51d32a-5e80-4079-b474-313cecd0fb67" xlink:to="loc_us-gaap_SubsequentEventMember_2212c811-c786-4f78-b574-8ffc13938b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a346f854-aff3-4feb-aeba-750fd24ea967" xlink:to="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_684be271-a420-4308-b1d3-f8c96386149c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_684be271-a420-4308-b1d3-f8c96386149c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_dc52c546-48c7-4c84-9466-4a65008c711b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_dc52c546-48c7-4c84-9466-4a65008c711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3caa038c-6323-43e6-a8f4-c1760a84ac64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3caa038c-6323-43e6-a8f4-c1760a84ac64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7d12209e-2e43-42f5-98b6-a3388e75a289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7d12209e-2e43-42f5-98b6-a3388e75a289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5b23dbaa-16d5-4c85-ac11-d085db2cebdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5b23dbaa-16d5-4c85-ac11-d085db2cebdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18e9ac3a-eabb-463f-9f1b-8468675aacd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_18e9ac3a-eabb-463f-9f1b-8468675aacd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6262fa51-d4fc-4ced-8bff-8937ea2a39c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6262fa51-d4fc-4ced-8bff-8937ea2a39c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bd85e0a4-ecf4-4714-9b84-0f58918f8ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bd85e0a4-ecf4-4714-9b84-0f58918f8ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ef99be33-e4e4-4aaa-a921-894b7ad7f400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ef99be33-e4e4-4aaa-a921-894b7ad7f400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExpirationPeriod_3b7590cd-3861-45da-a5b6-9fdcd5cb8d42" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_ClassOfWarrantOrRightExpirationPeriod_3b7590cd-3861-45da-a5b6-9fdcd5cb8d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b1fa78a1-23f0-45f3-83ab-0c9c4d42c0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b1fa78a1-23f0-45f3-83ab-0c9c4d42c0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5c2f6a7f-44b8-4bd8-9a4c-105b2212f24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5c2f6a7f-44b8-4bd8-9a4c-105b2212f24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_145520d8-ffe2-41cd-ba33-e6a914b4a018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_145520d8-ffe2-41cd-ba33-e6a914b4a018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e5314476-85fe-4680-a7c0-87dc92edb9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e5314476-85fe-4680-a7c0-87dc92edb9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued_0013ec28-fcae-485b-9b13-332c6fb83485" xlink:href="bngo-20211231.xsd#bngo_SaleOfStockAuthorizedAmountToBeIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_SaleOfStockAuthorizedAmountToBeIssued_0013ec28-fcae-485b-9b13-332c6fb83485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_e57c3000-4e5b-4ea9-a1b7-ba49008025bb" xlink:href="bngo-20211231.xsd#bngo_SaleOfStockValueSharesIssuedInTransaction"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_SaleOfStockValueSharesIssuedInTransaction_e57c3000-4e5b-4ea9-a1b7-ba49008025bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_7b75fa64-fbff-484a-a3e6-b58baadebb3b" xlink:href="bngo-20211231.xsd#bngo_CommissionFeeMaximumPercentageOfGrossProceeds"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_CommissionFeeMaximumPercentageOfGrossProceeds_7b75fa64-fbff-484a-a3e6-b58baadebb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_108321b8-5401-47b9-9541-72ecf43cb1fd" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_108321b8-5401-47b9-9541-72ecf43cb1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_124aad6c-3995-4947-b20a-b05f33b0b5a5" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_124aad6c-3995-4947-b20a-b05f33b0b5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c9b36f8d-e072-48fa-9d19-efbcdec20514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c9b36f8d-e072-48fa-9d19-efbcdec20514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c6cd0c18-f6b9-4048-b10a-e0f81d486455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c6cd0c18-f6b9-4048-b10a-e0f81d486455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_05054f97-1cdd-4d85-b1db-3fd275c600a4" xlink:href="bngo-20211231.xsd#bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_05054f97-1cdd-4d85-b1db-3fd275c600a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_835d6a66-0baa-4ab2-92e3-9731fdb91db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_835d6a66-0baa-4ab2-92e3-9731fdb91db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_43e10279-8ba4-4d04-91e2-3487bc9e5685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_43e10279-8ba4-4d04-91e2-3487bc9e5685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_7c65c555-8e70-496e-8696-6be0a7fa49eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_7c65c555-8e70-496e-8696-6be0a7fa49eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_760309d1-7c42-4e6d-8545-5e70f06ef4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_760309d1-7c42-4e6d-8545-5e70f06ef4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7c0e8758-5912-4549-88c3-94ce1708386b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7c0e8758-5912-4549-88c3-94ce1708386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73f12439-1176-47cb-b8f2-6e63f4e809ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73f12439-1176-47cb-b8f2-6e63f4e809ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b6a88104-9f52-4444-9594-c69c7f80ab56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b6a88104-9f52-4444-9594-c69c7f80ab56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_502e47e5-b6b4-496f-b5ec-19e37fb1f59d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_502e47e5-b6b4-496f-b5ec-19e37fb1f59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_82a8b332-ba10-4cee-a483-776547848e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_82a8b332-ba10-4cee-a483-776547848e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_222a66f0-9109-42d6-803e-74622cbcbba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_222a66f0-9109-42d6-803e-74622cbcbba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3c2983da-3201-48da-a0f7-4c3e5c0c4d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3c2983da-3201-48da-a0f7-4c3e5c0c4d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_278f145a-cf52-4c60-bcd5-792e093185f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_278f145a-cf52-4c60-bcd5-792e093185f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e80edf7d-71c1-4ea1-b836-3e9f3820c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e80edf7d-71c1-4ea1-b836-3e9f3820c7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15663b0a-0aa5-402f-865e-246df1c4b691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15663b0a-0aa5-402f-865e-246df1c4b691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ebfc925b-df66-413f-a632-d09136e92a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4391165a-317d-46d3-9264-599a51681157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ebfc925b-df66-413f-a632-d09136e92a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationWarrantActivityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5b87c529-d84a-4b1c-9741-673cff4f1b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_adb40d0d-1f0d-4026-b9d0-0291a5b0689d" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b87c529-d84a-4b1c-9741-673cff4f1b29" xlink:to="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_adb40d0d-1f0d-4026-b9d0-0291a5b0689d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_874ede85-1fe9-4b58-9f6c-d4d330e6e391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_adb40d0d-1f0d-4026-b9d0-0291a5b0689d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_874ede85-1fe9-4b58-9f6c-d4d330e6e391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_9f61974f-06ed-42a6-bbfc-d56bbf7a4319" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_adb40d0d-1f0d-4026-b9d0-0291a5b0689d" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod_9f61974f-06ed-42a6-bbfc-d56bbf7a4319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_884362d1-fa7a-416c-a934-eec13587fd5f" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_adb40d0d-1f0d-4026-b9d0-0291a5b0689d" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod_884362d1-fa7a-416c-a934-eec13587fd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_c82f0037-da29-4d4e-8650-65a4676784f2" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_adb40d0d-1f0d-4026-b9d0-0291a5b0689d" xlink:to="loc_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod_c82f0037-da29-4d4e-8650-65a4676784f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_547c81e6-2c0d-4a8d-a3c6-2af16db63687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightOutstandingRollForward_adb40d0d-1f0d-4026-b9d0-0291a5b0689d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_547c81e6-2c0d-4a8d-a3c6-2af16db63687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_e671b57e-ed62-40fb-975b-df8633273b62" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b87c529-d84a-4b1c-9741-673cff4f1b29" xlink:to="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_e671b57e-ed62-40fb-975b-df8633273b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd245fa5-9875-40ba-9f52-645f92bb4b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_e671b57e-ed62-40fb-975b-df8633273b62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd245fa5-9875-40ba-9f52-645f92bb4b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_4cb74a15-149a-4ab9-a210-6d52bc650dd5" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_e671b57e-ed62-40fb-975b-df8633273b62" xlink:to="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod_4cb74a15-149a-4ab9-a210-6d52bc650dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_06b08be8-ab99-446d-b098-e85b529237b7" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_e671b57e-ed62-40fb-975b-df8633273b62" xlink:to="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod_06b08be8-ab99-446d-b098-e85b529237b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod_d4c42665-089c-4d7f-84d5-9629c500d63c" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_e671b57e-ed62-40fb-975b-df8633273b62" xlink:to="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod_d4c42665-089c-4d7f-84d5-9629c500d63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dc719982-235e-453c-9fe7-54ebedd7225b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward_e671b57e-ed62-40fb-975b-df8633273b62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dc719982-235e-453c-9fe7-54ebedd7225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_13fadf9a-2414-4686-a711-6ec95e1eac43" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b87c529-d84a-4b1c-9741-673cff4f1b29" xlink:to="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_13fadf9a-2414-4686-a711-6ec95e1eac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_fcc4d7ff-e2f4-4382-97a2-384b03bf8795" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_13fadf9a-2414-4686-a711-6ec95e1eac43" xlink:to="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights_fcc4d7ff-e2f4-4382-97a2-384b03bf8795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_c9772346-1d17-4a38-8931-923d39f3331d" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward_13fadf9a-2414-4686-a711-6ec95e1eac43" xlink:to="loc_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights_c9772346-1d17-4a38-8931-923d39f3331d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_b5b4472f-49c5-419c-a2b6-71f5deb7b3ae" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b87c529-d84a-4b1c-9741-673cff4f1b29" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_b5b4472f-49c5-419c-a2b6-71f5deb7b3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_1e79565f-1c5d-410a-9a98-d41a4047ded6" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_b5b4472f-49c5-419c-a2b6-71f5deb7b3ae" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_1e79565f-1c5d-410a-9a98-d41a4047ded6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_57087e69-523c-4a78-b79f-9f90d19569df" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_b5b4472f-49c5-419c-a2b6-71f5deb7b3ae" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights_57087e69-523c-4a78-b79f-9f90d19569df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_c62bd01e-151e-4189-8078-9955c67c116b" xlink:href="bngo-20211231.xsd#bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract_b5b4472f-49c5-419c-a2b6-71f5deb7b3ae" xlink:to="loc_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights_c62bd01e-151e-4189-8078-9955c67c116b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_089e6882-de4f-49c1-b360-9f5648258a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_089e6882-de4f-49c1-b360-9f5648258a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18c851ad-103e-4d39-9e52-a5b15a4527ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_089e6882-de4f-49c1-b360-9f5648258a8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18c851ad-103e-4d39-9e52-a5b15a4527ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b2083e99-8f0a-41ba-9ce5-0a06a446bf96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_089e6882-de4f-49c1-b360-9f5648258a8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b2083e99-8f0a-41ba-9ce5-0a06a446bf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e7f9f60-7102-4ab3-8c17-5b3ca16731da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_089e6882-de4f-49c1-b360-9f5648258a8b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e7f9f60-7102-4ab3-8c17-5b3ca16731da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_046f1f00-96d5-4e77-b311-e8407bf9d4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_089e6882-de4f-49c1-b360-9f5648258a8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_046f1f00-96d5-4e77-b311-e8407bf9d4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d12c26d-e4a6-4c6f-baa5-0cbc315366ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_089e6882-de4f-49c1-b360-9f5648258a8b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d12c26d-e4a6-4c6f-baa5-0cbc315366ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_cae85b8c-9a2e-441a-85b3-f1d3d564c595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_cae85b8c-9a2e-441a-85b3-f1d3d564c595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72d9350b-5cd2-4097-9a45-7339320951d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72d9350b-5cd2-4097-9a45-7339320951d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4dde158-c131-4371-a2d1-612902270c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72d9350b-5cd2-4097-9a45-7339320951d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4dde158-c131-4371-a2d1-612902270c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c73601ad-7f74-478a-bbc1-85baf80fb2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72d9350b-5cd2-4097-9a45-7339320951d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c73601ad-7f74-478a-bbc1-85baf80fb2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3ac5b779-509e-4cb7-9553-bcf3a2b077a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72d9350b-5cd2-4097-9a45-7339320951d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3ac5b779-509e-4cb7-9553-bcf3a2b077a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_783eb548-d013-43ce-a6a5-54e1f3bd609c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72d9350b-5cd2-4097-9a45-7339320951d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_783eb548-d013-43ce-a6a5-54e1f3bd609c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e2ecb35-7e62-42b0-b98a-e7a6847eface" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72d9350b-5cd2-4097-9a45-7339320951d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7e2ecb35-7e62-42b0-b98a-e7a6847eface" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_fe309ad4-5c03-4737-848c-7537a91f1629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_fe309ad4-5c03-4737-848c-7537a91f1629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_888fdfc3-ba86-49b5-ab36-368b8b632a16" xlink:href="bngo-20211231.xsd#bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:to="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_888fdfc3-ba86-49b5-ab36-368b8b632a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c92a6f7b-602e-4eea-9c47-3d91f8729f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward_888fdfc3-ba86-49b5-ab36-368b8b632a16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c92a6f7b-602e-4eea-9c47-3d91f8729f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5cf01bb6-5a38-403d-89a5-4ecf23949bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5cf01bb6-5a38-403d-89a5-4ecf23949bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ca1aece7-62dd-48d3-a3a7-b4a4dfb566e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ca1aece7-62dd-48d3-a3a7-b4a4dfb566e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_75a3af7a-eb0e-4201-8751-9408c58f15e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ca1aece7-62dd-48d3-a3a7-b4a4dfb566e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_75a3af7a-eb0e-4201-8751-9408c58f15e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5e76e14f-4889-4ed4-94d7-808d4d5507e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ca1aece7-62dd-48d3-a3a7-b4a4dfb566e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5e76e14f-4889-4ed4-94d7-808d4d5507e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e5be11f4-a24d-4d8b-bc37-066028587de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ca1aece7-62dd-48d3-a3a7-b4a4dfb566e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e5be11f4-a24d-4d8b-bc37-066028587de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8dda7b51-3622-4606-ac31-287b28014bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0bf61f75-59ba-4a94-9f3f-b926050282d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8dda7b51-3622-4606-ac31-287b28014bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d591bb8f-4934-4cfd-83e8-b5d31cd7cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8518b76d-3478-41bc-aafc-c88ec70df7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d591bb8f-4934-4cfd-83e8-b5d31cd7cbda" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8518b76d-3478-41bc-aafc-c88ec70df7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8518b76d-3478-41bc-aafc-c88ec70df7ca" xlink:to="loc_us-gaap_AwardTypeAxis_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9ed6f0f-41a8-4d0c-8901-ee33913ef1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ba4e2ba0-5888-4cd1-8e38-b0c437127fb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9ed6f0f-41a8-4d0c-8901-ee33913ef1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00741660-1482-4b2d-804f-81c4bf885c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9ed6f0f-41a8-4d0c-8901-ee33913ef1dc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00741660-1482-4b2d-804f-81c4bf885c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PerformanceShareUnitsPSUsMember_407cd2b3-d191-49bb-9349-90ce2b24e419" xlink:href="bngo-20211231.xsd#bngo_PerformanceShareUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9ed6f0f-41a8-4d0c-8901-ee33913ef1dc" xlink:to="loc_bngo_PerformanceShareUnitsPSUsMember_407cd2b3-d191-49bb-9349-90ce2b24e419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8518b76d-3478-41bc-aafc-c88ec70df7ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e7976be4-8550-4af9-8da0-b930a454d7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e7976be4-8550-4af9-8da0-b930a454d7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c28b6de6-4b19-4f55-88fc-dcbe34244e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c28b6de6-4b19-4f55-88fc-dcbe34244e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff869fac-3e47-43aa-a5a8-31781e5f4b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff869fac-3e47-43aa-a5a8-31781e5f4b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_aeaeb370-de2a-4b53-acd7-d297b0142fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_aeaeb370-de2a-4b53-acd7-d297b0142fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_11ae196f-3d76-4fde-bad1-026f2d967a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a40a3a2-082f-4c7b-a6fb-85faeb23b9bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_11ae196f-3d76-4fde-bad1-026f2d967a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb29447f-426a-4be4-8e58-7c655361683f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb29447f-426a-4be4-8e58-7c655361683f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d82befa5-e8c6-4003-b852-ea484f245951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d82befa5-e8c6-4003-b852-ea484f245951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30175bde-bf8b-4057-8e1b-82f06fe3c734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30175bde-bf8b-4057-8e1b-82f06fe3c734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_400ff465-5b9f-4951-96f1-adb2f2a06a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_400ff465-5b9f-4951-96f1-adb2f2a06a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4688277a-8080-41ce-b4a7-826dc88728d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6248cd66-0d42-40b5-b448-fd8e0a8a12b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4688277a-8080-41ce-b4a7-826dc88728d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2b129e63-4f2d-4e94-b160-37153abd362d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2b129e63-4f2d-4e94-b160-37153abd362d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_752bc779-e987-4a7d-8827-ba91089d3ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d4b3858-e0a8-4ab6-af58-fa8bc8625955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_752bc779-e987-4a7d-8827-ba91089d3ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0018d4a0-c775-425b-86ad-5bdc908875a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a9449dba-eb34-4df0-a1b8-948291abfa75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0018d4a0-c775-425b-86ad-5bdc908875a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a9449dba-eb34-4df0-a1b8-948291abfa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a931d097-dc47-4fdb-b912-ba64c1befb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a9449dba-eb34-4df0-a1b8-948291abfa75" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a931d097-dc47-4fdb-b912-ba64c1befb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_55628a45-f775-4a43-9140-5ed7722052c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a931d097-dc47-4fdb-b912-ba64c1befb31" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_55628a45-f775-4a43-9140-5ed7722052c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_57ed34b6-77e9-453a-953b-526d31dcd585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_55628a45-f775-4a43-9140-5ed7722052c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_57ed34b6-77e9-453a-953b-526d31dcd585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14116f54-f197-4e81-bd5b-863b92bcb4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_55628a45-f775-4a43-9140-5ed7722052c6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14116f54-f197-4e81-bd5b-863b92bcb4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f682c39c-fb55-4513-8b22-0b9e1d1d96fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a9449dba-eb34-4df0-a1b8-948291abfa75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f682c39c-fb55-4513-8b22-0b9e1d1d96fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8b424ceb-3416-413d-8e1b-dc6d8c0c2aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f682c39c-fb55-4513-8b22-0b9e1d1d96fc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8b424ceb-3416-413d-8e1b-dc6d8c0c2aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7aa2a380-5815-4da3-b846-952810c5fd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e81fbea0-8b3c-448d-a3fe-6a918848bc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7aa2a380-5815-4da3-b846-952810c5fd4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e81fbea0-8b3c-448d-a3fe-6a918848bc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_920bf55e-5933-47a2-a002-35410e307521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7aa2a380-5815-4da3-b846-952810c5fd4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_920bf55e-5933-47a2-a002-35410e307521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d5422656-0b14-4630-b22b-5687afb78dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7aa2a380-5815-4da3-b846-952810c5fd4f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d5422656-0b14-4630-b22b-5687afb78dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_893053a6-8c57-4146-9bdc-1a8eef4a53ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7aa2a380-5815-4da3-b846-952810c5fd4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_893053a6-8c57-4146-9bdc-1a8eef4a53ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5167923e-c9be-4a9f-b606-3ec686c34667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_59773cf7-b14d-425e-82f5-11ff3314d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5167923e-c9be-4a9f-b606-3ec686c34667" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_59773cf7-b14d-425e-82f5-11ff3314d3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68a5a5e5-542b-4322-b915-067ae4593245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_0ab7b059-733c-41f0-8369-bfabe9331081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68a5a5e5-542b-4322-b915-067ae4593245" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_0ab7b059-733c-41f0-8369-bfabe9331081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5aa4abcc-4620-4257-b2a7-e9eef029b1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68a5a5e5-542b-4322-b915-067ae4593245" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5aa4abcc-4620-4257-b2a7-e9eef029b1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_a62cca72-be84-408d-9ab5-d3ec3136b3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68a5a5e5-542b-4322-b915-067ae4593245" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_a62cca72-be84-408d-9ab5-d3ec3136b3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_185d767f-4119-4320-8569-3a5407ca27c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68a5a5e5-542b-4322-b915-067ae4593245" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_185d767f-4119-4320-8569-3a5407ca27c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f3f1328-cf39-482e-88b6-ba95068fe1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f3f1328-cf39-482e-88b6-ba95068fe1b2" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_srt_StatementGeographicalAxis_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_df4c8b1e-bc0d-45d2-9098-66ea397eb4a8" xlink:to="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SanDiegoCaliforniaMember_c20f5659-008b-474a-90c5-960041c07da1" xlink:href="bngo-20211231.xsd#bngo_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:to="loc_bngo_SanDiegoCaliforniaMember_c20f5659-008b-474a-90c5-960041c07da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_SaltLakeCityUtahMember_5eaa3b50-7518-40c1-92c8-aac4b4be542d" xlink:href="bngo-20211231.xsd#bngo_SaltLakeCityUtahMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:to="loc_bngo_SaltLakeCityUtahMember_5eaa3b50-7518-40c1-92c8-aac4b4be542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ElSegundoCaliforniaMember_05f95761-e978-4ecf-9294-82af80245f10" xlink:href="bngo-20211231.xsd#bngo_ElSegundoCaliforniaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5a6ec177-6b0c-461c-9108-c5f58a61c5d2" xlink:to="loc_bngo_ElSegundoCaliforniaMember_05f95761-e978-4ecf-9294-82af80245f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a226ab6e-ef8a-4501-8bbe-ade840789f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f2c7b09-3fdd-4472-bd20-af5c8dcd3992" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a226ab6e-ef8a-4501-8bbe-ade840789f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_d53be963-0e71-427c-8541-db04625d81bd" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a226ab6e-ef8a-4501-8bbe-ade840789f8e" xlink:to="loc_bngo_BioDiscoveryMember_d53be963-0e71-427c-8541-db04625d81bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5de57334-1dc8-49e8-a269-42817d90b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5de57334-1dc8-49e8-a269-42817d90b3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f3b2d135-6db8-42b0-8911-3ac701a6024a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5de57334-1dc8-49e8-a269-42817d90b3bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f3b2d135-6db8-42b0-8911-3ac701a6024a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationLiabilityMember_c7eaaa11-6c1e-4d72-89f1-d6abd56ba588" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f3b2d135-6db8-42b0-8911-3ac701a6024a" xlink:to="loc_bngo_ContingentConsiderationLiabilityMember_c7eaaa11-6c1e-4d72-89f1-d6abd56ba588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d7655f85-e8c5-437c-9d31-3f2e25ef4623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d7655f85-e8c5-437c-9d31-3f2e25ef4623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0f29301-a0f9-4a8a-80ae-6c25841f07e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d7655f85-e8c5-437c-9d31-3f2e25ef4623" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0f29301-a0f9-4a8a-80ae-6c25841f07e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f93df9cd-9cc1-414b-a54d-e5c7f3d95386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c0f29301-a0f9-4a8a-80ae-6c25841f07e5" xlink:to="loc_us-gaap_SubsequentEventMember_f93df9cd-9cc1-414b-a54d-e5c7f3d95386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_3081fc8e-3ef1-4923-9dba-3e7a4404f393" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseAreaLeased_ee6a3b59-8e51-496d-aa52-cbb4e9d38cb6" xlink:href="bngo-20211231.xsd#bngo_LesseeOperatingLeaseAreaLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_LesseeOperatingLeaseAreaLeased_ee6a3b59-8e51-496d-aa52-cbb4e9d38cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeOperatingLeaseAreaAdded_2d0f05b1-5cc9-44a4-bf2e-670e53866469" xlink:href="bngo-20211231.xsd#bngo_LesseeOperatingLeaseAreaAdded"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_LesseeOperatingLeaseAreaAdded_2d0f05b1-5cc9-44a4-bf2e-670e53866469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeaseMonthlyRentPayments_ebd5d69f-e4dc-4cd6-8269-e463a2dd78b4" xlink:href="bngo-20211231.xsd#bngo_OperatingLeaseMonthlyRentPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_OperatingLeaseMonthlyRentPayments_ebd5d69f-e4dc-4cd6-8269-e463a2dd78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeFinanceLeaseAreaLeased_3e765471-1aaf-42c7-b173-1cc69faf10e2" xlink:href="bngo-20211231.xsd#bngo_LesseeFinanceLeaseAreaLeased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_LesseeFinanceLeaseAreaLeased_3e765471-1aaf-42c7-b173-1cc69faf10e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LesseeEstimatedIncrementalBorrowingRate_c5da3d36-6799-4ed4-830d-114214b37dfb" xlink:href="bngo-20211231.xsd#bngo_LesseeEstimatedIncrementalBorrowingRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_LesseeEstimatedIncrementalBorrowingRate_c5da3d36-6799-4ed4-830d-114214b37dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter_a175e30e-efe1-4228-b503-e154ac521f85" xlink:href="bngo-20211231.xsd#bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter_a175e30e-efe1-4228-b503-e154ac521f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurchaseObligationInitialPurchasePeriod_bc9cc7bd-a3a5-4ade-89dd-9aed170d3990" xlink:href="bngo-20211231.xsd#bngo_PurchaseObligationInitialPurchasePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_PurchaseObligationInitialPurchasePeriod_bc9cc7bd-a3a5-4ade-89dd-9aed170d3990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_PurchaseObligationContractTerminationPeriod_fca60366-d292-40d5-b2ee-cf78198ffe8b" xlink:href="bngo-20211231.xsd#bngo_PurchaseObligationContractTerminationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_PurchaseObligationContractTerminationPeriod_fca60366-d292-40d5-b2ee-cf78198ffe8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationMilestonePayment_7629b371-fe05-4647-93a0-eb39a5857fa4" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationMilestonePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_ContingentConsiderationMilestonePayment_7629b371-fe05-4647-93a0-eb39a5857fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ec9b5398-1411-4b60-a65f-3870437e8f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ec9b5398-1411-4b60-a65f-3870437e8f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_ContingentConsiderationFairValueOfContingentLiability_2059b685-3677-40b2-a71e-0b6fb93c65dd" xlink:href="bngo-20211231.xsd#bngo_ContingentConsiderationFairValueOfContingentLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_bngo_ContingentConsiderationFairValueOfContingentLiability_2059b685-3677-40b2-a71e-0b6fb93c65dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_fff7e8cc-4ca3-4eea-8234-42c2a9f2348d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_49a24b02-6cb2-435d-9c53-4ec59c8333c0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_fff7e8cc-4ca3-4eea-8234-42c2a9f2348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesSupplementalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeasePaymentsModifiedAndUnmodified_8d650a49-09d4-4047-94ce-b4fd16cb7eac" xlink:href="bngo-20211231.xsd#bngo_OperatingLeasePaymentsModifiedAndUnmodified"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:to="loc_bngo_OperatingLeasePaymentsModifiedAndUnmodified_8d650a49-09d4-4047-94ce-b4fd16cb7eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_0a5496a7-5ec1-4d9a-af3f-876c59cb1c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_0a5496a7-5ec1-4d9a-af3f-876c59cb1c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_85a3077d-6f59-4025-b095-b06f92685db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_85a3077d-6f59-4025-b095-b06f92685db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3443d9a9-a4af-494f-8110-c030d3f8be85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3443d9a9-a4af-494f-8110-c030d3f8be85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_6da27b0f-7f62-4a4d-ac60-9c810e02e020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_6da27b0f-7f62-4a4d-ac60-9c810e02e020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a34e702f-775c-47fc-be02-1954aeee12b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a34e702f-775c-47fc-be02-1954aeee12b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_dafb2b7a-2aa9-4479-886f-b7911d92b37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_dafb2b7a-2aa9-4479-886f-b7911d92b37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bfe3dd45-43a2-4ccc-920d-88569d25b579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_afff72f5-af53-4cda-882f-692c81fdd428" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bfe3dd45-43a2-4ccc-920d-88569d25b579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_34a5e2b6-8038-484d-96f2-522ed1c0574d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:to="loc_us-gaap_OperatingLeaseCost_34a5e2b6-8038-484d-96f2-522ed1c0574d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_d6dfcb99-b500-4620-8aa3-89b3c0e6d6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:to="loc_us-gaap_VariableLeaseCost_d6dfcb99-b500-4620-8aa3-89b3c0e6d6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e35c210a-e655-4444-946a-80a76d405fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:to="loc_us-gaap_OperatingLeaseExpense_e35c210a-e655-4444-946a-80a76d405fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_315ebdd9-0609-4f19-bda8-25953d04a6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_315ebdd9-0609-4f19-bda8-25953d04a6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_5122556a-8343-48fd-9f36-2e08a77699aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_5122556a-8343-48fd-9f36-2e08a77699aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseExpense_edd36230-1634-4475-be9b-b7ec29a8fbeb" xlink:href="bngo-20211231.xsd#bngo_FinanceLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:to="loc_bngo_FinanceLeaseExpense_edd36230-1634-4475-be9b-b7ec29a8fbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_06901404-6753-461a-b4a1-0211ee7f5130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:to="loc_us-gaap_SubleaseIncome_06901404-6753-461a-b4a1-0211ee7f5130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f3fd008f-2cc4-4201-be0a-cff7ea276591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f60a41ca-e75b-49fb-afc3-5dfe6da565c1" xlink:to="loc_us-gaap_LeaseCost_f3fd008f-2cc4-4201-be0a-cff7ea276591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0bd44e1-bd91-4a52-994b-e5a632dae60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0bd44e1-bd91-4a52-994b-e5a632dae60e" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e300d2f-8a5d-414b-ab9f-eda37416c15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e300d2f-8a5d-414b-ab9f-eda37416c15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6bf951f3-f527-4f9b-b636-8f704468041b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6bf951f3-f527-4f9b-b636-8f704468041b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8bcc5564-9b21-44a1-ab9a-c9957cc41c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8bcc5564-9b21-44a1-ab9a-c9957cc41c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_38a4a30e-5857-4513-94fa-4c19fbaddd39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_38a4a30e-5857-4513-94fa-4c19fbaddd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c1b88c37-c42e-483a-9e79-b867790a65f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c1b88c37-c42e-483a-9e79-b867790a65f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e6b099fd-b484-498d-adb4-b9ec5302f073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e6b099fd-b484-498d-adb4-b9ec5302f073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d164dcae-5d2d-487e-9b07-dd4ee148f1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d164dcae-5d2d-487e-9b07-dd4ee148f1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1781432-a6fd-4a98-96f6-33ec80e669c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1781432-a6fd-4a98-96f6-33ec80e669c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8bb339d4-8f2c-4b65-bbc5-76db60c1980b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7085faf-e8b6-4ab4-9674-77dd8651ed3e" xlink:to="loc_us-gaap_OperatingLeaseLiability_8bb339d4-8f2c-4b65-bbc5-76db60c1980b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0bd44e1-bd91-4a52-994b-e5a632dae60e" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a5a9b666-1bb3-4146-b931-0bd6a728ccd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a5a9b666-1bb3-4146-b931-0bd6a728ccd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b3ce6b52-3699-4a05-939f-29a79fa63786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b3ce6b52-3699-4a05-939f-29a79fa63786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_8c654860-a39d-49c8-bd05-fa221e4a2202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_8c654860-a39d-49c8-bd05-fa221e4a2202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4b509747-5959-41f1-bc7c-98742a6cec7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4b509747-5959-41f1-bc7c-98742a6cec7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_06f8aa20-cfed-457f-bd06-55b522c57285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_06f8aa20-cfed-457f-bd06-55b522c57285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_01accd0e-c97a-49da-8c0f-65c00388af09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_01accd0e-c97a-49da-8c0f-65c00388af09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_91696614-87b7-4b1a-9f53-14a6309a97c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_91696614-87b7-4b1a-9f53-14a6309a97c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ae76a15f-8efe-4599-a4bc-c4a61c503a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_ae76a15f-8efe-4599-a4bc-c4a61c503a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_b9a8b202-a2d6-4ab5-a754-e8fa1122742c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_858c9883-9353-449e-ae12-c245379e1305" xlink:to="loc_us-gaap_FinanceLeaseLiability_b9a8b202-a2d6-4ab5-a754-e8fa1122742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9876f216-d4f4-4c24-99c6-b258584263b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_89461b51-67d5-4c29-beb6-0d7561c794d2" xlink:href="bngo-20211231.xsd#bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9876f216-d4f4-4c24-99c6-b258584263b2" xlink:to="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_89461b51-67d5-4c29-beb6-0d7561c794d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1b395680-d54a-40f0-9efd-d27f2067db76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_89461b51-67d5-4c29-beb6-0d7561c794d2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1b395680-d54a-40f0-9efd-d27f2067db76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3b762f2d-59c4-4433-b11f-15d0cfe1f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_89461b51-67d5-4c29-beb6-0d7561c794d2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3b762f2d-59c4-4433-b11f-15d0cfe1f3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_f7ee854e-c3ff-4d6c-a9ba-c30cbee567fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_89461b51-67d5-4c29-beb6-0d7561c794d2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_f7ee854e-c3ff-4d6c-a9ba-c30cbee567fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_051419ed-3ffe-4d15-b997-bc78e15b99e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_89461b51-67d5-4c29-beb6-0d7561c794d2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_051419ed-3ffe-4d15-b997-bc78e15b99e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter_82321e0f-af7f-44e3-a153-7c29de2ec4f3" xlink:href="bngo-20211231.xsd#bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_89461b51-67d5-4c29-beb6-0d7561c794d2" xlink:to="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter_82321e0f-af7f-44e3-a153-7c29de2ec4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_208d0475-82e4-4657-9e5b-b3c4c47d21f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract_89461b51-67d5-4c29-beb6-0d7561c794d2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_208d0475-82e4-4657-9e5b-b3c4c47d21f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6fafb407-1f09-4198-979b-486e4130e905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_34eaed65-8b5c-484c-9d7b-e9648b58964b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6fafb407-1f09-4198-979b-486e4130e905" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_34eaed65-8b5c-484c-9d7b-e9648b58964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d41556-f597-41c1-9c44-363684dd0a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a9f02563-bf33-4476-906b-d3daeeb9a955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d41556-f597-41c1-9c44-363684dd0a75" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a9f02563-bf33-4476-906b-d3daeeb9a955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c8ce764d-14e5-4215-a5f9-054658d03cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d41556-f597-41c1-9c44-363684dd0a75" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c8ce764d-14e5-4215-a5f9-054658d03cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6604d559-00ae-4ede-9e28-0076520ad6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d41556-f597-41c1-9c44-363684dd0a75" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6604d559-00ae-4ede-9e28-0076520ad6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_18e2ff42-73f9-478e-833e-295ba6ddd798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d41556-f597-41c1-9c44-363684dd0a75" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_18e2ff42-73f9-478e-833e-295ba6ddd798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d84ee2c6-cdd3-4ceb-b3a5-37d98255d158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d41556-f597-41c1-9c44-363684dd0a75" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d84ee2c6-cdd3-4ceb-b3a5-37d98255d158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bc242997-eb4f-4fbe-ae95-837e08dbb934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6c38a05d-6c70-4e8e-ad36-b802004b1799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc242997-eb4f-4fbe-ae95-837e08dbb934" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6c38a05d-6c70-4e8e-ad36-b802004b1799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ae606007-6083-40cc-8c41-b52277d2b994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc242997-eb4f-4fbe-ae95-837e08dbb934" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ae606007-6083-40cc-8c41-b52277d2b994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_69d108bb-928e-429f-a139-0bf47bcd37c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bc242997-eb4f-4fbe-ae95-837e08dbb934" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_69d108bb-928e-429f-a139-0bf47bcd37c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_96f3086b-ec77-42c3-a5a1-ce903523f275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c6f2e83-ae6a-4ccd-83fd-35b7ecd4acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96f3086b-ec77-42c3-a5a1-ce903523f275" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c6f2e83-ae6a-4ccd-83fd-35b7ecd4acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_dab92ae4-dc16-4c76-9f04-9f0da1b99daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c6f2e83-ae6a-4ccd-83fd-35b7ecd4acfd" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_dab92ae4-dc16-4c76-9f04-9f0da1b99daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c138c749-9e8d-4759-8665-d255c9fd9328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c6f2e83-ae6a-4ccd-83fd-35b7ecd4acfd" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c138c749-9e8d-4759-8665-d255c9fd9328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_31d89325-f046-48eb-ac63-6750ecf539f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c6f2e83-ae6a-4ccd-83fd-35b7ecd4acfd" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_31d89325-f046-48eb-ac63-6750ecf539f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d3e983ae-31e2-4cec-aee1-6d46fa4cce59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5c6f2e83-ae6a-4ccd-83fd-35b7ecd4acfd" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d3e983ae-31e2-4cec-aee1-6d46fa4cce59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2148f110-364e-4d0c-8d8a-d8114a20da10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96f3086b-ec77-42c3-a5a1-ce903523f275" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2148f110-364e-4d0c-8d8a-d8114a20da10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_32113b5d-12ca-4f87-8dd6-2f2361c23cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2148f110-364e-4d0c-8d8a-d8114a20da10" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_32113b5d-12ca-4f87-8dd6-2f2361c23cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3ec2ad38-e7b2-4418-92ad-62d94313d1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2148f110-364e-4d0c-8d8a-d8114a20da10" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3ec2ad38-e7b2-4418-92ad-62d94313d1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_f28415f6-2bed-4e57-a94e-50837d734cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2148f110-364e-4d0c-8d8a-d8114a20da10" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_f28415f6-2bed-4e57-a94e-50837d734cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6bcb92a2-f8e4-49e4-b3a4-3e4f5740e5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2148f110-364e-4d0c-8d8a-d8114a20da10" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6bcb92a2-f8e4-49e4-b3a4-3e4f5740e5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4779d263-42cd-4d75-b871-7e46c7969421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96f3086b-ec77-42c3-a5a1-ce903523f275" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4779d263-42cd-4d75-b871-7e46c7969421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_88657143-ece7-4f39-9e83-5f96b74f0ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_88657143-ece7-4f39-9e83-5f96b74f0ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_296bb379-8582-49a2-a072-64948d9cff56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_296bb379-8582-49a2-a072-64948d9cff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b78baf59-98ec-484a-91ef-04b7302f59e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b78baf59-98ec-484a-91ef-04b7302f59e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount_e41c2c61-ae5d-4794-8bed-8ca9334ee6f0" xlink:href="bngo-20211231.xsd#bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:to="loc_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount_e41c2c61-ae5d-4794-8bed-8ca9334ee6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_7b0118ad-d86c-473f-bccc-9bd7bfc083d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_7b0118ad-d86c-473f-bccc-9bd7bfc083d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_9b320332-901f-4e1e-a6b7-fc60dbb9c9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_9b320332-901f-4e1e-a6b7-fc60dbb9c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_c3174195-cb11-4dc3-b70b-d8f6e0076777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_c3174195-cb11-4dc3-b70b-d8f6e0076777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8c8378bd-7f43-439a-a2e1-40e718e11a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d23ade7-b91e-4038-a4b9-372be504299e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8c8378bd-7f43-439a-a2e1-40e718e11a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c6fc24ca-61f5-4abb-8870-88902ae20b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_11ed9858-8448-48ff-8edf-fffcd4868333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6fc24ca-61f5-4abb-8870-88902ae20b5d" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_11ed9858-8448-48ff-8edf-fffcd4868333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3788f2dc-9505-4a87-8085-1df44c63a6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_11ed9858-8448-48ff-8edf-fffcd4868333" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3788f2dc-9505-4a87-8085-1df44c63a6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2d9fe364-9c12-418e-aa68-902ae058b035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_11ed9858-8448-48ff-8edf-fffcd4868333" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2d9fe364-9c12-418e-aa68-902ae058b035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bce40c77-23c9-434b-8c37-20bd2afbfa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_11ed9858-8448-48ff-8edf-fffcd4868333" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bce40c77-23c9-434b-8c37-20bd2afbfa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxAssetsLeaseLiability_c5717102-e2db-4402-9bf4-602d6aa2ab65" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_11ed9858-8448-48ff-8edf-fffcd4868333" xlink:to="loc_bngo_DeferredTaxAssetsLeaseLiability_c5717102-e2db-4402-9bf4-602d6aa2ab65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a7bf1278-77f7-4dc8-9a92-3bca26fba55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_11ed9858-8448-48ff-8edf-fffcd4868333" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a7bf1278-77f7-4dc8-9a92-3bca26fba55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8ce655d6-e39e-4aab-9e04-052c926526d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_11ed9858-8448-48ff-8edf-fffcd4868333" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8ce655d6-e39e-4aab-9e04-052c926526d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_88815d96-6ad6-4a8d-b764-928494bc5905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6fc24ca-61f5-4abb-8870-88902ae20b5d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_88815d96-6ad6-4a8d-b764-928494bc5905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxLiabilitiesAmortization_05d5ce09-652e-4535-afa5-e3755b2d4a71" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxLiabilitiesAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_88815d96-6ad6-4a8d-b764-928494bc5905" xlink:to="loc_bngo_DeferredTaxLiabilitiesAmortization_05d5ce09-652e-4535-afa5-e3755b2d4a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DeferredTaxLiabilitiesRightOfUseAsset_ae64f267-ef0d-4fcc-a30f-4a24f8a7f761" xlink:href="bngo-20211231.xsd#bngo_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_88815d96-6ad6-4a8d-b764-928494bc5905" xlink:to="loc_bngo_DeferredTaxLiabilitiesRightOfUseAsset_ae64f267-ef0d-4fcc-a30f-4a24f8a7f761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_0bd2e904-7186-48b8-abd8-5aa5767aae44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_88815d96-6ad6-4a8d-b764-928494bc5905" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_0bd2e904-7186-48b8-abd8-5aa5767aae44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f6c98b0a-2564-4f54-b784-d47b19398e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_88815d96-6ad6-4a8d-b764-928494bc5905" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f6c98b0a-2564-4f54-b784-d47b19398e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d4ab4b03-cb53-4f2a-9763-30cd5f3562b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6fc24ca-61f5-4abb-8870-88902ae20b5d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d4ab4b03-cb53-4f2a-9763-30cd5f3562b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c4e8bd77-060c-4777-ad3e-e096f47cdc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c4e8bd77-060c-4777-ad3e-e096f47cdc8d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a4458fb0-a302-422c-bbf3-0ae8c9b88e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a4458fb0-a302-422c-bbf3-0ae8c9b88e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_397110f5-6b36-4ba5-b535-0062e7294598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a4458fb0-a302-422c-bbf3-0ae8c9b88e61" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_397110f5-6b36-4ba5-b535-0062e7294598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e200fe11-01ba-4937-ae45-a5525395e0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_397110f5-6b36-4ba5-b535-0062e7294598" xlink:to="loc_us-gaap_DomesticCountryMember_e200fe11-01ba-4937-ae45-a5525395e0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_fee88d38-d997-4c37-974d-4d283ae76a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_397110f5-6b36-4ba5-b535-0062e7294598" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_fee88d38-d997-4c37-974d-4d283ae76a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_c2217f3c-212d-4639-9c5b-c4df76784ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_c2217f3c-212d-4639-9c5b-c4df76784ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d8eed451-977b-4d80-a12a-d120725ae7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c2217f3c-212d-4639-9c5b-c4df76784ea8" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d8eed451-977b-4d80-a12a-d120725ae7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_c4c26c65-cfd7-46ca-9d70-a0c3eaab8894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d8eed451-977b-4d80-a12a-d120725ae7fe" xlink:to="loc_us-gaap_ResearchMember_c4c26c65-cfd7-46ca-9d70-a0c3eaab8894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5129f33c-c71a-4344-8041-16941bdf3c85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_srt_StatementGeographicalAxis_5129f33c-c71a-4344-8041-16941bdf3c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a83f7a4b-76f1-4b15-8517-33e98fb5b201" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5129f33c-c71a-4344-8041-16941bdf3c85" xlink:to="loc_srt_SegmentGeographicalDomain_a83f7a4b-76f1-4b15-8517-33e98fb5b201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_fbdd57c7-706c-40cb-bd3c-8b2135b0f4a5" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a83f7a4b-76f1-4b15-8517-33e98fb5b201" xlink:to="loc_stpr_CA_fbdd57c7-706c-40cb-bd3c-8b2135b0f4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e7268874-3256-4697-8363-da00cff648cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e7268874-3256-4697-8363-da00cff648cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_094cab83-9168-4f55-bd85-4f7fc904bd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e7268874-3256-4697-8363-da00cff648cd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_094cab83-9168-4f55-bd85-4f7fc904bd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_50820a57-8870-4642-90db-7e3080e50846" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_094cab83-9168-4f55-bd85-4f7fc904bd00" xlink:to="loc_bngo_BioDiscoveryMember_50820a57-8870-4642-90db-7e3080e50846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_33790b7e-c505-4fda-b910-9ccd0b80716e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_dee772d1-e2f5-4e16-b1ad-0bc6ee3cc24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_dee772d1-e2f5-4e16-b1ad-0bc6ee3cc24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration_d71fd556-c585-48ef-a669-e4bd2c5cd059" xlink:href="bngo-20211231.xsd#bngo_OperatingLossCarryforwardsNotSubjecttoExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration_d71fd556-c585-48ef-a669-e4bd2c5cd059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_OperatingLossCarryforwardsSubjecttoExpiration_ab554b62-8fcb-44f4-abba-9c47021089d9" xlink:href="bngo-20211231.xsd#bngo_OperatingLossCarryforwardsSubjecttoExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_bngo_OperatingLossCarryforwardsSubjecttoExpiration_ab554b62-8fcb-44f4-abba-9c47021089d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1c5b7048-591d-42d1-838e-91ec2da002b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1c5b7048-591d-42d1-838e-91ec2da002b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d49baf74-8fdc-4c8e-ac96-dd35f10494c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d49baf74-8fdc-4c8e-ac96-dd35f10494c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3f4970a8-0f51-49b1-964e-cef4e33292f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3f4970a8-0f51-49b1-964e-cef4e33292f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fdf5d6f6-7f7e-4dca-9d45-f97e2dacd28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5ca9fd73-f94f-4a46-8e48-58224d63dd5d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fdf5d6f6-7f7e-4dca-9d45-f97e2dacd28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9bc20723-e241-40dc-adb1-7f48df7968c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b29d2c97-de53-423f-a6a8-8d2450eb9429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9bc20723-e241-40dc-adb1-7f48df7968c5" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b29d2c97-de53-423f-a6a8-8d2450eb9429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a93e2f86-fec1-4176-8f41-78cd39b9b422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b29d2c97-de53-423f-a6a8-8d2450eb9429" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a93e2f86-fec1-4176-8f41-78cd39b9b422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b7d71bf9-aa71-46b0-b47a-3b25c68885a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b29d2c97-de53-423f-a6a8-8d2450eb9429" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b7d71bf9-aa71-46b0-b47a-3b25c68885a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b432541f-72c1-4d7e-aa7b-9d8667061da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b29d2c97-de53-423f-a6a8-8d2450eb9429" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b432541f-72c1-4d7e-aa7b-9d8667061da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1ef14f76-a16a-4262-b978-4a1cdd007cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b29d2c97-de53-423f-a6a8-8d2450eb9429" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1ef14f76-a16a-4262-b978-4a1cdd007cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="bngo-20211231.xsd#EmployeeBenefits"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/EmployeeBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_607ab326-e6a8-40dd-8cb7-b26a235279e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_DefinedContributionPlanDisclosuresTextBlock_40267c96-72dd-49a1-8efb-25e8c3bce6b6" xlink:href="bngo-20211231.xsd#bngo_DefinedContributionPlanDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_607ab326-e6a8-40dd-8cb7-b26a235279e0" xlink:to="loc_bngo_DefinedContributionPlanDisclosuresTextBlock_40267c96-72dd-49a1-8efb-25e8c3bce6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/EmployeeBenefitsAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#EmployeeBenefitsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/EmployeeBenefitsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f0db6995-c1a1-43ae-a44a-3fd4f1058708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9e2be808-2fe9-4d9b-99d9-0cf39a0dc7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f0db6995-c1a1-43ae-a44a-3fd4f1058708" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9e2be808-2fe9-4d9b-99d9-0cf39a0dc7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/Acquisitions" xlink:type="simple" xlink:href="bngo-20211231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_cd20f6ee-8474-43bf-aaf1-52e90e3e4211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_df879e06-1990-4284-ab23-29d4befa0ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cd20f6ee-8474-43bf-aaf1-52e90e3e4211" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_df879e06-1990-4284-ab23-29d4befa0ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5ed55792-2e5d-4452-bc8f-a439ba6efef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_892b83a2-5bba-47aa-9209-2b89d766b2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5ed55792-2e5d-4452-bc8f-a439ba6efef4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_892b83a2-5bba-47aa-9209-2b89d766b2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_27a0716e-dd2e-411a-b2bb-3799036d97ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5ed55792-2e5d-4452-bc8f-a439ba6efef4" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_27a0716e-dd2e-411a-b2bb-3799036d97ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_39d72481-787f-4534-837d-abc5b85b993c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5ed55792-2e5d-4452-bc8f-a439ba6efef4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_39d72481-787f-4534-837d-abc5b85b993c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_784e98a2-b21f-46ae-9998-45b57233c081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5ed55792-2e5d-4452-bc8f-a439ba6efef4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_784e98a2-b21f-46ae-9998-45b57233c081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_2ff8cf73-fd3c-466c-b98d-bf89622c5dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5ed55792-2e5d-4452-bc8f-a439ba6efef4" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_2ff8cf73-fd3c-466c-b98d-bf89622c5dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a9fb0454-618d-4e1d-b913-3f3da1262604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a9fb0454-618d-4e1d-b913-3f3da1262604" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b78c80a4-8c59-4712-a449-4c6c04b1bd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b78c80a4-8c59-4712-a449-4c6c04b1bd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fdf6865-2f9b-4b8c-ace6-548221d60c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b78c80a4-8c59-4712-a449-4c6c04b1bd4d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fdf6865-2f9b-4b8c-ace6-548221d60c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_c4ed7ef9-4048-405d-a27b-d8d39eed46ff" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fdf6865-2f9b-4b8c-ace6-548221d60c62" xlink:to="loc_bngo_LineagenMember_c4ed7ef9-4048-405d-a27b-d8d39eed46ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_3ad71fd6-834a-417e-8575-6f0f5bbebbfe" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8fdf6865-2f9b-4b8c-ace6-548221d60c62" xlink:to="loc_bngo_BioDiscoveryMember_3ad71fd6-834a-417e-8575-6f0f5bbebbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_66a91baa-b174-45fa-b323-632b736f15fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_66a91baa-b174-45fa-b323-632b736f15fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f05fe81a-3d94-4edc-9491-5d0062719cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_66a91baa-b174-45fa-b323-632b736f15fc" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f05fe81a-3d94-4edc-9491-5d0062719cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember_2e9aefdb-0ff9-42f1-b967-70959402c0ec" xlink:href="bngo-20211231.xsd#bngo_EscrowedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_f05fe81a-3d94-4edc-9491-5d0062719cc6" xlink:to="loc_bngo_EscrowedSharesMember_2e9aefdb-0ff9-42f1-b967-70959402c0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_200ea1c2-458f-40f9-a437-2a9d8c98b783" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5daac73f-6570-4be9-9bb1-23e19edbfe57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_5daac73f-6570-4be9-9bb1-23e19edbfe57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6c4ad111-dfd6-4a3a-902e-21ea9cde6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6c4ad111-dfd6-4a3a-902e-21ea9cde6c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_66dc0fe7-3773-47ee-90bc-2b745d131213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_66dc0fe7-3773-47ee-90bc-2b745d131213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_38671cfd-8d1c-4d2b-96a6-abec439034cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_38671cfd-8d1c-4d2b-96a6-abec439034cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_4d3ccc8e-ee96-4179-81dd-2a57f63be996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_4d3ccc8e-ee96-4179-81dd-2a57f63be996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_282e4b61-e68b-4de8-b349-82cf2afa0f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_282e4b61-e68b-4de8-b349-82cf2afa0f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_51743572-94a2-4ca1-a414-468483455145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_51743572-94a2-4ca1-a414-468483455145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f2e07e3a-f2a9-4ab1-96f5-4178a8045047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f2e07e3a-f2a9-4ab1-96f5-4178a8045047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationConsiderationTransferredValueOfShares_bbd1d191-a34b-47f1-aa2c-ad31306f9760" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationConsiderationTransferredValueOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_bngo_BusinessCombinationConsiderationTransferredValueOfShares_bbd1d191-a34b-47f1-aa2c-ad31306f9760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting_defabf47-ca36-4e0e-9ff1-b6d0d688c83b" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting_defabf47-ca36-4e0e-9ff1-b6d0d688c83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionMilestonePayment_419ece54-349e-4110-ba0e-19ab58c812de" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionMilestonePayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_bngo_BusinessAcquisitionMilestonePayment_419ece54-349e-4110-ba0e-19ab58c812de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_d4e8f828-c66e-4f9a-bd04-4cf4ee0eba90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_d4e8f828-c66e-4f9a-bd04-4cf4ee0eba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e14fc98-a17d-4b2f-a3fb-e7d75c3e9492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_34587131-29a7-41b7-984d-edd538a98b06" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e14fc98-a17d-4b2f-a3fb-e7d75c3e9492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsAcquisitionPurchasePriceDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9f03251a-d45f-4298-9d23-a2686c3c95a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9f03251a-d45f-4298-9d23-a2686c3c95a2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8fe7a5b-cbae-4b7b-b13c-6fb409dcf635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2b5b8bf0-34b7-4a76-bb10-754a343cbf1d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8fe7a5b-cbae-4b7b-b13c-6fb409dcf635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_df11280c-7e92-41e5-8b0c-65b7e0d30191" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8fe7a5b-cbae-4b7b-b13c-6fb409dcf635" xlink:to="loc_bngo_LineagenMember_df11280c-7e92-41e5-8b0c-65b7e0d30191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_ab6ba2e6-3f95-48c5-8b41-dff6b2a0897f" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8fe7a5b-cbae-4b7b-b13c-6fb409dcf635" xlink:to="loc_bngo_BioDiscoveryMember_ab6ba2e6-3f95-48c5-8b41-dff6b2a0897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_67e9c9e2-cf3c-4335-a908-26c90b96a05b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_67e9c9e2-cf3c-4335-a908-26c90b96a05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b6991feb-87c1-45e1-abe3-48c79e52dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_67e9c9e2-cf3c-4335-a908-26c90b96a05b" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b6991feb-87c1-45e1-abe3-48c79e52dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_EscrowedSharesMember_ab760d05-acab-4460-ae37-7e0df312ded5" xlink:href="bngo-20211231.xsd#bngo_EscrowedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_b6991feb-87c1-45e1-abe3-48c79e52dd60" xlink:to="loc_bngo_EscrowedSharesMember_ab760d05-acab-4460-ae37-7e0df312ded5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d248c61a-ed07-4a38-93b2-5dd01b5cea6f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cd92819-bb4b-4bc8-a49d-a3b82dac5cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6cd92819-bb4b-4bc8-a49d-a3b82dac5cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_9386c698-7109-421d-bfb9-4e926538ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_9386c698-7109-421d-bfb9-4e926538ac3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59a96614-535f-424d-b068-da93ef3459c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59a96614-535f-424d-b068-da93ef3459c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_83474ee8-02e6-4a05-9150-1be544f2a4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_83474ee8-02e6-4a05-9150-1be544f2a4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_4a786456-8a26-4477-b185-dabed29e91c7" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow_4a786456-8a26-4477-b185-dabed29e91c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_c878d363-e051-4723-9510-d5da86245503" xlink:href="bngo-20211231.xsd#bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment_c878d363-e051-4723-9510-d5da86245503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_21c5d808-d9c8-454c-a6c9-71e2857a481e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_21c5d808-d9c8-454c-a6c9-71e2857a481e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c40d9b63-1dc0-4b5f-a5fc-e98322d3e2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c40d9b63-1dc0-4b5f-a5fc-e98322d3e2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_36ee3160-0e78-4ec6-b443-c1b9bf7295c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_77137d0f-478e-4c6e-b806-d6a1e62bafa5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_36ee3160-0e78-4ec6-b443-c1b9bf7295c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e0b8a8fc-28a2-47fa-8fec-8f2d723c4c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_53bfb226-9a4a-49e9-b1c4-9d30ab3087ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e0b8a8fc-28a2-47fa-8fec-8f2d723c4c8c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_53bfb226-9a4a-49e9-b1c4-9d30ab3087ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_53bfb226-9a4a-49e9-b1c4-9d30ab3087ed" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_231d27ca-325d-4cc5-869e-51d3b074999b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9d2ff923-b1e7-48fb-8a91-f8cd082a70ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_231d27ca-325d-4cc5-869e-51d3b074999b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_a4145df5-a90e-4dee-8846-72a03ea85974" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_231d27ca-325d-4cc5-869e-51d3b074999b" xlink:to="loc_bngo_BioDiscoveryMember_a4145df5-a90e-4dee-8846-72a03ea85974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_680d1249-7fe4-433a-8b37-642f3308addb" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_231d27ca-325d-4cc5-869e-51d3b074999b" xlink:to="loc_bngo_LineagenMember_680d1249-7fe4-433a-8b37-642f3308addb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_53bfb226-9a4a-49e9-b1c4-9d30ab3087ed" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d219d8d2-9564-4381-b14e-75d9a0c9aa44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d219d8d2-9564-4381-b14e-75d9a0c9aa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9253f58d-8c4f-4b96-8fde-4a99b5ddaa97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9253f58d-8c4f-4b96-8fde-4a99b5ddaa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2cc54012-7263-45f1-a6c1-8c1e48866b4a" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2cc54012-7263-45f1-a6c1-8c1e48866b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f22e1fac-d6c1-40f2-aa95-a7dd0de48f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_f22e1fac-d6c1-40f2-aa95-a7dd0de48f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d07847e1-350a-4af5-b2bd-5f045ade6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d07847e1-350a-4af5-b2bd-5f045ade6a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a49a2406-97ff-4950-8164-3968eb08d706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a49a2406-97ff-4950-8164-3968eb08d706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8206c832-c35a-4c0c-b077-3f4afa3fbc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8206c832-c35a-4c0c-b077-3f4afa3fbc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_41206614-1d67-4805-9112-49e7d3581763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_Goodwill_41206614-1d67-4805-9112-49e7d3581763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_2824e453-e71b-4811-8386-5285963c432f" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities_2824e453-e71b-4811-8386-5285963c432f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_cea1481a-c26e-4701-9b29-94ace6500bf0" xlink:href="bngo-20211231.xsd#bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability_cea1481a-c26e-4701-9b29-94ace6500bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e9465554-8ca8-43a6-92b4-18588aa992fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e9465554-8ca8-43a6-92b4-18588aa992fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4d535430-3b0f-43a1-9f3e-64d5e892390f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4d535430-3b0f-43a1-9f3e-64d5e892390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4485566d-f55a-473f-a5f0-cb788c5c4c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6dcc260b-9e00-4835-b9e5-bb5f94cc992d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4485566d-f55a-473f-a5f0-cb788c5c4c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7bbd73bd-08d7-4300-a65d-8dd4d213e36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7bbd73bd-08d7-4300-a65d-8dd4d213e36a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0f6bcf36-5adf-4b17-a2e4-6f56391669ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0f6bcf36-5adf-4b17-a2e4-6f56391669ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ac303f0-0c8b-45e3-82fe-7277504c1f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f6bcf36-5adf-4b17-a2e4-6f56391669ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ac303f0-0c8b-45e3-82fe-7277504c1f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_LineagenMember_32903073-ae98-4801-8f12-3a8a2783cb17" xlink:href="bngo-20211231.xsd#bngo_LineagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ac303f0-0c8b-45e3-82fe-7277504c1f93" xlink:to="loc_bngo_LineagenMember_32903073-ae98-4801-8f12-3a8a2783cb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_2c76c5d3-a7b5-45bd-85e9-47f5f59aec27" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ac303f0-0c8b-45e3-82fe-7277504c1f93" xlink:to="loc_bngo_BioDiscoveryMember_2c76c5d3-a7b5-45bd-85e9-47f5f59aec27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_975f45eb-c1f7-433c-81eb-203b161ac069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_975f45eb-c1f7-433c-81eb-203b161ac069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_975f45eb-c1f7-433c-81eb-203b161ac069" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_1e713d9f-94e2-4fc7-be7f-662aa72ce2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:to="loc_us-gaap_CustomerRelationshipsMember_1e713d9f-94e2-4fc7-be7f-662aa72ce2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_013950ee-ac7e-46f9-a4df-e2c25ef88d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_013950ee-ac7e-46f9-a4df-e2c25ef88d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_22f2501b-5df1-4c13-9855-ea94daa136ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc71d3bf-c57c-45ad-a822-d6753e2fb592" xlink:to="loc_us-gaap_TradeNamesMember_22f2501b-5df1-4c13-9855-ea94daa136ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cf58a6b7-48c5-4d3b-a06d-f7ef402d8450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22dce98a-c3d6-4428-976f-858be4478d49" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_cf58a6b7-48c5-4d3b-a06d-f7ef402d8450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_93889daf-833d-40fb-9c16-ca85f4e0c12e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf58a6b7-48c5-4d3b-a06d-f7ef402d8450" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_93889daf-833d-40fb-9c16-ca85f4e0c12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d7181ac3-db12-4395-873a-0e0da2d7e0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cf58a6b7-48c5-4d3b-a06d-f7ef402d8450" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d7181ac3-db12-4395-873a-0e0da2d7e0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#AcquisitionsProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b72bac5b-3575-4e23-9e40-3a42890bd0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95cf620d-f2c2-4f6e-bea3-9c24d2719a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b72bac5b-3575-4e23-9e40-3a42890bd0c5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95cf620d-f2c2-4f6e-bea3-9c24d2719a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_51688afb-25e3-434d-a7e9-7a6026bf6671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95cf620d-f2c2-4f6e-bea3-9c24d2719a2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_51688afb-25e3-434d-a7e9-7a6026bf6671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e40d9eba-ea9e-49f9-9249-12a04416b2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_51688afb-25e3-434d-a7e9-7a6026bf6671" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e40d9eba-ea9e-49f9-9249-12a04416b2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_BioDiscoveryMember_9eb78e9e-4015-47ee-aa31-a26950344a09" xlink:href="bngo-20211231.xsd#bngo_BioDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e40d9eba-ea9e-49f9-9249-12a04416b2ae" xlink:to="loc_bngo_BioDiscoveryMember_9eb78e9e-4015-47ee-aa31-a26950344a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_95cf620d-f2c2-4f6e-bea3-9c24d2719a2c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_3a3913ff-373a-4322-bdcf-607cca16a876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_3a3913ff-373a-4322-bdcf-607cca16a876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b602ad88-5866-4a48-a1e4-9c8a4b894af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b602ad88-5866-4a48-a1e4-9c8a4b894af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_766e9d5f-2546-4509-b5e6-4472c33e75c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_766e9d5f-2546-4509-b5e6-4472c33e75c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_cc4d8623-cd80-447d-951c-3dad09a9ecdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1b43c7ca-7c20-42cc-b485-25bdb73b8379" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_cc4d8623-cd80-447d-951c-3dad09a9ecdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="bngo-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e78b7bb9-7aa3-466f-9feb-40a8ec9c5e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_741c4487-02b2-4f2a-b656-37705d873e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e78b7bb9-7aa3-466f-9feb-40a8ec9c5e3b" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_741c4487-02b2-4f2a-b656-37705d873e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://bionanogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="bngo-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://bionanogenomics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_475d41f0-588d-4fce-9511-418ef2c533a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_431fbf76-fcf6-4e34-b59c-9f00f8469904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_475d41f0-588d-4fce-9511-418ef2c533a8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_431fbf76-fcf6-4e34-b59c-9f00f8469904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24938a20-ba37-4e67-98c5-34cb1d3f8895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_431fbf76-fcf6-4e34-b59c-9f00f8469904" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24938a20-ba37-4e67-98c5-34cb1d3f8895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_269b7f1c-67df-45c8-af31-3a5d2232249c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24938a20-ba37-4e67-98c5-34cb1d3f8895" xlink:to="loc_us-gaap_RelatedPartyDomain_269b7f1c-67df-45c8-af31-3a5d2232249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_dc5b5712-f47c-4d19-bbad-fbdc5171206a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_269b7f1c-67df-45c8-af31-3a5d2232249c" xlink:to="loc_srt_AffiliatedEntityMember_dc5b5712-f47c-4d19-bbad-fbdc5171206a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5c04491e-96aa-4843-ade2-867e7159ae31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_431fbf76-fcf6-4e34-b59c-9f00f8469904" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_5c04491e-96aa-4843-ade2-867e7159ae31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bngo_FinanceLeaseExpense_b8b1d2c0-ff75-4616-945f-53e1fae15d36" xlink:href="bngo-20211231.xsd#bngo_FinanceLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c04491e-96aa-4843-ade2-867e7159ae31" xlink:to="loc_bngo_FinanceLeaseExpense_b8b1d2c0-ff75-4616-945f-53e1fae15d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>bionano-nancyridgeleasee001.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".XN(;2VEN;
MF5(8(D+R22,%5% R22>@ K"_X3WP?_T-.B_^!T7_ ,56MJFG0:OI-YIMUO\
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M ($C_P")H [3_A/?!_\ T-.B_P#@=%_\51_PGO@__H:=%_\  Z+_ .*KB_\
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M!_\ T-.B_P#@=%_\51_PGO@__H:=%_\  Z+_ .*KB_\ AGOP3ZZG_P"!(_\
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M_P"&>_!/KJ?_ ($C_P")H [3_A/?!_\ T-.B_P#@=%_\51_PGO@__H:=%_\
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MGOP3ZZG_ .!(_P#B: .T_P"$]\'_ /0TZ+_X'1?_ !5'_">^#_\ H:=%_P#
MZ+_XJN+_ .&>_!/KJ?\ X$C_ .)H_P"&>_!/KJ?_ ($C_P")H [3_A/?!_\
MT-.B_P#@=%_\51_PGO@__H:=%_\  Z+_ .*KB_\ AGOP3ZZG_P"!(_\ B:/^
M&>_!/KJ?_@2/_B: .T_X3WP?_P!#3HO_ ('1?_%4?\)[X/\ ^AIT7_P.B_\
MBJXO_AGOP3ZZG_X$C_XFC_AGOP3ZZG_X$C_XF@#M/^$]\'_]#3HO_@=%_P#%
M4?\ ">^#_P#H:=%_\#HO_BJXO_AGOP3ZZG_X$C_XFC_AGOP3ZZG_ .!(_P#B
M: .T_P"$]\'_ /0TZ+_X'1?_ !5'_">^#_\ H:=%_P# Z+_XJN+_ .&>_!/K
MJ?\ X$C_ .)H_P"&>_!/KJ?_ ($C_P")H [3_A/?!_\ T-.B_P#@=%_\51_P
MGO@__H:=%_\  Z+_ .*KB_\ AGOP3ZZG_P"!(_\ B:/^&>_!/KJ?_@2/_B:
M.T_X3WP?_P!#3HO_ ('1?_%4?\)[X/\ ^AIT7_P.B_\ BJXO_AGOP3ZZG_X$
MC_XFC_AGOP3ZZG_X$C_XF@#M/^$]\'_]#3HO_@=%_P#%4?\ ">^#_P#H:=%_
M\#HO_BJXO_AGOP3ZZG_X$C_XFC_AGOP3ZZG_ .!(_P#B: .T_P"$]\'_ /0T
MZ+_X'1?_ !5'_">^#_\ H:=%_P# Z+_XJN+_ .&>_!/KJ?\ X$C_ .)H_P"&
M>_!/KJ?_ ($C_P")H [3_A/?!_\ T-.B_P#@=%_\51_PGO@__H:=%_\  Z+_
M .*KB_\ AGOP3ZZG_P"!(_\ B:/^&>_!/KJ?_@2/_B: .T_X3WP?_P!#3HO_
M ('1?_%4?\)[X/\ ^AIT7_P.B_\ BJXO_AGOP3ZZG_X$C_XFC_AGOP3ZZG_X
M$C_XF@#M/^$]\'_]#3HO_@=%_P#%4?\ ">^#_P#H:=%_\#HO_BJXO_AGOP3Z
MZG_X$C_XFC_AGOP3ZZG_ .!(_P#B: .T_P"$]\'_ /0TZ+_X'1?_ !5'_">^
M#_\ H:=%_P# Z+_XJN+_ .&>_!/KJ?\ X$C_ .)H_P"&>_!/KJ?_ ($C_P")
MH [3_A/?!_\ T-.B_P#@=%_\51_PGO@__H:=%_\  Z+_ .*KB_\ AGOP3ZZG
M_P"!(_\ B:/^&>_!/KJ?_@2/_B: .T_X3WP?_P!#3HO_ ('1?_%4?\)[X/\
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M_AGOP3ZZG_X$C_XFC_AGOP3ZZG_X$C_XF@#M/^$]\'_]#3HO_@=%_P#%4?\
M">^#_P#H:=%_\#HO_BJXO_AGOP3ZZG_X$C_XFC_AGOP3ZZG_ .!(_P#B: .T
M_P"$]\'_ /0TZ+_X'1?_ !5'_">^#_\ H:=%_P# Z+_XJN+_ .&>_!/KJ?\
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M$C_XFC_AGOP3ZZG_ .!(_P#B: .T_P"$]\'_ /0TZ+_X'1?_ !5'_">^#_\
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MZ+A(]K*X/W3Z<4 ?65U<K:6DMS)DI$A<X] ,UXQK7QZ"NT.DZ8QP<"69P/T
M->D:#.VH> +-[]V3S+!?,D/7!CY/]:\7EM/ACI,K>==W>IR@GY8U*_S% %6W
M^+'BB_U>*66\=(8\N8HOE5@ 3@U[[X2U^/Q/X9L]6B1D$P8%6Z@JQ4_J*\5L
MO'GA,3?8;3PS&ENZ,KRO]\+@Y/Y5Z_\ #^'3(/!EDFD3&:Q+2-&Q&",NQ(_
MDC\* .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV.0.'^\O7^[7.Z!J^I^&]<^*.J:78V=Q%97XGFCFD9"44R$A< \XR<GTZ'/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45574K%KI[5;VV-Q&,O$)5WJ/<9R*C_MK2O\
MH)V7_?\ 7_&@"]14,MU;V\D4<T\4;RG;&KN 7/H >O44LMS! T:S31QM(=J!
MW +'T&>M $M%1F>$3"$RH)2N\(6&[;ZX]*B@U&QNI/+M[VWF?KMCE5C^0- %
MFBHKBY@M8C+<31PQ@X+R,%'YFB6Y@@@\^::..+C]X[@+STY- $M%0P7=M=1F
M2WN(I47JT;A@/Q%,M]1L;I]EO>6\SXSMCE5C^AH LT4V21(8VDE=4C499F.
M!ZDU%]LM=T*_:8=TPS$-XS(/5?7\* )Z*B:Y@61XVFC#HN]E+#*KZD=A[TRW
MO[*[8K;7<$S 9(CD#$?D: +%%1K/"T[P++&9D +1AAN4'H2.U-%W;,LK+<1$
M0DB4AQ\A'7=Z?C0!-15--6TV2V^TIJ%HT&[;YJS*5W>F<XS2QZKITQ(BO[5R
M%+$+,IP!U/7I0!;HJO;W]G=L5MKN"8J,D12!L?E4D4\,Y?R98Y/+8H^Q@=K#
MJ#CH?:@"2BH;>ZM[I6:WGBF"MM8QN&P?0X[TZ&XAN$+P2QRJ"5+(P8 CJ.*
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M52JD],G/% %JBHFN($$9>:-1*0L9+ ;R>@'K22W5O!)%'-/%&\IVQJ[@%SZ
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M'$MQI]W#8RX.=VQQM_-"O/UKVVU\*Z9:^);_ %X(\E[>Q1PMYA!2-$& J#'
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MNY+N*"QDCE@DMY=DBLBE5.['H35-OAUIT^AW&D7NJZW?6\TT<Y:\O3*Z,AR
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M=.8]+:588SEF8G+ @8))IOQ#\+'5KKP#H%K81:)/+#J#Q6L$@*V\PC60 ,N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$=PGAQ/M]U" _EN#&'0[@'4G&067&1_A6SIFH/>S:A!+&J2V=QY+;3D$&-)
M?R<#Z@T :%%%% !1110 4444 %%%% !1110 45%<O)':3/$NZ148HOJ<<"N+
MT_7;VVL;2&&6.7R](AN8(7C9Y;^0QNS;6SQRJYX/WN>HH [FBN EUC4=1:U
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M=I&C:#+N?<.",^O'4U2?Q!J>M6*OE]L=Q(4>*/RRRM8SMA@K,,A\=^#@'D4
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MTHFD>S*[IX[42!P0^65G!'W5!Y Y&: .X?PK8O/#*9KH&/R2RJX596B??&6
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MI** "BBB@ HHHH 9+$D\+Q2*&C=2K*>X/!%+'&D421QJ$1 %55&  .@%.HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#R@#'#.[2_F#VQ0!K76LV5A/+'>3QP)%'&[222*!\[,JC&<Y)7TP<\9YIO\
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M(PJ_)%)'@#L/WA/X"G_\([Y6D:19VUXT<VE%6@F:,,"1&T9W+D9!5VZ$<XH
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M(H6G\C>JL449)&X@?B3BLW1O#$OA^&""PN(2BF*)Y&BQ(8(PV%)R=S9(&?E
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M.30%:4C=*QO4!9SRQP!QR3QVJ)85*-TU?_%$.8U[Z^EM9X8HX(Y/,5F+/+L
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M=I*UUWV^X5V:=QK=O:_:3-'(BP2+%N8H [L 0H);T(SG J?3M2M]3ADD@/\
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MEZNH6"3AHRV61_+.5W*2K8/ID''M6 VC^)I GFZG82LLJR$O$_S%>@(W8Q]
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M>*E?PQI[).J&:/SQ('*OU#R-(PP01@L[?@:6V\,6%E)(UF]Q;JZ!2B2\9"!
MPSDYVJ.^.,XSS0!:?5H4TE=1,4QB8 A0H+=?KC'OG%9W_"9Z/Y!N!),8!;Q7
M!E\EMNV4XC&3_$Q. /SQ4Y\,Z=_8\.F 2K##,9T8-\PD+%RW3'5CQC'/ &!3
M8_"FE1::U@D4@@:*"(?O#E1"<QD'U!P<^HH '\103:-!J5CB6.6\BM2'XVEI
MUB;\02?8X]*8GC#2I$W+]I.]4: >0V;A7;:K1_W@3^0()P#FK_\ 9-NVGPV<
MK2RI%*DP9V^8LCB12<8_B XK/3P=I<<0C4W(\L(MNWG'-LJ-N58_0 ^N<C .
M0,4 .OO%=E8926"Z$QMVGCC:(J7VH7*C/? /MP1U&*8GC'2C<6MM,\D$\Z(V
MR1<>67SM#'L3@_IG&1E__"(Z6U\UY(+B65@=^^4G<3%Y1)[DE./UZDYD@\,V
M5O<1SK)<,ZQ+$^Y\B55!"[N.H!QQC/&<XH CTGQ)'K%]>)!!*EO#:07,;S1L
MAD$ADYP?X<(I!]SGD8I-/\5V%[+:08E\ZX$8WK$WE!WB$H7<0.JY/X<X)&;&
ME^'K+2/-^SM<.9(8[<F:8OMCCW;%&>@&\_UR:+3PWIUDL AC<"&2.5,N3\R1
M"%?_ !P4 4+_ ,6?9+JZMTL+EC;7D%L[;"0_F!3\N._S5,/&6BF>TA\]Q)<A
M,*R$%"[F-0P/()=2OL1S@<U<ET*SEOY+MO-WR2QS,@?Y2\>-K8]< #\*A@\,
MZ?;7L=U;^=%(O#;7XD&]G ;/HSMTQUQTH <^JWDVN36%C9PR16HC-S+-.4(W
MY.$ 4Y(49Y('('KB*V\6:7=-&$:91+Y1A+Q,HE61MJ.OJI/\P>XJU/HEM-JG
M]H+)<PSLJ+*(9BBRA22H8#KC)^H.#D<52C\'Z9%;^2C70"+&D#><2UNL;;D5
M#V /KG/ .0* ''Q;I8N$A!N&+,JEUA8JFZ5H1N/;+J1^O3)J*U\8V$UH\]Q#
M<VI4W&U)(^7$,@C;;CJ22N!UR<=JL0>%M,MX3$B3%6\O):4L3LF:9<D\GYV)
M]ZAN?"EI-)8A7<0VVHMJ!1R6RQW-M![+YC!\'/3Z8 +FH:_8Z9=?9[@RE@J2
M2LD99849BJLY'0$@C\">@)IGA[5I]9M;JYE@,")=S01H5(.V-RF2<\Y*D]L=
M.V2^_P##]EJ5Y]IG\X,R)'*B2%5F1&+*KCN 23^)!R#BKEG90V$#0P A&EDF
M.3GYI'9V_P#'F- !?32V]F\D$?F2 @ ;2V 2 3@<G R<#DXQ5*'5&CL)[FY>
M"58I-@,1$>1A?O"1AM.2>"?3UIVMVFH7MJD5A/!"V\,SRAL@J01C:1W'?(/2
ML<Z-XD,?_(0T[S_-\[S_ "'W[]NS.-VW[O&,8_'FNNC"G*'O22=_,EMW-A=;
MAEM+6X@@GG%S*T*+%L)W+NSD[L8^1N0<<5=M;E;NW$R*RY)4JW56!((...""
M.*YJ'1?$<"P*M_IY$,[SKNCD8EFSNR2W(^9OS^E6;6R\36D)B2[TI@79R7@D
M)RS%C_'ZDU52C2M[DE^/GY>@)LT[N:\%_!;6KP*'BDD8RH6^Z4&!@C'WOTIB
MZC)(+ B)D\Z5HY< ,JLH8%<Y!ZKP0#TZ#-9=UIOB>ZGCF_M#3HGC5D'E0R#(
M8@GJW^R*CET;Q)(END=_IT"6_,:QPOUP1DY8DG!-.-*ERI.:O\_/R] NS4O_
M !%8:=<R03/S$ TK!T'E@\\@L">.?E!J2ZUA+:1U%I<S(DJ0M)$%P'8J O+
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M(Q4\=>!NVMCU05/J/AZQU.]6ZG,ZOB-7$<I59!&Y= P'7:Q)_$YS0!3/C;1
M;D"X9C <<+]\^8(OE_X&0,G Y!Z<U9G\36%LMX\B7/EV<7F7$@@8K%\@?:<?
MQ;2#CW'<T1^&K.&"YA@EN8HIRQ**XPFYMS 9!X))X.1@X&!4:>$=+BMIK6+[
M3':S0+!) LS;& C$88_[6Q5&?8=^: *]UXK\B]MH5LIG$MRL+1"-C,H:"60?
M+CKF,#KT))Q4T?C/0Y;FV@2[)-PB.K%2 N]2RAL\@D \=N,XR*LWOAVROKG[
M4SW$5QYJS++#*5975&C!'_ 788Z'-1VOA;3+*:-[9)8D6)86B#Y6157:N[.2
M3CC.>>^: $T;Q$FM:C=0P02I;Q6T$\;RQLC.)#)R >V$4CZD'D8IB>+M+<A!
MYXF-R+40F/#;RA<?^.@GUXQC/%6-,\/66E"80M<2>;#';DS3%R(TW;%&>@ 8
M_P SSS5*/P3I,6FRV"FY^SS;!*OF_?55VA3QP,8Z8/&<YYH N:EKD6FZ@(IL
M+;QV<MW<28)*JA4  #J3N/\ WS[UFCQQ86_VUM0CFMA#=&&.-HR)"JPQR,Q7
MV\SMUXQG-:FI:%!JEX)9V)B>TEM)HQD;T<J<@@Y!!7@_[1JM_P (EI^3)YUV
M;DS-,UP9LR%F1489(Q@A$XQQ@8Q0!(?%&FXN2C2R"WDCA)CC+;Y'QM5>Y)W+
M[<YS@&FS>)[99'ACAG$L;0"3SH614\UT55)Q][YNGMS@<TZY\+Z?=W4MU,UP
M9W"!)!)AHMC!UVGV8 \Y].A(J;^P;(QRH_G2&62&1V>0EF:(J4)/U49H S+3
MQM8&TEEOUDMGC,F-T3!90LWE?(3U^9D'U8=JLW7B>W'AY-8LE:>)KJ*W*A26
M!:=8G  ZD$G&.N.XIO\ PANDE95?[2X?=L#S,?))E$I*>GSJK?\  1VXJ]/H
MEM<Z0NFS23M$KI()!)MDW*XD4Y&,88#IZ4 49/%]AY#F%)VE6&:5D:%@(O*)
M5]YQ\N&&.^>V145[XVTRU6[B0M-=6\+R>6@X=UC\PH#Z[>>GKW!%78O#.G0P
M31!96\Z&6&5WD)9Q(Q9R3ZDDGV[4G_",Z>'NROG+'=HR31!_E;<@0MZ@X [X
M[XSS0!1T_P 6*/,75PELRJ"'",H_U/FL""3@A0QZ_P )K0NM>2VO=/MA:7#F
M^B>16"X$>T _,.WWJKZKX4LM3MFAY02W$$TI))W+'@%1SQN0%#[,:T[S38+V
MYMKB0R++;%MA1L9###*?4'C\J ,.P\<:=/HUM>7:RV]Q+' Q@:,J6:5"R[=V
M,CY7Y/\ =-:<GB*P73;"_C,T\5^0ML(8BS2$HS@8[<*>N,8YJ!_">EM%"JK*
MC01PQPR*_P R"(.J$9XSB1P<YR#6@VFV[BQ#[V-D_F1,6YW;&3)]>':@"B/%
M.FO)8*GGN+^(2VS"(XDRA< 9YSM4_P NO%1:?XML+W2K:^DCGM_.MH;DQ2)R
MJRMM7IUY_3FEMO"&E6E[9W4*3![146(&0D?(C1J3Z_*Q'IWQGFFCP=I@M[2
M/=B.VB2%%$Y&Z-&#(K>H4CC]<T )<>,](M87EE-PJ+/+ "82-[1EA(5SU"E3
MS] ,DBKM[K]E8PV\A\Z?[1&TT:V\9=FC4 L^!V 9?S ZFHYO#=A-#$B^=$T,
M\L\<D;_,K2LS..<@@ECP1Z>@J;4=$M=2$)E>>*2%&C62&4HVQ@ RD^AVK[\
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MI[U'8>+;N2QA6[MVCGDEAV2C:PD1[H0G@'Y>H_ YZ\5TTNDZ?.VZ2TB9MZ2
M[>0RC"G\!Q]#BD_LC3@(Q]CAQ'MV?+]W#AQCZ, WU% %#1?$?]KW1A:RDMPT
M1FB9G#;U#E#D#IR/R(^E.T7Q#%K-]>VJ0[3;)'()%?>DB.7"D' SS&V<9'3D
M]M&"PM+9U>"WCC94,:E5QA2<D?3/-1V.D:?ICRO8V<-NTH <QKC(&2!]!N;
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MN@(#$@'(!YQ6+<^&KZ\51/XBO7V]#]G@!&>HR(^A[CO4RZ)JB*%7Q+>JJC
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MV/?UITZ>'LN::OK_ #?+H#;-"[\1?9K$7*6WF%8WDEC!=B@4D'[J,,$JV"<
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M$2R*! $R2Y4LV64D/\@^8$'WH 2Y\6-!975U]@.R&ZDMH@TP#3LA??M !/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI ZERH8%A@D9Y&: %HI@FB
M,QA$B&4#<4W#<!ZXI] !14)O+83^0;B'S<X\O>-V?I4U !1110 4444 %%10
M7,%R)#!*D@C<QOM.=K#J#[U+3::T8!1112 **** "BBD9E12S,%51DDG  H
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M1&\@#<G X]SP/>I%GA>9X5E1I4 +(&!9?J.U("2BBB@ HHHH **** "BBB@
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MXUZN[  ?B:?0 44R2:*$H))$0NVQ-S ;F]!ZG@T^@ HIDLT4";YI4C7.-SL
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M %VBLI/$FE2/;(MP_F7)D6-#!(&'ED!]P*Y0*6&2V,9J?3]8L=4CD>TF9Q&
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MJ^(PQW;L?=;:I8*>H].< '24444 %%%% !1110 4444 %%%% !1110 4444
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MUK"\48CAA0?,&!)Q'R/GSM^[D XXJM%X%TR)[1Q)(SVX91YD,+@J7W[0I0A
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M89Z;1USFNSHI 8W_  C&EMKM[K$L FN[N%(6,BJ?+50P^0XRN0QSSS@5@O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\"L)=X5?) ;#+"#A7 #D[CU%_2XM6MO$,LZR7;6=WJ!62.2W"KL^R(1*3M#
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M_5)='H3S'3T5S>IZN()+KR[J<AX8I(!%&7PV6W#@'' 7(/K4=]K,D>KCRI9
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MM;17C:C;31WDFLV,L<CR;@[,T0E\OT4+Y@QV7([&O1: "BBB@ HHHH ****
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M_P"$9T#_ * >F_\ @)'_ (5J45I&K4BK*3^\5D9?_",Z!_T ]-_\!(_\*/\
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M6OHUNCW[7^S4%E:V6%Q<QK&% )(4 *,D9/(R/>FIMNUC.IA:<:?.I?+Y+?\
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MT//%4M9U633)M-93";>YN1!*7R-H*LVX'./X>_K6?)I\J^*Y(XD4V&H1I<W
M/\,D1 Z?[64!_P!TU9\2P22MH[I;R3I!J*2RA$W%4"/EL>Q(K1RERLY84:2J
MQ5[IJ_X?G>_X&F-2L6CBD%[;E)3B-A*N'/L<\U*MU;N90D\3&(XDPX.SZ^E<
M?=:1<26>OZA#&;?_ $E+ZQ61=I$D2+EB#]W>5(.>QSWKJ-,A=+3S9XPEQ<'S
MIEZX8_PD]\ !?PIQG)NS1->A2IPYHRO_ ,,G^%[>J,FY\4Q2Z.FHZ8\,JK=I
M!+')RP!F\K/!XYR1GJ*V5U*Q:W>X6]MC"C;6D$J[5/H3G -<:UG<#PA+IKZ=
M<F=-2WLGD$AT^U&3(/0C9_A4NJV4\L?BZ."QG(O+:-;<+"<2.$*G''KC_(K)
M5)+7R_S.R6#H2?*G:TGKIM>*7YMKT^[KSJ%D(GE-W;B-'V._F#"MZ$YX/M2R
MWMI#"DTMU#'$_P!UVD 5N_![US5_IS0:AI&H65O/!:J)/M M8!YBNR*JN4*D
MG 4KP,@&JJ:3+I^H6CHNI#33:2P#;&DDD;-*7.Y=IPK CH.-H!Q5NI)/8PC@
MZ4HIJ>_3TOIZZ+Y/[^RFN(;>$S331QQ#J[L OYFFP7EK<M(MO<PRM&<.(W#%
M3[XZ5@ZM:)9_#J^M%254ATV1%69@S@",XR1QFLK4-+O-719-*ADM671Y;=G=
M#'YC,%V(,]<8;GH,]:<JC6R)HX2G45W*RNU?II;?U.O&I6)B>47MN8XR [B5
M<*?<YXIWV^S\IY?M<'EQML=O,&%;T)SP?:N1O; W>AZE-%;:DUW+I;6@BFA5
M0#_"@"J-V"3\PR .]6Y['[)?:'J5MI[_ &:/>;J.&'#AS&$5RF,G !7U -+V
MDNQ7U.E_-KKVZ*]OGLCHY+ZSBBCEDNH$CD^X[2 !OH>]-FU*QMV=9[VVB*8W
MAY57;GIG)XS7*-I1M=379;7\&DS6)MD2&,2LAWL6# AB P8'/M@XQ3SIOE:I
M,IL+AX4T1+5&DB\PE@6^4L!@G!&<<4>TEV']3H_S7Z]._P":Z[G13:W80:M!
MILDZ+<31M(F6&, J,=>IW#'K@TNI:B;.2UMH8Q)=7<ACB5C@# +,Q]@!^)P.
M]<[IMO<VUWX9GGLK@K%IC6LQ\HDQR?NOO>@^5N>E:FL*8O$FA7C\0*TT#,>B
MLZC;GZE<?4CUH4Y--^GZ$O#4HU(Q6NDOFUS6^^RT-";5;&UE$-Q=Q)("JMDX
M"EN@)Z#/8'K5&?Q"(=2DM_LV88KJ*T>7S,,'D4$87'(^9><]SZ5D^*%LWT+5
M[BT:!K>.8-J404J\SIL.T/G"G 4?=.?;K6GJ>FKJMROEV:QYC$DL[KAFX(5!
M[\D$]0"0.O Y2;:7];E0H4(Q4YWL[K72S7*_+N[;]/17HK^:]M[B:QA1D0XA
M>1L+-CKC X7L&YSUQC&9=,OXM4TZ"]A#*DJYVMU4]"I]P01^%8OA][^#!O?.
MCMH[&(SFX&T).,[]O;:!CI\O3'>HM,@E3P#,'F^R&X$\H=ER4221F'&1SM88
MY')H4WOY,FIAH*\4_M12>^C3O^2.JHKS8W^K06T45CJ^FV=H)&"O%9!6?"KA
MFC#$C)+]@/E&>#6C:ZCK+:W.L_B334B&0JFVS&5P,,#YG7KQNSU[8I*NGI;\
MBY97**OSKKTE_EN=Q17GQBO([K4M2BUO2ENTD=HBD"AY_P!T !DR_=ST!SR,
M^U+I]_KEP8$F\2V4:+*Y+FW'SJ I7.7!P22.QXH]MT:_('EFG-&HO/27:_8]
M HKS'^V_$@M64ZW:>9+(@4-$ 5)5RPSN[;1R 0<\<=;HU+66LI;F+Q1:2@0Q
M",?9U&_=C<V-^<COQ]!FDL0GT?X?YERRBI'>:_\ )O\ Y'^M>QZ#2!@PR"#S
MCBO-CK6O;+:,^(+<3^6[*JVRX=A)A0Y+\ KSGC Z\UM>'6U"/62LFKV]S;S/
M<LT$4:C:?,RK [B><D_3\,.-92=DC.KEDJ4'*4UI?OT^7W'8452DUC3(9&CE
MU&T1U.&5IU!!]",TW^W-(_Z"EE_X$)_C77[*?\K/+NB_15#^W-(_Z"EE_P"!
M"?XU)#J-M<R(MK(MPK$@R0L'5"!GYB#Q2=.<5=H=RW1114 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %(55BI*@E3D$CH>G]:6B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :40R"0
MHI< @-CD ]>?P%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *MII]I8M,UM"(S,Y
M>0Y)R223UZ<DG'3DU:HHI)6V*E)R=Y.[*MUI]I>S02W$(D>W8M&23\I/7Z_C
M5JBBBR!R;23>P4444R0HHHH @O+.#4+.6TN4+P2J5=0Q7<#U&00<4^"!+:!(
M8MVQ!A=S%CCZG)J2BE97N5S2Y>6^@4444R0HHHH *9+%'-&T<J+)&PPRL,@C
MW%/HH!.VJ*CZ7823B9[*W:0$-N,8SD=#]1V-6Z**2213E*6[&2PQ3Q^7-&DB
M$@[74$9'(X-+)&DJ%)$5T/56&0:=13%=E;^SK'_GRM_^_2_X4?V=8_\ /E;_
M /?I?\*LT4K(KVD^[*W]G6/_ #Y6_P#WZ7_"C^SK'_GRM_\ OTO^%6:*+(/:
M3[LK?V=8_P#/E;_]^E_PH_LZQ_Y\K?\ []+_ (59HHL@]I/NRM_9UC_SY6__
M 'Z7_"GQ6=K"^^*VAC;^\B &IJ*+(3G)Z-E5],L)'9Y+&V9V.2S1*23^5-_L
MG3?^@?:?]^5_PJY16GM)]R;%/^R=-_Z!]I_WY7_"IX+:"V4K;P1Q*3DB- H)
M_"I:*3G)Z-A8****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9W \8H =132Z"/>74)C.[/&*&=47<S +ZD\46 =1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!B_;IH?[9F8DM#.L<2GE44QH02,CC+$D^F?2H/[3NKCP_)<%E
M%U%<K&OE9 D/F*%'/4,"!GH<Y%= %4,6"C<1@G')H95;&Y0<'(R.AH XWXDM
M=KH^F?97N$4ZE&)S"TR_N]CYW&'Y]N<=/:N5TWQ5XLM(=#LC!>^:+=4N3?6;
MONRLG[TL!O/*H><'D @DUZ[10!Y1:^,?%\\^EPB#RU?B2>XM6"7#B4*RJ57[
MNWE3A2<Y/0U/XB77D^(S7=NU^-.@N-/5FBFEVA6,@8",'8RL0JN3DJ"#7J%%
M 'E>D>)O&VJQVD<AAM9;FZBBF)LG+6FZ*9I%*D*, I& <GD\Y!%3>&]>\1W-
M_+<:M>SVIN+/3Y4MVTZ1XU9V"R[<=#G@\\;LGA:].HH *Y[8A\3[UMV>?S-Q
M,L!#(FS;N60'&S_9/.2370$!@01D'@BL7_A#?#.<_P!@:;G_ *]D_P *Z*$X
M1YN9O56T7_!0G<1A _B*U:V\K*O()HTAVR*2I^=F_NG  &.20<G%:D-]!/>7
M-K&7\VVV^9F-@/F&1AB,-QZ$X[UF?\(=X:_Z &F_^ R?X4?\(=X:_P"@!IO_
M (#)_A5SEAY;N6BMLN_J+4@TR);=Y+?3I%E#6[EG, 1HY 0%5B #DY)(;GBI
MM$6W%QFSB\N);6))1MQ\X)X/^T!G/?D9I?\ A#O#7_0 TW_P&3_"K-CX?T?3
M+@SV&EV=M,5*[X855L>F0/:JJ5J4HRLW=^2_'7] 293\86L]YH26\#NIDO;1
M9 J!]T9GC# CTP23[ YXS6$VO>(-\\=N/W@\Q6B:S;;:E;A$CYXW[D9FZ\XR
M,"N[HKB*.>U9K^VU+0E%],(6=X[@K$")6V?+NP/ER0?SKFK+5/$>EZ!IMHQW
MK]ELF>YD@*FW5XY=P/#=&BC&2#CS.>U>C44 <IJFLZA9Z3H#3W<5K->N$NIH
M;=I57]P[DJI&1\RCJ.E9D'B+Q1-+F>VAMI%M%D-L\3[G)MMY*C:>1*2N"V,*
M1C)!KNI((I9(I)(T9XF+1LPR4)!&1Z<$C\:DH XF;4-9LKI?/E8++;VGVB]6
MV)$(9K@L0G(X*QKWQN!;-4I]7UN_:P@NO-@S<6,BQI9N/M"_:OF<G_EGA$1B
MIZ;B#U&/0Z* *M]<Q6\2>>@:"1MDK,/E12IY;VR /QK$1UT_2$^R*MI]HNI6
M$HVQ+MWL5R2C=5QCCTK7U#1M,U8QG4=/MKLQYV>?$'VYZXSTZ"J7_"'>&O\
MH :;_P" R?X5UTIT8Q2E?STTZ^9+3(8+V[O8=*4WDMO)+YJS;8EW-M]=R<'C
MT'4\#L^/4I#;V,]Q=/''/9MO98QGSALQ@;3\QR_R\YQTXI__  AWAK_H :;_
M . R?X4?\(=X:_Z &F_^ R?X5HZF&??[EY^?G^ 690OM9OH].MY8I&6<62SE
M3@>:Y!^4+Y;%B".0"N 1]1H7UT[:Q:P1:FUO#+"Q8)&K'=E=F"0<$Y;KG..W
M6D_X0[PU_P! #3?_  &3_"C_ (0[PU_T --_\!D_PH=3#:6OUZ+K\^@6D.OI
M;V/4#9Q7$H-YL,#JBD0A3^\_A],$9SR<<5LUSP\">%1=&Y_L*R\PC&#'E?\
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MXQVZ5>J"SLK73K9;:RMXK>!<E8XD"J,G)X%3UQ3:<FT4%%%%2 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%17,Z6MK-<2DB.)"[$>@&30!+17)Z?XMN+GS+6YM1#>-Y<<+B-C
M")7MUE",V?4L/P'0D9Z'2K]-5TBRU&-2L=W DZJ>H#*& _6@"W17,^)O%,OA
M_5-+M?LT M[UF#WEU,T4,9!4!-RHP#-N.-V!\IYJ!?B1X<>:YACGFDEA8(J1
MQ%FG;S1%A .OSD#G'7/3F@#K:*YUO&FDQLR2BYBD6=+=XY(2K*[PF8 C_<!_
M'BL:Z^)EK"L5S!I]W/:S16\D2>2R2L)IO+5\$8V]".Y) [YH [NBL33?%6F:
MKJ L+8S?:OW^^)XR#'Y3A&W>G+#'J.:YRS^)!C@MKW6]/ALM-NX[F2"XAN#*
MP\@G<KIL&"0"1@MZ4 =]17'/\3/#ZVHG'VV0 3-(D5N7,0AV&0MMR  )%.<X
MP?7BI[CXA^'[:2X$DMQY,(E_T@0,8I&B7=(JMW8#\.#SP: .JHKB;[XB06=U
M$$L)[B*86FQ(ES*//DD0$XRI'[OC!.<^XKK[6[2[65DCF3RY6B(EC*$E3@D9
MZKZ$<&@">BJNHRW$-B[VJYER #MW;02 6VC[V!DX[XJF=4:/2(Y7F@>YED,,
M9VM&I?)QE6Y& "2/8XK2-*4E==["N:U%9 O[J30K"_BD@WRB%I<H6#!RH.WY
MN.I]:UZ4H.._]6'<**R-:U&XL-K1,J*(GD&Z(OYCC&$&.A.3[^G0TZ[O+E1;
MSV\D024)Y4#(2\I/)&<\ #OVY)XXJE1DTGW%<U:*S-1NKFSN;9ED!BEE2/9Y
M)(&6 )9\X7KQGJ>.<UIU#@TD^XPHK)BOKI[R%RT?V>:YEMUCV_,NP/\ -NSS
MDQGC'0CTY+6^NI+J%I6C,%Q)+&B*N&3:3M.<\Y"G/OBK=&2_KU_R8KFM15+5
M]0&E:+?:BR;Q:P/-LS][:I./QQ7.:UXFUSP]I<EY>Z7;O&)8XO-5V$<8+R!I
M'VAV"!5C/3J_L<9#.PHKE%^(>@1WL-C<WD2W#0I)))"WF0J6B,N _!(V D'&
M,8Z$@5)_PG>D)9?:YHKV"/['-?*)K<JS0Q!"S 'U$BX_'TH Z>BN4N?'%H+L
M6]I!/(8[];*9WA<*7*,Q6,@89L <=.>M1:7\1M*O],L[J>"ZM);N"*>*"2/)
M<22B)0I_B^9E_!@: .PHKCO$/C.]T35=2BATJ&ZL],L([^[D-T4D\MFD!V+L
M(8@1DX+#-22_$GPW#<WL#7,I-FDCR,L9(/E[=X'<D;AVYYQG!H ZVBN3D^(>
MBQPNQBU#SHWE66V%JWFQ")59V9>RA70Y_P!H=Z+CQYIKI<_V>WG&VGMH9))%
M(3]\\:C&.<XD!'&#Z\&@#K**Y;1_$]_XBM(KS3M)DBMQ<2P3"Z.UALG2,E>>
M?D\T^Q7'UV=&OWU+3_.E55E2::"0+TW1R-&2/8E<CZT :%%8.KZ]<V%U=Q6M
MG]I-K:1SR*-V[]Y(44_*"< )(QP">!BHH_&>E+)8V\]U UQ=+&0;:3S(QYCF
M-.3@G+ C@<$'.!S0!T=%8^C>)M,U^6:.PF,AB59.G#(Q(5A[':>N#[<BJ+^,
MK,RPB)7"+<M#="1?FC46\DV0!G)_=CCKU&,T =-16"_BW3H[>*=DN/+>'[0Y
M5 PABSCS'*DC;UZ9X!/8U!X@\4OHFJVUDEO!,98O,V//LDD^=5VQKM.YOFSC
MCIVZT =+16#/XMTVVFO(9%N/.M6C5HUCW,YDD\M=H'JV!SCKGIS3I_%>G6MW
M-:W"SQ31P&?8R<LH**0 #US(@YQG/&0#0!N45A6OBJRNY4BBMKTR,LK,ODYV
M"-RC9(./O*0/7MQ4/_":Z7]G\U4NI"/-WQQQ;V01!2Y.TD8 =3P3G.!SQ0!T
M=%8&F^)X;W5KBP>-UQ<-%;S!#Y<N(UDQN]<,3Z8'K44GB*\^WZK9K;012V\4
MC6BS-(&N"JJ<C*A2N6P=K$B@#I**AL[J.]LK>[BSY<\:R)GT89'\ZFH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IDT*7$$D,J[HY%*,/4$8-/HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M****YB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNDO9+>?VE:"W9_+\PSJ%#XSM)SC=[5.FH64ERULEY;M.A :)95+ G. 1G/\
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M!)/L\SRTD!;;Q\V,YQ\R\^X]:L5A^&_#<?AV&9$G$QE$0+>7M(V1JF.O3()
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M '7@$_0&K".LB*Z,&5AD,#D$>M)Q:U: 6BJEUJ5I9.5N)=A5-[?*3M7GDX'
MX/Y4^:^MK>=(990LCXP.>YP,^F3P,]3Q3Y)=@N6**KO?6T5RMN\H$C$#&#@$
M] 3T!/8'K5BDTUN 4572^MGNVM5F!F7JOY9&>F1D<=LBB*^MI[A[>.8-*F<C
MGL<'![X/!QT/!I\DNP%BBBBI **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?I-)IUTELVV=HG$9ST;!Q^
MM6** /.K2'4A;I=S-<)H:6"LD2IE# +4!HW'F##;]Q_U9;H,XR!V^C17$.AZ
M?%=DFY2VC68G^^% ;]<U>HH P_&6DG6_!VKV"6D=U<2V<RV\;A3^]*,%(+<
MY/7M7*76B^)+74[.VTN"ZMK-$LQ!]DF2*VAPY-UYR @L67H0#STP<FO1Z* /
M(8-$\9Z;HVFZ?IUIJ<4MM<2/),U\K*Q\]3T\T#88\GY@W.?E!.:V+CP[J:^!
M].LY=):[EM]<>\FM%:,EX?M4DG\3!3E6!P3WKT:B@#R5M%\9Z3IUXNCZ=<P1
M7L=^;:QMKF)18O(T9BS\P48"R'Y"<%\5T?AVR\41^,M0N-6N+O[$7G\M,*T#
MQEU\K!\TE6"@CB-<_-DGBNWHH \DNM*\0:=I C_L^>U_L3^UKP7XE39)YJ3&
M+RP&+;OW@)R!C;1;6GC2>R29DUU]-ED#^0M]&+LL;?&X/O $?F\[=P^F.*];
MHH \ZTG2O&D6L6%YJ-Y=R%+JW2X1;A?(:'['B5MF?^>X^O<#!-5KG0=;@U_Q
M==6NG7WGWQ9M/N8#;*H;R8U5O,)\U2&4Y&-N.QS7IU% 'EL.G>/FU#2_MES?
M(J-_I$D#)(IE^T,68KYJ#RFCVA00VT9&T-R9+>#QI:V=I*UIK$]ZLLRWJF]B
M*2LT<@1X@7PL88H<<$<8!(->G44 >467AOQ3!?\ GM#>/=32Z;/+--<J\?R1
MJLV06SN# ]!TZ&GZ?I'C><6L5Q-J]O$S6BW[2WJ%VD!D^T/$58[8R"F ,>P&
M*]4HH X.:S\4#P=H4$XU&:XBN"-22UN42YDA D"XDW 9SY9.&!(S[TWP;X;U
MJUUF]U'7Y+@W-SI5I;M+]HSEQYF\<'AE&SD=V8CJ:[ZB@#QO3O!_BBSL+*2V
MBU*UOK'31 I-XG[R47 8C[QS&4R0#@>V<5T&D:=XIL_$>G/-%=M9_:+LSH9E
M6&-&GF9'^63YF*F,;60\$$$$-7HE% 'FU[9>*;9/$EIIFG7D3W>K+>)=Q218
MD@Q"KHO[U7#D*W]W@'# D5 +'QPE_HH4ZD\4'E^?<-*BF1"\F]7C\XKN52F"
M=Y/!R"#7J%% 'D@TSX@/9V,)EU.&.-IE,RR+).[_ +ORY70W  '$GR[V7_9P
M1CTS2UF6.Z\];H$W4A7[2ZL2N[@KMZ)Z \@=:OT4 87B?5]-TRR3[==VL1SY
MBI+=+#(0O.8\GE@<<=#GFLL^*-"&EP--XCTXW4<S2(8;R L,E@,C(4G:V#[G
M/O78$ ]11M7T'Y5U4ZU.,%&46WZ_\!DM,XFU\2Z%IT5E,^NZ;<LGG^8JW\)<
M&1]X/W@#C&TXXY]*GA\:Z%IEIHUBNK:7-)(%AE9+^/9 JH26)STR  .Y(KK]
MJ^@_*C:OH/RJWB*,OB@_O]?+S"S.;U'Q5X<N;=+=/$.D%9)%$I^W18" Y8'Y
MN<@;?^!5GZUXA\/WCR16WB2Q1[F(12.E] $"@G!))R,;CTY.?Q':;5]!^5&U
M?0?E4TZ]*#347IYK_P"1!ILY'4O%OA^YN;:./7+']U/&^X7\(B=0P)W?/GCM
MQG(%7?\ A./#W]HBV_MC3?)\GS/M/V^'9NSC9C?NSCGICWKH=J^@_*C:OH/R
MI.K0:2Y'IY_\ +,XV#Q/H(N[>%M:TH+!=S7!F-]#M97\S 'S9S^\';^$^V7Z
M7K^EW%];6MK?V5Q/;B<JD%Y"[SDG(" -R2/F.<8(YKK]J^@_*C '854L12:=
MHO[_ %\O,+,1&+QJQ1D) )5L9'L<<4ZBBN,H**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/Y4]P)'M&LS($B7Y&<N3L5 F<G^[C'4&@#<L[R*^LH[N(2K%(,CS8FC;'NK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%,FF2W@DFE;;'&I=CZ #)H ?16!_PDT8TN.5K:1;^6T^T1VS*X
M5V\OS/+$NW:6P#P.>"<<5M6UQ'=VL-S"VZ*5!(A]01D4 2T5ROC#QO;^$);1
M)K-KCSX9Y^)DCPL6S(&XC<QWC"CDXJY)XST&&::*>],4D,32RAX7P@6/S&7=
MC!<(=Q4'<!VH WJ*YU/'7AR14*:@27G%LB"WDWM(5W@!=N<%3N!Q@CG-+_PG
M'AW;*POV;RV5 %MY"9"S%%\L!<R LI&4R,@T =#16'-XQT&WN9K>:^V20QM)
M)NADVJ%C\QEW;<;@GS%,[L=JIGX@^'VELD@FN+@W=Y]C7RK63Y',?F L" =I
M7!! .0<C@$@ ZBBN7U#Q_H.GQNSO>2-'<0P/&EG+O'FN51PI4%DRK<C.<8&3
M@%S>.M%M4F;4+E;?R[B>(!%>4A8F 9VPOR*,C)/ SUH Z:BL./QAH,NIRZ<E
M^&NHA)O41/CY "X#8P2 0< YP<T[7/$,>CM8KLA8WC,J-/<"%!A<\L1U/I0!
MM45FSZ_IUK/-!<S-#)#$TS^9$ZJ57&XJQ&'P64?*3U%4_P#A++!=56SE$T22
M11/'))!(OS/(\85E*Y3YE RV,EA0!O45@:QXG31]3CM'M3(A2-W<2 $!Y/+&
MU3]XY[#\,]*LS>)=*M_M/GSRQFW**ZO;R G>^Q-HVY?+# *YYH UJ*QK3Q/I
MMW=SVP-Q#)%<?9LW%N\8=_+\SY2PQ]T$_A[C-BXUS3[73(M2EED^QRQB595@
M=@$QNW-@':,<DG '>@#1HK%O_$UE9B58]TKPSPPR_*RQKOD1#^\(VDKY@) .
M?I3QXGT@SV\(NF+W"QO'^Y?;MD8K&2VW"AF4@$D9XQU% &O163'XFTB64QK=
M\[U12T3JKEG$8*DC##>0N1D9(YYJ%_%.G2):M8S)=BXF2,;"0 K2&/=G'9E8
M8[X- &Y16.OBG1WA:5+IV4% H6"0M)OSL*+MRX.UL%00=I]*@T_Q?IM[!8F1
MGBFO I2-8W<#<6"[F"X7.QNN.A]* -^BL=/%.CR1AX[F1]S*$5;>0M)N#,I1
M=N64A'(8 @A3SP:MW>K65C=VUK<2E9[@,T:B-FRJXW,< [0-RY)P!F@"[16.
MOBG2'@$JW$C!G5%06\AD<LI8%4V[F!4$Y (P"<\&DNO$VFVZW06<-+;Q/(0R
MNJ'8 6 ?;@D9&0,D>E &S163/XAT^-8Q'.CR/*8@IW+RLRPOVXP[@>_TYIJ>
M*=&D\_;=L?).&_<R?,=_EX3Y?G._"X7/) [T ;%%4(M9LI]+&HPF>2V)*C;;
M2%R0VTC9MW=0>U07NNQQ:;97EC$+Q;V2.. ;]@;>"022..!Z4 :U%8$/BNS8
M?Z2C6K()5EC?+.CI(D>T!0=V3(N,')W#CGB34O$]E8V5Y+&LLT]M9O=&'R77
M@(7"LQ7"$A3PV#[4 ;=%9,OB728)YH9KORVA5VD9HVV#8N]@'QM+!>2H.0 >
M.*E_MS3PA=YGBPBR%9871@K-L!*L 1EACI0!HT5CMXHTA5E;[1*PCF> [+>1
MLNF=X7"_-MVMDC(&.:@\0>*;?0[:SN-L4T=UN*,TZQJ0$+\,>"2!P.] &_16
M2/$FEB1(Y9VAD9 ["6-E"'9YFUFQM#!,MMSG'.,4S_A*M)^R371EN!# ^R5F
MLYAY?RAR6!3*C:P.X\8/6@#9HK)E\2:5#+/&T\C/!*(7"6\C_O",[%PIW-CG
M R0.3Q5.Q\86-S9175Q^X66&&1$0/(Y,AD"J%5<G/EG&.3Z#N =%160OB?2'
MEM(DN6=KL(8MD$C#Y\[=Q"X7.UOO8^Z?2JMUXJAM?$Z:*;?>[&-=RRKOR^[!
M"=2HVG)'2@#H:*RHO$FESQ2R02S2B,*Q$=M*S,K$A64!<NIVG#+D<'FEL=<@
MU">Y%N \$4$5Q',K<2+(&(P,<<#]: -2BN=T?Q=::GI=K?2>6BW;*L,=O(;E
MB2F\A@B_*0.OIWJ>/Q7IC65S>.+R*"VGD@D9[.7@H2&;A3\ORD[N@[XH VZ*
MQE\4::9KZ)OM*-9W"VS9MI#YKL@<"/ )?ANW.!GI@F6_UR"UT$:K;(UXD@3[
M/'$<&9G("*,],DCKTH U**QU\3Z2RV)\]R;V.*2$+"[\2<)N*@A<D$#..A]*
M0>*M&,32"[8J"@&()"7WDA"@VY<,5(!7(..* -FBLC_A)](V(ZW+NK0?:,I!
M(VR/GEL+\GW6 #8)*D=13[W7K.UTG4[^)_M"Z? TTJQ]\1^8 #TR5(/XB@#4
MHKGK+Q?83V4MQ<9B\N=H!Y&;A9"$#ED* [E /)QP00>E3#Q18QKJ$MP72VM)
MQ'Y\:/*K*88Y=YVJ=J@2=3QQG- &W16+'XFLY;Z:U598V@O/LDC3QM&I;RC)
ME21AA@>H]>A&1?%>C/#YJW,A!9%5?LTN]]X)0JNW<P8*V" 0<'% &U16%>>*
M].ATN[O+5FNF@L&O@J(X5D"LR@OMPI.T\'GVIY\4:9Y8E$^(5:19C(CHT>R/
MS#\I7/W<'MD$$9H VJ*IZ?JMGJB2M:2LWE-L=7C9&4D CA@#@@@@]"#Q4,^O
MZ;;S744L[*;49F81.40X!V[@,;L,OR@[N1Q0!I45BR^+=%@A666[= ?,)4V\
MFY!'MWEUVY0+N4DL!@$'I5>/Q7$^K7MK)!Y,%K=?9?.DWJ780&9B 4P0 .S'
MCGN,@'145AMXPT-(XG>[D5945T)MI>59BJM]W@,PP">N1C.1FU;:_IMY+!%;
MS2223!BJB"3*[6*MO^7Y,,"/FQR"* -*BL^YUJPLKHV]S*\3[6?<T+["%4L0
M'QM)"@G .< \567Q5H[V_GK<R%3*(@HMY-[,4WC";=Q&WYL@8P"<XH V:*Q[
M;Q%:2>']+U:Y#PC4(8Y(X8T:9]SIOV@*,M@9/ Z FG2>)M(AEGCDN]ODH[NQ
MB?9\B[F ;&"P7DJ"2,'CB@#6HK)B\2:5-L$<\K.\WDB,6\F_=M#<KMR!M93N
M(Q@@YYI'\3Z/'Y^^[*B$X8F)\,=XC.TX^?#D*=N<$C- &O16'_PEVD_:(8M]
MQLE@GN#,;=PD:PL%D#DCY""3P<8QS@D9L7NOV=CHZZI)'=M;M(D85;9_,RSA
M!\A ;J?3Z9R,@&I16=%KNG3:B+!)V^T$E0#$X4L%W%0Q&W<!R5SD<\<5G7/C
M"RM[J6 6]V3!?+93$V[_ 'FCW@IA3O[# YYST() .BHK*3Q'I,LELD=WN^TH
MCQL(W*X<D)N.,*6(( ;!)&.M5[CQ-!:Z_=:=/$Z0VMM%-).4D.YI'*(B (0Q
M)'8Y). #@X -VBN=N/%ULDL(M8C/')L&XDH59KA("I4C(*EB2#@_+CBKB>)M
M(DF:(7>&#A 6B<*Y,@C^5B,,-[*I*Y )&: -:BL<>)M,F2%K2ZBG\V14&"0.
M9?*)SC^\"!ZX/UI(?%>C3PO+%=.RH$.!!)EPY*KL&W+Y((^7/(- &S16>NM6
M3Z5%J<;3R6LP#1M';2,S ]#L"[OTJ#_A*-&\Z*(7F?-4.LBQN8\%#)RX&T?(
M-V"1QS0!KT5BMXKT9(!,UQ* 9/+"?9I?,+;-_P!S;N^[\V<8Q4K^)-)1F'VH
MLJ(KM*D3M&H8 KEP-H)# X)S@YZ4 :M%9]QK>GVUE->2W&((9O(=E1F_>;@F
MT #).X@<9YXJEJ'BO3[*SOI(V>6>UMI)_*:-T#E(_,*;BN V,97J.XXH W:*
MQ]2\3:=I<=XUQ]I+VMN]RT:V[Y=$ +;"0%8C<,X/&><4K>([&-G\UI$ ,81!
M#(97+J6 \O;NSA2<8)P"3C% &O160OB?1WN+>!+S<]PD;QE8W*XD)"9;&%W%
M2!DC)&.M5[KQ=I]NEE,@FEM;F9XO-6"0_=C9]RJ%RX^7JO'?/% &_16,_B;3
M8BQDFRAD2.$PH\K2EH_,&%52?N@GC/ JU9ZUI^HS+%9SF<M$LP9(V*;6&5R^
M-H)!!QG..U %^BL6?Q3I=EO^V3B(J\H^1'DPL9 =FPOR@;ADG@9ZU:N]8M[+
M5+'3Y8[AIKW?Y;1PLZC;C.X@?+U[T :%%<[I/B^RU?2[&ZB'ERW"VY>&0.I3
MS1E<$J-XR& 8<':>:NR^(+/_ (1R[UNW$D]K;V[SC]VR>8JIN^7<!D$=".#0
M!JT50O-:L-/FBANIRDDH! ",P4$A06(!"C) RV!44OB+3('N$EFE1X"H=6MY
M 6W/L78-OSY;CY<\T :E%9PUS3VOX[+SF%Q)@!3$X 8KO"DD85MHSM)!QVI)
MM?TJWNC;37L<<PD:(HV0=RQB5A^"$-F@#2HK#7Q38MJ$%GLF=KB<P1-%"[@'
MREDR_P OR<..OU]</\/>([3Q#813PAXYC!'/+ R,"@<'&"0-PRK#(X)4T ;-
M%<POCK3#]CF>.ZAM+F&XE,LUO(IC\IHU.5V_=_>$EN@V\^VS'K-A+J3:>DY-
MRI(QY;!20 2H;&TL 02 <B@"]17/Q>*[8W^I07$,L4=I=+:1D0RO)/)Y>]MJ
M!.0!G[I;@9.!C(/%5O)J,$$$:RV\[Q!+@2?*5DBDD#=.F(_U]J .@HK(M_$^
MCW141W>-Y4+YD3IN#*S*PW 94A'PW0X.#2)XFTRX^Q-:W4<T=T%=7&X?(T4D
MBD<<DB-N."!^ (!L45BQ^+-%EM3<QW4C1[E4 6\F]]REP53;N8%03D C )[&
MK,NNZ?!9V5V\S^5?%5MML+LTA92P 4#=]T$].U &C166GB'396G6.:61H02P
M2WD8L VTE,+\X#<';G%%AKD&I:@UO;#?#]E2X67D$[G=2I4@$$%._/;'% &I
M160/$^D%)&6Z=@A486"0E]S%5*#;EP2",KD<41^([*6XOX1%>[K)D60BSE.X
MLJL-N%)/##CK^'- &O16)'XLTF2XEC62;RX[2.\,Y@?RS&Y8+AL?>^4\=3G
MR00-*RO[?4;<S6SLR!BC!D9&5@<$%6 (/L10!9HHHH **** "BBB@ HJO?*S
M:?<JH)8Q, !U)P:X?0[GQ#);Z981SWJ6^;>.6XFL?+>+]Q*TB ,H&T,D0#$'
ME\9- 'H%%>>7U[XBOK>6)(+F>7>KR6\ML8HX)$NXO+5'"Y92F\D_-PN> <5=
MMM5\1S:KIT3"6*%HX6E\ZU9=[EV$RD+&P&T !?G4="2X.: .VHKC;"^UZ/\
MX1][V:ZF:\C5[J%+4(8V8+P?D("KSD%E;OSP*LOI-OKFL:]:ZAYG#0JFQL'R
MC"0/PW/-^- '4U%<P)=6LUO*,QRH48#T(P:\?N_^$EL/&6M7NGV^I221RWK1
M*()]A3[*#$V3F)U\Q<! -VXYZ<5O'5?&%KK5C:22W4[%K0@#3L17"2.?M!=P
MN(S&O &0>!G<30!L#P4WE1W9O6;58K;RT<A3&)/(,.?N[PO.[:&QDD]:ZFTM
MH[&R@M8N(H(UC3/H!@?RKQS1-6\;Z9X0T^Q^R7=HT1AB+&S=A%#Y#%6R(W8L
M9!AAM.W '&=U;%Y<^([T1-KDY6Q&L:= T"VICC8%879PS ,5\X[<'IR#SP #
ML_$/A+3/$TT3ZCYA,=M/;(JD# EV989!(8;%((Z&L6_^&]E(FKSVERYOM0M)
M8B]Q%"W[UX?*WE_+\P9')"L!DGCG%8L-_JVHZAHZ:F+AKM-<:".5H#"DD#6\
MI<(K(C;0 ,[@<,!\QKJX],@T;7M$M;'?@K<[PS9/E[4)/_?8C_.@"/2/ MGI
MMY:ZA-?7MW?PS><9I63YCY!@"D!1\H4G'?/))JI%\,='M]+O=.@GECM[K@C[
M-;,R+N+;=QB);D\%BQ&!@@\TVZUCQ"VL7T%G%=K" RH9;7<(V6>) 5^0 @HS
MM]YB0,_+TJEKUUK\NE7FGS/?LOE74<<D5EO:Z8/A%?:N%&PYR-N>O8B@#2'P
MVT1;J\=9IP;NW:&4,L+O\T/DEQ(R&0';Z-C.3CDYNOX(L#=I=Q7=[#.EU#=*
MZ,APT</D@8*D8*$@]\G((JE<75V]U/JT#SQ6]S>_8FN+>#S9(K>%9/F"[6ZS
M[AG!^5@?<7O#EQKE[<F75&DAC2UA(A, 0.[;MS$D9!X7Y01C)!SQ@ SK?X8Z
M5:Q78BO]06:X>!Q/F+>C0RF5&SY?S'<>2^XD=:FN_AUIMTUPRW^HP-=?:5N3
M$Z?OHYV#21G*'"DJ,$88<\UCE/$$<9NH+O4I;VRM]6(::U#%V$L1BC^X 58*
M",<D9"D8XNWM_P"(Y[G6(FB/E1B58[;R';<H*^6RD1X)(R3\YZ]!@T ;$/@S
M3[:[6ZMKBZAE2XGN(RK*0CRQB,X!4\  $9[]<]*T-1T?^T);.87UU;3VA8I+
M"(R3N7!R'5A^E4;>ZU2+0]7O[IKJ699;K[/;QP*&5$D=8]@QEBRA3SG/&/?E
MI?$VO1_9K>>XN+8!Y6DN3;9Q$LD8#OF(87:TGS;%!('. : .EG\$Z?<ZA=WL
MMS=--<QR1D_N\IN*-D-MW'!C4@$D#IC'%6W\.0SEWNKRZN)I$A1Y7V D12F5
M>%4#JV.G0#OS7/Q:GXIG:[!+0N;J.+8+9F,*FZ5-RYC"D>46))9^@/ R*3[1
MX@2[,DM[?1NMK>0Q;K0M$[QSLL;N%0X8H%;(X/8$9! .M?2;2365U61 ]RD(
MA0L 0@R3D<9!Y]:R;;P5I]M=3W N+IY)I8I6+;,YCF\U<D*"WS'&6)..]0SW
M5Q=Z/H$ETEPBRZA$+@7"A6X+%"<*O!D6/'RCJ.!TJKKN@SVVFIHVB1W?^G2F
M6>9)=AC6.-54A^@.Y8N.X#>] &AK7A--3LM1@CN95^WW4,[AF $6W8KE"!D%
MHU(Y)Z]LFK/B'PO9^)+)+2ZEFBA5'CVQ!""K+M/#*P! Z$#(['FN5'BK7KK4
M%6-);>:.(*UH\'[N2?[.7\HN4.',A7'S+E1TY!-NVO?$]U:1*+N9-[2$RK:'
MS%"Q!@I#Q(/O\?=Z'&<\T ;EQX4L[J.\MY[FX>QNIEGDLVV&/>'5S_#NP2G(
M)(^9NG&')X7M%7:]U=RG;:H&D<%MMO,TL8SCGEL$GD@#ODGG!/J4MRQU*6\$
M4^HV,AAEBVQ1H4C.%.W_ )[#:5S]1R29X[R_N[BP6\\][A-6,<<C1&-'C:&3
M<%!16P%SD'."/O'% &H/!EE]EEMFO+QD^SM;VV60&U0L'_=D+U#*A!;=]P>^
M767@S2]/WBW,ZHTT,JJ6!">5RJCC[I)9C[NW-5)M-@T"_P!(@TYY4(2Y#L5,
MC"(1#)VCD_.D/'<_6NJA8M!&Q8L2H))7:3QZ=OI0!S=GX'T_3K2."RN)K<PR
M1O!+%%"KQ[ R@9$?S_*[#Y]QY]>:I)X*N+37K2YM;E'M8(XHLW!5GVJSELCR
M^21(P#!EQGH><]I10!RT?@/38=%DTJ*>6.W?8-R00!PJ@A1N\O)(SD,?F!&0
M>N=NXTFVNKR.XFWL4MI;7;NX9)"A;/?/[L=^YJ]10!S5KX+L[&VMXK2[N+>6
MWD$D4\4,"N,(R8.(\-\K'[P)[TK>"M-:346WR#[>DBRXCBW R#YB'V;^>3@D
MCD\8P!TE% &&WA33VOKZ[WSB2\F@F90PVHT3JXVC' 9E!;U]JHZOX-2ZTL06
M4[K,A(7S' !5KA)V&=IP<I@'! [@UU5% '/P^''G\+V^DW]QAHWW[K=$VX#E
ME4@IM88P#E1G&<"IO^$:MUT/3]+@NKF!+!D:":/9O!08&<J5[^E;5% & ?"5
MEY17SYS(T<T<DD@CD,OFNCNS!E*DDH!C& #@ <8C3P?;1V=Q9IJ%^MM<VGV6
M>/<A\S]WY>\DKD-MQT('RCCUZ.B@#";PM;&Z>87ET$,DDT<'[LI%+(A1G&5)
M)PS<,2OS'CIBJ/!%DMO#!'?7L<<:['5#&!(OF^:%(V84!B0 NW XKIZ* .?O
M/"&GWMK!"[29@N9[E'9(Y/FE9F<;74J1ESCC(P.>N;M]H%CJ,=M%=)OAMT>,
M1X 5E9"A! 'H>V*TZ* .5N/!%L1=SP7+M>SVQB,UQ'&Y:3R?*#E]F\' &0K
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M >,KF,PNSHRY!&<N<YR".U:U% '/IX1L5V%I[IY XD>1F7+OYZSDG"XY=0.
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M>>2(YC>6)6*'KP2..@_*K-% !1110 V2..5=LB*Z@AL,,C(.0?J" ?PIU%%
M%8Z=8F^%\;.W-X!@7'E+Y@&,?>QGI5FBB@!LD<<J;)$5UR#AAD9!R#^8!H:.
M-W1V12Z9VL1RN>#CTIU% #3'&95E**9%4J'QR <9&?0X'Y"G444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLT7G/Y;9 !.S.W) '.,^].FT/3KB?SI(&+&87# 2N%>0;<,R@X;'EIC(.,5
M%70?%%EXB>46<<H1$617?:5=&) (VDX/&<'!P1QZ8&D^/I)[:U?4K5(IC8O=
MS10Y)8'R3%LR>0PEQS_$I&>#776&EVFF!UM$DC1_^69E=D7KPJDD*.>B@"JS
M>&M&98PVGQ'RK,V*9SD0''R9]/E'N* )M,U1=26Y4V\UO/:S>1-#+M)5MJN.
M5)!!5U/![^M+J\US!ILLEH\:S@J%,B[EY8#D?C19Z196)5K>-PP9F+M*[LS,
M "6+$ECA0,G. !BFZSITVJ6/V:&\:URP+.J9) YQU&.<'\*TI<O.N;83V(M/
MU%[FZNC*ZI#'"CE&&#$V7#J3WP4ZU%<7MS#H,M\9Q#-,X:$2KD1AB%0$=N,$
M^A+53?PSJ3BX_P")Z ;D*)B+-,R!> #SZ<?2I9]"U>Y>%Y?$#%H7\Q-MJ%PV
M,=FYX)X-=?+0YKJ2MIT?3Y=6+4U=+O?M^GQS%D9P2DA3[I93@D>Q(R/8BJ.L
MZ\FC74:RQR21FVDF*1Q@GY9(DSN+ *!YN3D8P"<C',$&A:O;R3R1^(&#3OOD
MW6H;+8 [MQP ./2KJ:,)HU.I7#W5RJM&MQ'F!E1BK%04((Y1><]JYZT()MPD
MGY:_Y#5R&]UP1?V1)&56&\+2RL2'VQ+$SG!4D$Y"C()&"<5F7?C&>U>TNFTB
M\6RDLKB[D0^49 D?E$/]_&-KMD=<XXK;DT2T,>FQ1((HM/;,**,C;Y;1E3GJ
M-K'\0*CB\-:3#;FW6U+1&&2WVR3.^(W"AD&2<+A%&!TQQBL!F?+XYTR.[N[<
M0W$GV?>NY AWNI * ;L@DM@%@ 2#STR^#Q+(WBH:/<6<L4LMK%/' =A=,O,'
M9F#%=N$CQ@D_-TZXT'\/Z9(;K=;L4N@1-'YS^6V<9.S.T-P/F S[TL>@:9'+
M%,+=FFBVE)9)7=QM+D?,22?]9)WY#$'B@"G=^*[6SO)H9+2Z:&&4P/<*$V>:
M(O-V8W;ON]\8R<9JG)XZL88%::QNX9G=52"1HE9@T9D#9W[0, ]3G/&*V)O#
M^ESWLEY+:[II,E\NVTL4V;MN=N[9\N[&<<9I)O#^F38+6Y5U*E9(I7C=2JE1
MAE((^4D<'D'F@"MIVN/>:A<0B"62)EMYX2$"LD4J'&\$CHR-GOR!CBM2_E>#
M3KJ:,X>.)V4XZ$ D56AT:WBO)[HM(\DCQLN7/R!$VJO7D<L><\L:OR1I-$\4
MB[D=2K#U!ZTXM)IL#-NX;JUM_.74[IRKI\K)%@@L 0<(#WIVO:I)H^E->16C
MW3B2-/*5@I.]U7J2!WJ3^R;4D;FNF (;#W<K#(.1D%L&I[RS@U"TDM;E-\,@
M&X!BIX.001R"" <CD5<Y1:5OR2_(2.<7QBMG=:DNIVD\-M;RRA)P%*XC@65E
M(#$EL;SG&.,9JPWBI+CPOK&K6ENRR:?#*_ES%65F6/>.48@CD X/7(K2?0]-
MD5EDM$D#.SL)"6W,T?EL3D\Y3@YIR:19IIL^G%)9;6=621)IWD+*PVD98D@8
M[9K,91U/Q39:5J5O831RR3RJCGR]OR*S; <$@GG/"@G /MF#_A,;,1[S:W"C
M[8;1@[QKL;GE\O\ )G' ;!.5P.:OQ^']/CEAE5;GS8>%D-W*6(SG:Q+99<_P
MMD=>.::_AK2Y4E62&9Q,V9=US*?,&,;6^;E.3\A^7GI0!1G\9V=NL\CV5[Y*
M+.8I $(G,+A'"C=D')XW 9P:GGUV?36CDU&T>.*[G2*!-R Q90$^8Q;;G=D#
M!.> ,U8_X1O2/-GD-F"9PX<&1BHWL&?:N<+N8 G:!D\FK5_IMKJ<2Q7:.\:G
M.P2,JM[, 1N'L<B@#$\4>*X_#MWIT)>V F??/YTFTK"&5&*\\L"X./16IMQX
MZTZVO+VW>WN"+,/YDBM'C<KJFTC?E26< ;@ >3G S6[/IEE=/<O/;I(;F 6\
MV[G?&-WR_3YV_.L6U\&VMO>73R7,TMK/YNZV)(!+L&RQSR5(^4@ CU)YH 8_
MCBS6W28:?>NOERRRE/+(B2-E5F)WX8?,"-N<CWXJY;>('EL=9NY[&2"/3994
MR74^:$&<C!./Q]:MMH6G/ 8I87F4PO 3-,\C&-R"REF))R0._:I4TNS07@6(
M[;TDSJ78JQ(P3@G R.N,9[T 9-OXE6%5M;Z,_:XK!;J9]\<:.=N6V;W' /?H
M.,FJ3>.K4&&[V,MEY%P9%RA?S4FAB4!@VW!,AYSCD9(YK67PQISVL,5VLMVT
M=N+??+*W("A2P4':K$#[P /O4@\-:0(3$;3<I5U)>1V8[V5V.XG.2R*<YSD9
MS0!3M/%]G=S6<2VUPANO,"M(4"@H2" =V')QD!<\<U57Q[8?98II;*\@>=()
M((YC$ID2579&SOVCB)\@D'CIR*V3H5BWD%EGD,!S'YMS(XSDD$AF.X@G@G..
MU4M.\':1I^EPV0BD<QI$OGF9Q)F,$*58-E,9; 4@#<WJ: (AXRMG@EGCTZ_>
M&*VBN)'VH-HD.%4@MG(P23T !.<5*OBNU>XB1;6X>%G@C>X1HVCC>8 HI(;)
MSN7E01\PYZXT?[(L_+E0+*IE1$=UG<.0GW?G!W9'KG)[U!%X;TB">":*S"-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44@96+ ,"5.& /0XS
M_44M !1110 4444 %%%% !1110 44FY0X0L-Q!(&>2!U_F/SI: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **;O4_Q#\Z=0 4444 %%%% !11
M10 444$X&30 44@92<!@3]:6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1134D20L$=6*-M;:<X/H?>@!U%%137,-O)!'+(%:>3RX@?XFVEL?DK'\*
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MR".4)7D8YP>*[VBH&<S+HMZGA*UL;<-+<P7<-P$N)AG:EPLI3<% &%&  ,#
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M8E4Y&."&#'_@585GHVL?8],GM+:**6/2%M)([QR%C=8F "@ ,IWE02#@J/4
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MC8['C9)0N3CY2?-08_V2><5V$1=HD:5 DA4%E#;@I[C/>GT4 %%%% !1110
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M9+$PZW^X[YY-B4WRN+2TTDNF_P!QZ!17 0^-M?$J&?1;1HB\8(BN#N/F1ET
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M+2+=!)L00R7/[S<\8<-C'W0#SQV;GBJEKXD\1&*TNWL[:93:1R3 7& V6QD
M#AN>?3%'MX_TAK*Z_6R_[>77YG>T5R.HW_B275HK>TL3"_D&0*MS&4R&'+97
M)'; YYJNOC#69)[J&/2+9F214B/VGCF7ROFXSU]A^(INM%.SO]Q,<MK2BI1<
M7_V\N]NYVU%<8NO^($O9XKFPMW,=VD8CAN ",Q!L=#D'.<^O':H4\8ZXVDO?
M/HUJD8*N&-XAPA!/W0<DC'L?;C%+V\?/[A_V77>SCT^TNNW4[FBN:U36=6BT
M>\GBT^*,Q(V9%NU;RR!W&.OM5>7Q1JYU:"UMM'MY8V56=Q?)@AF*C:>.A4YP
M#5.K%?\ #&<,!6FKJW7[2Z?/S.MHKBAXNUGR]S:7:?+="*3%T#A3MQC'WOO#
MD9ZCCKA1XNU@F3;I-JVX$QJ+KF/$BQXDXX)+>W0]<5/MX?TC3^R\1Y?^!+_,
M[2BN8U#7M<T^&U:72;8%W593]J!ZX!VCKU(]<9Z5FQ>)]=M+63S].@DW&1H7
M:YR>)MF&X]64#ITZ]Z;K13L_R)AEM:<>:+6NGQ+_ #.YHK@U\1ZW>>3.MB(]
MQ@4HET-N?M.QL<'AL%>IX]:T+WQ-J]IJJVG]E6HP(2T;78\Q_,<H-O'J*7MH
M[C>65T^72_JO+S\SK**X>'QMJ9CN9Y=)@^S6YC=W2Y'$;EE!Z'NO.0.,\5>N
M]:\0Q#2V_LRV@\^8+(LEP#G*,VWIP>/S '>FJT7M^0I9;7B[2LO^WEVOW[?F
M=517*:9XEU>_N2@TFV</&956.Z&Z,!L;7XX;\NA]*S1XC\2*J7#6=K(T*7;2
M()\*5C=<Y _B'('^]GZIUHVO^@XY96<G%M)_XEY^?D=[17*6OB36[K6)K5=#
MB$,9*9-X@8, #G'7'/IZ'-9TOB36;34;F0P+($>93;&Y0A0L>\' 7< ,'GOD
M#N*'6BM?T".65I/ENKVO\2_S.\HKCY?$VN6]S'!-I5F''EET%U\S^8Y5=G';
M'/\ 2J<'BW6HK JNE1RS"41 RW(!R2QW'.!MP,#GJ".O%'MX?TAK*Z[5U;_P
M)?YG>45R/_"1^('25TT6T7RH$=E:\4_,_3!^Z1P>_/'-+-X@UQ[+2[J#3[9(
M[F10S//\K@J3@9'R\C^5/VT?Z1/]G5NZ_P# EVOW.MHKA8_%&O65E(TVE13Y
MWM"WVH9'[[9\V1C ++Z< U:O-=UT^'TNWTR"VD\^(%_MJ[?]<JD$C. >AY.
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MVJ[JGB?6;#2[>Y_L>W2289"M=JPX0L1D8'0'G/YT>WA:_P"C$\LQ"DHZ7?\
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M?^!1_P SM:*Y:QUS6I+V_CGL+4K'.J1)]J567<BL >.<Y_GZ54U+6_$27MW
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M7$S:#')=23+HVKH&N/, $BY"F(1D?ZWKGY@?PZ5!9^&+>&*VCG\/:BXCF#R
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MP1041E"E5*CL1Q3J* NQNQ",;%Q@CIV- C01B,(H0=%QQ^5.HH"[&JBH %4
M 8&!T%(L4:*%6-0H.0 *?10%V,\F+<6\M,E=N=HZ>GTI);>&=6$D:MN4H<CG
M!ZC-2446#F>]RG;:79VB.L<18/MW>:[2$XZ#+$\"K>!QP..GM2T4DDMARG*3
MO)W(_(AV,OE)M8Y8;1@GWIS1HZA616 Y (SBG44Q79272;);PW0B/F%B^#(Q
M4,5VDA<X!QQTJV8T9U<HI9>C$<BG44DDMARG*7Q.XSR8MK+Y288Y8;1R?4TI
M1&3854KZ$<4ZBF*[&A$5F954,WWB!R?K1L3GY5Y]J=10%V1RPQS*0Z\X(##@
MC/H>HK,_X1RSW%OM&H[F&"?M\V2/^^JUZ*3BGNBX5JD-(2:,3_A%=.WQOYE_
MNC!"'[;+\H)!./FXY _*G_\ "-V6YF^T:CN;J?MTO/\ X]6Q14^SCV-/K=?^
M=_>9'_".6>_?]IU'?_>^WS9_]"IH\,V(*D3ZA\GW?].E^7Z?-6S11R1[!]:K
M_P [^\R&\.6C?>N=2/&.;^;I_P!]4?\ ".VAS_I6I<G)_P!/F_\ BJUZ*?)'
ML+ZU6_G?WF/_ ,(W99S]HU'.[=_Q_2]?7[W6A?#=DF=MQJ*Y.[B^E'/K]ZMB
MBER1[#^M5_YW]YD'PW9LH4W.HE1T!OYL?^A5%_PB>F[]_F7^[?YF?MTOWMNW
M/WNNWCZ5N44>SCV!8NNMIO[S'/ANS9E9KC425^Z3?S<?3YJ!X;LE+$7&H@L<
MDB^EY/K]ZMBBCDCV#ZU7_G?WF0?#EF00;G4<$8(^WS=/^^J0>&[-5"BXU$ #
M  OY>G_?5;%%')'L+ZU7_G?WF.?#=F5=3<:B0_WQ]OF^;MS\W-(OAFR3;MN-
M1!1=JD7\W ]/O5LT4>SCV']:K_SO[S(_X1VTVA?M6I;1T'V^;_XJE_X1VUP1
M]JU+!ZC[?-_\56M13Y(]A?6JW\[^\R!X<LU "W.H@#IB_FX[?WJ1?#5DGW;C
M45YW<7THY]?O5L44N2/8?UJO_._O,@>'+-79UN=1#-]XB_FR?K\U(/#=F'#B
MXU'<!@'[?-G_ -"K8HHY(]A?6J_\[^\R/^$=M,Y^U:EG.<_;YNO3^]0OARS1
M2J7.HJIYP+^8?^S5KT4^2/8/K5;^=_>8W_",V.U5\_4-J_='VZ7 ^GS4O_"-
MV>XM]HU'<<9/V^;)QT_BK8HI>SCV']:K_P [^\R#X<LV0HUSJ)4]0;^;!_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&_LHH8;4.L@6-5/*N'Y# @Y(YR#FH[7PMI%O!:I):1W+VIS%+.BEU.\N,8
M 8Y   '8"@#.;QH#+=PQ6!FDBD@2$I+\DOFRF('<5 X9><;ACN3Q2W7C-+.[
MO+=[$R&WMI)P89-P8QLBNF2 H;,@Z$]#G;6S#H6DV\DCPZ=;1O(ZNQ6, DJV
MY3^#$D>A-!T+23<S7!TZV,TZLLK^6,N&(+ _4J"?4@4 8P\4W9U*"W?3XXT5
MKA+S,Q8Q^6J-E,#Y@5<'MZ5#'XY:2R@F_L6]66YD1+=&BDPX:-I,YV9R ASM
M# $CD@Y'2/I=A),LSVD)E64S*^P9#D8+9]< #\*KCP]HZVOV9=-MA!O#A @
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M#<.&:6(0R91!)LW*-F2#R1N"\#L>*T=6\0II6I6EHT/FB9XD<HQW1^8_EH2
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MCZGUH Y?_A,[R]@L&M=.,,US]DGCC>56$D,V_ )Q\I^0YZ\8QDY VFU2YO\
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M-/($5Y%B4X)RS'"C\214U !14/VJ 7@M/,'GF,RA,'[N<9_,T6MU!>VXGMY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *P8;758/$>IWR6=H8)[>&*+_ $D@
MDH\A)8;.,B0GOR/?(WJ* .>CLM4BU?6;D6=H8KF.-8!]H(+%,_>&SY<[L]^E
M7O#MI<V'AS3K*\2-;BVMDA<1.74E5"Y!('7&>E:=% ' ZYX.US4O%;>(+>]M
M$DM;BV-E ZDYBCSO!?\ @+>;,, '/R\^F=I_P[O=-GTR6"PTLO8WUZX8SO\
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MZ+J8\;OJS_9DM-KIF-L/(A5 H8;<DAE/5L=,#K73T4 <&N@ZQ<:GJ=U;VUO
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MU% '!CPGKHLDA2YA2Y.D+9RW33%V,BH!\AV;E!.<G)!X.W-;F@Z--ID<*O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\CL: -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR);6MQ%>>2)@P58412))5SV=#R,?*_OF@#MJ*13E0<@Y'44M !1110 4444
M%%1M<0K<I;&11,Z,ZIGDJI )_ LOYU)0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44EO#-+#+)&K
M/"Q>-CU4D%21^!(J6B@"(6T*W;W0C G=%C9^Y522!^!9OSJ6BB@ ZU5M]-L[
M06P@MT3[-#Y$./X(_ERH]OE7\A5JB@#/O]$L=3E66Z28NJ[1Y=Q)&,?16 JI
M_P (EI'_ #SNO_ Z?_XNMNBM8XBK%6C)I>K%9&)_PB6D?\\[K_P.G_\ BZ/^
M$2TC_GG=?^!T_P#\76W15?6:_P#._O8<J,3_ (1+2/\ GG=?^!T__P 71_PB
M6D?\\[K_ ,#I_P#XNMNBCZS7_G?WL.5%:QL+?3;<P6RR",L6P\K2'/U8DU9H
MHK&4G)W;U&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<_N/L>S+C_EV!$>>/<Y]?:@!NF^/-&O=.6YFG$3+9+>W'EI(\4,9!(S(4 Y
M. 0"?2K-MXST.[N+:W@N)VN+B5XEA^R2B163;NWKMR@&].6P,,#TK+;X9:%)
M!!;S/=RP06+6$:,R#$;+M.6"AB>^"=H/.,U87P!I@AL(FN+ADLKH72;8X(]T
M@*D$E(QC[@'R[21D$D&@#JZ*KV-J;*SCMS<3W&S/[V=MSMDD\G ]<58H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWY/F?&?EX' ^;F@#KZY^"QUE=;U'49X+&20Q-#8D7+@(F<JK+Y?&X\LP)Z
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MR^6=A5#NR<D;M@]2* *]SX5U&YUJWNTBTVT@BC*".# *J8'C\O(B#, [ YW
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MJ[1N4X<[B<_,.,=+=GXKDEOK:SNK!(9K@PE3'<>8H25)64D[1\W[E@1[@Y-
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MSDDB=<-A#@JSY[YP>E4H_"&M>=I_F266+:S%N\J/AI!]E:,JWR;F'F$-]X#
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M\$R$#' &35?3/!FL6/B33-09[1U@FNFF=Y2_[N2::10B&/*OB1 6#CN"" *
M.T?1],DGFG?3K1IID,<LC0J6=2,%6..1CC![4EI/IM^VH1VPBD*3F&\7R\9D
MV+D-D?-\A09YXP.U<!K?@3Q%J>OZO?6]U8VR74$\,;1R%&D5@FQ7PF[^%@27
M; ;Y0.<UT^&VL+ XMGL-.%W?2BZM[>=V1;*580Z*=HRX,7' 'S'ITH [VQTK
MP_<6Z_9-+LO)@G;:!:JH253M) ('.4 S_LCVJ:?2=&A@O)IM.LQ',I>Z)@4^
M8!\Q+<?-SS]:X9_ >NC48Y[>ZM8G$E[_ *0TI?RDFDE=-B%,JXWI\P<="""
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M'=L608(!(Z,!@@?C7,Q^$=0'A?Q!IUQ)'-/J5R)E,=P4R/+B4Y8HW.8V."K
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MD7SV+,6B* *&!Z<[C@<<T ;_ /9FCW]J&^Q65Q;S*'!\I'20$EP>F""6+?\
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M_L\FFV;P;43RV@4KM3)48QC R<>F34CZ;826*V+V5NUHN-L!B4H,'(PN,<$
MU:HH K-IUBZ,CV=NRLLBD&)2")#N<=.C$ GU/6GVMI;6, @M+>*"$$D1Q(%4
M9Z\"IJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **SK[4)H;M;2TM_/G*>806VJHSC)/OSV[
M5%'<ZT7&^RM0G<BX)/Y;:=A7-:BN9TG4?$4U];IJ%E&EN\1+NJ[2KX''4X&<
MC\,UTHI#%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HJEJ%_]B$*)$TLTS;8XUQSZDYZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5>_\C!IG_7*
M?_V2C5+VXANK.TLA%Y]P^29<D*B\L<#G/8>YHO?^1@TS_KE/_P"R5!J,=Y%K
M,%Y;VYG MY(@,@!6+*03[<&ABZLFTS59-4)DCLG2URRK,SKDX./NCD=*U17.
M:1!?P:W=EK<P6;Y+*6!5Y<_>3T!')'K71KTH&+1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %>^O(=.T^XO;DL(+>)I9"JEB%49
M. .3P.@KC/\ A<'@_P#Y^K[_ ,%T_P#\17=T4 <)_P +@\'_ //U??\ @NG_
M /B*/^%P>#_^?J^_\%T__P 17=T4 >9WOQ/\*37B7=KJ6H6\ZIL).ESLKKG.
M&&T=_0BF?\+6T;_H-2?^".X_QKT^BG=D\J/,?^%KZ-_T&I?_  1W'^-:$?Q?
M\(A%#W=Z6QR1ILX'Y;37?44AV.$_X7!X/_Y^K[_P73__ !%'_"X/!_\ S]7W
M_@NG_P#B*[NB@9P@^+_@\D 7-]D_]0Z?_P"(KNZ** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CGF2VMY9Y"1'&A=
MB!DX R>!UKB/^%P>#_\ GZOO_!=/_P#$5W=% '"?\+@\'_\ /U??^"Z?_P"(
MH_X7!X/_ .?J^_\ !=/_ /$5W=% 'FVI?%'P?>K$T=_J,,\3;HY4TV8E?7@I
MR#Z5"/BMHP_YC,O_ (([C_&O3Z*=V*W4\Q_X6OHV?^0S)_X([C_&M%/B_P"$
M HW75\3W(TV<?^R5WM%(+'"?\+@\'_\ /U??^"Z?_P"(H_X7!X/_ .?J^_\
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MLY*$=N5QVK/EC\0B.RG@L+QAI.^Y8%F4S%IVW*%Q\Y\E6 'K** +O]O?$?\
MZ$G3O_!NO_Q-']O?$?\ Z$G3O_!NO_Q-)<[KC1+FSN%U".>'5+B8+)IMQ-%*
MAFD**P5?G0J0>#P=OIBNQTJ2672+*2>U-K,\",]N6W&)BHRN>^.F?:@#C_[>
M^(__ $).G?\ @W7_ .)H_M[XC_\ 0DZ=_P"#=?\ XFN[HH X3^WOB/\ ]"3I
MW_@W7_XFC^WOB/\ ]"3IW_@W7_XFN[HH X0:]\1LC/@G3@/^PNO_ ,37=T44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[>^(_P#T).G?^#=?_B:/[>^(_P#T).G?^#=?_B:[NB@#A/[>^(__ $).G?\
M@W7_ .)H_M[XC_\ 0DZ=_P"#=?\ XFN[HH X3^WOB/\ ]"3IW_@W7_XFNXA:
M1H(VF0)*5!= <A3CD9[T^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,'!^F #$7Q_:F"_E-H<6N3D3H1_KO*^<_P#+,YYY[9/8UTNG7?VZPBNL1#S
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MPRS10V\GG*X3@G>@(49(&3P"<5</AV!M"O\ 2&NK@V]XTQW?+NB$C%B%.W&
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M:(VDA\Q]CG<O&X-R1PQSR:[V^NX]/L+B\F#F*"-I7$:%F(49. .2>.@KC?\
MA;'AW_GWUG_P5S?_ !- %>ZM]9L=;NC;)>R6%UJUI#Y8+L(%3R&WKZ1E1(K'
MID#WK1\2RS3'3;>YMI[>]><,MQ9M-+'!&KJ68E5'S,!M ([GMFJW_"V/#O\
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MUG_P5S?_ !- '<T5PW_"V/#O_/OK/_@KF_\ B:/^%L>'?^??6?\ P5S?_$T
M=S17#?\ "V/#O_/OK/\ X*YO_B:/^%L>'?\ GWUG_P %<W_Q- '<T5PW_"V/
M#O\ S[ZS_P""N;_XFC_A;'AW_GWUG_P5S?\ Q- '<T5PW_"V/#O_ #[ZS_X*
MYO\ XFC_ (6QX=_Y]]9_\%<W_P 30!W-%<-_PMCP[_S[ZS_X*YO_ (FC_A;'
MAW_GWUG_ ,%<W_Q- '<T5PW_  MCP[_S[ZS_ ."N;_XFC_A;'AW_ )]]9_\
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M !- '<T5PW_"V/#O_/OK/_@KF_\ B:/^%L>'?^??6?\ P5S?_$T =S17#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>bionano-nancyridgeleasee002.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BD)"C)( ]Z6@ HHHH **** "BBB@ HI"0" 3UZ4I.!D
M]* "BD!!Z$''I2Y!S@].M !12 @YP>G6EH ***3(SC//I0 M%%% !1110 44
M44 %%%% !1110 444A(&,GKTH 6BBB@ HHHH **0$'H<TM !1110 449&<9Y
M]*0,I) ()'49Z4 +1110 44FY0P4D;CR!GDTN1G&>?2@ HI,C.,\^E+0 444
M4 %%'2@'(R.E !1110 4444 %%%% !1110 4444 %%%% !1110 44A(&,G&>
ME+0 4444 %%("",@Y%+0 4444 %%%% !1110 4444 %%%(2!C)Z]* %HHI 0
M<X/3K0 M%%% !12,RJ,L0!ZDTM !1110 4444 %%%-$B,0%=3GI@T .HHHH
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M)(I],MRL$Z QB0/)OR0BX;!0X.TG=TXPN<]_XG#7)C^W%@LWGH;1=L&)T"&
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M')/D/$),X5,@ =R!^'2@"CIEYXBN/$P2]\R"T^4^48&*.AA!)#"/ ;S">K]
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MMNQN.91LSNQSCK5"SCU6>\FDB;4I1/><7=Q9>3(H^Q2#< 4 7$F%!V^@YSR
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MKB'R9(=D9&WRA#PY7>/D '# >W)S>M/#\5O:ZA#+>7=TU^NV:68INQLV<;5
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M VC;'AB#@MC+=*UM)U>Y34KRUU-[EM]UY5I(UN41\^8P1044Y54Y)+#H0W.
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M <N<X&/:N<L4UJ.[M]0AFU%R;/3(9A/:X,V;B59=^4!!1'+<8(X)R.K[:_\
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MN7GC+)9W/EJCL# C97"A3AV8 X[8Y(S0 ^/PI:1:G%J(GEENXXT0O-%"WF%
M0I)\O*GG^ KT%3WV@1ZOX>BTK5+F:=@J>9<)A'=EQD],#=R"/0D5SEJNLQZC
M%J-O-J#J;;38I%GM0#,#/(LN_* @HK[N,8X)R*2/5/$CVD[>9>)-Y(>826#
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MD,)]\3Q0RQ-&K.\GF;\ (!NZ1L?P.<8ID7ABRADC='D'EM P"JBKF($+\JJ
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MC.X1&;&>WR#=GTH YBPU+7+RYTZ6YGOHX(]4:$E8/]=$;<,N_P#=KQYA*[@
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M;>U-OA2%MO,1MW4YD&W.<<XZU%;W^NWDT-M;7ER;62[5#?26(1POD2.PVLH
M =4 8C^+;R16M9^,-(OC9".29!=VKW:-+"R*L:8W%B>!][Z>_3-E?$>D.L1%
MZN99?)1"K!B^ VW;C/W2&Z=#GIS0!E2ZMKI\-6-Y+:BV:>.V:XEB5GEAW[?-
M/E%.-N2.K8ZD<&HDU;5VUJ&%'N7C\Z%$C>R*+- T09YF8K\C!BPVY&-H&/F%
M=1>7MO86YGN9!''D*."223@  <DD]A56/7]*D:-4OX2TBJZ#=U5@Q!^F$?\
M[Y/I0!R^F7_BDBQFNYI9 \5C++$;,)S,2LJDXR F WJ,\DC JI8ZMK&MV-JS
MM/<QM)832,+0Q")_M*[E4X&Y=@W$\XZYP0*ZX^)M'%LEP;Y!$^=K%6'  );I
MPH#*=QXPPYY%0S>)-"TNWNHDGC5;"*1G@@C/RB,?,J@#&0,<#H"#TH P;+5]
M9BO=$M5M[E$98Q<HT!V$-OR0=I((PN<LH&1P<TEOJWB2/3[=KV2<">WLIYYT
MLOFMC)YGFJJ@'.TH@Y!*[R3QC'73:M9P:>E]+(ZV[@%3Y3$],_=QGH">G:G6
M^J65W<O;V\ZRR(H=M@)4 @$?-TSAE.,YP0>] '.V&IZY/XI%O(P%@I4#S8'1
MIHS &\P#R\!O,)!!<  $;<X)JZSKGB:TUFXM+.R>6%7*)+]G)!\U (6R."%E
M#AO1<$XK=O/%6CV4-[(]UO-G&\DJ1H6)"$*VW^]@D XZ$\XHM?$^GW.K3:<9
M/*G1U6,."/,W1"3N.#@G@\_*?0T <_<'5?[1*M+>QV[KJ,?EQPDI*^4\O=\I
MP2-Y!XZ<=3G3\/2:M;Z9<6UW(\C06D+PRR6Y&&,?*X7E@I'3[W.,DUH#Q/HI
M@$POX]C2+&O#99F!9=HQD@@$@C@XXS4PU[2F8(+Z$L55MN[G#2>6./=_E^M
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MJI)+%; "2)[4MA@%/RB4A<]LC)R,UT)U_2P)2+Q&6)59V0%E^;;M (&"3O3
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MHV-IS@CCY@=IP1G.*S]+\7Z=?Z?974\B6K7JJ\4;%B0C'"%OE&W)XYX)X!-
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MR=E1I;:,L@R"=QW#Y0<#L>2 !R#0!;T/PXFB2[EO9[A4M8[2))%4".*,MM'
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M?P?#-!=+->2--=VUU!-($ R9RA9@.V-@ 'YDGFKE[X?CENH;RQG-G=QRO(9
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M[>6$'R[B^\L%SD'<<YSD'G.:BB\+1QE&-_<O(MPEP97(+LRV_D9)]2/FSZT
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M*"V!MFOS(4MXK6!WA'[J*,DKT(._G.X$<@8 YSL:;I+:;=7<HNY)DN?+9A(
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M#@XQ6AI6BC2;B5X[EGBDBB0HRC.Y$";L^X XH EDUS2X;?[1)J%ND.Q9-[.
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M,_+@9&3\PQOK8VJ0V\*V\8CMR#"@7B,@$# [8!-6* .$A\5:W9Z4FIZE'#)
MEG9WUPL-LRLB2^8KJ!N.2FU&^F[CD8W)[O6EM]!B)@AN[N0+>-Y1=8\1.[!1
MN&/F4+DGO6U<6T-W"8;B-9(B02K#(.""/U J6@#@K?Q7K<MK/-/]CMU$L<<A
M*%FLMTA5O,4-T"XY..>>G2X/$>I'5TMTEMY5\V.-85MF5IXFA#M<*=WRJ&)&
M.1\I&<D5V-% 'G6I:WKDFBV<=U=0PS75G#<_N[5PTKNZ[HD^;(*+R3S][)
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M -S#'7KD=2*KCQ?J[7=E$;41S26N^XMW@(,3_9FFR/FW$;@%Y4#.1G(KNZ*
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MK6ZGN((+B.26W<),BMDH2 P!_ @_C5;4=;L=-LGNI9E=5E6#;&P+&1F"A>N
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MW=LW#./7'I0 ^BJ=[JEEI]I=W-S<1K':1&:?!R44#.2.M20WL4EI#<N?)64
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M?)=&$BMA RN 1_M8P1V]#0!I-X=U2W\2:I>V%_;)9ZMY9NDEB8RQLB;,QL&
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MK>XOX+TAH\L2B*I4]B/D# ^I-4;?P.T&HV4[RQ30P+$NS<R>7Y4SRJ5 Z_?
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M<3>6FR+9E00#R=XQ[ GM4NB:Q<ZO<WQ:U2"U@=(TRY,C,8DD.Y<8&-^.IZ4
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MM^4Y<'C^ZP[9( Y/!MTIBG_XEHDBDA(M5A(MY!'%+'EA_>/FY]MB#G&:33O
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MO90T8MY7 ?@GJ%/'4BIM+\97.K7UE'!I9$$T-O+,QDYC\V/>".,$#@>_/IR
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M>OJ5ND31A4:*(.T9B9%8 *!Q@[N^,9;KFLCPUX9U>UL;8M#';W=I<13"2X0
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ME?;[]^* .AN9M)L9X)Y+>,2J(HH9E@SM$CB-55@, ;F' /0YZ5<,-F9GN#'
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MW!Q]*Y34/ CW$H6$V_V3S+C%J&\I467RSN4A6PP*-T ^^<$=[^G^%Y[3Q/\
MVDXLRBR7+^>JGSY1*P8*QQT3&T<G( Z8H V[>'35A:*&UABB4O%L,.P')&X
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M@*"1^[()+-D'MTJ"X\"7-PLC-'8)'+/-(UE"Q2)1)'$F0VP_,/+;G:,[SR*
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M?VW#"ZW>YF0;_D1F0(<#_= &.@[ 5KOIU@\YG>RMFF,BRF0Q*6+J,*V<=0.
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M'<_V:EC:*_D%O*6W4+Y>_)'3&-W./7FG30:1I+3:H]K;02,?WEPD(WL6(')
MR<G% '(I\1K^Y74Y+3P[)-%;-(L3>8PW&.<1,&&SK@EP$W'"D=:C'Q0!OX46
MPMIK)FMT:6"[)D8S0>:K)&4!91@@DD'OCJ!VDF@Z/,]P\NDV+M<X\]FMT)EP
M<C=Q\W(!YJ&U\-Z1::M-JD5E#]KFV 2% 3&%0( G'RC: ,"@#D+'XE7U_9V3
MKHD,$M_+&MJ]Q=-' 5:)Y26<QY! C(X4@DC!J.Y^(\NE)<&2%+MDOYT:-ICN
M2)9$3*;(MNT%^"Y'89.>.W&@:(+:6W&D:?Y$C^9)']F3:SC^(C&"?>GRZ+I,
M[*TVF64A1F=2\"':S=2,C@GC)H \[MO&^JV&IW<]V[7=C;?;&FC.%V1)?B+>
M"!SLC)..X%;FH>,-3;POHNLZ=9VD8U'4(X0MU,RJ8'<A&W!3@LNT].-W?%;>
MLVVA+I6IPW:PP1M93-<M"H$H@;)D88&>3D^Y]ZT3IE@^G1Z=):02V<:*BP2(
M'0!<;1@^F!0!YS:_$?4M*L;MM4L5NE#WCVLRS89Q'>B *ZA/E \Q.1N.%)QF
MNANO&5Y:^"9-=DTN..[28PBTFG9/-;?L4(=F<MQ@%1UYQC-;FH1:/86,L]W9
MV_D &-@+<.6\QQE0H!)W,1D=SBEAT_1+K3!916-B]C$^/LWD+Y<;#DC9C //
MIWH Y&[^)-Q9W%P)-)MVBA>6W(2\S+YT=L;@G;L_U?!4-GT..:JS_$6_25&N
M-.%O);M)(\$-R'29/L3W*!F:/(/ !QC!'4C@]Z-&TI9VF&FV8E:+R2X@7<8\
M8V9Q]W'&.E/;3-.<DO8VK$\$F)3GY=GI_=)7Z''2@#@+SXHWUG"\4F@Q-J'F
MA8X([IW5U:!9E (CSN.X+TV@]6Q79:IKL>F:!<ZB[6QEM@J2Q^:Q1)25&PE5
M9LY88 7)R..:KZ[X,T3Q"L8O+?88PP)A(3<&4*0W'/R@ 'J!T(JU9:-H]E:W
M.E0V2FWE_?31RH723=QR6R&^[C&> !T&* ./A^)US-9R70T1#':V5U>7?^DL
M"H@D>,A 4R22H/S;< G/3G9L_&,\GA2_UB]T^.S>UD"*)))/+ER$*D'R]^"7
MQC83D<9R*WH+/2K:7[+;VMG%((C^ZCC53Y;$YX ^Z3GVS4<MCHNEZ+=1-8V=
MOIB(TMQ$L"B/:!EB5 P>!Z=J .$D^+$\=FL_]CP9BBFFN$>\*'$4_DL(P8\L
MQX(!"^AJ:Z^*4]K+>@Z/!(D+7:1+'>Y=F@G6([UV?(&W@@Y/3\:ZJ#PUH-S=
M6FJII<*M%#LABDMPBQ@MOR$(^5L]^M36/AG1M-6Z\JP@9KJ6269Y(U9G+R&0
M@G&2-QR!VXH YFY^(5[8ZA+;76DVO[B<6<PBO"S^<;?S\JI09CQQN.#U..*K
MV/Q+O]0>UMK?1K-KN[FMEB"WY,82:&64%F$?#*(B"H!ZCFNMN(= OC+=S1VB
MW$D"Q/.\8294E&U5)(#+G. #WJ?3= TG2+.WM+*QMXTM]K(1&N[<%V[R<<MC
M(W=>30!Q-G\19XSI=J8$NY;JY,$C22L)(]]S+%&3LB";?D[D$@'@D9,.G?$O
M5GL=+6XT>"[O;J)YY1:RN0(UE$? V'#<DD$@<#GYN/0/[&THS13_ -FV1EA_
MU<GD+N3YMW!QQ\W/UYIC:%HSA-VE6#!)3,F;=#MD)Y8<<,<#GK0!R/BCQ1JN
MA>,'8*DFF6VG)*(!,$\R6681*7)0X4$CH>!D\]*LZ1XWO]6UZ#2$TJV$P>Y%
MU*MX6C187C4F,[,OGS!P=N"".U=1<#3)Y)EFB@GD.VVF7RO,.&P0C  _+SGG
MCG-26VGV%DL8M;.V@$2&.,11*NQ202HP. 2 <>U ''7'CB72H?$DMP$NI;/5
MH[.UMP=I".D(!;:"<!I"<X)[>E-'Q!U!7MDGT#R7GM9I(TDG8&:9/-Q$AV8!
M(B# OMX;IE2*Z74+308+M&O--M9+G47^SY^R"1YN,D,0"=N%R2>.*G70=%79
MMTFP&R(P)BW3Y8SG*#C[IR>.G)H XZV^)<UW?V%G;Z1]HEE1'NA$\@\K=.T)
M #1CE2C%@VWT!-6-!\6ZEXNB,]M9/86\)2Z20L3]HC#.&B;<JA6^4'() SUX
MKJAHFCC[*!I=B/LAS;_Z.G[DYS\G'R\^E$-KI%C?O!!:6D%U>J\KB.%5:8*0
M&+$#G!<=?[U '+GQE<WO@:XU?R39WD%Y#;S01/EX6:6,%6,D>,X?G ((.0><
MC)U#XE:P-.NY;72;.%A')+;22W3,&6*Z6W?> @P<MD8)XKT*'3-.M[+['#8V
ML5J&W>0D*JF<YSM QG(!H;2].>-HVL+4H49&4PK@JQW,",=">2.YH X>[^)=
MU:2:N?[#\V#3(Y?,ECG;:9(XPY&2@&TY(!R3P"0,\5M;^(VJ6^GZC9+IUI::
MI +M6D:]_=QB*&.0,C&/YG_?+A2 ,J><5WIT/1S*TITNQ,CQ>2S_ &=,M'C&
MPG'*X&,=*?<:1IET?])TZTFS)YO[R%6R^ -W(ZX &?04 <$GQ/N+>WO'?1I;
MB"PMV\VX#E2TJ0K)\WR;0K%L9!)'7&#5O3O&.HV^@>+=7U%+>X;3+PK'!;W&
M^)5$,1*K)M!(RS')'&2.U==)IVBQWB2R65@MU<*;=7:%-\BA3E,XR1M!X]!2
M6<&CBU^R6-K:BTN8V8I! /)D484YP-IXP,'J!Z"@#F9/B%C5%@2QB-B-3>PD
MO?/+*I'E;>%0\L92!G"Y7!89JSX/\;MXFB:>XT\6%O(D3VTCRG$N\L GS*OS
MC;_#D<\$X-;\>AZ/$8&CTNQ0P-OA*VZ#RVP!E>.#@#IZ#TJC+IGAZ+6;2V&G
MPQWCR&]400;070%?,D*C!QO.-W<\<B@#$UWXA_V-X@N=-6RBN4ABF)=)7#+)
M';F?:V8]HR!CAB1D'':L^Z^)&HK#+:'2K2WU L=K/?8B6/[-YX;>8_OX.-N,
M9'7%=Y+I.ESW37<NGV<EPZ[&F:%2[+@K@MC)&"1]"153R] U":*W^S6-R9HU
MNH\PJZLJX57!QC(R .^.E ',7_CJX\/^ M"U2>.*]O+G35NI4D=T:3;$KN5V
M1L!UZG:!D<U5UOQ_>BRN+NSMTBMK/58;8K%-YEU,%E19%\K;@!@Q .[/3IFN
M]N-)TV[@A@N=/M)H8!B*.2%66/C'R@C XXXJO+:Z+!?/--9VD=PQBW3O;@%F
M+;8QO(Y;<!@9R#CU% ')P_$:ZENK,?V3;/:2_8O.FAO"Y4W.[9L&SYL%>>1[
M56A^*Q6UBO;S2X8[*2&WNVEAN_,\F"9V0&0;!M<,%RO(Y//'/;V-MH\Z2&SL
M[4+%,4;; %Q)&Q]NS9P?<XIZ:-I,<-Q"FFV2Q7#;IT$"!93URPQR?K0!YX/B
M9=ZE'I]Q%8RV207L<6H1AP[;_+N"\&"O;RD;/&=PJPGQ,U"YTR!TT6&VFO#F
MWEGNFCAV>2TI.]H\[AMQC;@GG.*]!&GV*N66TMPS2^=D1KDR8QOZ?>QQGKBJ
M4FD:!:0"!M*L4ADE\TJMHI3S%4MO;"X! !^8_3O0!P6E_%"]CTV$3Z:;W['I
M,=W?7(D*NQ^RI,2 $V<E@N-P/4XQ6M!\0;XBP:[T1;6"XO/L\ER\LGEJ#Y>Q
M@/+W?,9-HW*JY7DX8&KVE^&O#-_JT>OV=M.'*K-&DD;1Q@-'Y0(5@.-@QMZ
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M@S-C+(!MQE>^6#=]N.:HW/C-K.2\>?3L6T N0DB3Y9VAQD%2H"@YZY.,<^M
M%GPQ%JEO96HU"V47%W&]W?2YQLF8KMC [X7*^VQ>N:H7GAS5[G3KNP!LQ"VH
M->(WG$^<K2E_+=6B91UZ_-R!Q5E?$>IOK-II_P!@M(W^W-:W?^DLP \@3 H=
M@R<'D$#D8Z'(EOO$L\/B!M)MK#S0BYFG\P@Q@QL^[&PKCY0.6!RPXQS0!G#P
MA<I)"$AMO*^P/:3"2Y+,RE7PB,(@8P"_WEQQQLX&(7\&ZE+!!'+_ &<["'RD
MDQM-D1,SB2(+& 7*LH) 3)0'VJPOCI+>Q+3V<KS0V?VR10X+- (!)YG  Y<B
M/''.3T&*NW.OWQ\'ZWJ?V)K.ZLK>9H@ZN5<K'O##>JL1DXY4<@]1S0!8LO#R
M6>CZI;&&%KB_ENI)71BAD$DCL@9P-PPK@9YQVK#_ .$)N9K2(7 L/M$%N\=N
MRH!Y+>=O5@511D #+!5Y[5MZEXCDLM<BTR#3IKIS''+*R!SL1W* C"D<;6)W
M%>!P355_%LT<,DDNG"(PW/E3B21Q]GCP2)),1G ..HRO/WN* *+>$=3EU>]N
MWELD2>0,/* 7>%N4E4L @.0BD9+-R2<@&M[1;6\TXR6,L2& --/YZMU:2>1P
MH'LI&3ZD8S65<>-'MX[B8Z:'@"W1MRMQ\\A@D$;!EVX3)Z')]\'BM'6=?ET+
M3K:YO+-6>7<C)%-N"R"-G502HSN*[0<#EAQS0!@1>![Y;:^A:YC6>X<;;U)!
MO $OF>9M$:_O%[%F;GVR#*OA"_%O<0[-/26;3A:QWB,WF6;")D_=@KG:2=WW
M@>6Z]:NZ?XPDU:6R6QTX,ES)MWRS[0H$:.YX4Y*ERF/[RGIUK.'BW63IMS<6
M]K:2)%I=I>1M/,0[-*S@[@J8QA#TQT]_E *T_A&]2.SMETRQN \D[R132@VZ
M;HE0'Y85"\KG 3KDYR<UT?A_P^^BW][*ZV\OVA(<W0&)G9(U1MPQT)7=G=U8
M\=ZK3^+YH+R_A_LF21+%7$\J,Y576 3$;BFW;R%!SNR1\N.:N6GB":73]4GN
M;%89K!=YC2;>'4Q"0?-M&#@X/'!'>@#FT\$ZM]@O$E_LYKB9H714*I"LB+(&
M<H(=K [Q\K G ^]D UM^)_#UUK1@,:64X6UF@*71(6-Y-F)EP&^9=IP.#\W#
M#NR'Q7>321V@TN%;^:98XXVNSY>UH3+DOLR#@$8"GGOCD58?%U[>[YTMHX;)
MH=/EB99<R@SR["""I7'7D'MQU^4 ?_PA@>_N#-;V,MM-J$5Y([KEY@L C*NN
MW!^8;NISN/3O!:>#+VWU+39I9HIH;6&",!9 K0F)F/R$QDD$$ @,F0,'(-7I
M/%TZ6,%VNFJR7ER;>S597=FP)"2ZI&2O$1X ;K@XYJ_/KEPECI+Q:>1>:DP1
M+>YD,0B;RVD8.VTD8"$< \_B0 <]<> 97T/3;"UG@M'6$PW\D0(,N=C;P0.6
MWQ(,G^$M]*F?PA?2V!%RUM/<S0DS@2E%,[3B8D$HV5!X 93D  C%7=!UN^US
M7GFP(=-_LRWGCAW@G?(TF2?DY^Y@$-C S@[N+FA^(AK-_>VH@5!!''*DL;.R
M2H[. 061?^>9Y&1R,$T 9>G^%;^W\0VVHWDMO-L6,[HB(_+98!&45?+)V$Y;
M&]1\QXR.8W\.WMYXMOKW[-;0QK>K*EVY/G,@M50HHQC86)SSV/!XQ-:>-+BY
MMX"VEI'/=16LMJANLJRSEP-[;/E(V'H&ZCO2KXSF8KMTM=D95;EOM/W#]H:W
M.SY?G^9"1G;D>AXH I2^!IDT^RM+:+3_ -W8I;&1LJUM,""T\6%.7)YR=IRJ
M\]:N?\(E=B]N7^TQ&!;N&6R0YS%']I6XF!XZLPP!TPJUJ3Z\S:C;6-C:-)+*
MLKN;K?;A4C,88C<A+']XN,#!P>>*S'\:2I&)/[,5DG1Y+7%Q\SA9DA.\;?D.
M9%(Y;OG!% &9_P (+J'D7"*;"&1HDC::,DM=E9Q*6ERA +@%3D/U/WAQ4EQX
M(NY(;>-8K%PL:J//E+&U83F4M%B,#Y@0N $ "J.0,5<;QK<V\-U)=Z3&@AAN
MG7R[O=O:W=4<<H, E@0?8Y J'4/%=]%)=*T8MGLH+OSXX9!(K.D<,B%79!_#
M+W7KG@XH U-?AO\ 5/"MS#]A7[0]PH2 MD,BSC!;'3*#)';)JA9^#9%GBFG6
MT@\N.\\F* %EM'E:,H8\@?=",<X'+'%37?C/[+?7ENMDLXACD>)XY6 D*2)&
MRDL@4$-(/NEL8(.#4]MXEN[J^BL%TZ%;L-/YX:Z.Q%B9%)5MF6)\Q2 0O?)'
M&0#,LO!,FZ 7=MIL5LDD!EM(<O%+Y:2J9""HRS&1<@CH@R3523P7<Z=I<$%O
M:VER673XYX>0DKQ2L9'?Y3P58#)!.!R.,5TGA_Q')KLDI&G306VW?#,P?#C<
M1@[D !X!^4L.>M9UCX[BO]0BL%L'2YD9(L&08$H!:=.G_+, 9/<L!Q0!3/@>
MY%E/&L>G^=<:;=6>_D?9S(SLBH=N2BA]G\/"].U:VCZ1<6_BK5+F3(LHF/V)
M2,8,VV28^X+@$'U+"LA/%.M7&FB6&& +LTN2)S+^\D,\D8=7&S:,@L,CIU ]
M-BZ\0WO_  BTFIVUG;K=QW1MGAEF)C#+/Y+88+DC@D' ^G:@#(/@F]NKJ_DO
M1ISQW,T#[%C7:XCN?,)*B,<E"5Y+')/.#3[WP5<2>>EK#8)$VHM=E!M43JT;
M+APT3@%2V1PV?8U-+XGU&SNM6CNK=3 L\L4$L<HW1NEJLVW:4P5X?YB<YQQB
MMG3-;DO-3EL9K?R2D2RQ,['=.N%RP&T+@%L'#$@XR!D4 1Z%X>32;R[NI%C>
M:58HTE+%Y!&D4:%2Y )RR$^_!K N/ <QT_3+:'[-B&&5+I%81^9(^S]Z&,;G
M> A . PSPPQ@W;7QW%=:G'IPL'6X=Q#CS!CS5?;.F<?\LUP^>X/:BV\:37C+
M#;:;%+/+/%'"?/=8W22-W5]S1@XQ&>BD'(P30!%>>$KZ>WU")$L1)-=_:!=%
MOWMPGFB0129C8!0/E'WQ\J\=JK7OA2]@LXDBMH+E2;.,VTDA9,)/*[AB$ V8
MD X7  QMP*T;SQC/::7=7[:="4BN+B&*/[0Y>58&=7;"QMC[G?C!Y([OF\67
M/VR>&#3HS$)6MX97N""THM?M RH7A<9&<DY'2@!NA>%I=)U2VO)(;%F6VDB8
MIG=!F5W5(SMY0!]G\/"CCL*-]X)NKXZFC+8@W,=X!<DDR3^=G8D@V\+'D <M
M]Q< 5H6/BN>1M+M+RRC6^OX8)8Q%*2CAPQD()4$;%3)'^THSSFDUCQO;:'JL
MEE>6K@1?O'D#\+!LR),8[R'R\>O/M0!8\0^&CJMA96EFT5M'$QAF4 J&M74I
M)&N.A(P1[J*I:1X0GM[G3KK5I;>]N;<3/*Y!.Z4^4L;J"."$A&3V/2I(?$.I
MR:W;V:VD(62]\BX6:;F(?98YL)M7G!9NO7'8'BIHWBJ_N-+TU+^';=216$IF
MCD5O-6=F7+#8 IRA) [$8/H 0+X#E73V@>VTN>4V-C$99 <M);E=RGY#\C!0
M,]?]DU)<^"KVXGUE_,@#7MO/'#()0I3S(P@1@(]Q5<<?/C@?*#6UX>\12ZT^
MV:Q6UWVD5W%MF\S<DA88/RC!&SWZBJWA+7KG6 6O1<1S3VZ7<<3I&(TC8L %
M*DMVP=_/'0<@ $C^&6CT+Q'IEG]GMXM1\P6J("J0AX$CY ''SAFX]<]:H7?@
MV19I_LMIILUDUR\D=A/E(5#01INP%(#!D<XQSO)R#3[#QI=W?V2271XXH)X[
M.8L+O<RI<L4CXV#)# Y&>!@@GI3E\:S/;0S#2T/VN."6S47/WTEF2(>9\OR$
M>8IP-W<9XH 9:>#[BTF8JUK(S2V4KW;9$TAA"!PWR\YV;LYZGIWJF_@J^?1[
M&S,.G!K9OWY1Q_IO[LKYLA:)L/DYZ-U/S=ZGOO%>JO:W)M[6VMPFG:A*[^<7
M>.:W<Q_+E<,NX9YQD'H,8-T^*KN")_M6FI&T%RL%Q()V:.)6C60.6"9'W@#D
M  ]6QS0!=O/#Z7<VAR.D4ATUF.Z;YWYB*##$==VTYXZ9K ?P)-'I=C96\6GY
MCT]+5I6RIMYA@M<184[G)&<G:<JO/6M/Q!K=]I6O1. #IT&GSW4L:N TKAD5
M0<H< ;AR&'4D],'.UOQ3J<5OJ"1JEG=V5O>"01L)D,B6Z2HRLRC.-XX('.>H
MH +WP"+I;N399?:IXM0VRLIR)9I0\#DXSE!D9ZC/%=#J-E?MKVG:C91VTJP0
MS02I-,T9Q(T1W A6SCRSP<=>M9]UXNFMY)S'IGG0+)<00[9_WDDL*,[ IM^4
M'8P!R><<<U2?Q[#>07XLH) 8%F=90X^:)-@$@R",,SD#/]UC0!6A\#WL6FWD
M$GD7%Q(4VS-.JB4J[,'=?((+9.<-YF<GGO4]YX0U.Y:^,<EE%]I2 R%<'SGC
M:(D<QG8C+&RE29%Y!QU!MS^,Y+4W;S::!!$MUY3K/EI&@D"$%=OR@EAC!)X/
M'3,\_B'4O^$0N=7CT^"*Y1V6.*65]CJ)-N_)0'!'(XZ$4 9B^"KI;K3I"T9A
M@ W1>>N86$S2EHV\GON PHCX4#..FCKOAV\U/6#=6DL-MOLY+9[@MND7*2!2
MB[?E(9P=P<9&00>"*_\ PE%[I^JZBFH6RO9I=F%'BERT96R6X*A=HW+\K_,3
MG+ 8QTT=-UJ_U?1[R>.P%I<K'FW,^_RW)3*DED4X!X.!CT)H R++P9)!_9LL
MMG8/);7_ -H>-G5D"F$QDIMA4*V=K8V\E1EL\B./P1<+IMM8A+&&*&&2%EBS
MB4-/#(&(VC!*QD$<\D<FK.G>(M1-Y964BAW$LL=_]M*QR0,L:/@>6"C##@@Y
MY!'?-/M/&<]ZT,-OIL;W$UVENF9W2,JT+S!]S1AL80C[O/&#0!@ZUX8N;?4+
M*"/3ENK".6::*WA3Y!NG214!V,(_NG)^48)&[TZ;7_##:O?37D7V9)FL'M5=
MU^;)<-@D#(4C<IQV8U&=>U,^"=<U66*VANK,7P@\IRZ_N7D5200.?D_'KQG
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M%92/D S\QR.G'6@#,M?!5[!J&GSRRP20P+'^[20+]F*S/)B,F-B5PZI@%,A
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M?G>=_9MGYGE^5O\ (7.S&W;G'3'&/3BG79L-/L;NYN8XH[<1EK@^7G<H7'(
MRW QCGTKCI_ UT=.TNVB:(>3#*MT(Y0A:9]F)E=HW.X!" <!@",$8Q3[_P '
M:CJ-]JTDZZ?Y-Y;S1!1C$A,B-$SCR\Y55/)9N3Q@<4 =1]CT?5;=T>SM+B/*
M>9%+ "58*"H=6&58*PX(! -3G2]/:99FL;8RJBQJYB7(16#*N<= P! [$9KE
M+[P;<--J/V&WL88+B_BNMJ;5\Z-81&8G!C9<!AO&0P)[#K6KH7APZ;?FZG"R
M.MG!;0N\GF/'M#;ANVCKE>0!G R.!0!;NM-T&W#+<Z=9 7TZAP;93YTO)!;C
MDYR<GWJY/IEA=626=Q96TMJF D$D2LBXZ84C Q7+IX2FF'DWEI82+_:'VF6X
MWEGNDWNP#J5[!@,9(X(X'%11>%-7CO\ 1GWV?E:>(QYBM^\"AGW+DH21M90
M&4<'.>* .RBMH(&W0P1QML6/*(!\JYVK]!DX';)J*TTRPL'E>SLK:W:4YD:&
M)4+]3S@<]3^9K@;WPK?Z1HMO'!##-OALHKI$1Y5DEC\PR.ZA&+ Y09VDG R
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MG+< YYSSZT]--L8YQ.EE;K*&=PZQ*&#/C><XZM@9]<<UR">"KT:-)$\T!O\
M[!:6J3;B?]5CS5R5.%?&"<'(Z@XQ6D?#UTO@_P#LJ(1^;YZRF&6;,;()A(T6
M510%905P$P V,$4 :MI::/=CS[:SM6\D_9@X@ *^2_"#CHKKD=@1D5//;V/D
M?8YK:)H+IV4PF+*.S9=MPQCGYB2>I]S7&_\ "):S!I;6UHEA$9HKV)HEN'"0
M":82(5.SYL#(Z#VK2/A:=7,T1@6XDU&>YEDW'+QM',D:YQV,J\=!SCW .A.F
MV)38;*WVY+8\I<9*[">G]WY?IQTIL=IIMC>>=';VMO<W)\O>J*KRD G;GJV
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M#/*R-$2NXQY5&5&4J=X^8''4&]/X9>;P;'I)@@EECN$N%BN) \?RSB39D1@
M8RHPF #C&!0!KQVFCZ@TFVSM9C;R2Q-N@'R,_,@Y'\6[G'7/.:FGTK3KEP\]
MA:RL'$@+PJQW  !N1UP ,^PKEKGP;=N]]/9RV]G=W1N1Y\3'<J21!4&<=%8
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M5_X5U.YEOGBN85,R7"QY=A]^.!0"0. 3$V<= 1C- &W';:#<:BBI96C7=D1
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M 0,CG&2.BGTVQN;N&[GLX);B'_5RO&"R=^#59?#FB+:O;+I-D('8,T8@7:2
M0.,>A(^A(H KZ;K5Q<RZVUU# EK83[(I(9"Y=/*23)&.OS]OIVR<:\\4:G=V
MT%O:6JV=U-)9R!_/5L03LP!!*$!_D8$8(&<@FNMAL;6WGGGAMHHY9]OFNJ %
M]HP,^N!Q]*KVVB:791^7:Z=:PIO63;'$JC<OW3P.W;TH J:IKYTO41;R6I\H
MV[S+,S%1(RJ[>6GRD%L)D@D<'(S@XK/XJ+W,5I:V7FW4SQI&KS;%.Z%I3EL'
M&%4CH<G';D;,NFV,]ZEY+:027,:[4E9 64<C /T9OS/K55?#6AI:FU72+%8"
MP<QB!0I8# .,=0"1].* ,W2_$%Y+K<]C=VP\E[N6&"8.,@HBMM*@=,$_-G.1
MTZ&H;_QU;6&HS6#V4K7$;R1;588,@4-$GUD4DCTVD5TD=A9Q.KQVL*,K%U*H
M 0Q&"1[D<5')I.G37+7$MC;/.SQR&1H@6+)G8<^JY.#VS0!@W7C/[+'<W#:<
MS6T:W?DLLHWR-;L5<%2/ER0<')Z<XS4ECXANW\72Z+=0*LK0I,$#@K$H'S8;
M +G)7C' R>.,Z_\ 8FE>?<3?V=:^;<J5F?RES(#U!XYS@9]<"IVL+1[D7+6L
M+3JP<2%!N# %0<^N&(^A- &)>>*C;:Q<:?'8O=-'%(R>0S,SR(@<QD;=H)#<
M ,3[#-,U76[V7PI!?:885N)[J"W)63B/?.L38+)]X9(PR<'.1Q@Z\FB:5+=2
MW4FG6KSS K)(T2EF! !R?< #\!Z5-'IUE%:1VD=K"MO&P=(@@VJP;<"!Z[AN
MSZ\T <OJ/BZXCT^\,%N8OW=T+6Y+ABSP/L?<F,#)SCKTYQTI3XNN+."]:2V^
MU&U:\GE.\1[+>&4KA>/F;'0<=.2.,]#_ &)I7G7$W]G6OF7(*S/Y2YD!Y(/'
M.2!GUQ1/HFE710SZ=:RE':1=\2G#,<L>G<@$^I% &%<>.[:WU&2P:RE-RC-%
MMW #S2X6%/K(I+#T -:FGZU+?W%S!]B,<EO<>6\;28=8\L!(00.#MR-I8$=^
M"!<?2=.DN3<O8VS3F5)C(8@6+J-JMGU ) /84D6CZ;#(SQ6%LCM()2RQ@$N,
MX;ZC)_,T 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **B2Y@EMA<QS(\#+O$BL"I7KG/I3XY
M$EC62-E=& 964Y!!Z$4 .HJ.:>*VA::>5(HD&6=V"J![DTY'26-9(V5T8 JR
MG((]0: '45"MU;O;I<+/$89-H20.-K;C@8/?)( ^M34 %%%% !14,]W;6S1K
M/<11&0[4$CA=Q]!GK4U !1110 444P31-.\(D0RHH9D#?,H.0"1Z':?R- #Z
M*B>ZMX[F.W>>)9Y 2D1<!F ZX'4T/=6\=Q';R3Q)-)DI&S@,^.N!U- $M%,B
MFBG5FBD5PK%"5.<,#@CZ@@BHQ>6QMDN1<1>1(5"2;QM8L0% /N2 /<T 3T44
MR*:*="\,B2*&9"4;(W*2"/J""#[B@!]%%-DECB ,CJ@+!06.,DG 'U)H =14
M-O=VUXLC6UQ%,(W,;F-PVUQU4XZ$>E34 %%,::))4B:1%DDR40MRV.N!WQ3;
MBY@M(3-<S1PQ#J\C!5'XF@"6BD5@RAE(*D9!!X(I&EC1T1W56<X0$X+'&<#U
MX!/X4 .HHJLVH626D=V]W MM( R3-( C C((;.#D4 6:*:CK(BNC!D895E.0
M1ZBG4 %%%0_:K?SC#Y\7FAMA3>-V[;NQCUV\_3F@":BBB@ HHHH **** "BB
MFO+'&R*[JID;:@)QN."<#U. 3^!H =113#-$)Q"9$\TJ7";AN*@X)QZ9(_.@
M!]%%% !1110 44R::*WA>::1(XHU+.[MA5 ZDD]!3Z "BH;F[MK*'SKJXB@C
MW!=\KA1DG &3W)I\TT5O$TLTB1QK]YG8 #\: 'T444 %%%([JB,[L%51DL3@
M 4 +154:E8M<_9A>6YG(!\H2KNP>1QG/.#5J@ HHIC31)*D;R(LDF=BE@"V.
M3@=Z 'T44UI8T=$9U5G)"*3@L0,\>O% #J*** "BBB@ HHJ&*[MIYYH(KB*2
M6 @3(C@M&2,@,.W'/- $U%,6:)IGA61#*@!= W*@YP2.V<'\J?0 45#;W=M=
MJS6UQ%,JG:QC<, ?0XJ:@ HILDL<,3RRNJ1H"S.QP% ZDGM3J "BBF1S12EQ
M'(CE&V/M;.UO0^AY% #Z*:[I&A=V55'5F. *=0 4444 %%%% !1110 4444
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M-N\MLEMJ@E&'S$=/<99>>+'L]4: 6<EQ#&9Q*L"#S%$:1/GE@#Q(<^O '/4
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M"D\"1S 2*KX*[BY5,X()Y&#QSUI8O&6G3&U,4-T\,\=O(9@@V1B=RD>[G/+
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MP9#Y8D !#$?=9>OK[5!!XL8ZN+:ZT^XA@DAM65\*WE/,SJ%<ANY50-H/7G%
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M'BB\\/V]S =159K:T:87%UODF;+&1H\2 H""G&Y"<=,YSK)I^NJ2DXU*X/V
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MV(N1&_F+TF0)GDY_=.ID]PV!F@#9/A;0I=.N+.6%I[>0H)3+<N[8CY52Q8D
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M,A^0L0!N.<8Q5>V\(:=;ZC]J)FD1!"(86F<HGEJ0I(+8<C.06'%4KJQU*_\
M \<$]M=+>1W$<AC2Y;S'1)PV0Q<D$H,A2QQD#/%4[FT\4M/K3PSW:.;>=;-
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MWHRA48&=PQG@'%:6AV.JCQ2+S4(;SY+>ZCDEFE5HBS3(4\M020-B^@Z#/.:
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M1S3Y!B$15RXR=Q!QR<GCCOFSX5MM?AT^Y.J3S-=M"@"3J-JS -O8'S'R"2O
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M+6]DNX//620[G7[0Y1FVA=Q7."< <X[9ZTUM$L'O);IHG,DLT<[_ +UMID0
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M)3Y&X[2\DAD=SZG)X] 3ZT 4CXHM;?29+^]7RE%[-9H@89=DE>,<G &0F>2
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M21_D. &@\_<.^W:&Y]01UJY:>';"RAMX8_/:*VD5X$DF9A'M4JH&3T 8C_\
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ME\90%;IH+68QP6+W;32#"H49U9&'W@0R$' ZU<N/%.GVL-U/*LXM[>7R3.4
M1Y-X38I)ZACC)P.O. <-'AK1IH&AC#F-K>6UD"SL?,1V._<<\MN+'/7)-2R>
M&=.E%RI^T!)Y?.,:SN%23>'WJ,X5MP!^N?4Y  ^)M._L!-95G:U>01#&,[]_
ME[<D[1\W&<X]Z:_BC3XK]K65;B/9((GF>/$:.8A*%+>NPY_3N,W)=+AFTS[
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MZ:9:R2K--*EQE58IY:[BHPX&3D8()%:DWAS3[A[[S!-Y=^C+<0B9@C[EV,<
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M>W9L42$B1HQ)YC;V,P<@@#*[0"1@?P\@BNKMY3/ DIBDB+#[D@ 8?7!-244
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M*T;D;[B41;FQC 0&0]^>.E '8T5QDWBW5TCC*Z7:K(J1M*DEP1DO<&%<%0<
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MX98!*-P]#G;@#/0_22X\5W\)DM)8+&&Z6X:(RO.PA"BW$WWBN=WS;>G8M[4
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M!T]U/I^CI)=2)%"974.40!I&)"C..3R14TL%E+'&DL5NZ1G**RJ0I'&1Z8K
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MR_FQ"FUL'J-V3^=2ZMX6OM2\0_;OM-NL"A]@V8<!K=XMIP,GYGW9)Z#&.,T
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MZ+J%X\L02:6)KJYFV;\+E4 /4_,1PH'.TTW4]'O9?#UEIEG+%));O;,TMRS
MN(G1\\ \DIC\:1=.OY8M:N'CA6]O3Y,2R/\ *L*C:N2 >I,CC_?P<4 /N9M
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M#(VC1B2*VNKJ59)V3,<'E_=^3.6$G0@8(/6NKF^S+%/-)&K@QD283>S(,\8
M);J>.>I]:CAL-/BMQ##9VT<(1E\M8E4!6^\,8X!P,CVH YY_$NH+=2P&Q4WE
ML;A#;PW ,<S+%'(@W,@/(D [<YZTD/C&>YO[6UM=/^T;DC>=D+KLW3/$<!E&
M"IC8D-CI@9K7O[S1[><P7D<3/,$+ P[@XD=8AGCG)*CZ>PJW_9FG9MS]AM?]
M&_U'[I?W7^[Q\OX4 4M$UMM36=+J*.UNHIO+,&\EA\NX<D -D<Y7(QWZU1N?
M$4NG)XCGF G%A<QQP0C"\-%$>2!G&YR2<' ^E:6D-I-U:1W.G6L,<+2L\;"
M1[FQ@NO ZC//<59?3].DN)+F2SM6G92DDK1*6*XQ@G&<8[4 8D7B:]$MBMYI
MHMHYY6ADE=VP&W!4 &W(W9XW8&1C/(J@WC>\%O#&FD!]1;S3+:B1OW1C6-BA
M;9RQ\U<$?+CG/:M[9H=K>6ML+*WBE21HK?%KM"-LWML.,8V]2.,Y'7(IT5IH
MDZSZ>MA9F.TE&^$VZA$=E# @8QG##D>M %/3?$=SJ.NSV2Z:Z6L4CPF<L<JZ
M@'D8Q@Y.,$GH>_%'4_$6H_:)K.""*"ZBOK=(T>0_O8FEV[BVTC!P>F2.AP:Z
M-XM.MM0CN'BMH[VX/E)*442284MMSU/"DX]J?'8V22RR1VMNLDCAY&6-068<
M@D]R/6@#FE\:/YFGQM:1>9/*D-Q&LCDQ%IFA!!V;=NY&(R02 >.*D\):G>W]
MPZW4[2@:=:R@$#[[23AC^(1?RK?:PT]I4F:TMC)#RCF-<ID[N#VYY^M310P0
M\Q11I\H7**!P,X'TY/YF@#D++QS/=6,<TEI:QRSVUM<0*D[R@^<7 0[8\[AL
M/08Z\C!-6M+\8MJ5QIEN+$)-J$$-U&/-R!"\;,S=/X67;_P-.F:OV^FZ!I=D
MFD"TMT@ BBVS0C$K 83)(P[87W/%7TTVS2_CO(XU$L,!MHPO C0D$@#MG:OY
M"@#"GU[48=9NK*WAAN'?4%M8%FD\M8U^R><22%)/*G\ZI)XTO?)GOS90M:-:
MV$MO$)#Y@:Y8*-V%Z GMZ>_'4M-8+J4-NRQ_:IE>X0[.NS:C'/K\ZCUP:>VG
MZ>Y(:SMC^Y\@@Q+_ *O^YT^[[=* .<?Q;?0P2S3Z2L:6MC->W"F8[\1LZ@(N
MWG=M!YQ@'UIR^*K](8);K2U@B:Y$4DQD8HJ$(0P&W=@E]N2 !C)(!KHX+6SM
MT6.W@@B4)M58T"@+G. !VR:SI8_#]@JH;6Q3[/<1 (D"YBEE940X X))7F@"
MG:>(;R+PKJ>KZA# SVDUTJI"YPRQ2N@!)''W>3Z<^U5IO%FHQR36J:=:27<,
MLD;D73>40L*RY#;,YPX&,<&NG2WM8Q((X85%PQ:3:H'F$CDGU.*9#96%M"L,
M-K;111Y"HD:JJYZX Z9H R[S6;OS?#CV<<(@U*;;,)F(95,+R # //R_ICOD
M8.G^,=1M=$MS?6:3W#P6SQ2)*3YGFR&/+@+P> <#.<X]Z[66WM9$CCEAA982
M)$5U!"%>A [8]:J6#:9K&DQ7$%K&]G<1 (LD&T/'U'RD?=[@>] &5J>LZ@/#
M=E?) MI=RWL$312R87!F"$%L9 (]LX/0&JR>-F+V*&UA+RW"V\Z)([;";AH
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MM;9PI?!:-3C=G?\ GDY]<G--DATVVM(K"2*VCMICY,=N44(QP3M"].@)Q[4
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M.S2]:[6V@6[==IF" .P]-W4CBH+RWTH*DUY!9X24!7E13MD<A1@GH22![\4
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MV\175O(^;:+3UN!& -Q;>X..YX4<5HO86,DB226EN[QOYB,T:DJP &X''!P
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M5VPM[&XB'[FWDCE5L?("&5^6^H/4^M1_V5IC1Q1_8+0QPG,:^2N(SP<@8X/
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M;&Q!X'0$=3Q0!=U#PQ]LUYM5'V<3"2T,4C+\Z+&[%P#CC<K8XZ]ZQD\"7/V
MPRQ::SQQVZ]"1>/%,)#)-E>&8 C^+&]N3TK5D\4WO^EM%I*;8;FVM%$UR4<R
MS+$V& 0[0HF&3DGY>E5D\7W<T*">P6U9Y(PAAN!(3_I2P.#N0 #)XZD@_P )
MH L^)_#,^NR6+)Y1BAAEBDMVDV#Y]F'5MC8*[2!@ _-P1WKW'A6ZD74$$&G2
M--="Y$\I/F7"^:LGDR_+PF%V=6X"\<8,L?C";]Z9["&%&60VS&X9O,*3B'#!
M8R02S+@*&SG%4I?&.H365Q=16D4-M'I=W<OB4B59879#M#)C&5XW =>1Q@@
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M?,3*,9P.N6'% "#P9<6UO+]C^PK/-&ZSEHP1,3<"0;LJP)";E!(;!.<&H8_
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M 7$K\,5.S8CH< KNV@<]MV[\6WUG'9H='2>[N89+E8;6=Y1Y:"/@$1_>/F#
M("^K#-:VI:O)I^I6%N;8&WN6V/<NS!8V)4*O"GEB>,E1D8SDB@"KJVG:EKGA
MR#88[#5E9)HR3N$+]",CK\C,O'K67IW@B2S6"*6>&6""Z81*P)Q9B"6**(YZ
MD>:2>W6IXO&AN(+3R+%#<75M9S1H\^%5K@N-K-M. OEGG').,4ZUU_44\0S6
MMU;PO:R7<5NK)/DPNUL)"%&P;UR#R2#\W2@"E:^!W2VL_,BL([BTMK*&)H@2
M$:&=I'93M!&\$?B3G/4R'P3(\C32-:O,K*T$A4DQD7;SD@XX.U@..X]*M#6K
M^W\4WL=P%:S%S!9P(LH&TNF\N1LSG/'WJCB\9RSR0-%IT9MF%L99#<_,OGSO
M"NT;<-@ID\C@T :NL65_=ZEH\UJEL8K*Z,\GFRLK$&*2/  4_P#/3/)'3'?(
MIZ'H%YI]];/<R0&&QMIK6W,9):19)%?<X(&T@1J, G.2<]JSH_%FISWIN(=/
M62V:S,T-M',7=QYZIO8!,J0NX[5W="!DUJ:MXG73_#]KJD$<%R;B+S4C623#
MKY9<E2L;$\#J5 QR<=* ,6+P7J$'VAHUTL2-"83(4W-<YG60O)N0@,5!'(;!
M.>>@6R\)WME?Z- S*UNBN][L'R-Y4IDMU!P,;6D)X X7MBK\GC)HKJ5GT[_0
M4E,/FK-F0M]D^U?<VXQMROWNO:I-(UZ]FDUFXU".-([6"*98;>7S0JF,N<-M
M4DGCB@!--\/7UAX4OM*C^QQO)N%LFT2(BE% 5V*#?R#RRDX(SNQSGVG@1O)1
M+Q;)R(+Z(?NPVSSW1EQ\JC P^< ?>Z<FDC\8ZC%>2"XLHG>X:VCMK>&9I50O
M%)*266,M]U.@4\X['-69?%&H7-[810V0LXS=6T5R)I?WJM)'YA39MY ! SD'
M(/'% $=MX/N8]6T^\ECM5C@B@3RX9=OD-&6)V?N\D-NY&4[@Y!K?\.:-'H/A
M^RTY4A62*%%F:)<"20* S>Y)'4UD0^-#=0V8M[%#<7=K9SQH]QA5:X\P[68*
M<;1$><<D@8%:6CZGJ%[JNIV]W!:QPVS1",PS,Y):-6(.5&1DG!_2@#:HHHH
M**** "BBB@!&4,I5@"I&"#WJK+I>GSM;M+8VLC6V/(+PJ3%C&-O'R]!T]*FN
M8S-:S1 9+HR@;RN<CU'(^HKAG\':PUEIULO]FQI:2[U*A0\8$B,,,(>3A3DJ
M$).,DT =>VB:2ZW"MIEDRW#AYP;=")6!R"W')SW-1WGA_2KY;9+BQMVBMY Z
MQ>6NQL1M& RXP0%<X';BN9N/ ;2_:)E6S%U*MZPE.<^;)/YD#DXZHN1GJN2!
MP:M6>@ZEH^KZAJJQK>32O-Y.)@I<22AE5QY><(,#)=L!>!S@ '3I8VD4Z3QV
ML"3)%Y*R+& RQ]=@/4+[=*JM;:-:W%R7M+2&2XV>>[0*HE+MM4,V,,2W&,DY
M(]:R?%?AJ]UR>%K*\2V4Q/'.22&)!$D3+CNLBC\&;Z50G\&7EQ8E;@6-U.RV
MTTD<Q)C>=+EIY>2IPK;V4'&<'D4 =,\&E:ZA\^UMKQ;:9H_W\(;8ZG!QN'ZB
MF1Z;H=ZUYLT^QE+R%+K-NIWN"#A^.2#@\UFZ;X8>PUT:FJVR2/-<O,T>=SI(
M5**3CD#;TZ#M5+4?!DVHR7IE-JZRK>-"').R241B-NG!4HQSU&1B@#HX].T>
M2:Y\JRL6DVBVN-L2$[=JD1MQTVE>#VQ5BVT^RLUC6UM+>!8E98Q%&%"!B"P&
M!P"0"?7 KD;[P==S2Z@T$=BHN;Z*[<Y -PHA$;1R;HV& XW@D-DGH#S2R^"I
MFL+I(WB6Y>TMK>&21_,95C.70L4^ZXPI.WD=5XQ0!UJ6-FEZ]ZEK MW(NUYQ
M& [#C@MU(X'Y56_LW1M1MS-]AL+F"Z*SE_*1UE./E?./F..A]*YZU\)W,%QI
M;B"UV6YD$RRRK*H1V)*HODJ!UZKLQG!# 5I^%["[T72['1I+&VBBM+1%:>!_
MEDD!V\#:.2!N/H6'7K0!?L9--OXYS:P(T<=P5<F J#+&0N1D#=M* 9&?N]>*
ML?8+/C_1(.#D?NQQ\V__ -" ;ZC-<O:>"EMY8"$M(EA^WNAB3E)9YE>*0# &
MY47&>HX XJO9>"I]T"W=MIT5LKVYFM(69XY?+256D.5&6<R+D$=$&2: .NDT
MVPFB,4ME;/&0RE&B4@ACN(QCH2 3ZGFLW3G\-ZN@BL;>RF6WC(5/LX79')D'
M:"!\K8;D<'!ZU6\+>&I/#[<F !K&WAE\HGYYD,FYSD<Y#*,]>/85BQ^!=0MM
M*-K%=Q.SP6JR"65F!:*0LR NK 1L#TVD C[I!- ':-I6G-<S7+6%J9YT,<LI
MA7=(I&"K'&2, <&GQ)9W$4QB6"2.5F24J 0Y7Y&#>N-NT@^F*Y-/!<H:&4^0
M)8$M! 7D+F$QW+RR;2$4 %&"C ''RX JY;^&9K?PIK.CP16=M)=RW30O#D*1
M*S,A<!1@@,%XSPHP>U &[<:7IUW$T5S86LT;D,R2PJP) P"01U XJ)XM):Z+
MFWMI+B-DMBRQ!V3&'5"0,J!\K#/ X-<U<^$;[59;N;4DL29VN'6$2-(J,\,4
M:')49(,9.<<9!'-6+?PM<P:E-<!+,&:]M[IYU)$C[(E1U/R\\J6!SSN/ [@&
ME'#X<N[*"=;.Q:#5V21-ULH^TL5,BE@1R<!CSSUK3DL+.:VCMI+2!X(BI2)H
MP53;]W Z#';TK &AZC:Z!X:M;<6LUUI/E&19)6C23; \1PP1CU;(X[50;PA>
MRZAJES<^5*;M)0"MUL)#@?NV(A+%5Q@$L1P/EY( !UDFF6$T1BELK9XRI4HT
M2D$$[B,8Z$@'Z\T1:;80M T5E;1M;AA"4B4&,-]X+QQGOCK7(OX2U>1$V2V-
MM.=/DLWN(L93*R!/+41KL(+J2RE0V#\@XQ/:>$'-Y;RW-II\%HEZ+DV$#%X5
MQ T8(RJ@L6(;H.@/)H W+>PT34DDOX]/LY?M:E996MEW2KG!#9&2,J.OH*+B
MPT.P2":;3[*,*5M8F%LOR^8VT(,#@$N1Z?,<]ZK/HTX\76^J01VR6ZP^5*6(
M9B,-@(NSY#EN2'P1D%<X(S;OPG<WFH:@7CL_L=U=6\[K(V]Y/+E5F!.P$ JN
M-I+#)X(% '0_V)I/E01?V79>7;L6A3[.F(R3DE1C@Y]*FBT^RM[N6[AL[>.Y
ME_UDR1*'?ZL!DUR#^$-36YTY8FL5M[.Z$L9'#QQBZ:38I,9./**H%5D P0=P
M-1W?@2X?3[""+[/^[6?[4JN(_,>0KME#M&YWJ%(!P" W!&,$ [06%FL_GBT@
M$WF&7S!&-V\KM+9QUV\9ZXXJK:G2Y[RXM[:VB\VS9(Y"+?:J,!N4!L8) ?/!
MXW=LUE>*?#UWK3QF!+691:S0 73LODR/MVS)A3EUVGT//##FK%GX=6SM]>41
M0,^IRL^Y"8F<&)4^9@,@[@QR,XW9ZT 7QHFG?VN^JM:Q27K!0)G0,R  CY3C
M(X)SBJM]I.AP6(M9+2"UM[FXA!6"$*)'#AD5MHY!([]B:P#X5UM-/CMHCIXW
M6[V[@.8Q&OFAU("1@,<9!^5.>:L?\(E-/YT-U::=(KZA]JDN"Q:2XC\XN$D4
MI_"I"@9(P.PXH ZYXHY'C=XU9HSN1B,E3@C(]."1^-5K?2M.M PMK"UA#2"4
MB.%5RX_BX'7WK$E\.W7_  B]IIBK:S_9K@2&WE8B&6(.2(R=IP I7C!&5 Z5
M4/A6].K+=>181J)$D66.9A)$@@$9MT^3B,L"<Y'WC\N>: .GGM].FU"W>>&U
M>]16>!I%4R*!@,5)Y &X9QZBJESIV@V%E/Y^G6,=M<21K,HME*R,S@+N '/S
M-WZ9S7/67@ZYMS8/+::;(;:&YMU4/L=$DV;2)%C&6&Q@2%4X?/)!S>B\-73^
M#UT6X%H"+B-]B !/*697()5%!8J#R%&2?QH Z&.QLX@HCM8$V,&7;&!@A=H(
M]POR_3BFS:;87%Y%>3V5M+=1#$<[Q*SH/9B,BN0N_!VHL+."T-A';VUW)/'P
M%:%3<"10A,;$#:",*5Y[D4MSX,U&6*[1;N%HUG3[)"Q^7[.)&D9'W(P'+X^Z
MPQ$GO@ VK_0O#L:64-QI]I'";H&.%+=0DDIC= &4#!^5FZ]\5J2:982Q>5)9
M6SQG9\C1*1\GW>,=NWI6#>^&YIO#>F:<D-M.;2=)7@NIB8W5<_)N"=.<#Y ,
M#I6=9^#+^#4=.GGFBDBMXX@%27;]G*2.Y6,F,L5PRKPR9"X/!X .MCTG389)
M)(M/M$>5Q)(RPJ"[!MP8G')#<Y]>:KZM%H]OLU34K."26)DCCF-MYLH+, JK
M@%L[F[>M<QIG@:Y@M$M[YH)_WUNT[-(&6Y6,L69D$:_,V[G<7)Z$\<ZK^%S/
MX8T_2;A+6;[+=Q2@2+N0(DH;:,C^Y\H_+I0!;U;2-!-K!/J%E;_9K5U8(8 4
M/RF-0RXY #G [5:MK?2+^1;^&TMI)86>W68P .FQF1E!(R "&'I^=<W)X6U>
M:22-Y+,0)]I\IA*Y9_-NHYAN&W"X"%>">:#X:O8=9T] P-O/<W,U\4SM*"Y:
MX@&>Q#/@CN"W84 =5-I6G7$!@FL+62$JBF-X5*D+]T8(Z#)QZ5'/8:6L"V\U
MA;-#+LB\O[.&4A22H(QC .2,\ FN=U/0KW4?&;W,=M L,:V3K>2,0\?ES2.Z
MQC:0=RX5N5X;G/2H-,\):M;W;SSS646^:WE86W"ED\W>P41J 3O3&=Q^7EC@
M4 =*EIHSZK>1+96GVYHEDN3]G&YT<L!N;'S9,9XS_"/:HM1GT.UO7N[R&!KV
MW6)=XM_,F42,40# +?,=PP/>LGPOX<U#09I96MM.1I+:TMI/)E?]X8S)OE;*
M#YFW@XYR1RW>K&L>%VU;59KF5+66!VL2$F7=CR99'?C!'*R8'XYQ0!MH+!9X
M+%(X5DMXQ)#"$ \M1E 5&..,CCM3IM.L;BQ%C-9V\EH JB!XE,8"XP-I&.,#
M'TK-O=/U%O$ O;06_DR6GV:1WF9'B^8G<H"$-UZ$CIUKFH?!&HP:&+95M&O%
MDC=6DG#0ET1E\QH_( 8G=R#DG@[P5!H [(:+I2R+(-,L@Z1^2K"!<JF"-H..
M%P2,=,&EBT;2X'@>+3;.-K?/DE(%!CSUV\<9R>GK7*WOA'4KB74/)-HD$]XE
MSY3.K&?!<L'9HC\OS*P5A)@K@$#&'VG@^[M]9L+IY0\%M%"JYN 7A*;LJI\K
M+*<]BF1D$4 =+:V&EV\DL-K86T)6197$=N$!?LV<8)]ZEO--L-0,9O;*VN3'
MG9YT2OMSUQD<9KG==\-7VH7-U/;?96=YHI8//?Y$9(V7+(48./FZ<>H92 :G
M\3:+J6IR,VGM;8ELIK23SY&39O9"&&%.?ND8XZB@#;&F6 NIKH6-L+B9=DLH
MB7?(OHQQDC@=?2J8T_0K>\L[%=.LHYE62YMD6V4;-I0,RX&%.6C]^GI6)+X2
MNTFN[JU^PBZN!>AVD!(D65PT:M\IR !T((&>AYK,G\":G+I\,!CTV1DBOHD\
MR0@6QG>-DDCVQ@;DV$X 7D\$4 =Q$;#4'G=(XI6CD$4C-'SNC;<!R.=I.1Z$
MY%1_V=H\<\\'V*Q66^1GFC\I UPH(W%ACY@"XSG/WO>N7U+P9?WESO\ /CDA
M,UPYC\T(1YA0JX8QOAQL(R "-W##G.KK_AZ;5-4@O;86\<J6-U:"X;B6%I0F
MR1.#DJ5;C(^\>>Q ->[T[3KJU2*\LK6:WAY5)HE94P,9 (P,"J=NNB:_:I*+
M"&XA?;<+]HLRN=P(#X=1R0O7KC'8BJ6D>'I+6SU.&:UL;:*\C6,6=LQ>$80J
M6.57EL\\=%'6J,'@ID^P0RI9M901VJRP ':WEI,'^7&""TBGGK@Y]P#IY-(T
MR66XEDTZT>2Y79.S0J3*O'#''S#@<'TJ62RM9?(\RVA?[.P:'=&#Y9 P"OH<
M>E<?;^$M6AU#1)6ELC'I\<:&13B3"JZLN3&6(^9<?,HX.0:CM_!%U96-M#%'
M83(D%F+BU=F6*ZEB$HD9SM.<[XR"023&,@4 =E9Z?9:>KK96=O;*[;G$,2H&
M/J<#DU4BT[0[EVCCL+%VLIB,"W7]S(0KDCC@D,IR/45CZ?X8N[;Q2=4F\GRL
MAHQ%* 8AY(C\K'E;F0$$@;P.0=N1RFHZ!J]TFN6L)M$M[^ZBNHY?/.\[5A#1
MLAC*X81,"<MPWW3R* .G^QVN%'V>'"LS ;!P6SN/U.3GUR:;]@L\J?LD&5QC
M]V.,*5'_ (Z2/H2*Y2#PI>6\VG/%%;#R$E67S+C=A7+G;'B%=GWAADVX'&&
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MH4.3A>&!0J<=B16(/!NH7-LEK?KI\L$*VT48+M)YBQ7'F,S I@$ID8YY[XH
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M!GA:7#V[W$TL8X* MR$R#C&#C)JQ_P )#JH\"ZEK;VEDM[;)<M'$LK&,B-F
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M<6LK:9:[+5)%AA\E/+4NRL6VX^]E!S[F@#.N_&?V1;FX;3]UI&;E(W$WSO)
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M+:$H(Q)$1)OQ\QY;(W= 1CY2: -1_"%I+'<B>ZNI9;J"Y@GF)4,_GB,,<!<
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MV58;><'T!&10!V,VF)<'3FGGEDDL9?.5SM!D;RWC); QR')X Y_*JS>'X/\
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MOJ-W+]C\LHLI5AE&9AC(RH.[! [*HSQRL_A-&7PY!%(?(THJLC,<-+&J@JI
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MXSM.,]<'&:R[KP;#=R7GF:A<^3<I<+Y05,(9U"N0<9/3(STR:M7'AFUFU_\
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MC:"=5;S9X60-%@J2&=4)!(P0"PSC/I5&/P;;)8O:M=SL'MI;?/ "J[AL*,<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN(,#S #MG"=\"HIO$I7P]INKQV4V+R2%?(9<N!(0. .IYXH Z"BL4>*=./V
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M2J3$SH%4?>+$* !GDXZBII_&>BVUS>6\L[A[2.227"Y_U:[W48Y) _J!G!H
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MV?V*:&XFLQ,TR6TMP[1QEED4A5)^48E?@>WH,58K+58];?4+-[X122VRF.8
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MGL\URTUQ QG^U>8DQ7RGV%&8>@*DY!X[U@7,OB>74]26V2]@A*NL9.UMK"9
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MAG\W=;F7$8,J[9" .?F'OP<XQDT 0OXOTB#39);596>,NHMX[9]X94#G*@9
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M'Y=SBG/KQ@TO7+J2 -)I+2AXU; <+&)5Y[91ES[YI@\,Q>;(_P!JGB874MQ
M\#;6190#(A)R""VX].,C'(S4\6BPRV6K0W$OFIJDDC3,G'RL@C 'T15&?44
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M*Q+QM7(P3TSR.V<=\9YK/E\&Z7->WMT_G%[R.6*0;@ !)MWX.,\[%ZDX[8%
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MF; $:D*"1M /\(.,X!Y % $TGBO21"V_[274R+)!]ED,B!%5G+)C( 5T.?\
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M>/JN,CIWQ3-/UVPU2Y,-E(\I$23%Q&P4*ZAEY(ZE6!Q_@:=J^C6VLV\,-R7
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M9Y8X(]\2M-.TD>2ISL1D7G..O4DG;E\0V-QX<?5K>-[FS;:%$D31B16(&0'
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M)8YO(D!F,KNJA%VY<'8"&7(.?:@"KKVE7^L6'AV"6.VN)5FW73W%L6B!^SR
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M*7-S:V_ER&V!LFD 0Q HP&S[X?DJ6R<$;>E:]MXLTZ?3(-0=+R&"9S&#):2
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M'(IE6&-;;("^<HB=&*;3^[R2-S<GD#&*;>0>)5LM2B,UW?(]O?11QSV\3*<
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MW=X))S.TTGV<.T+Y A78D;'9C<3QR0,L,UT;>*='00,;IBDW*.L+E=N[8')
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M_M$W9!M4:=;BV$0AN"3N2,[1O0>N6Z#YCF@#4?0;5O#<6AK),EM%#'"CJ1O
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MBQUZ6VDNWF'D*54)M(()4_Q*<'*#D8/7FJMKJUU:ZWJ$>H-<O:F:..V?R"J
MNX0( 4!8Y.2P9AC).VJFN:IJL7B<V5A-=?+!:R1P16PDC<O,ZOYC[3L78O7*
M]..>" 16G@4^=J,=]-$UK=RM,WEHI=Y//\U')9>-IR-I+@YY]#LCPM8^08F>
M4@PK"2 B9 D,@X50H.3V%8TUQK\-K%)<W>I(DUQ=;VMK)))(0K,(55!&3M91
MDL0>0.0#1"?%=W=6WVB[NK(27$4,R06\;)&IM [LK,A_Y;#;DDCDCTP :\_A
M6UN(S"]U<^0;MKL1?NR%<MO."4W#YLG(.1DX('%7#I9N=-6UO[EYV%PMP9
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M **** "BBB@ HHHH **** "BBB@!L<:1)LC147).%&!DG)_4YIU%% !1110
MA 8$$ @\$&F&"$Q)$8D,:%2J;1A=IR,#V(&/I4E% !1110 4444 %%%% !2$
M D$@9'0TM% !1110 UT21=KJ&&0<$9Y!R/UH9$< .H8 @C(S@CH:=10 4444
M %%%% !1110 4444 %%%% !33&C.KE%+KG:Q'(SUQ3J* "BBB@ HHHH :\:2
M "1%<*P8;AG!'0_6G444 %%%% !1110!!=65K?1"*[MH;B,'<%EC#@'UP:G
M   & .U%% !1110 4444 %%%% !1110 4UHT<H716*'<I(SM.",CT."1^-.H
MH **** "FI&D9<HBJ7;<Q QN/3)]^!3J* "BBB@!  H 4  < "EHHH ****
M"BBB@ IL<:0QK'$BI&HPJJ, #T IU% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$A5+,0 .23VK(?Q1HT
M=W:0G4+;9=QR/#/YR>6Q1D4J&SRQ+C 'H: -BBLR\U_3K.*[8W44TMHF^:"&
M16D49 Y7/'4=:9)X@LX=)GU*19%@@N6MGS@$,LOE$]<8SS]* -:N1L-7L_\
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M;#$%<8?'\;#G<,JWJ,27_B76+*ZOY$MH+BWADGAAMTB<2,T=OYRDMN(.2"N
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MG0;(6S?,?,_U7[SHNQ<XW=>V15.3QQ),(&M[S38+>6XAA:[E4M&FZWDE;/S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML?R_,*D!BW"G[V-N>,YIE_XOT_3;Z\M+B.7?:VLETQ1HV++&H9@%#;@<'C<
M#ZUHV^C6=K>M=PB=9FQO_P!)D*N0H7<REL,VT ;B">!S5>;PQI%Q<74TMJS-
M=)(DH,TFTAU"OA=V 2 ,D 'B@"A=^,$BM;A8M-O3?Q&53:L(]R;(UD+,=^TK
MB2/H2?FQC.:L3:Q>R0Z-!:K;K>:C$9#)*I,<:J@9CM!!8Y( &1U)SQS9O/#F
ME7[RO/;,7ED,CLDSH6)18R"5(X*HH*]#@<5-=:+87EM;6\L3A+;!@:*9XWCP
M-ORNI##@D=>1UH Q(O&#&SE26RD^V01W33/" T4?D.R%N64D$J, <\^Q-%UX
MVM8GOK:*&8SVEK+.\NU"B[$1SE-X?_EHN.!G/7O6Q'H&EQ6Y@2U C:![=AO;
MYHV)+ G.22223U)).:RX_!L"ZE>S274CV=V'66U!=0ZLH7:WS;2 .F%!]SSD
M LCQ5:F\N+<VETHB\X"5_+5)&BQO4$MQUZM@=>>*CTSQ/'K&J6<5H@%O+#=&
M3<59E>)X5 #(Q4C$A/!/;IS5Z?P_I=U')'-:!ED,I8;V&3)]_OW_ $[8I]EH
M>GZ?,LUO"XE7S,2/*[L?,*E\EB<Y*+U]* ,=_$-WIUUJTFJ2VGV*P:)!Y,15
MW:3&P99]HY8#G YSD"I8_&=E-$LD5I>2+Y$T\A01D1I$Q5B3OP>1QM)SG/3-
M:MQH]A=+=":#=]J*&8AV!)3&T@@Y4C ((P01FFC1;#RV1XY)-T#V[-+.[L8V
M.64LQ)/Y\4 9]EXMM[S4(K,Z=?V[22B$/,L>T.8C*H.')Y0$]..AP:GG\26\
M&I/9BTNI-DRVS3($V"9D#K'RP.2"O.,98 GKBVNC:>DZSK;@2+*LP;<>'$?E
M@]?[AQ_]>F-H>G-JG]HF!OM.\2']Z^PN%VARF=I8+QNQG '/% &-:>)K\>#-
M*UJYTYY[B^>W!@A*)L$S* 1ER#C<,<\\9"\X9_PF#16^I"YM9(I+;[8T,WEA
MHY%@?!&-^XG!7.< \X-;SZ+82:/#I1A9;.!8UB1)&4H(R"F&!W @J.<YXJ.7
MP_I<\3QR6H9'$P8;VY$QS)W[G\NV* ':=K$&I7E];11R(]G)Y;[RN2<G^$,6
M XX+ 9!!&162?&=K:>'M)U&_C(FU" 3"&)D'\ 9L%V4<9 QG)R,"MNWTRUM;
MZXO(UD-Q. '>25WX!)  8D*,L>!@<U1B\*Z3#;Q011W2)"<P[;V<&(8QA3OR
MJX_A&!P..!0!!/XQTZWO)K9HYW:.U:Z'EE&+JJJQ 0-O!PP^\H'O33XUTQ;N
MSMB',MTL3@+)$VU9'*(>'.X$J?N;L 9.!5X^'-,^V2W8BF6>0-EUN95P6 5B
M &PI(4<C!XH@\.:9:S12V\4T4D0QN2YD!?YV?Y\-\_S,Q^;/+'U- "7WB"TT
M_6;/3)U;S;HA4</'@$YQE=V_^'J%(YZ]<99\>Z8EK97$MM=PK>1>?$LAB#&+
MY?GQOR<[N%&6X/%;,^AZ?<ZFFHRPN;E-A#"5PI*9VDJ#M)&YN2.]-_X1_30E
MDD<4L0LHA# 89Y(RL8Q\I*L"P^4<'/2@!FK>(+31KJS@N5;_ $J1(D97C&"S
MJ@^4L&/+#[H..]%EK]M?65]=QPSA+-G5TPK.2F<@(I)!XX# 'D<5+?:'I^HW
M<5U=0NTT6S:5E= =KAUW!2 V& (SFGV^D6=J+KREFW77$LC7$C.1@@ ,6)4#
M)Q@C&>* ,B3QI91VD5S]DNY(GMWNG:)HG$42MM9F*N0<9SA23[9!%!\<:5]J
MN[=%FD>W9T^38WF.LJQ%  V5.]@HW!0>H.!FI'\&:5)=Q2LLQA2-T:$SR'S"
M[AV+MNRX)'(;(-76\.Z8ZW2&&7R[HLTD0N) FXMN+*N["MN^;<H!SSG)H R-
M7\37]MNAM+&1;HFT7RI41C%YTSQDG$H5N$X /!(.2"<2#QMI\,\5K<%GGDF=
M#L"IM G>%3M9\MRA^[D\$D#I6JN@Z<I#&%W<>5\\DSNQ\MV=,EB2<,['GUYX
MI%\/Z;'<)<112Q2HS-NBGD3=N<R$-AAN&YF.#D#)[&@"EIOB1M4UU+6&UECL
MFMI9DFE 'FE9%0%<,?EY/4 ]*B3QA;JRQR6US*=^))8HU"1J9VA4D%\_>7MG
MUQV&G8Z#ING7C75K R3,K+DS.P56;<0JDD*,\X  I!X?TL*X%H,28W?.W.)#
M*._]]B?Q]* ,S7O$=YIFN6]C:P13%XED\HHYDES($(4CA< DY(QQSCK3Y?&=
MA%/>P?9[B2>U>*,QQ-$YD,DOE+C#G'S$<-M(!K=^R0?;OMGE_P"D>7Y6_)^[
MG.,=.M9T7AC2(9'D2U;+NKX::1@"LGFKM!;"@/\ -@8% %2Z\9:?97=S:W4,
MT4MO;/<NN^)CM4*6!"N2I^<?> '7G'-+9^+;>^DMHX=/O2T_GGK$0BPN$=BP
M?&-S #!)-.U+PCIM^EXR+)#<7*L#()'95+%2Q";L#.Q<D8/'4'FI=-\-V]I:
M^7=R->2>7+%ND9RJQ2%2T:AF8[?E7J2??'% %2#QK9W<0-K97=S,;AK80PM"
MY+B(2GYA)LQM/][KQUINF^+X[_4_)%O*UG<21+:72J N)+<3 /EMV2-W08Z9
MJ:7P9I;FW$9N8TBG:=\74N^1C%Y7^LW;AA<#@]!BM&'0]-MS&8;1$\N1)4"D
M@*RQ^6N!G'"<8Z4 1R:C=1^*;;36AA^RSV<TZR!R7W1O$N",8 _>^IZ=JK7^
ML7-EXFTVPVQ&VO&*$F)P5PCMGS/N$Y4#9][!ST%7IM'LY]5BU.03_:HHVC1E
MN9%4*V-PV!MO.U>W8>@I@T'3Q<VUPRSN]L!Y0DNI752%VAMI8@M@GYB,\]:
M-*BH[>!+:WB@CW>7$@1=[ES@# RQ))/N3FI* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHZ4 %%("&4,I!!Y!'>E
MH **** "BBCK0 4444 %%%% !1110 4444 %%%("#T(/;B@!:*** "BBB@ H
MHHH **** "BBB@ HHHH ***3(SC(R><4 +1110 4444 %%%% !112,ZH,LP4
M9QDG'- "T4A(49) 'O2T %%%% !1110 4444 %%%% !12 A@"""#T(I: "BB
MB@ HHHH **0$'."#C@^U+0 444@(/0@]J %HHHH ***0$, 000>A% "T444
M%%%("#G!!QP: %HHHH **** "BBB@ HI 0PR""/:EH **** "BBD) (!(R>G
MO0 M%)D @9&3T% ()(!!QP?:@!:*1G5<;F R<#)ZFEH **** "BD!!S@@XX-
M+0 4444 %%%% !1110 4444 %%%% !12 @D@$9'7VI: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BD9E12SL%4=23@"EH **** "BBB
M@ HILK^5$\A&0JEL?2N>TSQ=;7GA]=9N5C2V8!O]#=[LH"FX[]B?*0.OIZT
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M<J8O+CD+Q*0"3)R%7([\9JGI<OB.YAL);\2RRK<(TB2VF&@;R)M^"8U&-VP
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M=X=1D2X-NJ7#$RPM'_#E2RA_E &<=,@8ZV;Q?HD$<<DEU*%<,>+:4E-K[#O
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MOWTS0KEHS=O&A8",_?C0 $;!EL\]MW6KS64\2V-O81W8M28O-=4#1,K,P?\
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M;4;(7A!D'IELG' (KEA=:_9:>83=:R6$U_NF^P^;)Y@D_<(!Y>#&RDG<!C@
M,HXK=U#^TFU'P],\MW"I++=Q6J;XRY3@/\IPN01G@#/7I0!?O-"M+Z\>ZE:7
M?)]FSM88_<2F5.W]X\^WI3KS2!=:K;:@EY<V\T$;1%8@A61&96*MN4]T'3!Z
M\UQ=A)XGTCPY8VD8NW1+*P+,UN ]ON602HH6-B=NR($%68;B3[=!=7>KQ>']
M*=Y;@2R2*M[<6MJSRHFQCN6-D)R6" _)P&)P,< #8O VFP:--I,,TL=K($7
MA@W!%!"KGR\G&>K9;(!SG.9+OP9IU]+<RSS3N\_E\D1G9Y;!E/W/G(QCY]W&
M1W-8$$_B!=;M[MTOEN;BVL8V4668IE%Q,)#(VTB-A$P;&5P3WZ5 +O6-%M+>
M..WN86FCMH59+?,I.^Z9U7*-DA50XVM@'.!G- '4IX0T^._M;U6836Z)'GR(
M<.%=G7(\O"\NW*;3S[#%K4?#]MJ=S--+/<1F:W6!UC*@$*Q=&Y!(96)(P<<\
M@US5GJNNWE[I$,-Q>3P3VZK<W:VX$3DP.QD3]SA<2!1\S#T*=ZBL;C7+?2K*
M0C4B_P!@LDN;J2S+7"'S'$N%*98KQ_">#NYSD@'2Q^&+>.9+C[9>-<B9YI9R
MR!IBR*A#84 #:B#Y0I&T<]<U++P/I=C (DEN& D\S)\M23Y+P\[5 ^ZYYQDG
M!)K-2\\421)*)+L+"H=5-HH-POVEE&\%<J3"%8@;2"<X'2MC1[C4KMM7M[I[
MH%)&%O<&'RU"DM@(&C4Y4 9)W@\$$Y(  ^P\.16/B*34T;Y!91VL29Y!!^9S
MVR0L0_X!3+GP?877VI);B[-O.)\0;EV1-,")'7Y<Y.YNI(&XX%<_9WWB*'3-
M*B$FJM,ME;%1-99,\Y<K,DS%/D"@+@Y7().6K2\0ZKJL'B 6>GS7.X6T4L<,
M-J)%D<RE2)&VG8NT=<KTSGCD V=;TJ754L5ANGM6M[I9S)'C< %8<9!&?F[@
MBJ$7@G3(;ZRNUEN2]F$V!BC;F4L=Q)7<"2[$A2 ?2L>77M>MI=8O9([Q+"Q'
MV@K<0 ?NTE/F*I\M0<Q@D89_X?FZU>U>SU;4_#6D1S(CWLMS')<))$6CC!#$
MJP4C*KD+G/8&@#3_ .$7LQ:V%ND]RD=E9/8+M9<O"RHI#97K^[4Y&.1Z9%4Y
M_ NESW%Q-)-<DSP/;L,IPK1"(X;;N^Z,X)(!YQ63IESXD@FT:Q*W,-NEO LI
MFA>3>_F,LRLPC8\*!M)9!R#EAG!976N:I?P_:[6^%O%>6TT?VB JT>1*'4D1
MH,+A.FX#=]XYH W-0\*V]Y=VDJN0L>H_;IMS<MA,;!CL66,D'^[5K5?#MMJU
MPTLL]Q$)8?L]Q'$RA9XLYV-D$XY;E2#\QYK)ET:^O/'$UZ#Y%O ;=UF^;<X
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M9W[L[I)4QT_Z99_X%[54E\%6$MW;SM<W7[BX^T*AV,-_GF?C*DK\S8.T@E0
M2<5HZ7H5MI,[RP23,SPK"0Y!&%>1QT YS*WY"@".+Q5HT\$LT=X62,(3^Y<%
M@[%5V#&7RP*C;GD8ZTMMXETZ\U*VL;<W$DEQ#)*CB!PB[&VLK$CY6#9!!Q@C
M!P2 :I\(60MX(X[FZC>"&&**564LGE.75N5P3D\Y&,=JL6/AR"PN[:ZBNKEI
M81.)"^P^>9G#L6^7CYAD;<>G2@ U7Q+8Z5#?&03--:6TER8A"X\Q4 )VMMPW
M49P3C/-4[/Q?'+=SPW=J]LL$4+.VR9BTDG(1%,8+<8]\Y^7@FENO!=C>:C?7
MLUS=%[R":!A\GRK(JJV&V[N HP"2!D\58U'PK8ZF+@S/)NFDBESA&"M&,+A6
M4@Y!(((/7M0!,?$FED+Y<\DQ:'SP(8'<A/FQNP/E)VL #@D@@<U&_BBQC\/6
M>MF*\^RW30JBBV<R R,%7*8SU8?7MG(R6OAN"RNEFMKN>)# L,T*)$L<P7=@
MD!!M/SM]W;VIW_"/Q_\ ".6VC&\N2EMY)BN/D\P&)U=/X=IP44=.0* (K7Q7
MITUQ>P7$GV9[1Y@QD#!2D>-S;B ,@$$KG(!J>?Q!9QZ%J.JQ>9+'81222Q%&
MC<%$WE2K $$C!&1T(/>J]UX2T^]@FAN'G=)C<%QN SYR[6[?E_6I(_#5HGAZ
M^T8NWD7L<D<KQQ11-ATV$@(@7..Y!_I0 6WB:P:UAENKBVB,Y81"*83+)AE7
M"LHP6RP&T<T/XITO_2$AN \L!8,K*R*=L@C?#%<-M8@'&<$C/6F7?AE+\69O
M=2OIY+.7SH)#Y:E),C#85 "0 PY&,.V<YXI6O@Q"LYO[ZXE9Y+DQ(A4)"DMQ
MYQ"_+DD[4SDG&#CK0!J/XDTM(;F;SIFBMI6BF>.VE<*RY##(4YQM.2.!WZBH
MU\364MW<6T2REH+F*W=Y(V5&,@4@JV,-PXX_IS4.H>$++4=+&GR7%RD/VB>X
M.-C;C*SLP(92" 9#CC(P.:E7PQ:I*S"YN?+:6"8QY7&^(*%/W<\A%!&<<<8H
M </%6BF&6;[8?+CV9)B?YP[[$*<?."V "N033[K7K>+0O[4M5:YC:1(D3E"7
M:01X.X94AC@@C(P:I6W@ZSMXH8VN[N5+<0);ARG[F.&59%0849&44$G)P.N>
M:N3>'[>71I=-6XN(TDN6NO-4KO5S.9^,@C 8]P>* (D\3VD=O=2:A#/:26<O
ME7">690GR!]V4!^3:P.XX [X(J1?$^FF>_B;[2C65PML^;9SYCLBN!'@'?PW
M0<\9Z8)H:AX'LM3LI;>ZOKV1YW>2>9O+9I2R"/E2FT84 #"C&,]2<S7OA"RO
MFN#+/-B:XCN@C+&ZI*D8BR RD'** 0<CN,&@#:LIK:XLXI[,HUO*/,1D& =W
M.?Q)J>JEC8"PC6*.9S"D21I%L1%7;G+ *HP3D9'3@8 YS;H **** (;FTMKV
M P7=O%/$2"8Y4#*<>QJ2.-(8UCC14C0!551@ #H *=10 4444 %%%% !1110
M 4444 %%%% !1110 5#=6=M?0^3=V\-Q$2#LE0.N?H:FHH :B)%&L<:JB* %
M51@ #L!3J** "BBB@ IOEQB4R[%\PKM+XYQZ9].33J* &2Q1S1M'*BR1L,,K
M#(/U%/HHH **** "BBB@!J1QQ B-%0%BQ"C&2>2?J:=110 PQ1M*LI13(H*J
MY'(!QD ^^!^0I]%% !1110 4444 %%%% !1110 4444 ->.-V1G16:-MR$C)
M4X(R/0X)'XFG444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% #5C1&=E15+G<Q QN. ,GUX 'X4ZBB@ HHHH **** "BBB@ HHHH
M **** "J]M86=F\KVMI! TIW2&*,*7/J<=>IJQ10 4444 -DCCF0I(BNAZJP
MR#3J** "BBB@ HHHH 88HVE64HID0$*Y'(!QD ^^!^5/HHH **** "BBB@!B
MQ1H[NJ*KN078#!8@8Y]>*?110 4444 %%%% !1110 4444 %%%% !1110 44
M5%'<P2S20QS1O+%CS$5P2F>F1VH EHJ**Y@G:189HY&C;:X1P2I]#CH:EH *
M*A@N[:Y9UM[B*4H<,(W#;3[XZ4K7$"W*6S31B>16=(BPW,JX!('4@;AD^X]:
M ):**:)(VD:-74NF-R@\KGID4 .HJ*XNK>T0/<SQ0H3M#2.%!/IS4H((!!R#
M0 4444 %%1R3PPO$DLJ(TK;(U9@"[8)P/4X!/X5)0 44=*165T5T8,K#((.0
M10 M%%% !1110 4444 %%%% !1110 4444 %%%% !113?,3S?*WKYF-VS/./
M7'I0 ZBH9+NVBE\N2XB23Y?E9P#\QVKQ[D$#U-34 %%%% !1110 44Q9HGE>
M)9$,B %T##*YZ9';.*(9HKB%)H9$DB<!D=&!5@>A!'44 /HHJG#JVG7$L<4-
M_:R22EQ&B3*2Y7[P !YQW]* +E%%% !1110 44R.:.8,8I$<*Q1BK X8<$'W
M%-CNK>5]D<\3MEAM5P3\IPWY'@^AH EHHHH ***9)-%$4$DB)O;8NY@-S>@]
M30 ^BBFI(CEPCJQ0[6 .=IP#@^AP1^= #J*** "BBB@ HHIHD1I&C5U+IC<H
M/(STR* '4444 %%0P7=M=&7[/<13>4YCD\MPVQQU4XZ$>E/2:*1Y$21&:)ML
MBJP)0X!P?0X(/T(H ?102 ,G@5%!<P74?F6\T<R9QNC8,,_44 2T44V21(HS
M)(ZHB]68X _&@!U%%% !1136=4QN8+N.!DXR?2@!U%%% !113'FBC>-'D17D
M;:BLP!8X)P/4X!/X&@!]%%,DFBBV>9(B;V"+N8#<QZ >IH ?1144ES!#)''+
M/&DDIQ&K. 7/H!WH EHHHH **** "BBB@ HHHH **BGN8+6/S+B:.%,XW2.%
M&?3)J0$,H92"",@CO0 M%%([K&C.[!4499F. !ZF@!:*A2[MI+J2V2XB:XB
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MEN \,N9 8/+0,=N$R#POON/-+#XQ@EU-4^S3&QE@M)([A4^XT[NBA^>Y50,
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MKNHZ'J<%])>/*^CB&WB%WM!F)FR&VL 6P8@6/!Y]ZT8Y=0TS5YKQK/4I=/\
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M<6JWC/,F3+YP\]HL$[4V9Z8XQ@9S0!UL&D65M<1SQ1%9(S,RG<3@S.'D[]V
M/MVJJ/#.FI<7%PD3F682\2RO)&IEY<A"V!GOC'ZFLFPAUZ#5=.$XNYX$:>*3
M?( J1B27RY"P;YV*>6,,IZ@@@[JENVUX:Z\$,-R;5KWS5F5D\M8/LI7;USGS
MAG&.X- &K8:%;V/ARUT999O*@B6,RI(R.Y'5B0<Y)R3ZY-5(/#6@I=6Q@0AK
M9(Q'"ER^T",%%)3=AB!E<D'WZ5@_V1KAMK,7;ZE<K$]E<28N/WGF8<3 $$<
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MFD4Q.WFKY/E $X 3=G@=1G)K/$'B_P#MX1%Y?[.^T>1YF]<^7YOG>;Z_ZO\
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M88-8D/A.P@AM8TFO0;1#%"YN&+)&0H*9_N_(OY4 ++XKTZ)+IR)F6WN%M20
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M+'+%AE**KE>,@DJZD 9SSZ&FW?A:UO-2DFE(-K-',)H>=SO((U+;L_* L8P
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M!U5BRY'J"S8/N: ,ZZ\;Z-8VZRW;RP-F4/%(F'C$>-Y(ST&Y3QDG<, U=O\
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M[3K#+)*\3*JHBY,I9_+&T9_O<<XZYZ<U-_PBFG&,QR/=2*]RMU+YD[-YLBA
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M@TZPMM0FU02EI=GDEWERL:@Y*CTY'?I[5$/#.FA)4*RLD@N%VF0D*)R#(!Z
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M^;Y-M=R2)*"C*\**X4CW##GWK8U77;'1RHNVER8WF(BB9]D:8W.V!P!N'YT
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MR2+.L,JSHT94,KL"!C_8/7'0YQTI=&\11:WJ-U#;PRK;Q6\$Z22QM&7$ADY
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M',WD[-@7KO\ E]<]N]3?\)/IH@M9B9UCN9OLZLT# ))YGE[6XX._Y?\ ZW-
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M@.<*4'R@>BYR<>K$]Z1?"FG"S-JQG>+[-+:J&?[L4A!*CCMM&.]85Z?%$5A
MZW=X&FN;GS76 .T(#,(0%5"=N,$\')QDX)I;V]\5#5+U+*&Y.RSE";D'EM*(
ME*,N5 &7W#!=N^<<8 -Z;PUID_VB-Q)FXAN8G DY*SLIDQ^*C'I5K4-'M]3N
M+26X>3%M*LR(I !=2"I/&1@CL1GD'(XKEKVVU:6>/4--N-5+P6$WEM<0(KRO
MYB$(RE <'![ X[TLMQXJ^TZP5DG5D$XAA6WR-GF#RVC8KM+>7DXW-DGD<8H
MU;'P?HNFI^[,C)$4SYD@PH1'50< =%D;.>3U))YJ_I&@6NC/(\$MS*SQ1P9G
MDW[8X]VQ1]-Q^O?)YKG%L+Z7P3XKA2*]EFNS<&V^T1A9908553MP.I&!D ^O
M.:@N;GQ.8&%M/J"V9N9!'<2VH,X7RDV[D6,G;YGF_P (Z+S@\@'0KX6ME60_
M;;XRM<_:TF,B[XY=I0LORXY4E2"",58D\/V;:=964330+8L'MY(I/G1@I4G)
MSDE68'.<[CWKG9CX@TY]:N[;[;=W*W<,\=L8QY4T1AC1@A(XPV\XSGY!ZY,'
MG>,$TY1<O.&ANEM)I8X06DB1'S<*JJQ^=S'D ' '0<F@#=M_!FE6MY97,7GA
MK-(TB#2;ON!@I)(R>';O@YR1GFELO#"6/AG4=)BD4/>FX)DP<+YF0HQGHJ[5
M'LHK,M9?$QURUCNKF3R5BB)*VI\N?]U^\)^7Y&WYX+#&!@<G.AX6&M(NS5IK
MB;?8VLQ:=$4K.P?S4&T#@;4X[9H 5?!UAY*>9/<R72.L@N7<,X(38!\P(V[2
M1@@]<]>:O_V#9>7*A$A$MQ#<O\W5XO+V?A^Z7/XUR4=QKD7A30[.RCOK1[>$
M0WC_ &5RZ.(\+@%&++NSD@$<#)P35VYGU]9]1C%Q=8\F-XYH[5MD; QAD"["
M6W?.=REMH)R/E&0#3'@_35B,?F76$"K;DR\VP602*(^. &53SG[H'08JYINB
MKI<JB"[G:W59#Y4C;MTDDAD=V/<Y/'3&3Z\8$-WXBEU"S+QW\#,;8B!HT:+R
MBH\XR.%'S@[NZ\A<#DU?M6UBU\$+/<O>76JO LDBX19$<@94 (0 .?X2>O4T
M 32>$[*2.2-KBZ\MKEKN-2ZD0RLS,S+E>Y=N#D8-22>';1[N"9KFX$T,#0PG
M<H*Y&"P^7KCM]WOBN=63Q9-I22B:]CFAM[R15$29F=9AY"ON3/,?;"D]^:MV
M<>JS^-(9[P7I2![M2&B401QDJ(BC8R25&3R><YQQ0!IVGA'3;&>WFMC-&\*A
M205(D =I "".,,[GY=O7'3 JWI.AVNBK(EHT@B;A(VQB,9)P"!G'/<FN?N9]
M5M(?$$-A;7:WDE^DT<GD,5,)\E7*-@@L%#X R<CH:6WGUZ.?3/,N+NY1UE$@
M%J8]HW.5=MR#) "C:=A/49SB@#:A\-V,6E:EI[--)'J6_P"TNS ,^Y A/  !
MV@<X]SDU2\2>$HM==)5:,2>:CRI,"4D")(JCCICS2>_2L1[KQ6UC9(DEW%Q,
MKW36Y8R2C9Y;&/R]RH<R?*0.F-V-I.C;ZCJ]EK.I76JRSK8V_G$0+;EE=-P\
MK8P7!8CMN))8C P, &O9^'H88X'N9GN+M)(II)L!!)*D7E[MHX ([4]?#]HF
M@1Z,))_LT001-O&^,(P9,''\)5<9STYS5'Q,NJ"83:7&QF33KL1RI$K,DI,6
MP D'KAN.AQSG I\46M+I&M6R74SW<4CBPN)U7<P\M64G  (WEATZ"@"U!X=L
MX-26]$D[,LK3I$SY1967:T@&/O$$^WS' &:CN?#%E=?;%>:Y6*[<2O"L@V"0
M,K;P".N47@Y'7CDYYR&[\8W<%^S17-KF)Y[8>4FY1(R>7'@@Y:,+)N'^TM6K
MRPU*+6(G$M]]GBU"$O-#&N^:/[.RDOM7YAO*@\<>V. #7@\)Z7!:M;HLI1DV
M'+\D>:9?_0F-))X4L)(7A,UT(_/-Q"F\$02%F8E 01R6;@Y&#CIQ6)%%XCC4
M&$W%ND)5U@BAC5)"UV^[(VY_U6#QCKGKS1X8UZ]N]8OVO;J>9"6%O;(H8%?M
M#)Y@PHV@ H,;FX!/K0!U5KI-O9R22QM)YDD$<#.3R53=@\# /SMTK/C\(:8D
M$\;><YGBN(I7+ %A,$#G   /[M>@'<]236]10!S\G@W2I;R\N7$Q>[CDBD&\
M8 DV[\<9YV+U)QCC%7Y-$LY=,O-/(D$-V\DDA#?,&<[B0>W)XK1HH Q&\+V+
M3W<K23DW<92X&5_>$QB,MG&0=H'0@=\58FT*RGF:5U?<5ME.&[02&2/_ ,>)
MSZUIT4 8W_",::'+;9<^;YWW_P"+[1]H_P#1A_+BH)O!VE3W,,["8-%,TX <
M8+&<S]QD#><\8R.#D5T%% &#)X3L)"K"6X1TFFEC8,I*><VZ11E2-I89YY!Z
M$5HW6EPWFGWUC</*\%XCQR O]U67:0OH,?J35VB@"@^EQ"#4UA)5[\EY&)R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL^^U(VMPEO# ]Q<.
MF\1IQ@9QDD\"HH]1U)G ;265>[><IQ3L*YJT5S6DZ]JUY?6\-WI30121[C+M
M8;6P#CGIR2/PKI!2&+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !152_OTL4C)5Y))&V1Q
MH,EC_3ZFJ8U+4R>=(8#U\]:=A7->BN7M_$&LR:E!;R:0P@DE*-* 1L&/?^==
M.IR,TABT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[&JO]FV'_/E;?]^E_P *M4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<Q_PM;P+_P!#+9?FW^%==%*D\*31,&C=0RL.X/(-0?V98?\ /E;?]^E_PJR
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M*<DR)E0=K$\Y'0T <?\ \)MXJ_Z)SJ?_ (&0_P"-'_";>*O^B<ZG_P"!D/\
MC7=T4 <)_P )MXJ_Z)SJ?_@9#_C1_P )MXJ_Z)SJ?_@9#_C7=T4 <(/&OBHD
M _#K4Q[_ &R'_&N[HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@".>1XK>62.(RNB%EC!P7(' _&N(_X3;Q5_T3G4
M_P#P,A_QKNZ\JN=0\0VNCS:A'<7\JKH4,<L0+%EED\X"9>^]66,'_98D_=%
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M_ R'_&NXA=I((W>,QNR@LA.2I(Z?A3Z* "BBB@ HHHH **** "BBB@ HHHH
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M^B6ULEV4,0+O X8K( &( (1OO$$8Y R*LWVB7%]KL5])>1-:QQ&-;62 MMW
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M:C))X[=, '745%"DJ>9YLHDRY*87;M7L/?ZU+0 4444 %%%% !1110 4444
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M^)H_X6]X!_Z&2W_[]R?_ !- ';45Q/\ PM[P#_T,EO\ ]^Y/_B:/^%O> ?\
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M^Y/_ (FC_A;W@'_H9+?_ +]R?_$T =M17$_\+>\ _P#0R6__ '[D_P#B:/\
MA;W@'_H9+?\ []R?_$T =M17$_\ "WO /_0R6_\ W[D_^)H_X6]X!_Z&2W_[
M]R?_ !- ';45Q/\ PM[P#_T,EO\ ]^Y/_B:/^%O> ?\ H9+?_OW)_P#$T =M
M17$_\+>\ _\ 0R6__?N3_P")H_X6]X!_Z&2W_P"_<G_Q- ';45Q/_"WO /\
MT,EO_P!^Y/\ XFC_ (6]X!_Z&2W_ ._<G_Q- ';45Q/_  M[P#_T,EO_ -^Y
M/_B:/^%O> ?^ADM_^_<G_P 30!VU%<3_ ,+>\ _]#);_ /?N3_XFC_A;W@'_
M *&2W_[]R?\ Q- ';45Q/_"WO /_ $,EO_W[D_\ B:/^%O> ?^ADM_\ OW)_
M\30!VU%<3_PM[P#_ -#);_\ ?N3_ .)H_P"%O> ?^ADM_P#OW)_\30!VU%<3
M_P +>\ _]#);_P#?N3_XFC_A;W@'_H9+?_OW)_\ $T =M17$_P#"WO /_0R6
M_P#W[D_^)H_X6]X!_P"ADM_^_<G_ ,30!VU%<3_PM[P#_P!#);_]^Y/_ (FC
M_A;W@'_H9+?_ +]R?_$T =M17$_\+>\ _P#0R6__ '[D_P#B:/\ A;W@'_H9
M+?\ []R?_$T =M17$_\ "WO /_0R6_\ W[D_^)H_X6]X!_Z&2W_[]R?_ !-
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M_$T =M17$_\ "WO /_0R6_\ W[D_^)H_X6]X!_Z&2W_[]R?_ !- ';45Q/\
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ME1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10
MSRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_S
MS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GF
MOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4
M ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_
M\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_Y
MYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]
M% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4
M?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_
M^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J
M?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>
M5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J
M/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_
M*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5
M'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/
M*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_E1Y4?_/-
M?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10 SRH_^>:_
ME1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_SS7\J?10
MSRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GFOY4>5'_S
MS7\J?10 SRH_^>:_E1Y4?_/-?RI]% #/*C_YYK^5'E1_\\U_*GT4 ,\J/_GF
MOY4>5'_SS7\J?10 SRH_^>:_E3Z** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>bionano-nancyridgeleasee003.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***3<,D9&1U% "T444 %%%% !1110 444
MF1G&>?2@!:*0D 9)P!W- (/0YH 6BBB@ HH!! (.0>]% !1110 4444 %% (
M(R#D&B@ HHHH **,C.,\BB@ HHHH **** "BBB@ HHI RMG:0<'!P>AH 6BD
M!!S@].M+0 4444 %%%% !1110 4444 %%%% !1110 44A('4XI: "BBB@ HH
MHH **** "BD!!S@].M+0 4444 %%("",@YI: "BBDR,XSSZ4 +12 @]#FEH
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M:4 7+@[6P5R.#S0!R^J7>NZ;K7B\Z987TEY<P0OI\@MV>(LD1W8;&T'T!ZG
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MDSD""*7=C'?S<=>V>]-@\6:<;J^M[MS:O:R2J6=&V,L:AF._;MSM.=N<X&:
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M-PDW;"-RC(;8V"...M,?Q3ID;2.T^8%2(JR1R.[-(\B*H0+DY:,@8R2>PXR
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M=W";\/"\>1DJ<;E&<$$''0\'!H YB_NO$UM \*S:BQC%V()HK1)'GE#+Y"R
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MAQ<^?'+;A(HB)0(?+?:-^4R3RWOM/%6+3Q?IUU9V]Z?-@MY[83J)HG67EE4
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M7-UL>60&?[&_FQ_(FP,OV?)&[><B,= -WKT-YXOTFT60AKFX,;PJ_P!GMI)
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M&NI;.W4E\Q.'!PA+*'*CV'/O6];>,=#NY8HX;J4F7R]A-K*JD2'"'<5P QR
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M...QW(MJJI,7G=9BVY P*Q[6(&W'7&#BMP>)M(,<TJ73/%#&DCR)"[( X4J
MP&"Q#J0HY.1Q3G\0Z9'=0VTDTJ2R^7@-;R (7.$#DKA"QX ;!)H YB34/$?]
ME6SK)J0NFN M^#9X%O\ (_$6(6+IN"#=A^,<C)(U]3N-5BTW2-T]T@<#[=<6
M%IYD@;RR1B-D8@%O]G(X!QS5E?$UG+$+R(2-IBQR&2[,3J ZE JJI7+[M[<K
MGE2.3TO7&K6EI9Q74[2JDQ"QIY#F1F()P(P-V< G&,@ ^E &%X9L=2_MBYU3
M5ED6\FL;5'!C0*K[29%4@9P&SQDCGZ51TX^(XHM/.;B&*&&P5[5+9%1B[LL^
M?ER-JX.%( Q6VGBK3VGDRS&#9"T$D2/(TQD5F 5%4MD!">G0'.,4MSXMTFWL
MY[F.2:Y2*U^U'[/;NXV;-X^8#:"5Y )!Y% &'!JWB""S5YH]0N-LLT;2"S.9
M3Y0,9$?EJR+OR.00#U8CFI?M/B%-/OKJ>34"X:WBAABA0;0T<1DD_P!4['#&
M0' ..0 ,9&U_PDM@C-YID0$1^6@AD,SEPQ \L+NSA&.!G@$G&*5/%.C27%O"
MEV6:X6-T*PN5Q(2$W-MPI8J0 Q!R,=: ,"TN?%4R6<\TEW&8XK#S(?LZ8E9[
MATG+93((C"MQMQUQVIDFH>(O[,B=9-1%TUUMO0;3 MUVR<0XA8NNX(-V'X(Y
M&21TEQXCL+34[NQN//C:UMDN9)3"QCVL6  8#ELKT[YP,G($L>N:=)82WHG9
M8(I/+E,D3HT;9 PRL R]0>1T.>G- &9>-<E?"OVUP[M=+]I8(45G^SRD':>0
M-^, ]#BL#2M+U;0_#XOE2:*YN8X8G@M(B'0AF+2R I(68[@"0A/'XCJ)O$ND
MN@$5Q#.XG,6U@P 9)DB;G:<$.ZX]>,<<BF?'&G#R)6@NTMGDN8G=[:3<AA;#
M$*%)*\$Y[8YP<@ %&UN_$K:<]Y=F_$D>F6S?9X844O.Q82'F-CE<*< <<_*<
M@5EGQ!KZ3:=;W=Y/9X<M<2- ,^6;HHA<>3GYHUP#B/DY]<=9!XJT^35KRPF?
MR6@F$<<A5C'(/(28G?C:#M9OESG"DU!+K^C7MWI\B01SR&X$?F7$#1/ IBDD
M#C>H.#Y9P1P>>>* ,?5+SQ19Z"9H&U&;4)7N715@3;'M8B)"JQ,2&&.3C/.6
M&0*KZK>:WJBZ_8V[WMRFR]MV@^R@1!/(.S:X7+.7(&-Q.">. :ZO2?$5KK-[
M=Q6J2>1;PQ2B62-XRX??T5E!QA00>AS4=MXJT*6W:>WG<JQC<*MK*'E\P'8R
MIMW.&"MRH/W3Z&@"N4U5=#\16L[7EX\:NMHPVQ2RJ8%.%95 SO+ '''OBL[P
MU;RVNAZE97,-PBW$KA)H+&2%<>0N2L)&8^01_M-DC[V!OKXGTAT9UNF*);FZ
M=Q"^V./YN7.W"GY&X.#E2,4Z3Q'ID1@$LTT9G *A[:12H+;07!7Y 6X!; /:
M@#E]/BEMHM,@CLXX%CU=5M)$LVM3.GD-YC-&W(./,&3C.T''2MGQ+;S:SI.F
MBVM/,$EW$[Q74+;0F#GS$Z@#C@]ZN_\ "0:4XBE#RONG:"(K:R,7<!L[,+\P
MPK98<<=:8_BG3+:-FNI_+Q),I\M'D"+&Y1G<A?D4'J3P/4]: ,2UA\0:7K&G
MZ4MU*]C!%"HE\AG2;EO,!(1BI P!EUQQ][FH8+GQ3#I\37=QJ#>;;V4MQ(MH
MAE@9F<3*BJG. $R"&(R374VVO:==ZD^GPSLURA<$&)U4E" P#$;21D9 />HF
M\3Z/'<SP2791H!(9&>)U0;!EQO(VD@<X!SCF@#E=+M]=M[)4@2Z@DD,*FX:U
M3S0KWLAD)RN,^6V[&,#.<4U];UR'6;.PNK^>W2*1!+*T"YD5KJ6--X$9^^B(
M 1L +9Y[=1+XMT:"'S9;B9<%PR&UEWKL4,VY-NY<*RMR.ASTJKJ7B#2(]9LX
MEMXKJ[$CQF=HFVP8@>;B3:1G"K\H.<-G% %+Q(-4N=<@M4^V_9%N+"6*."W#
MQ2;;@-*9'VDKM"J<9'X\XIVS>(M1A U)9F=+VT=X# P$16X!8JWEJ"@4=F?@
M9SSSTL7BC29)TMVN=DQ W?NW\M6,7F[?,*A<[/FQG. >.*EMO$.F7=C>7D4T
M@@LQF=I+>2/8-@?HR@GY2#QV(H YRQE\40)I]I%;E4DMEF),"HL3(K[HC@ #
M<WDX[X+XQBC2YO$]Y!8)/>7<7FW:BY?[*%DB002,PR\2KM,@C&0#UQN.170I
MXETIY8(_/E5I]I3?;R+C>Q5-Q*_+N8$+NQN[9IO_  E&DFV6X$T[1.VV,K:R
MGS>"V4 7+K@$[ER,=Z *?AR^U:\O=3BO7W)8.;0$JH\Z0$MOX'_/-HNG .\8
MXKGI(=?US2EMKQ]096?3WN5EM$3RYO/!F1 4PT:J <_,/E'S$9KJ!XFTFW\T
MF1=AF"1_9HGE:4F)92=J*3G:V>,\<Y["SINOV6JWUS:VGG/Y"1R>:8F$;JZA
ME*OC!X(H IZK<:G!K]C%9F=K5XV5XHH<*K8.'9RA7 P!MW*?][.*Q8]7\07$
M-NTJ:G;VX2U6ZE2P_>HQ27S2B%#N_>"('"D $D<<UK:AXTTZVT^>XM/,NI4*
M!(_)E42;Y!&&4[#N7)^\H;MZC.NVIV\-U:VDQ875PA=8XXW? & 22%^49(&6
MQ0!SNFV^K6WB*6X62[-I=ZCB6*2%0IC^QJ1*3MR#YB!>N.2,9KKZR3XETG[.
MDXNBR/##.@2)V9TE)$950,DG:W &>.14-IXHLKG6)M.=98I1*D<!:)P)-T*R
M\DJ C8+?*3GY30!N4444 %%%% !1110 4444 1W$$=U;2V\R[HI4*.OJ",$5
MSH\#Z6='_LQY)FA\Q7#JD4;X *E241<@J64YR2&/-=!=O/'9SO;1B2=8V,:$
MX#-C@?G7$0:MXKBT87OES7<N\1FW:U=7#/&0"<Q)\JR[,D X4MDG% &[?^$;
M.^DN)1=WEO)<>:)6A9,E)$173YE. 1$AR.01P:8_@K3&FOI TJB]B>.4!(B1
MNC\LL'*;P<#INQGM7/:\VN)8ZI9 7PBF6Z436MCYC7$@AB$:D!3A6)ERPQRH
M&X59GU'Q3%-JJP)(@M[:7[-#]F=P^(08RI$6"V_L7/<;<T =#<>&K>6\:\AN
M[NUNFF\WS82A(_=+&5PRD8*HO;.1P14,?A6&QGO+C3;EK:XNG=BYAB8QEW#N
M5;9O)/S8#,0">F  ,V:\UVUNGM;BYU#[(EXR"]@L1)(R^1&ZC:J$;=[2#<%_
MA SGFK>A7NN7.OWJ:ANCMD:=5B:%@ !)B)E;RPN"G)^=R2>-N"* -:]TD7>J
M6FH)>W-M-;1O$/)V$2([(S*VY6[QKTP>O-9,/@;38-(GTR":5+64*N!!;DJB
MYPN3'ENO5LG@'.<YP]3E\0:IIVJV3'4/WMM<K-$+,*L1$JB)8F*?O Z;L\MZ
M_+TK;U]=1TZ*!=(@9WM]-N1$R6X;;(!&(QA1@9Y^4  XZ<4 2W7@O3KV2X>X
MFN':98UY$9V^6P92?D^<@J/O[N,CH33E\':<E[:7:LPFMT6//D08=5=G&1Y>
M%Y=N4VGGZ5GR7NO6=]% \M[<PQZAY6Y;4!YXBL1#%A&4"J7<'[F0O#94Y@_M
M?Q'<Q"WBCO(9U\N.64V) 5C=*C%2RX8"(L<C(QS0!OZKX:M-8O!<W,\ZD020
M!8PB_*Z,K?-MW'AB<$[<@'&15;5/!FG:LDR337*B9P[A=C XB\KHRD?=[XR#
MR"*R-1U3Q';ZCJ4%C'?RI!93B)I;8,&F6-#&R[8@#N8MQN.3D;5Q5B2\URUO
MVM+FYU#[''=.@O8;$222#RHG0$*A&TL\HW!1]P#(.20#;M?#MG:7XO(WF,HD
M,F&88R8HXO3^[$OXYJG<^#=/O9;HW5Q=RV]R9F:V9E"*TJ;&9<+NSM) R2!D
M\9JKHVIZT=5O6U195MD>51"MM(Q'[W;&4(B (*<GYG]?E (JQJ6G7-YXTT^8
M11M:P6Q9FEC9E#>8I^4@@!\ ]<_2@"W%X;M(M O-',CM!=HZ2NL<4;8==IQL
M15SCN123^&;"?73JS9$SJHD0QQLK[00#EE+*<'^%AT%8*:MXCN[=8(TO()U6
MVCFE-B1MD:Y"2E=RX;$>3D94#FFRV.K3:Q+;M?ZJWEZQ&\<SP*5BA-J060^7
MMQN+*>H!QQD\@&A;^"Q!<2C^U+QHE@M([60E#+"8&E( ^3:1B0#D$GG/K5RU
M\)6%KY16:Y<QB'!=P2?*DDD7/'<RMG\.E8UCJ?BB;4],CN4>&-H(&EW6S[96
M.X2[L1G:W P"Z <=0:VO#M[<G3=.@U:YFDU6[M?M4D<D(3R\! RX"C;@N!AN
M3SZ< $3>#-,,M^X>1/MI=F"I$"CLP8LK[-^=PS@L1[8P*M)X=MQI.I:=-<W,
MZ:CYGVB61E#DN@0XVJ . .U8NFZ=>3^*K*]NHYDCMQJ6U3 H0$W("-DKD%DY
MR",@9Z$Y9/J.J6=GJT%G;WOVL:CO#M:RD"!G4%D;RV5L G@!L<G!Q0!M#PS
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M:B^H2WRF:."6.&2+$4>8EW;#MX(;<"N<^H[UD6&J^+;B^6TO+.586S&TWV;
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MC;&5L*3P W<X.*='J.OI/9)+-/();63+164FV-QYA5Y,Q MP$&U2AW=%(88
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MU=Q; W$8)QSBEHH **** "BBB@ HHHH *9)%'* )$5P&# ,,X(.0?J#S3Z*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"+S$!,GG P*V"<C9GC.,=:KWMEXEDU2ZN;>.\^VQQ7RPR.Z&$!G7R!&"?O;
M,YP-V<T >@4UY$B4-(ZH"0H+'&23@#ZDD"N4TFRUI[[3_M5Y?&S07$C!AY9S
MF+RT;+,S#_6GD^QXQF#5M$OKK5]2$:WNRXN;"5)$E^1525"^T$\, I/3ITH
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MB]R;N:1GVF%!L !FX=&#YP(\_*H4D=<-0!W5!.!DUP<:^+EM[?8MR]Z=/EC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ Q1110 4@ &< #-+10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &,T444 %%%% !
M1110 4444 %%%% !C P**** #%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>V-P4F5UC*R1NF2Q(7&0,@E2 1QD8S6=?>,-/BL[6;3V6_>Z>%8ECW[=LC,
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M^TRYU%6D@MK:26.5[B)H]OEL58\CI\IY_D<BD3Q)I,AA5;EO,EF,"Q&%Q)O
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M=M@W&(N5X"@?\M#GZ"H;?PK%:3,]KJ%Y )(?)F5"G[Q=\CCDKE2#*_(QV]*
M&W_BZSM;4SV\;W&TS+(C*T3(T<+38*LN1D 8XZ,#S6G;:O973QQ1SJ9G+J(^
M<AEQN'X9'/N/45AP>!-/ALI;8W5RPE=W9@L:G+P>0>%4#[O.>N>35ZP\/K9^
M)K[5=P*S0QQQ)G.T@ 2,>."P2(?]LQZT 3#Q+HYEN(OMJAK<2&0LK ?NVVN
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MU2.PE28RRW?V1#%&T@#^4)?FP/EX/]>F<37.N6=G>26UPY5E\L*$5I'<N'(
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M1@=<]-!KNFW%^+!+N,W?>'/(.T/C/3.T@X].:HW?B_3;6XGA)D+6]XEG,2A
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MD0?,6VX!/&<#+ <XZCUJK/XEM+;7;K3IL1I:VT<\LSDCF1BJ*HQ\Q)'KG)
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M;Q0^FW%WY;"6'3X)%A-J1OD=G#L1@ME556V 9!."#TK>77M(N(K:6ZDBCD6
M7BK*O^K'E[B0V,9"L<XYP3VJT^MZ;'I\5^]V@M9FV1R8/SGG 48R<X.,=>U
M'&WOB'7K:WMXUN0]R]K=S0"&T:4W#H\8B1OD7&=Y!(4 ]B*LW>O:^=4U*"SB
MG$:12>7YML2(Y%EC1<849#*SM]XD@ _+TK?B\0^'[E6OXKVVE\E%7S5&3MD.
M%"G&2&9<8&<E<=14O_"2Z-NMU_M&'=<8\L9ZY;8,^GS#;SWXZT 8,^I^)+?7
MKFUB"3QVZ$1)+&P-T!!NW@JFT-YOR_> P",9(-&@R7EU%KT\TUS<&2WB\N26
MU:$EO+.X!2!T)QQ]#DC-:#>-M(4PNTCI \MQ"TLB%=C0DAN,<C@G/8#)[ULS
MZC:6SVZ2SJ'N#B(*"Q;ISQVY'/3D>M '"6?B#6]*T%+DI/>6UI';(ZRVAAD:
M1T9#$H(!.V3R>>>&8$G%=%J=S<:==^'Y+R69U0NMU)!$[*S>4>2J@X!;I4EG
MXCT?6+.1I3&3;OO>%UWE2DI56 QR=RC&,X..]+)XIM!<QQVZ>?'(+<K*K8!\
MV5HNGL5.?RH Q%UCQ)(=49WAMQ$TBK&\4FZ,"8*A&(B/FCW')+C)!QM!%.D\
M0:V/->&"[<OIZ311M:G="V$W&10HR_S,0%8@X*X!&3T+^(K&'7Y-(N)%BG"1
M,A8\.9"P ]N4P,]2<"K5CJMAJ3RI9W*3-%@L%]#D CU!(.".#@^E '/:;?ZU
M>:I;P"XE-@)IB+I[3:UQ&@A*YR %RSR+D 9"Y'K3=;U'4]/OKZ6V281K-#D1
M0EY)D\MB5CRK+NW;>N,\C()!K63Q7H4ELURFIP-$NSYAGG?D)CCG<00,=2".
MHJ5O$>CI)<(^H0J;>-Y)2QP%5 "YST.W(SZ9YH SM?N=3@U,?V>C!FAA02^4
M7"EKA%;CIPA8_AFLN[US7K5;*%4N9)Q=R1N_V;Y9HEN1&"<*>?+^;C:/XLXX
MKIO^$@TO=&OVKF5"\8V-\P +$#CKA6..N 3BHK3Q1I%Y;6,Z7007J(\*R*5;
M#'"Y_NY/ SU/ S0!AG6M5^SR-)/<PN;TQ7 6Q)^QQ!I K)\IWY"IR=P^;=P*
MF;7=474A9+'.Y-U\KFS=0UO]CW[B<84F8$8//:MBR\16.HZS)IUI()FCA,K2
M*>!A]N!Z\@\CC@U#IOBO2]1LY)A,$>($R18+,!O*<8'S<C'&>>.M &))K&O6
MHT*-C<37-Q]F>Y_T7;&1)(JR+PI(**2>2N!@DMTJFVI^)+/3XX8;F624W5Z)
M+B[@;Y&63]S&=L;91E)/ Y P&' KLH]>TN4H([V-M\/G@C. G/S,>B_=;KC[
MI]#5>X\5:/!I[WAO4**64+@ABP7?C&,CY<')&,$'I0!'K5_?6>HZ0L.\PS2[
M)XX8RS$ED .2I&P98MRIQR#P0</_ (2/6I+8J(9XWBBB6ZD^Q/\ NF,^R1E!
M&&*IEN,CH>175P:K;26=G<2NL)NH1*B,><;=Q_(5$GB'2)+M+5+^$SN!A<^J
M;QSTR5^8#N ?0T <]#)JL6OO>6\\\UM(UG$X>U*^:K;@SG(!4C(/&/?@\7-2
MGU5?$,D%EOACF:UC,XAW[5(G+D9XR-J<]LC.>E:*^*-$:W\\:A$8]ZH.#EBP
M)7 QD[@#C'7'&:DN=?TZU@T^=IC)#J$BI;R1*7#;E+ \=L#K0!S<6OZZ;[18
MF@N-\B1"[4VY6-]Q<,P.TD$;03\R@9'7-)!KFJR:=ITD]U=PM.V;UQIK$VTG
MEY\H+MY7=QGD\8SE@:W+#Q7I5[;3RM<I"UNSB5&/("R&/(]<D8XSR0.M:"ZK
M9/IWV])PUMDC>JDG(;:1C&<[N,8SGB@#EKWQ#K:+J$%M!*;JW@OW7-HY7*$&
MWYQALJ>@/-37FJ:U9>([*P@^T7:@;9F> *DF8Y&# JO'S*JY+ #.,$G-;9\1
M:2%C(O4?S(O.0("Q*<\\#C.T@9ZD$=119>(M+O[&&\BN0L<L44H$@*L%D;:F
M0?5@1^% ',OK^LPZ1I\\4TEQ/>O]D99;,Q>1<R*I0X(&41@X/7K@GBMW5K^]
MM-=TJ&$R/;2L4E2*++$D@!B2I&T#)."I'!YZ4Z\US3"Z85+F>WNH8PA7#1-*
M_E!QD=/F89'7!&:N3ZUIMMJ,>GS7D:7<FTK$>OS$A<^F2I SU(Q0!QNE7NN:
M7X:MK:=KML:?8-'(MMAH7?>KJ25;A0B9)5B"W3D8=9R:K?ZAIM[>6\Z2RQ:<
M\P$3*H;%QOX(XP2N1VR,UUTFOZ5#;BXDOH5B**X8G@JS;%/XMQ]:HW'C'1H[
M&:ZM[N*X6'87"MC:K2!">?[I/([$8.#0!#>WFM1^(6$)8V,<UO'Y0@R'63<'
M8MU^7@\=.<YSQ@MJWB&\TKS&N+V%E^QS7+1V91K9S.HFB7*_.JIDGJ<#DD-7
M7_\ "2:.(8I3?Q!)695SD$%2%;<,97!(!)Q@D9ZU8M]6L+K[5Y-U&PM&9)VS
MA8R"003TXP<^E &;JU_=V^K:; DTT-I*CL\T=L92\@9 L9P#M!#.>Q^7J,&L
M--;\12K((A*9F \Y'LB%M)/M"(%7@;P8V<DY/W0<@$5M7/B[3U%FMFXNI+JZ
M6U5?F7:2A?+?*2!M&1QSD=N1:U/Q%8Z9>6]F\@>[FEBC$(/($C[03^IQWVGT
MH Q4U36HKRPMYY)W0W4]O(8[?$D@$FV.0_+MVA>6P5]1D<5DF;7#X=AVW6H-
M>1Z=.9;@P'S4D66+*XV\G&_L2<'%=M!KFF7$XABNT,ID\L(05);:S#&1R"J,
M0>AVG'2G66L6&HR%+.Y68A%DR@)&U@&'/3.&4XZX8'O0!@_VQJ3ZNNFH;@B2
M["I/]E(_T<V>[>6V[0?.!'/TQ67IFK>(Q!H%OYLC![2W::6[A<-+*7*S1MB,
MX*J!C)7DY)(!KH]2\6Z5865_.DZSR6:,S1)G+%6VD XYPQ"DC.">:T/[3MXQ
M9)<.L=Q=*"D2[FSTSV!P"P&2!U'3- &+KFK:E:>(K"ULHYVB9X?-'DYC9'D*
MM\P4G*@9/*@9'7.*@\1ZYK>DZNJVEE)<V86.YD,<!<^4I99E&/X^8V4=3\WI
M6V->L))1'!,LC^<D3+G:5W9P><9!VG!'7!QTIFE^(K'6-2NK6QD$R6\$4QF4
M_*WF&0 #_OWG/0AAB@#GGU?7UU2QL9HIF9H-MX!!^[W&W=RR$+T\P*N2P],$
M\TT:OXE@MWMK>Q:26'3OML1:!MK_ +@*L)_V_-W''7: .]=!;>*]"O)HHK?4
MX)'E*A "?FW?=/T)X!Z$\#GBI/\ A)M%\N>3^T80D!4.Q) ^9MBD>H+?+D9&
M>* ,72[W7[NXL8Y+I?L[SREYD@)8QJJ$*Q9$ )8N,A>G'4$BQJ6KZE#XOLK*
MUCG-JQ43 PY0JRN=P8*>A5026 &<8.:GO?&6E6L$CQ.]PZV4UZ@12 RQ9W*6
MQ\K9!&#T(YK5T_4[/5(6ELIUF1&V-M_A; .#^!!]P0>AH X^#5_$<>GVYO9)
ME$\%E/-<)9?-;&7S/,4* <[2B#D$KO)/&*GADO+;P%ILLGVH2I>P/-MA=7V?
M:@6)3[P&W.1Z5KMXHMH];DTV6VG14N#;?:24\LR" 3D8W;L;#UQC(Q5I/$.D
MR1O(+Z-5C221]^5*+&%+D@C(P'4\]F!H PGUK6I_$<R6YCBL%&81+!(?-C,&
M[> (\Y$AQC<.%(QD@U'9:YJ[MI'FBY=9)'BG40_-(VX .#Y8!B'//R,!@X-;
M<WBS0;>62*74X$>,L'!SQM.&[?P]_0$$X%6)M?TJWFN(IKZ)'MD:2;<<!%4
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MLX8A%4#S41#@ =A&,?4YS5C3O#HL?$UWJ>_,3VT<,29SAL 2.1C@L(X1_P
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MW?@2:\=YENHY%5Y(UQNVR+N9"O5<9P>,CJ.M.F\0ZC/XF@@L6MQIS+$R-(K
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MK>VB$1@%$N65CGU*E>.F<TV[\&K>WVH7$^I3N+NUN+55(R8UEV9P2<?+L&
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MX?T_6P7^PP:G/R"0HD;=Q^;;<>^.^*BL_#GDZFNI7-X9[OSFF=EC"*28EC
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M1S^[F:3_ $:"V^8 <1*0#^.:U: "BBB@ HHHH ANY9(+*>:&(S2QQLR1CJY
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M+(&*OOW\#9GGH1T[V;GQ3K"/J/D+;22PI=G[-Y#;K?RGVQ,YW<AQ\V,#.>.
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M@DD$$#(Q$T;!44%CR)=@SZ-[5NVGBFPN;J>&1);58A.PFN-BQNL,GER,"&.
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M76M-BD:+[;;O.(C,(5F3>RA=V1DCMSGICGI4"ZMHWV]V6ZM/[1\@;H1,GF[
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M=8SWES?0)# DCN0X)Q'P^!W(/!'J<5%=>)=%L[2>YEU.U\N"#[0^V4,1'V;
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MSGC  R<"DU'Q!J]Q#:6\ES:PF0VTBF!&<W>;HJP1@V!M1%9L;A\_7')]"HH
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M&2]D1GNI<Y+2ODL<]\$X'L!6U10!S%SX1DGM](MEU25+:PC@0Q[6Q(8G1@V
MP&3LP=P;CICK5<^!E7SY(M099I;S[>28R%\\AU8_*RG:5?&T,,$9R23GKZ*
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M#94@C& " :Z"W25+=%GE$LH&&<)M#'UQDXJ2B@ HHHH **** "BBB@ HHHH
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M>X$9 Z'CI@XSWP #I:*\^L/%^H6>FW?VQ_M%VKQM"ESMW,K0&0\P*5ZQR'!
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MBJ2J)'/ELQD52&V;2I,9(YR1S@8Y .QHKG-,\23ZSI&H7=M:K$]K$%Q(^<7
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M6-5*R0V\5H^FVUTJ!R75Y&E##.!D?)[=O7BH/&EVR74JZ4! DYMX97E*C?\
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M:3;DAMR[> V#CGNO][BO'X_-TEZUI8+)]F#NI:;"R1[HQ$X.#@2!V(/^P>M
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MVFD01"^GMK-$M(B!,T:_NHP#D XX &>*2Q.E1W3V=E#;Q26R [8HPH57Y^7
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M"K-% $<<$,6/+B1,*$&U0,*.@^@R>/>FBUMP !!$  H "#@*<J/P/(]*FHH
MKI86<;RO':0*TKAY"L8!=@<@GU(/>E>RM)"I>UA8H692T8."V=Q'UR<^N:GH
MH 8(8EW8C0;QAL*.>,<_A4,.GV5M&(X+2WB09PJ1A0,C!X ].*LT4 5Y[&TN
MHDBN+6"6.,@HDD88*1P, ]*?]F@)),,>222=HZD8)_+BI:* (%LK1;E;E;6$
M3JGEB41C<%_NYZX]J2'3[*V $%I!%AMPV1A>>>>!UY/YFK%% $*VELDJ2I;Q
M+(B;$<( 57T![#VJ,Z;8EYW-E;%[@;9F,2YE'HW'(^M6J* ,^#0M,M[<0+90
M-$LCRJKH&",Y);;GH.3P.U3C3[(32S"TMQ++_K'\L;GZ=3CGH/R%6:* (I+:
M"66.62&-Y(\['902N1@X/;(IL-E:6UL;:"UABMSG,21A5.>O XYJ>B@"O%I]
ME#$(HK2".,*5"+& ,' (QCH<#\J2*PMX;^>]1,7$\:1NV?X4W;0/0 LQ_&K-
M% $"6=JES)<I;0K/* ))0@#.!V)ZFA;*U1=J6T*J45,", ;5^Z/H,G [5/10
M!6GT^RN5"W%I;RJ'\P"2,, W][D=?>IA%&JLH10')+ #J3US3Z* *Z6%G%9F
MSCM($M2"#"L8"$'J-O3FFIIEA&T+)8VRM "(B(E!C!Z[>.,^U6J* *?]DZ=]
MG2W_ +/M?(C?S$C\E=JMZ@8P#[U(UC:/</<-:P&9U"-(8QN91R 3U(JQ10!6
M_LZQS.?L5OF?/G'RE_>9Z[N.<^]$FG6,T0BELK=XPP?8T2D;@, XQU  'X59
MHH C\B'?O\I-V[?NVC.[&W/UQQGTIIL[9KM;MK>$W*KL$Q0;POINZXJ:B@",
MV\+6WV8PQF#;L\HJ-NW&,8Z8QVJ)=.L4>!ULK=6MQMA81*#&/1>.!]*LT4 0
M/9VKQM&]M"T;*4*F,$%3R1CT/I3#IM@4A0V5L5@;?$IB7$;>J\<'Z5:HH B-
MM;MG,$1SNSE!SNZ_GWH^S6^2?(BR<Y.P<Y !_0 ?05+10!7DL+.9-DEI Z;@
M^UHP1N  !^H  S[4];:W3;M@B7:01A ,$# _3CZ5+10!&((1''&(D"1XV*%&
M%QTP.U0_V;89N#]BMLW/^O/E+^]_WN/F_&K5% %:/3K&&2*2*RMT>%-D3+$H
M*+Z*<<#V%+<6%G=QO'<VD$R.P=EDC#!F P"0>IP!^56** (FM;=MVZ"([X_*
M;*#E.?E/MR>/>F&PLS<R7)M(#/(FQY?+&YE]">I'M5BB@"&"TMK6'R;>WBAB
M/\$:!5Z8Z#V %)!8VEK&D=O:P0I&2R+'&%"D]2 .G4U/10!!)9VLUPEQ);0O
M.@PDC1@LHSG@]1S42:5IT:QJFGVJK$YDC A4;'_O#C@^]7** *CZ5ITAG+V%
MJWVC'G;H5/F8Z;N.?QIXT^R$LDHM(!)(GENPC&63^Z3CD>U6** *?]DZ;Y$4
M']GVODQ$F./R5VH3UP,<5+<6=K=E#<VT,QC)*&2,-M)X.,]*GHH QK?PMI-O
M>SW7V?S&F$JLLIWKB1P[C!Z@L ><].,"M)+*TC142VA55QM C  P=PQ^//UJ
M>B@"N;&T,\<YM8#-&6*2>6-REOO8/;/?UI196JV[VXMH1!)NWQ",;6SUR.AS
MWJ>B@");6W3;L@B7:=PP@&#MVY^NWCZ<4RWL;2TB>*VM8(8W)+)'&%#$]20.
MM6** &>5'^[_ ':?NSE./N\8X]."1^-0KI]DDTLR6=NLLK!I'$8!<@Y!)QR0
M>:LT4 0FUMSU@B/WNJ#^(Y/YD GWJ(Z9I[13Q-8VQCN&WS*85Q(WJPQR?K5N
MB@"K_9M@&+?8K;<8O))\I<F/^YT^[[=*?/9VMTT37%M#,T3;HS)&&V'U&>AJ
M>B@"L-/LEEDE%I;B27F1Q&,OTZG'/0?D*='9VL-Q)<1VT*3R??D6,!FZ=3U/
M0?E4]% $1M;=@08(B&# @H.0W+#\>_K3#8VAN)+@VL!FD3RWD\L;F7^Z3U(]
MJL44 1_9X0X?R8]P.X-M&<XQG\N/I5==(TQ$5%TZT5%D\U5$"@!_[PXZ^_6K
ME% $+VEM+<QW$EO$\\0(CE9 60'K@]13)-/LIH?)EL[=XMJKL:,%<+]T8QT&
M3CTJS10!$MK;H5*P1+MP%P@&, @8^@)_.FFSM6NENFMH3<+D+*4&\9&#@]>E
M3T4 06]G:VC2-;6T,)E;=(8XPN\^IQU-3T44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCND;0IL8V00F 1L24"$;2 I..1P3C)%*V@::\44;0.WE%BCF9]XSC(WYW$'
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M)GM+B=F(.X-&\*@#VQ(V?H*Q8?'=K<6$U[%I]V8$$;I(0 C(Y(#%NB@8R<]
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MFDD2&&*-78D+Y;NZGK\QW/GG/*@]: *1\9PB$R_V==F-X6GMB-I\Z-9%C9L
MY4 NK'/\)SV(IK^*IC?VL5K;+<QW$\,?R.H"*\+29#;B'^[VP/K6HGAW2H_/
M,=H(S-]XH[*1\V["D'Y1NYPN.:<- TM8DB2RC1(S&R!,KM*#:N".F!Q]"10!
M#J?B*WTO5+2REC+M</&F5D7*%VV*2N<XSWQ^>#A++Q#'>Z/>:@EG<9M=^ZU
M#395=VTH#D.?[I]NQ!JW<Z-I]Y?1WMQ;*]Q'LVN21]QBRY&<'!)(STR?4TMO
MI%C:V\\$,)5+C)E^=BS<8^\3GH !SQCB@#%_X3:S,UI#';33O.JN_D,L@C5I
M#&#P>>5;('("G//%6[7Q(ES]F?[%/';W=R;>WE9EQ)@.=V <@?NSU_O#W L)
MH.DPRV_EVX26+<R%9&#-\VX[CG+_ #')W9Y.>](WAS2/*F0V:A))!,P#L-K
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MN&YV>7";E@ %7*Q>3U=G"C_6GKP?48Y &^(]"N+[4X+FV@>4#3;NTR)RH1Y
MFPD$C(^5@>O)'ID58_#^K6FV"WGNQ:K+O(6[)< VCQG:6)_Y:%2 >,\TK^.D
MW17D5E/+IPM;F:X*&,M%Y,JHS9WX91\Q^7)/&*EG\4SQ7H0%/)#3H3Y'(9+F
M*$<;^>'/.1V..U "G3=5?P6EI);[KR*YBE6,R?,Z).K\DLP#%5Z;B,],#@1R
M6&N77B9=0874,!"-%$)U"QX5@R2 /CDG.5#=1R-HJ>+QG''9R7%_I]S;8ENX
MXP"C^:8'*[1AOOM@X'JK<]"=O5=4@T?2Y;^Z#>5&%RJXR22% Y(')(')Q[T
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M V,!,-\_) R,KD]:=#XH2:_CL!IMZ+PSM#+$3'^YVK&Y9COP1ME4\$GG&,T
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MS74M])?O-$GVMO+,>&"*PWKM3YLD*<@X.#C%6]&TS5K?Q+>75]-<M$S3%")
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M?PRN #L\O<%S@-L^7<!NQQFL!/#UT/AS%HYMKH74'EYC-V=TA1U)VOOX!"G
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M.T*6!7(.XYVGK6U?:5>37?ANYG66YFLI/])>"8QC)C(+D;E#+NQD<G!Z'D4
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MB#C($84MCL#6=?>&]<ET.[LXK.^,5RE\$@&H .LDA7RFE;?\X W@C+=>AZ@
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MFO$XM;?R_*6.5HRFS&W#*01C [U$/#>EJD CAEB:#>4DBN)$<[R"^YPP9MQ
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M#B-G;DXC)V[CC/ SU]30!C1^-(;9+QM4MYH$AENECG55\N589"NT?-G=C'4
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M06UY+#87DSVZRLBD*@F\J412;23_  L1UQG/&:MZQK5U87.C116Q5;V<B=Y
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M-[G."99-HD /SLL1C!)R,C.21FJ>HZ3J]_>7]N8[MK22\M)4E:XV%52=&8(
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M52"=VXJ5. .X'4XH KZ!::Y%KE[-J<UP8BTP53@Q.IES$5_>'!"<8"+U.<D
MG-U.UUO3]%NK]9KLW*2:A.[-/OV)MF\C:N2 ,&/@#ZUT+^([:!7^U6UU;21Q
M+*\4BJ64,^P?=8@\^AZ5#_PE=GYB*+:Z DO'LHW8(BR2(S*V"S#(!0^Y[ T
M<G8V%_K=H;FUGOVD@%XJR+>D[)&2(QJDGF-N7(_O8R"#Z5U.A:;<VNJZW+=0
MW*F\ECE$IN"R$>3&C +N^5@RMT XQ@\##_$'B0:1NA@MI+BY58W?"Y2)'DV
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M<G:4;<B;=V &R/OK]X 'Z T 5-$M=:CUQI+P7:Q;;@7#RW >*5C*IA,2!CM
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MBP=7M]DC*5(4KR0>1M)!!R#FJB^%],2TCM5%T(875X5%U)^Y*@@!/F^488C
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MOYY0@G:A&P<8']T"GK'XG6\TA#%=D0-&)IC,"'3S7#AQN R(PAR0Q.[C!!-
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M/Z1"%@C@"[5@POF-G$+[XSUR<,22>^><T^V\/Z;:L#'"Q 2:,*\C. DK*SJ
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M)<R;_,R><CR\9!QSCFL;2V\3VT<<UQ:WTD2WVXV_F*S^4;8C&6<Y F(ZD>H
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M&51GYHO)5@I/&/,.,_7TK'CM=6T33KO5)Q=QSV^EV<[_ +X&-FA&9HMN<!F
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M.0#IX],TVR5T$:(L\<=L5D?(=5!"KR>>"?K4%KX:TNSV&.*5F1XW5Y9WD8;
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MISS2VVE6MKJ%S?1B1KFX 5WDE9_E!)"@$\#+-P/7Z5@:C'KIO-:-LE\9BO\
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M=.ED>.!E$0"R;2PQC;[\9XJI_P (WH\B/;B+*++YC()3PQM_(YYR/W?'Z]:
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M8R%X0EPUX)EE*F.0@AF![#!8<\8)H J6WC"QNKAPD,_V41VLD=UM^63[0P5
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M/E%D>%8/('F!V'602[AD<\+CC-:EUXLT_3Y[J*[\S,#R9\B)Y,)&D;.S87C
ME7U^N>*:WC'3HFNUN([F(P79M%S$3YS!-Y*^HVY/Y>HH A6WU>'P+;K)=WAU
M5HH7G<IODW_*77"XP#\R_+R,Y'2J-E9ZY'J?]I>5=PM// 9K4R(RE?LH#Y..
M2' &[U7T)SK'QCHVR21)97C0Q@2+"VUVD1715.,$E74X[#DXJ.X\:Z6FFW=[
M;">Z6UL_M;K%$?NX. <]#P?I@T <]#:^(=1MXS>VUT0ET\D:S$%D#64R$9X)
M'F,!T')X&,5O7K:M8:7I'V2WN)-ENT4T4(4L'\K"9R>@88SVSSQ6G>ZY:6$,
M#SI<EYT9TA2!GDVJ 6)4#(QD9]R!U(HLM>LM1DNEL_.F%LJL\B1-L;<BN K8
MPQ*LIP/6@#D[6Z\23ZK+%"]XUS;RQHZR!/LZJ;-&8-WW>8P/XC'&ZI[*'Q%<
MM!$TVJ16KR0"=YM@E#;)?.P0.$SY0&.^=O%:MEXRTRYL;*Z:*Y@^UP0W#*T#
M'R5E.U"Y P 2" ?;/3FI[GQ)!9>(9-,N8Y%C$=NRSK&S*&ED= &(&%^95 _W
MJ *5T_B.'P=87%NLDVKP!/-A;:#,2I0[NW!8.<8^[^%5+"V\3SFSBO[FZC6*
M]^SRR1E 988X7_>GCCS)-I..V.E;NF>)M+U<3FSG+B&-96)0C=&V=KCU!VG\
MO<56B\9:3,D1C^UEYFC6*+[+('<.CNC!<9VD1OS_ +)S0!S=UHVLRV>HH%OD
MFN-*N8H4@8(GF^9(5! X!(9<'O6B!X@?7P8Y[R.Q"*8%DAW>8GE'(<Y^5]_K
MSPN.":TQXTT5S*$GED*,J@)"S&0L_EC: .1NX_(]"#4H\5:85M6S<;;EC&A,
M##$@8J4/'#;E(QZ_44 5_#T.LV\,R:A-<S%K2"17GVDB<JWF*, < A>.G-9
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M$VJ_VA-IAXQM\KS,]>-N><UJZ[XL&C7DUO\ 9X#Y8MCYMQ<^5&/-:4?,=K8
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MUJ9?&EQ-I=QJD&DC['96R7%[YMP4D3,8E947:0Q5"#R5SG% ":O8WB>+4O\
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M)J$4SBV6[9]GRRFX3S3#Q]SR]_MC;CG-=W10!QD:^((KJSCE^UW$8>YA96
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M/=BSI(V9S<'+]6,'D'\-GZ\U-'H]NEKI]N[RRBP</"TC?-D*RC.!SPQ%:%%
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MB@ JG8:KIVJB4Z??VUV(7V2&"57V-Z'!X-/U&WDO-,N[:*3RY)H7C5_[I*D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2V["U;_37)D!"_-QMV)G&?O9X!%="^L:9'<S6[ZA:K-#&994:5040 $L>>
M03Z9'K4(\1:*T*3#5;/RW<QJWG+@L,9'7J,C/IF@#EW\974HM6CN;:VMYIH(
M7N9+=F5"T$LC\9'1D ]!SGH:MZ3XBUF[U+3+&ZM8XY+NVCO6;RF4+%L(D&">
M&\SR^#T$G<@UU%V+11#/=^4HAE#1O(0-CME!@^IWE?\ @556U#1HYVO6N[,2
MA'C,ID7.U'"LN?9V (]2!UH YF_GU>76+ZU34-K)JUM]G0PD^7"8D);@C<N[
M>/3(/THM_$NNRZGIUK)':1!TBWF52GGDRNDFS)SD*H8 9^\,\<UT[Z_I*1K)
M_:-J5:$SKME!W1@$EA[85OR/I3;;Q#I%U'9O%J-L?MB!X%,@#.#P,#ZY'U&*
M ,6_M=6O?'#"TGEBMK>"SE+FZD5 /-F,BB(#8Y95"DMC;P1VK/G\1^(X-/TN
M1C9++>PR3;Y8C'&KC8$A)+=3N8YZG' XKLI]4T^UO(K.>]MXKF7'EQ/( S9.
M!@>Y! ]:2'5M.N+:>YAOK:2" D2RK*"J$=<GH,4 <G?ZYXEB-Y+;M:B.)+Z2
M.-K1F/[A@$7._G?D\X[<>M3OKE_:ZND>%6WFU%H63#/*X(B"E0S?=&YMVWI@
M'& U=*NJZ>VG'4!?6_V)<YG\P;!@X.3T&#Q]:;'K6ERVWVB/4+5H?+DE\P2K
MC9&0';/HI(!],\T <;!XKUV31[F]G-A"T?E%X3_K86);?'@MC=@ #<5R<^HK
M9\0ZY>V$5FUO)';)-;2S&:>W9\R*$*1;01AFW-QU^0@<UL+K-C]H\B2XBBE,
MQA1'E3,C#&< $_WAUP>1QR*8?$&C"*64ZI9B.)PCMYRX5CT!Y[X./7% ',WN
MLZ]+'>"2)(H)&DMA L+>9&?L7G;M^></E>GZU?T;5]2FUQ='FB4+;P"X>4H?
MFB9%$8SG[Q?S0?\ KE[UMKK6EO);(NHVK/<H)( )5)D4]&7GD<'GVHT^YTR_
MDGO=/GMKAGVQRRPN&S@94$CV;(_WL]Z ./%_J>E3WLDEY'"MU?7.;N>W9PHC
M \N,#=_%SC_=(')%;_A^_P!6U*>\EOTCMHXQ$B6WE'<KM#%(Q+$\X9V7&.W6
MM-]5T^._%@]];K>$9$!D <\$].O0$_0&J\WB/1X=)_M4ZA ]CO6/SXW#)N9@
MHY'N10!Q:ZEK\=I;7R7JW%U9Z?J$DZ/;DAWCDAQ&5###<$9ZX)P*Z'2M:U2\
M\47=E.MM';0O*ODGB4*I 1^O(89/0#D8Z'.A:>)=+N[V\LQ>01SVS$,CRJ"5
M"*Y<#/W<,.:</$NC-/9PIJ-N[WDC10['!#.HR1]>1^8H Y2[\0:OI^KZGJYM
MKLZ<T5S#;B4@P!X$+(VT-N&YDGRV!D%.>E7-'US6]1N;:/SH-C2S&4-;XD5$
M$15& <A&;>3U/!!Q6YJ^L:3!-%I5X\$TMZRP&T9E+,KY&2IZKP?R-5K;6?#V
MD:3)<I+;VL?V?[=+&)%=]FT?,=I.XX  ()S@8.* .>M_%NOR:1'=2K9)YDL*
M2N!@V99)&<2 MA<,J*-Q!RYR.!F6;6M7O-1TNWN9H(6\ZS=H8(G;SPPR\BOG
MA WR\@].3R*[*+5+"95:.]@8,4"XD');[H_'M6:_C#0DN[:+^TK4PW$<KI<"
M=?+RAC!7.>O[P'\#0!E^(-1NK6\UJT2XN(Y[FS@&GHA;YI"75O+QWSMSCH,$
M\5#?>*-4MI=1A3R',-VD?G*F8H(F9QEF+??^500V "P/(-=?!?6ES/-!!<Q2
MRP'$J(X)0^A]*K+K^CM%<2+JEF4MR!,PF7"$G SSW(('J1B@!FDZF]WI\:SM
M!)J"VZ331P'Y3NW!2">QVMCDUS%EXDUV^AB6&2V:2;[+OE%H^+:20L)(B"W+
M* .I!&>>HKJ!K.B12NPU"Q622(7#D2J"T87(<GN-HZ^@J2[US2K#?]LU*T@V
M.4;S9E7#!0Q')Z[6!^A!H QO$VO7FD7>GP6HWR2LI=3#E9%\Q%8 [@<X8G !
MQC)X'-)M?U^$7$[)!)$JWDRQK;LK+';W*IMSN^9GC+$<#D#M73OK6EQSR0/J
M%JLL<9E=#*N50 $L>>@!!^A!JG<>(/#]S%#;27]K/%?RM9J%D#*[;"Q4X]5_
M]"'J* *<NN7_ /PBUKJ?[J$W<ZGS7C)6WMW<[79<]0A7.2 "<G@8KG]0U;6[
MO3-0,EUY8ET>\\B..!E\]T:14D3G(+($?'H:[NVU"PN+5YK6ZMWMX<JSQN"B
M8&3D]!@5G7'BS2HS8+;74%VU[=_98_*F7 ;:7.3GT XZG<OK0!A:GXB\0:>\
MMIFTW17,D0O98C'$V(8I$4@MQDR,,YY\L@<FNAT>ZU&[N]2:\,20PS"&&)(R
M#]Q&+%B?FY8CH.E79=4T^"_CL9;VW2[D *0-( [9SC Z\X/Y'TIL.L:9<6,M
M]#J%M):19\R=95*+@9.6S@8S0!Q&C^(]9MK;3;:18$C@TZ!V6Y)$DX^S[V<'
M.20_!X/W3GDC$1\:ZPOAR:]+Q_;"Y\F+[,,C$(?:X\SC<^X* 22 ,#.2.X.K
MZ/=^5:F^LYOM:$)$9%/FJ<@C'?[K#'L?0U!:7'A_2;5I+:XLH(9$CF+B0?,K
M\(V<\@[2!].* ,Y+Z^M=)\47T4;O/#,TL$;J6'%O$< =2,YX'?-5I/%5T]^C
M0/"U@VH?9T*1DR3(4AP4!(#+N=\D<X (! -=(VLZ6EP]NVHVJRI&9'0S*"J@
M;B3SP,<_3FGG5+!=/_M!KR 6?_/<N G7'7Z\?7B@#"\+:UJFKW%T+Y;:-47_
M %*<20/N8;&&3V Y..03T(QEV'BC7KW4$L+BQ6/>3"THB8 -"A-PW7[I8HJ?
M4GFNDL?$^DWUO#*MY!&+B>6& /*N92DK1Y7GD$KQZY%/'B;0C<?9QK%@9MXC
M\O[0N[<3M QGKD8^O% '*Z5J6MV]CI-K<I]J=(;24,B/&3OAERC?,=Q!C')_
MO<CI2/JVL7EOI]_::A!)<):7,LH6T<(CB.-O**[^H;(YY'(QGFNQ.MZ4K7*G
M4;4&VP)P95_=Y.WGTYX^O'6FQZ]I$WV;R]3M'^T_ZC;,I\SG;\O///'UXH S
M-9U&]A%E/:B*.1[.>7=.SB-'"H5WX.,9/<?ES2'5M1N]!TJ>R81SW=R(7DFM
M]VU?FRVU6P?N\$'!R#T-:DNNZ9!J4]A->PQ7$$ N9%D8*%C.?F)/^Z<^E2QZ
MMI\VGR7\=];M9QAB\XD&Q,=<GH,=\T <HOBC5EN-5-PL$<5L9E$2INECVS!(
MW*EA\K*2Q)P ,'H#267BG5I1IK31Q2&<W">3$G[R1DDD5&P6X0J@.Y<X)]"*
MZ8^(=&%HEV=5LQ;NY19?/7:6'49SV[TDWB#2[02&]O+>U"2F+,TR#<0 3C!_
MVAUP>1QR* .9L?$6MWPABAFMI/.:V#7*VC!86D60R1E2WWDV)U/&_!%.@\5:
MH^H:+;/$HDN%B^U)Y&T'<74LI+9X*@]"!D DY&-AO%^EK8ZG/YR&;3A.TUL)
M%\S;$Q5FQGIP.O\ >'K5QO$6BK:"[;5K(6[.8Q*9UVE@,D9SV'/TYH XC0]4
MU6ZT?2K-[@SB%=.+R+"Z/$Y;#QN23N.%!/3KD\$5T>BZ[JFH:9J=U+:*9K%#
M;^2JD>;<QJ?,VG^X6VJOT/6M:77-.CN3;)=0RW*O&CPI,FY-Y4*2"1_>!]3G
M@&H;36= BM9VM-1L!!$^^8QS*0K2.3DX/5F)^ISWH YRY\4:C%IUO+#J%I*9
M+>:7SQ9OM:91&5MPN[[Q+-WS\N,9!J6YUGQ*]W,(3;01^;+$L;VC.4VP+("6
M#C.6)7I^M=,VM:6FGPW[:C:BSF.(IS*NQSSPIZ'H>GI2'7M(#*#JEGEH/M(_
M?KS%R=_7[O!YZ<4 <O#XLU&76#%^Z*K,B/9I;.THC-HLS/NSV=MN,=P.K"C2
M/$>M:LUO'&T*K)J'DF=K?/[G[/YO17(SN^7.2!TZBN@&M^'[-?M/]I6$(O9"
M_F&95\UE"H3UY(PJGTP*E7Q!I;JDL=[;R6[)(YN%F38HCQNSSGC/8''?'&0#
MC+CQ+J6H+=@2^1!;75FZ3M;D&,-,ZN'57/"A%)!((S\V*D/B#68UFU$1@LT$
M$7FF,K$$^TS)YVTGC*!6Y.!N!/ KM/[9TSS;>+^T+;S+@ PKYHR^3@8'U!'U
M%26^I6-U;27-O>02P1DAY4D!5<#)R>G3F@#GM1U'5#X/LK\7D%O<&Z@\Z>%/
M,C\HS!2W7@;3D\X'//>LX:MKNE1:A)$@NXV;4)88FA8LC1RC9D[OF!#-P .
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MN3W4*)J2_:8=3O%.ZW)$<820H&4,,@C:1GL1UJ:W\4ZW<ZBJ&"U@3[.LOD2
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MEYYY-:,M_:0W<5I+<Q)<2@F.)G 9@.X% '(6.JZK_:WVY2YLKJ:V5X);9A(
MUON)'S':00/EYYR,^E*#7M3UI+=FW[$NR4>./RR5:SG.U@&8</@8SP< \BNR
M'B#1FM6NEU2S,"N$,@F4J&(R!G/4CGZ<TDOB#2[<2/<WMO!"K*JRR3H%D+)O
M&WG^[SSC.,C(YH RI+O5H=%T"&RD2.:X@ FEFA,I7; 6Z9')8 <^M4K7Q+J]
MY?VL6V&!YFA46A@8N8W@#M,&S]U7)7ICY",Y(QT_]M:6;R&T&H6IN)P&BB$J
MEG!&00,\Y )^@HGUG2[:XDMY]0M8IHD,DB/*H*J!DDC/ QS].: ,'3M8OX/
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M7*?M%I#;F3: 0T;NX;CU9^GMBJB>(M;::W=EL?(6.Q,RQHS^8;B=XF*.'P
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M$Y9BTBJ%!D8<D8[DXP0"W8^#FMKPW5QJDUU*7MVWNI)(B,A&26/)\PYQ@<<
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M2+$FI69<Q><JB=<F/&=X&?NXYSTQ7/R^"IKBRE2750E[Y4$,%S;V_E^2D6\
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M/,+@D$$L., GG&>V:MQ:WISB!7O+>&6="\<,DZ;V49R0 3D<'IGI63IWA!;
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M4?E-.J/G&S:,AY'SCV('M3[;PO960TL6RI%]AF\YB$YF;R6BR3G.<-UYZ8H
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MIE" D2,%8(Q9 R@X;#$D9!P2: .9LO%&H*]A9_9!+)=Q^;"?F8E$,GG DGJ
ML8'O*OI5WPQK^I:_I5U<%+(3")6AV.I"NRD['59&(P<<DJ3G[HQ7444 >?0?
M$&_O+>ZE@T^-!'9RW\7F!N8HXV5@>?O"==N/[OOS5O5=7UBQNF1KZSMWC^P&
M>=HF,(66696&UGPO11NSD^W&.VHH X&?Q9JMA!*CW-C-,=1N(-[QK&L"KN**
M^Z51E@!@DCCLU:EIX@U2;7(H)8K1+1[T69106=6-F+@MOW;2,Y7&.>N?7JL"
MB@#E+OQ%J=MK5Q&EO!-:17C6BQ*C>:Y%G]HR&SCJ-N-O?KQSF#Q9J=REN\6I
M:6(!<6IFNXH280)0^Z(Y?AE*IDY'WUX'?OJ,"@#SJ[U+4GFFO!<NL%K:7[K
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M*3N'E]"RGG! I\'C2[N+_1;51;++?11F:,Q\HSHYW*3("5RG0*?=@:[C%&*
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MQO+,I)[)T.<GI3-3\17\67CUG3;JV;2;V9?LL943RQX(V,)"00#V)Z'VV]T
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M"D-(,G<FW.X<'..,5HZ;XGU"[\2IIDD=EY:[%<JZ@N# )/-CS)N9=QV@!2,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %-\M-Q;8N6QDXZXZ4ZB@!JQHA)5%4GJ0,9IU%% "%%.<J#GKQUIODQ<_NDY
M.3\HY-/HH 9Y,62?+3)ZG:.:7RT+[]B[O[V.:=10 P0Q!=HC0+G=C:,9]:58
MT5MRHH;&,@<X]*=10 SR8MK+Y:88Y8;1R?4T>5'N#;%R.AQTI]% #!#$  (T
M !W !1P?6A8HT "QHH'0!0*?10 SRH\D^6N2NWIV]/I0(8EV[8D&T;1A1P/2
MGT4 &,# HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<M)%-;7*6RC87,K-$LN5"@G 5N2>!BHQX-L3X4FT!I76&5_,,T$44+*X<.K
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MRQG,F%>&+<@=][#S @=AGH"QXQZ"@".P\;6MY92ZI-9W%IHV2(+^5D*SD/L
M5%)?+'[HQS^69V\=>&4%L6U:(?:>8\JW]_R_FX^7#C:=V,'@XJ@GP_@BL/L$
M.M:DEE#,MQ90#RB+219!("I*98 C #$C!(I!\.=,^SSQO>7KO<1-'-*63<[-
M/Y[/PN 2_H,8[4 :S^+]"C@EF-Z3''.;?<L,C;Y!NRJ87Y\;&SMSC:?2HSXV
M\.?:TM5U6)YG0.BHK-N#1^8N"!CE.0.^#BLBZ^&6F7<US/)>7!FFNUNQF*$Q
MHX5U/[O9L;(D;)().%.<BKT'@73;>>*5)IQY=Q;W 50B+NAA\I1M50 "IR0
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MEJJQ[/,0DAMQ7>/<!@#@>^<2V^&-G:10B+6]4\VW%LMO*?))A6#S!$H'EX(
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MMHX$GN"J):("=HXMYFE3H .68@^W3% %Q_$FE1VZSM</Y;RF&,B"0F5P"<(
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MW721R,[I'L5BY7<"0!G!'3ZY -N]O[;3H5EN7*AVV(JHSL[8)PJJ"2< G@=
M3VK,E\5Z=#+"NYYHYWB2&2W0R[O,4LI(4<#"]:=J'AY-7TNPMM1N#/<6C++Y
MYA0AY A0L4(*X(9N,<9XQBH_^$5M4,;07$L#QM R&-$4+Y2E1A0NT ACD 8]
M,4 +8^+-,NX[HRRBW>VDF61'#?=CE,993C#<@<#."P'4U:B\0:9--;0QW),U
MR7$<?E/ORA ?<N,K@D [L8R*H77@[3[NW,,LLY7%P!]TX,TZSDX(P<.@P",8
MZ@U;T[P];:;<6\\3?/#%+%A(DC5O,9&)VHH&?D']<T :]%%% !1110 4444
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M59F4YX8[5QZY;Y<#OQUXH K>';K6;Z:YGU4?9PBPJMJ(L .T,;N=QY.'9E_
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MCN@D:J[GS5*':C;6.#VR1^8JU>:QI^GW$4%W=QQ2RXVJQ[$X!/H"2!DXYXH
MY6RUKQ+<:EIL4T:01/%"S>;"Z^>&=PYP$.U@@4A=R[2><@\:&IZIJL/B-;:
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M);.2:=+(QLK.7$T6TKRJ_(>A(W8)-3KK/B:274,".-DF,:1&!V:,?:%16 V
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MR<$8&0-)?$NCM%'(+^/$DHA08.YG*[@ ,9^[\WTYZ5:FU.SM[V&SFG5)YO\
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M-;6<D32*?,D$2\98!LDC@DA@?7D'O6=/XDTC3EMA$R?9Y[Q[=GC0A5?9)(2
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M$L:R&\@\UE6ZB@>')-I.S+MSSM8(.<_> ^\,UI7^IWVGZ3HR)-]E26WS-<O
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MTZ\W)(GFG(C:W\H[4V\29_BW?=.,5;NO!<.H6DR7NH7$MQ,T>;A55&"*K)M
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M,[+T[5S^ASZQING1EY'>-+*:^N,6A>6:7<<*/F&3WQU/'(H W7\*IEC#J%S
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M-NTGVB==NR$8Z;LGW/;H:=8:EK,FO!+D)]CDGGA$8@(*! "K;\\YY'3'3TY
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MMG[GN00"?<]>Q% '2:EX?CU&[NIFN9(UNK:.WE15!!".S*0>QR[?7CTJE?\
M@NROKMKEY-SL\S,LL*2(5E";EVL/^F:X/UZYK,N=9\31_:9XWB,:)?3)#]C)
M.+><(B9W?QJ<YQVXJPNL:C;:G;Q;"8);ZXC:)59I&_>81AN/W,9)(/'!QB@"
MW=>#8+M;J&2]G^RS?:6CA"K^Z>=65V!QD_?? /3<>O&+5SH)N/%MIJX<+'!;
M,A4'EY>1&V,?PK),.O\ '[5S4'BCQ V@O?W#6R,#$TD,<9,R,5<O$JD8W A
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M3QY?<YZD,,$GOUY- &C;^%8;5K9X+N97M[F.X4E5.=MO]G*GV*9/U/X55M/
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M!]*T!J40O[2R=&$]S;R7"XP5 0H&!/KF1<<=C6)%X-1(8X9+^22.WC6"U C
M,<8E23#'^(YC49XX'3)).K?Z7-<ZK9:A;78@EMHY8BK1;PZ.4)[C!_=CGW-
M"_\ "0:1MG;^T;8B!@LF) =I)*@>^2"/J".U/;6M,0SAK^W7[.H>4EQA 0",
MG_@2_F/45A0>"(;;3YK.*>$A@JPR/ 2Z*K%AE@X)(.,$;<$ U-+X0,LTLAU*
M4,RPD$)R\L31LLLO.'8&(#. <$CTP :T>NZ5*UJL>H6[-=%E@4.,R%3A@!['
M@^E/FUC3K>ZDMIKV".:-#(Z,X!"@9)_ <_3FJ.F^'4L-02_>Y::YVS^8=@56
M:5T8D#L!Y8 '/N2:JZEX1_M/5)[N;4I]DB2*D1&1'OA,1 R< <EL8ZDY)SP
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M'Y8W. C("K?P\-Z'H.G.;,'AI(_#^HZ7)+&S7T3QR31Q;"0R;,D9.3CW_ 4
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M\TR1",;DEEB:)FW=QAV(&.IZ\ 5?E\/6\]GK%K)+)Y6J)LEVX!0>4(N/P7-
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M!;F5ML8ED"[SQP,]>H_,57_M717O91]OL6NK2.0R?O4WPH"-^><J 0N?H,T
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M^N,'JFUO2D>X1M3LU:V_UX,ZCR^<?-SQSQSWH&N:2T=O(-3LRERQ2!O/7$K
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M[5'#K^G3:O=:4UQ%'>02",0R2*&DS&LF57.2,-_XZ?2@#DM&\4ZIK"6EQ.8
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MDMNADF1IE!C48)+#/ &1U]1ZU7'B717GLX8]3M9&O'>.WV2A@[+U ([\C\Z
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M9#[,<3YG7]USM^;GCGCGOQ0!@2:YK=MXE33'%I($5"0R^4UR"K%FC!<G@@#
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M5+::*[2UGVK( )MLI8C##<FWR2 <CYCW QTMQXBT2TF>&YU>PAE0 LDEPBD
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M?VTD\D0F2-)5+-&>C  \K[]*FAMH8'F>*-4>=_,E(ZNV N3^"@?@* ):***
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M'DWH69H]SAL \8V-T.2.U>77]<^Q6%W=WEDBWFAW-Y]FC@>,M*$1E56\S=N
M8].<!C@<%0#:D\'QMI-I8K>,OV;3)-/5_+'.[RSO(SZQ#COGK37T'44\07VJ
M6\L(F>R5(=PQ']J8;7E*\D *D0QD\ C/>J)\5:H=2U"UC33XA:Q/L2ZE"-Q$
M&61B9-Q0L<'Y  .=W!KH-!UF+5M.@D,R-<.C.RA G =DR &88RIP0Q!Z@X-
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M:[1D,  @^8_*W0YP.:PM:\3:ROA;S);JPLY+VQNYHY!"ZD% H2)#YF?,;<S
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M4V7Q%J-E?ZC!/J6GHBZHMNLL\)"V<)@\Q6?YQD,PV@DKR3R>%$FHZU>/X?\
M#VI/<0Z=+/=(9I)0WE*IBDY8;@=IX(!([9Z4 7/^$.MVM=1MY+J0I?6LULQ5
M0&19)9)"0?;S,?A3!X/5[=UFNHS+)'.CR1Q-\QEC6/<=[L<@(._MQ6?8>+]5
MO-3TVV>WM(A/##(PD(0S!RP9H]S@X 4$ *QYP2,YK3U#Q+)8Z\=,/D!VFMEB
M1L[W21B'8#/.,=>@[T 1WG@U;B8SQ7ICE$PE4,C;,>2L)4A74G(4'J/3D5:@
M\+007$<J3;52\6Z"*F ,6OV8(.>F/F_3WKG'\<:H-.@9/[/,[22QR3G:+8.J
M(RHKF8!MV\G=NSA2-F0<7HM<O;WQE9VDEQ!"D5U-&]E&&\T*(20[G=@J2<CY
M1VY.#0!HZ=X9GL9])D.H(?L%NMLQBA:-KA%5E57^<@@;@<$'Y@2",D4_4/"Z
M7J7Q6Z:.6YOHKU6VG",D<:!3M8$@B/L0>?:LN_U[5K6[U**Q6W'DM<RYN$DD
M!$44+!0-XQDN1QQWQG.=35-1O(M5T#RKJ&VM;MG69)8]WF-LRJAMPP>N.O\
M2@#/NO"-S%Y#6-S !YMD;B'R2 XAN?-+*Q8E?O.2#NS@<C)S-'X-=9%\S4M\
M43+Y*"#!55N%GP3N^8Y7;GCCMZXFG^*-;TWPY8I=?9YW-E82?:G0@1K*L@)D
M+R ,08A\VY>7''KT<FK:H^C:-+#]C2[OIEBD?!EB4%&8LNUAG[HQ\QZ]3UH
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M=3C>3P81D C(;@C%17'@VXGM[>$:J(HTD\V9$27$K^8K[N92<_+CYBPYR *
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M;8&9=S?WP@SR?EP?3\ZRYO"]T]Q=S0ZE'")+F.YAB$#-&CJY8LRF3DMG!V[
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M>DV9ECFN%6Y2&XF6WW*9'2$D.5&<=0<#.>#TP<95]X$CO=;EU#[>Z))<)+Y
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MA$+7BRJDT+Q.R2,X2.82A#ND*\D8RJKZX[47'@A)K7R4OC$07966,K\QNEN
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MM6LKR[E@BE5FC*!7R-LFY-XV'//RC/X55U74='DAAL+R:*=;\I&D"2 F17.
M< Y*>IZ4 96M7VK3:#HDB1/#>WEPGFV\4WE'!C=MF_!P1@9/J*HZ7XMU*2?1
MK$^3.TMK;//+.4C>5G9EDQEUPR;3D!6R>/EXKKH-6L9_LR_:84EN4#Q0O(H=
M@1GA<\\>E26]_8WDLD=M=V\\D)Q(L4BL8S[@=.A_*@#B;3QU>7%GYIDTU@\<
M#-*F[99&2781-\W..O5>A'O5N+Q'K.HV\BVC6492TN9?/6)I!*4D>-&C&[[K
M;0W)/''.<UO6=[I-E>?V#"T<$D$:".%W WJ0<!<G+8"\U/>:UI>G6R7%W?VT
M,+&-5=I!@[VVI^!/?IP3T!H YBV\8S_;M#L_M5G>-=QPF=HXPN3('PRGS.Q3
MD!6Z')' K,T+Q+?WVD:3;O?17+*NG/)/;NV\%W*O'*2QRWRY/3J<CN?0)[VR
ML_*^T75O!YG$?F2*N[D<#/7J/S%17.KZ99&Y$]];1M;1&:=#(-R(!]XKUQ0!
MC>$/$=YXACFEN8((D$<<BI&Z%XV;=F-U#L05P.2%R<C:,5DV7B6[>QTTPWL$
M][;Z3.]]'+*JA+A3$JB7D;3NWC!([^F1US:O9+#93Q2":*^E$<,D.&5B59LY
M],*::NM:7Y,<DM[;0&:(3;)955MNT')&>P(H YJ'QG>7.I:=;6\=L\<\<3N\
MFV+S=TKQOLW2_P &S/R^9NR,$ @G2U?Q/_9FM'3V-N'<V(@61L-+YUPT<F!G
MG:H!XZ9YK1NM>TJR=!=7<,*,8Q%([ *YDW;0I]]I]JLG4+#?<*;RVW6PS.#*
MN8AURW/R_C0!Q<7CJ\>*9]VG2#'S&/=BR_TA8<S?-TPQ?^'A&[<U++XPU06C
MSP+82I;P7=Q),$8I<)!(B_N_F^7<&/)+8([UNV6L:'9Z!-?1316^EV\KHTK-
ME,AR"0<G()/'UK2CU"QDN([:.\MFF>,2)$LJEF3^\!G)'O0!GZKJ=]:ZQ:6E
MI'$\;6MQ=2AE+.PC,8")@C!/F=3GITKG;3QK?W&GVTTTFEVJ7$ZI]KD=6BA!
MB:0AU64\Y4*"67.[H,8/8WNJ6&G26R7MU% UU)Y,(D;&]\$X'X _Y(JO8ZYI
M>H6DL\5S"J0DF97=08L$C+C/R]">: .6OO%^H,-=C6&W6*SMKE@%E59040,K
MC#[R&ZCY!@$')JU>>)KTW=]8>0BO83HMPZEE^62:,0[3GO&S9]UQ74/?6PM8
M[M'66&5D1)(B&#;V"@@]",FF_P!JZ:5G87]KMM\&8^<N(\]-W/'XT <G<^,=
M1LXKB>>.S\EOM7DX5@8_)ND@RY+8;(D#<;<8(SSD:">(+X^"_P"US)I[W!D(
M5@RK$4\W;GF3&[;SM+CYN,BK]WJ7A_4DNK"YO[5A L<TP\_88QD,C[@1CG:0
M0>N*B@U/2-+9=/ME=T;R9 ZMY@D^T2.%;>22V65B2?4=: ,V/QJ'NK>W7R9)
M)Y8O*CP4DEA>W\W>$)R/F!7VZ=:HMXCU2]M],O[+4=-DD:">>2.(,T:8B5_+
M<!\E@3C/'7.WM75S>(-%MXUFEU.S"-,+<.)5(\P]%)'0_6IEU2P C\RXA@:6
M9X8UE=5,CJQ4A1GGD4 8/BCQ8^B>'[?48?)6::!IUBF4$.%3<5W%T /0=SZ*
M:S-3\5WL>N'RY(&6SDN?^)?&6$\@2V9U+<\JQQCY?3D]NVCO;.XN'MHKF"2>
M/EXED!9><<CJ.0159=:T_=.9;B.!8KC[-YDSJBR. "0I)YQDCZ@T <A9Z]J%
MS>3^5J5K>/)>^5%-:[C"/]!>087<<C<O(SR>>#T?:^*[Q;*VGDO+.5YK*Q9[
MQ@1!&TLDJLS*&P,; .",MCIT':+?61NFM%NK?[0B[FA$@WJ/4KUQS5>QUG3M
M2^V?9)XY8K5@DDJLIC.5#<$'!&#S^- ',Q^+M4E1)DBLC#&J-*P5CYZFY:'=
M&=W"LJAP3NZ@<YS4,WBVYO[VZLH94\N&]M DD(V.!]M2)T8;V/(R.0N1GC!K
MLDU33G:%4OK5FG++$!,I,A4X(7GG!ZXZ4U=6TMIO*74+,REPFP3+N+GD#&>I
MQTH QM:\3/IGB2PTV(PL)FA$L;J V)'9 RL7&<%3P%;IR1D&LVW\:7#VUK)-
M+8 M>?9[CR@'"Y"$"/$O[P?./G7)&1E!SCKAJ%@\\D*WELTT+*LB"52R%C@
MC.02< >M!O[!;B.W-W;":1F$<9D7<Q'7 SDD<YH Y.7QM<,KPVRV;W<8F$D9
M8GRV6Z2%0P!R,AB?PHU+QC=Z;JUQ8;K6X>WMY3(!%Y9$J0>;G!D+%3_NX&?O
M$@UT]OJUE/I*:HTJP6KKN+SD(%&<<G.!4AU'3Q)"AO;;S+@ Q+YJYD!SC;SS
MG!Z>] '+R^*=0MG^S7<VFVK_ &H1&\E1A"BF 2@$%Q\V<KG<,XSCM3?^$OU*
M2]U2*."Q1;59@BS3HC*490K-F3)5LY&50<K\W.:ZV>\L[>:&"XN8(Y9CB*.1
MP&D/^R#U_"H+K5K"VL;^\\Z.9+*-WN%A8,RA0201GK@'@T 9-UXE\OPK9ZI'
M<0J]RRHLDD.$+'.>#( !\IY,F/0G(S#H7BJ?5=0T^&<6T2WFGQW2Q1X=PS(&
M8,=V5 W<97!X^;/%;W]K:8;/[4;^T%L'\LRF9=@;^[G.,^U54\1Z6=1U"U,\
M4?V (+B:25%1"P!"G+9Z$=L<XSGB@#"F\6&PL]7"W,$][;ZCY0A>1<PQ,Z*'
M92R_*-W<@=.1UIT?BV^$]G'/_9T9N+:210)E8.Z^:025D/EH5C#;L./O D$#
M/4'4+ .B->6VZ2/S%4RKEDQG<.>1@'GVJ.;5;"'2I-3$\<MG&A8RPD.,#K@C
MK0!R$OCFZ73HYXWLO-6WEF*R1E?M4B/M\B'$C#=VW!G&2,#GCH]/U.]N;?5;
MJ86XBMYIHH$16W8C9@2Q)YS@< #&.ISQIR75I!<0VTL\$<TN?*B9P&?'7:.I
M_"H?[7TP0RS?VC:>5"^R5_.7:C>C'/!]C0!RO_"6:Q'/I,$L-B9+RWAN6Y$:
ML)'P8T+R [E'4@-DE?E7-1GQQ<NVK"![)DM?+:.23;'@&5T8%3+RP"9 )C)]
M.E=HMW:279M5N(&N47>80X+JOKCJ!SUIC7]@L\MNUW;"6-0\D9D7<H/0D=AR
M.M '+IXPGEU1(8FM&C:1(UMRC+.Z-;B;SP"W"9.W!'8_-GBJZ^,=0BTT27C6
M,5Q-%;30LL1V#SDD;8VZ11D>6WS%E!R.,X!["34=/BE1)+VV21W\M TJ@LV<
M;1SR<@C%,75+%MHDN(HF:1XT25U4L48@X&>?NF@#C=-\6WD^LP.9K;;?"R86
M#,3*!+%EFCYX"]3P<@'I5KPUXBOY5T+2ID$T]S86]T9W+$M#Y/SL3GEQ(%'T
MD6NC.O:.)+-1J5HS7DABMBLH82,!RH([_P#UAWI(;K2IKVUN_-A2]NK<"%))
M )&C^]A5S^>/0>E '-:KXEO$\4PVD<L.RUO70V,9(GN%%D\H8\X*%B !MZJ#
MG/ @3QQJ;:5;W!BL<W$ZQK.LD9CC!B9\,/.P#E<#+KG.<9X/;V][9WCR"UN8
M)WCP'$4@8KGD9QTJ/^TM-*W'^FVA%NVV?]ZO[LD]&YX.?6@#F5\1ZY<WT$$,
M>GP"6XBMB'#2[&>V\\MN5@& (*\=<YR,<SZ'XJGU34=/AG%M$MYI\=TL4?SN
M'9 S G=E0,\97!X^;/%=3&Z2QK+&ZNC@,K*<A@>A!I<#.<#- "T444 %%%%
M!1110 4444 1W$7GVTL.=OF(5SCID8KDY/ Y\NU\B]6-K86VQ51D5C%%)&<[
M&4C(DSP>"HZCBNLG,@MY3"5$NP["PR <<9'>N(TWQCJDT>B0F*UNI;FSMKB>
M972,/YKE6"[G'S+C) #9) PN10!?_P"$-9;*]T^&Z@BLKRR%LX$+&2(B$Q#R
MV+DA<8.#D]>><A8_"5Q%]GEANX8+I;GSY9T$S,PQ&"OSRG(*Q@$'(^Z<97)J
MS^*]8CTQ+M+:QS)#=W"H2_"08X)[LWY#/?')=>*K^V69IX8?.M))LK$Q".!:
M>>H.>>IV_AGCH "2Y\':A-IUQ8QZLD-O+*["%(GV(C(RD ^9N'+;L!MO&,8-
M2WWA>XAT35?L$B2:G/-#<VLFP*4EBCB1,DGE<Q9/LQ'UJ:EXROM,T^\-PEF+
MR"7"* VR1?($V,EA@C)&2>V0.=M2Q>(+Z34+I99HC$NI6T4,$8VR+&\,;\\_
M,,L1TZ@\]@ ;$V@!=*TNRLYEC_LZ2)XVE3>&"J5.<$<D$\YZU!I'AN73=3CN
M9+N*2.!+B.!4A*N1-*LC%VW'<05 X SDFLBT\:7]Y;Q&&*PDEN4M'38S%8//
M<KLD]67&>V>1@8S6CI.KW5]K.G^:0OVBSNA-&C$H)()TC#*#TSO?]/2@#.B\
M%W=Y%>+?36\*227RQ1K!EBD]SYF7;=AOE1>,#[W/2M:?PS)+K3W2W42VLEU%
M=M'Y/[P/&@0*K[L!3M!(QW;^]QAZOXMU&73M8CM'M8I5M;XQ["3+;&!MFYQG
M^+J.F#C[U;.M:Q/X>MM-M5GLD>5'5I[V5]@*)NZEMQS@]3GOSCD I+X'D\O3
MHYKR*5+2V%HR;94#QJP93A)!\W'.<@G' QS;'AB\2Q>U2\M=J7HN[=VMB6!\
M\RD.=_S=2,C'K[557Q9J$EK<79MK6V@6:UMU\\MF-YDB<M(>  OFD8[D#D55
M/C#449KQOLCV\5A>S>1&#FY>"0J&C8G[K  ]#@$]>#0!O:YX?;5Y7E2Y6)C:
MM H:/< WF(X)Y'&4QCWZU1O_  E=7\EZQU!(4N6BE,<2.%:6-XV#GY\C_5[?
ME*Y!R>0#4%OXLOY&MH;@:=:F627%S+,IB=46,X&QV"L?,. 6/"%L<XJ&+Q#J
MXA+%H+R[2YU!$@B!3(A9]B,,GDA1@\=0>: +R^#@(E07")PA8*KL"PN?/8Y=
MRQR<CD]\^U:E[87>L:#JFGW;10-=)-!$R*6V(P*JQ&>3CDCCKBN=F\<W<WV:
M73K*&:WNA-+;O)*J>='&RIP790"Q+$'G V\'.1I^)=?O])N EE!;2*EJ]U)Y
MS,"P5T7:,=,[SSSC'0YH <_AAI[UKR:YC$[W,5P[11;<;(3&54Y)'4D>F:CT
M?PN^BZ)>6JR)//):+;(X,@+*BL%SO=@/O'@8 S^5"]\8WUE'+%*MA'<6XNG>
M25F6.;R2F$09R&82#N<8/![5-6\67KWL@CEBMTM_M8-J)")_W=LS@N/0D@CC
MCY3SG@ O:=X1U&""SNFO+2+4+?[/L1;8^4HCBDCP5#\G$K<@CHOI3K;P3/;M
M9)_:$#0PPV,<I^S$2,;9BZE6W?*&)Y&#QGUJLNK:A::S>W,\DEQ&-1%O%!&[
M#"+8F;;MR026] #GOC #KWQO+9:/:W@N-,N9I4:8QV[$J4 C)7<6 ##S!ZDY
M!"\G !:B\&SVWV62"_B,]JENL?FP%D8Q><#N 8=1,<<\%0>:VUM;RZT^^LKT
MP)'(IAA,*$?(8P"2"3CYMQ SP,=\USDGB34+22=[AX[HP:E<1+;VXVOY:6\L
MBJPYR3L&.GK4EOXJU&ZN(+*V.FSS3W$<2W43,T*AH)92, Y++Y8[C(93QF@"
MVOA21RDL]U";A8[!-Z08'^C3M+QEB1N#8Z\=>>E3>&_#(T!I"9EG/EB))"9-
MY0,6&[<[+_%_"!SD]\"#1/%,NJ7]A%-'!"EY81W,:(=[%B@9@2#\N,CJO.00
M>U5G\17-@9KB61/*EU62&3S3N,,:;44*FX$YP#QG!?.#G@ M6W@NTMM)@M P
M>=9X)99Y 7+B.42!0&)VC.< < G.*KW7@<7+ZN#=(4ODN!&SB1FB,R[6XW["
M!_N@XP.V3%/XY,8=$2U,R"Y$JF3_ %/EW20*S]PN'+GV4XI6UW4H->>1;BSN
MK/R;".01,VTM-<S0EH^2 ?NDYS]W'O0!:O?!J7+WK17$<)N9II/EAZ"2V$&.
MO."-WZ>],O?!]Q=M=A=06&&9H91$B. 9(W1@S?/D$[ #LVYSGJ!5C5_$S:=X
MEL=,3R765HEE1AAE$A<*P)(_N'@ ]#G'&8;7Q5-)X4O]4EC@-U:-LEB0_NXV
M*J>7!8,H#@EAV[ Y  )K'PQ+8:A87-O<Q0K"'^T+&)"9]S2-M)=VXW2%LD$@
MYP0&P(-7\(W6K:E=W$FIA898IHXHS&Q\L20^5C[VTX.6SC)SC.!45WXMN;2=
M(EETVX,<<4C&-S_I6^9H]L/)^9=O(^;E@..M1R^,+^W%Q)-;6GE'[4("&8>6
M(;I8"TA_N_.'.,8"GK0!<N?"4ANVN;2YMXV,_F".6VWQA3;B C:&'.!D'TR.
M^:BM_"<[:5<V4]P@=;>VL[:79N!CA"L"RYZ,Y?*YY4 9HN_$]_:K?RQK8WD-
MAIPNY'@8XE8M*H"\D*!Y6223CD>]0P>)-6DOM.\[[)%#(\Z.J[7-QM5&79M=
M@K'+#;DGC/2@#1T[PRUMK*:I<SPRS[IW9$AVH&D$(RF2<8$//J6)XZ4[4?#;
MW^H74QN(A;W#6CO&T.XY@F$F,YQA@,8QQUYZ5#X;\27NL:7<7US9QJJ0I/&(
M)4<MN4DIA68Y& ,G&<]!@U0T[Q9J^I6UCLM;*.2]N$CBD,H=%5H9)3E4<G(\
MO')7=GH* )I?! DNDE-TKQ[YS)$PD52LDYFXV.O(SCG(. >,5>UCPR-4UJ&_
M,R[%C2*2%S( 0K[P1L=><^H(X'ISGV?C1KF$7,[65G$FG1WDD4K,TC[HFD)0
M#DJNTCH2<-TQS%:^-+F183,EJD8OS:32J0<C$97:@<GDR@$@MM(&1R< %R3P
M6KP.BW2HYCNPKK%RLDLZSH_7DHRCZ^U">#5"PA[I9"!:F4M%_K)(IVF=SS_&
MSGZ>]4K?QEJES!<3)86R@SQ0PAYERA>Y6'#JK%L@-GHN""/>D?QEJEI:S2W5
MG:R,%G$8A8@!H;E;=F8L<!27W]1@ @D]: +5]X,EO?MD1OHDMY6N9(L0'S%>
M:)HR&;=\RC<2!@=%&?EYM2>$HI+YI_-C$9N3.(O)&%_T7[/CK^/Z>]9T_BW5
MH;-9C9V8,5M<74V9 V](I%7"[&8*6#9Y)VD8YHG\4:AI\>HRW-Q9/';:DT+?
M+AX( A;)3<"YZ=.<$G!QB@"1_ Q6*U$%ZJ-;?9RH"NBL8X7B.=CJ1D/G@\8'
M45;MO"$5K+"\4L:"&2V956,\+#&4"@EB<')ZDXSWJ:WU1K.#Q-+<3$P:;<.R
M/)EMJ>1'*0<<D NW [8 K%3QGJ<UI(8+>S,T/VHN[D[6$*(XP%9L$[\?>.,9
M]J -N'0KRW\)PZ-%?HDL C2.=(B,HC X(W9!*C!(((SD8Q7.Q>%=7TW6[ 0J
M+NTB$/F.<*A(N)9"3F3>"@DR.'W$<XJV_BB>Z\3:?!]HMK:U2]9)(3(1,R"S
M>7<PZ;,L.W\(.><"*7Q/?:7IPNG\KS+FVFU01W3D-(FX;+>,9X?85!Z_-C@[
MJ +VG^#[JVO1=7>J"XE#V[%O+8;O*\WU8@9\SHN ,<"F+X(>#38[:VO(4ECL
M;2U27RF4H\'F_O1M<$$^9TSC@@YS6QINHWE\NJ2S)"D%O/)!"$SO.PD%F)XY
MXX'IUYP,/3?%6H2"Q+6\3VS"WB?YF,K-);^9D'IP>/?/;'(!O:=I$UE<ZD\E
MTLL=ZZ2$B/8ZL(DC)R#CGRP> ,9-8=IX-U"TMRB:I;HXM[6V!AMFC#1P>8/F
M(?=D^9U4C&W'2I=-\2W^I1Z.87TR1M0.^3RW9O(3RPY0C/+\XSQZX[&G9^-K
MVYTR6\FM[:U5_*\@LRN59V8>6ZB3((V]6*#.1@8Y +EEX(CM8+*.2YCE:UCL
M4W&'[WV8'U)QG/X>]-'@Z[CFT\IJ:M;V1C=8?+9<LKNW&&QR& ^8-C;QU-4I
MO&UQ+HYN&2& 3Z,UY$L;[G,HB9RN0?DP ,$K@YX.>*N7OBV^L)[Z1[6W>TMV
MN(D4,P=FB@\[)/0 X*XQZ'VH R=#\':LVEV\%]_HTUH\$D<C,5,A6)XBA\J4
MG:JL,,"I)ZKZ]A8:=/;Z?)I;"**QBMTMK<PEMV F&.6)(&> "2>.2<UCIXBU
M"\\#:UJ]O-:&>WBF:UEBC.U@B9!*EB0<YX/MQ4<6N:E#K[EIK:ZLG>TB;RRW
MWI%;YH^2 ,X/?/MCD E;PI?M96D7VVP\VVMI+,'[$?+:)T1<E=_WQY8[XP2,
M=ZG@\(107"2+<Y"W8GRT>7919_9MI;/)_BS^&.]'A3Q'>:_;2W%U:PV\7DQS
M1E948KNW91@&)!7 Y(7.2,#!K"M/%E]8V"6K3+J&H&Y2&6Z,\4EN28F?<A!0
M#=L^X2"N[N,9 -5/"5^3I"S:K&T6GI;KY:0LH8Q,3D /CY@5'S;L8XZFEM_!
M$=O# JW$6^*&SBWB#!/D3F8GK_%G'MUYJ-_%]VMIJ5P\5C!)8V?G&S>;=+(_
MV<3$J5."@)*Y .=K'/&*LQ>)Y[_619:=]CDA^W-;F?>7!188Y&(QP6RY7KQC
M/;! &)X,"AR;M&=A"%8P\KLNFGXY[[@/^ Y]JB/@Z]>:]N)=526:9H6C+PL0
MOE3^<N1OQC^'"A?7J:J67B?5%2:X+P2P1:5;WHMW!,KY>3S2K9^8A4Z8Z[?4
MYT=1UN>Y\&KJD<XLXY[N%8IT8?\ 'N]RB!\G@;HSN]MU #;WP?<7$EQ+%?0!
M[E;F*02VQ=0DXCW8&X?,/+'L<U-_PC,ME*U[92I)=1W$EU&LBXWDV_E*C-GU
M )-8[^+-0L%FM[22/4XC=R1VM[.\:K(B0HY7=E%8[V9<@]$/!*FK4WC6Y@U6
MY@-M;2+#*8C:1R;KCBT^T;N.,9^3ISD'/8@&QKN@2:Y9QQ27*12"WGB9ECR"
M9(BF0,]!G.*S;[PO)+J2QPKBUN+B2:5T"J(5^Q_9PH&<DDX(P,8!SVS5D\:W
M4-E+,SZ=+%"T3RW4#%HUC>-W("[@79=HR <[7#;>U6K;7+UO$EO;FY@BLGDO
M5=9AEF,;QA0K9&.&;CV/X $UEX4N$O+:[O[VWN)(;E)]L=N54[+=X0.6//S[
ML^V/>I_#NARZ7?:M/+D++.4M%./D@RS@<?[<DF/]G:.U;T4L<\*2Q2+)&ZAD
M=#D,#R"#W%/H Y'3?!EQ;74-S>ZBEW(D\,S$Q-\YCCD3."Q ),@; P!C %,B
M\%3VWV1([Z!H819EPUMER;=RP"'=\H.<=#CGUKL:* .63PW>M86$OGVT>HH9
MI;@31&:-GFY? !7[I. ?[HQWXT/#_AZ+05G5)?.\P0J'9</MCA2, GO]PG_@
M5;-% ')KX1NH(B+;4PCF*&(GRV&X)),Y&58,,^;C@@_+UYJ&T\$3VOV&/[?
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M?*>G%244 ,$,09F$:!F(+$*,DCIFE\M/[B]QT]>M.HH 8L,2H$6- H&T*%&
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M !2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%4;_ %6&PD2(I+-/("4AA3<Y ZGV'N<"JZ:U*\@4
MZ1J" _Q,B8'UPQIV%<UJ*YC2/%S:I?V]JVGO%YT7F"0,67H#CH/7!/3((KIA
M2&+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!#+HW_ ('Q?_%5M21I+&T<B*\;@JRL,@@]016%_P (+X1_Z%;1/_!?%_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!76]MVOIK,/\
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M0MM1MK2Z91;2(WFO$#M81X*[7)' (+<CH*[BYG@MK66>ZECBMXT+RR2L%55
MR22> ,5SL7C'P-!"(8?$7AZ.(-N")>PA0<YS@'KGF@#(N?$.KZ=K=S:37;2V
MLNJ6EE:RM&FY&S 9$;  .]'=@<<;6Z?*!JZ]JMP18+9WES87TTX6.UE2,"5
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M!>PAF Z9.<F@#IJ*Y[_A/?!__0UZ)_X,(O\ XJC_ (3WP?\ ]#7HG_@PB_\
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M_P"$]\'_ /0UZ)_X,(O_ (J@#H:*Y[_A/?!__0UZ)_X,(O\ XJC_ (3WP?\
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M>B?^#"+_ .*H_P"$]\'_ /0UZ)_X,(O_ (J@#H:*Y[_A/?!__0UZ)_X,(O\
MXJC_ (3WP?\ ]#7HG_@PB_\ BJ .AHKGO^$]\'_]#7HG_@PB_P#BJ/\ A/?!
M_P#T->B?^#"+_P"*H Z&BN>_X3WP?_T->B?^#"+_ .*H_P"$]\'_ /0UZ)_X
M,(O_ (J@#H:*Y[_A/?!__0UZ)_X,(O\ XJC_ (3WP?\ ]#7HG_@PB_\ BJ .
MAHKGO^$]\'_]#7HG_@PB_P#BJ/\ A/?!_P#T->B?^#"+_P"*H Z&BN>_X3WP
M?_T->B?^#"+_ .*H_P"$]\'_ /0UZ)_X,(O_ (J@#H:*Y[_A/?!__0UZ)_X,
M(O\ XJC_ (3WP?\ ]#7HG_@PB_\ BJ .AHKGO^$]\'_]#7HG_@PB_P#BJ/\
MA/?!_P#T->B?^#"+_P"*H Z&BN>_X3WP?_T->B?^#"+_ .*H_P"$]\'_ /0U
MZ)_X,(O_ (J@#H:*Y[_A/?!__0UZ)_X,(O\ XJC_ (3WP?\ ]#7HG_@PB_\
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M_P" <?\ A6O10!D?\(KX=_Z .E_^ <?^%'_"*^'?^@#I?_@''_A6O10!D?\
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M_@''_A1_PBOAW_H Z7_X!Q_X5KT4 9'_  BOAW_H Z7_ . <?^%'_"*^'?\
MH Z7_P" <?\ A6O10!D?\(KX=_Z .E_^ <?^%'_"*^'?^@#I?_@''_A6O10!
MD?\ "*^'?^@#I?\ X!Q_X4?\(KX=_P"@#I?_ (!Q_P"%:]% &1_PBOAW_H Z
M7_X!Q_X4?\(KX=_Z .E_^ <?^%:]% &1_P (KX=_Z .E_P#@''_A1_PBOAW_
M * .E_\ @''_ (5KT4 9'_"*^'?^@#I?_@''_A1_PBOAW_H Z7_X!Q_X5KT4
M 9'_  BOAW_H Z7_ . <?^%'_"*^'?\ H Z7_P" <?\ A6O10!D?\(KX=_Z
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M?_@''_A6O10!D?\ "*^'?^@#I?\ X!Q_X4?\(KX=_P"@#I?_ (!Q_P"%:]%
M&1_PBOAW_H Z7_X!Q_X4?\(KX=_Z .E_^ <?^%:]% &1_P (KX=_Z .E_P#@
M''_A1_PBOAW_ * .E_\ @''_ (5KT4 9'_"*^'?^@#I?_@''_A1_PBOAW_H
MZ7_X!Q_X5KT4 9'_  BOAW_H Z7_ . <?^%'_"*^'?\ H Z7_P" <?\ A6O1
M0!D?\(KX=_Z .E_^ <?^%'_"*^'?^@#I?_@''_A6O10!D?\ "*^'?^@#I?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>bionano-nancyridgeleasee004.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU[;6H7FF6]HDFI7-I%;.RE6N)%5&(^88)X/3/X5)=ZA96"QM>7<%N)&V(9I
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M.O3/7KAK6E%;=AJ=GBY)6 ^>O[TYQA>>>>..](NMZ2[7*KJ=DS6H)N )U_=
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MK\^T @'^$GDC-1S^$VGNYF:^ M6FFN8XQ#\ZRR1-&<ON^90'8@8!Z<\5TM%
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MW?, R\# X.#GK5B+PS=PZE_:B:E#_:$DDC3,;4F)E=(D(5-^5.($Y+'^+CG
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MGRU X&,GJ:O3>$DEU>^O3-%+'=,TGDW$;R!)&A\DG D"D;>H*YP2,CC'2T4
M<DO@N0RVLL^IFX:-/+E6992KIYA=0/WN>,X&\OT'I4L_@U)8D5+TH\9N'1O*
MR-\EREP"1GD!HP".X)Y%=110!S;^%Y9]:BU.YO(I9"L(GC\J149HG9T95$F
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M=!O(HY8A+9V"F2\DFQ(TQ@$H94VX*\CN/XO3GKK:;[1:0S[2OF(K[3VR,XH
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M63*CYFWC/7OR:S)_!%^=+M-/M8]+@CMY97#HH#9,BLC@F,D'"D$*1T!W'&*
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M[,&SY7D)L!Z9QC&>!7.6W@VZ@ET]1>1I;10*MPB9RTD0<0E?8>9G_MFE4H?
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MS"-T;LJN<''<."2/6N4F\"SS_P!L"?[-.]WYQBDE<8??*)%611'GY=H4,6;
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M^]+,1L<G'5<=>HXQ46K>!KN?3;ZPT_\ L^*"YF:14:,#RR;=(]PRC8.Y68X
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M<'* <_PC/05D6/@B[^T,VH_V?)$\UO++#'&!'(8_-W'8$4#/F+P=Q^7!8X%
M'77.EV5W;F"2!/+8C(4;<C<&(X[$CD=ZDN+&SO'C>YM()WB),;2QABA/7&>E
M<E8>%[JQUO28L@V4-N'N=H.PR1$K"!^$I/\ VR2NUH @:RM75E:VA96#J08P
M00YRX_X$>3ZTU=.L4LVLULK=;5AAH!$H0CW7&.PJS10! EE:1HJ):PJJA  L
M8  4Y4?@>1Z4R'3;"V9F@LK:(L^]BD2KEN>3@=>3S[FK5% #8XTAB2*)%2-
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M;66L+73(9U$\=OYLET8_G="XX"'@;>3G// -:5G::->QV>HVME:.$C MIA
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MHWF9E5<;#D KR3@X/0GBNAN[737MWBO+>U:&XD7>DR*5D<X R#P6X&._ J"
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M0'.V,_+\I^[O/8@&JM[XJU&06T4%@+-Q-8?:3-+AT$UR(RJH4^8$*W)VG#9
MR#CI6T;2W%P&TVS87)#3@P*?-(.06X^;GGFD_L72C);R'3+/?;@+ WD+F( Y
M 4XXP>>* ,[4_$DFGZF]LEFLL, MC<2&;:P\^0QKL7:=V""3DCVR:1/$<_\
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MV=NT:QF)4,2D!#C*@8Z':./8>E0-H.CO:16C:38M;1,6CA-LA1">I Q@$Y-
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ML<GD'([YKM:* ,;P[;W]KIEN+V*-9IT:YNCO)99W;<R 8^Z,E0<]%'%;-%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4457OVG33K
MIK89N!$YB'JV#C]: +&1C.:*\YM6NKI]#ME^UMIT36K0QK:EH9(#;Y:1Y-O!
MW$K@MT XYS76^$WD?PCI#2%B3:1X+=2NT8)]\8H V:*YKQV;I/#2R6D=U(\5
M]:2.MK&[R>6MQ&7PJ DC:#D =,US\^O^*;KQ9.MFLUKI?E[K<7&G3GS$,!8L
M0(<AQ)QM+KP,;26!H ]%HKS*P\0>+F;13)!J,QD:6*>-K39YC G;(6,"@1<=
M#Y;\@_-WI0>(/'K:"D\HG$DEQ"L["RE$MJ#&YD 'V;!7>$'RI)@$Y8Y#  ]:
MHKA]9?7I+#PE=*DLE\C/)=FVA<)O^QR\LA (!<K@,!R0,9K%76/&T%I$MY+?
M[)7LY)KJ+2]\L"R0R-(BQA3NQ(L:G@E=YS[ 'J5%>2^%KOQA8OX=TIX)K2RC
MM+8.DUK(1)G=YH8B)MK#Y<9= .^[/$VEZEX_(T^XO)KMPR:=+/ VFJO,TI2=
M"0N1L4!CW&<G XH ]4HKRHW?C*ZLT74(;FZ6?[--Y36&WR&6^52!A<_ZKYSG
MIC/ JC9V7B70(9KVRL[JXOY?[5E>:2R!DW?:8E0\*-Q,89U!^]@ < "@#V.B
MO-Y]<\2'7-'M=/?6)[.1HEGN+G3?+$B.[JSE?)^5E 4\E!T.T@UD6%UXML]+
MMKA8M3NM0@TZXCEGN;%FDC?[3""%RHWD1[V4<[MO?&* /7Z*\KN=7\=26$KV
M,E\4A@OYX)I-, ENA$8O(5T*#:S[I!@*I8#('>NW\033WG@S6Q:17/VL64Z(
MB1.KF3RS@(,9;DC!&<GI0!NT5R-_K&L7&NV:Z:L\.GNL9#36DJ^8WF$2*P,1
M*X4#!)3[V<D XJ/K&O):R-_I\CQ7N&\NS(,T1!PL8:'Y<'&=XQV\SN #N:*X
M635?%8?5W2)MT1E6. P.=JB951T/E8/[K<Q&Z0DXP!@K6JEUK'_"'RSM<'[<
M'/ER_9W+;/,XROE YV\;O+P/O8(H Z6BN(LGUK^UEU-$OHXY_L2RV\UNN7#*
MP<N0HP5R#\NT ]1V%>PO-;U6ZM3=VU]Y,=Y#,GGP%70-%,&5L1H/E.T'K@G[
MQXH [^BN1MTU"U\+^$TBMI?/BB03*T1+1$6<O48^4[PJ\]SCO547_B.""".Z
MGOO+D>W>>ZBL0TD(>%RRJ@0@@2*B\JQ <Y]0 =Q17G^@7'B.W.A6#QR6]LEG
M:[EEMWPY((E#8C;:PP, NF#C.0:GL;KQ7MM)[BXNGS%I\LL+6:J-TTI2=#A<
M@(@#>H)R3CB@#N:*X=;CQ$\48NEGN%FD@D*/:@"'%VBD#"Y_U9W'.?NY&!5:
MV_MC08(8X#*TNK:G=P%I8$#I(T[%)3A1E1$DC<YS\N.,"@#T&BL75=3ED\/S
MW>DM*[K.(6>.$NR*LP25E4CYBH#D<$' X-<G;W7B.T@ABL_M*Q37-W+]HN+1
MPTC></+WHL3$*5)/ 3/8C&* /1J*\]FCUS26O);+[0KWNHW!EN&M]S *,1#Y
M(7)0\\D'H ",UHS7OB>*]GFB#S*+AH([86^(BOV+S0^XC=_KALR3CG'6@#L:
M*Y'PS)>>9K-Y,=0N2T<+(]Q:>1(Y$9RJJ54'!XZ?GUJGIU_XEU&*.%I;VV5[
MXI]H>U'F"'[-OYW1*O\ K?ESL]LGK0!W5%< EYKFI:EHYOHKV%EFM93;I9GR
MMI@R[L^WY6$A9=I88 ''.:T[B/5;;Q9<W=J9_L[S6L3Q"$%)$(8,Q;&1MR#P
M1COF@#K**X"WNM=U*WMENX[R7][837"RVAB\B;SU,B)\HW(H&<_-@#.XYJ[X
M6DU.[UZ6[U'[9YC6"+*LUJ8DAE\QBT:':-P'&#EL]<G- '945P@U35X- M;>
MTAOHYTOI4NY)+64,D9,I4J3$X8$A!D*P /;.1.^I>(%DGBDEE,IT]'62*SD\
MF*7:F[(,18DDMC!; R"F5.0#M**XE=7UZ6YLML>H1%EM=D,EH&68-(1,97"
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MB""V9C"#<JC,F8@I41%CG<_0'(% '=45@:7<ZA_PD5]9W4ES/;HBF*5H=B#
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MI;@JJY([D,K<\_,<=.,6WDUK21>NJWTEO*^HRB&.W!,;"XS&5.TDE@S'G=D
M8''(!W-%<7IE[XCO/LGGO<Q(D=Z\C&V ,Q21!"&+1KC*LQX52V,C&*33KCQ.
MMS:/=7-U-&6MC+&UHJC$D9\P$A00$8#'.1G#$\8 .UHKS_0;GQ%;+HMB\<EM
M;0Z?:J4DMY&#_N?GW8C.'##&"ZXP,@YJS9:MKI72O/\ M\F;DPW(%J5,N3'B
M0$P@+&,MD,$;@X9MO(!V]%<=K-GJ2>)K[4+)KCS1:64%N_V=9%CWW#B4KE<Y
M"8)YZ$$]!@FO]>@UF2WC>\E\N4QA&M!Y;PBWW"4R! -YEXP#CMM[T =C17&:
M=/XF2\M6NKFYFB,EN)$:T501)$3)DA00%8#'/&<,3VGU35-9B\516MG#=FUP
MRR9@W1D>1(X92(_[X1>7ZG&WG- '645PZW_B.""".[GOO+D:W>>ZBL0TD(>*
M0NJH$(($BQKRK$!SGU$T$VI:;\/]$CCBO8[PPQ12&.'YXCL))=3&Y R,?=)R
M0..H .RHKSRT\3:W-J5NET]S 4A3S;:.VXDE-H)3$"4.)-QS@NO QCG)<FI^
M))=/N+C[-=23V[7/V9Y+4ER/LJLG'EIG]X67[HSC'/4@'H-%<9=7VOV+21M+
M>7*Q7RJ#':#S)XC$C$*1&4P'9ASMX&-P()-W3)K^ST+6GGDU*ZNH+BZ:-'B&
M_;O<QB+Y0&RNW'4<X]J .FHK@4U'Q5<6,@1[N-XDNW23[("TI18VB!W1KU+.
M.%4D XY&:V=-U+5;CQ3<:;.-L%O']I9]@&Y) HC3ZAEGSWPBYZT =+17#SZO
MXC?4]1AM8KU(02L1EM=WED7")E?W8!!0LP^9^ #\O(JEXBN/$$NAWVG2-J#*
MUO?1))#8[WN6!"Q*^U,*"I/("YQG(Q@@'HM%<QXMU+5;%[1=*BNWD;<[>5#O
M1L,@VMB-CD@G'*< _-Q4&@6EW#KXDEMYDC_XF/S.A ^:\W+S[KR/4<T ==17
M 1W6NV"&W@CO(L2RR6T:VA=;B1KN7<LC%3L79L(.5X<G) J:[U?7H8+\J;Z1
MH+S*F*S;][$?,Q'%F$X883)8,IXPXW< '<T5S'BJ_P!7M)$73_M2 VLTD9M[
M7SO-N!M\N-_E.U3ELGY?]X8IFGVE[8CQ7?A9FO9IF:'?$I)"P)M"D*"RAB0,
MYZ>N<@'545QC7?B6#5M-M3/(\+1022326YQ([2-YJ,$B(7:NW;EDQG)+8-5+
MF;Q-)ICF6YU%2Z1SDP6H5X=MP RJ A)S'R0<DXXX.* .^HK TB]OY=>O[>X:
MZEME56@D> QHHX&TY126ZG@L/]WI6'9ZIXDOI[F)5OK>%IK8))+:C?$KO()1
MS&J_*JI_? S]YLT =W2;@6*Y&X#)&><?Y!KSV^NM?O$LK6[%^-LEHP$5D2+A
MENR)#(P7Y,(D;]5'S'J.!>:ZO&!U:&2ZBM]1O61[BUM_/DCMHT98MJ[6^5G!
M;.T_ZSMG( .UHKG/#LVN7EQYVK-)"%M(/]'$(53*R9D.<$Y!&, X&3G/&, W
MNL_VO+?2IJ;S0VMU$8TL]JP$W$00(Q0AQL7=GYS@$@'I0!Z%17!)J'BRXTZ*
M57N898XY&Q]C!,I%R47<&13S%\W 4GKP.*??ZKXCLXH(8DOYITNI5\W[,-LT
M:RJ%WA8CR4)Y&P$ G- '=45YTOB/7KB34VMIYG=9&6"#[/P8ENO+>6,B([@L
M97H7Y.<'@5JVFJZQ!>Z8=0EFDMGCD,YCMF14 ,A5Y&>)1C:J@X*'=SM(88 .
MPHKF?$;37UKI%W80RS*7EF&(FR UI-MW+C(R648/<@=:P=5O==N8=0TZ*TOC
M;OI<T31FW.W?]F!4H1'W8E<;R<Y&T8H ]$HKSV\EUF^TVZA\J]NX1]HCBEFL
MC%(0;1N-NT8'F':#CGID]3>B74TUZU9FOK>T&H%'6&#*RJ;:/:7^4_+O##=P
M!Z@@4 =I17!:1?\ B19M*MY8FM8%LK8M&UJY5LQ9DR%C.&#<8WKC X.:W/#6
MK3SVL-KJ;7!U!S(0TL)02JFS<ZC8A"Y< ;@#G(YZD Z&BBB@ HHHH **** "
MBBB@!LC^7&SGHH)K/M==L+F""3[0BM*47;DG#/'Y@&<?W><U;O%F>RG2W5&F
M:-@BR,54G'&2 <#\#7/6G@R&%;/S;VX(A2(R0)M$<DB0^5NY7<,KV!["@"Q!
MXQTJXN;E$D<P110NDJQ.3*9#)@(FW<W$>[(R"#GH,U*?%VA@Q#[:29E1HPL,
MA+;UW(.%ZL <#J<' -8FH>!IC:PI::C<3R1F!"9Y$C(BB255566,@',N22IS
MCMP1K6'AE88K62ZFS=1F"1_)4+'OCC* *,<+@GT_#I0!=3Q#I4DELD=XK&Y1
M'B*JQ4A\[,MC"[L$ '&2,"J<GC+15L_M,4\UQ'YD*8AMW8GS7V(P&.5)R,C/
M((Z\5%:^"].M+ZUNHV9G@CCC_>Q1.6\LDJ<E<J>?X2.@^M/_ .$0M%LH[>*Z
MN4,5O:P1R#:2OV>3S$;D8)W=>,8]* ->TU&VOI)TMW9S VQSY;!=P)! 8C!(
M((."<$8-5M1UVSTXSQ,S27,4#3^4JL> &(W, 0N=K8SUP<9Q5>+0);34Y[VT
MOY$>ZFC:<&- I12Q( "C+'(4L<G:!SD5)=Z EU>W=PM[<PI>0>1<0H$*R !@
M#DJ2#AST/8>^0"*77M,M;"5&18S'9M<>0T;)&45 Q4-MVG (R!G&>E+/XJT.
MQFDM9;L(\&59%A<A=H!8#"X)"D$@=!R>.:HW'@6QN;BYEEN[H^?;R6^/DRBO
M$(SAMN<8&0,X!)..:OR^&;26661IIP9'F<X(X,D81NW8#B@"_;ZE:7=U-;6\
MIDDAQO*HVT9 .-V-I.&!P#GD4R\U>PL+B*WN9]DDN,#:Q !(4%B!A020 3@9
MXK-7PTUI>->6%_)%.T<<))1,>6I3).%^9MJ$ MG;N.*FU+PS9:GJ\&I2X\Z-
M%C(:&.0,JMN'WU.TY)Y&.OTP 2-XFT=49OMJMM<1E41F;>690N ,[LHPV]<C
MI3D\1:3(]LJ7BL;A4:,A&(PQ*KN.,*2P*@-C)! YK)F\&F-_,T_4+B*6:^2\
MN)'*L2XW9< J1DAE7'3"#&.IEMO!.G6M];7:.SRPJ@9IHHI#(RNSALE,JVYV
M)*X[8Q@4 78O%.C30R2Q7F]4V?=B<EMY*KM&,OD@CY<\@CM4LGB#2H;AH);M
M8W12S%U8*N$\P@L1@-L^;;G..<8J@W@^S-B+59Y=@M8[7YTC?*HQ8$AE(SD]
M?88I+?P;8VU])=QS2-+(@#/-%%*^X1"+=O9"V=H&1G!.>,$@@&[:W,=Y;I/#
MYFQLX\R-HV].58 C\JSU\3:.TEP@O5S;AR^48#Y&V.%.,,0Q"D+G!('<4FCZ
M-+H_EV\5X[V,:/B)E4?.S[LC  55'"J.,$^@K(C\#QW$%RFIWLTV^2Y,,:A-
MD*RW'G9&5^8Y6/ALC@CD&@#6D\4Z-$D327FWS=^ 8G!7:P5BPQE I(!+8QGF
MC4/$=G9+<*N^2X@ 8Q,C)N&]4)5B,, 6&<9QD>M5CX0L6LWMC(ZA[6:U8PQQ
MQ#;*5+':J@9^48X^N:C?P592ZA=7DEW<M)<!U.=F5#2)(1NV[B 4  ).!P*
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M_P">F%)!X.,U:;Q'I"SI";Q2[OLX1B%/F&,;B!A<NK*"< D'&:JR>$K&2V:
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M$K-EF9<C>PP!N"\9'7<1@8%7)/#UI+-<2L\F^>^BOF/'#QK&H X^[B(9^IH
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M:L_$6GWFB#5PTT-H3C,\+(V<[0 I&222 ,9R3@<U2L?"ZQVEN+N;_2%6UWB
M*L8,!)4*,#CG!X'3@"K(\.0C0_[*^UW'EI,LT,GR[XBL@D3'RX.& Z@Y[YH
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M5=/F>^OW6Z>H'Q;H2;P^IVX:-5+A6W8SC &.IY' YI(/%FC2:<E[+?VT2,2
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M;0;8DK(AC";=J\A@SD#<2<<!<4S4+O5[_3M0CV7-S"+:]2WN#;-&\HV0E?E
M&#N:11QSLKIT\56']@VNL2[UMKF<0Q[%,F27* \=CC-7H-8T^YOWL8;J-[E-
MV4'^R0&P>AP2 <=,\T <N&UEM;18;FXM$D&HQQ@P[HFE$B>47R#VW$<CA3CJ
M<V[/7=5U'P;J.MPVS1SLCO:6WE[G78H!!'\1+J^/4$5KZEKUGIEVEI*)&N)+
M>6XC54)!6/&03T!^856T[Q'H9T:":VGAAMU"1K#&I^0E-P55 Y^7G@8P">E
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MUSO-"TL"R)]D"<21%GY'0*X&/3)!SQCH+?Q#I-VT*V]ZDIF=DCV*3N*XSVZ
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M/RL%;(QE<$@'.,9YH YS4]2UF0ZC$+B\A\B\M766U@RJ0F=0Z\IDD+N+?>!
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M!Y<<#EE4Q%I"RX&-A&['4_<^\0: .IN_#MM=Z=8V6\Q16:LJ")%48,+Q= ,
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M>3 PS+.EPRJ6WK+Y@)&,=?857/AB:WDDFLM1=9%:=[59$4K \[[I'Z9;!+$
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M(LXI#;:?<1M(TWV-YS+('0"'C[F59CD^GL: +%WX<E&C65A87;))!>+<M/(
M6)WEW.,8R2QXP!SVJ&W\$V5M?V]X)?-E0*9#/"CEV65Y0PR/D.^1CQ[8QC-<
MEI?B_P 5ZLY@B4PB:\M8TGGT\AHXY$F+@INQE3&O<X)P2:EM?&?BB6V,DUOY
M=Y'I/VB"S%A(WVZ?9*6^8'Y,%$^7KSCN* .P_P"$7A$.DQ)=2(--(*.JJ)&
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M(+BU^R-N7S;;S)&WYXVN,8QQG!- &_J?A+[6MZT5Y)B5IIX;=P BSR0M$6+
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MM@\GVAO/%D[$!(%D"LIP 2^5[\''45M>%]6URXU/7Y+YY9&\B"YM+)H"BC=
MC$*Q[;]RXZY!- &M=^#;*\@,4D\V/]*(X4X,UPLY.",':R# /4=:4^#[1K.2
M R[/-M9K9S!$L8(E926P!U^45R&E>*/&6J6EBF^VAENKI(WD^Q.QMP;>5W5D
M. ,.B@9/?!SWJQ^*_%T<5UJ$GF>;<:=ITZ6ILWV0>80L\B_[F22/<$\+R >B
M_P!@0O9ZO92SR/:ZD9"Z< IO7:^#[]>>E,_X1X7!W:A>S7;FTFM&)14RDFS/
MW1P?D'YGVQQG_"3>,S97%S%';3&UTDW02*T=A<2F69%P>#PJHY4#D\#@UC^(
MO$WBF[\*W%LTH5+BTO/+N+6RDD:X9=@2/Y0-C89SN''R^Q% '<2^!+>7238?
M;6C5B1(T4$:>8NPH-X PQ&<@GH>U6;KP?;W/F@W3[7N(KI%>-759$B$62".0
M4 &/7D'TR/%NI:SINL0RZ5 6E_LX!7:-Y$#-=0(<J" ?E9CZ\=0,UC2^(/%]
MMJD<CR/.;>WU.%($LF"7DT+KY6<$[2R]/]UL=> #L%\(0QW$+PWDD,*-!(\$
M42*CO"<J>GR@]P/0>^;-WX<CN]4:[-W,D,LL$TUN N'>%@R'.,CD+D#KM'3G
M/)KK&LZQX#\7"61[GRK%Q:745J]NTKM 2RA3SE6.,CZ=168WC3Q5I^EM.D:W
MT NAI\$K63P,\TD*F,E6.=JS90GON]10!Z)_8,*^&H]$60-%'$D0:6-7R%QU
M4\'I_ABJ,7A%8KFUE&IWCI#Y#.LFUC,\0(5F8C/(/..X'OFEJFJ7.D^.=*%S
M+<O;RZ7/'MC1S%)<^9#LR%! )&_!/0$\URL'C;Q<WAY[^=(%D66$R01VC^>N
MY)#)$JD8+!E3 )R1N&<E: .YD\'V4NG+8R3S&-;%[+/&=K,K;NF,@J/;VJ:Q
M\,VUG-%-N0ND<T;"*%8E?S/+R2%[XB49_P#K5Q]QXP\01WFH6[9BACU%(C>I
M8M)':V[>;SC@E_D16!! W @D$5J^$-9\2ZUJ2G5$2UMHK"&5XS:,C32.THR"
M3\O"*VW!(W8H O6?@JWT^UMH[6[,,]K(CPW"6\8;"H\8#\?/\LC]>YR,5=/A
MQ4T33=.@OIXVT]D>*?:K,Q52!N&,<YYQCVQ7$IXR\4W6I7EM:1,L;7-O%%)/
M8$&'?<^4^5!YPF&ZYQR<9XH:SXC\4WUA!87/F0L2OS0V$F;MTOFC;!!_=@1Q
MHY]0_I0!W5MX22TUO2KJ.5FALK>02%V^::8D[&( QQYDY^K].*LZAX934)]2
M,E[*EMJ,(BG@5%[*5!!(R",Y[CBL;6M;O-(\:WXC6ZFWZ(K65L$D:*6Y#RG;
MP,!B HSQQBL.T\9>*#86%S.898Y;Q8W6"U<SLI5,J%("Y#,<C(./<&@#L%\)
M0JMGMG6%[>X^T%[>W2)G.5XR!D A I]1P>V*[^!K9T&ZZ+.L[3(K0H8EW+M9
M1'C SC<<8^;GN17)W/C7Q6EM(D<:!Q?/$]Y]E;R$78S(%.,\G .X9!XZD$;.
MA^)/$M]XS^P7T%O;VJ\/%Y3@E?)5A(C$<@N2.<<<=1R ;2^$HK*^N+_3VA2Y
M92T(DMT(CE\H1 A@,JN .![]CBI_$'AL>(=-CL[B^GC4(R2%%7$FY=I)4\9'
M4>AKB]4U7Q%JFMR::DKQM;:W (+B&U8Q1Q$RC#9(+, !N!XZ$$@BD@\:>)9[
MS1+:2VD#SK&EXGV)E4AC(I=6R2,;5/8#('.> #L[KPE9WJ3QS33&.::25P"!
M]^W,!&<?W3GZU9TS138B]:>]ENY;O;YCNJK@*@08"@=A^=<)X+N-8L/"NLW;
M1W+7<&B6<D"SJQS*MJ21@]3N R/6K2^(?%L7B'3-.N#;M'+%!+)(UJR";S&;
MS N,X*#: ,]LG@\ '30>$X8[6.&2\FE*0VL <JH)6WE,B=!U.<'Z5-HOAJUT
M.YFE@*-OW;"85#J&;<07 RPSZ^@SD\UY[X9\2>*+.'1-.DMREO#IUNS)/ [2
MW ,)+LI[N& &,CH<]01):^.?$\EF)WC9HA?1H,61$\L31J=J+]TD.2",C@$
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M+B.[DMP%VM*B!%.<9 PJ\>JCW!YJ\U+Q+?\ A/PO>11F'5)M3C$JE)(D>/\
M> &11\RJP"L0>F16''XH\4Z5#! R7$MV^IW)E5K=Y(WC^U[-J.3N "$D#'"@
M'..* /13H*#PQ;Z'%=311P0Q0K,OWB(]N,^H.W!'<$BLM? T$=NMNFHW"P&-
MHID")B5&E:4CI\O+$<=O?!'*7OC?Q#'I>HS6TLLDHO98K0?V8P(1$8C?D_QL
MIVX!)&.A/%R?Q/XI^S7-Z[I:6HO[>TXT]Y#!&T*2/+URPW-LZ<9]J .B;P7"
MUQ?3MJ%RTMR" [!24_>B5><?-@@  \;0![TL_@JSGEU%WFR;^.178P(71I(_
M+9E;&1QDX]SVXKB-"\1^)[&PTFR\N7?M@*0S64C->&2Y=9LN?]7L0!L'IGGB
MK3>./$DMC+Y<2PW%O;;K@RV<B@2BX*LBDC&[R\8ZC)&>M ';W?A:SO99VFEE
M*SW+7#H"!]ZU^S%?IMY^M,T_PI;6'V0B52]M,90R0)'O_=-$-VT<\.3GU]!Q
M7,>-=0O6T;P]J<3WYE,?G/I:B>WDNF94^7=#G9(I/"L2"2?3(S/$OB?7[_3M
M7TF.VN%FC34%D\NTD!4)(GV?:PX)*%CP3F@#NK/PY-I*1+IM^R8M[6V?S45L
MI"<%AQ]XIE?3G/:I-6\-QZOJEK>2WDR+;O$XA !7='() 1GH21@D<D =,5QM
MMXN\2/=62,XGM)=2>U6>/3W26>/]UM<1MP%4O(&.0<*",X-9]MXO\3Z?HNDQ
M&6YO+\S.+D2V# $"94*%LYR%);@=.<\4 =W)X0MFMXHTNYT>%5$;@*=K+,)E
M.,<_,HX]*LIX>1- FTI[DS^=+),\L\2-EGE,ARN,8R3CT^O-<3+XL\86\-S.
MT*21R1W#1A;%\VPCO$AW'!R_[IFDQQG;QWJ;_A*_$A\116=O);R60B1DGGLI
M8Q=*4<LX !((8 8'H?[PP =9!X6@@6(->74KHUNYDE8,S&)=H)/<GJ:JZ=X*
MM["5)6OKB>19$D+R!<N4CDC!8XY)$A))ZD?A4?@SQ/)JME!:ZH[C57$K;?(*
MI(D94,Z'&"F7 !."?3@US<GC;Q-(DL%O;%;N%95EWV,FU9!>QQ(.P;]RQ; /
MOQ0!V=UX9BN-"T_2ENI(DLD1(YE5?,&U=H96_A;'<>IJM-X-AGDNM]_<&":.
MZ1(=J8C^T.KR$'&3\R\9Z UQ5WKWBJTOY[WR'N+JSMKJU\Q;=EC91>PH)=@S
MR(]S<>A[5?C\6^)UETY96MI%N+:=@T-M(PWJ9=CR< A,(F=F3G/&&6@#L+_P
MO::AJTVH232JTMHUL8UQMR0RB3I]\*[+GT-5KCP5I]U->/)-/BZM/LQ08PIP
MH,@X^\1'$.<CY!QR:F\&ZI>:QX;ANK]9!<[W1R\80,58C*XZJ>QXR.U;] &*
MGARW'AZ]T@NJ)>)(DLD$*Q_>7;D #&<8ZYZ4C>&X9I6EN+B221YTN)#@*&98
MO*Z#H".:VZ* ,;P]X=M_#ULT,#(^42,/Y*(Q5 0NXJ!N/)Y]^@K9HHH ****
M "BBB@ HJ"\G:VL;B=0A:*-G D?8N0,\L>@]^U>67'Q8OX=/AF":7YXMYYI8
MY69/,DB=%,$6&8.QW\$$@X^H !ZM%!% 9#%&J&1R[[1C<W3)]^!4E>8S_$S4
MXY]9(TVT6"R>2)1+.JO$5G2(/(H<MLPY<G:H  Y.<U6U+7]8U+6(K.SU6 QR
M7UA%)-9S/Y4BN)B?+(.5!,8S@G/3- 'J]%>6Z/\ $2X33P+J>R@2VTTW;?;)
M'>>Y)$IS&!RP7RQG@GKTQSD:MX[UC5-/:>*Y-I)!#?Q,;23"2,AMBK\,P! D
M(^\>IYYH ]IHKDO#_BJ^U?Q+J6CSV<<+:6'%VXSC<S_N-N>S1@L?J*Y<_%*_
M_LU'8:3!= W)E>5R8%,4<;B)75B)&?S.&!Z _+GB@#U6BN#\7>/I_#VFZ5=1
MV\*SW=O]IDM;@$-M'EY4-E0&&_'<_P"SUQF'XD:M/=ZK'9V^F,MK>)9I&\A#
MAVNQ "V&SC;\V=HP2!SCD ]/HKS&[^).L65WK,;Z7:2KIJ2JR+,J/O0+\^TO
MN*$L3]T87!W'MF>(_B-K)\-7,2MIUA.]I=2)=K<C][L**HAV.P$GSYVEB1M]
M\@ ]AHKSCQOXMU#PQXGMY;>XMC$-+>4VES(RBX<2H L8'60@D#KWXK:\.^*K
M[6/$NHZ-/91PMI@<7;C/WFD_<[<]FC!8_44 =;17D\'Q*N[?PAH;6\]EJ&IW
M E%T\T\:B)T!*H^74*S8XR>@)P<8J[??$C4+5]50P:='+:^6ZQF9)-L1.'8L
M) &<?-^[^4\<;J /2Z*\QG^)UXES<&""QDCC$P6W)=;C"6OGB9E/2,G"],\C
MG/%;.K:]J=IH/AV_N1$MU=78,D=L["/:897"G/+#Y5STR>>* .UHKB?#?BO6
M];T[4C)960OHM.M[ZU2$L4;SHV94;/.05P2/6N=@^+EY?P74MGI<05+*;486
MD+8>WCB?)/OYZ[/H: /6**\MU#Q7XAL]757NK&U)GT];@N6:!$F\[@;L;?NJ
M">,GTHM?'NKV\*".WMYK>%A).UQ(QE97OY;?:I'' 4$9Z8Q] #U*BN'\(^-K
MKQ%/J\LRV4=I9(2!$Q,BL&<$,-Q. J*<[1DM@#@U@6?Q'U?59]/,,^FV]L=4
MAMYIV7Y)(I8'D4?>.TY7'4'.W@<B@#U>BO,_&?B/7+/6M;TZVO[:&.*VT^>S
MBR4E)>YV.=PY*\8;K@$>IRR7XD:S#>06!TZQ:Z6>XBF<S"*.8Q3B,B,R.N#@
M[OXCT&.<@ ]/HKSGQOXFU72-9U*TCO((K-='^U11 [)FD$A!*-UR!C/M5;4O
MB'XAM)+^2&QTQK>W&HNF]I-Y2SD56SCC+!ACT()YZ4 >GT5Q.@>-+[6?&-YI
M;65O%:0O-'DS()E*;<,5W[B&R3]T #')S7,Z[\0M9N]*UBWL39V\HM[HKY+L
M;BR\J=8OWO/#.&)7IC'?K0!ZS-#%<1F.:))(R02KJ",@Y'!]P#3ZX_5_$5WX
M<U'P_I3FW>.Y58997<R2-)\JJ I;?@G/SD-R.<9S7/6_Q5FO+2U: :9&TL%A
MY]Q)(?)M)9_-,@DYX"^4!C(.6&30!ZC17G7ASQ1J[^*I+2XDM;K3[[4Y8(I$
MD9FC*VL<OR9X\L\X'7YLU7U;XH3Z;K6K6D<5I-#:1RE6.5,;I+%&=XW9(_>$
M]%'R\$CD 'IM%>91?$+7#8RW@LM-N(H-+FU&00.Q+JLDB(JX+ 9VJQR3CD=>
MD%Q\3=9@M+7;I^FO-*\Y67[7$(I5C$9"AO-*HQ\P]68@+G:0> #U2BO,-2^(
M7B&UEOV@L-,,%N-19!(TF_;:,N[..,L&P/0C//2B[^)NIQ7&M-#IEIY%@DI5
M)9U63*!2K%=VXJVX]$&!@Y.: /3ZH:KK%EHEL+F_=XX"P4R"-F523@;B <#)
MZFN'B\9:V?$^GV-]/IEI E_<V=V<'9*4CCD7:6.0</@#N0?I75:WJ&F7&@6T
M[W5L]E=S6QC=G&R5&D0Y'J-O/TJ9MJ+:-L/",ZL8R3:;Z;FA<:K;6US:V[^:
MSW1Q$8XF=6X)^\!@< GGM5VN-L8[G2-=T_1&#S6(D>>PG)SB/RW!B8^JEA@]
MP?:J]G=W4FG:'/\ :9FU:YOO+O(O-;.W+>:I3.%"@<<#&!Z\YJKW7]:?YG;/
M +1PEI;?O?FMZ:1UWLSMH+B&YC+P2I(@9D+*<@,IP1]0014E>>6L(C\)ZC-9
M7=R+VPOYYWA2[DR42=B59=W\2Y^N<UIVT]]>ZW]BN9+G[/>[-0@9':,Q1#(,
M>01CI%D?[;4*M>UUN%3+U%R<9:1;WWTM^CO\C4NK;0]:\F;5=,A9XYVMX/M\
M W%L]%W=0VW(]<"KUGJD=WJ-]8B&6.6S*!R^W#!@2"N">..^*X>22">QM'GO
MIGBM_$4D7F-=O\D>YPN6W?3!)^G6I-7D@$OBZY@OI$EMK2"2!XKEE.X1G!X/
MS<XZYZ^]1[9[_P!;,W_LV#;CK?TV?-%?DST*HX;B&X\SR94D\MS&^TYVL.H/
MOS7'7U_,=6^TK<+=VPDME>.&Y:.6!CM(*K]V16W#/KR.U58;BSTVP\0@WEU'
M.-3,>V.Z.]59HP"=Q(4'."^,X/6J=;4PCES<;WU=K:=[;]>O]([^BO.[O477
M1=?0:B8C;ZA!Y!ANV.Q6\K(#9R5Y?@\=>.*L:C?3Z?+XDM]/O9BL45K*,S-*
MT2LQ$KKDDC"\^W6CVZ[?UK_D-97-Z<VNG3OR_P#R2^YG4MK4::E=V+6MSYMM
M;BYX56\Q"2/E )).5/! J_;S"XMHI@CQB1 ^R1=K+D9P1V-<3/)I\>OZJ+6^
M^0Z*K*ZW;$@AG.0V[(['@]_>G6<\=]J&@17&HSF.XT9GF5;QU#L/+Y.&Z\OS
MUX-"JN_]=RIX"+BFKK2^W]V[ZG<45YRFKN?#^AW%YJ9,4MM/"S/<F(&4$!':
M0'J!V)SR2,XKJ$N(K#P.UPVH2W2Q619[NWD\UG8+\SH6)R<Y(SP*J-52,:V7
MSI63=VW;;S:_0WJ*\^.H,D'B"$:@51=(CGBV7K.5DQ)\P?(^;A<XXS]:N66R
M?6K6Q74KG9?:.9)"+MBWF!DPZ\_*<%NF.GM25:_0N67.*;<MO+R3_4[*::.W
M@DFF=8XHU+N[' 4 9)-9E[=6,^JZ;87-F9S*3<VTS*K(KH,Y'.0P#<''?K7,
M.EQJ7@[4C>-=BXTZPGM)0)Y )9E!RQ&?FX"D$Y^^1VJ9O[/N-3\+PI>%XFM[
M@DK=L6/R)QNW9'T!I.JWMY?F5' 0C=2;=N:]EVBVGN=?<78MIK:,PSR>?)Y8
M:--P3@G+'L.,9]2*L5P-CJ+'3O#;G49&?^U9K9B;DG?&#, &Y^;HG)SV]:B-
MV(;:>[74YS+!KZPH6O&8"(R*"I!;!&TMU_I1[;K_ %L-Y8[\M]=MNO,U^AZ'
M4<MQ# T2RRHAE?RXPQQN;!.![X!_*N(ENTD\2O97.LB"9-1WG?>-"7@,8VQ*
MF1GDCGH<$Y)XK4\71P?:-!EN)7BB7455G$[1@ QR=P1@YQSU_.J]K=-KH8_4
M>6I"$G\2;V\KKU.GJ.>XAME5IY4C5G6-2QQEF. /J2<5Q-[>W']G:_<?:YDU
M*VN0EC&LK?=POE!5SA@Y)R><Y/IQJ>,D1M(L9;AVC6._M3(RRL@4>:N22".G
MKVZT>UT;70%@;5(1D_B=OP3_ %-B#5(Y]8NM-\F5);>-)2S;=KJQ8 C!)ZJ>
MH%7JX34_LDFL:XT=\ZB'1HGB>*[8'(,I!W!LMCCJ3UI#?W6HSI#<:C';)+I4
M,MM,\[1@R$-YC@J0"P.W@]/Q-2JUM&:RR_FM*+LK*^GDGI]_R.\HKG=>O+FT
M\.V4IN&"--;K>7* H5B)&]O5?Z U2E98=7L+:/4Y9]+N+J5I6$IVHWE@QQ;P
M>F=QQGK@5;J6=OZU.>G@W./-?OT_E5W\^R.OJ.>XAMD5IY4C5G5%+'&68X ^
MI)Q7"O=S,+-)+^X2V.NO;V\@N64RV^PY&<_, V0"<G@8-07;Q2:5>Q27DKP6
M6OPHK-=.?+B+Q'ELYP"6P2>.W2H=;31'1#++R2E+?R\[??Y'HM%<B(H+WQC-
M9QZI=B!;&WGC6*]8Y82-SR3G*JN?4'/4YJCI>K+/K.DO'?2FWNQ=+()KG,C<
MY7>HP$(Y  YP/K3]KJ9K+VTVGLK[>3?Z,[RBN"TW39]6\(R7MIJVH/J""98L
M7KE2RRL5!Y[@!?H:Z709AJ4!U@>>B7:J8XI)&PB@#^$G ).>1U&*<:G-;3<S
MKX14E)\U^5M/3K_P=?N-BBN)LKJXN;*6[_M"5=;@GN@UEOSO8;Q''L[*!L8$
M#W[YI]C<DR>'3;WLTQN[=SJ&Z=C\OEY+MS\A#X'&,9Q255/H:2R^4;^]M?IV
M3?W-+1]3LZB@N(;F,R02I(@9D+*<C<IP1]0017!:+=_NO"L[:E<22WCS0S[[
MMFWKL? ()QD$+@]?SI=/N;.PT%XOMEPL[ZO)"Z+=D8_?N0'+$[%(') R<]\T
ME7OK_73_ #-)Y8XW5VW>VWG)/_TD[F[NQ:+$3#/+YDJQ8A3=MW'[Q]%'<U8K
MSY-38:;&6U%@T'B!(EVW38\HR#Y2<_,N"<9[4FJ70AA\3W*:E<++97L)MQ]K
M?$>5C)&-V""2PP>.HH]OU&LL;:A?6_;S27YK\3T*J&K:HFD6J7$L$TL32I&Q
MBV_(68*"<D<9(Z9KF+FZNKO5M6B;4X[.:&:)K0M*P_=;5(*H#APQW ]<].PJ
MCJMW'/H^I2:C=E;^'5HT\EYRH2,3IL 3."NSYLXYZ]J)5M'8*&77G#G=T[77
MK;_/?H^FQWEY=BSA64PSS9=4VPIO8;B!G'H,Y)]*L5S_ (ON!;Z'%<I=/"PN
M[?:Z3%,@RJ"#@\C:3P>*Y[6[@+_PETL>I7"R6:12VP6[<"-]F>!NQ@GMT]J<
MZO*_Z\_\C+#X'V\$T[:VV\XK_P!N.YOKV'3K*:\N-XAA4NY1"Q"CJ<#FL;3F
M\-3:Z+FULH(M5N(C.LKVICDE0X!8,0,]LXYZ9JQXCGC/@[5)3(FQ[&7#;A@Y
M0XP?>L6&TAB\/0^(;J]DE:TTHI ;1 /*!0;BN2<OP.2<<=*<IM2LA4,-3G1Y
MIWNW9>MM.G??78[.BO/FU!DM_$4(U JB:3'/#LO6<K)B3+!\CDD+G'&?KS>=
M[>TBT@G4;N4Z@?,(EO"(25BP07Y('?:.K>PX2K)_U\BI9=*.C?X>2EW[?D=G
M17G4>KN-!T6>]U(F)H[F&3=<F+,@.$9I,]0!T)SSGDBKACCEN/#=B=<GF%S:
M3)-/;WSXF8*OS [NN[=C\O:DJR>R[?C8J66.+]Z7\W3^6]_R_$[FBN"N]3$&
MIIY-_./(U:&VD-Q<X;;M56&P<;#G.X]2<^AIEW-)'8^(9+>_NCJ-IJ.VRC^U
M.QR5C*IL)Y!)88(]?2AUUV".62=KRWMT[M+]4=E8ZI'?7E]:B&6*2SD6.3S-
MN&W*&!&">,$5<=TCC:21E5%!+,QP !W->>ZQ,D3^+[V.\>&ZMI('C,5P5VL(
MDZ@'!Y&.<UT7C/=-X8;RW/V=IH3.Z8/[GS%WGT(QU[8S3571^7_!_P A3P*]
MI32=E.R]':+?_I1M6=[#?P^=!YAB/W79"H<>HSU'O5BN7MM4_LW6M22XU%I]
M(@M8YFGE(/DR,Q&S<!SD '';/O6=XFN=':ZU&U;5+9=1N(XPCW4Z(MEQPR'[
MP)SNP,\XS@&AU;1N3' .=7D5[.SO9OMOMLGK_P %'<U#=W4-C9S7=P^R&%#(
M[>B@9-8WB"[GA\,1SVERS1LT ENHSR(2RAW!'3Y23D=.M<[XF<"S\1VT-Q(^
MG1Z<DG^O8A)R6&T'/.5VDKTZ''-.=7EV%A<#[9J[T;M^*7ZZ':0:DKV4]U=0
M2V44).XW.T?*!G=D$C&/Y&FR:K%'K%KIQAE+7,3RQRC;L(7&1USGYAVK,\2P
M1-X#U-(9)'C%E(R,)F8M\I/WLY(]B<5FRC3[G7?#L*7I>!K2Y.Y;MBQR(^-^
M[=V/?M2E-K3T_,JCAJ=1.>MO>^5HW77\#M*9+((HFD(8A1DA5+$_0#K7 :?J
MES-9:#'->AK20W4<DTT[ /(CXC5G!SG;DC)YQ77Z,6@T*'[3?+=>6&!N2>&4
M,<')ZX&!GOC-.%3GV,\1@GAU[SOK;\6OT_$6RN=-\0V=KJ$47GPQR>;;R2Q%
M2K %=R[AD<%AGW-:5<5X7UNTL/ .EJL\3W4@\F&$,"S2,Y"C&?7K[55L=0D&
MBPZI+JSAEL)3>10NTDS/MR3M;A&1@>P'..F*E5E97[&U3+9>TFHZ)2:5^N_^
M7WG?T5Y_'J,BR:I;)JR6Z/8VK1.URTH61G922W!&?E#%>F<^].;4KR+R8)5^
MRP_VB([Q_M;20\PY0+)U5"VW(XY..AH]N@_LN=VK_P!63_6VE]>UT=]5"_U>
MTTVXM8+CS1)=/Y<6R)G#-C.,@<< GGTJCH]Y#91QV=UJD5Q+<7$HM<,6RH^;
M8&/WMH.,Y]NU5?%5Q##JWAOS9HTQJ&X[F X\IQG\R*N4_=NC"EA;U_9RNU9M
M=+V3_5'3T5R.M:_'/K%C9VMU']D28I=R^85C#E"8T+J>^,X]<#VJA=RWD%NB
M+JD5^L$,SO#]J>%FC+G#1R?Q,@!7)_.I=9*]C2&73DHN3LWY>ORZ=;;H[VBN
M(:^F.KQS"1[BU>XMH_+%PT=Q:L0GRM']UU.<GOR?3B/3+K4;J"*Z^WQKJ<<T
MXFM6D9GD;YP(S'G"@?*0<=!GN:/;*]K#_LV2CS.7]-7_ .!?TZ:G=T5R'AB:
M:Z;3+HZHCN]LPNK?S6=WDP"2RGA"K CH.N/2DU:[GB\02R";[3;1SV\;PQ7+
M136[$J1A/NR*VX9[GD=N'[7W>8CZ@_:NE?5+];?UK^.AT6F:I'JB7)2&6%K>
M=K=UEVYW* 3T)&.:O5YW+/%;V^J7\5\\<\6OHHV7!5=K/&&!4'!!4MU';VJS
M>ZN!K(EAOI$\O6(X)/.N,$)M 91&./+YSD]2<^AJ%6LM3>>6N4KT]%^ME_F;
MQ\40+#)(UE=J(KY;&0'9E'8J 3\WW?G'3)]JW:\]NKJW%CJ^9XN/$<!/SCIN
MA_P/Y&NA\7S>3IMG(+N2W)O[==\<QCRID4,#@\C!/6G&H[-OI_P2:N#BYPA%
M6YG;\(O]3>\F(3F?RD\XJ$,FT;BH.<9],D\4EQ<0VL#37$J11+C<[G &3BN&
MN;V:SGUJSM;V;[+#?V@D8SL[P0N%\TAB20.O.>,D\5'XC):VU^WBGFDTV"*V
MD!\YB(Y2YW*#GIMVL1T&0:'6LGI_6O\ D.GEO-.*<M';IT?+^/O+0]!HJ&T,
M!M8_LTOFPX^5_-,F?^!$DG\ZFK<\MJSL%%%% @HHHH **** "BBB@ HHHH .
MM95E;:1J4UOK-M KR)$]O%(59=J;P6&TX_B0<XSQQ6HPW*5R1D8R.HKB;6_U
M&XTWP\S:C<![G4)[>9P%RZ#SL9XZC8M1*?*_Z\CJH8;VL&T[6?Z2?;R_KIVG
MDQ[F;RTW.,,=HRP]#5/3[ZSOVN$MXV5K6412*\6PJP4$=?9A^=<S#JM^ODV#
MW<FQ]9ELFNFQO$:J65<XZDX7/7\:KF\N=+GUA+:5F,VMP6[S2.,HC11_Q8..
MRYQW]:S=;J=4<M>L6]>GWI:_U<[KR8\@^6F0"!\HX![4"&(+M$2  8P%'^>P
MKDKV76+06\<FH>7OU2*)!%()'6%P,JY9>3G)!],=:JW-YJ5K9ZQ,NJ7+'3M2
MBBA#[2&1O*)5N.?OL*;K)="(9=*=K36OKU:7;NT=?:Z;:6=W>74$.V>]D62X
M<L278*%'4\   8''YFD$UC]M.G;4\Y(Q<>7Y?RA22-V<8SD'WKE]7NM0CF\4
M/%J=S$+"UCN+=%VX5MCL0<CD?*.*M75S=3ZM=6YNY5AET<7&Q<81]Q!(X]!3
M]KY?UJ)8%VNY;K](OMV9MV>H6>K;C"CR)& RR/"0KAAP4)&&!'<53M/#FAZ%
M<3ZE!;&)]K[G>620(K/O8*K$A 6^8A0.16#8W-QHFB>&+][NX?3I+6.&XBX(
M5FB'ED8&?O#;C/\ $*ZRUAG@T@)<S/+/Y9,C.0>2.1P!P.E$)N2UW)Q.%C2E
M>+]V]O/1M/IY?BAUE<V6HPB]LVCFCD&T2JOWA]>XJ<6\(14$,85<[1M&!]*Y
M;P]J*:9\.-,N#@R?956%.\DA!VJ/J:@M[O6Y-(M[^/4;5%N[$G=-/N!G8*49
M1MPH!)!'(''!Q25565][7+E@'[2:B[)2<5?K:_\ D=DT:.0616(Y!(SBJUKI
MMI9W=Y=00[9[V19+ARQ)=@H4=3P % P./SKEQJ.IO');11W,=\EQ&)+&XN%W
M.A1B1%*.#G;NYP?E(XJ33-3N-3U*SL#<7D4!M[B5S+A)6D6;84)']SVZ\4U5
M3T)EE\XIR;5E_E?_ (;H^CW.K-O 5*F&,J3DC:.308(6W;HD.\@ME1SCIFN+
MM=0U34SHL1U&: W+7D+RQ*O[T1[@DF".IP#Q6YK=S=6%II5O'<-FXNXK::YP
M-P4@Y/H"Q '_  *A54U>Q-3 RA-4W)7=^_1M=O)FR8HRY<HNXC:3CDCTJ*]N
M(;.RDN9T8Q0J7;:FX@#J0![5R.J:CJ%LNLVT%[,J65U9B&;@L!*RAT)(YP#G
MGGYA6_>6TMIX:U*.:[ENF\F=A)* " 02%X';I352][ \)R<KD]&UIUV3_)HT
M;66&XM8KF #RY8U=#C&5(R/T-/\ *C P(UQC'3MZ5PZZA?Z+8:/):3RW:SZ5
M)*UO)@A3'"&5EP 0,X7WR.];.A2:E+/:7$UU%):7-GO(,V]GD^4[U&T8&"<@
M<#BE&K=VMJ56P#A%S4ERZV^3?^1>EUC3EDU&.8,IL(UEN-T).%.2"./F^Z>E
M:$8ADC5T12K@$?+C(ZUR.IRS0:EXMGMYGAFATR"5'3&0RB8CK]*AUO6KR&QO
M)[6]E,]G903,H4*D;L2<L3]\L.-N,#'4$U/M;7O_ %O_ )&O]G^T<53=KVW\
MU'R[R[^6^^MX?TK0-,U6^@TJUEBNK=$CE\UY'"QDLRJF\D!<[CA<"M.*[L7U
M*;3%BVSPHLS*8L*5)(!!Z'D&N=NTD_M[Q/-%?2VDD%G;RJZ%< A9""V0<CCI
M5*YUB]@>[U=80M[_ ,(]!,4*\(Q=R3CT&2?PH=6V_G^HXY>I_ ]U&WJU%]MM
M7Z'>-&C-N9%+8QDCG%(88FQNC0X.X94<'U^M9&E#4$U!_/N8I+.2W5XU,_F/
MO!.Y@=H^4@K[ ],9K&O=6OQI>O:FMP\=QI]X88+<8VE5VX4CN7W=>OS#&*MU
M$E=HYH8.4Y\D6NGXZ+\=SL6C1R"R*Q P"1F@QQG.47G/;UZUSED+Z[\3:G&=
M3N(X+2>%UAPI4JT>60\9QD^M.U@7L_B6SL+;4KBTCN;.=CY84X92@5AD?[1H
M]II>W];"^J?O%#F6U^NFG-V['0B-!(9 BAR,%L<D?6D\J/+GRTR_WCC[WUKD
M[.\UB^N)YTN(HQ:ZF;>02S;5\I6"[=FW[S A@<]2.W%00ZCJ.V9;J>YCEELY
MYK>XAD5X)P,,KKW0@8&",$$]32]LNQK_ &?.[7,M/Z_K_+4[0QHSJ[(I9?ND
MCD?2F^1#M9?*3:W4;1@]ZXMM6U/3[;2+N*YEO7O=-EGEAD (WI"'5EP!CYL*
M?7<.]7;>[NUNM C6^EG74[:1KAB1P1&&$B\?+R0,=/F%"JI]/Z_IA++YQ5^9
M=?PO?\GZG4A$!R%7.<YQWK/UJPTR[TFZ74X=UJ%$LI0LK#80P8%,-D%01CG@
M5S6BZCJ!3PQ<W&HS3?V@DJW"2!=IVQLP(  P<K^M)#J.I"SNDNY[J*[.G37$
M4\4BR03[=I\Q#_#U'RD=&I>V35[%/+91GRN2?_#M/IY/H^_<W=$;1[*0:5IL
M4D9:(W>9 Y,BNV2Y=\EB6)SDYJV;JP34HM*,.)FC:>-?*^0A2 2#C&06'YUS
MELDNH^(+-GO)H99-#1VEB(#$EP2>0>YS56SU:]N)-'U2:,2W@T>\D "X$I5H
M]IQ_M8!_&E[5_P!?+_,T_L^+>CZ?C9M=-M#NS&ASE%YSV]>M5EGLY-2FM %-
MTD2O(#&?N$D#YL8/0\9K%T";4[AM/NYKJ&2UNK3?(K3;F>0[2&0;1@8+ @''
M2H]2N[R+5M<@CO)DCCTI;F(#'[M\R#(X_P!D=<U7M-$SG6#?.Z;:NE^MNW]?
M@=.8XR<E%/.[D=_6@QQE0I12HZ#' KE](NKU=9TJ.:^FN([W2S<2+)MP)%,>
M"N ,??-1^*M4N;8ZE]BO)5EL]/\ M'EH JQMEL,S'[V=N-N"..V:'57+S!'
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M#U0W$C7%_>B&>W.-H5BP*@=BF,YZ_*<YI>TM)I_UM_F4L'STH3B]7_G*R_\
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M3J>.U/VD7I8S6"JQM+FZ7Z_=:W?I^ESJ+:W6V@$0)?DLS-U9B<DGZDT\0Q*
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M@%&("D ^F%%<Z^LZE9RSS3+-*Q6ZDM)(G5X+G:K,J%?O(P Q[X/)-/2YUO\
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M$;39+-@D*B[>"I!&,] <Y(I0JW2NM?\ AO\ ,VQ& =-S<9+E5_SDOO\ =?\
M6V]<ZI865Q':3S*DLBDI%M)+ =< #G%2VDME>6T<]HT,L)&$>/!'T&/QK!UX
M3-XQ\."WDCCE*7>&D0N/N)V!'\ZQ]*NWM+6R@M9)(BFO26ETX(*7)(9F8<<
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MT)ZXKGA?ZS<ZLT$+.@34&AD5(08TMPF0V\C[Q.WC/?&.]&GZOK&IO'=00/\
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M44NHU5H$TZ J\%K' %V. ><@X(YSC Y[UIT4^5$JO4[A426T$8B"01J(1MB
M4#8,8P/3BI:*HS3:V*+Z-IKN\G]GVGFN_F%S I)?LQXY/O2Z=936P>6\G2XO
M)%59)DC\L$+G  R<=2>O5C]*NT4N57N6ZTW'E;*\MC:3W,5S-:P23Q?ZN5XP
M63Z'J*1-/LX[DW*6D"SDDF01@-D]3GWJS119"]I.UKD%K8VED'%I:PP!SN81
M1A=Q]3CK4,VD:;<RRRSZ?:RR2@"1WA4EP.F21SC J[11RK8%4FGS)NY2;1],
M?SM^G6C>=CS<P*?,QTW<<_C3+;3Y8[TS3S1/%%D6L4<.SR5( P>3D\8!&.":
MT**7*BO;5+-7(+JSM;Z'R;NVAN(LYV2H'7/T-1R:5ITWD^;86K^0,1;H5/E_
M[O''X5;HIV3)52<=$V4GT?3))7E?3K1I)'#NQA4EF'0DXZ^]":/ID;AH].M%
M8$D%8%!&<@]N^3^=7:*.5=A^VJ6MS/[R@FB:3&H5-,LU 4H (%&%/4=.AJ4Z
M;8FR^Q&RM_LG_/#RAL]?NXQ5JBCE78'5J/>3^\III.G1I*B6%JJS "0+"H#@
M= >.?QIXTZR%K):BT@^SRY\R+RQM?/7([U9HHY4)U9O=LHC1M+564:;9@,H5
MAY"\@'(!X]>:M06\-M'Y<$21)G.U% &:DHH22V"52<M)-LJ0:5IUK*);>QMH
MG'1HXE4CMQ@4U]'TR29YI-.M'DD8.[M"I+,.A)QUJ[11RKL/VM2]^9W]2H-+
ML!<?:!96_G;M_F>6-V[USZ\]:='I]E%<&XCM($F+%C(L8#$GJ<^IJS119"=2
M;ZLH'1-**.ATRS*O)YK#R%PS\_,>.O)Y]Z7^QM+./^);:<2>:/W"\/\ WNG7
MWJ]12Y8]A^VJ?S/[RG_96G>7/']@M=EP<S+Y*XD/JW'/XT/I6G26J6KV%LUN
MAW+$8E*J?4#'6KE%/E78/:U/YG]Y$;: VIMO)C\@IL,6T;=N,8QZ8J*+3+"!
M9%BLK=%D78X6( ,OH?;VJU119$J<EHF5DTZQCLS9I9VZVIZPK& G_?.,4?V=
M9&T>T-G ;:3)>(QC:WU'0U9HHLA^TGW??YF/?^'K2XM?+M(K>T8NA<K -LJJ
M?N.!C<I],U%:>%M/AN+F6>TL66=8U-O';*L0V%B&VG.6^8\^@%;M%3[.-[V-
M5BZRCR*3M_PW^2*G]EZ?OF?[#;;ITV2GRES(OHW'(]C4UO:V]K;K;V\$<,*C
M CC0*H_ 5+1561DZDFK-E2/2]/ACDCCL;9$D7:ZK$H#+Z$8Y'M21Z5IT3PO'
M86J/ -L3+"H,8]%XX_"KE%'*NP_:S_F?WE--)TV.*2)+"U6.5M\BK$H#-G.3
MQR<]ZL06\-M$(H(DBC!)"HH YZ]*DHH22V%*I.6[N47T72I3,9--LW,S;Y2T
M"G>WJ>.34BZ;8I+)*ME;K)*FR1A$N77T)QR/:K5%'*NP_:U'IS/[RO:6-I81
MF.SM8;="<E8D"@_E21:=9074EU#9V\=Q)]^5(@';ZD#)JS119"]I-W=]]RNM
MC:+>->+:PBY88:81C>1Z%NM,72]/2>6=+&V667(D<1*&?/7)QSFK=%%D'M)]
MV4DT?3(O)\O3K1/(),6V%1Y9/4KQQ^%(-%TH(J#3;,*K^8H\A<!_[PXZ^]7J
M*.5=A^VJ?S/[RM#I]E;RF6"T@BD.<LD8!YZ\CUJ--'TR))433K14E_UBB%0'
MYSR,<\\U=HHY5V%[6?\ ,R*WMH+5"EO#'$I.2$4 $^O%1KI]FMT;I;2 3DD^
M8(QNR1@G/KBK-%%D+GEJ[[E>VL;2S,AM;6& R'<YBC"[CZG'4TV;3;&YN!<3
MV=O+.J%!(\09@IZC)'3D\>]6J*++8?M)WYKZE./2-,B,)CTZT0P',)6%1Y9_
MV>./PI\.G6-O<R7,-G;QSR9+R)& S9ZY(JS11RKL#JS>\F5+G2]/O)UGN;&V
MGE485Y8E9@/8D4KZ;8R68LWL[=K9<$0F,;!@Y&!C'6K5%'*@]I/17>A1.C:6
MT;1G3;,H[!F4P+@D="1CJ*>-+T\&<BQM@;@8F_=+^\'^UQS^-6Z*.5=A^UJ?
MS/[R@NB:2JLHTRS"NFQAY"_,OH>.1[4\:1IH<.-/M PC\H'R5R$_N].GM5RB
MCE78/;5/YG]Y@W/AFWDNXWBALOLJ0^6MG/:AXHSDDNJ@@ G.#QS@=*O:=I$&
MGZ,FF$": *RLK+\I#$DC'9>2 .PXK0HI*$4[I%SQ-6<5"4M%_7ZE!]-2"VE&
MEI;65PX $H@! P>A QD=>_>I[.U6TM_+!#,S,[OC&YF.2<?4U8HIJ*1#JRDK
M-_UZE*;2-,N9999]/M99)0!([PJ2X'3)(YQ@?E0VCZ8_G;].M&\['FY@4^9C
MINXY_&KM%'*NP*M47VG]YGVVGRQWIFGFB>*+(M8DAV>2I &#R<GC (QP347B
M#29-:L8[5)8D59XYF\V/>&",&VXR.#C!K5HI.*:L5&O4C-5$]5L4_P"R[!K-
MK62RMFA<AGC\H;6;UQZ\4TZ+I3*ZMIEF5<JS P+@E1@$\=ATJ]13Y5V)5:HM
MI/[RK<Z=:77E-);6[R09\AY(@WE'U&>G0=/2F:?9RVR-)=3)/>2A1+*D>P'
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M-P/F'-:E%')&UK#]O54N92=]%]VWY')2>$I9IYYG$"WDER91J$<SK(J[L@;
M,9"@+UYQD^E;R:-8)=O=)!MDD?S& =@A?^]LSMW>^,U?HI*G%="ZF,K5%9R_
MK_+3;9=$9:^'M,6*.(0.$CG-P@\Y^)"<[OO=<Y/XGUISZ#ILDMQ(;<AKAQ)+
MME< N,8; . WRCD<\5I44^2/8CZQ6O?G?WL@MK2"T5UA0C>V]V9BS,V ,DG)
M)P .>P%01:-803I-';A61F=%W,51FSDJN<*3D\@=SZU>HI\J(]K-7U>I5L=.
MM=-21+6-D61S(X,C-EB<D\D\D]:CET>PGO6O'@_?N KE791(!T#@'#8]P:O4
M4<JM:P_:U.9RYG=^91_L>P%SY_V<;_-\[;N;9YG]_;G;N]\9J)_#VF217$3V
M[E+B432KYSX=QT8\]>!^0]!6G12Y8]AJO56JD_O90?1;"2ZFN3$XFGC$<K+*
MZ[U P,@'!..,]::VAZ<UE;6A@;R;5@T $KAHR!@;6SD<''7I6C11RQ[![>KI
M[ST\S+_X1[2O(, M=L?G&=0LC I(>K*0<J>3TQU-2OHNGO);2& B2V+&)UD9
M6&[!;)!RV<#.<YJ_11R1[#^L5?YG][**:/81W G6W 99#*J[FV*YSE@N=H)R
M>0,\GUIJ:)I\=O<P" F*Y?S)5:1F#-G.>3P<^E:%%'+'L+V]7^9_>9[Z)ITB
M!)+?S/WJ3;I'9F+I]TEB<G%:%%%-)+8B4Y2^)W"BBBF2%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=474_+O(3-):B>U8HRE?)P^XX&2&P,C R.G)JI91^(-1DMGOK:[\N.[$JK.
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M8Q@#Y0SQ,,<$@@$B@#T"BN)5?%<&KO ;N27R8@(2T&8KC%OR68#"DS9/)!P
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M22:=&"CSI&55!.T   +T Y)R3G.2;PUI\\MS(_F[KE9DDP_:545\?A&N/QH
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MK-9M)+(N[RY=FX< #.$7''KUS6A/IUM<WL=U*I9T@EMP,_*4D*%@1_VS7]:
M,R+QAHT\<;133,9)$CC06[[W+*SJ0N,X*HQS_LD=>*=JGB>SL=+O;F%O-F@B
MN72,@@,T ^<9QQS@9_*H?^$-L/[&;2O/N/LC8!7;$"4 P%SLS_P+[V>=V:?/
MX0T^YENVDENC'<I.AA\P;$\X 2%>,Y.,\DX/3&: +EEK<-\VIJD%RO\ 9\S1
M2;HF^<A0<KQ\W7M[>HK+TKQG9W6E6]S?+);S262WTB+!(RQ1-NVY;;U.T@=V
MQP.16W:Z;%:7-[-')*1>2"5XV(*JVT*2O&>0!G)/3C%4E\+Z:MC)9XE,4EE#
M8GY^1'%NV$'LPWDY^E $4WC#2+>%I)7N5*,ZR1_99"\915=MRA<@!65L^A&*
MLQ^(+2YTN_OK42.+)6,D<D;1-D(' PPS@J5(..]0#PK8LLQFEN9YIQ*)II'&
MZ3S$6,DX  ^5% P!TJTFD62P7L2LVS4 %D^?K^["?+_P%10!0L?&&GZA+,MO
M^_2&UAN':W)E(,C,-FU1GC;U]^V*M1>)=-GDLTB:X?[9"T\)6VD(95&6[<$>
MAYR0.I%,O?"]A?(5D,JDQ0Q @@X$3ETX8$'DG.00?2J\?@_3[>,0I<W:P&S:
MQ,7F+@QMNS@[=P.6SE2,[5]!0!9B\4:9-)#$C7!FEF: 1?9I-RNH4G<,?* &
M4Y/&#5.#QII]Q=SA%F^RI!!+%+Y$FZ<RNZJ$7;E@=H((R.?:K>F>%[#2IDF@
M,K2+(\F6V@%F1$/RJ !PB\ "JT/@S3[>+9'<WN42&.!S(";=8F)C"<8XW$?,
M#D<'- %R/Q-I4D+2K<,%5=S!HF!7]X8L$$9!#@J1U&*L6NKVU_#=2V@EE%N[
MQMB,C<R$A@I. >5(K-D\':<Z1KYUVN,^:5D ,Y,OFDOQ_?);C'4CIQ5ZST:V
MLKN^G2:5I[['F,2JD!<XQM Z;CR<GIDG H IZ/XH@U&P@N+CR(9)V95BAE:4
MJ53>ROE%*.!G*D=O>F6GC"PGU"6W?S$B+QB";RGV.'A649;&%)!/!/;W%.;P
MC:2;I'O+YKIY?->Z\Q1(W[OR]O"@8V<< 'OG/-+#X3T^"ZC>.XN@(O+?R?-&
MS<D?EHY&,Y"CUP3R0<#  ^#Q38W-SIT4$-W(E_%)+%*+=PNU=O)XZ'<,&@^+
M-*6+=FZ+^>;;R1:2&3S/+\S&S;G[G.>GXTRV\*6$"QM%/<;@\K,ZLJ^9Y@ <
M$*H !VJ?E .1G.2<KI?A'3=)\HP&9FBG\]2Q4?-Y1AZ* ,;#Z=>: )O^$HTD
MI)*MP[01P"XDG6%S&B%-XRP& 2N#CKR/492W\4:7=3000R3-/-(T8B\A]RE0
MI;<,< "1#D]F!J"/P?IL5G+9+)="RFMEMYK?S!MD"QB(,>,[M@4<$#@'&14A
M\+6CP6L,MQ.Z6\XN -D2[G!4J3M08P5'*X/4$G- %J[U_3;&^6SN;GRYWDBB
M52IY:7<$ ..Y1ORK,M_%6F:CJ8LY(F>"00O;3- Y1S(I9<DKA2<<9Z_B*M:S
MX6TW7;@7%V)A*(&A5HI-I&3D,/\ :4YVGMN/K4P\.Z>CJR(Z!6A955N!Y0P@
M'M0!1;Q=:G1GNX4::X73_MI6))&B7,9=09"HQD*<9 /3@9 .A9:]87MA<W8D
M>*.U&;CSXFC,?R!\D, <;2#FJ<?A&PAMVMH9[N.V>T6SEA60;9$5#&"W&=P4
M]B.@R#@5?.BV30ZA"Z,\6H+LN$9N&7RQ'CV^44 4?^$QT40><]Q)&OF>5AX'
M5M^P.%P1G<5.0.IZ#GBIH?$5H]V+1BQN'DF5$A1W^6-MK$_*,<D#TYX)ZU7;
MP?I\MC':337,B12>;&<HA23&%?Y%'S+U!.>3GGC$[^&K)YX)#)-B&Z:["97!
MD+;LYQD<^A&1P<CB@"M!XUTF33[*[F,]N+J/S%22%LHN0-S8'"Y(YZ=?0XGM
M_$EO>^(H]+M4D=#%<.\S1LJ[HI(T*J2,-R[ X/!7WJ%/".G*;1HYY\V@:*-C
MY;_N]P/EG*G@$<'[PYYJS9Z!9:=JGVY+B<L!,(XI)!LC$LBO)M&,\N >2<9P
M..* &R^*](@:Y$D\JK;I*[2&!]C>4<2!6QABIX(&3U]#3I_$EE%H.HZLB7#Q
MV".9H3"R2 JNXC:P!'!!^AS4,GA'3IOM*R27+0S"<+"7&V(S'=(5XSDG)Y)Q
MDXP#5Z31K.:UU2VD5S%J98W W==T:QG'I\JB@"A#XIM6UI]/FBGASY0B=H7
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MXST6*U%R\TZQ,9,,;:096/&]P,<JN0"W2M&ZU:UL[JWMG,KS7 +(D,32':"
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M4'"J^Y<].!SS0!3>WUA/#WA^TLY;FT<0*ERT4:,Z;;=L [U('SA1T]JJ6_\
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M"I1 8)3%L?:/E+%!D'C..,D5-;OK]Y-!!#?:HEE)=JK74]I''.$^SR%QM:,
M+Y@C .WJ2 <8K3A\4HVE:UJDUI,EKILDRX6-S)((\[C@J.X/0D>I'-/A\564
MFLMI\B31;EA,3O!( QD#85LKA#\N &(S0!E:?K.KVDL%UK(NS#_9D<MPBVQ1
M8IMBEE^Y\[,Q( 5L@\;>]7/%E[K%M)9KI$5VS'+,T2!D.&3Y6'EL>06[H.#S
MG&-+3=>L]4,$4;%IY($N"L<;LBJV2N7*@#.#@'!XZ4JZ[:K%J$UP&ABLKD6S
M'!<NQ"8P ,DDN  ,DF@"IH]UJ37>L)=BYF2*0M;R-%Y:L"SX10R+RH"C=EE.
M001R!AZ9<>)]06&*:;4+2*2] :9H4\Q(OLS,1EHE&/-"C.SJ< XQ73#Q'IC1
MVT@EF\NXD\I'^S2;0^_R]K';A&W_ "X;!SQ33XGTH6BW0FF:)Y#'&5M96,A
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M8&03GGCO5&WD\3#[1?[=0:]>ULX[EI;8+Y3>:YF6(",[E4-P0'X.02:])HH
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MPVVN"=?[5FN)4EM$D831(@BEW,"HVJ/X=O!ST]ZZ6B@ HHHH **** "BBB@
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M 06MK]E5E661TPH5&"@( H&%  P.,_4^G%3T44 %%%% !1110 4444 %%%%
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M02#S9(OL^&8[QE6WEO[X*@U9U+P#JEI%JUU80V/F-=W%_&;7<DTQ>TEB"8P
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M,+^6"UFN[)H ^EQ7&)RJB:5W11M\LNV"6P!MR20,5VI 8$$ @\$&JLFE:=-
M(9;"V>(1B((T2D! 00N,= 0#CV% &)9^*Y;PV#+8Q+'.D[7!>=E:W$3,K,04
M'R[E !)4_-]W@XBL_&$]\T4,.F(;B2]%KAIG1,>1YV_+1AL;>,;>3WQS6VFA
M:/')%(FE6*R0J4C9;= 44DD@'' RS'\3ZT0:;I&FF&.WLK*U+2DQ+'$B9DV$
M$K@?>V!AQS@'M0!S0\8WAODG-H@LYH!]FB$P)D=[A(4+G;\G+<@;L ]R,5;E
M\9?9[:[:XL0LUI;7D\J)-N4M;E 55MHR&\P<X&.F*U4TK0C=W=NFGV'VB6,/
M<H($RZ.QY;CD%D;KU(J230-&FMH;:72;%X(=WE1M;H53=UP,8&>_K0 RPU=[
MS5;ZQEMA;O;$; S-OD3)&_!4#:<<$,WO@\5CZ1X@O(KF+3]7#G4I)TCECVJJ
M1ATE97C9<[D/E,!GYAW]*Z.#3[.UN)KBWM((IISF62.,*TAY^\1UZG\S59?#
MVBI:/:KI%@MO(P=XA;($9AT)&,$B@#G;;QA=37\=P+56TZ>VL'*^< \+7$LD
M8(&WY^=F<D8 XSTJU'XGU"YN]-ABL+>%YM0:UN89IG$D2B%Y <; -QV9XRI[
M$YR-6ZT[0M/1-1N-/LHA91@1S?9UW0HO0+@9 &3@#UJ:/1-*BC6./3+-$683
MJJP* ) ,!QQ]X#C/6@#!A\:27#R10:?'+*9(%@83LL<BS%PK[FC''[LG*AA@
MC!-3VGBQ[P%TL L<%HMU=EI_FC!,B[4&WY^8FZE>WT%RQC\.I>FVL;2SCN&9
MW*QVP4EH6 8YQU4R#_OHX[U/;66C7KQWD%E:.]L\D,<OD -&RNRN%)&1\P;I
M[T 8T?C&Y;3%OI=&DAA+INEE,BQ)$R%MY8QYP,8)V[1D'=CFKVO>(WT9Y%CL
MQ<""TDO9RTWE[8D(SMX.YN3@<#CDC-7!X>T58! -(L!$'\P(+=-H;&,XQUQQ
M5B[TRPOWB>\LK>X:$YB::)7*'CID<=!^0H RK+Q')=:U]B:Q$<#2S0QS>=EF
M:+&<IMX!!ZY/3IWK/N-?ULZ@\$-M:8CU@6<:B8CS8_LYD^<E#MY*G(SZ=LGJ
M5L[5)!(MO"L@9G#! "&;[QSZGOZTP:=8BZ>Z%G;BX=U=I?*&]F52H).,Y"D@
M'T.* .>LO&;7]Y90V^E7#K-#!+,R[F\GS20.0A4A=IR2R\=,]*+_ %75QXR_
ML^Q#/#'':R/'Y(*;'DD$C,_\)"H"H[D=#VW?['TP303#3K3S;=0L+^2N8P.@
M4XX')Z40W5A)J+I%L^UO&=Q\LAF2-RO)QR Q./J<=: .</C6Z%G8S+HDDDM[
M!)=100R/(QB38/X8S\Y+C .%]6&<4Z]\97=K+="/1TDA@%R0YN]I808+\;#C
M(/'/7K@<UMI9:-JEK&HLK2>"UD>*-7@!6)D)5@H(XP01QZ4MPNDQWL-E-;0M
M<7:S%4%ONW*<>86(& #E02< D@<T 9A\320WTD9MV>W^W"W:>1BJ0@QQ,!\J
M'DF0XW8&006&0*@@\8W-U9W-U;Z)<R0I@Q/MDPZ^9L);]WU ^;";^,UT$FD:
M;-*DLNGVKR))YJNT*DJ^ -P..N%7G_9'H*C;0='83AM*LB+AMTV;=?WASG+<
M<G//UH JWVNR0V^EM8V\%W)J)Q%FXV1X\II,[]I)&%XX[BLR+Q=+J%H+JVLV
MBM?]"/FM*-Y,[1$+MVD8"R')S].N1MZAH.FZHEG'>6D4L%HY>.!D4Q_<*8*D
M8P QQ^%26T>FW<<WD00.BS!)!Y0 \R,@#/')4J,'M@8H P)/&DD<1E_LP-'+
M')):[;CYI DR1'>-OR',BD<MWS@UJ:CJ6I6EUH4*6MH6O;DPW(:9L1@0NYV'
M;\WW.I SC&!G(N)HVEQR3R)IUHKSG=,PA4&0YW98XYYYY[\U/<6EM=B,7-O%
M,(I!+'YB!MCCHPST(]: ,?1/$;:O<1(]F(([FU^UVSK+O+1[@/G&!L;E>,GO
MSQ50>*)[;0[*XDMC<W=Y>S6L:(K@?(TIR=BLWW8CT4\^G)&_::986$LTMG96
M]O),=TK11*A<Y)R2!SR3^9JO_P (]HNV9?[(L-L[B24"V3]XP)(9N.3DDY/J
M: ,P^*;K<ZG1IXY#9"YA@E+++*VU2R !"/EW8(!+ C[IR,L@\8&YU&VM+;3W
MN Z0M-)!YC+'YC,O'[L#"E26W%".>"016M)I.B"8"33[ 2SIY(#0IET 'RCC
MD *./11Z4DNG:+:26DLEC91/$5AMF,*@H<_*JG''/0"@#,T;7[SQ+!'/;6DU
ME!^YN$ED1L31-G*?,@ ; &=N1\PPQJ:#Q/N\-WNK7-H89+0-YMH'.]&"AMC;
ME7#?,/48(()!S6M:Z986+3-:65O 9CF4Q1*N\\]<#GJ?S-)!IFGVMG)9V]C;
M16TF=\*1*J-D8.0!@Y'% &+'XFNY+\Z8--A_M%)G21/M1\H*L<<A(?9DG$J#
M!4<Y[#)EB\22R()S9(MK)??8HG$^7)$IB9F7;A1E>!DY'7!XJ^= T<VL=J=*
ML3;QOYB1?9TVJW]X#& ?>G/H>D2&Y+Z79-]J(:?= I\T@Y!;CG!YY[T 83>-
M6^_'IP:!$629S<8*J9WA^4;?F.4SC(ZXSGJK^,R)[R&.P69HI(4@9)F"2^9/
MY'+,@ PQR=NX=>:OVFB:!=7BZA;V5LYM_P#1HQY*A86BD?.P8^4[RW(]!3KB
M/P[I-PYFM+.":=3<.5MAE]DB'<2!R0[H?7)S0!6L?$MSJ-S%:P:=$)U\S[2'
MN<+'LF:$[#L^?YD8\A>,=SBK6@>($UY)7CMVB6)8UDW-DK,5R\1]T^7)]3[5
M=?2--DEAE?3[5I(7:2)S"I*.S;F8''!+<D]SS4%MH%A;&,K&6,=W+>@L?^6L
MF[<QQUX=@/;'I0!!-XA2'4VLC;DLMW%:[M_4O&7SC';&,5CV_BZ[U&"Q86@L
MFG-C< +*)=T$[,,'Y1AOD.<9ZCGTZ>32M/EOTOY+&V>\0 +<-$ID4#.,-C(Z
MG\Z5--L8Q&$LK=1&J(F(E&U4SL XX"Y./3)Q0!S5MXUN+O2&U*/1)Q;E(I8Y
M'\P)Y;[CN8^7GY0 3M#@;ASC)&SI^M&]U:ZLG@6(1J'A8N29T('SK\H4KDXR
M&/N!FGR:%H:6\RR:7IZP.?,E#0(%)&?F;C'=N?<^M6+6QL(9GO+2UMDEG +S
M11J#(.V2.HH R+7Q29IXH+BS^SS/<O T32'?$%B:0%@5'4(>F1SD,:S[GQ;>
M7OAC5=0T^T2 6VFF?S7F!=)6MQ,H"%<, &7DD<YXXK8.G^'C='1_[,LV<@7;
M0BT!0$Y4.QV[03A@,\G!QTI+V#PW97"+=V5BDK6WE+FV!/DY6/9P/NYD5<>C
M>F: &CQ#+%I&MW=U9+'/I._S88YMZOMA648;:.JN!TX.>O6H/^$GNUUB'37T
MAVFVQ-<&%GD$0D9E4Y$>TX"Y;)7'.-V*WFM+9TN$:WB9+G/GJ4!$N5"G=_>^
M4 <]@!4 L]-OY8-0-I;RS(H\F=X1O49R,$C(YH YRU\:W4Y@=]'2."5;60N+
MO+*D\IB0XV<D,,D9QCOGBGP^-);B"2:/2)O+:5(K:1RZ)(S3"(!F*87D@_+O
MXSWXKHUTVQ50JV5N%4(H B7 "-N0=.BMR/0\BHCH>DD7(.F69%R<SCR%_>G.
M?FXYYYY[\T <UI_BF\6W:2]$9F#70$9?Y,K>&%$!5"Q.-JC R?3)ILGC&^FL
M[FZBLXX;:/2[BZ<^8?-22)F0@!DP1E?X@#SR.U=1_8FE?91;#3+,6X4J(A N
MT MN(QC&-WS?7FC^Q-*\N./^S+/9&CQHOD+A4?[Z@8X#=QWH Q+SQ@;-KF1K
M -:1O<0I()OG>2&-I&!3;\JD(P!R>W'-7;77Y9+#59[FR$,VG EHDFWAQY2R
M##;1@X;!XX([U9:RT5M6E1[*T-_<0,96, +21\*=S8Y'08/M5W[);;9E^SQ8
MGXE&P?O.-OS>O  Y[4 <S!XPN?M2I>:4L,/FB)I([GS""T!F7"[1GY1@\\'&
M,CFFQ^-)Y-(^W'26B9]A@24R@3!D9\+^Z+%@%.0%*XYW8KHWMM/@9)'AMHV,
MBE&95!WXV+@^N/E'?'%58=$T&:T:&+2;$V_FDF/[*H7>I*DX(ZCD9]#Z&@#,
M;QB%#R/8F.$VT=S!YDA#3*WEY*_+MPOF8/S9!'3!!J?_ (2=Y-56R@L0X$EP
M)9&FQL2$QAF "G)/F<#VZU9%KX>\N>86=C\UOLF'V==S0_=P5QDK\F,8Q\OM
M5ZUTRPL=GV2QMK?8&"^5$J[0V-V,#OM7/K@>E &7H'B&77;&2Z;3YK2/RDFB
M=@V'5P2,%E7YACG&1R,$TS0O$,FHS6EO/;F+SK&.YCEE8[I\HA;: NT@;L'Y
ML@C[N"#6O::98:>LBV5E;VRR'+B&)4#?7 YJ.VL-*M[YGM;2SCNTB5&,4:AU
MCZ*#CD+\F!V^7VH Q)_%UQ"FY=+W^;?2V5L!*[&0Q^9O9@D;%1^[XP&Z\X S
M3HO%DLM]!#_9;1PO-';2&:7;+'*\'G;2FWH%(!.<YSQQFM.:/1+L16$L%G.D
MTLKI$8E=3(K'S#TQN#$Y[YS[TL_A[2Y[ZTO?L4,=U:LK1RQQJK8"E0N<9VX8
M\4 9,/BP7O\ 9XB@>+[1%97!PX; N/,^4Y';R^O?/:H%\:W36>G3#1)));ZV
M-XD,+O*PA&S^[&1O._H<+QRPS716VBZ59EC:Z99P%F5SY<"KEAG!X'49./3)
MI9='TR>*WBFTZTDCMAB!'A4B(<<*,<=!T]* ,6T\07E_XHMK9(4BT]A>1@^8
M&>1X9$C)*[?E&=V,$Y!YQTI9O%DB:E>64&G&Z:*&66(P.Y\PQNB.I^3&07'"
M%SP1C. =N+2M.@OI+Z*PM8[N3.^=(5$C9QG+8R>@_*HVT/2'EGE?2[)I)P1,
MY@7,@)!.XXYY /U H J7&OB/0[74($@FDN2%CB$DA#,020NV,N2 IXV9X.<8
M-,;Q$\NE:'>65D)7U=D$4<LOEB,-"TN6(!Z!".!5\:?I5]IEO +2SN+ *KP(
M(U:+&/E*CIC!XQZTCR:;;7>GZ<8464*SVD20$B-47:2,#" !]N>/O8[XH Q(
M?%]S<Q7DUMHES+%$6$3A9,/ME\ML_N_JV$WG"GC/%68/%4,\D*I$CB6:")9(
MY=RMYL?F!E.!D#Z#/M5V/2]#NVO-FGV,K/)LNOW"G<X(;#<<G.#SWYJ8:-I8
MN8;D:;9B>!%2*7R%W1JO0*<9 &3@#I0!A^$M<U35?(BO([=HO[)L[HSJY$CR
M2JV[*[=H&5/0\>^>*FJ>,+XZ3>O96<<,CVMQ+93-/DXBD6-BZ["%/S@@?,#C
M!Q760Z=8V\R306=O%+'"+='2(*5B'1 0.%'ITJ-=&TM)+B1=.M%>YSY["%<R
MY.3NXYYYYH JR7=W:ZGHMD[AO/203DX)9E0'.0!WSV'T%9D7B^YN4O)+;1+F
M6*$N(W"R8?9*(VS^[^K83><*>,\'<N['3-6D\B]LK:[:W(8+<0!PA(ZC<.OT
MJ&[TO1+>WO;JYTZR$;J9;IS;J=X'S$MQD\C/U% &5<>,TM8I)Y+13 +);J%X
MY&;[22%XC^3! +8)R&[[<5'/XSNH%@C.A73W<BS2&%4E^9(R@)3]WN)/F+C<
MJC(.2.,[L>CZ0P\V/3;/]Y"(2P@4;HL ;.GW< #'3 %538^'7E333I]DQ@D&
MV'[,"(V92V1Q@9"GGVH ;-J5WI>H6MK=JLT5W/(!=,2J1 L!''PI&X@X&XKG
M'4GBG7?B!+349;,P%BDUM%NWXSYS%0<8[8_&M*;3[.YN8;F>T@EGAYBE>,%D
M^A/(IDVE:?<7L=[/8VTMU& $G>)6=<'(PQ&1@DG\: .;?QM,MO$JZ1(U^[R*
M;-3(7C"*K$-B,D,=ZXP"ISG=CFK^L:O<075FD)>%6LKF]D!4;B(U0!#D'!S*
M#_P#TS3EM/##R'2186!VW!'V?[*-HE$:N3C;C.QEY]#CVK3N=-MKN:VEECR;
M?>%'&"K*592.ZGCCU H YT^,VMW<W%@3:1,8FG64%V<6GVD_)M QMR,YZXXP
M>'7?B2_LKJSFN[:*.)[*>9[>*;S Q$ENJ'>5!&!*W&,?7BM\VNGQSQQ_98!(
M[&5,1#[P0(6SC@["%SZ<=*9%H>D06YMXM+LDA9'C,:VZA2K8W+C'0[5R.^T>
ME '-Z_XPNH-/U6+3;5/M=M;WDGFR3 !!"$!8#:=S9D7Y3@<')]9;SQ=<6#WB
MI9?:OLXNIGWS"/;' L18#"G)/F< ]QR?37ET7P\3;Z=+I>G'(>6&!K=".-H<
M@8QW7/X5>;3K%S(7LK=C(KJ^8E.X/C<#QR#M7/K@>E &3I_B.74?$$^GPV/^
MC0^8&N?,;AE*C!&W')8X^8_<;.,8JOJ]YJFB:?=SS:A&\ES(L%F/)SY3/*_S
M$ 98+&R$COY1]:N6?A?3['7)=6B,GVB0N<$(,%R"WS!0S#C@,2!V P*V)(8I
M7B>2)'>)M\;,H)1L$9'H<$CZ$T <,/&&IS6=G=VD=O)));P"6"4E$69KD0R<
M@%N#N'ZX['0G\9R0'5'&D3R06$<Q:52X#/$N2N2@4 G(!W$\<@9KH)-)TV59
MEDT^U=9@1*&A4[\G)W<<\\_6FG1=*,TLQTVS,DR>7(Y@7+K@#:3CD8 &/0"@
M#(G\37-OJMMILEC ;B;*-Y=P[+%+Y3R!6;RP,$)Z[N<[2.:I67BV]>TL9+BU
MB:\O+.TD2&.7$6^9G .XKN PN3U]!D\G<0:'=26.M"&T>:Z"?9;IH@)'#(2N
M"1D94G\,U.-#TE;4VHTNR%NRA#$(%VE0Q8#&,8#$GZG- &"/&<K$8TL;8SMN
MC]H_U9^T-;ML^7Y_F0D9VY'H>*M?;]4UH75M9R)IEU:S.K+("[LA2148AD
M+!6!4L"%(SU%;":7I\<0B2QMEC5%0((E "J<J,8Z \@>M/M=/L[$RFTM(+<R
MMND,487>?4XZF@!FI7RZ?I\UT?+/E@8#L0"Q( &0">20. 3Z UBZ?XL>]DL
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M=QR2I<8YYR03WR: ,NPUN[D\-V%[<D^?/?B!]FT@ W!3&<8( P,XR<59\/\
MB*76WVS6(MM]K%=Q8F\S<CE@,_*,$%/?@CZ5H3QZ9IFG*)(+>"S@965%B&U&
MW<$*!P=QSQWJQ#9VUL5,%O#$5C$0V(%P@SA>.PR<#WH Y>W\:R3VJROI\43S
M6\5Q;(;AG\P.Y7:=L98-D< !L^V#B2V\8O=P>?'81QP+80WDCSSE<-*SJL8
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M[MB96//;<X0>T0JA!X0O5>UGED@:YMH[%(Y/,8E/*G=YL<<;D8+[]#@5VE%
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M[;[=Q$Z,%&TY5BP).03SD' KN** .-G\.ZY)=R1PW$$-NT[3K<+,WF(39F
M)MQP_P V=WX9J'3_  GJ%M,LBP6-BGGI(T-O.S+@6TL1.2HY+NIZ>IZUW%%
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M/)Y4NYXG(4_(Z *3D^X(KK** .7'ARZD\(W>E.((FN)F=($<F.%#(&V*< X
M] ,$X'%9NI^$=4DM1:6 L8[=+B:6#+;3!N9&39E&V@8?(7!R1@@9KNJ* .+O
MO">JW!U1([R,0,X-BF\@A'F6:='RI&&*[1PP"GICBK__  CLS>$8M'SAOM$<
MCJ\V0$%P)&4%47 VY  4 <#H,UTM% '&OX5OXM=O;VV>$(486>7"I&OD"-8F
M01[C&&&[ <#OC(YK6OA/5K>"(!+/?'J'VF)&D4Q1(4C!&P1!2<JY&T*02.>6
MKNZ* .%/A#4Y/M2EK:-I(YDDG29]]V7F1U:3Y1M*JK*.3C<0,#J:IX1U26U^
MR:>+&.W2>>6 $[3!N*%-F4;:!A\A<')&"!FNZHH X*Z\&ZE/)JXB2RA-W'?*
M)UF8O-YP(1'&WA5)SU.".!R:UM-\/7EKXKNM4N)?,21Y&2195!*,!A&7R\D+
MCCYR!@$#DBNGHH XB]\+ZU=:SJEW'):0I<6TT*&-RAEW/$4#X3=]U'4L6;&[
MY0.E7(M NUU*WN!ING0P+ (XXDF)%BX=V+Q#9@E@RY'R_=QR*ZNB@#S^#P7J
MD&@-;?N9;W=$W[VX5H7=$<&1D\D;LEAG=EC@'<"H-='I.E7=EKNIW4J6XM[K
M# AM\C-SWV@A<=%);'."!6[10!P+^#+V/3([."RTPQQB\18O-9$#2LICGX3A
MU (QU&>&KH=0T1[K4-"NS%;74FGR'S'GX;!3!=>#\V0#CCZ\5NT4 <#%X'O[
M31DL[:2WC_T6R2>-'PL\D3.9<[D888,HR5.=H!&!6U/X>N9?"UEI45PT,L-Q
M!*9#('9%297(4[ #@# &T#H*Z2B@#DKGP=_Q^BRE$3-ISV]I.[EI(IW:5GE]
MB3)G<.>3TJG_ ,(5<3:<+>1(E7-P_DM,&1'>)40J$C10 R[ON\'YNIX[FB@#
MCXO"MY;LJ0O$L N?/:-9G0MFS>%N0"0QD8-GZMUJB?!VJRP:=%*\"PVRRH(H
M)$C,>75ED!\DC?@')54.>G4UWU% &%HFE7>G:EJTLBP+!=2^9$0V^0L6<G<V
MU3MY7 .XKR,XQ7.V?@W4EA#7MMIDSK=V]R+?(\K<JLLA&(QMSD$9!)P,FN_H
MH P-8T";4]2ENHY4B<:?);VTI)+03-G$@'3(!Z]>H[USMSX-U5_#DFGVZ6J/
M+(SLLDRLL;>5L5HR( %^;DX7/?<"37H-% '&7?AK59KK4)(OLI2Y$+.)926F
M*/&60L$RJ,J.I!+#YL@ 9!@G\&7MS9,A%K&RV]Z+6%9&*6LLCHT)0[1]W:W(
M VDX Q7=44 <+J7A/6+_ %'6)@;)([RSN+=-K[?,+M&8R^$W9 5@26;&[Y0
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MM44 9W]@:1LG3^SK8+.VZ0",#<<YS^9)_$U(-'TU9/,6QMU?$:Y$8'"$%/\
MOD@8],"KM% '.:9X)T?389(3&;J)UC79.D>!LW8/RJ,M\QRQRQ[FM0:)I:E"
MNGVP\N%($Q&/EC0[D4>P/(':K]% %*32--E2Y62QMV6Z=9)\QC]XX  9O4C:
MN#VP*=+I5A-8I92V<+VJ$%8F0%01R"!ZU;HH IQZ3IT4:QQV-NB(L:JJQ@ "
M,[HP/]T\CTI+/2--T^XEGL[&W@FESO>.,*6R<\D>Y)_&KM% %&?1M-N;>.":
MQMWBC<NB-&,*QSDCTSDY]<FI?[.LBY?[+#N+F0G8,[BFPGZ[?E^G%6:* **:
M-ID=REPEA;K,B"-7$8!"@;0/RX^G%,MM TBR4+;:9:1 ,& 2(#D*5!_[Y8CZ
M'%:-% %"TT32[#9]DT^VAV/YB^7&!AMI3/UVDK].*EFTVRN(KB*:TADCN&#S
M*R B1@  3ZD!5P?]D>E6J* ,V70-+D11]BA1TB:*.14&Z-2"#M/8_,W_ 'T?
M4U%;>%]%MM-6P33;8VX*L08E^9E& QXZXXS6O10!472[!%55LK=541JH$8
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M2)(9C'&'0HFP%"%^1L?Q#GD_2M/5M$&KSVQFNY%@@ECF\E40Y='#*0Q&Y>0
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M]LC,R0&'YMPYRK$GW]*A?P+IQM;>%)9?]&\GRC*J2#,<;Q@LI&#E7;/OR,4
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M+IS'>!!]E*[/)N$B1SC.XLC,^ .=O ]:6MZMKL_AR>W><#S[.Z\N:UMGE,[
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MIV5E/#!<W*123,%C#'J2< >V20!ZDXH@U.RN8)YX;E'B@)$C@_*N.O/IP>:
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M+Q*'NKJ;4(O[02(["DB8:3RPN!D_+M((]1BI-0\0:C-K=G%I31"QD5"))HW
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MXHT</;(MXKFYN/LR;%)Q)L+X/I\HS^(J7_A(=(V3O_:$&V A9#NZ$MM&/7+
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M%GB_TA8T8J#DJ4);/';'%:K:IJT?AF]GQ$]_;W+P(YA.UP)=H8IG/W3V/Y4
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M"B!4#*7.<=-QW\MQG:,\\FMI_@R.SCM5EU":X-JEM%"2BKB. DJ#CJ26.3Z
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MRCYBGG.1+Y?OMD[D5H0Z_<'P:VIR%O/5_*,BPJ5SY@3</FVE.<[LXP,D<$4
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MNGC,:7!\S:R+SU"^F<D@] 151_$VJ6LXMHFB20%WCMY(9)'N#]KDCV!BW&4
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MH1U"X:S4AHC)$B9F0E'+Q*A.-X(3"L03\PZXH Z&Y\(VUU;SPO<RA9H[V-B
M,@7+;FQ].U3IX>7^THK^:Z>2X6=9VP@5680-#T[##$UBS^)=1CN[VW:6&-([
MM(VNA"7BMH6+X+<YW_*H(. "P/(J[X?U36-4U "Z\J*VCM$E(%NRF9FDF4,"
M3\H*QHVW!/S]: $M_!<5L;-$U";[/;I;AHBB_O&A3RU)/497J!W ]P;F@^&8
M-!LY+:)T<-$D D$05RB A0Q'WC\Q]!R>!FN:UC7-:N]/UNU@D"2BUO@8HH&$
MEMY9(B;=GDNO(Z=01T.='Q#/?:+/HGV)2T444D<\BQDI$G[L&0H#S@9.,^O7
M% &A8^%+>Q6V5;F5O(EAE&0.3'"(0/Q S]:FOO#RW<]S<1W3PSRRP3*VT,$:
M(Y''<'O6)/X@U^W^TS".&6(B]\I!;-F(0SK&K'#?/E69B!C.WBH+KQ-X@BM2
M;"&"_P#-GDM;2X6%E69\1LKG!X4#SU)Z$H,=<4 ;%KX/@MO+)O)I&5H6+,J@
ML8YGFR<#')D(_"K>H^'H]0NKBY%S)%-*MML(4$(T$C2(<'KDO@CT';K7,3^(
M=6=5UFWMW"36Y\E'C8".)KE$$C#U$>7YQCOP#3-1UW6+FUMK>6XMXB_D2(UO
M$S_:LW14A6!XVQJC-C(^<]A0!T,?A&V\BZCGN993=V]Q!<, %W><VYR/3K@#
MT]>M,N_"?]H36T]]>K<SQ1M"YEME*/&Q4XV]C\O7GJ>.F,"/QCK,R7TR>0$2
M5$17B *(9F1I/O<H%"?,<8+$D8&*WKC6=1A\.Z;=2RVT4EQ,([B[1"\4*88B
M3&>^%'7 +]P.0"UK7AP:S?6EP][-'' \;^2!E24D60$>A)7!//'3%5YO!\$D
M,2K=RH\.YHWV@X<W"7 )'?#H!CN,U3\/2:EJ?B+[?J!VJNFQ>6GE,BY:64%P
M">-RHK8/."!VK)^WZ^J?:8[\37=G'JI</;$@^7+'Y<94,.2 ,'^Z>/6@#J&\
M,1R^'I]*GNY)3-<FZ:8HH/F>;YH^7I@,!QZ?G43^$+:2PEMC,(_-LKFS<PQ!
M%_?$%F YY&/?WJ'3-<U6\\4W%G,EO%;1LR^2W$NP*I5QSR"2>V.<=0<T+OQ/
MK,-Q?""**:2'[4#:"W<M L9_=R,0?F##!P ,[L#H: -2[\&V5YJ5]=2N&CO@
MWFH8P75FA\DE'_A^3V]><'%6#HM^CVUV-2$U]:PS1(TD05'5PG! Z?-&ISSW
MXZ8SX=<NY-3@MEU*VDA: 20S"U;%XY=U9%^; VA5R1G[V>@JG:>)M7U4V45F
M8HVF6U6:5K9B(W>.9I1@D<@HH]B2#Z4 =%>Z1/=K82K?M%?6@.)Q$I#EEVME
M3QSU'H0.V05T30;;087AM7D:,I%&H?!(6.-8QSWX45SE]K^OVUHLVZUC6>^N
MH5DDA*I"D;NL88EN2^T'/'H.2#4EQKWB*WFN)EMH9T29H([6.%LLPLO/!#YY
M!D&SH.OK0!<A\)![6&*XN"IM_.CC\OD&-KA)5SGN!&H/XU<306GTK5;2ZD"O
MJ%Q+([1\[5) 7&>^Q5S[YK"NO$NK1FQ2RO+*Z29';[2\)BCDD!3$7+'!^9NF
M3[?*V='Q)KFHZ;?^3:>6N+<2PQO"SF\E+X,2D$;2!CU^\#T4Y -0Z'"VDZGI
M[2R&._:8R,,97S<YQ],U7_X1M9)?.N+MY)FDMY'8(%!,6<<=LYK.TXZA8Z#K
ME\;B(WC7ER8Y+E2J +(RIGD\8 QVQBH8_%EXSVT?EL&N!9&$20$,X>=DF/!(
MP%"G(.!D'H10!JZ#X6M="LI;2-EDC:%+<-Y01_+4$*&8?>/S'GCZ<U0C\#0Q
M:1]@BNUC8;%2Y2W59E5%95(8'(<;B0PQU/&"0:,>HZQK":++%?117;7+&>(6
MK8M3]GE)C<;OF(( YQSSW%==H]W+?Z)87D\?E37%O'+)& 1M9E!(Y]": ,R?
MPM'<22[[R3RWN9+E4"#*L\+Q,,]Q\Y/X4X>%X!(KK=3*RRQR@J ""D)B'Z'/
MUK>HH Y?3_!PL#%(NI2R7$=VEUYCH#N*Q&(@Y.3E6))SU.?:F6W@BWL[<1V]
MR(WBDC>VF\A2Z!&+!6/\8YQV_/FNKHH HZ1IHTG3EM!.\^'DD,C@ L7=G/ X
MZL:O444 %%%% !1110 V1Q'&SMG"@DXK)@\3:;.D$AE\J.6S6\#R$ *C$  G
M/#98<5JRIYL3QDXW*5S]:YB+P1;6=I''IUP+*5+.*U:6"((9-CJVYMI!.[:0
M<$'#'!% &TNNZ2SVZ+J5J6N5+0#S5_>  DE?7 5OR/I31X@T=H4E&J6AC>7R
M$;S5^:3&=H]\$''H<UE6?A.>S-LL>JDQP13HN8<LKRNS-(AW<-\P&2&X!_O&
MG:3X2_LZYCN9K][B9;HW)9E/), AQEF8]!G))Y)H N+XIT=[^XM5OK<K;1>9
M-,)5V1_/LVDYX.>*N)K&F20"=+^V:(H9-XE&-H.TGZ \'WKGX_!31QHG]ID_
M9TBCM/W _=B*42INY^<Y !Z9'3!YI9_!;30LJZF4DG69;IQ ")/,D$AVC/RX
M(QWX/KS0!T<.H6=R]PD%S'*UN=LJQMN*'G@X[\$?@:J:3KUMJUC;7BQR6\5U
M_P >WGLF9AMW97:Q[ G!P1@Y%-T[1Y-/O=1N!=?)=MN6&-"J1G+$M@DC<=W)
M& < XSDUF1>$)8I3=1ZA'%>&Z^T[H;4+%GRFB/[O=]XAR2V>2!Q@8H T;;Q/
MI5SJ;V"WD FPC0YE7]\KIO!3GD8_D:>OB71WN;2"/4()'N]WD%'!#[<9Y_$?
MG65:^#/LIM8UU%FMH1;;HS",NT"!4.[/ ) )&#TQQSF:R\*RV0M3'J1#6\DA
M55B.R.-T52D:EB4 V@CD@$GC&  #0/B/1%M3='5K,0>9Y7F&9<;]N[;UZ[><
M>G-3'6M+6983J-J)&B\X+YR\QX)W=>F 3GT!]*QM*\(&PN(+B?49+J:*Z%R6
M=3\Y$#P\EF8\A]Q.>OH*9!X+$&E3Z4NHO]AN;)+6=?*&]BL(B#*V?EX .,'D
M=>30!M-K>FC2;C4UNXY+.W5FDDB._&T9(P._MUY%1#7[6"T^T:I&^DJ6VJ+Y
MXU+<9R-K,.F>^1@YJO%X:B.@WVEW,BG[;N\V:!"AR5"AOF9CN 4<DGH.*9/H
M.I7+07$NL1F]A62-9!:#9Y;@!ALW?>^4'.<>V.* -)=9TQK\6*ZA:F[//DB5
M=_W=W3/]WGZ<U0@\6:5=W<D-M<1SQQF,&>.5"GS*[==W.!&3QD\@XQDU7B\&
M6<,"6ZW$ODI.LH!^]@6GV;;G_=^;/K18^$WM[JWN;C43/)"T)7; $&(DD11C
M)ZB3)/J.PX !=M/$^DWEG'>Q7<8LY+=;D3O(JJ%8X ()R#GCIUXZ\5,?$.C*
M+<MJMF!<?ZG,R_O/FV\<\_-Q]>*R(_!I2QLX/[0)ELH((()/)X AD#H67//W
M0#R,\D8[/_X0Z-H+A9+QFEN(IDE<1@#=)+YC$#/ SP!Z=R>: .BN+B&UMY+B
MXE2*&-2SR2,%51ZDGI62WB?3FU#3K.UFBN7OC)L:.5< )@-WY() QUZ^E276
MF7.IZ1/:7MPB2M/YL3Q+D1A9 \60?O8VKGUY%0Z?X>^R:BFH2W1EN2TSRE8]
MBLTGEC@9. !$HQD]^: +R:M:$ZB9)!"FGRB*>24A5!\M),YSTQ(OXYHCUK3)
MC (]0MG,^[R@) =^TX;'T/!]^*RK[PO+>MJL9OPEKJ$T=R8Q"=Z2HL04AMW*
M_NE)&.YYI(_"IBELI$NHH7@9VD:"%E,NXDE22YRIR,AMV<9&#S0!HOXBT:.U
MCN7U6S6"0D)(9E"MCK@Y]P<^].DUNS%Y]D@E2XN%E6.:.)@6@R"=SCL./U%8
M8\%RK:B)-4*$PSVQ A+1I#*$W)&K,2F/+!&20,GC& -S3M(BTV.\CB<E;F7S
M/F&=OR*F/?A!0!-%JNGS6#W\=[ UF@+-.)!L4 9))Z8QS5"V\5Z/<0S3M?6\
M4"7#6ZR22J%D(4$D'/0;N?3%0P^&2GARYTA[UBLK;HV1"$@QMVJBLS84%0=N
M<<D# P!1N/!'VJ0SSWZ2W#O,9=\!\IUE$8==BN#_ ,LEQDGOG- &_)K-BLC1
M1SQRRI,D,B)(N49FP,Y([]NOH">*C'B/1#"LHU:R,;N8U<3+@L,9&<]LC/IF
MJ)\+[K^>X-X4BDN(;A8(HRJ!HWWY(+$%CP"P SCD$U7N/!4$UIIL N 196KV
MC"6,LDL;[=V55EY^0=R.3D'L ;=QK%A:ZK;Z;/<I'=7$3RQHQQE4*@_^A#\C
MZ46^LZ;>6DUU:WUO/! "9)(Y P0 9YQ[<_2JVKZ$NK7,<C7!C3[+<6<J!<EX
MYMF[!S\K QK@\]^/0TO1I+)[F:ZNQ<W%Q''"SI%Y:A$!"@+D\_,Q)SWZ #%
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M174)KOS;HR2RRE8]BLSJB<#)P L:]SWH +OQ;I%G+<1O<IOMKF.VN 6 \MG
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M<6TE]"A#(K R(N5W#U SMS^'M5!O%%HHO7$%P\-JYB,J[,22!_+V*N[=G?\
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MDNGRZAINHV.H/&8;KS(D6(8V1%=H&>YZGVSCMFL*S\!P6HN2^H32R7"QEW9
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M.3TK4F\7Z)!-Y;7\.%O#9S.9%58)!&\GSDD8&$(^O'K6B-5TXW$%N+^U\^=
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MS#;7%Y!%/,<1122!6?\ W0>30!@Z_K]WINEZ;-:36DHNGVO>D#R0-A8$9D4
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MXFN8Y9X)VF+K&_[S,7EC)>1SD#T/MBL:?QCJMM:IYT5FLDLT0\X)B.))(#(
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M_M[Z2!(K>X:)GC^PJ&^TE5MS*)2<_=9@$'R_Q#G/% %F'P??0PD+K063RK>
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MG>8KQ;K!C'.+3[-MZ_\  L_A[U'=^(;BU\*V>HS/;0W-PRIN 66+)SSGS%4
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M>O=,W3Z9>0FX\B:)5GA.W<\C2*<AN I8Y&#D#M4$.LZDVN-96Z1&/S;N23S
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M06Y$,=O<+<R6;;0Y N$M97D(&1N02 * ?[I[XQ#I^OZL9[:^%]:WD,EEI@G
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MQWH U/[9TK[-)=?VE9^1&_EO+YZ[5;^Z3G //2FVFL6UYIVGWT8<0WX5HMV
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M4M(7&5SR 3CJ,X[5GS^#7N;^^N9;U&-V&<@I)^ZE:W\@LH\S;C&>JD\D9Z$
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M[>,1PQC"J.PJ:B@ HQ110 4444 %%%% !1110 4444 %%%% !1110 48HHH
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M(J2(S1MM<*<E3@'!]#@@_0B@!]%%% !138Y$EC62-U=&&593D$?6G4 %%%%
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MWD+<RQ7'DXF2/Y$:4X16YR"?T[]1ES>*+.2"WDMRW[\6SKO0_<FE$8Z=\YH
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MK.H50IX'0MGJ>@W'ZXJLWB_3HY)UDCND2'SLRM%\C"*01RD'/12P)/IG&<'
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MQ+%+X:?6[FSN;:%"V8B [D!MO 4G/-1-XRTJ+4OL%P98;@#]XC[28V\OS=A
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M-\Q&44L5 P>""['(Y_(5Q\FG:[.5F$%RZI#=QV_VEE:54::V*!^3DD)(1GG
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MBV5OAI=V&#L9E + ;@A..1U&#0!W!TFV?3)-/F:::"4$/YLK,QS[DYJ+^P;
M-N198W!F(>.5E8&5P[D$'NP!K"L8=:6ZT]+V74Y[4JVUX@(BK&7@2@N25"8
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M/,4L1DICDYY R:Z+PX=0@M3'?&\G\V9C&TT6TPH$7ALNS'+;B#[XZ 4 68-
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M0-B(O*8@'/\ "?,4J1[>@)J?4?$NF:7J4%A=3%9Y=AP!D*'?8A/U;(XST).
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M9TD2\Q#YQ=UMF*XA;$ISCHN1D^_&3Q3[CQEHMM=WEO)<-OM(Y'D*H2/W:[G
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M"LY]*M=.'FPP6OEF POM9-GW<'\*CA\/6L%S-<13W2R3+^](E^\VP)O_ -[
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M66<Z;K5)B ]LK/+$RH//:,*,X^]B4'';OBH8?&-J]J+NXMYK:!4NI'61"7Q
MZJ2H .?O?7ZUJ/HEBXG!C8":XAN7 ; WQ;-F/0#RTX]JK-X5TQXI8G$S1R"X
M7:9#\JS,K2 >@RH(].: (9_&.F6UL\LD=V'C,@DA\@[XP@4L2/3#H?\ @0]Z
ML:GKL>F7Z1S+BW2TEN[B3!)1$*#H/]XGZ*:R]?\ !B:I>I>6UTEM,K22EG0O
MME98U$BX8<J(AP<@YK8NM*@O]22Y:175;:6SGB(R)%?8<'T(V_DQH J3>+M-
MQ.EO+YDT,TD+JRL K1O&CY('8RICUS5-_&J*89&TZ[6$SW4,@$99_P!R2"P
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M79Q<+<9+D_.L7E _]\\?6H;;PS86K:;M>X==-7;:I)+D)\K*/?A6*_3&<X%
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M9LP/\R JI*\?-@NHX]>*8OBK23&[-++&421FCDA=7&QE5AM(SG+IQU.X8ZT
M8$MIXDV2"VENK0)),Z+!'& Q:\;!(*G/[HY]\Y.36]HEU<PN=,OFN);D/</'
M)( 3Y*RX3<1W(88]0I]#5B^U_3=-NA;7=QY4I,*@%3R97*)@X]5.?0<G J/_
M (2733):J&G(NBPA<0/M<C=P#C&3L./7CU&0#!G3Q3%]JF@FNY&E6]"QE8\1
MA9U$.S(^\8]Y&2<\9Z"BVM]6EU;3[F9]3-C'>RK#Y@ <Q-$F#*N,X\P2#)&<
M8S6E;>-=)FL=/N9C/;F]B298Y(FRBL0 6P. 2<9Z'D] 36A%K^GS6%[?AY4M
M+,R"65X64?(2'VY'S8*D<9Z4 <K9#Q+!HYA$=Y'J$>E1BSBCBC%N)!;_ #!^
M,!A)D8X'"XXW5N>'[RZB5+2_FN9YKB21X/-@*-'&JIG=GD_,3@D?Q =LTV+Q
MA:"WU.ZNX+J"VLKGR2S6\FX*(8Y"SKC*@;S]0.,U+=>,-(L[F:WD-VSPEU8Q
MVDCKE5#, 0N#A2#0!G7*ZM/<7T<B7CR"]A,:&-#;^0)XB"N1][:&)YR#N]%K
M+N5\1:?H<UOI\>J27@N[V1)&(89\PM",;3N5E8'J%&"#S@5UEQXFTNTF>.XE
MDC"P-<"0POL9%4,Q4X^; .>/?N#5:3QGHT$/F3RSPX:1762!PR"/&]B,<*-P
MY]Z ,HV>L0ZG=&W2XED_M5YXS<@-&J&UD"%21P/,(4XY'3ORVR3Q%<O!$;C5
M(K1Y(!-).J+,K>7+YP''";O* ('4G:<8KHK_ %^UTW58;&Y255DM9KII]A,<
M:1E=VX]OO?YR*(=?L[FSO+B)+C-HF^2&2!DDQMW#"L 3D=/Q'4&@"/0+VXN+
M"*SOO._M""UB:Y=E ^=@PQD<;OER1VW#UKG--F\9_;DCO8IF@ P6 12?)C96
M.>WFR%6'^RIZ5KVOC*UGOX89;>XAAN+6UFC=H7X::21 K\87E% )Z[O2M+3?
M$&FZO<RP6<Y=XQNY0J&7)7<I(Y&0>1[=B,@'-:0/$EXUNEU)?V]N=0W,2!O\
MG[/G:2R@X\WC. ?3C%*MMXB,<8G:XN1*\,DB3(C",K=I]T8X_=9/_ 0>O-6-
M-\>6UTDTEU;K'&@C*FUD-RVYY#&J,JJ"KD@<<]>O%:4GC#189+E)+B13;1O)
M(3"^/D +@<<D9&0.>OH< '-ZE=^(])TZ6[EN;IO.8JRR%%"$W:(BJVWY<Q,W
M)ST!ZBM_PEJHO=,AMY+B:ZN51I)97&0/WKIMW8&<%& ..0N>])/XPTI[:\ 6
M7?!#,S)=6TD:$QKN922AYQ@X )P<@&K3>)-*MXKG+NJ6LJV[;86P9"0 B\<G
MD?SZ4 822ZY]BA-RVKAS=8U#RXURJ[9,>3@9*[O+Y&>,=]U-CM_%5Q]E:YO+
MV!@EHLBQ"/!W%Q,3\I^8+MSC@'I71V/B+3=2NH[>TEDED>$3<1, B[F7YB1P
M<HXP>X^E)>>)--T^XN(+MYHF@@>X8M ^&1,;BIQ\V-PZ?AT- '*+>>(SJ4%D
M9M0:ZBM[5MJHFPYN)5=I3CC,2=L=#CG%2P+X@LKC3;:WMKN.);G?*PP8V1[F
M3>",<80J<D_Q# X-;-]XPTVUT^XNHX[A[F-91Y'V:02 QJ&.Y=N54!U.3_?'
MK6A>:Y:Z;I<-_>B5(7C$CLD3.L8QDEB!P!0!S=G;>(XEM&#7$*01V(^SHB+&
MQ:=Q/D8[1[3P1CKUJW80:O9>#+Z& WC:E'//M,V&<CS"04SP?D.1GC/Y5HS>
M+-(@GN8I99D^S"0R.;=]G[O&_#8P< @G';/H:M3ZY86]E=7;RMY-M-Y#L$)^
M?(7 ]?F8#TSGT- &'IL6MW&J6XDN-0CTQ9IG0RJJR.@6+8LF1D#?YN.AP!FI
M-9CU_P _5I[":X 2.!;:)0NW!8><RC&2P7..>O0<UK_V[8"3RVD='WQQE6C8
M$,Z[E!&../RJFWC#2%L;>\W730W$3S1%+61BT:!2SX ^[A@<_P!>* .:N[OQ
M"GV:TAN]0ENWM)Y8 D 3,@E B$H89"@'!)QD<GG%6KM_%!;4_LS7PN1'>X!1
M/* R?LQBXY;&W/7G=N[5NR>+=#BNIHWNP#"C,TGEL5PJAV 8#DA2#@?S!I)/
M%=C#>"&>"\@C^R27;S36[HL:(<-NR./7\O44 1Z;875EXMO&EN+^>WDL8!&\
MS!HRRM)NZ  -RI[9R?PYR"]\3W<%[-82WTF&N$D,L:;5VW05?)XY(B$OKR%S
MS707?C73(=,N+F#SYIXEE_T<0.7!1%<[@!D##IS_ +0K2.KVL!T^&0,L]\-T
M4<:%O0L3@< ;AD^_UH P+:SUV\2**>_O?)^R7!W",1%G+XC#;ANR%)QTS@$\
MU6M)-?BE\/P0PZB(HXH!<M/R&R6$H8;>"N%Y)YR,#@D[@\9:(R3,MTQ$14#]
MTW[S<VP;./F!88R/KT.:5?%^CN\*K-,PD6-MPMW*QAY&C7><87YU9>>XH Q=
M-MO$4,6G,S7$2P0V"-;(B+&<L1/D =EP>",8&*+*V\11)9-NN(5@BL5-NB(L
M;%IF$^1CM'@\$8X-;S^)]-2:XA8W G@:-3$;=][%RP7:,<Y*M^6>E,MO%VC7
M4UG%%<2;KM(WC+1,!B0$H&)'RE@. ?;U&0#$\":M=ZS]L>\OI7D>WAD6+>&"
MAM_S@@ +G&-G.-OO5."/Q)::%86L!U07$5CLCRJMF[! Q*2/]7Z'H1NYSMKM
M+Z_L]'2)I8W!N9O+1((2[22;2W11Z*>?:JD?BO2)GMQ%/(ZSB+$@A?8AD.(U
M<XPI)XP><D9QD4 4?%+ZV)P-,-V!]ED-O]F52#=9&P2Y'"8SZ#KGG%7=/@U'
MR-6DO)9I)))I5@B<+M6,$[-HQWSWS4+^+K&6*-K+?(TDMNJ^9&T8DBEE6/S$
M)'S#G/'MV(I]OXMTZ5K6*5G$TZ1/F.*1XT\UV2/+[0!N92!G'- &186GB+=:
M>9/=P1AX8&B14")&;0;V QU$OY$8Z9S&DWB>6T@FU%;^!&D:.:.R13(I2,*&
M P?E:0.V?39G S73:7KUCK$TL5FTK&-$EW/$R!D?=M921R#M;\JKZGXDM['4
M8+"..2:X>XABDQ&VR/S#QE@, XR<$^GJ,@'.B'Q7:6T]W%"6U&>2))T4+L9V
MM40R#V24 G'\(:I;RS\0JU]'9S74*JMW)')$D8,T@2'R=WR\Y;?]<8/'%;K>
M*],4NA^U>:LJP^3]ED\PLRLRX7&<$(W/L<XJ.'QEHUQ;>?%)<LI$)0?99 T@
ME+",JNW)!*L,^U &-HVLWMYXZN;>ZNY%@0S1QP!@5=E$?\(&5V_/R3SN'H*#
MHVH3ZHD33:E&J:W)<&8$82%K:4 H2",98*?3/:MF/Q5HC7$10R^9.(P7%J_R
M;Y&B4.<?*=ZE<'H12_\ "8Z+B;%R[>4RJ,1-^\)?RQLX^8;\#(]0>A!H Q]+
M?Q3+JNF-J,L\*_9[=I$$&4<^5^]#$<*V_/7T7'>I=2LM0M=8UG4+:*\<W MH
MD,3#Y4&=Q&%+8'H.>>W6NCM-6M;V^N+.#S3+;[?-W1,H0E58*21UPRG'O[&J
M+^+M'C$Q>:8+&&8-]G<B0*XC8IQ\^&91QGJ.QH P;.TUVYN-*GO[9_.6.R>=
MRB@^8JSB3)'H63CH,\=:6TD\3W\-M#-_:%KB&QBN)-B*QD!E^T,O!X^X,_B/
M6NGO-;M+&"WDF6YW7"EHX4@=I, 9.4 R,#KGV'4BLJ?QI:A9GM;>>:.*XMHO
M,6)BLBS;"&3 ^8X<<4 )HO\ ;I\1WG]H3S"W5I@L30_NRF\>4ROTSLZ@<Y)S
MT%8^K6WB+4K#6[,B_9IK2_C>,JHB.21;B(XY)7KSW.[!Q72#Q=HV^V3[0X:X
MVX!B8;-SF,!^/ERX*\]P?2K$/B#3YM+N-2#RK9P%@TCPNN[;P=H(RW/'&<GI
M0!2U>*2RN]!FBM[FXAM)7$ABCWL 874$@>Y'YUD*?$SRZJTUY=08,HC1+4N-
MOG#RBA'_ $SR#MR?F)/(%;\OB?38&C2;[3&S*K.'MG'DJSE%+\?*"P(!/7!/
M09I@\7:1F<&6<>3O'S6[CS"L@B8)Q\Y#E5XSRP]: ,.:X\4F.1K6"[%Q)IF4
MBDQBWE"C^(C;(Q.?0@CD8/$-Q_PE7V6U6"]NQ$YGQ-]D8R1O^[\H,I&YE_UI
MR0 > >Q.D?&\,=I/=2V<NR+[21$$<2D121I]PKQ_K!G)&.P(R1HOXGLX9)TF
M64O'+Y:Q0PR22$>4DI+(%R,!QGJ.G.3@ %/Q4VLK)&---X%-K-Y1M%4YN?E\
MH/D'"?>]O7M5[2;?4&EU.34+B?,D[)"G 6., 8*8&>I/)S2V_B?2KJ_BLX)I
M)'E94200OY;,T7F@!\;<E/FZT^X\0Z?:S7<<KS8M!^_D6!V1&P&"[@,%B&4@
M#DY'<T <?8:7KL.GZ;/$^HI>6FEQ1.)-I,DRR#<C9'*X#8QU!SGH:WM!.NMK
MUZ=2FE$(:8"%H?DV^9^Z97Z?ZOJ!DG/."*LS>,=(MXF>5KI63S/,C^RR%X_+
M"LY90,@!74Y/4$8SFH[[Q?8VFHQVRB1XU>1;B?RGV($A:4X;&&( ' /<^AH
MP[;PUJEG%J6IVSBVOI;FZ2-;>W"R,DEYN#NQ)#D(/ER!@,>N:MS)XDBUR[BC
MNKK[-$A%L#%O$R?9^"6Q@/YN3SSP!C!K=G\1Z=;R&(O-),)!&(HH7=R2GF<
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M;'_32(E<^NT]235OPH==:6Y;69I2^T!H7AVJDFYLE&Z%<8Z9X [DU;'BW2"
M3+,H\J660M X$*QDJY<X^7!4CG\*6W\5Z5=211123--+,81%Y#APP56.1C@;
M74Y]_8X ,+2W\8'6(+>]$OV/S?)>8JH^6 ']Y_VV9AQV"GI5>YTS7IO#]KYT
ME[+>OI6^XD 02K/OA8HI &.C_*.N.]=%_P )CHI$Q6XE;RF5?E@=B^Z01C8
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M2/Q!=2V\2W.J163W$7FRSHBS#]S*9!]WA-XB ..I..,5VU%% !1110 4444
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M\F"NP@YP0..<YK0D;Q+-J5Q;6]U>1S%IT#2VZ>1'&(SY,BMM^9BVS(R>K\
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MQ:M&Q0LH#.S1#&P;N"$W \$D#(!IP^$-.MY;5H9+I$MEB"Q"7Y28U*HQXR2
M<=<=..!5)O!=I+<J8=0N5CQ<+=&-U5Y&E$0(.T  ;8^< ')SUYJ35KC6U\0K
M':M=K%OMO)2.%6AD0R'SS(Y4[2$Z<CMC)R*BTVTOM%\&77EQW<MZUS-(0JJ)
M3NF/S<(<_+\WW6..@/ H NOX4T@/>+\R0WB,DL *A?F4(2#C<#@#H<9YQFII
M_#-I>(%O+F[N<V\MK*9''[Z.3&X-@#&,#&W&*Y86NMZA#:3WMM</."%+-'@[
M%OT*D\+SY2AN@XYP*Z'6O[=^W7DFF22A8=-=[:'8GES7)WA0Q(S_ '> 1VH
M6;PE8S6R6\EW=!MLL?F(R1N\<@4.AVJ!@[5Y SP.:O7^AVNH16<,SRB&T=)%
M12,,4(*Y)&1@J.00>OK7*,/$<MHEY#YUU>0K=&U\^ QLC& ;%;<B9R^>< <X
M[5,+CQ2NG1R6TUQ<//.]J!);;&@#HNV9MR(6".&/W<$/CG&: -=?!NEK9RVB
MF40-(LD:X3]R5;<-IVY//9MW''2FGPC#)JGVB6[G:V$%O%Y"D*)#%))("^
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ML^_LP< <G'':KL$&N7%[ILDNI:@@DMKR$2K;$!'9HS$9%:,<@!\,5 ^4>IW
M&MIG@W2])>)[?SBT3HZ;F'&Q'1>@&>)&Y/)ZDDU%<>$;5[>WALKF:W:W%K%O
M5\L$@+,@'^U^\/7@\<5!INIZ[J7@S4-52/;?RQR&SMP%/ELB;>.S9=689X(8
M5AW$NO66FZQ+I<>KRSW-Z\EO/+ %D?;:Q*NY/*/!=2HR%'R\D=P#K8?"NFP1
M%%\X[O)WLSY+&.9I@Q]R[L3ZYID?A.Q@M;JU@FFC@N,Y0+&0@+$E1E#D'/1L
M^V*R+A]7LY];*'59&GOHFBV)\D41A3)4B-R1O5E( )'!.,EC:OKO74\&Z3=
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M!(Y'&,C(JH/"-G]EMK9KB8QP7 N!MB@0LXVXSMC&/N]5P>3S5BW\.6EO;:G
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MA"PNOM22SW1MYQ/B#>NR)I@1(Z_+G)W-U) W' J_K.BV^N6L5O<O(JQRB4;
MIR<$<A@5(PQZCK@C! - %=?%6CO<10I<R.TJJR,D$C(=R;U^8+C)49 SD].M
M6(M=TV:TGNH[I6MX(%N9) IVK&R[P<X_NC..N"/455M/"VGV45O'$T^V!H&3
M<X/,2;%SQZ=:-#\/IH^DW5FLI5KF>64NG.P,<(J[@1\B!%&1CY>E #I?$UA
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M,K6P<LB6TF7V2"-]A*X;:Q ."<9K0N]8L-,MX&F\U!,"8XH[=W? &3\BJ6
MZY'%9%MX,A\BZ2]O;F9IOM2QA64+ DTWF'9\N<\)][/*\<<5JW^BK?BV<WMU
M#<VZLBW,)0.RL &!RI7G / &"!C% $.EZ^FK:Q>VMO'FUMDC9;C#8E+J&!7Y
M=I&".A)]JL0:Y8W%O=S(TRK9C=.LEO(CJ-N[.UE#'CT%+I^BV>EI*EHKI'(L
M:;-W"JB!% []%%5M!\,V/AV*>.T:1Q,$#F0(,[1@?=4 G'4GD]Z !_%>B1B<
MF_0BW)$NU6;;B'SB>!T\OG/3MUXJ"X\765O(F8;ETD,"H$MY?,'FLZ@LA4$#
M]V<'DGT'&:UKX T6T@DBB-SM>QDL"6DR?+=B2>GWAN(!].*T[WP_;7MQ)<&:
M>*=Q!B2,KE3"[,A ((ZNV<@\4 5X_%VEFWDFE%U$$N);?:UK(68QDABH"DE?
ME)SV[X/%68?$>EW&I"PBN&>=F"*1"_EEC&)0H?&TG80V,YQ5.Z\'V%WR\TX*
MW,ES'E8G$;29W@!T(().>02#T(J['H%G%=K<J9-ZW8NP,@#>+?[/T Z;.WK^
M5 "3^(],MKBZ@DEE\RU=(Y0MO(P#N%*H"%PS$.IP,GFHCXLT;?;J+F0F<QA=
MMO(0A>0QJ'(7Y"7!7#8Y!]*=?>&K#4(+V*;S/]+NDNV;Y3MD1452 P(QB->"
M"#DU1O/"$<@MVM+R:%XWM?,4*BI,L,_FC<JJ,'E\;=HYYSB@#1?Q'I4<0E:Z
M^4JS+B-B6VR",@#&2=Y"@=23QFD@\2:9<R1QP2322.COL2VD+*$8JVX;<J=R
MD8.,D<50D\$Z;,LR33W4D<@8)&[(5AS*)OE&WG#J#\V[T.1Q5J/PQ:1S:=(9
MY6^P,SQ*(XD!8YR3L0$=>BX!P,@T -'BNR/ABRU[[/>?9KLP!(Q;L9!YK*HR
MN,]6ZCKVSD9C@\5:9+<WD-[FW:SDE(>2)]FV-068,5QN ;D YQFK2>'K=/#L
M&BBYN?(MQ$(9<KYB>6RM'CY<':57J#G'.>:BN?"FFWD,T5QYTB3&8R L!N\U
M-C]!Z=* )(_$^E2RPQ)+.9I93"L1M90X8!6.Y=N5&'4Y.!@YJC>^-+%;)9=.
M5[N62:"-%,,J@K*Q"R<(24(5L$ @XQFKUAX<M+!X'5WD>#S-I,<: [PH.0B*
M#]T=JKZ=X/T[3+6.V@:3R8I8I(UVQJ5\LY49506'^\2?>@"9O%FC()B]S(%B
M!8L;>3#@.$)0[?G 9@#MSU'K6O#*L\$<JAPKJ& ="C 'U4X(/L:PE\(6 .&G
MNGC7(@C9UQ IE65E7"YP61?O$G P,5N1Q&.65S+(XD8$*Q&$X PO'3C/.>2:
M )**** "FJBH"$4*"22 ,<GDFG44 %%%% !1110 4444 %%%% #617QN4-M.
M1D9P?6G444 %%%% !1110 4444 %%%% !1110 4444 '?-%%% !1110 4444
M %%%% #4147:BA1DG &.M.HHH **** "BBB@ HHHH **** "BBB@!NQ=^_:-
M^,;L<X]*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116+
MI?B.WU;5;NSMV@Q;/)&?](4RED;8W[L<A=V1D^G3D9 -JBLG3->AU35=0LH8
M7"V80B8D;9=Q=25]@T;#WQZ5K4 %%<Y=>--+T_4[^SOVD@^RRPPJX1I/.>2-
MI JJH)SA34B^-?#SPO,FH;X8[07LDJ0R,B0E2P9F"X!(!.T\\=* -^BN=/CO
MPX+1KG^T&*+(T3*+>4N"JAV)3;N"A2&W8Q@@YJ/5/'N@Z7;WDIFGN?L@0RBU
MMWD W%0 ' VD_.IQG.#0!TU%<TWCC1[?[4UY,85BN#"@2.221\1)*24";EPK
MC/& .I'2K$?C+P_-JJ:9%J*O=/@*%C<J28Q*HWXVY*'<!GD9QT- &[16#JGB
MFWL].TVYLH)+^75)5BLH8R$\TLI?)+8V@*I))].E*OBS38KRVT[4'-GJ4VQ6
MMF!<1N^=JM(H* M@X!()]* -VBN7MOB)X5NYX88=4W/,T:QYMY0#O.U#DKC!
M;Y<],\9SQ4=Y\0M$CM+A]/F^V7$#1@P[7CW*TRPLRLRX;:S<XSSP<9H ZRBN
M>M_&6F-# ]TY@,]S);(4CDDCW+,8AN<)M4EACYL<G SUI(_'?AJ1;IEU,8M5
MWR$PR#C?Y?RY7Y_G^7"Y.2!WH Z*BL6/Q;HLM];V8NW%Q<;=B/!(N"V=JL2N
M$8[6PK8)QTJ]>Z@EE<6$+(S&\N# I!^Z?+=\G\$(_&@"Y165-XCTFWFN(I;K
M:UNK-(3&^WY<;@&QAF&1E02?:GG7M.61D>62-D@^T2>9!(@BC^;YG)4!/N-P
MV#P: -*BL<>*-(*(?/E#/,+=8C;2B0N5+@;"N[[H+9QC )JY<ZI:6EY!:SO(
MDDY"H?)<H2<X!<#:"<< D9H N45BQ>+-%GMY)X[MV1!&>(),N)"538NW+Y((
M&T'D$4V#Q)%/H46JB!_+EO1:*N>>;CR W(&.S8_"@#<HK.GUW3;:^-G-<[)A
M][*-L4[2V"^-H;:"<$YQS20Z]I]P]JD;SE[I2\2FVD!*@@%B"ORKR.3@'- &
ME16*/%NB-;O.+MBB^7C]Q)EQ(<(4&W+AB" 5R#VJ>'68VN4MKB*6&XF=_)C$
M;L6C4@;SA?D!R/O8ZT :=%<]KWB2XT&'4+N72Y);&SM7N#.LF-VT [0,=>O?
MM5R^\2:5IEY;VEY=>5/.%*KY;,%#-M4LP!" L=H+$ GB@#5HKG4\=>&W-X!J
M:C['&\DQ:)U 5'V-@E?FPV%PN>2/454L_B%HTUI=75T\EK#%=RV\>8I&=UC5
M69R@3<@ ;G(PO<T =;17/77BNW>6[M='A;4[ZT_UT$890OR%A\^TJ2?E& ?X
MLUI7>I"UU&RL_+W-<"21SG[D:+RV,<_,R#'^U[4 7Z*RH_$>F2LB)+,97F,(
MB-M*) P 8[D*[E&&4Y( PPYYJ/6_$=IHI2)PTMR[1 1*K$ /($#,P!"C).,X
MR00* -FBN>U/Q?I]C974MOYES/ =HB6*0!SY@C.U@IW ,0"5#8^N*D/BO3;:
M+-_*('S)E8TDD"B/:'8X0;0NX9)  SS0!NT5ER^(])@GN(I;L(;=7:1FC8(-
M@!8!L88C(R 21Z57@\2P7.F:Q?I$R0Z:[J3,&C+!8ED)(*[E^]C&#TS0!N45
MG6^NZ==:D^GPW!:Y0N"IC<+E<;@&(VDC(R <\YK.C\60MK<VGR6KJJ/*BR(V
M]B8U#-E!\P&&X(SD\=Q0!T5%94?B32Y9+:))Y3+<,Z1Q_9Y ^4(#[EVY7!9<
MEL=14<GBK1X;:2XEN)D6-RCHUK*) 0F\_)MW8V_-G&,4 ;-%92^(M-=[A(WN
M)6M]GFK%:2N5+*K <*><,IQU /--7Q/H[SV\27FYKA(GC(B<KB0D1Y;&%W$$
M#)&3QUH UZ*Q] \1VFOVJO$&CN/*622%E8;0Q(!!( 894C(XR*HKXO#W%W:I
M9K)<PSQ0(L5PKJSR%OE9A]UE"$L.< CKF@#IJ*Q=*\0KJ=W' ;9H6DAE<!FR
M0\4IBE7C^ZVW![Y[5+-XCTNW:Y6>>2)K<H'#V\@)W/L7;E?G!;C*YYH U:*Y
M[4/&.EV>FBZB=[AW5BD0B<'Y7V'?\O[O#97YL<C'6M6XU2TM;V"SE=_M$W*(
MD3/@9 RVT':,D#)P* +E%8J^+-%:!YENV*+Y>#Y$F7#MM0H-N7#'@%<@U+%X
MCTJ;;Y=P[[H3.2(7^1!N!+_+\G*.,-@Y4CJ* -6BL:[\26=O/:1Q9G\Z3:^P
M-E%,$DP(&,MD1XP/7\*6T\3:==VFGW ^TQ)?HC0^=;2*!N^Z&.-JDG@9//&,
MY% &Q17/R>,]&6U-Q%)<3H)(4Q%:R%B)9/+5@-OS+NSR,]".N =6SU*UOY9X
M[9G<P-L=C$RKNZ$!B,$@@@X)P>M %NBLV#7M.N)A"DSK*91$(Y87C8L59APP
M!P0K$'H<'FLV[\:Z=#'<M!'/.(+:&ZW^4ZQM'*Y48;'4;2<=^V<' !TE%8TG
MBK1HK9+A[IU1O,R#;R;D$9 <NNW*!21DL !D>M/;Q%8F\^RPR&21;@6\GR.%
M5BI; ;;AFP,X!Z$>HR :U%8I\5Z,+?SVN9%3=(K;K:5639C>64KE57(RQ  S
MR:5?$=G+K\.DVX:61O-WR;6"J8]N0&(VL<M@X/!ZT ;-%8$7B_3/.O8;MVMG
MM994)9'*LL>,D-MQG!R1DD#GI5V]UJVM;"ZNTS,MM*(9%7C#$J,9/7&X?RH
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M[5;I_P!VPC*LS#&_!&?E/],\XF?Q3H\=L)WNG5,N&!@D#)LQO+KMW(JY&2P
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M0>7MB,L@DEVY7)W$=R< G&.,9-UJVM1W>I0@WAB2YB N(K0L(82Y#;%,>6<
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MK*OF,96$JL#$2,(%(R4Y;.2 <9HUWQ#)!J<BI?1QQ^2\(DM#YO+2[XUQ"5!
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M8CMW^3,865)4/W<$JT:]>HSFG-X/M)+>Y26ZN7DN;>Y@FE.T%O.*EFP!@$;
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M>[U"S9':.,&5RA1BH!9<Y )7!)!Z<DBJMUXGT$J]I>7$;%U"R0&)I =R!]G
M(8[#NV]<9., T[3?#%KIFDW.GQOE+B/RFD6&.-MNW:,[%&3@]32P^&;6":.5
M9IB4NA<@$C[PMOL^.G3;S]?;B@!D>O>&]+"6=M-;PJ<%(K:$[277>H 08)8<
M@#DX.,X-3'Q-I:8=KE#"Z1-"Z9<R^8K,H50"3D*<>M0V/A2SL!:B.>=OLTD4
MB[B.3'#Y(SQ_=Y/O267A*SL9+)XYYV-HL*IN(Y\J.1!GCN)#GZ"@"ZGB#2I9
M;:..\1S<HCQ%02I#YV9;&!NP< D9QQ5!?%F@06/GVLK20M-$,6UNQ),[G:^
M.0S;CN'4@]3Q3+/P5I]E>VMU&Y=H(HH_WL,;EO+SM8,5RIY[$=!TIP\(6L=E
M%;Q7=S&T-O9P1R#:2/LSET;!&"23S[>E &Y=74%E:R7-S*L4,8W,[=A5&/Q%
MI4TEM$EUF6Y=TCB\MP^Y2 P*XRN-RYR!C(HGTJ74-*N+._NV9I)C)')$H4Q
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M-):2&-;V+=,H:,<\@YQ],[6QZX.,U2TWQ?IE]86MU/-':_:SF%'8DE-VU2W
MVY) ],G&30!AKXGUFWTGSIHYY91#<H9$M&99+A4C:/RP%!V$EP,@'*D')&2_
M4[W5;^VU6V:6:*='B$%NMHQ7;F(^9O[\EN,]B.JDUU]GJ5G?O<):7"3-;R&*
M79SL<$@J?<$&HEUBTWZD)6\E-/<)-)(0%YC5\@^F''XT 9$MSJ9\+ZD)E>>Z
M@G>*-O**F50XVMA?8]N.*IOJ?B%'N7\U%1UOA$)+8A83%.J1$D D[E).<'H#
MC@YZ*+7-,G:!8KM&><L$4 YRIPV1C*X) YQR<5&WB/1TM$NVOXA;R$[)#G#
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M5E<@MR%B8+(<?[+$ _6@#CVU'Q)+HL4ES=7$+M'IMV\D-IM:/S)B)DQ@Y"J
M2.O7/!P+%SX@UTZGJ,-G'-Y:12>7YUJ3L=98T&  ,AE9F'S$D 'Y>E==-J-I
M;W:6LLZK.ZEPG).T9Y/H.#UZX-02Z[I<,(E>]B"%8W&#DL'SLP!R<[3C'H:
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MR)$R/!]E=%@/VN(;0W\7R#.>>YZ$"K(OM;M;6:2,7-_>P7&HE(Y83QMWF%>
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MO,$A3RMF>#MS*&/.-@)'.#3CUKQ+-IL=PH97AAN)67[*29S'<;$'(&-T8SP
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MWZ>E %U=!A65)/.DRE^U]C Y8JR[?I\U9P\&PMIL&GRWTSV\>G2::WR*"\+
M <]F 4<]_2LRQU[7=1C07MD8'@N;5955'7)EF#8!!Y"Q%,]1DG/3%6_!WVO<
MWVCSO^079_ZS/WMT^[KWZ9_"@"[#X2MXXMK2J'*S*S0PK&&\Q%0D@=P%'/\
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M:7/V1M-</"T<2E>(FCQMZ ;7/ Z<5:T>>YN=(M9KPPFX=,N8<[#[C/J.:O4
M<U'X-M8YKV0/#)]J\UCYMJCD-(VY\D]5)SQ[]>!ADG@J&>%89]0N73[&]I(P
MP))596&&;^)1O)4'."!SUSU%% &':^'!%J$>H7%Y)<7:S^<SE%4-^Z,0&!T
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MY7CC";0K2$,HR<?ZSH<_='6J%[X*:]TQK,ZCY*R^:+CR(F59=ZJNXC><L @
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M\V2+S@2@VAC^0.?IS5=/#^/#DVBO=%HGW!) F&52V0#SR1Z\?2JMWX16\FN
M]\XM9)9KA(A&-R2R1-$QW9Y7#L0,=3UP * -=M:TQ=.34&O[<6;MM2<R#8QS
MC /?GCWIG]O:1FU']I6N;H*T'[T?O QPI'U/ ]3Q3KK2TNK:RA,A46LT<JX'
M79T%8P\&HK%4OW$$HC6X0Q@EU29Y5"G/R\R,#UR.F#S0!H6OB?2KQ/-AN4,
M,XDE9U58_).'SD@X[Y (QR<9%3KKVDM]GQJ-M_I!VQ#S!\YW;<#_ (%Q]>.M
M94_@Z.YMY8);Y_+9KLQ[8P"GGN)#GJ#M;...F ?=\_A9[S4H-0N[R*>=42.8
M-;D(ZI(77:H;Y2"QY.[MZ4 :4VNZ;;:E+83W<<4\5O\ :7#G:%CY^8D\<8-)
M-KVGQZ'>:O%.+BUM(I)93 0Q^1=S#&>N!T.*K:OX>&JW$\ANFB6>U^S2*$!/
M#%E8$],$G@@@TUO#AFT76K*YO"\^KB3[1,D>T*6B6(;5R<855ZD\YH TKG4[
M&SN8;>YNX8IIB!&CN 6R<#'XD#ZG%1?V[I14,-0MRIE\D$..7]!Z]#^1K+G\
M+27FJ0ZA>7D,\X1(Y@;<A'5'+I@;_E8%CR<]N.*B;P>YA>-=1\K=<^?&8HBO
MD<8)B^;Y&.3DCY3D_+R: -HZYI0>X0ZA;!K8$S R#Y #@Y^AX/OQ5FUN[>]M
MUN+69)H6R Z'(R#@CZ@@C\*YEO ML\=Y&;@;9I&EB?RSYD3-.LY!;=@KO5>
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MXNR\Q:U9F2/:"86+# R<9SZTOASPU%X=A:*.1)5$201OY9#B-,[0QW'<>>P
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MEP9MLD99,-#'$5(# GB)3G/YBKU]HTLTFG2V5TEK)8AE3,.]2I4+C&1CIZT
M3_VYI6ZX7^T+;=;?ZX"093G;S_P+CZ\=:9;:EHWG?Z-=6OF7@^T$HXS(-NW>
M?P3&?]@^E9$?@P6\=TEO?&(R.S12JC"1 THE9"P894D;2!M)'?/--3P/$((;
M=KZ00K#-#,8TV23+)YF59LX*CS20"#@@$$<Y .BL=1LM2A:6QNHKB-6VEHV#
M ' /\B#]"#65J'B@:?=7\$FDWS?8[5KMY0T6PQ@-@CY]W)0C[N:FT?0Y-(C5
M5N8F)DW3,D&TRJ$V@'+'D'!R/3&!3M1T&/49-0=IV3[;8&Q; SM!W_,/?Y_T
MH >OB/1FLOMG]IVOV??Y9?S1@-MW8^NWGZ<]*35M=ATI+9OLUQ=FXW;%MMAX
M5"Y.691C [&L_4/"$5[=/=)=;)C.)@'0LF/)6(J0&!/"@]1S[5=O?#=AJ"Z9
M%=00RV]AG; \09&^0H!@\8 - $L?B+2)5W#4(%_T?[20[[2L>T-N(/3"D$^@
M(J#_ (2O2'FFAM[N.>2*%)R$=0&1V*@AB0.JGOZ>M4=2\&C4[^[GEU*813PR
MPI%M)$0DB\LA><8'W@ !R3DG/%W4/#HOKNXE%T8X[BVA@D01Y_U4C.I!SQ]]
M@1].F.0"VVNZ4CW"-J-L&M_]:/,&5YV_^A$#ZG'6I+G5;"SLDO+F[ABMG *R
MNV%.1G@_0$_05A1^#(8A>JDL#B=I&C,T!=H]\HE8$[QD;@,8VD8!R2,U;U#P
MY-?Z%9Z9_:MRI@4)),Q+-.-A0[\$$GG=R2,@9!H NRZ_I$%RUO+J5JDR(9&4
MR#(4+N)/T7!^A![TL>NZ3-+!%'J-LSW S$HD&7&2!CZE3CUP<=*Y$>"K]M2U
M"%Y4^PW<#VYE9RVR-K=8MR)T$F4&2>W&:Z"Y\,PW'B :IYB$,(O,ADC+#,9)
M4J=PVGGN#T&,4 :5KJVGWJ3/:WL$RP\R&-P=HYY/MP>?8UEVWC/1;J6R"7D:
M17MNL\$DC!0V6"A<'G.2/SJ3PWX;B\.VYACD24"*.!'\LJ_EIG:&.3D_,>@
MY/'-58O!Z)IL=G)>LZQ62V*,(P"(U8%2>>3A0#Z]>* -"\\3:/8QW+S7\/\
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M#=NBMYN =HPQ#'#*>">M '+6WC'59-"-Y.UI'+(\2)Y<:MY3LCLR2*90$QM
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M(O72W6-D,TL3LH*LKY!("GY3D#H>A'86WB31;JWLIXM4M-M\H:V#2JK29..
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MNYW\FX>,HRF'#A5XD90S$(V W(S4=WXLU>.[U@6\=H4L[>:2&*0?O'"PATD
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M6R[< G!&%.#3M4USQ#]AU7R&A0_9]1^S>7;,7C:!@J')8ABP)[#G'7H>ZHH
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M^M?;HYD:$.LBPE'_ ';B$0Y3Y]H&T=U)Y//IT=% &59Z1)::W>7XN1Y5P/\
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M;!#1"/;\K*3C&X9.,]0:CN/!<5S'>1O>N%NHY8VP@RHDMXX#CGL(\_C74T4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/M<8@8W--#D_K2L,[ZBN$_X3KQ%_T3O6O^_T/_Q5'_"=>(O^B=ZU_P!_H?\
MXJ@9W=%<(/'7B(D#_A7FM#W\Z+_XJN[H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ.>1HK>61(VE=$++&O5B!T'
MUKB/^$Z\1?\ 1.]:_P"_T/\ \50!W=%<)_PG7B+_ *)WK7_?Z'_XJC_A.O$7
M_1.]:_[_ $/_ ,50!TU\0NOZ82< QS+D^OR<?H:CO[&\DU**\LI(580/ WF9
M^7<5.X8Z_=Z<5R=_XLUS4(!%-\.M;X.Y66>(,I]00W!JF/$'B4?\RCXJ_P#
MFW_PIZ$ZW.RT_2[ZWUN>]GEA\MTV;8LYDYX9P>,@<<=<UO+TKR__ (2#Q-G/
M_"(^*O\ P)M_\*U$\<>(T4#_ (5[K9QW,T.3^M(:N=[17"?\)UXB_P"B=ZU_
MW^A_^*H_X3KQ%_T3O6O^_P!#_P#%4#.[HKA/^$Z\1?\ 1.]:_P"_T/\ \57<
M0NTL$<CQM&S*&*-U4D=#0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MALT?_P %A_\ BJ/['^)7_0V:/_X+#_\ %4 =W17"?V/\2O\ H;-'_P#!8?\
MXJC^Q_B5_P!#9H__ (+#_P#%4 =W17"#1_B5D9\6:/CO_P 2P_\ Q5=W0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!(X<H /3$9!]W3WH Z6BN%B\;7\NH:= ((,7,5J[)Y,AW&:65&_>9VIM6/<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\TN_!6LMI$CVT<2Z@NCPV"J9!MD!\T2H3Z?.C
M^J#MFO2Z* .871;T7$3E%PNM/>'YA_JBC*#]<D<5D7WA77+Z%H8I+:W%M/=W
MENTJF3=/)<M)$PPPVE5 Y.?]81CBN^HH XUM/OY8-4@NM'O")[Q+V*6VN80R
M,!'C:6;[RLI/(VG'?.#TFCK?)H]JNIE#>B,>:4 QG\.,^N.,YQQ5ZB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\R(\'FV\(6(;1EPNYVC)RI. 2>N*O:;H]_%K\32V9CCM[N\N&N]Z$3+,Q*(
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MXUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\
MHG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_
MPFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\
MX'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^
M+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!
M_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)Q
MJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG
M_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/
M_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_
M *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W1
M0!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z
M)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PF
MOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^
M-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)K
MXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C
M1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^
M!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"
M?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@
M?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG
M&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=
M% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H
M_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOB
MW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?
MXUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\
MHG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_
MPFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\
MX'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^
M+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!
M_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)Q
MJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG
M_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/
M_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_
M *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W1
M0!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z
M)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PF
MOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^
M-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)K
MXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C
M1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^
M!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"
M?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@
M?!_C1_PFOBW_ *)QJ/\ X'P?XUW=% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG
M&H_^!\'^-=W10!PG_":^+?\ HG&H_P#@?!_C1_PFOBW_ *)QJ/\ X'P?XUW=
M% '"?\)KXM_Z)QJ/_@?!_C1_PFOBW_HG&H_^!\'^-=W10!PG_":>+?\ HG&H
M_P#@?!_C7=CD#C%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>bionano-nancyridgeleasee005.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI5G\I@5?:&*%MIP<;@1G&#0!<HJO>7UKI\227<RQ))*D*EN[NP51^)(%6,T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<WX?T?5-(B,L[6<U[?WTEUJ4F]L!2"$6/CG:!&O.. 3
M7244 %%%% !7DD_PGU26QN;07]H()[6=GA);:UX?-2.0G;]T1RX/?*+7K=%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGC=(HKAX@SJS.%4 XR/F;'XTJZ'I*7$$Z:99K-;J%A<0*#&!G 4XXZG\SZT
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M%K_H_E^6 8]S('RX^9020< CFB/#&HV5GIENUB+S=?A[BV>YS"P%M*I9BL0
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M%*SQH!#L!'R@$E_FQC' /6GR>-G2TM9AHUS(]TDTT4,1,CM%&5#'"J?F)<
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M)"RY2+S#SC;@C@'=R>V"#0!3_P"$6U8WWF%K?>&W"\\YO,V?9O*\G;M^[O\
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MW)')KMJ* ,;PUI<FDZ=)#*"A>8R"/S%94& ,+M1 HR"< =23WK9HHH ****
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M84<H 0I(R<<\D]30!L6^BZ9:8^SV,$0#B0!4 "L,X(],9/3U-/72=/0(%LH
M$"*N$' 1BR ?0DD>]>;ZII.M645K;36\\UL7N9?)BWN0I,)5$V+M63B3&?E
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MB\GR@R)<ERP2WF1CT'5W4X]@>O% '26>@Z3IZJMGIUM %<.HCC PP! (^@)
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M[@W; V\@1PW&/FW%EY[XY^Z*6\\*:G=P:E TD6R[68',AP2UI%$I/T=&/TH
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M';;M'!- &["VA2NT4(M6:=,$!?OK*7?'ON(=OSJ6*RT>6Q&F1P6TEJZ"80@
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MD.%V@@X..3QTY %9DGA?7&LY(WNC(D-RD442S<RVB;RH;<"-^9%SG@^6.>:
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M.0RJ>1\QD\S)]?G);GH3F@##7QY;.MRZ64S)%)'$C*ZMO=W9 IQG:1L+$'D
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MB\.Z3I^ER+?,LL*!V:6<A1$I97(7& B@HI&.A7/7F@"&T\7P7C686RG07(E
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MLJB1U(SM5"<L1T)' />G_P#"760N=-AV;OMVS8T<\3[2Q8+P&)(RIY Q^1P
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MP21%H_W>$60L6W8*[7!XR<\8K-3QTGG27,MG/'8/:V\MKNV;IC+(RJV=V "
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M8-&@=E0$$$94'!P5!&0<$5R]KI&OQZU8//=7[VL44(#^8,J5W;UE'FX).1R
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M!8GH>A YR>^3!J.BZTT4\UO-=N\NI&22-;ILM;;6"J@\Q0OS%6(#+D YSTH
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M@#OUL;==0>_6,BY>,1.P8X9021D9P2,GG&>359=!TQ?,Q:C$AE+ NQ'[WF3
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MLWCB>;]V$:239M0%F'/SCDX P<GU@'C:Q:..1+.]:(HLDLBK&5A4RM%EOGY
M93]W=D<C(K7N-'L+J.Y26#(N9$EE*NRDN@4*P(.5(V+@C'2J,GA33Y]22[G-
MQ*L<*1+')<2,#M=G!8EOGY(X;(X% $$GBZT:\N+.)62>WN((F),<H823B+C8
M^5.?[V",@X.,5!-XWC%I)-;Z5>NX,9C1S&OFJTPB+*=YQ@GH<9R.W(U(O#.D
M0RO(EJVYW5_FF=@"LGFKM!.% ?YL# IS^'=*DM_(:U_=^7Y0VR,"%W[^"#D'
M< <CD&@#.N?%\5B]TDMG=SO"TI*01H"B1I&[Y+/@X\P=.O3'K9M?%%G>^('T
M>"&=I45F:7*;!M"$Y&[>/]8N,K@U:;0-,=I6:VW-*LB2%G8E@ZJKY.>X1?RJ
MC8>&!I^O3:C%>RB.1F<P+N ;( PWS;2!CC"@^I/.0"OJGC*.SLK^2WL;F1H8
M[GR)6""*:6 '>H^;=P5;J!G:<9XS<EUB\LH]"BGL9)Y]0F\F4IL3RCY3R9(+
MD?P= 3QGG. 9G\-:3)+<R/:EC<K(LBF5]F)!ARJYPI;N5 )R?6KEUI]M>_9O
M/1B;:430E9&0HX!&<@@]&((Z$$@T <U9>.85TD7&IVLT$P2-A]Q4FWR&,;"7
MX&[&=Q7KGI5V_P#$V/"T>L6$9'FW$4 $L1E*[IA$QVQG+XR2-I.<#!.:O/X<
MTIX%A-IA%18UVR,"H5]ZX(.00W((YSWJ:XTBSNM-73YQ-) K*X)N)-X96#*=
M^[=D, <Y[4 8VG^,8)=*^T7D,BS)$\DBQICA93%]UB"K9&=IY&<'D4T^+##>
M$21F6 &:-4BCQ(\JW2P(HRV.2V,D@=_E' OR>%-%EBBC>T8K'NQB>0%]S;VW
MD-E\L-WS9YYJ:7P[I4R.KVG#ER2)&!!:02D@@Y!W@,".01QB@#%MO&+K$TU]
M:RH0]R/LZ1@R?N[A85&=^W/SC.,@]01T,\_CBQMQ;(]E>?:)I7A^SYB#HRRK
M&0<OAOF=?NEN#FM&/PUI$421K:95=Q!:5V)+2+(Q))R2756R?2J.I>$(;S4(
MKNUNY;)UWEC$6#9=@S,I##!)'?</;KD Z2BHX(([="D>[:79SN<MRS%CR3TR
M3QT'0<5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2R2\,S1C8BOG:#\P))VMP.F.>U '245S<GC?2([C4(296-C'-)(4VMN\H@2
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M7CR&^]E3@]:J7&DZC:W^IW$,5^]M=ZLLTZ6]T1)) +55RA+C;^] S@@X7'0
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MQF+)P%4=L$BJNOZ3XAN-%NM.6/4;F%X+^&%8[I0Q9F'D&1F8%EVEQR3[@G%
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MMS(?,;@Y' "C '&<UE6/A34K/2FG21H+^:2*%EM0L3)!]J#N6;)W-L+<]AD
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ME@>)O-68-!,\;*PC$0P5((&P!<#BI?[+L;>^_M-S)YT41C$DUP[+&F%W8#'
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MC70*F3SSYP(SC'E8&.G?EN:BNM-\1WEOJ,!CNB\L%RLGG3*T4CF53 8EW?*
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M!VD/$8V2X^;S!*PN'#3+(075R#R#M'Y?6M:ULH+/S_(3;YTAE?GJQ 'X< 4
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M?9QQ,(-/*&W4N3MVJ5&3U/!/6@#/MO%^GW=G-<PPW6V.&.<"1!&7C<D*PW$
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MC>-]*%FMR([IUVSNZQH',:PE1(25)&!N!X)SVR>*U9M&L;BTU"UDB)AU DW
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M3/&F5@1F*JS\]"0W3/0GH,U6TW7Y9['5]0OH#!:V4\R*HCRVR(D,>&.XG:>
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M;6)//K]*NW.CVUUJ46H.TZSQIY?[N5E5ESG:P!P1GUH Q[?QYHMU:M/;O)(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME+QNCNCJ.N"$;K@\'CI0!T-%<S-X[T6VL+2\GD>.*Z1Y8\E<^6N-S\-R!N'
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M$U!77/)Z1*#U)X]:T-:M-67Q:UUI\=Z/,@LXTDB*^42L\AD$F><!'/Y\<XH
MU'\):0_A^RT00R)9V)1K;9*RO$R?=(;.<X)'XFA_"6D26U[;R132+>PQ07!>
M9F9UCSMY)SGYCSWJIX8CUT7UV^KSS'.X&)XL(&WG!1MQXVX& !VSSFLJZM/%
M*:=IXCO;Y9)5G:XD""5XYLJ(1M!7Y -_'3.-W7- &S<^!M!N[N[N)K>9C="7
MS(_M#^6&E3RY'5<X5F4D$CU/J:LS>%]'EO!<20MYQ:V(/FD9-NQ:+C/8L?KW
MKFM0G\1KJEU;127RW=Q'>BW&4$#8C_<;/0CC/OG/:K%\WB*]6^NK6TNHB'N#
M9K*J!T'V10F.3C,N[^M '3Z7HUIH\7DV0E2(!L1M*S*"SLY(!/4ESS]!V%,M
M-.TS2[A3"5CE6,0@-+SM9V8#!/=BV*Q);37X/$=K%'>W9L42$K(R"02'<QE#
MD$ $C: 2,#C;R"*PTM-6%I>7.HQWHO)K?3X=]R5(-VMPQ/E[?X0S*1VQTH [
M ^%]/(E :Z4/.;E0+AL1REBQ9.?E)+-[8)'2I9/#]G-<0SR2732P1E(F-PV4
MRI4L.?O8)YJEKVK2OX6N+RP-S$ZW*0JR*H=L3K&2N[CGG!/!!!K#DC\5.;98
MY[Z"U+S^4[QB25?G7R_- 89&W=C.1C[W.* .ACT#1](:"X262T*$(7-R4$I,
MC. V3AOG=B!_M$=#BKVG:1;:4'6U,PB;[L32LR1C).%!Z#)_ITKGCHVI7=YI
MMS=S7CM'K-Q*R&0!8H MPL6 .Q!C]3\U4[2#Q1/:I'))J,,CBT6[=V3(E\T>
M>8NN$V9]L8QSF@#H9?">DS-;EHI1Y!^4+,P!_>"3!YY&\ __ %JD/AO3PLHC
M$T1E#*S1RL"0TC2,/Q9V_/%<_>Z=XC>>Z:&^U%5)N1&J2)C"HIAQD?WL_7H>
M.*UM7;5@VCRVR3NPD7[3!%\JMDKDLV>-HW'!!!Y'7!H T6T6R-OIT"(\<>G.
MK6P20@IM0H!G/(VL00>N:BTO1--TJ=_L>_>D2Q*CS,_DQ9)5%!/RK_@/08YQ
MYO%#PM%Y%\ODKMF==F9!]I7<8^>3Y.[!XZ^O26/3M536SJ-LVH(A-FFR9E^>
M,,XDWCN0K ^HX[YH OV/@O3K:Q$%Q)/<2X4"4RN#'B3S!L&3L^;!X]!V&*O?
MV5ICVTCR2M*ES;BT>5YRWF(Q.!G/4ESC'J!Z5FZF-;/B)?LWVORO,MO(,97R
M/+W_ +_S,\[MN<?\!QWK"TO2]<73[:S>WOA#"]DTD=R4P'2Z1B8\'[HC&3^'
M?- '7_\ "/Z;)?)>A9"P9)-BS-Y;N@VJY7."P  S[#T&!O#>F-90VAA;R8;,
MV*#S#Q"=N1G_ ( O/7BN*M]2U.U\1Z7IMU-+ D20[XHY%7<[&7Y#&.6#?N\M
MT4*?4U:M+;Q#=&UFOXM22*&_BF\L2Y=5,3*XSG+ .1Z#J0,4 =A+H]A<V&H6
MC(6@U N;C:Y^8LH4X(Z<#M4<?A^TBNXKI9KPSHJHTC7#$R*K%E5^?F +-CZD
M=*YH0^)(GCC2.[C(*FW$.P1AS<R&3S1_=\KR\?\  L?-4C6WB-(YW-W?#SEN
M2WRB3RRMROE!5&" 8BP.#G'/4"@#;?PIIDD<R2?:76>42S;KACYI   ;GD *
M/RIY\-:<8+B#%QY$TGF^4)VVQOO\S<G/RG?\PQT[<52O6U631-&9H+V'++]O
MBMI \ZKY;<!N"?GV9(Y_#-4;.W\4>;9W%W/=>9&+-9(@R;&SD3E@."<8SC@$
M<4 =*^F12Z:;!I[DICE_..\Y.>3Z=>.F.*AF\/V$MG96JK- EDH2W:"9D>-=
MNW&X')&WCGV/4 UE:D-5M]:UM].M)FN+K3(DLYPH,8F3SR Q)XY9.O'-484\
M0Q06<GFW]R/MF3 \1B.PA 0S[B< [VYR#DC^Z: -V+PII,%U%/%#*@BV%(1,
MWE HFQ#LSC(7I^?88S-7\$6%Q96T5O*EM%:E&/G;V4B.(QIDJZD;0<YSVYK/
MG'B=K=HD:]$0O6,EQM_>/&4;&$#9 5MH^4X/!QC<*MVMGK]SKQ@U2YF>Q9%1
MU$&(YXC;@/DAL(WFECT)X !P: -2#PIIID^TSM-=3R1XED:4A96,0C9RH.,L
MJCI^&.:>/#>ESQQR(\[.@C$=PMPV]3'O"D,#UQ(X/J"0:9IB7\/B2^BD2=M/
MV#R7?Y4BP% 11D[L_,=PP>Q[5R]K:>)[33YX+%+^+:#YJS;".;D']R ?^>)D
M[@_=_BH ZZ+P]I$1$$<6&"6_R^:2V(96DC)R<GYV8DGKGG-21:+IMG;7T<FY
MTOSMN&GE+&3("!<D^F!_]>N7&F:_YL=\MS>/<Q6RA&VB/S/]()".I))Q&<<G
MGJ>>BRP>(;[4;M);6Y%H;NWD6.1PP'EWB-N4YZ>6-V ,8XY(- &_IVA:1#,7
MMI9+B:"Y\QW>Y:5EE$7E8;).#L.,?C1#X2TFWEMGBCF5;<1[(Q.^PF--BLRY
MPQ"X&3Z#TJ#PQ$=)A_LN9+DW$T]Y=%G.X*GGG;D]BP8$#OAO2LF;_A*)]3U!
M84O;>!VVH=ZMMQ<( R$\<Q;FP!@=#D@T =%!H.G:=;0#?*(+-Q+")IV*PA5*
M@#)X 5CU_I4VHZ+9:I*)+E9"P@EMCLD*AHY  RD#KT!]B*XW7+#Q%<:3=:>1
MJ4\30WD4/E,A9V+XB\TGJOEDC\\_-MK3\87.JC4K6TTM[WSI+"ZDB2U*@&=6
MA$9?=_""QSVYYXH W7T&P>X-QLD64R>;O21E(;RO*R,'CY#C]>M$6@V$.EC3
MUC<P>>+@[G)9I/,\S<3_ +XS7-ZI%XBODU'35BNPKI>!9E951@T?[D*V<]21
M[8.>U:&I6=Q<:7H;Q+J.+>ZCDF4.1+MVLIW<\\D9]J -&]T/3-7O(;Z7>\D1
M4!HYB%;RY Z@@'!PZYQ^=0WWA32+VQ2VN(Y%A03+\LS(=LIS("0>A)KG5T[Q
M+IUC.M@]SF8W$CHQ5A'F[!&P<8)B:0CGDXYS6C>:=J=_X'^QRLUU=/<Q,/M,
M&/W8N%;#H6RP"CN<D#GDT /MO!D:ZI?W4UX)+:^,C2Q(K*9-S!E!.\CY>0-J
MJ3GGOF_?>%]/O+R>]_>)=2ACN\QB@<Q&+?MS@G8<5D+H6L:5&]OIET^(K.YF
MA2-5B@-T[ED79SA!N.%SC'7-5XK/Q'/8)']NU%0TDK$E!'(F(?E4DEB1YG/U
MX^[0!O:=X8T[3!:$M+-<PNC+--,S,66)HP.2> KO@>Y/7FKG]BV/]CV^D^6W
MV*!8E2/>>D9!4$]Q\HSGKWKFH[3Q"K6XEDNI=LPE,SK&[QEK.4,5' XE*X''
M7'2JX7Q5*NG)ON[:-0X,@0RL\@D&&=2P(4KG 8D#)SSM- '6ZEH]MJEI=VUU
M)<>1=1^7*J3LHVX((&#QD$YQUI]E9&VFDE^USS(\<:(CN6"A<\^[$L<GN OI
M65I0U0G6HKI+B12[&WEFXW9+_($R0 HVC(X;(. <U0TJT\0175C+/)<K&DL,
M3P941B+[*-YP!_SU_+''!.0#4A\)Z=;VUM!%)>(MJ-L#"Z?=$N-I53G[N ./
M8'J!4\WAVRGNIKEWNO.EC\K>)VRJ9!*CGH2!D5R>HZOJTOC+4;&RNW2:,21V
M4?FJ4>7[('5&C[ ,2V\\=%]*M :Y@<:S_99N!N!9?M6/*.>^=OF;??.?X: -
MR'PQHUC/;R1H\2QF,1PF=O++H@C1MI."P0 9]AW -7AI%F-*MM,$9^RVWD^4
MNXY'E,K)SU."J_6N0CM/$=SJ&D_VHEY)-#+:R.8RGD "+]X6Q_'YA/3MC'&:
MU;X:V?$O[G[6(A/!Y)0K]G\C_EMO[[OO8_X!C^*@"]=^&]'DMW^T1E8U$[,Y
ME*[?-E69SG/'SHI]L>E1CPI8QWFE31%@FGS3SJ'8NSO*26RQ/3<=V.>0O3%<
MQJNF^(YO"L%I,VJ7,]SI<HF6-TS]J94 5\X 3&\8''7OMJ[<1>*GN=::.YN4
MD\N<6R)$"A!(\DJQ. P';'))SVH ZE](MFU7^T5::.<JJN$E*K(%SMW+T.,G
M^O055_X1?2_LB6RQRHB06\"%)6#*L#%HL'/4$DY[]ZGBF<6]Y8V;327-I&$6
M6XY#2%<@%NYY7/U%<O*->.F6HC77 ?(F\W+1^;]JVQ^7WQY>?-_V<X_AQ0!T
MG_".:?BZ3$_DW+,[P^<VP,S[V8#/!+<_B?4U+J6G6.K&**XD<202;D,,QC=6
M*$$94@\JS<?CVS7.36_BM)KBXAGE:Y:1XXXB5\@+]DRK ?\ 7<8R>>3VJI9Z
M5JLMT[K#J"Q3W8)DO&3S0GV.1"<CD?O"HSUY]* -RT\'Z;;Z@\K/))$OE&*V
M,C;$"1"-2RYPQP#R1^>!5JT\+Z79F-HTF=HC'Y;2S,Y18]VQ02?NC<W'OS7-
MVMKK=O86NR&_6);.RBN2"IN/E>;S0IZDC*=_ND[>:FAM_%#B.62:]4PB Q1E
MD^=3=/N$F.K"#9N]R3UP0 =+)H=C)I4>G;9$@CD61-DA#*ROO!#=>M1S>&M+
MGC:.2!F5A./]8P_USB1R"#P=P!![8XK.UU]:_P"$@L%T^&X%NKPF21&!1E,F
M)05[83!R<]1@#!-9BP>)X+$%YK^7S8H&N &0R(?._>"/T/E^GIQ\W4 ZH:9:
M7.E26,DLMS;N2KL\I9B0W(S[$8Q[5-/IUK=727$T6^18)+<9/!20J6!'?.Q:
MYJRL-5B\'16L1O+>ZDU)W=BR><(7O&9B2,C)C8DX]>*S]4D\26$7B"[:\NHT
MM[6Y:W C#(5"#RF#%L!@1D\9)SGC% '5VV@65LEJ@:XD%K)YD'FS,^P^6T>.
M3TVNPY]<]:CA\-Z5$8#%&P-LD449$K941*ZH.O4"1OSKEM0;Q2NE7:V$.IEC
M-*UD\KKYJXB3:' /(,GF8R< #D$%16O!;:FNO>9<2S6VFQRW4\A0JJO@P^7N
M[D8\T_AS0!?C\*Z;"ZRQ&Y2<.[M,L[!WW[=P8YY!V)^7UJY;Z1:6U]=WBB1Y
M[M0DC22%OE!8A1GH 6;\_85EZ_=:A>>'K2;2[:\62YVL0IV20@QLPW+GKNVJ
M1D8)R3@&J%O#XH:XANWEN!+YL:F%BHBVFT^<D#_IM^6.."<@&MI_AC1].>..
MV60O T<BJ\[,4VHR)P3TVEA[X]:>GAG3D,3PM<QF-I"C1W# A9&#,G7[I(!Q
MV[8K+\)6FHQWU]=7\=^&FM+5"]X4+-(OF>8!M[ M^O'&*RD3Q"/"^@6-I%?6
M'V6R$%R5A#.)EC0(0 PW*"']LXR,4 =U:V4%G%)' I59)'E;YB?F=BS'\R:R
MD\)Z<EL(5DO05G>X6073AU=]V\ALY&[<V1[Y["LB\'B 2ZJB/>LI,;Q3*A X
M89B50W0@'YU.1NY!(J)E\72:A=2QO+;R>03;0.HDB.;885GW8R)LY.,G']T\
M '37/A_3[FTL[7RY(8K-=D'D2M&47;LV@J<XV\8^G<"JUKX8T>SU&&:!7$T
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M]!=;=4GCN;2S9WD=0XE8,9'0+R4QY? QU_WJ .Y.D6;0WT1C.R^7;.-Q^8;
MGX?*!TJO/X;T^>3S<313;UD$L,S(ZD)Y?!!Z;>,?CUK TBX\0G6-)T^_FDS)
M8Q7MX6VY1U0QO&<=-SE&&./E>GW=IJMMJ>KR0#43#<7L$C&%\DV_EHKB/)X;
M<IR!SMZ<XH VE\,Z5$4\N)XXT2WC6-96"8A<-%QGJ"!SW'!IJ^%M.2%(HVND
M6*7S8-MR_P"X.&&$Y^48=ACI@X[#&=<PZK)X1M/M,%Q<745_#,8_E,ODI=*R
M[L<%A&!GW!J%SXAN?$,\RS7EK9E=UO&MN&'EF#H<M@.)<GD9X S@F@#I+G2[
M>Z2S60RYLY!+"XD(8,%*Y)[Y5F!SUR:ATW0+#2IC+:I+D)Y48>5G$29SL0$_
M*,]AZ = ,<[:-XB#:63#=L5,D<B2,0K#)Q*Q)R.!_JVSP>#D5#96_B6XBBBD
MEU.&-S:BY:5D$@DR_G[",X3&SIQ_=H Z!?"NGI&$22[4),9XB+E_W+G=DISP
M#O8$=.?85-+X?LY;LW3277GB'R$?[0V44[<XY[[%SZX/J<YOB=M:%YIZ:5%<
ME596>6-QM.)$W*PX_@W')_ 9Q4NKC5O[?M?L/VAX'@=&4'9'$VU\.6S\QSM&
MTCT(/6@"U9^&=-T^2)K1)HE2-8C&LS;)%4$#<,\G!//?OG JSIVD6VF6AM(#
M,T&T(L<LK.$0# 49[8KF;;_A(M2DM$G74+. O L[$HKX$,OF$$$X!DV#/7N/
M6M#PO#KD"D:I-<2M)I]K(QN"IVW)\SS5&T# &(^.GYF@"UI_AJWL4LV\^<SV
MUO';&1)"@E2/.S>H."1D_7)[<4U/"&DPQJL"7$#"02AXKAU;S-I0OD')9E.&
M/?@GD9KG;&/Q2--B:_GU!RTL/VV*&,+(GR2>88VW'(+^5]W  !QU-.TN_P#$
M5S8Z=($O9Q<Q6#&;Y,)B=OM&_!&"8]HX'/;H: -W4?#-E+I^H6T=S-;+?JZ$
M&9B@=SDL%R/F)YX/4D]2:M0>'+"VEAF3[09XYFG\YIV9W9E"G<2?F&U5&#V4
M5S5I!XAO;YC>6MRENMW:3)',X;8PDD\W!SR !'T 'H.M7-7M-6BUW5+JQ%\1
M/:6BH8G!7:LS><$!.!)Y9RON: .@;1K)K_[<8SYXF\_=N/W_ "S%G'^Z2*9_
M8MA]@TVT0.D5@4-J4E(*[4*#GO\ *2#Z@FJ>F1W#:!=)JD%S/"99/*AF :9H
M<_*& ZG'8\XQGG-8-O93Q^'/!J2Z1=F[T\PK(/+!,(2/:_?N<=.HS0!T,GAS
M1Y(1"4($2;01,0R8D$@(.>"' .?:K4^DVEWIZ6$TDSJC+*LGG'S%8-N5@W7J
M/IVZ<5S']B,-1U2..RN?L4OFW,TK6T0E:83+*B1M_P M$/S<-D8"C(Y%7/"E
MAJNE7DME=VZF!8$47'4X5(PB!L\@9D'"CE2W\= %^3PWI-O<G4I9)XWC&]I7
MNG !$1BWDD]=AQD_7K2VWAO2K<0W-L\R%=SF9+AAYH9MYW$'!!//MDXZFN9G
MT[Q#J=C+;7(O\LJ&Z#NH4S"="/)Q_!L#_AM[YK<U[3KJ75["6!;MX5LKJ!A$
M_P N]@FS>,\@[6Y]<4 :5]H6G:M.MU,)&W1JC^7,RK-&#N56 .&7))_$]B:D
MDT6QETRZTYXF-M=-(\J[R"2[%F(/4<DFN0^P^);#3+>T@FO&ME-N9F.'D5?)
M<.%VD' D$? Z9..,BMK4%U9-(T9&DO9B-HOY+15CF?\ =-SC/&9-N0#^F: +
M:^%=*%M+ T<KK+#/#(7E8EEF*F3G/<J/IVQ5N]TBVOKJ"ZD,T<\*LBR0RLA*
ML02IQU!*C\N*YF1/$;WMT%DU"%S]I#2;4>)8BI\DQKGF0':2/4/GC;4^BVVI
M'7+*]OH+V(-9/$5:8N@99&P6!.064@C/(Z$Y% &M/X?TF1'AFCP+E+F'!D(+
M"<[Y0.>IVY]L'%.D\.:?(+Y&$XAOE=9X1,P0[QAB!G@GV[Y/4FN>;0[Z?5MC
M-J$<8UI[DS"7A86MI5!0G.!N8*<<C(^M&FIXJDU+37OY[B)1;0&15B#([>7^
M]#D, K;^^.PQW% &C<>$A<>*)=7:Z79-A98O+;+1^7L,>=^W:>IRN>V>F-&'
M1;&QBMV:29DLG,T3SSLWE_NV3J3T"LW7ZUS"VGBF.#1$:]O0S6L;W,A02D7)
M*EPX!4!<9 _A^]WQ4>HV'B'4[+5;25;\^=;722JSJ(V;S!Y BQVV;@?8_-S0
M!TECX=TJ"!'L"WD/;)$$$S/#*@C"*S+G#?( ,]P!Z"I-$T$:+:6%M'=S/%:6
MOD;22!*Y(+2MR<L2,^VYO6M&V;"O#Y<JB$B,/)C]X-H.X'/(YQSCD&IZ ,D^
M&],9)E,+8F$@?]X>=\IE;_Q\D_I6M110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 8&<XY%%%% !1110 $ ]1FBB
MB@ HHHH **** "BBB@ HHHH 3:I8-@;AT..:6BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *,#.<<T44 %%%% !1110 4444 %%%% !1110 FU=V[
M W8QG'-+110 4444 %%%% !1110 4444 %%%% !1110 4$ C!&0:** "BBB@
M HHHH **** "BBB@ HHHH *" >HHHH **** # .,CITHHHH   .@Q0    ,
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M+AM(L/LOEK<'%R^_R_M/D$8VXW9^8<XQQS7?2KI4$4$A@MR(0&@$<08J">J
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M+A<=!D9] .>M=6391333DVZ2@ 2R<!@.VX_XTXK:;Q&1#N?.%XRW.3QWYYH
MXBZ\9WD.J2W(2!K:WM;[%JDWSEHKB*(-)Q\H^\<]@3Z9JS=^+]6MK/S?[,MO
M,BMKJZE#SX#I"T8^7;NP6$G?H1WKJPM@#-.JVV2/WT@"\@@?>/TQUJ.)M+29
M-/B^RK(82ZP(%&8R>2!Z$B@#F[KQ9JEO]H@%E9M<VHN6ES*P0B)(W&WC.2)
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M,?X>>IA2PA1#"MLB%OE*!0-W3C'?DC\: M@&\T"V#0#RMX"YC']W/;Z4 4]
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MD<L,S*K$J,'='S@>E63XGDU7P=K>J64;6_V:T<Q2%LL)1#O88Q_ QV_56]*
M+PT*X'@RUT 7*AEMHK6>49^:,!5DV]P2H8 ]LY[5)KNFWVHZ'J&F6OV2-+B$
MP1%]PV*5().!VXP!6-)XSO8F%HNFP3WIF\M?(G9XF'DB7[P3.[!QC'3YO:M7
M4M>N+6.P6"TA%Q=PO.5NI_+2,(H9E+ 'YN1^ 8]N0"AJ/A^_U*XOUDBM?W[6
M5R#+EXF>)\O&1UQA5YQ_%TXQ4VC:#<Z=JE@7">5;6]V6:,80/<3I($0==JA"
M/IM^E9EIXNO);NY;RD^RW,\:0J\N)H-]DDP&S;R 0V>>Y_N\PCQM>6&E(Q@-
MY=OY2HLCX#-]ECE(&Q"1N9L<Y )SD# H TG\+WRVMS!"=/\ WEV\_G-%^\F1
MY&<JS%3MQN !&>G\.>(]/\$M:1V#236\ES:16,8F\OYL09#8/4!@3^=,UGQE
M=VAU2VM;>W::VL;F>.3<Y598D1F4Y0 _?[$]!GKQ<;Q5>1ZO)9G2_-CM@HN9
M(7)VDQE\KE0".@Z@G)XXY *4/@9[2SMX[=K,M%!:))&T>([AX7=B7QZ[^N"0
M1GFK^B^%Y-)U*VNS]E?$,R2;4VF/?*TH6/\ V1O*XXX ^E)X<UK4-7U#4&F%
MLH%G:S0PPS^8BF02-RVT$$C;G@\ $=:H6GC/4!H=C=7%I:23?V;#?W6V<KN6
M0X C&WEN#QZE1GG( "[\#7%Y/J'[^T@6Y-TRSQ1GS6\X8"OZJ,9Z\X XQDZ*
M>%R?"NHZ25AB>^+%P':1,D =P.R] !_,T[Q!XFFT6\,,=K!,D=J;N3S)RCE0
MX4JB[3N;GCD<X'>JLGC4Q7U[']ECDMK4&1ID=QB-)A%*QW(,[>6XR/E(SW(
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MF>;(8\N O!XS@9SG'O0!M>&?# \/",(8 !I]M:R")-N^2+S-SGUSO'OQ64?
M\XL&MEFMMSZ;:VCR["&+0.6Q[HX.T^P[]K,OB^_MX+J:;2$C6SL%NYT:<[MS
M/*BJ!MZ9BR2<$ ],C%-N?&&H6UNYETN&*>*"XN7$TYC5XXMGW<KG)WCJ!C!Z
M\4 13> X[JR$4D=JK?9YXPK9E"222K)N4D#^Z>@')K;TK3KG2;N2V@BA%A-+
M-<$I\OEEBNU%7_OLG\/6H- O;NZU36GO90L8O%@M8B_W5$*/C;@<_,2>3W[
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M110 4444 (0""" 0>H-4QI>EFVDM18V?D2MN>'R5VNWJ1C!/2K%S$9[2:%2
M9$903VR,5R.G^!8M/N;6>&.SCD@:V;?''AODC*28..K9_'O0!T5TFEVIA,]M
M!^_"V:?N@<JV<)T^[QTZ4L?]E:A"42&"XM[N,3,?)W1RKP 2<;2< <'G %<W
MIOA'48?LBWDMFT=K#96X"%F\Q+?S02<@8+>8..<8/)JE<>#KVUT"SM(;6RE,
M"6ML84!V2A;J)V=QM'!526'/?K0!UXBTC^TK:V%K;?:8(?,MR(1^[3./E../
MH*LQ?98IGBBB6-HHU!(CVJ$^; #8P<8/ /'MFN-G\)WUGI-Q<0+ ;N&*6>UM
MK<$JDWG^?&BY ^7("GIG)X .*M1^"3YUI]H>WN(8UMC.LJY\UX_/+L1C'S-,
M&_.@#IULK% R+:VZ^;OW 1J-^[&[/KG SZU6FGT>RO9;IDMUO"\5O+(D8,F9
M&"H&(&<$D=:XNT\-7UCXJTKSK+[5#91P1QNJ@(NU9 6#%20%#_=RN<#@]]W4
M?"0OM4OYC;V+0WDUI+(SK\["*169&&WD$+Z]>W>@#I&@MGA>%HHFBFSN0J"K
MYZY'?-)#:6EJ(T@MX80JE46- N >2!CMP*XY?!$Z:A:2;X)+:&1MD0?R_LZ_
M:7F4Q_(W\+*I *_<'.*U=4\/W%[K<]V@M2L]HMND\F?-LV'F?/%P>3O'=?N]
M^P!KC3M-%JUN+.T%NPV-&(EV$9)P1C'4DX]2:;:6VEM+YUG;VGFVX-OOBC4-
M&!U3(Z >E<D_@J\:R<16^F6T^Z$Q10L3#&\:.GFE3&0[,'P5('"CYL@&MB#P
MY)#IOB"RA-O:G4GF:*Y@&'!D4\L,#E2>.3GVH O7K:193QS36L+7%_)]F#)
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M+2U$CH(781KEDZ!">X]JK7EIHMAI;27%C:+:6*-<!! I$04$EE7'!^E<U>^
MVELK>*);5R);E[B,D1B;S6R'+;&.Y1P#C."<$5!-X.OM0N]7/E6ML))+A8[I
MB3-,LEMY05N/N;CNSGJHX[T =PUM:3W,=R\$+W$0_=R,@+H#Z'J,TR2QT^>$
M126MM)$RJH1HU*D+RHQZ#)QZ5R=]X.U*]U;4+HW%FB3V\L*;4 ,@8QD*X" D
M?NR"2S9#< =*E?PC/-K-E?-;V4$,2Q VUO)M6W9)FDW1GR\G=N&<;,[><@\
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MU8XQT1, D<@*.IZFJ%UX,N=4^U2:@MBTDZW96/EUC>5(E0@E1G;Y9YP.O H
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M1;.1%,J'"H!DQ#D*.6Z<FM#Q9X>N]=U:&."VMFB;3YX/M,^<VSLT>'3 /S@
MD=.G44 =>749RP&.O/2C<,XR,^E<??\ @QYK=S"+4SR:F][,& 47"$2!4=BC
M?=W@C*D9';J*UKX3NUUU&6VMHH;4VACNY&+S 11X*H<?,#]TDE>,\'/ !W(9
M3T(/..#4-Q=P6H#3.50AFW[254 9))Z 8'>N"/A#6;'2IY();==3:>W,#6J
M+&Q!AD?:J( -DC'&#C Y.!72:KX9COK*RL8/*CM;:"6 (ZY 5HC&O'?&1^5
M&ZDL<BJR.K*PW*0>H]:?7+Z9X=NK+6+"\%O8VRPVH@G6%M^[ ; 0%!MY;.01
MG)!4\$=10 4444 %%%% $-W<I9V<]U(&9(8VD8*,D@#/'OQ7(S^*=3FN+"WB
MM+:&Y>>W?8+K=%)%-',54OLR"#'DX![8/-=I6>-"TA;5K4:58BW9][1"W386
MQC)&,9QQF@#F[7Q5<7FH0RG?%!-'9GR592$9VN _S%?F4^6O/' !XR:2V\=7
M-SHK:E_9<4:NR"W1II29LQ&1@ (2<J!@X!7@\\5UATZR*!!:PJ BHNU "H7.
MT CIC<<8Z9.*RM.\'Z-IT#P_9([E'V#%Q&C ! 0N % R QYQDYY)H SHO$]]
M<O/*8(X[3S[!86CE_>8G:/(8%2,?.>ASZ8Z@7QK<-!%*-,C/VM(I+11=<LKS
MI"/,^3Y#F13@;NC#M72C3; 2B465MY@5$#^4N0JG*C..@(!'H:2+2M.A>5XK
M"UC:9Q)*4A4%W!W!CQR0>03WH SH_$#GP]+J,T$44T5P]L8C*S*9%F,6 RH6
M.6'&%R<@8JGHWB6^UC5;2,6<$5I+:RR29E;S%DCE,9P"HR,CO@\]!C!Z&2RM
M)K:2VDM87MY"6>)HP58DY)(Z')Y^M,CTVPA:!HK*V1K<,(2L2@Q!OO;>.,]\
M=: .>O\ QI]AOM0MULDG6VM9YT=)'&]HB@9"2@4'+_PEL8YI+CQE-8B2.[TU
M%G6:2T18K@LLESM1XHP2@/SJYYQP5/!KH#I.FFXFN#I]J9IU*RR>2NZ0'&0Q
MQDC@=?2DNM*L[N6"22(9AN1=#: -T@4J"WK@$?D/2@#+UO6+^PU:*VAAA-JV
MG75U(_F$2*T9C VC:1_'W]?;!I?\)7J+726]MI<$P:=;599KPH6D-J+@D@1G
M VY&1WQP >.GGLK2Z>-[BVAF>/=L:2,,5R,'&>F1P:%L[56#+;0A@^\$(.&V
M[,_7;\N?3CI0!SNF^,'U74;>&VTN4V\B1-+*2V8O,A$H/W=N &4?>!R3QQSU
M"L&4,I!4C((/!%5!I6G"XBN!I]J)H4$<4GDKN1,8V@XR!@D8'K5F**."%(88
MUCBC4*B(,*H'   Z"@!]%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1\\J%VOM^;[XZ@9]N2+'_"6:+Y4DGVI]B;,'[/)^\#.$4I\O[P%B!E<CD>M
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MW)N9'7:R$L"< \ ;3UQ].YJVOB>.?PS?:U+9S0):"8M#(?G(CR>?0D#IV/%
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M-Y.W;Z#H<'Z]* -&BL,>*],>XLX(A=2/<W1M!BUD!C<1^9\X*@J-N#G'0YZ
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MN@=D:1M*YP"3P@). "<XH V:*R3XETD).XN7>. QAY(X)'7+[=BA@N&8^8F
M,GYA3SX@TT7L=HTTBS2%  T$@"LPRJLQ7",1_"Q!Y''(H TZ*PY_%%D/#O\
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M09$ZD-O+%(MJL#@#YD P.#GFGIL_BL+8S7=S>2;HK"6:%[-%&Z9BLZ'" @(
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MG5[.5P%V QN (>6SU!9CU&W(H W!H :[ENFO+B(W04WMM"5\F=P@7)W*6'
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MG>#M-TN*.&W:01Q2QR1+LB4KY>=J[E0,PY_B)/'7KF&_O]5_LG1I7^V6GVA
MU[):6AFEB;R\A=A5L#=P?E.,8XSFHO#5EJ,FL7>J:JDL=Y-86J,#$H6-MA+J
MAVYP&[9(R?I0!:/@ZQ$L;1W=Y&JM$SQJZ;9?+F,R;LKGAV/0C(.#FFP^"M.M
MX9HK>::$/*LL;1I$&A99/,&UMF6Y[.6XKG(X?$$=E9WD-QJDE]9:;>;S-:@M
M+*)(BL1RG(;:<$<GLW%=!I%YKD_B>\BO=T=HCS*L30MMVA@(V5_+"Y*\D>8W
M7H,$  O?\(W;_P!A?V5]JNMGVC[5Y^Y?-\SSO/W9VX^_VQC'%5/^$1@34=)N
M%F>064L\\KRD;YWD.[Y@ %QOPW &"JX%9%OIVJ64VK:T$G0I+=JD4"L9IPTH
MV,0P(PH'RX5C@\>AGTR;Q)J4=M'<7%Y:KY-X7<6ZJSLLH6')>,8RA)^ZN<9Q
MU% &]?\ A^VU&[GGDGN$\^!()40KM94<NIY!((+-T/?G/%5+WP;IM[=BZ=I!
M,)))-Q2*0?O-FY<.C#'[M><9]^37/0W7B"WTF"6".^EE-C8I-<3VQ$X/F2B7
MCRR25^7^!L [L'.3KZ9?:U_;&G0WCSS0RVW[SR[9HT1QO.]R\0Z@*, J0W\&
M#P ;T^EVMQJMKJ,J;I[:*2*($ @!RA)Z=?W8P?<UDGP5IK:A=7C37+27&\-R
MG :1)",[=Q^9!C<3@<# K*N;/5;G7+F'[7J85=:BEAD, *0PFUY,9*;<;MRG
M.<'&1DY)!JOB.2_T6"2*^0R11B\8VV(SN#AF_P!6=K A2<NH&1\I!H Z*?P_
M;7%]-<M/<#SI8)GB!7;OB8%6Z9_A (SC'H>:SXO ^FP:5<:;#-)';3!5VB"W
M)55SA<F/+=>K9/ .<YS1C75C\-K4&[U8:E$(//D,/^D JZ^8 -F6& W.#N'<
MYYA/_"0:?=:G=:<MS<?:+B8QV\UN%1B+161R=H8$R(%Z@<XQF@#I[O0[6]2)
M)7FQ%;2VJD/DE)  Q).<GY1S6>W@K3&EOG#2J+V)HI0$B)^:/RRP<IO!VCIN
MQGMS5:TDUJ^\(:QYEQ<F[:.06KB)HYE/EC ^:*/)W9P0O?&214%K?Z\^MV,"
MR77V'RH3ON+5P9@0WF;\0_*P.,99,8&0<T ;<_AJRGUV/5\LMPJHK#RXV#!"
M2O+*64_,>5([>E4W\&6;VHMOMU\L/DR6SJ&C^>!SDQ'Y/N]@1AN3\U9#3>+1
MHEA,MW>&\;3&NYU-FG_'Q^ZQ"5V<#E^/O<=>*M_;=>M;^T@EDO;B%;YX7*VH
M#S1DQ[79A&4"KN?/W,@9!R,$ W]0T:'4;F&=YIHFCAEM\1E</')MW*<@]T4Y
M&#QZ9%9U[X-TZ_B\MYKA5_=@@%&!V1M& 0RD'ACVZX(QBH=6OM9C\0K#:_:A
M$'MA#'':[X95:0B8R2;3M*IR!N7H/O9Q5"'3-0L/A_>)!+?QW[W,D[R11*)V
M_?9)PJ?,2HST).>.PH Z33-%@TJ:1[>><H\4<;1.5*Y10H;IG.T 'G''2LQO
M!5G)9V]K+?7<L=JY:V\U('\H$$%0#'@@Y_B!/ P166\6LVU_JD]L;R:VO+MD
M,,EJ,.GV!2)/N@Y,B!.RY)&,UJZ%=ZFVLRVMVMP;86R-'^X,<<1"H"A)098D
ML059AC((7 R 3S>%+2:XN)S<S!IK<6Q B@VB,%3C:8\-]W^+=@$XQFFVWA&R
MM9(/+NKPPQ&%V@9U*2R1*%1V.W=D!5Z$#Y1Q6+_:6KVVBK;6<%^EPFJ7 NI&
MM904A:29D9"8G# GRQE5; ;MU$G]J^(AJNGP%;G:8 +J06;F$G[.[[U'E!A^
M\"C!<'/&SH: .C70[5=!M-'#2_9K5(40[AN(B*E<G'^P,\5G7O@K3;Z:.26:
MY&R9Y]H*$%FD$A^\IV_,HY7!QP2:Q?[6\4O%IZ(MU'D2"2>:V9A)('4#<JP9
M"$$XRL9/][C)O>)-:O[7Q)9V5O=R6ML%ADGD2$.H#3;2'.QL956 /R\GJ0#@
M O7'@O2KC[<6\T->7"7!)VL(V4E@%#*1@LSL00<EV_#1&BVPLK*U+/LM)5E0
MJJ)EER1D*H7OV KEXM4\2[9I@MY(\,33W-O)9;0C)*O[J$[09-T?F $%N0IR
M,X+X=0\4OJVGI.'AAFCAF8&!BOSR.9(F*QM@HFQ02R<\G=S@ U1X/L5==ES=
MK$0@FB#+MG"2-(H;*YX9V^Z1D<'-6M0\.VVHWYNI+BYC$B1QSQ1E=DZQN70-
ME21@LWW2,YP<USLLWBL:-;S)=7GVIM.NKN119I_KU\ORH<;. <OQ]X\X(P,;
M&MK>G6]*>*:]2V:.=)8X(]Z,Y"E0_P IP.&YXQZC- ")X.L0[,]W>2KN=HD=
MTQ#OF69PN%!P71>I. ,#%4+CP;.GB"VO[&XC6*-@Y,P5F4F>263 *'.[S"HP
M5*XSD\8S;6;Q/I6A6-FGVN2-;>SWRM;X> -'('10L39VLD8Y1B YSZCHIGUJ
M;3-!C6YDBN+B55O;B"WY5?)=B=KK\F651RHP3C':@"*U\#Z?9QSB"ZO%DE:!
MO._=[U,+LZ'[F&.6.2P8GN:EN/!]C.)5%S=QI.)EN41EQ/'+(TC(V5.!EV V
MX.">:QEU'Q0Z:FTDDENT;,$C^R2/MQ, NPB @@QYR<R8)#8 !%%OKFMW.L1Q
M0_;MZFVW6DMJ-H1X@TGFR!,*P/;*\\8.<  WYO#J*C/974UO=?Z28YN&\LSN
M&=@,<D$?+^N:L:IH=KJTJR7#2@K!);C8P'RNT;'MUS$OZURECJGB9].@DOY+
MR)9)8EN6AL6>:WS'(7VJ80&7>(UX63 +$L>"+,::JVJW<9GU&4/J<+1-/:C9
M%";8?.AV ##[@1G@CD DD@'0SZ#:SV&H69DF5+Z0RRLK#() '&1C'RC@@@\Y
MR*HP^"]-@L'LUDN/+>"X@8@HORS.'<@*H .1Q@8'I6'+JWBV73X9F@GM2TWD
M2[+<ED*1?,X CD.UI=V#MP55<$;LUW%J9FLX&N"IF,:F3:"!NQS@'D#/KS0!
MFZ9H:6&NZOJ>X%KYX]B@G"*J 'Z$MN)QUX[UL444 %%%% !1110 CNL:,[L%
M51DL3@ >M8$_C#3$2VDA:29);A(6 AD#J&1V5@FW<P;9@8&#V/%;=S;QW=K-
M;3+NBE0QN,XRI&#6"/"$8,<IU6_:[B:(QW)\K<JQJZHN-FTC]ZY/&23UZ4 3
MQ^)[2>_2"#8\$D=O)'/OP'$IE &,=1Y7?U[8I\?BG2)K:6XBFGDBBV[V2TE/
M#*6! "\@J,Y'&,>M5XO"%G;K&89[CS(DB"L[ [FC,A#-@#J96)QCMC%8VE>
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M!\8Z.T$,T,MQ.DLT<*^5;2$_O 2C8QDJ0#AAD'MFK#^)=(B,XDO H@SO8QL
M<.$.TXPV&(4[<X)P<56_X1.T6.(175U&\26R)("I(\C=M/*D<[B#Q],5'#X+
MTV![DQLZK/+YO$4093YHE(WA-Q&X#@D\?08 +W_"1:7]GAN//D$4LAB#&WD
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MK# W;.,CYOF^7C/)QUJEIOCW0[ZU2>6ZCMA+<S00AB3O$<IC#G ^52<<G'+
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M.^<.40A@V$)#Y&,C:00<XQ0!N45S;>.] ^U65M%=-++>2R01A8F&V1%#%7R
M5."O4=P>G-/L?&FB7:Z>DE[##=7L,<J0;]V-Z[E4L/ER0#@9YQQ0!T-%<]!X
MY\,W-L]Q;ZO!+&K(O[L,Q)<$K@ 9.0K= ?NGT-= K!E# Y!&0: %HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[A@@@8[@]A:6[VL/EO<RS@'Y3+C(& ,9 YZ9R>>:GHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.;M-N5VG:60L1\I ZXP"* /0J*X7^T-<:>XG@FU&-[BRL6@@N+4%8RTI65B
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M>,2 @IG<1O; + J.W0K=:SXE2YUDP#Y;:WG:VB:!RTFV(-&X CP26ZC=CG&
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MW]V\.GP&X14:#Y9"DJH#&P7+$<AADG+# Z@=K0 4444 %%%% !1110 4444
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M^DO=VEM#<^>UTQ6-X5+ID(K\L.!\K*?QJ27Q%I$,"3/?1"-TBD0C)W+)N\O
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MP0HEW/&\"CRI %)5A,)@<$8/S*!CTJU%X>B31/[-DNII0;HW33,%#,YG\X]
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MO;I=S)OABAW[%+*(VE(921\K9E.&'(P/?(!K2:_I4,\\,E[&KP*6D!S@8QD
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M<,"3RZC$B,7'S@@C9C?D$97;N!.<8!STIQ\3:,+7[2;^/RMYC)P<@@;CD8R
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M=%)B"%SE3C()\PY^@K,N?!=C<6VG0L^_[# ]NOG0I*'C<J6RK C/R#GZ]<T
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M_:W:\D1T+DG8%C"MDG^+/08KUBB@#R]O$_C&.WN9G:!1)!/)")+-U$)CNUB
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M>^0:VZ* .4N? =A<ZJU]]IG3=/%,(AC: B[73_=?"[O=14]WX-M;RW:&2YE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT33O LB&5%5F0'E0<X)'H=I_(UQP\+ZA+<VSW%U>2)&ULK%KUPS1K$5DW!2
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M>R*@!_WF)K0U/PW<R7:&&.6>SMYK62&$W3;OD,F_DGK\ZGD\XH Z]75QE6#
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M6YX( \M<GIQD T =K17)6.EWNFLNH7 OKE;2R<Q6[3EG,A=VV[5)4G:0HSG
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M3-&)5"LR%AD!B0I(]R"!ZX-<\GAZZ?P1J6E/*?MU];W$;233-(-[AE4Y.<
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MADDLY)-A24)(L;-C=D8+J<'&0?K6]-H.F7$\$TMJ"\"HB89@"J'*A@#A@IY
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M/E4\D8R*MIX@CBT?3=0OX'MDO-H?+*5A+*6!8@]"0 /=A4IT/28+E[YK9%<
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MDC\J9V;S-@+J@W$G"A20HX&#@4 45\8X5S_9UW-(TH5+=41'C'V:.<ABSX)
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M"$,03E@3]QON@]O6J+^,;6%0+BPO;>8R1KY4IB7 D5BC%M^T [&')SNXQR*
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ML@"Y6)-NYCN9>F]>!R<].M '-Z?H7B%K4Q7]U?>:TUO]H9;DJL@5R9'0B0L
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M/,4$%=W)#^F.:H7.G:[:Q7M[]LNHSY=_,3)=%D5EN%>V&W) 4QA@0!T)![4
M=)#H&FP(8XX9/*\U95C:>1D1E;<NU2V% ;G  %#Z!ILC79>!REV&$\7G/Y;;
MNIV9V@G'4#/?-9@M-6O_  C;!I+F.]NKB&XG"3%'BC>=7>,-D$;8R5XYXXYK
M/NM-\2_:[P6#W<<X^T"*XEN]T#1F$B%0A8D.'V$L5_A;DYY .@&GZ-HY@FD9
M(7\\F.6XN&9GE==O+.Q+,5  R3P!CI4DF@:9+J@U)[<FYW^9GS7VE]GE[BF=
MI;8=N<9QQ7.6VAZC<ZEIUQ-#J$5I;:D)XXKJ^+R1I]FD5B6#MD&0J-N3U;@
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MMYR1_:SNCA:V*$G,S9 E)X+$X)P,'% '4_V+I-X$G1#)&TPN1Y<[^6[C;AB
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MXW-RLQ!D'7^(@?3MBJ^H7-W?^'[A["SG\\RF-(V<Q,RK+M9U(93C:"P&Y<C
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MJ[N#BY>,2&63>5;##=ESD ]SQUJ8>'K-K'[-.99#]I>Z\Y9&CD$C,QR&4@C
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MH+1X4H0&YW8;J#\A;CFK5QX<TVZN+N>6.<M=X\]1<R*CD*%#;0V P"K@@9&
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MQ:-(I8EFB,[LB%B6.$)(7))/ % &1!XQ1[(32Z5>I,7N<0(8W;RX'V/)G=C
M)48ZY. #U-W5/$MGI=M!.8;BY2>%YT^SJ#^[10S,<D=CGU/UXJ*7P[H4]O*Q
M+B)9)V=TO)%"&0YE7(;A21DKTR.E:-UI%C>(B3P JD+P*H)4!' ##CV ^E &
M3<>,["UTVYOI[:ZC2VE\N5)#&C#]V) WS. <J0< [NV,@BHU\9V<5YK<5R?W
M>FE79XU^[$T4;*6)/WF9F _W>V,U=OO#.C7:2-<PNH<[G9;AXR<QB,@D,."@
M QT_&GR>%]'EEGD>S^>=2DK"1@6!5%P<'TC3'H1D8/- "V?B&SOM'GU*%7,<
M#,LB%X\@KU^;=LZ$'.['O5 >-]->UAN([>[DBD61W:-481+')Y3LQ#8(#?W2
MV1R,UK2:/:3:8^GS>?+ Y!/F7#L^0000Y.X8(!&#QBJZ>&=)2V:W^SNT;QR1
MMOF=BPD?S'R2<DEN<]: *]OXD^V>(X=/M[646K+<AKB10 [PNB,$P<\,6!R!
MG''%-D\9Z5%=O:-Y_P!H429CV<Y641!>O5F/RCN.:O6WA_3K34VU"&*1;@F0
MC,SE%,C!GVH3M7<P!.!R:AF\-Z)+JIO);5#>R3I=Y,C9+QKM5L9Z -TZ9(/7
MF@#-M_&&^VG%Q;/!.DLPC<QYCE2.Y\DE?FSD;DSG')R,BI[SQ2ZPQ366GW,T
M37JVH<JN)OF96\OYAT9<9; [].:N_P!A:/.6C$*N83(K*LK90R2+,P//!+!&
M^F,<&GQ>'M-@E+I%+CS_ +0$,[E$DR6)52<+DL2<#G- $;^(K5=%MM32WN94
MN72..%$'F%V.T*02 #G@G./?'-4SXXTA;J[MSYI>V$FX+L8LR,%9  V0VY@!
MD $YP2.:UUTBR2T@M5AQ#!*)HUW'Y7#;@<Y]358Z!I4_VZ/;(T=P6$\*W+[
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MENP*QB0G<'VXVG/WNO'7BAO&EI%]MDGM9H[6!X4BG+Q@3F5590,L-OWOXL#
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M80WHN"\:AA(7&W#,,$>6>3QUZ  E]GX8T)K17M!+)$XB:.=+R1V 0,$*/N)
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M4OEJ5?8KC)+[>5=2 "2<XQD$" >.=(:6[C3SI#;%@?+"L7VR")L -D8=@/F
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M$$F[YU8G:9/+X!Z@XP*JPZ?XBN;K1VU.&]DEB-G)(ZSH(4VQ_O=Z[N7\S)R
M>,8.,UMV_BK[1)(GV1XA'<6\'FO@I(951OEP<C[_ 'IR^,M-:W\X17>UUB>
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MF9;8JKS%,1DLBN I[_*ZGIWH YV#2-3CU==0MDOH5+6B^7+<9S&-PEWC<=Q
M/<GMBC7M#O;S6M2D@BNREU;62I*D^$4QW#,^%+<,%*D''KW)S8F\9-;Z)9:D
MU@9!/IDVH-$DG(\M4.T$^N\\^U6+GQ-)%?06X@";Y@DB2CYHP;>67G!QG,8'
M&>": ,BZT_Q.)+>"&YO$MHY+@1R*WFN/WH,1?,B[ALR/FW#^\,XJSXJ?59=:
MBM-,-\96L9'A%O*J(DP= CR9(RHR<CG(SP>*OV/BV&YE9)[2:*,-;QBXX,;-
M,JE>^1RP'([BK;:]$]OI-S;1F2#49Q&C-\I"E'8,/KM'X&@#G7L?%,D^K'[5
M=H[F581'M"%3,IC*L9" RQY'"+G)SDXS;FT757U<!;S4EL1=I'\MX1_HWV;Y
MCG.<F4#G[WIC)S:B\;:7+9"Z$5VJNL#QK)&$,B3;O+8$D  [&')'(]QF;_A*
M(T.JF:PN8X]/N%@+ED D)17R"6 '#CJ?3N<  P5TG79X],GU&&[DEA-E).(9
MPCEQ$ZRGY6 .&89Y]<5LZ4NL06FL":"XEDW.]JT\VUI202%QN8(!P,C /7:.
M\</BS[5J=I';1I)9W4L0CDP=QC>VDG!QZ_(H^A-/A\8VMU/9Q6EI<3&>^-E)
MAD_<N(C+DX8@C:!T/KW&* ,>TTWQ+<VS0W,FH01?:)63%QM?9]G38"WF,V/-
MW]6_(<5)#8:]<>)-,N-0@O&\BY24R"9/(2/[&R,-F[[_ )S-R!T/7'%:]OXN
MLI([8R)*WFK$9)8XR8XC*VR/<3SRPQP#CJ<#FD_X333/L\T[1W21QJK*9(PH
MD!D\O*DG &_@EL#OTYH S=3T&\N=5U/9%>;+F[L9EE2XPH1'CW[06^5@%)X'
M3H:B%CXH%_9(]Q=K;1.55U(D.!</@R?O%R##Y8R0_P#%P&Z]1>ZU;V"6)F27
M=>R".)!MSN(+8)) Z \9R>V:S=/\5QW#745S;3)-"]WL*IA)4@F,9*DGJ,IG
M.!DGT. "CKCZK-XK:VT\WQ,=O:R1^5*JPQDS2!VD!(W HI&,'IZXJK'8^(K:
MZT^*WMIXXH[LR2.DP*,CW3EPR[P/]65.2K$[N-I!-7IO&:RK;3:?&DD$JG)D
MZAEN8X&'!P<;VY!(.!SBK^I>)$TK6S:7$$K6HMDF>:--WE[G*9;GA>G3)ZGH
M#@ Q%T[Q'%IKAY]0:66VB:3$P<B42DLH^=2H*8!VL..>3G-SQ*FOS^&[5--M
M)TOV@)?R;G)AE\OY03O3>-W&22.,E36IIOB?3-6U2?3[24M-%O/;#!'V/C!R
M,,0.0,YR,CFJS^--*B6=YA<0QQB0J\D>U9=DHB8*<]G95YQ]X'IS0!GWECXF
M^TWEU9SW GDDF2%7F!B5/LW[L[<X'[X#G&>3VJ;0]/OH+77G,6I6S7)!MS<2
MI+/D0JN02Q&=P.-Q_(5:3QC87$*-9P7-S(\4TNR-5(41':V6SM^]@#!.<Y&1
MS4>E^+4ELK$W\,JW$Z0F=XH<1PM,<1J?F)Y) XSU!.W- &!,WB)FM;&.+48[
MP6DK1".Y^42"8!)9=SDE<<E=S8!QSQ5QK/Q5YVJ2&:[+%Y L<>T*\1G4KY;&
M0A7$(91A5Y/)R 3JR>-=.CLDNVMK_P EXI9U80?\LHMN^3&<[1N'N<< \9+K
MQOI-E TET)X9%E:)H9%"NNU%D)P3C&UT/7/S 8SQ0!G7FBW^H7$>(+]+16L'
M02W/[P%)YC)N8,2<*R'DGMW!J6RMM;@U%3=6][)"/-: 03JB*YGE),@W#(,9
MBQPV,-P#6@?%$4^M6-C9PR2Q3W#0R7)3$>1"TN%.>O"]L<GN#A;KQ3;6-Q=P
MS0SS/#,T82WC+'"PI*Q.<#@/G].O% '/66F:_.]E/J-O?[+?4DG$0NCO1#;L
MC<^:2P$A'4],X !Q4RV?B5)+=-EX&41>2T4RK%&WGN9?-7<-P,93'![XP>:Z
M35O$-CHVE+J=P7:T9=_F)CA<9SR1GCL,D]@:-9\1:?H,?F7[NB>2\P*H6R%9
M%(&.^9%P._/I0!SYT[Q#';S$W&H%IXY3)B4.587 ,84;UV@Q%@=I!QWW8JSK
M,^H)I?AN.2"^CEGN%2[MK.Y_>D?9I6*^86&<,H).<G%7[GQ=IEL)6Q<2I")&
MF>*/*QQQMM=R<_=!R.,GY3@<&J^H>,;6SEB/E2K;"_:RFEDC.&81RG;&!RS;
MD5>G.[ YZ %"WTSQ&]CYE]+<27BQ6*A/.&PL&0SG .">#S[<=>8FL_%$AN%1
MK^*5ED6:0W"E&8SH8VA&X[0(O,SP.HR":V[CQ;9V]X]H;*_DF63R<1P@@R^4
M)=@.<9V'/IP><XRY_%VEQSVT9:3;<VYN(9,##KY9DX&=WW03G&.,9SQ0 S6-
M+E>[\// EW-'97>9-EPP8(8G4,Q+#>-Q7.<G!/7)JOX7@UN*X+:D+M1]E07/
MVB9762YR=S1 $[4QVX'*\9!I[^+HI3:?9H)$\RX,<BW,95@AMI)E8 'OL'OU
MR :CL_&EFSZB+M@BV<2W#M&I(2$P1R;F],EV '4XZ<&@"C%;ZY_9UFMU;ZP\
M@E_XF(BNU#2ML;F([QM3?M. 5XQQ]ZB#2?$D[V;7]Y>JX-LD_DW(12OE$3'"
MD<E\<CGNN.:W;?Q1IMSHE]JR,_V>QW_:  '92JAR!M)!^4@\$]?6F6WBNSN+
MMK8VM[%*I=")8<?.BARG7D["&';!ZYXH Q$TOQ)<):-<W5^CQPV4;B.Y"AOG
M<7!.#R=A7G\5YHALO%']I:>LUQ=K;1!%#+B0G;.^[S/WBYW1>6,D/W(PW74_
MX3?2S:^>D5U(090\<2*Y3RPK.25)7 5@>"<].O%6'\6:9'>RV\GGI'&Q1KAH
M_P!UN$/G$9ZY\O+=,<'O0!A"P\2P6A/F7\QECC:Y47(W\3_.L9) 4F(D<$=!
MSNYJQ'::^WB&&027\-@J)Y2.1)\NPAED/FXW;N^UC]W!ZU?M?&FEWR0_9DN)
MI);@6ZQ1JK-N*&3)(. -H)Z\8P>>*N7WB/3M-U!+*ZD=)GDAC0;<AC*7"<_6
M-L^F* .=TW2?$=LUE-+=7\DBI9-*LMT&4N<BYR,X(QMXZ \KWIFEZ;XGDM(X
M]0NKX2O- +H*P0#&_P UD?S&.TY7A0@  P <XU?^$PA>:V^S6DUS%<R0K&8P
M%8+(CL&.X@8PG;UJSH7B-=5FDM9H)(;A7N-A*821(IC&2ISV^7.<=>.* *&@
MZ;J5MKD5UJ*7;LVGI 96GW*&223[Z[N259#G!YSWK,U72O$&HVFLVK1WI:>V
MOHVW7($,H8G[,L8#?*=N >!_%NSD5OCQCIS37$2PW3&%E12$'[UFE,0"\YR7
M5ASCH2>.:&\8::D7F&.Z(C5FN0(N;95<HQDYX 96'&?NDC(YH 76-,E?4/#T
ML*7<L5G='S-EP00IB90SY8;QNVYSDX)ZY-<Y:Z-XETW08+2U>Z ^R68E0S;V
M5@S"98_G7;\NP?*PX'!SUZ2V\2+>^(XM-M[>3[.T=R3<.F%9X9$0A3GH&9@<
MCMQQ2W/BW3;2\N[683K+;*'*JH8NN]4R "3U9>H!.>,T 5KN'7[?PE:O9/+<
MZK;NKB.7;&9E)*E7^8CA6SRQR5!ZUEP67B>.UC34'O[F*"Z%O(+>=4EN+=(W
M"S9###,[(6 (/R^G%:.J^-;>ST6ZNK:TN9+N*WN9?L[1\QF'AO,P>%W%1P3D
M'(X!(VKO5K>SU*RL'5VGN]QC"XQA<9)R1_>' R>IQ@&@#DY=&\1WFD3B[FF>
M\^RVB1(TH,?F!LR,R@@,1A<GV^7&:Z+0;FY%O%87T-R+V&$/<2R,'5F+,.&'
M7)4L!@84KP.E4=3\71QZ2EQID,D]Q,ML\2LG 6>41JQ&X9P<\9';D=1%;>+9
M$ENY=2C6WM89KA ?+.XK"N6;AFSGGC ].: *%A9>)KF1DNUO;6WEGMW=!<Y9
M!B3SE5][''^K&1M]545%/IGB*Y.G0W<5].(FL65EN$"*8[G=*THW#<=BH0<'
MD<8.:Z&Z\56UAF2^BEM8Q"',<R@/N,BQJ.NWDL._?G'-,3QKI4D<,D:W,D<@
MRSI&&6("4Q$L0<<.,<9]1D<T 5M<@O)=<O4ME+33:;&+7IU68F7&>.C1?E6=
MJUEJJ:-JWGQMB2UU".+!4DR27!^S@8YR05QZ=^:Z.T\0QSZ3J.HW%I/;06,D
MZOOPQ81,P+#!_P!D\5';>*[*YO1:?9KV*0RF',L. )/*\T+UZF/YOT.#Q0 :
MS'?OJNG-''>2V*I)YJV<HC82Y3RV;++E /,R.1R,@UA"S\42><JF_BE966>1
MKA2KN9T*-"-QV@1>9G@=5R"<UKP^,;6[N+.*TM+B8SWK64N&3]RXB\W)(8@C
M;@\$]^XQ3(/'>C7<4DEJ9[@JT2HD2AFD\PE4( /&2I^]@CJ0!S0!C:A;:_I&
MEZG=)=WY5+6_VE[@.4 =3;E<D\[=W)Y_O'I1<Z5KUQ;7CPV]V,0WJ6274RO*
MF^&,*&;<>L@D(Y. 1TZ5OR^*[.TB62[5E1KM[;<H "$.%YR02<D?=SW[4[3?
M$L=W=QV4L9%U)/=(H3 4)%,\8)R<DG:,XSC/.!B@#&OH/%$VK:J;6.Z@@>UG
M2(B<$&3='Y3+ER =OF<!5 [EN*G-EK-OJ"0N-2N-,CN)MGDW0\WD1&,LS,"R
M ^<,$G^'((KL** .8\.6VN1:K>2ZK/.4)D&QE!C;]X2A4^8V,)Q@*O7GD5T]
M%% !1110 4444 %<];>"M MH62"T*H]G)9<2L?W+L6*]?5C@]0.!Q6[<*7MI
M5499D( _"N$9/$3Z%H=I91WVGBWLC!.1"'=9U2,(=H<97_6=\$]10!UHT*Q%
M\]WLD\QYTN"/,;;YBQ^6& S@?+@>^!39?#]A+IUK8[)$AM7$D)25E9& (R"#
MGHQ'XUSU\/$ ;5UB^W.OG(\,BC;O&YLQ !N!@#YU]1D9!RR5/%SWVI20R2PS
M>1)]DA9%>(Y@&P%]VW(EZDKDX/\ "1@ Z*T\-Z79-:-! RFT$8AS(QV[(VB7
MJ>?D=A^.:;<:!I=W=WOF&4M=H#<0K<.JL=H0.5!X;" !O]D=Q5'3H=6'AG45
MEN[S[2^_[,[V_P"]A^0#@%SOPVX\D=<#@"LJ&PUZ6[341'=VTZ06D>SS@PD"
MW,F_=GD_NFS@\C=W(R #H?\ A'=)@1VE#LTOF))+-,Q:0RA4.23R2%11Z8 %
M,7PQH\\XNT$CJ26"K<,8]QB,)8*#C)3C/]<U@K;^(;V]NA<6MRMM]LM)4CE<
M,%*76YRIST\L*> !Z9.:L7'V[2?!^CVY%U#,;J.*9+8KYA0LV0,^WISZ<T ;
MR^'=.24R+'(,M"^WS6V[HL!&QGKA5'OBHK;PII-JJK'%*50Q>4'F9A$L3AT1
M<GA0P''L!T K"AMO%+V5U,TUXMQ%IP^RQLZ9:4O-][L9!'Y74[=Q[TV2U\17
M$,R6\VIPVP:=K;S'438$*; Q.3CS=Y&><8SQQ0!TB^'M/6YMYPLN;>:2XC0R
MML$CL[,V,XSF1_S]A@ET335U/^TY=ZR-,LA5IF$;2[1&K;<X+8PH_#OBN7O'
MUJQDM+:YGU26&XOP,P,GG.OV1F8 \8 D4G QCMQQ21:3K<CA[^.ZEO)5TJ64
M^8#%OCFC,V #@$;2>!TSB@#K)-#LGT.+1P)4LXHEA54E93L"[=I/4C''-4V\
M':,SW!,$NV>)X703/MVN@1L#/!*JHS[5!X7FU.YFU$7T[/'9R&QB8D'S2C,3
M*2.Y5D4^C(U83WWB*.QM?MT>I0?)I]M+L*>9++F47!3GO\G/!...U '70^'M
M/@U7^T8UF$V]Y%7SF,:LX^<A,X!/4\=<^IJFOA#3Y+N^GO3)="[DD?RGD81H
M)(Q&V%SC)7(SQPQK$1/%.;42?;_,V1?9R&3:/W[[_/YY/D^7GKSNQS6MH=OK
M,.IB2^FN9(9DN#(LK*51A-^Z"@=/W9/UP,\T :MOHUM;R02;[B:2 L8WFF9R
M-P /4^@%0Q^&]+CB2-8&"HD$:CS&^[#(9(^_9CGW[U@XUS[.?/35M_VT_;?+
M9>8<R;?(P<@?ZK.,';_M9J);+Q1.L+37=_$R1V:X1T&0T\@F+8!!<0E,D<9Y
M'- '1IX=L(G5X//A<1O'NBG9259BYSSV8DCTS2+H&ERZ3;V$0?[/;3&2-HYC
MN60,VX[@<YR6S]37*22^(EOTL%EU%KJ*(-%M9-O_ !\R*K2D]08E&?7G^+%3
M)8^(X+Z&**2>VM#=W$JF.,2 LUY(_P XW#Y3&5QG(Y/0XH Z6#PYI5K%!!%$
M56-8%C4RL3B#F/J><?KWI^E>'M/T:5I+-9@3$L*B29G"1J25103P!N.,5RT>
MG:]:6<Z6,=T;J.74F1YV5SEY"T)0L<<J1[9ZU.+37[D/'%/JD%D9I6A,DBB;
M;Y*[0QY./-W8SS^'% &J_AK0K.V,4K/%')Y<,)DNF'E8<,B1DGY<, 0!Z =
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M/YF\E@0&C$>-V=N3_$.='PK'KJSW+ZQ/,S%0&B>+"!]S9*-N.1C'  & .^:
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MM)GN(5D5(PH5?M WM&Y8C'E9X '&/XLT ;]SX3TF[E$LD4H;>[G9,R[M[J[
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MT'D>0"VW*R/*BL%7_OKOVY/%7'\):,\WV@V:BZ,TDYN0 )2SA@P+]2N'(QT
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M?Z=/;TIMKX;M[348[M;B>4K)).XF;>7F9$C#Y[812N ,?,: (W\8:2BR.S7
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MI%=&252$Q(S* <9.?E/KFK">&+&.>6:.2Y1F\TQ@2_+"9&W2% >FYN><]P,
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M9V8-ZC+DX]0/2KE !1110 4444 %%%% !00#U%%% !1110 4444 %%%%
M, 8%%%% !1110 A4-C(!QR,TM%% !1110 4444 %%%% !1110 4444 %%%%
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M=S+;.?+CVAO*:4DX  &[S!QVQU-/U/Q9?1)>);6T$,B)%+;&=V/FQEHP[<#
MP9-I&<C .,$5K:CJ%_;:OHEM"MMY5V[K<;F.>$W?+QST- &9>>'[R/0O#&FP
MPVUV^G2QB7SU_=$);R)DCK]XKCK@D''%5[;P5=0WFD>==6TMK81HI7RMI;$;
MHR@8^Z=_&3P!C'.:KZ7XRU*'0+$7MG'/>2VEB\<B2EA)Y^]<O\O!S&3@9R6
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MJ**YN)9&>ZBBVOM:T\C QZ-AL9QP*K_\(/-]C1%CL/,+R>9%+NEA.Z)8]X!
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MD64%D8$QJA7:.,?+QSQP,<9I]QXFN(]:ELHK2!HTNQ99:8B0R&#S@VW;]S!
M/.>">W,&F:S>6?@31[^[D2>_O(HF_>,[;W==W&U2>F3C  YYP* *^H>"[B]D
MOU$]JBS_ &IDN-A\YC-&R;'/=%W?CM3@8YU4\-11Z=KMC'Y,5OJ1.Q$C 6(&
M!(NG3JA/XUGV?C*ZOOL,T>G0K:W$=HSEISO5KA3M &W! .,G(R#TJ]I'B.XU
MK3[ZXMK$>;:QA#$TG_+T%)>(G'125&[U)XXH JIX19KJ*\D6SCN4^Q[3$GW!
M"[%@IP" P8C\ZF\)^&6\.QR+*R22&*.'SE=B90F[#,IX!.XGC/4\UEQ?$>&Y
MBNIK>P9XXK>2\0F3'F6Z)C?TX_>@ICT!/M6C#XEU"74TTT65HUP+LP22+<,8
MPHB67(.W).&QC\<T 167@:TM=(TJT?9/+;&W^TO.S2B41*P"@,3M4%B0HX&3
MQ58^!6>74?,>&07,DK+(S,24DG64HR8Q@;0N<G@#IS5OPIX@N-6\/3RS@B:U
MC"LS-^\=MF[<1C !R,'G.#]*;I?BF[N;FRB>TC-M+)%;M,TV9-[VPGSM"@8[
M=1US@8Q0!%+X%79="U:V@:X2]0E(L<3NC+G']W;27?@Z[GFNVCF@CA>\6[CM
M\G#MF0L6?&1GS <?, RY'7%;NK:N]H-/2S6":2_E,<4DLNV, 1M)G(!SD)QC
MU]JQ[+QE<WTMG(NG1):3"UWL9R74S@XVC;@@$#G(R#F@ @\.WVCSI=:7';;H
M;(0+"SLPD<+A 2W*JI)Y!R1QCI5KQ3X6;Q']G5;K[.@5X;@@'+Q,5? /8[XT
M/TW>M.OO$DMIK+VB6L3P13VT$I:4B4M,VT%%QRHR">>S?W>76GB"XD\)KK=W
M!;VYE17BC$CN,-@*"0F<DGH >U &9_PA$DULK74]M+?&!@T_E=)VF\UG7N!G
M@=^!Z5:M?#%Q::M'>;K.X0RS,RSQDF(/</,&C_VOF /3E5/;%9+>-;[>E^L$
M ACM+AY[9YRI8PW'E$I\N2QQP#CJ!5^X\:S6XN9FLH3 BW9C G.\&W?8Q<;?
ME!ZYR<<>O !=\-^%QX?151H0/[.MK1_)3;NDB\S=)^.\>_%4(/"-]#I-K:1R
MZ?!-:V\D"31P9\TF+RP[J>"<\D'/U-6AXCN[GQ)!96J6WV47<UM*[2$EMD:/
ME<#KER,>U5]:UK6(;[4K>V^S!(+C3U@^<JS>;.BL&^4X4C<,C.* *Z^!KEK.
MXAEN8/WT=TA0 LH\XPG'09QY39X&=W2K,G@B 2W3PPV@2=KG=&J&/>DJ*NPL
MO(&5SQ2+XRO7N(+:+21+.#*+@)*< ).T)*';S]TMSCJ!WR)==O=;_P"$F@L=
M*>;'V=)2BK%Y?^MPQD+_ #;=N?N'- %B70]1?PQ;Z<;FW>YCEWNS1J%9-Q.W
M.W@@$#=MR<9P,\9L?@1ET:2T>X@:Y-A:6BS>7_SQ))'KM;."/3-2S^+]1CBC
M:+2HI))[FYBMT69CN6!F4EOEX9BO Y &3GC%+/XKU07TD%OI=KL$YMU,UTRM
MO%NLYW (1C!*\$\T 6SX:?\ X18Z7'Y,4AN%N2C,TD;$3"4J<@':V,'C^(\4
MW2/"HLM3@O[@6K/&+@K'''\L+2R*_P F>@ 4C/&22>,XJJGBZ;8]VMN3:F>$
M2/*^1;QO!')G"KNQE\9YP3DD#@.A\6ZC=)>26VBEXHG=(F\P@DI,(FR,<G&6
MPN3\I7J1D ENO!MO>:U+J$\=K*9+XW+>9"&)3[*(0A)]&&[T_&J47@BYDN[,
M7]S;SVD$ @D4)M:13;&%E/'.22V23P0,#'/3VVJVUSHZ:BL\+1FW6X8ACM"E
M=V>1D#'J,^U<Y;>,KZ]3R[;3[=KDW;6X\R9T3:+<3AN4W=#C!'O[4 26/AV_
MNO =S8:A*G]J:BA>YDF3(+D!1N4'G"*BD ]JI7/@2>[)DE:T"RO.9+.(M'"B
MRK$OR$#.1Y6>@R9&Y%3)XLNM3U+2EMHXK>UDNX8Y TW[U]]J9L!=N"OS*,YS
ME36A>>(I-,D\1338FCT^..2* $*3F/)YQG&>_.* +6K:-/?:MIUY;O'$UL2&
ME;);82I90I!!SM'/!4C()Z5@6'@6>PLK9%-I-/;/"2)F9H[I8TD0;UQ\I_>%
MN-W*CD\8TH_$U^LED+S35MXYK@P23,[$ DH(\*%W#<7(R0 "N"?F!JNGC&[E
MC2(65K%?9E,L4]PR)$$17P7VX8D.,%<C&3GC% "77A*_N)YE6XLX[62628*D
M; JS6AM]H'0*#\WT..W+W\&(NL6-S$L'V:"&WC\E28_+:)V<,H4<Y+<CCISG
M.*TM!UVXUR:Y<6:06D0B"EI"9"SPQRX*XP,"3'7J*PY?%.JSO:O!;01W,3SB
MYLY)F  6$2 %MAR>1@KD'.<]J -#PSX8GT.\::5K0A;2.U#0QE7EV,Q\R0]V
M.[GWSR<UCGP9?Z?I-Q);"T-];6Z_8Q;1[?-F23S5:3)'?Y3ST9SWP)]6\:R&
MWO(;2-4W6$TD<RLV^&46XF .5VDX8=">WK@7+K5+]/#7BBYCG;S[1Y!;L<#9
MB&-@.GJ3^= %G4/#4TOANPTBSGBQ;X$K3(#YHV,I.<'!+-N)')Y&1G-5+/P2
ML,EO)<-;S2QRPEY#'\SHEKY#+GK@DD_0TS4?&MQI=I=-<6=N;NTDE$L*2NP=
M$2-RRG9QQ*HRV.3WS3[SQK):RWT T_?/92"*=1(<(9)D2 GCHZN7/IM(YH O
M>#])NM+TE_MS,]U+(06?[WEH!'%GD\[$4G_:9JZ&N:O=;U1/"T>H1VD5M>&[
MB@:.=CMVF<1DYQD9!SR,C/M6<WBN_P!*EU66]MDN+2*6Y,1CE.\>5")-N-N,
M'##.<T =M167H>I7>I6LTEY9_9GCEV+AB1(NU6W#(!'WB.1VSWK4H **** "
MBBB@ HHHH 0@$$$ @]0:K 68F\L1(&10^X1?* ,@?-C&1SQG(J6YB,]I-"I
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M_E'[LD$YX^^WR\U'=>';N^\87%X+>VBA6:VE2\8?OE"*=RIQT;.T\C@G@YX
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M6CHGA^?3=6^W3I9222:?!;2S11A'#QELX 4#:0P]/N#CT +41\/Q3644%O9
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M' ZRNJ.S7 @^8M& ,,PR5W=".PS!IWBZ[CCB@OK9);NZN[B*W\N;*LR79B*
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MSNE>*-5,A]6('/4]?6J=\FAB&.*\M[.1+:6*)(VA5_)>1@B +@[<E@/_ *U
M&/<>,YK1KMYM-3[/$+KRF6XRSM X4[AMPH.>N3C%5!XOU.TN[^VEL%N[S[9(
ML4$$CNB)'! Q4,L9)):3NHQDY/%=BUE:,"&M8"&W@@QCG?\ >_/OZU7.AZ0;
M5;4Z58FW5MXA-NFP-C&<8QG'&: ,2Y\6W4#7&-+!1;U+*',K%F<QB0EE5&*@
M XXW$D=AS5>Z\4ZC/):10V2V?[^R6Y\V7]XIEDY14*_,, C)(/)XXKJ9K"RN
M()()[2WEAE;=)&\897(QR01@G@?D*9_9.F^;#+_9]IYD"A(G\E<QJ#D!3C@
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M32WFNOIU]KTDX,EKIVG178C0#<3^^+8/N(UJ^-#TM9%DCL+>)A,)SY483?(
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M;SX$!R0>TC?G]"-8Z'I+0PPG2[(Q0[O*0VZ;8]W7:,<9[XJU+;6\[!IH(I&
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MCC;SC(Y(7!W$J,]!SW]!63X8\,'0YHYYEM6G&EVEDTL:_,6B#!CD@'!RF/\
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M6Y-1M+/3H UF(O)$NX;P%"JI\H%$&#T)!X.T'-=/110 4444 %%%% !1110
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M!&?44 7J**;)(L43R.<(@+,<9P!0 ZH+VY^QV%Q=%2WDQ-)M'? )Q^E3*P=
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M-:C:1HER]WG3["5V8"Y_<HQ+ !@'XZX(//J#WI\&F:3-)%J$-A:^:T0"3>0
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MCW .&48;D'&"",$$@YJ*Y\97%K(]H='>74(Y9$:"%WD4A(XWRK+&221*@P5
MSGGC)Z&'2M.MK*6S@L+:*UESYD*1*$?(P<KC!R./I3)=-TC4XV:6SLKI&E+L
M6C5P9 -A)_V@%VGOQB@#&N?%TT#3[=+8JMXME#F1BSR&,2'<J(Q4!3VR<CIC
MFF+XINVNHHDTZ07%P+=5MKB3RA$TBRL<G:3QY7I^':MC4(](01V=Y:PN+Z8
M0_9_,$D@&=Q !Z!1\QX&!S0ZZ-9-&3%:1M%)% NR,9C<_+&O ^7AR!Z!CV-
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MT^*[MT$@=BKN^&;Y05; &5Y ]>M5'\2ZBNDV-S&())Y4O&=&&%)B#8!QR.0
M:VK/_A'[#_2K)+"V^UHTQEB14\Q5Y9B0!D#.3GUH\K0K'47D6UM(KR[;RWD2
MW :4L&;!8#G(0G\/I0!D?\)!J$E]8POLADE%F\J1D.F)?.R 2H/_ "S'].^8
MM.\77S6WVJYM(GL$TZQNWE\W$H$Q(=F 4+A0&8XQPOOQT-C::.4C%E:V:B-(
MV14B52B_,4XQE?O-CZGWJ+4-)T?[$\$L$%J+BW_LY9(T57$;?*(U..!SP.E
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MW]G$<VYY3;RB-@5V\9+ C&X\'CIFY-K[C1[&]MK>*XENYDA1%F*H&8D<L5R
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M],_,0>"<]T[K&C.[!549))X KA=,\:76IVDK+) )3?6C1"->EK/(JJK9S\X
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MD*(\(&C&3S@XQR%!JS8>%9EU&"XN;>TALX[I[A+&*0M'#^[15VC: ?G5GZ
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MI98X88V955IT=40A&5#@$'.T;21G!XZ:3Q5+'>O;2:>8T286SS"8-ME-N)@
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M-D,,S)\HYW-\IP..G)!(R 6;?0)K#PYJEE9PV2W-U<7,J@K^[822,R[N/[I
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MAT-\"R:X5+2:]F82!=D417=@'JWS\#CIU% &+'X/U%-1L7>=6MK8@1)',%,
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M.\DMBS$)ZCKO!/T_*NJHH Y/4-$UBX'B"VM_L\<.HW$=Q',)R'PL4*-&R["
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MZUH44 9%KX8TBTOYKV.RB,\A4AF0'RP(EB"KQP-J_P#CS=C5IM'TU[5[9K&
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M8K&WCE@01Q.D8!11G 'TR<>F36A10!G_ -AZ:=*M],EM(YK2W55BCE&_;M&
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M&\YW9/OGG/KS6A10!7MK"TLO^/6VBA^18_W:!?E7.T<=ADX^M6*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0JDD@ <DGM4 OK1A&5NH"
M)(_-0B0?,G'S#U'S#GIR/6@"Q152;5;"W=TFO(4:/=O#.!MVJ'.?3"D'GL:L
MJZ.6"LK;3@X.<'KC]10 ZBF/-%')'&\J+)(2$4L 6P,G [\<T^@ J"\N5L[&
MXNF4LL,;2$#J0!G^E2JZN"48, 2"0<\C@BJWVZQN+A['SHWE.]&B[G:%W#\
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M>,FNE<65I<1JMW#$D\D9*.INDA<=, D,2.O'/!!%2VWC*#;'%<12&:0@H0H
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MK:*HG;<X1F49SN)&#QD\G&,FD/AW1R'!T^ JT0AV[> @VX51T7[B],?='H*
M*=GXF:\U*#3UTZ5;AC,)\R+MA\ID!.?XL^8I&/QQ3+OQ;#8ZC<P7%G,MM;S-
M ]R&4C>+?[00%SG&S//KC\-:UTJQL3&;:UCC:-756 YP[!FY[Y(!)/4BFW-E
MID>^YN8;=09O.=Y< &0IY63GN4.WZ<4 8C>*[LWMG9KI+)<2SQ+(DDR_+')'
M(ZL".,_NV!'MWR#5V^\2Q66O1Z4MG<SR$1-(\2$B,2.R*>!T!4D],#GFK,7A
MW2(+<016$2QB191C.0RC"G/7@<#VXZ58FTRRN+Z.]DMU-S& %D!(. <@''4
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M.+-OXG@E\.3ZQ);R1B'(>VR#*K<81@<;7Y (.,9].:T1I.GKC;9PJ RL %
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M!))KNZF687)!S(6:-A\PQ@L <@D8R >M7;G0=76_O;RWCA=Y!<F,-(5R72W
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M2=#6)3?7-C<)-.3(%,I\MU8@M_M/G'I6<VA:S/J6IW%Q-?J+A)1&;>Y5<(Z
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M,TLY=5C!DV;><[\&,$G(('8J*+WPU=7NN2W4LLY@DO\ <56[D0&V^R!=NT$
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M^YT^WJ^+C<81+,KQ>Q 52N!T)'89#+SPO-<ZGJ1^SGR;O4+6Z,HG*Y1 @9<
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MT7F"3<67H#CH/7'U!%=(*Q(?$VF3^(&T:-V-VJL?NG:2/O 'U%;8I%"T444
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M*%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_P B_\ B:Q?^%GQ_P#0E^,__!.W_P 51_PL^/\ Z$OQG_X)V_\ BJ -K_A
MO!W_ $*NB?\ @!%_\31_P@7@[_H5=$_\ (O_ (FL7_A9\?\ T)?C/_P3M_\
M%4?\+/C_ .A+\9_^"=O_ (J@#:'@+P>#D>%=$S_UX1?_ !-=#7"#XG1D@?\
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M_@!%_P#$T?\ "!>#O^A5T3_P B_^)K%_X6?'_P!"7XS_ /!.W_Q5'_"SX_\
MH2_&?_@G;_XJ@#:_X0+P=_T*NB?^ $7_ ,31_P (%X._Z%71/_ "+_XFL7_A
M9\?_ $)?C/\ \$[?_%4?\+/C_P"A+\9_^"=O_BJ -K_A O!W_0JZ)_X 1?\
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M%P@5%D?M]Q?4UV=QJNGV6HV]E.)(Y9F/E.;=_+WD,<>9C:&(#'&<_G5$>*M
M&G7=X966VAB667-K("T;!BKA=N64A6Y (X/H: ,J?6;NXT2<PZK EU#J=Q'(
MAGCBD>%)9 $4L" VU5(R.0IY&<CJM*NX]0TBRO8FE:.X@253,H#D,H(W < \
M\XJC-?Z(NJG3I8HS<2.J,?LQ*;R"RJSXVAB!D G/3U&;DNJV4.K0:6\P6\GC
M:2./:>57KST'? ZG!QT- %VBL4>*]':>"(7$A,ZQ,C"WDV 2.R1[FVX7<RD#
M)'-6KO6K*SO4LY#,]PRARD,#RE%)P&;:#M!(/)QT/H< &A16&/%VC%+A_/F
M@SNS;2 L!)Y>4^7Y_GX^7/4>M:]M<)=VZ3HLJJV<"6-HV'..58 B@"6BLI_$
M6F(U^@G+O8/''<*J'*ER N/49.,CN".H-.DUZPBTQM0=I1 MP;;Y8F=C()3%
M@*H).7&* -.BJ%KK5A>P^?#,?)V%S)(A0+ABI!W 8(92"#R,4L6KV,]_)9I<
M(94C23[PPP;=C:>_W#F@"]152UU.QO889K:[AECFR(RKCY\=<>M5WU_3H]7_
M +,>607.]8_]2^S>5W!=^-N2!G&: -.BH?MEKL9_M,.Q7V%MXP&]/K[4OVB
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MGG&,_.=FP$?+VSGOUJ6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_@%'_\ $T 0_P#"<^$?^AHT7_P/B_\ BJ/^$Y\(_P#0T:+_ .!\7_Q53?\
M"(>&?^A=TG_P"C_^)H_X1#PS_P!"[I/_ (!1_P#Q- $/_"<^$?\ H:-%_P#
M^+_XJC_A.?"/_0T:+_X'Q?\ Q53?\(AX9_Z%W2?_  "C_P#B:/\ A$/#/_0N
MZ3_X!1__ !- $/\ PG/A'_H:-%_\#XO_ (JC_A.?"/\ T-&B_P#@?%_\54W_
M  B'AG_H7=)_\ H__B:/^$0\,_\ 0NZ3_P" 4?\ \30!#_PG/A'_ *&C1?\
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M7_Q53?\ "(>&?^A=TG_P"C_^)H_X1#PS_P!"[I/_ (!1_P#Q- $/_"<^$?\
MH:-%_P# ^+_XJC_A.?"/_0T:+_X'Q?\ Q53?\(AX9_Z%W2?_  "C_P#B:/\
MA$/#/_0NZ3_X!1__ !- $/\ PG/A'_H:-%_\#XO_ (JC_A.?"/\ T-&B_P#@
M?%_\54W_  B'AG_H7=)_\ H__B:/^$0\,_\ 0NZ3_P" 4?\ \30!#_PG/A'_
M *&C1?\ P/B_^*H_X3GPC_T-&B_^!\7_ ,54W_"(>&?^A=TG_P  H_\ XFC_
M (1#PS_T+ND_^ 4?_P 30!#_ ,)SX1_Z&C1?_ ^+_P"*H_X3GPC_ -#1HO\
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M/A'_ *&C1?\ P/B_^*H_X3GPC_T-&B_^!\7_ ,54W_"(>&?^A=TG_P  H_\
MXFC_ (1#PS_T+ND_^ 4?_P 30!#_ ,)SX1_Z&C1?_ ^+_P"*H_X3GPC_ -#1
MHO\ X'Q?_%5-_P (AX9_Z%W2?_ */_XFC_A$/#/_ $+ND_\ @%'_ /$T 0_\
M)SX1_P"AHT7_ ,#XO_BJ/^$Y\(_]#1HO_@?%_P#%5-_PB'AG_H7=)_\  */_
M .)H_P"$0\,_]"[I/_@%'_\ $T 0_P#"<^$?^AHT7_P/B_\ BJ/^$Y\(_P#0
MT:+_ .!\7_Q53?\ "(>&?^A=TG_P"C_^)H_X1#PS_P!"[I/_ (!1_P#Q- $/
M_"<^$?\ H:-%_P# ^+_XJC_A.?"/_0T:+_X'Q?\ Q53?\(AX9_Z%W2?_  "C
M_P#B:/\ A$/#/_0NZ3_X!1__ !- $/\ PG/A'_H:-%_\#XO_ (JC_A.?"/\
MT-&B_P#@?%_\54W_  B'AG_H7=)_\ H__B:/^$0\,_\ 0NZ3_P" 4?\ \30!
M#_PG/A'_ *&C1?\ P/B_^*H_X3GPC_T-&B_^!\7_ ,54W_"(>&?^A=TG_P
MH_\ XFC_ (1#PS_T+ND_^ 4?_P 30!#_ ,)SX1_Z&C1?_ ^+_P"*H_X3GPC_
M -#1HO\ X'Q?_%5-_P (AX9_Z%W2?_ */_XFC_A$/#/_ $+ND_\ @%'_ /$T
M 0_\)SX1_P"AHT7_ ,#XO_BJ/^$Y\(_]#1HO_@?%_P#%5-_PB'AG_H7=)_\
M */_ .)H_P"$0\,_]"[I/_@%'_\ $T 0_P#"<^$?^AHT7_P/B_\ BJ/^$Y\(
M_P#0T:+_ .!\7_Q53?\ "(>&?^A=TG_P"C_^)H_X1#PS_P!"[I/_ (!1_P#Q
M- $/_"<^$?\ H:-%_P# ^+_XJC_A.?"/_0T:+_X'Q?\ Q53?\(AX9_Z%W2?_
M  "C_P#B:/\ A$/#/_0NZ3_X!1__ !- $/\ PG/A'_H:-%_\#XO_ (JC_A.?
M"/\ T-&B_P#@?%_\54W_  B'AG_H7=)_\ H__B:/^$0\,_\ 0NZ3_P" 4?\
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M_A.?"/\ T-&B_P#@?%_\54W_  B'AG_H7=)_\ H__B:/^$0\,_\ 0NZ3_P"
M4?\ \30!#_PG/A'_ *&C1?\ P/B_^*H_X3GPC_T-&B_^!\7_ ,54W_"(>&?^
MA=TG_P  H_\ XFC_ (1#PS_T+ND_^ 4?_P 30!#_ ,)SX1_Z&C1?_ ^+_P"*
MH_X3GPC_ -#1HO\ X'Q?_%5-_P (AX9_Z%W2?_ */_XFC_A$/#/_ $+ND_\
M@%'_ /$T 0_\)SX1_P"AHT7_ ,#XO_BJ/^$Y\(_]#1HO_@?%_P#%5-_PB'AG
M_H7=)_\  */_ .)H_P"$0\,_]"[I/_@%'_\ $T 0_P#"<^$?^AHT7_P/B_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>bionano-nancyridgeleasee006.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-+N??G857;E@VUL$ @X-21^)M(E>W1+HL;@(4(A? WL54.<80E@5 ;!R,=:
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M\1375A<W$FH?))=1JIAPLN0AB\S]TI ^\-Q5<8[$\Z/ARZU^;1;R:\9Y;P1
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ME:+9\A5ER,^8#R/3KF@#(TN?Q9>V=NMU=75O-+- MQMM0&@^60R[2\04KD(
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MKG[, +20&-O+,@+@J"H*CKCOGH"0X^+-%\F27[4Y1"@&+>0E][%4*#;EPQ!
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MKLJ* .'8^(XEF-J;BW6*2YF6**VCVS'[8^T'*YYCYXP3G.<\UW%%% !1110
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MQ#2P%UE\Q$0(<X9(P058J')/; !<\1>#6U.19;.5-S2F219RNW=Y0C4C*,"
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M1(V&!0!1YA9<[02!QS\U &BOA*P6"6-IKES*C++(S+N<M*968X&,EB>@QC@
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ML-1UM_">IS&.XFU. .(6EMR@E;8""B%$;&2?E()R"-S=:CL;G7;N_@A6ZO\
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MTDVT%""SNKG[RG'*CD8..,FJNH:QK%SK=FNFI<0V#K&=\UG*N]_,(=7!B+*
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MRV\D$DEP\4F0Z[@,@VPMR.!_<&?K^5 %M?$^CM$\IO/+5 Q82QO&RA4WG(8
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MEZJ?9DDDE9D8(!'_ *S#8PQ7N 21WIK>)](6V-PUTP0.R,ODR;U*@,V4V[@
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MK+[!Y<LQ^Q1211[B.0Y!.>.ORC&* $/B72A$[F>0%)%C,9MY!(6()&$V[FR
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MG%?2:C>,ZO%+(F(PLLD8(#'Y<C@\@$#@5!)X+TZ2'2XRS-_9UJ+1#+%%+OC
M7[P=",_*.1CJ: -JTU"VOGG6V=G\AS&[>6P7<"5(#$8;!!!QG!&*B.K6Z7]]
M;2GRELK>.XEE<@*%;?\ ECRSFJ<&@R66I3WEI?2(;JX62Y4QH%*KO. %4#<2
MP!8Y8A1SD9HU#PW#J-Y>RRWERL-]:"TN;=-FR1 ' Y*E@?WC=".U $\7B+3)
MC&L<TADDD,0B\B0.& !.Y=N5&&4Y( PP.>10WB+3%MS/Y\AC\TPJ5@D8R, 2
M=@"Y< *QRN1P?2J \'6@M8(!<.@BN!<;XK>")BPV@<K&,'"XR,'!(SC&(YO
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MCCG/4QZU;?9]1N;EEMK>PF:.621OE 502WL.:$U_2Y)XH!=J))5#*K*PZ@D
MY'!(!.#S@$XH PY+SQ#;^([2Q\]7MPD+-+)"P$^YV\P?+&0"J@8&Y<<%L@U4
MLK_Q25MIYYI6!CL)9(39A<F:8I*F<9 1 &]03DG'%=#:>*M#OIXH;;48I))2
M @&><C*]NA&<'O@XSBI%\0:?+)&D$P<M,(6!RA4E&<'#8)!"G&.O;I0!S,>K
M:[:")(;6:5VM;AHK98& \U3,RF0E?NG:@&&!R>00P(6'6-?2RMIIIFG1KL*5
M@MW\YT*KE?FA5>&)XPO'\65.>IL-<TW5())K&[2>.-0S% ?ND9! QR".A'7M
M69;>-=)N9+$^8T4-[;+<0R2J5X9@H!&..2.>G(YYH H>(KG4K+Q.)[ W&YK2
M)8XTM3(D[^:<HS8(7Y23G(/?. <Z&@ZEJ5]JVI6EV $TYC [!,"5V8NI'TB,
M1..[GTK5M]6L;J]ELX+E'GCW;E&?X3M;!Z'!(!QG!X.*I)X@\/P/>;+VVB,1
M>2X8#:,JP1R3C!(.%)YQQGM0!SMMK'B2YM0$:=9Y1:B<O9%?LDKSJDB)D#>%
M0L<G.-H)."*T/$EMJ(U2PNK19;N2RT^[FBB:)622X41^7GCACEL8(/7'>MI-
M?TN2ZBMENU\Z4 JC*1R5W '(X8J,[3SCG%10^*-%N;9KB"_CDC79]P,2V_.S
M:,9;.#C&<X/H: ,2UU#7+NZM[>"[N'LWO51KV6Q\MRGD.[#:5  #JHW8_BQR
M1FKU]?W-CXFOO+BGE:338OLD?ENT;S!IB5R!A3RF<D<8JS>>+=%LK:2=KP2A
M+=;DK ID/EM]UN.QYQ]#Z&KT.K6,[HD=RI=Y/*"$$-OV;\$'D':0>?6@#D(-
M:\0KI<-S/(TN;A-T<%L_G,NSYD :$*#N[$#C(W9&:?=ZWKZ&YBB$I"W^Q[D0
ME8XH")2NW]T3N!2-6RKCYP0<'CH;[Q/I5BMX'N0\MI$\CQH"2=@RR@]"P!&0
M.1GFGPZT&M](>> I)J<GEHJ$L$/E/)R2%.,1D=.I% &#9ZMXB;7+6*]-O% L
M432XBD"2@Q;I'4F/@A^ &9< <C)%:>LZK,;'3+FQFGBLKMPTMU%;&1XXS&S*
M=A4XRVT9*\9QP3Q=GUS2%DN;:>[BS"C&56!(P,!ATPQ&X @9(R/6GC6].#E#
M<A"L/GMO1E$:<\L2/E^ZW!P>#Z4 9GARZUN^G,VJ[H%6U@)M_(V@RLF7.3SP
M>,9XR<YXQD1ZUX@NKN_B@6YCB,]ND3S6OS1!K@I)QM X0!NK8ZD\XKI6\2Z.
MEM]H>]58]Y0[E8,I #'*XR %(8DC !!Z&K-[JEEIT<<EW.(T?H^TD >I(' Y
M')XYH YB#6->34--L)@6:]EDB$K0[=@@F;>[#_II%MQVSR.M-\1)J<NKZE!#
M<WGEO#8O;1"'=$K"Y.]@0.H 4D9Z'G@#&\VN:&;Z;?=VPN;..7>[#!B12OF#
M<1QC"DC/]TGM18^([&^M]2N0_EVMA-Y3ROD9_=HY.",C&_&.N10!ST][X@C8
M"-9'N(UN(5N&MLY NH51BHP.4+'C&<$C%/EFU27QAI]K/-=O%:W^ OV3"/%]
MC?\ ?-(%QDR,RXSC@#'&:VV\4:='JR6$LAB,L,4L3R*5W%W9 I!&5.5 YQRP
M'6GWGB.QMEG$;&6:"2*-XL%3\\@CR,CD D\C/3% &)<:[JB^*;NU@:>:*WNA
M$;:.T+#RC;"0MYF,;@Y  R.H&.01#I&J^(=2:WB=[B&)[_8T[VWS^3]G\S!R
MB@?O/ESM]LD\UMMKMI::'?:U]E6-$NI(YL$ N8Y3!O)QZ(#SV ':K#>)='2U
M2X:^18F+KD@@KL^_N&,J%R,DX R,]: .6@U37=/LK. W%S<SWEY/8[KF$!X9
M?,RC]!E!$LC=P< "N^J-X8I9(I'C1WB):-F4$H2""0>QP2/H34E !1110 44
M44 ,FB6>"2%QE)%*M]",5S5EX/CCET^[NGA>\M[:"&7]RLBLT.2K*6&5.3GC
MVQR,UT=T[QVDTD8RZHQ48SD@<5Q@UCQ)'<:1#(]OFXMX9I'EA9%D=W^>(  X
MVKTYS\P)R : -&V\&16(5K/4KJ*87#77FE48F5T*R-@C'S9W8Z ]..*AOO!,
M36NK?8I8Q<7L<VQY(4W(\ARQ\P+NQG)Q[^@ %,ZOXG4M/YB&,*\HA^QG.%N/
M+"9SW0YSUR,CCBG-KVOM<7GD1^;)"MS(]J;9AY0BE C4-W,B9QZDY' - &U;
M>&A;WL=\;^>2[%RUQ+(R*!+NC6,K@# &U$''I[U)>^&K.^GO)I2WF7+0L6V@
ME/*((P<=\<U@'Q!X@EO;#RXX8+>ZQ-%Y\;+YB-,0$/!(81;3C@Y;T!%3:#?:
MAJ'BL27<CX6UN%>#[.T:P,)D 7<>&.T _F>A% %B7P3%+)J$G]IW6^]5HW8J
MI/EM)O*$D9(QE.?X>!ZU+<>#XKS4DO;B_N)'52 NU< F%H3MX^5<,6VCC<2:
MP;'6=9L8KY8F:>.V:\NIHY+9E,2I=9"!C]XO$9,?[H(XK9O-2O)/"=CJ<S21
M-+>6\[")6!2!IU(# <\1D!OQH LW?A2*YEB9+ZXA18K>&5%52)5@<O'G(XY9
MLXZ@U$W@RW=)(VO[DHL<L=L,)^X$DBR'''S89%QGL,<Y)JG)K^L3^(+F*U:U
MCLD4F'SXW_>Q^1O$@PN3^\.T\]%(QG%,M?$6JNVEDK)*)?-1XUB&Z1P2 P.,
M&+C[PP>A(YX -*/PFBS6TSZA.\L5TUTTNQ%=F9@Q4,!E5.T @=1P?6K>H^'T
MU34K:ZN;J0Q6[%XX0B##%"AP^-V"&.1GGZ<5RL/B3Q(^D0SR?9AYTT:32"-@
M;7,;LX8%<+AU11D$C<0><&NPLM28Z0)KW:;J&V26Z$*/MW%-QV9&2.N!U]:
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MC9S2K%'<Q/(S.@4-DEE^\/P_K5.'5-,\FZU-]MN%F:TDED #.T<C(!QU^8G
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M;RTG282""*&-EFB#$F+.UE.?E//H>@QBET[PF-.UO3;A)2]M8:=';*&/,DJ
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MXUF<M>R.]P5C"JVZ%(N%![",8SGJ<YZU?G\+V]P\I>>3$DTTK  ?\M(O+(_
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MLBPLZR%I  A0 MGTQD9],BJNG^'8K32[[3YYC/;WA8-$%V1HK*%*HN3M!Y)
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MSAF8#MC: !Z=<GFFW?@Z.[GNIFO"IDN$N(XUCQ$C@ODLF?F+!R"1@G /49H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[X;*QD(G*[N21GE35=?%FKRMIJ0K;J)@=TMPH1)W$NPHA#D?=&01NSD''!%
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MD==QQM.."0>H(&*Q+/Q1K,>C:7NN8)KEK"&4A[=M]Y.6VO",-\KKCGKRV2
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M5;)4#)?'.#6/JU_JB7&H-8W-Z=426[$D",[+';"%C$ZQ_=!W>600,DEASR*
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M[53 7RDB0*.>F(A],UGP^"WA@ME&I@RV4<$-DYM^$2)MR^8-WSD\ D%?8 T
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MUG3&N)+<:A:F:)U1T\U<JS-M (SU+<?7BJ]]H%EJ.LVNHW<4<_V:%XTBD0,
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MDR$:&4RJQ'<;B,CT'7FJ+^#A,9)9[XM<3+-YK)%M4M(\+95<G  A48R>I.:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT9I+W4C9PI'N/GKOB83NS"0>=A@8RBY_>G ['D@'I<DD<0!D=4!8*"QQDDX
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MQ'S.A D^9@K!N=V#Q')H_B,KIZK<ZB(%$FX"4>;"YD!4M^_PRA<@99^.,<T
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M*F3:#YOH@Z9W')H [G[1#OC3S4W2@F-=PRX')P.]*\T4<D<;R(KR$A%9@"Q
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MK))%Y10,-ZD.2KD,02I4$#& * +-[XB=;/0[RPM9;F+4IPGE  2%3#)(,;F
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M+*WW03@9P!BKR^'-(C>YD-KD3I*DBO*[(%D.9 JDX0,>3M S3;/1]&ECLY[
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M27-L(;QK^WB-XSE5O"KK']FP!N$KMCSNV[WP!Q7;75PEG9SW,F?+AC:1L#G
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MCDHFW=A58D'YUZ@9[9I8_$J3W*PI:SK*OG++;2*HD#1A&QG=MY#J>N.>HYH
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MJE5:XD94"R"4!06PH#J#@<=NG%<])HNN6]MJ0M!<$W2:D?*:52@=I@T!52<
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M*"SOGO@LW?GBL^XL_%,B1K;RZA;VADG\G>PEGBSY?E%_WJ[@#YQP688*AAZ
M'2RZ1HUA;R-<2&&U:=)=LUTXB602B1=H+87YP#@?3IQ4TGAW2Y1A[8D?OO\
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MP4<*2^)&)SRP!!'WB#4-Q8^*3:VL<%Y?+"3.=PBS+$Y\ORL@SY91^\/S,1R
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MW99B26/89Z9;GFM>BB@ HHHH **** "BBB@ HHHH 9--';P232N$CC4N['H
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MPW4QC"P.OS?.K,#P<8PC\_[)I)_$VGVVI264PG3RY1#).8_W2N8_,"EO=?\
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MW_"*:5]L%R(Y@0=PC$[[-WD^3NVYQGR_ES[?6G3>%],GN+69XY0ULD*(%E8
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M\,:9#(K1I,BB'R'C$S!)4!8@.,X;&]NOK5JQTJ#3[)K2&6Y:(C:#),S,HQ@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !115>^N&M-/N;E$WM#$T@7^\0"<4 6**X+2]?OH+Z.RGN8[
MN*7['"Q:8B?,L()=0!TR"Q_'IMYZGPU=S7_AG3;JX;?-);H7?^^V.6_'K^-
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M)N+8&%R(\]< 9.3P*K/X[G>\O8[>TA*6EHUS(C.V_ MUE!SC')?;CK\I/0T
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M,H.Z.81'()Y)!+ <?=VYR0: .PHKC;CQP;>"2Y\B*6 Z>+JW*%AYYVAFZCY
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MVZ"I:* (FM;=XS&T$3(R["I0$%?3'I[4@L[82QRBVA\R)=L;[!E!Z ]A4U%
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MH8XHS:P%(3F)3&,(?]D=OPJQ10 QHHW.7C5CC'(SQUICV=M*RM);PN5)92R
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M0!H45#;74-W;0W$+[HYD#H>F01D<?2I597&58,/4'- "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7):;X
M;U+3O$-UJ:-:$S-+N)D?]XKRJP^3;B,J@(.TG><%N>:ZVB@#!T?2+RTUW4=2
MN3$BW2(GEI.\VXJSG=EP"@PV B_*.?6MZBB@#C[CP-%?>)]4U>\F:19S"]K
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MEU(!/VFY;'Y,I^A%8TLOB&^TR/[4=38HUE-<_P"A /;SB8&40C9\ZJ!G.''
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M$H,?EE/W8!SE^-S].<8Q1?WOB/3G6V2YFF^T7KZ?!++%&'_>(CI/PH!"8E&
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MW9MR\/FLJ!HF5I"KY_=G!5>>77J, \UEG4/$>EZ5+J5[/<RQP6L5Y/')!&N
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MFM-K<*12Z@\/G0B-9;0+'+;F,&221M@*R!MWRY4\+\O)J'7+'4KG5]2BCGU
MQRR:=) JQ!HHPMPI=E.TC<H&X@GIDD$#@ [6BN&DNO%4=Q:0>9<+&)9T\]K?
M<9-MP53S D38!B"G(V Y)STQW- !1110 4444 -E<11/(1D*I;'TKF-+\<V5
M[;+)=PM;N_D^6L)-QO,J,ZJ-BYW *V1CCCU%=/(@DC9&SA@0<5FVWA^QM+32
M[:!62/36#P[<#<1&T>6P.>&/IS0!')XHT>(S[[I@(20Q\E\-AQ&=IV_/AR%.
MW."1FH?^$OTJ2"=K>9FDAC>0K-#+$/D8*XR4ZJQ ( )!(R*CA\&Z9;M<^6TB
MI/,)BHCB!5O-$N X3<1N'0D\?AB:;PI83HZ/)<89;E3AA_RWD61^W]Y1CV]:
M +#>(=-"3/YLK+%,;<[;>1M\@)!5,+\Y!5L[<XP<T^SUS3]0N%AM)FF9HEFR
ML3[0K9QEL84G!X)!]JS;OP7IU[/=3SS3-+<3)-DI%A&3<!\NS:W#LN7#'&.>
M!4X\,6ZW4-S'=W$4L%L;>)HHX4* C&?E0>N=I^7/.V@";7-5N]*6V:WL8[E9
MYD@^:X\O:S, O\)R.>:K6OBRQ>XO;>]/V26U>0.6#&,K&H9B'VA<@'.,YP,U
MJWMA%?QP),SXAFCG4J0,LAR,^V16;=^%=-OHYX[CSGCG>9I%W  ^:FQATZ8Z
M4 7+34K"[L9Y+</Y,&4EB-NZNIVAMIC*AN5(.,<Y&.M4Y?%NB6MLLLMS)&F)
M,J;:4,@CQO++MRH7<I)( P<]*DM_#EK;Z'=Z2LLGE7*LKR)'%$XW+MR/+15S
M@=2#5.+P3ID-G/;"2XV307,#D;$^6<)OP%4 ']VN,#'7K0!;/BG2!!YOGS'$
MC1F,6LID#*H8YCV[@-I4YQC!'J*L)KNF2%1'=H^Z41*5!(+&+S0 <?W/FST_
M&JMSX8MY[N:\AO+NUNI96D,L+)D;HTC90&4C!$2'IG(ZU%%X0L(+N"6">ZBA
MA972U5E\O<L/D!N5W?ZO QG' .,T !\9Z.UO#/ UU.DLL42B.TEW?O 2CX*@
ME" <,,@XXJ_J&N:=I<R17D[(S+O.V)W"+G&YRH(1<GJV!U]#5/\ X12R6*)(
MKBZB>*.VCCD5E+*("Q0\J1D[B#D?E4NJ^';;5KAI9;BXB$L/V>XCB*[9XLYV
M-E20.6Y4@X8\T 5;;5[#4EU+4;ZQBBM])FD1+B:)BX"??8;D&.G\)/\ 2M$Z
M[IZJ3),\9"(Y62%T8!W*+D$9&6!'Z]*='I4,-G=VT4DBBZDDD=L*Q4N<G ((
MQST(/XUDKX*L4B@BCO+V..(*KJA0"4+*95!&SY0&)P%VC!QTQ0!/>>++&W5&
MA6>=/M:VKLL$F,DL#L(4^805(PN>:O'6+9[&RO()%D@NY$2-FW+G=TXQG/L<
M>^*JV_ANWMRBB[NW@BN?M,,#%-L398D#"Y(RYZD]L5.FAVL>GV=D&E\JUF6:
M,EADL&+#/'3)H KP^+M%N+<S17,K(!&0!;2[G$A(0JNW+ E6Y /0^E6%U;2K
M4&%95B"S&$H(F7$GE&<C&.NS+?\ U^*I/X/L#I_V)9IUC^QPV9RL;YCB+%<A
MT(S\YR<=AC%'_"(6?VM9OM=[L#^9Y)D4J9/(-OO)*[B?+]\9&<=: +4?B33)
M8K299+@0W;*L,K6DJHQ8[5RQ7 W$C&<9R,=:CC\5Z-+'-(ET^V(*3FWD&_<^
MP; 5^?+_ "_+GGBH;GPA875UI\\DUQFQ6!8E^0@^4X=3DJ2IR.=I&1@'H*5_
M"-@]O'$LUS&T2*L<BLNY"LHE5AE<9# =1C'!!H N+X@TUKN&V\V59I=N \$B
MA2V=JL2N$8X.%;!]N:AU;Q':Z9:ZDZJ\T]A 9I4",%'&0"^"H)!!QUQVID?A
M:T364U5II9;L*HD>2*%C(5! 8G9E3@_P%1P.*74?"]GJE]/=7$\^Z:V:V*H$
M7"-C/(7<>F0&) )/% $C>)M+6R:[:2X$".R2,;24&(K@G>-N4 !!RV!@YZ5'
M9>(#>:U_9WV;9_Q]?O-^?]2\2],=_-S[8[YJMJW@K3M8-Q]HFN5$[R/(J[",
MNB(<!E.#B-<$?,,G!YK1MM#M;74_M\;2F;]_PS#'[UD9NWK&N/QH IVGB[3I
MOM2W+M;26TEPK!T?:RPR%"5;;AC]T[1DC=BKZ:U8/ITU_P"<RP0$K+YD3(R,
M.Q0@-GD8&,G(QU%9<W@O3[G[2MS<7<T,WGE879-L33/O=EPN<YZ;B0/Q-6_^
M$:L6\/S:-(2]O-DLPBCC.<@@X1 N00/X>W.: &S^+=%MK<3S7,BIB1F'V:4M
M&(R Y=0N4 R.6 ZCUJX=9L!(8Q.6</)'M6-F)9!E@ !R0/S[5AZGX)BN=&FM
M+*]EM[AK6>V#I'$BR"3!PZJ@&,@<J >O/-6[GPC9W5S<RO>7JI/YW[I'4+&T
MJ;'93MW9(&>2<&@"S;^(+:\U*UM+9799DG+M(K1M&T90%2C 'GS,\X[=<U&G
MBK36^T!A=HT-TUIM-K(6DD ).P!26& 3QT R>*32?"UCH\Z36[RLZ&4C(15S
M)LW?*B@#_5KC '>EE\,PO<//%?7D$INC=1M'Y9\IRA1MNY#D,"<AL\],4 )+
MJNCV"V6HPV_F#59$C2>UMB[/N4L"Q49Q@=ZCL?%^FW,-PT[/;R0/,K(T;D,$
MF,64.W#DG;PN2"P'6K;:!:C3+"PAEG@2P9'@=""P*C'.X$'()!X[U4NO!^F7
M=MY$QF*;9@,E3@RS+,3@C!PZ+C/&."#0!-J/B2VM/#EQK%M')<+$2@C\MU;?
MNV;67:67#=?EX]*9>>(K&STVYOMJ/>10R Q!64L\<9D:/<5!  ]1WZ9XJPN@
M6JZ&=)+-Y!.2R)'&2=V[HBA1R/2JEWX0LKRYNI9+N\\NX\TF!638K21^6[#Y
M<Y(]20#0!.->7[!K%V\2QIIK,#N<X8")),DA21][' /3\*5_%&CQ3W,,ETR-
M;+(TK-"X4>6 7 ;;@D @X!)J230;273]4LF>7RM2W><0PR-T:QG;QQPH]>:C
M?PY:,[2++.CF2:3<-IP91AN&4@CT!!]\T 3G7=/529)GC(1'*R0NC .Y1<@C
M(RP(_7I4#^)]*2VN;DR7#06TKQ2RI:2LJLA(?D+@A2I!(X&.M4E\%6*1011W
ME[''$%5U0H!*%E,J@C9\H#$X"[1@XZ8I^I>#=.U33!I\TUPL/FSRG&QLF9F9
M^&4CJYP<9'KUR $GB^TBN-4MG1A/9NZQ JVR<K LV ^W:&P3\N2<*35ZU\06
M%U<PVHD*W,@'R;&VAR@DV;\;2VT[L9SCG%4Y?"%G-=S327=X8Y7:7R-R;%D:
M'R"X^7=G9D8)QDYQ4EEX5L-/UAM2@+"5L%E:.,Y(0)G<4WCY5' 8#KQR: )Y
M?$6F0W%S TTIDMI%BE"6\C?.P!" A?F;# X&3@YIG_"4Z,9H(A=,6G6-E(@D
MVJ)'*)N.W"$LI7#8.1BFW_A>PU&"ZBF,G^D7:WA;"MLD5%08#*5(PHX(/4_A
M3'A!#JHF:\E6R2WM8Q;QK&@D:&620%P$  RZG"[>ASQ0!<LO$EK<06;7"202
M73%$'ENR9W,H!D"[03MZ$C^5._X2C23:K<K-.T3MMC*VLI,O!;* +EUP"=RY
M&.]4_P#A"M-^VV=UYUR6M2AC4[",J[..2N1RYSM(R ,]*1_!5C)I]G927=U)
M%9$?9/-2%_)0*5" -&01@]6!/ YH M2^+M%BG\G[3+(Y*JODVTL@9B@D"J54
M@DH=V!SC)[&I(/$&C>9;V]O<+ME1&B,<3>7AEWJ-P&T$J,@$@]..12Q>'K.&
MZCN$:7>ET+H#Y0N\6_V?& .FSL._MQ5*Q\%Z9IUU;SV[2;H8(X,.D3EPD?EJ
MQ8IN!V@?=(''3KD >?&FCM;17$#74Z2RPQJ([27=B7.Q\%02AP<,,@XP.:U+
MC5+2UOH;*1Y#<3#*I'$[X&<98J"%&3C+8'Y5F_\ ")V2P11Q7%U$T45K%'(K
M*646Y8H>5(R=QSD?E5VYTA)]5BU!+JX@E5!%(L>W;,@;<%;<IXSGI@\GF@"L
MGBS1I(FD2YD91L*@6\F9 Y(0H-N7!(."N15FPUFVU&_OK.&.X62R=4D:6!D4
MDHKC!(P>&''7\,&LQ?!=DM@]F;R[DC,"6J>:L3^7"A)5 &0@CGJP+<#GBM/3
M]'ATV>XDAGG99U0/'(P891 @;.-V2JJ#DXX^M &7?^--/ATY[FQ$EW+O@2./
MR95#B601JX.PEDR3\R@@XP.2,V=5\06VDW9A>UE>\>PFN@4B;85BP2K28XY?
MC/3/8D Q6W@^QMX8XC<W<RPBW2#S&7]U'#()$0849&5&2<D@=:O:GHD&J7"3
M2SSQE;::U81E</'*%W Y![HI!&.GIQ0!7@\5Z5-9K<>9,&+B,PBVE,F\IOP$
MV[B-O.0,8YHU?Q%%I]GIUS;+#<QW\FV)WG$4>WRGEW;B",$)Q]145]X.TV_8
M/(THD$J2JQ6-]I6/R_NNI4@KZ@\\C%7[C1;.Z334F3>FGR"2)2J[2?+:/D8Q
MC#D\8Y H HV7BK1I+)'C\V!1!%,T7V9_W?FA2B' (WG>H"@DD]!Q3YO%VB0)
M&TEU( XSQ;2DK\YC^8!?E^<%<-CGBI+_ ,-V.I07\4YD(O98IG^Z=KQ[=I (
M(_@4X((//;BHE\*6 A$9>7 C2/Y%CC&%E\T?*JA1\WH.GOS0 O\ PDNE*RW
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MK?W$LPDMFC9$785S'()%^\I*\CG:1D<'H* &)XQT.2<1+=2[BRJ";64+\S[
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M!VJ'0N#NQMR0,[<YP<]*MW&MZ=:W,UO/<A'AC,LK%&V1J 6^9\;5. 3@G.*
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MQ@M@9!3Y3GIX=5L[BQDO(GD:*,E7'E.'5AU4IC=GVQFJK>*-(5('-TY$[;$
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M6.!\J@R*"3P,CGFK%UK6GV5['9W%QLG?9QL8A=[;4W,!A=S @9(R1@4 87A
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MD\T892IPI!;CH!GC@S>*8+YKY8[:2^^RR:1>Q?9X(MT3RX38&PIP2-V.1]W
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MG0Y!C.3G/0GH<5+=:MK]HM_'9QS-+;Q7:I:_8CY<:1H?(=6 &XL0GR@G[Q
MVF@#<N_"L5]O>XU"[DFD2%'D*QX<1M(P!79M(_>D8(QPO<9HL?"-C8&Q\J:X
M;[&D"1[BO(B1T7.!W$ASCT'2J-W?ZW8WEY;K-/<W$%D9+2/['\EY)L<_,ZC"
MX8* ,CMG.X5234?$T]@OEW1RSS$2I:LSX6$,JL&C09+Y'"]..O- &SHWAA--
M\-W>E/-(ANC*&D@<AHT;Y4"MC^",(H./X15'_A!Q#+$MGJ,UO$3.T[QI$K$R
M)&F%4)M PGIG//-4[G5O$\%NL9+'?/'ON3;E?*5H-Y4 (_ D^7)4\'!.>:N0
M7GB.74(A-*4B:XCMW2*VPH#6N]I S#/$O SQU!&>@!-!X-C%_=O-=S"S,XDM
MK6,KM3%JEODDKNS@/QG'0]:MW/A2UN&0?:[J./[/%:SQH5Q/'&Q90V5)'+-D
MKC(8^V,^SOM4@^'^E3M->27A6!+N>6W+319($C;-N25Y&2#ZG.#F/1XM0U'Q
M'IVH:@9F6"UNEB,EN$#?OMJ.05RK-'M)QCZ $B@"Q;>#%9)_M]]/*7DNC%&A
M4)"DUQYIQ\N2?E3.2<<XJSJ_A"SUC[3YUS<1BYE\R15V,I_=>7C:RD=.0>H/
M-9%QKFOMJFH0VD5P(AN6,RVI/ELLZ)D84 @HS,/F8D 'Y>E22ZOK]I-:6C%I
M6N[N6QCF> !@5D#"0@ #'DB4],$H/6@#1N?!UE=1S1O<3^7))#,$98W59(T"
M!L,ISE5 (.1Z8/-:>FZ?+I[-$LZFS2)(X85B1 K L6?Y0!EMP& ,#;[FN=\6
M3ZO_ &K!+IUI>2PZ7&MW)Y+;1*Q?E,9^<^6LHVC/,BGKBL^\\4:Q$FLW%M,\
M@M([X[&LR(X1%GRFWX^8D\$9YYX!4F@#;_X0FV%LT4>HWD3-)(Y>-8EXD0(Z
MA=FU0< \ '=D]ZG'A2!8;NW6^NUM;H+YD V8W*J+N!VYSA%XSCKQ7-W]UK%W
M;W<R)=7:V\-ZMK*]JT;2C[.A&4P/^6A=1P,[>YY.K<:SJ4:ZH7>]6>.?RHX(
MK/Y8X_,55D#E"#E3N/WL#.%^4T :FI:!]HT/6+&UF*2ZB7?>YX1F4#C Z<#U
MJL_A")GDG_M2^6\F,OG7(\O=(LBQHRXV;1Q#'C !^7W.>=M]3U[^T;>\=;I+
MN>TLXS"+)BDQ%Q*KAB5&S"-N_AZ@]!BK%A>^(+:]L;&)/(MB^_,T3GS=US()
M%.$;&(PI'*_>!)(S@ W)O!FF3)<1EYUBF#J45A\H:&.'CCLL:D>^?I2W'AN2
MYU;1[RXO9+G["96D>7:K2YP54JJA<!E#9Z@J.N365XAMM3?Q>EU +@6D"6)=
MHC)N -Q+OV ':W&T."#\I^E0QZUXE:"\EG_= 3(CHEN[R6RF<*S*/+ 8"/)Z
MOTW=.* .COO#D%]J1NVNKB-9#"9H$V[)3$Y=,Y!(Y/.",@4V^T'?X/OM#LY2
M#/;311R2GHSAN3@>K>E<Y#XGUC^S?, GG:07$<$B6+99X[IHQN4#Y3L )!QW
M]#5R.Z\0(US]EB=1"FH3I"8>)Y%G<1*6/0,,'CKP0<=0"^?"4?FO<C5;Y;Z1
MW:2Z BWL'1$*XV;0,11]!G*Y[G(_@K2WMY;;=.L$@93&''"FW6WP#C/W%!^O
MY5D0ZCXFN;"()=$%Y9/WR6K%U58=P5@\: ?O!C[O0XSGFFSZOXGAM8U;>?,E
MA:2X^SE?)5X68J $?@2 +DJ2,X)SS0!N7OA.#5(0FHWUU=2"(QB1UC'_ "T2
M0':$VG#1KP00><@TZ'PK:PSZ=*DS(;%F=!%#%%N+$DY*(" <\@8!P,YYSG6]
M[XCDOH//E*QF:&"1(;8A,-;;GD!8;L"3IGIR"/2OH&I:O''X;@NI[VX\VT5;
MH26Y619MIW&0E,;01C(8'.,[MU &U?\ A>UU'4;F\FN9U,\'D,D811MRIY(7
M+8V\;B<;FQUJOJG@JQU4R^;=7*++))(Z+L9<N$!(#*<$>6,$<C+<\U7U:^U^
M!M7GM6?RH;J""",0?=C98C)*"%8MC<XZ$#!R#BL^YU_7;4V7VF<IN^RA6CM&
M:.X,ER8WW,4&TB/RST498GD8% '4VFA6UEJ(O8Y)3(/M'#$8_?2+(W;L4&/;
M/6JK>$[%H[A#-<8G$H;D<>9,9CCC^\Q'T_.L676=7NC]E-K.S1NPF!M7496[
MC5,-C!_=DMP3QS2WEYX@BL'O@)9KD-J!AC%MQ$(Q((A@<G=M7KUSQUH UF\)
M0&YN+J._NHKB6X2X5XUC41NN_D+LVDD.02P)("\\4)X.T]=,N+!Y;B2*>SBL
MV9RI.V-G96Z8W9D/48X''7.!K>N^(-,6>R6XF:83R"&Y6T!)001ON90I_=K)
M(02!G QG/7<U:2Z.JZ/);WEU]CDAF63R8PR2L54INPIQGYL'B@"VOAVW709M
M)29HXY3EI(8HXCG(/15"GI@Y!R.#6!)X&N+6_L7TVYC\BV)?]]L&&:<RL=@C
M*D9/RA2F"!R>,4[6]\2Z7H5C: RNH@LR]P\!5H%:.3>HPC=&CC'*L1OY]1TD
MNIZA9Z7H=S=+O,DBK?M;V[N IB<Y"[=P'F;.V1G% $5KX*L;6YGN/M5S))-+
M#(Q?9G,4IE7)"@MR<$DDXQS4C>$+(V0MA/+M%LMM\Z1R JKE^0RD9R?2L*S\
M1ZY->:?%*TJW!M["2:U^QD ^;GSR[8^3:H+ 9'(QSG%1:%KVOZU#:_Z9-%)<
MR0&16M &AB:*1F=05 V,R@*QW=.<]P#L-,T6/2[B22*ZN9%DBBC99F#9**%#
MEL9+$ 9YQ[5FZ=X*L=.G\Y;JYEDWPN6?9EC%OV[B%!8GS#ECDGCFLF77]=-W
MJ:Q1W:6RNBJ[VI9X%^T"-V4! &Q&2X&7X )X.*KZ?/K=O8QFW6X,LDT^)Y;1
M@V'U'&XH<8_=L6QQQSP* .OM]"MK:RT:U224II.WR22,MMB:(;N/1R>,<XJH
M?"=H;FWF%S<#R9)Y% " DRN[,"VW=MRY^7./E7/3GGKKQ#K=O>VEC+<RQ;)G
M$US]F&#$+G8K2?*0H:-3@@*"Q!Z9QTFKZK(V@F\TN1RIN$A>:.$NT:"4)(P7
M'. &YP1QGD4 58?!-C;:=:V$%W=1VMK,LT2 1DHPQG:Q7*9().TC[[=B +NI
M^'(-3O7N'NKB)9HHX;B*/;MG1&9E4Y!(Y9OND<,?;'*:=?\ B*W6RMX=Z0R7
M%Q+YMS;R*9BUW)PRB-BO[L@@?+][.< BK<E_XI4RSK-*5 N)5A%F/^6=QL1,
MXSAHSD]S@$$#- '2/H-K)HUYI9DF$5U)-(S@C<K2.SDCC'#-QD'H,YJA)X-M
M;B&[6YOKR:2[6<2RML!/FQI&V % &%08X_.L35+_ %N]M]5M2ER^Z*\1[<6I
M40A7Q"4?'S%UYQDYSQC!%27$NK)?,P:\CA:+5%$"0DQRN)%\K=P3DKN(.1G'
M'4Y .@N/"]C<:\=6< S,$#JT4;@[<X(9E+*>?X2.@IMKX:6U@TV$:G>2+ITJ
MM;EQ'D($,?EG"<C:QYZ^]8O]KZ\EX8HTG#(2@MOLAV"(6V\2[\<MYN%QGVQG
MFM31-3OHIOLVLS.\DYA%N[6^S<[1%W08&,+L8\].A)H ?=>&WO?$4U_/>2+:
M,+5A;1[<.\+LZEB5R &*G@C..:@O?"$;:)/:65Q(MS]B6VMY9&'[MD8NDG ^
M\K8/X"HM7OM?MWU>>T+F*"6"&",0=$?R_,DR%8MM!?& 0,'(.,5%9ZKK9N;:
M.[E?FWWP^1:LR73^9(-KL4&S"+&<X498GH* +MSX+L+F,1>?/%"+!M/5(@BD
M1%"F"VW<V <@$D \XJ:?PO'-%>P#4;N.VNIO/,"B,JK[P[=5R02#E22"&8>F
M,2QU7Q#>"&))KC;*UL);B2Q\MH7<2><BJP PNU,$@X+<ENE-DU/Q#<6Z6[-=
M+-/IL@'V>WVLDX63YVRN #M4#:W!.,<@@ Z/1?#EIH9S;R2O^X$'S[0-H=WZ
M* !S(>G& .*J1>#;.'R$CO+L0((!)#E-LQA;?&6.W(YQG!&<"L\:AKBV=Q<P
M7%S-#;:?!*@>T^>9V9_,)&T$D!1\H //?(IT>N:E<ZE"&:ZMK!YYPDJV+L7V
MF,1H05)"L&D.<#.W@C'(!</@NU,+QF]N0'NA=$JD2[7P!E,(-A..67!.3S5S
M5?#D&JW3S/=7$*S0BWN8XMNV>,,6"G()'WF&00<,?;',PWFNVEHSH;R\NH1J
M +SVY+(1-&$P !N&PE@!G.,#TJ:34_$4L4ZV=Q<-#&+EX+I[(!YPD<;("I4
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MX9FD$D;/##;/Y_*,7C4-$%!W!, Y[@MD@U)K>J:M>6&KZ8+:Y,GV;4%8+:N
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MCL$94CYOE"E,$ Y/&-&WU+4YO!DEUODCOT8KYD\1^;#@%E"QYVD9PQ3C@D$
MYSK2XUAM634HUO(XITL4EMY[<;F#;@Y; X*Y!XQCOZ  W]$\-66@R3-:='R
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MQ5(8T;$+K)CYBZX.,G[QQC:: +">$K6.]29;NY$*O%)]E58UC+1QA$. H(P
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M@JQLKF2X%U<R2220R%GV9)B=W7)"@L27.2<D\<UTM%% !1110 4444 %%%%
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MTFZAFE%R8EA,^_SD*<0MMD;GJ <?G]:J:7X/L]+%GY<@)M)5D1EAC1G"QO&
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M]4_M&VOIX)S)*SX56#+)Y99<$'',2X/UI=#\,VF@RRO;[6# JA,*!U4L6P7
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M\1&SFDM'$B6]M>W$<QM#_I7E&+RQC(QNW../O;<C%=A>:I8Z?"DMW=10QO\
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M].3C(Z$5UUYJMA86\=Q=7<,4,GW'9N&XSQZC )^@S37UG38T9WOK=44N&8R
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MK_8HF#6I42J[.K..?EP"#P/T-=K10!R^I76J)XB>VLLQ),UM&9C$9 JD3EB
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MLAN+F)BK+(Z;"N/O;$,N['>,>M=I10!Q]IJVN2>0\LL;P1VMS<.UM;F0S;'
MC49V_,03D <D<8%8MQXPUU=/=4)64S3"&?[/N^188G#/VV!Y"&8#@+QD]?2J
MJ7VEV&I!!?6<%R$SM\V,-C/4<]C@9]: ,#2=7U>\\37%M,8!9HSJJ%2'* +L
MD4XP0V2>N.0!R#FC'?ZOI4^HS'SIK5Y;YUB2V+.A0@H0<_-GGC@'CT)/<
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M0.H.#RJ!2.GW@3P*[ZB@#FM7U"\&LW%AYK0P?8P\*K;LYN';S PW#IM"H?\
M@7/45B1Z_K<#165G!-(T=@5\N6W/^L%L)%8'J<M\O)&3D 9&:] HH XFX\47
M\BR7%KN-JEW&@"VS"25#$K$1AAACO)';@$ Y%6=*\0:B=5OVU5H+>RA>5/+*
MMYD9$P2(CY>0RG/4Y)&.,UUM->-)5"R(K@$, PSR#D'Z@@&@#DO%\FH+=RQ0
M7,ZV\VCWH6&./(>8*NWD=&P21]#[U5O=8\16$36V^)MMT(S>O 454, < CYA
M]\E<^@QU.:[FB@#EO$.I:G!I5BH=;=KF%_/FBMWF D$>511U^9LX)YXQP2*R
M;'6_$4,B6T=O$RV]HGEV\JL)+@"U#[AQR?-^3KC (QG%=_10!P.EZU?6^H/>
M3W$MS9S74*33_8W0*GV>0\+_ -= BY'K@\T^+6M<U#376262SO7TI)884LVW
M2R-"69@3]TA^,=L<\L*[NB@#SV\O;YY+*87<PB5K-VO/(=NJ7 <E1QQ\O; R
M"<TAUG7H\WQA:.2XMK))97B94C7?<YDVD':3B/((.W>,]*]#HH YC4=6U*U\
M+6%PQ OKC:KR6\1:,,49L_,,A20!T)R0.^:H6^K>);^6S972U2=[>.1#:%BF
M^W\QVR3V88&>!DYSV[:B@#A[;Q%KDTFG>;'Y<TL=F3;"U;$PD($[[OX=@R<=
MMO.=PHB\2:U=VRQP(8[E4M$F9K1L1RO<B.48.,[4YQGCKTKN** .1TN^U:;Q
M#8K?7,BQ&*\A,8@VI,\4Y16/H2@#?GCBJVJWVJWEW>V$<C!H[ZT:&2*$LD:>
M>@(;H=V,D@Y!'(.,BNWHH X=_$>M13Z;;F.1IC="&;_1L)+']J,)<=3D(-YQ
M@#(/((%6O""W2W]Q]H68+]@MP/,!QN\^ZSU[XV_ABNNHH X6WUWQ"FGQ27C!
M?/M[.:2<6A'V7S6<2#;DYVA5Z]"Q)XXJWHFH:M=:[:-?7$B02VLP2/R"BS%)
MF"OSRI9-C8]ZZ^B@#B9=>U\7VK@""-;99A#;F)F<E2!$0 /F#]^?XAC!!J6Q
MU[5[BYM5NP;5WA\SR/LS-YDWF.KP;NVP*OS?Q;MW3BNQHH \]@\2>)'TB&XE
M^S RS1+-((V!M<QNSA@5PN'5%&02-QSV-32:GK-WJNEP7;B-UGM7:&WMW*2J
M8]SR!ST4.2N#Z<\D5WE% '(7\H@\>VL@:6[D91&(%,R&V0@[I !\CH<+G/<#
MDD 4SPO>M86DUE+</=%?*B@OG:8BYF96RN)"2&&W)P<?-VP:[#8N_?M&_&-V
M.<>E#1H[(S(K,AW(2,E3@C(]."1^- 'F=E-=%;$RSZI_9K1VG]K/(\P9)MDV
M\9ZK\_DA@N !CMFI+&75#+:+<2:D+T2V?V)6:4!K?SCYA<="WE9W;^1\O?%>
ME44 <E>Z[J,?BUM/MY%9$EME%L+9B71\^8Q?H-H&[\.<Y%4;'7?$MYILTC_9
MXKAYK6/RQ"S/;-),$D#+@9"J>.3R">A%=ND$2323)&JR28WN!RV.F3[5)0 U
M RQJKMO8  MC&3ZTZBB@ HHHH **** "BBB@"*ZMH[RTFM9<^7-&T;X.#@C!
M_G7.IX2D66&[.J.VH6YB$,YA7:%C25%!3OD329.1R1C&,5T]% '/2>&9'BOH
M!J<HANI!.%,2Y28%#OSW&4!V^YYQC#['PRMK/]HDO))IBETK,4"@F=T=B .F
M"@ ]CS6]10!S3^#K9I]/D$JM]EMHK5EEB#B1(SE2!D;6SGGGKTX%+/X/@EBC
M5;N5'B,K1N%!P[W"7 ..^'C QW&:Z2B@#GF\+B36(]4GN4GGVQ^:)(!AFC9F
M4KS\G+>_0=\DV;K2;W4=%M;:ZOS'=H5>:2%2$D8 Y4@$$KS[=!GTK8HH YRR
M\(6]E:VT"74K"W6S4$@9/V<87/U[U-H/AS^PY-WVV2X5+2*SA5D5=D41;;DC
MJ?FY/MT%;M% '*MX-9[&TMI-0$BV4I>VWVXP P8%6 /S<-UXY ]Q4S^$8S+.
MT<\4<4ENL @%N/+.W9AG4$!B!& IX*@D9X&.DHH YB#P7;Q7D<\MT]U^[C24
MW*[W=D38'#YX)&,]>G;FK>A^&XM$L9;5)(Y"\2PB3R0&**"%W=0QY/H.3P,U
MN44 <NO@N(Z?+:R7TK"2SNK,!5PL:3[,A 2=H7RQ@9QR?847/@U+O4;R[GU&
M=_M$,L*JPR461D8C)/0>6   .#W/-=110!C3>'DET6XTY;J2/SKIKKS0H)1C
M-YO /'!XYK-D\$033)<370FN&,IN#+ &242,I("Y^7&T <GC.<UU=% &1JN@
M1:K=QW$DSH414 4#G$L<G\XP/QK+/@K=-=SMJUPT\TD3I(RABGES^<N<YSS\
MO88 P!75T4 <K+X(MY[5HY;R5I7)D:38,&0W'VC.WTW#&/3OGFM,:#$-$ATS
M>J*DZ7!:&,("RS"4\9/5ASR3R:UZ* .8N?!L5U'=P27TIM95N_*C"#,37!)D
M.[^+EFP.V><\8T]=T?\ MJP6V%P;=E?>LRKEXS@C<AR"K#/##\B"16I10!R]
MUX,CO)KH2ZA.+:87&V)47*-, &.[O@C(^ISFK5SX<:_61KV_:6:6W^SLZ1!!
MC>&R!^&.M;U% &%K?AS^V)WD6]DMO-MS;3!45MZ;MPQGH<Y_ GO@BF?!-MOO
MBLX7[0\DL;^4#)$[RB4G<3RN\ XQTX.:ZFB@#E+KP6UU;3J=6E6>Y6YCGE$*
M\I.$#@#H,>6N#S[YZU;E\,L\.HVRZ@Z6UXQE$?E*3'*2IW9[C*YQ[GGICH**
M .;NO"LD]U+=Q:F\-S+*\C,(58?-#'$PP?:,$>Y[C@P2^!;,JODSE2D@9!*G
MF+M\B.$J1D9XB4YSU]N*ZNB@# \0>%UUW38[ 7LMK;K"\#1QCY65E"YQD#(Q
MQU R>/19_"T$[SN;B0&5KACP./-0(?RQ6]10!S8\(0_:/GO)6M/-,_D; #YA
MA\DG=UQMR<>O?'%+I_A/[)<VUQ/J$EQ+!)&ZDQJHPD+Q 8'M(2?<=AP.CHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV89!&0%)&0>:XA/!/BBW&GV\=Q*L$$MP7DM;D(SR-<>8+@C(&67@CG'( P:
M/59)$AC:21U1%&69C@ ?6F7-Q#9VLUS<2+'!"ADD=NBJ!DD_05Y?J7@+7[ZP
MU2)IY9&OK>_5TDOG*,YN5DM@!G"@(&'  &<'K4FI^%O%%_JEPT%N+:QDL)K9
M8C?/)N5K38JON8@D2]2 !P&R22: /24OK226*%;F(RS1F:./>-SH,98#J1\P
MY]Q0M_:26'V^.YB>T\LR>>CAD*@9+ C@BN0\4^&]9N]$T>316B35[&)K<L[X
M41R1&-^>^#L<>NRLK4?!^OC78H=,1(M'M[5K6/;<L/,B^RM&%9"V/]9M/"@<
M Y)S0!Z1!/%<V\<\+AXI5#HZ]&4C((J2O,X/#7C&WGM[2"58K=)(IA<?:SB/
M;8^04V8Y EP_IT/6MKP+I&MZ)9-%J8N)'F=!)YMT)!&5C(9UY)(9@.^<G.!S
M0!OS>(]$MYYH)=7L5GA5FDB-PN] H)8E<YX )_"M.N:UW1;R_?73 J$7FCFS
MBRV,R?O>OH/G7FLO4?#>L RPVDUT;#[676*.Z)DVF!%!#.PZ2!S@GJV[J* .
MV::))4B:1%DDSL0L 6QUP.^*?7,>(=&U*]M(!92L;B*PN81*TFU_->(*IR.^
MX=1TJI<:%JMO<$61GDB34%F@22Z9D$9CB#;\MN^\)",$X)S@Y- '94R.:*5Y
M4CD1VB;9(%.2C8#8/H<,#]"*XN71O$-SNMI&ECA0R)YJWA!E#722 C!R,1!A
MZCD=,$SWOAO4+BZNHUFF6R\R0P*MVZD+]FB1.ASQ(KGZ\]30!V%5(M4T^>^E
ML8;ZVDNXN9($E4R)TZJ#D=1^=<7HHU+_ (3MCJ'VM]F47;OV@^1'EFR=NS<K
M[<#[S'WK0?PU>J^JWZR-+=F6X>QMV<+&ID4+N)4!\D C[WY=0 =?2*RNBNC!
ME89!!R"*XW2O#FI/):#4WF^S1+>8C^TL,&1XS$"%;G"B08R0,\=JK:5H^JZ?
M/X<TT":"W^R)]O3SF8(UN05*L"1\[N,CC*KC'!  .WN+B&TMWGN)%CB099VZ
M 5+7'Z]H>J:A?ZFENKM;7=IY>Z6? 5OEP(\-\O1B<CKR#R1575-!U\0-:Z=N
M\E;B62WD-T^^+/EE.2PXR).NXC@  $T =C#J%G<3^3#<(\OS_*#S\C;&_)N*
MDGN(;6+S9Y%C3<J;FZ99@JC\20/QK T?1;RRUHW4RH(C]LY#9/[RX\Q?_':P
MY_#>NW%M-&ZR,_'GEKUL7;BYCD5UY_=X17'8C< .%!H [_>H<(6&X@D+GD@=
M3^H_.FM-$DR0M(@ED!*(3RP'7 [XR/SKB8?#^K0W,%\ML6F2WOHH(Y;QC]G\
MQE:%68-DCY6!VDXW#' !$4>@>)#IE["LLL1DCNU@3[004WQ1A.C'&'$AZG&>
MO- '?45SR:9J%EI.N6UIF0R2,UBDUP[84Q(""V[</GWGJ.O45@_\(UKTVEF-
MYITEBMKXVRB[9=DKO&UOG:Q!VX;J2!TH [I[B&.>*!Y%667/EJ3RV.N/I1#<
M0W <PR*XC<QMCLPZBN7LM%U)/%RW]S$[)'+<DW#7)971\>6JQYXV@;3P.F><
MFJ4_AWQ LFL&"8[+N7S(-DQ0QKYRLZ8Z9D3(W=01C(!H [JBN%7P]K8N-.)N
M=0^S1C(7SUWP-YQ<[OFP5VE5XW8"XZ$U9\*66IC4GO;A+B*#%TDGG7+/Y[&?
M,;!2?E"HK#H/O#&1S0!UT,T5Q&)(9$D0DC<AR,@X/Z@BHGO;:.]CLFE47,BE
MUCZDJ.I]A7)CP]K+S>?)<3>;$T+0XNF &+N1WR <',3*.>W%6]=T&]N]5NK^
MR)65K*.%2L[1EL2[G0$?=W)D!NQ- '4T5QUIX?U5[J.5Y)K:W1;I[>!KIG\A
MV,7E!L'#XVRMC) W8%4KC0-:FT^PBC2]M5C21+A([[S)&F*QA9@S-C *R=\_
M-G;DF@#OJ*YCQ3I^LWUQ8C31\L9W-*)BC*P=#R-P&"H;LQ[< FJOB2RU.^\1
M+%8I<?\ 'HACF6Y:.."3S?OD X; !XY/;&"< '67%Q#:P--/(L<2XRS=!DXI
MT4T4Z%X9$D4,R$J<@,I*L/J""#[BN(E\/:W.]TK;\MYWF2/=%DN=TZ/%A<_+
MM0$=!C.!D<U<@T;5!JB-?)-=6S23[-EXR>1NN)'#$ C<#&R #G&W' )H ZZB
MN0T6RUR?PMJHENY%U*5)+2TFD9A@1*8DD/'!9@9,X_B'7%-L] U"2\MVE2YM
MM/6\$QM&O6=E40E>6#<@R8.W)'&3R2* .QJ*>XAM8Q)/(L:%TC!;NS,%4?BQ
M _&N3U>RU.]\9,+1+@1QQ6+I.+EDCBQ/*9?DSABR#;T/4 X!S5:W\/:VPB6?
M>&22V:Y:2Z,BW4B74<AE4$G: BMQP?F QA10!VJW5N]L;E)HV@ +&0,-N!U.
M?PIZ.LB*Z,&1@"K Y!'K7&PZ+K:2-]H6:=S9F."5;PJ(),RY)&?FR&CYYZ<X
MP*C30-<.H73W-U?%7@*QO;7*K\IMPFSD\,'RP.,9P<]10!VLLT4"JTLB1JS*
M@+'&6)P!]22!3ZYVWL-5/AJRMG ANH[R)W"R$?NEG#')W'DQCD D9) XIGAO
M1;_3)@UU+*ZR6:+-ON&DS,&;)&2<<$#CT ["@#?%W;FXC@$R&61&D10<[E4@
M,1]"RC\:FKSX>#M0738HH(Y(+BTLKZ.!UNV&9W>-HG!!Z?(3@]".E;6DZ3JE
MOXGO+R\GN7B9Y2C"4&)T9@47;G(*@8Z =>3N- '3T5QCZ%K4#W-S;LTLTRWP
M=)+M]K!YU:$ ;AC$>[&",9QD9-5!X8UV?3$CFGN$EBBN?)"WCH4=IPT6=K=D
MR.I Z"@#OJ*X2^\-ZV9$AM[F[%BDMQY:PW/[R/>4,;Y=N=N).I)&> 16GXIT
MO5=0G!L3(0;62*%DN3%]FG)&V5@"-P'XGC&/F- &Z-3LC]K_ -*C"V?_ !\,
MQPL7&3DG@8')]*MURDWARX'AGQ390(/M.I_:C$&D)!+H0N<].33+_3]:U/7;
M.\9+NUM56,"**=,Q.LA9F;#8(9=HXR< C'- '745PQT;75MV6..=F2^\Z'SK
MG.\$'/G8?E03P5P>!E3CE)M U^9[T+)/%)(ERKSB];$^^56BV@'Y-B C/&.@
MR#F@#NJBEN8(75)9HT9E9@&8 D+C)^@R,_6L/Q!H]]/IUG;:/,\!1S#(?.8$
M0.I1B">2RY#COE?>L.7PSX@OM!N+:_N/,N;FSNH95\\[-YCCCB/T/EESZ%S0
M!W$=Q#+-+"DBM)"0)%'5<C(S^%"7$,D\L*2*TL6/,4=5R,C-<M#X?O%UE=2A
MCEMSY]N1&;DG$2QE75@"58Y/OG YX%.U71M1DU>>ZCA>>SDN(GEMXKCRGF18
M77&<CHY4X)&<>V" =917#QZ%KR((YY;J9GTT03S)=?,) H'[HDCG.<EQS@'(
MR15K4K?4U\-:1!+;2/<"[C6>"UF9-R?-D;MQQQC(+8SQG'- '745PL.B>(A>
M:0)2?*MPGF2"Z9F"%Y-T;$M\V$9!G:<X))X%51I7B.]\/S(&DFF\]K2-VG=&
M\J%7C27[R_,SY<GG@@@$@4 =Z+RW/VG$RG[,VV;G_5G:&P?^ L#^-212I-$D
ML;!HW4,K#H0>AKAO^$=UIM6N9O+96GD$DEQ]K.QT^QK$4,><9,@!SCH,YX J
MWH^A:O::_#/=S7!MXE39Y<H\L((%0QLI.?OAFX'7!SVH [ .K%@K E3A@#T.
M,\_@139)HH0IED1 S!%W,!ECT ]S7(76@WT>I:I-!;2R076H174B1W10W$0A
M5#&/F&TAUW=@1@9["U)IFJIX9TV%D-U>6MW'.T9FRVQ9-P7>WWB%P,GKB@#J
M**XR31M:NM;OKN:2_BCF1C"+>Y5=BM $\OKPP?+ @8S@YZBF0Z1XA!T]D!AF
M2*:)F>7,<2DR;&VAR?,Y3/WEZCC H [:BN'L_#NJRR6ZW N;>R$L!G@-^[LY
M6.42/N#9PS-%QGG9D@9K1\0Z?K%YK>G26*[;>&6!WE68J0!*#("-P&#&".%.
M<D' Q0!T]107$-RC/!(LBJ[1DJ>C*Q5A^!!'X5Q9\.:U#:MY<L\C2JIN8S>-
MF7%P'*J2?ES%N7C Y X'2]::3J5EX,FLHK8"Z>[EE$+7#.1&]P7QOW#+;&[L
M 3P3C- '5T5PUKX<UWR('N+B;[1;I (L7;8!6Y=FR,X;]T57G.1D5J>&;:_C
MU'5#>2RO;VTIM;3>S'='N,F[GJ1O6//_ $R]Z .BAFBN(4FAD22)P&1T8%6!
M[@CK3ZX)M%UZ7P[I&G>1<0+8Q^3.L%P@:4[-JNIW#@'/!(Z@XR*MW'A[6S<W
M%S:WLR7,DSJDKW+%1$;/8/D^[_KP&X'O0!UL=Q#+-+"DBM)#@2*#RN1D9_"I
M:\\_X1K61'*\%O<6T$ES')+;"]\R5T6$H?F+ ??PV-W;/7BMW3K&]TB:>[N!
M=WT\C6UO%NG+'9LC5W(^Z#N#L3CG'N* .C$T1G: 2(9E4.4S\P4D@''ID'\J
M?7.:SI.HW^I2&*61;1Q:*52=HSA)F:7H01E"![]*S4T+6XY[9$DE*K%<0&26
MY+)&A:7RROS;M^&C!)# @=BHH [6F0S17$?F0R)(F2NY#D9!((_ @C\*X^WT
M;6KZXM6U%98+=;B%I8EO#ED2WD4Y*GH9"AQGD8)]*1O#VLR2-,]Q-YL;!H,7
M3  _:W<Y .#^Z*CGMD4 =I4(N[<W$< F0RR(TB*#DLJE0Q'T+*/QKC?!?VQ]
M;U.2^6[+R!MI?>$1?-<@-N/WR&7H -JBJW_"'7XTV.&".2"XM+/4(X'6[89G
MD>)H7!!SCY"<'H1TH ]!J*"XAN59H9%<([1L5[,IP1^!%<[I>DZI!XIN[R\G
MN&B9Y"C"4&)HVQL4KG(*X] .IS\QK,O_  ]K;+<);ASYK7A@,5T8OL\LDNZ.
M9L$;@!]2.F#DT =U17$WVC:T_P#:RPK<.DLRRP%K@;G8%CM/S@>5RO'RL.G.
M!5_Q%INJ7T=IY,;RJMM+')##=M#MG8)Y<F[()"X?W^8$ D4 ;\=[;37<]K',
MK308\U1_!D9 )]<$''H1ZTZ.[MY9S!',C2"-9=JG/R,2 WT.#^58NBZ#+9MK
M9NVWR7\R,9 Y^<"WB1CC/R_.K]/;VK!T_P )ZC!:6#+');W-I964"A;IL;XY
MF:4\'# J3C/9B,#D4 =]4%K>VUZ)3;2K*L4C1.5Z!U.&&>^#Q]0:Y_PWI.J6
M.IWD^HSW+ES(-QE#129D+*P&200O'08Z<@ UE2>'=;T_27M=,C8M-!J$1 NR
MOEO+*&BDR3V4'IR"?<D '9Q:A9S7/V>.X1IOWGR \_(5#_D64'ZBFV^J:?>7
M4UK;7UM-<0DB6*.96>,@X.X Y'/'-8VFZ+>6OB,7LBH(1]NY#9/[V6%DX^D;
M5C/X5UN)KV:VN3YTZWZPYD"_9_-N?-785 /SJ.2<E2%QCF@#O::'5MVU@=IP
MV#T/O7#S>&M7GT[9'->QNEI>&!)+O88[AC$8?N,00"KD9) S^ V]+T=[6Z\0
M++ PCOKCS4D$Q(=6C4$8SE2"&].HQ[ &Q9WMOJ%I'=6DHE@D&4D7HP]1ZCW[
MU/7!V?AK6+*'2;:,2#[/;62+*MVP2W:-LS@KGYMXX'!ST. !6O#HNHV_@^ZL
MX9Y!J<X=FD:Y8DL2> ^25^7 !'3MTH Z6BN&?PWJMU%.N;FVMF^TM;6WVY]T
M):*)8P65N?G61^I W"KNFZ1K$?BA[V^N+AXMVY624>64\I5V,N<\."W QGG/
M)% '645P]]IFNWFI:W;6=U,D$(#VI\QEWM*4:1,^H".%/;SNV*9-HFO^3ID5
MMYX6*?S6>:X^>(><K%3A\;=@8 #=UV\"@#NZ9--%;Q-+-(D<:]7<X _&L*UT
M.Y7P_J=J]S-'>WDER1/Y[,4W.YC*Y/RX4KP/2L.VT/Q7*MV]Y<E6E1IXXTN2
M1'+(R9C!_NHL9 /?S#0!VS7=NLL41F3?*S(BY^\R@DCZ@ _E4U<./",TDOE/
M!(D2ZA=7)D6Z9=ZR*^PC#9&"X!''(SS5K7]-UZ\\*V-G;?/?"#;/*)RK++Y>
M P(91]_DGDCJ 3T .NHKE[71=3BU]=1DFE.Z\)D!N&*^1]F"X"9V_P"M&>GO
M56YT36)-;U2X=[J6*59/LXCN?+1D,041GG*D-DY X/.<DB@#L2ZAPA8;B"0N
M>2!U/ZC\Z6N$C\-:ZK6TTLQFU2.SOK8W_G$ 2R%&BEV9X7Y2-H!P<=0,T^V\
M,ZE+:0PSR7R1>;(\D3WA!&8=JX*,21OYY/7G - '9RW$,#PI+(J-,_EQ@G[S
M8+8'X*3^%2UP8\/Z_-JEG<7!9IXI$E%VUT2D8^R&(KY><$^:6;..C=>U):>'
M];ATZV6<7L^V=&N;9K[;YF(G4LKALXWE&.2"=N<9X(!W%M<0W=K%<V\BR03(
M)(W4\,I&01]14M9GARQFTSPQI-A<@">ULH89 K9&Y4 .#WY%:= !1110 444
M4 %%%% #)I1!!),P)5%+$#K@#-<Q_P )W9I!&TUA=PS3>2889#&"ZRH[JV0Q
M XBDSDY^7W%=-/$)[>2)B0'0J2.V1BL*P\-:%:VD>F1+OEBCBDWB=A* H*(P
M8'<HQN VD#E@.IH B;Q<DT1>WLKJ-%2V=I9HUPOG,H5"N\-NPQSV'OT*MXSM
M$R6L;O8X<VK?)_I!658B%^;C+R)C=C@YXYK8_LBQ*.AMPP?R]^YB2WEX*9).
M3C JM_PC6CDW&;)3]H#!P78@!FW-M&?DRP#';CD ]10!4LO$4G]C7^H7]K)&
M;>[>W6!=I<G>%1>&VDDD#.<<]J@'B2[O-=L-/M[.6W_?3)>"38Q0HJ,!D-C!
M$BG(SU'O6NNC:9!I<]C]G06<I9Y5=B=Q/)8L3G.><YSGFEL=+TV!()[.)6P&
M>.;S"Y;?@EBQ)+9P.23T% &9=^*18WEY;_8[B[DBN&C5(%12 L$<K9+/@\/U
MX],<9,%SXQ3[?9K;6\OV'[1Y=S=.%V@?96GP!G=G&PYQCJ*W'TK3WN7F>W0S
M2LSL23EB46,G_OE5'X5 OAO2%O([H62>;'C;\S;00GEYVYQG9\N<9QQ0!F6_
MC:"[MX7M]+O9)9YA%%$#'ELQ/*#NW;?NHP(SD'ZBEM_&L%U!"\6F7QDN/),$
M1,8:1)5=D;._ 'R-D$Y&.E6XH?#VG:=9WGVB".R5EEM9I[HE 6C*KL+M@#8S
M  <8/ JW;Z-I<8MI(+:/$*1+"RDD!8PP3'/0!VQ]: ,23QBS^1)9V,LZS+9D
M0D*CQ^<\BG+%L$@IC []R#QK:=K]OJ5[):0Q3":(2&8,!^[*R&, \_Q%6(]0
M,^E.?0-)\@Q&U5$(B3*NRD;&+)@@Y!#,2,>M26&D6]AJ&I7L?,VH3++*< 8V
MHJ ?3Y2?JQH YVQ\9SQ:9+=:A8W#NOVBYD6$1@06\;E<GY_F/!Z<G!XZ9Z"P
MUA;\WS+:S1PVDK1>;(4 D920VWYL@#'4XJ"ZT70I#;0W$$0R[Q1)YA7S"V9'
M0@'Y@=I8J<CCI6BEC:I!- L*>5.SM*A&0Y;[V?KF@#GX?&UM=0@VNGW-Q,;D
MVPBBDB;)$/G9#;]N-OOU_.KFH^*+/3] M]9,;R6]Q&)8UWHC%2A?H[#)P.@R
M?PR:LVGA_2[+:8+7#+)YH9Y&=MVSR\Y8DGY/E^E-N-'T>\@@TN6*-DM(QY<*
MRE62,J4 X(.T@,O/!P>M &5>>,5CU"U6&WE%@MP\=S=.%VX6U><A1NW9X7G&
M.&%,M_%5Y-J9ADL9;=7EC2*"149VW02R_>#X&?+'//<8YR-G_A'-(^V"[-DA
ME'3+,5SY?EYVYQDI\I.,D8':BS\.Z58,C6]H%='$BLSLY#!&0'+$GA691Z X
M["@#(LO&+36=G<3V4JRW=G;31VJ!2Q>9F4 /NQCC/(&![\"4^-+8;?\ B77I
MVY^T?ZO]QMF,+;OFYPP/W<Y'-:"^&M(2T%JMIB)8TC0>8^45&+(%;.5VDY&#
MQQCH*)-(T:SM");>*.#:(F+L><ON&23R2YSD\DF@#,O/%\?VFXLK6/%Q!<0(
M6+HZLC7"1/\ =8D'YCP<'D=P0-34=0N[36M(MXT@-K>3/#(S9+@B*1QCL/N#
MUZ]J8NAZ'#?%!!&+F;,X1I&)(659"54G@"0JW'&3[U/J5AITL]M?WQ96M9%,
M+F=T57)VC@$ D[MO/7..] '*VOC/4[FXGM_*M4D>:.*W9H6"C=,T>X'=^^4*
M =R[1D@<9XV[;Q#(N@B[NX/-NA>O8B.V&T2R+,T0(W'Y0=N>3QSR<<V1X7T9
M8Y$%G\K@#'FO^[ ;> G/[L!@"-N.0#VJ9M*TM[$:1Y2>2F)1$LA#J=VX/D'<
M#N!.[.<Y.<T 8EGXR5;>S_M"W9)KJ\DMP@>,-'_I+0H"N[)YV@E<CJ:E?QM9
M+;&=;2Y(0)YV=BK S%U*NQ;"E3&P.3@$KSS6@GA?1HS 4L@OD,&0*[ 9$AD!
M(SAL.2PSG!)QUIL7AC3EM[Z&1'=+VZ>ZF"NT>YF&,':1D;>"._.>M "ZG?7:
MZG9Z?8&-9I[:XN T@R#L"*H_[ZE0_136%KGB36M"EL[>5;62>5)Y2!;R,KXF
MC2--X($65D&7;(!KJ9M.BEOK*[4F.2T#HH4#!1@ 5/MD*?\ @(J'5X-),+SZ
MJ(1&\36A:5L I(1E/Q(7\J ,N;QO80SZ@@M;J1+))F9T"D,8L!E SD'.0,X!
MP?;+X_%$LVJ6EDNESHSSRP7 DD3,)5%<'AB""K@\']:T6T'36:Z+6[%;I66:
M/S7V/NZG9G;DXY(&3ZT^71].EN!,\"^<9O/W!B"7V!">#R"H (Z$#I0!BVOB
MZ/4[^P@LX]@>^^SS;G20%#;RRJ59&(ZH._8^QJ>?7[J+69-)\J+[4UY"L&0<
M-;LA=G//4>7,H[95?7%6]+T7188;:ZT^%&C^6:"42L_'EE%())XV.0.V#5U]
M-LY-2CU%[=#>1Q-"LQ'(0D$C\Q_G- '/1^,8[VZMXK2/;B[6*;+I(&C:*5P5
M9&(SF/U_G4TWC:PA@@D\B<M<0V\L2':-WG+(RC).!@1.3^F:T;3PYI-B4-O9
MA3&5*9=FV[595 R3@!78 = #44?A;1+>$PQ6GEAB@4K,X==F[9M;.5VAF P1
M@''2@ ?74:STB[C22.._DQLDB^<#RG?!^8;3\G7G]<C/3QQ;&P%U)IUY""L,
M@$K1@".569'9M^U1\C#DCG [UN36^GYLK6<QEXR3;)))ER0A4D9.6.UCGKUJ
MA%IOA[4X9K:V:"9(D2VF2WN3\JH&"QOM;IAF&#USS0 R\\6V5E!<2R0SLL!N
M VT#GR4WMCGN.E*_BB&'4K"PNK.6">\( 1I8BT9.[;N57)YV'D CD>^+$OAG
M1IIYYI+%&>='20;FVD,NQL+G RH . ,X'I4\VBZ?/J2:A);[KE"I#;V RN=I
M*YP2-Q )&>30!C6GC6"\MX733+U9KA+>2V@<Q[I4F#E#D-@<1N3D@@#WQ4C^
M*5N-2FTBTM9DOP#&&DVE(YO)\T*^UB< $ L.,\9J]-H6C):B*2V2.**"-%*R
M,C1QPY*88$$;=QY!SS4MII6G1SI?6B%6=%PR3/L<;0H8KG:QV@#<03@#F@"K
M#>ZC;:K86=^T+?:EN<^4.A5P8_\ R&3GW%-\1:M=Z2UI*@CBL"6-U=R0-,(<
M8VY56!53ELOR%QR,'(O7>DV]]>I<7!9@EO+;B,' Q)MW'(YSA0 1TR:;JNG:
M9>Q(VI &%#LP\S(C;B!M8 @,"<#!R#0!EW7B^V2]N;*-2L\#(-^4E4CSDC;A
M7R#EQP<$9Z<$4^P\1RZEXA@M8K22*Q>WN9%EDV_O6CECCRN&) ^9NH'5?>KR
M^'-)6>2868WR,6;+L0"7$AP,X&7 8XQSSW-&GZ5I$%[->V,2>?NDC=UD+!2S
M!G4#.%RPR0,<\]Z ,O\ X3&.'*R6EQ.%DE\R6)$58T2X:')!?)P1VSD G Z5
M<M_$]M/>FU^SS))]L-GABNX, YW%<Y"D1D@D<@@COBRFD:3,DP2WA=6+I)M;
M/)D,C \]=Y)^M))X=TN8S-);NSRNKM(9GW@J6*[6W94#<V "!\Q]30!1A\7V
M]PK2165QY*627DDKO$BHKEPJDLXY^1O8>M5_^$YM#:1W*6%W)&4GDE*&,B)(
M9!&Y)W<\G(VYR*V%\/Z4EF]HEDB0/#' 44D?(A)0#GC!8D$<BD3P]I26[0"S
M4QM')&P9F8LLC;GR2<G<W)/6@"C<>++>VM;BZ:RN?LT=R;6.7* 2RB3RV RV
M0 P;D@<*?;,TWB:WA\/1:P;6X\EV"E&"J8_F*DL2=H4$?>SC&#WI\^BZ*)G2
M6((][+N"><R[I!\Y9 #\K97<2N#D9JS=:?9-I9MKDRBUC4LS&X<$  Y)?=N/
M&<Y//>@#(M_%+#6+VTNK63[.MT8;>X5D"'%LDY4DMUQO.[[O3FL^_P#&[R:;
M<7.FQJC6\=T'$A60;X[<2K@JQ!'S+W]16XUGX>DL[J1H[0VL#&2<Y^1,P!"6
M[ >2P'^Z14B>&M(6WDA^R!TEW^89)&=GWH(VRQ))R@ Z]!0!+>:M]EO[2RCM
M)KFXN$>7;$5 1$*AF)8CNZ\#FLIO&EJJ>8;"\V2(7MB-G^D*)4B)7YN/FD0_
M-C@_4#3U2#27EMYM1>.-X%=XW:8QD( "^2",KP"0>.!GI43Z'H=C'/<RV\<<
M9(=VDD;:GSA_ER<(-X#$# )'- %.'Q6T^I6UN--F2-X;IYV>2,&%H'1"/O8(
M.[KGN/?%?_A.;1[:2[6.016YG$Z*$D+>7 )OE97V_=8>O/''6M>?2-&DNHX9
MH(_.D$[K'O(+JY'FY&?F4DKD'C./:HI= T*ST^X-Q BVVV1YY)Y6;@Q['+,Q
MS]P 9)Z"@"6SUQ+JUU"66UFM7L6*S13,@(_=K(#N#;?NL.I&#G/K65_PG5JU
MJTL.GW4[H9MZ1/$=HB578[M^"-KKC!Z\5NK9:?>6ER5ACEM]07,W<3 H$Y_X
M" *AB\/:7"KJMKNWAP[/(SLV]55LDDDY"J/PH @USQ-9Z%IL=_.C20NAD^5T
M5MH&XD!F!8X[#-49_&]G#>7]NMG<S?8DD:1HVC)RC*I&W=D$EQC<!G!/05KW
M^A:;J<,<-Y;"2.-&B4!V7Y& #*<$94X&0>#@>E9UOX1M8M1NKF2XEEAN&E9[
M<\*Q=PYW8ZX(^7@8!.<]: &OXSLX=1>RN+6YB>$?Z0WRL(6\KS<':22-N.0"
M,D#UPRV\:07D,9MM-O9)Y9 D<(,>6'EF3.[=MX ((SG/'?-:QT_3)=6FE"@W
MFQ3-&LK ,K JI= =K<!@"0>GM5:;0M%@LX;>=&6%9E\GS+F3*N1L"J2V0""5
MV@XP2,<T 5[;Q1%;^&-&U35 4^VVBRR2(OR(WDF5L\\#"MC\!535O&BVMMJ,
M,-NT5_!ITUW&)'C<*Z1A]KJK$@_,.N,X/MG>FT73;C2X=,ELXWLH1&(X2/E4
M)C;^6!5:ZT/0S-<7%U#$&N089?,E(5O- 0@#. 7^4<#)XH ;)XFM(W=6CE&Q
MYT)8JHS$NYN20 #V)(]\51M?&'V^[M(;6PD:.4SI+(9$(B:,*<\-A@0P/!JW
M+I'ARY\W498H)$NB8FD,A*,9,1D 9P"QVJ<<DX[U:B\/Z9#Y92W8-'(TH<RN
M6+,,,2Q.6R ,YSG% &;8>+X;I+/-M<.DOD12W*JJHDLL:R*NW<6Z.O3(&X#)
MY(M:'XEAUR)G6SN;;_1H;M%FV9>*4-L8;6./N-P>:L1>'=*@N8;B*S5'A55C
M 9MHVKM4[<X+!> Q&0.]3VVEV5DFVU@6+%O';#;GB--VQ?H-S?G0!A0>-H;B
M"%DTF_$TZV\D$),6Z1)@^QL[\#_5MG)R*EF\9VMOYTDEE=BV0SA9_D*OY+;9
M<#=D;<,>1R%..V;6D>%=+T>RMK>& N\"Q 2R,2Q,:E5/)X RV%' W' YJPNA
M:5#<3W7V5 \JN)-S$J YR^%)PNXC+8 SWS0!F3^+H8I)I$@FDMXD?A8QEBDP
MB+[MW" DYR.@)SCJ\>*5-R88;>2ZEE>-8(8=G.Z'S2=Y?:1CN,=@,]:N'1M'
MMX;:S6-;<"+[-;K',T;[1\VU2"&S\N>#G@^]*WAO2#;K"+-8TC*%#$[1LFU-
M@PRD$?+\O!Z$B@"A:^,K2\N+58;*[,%P(?WY"!4,JDH"-V[/&#@'!-37OB+[
M%JLED+::ZD:2****)54[G21\EF<#&(SV&/>K<.FZ.LWV>"" 20K#+Y:'&Q5R
M(C@= -K ?0U8?3+.2]%XUNIN%97#\YRJLH/Y.P_&@#-EUXSV&AWMFI6'49D!
M65?F5&B=\<'KE1WJC8>.+2Z:TA,,\DDD$;RR(BJJL\(E *[B0-I'J 6 R>2.
M@33+)+:UMUMU$5H08%YPA"E1C\"1^-0V^@Z;:S12V]N8C'&L05)&"%57:NY<
MX;"\ D$XH CLM?M;U)759(TCM(KMF<#A) Q'0]0%.:Q+WQ=<S6L4=AI]Q!=S
M26I F$;8AF9@' #XS\C#!/!QVK?T_1-,TA'2SMEB$JK&P+EMRJ"%7YB> "0!
MV''04VU\/:59H$@M  &C8;G9BNS[@!).%7)PHX&3@4 1:GXAMM*U.TLID9FN
M71 RR)E2[;5^4MN(SW Q^N*5MXSM9PCR6-W!&_E,CR;""DDAC#<,< -C.>Q!
M]<7VL=&U;46NL1SW5JZ(Y20X5D8LH8 X)5B2,YP2?>FWWAK3KS2;G3UB$*3V
MIM"R<E8SG@9^I(]Z $/B*)M,T^\@M;B8ZA)LM85VAI,JS@Y)  V(6Y/3WXJK
M<^+8H9)8S9W,:JSP"=@C*)EA,I0@/DX52,],C&>AK3OK'3)K>TL;I51/,"VR
MJYC8.JDC85(((4-T/3/:J\NB:)#>)++;QK+<$Q(K2-AV,94X7.-_EJ1N SM!
M&<4 5(O%T370MVL+QQO$/GHJ[7E^SBXVJNXM]SVZ\9H7QE9'3S>&";:+.:[*
MJR,0L14,IPV V6'';!SBM3^Q=.'2U4'S/-R"00_E>5GKU\OY:JR^%=%G@6&:
MS\Q5WY+RN6??@MN;.6R54_,3]T>@H KW'BR&VM[RX:QF$5M<-;!WEB02NN[=
MMW.,XV_4YZ8!(;'XRLY+F-1:W0MG*+]J(78I:'S@"-V[[OMUQ6G<:'IUU#Y4
MMM\OG-<?*[*1(P(8Y!!Y#,#V()%+%HFFPJBQVD8".KJ.>"J>6I_!.* ,>Y\:
MP6=E:W$^FWJ-=1M-#"3&7>)54EN'QGYU&W.<GTYK5N]76WO+.TAM)[F>ZC>8
M+'M7;&I0,QW$=W7CKS[5$GAG28[>*&.WD1(B3&4N)%9 0!M5@V0N !M!QP.*
MMWFEV=_+!+<1%I(,^6ZNRD XR,@C*G R#P<#(XH PK;Q?'&ME%>INFNKEX08
MW0;?W[1)\A;<1P,D#'ZXFD\8V:6*W2VMRRFWCN, *,*TFS+'.  >2>@'-7SX
M<TDW$<_V,"2-@ZX=@"0YD!(!P<.S$9SC)QUID?AG28?.,-L\33##-'/(K ;B
MV%(;*C))P,#D^M %>W\6V5UKBZ7%#,[EE1I5*LBL8A* <$G&TCYAQD@9JUX@
MUZW\/:?]LN(S(@S\JR(K$!2QQN89. >!S_.C_A'M/C#FUCDM&:'R@;>1D"@)
ML4[,[2P7 !(. !Z5)>:%IU_9P6MU 9(H5V(/,8':5VD$@Y((X(/7O0!FS>,;
M.WNYXYK6Z2VA=HVNL*4++!]H( W;ON9YQU&*?IFNWE[)J[3:?+!]D1&BMW*;
MVS'NY(8CGZ\5HG1=-8G=:1MF0RD-R"QC\HDC_<^7Z4NG:-8:4DJ6<&P2X\PL
M[.6P,#)8DG X^G% '.VGC&Y>>UDNM-E2VN+*SF;8R'R&GD= 6.[D'Y,8!(&<
M^E:NC>)[36[V>WMH9U$88K*P&UPK;3T)QSR <$@_7%F#P_I=O L$=J/+5(XP
M&=FPL;ET&2<X5B2/RZ5-9Z7:6$LLEK&\?FDLR^8Q0$G)VJ3M7)))P!F@#%_X
M32T:6[ABM)YIK>2&,)%)$^\RNT:X(? ^9#D$C%)!XUMY82[Z;>Q.P3R8W\O,
MK-+Y.T8<@8? R2!CFM.W\.:3:NS0V84LT;<NS8V,60#)X +$@#@9Z4Z30-*E
MA,36:;-NW@D$?/YG!!R#O^8$<@]* ,__ (3"S6WGDDM;F-[>*:26(A25,3A&
M7(."<D$=L57U#QHMK:ZD\6F7+M:PW4D3.R!)FMSAP,-D#G.2.@/MG2E\+Z+/
M!%#+9!DB#@ R-EM[!FW'.6RP#'=GD9ZU9DT3394=)+2-E<3!@<X(E.9/^^N]
M $=[J[645D#8SR75X^R.V1DW A2YRQ;;P%/?TK/T7Q!/K>O2"&)X]-&GP7$9
M=5W,TA?K\Q(P$QC'4-STK5N-'LKNS@M9XY'2 AHF\YQ(A (R'!W9P2,YY!.>
MM26NG6=BV;6W2']TD.$& $3.U<>@W'\Z ,F/Q2)[6TG@TN\<7K[;,;HQYZ[6
M?=RWRC:N?FP>1WSB%?'.EFW69H[E%,:S89!N$1A:4N0#T&QU/^TN.X-:'_",
MZ1Y)B6V94\SS4V32*8VP1\A#9089AA<#YCZU,NA:4DL<JV$ :.U^QK\G A_Y
MYXZ;>.E &7:^,(KS[.D.FWC33W'D*F8\#]WYA;=NQ@*#G!)R,8J)_'6G1_:U
M:)MUN\2?Z^+8WF%PIW[]J\QMG)';N:VK;1K&T$(BB<^0Y>(R3/(4)7;P6)P-
MO&.E9=YX,TR:!4M4-LZR(^<EP0@<*F">%'F-@*1C/IQ0 VS\:6=Y>V=JMG=I
M)<1Q.P8+F(R+N4, <],9(! R/?!KOB@Z>NJ6]O;N+NTMO/0R;0).GW5)!8<X
MST!X)K0L?#]G8FVDWW$MS#$L9G>9MTNT$ N 0&(R<9!Q4MSHFG7ES)<7,!E>
M1#&=\C%0IQG"YP,[1D@ G% &3=^-+2QLWN+JSGA:*9XIH7DB#IM"DD#?\_#*
M?ES^!I^F:W=W>O"RE\ORC]MZ+@_NIHD3]'.:OW?AS2;YW:XLPS.7+D.R[]P4
M,#@C(.Q.#Q\H]*LPZ99V]S]IBMU6;]Y\XSG]XP9_S*J?PH YR'QLMK!<MJEI
M.FR6[$,J!-LRQ7'E!1\V0?F0?-@$Y/ K6@\0P3Z'+JAADC2)F1DE=$Y!QPQ;
M;@\$'/Z\4X>&=&#W+_84)N0XDW,Q'SMO? )PI+ $D8R0#V%66TFSDTXV$B22
M6Y(;]Y,[/D,&!WD[L@@$'.1@8H YR[\;B72O/TRRGDEV[Y"VPK"/.,66^;YL
MLCXVYX&?2KH\5V\,%V\\<KFW6ZE.R,+\D,WED<L<GISQGKQTJVWA7172)&L0
M5BW8'F/SE]YW<_-\YW?-G!YJ)/">FR6BPWT9NW$D[L[$IN\V0R."%(!7=C .
M?N@]1F@"O=^+3&TT=MITTLT-]%:/&TB(V'<KOVEL@''!.,Y!'?#?^$WL#/=Q
MI:W4GV=GC5E"D2.LJPE1\WRDNP W8SR>@K4E\/Z9,UPTD#N]PR.[F9]P*L77
M:<Y0!B2 N!DFAO#^F.+I6MR4NLF6/S7V$D[BP7.%8MSD '/.<T 5-.UZ632-
M1O[ZW\G[+<RQ^4SHI55.!EBVW\<U4'CFT:UBN8["[DC9)9)60QD1+%+Y3D_-
MS\W(VYR*V4T/38]-ET];;_1I6+NI=B6<G.[=G.[(!SG.>>M,3P]I4=N;=;-?
M+9)(V#,Q+*[;WR2<G+<D]<T 9TOC*V@:[,MC=K%;I<L)?D(E\A@KA1NSW&,@
M9YIVJ^,+'2(KR2:&0K9S-%+AXU)VQI(2H9@6^5QP.>#[9TI-#TR:-TDLXW1Q
M,K*<D$2G,@_X$>M57\)Z)) T+V19'+ER9GW2;U56W-NRP(1<@D@[1F@#+?Q7
M/::G,+I UG#]K,AC7YE2)X%#<GH!*Y/L*T;[Q&8=$.I6=E)<#[:MJJ%E7?F<
M1%@2>F<X]>.U7)]$L95N"L*)+-'-&9,;L>;MW\'@YV+^5+'HEC'H4&C&(M9P
MQ)$J[B#A,;3D8(((!R.<\T 58/$D,^J1V?V2X1))WM8[AMNQID4LRX#;N K<
MXQE3[9KWGBZWLI+I9+*YVP72VBR;D"RRE ^!EN %.23CH<9-:4.B:=;Z@;Z.
MWQ<$D[B[$!B "P4G 8@8+ 9/<TZ?1["YBECD@XEF$[,KLK>8  &# @J< #((
MH YB;Q9?SZ@&M+=H;(0V$G[]%W$SW)C8'YL@@*<8&,Y.<8S=A\<6-P)?(M+J
M3#K'#M"8F+2>6 #N^7D@_-C@Y]0-HZ/8'[UOO.V%2SLS$B)R\>23DX8DY]^:
MA/AW2S#/#]G;RIF#M'YS[58-O!09PAW?-E<<\T 1Z?K%S>:W>6$NG2VR6\$4
MOF/(AR7W?*0I/3:?R/MG8JG;:59VES]I@B99?)6 MYC'<BDD9R>2,GD\\GGF
MKE !1110 4444 1SQ">WEB)(#H5)#%3R,=1R/PKA-/\ "^J06>GND=U;7-I8
MV< 'VT\O',3+G#D,I4G .1AL8'0=_10!S'AS3M8M=5O)M3FN6#&0#+AHI 9"
M4*C>2"%XQM0<XYP#6'8Z;KVH02O&VHP)([)*\E\V9?\ 2U(,8W90+$L@/"YW
M <]:]#HH XJ\L=4L=3GN?,NTM()"ZW#7A:(6PM]HC*%LE_,^;)'ONSQ5:RTO
MQ/+-'.UU=QLUHA@D+Y1#]F"[9%+]?-RWW">GS=AWU% '%)HE^UQIEW#9W]O/
M#!<0DW%^93'(ZQ[9&_>$,F4/'/8[?2O::/K\>GVPN1J<P%PK7-L+W8[8B9=R
M2>:3MWE2067IG;V/>T4 <A_PCVI/X7\*Z<L[6ES8"(3S1;&,16V>,D;@5;YF
M Z'@U5TS0]=M;W24D$]O9VMM;1".VFS'&4!$BL#(,AN.=KG&.A%=S10!P!\,
M:P=&BAN3>W3K#ILTL9OV+-<1REI]K%Q@[=N.0,@8Y&:U_%.GZO>2K_9_VDJ;
M62.$P77DB"X)&R1_F&Y1SQ\W?Y3FNHHH XH>%[B75"LL5RL!UAKQYEO&7=&U
MM(GRX?<N'8 @8X/<"FZ=I/B5-2TV34+FZ98[:W#O',"H=8\2*X,@!RV3D(V<
MCD8%=O10!P4WA_Q-!I&E0V%[<BY-F/MSRWC.1<(%D4@L3PSAD;'&UO2II])\
M0M82L\EX\\MO"_EQ7 XG\V621.73Y!O1>&'R@ =,5V]% ')Z;IVNKXG:ZOI)
MQ!D,HBFW0[/*5?+(9\\/DYV9/!W<D51:WURXU_5)K.*[/DW,P5IKUE@DC-J
ML00-E3YK*VX 8P?FSQ7=44 >>-8>)+:TAC,]U%)>7SVBH9F)CMY8D+2#YWPZ
M-&Y&6.,G!&<5+J.B^(KZZU-?(D%M*"$C%VV'*W",C*3(=I\L-R%3!..< UWU
M% '!2Z'XA>$RVWG0N(;I(4FN=\L:/- PC+[B<E8Y,$-\N0-PQFM&?2-1G\$R
M6)6ZENFG218YI@LBJ)E?:'#MC !P=Q(XKK** .$^PZ[!<:; LUY#%>W4L4D,
MERTCV\ <2@E@3SM1TR"<>:HR=M;=];ZC'XCGN;2U=TN+!;=+A63$,@9SE@S
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M?BCI(CL&%I<N]VAD*1/&YB0.$R<-R<GE1DC!R..0#N:*Q=!\26^OS:A%#!+
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MXXP5= 07<(#L+;B-S#) .* -FBN?U#Q"=,U>^AF17@AM[9XU\Q(R7D:8'EV
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M[(%.XQ??7&[(.<@9P"0>>F98_%$LVJ6EBFE7"/)<R6]P)'CS"5C60'AB""K
M\$_G0!T5%<_=^)6LM5U"UFT^9HK9+;RY(V0F629RBH 2,?-@9.!USCC*W7B4
MQ^'+O4X+"9IK:4PR6KLH8.'"GG.,<YZ]* -^BN67Q:;75=0@U&TFBMH;GRHY
MQM*KBT2X96PQ)./,Y QP!FK=EXFCU+1K^^M[:6)K6,N%FVD-\FX<J2#Z'G((
M/L: -ZBN0TGQ9?36]N;NPDN7NYTAMI+> P*Y,)E;Y96Z+M8;@2#V[U-%XYL9
MXII(+.[E5'C2/9L_>EY1$,?-A?F(.&QP<^H !U-%<L/&22PM_H-U:29(4SHC
MABLZPR !7[,V,DCU&>E/F\:V4$;E[:82B[-HL3/&K%P';)!;Y051B-V,@C'6
M@#IJ*QM-\1V^J7ZVD=O/$S6R7*F?:A96"GA2=QQN )Q@$$9INKZW<6&IPV4-
MFT@ELKBY\[<N$,>P#()R1\_;V]\ &W17)0>.(8]-MWO;*XBO)#$@A)C&\O$9
M P.[ &$?J<\8[BM636RZZ!+;Q$1:I,%(F4JZ*;>24<=FR@!_&@#8HKFW\:62
MW=];QVEW-]D67+1*K;VCP&4#.1R2 2 #@^V5D\9:?"-\T;K"+%KXRB2-E**&
M+!"&^<@(2=N<97/6@#HZ*Y23Q[8Q6PD:RNO-,CH(08\D*BN2&W;3PZC@YSQV
M)K7O==@LI=.1XI2M\P5)#M14SC 8L1R=W"]3@X'% &I17*:;XP+V,CW]I)%*
MB/(KL\:)*HE,>02_&#M^]C.>,]*B_P"$OENY(I;)%6WD^R#;( 6!DNC#(,@X
M/"G!'UH ["BL74/$D.GZH;)[.YD5!;F6=-FR/SI&C3.6#'YEYP#@55A\9Z?)
M=S0-'(@AEBCDE$D;HHD9U0DJQQ\R;<=06'O@ Z2BN<O]>NI+'0I].MY%&J7"
M+F15W1QE&?)!8<D+^'/>HQXVMC:K.-.O2LR0R6JCR\W*2RK$I7YN.70X;'##
MW  .GHK%UOQ';Z!9PW-Y"X#J69!)&&0  MP6&XC/\.?Y9JS^,;>WENEDT^]\
MJW$_[T!"'\G&_: V>AR,@9P?;(!TE%8T^O1-I-Q?6V?+BNA;B0H'#GS%1B &
M&1DD9R.A.#WIGQG:J\PDL+Q IF6$G8?M#1SK P7YN/G= -V.N>U '2T5S]WX
MKCL'N%N]-O(OLMHMW<-F,B,,SJJ\/R28SC''(R15>7QQ8P6$=W+;3(IE:-E,
MD0(V[<LOS?./G!^7/<'!XH ZBBN;N/&5E;?:5DMYEDANA:K&S(K.QW<X+?*I
M",P+8R.F>E7&UQ)++2;N-)(X[^4+LDBRP!C=L'YA@_+U^;Z<Y !L45BZ)XCC
MUN)WCL;F!Q;Q721S%,O'*&*$;6(&=K#!(QBL:W\:W+1:=>7.ES):W.GK=S*C
M(QBRRC=G=RN&S@<^W:@#LZ*Q-,\3VFJZO/I]O#-F(RKYIV[28W"..#D?,>,@
M9P2*J2^-;6#[2TFGWHCB%QY;@(?.,$@C<*-V1\Q&-V,\T =-17._\)?;+JIT
MZ2SN4G3"S#*-Y3F/S-IPV?NXY&1EASUQ'8^,XKVXMXFTJ^@69H@))#'A1*I:
M,G:Y/.".G!ZT =-17.Z=XKM[JPLY9$E:2:.T)98P@)G&5.W<< =QDX]34%KX
MW@N6@/\ 95_'%,MLXE<Q85)W,<;$!R>6!&,9 YH ZFBL6W\0I>Z1J-[;6T@D
ML_,!@D90Y91G! /RD^C8.#6?IGBM_L=FM]:W#RL+=;F=%14BDG($:XW$]67I
MG&X9[X .JHKGI?$[GP?=>((--GVQPM+%#*R!I% SNX8@#KUYXZ5#'XIDAUFZ
MM;^RFBMUG6))AL(C)MQ,5?#9)X;D CI0!T]%8>C>)[76K*XNH;>>-(8UE^?:
M=RL"1@J2,\'(SD?B*J1>,XIA"BZ3?_:9S"88"8MSI*CLC9WX _=/G)R,=* .
MGHKFIO&=I LTCV-YY*+.T4@"$3^2X1PHW9!R>-V,BHKOQU9V6Z.XL;Q;I'E6
M2V_=EU$:QLQ&&PW$L> "2=WL: .JHKF[GQ5*L^RUTFYF07ZV32%XU#$@DE06
MSQQU ZU?TS7[;5;J2V@BF62)6,P<#]V1(T>T\]28WQCL,]Q0!JT444 %%%%
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M(.1D<$U=AT7QT;C3?,N=3BLU>1D47*RS0#[0643$S*)/W6U23YG?C.#7JE%
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MM=-;BWA4;\FX,*#EL9SMSSCK0!T%%<Y;^,;6=)6:QO(/+CDD G,2!_+D\N0
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MQ\%B0,J6#GD=0I'/UQ0@\:6<]OYJV%^K.L+P1LL>Z<2N47;\^!R#G<1@<]*
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M*(E'+ 9W$=\8[T =!17.W?C*PL;JZM[J">.6VM)+MU#Q.VU%5F7:KDAL,.H
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M!VDC<V"1WK$N[/Q"?"FG0(\S7B2J;I5DS*T7S87<'3+#Y,D.,X/)S@TI-/\
M%BS)]FN+DQC3S&&FF0'[7Y3[9&4,WRC(4C)RV&QP20#HV\-:2ULD'V4JB10P
MH4E=618B3'A@<@@D\@YYJ>+1K"'3H[!(,6T<JS*A=CAQ)Y@.2<GYQGK7+7>G
MZ]*UB+%-6M+94<.LMR)IDERF'8^> RX#<$L.OR\BFMIWBDRZH[37A9GDV)'(
M%66(SJ5$;&4['$(91A$Y)))(!H Z&31=#N8),QQF.)I0SI,P\MC*)7^8'Y3Y
MBAO4$<8J*RTOP]-86D]J(Y+>4J\$AG9O,/F^<#DG)/F#=ZUG6NDO%X.U6VOK
M&_*37$TRP+,DEQL+[E^8L0S#K@DYQ@Y[P/9:I+I^C2SZ,]Q=6]^9E=5@22*'
M=U<;@H=A@D)P<=NE &[>:/H2F,7:1Q^89XU5YV02>><R)C/S;CSM.>0,=*B7
M0_#V+JS(21\.]PLET[R /&(V+$L6&4 '/8<5C^([.]UW[2]KI<LR36-WIT9D
M*+Y4A=0)?F8'8=N<C)^48'(JC>^&M6N%EA33R7AFO)GG,D>+Q)9Q(L0YSR@"
MG< !M':@#M8;33;NUNG@$<T%^/WSQR;EE^4)U!_NJ!QZ4G]AZ=NW"W*MYWGA
MED8$/Y7D[@0>#Y?R_KUYKG;J&_L/"OB&[B@GLIKJX,]O CJ)(QMC3JI*@DJS
M<'^+GO5*YTSQ1(B+;OJ-O:&2<QQF<2W$.1'Y;,WG*& (F."S##*"I[ '23>$
M=%N(!#+:R,H$@8FYEW.)""X=MV7!*KPQ/0>E6;C0=.N8O+D@8 7#7(,<KHPD
M8$%@RD$9#,,9Q@FJUA8ZC#!J\KSR_;)YI?LWG3%XT7GR\+DA1SD\9]>@QS\-
MAX@$49:#5OL>^#[1;-?J;B0B.42,DGF?*I<P' 9?N-@#." =3#H&EVZ1I%:*
MJQF-D&YC@QKL3OV7BH4\+Z5%;Q01Q7")"V82EW,&B&-NU&#95<<;00/:L:2U
MUQ6U!TM]2-P)(Y('^V+Y;0JT1,87?@.0K@D@9.?FP:=!8:]=W*7%U]M@15O7
M2'[4!AVD3R VQL'";N,D#\J .BO=)L]0\@W"2%H"?+>.9XV&1@C<I!(/<$X.
M*@3P[I4<\\PM<F=9%=7D=D D.9-JD[5W'DX R>M<Y_9'B&&[TE%NKXVZ00&9
MQ-YC+-OS*7W2J"I&!C#@ -@#C*-I7B2&W=DEOI6F!-PGVSYB!<J=L9+80F'>
M 1CMD@\T =)'X=TR%;,00R0_9(Q%$8KB1#L!!VL0PWC(S\V>_J:KZIH^@?8D
MAU'RX(#)*ZEKEHLM*6,@W!@2&W-D9Q[<5EQ6.N'Q%:R@W\&G(L1C1Y1(4 W;
MUE_?88G(YVN>F#D5JZ]:3ZSX6FA6S*W,T:D02E=R-D$@D$KD<]#B@#/L_#6G
MW&J7MS%J*7-I<!O.M8W)5U= H5\,5(P,C"@]\GG.\-)LSILNGR++-;3*5=9Y
MWE+ C!&YB3^M8,VBZC'XCGU"R,L2M<P!56;$;1",J^Y,X/)'49XXIWA6TUNT
MT^Y;6);DW!A0%92&7S &WLA\QS@G'&%' PHR: -:'P]ID(^6W9F)<L\DSN[%
MU"L69B2?E ')X &.E%]X?TS4;2&UN;=FAA0QH$F="$*[2N5()!'!!ZUQ^A6.
MO:CIVGR2OJD-I.EH\YEOOWCGRY#,ZL')5&S%P"#D'@=:M36'B<RWI@^VK*1<
M[I&NU,<RF0&%85W?(PCR,X7GJ3UH ZR+2+"&\^UQVX6?>7W[CU*JA/7^ZBC\
M*@;P[I;W<URUL3)-OW ROLRZ[68)G:K$<%@ >3SR:P'L-<?6+![<:E;:<BQ8
M22<2R1L)F,GF'SL,&38!GS,#.,'K5MM-\4K9SF[DOY9&EB\^**8)YJB0ES$Y
MF.W((X CXXQF@#K)]-TW5;&"$DO!;R9B:WN'0HR93AT8'(^8'GUS4$.FZ0M_
M<P03R+=/&&GACOI V" N\J'X8@#Y\9]\UA:%IFM:?>:6'M[L6X,_GI+< I$&
MEE=6)63YW(9 058<@@J0<SS^'[Y]8OIHGO(H;O4HI)6BO&0M L 5L8;Y?G&.
M,'\A0!L+X:TE?('V=W2'>422>1TW/NW,5+$,Q\Q\L03\QYH_X1S3?LL5OMNM
MD+^9$QO)B\9VE?E?=N48)& <<USD^G^)I'OQ";Z.9DNAYINP8Y-T@,'E+N.P
MJG!.%[YW9S6AIFDZK8ZXLIGO9+3SYTQ/=M*!"54IPS'G=NY^]CC.,4 ;E[I-
MIJ%O';W2RO"F/D\]P&'HV#\XXZ-FJFH>'++5=5CO;SS)%2'R?)$C*K#<&^;:
M1N' ^4Y%8%]9^*)]7U1K9+F"WDM9XXBMSD-)OB\MES(=IVB3HB8Z$MP:;?VF
MN6,T%I;75UY5W?264>^X9V2!U60RAB2=R>7*!DY^;Z4 =-_PC^F_Z2/)D\NY
M8M)%Y\GEEBVXD)NVJ2W)( R2?4TMWH&FW]S+/=0O,\L9B.^9RJJ=N=JYPA^5
M3E0#D9JCJUOJC^(+*6R%PUOY;)+^]V1)D-\_#@ENG!1ATP5()K%C@\3S0VYN
M[341 BVJ7,$=XBRR[8Y1(499!C]X8B3N!(4_2@#HH="T5DFACB$I EAF+3M(
M_P"\"[P[%B22H3J<@8Q@4P^&]#N9[MC!YC2J\,Z"X<J-Z*KC;NPI*[<D 'H:
MSM/T?4K7Q U^OVI(I[\M-&]SN4P?954$KNP6\U0,_>]\5'J6DZW=W]_Y<MW'
M;O+,\)@NO+)_T>(1]"#CS _'Y\'D V-6\.66M:A;7-[YCQPV\T!A61D602&,
MD-M(R/W>"IR#GFIY]#T^XA:)X&4&<W.Z.5T=9",%E92"IP2."."1WKG9;;Q*
MMU=2QQ7<F1;RY-PJ\H\1DCC7S-I#*LG)5.3@D@\26UEK\\PNKE+M=B7LD=LU
MYL!=ILP*Y1B#\F1W _ 4 :*>$=+34TN_+?9%#!%% )'"+Y3NZLP!PYW/GY@<
M%<]:MP^']-@C,20R>494E$33R,B,K[UVJ6PH# '  'X5RUGI'B.XMC#=R7\$
M/VB5U5;PJX0VZA06$KMCS=QQO/X#BI7L_$SVVH;DO/[0D@3[/.MRHA4>5&'3
M8''[PN),-CN/F Z &[JOABPU2TOK=U95OYH9;D;F97\LKT4G"DJ@4D#TZXJ]
M:Q117M[MNFEFD=9'C+Y\H;0J@+_"#M)]R36+#9:H/"5S;M+?_:W<F/D>:B[@
M=N3,21U_Y:!L$X(.*H6NCZU_:$6I-'/!<8LE>);PLA5=PE# L=Y ;JVX^A)Y
MH Z46&F61M,K'$8YI'@W2$?O'W%L9/).7./KZ5G0^'O#BV\8A \N[\KR'6\D
MRP3<Z")MV5 #.0$(X)[5B:=IGB*:ZADO[:9(DN8IQ'+<>9Y9\J99,$R.2,L@
M[9ZA1S5FZT:_7PYX5@:SNY9-/$?VJ*SN5BE7%L\9VOO7^)AT:@#>M_#FEVDD
M$EM#+"T"A5,=Q(NY0Q8!L-\XW,QPV?O'U-7UM(%O9+P1XN)(UB9\GE5+$#'3
M@LWYUR&E:?XH36+!]3N;ADCAA\QXV#1DB'$BN/, R9-QR(V/W<$#(%V[CU[^
MWGCABNFLFO!.)XYD"K%]G*%-I;.?, ;&,<YS0!HQ>&-&A,1CL5!BB$"$NQ(C
M">6$R3]W:>G3//7FHV\.Z(MU9JZ-Y\2)Y*O=R$L(FW*2"WS[&;()SC/O7--I
MOBM[2QA#7L21B9&D6;?,7RGERL#/C^_\NYU_V><#1T[3-5'C!;V\@NRD?VQ3
M/)<AH61Y$,(C3<2N$7!^4<CG/6@#9&BZ3=00)"&"VA>.-[:Y=&0D_.NY&!Z@
M9!/4#THN-$LOM1O#-/%*\L;/(;ASD*X94&XD*I;&0N,].]<S_8^MQWFH^0UY
M8J[WDOVE[H&$ACNB*H&."&Y)VCC().<5=$>J:KX(AO)+>:2]NKJWO_LN\;HX
MQ.D@C&X@ K&H'49(/K0!O7.AZ?>:BE_/"S7">7AA*Z@[&+)E0<'!8D9!ZFHW
M\-Z2]NL'V4JB1QQ(4E=658VW)A@<@AN<@YK%DM_$%UXF%V1?6UD0K1QHR'8-
MA#(X\[;N+<YVM_#R,'$%E9^(HAI/F0WKF"X991+=<21DI^\D_?$A@ V%&]3S
MPN1@ Z3^P=-_LC^RA XL]_F;1,X8/YGF;M^=V=_S9SUJ&73-'TLF_GN)+8*J
MH\TM](JM_"N\E\,>< MD]/05RUOIGBY=)<33W;71>#[0F_B3!;S&B;S\C)*\
M QC X .16W=Z->7N@:/;3O<RSV]U!+*S2^4^U6Y+%7.2!_M'.,\F@#03PWI:
M",>5.VR87'SW4K;Y 5(9\M\Y!1<;LXVC%"^&]+2T:U6*80%E=$%U+B(J<KY?
MS?N\9_AQQQTKF_[-\32>>H:_BD976>4W@*RL9T*-"-QV 1B3(PO4#!-;>L:2
M\EWX>D@CNIH["\W/MNF#!#$Z!F)8;\,5SDDD9ZY((!??3].U/28K<DW%I\KQ
MR"=F;(.599 =V<\[@<^]1#PYI(@@A:UWK!<B\1I)&=_.'1RQ)+''')/'%<I!
MH7B/3M$2VLWN03;6WFQFYW$,LA\Q8_G7;\A ^5E!QUSS6X^G:I+X9LK,W%Y]
MH^T1^>_F^5*(?-RPW!V/"<9#%CZYH NQ>&-&@L$L8K%5MDMYK58P[8$4I!D7
MKW*CGKQQ2RZ+I!N+B.53NOT<26YN'"2@@!CY>[;G&,D#-<KJ=OXCL8?$%VUS
M>JD=M<FV:-\HRX'E8)E)#J!U\L$G.2<\SKINNAY;F.SNV6,77V2"ZO TJ!HH
M@%,@<GEUD(^;@$<CL =-%H&FPZ?>6(A=X+PEKD2S/(TI*A#N9B6/RJ!UZ"I&
MT73FOUOOLJBX4H0ZDCE0X4X!QP)'_/V%<OIUEX@CDLAJ$.HS6R2S_)%=A'0E
MT,3.3*2RA?,&TLW7D'C#+72O$[V]PEW<WHEDN(!(4EVJR"X!D:-O-8J/+W#
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M $G''IU[U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 44TR1K(L9=1(P)52>2!UP/Q'YTDLL<$+RRNL<:*6=W. H'))/84 /HH!!
M(.0>A%% !1130Z,S*&4LOW@#R/K0 ZBBB@ HHJ%+NVDNI;5+B)KB( R1*X+(
M#T)'49H FHHJ*6ZM[=@LT\4;%&<!W .T8R>>PW#)]QZT 2T444 %%%% !138
MY(Y5+1NK@,5)4YP0<$?4$$4R:ZM[<@3SQ1$JS_.X7Y5QN//89&3[T 2T444
M%%,DFBB:,22(AD;8@9L;FP3@>IP"?PI] !114=Q<0VMN\]Q+'##&-SR2,%51
MZDGI0!)134=)(UDC8,C %64Y!![BG4 %%!.!D]*;'(DL:R1NKQN RLIR&!Z$
M&@!U%%% !114,UU;VW^OGBB^4O\ .X7Y1@$\]AD?F* )J*** "BF+-$\KQ+(
MADC +H&Y7/3([9P:(9HKB%)H9$DB<!D=&!# ]"".M #Z*** "BH9;RV@D"37
M$4;G!"NX!.6"C\V('U(%34 %%%0_:K?SO)\^+S=Q79O&[( 8C'K@@_0T 344
M44 %%%% !113#-$LR0F1!*ZEE0M\S 8!('H-P_,>M #Z*** "BBB@ HHHH *
M*** "BH[B3R;:67^XA;\A6%:^+;2>6"%H+G,FQ6F6+]V)&A\X+UW9*Y['T/4
M9 .AHK C\7Z<^G+?%)EB:SGO1]QB8X=N[[K$9^<<9]<XQ27?B^PLS<^;#<*L
M-P+4.VQ%DE*[MJEF X7DDX'OGB@#H**Y>;QE!,+(Z;;S3I<2VH>9D&R)9G
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MTG*@I\MLL[*Q#$[@"YX&,+USU ,NZLO$S+<)"MX8#?\ F,[3_O9(2)?E4+,
MH5C%RK)D9^7C#;-Q9ZL=.T)(Y)I9X&/VJ1RJ,W^C2KE@"1GS"G )Y]AFG6GB
MFTU'1=0U"R5F-DC,T;LIR0F\<J6'(QWR.^#5+2O&#74,7GV9F>>X6"W>R^9)
M28O,8Y; &T!@3DC(]>  9\FE>([;2C'$^HW$NRWEV&\R9)O+<2JS^8K*A;8?
ME. <$ C<*GU"'Q1(]_!;172\7;0SK<(%;?%^Z5?FW A_4  C-7HO'6D7"3M
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M.0Y0G#\@'D]"WP]IVKQ7BW&KSW#M'8P1HIN,IYGS^82H.&;&P%B.W'>NDHH
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M2JH1E2#@A$XZ?*#UYI)O#UA/<3W#FZ\Z=-C.+J0$+G.U?F^49["M6B@#,N-
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MF3'S9G=!\Q^4["GX_*Q'-6J* ,N+P]IT,)A1)O)\U)EB:X<HC(XD7:I.% 8
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M)TC9V$<9$*Q?<SM8X#<D9^;V%3VWA_3[2"""-9VBMY%DA62XD<1E00H7<3@
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M3&!JMCF1_+3_ $A/F? .T<\G!''N/6I%U;37DFC74+4R0*6E43+F-02"6&>
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M1/J%HLBL$9#,H(8D@ C/7((_"LC0_#4^C7EO(MZA@CLX[>2-$8><ZHB!VRQ
M("'H 2" <[156Y\$1W$-ROGQ"2:'48_,\C)#74JN&Z_PA<>_M0!T@U&R,\D
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MC9E&\]LD#IT_ES+?$"74=/U%K2T\M4LI[V&3>0QMTC*ANG#><&'T&:]  "]
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M829;8P-LW.,_Q=1TP<?>KNQ%&LC2"-1(PP6 Y(^M'DQ;G;RTRXPYVCYOKZT
M<WKVJW'AVQ@9 9G@L+F8AI&P[11!ADG+')[DD_6H)O%-]9W!@O$LT\F_%K/*
MA)&UHXG4JA(8_P"M"DC." <8/'6,BO\ >4-QCD9I&AB9@S1H6#;@2HR#TS]:
M ..E\;2E?+MHK62Z D#Q&0_(PND@ ;'(R&)_"DU+QI<Z9J%[:E+6X>UM)G<(
M"F)HX!*1RQ)4Y].,CYB<BNR$,08L(TRQR3M')X_P'Y4&&(NSF)"S#!)49(H
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M5F8L2R@9"GN,8/)) K<O_#^F:F$%S;MA(WBQ%*T0*/C<IVD9!VKP?2M PQ%
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M53&KZ:8))QJ%H88SM>3SEVJ<9P3G@XYIYU*Q5IU-[;AK==TP,JYC'JW/ ^M
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M:II]X81;WMO*TT?FQJD@)=/[P'7%/.H62W$MN;NW$\2>9)&9!N1?[Q&<@>]
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M)#=0R(Q"JR2 @DC('UP<_2H=1U>STIK47LRPI<2&-9'8*BD(S_,2>!A3^.*
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MK#IMY4&J]M\+8[>?3_\ B:M]G@M]ES$D.WSI0)?+D'/R[?/? Y^ZO/%>AT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLF+=9RN?[V-_'^SZFM"RT"PT^\^TV8DA!"YB20^62$" [?\ =51^ [T@\/6
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M?:'C($C"5(E"=B"S$?D>A!JY%X4TE,,JRNH*F)6F9EB42++M3GA2Z*<>P'0
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MS8&0$A6;!R.#A2?_ *Y%5X/&&DW-NLL1NF,GE^5$;9Q)*)%9D*J1D@A'.?\
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M:6EV71&:-EG?;A3M!)&"1QD^G!K:77K!M)DU(M*D$;F)U:)@X<-LV;<9W;N
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MP_RW)@4LNWCL2,YSQCO6K;^(X&E2VF5VNFD>/R[>)W("%0S,-OR@%U]>O4T
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MHS&]S)Y0A6/S9=VQ8=_EJ/8;V^O?FLFYA\1BV^U0^9<WXNKXP)/%'MA 698
M#@$ _N^2<G/7!IUK_;UU<V\4=WJ::>UZNZ>X@1)O+$#E@04&%\P(,XSR0#C%
M &N?"VGB/3EC,L9L+<6T3*028AM^5L@Y^Z.>#UP1DU+9^';.QU0W\4EP7_?;
M(VDRD?FN'DVCW90><X[8'%96NIJ\.M7=SISWA9M,*P)&H:/S0S$]1@-@@C)
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MLY/IP =>F@V23K,!(76=+C);^-8_+'_CM5[?PO96_P#9@$UR\>FC%M&[ A,
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MDV@M+VU*L8;QI&F!;KO&&QZ563P[9@ R//*X^SY=WY/DN73. !U//K7/2?\
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M3K[5Y=2F>?SI V0"N!F(Q'!V[L;2>,XSSC).9F\-:=(^7$CCS5D92W!*PF(
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MRO<;[V*6&0!E&%D55;#;=W11C)(';% #W\6V"SIAF2!1-]I>:-XVA\M%?E&
M/*L#]"*ENO$EJGAW4=6M0THL4<R12(T;!E4-M((R."#TZ$5%)X/TV>&X6\EN
M;EK@2^?+*X#/O18SG: !A44# '3/6K*^'K7^PKG2'EE>"Y5ED<*D;888.-BJ
M ??% $:>*-%2*8^<\/DK+))');NC+LVL^5*@YQ(AQC)W C-7GU%4UJ+3?+.9
M+9[CS,] K*N,?\"_2L>Y\(6\[69:XEF>/45O[B:8C?,5CV@?* ,?+&,8QA?7
MFM2[TE+O4[;44N[B"6&-H\1;"LB,58JVY3P=HZ8/O0!3C\7Z+-&'BN)7W,@1
M5MY"TF\,4*C;E@0CD$<?*:L2>(],B6Y9I9=MO*('(@<@R$XV+Q\QSV&<5GIX
M)TZ+1I=)CFF2SD"IM$<.0B@@+GR\GKU.6X!SFI+KP=IU[/<S3R3O+,8R&(3]
MWL.5_A^;'3Y]W''2@"PGBK1GEMXTNF)N-FW$+X4NY10YQ\A+ KAL'(Q2W'B2
MQL]4O+&X6>,VMO%.\ODL4(D9E55('+97  ZDX&2#B*/PI81:A;7R.XGAC2,G
MRHL2!&9ER-GRG+-]S;U]A4^H>'[74;J>XDFN$::&*)Q&P S&YDC<9!(968D=
MN>0: $G\0VJ:'=:I LDJVQ*O$ZM&ZL" 5(89!Y!Z=,>M376NZ=9ZC'83SLMP
M^S@1L57>Q5-S 87<P(&3R:@/A^T;1KS3Y+B=Q>,SSW#,OF,YP-W V@\  8QP
M.*C7PQ;?VG#J4MU<37:*J/+(D1,H5F9<_)\N-QY7:>F<XH EM_$VF726;0R3
MN+QB+?%M)^\ P2P^7[OS#YNG-1MXNT9%E9KB4+&,AOL\F)!O$>4^7YQN91\N
M>H]14"^#K$1A&N;E@;L7CY6(;Y!MP>$&W[@Y7:3DY)S3X_"&GH5#374B1X$"
M.XQ HE67:N!G!9$ZY.% R* -*75K.W2%IG>/SHFE17C8-M5=S9&,@@'H>:IC
MQ5HYN_L_VEU;(!=H7$8)B\T N1M!V'=C-3:OHMOK*QB2XGA>+>N^!@&*NNUE
M.0>"/QZ8(K,A\&6WVVZ>ZN)IK2299([7< @Q;)!EN,EL!N^.1QD4 6AXMTAH
MU827.YG5%B^R2^8Q9692$V[B"$;!QCY3Z5:DU[3X]-M+_P UY(+S;]G\J%W>
M7<I880 M]T$]. #GI5:T\,6EM<P7+W%U<W$+HR2S.I;:B.BKP , 2N?7)R2:
MD;P_:G2]/LH9[B$:>5-M-&R[T(4IW!!RK,#D=_6@"MIGB_3KZVTXS,T-Q>0Q
M2>6$=E0R9VJS8P"2" #C]12VOC+1+R2%(9[@^=Y11FM)54B0XC;<5  8@@$\
M$C%)9^#]-L+NUN+9I5:WACAPP1]X3.TDLI8'GJI&>]2P^%M.@@AB0S;88;2%
M<N/NVSEX^W7).?7VH ?)XHTN)I5D>Y62)XT,9M)=Y+E@F%VY()5@"/0U5O/&
M.G10VK6OF7$EP]N HAD 199A&"YVX0YW<-@DJ11I_@O3--F,L3SLQ>)\L5_Y
M9ERN<*,_ZQLDY)[FE/@^P$D;)<7<:*8F>-7&V4QRF5-W&>&8]",@X.>* -#7
M=5.C:5)>^2)=CHI#,550S!2S, =JC.2<' %,BUZR,2>=-$LI6 L(F,B9F;;'
MM<## L",_B<58EL9)+(VZ7]U$^\L)T*%QDDXY4KCG'(Z?G63%X-TZ![8PS7<
M:0B',:R#;*8I#(C-QG.YFZ$ YZ<#  7'B^RC%C+!%<SV]S<&'S$M93D>5(X9
M %RX.SJO&#FM"XU[3[:RL[MI9)(KT@6WD0O*TN4+C"J"?NJ3T[5!9>&[6R2S
MC6YNI(K%]UK'(RXB7RVC"# !("N>N3P.>*AN_#@DL]$LK.]FM8]*=2LB%3)L
M$+Q#J",_,.H[&@">+Q1I$\UO'%<LXN!&4D6%S'F090%\84L,8!(/(]1FII_B
M^UN=/M;FY0QR7$$$B0P+)-(6EC+[0JKS@*QXSP"3BI+?PCIUI) ()+E+>'R6
M^S;P8W>)0L;MD;L@*O< [1D&D3PA8016RVUQ=P2VJQ+#,CJ63RXVC'52#E78
M'(/7M0 ^;Q9IEH)C>3>6(W<82.1R$15+,PV_*!O7/89'/:M&SU.UOYKF.V9W
M-O(8Y&,;!=P." Q&#@CG'2LNY\(:;=SK<F243!W?S"(Y,[P@88=6&#Y:'.,\
M<'DU>M-'M[/5;S4%FD:XNPJONV !03@#:HSU/+9/;- &;/XTTZ);&Y5;A["Z
MBEE$ZVTI(5 K;@H7)4AL[NG%6-7\3VFFVM\461[FWLY;J-&C=4F")N(5\;3U
M'0GOZ&F0>$-/A28&6XD:83"1B47/FJJL<*H4'"#H.N2<DFH9? ^E37-U.[W!
M-S \#C*\*\8C;!V[NBC&20.P% $]SXB-MHVJZ@UOD6$[1;02=X4@9X&>_2G2
M>+]%AA\V6XE0 R!T:WD#QA,;RZ[<J &4Y( PP]:L3Z%9SZ??6#/*L=[(TLA5
M\,"2,[3VZ"J$G@S3Y9(YY)[B2[5Y'>YD6)VDW[ P(9"O2- ,*"-O'?(!8U;Q
M"FEZO9V<B;89;>>ZGN'5MD4<6W)R 1_%GDCI[BG#Q3I3&-=]R)9)Q;K";242
M;RF\93;D#:"<XQ@'GBK&HZ+9ZJQ-VKLK6LUHRAL QR[=_P"/R#!^M06OAVVM
M[N.\DN+FYNTF\XS3,NYCY9C (50,!2>@'/- %NZU:TL[VWM)S*DEP0L;>2Y0
ML<X!<#:"<'@GT]152X\2V%IJ5[9W N(S9Q12/(86*-YC%552!RQ( P.I.!T.
M$O?#-C?ZY!JTS2_:(?+VJ-NW*%BO4$C[QR 0#WZ4:EX:LM5GN9+B28"YBBC=
M%*[<Q.7C?!!^8,3['N#0 W_A+='VAO/F(\J69L6TA\M(R0Y;Y?EP5(P<<TZT
M\4Z5?7R6<,EP)WD\H"2UEC&_9YFW+* "4^8#N*1?#5B+:6W9Y6\VT>T<@(A*
M,22<*H /S=A4ZZ#9K>+= R^8MT+H?-QO$'D>G39^M #9_$6FV]^]D\DIF1MA
MVP.R[]F_9N QNV\[<YY'J*ATG7_MOA>SUJYMI8Q<QK*(H89)&4-R!C;D\=\8
M[]"*D;P[:-JK7YEN,-,+DV^X>69A'Y8?IG.T 8SCC.,\TEQX:LKC0[+2"\JV
M]F(Q$?E8_(NT;@P*MQZCKSP0* ':;XBLM5U&2TM!,X6VANEF,3"-TDR5PQ&,
MX'^<'%:T\6Z?(L"73&&>60IL5&<+^^:)"S 87<RX&<<Y]*M:7H%KH\D36DLX
M2.SBL_+9@59(L[">,[@&(X.#GI56/PAIT5_!>Q-(LL77*QOO'F-( =RDC#.W
M*X//7@4 3R>)]+B>6.1[A98G1#$UK('8N6";5VY8'8W(_NFIK#6K?4+O4K=(
MYXSI\PBE>6)D4DHKY!(]&_KT()RH_ NF0VM[;QSW 2\1(Y25B;**7(!RA!YD
M;YFRQXYR*UK31K>SDO2CRO'>;3)%(P9<K&L>0<9R510<D]/<Y *B>+M'>+S%
MFN#DQ[%^RR[W$F=A5=N6#;6P0,<&GIXJT>22U1;IB;E8V0^2^!YC%4W''R$L
M" &P<C%1VGA2RM'A<SW4[P^4(GF<$HD6[8G &0-[<GDYY)IL'A'3;>_@O(&D
M66%50Y6-]X5F=<EE)&"[<J0>>>@H OW&N:=:W#V\]R(Y4=4964\%E+ ].F%8
MYZ#:?0U0B\1Z&MK<ZC"LH52//9+*3?C;N#, N[;CN>.W7BI+[PY;ZAXBCU*X
M"M$MF]LT63\Y8X!/^ZK2 ?\ 71JIR^!=,FTM-/DFG:%'W*=D(.-A3!PF#P3\
MQ&X'G- &S::Q97][<6EL[R26^WS6$3! 656 WXVD[64X![U'=Z]I]C?+9SRN
MLK>7G;$[*F]MJ;F PNY@0,D4R+15M$9+&YD@$MS%/,W#%@B(FT>@(C4'V+>O
M"7OAZUOM1^V237"[_*\Z%& 2;RF+Q[LC/#'L1GH<B@!DWB>P3P_?ZS$MQ-:V
M22,^V!U+[,YVY SR",CC@\\5%!XILWUF73YDFA.Z-8G>&0!BT>_#$KA#P>"0
M>*N_V):'09M&/F&TFBDB?YOFVOG=S_P(U#_PCUH\A>>6:>4RQS.SE<NR)L!(
M  Y'7 % #[#7]/U2">2QE:3R8UE(>-DRK E6&X#*G:<$<<&JEEXNTRX@M?/E
M,5Q- DCH(W949HO-V;\8W;.<=<8]15G1_#UIHEE)9VK.864( RH"J@8 RJ@G
M@]6R?>JEOX-TRUG,L+2J&A6)U*QG?MB$0;<5W [ HX(''3K0!(/&&C&T-R)K
MC8&"A?LDN]LH9 0FW<1L5CD#'!JK-XULU25H+:ZD6*XMHF8V\@W+-L(*C;DD
M!Q\O6H=<\%1:A%;K;,A\IXR\=P05<)$\:_PD<;R>0<^U:4'AN,;9+J[FFG8V
M\LQ4*B231!<.% R,[1D9QC\Z +)UW3_[)CU+S7-O(P1 (G+LY;;MV8W;MW&,
M9&#Z53MO$T5_KMI864320RV\DTDSQR+L*OLV8*X#!@P(8@C&*LR:!:OIBV*2
M3Q".X-S'*C#?'(7+Y&01U8\$$8XIVG:%::9,DT+2M*$=&=V!+EY#(['CJ6)/
M&!SP* ,R7QG:I)%BTO/+-[+9R'[-(6!C1V+*H4EA\G;IGFM"+Q+I,][!:0W6
M^2<+Y;+&Q0ED\Q1NQ@$I\V"<XQZBB/P_:QW?G^;.<7+W*1EAM1W1E;'&<'<3
MR3S^55]/\):=IE]#=6K2*T<:1E65&W[(Q&K%BNX':%'RD#CIUH L3^)=,MKB
M[@DEF\RTD2*7;;R,-[A2J A<,Q#J<#. <FJ\GC'1(_+S<3L)$C<>7:RO@.[(
M@;"_*2ZE0IYR,8J:^\-6%_%=I+Y@-S=)=LPVG9(B(@(# C&$'!!')I!X:L0.
M6E)Q; D;5SY$IE3A0 /F8YP!QZ4 /7Q)IK16LH><17,@B1S;2!0Y?R]K';\K
M;_EP<<U!%XLTPM!%-*RS2E?]7%(Z+OD:-,OL &64CG'/YU%+X+TR6\M[EGGW
M03^>JY4@MYYGZE21\Y/W2,C .<"IX_"VGQHRJ9L-Y(.7'_+*9IE[?WF.?:@!
M@\4Z5OA2Y?$QD(7RX9)%3]ZT(8ML 7+ CG'7J1S5RQUW3]1OYK.UDE>:$%FS
M"ZJ0&*$AB,'YE8<'M58>%M/"2KF;$@ ;YQVF:;T_O,?PJIX:\-7.AZC>SO/
MT=P79PD8W2,TA<,3C(QN(QENI.: )8O&FD-IZ7DYN;=&:8;9+:3<%B;#N1CA
M1D9/09QUXJQ+XHTN*25"]PS13BV/EVLK;I<$[%POS' )XSBJTO@[3YO*)FGW
M0R3/$66-]BRL'= &0C;N ()&X>N*T%T.T61'!DREXUZ/F_Y:%2I_##'B@!-)
MU_3M;W_8)9'VQI+\\+QY1\[6&X#(.UN1Z&LR_P#&MA%IKW%@LMS+N@$2F"51
M(LL@C61?ERR9.<KG/'J,ZFF:'::45-OYAVVL5H-[9^2,L5_'YSG\*I6WA#3[
M>)(O.NI4B$"0"1Q^YCAD$B(N .-RC).20.M $NJ>(H]+N%M'MYGN7LIKM2L;
M&/\ =[<@MCC.X=?ZC,5OXLL+BWMI0QC#R>7,LZ21M'^Y:;(!3GY5SG@8SSD8
M-[4=%@U*XCGEEF1D@FMR(R,/'(%W Y![JI!&#QZ9%0GPY9?:([A7G66-UD5@
MPX986A!Z?W7/XXH =<:[!'H)U>&*62'Y2JNC1E@6 SAAGOGI4ESKNG6FI1Z?
M-.RW#[!@1L54N2$#,!A2Q! R>?QJM'X9LXM FTA99Q#,YD:1=BL&+;L@!0HY
M[!<>W6D3PQ;#5(M2DN9YKM%57DD2(F4*6*Y^3Y2-Q&5VYXSG% #F\4:6A96>
MY659%B\EK642%F#%<)MR00K<@?PFIH]:TR[U-],67?.I8%6B;867!(#$;21D
M< ^OH<9,7@+2X=.N;&.>Y$5RL:2Y$1+*@8 '*=?F/S?>R <YYJU_PBT-O-?7
M&G74EK<72O\ /L1O+=@ 74E=^>^"Q&>U &_1110 4444 %%%% !1110!'<))
M);2QPRF*5D(20 '8Q'!P>#BO.Y;OQ?K&EZC;7EA/#%<:=/,(_(&0PB:+R.F2
M6DQ*#U(..G%>D44 <3=_\)';><L"RWTUM-*;66>W3)S9Y49"@ >:2N1CT)J&
M^CU>62+4=-N]6DEMM.NBCW%DJ/+)NB*Q,AC'!VGH 3@X-=Y10!Q)N_%4E]JV
MQI$: 3/;VY@)20*X,05_+"_,@P?G8_.<!<<-:_\ %,MY8,?.MX+G$P4VQ;;N
ME.(I L;%2(M@Y*<EN>..XHH Y>1-7D\%:X]PTUS?2Q78@MY($( !<1J$"_,"
M OWLYS[XJYI-SJ#Z]JD%T;B2V0AH)&A\N-1DC8,H"QX^\&8'_9Z5N44 <#HS
M^(K271[$K-;6D=K;@H;=F5_O>8&(C.UAQC+ICCKS4UGJ7B$1::9FU"9A=^5/
MBT*?:%/E_O!F$>6@R^5;:3\V'.T9[BB@#%ULS7VD6S6L4^[[?:,5*%6"K<IN
M)'7&T$_2L>RM-5T;P3>FR69]2>\FE)>)1(5:X.Y\*GS'9EA\K9XX(P*[*B@#
M@+Q=?N=.$OFW?FBV=OM$%J5FP+A"%^:-6)V \!1NQG!J;R_$%C?:E=Z:;F87
M-U)L@FA54?%DI20G:&!,B*IY Y(QFNYHH XS2Y?$5W]A6:]NTB>[/G.;7;(L
M8BSM;?"@P7'4+WQFIM2T.[U/QL;E=L-O!;V;K<E"7!2:9G2,Y &X;5;V8<5U
MM% '"6E]XGOIIXLZA:PO-;!9)+=3)$K-*)0"8E7@+'SAP,_>.:;=7FNZ);W\
M\4]Y<R?VDT*0W,2[2)AMA*-M&0)&CS@G W5WM->-)-N]%;:0PW#."._UH P=
M7FU.SN]&2WEN9T,@CN5B@YDR4&]FV,J@?,2/DR"<$8P<&P_M_1]&\H#4)$:W
M1E1(5#6[F8@@8C8D;3D@JYP,BN^HH \_M;?6;ZYM;N^M+@SE=/$C-$5R4N)R
MQ/ Y"E2>!UZ"K^KVU]:^(M6U6W2]D)LK." PQ(=F9I-^T^6[<#!( ;ANGW<=
MC10!P5NFMWYLYK^SE,H^PL[F#:Q*W$VXD[0>%V$C  W9P,U?UAM8M=>U.:SF
MU QO9VGE)' )(T F<3,GRG]XL9#!226)Z,  .NHH Y&?4M5M?!NH7C37/G1S
MD6TTUN%F:(NH!:/:!GD@#:,C''-,L9O$=S=PA;B]^RHMW)&\]LD3W&UHA$L@
M*#9DM+T"DA<UU[QI*A21%=3U##(IU '!P:CXB,"&2;5?LA-O]HN#IX$\+%93
M*L<?E_,H80C.UN&;!.,BU<:IKRW<EK!%?.1.S)(UG\I@^QDKEMNW=Y_;KGC&
M,"NRHH XLS>)H-4TRW:ZN&@:&!Y)GMLB21I#YJ.$B(4!=H7)3&<DM@XNZO?:
MQ%XJL+>RBN_LA:/SB(]T3*Q<-SY9P1A3RZ]1P>:Z>B@#A(+KQ3%IT+7<]^WG
M6UE+<2)9HTMNSE_.5$5.<83((8C)-7=/AU:W\%V<-NUU!=O>XD<PKYJQO<G<
MQ4@@'82>F!7744 </'=>)K2SE:XDU"Z+Q$ K;HK1L+C8&&V(]8SN(VMT)4#I
M3+67Q+<0QR.EQ!<R1VL3W ME\P+]ID5SR@&?+PW*@#.<#-=W10!PRS:];W)N
MKB359G2QNHTCBA7$KQRL$8_NR%=DVL.,'L#T,,=UXFEMO/\ )N/M,=O>)%.]
MJ"_^L@\OK&O4;^-HSMY!QFN_HH Y6]BUJ3PAXAM?M%Z][&)DM)U15FD&P,N-
MJ@$Y)7( Z>O-588M9M]:GO;*2\DAGN85,<]NJ"9/LWWWR@93N"@XV@'(Q7:4
M4 <KX:N-;N](NWU5I'F,*XBEMRC))M.]>8T#+G&,;N_S'(JI8/XCC:T=WN(H
M$>*%K86B;%C^R!F; 7=Q+QP0.V*[6B@#@7UCQ+!HI?R=1FN#9WD:.+,L9+D>
M7Y+;?+4HI_><,H'!!)^4F_?W&NP07TPEU!B]\88$AA3$,04D/_JG8@GC.#R1
MT&377T4 <797/BF5[.ZG-PI/V99;4P*J'?#F0D[=PP_H1C&*J2ZCXE.CV#0S
MZD)Y WVR26QVM!-L&$55A8M'NW<@'H!OKOZ* ,:\_M634]*CAGDB@\N22Z,4
M:[79=FU26!*@Y;I@XS7,V.H>*'TV*2_FO8B\L(NO)LBTUOE)#)L!A 9=XC7@
M28&X[CP1W]% '":=KNO3V>GLRW<QNHK!ED2TRO,["X+$+A?W>WKCV[TZ%O$T
M6GW3VXFB:WTY7@MEMT59)VDF#?PYR%$9"CN1D'-=ND:1($C141> JC %.H \
MXUN7Q%=^&[BU>74)([FTO$4P6):223:@CCD#1*0#F3Y@J]!\V>O2ZTNHIK.D
MSVDEV(UCF1HHDW1O(54H)/E.!P>>,>HS7144 <SX9N=5N1<B^>\EA^S0D-=V
MPA=9SO\ -10%7*C"8//4_,>W-:5<>)[+P[:6T"ZB88;>SCE:>TV20-M<2K&!
M$2R@K$,[7^\W)[>ET4 <U>7.K1:#I#//<B1Y%%]<6EJ7E5/+8[A&4)R7" _)
MP">!VRK[4_$WV[4DL(K_ ,M+"<PF6W!'G!$,;*!$!DDM\N]N^0.E=U10!R-_
M;ZV'OH_M5U=P0I;"%)+>(B9C)F1CA.2 !TP!UJD+_P 5'^T6D:X39*5,:6I=
MHX_M"C?$?*"L1#N.-TA)QP.0>[HH X86=\? -Y&$OFN'U%YD+V^)V3[7O#[-
MHYV_-C ^G:D&I^(8I+"$37#QZA=26L,EQ;K'*JJX<2,NT8_=+,.0.53CDUW5
M-:-&=79%+IG:Q'(SUQ0!R?B:+4FOKF2T-Y#$BV#>=:0AI"!<L90/E)8!.=O/
MTY(-_7+B74_"6L#29;H7,<4T4;P+B0R(""%R.3D$<=\XYK?I  !@  >U '%P
MQ:U;ZS<7ME)>20W%W&#%/ J+*GV0?O&^0,IWJH., '(Q5OP[=^()M%O9KPO+
M>B$&&&>%HRLNTY7)C0%=V.F<<_,>*ZJB@#@5FUVY%M(UWK/V2*YMG>1K,1S;
MBKB5=@CRT8/E\[3U;D@<)&OB72;&X%E]JD$S7<OE/"N(/],&"F$)),3R, =V
M=HP.Q[^B@#EM';7;F^L?M=Y<?95AFDD/V<)YC>8 BOOC4C"D]%7.,_6HVCWX
M\3:QK*QL@MK@R0B)/WUTOV-%$:DG;LWDG!!&Y:[2B@#BM(N/$E_/!'<3WMO;
MB\DW2M;J':(0QLH)>)<#>7&=@/&/>JUI=Z_I]II%E]IO)9;V9[.1KJ%0\,@?
M>7&5&Y?*67!Y!(7UKOJ:T:,ZNR*73.UB.5SUQ0!S6O'7FU1QIUS<P6Z):[1%
M CAF><K*264GY8\'CIP?KFS:AXE@;3X%2_DD%ZR22F!=LL(NR@+!8B ?)&[.
M8QSD9Z#N:* .4T36KXWEW%JDK%+>Y73H\1C,\VYF\SY1T\LQDXX!#^E0:E_:
MEOXUDFLOMH$RV,85+8-!*@ED\[>Y4[2L;$CYEYQUZ5UZQ1IG9&JY8MP,<GJ?
MK3Z . N+WQ#?Z<(W_M2W>V6U:XDAM-K-(MR/-V?(=X\L9PH((]<D5T.KW6H0
M:GH_V1KJ2W=]L\4<'+ L@#LQ0A0HW$J2A()P<C!WJ* //]-_M_1] BMS_:,B
M?8K78%A4-;N78.HQ$Q("A<@JQ^F<A;.WUB\O]/O;^TG\]HM/,S&(K\RM<[\\
M#!&Y2>!C<.!7?T4 <U>2:ZOB!I+>6?[&D\"+ (5,;HRG>Q;;NX.#D$8K!,_B
M2[TH--<ZO&4-C+<%;,))'+YP\](P(\N@7G@-G Y8$BO0Z* .-\7?VI#JUK>:
M9]N$Z:?<I";>V$JO,6B,:294[58J<GY>A^85:T>ZUV;Q-=QW[/':HTP6$PML
M*!AY;*_E@9*\D;V.2>!CCJ** .*OI_$T-IYR3W9$NHSQN%@4F"!3*(RH6)V(
M;$>25;C'3)-1G5->AUVQM[JYN5,UQ'"$2T"V\J&U+L^]ERK>:&&W<" !\O>N
MYIK1HY4NBL4.Y21G!QC(_,T <787^N:C/IQN;2YV1BS,WGV>S$NR;SB,KV.P
M9''IP>85N/%D5MHBR7-R9)[5);B1[4'$Y*[HW5(CM4#/7;U.6XKO** .-T?^
MU+GQDES??;3Y5O?1,LML$ABS/%Y81]HW[D3.<MT[<BH%EUFS22&2[UD1'4+H
MRS1V8FD126:((/+(*$$<@'! &5KN:* ,*VU6YD\.7#3XCU6TM%-T%7Y8YS$'
M('8XR/S%86EWGB+4A9*EYJ*VL\\)ENI;-(Y%!@E:10"F-F\1 -@\L0":[@HK
M*RE05;[P(Z_6E50JA5 "@8  X H X9M0\3@W)3[<6"R_:$-F-MOB= I@.S]X
M?*,C=7R57H3@VY=3U>&ZC@MO[2N(9OL7DS2V6#C[2PN"^$ 3]UMZ@<<CG-=?
M10!P=W<>+(=/LF6YNO,N/M#2R&U#&%P0(DV)$QV$;B<C)(^\,@5J>++_ %FT
M%FNE1732L&=C#'O0D%/E8>6YY!;'*< _-G%=110!Q5Q<>*81=S1274N];[9$
M;="(MDRB$IA<DF,L0"3NP*?8#5+;PWXFN+0WKWLDTLMG)<VP260^3&%.S:!U
M&,;1TZ5V5% '&-+XDL+FZ=KC4+Z".2>-(_(B#.@@#HP(0?-OR@/W>V">:I+=
M^)Y;*XG$%PUS##>BVEDM07SLB,?6-#RQ<8VC.WD'&:] HH XXIK46MV@N+S4
MY;6VU!XPZ0I^_C:!&7>%3&T.77=@ =SGFJ6G7OB*\D@>YM;LJET)$-S;C?&#
M;39&?*3&'V#('5L;B#7?44 <[X>_MIX9X=3N;EV>U@D6:2)$9)'5O,5<*!\I
M .""1GG-<YIUMK\5KIU['/J9NX-,M8YQ/;C=+()<2(VY,D %N1@D8.3U/HM%
M ',>'KK7;C6;Q=39TA5I0(6A8*,28C*/Y:@C9U^=R<CI@BLJ\U3Q''IMXD*Z
MG+<"Z98;B.VVKMV.5&PP%L A1T8$D?/UKO** .,'_"37FH(3>WMI!)=+"R1V
MT>(XOL8D+@LA.?.RN22.2,9QAFE:CXGN-6L?MZRV\+00O)%]F8J^8,R9(C.U
MQ(6&"Z_= VG//;44 1P2B>".95=1(H8+(I5AD9P0>0?:I*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-=TCC
M9Y&54499F. !ZFJG]LZ7_P!!*S_[_K_C0!=HJE_;.E_]!*S_ ._Z_P"-']LZ
M7_T$K/\ [_K_ (T 1Q_\C%>?]>L'_H4M<WJ]O>7GBN>P\O-O<QP%W':&,NS
M^[-A?H3Z5IWNIPP:C]MLKRRG#Q"*6(W"*3M)(*DG&?F/!]:;_P ))SDVL.>F
M?ML/_P 53L1>QE^'/#LYO+76I_,M[D0_O$=1N9V)9R?098CBNW7H*YW_ (23
M_IUA_P# V'_XJM./6=.,2L]]:H2.5,Z<?K2U*N:%%4O[9TO_ *"5G_W_ %_Q
MH_MG2_\ H)6?_?\ 7_&@9=HJE_;.E_\ 02L_^_Z_XU=H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** (;NU@OK.:TNHEEMYT:.6-NCJ1@@_45R__  J[P/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=7%$D,*11J%C10JJ.@ X KA_^%LZ#_T#]>_\%<O^%=Q#*L\$<RA@LBA@&&"
M1GD=J 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&LEK*9(V3>'",%QDJ1DC ((((ZC'(J2.\@DO9K-'S/"B.ZX/ ;=MY_X"?RH
MGHJ.&XAN84F@E22-^5=#D'Z53;6].351IK7&V[)"A2C8W%=P7=C;N(!.,YQ0
M!H44F1ZBER* "BC.:@O+V#3[">]N7V6\$;2R, 3A5!).!R> : )Z*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM#<&] CFW[3Y;Y78VURXQE K<$M@ \&@#8HK.N];L;&XFAG:7?#&DC^7"TF
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M?+1\D#C(+E3@#[M<W_PEU_8ZQJDEX)'L+5+R0(8T =8=N!&P.2W)R&'N.AH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!K_\)%H?_09T_P#\"D_QH_X2+0_^@SI__@4G^-9'_"MO!7_0KZ7_ . ZT?\
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M / I/\:/^$BT/_H,Z?\ ^!2?XUD?\*V\%?\ 0KZ7_P" ZT?\*V\%?]"OI?\
MX#K0!K_\)%H?_09T_P#\"D_QH_X2+0_^@SI__@4G^-9'_"MO!7_0KZ7_ . Z
MT?\ "MO!7_0KZ7_X#K0!K_\ "1:'_P!!G3__  *3_&C_ (2+0_\ H,Z?_P"!
M2?XUD?\ "MO!7_0KZ7_X#K1_PK;P5_T*^E_^ ZT :_\ PD6A_P#09T__ ,"D
M_P :/^$BT/\ Z#.G_P#@4G^-9'_"MO!7_0KZ7_X#K1_PK;P5_P!"OI?_ (#K
M0!K_ /"1:'_T&=/_ / I/\:/^$BT/_H,Z?\ ^!2?XUD?\*V\%?\ 0KZ7_P"
MZT?\*V\%?]"OI?\ X#K0!K_\)%H?_09T_P#\"D_QH_X2+0_^@SI__@4G^-9'
M_"MO!7_0KZ7_ . ZT?\ "MO!7_0KZ7_X#K0!K_\ "1:'_P!!G3__  *3_&C_
M (2+0_\ H,Z?_P"!2?XUD?\ "MO!7_0KZ7_X#K1_PK;P5_T*^E_^ ZT :_\
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M7_0KZ7_X#K1_PK;P5_T*^E_^ ZT :_\ PD6A_P#09T__ ,"D_P :/^$BT/\
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M_&C_ (2+0_\ H,Z?_P"!2?XUD?\ "MO!7_0KZ7_X#K1_PK;P5_T*^E_^ ZT
M:_\ PD6A_P#09T__ ,"D_P :/^$BT/\ Z#.G_P#@4G^-9'_"MO!7_0KZ7_X#
MK1_PK;P5_P!"OI?_ (#K0!K_ /"1:'_T&=/_ / I/\:/^$BT/_H,Z?\ ^!2?
MXUD?\*V\%?\ 0KZ7_P" ZT?\*V\%?]"OI?\ X#K0!K_\)%H?_09T_P#\"D_Q
MH_X2+0_^@SI__@4G^-9'_"MO!7_0KZ7_ . ZT?\ "MO!7_0KZ7_X#K0!K_\
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M7_0KZ7_X#K0!K_\ "1:'_P!!G3__  *3_&C_ (2+0_\ H,Z?_P"!2?XUD?\
M"MO!7_0KZ7_X#K1_PK;P5_T*^E_^ ZT :_\ PD6A_P#09T__ ,"D_P :/^$B
MT/\ Z#.G_P#@4G^-9'_"MO!7_0KZ7_X#K1_PK;P5_P!"OI?_ (#K0!K_ /"1
M:'_T&=/_ / I/\:/^$BT/_H,Z?\ ^!2?XUD?\*V\%?\ 0KZ7_P" ZT?\*V\%
M?]"OI?\ X#K0!K_\)%H?_09T_P#\"D_QH_X2+0_^@SI__@4G^-9'_"MO!7_0
MKZ7_ . ZT?\ "MO!7_0KZ7_X#K0!K_\ "1:'_P!!G3__  *3_&C_ (2+0_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>bionano-nancyridgeleasee007.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD,(69BP89'[QAC&..<\BL'3_ !'K7B*.PE2XM+=FNX&5%C)*!HI2V]1(2R<
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M](N;6*_N([=+@.5FED5$&W'!)(ZYJRNHV+7WV);RW-V%W>0)5WXZYVYSCD4
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MI6C9-B#=(-I8.>['Y20#SCH-*U2XFEN6U":WC1[V2UM(EC*L=A?J2QW$A2>
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M>HK")'AFCC6%B@DBD1P[J7PQ.P [=F03G)P1DV7C?4+[4M(M0+&$W,$,LPD
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M4%N=1DM)6\I2MQ^Y61 I$K!6RQ'#-DCZK2:9XMOGCTF(FU#2PV.;63>T\XF
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MOEY8@]>/2H=)\7WFJ^)+:Q'V.&%HT>2)_P#6$-;K+\I+@DY?& AX4G/8.O\
MQ==0>(;[3K9K-A#!,R^>!'Y<B1JPWMYF=IW=2JCT)Q0!?7PU=1V1M(]1A$<5
MX+JV+6I)0^:9"'._Y^I&1M_&JUUX+><2I'J*I%<+<QSAK?<3'-.96"G<-K#.
M >?7'H7NO7DW@JVU:SO8+>0W4"2SRP?NU3[0L<AQO(VXS\P<@@$@\@BA_P )
M!J^EOJDVV.^@\R\:"$*WF;HHPZ@-N(VGD;0/3D]* -";P4DETLXO P+SF6.1
M'VNLDQEQA9%Y!8C)R#Z5K:1I$NF7-](UT'BN9-Z01HRI$<L6(!9N6+<XP,C.
M 2<XZ:]>77@?7-2<VTDEM!.87MI!APL08']W(^TY)'#YX!XS27'B/58;Z[ 6
MP%NLES!")0R8:.+S%9W+8"GD'@8ZY[4 ==17$'QP\=G%*[VQ>:',.]-GFR"?
MRW50'8, ,'Y6([YP:-3\6:EI^C7-^[V2,;VYM[:,P$@K"TH^9FE49;RP>/?
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M=D8&D\L2B==I?^[G.,^U17GB#3+*":9[R&18)HH)Q'(I,322",;^?E +<Y[
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M\DU-110 4444 4)]&L+B_6]E@+3@H<^8P5BARA90=K$'D$@D=JOT44 %%%%
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MY&P6-I]R+_HX=RB%\'NRG[N>!DX'-0-XSTU([B1XKI$A#%6>,*)0LHB8J2>
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M!3>K3L/L?V\8B/-OL+>9].-OKN('O3+GQMI=G$QN4N(9A+Y?D2JJ.?DW[N6
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M'V07'&3@')(Y[4 5[BU\2R7]P\27D<I:4[Q<J8#$;<B-%7=PXEVG=M!X;G!
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M=I;7<;QSIOW+(P9AEV(R02"<'M6=+XMF6YBCCTFY(_M.2Q91M9I L4C[D^;
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MEV3RK+*BS,JR%551N /(PB\>WN:G72HY-/-I=RRW2F?SRTCG.[S/, 'HJG
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M/)!%9,EOXJ>XU=A=72.?.6!$1=FTRCRF5BQ 81YR-HR2<YP* .I71[--3CU
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M./<'!R*LIHMHM_;WI,\DUNA2(R3NX7(P3@GJ1U-4?#UKJZSWEQK,\K3'RD1
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M<PF,,6(RN4.>W'/&:)[775$T\\M_(CWX$T5M( 1;"/\ Y9#C'[S!)SNQGVH
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MPID B;D]\%]O _E6#;1>*4L+MKLWDT\C(LD:#8$.\[GC829*[<?*NWC'0YH
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MJ ZM=V-Y#+;B.X$44C1G9_Q[K.0S= P!?C_9]QFSI7B;3-8M;BXM)6*6ZAY
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M@$S;)%$?E@L.YV #/L.X%.'ABP^T13N]S(R>475ICME:,YC9QW*G!_ 9S@4
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MF  [G!K@+-/$]MH]M!#_ &BEK&+:.?SXU,R$12"4($&2N\0#C/\ %CBO1J*
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M\=Q+:I=-&ZX\M&SMS]=IZ?ID5-J^N6FC"/[2D[M(KLJPQ%SA!ECQTP.?_KT
M:5%<[=>,](AGN+:.X#SQ1,PR#L+"+S=N1S]SYNGZ\5#-XPV2RHFGW#>3?Q6;
MD(6\S?$LF4Q_O#KVY- '445@+XRT5KBS@%PP>Z6-D!0C;YC%$# \@E@1CL1S
MBGR>)8'\,W.MVL$SPQ(6195,?F 8Y&1G'OCM0!N45D7WB73-.U:'3;B8K<R^
M7@ <+YC%$S_O,".,^^!4<'BK3KF.S>+SF%Y*8H/D^_@9)Z].>G7KQP: -NBL
M%_&&E1K*SFX"(K,C>0Q$RK(L;%,?>PS*/?((R*M7^O6VFV]M+<076ZY!*0I"
M6?A2Q! Z8 /Y4 :E%8R^*-,>Z2%'E='94$ZQ'RP[1B14+>I0@_B!U(%*GB""
MXT2WU6!)%@N)8$C\]&0LLDBH&QC/.\8S^.* -BBL"P\66E]]E1K:Y@FNIYH8
MHG09(B?8S=>F2/?KZ$U>O-;M+#4K6QN/,62Y.V-]OR%N<#/KP?TSU% &C17-
MKXXT<VWGYN%5G18P\>TR[T,BE<GIL!;G'IUXJ>'Q;I=S<0Q6YN)1,$\N1(6V
M,7C\Q!GU*\_H<9&0#=HK"TCQ5::LFFA;>XAGOK87*Q.O*(>Y/<?3VSC(INK>
M)X+&/45@C>6>P\OSAL) W%>!CDG:X(P.>G4$4 ;]%8<GBO3H;2.YE6XCC:9H
M'WQ$&)PP4AOQ(Z9R.>E-TK7I=0U0VCPHBC[5\P)S^ZN#$/S S0!O45S%IXVL
M#:2RZ@LEL\9EQNC8+*$F\KY">IW,@^K#M5R3Q'!-H<.IV&)8Y+R&V(?C:6G6
M%_Q&3[''I0!MT5AQ>)[/_0EG#*UY(8HW124W;RH&3@Y)'IQGW%9]EXS6\TNS
ME%L\=W,UKNCD1E4I+*(RR$]0"3^G8@D ZRBLC1_$NF:[--%83&1HE63D8#(Q
M(##V)4^_YBHV\5Z6+6*X5IW66&":-4B)9EF8K'@>I(/T[T ;=%<S>^,[2*TB
MDLXIYY7,6Y3"V(0TWE?/_=.X./JI[5*?&VB[[E%FD=H&VX2,L7_>"([0.3AV
M4?B",CF@#H:*S-3UVTT?3DO[U)XX"NYSLYC&,G=]/09/IFJL_BW2[:>ZCE^T
M*+82;Y/(;83& S@'N0ISQ[^AH W:*SI-<L8[.[NR[&&VE\EBJ$[G^4!5Q]X[
MF"\=^*IS>*+:VG=)X+A2$@*PB)C*7D:10I7&.L9YS[\#!(!NT5DIXBL79\+<
M"-;@6PE,1V-(9/+*@^S\'Z'TJM<>,=*MSAOM3C)#&*W9PO[TP\X']]<>O?IF
M@#?HK%@\3V%S-;P1)<-/,)2(O+PR^6Q1P0?1ACC/KTYJ"T\7V4^F:5>SV]S;
M+J7EB,2)]UG("@GODL!QZY.!0!T-%8*>+]+=93_I*[.$W0,/./F>5A/[WSD+
M^([<TYO%FEQZC!82O+%<R[,I)&049L[5;W.#TSV]1D W**P;GQ/#_P (=>>(
M;*"2>&&V>>)2,>8 N0?I^HYXR,4L7B>T22.VN_-$XQ'+((&6-9?+\SR^IPVW
MG&3Z9SQ0!NT50TW5X-4@@F@BN5CGC\V-I8&0%>,')'&<@@'G':LA_$TYM+B6
M&&%G$=]+!&Q;+BWD"<]OF))ZC&1P>: .FHK(O]?M=/@@NI6 M9+>6Y9L$ML1
M-Y( '/%5Y/%EBB&5EEC2*21)UFC99$V0^=PN/[F#VZ^O% &_161/XCL(+A;?
M$\DS7"VZI%$6)<Q^;^6SG-2V&N6&I9^SR,=L"SON4KL5BR@-GH<HP([8H TJ
M*Y]?&.F-") EYN;RC%']G;?*LNX1LH]#M;KC&.<5O@Y .",^M "T444 %%%%
M !1110 4444 %('4N4# LN"1GD9J*[,XLIS:A3<>6WE!NA?'&?;.*X"!-=AB
MO+B.'6'EN1;1M-*%612$D+'"J25#[1T'+9SM% 'HM%<3!;^)[R6SDN;R^M][
M6Z3I$(P IM\RG[IP?,P,]NV*A6^\30SZ0]Q%=J(K:-KUV"E'_=/O) 7 (<)W
MSZ #.0#O*QH_#%C#<331R72,ZSA-LQ'D^<VZ0IZ$MSGMVQ7$:5JGB'4=(1TO
MKEY3/$UV(\3-#&T!((*K_%(,D*"5R!TKK-1MM0D7PS-)-=/)!<J;QK==N[,+
MJ69.>-Y7([ GTR "^OAZQ75O[1'G>8)C<",R'8)3'Y9<#UV9'ISTSS6F74.$
M+ ,02%SR0.O\Q7,^&GUM[[_B8F[V_9_]*%PJA%N-W2+ Y3&?48V]\UAC1]:$
M"F";4TN[5=3*RMM+%VD5H0"0058 'CT(]10!T]SX3L;G4[W4!<7T,U['Y=PL
M%RR(X"% <#C(!X/KS5*/X=^'[?R?LL,]J(&D,0AF*A%<J70#LI*@X[')&,FC
M3VU^3Q7*;R66.T#';$(<QM'Y:XPW0-OSU.>HQC!&=/>^(I]8U5-*DNI)8)YX
MT25$%N%%MF, XSN\XIU/0MVH V)_ ^B7,=Q')#*5N$NTDQ*1D7+AY?S(&/2J
M-K\.],%SJ4^H2SW?VR6Y*QF5ECB2<;7 7.-VWC<*-,AUZ=[%9[Z^^SFZ9I2T
M(C<((AA6+#)!?)R,=< XJM'-X@^RHER=5,"SR"2X@C FE^0%"$(^1=VX$#(R
M!SM)H TW\!Z.Y$OF7RW2E&6Z6Z82@K&8_O>Z$@^M3VO@K0[)H?LULT:PRP2Q
MJ)#A6AC\M/R4_C5#3X_$_P!OM)[Z:?(GACGA0)Y.PVP,C#C/^M[Y[<<$YFNG
MUS_A)RL1NQ"+F+R@JK]G-ML'F%SC._=NQSGA,<;J +4W@[2+C67U.1)S*\OG
MM$)F$1E\ORQ)LSC=LXS^/7FG77A+3+K1=,TK-S%!IAC:U:&=DDC*(44[AS]T
MD5EW5SJVD?#JWN;FYN'U606OG&5D5@\CQJZ XPO5@#@XZ\UG6EYK]U86TEK=
M7UP2F('C560SB=Q(DS$?<50JAN 0&(YQ0!OP^"=+MWO&@EO8OM>XRA;@XW,0
M6;GN2.>QR>.353_A7?AJ6*.$Q3R16]L;2.,W#$1*<9QSD-P#]>:J2R>*=]Z8
M?MWFA+CS0438H\U?*\C(Y;RMQ[\_>YIEA%K%G<0R0IJ3PS:F[-%,@5Y(V\H"
M1V ^7:H<[2!N&<D,!0!OZ;X2TO2[Z*^A$\EVAF)GFF+O(TNS>6)ZG$2 >@%5
M+[X?Z#J&HWM]<13F6\6190)F"_O(O*<@=B4 'MCC'-6M4U&]N/#D>JZ)#--*
MKI,EO@!IX]V&'/JI)'X5@QMXMCTJ6.]^UR3QS+:"6#:I=5$C?:,!22&S&N!C
M!'89H UK_P !Z'J$\T\J7*2S.7=X;AXR08EB9<@_=*(H(]LU:OO"6D:C9V]K
M=0N\-O9RV4:^81^ZD558'WPHYK$QXK?2+FZ:6Z6\\BT40A4P,B,W#* ,EQ\^
M.>O05-:SZS:7.ERW5Q=7%L%E,^^$PK&FYR'<D<X4*,-@GAASD4 :UEX6L++6
M(]5$EU/>1V_V9))YR^U#MSU]=@/USZFL/5/A?H5UI!MM/@CL;P1O&+Q4R\@<
M@MYI!!DS[GCJ*V]1:]U2VT=K&2[M(;F8/<LBA9$B,,C -N!VG?L![YKG0/%T
M.F0"2>\D:6"SENG,:EXW82><J! #P1%P 2 3CF@"[I/P^M;.&T:\NY9KNU++
M') 3$JQ%]XBP225![DYY//.*MR>!] F@>T,<N/(EB(68AE66;SB?8^8N0?;%
M4FB\3"UN)OMEY+)%8VXC"1(GF.6;SF"D?ZP*%P#QG''--:RU7^USJ-E)J2J(
MK&,"=5#2J+J7S X(S\L;Y['!!/- &[8>&['3]8FU5&N);V6$0-+/*7(0'..?
M?FJ8\%:!!82VKP-]F>Q%@X>4_P"JW,P&<\'<QYZ]*R8I/$]U<WZ8OK:%Y[8(
M3M9HQ]H(EVDKC'E[3P"!V).35?4K?Q%<VJV=P-1E0,5A\I$/F[;IN93C_GBL
M9'3.6[XH W$\"Z)MD,@N9Y95F66>6X9Y)/-C6-]S'_850/3%7/\ A%=*^PZI
M9^5)Y.IQ"&Y'F'+*(A$,'M\H%8T0UZVO;8112E6N;S, C$<8#3RE)&8#!^79
MP<$YR"3FK7AHZ^='NWO9I9+TPKY<=S#LV3;3N&> 5+8Z<#G!QT ";P!HURB_
M:'OII$6-$EENF9U$;EUP3Z%C3;?X=^'[6>UDBCNE6V$(6+[2^Q_*8M'O7.&V
MLQ(SWJE9IXBNC!%]HU2*V>2 32S(BRJVR7S@/EP$SY0! ZD[3BM#Q,^MK=[=
M--V!]F/V7[.JE&N=W ER.$QCT&-W?% "VO@;P_826OEQ.K0M%Y0:8G)B20*/
M?Y99/\BH8? 6GVNK>';J"1_(T.*:.".5B['> %&XG[J#.!@]1Z<T_P"QM1GU
M".)I]2C\O69IS-D?)$T$H4H2",98#VSVIVGR>*I=2L6OI9X1]FA9T$&4<F']
MX&(X5O,SU/9<=30!U;:; \-G'*TLGV1UDC=W)8L 0"Q[\$UDKX*T:.V%O D\
M$7[X$13,N4E(+Q_[IVK@#I@8Q5.ZEU73/ -I+/=WC:F[68G?"&4-)+&LBJ,;
M<_,P Q45K'XEF"NLUVJQP7;VZSA%,K[P(!+QG[N>.#CKS0!LW7A;2[V&]@FC
MD,%Y)'++$)"%#(%4%<=,JB@CH0/<TL/A?2K=2L<#;3<RW)!<\O(A1OPVM@#L
M /2N8DO=9M_L:R3ZPMG<7<41+Q)]I8^1,TH4;?NY5#P,\-MXQ5G3F\5MJFFB
M_FGB000%P(0ZN<'S1(5X5^G< <;<\B@#H(O#=A'&J'SI"JVZ[GD))$$ADC_)
MB?J*9%X8L(IEG5[@W NA=^:9/F+A#'SZC82OO]>:P;33-;=M"EN]0U-;J;2Y
MTN9?E(AN7$)&Y0, ##XSW4<\\V],U#7=3\%7NJ(I34+E&:U@7:?+VJ%^4G@Y
M96<$\?,.U %RS\+:+HS0NC.FUXEB\V;NF\1J,]?]8WN>^34@\(Z6)8&3[0@B
M,1V+,P5S%(9(RP[X8G^O08Q[?3]2O]7TV>=K]K*UU%Y(#<@*_E_9\9<8S_K-
MX&><'Z58OVU2UO\ Q$-/M;@W=S;HUG*(\H76,]SP#GH#QG% &K'X9TR)2JQO
M@^1_&?\ EC*TR?\ C[$^_2J?A;PO)X<:X_TM)8Y@,JD97<X))D.6/)R!@8''
MY9\#Z_&=-<SWMS&;LAH3 8CY9,8R[D9^7]X<,!N!QG(!-267Q2;%8UDOE073
MB2[$),CCR\J1'C*J&X(&1D#G:30!TJ^%=-%HUJ1,T1MY+8!I"=L3D$J/;Y1B
MK-EHUKI][/<6[2KYS.[1%\H&=MS$#U)R>O<^M<]#=:[9Z[<7.J7,RV%LID95
MM_W<D0@!)!'"MYFXX)SQCH0:T]:DE%[H5^EI=2Q0SN\JQ1%G0-"X&5'N0* )
MYO#&EW$31RQ.RL+@?ZPC'G2"5R#V.]00>V*R]3\&->WMA<P:@4DM%81R3)O=
M&+*V]<$+GY<8((_K3!\3/-JK37EU!@S"-$M"ZA?.'E%"/^F>00,GYB3R!1-<
M>*#&[6L%V+B33"4BDQB"8+Q\Q 61B?7!!'(P3@ TM7\&66H6,D$)$;22^8_F
M;F5P9S,RD @C+L>0>*FTOPW!:FVG:\>6[@189'B.U75&8HI7G[NX@<Y(ZDU@
M7!\4_8[98+V[$3M/^]^R,9(VQ'Y092-S+GS3D@#H#QR=S4(+RQU;3CIR3M#-
M.SW4,0(5BS)F0OR!M 8[3C()P<@4 6&\*Z8;>*)5F3R8HHHG20AD$;%D(/J"
M3]>AXJ>WT&UM=1^VQ27 E8+Y@:0L)6"[ S9Y+;0!^ ]*S+TZZ?&$2QS2Q:<!
M$4"0[T<9;S Q'0].21VQGD5FV%MXIC2TGGO;^201:?)+%(L>TR/*5N5.%SA8
M\'&>.O)H Z&?P_IS:@]]*T@,DHE:,RD1M+L$0?;_ 'MN%].AQGFIY]$L[C18
M=*;S5MH1%Y920JZ^4RLA##G(*K7%V+ZYK%K"Y-]<0&XMI)?/1 H9+V,@QX R
MHC5B?H.^:L/=^([6UO+V66[3[);RW-TLZHL9>.565(CC[K1"12>V5)(;- '2
MP^&-,B@EA:)Y4GAE@F\URQE61BS[O<EC^?%5[SP=IM_8K:7<EU,BAUW-+\Q5
MU"LN0.A '/7WY-9$+>*)-2TUIIYX8)8X9F"P;P&:5VEB? XVQE$!/ID9-00-
MXI_LN\DNKJ[6Z'E[H5MB1O#L65& ^ZPP,J#@8/7- '3GPY8F:=]UQY<TR3M#
MYI\L2*ZON"]B612?Q]3F:30[*73IK$JXBEG-P2KD,LAD\S<#V(?D?2J[:A>7
MF@ZB-/A=-4MX&C19<$?:/*# 9Z-@L 3TR#6!J$FN?8X_[.?6B#;2F RQ)O-U
M\NP2 CA/O=<#KD_=H Z:RT*RL+B*XB$C3QK,#)(Y9G,K(SEO4DQK] ,#BD_L
M*S_M![W][YCW"W17>=HE$?E;@/=< _05SFH6?B.Y3446XO"MPMY"D:E55%V#
MRBIQD$MD9)[_ $Q-C64@NKB)M3DBCLH%MX&VHS.2PD8Y4MN VG&/H,F@#3D\
M(Z7)8R6>)T@E@CMY%63[\:;\*?\ OXWZ>@J[>:/;WEU:7/FW$,UJK)&T,FWY
M6*DJ?4'8OY5S>E2:^\FGKJ9U)(B9@#"BY)%PP3S<C('E;#V_BS\V*H)%XCL]
M"M;:!M5\^.UF5#M5B;L,-@<D?ZO&>?NXSD]* .F_X1+319O:*UP(/,62-!)Q
M$5;<-O'3/8Y]*:W@_1VMX()DEDMK>W>WCB>4E55E*-SUR58CK[]1FLS4$\00
MV-Y=1SWTD_VYO*M8U&'B ;:BL%)0$D'><] #QFM?5;B35/#6K+80L\ZI+ BO
M&"'D48. >&&<CZ@T 6#H=K)H]QI<\D\T%PI60O)AR",<$8QT[50N/"5E,UB/
M,D8PZ@+^5YF+R3.J;1DY]H_;" 8[U1EM_$SW%TT%W<JTOVQ8ED">7'M8& ],
MX//4\@GVQ1U"VU_4].>ZD@NH)9[2>01QA1+#^^B,<0(YSL4DC/)S[4 ===Z1
M!=ZE;W[2SQSP(8QY4F RDJ2K#N,J*HCPEIXT>32A)="R=1'Y7F\", C9TZ8/
M?)Z<\"L>9O%)U._-I-.%6%S91S0924?9QLW-P%;S>N>>",8.:9"_B&.SMI//
MO[@_; ?(:W,;LFU059R. &W-DC:>1G&* -Z;PKIT]S+<NUQY[[-D@E(:+8VY
M=I]CZY].G%6M/T2RTR7S;97\PH49G<L6R[2,3GJ2SL2?>JFIWUS>^'9+G21<
M!O/5"40>88EF"RL@/7*!RI[\$=JS7NM:COHH((M1DMY6M&226-<J@D;SMYXP
M=NWCKR/0X -.?PKIES/<22B9DG,C&+S3L5Y$*.ZCLQ4D?B>Y-:5Q807*6Z2*
M2+>198\'&&7I7'V<6M33Z3+>-J3"VU%EDEQL\Y&A.&:/&57?\I'(')!P1AMG
M_P )1/:JCRZC'(XM!=-(B I*91Y_E<8V;,\\C&,<YH Z&+PQ81"Q0/<-%8OO
M@B:3*H1G;[\9P.>G7-0ZKX1L=2GN[L/+%=SHX$@;*J[0M#OV]\*W3./QR:Q&
MC\6VUA+Y5Q>3R.A#&54)0+<A<J !\Q@W'OD@'K5NV@U^6-6EU*]5([*=D=;<
M F4NPCW(PRQ52, XW8!- $^F>"X;2T2&:X(,,K/;_9@4\E650R@L6)#$;CGO
MC&,9K6;0-/>4R/&S%IVN#ESRYB\D_ALX_6JWA[4)Y;:&SO8;A+Q8WD<R9/R>
M855B2 1N R 1G .>E8"GQ3*K(LM_'*VU;IF1-L;FXC&8>,%1%YN>HP%SSF@#
M=D\+6YAMQ%=W236D#0VLK2;C"2I3>.F2%8CTX'&1FM&ZTJUO#$9P[F*)XE.X
MYVN,-GWP*P_%SZU:Z7##HJWDMPL4FV:,@GS%4; XVG.XYZX7@YZBH)[?Q(]W
M=/#>W$0E>YCBWA/+B4*#$W3/W@>IY!/M@ UAX6TY3<A/.6.YB,<T0D^5OW8C
MSZYV@#CCC.,\U+_8%A'<O=9D&9H[AE,GRB1$"!L?[H /T%9-K?ZQJ7@HZK"L
MR7-[(EQ'$@4O#;,Z\+G@MY66&<_,:S7L]9N+B*:9M2>W-O?00JX 9@WEF+S5
M XSB3!.#@+GD\@'26WAK3K:Y@NK4RQLB*OR29$BAF9=WT+MTQU[BK#Z)9/H)
MT7:XLS#Y. YW!?KZUR36_B:PL(+2&>]:V5X/,E*!I$3R6W!0HS@2!.@R,GMF
MN@T&'5OMEQ-J=W/(%CACC4HJ(Q\I"[[0,@E]W&>.: )X_#UM'?17OVBZ:X15
M1Y&ER955F90W'8LW3'7!S4)\):<T<B.]RXEN%N9MTO\ K77;C=QVV+R,'CKR
M:Y:UOO$]YITUQ92W\@9<3--&F!BX _<X'/[K?GJ?N_Q5JP0>()(7:74KU5CL
M)#%(ML,F4O(%+(1N8JFSCC.,D9H U5\)Z6K,2)V7D1HTI*P@R+(P0=@653^
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MTDN#,JLP_>HTG&,# W=!QCB@"['X>L(M*O\ 3V\UX=0+_:6=_FD+J$)R.AP
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MAH ZBBN&LD\277D1&XU2*W=[<3R3)&LJOME\\+\N-F?* (&,D[37<T %%%%
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M[#'(7@>)D?>@SM((R.QSCH<T'PIISPRI*T\CS0SQ2RLXW2>:5+DX&,_(N,
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M;;@?-AV"G'K2)X7TRWLH[1Y9C$(%M(_,D&1&K;E4<#., >N!WZTJ>%M-A-P
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M2);Q).UT98G1X3$J/@H1GE7!^A%6;_Q3I>G/,D\DQ>%V218H'D*E8UD;[H/
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M2(2"F\;0R@ME2#QGK0!SL%WXGN[J]C'V^VA:>V",\2%XP9G$NTF, _($.?F
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M! "X#8PQ /(!)Z^AI;W6K&#^RGFMKF3[;<>7!FT<M&VQFRRE=R\*1TSSZ9H
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M;S)/+##Y"64'/W0>F.I% $>EW&MC6+".[FN;F"2U'FD6QB5&&X[V+(,D_*,
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M"HJLS, F5 WKD\@9'.3BD/BC0[>2:V^T^6MLC%F$#B)0B!R ^W:2$(; .<4
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M*:( A5 P%8\ #GGUK+\4SZK)I5M'"+R)+BUE\XVEMYS^;L&R,@JVU22V3QC
M&1FLN74?$EL\MO8VU\J0Z<ZHCV^Y?-6W5D*_N_[_ ,N"[9.1M'% '2W_ (9M
MM0N+YYKJZ$%]$(KBV79L<!2H.2I8$9SPPY I@\)V8CLHS<3%;2<7"A8H4W."
M""=D8Q]W'RXR"0<@UF"7Q)97\K/<W][;QW;PB/[-$"\7V0RAP0@Y\[Y >G8Y
M/-85WXC\20V#QO<75M(TL[13R6V76)(8CO93 "45Y&SB,=,;O[P!U:>#;2(,
M\5]>Q7#O(SSQ^6K$2*JNN FT [%.0H.1G.:U=-TBTTI+A+566.9U8H3D+MC2
M( >VV-?UKEO[0\1RWVI!;B2*%8Y?LY-H\BE=H\N1=L6">Y&YNI^7C%:,U_JK
M>&+"X"7T$KS*MTX@$D\<>2"RIY8SG"_P9"MDJ". ":T\(6%J(1]HNYA;B%(/
M,=?W4<3;D0849&>I.2<#)J[JNA6NKL6N'E5OLTEL#&P&%=D8GD'D&-<=NO!K
M+T"77;O4$;49KF.VCM@RJT")Y[&6907^7(;RUB8J,8)Z#I6=?R>(XOMQT_[1
M (TU"Y18K5#YTB-%Y*G*G.[+],%L'GB@#I;71(K;6)-4:XGFN7A$)+B-1MXZ
M[5!8Y7OG&3C )%<[>_#ZV$$GV&5GDEEB>5;@J ZH9"!N"')S*3N8,3@=^1%>
M:OJUI)JSV,,TB![R.,6UIYI^T".(PYVJ>_F<GCL>U6-0U+7-+MM2UB62XE@M
M+R,+9>2BB6 H@;:=NXMO<G.?X,>N0"]I_A&WM9[:\N)@]ZD*1S%((@DA5=H(
MRF5P,#Y2HX'%3CPI8I#"D4]S$T,5M%'(K*640%BAY4@GYV!R.?:L_78=1CLO
M#CW%Q>?:;>XW7=S8VOFNI-O*I8($88+$#[IZ_C5?2;_Q3/K%A'J*M;H886EC
M\AC&^8<R981D*PDR.9!PHX.<D Z*PT2WL+F_N%DEDDO2#+O"*.,XX51SR?F.
M6.!DG J@G@^RCB@C-[>M%%##!(K,F)XXF+1A\+_"21\N"1US5"_EUBSU;5VA
MN-3,,DUL4\NV\U8H3M$C1?(<L,'Y>3SG::6_MM3UGP3'!<M=>?)?QJ3Y"B22
MW%T &="N!F+#,-H[Y &10!LW?AVRN]<AU=BRW2(B'"1L'5&++]Y25P6;E2#S
M[#$:^%=/6*",-/B%857YQTCE$JYX_O 9]JYJYCUNRD>YL;*198ENXT*08Q&U
MW%\P 4@MY09A\ISCHW2ML7FJQ>#S<2&YGO3)M5H82L@4RX!*M%GA3R1'R 2!
MTH EE\(6$QN%DGNFAE$^R$NNV$S-ND*_+G))/4G&3C%37OAJTOY=0\V>Y$%^
MFRZME9=DAV;-WW=P;:!T..!Q6>+[6SX/L9YA=1W;3*EU)%;;YDBWD%Q'LY)
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M%1VUK;V4 @M;>*"(<B.) JC\!4U% #6C1V1G16*'<A(SM.",CT."1^-.HHH
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M6>2>-K<H'5[:4$[W\M=HV_."W&5SV]:@L?"UK93PSF[O+B:&99E>9ER2L31
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M&C@69[F0(0Y;_1Y,Q!&VN9!MR@!X); H3Q5IS&Y#K=QF"Z-IM-K(3*X4L=@
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MKDGB;2(FN!)>;?(W;V,;[3M<(VTXPV&(4[<X)P<4 8)U#Q"=:DCADN39I&#
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M<RV\8O-S7 C,96-RO[PX0%@,*20< X/!]* ,G3]7US4?!VHZJL)6\*.+6W5
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M<1L4#N5"KNQM).]> >,\TAU_3!=16PN&>:5I55$B=C^[;:Y.!P V!D\<CUH
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M.26RS0^8)H99^95C8B,H"JAOO.?,&%[X-7[C7]-M+B:"XF>)X8VE;?"X!5<
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M8;4$M"JG 0B-B"QQ\S KP!\N=U=+I>H1ZKI=M?Q(Z).@?8^-RGN#CN#D5<H
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M1PQP,SN%4;'3]UM+'DGYB.<!<C% &E/X-LY3)LO;V%96<S+&4Q*&F:;!RIP
MSMC&#@X.:(_!>FQ27;(SJ+F1I& CB#*6E$IP^S>06'0D\?08QK*_\037-A<3
M27WR?;(Q&(2$G8%#%YF8UQD;OFPHXXQGF72[[Q->P6"37+Q_:+M5FD%J=\2>
M1([ AXE &]4 .#C."2<4 ;H\-PQ:BM];7MW;S^9*SE-A#K(RLR$,IXR@Y&#U
MYJ./PG8Q(466XP1 .6'_ "QF:9>W=G(/MCIUJQJ\<6J^'KY5CE?$<H1=CHV]
M<@8'!ZC@]#P1D$5S(LM2TR:UN--6XB\K3K<R1^49/-<R_.K%@2."Q.,'H>W(
M!J>%/#M]H5Q=-<S0/',H^YAF9MS'.=BD#YC\I+\DG/7-@^$+-[)[1[JZ>)K2
MYLUR4!2*<J6 PO4;!@G/?.:@T"_UN[UR]34 ([=&F40F-P5Q)B,J?+ P4Y/S
MMDD$8&163;^(=9E>^D1KVXB0W:.L5GM$#)<B.+8Q0[\IO+??^YG'&" =)8^&
MK+3]9N-2@_UD[O(RF*/AFY8A]N_D\XW8Y/MBL/!NGK-J$D<DD8OO,\P)'$&'
MF-N?$FS?SS_%QDXQ@8S+"Z\2:G;1I-/<VO\ HUV2ZVX5I'64I%RR#!*8;[JY
MX. .*J)?Z[;Z='-;K=RNUE8K+<SV[+*I+S"7(\L\KA1]PX#9(/6@#>_X0ZQ6
MR:T2><0^0MLJLL<@2)79E0!T(P-V!G)PH[\TD_@VQN()()+FZ:-_(;$FR3#Q
M !7.Y3N)"@'.0>>,\U!INHZR=8TZ"]:26*:V_>>1;LJ*XWG>Y>,<$!1P1AC]
MW!R,_6?$6M6.IZJ;>*Y%K!:S;/-@RHD C\LJ0G.2S8&YB2/NC&* -Y?"MBJ;
M1)*,K;*=BH@_<S-*ORJH RS'.!T]#S5>7P;:3V4=G+>7,D$$_GVL<B1.L!PX
MP 4(88D8?-N[8P1FL[2]1UV]>W"7<\@1+R29)+=4?>CQ^3#(2B[25<DX )Z@
MX%4XM8\4G2()79LRSHLT@@D$D ,3%A@P<#>$'W&QD@GH0 =9<Z%%-9Z?#%<3
M6TE@P:":!8P5.PH?EV[,%6/&W'IC%.TO0K32)-]LTI_T6&UP[ _+&7(/3J3(
MV?PZ5FZB^J&V\-3O<W$+_:$^WFSA)5LPOU5E+!=^T<@8R,X(R,:QN-;TC2W1
MOMLD<D;N@2V&Z!C<[>#M/&UMQR&.%) [4 =!_P (I:&*6)[FZ9'6[102OR+<
M,&<#"]B.,YZG.>*?9>%[&PUF34X"?,D.XJT49PVT*2'V[QP.F[')K)T"ZUFY
MU?3YM2FOHTDLY5:$P%8F=)2 S90%6*;3SMSV':G3:QJ]M?ZB"MU+##=0$-':
ML46$RA7 &P,6"Y)(+C'(QTH T[_PM8ZA!-%*TF9+P7H8JC[9-H3A64J1@8P0
M>I]L5+GP@H>V>QO)(1'+:M+#MC6.40R!LD*G!QGA<#('%0:;J^JW>I6PO3>6
MMN^]H@+%OWQ\^1=LF5)C C6,C[N=Q.3BG>!UU6UTRTL=0:9XX]*LI$,L.PQR
M,KJ\?09V[$X.2-W/44 6;?P;9P,,WMY(B&'RD<IB-8IA,JC"@D;ACG)QW[TM
MUX-TZ[MK*)GDS9B58W>.*7*R$,P(=&7J!SC/'USDZ7=>(5@TMF6:*&.WL%DM
MOLV QD!$N21D;>#P1C'.:FT^^UR^MM)#75Y%<3W _M!7L=HMOW3LT:%EP5WJ
MJ[CNZ]>10!L0>&K>WU9;Y+JYV),\Z6WR>6KNNUB/EW<\G&>"31-X9LI[JZN&
MEG#W'F[P&&!YD:1MCCTC&/<FN>M]9\1FSOYKM9T8,J"*&!M\#&7;D$PX*;>2
M?WAXR.#2Q:WXE$%K(;:>:YDTZ1A;BV9!YZK(09"R#AMJ  ,I!/*X;@ V)?!]
MI---,;NZ5Y(XXU*"-=AC9&1N$^8@QKC?NQR.A-36GABVM03]KNY)&CN8VE9U
M#'SY!([?*HP<CC&,5G6MUJ]SX.UJ6X)N;@0R_9AY+AV_=9VE3''D[L]%]LD@
MU-:W.MC7U\QI38M>-;>3]G 58A;B02;L9SY@*YSCG&,T 2Z9X-L-, \J:=V$
M[3Y*QJ"S0B$\(H'W0#TSGFD7P;9+97-B+R[^Q7,"Q30$H5<K$L0?)7.[:B=\
M97IUK#F_M*#Q]=7,<5Y)&M[G9'#+\T/V-1]\_NR@DS\O!W=^Q+;7?$+:>TTB
MWI"7JA5^RGSI8C$I*C,(7(<D<J!P1NXS0!U.FZ,^E/#';W(%JHD:6,01QF5V
MV[2=BJ!@ ]LG/M2+X?MUU$WGVBX/^F?;5B)7:LGE-$<<9P0V<$]0,8Z5GZ#?
MZW=:_>QWX$=LC3J(3&X*A9,1,K>6!@IDGYVR2,8P17/PIX@TR\U._@MYWDD7
M4#;J%D8,PN?D,BG()"<Q[1R-PYXR =)9>"]-L+VTNH6<O;0Q0CS(XG+",84[
MBFY3C^Z1T%6+SPS;7VK_ &^6ZN0"\#O;KLV,T+%D.2NX8/HPSCTS6!-J'B@Z
M<7@N)&:.TO+A'2U+-*\?E>5&VZ-.26<?*HR!QR,UN:*UZNK>(%N;B[D472-;
MI-'A$C,*'Y#M&1NW#&3ROJ22 4D\!:?'9W=L+RZ(NEC21V2%F(3?M.3'RV7)
MWG+9 .:T+#PO8Z=J\NHP%C)*Q8AXXV(8@ G?MW\XZ;NYKGQJ'BJ.WT0/*WF7
M-JD\[R6Q \XE<Q,J1,5 !/!*G_:X-1KKWB"X;4C923S-&;Z,*;$^7"T=QY<6
MUL#>2N[(R?N]L'(!T-SX1TV[EN))3-FY:;SL,!O26,1O&3C.WA6]<J.>U%GX
M4LK..%5D<F)W<,L44>[='L.0B*#QWQG/MQ6<][XAA\2-9^>3:P@!9);=F\]/
M*)+_ "18W!^,!UX7&W+ UG-K7B=K2Q6$3(Y$PDN)X&*R2J4V#"PY\L@M_"A.
M/O<9(!UFEZ'#I,S/;W$Y1H(H3&^TK^[7:&Z9S@ 'G'M52T\)V=K(9/M%P[&:
M2;D(B[GCV'Y54 <<\#)/)S6+JD_B:6SU589KL&6#4$@6&W"M&T9'DE6QG+#/
MUXQ@C)U=/U"^?Q$ELTMW<V3VH9)&MC&%.!DR9C7YCGC:?4%1C- $?_"":<;A
M)3<W;;(?)4'RR0OD>3PVW<!MYQG&XDXYK1/AVT.F:K8&2;RM24K,=PW*#"L/
MR\<?*@/.><_2N3OWU?1+;6KNQ6^DOKJ^F:-Q;*V0D?[M3B-F*GH..V-R]]BW
MEUB7Q T*^;:VKWCO*ZP [T6"$@98$ %BXS[$#D9 !+<>";&[/FW-W<7%T9C*
M;B:.%R<H$V[2FS&%'\.<C.>35G7O"MGX@L(K.YFFBACC>+;$L>"K+M/#*0"
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M><2V3*+:7S0#%&1&=P*;_F(<#"L>#3FOM:7^T;E+G4H7EM[2:&"XMLB,$#S
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M!35VA=KZ[MI(HI(=\&S++( &!W*1_".F*AT[PY%I_B*[U*/"Q/;100Q D[,
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M\*Z?<:U+JCC,DP E0Q1L&(79D,5+KQ@?*PZ#WS1M_!KPW4C-JUVRHEL+:?\
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MZ7$A9[V(!3(#_P!LR _Y$@>^1CJ*AD\4:-$D+27RIYN[:&1@1M8*VX8RNTD
M[L8SS5.[\&:;>7&HRR/*/MJ(NP;=L)78=R C')CCR#D'8..N5/A"R:SDMS(4
M$EI/:L88DC&)2I9MJKC(VC^N: -&QUNRO_MWE-(@L96BF:6,HH*]2">"/>H7
M\4:-';)</>;(GW$%HG!VJ 6<C&0@#*2Q^7!'/-/70X/)U6WDFEDMM19FDB.!
MLW+M;:0,\^^<51N?"K7<")/K%ZT@MY+5Y0D0+POMW+C9@'Y <]<D^P !>;Q'
MHZ7,]N]_&LENKM+G(50JAF^;&,A2"1G.#GI5>Z\5Z?;.\>)_,6SDO!YD#QKL
M3.=Q8?*>#U_PH;PO:$MLED7,LDH!"L 7B\HC!!! '8Y]\U5_X0RW^P&S^WW7
MEO9W%G)]WF.8DX''RA2?E X  '- &E:^(-/N[VXM%>1)H+K[(1)&RAI-F_"D
MC!^4$_A[C,2>*M(DN9H1<-MBM8[LS&-O+,;E@N&QR<J>.^>,G.&7'AI9;F>X
MBO[B&22[6\C*JA\J01^4<94Y!7L<X/2JA\$V9L?L9N[EH3906C!@AW>2Y>-S
ME<9!8Y&,'TH VX]5LY=/:^CD9H%)4XC;<&!VE=F-V[/&,9S1'JMC+:0727"F
M&=Q'&Q!&7)QMYZ'(Q@]^*I'P[#_8#:2DQA5G#M)!$D>3O#8*J-I!Q@C'()!Z
MU'_PBUJ/"S:"MS.D6YI$G3:LD;F0RAEP-H(;!'&.* +*>(M)EMA<0W8GC,:R
M@P(TA*L6 ("@GJC?]\GTHAU_3YKCRA<Q;756B</D2 H9,C_@()^@-9<?@:PM
M[6>WMKFXBCEN!,%^5E50&_=[2,%-SNV#GYFSVQ2/X%T]]'&G&YN@@C@B6164
M.%B3R^#C^)"RGV8XQ0!J?\)+H^6_TY %B,I8JP4*$WGG&,["&V]<<XIZZII=
MMI:7L;K':2N2FR)@9'9B3M4#+%CD\#G.>>M9MQX+T^>ZU&;=L%\DBN!#&60O
M'Y9*N5W#Y>V>I/;BM34M*74(+95N)()K6430RH 2K %>00000S#\>U %6V\2
M6]_KD6GV2^=&UJ+IKCY@H4DJ /EP3E3G)&/<YQ/%KUFVGO>REXHUN9;4*5+,
M[QR-&0JKDG)0D <XIFE:!;Z3-YL,LTCF$1,9"/F.]Y"QP!R6D8\<>@JA-X.A
MN+=[>6^FDA%Y)>PQR11LL4CN[-P5^8?O&&#G@^HS0!I#Q#I11G6\5HU@%PTB
MJQ18R,@E@, D<XSGVIS:[IJ2P1/<%))]NU7C=2-S;5W9'R98$#=C)&!S6<?"
M-MYR.DYC5+4VOEI;Q*K*1C#*%PR\D[3P"34=OX)L;>\M+HS/-) B(3/%')D)
M(TB;2RY3!<@;<8 'H#0!HKKUK<L4T_-W(LL:.J C",VWS 2/F48;D<?*>:6;
M7[)/#]YK4)>>UMH'G)5"OF*J[OEW8R".AZ'/6H=!\,V?A\2+:D%64(A,,:LJ
M@D@%E4%NO?/3UR3'!X6MX= U/2#<S-#J"R*Y"JGEAT"'8H 5>F<8QDD]Z )(
MO$ENLEQ!J$$UE<P",F)P)#()-P0ILR6R4<8QGY3QCFHX_%5G-JTMK"K26T5G
M%=M<(KMN$C$($ 4[ON^N>> <'$-UX.MK_=+>7D]S>%XW$\T<9"B,.%79MVE?
MWDG49^8\\#$LOA2V>VEACN)8/,@MX#Y2(J[879Q\H&,,7(88P1QQ0!?CUW3)
M8A(EY&4*QOGGI(Y1/IE@1]1533/$]IJ-\MB(IH[EEE<#82FU)6CSNQC)*$X]
MZI1^"+:&.WBAU"[CCB$0D4+'B41S&9 ?EXPS-]W'!K0L?#\6GWT5U!<S?*LJ
M,C!2'#R&3GC(PS'&/QH DE\1:3#/<0RWJ(UNCO*6!"@(,O\ -C!*CD@'([U%
MJ7B.UL-*M]013-%<2K%&2PB&3GDE\8''6JEUX-M;Q;N*6]NOLT_VDI"-F(GG
M5ED8'&3]]\ D@;C[8T]8TE=7MH8C.\#0S+,CHJM\PSU# @CF@"M:^*])N;6W
MF>?R&FM!>>7*.4B()W,1D ?*><X...HJ8^(M+6W6=KEEC+F-BT+@QL,9WC&4
MZCEL=1ZU0B\&:?%IUY8F6=XKNT6UD)*Y #R/N  P#NE;C&T8 QBH+OP+9WEE
M':O=/&@\S>L,$2*Y?;\VT+C<-@ ;J 6YYX +^H^*=.L(Y'#F7R;B*"7:K84O
M(L9P<88J6Y R<\=:OQZK8RV<%VEPI@G<1QN01EB<!?8YXP>_%9Z^&T421?;K
M@VIO!>I 0F$D\[SCSMR07SU/ )]L/N/#EO/H%QI/VB>-)9GG69"-\<C2F4,O
M&,JQXX["@!P\2:9*EN]M=1W"S;2IC.?E;> 1Z\HPQUX-9]MXQT6:YL[C:T*7
M]HLJ3RQ%6VAP K<< %^I.T9Z\U+I_@W3M-;-L\P472W*(2,(%#80<?=W.[>N
M6-)'X0MET];-KNX>-+,V2$[05BW CH.2-H&: -:ZU:QLKN&UN;E8YY59T0@_
M=7[S'T R,D\<BH(_$>E3(C1W)8O)Y2H(GWYV[ONXR!M(.<8P<YQ3[[1;;4;B
M26X+D26DMFZ X!20C=[Y^6LE?!=JMA':K<F/9,LOFPVT,<F0, @J@PV/XASR
M>W% &D/$NCM+<1_;XPUN)#)D$ ;&VO@XP2K$ @9P2/44Y?$.EOY 6Y):=F5$
M\M]X*D*VY<97!(!W 8)'K6)'X(2ZANDU.]EE$DMVT,:!-L*S7'F@C*_,?E3A
MLC.X<@UH6OA>.RN+:XM+M[>6(,DGD01(LJLP8@J%P.5ZCG!/L0 /7Q3IS>&Y
MM> N?L<.[<# P?Y3@X4C)Y_SUJTFNZ:]['9BYQ<28VHR,.2N\*21@-MYVGG'
M.*@'AZ+_ (1Z[T9KJ=H+CS0KX7=&').!Q@X).,@^^:C3PT@U(7DE]<2*9TNI
M(2$"O.L8C#\#(X4' .,C\* &:AXML+"6[B9)C):36\4V8V"@3.J@AL8.-^<#
MDXJV/$>DE;=A>+BXX3Y6X^;9\W'R?-\OS8YXZU'<^'XKF^GN6N9E6:2WF:(!
M<;X75U(.,\[0"*I-X*T\WT=WO+.LDCL)88Y P>9YL#<IVX9V (['U ( +MWK
M\5IK\>EM"Q'V9KF67:_RJ#@  *=Q)[9'XYQ45SXHLXH8I;<>>DG3G8P/G)$P
M*D9!#/R#T(Q5C4]"BU*6>4W,\,DMM]FW1$#"[MV>GX>XK.@\%6,%O%"+B<B,
MN1@(HR\ZSG@  #<@ QV_.@#4FU_2K>$S37T21A9&+'. (W".?P8@?C2PZYIT
M]W%:I<?OY -J-&R\E=X4Y'#;?FVGG'.,5EGP;;M-(SW]TT9\WRXB$Q&))EF;
M!VY/S*.I/'YU;3PS9Q^(Y=:7:9I7$K*T,;$.(Q'E7*[E^4#@'^9R //B735N
M+^&226-K&5(9-T+89V"E0F!\Q.X# Y]JL/K>G1Z6FI-=)]D=@JR $Y8MM"XQ
MG=NXQC.>*I7?AM+B[N+E+VXADEGCNEVA"(Y44)N&1R"H (/OC!J:/0+>/2X+
M#SIF6*Z%V9#C<\GF^:2<#'+$\ #KQ0 6WB;2+R.62VO/.$:!V"1N203MX&,L
M=W! R0>#@TT^)M+53*UR@MO*CD$O.27<HJ[<9SN7&.N>.M59?"%M);^4EW<Q
MG:R[E*\AIA,01CD$C:1W4D4EIX-LK.**-+B<B,PD9"C_ %<[3#@ #[S$<=NE
M %E?$ND75RMFKO*LUJ]QN\ABAC!*L"<<'((*GGMUXIQ\2Z8 )#<*EN(II9))
M,H8Q&4#!E(!&-XSD<?C59_"<.V00W]W!YL5S$YC*AL32&0D''!5F.,?CFH(O
M ]C';R1?:9OWD<Z-M5% \TQEL # QY2X^ISF@#9CUG3Y=.EOUN1]FA+"1F4J
M4(Z@J1D'VQGD>M*-8L/XKC8<1$JZ,K#S7*1Y!&1E@1@]Q4;:-";;4H!(2+^0
MR2;T5P"552-I!!&%Z'U-9:^#84:VQJ5[MB%N)%.P^;Y$QFC!)7( 9B,#'&!V
MH LW7BW3+=K;9(TL<MT;9I$1B%.R1LKQ\_,97Y<\_2K[ZM:B&PGCD22"]8"*
M0-PP*,X(]>%JC9>&TLQ8I]NN)8+"<RVL3A,1C9(FW(4$C$AZG/RK[YE3P];1
MZ9I-B)9?+TS;Y3<9;$31_-QZ.3QWH 2'Q3HUQ;^?#>B1"RJH2-RS[E+*54#+
M J"<@$8!/8U9FUO3;=)'ENXT6,R!R<_+Y:[G_(<UDW'@RTGL?LJW<Z#[/!;[
MPJ%E$0<*RDK\K?.3N'((&.^2[\&6]Y)=^9?W8AN%G'DC9A#+'Y;L#MR3CD9/
M4G\ #4CUW399;:-9VS=?ZDF)PK]<#<1@$[3@'J!D9J"'Q3HMQ:O<PWRR1+LY
M5&);?G9M&,MNP<8!S@^AJ.]\,P7NO6VJR74^ZW*,D6%*@KNZ$C(SNYP1G ]*
M@3P=;0PVBP7ES%-:6]K!#*-I*^1Y@4D$8)(E8'],4 :<6MZ=->I:1W(:>0#:
MNTX)*[PN<8W;?FVYSCG&*?J.K6.E)&U[/Y?FL5C 4LSD D@  D\ GZ UE?\
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M!;Q#]I"F,A6Q\S;5W''RY;*C=C)&.O%58_"MG&5*R.NT6WRQHB+^XD:1<*H
M&2QSBJ\?@K3XM1@O0Y>2/&1+#')D"5Y5P64E2&D;D8XQW - #HO%&EK?/96*
MHT8*,SI\BEI9_+)&1ALLQ.1G)SWJ]_PDFD8E(NPWE,%(6-B6)8J-@ R_((RN
M>0:S[?P9;P>6IO[N2.$0+ C! (TBF65%X7)Y4 D\X]^:CB\#6%O87%G#(JQR
MX56-M"650Q8 MMRV#C!/(P#UY(!M:AK6GZ5;I/>W'EQNI<81F.T#); !( '4
M]!GFHF\1:6OVG%P[_9G"3".%W*-C.. >0!DCL.36-XF\+WVIQ:;'8W 86D$D
M1-Q-@R$A I?*,'7Y3N&!G/7K5^[\+PW=DUL]W,@>[:ZDVA2KLRD%2K @KSD
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M$5Z!4?D1>?Y_EIYVW9YF/FVYSC/IF@#BCKWB,2ZHQCC5(7D01>2[21()U19
MH4;AY19R-QR0,<9%,U9+W5=]O'//-;O_ &=F?[,1YRFYE#@J1C 4*3@#(Z\$
M5WE% '"?VMK\-Y;VT$4<$+7%P0TR/B7%TZ[<[6(_=@$=,[@1P"*LZ+>:C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45!>RS06%Q+;0^=.D3-'%G&]@,A<
M^YXKE? WB74]<DU&VU:()<6GD'/V22V(,B;F0HY)RI!&>XP: .QHHHH **J:
MG<O9:3>7484R0P/(H;H2%)&?RKA+'QYJEDMNNL+873W>F0:A ;8&WVF1@OEL
M&9LG+<$<G!^6@#T:BN B^*,5TMJUGH5[.LRVP)$L:['G9UC7DC/S(03V'/M4
MJ?$ZR9M,W6$RK>860"5&>!RSK@J#TS&W/&>V>< '=45YW'\5H9;*.X30[QS.
MY%ND;A_- B$C8('4!E7']XD9X)K:UWQO#HJ1LFFW5S_H#ZE.H*QM#;IMW$AC
MRWS?=]C0!U5%<=<>,YYO"OB?5[+3VB&DI<K!+<,&6>2(/GY0<A<J.N#S[5FR
M>/[[0[^73-8A@U"Z86S6SV,31!C*LK;74L^T@0L<@G((X% 'H=%>>ZG\3)(+
M*Y>UT2>.XCM8;F.*^;R6D#F/.%/4+YF"0>&!'H3JP>.#)JBV<ND3PH=0&FF8
MRH0)O*,I& <X  &?4T =;17GLWQ,EN?#FHZKI.B2S+96"W<K33(JQLR%U4C.
M6&T9)'KCZ3'Q[<VVIWMC)ILMQ>JX*6J,B")%MHYI,R$X;&\8X')]!F@#O**X
MS2OB':ZOJUI:P:;=+:74HACNW9 -YMA<@%<Y'R'KZ_IV= !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #719(VC=0R
M,"&!Z$&LVS\-Z+8>3]ETVWB,$K3QLJ<B0J4+9ZD[3C/I6I10 4444 ,EB2>%
MXI4#QNI5E(X(/!%8T/@WPW;V<EI#HME'#(R,ZK$ 24^Z<]>.WI6Y10!E0>&M
M$M518-+M8U0Q%0D8 !C):/'^Z68CZU6G\%^'IQG^R[>.0*526-0&3ECN!]07
M8@]LGUK>HH Y'2/ASH6EV36DJ/?1ET=/M 0"(JNP% BJ 2.IZMWK;U#P[HVK
M?9_[0TVVN?LXQ%YD8.T<<?3@<=.!6G10!2.DZ>;&ZLC9PFUNS(;B+;\LA?._
M([YR<U27PAX>CL&LDT>S2W:02LJQ@$N. V1SD#C.<XK:HH QG\)Z!(93)I-J
M_FP"W?<F<QX4;?;A5Z?W1Z4Z7POH4]@UC+I5J]JTHG,3)D&0 *&^N !]*UZ*
M ,4>$/#H8$:-9#%N;8?NACRB"NW'IAB/H2*;+X.\.3V_D2Z/:/'N5L,F>0@0
M<]?N +[@5N44 9;^'-&D5E?3+8JSF0CRQ@L8O*)_[]_+].*T888[>"."% D4
M:A$11@* , "GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5C6'B.WU#4S9);W$>[S_*F?;ME\F01
MR8P21AB.H&>U;-8,?AF.+6Y]7CEBBNW#(KQ6R(0C.K-N.,N3L R>@Z<Y- %_
M3M5CU&YOX$@GB:RG$+^:H&\E58,N">,,.N#[5?K,T[2IK'4M1NWO#,+V02&/
MR@NPA0HP<\_*HK3H Y33?'^FWTL0N+2\T^"=)WM[F[\L12K"2),%7.W&"?F
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&D"YN+<ZC;"6W5WF4N!L"XW9], @GT!% '*/JWB+3K"&U+JP$D*M=O 4$2-
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M$6Y@&#]#GZUSFH^ KQ;94L[LW+/*\DQDD,6\F%8@#PQ92%^8$\Y/TKT"B@#
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MTY!]@#LZ*X6WUSQ"FG127C >?;64\DPM"/LWFLXD&WG.T*O7H6)/'%6]%O\
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M#RSG^X)05/\ O>QH [ZBN-\7WFH:;J=C<V4TBR)IUYMQ;-*LLNZ HA"]"Q!
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MF3O<).@&^.0S&8$=N&/Z56T[P98Z7(IMYI-D=X+F)"!B-0K@1C_9!D=O^!4
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MLL$0C/*A<XYR0 .OY8XI;/PX(-274KB\:>[\YIG81A%8F,1@ =@%4=SSGZ4
M3ZIXAL-*N8+669&NIY88U@##=B20(&^G4^^T^E._X2'2"DK#4("(F"OALG))
M P.^2"./0^AJK?\ AO[;JIO%O9(HWDMY980BD.T+[UY/(!Z'Z#ISFA#X&M[;
M3);&&>,*51(I6MP9$122OS @EAGAAC!&?7(!J?\ "4Z,LEZDEZD?V.98)3)P
M-[*&4#UR&'3O5MM8TY(S(][ J*)6+,X  C.)"?\ =/!]*ST\-*EVTK7LLB-=
M0W95U!8R1QK'DMWR$4].N?7BI<>#([F:X+ZC.()!<>5&J+^Z:9UD9LXYPRY
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M110 4444 %%%% !1110 4444 %%5?[1M/[-&H^>GV,Q^;YW\.S&=WTQSFK5
M!15:]U"TTY$>[G2%78JI;N0I8C\E)_"I+>Y@NX?.MIXYHBS+OC<,N5)5AD=P
M00?<&@"6BBB@ HJ"[O+:PM_/NIDABWHF]S@;F8*H_%B!^-.6Y@:Z>U6>,W$:
M*[Q!QO522 2.H!*G!]CZ4 2T456O-0M-/$9NYTA$C;4W=SC.* +-%(2%4DG
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MKK7\:6BS7L*6LTTMM)#&$ADB?S#)-Y*X(; (;J"1@>^0)[/Q1'?3QPPV%T9
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MYDB-LS>9>R."0A6;()(.3CZXS6'?Z?XDL]-5;@-$+FZ0NBRRR1IB"4.?E8L
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MK%KC>MDMX8V"_9HT7Y@?X75\C/?<,D"K4GCBS@65[BRNXHQYHA9MF)C',L#
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MCB/(Z8QQ6_J/B.'3]0:U:UN)5B$)GF3;MB$KE$R"03R#G .!5?2-=NI=!O\
M5-2B$8BN[B-(RT:!4CD9!\Q;'\/))'.<<8H Y^'1]<OQJ3P_:K<R/?Q>:]XX
M,N;G]UM7/R;55L$8X(QG<<:<V@:A_;@$/G"U$T1BG%VV(K<(%>(IG)+'<<\_
M>!SE14P\<VC6L-Q'87<D;)*\K*8\1+'+Y3D_-S\V2,9R*T]/U^WU'4)+***5
M9HA)YP8#]ULDV 'G^+!9?4#- '+R>'O$DFGPBZNIIG2<1R1PW&&DA2(HCY)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-DD2*-I
M)&"H@+,QZ "G5#=VRWEE/:N2$FC:-B.N",?UH Q_^$LL/+TU-RB]OQ&T=F9%
M$JAU+#<,\=*U=.OHM3TRUOX PBN8EE4-U 89P?>N<L_"]Y']DN9KM Z-#<SV
MZQ@[YXX1%\KD\(0!QC.><\D5N:%82:7H-A8RLK2P0*DC+T+X^8CVSF@"74KT
MZ?9FX%O+<8=$V1#+?,P&?H,Y-8-EX\TV\UA=,:VO;>1I7A$LR*(_-2(2NF0V
M00ASD@#WKJ:XFY^&VGW&JWVI"Z>.YOI;C[1(D8#/#-"(S$3Z J'!['/')H W
M&\7^&TLOMK:[IPM=YC\TW*[=P&<9SUP0?H14/_"9Z)'<7R75[!:PVCQ)]HFE
M58Y?,C$@*'/(VG],]*YA_AS?VS:6ECJ,*R0SR-/>&WRVTV[1+E6=MQYQU '8
M<8JS+\,4&G/8V>MW=O Z0Q.H!^=([<0 -M9<\#=Z9Z@T =7+XCT2"XFMY=7L
M4FAA\^1&G4%(^#N// P1S[BH9/%WAR&*WEEUW3HX[C_4L]R@#X.TXR>QX/H:
MY]_ASG3=1TQ=8E6QO1%(R" ;UFC6)5</G.W]ROR^YYI)/AK;36DL4EZH>6TE
MMY&C@(!,DRRE\,S'.4QR3G.: .B_X2OP]]D@N_[;T_[/.YCBE^T+M=@<$ Y[
M=ZCO?&7AVP6^\[6+/S+&)Y;B%)E:1%0X;Y0<YSQCU(K U+X:6U_>2W(OR&EF
MN7DCDB+1LDVS<A 9?^>8YSCDY!JQ<_#RUNA=!KV15N#?EML8R!=*%/?^'''K
M0!L7WBK3;/3+&^A\V^74'6.SBM '>=B"V%R0. I))( Q4L7B32FN+:TN+N*T
MO[A Z65S(J3#.>"N>O!^N#C-4M0\,3WVG:0HU0PZGI4@E@O$@!4ML*,&C)^Z
M58C&?QJA+X$DN=6%[<ZP\JR3V]U<QFV4>;-"N$(.?E7IE<'..O)H TV\;>'?
MM-E;1:K;3RWK.EN(I PD90"5!'&3D8]<BKMEK,5SI;:A<Q/8Q)][[5A-HP.3
M^>*Y_2O DFE2Z;+'J[L;&ZDECB\G]TL;HJ&)%+$HORY') ).!C@=/J=D-1TZ
M:T/E?O !^]C+KUSR 0>W8@CKF@"G%XETN75_[-^UPK,T<<D.9%_?!]V-G.3]
MTTYO$6G%H5MKF.Z,EP+<^1(&V,59AGGIA35*'PKL5#-J$T\H-H6ED&68P.6&
M223SG'))]S5>P\'/:W:W-SJLUU,'A8O(I);RQ(!DLQY/FDG&!QP!0!K1^(-.
M_L2QU:[N8K*WO(DDC-Q(J?>3>%Z]<9Z>AIR^(-&>VDN4U6S:"-Q&\BSJ55CT
M&<]34$/AZ.*PT.T\]F&DJ K%?]9B!HN?3A\_A68_@>/R+-8KYEEM([9(F*':
M3%')'E@K*>5E;@$8(% &\-9TLSQP#4+4RR1^:BB5<LF-VX<\C )^G-%MK&F7
MMK-=6E_;3P0Y,LD4H94XSR1TXYK#;P:6O+.3^T76VM4"QVRHP1#Y+Q?*-^ /
MG+="<_Q8XK5TO1(],:0K,7#V\-OC;C C4KG\<T 5K3QAHM[<VT4=["%NK>.>
MW=Y HEWLRA0"<[LK@CU('6M2WU*QN[F:WMKR":>$XECCD#,G..0.G((^HK"M
M_" CL8K>6^\QHK6UM0ZQ;?E@D+J<9/)& ?IGVJUHGAJ/1;N:99EF5O,$19&W
MHKOO*EBQ!&<=%7H,YH N-X@T=$F=M4LPL+^7(?.7Y6Y&T\]>#Q['TIEYXDT:
MQM)KF;4;?RX;?[4VR0,?*QD, .H/;UK/B\,75O;64,.IH#I\QDLB]MD*I5T*
MN-PWG;(>05Z#WS7_ .$(06KVB7[QVSZ>UC($3#2[DV[G^;:V,DCY01G&<<4
M;=SKNF6@L#->1*M_)Y5LV[B1MI;@_13^GK4UKJFGWUQ-!:7MO/-"<2)'(&*<
MD<@=.01]0:KWFF7%XFFR/=1K=64XG\P0G8YV.C#;NR 0[8Y.#CK571O#ATJZ
MBE>\\]+:W:VM5\K:4C9@QW')WM\JC/'3IR: +3>(M%6-I&U:R$:R&)F,ZX#C
MDKG/4=_2I/[;TK[7+:'4K3[1$K-)%YR[D &22,\8!R:Q;KP9%/:64270#6PG
M0^9&Q21)F#."JLIZ@=\=<@YJ)?"=Y-=WKR:@;6$W$TUH($ >-GA\H/NSV!8@
M8ZX.>@H VQK^F,J2)>6[VY21VG$R;$$>-V<G/&X=N.^.,S2:QIL-A'?27]NE
MI)@),T@"-GI@]^AKGAX&5K6YBFU!W>X2X1VV$C]ZL:G[S,3CRAU)ZUN:KIDM
M^]E/;W*V]S9S&6)GC\Q#E&0@KD9X<]".<>X(!-#JNG7%TMK#?6TL[Q"98TE#
M,4/1@!V/K4+^(=%C25WU6R58I3#(3.N%<9RIYX(P<CM@U#H7A^'0@RPS/(#!
M##EP <1@C/'KDGVJA=^#XY[6VCCNMKP3W,H+HQ1A.[.RE593W'.>W3F@#0A\
M2Z7+J-[8/=PQ7%H^UDDE4%E$:R%@,_=PW7V-2WNMV=FF[>LQYRL<B9&(VD'!
M()RJ'&,GOTR1DR>#4ENY2][BR>5IQ;I"%*N;;[-PV?N[,G&.O?'%-3P=(Z[K
MO4C++OWED@"# MW@ QD]GW=>H].@!H_\)-IIO=.L5G1KN^8 0!U+Q@Q-+EAG
M(&%_\>'K3+SQ;I%G+<1/=1[[6XBM[@;@/*,F,$Y[?,*KVGA1K34[:X6_)MX+
M@70A,(W&3[/Y'WL_=V\XQU[XP!9G\/>=J,]P;K$4UU!=F/R\D/&%'WL]"$';
M@YYH N#6]*)M0-1M2;H P8F7]Z"<#;SSD\?6BYUBQL9YH[RXBMUB2-S)+*BJ
M=Y<*.N<_(>H /;.#C%C\%Q1:C#=+=!PI7S(Y8V(8+.\R[<. "&D/)#=!P*T;
MS0([O61J+3LK#[/\FW(_<M*PY]_-/Y4 2Q^(]$EMY;B/5[%H8@ADD6X4JH<X
M7)SQD\#U-/77M(<PA=3LR9T,D0$R_.HSEAST&#D]L5@7?@^:.Q@CL+H>?$;5
M TD8P!%<B4MC//!/'MUJS'X-A^QWT$]V\C7UK/;S.J!>99'D=E'..9#@<]!G
M- &O;ZYI5TF^WU*TE7#'*3*>% +=^P92?8CUI#KFDAYD.IV@:&,RR@S+\B
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MU?ED63S8X2&9D4B,MN9LX)R0, ],8)! .@76K R^5)<Q12-*T4:O*F9",9P
M3_>'7!Y''(JM;>*='O+>.YAO83:O')(9VE150(RJ<Y.>KCG&/4C(S6?PPYOH
M;J.^\N1;MKEW2,AR&*%HPP;A6V $$,"/0@&HCX/$EM'!)?%DBBGACQ%@[))8
MY.>>2/+QGC.>@H U'\1Z+':Q7+ZM9+!*2L<AG7:Q!P0#GL2 ?<BIKO5;2QF*
M7<T<""/S&EED154;@O.3GJPYQCWS7*:[X4U&75([K3RDP+3R%)'*)O=HF <
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ML4^"(O.NS]J#1W$;##QL6C<P>264[]H^7_9SR1G%6YO"=O/([/<.%>X$S!5
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M0&Z$=*Z>YMH;RUDMKF-9(95*NC="#4=E86VGQ-';1[ [;W)8LSM@#+,223@
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M_P#+(X//';U#+:P3S02RQAW@<O$3_ Q4J2/?#$?B: .2\8:AJ-M-J-O!?)#
M^B7,D,00B1YE!Y1PV<@$'@?XB+4O%&M::TULXL?-BNW@^UO'Y<)Q!'*H(>4
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M1F4/N964EONKU7!/6N[J*YMH;RW>"XC$D3_>4]#SF@#E+#Q#J]]?0P0O97$
M-RYN886VW*1>3@1_.0I)E9<Y890GVJC9>,M3N=.M[BXETRU2>:.-[EP"EKNC
M=V611*<'<BJ"S*<OR 1@]]10!P6J>+;S28KEHO+>7[1(45XRRRJB1$@%I!M)
MWG 4,>I"\',KZYJEM<W&^1+Z:#4[A$MHE:-U06TLB*0&^;<54#(QWZXQW%%
M'%6OB35[Z:WMK2ZTVX$]S'$+Z*W<Q+N@ED9=OF<LIC7^+^, C-=%H.J_VMI%
ME/+L2[EM(9YH5S\A=<]^V0<?2M.B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1U4-]X@<-G!.?7%5D\8I:W6HIJ=K-!;VTLH2X"J4VQQ+*RG#$[@-QSC''7-
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M0R@ +YK[,A/+#;,[=VSY=V,X[U:M]*LK576& ('A2!OF)RB A1U[ G\ZN44
M9\&AZ;;&,PVH7RY%E3YFX98_*!Z]D&/_ *]5O^$5T4645I'9F*&)W=!#,\;
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MNEGDN1("<B210KMU[@#V[]:?'H&EQ+"J6B@0I#'&-S?*L3%HQU[$D_SK2HH
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M60G*[1R=A.2-JXK1NM?E_P"$7TG5+B>*T,MU MP^[:@!?:W)Z*?>M]-3TYQ
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M) 'N![9% ')ZEXKOHM:G>-X)/L(O2--B+"9O*CRI?GD-U'RC (ZUH-KU_=^
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MR?F.W)&<C-+:>)Y[CQ#'8'[(T;W,EL8D)\Y D9?SFY^XV  ,?QH<G.* ()O
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M8S!V+,IWR'()QG=DYR1C-4I/ DTMM;PRZ@DD<*30+ 1,(Q#((P4&)0Y \O\
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M5))Q@_N6B$FX1B0DG) P"3CG;VJ_;^)9TU"TMY3$L$][=0%F;>^Y9V1% R"
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M3&-_);S!L9 0"NUPO?NIQSZ\8]IXSN]5BXM1;M%<6HE 8Y GG41#\8B&8>K
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MD92I8KP0!D#)P.G.8;?PG(M_%+/- UI%?F\2U\LLH)293RQ)&6E#8Z#;QUH
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MW2*/3N16!)X59/WUM);FX743??OHLK)F,Q[7P<G ;(/J!Q56#P5-;VT]HMY
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M7>E^+I8%>"2V-O8C[/)*0Y,L\L9:,8Y/W2?]T#OD;=N--U:UM;TVR#.R2,2
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M'%2V7B&]B\'W>JWOV::X@GFCQ&2J+ME*#>>< =2?09K<FN-.M+'[4QA%LI1
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M%%UXWGMOMJ#3LS6<9FE1GV[4;R_*)],^8<GMY3^E=0T&G(B1M%:J@DW*I50
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M,N[//8'!P3QTS7=^5 A7]W&IX"\ =,X ^G-59$TV*-(C! 8YFQM6(%3D,<G
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MFL>/P/J2V-PKW-FUY(T31RA=JQR(CH9-@7:<A_N$8QQG@&KL/C66[MK4VMG
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M)<,QQ'EE5> ">2W7H,#)&:PM.\57UO:2#4(X"2)GMY3(Q+XN?*"LJID'YT
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M)+P/E4#;U.0!C;C%*_@<W:3_ &F#3XTE-PRVB+NB@:2*.-=N5'="Q.!RY^M
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M$H\K/7''RTQ].TJ&T\DV%KY$1,PB6!2 >[!0.OT&:Y*R\#75G8>4WV2YF22
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MB0J"O3&,RCCW-<[<^$);BVOH7M-+G>2^6\CN)@3),!<";RY/E. %'E@Y;C'
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MN/F&%Q<&8E6VK@<X& ,=, 5H:]X8_MC4&N_]'\Q;=(X&D7+1.LH?<#CCIU%
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MAWRQ\2/;/N;<<$X8 #.#QVXI;CP1<7$NM%G@W7T%Q'%-YA!3S4"[&4)DJN
M=QX4?** .K:/3;5((VCM8D=O+B7:H!.=VT?B,_A4TMM:W,T<DL$,LL#;HV=
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M]KFM"]O88(;4+;ZM;VL/[X@R(\<;D/\ (<??ZC/ICC)Z.2STZVN!J#64 N$
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MJ>]M3,R&,Q/%G&Z,$N S<$ '/7H:Z>T@TFWGN].M+2VA8(LEQ%' %5@^X G
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M:1-$T=K"C0H8XBL8!13C*KZ X' ]!0!CZ)K]YK.ESW1TW[.PB66#>S[)-RY
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M5T\Z1(!#8VT*K'YT0"6^U5VOMD4'&!\R\COC/.*F31]+CDMY$TZS5[==L#+
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MGDAH/*$941Y* \XWXZ';D<VW\87*Z9IUVND^8^I+YMK%'*\A,>S?EMD9*MC
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MBQL!?BX20S)&0-@M!"4 QPN_YMN<8QW%=A10!P5GX*U..Q>*62RC9KAYMD1
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MD;&3&Q'RD9P2/3%@\.ZA9>(M'CN[+[9'9QVZHZ+E5*R2DLK^7A0JNI(RF=H
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M(I7H.>V*S=7\-75MJ-C;KIPNK&*:66*"%/D&ZX614!V,$P!SG8,$C=Z>ET4
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M[&*QMDM) 0\"Q*$;/7*XP<TMMIMC9K$MM9V\*Q;O+$<079NY;&!QGOZU:HH
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M+:!*;LOHUBWVS_CXS O[WD-SQS\P!^HSUH YFS\6:L_A2RU&98Q=3Z_]@=&
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MTDW$5Q_9UKYT./+?RAE<,6&/H68_B?4T 8J:OJ4_A?P_<1SQI=Z@\*2RM$&
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M56258@\FR-I6C5P0G(.QFYV_+SSTIWB/7M3TY]6AM8(=EMI37D<V_P"<2?,
M-I&"/E'4UI6/AG2[*"VC^SI.]LS-%+*B[EW.7(&  !D\   8&!Q5J>PTW4)W
M:>WMYY41H'+*&(5@"4/L00<>] &#?>-#IUE=2W%@!/9R2+/ DQ=MJ(DA9,*=
MWRR+U"@$X)'!.A8ZM>7(ULW%O%$EC.\4+1N6+@(&R00,'D?Y',\FE:)K, N)
M+*SNXI\R"0QJP?<H4G/?(51_P$>E7$L+2.6YE2VB62ZQY[!1F3 P-WKQQ0!E
M:-K[:C=I:2P&)C:QSH\A(:8%4)91C!4%\$@\$<@9!-)O&?EM+YNFNJEIDMB)
M03*T5PMN0>/E!=TP>>"<XQSO6^E:?:W)N;>S@BG*"/S$0 [0 ,9]/E7\AZ5#
M)9:1)/\ 89;2V:1XI6\IH@<H[@R=L89MI/J>: ,RU\27UUKUMIPL(8_FG2Z)
MG)V-'Y9!0[?F!$H/./PQR[4_%L>F:G-:-;>:D<<C&2-R<.D1EV-\NU25'][/
M0XP<UJQ:-IL"VZQ6-N@MW9X=L8&QFZD>Y[^M)+HFESW<EW+I]L]Q("'D:,%F
M!78<GW7CZ<4 4;?7IKK3-4E:T^S7-DA8(7#@YC$BG(QZX(]0>3UJI:>+)I;B
M"!]/9U9D@:9)!DRM;>?@)Z8R.O4CWQT(L[91,!;Q@3 "4!1\X V\^O'%1_V7
M88Q]B@QN#X\L?>"; ?\ OCY?IQ0!@CQI$NG/=2V95X[&YO)(ED.Y/)V9C8,H
M(8^8.".,=^#3[KQ9);/,JZ9(_P#IIL8,.6,L@1G8E45B%"J><$Y[ <UI2>&M
M$FMTMY=)LWA0L51X00"V-W7UP,_0>E2WEAIC6K1W=M 89)E8AD&#*Q !_P![
M) S0!@S>*KNYGL4M;"6W1KBUCN3<$+)&91N*;",\ @$]B>G4C0NM=.GWNN-<
MKFTTVQCN\(/G.?-+=_2,8JZ=#THW4-R=.M3/ JK%)Y0W(%^[@]L9./3)I\^C
MZ;<WOVR>QMY;G9Y9E>,%BG(VD]Q\S<>YH QI/%<UL[Q76F^3+%<)%._G%H8E
M9-P8N%X].0!GO@@F]9Z^DZZFUQ ;?[ 6+QL29"@W8<J0.&VD@@D$=^H#(--\
M.2:7:R0V5F;*9TEA(B&UV8 *>G<;1SZ#TJY';Z9IER$CA@@FOI"ORI@RL S8
M/X!C^?K0!C1^+IGFAM#I>V_N/):"(W *,LB2N"S@?*0(),@ \XP3G-6&\2R(
MMW,=/(MK:=+9G\X;C*S("-N.@W]<\[3QT-75\.:*EHUJNE6BP,P<QB( ;AT/
MX#@>E.;0-(9YG;3+0M/'Y4I\E?G3 &#[851_P$>@H H#Q,\VHI9VVG/,V;G>
M?- PL#HAP.Y)<8'YFM#1=4_M?35NC&L3[BKQ!B3&P_A8,JD,.X(%/M]'TVUC
M$=O86T2!70*D8 VN07'_  (@$^N*BL])TRUO!-9Q11R6ZO#LCP F\J[9 _B.
M$//8"@#,NO&$-M;2S?8Y'*)>OM#C)^S2B,CG^\3D>E5+OQA+:7#/<VS1+:1W
M7VFWC(D+N@B9-K8'42#L.3[5L)I_A^;4)&CL[*2ZNX&D=UC!,L3$9.>X)"_6
MK(L=+O/.D^RV\OF-)'*3&#N)PC@YZYV 'UVB@#*A\4S,]FMQI<UJ)YS \LX=
M(U.4"X+("2V_"[@N2K#.<9F@\3HV@:AJMS:O";$.TMMNS*NU0VU@0-K$'W'0
M@D'-6HM)T0S)!'9VC26;"0)M!,3'!!^OR@CZ#TJQ!I.GVMK-:P65O';SY\V,
M1C;)D8.X=^ !]!B@#)OO$LVF364-Y8H)9Y8XY$BG,AC#R"-6X3IEADMMZ'&3
M37\6C[.'@T^::1HI9!&A).$F$1R "<<[C@$X!X)K17PYHJF C2[3,!#1'RAE
M"&W CW! /UI?^$>T;?.XTRU#SY,K"( OEMQR?]X;OKSUH R4\9Q27HBBL9I[
M98T::YMPTB(6B\P$$+M*XQR2#EAQ4NAZW?:I?7_VBW6VB2TMYX8@X?'F>8<D
M@=<*HQV(.,CDW[33]%DN//M;.U\VU_T8,D0!CVC&WIV!P/3-1K'H/AM9%C@M
M;$20M*XCBV[HX\9)P.B[Q^?% &'I7C9UTJQEUFV\EFM;6>>X$@*!)E?:Y '&
M7CV[1TW+SUQJ:IXF.E^'[;4Y+(^;-%YIM&<^8H";V "J<D >F/4@5/+X5T9]
M+GTV&P@MK6=D,J01JH<(P(4\=.,?0G&#S5Z_TNPU2)8[^S@N44DJLJ!@,C!Z
M^H)% &=K/B%],BMVM[)KIIH)9P#*(]J(H8\X/.#Q[^@Y%&3QO$D]X4TV\EM+
M2-VDG2-L K")L'C:!@A<[L[B!C!S6[=IIRKFZ2#$,#G#@$K%@!^/3& :K7GA
MS2KZ"Z1K2.-[F!H'FB4*^TILX..NWCZ<=* .?N?%UZ86N1"MO"EM>2?NV\T2
M^4(BKJ2HXRS#\*M3>-EBGO@-/>2"U9HM\;EF,OG+"JE0O&YCD8). 3CM6EIW
MA?3-/M9;?R5N%E+EO-C0 !E564*JA54A%R !D\GDU6@\*:/9ZI/-*3,]]YP:
M"9$*OO;S&SA07P1QN)P.!0!7E\930PI))H\Z%8I)YQ(QC*1I($)4,H+9R&&0
M,CTJ[::_,-,UG4-1MHXH-.EG \ER[/''DDX('.!5\Z5I<%JRM9VZP+$R-N08
M"$[F!]B1DT6$>G7-M)>6=N@COOGD8PE#+QC+ @$Y'J.10!D_\)3<K=Q6#Z5B
M_DN$A$8N04"M%)*&+X[")@1CKCJ#FI=:\5V^AZE%9W-O(3*8MC@C!5F8.WT0
M+N/LPJ?1X= =(QI5O:A4"7:>5%MQO0JKCCNFX?3BIEBTCQ%:Q7AMH;R%XGCC
MDEA^]&X 8#<.58 >Q&.HH PU\4W%Y>6/V<-##<- ^QU!S'(D[#GU/EJ?;IZU
M6T3Q-J<TUO/?X>W>UL$ 1E&Z6<#<Y&W(Y[!L8'3GCKO[-L?,63[)#O3:%;8,
MC:"%Q] S ?4U&^C:8]JUJUA;F!E1#'Y8P0GW!_P'MZ4 9VD:Y)JNM3QJ-ELM
MON5#@G>)I8R<^_EBJD/C,7,[6L%B)+AY(EML2D12K()"&WE1QB%SE0PZ8)SQ
MT%IIMC8 "SM(+<!-@$2!<+DMCCMEB?Q-4+C1?#UC8SF;3K**V<H9?W(P2#\G
M0=BW'IF@!-,U>\N;S6$O+6*""QD5%9)"[',22$$8[;^H_P#KG$O?%>HW>GQI
M96@M+F=K*2-S,K8@N)"H/*$!_E((((&<@G%=9;Z=96LSS6]K#%(Z+&S(@7*J
M,*./0<5D6G_",VTGV2SM;=&DNO+"16IPTL1SP0N,(1UZ*>,@T 7'U"6/Q&MB
M=OV?[$TY./FW!P/Y$UBP>-WN-).HKHUU' 1%(LLJND8B<,=S-LXP%^; 8#<O
MS8)(Z.YTNPN[N"[N+.&6X@_U4KH"R<@\'MR :JIH.A26TEO'IUDT!?YXUC4K
MN&1@CZ$C'N?6@#.O/%ZV<EY&]DYDBEBB@CRQ>;>P4. %/R9/5=W0\9XIL?C!
MY+VUM5T:^\UUC>=3$^80\K1@XV=,HS$MM^7GD\5L/H>E2&X+Z=;,;C'FYC'S
MX.1GZ'GZ\]:CN=.T6RBCO;BTMHULU^23R\E #D 8Y//('K[T 4-6UJXL]4O(
MT<K#:6D$I4*"7:69D!Y]!&?^^O85-IOB)M0U8V;6+0QL;H0RF0-O\B81/D8X
MR6!'7OT[OO#HQO)+VZE0D0M%*K#*%4D4Y88_@8]>VX_AH):V-O<Q[(H(Y\2L
MF  V'8-(1]6P3[XS0!STGCJUCU-].:SE^TJQCV[ACS//\I%SZL/G'HHJO;^+
M+Q;25+N K(99C!,K*=Z)="$@KCC =,=<\G@UTS:1ISW1NFL;<W!F6<RF,;O,
M"[ ^?4+QGTI3I6GL #90$#=C,8XW.';\V 8^XS0!@W?B/4);2*YL;)1$^H+:
MQ%I1F4"1HVW#'R#*YSR<>_%6YO$Z1>';;5/L<K27$JP+;KEB)"Q4C*@G (/(
M!.!T[5>MM,TAII;FVLK7S&F+22+& 3(K')^H;/XYJ2XL=._LY[:YM[<60.]D
M=0$!SNSZ#GG/K0!CQ^,$\VW@GT^YM[B<1LD4H*L03)O." ?E$3-TY!7IFH+/
MQG-?6MO+#HMPKW4D2VXE+1HXD1W!+,HY 3YMH8#(P3FNA33+&.6VE2S@62V1
MD@<(,QJV-P4]LX&?7%5([/0M,V+%;VD&VX155$'R2D848'0X;CV;WH J:)XA
MN=9U3RULXXK)M/M[L,9,R*TC2 J1C!QY?K^>>(SXFDM=(ENYH#/,=2ELH8XE
M;G$K*N<!C]U<D@'ITK7@LM-@OD$%M!'<PP!%V( RQ$G ^F0>/K5>;1M"6=TE
ML;,2WSDL&09F8'>3[D$;L^V: **^*I2\2OI%U$\EHTZ1RADDED <F) 5PS?)
MG!(."#C&<0CQF'EM(8=.EN9)%#SBV$C^4#(8_P"YG(*MD,%QM/?BMHZ'I196
M.GVQ*QF)28QPA!!'Y$CZ$T@T'25^S[=.MA]G),1$8^0D[CCZMR??F@"GHOB/
M^VKV:)-/N8K==_EW#HP5]C[""2H )/( +<9S@C%9\_B>_FN;**SLE6X.HO;2
M6LLFUR@AF8%LK\N2@8$;@0.">:Z&*PT_3I+B[AMH8'?+RR(@!/<DX]3R?4U'
M8Z=I02*[L[2W =A<)(D8!)*D!A_P%B/H30!C)XSBN)=-2&V.S4(%D1]Q+0LT
M+2J' &T?*O\ >S[8YI?#VNW=UI5Y>7K"7[/;03850N2UNDC=/4DUKIH.D1SP
MSIIMJLL"".)Q$,HH4J /3"DCZ'%2VMKIZQ3P6T$(CXAE1$ !PH4*?HN!]* ,
M*S\7RSWD,-QI9MXY)$C,AN%;;OB,J<8] 0?0XQN'(S[KQ[Y<5M<?9VCC6^$,
MJH=RS1O;R2(59E7 W!<M]T $YQDUU<-GILP\R*VMV"R8R$'#("GY@96F0>']
M'MHO+ATRT1,[MJQ+C.PI_P"@L5^AQTH I6OB1KG7Y-,73K@I%)Y,EPJN4201
MB0Y.W;MP<9SG./EP<U0O/$.KK>7D,-I!BWU6&SBQ+S*KQ(YW97Y?O]1GTQQS
MT$.D:=;W8NH;*".<*$$BH < ;1^@ ^G%,GMM)AO7N)X;9+B0>>\CJ 3Y8 WD
M_P"R".: ,6#QH+F[M+>'2KJ1Y4B>?8K/Y/F2-'U52" 48DDK\HR,]*N:MXE_
MLJ[OHVLGE@LK);N:57&?F,BJBKC)),9]!S5X:5I+74;K9VIGML;2J#='D[A]
M.<GZ\U9ELK6<SF6VBD,\0AFWH#YB#=A6]1\S<?[1]: .;E\87$4 )T683".X
ME=)',0V0A"64NH)R) !\HY!' YINH^-(X1?QPPG;%83W4<Z$MAHXU<JP*[0<
M,.-Q/'(%:<_A31;F6V:6PA>*W214@9 4.\KN)!')^0#Z$BK$^C:,KW-Y<6-F
M&EC99Y7C4;D( 8,3V( SZX% &;=>*9K>.]G&F$VUK=?9C,TORC RSMM4E4'
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MM$Z1%"$&"J'='^1.1Z$U0DLO#"72:2\&GK<2OYR6Y50S/M/('KM!_P" @]J
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M2'6.1(V8CM@NI /4=<=*O:GKTVCZOHEE*&E-[!(A7Y06F#0A26X &'?/3/
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M+&(TL5,<J07*_OOD*AP60@8/.".^0<@58N?#FIO-J*KNDAN(HLN]PIE=T,>
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M"*IEN81YD:$Q>:.0,%=I7YL]6''>K>B^(O[9LI[D:==P^6BR*KH<R*RY&TG
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M0. K !E'H,*!CT KEH?#NN6NEI;Y:Y,MM:"Y$MT[L9E$GG."6'))BZG&!TR
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MAKEK=W,9E"6TMN)3.6,:B5FC!!//R$#OC% &YIRZ7'<W$&GQPI);)';RK$F
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M7)'5A3]2\40:9X?M]6GMI0LT8E\AG1)%&S>1AF&6 '09_+FEGTS2/$>AW%O
MT<EE>3+)*T>&60JRD]?7:!D?45?U'2+'5HDCOK<2JF<#<5X(P1D$9!!P1T-
M&7/XMMX&OA]DN&-H(VQ\H+JY7YP"<[!NY;H-K>E3Q^)K265$6.0[YXX RLK*
M2\7F@@@X(QQD?RJ1-(TB[>>6)2[\PL\<[@Q[2,JI#?)RHSMQG S3D\.:/'=6
M]Q'8QI);JBQ;20J;5*KA<XR%)&<9QQTH RU\:VXL=+NYK&>&/4?+,2/+%O"2
M,JJVT-DC+C..GUXIW_"9VX,N_3[M!EU@)*'SV2=8"%^;CYW0#=C@Y[5I2>'=
M)E%HK6:[;1$CA4,P"JA!4$ \@%01G.",T^70M+FB,4EG&R%9%QSP'<.V/3+
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MT337656M(RLJR(XY^82-O<?BW-.OM(L=2>-KR'S?+Z*78*>0<,H.&&0#@@T
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MVFE7ER)9$ACD5HU#.T'G@?,P(^3.3_.H5\8/<36365F]Q#>/;;5(5&C26)I
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MM6W><EE7R]X7. =K;2<=Q0!C'QI;B 7?D3-;206TR@JJ>4)1(<R.6V@?)CL
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M7ML)4C1HP"S#Y& #*<'E3@9!X.!Z4 9=SXQM;.>\%Q9726]J)P9_D(=HDWL
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MZ+NMSE2SDM( RG!'\0'("X)K4\16>M76L:<VG(P@BEA=Y4F9< 2J9 R[P,%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH RK^XO9-0%E8LD96(222N,[020 !ZG:?RIL=KJZN"^IHR]U\@#/XU-%_
MR,5W_P!>L'_H4M<]XANKZ#5KR:WOI8UM;>W:&!0-KRO*R[6XYR !^/&#S3N2
MBUI%AXBM[^W>^O1+;B(K*A;/S8 STYYR?QKIQ7%:=XKOKWQI]@*PC39$<Q,>
M'^4D;LYP02#V]*[44BA:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS_OY%_\ %5W$+M+!'(\;1LRABC=5)'0T /HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,51_9'Q,_Z&G1?_  6G_P"*H [NBN$_LCXF?]#3HO\ X+3_ /%4?V1\3/\
MH:=%_P#!:?\ XJ@#NZ*X3^R/B9_T-.B_^"T__%5W$(D6",3,KRA0'91@%L<D
M"@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#P<JQQV#+0!W-%<O8>+?[4U^PM+.!393VGFRRMG>DA4,(\=B%(+9_O#WKJ*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!FWN@:=J%W)<W,,C22P?9Y0L\BI)'\WRLH8*P^=NH/6HE\,Z4J!/*G9?.
M$[![J5O,<;0"^6^?&Q.&R.*UZ* ,_P#L33_[.N]/\EC:W;2--&97()<Y;'/R
M@DDX7 R2:KW'A?2;R%(KF*XF54>/,EW*S,C8+*S%LLN0."2!CBMBB@#-?0=,
MDE61K;+ RG[[ -YN/,##.&#8&0<C@<<5$WAK2WM8[=X[AXXGWQEKN4LOR[2
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M;);17I>6Y\M9/G)D(WOMSGG _*M:N2TS3]9MO%5S.4F6TN+EYYFD,)1D,2A
MN/WF\, .3MPI]176T %%%% !1110!7OIYK73[BXM[9[J:*)G2!& :5@,A03P
M">G-<9_PFWBK_HG.I_\ @9#_ (UW=% '"?\ ";>*O^B<ZG_X&0_XT?\ ";>*
MO^B<ZG_X&0_XUW=% '"?\)MXJ_Z)SJ?_ (&0_P"-'_";>*O^B<ZG_P"!D/\
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MBK_HG.I_^!D/^-'_  FWBK_HG.I_^!D/^-=W10!PG_";>*O^B<ZG_P"!D/\
MC1_PFWBK_HG.I_\ @9#_ (UW=% '"?\ ";>*O^B<ZG_X&0_XT?\ ";>*O^B<
MZG_X&0_XUW=% '"?\)MXJ_Z)SJ?_ (&0_P"-'_";>*O^B<ZG_P"!D/\ C7=T
M4 <)_P )MXJ_Z)SJ?_@9#_C1_P )MXJ_Z)SJ?_@9#_C7=T4 <)_PFWBK_HG.
MI_\ @9#_ (T?\)MXJ_Z)SJ?_ (&0_P"-=W10!PG_  FWBK_HG.I_^!D/^-'_
M  FWBK_HG.I_^!D/^-=W10!PG_";>*O^B<ZG_P"!D/\ C1_PFWBK_HG.I_\
M@9#_ (UW=% '"?\ ";>*O^B<ZG_X&0_XT?\ ";>*O^B<ZG_X&0_XUW=% '"?
M\)MXJ_Z)SJ?_ (&0_P"-'_";>*O^B<ZG_P"!D/\ C7=T4 <)_P )MXJ_Z)SJ
M?_@9#_C1_P )MXJ_Z)SJ?_@9#_C7=T4 <)_PFWBK_HG.I_\ @9#_ (T?\)MX
MJ_Z)SJ?_ (&0_P"-=W10!PG_  FWBK_HG.I_^!D/^-'_  FWBK_HG.I_^!D/
M^-=W10!PG_";>*O^B<ZG_P"!D/\ C1_PFWBK_HG.I_\ @9#_ (UW=% '"?\
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M_P"!D/\ C7=T4 <)_P )MXJ_Z)SJ?_@9#_C1_P )MXJ_Z)SJ?_@9#_C7=T4
M<)_PFWBK_HG.I_\ @9#_ (T?\)MXJ_Z)SJ?_ (&0_P"-=W10!PG_  FWBK_H
MG.I_^!D/^-'_  FWBK_HG.I_^!D/^-=W10!PG_";>*O^B<ZG_P"!D/\ C1_P
MFWBK_HG.I_\ @9#_ (UW=% '"?\ ";>*O^B<ZG_X&0_XT?\ ";>*O^B<ZG_X
M&0_XUW=% '"?\)MXJ_Z)SJ?_ (&0_P"-'_";>*O^B<ZG_P"!D/\ C7=T4 <)
M_P )MXJ_Z)SJ?_@9#_C1_P )MXJ_Z)SJ?_@9#_C7=T4 <)_PFWBK_HG.I_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>bionano-nancyridgeleasee008.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8S( 7"[5)12V"<XYJ-?%^G16+W5Z_DJFTLL:23,H\E)6)"KD *_)Y&,<@G
M.@KB=,L[G3O%5Y>A9IK6**[>XE6SE229FE5XTY_UI4!U4J" , 8SBM^7Q/I$
M#W"RW3)]GC>25FA<* B[V&[;@L%.2H.1SQQ0/$^E-&&6:<L93#Y0M93(&"AC
MF/;N VLIR1C##GD4 9)M=8/Q#M[V>U)LA%-#'(DV4CCPA&5Q]XMN_#']WGK:
MH6NM:?>7TEE!.6G3?D&-@K;&"OM8C#;6(!P3@G!JJ_BK1HS<;[ME$"NSL89
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M#;S[;,6M:?/J3Z?'.3<*6&/+8*2N-P#XVDC(R <C\* .2%WX@:UAN1;W8F6
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MS';VX9KMH@XD=2$<)O8KU&T%,?+G-=%#XGMSX4EU^:,)!&'XCD#+)M8J"CG
M*L0"&.!@@\5=T:]CO].$\0M I=LBTG$J;LG/S #G.<\=<T 8OB6RU&76;2_T
M^.22:TTZ\>"-D1HS<?N_+!)'!)ST(Z'WSDW<6KZE$@QJ%Y;1SR&&6ZM?*E^:
MRF5LJ%7Y=[* 2.K8YXKT"B@#B+>3Q";Z*RCEO+?!6)5^RJ8$@^S?ZS>5^^)>
M-N[MC;CFJ/V_QCJ-A?I<V$L*RV$UPD36RL PB:+[.00=Q:0"4>H..G%>BT4
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MLI9(!-=QV(-SY?E2'.SR\D[P@/R' )X'4=I10!Q=I-XI>2TGN9+E-BV0DMQ
MFV3>[+,6.W((7:2%( /M6SK/G7VFV,EK%.";ZV=E*%65!*I8D'D# )^E;=%
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M1Y(B-Q4C@)*5)]%#9KJJ* //;S5?%Z^'6G%O>IJ#&01I% " T<:KAAY;DAY
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MC%+=PSW3+=0+ @\V. R!E4#!R?+P2.3DD5US*KJ58!E(P01D$4*H50J@!0,
M < 4 <0(M?LM1U&[TYKF87-X^V">%51P+%2DA.T,"9453R!R1C-6;34]8M?!
MNLZC>7$C7%O;R2P&XMRC(RQ9P08XPPW<\#'.,FNOI&570HZAE88((R"* .)T
M.[US4+J!'U*Z9([B;[2IA0&/"Q-'$[&)>H8G( .&QGC-5XM0\3G2Y96FU 3"
M"!Y1)8[66XRWFQ1[8FRN !OVN!QR<DCNK>VM[2$0VT$4,0Y"1H%4?@*EH Y[
M2+S4Y=?NHKI;LVK0K)&)(@BPG"Y0G8-[9+'<K,.H(7 ST-%% !1110 4444
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M];6MVEXUQ<SW0F>9YI2N9&9%CY"J!PJJ!@#I6O10!AWWA>VOY=0,UW="#4%
MGMAY>PL%"AAE"P(V@]<9'(IB^$[-5L5^T2@6<WGILA@CW-D'DI&,=,';C(R#
MD5OT4 <NW@33'5=T\[2B9Y?,:*!N750PV&/8 =BGA<YR<\G,Y\*06]U?7NG3
MFVN[E6VOY,3")V4+O!V;^V<;L9[5T-% &;J&D"_N+.Y6^NK6>UW!)(1&2P8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5&VUC3[R^EL[>Y5[B/=N4 \[3M;!Z-M/!QG!X.*O5RUKX?O+/7
M9]2MTB5(HKD6MNUV[([S2*Y)^3]V"5R0-WWCCH,@&['JEG+J4NGQRLUS#_K%
M$;84[0V"V,9PP.,]ZN5@#2;P>*AJ$(2VMBY>X*7<C_:?W80!HB BD84[@2?D
M [FM^@#(G\4:):ZN-*N-2@BOBRIY3G'S,,J,],GL,Y-:]<)K7@_6-4UC64CD
ML$TS59;1Y96D<SQB'!(5-NW)*\'=QZ5CP?#;6)M3GFOY-,-M<7,$D\,)VK,J
M2NS$JL:\E' ^8L3@Y8B@#U.BO*X?AGJEA8B&S.F-YEND-S'*2RS;9V<??C9<
MB,A065L8QC&#6);^"M>@U^TT^ZMI9G@M5MH+^+.V!O)D42ARG*H7'R;D.X*0
MIQD@'L]]?6NF6,]]>S+#;0(7EE;HJCJ34=GJMAJ$A2TNXIF$,=Q\AS^[DSL;
MZ':V/I7$Z;X$U"U\!ZSHC-;Q75^@5<3[X0P15W86)-N<9/!)ZDDDUF77POU5
M+C44LKVU?37N;=[6TD;'[A//9H7W1NN T^5RK#"@8& : /5:H:KK6G:)!%-J
M-TL"2R>5&2"2SX)P  3G"D_A7G%S\-]>FNXFBN;%(HK![19&F+2D-:-#M=Q$
M&<"0AL[@, ?("*W];\%W$OA_P_I^DQVZ'2[H7$D?VN6V#_NI%;;+&I<$M)NS
MWYSUH [2*5)X4EC;<DBAE.,9!Y%06VHVMW=WEK!+OFLW6.==I&QF4.!D]?E8
M'CUKSZ_^'6J7MU>W\5U;6E_=33GSTFD=HXI+,0A-Q4$XE^;MP,]>*L:=X%U*
MU\+^)-/C&GZ;-JFPP16<CM%%MB1""Q53ABIS@?Q&@#MKS5K*PO+*TN)'%Q>N
M4@C2-G+$#))V@X [DX ]:JVGBC1;[5Y-*MKY9+Z(D/"$8%<9SG(QV/Y5R>B?
M#Z:S\0V.K7-MID$=O<W$Z6=N6=+8/'&JK&2H_B1G/"X+G J]K_A#4M4D\3/:
MW<,)U2"TCARQ!_<LQ=7^4@*P;;T;@G([$ [6BO+F^&-Y+I]TA-JDS:7<6UJK
MW!<6\\CN=RE8D"KM<CY5&,D 8K0T[X?S:-XB75=/2R3RKV:6.,2.N8'M@@C/
MRG \[+GKUSR>* .XNK^ULBHN9UBW*[C=W"C+'\!S3[2ZCO;6*YA#B.1=R^9&
MR-CW5@"/Q%8OB/0I]<BB7_1QBVN(G60DKNDCVCMR :K>(O#=UJ'ARUTK3X[%
M$B4HRR*H5?W94%,HP&"0?N@XZ$4 =-'-%*\J1R([1-LD"L"4; ;!]#A@?H13
MZP-$T.;2K[59VBM-]ZT<@N%SO+"%$(88&1N0MG/.X\#OAZ7X)O%,*:HFGR6W
MVQ;B:VCP8VQ;R1G"B-5Y=E.".@Y)(H [NH#>6_F&,2AG$HB8)\Q5RN[#8^[\
MI!Y]1ZBN2T;P]J%CKFG17$IDM;:PAEN&!8J]XL9AR&/W@4R3WRJGO5K_ (1B
M=-;O+N"*SBCGU%+PRJ2)&46_EE6 7^]\PY.=QZ'J =517#Z=X%?3VLY8UM$G
M@6SS(F<[XP1.P..K@@9_BQSTJ]X5\,WFB6-U%<SC[1+#'$9XY V]E#?O2HC3
M#$MDDEB>,DXR0#HTNX)+V6S5\SPQI(Z8/"N6"G/3DHWY5)-,D$32R9V+R=JE
MC^0YKAM-\(ZIIS)<PV^F131?9/W44[A9FB$JNS-LR"WFYZ'D<^M30^#+O[%-
M]H:T>].G0VL4N6/ENKR,Y!(R 0ZC(Y..>@H [:F2S101^9-(D:;@NYV &20
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MYZ'D?C3;>YANXVD@D$B*[QDCLR,58?@P(_"N:\/>'+[2-3@FE^RF-=/CMYI
M^]WD1(URN4!5?E;(W$'@X!)JM=>&]9N-,?3R+(0)J4UXN)\_:$DED?8ZM$RK
MCS%/1P2G;J #LZ*X@>$M275-,F4VWV>SA$>3-B5E\ET*%Q$&(W,"""HP/NY%
M5_\ A"=3>&PBD>V\BW$B"&*14,8+*5<-Y)!<!3\P5#TYZD@':WFHVFGPS2W4
MZ1K#"]PXZL(T^\V!R0/;UJT#D9%<OXE\,RZQ>R7%O#9F272[JQ\V;(>-I -A
M!"G(^\#R,!CUZ5G:CX(N)3+%9_9EL6NS,MF&")M,"1D\QN P96/"_P 1.0:
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MLN\;>#@A<88?*.HXK'_X06]ETHV\S69ECMK];8;LK!+,Z-$RX10-NT\A1C/
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M6L5U(1&)MBJ['& ,]2< #\*:^AZ3+<S7,FF6;SS*5ED:!2S@C:03CD$<'VH
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M8:-8>1OW^7]G3;NQMSC'7''TXJ6>/2K(-)+%:Q&,-<_<&X!4",X'7A"%R.Q
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M%*MC<N,=#@9'L* ,CQ=X@O-*L[J'3X%:Y2QFNC*\@41*N " 0=QR<XX&!UZ
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MR:UED)95MU"LZ,1G&.H(-6[C2M.N[6*UN;"VFMXL>7%)$K*F!@8!&!P2/H:
M,[1-:N]6O-0!MH$M8?*-NPD.]@\2/AAC ^]U!_#O6$GB_6([>PO[FRMFA;3I
M[NYBAF. J/&-RDKDMAF^7I[UV4-A9VTYG@M88I618RZ1@$JO1<CL.PJO!IFD
M-#((+*R:)_-C<)&I4[F_>*<>K+R/4<]* ,#5/&5Q;/J,%E9P2RV\4DD,CR/Y
M;^7(D;ACL R"_12W((.*ZV,N8T,BJLA W*K;@#W .!D?@*I'0]),EQ(=,LR]
MRK).WD+F16Y8-QR"1SGK5V.-(8DBC14C0!551@ #H!0 ZBBB@ HHHH ****
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M73;;+]H=I+?<V]BS;B3(P521DC'5@.YXJJGC<20Q2KIDI3:6N"9 OE!9S"V
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M2!0!OWUCI%OHCQ7EM;IIUJAE*E/EC"\[ACH1R<CFIDTG3HT5$LH%55B556,
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MZQW'E/:.)6NF'D>5<&23"X^;<NT?\!YZ"@#LO[-L>/\ 1(>/+ ^0?\LSE/\
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M1HW2=V=L,N=D@*\<$KP<5NZMH=YJ.LM)YG^@O]D#1^:RY"-,9!@=B'3ZXP:
M-&;2='BDEDEL[96NOW,A*#]YNP,'U)  _ 5;:PM'G,S6\9E+J^\KSN4$ _4
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MVM(S=#GS,=P-H..F=I(SUQQTJ&/3-'FGA2.WA,NF!88PN081A65?IC:<'V-
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M;'H^GQ!0MLGRF,@L23E/N')Y.* ,*S\<17]HEQ;:7>,LS0BWW *)1+NVG)P
M1MR1S@$=<XJW=>(Y1X=L]5L[$R/<7,,!@D<*4WRB-N>F03BM"WT/3;50L%HB
M*'615R2J,N<;1G"@9/ P.:DETJQFT_[ ]LAM=P;RQD $-N!&.00W.?6@#FG\
M77-M;ZL+FV=#;B]>WN %96$';;N!Z$=<9P>G!.]8:PE]J=]8^2T,EJP&)" S
M@_Q!>NT]CT/X8J631M-FC>.2SB9'$H8$=?,^_P#]]=ZD@TZTMKN:[BA"SS<.
M^221G.!GH,DG [T 6J*** "BBB@ HHHH CG0R6\B+U9"!^5<-/HNOW6BZ+:>
M5=6BV=H;:9+>X0.9-L8253N PNU^O(R#@UWM% '%7&CZ[<:UJ4K>?':2VTT2
MFVN<,Y+1F-AN;&X*'SPH&<#@YI+?1=?;5M.N+N26.*.*$;;6;"Q,KL7#!F/#
M*5!QN[C(P#7;44 <CXDT;5-1O-0%FC/%=:;+;'S9L(K%'"[ #P2S#.01@ Y!
M&#4U?P_KBZ=?V6F;VBEN&>W9[MR\0-NB@@EQC]Z&)R21G(!)KN:* .8LM%OX
MO$9OY@GEFYDE)W<X:WACZ?[R-6??>'M3%SJC6<<JQW.IQW4GES\SQ>3L* %A
M@B0;L' ( &>U=O10!QK>&]3>TN<W5VTYM+:"%WNV# J?WI.TXW$8RW4XZU#+
MX9U>"&^%C/.KRP7T4>Z\=L!RI@QDG&,-R.F3ZUW%% '(3:)K,5U>7EJ[//*;
ML*DMV^PJRCREP#\HW#^'!&3SS56P\.ZM'<V%S<QNS6]S<>6#/DPI(J[21N((
M# Y7)Z\9%=S10!RWA;2=6T_3+F.]N+@7<D2)NFE$B>:%(:1>2>21G.,X' YK
M/LO#NL.D4=Q]H@M]UJ+B(W[NTC()/-D# YPVY!C()V\@5W-% '*7FAWMSX.L
MK&='N;JUN()2GGD,ZQS D;R1D[ >IZ]^]4YO#.L1B_ET^=[>YNA??-]I;:#(
MP,1QG"D8/(&1DGO7;T4 <O;Z3J<?A'4K2&6YBO)PY@6>8 QY4#:K*6V@D$YR
M2"V?:L.\\.Z__96H0Z;:-;-=7,LT(:\9I(3Y$:1DMO X96S][;P ".:]$HH
MXB^\.ZF+G5&LXY5CN=3CNI/+GYN(O(V% "PP1( V"0" !GM6AJNEZF_A;3[6
MT>YGOK<(?WLP'F,$(_?$,"RY()VG.0",XYZ>B@#@&TO7[Z\U9[)[BTEWWD<=
MS)=-L8,F(U5/X</\V0.,<9R15FWT358EM3)%>SVPEE9[1[P1M&Q6,(P96/R@
MJYQDG+YQQ@=M10!Q%WX9U6;[5<J[?;39ZG#!)]H8%6EF+0]^,*?PP/047.@Z
M_)?:S+'=W*RS1SBVD6?;&58#8G7<I7&,A>.3GDUV]% ')6FBZA#X<\2P6\#V
MEQ?M*]FC7)=T)MT1<ODX.Y3W..,58M]&U"+Q'_:)EE*/>2%P;ABOD&$!0$)P
M/G&>!_.NEHH XZY\+S7&JZB3 _D76IV]X9!<$;HUB167 .0=RGIU!'/800:!
MKR:CIIGN;IK>!(E4Q7&3&4F=FW[C\P9"BD_,2 1QUKN** .3UW0]0N=6U"\T
MX,DUSIJV\4XG*^6ZLY((SQN#  @<$$\4FF:!?+=V$ES)>"W@2Y?RI;C!61FB
M\L81B"H"R$ D@9_ =;10!P^F^%]5LC92FXN3-%'8F3?>R.#("1<G!;!RNWZX
MXJ2W\/:T#:3S7$QN+>*P13]J;&4F8W&1G!S&0,D'/2NTHH \^;PYKEW%?F^M
MRRM/9SQVZ7389HYV:4J2YQE"H!)&2!D# JUJ>AZ].LPC,T@?[6(-EX8_(D=P
M89#@\A0#QR1V!R:[>B@#F;+1=1M]?%_)/*P:YE\S-PQ4PF,!0$S@?.,\#CGU
MJM>Z#K,FH7MW97<D-Q-/,(Y&N&*)$UKM3Y,X&)@&X&>]=?10!PR>'=0DEM;A
M[.=8+>]BF6SDO3(ZXB='<,6QR64XSR%)ZL15JUTC68M0C>Y$LZ['$+BZ(%L_
MG2MO9<_."C1@#G[F. :Z^B@#F/"NEZIINFW"WKSO=-&B[9Y]Z-(%(9U().&)
M&2<'C. :S-,\.ZU-'#%J1ECMC?B>6%+MQ^[^S,A (<G'FE3C<<]3SFNZHH X
M.#P_KKW>DO?J]Q+!]C=YS=G:GEIB52F?F8OELXYSUR *U]2LM7.KZN]A$4^W
M:;';P78D4""5?.P2.O61>@-=+10!P\6AZS%96QB%X9DO!+Y-Q<@QJ-JJ<X?.
MWAB,$G=SM.2*;<Z)KSI.D9G^S?;_ #V4SCSIHRLF5SO"[0S1E>5.%P1P,]U1
M0!QUEH6L1:_:375W>S6\4<060S*>%BVNL@SR2V6) .21R,"M*RTV[L_%4TL4
M1736MPB[W^5" @58E!X7AL@KUY!Y(K?HH \_U72]>@M-8N4-R)1;WI\Y+ICY
M^]LP*B@Y4HO&< C'&<DU<M/#]^-3L;V:UF$,.H/)%;O>%WMXFA5<DEL-^\5F
MQD\-]17:44 </9Z'K\;Z6+AY7GABL@;D79VQ",#ST9<_.7PPS@YW#)&T5I^&
MM&U#2YE:ZEE<26<:S>9<-)F8,V2,DXX(''H!VKI:* .'A\,ZC=?9X;U)OLT-
M[)*&>Z83,K0NN696Y^9ATQD=0#3/[%\2S7=D9\82U\J>07!(ES;,I# MR?-(
M/"@8 .2<UW=% '*VF@WT/A_7K-U3SKV(+"-W!/V2*+GT^9#64WA[73:!(Q<P
MVHN49[-;PR.RB$J6#LPX+X;:6'3=UXKOZ* .7UW2=5N=(TJWMY[F408%T%E"
MRR_NRH;.5!(;!/(]1R!69J/AC6[Y=3@>>26TN=-DMHXY;DY^T&)5$S8XPQ!4
M@<#!;'SG'=T4 <F^AW]W>P>8)X=/,\3O!]K8,L8@D4J2K<_.R9YYQWK!M+?6
M(_$NE6NH/>.UO;P1,R-(Q:3R&#,3D*4W-EC@DLHY[5Z510!QFG:9XCWVC70>
M(0):1NOVK=YAC642-_P(LGN< GG@4U\+:M<V,<<_G*]O!=I;R-=,LQ9UB\MI
M&5B"VY6)P<< X!.!W]% '$3Z%XBEU'4YEO;B.:6&06LRS 1*6@"*K#.1B3YN
M%]\\D5I>&M.O-,FOF;3W@AO+I7"27?FM$@A5<DDG/S)C /?/M72T4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !5>*^LY[J:UANH)+B''FQ)("\>?[P'(_&K%<A8Z->V/B1KV&"
MZ-G +E4BF>$%VGG21F0KSM&UC\Y!Y  H Z>&^M+BYFMH;J"2>''FQ)("T>?[
MP'(_&K%<KX4TW6=,G>WO&E^R(CY\UHV$DID+;TVC(!!).[G)'N3U5 %.;5=/
MMTNWFOK9%LP#<DRC]R",C?\ W<CUJY7C\_@;Q:UMJ\YBM)+C7;*X2[BC?8T<
MID\R+<Q8AMH9H\@<#'6IM0\/>.'T>:"PBNXB]S/+:K)JKO-;#9&$#/YH# LL
MK<[\9 QR< 'K*LK9VL#@X.#T-+7EE[X2\202ZHNG)>)#<ZPUW(8K]LSPM$0-
MH,J[2KD$C*Y^7[P4"K+>$/$=UJ4,EUJ.J-#]H@24KJ3Q;H!9[9"51\ F8*3C
MGJ1P30!Z52,RKC<P&3@9/4UY?I_A[QN-0T^2_O;P^790(7BN@5#K"5D60&0
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M>85"A92"Y)127## !W BO0020"1@^GI0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(
MS!5+,0% R2>@J@NNZ.]K)=+JMBUO$P2247"%%8] 3G /M0!H45GS:WIT+B,7
MEO),P1A"DR;RK,JAL$CCYAS[\9R*?_;&E[KE?[1M-UJ";@>>O[D#KOY^7\:
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M.KZ8LD\;:C:![< S*9ES&#_>YXZCK38-<TBZW_9]4LIMD9E;R[A&VH."QP>
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M"ET?LPC;?;&*0)&9#NY#@[APOMD<UU$6NZ:^DV>IRW<5M:W<:20O<.(\AEW
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M)#'<1A@#%YKJJLV2,*-P)/85<_MC3-MLW]HVFVZ_X]SYZ_ON<?)S\W)'3UH
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MOC W'+'<!V _2I=:UG4+"_G2U@BFAMM.DO7C*,9)F7("+@X&2.N#Z8YR,/\
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M<2-&QR$V9"#=P3N/4G'OCD +C1[FXTFPMC>1"ZM)(I1,(#L8H?[F[/(_VO\
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M.GZ18Z6'%K$P+A5+22M(VU?NC+$G R<#H,GUJ[@>E+10 F .PYHP,YQS2T4
M&!G..?6C'&*** $P,YP,T;0,8 XZ4M% ";1@C P>OO2T44 )@9!P..E& <9
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M_=+9'(S5Z7P]I9ANU=9E@G8R2)]ID$:L6WEU&["G<-V1CG/J:$\,Z2EL]O\
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M1G(A<[GFDP97(!E_UF!GC)).!W)-+%H&F0R"2.WPP?>#O;KY0B]?[B@?KUH
MI:QXA>TT_3[JQ6)HKSYEGG#"-%V%US@9RW 'U[G -+3_ !?/J,UI<1VD:6$T
M\-LP9SYJO+;K,&Z8P-ZKCKU/;!W9M&LYM-ATX^?':PH(U2*X>/Y0-NTE2"1C
MUJ-/#VF1ZBE\EN4E0AE59&$88)Y8;9G;N"?+G&< >E %2]\2>3KEMIMM:RR
MW@MKB<J-B,86EVCG.[&P],8/7-1P>-M)F1W<R0K'(T3LQ1E4K$9>61F'W5;O
MV(.*O3^'-,N-2-_+#(9B_F$><X0OL\O<4!VEMGRYQG&*H77@W26TA[% \=NT
MT$LIEE>0E8BN%RS< JNT^Q- &AINNV^J7EQ:Q0S1R6ZH9!+M!4LH8#;NW#@]
M2,<'!.*R-3\9!(;V#3;5Y+^VGMX2C&-P!+-Y0; D'<'Y25/3. <UO0Z9:)J3
MZDHD>XDC*!VF9PJD@D*"<*"0#QZ53@\+:1;&3R[>3#M$V&G=@OER>:@4$_*
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M<4MI97,T;7HM=_E\2\LK;.>S+C)P._3FKK^(;-=(M=15+B2.Z=8XHTCRY=N
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M:%:18PT8'4;G4<X/S ]#6A<ZQ#:SV-O)!<>=> E$5 2@&-Q<YP -PSS],\4
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MN#PM9V^J_;(F= NG)IT2HQ5D1223NSU^Z,]1MZG/%N'0K"#2XM.2-OL\<ZW
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MJ6\T*,CD#T(/)QS5ZT@UIKN&"_FU*6)K15BEB58AO+2;_-&200OE8)],CG-
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M(<8QT\KM^/7FDA@\52?;!+=W:2O<(I5(@ J?:5^:-B2,"'=P!TZ_,.0#H?\
MA%]+,#Q-%(_F1312.\K%G$I5G).>22J\]L8&!1>Z'HQ%U-=@(+E)HY6>4J")
M54/WXR(U^F#63:1ZY%J%I%>'49+5)9UC>)E).)SL,IZE?*V_KGYL4SP_I.HZ
MG8SP^*#-<;HX]\$J%%6;#B0HP8Y4A@., 8&.2: -R?P[I]Q.]R!-'.\OG&:&
M9E;)C6,\@]"J+Q[ ]>:'T'2;Y'9XA/'-*TS_ +PE79H?);OTV9'_ ->H-=&H
MQWVE-8+<21+,!-#'\JLI91N9\\;1N.""&Y'!Q6!:6.O:3I;11I>RI)""T8D
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MOX:TJ&YN+S;MDG5XR)9&,>9 JGY2<'=M4?RZT6/A:RL['2;9WFF_LU5V%I"
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M444 %%%% !2!57.T 9.3@=:6B@ HHHH 0JI8,5!(Z''2EHHH **** "BBB@
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M1C)QG?TS[9S0!I45#]KML1G[1%B3&P[Q\V>F/6EFN(;>WEN)9%2&)2\CD\*
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M''((- %ZBHGN8(]^^:-=@RVY@-H]_2E:>%9%C:5 [C*J6&3]!0!)140N8"5
MFC)<E5PXY/H*AN]2M;*VEGEE!2+&\)R1DX''UH MT5'Y\7D&;S4\H L7W#:
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M5G.\O,!@HNWYE&1DDCHW]WF2]UY],O\ 7WF_>V^GZ?'=I N S'$Q8 ]>0@H
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MVDB)YK9WC1YL>9,HD/E [<+Q&&RV.&]5(H L/X:/]@:OI<,D4*7LLCQ!4^1
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M%YJOBB"(K#%9M:W;+$DNYR8YXXPSC:-I^]P">I':@"K=> HKA+IL6@N)HM0
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MQ6*>8D."6@9C(P/^V#C\.:B@\%ZC&9YIY[*>5WMG\IH]L4IB:0G< H"Y\P$
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M)(# N'<=&/')]Z>VF6#?:-UC;'[3_K\Q+^]_WN/F_&K5% $45M! $$,$<81
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M8Q+E%/4 XX!JS10 Q(8HR2D:*2 "54#('2H8-/LK6/R[>SMX4W^9MCB"C?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M87!("$\E20<@<&K,^O:B_A+6=06Q^R7=I#*T0D+['VQA@PWHIQDXY7JI[<T
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M);1"**9XU:0* 1C=C/0G\S2V_P#94]U<V4%M$7M&02@6^%5M@VC.,$A"O Z
MBL/3/"]_:^)5U.[G2<#:PE$H#C]P(RA'E[F7<"V-X&2#MR.9)/#5U;:K<:GI
M\-CY\FJ"]VLQC\Q/LODE68*3D,SMT/7L2: -Z+2--@2%(=/M(U@<R0JD*@1L
M>K+@<'W%0M;://K$Z/9VKZ@L*O*[0 N8WW(,MCD':PQGI]:YS3_!EU:C3YII
M+5KRTCLHQ,"Q91$I64*2. P/X]ZHV_@;4(K"YB:WT[SGMK6'<DQ_?R1-(3-)
MNB8$L7!*D-WYZ&@#M;S2+*^B6*6%0@FBF8* -[1L&3/J 57\JLRVT$YS-#')
M\K)\Z@_*WWASV.!D=\5S/BGP]JFMZ3:VELUB)$@=7=U"[)2JA70E'*@$-P,-
MTPPQS7U'P=/<0S/#]E,\NI-=3!L8GBVN%1BR./E+A@"I&1Q@G( -34/!NBZ@
ML*&U2"*)'016Z(BE6(+#&WY2=H^9<-[UIKI.FI-),FGVBRRMND<0J&<Y#9)Q
MR<@'ZC-<AXNT:Z?PYHVFQ6\MS% #',#NF.!"R#)$;$G)X8IU&>.A:_@Z_NI-
M0G C@-W:ND :8!H-]N(Q$P6,DJIYX?'0[<B@#M)M/LKFZANI[.WEN(?]5*\2
ML\?^Z2,C\*E%O L#0"&,0MG,84;3GKQ[Y.?K7%ZAX(N)!)%9_95LC=F86FX(
MA!@2,GYHW ;<K-]W^(G(-6)_"4_D:BT4=E-<W=Q"=]SB1C"D42%"S(PSN1F^
MZ1SG )X ->YT#0+VSET=K"Q$:IO,,<2 Q;PRAP,?*3A@&_V3Z5+=V>C6$<NI
M75G:@QQ[9+AH SE<;<$XR>#CZ&N57P1?I9-&K67VI]+M+22Y#?.7AD+,N2AR
MCJ0I)'11E2.*2[\$7LUE% D-C(!"Z*MQ,2+5VEW[HML0'(XP%7& .10!V4VC
MZ9<%S/IUG*9 H?? K;@OW0<CG';TJ%[31+>]AD>SLXKBW6-(96@52@8E$5&Q
MQSP%![CU%9/BGPU?:U=0RV%VEL/*99MS,"S(1) PQ_=D&3Z@FJ,_@RZFLR)U
ML;N8K9RO'.3L>>.XDFF.2IP&\P@'!ZX(H Z6UM='O'CNK>SM7>T9K>.3R &B
M*,5*J2,@ @].*NFUMS,)C!$90P8.4&X$ J#GUPQ'T)]:Y_2O##Z=K@U("W5W
MDO&G9,[I%EE5XP>.=H!^A/'4UGWW@N>:S B%JTSZC<75RK$ 3H[2F,,S1ORH
M=< J0,'&.#0!T"PZ+<7\UBMC;O-!;K#(/LORK$>1'NQC'?9GWQ5RWT^RM$6.
MWL[>%%4HJQQJH"DY(  Z$\XKD;KP3.T5P;<V_F2RVSOYA#-.D<80K([1L#S\
MV2IR0.!V?)X*F>RNE1XEN&T^"TMY'?S&CV,Y==Q085@RKD+R!RO % '2)H6C
MQ1QI'I5BB1R>;&JVZ *_'S#C@\#GV%64LK2)9UCM8$%PQ:8+&!YA(P2WJ2/6
MN,F\#S7&G"$K;)(EG>) KR;UAN)6C,;IMC0+M*$\*"">,\U/>^%;^XAU.-$L
M1+<7(G%X7_>S1^:K^3(#&P"A1L'WA@#Y>2* .F2STO2[>(1VUI:0QR#RPL:H
MJNYVC'H26Q[YQWI9=)TV>\-Y+I]K)=%"AF>%2^T@@C=C.,$C'O6'<^&&G\'0
M:28+:66&XBN!%<.'C.V<2%-PC& 5!483 !QC%)I_AR[MO$8OY%M%59YI6N8W
M)FF1Q\L3#: %3(QR?N+P,F@#0^R^';6:TA2ST]9([DQ0+' O[J8IO(&!\AVK
MGMV]JLG0='-K]E.DV)M]_F>4;=-F_&-V,8SCO6"_@Y9M6N9);/3VM)M46^?(
MRTJ^0T95UVX.'.[J0=QZ=ZUCX.U"VU+2Y[B>.9+2WMX]RR[6B,><A<QEBK9&
M0&7/(.: .E;5-*L]4^P&6.*[F*,5"$;B1A<MC&2$P 3D[:GDMK"VC#-:0A2T
M:#;#GD/E. .S-D'MDGCDUSNJ^&;Z]\5+J4+Q+#NM6WM<R KY3LS#R0NQ]RM@
M$G*DY'(%06WA?6%$4<TMHL=O]F2-DE=C(L5T)2S J,$J,8YY[XH WII]%NK6
M+5)XH)8W(MDFD@W'YY FWD9P6('I4[Z?I>IP[IK"VG0R%\36X/SCY2V&'7C&
M?3VKDG\%W[3V99;"<1/;,)9'8-;^7<M,WEC:<EU8*>5^Z,Y'2Q_PAER\GG2O
M:O/&8V@D)8F,K=/,Q!QP2C!>/<=* .Q,4;2K*8T,B JKD#*@XR ?0X'Y"H9]
M/L;F"2"XL[>6&1M[QR1*RLWJ01@GWKD/!6GW5KK6I7%WISQ33!LW#)M_Y:NP
M4Y0;C\WW@SC  SQS#!X-U93<27":9,LLEO(]F&V03E#+OW!8AC.]",ASF, D
M\&@#J8[C1DTZ"]CC@6U:2**)EAQAMXC0 8R,,<#TSZ58FT?3+B+RIM.M)(\*
M-CP*1\N<<$=MS8_WCZUQL?@>_0:>C1Z=*+?[*0[2/FV\JY:5_*&WG>I"]5^Z
M,Y'26]\#3RV%O%%]F9O.N9+E-X3S3(Q*ON:-_F5>!\N1DX(QR =;)I&F2SRS
MR:=:/-*GER2- I9UQC:3CD8'2EEL=.73&M);2V^P(O,#1+Y84<_=QC'>N8N_
M"E[-+JFV*V:&[\MAYDX,C.C*0Q8PGY?E^XP<'_9'7H(+6^;1I+*Z%J)/LXB5
MX<A6;8 QVX^4;LX SQCZ4 &C7FCWT)?2O(VQ(L>$B\LHF,J,$ A<'([<\59:
MSL89I;TVL"S9$CS"(;R54J"3C)(4D?0D5QA\#7\.GI:Q7,4T8DMY76>4N9-D
M+1M&6='&P$JZY4\Y&!P:G'A+4AJVF3*]JMO9PB+>7#2LOV=XRK-Y89_G8'.Y
M1@?=S0!M7$_ART@T[4YH+55=%6SE%KEU7:7 7"Y4;03VP,UK0?9I5%W;^4XG
M16\U,'S%QE3D=1@\?6L*?PY/<Z=X>M&NC%_9Q'GO Y5F @>,[#CU8>G&>]4Y
M_!B)%?BS@M/GDME@CD)P;>(1 P,<$A6\L@XR#QD'I0!T<NE:=.MLLMA:R+:X
M^SAX5(BQC&WCY>@Z>E01^']-$/EW%K'=_OWN-UU&LA#L<DC(P/3CTKC;KPAJ
M4LL5FEK9[6M[G9(7;R[!GF#(8CMY9!TX7IQ@<5<?P7>RSZLTDT;F\,P2;SL%
ME>57"NHC#?*HV@EVP!P #@ '4'3=&N+B\4V5C+-*%%V#$A9^Z[^.>G&?2H+T
MZ-H>F3B]C5;.X=VF#1-*KENNX 'CMSQC K"U3PS)8?VO?Z3I]FLOE0360@3;
M)YL.,1%0OW&P 3GH3QWK8GT&4^#3HL4RM.8 C329 =\Y9C]3D_C0!:M-*T62
M"TGM]+M%2'YK?_10ABR<Y4$ J<\]JD70](145=*L55)/-4"W0!7X^8<<'@<]
M>*PM3\.ZC>>*HM35+![:+=\KX5I%,#IY;D1EB"[ _>Q@?=)&:R6\":H=.M;2
M:[BNQ"9A([2[&FWK&%D+-')M= A12.=N#N!R" =LNE:<DL\J6%JLEP09G$*@
MR'.?F..>>>:;?)ILUW9P7T$$T[,SVPEB#[649)!(X(]:H:1H]SI^NZG=LL"V
M]T0RX;?*S GDML4@8Q\I+8[$#BL*'P/-+:1VMY#8&WBDG:.(GS"-\052S;%W
ML&!.XC.,9)/- '7W_P!B@M+J[O8XC"D#>>S1[LQ $D$8R1C/%8]AH.ASZO>W
M\(,\JR/'*DB#:K.JLPY7+ @KP20.@QBL:[\'ZS=W<TCS6(+V3VWF@X=]UN(_
MG/E[F_><Y+$8Q\N16[_8U[%I>N01/;--?2%X?-&Y!F)$PX(/=#V(P1P>E &A
M-'IC:E!;2V\#7;[[N+=$"<IL5G!QPPWH,]<'VJ6?3;"ZDDDN+*VF>6/RI&DB
M5BZ9SM)(Y&><=*X^W\&7Z6(@F-LZB&[C$*3; /-EA=0"(MN (VR-F#D#!!-2
MQ^%-3-W9RSC3VDB%J?M$>5>V$3;G2)0F-KCY3@K]X\8P* .I6UT]K=]+%I#]
MF2,!K?R0(MIS@8QM/0\?XTR73M*@M4,EA:+!:1OY8\A<1*1\VT8X!&<@=:RM
M5\-R:IK1N93!)9L;7?#)D[A&9BP(Q@Y\Q>.^#FL^U\)WMLZ+)%87*K8BUBED
MD;=:D>9_JQL/!#J#ROW>_% '3&QTO4[-7>RM;BWG"2@20@AN/E)!'4#\J?;2
M627=Q:6RQI-&J/*J)MX(*J2<8/"8]@![5R\?A?6([B&-+BV2W699VF65O,5A
M9_9]JKMP1NPV=P^E4$\#:BML52'3;8;K8R6T$F8Y_+216WEXB,DNK\HW*^O-
M '="PLU&%M( /DZ1C^%BR_DQ)'H3FH'T/2'CGC?2[%DG?S)E-NA$C?WF&.3R
M>3ZUC:MX=O+OPMI^DVXMG\D*DHNF$GRB-EX9HV!(8KSL&1GH356V\&S"Z@N;
MPVTTZRQ>;*2Q9HA:^2Z9(SRV3CN,$\T =2]M8P1F62"WC2-58NR* H3H<]@O
M./2H_P"S-,E>WN/L-H[PC,$GDJ2F3G*G''//%<]HF@W<WA/4;74VWW5ZKV^Z
M9?\ EFB^5&6!]54.1ZN:KCPMJ?\ :FDW(M]+@ALHT4QPD \*ZLF?*W%26!ZJ
M.N5/4@'736%G<3B>:T@DF";!(\8+;<YQDCID XJDT.BZG>W%G)96]Q+:2!Y/
M,M=RI(R@_>(QNVE2<'."*S?#.DZEX>BCL)EBNEFD,DETLC?NT$:@)AN3@@*O
M/W5R><YJ:IX.FN9[^>U6T4W.I)=NA"CSHQ;B/8Y:-QP^7&589QT)R #J)]-L
M;JW:WN+*VEA9_,:.2)64MG.X@C&<\YJ.9=-M)+6&2"%&N)5BA B'+(K.HX'&
M%1B/3'%<S:^%+NQUJUOW<SPVT,03]^#+'LBV% 3%EP3D_>0$L<CUV-1TZ_UB
MSTF1F2RNH7,TP5RWE,UO+&0IQR0T@YXX% &B=*TYKB>X-A:F:X0QS2&%=TBD
M8*L<9(P!P:6YTVSNHIHY;=/WNXLRC#9*;"P(Y#;?ESUQQ7&0>"M3M]&$5M<0
MVNH"0#S%ERA4QF)V 6),-AMPX.61<FKEOI-[I>O:A-96IELK:)386Y)5?-E"
MJXR?X5\L'//^M>@#IKC2M.N[:*VN;&VG@BQY<<L2NJ8&!@$<<<5)]CM=V[[-
M#G<7SL'WBNW/UV\9].*Y_P 5:#J&M7-BUHUHJ0'>7EP)$8.C J=C'HIZ%3G'
M-9UWX1U&6'4$AAL!YMW]JMQ+('PY\S+29A_>+\XPC D<X<87 !U$&AZ7:302
M6MC!;F L8UA0(H+#!.!@9QQGT)]:D&E:<)IYA86HEN!B9Q"NZ4?[1QS^-<LW
M@^\>_P!5GG:.X^UK,$<7 B++(00C8B)PH&!EF' ^7D@1S>$M6FB ']GQS/IL
MEE)(I&!E9 @11&-F"XRRD C/R=, '87NGV6I0B&^M+>ZB#;@D\8=0>F<$=>3
M^=1-HNE-)+(VF61>5/+D8P+EUX^4G'(X''L*YK_A"##>2SV!MK-VNF=)8@0\
M<36AB*CC_GJ?,QT/7K4>G^"&6VLH+^&U>&.Z\ZX@+AXY ('CR%$2#.YE/(/3
M.<T =/#IVCK=%8;*Q%Q#$(B$B3<D9SA>!D*>>.E36VF6%E''':6-M D;%T6*
M)5"L1@D #@D<5A^&_#MQH]]]IN4M)9I-.MK>:Y0GS6EC7:W5>5/!R3G@<5E+
MX*O75XY?L2!@J32([%KW_2$D+R_*,,%1@!EN7/(% '9FQLS>B]-K!]K"[!/Y
M8\S;Z;NN/:JUG;Z1=S3:C;6EJTS/);R3B !V*.4=2<9(W*1Z'%4=:T-[J33?
MLUG8SVMH&3[%<$I$,@!67"L,K@@#'1CR*RCX/NH#<SV@L!<7"WPF+KD2^=<+
M)&&RI!VH&'((!/ (S0!TB:#H\<4<2:38+'&_F(BVZ *_]X#'!X'-6/L%F0P^
MR08;.[]V.<MN.?JQ)^O-<9'X1O;/2_,EC@GN+6TOQ;1Q'<4DEDWQ[/E0 @97
M("XSQ@5F6'A&\O\ 2_+2S2!5N6:6*3$*3[H40.H:#Y2NTC[G4L0W- 'H#Z+I
M4LD\DFF6;O<#$S- I,O(/S''/(!Y]!4D.F:?;7 N(+&VBF$8B$B1*K!!C"Y
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M1D6:W#*%VC<.'^8D'+ 8QTVM.\/V&G:9/IZQB:VG9FE25$VON !&Q5"@8'0
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M+2$Q@+CC<%!(ZGH">^.UQ?$DPU5;22Q01+=)92RK/N*SM")>%VC*8(&[(/\
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MJ1*%!V A <#HN<@=B!0!C:MXDGTG7[BV\IKA6AM%MX55N))&N-Q)56;&V(=
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MX&,>^>-JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK$L<QD+NMPMNP.%R!O88(!)7G /% '845RDOC"YABC=]&D3;$\]P)9#&41)
MA*AD!;.=PR%R.N*NV>O7 TS6;_4;>)(=/FG"_9W+LZ1Y/((&#@?_ *J -ZBN
M5TWQ'?/K3VFH6T<9FNHX(DCF#K$#;/,3NV@G.S'3OZ=33?&9U2ZL8[?2[AHK
MB""6610S>3YL>\<A=I !&26'7@&@#JJ*Y^_\2M::['I<5M',TI:-7\QQLE$3
MRA7PA5053^]NY!VXYJ)-:U"?PEHVIR+%!=7DMGYBQ'>NV61 P&X=U;\,]3C-
M '2T5R=IXT>]L'NTTR2.-Q&UJTWFJLP<D!>(R=^!G"!QSUZU'/XTG;2OM=OI
MZQF73#>VYN791(X1G,8PN"0%Y&0<=L<T =A16+J=]<P^&Q>27*6,^Q6/E)Y^
M6/1$! W$D@#C)Z>]8RZ[K:W$1NF@BD@FLK:YM$3(=Y@OF,&SD!2_&/[C9SG@
M [.BN9U;Q!>1:O%96<"B*.\MH;B=I!N_>'.T(1R-O?(.3P.#5>+QU;A9)KJV
M$5I$\1>Y21C&(I%?9("R+D%D"\9'S @F@#KJ*Q-+UZ:^U(6=U8&RD-LLZK*Y
M+/E4+;?EVD*7VDAL@CD $$YLWC5X!<N^F$QH+OR-MP"TIMYA$P(Q\N201R??
M'&0#K:*YD^(;V/46L/L<<E]),D*0F?;$A\DRM\^S)&%/\.2?0=+&A^(WUVX7
MR++R[;[+%<-+)+\P,@)"A0.<8.3GTQGL ;U%<K;>)]2DB"-IUJ]W)=7<<2+<
ME$\N"1E)9BAPW &,'.<\#@6YM>N94\.3Z?;1/;ZM(-_GN49$,#RC  //R]_I
MWR #?HKB;'QI=P:0CZC9&2X:.)H6C<MYWF2^4-RJF5YP> W!]>*W&UV1?#Z:
ME)9F"=W\L6TY="6W[!C"%SGJ/DR01P* -JBN2B\;&9;:5--/D/#:RSLTV&C\
M^5H@%7;\V&0DYQQ[\5%/XPNIH8UCM1:F:5#!()1(61;J.&0,-ORD[^.O!/0B
M@#LJ*YO3?$<U[=-;1VZN(?,DN)II@FQ//EC7: N&_P!4V<XP,<DFL\>+[Z_G
ML([&TC65K\0LC2L(YHVMI95(=HP0,J#D*<XX)!H [2BN*B\;2LZ3I:R2K>);
M"UM\$[&>.61MQ168C$9Y /;H#FMNXUR=+#2I(M/?[7J+!$MKA_*,9\MI&#G!
MP0$(QCKCIU !M45QN@^,+J^ATFWDL9[F66TMI+JX1&PKRINSA5VX'?+#KP#B
MF:3XKOIK#3%:$7E[>06@^=Q$F^2W>5F)"G ^0]CUX% ':T5RD'C,W/V.2'3C
M]GF%IYK/. T;7!PH"X^8#N<CV[X)?&T4=E%.+&1GF@AD2,,6^:67RPIVJ3P>
M20"?0$T =717*GQ?<*T6_1Y(P$C>X\V0HT8>9H054J"W(W#.W*GL>*F/BOR;
M/^TKJT2'2S<F#[1Y^610SIO==O +JHQD_?YQC% '245AW6NW,5AICQZ?_IE^
MNX6\LVP18C+L&;!Y &,8Y/H,FLG3?&%Q):Z- \$=S<WEI&6E#L )S;&;#X3:
MH(4]&SR#MQS0!V5%<C8^,;N==*AETII;JYM+:YN/LWF.L:S,54@[".-K,=Q7
M '!:MO7;Z;3]/BGMRN]KRUA.1D;9+B.-O_'6- &G17-:1J]\OA_4-3U-XBZ7
MEPD2>9\BJDK1JH(C!ZKCHQ/X[15/C>3[$ERNE$A([F6Y#3%/+6"41OM#("Q.
M<@$+TYQ0!U]%8VG>(%U#5Y]-6V9)K;S/M.6SY6' CSQ_&I+CT J"U\3^=>Q6
MD]GY$TEZUKY;.=Z 1R2!V!4<$1'&"0<\$X- '045QLWB^ZO_  U?ZAIUHL(A
MTO[697E!:*1X#*@";<,!E<DD?0X-:8UV=M'UJ:>V^S7.FJX94D$@)\E9002!
MV8<$=0>HYH WZ*YD>*IQ?O;#3&EC64VR2+,-\DHMA<8"8P 5R,YZ]L<U%#XK
MN9KNU)M[*.S:RNKBY9YW5H6A9 0=R+C&[G< 1SZ?, =717!ZEXPOY-.NY;9#
M9SVL-X'4J6!=+=948;T5L?.O51^(Y.C>^+KNWO+B&'2%F2)Y8UD:ZV;FCC$C
M<;3@;3@=>1T YH ZNBN5/C0-<W8@TNYEMK9&+S!6 #" 3<G;M P0N=V=Q'RX
MYI%\4:C->65M'IMO')+>K!,LEP2!&UNTP*D+][Y<$8QQC)SD '5T5SVO:]/I
MTT]JD(BW6<DL-TY.&D".VQ1M*E@$R02.#D X.*1\87-MI4DES81_;82@,(G9
MO-!B\S*[8R<X!R,8&#SCF@#KJ*Y.RU^[O->CC24BTEO=BH47(C-DDH&?]YB?
MTZ5UE !1110 4444 %%%% !14-Y%+/93PPRF&62-E20?P,1@'\*XN?PMJ,NF
MVT":=I\>R":)H!=OL$S+&%N VS.X%'[9^;.<DT =U17%7GA36)FU"./41Y+1
M$VI,A#&5]GF[N" #Y;8//^N;C@9MZ3X7DM;[3I[A08;6.X*Q/*'\N1WC*E0J
M*H "OVXW<=: .JJC_8NE?:+BX_LVS\^Y0QSR>2NZ53U5CCD>QKF=9\-ZSJ&N
M7UW ]K%'+!-#&ZOM9E:#:H?"9)$G/WL 8P,YJ'4_#6H6=O(NE,8C/>(D8B+'
M9%+"L4S'T((,N>Y4=R: .MCT?3(8$@CT^U2*/=L185 7<,-@8[@G/K3K#2]/
MTJ)HM/LK>TC8Y*01! ?P KFO%>C7>HWEA:6-DDT0L+J(&65HXX7/E"-L@'YA
MR1WX)!R*JW/A#5IIM9<WC//=6T\4%QYX3.^((JL!'NP&Y^^0,9 R2* .QECM
M+NX6.:*.66V99DWIGRV((# GH<;AD>IJI=Z?HEMJ":Q=6-FM[YD<27;0*9 S
M$1J V,\[MOX^E8VH>&+C[9FS@MI-.1H";"20JDJJLP96X(^](C\YR4Y]:H+X
M0U7SK#S_ ++<F V;"9[A]UN(IB[H@*_,", $D9P,]!0!T6F^$]&TS1X-,6RB
MG@ABEB!N(U=F64YD!XQACU&,'CBHGL/"^L6UQ-/IUA/!'<-YLEQ:@*95 C+9
M88; 4+N&1\N,\56UC0;^^U];N(0&/-L8YWE97M?+D+2!% (.]2%/(ST.0*8W
MA/;X(O=$CMK/S)I9I53&(V)E+IGCTVC..,>U &R-*T:X:>/^SK-RKR+*# OW
MI%!?/'.Y2,^O>BX\.Z+>6-O8W.D6,UI;8\B"2W5DBP,?*",#CTKG[WPG=W\E
MSYBVZV\DCR1P"1ML>;6*)1P /E=&(].".>E:Z\&Z@;<0PR(;;[0DTEN)1B0^
M1L8DNC G?\W(Y/.0: .UAM+:V>9X((HFF8/*R(%+L%"@G'4X4#Z 5G7F@^'V
MMK9+O2-/>&W(C@5[56$9=@,*,<9.*R=>TJ[EM] LX[/^T5A9DG2YG8*P$+ &
M1PIS\V#DKR?0XJ.T\)WT%LS37$<]]YMA_I+.V6CA,!E^FXQN<=\C/L ;LOAO
M0IHFCET;3W1EVLK6R$$;R^.G]XEOJ2>M,'A_P[!.N-)TV.66+R%'V= 7C ^X
M..1@#CT%<W'X0U-T,4IMXP?+6YD2=RU[BXCD:1^!M;8K@#)^^1D "M[5="%S
M?Z)<6UK:E=/D8 .,&)"FT%.#R"%...G6@#6GLK6Z.;BVAE.QH\R(&^1B"R\]
MB57([X'I226-I+#<0R6T+Q7!)F1D!$F0 =P[\ #GTKG_  MH-_I+R-=""+-K
M#"_DRM)Y\J[MT[9 ^9LCU)QR>!679^#M1^RI!=+;(F+1+D).["[:.3=)*_ Y
M8<8.<Y()P!0!U+^'=$D@C@DTBP>&,L4C:W0JI;[V!COW]:KQ6_AV]U&[9;.R
M>[=G@FD>V ,IVX==Q'S\#!P3TP:I>*M#U'5&L4TX6R1P D.S;7C<,A4J=K8&
M%8<8/3G&:K1>#S;W]I=Q6=B9(M2N;EFQAE27=M8?+RP^7CCIUXH Z<:;8BZ>
MZ%E;_:'<.TOEC<S!2H)/7(4D9]#BJ9M-!T2"1EM;&T2%6NV$<2J0$&"X &>
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M1[58*>A<=AP*QO\ A$]0>[U6:XD>1KH3!62Z5-RNX95(\HD[ -HW%A@8QAB
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M3JJ9&>V<#@TR_P#".J:A=:N\T=B8KJ*55CW865O-5XBPV9R%4@DEL$G  XH
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M:1')<2)IMJ'N5=)B(Q^\5SE@?4$\D=SDTV/2=&N'@N([*U=K7$,3A!^[\MB
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MK"'3'N-KQ1F3SE0;Y0VW@]OEY/;/ /2H(O&:3)#*FGR>3MMS<L9 #$9I#&H
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MJ..2>>RTZ.XN?/.XO#*#*,]>0,AO4=JO6^@:E:7^G/$%:*VN9R!)-N1('E+
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M2Z8_:?,N5E08Q\F$#KGG&_C/-6/^$1OC%'+!(T-TFGWT$,DTP+P22LACP4
M48?I]W(Q4T7C2>22:[_LZ86!L[>Y@&5)99)&'F,1G:H4 G/05LZGX@%A!9R0
MV;WC72,Z+%(@&%3>3N)P>.F,YX^M &19^&[QKV"2>$6]@MZ9Q9+<LP11#M'L
M<R?-MZ=^I-6/"NAW^ERW3ZC--++(H1W:9629MS'> %!!(/<^@Z 4A\=6'VF5
M1:W;6T,>^6X6/(3]QY_(]-A SG[Q ]Z$\8M/; 0Z3=_:W9E2)MJ@JL>\L&;
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M.I6<V(Y+PPR1[2)5AN?)"@9R#\\8R>O)^NO!X@270IM3DMI(/*8H8YR$R0<
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M0Q2RPK?K<(DEP/,F4F0.H.[;L 9"H.TX&#G - &SK&B:;?PVCWPQ;6!:4+G
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M!T\?A[2(IGE2PB#NX<G!/(?>..P#?-CIGGK2Q:!I<$L4D-FD;11B)=A(&P9
M! ."!DXSTSQ7+OI>KW4VMP>;>/!:S".R\N7:TF]UG?.X@,HRL?7[JL 02:U=
M5T_4[FPTD/ 9_*3_ $NUMKIHMSF/ (<D$JK9ZG/(/) H T+*UT>TU VEHB+=
MQ(96 )9@'P,L3W.Q1R<X4=JL6UIISM'?6L<+[RTJ31G(;?C+ CKG _*LGPUH
M=WIEU<W-_)YUU-;VT<DXD)\QTC"NV#TRPSTK%;1=>E\.Z/IWD7%NMC'Y,ZP7
M"!I3LVJZG<. <\$CJ#C(H [%M)L'NWNFMD,SLCLW/+)]TXZ9''/L/2HQH>FK
M/%.MHB2Q'Y60E?XBV#@\C<2<'/)-<W=:+K#2ZDJF\DBF2(B3SU\QG4IPHW!=
MA"MN4[3R0#\W"P:1KQU2WGN 5E#PN9HKMC%%&(0LD(0G+9DW$$@\,"3E0* .
MEGT?3[G4$OYK5'NH]NV0YR-I)4^F1DX/;)]:$T;3HXTC2SB"1I#&H Z+"VZ,
M?\!))%8\>DZA9>!K>PA5I]0$4(N/-N'8NV5\TABP). V!N )P#Q69:^'-=\B
M![BXF^T6Z0"+%VV 5N79\C.&_=%5YSD9% '0?V)H,<TME]CMUDND+M'SDJK
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M>X=@W!SP0?E&><#%<;_PC/B#;<2*)([HPI'+,;PL;DB<.Y4$_(&0$ <=<'
M-;FB:'>6^H6UQ=RW;Q0VS+&DUP25=I'."JDJ<(P49S@<9H T/[,T*TO;>Y%M
M;13JRP0E1@!@I"@ <;@N0#C(''2IX+&PM[ZV2!@DEG:>3#;JV!'$2O.W_MF
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M6FR2K*;<I(KNX>*5T;+D%@2I&02 2#P<#BG/HFFR(Z/:1LKB96!S@B4YD'_
MCUH AM=<2XU@Z9):RV]PL(F(E9!G.,A0#E@,X)&0#QFLN[\;0VDER#I-_)'
M+AC(ABP5@($A +@\9&..:VX-'LK>[CND21IHX_+1I)GDVC ' 8D9( R>I[FF
MR:)ILJR*]HC"19D<9/(E(,@_X$0* ,R\\8V-EJ%U:20RN;:![AVB>-_D387R
MH;((#@X(&0#[9DU'Q RZ!<:C80M)Y5VMNH('[W$RQMMYQUW $D<C/2KG]@:<
MEU-=Q6X6XE1U+$EE&\#=A2=HSM7.!SCFDMO#^GP>';;0FA\VR@B2(*_\6S!!
M..^0#]: ,J?QU96Y2.6RNQ<[I1+ -A:/RV"GHWS9W @+DD>_%7]4UU],UB"T
M-E)+;M97%W),K+\OE%.,$\YW_P O?$R^'-+18 ENZ&$N5=)G5SO(9MS!LMD@
M$AB<X&:L7FEV=_-'+<P[WC1XU.XCY' #*<'D' X/< ]0* ,;_A,[9;NSM9;"
M[CGN$BD,9V%HTE<HA(#'.=I)QG '-0S^-H_])CLK"2XGM[BVB95FB(*S3&($
M,&(R"K<'V]\;KZ/8O=07/E,DT**BM'*R953E58 C< <D!LCD^M5D\,:/'#/$
MEGM2;R]V)7R C%T"G.5"L20%Q@]* *#^-[!;B]C%M=.MKYB[T"D.\;A"@^;@
MEC@;L X/..K'\0WX\->)-0:V\BYTXS"&%P&(V1*PS@D'DGOTQTK7;0-,<W6Z
MW)2Z#":,ROY;;OO'9G:"2,D@ Y[TZ/0]-BTZYT\6H-K=;O/1V9O-W##%B222
M0.3F@#*E\9VML)UN[&[MY8#(C1ML8F18TD6,%6(+,D@(Y[$<8K4EU"5/$5EI
MP1?+GM)YV)^\&1X5 ';'[PY^@JM+X7TUXK2)8ML=O>K?'<2[/(H(4EF)/'R\
MYZ*!TJ[>:59WUU;W,\;F>W#"-TE=" 2I(^4C()5>#QQ0!@Q>/+">RGNXK.Z:
M",1LLGR!61V(#%MV$ QD[L8!'OBW+XMM89[J$VTYD@,*HH9-TS2E%38-W*EI
M%7=]W(//%7%\/::EO+;I',D,AR42YD4+UX4!OD')X7 YI'\.:3)OWV@8-&(@
MID;$:@J0$&<)RB'Y<<J#U H K6OB=+O4+:QCT^Z%Q(9A*I*8@\ID5BQW<_ZQ
M2-N<@]J6]\4VMCJ[:<]O-+*(W8"%D=F*QF3;L#;@2H.,@9/U!.A::18V+1/;
MVX1XU=5<L6;#L&?))R22H))R>*BDT'39;Y[U[<_:')+.)&')3RRP . VSY<C
MG 'H* (TU^W?P_\ VP%7RNFWSX^N[;C=NV]>V<]L9XK.C\;6DR6\D=C=O%(D
M;R2#R\0AY3$,_-SAE/W<\<UK_P!B:?\ V:=/\@_9R_FD>8V[?NW[]^=V[=SN
MSG--BT#2X8?*2S0)M5<9)X5S(._]XD_C0!#JOB*VTB_L[6=&9KF2.,%9$RI=
MPBG:6#$;F&2!Q62/&A:]$@L+@6+P!K?.S=<.TZQ)M^;@$L/O8X(/KC?N]%T^
M^O(KNYM]\\90JV]@#L;>F0#AMK<C.<'..M5AX6T4>=BQ7]\,-\[<#?OPO/R8
M8;AMQ@\C!H PCXRO8;":XDL2TZ?:V%KA00(KA8AE]^,@-SC.?4=#J'Q,R7EQ
M:"RGN+I;CRDMH@BLH$$<K99GVG'F 9XY(&.-QNKX<TA+4VPLD\IHY8R"S$E9
M&#/SG.2P!SUS1-X=TNX0K);,27$A<2N'+;!'G>#NY10IYY YS0!0M/&-G>W5
MLD%I=&VN&C5+D[ F9(?.4$;MWW?;@XJ*T\7)JE[80V<>P/??9YMSI("IMY)0
M59&(ZJO?L?8ULC1=-7 %G$ '5PH& "J>6..G"\8]*CL_#VEV!C:VM=K1N)$9
MI&<A@AC'+$]$8J!V% &9?>)9=(U>^&J;;?3X(6EMP+=F:Y58P[E9-VT,"'&P
MC.%SG'22U\6Q7K10V^FW<ER[NOD@Q_=0(6<,6VD?O$'!ZG'8UHSZ#IES=RW-
MQ:B9Y$9&$KLR89=K80G:"5X) R13&\/::\4,;Q3/Y+%D=[F1G&0 1N+;MI
M*YP<=* *5QXOL[:!Y3;7+[4NVVH%R?L\RPN!D]2S CVZXJ*3Q-=1ZI!:#3I&
M:6[CMWC)16AW0M)RV\AON]L=^O&='_A&M'^T3SFR4R3AU<EV(P[!W &<#+*&
M.,9/-3SZ187,IEE@_>&59MZLRMO4;0<@YZ9'N"0>M $&DZ_;:Q*\4$4RO%&'
ME#@?NV+NA0X/W@8VS^'K6!:>,;NTT^QOM86W>"^T\WL8M8RC1D&,>60S$-DR
MJ V5''(YKI-,TBWTN2^DA^_>W+7,IP!\Q '\E'XY/>H(/#&C6UO+!'8H8Y(O
M)(=F?$?]U2Q)5?88' H S9?&]O':B<:;>OB&XGE5/+_=QPE [9+ ,/G!&W.?
M:K$OBZWCEEQ8WLD"M-'%+&JMYTD2,[(J[MV<*P&0 2I]LR77A/3+RXM7N%FE
MBMX981').[[Q(R%MS%LL/DQ@D@@\BK9T#3#=S77V;$TH;<5D8 %AAF4 X5B!
MRPP3ZT 8UUXP9(([BTM?M(=("(D=#]^?RB=X?!^F.O4]0.J4DJ"5*DCD'M68
M/#NE"V:#[(-CKM8F1MQ^<R9W9SNWDMNSG/.:OP6T5MYGE*1YC;VRQ;)P!W]@
M* ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEX@X"!2V07P&&Y1LSOR<;:F?Q7#>W=YI>E#?J"1R+ \A7RS*J9 90V\#)')
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M *X<G RWM0!V5%8EAXHL-1UJ;2[<2&6(RJ7RA4M&P5Q@,67!./F S@XS5/\
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MK%IXC>_\2PV$%I*EFT5V3<2!<2/#+'&=F&) !9P=P&< CB@#H**** "BBB@
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M)5NI0[;B"VYMV7!('#$CBHY?"VF-)<RPK-!/<+(C21SOE5D8-)L!.$+$9)4
MYYZUM44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%(2%4LQ  Y)/:J7]LZ6;=[@:E9^3&VQY//7:K8S@G.
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M;FZ=4CB5U+X.<-C.=O!YHN=9L;/[=YK,/L,2RS83.%;.,>OW30!R$'CG49-
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MD#:!GD\CCW%1_P!KZ7Y#3_VC9^3&_EM)YR[5?^Z3G@^U '*0>-+EK6VEEFL
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MD\RU)\F,;"S8!9L$=^>W;I618Z[J[P/#?F\@N+B]LKN 3#85BEN$5X1CJJ\
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MK73-=Z?-/)8&YMVFV$O )!O"]R5SD#GK5*PUG2FL;L:>ZRVNF($+0L'4J$#
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MDO(C-;20QSQJPW1>:ZJK-DC RX)/85<_M33]MLWVZUVW1Q ?.7$O^[S\WX4
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M6(I-S2HQC5E=F4H),LR[!W4G)PN5P0#>U/0+RZO+Z6RU"*VCU"V6WN5D@,C
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M@4YX(PX  Z!1USQ!)XKDL],OBLT-S>QZF]L(V=!Y*&7:K,"R\ $8R1DD#/-
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M;L!<8/3.1UHU#5;^,^&I$DMK1;ZY$=U')B0<P2/L5P0/O* ".IQVX.'_ ,+
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MI)+:W8@DU"7;O)D@6*XP/,YX7:W'3 4=<\: \43W6NVRV]W9IIPNI[=VQO\
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MQ,682[$+,-SOD9QU+,?9JF\3>([O1(+22ULDN&O%,4",Q!:X.THGT*^82?\
M9H CO?!J7HNP;OR_M,TTCLD?S 26WD8SGMPV?;'O5FP\/W$%KJR7-U;O-J(
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MZB@! J@Y"@'GMZ]::88B6)B0[QAOE'/UI]% #/)B!!$:9"[1\HZ>GTH$,0"
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MBLS*JAF^\0.3]:=10 P11KG;&HR<G ZGKFAH8F!#1H0QR<J.3ZT^B@!  ,X
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MP.>] "T5%)=6\4@CDGB1R0 K. 3G../?!_*E\^'RDE\V/RWQM?<,-GI@]\T
M24444 %%%1K/"\;2)+&R(2K,&! (.""?4&@"2B@$$ @Y!Z$44 %%-CD26-9(
MW5T895E.01[&G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN,PVS31QEY@I+QS"+#=3ALEL@< #KD5U FF-G(N^!KZ./YU0DJKXR..N/Z4
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ML<I<G<3AR[! /JBA_HZ^M9D'C4B%6O([:&0/*DJF3"Q%8O-5=W1LCN#@CTY
M .PHKA[WQ5>WFB:M+;?9;:2WME**9B)3(T*2[E&/N_/C\"?:MN+6;XZ3JLK6
ML#WUA*T(C27:DK;59<%L8R' Y[T ;M%<?!XRN;O4K.UM+..>-TA>:3=Y?WY7
MC;:&((V["2.<]!V)0>+[^+3["YN+&W!U,%+-8Y&(\TL@C1B1W!=B1T"'KUH
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MZ@G/&>:?IMUI=UHT=U9B!+&>)9<;0H"NH;YAV.",YI\VGO+X@L]2#J$M[6>
MICDF1HF!_#RC^=<HG@![?3;:VMY;=##;64;QHI1)I(/,W,V!_%Y@(."<J.M
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M;GKQZ5CW?A<7.MR:F'B29KF*59 G[Q52,H5#>^X_G2>&/#<^B.SRM:@BTAM
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M63=\V/;VJXMM A&V",8<N,(/O'.3]3DY/O4=O86MH\S00(AF*[\=#M4*!CL
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MA'8V3WKW*PAENF,.&@>;.[9G(V8QCN#GFNA33;2._P#MBQ 2B 6RX^ZL8).
M.W;\AZ4^"PL[6-([>T@A1&+JL<84*Q&"0 .#@GGWH Y!?%]WJ<^E&UBBMK>:
M>U$H>;]ZWFQ>;M"[<%<$#.1R#Z5J7OB!],NO$,LW[V'3K*.YC@& 3\LA89Z\
M[1]*VAIUD)HYA9VXEB0)&_E+N11T .. /2B33[*6[6[DM+=[E5VB9HP7 Y&,
MXSCD_G0!SZ>*+]!:M=Z8MO%)=>1),SL5 /E[2!MW<F0KD@ %>3A@:9'XMNY7
M2U%G;17SSO&8YYV5(U5"X);;AB1TVY&,G/!%=!'I&FQ"$1Z?:((7+Q!85&QC
MU*\<'CJ*#I&FFW:W.GVA@9_,:,PKM+_WB,8S[T 8FE:U?>)DW6T2V-NJ6D_F
M&0M(=XCE:,KC &TLI.>_2GQ^)Y?[!UF_GM$2YTV.21K4.<X5"ZY;&#D#JN1S
M^%=$L:(S,B*I;&X@8S@8Y_"H8K"S@@D@AM((XI23)&D8"N3UR!US0!@?\))J
M*:Y%ICZ6C.JPM<M%*Q""1F *DJ 0H7)SC/..G-%/'4TMG=7$=E$\4'E2F97D
MV"!U=O,P4#D#9V4\-GH#77265I-<Q7,MM"\\7^KE:,%D^AZBH?['TSRS'_9U
MGY98.5\A<%AG!QCKR>?<T <[>>-);4W4JV4,EM&US''B<^86AB:0EEV\*=I
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M*R@RG&0S;>?O8R3D]*L2^"[^YDMI;J2WE(DN'DB60H(S+/YH9&*,<@8'&TG
M.17<T4 <9+X0N));I_(T]XFOX[R&"7Y]S!W9RS[,C(?@'=M.0#@X%SQ+X:N-
M:O#)%]E97MC;AY\[[1MV?-BP#\_3TY5>:Z>B@#$L?#ZV>GZK"C1PW5_-<2-<
MQ+AOG9BA)ZDJ&K%TOP==6=S#,8].M0DT3F*T!VG9!+$3]T<DN#T[8YZGM:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'%<0VT3/,ZAGDG,6"=G8 ,2NX?,![T =I17'S^-+JV.J2OI#/;6"S!Y$D/\
MK(U!(.5P%))Y&2  <<\6$\3WZ-9_;-+%O%+<^1),SMM&2@0@;=PW%R,L  5P
M3\P- '445S.J^(;W2]8U%#!;R6=M9031@R%6,DDCIR<$!?E&3V SSTJ4^))8
M=$U6\GM8OM&G3-"RQS$QNV%((<C@?. >."&ZXH Z&BN$7Q?JEK/=VS64=[>&
MZN-D<,I**D4<)*!@N<DR=QQ\V3Q4[^);RRO;YG26=(#=R^5N48CB\@D?=))
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M*Y>8V[[@L$$AR%.!D%O+3IT8T =E17&P>,[VX@A,>G6K374=I- !=$J$G9E
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MR(E W%MTF<=R2%'%947C&_.EI?SZ2L,!9&>8RL42%D+;_N;B < D#'(;.,X
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MH48!ZY'O7#>(?"\J6TDEO;I-)=:F9YY$A$C>5Y+*H8%6W8;'\+8)SQU%K0=
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M)OW9S@ONW_O,G;R<5W6AVMSI]NFGM;K':VT$:QOYN\ER6W*.!\H&T X'4C
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MVUK!"\S;I6CC"ESZMCJ>3UJ>BB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI/</]ODMH]YMU^SX<J(F# &248"KD@?-Q7K5G=_;(7?R)X=DCQXG386VL1N
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M'/:NPH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML*C#*NU2..H7Y0>PXI(M*TZ"U2UAL+6.V202I"D*A%<-N#  8!W<Y]>:N44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME?E*F4'<&&<$$'@B.'P9=PV-ND4-E'<QW2SY,H>-,*JEA'Y(4D@=, ]"'!H
M[FJ\E[;Q3>5+)L;* %U(5BQ(4!CP3D'@'(X]17.^)O"]YK&HP7=C=QP%8P9
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MNEV3_:&#3;K=#YA'0MQR>3U]:D_LO3OM?VO[!:_:=GE^=Y*[]N,;=V,XQVH
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MU-7.:9X2M-+OH+J.XE:2&/R^<888 YQ[ 5T0I%"T444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#.B_Y&*[_ .O6#_T*6N2\1I:W.OW\:H#>O%:6T)(Y5S([[@>V -W_  $U
MT\MS%9^(7-PXC6XMXUC9N 65G)&?7##]:9)::5-K":FTL9N%C\M?G&!UY^N"
M1]/J:=F2FD<KHDVJ7?C*+4S)=/97$!<Q*V8T5B?+!7H#MVGCGDUZ&*S;)-,T
MVV2VM7@CB7@*&%:*$%00<BD,=1110,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*O?^1@TS_KE
M/_[)5;58HM0URPLIT5X(U>Z=&Z$J0%S]"P/X5-JTJ6FIZ?>3';;H)(W?LI;;
MC/H.#^E-O;;3]0G2=KTQNL;1GRI0-R,02#^0Z8IV;)NKLJZ$6:^N$O+NX:_C
M9B8V?Y&0D[64>F*Z-:P[2PTZSU![Q;UI)""JB28%8U)R0H^H]^E;:$$<'-(=
MQU%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (JN[HH X3^R?B9_T-&B?^"YO_BJ[B$2+!&)F5I0H#LHP"V.2!3Z* "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@".>%;BWE@<L$D0HVTX.",<'M7D8\.>!,/F?Q"I7
M3?[3 .H2_-%\V0/F^]\I./\ Z^/8*X^Z^']M=:.]@U]*CFTAMHYU0;H_+\P%
MA_O+*RD>A- '*W/@SPO!,L45IXHNMUTUH&AU,@>: 3CYI5[ G/2GS>#O!<$%
MM+)/X@ N+U[%1_:,I*NLAC+-\W";AC/N*[X>'T$J/]H;Y=1:_P ;>Y4KM^GS
M=:SKCP-:7JSI=7ERR.MR(Q%(T7EF>9I7/RGYN2@P>/DSWH Y:Z\#>#[6TNIV
MDU]_L]TMF474I 7D8J% )<#&77DD5J0?"CP[-!'(SZY$S*"8Y-3EW+['#$9^
MA-;J>'K^.._B_M&SFAO'\R2.XL/,#,556W#> 5(4\8'7KQSJZ1IRZ3I%KIZR
MO*($"!VZG\.P]!V&!0!R/_"I/#?_ #\:S_X,YO\ XJC_ (5)X;_Y^-9_\&<W
M_P 57=T4 <)_PJ3PW_S\:S_X,YO_ (JC_A4GAO\ Y^-9_P#!G-_\57=T4 <)
M_P *D\-_\_&L_P#@SF_^*KN(8E@@CA3.V-0HW')P!CDT^B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH 1MP1MH!;' /K7F_AZ]GFO8-]_?R
M:P9XQ+;-)E AQYA9>H.-_!X5@  . ?1IIH[>"2>5ML<:EV.,X &36')XJBCT
MVVO_ .R]1:"XD2./:L>27*A#]_HQ<8_'.* *.N:@B>+;"TL]1:*_13++ ]SM
MC>,HX6,1DX9V?!X&0%ZC@'G6U:8>$]9N(==N@$TB&;SFGRRWI64O&"WW6)$>
M8UQCC &:[2/Q5IKW5W:MYT=S:36\,L3IR&F*A,<X(RX!(Z8-6M5UB'1TBDN(
M+AX68*\L2 K%E@H+<YQEATR: .;N[^[?QA9FRU"*YCN)HFCC@O"0MOL.\M$!
M@@GY@Y/=0#V+]1UC4(O&44L4=V=)M)8K*X*[?*+RCEB,Y)5F@P0, %_>M^+6
MDDULZ4]E=PS>6\JR.J['56"D@AB1DL,9 S^%0W7B6SL;NXM[N&YA,4+3JS1@
MB9595.S!)SN=0 0,YXS0!Q<&H:T]YIUPUS<^1'!I[3RF=QL\RXF5R8\;7W!5
M4DD%!AATKI-1NXAXM:WU/49K*W6VA>Q5)S$LTI=P_3_6$8C&PYX;IS6YINI1
M:G%*R1RPR0RF&:&8 /&X .#@D="#P2,$54@\2V,^IR6)6:)D,JB610(W,>-^
M#GC&1UQ[4 <(=1UB"QU*2>ZGA65&>(O>.1(!>;&;<1F':A4$+D8<'M7?Z+>6
MLEA!##=0ROY9D_=W;7((W$$B1N6&01D^F.U3Q:QID\)FBU&TDB"/(76=2H5<
M;FSGH,C)[9%)%J]C)(D37,,<TDDD<<3RIND*,5;: 3GD?4=\'B@#A/[<U:87
M\LPOHK?4E2XL&<@*JK,JX3:<C=$T;$''.^M6ZFU!O!K>3),UR^LM"#Y[Q$H;
M\KMWKEE&WC(Z"ND_MW2/LKW/]JV7V>-Q&\OVA-JL>BDYP#[57D\2647A>/Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)'_0Z:;_ ."D?_%4 =W17"?V%\2/^ATTW_P4C_XJC^POB1_T.FF_^"D?_%4
M=W17"?V%\2/^ATTW_P %(_\ BJ/["^)'_0Z:;_X*1_\ %4 =W17"?V%\2/\
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MB1_T.FF_^"D?_%4 =W17"?V%\2/^ATTW_P %(_\ BJ/["^)'_0Z:;_X*1_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>bionano-nancyridgeleasee009.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **:)$*E@ZE1R2#Q3@<C(Z4 %%%% !12 @D@'IUI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHH!!Z'- !1110 444A(&,G&: %HHH
MH ***3<N"<C ZG/2@!:**0$$9!R* %HHHH **,@YP>G6@D#&3UZ4 %%%% !1
M110 4444 %%%("",@YH 6BBB@ HI 00"#D'H12T %%(2!U.*6@ HHHH ****
M "BD!!S@].M+0 4444 %%%(2!U.* %HHHH **** "BB@$$ @Y!Z&@ HI-R[M
MN1NQG&><4M !1110 444F1G&>?2@!:*0D $DX [F@$'H<T +1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$@=3BE
MH **** "BBD#*6*@@D=1GI0 M%%% !1110 4444 %%%("",@Y% "T444 %%)
MD9QGGTI: "BBB@ HI"R@@$@$\ $]:6@ HHHH **** "BD8D*2!N(' '>N6G\
M8/:Q3"YL8()H;T6DAEO L*DP^;N,FWCC QCJ0/>@#JJ*YJ?Q?%;ZC+9-; R!
M5$3"8;9&*HW7'"X<G=SD1R<?+SK:EK-CI*H;R5UWAF58XGE;:N"S80$A1D9/
M09'K0!?HJC::O8W]Y<6MK*TLEOM\TK&VP%E# ;\;2=K*< YP15"V\8Z'>2PQ
MPW4I,WE["UK*JD2'"'<5  8@@$\$@@<T ;M5[\SC3KHVO_'QY3^5_O8./UK-
M/BW11%+*;M]D>TY^SR?.&<(I3Y?W@+$#*Y'(]:LV^NZ=<WXLHIG\\YPK0NHR
M &*[B -P!!*YR.<C@T <5HHO+>\M&L/MGV*XCL\(;<&WD@$ #LTA7@@?[0R<
M<'FNM\)&0^$-(,F[/V2/&[KMVC;GWQBH=0\4:1IUK?(-TC6D,K&)('V.8URR
M*VW:2.X!..<]#4PU^.VM]&%W;3)+J4GE1I!#(ZQML9_FRH(&%[@?3 )  [Q-
M'.^CJUO'+(T-W;3LD0)8HDZ.^ .2=JMP.3TK!QK5S=7<]A)?65O>WTDJO]G
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MW>K#_5C[HY&<F^/[9NO%FF?;3>,EM>[]B6NVW$1LW'F;]N=QD=EP6XSTZ$]
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MKCGA3D'(]12:\UO_ (1/2)I_M<-U(T8OY(+</-&N#EA'M/)8*#A> 2<#''4
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M;^2"TC2! !)YFX8!'0?+@YI0=2L/"OAN!?MMJBP11WCVMOYLT6(3@;"K?Q@
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M^>[6T0S/=PE&W=&4DJ,D$'W(P><Y.Y10!P<OAH0G5!86 LW?6;0PS6\"AE@
MMRQ7((VA@YZ$9!IZWGBH7]C!)).D(;:9FMBWG%;AU/F!8R%S$$(.4'S$YXX[
MFB@#DM?_ +8M]6OY]/GOMS:2WV6..$21>>I8\_*<-RN,D9Z<]*9=76O6OB2T
MLK=K^>U4%9II8D*2#R9&#96( '>$'WQ_NX.:["B@#@WNO%-II.Z2XOYIO*MI
MB!:+YCNR/YD2E8B%PRJ<LIQG!(SD,N;?7--NM2NK/[6GVW4R991 K.L0@&S&
MV)R5W?+T;IU&2:[^B@#F].O-0MI[NYUFZF,7G6]K;PI %1V>.++J-N\_O&<<
MG  .>G$>NW6M1:T([(W:Q>7 ;=8;</',YD82B5RIV ($(Y7J<9/ Z<@'&1TZ
M4M '-:*^N?VL#?S7$EM,MT2DD**L)2<+$%(4'YHR3R3G&:;H-]K%SXAU&.\B
MNTL0I\H7$8&UA(PPI$:@@K@]7XQSG-=/10!QUGJ>L0Q6=Q=G4Y'%WMU"#[#E
M8U,<H"Q;4RZ[_*^8%N,$G!-5[=_%EW%I\DUW>VS-#9"=%MHOO.K>>3E#@J<=
M. >Q'%=S10!Q4>I^)(A;0SQ7CRRBR4.+3(R+EEN&<A<+F+8><#NM5[:;7K&;
M3+*VMKZ.+S\S?N@8V1[B0-G]V2"%PV2Z]5P#S7>T4 <#:)K]O8VSQ&]GO+6U
MNR[W5NN]G6:%EB#%!PZAP".#G.?E&)Q>^*7U#3R[36\%P$FP;8L%W3,3%)MC
M;;MB\M<EDY+')QQV]% '&ZV-4M_%KW&G_;5:6VM(T$5N'BE(GDWK(Q4[0$8G
M.5Z]<X%53J?B61M6*_;X(D\LP>9;%V!$KAD4K!W0+R!(!D')YKO** .)>ZUR
M&9[B.WNXO-OHF:!+9?,E0V\(.YQ&RY#;@2< [<;E K;U/4I[CP_)=Z09BWVA
M8V>.+<XC68)*R*0=Q"ARO!SP0#T.W2    # '0"@#C=,L]2OO$>E7]^UW)#;
MPWRQ-/;HA(,L0C+C8"K%<GC:<+T'S ]G110 4444 %%%% #74O&RAF0D$!EQ
MD>XS6)9^&GL-*^P6^MZDJ;BQE*P&0YSNR?*Y))R203GO6[10!A3^$]/GLX+4
M//'%;0106X4J?)6-@PV[@02=JYSG.T5)>>&[:Z@M(X[JZM3:V[6J20,NXQ,%
M#*=RMUV*<]>.#6S10!2T[2K;2A<+:AE2:19"I.0N(TC 'MM1?UJA#X4L(((8
M4DN-L,-G"N6&=MM(9(\\=22<^HZ8K<HH YZ#P?8PK$AN;N5(/*6W5V7$"1RK
M*J+A1D;D0'=DX YJS:>&[*RUNXU2$L)9W+LACC(#$ $AMN\9QTW8Y/%;%% '
M/S^$;*X:Y$ES=F";SRL&Y=D3S B1U^7=D[FZD@;CQ6E>:7'>&Q8S31/93B:)
MH]N2=C(0<@@@J[#UYX(-7J* .=G\%Z7<64=L[3E8XHXD)V,1L?>IP5()SZ@@
MCM5NY\.VEUX>_L9Y)4AX*RPA(W1@V\,NU0H(8 \"M>B@#$'A:R2]2:*6XC@6
M2*4VB%?*9XU"HQ^7=P%3@,!\HXJ.'PC8Q06L1N+J1;58DBW,ORK'*DJ+PHR
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M=BXCW2NYRQ9@@(STPI4$  C%=!10!BZ-X9MM"MT@LKB98U9>!'"I95! 5BJ
ML.<Y.3D=>N=JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB9<(H&W!Y"C'85:NO#&I/-JOD0Z<;>\N$EV3E9'<!F+99HCCJN PDQR 0,8
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M*K-EM@(!48"DL 3P0*I)X,O8=-CM+=;&W6*&YBV1,RK/OFA==V%& RQLC=<
M\9H [FH[BXBM+:6YG<1PQ(9)'/15 R3^5<1/X'N+NVN$>.QA5X;P6]LC,8[6
M258A&4.T=#&S$@#!?@=ZZ'4;2ZUOP_K&FS6\<9FCEMX#*VX."F [#''S$^O
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M([E&['@C@]* .AIC3(LR1'.]P2N%)'&,\]!U%<78>$M2LVTUMMF6M;J63YI
MRQQ.ZL55!$!NP#AEV8/J,@T[GPMJ]EX>GCB2#$<-Q'%#;L7<K((@-S!%\PC8
M^25)(QD.<Y /0Z*\ZL_"$NHZ.<64-I(D%XD'F@KB>21'295V*4 VD#Y0P &,
M]:NW_@1KU[V4I:&>=+W$C9SNE(,))Q_!@G_9)R* .XICS11R1QO(BO*2$4L
M6(&2 ._ )KB;SP;J-S=:U*;B-I+V">.&<S;2/,B"!6 CW%0?]L@8! S5P>$1
M;ZQ;W4%I8-;6^I&YAA8;?)C:!$;;\IPWF*7P, ]<@T =;17+WWAV\NO$OV]1
M:E//@E2Z9V\^!(_O1(-N-KX.?F'WVX.!6GX;T=="\/V5ALB$T<*"=XAQ)*%
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M(9V#2QB!0KD'()&.<'D>E+_86D%V?^R[+<T/D$^0O,>,;.GW<<8Z8XH H?\
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M1+J:.W,RJZ+(0SQ2"-@3LQUW$;2Q(4\9P*GB\60R;-L*/N-HNZ.7*DSN5XR
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MFX:1 8S \N4)C&2-F#QCL"<Y#?%/B'5-(O)[.Q2.6YG@26P1E^^R%FG4_P#
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M>[%G$&9D#2,H9"-Z*=AR06QP5Z$<UK6QT/3Y&TJUAMH#)+Y+6\<.U6<QE\$
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M[[2-'L[@11+8VK6KQV]V/F;;&%F5FB.UEVOC R-V0>HKN99%AA>5R J*6))
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M>:"4G:(2A0O=<,HW9ZGIC)H I7^AZS<1:Y:0"".&]NX[F.83D,RJ(0T;*4(
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M8BW+0\#N>,^X![\$ FUK1KZ_M=-4PV]\((V6>WN)F1'<H ),A3DJ0>W\1(Y
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MM$A@A6WC$=NP:%0O"$ @$>G4U ^B:9) 8&L+<Q;$CV[!C:A+*/P))'H:OT4
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M057.@:0SLYTVV+-#Y#?NQRF-NT^V./IQ6C10!D0>&-(AGO9VLXI9;QI#,\J
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M:0B>7 \QVC(WKL.]!Y8.W*DG'/IK3^$K6>)HVN)@&%V,C'_+Q*LK=NQ7 ]J
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M"\A:,7MQ&K^6' "D.$C:, @C!X;=ST8 ]J<OA46<9EL;MUNXSOA:4 J'^SK
M"1CD84-]: -B_P!3L]+B$M[,(HSGYB"0 .I.!P!W)X%16>LVE_-J$4!D+V$O
ME3!HRHW;0W!/7K5+Q#X:3Q%8):7%]/&@B>.38%(<,N"Q4C&X=CVR:NVFEBTN
M=1D6=V2]D$IC('R-L5#@^X4=: (5\1Z:NE6.H7$XMXKR!9XUDZA"H8DXS@ $
M9/0>M2R:[IL8F+70Q#((GVHQ^<G&T8'S'(((&<8YK%/@>&6RT^WN;TW/V&!K
M:(SVT;CR6" J5(P3^[7GZ]0:GNO",5R^H-]K9!>%246%-JE22&QC[_(P_7Y5
M]* --]>TM+MK5KV,3*"2ISQA=Y&>F[;\V.N.<8J!/$=BZFX#,; QQM%=!6*S
M,S,NU!C+$;0>,Y# ]*IMX/A>1@]_=/ 7:81/M)\UH3"7+8R?E)./4YZ<5?U#
M1([_ $--+,I1$5%#E%8C:.",]#W!'((% %B_U>PTR*.6\N5B23)7()) &2<#
MG ')/0=Z@D\1Z1'<R6QOHVGC!)1,L?N>9@8ZG9\P'4CFH]0T#[8MHT5_<03V
M\#VXFPKL\;A0V=P(R=BG/J/J*SK'PA]GU.:22Z<6*7*36UJF"!MM4@!9B,YP
M&XS_ '3ZB@"_;>*=,N;5;OS3';O;Q3JT@PQ$C,JKL^]DE<#CGMFI?^$ET;?;
MK_:$.ZX"F,9/.6V#/I\PV\XYXZUGQ^#XXX+<#4)_M%M#;Q0S;%R/)9RA(Q@Y
M$A!_3!I\?A"UCAE0W,[-*%,CG;EF$[3EN!@9=VX["@#3UC58M&TXWTXS$LL4
M;'.-H>14S^&[/X5%_P )'I'EP2?;H]LY94X/!5MK;ACY<,0ISC!..M-N=*N-
M2T9K.]O66<SB<30JO[O;,)$4 C!V[57)'.,]ZS#X'LVGBN)9_/GW2&9IX(W$
MN]]Y^4C"X/ QVZY/- &]=:G9V5Q#!<SB-YF"ID'!). "<8&20!GJ>!6?JOB2
M/2KR>%K"ZGCMK9;JXEAV8BC)89P6!.-C$@ G'3)XI-7\-QZQJ5I=RW<R+;O%
M((0 5W1R"0$9'!) !(Y(P.*-5\.+JEY<3&_N((KJU6TN(H@O[R,%SC<02N=[
M D<XZ8/- #M1\4Z5I]K?2M<"5[.!YWCC!)8*H8@'H3@CCMD9J2'Q#8^4@NYH
M[><P&9T.[:H"[CABHR0O., XYQ6?)X)L'?4]K!4OHYD.(4WQF5=K%7QG'4X]
M_3 I][X/MM0U:6^N+RX99%=?*^7Y T)B(4XR!@EL?WB3SG@ N:AXBLK"2%2Q
ME#2,DA3DQXA>;..^53I[U,FN:>VCP:HTQCM9PIC+H0S%N@"XR3["LZW\)1I(
M);F_N+F7SO.9F5%S^X:#& .FUL_6K+: 6T?3[(7THGL&1X+G8N<J"HRN,'Y2
M0?Z4 6QK&G, 1=Q\OY8Y_B\OS<?]\?-]*AB\1:3.EL\5XK)=$"%PK;7R<#G&
M.3P/7MFJ,GA19=1^U2:E<LIE\]XRJ8>7[.;<L2%S]S!P,#/Y4ESX1@N9=-9K
MVX$=@MN$C(4@F%PZD9'RDX 8CJ .F* "V\9:?=:>EQ#\TQFAB>#=\R^9,(=V
M<<@$\X],=:U[/5K"_GEAM;E)9(OO@9]2,CU&01D<9!%8L'@R&/RQ+J%S,(3'
MY 94'EJLZS$<#G+(HY[#UR3;T+PS::#)*UN48,"J$PHKJNXG!<#+=>_IW/-
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MSCC@J6./UH NMXFT9;7[2;^/R_,,? ).X#<1MQGA<-G'0@]*L-K.G!2PNXV
M?R_D.[+>7YN!CJ=GS<=JS[KPPLNH3W]O?3VUU+*TA=55@ T4<;+@@]HE.?7V
MXJ*U\(6UG?6TMO>7"6MO(DJVV%*EU@^S@EL;ON8XSU&: +1\4::/#]IK9:?[
M'=-$L9\EMV9&"KE>O4_X9XI+3Q3IES/>0R7$<$MH\HD$C8&R,C<V>G ()'4
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MC1VJ7+W\:Q,7&2#D;/O9&,@+QDG &1GK21^)+">]FM(69I(+I;60L-HW-&)
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MX7N,U=T?0+?1I7DAEED9X(X6,F.=K2/NX Y)E;/;TH UJ*** "BBB@ HHHH
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M#NJZXCZ'I[K'% MC:[EN%8/,#%EV!Q]X-QC/&#GJ,.U*;4(_B GE27+1">V
MA227YHV5E<A1^[V@D,Q//R\<XKKX]7TZ33Y;];R'[+""992V%CP,G=GI@<\T
MR'7-*N(C+%?V[H Y)#C@( 6_($'Z$>M ')2ZYXGBT[2)"UL)KVV:X=Y8&1%D
M^39"<9(SEL]SCC&,5)=>)]834]1BMX7,$08;I+8DP;9TC+8'WAL9W )R0H/
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M/"T\W[SS?[+O;HOEOENEF#!>N,A\@#KQBNEURYO[77=+:WFD$#0SAH F5ED
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M',! MQ^[8',;9VM]#M./H:KCQ!IJZ;97UQ<I;17D2RQ"9@IVD \_0$9/0>M
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M".[8(PPQULFLZ;%'YCWT"KACDN.=KA&QZX8A?J0*A@UZQGOIK7S50HJ,CLP
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M]W]K<6\MS'=R6^P?-+&H52&ZA<*N1ZCKR05D\.HWA>VT1)QMMXXXUEDCW'Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG5&V>;N39@;C^[V>8W!_@X/->@5#+:P3S02RQAWMW+Q$_P #%2I(]\,1^)H
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MM-)T6YN#:M<Z@B3F%+8J-C-&"H9I0=PWD\!OH .>NGT>PN;Y;V:W#3KL.=Q
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M<A"V]_,&T9<[<@*PQ\XYKM:* .)C\7WD]W9+$UMB7[+MMY("LURLK[9)$PY
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M?>Z79:C<)>V]](UY*\3+%^ZE1(H3M0M*-N2QX4N3R0#@UHZAXC\00R7CV_V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KW\\EMIUU/$F^2*)W1?4
M@$@4 6**\YFGU&*UO;I=3FE2Q\/VES;@.X+REI&W,=V&+&( Y7D$#CG=Z-0
M445P:^,I8/#VGFWNK6XO))WAN9)9$80$>80'!= "=F!EAWZ]* .\HKBY?%U_
M'->0M_9T<\=K%/''YJ.HSY6_<_F  @R$*I"AOE(;DX6#QC/<WUFD3VC)*;91
M T;)/<+*H+2H-QVHN3D8;[C<T =G17,0:YJA\#P:U*MH;NY2&2.-48(@D*
M\DDC<>>/IZT5\5:G:^>=0-D(DCO )(H'X:"1$#$%^C;\XR,8^]CH =K17$6G
MC/4)X;#-M;O)?3RVL#H/E,J3;23M9ACRMSX#'_5MR>*TM;UW4=.O-3^S0P26
M^GZ<MVR,I+R,QE  .0 !Y8).#W^H .EHK@KSQQ>V6EQ7#FQ>9GD*A-C+/&GE
MYP1,0C?/C +GC.WKBU-XON8[N\M6GL(6BO5@\]AOAMXV,F'D82<D^7MVG80S
M8Y&"0#LZ*XJW\6:K.T$@AM! %LS+\C$R^?<O!N0[OE7"AQD'(./>L^Y\975Z
M+I(KRV@BM[JS9;DKL55>9U99 )"< )R"4)SR!UH ]%HK@H/%EY&\VK7)1K.&
MVA-QLW>7Y7VB>-IXQDX!55?O\H[\&M?5/$.HZ5X;L-3FLX_.GPLT.#^[=T;R
MUZ]3)Y:'_>H Z:BN D\5:KJ&EFYMXTMIECN(TPK-B:.WW/\ +G#;9=R '^Y4
M]MKFIKJXN%O;6\LY$L(Y-BMM8RNZEH\,0N#@GKG':@#N**\_TSQ/JUEHEJEY
M+:N7MK61;N96Q$))&0M*2WS8P#G*\G'O3O\ A*KX.;TRVZJ8DA\UMWV8 W;1
M>?C=]TJ WWNA'S8YH [ZBN.L->NK?P3_ &D]S!-*^HS1?:I"3"B-=N@?KG8J
MD$#/0 9 YI1XJN?[7AM4N-.G4RV\0CC!\RZ609::+YCA%R3T;[C<T =A17!Q
M^,=671_MER-.1GLK2]4XVA$F\S<N'D =@(\CYESD^G+[CQK?K<ZIY-M;&*SM
MY9%24A)&VP"57VE]Y!)QC9P.=W!% '<T5QKZ[JZZK96L]W8P*NJBTG<0';,C
M6OFJHW/\IW';G/) /JIEUC7[_2M=U-/M5J;:*RM988)8\%"\SH\I;=DH@"LW
M'3'(Y) .MHKFH?$<G_"-7^HS36S?9IFA2ZAC)AF&0 X!?IEL'Y\ J?F JNOB
MJY;P0-;;[)'-]K%L7?\ U0'VKR2YPQXQ\W#$>Y'- '6T5Q<'BO59XFEBBM+A
M(+:[N&:%&/VKR7**(OF.-W7)W>V<YJ%O&=THAC_M#1C%)=I!_:05OLZAH))"
M,;^6!11]X<..AH [JBN(L_&=[<S6'F1VD#S"UW63AO.D$J@M(AR,(F3G*GA&
MR155_'>HBPMVC2Q:Y=IED<LBP*Z+&PC5S,%;=YF0X8G"GY,@@ 'H-%<9#K]W
M?>,K2S:YMXHX[B>)[)"?- 6/AI/FP0<Y' [<FDN_&%S'KNHZ?;&S<06\SJ9L
M1;)$,8PQ,G(/F'DA <#!(YH [2BN#O?&<[6,I26W9)-*EN(O+7;(TJI(QR!(
M6C7Y!A@&![/TRL_C/4%U#5H;?[ 4L(I2(9/]864H%S\^2#N8GY1C Y.0: .[
MHKB+_P 4ZU9Q7<:I8//91WDLKF)PL@A6)P%7=E21)C))QC//2FZAXNU;3S+;
M/%9&XCNFA^T$!(3B".55^>1<$^9C.[^ G'8 '<T5QT_B+66NYXHTM(HVG>TB
M 1I'206GV@.3NPPSE< <\'/:K \07$7A+1[]KVRDEO#$DM\R8@BW DLP#>HV
M_>'S$=.E '4T5S&@:]J.LZ@B.MK';1VB32,J,3,6DF160YP$(B#C.>&_&J[>
M+Y+?4+R&YDLUCM[V.%V4C9%$[NH9I Y ;*@$,%(.1@C!H Z^BO/(_&%XVK17
M*7-ILN;:TV6;EB9MUS-&3$-W#;=I)P>@Z#D2V'BC4HKRQTX+%)YC[FDN9%#2
MAKF1"%+.IRBJ#@*^<J/ER#0!WU%<%8Z_J[O8"ZU>Q=9/MT<ZK;["TD;@)'G?
M\KXR?IV/6IK/Q3J06WD>*W:T#1P,I#F4EK,3[MV3WXZ$G/MR =O17&:5XFO-
M6\'ZSJDDEHY@@=H1;':1B$.=V)&(.XD#D'"Y[BK>CR7KWGB6YGNC((Y4CMT&
M\"-?LT;\ L1U?J #G//(  .HHK@6\;3QZ+HAT^:SO)I[(O--)/'M,R+'^Z+&
M10K-O)[D8^Z>UF^\875J=67S;!7LYU&,JP6(EQG/F@,_R?<.PC!QNXR =K17
M#S^-=02[U3R;*&6*SAE=82RI,VV(.K;2^XAB<8V# (.3TJZNO7ESX+U?49/(
M:2W23RGMI5PX"!@?DD?:<DC&XGC/&<4 =716'HVM2ZAJ^JV,SP%K23"+!A@$
M+,!N<,?F^7E2%*D'@C!K$TCQ-J<T6ELR6_V9XK)90P=I6::/)(8MV..H)//2
M@#MZ*X;Q!JLUMKVI)!JDD5]#;VS6%DL@Q<.S/E?+/W@V "1R!SD8S5?4?$^K
MZA9:Y;0&"T\A9HU8,/.BV3",'"R;_F4E@VU-O&-V0: /0:*X6Y\87.G7]_80
M^1<K8V,TGS*0RO$(_O9D9V!WDY('3@MUJ'6/$][<_P!HW&D7<8%I;WPMY(OW
MB2%(875B,X8@LP';V/.0#T"BN9\0^(Y-'\/6UY#=VDTTW"2B,&*4A&?C,B@
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M:45P3^+[^/[3>I<6TT TR.XAMC!Y;,_F2([@^8?E7 )Y(Q@@@')K:YXNU/\
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MSBBB@!,#T%+@9SCFBB@!,#TI:**   #H,4FT<<#BEHH ,#TI,#C@<=/:EHH
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MOBK&EZ9XSLKS2K-3=V>GJY8B%%=<M=RM()/F& 8RF#SC)(Y% 'JS,J*68A5
MR23@ 4*RNH92&4C((.017D%IX<\16UMIH>+69)(8-3MI4DE1T+N5,1()YC8
M_B.U69U\9:/92ZFUQ>Q06B[?L^(S$D*Z?N+[0.HG4#^F": /5Z*X/X::Q<ZE
MIEP;JYN[R8W)5F=UDC@ C0A1("0V<D\="<'&*[R@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ I" >H![TM% "8&<X&>F:6BB@ HHHH *
M*** "BBB@!-JE@VT;AT..:6BB@ HHHH **** "BBB@ HHHH **** $55084
M#T I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMBVGWLWEN=Q:2)E"LN">""#M[9(/2I8_$FH_:+>%!;SW%Q#9X.\B)6E\_+#
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M^#[#>"V9NFD @^T+\K, -XSC@GKS@?E21"RM<I"+>'>Q8JFU=QYR>.IX/Y4
M<>-<UG5VT51'%:)/J(1VCFR)H_LTDH&5.0,K^.!V)%0Z-XGU:&WTNVDMQ>7%
MS#'=SR--C(DD*X3<>-H!.!Q]T #.:[6&.Q@6(0I;1K(Q>,(%&YB.2,=3@]:B
MNI=*@B6:Y:T5+9E"LX7]TS$ 8],G% '.'Q/J-S!97%N^G0QSWRPM&TA9XXR9
M%PX_A;*#\<CMDOMO%5PMY;6+6_F2WEQ+';,S\N([B1)LX QLC56'KG';-=*\
M%@B,9(K95G<%BRJ!(W8GU-5H=3T^6[OHHU&=-/[Z38,(S*'('?.&!/U]<T 9
MWA?Q%>^(;62XDL4MXV@CF@/F _?W?(P!R",#)XSDC'%8]KX_EU%GMXK#RI##
MY@;S.0%B9INW6.15C/NPKIM)U;1KV*XN+ I$N5>8R0- QW#*L0X!((/![U>V
MV:2;<0*Y#<< X/+?GP30!QAU[6IUE2.:W#)>V4<*EB&*R)&S;R!R#N/0>W%3
M_P#":W.U2;6V5HDC:=&E.Z4M.\)$7')!C)Y_O*.,YKJ+:73KNVCU"W-O)"\:
MLLZ@8*CD<^@_2G[+%W@<K;LX):%L*3D\DK]>>E '):CXSN?L-RMB+5+N*&[D
M;>^[R_)N%B&X>X+'GTK:U/4;ZVU'0(HI;417D[1W!;.&_=,P"'_@)Q^%3PWN
ME3WNI0+'$&MF$=U*R*%+,JG:3WX*Y_ =N+Q2U8QP%828\-'&0/EQT(';'% '
M#Z=XPU2U\/V?VRWBN+F2TLI(Y1(3N\XLF7SCGY,\'DL!GN=N\\1W=IX=L;Y[
M!5N[J98/+,@9(V)/S$@X(^7@9') XJ\-3T6=X[57MI$G$D0P 4_=,%9#VX9L
M8J^8K1XS9&.!D"#,! (V_P"[Z4 <HWC.[CNX+6?3XHY9+(W;?OMP0A)"8\C@
ML2F5]5#GC;R6?B^_O9+6W@M["2:YGB19(YV:)5>"27!(&2P$>,=]RGC-=-):
MV$\4EFT<.UD(:-< A<;>W3CC-):Q:=:6L2VXMTA4_(5(P3]W.>YYQGKS0!S,
M/C#4KF"]FATJ/RXV98BTR@C;-Y;!ESDG&6P,<@KUP3I:3XD.I:NMJ1"()K1;
MFV=,DS*5C);_ &<>8!M8 ]#SGBU87.CZQ9_:XH(#%>' ,L:@W '0X_B'<9JZ
M#8PS/,#;I+@([C:#QT!/]* .5'CF8ZU_97V!?/\ .-MNWG'G";;MZ?\ /']]
M_NU#?^*-7&BR7\:002M87UQ JL74>3MP7!')ZGC@9QS79%K-<S$P#$G+G'#X
MV]?7''KVIP%MO$($.\*0$XR <9X].E ')WGBC4M.N=2,HL[B.%+,0I$2/FF?
M86)/503G\ ,BG-XLU-!&TFG6Z!$22X#39.&G:+Y<9'(&_D\=#ZCI!'IQC7"6
MNQE\A<!<$?W![>U2>59VZQQ>7!&IPB+@ ''( ']* ,77?$ITG5[*R1(I3-+
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M ^]P1W[.+SMTOF^7MW_NMF<[<#[V>^<_ABI** "BBB@ HHHH **** "BBB@
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M898$D8YX&"3PKI\BNA><1RQW,4J!QB1)W+N#QD?,21C!'O0!+<^([*VU.WL
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MYSEMV>AR*E7PCIZVK0B6ZW,#^],@+AC,9]W(QG><\C';% %W4M=L=*6,W33
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M59ZA""(KJ!)D!Z@,H(S^= %JBBLM==M5CU"6XW0Q65R+9FP6+L50C  R23(
M ,DF@#4HK)B\2Z5,RK'<.28WE;]Q(/+52RL7^7Y,%&&&P<J1UILOBG2(+:&X
MEGF2.6-I06M905C7&78;<J@R/F; ]Z -BBLAO$%L\[I;*\L5O,T=[,4=$@"H
M[$[BN&P5 (!XW ^F;']LV(TK^TVDE2U.,,\#JS9(  0C<220  .<C&<T 7Z*
MR3XDTM;B&!YIDDEV ![:1=A=BJ!R5PA8C #8)-11^+=%EBDD2ZD*IL_Y=I<O
MO;8NP;<OEACY<\T ;=%94GB/2H;EK>2X=)%!+;H7 4B/S-I.W ;9\VW.[':J
MW_"7Z4[6HA-U+]HN1;#;:2 JQC,@)!4':5'!QC\ < &]163=>(K"RU.XL;GS
MHS!;"Z>4PL8PA+#&X#&?EZ=^@R:L6NKV=Y:3W,#3,D#%94,$BR(P .#&5W9P
M00,<@C'6@"]16)+XMT6&&.62YE57$IP;:7*"-@LA<;<H%+#); &<]*O0:O8W
M-RMM#.&F8R@)M(/[I@CYXXP6'UR,9% %VBLF7Q)I<#SQRRSI) R*R-:RAF+L
M478-N7!88RN:)_$-DGGK&S-);O$DH>*1%0N4P"VTC=B13MZ\\XZ@ UJ*Q&\6
MZ*K3J;F7]P5#$6LI!+2&-=IV_/EP5&W/2DE\7Z'#'%(]U(%D7<,6TI*C?Y?S
M +\GSC;AL8/% &Y16,?%6CK#%*;IPLA<<V\@*;&V,7&W* -P2V!4-WXQT>TM
M[Z3S+B5K*.621([:3+")MD@0D -M8@'!XSS@<T ;]%4+O6;*QMX)KAI@+C_5
M1K;R/(W&[_5JI88 YXX[TVRUS3M2NFM[.<SNL2S%DC<IM8!E._&WD,"!G/Y&
M@#1HK-M]>TZZ$1BG<K-(T43-"ZB1E4L=I(&1A3R...M4;3Q=IUWJ+6H9U5S%
M]FE\MRDHDC$BY;;A203@$Y.* .@HK T_Q;IUY9V$DK/%<75O',8DB>0(SQ^8
M$WA<;L9P.IXXY%5X_'&GSV*7,4%V@DTQM24SV\B(L8!.&8*<=.H!]LY&0#IZ
M*R'\3Z/'<W,#W3(]LLC2EH7"#RP"X#;=I(!!P"3BI(_$&FR:;<:@)95M[>0Q
MRF2WD1E8$#&QE#$Y(' YH TZ*PU\468ULZ=,LT6Z.!XI'AD )E+@*WR_NSE,
M#<1DG%.E\2VOVB*"W25Y6N8X9$EB>%D#AL, RC<#L.".#@\\4 ;5%8L'B2T_
ML#2M4O%DA_M&*-HX8HWF;>T9DV@(I)P W;M3QXGT=I($2Z9_/6-HW2%V3$@R
M@+!=JENP)!.1QR* ->BLFS\1V%WH":R?/@M6QQ- RODD  +C+$D@#&<D\4I\
M2:6MQ# \TR22[  ]M(NPNQ5 Y*X0L1@!L$F@#5HK$C\6Z++%)(EU(539_P N
MTN7WML78-N7RPQ\N>:0^)[1KJXMDBG5[>>"%S-#(BDR[<;3M.3\PXXY]!S0!
MN45AVGBS2KK31?,\UO'Y$UP5G@=&$<1 =L8Z#<O3KGCH:<OBG32]VCBZC:VN
MC:8-K(3))MW?( I+\ GCL,],&@#:HK/N-:L+;2XM2:21[.5!(LL,+RY0KN#8
M0$@8YR>*==ZO960MS+([&X_U2PQ/*S #).$!.!D9/09'K0!>HK'?Q5HT;7 >
M[91 KL[&&3:0C!7VMMP^UB =I.#3X/$>F7,L$44LS2SNZ+']FE#@H5#;E*Y0
M LO+8'S#UH U:*Q1XLT4Q/(+J0JI0#%O(2^\E4*#;EP2" 5R#3[+Q)8:AJ4=
ME:_:':2W%PLGD.$V[BN"2/E8%3D''IUH UZ*Q$\5::PN-XNT:&Z:T"?9)&:1
MU!)V*JDL, GCH!S5R;6K&'2XM3\R26SE02))!"\N5(W!L("<8[XH OT5COXI
MT9+EH#=.749)6"1E_P!5YN P7!.SY@ <D=JLG6M.%K=W7VI3!9H'GD )" H'
M].?E(/&>HH OT5G?V[IX!WS/&0L3%9(71@)',:9! (RP(_7I6=9^,M,G@F:Y
M:2WEBDE4H89#O"3>5E#M^?YBHPN<%@* .BHK,/B'3%NX[5YW260*0'A=0I92
MP#,1A&(!.UB#[5'9^)](OW1(+ERSF,*'@D0MO#%"-RC((1B#TXH UZ*R5\2Z
M0\MO&MT6,X0H1$Y4;V*IN;&%W,"!N(R>E5)/&NC"S-S"]U.@>!<1VDNXB9]B
M, 5&Y<YY&>F.N 0#H:*I7VJVFFB$W32HLK!0X@=E4D@#<0"$Y(Y;%5SXDTP*
M6$LS#[0ULNRVE;?(-V53"_-C8V2N0,&@#5HK$E\4Z;:EENI2K><\0$,4DI^5
MU3)VK\OS,HYXR>II3XKT56N0UVZ_9O,,A:"0#]V_EOM.W#[7(!VYP2/6@#:H
MK$A\6Z+,9<74B>4DDC^=;2Q[1&0''S*/F&1E>O(XI)O%VBV\7F2W,RC]X64V
MLN] @4N67;E0 ZG) X(/2@#<HK.L=:M=0N]2MXUF1M/F$4KRQ,B$E%?*L1@C
M##^?0@FJ/%VBM 91<S$9C"K]EEWOOSL*KMW,&VM@@$'!H VZ*IRZG:PW\-D[
MR?:)4,BHL3MA1W8@84?7%9MYXLT^WBM)8&:X6X,#XCC<L(IM^QPH4DYV-\H&
M: -ZBL&/Q9I[W,HW,;86\$L<BH[/(TKRKL$87=D>4<C&>3D#%17'C;2H%NW5
M+R:.VM(KLO%:NP9'9E ''4%3D''?T; !T=%8DOBG3;4S?:7D0)+Y:JD$KR']
MTLIR@3((5LD<X'7!R!/%XATN?4H["*X>2>3[NR%RA^028WXV@[2#C.<$>M &
MI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !4=Q!'=6TMO*,QRH48>H
M(P:DHH P;'0+BQCBN([^07HM(X94&WR9W1"JNP*EAU[$=!UQ6EI5@FE:/9:=
M&Q=+6!(%8]2%4#/Z5<HH *P+OPG:WOV])KRZ-O>S)</;D1%$E785<90GCRUX
M)*GG(K?HH P1X5M5DL7%S,IL@XBV10IRV[)^6,?WN@PIP,@]ZX\#Z>MJ;=+N
M\1'CEAF"&-1-'(<LA 3"C_<"D9//-=-10!3MM-BL[>YA@>11/))*6X)5G.3C
MC'';(-4(O#%G#H3:2DTXB,PG61=BLD@<2*R@*$&&4'&W''(.36W10!AOX8@E
MNUN)KZ]D):%YD8QA9WB;>C-A!@@X^[M!P,@TUO"5B;/[,LTZI]G%L25CDR@8
MMR'0J>3Z5O44 <Y%X*TR&XDFC>;,L(BDWK&[-B(1;M[(7!V@=& R.G)S9;PU
M:>='-'/<Q2QRQ2HZE208T,8ZJ1@JQ!^O&*VJ* ,G4O#]MJEQ+-+-<)YMO]GD
M6-E (#%E;D$AE))&#]0:0>'H#I>H64MU=2MJ#%KBX8J)&8JJ9X4*,*JC&W''
M(.3G7HH YR+P5ID5C+:"2XV2V]S;L1L7Y9RI<@*H .4&,# YXJWI^AK9>(=6
MU8L"UZ8PB DA J@,?8L0,X_NCO6Q10!S*>"-/C-^5N;C=>C;*7CA?Y=Y?!W1
MG=RQY;<<8YXJ7_A#[$SB5[BZ<K#% H)3.V-D9<MMW.<QCEB<9;&,UT-% '':
M-X-GLY[C[9<1F"2=+C$(7<\B3>:K$[ 0,\;26ZGG/)U?^$4T_$OSW'[UBS?,
M.IG,_I_?8_A^=;E% '/3^#=-FNX[K=()4DE<EDBD#>9)YC##HV!NZ$8/O4LW
MA33YX)86>X"RQ7D1(89 N9!))CCJ& QZ#KFMRB@#,O=&%ZEFQOKN&ZM<[+J+
MRQ(<KM;(*E>>OW>HXQ3M)T6ST6-X[,.L;+&@5FR%"(J*!^"CK6C10!SH\'VJ
MLTB7UY'.UR;GSH_*4ABA0C 3;RK')QN/7/ I;;P?96LUNT=U>&&'R2+=F38S
M1($1C\N<@ '@@$]JZ&B@#GM/\':;IE[;W5LTFZ&*.+#I$V_9&(U8L4W [0/N
MD#CIUR@\'6?]G1V)O;TPI82:<<F/+0L, $[.JCH1CWS7144 <YJ_A."_TZ]A
M@E=)YQ<,I<Y4-*FUL\=,?Y/2I-)T&>V\/W&F74Z*LKL5$*1ML0XRIS&%<D[B
M24_BQSC-;]% &%;^%+"VA2)9+A@@M@"SC/[ARZ=O4G('&.!BH-.\%:;IDWFQ
M37+N'B?+E 28]^W)506/[QLDY8\9-=)10!F0:':V]IH]LC2[-)V_9R6&3B)H
MANXY^5STQSBJ-MX/L;3[,D5S=BW@%OFW+*4E:$ 1NWRYR-J]" =HXKH:* ,<
M>';<:$-)^TW)A219(7RN^$JX=-IVX.UE!&X'ISFHW\,02W:W$U]>R$M"\R,8
MPL[Q-OC9L(,$''W=H. "#6Y10!@OX2L39_9EFG5/LXMB2L<F4#%N0Z%3R?2G
M1>%K.(@+<W9C!MVV,X8%H=NQB2-Q)"J#SS]>:W** .;N?!=G<V0M#?WZ1"*>
M#Y&C!\F8J7CY3IE1@_>]ZEOO"-C?O,\LT_SW0O$4K&ZQ2>68R0&0@@J>0V>>
M1BM^B@#$U;PQ9:SI=MI]Q)*D-N,+Y:QX(V%.5*E>AXP!@],5/<Z'%.;%XKJY
MMIK-#''+"4W%" &4[E(P=JGIGC@BM2B@#GF\'V+F427-V\3"41Q%EVP^:X=]
MORYY8#[Q.!P,"IKCPQ9W%TD[3SJ4O/MNT;.9/E[E2RCY /E(R"0<@UMT4 <]
MI_@W3=-A2&W:011RQR1KLB4IY9)5=RH&8?[Q)XZ]:MV.@6VGWD=S;SW"E4>-
MD)4JX9R_/&>&8XP1UYS6M10!AR^&87N'GBO[VWE-R;J-HS&?*=D*,%W(<A@>
M0V>>F*2^\)Z??:)9:27FCM;,!8PNUL@(4PP=6!X)YQG/(-;M% &-;>&K&U>)
MD>8F*X2X7<P.66 0#/'38/S_ "J/0_#B:1X<;2O-(:0OOD0!L!N% W @A4VH
M,@\*.*W:* .:3P58QI;QQWEZD<6P.BL@$H28S(&&S@!F. FT8..@&'KX/M%,
M_P#IMVXD69$601.L2RR"20*&0@AF4?>W8 P,5T5% '.6W@K2[6ZCG0RL5A2%
MUD6-_,"IL!+%-P.W'W2HXZ5#;^#?)N9&.J7C(L=LMM,3&98C#Y@_N;2-LF.0
M3USSS74T4 <[:^"]-L[RTNH7E,EO&D>9$BD+A"Q4DLA(.6/*E>WH*>?"5B+.
M.WCGNH_+@MX8Y%92RB"3S(VY4C.[KD8/I6_10!B:WX8L]>GMI;N:<&W&%";"
M#\RMGYE.#E1RN#U%5[KP;97:7ZRW=S_ITBO-M2$=-V,?N\ _-]_[_P J_-P*
MZ.B@#CM6\&S7&J6]Y87$:&-Y),S@/Y<CR*Y8 HP8#:,#Y3P/FZ8U9?"FGRH%
M9[C ^T=&'_+>99G[?WD&/;UZUN44 85WX2TV]CFCG,S)-Y^X;A_RVQN[=MHQ
M_6FKX1L!:M TLI#6T]L65(H\K-L#'"(HS\BX./KFM^B@#/M]'@MY]0<22O'?
ME6EA<C:"(UC)&!GE47.2>G&.:HVGA.SM9(9&NKNXD@\D1O,RY5(@X1/E49 W
MMR>3GDUO44 9M_HL&HZC97DTLH:T;?&BA "?][;N'N P![YK+@\%6EO$B1ZC
MJ >)8$AD+1EHEAW^6H^3! \QNH.>]=-10!S4G@C2Y+<1,\Y8+$/,;8YW(\C[
MR&4J23-)G(QSP!5B3PK:2131_:+A$GLELI%C$:AE4L5; 3 8%VZ8'/(/%;M%
M &./#EH;I[EYKB29Y#([,5&YC"L).  /NH#QWSVXK&L?!US8>();NWO%CMG4
M1^8 K2A! L0493Y2"BMN#8.,;>:[&B@!%&U0"Q8@8R>II:** "BBB@ HHHH
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M*R7=M.2Y.-L<R2,/KA3CWK+T'PU)HVH"Y_< R0RK<&/.Z5S+O0GCG"DCGIG
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M>]1R>'-2N_$R:O="#[J$)'=<PE58%58P[BISDX*]3P<<@'745Q-EX3U&U&E
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MVKR-,R20D,YWJH0AOOC@D=* -VBN!A\%:A#HB6Z):?:TF252\ZM#N5"N\QB
M!LYY!&3P=X(!J>]\(ZE.^H>2;2.">\2Y$3.K&;#2%@[&(\?,K!6#X*X! Q@
M[>H;.[AO[*"\MWWP3QK+&Q!&589!P>1P:Y&V\'W<&LZ?=/*'@MH8$4&X&^$I
MNR%;RLLIR.A3(X(Q6M'HT\/BW^TH8K:.U-OY+9(9S@#:%&S* <Y <@_W<\T
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MI 0?D8KD@@$$D?=QG/%-E\5Z+# LTEVR@^9E3!)O79C?N7;N7:&!.0, YZ4
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M.W^>3*MA!O?<0.H'/7-^ZU3Q-;B]G@1[C*WH@@-MPIC8")L@98D%N/XN,#U
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M">#4E?4AJ<5U9V\YO[JU -I+',38M]G)!\TGRV&\!3D9)8\Y&* .B7PS%_:
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M^7RS@%P1G;CC&03FM>;4==CMM2N+B29=DT%O#';6WRKNBB9Y,LC,5#,XSM.
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M$$4D4#90&,-)'("/EY*M$N,Y[YS3CX1M)$N#-=7,LUS#<133$J"_G*BL<!<
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M 'T4UY$C +NJ@D*-QQDGH*=0 4444 %%%% !13$FCDDDC1PSQ$!P/X21D9_
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MW)\\T<)E88';"L,XQD=,8-)-XPD@,:MHMT6,=O(ZB6/*>?*T40/S8)+*,XX
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MK\H\M@)"?3'S$>NP^V0#&'AO7VMM2,J1B2?R'CACG_=&53*68J1RAW1YR=Q
MSD$"M;3-#U.#Q3+J%[/(RLQ96CF'EE"BKY94KNP&!(YQWZDBGR>-;87J6\-C
M=3[G8%HUW802F+> .H+*Q^BD^@))XSA@MVN;C3[B* O<1P,64F:2$D;  >"V
MU]N?[O:@"I>>&[^]OK]&1#9W%W;3DR3'>P2968 C&%VKP#R"2,XJ%_#NN+<:
M:D1B$%I=!TD$QWI$+IF*<YX\G:H Z\@G %;>K>('TC5(8IK7-E]@N;V>8/\
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MGBJ^N$M[:SL9;6ZFEM2=[(Q$$Q?:PZC=^[8$=O>@"*X\*:GOOY["86EW=-=
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M0"5Z<#BK(TVS7R\6\8\N5YTX^[(^[<WU.]OS-6J* *MMIUG:+MM[:.,&)(<
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M10!FQ:!I</D>79HH@<R1C)P&+%BQ&>3N).3DY.:TJ** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[9VK_3+/5(XX[R$2K$_F)\Q4JV"N0001PQ'XFH1H6FJ\SK;;3.,2;9& /3G
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MB\;6HA6:]LY[.+Y&9Y&5@B/$TBLQ4G&=A7'KCUJUK'B>+1=%AU&ZM7&^(S/
M9%$B@+N8 9^8@>G'N*L7_AS3M0L6LW@5(7:#>%4?.L3AE4Y[<8^A-6-2T?3]
M7C5+^U2=5#* V>C## XZ@]QT.!0!F77BN.V?4%-E,6LW12I(#,K$#S,=1&,Y
MW<C@^E4[[QO!IZW3M";C;-LB2-E7<!;QRX5MQ#L?,P .I.!TR=R70M-FDFD>
MVS)-C>XD8'&<X!!^49Z@8S6=JG@[3M1$0BS9[-P_<(N.41,@$'#!8U (Z8H
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M]#;L+?<UN'$;.[,P#_>!).2#@9!ST'H*2#0],MDC6*SC41B-4ZG:(V9D'/\
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M)&! R#A2#\O(&<8SCF@##OO&]OI\5Q,T?VA1(JPI&Z ,/(6; ?=AR<X&.I(
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M?%MQ)>BW33FC"V]V\[.ZL8G@:,< '# ^8#U'4=.:EB\71%XPUI,T.]8&N!M
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M*"=BT@21E&2VXD8/RDMR2,9--_X1W2,%380E/(^SA""5$> -H7H.%4<>@]*
M,>7QS!$D(;3+XS.)&:)8R2%0J"5_O9W#'KST/%6-?\13Z'JB?Z*\]DEA/=W'
MEE0R+&T>6Y(S@,W ZUHMH.FLL :W),&[RW,C%QN(+ MG)!P,@G!P/2GW^BZ;
MJDL4M]9QSO$"JEO[I()7W!(&0>#@4 5[#7X-0U.73XX9%GA\WS@V/W>UPJY_
MWP=R^PK /C+4(XK:\FTMO)\B^EGABD4L%@=!N!)'8L,=SCMS746>DV]GJ>HZ
MA&,W%^R-*Q '"(%4<?B>?4^U,&A:6JRJ+./;*)0X.2")2#(/8,0"0* ,X^)T
MAU![>2)FC-[]F$Q CCCRD; %B3DGS..F<$=0,W9-5:#7+JUE""U@L5NBP!W9
M+.#^&%':II=$TV:0/):(3YHF/) +@* 2,X/W$Z_W13KC2;&ZOH[V:W#7,:A5
M?<1\H.<'!P1DG@^M &#'XXADTI[[^S[B/!78DK*GF!D+C:3U8!3E1G'TYJ67
MQK9PI<2/;3K'';QSQ[L!YP^S;L7N,R*I/0'(..,Z/_"-:1]E6U^Q*8$;>B%V
MPGRE<+SP-I(P.,$C&#3CX>TEBVZQC8-#Y!#9("848 / ^ZO3^Z/2@"&+Q%&^
MA-J<EI/$$E$31.,'.\)D9ZKR"#Z52U#QE#8^<5T^XG$"74DI1D&V.W*!VY//
MWQ@#]*VCI=D=-?3WA\RU<$,DC%]V>N23G\<U"GA_28[=H%L(A$\<L3+C.Y9<
M&0'UW%1GUQ0!B7/C+^S;J[@GM9KJ5;B811VZ9;RHTB+?5LR  =\]JMW/BR.W
M.H V4VZS=%*L0K%6./,(ZB,==W(P#Z&M*XT/3;E]\MJN_P PR;U)5MQ #<@@
M\A1D=#@4DNA:;-)/(]MF2?&]Q(P/7. 0?E&<\#&: (M0UV*PAL)3$7BO'51*
M' CC!&02_3GH.Q/>J<WB^TAC#&VG8M]I"*N,LT-PL&WK_$[C'MUK5GTBPN8(
M();9##!@1QC(4 8P,#@C@<'CBH#X;T8RW$ITZ O<JZRDC.X.P9A[98!CCOSU
MH RYO$MY9ZXUO=:=(MMY-KO"NA,+RSR19)S\P)"'CH,]^*LZMXCETG4;M)+(
MR6=KIKWSRHXW';G*@'Z?K6@FBZ=&FQ;1,8C!+$DG8Y=<D\G#$M]33[S2;"_D
M,EU;)*QA> DY^:-QAE/J#[T 9C^)U@U6QTZYLWBGNL*5$J.T3$.0& /0A#SZ
MGC/)%.'QQ')IIO&TRYB!@M[D!W3 AFW;79@2% V-G/3CUXW9='T^;44U"2U1
MKI,%9#G@@$ XZ9 8C/7!(J-] TM[<0&S01"&. *A*_NTW;%R#T&]N/<T 8+>
M++BTU+4OM,#R0B]CLK**,J0Y-N)BQ(R>A)].@QU-;&E:_P#VM>&&*PN8HUMX
MIGDFPI4R+N"%<YW 9SV'O5F71--FB>-[2,*\BS'9E2'5 @8$8((4!>.W%6+>
MRM[5F:")49E56(ZD*,+GZ"@#%LO$JS7UO9RQ-F>:XC69@(T)CED3:N2=S83.
M,YQSCJ [4/%$.G7=_!+:3$VD(F W*K3CY?\ 5@D9 W $YP",''&= :+IRW$4
MXM5$D3M(G)P&9F8MC.,Y9CGW-0:IX<T[5H[H3Q?O+F+RGDSD[3C( / SM7/'
M.!0!E77CB&T+0R:9=M>1M*);>/#L!&(V)!'WB1+'@=\XXQ5N;Q&S1S2PVLB6
M\5Y%:"X;:0[F9(F&W<".6(S[$XZ9N?\ ".:2(8XA9JHC9G5E9@V6^]ELY.<#
M.3S@>E2'0],-S+<&SC\V5UD<\X+*RL&QTSE%.>^T9H YNR\67<*27&I1MAGO
MC'!&JDD0W"0HH;(Y);'/4DG(  K6NO$RV-Y8VMW9M'-<NB,@F1FC+N44X!R5
M)'7C\P0+\FBZ;+&T<EE"R,LJE2N01*P>0?\  F )]Q40\.Z2)89?L2&2';L8
ML2<JQ=2<GDABQ!.<%CZF@#!TSQ;,'C?4MOV=[:T9I% 41O+).FYO8F.-?JU;
M+Z_C3]+N(K&>2?4L>3;EE5AF,R?,2<#"J?QP*6^\,Z9?:7<:>;=(X;B)()-B
MC)C1BP7GW9OIN-7;[3;/4H4BNX%D2-MZ<D%6P1D$<C@D<=B1WH Q;GQA#:F=
MY+&X%O&T\2R[E^>6*-I'7&<CA' /3*GV)&\7)'&3/IT\#)<K;R>8Z;8PT8D5
MF<$@ @@<_P 7&>AK2/A[26GFF-A"7F1D?C@AEVMQT!*@ D<D4^XT33;K>)K1
M&#L&<9(#D*%^8 \C  P>.* ,8^-[;??;-/O)([4R*'51B1HY1$RY) !+'C)Y
M )XQ3U\5RM?V\+:<T4>+G[46D!,)A*YQC[P(;-:PT/30\[?9%_?G=(N3M8E@
MQ.W. 20"2!R>M/;2-/:9)C:IYB2-*&&0=S##'WS@9'3@4 8EIXS6]A@,.E7A
MFN)5C@B;:H<-&TF=Q..%1LCUQV.:6W\0WW_"+^'-0^R+<7&I"W$R[@FTR)N)
M'X]JTAX;T@6BVOV)?(5PZ(6;Y" 0-O/RC!(P,#!(Z&K#:18/IT&GFU06MN$$
M,:_*(]F-NW'3&* *.G^(X]0U)+46DT<<PG-O,Q4B3RG"/P#D<D8SU'ITK,A\
M8R6L=T=0L9C''->;)HRN&C@F*MQG/"<\]=K>V>@MM'T^SO);NWM8XYY-VYQ_
MM'<V!T&3R<8R>342Z!ID4US<06D<5Q<+(KRA<GYSEC@\<G!/K@9Z4 5;O7S_
M &%/J-G&"$NA;H9.0X$PC9A@]/O8^@-+<^)H;?Q ND+:7$SYC$DD:Y$9?.W\
M..3VR.O.+4&A:?!H$&B>2'L884A5&/4+C!)'?@'/K2QZ%IL,\4\=MB6-0@;>
MV2 20&Y^;!8XSG&3B@#+M_&$,\5E(UG)"+F?R'\UU7R&^7"R?W7.\80\G!QG
MC+&\:PI$)3IUT4EC,MKADS.HE2(D<_*<R(<'L>QR!J+X=TE%119J0DOG<NQW
M/\N"V3\V-BXSG&T>@IT?A_28GE9+&(&5@S<'J'W\>@W?-@8&>: *^KZXVDP6
ML\\3*&BEEEA4!B-D3.5#9 _AQGG-6-(U;^U/M2O:2VLMO(J/'(RL?F17!RI(
MZ,/Q!^M6;NPM+]0MU DH 90&'9E*M^8)'XT^&U@MY)9(HE1Y2"Y'\1 "C/X
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MTBV::Z21)W*\N'&'S]1P3UQQ6W10!DGPQHC3W<ITZ$M>(T=P,';(&&&RO3)
M )QDTU?"NA)*DHTV'>B1(&Y)Q$P:///.U@"">>*V** .:U?P-HVJ:=':)"+3
MRRNQX54X"R>9M(8$%2W)%:.AZ%;:%816T,DTS)&(S-.^YW 9F /; +M@ <#C
MM6I10!5&G6:LI%N@*SFX!QTD((+?7!/YU#%H>FPSPS0VJQR0HL:%&*C:N=H(
M!PP&3C.<9-:%% %.ZTJQO?.^T6R2&8(')X)V$LG/8@DD$<@U''H>F1)&B640
M6/;MX[K)Y@/N=_S9]>:T** ,M?#FCK%=Q#3X?+NT:.9""0R$DE0.P)).!@9.
M:EBT7387D>*RA1I)4F8JN,NH"JWX  5?HH P]1\*Z=?6D$$<8MQ (E38@8;(
MPP1"#G*C>U6XM%M5TJUT^<R7,=MM*23.2^Y>C9&.?IVXZ5HT4 9\>AZ;$TA2
MU4"259BNX[0X<.&"YP#O ;CJ>:E;2[%Y6D:VC+L[2$XZLR;"?Q7BK=% %*VT
MBPM+H7,%NJ3"/RE;).U.. "< ?*N<==HSTJ&'P]I,$CR1V,:L[JY/)Y5]ZXY
MX ?Y@!QDFM.B@#+G\.:/<.C2V$3%&9AUY+/YASZ_.2W/0\BK-QI=E=7D-Y-;
MJUQ#PDF2#C.<''49&<'OS5NB@#-M?#^DV0Q;V,48#(PQD[=F=@&>@7)P!P,G
M IK^'-'DFAE>PB+PD,AYX(<NI]\,2PST)..M:E% &<^@Z7(,-91D&-XB.0"C
MDE@?4$DGGU--;P]I+S7,K6,3/<HZ2YSA@_W^.@W8&2.O>M.B@"A/HNG7,IEE
MM59FE$S<D!G 4 L,X/")U_NBENM'L+ZX$]U;++($*#<20 05/&<9PS#/7!([
MU>HH S;KP_I5Z"+BRC?<03U!/R[.W;;P1T(ZU-%I5C!.)XK6-)0VX,!SG8J9
M_P"^44?0"KE% &+?^%=)OHKP-;+')=H\<DB\G#D,^ >!N*@GCDCFHYO!^C3R
MVY>U!BA29?*))#F0IN+'JQPF.3R"0>*WJ* ,N[T"PNY[61HE7[/>"]VA1AY0
MA0$_3(/']T58N]*L;Z42W5LDK>4\)W=&1OO*1T(/H:N44 48=&TZ"PGL4M4-
MO<9\Y'RWFY&T[B<D\ #GL .U1QZ!I44;HMFF'617W$L6#A0^23DYVKGZ5I44
M 9]MH]M:ZQ=:FB_O[B&* \#"I'NP!^+']/2F2>'M*F\\R6BLT[J[L6;=E22N
M#G*X+,0!CJ?4UIT4 92^&=%26WE33H%:V5$BVC 548L@QT(5B2,]#S4JZ'IJ
M3PSI:JDD(PK(Q7C<6 .#\P!)(!S@DUH44 9RZ#IB%"MHHV2/(N&/#/\ ?QST
M/<=/:DDT'37M6@6V6-3@ADX*D1^6&'N$X%:5% &)HWAJUTBPN+/S9+B"=0C1
MN $"A=N H  R.I[TLWA729+#[#';)%;FYBN'51G>8V5E!SGCY5&/3@8K:HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,M4L6LE23R6Y.97+9]=Q.[]:8;72[6VMX"L$<-M*@A5FQMD/"_\  B6^I)H
MY\>-I;BPAGM=(G$DOV*1(Y9$&Z&Y<JK9!.#E6X^E3OXWM5>_V6%Y)':"7YT4
M8=HY!&RC)P#N)QD\X/2M=M!TMK;[.;.,1"*&$!21A(B6C (.1M))%+_8>F^9
M</\ 95_TC/FKN.UB2"3MS@$D D@9- &:/%J#5CIS:;=F9,)-Y8#^7(8_,V\=
M>,#/JP'KANG^*)-2U+38(+']S=P3RR,95+0F-HQM(]?WG(Z@UJ3Z=I@OQ=S(
MB7,_[K/F%?-.T\$9PQVY[$X'M1!H>FVSP/%;!9(&9TDWL6RV-V6)RV<#KGH/
M04 9MUXF>TOKJU2SENY5N_L\<<>U,8MUF.2S<\$\\>F.]3:EXGM=/T"WU<1-
M+#<1B6--ZHY4H7X!/)P.@_EDUHG3+)KAK@VR&9I#*7QR6*"//_?( ^E17.AZ
M9>64%G/:(]O;KMB3) 5=NW'!Z;>".A'6@#(M-?N;KQ#]E4I]E:\:)?EP=GV2
M*4?CN<U4?Q?=6_BF_M+@1?V?:O+O(MW5ECC@24L)"VUVR^-@&<<]N>FBTJQ@
MG$T5M&L@?>& YW;!'G_OE5'T%#Z3I\LADDM(F8RF8EAG+F/RR?Q3Y?I0!AQ>
M,OM$$)ATB\:>:?R8XB57/[HRYW$@8PI!]_;FK>B^('UJ_G2.T*68MH+B&9F&
M7$J[@"O;_P"M5ZVT73[1(EAM\"%R\6YV;82I3C).!M)&.F#3[72;&QF66UMU
MB=8$MQM) \M?NKCIQV/6@#%C\90LKM)8RP*8Y)(&EEC590DJQ-SN^7YF7&>3
MGCGBEM?&=G=?9E%M.LMR4$*'&7/FM$X'/.S;N/\ LD'VHBT'PYI4;VDXC,L[
M!F:5R'.Z8%=N/N_O&7&,?-@]>:OIX=T^*^TZYBA$8T]9O(C4<*TN-S9ZYZ_]
M]'VH QG\9M=211Z?:&247<4;(LB,)(Y%D(*L#CJASSVXS2#QNBSR2M!(89(+
M;R8,#>)G>=7#$'&!Y/;/0XSFM=/#&A+$UNEC$%&QMH8Y3;N"8.<KMRVW&,=N
ME3GP_I)@$ L8E0)'&NS*E5C)*8(Y!!9B".>30!"_B!?[+L+N.RN&FOW$4-LX
M"/O*LQ#9.!@*QS[<9R*H1^,X)98533[K8WD"9R4'DM+,T 4C=R0Z'.,C'-:T
M]GI=W9/9R^7)#:,-P\P[H6 # [@=RM@@YSG!]ZJRQ^&]/L(+B=["UM)%A6*2
M218T81DR1@$D9P26'XF@!^I^(K?3-5M+&6,NUPZ)N5URA=MJDKG.,CK_ #P<
M4+7QG!.B22V%S!$XA=7=D(V22&,,<$X 8#/L0?7&Q/I&FWUY%?RVZ2SJ$*29
M/.TED/!P<$DCTR?4U6O_  ]IEUI-QIYB2"*YMC9EDQD1G/RC/U./>@".X\30
MP:!;:P+64V]P05+$*$0Y(=V/"J0!R?[PSBJNK^*DMM-OVMHW%Q$+E(V8 KOB
MA,F3STK7U"QTZ;31;WJ(MG& -I<HH&-N#@CC!QCH<XJ*3PYH\MS+</81-+*K
M*YYP0R[&XZ#*@ XZX'H* ,:X\8-;O";FVDM!!*_VQ'VN?+%M),"I4D?PCCV(
M]#3I?'-O!I$U_-I]Q'Y3D&)W52X";R4R?F..,#N#VYK3CTG0K/R;=;:W7S9V
M"(WS;I/*92.>O[L,,=E&.E.D\,Z/+:+:R6?F0J20KR.< KM(R3G:1QMZ8[4
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MIUO*]Y97,<D/F!XUVL=R/&I4$'GB56'MGT(J:;QE9PO;?N7:.XNC;JPD3/\
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M4?;!:.YD7RT)17!WYQ@AU ]3QZ9L:?XJCU.ZN8+73[N3RO,V, H$FR38W)(
M.>0">1GTQ5M/#6D)#Y(LQY9D\U@9&.]L*,MD_-PJC!R/E'I3#H^DS27EM#F.
M1V5[A(I",9;>>.B[B#G !.3WYH 9KOB--#<*UE/<*MK->2M$RCRXHMN\\D9/
MSC '7%1-XGS,\46FW#L;PV4'SH!-(%9VQSPH5"<GZ 5;U+P]I^KZC;WE]%YW
MD0R0K$Q^5@[(3GU^X!@\'/(J>?1]/N8&AEME*-,9_E)4B0_Q @Y!Z\CUH R;
M?QC:730Q);7"3S^7Y<;A<_,)-QX./E\F3//88ZBJ<?B^:Y&E_9[9S%+);I=7
M+!553)#YNT+N)'!4\9QG'/)KHH]&TV*6VECLH4>UA:"!E7'EQG&5'MP*A3P[
MI$=S!<)81++ J+$1G"[1M4XZ9"\9ZXXH R;+QO#J%O$]MIEXTEP\:VR-M42A
MU=Q\Q. 0L;$CMQUR*U_#M_/JGAZRO;E=LTT>YUP!@YZ<9%0S:)H=I8>3+ D5
MKYL>P&1@$;.U G/R<M@!<#G%6['2+/396>T0QIY*0)$IPD:(6("CMRQ_3TH
MO456@U"TN93%#<1R2#?\JGGY'*-^3 CZU9H **** "BBB@"&[C::RGB3[SQL
MH^I%<7!X<U;3[.UMXQ<S64?V9KBU6];?*5BD60*S,,#>8FQD [3^/:7<K0V<
M\JXW)&S#/J!FN6MO'4*:=:MJ%E<0WLJ0$1$QJ)/,C=PP._ '[J3@D'Y>G(H
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M;B)(;B18(V=I$"D9$/G8QNR/E[D8SQF@"QJB7][:Z)?Q:?(9H+A;F:T\Q0Z
MPNI7)(!(+COV-9+:-K<VI:I-/-J"+.DHB-O<* $90%09;AU/0X R"=W)K0'B
MQY+RRMHM)NA)->_995D>,&,&!I@W#$'@=,]CWQFY?>(X+'43:-:W$BQM"LTR
M;=D1E?8@.6!//7 . 10!@_V3XD8V[0Y@N#92P,[3$Q0MB7RW5=Y._+1[@=ZX
M'!^49KMX?UXZ9#&LFH!/M#--;_:1O ,04%&\SD!LG!8<G=C-;6F^(KG_ (1B
MXUG4K64;;F15AC5<J@DV#)W$8'5F)&,$]!5I?%%B<920 R11[@59<R1^8#D$
M@C'<9]LT 5M<T:_U&TL8([BX_=02B1EN&B9Y#'A"2I&?FY],\UD7V@Z^FEW%
MI:&6432(P9[QRZ-Y&TL"7'_+09/)QR0I-7[GQ=<(FG7<6D79M;F*6;RR8O,:
M-4#AA\^!P>AY]JU[S7K:S.G$QR.E^P6.3*JBYQC<6(&3G@=3S@4 9.E6NK+X
MK>&ZGE>S@MTNB2YP9Y%$93T*CRW?'K*.F!4-QI6L,NH#R;F29[L2&5;XJ)[?
MS0PB1=WR$1C;T&<'GYB:LZCXN6.PCEL;>9YI&4JC*OS*+E(6'WOO'<<<X]:B
MF\:Q6]QYD\$D,$<4JRPN%\P3+-'$JYW;<$R=<XY!)'- %-?#FKR"W>5<[9$9
M4DGWM'&+U)@A8DY*QKCJ>F 3UID6A>(4@O#-->2RM,AD5;D*EQ&)MS;#NRI*
M97^ <[>F"-?_ (32Q"6#O!,@O)A H:2,,K&7R@=N_++N(Y4$8.:9+XYL(;82
M-;7'F&=X%@+QA\JNX[@7^7CLV#R..: )='TF6S\1W5\UI-%%<64"*7N3)L9"
MV4;+')P5Y&1P>?7&O-'\1/IEY:V\,K"2Z9TDENB)@"CX.5D"X#%<'@X_@R :
MZ^?5((-$EU8K(8([8W)7;ARH7=C![X[&LM/%B2/Y":7?&]\XQ"US$&/[L2;L
M[]N-K#OG)QB@#(OM%UZXCE$_G7,4DN3#'>&(Y-K&@;((^42+(2/]K=@FKNH>
M'M0O=&\/V<-T]G-9C$TT6TF/_1I(^ P(/S,!]/2M+1_$4&N3$6=M<?9Q!%-]
MH<*%/F(KJN,[L[6YXP,=:S-.\9AK>$:C97$4DC';*H38Z>>(BPPQ( +IG..#
MGUH J:?H6M0ZG8O()K>VAMX4CBMY\Q0A8MK1$%LD;N0=I)XR1@5 OA74TT^U
MCF%Q=");":2-KUBS3H7$Y#,W<%.X!QQ722>(X1I5G?PV=S<+>S"*WC38&?.[
M:W+ !2%SG/0BJL?C2PFGO(DAEQ:B7,C/&J$QR"-ADL-OS'C=C(!QF@"YK5K=
MZKH%U;) (YW<!%9P<JL@PV>V0,X]ZI:5H^HVFMB\FFF9)&O?.#7+.NUIE:#"
MDX&$!Z#C)]:+?QKITZV[F*:**:.:0R2,@4>4SJX!W?.048X7/&#T-*/%\9>.
M Z5?B\E:(1VQ,6YED21E;._:!^Z<')R".E &>/"LLNH;)8)5MO[7DO'D6Z8;
MXV@D48PVX89P".,^XINEZ+XACU739]2N;I_*M[<.\<P*AEBVR*X+<Y?)R%.<
MCD8%;Q\10-I6F7L%M<3-J146T"[0Y)1I,')"C"JQ//;C-4](\0SZUX@>*"!X
MM/2PBN,R*NXN[R*5.&.,>61P,9#<],@%>ZT35+OQ7/--<WBV$G$;6\VU4C,1
M1D8;@<[B6R%/)7D8K,GT+Q1<Z?;O>7,[3L[BXBM;C:1B-8T=264=59\9X,G<
MK5L^-KJ-(+N;2+A;?RKZ2:)&C9PMO(B[P=X&,%LCKG&..:V+3Q397NNR:5#'
M,SHS)YORE=R@$C&=PZ]2 ,@^V0#+E\.:G-?3RO<3L)YWC<M=-M-N;39C:#@'
MS0#P,]Z?<:%<3>"-*L#9R^?9R6TCV_VG#'RW4N ^[!X#$9/IT[:$GB:)%GD2
MPNY(8[C[)'(ICQ--Y@C*J"V1ALC) 'RGVSFS^+9Y+F,6L/E)YD,4D<R@NCF\
M6WD&02.A;!'L: (1X?U>S>[N+(,TL_V\M$UTX1C)*&BX##!QNZ8Y)Y&2:-&T
M'4[?4]*O+Z*60V_VR/FXR8DD=&CR-Q! "L,9;&1U R+MOXYL+M7-M:W4I+HD
M 79^^+,5&#NPO3.&P<?E4C>)K@7ES!)I\MJL$]I%ODV29,S("I"OP1NQG) Q
MGGH0"E?^&9[K5-2(@D\J[O;2X\U;DJ-D93>N V0?D)X[$<U N@Z\M_8B2YNS
M:PMM3RKC)C"W#L"^YAN!B,:_Q'"D8YK2'C6U-NDPT^]*S+%):@"/-RDDJQ*R
M_/QRZ'YL<,/<"Z/$4!T5=1^RW&YK@VHMOE\SSA*8BN<[?O \YQCF@"CK=CK-
MSXDL)K-=MI"T+-*LQ!P'/F*R[@,;<8^4YYR1@5FVOAC6(!;S&YNC.B6;-NOI
M&!D6<F8X+8.8\#TQQ6G:^([G4O$5A9V]K)#;&&Y:Y\T(662*01[,AN@))R <
MY7WJBGC66#6=2BO%C^PV:74C[('1T2$KR'8[9"=V"%QMXSUH B31?$2><Z&=
M9D5C*S7A(O'$Z.I09^0;%=<';]\#H,TMWH>OW]M-*[SP3>3?/;QK>L-DSNC6
M^=IP< -Z@5?;QQ;"V,J:;?2LHF9TC,1PL:H['=OVD8<="><CM6GI&LOJE]J<
M/V1XHK.=8HYBRD2AHDDS@'(^_P!^V.^0 "IIVDW5E+XB$*M#+>3M-;SM+O4E
MHP =I)QA@<\#MU[8TVC:P^F6T<=G>IM@FC>(ZFV_[0RQA)B^[[H*R<9S\V[;
MD\;%QXDDLO$5Q97%K*UFIMD%Q&%Q&\S,H#9;)RVT< XSS4NA>*K'7XIIK:.:
M.*.))A))M(9&W8(VDX/RDD'!&1QS0!B77AS76DOI;>=%NI%G\NX#[3O:W@0-
MQR,M&WTX-/MM&U6)K)I8K^>U$DI>V:\$;1.WE[&RKG*#;)QN)R_ ["1/'2K<
MRR7-C/!;206CVD<AC#R&8S')._:!MC!Y((P?:KEOXUT^YOK6TCM[K?.L;'(4
M&(R9VAEW9/3D@$#(YQG !B3>&=8BLQ:VHNXH!>WLD@@NOG?S9"T4BDN,;02"
M"1\W.#C-:$&B:I_PEEO>W*2RI#=22?:7NLJ8C 451'G (8G/ ZY&=QQ/9>-X
M+QK;_B5:A#%.EM()9/*PJ7!*Q,<.3RP(P!D=\46GCJQOXM]I9W<ID:,6ZKL_
M?;]V,'=A>%+$,00,<9XH J2^'=1G\2WTBBXM[:ZNFDDNHKP@&$VHBVA >'\P
M!@<?P@Y[4ZTL]7UCX>:I]L^;4]4MI0L98A%)C\M ,_=!"AOJQJ[;:]>3^']-
MOGC6.:YO5@D1E^ZIE*8X)YP/4\U';^,K=X]+A=2UQJ%LLJ."B@,8VD&8]Y=1
MA#ZCMD]: (K^QUO4M<L[S9>6EJJQCRHYTW1.LA+,V'P59=HXW' (P,U4?2->
M6VD6*.Y9TO?.@\VY_P!8"#GS<2?<!/!7!X!*'',]EXSEGM=*^T6SVL\JP2W/
MFJI#120RN'3:QQ\T3<'D8Z<UJZ5XH@UG3[JZM+6?,$0E".4_> J2N"&(SQ@@
MG([]J ,.XT/Q!,VH".2XBFDCNU-P+P[9M[YA"+GY"B\9P,8XSDFM;Q%I-[+I
MMA;:6T_D03YGB28^9)'L8 ;F89PQ4\L.GM@QV_C*-[*TFGTVZ0R6UO<7&THR
MVZS,50GYLD$@G@$@#D \4OB#Q)=Z6^IP6]BS&UTTWB3EE*[LL I7(/\ #0!F
M3Z%XE\Z<V]Y<>4VGFWC\VZPWVGR@//)'3."F!T/SXYS4EQHVK37U@]NE_:62
M* (5NP[PN)-Q9B7P01@8RV ",<FKMWXYLK)2MQ8W:72O*KVQ,>]?+5&8YW[3
MQ(F "2=W3@UJWNM065_I]H\4A-\2$DRJHI&W@EB/F.[A1DG!XXH Y=="\0"/
M4#)/>22O,"RK<A4N(_M <A#NRK>4&3HH&[&<8(ETK0]6L)M,*P3(B75S)+%)
M=;XTCDF9P2=VXR!2.<,.2#ZU=O/%ZM86L^GVLTDDPLYA&P7+1SR[-H^8 -@'
MJ<#CFHF\;0Q32S2PR);K&B"%MHD$_GR0LI.[;@%.N<<$YH EU*QU@WVNKI\+
M(U_:*EO=B55$4BHX&>=PY(Y -4X-&UB%=/>(7S,EX9&AN+@>7'&?+!SMD)/W
M7*\MRQ!&#QI1^,;24H%LKS+VKW*J57<^W>"B#=EV^0_=R/F4YP<U&?'&G"2S
MC$,LCW"JY$3QOY:M(8P>&^;D-PN2 #G!XH R)M#\0O9^2#=_9UO'=E^T_P"D
M2H4(!)\P*<,>.5XP=N1S>L]"U7_A(VDU">ZN+,@ $R*4>/R C)(N[J7W-PN,
MX.>HK5T;Q19ZY>3V]K%,!&"RR-M*N Q4]"2.1G#8.#]<9%CXSFCTV6ZU&PN&
M9?M%Q(L*Q@6]O&Y7)^?YCP>G)P>.F0#5TZROK?Q+J$KI)]@F0;&EESA@% 5
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M6J,D3 *(FE9U4#HJJQ(4>PP*J:=H>B):12V,"/ _E2Q2"5I 53F/:23\HR2
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M05Z':.* &7&N26MQH\)LGE%^&,DJ.H6'";B2"<D=>GI^%/T?Q!;ZQ(4CMKF
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M5(+,,JQQ2O&2&7;C<I!Z>_-/A\.:5;WPO(;79,O*@2/Y8.P1Y"9V_< '3H*
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MY)QU;-7=;\16N@6,=W?12+&P)8"2,,@ R>&<;B/1=QXXS3?^$4T8&X/V5_\
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M@P^ZC #D#Y5P<CB8:'J]O->RV[WT0NGO-PBN =H;'E,JLP4-G)SP>3DUVM%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114-U<)9V<]S)G
M9#&TC8] ,F@":BN2T[Q5=O.+74+4JSBW07,* Q1RRQ!@&RVX_,<# ],D5O:'
MJ#:KH5C?2($DGA5Y%7HK8^8#VSF@"_16?K&H/IME%.B*Y>ZMX"&]))DC)_ ,
M3^%5]*\16^K7;6\=M=0G8SQO,JA955RC%<,3PP[@=1C- &Q17'MXUN%$$[Z/
M<K 7O5EC4QO)BW?;O!W@8X;(/.>!G@G3MO%FFW>N?V3"7>;=LW@KMW>6),8W
M;A\IZE<9XSGB@#=HKF[GQMI=K?7MJRSNUFLAD:/8W**&8;=V[@9Y( ." 2<
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MF4NYX=2"$*)RRGY'P?F% '1Q^'-+B5@+=V+>9N>29W=]ZA6W,Q))*JHY/
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M:?( +PB5Y$N'>;#%QSM((Y Z8Z# !OGPQI3(Z-'<.LD@EDWW<K>80 !ORWS
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MH<2-N=6PPW*3R5.1[5RYT_Q6]M81;KV%(Q*K.DN^4ON39(X,^.F[Y2SKZKR
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MF0S"3YSOQ&_\1/#<<C@ Z*TT'3["X2>TBEA9$5-J3R!&"H$7<F[:Q"@#)!/
M]!45[HFD75VSW@9Y[I#$H>Y<''RL1&-WRG,:ME<'Y0>U9FO6FN3:I<'3/M.R
M6PDB1S-Y<<,NQ]KKA^6+% <IQP0PQ@YU_9ZWJ-TEY<:9J@A2^,D=O#=QQS)&
M;4)PRR  >9N. WO[4 ;A\*^'[A?L_DM)Y!D211=R%CYI#NLGS98-\I(;.:N/
MX?TUYUG$4L<JN[[X;B2-B7(+ E6&02 <'CCI7(R:/XI2WRS2F666)KM[9P'D
M(M40L,21\"13QN';@BKEQ8^(/-OT#:C(LD$16<2*I#J8\JJ"8#:V'+$;&'S
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MS)%()4DEG>1@P1HQ\S,20%=@!T&3WJAIL&I1>(VD:"]&GO:@#[5<;O)8!,*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;HJNU_9K="V:[@%P5WB(R#?M]<9SC@_E2/?VR/"HD5S*P VL#C*E@3[$*>:
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MC^>9B>O0^:./]FJ^L^$)WTZ]:R=)+J7[60H0*7\]E.,D@<!1U(S@<CK79T4
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M]GP6W<K@EL8ZX%*/!*_:[N226*XCG5B%F\WY6:$0D%1(%((![9P<9X!KKZ*
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M+G9<](<(KS2(^5&<@#9SSSDGBN@B$@A02LK2!1O*# )[X&3@?C3Z* "BBB@
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MK9/,DD>^2)X#DJC X .3S]?[W&_X?LY[+2BERFR66YN+@ID'9YDSR!>.,@,
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MN8[I+=T+)(ZL22^>1G(X' 8!L=J .@O=5L[&RENY9E9(X6FVHP+.H4M\H[\
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M!=^%KFX?4U66SV75PETCR0EI-RM$WEN<\H?*P?8@=N0#H_MUIY<;_:H=DO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\2Q[=^XN -OKGTH EJO?SM:Z=<W")O>*)G5?[Q )Q3Y+F"&#SY9HTAP#YC,
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MF4[L\?*>^>G% ''WOBK4KJ/5XHK=;>&W\Y$E651(C1RJF2N[=A@2?NC QUW
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MBD29TCE!X="RNRD$GG[G0 ]\D=^BV)NW;5SG.<=\8_E2&&)I1*8T,@& Y49
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M(+1A##(7#*%.#DGH?[HZ]*C'@6-T N'MIF5;-07AS@0W+S,.>S!POX<UV-%
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M[DL9-K,RI(Q7VY5!G!^\?2LF/X@QV$DMOXALTLKD1030K;3&=9UF+!0"57#
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MV*K,2#V"NAXY.X8&>*GDT#1[Y+B'_6 F=)0DO*F;!D!QT/3Z4MSX>TRZOGN
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MS@-]&=OSQTIT?AS3TL-1LV$LL>H[OM+/(2SY4)U_W0!GK0!2?QMI*6HGQ<L
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M\@BNFK)MO#MC;3Q7&Z>:XCF$XFFE+L6$;1C)] KL,>^>O-:U !1110 4444
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M98C=!5D"?9G!+#&<>8<#//S'MBG:QI.H76K:DD;7^R>XT^6)D(*(J3(7*Y!
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M##'1HR6R2!R>I(Q8O1K]_P";8R6MTT:-<EV95"/_ *7&T&T]\0[OZ\BNZHH
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M9T &%((!4'/<'H*C'BZ\:*>Y2T!:.VA>2+S-R1DRS)(P 7<V/*S@<D8P!@Y
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M8VD!/G&3V )[8JE=^,M0MDNT2PM)9[,7+2L+AA&ZPQQR?(=I.2)=O/0@]<4
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MAL><L6(?("K@#.6YP3QD8ZFL6P\:7U]96<W]FPP?;GB%M)+/B,!XY)#N.,Y
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M&#S<D[0<\$8Q[^U=;93O=6-O<20F%Y8E=HBP8H2,E<C@XZ<4 3T444 %%%%
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M@J?M$8^SF'RU..%S\^<]2>.]0:/X+GT^"S5F@22WF1G9')$H6&2,-MV@*29
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MS^<5)F</ 8O);C&P9SU_A48XS0!L17FD7^D0W,L4*V=^P*I<1!?-9NF5/4G
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MS1-&K(24 SF0?=+8P<UT4VEZ?<Q0Q3V%K+' ,1(\*L(QC'R@CCCCBC^R]/\
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M7@6-#;RJ'660(LBD(2R<DY4'/ '49 .FHJB=25=7&GNFUOLIN&DW< !@N/\
MZ]4H_%FC3)&T=Q,QD=4C06TN]]RLRE5VY*E4<Y Q\IH VZ*RF\1Z8J2OYLS"
M.<VWRV\C;Y06!5,+\Y!5L[<XP<TV'Q-I%Q<6T,5T7:X5#&PB?;\X)4%L84D
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M/?VL5TK_ &:>UGN#/%&\FP1F/J%!^7$A);H-OO0!M45G0:[IUSJ1L(9RTXW
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MB:1[B622-4C@=N8RH?.%X ++R>.: -.BL9O%6E+'N+W(?S_LXB^QS>:9"AD
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MQ,MD2))F>8993&'+*HC) 4<G.W!P0"_;^"],M[>:%7G(FBGB<C8G$P0/@*H
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MKKD!(Y(E'"C@+(WXX)[YIW,^O6FM16J7-].JR6PC)M$,4\;/^_:1U3"%5S@
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M2HII8[64*NP109"+D!<F/)Z]6RPP#G-5O&ECCPS'9VD$DMS'$5MQ'9O(V0H
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M3B-87)6#$B!BP!Q'Q]X\C!JM-X.BN8;Z.;5K]S?J$NW*P9F0+M"D>7@<$\@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2@N6U>8QQREVBW,0X]P374*,#FD,=1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 5[Z2YBL+B2R@6>Z6-FAB=]@=P.%+=@3WK
MC/[=^)'_ $)FF?\ @V'_ ,37=T4 <)_;OQ(_Z$S3/_!L/_B:/[=^)'_0F:9_
MX-A_\37=T4 ><WMWX^U *+GP/I;[#E2-7PRGU!"Y'X54\GQO_P!"5:_^%#)7
MJ-%.[%9'E_E>./\ H2K3_P *"2M*/6?B-%&J+X,TW"C SJ^3^96N^HI!8X3^
MW?B1_P!"9IG_ (-A_P#$T?V[\2/^A,TS_P &P_\ B:[NB@9P@USXCY&?!FF
M?]A8?_$UW=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^%=Q"C1P1QO(9'50&<C!8@=:?10 4444 %%%% !1110 4444 %%%% !1110
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M1^5I[BX;Y5#H^'79U=D7<03@*H ."34_M3XE_P#0MZ%_X,7_ /B:/[4^)?\
MT+>A?^#%_P#XF@"Q=:'KMQ#.GV>P:'4+TW-] ;IE^14C1(U;RSD-Y>6.!W Z
MY%NPT*_M]9B>;[/]CMKJ[NHY%D)DD,[%MI7;@!=[<Y.<+^&9_:GQ+_Z%O0O_
M  8O_P#$T?VI\2_^A;T+_P &+_\ Q- '=45PO]J?$O\ Z%O0O_!B_P#\31_:
MGQ+_ .A;T+_P8O\ _$T =U17"_VI\2_^A;T+_P &+_\ Q-']J?$O_H6]"_\
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MA;T+_P &+_\ Q- '=45PO]J?$O\ Z%O0O_!B_P#\31_:GQ+_ .A;T+_P8O\
M_$T =U17"_VI\2_^A;T+_P &+_\ Q-']J?$O_H6]"_\ !B__ ,30!W5%<+_:
MGQ+_ .A;T+_P8O\ _$T?VI\2_P#H6]"_\&+_ /Q- '=45PO]J?$O_H6]"_\
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MA;T+_P &+_\ Q-']J?$O_H6]"_\ !B__ ,30!W5%<+_:GQ+_ .A;T+_P8O\
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JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>bionano-nancyridgeleasee010.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOIK/L&H6A;R?/P)ESY?7?U^[[]*C.NZ0+>*X.J60@E8I')]H7:[#J <X)]J
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M8QWTVHVD=I)]R=YE$;=^&S@]#^5.&JZ<U^+!;^U-X1D6XF7S.F[[N<]"#]*
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M.56:/G'S '(Y]: .+?Q7J46G#4F6WA9[2SFE#[CRZ2LZQHSJI;*C R"1GDD
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M!U.CZ)'HR7"03,Z2",+O'*A(EC&3W^YG\:AT70#I3W\C36Y:\*EH[6W\B)2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IKNL<;
M2.P5%!+$] !3JAO+9;RRN+5R0LT;1DCJ 1C^M &3_P )5IWEZ<N\?:[]4:*S
M,BB8!U+ LN>!QC/K6GI][%J6FVU]!GRKB)94W#! 89&??FN:L_"]ZAM+J:ZC
M5D:"YGMEBW%IXX1%A9-W"$ <;<Y[\XK=T&PDTO0+"RF96FA@59"O0OCYL>V<
MT /U?4TT?3)[^6WGGA@4R2"$*65 "2WS$< #ZU4M_$MC)J2Z==9L;MXHY8X;
MJ2-6?>SJ H#')_=D\?WA5W5K :KHU]IQD\L75O) 7 SMW*5SCOC-4+WPZE[>
MRW)N-I<60QLSC[/.TW7/\6['MC/- &E;ZC97<LT5M>6\TD!Q*D<@8QGD88 \
M=#U]#6;IGBO2-3@29+RWB6:=X+<23QYF*MMRH#'J<8'7D<<U'X?\-+H4LC?:
M!.NTQQ,P?>J;BVTEG*GK_"JU4N/!\TT%C;IJTB6]O)YCQ[&PY$PE!P' SQM^
M8,,<@ T :T&O6<]XUL3Y3*H.]W3:296B"@@GDLN,>X'7BK#:MIJS)"VH6@ED
M+!$,R[FVDAL#/."K9],'TK#;P>0LABO]LID66-FAW*K+=-<#(W#(RVTC(X&<
MBB+P:ALKVWN;YI&O+2YMI)$B"$>=*\C%>3C&_&/84 :T^NZ?'H=YJ\%Q'=VE
MI#)*[6SJ^0B[B 0<9P/6I8=9TNYC,D&I6<J .Q9)U8 )C<<@]!N7/ID>M9D?
MADGPYJNE37*&748Y$DN$1\_-&(]Q#R.20 .^. *S=1\'W-X@,ETDMQ<WZR74
MD4?E)Y'E")X]I).&10.O4@\ 8 !U#:A -1M['),MQ!)/&1RI1"@//_;1?UJ(
MZYI(2=SJED$MV"3-YZXC8G #<\'((Y]*BO\ 3+J?6;'4K2[AA>VAE@=)8#('
M21HV.,.N"/*'//7I6'!X'-MILEI'>QLP5$@GDCF,D2H25Y$PPPSP5VCKQSB@
M#I&U?34:=6U"T!@4/,#,O[M3C!;G@<CKZBD_MC2_]&_XF-I_I7_'O^_7][SC
MY>?FY('%8-WX/FNS<[M5=!-Y+X1&7=+&Z,)'P^"W[L E-AP>N0"!?!2K=VTX
MN8\*JB>(K+LE(F:7<!YN=VYV)+%^<'% &Y+K6FPZD^G37L$=TD'VAHW<*1'S
M\W/;@U+#J=A<6+WT-];26B!B\Z2J44#KELX&.]9FL>'6U6XN)!=B%+BS^S2+
MY6X\,65@<CH2<@@Y'I5>^\/W;^&/$=J)X[C4-6BE)98_*CWF$1* I+8&$7J3
MSGZ4 :J:[I$D44B:K8M'+)Y4;"X0AWX&T'/)Y''O3X-8TRYE:.#4;2619!&R
MI.K$.<X7 /7Y6X]CZ5F6/AIX-5&IW5XDUR9WF?RX/+0EHDB&T;B1A8QW.23T
M'%4(_!,B:>+<ZH!+;VT-M8S);X,(B?>C,-QWMD#/W01G@9- &\VNZ9$)GFO;
M:*"+:#.\Z!"6R ,YZY!'./;-,L/$&FZA;V$B7444M]"L\%O+(HD96&1\N>>A
MZ>AK,_X1 6\MK+I]XL+VAA\@2P^8H$<4D7S#<"<K*3U'('6HM.\$KIUS8R"]
M$T5O#;QNDB.-S0@A64*X4'H>5;&.* -N76((;^6T*,6B\C>VY0 97*J.2.>,
MXZ\C&2<4MOK%G+I9U":5+:!'>.1IW"B-U<HP)SC[P(JA<Z%+<ZO>2&0);S26
M=PK 9/F0R;BN/0A4Y]S26^@23>'S8W3K')+?&]< ;@,W/GA/?C"Y_&@#276=
M+>7RUU*S,GE>=M$ZY\O&=^,_=P0<],4)K6E2I"\>IV;I.YCB99U(D?.-J\\G
M)' K'F\)N^J7][#J#1FY+RQG:Y>WE:'RMZ?/LX'JF>2,^D5OX/N+=XY5U0"<
M7AN7F$<F_!$8:-6,I.TB/G=N!R..!0!N?VYI.+@_VI98MB%G_P!(7]T2=H#<
M\<\<]^*!K>E,+8C4[,BZ.+<B=?WISC"\_-SQQWK"B\%D);QS:@LD5H(TM@L&
MTB-9XYB'.X[V/EJ,\=SCFG77@^:=H435I([=+M[IX=C89FN?/[.!_L_,&]0
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M<B)=TS0\/,)Q.9"H8<%\_+GH>M7X/#PAU%+UKD-(+R2[8"/ ):(1D=?;/Z4
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MX(M+F]O[L3^5-?>>EQ)'& [0RQ",IGV*JP/;!&.:B;P?=1VN^"^@^W#S,R-
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M$N>O.TKCW]JG;1]4@U*?4;6]MQ-/&B21+"Z1N_[L-*P+L"P56 P <$ DX!H
MOZAK$&G3^5(C,PMI;IL,JA4CVYR6( R6&,D#KR,4+K$#:A%9[&#2O+&K[E(W
MQX)7@G!()(!_NG.*HZYH,NK7<P601P76F7%C*_4H7V[6 [_Q9_"A-"EBUFTF
M60-!'=W%ZS'@AW38J8[C#N<^PH DN?%FC6LTT3WL):WNEM;CYU A=EW MDC
MQW]<CJ#5\:OIIDMHQJ%H7NE#VZB9<RJ>A7GYA]*SG\/-)J<]R;M?)DOHKX1^
M5\P=(ECQNW="$4].#GKVHVW@I+:_MK@7@DCC2)9(I$?#&.1I$("R  @O_$&Z
M C'.0#HI-1LH;DVTEY;I.(S*8FD 8)_>QG..#S[5!_;VC^3%-_:UCY4S%(W^
MT)AV& 0#GD\C\ZS=9\+MK%U=.;XVT%U:/;2I"C!I 5(!8[MIQG(^7/;.,@OT
MWPR+*^@O)IXY9XS*7*H_[PNL:Y)=W;($8'7IZ8H TWU2S6>")9XG:;&-LJ<*
M59@QYR00C8QGH>P)$2Z]H[Q12KJUB8YG\N-Q<)AVXX!SR>1Q[BL)/ =NNFFR
M>^E:/S9"&" ,L36[VZ1@YXV(XY[D$XYJ6]\)W.I/;2WFH022QPO;R*MO)'%+
M$Q3(VK*#GY.Y(.>G2@#H;C4+*TF@AN;N"&6=ML*22!3(>!A0>IY'3U%5QKND
M&.>0:K8^7;L%F;[0F(R3@!CG@YXY[U'=:7/)K<&I6UU'$5B\B:.2'?O3<&^4
M[AM/!YYZ].*Q[7P688K6*;4%E6S2VAM]MOMQ'!*) '^8[F.T#=P.X'- &P/$
MFBFY2W&J6F^2W-TI\U=K1#JX.<8X/Y'TJ:'6M*N)H88=3LY)9U+1(DZEI ,\
MJ >1\IZ>A]*Q)_!QEMKJW2_"QW5M>6TNZ#)Q/(S@K\PQM+8[Y [58U+PS+J6
MMP7CZE(EK"05M0&P"$=3C#!1D/G)4GCKCB@"X/$VAM<VUNFJV<DES(T40CF5
MMSJ 2N0>N"./<>M7K2]M;^'SK.YAN(LXWPN'7/ID5BVWAZ]@ATI'U&WD;3CL
M0BT*AXO+V;2-_P![ONZ?[-2Z+I-_H_E6OVN*:R&]BH1AY?"!(XPS,0@PYY8X
MR ,#@ $SZ_:QO<@H^V"5X2Q=%#,D7F-C<PZ#(^H.< 9J0:W;F]AMBC@S3&!6
MW*1O$0EP<$XRN3S_ '?0@G(F\+27BWL$L_E1-=7$T+!=Q99H"ASR,$,[?@!Z
MU.OAZ6'5+65)0\*WYOI"1@@BV\@*/7/WL^V* )[KQ9HUI+<1/>Q%[:XCM[@;
MP/)9P""V2,#YAS]1U%7AK&F%K91J-H3= -;CSE_? ]"G/S?A6?-X>:;4;BX-
MTODS7D%[Y9BRP>-57&[=T(1>W!SR:HQ>"DAU""Y%X'1=@DBD1]K;)GF0@+(
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MJV1[=&N[N-9 9!P,L5SGI@#\!4\.KVTD.G.59#J!VPKE6YV,_)4E?NJ>02*
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M@DG-Q$P1-Q"N"2"-PQSW X]:@M]?TFYTP:BNH6JVO :1IE C8@':QS@-R.*
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M19S;O<[C&0@12H;Y^F?F'%1Z5KEIK!D6W6:-D1)=DT90M&^=C@>AVM[\'(%
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M75:SK(LM%EOK.2!]DZ0-*YW1Q$RB-V?!'"98D9'W3DCJ-*>VAND5)XPZJZR
M'IN4AE/X$ _A2PP16T0BAC5$R3M48&2<D_4DD_C0!S.CZ_J>J:E:VX:R-OMN
M'DN(XV*SK'($4Q_-\H.[.26Z<9SFH9]4N(=9NV:<(HU4VP,KMY<4:V!E!(!
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M5=TCLD#^3S_H]PTW=B?FW;>O&,\U:\.Z#+IG]JM-C_2)W2V5P&$=N"Q1, ]
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M;Q==2=;1(]9$<_VM[2W6\7SE 2$(7<OR!(7(&X\,,\9% 'HM%<'>6WBZ2\U
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M1MP54$J^ !MP1SUUC=B^L8+M8I8EF0.$E7:X!Z9'8T 6**** "BBB@ HHHH
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MF657_>-R)9/,?OW8Y]JB?PGI$MQ<320S,9UE5D-P^U?,8,Y5<X4EE!R,'/-
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M-Q:Q7%JMS<B79L2*++$N[QJ.2,9:-^O'&3@5IRZ+8S:#_8KQ-]A$ MP@<@A
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MXQG(S%-XYT."[O;>2X(-HLA=N""4(5P!G((+ <@ ]LX-6;GPKIEVMZ)Q<O\
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M!MO.2 5(S^5,?PKI+I GDRK'%$(=BS.!)&&W!7 /S '/!]2.A-71I5F-.N;
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M=.*3IJ$ES+>C:5>!K8H(PV=QPY4;2/X,^F67]MKDGB3[2+6^G^S7,TD($J+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV,Y!VF1$)!Z#E_<GT[@ Z2BN.;Q=?P^=+-96YMU%U*NQV+"*VN%BD)XZ[6+
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MY K#KAMXZ>AH Z%KB!"H>:-2S;1E@,G.,?7-00:E:7*R8D"A9VMR)/ERZG!
MSUKEI_!,U[:S_:YK1KB2"^5&$1(BDN)%=67//R[<9Z_2EU'P3)>W?FO-'+&T
MESOB9F0!971L@KSD;,>^>HQ0!T$=EI%K#;1KY*1Z:5\L&7_5'847.3_=8@9]
M:OW$Z6UM+<2;BD2%VVJ6. ,\ <FN2N_"-Y,-2$,EK&L]P)[=3D^5)F0M)D@Y
M)WCY#E>#TW<;%[8WVK>'M6TVY,4+7$4MM X'\)3:'8 ]VW' [8[YH U!) \^
MP/&TR@G;D%@.GUK.FU71E<VKR6[@S?8Y%P"$8(TFUO0;0:J6GAD6NN#4U:$2
M&YGF=E3#.LB@!2>^-H_(5"_A02ZM+/*MH]L^I+?[3'EFQ 8RK=CAL,#[F@#?
M=;-XTM'$!1U^2$XPRCT7N*5A:+<1[Q")U0[,XW!>^.^*Y.P\$26=_ITTDT<Z
M6T%O']YD,9AW8V@=0<]#C'/7.*T+[P_>3:EJ5S;R60-Y!L2:>#S)('$;(-H/
M!7)S@^K#!W< &LJZ888 BVAB+$0X"[23G.WWZ]*L1FWD9A&8F:-SN"X)5CUS
MZ'D_G7(VG@^]MI+659[=9H[UK@R#+;(V,99 ",-GR^N 02",8P;_ (7\,-H#
MS&1TE=HUB$P=BTBAF.64\ _,>F>2?7% &A?ZAI6E6MQ>R"$XE1)/+"EFD+!4
M!]\D=>GM5MOL@>W:184E))B#@!LGDX]_7%<E:^!I$MHH+B2S(@6TB!2(_OUA
MF60O)GJ[ $=\%F.3GC2\1^'KO6;ZRDAN88X('C=E9/F!25'R"!DY"XQD 9SS
M0!NJ+2T;RT$$+2-G:,*78^W<G!J"6YTO3H'9Y+6"*%P7Q@!&;@9QT)S^M8&O
M>';O6/$;2)';+;-:11FXE3<\968N?+]&P!^8/;!K#P*_E:@K/!)+,SM%-(6.
M[=.)L.O3J ,C)ZD8R10!TK7VEF_1)&A6Z=C%&73#/A0Q"D]1AATXYHDCTW5+
M2WCD5=DPBGCB;,;,$(=<KP< @<'Z&LI?#4RZS%J.;5F6]-P4*'"JT"1$*?4%
M,BJ-CX*N+0V$;7%M(D"V9:<QGS5-NH&U#V5L<^FY^N> #K3]DO%(/DSK&P8@
MX8*>H/L:R[?Q-ID]M]JB$OE23+&L@CXD+2+$IR.VYAUYQSBH?#?AA= V;3"1
M_9]O:R"./;O>,N6<^N=_UJE%X,>&"SBCGA06XB!VI@,4N4F/YA,4 =(OV&-)
M OV=%BQY@&T!,'<,^G))J*QN]/GMYK^W$4<9ED264J%W-&[(Q)[C*GFN7A\#
M30P3J)+>2;SDD225G(F"S^=MD7H,],C/))]JTH?#MW;>$CI,,UJDYN7G^2+$
M6UK@RE "#MX.T'!QU'2@#;=K#=;[S;;B=T&[;G)[K^?:FO-8L F(Y5ED,+!%
MWC<<L0V.G?.?ZUPD'A75-.U_3 ;<7=M;);KN4*$)6:5BVXG<NQ9 0!][&/IJ
M:7X.OK2Y2>ZO8'D$L,C^7'M#%(Y4)P  ,^8#@#C&.>M '4^98"#=OMO)B^3.
M5VID8Q[<$<4D%S87,MPD$D,DEJPCE"X)C8#(!].&_6N3_P"$$DM]+2VM'M4E
M2TM8D<(5"RQ+(IEP 0Q/F#A@00"#ZC?TK2)-/O-6E8P,M],LP=$VMGRU1@WX
MKD?[Q_$ B33]"OWM-;4_)<"&:%C*R)(0,QG82!GG(R,_E6I(]BL[SR-;B:%<
M-(Q7=&#ZGL#7(3>#+^[TC2;*\EM)5T^T:R,:NZK*C(B[R1R&&P\>C'D59N_"
M=S-)J7E/;K%<2)+$A9LB56SYF[!(/3Y?F4XZ#)H Z9H[*4K;.ENY7]XL1"G'
M/W@/KWI\1MYT\R+RI%)/S)@C/0\UR$G@>>>ZOI)[Q6>ZB8"Y3<CQ.UN("0@^
M4CJPYXR!C@&M30M)N]$V0);VX2>5I;ITE9@,1JB[0>YP.V %/?&0"S)J.AVL
MLD6;8.LJV<H15^0E=P5O08.?2KD\-C<7-K+,8FF ?R<O]Y6'S #^($8XY' /
M:L6?PK]HU.[FD6T:WN-0AOB&CRQ*1JA4]CR@8'U)_&C;>"'M]0L9GEBFB@2%
M-FYD\ORI7D4J!U'S 8./N]P<4 =5#%9V=Q.(RB37#&>4%_F8@!=W/8!5'IQ2
M1OIZ0(T;6JQ-C85*A3@\8^A/YFL;5O#][>:M/>65Q;VS36C0,[Q^;O.U@F48
M8 !;.1U&00162W@&2>PN8+F:V9I8;U(P4+B)YUC 8$C^'8W.!G=VH [%'L8%
M>>-K>,2/AY%*C<V<<GN<T.UM#+'"T:J67*G9\H"<\GH,9XKE-1\#?:)93;FW
M%NURT@M.8X]C01Q'[O0@H3TZ,1WS6MJ_A_\ M&.WCS&\45I-;M%(S#>'51]X
M<C[O7KS0!JH+&*#[0@MTA/S^8NT+WYS^)Y]ZJV6I:9<PF2$+'$BDEWCV* &:
M/KTZH1],5GS:!>S>'K*REGMY[FVN%G(EC_=288D(P [ CYL=5!QVK,3P1<1:
M<\ EM6?R8TC"AHUC9)I9 R@9P!Y@P""/EP>#0!NC2M%MM5-_N5+A6,V&N#L1
MB@0N$)P#M(&<=#[U=,EC]HG+K&DF5BD=TV[\C(&X_>ZUSP\%1RWZW=Y]DN93
M=B>1VMP"ZBT$&W'8;AOQT%0?\(9>)80Q1W<!N8S 4G<$^6R0"(MM.0^<'Y3U
M!Z@\T =7.]C)&_GM;ND+ MYA4B,]LYZ'FHKN^L;%X!*R"2:54C"@;BS':#^N
M,US5SX.NYI+ADG@2$WHNX[8%MK-^]W[GQN&3*&QR%*\=<!8_!<D%[9/$;,00
M-:N"Z,\D?DC&Q&/\)![^IXYX -]M'TPZ/%H^W;:P^6D:+*P92A#+\P.<@J#U
MR<5!;?V%IWV>S7RT;[0P@,^6+RN#*Q5F^\2"3D'V]JR_$7A&\U75FO['45M'
M"1R1 H3MN4) DX/(,;.A'T]*D3P@+:[M9;4VYBM;Z*>*.5<XC6U^S[<^O\0^
M@^M &O;ZCIE[IR7,2K)#)MC*"/<1O8 !E'0$GG/;FK<*V;*T, @(50C(F.!V
M! [=>*Y>V\%&UBMUAE@C*"V\TI'CS&BN1,2?4D9'/<U?T+PR-%NXYT:'/V=X
MI?+3:9&,A<,?7&3^9H L)K>CP032QJZ0V[^3OCM7VLQ<)LC(7#G< ,+GD59L
MKG3+NR:_MQ$L+LQ=WC\LAE;#;@P!!#*0<\@BN8M_!%Y:<P7<"&"19(1A\3%9
MA(#*,]=HV9'J3Z :<GARX?P[]B,L#W)OOMSAU/E.QG\XH1UV\XS[ X[4 :EO
M>Z;J5N&4PLDD\B*L@'SO&Y1B >N"IYJ6==/:T=)OLX@=,') !4C:.?IQ7)KX
M*OE73HA=6:0VUT+EDBAV!2+HSX7OC!V@9P,9YS4<?@Z[EL]00&-)1=%-/:7C
MR($+E, 9!PTKX!&"NT$>@!T&DZ;H\1OK:W@9VCE2&<7+&4DJBL@^8G@*P(^I
M[YJXU_9)?R6OEDS1F)F*QY ,FY5Y'?"G/H,>M9EMIUZFM7%S):0R))>HPDD
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M#KC&> >AYKLY;>TFRDT,#[L,0Z@YV]#SZ?I0(+1E!$4)7!(.T8P3D_J ?J*
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M W$FW5VQ[DY_.NG>ULS<?:Y((#.B[?.9!N4>F[J!R:?&EO#A8EBCW  !0!D
M<?H* .+N?$6JZB+:SA%M!))<6C/+;7!93%*';:&V\,-G/LP/>MZ?5GM?$=W;
MR29MXM/2X6( ;F??(#CN20H&*M2'2]*M@P@@AB^T1KMBC'$DCA%.!W)8<U*(
MK"]DANGMHGF4GRGFAQ(N#VW#(Y_QH YB+QG?MHJZE-I<<4&4D:4RED2%D9R^
M -QVD ' Z-NZ @37GB^XLYKNW:Q3[2ES'!#'N8[D=F42$@8P=AX!SGY3CK6O
M+%H=L]O;O:68%S,S1@0KM,BJ6+'C . >:DC32;B34;<6UMD2JEV&B $CE58;
MLCYN&% &+!XLOY]3M;+^QRKF.![D&7F/S'9,@XP0NPGG!/3&1BKMIJ-U9:O:
M:+>%9<VX"W;$YGE )88 (4@#."1D'CH:O31Z7!?6$$EK )\,+4^2/W849.TX
M^7BK2P6C7/VQ8H#.4V^<%&XKZ;NN* .;N/%LZ:U>:?:V<5TT4$SQ;9&0M)&8
MP4)90.3)V)QC'.>&2^-#;Q)</;(]JUG),KH7S++&LC/$%*Y5@(S][&<G&=O/
M2-I]C))-(UG;,\PVRL8E)<>C''/;K1'96"3))%;6RRQIY*LL:@JO]T'L/:@#
MFX/$>L7-SI*M9VUO'<7Q@D+R$B2/R&D!3C(.01SUP.QXD?Q!=7G@[7;O8MI?
MV=O-F-&+&%A%O7DC#=0<C(/'T&O=1Z/I.ES3R6MM%:6JM>,J0KA=@R7"@=1C
MJ.:MPVEE#;/#!;VZ6[EMZ(@"G/7(''UH YFZ\92V4T[/9I);0R2P;4E_?EHX
M#,6V8P%(4@<]U/?%+J/BZ?3+6UDFBL9II/G>.WG=P(\QC(;9@']X.N,\8Z\=
M*+>R%R;L0VXG8>69@HW$?W=W7\*B73=+VI&EE9[86)11$N$8]<#'!- ',MXK
MU2VC='M+>XN)-1GM8%1V "QAF&[CJ0O\SVQ3CXFOKS7M-MDBBM(?MR03QM-F
M5BUHTQ&T#!4%E&0>JGM7126VF7+W,,UI ^YD:;S8!M=NBG)&&(QCOBGQQ6$D
MXNEMHEG1C"LCP['^7(P"0"1UQC@]J ,74?%$MMKXTJVAAE9R\08EP4E$#3#=
M\N,84< D_,#[5')K>JCP1I6JI]C-[<O9B0ECY>)944XX]'_#GKBNB^S6;7GV
MCR(#= 8\S8-X'(Z]<<FJUT=+LK-+2:&!;6218?)$8*;G/ *]!D\T <T?%=]I
M1U26\MTN+6)[QXBDIW_N5#;<;< 8R,Y/3WXOS:YJ+^#=<U!K86=W9V\S0L#N
M#%8MZN 1ZG&"/X?0UT(BM@R@1PY;)7@<YZD5F:7?:+<V,D6GPQ):_9TN'C6#
M8I20$@XQCD*<B@#,L-2UZWN+:TNH#+]LNF$+WKQI*D*QJQ+"(%2=V\ #'&,U
M!9^,M0OK!;J/2$19WMUMS),5'[URF&^7(*\$X&.2.V:ZFVNK2]M(+Z)D:)D$
MD;L,%0P!_#@BE6RL;<R2K;6\1D<22.(U7<P/!)[G/>@#E(O%M_/#&+BTCMVD
MD@V&WGWG!NE@<'<G3G/3H2,@\U)-XRNHL0#3T^W/>&W6'>Q"KL=U8D+AMP3C
M;GJ?0BM];C3WU9]-2%6N(8EF?$7RHI8E>>F2RDX]L^E2'3],:WFA-G:&!V\R
M5#$NTMUW,,8S[F@#.TS7[B\U=+*ZLA9F2U6>)6?>S':A<9 VC:7P1G/ (R#Q
MF77C6XMTO9A8P2111WIB03GS-ULVT[QM^4,>AYQD=<\=!=RZ9H\$FIR0Q(2$
MB,D40+ODA448Y/)  J9+:Q:2:46T EF0><3&H9AC@/W/XT 4=1U2\T^VTZ-H
M;7[;>S^1S*1%&VQW)+8R1A"!QR2*S- U>^USQ!]H?$5E_9D$ZP+(2-\CR@GH
M-P_=\'TP<<FNEGAM;V$P7$<,\3C)CD4,&Q['K3XTA'[R)8QE0NY0/NC.!GT&
M3^= '+#Q1<6VC12E5N[R?5+BS0= @668+N"C^[& /4X]<T__ (2F_#*CZ4D<
MTECY\$+3\RS!=QC# ;1CC[V,@Y'>MPZ=I3K*39V;+<G,I\I2)3G^+CYN?7O3
MVT_3@YW6EKN:+RCF-<F,?P]/N^W2@#G(O&-Q<W]I:VE@+C<D3SNK,FW?,\1
M# 8*F-B0?8#KFI=(UN_\2!MELUC '2:.8-N+*LOS1L#C!*K@XZ;B.W-G3]2T
M'5);!+6T1B(/M%L6ML"*+.%8$CY0<<?2M>&WLK>5YX(;>.2X.7D10#(?4D=:
M *.@:Q)J\%P;B%(+B"79)"K%MF5##)QAL@YRN0?TK7JIIPL/L:R::MN+:4^8
M# H"L3WXJSO3YOG7Y3@\]* '456O-0MK"S:ZN) (5 .1SGZ>M6: "BBB@ HH
MHH **** (KF(SVDT((!D1E!/;(Q7*V7@L6]U;W$WV62:.>)FDV99HEM/(*9(
MZ%LG'3!KJ[B7R+:6;;N\M"V,XS@9KE;;Q?>W'V:!M,MX[R[:'R4-V3'MDBDE
M!9MF00(F& #SCGG@ I6G@:X@&C+(+1H[&VAMV2*0H%,3[O-3Y"=S<$CY>0/F
M-/O/ AEL;:&);5RLMR]Q&3Y:S>:Q(8ML8[E''3H3@BM/P_XAO=;U616M8(K+
M[!;W*XE+.'=I5(^[@K^[X/' ![X&7JGBZ]N8[ZSTZ*))4E@6*X65P&1[GR6P
M6BQGW&X<GDXY )KSP=/<RZ@52R,,TL$ZQSGS/-DCD1LLQ3<H*IM(RPYR .0=
M'Q!X=EUK9M>&-!8SVK(P)&9'A;TZ 1$?B*QXO$VK6$]U'-:F^GEO)H;>)96*
MJD2C/W8L[CD=B.2<C&#=OO%&I?V;J=U8V-J@LV$8^TW!#E_W9;*!3@ .><]A
MV- %F;PLK^&M=T>(6\<5^9C @C_=Q;T 'R^S MQZU"GA/_B;)J?DV<%P+F*4
M>4N3&BP&,QJV <9)[ 8[5HZAJ.H6VJZ);10VQ2[D=;G=*V5PA;Y/EYZ'KC..
MV>.<TOQIJ$6A6 OK%9KV6TL9$=)682^>'&Y@J94_NF. #]X#- &EX?\ #-UH
MVH6LI:W\N+3XK:9E.YI71$4$97* ;3T;!XR,\U#=^&M4N;"YL=UIY!U!KV,^
M:<RAI2^QP4('WNOS<@<5I77B3^SM#L]5U"S:V@D<+=!VYM@0V#TY!<*O;[V?
M:L?4O&5W';SVWV1;>Y-E*Q9)&=K><6_G;&S&$) ]&)Z''/  Y?!]ZFHZ3+&]
MK';V*QX7.77&_<H;8&*G> .5  (V\U4?P'=R6%M;.;4V\/G1K:"3 6-UC /F
M>7EF78V&*AL/C=QDSZEXKOK>UU.WM8U>ZBBN)%EGF"+&L<$+$KA#DYF!"GT;
MYL8%68/$&J/J\%G;Q0S(URT,AGEVGBUBE&S:GJYZY/O@X !LW=E<ZQHNHV-R
M@MS+OBMW#;F '"2'WW#</P[Y%<U!X$NS'=K?7=O<?:"DFPJ2JN\D<ER,'^%F
MB! ]S6O8^+H[S0]2U?[&ZV]A!YDBALN9!'YDD>,=5R%SZY'&*HW.O:O=:GI^
MFI#!;2F_CCN&@NMZM&8))0%8Q]?DY&!P!SAL@ ANO LDDL(1H&M4DN<6X;RA
M$LLH<,A"-AACMCM@C%2WO@IIK0"(6K3'49[R=6 43K(9-H9BC<J)!C*GH1QG
M-2Z]K>KVNH:G:VL=NL5O%8R0OYA#LTL[(01M( (4C/;KSGA'\9W:RQ6R:.9K
MO,_G1Q2,P BD"'80G).<_-M Z$\YH N:IX>FN=.TFWM?)$M@4V23N7V84*3@
MJ1)QD<X/<$&LVX\(:E<--&T]GY"B[\H'<3+YUS'.5D&,!<(4.,Y!SWQ6QK/B
M"72;QXULEF@@L9;Z=_-(8(G\*KM.XGW(K.;Q=J0M48:(@G=W"B2X>-&18O,W
M F/=ZK]WKSG% "R>$3<7JWK6VGVTZ"S$2PID0^5<O*X4[1]Y6QP!DYS4^N^&
M[K5-6>YMIHK42V3VLEQG=)@I(%VJ5^4JTF[<&!/((/!%27QM/#ITT\FGP+<*
M4:.'SW?S$:$R]5C)#  YXP,9W=J<?%EV99A9V0N&>;"+<7 C5%%K'-P50G^(
MCG//?&  ".U\(W=K: PI8QSJ9F\IF,D+,T(C7("* .!D8Z=S3%\'WT-E;6UH
MMC;Q_9XX)U\QFV[)O-WJ0HW%LMGA<$YYJ=?%MU*[?8K(3M-,%C2XN!&J+]E2
M?JJ$]R,'/)ZXX$VE^+Y=7UR*RMM._P!'**\LS2-NC#0I*#C9M/WU7&[/4XQ0
M!3O? YFM$6);5Y#?75U.C?()Q*\A7<VQOF57 Z'N!BM;5?#S7]K9P#8\4%M+
M \<DK#S \>S&\#(^O6J5]XRFL;R\1M/B>WMYIH%9;G]XSI;F?E=ORJ0",Y)S
MCCFGR^*KVWF6.?3;<&-;9[D+=$E1/*8T"#8-Y&,G.WT&: )O^$=FN/#-II=Z
MUM(T5U'-(OEC8R+,'VX"@$[1C.T9/.!FLJ3P1<\1(UDT1!CC9P0UFHN'E5H1
MC[VUU7^''EKR0,5;A\727T\$<=J\12X2WN=LJD+-^]#Q<KR!Y8.>,AU/%0GQ
MG*D<<\]H8IE@G,UH)<".16@ 5RT8(_UP.X?+@Y^;(P 7HO#4D7A[6])B^S6Y
MOGN6BGA7!_>EF!88'*[L<$\#J.@SX?!LVVZ,D&GPQW$\TK6ELS)&%>U6';N"
M@C)4DD =?6I;KQC?6WVF$:5;R7-HMPTX%V0F(DB<[6\O))$H'(&""/>MBQUP
MW.KW-E/ MLJ*KP,[G,R' W#Y=N-S8P&)!QD#(H RM.\,7UI>VEQ<IIUUY<7E
M?.F#;8E=PT>$ +$,H)PN2@/M5.#P/<6&F16EG]@4?9;.&:,Q +*\0D#ORC %
MMZ_-M)^7''4=S10!Y_=>#KJR\.2!4BNK\6MA:B5(PSA8F7S"-PY! )V\YQ@@
M]*--\'7$HTVYDMDACA^5H'D",A6X:3S5VIP7R"5&S& .V!Z!10!RWA_PQ/I&
ML&\E%G@02PF6$'S9RTH</(<=>O'/.3GG HVW@>[AUV.[>^C:S2X.8 #S LGG
M0IZ924M_P$XKMZ* .(7P-(+=H'6QD\W3K6SEE93NS%(S'MRK!L=1]T=>TMSX
M*>5)H8GMH[9TND2$*0JK-+#(!@#&/W;9]VKLJ* ,:RT>33--U"VM$@"S3R20
M1*S1(BMCY<J,KSDY'0G-<^/!NI1Z?);Q3VH^TV]W:RH[NX@2=PV58C,C+\V=
MV-Q;J,<]S10!RGBSPM/KR!(!9R*;*:T NP3Y)?:1(F ?F&W';L<\8-._\)WT
MVHZKJ$LD!#VMPL MXP)-Y>.2)L!1ED,?4LV2<\=*[>B@#CK+PW?6L^F:B8H&
MNXX7DON0S2R/O=T16&!\[G#!E..#D5/K&DW=UIWARWCTNQD-M<*\UJ__ ![Q
M@6\JXZ'Y0Q4#@]N*ZJB@#BHO S1:9+"TEK+<_9;2W21XSAA"<M&>I$;XVD<\
M'O2CP7<,8'$MM;K)<NUW;0@F/R&=',2<#.6C&20/]9)P,UVE% '#7/@F[EE!
MW6,P:3<'G4EK?%T\^8^.K!PIY'W1UZ4#P/<J+_+V\LDLQD5Y)#B=?M"S&.50
MG0A=F26X)P "17<T4 8'AW3;W1HEL&M[5+8M<7#M <*C22[DC0>@!;)P.@QU
M.,J;P.[+<-"]K'-.+WSF"']]YURDJ*^.2H52A]F.*[2B@#A;OP)-?6Q0RV]F
M+BX<W$%MG9';N(]T<9P.2T*,3@?>?UH;P1>S&QFO+B"ZG D:[PYC'F/()"\9
MVL>,!0/E.%7D8KNJ* .*NO!-S,M\%NXC&9T>SB88"Q^:9G1C@XW.<=" $3@X
MQ5JR\-RZ.TFH6UG;SWD5@EO:1,^[RY \K$!R!A#YBC@#A>G05U=% '/^(_#\
MNN'Y)8D4V-Q:D.#R9&B(/T_=G\Q4<WA9'\.Z_H\0MXX=1\WR$$?R0[XPH^7V
M8%N/6NDHH Y3_A$B^I+J/EV=M<">&13 N3$BQ%"BM@<<G' X[4[PQX7FT33+
MFVDD1)I8$@,\,F=VU2!)MVKM;YL_Q'IEC@5U-% '!P>!;RWT406UQ!::BC($
MN(W+*1Y;1.VT*N"4<D#GE5R3BI+CP([7.J>0T*Q7$$L=LY<JT(: 1!"H7YE&
M,_>]/ER,UW%% ')GP>D.HP7%M;V/DP:FMY'"4VA4^S>2V, X;=A_<J.1U$FM
M>%CJ>IW]PL=F4O;.&W=Y%^=3'(S'MR&#8/(^Z.O;J** .'U+P5>3Q?9K*2RA
MMA<33(GE@&+<R,NT["1@JV0I7D@YXQ6Q9Z%-8Z?K=M;K9Q/>2S2PRB/<"9,D
M>8N,'!.,9.1Z=*Z"B@#A8? <DEM+%>_8Y%=KATB*AE0R11H,811P48Y"CK6A
MI6@W-KXKFN)6+6<4"21Y'#7+J$D8?18E_&5ZZJB@#@&\'7NH-JY>*TM/M!OX
MTFP?-E$Q(7?@?<'WNI[<#'.G<^$=VLK-;0V,=J);>1'"8DMUB.3'& ,;7Y!Y
M'WVX.:ZRB@#C;3P7<6ZPB6XBG\BX*Q [EQ:K!+%%$2.<CS22?<U$/!E\VGPP
M--:+Y43QK#C*%3-%((V(5=RD1%6.W)#=#SGMZ* .'G\"/=VLRRK8H[V]ZL,2
MJ3':RS&,H4X&-OEDD@ Y8D"M/Q1X<GUR2-HA:2+]EGMBMT"1$9-N)5P#\R[3
MQQG/WAWZ6B@##L?#L5K'K:,L+#4Y=S-L&67RD0[_ %.58_\  O>L>W\$NJ6D
MDD5A'<6T%A%&T2YV>1.TCE3M!&]2/QSGUKM** .5T_PQ=6.LV%XK6V(1(LTF
M=S.K-*RJ%*_+@R [@P)Y!!&,-OO#%[/J>H75LUK$L\D$ZJY+&26*2)QD[<H"
M(MI +#D$ $'/644 <'>>"+^\A E.G/-(MXK.P8FW,\_F"2(X^\@Z=,GG(HA\
M*:E-<ZC<I%8VDCRWPCE>/<\PE?Y1("""F!GG=VXXY[RB@#CM+\&RVLEK+<&S
M=[=+PPJ8PZQ/-)&ZD#:H^78P. ,Y[9-<]J?@W58-,^SR0I<I/</++';(A49M
MQ%C'E@ L0>0GRYZCOZE10!R$GA6:2UO98;>QBNKVYBF=)$5BL:Q(GE;RC 8*
MD@[3[8SD9]AX/OXM1LHI8[1ELK?3T-\0?,S 27$?'1L!3DCACUKOZ* .<\->
M&!X?D1D^SKFRB@E\I-OF2(SDN?7._J>:@TCPQ=:9JFGW&ZVVP6H@GD!W-* &
MV@ K\N"V=P;D9!!X(ZJB@#D)_"EU(+U1#ITADO/M0FE!WW"^:)/*E^7A0!M'
M+<*O'&# O@5VAS(;,3*C&$*A*V[&X,V$.. H(4$8Z=!TKMJ* .4M/""17\+S
M6]BT$%_<7BX3)?S-Q7(Q@,I; Y/ !XZ51L? ]UYY;4FL9HVFMY)(DB 20QB7
M)VA% SO7CG&W!)KN:* .:T'19K+7M6GE!%HLACL$8?=1R)92/8R-CZ1BLB7P
M-<'3ELXX=,V+'=P*&4[4$K*5F "_ZQ0,8^F&%=Y10!S'BCPY?:VMG';3VX2%
M2&:91O#;D(8-M)_A/ *\D'/&*I7'@P+'=SKY0FDCOV:2&/\ >,\LZRPGW*;1
MC/?&*[2B@#F$T34)/!L5FQMQJ,SK<W0E4,C2-)YDBC*L!R2 <'&!Z5B6W@S4
M$U"VMY([-H[:TLE%ZP.Z,Q7$LC"+C^[M!Z8R.N,5Z%10!P&D^#[XQQS2Q6ED
MZRHQ$8.^<+=I-NDXZA4PO)^^3QTK0M?"EY:7?G :?<%H#$LEPA9K=O,E<,@Q
MSGS0",K]WOVZ^B@#@8/!%_%;J9HM*NF%Z;DVTZ_N2#;B'^&, '(W<+[>]/F\
M"79LX8#=178B>,LDQVB8+;+"2Q*OALJ3T/!(XZUW=% '/ZIH-S=6EG%:31(]
MM:RP*9QYH):,*"<@[AQSD<^AK!D\ 75QIR6KWD4 DFF\\1=H9"C[5(51N#QK
MS@#!;UKOJ* ,70;/4--BCM+I8I2R/<7-RAP'GDD+%5'7:,GKVVCUQDP>&-2M
M)UGM39)Y5^UU%"S$@AHY4;+A QYEW '=C!&[!X["B@#A8_!%W'H]UI[_ -GS
M-/I:V8NY ?,A86_D[5X^X3ENH^\W!S6CJ'AY[7POXKL]/AC OXIFM;>!=H4F
MV6/:!P 2RD\?WJZFB@#D;#P?Y>HQ7=U;Z>D:7;7*VD"9CC/DI&"N0.<INZ#&
M>^,FG;>";ZVL_P!U+90WMM!"EO-&&_?RQON$LW .6Y! SP[\G-=U10!Q-UX)
MG6S\FTDMWD18!#+.?N.B.ID92K!\[R2I'.3R#@T:EX+N[P7"A[.47 NT!F!S
M;^=)N$L?!^=?3CD#D8Y[:B@#F[#PQ]AUP:FOD"4S7+RNJX=UD*E5)[XVBJLG
MA&6XU"[:5+/[%/>Q7)A8>87*NS,6)4'G(^4E@#G&!Q7744 <2G@Z_CO-+*3V
M8M[%T9=J .H65V*@[<X*,J@;@!@\'-:FA>'9]*M9(I)XW+6%O:Y7/WHU<$_0
M[A7144 >?0^ ;V*QAC!L(C#]F4VT&5BN/*252[DH<,QE!^ZW^K7D]1NWGAV1
M](T:UABM9ETXKFUNG+12 1,F"VTGC<""5[=!U'244 <[X=\,C0[@S.T,LIL;
M:U,JIAB8]V3GT.5P,G[H]*RH_ TEM9QQP?8MPBMQ-&4*I<O'*9#OP.00<9(.
M/0]*[>B@#F1X6,GA>/29Q:M_IJW1CV9B1?M F,:@CH%RHX'T XK-NO!%S<_V
MA'NLT$Z7BK<*#YLPG;(23C[J# ')SM7IC%=Q10!R-]X0>:75([2.PAAO+8PP
MS[,2VG[HIM0 8V9.>"/O-QSFIX/#$J>%=1TM?)MYKQF8A)#)'DJHQPJ84[<$
M #J>I-=/10!R>G>$?*U:&_NH+%42>6X2TB7=' S)$J[,@<_NBQ.!RY^M27/A
M9[GQ:VJS>5/;L48!WPT6U"I4#:=RG).-P'S-P:ZBB@#AE\ ^7I$=K$;2.=-,
MM;/>D>-[1/O?)Q]U^AZ\$Y!JU8^$Y;2[LIC:V$T:*ZO#.YD$!:7S"\1V 9/<
M87H/2NOHH P?#FG7>B6EMI1M;5+6"%LS0G&]MP"_+@<D;BWH<8)YQB_\(5>7
M%]?2WDED\5S-"S(L8 D1+H3?,H4<E<KR6YR2>37<44 <)=^!;B2/R8QI\D>9
M1'YRG_15:Y:93& .NUE4],;5Z@8KNZ** "BBB@ HHHH **** $(#*58 @C!!
M[U6FTS3[B!H)[&VEB8*K1O$K*0OW1@CMV]*M44 0+96J3I.EM"LT<?E)((P&
M5/[H/8>U1QZ7I\4DLD=A:H\K!Y&6%078'<"3CDYYSZU;HH JW&F6%W$8KFQM
MIHR_F%)8E8%O[V".OO2/I6G232S/86K2S1^5*YA4ET_NL<<CV/%6Z* ('LK2
M1($>UA9+=E:%6C!$9' *^A';%,?3;"6 P265L\+(L9C:)2I1?NKC&,#)P.V:
MM44 0&RM#9BS-M";8 *(?+&P =!MZ5&^F:?+<O<R6-L\[KM>5H5+,,8P3C)&
M"1]*MT4 5)]*TZZ4+<6%K,H?S,20JWS8QNY'7  SZ4]K"R=E+VD#%)!*I,8.
M' P&''W@ !GKBK%% %6QTZVTZU>W@3Y'EDE?=R6:1R[$_4L:+;3;"SC2.ULK
M:"-',B+%$JA6((+  <'!(SZ&K5% %>2QM)K@7$MK \P4()&C!;:#N SUQD X
M]1FF3Z7I]SL\^QM9=CF1/,A5MKGDL,C@^]6Z* &&*-I/,,:%]NW<5&=OIGTJ
MO;Z5IUI'Y=M86L,>2VV.%5&2,$X [CBK=% %2;2]/N8Q'/86LJ J=KPJPR!@
M'!'8<"I%LK53E;:$'KD1C^Z%_P#00!]!BIZ* (%LK1""EM"I!R,1@8^7;_Z"
M /IQ69%X7TR'6EU6.-EF5]Z*,!5;R_*R.,XV<;<[>^,\UM44 9T.A:9#>7=X
M+.%[B[),LKH&8@J%*YQG;A1QTJQ)I]E-<PW,MG;O/!Q%*T0+1_[IQD?A5FB@
M"#[%:_-_HT/SR>:W[L?,^,;C[XXS4<6E:=!!Y$-A:QP[63RTA4+M;&X8 Z'
MSZXJW10!5BTRP@@6"*QMHX55D6-(E"A6^\ ,=#W'>D&EZ>LLDJV-J))65I'$
M*Y<J<J2<<D$ CTQ5NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>%0UM<FZ4*  TNQDW-QR<,?T]*L36EM<%C-;Q2%D,;%T#94G)4Y[>U '._\
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M8P.,X&?7 H MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ>"<M);PRRLDL4D7^K^^"67@C(R.H!!QS5I/$.ER7DUHEP[3PB0NHA<_<QO
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MC$X$)4XR2RY^O&,$9-Q=>O+76WMKFXD;3K>U_M*2[D@PQM_+V[& 4$/Y@9^
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MSGG-:(\.6:V\\(>4)-=6]VP7:,-"(@H  P%_<KD8[G&.,8-GK>L(NGV[V-U
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MP3*4+((5D53@J025E<'(QSQBJ%C>:Y=ZC! EU=FP^U,/M<MF(Y)(Q$K8(*@
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M)^8]&9BA&T<Y^92/?I7,2ZKJ^IV^GO<)J%N(!9//*FGONCF*S"<A2O.,(.A
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M9PK?N_W@Y_CW= >O)SK?6M7M;.WB2PNH5E2(6Z+:RN ?M++(26!*CRMK -C
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MBOXD<J+L2;76&,21%W\S(?;DX;!&<]!G.* -/_A(-*-Q' +Q#)(^P8!(!WE
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M64_9[R>\7..6E\W<#QT'FMCZ"@ N-;T@"-))%E5HQ/%B)G5PJ^8-AQ@MA=P
M.>,U':>(]-U-8%SMBNX(WC6=2I?S-^%*D<<1MUX/:J5MX)L[:\L+C[9<R"RC
M6.)'V'@0&'KC(!4DX! W9-.;P;;OIC6CW]WO^RV]LEPNU7C\AV>-Q@8W MZ8
M..G6@#2M]>TF::WMK>[C9IE'E!%.T@@E1G& 2 2!G) R.*DN-:T^TNFM[FY$
M+JC.2ZL$PJ[C\Q&W(4$XSG S6?;^$=.M-7CO[=538L8$30QMC8FQ2K%=R_*
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MK,!G&2 5"C)X7@>M6HO#:6VHK>VM]<0R>9*T@ 0B19)/,*G*G&#D CG!/L0
M7['5[#4GE2SN!*T8!; (RIR PR/F4[3AAD'!YXJH/%6B&"2<7Z>7&4R=C?-O
M.$*C'S!B" 5R">E,T#PQ9>'H7AM=K1E%B7,**P1<X!95!;KU.?SR36M/!UM;
M+;A[VZG^S+;QP;]@V1PMN1>%&>>I/)P.E &S+J5K#<V]N\C>=< M&@1B2!C)
M.!\HR0,G') JHOB71VA>5;P,J%1A48E]V=I08RX.UL%<@X..AI^IZ+'J=[97
M+SR1M:/O7RU4,>02-V-P!Q@@'!'!K)LO ]GIUI##9W+P26[QM;SI!$'0(K*
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MZ>UE^T,(/D 1YE99&!"YSAWP#P-Q]L &E>:_I=@SK<7:JZ2>44569M^P28
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M2@M&5E$18 ?>7<0<\<>_%0KXNN8[4W5W9;$26]!CA.\NENY4G/&#A3QSGVH
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MKGL*P_\ A,9RVH,+=C;/*8[*X^4;3]C6X 9>O][GW ^@!VE%<9)XV-E;R>;
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MKPVUR&F!V#R?-#*1UX^G0CT- '345RMGXQ5])>_DM99+>UL%N[N==JE<QF3
M3/)P/7^(=><2P>([BZN-.;[)-:I+?-9S1S(1NS TBNA(!(!4#Z[O0&@#I:*S
M=2OY;._T>",(4O+MH)-PY"B"63CWS&/PS66?&*M<7T<&E7TZ6OG*)(XB0[QL
M$8=..<XQDD*W'0$ Z:BN9E\9VT"M)+ ?)%D;I9$D#"; )*QG@.1CGD8R,C'-
M21^)Y7U"/3CI<@O3<&"1!*I5 (UDW;NXVL.,9SQTYH Z*BN?U/Q,]AJIL8M,
MFN=IA5I%D10&E+*@P3GJO)[ ]^E0+XR@:33D%H^Z[VJR^8"T3LS( 0.VY",\
M>V<' !T]%9.AZ_!KR226\4B)&D9<OCY9&7<8S_M*"N?]ZJ&K^+!IU]<V45J)
MIHX9&1A(,>8L7F;6Q]W*_C[8(- '2T5BR:O<I8Z1,T 2>]E"&('<,F-WQNXQ
M]T<\U4T;Q3-?Q:(+RQ%M)J5HEP'\S]V2REMB''S-@9*]0".O. #I:*Y^Y\4Q
MVVH2P&SE:WBG-JTX8?ZT1>;C;UQMXSZ]L<U27QA<SS64,.E,DMQ+!N269>(I
M4D96R,C=^[8$>W?- '6T5RL?C *CEK6698#NN95VIY:-/)$I"Y.[F-B?8>IQ
M5[2O$8U/46M392P!A.89&=2)!%+Y3\#IR1CU![4 ;E%8>M>)!HURT9LI9TBM
MS=32(Z@1QAMI.#R3SG'L?;-$^-HLWACTN\DB@=XTD"X61EF$)&3A02S9'/(!
MZ8H ZJBN2C\1:DFM7D%Q9DDSQ6EK;)*NTR&'SF+-C(P W/3@8&:D_P"$U1H)
MYX],N'BMK-;J8[T!4EY$\L#/)W1-STZ<T =317/Z;XF>]U06,^FRVS%Y8MYD
M5QYD>"1QS@A@0?8C'J[_ (2>(7\]I):O&\=U';A6;#MO8J'V_P!PXX(SGV((
MH WJ*YV'Q0;YIH[*RD8Q0M++(SJ!&-\B+Q_%DQ,?88Z]*-!\2/?:2\VH6SV\
M]O:17,W(8,CH6W#'0_*W'M0!T5%<KIOBFYN=9%O=V3P1W'V=8$+*Q7?'+)N)
M'M&!CL?4<EL'C)Y7EN&T\KIR65K=F7S!O19G=26'HH4L?93ZB@#K**Q6\0H=
M*M[V&UDD-W<&"VCW >9\S!6SV4JI;/IVSQ4>E^)?[6U!;2&PE3;&7N'=UQ$P
MDDB*_P"T=\3<CC'- &]17(ZSXP>VTS4Y;:U=/+AO%M;ABI#30(Q8%>H&4;!/
M7;VR,QZGXNN;<7/^CM:R6<=R9XVVR<I;B9""#@\,.,CG(]Z .RHKF3XPB_M"
M]MDM08[19-\K3JH#(RKAA_#N+?+GDA3@=JIR>-+B6W:>"Q\N!;"]N)'=LM')
M;OL("\;AGUQG(Z<T =E17,W7C&*T,SR64S6T;S0K,&7YY8HFE9=O4#", ?4>
MF"=/2-6.J?:DDM'M9K:14:-V#<,BN#D<=&&?<'KUH TZ*** "BBB@ HHHH *
M*ANXYI;*>.WE$4[QLL<A&=K$<'\#7'67AO4Y'@6X66WL_-@,]O\ ;7<N5CE$
MC[LY(=FCX[[,D<T =G+-%#L\V1$WL$3<V-S'H!ZFI*YB33-4C\.:'$4^U7MC
M+"\RM-R^T$'YFZGGJ>M4GT+6+G5]1NIY;U%N(Y/*^SW2KM5H0HCYZ,K9((&,
M@-GDB@#M*SSH6F&ZN;DVB&:Z3RYG).77K@\__JKF8M%\0!K%DV03+;S0LYDS
M'$#YFQ@H)(D^://53R!C:M51X9UL:5!%YMY@7 >XMS=*2X\HKE#GD;L-\Q&3
M\W!Z@'66NFZ.%DM;:WAQ;2,DB@<J[H"V3W)5P2?>GZ;9Z7I3MIVGQQP,J+(8
M5)X7E0<'H."/PK*U+1KW[-I?V(/)=0R(\[R2 +*P55+RXP6.%X(Y! X(XJ#Q
M#H>HWVO+=V4?6WBBCG%R8_(=92Q8J/O#:?UQT)H V;[3=&1WO+RUMPTD\+M*
MZ\F56"Q'/J"0!]:;;>&-#L\_9],MH@95FPJ8 =22I [8))&/6N9_X1;5[C[<
MEW/<2--<*Q;[1B.1/M22 C'S*RQJ0.F.@SP0^[T#7@MG;VF/*@NY)8Y/M#;H
MT^T!U7)/3R\C&">W H UQIWA6Y,>GBSLY//26!8A'G*QR$N/8+)SG^]TYJ2?
MPMX9FFL[>XTNRDEAC8VZR*"P4,"Q&>2 S ^Q.>]9EKHEWI%^^KM9_:9HH[WR
MXHI#N=I;II(U]!E6Y)Z=^E:'B32]2U&0?89FC0V4\+;9BA\QGA*GCT"/SVS[
MT 6Y?#&ASR1R2:9;%XY'E5MF"&=MSG/NW)'0FDT[2-#$CW]A:6^^28NTR#DN
MI9>OL6<8Z<GUK&&@ZC;:C%B-[G3HYYC';_;&0Q[O**/G.2%*R\<D;^!4 T/7
MK51#;JK1S,FXBXVB+;=O*QQWW(X''I@\4 =-<C2;>^5[D6Z7+GSPS\$E<1[L
M^WF!?^!4^XT?3KN^^VSVD<EQY?E%V'5/F^4CH1\S<'U-<@OAK6O[0DN-I68)
M,C7)NV8S%KF.12%_@'EH1^G0 TW5M&UC3[&[O())VDF^U"8+/(^0]W&T7R@Y
M"K%O!VXP": .HFT?1+.TB6>VB2W29-@<DC>S*JCKSD[ !TX'I4C>'M)9&4V,
M7S2"4MSN# $ ANHX)''8D=ZYVVTRZU#P MG%!*;C[8LI261HMX6Z$AV,?F5=
MH(4]<8^M1/HGB**P:*V4_OH;F-8VO#_HP>4/'\W.<)D<=#@#CD '60Z9IJWO
MVR""(7"_(70^@V\@<9 XYYQQ1<Z-IUX'^T6<4F^43,2.2X39N^NWY?IQTK(L
MM%N;.P\0V\,7E2W<LTD$HESNW@[?=2"<5GOX=U.W"HBRW5B)XY9+4WC!I?W!
M1OF)_P">FUL$X.,]>H!TBZ/I(_<I:6XV ?(!RH\LQCZ?)E?I45M;:)=Z<^FV
MZ026QRS0@YYWG+'OG>K<]<BLWPYH5[I>K&YOAY\TFFVT,ET)BV98]P8$'DYR
MIW8YP<X)YI)X:U7RF@:0K \L198YV7Y1>22OTQUC8#WZ4 =)_9NDV%VVH_9X
M(9V(4S'CEL+^9^49ZGBJ]KX<T=;N]O?L\5Q+=R2&5Y &'S (R^G1<'OV-85O
MX9U:T5!!/(,LOF;KIVRJW:NHY)Z0AE_2JLWA354LUM;<30P+=WKNMO<@,_FR
M;HI 2>"JDC'4$Y&<4 =?#9:7ILUK%'%''*S.( 22Q)7+ $_[*C\!36T/1YVA
M!LK9S:81  /DQA@I'UPV#[&L.VT+4E\60WUPAD2*XED-RUR3NC:+:BB/H"#U
MZ>H^\:9<^'[U-1U.:"U,D%SJ,=U)&ER4-S$( A3KP1(-V#@$ #/:@#IFL-/C
M2,-!"JK*[ID8P\A;<1[L7;ZY-,M+;3);>86L,#0N#;2@+D,(\H4(]!@C%8=U
MH-[<>$].L[E/M5U:W,4[1F<Y*K)G;O/4A3C)ZXJE+X6U>*.]:PN&@GN1?ER+
MA@"9)U>+ Z*=F\9 X+'U- '46VA:79KB"RB3YB^<9)8J$)R>IV@#Z"H8--TV
MR\0+/'M2\EL5MXHL ;88FR=O&<9D7//]VLZ+2-1C\(W-E!)<)<R2;T2:<!@F
MX%HPR9V@@,!@G&[\L6]\,:Q,!)%:MM\N[2W@^WLC6GF"'R_G'4!HV; )QD8S
M@4 =?_8FCRW5U-]BMWFF#1SG&<[@-P([$C&>Y&,U8>&RNY1&Z12O;'[IP3&6
M4CIVRK$?0UR5QX=U.)M66"V24WM[%,\IF(+IY"H<#( 82+GGC#9&2 *DMO#F
MKSKI\6ISO+$CP-=!;E@7"VCH_(()S*5.._6@#H+32M(M[M/LUO")[1 B@')B
M!!QQGCC(SUQQTI6T#26GN)FL(#)<(\<K%?O*^-X_' )]<5SMKX=UB9=-BU.=
MY(D^S_:P+E@7V6TB/R""<R,A/KWK,TZVU>#Q5I,&I"ZF^RQ6\;,ID;<X@8,Q
M;[ICW-DGJ6 ^E '>MIMD\K2-;1EVE\XL1R7V>7N^NSY?I56SM]'U*RBFM889
M;;RUBC8)P40Y4#/500"#T[UDW.C:G/XF>X.XP-<I(LXN6 2W$(5H?+[DON;T
M^;.<J!2V_ARXA\%:+HHRCVXMA<B.9ER%*F0!@<D'!X[T :\V@:3<2I)+80.Z
M.9 2O\1;>2?7Y@&Y[\U+%I&GPS-+':1*[.[DX_B?[Y_'OZURW]@ZY%>ZK.DD
MLLDBS"WWW&(71B-B$ A@548'0=>?F-)8:'KMN=,9BQ>"XF)$D^Z..)Y-PR <
M[PN ,9'53QS0!TJZ!I*16D26$*):+L@"#;L7CY1CMP..G J2^T73=2FCFO;*
M&>2,85G7.!D'\>0#[$9KDK+PUK)@CBN6DB3%HMT/MKL;AT<F60'.0&! [$]"
M!@4\:%X@2[TM5(\FTE0^;]H8L(Q.Q93D\CRB@'&3SD\"@#;_ +/\-M#)J7V:
MT,5^/)>;;Q*)G4%?^!-MSZGFKDF@Z7+&$>SC(#AP>=VX($!W=<[0%^G%<CIO
MA75X+:*!HA"D3VAD4W1D69H[E92X!^[A%(Q[XZ &MCPM9ZA$NHF\EE98I#96
MF]F^:&-FVN<_Q'<03WV T ;D.F65O>/=Q6Z+<.NPN.NWC@>@X&<=<"H8M TF
M%Y'CT^!6D=78A>ZOO&/3YOFX[\URJ^%M6ACT6,7%T4AM8UG,5UEEN 5+R$N?
MF!QCOW&,,:A?2-=35)H5283R6UW)Y_VMRD["XB>,8Z(=F5'XCHN: .QU&PTO
M4Y(;;4(()Y-K/&DG4KP&Q[?, 1T.1FFG0-):]DO#I]N;B0$.^SDY39^>WY<^
MG%<Y<:+X@O8[EF=H#/'=A46Z.4\QX3'R.A"I)TZ9X/.:DE\.ZHOB&66VN;B*
MV"XM'28%(5\DIL=3R1ORW&<Y'/RB@"UJOAC1M6N&C$IMIK="91"J$@.JJ&^9
M3A@L0 8<C%:%OHFAW,3W<5G!*E[ RM(1GS8Y,%NO9L GU/)YK+\,Z)>V']H/
M<6WD&XMX8PK71F+.JL&8D],DY]\Y/)(K(TWPSK5GI]O"]NPMH5M4GL5OF;[0
M8TD61@Q/ +-$<$C/E<XS0!V$WA_2;B'RIK&)UW!^1SN"!,YZ_< 7W'%+]BTG
M[5]E^SVXFXG\L+CHOE!L?[OR_2N;M_#6L*]O//<R-/ MD(S]J<A MP[3 \_-
M^Z95W$9;%5(_#&K@7+S13><UN(GFCO-S7$@F#E@&X"D#!7(R,KQ@&@#KK?1]
M/TZ=;N&/R?*CD7[WR@,5+L?4G8O)["E32-)GN%U!+.V>5Y5NEF" DOLV!\^N
MWC/I4%FVH3Z1/9W%L(+J&W6+S$8['D,8+%">=H)QD^A]*Q;?P[JL=U%=23RF
M99D#%;IA^Y%GY; #IDR\].P/:@#HFT+2WQNL83B-HL;>J,<D'U&23^)I\NCZ
M=.TK2V<+M,'$A*_>W!0V?J$4?@*X^31?$L>B_9[9/G:RO+1,W.QU,GE^7*Y!
M(+#:^2O<C&,G%Z_T'4FMKXPIYTUW?,[[[AOE@VG:%&X 88CCI@DX)Q0!U'V.
MWV7*B)0+DEIL<;R5"Y/O@ ?A5#_A&-$^RQ6QTV PQ%BB$9 W8W#Z' R.AQ6%
M9^'M:26TNI[IS>1FW#2&X9AM$&R7Y<X.7YZ<X!["J<OAS6I='L+?9<0F(,MV
ML5]N>:4HH$P9CCJ&/.#SG&10!V.HZ-INKA!J%E#<A%95\Q<_*V,CZ' X]AZ"
MJ]SHFE1I?77V>*"2:"5);A5&55\%SSD<E03QR1SFL?Q38ZA=W&FVMM#<7.;6
MX5]MRT(#X0(S,N!D'G\R.1BJTOA[7)+N3S)3)(2^Z[-P0LD1MC&(O+[?O"&Z
M8XSG)Q0!T&G:9HWEV?V..*3^SXD@A8')C 0;>/7:WUPWO3QI&C7MS->BUMYI
M9"\<L@&<G'EN#[X7:?H >E<__86KQR(98VNK59@?LR79BX^S0HK9'9720X_V
MMPR13+GP]KDU[ [W5P8%GN' @G :(M<LZ-\W4;"!W(QC&": .HGT33+EY&FL
MHG:2-8G)'55.Y?R/(/4=JFMM/M+-MT$"HVP1[NI*@D@$GKRS'\36'I,.I:7J
M%RDMK++;W=V2DCR;G0'>S,Q'&P?*J]#S@] :9=Z3JLOB;[4A;R_M$4D=P+@@
M10JH#Q>7W+'<<_[62<J* -E]%TR2\-V]A;M<&99S*4&XR*NQ6SZA20*>=*L&
MC$;6D)0>9A2N1^\SO_[ZR<_6N9O-.O\ 2/AQ#:Q>;)J(6V%PWF22[GWQB4L0
M=Q7&[./X<]*SK+1M7NM/M7@2Y4>6$A>6X>,VLJSNSR[2<LC*5V@Y.U0#PQ-
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MUT&GZ7=66GZH^=]_<S7#H99G*X+N8AU^4!2O"XQS0!I1:;9PP6T"6Z".U;=
MIY\LX(R,^Q(_&H(-!TNU>V>&RB0VPQ"!G$?7H.@QN('H"0*Y6Q\,:O-;^3?L
MZ0&[DE$*W++M0VZJ!\K=/-#-C)ZYZU?U_2]<OO"UC96^V2]$(6>0S%663RR
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M% '7:E8Z3]CN[C4((1 /](GD88P47[^1R"%'4=A3QI6EQQFV%I;HDL*P>6%
M#1IDA<>@W'\ZY'4_#WB"^N-24"-8IM/GM5(G.)"\*JFX$GD.&[ #C&<FM_6M
M)GO-:TN^@C#-;K-&7WX,9<#:^.C %>GO0!JII]HDXG6WC$H=I X'.Y@ Q_$
M5E3P>&)+2_O9WL#;^9B[G:4;4=&W8+9^4ACGM@G/6H/"NEZCI[S->*T2-;P1
MF-KDS;YEW^9+D]-V5]SMY JA/H^HS^&O$U@NDHDE\TGV2,RIM&^(1@_[.",_
M0\4 :YL?#%KJ-K9>7I\-XL>(+<,JOL)8\+GD9WD<<'.*M6,FBLJ&QELW691
MIB=6#J@.%XZX!/X&LVZL=1GUNTO;6VEM)'$2W4C7"F,Q*6)C*<Y;YFP1ZYSQ
M@T=.\.:CI6M6]S9 1VK,8WC>02>7$NQ5!+9.2J#[I'(0'(7- &ZGAC0X[=K=
M-,MUB8H2 O=<[>>O ) ]!QTJLFFZ#J&D2?8EAAMY;4Z>DT2A0(SE0JY&",M\
MO!'/'6JEWHVIS^)6N/F,#7$<B3BY($< C"O#Y?<LVXYZ?-G.5%1'PQ*GP_TW
M1Q;K)<6AM)'B$I 8QR([@-[A6 [<CI0!NQV.E7NF#35BBEM+4K"(_P#GFR8P
M!Z$8'(JQ:Z=96./LMM%#B-8AL7'R@D@?FS'\37)S^&-55]0GT^<VMU=&[ D^
MT-A0\8$9QT&' / R.3WJ]9Z/J</A/5+.&6X@O+@2>0)I@?*)0* K+G:,@G/)
M!)/M0!K/H&DR37,SZ? SW*/',2F=ZL,,"/\ : &?7'--&@Z+!;&W^PVR0R%U
M*D?>WKM8<]<J OT ':N=OM"U6X1!9VLEJI@,=NGVYO\ 0YM^?-.#\W&.!GIC
MHQI+KP[J-Q+>>9;&> :C#=PK+<?O'Q(Q< @XVA67:#@CD'H#0!JP^#=.CU&Z
MNY&DF6Y,C20N%"DNX<Y( 9L$#;DG;VJ__P (]I'DQQ?V?!Y<:2HJ[?X9>9![
MACR<]3S5/1K#4;.ZU<RK^ZFD,ENTTNYRQ+D@D'&P94+P"!D'H#6)I?AK6)%A
MCU/<EL;Y9YH4N6 V?9G1@,,3@R%3C)SU/.: .DNM)T2*X>YN;2W$MT?(9F7[
MY<;,?4C"YZD<5HQ6T$$DKQ1*C2D%R!]X@!1G\ !^%<1!X<UQKG27O@;F6W%D
MSW#7;83RU E7;_$2V6SWSURHKO* "BBB@ HHHH **** (KFXCM+6:YF.V*)#
M(YQG  R:YC_A/;-=.%[+I]['&TJ1+\JG+.I,8!!QR?D]F(SQS75LJNA1U#*P
MP01D$5CS:%H=KILBW-NGV*%'9A/(SI&FPJV-Q. $)''0$XH I77C2UL7N6N[
M*ZCMX#,AG^0AWB0NR@!L_=!P2!R/I4;^-HEMC(-*O7=1,SHI086)4=F!+ ,,
M.,8[@CM5R'PWHEM=SO.D<TU^\ORSMG>'7YE"DX/RKR<9('/%65TO24D6R9 \
MK0R[4EE9W,;;5?EB3C[H_*@"A=>,K.T:\$EO,#;M$J E0TID*A2JDYVY8?-T
MX/I4UCXI@OKVSM?LEQ UU&S*T^U 2K."JY/SGY">,\%3T/%B71-&DN'CE@1I
MIH\A6E8L%5E.4&?EPP0Y7'.T]<5.FC6*7%O/Y3M);#$1>5VV]><$G+?,PW'G
MD\T 9-YXK^P75[!]CGNW@ED4+"$3:J0QR-DL_/\ K..GICC)F/BF$I=3QV5P
M]G;ND;7 * %VV< $Y_Y:#G'8_CI/I&GR32S/:H9)2Q=O[VY51OS5%'X5 WAW
M27:<M9)B>,1RKN;:PP!G&<9PJC=UX'/% %5O%$7]H+9Q65Q*^;C>P*A46$H&
M8Y/K(N .:J)XW@9K%&TV\22ZBBGV?(S1QR-M1B 3G."2!G !]@=FUT/3;+'V
M>T1"%D7.221(5+Y).26*J23Z4IT73S);2"WV/;(L<1C=DP@Z*<$;@,=#D4 9
MFE^(IM5UZ.".UDAL7M9)HY)-N9=LBH&&"2!R3@@=1[@4[#QDRPJ-2LIT9GD*
M3+LV-&MP(2V V0%WH3GMD]JVHM+TC199=02&*V9@5>4L< ,V2!DX +<X'&2?
M6H9O"NE-9:A;P6X@:^@D@DD7YBHDR6V@Y R3DX')Y.: &RZ\9--T^^M8OW5W
M>) OFC[T;.5#C![@!A[$5#/XOMHM4O+%+&\N&M=ZLT"!MSK%YA4#.>1P#W;C
MN*U)]'L+C38=/D@!M80GEHK%=FS[N""",8JN^DZ19N9G4Q&?; 29W D) 09Y
MY<C"[OO<#F@"D/&5D! \L;)#+;R3F;S$9,)NW*I!^9AL)*CD9&1UP@\7?OHK
M5M)O%O9I(U2W+QY*R)(ZL6W8 Q$X(SG([\5HIX>TI#"1:!A%NVJ[LRY;=N8@
MG#,=[?,<GYCSS2VF@Z78^6;>T56CD$B,6+,&"%!R23@*S #H >* *NJ>(/[,
MU"2 P27&([?9%$JAF:64QCYF8#&<=ACU/2ED\211^'O[7-I/M$IADB.W,;+(
M8VW'. JL#ELXP,UHSZ;9W,_GS6Z/+^[^8]?D;>GY-S39-*LY+)K/RBL#.TA6
M.1D.YF+,<J0>22?QH S)O%MA KO*DHCCN# SKA@,6OVDMP>1LXX[^W-4M0\6
M7=A/:SS:3<I:FQNKN>+=&75(S"0^=V,;9&&.N?;FM<>&]&%TER-/A$B#"\':
M/W?E_=Z?<^7..F!V%+'X=TJ.W-N+-3$89("'=F_=R!0ZY)S@A%&/]D8H AUS
MQ"FBNB_8KBZ)MIKIO)*#9'%LWD[B,GYQ@#K5"7QS8QO?E+2[EALXI7,J*"',
M8RRCGCN!G&2#[9N7.E:/XGN+>^D=;N"WCFMPBL=C;RF[..H_=XQT()SFKCZ%
MILDET[6V1=*RSIO;8X(P25SMR0!SC- &(WB:_@UVYAN=/FCAC@MEBMPT99YI
MG8<MNP  OTX;KQ4I\:0B*>0:;=D6UM/<7/*?NO*9T9?O<G=&0,<=\BM:\L-+
MN[EK>ZCC:XND5L;B'98F!# CD;6<'(Y!(JM<VGAW2[;[/=FRM8KF)K;;/*$\
MU"267D_,26)/<EO>@"K#XN1KUK:XTN[MMLS0-)(\6T2"'SPN0_\ SSYST!XS
M4*>.();=GM].N9Y5EDC:.*2,CY(EE)#;L$;7'3OQ[UN3:-IUP9#-9Q2>9(97
MW#(9C%Y1)_[9_+]*CM] TNU4B*T&2S,69V9B60(2222<JH'T% &?)XOMDM;R
M\6SN7LK4(&G&P;I&5&5 "V>?,49Z9SZ9JS#XCADT7^TGMIXU%PMN8V SN:01
M@@]"N6!SZ>_%+)HFAI<>5);1![J/RO*+'$@50/NYQD*JC=UP!SQ5LZ59OIK:
M?)$TELX^99)&<GG.=Q).<\YSD4 8][XRM[,2L+"ZF2!;F29D*#9' X5VY89Z
MY ')HNO&=K:)<S265T;:$7(29=F)7@!\Q0,Y'W6 )P#M/MF:3P=HTEQ;NUK^
MZ@CE00[CM<R.KL6YRV2O(.0<G.:N/X=TF2:YE>R1FN5=)02<$/\ ?P,X!;')
M&">] $'_  D<::/JU_<6=Q"VE[_M$!*L_P L:R<$$@Y5E[]359O%\$6IK87%
MA=12@+Y_W6$)8$@':3G@#)&0-P]\;,FFV<L-[#);HT=[G[2I_P"6F4"'/_ 5
M _"FOI5E)J OFA(N-H4LKLH<#.-P!PV,G&0<9H P[CQK%:V-I<RZ7>!KN-IX
M(04+/$JJQ;ANOSJ-O7)].:)_%ZVTEP@LKB[,9G?$2JA2.)8V;.Y^3^\&.F3Q
M@=:TE\,Z1';QPQVA1(F)CV2NI3( VJ0<A< #:#C Z5%?>%=*U"^CN+B#<JK*
M'B!(60R; Q;'7B,#'0@D&@ TS7S>G5Y)K8P6MA*%2;<#YB>4DF[ Y'#_ ,N^
M:RKSQ9=SQ0065A/;74TMJ?WIC8B&8OM88;&?W;#';WKIH=/M(+BYFBA"O=;3
M-R<.0NT''3. !TY 'I5:U\/Z59*%M[-%"NCKEBQ!3.P D\!<G Z#/ H BU#Q
M%;Z=K%IITL99[ED4,LB94L2%RN=V,CKC'UP<-T'Q''KN=MG<6V;:&ZC\XJ=\
M<F[:?E)P?D/!]OPMW&C:?=:A'?36P>Y3;M?<1]TDJ2,X)!9L$],GUJ6TTVSL
M=OV6W2+;"ENNWM&F=J_0;C^= &!8^,5GCL0UE<2>?#;,]PJHB*TX.P;2Y/48
M/7&1R:DA\96UX+=;*RN9YI_+5(P57#M&TC(Q)P&55&?=@/7&M%HFFPQHD=G&
MJH(@H&>/*_U?_?/:HV\.Z2T#PBR1%>X:Z)C)1O-;(9PP(()!(.#T)'2@#*M_
M&,5T\7V6UGN&NO*^SP!51ANB:0[F+8X"'TYXYZU;L/%%OJ&M2Z;%:W ,;.AF
M(!7>F P.#QR2 >^T^V;,GAW298EB-C&BILV>62A38I5=I4@C"DKQV)%3V^DV
M5I=R75O"8Y)/O!78*3QSMSMSP.<9H Y^7Q3J7VF%8M*=O^)G-9F-9$S*B12-
MD$D!>4'6I8/'%A=7445O:W4D;QHYD"C";X?.4$9S]TKSTRP'KC;32+".Z:Y6
MW E,IGSN.!(5*%@,X!*D@XZYJ*+0-+@D1X;41[(EA"H[!2@7: 5!PV%X!()Q
M0!DIXV@,EC&^FWB27444VSY&:..1BJ,0"<]"2!G !]LU+/QC<PV-S<7]C/*Z
M/=S-'%Y8\FWAD*$_>^8\=.I(/08KI&T73S+;2BWV/;(L<11V7"KR%.#\P'H<
MBH[CP[I-TB)-9(RH9"!DC/F-N<'!Y5FY*G(/I0 [3-6&J37BQVLL<-M*81,Y
M7$C#KM .<=.N*S[GQ)+::Q/8_8FN6\Z*"W2$A6+-$\A+%B!@!#_]>MA=/M%(
M*PA2)C<<$C]X006_4TC:;9M>"[:W0W <2!^^X*R _P#?+,/QH RYO$;-IVB7
MUE9/-'JDD:A695:-70OSSC(Q6;;>-A;V<SZG9S*ZO*(739B8+<^0 /FXY:,<
MXZDUT;:18/8V]D;<"WMBAA125\O;]W!!R,=*CDT+2Y8O+>SC*;77'/ =P[8]
M#N ;/8@8H IOXHMHO#HU>6VN$4S" 0L &+F3RQ@YQM)YSZ<^U0P^,;25H4>T
MNHI9M@CC=0"^9'1B.>0NPL3_ '2",YK7?2K.33OL$D326V0</(S-D-N!W$[L
MAN0<Y!%-71[!9[.<VX>:S#B"61B[IOX;YB23GWH P[/QQ;W]O%):Z9>R&=XE
M@7Y '$BNRG); P(SD=1D=<U;T;Q&^LZFT,=C)':_88+M979=P,AD&T@'MY?;
MT/M5ZVT+3;-8U@MMJQ.)(E+LRQD @;03A0 Q&!@<U);:186<\<]O;B*1(1 I
M5B!L!)"D9P<$G&>F3ZF@#G=5\9O%IE[)8V$PE\B>2TED*%)?*<1L<;LC!8$
MXR/RK2U?Q#'X>T^VEOD:1V3,F'C5\*!N(7(W=?X>/TS9'AW25>X<64>;@,L@
M))&&;<P SA=S<G&,GDU+J.C:?JQ0WUL)MBL@RQ'RMC<IP>0=JG!XR!Z4 8?B
M[Q)?:%=6Z6D<;H;2>YD#6[R9$;1C&5(V##L2Q! QTJ:Y\8P6WF$V-P5%X;*%
M]R8FD"L[8YX4*I.36KJ.B:=JTD;WUL)C&C(,L0"K8W*0#AE.T9!R.*6;1M/G
MA,3VX"F8SY1BC+(>-P8$$'!(R#T)H R)/&^GPRVHFAFC2X@\[+%=\>(6F(=
M=RG:C=NOYU#J'BR[L)K6>;2;E;4V-U=SQ;HRZI&82'SNQC#L,=<^W-;)\/:4
M;M;EK-6E48!9F8'Y#'D@G!.PE<GG'%)'X=TJ.V-N+13$89("'=F_=N%#+DG.
M"$48_P!D8H ?KVH2:7X=U'48%1I;:VDF17!VDJI(SCMQ534/$]MI^MPZ4;>X
MFF<1,YC (19'**<9R>58G'0#-7O[(M6L[VTF5IX;UG,ZRMG<&&"O'0;< 8]/
M7)J./0-.BFAF2&02P\*_GR%B =P#'=\P!)(#9 R: ,V/QC;O%"YM)HQ)=?9F
M$CHODM@$>9D_(QR,*>3VZBF2>-;>-&D.GW9C=7>V*E/WX25(FP-W'S2*1NQD
M'MTK2_X1S2MI4VQ8&02-NE<[R,8#9/S 8'RG(XZ4Y/#NDI)+(MDFZ4Y;)) ^
M<.=HSA<L Q QDC)H @U;7VTFVMGDTZXEFG1W,,;IE-B;VR2P'0$<=35&;QM;
M0:;/=RV,\;0NH\F26)693'Y@*_-@G;V'.0>W-=!<V-M>%3<0K(4#*N>P88;\
MQQ5.X\.Z3=)MFLD(XZ,5)PFS&0>FW@CH1UH BLO$EK?:DMA%%-YY+$A@!A B
M/OZ]#YJ#ZGV-,U_Q19^'.;R*9E,)F4Q@'< Z(P'/4>8I^F?2G2^&;&6ZO9R7
M1KNTBLV\O"E8D+':#UYW$$]< 8QBK]YIEEJ$D#W=M',T#,T1<9VDJ5/Y@D4
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M#NDPO(R62 NRN<DD*0XD&T$_*-X#8&!FK-YIMGJ"[;NW24>6\6&_NN,,/Q%
M&5<>(Y(_#^M7ZZ?*EUI:R>9;2NO++&)!\RDC!5E/YU7C\3W$6N26MY82I;DV
MZ"160B)Y%8X;YLGD#D#C-;S:?:-'=QM A2\)-PI&1)E AS_P%0/PJ&/1M/B"
MA;<$J8V#,Q8Y3[I))R2* *.A^*K37;:>YBM[B&".%)Q)(HPT; D$8SSA3D=1
MD>M9X\?V(TIM2EL;V.V!C&[:IXD!V=#U+ +CL6&>.:Z&QTJRTV)XK2$QQ-@>
M7O9E4#H%!)"CGH,"JR^&](6V%L;)7MUSMBD=G105*8 )( VLPP. #0!F7'C>
MTMIM01[*Z9;&*5Y70*1NCCWLO7CC(!/!(^F9KGQ+-'!?8TVXB>SM6GG=S&PA
M.QF4$!QN.%&<'^(<]2+[>'],8W&;;*W,9BF0R-MD!7:<KG!)4 ;L9QWI]UHF
MG7ET]S<6JO+)$87.X@.A!&& .#PS $],G% &7<>,;6S-VL]O,'MVBC"DJK2F
M0J 0I.=N6^]TX/<5;_X2*,Z-;7ZV=P7N9A!%;D!7+[BN,DXQ\I.<\@9&<BII
M?#^ESO,\MKO:4 $L[';@AAMY^3Y@#\N.0#U%32Z593Z>MC+$7@4AE#2,6# Y
M#!L[L@\YSF@#&T_Q#=:MXBM[>"W>&S6WE:8.%+>:DK1%203P&0\CK]*6;QG:
M0W=Y;"UFEDMV15$,D;>86F$./O8!#,.#C\#D#:M-+LK$H;:V2(I'Y:E>NW.X
MCWR223U)-5D\.Z3'/),MDF^1][$L2,^8).!G ^<;L#OSWH H)XPMCY:2V=Q%
M/(S1I$=I+2+.('4$''#%3G^ZV?7$NL>(CI\U_;Q6LI:TLENY+C:K(@8N%&W<
M"Q)C;I^=6I= L9;^PNA&%-E-+<1J .9) 0S$_P# F/U/L*M3Z;9W)N#-;HYN
M8EAFS_&BEB%/L-[?G0!S-]XVRU[!I]G))+:3+&S;D.2+A864C=E2<MMW8R!F
MK]EXEEOM9L[)--DC2:.Z,S/(N8GAD2,C@\@ENH]1[X++PC:6E_<7+SRS1S2/
M(86P%+-*)=S8^\58?*>PSUS6HND6"7,5REN%FB>1T=6((,AR^>>02 2#QD ]
MA0!F77BNWM;R:)[.X,$<KV_V@;=IE6(RE0,Y^Z",XZC'O4\NOM#H=MJ3:;<[
M[F2...VW)OS(P"Y.[:.H)YXJQ)H.ERWLEW)9HTTN=Y)."2NPMMSC<5^7=C..
M,XJT]E;200PO"ICA9&C7LI4Y4_A@4 <])XXM(WOA]ANV6S24LR!2&:,@.O7@
MY) S@':?;*-XV@MQ<M?:;>6J6RS[V8QMEHE#,HVL<Y4@@].U;#:%IKR7+M;9
M^U B9-[;'SC)VYQDX&2!DT^71M.G\SS;.)Q(7+AAD,77:V1[@8H YZ\\:M_9
M=R]GIMTUZD-Q(L;;-H6)$8ODL PS*@XYSD=C6IIWB.&]ODT_R91=C=YHP,*%
M6-MW7H?-3'U]C4LWAK2+FU2WN+4S1INQYLSL<, &4L3DJ0!E2<<#CBI;;1K6
MUUBZU.-?W\\$5N>!A4CW$ ?]]'\AZ4 :-%%% !1110 4444 1W$(N;:6 NZ"
M1"A9&VL,C&01T->?CP_XNO+&^AU*XWBYL9B8UN/E^T^4T"H!_<92)/0-SUKT
M2B@#C+G0M=A2[@TR[FC0R2M;/+=,^S=:;%)+$G'G9..<=:BO/#M_=JES:6][
M9306,Z0+)J#,ZS%HRNY@YR/E/!)'J.:[BB@#$U"&\C\3Z=?P6;W$"6L]O(4=
M 8R[PD$AB,C"-TR:YF#0O$<>BW"3RZA+?_NL@7 \N:1=^YO]:&V,2,@%#@+@
M<8KT&B@#B[G3-?>YORB7#02O#(Z_:RK. R[XXF#\*5!ZA#GC)!R+>B:-J46H
M6]Q?RW/DPQR^5"UVS;"TK%%?G#E8R%R<_4]:ZFB@#C;_ ,.:E>:G=7!N+P)+
M/+@1W\B*(C H0!0P _>#/'-0MH_B.\U0?:)9;6%K8PR7$5RW4P ;L;\;A)D\
M*.@.3DUW%% ''VUEJFN> Y6O ZW^IE;AHO,*B)2R[57."N$4'MSD]3574M&\
M1)"MMI_FM&ES+)#*;MR\:ED* DR#(QOZA\<# !-=U10!Q-[HOB1QJ"174IAB
ME7[(%N#OFB:;S90?F&"%Q&N2.%(R V:MWNCWTWA&SLREU<SQ744SI).$E*++
MN*APQY"\#YNPR>]=710!P]GI^N6^JZ1:2W%P(+@237*-.SF".&4O$F[)R2)$
M1N?F"=Q5[6=&U:YGU:YL[B=9)$@2V47+*NP,#* H8 ,R@C/!Y'(ZUU5% '"R
M:3XA TF.W%SLBG26226XPZ+]H#,C 2D%?+R!]\D<<4X:5K@!66"]N+-;QI&B
M%[Y<\RE&QEA)MPK$8 *Y'\.5Y[BB@#C;#0M=AN+*YN[R>6XA:V61A=-L91%M
ME.W.#EN>1D\&K-_IFK3^)#*AN/),\+1SI=%8XH0/WD;1AN68[L'!^\.1M%=3
M10!R<>A7MEX!M-+@%R+N)(]RPS9)8$$@EG7*G&" PXSBH6L?%#7:QKF(-/\
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M3S6A10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI'<3O(LK!P(P(^B!0#RI&<_EH-KVL0^)QI4OV,K&%W%E$;3@H6+Q@R$X#<8
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ML<#;@C^+.10!VM%<+JOBW5-*MF23R)+N*>9/EMBJ3JFPX&9 5.),8&\G!(&
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MM/Y;,^7^8!3N_AQ@YXZ4['Q-J]O%9P)):R_:+BZ<7%Q\B3_Z6ZA$+."HV8(
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M\V2+#=<H[(?U4U:JEI>GC3+(VPD,@\Z67<1C[\C/C\-V/PJ[0 4444 %%%%
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M'4+22\,<<4:MN)6P68&,[B K,A 7!Y?.?7L(;VTN+B:WANH))X>)8TD!9/\
M> Y'XU#'K%@VGO?/<QP6R2R0M).P10R.8SR?]I30!S]CK]_J?A#6+UGM_-AM
MW:&6U93SY6[D*[X(/OZ<"H+OQE*LNF0Z9+8W,<T(9IGF0K(X*@QAC(H#8.3@
M,>1\M=4VJ:<CE&OK56$7GE3,H(C_ +_7[OOTH75-.9[=%O[4O<C= HF7,H]5
MY^;\* .2NO&=W;0WKM-8 VMYY<FT!P(2),;/WH\R3Y!E/E8<_*?ERV;QIJ<<
MVK[+2V*6?G 1%E$J;)5178>9N*%27.50 8Y.<UV5O>V=X\J6UU!.T+;91%(&
M*-Z''0_6H%UO26AFG74[(Q0X\V07";4STW'/&?>@#%;Q)>1>#9=7D-EYJ3*B
MR!@T14RJFX[';& >0&/(_"JMKXGU:Y=! ME<QQQ7DS2P1,1="%D51%\YV[MY
M&26Y7C.:Z&YO=&O/,LI[RS<H$F>(SKE0"&5B,Y SM.?I5B;4K"V<)/>VT3F3
MR@KRJI+X!V\GK@@X]Q0!QP\;7EO9R7LGV+4+*'RC+/8HP&9$?$8^9LN)!&#[
M2C@8J4>*M974KVREBTV.:UB;<LTJQ@L( _F9,F[87.W[G YW<$5U\-Y:W$LT
M,%Q#+)"=LJ(X8QGT8#IT/6J[:YI"P-<-JEB(5D\II#<)M#_W2<XS[4 8S>)9
M3X2MM522W5Y9U@DN)H]L4/[W8SD!R"HQU#X/!S@U73Q3=MK,5HD^GS@S0Q"*
M-&\RX1X@YGC.\XC!)'0_<;YJZB2]M8U?,\9*DJ5##.[;OVX]=O./3FL]?$NF
M.VF1B8?:-1"-#!N7S%5D+AF7.0,*1GGF@#FK?Q;<:R=-,+(2HLIIUMF.?-D6
M;S(CSV*+P>0>M7?!^M76MZK>W$]Y;SHVGV<@BMMP2!V,Q9""Q^<?*">"<#(&
M*WX];L)-7GTLSI'>1$ 1.ZAI,J&RHSDX!YXJS;7UG>+(UK=03K&Q60Q2!MK=
MP<=#0!PFE>*-4L/#5DE_<V[3'3[&:.X>(G)E60$2%Y5!;]UG<67);&,XS:A\
M::I);6Q&FI)<3Z<FJ+$@;F+R"S*#G[_FA5^D@X/?JUUG2I!"4U*R83.8XL3J
M?,8=57GD\C@>M*=8TP+<,=1LP+8A9SYZ_NB3@!N?EYXYH YH:[?ZGX$U^\:6
M 2PVLWD36<BYSY.[/R2/M8$_WL]#@52G\:ZC# 5B?3KA?M!A6_0!8#^Y#[3O
ME4;LDC._L>,\#M1J>GFZ2U%[;&XD3S$B$J[V7KN SDCWJ$:YI!M9+D:I8FWC
M8(\OVA-BL>Q.< T <K<>,M5CN]206EFGV.WDD\EY%+G;;B4,,2;G4L=O"8QS
MNXQ6LFMZC#H^OS7*VTEUIBLT9BC94?\ <+* 06)ZL1UYQVK2BUW39=5?31<Q
M+= *41G4&4,N[*#.6XZT_3M8LM3T^VO(955+A$94=@&!=0RJ1GAL$'% '/OX
MCU>W\0V>E3)9,SI"[M@1"4.[!O+W2Y^0 <!7R?[N168GCZ[DT^ZNEDLO)A>%
MQ,T84F-UD) C\[YG&P?+N5L$_+D8/;OJ>GQW,EL]]:K<1)O>)I5#(O')&<@<
MCGWHN-3TZT(6YOK6$F3R@))E7Y\ [>3UP0<>XH Y*^\9W]L^I-"MG(UM'>$6
M91O.A$*%DDD.[[CD#C:/OKR:9K7C'4M$L-0\\V;WEI.Z)B JDX6".7 W2C:?
MWFW@L3C(4\@=+J/B+3=*L+N\O)TB2W+KM9T#2%5W%4!/)QT'6K@U&Q-P]O\
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M>>FU6QG:3G ..<4 <3KOB:_ATR^MHKF&S8_;2DDI<R2E)R@2([AA@.>^,C
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MV$>9*L"RIO@=R6$*E;P6YE*YX4#YL9]L]Z +=GX+DM([.W&H(UM$MGYH-O\
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M%%([DYQA!+GIR%-6[S7[RVT;2+F<6MC-J$@61[K/EVP,;R -R,GY0O4<G\"
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M2C1%%7YE\SE_E'((')&.:=X>N-1U'4-:O)Y3&?W*06[A\0;H(Y,%=V"<N<D
M$\\XP!AZ=XDUEK?3M1>\M;I6TRUENE"D!F>7:VT!L*XR<GU7&!V -B#P;):W
M-NL.HC[%#(LWEO!ND9UM?LP^?=C&T!ONYSGFELO!TUE>6;KJ$3V]O-%<,C6W
MSM(EN(.&W<*0 <8)SGGFJ8\4:C%YGE1P-#!)*\OFEF=E%X\.U3GC@9R<XQC'
MI''XUO[AM6: Z=LLY/+".P5U(G9#G=(N[Y%W8^7);&<B@#7N_"\MWK<MX;V-
M+:6>*=XU@_>[HTVJ!)NX'?[OJ.]2>'/#/]@V4ENUPL[F".W$H$FXH@(4'<[#
M^(\+M')X](-9\37%AI&F7ME#'<_VBHB@WJR SNFZ'(ZJI((.>1D5E/X\N)M.
MCOH$L[6WFAN)X'N]P\P1",&+J,.7:0#K@)]TT :!\$H%TM%NE,=G9Q6<D;+(
MJR*A!! 21<'(Z'<.GIRUO!UW)<7T\^J)/)< ",R1RCR]LID4C;*,$9 &S:.,
MXJIJ_C"4V>HV2>7;W@6Y0('Q-$JVOFJ^,Y!R0,U)%X@N[OQ9I]C]IMXXH[N2
M%[96/G,%MBP=^>5)((X[*<G/ !=B\)W*W:23:FLT9GBNI2UOB5YD@6'.X-@*
M=H8C;W(S@U&G@Z>VM8(;/4_),=K:VS;8F4.(5D'.UU89\P'@C[F,D$BJ$WBJ
M]TO7=8A#0WRI=2A+)6)G14LQ*&'/"%EVXQU?.>U6CKM_?^!=?O7:&.:"UF,$
M]K*AS^YW _([[2"?[V> >,XH =9>"I;-[)/[1B>W@2S$@^S8D=K=<*0^[@$\
MD8/&1GG-.TSPG)IVMZ6_FF2TL=/CB8X"B2X13&CXR2#L>0'ZKSQ6?>>)+RR\
M10JI/D>=<P2-(Y,40W6V)''H-[ >A;D@9(67Q3J5_P#:HQ%';Q17D<8*2J)4
MVWD<6U@'+$,I)Y50.G.0: -:]\)OJ6MS7=[?F:SD62,6I5AM1XA&5SNV^ISM
MSSC/%5&\$W+6"Q'54DN9K:YM[RXFM=WG"8J691N&U@% &<C &0<5HZ%KEWJ]
MS?6[P1Q/8_N9FP2//W,, 9^[M"/])%KGH/&FHP:'933W.GSW7V'[3)N4H;F0
M$ P1@-Q)G@]>67Y>: -+4O!,MVEV+?48XS<Q74#^=;^;B.=8P<?,/F'E#GIR
M>*6Y\#K<S:GOO,Q7JR[=RR%HFDC"$@>9L(Q_LYQQGO6AK6LWUAJ/E6L$4L45
MC->2*03))LP B8. 3NZG/3ISQBP^,K[[#;W-P+!87N5C:6.1)"4*J>$64G.Y
ML<$G&#MYX -G3M'O["^>:66SG-U>&ZN'6W,8C @6(+&-Q()*@EB>FX=Q535O
M"-SJVI75Q)JI$,L4L<<1C8^4)(?*/\>TX.6SMR<XSBL^_P#%TMU%)9P211W"
M-/YHBD^>+RKR.)01GC<K$\_RJ[%J^JOX1\077VVVDU"SDO5AV0\Q>6[A R[C
MDX4$>Q&<]2 3W'A20WC75I>0Q2&?S DMMO0+]G$)&T,.<#(/X8J?^Q)K2S\-
MPP.)O[)D17)^7>GD/"2!V^^&Q[$5DP:YJ4>MF3[5:W=E(;.)O+#8)DW#='\Q
M"C.">N?:HM-\8:QJEG!)':V43W4L"1EW#>5Y@<LKJDA;*[!UV9)(PN* -*Q\
M(#3KS3;H7;2K8VJ1-"(PHFE165),YX^61QCOE>?EJ6'0;X>%--TU+T6MS J-
M.RABKG!W+E65@,GJ".@[$BL+4?%&KWUCKL%NL%IY"3HD@=?-C,<HCSM$F_YE
M)8':NWY>6R#6@^O:C8B:%Y+**"&]CT]+B?>P3]T',DA9\D$G:!G.2,MS0!/8
M>#5L;>TC^V!VMULEW^3@M]G7;Z_Q9/TSWIVA>&6M-#U.QNG=/M;RP1[2-T-L
M,QQ*"/1,'ZL:SE\7:O<)&]O!8A=EIN+[R)#/<20!T(/W/D#CKD''O71Z'JQU
M&S7[0\*WBO-&\<9QGRY6B+A2<A25SWQG&: ,N+PK=K+'=2:A;F\CD@*F.T*Q
M;(E=0-F\G)$C<Y[+QQS'<^"%GM1$M]Y; 3$,L9&6>Y2X!.&!P"F#@@D$\BJM
MMXHU$&,)' T$9MC-YI9I&\ZZD@P#G P$!YSZ>X5/$=W?G3ITN;;<;YU:S@8^
M9&!#<8CEYY.4!Z#D'CC- &SI7AM--OH;LR1M(D,L;!5?YFDD#ELN[-U'/)R>
M>.E4=6\'W.K7]]/+JI$-Q!/!'&8V/E"2(1_W]IP06^Z"<X)XJDOCHW26_P!G
MFTZ-)?LP>ZD?=% TD4LC;L,.\84#(Y<?2J^B>(=4>STN&.2.6YNK:R!EN&9U
M!DCF9FQD$G]V.XS[4 ;5YX.ANY;IOM/E+<73SMY<8#!6L_LVT'/;[V?PQWIB
M^%;Y;B*^_M*U%_%+$Z,MF1#M2*2( IOSG$K'.[LHQ@<T=/\ &EYJ&M:58!;*
M%KF"*6='R6(97+%"6'0HH P2=V>QJ5_$%W9^,;RQ%Q;S1R7<,2VC,3, T 8L
M@SPH()/!SSR,<@%FQ\&K9V]K&;P.\"62;_)P6^SY]^-V3]/>K:>''/A@Z+-=
M1N@<%9!#CY!(' (+')XP3Q]*P#XUNM0M+26RN["W 33Y+J1AYBH9S('C/S#;
MC:O?/-;.OZ]?:9?F.VCMF@AMUN)?,#%F!D"%5P< X).3GITYX *U]X)%W=--
M]L7:[7(DB=9 C),R,R_)(I_@[Y!STJ2X\)W,]G<6@U"-83>F]@(A=9%<S>:0
MS+("PR2!C:1QSQ67J/C#4C::J+26RCFAM[QT4(7DM3 X4&0$X.\9(X&./O"M
M+Q1J=Q9Z=8W,-R'S!<2,T#%4EVVTC C!/&0".3VH </"+H\7E7-M'%]F>"XB
M$,C+<!A)P^Z4Y7=(6_O=0& 8U%)X1U"9+".?7'DBMIDE9&1SG9.)5 /F9/ "
MY??TSUJ*Y\2:TM[-%;1V B662!#*KLV4@6;<<$9SDKCC'!R>E,B\1WUQJMDT
M5Q#;6T^I)#*DPW[E:R28(IR-IW$@8ZG'N" 6-0\(M)IVF65NX(2]D:YD50H:
MWE9VE0C/(;*CCG.#ZUJZSH3:M=1R"Z\E/L=S9RJ$RQ2;9DJ<C:P,8['J:YNQ
M\;ZA>:?'<RQ6-HD\D"K--(I6VWAR5E59"<C8%!.S+-C P:L1:SJ,?@71]034
M+>.66YA6>XG7S$*-+M/)(XY'.>E &O9^'94M]16]NXY);ZW6V9K:'R51%4J"
M 6;YOF/.?0=JI7/A6_NK6%)-1LA*EI-8LRV)V&*01@D+YG##RQSG&#C'%2:3
MXEN-0U\V3?92C-<J88\^=;^3($!DYZ/G(X&,C[W6LLZOKDU[#%%J%FUQ'JMU
M#L,; +&L4I4.H;+=%(Z>O- &J?!T)F9_M .9I91NBR?GMQ#@G/. ,Y[]*HV_
M@Z[>]N4N;J-+);B.1"D7[V7;:)!NW[OE&=W&,\=<&GZ5XPO=5UNUMELX8[>5
M(F=7E0/AX!+O7+AF )V8"'HQSP14NH>*I[2YUA1)8K]A98UMY6(E(*QGSFY_
MU8\PYXZ*3GL !^E^#A8G3VEN8Y9+2=92P20^8%ADB4'?(V,>9GC XQCO4=OX
M/O+.UB@M-7%OY>G)9EXX6S(R(J*[#?C(P>@#8.-W%11^+KK[5:PR2V#0O>-:
M-=0C<LQS&$,:;\XS(5)&_:R\\'(FLO$-[%X(.J75Q:W-VDOE2.J[$B)E"$N
M3@)G<W3@=NM !;^#988T1M1#%DO(ICY;$E+AE8[2SDA@4')+9YJYI?ALV&CW
MEE)<(\MU'Y33*LG0)L!(>1N@[ @=JR['5-0UCQ+IB-=PFUA%X7:VWK'<F-HE
M5QA^G[PC!W#(;KP1+J7B?4K)KYUAM?(CU!+&)B/N9C#EW+.JXYV@9')'/.*
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MQ\Y3<O!NC.> P7>"<]0.<YJ_X@\2W&E:F;:+[* D,<PCFSONB\A3RXL$?,,
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M'4(H)8_+W2CSHT< /QQNQU_&GSW%F',$FR1I6"-&%W'GIN'IQU- '&IXUOS
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M+,O*_)@#G< <$GG!J>#Q+J$^I1Z<MK9O.+LP22I.QCVB)925^7).&QC\<]J
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MY6[-R;>&+]VI\CRAMSWXSG'MVS5'_A-;CRTN'M@'2.Z1H_,VQEXYX(PS$KN
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MUCI]^B6Z6S6R'RU:-9$:0C ^9DE88[;5Y.* .RC2UBV+$L*;(\(% &U/;T'
M_*D\JS5WNO+@#$Y:7 SD KDGV!(_$BN1?P)LOKMH#%]G>$I;,9"&@'V;R F
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M8021ML>US;^2%50O*CEA\P&3TR,U;T?PS+9V6K0RQV-J+^-4$=DA"1XCV9Y
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M6X>!\WHN77&4V?:O.*8P,_+\O0#V%4+KP//)#)!$UD8I%N8T+J0;023M(KQ
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MR%R25R>!R?Q(!TJPV*0JJQ6ZQ',8 50O)Y7\2.E0VVE:=;-<&*VA+W+.TK,
MQ?<Q+ D]1DGCI7(:AX'U&\TV\MH&TVU%W)(QABC^2 F)(U*$H3U0L0 N2W7C
MG:TC19[7Q5JEY("+-2?L2D8VF7:\Y'J"ZJ?KNH V5M]/CB\I8;98P#%L"J
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MT4$R[ Q<,X4C/;'/;/3D=[:Z-I""#9IMDHMF+0X@0>4<Y)7CY3GTHO=-TB6
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M\1<(2W[ODJ=Q./0D'I-8_M!-9TB>TFO3$(IE:-(\I)(0I02_*=H.#SQCU&:
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M9P&*R3Q2(,$?>A575OS- 'H=&><=ZX>XF\108<)<2RPI=1&Y^RJ9?+^TQ ,
M%P6\K>P &&*C@TXQ:LNN-J-E<:C)$8=/B;SK55-PIN95DW@H""J/NX"XX)H
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M2F2H;"@D\9XYYH [VBN#L[SQ1=6J)YU^DD@M!</)9*AMY6DQ,L8*890O\1W
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M=;TZ\OWLH)RTZ[^#&P5MC!7VL1M;:Q .TG!ZU6?Q5HL;W*O>;/LRRM*S1.%
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M "7Q)I,,L\<ET5: ,7/E/M.T@,%.,.06 (7)!..M/.OZ<CR*\TD?E0?:)3)
MZB*/!.7)7"<*>#@\=*H1>#[&":^EBE<&\\SS,P0,07;<YR8R3DYX)(Y/'3$;
M>"-.DBBAEN+J2*.T>T )12492#E@H;'S$A<[00" ,"@"\OB?26$8\^8/)/\
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M$,D<<EM(&"CC+<849/4G![&K]]J-MIR1/<NX\V3RXUCC:1G;!. J@D\*3TZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"D(##! (Z\TM% !1110 4444 %%%% !1110 F!NS@9Z9I:** "BBB@ HHHH
M**** "BBB@ HHHH ***.@R: "BJ?]JV7]CC5O._T$P^?YNT_ZO&=V,9QCFKE
M !1534-3L]+BCDO9Q$LC^6F026;!;  ]E8_0&K$,T5S!'/!(DD4BAT=#E64C
M((/<8H ?1110 4444 %%%,DFBB:-9)$0R-L0,P&YL$X'J< G\#0 ^BH;6[@O
M;<3V[[XRS*&P1RK%3U]P:FH **** "BBH3=P"]6S+_Z0T9E"8/W00"<].I%
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M%+,W;/B 1^86P?NXSG\J )J*9#*D\,<T;;HY%#*?4'D4&9!.L))\QE+@8.,
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M'0<L%)(!VCG'!_(U/0 4456N[^WL6MUG9@US*(8E2-G+-@G&%!XPI)/0 <T
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M9 3AW;^(MC)XP,^@ [5F:EX)O)V:*U:!+ 33M':)((Q&)$C 928W"LK+(1@
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M"Y9]/:WV36IMY/.E9"AWJP8 *<\ CMVJFWC"XOUTZ33[4QV\TEF9I)'&Y1,
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M(D,2W)R794AC1LYZ9="V!UXS3_#OB,^(%>1=/N+>W,:3032(X61&SCEE W8
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M* "LI=:#WVIVGV.99+&))<NR*)5;?@J<\#,9^]C\JU:R!HDBZK?WZZG<*]W
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M5I8WP5P3N;G(Q@=*O^(/!>G>)+E;B^DF$J6DEM&Z;08RS(PE4XX=3&"#]>*
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M'<+<+.$BR6$31<C9@Y5B23R3SFGV_@>PMKRRG6ZNF2SC$<4;E6P!"8<;MNX
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MBM]20BX@0)@L8Q'N!*D@[57C.,@>^0"<^)-)%I]J-RPA#E';R7_=D8)WC&4
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MW2[VUFE>80/"S!XV#$\2&,;>/FRP PN>2!UK0U+35U%;8^?)#);3K/&Z 'D
MC!!!&"&(K(NO!>GW=HMO)-,516"Y"GDSK."000<,@X(P1P: -4ZS8#35O_/S
M;LVP$(Q8ONV[=N-V[=D;<9R,8J"T\1Z;>3QQQ7";)D1X&.1Y@97;H1Q\L;'G
MJ :S]6\,RS>&H-*T^1(S%<+,63;;YPY<[=J$*<GKM/Y\U"O@J*[T7[+?W#QS
MO!!"SVF%$8B+XV?*,95V4G R"< 4 :!\6Z0D3S2W:K%N C90S%QY22YP!D85
MP3Z#FKD>N:=+J8T^.XWW)!(548KPH8_-C;G#*<9_B'J*IOX7LVN[BX$DJ&8N
M2BX"KNACAP..@6,'ZDUFZ1X6OM+\42WXGB:T;*@,^YMGEH@ 78-K9123O((&
M,=, &S+XDTB"6YCEOD0VR.\K,"% 09?#8P2O< DCO4L^N:?;65O=S3,D5PVR
M',3[G;!. N-Q.%)QCM67<>#;6Z6YBEO;HVTWVDI"-F(FGSYC [<G[S8R2!N/
MMB[KFE76IS:6]K=FU:TNS.TB@%L>3(F &!!Y<=>V>^* '/XDTB-(W:\'ERPF
M>.4(Q1TV%^& P3M!;&<X!.*+GQ%IMK<.DEU$(X8WDGD+<1A51CGU^5U/T(]:
MSK7P186E_87*W-Q(MBJK%%+L8<1-%UVY (8D@$ MS5?3_ \$6@P6-W<2F803
MPR.C;LB7:.I&3M5$4''1>: -:3Q5HT5L+A[PA-S*0(7+KMQNRH7< -R\D8^9
M?44:AXCLM*U6&RO&\I98&F$I!(7#*O.!P/F&6. .]8GB'P=>7VI"]TZX0,[2
MR.LS@*'9857*[&WH/)!*\$D]16QK7AN+6IM\E[<0J]L]K-'$$Q+$Y!93D$C.
M,9!'4T :%OJ=E=2K%!<(\C"0A1G/R/L?Z8;CZU4C\16!TFWU&=GACN"0B%"[
MDC.>%!)P%)/H!FH])T+^SM;UC4"P(O95,2 Y$:!<GMP6D:1CUZC\*+^";>2T
MMK:6^FF2UD9[<30Q.$#!@RD%,,/F[\\#GKD U6\0:6HF876]8=@9HXV=27V[
M54@$,QWKA1D_,..:4Z]I@O$M#= 3.!A2C  E=P4G& Q7G:><=JSI?"%K)+<.
M+AD6:!8#$((O+VJ5P67;AB-@ )^Z"<8XP0>$+>"2/_B87LD*O'*\4K*WFRQQ
M+$KLVW=G:JDC."1GU! +<OB?3(]%CU=))9[*66.)'AA=MQ=@JD#&2,L.1U[9
MJS#K>G7&H&QCN0;@9&TJP!( )4$C!8 C(!R.XJ&30H7\/6VCI/*B6RP"*88+
M@Q,K(3D8/*#/%16OAN*VU)+O[7<21QS2W$4#;=J2R [VR!DYW-P3@;C[8 )I
M?$>D037$4MZB-;([RLP(4!!E\-C!*CD@$D=ZAU'Q%#9VFGSV\+W!O[A8(04=
M1SDDGY20,*>W/TYJK=>#;6\6ZBEO+K[--]H9(1LQ$\ZL)&!VY)^=\ D@;C[8
MV;RPCO9+-Y&93:SB=-O<A67!]L,: *1\4Z*(9I3?H(XMNYBC?-N;8I7CYP6^
M4%<C/%6SJ<0U.TL0CEKJWEN$8C "H8P00><GS!^1K(M_!MK EO&UY=2I:B".
MV5]@\J.*59%3A1GE%!)R< =\DZ5_I+7FIV=_%>S6TUM')$/+5&#HY0L#N![Q
MKR/>@"/_ (272"LA6[W;&5<+&[%\D@; !EP2K<KD<'TJ5]=TV/[06N#BW95D
M(B<C<V %!Q\S98#:,G) Q6-%X$T^#39["&79%(%56^S0[U522!NV9)&>">00
M#USE]UX)L[QYVFN[AC*(NJQD%HV4JSC;B0_*!ELG!(H U%\0Z4SVZ+>*6GQL
MPK<98H W'R$L"H#8RP(ZC%27.M:?:7R64]R$G?;A=I(&XD*"0,*6(( )&3P,
MUE1^"].BU"UO%\OS(41"OV6':VR1I%(&SY#N=N5Q^8S5J\\.0WFIM=M=3I'(
M\$DUNNW9(\+;HSDC(Y S@\X'OD 72?$,6I:*^JO!)#;^:R(H1W=E#;0=NT')
M/8 _4T\>)M'::WB%\A>X5&C 5NCL57)Q\N6!49QSQUILOAZ%] 72$N9XXE<.
M'&"3A]^"",%3T(QR*JVG@ZRM+80)<3E0MLN3M'^HG:9>  .6<@X'3&,4 :]G
MJ=E?E1:W"2EH4G&W/W&)"GVR5;\C5NL7P_H7]C2:E(S!FN[MY4 .1'&22J#@
M<9+-CL7(K:H **** "BBB@ HHHH AO))H;*>6WB\V=(V:./^^P' _$UQ%[XC
MU:WT6TFLYKJ[NG#R,38&-=RA"8B-N>K-C&#PV6^4Y[MW6-&=R JC))["LN/Q
M-HLULUQ%J,,D095RA))+#*X Y.0"1CJ ?0T <[>76K:A?S60EF5H=3A,<\<&
M8TC+N,<@$L !G.X<@C@XK1EU35$\+65Q+OBN'F6*ZG6W+&)-Q4R!.>N!V(&[
M/059U/Q?I.GV4T\=S'<R1Q)*(HFSN5R AR < [ASZ9QG%65\1:6IDCFOH(YH
M8C+,N_A JAFY(&< Y/<#J!0!F:#?:WJ&H1?;':*UCMRYS;;#.3+*B,<_=RBH
MY7KEAT'%4;_5->FN[^TMFG27-S&(4MB/)C6(F*59,?,S,%&,G[V ,J:WI/%6
MA1-&LFIP*9%#H"2,@DA3^)4@>I'&:L)KNER-:A+V-OM8!A(SA\YQST!.",'N
M#0!RMK/JZ:G'?P7,\\+V^G1R"2V_UN^:19">!M*AL\ =!GBDL=8\47EI(9&B
M@FDFMXV00,SVQ:4K(,%0" O0Y;D9R0172Q>)M%FMY9XM2@>.+9N93G[YPN/7
M)! QU((ZBIX];TV:[BM8[R)II5#(@/7*[@/KM!..N!F@#G?%USJ&GZE8W-G-
M.LD>G7@4I:M,)9<P%$(4<;BI_4#!-0W>O:_'<W@ABD\Z/[0/LGV4E8T6%FCD
M#X^8LX48SSN(QE373SZ[IEO>/:2WD8N$!+1]3PN_'^]M&[;UQSC%5].\0VUY
MX<M-:N%^S0W*!U7ER >@X&<XZX'KR1S0!DC6-7T^X5+XR30+>"-YDM&R4:V+
M@ *#_P M<*#] <GDLTOQ%?1SQ2ZRSI =-CN)-D!"POL0N'^7.XLQP%)SR, C
MG63Q+;2ZI!9PIYJ3S)$DR."K!H'F##U&$Q^-6+K6M)CN7LKBYA,\?SF(C<05
M7S,?[P4;L=<#- &=XDN]2M+V)].C+.+&<A_+9P'\V #(!P>"QQUX/O7/^(M1
MUX:-?Z>\LX!@OHTN([(NT[J$\I,*.-P=^1C.SC'-=-;>*K-] TW5KI'@CU!D
M6)%!<@OG;G@=AS_7K3['Q5I5XEWON8X)+62=94=N5$4IC+?3(!]MP]: ,B^\
M0ZS;W%W:VMG)-<PR3F.,V[[71;;?'\V,<R<=<GD=C4-WK6M*UC'IUT)X9$=O
MM5S:O&)) R8C("' P6Z $^ORG/2W/B#3;71VU5IR]HC!&9%)(;=MP1U!!X([
M4KZ_I,<LL<E]$C11F60,<;5"[SGW"D,1UP<T <Q>ZGXHC6\G@E.V.+4)HX?L
M><F"4+$F>I\Q2?<@?+CDTMUK?B1;K6_*2)?LT5P8(&B=F^4#RG&%PV[J?FYS
M@8(-= _BK0HC&)-3@4R*'0$XR"2%/XE2!ZD<9JS;ZSIUW+#%;W<<KS1^:@3)
MRIS@GT^ZW7^Z?0T <]]IUE==LH;F]N!;PZB]NTB6X"SH8%==V 0!N9ER,#CU
MJQ?ZKJL7B06L(<()H$C@%L66:)C^]D,F."HSQD?=&<[A6]?:E9Z:L;7EPD(D
M;:F[JQQDX'L 2?057/B#21<R6YOX1+&=K*6[[@A&>APS*#CH2 <4 94-_K47
M@9-1F9I=1ECCE91;8,(;:&P@Y8J"S8ZDC\*IW&M:JE[!%:SS3Q[8# 6LF'VO
M=,RR[C@;=J '(QUW<@@5T4FNZ7%.D+WT(D>0Q@9_B#;2#Z?-\O/?CK38O$6D
M3&X$5_%(;?/F!221AMIQZ_-QQWXH YPZKXBCMII))57S(Y'0O;%1#LN @ (#
M<M&<Y((R,XQD4UM9U3=',$N[2"Y>W\V>2T9Y(U-NS<H,@$N%4X'&<=2#72?\
M))HP:W4ZC!NN #$-W+9;8/I\WR\]^.M,M/$VE7BJ8K@@M<26RJR,&+HY5L#'
M3(Z].1G% '+^'=1\01G0["1%A@2QM0Z3QN&ES%^\/W3A@PQ@L,8YZBI&USQ!
M;Z=H#2&>6\NT@FN%%IM0!VC#I@ D%0S'J,8R3QBNPGU.RM;R&TGN%2>8@1J<
M\DYP,] 3@X]<54C\3:)-;RSQ:E \46S>RG/WSA<>N2"!CN".HH YA;_7+2UF
MDC^TWUY!-J15986^7:S&)< #<"NTCU!P*L)J>O7)\BTNY&@-PZI>O989T$&_
M[I '^LRN<<].HS6_9^(;&ZT0:L\JQ6AE>-7)SNVR&,8QUW$# 'J*E77M*>ZB
MMEOH3-,H9%SUR-P'L2 2!UP* ,;4H[S5HO"<TB.F^Y6:Z@$8*Y^SR. P(. '
M  ST)'<"LVSUKQ%>6J!'<2RBT\YWLBOV6623;+& <;MJ^N<=22"*Z6+Q1HD]
MHUU%J4#PJ4&Y3G._[N!U.><8ZX/H:I0^--,>R@NY=T<4XAV%</GS7=5X'./W
M9.>GI0!+J-VUAXFTAII)_LS6MQ&[*C,ID+0[=P48!P'QGWK!AUWQ))I]]/.T
M,#H5S%Y3[X3YA#(/W>.5'!.[GG.",=0?$>F1*IN;J* M++&H9P?N2&,DXZ#<
M,9.,$@'FG?\ "1:/YUQ%_:,'F6X=I5W?=V$*WX@D CW'J* .;N_$.MQM??9X
M)W;R(985:W(\A28@_F#:3Y@#R, -P(4\94Y8=:\2[].C#6VV0,WG['*3$2[0
MA_=\'9@\!<DY' (KKIM4LK>Q2\FG"0.0%9@06)Z +C.?;&:I6OB.UO\ 7$TZ
MS*SH;5;HSJWR[6)"[>,'[ISR,<=>< %0R7&E>(['3X&FDL;@RR,JIN97=I')
M=BN-@. ,$$' (.1BG>ZQKZ>(=0@A2-+:!6\J-HV)E00;PZX3!/F?+]X# (QG
M!-T^-M&#0LTQCMY)+B-I9%*A6A;#<$<CJ<]@"36D-;L1=/;/,JR"?R44$,7.
MQ&S@9P/WB]<=1ZB@#F6O->\^R6ZO+A(TO86EEBM< I) Q*D8/RB3 ]LC)R,U
M';ZSXGN8;HGRHI3<0Q"/R&9K?=<*C'!4 CRR3G<>F>AKKQJ,/]J3V!#*\-NE
MP[G 7:S.!S_P _I5;_A)-'^QM=_;XC C;6< \?+NR>.FWG/3'/2@#GKN[U^"
MXOX;-W38UQ()3;;_ #2D,)3V&YBPXZX(&#R)=*\0:A?^,)+2:1H+1"R+&T.$
MD81QL%5\<L"9"PST XX-=$^MZ;&;@->1C[/M\T\X4G&!GH2=R\#GYAZBFV-M
MI%S+_:UE;VK32YS<I& Y/1@3C.>,$'GC!Z4 <S?ZAK\!OOL"M&(DO[D VYD\
MUHC%Y2<]FW-TZXXQ3I=1U6TO]2C>\NE@;4T0RFVW_9;=K?<&3Y<$&0!,\@9)
M/.:W5\261@M)W62.*XEGC#.  GE!RQ;GI^[/Z4\>)=&:V-PNHPM&)!'E222Q
M7<  .3\OS<=N>E &1>7FK3>%M)O));BSN3<PFY,,!W>66P24()4$$$CMT-9@
MEUNSM+Z("6:"=M2E2(P$&-ENQLPPY.Y78_0#'0YZU/$&D2WD-I'J%N\\P5HU
M5\[@R[EP>G(!(]<''2JMQXGMK;Q"FCM;SF1FC3S5*;0SAB.-VX_=.2 0* #0
M]0O+K4]6MKLNX@E_=.L>V/:6<!02 =P"C=U'((.&P.9CU[6(_"F@16+.MP+1
M4O)[J&3*3+&N%;*,3EMV3CG;@$$BNL7Q/HC01SKJ4!BD8JK@\'&-QSZ#<,GH
M,\FII-=TN*2XCDO8D:W7=*&XP,XX]><#C/) ZT <S<:]KG]M7MM IC1+67!F
MMV\N.550JP(7.TEFY))./NC!RD.NZ]<:EIT4<;0V[I$2;N(@S$RNL@^5".$5
M67&W[P)X.!NQ>*=+EUC^SC<*KM%%)$S''F;RZA<=CE".>YQUJ[<:QI]I>QV4
M]W%'<2;=L9//S$A<^F2"!GJ1@4 4-7UC&@+?:=)*ZRR*B2Q1YV@M@L<@X7CK
M@_0USEE+JM_J6F7MW;SI++%I[S 1LJAL7._@].2N0>F1FMVR\5:?_P (Y)JS
MQ&WL(IS;QA%).T.$!VX&.>PS@?E4L?BO37N=0MC*JSV9;]VS &0")9,C/ X;
MH?0GI0!3OM4U9/$AM(3(J">&.*$6Q998F'[R4R8P"OS<9_A (.X57TPWVA?#
M^VO%CEFN4*7%TAAS)(I<&7Y0,EMNXCN2!736NIVEY,\,,H:6, R*.=N0#C/3
M."/S%5H]?L&TR/4)9#!#)(\2"0?,S*S @ 9S]TGCL,T <G%>>)=7@MXKV-K.
M>VO8(Y'C@.-^YV9AG@KY9BYZ9)SG&*F&KZVH\Z9)(2T%K'/<K;,VP>;.KN$Y
M&<*G8XWY/%=2VO:4L@1K^ 9B,P8M\I0+NR&Z?=^;KTYZ4-KVEH+??>(GV@XC
M#@J3\VWD$<?,0.<<D"@#GK"75HO$$DZ32RV=U?11R*]L5W*;-6,G/*_.H&.@
M.X'D\3ZGK&JV][K*P>9YMM'FSMA:,ZS+Y08R;@.2'++M!&=N.K UJW7B*PL=
M;&F7<JPNT4<B.YX8NY0#VY Y/=@.]7+?4;.[9%M[B.1G3S %.?ESC/YY'X&@
M#DCJGB"=)([.YD:%9)O*O'LOFF584=?E( _UA9<XY"\<\TZ;7];\G4Y4CD6[
MBB0V]G]D<J5,<;-)N ))#,XQ_LXQFM^/Q'IIT6QU6><6T%["LT8E^\%*[N0,
M]!U/0>M32:YID7G[KM/W#*LF 3AF( 48')R1P,GD4 <[;:SK*RZ5]HE$\,TS
MHWV:)F=U+ (S911@#=NV[>@(R,BJ<>MZZ]B+A;>6YO((;K+B!O+=PD;*4 "E
MERS  C=E2N21D]?_ &WI@NQ:F]B$Q7=M)Q_#NQGIG;\V.N.>E2V&I6>IQ-+9
M7"3(C;6*]C@$9!]001Z@@T <E_:FOW >*TN9&@$LHBO'LL-*BPJX^4@#_6%E
MSCD#'7FM/1M6U"[UV2"[1Q$]JDR*D1"1';'E7) .XLS8P2"!V*G.K/K>FVMQ
M-!/>1Q20Q-+('R J* S'/3@$$^@-,A\0:1/&SQZA RJ'+'=C 0!F_)64_0@]
M* .7_M[7[B[U&&V29$\Z".%YK7)BW70B?C ! 0[NIXP20#BM'3M1UN3Q7-9W
M+1BTB8IM=&#.@12L@(3&2Q.?FQVQD<[\FI6<4UM"\ZB6Y&8DP26''/L.1R?4
M>M0MKNEI;B=KZ'RC&DH8'.5<X0CUW$8&.IH Y>2ZU_2[K5I[*)[E9)[HPVK0
M'!98 R'=UY9=OISZU8TS4-?O)K&-[J,P27,F^9("6,:QJP5MR* 2Q89 Z<=0
M36O:>)]-N]6ETY9T68,@BRW^M#1B0$?AGCOM/H:DG\0Z=:75S!=2^08'1-S]
M'9U+!5QR3A3Q0!S6E:KX@OXH)+^)-QN;;S(%1P]NQ9O,4_*HV@!>[=R2011!
MK>OQ:4)+TS&2>TM)@\=KM\B21G#J<@\ *N<@D9/'( Z"[\4Z7;-9I'<QSR7C
MP")8WSN65@JMGICJ1ZA3CI5I]<TM+?SVOH1&8UE#9ZJS;5(]<G@>IH X:7^W
M+V&7699;JWNUTFR;]W;<QL97\[:"N0=J@D=<$9Z"M"YUSQ$EYJH@"&.V@E:"
M-X6+2@0!DD4!,$E^#\V.V,CGJ%UW2VN(H!>Q>;*@=%SU!!8?0X!..N ?2H;3
MQ1H=]/%!:ZG;RR2D!%5OO9&X?F,D>N#C.* (K\ZO#9Z7;P79-Q/<B.XN1;@[
M4V.Q(7H.0H!.>V<]^8OKOQ#J]GJMI.PAC,AC,,<3&1%%PJKC*8*M'DG);/48
M&177?\)+HODM,-1@,:LJ9SU+9VX]=V#@C.<'&:=::_IM_J/V&UG\V4VR72LJ
MDHT;EMI#=/X30!R[:MXCADU2&!(8Q:I*D$!@8D!658G "@$%<DC=W &,&K>H
M7OB*RCU-XIC.MM);P1DV^,J_E^9*2 <[06Z# Y)!QBK\?C"P^US1744UI#']
MHQ<SE!&PAD$<AX8D $CJ!5W_ (2+2!*D1OHA(Z!U4Y!P06 /H2 3@\X'2@#D
M-0U+7+J&TMKB5AN:VD0VUJ[K<_Z40V6VC;MC6-CP!\Y/(Q6OKU[JUAK=U+:2
MW#I_9VZ"W$!DC,@<[CP,DA2#MSD]*V9M?TZ*2-3=0E&7>TGF*%1-C2!CD]-J
MD\=N>E(VOZ>GSO,J0>5YOF.=O\>P#:?FSNXZ<GB@#-MM6OET#5KIS<7*V\K+
M:3K;;9)DV(=VS !PQ<9Q@A<X/>AI>NZS+-I0NQ(R2SS0R+' 0[@2%4<Y0#9M
M&21MZ@X(.*Z!O$VBHL#-J4 $^?+RW7#;3GTPW!ST/!JY-J%K!=Q6LDP%Q*"R
M1X)) [^P]S0!R_C;298="U;5-.DO?[1>+:BP,<C<T(.T#GI$/S;UK$O_ !'X
MTM)=1F@@-Q'_ ,3!+> 61S'Y+KY3Y!R^0S<?Q8&*[#2_%FDZIHT6HI<*JM%'
M))&,LT9=<@8 R>XR/[I]#2KXFMI-4M[.%/-2X>-8YT<%6#Q22AAZC$?ZB@#S
MVQ\0:]I$6IW*?;KR&ZOKLQSMIL@:1Q:P^01'C*@L&'0 X/2M"?Q5XJ2TU:41
M3"^@BA^SV?\ 9SE3&RPEY_, ()!>7Y/]CH<&N_GUG3K6Z>VGNXXY41I&#9&%
M W'GIP.<=<<U#=>(=-M+JVMI)\RW$X@4(I;#E#(,XZ94?J* .!N/$/C<V$<M
MM)$S1VKS[UL'<3D7 15.0A!V')P!G&1@4E_XE\;6DD=HBH3'<W40O);-PDY1
MT$:L$5L!E9N@&<<'@Y[[_A)-&"SL=2MPL! D8M@#+; <]QN^7([\46_B71KL
M2?9]0AD\M"[A2<@ X/'J"0".H) /6@#@M9U;QK+;:S';R3*LD6II;"&S*R1&
M!U\DANI+@L!Z\$<BM'Q1%JVK:5X5BT^2XNGN)SY\AEFLPP^SR$-(8QN0;L'&
M.2 .]=+-XLTF-@D<YE9K6:Z3:,*5B.&!8\*0<C!QC!SBKAUS35EFA-TGFP*&
ME09)7IQQW^9>!S\P]10!PSWWC'1[2^@DO'N4TY+*U\_[$9&?>(_.N/5]OSG
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M-A49L&4>2DN1GI\K'@\_*3VJ]9:K:7\AB@E5IE17=!SLR P!(XSAE/7H0>]
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M'&8U++N3&X9Z<9Q]<^E1Z9XMTC4M&AU%;J-%>.)WCSED,@RJX'+'J..N#Z4
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M (5JT %%%% !1110 4444 0W433V<\2XW/&RC/3)&*Y2W\"A["T-_?--?0)
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M75M0OM<U"PN8T5-.+)*X0@2,[;HMI]HMI;W?VH J?\(0C:=IUI-?^>-/B-O
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ME4-$0T6R[P@W$\AED)' X48H E@\&16WV5(=0G6"'[,7CV*?,: Y0DXR,\9
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M& (996"C.<[D3;NXP#C/W@!F:7J.JS:1:V32R3I')8,Y$#QO"WVM 48D_-E
M2?8$]&% '3)X0MA%(K7<S/*"9'( W,9S,QQCC+$C'I5R70(I-'O].$\BK=RR
M2F0 91G;=Q]#6?X5UC5M5N+K^T%MXU4<PJ")('W,-K#TP!R?0GH1C!TGQ!JU
MAI#N\@N+>R@%Q=;[9U:!%EPZY)^9O+W,/]WT84 =1+X9BGD>66ZD,DET;IR%
M !8VOV<C'ICYOK3]-\/)INI_;([ER/LZP>4JA0^ @#/C[S )@$\@$CTQ1OM1
MO8_#VD:A>,]M))=0R7"Q@CRXV;.UL>@(!]<54?Q#K$VN7L-JUE':QHS0>>&^
M=/(#K*,<D;S@XXP"/O"@"Y-X/$UOY$E^SQ1WLE];H\*D1N[2,P/]X?O6';M2
M_P#"'0C4;*Z%Y(J6B@10"-=BD1-'\HQA5(<G '7VXJC;>)=2DDTP[3*LZRJT
M2QCS)'4L W7'E_+PR^H)&#Q2A\4>(7T>&YD^R#S9XTEE"D?908W9@X/"X=44
M9Y&_!YP2 :H\"6A6WWW E,0DCV2P*\7EN5)14/W0-HP.@R>.F-#6_#::W=VL
MTE[-&D#*WE* 5)5U<'GH<KC/H3TJKJ%YJ8T_P[<M<I;/+<1_;3"A>,AHFR.>
M0N_:!GU%-T#6M2U#5S!<[6C,4SS1"!D-HZR!40L3\VY2Q_X#D<$4 2S^$+::
M)%%U,CQ^<T;@ [6DN$N <=]KHO'<5.OAQ3HMSI\M[-(]Q<&Y,^U0RR;PX(&,
M8# <'L.<UAGQ#>6FC2QP2E[Q-6N8IWGR?L\)N)MC'/1<!%'8!AV%2'Q!K2NL
M<DEEYTFFF5#&C&))0I.Z0_>5"=N",]P><4 ;5CX>2TU!+^2ZDFNMTKR,5"AV
MD"#H.@ C4#]<TR]\+6E_)<&>64I/=/<.HP/O6QMBN?3:<_6L,^*-5<6QB!4M
M%&T4<MMEKQS,Z.H*G  558,.SANG%;VCZC<R*S:G/&LES>W$%K"L10A8WD Y
MR<DHF[/ H FTO138/<33WDEU<3QQQ-(R*F$0$*,#C/S,2?4]A@5GCP?&ALEC
MU"=(K>&SB=-BGS1;/OC)..,DG./;IWBN]7UR#6K@0Q)-:)>&VCMQ"0SC['YP
M;?G_ )Z?+TQSZUEC7=9NH8)!?@6Z3VC2W4=H4 +[Q)$03T4A/<;\'D4 =)#X
M=CMTTT0W4BFQ:3!*@[U?.X'T[<^U4)/!%F]M;1"Y<M;6]K#$SHK#]P) "R]\
MB5@1],8J@GB7Q ==&FFQ'EFX-KY_DMC>)=Q;TVFW^;/3=Q5"ZN]8DTR_C-S+
M$)='D:"#RV),H>0$AB=V0-AQGN* .TTO1(-*FDEA(^>"*$HJ!% CWG( Z9WF
MJ,_A56P]M?S6\VZZS($5ODN'#NN",<%5P?;O5"76]8LKR*WN9(Y$34/LSM'!
MB292L14JI.,#S&#8.<+D9P169/XDUC3-#8B>2ZOUNKSA[;@B.3Y8SSG)4@@
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MZG_Z]:@US2F-L!J-L3= &#$@_> G Q]3P/?BJ[^'XGDG8SM^^U"._(VCAD5
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M\/C3+Z.XANBRB.2.1&3[P:1I!@YXP7([YXZ4 6GUW28Y[B%]1M5DMD:293*
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MXFTK4]/:9S'J#3%V  *^8"#CZ9H CM_$^E7.JG3UNHEF9(WAW.!YH<,1M'_
M35J&\TO6HY889[>\2-E+JK!@"#E3^:\'V]JH?\(WYLOG7%V7F9[:1V2/:"82
M2,#)QG/K3O#GAN+P[ T,<B2@11P(_ED/Y:9VACN.3R>@ Z\<T 1:=XSTJ_LW
MNIO,L(5BAFW7;(H9)<^6059AD[2-IP>G'(K2&N:49IHO[0MO,A0R2+Y@RJC&
M2?ID?F/6L#2? =OID4""Z4F'[,!Y5NL880MN4N ?F<]V_("ISX/5)[^2"]:$
MW)E>.14/FPM(P9L/NZ9SP #@]>!0!KKKNDLML5U&V(NF*0_O!\Y#;2!]&(!]
M"0.M5O#^L:5K%O)<Z<T(FFVS7,:L"ZL1M!?'?";?^ X[53TSPI)I,\$]MJ)\
MQ3+YVZ'<)%DE\P@9.5P<@')X/.3@U=TC0(M(>%DG:3RK..T&5 R%9CGZ_-0!
M:76M-D0-'?6[Y2-QMD!R),^6?^!8./7%4],\4Z;JUA9W5I-')]I,8,:RINB+
MKN ;GV/3)X/H:S;'P):6&K1WZ7<S;)I9/**C:05VQI](P6V_[V:GB\'6\0M%
M-U(RV\%M!C:!N$*R*#[9\T_E0!8G\8:)!);DZA;&WF+C[0)5V*5 ;D^X.?IS
MTK1N]3MK%HS<2(D3H\AE9U"JJ#<2<G.,>@/OBLF'PNXL[6VN=0,RVMO);1$0
MA?W;($&>>2 ,YX!ST%2ZIX9BU/38K-[ET6.SEM-P4$D21["?J.M $L_BC28;
M0WBW<4ULHD+RQ2*P78NXC&<DXQT!Z@].:>/$6F>6\SW4<=NJ(XE9UPP?=C S
MG^$]0/QP<5+OPK!>7-Y,]S(!=/([*JCC?;I 0/P3/U-17/A6>Y0L=5D29UB2
M4QH560(LBX(#9P?,SC/51U'% &@OB31VN+N'[?"&M51Y26^4!\;2#WSD=/45
M'?>*=(LH;9_MD$K7+QK"B2 LX>01@CV!/Z&LYO!2&Q^R+?,(Q%:JN8\GS(,;
M6."."!@K^1%*W@T;XS%>K C"#[0D< Q(8IVF4KDDKEG;/4G/8\T :&K>)].T
MAKN*:3=<VUFUZT(X+1KG.">.QJ8^(M&%HMT=4M!;LY02>:,;@,D?@.3[<U7U
MCP^-6EN6^U&)+FQ>RE79NRK9PP.>""3ZY]JIZEX-AO[Z:\%R!++,[E9(RZ;7
MCBC92 PS_J5.<]SP: -N^U73],1'OKV"V5\[3*X7..IY[#N>U,_MO2OMSV7]
MHVOVJ,$O%YHW+@;CD?0Y^G-4]7\/G46A>WN_LK);2V9Q$'!BDV;@ >C?NUP>
M1UR#63_PA)NY;Z"\NV73GF=X(8P-XW6HMR2_^Z7XQUP<]J -]?$.CO'%(NIV
MI667R8R)1\SX!VCWP0?H<]*BG\4:+;QAVU"%E,Z0'8V<.V=N?8X//L:KZ=X8
M2QGMKAYHWF@E>0M'$4\PF,)SEF.0!US^ JG;>#)+?S96U:6:Z9K9EFE0N<PN
MS MEN2=YS@@>@'2@#8_X2#3(PGVB[@MVDEDB1994RQ20QD\$\;A^&0#@\5-;
MZOIUW>RV=M?6\MS%NWQ)("R[3M;(]C@'TR/6L2?P:DBW$<=^Z17@FCNE,8)>
M.29Y2JG/RD&1AGGCMD"M"RT"*ROH;I9V9HFNR 5'/VB82G\BN* #4?%&D:;:
MZA*][#))80O--#&X+X0<@#/7) ]B1GK4AUZSA&EK=2+#-J1VP(&W!FV[L9'M
MW]Q67<>#4N8KRWDOW^S2QWBPH(P&B-R29"6S\V"QP,#KSG@ULZAIS7EUI]PD
M_E/9SF493<'!1D9>HQPQY['UH I:;XJTS5=.M[NVF1VE\D/")4W1&0X4-DCO
MD<<D@@9(Q6A%JVGS6$M]'>0-:0@M).'&Q0!DDGIC'.?2LBW\(P6\=F@NI#]F
MAM(0=H^86[LX/X[J9+X9GA\'ZUI$%RLDE[!*D*;=D4):/8%526VKD9P.,DX
MZ4 :?_"1Z+]E^T_VI:>1O,?F>:,!@ 2">W!!^A!ITNO:3"]PDFHVRM;L%F7S
M!E">@/H<<XK"U#P5-J5I>13ZS,'O6<W)2/:CAHEB&%##D*@QDD9)XZ8T+KPV
MTUM/%!?RP&:\-TY4'#97:4.""1T/7J!G(X(!=?7](CG2!M2M1(Z>8J^:.5V[
ML_\ ?()^G-$6OZ1.UNL6HVSFY_U.V0'S.2./7D''K@UR5MX*O[75/)657L/)
M6 2/(3M06HAW!!P)<CKS\I(SVK=N_"YNK^PG_M"98+,0;8,':6B8L"!G W9
M/!^ZN,8Y );CQ;HL-HUS%?V]Q&DL,<ABE4A!(X0,>>F2?R([5?;5].73TU W
ML'V1\;)MXVL2<  ]SGM7.:1X.GBL;(:C>[[BWCMD18XP%012"3;G^+) &>.
M.,Y)U+CPXLNA/ID=P%W7$DXE>,DH7D:3*X8$$%N""",4 2VWB33+C4[S3S=0
MQW-M)M*/( 7'EI)N'MA_T-5]0\6Z=9V374+B[B6.=V,+ X,4?F%3Z$C'YBFM
MX65BS#4+E93<FY\X8WAC:_9\Y]<?-GUJDO@6-K&[@FU&1WNO.+R!#P9(%@.-
MS$\!0>2>: .AO]8TW2Q&=0OK>U\P$IYT@7<!C)&?3(SZ5%<Z_I5I-/#-?P+-
M!&TDD6\;E 7<>/7'./0YJ/6-"CU<DR3-'FRN+/A0>)@@+?4;/UJD?":/=EGO
M7-IYTERL(C 997B,3'?W7:S$#'4]< "@"Y<^)-.M]+LM3,H-G=R(B2Y  W9P
M3GZ8J==<TIWMD74;9FNE#0 2@^8#P"/J>!ZFJDNA3RZ+I]E]O"W%B\<B3B$8
M8H,#*YZ8Z\_3%4+;P3!:WUO="Y$I01^<)HLAV25Y0RX8!3O=CR&Q@8QC- &M
MJGB#3]*G@MIIXS=3RPQI '&\^9($#8],DGZ*?2GC7M)*3N-1MBMN0LI$@^4D
M[0/Q(('J01UJEJ'APWNJF[6]:**22VDFA\L-O:"3>N&[ ]#]!TYSG1> K>*P
M^RK<K^Z:,V\IB.]0C$A7.[YASCC;Z]>: -:^UWPZ]N+>]U*P,-U"&V2RKMDC
M;(S[@X(]^E61KNDD6Q&HVV+K_4?O!^\YV\?B0/KQUK-3PE @XF"$BTR(X]JY
M@G:?(!)^\SD'D_C4 \%VZW\=T+@/\[&5)H]P8&=YAC##!!D89.>W'% &K;>(
M-/O-:;2[6>.>9(GDD,;@A-K!2I]\D_D?2K5MJ5E>SSP6UU%++ 0)41@2G)'/
MX@C\#Z5EZ1X<.E7Z3F]::.*&2""(QA=B,X?D_P 1&,9XXQQG)+M'\.MI>JW=
M_+?RW4EP@C_>9R%#LPR23D_/CC P!P* +T>LZ9*%,=_;/N6)QMD!RLA(C/T;
M!QZXJ ^(]*\I)H[V"2$R-&\JRKMCQ&TA+9(XVKGC)P<],D9%EX$M;+54OX[V
M?*32RA,#&&7;&OTC!;;[FGZ=X,2TDBDNK^2\=9Q,YD4GS,0/#AMS$G(<D\]?
M04 :UUJFBV5RUQ<WEI%,@\EG=P"HP'VD^F"&^G-2M=:;J9O--\Z"Y*(4N8 P
M; 8?=8>X/3WKG5\ P1V-K"+UI9H!*CRW,>\3(X1<, 5R0L<:@YZ+R#FNBT_3
M(].^UB-LBYG,Q&,;<JJX'_?(H J:-XFTG6K&TGM;N /<)&1!Y@+*S(7"D#OA
M6_[Y/I5M]6M%.G;'\U-0D,<$D>&4_NWDSG/3:AY&>U<Q-X'N(]!DM(-1>2\2
M"UM;6?8(S"D+$JW&<MAVSZCC YSO7VB&6#2X["=;,Z;*'@S%YBX$3Q;2,CC:
MY[]A0!8?6]+CFN(7U"V62W4M*ID&4 QG/TR/S'K4<^HZ/>0R6EQ=6LD<D!DD
MCD88,1!R6SVP#U]#64G@Z*.6];S8)1<F5@)[<N4:5P[_ ,7*DYX !Z<\"FR^
M#/M$/DSZI.R-9M:2NH(DF!5@-[$D,%W94,"0>YR00#77Q#HSQ1RKJ=J4DE\E
M#Y@^:3&=H]\$''IS4]QJNGVM[%9W%[!%<RXV1.X#-DX''N00/4UG6GAPQ:FF
MI7-YY]WYYF=EB"*3Y7E  9., 9ZGG/; "ZAX<^W:F]S]K:.&8V[3P^6"7,+E
MTVMGY>>O!X'&#S0 VV\6Z=-H5UK4C>58P3O#YFX-NVOLS@=,GH/3%3VGB73+
MO4[K3UNHDN() H1I!F0&))=RCTP__CI]*1] 1O#MQI"W# 2M(XEV@E2\A?IW
MP3^E5[CPK#>-*US<NQFNFN9=B[<EK3[,0.N!@EOK0!IVVKZ=>6DMU;7L$MO#
MDR2(X*I@9Y/;@@_0YJ >)-$: 3KJMF8C*( XE&#(1N"CU)'(]1S5&W\-O8^'
M=1L(I(I;BYMVB$@C*;OD*KNRQR??@>@%-T[PL\%S:7MY>F>[@E24E8PJD+ \
M(7'TD8D]SV XH U$UW29)Y(4U&U:6-Q&ZB49#%M@'UW?+]>.M,?7]-CEF62Z
MB6.$+NE,BXW%W3;C.<AHV'3MQG!QE#P8C0/!+?NT:6\L%F5C : /(LFXG^)E
M9$(/'W>Y.:63P;%]C,$-WAS;00>9)'N(:-I&\P$,I#DR$Y!&"* -27Q!IEL)
MFN[N&V2*7RMTLJX8[%?(P3CY6SS@X&>F"5;5]&.I?9VOK/[;$I^4R+O12H<_
M3*X;Z#/:LR7PFXN)+JWU.1+F0N&DEB$F5>**-N./F_<JP/KG@BGQ^$;:!56*
M=MB7(G59$#CBT^S!3GJ-O/Z4 :ZZI8-IQU 7</V-029BX"@#WJ@?$^GR:GIU
MC:2QW+WJRNKI(,*L9 ;\<G&/8^E1Q^&ROAW^RGOG9EF6>.0*2(F202(JJQ)V
M J/E)Z<9'9^G>'A9:A'?R732W.+@RD)M5VE:,D@9. /*4 <^YS0 VY\7:1;3
MRQ-<+F"\6SG).!&[)O&<]1V^O%6CX@TQ<NUW"L'E12I/YJE9!)NV[<'/\!.<
M8/;.#BN?#P;5);LW1\M[U+X1^7R'6(1$9ST("GIP<^O%!_!:?8F@AO2CF"&%
M96CRT?EF4AT(8%6_>G!!XQWR10!NW^L:;I80W]];VPD!*>;(%W 8R1GL,C/I
M39-;TN&:>&34+9)+>)II5:0#8B@%F/L 1GTR/6LS7-!O-4O+/R+WR(DL[BVF
ME9 [,)/+' X&<*QSV('!'%5;GP0EU/=M)J4[0S6DUI'&P+>4DB*I R<8&W(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHK".J:@=3UBS*V\8M8(9H'6-YCAS(#N5<%C^[SM7UQD]: -
MVBN:MO%!'A!=7NQ"MPTCP+'DQAI1(8U!#$E"2 6!Y7G/0UH^'-3?6?#MCJ,A
MA,D\09_)/R;N^.3WH U**QM0UB:T\4Z-I21HT5_'<.[G.Y3&$(Q]=QKF[KXG
M0"22"PTFXN[F*\MK=XTN(""LTC(&#+(1G*$;20<D9P,D '>T5S6B>-M.U[7;
MK2K6&X#P>;^];:4?RW$;]&)7YCQN R,D5@MXTU^3PRGB2*UL387%Y%!;VR*S
M7&UKI8N26"EBN[TP<=>: /0Z*XS_ (61IBC3C+9W,1O+@VS(\D.^&03& @IO
MW, XZJ",<YJ"7XH6$5M:3G2-2Q>/(MLA,*M,$=$)4&09^9P .IP3C'- '=45
MQ#?%#2/^)@8[.^E2SW9= A5PLHB8_>^0!CG+[?ER>@KJO[0$FB?VE"H(:V\]
M 65A]W<!E20?J"1Z&@"[17-7?C&TTVQTV6\BD>>\M?M)2';\J@+N(#,">7&%
M&2?2GW'C"SMTOF>VG'V.<02!FC7&21N.6&Q/ER&; ((QG- '145S4_CC2[:[
MO89$FV6:2-+*NUAE$WL,!MW3C) !(QGIET_B@3>$M8U:RA9)K"&4A)=K NL>
M\8*L0PY'0^HZB@#HZ*YBZ\;V5DC+<65W'=)*\36S&(.-J)(3G?M/RR)@ DY;
M&.N)+CQE9VWVEFM+KRH9X[=96,:+)(Z*X4;F!&%8$EL#@CD\4 ='17*1>,@^
MIC-E<'3Y+>T<2!5!A>:62/#_ #<C<JCY0>YSC%:VDZ_:ZP7%O',ICA227> /
M+8EE,9Y^^I0Y';CGF@#5HKF;;QK9WHV6MG<3W)G$"0120N6/EF3(8/LQM!_B
MZC'I4</C&-)=8CGMII7TZ7#K"JY56*JBG+#+$ENG'R\XXR =517-R^,K>*!F
M.G7S31+.\\"^7NA2$@.Q._!^\, $DY^M-N/'.E6UP]NT=R95$ORJ@Y9 I5>O
MWG5LH.X!SB@#IJ*Y,>-K>T;R;V-WG:YN5 AVC;''.T8.&8%CP.%R>#QT%%QX
MT6'4F+6<ZZ;%;7<C3,$_>O#-%%\GS<#+MDL .ASC- '645R@\>Z=LMBUK<AI
MR_R[HR0JR>7N&'^8$@D;<D@9QTSKV&MQ:D+\06\HDLY&B:-V0.Q!(^[NRN<9
M&[&00>E &I17'6GC6>06%S<Z7/':W5A!<N$*,83(^W).[E>0> 3C/':K%]XU
MAMY+V"VLI+BYM7C4HLT1#!I1$3D.=I!/1L'D>^ #J:*QM2UA]/U"T1T40/:7
M$\JLRJP,?EX&XL%'WCG)Q[UGP>-8+FXMC'9R_9'BNI)Y_,C(A\AE#?=8[A\V
M<KGM[X .IHK#TSQ1::IIMY?1P3QI:IYCJQ1BR[=W!5B,XXQG((JK)XUM(;&:
MXGL;F!HO+;RII(49D=696!,FTY"L,9SD=,<T =-17-S>-=-A@GE\FY?R8GG9
M%0;O*6$3;P"?ND,J_P"\<>II/^$TM8IIDO=/OK-(&DCEDE$9572'SRORN2?W
M?S9 QVSF@#I:*YB/QK;3P(\&FWLTKS&)88S$22(S)G=OVXV@CKG(Q5W1]?\
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M1O*$K%4_BRPR"?E!P.3B@#J:*Y[2/$<FL:SY45I+#8O9BXADE"YE!<@,,,<
MCG! /(JII_C,&WC_ +1LKB*1V;;*H38Z"<1%AAB0%+H3D#@Y% '645A7GB3R
M]%M=3L[&:Y2YNHX$3<JDJTFP.,G&#P1SSD9QSC.'C"2*VU(7-K)%);_;7AG\
MM6C=8)-N-H<,2 5Z[0>>: .NHK.T[68=2O;ZUCBDCDLY/+<2%03R1G:#N .,
M@D#(Y&:R/^$R@M?#VDZA>PLUQ?P^8(82J]%W-@NP'H,9R210!U%%<[-XQL(;
MU[;R+B1UMFN5$11G<*@?;L#;PQ!X# 9_++#XVTX7%G (Y'>Y6-_W<D;A%>0Q
MJ>'^;E6SMS@ YQ0!TM%9FNZK+H]A'<Q6;W;/<P0>6C*I_>2*F<L0/XOSQT&2
M,>+QFEK]O_M.UFCCMWNC',H79(L+@;1\V=V".H )SS0!U=%8<?BFR;0;O5Y(
MY8X;5BDBDJ26XP%(8J<[ASG'/.,'%>/QG8R-9(;6[#WDS6\( 5@TBD9&X,1]
MTE\YQM5NXQ0!TE%<VGC.RDN+BUBMII;F*2.-8HI(G,A<N!@AR!CRW)#$$ ?A
M5[2]8GU#4]0M)=.FMEM#& \CH=Q9%;!"L<$;L>G'6@#6HKF8_&MG.[Q06=Q/
M.LT<*Q0R0ON+ARIW!]H_U;9R<C'2BU\:VMU KIIU\LDJ0/!"XC#3"4L%Q\^!
M]QLY(X% '345S\7BZQEBD?R+E&BV"1&5<JS3M 5X.,AT;..,<@FJEWXV2&UO
M)(=+NW>%9FB#M&JSB*812$'<2,,1U R#Q0!U=%9>H:T-/^S1_8;FXNKA'D%O
M$4W*J %B2S!>-P'!Y)'UJCHVOW&KZAJ,L4+'3X(HFML*NZ7?&LF<[LY(8#!
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M>QI&V80?/G.9%&?N]>:A3QA%<1I]DTV\FE:&>8J#& HB.TY8O@Y)&-N>OUH
MZ6BN;@\7P'^R([JUD@GU*.-E3SHB4+YQE0^XCCJ 1R/?#+#QA#<+8*]K<O\
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M7EEVCEC9UC DV@%58C(0@XY/4;FC6^HP:UJ37$=S]CD(:%[B;<0<GY5 =AM
MQSA3Z[NM &W%-'/"DT,B21. RNC AAZ@CK67-HVE+?RS2O,EU?@1$_;)5+[<
MN H#<8PQ&W&.?4U@V6C>($^PSSSW7GP16*%?MAV$AB+C<H;:QVD<D'H,<U$F
MBZY/I=DC1W<6I0^;Y]S/>;PTK6\J>9'\QVJ79< !<9Z#% '5VNC:?9QJD-N
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MMVJ6_,S)YFTF1, $?,I!8$?,,'!KE[C3/$S121Q"\,'VXR-NN/WTL95^!B<
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MDTZ6SN+F5HS&[Q"-XP6)#[< .V0,MQTX(KJW021LC9PP(.UB#^!'(K*7PSI
M@EB-LSK-%+#(9)G9G67;O!8G)SM7G.1CC% %#5/%T-K-?65O'_IUM$95#LC*
MRAT5LA7++_K%^\%SGC-.F\0747AN74A DDT>I-:"-%^\@O/(X!/WMOOC/MQ5
MJ;P[H<4LMS/%M\\LC>9<.$S+(K$*I;"EG"= ,GZU8NM+TO\ LM[*X18[26X\
MP@RLF97EW@AL@@F0@C!ZD >E &5+XZTNW:*.>*XCF9G62%S&'BV/L.1O^;GL
MFXD<XJ?Q'XD;1XY(K:UEN+I(EE8A04B4OM!?+ \G/W<G@U:C\-:7"86BBGC>
M$N1(EU*KMN;<V]@V7RW/S$U)J.@:;JTRS7D+NZKL^29T#+G< P4@, 1D9SB@
M"I<>+=,M('FF\Y447))*C_EA*(G'7NS#'ZXJ[H^KV^M637-L&55D:-E8JV&'
MNI*D=.0352?PWH2333W$.&N=\1$EPX7,K L$4MA2S*I^4 YYZU<M]*CMKF&6
M.XNF2*-T$<EP\@)8J2S%B22-H ],GUH Q)?%EV)X5BT:X(.IRV+(K1LTJI%(
M^Y/G '*#[W8]S4T/C?2+B]M[:%I',\:.K#:,;X_,4%2V[E<<A2!D FM1-%L(
M[O[4L+>;YYN1F5BJR%"A8+G RK-G YSGKS4=MX=TRR>-K:&6$1Q+"$2XD",J
MKL7<N[#$+QD@G@>@H ;HFOP:XC&*VN;<B**8+<*H+1R E&&UCP<'@X(QR*AO
MO%>F:;J(L;MI(I?-6,DK\H#(6#DYX7(*Y_O<>]6%T&SAEMGMO,MQ (D(CD;Y
MTC5@B-ST&\GWP,YINI^&M'UB:6:_LEFDE@%N[%F&8PX<+P?[P!SUH SX?%C3
M7UI#%I]Q*EU=K;]%C: &V6?Y@6^8X/..F#U(&Z+2_&B7.EPR7EC<I>/%"RQ(
MJXG,C%5\OYN!N4_>(P.>E;<FB:?+<BX:%A,+E;O>DK*?-$8C!X/38-I'0CJ*
MA;PUI+6Z0?92J)''$A65U9%1MR88'(()SD'- %=/%M@\$DABN4,2%I(V5=R$
M2F(J<'&0X/0XQR":GTS6VO["^NI;&6V6UGFBP\B'S!&S+D$-@9V]\8]<<TR3
MPGHTJ0HUK)MB! Q<2#?E]YWX;Y_G^;YL\Y/>K?\ 8MA]EOK4PLUO?%S<1-(Q
M5MX.[ S\N<G.,<G/6@#&_P"$ZT]K0SQ6EY/M\XND)B<H(@K.=P?:1AU/!/IU
MXK3M?$%E>:C]@B$IN-\BE2H^4(J-N//0B6/'^\/>DC\-:5&L@^SNYD617:2>
M1V82*JODEB>0BCVQQ3+'3M-@\2W]W!/"UZ;>&"2%6&Z%%W$$C.<MD<GJ%7TH
M JW/C.QM(W>6VN5073VD;.T2":1-^_:6<  ;#RV,\ 9/%/A\7V-Q<P1PVUV\
M,S)&+@(H17>+S@I!;<#L(/3'(&<U<?1M+N8S $(,-R\^89W1XY7RS'<I# D.
M>,]&]*@N/#%C+J=KJ"&6.:"997_>NRRD1F,%E+8+;2!N()P ,T ,3Q1:W+V*
MVXD7[2MM*/,CS\DPD*CAN#^[.>N/>JG_  GNF+;6,\MO=0K>Q">)9/+5O*.W
M#XWY(.[[HRW!XK1L_"VCV!0V]LX*&/87GD?:(PP0#<QP%#L .G-.AT729(;)
MK4,J6<7V>![>Y=<(I V$JWS %1P<\CZT 9\_C:S@DF#:=J!BA^T,TP2/:4@D
M\N5Q\^<*<=LG/ /.%E\<:3%<7T.)G-FLK.8]C;C&0' 4-N!!./F !P<$UI2>
M'M+EBDB>U!22.XC<;VY6=]\HZ_Q,,^W;%#>']-<W8,4OEW>[SHOM$GEL6.6(
M3=M!)YR #U]30!2B\4&?4[2RCTN[#S2RPS>8T8-NR*K<@,000P/RD\>_%17'
MB2XM?$5[:2V<C6L"01PK&JEYYI"< $N,# /4#H3GIG5;1;!KM;KR66=9S<!T
ME927*A3G!Y!50,=..E%WHFGWK3-/"Q>8QLSI(R,"A)0@@@J1D\C% %6P\2V^
MI7T5I;VEWYC([2EE0"#:[QL'.[KO1A\N?7IS4,_B^PM;JZCN(+J*&V\T/<E%
M,9:-/,91@[B=O/3'!&<U<L;/1].B2ZM#$D;JL*S><6#[G) W$G<Q=SSU);O3
MYM!TRY$@FM%D$CR.X9B0Q=-CY&>Z\8H S6\5G[?9V2Z1>">:[%M+'(T8:$&%
MI0_#D,"$/0]CW !6T\5V\T'F/#.Z16WVFYN$15C@0[\;@6W?P-PN[MG&:NQ^
M&],B$>V*8O'.+E96N9&D\P*4!+EMQ&TE<$XP2,4S_A'M&MY(V\GRP8Q;[//<
M)*OS85EW8?[S8W ]30!#9^*;;4=&O]0L[>5S9H6:$O&2_P FX ,K%>1[\=Z9
M'XM@*VWG6%W&9$@:8_(RVYF;;&&(;G)_N@X!!.*U;72[6SLGM(Q,\#C:5GG>
M7C&,9<D@8[533POI*26[B"4F!8U4-<R,&$;%DW@MA]I.1NSCM0!)+K"V^K7]
MO<!4MK.QCNVEYSAFE#?@!'G\:S;?QQIMS#%)'#/^\N%MP"\6 67<"7W[>1QC
M.[/&*UKK1+"\OS>S1RF8Q"%]L\BI(@+$*Z!@K#YFZ@]:K3Z!I,6EM!<O<"QC
M!=Q-?2E H'(8E_N8'0\4 59_&FFV\<SR)*ICNS9A6DB4O( Q/WG&T81C\^W(
MQC.12VWC72;O4+2SA,K/<K&P)VC873>H*EMW3'(! R,FK(T#1[P&\3S)6G9)
MEN5NY"W&[:4<-E5Q(^ I PY'0U)#I5A(Z:A932[Y(5"3QW3LL@"X5F&[;(<'
MJV<\<]* )=2U![*YTR)45A>77D,3_"/+D?(_% /QK,E\:Z7%?7MKMFD>T60N
M8]C;C& 64+NW \]6 '!YK1ET*SN--L[*X:YE2SVF*7[3(DH95*[BZD,203DY
MYR:2/0;&)YWB^U1F<'S EY*H)( +8#8#' ^8<]\Y)H I-XOTZ,CS5DCC^Q-?
M-(7C91$ Q)&USOX4YV;L9&<9JJ_C_2$M!.R2[C(T?E>9#D[4#DAM^P\,. Q.
M3C&:TO\ A%](VQ(UL\D<2N%CDGD=/G#AV*EB"Q$CY8C)W'FEDT#35MXDD>Z
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M=TKM=F20JI#+M8DD\# ]J *O_"2VXOUM'L[M/WJ6\LK!"D,SH'6-L,3G#+R
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M^PRK&&<I^])C23@9X/SC@^W/4  X?69-2TFVT>VO+W45DFAFFNV6\/F;P\6
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MS%D:13PV -J,>2",<@58'B6&7R'B@G6WEN3 DSQY68!9"2F#GK&>H&>P.0:
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M1QN\?2-]I;.[GKT&3P>"!FKUYK]I8:Q::;.'$MUQ&^5P3ACC&[=T4\@8Z<T
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MB%RR[>HB\[&W.[[G.<;>V<\4I\9Z8EW9VLR3PSW0C98Y0BLHD<I&2N[/S$=
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ML,4,KJBY(.-N6'OSR!4B>-M'DO[:T61]]P4V$[0/G9E0XSN(8KD$ X!!.,T
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M#H(H888F29U9%B+&/# Y!&YN>^<'(KGI8_$LMYJQ"7UO;N#Y85O,Y6<8V_O
M0&CSG;MP#W89JQ81>))/$%I->&XM;<1Q'R01*@7R?G1VWC+>9GYMI/"X.,T
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M4\D=T;!)(9=I*PB13/PRY+R8!&1C )X!% '46^@Z9 TQMF?[2HE1Y6F,C*9
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M+.0JG.1CC!'(P,5/#H-A;W4-Q;I+ T420A8IG5&1,[ R@X.,GK6E10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ! /44444 %&*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **H7^JQ6,J0^7+-/("RQ0KN8@=
M_0#W-01ZS</(%.CWR _Q,$P/R:G85S6HKF-(\5S:G?V]M)IK0K-%O$@<L <
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M=T9K>\2$*Z!AEW)+.S=1RQ.,=J[%>@HN4+1110 4444 %%%% !1110 4444
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M_P *W?\ A#?"_P#T+>C_ /@#%_\ $T?\(;X7_P"A;T?_ , 8O_B:=R>4P_\
MA86E_P#09\-?^#A/\*U(O'GA,QJ9/$^B*^.0-0C(!^N:L?\ "&^%_P#H6]'_
M / &+_XFC_A#?"__ $+>C_\ @#%_\32'8B_X3OPA_P!#3HO_ ('1?_%4?\)W
MX0_Z&G1?_ Z+_P"*J7_A#?"__0MZ/_X Q?\ Q-'_  AOA?\ Z%O1_P#P!B_^
M)H&1#QWX1)P/%&C9_P"OZ+_XJN@K$_X0[PN#D>&]'_\  &+_ .)K;H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LD
MB11O)(ZI&@+,S'  '4DU@_\ "=^$/^AIT7_P.B_^*K>=$EC:.15=&!5E89!!
MZ@BL;_A#?"__ $+>C_\ @#%_\30!%_PG?A#_ *&G1?\ P.B_^*H_X3OPA_T-
M.B_^!T7_ ,54O_"&^%_^A;T?_P  8O\ XFC_ (0WPO\ ]"WH_P#X Q?_ !-
M&3JGC#PO.T%Q:>+-#6Y@)V;[Z,JP/53AN^!S[5 /B%IG?6?#1_[C"?X5N_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M: -G_A94_P#T(?C'_P %Z_\ Q='_  LJ?_H0_&/_ (+U_P#BZDN);V[NXO\
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M_P""]?\ XNNXAD\Z".4H\>]0VQQAER.A'K3Z* "BBB@ HHHH **** "BBB@
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M&R]>I!)!Z@X]\@&W_:>G^4TOVZV\M9/*9_-7 ?\ NDYZ^U.-]9B26,W4 DA
M,J^8,IGID=L^]<A!X$FM=)2VM[J".\B$2Q7G[YF3RT=%8*TA&<.WR_=()!SQ
MB9O JR27WF3QR+<22NKOYC$+).LK(5+[,?*!P!T'H<@'5)?6DL2RQW4#QO\
M==9 0>,\'Z<_2JE]KVF:?I,FIRWD+6RQO(K)(I\S:"2$Y^8\'@5BZIX*74;W
M49%O/)M[JW94A$?$<S*J-)P1D;(U7 QU;GGBI>^!9KJRFBBN+2*2YM[F"?S8
MY)Q^]V?.I=\AAY8[X[]N0#MZ*BA$P\SSFC;YSLV*1A>P.2<GKSQ]*EH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *3:N,;1C&.E+10 FT>@ZYH"@9P!S
M2T4 ,,49SF-#D8/RCD4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2ZNHBQ.]RR3.J(%&",A>"01Q@D=3+'X[\"Q1K''XCT-$4[@JW,8 /KUZTO\
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MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
MP,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X
M,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3
M_&@#I:*YK_A8G@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8
MG@S_ *&G2/\ P,3_ !H_X6)X,_Z&G2/_  ,3_&@#I:*YK_A8G@S_ *&G2/\
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MKHXRK ]00>HK,_X1;P]_T =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\
M"C_A%O#W_0!TO_P#C_PK6HH R?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\
MP#C_ ,*UJ* ,G_A%O#W_ $ =+_\  ./_  H_X1;P]_T =+_\ X_\*UJ* ,G_
M (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"M:B@#)_X1;P]_P! '2__
M  #C_P */^$6\/?] '2__ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_
MT =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK
M6HH R?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\ P#C_ ,*UJ* ,G_A%O#W_
M $ =+_\  ./_  H_X1;P]_T =+_\ X_\*UJ* ,G_ (1;P]_T =+_ / ./_"C
M_A%O#W_0!TO_ , X_P#"M:B@#)_X1;P]_P! '2__  #C_P */^$6\/?] '2_
M_ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_T =+_P# ./\ PK6HH R?
M^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK6HH R?\ A%O#W_0!TO\
M\ X_\*/^$6\/?] '2_\ P#C_ ,*UJ* ,G_A%O#W_ $ =+_\  ./_  H_X1;P
M]_T =+_\ X_\*UJ* ,G_ (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"
MM:B@#)_X1;P]_P! '2__  #C_P */^$6\/?] '2__ ./_"M:B@#)_P"$6\/?
M] '2_P#P#C_PH_X1;P]_T =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\
M"C_A%O#W_0!TO_P#C_PK6HH R?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\
MP#C_ ,*UJ* ,G_A%O#W_ $ =+_\  ./_  H_X1;P]_T =+_\ X_\*UJ* ,G_
M (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"M:B@#)_X1;P]_P! '2__
M  #C_P */^$6\/?] '2__ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_
MT =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK
M6HH R?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\ P#C_ ,*UJ* ,G_A%O#W_
M $ =+_\  ./_  H_X1;P]_T =+_\ X_\*UJ* ,G_ (1;P]_T =+_ / ./_"C
M_A%O#W_0!TO_ , X_P#"M:B@#)_X1;P]_P! '2__  #C_P */^$6\/?] '2_
M_ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_T =+_P# ./\ PK6HH R?
M^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK6HH R?\ A%O#W_0!TO\
M\ X_\*/^$6\/?] '2_\ P#C_ ,*UJ* ,G_A%O#W_ $ =+_\  ./_  H_X1;P
M]_T =+_\ X_\*UJ* ,G_ (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"
MM:B@#)_X1;P]_P! '2__  #C_P */^$6\/?] '2__ ./_"M:B@#)_P"$6\/?
M] '2_P#P#C_PH_X1;P]_T =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\
M"C_A%O#W_0!TO_P#C_PK6HH R?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\
MP#C_ ,*UJ* ,G_A%O#W_ $ =+_\  ./_  H_X1;P]_T =+_\ X_\*UJ* ,G_
M (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"M:B@#)_X1;P]_P! '2__
M  #C_P */^$6\/?] '2__ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_
MT =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK
M6HH R?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\ P#C_ ,*UJ* ,G_A%O#W_
M $ =+_\  ./_  H_X1;P]_T =+_\ X_\*UJ* ,G_ (1;P]_T =+_ / ./_"C
M_A%O#W_0!TO_ , X_P#"M:B@#)_X1;P]_P! '2__  #C_P */^$6\/?] '2_
M_ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_T =+_P# ./\ PK6HH R?
M^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK6HH R?\ A%O#W_0!TO\
M\ X_\*/^$6\/?] '2_\ P#C_ ,*UJ* ,G_A%O#W_ $ =+_\  ./_  H_X1;P
M]_T =+_\ X_\*UJ* ,G_ (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"
MM:B@#)_X1;P]_P! '2__  #C_P */^$6\/?] '2__ ./_"M:B@#)_P"$6\/?
M] '2_P#P#C_PH_X1;P]_T =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\
M"C_A%O#W_0!TO_P#C_PK6HH R?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\
MP#C_ ,*UJ* ,G_A%O#W_ $ =+_\  ./_  H_X1;P]_T =+_\ X_\*UJ* ,G_
M (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"M:B@#)_X1;P]_P! '2__
M  #C_P */^$6\/?] '2__ ./_"M:B@#)_P"$6\/?] '2_P#P#C_PH_X1;P]_
MT =+_P# ./\ PK6HH R?^$6\/?\ 0!TO_P  X_\ "C_A%O#W_0!TO_P#C_PK
M6HH R?\ A%O#W_0!TO\ \ X_\*/^$6\/?] '2_\ P#C_ ,*UJ* ,G_A%O#W_
M $ M,_\  2/_  K6HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>bionano-nancyridgeleasee011.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6\C8R0K=+#9EI+?._P SR@8@'7.P<>9@9.3G-=#'XNTF2>5%DG\J.TAN_/\
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M;Y)8["\2-[2V$V96,)C1@58!6*GGCIU%=+::E:WTMQ';.[FW<QR,8F"[@2"
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MBB1V1,OM 7<RD#=C)XJ+5?%":7K4>GM;!U(MRSB4!OWTK1KM0CYL%<GG@>M
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MF\Z/S_(W?O-N_&.V<4 /HJ*6XAADACDD5'G<I$I/+L%+8'X*Q_"I: "BBB@
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M'0G%=%X9M9K+PQIEM<(8YH[9 \9_@./N_AT_"L?_ (3:3>2=(E$ R_F>>O\
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M* Y@D$;9_N@EACKWXZ9JR>.MEBMRNE3.4CN99T$@78L#JCXW $D[@0"![XH
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M]1\+ZK?OJ<;!";A+L&X:X8^>DBD11E/X0A*\]MG'WC6WJ>G74::$VG6L<O\
M9USYC0F39\OD2Q\$@]W% %V70=)FGN9Y=/MWEN1B9F0'S.G7U^ZOY"I%T?3E
MA\H6<.S9Y>"N<KNW8_/GZURH\-:J]UJLMQ-=,UP)MAAND4.CR*R+@KU11MYX
MZCHQPDF@>()$)B,$%Q)IIMW=9B$C?:=HBQ\R<GGJ.A'(H Z;_A']'^T7$_\
M9EJ9;A729C$"75R"P/J"0"?4\T[3;73/LUM=Z?#%Y9C)AD5>=C[2<$\\[5/X
M"L"P\-WAU"":XB$%BEV\Z62W+,(AY2*HXX/SJS8Z G/6M"/2KFW\5I=6\4:6
M MQ$P9AA !\HC4#Y>>HY& ",&@"YJEAH[0W-_J=I;.B0#SI98PV(XSY@S[ C
M=]:6\72+64/=I;H[L]QN=>K+'M9O^_?!]N*Y?4O#&L7HU:-2@DN8KU/M#7+?
MOUE5A%&5Q\H3*\]MO'WC39O"^L36EZ(%2U,BW/V>'[4S^27MEC!#D9YD#-QZ
MYZDT =0OAO15M#:KIEJ+<MO,?EC!.,<^HQQCICCI4HM=+T^[GO1%;P7$B-)(
MXP"RC&YO_0<GZ9KATM-7N?$FL%;1WE<7$<#2K(J;=Z8WD@*<JOR;3T+9ZG%F
M+PGJJ06[O'&UTEGJ-LDAG^:'S9 T."!T"@KQTR,<"@#L'TG3;B$J]E;R1N),
M@H"")"&?_OH@$^]1_P!C:1;6CI]AMDMQ'(KC8,;'(:3/L2 3ZXKF[CP[K4E]
M/(CA9&:1A=?:6RT;6YC6';VQ(0WI\N>I-:=AH=W8:?JMK'(0+B%1!F9FQ)Y0
M5CD\C+#.?QZT :<VD:5?J));*WE#OYP8H,EBH!.?<  ^H%/OM)T_4S&;ZR@N
M#&"$\Q < XR/IP#]0/2LG1=*U&RUR>>< V\MNBN[R;V\P*B@)Z)\K$@]SD=3
M6?;Z/KMG(LL,4;K%?O,(Y+G#R*T4BG>X&#AG4CC.!SD@9 .BO;+2+>QN)[RV
MMQ;1QS/,7C!4(_S2Y'H<9/K2II6E66FW-L+.VBLI0S7"%0$<%<,6SUX')/I7
M)?\ "+ZP^BWMC=1QW%S/I0M8KEKIAY3?9A&R8QR#)EL_[6>H%;$OAR5M!\1Z
M4A407I<6:/(S! T"+SG)'[P.WXY[T 6O["\.W8>P.G6<H@.]XC$#CS!R3Z[M
MO/K@9JQ-HFC&[:ZFL+3[1/E#(Z#<^Y=I'U*\'U ]JPHO#-TNIQZC%"MM*K6N
MQ%G)V(FX2+QP<AL>_P" K/M?"NL,BR7]O;R%+JWN?LZSG9N4.LI7CC.X$9))
M Y.: .TDTJPFNH;J2TB:>$!8Y-O*@'('T!Y'I4 \/:.J!!IMMM$GFXV#[W')
M]>@_(>E9?B#P]=:MJ+3QR,J+% L>VX>,J5FW2'Y3U*9&>O)'>LN[\+ZP;=K>
M JR[;E+1OM3+]C9YBT4H_O;4(&.VW X)H ["?3+&ZNDNI[6*6>-2JNZY(&"/
MY,WYGUJ"XT?1Y5CBN+*U8,56-74<E58*!]%+C'H3VS7.W_A?4);9FC=VDEU*
M6XN$$_,L)\P1J-P*C;O4[>!P3UQ6C>Z'--!X;RANY-,N$>5IY<NP\EXRV[&&
M;<RL>!G!^E &E86FE2P6]U96\!C!#PNB8QA#&"/HN5^G%3R:;8RNSR6D+LTA
ME8L@.7,?EEC[[/E^G%<?!X5U/3]-:&U2)S+;Q)/&\S$.PF+,0#QG82!GC@ \
M#%.M/"VKK':27,^ZYMH[)(V%RQ"^7<.TOH#F(JN<<\CI0!N-9^&;"2'2WAT^
M&2:9)X[=]H+R+C8P!ZL-@P?]GVJ:P.A7.J74^GO9R7RG%PT+ L#TRV._RXS_
M +..U5=>T[4-1U+3?LR8AM[B*=G:8>60KY8-'C+';]TYX8@]N:WAK1-0T^>U
M^V)$B6-@+%&23<9\,#O(P,<*..N6;ZD TQI6A_VI<*+&T-[-$S3YB!+HYPQ/
M'.[&#ZX%2-X?TAK>.!M/@:.-BZ KG!(P>>O(X^G%<A;>%];@BN&:VMWGDMH(
M)W>Y9S<LLI:23!X!8'(!XSP>!4UEHFM6]]I-E-/*\7V3S+PK*V!)"2(P'QU8
MR*3[0]* .S6PM%F$RVT0D$AE#!1D.5VEOJ1Q4-SH^FWB,ES8P2J\OG,'0'+[
M=N[Z[>/IQ6)9:5JMMX/N-/$4!N-Q6%9'R6CR,[R, N1NZ8!.,]35&S\+:N+'
M;-<^5<QVEW':OY[,()))6,38& =J$#IQT'% '5QZ5I\4/DQV<"Q?NSL"#'[O
M&S_OG:N/3 ILFC:;*K*]E"0V[/RX)W/O;\V ;ZUA66A:A!X1UBQC>:*[NXI%
MA62<,(W,04%2H&T;AGUSD]33)/#5Y'XDMI[>69;"%8O*"3@>659BX;<"2'R,
MD')Z'& : .BBTK3X518K*!%0H5"H %*+M7'T' ]J@'AW1A:FV&FVWD%@_E^6
M, CI@=L9/3U/K7(1^&O$(TZY#I$+AY(IHX5N/W/FA'5RP(R4)*GKNX#9W#%6
M;[PYKEP^I>4ZQSS1W@6[%RP,HD4B&/;_  [,KSVV9'WC0!UK:5I[V$5B;.'[
M)#M\J'8 J;?NX';&*JP1:'8-J&I016T+0E_M<R)@KCYWS^>XXZGGK7-:UX8U
MA['4++2_+$,L[R6I:X;=#F"-5()SC]X)&)Y/.1U--OO"NJW%YJQACBC^UFY;
MS_M+'S4>W\M8RF,#Y\-G_9]2: .I_P"$?T:03-_9UN?M#^;(=GWGSNW?7))S
MUR:D;0M*9]YL("PC\H'9T7&,#TX _*LC2;"_B\67WFO(=.MTWVX);!DE"[QS
MUVE"1_UV([5FWWA349+-%265F>\NIKE([C#.KN_E$%@1\BD<<8ZCD"@#J4T/
M2HI8)(["W1X!B-E0 J,D_CR2>>Y)ZFG6UEINDR;;:"&V:Z?: @QO8!FP!]-Q
MQ]:Y"\T/5UUN$?O7^T3R(+[[0S%8S9NJJZ   "09SZD$<L<6H]&\07#)+/L@
M(=<HMR7X%I+%UP.LC*?PSUXH Z>+2=/A1$CLX$6,1A J !?+X3'^[V]*@O+#
M1]0OV@O+2VGNI+<JRR1ABT(<'!SVW8./6N<_X16_BOM*,<TXMK>" ,([CYDF
M5RTCDL"6W@@'!R<$'@U9\.:#J&GZVUY>1(#]F>&2<7#2-.YDW;]I'RY'^'0"
M@#=MAIFH_:6@BCE N@9F\L@--&0,Y(^8J449&<%<=J!HNE1JW^@VX4[RWR#'
MSLK-^952?<"N2G\(:C#I_P!FLXHB&-\45;EHQ#++-NBFXZE5X]1VZFNDTG29
MK)]3FG<O<74S,LA<GY,#:,'A><G ]: *FH>&='\03Q7:3%&",V8!&21)M;=D
MJ2K':,,I!]^F-RXL;2[+&XMHI=T30MYB!LQMC<ISV.!D>U<7'X4U"&SN5>$2
M7,]I9JTT<XW-)$ &5@PPRDJ,YZC(X-7]>LM1N+?0;=K%;MQN%U##.\46?)(^
M]UV[L8W>W>@#H;72=/L?+^S6<,1C+%2J\@MC<<^IP/R%5KJUT6;5O)N;:"6]
MN8'4AHM^Z+&&W<8 (XYZ].:YF#POKJ7IDNK^:XE%LJ).DX521;",JP*[L&3<
M_!QD@]14T_A"XC3S+((EP-.2WWF=@SN)-T@+\D;AN&[K\V: .A'AO11"L0TN
MUV+(90/+'WR "WU( !]<<U<BL+2"598K>-'7S-K*N"/,8.__ 'TP!/J17,Z=
MX<O%U.WN+E?*LXFN)(;07#,("WD^6/0X*2-CH"^!573?"%_8_89?-;SX8[$N
MQNG;,BDBX/)YW+M'OCVH Z"T\+:/:)> 64,K7CS-.\J EQ+(9&4\=,G\@,YQ
M5JWT;3K1 MK9PP85U!C0 @/@O^952?4@5R6G^&-9>7&H^6D$D\$LT,4[;&*K
M*),8YP2R=220.?2I;?P]K<2"-W#S_P!GBWM[LW39M) L@SC'S9W)SU..>@H
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MS'->"!%%Q%.T:2DJ&$<JR%1C/)=.I)(&2<T =1;V&D7D<-_!:V[I+%$T<BH
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M\%4?@/2KD4$4'F>5&J>8Y=]HQN8]2?>N2N/"$D^J/*<_9S><(+AP/LPM @3
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M+=VRS-$05W$XX.1D=#@C/.>:+;2-/L[V6\M[6..XEW;W _O'+8],GDXZGDT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(+BZ"F&*1P&;<<#CW/ ]3P*AB\5:#,(#%JMJ_GRF&+:^=[#&<>H^9>>G(]:
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M:_I,IM@FH6[-<NT<*A^792 P ZY!(R.V:>VL::FI#3FOH!>DX$!<;LXW#CZ
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MGTPWL5H9OWLSLL."&#[55L\$XX<=<&FZ9XJTW5K"SNK69'^T^6&C$BYB+H6
M.3ST/3/0^AH VZ*I:=K&G:LCOIU[!=*F"QB<-@$9!^A]?8UEIXMA=GA&G7OV
MQ;E;9;7,19W,9DX8/L&$5B<L",>XR =#169'K^FMH]MJDMPMO;7 &PS':<D9
MVD>HP<CV/I4-EXHTJ[L+*Y>ZB@:[MEN4CD<9"E-_TR%!/T!- &S15%]9TV.=
M(&O8?-=@JH&R22 1^A!_$>M/N-4L;2ZBM;BZBCGE^XC'!;KC\\''KB@"W17.
M:5XTTK4VC4RK TL<LT>]N#$AP68]%[G'H*T4\0:1((=NHVY,\GE1KOY9^/E
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M9=Z0N&,B8_>>9CG=@X\H],]?K4J^)]$>W>==3MC$CA"P?C<5W >_R_-].>E
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MQD$[Q$&$2,ROO);YB J\DC!8D\<5OW.N7EMX3M;Z9X5NIF5#)"H>/DG#9+
M$ <EB 3@9XR ,MO!5K;!T$P*>>DT;>4/,4+.LVTMGD94#H..N3S6MJ&ER76H
MVE_;W9MKBW22+/EAPT;E"PP>AS&N#VYX.:YBW\1ZQJ5D TL-C=R:6D\5O]F9
MGED:)F8IEN K #&#C'/45+#XHNXA9V[30W,D\=@8I%B/[WS)BDQ&#_"H'T)Y
MZ@4 7#X-1YI#)J$K0GSO*C\M1L$DZSMSW^9<?3WY,\OA2WDUN[U'?&WVEC(R
M2P"3:_DB'*DG&-H&00<\\X.*P[?Q#J&L7IBP_D17EFZ,L7EL TD@=& 9N@1<
M@X(W<BM74O$-W;>+[/2X%#1.0)5:+G!CD8,K;LD JH)VXYQG)X +D?A[9X<;
M26N1-N?<&FC+JGS[@JJ6R .-OS9&!@\"J+>"S+=6\L^KW=P((MB^<=S9\AH2
M<YQR&+'C.XGGL,Z'Q+KB65L;V2TA^T16D\EV;5@ELLRRE@REN<-&JYR.9!FK
MFGWNJQ^"]%:"1?MEQ+'%)+/"S;0S'+;20>GJ>.] %VU\*"UU.WN4OY#!#<"Y
M$!C7F06_D9W=<;><>N><<!UQX7%QJTUVU](();D736XC'$@A$(.[KC SCU ]
M\Y(\4:JEWJHG6W2*T$P\I8\S+M<+&^W>,JP)8D[0 1S@&DL/%6IS?V6TRPLM
MQ+/$T<2#S)-LC*C ;ON%5R67=C(/W: -)_!ULT^GRB56^RVT5JZRQ;Q(D9RI
M R-K9)YY'/3BH5\%E;FXNCJL[W+O&\4DB;MACD9UW9/S?>*G&!@#&.M4+'Q+
MK=]#&L4EJ[R_9-\HM7Q;/(S"2)ANY9 !U((SR.13U\5ZF+S2;9XT,TKHEPOV
M?:KAIGC+*2^1C;NP 0,C)^84 ;B^'E-T+J:[>28W,5RS; -S)'LZ=@>M4=;\
M#VFMZE/>O=SPO+$(]L8'RG@.P]VC 0^@Z5S^E:MJEQI-G9M<&X6.2P:1TB='
MA8W2*8W))W93GMQD]"*Z+PIK>IZQ-<F_2VC5%!,*<20/N8%&&3V Y.#D'C!&
M "W_ ,(XB:D+V&Z9'^T/,RE 05>-4*CT^X"#4-OX2M[=[)A=2'[+#;0K\H^8
M0K(H)^OFG\A63#XHU"73+&>:_L[9KB3%T[6K8L&\MF\I_FY;< N3CZ?,*@O/
M$NNSZ5>I\EK>MHQNXXX82[P2B-68."VY3DD+P1[Y!! .HTC08](V^5.[E;"W
ML@2!TAWX;ZG>?RK.B\'F&<WD=^L=\+A9T>*V5(@PC>,YC!Y)61LG.3A?3%3:
MM>W<9\.S6^HQ"WGNPES,L64E0PR%>_ +!0.>I7Z&'PWKNH:IJ'E7/DLIMS+-
M''$R-9R!\")R2<DC/I]TGH10!<;PXL>FZ5:VEY)#+IK[XIF0.6)1D8L. <AV
M/&.<=N*I6G@M+6ZTJ1M1GFATZ.-(X9%R#MB:+UP 0Q) &<]\<5BP^,]8DT^6
MXB^RW/R1F1HX&46A,P0[\MS\F6[8VY/RFK-UJWB"]T;4=EQ:Q>5I,EP)+>(N
M9')F52C!L#A%/&>3P<4 6M,\&/;:19P279BN(;DS-,HW2!00J(K\8Q&B(3@@
M@'(-:FJ>'3J>LVU\]],D<#1.+?JNZ-RV1S@9S@\$_*O3'./;:MJ.GZI!I*-
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M9T&XG@X& #T.3R, &AJ_AQ=5NI9?M;PQW-NMM=1A WF1JQ8 $_=/S,,\\'U
M-6!HL::3>6 =76ZEFE;SHPZ_O'+$%>XYQ5'7M?%M8Z/=65];0VVH7 3[5-&7
M18S#)(& R.NQ>3QS65%XBU^339;Z2*"$1VMHS1M;.2K2D"20_-G:@RVWK@$$
MT 7X_!["\T^>75[J=;,HP24ELLI8\9/ ._'.3A5YXY+/P8ME]BCBU&7[/;_9
MF:,QJ3(\*!%.>P( R!W'7J#23Q+K.;=$CAN8[N=[6VNHX6".P=<2$9/R^693
MUP3%P?F K/O=;U-XX;/S1:J;B)D4QR/)<9O65E5BV0%1%)ZC#]A0!UMUX?AN
MKZ6Z:9P9)H)2H'_/+.!^.:SHO!GE620?VD[/!';0VKF(?NT@D$B!@/O$D $\
M<#@"LQ/%6M-'?2.MG"L4PC964E[4&X$99U#9*A"6R=HXS]T\2PS:A/X$\V.Z
M9[M]7^2?RV *G4, [<YV;>V?N]\4 ;,'AMK34EO;6_>-R\IF5HPP=))?,*CT
M(.1GT)XZ$0Z/X7DT".*'3[B'8IBB:1XOWGD)N.TG)W$Y SQC)/7KDW?BC6K:
MW*M]G6XB6Y\L-;M_ITD<S(D:#=\I90#W^]D< TZ;Q3KL6NR::+%"!<?9!,(F
M(\QY-T9Z_=6 %F_VN..E &Y>>'%N]4:Z^UND$LMO-- $!WO"P="&Z@9"Y'.<
M=LG,HT"(>&8]$\Y_*2-4\S R=I!SC\*YVW\5:TR7UU-#:B&T?=/;JI,T,:R[
M6^4$DGR\L"0,E> 0>);7Q'KLNLV%K<06MNLT<,K12C:SK(6+!26Y9!M! !Y!
MS@$8 -V30(I-#U'2S,^R]:=F? ROFLS''TW5G:QX-75A>I_:4\,=X\CRQJ,J
M=T4<?3(Y CX)S]YN.A%WPYJ5S=Z3IS:G/#_:%[;"Z$,<1CVKA-PP2>A< GWZ
M5SAN]<FN8DCU)#<P:C>J0UN2$C"R%%90PR"-I!/8CK0!N2>$;:34+Z[^T2C[
M5-#*L>!MA*.KMM_WV12?<52U?P=)-IBQV-P_GQLVW+>6<-=).Q##HPV8!_E5
M*;Q5JUW=I:6J>7)-:$E3;_-%(;;S59?FRPW?+RH&<CJ#6C>:Y>6?@NPU**[M
MYI65#-*4&9!M)(12P!?( P2,\]\4 6;70;I_#=E97$T=O=VL_GQ21#> 0Y*[
ML_>)4_,>,DD@TI\+E[XSRZA(\<DZ74L?EJ"\ZQ"(-GLN%4[?4=<9%9E]XMU"
M"6\@M[99;J W+"#R7W%$AWQYQ_>/'OR!R#4%WJFJ+=IJ%AJ-O>QPV,DCLELW
MES8E3Y0 ^ <9&>?IUH VK?PG!;K;JMS(?(6T4?*.?L^<?GGFFP>$;>"V@A%U
M(1#!80@[1R+64R*?^!$X-1>*-=U#2KGR[3R5(M6FA22)G-W*" (5((P3^)^8
M'H#6.+74VUJ*:2[)C;6IV=6C?!2.)R@.&^Z,<<8S@XXH V+#P7;6$21+,"D4
ML+Q-Y0$@6-]X5FS\WIT'YU-;^%5M;B5X;Z017,;17,9C!\Q#++( #_"09G&>
M<C'0\U@-XOULV=EY0L_.<3"2>10L$DJ>7M1'WX*MO;!'S?*>,@BMW3+[4/(\
M0>=>027%K<2^0DJ%!$NW*;L$DKTY],T 16G@T64%K]GOECNK616CN%MQEE$;
M1X<$_,<.QR, 'MC(-F?PNLGAO3M&BO'B%C''''<[/WJ[$V!T((VOCN..2,$'
M%<]_;FL3M#JEM(#Y-E(9D: E)BLX7";7(Y&<,,Y&#CJ*DO/$.H7VH7EA&'\B
M*XBVLL6QT*7<:$'#'@J2>0,CG&#0!JOX-6749[R?4IY3(Q*AADJ//28+DGH"
M@48QA<=^3;TKPY_9FHI<_;7ECBCFB@A,8&Q9)%D.2.205QGTQWR32@O-2MO"
MT3VS#[5)J30[IT:3:CW3+G&03A3QSV%9[^*-9CV1N+=)T&$C-NV;YQ</$RI\
MWRD*BMWQY@/0'(!L+X8FBMHX(M395MKK[3:9A4^427)#<_/PY';H.IR3&G@N
MV72I[%KN9Q-9P6ID*@,/*9W5O3.7Y'3BHK+5=4M_#&N73R+?ZA9SW?E0"(J0
M%=_+4@')RNTCN01]:H'Q3K*6UI(ILKE)KDQR2PJ7$<'[O,S;6(^4L5*YYR#D
M8:@#?'AU#X>N-*\U(VG)9I88MHWY!!VDG/0=3S4-UX3@OO/^U7,C>?<M<2[%
M"Y+6OV8@>@P=WUK(G\4ZFEE),LML)?MI@FB,)7[#&&D 9R6 .[8@!.!\V>1@
M4ZW\2Z[)JUI:R0V(W01.R!L?:-RDLT1+9."!@ '&#D\@@ EN_!(ETN"S66)G
M^UH\TR1^66AVE)%;D[BT99>WWLC&*U/$'AO^W0VR]>U,EI-92E8P^Z*7;NQG
MH?E'/N>.A&7X1U2\U/4K^[N[E9P=/LV*0PLBQ2$SEX\$G+#@'OT!&1572_$^
MM:N888&A3SKQ(Q</:YVQM;R2'*K(1N#(!][C.#R* -^W\.+!JRW1NW:"*YEN
MXH-@&V612K$MU(^9L#MNZG Q#?>$;74([F.:XE"7$D[OM !'FQ>60/H.:JW_
M (COH/!NE:EM$-[>Q1EAY.Y%<Q%R"&9=HR,#DG)  R:KPZWXAO[JV$+6MM%/
M<108>U9R@:T$[-G>,X;Y1QWYS0!J1^&I!>17TNH&2]2\6Z:00@*P$30[-N>/
ME8G.>OMQ3[[PY]LU8WBWKQ1O+;S2PB,'>T+[E^8\@'N/8=.<XMEXJU:ZFTWS
M(X(I;A+-C9>2V^594!ED5L\!"6['&PY^\,):>*M5U"W@2W$"7)AL!.QMW80S
MRNZS*1D?=VCC/'>@"^/!L<,,?D73-+##%''O4;28UE"Y^OG'/TK,TGP/=KI\
M4-[+&DEO*LD3NQG+GRO+8/R,K@#: 1C ^E7]%U35;K7[=+ZYCCC>TD'DB$J)
M9(Y70LI)XX"G'/!_&JDOBG6UN=6"PVJK:^<%A929(U61524J&RRE27/ XP >
MM &W!X7MK>>.2.4JL=VMRL:H HQ:_9PH]!MYK-NO!TRZ ]K:WS->I9V]K;3%
M0GEF%RT<G?D9&?7';-4'\:7UO97<S36UQ'&EXD$\<#!9I8UB,2@9.2VY^!][
M'%)K?B/4;B?6=-@#>6FGW!RL6QXY%5-N"&)P=[8) SCCIR =#J.A3M;Z%;Z5
M,EJFFW 8,R[]J""2,#'?EU'4<9YJK;>#([.6S$&H3"WMQ;EHV129&A!"DMVR
M#R .H&,<@N\0:CJ6G:Y:M:R!X3I]W(MKY>?M$Z>640-GAB"V/8-^!I&JZAJ=
MEJ:I=07/E1*;>\@@*J9&0DKM+')4X[]\'D&@":+PNL$>B1Q7;(-+B2(.J8DD
M50/EW \*VT;E((/L1FL^/P&BVR1/J4DK016T-L6B&$2#S @8 C=D2L#R/48K
M.TW5-9\VVOTO([E'L=,2X#0,1(TEQ+&^,-A64'G@\J,X'%;7AC6]3U:]NUO4
MMHTCS^Y7B6%@Y&UAD]@.2!R,C@\ &DNB0K:Z9 K*BV$PF41H%5CM9>G8?.34
M">'2GA:UT07A/V3R/)G\L9'DNK1[AGG[B@],\]*W** ,*T\."VU-+IKQY(8I
MY;F*'8!MEE!WDMU(^9L#MN[X&-VBB@ HHHH **** $)"J68@ #))[5F1^)-#
ME16CU>Q96D$2D3J<N1D*.>N"#CTJUJ<$MUI-Y;P;?.E@=$WG W%2!G@\9]C7
M->&O#5W9F"6^PC6TYECW,7DDS"(B78LW0# P>@'2@#?_ +>TCRYW_M.TVP,%
ME(F7Y"20 >>.01^!]*K0:YH*7]Y'%?6BS>3'>SN)  R,-JONZ$80?AM]167:
M>"GL; VMKJ9C*^6D4H60.8D)(1R) 2.?X=GTY(H'@@+IRV2ZBWEBQM;7<8SN
MWV\ADC?(8<$DY'?C!% &_'K6ERR6\<>HVKO<Y\A5E4F3&0=HSS@@@^E-N==T
MJTFG@FU"V6>"-I9(?-7>JA=Q.,YZ<_2JNE>'DTV[CNO,1I5ADB81QE58O)O+
M?,S'.?4G-5Y?"QFU"25KW_1FN)+M8?*^997A,1R^>5PS'&,Y[X&* +MGX@L;
MC0;;6+B:*TMKA0RF:5<#/09!QGV!I\.K:+%+;V<%_8I).HDAA2509 V2&4 \
MYY.1UYJ"XT-VL-*BMKL17&F,KPR21;U8B)HSN7(ZJYZ$8.*IVO@^"UB1$NW.
MW[(<E!DF"0R?^/%C]* -NTU*QOWE2SO(+AH3B012!BAYZXZ=#^1JK!XET*ZF
MCAM]8L)99&"HB7"$L3T  /-5?#?AI/#T;1K,LZK$D$3E6#B-,[0Q+D'KV"CK
MQS4%MX/AMK:VA%TQ\BWT^ -Y8&1:R&0'K_%G!]/>@#4_M_1MEP_]JV6VV(69
MO/7$9+;1NYXRW'UXJG>>+M&M(7=;V*=Q92WL:0N&,D<8.[:>F>#^1]#5*W\&
M"..VBEOS)'9K!'; 0[2L<4R2@.<G<Q\M1NX]<9)I\_A#S89XDOMB7$-]#+F+
M)VW,ADXY&"I/OD>E &FOB#3Y4BFM[B*>U8N);F*16CAVIN.]LX''\Q3[S6K6
MUTM-0C#7<4DD<48MRI+L[A% )('WB.I%1_V(@BU=-\;C46RR2Q;D7]TD>"N1
MN&$Y&1UQ52Y\-/=^%TT>>]$[I,DWFW$1E5MLHD"E6;)7@+@L3@<DT 6[3Q%I
MEU!:R&ZC@>Y8I'#.ZJY8,4*XSR=P(XR#VS4KZ]I$=NUP^IV:PK(8FD,R[0X&
M2N<]< G\#6"O@ET2PA359%MK:=+@VZH5CW+/YP"*&"JN<* 0V% Q@Y)63P4[
MJI&HA6CN&EBC$;B%%9"K*$$@(SG/# 9[<G(!IZIJMEHDJ7?V.6XFO%(+6X0L
M4C5GR2S 8 W'CUX'-6H]<TN1HD%_;K))$)EC>0*^PKNSM/(XR?H#5+5?"FG:
MS:6%I>11M:VB,BQ;!CF,H",_=(SD'J,537P<3>RW,]\)VG0&5I(FW>;Y A+K
MA]JY49P5)Y//- &DWBG0PL#+JMK(L\_V=&CE##S-I;!(Z<#]1ZU<N=4L+.ZA
MMKF]MX9YB!'')(%9\G P#UYX^M9 \+>7-!/!>;)87@=-T6Y?W<;1X(R.JN>_
M!QUJ75/#AU'49+@7GE0W$<$=S$8MQ98I&D7:V1M)+$'@\=,'F@"W-K^E0Z??
M7WV^![>Q#&Y>-P_EE1R#CO[5%;>)M*NM4;3TO(1.51H@9%_?!E+#8,Y/ -"Z
M#$/#=WHIF;R[E;A6D"@$>:S$\>V\_E4!\-F:<W%S=AYFEMY7,<6T$Q C@9)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$EU\PE!SD#!!'\>:EM_%=^7TPSRZ<T-U<M"6@*R/(-R!2J+*<#YF#$%\8!(
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MWECC""12WX[0<>Y%-NM.N]3T*ZLKV>-)IF?:\:Y"+O)3(XS@;<],\]*YV_\
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M+. ZB-H\-^^W=&/W6 ]L5LS^'XIK?2H%=(X]/!"(J9!!A:+ R<C ;/4],>]
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M!8DB,3#)%NT!.-^T9W%N5+=MV* ->W\1VESIE]?I%.(K*,22 @;B#"LO'/\
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M)EM\>>1<(1%DX&[GC)]:Q8?!@@GNWCOSMN[Q+R56BS\Z7/GJ <\#&5(Z?Q
MYS2U7P?=1Z5$NGSF2>+RUPB!6(%PLQ898#(P>,CZ]J .FFUFR33X;Z"9+J">
M6.*)[=PX=G<(,$'! )Y]@:?_ &SI>^X3^TK/?;?Z]?/7,7./FY^7GCFL:'2+
M[_A&M*@:"*.ZL[J*7RE8X*+)SDDM\VPDGYC\W<]:@;P4TJ^5-J"/!&LJ0*+?
M#!9)TF8.=QWG,8&<+U).30!T+ZI9I';R^?$UO.I=)Q(NS:%W;LYY&.<C/Y5
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M5NEE$;LAD$OF996<L<GK\^<G.13M)\.G3;R.[>Z$LH2X\P+%L5FFE$K$#)P
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MU8_)^8.L(B(W;N0=JD<<'/7M7M/!R6LUH_VS>+<6X"F+&?*,I'?C/F_AM]^
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MWB$8M(HV520$56;+$%@J;00J\'G.!C-B\'W'VNYN+K5WN'EEMG!:-L@0W'G
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M,H3#GJ "V47D#D\D]=0 4444 %%%% !1110 4444 17,RV]K+.QPL:%R<$\
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MD:ZDBQ ?,#SHRG<V[YE&XX&!T7GY>:L7CBZDUQ=*^PQ^<9S:[MQQYRRX=?\
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M;9!DC>!E]WW03GG-F#PQ.GAG5M&DO4\N]BDAA"1MLMU:/9A0S$D9R<9P,X&
M*QF^(%S#:64\UE"5N0S;E?@)#*ZW#\$C"HJL.3RV,GK5N'QE/)JFCVYBA OA
M&TD1!#QK('9#DMR<*,@*>_(XH OS>%4D\1+J2R)Y.(<P'S %,18J5"N%[]"I
MQSZU6L_!,=I;VL:W$>^"WTZ'>(,$_993(3U_CSCV]ZQ]2\7:J_ABWF>6PLI[
MS3/MRL'93AMH"1DGEQNR3_NC'.1U.JZU)I^N:=9GR5M[DE6<_,^\G"J%!! /
M/S88<<XZT 9MAX.NK>]^UW>J"XEWV[%O*8;O*\WU<@9\WHH &.!3['P:+$6
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M@9,#)^89&21DD#/<5G:?XRN[C6K5WAQ!>:9;SE=VY%DS<$HF.KOL&.V$/).
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M< AF.=X9L D\*6'\7 !UGVO3ELW;[1:BU0^6QWKL4]-I[#Z4\2V8NDB#P?:
MI")D;P,#.!UQ@C]*XY/!%U+;P2RS6L<Z21O]GA1XHB%A:+G:V0WS$YZ8 '/6
MK\/@V*":.2-H 8YXG7,98A$MO(V9)W$<D\GN?K0!OB\T\Q1R+<VOENXC1@ZX
M9@>%![G/:FV-OIUM'+968AQ&<2QJVX@G)^;OW/6N4?P)/-;VL4]U%+%#'- +
M<M(JI%)Y?RAE8,Q'E_Q=<]> :V+/2M1TS4[J:U:W:VN[E6,.#B(%G:1\DYW-
MD#:.,\XY- &B;^PAN;FUD,</V6*.21GPJ*KE@O/U0_I4IEL PB+VVZ0><%RN
M6 _CQW^M8^J^')[S6/[2AGAWHT#I#-&61C&)@0V#_P!-LCT*@U0B\%RPHD2W
M%NT)LWMKE2C!9PPDPFW=\J@R'!4A@/ER: .H$UDUM]K62W, 7/G!AMVC_:Z8
M%5#JVG+JUKIT6R2>\C:Y!C*XV+CYSSSDD 8R?P!-4GT"\E\-V]A->1RW,%PM
MP'DCRC;9=ZHPZD 8&[J2-QYHT;PT=,OH;N26)W6.X#*D>T!I9O-PO/"CD4 :
M5KJNGWGVA(YHU:WD=94<@%=K$%L>F0>:GDFLHI#YDENCR,(CN8 LV,A?<X/3
MWKE+GP1/=2:@&N[:..Y%X4>. ^9NG&,.<_,%'TS@=,<SMX7U&6Z:\>\M4O)+
MX71ECC8"-?+B0H 20V1%SN]01@B@#H%OK*X1%>2,>8Y58Y2 6()' /7E3CZ4
M\W5BGG$W%NOV?'F_.H\KTW>GXUS0\%\N[SQ-(?+V.8N4VW3SG!]]P'U&:BB\
M$&**\4O%-)(S-%*\DH;F83#.&P"& .0.2,]R* .L2:T>80QRP-)L#A%8$[.Q
MQZ>]1M=:<6F@:>U)B3][&77Y%']X=ASW]:RM)T&\T_5Q>2WD4BM:K'<;(]IN
M)0J+YA&<)]P\+C((!^Z*YNP\+:M-=ZBMS L0DN#/%+,J%!MN_/6/"L2ZMDDD
M@$<=>@ .Y:YT_9 [36VV;Y86++A\]E]<^U0RZGIL6JK8M)%]JEC8N!CA5V\-
MZ9WC&>M<W-X'N);>:/[7:@W<4\4^8#B$2R%RT//RD9[]2 >,8J23P3)/=W1F
MN+?R)4O51TA(FS<.'R6S_ 1@?0=,4 =1/=VL$3,[*P+;65?F).0IX[XR,U5L
M=8LM0NV@@5_,3S"2R8^Y(T3?^/(?PKG+/P+<0_:7GU%)9)]DF1$0%F9XWG8#
M/1VB0@=N>N:VM(T!],U"2Z:X60.)QM"XQYEP\OZ!\?A0!I&[L'2=C<6S(AV3
M$NI"GT;T^AJ"]U/3+"UB>:2$QSE$B52I\P.P48'<989QVKGK7P7<BZFGOKV"
MX\R6U<CRCAA#)(_3.!G>. ,#'>FOX'G#QB.YM#%NAW>9 28Q%<O.HCYXR'VG
M_=% '1-J&GBZN8)?+C2R\LO+)M6-7?)"@GHP&"?]\>M6S+:R7"1EX6G WHI(
M+ >H'7N.?>N='AZ]FM+6Z<VZZ@+V2]FBG7S(V+HR!3@]41E4'_8]\U:\.^&8
M]!8MYB3/]E@MA)Y>UL1J1^1ST[4 6+/Q!I]Y<75NBW$)MFVSM/;O$BL0IP68
M 9(=3[YJ[%<V+,8H9K8LB!RB,N57'!P.@QWK*O/#?VQ=2226-H[W4+:[*,F1
MMB\G*$=\^4?^^JS=2\&76I:C?3/?Q)#-;S01*(C\BR*@P0" 0"G/<@XR,4 ;
MUIJ^E2BZ:&>!(XK@0O)N4(\C(KC!Z-D.OXYI=0U*QTRYM4FAD>>8,L*P6[2-
M@8S]T' Y%<U<>!I[IIIIIK3=-<RRO;Q+)%%MDACC(^5@<_N\Y[[FX&>-^^T"
M&_O=,ED=O*L5<; [ L2% ^8'/&.^<T 6X9K!T.!$@BD(VNH7#!BN0/J, TVS
MU#2[Z!KNTN+:6-MQ:16'.P\DGVX^G%84G@^5]1LKL7<0-I=SW*H8LB3S9O,*
MMST Z?[8#=L57NO!E])I9L[:\M(LVU[9[C Q'E7#*V[ 8?,-@'IS0!U,MSIZ
M;S-/;+Y'SOO=1Y>3U.>G.>:>9+.298"\#2E?,6/(+;3QN ].>M<]?>$/M"3/
M%+&L[ZE]NSADW_)L",RD-QU!]0.*;#X<OM(E6XTDVRM%9"!8"7*R.%VIN+,<
M*IYR#N(XYP* .B2.TLTDC7RHE=FE<$XR6.68Y]S5>ZU73--S]IFB@C0 ER %
M7D*!GL?F Q6?XH\+KXD%LC7'DHNZ*XPN3)"Q5BHYX.Z.,Y] 1WK//@RX?3Q'
M-?0RW;0/YLC1';),TRS%L9X7*XQV&/2@#H;'4M/N;NZM;62(30R8D08!8E5;
M<!W&'7FIHYK&ZC4Q26\R;RJ[65ANP20/?&?UKGKOP;]LENI3<1P2W-Q)*\D,
M>&57M/L^T'V/S#Z"FQ>%;^*XBOH[BQBO(IXY%CC@80X6&2'INSDB0G_@*CMF
M@#?COM-N[V2RCGMYKB)%F:($$A6SAOQ_SUI[7FGQN\K7%JK!A$SEU!!/12?7
MVK)\/^')=#GA8S0RHNFVUF[",JQ>$,-P.>A#=.V!6?=^!UFLK:%)(28Y;IY4
M(=%E$[$DDH0<@''N"?7@ Z=[G3TN9(GGMEN-F9$+J&VXZD=<8I?M=C,D+?:+
M=TE.83O4AR/[OK^%<1#X;UG^WM2*1B&*9)H[>XD5&6$,L8##YBSEO+7(8<8Z
M^NGI_@PV[1M<W$;LD=ZH*J28VN'1LJS$G*[",]\]J -VWU/3KR>[MX9(I!;1
MJ96&"@5MW&>G\+9J+[1HFKZ?8L+BVEM)V26U D"ARI#+M&1G!QQ^8JGX<\/3
M:.]R]PUFWG000[+: QKB-67)!)R2"/IC'.,UE)X(NETZULS=6A5+&&PD?R#N
M58F)$D?/RNV>?<*><<@'8-]F1U#>2K(% !P"H)POTR1@>XJJ-3TY]4.G>9$+
MB-$D4$C!W&10%]2#&^0.E9/B;PH^O7D$\5X+;9$RR#9G>X^:%NO\$GS>]01^
M"U3RG:>)YTCL@93%\Q>&X:>1L]MY8_\ UZ -V\U+2;>.62[NK151T@D+LIVL
MS *K>F2>]+9ZEI]]-/# \?FP.4=#C=\O<#TR>M<S!X&:"TGB$T+S>9&\4TAD
M;>$G$P#J6P,D8)'J3WQ4][X*%XEX/M,<,EV;K?+'%\P$T0CQG/., _@* .CC
MNM.\M)8I[7RY'^1U=<,V<<'N<G'XT(+&UO656ACNKG!V[@'<*,# ZX ]/?UK
M#TWPFEI>VMW,L!>&669E!>3+LB(&!<D@@)V_Q)DO_#4UYK;7@G@$$DUM,Y:(
MF5#"VX*C9X5N_IENN[@ VXI;,QN\,D!C5LNR,,!NO.._(_.D-]8^3'<&ZM_*
MD.R.0R+AB>P/?IT]JQU\,1IX,_X1]6A&Z(1NXC^5SG))'?-4;[P9+-+<-;3V
M@2<74?E30%D1)Q&"0 1\P,9^NX]* .BM;W3I9+F"VGMRUD^R9$('E-@-SZ<&
MJMMK^C7ES;?9[J"0W4 EAF!&)%)P%!ZYSVHTC1FTN[U)O,CEANY$D4E?GR(D
MC(8]_N9_X$:Q(O!##3+:UEFMC);:>EE%(L/3:ZL'Z\$[1G'>@#IH+JQ(CB0Q
M1%I'2.-@%+,C$-M'?D'I2QW%G+>7<*!//@V>>2F,9&5R>_%8D/ABXM]2M;J*
MZB4QW-Q+(X4[G229Y?+QG;_$.<9!!QUQ2ZIX<O+^768DNX8[35(!$^48NA"%
M1C! (Z9''&: -G[7IS+'/]HM2)SLCDWK^\/3 /?OQ3I+FPVS^;/;;82#-N=<
M1GMN]/QKE+WP5=W6G?98;J"W$IE:<#S)-SL$"L&9MW 3[N0#NR02.9KOP?=7
M$MTR7<<<+7BW<5NN\*7#.6+,#N&[>#@' 9<@<D4 =.\MO%)%(%!:X8(KHN<\
M$C)'; J">_TN#3[C4);BV%H@)FG!!7'0Y(Z] *I'P\!I>DV431QI82!]OS,I
M 1UVC)SCYNYZ"JT/AF<>#[[0Y;F,^?&\</REE@4J JY)W,!C.2<]L\4 ;:W%
MB66)9K;+1^8J!EY3^\!Z>_2FF[TURFZXM&RQVY=3D\@X]^#^1KG9/!\D^K7-
M]++"3<#>,-(/)D^S^3A5#;2N,GD9Y/L0Z?P3;3I%'BVV1V]I JF 8 AF\QL#
MT;IB@#0M++0[2^^U6XRTT4CK*T[/$%DD!?;EBJ[FP2!C-7Q/II2WVS6H$H*V
MY5U&X'J$(_I7/R>"_,4QFXB,1ED<QF+Y2K7@N-N/H-OXU'=^#;J;R8H;Z&.V
M2[DN3'Y1&"UP)AC!YZ8P>,G.* -A)/#]YIT"I-:-9V<_E1 2!4CD3*;>O;D8
M[U;FU*QMM0MK%I$^TW#>6L:X)&$9^1V&%;%<U=^"9;B(1&:W:-+F[E$9#H'2
MX8L0Q5@<KN('8C/3/%JU\*2VWB"&^$UL8(;I[E<Q$S'=!Y6TN3T'!_ #MD@'
M0">QC8VPEMU:-=YB#*"H'?'8>]$TMD@S/);J V/G91AB/?N0?UKDI?"%WJ6I
MZH]PUO;6TUS-)&Z19E<26PAY.?NC<QQURHJ[:^%KEK^&]U*>UF=+Q;HI'"=O
M%L80!N)YR=V: .ACFLI96:.6W>3<8F*L"<CDJ?<>E0@Z6;N$J]MY\41>,!QE
M4(&6 ], <^E<_%X5U"V$;6][;1F"Z::&)HV9$5HW1AG=NZON S@8P..E=?!%
M[NLD?4HFAM+<0H!$0?\ CU,!Z'!Y.[)R>W % '3RZMI<+0F2]M@9IS#&=X.Z
M3:3MSZX!IPO-.CO6T[SK=+@)YY@R =N3\V/J#^582>$#;36\ML]LOD3P2K&8
M<*=D+1-T[D-D?[HJQK?AN35;NZECGAC6YLOLK[X]Q!#%@>HRIR01W% &I<7V
MF1Z5+?S3VQL(U:627(9 !R3QUIMMJ^G75_+:Q3Q&=57'S#]XI&X;?[PQ6:OA
MN270M=L9YH$EU?S"WDQD1PEHEC& 3S]T,>F2349\+--??;I9+=+@S6\I:*/&
MT1H5*J>N#N/YT ;T#6<L;I;/"RQDHPB8?(>XXZ&H(9]*AT\1136BV< $>T.N
MQ !P/08%97ACPR?#UE+$SI+*8([?S59R76,,%)#,0I^8\#U[\8R-!\$W$=AI
MCZD+-)(8;)7MHX?E_<K)][D@ONDZ]/E% '9?:+)I)(?.MS(@^=-RY7<>X[9/
MYTQ[NQAE,;M$@A0R%S@)&.AYZ \USC^"GGDN4FN81"PNS%)'$1-NG??EFS_
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MF:[AXK:& EHHUC1,?<& HYQCT]J@@;3IH8[V)8 EXJE9"@4RA@,9SR<C'!H
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MLNK LA73YF@@%Q*8YSB8&0ILBXY?CD'N5'?(Z6$6-O \< MXXD)#JFT*I[Y
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MY>['WSYGY*6QVKKDBCC^Y&J\!?E&.!T%1?8+/RA%]D@\L/Y@7RQ@-_>QZ^]
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M+="%..,;\CC^$=.VU10!QT/@DVZP^3);QL#$TI2/'F%+I9\GU. PY[FM#3-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1QP11.[QQ(C.<N
M54 L??UJ2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=[X@?3+KQ#+-^]@TZSCN8X1@$_+(6&??:/I4*>*+Y!:M=Z6MO%)=>1),SL5
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M?D)AF'\1&.3SUH QIO%%['+>0KI?[Z-$D@A:0EY4)0._"D';O.5!+?+T^85
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M9;<1QM4L<@9' XZXYKEKKQ%K>I1O?63I;03:;ITL4?G'Y&N)F5C]SDX7 /;
M(')KN9[?3$MX-/G@M1!*WEPV[HNQB 6P%Z<!2?PI+%M.OK"*YM8H3;O&FW]V
M!\JG*C'8 Y(]* .4N/$%[;W2KY\^R-;M&&Y"2R7%O&ISLQP';J">>N>:?>^,
M[LR7L%C!:L\,D?ERL[A&4W A<'*#GKR,CKR<<]>UK:D%F@A(Y.2@[D$_F0#^
M J+^S=.S./L5KFY!\X>4O[W/7=Q\WXT <Y<>,[FWDU1SI1>VL%E#R"0CYXT#
M<Y7 4Y(SDD#!QSQ/I^M:B+#Q+=7$4-Q/87+".W@EW*0MO$^U6V@Y)+=1U.*W
M18:>)FN!:6HE*>4TGEKN*X^Z3CIC'%26UK:641@M8(8(^ICB0*/3.!]/TH X
M[_A/!?Q7JV=NRB#S'69)!\T0:-8Y!E2,/N;''1&IS:_KSRVYCCLV<:E=P>7Y
MS*KQQK)C<=I(/RCIUKJ3%IEL8H3%:Q^?BWC38HWA0S! .^ &..W-2BTM$G:0
M6\"RR-N9@@#,<8R3W../I0!DRZU)*/#5S$WDP:E+F1&P?D-M)(!GZJO3TJBG
MBR_N)M0%KHS316[31QMYA4L\4@C(.5QS\Q&"3@#N:TGN]#U#2));B"&33[:8
MQ#S[?*!E.S*@CIG(!%7GTK3'DE9["T9YUV2%H5)D48X/'(X''M0!SEQXW^RV
MSW3VJ/;?86N8G1G_ 'SJI9D&4^7&.=V#C)QP:;<>,=2@6*+^PV>[D$SK&'8"
M1(Q&?E^7()\P#Y@ -I/3&>F2PT^.02I:6JOY?D!UC4'9_<SCI[4S^R-*-LMK
M_9UEY$;[UB\E=JMZ@8P#0!F^(_$O]@_9ML*2M("[QL6#! R*2,*1U<=2.<#O
MQ7;Q1=-$TD5I:8EOFLK</<D'<LC1LT@V_*/D)&,]0.]=!/96EXT;W%M!.8\F
M-I(PVW/IGI5&^71;>1([BSMY'U.41$+;AS,P!;Y\#D *3D],4 8UMXW\VV$L
MEK"C$6^T+<;@QEN7@.TX&<;0W3G/:F+XNNH+:]F-F)X+*VN+J9WF D(269%5
M0J ?\LQR<8'J>3NZ?INC&QLI+6"VGA4&2UE*J^ YWY0^ASGCVJXZV=K#-,ZP
M11HA,KX  7ECGVY)_$T <^GBB^06S7>EK;Q27/D23,[%0#Y>T@;=W)D*Y( !
M7D@$&K6J>)/[/U^STU8HY5F>))""X:/S"P4_=V]4/&[)YXXYLVUOH;70M+:R
MLQ):A+A%2!0$WYPRG&,G8>GI5Y[.SGNEN9+:"2XC&U960%U[X!ZCUH Y6U\;
MS_8H[V_L(;>U:"UNGD2X+>7#.SJ&;*CE2H)[8)YXYU)=<OAI^B2Q:?&+K4Y5
M3R9IBHA!B>4Y(4Y("8QCJ:T+O2K"^L);&6&/R)8Q ZH N4'\'';D\>YJTXB8
MJSJK%"73C)!QC(]\$CCUH Y"W\873:G;:;#:>?++,P9I'.0GVB6,D;4VC:(R
M?FQG@9)R:J6OBK6TT.V#P6K73"S=9I)B0Z2W B;< HVG'IGK[<]%-X?TC4KN
M#4WC=6"QR!>8P=CF1"5(!!#,2>A.><]*N7/]E)'+;S0P.%M]SP+#O)B!/\ !
M)&<\ 'F@"OIVL37FJ7]A/;QP2V^&C7>6\Q,D;\[<8R.Q)'<"N?C\9ZC!H<-U
M<6=G).ME-?3 7!0&.-@"J?+RYSTZ#CUX[""TL[665[>W@ADDP96C0*6]"V.O
MXU&=+TU]N;&T;9*95_<J=LA/+#CAO?K0!E:YJNH6FJV]K;"%;>73[J=V=B'5
MH_+V[>,?Q]/\.<F#QAJ,%C:6]SI\<E_*T$:E)696WPM)N;"9S^[88 [BNFU*
MXTZ%K-KR))GEG\JW'E>8V\JQ..#CY0V3Z U8FT^RN(6AFL[>6)@H9'B5E('3
M(([=J %L+B2[TZVN98&MY)HED>%CDQD@$J2.N.E6*:B+&BHBA44 *JC  ]!3
MJ "BBB@ HHHH 9,AD@DC!P64@9]Q7*6O@>UAL=&@F"7+VKQ-=FX9I1*(X)(U
M50W10SY X'7O753M(EO*\2JTBH2BL< G' )P<#\*XJR\5ZQ_H-W=6MN\,^G6
M4\\<<Q C::5DW)E,L<%3M) &,9/4@!'X&F)O%N&@E\^X#F5GSYT?VE9BKH$&
M3A2H)9NIZ FGCP*8$D%I]D@,BW:N43;N$ERDL0.!T1%*X[9XXK1T_P 1S2WM
MK;36Y$-Q/<1+<ROU=)95"#:F,XC!^8KP>"Q!IUQXADT]/$5Q.AFCT^>-(8U&
M"=T49P2 3]YSS@X'8T 95WX.OIVNO+-HD#WPNUMRP;S<^;NWN8CP3(K!2'VE
M>#@C;HZ1X;GTS6;>YC6!(([-+>3,GFR.550 "4!4#!Y#8/=0>:AN?&4UG;6\
MEQIGERO(5DB9I0P3>J!U_==/G'W]G/'/6G7/C&:VFDMFTW%X;S[-% 6D)*D2
M,LC;8S\K+$V-N[G@D8. "E=^"KNZ;45W6:&XCO%%T"WFS>>2523CA4R .3]U
M< 8Q6WK.@K<V>GP65I9-!9S^9]BF&R"1=CKM.%.,%PP^4\K^(T(-1WZ.E_/!
M) _V<3RV[<O'\N2I'KU%<]'XOO9## NE6YNK@6SPJ+PF/9,)"I9MG!'E-D '
MJ,$T 54\"R)$T+"RF$MC:6TLSJ0V892S+C!RC*0.3QL4<]DN_ TTDL*QM;FT
MCDN-MNK^4(EDD#AD.QL,,'IMZ\,*U]<UR32M19R"UO:Z;/=R1 @>:P9 HR>@
M'S?F#VJC::UJC:L5NVB3;K7V)H(7\Q!&;-9,!MJDD/\ -R.Y% %Z/0?L&@ZW
M'%#$UW?-=2EXU^:3>SL@)[D!@*R=+\%R'[#)?6NGQ0QW$4\EE&I:-MEO)'N(
M( WEG4GCC8.215O4]6U)M?@T^SD*1MJ<<$K%U!V?9FE(7Y#U*\Y],9&>(]9U
MW4['Q<L$32BPC^Q"3Y(S&/.EDC.[/[S)PH7;D ]>* *\'@:8)=1W+02^=<QN
M\C/GSXUN5F8.@0<[01RS=3T!-2)X&-NI%I]D@W&XW^6FW<&NDEB!P.=B*5'I
MG XJ9?&LLB7Q@TY9A;+#*)(WE*-%(T@W_P"JW$#RR?D5@<C!ZXO:=XG?4M;D
MLX+!VM$<QFZ4L0&"!\_<"[3G PQ/3C!X ,>Y\&WTWGB,VBP&^^UBV+!A+D2A
MM[F(]Y P#*^"O!Y&W3TCPY/I>MQW,:PI;K9I;OF3S9'9511R4!4#:>C8;@[0
M>:RY?%.H6/B34OM)F;3K4W!V&./8RQ0))MC(^;S,L3AN",XZ5>'BS4F@BVZ(
MHN)9'5!+.\<;*L7F;@6B#>J_=ZCKB@"K)X+N9Y[TL]I$TBW92[CR9I6ED#Q^
M9QTC(&.3G:,;>E16_@6\,=RM]=V\XF>*4(0Q57:6.6Y'/\+-&"![FMW0=;N]
M8OKS?!#'9)'!) 0Y,F)(P^&&,=^QJ#1O$<UW/IUO/;E([NW$D=Q*_,C_ #$H
M-J!<@+GDJ<<@'!H R[CP-,\UN$:!K6*2XVP!_+$*R3>8K(=C8('&!M[885?T
M?PQ<:=XG?4I$LMNR[4S1Y\Z?SIDD7?Q_ %*]3VQCI4=]XLNK"6^2&R%U]G^U
M2MYMP(]L<*Q$A<(<D^9P#Z<GTLS^*+E(;^X@T^&2"VG6VCW7)6220M&O*["%
M7]YUR>@XYH RI?!<_G:A,ZVL8<7DB3VP)GD:6021[A@<H5!')Y Z8YTH]$U"
M7P;#;/Y(U22>*^N [$(9O.69UR 2!D%0<'  H_X2V=-1N[:;3@D5EE;JY\Q_
M+B<0"8DMY>-G(7.=W(.W%,M_&,TH4R::(D6]^R7$K/($B)6-E/,8;GS /F51
MD<GD$@#)/#-]=>)!JUVMNQ8*VU+@@PE49=JGR]S*<YZK]X\&H++PC?6O]E;5
ML4-E.Q0@A_+A)0E,>4 [$)P_R,..6YW3P>-+BYMVGCTAQ')+'%;/([HCL\OE
M@.Q3"]0?EW^G7KJ^&-0N-1T?SKQT-P;JZ0A&# *D\B  X&0  ,XYQ0!SMKX%
MG%JEO=+8>6JVL<P0$B\$4H=I)05'S, 1CYOO').:U/%7AR\UI;.*R:TBBA5A
M^\10R-E"I0[&( VG@%>QSQBJT'CM)]6CTT:>PN'D\G'F\>:LVR5.G\"8D]P>
MU5=/\:7T&BV[:A9":ZD@MGB>.0MYOFN4RP5,J<C.%#=<4 37/@B21;MX'M8Y
M[E;X2R;2#*)IED17(&2 %VGZ\5;M_#-PGAK7=."65J^I/(T<=OGRHMT:ICH.
MZD]!UZ51U'Q/K1LM2:.RCL_)TIKI=[GS4E#.HP&3!4[ 1D X/(["Q<^,KNVE
M:S_L?S=02296AAE>12(TC?Y6$9))$R=5 ZY/'(!!=^#+RZGOBLMI"TWVHK=K
MN,TPFSMCDX'R+D#ACD*O I]WX6O[NZTR2*WTJQAMIHI3%;*/W9682-M;RP3N
M48X*<DYW9K>TS5+C4;G4%:T2&"UE\E',N7=@H8Y7;A1\P[GH:YK2/&\\6BV,
M^LP1!?L=G<7%VD^X!)E<!V&T8.] "HX ?(/&* (Y_ <[VL-LD=DL$4MWF&-_
M+#K,ZLLF?+;:Z@;>!G!X8=*T['PO<6OBD:FZV919;B3[0,^?*),85N.B8P.3
MP!TJSJOB:;2_#UKJ4EBHN9HO-:T>1]RX0NR@I&Q)&,$D >]4)_'$J3ZF8-*,
MMMI]K+<22&5E/R1)(%^YM^;?C[Q/RGCB@"&_\$7MUK<]S'?1)923\0'=_P >
M\OS7*>F7=5(/UI]UX,GF,S*+)Y9K?4H/-<$-']HE:1"#M.<;B"./O'&>AO\
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M+[,(!*)7B4L@<_9'@;D#@EF!SUP/6MOQ#J5UIVCFZL$@EF$\,6)7(7#2JAY
M//)^GZ5A-XLO-+N=4?4+59;.&:<1O%+EU\NW$I0+M&1@/@YSGM0!7'@F^?\
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M@DDE*S*%W825Y(Y+C&?X2T2E?3)J;_A!XY$,$UKIS6ZW=Y.!LSYGG;RI9=N
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M1PA;)) P%/./6H=%\2WNL:K;1BS@BM)+:5Y,R-YBR1S&,X!49&1WP>>0,8H
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MM9,",LQ9D+,%<Y4##;21M+#J,Y!%:M !1110 4444 %5(=+T^WB$4-A:QQ@
M;$A4# 8L. .S$GZG-2W<+W%G/#%*89)(V19%ZH2, CZ5P@\"ZC_88LXY+:WN
M/,$C2+,2K8B*$ )&F ^=K'D[><DX( .W&F:>MTET+&V%Q'NV2B)=Z[B2<'&1
MDLQ/U/K3)-(TR:ZDNI=.M)+B1#&\K0*792,%2<9(QQBN4F\&ZC+=ZM,)XEDN
MHY5AE6;! < "-@(PQ48P/G.  0 >!-=>&]3=46RM-,LHI8DBE@BF8)#MF\S*
M8C&[()SPN#ZT ;\.DZ'/#$(=/T]XK=W6,) A$3AL,!QP=PYQW%-N+#0X2EI/
MI]D!J$^/+-LI$T@5GRW&"<*QR?2N8N_!%U);FW@AL5A^W7,[1HP03+*6*LV8
MG 9-VT<'CD$=*MQ>%KZ#Q)#J(CLI?)N&G6YEF8SLIMC$(C\G0,<YS[XSG(!L
MW,^C^&RUQ,/LXN2D>4B=A\H"(@V@[1R !QR3CDT_2HM%=)ETVSMHA#,ID5+8
M1[9#&K XP/FVNO/OCUIVK6%QJ>EP09BCG6YM9W&XE1Y<R2, <9/"D#@=NE8M
MYX2GGU>[U&"6&WN;B[>07*9\U8C9^2%SCM( ^,XX!ZT ='/IUM<W<=S+&&DC
MBDAP>0R/MW*1W!VK^50QZ)IL#VQM[2&W6VD:6..% B!RA3=@#KM)'XU@:?X>
MNM)\):O:F-?M,]NX6."0.K-Y6W("QI@DCT)/&35?3?!TSM9R7MK8PVR7<=S)
M91LSH=MO)'N(*C+EW4D$?P@Y)H [(VMN9O-,$1E#[]^P9W;=N<^NTD9]#BJT
MEEIMQJHGELK>2_A12L[P NJDMC#D>N[@'C/O7*Q^#M0'GN&LX;A8I#'<1NQ:
MZG\Y98I)OE&-I3&,MP[ <=73^#[Y["6/?;SS2V\&_?*54W"R322.04<%2THP
MI!_# - '1)HVAS+<PC2;(J9!YRM:* [@;@3D8;[W7GJ?>K:Z=8I>F]6RMUNR
MNTSB)1)C&,;L9QBN3O?">HW$TTLB:=>K+([?9IV9(@6@AC$@&UL,K1/@>C]0
M:DB\'7$5X+MY89[D7 +3L[)))#]B$!0L 2,R#?@<=^HQ0!U1L[5FW&VA+;S)
MDH,[RNTM]=I(SZ<51$.BZ7<6MA#8V\,DY=XHH+7C@ ,QVC"C!4$G'4"LN'P[
M?IX-;2#]D642JRQKQ&\:R!C&[*BYW*"K$)T8\'NW2/"C6>KV>H3P6*>0+K9#
M$-PM_-:,JL9*C@!'SP.7.!B@#9\S2+.[5D2VCN"Z66Z.,;@=N]8R0,@;3D \
M<CUJ2&RTV/4-\-C;I=0Q*!*L 4JA)P V.G!X!X_$5S\_A!;C5KV62TT]K6YU
M**]<D?-(JPA&1EVX/S MU(.X].]2;P;J!TUK<-:S.MK;0Q*\I"*T33G)#1L&
M7$B#!'8]" : .Q:QLW+EK6!BX97)C!W!L;@?7.!GUP/2F'2M.-T]T;"U-Q(%
M#R^2N]@"" 3C)P5&/H/2N;\5:+>ZM<Z=!'96ET!9W,<C3EDBC=A&%88#<@@D
M#V/(JG>^#M7NKS4)/M-IB>PFM%F!V/)OC15+X3=PRDDEV[8 H ["32]/ENVN
MY+&U>Y9"AF:%2Y7&,9QG&#C%1IH>D1K$(]+L5$+^9$%MT&Q^/F''!X'(]!Z5
MS>I^%[U-:M[W38+*&TLXSY4<"JDN/*D4H,)DY9P?OJ/;/-9GA;PN\T%J+S38
MXTM[Q+B?SHRJSD6YC&$,:<JVT\@@G)!)Z '<'1=*87(.F69%R<W&8%_>\Y^;
MCYN>>:BM;;2K75FAM88XKJ.V7]W&FU4B9V/ ' RP.<<G SVKCI_"NL0B\EDM
MK&Y^UW-H3;Q';&^R9V=G"QC *L <[SP<DU<A\$7 6.23[&+B)8OL^TL1;$73
MS%4.WA0C! >.!C % '8"PLUG$ZVD F$AE$@C&[>5VELXZE>,^G%-?3+"2 P/
M8VS0L@C,;1*5* Y"XQT![5A:_H.H:IKNGW=NUHL%M) ^]L"5=LNYP#L)(91C
M 9>^<@\95WX%N'TZQMX?LY*"?[4BN$\QY"NV4.T;G>H4@' (#<$8P0#K#IVE
M++!;G3[;<L+K$/LXPL>1N4'& #D<=_P-+=V&DW4BV]Y:64SRN95CFC5B[  %
M@".2!@9],5F^(M N=8=?)FC5/L,]L=[$$L[PL#P.F(V_,50'@]X=2AGMX;%8
MH;BX:$ ;3;I(JX*#:0&#*3C@?-UH ZU(HHM_EQHF]MS;0!N/J?4\5CWVD:%;
M:8]G):6]K:W<T2.EO"$$K%AM!VCN<#Z'M6#I?@>6&VLH+]+:6.*Y26YC,@>.
M8+#(F=HB0;BSJ3NR2!R3@4D'@W48Y]+:?[#</:I9 W,DC&2/R?OJGR\ANN21
MR>1T- '97EA9:A&L=[:07**VY5FC#@'ID CKR:P;;1/#TMT=;#*\=P[(!*%"
M%G_=%>0&(.-H4DCT'2L>R\$ZA:Z=Y4WV6[E$D!F2:;]U>A-^3(%B&&)8-D[R
M2 ">,UI/X5E?P79Z1);V$\]K<13B*0DPG;,'*Y*DC*Y7..] '1R:?937D=Y+
M9V\EU$,1S-$I=![-C(ZFF6^E:=:,6MK"UA)?S"8X57+\C=P.O)Y]S6%IGAR[
MM/$1OY%M542W#M<QN3-<+(V4C<;1A4& /F/W5P!S4+^&]3CO[ZZM4L@'O(KJ
M-'E.Z0J[%MT@CW $'@'?@\ @4 =(^EZ?+ T$EC:O"R+&8VA4J54Y5<8Q@$D@
M=LTY-/LHT"1V=NJJ$4*L2@ (=R#I_"22/0G(KA5\*:K)J4<4L%HS1P0-]L+M
M^X<7,LC>5\O+;2!SMZCM5F'P1=E+N.YDAE\^XC=Y#*,3QBY65MZB,'=M!499
MNI' - '9)86<<,\*6D"Q7#,\R",!9"WWBP[D]\]:KM%I>BVB2K;6]K!"=B>5
M" $WL!@!1QEL9KFM0\(7TTVI"Q%G;6UR865-P)?RW0["3%\B%4*[3O'(P ,@
MP3^"KUUM46*RD6-8@IN)BS6A6X:5C%B,#Y@P7 " !%'(H [-]/LI+Y+Y[.W:
M[C&U)VB4R*.> V,@<G\ZR=/TSPW96D.C6UM9R1SH8ROE*_G>20K;R!AF4\'/
M.<U7\.^'+K2=7O+RZD64RF7$JR#,@:3>-ZB,'(' )=L<@8!K,;P)YEK);/::
M:L2OJ#Q;0<%IVW1L1M&"HX[XVC!] #L!IM@L#P+96PA>,0M&(EVL@SA2,8V_
M,W'3D^M,71],2.*-=.M%2$L8E$"@(6&&VC'&>^.M8.G>&;VV\4OJEU,LP+;E
MD$H#@>4J%"/+RRY!.-^,X.,BLV?POJ.HZQJ\Z06UL'GG\NZ=V$LJ/:B,1XV_
MZO>V[.3RG3/- '9#2].%T+H6%J+@)Y8E\E=^S&-N<9QCM3]EK9E2L*QF3;$/
M+C[#.T' X YZ\"N5NO!\OVVW^QPV*6\<=LL<A)5[1HY6>1HP%.3)NP3E<XYW
M=*=:>$[ZWGWO<PND%TGV50S#9:H795/'#9DV\<81>: .A@L-+L72VM["V@\Q
MC,%BMPJ[EQ\QP, \CKS4TVG6-Q=1W<UG;RW$>!',\2LZ8.1@D9'/-<=#X-U1
M-,-HDMI;JD%Q#$B.2<.(MH=U1=W^K<%L X8?>.27-X(ENHYEGM]/B@D-P\=E
M&2T4!>*-%V_*/XD9SP,%N,GF@#LXK6W@(,,$495!&-B 84=%X[<GBLV_T[0+
M&PN[F[TVQ%N3YMQ_HJMO(S@D $L<DXZG)]ZJ:1HM[8:_<WLOV?RIX%61]^^1
MY $&02@*KA3E=S G!&WG.*_@>[N(KF*XCT_#Q/&\F2QO&:9)%DE!7AE"D#EO
MOGD"@#K?[*TJ[+7+Z9:L]Q$$D:6V4.Z<85LC..!P?2G'1],-M]F.G6A@V[?*
M\A=N-V[&,8QNY^O-8GBSP]?:S%:0Z?\ 8XXX4;!D 5HVRFPH=C8 "G[NT].>
M*J3^#F+7=QNB22=;TR2P@F0^9('A(XY*;<X['IU- '3_ -D:;M1?[/M,1HT:
M#R5^5&^\HXX![CO0=*TXSW$YL+7SKE"D\GDKNE4\$,<?,/8USXT/4K_P*+69
MTAU2[=+NY!/R[S(LCQ$D-\N 8^0>.H/2J3>$-2W:0L/V2.*SFCF)9U:2/%QY
MCJK"$?*5^4*OE@=#D4 =5=W.GV;O#.BAKE'E=%A+&4(JAB0 <G;M'J1@4JZ+
MI2VOV5=,LA;[=ODB!=F,[L8QC&>?K7,2^"IQI#6UNUK'<26M['+("1ODFQL8
MG&3@  ^@  IEQX,OI[G6G:>-FO8YTBF\[:<2$$*X$>["@8!WG&!@#/ !U1T;
M2BUNQTVS)M_]03 O[KG/R\?+SSQ2'1-):"2 Z79&&1_,>,VZ;6?^\1C!/O67
MXE\/RZCH<&F:9!8QP(Q!BD10JKL8#9E' ()'\/3."*Y-_#FJ76MZA!-:%YY;
M62VAO'#!8RUHL>\OY?*EU(P'R"Q.WK0!Z5]F@Q$/)CQ%_JQM'R<8X]."1]*@
M_LG31/'/_9]IYT4?E1R>2NY$QC:#C(&"1CWKG9?"#IXCM;NV6%+&!(1'&CK&
MT!1F9MO[MB0V[G#+GD'.:I:7X&N8+.*WOF@GQ+;M<%I RW(CW[F9!&OS-NR=
MQ8GH6..0#L)=,T^=[=Y;&VD:VQY#/$I,6,8V\?+T'3TIXL+, @6D !QG]V.<
M,6'Y,2?J<UQ0\"7<&F&VM9+6,M#;K*BG"SM'*S$,2C @J0N2IZ8QBK*>"Y0T
M,O[@2P):B O(7:$QW#RR;2$4 %&"C ' Q@"@#HH[?2(M%GB/V9]-4RF<RD/'
MG<QE+D\?>W%L]\YJTMC:+C;:P#!+#$8X)7:3_P!\\?3BN=B\*E?".MZ']GL8
MOMKW9B:,?*1*S,C.-HP5W <9^Z,'L(1X7O&UB"Z%MI\"K)!(LD4A+VJ1@!H8
MQL *-@\Y7[[<<"@#:,>A:1$T:6]E;K&R;HXH5&TRGRU)51QN/&?;VJY;Z=:6
MOVCRH$47+ RC'#84(!CT"J!CI7/:OX4;4=8O[E+>Q,=[#:(\KY$G[J;>RG"\
MAEP.O50,=Q0N?!-V\MLD;P?8X9+@I D@C\E7F#HR$QOM8#CY=I'8T =2OA_1
M4ACA72+!8HW,B(+9 JL<?,!C@\#GVISZ'I$BRJ^EV+B63S9 UNAWOS\QXY/)
MY/J:HZCI$]SXBL]0%O:74$483;<.0UNV\-YD8VD%B..WW1SUK!LO!%XMM'!=
M)8J@%HDXC=F%X8I-SRR J/F8<8.[.3EB* .L-AI+:A,S6ED;V>$B4F-?,DCZ
M$-QDKP!SQ4]W8V=_ (+RU@N(@0PCFC#J".^#7&S>"+G[/<1PQV'F2:?=V4<I
M)5H [N8@I"DX"L%(!&,<9JY<^%;G_A);"[L8["VL+3&P1J$<+LD5EX0D@EP?
MO@=>">: .F:QLW#![6!@Q+',8.25VD_BO'TXJ*/2-,A@,,6G6D<1# HL"A2&
M ##&.X !]<"N4B\)S6$OAVRMD1(1 D>J-$IVRF(K(K9[DR CGDAV]*[2 S&%
M3<)&DO.Y8V+*.>.2!V]J *=[HFGZE?VUY>VL5Q);(Z1+*@=5W%"3@CKE%P?K
M3WTBP:2YF2T@BN+E&CEN(XU61@1@_-C)Z#KZ"KM% %-=+L5TJ+2VM(9+&.-8
ME@D0,FU<;1@\'&!^5206%G:I&EO:00K&A1!'&%"J3D@8Z D XJQ10!3M])TV
MTB$5MI]I#&'+A(X54!B-I. .N"1GT.*3^QM+\WS?[-L_,\OR=_D+G9C&W./N
MXXQTQ5VB@"O]@L_MBWGV2#[4J;%G\L;POH&QG'M2)IUC'>O>QV=NEW(,/.L2
MAV''5L9/0?E5FB@"I<:7I]Y$8KFQMIXV?S"DL*L"_3=@CK[TJZ;8+>"\6RMA
M=!=@G$2[PN,8W8SC%6J* *[6-FY<M:P,7#*^8P=P;&X'US@9]<"FW6FV-_Y?
MVRRM[CR\[/.B5]N>N,CBK5% %&31M+E:X:33;-VN<>>6@4F7'3=Q\V,#K3DT
MG3H[F.Y33[59XHQ''*L*AD0# 4'&0,=JN44 4YM(TVX6!9M/M)1;KMA#PJWE
M#@87(X' Z>E"Z3IJ323+I]HLLK;I'$*AG.0V2<<G(!^H%7** *DFEZ?-)%)+
M86KO#(98V:%24<G)8''!)YS3K73[*RDEDM+.W@>8[I6BB52YYY8@<GD]?6K-
M% %9-.L8WWI96ZM\XW")0?G.7[?Q$ GU/6D&FV F\X65L)<*N_REW84Y49QT
M!Z>E6J* *\EC9S6CVDMI!);.26A:,%&).3E>AYY^M'V&T((^RP8.[CRQ_%][
M\^_K5BB@"K#IMA;6;V<%E;16K@AH$B548'@Y4#!S0VFV+7IO6LK8W1789S$N
M_;C&-V,XQ5JB@"I#I6G6UG)9P6%K%:R9WPI"JHV1@Y4#!XIHT?2U:W8:;9@V
MP(@(@7]T#U"\?+^%7:* *DNEZ=/ 8)K"UDB*JAC>%2I5?NC!'09./2D_LC31
M/#/_ &=:>="BI%)Y*[HU'0*<< =@*N44 4X-(TVV9V@TZTB,CB1S'"J[F!R&
M.!R023GUI]KI]E8O*]I9V]NTQW2M%$J%SSR<#D\GKZU9HH IP:5IUJKK;V%K
M"KR"5A'"JAG!R&.!R0><U)<6%G=NKW-I!,ZHR*TD88A6&& R.A'!'>K%% %2
MYTO3[U&2ZL+6=6<2,)858%P-H8Y'7  SZ#%+>:9I^H)&E[8VURD9RBS1*X4^
MV1Q5JB@"O+86<\,T,UI!)%.094>,%9"  -P(YX4#GT'I35TVP2-(ULK8)&%"
M*(E 4*=R@#'&#R/0U:HH IPZ5IUL[O!86L3.XD=DA52SC.&.!R>3S[FI+>QL
M[22:2VM((9)VW2M'&%,AYY8CJ>3U]:L44 5TL+.-56.T@0+MVA8P,;1A<?0<
M#TI'T^REO4O9+.W>[C&U)VB4NHYX#8R.I_.K-% %8Z?9&$PFSM_*,0A*>4-I
MC'1,8^[R>.E1+HVEJ+8+IMF!:L6MP(%_=$G)*\?*<\\5>HH J_V98?9);7[#
M;?9I6+20^4NQV)R21C!)/-$6F6$#0-%8VT;6X80E(E!C#?>V\<9[XZU:HH K
MBPLUNFN5M(!<.P=I1&-Y8*5!)QG(4D9]"148TK3A/!.-/M1-;H$AD\E=T:CH
M%..!ST%7** *\EA9RW/VF2T@>?"KYK1@MA6W*,XS@, 1Z'FC[!9[=OV2#&,8
M\L=,[L?GS]:L44 5H=/LK:ZENH+.WBN)O];*D2J[_P"\0,G\:1=,L$,I6QME
M,I<R$1*-Y?&XGCG.!GUP*M44 55TVQ2]^VK96RW6W;YXB4/C&,;L9QBHWT72
MI9YYY-,LWFN%V32- I:1>.&.,D<#@^@J]10!1&BZ4K0,NF68:W_U)$"_NN<_
M+QQSSQWIIT+2#;&V.E6)MS)YAB^SIM+XQNQC&<=ZT** (I+:"41"2"-Q$P>,
M,@.QAT(]"/6J[Z-I;I CZ;9LMOGR5,"D19Y.WCCH.E7:* *]M8V=FTK6MK!
MTS;Y#%&%+MZG'4^YJQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !12,P52S'  R35+3-8T_6(FDL+E9E4*6&"I
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MQ!S<+*6E*;\892-Q"D]!TK7D\.Z)-;"VDT;3W@#*PB:U0J"JA5.,8R%  ]
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MI*7CO)9V0N;U3&[-$F^<8Y4G&6&!T]!4]W8V=^BI>6D%RB-O59HPX5O49[T
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M\P8.!\V,@CU'4U2TWQ+?2:T;6_MHXQ//%#%'','$6ZWDF)W;03GR\8]3QQU
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MM+0Z.\4TTDBL97>-0B!"77>@9AB3 ^4?,I'3F@!^CZ%-9OJ\=S%:_9;V1F5
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M"96BN%MSN&/D!9U.<GC.>G(OB?4)=6CLA8V\>P7*W1\\L5:,1L#&=N&&)!U
MYXXQR +8Z7JMSX)9+E+?^U[\BXN4N%^0,S E""& VH @R" 5&0>E9D?@2YDL
M(HKLVDDD2;8OF)$7^E&7Y2%4#$9"\ >@ %:,/B^3^R+G4#9&2VLX(_.?S/WC
MRM$D@ 0+C&)%&<]<\8%6;KQ!?IX2U#58].$-W:A]L-SO5'Q@[@2JL1@]U'(Q
M[T 8][X*O9+=[:W6P:$K=);AW919>9+O26(!3\RCL-N,#! J:_\ "VL78U"W
M66U6WECO1#(9GWEIP,;EVX4*<\@G\.E:H\22C51:26*");I+*659\E9VB$N
MNT;DPP&[(/\ LXYHN?$#Z>?$$]PADATXQ^6D:_,VZ-3C\S0!1_X1#R-6@N;>
MTT]K>#46N((6^7R8V@1&VX4X;S%+X& <YR#3K/PW?V_@Z_T;-K#)+N$ 1LC9
MM4;9'"*6)(8%MN<$9R02;$/B>X:2R6YTJ2U6>=H7EF\Q44Y4+@F,$EM^!N"
MD$9SC,,?B^>>)$BTQ!?$2O):RW!C,*QJC,')3A_WBX !!!R&(YH S3X1U:&V
MNOL,.F6[7!ND%NDSK%$LT4:@@B/D@Q], <]16CIGAB\L_%$FIW$J2H3E)%E
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M"",@@@@\ '8_V)I@DBE2PMHY88Q%#(D2AHE ( 4XX R<>F:8FDZ1<Z3;Z?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ>8XC3<<;F/0#WH EHHHH **** "BBH4NH)+N6U60&>)5=TQ]T-G:?QVG\J
M)J*BM[B&[MHKFWD66"9!)'(IR&4C((]B*EH **** "BBH9[J"V>!)I K3R>5
M&,'YFP3C\E/Y4 34444 %%%% !113&EC1T1Y%5Y"0BDX+$#/'KP": 'T444
M%%0VMU!>VR7%O()(GSM8#&<''\Q4U !1110 44QY8XVC5Y%5I&VH"<%C@G ]
M3@$_@:!+&9FA$BF55#,@/(!R 2/0X/Y&@!]%,EEC@B:6618XU&6=S@ >I-,A
MNH+B:XBBD#/;N(Y1@_*Q56 _[Y93^- $U%%,>6.-HU>15:1MJ!C@L<$X'J<
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M8O+(Z)+=O(84Q\B;RI+\YR3TSWQRSPUI=[IIU*2[POVJY$R(9S,Z_NU4[I"
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MVA?VE;@[7MO/C#CL5W#-8USXM:RL]++6$]W=7=G]K=+:-FPH";MH .3EQ@'
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MZ;BW%A=7=Q"LRL0D9A.X-CDA78;>Y[XYJUXBU^ZT/48&CMC<6BV%U=7"!@I
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M5;31TM;679FVM1<1K.?WKI(QD W9 RI ]" %/'3:T/0)[+4DNKJ2:18K..*
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MV\2^1<!5C*1;70Y7."W.1UR,XVB@#J!X?TQ2/*M4A'GK.RQ#:&9267/L&.[
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MC-*X\P370.QA$5WH0!C+8))!/?&Z@#LCH6E%HV-A QCC,:$KG"D$$?DS#/\
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M[3$U6XOFWO\ :-XDA94VL&4*58A=S+@<*20/3@8U)=/TYM2CO)8(/MA&U)"
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M']F#*$=/WC,YVN &&22<$ ?E0!EW7C&UM&O!);3#R/*$8) :;S"BJ57KMW2
M;O4'TYELO%$=W=V-NUC<6QN@^&N/D&Y692JY^\?E)P.=I!]<79- TJ5I6DLT
M<R*$;<2< $$;>?EY53QCE0>H%#Z%8.(B(W62%2L4F\LR$Y^8;L@L-S8)!ZF@
M!NO:U'H6GBZDC\TEB!&)%4MA2QQGJ<*>!_+)&--XNO=MW);:6)88[JSAB9I0
MI=9S'R1V(\RMV;0].N+"VL9[826]LH6)68DJ NWKG)RI(/J"<TV30-+E616L
MTVR)&C@$C(0@IT/48&#UX'I0!EW7C*"S2YFEL;C[-"+D)*&4^8\"L9% SD?<
M< GKM/3C,K^*&@OX[6XTNXC/^C^<_F(1$9Y&CC!P>3N7G'3/>KS>'M)>:XE:
MPB9[A'CER#A@XPW'0;@!DCD]ZLRZ=9SRM++;HTC&(LQ')\MBR?DQ)% &!9>.
M+2\C$_V*ZBM&>(+<.N$VR,55B>WS;<CL'!]<2P^(Y=6!M;&W:TNI[+[3:O=$
M -N&5PO<#(SCIG!%6[OPQIESI5]IJP^3;WJ[)50Y&TG)"@Y"]3T ZYJ\NF6:
MWXO1 OVA5V*V3A1C' Z#@ 9'84 8WB#7;C2-8M0RL-.CL;J^NG0*6*P[/E /
M^_VYSCWJO+XYBBMU9M+O3<,[J(0O+*B*Q93W^^J_[V1T&:Z2XL;6Z??<6\<K
M>4\/SKG*/C<N/0[5S]*J'P_I;6\<!MB4C<NA,K[E)&#ALYQCC&<8H ;I^N1Z
MAJ=U9""2%H%5AYWRLZD [@IYV\XSZ@CBLF;QO'#:Q3'2KMFG,QAC0JS.D1 =
M@ 3W( '?(Z5T$.FV=O>R7D4(%Q(NTN23@>@ST!P,XZXJ*;0]-G@AA>U79"6:
M/:2I7=][!!!P>X[T 9D_B^WAU&YLTLYYWAMY)U$)#LVS9E=HY#?..#SUX'&4
M/C"#,;):O-"$@>>:*5&6(2R&-<<_-RISCH/?BM(Z!I9NIKG[&@GE#*[JQ!^;
M&[&#P3M4DC&<"FCP[I"R02"PB#08V'GLQ89_O$,2P)S@DGJ: ,Z+QA$ZS-)8
MRP*J.\+2RHHE"R^4><\?,1C/)SP,\527QL[3K=+8S-IXM?,F *AH2)FB8\GY
MAE>@[ ]\ ]%+H6F31")[.,H 0,9!&7$G!'(.\!LCN :A_P"$8T7,)_LZ']Q_
MJ^#Q\Y?'N-QW8/?GM0!F6GBP(QM[R)VN)+N:*WV  2!;MH,#W0;"Q]#FK>H^
M(&T_5I;,6\EPVRV$<:!5.Z5Y5R6+=/W?IQ[YP+;Z#8OJ%C>"(*UE)-+$J@8\
MR7.]O7G<W_?7TJU+IUG-=?:9+=&G^3YR.?D+%?R+M^9H R+/Q4E\P^SZ?.0E
MLMQ<$L@\D$NH'7YCF)^GMZTQ_%L9-NEO83SS7 @,<895_P!:CN,DG P(SG],
MUIKH6EI<13K9QK+$I56&1QDG!'?EF(ST)..M,L_#VD:>5-K811%&5E(SD%05
M7\E8@>@.* ,NX\9)!&7_ +-N6W7<UI  R_O3$7#MP3@90@9Y)([<TA\4RW>K
M:=;V=E,EM)=K!<2S!5(+6S3[-I.X'!3G'7(K9FT;3[BW6"2V78LS3KM)4K(Q
M8LP(.026;./4TT:%I8U!+\64?VJ,@K)SD$+L!],[?ESUQQ0!F:GXUT_2-1DL
MKN*9&C9RS8& BQ"3?UZ$D(/]JFQ>)+N36H+);+<LETT$FXA3#B".7'4[C\YY
MXZ8QW.M>:'I>H3O->6$$\DB)&S.N251]ZCZ!N:D?2;"2X6=K9/-6?[0'&0?,
MVA-V1_L@#Z"@#)\)>(9];T^W6\M7AN_L-O=.Q*[9!*&^88)QRC<'MC\*A\=1
M+9V5PVE7F;R%KF.),.YA7;\V%)Y.\87OCMTKI+73K.QV_9K=(ML*6Z[1TC3.
MU?H-Q_.H'T/39(K6,VBA;1-D&PE2B\?*"#G:<#(Z' ]* ,V3Q6B37$"V$S3Q
M726JPEU5V+%@KD$C"':2#W'3G(J&'QO;3WEM:QV%VTLFP3!5#>26E>+G&<@-
M&^3T &>:OWWA?2[\EI(2K/.D\C!CEBI) R>@RQ/&,$YZU8CT'2X9+>2*S2-K
M= D9C)7"@D@'!^8 DGG/))[T 9:^*+JX329[72G-MJ-R(XWDE4%HS&[AP >#
M\F<'L?7@-\0^(;[37U6&VM%(M=+:\28L#\_S #:>OW:U$\/:3&FV.R15\T3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M07Q:D(^T0Z9';I>M%)*6*3%3"(B<D%=JEL GYAGOF@#IX[B&:6:*.0,\+!)
M/X6(#8/O@@_B*EK@]5TS6KJSU>TT^%_/>_E?S1*T;?-"OENI#*" 2%)YQMX!
M(XW-'LM2M]>OIK@2-;3(IWS2[COP!A &QLP">5!!)Z@\ %M_$VA10+/-K%C#
M$S!%>:=8PS%5< ;B,G:RGZ$5J*RNH92"I&00>"*X?QGX+N=9;3XM&:.P2*.Y
M$DD:H.7@$: @@Y!PJG'( X(K'M_"GB<:B7=[NUM19+%!%97P @7[+Y?DC<>H
MDRP;!YP2>,4 >HT5XX^A>+Y;ZSTT)<QW$5DK1S1W\B1P,+IB)'&XAW\OJH)'
M.!QTT)?"?C"5KT+<W$4L@E66X&HOBZ+7*/&R+G]ULB#KQCK@9'- 'IEY>6^G
MV<MW=S)#;PJ7DD<X"J.I-+;7EM>+(UM/',(I&B<HP.UU.&4^A![5Y3KO@;Q/
M=V%WI\/G75DPO([2)]3=?)WR*T;.229!L#+M;.,XZ'(NZGX0\4WDFHNEW<*=
MM])9>7?N@$K3(T!(!' 4-P>!0!Z?5*QUC3-3>5-/U&TNWA.)5MYUD*'T;!./
MQK@?!#ZC+X]UB34$U(Y:Z$1D\P1(@N/E#;CC<5V[-H'R@]>M0V?@'5M-\/&=
M&-SJ[C[.8/-$:16YN#(P4H4+,<@_,V.W3@@'I\DB11M)(ZHBC)9C@#\:;<7$
M5I;27$\BQPQ*7=VZ*!U)KRN3P%XBU+PWJ%KJL\TUW_9$5M:J=0DV&</*6W '
M!RIB&6S_ #K5TO2-2?QU)8W'VD:#%9K>-;33/*%FDC$/DLQ)#J CMC)Y;- '
M=6VH6EY(4MYTD8('(4_PEF7/YJP_"I);B&&2&.215>=RD0)^^P4M@?@K'\*R
M5M/+\70-;P>5;P:?*LA5<*6DE0J!ZD>7(?;=[UB1^&]0O+R".]2<V46I/<;I
M+IA,5,,RGE&Z;G0#&TXX(XY .TED2&)Y9&"HBEF8] !U-16UY;W@D-O,DOEL
M%?:<[25# ?\ ?+*?Q%</_8GB>:2P6XR3'9"&YE^T$B4FU9&#9;!/G$'A<8 .
M<Y%;%GH5_%HFMVOF?9[FZ*M;RH_*L+:&,'CT>,_@/>@#I)IHK>,R32)&@(!9
MS@9)P/U(%,-U;B:.'SD\R3=L7/+;?O?EWKBK31/%+FXDO+EE+LL\4:W)(1I)
M(WDC^B"-@I[B0BF_\(A=M$\*Q31>7-J,B2)>,I8S.6B((;(P",@XY7//6@#N
MHYHI6D6.1':)MD@4Y*-@'!]#@@_B*;/=6]J(S<3Q0B1UC0R.%W.QP%&>I)Z"
MN0NO#^M7LESY]Q/L;S63R[MD^8V\*K]TCI(LA] >>]:6OV=[=:-8)'8_:[R*
MYM9G8,@*^7+'(^"Q'4(1QWQ0!LKJ-B]^]@EY;M>(NYK<2J9%'')7.0.1^8J5
M[B&.>*!Y%667)1">6QUQ]*YBST?4$UV%I;=4@@O[B]^T^8"9!(C*(\=<C?SG
MC"+@G/%"YT/7#J]S>1VYEG47?ES27C!)!(!Y2J@8%=H&TD;>1D'DD '=45Y_
M'I>OVPTZV::X07=W+!,GFL?*MB1+NR"VT@(R#GCS>"<"MO3++5[6QUF,QLTD
MA=K0W,YWNQ!X9E8X7) !&TX[ C) -ZYO;:T>!+B98VGD$<2GJ[8S@?@#4RLK
MJ&5@RL,@@Y!%<-IWAC49KBVDU)9!'#=3/&K7#9CC>!5QP[?QACC<<9J/3?#F
MM6QT.)OM<%O:6MM$R0W /ERQN3*S9?E7&T<!CCC"T =]17-V^BW\'@^:T2>4
M:JZF42/<,V9@=R_,2<+D*"!QCBL>W\/>)9H9XK^\E*M+ Z>7=,&Q)/'+<KD$
M$!=K*O\ LG Q0!VZ7,$CNB31LZ,490P)#  D'WP1^8J165T#HP96&00<@BN1
M;P[='7H+J6.6:VCN)5C N6!CB>*-0?O#@,C9'7G-9VG>&]:M8]"@)NX+>TM;
M>%DAN0?+EC<F1SE^4<;1T)P",#- 'H%%<UX?T?4-.OA-<S3.LL#B<27#2 R>
M:2I )./E..,=AVK+_P"$>UR"U_=S7$C2(ANHS>MF7;.&*J2?E)CW+Q@= 2.H
M .UFN(;>-Y)YHXT1#([.P 51U8^P]:DSD9%<#+X:U@QM.B3?:7L+^WMR;PEK
M8R-NA#'=S@<9&<''4 &K=]I&MRKJBQ"?[1+.KI<B[(62#S$/E*FX;6V!ES@#
MW^8D '67=Y;V%LUS=2K%"I +-ZD@ ?4D@ =R:F!# $=#R*YB?0+B\\)V>GS&
MXDECO8)V$\V'5%N%<@LK'HF0.3T'.>:JS:#J4<2R.EU=B2^NI;B!+YD9D9Y/
M(P2P "J5^4$>N"5% '94A95*AF +' R>IZ_TKBK;POJTD]HVI7EQ,RS1+</'
M>2(LD2VFU_E!'68 GC)JY+HM_/H_A<7:27-YITD3W6)R&8^2R,=V1N.Y@3SR
M ?7! .EM[B&ZA6:"19(VSAE.0<'!_45+7 _\(OK=IIK16,TL;2(#.@NF.\BX
M#D+EL*3&67C Y )'4:\FF:D/"MK:H;N61)Q)-$\X662+S"QC#AL# ( ^;D#!
M/)- '0W%U;VD,LUQ,D<<2&1V8XVJ.I/M4U>?3^%-4FM+H21223W.F7-K&S79
M/D[I':-&)/S81E7=SROXU/J?AS6O,DAM+B\_L\3RF..*Z)E4-'%M<,[C[KB8
MX).-P(!H [HD 9/ JK8ZG8:I$TNGWMM=QJ<%[>59 #UQD$U0TO2[BV?5)KF2
M62:YF;RR\Q8"/: H"YPO.>@'6N<7PIJ=CX9LX8'EN=1D@MX+HM*$,:1Q.%";
M"@(#MU))P2>2%% '=LRH,LP49 R3CD\"EKAIO#&I7>EW+WWG7-X9K)T3[6P#
M+$(&D &X*&+))SQDD<UI:);:@OB;4Q/+,;"T)%J'=CN,VV1PV>NPC"GG 8CM
M0!OB_M&BED%Q'LB+AVSTV'#_ )'@^E31NLL:R(P9& 92.X-<)%H%Y<);R?99
M&EABU.TD)D*8>67<DA!(!5L$]_O#\%G\-:S;VL=O:RW+6:RQ/)"MT6=@(2C8
M+./X]K8W <9Z]0#L[O4+2Q\O[5<)%YK;4W'[Q]*CM-9TO4+J:ULM2L[FX@)$
ML4,ZN\9!P=P!R.>.:;!IT;Z=90WR?:I8(T'F3@,Q< 98GIG(SQ7F@\!>)[1;
MR:TN%^TW$-\D)\X(;7S+OS0$90"1(G!))*MT(% 'K5%>.:_X>\5V/AYIT.I3
M)%:S^7$E^RR6TC2*0V$8^8-NY0N6QG'0\:^H^'_&US/J$-I.8(P;]K>X^VG]
MX)G1HUVCE=JAE![9XH ],JNE_9RW2VT=U"\[Q><L:N"Q3.-P'IGC->>VGA?Q
M%'/HY+7K11W$AN(;B]^2.%RN<;'W;@ =O+#D@X%4=/\ !/B6TT*RTZ(S6JPV
MT4$OEZ@WS,MW&[NI!RN8E?&,=<=Z /6*I2ZQID&HQZ=-J-I'?2@&.V>=1(X/
M0A2<GH?RKR:^L-=TSQ+IFG7)U66PBN6>)8)99&,37C%%#;@#B/8&W$D)Z=:[
M'4/!DVK^.;C4[N=X].$5D\<<>W,LL$DC@,2"R@%E/&,Y(H [6FI(D@)1U8 E
M3M.<$=17EFF^$?%D\C1ZF\L%K-=VLL\4&HR8VJLPFVMO+8.Z/OD@=B*@U#PQ
MKVBVDL>E-<V\]YK-Q KI=/(KVUUN_>8R=K1_*V3W4\\\@'IXUC3FE>(7<1='
M6-QG[K,[(H/U96'U%7:Y[7-+AAT;R;&V GEN+9 Z+EN)U;<QZG:2SDGW/>H=
M<TK5;SQ':7$$]R+)4C %O*%,3B3<S,"PR&7 Z,< C'- '3T5P+Z#XD\F</-/
M)$]XLRQ+<Y86W[S$ RR@E696))&1\N3M&;#:%K1M[RW+W<L\NG>1:7DEZ5\A
M_)*D.JGEMYW;@#USG*B@#M2RJ5!8 L< $]3UI:XXZ3JM]J]KJ=Y9RJL6JB=(
M/M0)BA-J(\\';Q(-Q4$\$]<D%WAJSUC14 U(7MU<SF&"0F0-&7&XO,/F) (]
M=N<*,=* .OJ)KB%+B.W:11-*&9$)Y8+C)'TR/SKF=7T[7;GQ3;7%D?)M8_\
MEL)3@@QR AEW8/S%#@+VSG( K-;P_K4EMI<D,$T$MHK_ &I);XNUSGRMP5\D
MJ&V-SQ[@;C0!WM%<5/X?UP?:I;:YF6>=;T/F\?!#3JT*KSA#Y88 @#;NJ&Y\
M.^(+BU9+*YN+&*XN7C\I[LL]M;.L>X@Y.7WQL1@G E.#0!VQN(1<K;&11.R&
M14SR5! )_,C\Z6XN(;6!YYY%CB099V. *XB;0?$MS9I=/((]1D@E\\)/]W=<
M1/Y2'C'[I&7(P,\\9S45]X;UFXL(K?9=W"&)A&DUYL-NYFW_ #A6(8;,*!EL
M8QT)- 'H%%>8V]OK6H7NLQQ27JW+RN4^9U40K=@E&+-@.T?RK@*-H//>NH?3
M]2B\'I9PK//<^9EDGE_>",R9*@JX!(4X +XP "3W .FJ/[1#]I^S>8OG;/,V
M9YVYQGZ9KC+/P]KH2SFN;B<W-O%8HN+MMN4G<SY&<,3$0,G)/2K/AK1=2LM:
M>[OXI-WV4PRS/=&3SI/,W;U4D[5(QQQZ8X% '5?:(1<BV\Q?.*>8$SSMSC/T
MR:CEOK2"?R9;B..3"G:S 'YFVK^;<#WKA#X;\0'[1*@ECNC"L<LYO"QN"+A7
M?8,_(&C! 'R]<<  U?@T#5H_(D22?<!;@M-,/,"K>>:Z$@G@1Y4#)XXR: .T
MHKA)- \1FS*R74TB07*0K%'<$M/:(LFUB2RCS"SH6R1GRQSVK;T+1[NSO7N+
MV>YF(MH(8C-<%CPOSDJ#MW$XR>^.M &^K*XRK!ADC(.>0<&@LH95+ %N@)ZU
MPA\.:G;6C6\-K</"+F^<QQ7QC+M+)NAEW;L@*"01UR<@$@&MN]TBZFN_#ES,
M&NIK%\7#I)LR3'M+XR 1N ./3M0!N6]Q#=VT5S;R+)#,@DC=3D,I&01]13+R
M^M-.@\^]NH+:'(7S)Y BY/09/%<-;^%M<T_0[>SMI9@B6EBL\*W18O(GF"8)
MN8 9!BXR 0N.E;=UHE_<Z!I%FEU<I/;W$<DD[NC2HHSSDAE)&0.<_CUH Z.*
M6.>%)H9$DB=0R.C JP/0@CJ*?7"6/AW6[:[TE)'FCMK6&&/_ $68;5=)6,CL
M"PXD7;V8XR..M5[/3O$$%Q) 8[LW,4-I+*S7A9;ITN=TK)DX7>BD8..N" *
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M5HX1%T(X#*YYZ=>])J7AO5Y+/5;*UDD:VF%RL"2W+/D26JH 2Q)_UN\\^N:
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MG^TK;NLK1A8RRAE)??MY#8 SDD$8K3FT33;CS?.LXY!*SLX;D,738V1[KQ4
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MT:ZT6VTB:PC:QM0GV>+)!BV#"E6!W @<9!S4<7A/1(+A9XK+RY!&(CME<!U
M(&X9PYP3RV30!S%Q\1[IX'F@T.ZMK9]$FU6*YG,3E5094F-9 2#D<9!^8=.2
M(HO'NH1ZY>?VA&+?3(+_ .RJ?LX8LJVC7#MD2Y!. ?NG ('7.WK9_"FAW,5O
M%+IZ,EO:-91*'88@9=K1G!Y& .N?7K4C>&]'>0NUA$S&<W!W9(,AB\G)&?\
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M,C %V8)L?>H4$_*H8 [1@9[5/;Z5;6MZ;F'>GRN!&&^0%W,CMCU9C^&.,<Y
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MVN;@VQ1I(M\<@F\D@KORP#]UR,<U?TG7[;6)7CMXIE>.,/*' _=L7="AP?O
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MR0"N?Q/:M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVA%;,AFMX+R2,-!@$P^5@%MYX_>8Z<Y_AQR ))HE^OAJSMUBCEN+6^%T8"X
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MFM5FEE50L0E8?*1NSNQW (Y')H =I.A7MAKAO-TBQRS7;3+]H9E*NX:/Y2<
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MJG@%MV!NY., @CKP9YO%)MKB>%K"ZGF%QY*P1*BLA%NLS L9-IP">1CTP>I
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ML\;*![D5P%MH?B6#2H((4O8((_LRS6SWGF22;8Y%D9&$J[5+&$A=Z\(>.<$
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M$.A:=;O"Z6Y+P[-CO(SL-@8+R22<!WZ^M4M)L[^UU_4#(MRU@ZKY3W$Y<@C
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M"EPI"[ATZ#.*M6>C^)Q?6W]H75Q*%MHE9XI08RP@VNK@R#.9-S9\LGE>1C@
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M61]VYOQWO^=44T+0]-C#?9XXD,D*J9)6(5E<&)%R?E <C"C R>E8%EHNMRM
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MWGV*XN;B[9(-MLJA7G\II'"[V'"[&!)/7CGFM:'PWI=M);R0PS1O S,K+<R
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MDE&QE$8?8SD!B5"]3N ..0#BIQXMM3<01FQOE206Y:5D4+%Y[%8@PW;LDC'
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M\DEO<2Q-,K>21>I*4ZX.R,8XX.WC.:U'\::9%J+6$RS1W**3)&Q0LCB+SBA
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MHE;S7AG#/M,:B,C$D?W3N#<X9OFP0>.EN_%VG65]<VDPDWP6SW.4*,'10I.
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M]G\R4M&J ?+M7.%&<GIGUZ"N2@T?Q(D<L\<&H1/(EFESY]V))9=@F\S85E!
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M7$UQ' PGW<%V"@C'IFJ$/C"*VFOX]5A>!+5YA]H1/W3") [#J6S@D],<>O%
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MFE:R!V,YG7.V%"J-P<YE9@Q]DP<9J%/#6J2021SP7GGW"Z6TDHN_E!BDC,H
MW\, A.0/H<FMS_A.-,-I#<I#=21NDTCF-480I$X21F(;! )_A)R.1FIHO$GV
MKQ%!IUO;2?9W^T*URZ@*[Q%58)SGAB0<@=.,T 8EQIWB58?)0W[L@G2SD2\
M$3>>_EO-EP9%\KR^#N/#9&31JNF^(=3L]4TUX+HQ/:ZBB2&Y54F:1PUNHPV[
MA<KR !R.0:VKKQAI]F)C+#<*L=U]D1GV(LLH#$JI9@. I.3@=@2>*!XPTPSV
M48\TK>P>? X"DL/+:3&S._.U3_#C(QG/% $'B2#59_#UM!I-K>"8C!_THB6+
M]VVW<PE7<=V <N?7#5672==GU#SI[J]C$MP(Y-EUA4@-EABJ@X!\_G(&<\CB
MKS>,K!;"*\^SW+Q- ]U)Y?EOY4*G!D8JY&/926X/'!J=/%%F][/;"WNAY7G
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M+F22W&1\P(7!].QZU1N++Q-']KFMIKMI95O0$,RD*/-7R-@/"MLW8/O\W08
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M)\@S.1B?F3;SP&//'3)QBJNBZ5=VDNOS70<S7DZ.I\PE'Q;1*2H)^4;PX[<
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M9C:7\9,P6Z<0N&4 L &VC(QR/KUYI8?#>E*(G2.5]KO(':X=B_F !MQ)^8'
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MNFQMVN+>=D+2VZ-'&S,20&QG/KG:.M<I';>((IK,&74)U-I(CR86/R3^]*L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>GTH U**@6]M6:-5N82TA(C D&7(Z@>N.](+^S9PBW<!<L$"B09W$9 ^N.:
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M^>UAN797NI/*B C9LM[D# 'N<5#;:]I]WJ3V$,CF9?, )B8(YC8*X5B,,5)
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M%OL.IPW\[6\DB+<G8D6%C:617^3/0#;CW))XSBF^(]=ET>:VO$5Y(4L;JX>
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M $W;F4<MV''/)."!4_B;5+S3-9MIT)>RMM-O+Z6!'*M*T7EX''^^>#QR3V%
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M _>;OF7/8;?QY Z<U['QCJEPMI--I]FD$T5C.VR=BP2ZD,:@ KC*D9/MQ[T
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M$MY[8QW$.] LH4;@ 1\R[>/8D<507P2/M]U-,\-S',A($C2#:QMQ 5*A@"I
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MJ%G:6%K'>&2$32.)0 1N"D*>F1G)_ =\B"Z\87-K#?M);0(UI<8E!<MY=O\
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MTUQ=1,@>]E5G<OG>P4( /P4<#W]34D]M9RQ"*>"!XU.\)(@(!'?!^O6N,N/
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M $/^JQ&/W?\ N\<?A3FM+9S&7MXF,;;TR@.QO4>AJ:B@!@AB"A1&@4-N VC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M6=?ZE);7*6MM;/<W#IOV A55<XRS'I^IJ&.^UAG ?2HE3NPNLX'TVT["N:]%
M<OI&M:[=7]O%>Z88H)(MS2>4R[6P#@Y/'.1ZG&>AKIQ2&+1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !15/4=06PCCQ')-+*VR.*,#+'\> /<U3%_K)/.D1 ?]?8_^)IV%
M<V**Y6WUOQ ^IP0RZ3BV>8I)+Y;*47'N<'Z]^U=0I)&32&.HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH @O;VWTZPN+Z[E$5M;QM++(02%51DGCV%<=_PN'P!_T,<'
M_?F7_P")KN" 1@C(IGDQ_P#/-/\ OD4 <5_PN'P!_P!#'!_WYE_^)H_X7#X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!&,GW%=1H-P]UH-E-);2VS-$,Q2NSLOU9OF/KD\^O- '*_\ "7>./^B;3_\
M@XMZ/^$N\<?]$VG_ /!Q;UW=% '"?\)=XX_Z)M/_ .#BWH_X2[QQ_P!$VG_\
M'%O7=T4 <)_PEWCC_HFT_P#X.+>NXA=Y((WDC\J1E!9,YVG'(SWQ3Z* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>C2D99%<QR--Y60,_>R6QQU[>M,_X7-X _Z#_P#Y)S__ !%'_"YO '_0?_\
M).?_ .(H ?>7\\WB3?;75R\YNK8V4,<K"*6U*@R-M!VL.9/F(X(7D<59UF_$
MFLZ+;O-/I^HO*DCJ;IA$L2ORI4'8[/\ = P2,D\8YI_\+F\ ?]!__P DY_\
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M+F\ ?]!__P DY_\ XBC_ (7-X _Z#_\ Y)S_ /Q% '=T5PG_  N;P!_T'_\
MR3G_ /B*/^%S> /^@_\ ^2<__P 10!W=%<)_PN;P!_T'_P#R3G_^(H_X7-X
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M+F\ ?]!__P DY_\ XBC_ (7-X _Z#_\ Y)S_ /Q% '=T5PG_  N;P!_T'_\
MR3G_ /B*/^%S> /^@_\ ^2<__P 10!W=%<)_PN;P!_T'_P#R3G_^(H_X7-X
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M+F\ ?]!__P DY_\ XBC_ (7-X _Z#_\ Y)S_ /Q% '=T5PG_  N;P!_T'_\
MR3G_ /B*/^%S> /^@_\ ^2<__P 10!W=%<)_PN;P!_T'_P#R3G_^(H_X7-X
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MHQTGP7I.Z_EMY(YK7)C<Q^9F1"X/))&TL2,]CGBJO_"YO '_ $'_ /R3G_\
MB*/^%S> /^@__P"2<_\ \10!8TW4KN3QK<1S;YA).Z(BSR 0PB-623R_N%6/
M&[KN;KQ@=G7"?\+E\ ?]!_\ \DY__B*[L$$ CH: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>bionano-nancyridgeleasee012.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHI 0<X.<4M !1110 444F1G&1GKB@!:*** "BBB@ HHHH **0D $DX ZDTM
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M),\):WQ$R?9MT0WXQS+QUSV/&*B@OO$*V]I*T][.&O K1"S9)&CP@(9F@4
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MH6* *$P >/+PW3[K949. *CA\&V,'DJEU>"%!")(=R;9O*<NA;Y<C!/12HP
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MP_8CY+DEO/WN5^0HK$@97G YSBI-.M]4^V6,CV<T326]@DC?9\",C[3NP",
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M2I!$8)!!&<D8XQST6J>*7N+",^>D#,VV:6U8&91<,H\U5B;83$$/_+/EB>Q
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ME^4K\Q()R.I' ( +4'@R<ZOJ4MQ<1_9+WS=_EA3(P9E*@$IE<;1GYF!P.!@
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M^@QB@"POB/27-L%NPWVE4:,A&( =MJ[CCY,ME1NQD@CK4=CXCL]2UI]/M"9
MD)E,NUE4X?;A<CYAG/S D<&J<?@O3HK^WO%9FDA"K^\BBDW!9&D7ED)4AG;E
M<'IW (FL/"Z:;*)(-2O?DB$$*D1D11[P^T?)STVY.3CWYH WJ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!@BC$K2A%$C*%9
MP.2!G )]!D_F:?110 4444 %%%% !3$BCC>1TC56D.YR!@L< 9/KP /PI]%
M!1110 4444 %%%% !1110!'';PPO*\4,<;RMND95 +MC&3ZG  _"I*** "BB
MB@ HHHH **** *\^GV5U/%/<6EO--"<QR21AF0]>"1Q^%6*** (Y[>&Z@>"X
MACFA<8:.10RM]0>M);VMO:1+%;010QJ-H6- H YXP/J?SJ6B@ HHHH ****
M*Z:?91WCWD=I;I=2##SK& [#W;&3T'Y58HHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R8\MLE@,'
M[O7\*\>G74)O!DMG;6^L@+K\CAKRTNG_ -&)D*&1<>9(A&W@<ABI.,5['10!
MSO@ZYG_X1W2["\M;^&\AT^!I3=JQ.2",%R "_P N2.HR,CFNBHHH *\EFG\0
MZ1JOB*31K.]O&ED\W[=-:SI)"&N%#1A65EE"H6*LBM@+T.<'UJB@#S>UU7QO
M]JT>V8/<1ZAC?=+:,JVXBF8OOWQH5+Q;%&5 W E0,U3TK5O'NH6<2W$LUK//
M=V\4V+!B]J&\SS<;X50J,)@@OCNQ!%>J44 >0:]J'BO51KEB;35&LU:-X UD
M2R/'>Q ;-L:A@4R^-SY SD<BFWW_  DNL6S-<V5[<IY4B07$EB8I98UOK<H6
M4*-I*!CC R%SBO8:* /*+2+Q7'J0^RW%_8F6VU,6\7V3-N9Q<NT1DRI"[DP0
MQ(SC@\D'J_!7B2\U[2X+^^@G0:FTMQ:((?D@@4JJJS@8W-RPR<G)]*ZME#*5
M8 J1@@C@BFPPQ6\$<$$:111J%2-%"JH'   Z"@#A[_0&676FL[26*5K^R\B1
M4+;5WPL[*#P0"&)[<'-+-J'BF.>UMU:4*LLZ?:)+<GSMLY5-X2)L QX.1LSD
MD$8KNJ* .9UU]5353_9RR)OCMH_/2 .5#7*K)U!'"%CSTZU4@OO$J75E:NLT
MB7$\D+7#6X'E+#<-EWP !YL( !QC(!'6NQHH X"RO-;U6]M_M=K>^1'=P31^
M? 5:/=','4XC0?+A,XW %OO'(J*TDUFYN-"@O(KV(0/:M]G6R(BV?9LN[/M^
M5A(67;N& !QSFO1** //+.]UG2=-FU"YEOD6VTVRNI+5[<")451]H5?E^5P
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MVR,ZQ0632B*$R/Y;3R*_ !)^4=NG)KJ:C2W@CGEG2&-99<>9(J@,^.!D]\4
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MCKC0I<BWOHR88HY9VMM\JK]H9790(UW?)\P&P'!!*]J<+[Q/) )4>Z"PHTB
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M"RK$25 !PI^8EN < D8R"0#AZ9XMNQIQ-_;1>=Y?F0R&7 FS,8@"%0E3DK@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/Z6$D<.ZBT3#,,X)X_VC^9IH\(Z+_:$MT]E$XDLH[ 6[1KY20HQ8*JX]2/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$HI;$H."IP.,'OTJ]7!Q>%M>6>6W;[ MG_;W]JI,MP_F,AEW%"FS ./]H\T
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M]0CG+VT$LD,CK&Q(='*,,8R<,".!^E11>)='E,N+Y%6%I%D>161%,<GEL"S
M#A^.O/;->?/\-=::YU-XGTZV-R;PB:.:3?<>=<+*@D&W "*#TSRWU)GU+X;:
ME?PZFC2V,BW O&B21FV[Y+M9TS\O'RJ03S@GC- 'I]9VH:YIVE310WD[1R3<
M1@1.VX\G P#S@$X]JXNP\.:Q9^,[^>SMX8[.VM!<V5M(S"W6\E14=0^W)15B
M[+_RU/%=GJ5A->W>DS(R*+.[,\@)/(\F1,#CKEQ^&: +=K=P7L+2V[[T61XB
M<$?,C%&'/HRD?A4]<1-X*N]EXUI-;V]Q=)?"61"09#+<++$&.T\! RG@XW'
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M6DR/*[Z;:%I4".3"N648P.G0;5_[Y'H*<FBZ5'<P7":;:+-;H(X9!"H,:@$
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M0$^X.G\/;TH Y^/QI)):PS#2^;N.WFLU%P/G2:01J7.WY"-P)'S<="2*T/\
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M"^+9;V[6WMXUBVW-M^]0ETFAE9U&"RK_ ,\SRN1TPQKI(]*T^)%2.QMT11&
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MYUJ&X2"5C,UO>,J7#6S ;#9LX)5>H$AV_D.3S0!V-%<C+?W]W\/[JX<77VQ
MP+!"&;:_+)M4$KCH=H)':ENM;U6X\1VD6G[$TYUA96FBD'G9D991_JR<JJ@C
ME>2"<CH =;17 KXBUV6WU211/''%Y$D1EMB)!N:021C]V5# (N 0P!;!;D8T
M+/6=:E\2R).GD:?'R8987\QHO)#[P A&[>2I^;'!&,XR ==138Y%EB21<[7
M89!!P?8\BG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% #$ABCDDD2-%>4AI&50"Y P"?7@ ?A3Z
M** "BBB@ HHHH 888FG2<QH9D5D60J-RJQ!(!]"57/T'I3Z** "BBB@ HHHH
M **** "BBB@ HHHH ANK2WO;=K>[@BGA;!:.5 RG!R.#[C-+;VT%I D%M#'#
M"G"QQJ%5?H!4M% !1110 4444 %%%% #(H8H$*0QI&I9G*HH W,2S'ZDDD^Y
MI]%% !1110 4444 %%%% !1110 4444 %1S017"A9HDD565P'4$!E(*GZ@@$
M'U%244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:TZ+4AI[W(%R2%V[3@,1N"EL;0Q R%)R1SBFQ:]ID^D?VK'=!K$XVS;& ?)
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M"NV)<G:.(YVF' 4 ?,Q' Z=,5'%X(T^".=(96B+RB:*1(8A)$PE$H^;;E@&
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MU#38+^*Z"PS0)<+Y@*L$8X!(/OQ3G\1Z.BS,U_%B&4P/C)Q(,Y7@<D;6)QT
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M_:P%+*_RDE&.-A'RJ<]L=XWB#25:=3?19@.UP,GG=LP/[QW$+QGGCK5]9D>
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M!('>JD/B+1DT&\\00AEM S/.ZPD.[+A,D8R3A0,^@'I0!@WGBG5H+>;"/')
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MGZUT-% &+HOA[^R&E9K^:Y9[:&U4NJKLCBW[<;1U^<Y/KZ=*RX_ D26,UO\
MVG.TLS1L;@HOFJ44J'5NHDP<[^N<]CBNNHH RM5T.+5;B.62:1%%M/:2(H'[
MR*7;N&>QRBX/UHTO13827$T]W)=7$\<<32,BI\B A1@<?Q,2?4]A@5JT4 <Y
M!X1ABL8K9[R:3R[:WM@Y50=D,A=.G?H#]*L:-X:MM%O)YX2C;S)L)B4.H=][
M N.2,X_(9R>:VZ* .8_X0Z,&8&^>6-DECBBFA1TC5Y1*>,9;D8!SP,=QFEMO
M!\-E?1WL<YN9XXXP3=HKL\B)L5]^,J2 ,]>G'?/344 9QTR2>+26O+DRW-BX
ME:15"B5_*>,DCL#O)P/:LFU\&0VM[I<XO[ATTY(UBC< C*1M'^ (;) ZD#GM
M73T4 <M_PA:_8;.T75+A8[>V2T)$:9DB1@R \<$8P2.N3T[3W?A&UNK2"+SC
MO@NY[I&DC5U)F=V92IZCYSCOP/?/144 92Z2TNF7VF74BFQFC^SPQPJ$\N'R
MPA' ZYW'T&0.U94'A6]%Y+<3ZJYG2XCGM[A8TR-L+1$%<8^Z[>O//M7544 <
MK;^"((+C37_M"YDCT^%(HD< _=A:+KV!#$D#O^56;?PG#:?96@O)5>VGBF5B
MH.=D'D8(]T)_$UT-% &%H.@'24U/=(0UY<R/&4;)BB).Q%.. ,LP'8L1SBJ^
ME>#H=,GAG-[-/+%<"X+. -["%H>>YR'))ZD_E72T4 <Q:>#(K(V:0ZA<""W^
MS%HBJGS'A0(I)QD9 &0.X'OFY?>'?MD^HLM]+#!J,!AN(512"=A0,"1D<$<?
M[(]\[=% '-:KX/AU..Z3[?<0K<R;Y54 J1Y(BQ@]> ",]#VJ>7PQ&UG=6\5[
M-%]HN([AB ,'9'''M([J1&,CWK>HH YW3O"4>F1K!;W\_P!F-HEK-&43]Z$5
ME#9Q\IPW./0=.<L@\'017UG=R7"SRP0PQ,98$;=Y3%D8?W6YZCT!&#S72T4
M9!\/P'PRFB>=*(XXU1)1C<"I!5NF,@@'TIEEX=2UOUOY+J2:Z,LDTKE0H=G1
M$Z#H L:@?3FMJB@#&G\/I-?SW!N9 DUQ!<M'M'$D6W&#Z$(HQ]:I+X*LDU"*
M[$@=E;+K-"KA@)GF7&1\I#2,,CMCN :Z:B@#-DT*QFUX:Q/#'+<I"D41DC5O
M*VLS;E)&03N[>@K,N_!MI<VMG%YN6M3,%,L2R*RRMN8%3QU P?;ODUTM% &$
MWA>U,SN)I%#2R2[0  -\(B('L ,U7;P=!Y02.\EC(GCF\P*N]2D4<?R-U4D1
M\G_:(KI:* .8C\%6D$5Y'&\)6<L5,EJCL@:02$$]6&0,=", YR :VK"PDLK-
M;5[V>Y1(4B5IL%_E7!8MU)/4Y[U=HH Y72O ]KI:P8NY)&A%NJD1H@*P[MN0
MHY)WG)//3I4ESX,@NX[N"6]G-K,MUY<6U?W37&?,;.,GEFP#TR>O&.FHH Y=
MO!%D6M0)M\5LC01Q3Q+*HA+!@@R/X<8!].N>M6;KPO%<:>MHEU)%MNY;L2JH
M\Q&DD9SL;JI&\@$=NN:WZ* ,G5-!AU669Y)I$,MJ;8[<< L&S]>*SG\&02W5
M_<37]Q(]W'+&K,!NBWN) 0>Y0@;>P  QQST]% '-1>"[&&\LKE'#M;PPPMYT
M2R&3RF9U?)'RL69B2/T(S5^]T&&]O9KIYI%:7[)D#&!]GF:5?S+8/M6M10!B
M:3X<CTJZCE^URSK;P-;VR.JCRHV8,1D#YC\JC)[+ZY)K7?@ZTN;:TB\W+6SS
ME3+$LBLLK;F!4\=<8/MWR:Z2B@#E=2\)23&>6QO/(DEFM6"HBHBB*:-RQ &&
M<*F 2.F ?97\%1/#+&=1N/\ 2HY(KT[%_?K)(TC <?)R[ 8['UP:ZFB@#!D\
M+6[AOWQ;/VKY9(U=3Y\@=@5/! (QCTJN/!ZI&A34[KST6W"S. Y!A>1UZ]LR
MD8] .>]=-10!SEMX0MK<JWVJ9WW0N[$#YGCFDF)X'&YI6X[#&*CD\(K%IES;
M6UP[^9I:V 23"ABF\QMN RI!D/(![>E=/10!AOX;2;PG'HCW4J.J(3=1X#^<
MK!_-&>,EQN_&H-.\&V&F.#;RRA5NQ<QH<80 -B,?[.7=OJQKHZ* .;C\'PII
MR63WDSI'9"Q1MJ@B,,"OU("@9[UI7^B6^I7$LD[/MELY;-T4XRCD9.?7BM*B
M@#EU\&0K8QVZW*QNDRR^?#;)')P  0PZ-C/S>Y&,<573P2;N&Y34[UW5Y;LP
M1QJNV(37'F@Y(^8_*G!X^\.>*["B@#G[3PP+&YMKFUNQ;S1ATE\FW15E5F5B
M-N.#\H&?<^V)QX>3_A';W17NI&@N!,JOM :-9"3@=C@D]:V:* ,-_#,,\K27
M-Q)(\ERMS)@!0S"#R2/8$<_6H-+\(6NF"RV2AFM)5D1UA1&<+$\8#D#GB1CG
MCGL*Z.B@#EX_!-I%#>1QS!//+-'((4\R,M()<;L98;@.#V SD\U;A\-K'JJ7
MCWLKQI<F\6#8H'G&(QELXSC!8X]3UQ@5NT4 <_<>%HKB_FG:\F$$D[7/D!5P
M)3%Y6=V,XVG./7OCBK5[H45[X<71_M$L02.-8YTQO1HR"CCMD%0:UJ* .;T[
MP98:8W^CRRA%NUN(U.,1JH;$8_V=SNWU8T1^#X%TY;)[R9T2R-DC;5!$>X$?
M4C:!GO7244 9M_HMOJ-R\L[/MDLY;-D4XRDA4DY]?EK)7P7"M@ELMTL;K*LG
MVB&W2.3@;00PZ-C/S>Y&,<5U%% '()X)-W!<IJ=Z[J\MV8(XU7$0FN/-!R1\
MQ^5.#QRPY&,7[7PP+*YMKFUNQ;S1ATE\FW15E5F5B-N.#\@&?<^V.@HH Q1X
M>3_A'[O1VNY#%.TC))M&Z,.Q;'H<$]Z9%X:"ZHMY)?2N@N!>&'8H!G\KRMV>
MN,<[?7OCBMVB@#F=2\&PZIJ%Y=3W]QBYBEB"8!\L21>60I/8?> ]2<YSPFL^
M$DU%R4E(\_4([J?<<?NQ$L3QCCD,BX(_VL]A73T4 8>O>&UUPN1>S6OFVLMG
M+Y:JV^-\9'(.#QU]"?8BJ_@JR=M4'F )?I.I/DKYD9FY<A\9QDD@>_L*Z:B@
M#F;_ ,&P:EJ-Y=7-]<LMS#+#Y?'[M9(Q&P4GH !D#U)ZYI3X0CF%TUY?SSRW
M32M*^Q4^_ L)  '&%0$>]=+10!DW6C2W-KIX^W.EW8R>9'<"-<%MC(<KTP5<
M_I1HV@6^B;A;RR.&ABA/F8R=F[G@=3N)/:M:B@#F/^$,B:1S+J%Q(@:9H4**
M/+\V=9W&0.?F10,]!FI9_"5M+JU[J"3M%)=[F+K&OF12&'RMT;XRORC\\]CB
MNBHH YBR\'#3YA<VVI31W7FN[2"),%72)64*0?\ GBA!Y.<YSFM&QT&&QO8;
ME)I&:(70 .,'SYEE;\BN![5K44 <W=^#+.\M_)DN)L#[3@X4X,UPD^<$8.&0
M#'<=:DB\)6:P/%(PVRVDUK*L,:Q*RRD%B .AXKH** .9@\(+:)#):WH@O(G8
MB>*VC7<K(%(9<8)P <^H].*TM&T*VT-&CM6D,9BAB57.=JQH$7GZ"M2B@#C)
M_ SIH,EE!J4TERL%M:VT[A4,"0OE2-HY8;F^O XY-;&J^&;34K:PA3;"+$XA
M4QAT"[=NTJ>V/Y#W!VZ* ,*+PQ#;W45Q;W#Q-'=K<A51=N!;K 4QC@;5!XZ&
MJDG@BS>SMX/M$A-M;6T$;.BL/W!?:2.ASO((_+!KJ** ,O2]#@TJX>:%AE[:
M*W*)&$4!&D;( Z9,K?E58>%;**RU"*W/V>YOI9)9;N)%64[I"^TL.2O.,9Z5
MNT4 <_IOA.UTZ$QBXED#0SPMP%XED,C8P.,$X'M4,/A>2+7-+O&N3(EE9F%F
MP 99!E8F*XQ\JO,/^!].*Z:B@".!'C@C224RR*H#2$ %SCDX' S[5)110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (S*B,[L%51DDG  K&_P"$P\-&Q^W?\)!I?V3S?)\[[6FS?C.W.<9Q
MSCTK6GW_ &>7RXUD?8=J,<!CC@$]@:\PE\*>);OPMK-M/IL<>JZO*TES-;WZ
MHAS'L5<;#^[4!01U.,YYH ]2!#*&4@@C(([TM9VCK?Q68M[^""-H D:/ ^5E
M 1<MMP-OS;@!SP!ZUHT %4K36-,OU@:TU&UN%N-_DF*96$FPX;;@\X[XZ5=[
M5XY:_#/Q+IEM;Q:;=P0+_9L@=1,5,5VRHK[& R%=47D<@Y/>@#UV>ZM[529Y
MHXP%9_F8#Y5&6/T ZTZ":*Y@CGA=9(I%#HZGAE(R"*\O/@76VO(+X6RH$ENQ
M!:G4'8V:21(J88]?G1V(_P!NE;P?XK_L^]@+^9>2+;[+S^T7&8D$.^WV8P,E
M)/F[[N?O&@#U.BO.--\-^)=)U33KV%'NA;VLJ20WM]N .961$*CY3ET4DAAM
M [J,^BQEVC4R*%<@%E!R ?3/>@!U%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;1('B$4C[4",JF*, GN Q4?7% '/#XF6[Q7TT6C7\D%NX2*0 !9C]H6 C)P
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MX8))D\@[R^QD5E( X(,@X&3@'(!X*0^,(;C4;:T@LYK@2+$TDUOF1(_,) Y
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MN3N&.1CGD58M=/L[+!M;:*']TD0\M<?(N=J_0;F_,T 6:*** "BBB@ HHHH
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M<\]A&(F@MKQG63#CS(EC92"#@C$E $47AOQ KG4;DVUQJCV4]K(WF$*1N@"
M8P>5BD?&0 SD9Q3X/#FN&PMH9Y 1&SDH\V<#[8DJ#TXC4CVZ#BM?7_$4VAZG
M#FUDN+);"YN[CR]H9%B:+YN2,X#-P.3Q4VG^)[;4M:FTZ&VN,1M*GGE1L+1L
M%8>HYSC/7:?;( [4!J&J>'Y);2!K:^27S;>*1RN_RY,J&/8.JC(/0/@]*P]+
M\.:_;(L=[?-<"&>!4<S-F2(.TDC'W)?;CTC'K5B3Q5J7G0>7I3,#J-Q:&-)$
MS(D:2'()( Y05/+XUM=\"6]N\K7-L9H/WB9)\DS!67.5RH/)_ES0!C)X-OET
MNVABB\BYL["YA@9+EA^_+QF-^#T^0GGIZ5H>,+#4M1U.UM["*9B^GW2K(MPT
M20S%HA'(<=2OS$#KUQ5J_P#$-Y#X5T[4XX4M[B[D@5E>)K@1B0C)"H06X/ !
MI+7Q6Z/I=KJ5H8KR\"A@I"E"Q8*3&3O4';GGIG'.#@ I3:!K$M]=LSSKO-SO
MNH;LJTT3J1'&JGA&7(YQ@%,\[C4<>@:O&1=BSMFO3ITULG[YE5&WL4W -W4C
M.TX!S@@8J[#XQN;C[#-%HER;:[T^>_0&1/,*IY94!0V/F\SIGT]ZM?\ "1&X
MAGU.QC>XTRU1P_E+N:=\1LIC_P!D;G!]Q[4 <;J&GZU9?V?:W,5U);J\\ICB
M+NVTRQLB(5^4/@,,$X +#IS76:!HVI66NWMU?3SR!VFPWF@QR*TFY/EZY5?E
MYX'(&16A<^((+?1(-354D6?&Q5GCPQ()P&S@]#TS_/&2_C(7<FGO86LWV2::
M!9KB0* @DB\T+C.<[2IR 1SCUH R;;0]:OA?.HN+8227<;N]XX:<&[!C('5
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MA%F)4F.X+NP!)/*;>3R2,8  K7OO$$O]C6>H:?;/()[U($0[<R(9"NX$G #
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M>TDO*ZHN'W8 RPZC@<^U75\51'6X]*:QNEGRB3$;6$3LNX X)R,8R1Q\P]\
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MH9<1E@A&).<LF3G@Y! (Z8I;?QO9W-Y:VT5G=EYA'YF%!,)=V0 X/.&4Y(X
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MND92)8%V]D4DA?H,G\ZX^31_$OEW"023AY+*%7EEN?\ EHOE!DB(?C<%DR2
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ML=;M_$%G9WUY+-#!90W=S)YC$-<^682G/5#M+X_O<XYH Z:UTZQTT%[:WC@
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M:&^8AR", \$D<XH W8_"NB10-#'8*JDH<AV##9D+ALY& Q P>AQTXIZ:5HL
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M1DBVR(P+#.3W"MGCI@5!<V/B*P\/R-NNE$-M<1*S3LTK%C"$>3:[?-Q+DJ0
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MF"C<Q.22%0*,G@<>F-*BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HI&944LQ 4#)). !3)+B&&2&.215>
M9RD:D\NP4M@?@I/X4 25@+J.IG7M0L5EM988;8RB2.W<FW<GY$<;SYA*Y; V
MG@?WA6_69'X?TR&6ZDC@=6NRQFQ,^&+').,X!R.HP: (/#FJ76K:3-+<>6MS
M%/+"?W31_=8[2T;$E21@X)Z$>M+X>U"]U".^-V]O,D%T88+FWC,:3J%7)"EF
MZ.77.>=M68=$TZW@6&*WVJ"[9WL2Q<88DDY8D=SDTEE8Z;H%M';VP^SPNRQQ
MH\K,,]%5=Q./H* *'BK5M1TQ-)ATPVJW%_J"6F^YC:14!1VSM5E)/R#OWK!M
MOB3'!!;1ZG9K]I-Z]E,UM,A4,L_D[U5FWE2Q!Z<<C)(KK]5T;3]<MX[?4K5;
MB*.02H&)&UP" 000<X)_.J3^#O#K_91_9-NJVJA850%0H#;QP.#AOFYSSS0!
MS,?Q06#3(;C4-%NDN)IKM4@@=')C@DV,P^;DY(&WJ3G'&#6YXA\:6WA^78UC
M=70CM&OKAH=H\F ,%+'<1DY/0<\&K4G@_0)"2=-C!,TD^4=E(=_OD$'@-@9
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M+1=R00PZ5>&>:9HMI*  *JN6W$X(PP'&>01[UIIH&DH5(L(,K:?81E<_N/\
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MGBA2Z0+L0O&& ;YMW)R.!W% %*^T/77O+ZZL;N:*XFEG6)GN6,:1M;XC^3)
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MX=0N+\8N(FNP;L@.%BD#,K+(6(9RF1\N<#Y1S6G'XBOTTCQ%J<UD633I)A!
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M,Q;!'G[WFDG..C9SVJ3_ (1_6H9M(1;F^,,5O")F2Z+LDX;=(S%G&X,,#HW
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M6NGF\96=O+=+-9WB10"?$NU"LK0D!E4!LYY&,@ U<T+5+G4Y=4%S:M;&UNQ
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M"2VMS&D4EX(S#([#:7PYW+C< -S8SC&#QK>+]'U'4+RVGT^&9W2RNH$DANC
M8IG,1C<X(RH*$D<]!P:ETCQE:WT]A821N;R:*+S6CV[$D>$2XV[MV,$<XQR!
MFI[GQ0UG=ZG%+I=R\=G-;PQM$R$S/,550 6&.7'7 Q0!%H\&I#Q3J27%Q*]C
M:9,!+-AVFVNP.>NPJ=O8"3':JL>CZJ+BWM?LVR*TU&\OENO-7;()1/M51G<&
M!G&<@#Y3@G-7;OQE8V-U>6UQ;S++:VDEVZI)$[;8U4LNU7)#?,,9 !YYIX\6
M6XFC@FLKJ"9KO[(Z2M&HC?:C#+;]IRKJ0 23R ,B@#-T_0-8M7LXGN+EK?\
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M#O><H@68/O\ N A^,Y^8-MS6SKGB-]/NTLK2TEEF$UH)I<+Y<233B,9RP))
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M5VKN7.UB%P,D$\#T%/ET:PGNY+F2 M+(8F?]XP5FC8,AVYQD$#G&>,=*O44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMY?LEM?@V$08-&8YHD1Y<M@Y7+CA<*3@D<UVTNK6,33H+F&2:WQYL*2*73)
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M[,!>%D=Y 3&%VHLQQR[ D,Y&%)7!..THQ0!R,/B"[U#P?KUUYT(O+.*8*]J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 44$X&32*RNH92&4C((.010 M%%% !114,]U;VS1+<
M7$41F<1QB1PN]CT49ZGVH FJ*ZN$M+2:YDSLAC:1L>@&33I)8X0IDD1 S!5+
M'&2> ![FB6))X7BD4-&ZE64]P>"* ,"V\3+OTK3[Q1'J-_ K*R%"@D,;.1MW
M[\?*W.,<=<UIZ)J#:KH=C?N@22>%7=%Z*Q'S >P.:HVGA:RM?LDQ:22]M8T5
M9VD<!G6,QAV0-M+;21G'>M/3+"/2]*M+")F:.VA6)6;JVT8R?<]: *?B35+K
M1]%>\LK5;JY\Z&*.%GVAR\JIC/;[U9UIXSM[SSC;VL]UF;9;Q6X&]T$$4K,P
M8@ @R;2,YS@=:Z&ZM(+V)8KA-Z+(DH&2/F1@ZGCT90?PK+;PIHQ\XI:O"TUP
M]T[P3R1L9'4*YRK @$ 9 XXSC- "7OBG3;'3+;47,SVUS;M<0-&F3( @<*!U
MW,#P.^#4%SXTTNWMUN?WCVQE\H3*T84_*AR S L/G ^4$Y!XK3N-%TZZM[*W
MFM4,-C+'+;("5$;(,*1CT'&.E9ESX8\-V6EPI/$MI8VB.BDW3Q(JR.&96.X9
M!8+P?04 .B\56@9XIQ)YOG/%&%CQYF+DP8'/)#;<GCA@?85X/'FE7<3O:Q7-
MP0T2QK%Y;&7S&*H1\WRY(Z-M(!!( K5&@:6;BTN1:J9+6:6>%M[?*\I+.>O.
M22<'@'&.@I(/#VG6T:Q1QR^4DB2QQ-<2,D;*<KM4MA0#V&!T'0"@"GK7B5M$
MU"!9K.:2S-E/=W#1J"\(C:/+'+ 8 =L@9)P,9J[9Z[:7U\;.$2^>OG;U91\G
MEN$.[GC=G*^HYHU30-.UF2-[Z&1RD;Q?+,Z!D<@LC!2 RG:N0<CBFVVEVFEZ
MIJNKO*B/?O$9&;Y0H1 BC.>><\\=0.U %(^+;:UT:WO[Y-KW%U+;11HZKN9&
M<?>=E4?+&3R1Z=<4#QGIK13S)'<-%#;1W);"*2CA2N%9@P&'&6("C#988-61
MX6TM4*JETH\XSIB\F'EN=V2GS?)G>V0N <U-)H%C+<_:'-V9O*\E7^V2Y1?E
MSM^;Y2=BY(Y..>IR 5O^$IM/M$4?V>Y*,84DF78T<+RX\M6(8Y)++RNX?,.>
M:?!XDMI_#ZZR;6ZCMI"@A1U7?-O*JFT!C]YF &2/RYI8?"VCV\L$D5JZ>0(]
MJ"9]A*?<9ESAF'8D$]/05:;1[!M'CTDP'[%&B1I&'8%0F-N&SD$$ @YSD9H
MR(_$MQ>Z_I^GVME)$CBX-WYZ*6B,1C&WB3OYBG(W#D<<DAESXKNH[][>+2)R
M(M3%B<,C-,# 9<I\PVG.W[W&#ZY V+/1+"QEBF@A82QB0"1Y&=CYA5G)+$EB
M2B\GTP.*!HE@+][WRF\]IUN"?-;;Y@C,88+G .PX.!SQGI0!F0>-M(N+VRM8
MS*7NXXG7.T%/,!*!E+;L\<X! R,D4S4_$-]87^H,EO;R6-@(3,"S"1E?J5/3
M@<X[^HK2MO#VG64\,MK'+"T4:Q 1W$@5E7.T,N[#8R>N:6X\/Z;=:B;Z>&1Y
MF*%E\]Q&Q0Y0M'G:2#R,CTH P[_QW;FUOETF%KB\@.V,$HRL1*(F.-X( 9AP
MVTGMQR+S>+K*VO);&Z2074$0D?:8SN^9$.%5V*\R+PV.#QG%75\/:<B31B.7
MRIG\QHC<2&,-OWY5=V%^;G@"HG\*Z/)+<2/;2$W"R*X\^3 $C*[[1NPI+*K9
M7!R* ,[5O&!L)YC;6;7,=O;W3RQY"NSQ/ N 2<;<2L3WX&/0Z]_K2V"VRM97
M4US<(SK;1!"ZJH!8G+!>,@<$\D8S40\+:.()(3;.RR1S1N7GD9F$I4R98MG)
M**<YR,<8J>]T2QU"&WCN%G/D K'(EQ(D@!&""ZL&.1UR>>O6@"/2M?MM9N)D
MLHIWAB5&-R5 C;?&DB@<[B=KJ>E<]I7CMYXIY+VS8@)"\201LKNTLQB"@/@/
MABGS [?F[=^LLM.M-.$HM(%B65E9E7IE45!@=L*BC ]*H6_A71[8 1VTAVE"
MGF7$C[-D@D4+N8[1O53@8!P,YH KIXQTY]0GL0DHGA5RZEH^&10S)]_@@'J<
M+D'YJ=9>+;/4C;I9VUS/+*T@9(S&WE!&569F#[2,LOW2Q.>!P:FFT;1KB>]B
M=B6O,I<0+=.%9F7GY V Q49R!GC/O21>'-(CN(S$)EN(6:7<MW+YAWD$[CNR
MRL4'!R/EH B\.>(SK,8BN+62"Y\LR@E0$D7>RY7YB>".^.O'%4=0\:8TUI=.
ML;AIY1&UH9439-&\JQ^8HWC(!=3@E2=P[<CH+32;*QDC>VAV-'$85.XG"%MV
M.3ZU1@\.:'%+)!'%EP(W\IKAV\I1)O0*I;Y%WIG P#MQVQ0!)J?B"WT4V27R
MMNN66/<K(H#%E7[I?<>6'W=V*JKXQL/,=7MKR)%=E65T7:X280NPPV0JLPR2
M!P<C-:&H:%I^J7,5Q=Q.TD0 !69T! 8, P4@, R@\YJ"\\-V%Q87-M%&(GEM
M[F!9#E@HG;<YP3SE@#^&!B@".\\2+!I$.H6EC/=I+>+:JBLB$YE\O>-Q (SR
M/7(Z#D56\<Z2L]Y"HGD:UWAO+",7*2+$P"AL@AV ^8#/)&16A<Z?I,&C6>E7
M4BPVJM##;AIS$Q="#&%8$'=E0>#DXI3H.F(9E*R!+F0NT)N'\LN6\PE4W8!+
M#<<#U]30!2E\7117GV3^R=2:?S1!L58S^],/G>7G?C.S)SG;P>>F=:'5+6?1
MH]660BSDMQ<AV&,1E=V2/I2'2;$WGVHP?O\ [1]IW;C_ *SRO)W8S_<XQT[]
M>:CLM&MK&"6V0N]HT20);R,62.)4"A0#^.3U.>>E %";Q7#!;1S2Z9J"L\,E
MQY6V,NL*!2TA^?&/G7C.[VXI+CQII-M%([M+^[+AAM QM9%&23@;C+'MSV8$
MXYQ,_A/2)+:.!X[IDC5HU+7DQ;8P4,A;=DH0J_*3CCI4G]A:+>FZNTMXY/MZ
M1K++%(<.$^X5(/RD8'*X/RCG@8 *'_";Z<8(YDMKN1&5WD,81A"J.$9F(;!
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M][) YED8NP\Y]A<IY>_9G;NV?+NQG%3W&DV5SIT5A)$WV>+9Y821E9"F-I#
MY!&!SF@#)LO$<^I^(+6TM;5X[,P327#2HNY9$D,93A^"&4Y(# \8..:=/XQT
M^WN[RU>*<S6Q0%(S&Y?=((Q@*Y(^9EX;:<&M.RT:PT]T>VA*.B-&&+LQ(9M[
M9))R2Q))/))JJGA?2$G>86SEG?S"&GD*AO-$W +87]X W'\J ((_%U@RJ'AN
MHI6)18G1=Q<3^0RC!()#E<\XPP.:FU'Q+9Z9=W-M/',6MK-KV0KL_P!6H8G
M+!F/RGH"!D9(S1+X;LI-1T^[50GV*XFN57D[I)<[B23TRQ;'J%Z8JQ>Z'I^I
M7 FO(GF(1HPCROY8#*4;Y,[<E689QG!H SM1\3FVU.&UM;*>Z*W+6\\<:KO)
M$ F!7+ =&7K[CTI/^$WTGR+B<&3R(889O,)1=XE">7@%@W/F*-Q 7.1G@U/_
M ,(CH_E;/+NMWFF8R_;9O,+E!&3OW[ON +UZ5))X7TB4_/;.0L(@C7SY L2
MH0(QNPG,:'*X.5!H H_\)OIQM5N(K:[F0(SS>4$;R55]F6.[!!8'&TMT)Z<U
M9N?%NF6D#S3&5447))*C_EA*(G'7NS#'ZXJ/5O#&F7]M';27$\5PR&**5KJ1
MG<9WD'+?O ,9P<XYQ@58?PKHSSW$\ELY:=9%<&>3:HD8,Y5=V$)90V5P<C-
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M65Q;"20M&JA?DVKT SD^OY"IKOQ#:6>H?8WCG8J\4<DJ("D;R'$:L<YRQP.
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M)YHD .'80% 2<@GID\U=U;2=2D\22ZE9F=-L=@B>7-M5PMQ(9@RY^8"-^_\
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M5*D;B-X*G) Q[FL%=%UZ[MX?/%_'-;)=".X-UMED9HX]C-AVVY<-\H.WY<X
M.*Z*Y\7:9:7=S;S&0-!;-=9&TAXUVY( .1]]?O #WP#2/XPTN*_M+*5G2>Y6
M)@I9#L\QBJ9PQSD@CY=P'4X!S0!SVK6'B?47U2$6LXBGTV>W*^>#'*[0*$(!
MDPIW[AP@]V(-;<FGZG'HNM16HDBNKB\>2!HW ;:2O(/0< ]:N:CXEL=+N;J&
MY6<"UMUN)I0GR(K%@@SGJ2I  _'%4V\<Z4+(W2)<RJB2R3+"BN85C(#,Q!P1
MDC[I.<YZ D &7?Z?XBBCEMX/[2F@3[4+4Q78$BR'886=F8%D'[S@D]L@\5JZ
M3IEW:S^(A/%.7NYA)'(TVZ.3,**=H+';A@PZ#C'8#$^H>*+.TLKN52WF0K<X
MW(=NZ%=S9QVIS>(X6OOLT4,H"78M'ED3"%]A8A3G)( '.,<^M ')V>F>*+?2
M+:WACU""WC%LD\,LXDE)6.02F,K*N%W>1P'7[K8'8]#J%MJW]C:-%F^N6C*B
M^^SR+#/)^Z8 YWX'S[20&_,9R^#QIIUQ:+.D%X#(L+Q1/&%:5)0Q1ADX (1^
MI'W?<9MR>)+./3--OS'-Y>HE!;H0H8EE+#.2 . >,Y[#)XH Y?1])\46?]EP
M/)- EM8V\:*N'B4K#M='_> 9W]]C'I@]:GTS2O$4UM90W]UJ**]RINQYOELJ
MB"4,0XE<D&3R^!M QP ,UT$WBC3;>-Y)&E"K]HSA,Y\EPC@#N=Q 'K527Q7]
MFU5+>ZL+J&!H(W8M&"T3-*8_GPQ&W.WIGKGH#@ Q!IWBN+3K=#->2%X;.2\W
M3;Y#+ME$X3#ICYO).%91C.,\@R/I>O37VG+=K?W0ADLW$WFHD85#F3S$#G+Y
MYR-W;!ZUU=QJ\%OJ2V/E322^6)9&C4%84)(#,21P2#TST/85G)XQL'B#BVO=
MT@A:&,Q#=,LI(C9>>A*GK@CN!0!1U?3=377=3O+"*\;[1:6B!XKG:"J3-YR*
M"P"N8V^4X')/(.:G6TUI_"UQ C7<-P]T/LX>8&>.#S5X9\G)V[NI)Q@')JU'
MXOTMR"3*B"T:\D:0!?*C7<&R,Y)!1@=H.,#/49@C\;Z9/;B2"&ZFD,K1>3$J
MNV1'YAY#;<;>>OMUXH SKK3O$B:KJ MKB\%ND3K9X?<KI]GVJK,TO#>;EMQ0
MMG'S8)P3Z=KT'[G.IW-E]H5V$5V!,08,'#%A\HEY*Y ]MO%;^E:\FK7]W!#:
MRK# D;I<,1ME#H&&!G(X/<5KT <!I&E>)K5]/AE>XABM[*&-$C(9!MMPK(W[
MP#/F9.=C'[N#C.-S[+JMEX2LDB:[N-0C>VEN TP:1\2(9@"QQRN_C('85T=%
M '$?8?$UPAN':]AE0O)%#]I4#<;IF4, V&Q"5&"2,>X&"XT[Q0D=U):SW1FG
M%YN#SA@H^TJ80@+ *3#YF,$=LD$#';T4 <=8VFM176G?:_[3N+4%R DHC:)S
M(I7S<RL70+G&68XSD9Q6?!8>*UT6X-S+J$E]^Z+0H0JR2#>7VOY^X(Q*CY=@
M&%^7[PKT&B@#C+F+Q )M2"6=Y+',8BK?:BIC^90RH%E&X 9.1Y9/0Y-10V'B
M$:9/<WUY=6]Q;:5$82UQA/M"M*7+A6.>!$"22,$\GFNXHH Y"XM-0UCP-#+-
M'=/=W%Q#?&!)C'(B><LGE@Y'*I\O4<BJLFC^(+9]1N-+>XBN+E[HHLDX9%S$
M/*;:3C.\#GKUSQ7<T4 <M:6NN1^%-2CCENC?ON-JL^ Z#8HVAFDDSR&(+-P3
MZ 5CW>EZU+(DZVFKM;QRS_9HUO%%Q$K11A=SF3)!D#G&X\8SQQ7H-% '"C3-
M;M5U,FVO)[F[GMY'FBNR$QY**Y51(AR'1N 5X(Y(&*DLM,\17 TU-0DNHPZV
MHO7BG",=MO*).5.?]88\X_#UKMJ* .*M-,\13G3TOI+I%9+5;QXYPCG;#,),
MLIS]\QYQZ\5F6%_JJ>*M)L-4NKM9(8H%E19QF1_*?<&0.-P+%6+A6 VXSC./
M2** .5N;36I?$SD"\%NURNR5+@+ MKY(#J5#9W^9N(.,C*X. 14$&DWVG>"_
M#-JMG//<V!M7G@656<%5PX!9L'!/3.,=.*[&B@#BY+7Q'<:OJ$[2W]O#)&_D
M+$$;:AA 5>9=H=9,G.WJ/O;338X/$P-DT4%PDHMYHRLMP3%&W[S9(<R,6)_=
MY1@^,C##:<]M10!Q-GINNSS6T;G5+:P,\1G6:\!FXAE\P[E8D(7,(P#U!( %
M:LME>6GB>Q-C!.=/(<S*)-L4;,9&9^'^9BQ&05(Y!!&#70T4 <EJ%OKC7>LF
M"._,K%?LDD5PJQ>3MCW(JEAB0D288CJ1\P%4IM,\17%O.()-2@A6&[>TC>['
MFJ^V+R0[;CN^<2D9)&" WI7=44 <5J%MXE:;4Q:+=%)'A99&DP0@==Z1J)0/
MN[CN'EGMDGD":9XA_<R&ZOG,*6QC#2B,,?M#F0.N]MV(BH^8G(Y^]T[6B@#C
MTT*[/@CQ#I(ANEN;A[[R?,N2?,\QW:,JVXX!#+G..<Y'7*&WUH:M#)'%J,4"
MR0-$TMT#''  /-65=Y+.?FYPW5<'@UV-% &!JDU[J6D:;<V=M?+!+*DEU;QN
M(;CR2C< [AM.XH2 P. 1[5!X?L-96_2?5IKK;'91+&C3@KYA>7=O"G#.$\H$
MG(STKIJ* //M5?Q';3ZG<^7>P6K,$01SABQ^TQJA0ER 6C+?PH!G!SC-0WJ>
M(@T-E NK"66WOI+.,7:[XF#Q"%IF+_, 6;C+<'!!KT>B@#D+C3]94232-J$Z
M2:BQFA@NMC?9@K[!'\PV_.4)P0Q&1VQ45K:>*XI;-)FEEB-LL\Q,ZAA*B.OE
M$C^\3$20",H_J*[2B@#BM"T_73>VDVHPSB.&^>1!-)N:.-K8+U,CDCS"W4]^
M@'%.OM/UV[U.\CVWOER/,K2"Y"P-;F A$50V0_F%3G /#<X(%=G10!CZ(6M=
M,CTQ;>?S;*UB5FD?*LY7)0,222,#/8;ACVYS2].\27(@AOS?VUL]ZLDJBZ(=
M8_LSAEW^8S8\W9T(]0 *[NB@#B]'.OC6],L;^>4C[!#>WA+@E9A&8FB..,,V
M'XX)1JFOHM?35-1DM8KR6 RP2QDS!?E26,O&B[]I#().2$/.#G.1UU% 'GMY
MI_B2X=+Q;74$O3%>) R7,:^2[7&Z#S</\R! ,@;A@8P3BK5Y:^)3)?I;K=F!
MKU9#(TOSO$3)E$42C 7]WRI0E>""0<]Q10!P4ZZ]8WFFM=2ZC(OF640G614C
MP7Q()4#G+$D<C=VP>M#1>+I=/,7E7<;Q06T4K-*A,S+*WFLFV0'E=O)*DCI@
MUWM% '%IIGB'?#(;J^<P):>6&E"!O])?S@ZAVW8A*CDG/7[W2S8Z;JEAX3U>
MTLX[F._-S=/ 99PY<-*S*49F(&5(ZX^;)/<UU=% '(Z?I^L2ZE 9FU&#3$N9
M)$BFNLR!!''M61@Q+ R"0@9/! /'%==110 4444 %%%% !1110 UT$D;(2P#
M @E6(/X$<BL=/"NDHN##(['>6=Y6+,6='8DYZEHT_*MJB@#)F\-Z7<)(LD#$
M2"=6_>,,B8@R=^Y ^G:H[GPII-U*)9(90V]W.R9UW%W#D'!Y&Y0<>WI6U10!
M1.D61TRZTXPYM;HS&9"Q^;S69GYZC)=NG3/%4D\*Z9$RNGVI9A(TAF6ZD$A+
M*JL"P.<$(G'3Y1Z5MT4 9W]AV/V"_L2DAM;\RF>,R,1^\SOQS\N2Q/'<U0NO
M"%A/!#"#(0M]'>R/-(TKR,@P!N8YQ@!>_&1CG-=!10!0O=(MK^\MKN5ITGME
M98WAF:,[6*E@<'D$HO7TJNGANPCLI;.-[M+>3CRUN7"H.?E49X')X]..PK7H
MH Q'\*:3(<O%,=L*PQ#SW_<JK(PV<_+AHT.1W6I_[!LQ/!<>9=>?"NSS/M+[
MI%W;L.<_,,DXSTR0.#BM2B@#-;1HI]*-A>337(,OG&5I"KA_,\P%2#E=K8VC
M/  %+8Z)8Z=*DMO&XE577>\C,S;V#L22>26&<UHT4 9$OAG2Y]1FOIH9)))G
M,DD;3.8RYB\K=LSMSL^7.*G@T:TATV;3V\Z>UE0QNEQ,TF4(V[<L<XQ6A10!
MB3>%-,N(4BG-Y*%C>)F>[D+/&V-R,=W*G:./KZG-EM"L"Y=4D1]\D@=)64AI
M!AB"#QQ^5:5% &(/">DBW, BE$;02P.!,_[Q)6+/NYY)9F.>V>*GNO#^GWFI
MIJ$R2^>IC;"S.J,8R2A*@X)!)ZCO["M2B@#&3POIL=DMFGVI88V1H5%R_P"X
MVYVB,Y^4 $C [<=.*E;P]IQTJWTT)*MO;R"2(K,^]6!)SNSDGD]3WK4HH RK
M3P[IUE-920I-_H47DVZO,[+&-NW@$]<<9J1=#L5OS>A)/--Q]JP9&VB3RS'N
M"YP,JQ!_/K6C10!E6?AW3[":"2T6:'R8DA"I.X5E087<,X) /4_CG HG\/:=
M<ZI_:$J2M,61V7SG$;,@^0E,[21GCCK]!6K10!SZ>#-&CTZ6P5+D6TJ)%(GV
MJ3YHU4J$Z_=PQ&/QZ\U;?P[ITDD;LDN$N/M003,$,NX,&(S@X(!%:M% &9<:
M#I]SJ0OI4D,NZ-V42L$=D.49E!P2IY!([#T&'2:'82Z0NEF-Q:JZNH60AE97
M#J0<YX8 UHT4 8\7AC2H(3$D#[2$4[I68G9*95R2<_?8GWJU/I-K<:C'?DS)
M<(JH6BE9 ZJ2P5@#A@"3U]3ZFKU% &0OAK3EF\_%P9_M"W/FFX<OO52@YSTV
MLRX]":IW/@S3I+0P0-/#^\A*MYSMY4:3+*4C^;Y 2N/EQCC^Z!71T4 <W)X*
MTV6YB9GN#;+#+')#YS_OC)('8R-N^8$@Y!]?3BK_ /PCNGXNDVS>3<LSR0^>
M_E[F;>Q"YP"6YX]3ZFM6B@#/O]%L=3F66[B9R();<J'(5XY  ZL <$' Z],4
MVWT*PM[2[MBDDZ7@*W!N)6D:1=NW!+$G&WC'U]36E10!F1:%9QK"&-Q,82Q1
MIIW<C<NPC)/I_CUJ,^&=,^SB%8I(P#$4=)65D,:[4((.00O'ODYSFM>B@#)3
MPUI4=K<6PMB8KBW%M*#(Q+IN=N3G.[=(YW=<G.:5/#]FEQ#<"6\,\2[3(;J0
MM(N[<%<Y^8 DX!Z9(Z$UJT4 9VH:'8ZG)(]RDA,ML]K(%D90\;=00#SWP>V:
MCN/#VGW%R]T5FCN'E,IEAF9&R41",@]"L:<=/E!Z\UJT4 8VK^'8-9N[22XG
MG2*"*6)DBD9"XDV@Y92#C"D8]_45+)X>TZ2"6(1/&))TN-T4C(R2*JHI4@\8
M5 ,#CKZFM2B@#*A\-Z5!<V%PEN?.L/,\AS(Q(,GWRV3\Q)).3DY)]34#>$M(
M>"*!XIFABM#9QQM.Y5(RH0@#/!*@#-;E% &++X5TF=[HR0RLMRLJO&9GV+YH
MQ(57.%+9.2/4^IS=DTBQEAU&&2'?'J))N5+'Y\QK&?I\JJ./2KM% &7:^'["
MTG2=%E>=)3+YLLS.[,4V9))Y^7C%0W/AJUO=??5+F25P8K=%@61E3=%(\BLP
M!PWS." 1QM]ZVJ* ,>?PSID]M! 4FC6!9$0Q3NC;)#EU)!R0<#CV'I2R>&=(
MEFNI3: -<VPM9-K$#RQV !P. !D<D*OH*UZ* ,K_ (1W3C?27LD<LEQ(Z.6D
ME9L;"Q4 $\ %VX]_85':^%M*LP@BBE/EF+R_,G=]BQDE%7)X4$GC\ZV:* ,J
M/P]I\5U:SJDN;5WDA0S,45VW[FVYQG]XX_'V&%;P]IS:DU^8Y#*TAE*^:WE^
M84\O?LSC=MXSC]:U** ,^71;*72[;3BDBV]MY?D[)&5D\O&W# YXP*BD\-Z7
M*A1X&*D3C_6-_P MI!+)W[NH/MVK5HH I6FE6MG>W5Y&)&N+H*)'DD9_E4L5
M49/ !=OS^E4(/">FVUM;00O>HMJNR!A=R;HTP 4!SG;A5X]@>HK<HH QQX9T
MU;^:]07$<\H?+)<.-I?;N*C. 3L7GV^M+:>&M-L)H9;19X6C0(=D[@2 ,S#>
M,_-\SL>?4]JUZ* *%UHUC>F[,\18W<212D.02J%BN,'@@L3D<_E6;J_A&SU7
M3)+4W%TD[6\L"W!G<MA\9#?,-PR <'CC'0FNAHH Q+CPII-S<74TL4S&Y659
M$\]]F)%VOA<X!('45<_L:QW;O*.?M/VO[Y_UFW;G\NW2K]% ',:KX*L;VSM;
M>V(@%NL,8#[W5HXED5$.UU88\UCD$$]\CBM&308;S0H-+U&XGND2,1ROYC)Y
MW&#NP>0?3]>]:U% &)+X3TB:XN)9(9F\]959#</L7S""Y5<X4DJ#D8.>:F_X
M1ZP9&643S,R*C/+.[LP5RXR2?[Q_ITK5HH H7&D6ESJ,=\_FK.J",F.5D$B@
MY"N <, 2>#ZGU-5;3PMI5GL\N*5C&8O+,D[N46,DHHR>%&X\>];-% &-)X6T
MF7REE@DDBB$@2%Y6*#>'#';G&2)''T/L*FBT*SC6$,;B8PLQC::=W(W)L(R3
MTV_X]:TZ* ,NWT"QM&W6_GQ?)"A"3N 1%C;GGT !]1P<BM2BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHJO?I-)IUTELVV=HG$9]&P<?K0 L
M5[:SQ-+#<PR1HH9F20$ $9!)],<U*CK(BNC!D895E.01ZBO/M(L[^*ZL[VS@
MNX+.1+1_-\Y5@6!8 )%=-V=W&!E3@@8QS75^%(Y(O"6D)*K(RVD?R,,%1M&
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M=BL"R@ X9@.H/0FL1+'Q,8]3-Q<WPE9FVK$H*L/.!4H?.! \L%2%"'!/\0%
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M[4X:1'(+*Q!Y&0..WT)H DU#78]-U:VLYK:4Q2VTUR]R"-D2QE,Y&<_Q]O\
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M(^@Q_%66TGB2STZ674+J^\V2ZMHI(H8U!RT^&\IBQ&"IQ@ <8Z-FO1*,9ZT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM[.,2&!-L;QPNWS>7@'+L,GL:<VLZO%XEAA6]F-D)(8F=S$T>6@9L$JNXL6
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M^6+@1^8)/,VXZYCVYZ]JSX/$VN1VSQW%T6O-,TT7\X\M0+N,,K!NG!:/>O&
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M !1110 4444 %%%% #)94@A>65@D:*69CT ')-8S^+-+CMX)W74!'<.$B/\
M9UP=Q(!&!L[YX]?P-;,RL\$BILW,I WC*YQW'<5S-AX8N;>UCA>>&**._CNH
MK:(LT<"*H!1"W(!()QP!G % &L=?T[[5=VJRRO<VD:230QP2,ZJ_3"@9)Z9
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MHH 9'%'#&(XHU1!T51@#\*;):V\L2Q201/&I!5&0$ CI@5+10 FU2X?:-P!
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MD,:J,8 4 <<C\JEHH K#3K$(4%G;[2V[;Y2XSZ].M6-BAMVT;L8SCG'I2T4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&1V%>LT4 >9&[\<6U[<230WURD<UI++Y,:JH0.@FBC0CY^-YW ]." <4Q?\
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MDK^4=N]]NQ W0L=Z\=N^*:GBK2Y([*57E,5Y)Y,<GEG:)-_E[2?7>-O?\N:
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M?*WEECP<Y"] >O7GG%='10!C3>%],GB".DO FVE9""IEE69B#ZAT4CTQ2?\
M".Q?V[IVIO/)*UE!+&IE)+.[D89CTX&\ 8XWG&*VJ* ,R[T&QO8[Q9D?_2Y(
MY9"&P0\>W8P]""JG\*KW'A;3[J 1SM.[!$42%AN^63S%.,8^][8[8K;HH PE
M\(Z8EK]F3SUA-LUJZB4_/&Q+<^X+-@^]$WA/3+@W0E\]HKA9@83*=D9FSYC*
M.Q;)^F3C&36[10!D7?ANQO7E:4S;9KE;J5%?AW5449],"->F#UYY-(WAG375
M%*283S,?.?XY5F;_ ,?45L44 8>C^&H=+NI+MYY9[AI;EDW,=D2S3&1@J]OX
M0?\ =XQDTC>$M,=I]_GLDHE"QF4[8O,8/)L';+#/?'08'%;M% %>XLH;J>TF
ME!+VLIEBP<88HR<^ORNU8ESX0MGL);2TN)[>.2XBF #?ZO9,LI"$8(R5.,DX
MSQP,5T=% &/!X9TV&*2-HY)1+#+#,97),JRMN?=[D_ET&*8_A>SET];&:>ZE
M@$@<JSCYL8P#@=L#GK[UMT4 8T?AC3XA,BF;R99A-Y6_Y582"7CC/WQG!)]!
M@4LOAG3Y7W'SER+A7"R$;UG(,BGV)"GCD8%;%% &'9^%-/L1%Y#W >*Z%V'W
MC)?RQ%@@#&TH,8Q^M)%X3TR%K?R_/6.%81Y0E.R0PG,98=RIP?? SG K=HH
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M0,G)P.II:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]/M&GN4M98=MT2@2??C<=G4;#T'.:Z.UL]+_ '+P6-O&8&>.'_1Q&4P2&VY
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MM[6V\U^56W65L!(F.><DG(Y/(VC,]OXEOKK6X(+:&-K6:Z,;F>3#(OV:*4;
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M;RBQ:1\-@*<(%  ;N0PQQD@%<>$]8OK32)[A[2.Z\Q+R\W(-Z3&996"MM8D
M#8 &7H,YZ59;P7EYGF2VD$MM=0M,B_OHB\KR(R<<D;O48(XS4R>-)9$C==-0
M(B0-= W'S(99FB C&WY\,AZ[<\8YX#;3QVEUJL6FC3V%S)((,>;D>:LFV=.G
M\";7S_$#VZT 6;'1;Z?PE;PWA2/4KBXBOKO/02><LK+^ &P>P%/T3PQ_9&IK
M>+]G5G2Y$YC7#2M),)$)..=JY'/3/%2>'?$5QK8_?6$=LSV4%[$%G,@9)=^
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M"C7,S*Q.8SS@8![8S@YP-4>,IT%X?[*E>"V>2!9V=@&E258L,2@4 L2<J6P
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MX96+A<J+QX57IV 7GO6CHOB*;6-1N(1ITD5K&TR)<'=@M')Y9!RH&2<D;2W
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M .9NK60C48[30;^.&=(8X5:VD9E\O;M?<T9. (X\QG<K;3TR<I<V=S<O<?\
M$LO8Y,2F&[339%D.ZW,*QXVX2-0Q8 $Y(' YKHM=\875K#JMI%%%'<0:?<2I
M<12.X2:.-6*_-&%."W8GIR!G 9K'BN_2QU2-8Q:7MI!=#,$HECW);I*C L@)
M_P!8...0>HH Z+1K&UMH=UEI\5E;/!&J*(S'*,%CAUQQC=D=\LV:YNT\+:I+
M%X>,GV:$:;!:Q.&51(&A8A\-M)*L.F&4#G(.[B\/$&JG6S:6EK#<1_Z9\LTV
MQBT1C"JI"8 ._'.3SUXYLP>+8+KP[?ZY!;L]G;+NB.[!F^16/;Y<,Q4^A4T
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M8F7S!+NV,?,/&[&W)4$$#@6V\'&(0R1VNFW+_;+JXGBN%PDOFNS*Y.TY9%;
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M+/O+"&81-N&T;<D@C!/>@"CJ/A^>'P?+I5M!!.6U%9HX-N(Q&UX)-I'90AY
M[ XJB/ UT9K220VQB1Y6-M')L2VW3>8/*/ED\<#@)D@'(Z4]O$VNA8+C[+:.
M5GU!6A6X*JZ0.RJ2Q0D'Y>PYZ\=!JZ=XIDU/6C9P:;*;57$;W!W?(QA64$_+
MMQA@OWLY(XQS0!6C\&0J]I+Y=J+B+4+J\DG6,;SYOF[,'&=R[T_[YXZ"J5EX
M&D"P)=PZ<L,9M5D@B4LD_DB3,C @?,V\<'/W>6-2:SXIOHKUUMXTAM();J)G
M68&61H[9I/NE"%&[&#D]!D8-))XKN-/N=0DG,D\<!F=(\J 0D%NP4X4D_-(W
M3UZ'@4 -O/ $=U'=L([+[1-%J 64Q\B2>0-"^<9R@!&>HSQ2WO@V_O\ 5M1N
M)9;,0W,$T("H%+AY(V7< @/ C(R6;).1CI4P\9WQ%L@T-WGF$LHCC>0[HDD"
M!E_= Y;.1N"C&.>:;J/C'4(;+4I(-.MU:&"^DMGDN"0QMI1&V]0O&<Y&">F#
MCK0!*OA*2VU.*>&WTZ:TCFG9+692$A$AC8.@"D;@4;CC[YY'.;'A?PU-H=S<
MRSLDDD@V>>LG,PWLVYUV##<]2S=3S5CQ%XAD\/Z2ET]M#+<;&=H!)(<A4+-M
M*QL2!CJ0H]2*S9?$FM?:;M8+2Q,4>JP6D1>9@3')%&YSA3@_./S]LD J6_@.
M4VJ072:>1&+5&95+?:_*G61I905^^RAACGEVYP:UO$?AI]7O3<01VF]]-NK$
MR2C#QF0#:RD Y P01QPQ^AK#QG<NEU+%H[M#',88I&=D5G%PL&&)3 R26&TM
MPIS@TR3Q3J;SA!9V\,:6E^\^V<LRR6[H@*$I@@[L\CO[88 AU#P,\AD2T6T6
MT-UYPL^(XR# L1_@8!LJ3]T]3T-7/%'AF]UG1;?3[.6W41P/$6GPS*Q4!7#E
M&/&#G&TG@[ACEI\8RQMDV*O;K(;?S#/^\,HMS.<IMQMP,9SGOC%:&E^(9+RU
MO9;VUAM&M8DG.)RZ;&3>"6VC&.<\'IWH Y+_ (1C4-0UG6!):M%)<&X"73JH
M54,R,J$[<N'5 /O-M&1@9VUIR>!3/9!&CM4E2UN$B#-Y@AFDD5PZ'8N,;2>%
M&">*FC\:7=Q&R6^E1-<K<20E9)Y(TPL"S;LM$&Y# 8*CGVI5\576HZSI<5I"
MD-E)>I!*SR_O'+6;3A=FW[OS)SNSE3QB@"_;>'5M[/7+4VMH4OY99$*,4+B1
M2"'(7*XR1D9.#GVJ%O#UZ_A*#3)39R317"S&)@!#(BR[Q&VU #Q@%MG)YQ3[
MOQ-+#JD]JEHAMX[H633>=^\$K0B4$)MP5PP&=V>O&!SE:?XSU!-"AEN["*6:
M.SM;F:=)V9!%*CGS'VQD@@Q'(52!N!SC.  C\&ZE;V:6]N]@BR!UE5=RK$OV
MIIU" #GABO.,8!YZ5)-X*N'M+JUMY+6T$DEZR30@ACYX;:6&!RN['4\#MT%B
M;QI*G]J2PZ3)-:V2SXE#LH=XL<$E-H#'."&;H,CGB:?Q9)97TMA?6<$-W%&;
MB3%P3&MN(F8REM@.T.I3IZ'VH I0>$+F#[!)##:0SPW9G<F7S$13Y>X*GE!<
MD1]@I!Y!Y.=K6+6]NM-M&,:/<07L$SQQ$D%5E&<9QT7)^HK,LO%.H:AJ=G;1
MV,$2M=2V]SYDD@8;8UD!0-&IZ/T8#D>G-,TKQA-=6NGR&S#PR"TBFEDG'F^9
M/&K@A @# ;QD_+_%@<4 4I_"%];PZS+%!9F2Y@U".,P ^9<-<R[T\W( P@XZ
MGJ>G?<U_PT^OBUMI;Z6"RBAE5_*"EW=T\L'YE( "-(/7+#TI?#OB.?6H]US8
MI:[K*WOHQ',9<QR[\ _*N&&P\<]1S6+>>+-4O]*A%G;0VLUU]AGBD6YW$03S
M!,$F,A7QQT(Y)!.* -35= O]4TS2H[K[#>7-LI%PEP#Y4CF,H7 P>03D#'<C
M(ZU2LO"5_:RV,+R6<EG$\$LQ)8LS);>05"XP0< Y)]1CO6YX@U&ZTW0Y+NP6
M":=)8TQ,Y"\R*IR0#SR:PW\67NEW>J/J%JLMG#/*L;12Y=3':K,4"[1D</@Y
MSDCC% $%CX2NK&X\.V8B@CMK>W6._P#('R3>0P:!N@PQ=BQ&#U;DXR=+4?#,
M][XA^VXM&C:6WE$\F?.@$1R8TXQM?D'D??;@YI\FOW\OA+6=1-D;.YM+>5X2
M=S*Y$6\,-ZJ2,\<CM6;-XIU+0=&N;O4('N IDEMUN!Y<\D"1JSL5B1E&&+#)
M"C&W.,Y(!HIX4C7PA:Z'Y=KLCN()95"?NW"3+(PQCG(4CFLR?P1<M&88_L31
M,)DB9P0;)6N'E5X1C[P5E&/EP47G K0N_$6J_:&6TL+00IJ:6.^:Y8%P1EC@
M)\O4 <GO4,/B^X-XME#I\]W()I?-;)RJ"YDA&-J;> A/S%> .2230!!<^!I9
M([HP2V\,]RMZ)9%7!E\ZY25 YQR JE#G.-QQFI;?PC/!-ILB0VD9@ED:7=+Y
MJA'8%E53$!SCJ-A!_O#(.WH^LMJ3W45Q MK/!*8_)+DMCDJ3E0.0"1M+#KSP
M:R+SQ/-;^-X;!6/]G*R6LY\AB!/(I929,8&/W2XSR9O84 2P>'+NU\$0Z'!'
M8)-"(TX4&.559220R$!F /\ "V">^,U0M/ TL45NT[VKW%O':)#)MYC\JY>5
MMIP, JP7C'3TK8\.^(I]:8"XL4MM]I#>1;)_,RDA88/RC!&SWZUD-X_Q$Y2Q
MCD8O$(66279(LB2.K#]UN/$1^ZK Y!SC. "YX>\,7&D:PUY*MD ()(3+"#YM
MP6EWAY,@<]>YY[\X&?=^![HVEM:V9T^*..ZGN&(B565GG$BD'83PH"X!7H.3
M@"KT/B^[DO&@;195\A%^U$.Q\ES )L9V;2!E5SD')^[Q42>*]4N)+&--.M(9
M9KB .K7+,/*EB=Q@[!A@5((P1[\\ %W2_#'V/61J%R+>9D-R8CMRR&6X>7(R
M.#M< _C6;J'@N[O=3O)TEM(3.UPRWJ@_: )8#&%Z=$)!'/( Z8YU=6UVYTW4
M+N."UDN1#;02E-WRJ'>16;"HSG 3)QGV Y-.UCQ%-8V]I)96D%X;BWEN 3<%
M$VHH;@[3G(/' H YZ]\#:A<:!+86XL+=IFE+C<KA&:-45T/DC;C;RJA2>#N]
M="_\'W%[-=L9X-EPMTNU@>DKP,,\>D+9^HJ9_%T[SE;:PC:%IC;1O).0_F_9
M_/&4"G"8XSG/?&*VM!O+G4= T^]NTB2XN+=)76)BRY8 \$@>OX>_6@#A=?\
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M[3R"I&./O'GL0"];:=H\]I;36]A:>1Y.(<0* L;<X QP#UQ2W^BV&HV4EK-
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M#A@S#:,,0.F#]35*]\&WMQ/?>1]BA\T7/EW09A*ZR0M&D+@+PBD@C!/W%XH
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M6VM;>RMTM[6"*"!,[8XD"JO.> .!S4M% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445%-<16Y3S6*
MAR0#@X& 6.3T P#R: ):*K0W]K<W+V\,RR2)#'.=O(V.6"L#T.=C=/3W%6:
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MV9&%K!;E87$1V1@!6CX Z?P]O2I8["SBA:&.T@2)G\QD6,!2^<[B,=<\Y]:
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MHTV'[1#;3W5U ]RT9A6+9N7YHP2_SCC '?=@BNB31=*C,)33+)3"I6(K HV
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ML'.[GZ]:S+3QQ=V^B6LTMNU]>RV\#;-VS>QMEE;&U"<DG &,9(Y'%:,_C22
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M%#I5U=/.[_O%DB\L @;=IY?VS[8P0#.M_!ET+V'[4MG)$ICWW(=O.$8MQ$T
M&W[A8%OO?Q'Y<\U4A\#ZXUO=)>:E!,\]E*I.Y\?:O+:!).G"^41G_:'>M+_A
M,KJ"&.";2R^HM*L0CCD9U8&'S=Q*1D@XR,!3SWQS5_7/%']C:'#J1LF9W@:=
MK60LLJJJ;F&%5N1T.< 'J10!CZUX4O%@U74+-8VO9A<D-%GS7C>WV*@..S@-
MCIW'-3:'I-S_ ,(CJ=E;V,%K//.Y7SHML4N0N6V&-=HZK@H?NYPP/,USXV,%
MUJ"KIK26UFK[I5=BQ=610I 3 W,_&&)PK<9&*+GQE=6UL)7T616C@N+F=9)&
MCQ%"4!*;D#-D." 0O0].M &<G@*:33##<QZ>\XL=0MHRRAA&9Y T>"$7 4;A
MPHQG@<UJ?\(B&U.%Y([1K&*\6X6WV_*%6V\H#;C'#X8#VSUJ>WU+6+MK^;R(
M1'I][*GDP/N>ZC6)L+\P 5MS(<@]B/K+_P )&3X>BU%;>-YY9TMA )&4+(TH
MC 9F0,N"><KD<\'N 8D7@-HMDJK9BZ58F\T9SYJS^87SCKL^4'KVZ5%+X*U"
MYFU*6YBTN43S02K#@".0QW'F_,!'QE/E).\\GDBKMAXOGCTZXDO[<//$URY"
MR# 5+IX50' S@ <XYQZFB3Q==6=K+>ZC;(D,%Q>KMMGWEXX%<\AE&#\G8_ET
MH 6?PG>RW*2)/!''+=2?:HPS8:V9T?8..N8]O8;7:K/AKPW=:/J5W<W4BR/*
M7'FK(,R@N6!=1&IW '&2S8Y XI8_%-UBW-SI,ELDESY$DTID6-00F&!,8;DO
M@;E494C=TSTP.>E ' 'P3J#6;Q-'IQ<"$2'S&Q?LEPDI>;Y.&*HP_B^^><5:
MM_"%_$D.'M(0LJN(8F8I$HO%GV)\HX"*5' Y[ =(8/%FI00VM]+&MS:RZ=]O
MF0N$:-6EX"X4[BJL !QG;R<GG=AULV>G:[<WSF1-,N)1N  +)L615 '<!POO
MCUH X[1?#VI7-M>H^F0I<S>29Y+N(*' :0E/GA(+@MDOB0$8&[@&M>S\&7ML
ML!86+7'V'3H)KK<?,+V\@9^=N2K*!R2.5&1W%W0_%$C^%]1OM4*RW6EB1KKR
M$*AP$\P%0?\ 9('U!HT_Q)??VO<6FI6\:,UV((TBF#K$/LWG'YMH+9P>HXSZ
M"@"@/!5\YD63[$@;*RRH[%KW-Q'+NE^488*C*.6^^>0*MP>%;JTU"PEMH[-8
MK6ZG=06RL<,DA;8B%#@XQ@JRX]QQ19^,;F827EQ8P1Z;Y=G('6<EXQ.!DL"N
M,*6Y.>@)K2/B"5],TJYM[(-/JDFRWBEEV* 4>0%FVDCY$)Q@G) ]Z (/$]Q,
MV@Q6=S:SM-=&,3K9V\MPBH'0RKE5SRNX#(&?;FN=CNBWBO\ M2?3-1V1W33I
M<#3;DS,AA\L0X\O"H"2W#') .,DUO:%K=]K?B!WQY.G+IL$ZP[P3YDCR@Y^3
M)QY9 PV.,X.[Y:>G>+[U;");VR62YE"?9W$P E+S^4-^%^3!*GC=Q[\4 <Y=
MVD-W+>O)H=R3+<75TI.E7!\V1D*0F0>5T4,^?O<\CKQ>T-H].UV6^O+#6;@H
M"MO/]@G+A-JJ%*^2#@ =W89YP">-Q_&DR _\2L$P"0W7^D<1B.;RFV?+\_/(
MSMXZX/%2)XON)VO3;:)=316[2HDBK)AC'*(FS\GKN8!-Y(4\9X(!R-Q+J%WI
MD-E/I=\8DO9[F5%L[@K<>8TC?-NMV VE^%P>QR"HIEW!(ZZC':Z/?+'.8A 9
MK&XD9?+& 6+6Y++A8\QMN&<D,.*[S1M;NM5U:YB\JT^PI:P3Q2PS,[,9 21R
MHX^4\\'CISQ13QH\TT\$&GI+(LD"PLLS".59G=%;<R#@&,DE0PQT)H Y">UF
ME.H2_8M4^U32GRI5L)UW0&96,1'D' \M F"7'!X )KO/#%C':Z? \%C]GC:'
M_EH660,9'9E*%%PN6)' Z\* !65=>,+RX@@%E9K"XDM/M3O,#Y8ENC"54;?G
M^XXS\O!!'/ O:IK%_9>))5W1+86]DLNQI-OFR/(44'$;-U  "G.3T.<4 ,T#
MPWJ&D:HE]/?1SM<0.+U N!YAD,@*'&2 SRCYN<,/3%4YO!=PMI<16;6D#2_;
MRVP%0YFE5D#8']U=I/;MFI5\9RR0K<1V+M(P6(6S/L'FF[^S?>*A@-W/(!QV
M!JUXJU^^TG3)8[.VC-^=.N;LL9L+$(E7)&5.\[G7 ( .#DB@#*_X1'58(+HV
M4&F6S7#7*BVCF=8HDEBC3((3D@QYQ@ YZBK7_"+7WF7H,5BTD[Q.EZ7;S@JF
M+,1&S[O[ML?-Z<=35E?%Y-U>1_8)!;6HD5[I]ZH'10QW'9M"DG ().?X>:H2
M^+[J9XI%B>V58;H30@9/F1S6Z*070-C$C<%1UZ< T ,_X0S4+B\U![LV'D7<
M\#21Q\+*J7/FG<HC')3*_,6R2><&M/2=%FM/%E_($\O3(%S9QA=JJ\H4R@#I
M@>6""/\ GHXJ*7QHT!G:;30L0^T"!A/DR&&X6!MPV_*"SJ1C<<9XS@&_'K\_
M_".#5)[.."5I3''"TKD/^\V*01'N.[J $)((H P&\%ZB;N[G5=/25XKI5N!(
MWF7#23QRIYGR\!0FW@MCMQQ5I/"=Q<ZE%>ZE::=,7DNA*F\MY<<P3&QBF21L
M(_A^\>>U30>-'N#;.FF$0NEJT[--AHS/,T*@*5^;#)DYV\>_%3:+X@O-7UU%
M:%(+"6R:>%1('9QYFT,W *G';)'/7- %;2=$U2?P9?P7=PR:I?HZ&5\J0%41
MQD]QE4#$#H7:BP\(M'J5I>S6>G0)!?/<QVL'SI I@$>(R47DN YP!SZGDK:>
M-)[[F#2E*S2QQ6KM<$+(S[SACLPI"QY.W=]Y<9S3H_&AE&]-._=P^4+LF?F,
MO.\(V#;\X#1L<Y7(QC)XH ENM!U"?Q 9O]%?3I+M+J3S';?@0&(ILVX(/!SG
MU&*R(? ,ATJQM9H-/5[2S@MT\LDC<DH9I!\HP64'WR2,D<UL:/X@O-6U^-#"
MD%A+9R30J) S/B4*&88&TXSQDCGKGIG6OBR_L;$3ZE''<237TZF..0DPPI/Y
M0*A8N@]7(S_>YP ".]\$WDEL]M;K8&$K=1VX=F7[#YDI=)8@%/S*#T&W&!@X
MJ:[\(75Q-?L;7398I;Z&[BBN&WEV61F;<_EY *G !WXR0"!Q4>H>*=52RU0V
MJ0A(+#49UG=OWB202NBX7;M(X7K^/3GI])U.6_:]BN;9;:XM+CR'19?,4DQI
M("#@=G&>.H/7K0!4U#2+BX\1VNH"WL[J&.,(!<L0UNP?=YD8VG+$8'5?NCFL
M'3/!-ZKPC4UT]X/M4=Q-;Q >6Y6&1&(41J.69#@@\+R3BM4Z_=IJ5W;Q0K<2
MR:C]BM8GD\I%"VXE9F8*3S\W8_P].35RRU9HY-=-]*!!82A]YQ\D9A20@D=<
M$M^&* ,G2M!U+0K^[OO+2\GGE90RSA?,1Y@VYP(P<HI/5FZ$#&:NZYX=FU>_
M>0M";9UM5>.0GYA'<>8X(Q@@KQ[]^*@\*^)IM3TV_?4<"YM,3.B1E2(G3>HP
M>I4[TSW,9/>HM-\57MQK*QW=JD4-TEKY$:3!]GFK,^XMM')$:C'0'H3W *LG
M@FZ"2+;_ &**1K.\M(KA<A[99)6:()\O0*VTC(P.F:R-:\,WMM#9V_\ 9GVF
M _:))+:$B1-Y\G:J%8 L9.QN=B@98[AN-=!!XQNI6N+LV$/]FQ6-M>,PF/F(
MLDDBNQ&W!"JA;K_#[\7KSQ!=GP_;ZGI]I"YGO8H(UGE*JT3SB,." ?O AAZ!
ML\XP0"K_ ,(AG!*6N^74+FXN6*Y,D4B3HBGCG'FC@\?>Q[TK+PY>:??Z)#]G
MBCM8+,/?16N3&\D!/E;3A?F9I"YX_P"68K;L?$;7>JI;&S"6\TMQ##,)=S%X
M&*ON3'RC(;!R>@SC-8^I>+;Y+F:2&$0V,5O?[6616DD>W=4)*E?E^;=CDY!Y
MQTH V=0TF37[;16U*TMQY$XN+NUD/F+DPR(5'&&PSCKQ@5BV?A#4H)M.,SVD
MLENEF#>&1C-#Y(&](\KRKX()R/OMD&M.3Q3,E[+8C3U6\^U+;P12S,F\'>1(
MQV8"$1L05WYZ'!R*K#Q-?Q:CJ%H+6.XN$G=HXWF$:1Q);P.XWA3D[I>,CG)Y
M % &>/ EY!I:6UM):HQM[1;A%.%N)(G<N6RC @AAR5/W0",5,_@RY?RX@EJ(
MC8/:2F>03$ K)M"#REV@,XY! *C&W@$6Y?&Z1122FPD5&C@>U5RX><2F-00H
M0C:&E4':6(/\/(SHG7I5\/KJ,MD8)VD\I;><NI9M^P8^0N<]1\F2".!0!B0Z
M'>V.LV3I9QI9P68N)[:U.8VN8U9$520H.X.2>!@QI5_Q5HNI^(="@M8H[*.9
ME)F68AA&Y0@%&,;=&/4 $CH15&W\4WFH:G9/"3!;7"63&%E!*^8;@.,D9_Y9
MKZ=.V35NZUO4;/Q#J@?R6M((X([: R$>9(^220L3/NX(P,C Z=2 "O<^#KN:
MYN;N*XAAO9Y9/]*4GS%C:S\D+G&>) 'QG'&>M3Z3X:N+/3-:@^RZ?9&_C"QP
MVCLT:'RMF22J]3SP/SI(O%]UJ&ESWFG:='MBT];IS<3E2KO&SJNT*=PX )R.
MOL:OV&NW,VH6EE>6<=NUQ;+,L@E8K(Y!)5/DP< 9()!]B.: ,=?!MQ-J.;M;
M1X&<F2Y5V\]HC;^28,;?N9.[[V./NYYK/;PKKVK>&X3.]M_:%P)))Y+A=KH^
MU$B9<HY7"H"0-IW'AA@YU(/%\\<VKP-;&YDLKL1C<XCR))A'&%XY YRWMCDY
MQ)-XTEAM9Y3IBF2SBN)KQ/M/")#(4;RSM^<G!(!"^Y&: &OX.\_5EN+JWL[B
M)_MT<I8D.L<[*05.T\@*PQD??//JNF:-J=UX'O8+V7&K:E&QD>0%<':$3(ZK
M\JJ2/4FEF\=00ZI)IS6,GVE',6-XQYIEV1)TZNN7]@*OZ1XBDU+43;26(@1U
MG:"03;RXAE\IMPP-O)!')X/:@"#3?#3V&NC4OW =Y+LS.F=\BR2*T8)QSM Z
M=CTZUDW?@O4;B]OY8VLH9)H[Q5O5=O.E\Y@R*XV\! -G5N,8 Z5=@\5ZD;7$
MNFVKW1DOF5$NBJ>3;R^626*?>Y4 8P>3E>@TI]:NFO=#%E;PM:ZBK/(TSE'1
M0@88 !&?8_\ UZ .=N_!>IRZ9!:VRV,.V224AI%;R7)3:8R( %'RL2%53D@[
MNM7+CPA>7&]6FMS$\TKLI9N5>\2?'3^XI'U/IS4&F>-KQ=$T_P"WV'F:A/;6
M<B&-RPE\Y'.Y@B$J?W3DA5;J/PW+SQ#):Z#:Z@;$I<7& +2<NK[MI8J J,Q(
M"D_=Z DXQ0!R.J>'+NUU2PMQIPNK&&9Y8HHD.U0UR)%13L8)@ 9SL&,@$]NG
MTKP[)!9ZQ97B0+:7[/A8FWOAP0VY]BD]>,Y(_O'M2/CU"9IH]-=[.WM3=3R!
MSO1?LZS?="[>0RKRP.<\8ZROXNOEMP?[#<3DRG;+*\2,L<:N64O&&/WMOW1\
MP/;F@#+B\%:Y):WRWVHV\TMW9SEB&? NY%\L/TX41!5]<D\5HGP;'+J3M/9:
M<]FVJM?."N3,K02)AUVXR'?/4Y&3P>*U-#UBZU6]U(26\,=K!)&L#JY+L&AC
MD^88P/O]C[=LG+L?&ES=&U>72%B@GCLYBXNMQ5+ERD?&T9.Y3D9X&""3Q0!8
MD\-SR:)X;MYX[2[NM*:%I?/)*N5B,;$,5)SD[AD<X'3K67)X&NDLI8[22UAE
MF0_:"O'GG[2)0')4Y!3<F2#C=C!'%63XSN[E_*L;&V=Q<6P#O-((Y(9F=0RL
M8QD_(>0"O.03TJ7_ (325ENI(M'G>&*4PQ2$LBNXG6#!9D"@DMD8+<*<X/%
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MC21ABH888#/3(X/K7(VGA+4;=HG<6C736VFI/=^8?,9X)5:4$[<D,J\$GD@
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M;[$>MOY2^6><_=QCKS]:Y>W\,ZE#=64\<-G"(KQY5M_-WQ6\3%-RJI3EL(S
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M!IO_  G44D$+6^GSRRRO'#Y8R=DY21WC;:K'*+'S@'EA[FM]='TU91(MC '
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)9=S?Q'[Q&"2?]L>M1^'M"UC3-:.HW<ELXOX7-XD:%6CDWET!8L0X4.Z9 '
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M_O+[XFU'Q1;Z;X?M]7FMI1'/&)1"SQI(!L+XPS#+8'09_K3]0\+Z9?V%W9F
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M$(((Y#EMVWJ[<D@8QG%6+G2-'MXKRYN8PD$D3"Z\R5O*9=N&9E)VD[1@L1G
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M"&UW"$0R-&4#'+#*D'!/)'0X'I5JZTZRU!EEN($E(C**Q/\ "Q5B/Q**?PH
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M<L ;95BWJJ[U"L663NI/J :L6/B^/4K^QM[2PFDCN&F2202Q$1-'M[AB&!#
MY4G\\XGO/%,=IJC:>FF7US()EMPT0CVF1H_,"_,X/W0><8XH P[C3]<LX8YH
MWU"18["996GG_P!6<2E=H60DOED7D/D!3N!'-=-)\1S:?$\0OXK=I8GDMI+P
MR3./)8.P;S5P"Y0[=Z_=)P#P=\>,[!I-/2.">1M0@$T"JT6\YC:0*4W[@2%(
MSC&<#-3-XGM+C0=3U2R+M#96QF\TQ[E/[D2C W#.%9<C(ZXSZ &'>:!JUYIV
MKV-R+VYEN; PVUR]YL0?Z.%*NBMC<9 S$[2,-UXQ4][IOB'RYKC2S/#*#$+>
M"XN=V%,1C;=\Q!*LP?J<E.#S5V[\906EW/;C2]0G\EI$,D0BVLR('8#<X/"G
M/('3'6IE\66CW_V9;6Z,1E$ N<((S(81,%Y;=RAZD8SQF@"EIND:O:^*'DGN
M;R2RC.(7,VY'B\I5"N"^=VX$Y"<GG=R139/#EZ=0UC4@[/,)Y)]/M]X1&=K9
M(MS.OSCD,.HQUZX(M6OC.SOP%L[.YN+@SM#Y$+PL?E19"VX2;",.O\6<G&*M
M6?B S:?JM[<V,UO%I\LR'+*QD6/.2N#[=#B@#&TC1-9>YMO[2DNTM(IYI!&+
MMU."L6P-B1B0&$AP68#Z53LM)U;38O#^EPFZ@20&WO ;AGVK&PD\Q3DX#!63
ML?W@X&*W/^$RLDOK2SFM;F&XN%B;RW,>Z,2.4C) <DY*DG;G:.6Q5>3QO&UG
MYUMI-Z[,UN8T<QKYB2S"+<IWGH>QQU';) !=U0WVK>'XY+6VN8F>>-WMUE\J
M5X1(-P#9&TLHS@D=<'%8-OH.MV^D20 7D0*R,L<-R'?<;MY0"2Z[LH0&.X$@
MD9S77:M?'3M$O+\C:8(&EP4WXP,] 1G\Q]:RY?&-E;S72S6EXD4 G_?%4*R-
M$0&50&SGD8R #0!E7&CZU>66J0W5K,]S<V@2!DO28(LPHK1[2V2?,#G<5.00
M=W:GRZ3KDE[>DMJ";_M0>>&\&)8W/[E8D+81U&.2%Y4\G<36F_B.2WU-(KNR
MFMXGCA'E/L:19))Q$N2K%=O(/!SC\JK:KXR6"RN#I]G/-/%YF\E5V1!)FA+-
ME@2"R-C&3@9(% %&'2O$;ZCILMRUQ%!&D0*V\V?+997+;PTO(="@(_>8^8#H
M";FM:-J,FM:A>V"3^9<Z?%"DB7)0!DD<LN-W!97 5@.#DY'>:3QA!:AO-M;F
M?8]P9'AC55BCBF\HLVY\G''3)/)P.E7-.\36NJ:U<Z9;P3[[?S-\I*;<H^PC
M 8L#D'&0,@$B@#-ET74+WP;K^G.D\9O%F%E;SW)>2)3& %9PQZN&/WB &QTX
MJ--!U!=7.HVPN;8M/!A)+HMB(0E6#J&*L0<<G)X!!J\?%<%KH\=]?( TM]/9
MQ(CJH8QR2J/F=@H^6(DY(]NPI%\96+I(Z6UV0EDM[C"!F0@'"J6W'&<$XV@]
M30!#X6TW6K/3;E=0GN1>/"B SN)$\T!MTB_.QP21UV]!\HYK(7P]K$UI&;BW
MORL,EG(UN^H%Y))49O.D5M^ "&7 )&=N< ]>@/BZSWQ;;:XDB98&DFC:-TA\
MYRD>2'^;)'\.[ Y-">(I9K)]6CL;A-,@28R!U4RRE2 I0!C@</\ >QT!X'-
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MX$:82W!D9Y?E+ ,QP.1QR!3T\;VDUNLD&GWL\C2M&(HFA8_+'YA.X2;,;?\
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M& );(PAQWVJ#5&]M=;1O$<-A9SI)>74=Q!=+)&%9!% CJ/G#AB$<#IV.X=:
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M"YNIU@^2Z=)")I,1D!\^9'GYN3\W4]#BLG5[?Q+9PZM=>?>M:KI[B$K.H<7
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MQAD1FC6+YYG<+&I)5%#$A5&XX P.: ,J'QI$VEQ7EQI=[&[1S3O"AC<QPQ,
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M-#/'+,K6\MLS2SN[&.0@NNXG/.T?3'&*D_LFV1=0\G?&U]DRG>S+N*[=P4G
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MK=6]NTWGSW$EP@MS"+)4.5W9W^:HYQVZXR"ZQM?%,D\4RW$\:_9$-OE08O\
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M/J#72"L&#Q5IUQXC;18Q)]H"L0^WY&*_> /J/Z&MX4BA:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH JWU_%81HTNXEVVHBJ2S'T %4AJ]T3_R!KT>Y,?\ \53KX Z_I@(R
M/+G/X_)3]2OWLY+6&W@\^>XDVJF_: HY9B?89^M/0G4R;?Q3>RZE!:OI$BQR
MRF,RAB0@QGD8Z_I[UTZG<,UFV>K6^H2E;>*X:,$@3&(B-L>A/6M(4BA:***
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MBBB@ HHHH **** "BBB@ HHHH **;)(D,3RRNJ1HI9F8X  ZDUSO_"PO!O\
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M_P#&@9TE%<W_ ,+"\&_]#3H__@;'_C711R)+&LD;!T<!E93D$'H10 ZBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DT,5Q"\,T:212*5='4%6
M!Z@@]167_P (IX<_Z &E?^ <?^%7[ZY:ST^XNDMYKEH8FD$,(R\A SM4=R>@
MKC/^%C7W_0@^*_\ P%3_ .+H Z3_ (13PY_T -*_\ X_\*/^$4\.?] #2O\
MP#C_ ,*YO_A8U]_T(/BO_P !4_\ BZ/^%C7W_0@^*_\ P%3_ .+H Z3_ (13
MPY_T -*_\ X_\*/^$4\.?] #2O\ P#C_ ,*YO_A8U]_T(/BO_P !4_\ BZ/^
M%C7W_0@^*_\ P%3_ .+H Z3_ (13PY_T -*_\ X_\*/^$4\.?] #2O\ P#C_
M ,*YO_A8U]_T(/BO_P !4_\ BZ/^%C7W_0@^*_\ P%3_ .+H Z3_ (13PY_T
M -*_\ X_\*/^$4\.?] #2O\ P#C_ ,*YO_A8U]_T(/BO_P !4_\ BZ/^%C7W
M_0@^*_\ P%3_ .+H Z3_ (17PZ/^8!I?_@''_A6O7"#XBWQ('_" ^*A[_94_
M^+KNZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH :Z+(C(ZAD8896&01Z&LK_A%/#G_ $ -*_\  ./_  K3GE,-O+*(
MWD*(6"(,LV!G ]S7$?\ "QK[_H0?%?\ X"I_\70!TG_"*>'/^@!I7_@''_A1
M_P (IX<_Z &E?^ <?^%<W_PL:^_Z$'Q7_P" J?\ Q='_  L:^_Z$'Q7_ . J
M?_%T =)_PBGAS_H :5_X!Q_X4?\ "*>'/^@!I7_@''_A7-_\+&OO^A!\5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%E4JWR[N#GTY^G-5+_Q'I.GZ0^J2WUN]LL;NACE4^;M!)5.<,>#Q0!J4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>57/B/7;31YM2%Y-) NA0^:
M  3'-)YVR8<==R(I]FS_  UZK10!Q%P]W>7<6[4+V,-K<EH1#,4'E;&8#CW
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M/$5CIVE/J%\7M557989L)*^T9(52>3CM0!K45G+KNFG48]/>ZCCNY3)Y<+L
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M9H]N=IZ[]QY91C!KL: "BBB@ HHHH BNKF"RM)KJZE2*WA0R22.<*B@9))]
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M:VO[#TC_ *!=E_X#I_A1_8>D?] NR_\  =/\* ,7_A97@K_H:-+_ / A:/\
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M (#I_A1_8>D?] NR_P# =/\ "@#%_P"%E>"O^AHTO_P(6C_A97@K_H:-+_\
M A:VO[#TC_H%V7_@.G^%']AZ1_T"[+_P'3_"@#%_X65X*_Z&C2__  (6C_A9
M7@K_ *&C2_\ P(6MK^P](_Z!=E_X#I_A1_8>D?\ 0+LO_ =/\* ,7_A97@K_
M *&C2_\ P(6C_A97@K_H:-+_ / A:VO[#TC_ *!=E_X#I_A1_8>D?] NR_\
M =/\* ,7_A97@K_H:-+_ / A:/\ A97@K_H:-+_\"%K:_L/2/^@79?\ @.G^
M%']AZ1_T"[+_ ,!T_P * ,7_ (65X*_Z&C2__ A:/^%E>"O^AHTO_P "%K:_
ML/2/^@79?^ Z?X4?V'I'_0+LO_ =/\* ,7_A97@K_H:-+_\  A:/^%E>"O\
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MTO\ \"%K:_L/2/\ H%V7_@.G^%']AZ1_T"[+_P !T_PH Q?^%E>"O^AHTO\
M\"%H_P"%E>"O^AHTO_P(6MK^P](_Z!=E_P" Z?X4?V'I'_0+LO\ P'3_  H
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M"NHY$F\1:0ZR(8VS.O*D8(S^)JK9>,/AUI\<B0>(M-82[=YFO3,6VC"C+DG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>bionano-nancyridgeleasee013.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIKN(XV=NB@DU177--
M_L^SO9KR&VAO$5X?M$BH6W $#D]<'I0!H452;6=+22XC;4K0/;#=.IG7,0Z9
M89X_&E75M->X@MUU"U::X020QB9=TBD$@J,\C /(]#0!<HJA=:[I%C<&WN]4
MLK>8#)CEN%5@,9Z$YZ<TK:UI2R1QMJ=F'DB\Y%,ZY9,%MPYY& 3GT!H O57O
MY98-.NIH%WRQQ.R+ZL 2!^=07^KVEAIE]?%Q,EE;M<2I$P+;0I;IGN!QFF_V
M_HPM/M?]K6/V;S/*\[[0FS?C.W.<9QSB@#C-(U6[M]1M[)+Q+F"Y6SC\B4,T
MLJ- -\BMNP /O'@]\D9%=;X6GENO"FE3SNTDCVL9,C')?Y1AC]1S^-)>:GI&
MA)9Z?<R0VEI-$ZQL[JD2*@'RY)&.#QCTJ?\ M71K%7M?[0L8!:(H>(S*ODJ<
M!<C/RCE<?44 4?&=Q+;>&WEAE,1^U6JL_GM" AGC#YD7E1M)R1T&:P=+UW7$
MTP>6J7(MK2[N"&5Y6N2DC"-(Y,C*D8PQ!+  XYKLTU.PEC62.^MGC94<,LJD
M%7.U3G/0D$#U-4+WQ3HUDLA;4+61HI8XIECG0F'>X3+\_* 3SGT- ')W_B;5
MBMK<6LD&H)!? "YLXG6)U:UE+[D#$OY9PQ .3@#AJMW7B[5H[C6!!'9.ME;S
M211MP\FV$.D@ ?<RLWHH&#][(YZF#7M*N;^&Q@U"WEN)H/M$2I(&WQYQN!'7
MH?RJ0ZQIBR7$;:C:![9=TZF9<Q#U89X'UH RK?5;^'Q/#I-[/:3![??FWBPV
MX9)+ N2BXQ@X(//() K*36M3TJXU&2:19+(S7K(OD,\D9C 93G> R]1M^7MR
M*Z>/7M'F, BU6Q<W!*P[;A#YA!P0O///'%)%KVF.\$3WMM#<3_ZJ"2=-[\E1
M@!CG)4]/2@#EK?Q=K$EK PMX)3<W$EE#(D9*^;N3RV.UV&S89"<-_!P>:T_#
MNO:CJNKWD%S';1Q0M*OE @2Q%9-J[AN)(9><D+VQD'C3D\1Z-%/;PG4[4O<7
M!MHPLH.90I8J<=#@=^Y ZD4R\\0VMCJZZ?+#<%B(=TRJ"B&9V2,'G/+(1P"!
MWQ0!S[>)];@@>69+39*&*,(' MU6Y6$N_P WS (V\_=^Z>W(OKKNI2>%I[Z'
M[--<K="""=8F\J9#*J"0+NSC!/1L'&0<5K/XAT6.)I7U>P6-9/*9FN4 #XSM
M)SUQVI8M;L7N;V"2=(6M)"C^:ZKN C21F'/W0)%R>U '.R>(]9BUR\T\G3E^
MRHPS/^Z\S%OO\T#>6V>9\I 4@ 'YLC%4I?&U^(;8PS6?FO;O((Y(#NNI%FV>
M7&5D(Y'0@MGKC&0.R36M*D^S[-3LV^TL5@Q.I\T@X(7GYB"0.*@NM5T&RU)W
MN]1L(+U(]C"6X575.&P03TY!_&@#FY_%NK*]^(5M))(DNC]F\EM]L8Y D9D.
M[D.#N PN>V0":LMXCU2UO[:UNY+1A]O:TD:.(AY0?+VE(R^<#S"&(+$8!QC.
M.D_M;3?M4-K_ &A:_:)U#Q1><NZ12"05&<D<'IZ5$NOZ,Z1NNK6+)*_EQL+A
M"';CY1SR>1Q[CUH XNTU_4K?5[5A-&#<6E@OV.82.TI:XF20QL7X*J0Q)W<*
M,X J>QU'4)+^)CYH\V.R7:TDI529KH,?O9/ 7()(.!GM74:KXCTW1Y)(;FX7
M[4EI+>+;@C>\<8RV >_^!]#4@\0Z,;,79U:Q%N7\OS3<)MWXSMSG&<<XH Y;
M3/$NL)9:)!-);WESJ*B(2B$KY<R,#*K@-U$>]L<<QGU%7O$GBF_T+5DA6T66
MTVQW#R"-B5@!83G@\E<Q$>NX^E;IN](N-8CMS=6DFI6X8I#YJF1 0,G;G(X(
M[=#[U(^K:;'>/9OJ%JMRB%WA:90ZJ!DDKG(&.<T <B=7UI;RQ:XFAL2US;+=
M[D9D&^!R4Y?"_/M7(QDXZ]#>\*7VIF9+2]D26&6.>:-O+8.FV<KM9BQW9!&.
M!C%;8U[1S:-=C5K$VR/Y;3?:$V!\9VDYQG'.*MO>6L>W?<PKO1I%RX&4&,L/
M89&3[B@#BKWQ1KMK8V\[?8$-S+<A'ECV1Q^6VU$8M(!EN3G/8@ ]:EO_ !;?
M6<FHQO+8QM#-;(C;#)'"DDJ1L9"'!W#<QP0O0$$C-=1_;.E^9+'_ &E9^9#'
MYLB^>N43 .XC/ P1S[BHI=1T2^CM(Y+ZRF6XE#6P\]3YKQL"-G/S%6 Z="*
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M!!R2O+9/%=G_ ,)#HGV=+C^V+#R7<HDGVE-K,.H!S@GD<>]69-1LH@YDO+=
MA8,6D VE1N;//8<GT% '-ZI>:C>>%=,E&#<W%U"L@L[DQJZE\'#H25!'/!..
MF3UJNFMZKI&J:/HMU-'<3N(UN=R;B0Y?!5RP+;=J@G9]2"W'1V?B#2-0U!K&
MSU&VN+A8EFVQ2!LH2RY!'7E3G'3CU%/?6])C^T;]3LE^S$+/F=1Y1)P W/!)
MXYH Y'^V]=>UTJ[O+RUC6^T>YN6MXX'CS+MB9$#;]VX!GZ<X#<=Q+'XHU=K^
MZM42PA$$)*+=OM) @#K(27W%=YP?EZ9^;((KIY]?TBV@,TFIV@3R#<C$RDM$
M 3O !Y& >1Z5):ZQIMZT*6U_;2O-&)8T24%F3^\!G..#^5 &*?$<@\'1ZL9
MLK2>5YAA7:#YFS./,V[?]K?CO[5DZ?XRU2^U72+5EM+=9X89+@R)C)8R A29
M 0247  ;[QYKL&UG2TEN(FU&T62W&Z93.H,0Z989X'(ZUC:KJ7A6UM6\17%Q
M93!$9XW2X4^>T0) 4;MKN#D#N#Z4 9"^*=?2TT1IEL%EU"T6Z)=/*0LVS]R"
MTF=P#'GDG(^7@YUO#^O:CJFMWMM<QVT<,+3+Y0($L923:F1N)(9?FR57MC(-
M;MUJ5C9&$7=Y;V[3';$)I A<\<#)Y/(_.J"^+-">XC@&IV_FR736:KO&?-4$
ME?\ QT\]S@=Q0!RO]J:\=LL>HV\MU:RZF'5K=MH6-_W:,H<<E0I!_NL.O4S:
MGXLU26YU"RT_:D@L)G0>1EXI1"KJ1\^6!+$#* $],X.>M_M[1PER_P#:MCLM
MB%G;[0F(B3M ;GY>>.>].BUK2I[DVT6I6<DX3S#&LZE@N =V,YQ@@Y]Z ,VY
MU&_:PT06%U:2RWTPB>Z\DO'M\J1]P4/ZH!][O61:^+=4N)=.#I:Q23I9DV9B
M;S)Q+CS'0[N%3)/0_<.3R*ZF'6=+N(C+#J5G)&%=RZ3J1M3&XY!Z#<N3VR/6
MFMK-FTRPV\J74GG+#(L#JYA)!.7 / ^4T <]K>LW.D:QJ+QRE \=K'$9(]\:
ML1.3U= N=H&<\G P215"X\=:O:I;RR:6KH]I%>R".-LB.2-55!S]_P \D?[H
M_&NH;Q+IL>L7NGRSQ1&RB22>:29%5"YPJG)SGIVQR.<FK@U?33+;Q#4+0R7*
MAX$$RYE4]"HSR/I0!S,WBC4;*[O(+I[)VMFMB[0H2D<;21)*SG?E" SL P P
M <MAJI7OB/4[JSDO+2:.W"B4K/L=D\I+P1ABI8+S&,EO3)! KK5URPEGM$MY
MX[B.ZE>%)89%=1(J%]I(/7:K'\/>K5[?V>G0>??7<%K#G;YD\@1<^F3]* ,'
MQ'KUUI:6GV>YLXDEMIIOM,T3.DDB!-D:@,.7W,1R3A3@&K>BZAJ=_<ZE)=QQ
M10P2)'%;B,B0$Q1N=S$X/+D< =*GM=>L[W7;C2K9UDEMX$FD=9$( ?[HQG/3
MG.,8(YYI_P#;^C>0\_\ :UCY*/Y;R?:$VJV,[2<]<#.* .-/BK6;O3%G2]LH
M0IL99YDMVVVOF3;9(9,OU48R>"!G(&01,-<UO2HM0D5$O(BVH2PQF)BZ&.8;
M<MN^9<,> !P!@UV<>I6,RJT=[;NK% I652"6&5QSW!!'K5)O$5HNM_V6T-P'
M\X0";:/+,GE>;MZY^YDYQCMG- &5I.MZQJ-]I\'FV!@E%Q))-$OF;TC:(*!M
MD*JQ\Q@>6^[G':JFKZ[J.D:IJ @*".6]CC\ZYP8X1]G#?Q.H&6&.H[]R*Z5?
M$.BND+KJ]@5G8I$PN4Q(P(!"\\G)'3U%);Z_ITT$\LES%;B&25'$\BJ0(Y&C
M+=?NEEX- '+#QEJ0U:ZAF^R0PVMNSR(L?F,["W27$?[P%SN9N-H&U>HJSH&M
M7VL:W9O.PV(MY&6BX20 P%6P&9<_,1D,>^*V8!X=?5X;F">R>^N09H=LX)DR
MI4NJYP3M4C<!G (S6@VIV"!MU];#:LC',J\",[7/7HI(!]#P: .,?QAJIDU!
M;9K&=X?MBB%87W0&*<1QF0[N0PR>@Z<=#5Z?Q#JMIK?V!FM9Y8YHXOLR0,LM
MRAC#-,AWG:H8D=#]PC.2,77\2Z'I%O=Q*Z1RPQW5X;5'4NX1W,C#!QDL&.,Y
MZYQ@@:\&J:?<V4EY!?6TMK%N\R9)59$P,G+ X&!UH XN;QCJBZ583PW.F2R7
M*.TDIC\N*"0(A$#%I!ALLW.<X4C;FI[CQ;K,=YJR+:V@^QQ2LMLQS)\J J^
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MF5I&EE-]GG+RJ@C?^Z<_YX/I5N?4["ULTO+B]MH;5P"LTDJJC9&1AB<'(YH
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M=-_9EHUVIA;#NTI5P &PKC)!.#R.@Z5K:?K]XNL6=E*8A#<7-W'L&Z2;*SS
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MSGCE8O%VJ6D>V*:SO#/<W3)<R.$ADV,@6-"\HVA@Q.07P!P&K1@\22S>+?\
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M9&L84%]Q&W=$K8V@Y[XJG:>#KJW+32:RUQ=^9;N)IHF;)B+_ '@9#]X.>A4
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MY/F0R%BN/0@)S]:J?\(:([>V6"^"36T4*QNT.Y2T<ID!9=PR"21C(]<UC_\
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M*GVGRS(ZO%@(F")7P6 0XSGJ*N7'B/4H0\DL^G6EL^I/9)//$VV!45SOD.\
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MQ4?@7;\ZFHHH **** "BBB@ HHHH **** "BBB@"-8(DFDF6-1+( '?'+ =
M3[9/YFFVMK#96D5K;1B.") B(/X5' %344 %%%% !4<\$5S"T,\:R1M]Y&&0
M?K4E% !1110 4444 %1Q010;_*C5/,<N^!]YCU)]ZDHH **** "BBB@ HHHH
M KWME;ZA;&WN8R\996X8J0RD%2""""" 012V=G;V%LMO;1[(E+-C)))8DL23
MR22223R2:GHH *H66C6&GSM/:P%)&!4$R,P0$Y(4$D*"><# X%7Z* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (1:0+>/>",?:'C6(OW
MV@D@?FQ_R*FHHH **** "BBB@ HHHH A-K UXEV8P9TC:-7[A6()'YJ/RHM[
M6&U5U@C""21I&QW9CDG\34U% !1110 4444 %%%% $,MK!-<03R1AI8"3$Q_
MA)&"1[X)'XFJT^C6%S?K>RP%IP4.?,8*Q0Y0LH.UBIY!(..U7Z* "BBB@ J&
MZM8+VUEMKF,20RJ4=#W!J:B@"M9:?;:?&Z6R,/,?>[.[.SM@#+,Q))P .3T
M':H;31K"QNWN;> K*V\9,C,%#MN8*"<*"P!(&,D"K]% !1110 4444 %%%%
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MC0R/$\ZAE4#)8C.0 "#GT-9FK^&9-0T&VTFUOS90PP^2RQJ^UD\LIC <'CJ
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MB?-M]Z[&BAC88##G]PI!SQDC!JNW@ZYDN+RXEUAI99BAB:2-F$>R?SER"^"
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MLE[NEGCD$CK#@;GG,S%1G@9. ,GZDT ;UWJFGV$L45Y?6UO),<1)-*J%SD#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>0,"3R-J'I]>F2+-SJVFV:EKG4+6%00I,DRJ 2,@<GN!GZ4 7*\@.N^)]/\
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ME<7"8C8G #'/!SZT >9:3XX\16UCIEO-Y+W#+$WE7$4DDM\TET\;K&^1CRT
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M)U)9,9W 9Y&.<T 86@^)KS4]1L8;I;>,76G177E1+N='**S!_FR@RW&5(/\
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M?VJSPH9)8VF4,B 9+$9R!@@Y/K0!B:AK:Q6_AG4);O[+:W-P#.\O[E2K6TK
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M"V*:E9L+HD6Y6=3YI!P0O/S8/I3%U_1FMGN5U:Q,"/L:47";5;&<$YQG'.*
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M$AD/VC>78A]TIW+N?)#;CG.",UGPZYJEIK-XZR0W]G+?"%$C5MQ(L%FS&=Q
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M+L B*2$*P7!(R^,@>] &[:>#([0@B[\S9=F:(219"1>7(B0XSRJ^8Q_&HO\
MA"G>T2&74RQBAEBBQ$2D8=X74 ,[':IA'RECD,1D  58\1:Q=Z9J,:VJ(SM;
M$J)"VS<9X4Y /HY]ZBO=8U0>"]6O$FMX;^R>:/SUA)CQ&Y&[86./E'<G'O0
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MD,#N&50<J-W.:KWWC*<Z?.R2V[))I$MS%Y:E9&D6-V.0LA:-?E&" P/9\XR
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M[A>.2S-K(D]N6#?.SJ1AP1C>?TP1BLBT\8ZKJ%FWV3[ 91=R0B9H]R,BVRS
M[4E89R=OWSZ]>*=<>,M1M=+DEN#9QW+&)H2(24(>%I-AW2*,C:1NW#/9<\4
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M1PJVY0A1EB<';QDG&>]5&\%3M&B'48L6P(M"+8][B.?][\WS\Q*#C;D%CWX
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M^#CIT=D&ND>2UEB;S LF9$CC=%4[Y&Q]\GC 'IZ+!X-6%$!O%9T2R0-Y//\
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MMLF[)$I/##! ZCBM:X\//_9VCV]E-! ^F,#&)(6DB8>4T9&TOGHY(^8GCJ:
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M9M*+"Y:3RV9%BN"X*'+#D%/O9&<]!UKN]B;@VU=P& <<X]*#&A7:44C&,8H
MXF3QA-/J5W9QF-XH[F%4>/Y&7_2UA96&XD]3R0N<'@CFB7QGJ5M9RW$MK:N)
M%+0!"1Y8%RL!+EF ( 8/U4#!&>]=L(T!)"+DG)..I_R*78N,;1C&.E 'G^J>
M+=2?3XXFDLK&9D5RWG M/FX,>(BKD [5#$9;&\+[UK:]JVH:9KYEMFC:UBLE
MDFADW?-F4*=N#@-@GDYZ8QSQU'E1X4>6N%X7CI]*<5!Z@'\* .)_X3+4Y'U
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M<HC7<-Y)#9SDJN.!\V0:ZFF^6FYFV+ENIQUIU !1110 4444 %%%% !1110
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MS$Q7=\V3TP>OU'8XL3ZG86T9DN+ZVBC 4EI)54 -G;R3WP<>N* +5%12W5O
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M10!JT53;5M-5+AVU"T"V[!9V,RXB.<8;GY3GUJ2XU"RM(XY+F[MX4E(6-I)
MH<GH 2>: +%%4K;5K"\FO8;6ZBFELG\NX1&R8VQG!_ _S'4&HK37M,N[:"87
MD,;36RW0BED59%C*[MS+G@ 'D]* -*BHA<VYD\L3Q%]_E[=XSNV[MN/7;SCT
MYJ)M2L5N);=KVV$\*>9+&95W(O\ >89R![F@"U157^T;9HH)8I4FBGD\M'B<
M,I//?/L>E.M;^SOPYL[N"X"'#F&0/M/7!P>* +%%4CJ^F"":<ZC:"&%]DLGG
MKMC;T8YP#[&IEO;1U#+=0L"%((D!^\<+^9! ]30!/167#XATJ:Z%I]MACNB@
MD\F1P&VEBH/7')&/R]:TDDCDW;'5MK%6VG.#Z'WH =1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ,F61H)%A<)*5(1V7<%.."1QGZ5Q=IX(U)/"NI:+=ZU!+)J,H
M>ZO8K1HY90Q'F[LR-RRC:",!1T'%=O10!4@MIX+I@LL2V"PI'#;K%@HPSD[L
M\@C: ,<8]ZMT44 %<3<>!K^33M:TB'688]*U*2>=8VM"TL4DIW'Y]X!4,2<;
M<]LUVU% 'GUQ\-9M02[?4-4MYKBZ%\69;/"H]Q%''E5+G&WR\]<G/4=:?<?#
MB59WFT[5(+5VF+JIL]R*C6JV[#:''/R[@?7@@UWU% 'G-U\,;J739K*#71$D
MZ1QRC[.V&5+5;?\ A<'^'=C..<$$5?B^'[QW[2_VA"8&N[2[9#:_.6AB6,J6
MW8VL%!Z<$GK7;T4 >;1_"DPV"1)K!DGANQ)"TD;JHMUB:)(3LD5OE5F^8,,D
MGC!Q6UK/@&RUO2]$TVXE"6FF0O%Y<:M\X,!B&TEB5QD$9+=,$GK77T4 >?1?
M#67^T5N[G4X;@M!$KYAD3;*D!A#HJRA "#G!5L9(!YX?:_#&WM7MV2\B5H39
M'?';!6/V>-D.#GC=NS[>]=]10!YO8_"Z73[&UCAU&U:ZM)H&BFFMI95D2))$
M"R(TQ'25B-FT ]NP$^%;PV,$,6L_O;=+,1MY+HI,'G#G9(K883'HPP5'7I7I
M%% '$V'@:]TB]2YTG4[:RV6(MA'';R.CN%"JSAY3D+SCHV#@L0*V]:\/+K-Q
M#,]P8GAMI8HV5.4D9XG20'/56A!QWS^>W10!R-GX+EM([*#^T(WMX4LO-S;G
MS&:VQMVMN^56*C(P>K<\\7]6\,IJDFJR&X\M[ZUA@#!.4\MW8$D$$@E^0".A
MYYXWZ* .1G\$)<V<L4D\0>6SN[=V$;N-TYC._P"=V.1Y?3/.>U&I>"1>W<TZ
M7:*LLDQ:%ED"%)4B5E/ENI/^JSUQAB,=ZZZB@#E6\'"74':>XAEL&DG<P& ^
M8PFCV,IDW<CTXZ8';-.T[PY=R>"?[-U"XQJ5T/.N9F4/^])#88 X8#"J0#R!
MUKJ** .>T_PRUOK"ZI<W,4MP7FD=8X=J!I%B4;022,+%SUR6)XZ43>&!+XF;
M53.&C=HY#$_F95T4J"N'"]#W4]_7CH:* .-LO :VLD >]\V)((HVXD5@Z0>3
MN0"3:..>5.,GGGC1L_#][;_V2TEY:,^GDI^[M2@>(H$QC><-P#GIVQWKH:*
M.1L/!<MDEG!_:$;VT/V1I,VY\QGMT55VMN^53M!(P>K#/S<:6@>'%T/RMLZR
M;-/M[([8]NXQ%R7Z]_,Z?J<UN44 <>W@8?8(+>*^"/#!;1AEC90S0RF3<=K
M\ECT((/.:G_X0N%K&_MS.J&[T_[$6C1B4)>5V8%F+')EY!/;KZ=310!R$_@V
MY>T=8+^"&YF2>.>1HI90ZRHB$_/*6W 1KCG'M4\_@U+CSMUWL\ZX:9F2/#8:
MS^S8SG_@6?PQWKJ** .-;P5=2E9Y=1@%RL\<R^1 \*?)"T6#MD#<ALY#=L<B
MMO1-!AT5YVB,>)(X8U5$(V+'&$ R221QGD]^_6M>B@#FK3PK)#=V\LUY&\%O
M>M=16RQ-L3,4B$#<S$9,F[T&, #-5+?P5=0R:2KZMYEOIT"1I'Y3#)6W:$G
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MGD\MR\R'S-J-ER"J^8,$@M\I^;YC7544 <E'X-F2]#F_A-OYJ3E1;8DWI;"
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MJ3NP00@/3C)ZUF)X":*TAC342\L%P71G5U'DB+RDC.QU;Y4QSGDEN/FKM**
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M+W#MO=@<X"[BW&/3GBM>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>4EAVR*RA =Q5)& Y)&-_09R,\4=+\5:IJ3VJ1Q6K?+>23%4W&00O&H"!78
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M9&VS?.,L3&%ZIR?H"ZT\5ZK<R6DK6]K';LMEYT95B[&X=DRIR  , C(.0>U
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M4=>E:D_AF"XTG2M.,GEPV$J.1$SKN"HRX!W;E'S?WCTQS0!=L]:TN^6V,%Y
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MB%SCR?-<*7)'  /4\]*R['P_/;:5J5A)>*8KL.L2)&P2 ,I!P&8G&3G&<#H
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M>E,_MC2O)DN/[1L_*B;9))YZ[48<X)SP?:N:@\(7*:JJ*]M#IT26)!6(L[M
M[/A6+DJ,X!W;N">:DL/!D\-W'<WVI+=R++;R,6B;YS$)!G!<@$F3.%P!C@4
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M_L;B6"V@AGD,TY5Y955&$:Q$("SJ%W>8><G 4G![=N8T*E2B[2,$8X-(T4;
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M#$D@#J:0Q1L,,BD<'D>G2@#B4\576I:_I,"2V]M$UW&KVWF'SI%:S,V[W3+
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M$AACJ<8/X<]*S+_QQI.GOJ2F.]G738Y&N98+9FC1DC\QDW_=W;>V>I SDXH
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MQ863EC%ND=H)7DVJV[Y1G:#D'@G%5;'6]836L7D<(AFFMH98"S%H7>#<0G;
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M<EW=!H%FE2- ^$AF0L SJ#N,@XW#'O6C8^%G"6MS-Y-M< VDC11KN$9BCVE
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M<RLRK*;=T 5!G.7#^IQCO4AUV^@U"_V9D99+IHHIY@B I#"RJ2> ,L>XQDT
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M5T/(93D&@!U%%(2 0"0">@]: %HHHH **** "BBB@ HI-RC/(XZ\TM !102
M,DX%,,L:A29% 8[5)/4^@H ?1110 44R*6.>,212)(ASAD.0<<'FGT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBN$U;7M0T[5=5CAOW:$64DT1<Q2+$RR(K,-HRH0/T?.<>QR =W16
M#H-_)(VI6LVH"Y$%X8;:>39NE7RHW/W0 VUF8<#^'GG-/\*WLU[I4QN+T7DL
M5Y<P^;A02JRLJ\* .@% &W17)_$#4K_2]$@N;"_2UV3[K@":*.:6$*Q98C*"
MF[.#@CD \BL.;XC^:C65N%$\CB*(RN%G\MK#[2)B@Z'=A?2@#TBBO*M%^).H
M2:996DRZ;)=2"TC%\UV3 ID@>0^:VWAQY1! [N*MQ_$O49]*N=2BTFU2WMK&
MVN)/-N&!WSN47!VX\L%2Q;^[VH ]*HKR*W\>ZI9?:[R>6.^:)M1=8X;@&!A'
M);JH#;<D#S#@]N>#6CJOQ-O='L9C=65C]NM;F>*:%)7(D2+R\LC;1CB51SWZ
M YX /3**\R?QMJMMJ%P;TQRI::O=0+!:/AVBCM990K@J<YV#&,9/TP9K7XAZ
MK>O!:6UCIDUW<7$$22QW3- !+!)+@L%SN7R\$=]PZ9H ]'HK&\/:ROB7PS9:
M@A%O-=VD<SQQN&:$NN1U'UQD<XZ5SUM=ZXB:<T6IR7<\^M75KMN]B)Y<0N0
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MA^S-Y=K'-EE8W*0J9<CY2,DG_@0[9(!Z!17&_P#"7ZG]IM+;^R%\]U+R@S*
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M9BXECOP)3#\PDGF$D;YZY0 C/7GBB\\&W]YJ5_=275KMF21$7R\!PTT<BJX
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M.#TI$\$,E]8S?NC#"J!H3,W[IEG:;<C;><ENGRCY5[<4 =8_V)?.NF$&8_\
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MTU5CMDMK0!#YL<01?E/]X#M]:ANFTNRL+C47@@:$ R2-'&K%SD>G4D@?B!6
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M0#CD'H/I4]QI^DJLC3:?;.+EPLN+8/YA+#!; .><9)X&,GI5U?+1 J;51!C
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M$^HS:K#:76FVT4;W*VQ>*Y9R&:W,X."@XP-IYZ\UT26EG''Y26\"(D?E[%0
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M(;*D$?,1QSQP03D:FD^&=#M(&$-KYL<@2(+=H3\L1;:-K#L2V">3G.3Q6O\
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M'RPQ!+@_> ZC;WKLJ* .&A\"RV=I:Q01:?)'%%:>=:R K%<R1+*KL^%/7>C
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MMY)9@#NR5& >A@E36[J6-YYM4>V>TU""-3;A?-R8_*\U0GRD@/@D+]T="Q!
M.^ZT5P3R>)]-L(;6.2\EA62$//Y \R.,P-D*$B;($@4?<8C/)[C?T(:Q)>7$
MNIW4K(D4*)&(1'&[&-"[C*[OO;A@GCD8] #>HK@;W7=?@LY-XO8&AQ'++]D'
M+F[1!LRN'/EDXQD'/KT)[_Q.+(F)]2^Y<FR?[$I>>0./)6==G[M2.^$XY)!H
M [ZD) QD]>E<WI[ZY_;P>YEN&LY)KF,PM$H2-%(\M@0H;GGDDYS69+IVJ7.M
MF(W>IJ$ULS)*8E*PPFTD ,;%-I&X[3UP<="<D [BDW+NVY&[&<9YQ7%:=?>*
M9M3TM+WS88VMK=I0;<E9&*GS0V(SM;/JZ@<<'FGZK::E;>(]3U2V-WM>*SA\
MR*!9&CB\Q_-\L;"20.<<_>)P>, '9T5Q44WBJ2VFECDN2\-E<R6T<L")]ID#
MN(?,RHVDIL) V\GG'(IEO>Z\8;8W-UJ(M7G?=+!9%IUPB;$96A7Y2V\[@@ X
M&>M ';@@]#FEK@)'\06$$T-HE["QFO9;58K82+-,UU(464E3L0J5.<KPQ.>!
M5_\ M+6[>_NS(M[/:PWR$NEH<>2S2 HB>6&;;\F64N",$$<B@#L**XA+GQ7-
M875TINDGBTQ)(;=H$423L\P;/RD[E58R%'&2,@YJ_#<ZV/"5Y.LDTUZ'/DDP
M$2K'D9^5HTW,!N(^09P!SW .HHKDM,DUVZU6V1[J^735EG=9IK9(Y)D40[%D
M!0;<L9@,!254'WJ+67URTU;6)K"2^DWPVAAC$6Z)%\S;,4(1OG"Y..2<YVM@
M  '945Q0E\3/933+=W1>'3IY8@MJ!YLVYQ&K!XPV0NS@!<GG&#BE*>)(;J97
MN[R[M_M+P!);>+:T1M#)O.U!_P MOD';M@F@#M**XRSD\10S02M]J^SI,D)M
M$MXU7R_L8<L#MR#YWR]< \8JG87'B"\DT^>\DU6&"+51G$/S-"ULW#CR5)42
MG!.T 9SG@$ '?T5PEO<>(H#90+'=0$+!Y4,5FODR$S,)O,.WY,)@CE>O&X\5
MK: ^N?V@#J,UQ+#-#*Y66%%6)UEPH!50>4.>2>F: .E) !). .I-("" 0<@]
M"*\]OU\0ZMIU_92MJ!$L$@N(S:JJQN)D")$2GSJ8]^>6X Y!-;/BFYU;3;6S
M@T6&[=UC;!AC!0E=H56 C;J"<8V#@\@XH ZJBN5\3V[_ -LZ7>06TEW<0L%2
MW>U>2(AG7+"0<1.N,ACP1D8],V*_\4F&\>=KE&695DCCM2[1)YX#-%^Z ;$>
M> 9#T/7@@'>45R7]HZPFI0VL:ZA-#)+;,DTMIC]T0?,+D* IR!D'!&1@"LR[
MMO$4V@6LDDU\U_+I$TLTJ0(LL4I:W(C7"<<"3Y>IP>X& #T"BN7T^^U27Q6V
MF--+)9Q0K>^=)$JLT;J$2-A@8.]96/ /RJ/6LQ+*X&O326=A<)J0U1Y6N6B9
M(VM]G1G( =3T"@G!P<#&0 =W17 V>I>+8M%_M"2.XNKB)HS+8M;E79F1E903
M&@VAS&WR[L!6^8@BK!.MV5W)%/+>+ UT!+>6=DKR3$6L(#;0A^4N),MCC:!D
M"@#MJ*YC0KG79_$%ZNHM(ENC3A86A;;M$@$3*_E@<IR1O8DG^'!%9BR:U9P/
M#)=ZR(_MUX99H[02R*"[-"$'ED%"I!R 0" ,J.* .ZI,C.,\GM7,:M/XE30]
M*>U0KJ-PBV]VL<8=8))(\>;CT1\<=,$YK%=?%&HQ6^J.MW97J6EXT<4<*$QL
M%A"QG<IR'='8=R#P: /0J0$$9!S7'-/J\6K2!UO+6RENG9I+.S#NS>3!L!^1
MOE)\T%B.J@9 J?PY;:K8ZEY4SW!LKB34)6CDC4+"WVK,>T@ _,KNW).<<8H
MZK(! )Y/2EK@?[.UB6:)1>:HL\&H7S^<T*G8C"0Q[2R;2I!7UQTXZ"4W>OQ(
M;KR+B.66Z@:2&"UPTP-O%N&[8P&'W<MC[N-RXH [FBL"]FEM?%UO+Y-R\4MD
MT2-'"[H)#(I 8J"%^IP*Y^UU'Q0=$,EU]N-U(T2LL=N5:!]CE^3;G*9"@;5?
M!/WL'( ._HKA&U/Q4+>1DBN9+I],CEV"WV)!+MCWCF,[VY<C#'!&"G&:TE;5
M+CPA,9=]U=&8>6)+<AMGF+PRM&F2!GG8.@/O0!U-%<_I%UJ<DFL1W37+")V-
MO.]N57!+854**25 4'E@W!#<D#"DU?Q+!HNY8=0EN#97D<;BTW%[D>7Y+[?+
M4HI_><,H'&#GY20#O 0>ASBEK@&?Q#8ZAJXTN.]>5Y;N589;8" CR\QLKE1E
MC( -N[H3P.M7[.77;J]@B2\U$:>;W_CXGM$CF:(0[B&4QC:OF<9V@GD#L: .
MPR,XSSZ45YU;IK=U?BZN8;V:XQ:I,L]FHCB87:&18_E&Y53)#<\#(;/2^+KQ
M+;6TLLS:A<>;$QV)"BF!A<!1MQ&QQY9W'(8D+D#- ';4$@#). *\_CG\4"'[
M:3?F].F3K# T(\MIDD;87^088KM(SMSZ=JBU:7Q#=>'YK=YM1DBN+>[53!9%
MI6?8@BC<-$N%),OS;%Z*-W<@'HA8#&2!DX'/6@,"2 02#@X[5S>KK(-0T2-D
MRODW 12,YG\KY1CUV^;^M-\,B9=4ND=/+ TZQ\Y H4+/MDWC X!VB+CTQ0!T
M]%>?1WVN0^%="M;&._MI(;<0WDCV<F])1&-HP8G++G=DJ,<#YAGF[=WOB!)M
M3C6>Z^58GBECLWV)RFZ,#RF8EOF^<;P >0,#(!VE%<0FH>*I=38K%-"OD*\-
MO/%N63-OG#LL>U7$I(/SJ,+PO.3?T*XUF;0+^2\N9A<;"86EM6WQ-LY^7RTW
M_-R  ?3)H Z?(SC//I02 ,DXK@,>()S#J<7V^*Z@LI%^:)3Y["<84@QJ0"H)
MQM5L?F7WL^NZAJ%]:M:WILA,A198^ 4NH\%2(UX*9;[S\ 9((- '> @C(.:6
ML'PU*+>"3394D2Z6:YN"C(1A'N9=I)]QR/45O4 %%%% !1110 R65((7EE8)
M&BEF8] !R36=_P )%I8M?M+SO'%]GDNLR02(?*3&YL%0<?,OUSQFM*1/,C=
MQ4L"-RXR/<9XKF7\#6#6/V5;V]B0QSQ2&+RUWQRE2Z[0FU1E1]T#OZF@"7_A
M,+)5U)908I[(W&%D5PD@B&2=^W&<<D#) [&KTOB328)IXIKK88%=I&,;[!M
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M-C;D?)@8!QP.* &/XPTV/2)K\B>46]LEQ,MM!)(%#*K !MH!.'4XX.#D@"M
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MO:J=OX5TZUCBCA:=5C,!4;P?]2,+U'Y^M+;^%[*#1[[3#+/)%>NTDC_(A#$
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MN P,OF*V[>21@L3DG(P<GBJ-SX'TN[B@6>6Z9XEN,R;P&D:?)=FP,9!)(P
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MR)YKA%^3[\KL[?-MW 9<\ @$ 9S0!):^)],N&M8S/B:=(R-L;M&&=-X7S-H
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MX3@=9G.H27449E2 [EB:X52Q5D7D1DDG8!P3C%$_C.R@MM68H?M.GK<,(3N
MF\I=Q ?;MR1@XY(!S5R;Q-IMH9!=S&,K*\8$:/*?E*@DA5.!EU'/&2.>: .?
M;4/%*W=G;DRJ@DE3SWMR?.VW+(-X2)L9B"MD; =Q(.!PL&J>*WUV.RDMI1:F
MX-LUP;? ^23>9,XQM>$[0>@<8ZUOW_BC3-/6X,IN6>W9%>-+9RQW.$!7CYAN
M."5S_*ED\3:;;"8W,QC\N1DPJ.[85%9F*A<J '&2>!D9/- &?JM]K,7B%8;;
M[2(@]L(HX[;?%,C2$3%Y-IVE4Y W+T'WLXK/TW5/%DVLP6=W;2K;F7R'N#;X
M'[G)DE)QC$N55?3!(KHF\2Z.EU+;-?('B!+DJVP802$;\;<[#NQG..:T+6ZC
MO+9)X1($?IYD;1MZ?=8 C\J .&34?%L&E0-*;F62:WLIIY#;!6@:02><JA8V
M^Z4CX*L1O)/;&M87^IV\SW>LW<BV=O8P,0EL5665RX8\H'W<)\H Y;IR!6I_
MPD>D^9(AO OEL$9F1@I._9PQ&& <A21D ]<4G_"0Z/+M'VI60PBYW^6Q14P6
M#,V-J\*2,D9 R* ,OQ/%?/JD(AFOOLLFF7L;0P1[XWEQ'L#84X)&_!R.F >2
M#2@_MVV%E;2--,L$RLMQ+:;C&ILY2>$ R!(%'K\VW)S6\_BK1XH1*]TZ_,R;
M#;R>8"JAB"FW<,*0W3H<]*GL-=LM2NKV"V\YC:%0[^4VQ]R*X*-C#<,.G\L&
M@#"DN=2NO KRS1WK7B3)N_='S'"S+EE541B, X^0''8]2Z75M9N/$\(M5FBT
MPK&R"2UD7S0=WF;LQ95A@8RR=C@@U/#XXTN5K%V6>&VO+=YUEFA=2NUD7YEQ
MP/G^]G:/6KNH>)],TV.Z,[7!>V7>\:6[EF&X*2G&& + $C.,\T <M%K?B5M-
MGG:/41LFB=(S:'SY$,;%HP?("@A@O)4C/&_D$;6C7NN7'B6\COMT=JC3*L+1
M-C:' B96\L+RO)_>-R>@P0-R;4[2![5)'D$EU_JD$3EB.,D@#*@9&2< 9&<5
M#)K^EQP^:UXNPJ6&%)) <1G QDG>0H Y)(Q0!S+ZIXK77FLA;2FU^T?9A<"W
MX^:7S!)G&-JP?+GIOXZU6BL]1EO4EDLIE_>6><0E1A;V<GMV4J3[$'O72Q>*
MK"363ISEXV9(FB=XW&XR%P%8%?D.4P V,GCK5R?7-.MM333IKG;=/LPFQB!O
M)"Y8# R5(&2,D8% &/J6HZO'XNLK2TBNOL9*B8F+,14HYW!A&<$$+U<=OE.<
MUCG4]>U&QMGD;5;3R%T]KAHK(HYD+.+@!2AW*/DS@$<>F:ZR#Q'I-S((X[Q2
MS,JKN1E#;@Q4J2,%3L;##@XZU+9:UINHP>?:7D<L7D)<[P< 1OG:V3Z[6_*@
M#E9]4\2[[_[.+LS*EU^Z:R_=PE9 (#&VT>863DC+?\!QBI3=>(["6Z>66_O8
M8_M2(JVL8<A4#1N"$Y8DE1V/'&>N[%XGT>9-RWH49_Y:1LA^XTF<,!P51B#T
M(4XZ4DOBK18H4E-Z&20*R>7&[E@R>8,!02?D^;V'- '-V5SKUS=6$M[-J*Q+
M)=0E5MSMF&$,9D'E+Q]X!MJ]/?F2RU+6(+"87*:E'-!91?9[6WLOD<>0A9MQ
M0X<2%UVYZ*/E.>>E;Q#I2SB$WBEBN[<%8I]SS,;@-N[8-VW.<<XQ3AKNGG3(
M]1$SFUE8+$PA<M(2<#:N-S9[8'(YZ4 <3,NM:I;P37=K=22I#=1!S"P++]JM
MRF?D3DJI/W5R%)Q72Z#J&IWFL:G:WA_=:<Y@+A !,[$NI_"(Q9QW<^E6+;Q/
M8SZM>:;(6BGMYO+3*L1)^Y27@XP#AC\N<X4FJ=_XKL-.LY[FSMC+M6XEF0H8
M'#Q1>9AE9<Y*[>2.A!Y% '-Z;>>)+#0EM[1+YUBA@603V9C-N3+AA'^[)?Y,
MDG#XP#WQ6S;:AKWVB)+F2Y9A:![<16;>7<R[Y 5E8Q@IA1%VCR6)&1P.@U/7
M-.T?R_M]QY/F(\@^1F^5<;F. < ;ADG@=:AN_$VE6;W,<D[M);H[,J1,VXJN
M]E4XPS!>=H.<4 <]97OB*\:"%+G4!#+) );F:Q6*2-BDIE4*R ;05BPQ!Y8C
M)J%=1\6PZ6KR_:)9);>SED<VP5H&=I!*JA8VS@+'P58C<3TQCL['4[;48T>
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MIMR+4PS2O]KR8 +>3+J-N6^[]SYU^;[OS#GFH3XHT,)+.UXH$(4%S$_S!G"
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MH R*BB)VE<LI;'EA=V< G&.@)XQ3H_$NCS74%M%>J\DZHT956*D."R?-C W
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M;O/^T>9YOS[OLWV;.[&?N<YZ[N?:J=CJNL/HFN2B&6YO[42M;!H2L<K;245
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MLM%RHQUPP^O/)-9DNN:R;#1H],$D8^RXFEN;>49G41X1OW;'!W-G&"<<-P:
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M%)+Y]S)91RFW)*%MA29OD7Y%4RY.T X7UY -\>%K*/'DR31A9S.@&U@I-O\
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M./O 87&W)!H LZ?X1M]+E@ELKZYA>-I-^Q(@)%=PY4KLP!D<;0#@GZU:'AV
M:'+I1NK@PM*98W^7?"=_F+M^7!VL 1D'WS6!?Q:K/K-[;K>7P U6V>#, 9(H
M3$N64[<8W;QR2 1DCU(M<UXZAH\#PW.YBBW6;8A'!=U+<*<$!5)^90-PX.:
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M0E#&\KC *XQ^^=<8P%P!C%21>$;&**1//N6,GEF1V*Y9DG:<MP,99W;..,=
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M ")KE)Y!D*<'*84X(&>0U.'AV_?PG!I374<5Q'=Q3B6(#Y%2X67KL 9L#J5
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M#3S16UWY1MHK0L/*^RK*6\S&-V\@ 9[@8Y!%"#6?$4]D]RMG-<3P3S&V$L#
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MC-(%#R-T49ZDXZ5)!=070D-O-'*(Y&C<HP.UU."I]P>U $M%%9K^(=&CU?\
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M115:UO[6]&;:=)/D#_+_ '22 ?S5ORH LT45"MU \B1K,C,X8J <Y"D!OR)
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MR<=-W?%)X9TV]L&U.6\!'VNY$R+)*)9!^[13N8 9^[P.< #GL&Z-XCEUC5#
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M2SO[NQN6U"27;*GD+'N*QJN-Q*''( S^%7+OXD+9B:)]"O&O;=KA;BW66/\
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M9I(M@;<<9P<$#'J1SU(?XK\4G0](M+FV\A9[D[TCNSLRBH788)&&( 0>C.*
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M 227&P8)R1\RY/;<.O.,ZT\0:I'X,AUB>V6>ZGN(P(2RJ%5Y50 $>@/?GUH
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MFN0VTB(KO0A1C+[2203U.-U6;KP]KTK7HAF"M<6L2R2O/EV=?*W(AQ\JLJR
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M&:!XYUN2J0PK_K8S&#R6^;G!^\,D;14+>&)D\ V>D" O/;R6\K1"<C<4E5V
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M[.[#%<'&P+S@@'.1SGBP=*NF\6S:D+J6&V-G##LCV$2LKRDALJ2  ZXP1U-
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M4R11Q";?E9(W)" @'# ER!G^\:Y^QT'Q+%K<)N+UFTY9S&P^T$MY$3>9 ?\
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MF@#H5TBP3&+5,B029.2=XC\L-D]3L^7/I26VCZ?:7*W$%LB2I$(4()^5  ,
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MGMD>5HUC9CGYE5MR@^N#DCTR?4UD>*+/6+A=VDJSL]E<VQ43^7MDD";)"?\
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M:%9ED90X&<;E!PV,G&0<5#;:)IMBL BA*I!('A#RNPB.TH H8D*,,0 ..>E
M&,GCRR:S2=[&[B,R0201RF,&5)@Y1LAB%XB<D$YX]\5/'XQMY9[=%TZ]$<JP
M%I&" 1&9F5%8%LYW+@X!'(.<5=CT71+F Q0P1E8%CM@8I&5HO)+;%# Y4KO;
MD'/)JR-'L,@FW#-^Z^9V9B?+.Y"23DD$DT 8DOB6_D\"S:W#IYAN]I$<+,K
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M%ID\;QRV:2)(79PY)W%TV-GGG*\4V'0--@,;1P,'CG^T+(9G+F0J%)+$Y.0
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M&ZM\S,%;EAZ5TE% '#C0=9AM)%C$\$<JW$OV>SF4>4SW"2*@RR@_*&W8(ZL
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M7OKJ4RO<!UVO(SH1EB>0P!&!R"?<]!110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5<7]F7G
M07<!:W&9AY@S&/\ :]/QJQ7":OHFJ7NN7-U!I\S6ZJF4G,"B39<Q2E8MIY#J
MCY\SN5Y&6H [>&>&YA6:"5)8G&5=&#*P]B*6*6.>)989$DC895T8$$>Q%<K#
MIFJR:+?645M]C-]<RSXD==L<;2#=&2A)#,NXY7(&X\YK4\*6-WIOANTL[V&*
M&:+</+B.54;B1C\,4 :9O+478M#<PBY*[Q#O&\KZ[>N*2>]M+5T2XN887=69
M5DD"E@HRQ&>H Y/I7 Z[H/B'_A+]1O\ P[:O!)=6TBR75RT+1&00%8GBY\Q'
M#84@C:0":R)_"'B?4M($=TM]+)]GOD5+B=0\;26Z*BAO.D)5G!ZMW.0%P* /
M4%U73GT^/4%O[4V4@!2X$R^6WT;.#5F*6.>)98I%DC<95T.0P]0:\_\ $7AC
M79_#.FV4#F[AM;BTD6WB1#<1J@^<F29RDAST! 'UJO>:5XU;57ETO[9:V)TX
MQ0PS740\N[\A@LI1#M"9(4JO&_Y@,"@#TN@G'6O,++2/%T46GF[&LSVHN9&G
MM4O5AE0F.,(=_GN6C#"0D%^K?=P *K:GX?\ &6KZ9?Z==P7K11VURJ,;]0+F
M0W:R1$8?(_= J-V,<C@8R >J17$$[RI%-'(T+[)%1@2C8!P?0X(.#ZBI*\RN
MO#OBFZGNUADU.UM9)9Y(U74-LF/LD*Q!F#DDB56SR><DY!YI^']4UH_$":/4
MGU2XFMXW5;2*;Y'=8(\[U,@51N\S:Q3!9OO' H ]/NM2L+%E6[O;:W9AE1-*
MJ$CVR:FAGAN$+P2I*@8J61@1D'!''<$$5F:YISW\VELD"2""]660MCA K@]?
M<CBN=DT+7[6.^?39)XIKC[>VTW&4!>4-$57=A6*[N1@Y/)H [FBN9MK;5X/"
MEW'LNIKQV)BBFEV.JDC@,)6/'S$9D![948QRLL^M6=[I5EJ=Q?Q8DWE8[@^8
MRFZ.U<"7,G[L*I&9"H.>OW@#U"BN$O-&\1BPM1#<WY>22Y:YV7)>16+?N67,
MJ *JY^4'&2,J>2'76F>*7N-:9+F[\Q[>=;1XW"QL3&!&!F7",&[A!SGYB#0!
MW-%<5/HGB"VFO&TR\O-QDF2V:YO&D18VMOD)#,<XG[D$@<?=ID.BZ[/9QQ2W
M&IQH7F9D-T8W7]T @W"9V(W@GENN> * .XHKA'T?6HHM3E6'4/MMU]FEWPW0
MV.RQJKH1YJ%?F4Y*D<$8)'%;6J0:E++I3_9[N2W6-OM,%G=^6RRD)L)8LI9!
MAP1GG(.#0!T-%<*^F^)I'N@C7T4C+,LLIO 4E)G0QF)=QV;8PX/"]0/F/-3#
M1=4M]7MKKR;RZ2V-Y'!NOFR%<HT>\E\E<JPYW$?+QP, '8M+&CHCR*KR$A%)
MP6(&3CUXI]<!;Z;XK.FW (N8Y3+,T*O<Y9 UIM7DRN?]=G&6]^!4U_I'B*)7
M@M)[V2T^U!R/M)>4H8 #AC*AP),G&X=> 1Q0!VSS11/$DDB(TK;(PS %VP6P
M/4X!/T!]*$ECD=T216:,[7 .2IP#@^G!!_&N-BTG6G\4:=/=I>3QVUV)?M+7
M"B(1?8VC(\H-]_S68DA3PWWL<"U?Z3J]YJ=R/.NH[.2[9U,%T8B4^RHJ\J00
M/-!X]>>AH ZNH5N[9[>.X6XB,,A4)('&ULG P>^20!7/WFFW]U'X6N+F*>6Y
MLYU>[$4^PJ3 ZLQPP# .1D<\9P""0<S3-!UO3K*T@C:X"!+)I4>YW!&2?,H4
M$X4>7V'!QW- ';NZQHSNP5%&69C@ >IIEO<P7<(FMIHYHCT>-PRG\17+0:=J
M\W@[7M/N(KA[B:*:.V:YF#22[HL#=\[*OS''! [[5S5+6?#^M66CW":,9I[^
M[9YI)H9! (Y1$J1X42(-ORC));D<JV> #NZ*Y&_TW6?+OY(UO)Y+B^PBK>.O
MEVX3@HHE0?>ZC<#SDYP!7/07&N/K4-A>W5Z-0CMDCV17'#2_8\G<HD V^82=
M^PC< -W8 'I],EFB@4--(D:EE0%V !9B !]22 /<UQ\NFZ];W^CQVJW;0PB!
MKB=[QGWDN?.#!I .G3Y6ZX&W:*RM-TS6]9TBV:4:B(91922M<7F6D9;A79X_
MF)0!!_LD\<9&: /1)YX;6%IKB6.*)!EGD8*J_4FHS?68:!3=0!KCF$&09E[_
M "^OX5D0VU_!X9>VN([N>X2:58S&\4DPC$S>6V93M)";#\V3^-<S:^&M7ALX
M+633@S26UI"DHD3_ $4Q7$DA9OF^\59#\F1N!' Q0!Z%++'!$\LKK'&BEG=C
M@*!R23V%.!#*&4@@C(([UROB2PU:\U"9;**XFMI]/E@96F"1(Q23! WC+$E5
M(9",8(88(.?J&D^(K?2[FRT];R96D4P2&]8O'^X )!\U#CS!T+8&<A2* .T%
MY:M<&W%S"9@Q0QAQN#!0Q&/7#*?H0>]21S13;_*D1]C%&VL#M8=0?>N6T[2-
M3C\1_;KF'"-</*S[U[VL"9P#_?1Q^'I6=-I'B..^U5M,2YMI9GNI$F>Y!@<-
M'B,+'N.'WX.2HX!YYQ0!WM03WEK:O$EQ<11/,VR)9'"EVZX&>IKG;>RUQ/".
MIPPRW*:A+O-L+AANC^4# ;S9#U#$$OP3V %9Z>'-1NVMI;HWS;(+Q )+ED:/
MS%0*O$SDC(8Y+''M@4 =G:W=O?6R7-I/%/!(,I+$X96[<$<&IJX:RT;Q!:7^
MGQ+-=1VD%M J;9?,1&"D2*^91G)[['XQ@C%/LM(U!F\/W%W9ZH;BTG)NS+?[
M\LT6UI!B3!3=CY>."<+@D4 =G%+'/$DL3K)&ZAE=#D,#T(/<4^N&M]+\6QVM
MK;)<O&1IJ2M+).&V7:P&/RR,G*EBC\<91O7G2TC3=6;P[J-M<W-[!=3JRPM,
M^7A8Q@95O-D)&[GENN> * .DEECAC:2618XU&69S@#ZFAYHHY(T>5%>5BL:L
MP!<@$D#U. 3^%<)#8>,KF&]:\,D9EADN(HUN%^260J%AX/1%1CGH3)QTJ9?#
M%U)>"-HKZ*)=5N+IIEO6&4>*0*4(?<O+ $#'XB@#N**XJQLO$QO;%[S[7YX-
MNSS"Z7R%C$*B5&C#?,YDWG.T_>7GBJG]E>(;_3[9=1M+]C:1Z<#&MZJO-+$[
M^>ZE9!U#*<L03@=P* .]FFBMX7FFD2.*-2[N[ !5')))Z 4\'(R.E<EXKT2[
MU"_DGM;>>8R:1>6BE+C:BR.%V;E+ $'YAG!YQG& 13O]'\0Q*]O9S7KV0N]P
M N2\NPP*,AC*AP)-QQN'7H1Q0!W-%<KXBL==N++38[*>Y8(C+=-"0DI?: K\
M2QC@[LC<1DC@@<4;S3_%9N=3-O-<&"1%%J#.H*D-%YO 88W@/L^8;?FY7<,
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M$6ACV'<V\GS0&Z8YSG-9E]X7U)[#:([ZYNY]!GM)))+XL!<,O\09\$$D@8!
M..@ H ] HKAM2TCQ$AF@LI[YK$7;&/;<EYMA@CP0QE0X$GF\%NXX(QC?T>PO
MH+S4[B]GN)'DE58/,E)01B*,$A =JDN')XS^&* -<31&=H!(AF10[1AAN"DD
M D>A*M^1]*?7G=CHWB&+S+B:VU+S'@LH[S-^IEN&1I3-Y3;_ )%)=2!E.,@
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MG **-^\$!3N4AJJ2:?XH?38HA%?B9;>:.!H[W:4GW#RY9LRMN7'.W<X&#QR
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M-MV@-LW8S\BC.,\>YJ+5/"MC?Z>]O$/(D)E*R99L>9,LTG&X'YG0=""/X2*
M)(O$EK+H9U4V]PD?GFW6(A"[R>;Y0488KR_ .<=\XYIMKXFM[R]M[.*SO/M$
MIE$B%5'D>6RJ^\[L=67&TG.<BG6?A^*/01I5[-)=1[]X;<ZE,/N0(=Q8;2!@
M[B1CK5FRT6PT^6.6WA82HLBAVD9V.]@SDDDY)*@Y//% %*^\5V.GRWRSPW 2
MSEC@>4[%1I7"%4!9ASB13DX YR169)XRDGNEDLH,:>MI]HDEDC#DMYACVC$@
MQ@J>0&!['')Z"XT6PN8[I)(6_P!)G2XD99&5O,4(JL"#E2!&O3'3W--?0M/E
M1EECDEW1"%FDF=F9 VX DG/7O0!4C\56<EQ<1"VNE\I;AE=PBK+Y#A)-I+<8
M8CEL#GKP<5O^$XTTV<5TEO=R1ND\DAC",(DA<)(S$-@@$C[I;(Z9K1F\-Z5<
M1-');$J?.Z2,"/-D$CD$'@EU!]L<8IJ^&-)%L\!MW9)(IHGWS.S,LS!I,DG/
M) .>OI0!'+XBCQ(T-O,(8[R.T^T.@,;N9EB95PV[(9B,D 9!ZXJNOC.P:&25
MK:\15"&/>J#SMTOE#;\W'SD#YMO4'IS5\>'M-$LLGE2XEF6X:/SW\L2*XD#!
M,[0=Z@G YYSU.:6J>$;"_P!-%I /LY78%8EV&U9!)M(# X+#J"#[T 64\1VT
MFB6NIK;W)%VXC@@ 0R.Q)  ^;;V)SNQCG-5++Q'-JGB"VM+6V=+,V\DD[RH-
MRR+(8RG#\%65@>&!['O5R'08CHD&FWL\MUY+[UF\QT=6#%EVL&W#;G ^8G P
M2><V;+1[#3G1[6$HZ1F,,79B06+G))Y)8DDGDDT 8<GBZY$D&S1[DJVHS6;(
MI1GD$:2-N3Y@!R@^]^M6;;QGI%WJ=M802.[W"H4;Y0 7C\Q05)W<K@YVXY S
MFM"/0]/CNOM"Q/YGGM<#,K%5D92K$#.!D,V0.YSUIMGX?T[3YHI;2.:'RXTC
M")<2!&"KL7<N<,0H R03P/04 94WBBXB\52:6L$,L,<BHZH6\U5,1D,A[;0<
M+SCKUSP5_P"$ZTM5L3+%<PF\C26-9?+5A&[!5<KNR02>@RPP<@5OI8VT<UU*
ML>'NB#,<GYL*%'TX Z54&@Z>KVCQI-$UK$L,9BG=,QKC"M@C<!COGOZF@#-?
MQM8I+(IL=0\M#)F7RUV;8Y/*D?[V<*V.V3G(!YQ/!XGMFO8K216,LLUQ&K#:
MB@1.5.=S9)X_AR>^ *M/X=TMXWC:VRKI*C#S&Y$K^8XZ]VY]NU*WA_37DC9H
MI"(YVN!'YS[#(S%RQ7."=Q)Y'% &3!X^TBZM/M$"S.I>)5 :,9$@8H2Q?:N=
MC<,0V<#&2 =K7-0;2= U'4DC$CVEM).J,<!BJDX/Y56_X1C3/[+;3<7?V-@%
M\G[9+@)@KL'S<+@D;>G3T%6#H\$NG7UC=/+<6]YY@E5W(PC#;L7!^4!<#CW/
M4T 5=3\4:=I.J0:=<,WGRA#A2OR!WV*2"03E@?N@XP2<"H1XOL&BCD6&?$EV
M;-,M&/G&>N7^7I]UL-T^6KD?A^QBN(KA6O/.C 7S#>2EG4,6"N2WS $G .<9
M/J:BD\+Z7-'<)*ERZW#!IMUW*?, & K?-RN/X3Q0!2?QWHJ2WL;2/_HN\,V4
MPQ201,!\V5.]@/G"@YR,C)K0M_$-I=:%)JT*NT,9964O&""K;3\V[9U[[L8[
MTI\.Z:4N8S'-Y5RQ=XOM$FP,6WEE7=A6W?-E<'/-32Z/:7&F?V?-Y\L&Y7R\
M[EPRL'4[R=V0P!'/&* ,I/&NG2QV\D4%W)'*H=W15*Q RF++'=SAP1\N[U&1
MS4MGXD_M#Q'%806LJVC073_:)% $C0RQQG9@],L^<@9P"..MF/PUI,4#0K;,
M49=K;I78D>89.23DG>Q.?>GV>@:=8:BU];Q2+.PD S,[*HD<.^U2=JY903@"
M@"FWBBWM=)FO[Y1&%OI;-$5E&]EE9!RQ &0N>2!UIL?C+39E+1QW#*+(WI("
MYV#=D!=V6.5(^4$=.>15EO#&F-YWR7($LQG(6[E 20MN+(-V$.2?NXZD=#4L
MF@6,LT,LANGDA0I&S7<I*94J6'S<-AB-W7GK0!2?Q=8I%'+]GN'C,*SS/&8W
M6")F*J[%7(()5ON[N :MV^NP7%EJ%X+:Z6WLGE1G9 ?-,3,K[ "2<%".@SVJ
M$>$M& C MY<+G</M$G[W+F0^9\WS_.S'YL_>/J:THM/MX+26UA5HXI7E=MDC
M [I&9W(8'()9B>#QVQ0!S[^,D2ZMG^R2M836OGM)&4<Q?O FYBKE2O.?ER?R
M-27WBZ&&XN;*WC_TRWEA4B1D961IDC8_*Q((W<!@#R.#5Z/PSI,<#PBV8K(C
M(Y:5V9@S[VR2<DEN<TB^%M(6>246\A:1RY!GD*@F42G +8&7 ;C^5 $*>)8K
M;P^^JZCM11=RVP5"!N(G:)!EB "<#)) ZG@4V#QCI<\EG&HG#7B,\.4!!"%A
M)R"1A-O)SCYEP3D5H2:+82:<;$PL(#*9P%D9660N9-P8'(.XYX-1MX=TR2Y@
MN987EG@ $<LLSNR@;NY/?>P/J.#D 8 ,VS\<:9J$*-9PW,\LCHD4,?EEI-R,
MX(._:/EC<D,01MY )&;5UXGM;>&9EM[B2:.22(18"EG2'S2,DX'R\9]:D'AC
M3%LXK4"Z$4+AX?\ 3)=T)"E1L;=E1M8C /0XI?\ A&=*^W&\,$C2DDD-/(4)
M,?ED[2V,E."<9_&@"E%XTL#<V%K<0RP75W'"YB9XR8_-)5 <-ELD?P@X&"<5
M;U#Q+9:;=WEO-',39V;7DI7;_JP"3@%@S?=/(&.Q(J6V\/:?:302P"Y1X8UB
M!%U+\Z*25#_-\^-QQNSUQ3K[0=/U*X::\B>8F)XMCS/L"LI5L+G )4D9 SS0
M!#/XCMHKV2RBMKFYNDF,)BA5<G$:2%OF8# 61>^<G !J#1O$9U"^EL;BVDBF
M$UTL4@4>7(D,WEG').0"F<@ DG'0XE7PII2+\J70D\XS&;[9-YI8H$.7W;L%
M548SC@>E78-(L;:X2>*';*AF*MN)P97#R=^[ 'V[4 9%AXFDDO[V*^MVAC6Z
ME@M@$&2(DW,20YSGMP,>]-N/&42VTDUGIE[=+&ULK$;$7,QCV@%FY.) <=..
M2.M:-UX<TR\0I+#(,S/.3'.Z-O92K<J0<$$@CI2_\(]I@L9K);=EAF,9<+*P
M.8U54(;.00$3D>F: ,R/QA#;W6HIJ=O+;P6LDH6XV@IMCB61@<,3N"ECP,<=
M<U-:>,;&^:".VMKJ6:6X-OY<?EMM(0.26#E<!6!X)].O%7I?#VES*ZS6HD5V
M=W#NQW%T\MLY/.5XJ2WT>TMG@=?/D>!F:-Y[B25EW#:>6)XP.E %6^\3Z=IN
MHI8W321S/+%$,KQ^]W[&S_=RC#/K55?%UO<Q![:VN0G^BDRRQ@(//9 JXW9W
M$/GIQCGL#=U3PUI&M3-+?V@ED:W-L6WLIV%@V.".00"#U'.#R:G?1K!_-!MQ
MB62*5P&(!:(J4/7C&U>/:@#&3QB@M'O+NRGM(8OMI=&VR,RV[%25VMCL>#W]
MN2^[\;6%C:RRW%G>I+"[I);D1AUV(LA/+[3\KH0 23GID'%Y_#.DR13Q/;NT
M<WG[U,SD?OO]:!SP&//'0DXQ5'7/"$6JW0NK:Y-I.6>1W&\DNR1H'!5U(8")
M<<E>Y!/- &II^LP:C>WMK%'(CVCA)-Y3[Q]@Q8?4@ ]1D<UF-XVTU1<@Q3>9
M;RQQ.@>(\ONVDMOVKRC##$'.!C)&=:UTFUM+V6]7SI+F5 C22RL_R@YP 3A1
MDDX  JA'X0T>*TEM8XKE(98TA=1=RC,:A@J?>X4!V^4<<T 3:UXBMM#"&>WN
M9=T,MPWD(&V1Q[2[')'0,.F2>V3Q5.Z\9V%EIMS>W-M<PI:RF*=)#&K(1&LF
M>7PV493A26YQC((K5N]&L+Z/9<0;E%M):@!B/W4@4.O![[5YZC%5;[PMI&HF
M8W%O(3.S-*8YW0MNC6-@2I'!1%!'3B@"6VUZSNM1-A&)?M :564K]WR]F2>>
MA$B$>H85D0^-;>"*[;5();=89;L)*%'ERK#,8\+\V=V"O4 $DXZ'&O::+!::
M[?ZLI!FNXXHB ,;50'WY)SR?15':H#X4T<R7#M;2/]H$N]6GD*KYC;W*@MA"
M6 .5P>* "+Q182Z#<:NJS&"W8I(BA78,"!@;25;J.A/6HE\7:>=832GCFCO#
MA7C8QDQN8_,V$!B<[><@%>0,YK2.E6KZ<UA+YTT#_>\Z=W8\Y^\3GJ/6HY=#
ML)KN>Y9)=UPNV=%G=8Y?EV99 =I.W R1V'H* ,V#QKIMRB&..8NUW]CV[XB
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M#C!/K0! OC+3Y(FEBM[R2);>*8NL8 S*=L:<D'>6XQC@]2*JP>,=OGR7UM)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=I82]<G&QC@CI;\4SZR^J:?9:1)<1SSV5U*HC:,*LJM"$:3=G*#><@9)STH
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M1E+I[A@G/"G>% [!1UK5OM/OM8T,0W)@@NA<).J[2Z828.BL,\Y55#8/7)%
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MC4M;=POV>1T-@DC$",LR2RL"IW#,BJ<\$,IX(Z@'11:A8A;G85CALU#/)@!
MI7=D'TQ4>F:O8:G964\12/[5'YD$4C)O9!W !/H#[=\&I8+&9=#CL+FX$\PM
MQ#)-Y84.VW!;:.!GTKGX/!0AU&SN&F22.&"WC(W2(5:$'#*%8 Y)S@CCGKG%
M &G?66@7\CWMU-"?*(AE9;HHF0VX(X#!6^8]&SU]ZTK^YM;&RFOKPJL%O&SN
MY7<0H'/ Y/T'6N0MO <MIHWV2&X@%VBPQQ79:5B!&KJK[2Y /[QOE^Z<D'((
MQU<UM=3Z?=6\IM)3("B"6$LC*0!AUSSGG.,#!Z4 +%=6EU;"61#$#ERES'Y;
M#:<%B&]..?I3+[5[#3U9YYX]T<D43JK LGF.J*2,\#+#GTKF)?!>H-IQMHM2
M@7S+:YM65XW=8HY60A8\MG"[,#)[\8  J\_A666.YMI9+1[:6_6\#- 3(?\
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M#LC)S"6.05.X9+9&#P1WI5\+:D+BV>34X)5'V1KAF@(9V@<M\N#@ Y].WOP
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M_P"[GCH)-1U/2M-BG%T\0,%K)<-$%!;RE&7('<<?C4[)I[31WS&'>A9$EW#
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M8B-KP;ONXWD[R#N!P!GL#74V]S8B>2W@6-!;0J^54!%1\XP>F/D/Y"HM,O\
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MM]F0N4SEA(."!@CO5H>(KN[\4V-I$(8;/[9-;L/-S+)L@+<ICA<D'KV'][@
MN_\ "/R6^FZU:V+V\'VV;S8%\H%(AY<:D%<8Y*,>G\70UFZ9X1N]/GLI6:QN
M/*><NDR%A$))A+F,X^\,8Z#)P>,8-C4_%LVF7-]#)8J7C>)+9=[9F#ND>_(4
M@ -)@C.1@<<BD7Q+J\@=8]&C\Z&SDN9(GG(9BKNJJHV_Q; ><8S@C- %>#PC
M=V]AI\.S2YGL'X\R(XNAY;IOEX^_\^>_.[^]P1^!_(TN6W$UO-<>39Q)++%]
M\0%24;OL8K@CG@]Z27QJ'V7UM%YEE)#<-;GS0J3!);>,.WRDJ-TC\@X"@G!R
M,6W\37\>M0Z8NG13N%B>XD@F)51)*\>5)4?=V$D''H,F@#-E\$W\EK;P)<6,
M4:W,MPR10[0A:=91M.,\8(QD#//;%6)_!!=)C%+;1RS?;#(WE?ZTS7*3('_O
M* A0^Q.*T-4\22V&KO:QVL3Q0FU$I>8K(WGRF-=BX.<$9Y(ST[54T[5]1M/"
M5[JMVJ7-U]LF5(_-(7 G,:J#M^4#'H>F>I- "/X2EGUJUU"9+1418=T$+,BQ
M-'*\@*8'S9+#.=N2,\YQ3O$?A.[U;55O[&^2V=$CD0,A(^T1,QB8X/*XD<,.
M_P OI45SXRO+:&96L;47-M'=2SA[DJA6 J"$.W))#CJ./>G+XCOQ?7(N(U$$
M>IK;QI"?WA0VWFX<%>O(Z$'/? Y '+X-^S2VC6[6\B6DUN\:3J3E8X6B.3Z_
M-N^H_&K>B>&5T>_2Y0P@^5.DOEIM,C/-Y@)/? R.?6L^7QC?I8Z?)%IMM<7-
M]"]Q'%!<LRA%1&VEMG#'>!Z8!/M6UIVM2WFL7=A/;"W,2AX06):1. 6R!MZG
M& <C'/44 82>"KJ6ZO);VXM94N)K=F01 *ZQ7!FY4 #D';CGU).:</"<]OJV
MEK$5^QB:XENPBX5D$YGMT]BKOQQC&[VJK=^+-3U+2(_LD,%M)=K93Q.EP2R1
M33K&5?Y?E?!QQG^+'*\ZNOWMU;ZK;VZ:R=.@33[BY>0K&RLZ-&!NWJ>,,V<$
M$^M $FI^&Y[_ %2_G22W6.]M/L_G.A,UL0LBYC/_ &TSVQSUSQ4@\+7]O/#>
MP'3K>YBN8Y5MX48086"2'/'.XB3/3^%1[U'9>+]4OG\E-(\N1(4$S.Y'E2M;
M";D8^Z"P7&<]3VJ/2/%%U;Q:#8W06ZFNX8C<2[W+J\B.X.=@7G;TSGGT R 2
M0^!1'H<]I(]K+<OI]M:),\6<&%<?7:3S6WJ&B?VC+I4K^5$UDSL=BYV[HF3Y
M#VP2"/I6(GBV;5!IHM52)I4L+B0+)N_UXE)C/'&-@Y]ZOZ?K]T?!-KJ]\+;[
M5*D?"%RA=V55& I.26 P!UXSWH QX/ 4T&F6T(>#SK>6)F D<)<*D;QC/'R'
M]YG@-]T#)XQL:EX;DN- TW3[(PQ2V(00R2,SB(A"F0"#OX)&&Z@]0>:H0^-;
MNXAAFCTZ'R@D;7!,Y!7=<- =HV\\J6YQZ>]6-*\07FJ>*8(B(8K-K:\*Q)+N
M<F.>.,,XP-I^]C!/4CM0 A\)/(D]O.MA)"^H"\\UHLR2+Y_G%'SQ@?='7H.F
M,567P.Z7]K,9(I8(FXBW-&(@+AYE*8]F48X^XOTJX/%-U)$LD=K:#[1>M9VX
M>Y(*E7=2T@V_+_JS@#/) ]Z@A\9W<[Q,FG0>2OV<3M]H)(,MR]OE/E^9<IN!
M.,@CUH KQ^"+N(NRS6*R(@6.18B&F9;A9U:4^Y7!QGJ3WP)+CP9>W=HZS7L"
MS/\ :&81JVTF2YCF"^NW"%3ZY_"KUMXK9KN*WO+>*W=[QK=U:0_NT\J217)(
MP01'U!QR><C%9=GXIU2]N=/N(%@6&^DM"T4SG$2R6S2$*0.N0.?\: .@T.PN
MM*2.R%O$EKMDED992_[UWSA<XXQN)X')&.]83>"+II+YA-91&3[8T4D<1#R-
M/.)1YGJ%V@<=<]L<D_C.]G-S'806NZ*>S"2N[A'CFN#$>J@_PGD9'/'3F6Z\
M7W-DMX$MXYFMQ=W#_:)P@,<+*"J83DG=QGIQDG- %JT\-W<6K6^IW#64DZW,
MTKJ%.%60(/E)YR-@],Y/3I3=5\*SZCJ.I2(]O';7T(25&!<RL/+ )R/EP$(P
M#@Y&1D9H;Q5??:[B./2XI(PT\4 ^T;7DDCC#@,"N%!R1G)Q_*TVN--X?M-00
MD/)>PV[B/*[2;@1,I#KD8.01C/!P>AH RM4\%7=U#);VEQ:PVSSS2B/RL>67
M*$%2!D8*-P,9+ ]L5L:;H$MCJPO&G1E'VOY0#G]],L@_(+BH_#_B&ZU>X\NY
MLXH%DMA<PF.8N2N]E(;*C!X!XSU]N:L/BJ\N;6PEBM;)6U&;9;J]R?W:[)'_
M 'GR\-B,C SR2/X<D H2>!+F;[8IGLX1)]I*/#&0TWG7"S8E]0 FSOD,>G0[
M"^'-OA672_)AWR2F8IY[[ _F!\AL9'(STQGM5*S\97-[)9R+IT26DRVOF,9R
M74SY VC;@@$#G(R#FH8_'%Y]@2>;3(A)<16LMNL<S.,3NR#=\HP1MSQG.0/>
M@">/POJ:W-JTE];.BFVDG<1%&9XE*G:!\H!R#[8QCGAEKX+/]GZ;9WD6G.EB
MK)E(<^?^Y,8=L_Q<Y[]^35JV\1ZC>7!MA86UM/':K-*EQ<$'<[2*H4!>1F//
M.#\PXR#5"R\67YLK&6>.&2ZN[*R< 2[8 \SNNXG;D=!W/. ,=2 7-;\,7VI^
M&++28KJ#=%!Y,SRIG?\ NBFX'!(P3G QGID5<TK1+C3]<NKPR1"">,!U7+-)
M( HWDD97A<8!(/!X(YS!XSO&4.NG6Y2+/VAOM![7#0$Q_+\P^4L,XXX]ZF\5
M:QJ=A+?06K0QPKHUU=+(2?,61 ,%1C'&1_GJ 59?!=Q]F\F-=-9 UZJI+$2F
MVX<,'(_OH!MQW!/(S6W=: ES+I+/(K_8%==\B[G;,>S.?7.#63<>+M1MG:S.
MEQ2:@+DP!8YF9"! LW79G.'QT[$^U/N/%M["EY(-,0)#<V]I&IF)<RRQQ/\
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M0O9RL^D6UB9'C.?,A+$'_=;</<;1U[6)/"5S-J;W!>SC1YC<;T0^8I-OY/E
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M5F89CRN"VW+8'&><BMB#6)+;3];N[B566UO'2/S,X VIA?E!/4]@3S0!BQ^
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MTV=V>XM8WFF4VQE2+=(%8$$;@,J,'Z4P:=I%K91VHL;=K<2KB-;<./,/ 8@
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M(B7]W_N<<?A7/:CX,CN(]4-HEK!)<O;^3MC"[8XBA,1X.%;81C!'/0]*K_\
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M[@Z]* -1]/TV1;G?9VC+.?\ 2-T2D2$?WN.<>]2BWM5 40P@!5 &T?=4Y7\
M>1Z5Q]EX(=3 +J'3DAC:V$EM"I:.7R5D!D(*CYF\P<8. @Y-(?!-T88[=);6
M-?[->PEF^^2I614"J5^7:7SD,,C((/! !T=U'HMBL=O<6MK''<S,X7R5VF15
M+EFXQG"DY/I5E;?3KBWC"PVTD+A70;%*D+C:1].,>E<X?"U_?22RZ@]FIFN&
ME>*,LZA3:>1C) SSST'%01^$;\WFC2.NG0P6,<*LD*C/R[PX!\L,0P;U 'S#
M!SF@#HK>+1KF-EM[6UDAO$,SLD ,<PR.6;&"<GH>>IJU)9:?,L1EMK:0*_F1
M[HU.&_O#W]ZY%/!-S'I5M9I]AC%M;F#8H.R<":*3YQM& ZQE6'/WN])/X$>Z
MM)5D6Q1VM[U8(E4M':RS-&4,9P,;=A.0 <L< 4 =7";"_-U$((W,,K13(\8X
M8J"<YZY5E/N#5B.UMXK=+>.WB2&/&R-4 5<'(P.@P>:R].M;V'5M4N?+1(;F
M]!PYY,:P(FX =RZ]_P"$9K:H C2"&(@QQ(A"[1M4# ]/I4#Z5ITD<T;V%JR3
MOOE4PJ1(WJPQR?<U;HH B^SP9SY,>?E_A'\/3\NU,>QM)(6A>U@:)D$;(T8*
ME1T7'I[58HH K+IUDCP.MG;JUNI6$B)08P>R\<#Z4@TRP%NUN+*V$#KM:/RE
MVD9)P1C&,DGZDU:HH A6SMEC$:V\(15"!0@P%'0?0>E$UI;7+J\]O%*R!@I=
M Q4,,,!GU'!]:FHH KW%A9W<;1W-I!,CL'99(PP9@, D$=< 4Z2SMI8989+:
M%XI?]8C("K\ <COP /P%344 5_L%GY2Q?9(/+6,Q*GEC 0XRH&.AP./:G2V=
MK.K+-;0R!BI(= <E>G7T[5-10!5N--L[J(136T;(&#8 QR&#]NQ8 D=#WJ:2
M"&8J98HW*@@%E!QD8/YCBI** (OLMN !Y$6 %4#8.BG*C\#R/2HO[,L";@FQ
MMLW/^O/E+^]_WN/F_&K5% $2VUNN-L$0P21A!P2,?RXIEM865FBI:VD$"J2P
M$484 GJ>!WJQ10!"]G:RW4=U);0O<1 B.5D!= >N#U%.\B'R?)\I/*QC9M&W
M'TJ2B@"O-86=R )[2"4!Q)B2,-\_][D=?>I%MX4G>=88UFD 5Y H#,!T!/4X
MR:DHH KV]C:6D;1VUK!"C_>6.,*#]0/J:ANM&TV]CD6>RA)D@:W+A KB-@05
M##D#!/0U>HH R;3PUI5I%)&;5)_,E\YFN%#DOM"@\C ^4 <5HM;0/%)$\,;1
MRY\Q"H(?/!R.]2T4 51IE@%@46-L%MVW0@1+B,^J\<'Z4X6%FHD"VD $F[>!
M&/FW8W9XYS@9]<58HH KQV%G% L$=I D2HT:QK& H4]5 ]#@9%/GM;>Y0I/!
M%*I4H1(@8%3C(Y[' X]JEHH 9%%'!$D44:QQH JH@P%'H!VI]%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O?7:6&GW%Y(DKI!$TK)$A=
MV"C.% ZGCI7&?\+7TC_H#>(__!5)7=T4 <)_PM?2/^@-XC_\%4E'_"U](_Z
MWB/_ ,%4E=W10!YI??$/2;JX2Y@T_P 2VUPB[ XTF0@KUP1CD5#_ ,+%3_J8
M?_!"]>HT4[LGE1Y?_P +%C_ZF'_P0R5IQ_%32DC4/I7B)V P2-)D&:[VBD.Q
MPG_"U](_Z WB/_P524?\+7TC_H#>(_\ P525W=% SA!\5M() _L;Q'S_ -0J
M2N[HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB/\ \%4E=W10,X3_ (6OI'_0&\1_^"J2NXAE$\$<RAE610P##!&1GD=C3Z*
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M/MWQ1_Z WAG_ ,#)?_B:[NB@#A!>_%#(SHWAK'?_ $R7_P")KNZ** "BBB@
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MXME@LK%0;&[O-0B\Z8Q!I3<NT.W"G<-F[*G PZ\T 6_MWQ1_Z WAG_P,E_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<R";RL %4_VO7@&H_P#A:=G_ -"OXM_\%#_XT?\ "T[/_H5_%O\ X*'_ ,:
M'WD%S=>)/M,5E=-=/=6TMG<O ZK';!1YJ,Q'R9_> J<$[EX/:SK*/=:SHL=W
MISQWB2I,][;0RS+$JOD1JX3C?P&S@;<Y[53_ .%IV?\ T*_BW_P4/_C1_P +
M3L_^A7\6_P#@H?\ QH MZ,DG]M:S>:=ISVKR;(EM[F&6!)=C-NF9]A!9MW&,
MG:JY/.!GZI;/=ZMK,UCI]Y;2);F!PEM(IO09$:1M^-K852J<Y^9L8&*E_P"%
MIV?_ $*_BW_P4/\ XT?\+3L_^A7\6_\ @H?_ !H IWEG$UD]LNDWD5K<:@SV
M,J6,I-C"%BWLJ*I:-F</M&!]XGID'3TNRN5\5+*UI<)=+<WC7=RT;!)8&;]R
MN_HV!Y> "=NUNG>#_A:=G_T*_BW_ ,%#_P"-'_"T[/\ Z%?Q;_X*'_QH [NB
MN$_X6G9_]"OXM_\ !0_^-'_"T[/_ *%?Q;_X*'_QH [NBN$_X6G9_P#0K^+?
M_!0_^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ*X3_ (6G9_\ 0K^+?_!0_P#C1_PM
M.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=G_T*_BW_ ,%#_P"-'_"T[/\ Z%?Q;_X*
M'_QH [NBN$_X6G9_]"OXM_\ !0_^-'_"T[/_ *%?Q;_X*'_QH [NBN$_X6G9
M_P#0K^+?_!0_^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ*X3_ (6G9_\ 0K^+?_!0
M_P#C1_PM.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=G_T*_BW_ ,%#_P"-'_"T[/\
MZ%?Q;_X*'_QH [NBN$_X6G9_]"OXM_\ !0_^-'_"T[/_ *%?Q;_X*'_QH [N
MBN$_X6G9_P#0K^+?_!0_^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ*X3_ (6G9_\
M0K^+?_!0_P#C1_PM.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=G_T*_BW_ ,%#_P"-
M'_"T[/\ Z%?Q;_X*'_QH [NBN$_X6G9_]"OXM_\ !0_^-'_"T[/_ *%?Q;_X
M*'_QH [NBN$_X6G9_P#0K^+?_!0_^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ*X3_
M (6G9_\ 0K^+?_!0_P#C1_PM.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=G_T*_BW_
M ,%#_P"-'_"T[/\ Z%?Q;_X*'_QH [NBN$_X6G9_]"OXM_\ !0_^-'_"T[/_
M *%?Q;_X*'_QH [NBN$_X6G9_P#0K^+?_!0_^-'_  M.S_Z%?Q;_ ."A_P#&
M@#NZ*X3_ (6G9_\ 0K^+?_!0_P#C1_PM.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=
MG_T*_BW_ ,%#_P"-'_"T[/\ Z%?Q;_X*'_QH [NBN$_X6G9_]"OXM_\ !0_^
M-'_"T[/_ *%?Q;_X*'_QH [NBN$_X6G9_P#0K^+?_!0_^-'_  M.S_Z%?Q;_
M ."A_P#&@#NZ*X3_ (6G9_\ 0K^+?_!0_P#C1_PM.S_Z%?Q;_P""A_\ &@#N
MZ*X3_A:=G_T*_BW_ ,%#_P"-'_"T[/\ Z%?Q;_X*'_QH [NBN$_X6G9_]"OX
MM_\ !0_^-'_"T[/_ *%?Q;_X*'_QH [NBN$_X6G9_P#0K^+?_!0_^-'_  M.
MS_Z%?Q;_ ."A_P#&@#NZ*X3_ (6G9_\ 0K^+?_!0_P#C1_PM.S_Z%?Q;_P""
MA_\ &@#NZ*X3_A:=G_T*_BW_ ,%#_P"-'_"T[/\ Z%?Q;_X*'_QH [NBN$_X
M6G9_]"OXM_\ !0_^-'_"T[/_ *%?Q;_X*'_QH [NBN$_X6G9_P#0K^+?_!0_
M^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ*X3_ (6G9_\ 0K^+?_!0_P#C1_PM.S_Z
M%?Q;_P""A_\ &@#NZ*X3_A:=G_T*_BW_ ,%#_P"-'_"T[/\ Z%?Q;_X*'_QH
M [NBN$_X6G9_]"OXM_\ !0_^-'_"T[/_ *%?Q;_X*'_QH [NBN$_X6G9_P#0
MK^+?_!0_^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ*X3_ (6G9_\ 0K^+?_!0_P#C
M1_PM.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=G_T*_BW_ ,%#_P"-'_"T[/\ Z%?Q
M;_X*'_QH [NBN$_X6G9_]"OXM_\ !0_^-'_"T[/_ *%?Q;_X*'_QH [NBN$_
MX6G9_P#0K^+?_!0_^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ*X3_ (6G9_\ 0K^+
M?_!0_P#C1_PM.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=G_T*_BW_ ,%#_P"-'_"T
M[/\ Z%?Q;_X*'_QH [NBN$_X6G9_]"OXM_\ !0_^-'_"T[/_ *%?Q;_X*'_Q
MH [NBN$_X6G9_P#0K^+?_!0_^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ*X3_ (6G
M9_\ 0K^+?_!0_P#C1_PM.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=G_T*_BW_ ,%#
M_P"-'_"T[/\ Z%?Q;_X*'_QH [NBN$_X6G9_]"OXM_\ !0_^-'_"T[/_ *%?
MQ;_X*'_QH [NBN$_X6G9_P#0K^+?_!0_^-'_  M.S_Z%?Q;_ ."A_P#&@#NZ
M*X3_ (6G9_\ 0K^+?_!0_P#C1_PM.S_Z%?Q;_P""A_\ &@#NZ*X3_A:=G_T*
M_BW_ ,%#_P"-'_"T[/\ Z%?Q;_X*'_QH [NBN$_X6G9_]"OXM_\ !0_^-'_"
MT[/_ *%?Q;_X*'_QH [NBN$_X6G9_P#0K^+?_!0_^-'_  M.S_Z%?Q;_ ."A
M_P#&@#NZY[Q9I]QJ4.EP06\4Z_;@TJ3QEX]OER<N!VSC\<5B_P#"T[/_ *%?
MQ;_X*'_QH_X6G9_]"OXM_P#!0_\ C0 37&MZ#>:?8Q27D]G96^VXN)8P8I%6
M"0[\[.,.J#F7/MCDY]EK/B6YTM6%[<O,9U^T;;?=);H8 5X$'(9\G(0X&!D<
MU?/Q2LB,'PMXL(/_ %"'_P :BMOB1I5G$8[7P?XG@C)SMBT5E&?7 H V?$JR
MOH&F//'=3WD=W9RM]DAE8966-I&**#QM#'##VZU'J$#R^.-)NK:U<F-SY[BS
MD0[#$XRTQ^4H"5_=XSNP>U4/^%IV?_0K^+?_  4/_C1_PM.S_P"A7\6_^"A_
M\: )-8E\07%[J%K ]^H9IHQ'';+Y0@^SDJZR%>9#+M&-Q/)^7'-3ZM8+9>#-
M*ME@O));>:U94MX7)&V1&<LD2XP%#=1C/OBJG_"T[/\ Z%?Q;_X*'_QH_P"%
MIV?_ $*_BW_P4/\ XT 6--CU!?&MQ-+9B033OF>6S=6BM_+79LE)Q][ ,8 .
M2Q(XR>SKA/\ A:5G_P!"OXL_\%#_ .-=V#D T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>bionano-nancyridgeleasee014.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **3<-VW(R1G%+0 4444 %%%% !129!) (R.HI: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "B@$$ @Y![T4 %%%% !12
M@C(((]J6@ HHHH ***0D#J<4 +112!E;H0>,\&@!:*0$$ @Y!Z$4M !1129&
M<9Y]* %HHHH **3(SC//I2T %%%% !1110 444@(/0YH 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HI"0,9/7I2T %%%% !112,P52S$ #J2>E "T4
M44 %%%% !1110 4444 %%%% !11D9QGGTHH **3()(!Y'6EH **** "BBB@
MHHHH **** "BD) QD]>E&1G&>1VH 6BBB@ HHHH **1F51EB /4FEH ****
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M+<RD.ZQHHM9=[EE9EVKMW$$*Q! P<'FK]CJ5KJ(E-J[NL4C1LQB95+ D':2
M&P01D9% '+V\5U8>$/"/G6UV'M#;_:8XX6=T A93E$!/!(SQ37OO$<^J:GMG
MGM8!'(;<&R>10IC!C< 1<L&Y*EB>HV]*W9?$5K:WUW;72N@ADCCC\M&E>5F0
MO@(H)X )XSP":6+Q-H\UW#;17>]Y@I1EB<H=R;U^?&T97D9/- '/C4_$A-J\
M,-Y))):2@6\L.U1*OF[7=S$H*L0@"YC89!*G)P^TF\07<]M#%>:FMF]U&)+J
M>S2.8+Y$K.NTQ@!=ZQ -MZL0":TK;QEIES=7*H9?LT4-O)'+Y$FZ8RM( $3;
MN88CR"N00?:K+>*]&49^U.P%NMR2L$C!8V)"DD+P258!3R2",9H J[+O3/$M
MC9V8N&TV42/)$D1V([&1V=G*$$$D#:&4@XX8'C)\0:WKVGZEJDELETEI;VLY
M5I8@8MPA#(RGRQ_'D8+MSG@<5VL,RSPI*@<*XR Z%&_%6 (_$5C-XKT*6TED
M>X9X $R#;2'S5D;8A0;?WBL> 5R#F@#EEU7Q--:HMM?7#L)KA)I#;%VMY (S
M%&X6#++M9F)"C/ W#OH:DGB:>/4DBN;W;,EY%%&D2*(\)F)E;;NR3D9)[^HS
M6^=3TW2;NPTR.VD@6ZC>2/RK8K&@7!.[ ^7[W?'OBF#Q9HS0K*MQ,0[K&B"U
ME+N65G7:FW<055B"!@X/- %+3+O4CKMM$TM_<6+V@),UL8O+<#DN3&,D],!@
M1_=[UGWR:SJ-]<V;/>F./4;>2&X2W"+$GF'(4-'R5 &6RZG@\=*Z1-?TV1[-
M4F<K>H'MY/(?RY 5+C#[=N=H)QG/'2J1\::.UM%<0/=3I++#&HCM)=V)<['V
ME02AP<,,@XP.: ,@:CXE2[TJ QWS$2(MQ(T(V2IYSHQ8",X8(%8_,@^8$ \B
MK7@ZQN[.4FYMY8A_9EG'\ZD?,K3EA]1N7\Q7166I6NH&;[*[N(9&B=C$RKN4
ME2 2 &P00<9Z4RXU>SM;Z*SG>5)9<["87V,0I8@/C;G"L<9SQ0!Q>E_\)#H_
MANSLV_M*15T^PVE85#6[E9!(G$3$A0D8QM9ANY.#D6[>^\8/#9QF!S/+I\=X
M[21*JK,(6#P'@8)E\MO7!<<8XW(O%NBSVOVB*YE9"R*JBUEWOO!92J;=S @$
M@@$8!]#2VOB2TE\/6.KW(>&.\"[$1&E8LW10%&2>/2@#/TEM:OO#6I+=7-R;
MEXV6!GA,4L;&/I\T: _-R"%(YZG%9MG!K4=[!J%O/J)/V73895GMU!F'GR+-
MO!0$%$<GC'8G-=):>*-)OH));6:>98T20A+24L5<D*57;EAD$< XP<XQ4=OX
MIL+G5!9QN"LMM#<6[@-F7>9<C;C*A1%R3TW8..X!4\*W.NW-Q='6'D4A>87A
M*B-]S9V-Y:AEQCHS] <\\X]Y=:_IVD6NHW$DTEVUE.7DEMXP897D@5$7"<9^
M;@@Y(Z-@"NDL_%6EW36D)GQ/<1QN L<AC!=-ZC>5 &1G&<$XZ9XJ6UUS2-9L
M[MHY#+;0QAIO.MW1"C+N!^=0&!7G(R,4 <?"VNWB+J=M?7<UW;6MVI*VZ_,X
MG4K P,:Y^48. "<$@UT6FP:A]E\06\EU?F=KB7R&E0 (K#*&-MH!'/OC':KD
M.MZ-:Z>KQM]FMEMI+E4-L\6(D(W,%*@X^8=N<\9J+4O%-E8P321K+.8+F&"7
M;#)M!>9(VVL%(9EW_=7)R,<4 8%M=^((X=-BCEU1F%M:;!+9C$SF0B<3,4RF
MU0,<KGJ"QK5U>YUU?%5K!:O)%IY6$AEA,BR,9&\U6(C;'R!<$L@!8G)P0-J+
M5K.?3/[0A:62WR1\D#EP0VTC8!NR&!!&,C!K(N/&=A Y<13S6I2W9)(8G9RT
MTS18*8R,%><\]L9P" 8MR/$\FF/YUWJ672*=O*MT#Q%;@;E0*F3F/G!R3CW(
M,MS?>*?M&L^0]P#%;SFTC-J6#XB!B93Y0&_=U!<]2-HXQT4WB?1X'N5ENRGV
M9'DE9H7"@)C?AL88KD9 )(I[>(-/5X4?[4C3J6B#V<R[L*6VC*_>VJQV]>.E
M %'7;:_BTW31%?Z@[0WD;3S01JTCID@Y54P1R.B]JPT3Q+I5K>?8?M,@F?4)
MA$\*XA/VP%"F%R2T;R, =V<# [5OVGB[3KJSAO3YD-O-;17"+)$_FGS&*JNP
M+DDD8&,Y[<8)E;Q9HJB$FZ?][G'^CR?+A_+._P"7Y,/\IW8P>M &5>0ZIJ/@
M=X9MUW=2746!+ REH_/0X=2B$@+G/RC('XTV/3=>TA/LMC=,Z0VES<1Q1Q*(
M7G9R8XLMDJ@#8 !'3L.*Z:RU*UU!IQ:N[B"1HG8Q,J[E)5@&( ;!!!QGI5>Z
MU_3;.[GMIYW66"-990(78*K'"Y(!&2> N<D] : .9MY?$]U8PJ+Z]C+S/ND^
MR!9440$@'S(5&#(!R%[XR:? WB$R67VLSS8ECF,LMHI,):TEW !5' DVC^]\
MVW)S6W+XMT6")))+J15<2,?]&ERBHP5RXVY0*2,EL 9J6[\0V5K)/"699XEW
M;9HI(U9=RJ2K%<, 67[N>H]: .6.H^*GM[!4:[BR)5>X>V+>9(&78600;E0@
MMP53H?FZ$]#HUUJ+ZCJ\5W]IFBBDW6\C1>6A4L_R*"BDD *"V6!R"",D587Q
M+I32F))IG<7#6P"6LK;I%+!@,+SC:V2.!CDU<O[Q;"V$S;<&6*+YB0,NZH.@
M/=O_ -76@#B+2Y\17HMIKM]6@ABOX7.( 9/+:)@RL/)7<H<KG"X&2<D $;6N
M7VL0^(;"#3XKLVY>'S2L8:)E:0J^?W9(*KSRZ]1@'FK7_"8Z'YYA^U2[@Q4G
M[++MX?83NVXVAOE+9P#C)&:D?Q7HL;7*R7;(+996E9H9 N(FVR88KABIZ@$F
M@#G3J'B33-+FU*]N+F2."UCO)TE@C7 60^;&N%')CZ G.0/4UI:BFL/X=TB:
M:XO(KQ;F&6[^QQAF52?F7:%.57<!TZ+D]ZT7\0Z/+(EK*\F9=HV2VD@ +?=5
M\KA6..%;!/''(I3XGT@11R+=-()4CDC$4+R,XD5F7"JI))5&. ,@#)Q0!SDP
M\2K%,+-[BT$<ES(J0VL>)";Q@N<J>L9W<8)SG-%Y=>*X'AMXYKC8LER@NFMM
MY<AU\K>J1-\NTMR N<?>!Z[TGB[1$ECC%U)(T@0IY-M+(&WIO4 JI!)7D#J:
MGC\2:3-+:QQW>\W*1O$RQ.5Q)G9EL84MC@$@F@"'5KHZAX>OSI\9GD1VA"F+
M<&9'PV 1@X(/Y55TI]<_ML->37#VDK7H,3PHJ1!)U$."%!Y0L>2<]:>WC311
M9"Y@:YGC+P*%BM)=Q$S[4< J"5)SR,]"!D\5KV>I6M_)<);.[^0YCD8Q,J[@
M2" Q #8((."<'K0!R)TW5;G4H86O=31HM:FE\XPJ1#$UO,%*%DVE26 [X)QP
M:DTJ_P#%%SJVG"_$MO&]O \L?V=MCDQ9D#$1G8P?(P77&T<'/.T/%VB&W><7
M4AC7RR#]GES()&VH4&W+ACP"N0:NWNKV>G0Q3733)%)T<6\C!>G+D*=@Y'+8
M_2@#$OK[5(=1U?\ Y"1$4>;*"VMU,<B^4"6\PQM\^_<-N>P^4YYHV&H>(BVF
M&X^VNK7<L<D?V8JSQEU".S&$ !5SD$1DCIDC!V)_%VFPZJ;,NWE1Q3R3W#(X
M1/**A@#MPY!8@[2<$8ZU7_X36T6._F:WF$%H\JX,;K*XCA24D1E00?GQ@XZ9
M[T )X2N=>N8;A]89_.\J/,,D+)Y<OS;PK>6H9>@&"_3[QS6%)#K^N:2MM>/J
M#*TFGO<++:(FR;[0#,B IAHU4 Y^8<#YB,UUG_"36"L3*9$4K$8T\F0S,9-Q
M \L+NSA&/&> 2< 4J^*=&>>WB6[9FN%C="(9"H$C%4W-MPA+*5 8@Y&.M %#
MQ%>ZO;:MIL&F0W7E&6'S3'&&B9#*JN#^[;&$W')9/;/2G:$^N?VD#J,UQ+!-
M'.Q66%%6%EFQ&%*J#RASR3G&:U$URRFTJYU* S2VT"LQ98'!<*,G8"!N'H1D
M&JT7BG2I%M"TLT;7*1NJR6\@V"1MJ;SMPFY@0-Q&>V: .?AN_%<WVQ7FGAE-
MRD>Q;;/E*;E5+(QB"D>46)^9^QXP:))O%MI;3M'-=W3F.[ \V",;/+N$2-EV
MIRS1%VP00Q P.U;FM>*;;2&U"$V\\D]I8-?']VPC91NXWX(!^4U*_BK1TMC.
MUQ*%#LC(;:7S%*@,VY-NX  J<D8PP]10!A"\U^*T2[GOIUMK>SO+F1VM@F]D
M9/+63?&I'!?H$SC/O69;ZOXFGT_Y+ZZ>3[05G(MMTEL#"I0$+;Y8%BS9"=U&
M1S75^(O$D>B10-Y$=PDT<LI+3B-=B+N."1@D@\#CZT6NNZ%9Q30VR-;K"R"2
M**S<8D<*P0!5P7PRG:,G!H S)9O%*7DLT4DLW^D-#';F!5A*_8MX?)7<,SC;
MDMCG%0S:GK,,&EK;7=_,VH2&S8WEHD4D,I"OY@78N55$F[$$XZBMN7Q?HD)B
M#7<A\U$D79;2M@.S*@.%.TEE90#@Y&,9XH;Q+I+E)VD5H1&KQOY3F0,SF+:$
MV[@=P*XZYR"!0 _4=4>;P_<7FFK<R.)3$ODI\^1+L9@"C9 PQR%;(' /%<];
MW/BN:UAF>2\C>*-&,?V=/WQ^TLI#90'F( G 7KG KI7\1:3!<&VDN#&ZKEMT
M+JJD)YFTMC ;8-VTG..<59CU.WETX7Z"X,!&0/LT@<C..$V[C^5 ',Z,-4N/
M&27-_P#;3Y5O>Q,);<)#%F>+RQ&P4;MR)G.6Z=N15/49?$UY::Q;Q2ZDDQMK
MX;$MU18RK?Z/Y+[<L67K@MU/W3BNLM=?TZ]GA@MII)))D+A1!)\H!93O^7Y/
MF5AAL<@CK1_;5LDNJ"?]S%IQ7S)&.004#Y '/?&* .=AAUB#7)KZSEO9()[F
M%6CG@5!,GV?!=\H&4A@N<;0",8J'2Y_%5[:VB7-W=P22SQ+<$6H#PCRY#( 7
MB"[=P0 @-C^\<BNFA\1:9<300Q2RM-,SJL7V:0.I4J&W+MR@&]>6P/F'K4?_
M  E&D_8HKL33M#,2(BEK*S2 #<650N67'.X#'O0!SXOO%W]O?9/*E^Q_:/LW
MG^0N,>;YGF9QC;Y'R9Z;_>FQW7B.T6&.UMYGD:TG*6PMA'&DP\UD9VV;2&(0
M8#*0<'!!)'5V>M:?J%W);6DYFDC19&9(V* ,JLOSXVY(8$#.<?0U13QCH;SB
M%;J7<6"@_990O+[ =VW&W=\N[. >": *VDW>KCPYJ-S<M=7-PBLUNA@,<W$8
M.T;HD!.[.#M(YQSBLS39=>N-0TV>^FU)(([V:(X@XD0QJ4,@\I3MW;ANVKCZ
M\UTS>(--2Z>VDFDBE1TC(E@D0$L^Q<$J P+<9&1R.>13Y-;T^*P6^,S- \IB
M0QQ.[.^XKA54%FY!Z \#/3F@#%UB3Q#'+J\]C+<%(A EM"L2E2K,OFN#L9F9
M5W8'//\ ">!5"34?$D8TE(_MLSO.AED%N51HC<!2'!A!#+'DDGRQW&:VM/\
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M-K'YD#-)!O5 $ZJOFD*<Y*\@X%7]*DUVZU2S6:ZO5T]?M+^9+;(CSJKQ"(2
MH-N=TO "DA0:U9?%&CP-<B2[*_9P[2,87VX1@K[3C#;6(!VYP3@TX>)-*-PD
M#7#QR,,_O8)$"G87VL64!6VC=M.#CM0!FW4GB!=>EDMY)VM%NTB2W,2>6T9@
M)+%MN[B3'.?:L7SO$5WIZ/+=:PJ1O923.+-4E63>?/15$>70#8> WU89KID\
M4Z?-=64$,=XQO YB<V<J+\H4Y.Y1@$,,'I19^*M+NGM(?/Q/<QQN L<A0%TW
MJ-Y4 9&<9P3CIGB@#+M)=5AU2"&<7EK:/=73#[+9JPE;[2=HD.P[5*8.[Y<Y
M)W9J?PE<:[=Q7#:U)(DIBCW1-"5\J7YM^QC&JLO3&"_3[QS6QI>N:?K(E-C+
M)((PI8O"\8(894C<!N!'.1FGR:M8Q7#0/<!95E6$KM/#LNY1T[CF@#A[&+7]
M'T>QM;8WZ2FU66-5M$837+.=ZSD)\BXV\G:3ECDD5V&A+J#17<VHSS.[W<ZQ
M121JHCB65UCVX )R@4Y).>*A/BG3/L\5X)BMD]O+<F:2.1#Y:!2652OS+A@<
M_EGL2^+=%@M6N9;B940N'7[++O38 S%DV[E #*<D8PP]10!MT4@.Y01G!YY&
M*6@ HHHH **** $(#*0>A&#6#!X2LH;..V:YNI5CMX;=6=EW;(G+H.% ]LXY
M ]>:VKEVBM99$1W94+!4 +,0.@SWKB=.OO$VHPI$TM];*]ZR^>]J/,$/V;>,
M[XE'^M^7.SVR>M '1Z3X;LM%N[BXM"1YS.VUHXQMW-N(#!0Y&3T9C^E9MKX+
MC^SRK>W]S+(QF$)0J!;B2<3?)\O)RJ'YMWW?3BLM+K7-2U31S?Q7T3+/;2FW
M2S(AVF#+NS[?E82,R[2PP ..<UJZD^OR:ZT=K=7,%F)X8@([9&&QD8N^YE/(
M(7!Z ]0<XH O6GAJWLG,R7-Q-<;+A?,F9?F,S*[DA5 ZH,8P!S5'3_!<=K96
MGG:E>/J%O' J72F/,7E(Z!5!3:5Q+*/F!/S\G@8HV^K^(FU#1(I;>]&^.(7F
MZVQ&V0X9N(SM((4G+KC(^4YI-+F\1K;Z86^TP1)!8QR6PM%5?G3$I.5R-IP<
M @#'.: -23P3ID\<<4TEP\*6TEL4)0%UD5@Y9@H8YWDXSMS@XR!5R#PW9PZ'
M=Z2S/);W2LLC"..)OF7:?]6BC/'7&:Y6/4?$-CI&DP1'5[B[#D7#3VV0V)55
ME;$1)&TL0<J",G<<5::?Q%$DIMEN(4A>YF$26H(F/VM@JG*DX:/GC!.0<^H!
MT%MX<MX+J.[ENKJYNDN?M)FE* NWE&( A5 P%/0 <\^M,U'PO9ZI>SW5Q/<;
MIK9K8J@10$;&>0NX],@,2 2>*PIY_$445PUFMQ"(?MTZQQVH/GLMS^[4Y4\,
MA)XP3U!JQX>UJ^U#Q3>PW-W(+=3<K#;M#A'$<VS<C;!G P#\YY;H.@ -.[\+
M6MS=374=Y>6UQ,TA>2%DSM=(T=/F4C!$2'U!'!JM=>!-%N[GSB)TXB5420!5
M"#:0./XT 1O50!QUK#U.7Q!JFG:M9,=0_>VMTLL0LPJQ,)%$2Q,4_>!TW9Y;
MU^7I6_KEU>Z':VD=A#/) MK-$!;VOF'S @\KY47Y1D'L%[<<4 3S^%;"X-T7
MDN!]IBN87PPX$^S?CCK^[7'X]:IZ3X;O-.\47>I&> P3M(QP 78,5VC[F5QM
M&?G(.!P, "E =7_M"Y\]K^8O?V<BQRV^8HXS''O*';QA@^1GC&<<Y.=9P:Q;
M:9IB@:C9I!#IPE:WM\R$?O!(I!4D@97(QQWH ["/P_;1WHN?/N#MNVO$C)7:
MCM&R-CY<X(<GDGGVXJII_@W3=,O;:ZMFDWP0Q18=(GW^6@16+%-P.T#[I XZ
M=:QC>>(X;V"W@A>VMVN;A@WV9BK_ .EN &"Q-@&/:0<IG<3N.*UM&U>Y6\N;
M;4VN6:2[,5K(UNR(^0[!5!12-JIR3N'3#'.  3ZCX6M-3OKB[GN;E7G@\@B,
M1J%7*GKLRW*]'+#EN,&HH/!FFP6)M%DN-ABFB)!1>)91*W"J /F'&  !VJGK
M.I:]:ZEJ<=A'<7"K:[[<);GRXR-F<DQG>W+$;6;H04R,E+)_$5]+90M?SP1-
M#=.\XM>2P:(1*_F1+@X:0\*NX+[&@"]>^#=-O;H7+M()A)+)N*12#]YLW+AT
M88^1><9'//)K0U'1;?4[F&::25?+AE@9$(VR1R!=ZMD'CY5.1@\=:Y4ZEXGN
M;%-1_LV1+M8Y_)MGM^4=(,<]\-*&QS\R[<=:ENM1UT7-A'I]Q>R6KJ2;BZL7
M1G?>/E=5@R%VYQPF<_>XH Z"PT*/3TN2+NXNIYX4A,UP5W!$#;%^55&!N8],
M\G)JAH_@^'3[>Q:ZO+FZN[9(%\QBN (D=54 */E'F.>?F.>32Z3J]RFH7=OJ
M;7)WW?E6CM;LB/G>P1044Y54Y)+#H0W.!5N]6U3_ (3![*UEN6CBFMQY"6NZ
M(QN#YC/)M^4@#(^8<\<YQ0!H#PI:B65A=W6QO/,<3"-DA,S;I"H*'.3GAMP
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MP( ));(Y.#G'7F@"_+X)TJ6*Z0F;,]W]KW'8_EOR<*&4KMR[G!!Y=O;%C4-
M>XL-,M+6[>V%E.DOFQHBMA58< +L!^;IMQUXK)TA]3@TCQ3=VHO+JZ:9I;)K
MVV,+SL+6(+\FU.-ZE>@Z?C4&H:GK4=JATZYU:?\ T:5X'DTW#SW *[8I!Y8V
M)SUPO4_-Q0!K+X-L8WMS'=WJ+$(-Z!TQ.893*C/E<YWLQ.TC.?IBP/#=O&+(
MVUY=V\EF)$22,H69)&#.C;E(P2J] ",#FL:[O?$\#7T\ GFR+Q8(#;#:FS!B
M8$ $D\]3ANWK52ROM4TZ2_N474[FWN+^3][+I["60"TB"$H$! WJ5SM R.:
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MNVJ;0,#M1>0)&9>!DXV\GJ 7H/!&FV][I]RLUR6L8DBA5BAX2-HQSMW#ACD
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M\8MC&L4NTEBY:,=>  &!!XV]P 27'@J*>2"#[;-'8BTGMITB2*-IUD9"5(5
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ME';17%U'Y=O:P1R*REE%NY>-N5()R><C!]*N6.B06.IWU^LTLDMYM$@8(J@
MG'"J,GYL9;)P ,US.CW.LZE?:=+?P7AC@U)F1YX"C+&;-_O?NX^ [%<[>O&3
M3]1UCQ%'K.IQV-M>-!':SF,/;[E$BA-C)B,!LY? WL3C&!TH U;7P?8VJ0H;
MJ[F$ @2#S&7]U'"^]$&%&1D#).6('6I]?\,6?B(P&[EG01*ZA8]A!#%23\RG
M!^48(P1D\\US$$^OV:WTU@+ZY%[J#0))<6>QP7@A6.X9=JX1&1@> #GVJQ)J
M/BHSZN$\Q&B$RP1_9F?I(HB=3Y04Y3)(WMDG@+@@ &O+X-L9Y+@R75X8I5N
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MG:C=/=2/*L[S--NV1R %HT0@*Z,N"(D/3.1U[5%X5GUN0*-7>>3S-/M;@F6
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M5?NQM@M$ <A"/FW8Q3X-4\1SZN@9)[2V\E'5)[5G+*8-Q+;(L>8)"01O7[N
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MA,DZ.?W:<3*BOA54*/N \ <DDY)JGXA\'3:E>_:[">-9'DDE<3[659&2)%8
MHP( A&5(R<GY@.#)<7FMOXCEM8WO(XC<&-42U'E"W\C/FB4J1O$G&-W;&WO6
MCX/L6TWP?I%K(CI*MK&95D0(P<J"P8 #G)/;/KDY- &TH(4!CDXY.,9I:**
M"BBB@ HHHH :[K'&TCG"J"2?0"LJ/Q1H\L=M(EV2EP 8F\EP"I(56)QPI) #
M' /8FM2:)9X)(F)"NI4D=<$8K"E\(:?)<V%P6)>T@CMQYD44F]$.5SN4X.<\
MKCK], #[GQ?HUM;7DPFEF^R!C(D4#LQVOL;;QAL-P<9QWQ5^\U>RL+>&>YDD
M19O]6@A=I&XW?< +< $GCC'-9TWA*RFMWA,]RH:*YBW KD">42L1QU#*,>W7
M-7+_ $<WPLY!?W,%U:Y"7$03<VY=K9!4KSP>G4#Z4 26FM:??7;6MI<B:58E
ME/EJ2H1@"IW8V\@@CGGG'0U3L_$D%RDKR1-&(PY*H&E<[9GB&%5<G)3/'K[9
MJSI&AVFB1O':&01LD2!7.=JQH$4#\%%9\O@^SDAEC6ZND\SJ05/_ "V:;!!7
M!!9B"#P1^= $B^+M,.II:F4B*6"&:*?:Q5O,=T /'R<H!EL<L!UI%\3Q-<F+
MREVY1=_F<9:X,&.G7(_I[U7B\$6<*0Q1WUXL"11121#RPLJQRM*H/R<?,Y^[
MCCBK*^$[%6R)KC_6))]Y>JW)N!V_O''T]^: 'VGBO2;NT>Y,LL"()V(N(7C;
M;"P5V (Y )'3UQUR LEYHVDZ\MN;18+N[@EN9+E+;"E$*[B\@''W@>3]<9&:
M=WX129=/B2X=H;?4GO7\P@$(Q9S$,#E2Y7@]AU.!6EJNA6^KW"23RRJHMI[2
M2-"-LD4H7<#D9'W%(((H EL]9LM0MYYK61G\D9=6C:-AD9'RL <$=#T-5_\
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MK(U#Q3IEG87T\5Q'<2VJ.3"C<LPA,P7..,H,YH 9X4N[@Z'IEC>VM]#>PZ=
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M=!FN&U*>YBEM6NC) YGX<>9N15#''(Z<@9YZGLJ* .-?5-?GU^Z$+/;V(4M
M)+25@T9@W!\"+.\2'&"X.%QMR02VTU;7&?2BT=])O\Q)HV@VEV#$*[,85 3C
M_IFV,'#9KM** .%LK_Q+=PQQK/?+YOV0332V C:"1B_G(@9 "J@)@D-C/5JU
M;H76D:QIT%D;E[2XFD>Y2.+)+NX.]FV%0HRV1N0^F>E=+10!R-_JVJ+XO:QM
M);ADC>UQ EKNC9'9A*SR;3MPHR/F'([YQ53[1XCAT^QO'6>XO9--GED)M1F!
MR]OA54 <A?,8*<EBI],#MEBC61Y%11(X 9@.6QTR>_4T^@#DM-N=<N]3MX3<
MW@T]9IF%Q+:+')/&HB*AP4&W+-*O"@E5R/6H_$.L>(],UAQ86,UY9QJET1'!
MNWIS&T(('W@Q63UP".E=C10!R#+KY2X^US27!@O+"%(Q;+L<;K=I91\N3@F3
MD'"X/IQ3T_\ MJ&?3C+?:Q*8[N]CE26'Y7.[,08^7]P@<-T&< C@#NZ* .&T
MJ]\47UK9K<7$\#3W$:SN+4AX!Y4C./GB50-RH <-@GECD5HS7^KCPQHT\WVF
M"XF,8OY8+7?+$"C$L(]K<EPH/RG 8^F:ZBB@#C'U/7O[4=(3>L [*L366(S!
M]GW"7?M^^9<#;GOC;WJ";4/$MGIK-)+>3R+Y$IV68\R3=&Q>)-L;*,,!C<.^
MTL,@CNJ* .'GU/Q3]HUKRU=##'<?9X?L[.."/*93Y84DCDC>V<]!@U84ZTFN
MV27-[J+6T%_)"9$@7$Z&)64R!4QMW%EW# XZYYKL** ,#7;MFT_2[Z".[,7V
MR&614MY#((^<[D W=QD$5EOJGB"?6K\1,]O:*CFW$EG*P*>0&5\"+);S#RI?
M. 5VYP:[.B@#B[?5]=+Z:PAOI#)'*KPO!MW."^UW?RE&P[1C_5M@@D'.*BL[
M[Q'>"&%+F_6.5[827,M@(Y(F99#,JJR ;5VQX8@X+$9:NYHH PM4N[^WU_3(
MH#.]I)E9HX82>3T9F*%=HYR-RG_>Z5S6E3:]I'AJTLY/[0<+I]AL9;8!H'8.
M)$XC8X4(F<JS MSUR/0J* .!L(]6O=2TJ_OK2=9Y%L9+@^45"OY-QOR,<89A
MGTR*V+NXUQ/$#M TQLDN88E@$ V.C(=[%L9X;'(.!WS7344 >>&]\17FE;Y+
MG5HBAL9;AH[+RY(I#,//C1=F715YZ-TZL"16CXODU*VU6SO---X)H].NUB-O
M:&8/,6A,<;_*0H8J>>.AY%=E10!R^E7NNS^*+J*\!BM$:11$8FV[1C8ROY8&
M2,D_O#U/ Q61K=SKU[::W9K'>2&2WOHFMOLF(TC",(6CDV_.S?+QN/WCP-M=
M_10!Y[>R:Q>032+'>W:0-<BVDGLS&[@VAX*;1QYA*CCGISU+QXAU7^V=1C\Z
MZ$$$<R06\-N#YKJB8$9,9RRGS"1N/;Y>"*[^JT>GV45X]Y'9VZ74@P\ZQ*'8
M>[8R>@_*@#C+*\\12W%A<SO?Y5;V-8O)(2=@R&'S/W:X! ;YL)T[9.2UU3Q&
MVG6SW<]VD<EPHFEAL7>:$>4Q(V&%1@R!1D*V,D;NX[RB@#C(8-1MO!OA%1)?
MVKP+:K=K!%N<+Y.TAUVL<;L9XX_"K>A7^L7&MM'=_:3%LG,\<MKY<<#K*HB$
M;[1O#(6).6Z \9P>HHH X9=3\4LVJ-M<2QM(MO;_ &=B"PF B ;RPNQD^\=[
M8#;AMP<.MM4\33:EIL<JR0QO% \WF6S!6<NPF0[8VQM  4[U'0DL#7;T4 <;
M:WFN)'HYU"ZOT6Y226=HK$,4D!C"1$!#M0@N23SD?>'2HHK_ %ZTE@CAMIWW
M1W)6V6W**) TQ1I&*8VG"#AU()!PP;CMZ* .8T*_U=]!OKJ^\^>6-"\2"!EF
MR$R5 :.,$[NG!ZX)-95K?^*+VV:,2WD&)Y@LYM079! CI]Z)1_K"RYV#.,=>
M:[RB@#E=+U76;GQ''IUTNR,6Z7\C>6!M1T""(]P?,$K>N% JEJUUK4LFIPI<
M:FD<-W:R1S6EM@+%YZAU ,66(7<3@N"!V!VGM!%&LK2B-!(X"LX'+ 9P"?;)
M_,T^@#AKK5_$1U34XK**]$*6TQB,UKD+(KQJA7$8!#*SG&YB0/X<8JOX@G\0
M?V7?Z<\FH/$8[R)+B&R$DD[;(_*1@J8"MOD&X!?N#D'KZ#10!PE]J_B*&]U"
M*QM[SRX;"?RE>VW+YRQ*8RF(QG+$C&]L\C Q3]8&KG5K6PDN+^>**YLI$*V8
M*3#SMTCNZIA=N!QD<#G.<UW%% '+ZQ?ZQ#KZPVOVD1 VWDQQVN^*8-(1-YDF
MT[-J8(Y7U^;.*KZ?::EI/@W4&M#,=3EO+B0/);J7),Y 8J%&[Y<'GM[8QV%%
M ''M>^(;?Q');,\\MG !LS!DW*"');*Q; _F9'WU'&-O()HVNM>(FL?-E6_(
M2_553[*?.EA,2$C)@"C#LPY51QC=QD]]10!PTVJ>)=U]Y NS.L=UF)[+]W"R
MR@0F-MH\S<F2>6SU^7I2:MJGB33[2:&W%_<7$,\WDS"V!$RJL;*KA8FSDNP&
M @(0_,".>ZHH \VOUUC[/XBL+>.^E2X342UN;0A I0^6R/M^9F8XP"<@].,U
MHW>I^*%NM<\E77R(+@VL/V=G#$(#$RGR\$D]1O.<D8!%=Q10!P^I7WB>S,MK
M#+.\:7;QK>M;98KY,;ID)$X*[VD&0H^X!D'DRW6I:\DVIQ+).&5(GADCM'\I
M.4#H,PEBQR^&'F #D@8P>SHH YK4;G49--T2ZM[6X\]MTDBRQ!I(S]EE(W #
M ._:#CN<=Z?I$^MI::@MT9+J=((Y;<S1"/<[1Y*< # 8?49Y)KHJ* /-H;S7
MXFN+R ZA*;@VJ3W$]D8GC41REMJ^4W1]BYV-@-S_ 'JNS77B2U:\N%FNY[E]
M/LF6-;=O(5C(5G= 8R0X7YMI!//W3@ =Y10!QL-UXDD@#FXF/EV-Q,-EK_KI
M Y$:MOC4YVXR JY(R.."6TOB2._C%Q<W-Q ;A8V1[5%!1K8NQ)"@\284?D<G
MFNRHH XK29_$(;3C*)X[=?LL,EM]F"KM:#+DG;D;7P." .0?:/2KGQ#%;:7)
M*)X8(H+%);;[*JK\\>)221D;3CH1C'-=S10!R/@76-0UBWFFU&ZD>5H8)E@D
MA\LQAU.6'R+E&(;'+<+UKKJK6FGV6GJZV5G;VRN<L(8P@8^IP*LT %%%% !1
M110 A 92" 0>"#WKD[7X>Z5:0R1)<7C"2QDL27=2=KEOFZ?>56*@_P!W@YKK
M:* .>U#P?8:C</<2._FM.)P6CCD4'REB(VNI&,*#ZY[]JF'AFV6=W6XF6-I8
M)O)4(%#Q!0I&%X!"*".G'&*VZ* .;7P7IR:A#>AF:2,Y/FQ12;AYKR@?,I*X
M:1N5P<'U (T?[#MO^$>N-%+RFVGBEB=LC=B3=NP<?[1QQ6G10!A'PQ&]Z+B6
M_NI TD,\T1"!9I8L;'.%R/NKP"!\H]\LN/#;WGB&>_GO)%M&-LXMH]N'>%F=
M2Q*Y&&*G@\XYKH** .;TWP7IVEP10V[,(X9(GCQ%$K 1YVJS*H+#GJQ)_'),
M]QX4LKB.X1IIP)TNT;!' N""^..V./US6[10!CKX=@CU!+V*YG25;EK@XVD-
MNC5"IR.F$!]<]Z@O?"=I?:X-4FN;CS!DJF$(7,31$ E=P&')V@XW<UOT4 9E
MIH=O9K.L4TX\ZWCMRVX J$4J""!P>>M95KX(M;* +;ZA=Q3"X^T"9$B!W>3Y
M)&-FWE>^,YYS7444 <Y!X/MK>QN+"*^NULKFU%M/#\F'Q"(=^=N0VQ5Z'&0.
M.N99?#"23I=_VC=+>HZ2+< 1YW+&\>=NW;RKMGCTQBMZB@#!M_"5C;1)''+<
M;4^S=6!),#EU)X[DG/Z8K:@C>&!8Y)WG<=9'"@M]=H _2I** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZCNIK.WDN8O]7,\2ET^A(R*LT44 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHFN3=1^>R1,,+S\Q!4%>,9.!SV%1^%KC6YD U:29C+IUK<YD@$?ES/YGF1C
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MXEMB6G,JJ-ASM)49PV,C.<4 ==JWA6RUBZDN9W<2MY)7*(ZJ8_,P=K @Y$K
MY]L8/-,/A.U\Z*1)VC\NU-L$C@A564@C# )AEY)VGY<]J9HESK5WJ2B_F001
M6,,A$4)"RRNTH8[F / 1#C Z^XK!UC4=>O;'7+2-KE9#:WZF*.U*^2$)$)1\
M?,77!ZG.[(QMH VH/!&GPW%I/YKRR6ZA,S112;E$C2*!N4[ "[ ;<8&!V!&F
M=!M'\/W.BR-(]K<)*CDD;L2%BV./]HXK'\47M]X=\/V\.CQRF>.)_+\JW!1F
M1,A2%4XW'H% SZK39KSQ))J-RMM(%22>:W@1[?Y(\0!TD+=3\_R^F#CKS0!;
M'@^U$%M$LYC\FY%SO@MX8F9AM[J@QPN"1@D$CIC$6H>"+74;&2RFO[O[.\ER
M^S$9"^<VY@ 5/().UNH#'FBRUK4=4\(76LP@6SSDM:)-&<Q(,+\V 3R0S9P<
M!AP0*JIXBU0R6T?V>[!N%L3'YMJ=Q#3,LY8J-HPH![8R#@9H T;[PC:7\D[R
MW$AWWBWJ(\<;K'((_+/#*<@J>AS@\C%7I-$MI+;3K?<R)8-NB$:J@/[IXN@&
M ,.3@ <@=N*YB.?5]831'-W<P7GVPM<K]B*BT)MY\H,C# ' R<\X/<5>O+O5
M;G1O#&HK9NU^3]HE@"E0)#9S':P[#>0.>Y% &UI>BP:4^Z&21C]E@M?G(^[$
M&"G@=3N.:SX_"%JNG)9-=W+QI9FR0G:"(L@CH.HV@9K%AUSQ NEPW,THE!N5
MW)!;OYS*4^9 &B"YW=C@XR-V1R^[UW7HS=11!SMOPC7(A(CBA(E(V_NR=P*1
MJV58#>#G!X -_3/#5GI6J7-]!@M.\KX:&/<ID?>_SA=Y&[L3W]AA/^$7TX6.
MI6RIM;47D>>=542'>Q;&<<@9XSFHM"N-9NKUVU&5%CCMH/DBA*H\C)EV#, V
M >@P,9.?;'2_U^/<85>.*%RYB-N6\W-Y(A&3R!Y8!X]0>G! -V3PQ92>(&UC
MCSGVEU:&-OF5=H(8J67C'0CI]<L@\*6=O%;QK/.1!':1KDCD6S$IGCOGG],5
MSLNI^(K.S:&&YE>0W]XKSW4+8B =C"ORQME64@YQT& 1D5=OM2\1PPWTZD*J
MWD5NJK"0L41C1GD!VL6^9BN=I [C@T 79/!%A+#'!)<7!@2R>R*@(K/&RLI#
M,%R1\Q(!. <'%/'@ZU%K! +@Q^5<"XWPVT,3%AM'54&TX7!(P2"1TQC'N]3\
M0R6SVQED-Q-I;M&UC WRS!'(8[T!&<*!@]3C;T-=/I>H17%DL2W3SW,5NDDC
M21%6^;."1@<_*>!S^8H @U+2;_4?#LUC)>*;J282"8*%"*)@X X.=J@*"1SC
M)ZTEIX8M;><SRW$]Q,\=PDK2;1YGG&,L2% Q@1*!CMZGFN6:^\074,%]$\XO
M+.QOBTGV;='.ZB!E5!M7Y2<@9 ;AAU&:FUS5=8O)M:T^*"Z-L=/N0$,!!60*
MFW:0O1MS8RQ)QP!B@#8?P5;3:=/:SZC>R22100I<Y19(DA)*!<*!G+-DD<Y-
M6IO"UL;D7%K=3V<R2K)&T(0A,1>5M 92,;?UQ]*IB?4-/\/ZM/!'+YXU"7:3
M$7*QM, SA>K;4)8 =<55FUG5EU"WBMI[B:/_ $?R=UB0+H-*5E+':-NU #QM
M]>00* +MGX'TRRN+:5"7$-O% 1+%&Y;RTV*VXKN4[0,[2.G;G,NG^&IM*D1K
M75+B0[+>!VG5"1!#O*HN%')WX)//7&*R/[5\1QV4LDLV&EA\U2]L5$)$^TJ"
M%;DIW8$ \].*1+S5)KJ61VORLS:;+%:SP;?+5I(Q(?E'##YLC/'.>* .DO-!
MM[V\ENI))0\IM20I&!]GE,J=NY8@^W3%9X\&6GV62W>]NWC%N]M;9V VJ,P?
MY"%Y(94(+9^X/?.(NMZUI6BR%Y+V[G$.H*&DM&=A<HZ^0F%7H5WD=CZ\5/>:
MCKEE=:JL5Q<.K:G&NZ6([;:W:W#;D(1L@R#9T8#G..30!>3P!I,5I<6T;S;)
M6@9 X1Q%Y7*@*5(()+L00<ESTXQ=3PGIZWFG7.6#62.@CC1(XY=V[!954#Y=
M[D8QRQ/)JM?7MY#IWAN\O&;?]H1KQK6.0K@P29^7&[;N*\$<'%4&UGQ!-J&J
M"-X((8TE\A)H9#@ #RY.(SG.<GD]<8RI% &GI?@VPTJ*VC@<[;>2-XR(8D8A
M%95#%5!;ASR>?S.="?2Y=0T:^T_4+IG^U>:F^)0IC1B=H''55(Y.<D5S3>(-
M;58I+>VNIW>PE>*W>##-.HE(,A"@;&VH%*D')&5^88FM=2UN[NK>WM[N9[1[
MU4-[)9;&*>0[L-I   =5&['\6.2,T ;)\.P/.9Y+JX:8W"7+."JDNL/E=AQQ
MSQWJC8>"K73HT\F^N?.2XCN!*5C!+(ACY 7!RI.2>23G-/BDN=+\2V6EPM-)
MI[Q,0JIDHY,C%I&*XV_= P>#P0<@C%UV_P!?NCXCL@BK;K:7,<4(C<NZ^1E'
M0A,$ESC[V.V,CD ZF\T1;K51?B\GBS!]GEA4(5E3).#D$CJ>0164G@6QCT9M
M,CN&CC)0>;';PK( JD*=P3[PR2&Z@].^:5UK7B6._P!7\F&,K;)-Y-N8G9B%
M4%'4!/FR<\;^>@ (-1:G=ZD5FDM[^^NX7T>[,2&T*+-,OW<@*"#@\8QG''>@
M#;F\)P2WES>+>W$4\LL<R-&L:A'0DAL;<,<':2V3C SWJWI7A^WTF<SQ3322
M-&RNTA'SLTKRLQP!R6=CQQ[5SU_KFO0W5^+9)6EB%R!:_9"52-(6:*0/CYBS
MA1C)SN(QE36I#)K$FEZ[;33R-<P@K:SI"$8[H5;Y1T.'9@/H <D9H GF\+VD
M[3,TTX\TW!."./.4*W;L!Q5?_A#++^T9;V2::X+PO#Y,NW:5:-4*[MN[;A>F
M< D\<UE0ZSK*OI\<<US+F.TV+)9G_2=\A68NVT;2B\]L8R<Y J[J9U6V\63W
M=FTGD>5IT3Q^3N60/<RI)SVVH^XX]B>.H!:M/"T?_"&0Z%?S--)M62><88O/
MO$A?YA@_/S@C&."*9-X*TZXLUMY&("IM_=PQ(N?-64-L"[3\R+P1@C.<YK)A
M\2ZXKZC=&VNI;.T:"4Q-:GS2C/(DJ !1DJ CX!8\=3G LV6I>)FU^TM+T01(
M$B,J%&Q)NC)<J0A&5?Y1\PX7D?,#0!K6?AJ+3[FWGM+N2W9$\N5(88D29=Y<
M J$PO+-RN"=QSSS3U\.Q+X;&B?:YS"@"Q2D+OC"D%>V#C ZCGO67J.LZM::M
MJ<42RRQ0I'+%Y5N66- T0<-\N2Y#.1M)! / *\L@UW4KK4+82-<6UE)/<!)!
M9,3+MD58T(*Y4%2QSQG&0< Y -6'PW%%JB7K7ES(J7!NE@8)L\XQF,OD+GD%
MN,XR3[8;<^&8[A[\?;[J.&\D6=H4"829=F'4E2<@QJ<$D9SQVJAX1.JVYBM;
MQI'MWMVE4/#M,3"5AMSWRI!Y]/0XJE:ZYXD\B]O;B-"ELX>6T2%S(B"7#JHV
M#/[O)&"Q) QP: -=O"%K*EUY]W<RS74%S#/*=H+>>(PQP!@$") /ISFK)\.0
M&_DNC<SD/=K=^5\NU9!#Y7'&<%<'&>HK$MM5\3/K-A!<I% DD4,LB/&V&WEC
M(H(0C*# 'S+TR<AN*;W_ (DET6.2YNKF)VBTV[=X;3:T6^?$R8P<A4 )'7KG
M@XH WAX0MHXK=8+RZBEMX+6&*4;"5$&_:<%2"2)&!X^F*CM?!.GVEY:72R/+
M);QQQEIX8I"^QV=3DIE3ECRN.W3&:LZK?W<&MZ=;K++!:2HS-*EL9?,D#(!&
M< [006/8\=1@U@PZWXBGCQ'YGG2>2)U>R(%G(UPB,B\#> C.<Y/W <X84 =!
M>>&;>^\06^KRW,_F0%62+"%05##@D$J#O.0",X%9]_X+BDT-[&SN94F^R6EG
M',[8,:P.Q5P0/O8=O8X X!-10ZIK2WFGV]P\S*\]Q;N8[?#L%E9(Y&RNW;M4
M$X(Y(."#BLA;C7&\.6;?:M0^U)I\;7%P8#YJNLT?F*1MY(&[L2<'K0!V=[HD
M5Q'8BVGELGL3_H[PA3M&PIMPP((P?T%5+;PEI]I#%#%)/Y<30%5+ _ZI=JYX
M[CK6=<:QJLM]+ID'V@.UPZI,+5A^Y^R%U?=C;GS>/J",<54L-6U]KC1K=92T
M#6ULTDMU"ZM,[.PF4XC.&50,<KR<G(H Z#0_"]CH5E+:6X#Q/&L/,,:,44$
M,R*"QP3R<_J<PV?A&WMG@DDO;JXD@\A8FDV#:D.[8ORJ,_?;)ZFLSQ.-2>_U
MB"&YNO*DTR$VT*Q;HS()) Y! Z@;,C(SD?A#J.K^)[4BUA93LEN$%Y- P#E1
M&8E8(C<'>^< 9V<$'J ;^M^&;?7;JVGN+F=! 01&H0J2'5P?F!P<J!D8."14
MVG:#;Z;>/<Q22L[B4$.1CYYFE/;U<CZ8JEK<VHV^NZ9);2S^28+@- B9CEE
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M=L!<GU. !] *DHH CG@BN8)()XDEAD4J\;J&5E/4$'J*DHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 9##%;01P01)%#&H1(T4*JJ!
M@  = *?110 4444 %%%% !1110 4444 %-5$5F954%SEB!U.,9/X 4ZB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD:2=4>,*K$8<D)DXP,E2!G&2,=:+/Q#I][HQU56FBM0Q4F:%D;(;;@*1DY/
MQG)..O%5T\+6: !9'48M>(T1%_<2F1<*J@#)8YP.G3%31Z#'%HD^E?:'D@E=
MR/-C1]JLV[;@KAAR1R,X/6@!D?B>P;6CILA:)VCA>)G1AN,F[ .1\A^7@-C)
MXZBG/XCLS/!#;[I7>Y6!U96C*;E9@V& RIV'!'!YYXJ&W\*6L$:)]JNI"GV;
MYY&!8^0Q9<G'<GG],57T[P59Z=.LXN[F:17B?=)LRQC$@!8A06)\PY)Y) H
MG/BJWBTG0M1G@=(]5V85<NT>Z%I0,*"6^[C@=\U=BU_2Y[BW@BO$D>X57B*
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M 9ZU@Q^ K.*PEM1?W),KH[3;(O,!12H8-LX?!SO'S9[]JU-9\.0ZQ*[O=7$
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MEMN64D8*L2"O!]:1/ U@L5M UQ.888YHRH6-#(LN_<I95!V_O#\HP,JIQQR
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M'D:RBEEECBB9FQ'PX7C!()&1GC()P#FKMSJ]E9VD-S/)(B3D")?)<R.<$X"
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M94Y!4 $'WQ@T 7AJUDVFKJ$<K2VS_=:*-G8G.,;5!;.>",9&#5=/$FCR7%M
ME\C/<I')%M5B"KYV$G&!NP<9QDC%0R^&H'T--+%U<*JS&=Y#M)E=G+MO!&T@
MLQ)&,?E4-IX0LK.UAMXY[@K$EHBDE<D6[ETZ#N3S^F* -6?5+.VOHK.:4I--
M]S,;;2<$XW8V@X4G&<\523Q3I<UQ8PPO/+]M=DA=+=]IPH;.<?=(((;H>N<5
M%J'A6UU/6XM3N+B<F+;B'Y2O 9>"1N4$.<@$9P*=:^'#;)IJG4[N4Z>_[EG6
M/[FS9L.%&1COUSW[4 /;Q+8PZW<:7<,8I8M@5B&(<LI8#(& >" "><<5=AU:
MPN(GEBNXFCCA6=WS\JQL"58GI@@$_2J%QX;BN=8-^]Y<A'EBF>V&S8SQ?<.=
MNX8.#UYP/?,&D>%H;+0-2TNY.^._DF$@1C\L391$4X& L81?PH MCQ1H[1))
M]K(WS"!4,3ARY4L $QNY4$@XP0,TR]\1V]CKG]GS)LBCM3<SW#[@J+G:H&%(
M))!XR.V,GBFVWAJ*&^AOI[VYNKN*82^;($&[$3Q!2%4#&)&/KD^G%3:EH%OJ
MDTTLDTT<DD,<0:,CY"DGF*PR#R&P><CCI0 Z/Q%I4TEM$ET3+<NZ1Q&)P^Y2
M P*XRN-RYR!C(JIJ'BRQT^6[A:.=GM)K>*8F)@N)G505;&&QOS@<G%3Z?X>A
ML=1&H&YGGNR)O,=]HWF0Q9.  !@0H!CMUR>:+GP_#=7T]RUS.JS26\K1#;MW
MPN'4YQGG: 1GI0 \>(])*V["\&+CA/D;CYMGS<?)\WR_-CGCK4UYK.GV%U';
M7-R(Y9-N!M)"AFVJ6(&%!;@$XR>!64?!6G&_CO-Q:19)'82PQR!@TSS8&Y3M
MPSL 1@X/J 1:U+PY#J5^]RUU<1+-'%%<1)MVS)&[.H.02.6;.",@_0T 5#XW
MTM3"["XCMWEN8FDDA=2K0MAOEQDC@G/8 YQ@XTI?$&E0SRPR7B*T2%W.T[1A
M-Y&[&-VSYMN<XYQBJ@\+6_[Q6NKAD9KIE4[?D^T$LX''."21GU[U6/@?3?-N
MV#M_I431N3#&74F(1%E<KN'RCIG&2>QQ0!HWFOPPZ7;7UK$]TES,D,*C]WN+
M' /S8X]^_:FV'B73[Z&R?,L+W@_=K)&<9^8;2XRN?E;'/..,U8U/1K35K."U
MNT$D$,J2[&4,'*'(# C!%4KOPM:W>MVNI&>5/LOE^7 JIL79NQMR,J#NY (S
M@>E #5\9Z(\D.RXE:&6VENEN!;OY7EQ[=S;L=/F'/3],[,-U!<23I#(KM XC
MD _A8J&Q^3*?QK+M_#=M;)I2)/*8].LFL0CA2)HF" A^.O[M3QCOZU#X;T*\
MT/3M/M&NPR112&Z'WS+*Q!!W$ X49'8GCTH T4UFP>5XUGY280%BC!3(21M#
M8PQR"#@G!&#4,GB+35^6.?S9#&TBJB,> 6'S$#"Y*L!G&2#C-4YO"<,MW=W2
MWUQ%-/-'.IC6,!'1BP.W;AB<[26R2 .>,T6?A.*P;,&HW@#P>1.&$9\Y0TC
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M&,;!@&0@R$  <DC+^XYJ6/Q+HTML]Q%J,,D2LJ9C.[<6&5V@<MD9(QG.#Z4
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M64L< 8 ^;D$<9Y!':@#$N=?UTZIJ$%G%-Y:AQ&9K4GRW6>-!@ #(*LS#YB2
M#\O2J7B/4=>;0[_3WDN!FWOHDFBLB[7#K@1K\H^7*LW(QG;D8 (KKT\2:8\U
M[$)G#6;(LO[INK*&&W YX8=*>OB+1VN+>!=1@:2Y1)(@&SN5\[#GT;! ]2*
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MJQFC:Z2TS'@XD:41?HQY^AI9M9TVWO39S7D23@$E6;&/E+8)Z [06QUP">E
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MR-8U77IO#MQ ]PQ2>VNQ'/;6KRO(P1!'&WR+@DM)R /N#G.:[(>)M%,4TO\
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M,EY=BT4 E=C;"Y+<$CY1D<<Y';D:4NJV,%\EE+<*EQ("50YYP"V,],X4G'7
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MORF9[8O.$8,O&0$.<D]1GH>$?7_$MK82R2)%/(4."MLR"(+<B)G/)S\A,G_
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MJ%L3=$B "09?!VG'X\?7CK6.O@Y8GOFM[XQ-<-*\<JH?-C,DHE==P894D8P
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MZ_WOE^E)'X-"N/,U!WBC9/)3R@-BK<+. 3W.5VYXXQQGJ ;D.L:=<7:VL-[
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M8EE\*P.7(F!#2SR;)(PZ'S8]A5@>HQV[T :!US2P;<-?VZFY.(0S@%^=O'_
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MA>+,6]<>6T>W&1V;U[5F1^#88GOB)8)!<F9E\^W+E#+()'!.X97=T  (XYR
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M,N]3NM/%S$ES!(%",XS(#$DFX#TP_P#XZ:L1:UIL]A<7T%Y#-;6ZEI7C;<%
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ME'\MI/M";0V,[<YZXYQ0!DZ]KVH:=J\EK:K#+FQDE@A5-\AE5)&^<;@0AVJ
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M\"1O,LDJCRPX!7)!(.=P'!(R15ZXU*PM(X9+F]MX4G8+$TDJJ)">@7)Y)]J
M."N/%FL:UI&K1PVC6JM8W%W;R>6X80[=D>3GARX<_P"ZH]<UH7FNZS9RW0>*
M.XGLA<A7CCD1'Q'"ZDH&.<>81W/RG&,FNH_MS2=EP_\ :=GMMV"S'SU_=DG
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M%;33A/YT3-+*TY*.Q?=P5P#T/?-3>)+S5%U75+2&^6./[)9R6L/EG=O,[*[
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MP@CDE4-)ABN5&><D<8]:+;Q/H=U:Q7,6JVGE2RM#&S3*NYU."!D]<D?F/44
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M2.;A)T\M1'C=D[NV><9QWQQ0!Q/]IZS/8&/[8(C)ING3P0,CLP=IB)#N+[F
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M(7<#VXR?SK*A\4:Q#ISS:@UNK/;V\J/%:E5C9Y&1@V^0#'R@Y+#&>_ KN:*
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M99XY!"6C+Y.<H7R0=S?Q9R<YK;HH Y*V\$+;7=K/]M$WEK&LJ2QMA_+F>52
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M+_9?LWS-N&5VX.,=<\\\=110!RJ^#2UO#%/J3R&.-XQ\A*A6ECD"C<S$ >4
M 2>OL!1>^"H[JZ,XNQ\[7'F1R(Y1TF9692%=?[O<D')R#QCJJ* .7NO"<\_]
MH>7J$<(N91+$JPN! V7)=<2 B0[^64J#CD')JUKGAV75HXO*O_)E6TFLWDDA
M$F^.4+N.,C#912#R.O!S6]10!R\OA#[1J,MQ=W\MU;-!) +9@PPKQJA4'=M
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MMMSD$N-N<>W45V5% ' WWB#5%^SZE8ZGIUZ(-+OKF401OY,GEFW8)@2'#\L
MQ)QD\=:UO%-Z]O?6$4]W]CT^2&9GE-P;='F&SRXVE R@(,AXZE?P/444 <5;
M>,'6.PAVHCW,.GO!'.Y:5Q-(4D.>-VU0#G'4\]:AL_&.I:E+/!9FT8^=;)%-
M) 0%65I 0R+*3E1&#@E3S@@5W=% '#7'C*^34M1M+86TWD1OL+1;=CI-'&0P
M$A8@[R02$SC(R#FI#X@UB/5;9)Y[79&;R*2)("OVJ2/88PF7)5B"<#)Z'KV[
M6B@#A[/Q5JU\88;6?3)VGDMU%U%"YBC,B2L\97?DNGEJ>H^^,@5M:KK4UCX@
MTZQWP""Z!!  :4MSC"[P0O!^8!O? YK>HH \]TSQ/JEAX<M([^YMVG-C8RQW
M#0DY\U7R)"\J@D>43N++DMC&<9ET[6+[4]5TB[=Y8ENVM)7@5VV+OM)W9<>F
MX#\0*[VB@#D6U34K+Q1>CS$DT][Z. Q,CLZ9M@^4(; &5Z;3G)K.MO'EZ=-G
MU!H(;FVAG6,M#'M9M\6Z, +(X!,FU.O\8R!@UW]% '*:;XAU2Y\42:5<Q6B"
M%MDJ@JKG$:MYB@R%BI8D8V8Q_%P15*ZU'6)=;NK./4[<20ZU%'#'Y)_=PM;;
M_G <%U))].5//8=Q10!Q%IXOU.YU+3+5K>UC\^&"20.53S2[,K^66D!^7;G
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M!R"2G"G /44 =#16/H&H7VIZ7-<W"VY;SI$@>(,J2(IVAL$D@$@XZY&#WI=
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M(I5QO!)WQ,N%SGUQS4J^+8(IKQ;^SGLX8+J2V6=V1D?9$9">#E?E4]1Z=S@
M'145D7OB"*RAM6-C>337$#7 MXU3S$C0*7+;F XWJ, DY/&:K:3KUSJ=[K#I
M;DV-H4%MM50T^Z)),YW]PXP"!VYZ@ '045R%GXUDFDLY;G2[B&VNK*UN#MV,
M86FD9!N.[E?NXP">22!T&KI/BC3]:U">SM-Y>(,0Q*D.%;82,,2.?[P!.<C-
M &U17.Q^,;.2.1S:7<:K&TL9E,2"95<1L5)< 88C[Q7J,9JO/XXMO[+N+RQT
MZ[N_)L&OF"F-551Y@PS;NNZ-A\N[U&10!U5%9$/B*VDOX["2WN(;QY%C\EPI
M(S&9-Q(8C;A67.?O#%0W'B6!;JYMHT=9+:ZM[>1G"G)ED11A0VX#Y_O$ =QG
M&* -VBN8@\<6-UN^SV-]*=\:1[/*/F&3?MQ\_P OW#D-M(XR!3E\86SLK1V]
MS*LL5NT4"1J)-\K2KM)+;>L1'H,=2#P =+17.1^,[":\L+2*VNFEO A Q&#'
MN+CY@7R<>6^=H;&*N7'B*VM]3-FT%PRI-'!+<*J^7'))C8IYW9.5Z CYADT
M:]%8VB^)+;7$9HK:Z@'V>*Z3SU4;XI-VUAM8_P!QN#@\=.1699>+G:U2_O\
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M0WI8W$3NS(^X8;Y2<#.3G&,YKE]1@U*T^SM,VIS/>:Q(K0V]WM8VX29D5/F
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M\41:7(;:QN/-D@O8DCB:")UD?9Y,CA6"Y&U^021GI0!T@\,Z8NG/IZK=+:,
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M>^T\PW/V60W6)_M"JCJ\>(U&&W##$CH,8H W;'2+.POB;6:4%(V+0M.SY,C
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M.6"%O-C\PB1Y7=R7V[B68DL3M7DYZ 4R/2M+N9_[2B42FX>.Y$B3,4=@FU7
M!V_=P,@<@#K@53U&PDN-=T*_BANI(8/,5]DQ38&48+J6&X<<]3[5S=GH?B73
M/#]I8VS701+.P$T9N-[!U$@G5#YB[<8BX5E& <<YH ["'P_IMM<13V\4L,D:
MA!Y=Q(H902P# -A@"S?>SU-2R:19R:@;[$R7#*%9HKB2,.!G&Y58!L9/)%9D
MMAJDOA_3+0W%V9Q-$+J02"*4QY^;)5CSC .&)]\UCPZ;XCL].D4_;;IY;>%7
M#WA+*XF(8J0ZD$1X) 9=V.N<T ;L?AK0HV%M;PF"2+;*%M[F2-T!7RP?E8$
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MI/($;:@0%DW;6(4 9()X'H*AF\,Z1<75S<2VK.]RKK*IF?8P=0C_ "9V@E0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%5AJ-B;5KD7EO\ 9U.UI?-78#Z$YQ0!9HI%974,I#*1D$'((I:
M"BBH?M=M]J^R_:(OM&-WE;QOQZXZXH FHJ.6>& *9I4C#,$4NP&6)P ,]R>U
M24 %%1/=6\4R0R3Q)*_W$9P&;Z#O4M !1110 45&9X1<+;F5!,REUC+#<5!
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M'8X.#[&@":BH;F[MK* SW=Q%!"I ,DKA5!)P.3[G%/EEC@B:6:1(XU&6=V
M'N30 ^BBB@ HHHH **** "BBB@ HHI&944LQ 4#))/ % "T5'%/#<*6AECD
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M8XW"B2+[0I_=L93M;R0RC"IR>3D UJKXYTDV0NBMQ&KB%H5E58S,LH8HREF
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M>%X^"4N''F?.TGS\_-\SN>?[Q['%:]% &*_A72Y(YDD6Y=9Y!)-NN9#YI
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M8D[1N; ]SZUKT4 1P0+;Q>6K2,,ELR.7/))ZDDXYX]!Q4E%% !1110 4444
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M>ATL-''LNH[EB-[@D7 F;[[$\D$9)[_A0!<NM;L;.TNYY)D+6D!GG@1U:1%
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M\,NWRY4?<N]=K Y7U'M4E<SH6AWFF7NI3AD19+K9;+(N[;:ABY48/!WR28]
M%R.,5TU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%-$D;,RAU+)]X \K]: '44U'21
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MD9!P1]001^% #J*:LB.SJKJS(<. <E3C.#Z<$&G4 %%)N4N4##< "1GD _\
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M3!C/F&+# ]/G5EXST)Z#-6X_$5C)I%YJNVX2SM/,+NT)!8)D,5'4C((]\<4
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M ",:_AR'75U2\DU6XG*DR#RFC_=_ZP["C;SQLXP%';/(JZ?$'E+H8DM)7;5
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MLOMK"*,@!,N "QX!S&XQ[&M.#7K.>[6T'FI<F7RC$Z896\H2\^VTCGIDXZT
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M4XV?P>@[#KBI-'L-3F>UU2"[O9DF2S5Y6<*)TV$2NRYZ\YZG'&/?OB 1@T4
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MIGGBA,$9>0D*IVYQ]=JY_P#KFJA\)Z6SREEF99/,VQM*2L?F.'?8.V6 /Z#
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M_P!GT)%-3PEI<<S2XN&R^Y5:9BJ?O1-A1V&]0?TZ8 W:* ,F3P[8RW%S(S7
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MT4[L2,1YF&^4@@Y."N&/;>*<6")?7@@Q(1)]GRZOY@*!U,F2 N0"Q((SGG%
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M>-O/(Y;:10!V])N7<5W#<!G&><5PJ1^*99--!:ZM85!&5!E+.)CR^7! :/&
MV[ )'4"M/Q!;ZJUY=RV0G5#;0!&A4$NPD<LF00P!&T9!XSGUH ZBBN1\176H
MA-&A1-0CDGBE,T%E*IDWB,$ L<9PW<?CQFJ7D>+S=733W$RRK;'RUAC!C<_9
M@,!MV%/G9.=N> ,[3P =W17&WEMXBM)DCTV2[NI3I[JKW#@)'/LD8.3G#9<H
MNTKQP1QD4V&SUNZEBA6;5;?3FN\DS2J)PGV=\Y8$D+YNS'?.<?+B@#LV944L
MS!549))P *%8.H92"I&00>"*X%T\57;VD<]M<KOLO+N\NI20M:MGC.%/G8'
M)XSD XK9O-/N]_AB14N?]$?;,L4F N8B 7 /*AL ]>IH Z:FF1!*(BZ^806"
MYY(&,G'IR/SKF?"T>M;W_M/[:JFTB$WVEU.;GYO,,>T\+TZ8'3'>L*'0]:AT
MZT>W_M"*]L=.N44M,"7GWQE%R2<J=IXZ'O0!Z+17,:-%KH\2WDFH3S"WW3!8
MO+_=,F\>45;?P0G4!1DEL]!69)#XI<W@B:_CF9)Q(Y=-FXS+Y)A'.,1[NW^]
MDT =R&4D@,"5Z@'I0&5BP# E3@X/0]:\Z\53ZGHIEAAN)HHKBX"QS-<+&Q1;
M;[Q=B,D/@X)RV,=,UH&SUF\:9K6:]BM)I&ECEC(C>1?LD00MGG/F!NO.1@\4
M =H[I%&TDC*B*"S,QP !U)-+N7CD<].>M<#J,/B>^EN83:W(CEL)(9%W@QR,
MUMP0,X4^;E< 9X))P0*WM32YM]2T.[2RGN([=94E$(!*[D '!([B@#H:*X9+
M?Q.R:FUQ=WB2%FVI'!N4CS@4V$2=/+RIVA3@Y/S#E9_^$I99VMH+I)Y=.7:K
MRAA;2[4RJG=MD8_/\Q ((Y.", '<45P4]KXI,%FD-]>+"?.(D^SYDC<E/+#*
M9<LH&_[Q(/\ $.AKIKV^FNM#OI=/MIY)HV>%%#>6SE6VDJ?3@X[G'':@#7II
MD19%0NH=LE5)Y..N*X1;7Q5+I2$S7R3P6]X\2AU!>03 VX?))/R9X)Z=>:NV
M5GJTGC**ZO(KTI"]V#(SKY C9E\G8,YSL'/'7.>U '845R%Q_;2KJN;?4I;A
MI]L9CE"PB R+M* '.X)DD#!)##/*U5M;7Q2\-M+<37BRP1VWR;U =OM+B3>,
MG/[G;GGOGDX( .YHKB9+;Q/"DTD4U[(TPG,JET)11=+L$>>%8P&3'N!GFI+"
MQU0ZYIMY<KJ)M8WNHXA)+ET1C&4\T \CY9.N3C;GF@#L%D1V=5=69#A@#DJ<
M9P?3@@_C3JXN>SUN'Q9>S6,=V@GNTD#LR_9FC%N%;<,YSO51T[#'&ZKGAB/7
M(=*NGU*2YFN3$I6&9 A$H4[\-N8$$XZ84=AB@#J*0LJD!F W' R>IK@;8>*!
M8%Y(K\LM\KQ6[/@O&8ERI??N4!]QR<@XZ8(JT_\ ;<5S<2R1W#P07S3B>7'^
MKV3?*$R<!?W8ROWLCC.: .UHKS?PU-JNN6=NK:A? FZ1KSRKI7\N,VS8Q("1
M\T@#$#!7<!TQ5^RC\727]G)=SS1.+6$E?*#1LWD_O%<AP ?,R<[3T7'&: .W
M$B&1HPZEU +*#R <X)'X'\J=7(^%;/5(KJ_NKN*]6:6RMDWWSJQ:9?-+XVD_
M+N8?GQQBJ5E:^);B".*634X4?[(+EI94W^9EO/*$9PA&WIQ_=QS0!W=%<OXF
M@UV2^L4TRXGAMA$X:2&/S")LIL+#>N1C=URO7/:LZ[C\5F351$;D6[3(;3!4
MNL/G?O00"#N(Y7G.S &&S0!W-)N7=MW#=C.,\XKC!9>)?LES(EY>23Q::?LH
M8+&'G+2XW*2?F"^6!N.,X)YZ+=6VJ/$SV2ZG#']E"J\P#S;O.4E3AMV"N1UR
M <CD"@#LZ:)(R[('4N@!9<\@'IG\C7%Q1^*Y=525FFM1Y"&* @2QC]Q\R.^X
M#(ES\VTDX&#@FK/A:ROXY]2GO(;]3/;6ZAKUU9V=5??C:3QN/Z\<8H ZN.1)
M8UDC=71@&5E.00>A!IU>:V3>(O#_ (:CN!'>@6,%D@M+N1"9IB&BE1<$_+\\
M14?WEX[UT'B*'7(/#=I::>UU=7RQ['N8GVMO$9PQ&1G+X[X&><CB@#JJ*Y#[
M#X@N-2>1[N\ACFN3"0KKLCA-G]]5]1/WZY]JSK>Z\1:KI%MJ,PO?+N1*3#82
M*&1U5$C()(RC,LC^GSKGC- 'H%%<:EKXI6[^T-/*9_/$?E[E\C9]B&6V^GV@
M=>OX$U8T*+7X] OS//,]^T7^CK=1A=DVSGG>V06P>PZXXH ZJFQR)*NZ-U=<
MD94Y&0<$?F*X5;'6+A[661-7^R07<$FR:8>=G8ZRGY6Y3<R<9_O8&,4U=,\2
M:?8W"Z>]R&G^TNZ,RL$)NPR[!D8)B:0CD9.,G- '?4UY$C +NJ@D*-QQDGH/
MK7,:/9ZP;ZP:\O+Q[6*&9R&'E[F,@\M7&YF.$W 9//4\U3O]$OKC5=251?!)
M]2M+A)%E^41*(P^W)^4@JW;.,8[4 =K17#[?$Z76EQ".[(AF023&0$21^>RM
MO&0,B(*<D$G=P 036GX<MM9M[E6U&:YD26U#2"9PP28.W"XZ?*1^0[YR =+3
M3(@#DNH"?>.?N\9Y].*X*\'B@:+=06\&H/<&X<Q77F[7/R$J=F[ &["\-M[X
MQQ4FJVFORK?(8;PP7$LAVV;(KLQMH50G)'R;Q*#GOC/% '=*RNH92&4C((.0
M10S*@RS #(&2>YX%<QJ$&I1:5H\,<=]Y$<.VZ2R=5E#B,!.21QNSG!ZXSQFJ
ML-AXBDMGEOY)9+L36 \H,OE8!@:=U'U$G/;''6@#L695QN8#)P,GO2UYMX=U
M#4M9G=S/--*)[:4Q&59%6/S7+/C.(R1@;" 1LSW.-"&#Q+:Z81-]ON9)K6V,
MN9ANCEWL)2NW!X7;D C..N230!VXD0R-&'4R* S+GD YP<>^#^1I00P!!!!Z
M$5S/A>UU6.Z:ZU:-Q/)IEI$[N5RTB/.6!P3SAU/XUC)#X@7POHEA;07UB;6(
M0W16,,^X1X4KAQE0WOUQD$9H ] HKC+F/Q!YVHQB2^97BB9)U3&Q@8]R*@?D
M, Y+*0RY(Y.VF0Q^*I=6CE=IK4>0AC@8"6,?N/F21PP&X2Y^;:2<+@X)H [:
MBN7\-IK<&CW;W[W4]T8P4AF41L) GS ,688+8Y^Z.PQ6986GB6[@$-S+J%O"
M;QVR) '$7V8$#<26QYV>^?H.* .Y>1(RH=U4N=JY.,GT'Y4ZN$BM?$%WK.E2
MZC#>LT4\$K%600(GV;#[AG[_ )I;H.F.U:=XFMGQ-F(7?DBXA,3*R_9Q;[1Y
MH<9R7SNQQG[F.-U '3/(D8!=U4$A1N.,D]!]:=7"VFF:^]K8I?/=3DIIT\WG
M2*2DX=C/C'0 !.!QZ<YK1\,MJFHZ?J(OKJ0-&S:?#*I'SF+<C3C'1F8G/IL%
M '3R2)%&TDCJB*"S,QP !U)-(\L<2[I)$1<$Y9@!@#)_2O/?L_C/4K"_@U&&
M1$N+":3RU9,"7RFA$(P>C'$H/J>W2KU[I6MFWN+1?M%U")91$TS*S;&LF'7T
M\TX]L^E '; AE!!!!Y!'>D>1(]N]U7<=J[CC)]![UR>E6VOIXD'VJ:>.RCP$
MC$8,;1>2HQNWX#"3)^[NXQG:1B"ZT.]GUB_7%\L<NKP7*RK-\HA$"JVWGY3N
M# X .,8[4 =K17#VT'BDZEIHN;FYC@CCA!81A]["1_,$F& RR;.2#UR.<UW%
M !1110 4444 %%%% !1110 R66."%YI7"1QJ6=CT ')-88\7Z<47]U>B5VC5
M(#;MYCB169& ]"$?D]-ISBMR:&.X@DAE0/'(I1U/0@C!%9-IX9T^TEBE!N)9
MHG1DDFF+L BNJ+D]@)'_ !))R: (#XLLHBB2K(\CW#P8A0L%Q<&!2Q.,9< ?
M7/;FB/Q=8!HHYA+YCL S11,R(&F:)2S8&,LN/UZ FJ=[X+676;:_L[I8#"[.
MNY"[(S3-+(5.X#YBY&"#CM6JOAG3$5U$;X?9GYS_  2M*/\ Q]B: *UWXIMX
MY9K:!&-U!<VT3I*NW*2SK%N'YD\^@[&K[:M'%JUY9S*(XK6SCNGF+<89I <C
MV\O.?>J4'A#2;>661$F)DD23!D) *3><N/\ @?/J>G2K=WH5I>:@UY(\P>2$
M6\L:R826,%B%8=_OM^= %&W\::/=I$8'E=Y9U@2,)\Q9D+@]?[H)]>",9XJ6
M7Q;I<,$TSO)LCNC:#Y0/,E!8%5R>VUNN.!GH0:'\*V,FE_V=+-=R6I(RC2YW
M*!@*3CIQUZ]\T3>%=.GN9[J1K@W,LB2";S/F0IO"[>V )''.>&QT P ,A\9:
M)<7=G;0W1=KM(VC8*0!Y@)0'/()Q^'&<9&9KOQ%:V.H26TX)?S8X(EC!+,SH
MSXYP.BD]>WK@5+%H%I#J"7L;SK*$1'_><2[1A2WOSU&,\9S@4W4?#EAJBW27
M'G!;O:)U1\"15!&#[8/;GN"* %U37;?2+E4NLB(V[S'8K,_RO&G  YYD'O[5
M7OO$D</A;4=8M;>61[1) 8)$*L)$X(8>F>X[<U=O]&L]2F26Y1F9(S$,,1\I
M='/ZQK1)HUG)87MDR-Y%ZSM,-QR2_P![![4 4Y/$<,%DXD)-Y&Q@9/+*@S"W
M\\C&3@;/<^F:33O$0GT[5+Z\18H;#:S%,GY?L\4Q./;S"/P%27'AC3KG49+V
M3S]\CF1D$Q";S%Y);;TSLX_#ZY6?P];'1-4TZU8P_P!H0M&SMEMI\E8@<>RH
MO'M0!&/%=@P*+%>-<>9Y8MOL["4_)OSM/;;SG\.O%-'B_2'@N)XY9'@@MTN7
ME5#C:X#+UYY# ],=>>#@3PG8(@837@N1)YGVK[0WFYV;,;O3;QC\>O-2+X7T
M^.6-X3/%Y-M]E@"2<0QX487/^XO7(X]SD 1_%>EQ:A;6,LCQW$XC(5E^X9"0
M@/N2".,]LXR,EMXJTZ\CL'A$S"_8BW^3&\#&6Z]/F''7KQP<+9^%M-T^>"6T
M\Z$Q1K&563API)7=]"QZ8].@ I@\):=Y>QGN7#70NY-TO^MD&S:6^GEKTP>#
MZG( V/Q;8!$\[S"QP96BC9DA4R-&I8X& 64C\">@S5K3_$-CJ5]):0"<2+YF
MTR1%5D\M_+?:3UPV!^(J ^$]++JP6=5  D192%E"R-(H<=P&9C^)!R.*N6NC
M6=G<1SPHPDC$X4EB>)9!(_\ X\!]* ,G4_&=I::=J$UM#/--;P3RPAHR$G,3
M;7VMW"L0#[<C(J_+J[6=QI%M/:2R3Z@2K/$FT1L$W$L"20/;)Q41\)Z6PN59
M9VCGCFC\MI25C65MT@0=MQ /MT&!Q6C=Z?#>SVD\AD62TE\V-D;'."I!]003
MQ0!@Z=XXL+C0X+V]26VG:"WE:)HRNXRY"[">H+*PR?[N3QS5G4?%-O;^';?6
M+0P207$T<2O<2^2B[GVDLV#C!SV[5*?"FEFVB@5)5$,$$$3K(=R+"6,9!]1N
M;ZYP:O/I=O+:6UO*9)%MY$E1F;DLIR"?QH R+7QG8O9">[AFMV2T^USE49XX
MX]SJ&WX&0QC;;QDC'%#^.-&2U-P6N&51*T@CA+F(1!2Y;;D8 =3[YXR>*U+O
M1;&^:]-Q$7^V6Z6TPW$912Y&,=#F1N1ST]*KR>&K&>V:"X:>8-;S6S,\G)27
M:''&/[BT 02>+;!%:1Q)%'"91<+-$RR1[(A*?EQ_<93^/KQ3IO%^DV\UI%/(
M\<ERJ,JLH^17?8A.#T+<#&?7IS5J30;)[N6Z'FI/+(TI=)""&,2Q$CT^5%JM
M:^%--LI8);;SXI(LAF63_6CS&DPPZ?>=CQC[Q'3B@"[I^L6VIVLUS;"5HHG9
M-Q3[Q4X.!UZ@C'7VK-/C+2S 9 ET[K*\311PEW5D02-G&1]P@YSWQUXJ[#X?
ML8H=1C;S91J *W#/(=S#;MQD8['&>OO4%IX5TRS4[%E9B[R%GDR26C6,^WW5
M P/2@"*3Q5;/JUA8V<<DZW%P(9)O+;RTS TP&[^]M"''HWK6CJ.HC3Y+,%-Y
MN)6C"C.XXBDDP..OR'K@517PI80W,=S;//%+$0\:F5C&)!%Y(<KGD[,#\/7F
MKXTJ%H-.2>26=[$AHY9'RS-Y;1EF/<E7;\30!F:?XEW>%=-UC4()%DOA&4A@
MB+-N?E5 R<]N>!WX[*WC/15N;J SOOMU<L A.XHP5U4#DL&8+CN>F<&M%-'L
MTL+"R5&\BQ\LP#<<C8,+D]^*JMX8TYEO4/GB&[+L\0D(579MS.O<'=\W7@]*
M &+XITQTE:03QM DTDB2PD,GDA"_'MO7Z]J9-XST6"[N+:2Y8-;H[N0A(^2/
MS&48Y)"<]/4=014 \%6<D%S%=75W+YTLK>8LS*Y2555T9@>0=@/;H,8Q6C'X
M?M(+JXG@DN(3< [UCDP-Q4+N'H< >V><9H JOXMLX;C$]O<16PL6O7N&4%41
M20<X)ST[9SD>M5[KQQIR:5<7-HLT]Q$DQ\A(RS*8T5F+;<_* \?()^\.]6E\
M(Z2ML+?9*8C#-!(OF$"196+/NQ_M$D8QC/%+<>%;&[MDAGFO&*K)&9!,5=DD
M #H2N/E.U?R!H 34?$1TUM,+VLLJ7<;NXAC+LNU W ';K_\ KJQ:>(=-OKB.
M"VF:221RB@*>T:R;O]W:Z<_[0%+J&@VFI1VR2/<1&W5DC>"8HP5AM(R.N1Q^
MO7FHK+P[:V.OR:I"%0?8X[.*)00(U4DD]>XV#Z(* $;Q):V]E?W=X/)BM+O[
M*,'<7;*A<>F2P'H.YIEOXMTFZ*>3)(X,#W#$(3L1696SZD,C#C/(]QE\WA>Q
MG:[WR76RYE$[1B4[4E!5@ZCL<J/;KZT]_#UI+-:2RS7+O:!O*)EQAB&4MQWP
M[#CCIQP, $$GB[38K.*Z<7'E20M<L5BW>7"IP9&QD!>??OZ'&A8:K!J,]U';
MI-BVE,3N\952X)!"D]<8ZCCFLP^#-),'E?Z0%<2+-ME*^>LC;G5\<$$^F.I]
M3G172EA>+[-/)#&+I[F5%/\ K2P;*D^F6SCV% $%UXFTJRO_ +%<W!BF\WRL
M,IQGR_,SG^[MXSTSQUJK'XKBEO[:V2UFD%S="W5D4@QYMUFRX.,'#=!G^E3:
MMX2TC6[F:XOH'>2:W6V<K(5RBN' X[Y'7TXJQ)H5D]X+L>:DXNQ=[D<CYQ$(
MOR*  B@"MX:\1Q:_9Q%H9(;K[/'/(C1E5(?(!4GJ,JP_#T()C_X2RR@T.RU*
M]4PF[9DCB0[B2-Q//'92?TZD5H:?HUGIAC-LC*8[:.U7+$_NT)*CZ_,>:HKX
M2L$@BA6>\"PR&2 ^=DPDA@0N1T(8\'/;T% "_P#"7:28;F9)9'@MXXY'E5/E
MQ(%*#GU#J<GCD\\'#G\5Z5%J4%A+*T=Q*J'#+C87!*JWH2 ?TSU&9)?#MI+>
M/=F:Y$Y@^SJXD^XA*D@<=RBYSGOZG++/PMINGRQ/:K+$L<21&,/E9%487<#W
M ..V>,]!0 [2/$^EZW%/+9SDI BRN7&/W; E6^AVMUYXY JM<>--)M+&&[N?
MM,,<RL\8DA*LT:J&+@'^'#+[\XQGBK^FZ)::79-9PF5[8H(Q'*^X*@& H]L>
MN3[U4'A2Q6&VC$]YNM@5AD,Y9T0A04!/\.%7WR,YSS0 R[\6VD#LL%I=W6R[
MCM&>.+Y0[X/!/7 (/'J*JW'C#R-0AC:'%FJ7LMS.J,P1+>41GTP><DX(XXSG
M(UY]"LIX)HCYJ>;<K=%T<AA(NW!!_P" CBA-!L8G,B19;;<KAR2I$\@DD!'<
M%@/PH JW/BJPM;F169C#$DI=E1F8M&\:$* /F&90/7(Q@\TR;QAIL,,;M'=;
MV9U:(0G?&4=4;<.WS.@]]P/3-)8>$-/M='L+&8O,UI;& R[B#(6=)'8\]6=
M?SJIK'@M;_4H+VTNEMI(FED5G0N4D=D)D7Y@,C8.""* +^N>(SI,\MLEG++*
MNGSWJR8_=CRP/E/?G(_3UII\76$>ESWTT5TBV[!9T:$JR90/D@]MI!]>V,\5
M>U'1+35)A+<>:&%O+;$(Y4-'( &4_P#?((],54U#PGI>I;_/24%WWL4D(/\
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MHHH *,8Z444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCUH EHJHVI6JZG%I_F W,B/(%7G 7;G/I]\5/]HA\QX_.CWQC<Z[AE1ZD=J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO-DO&^QDCQN(8KC."#M!)JQ'XGTJ6:&%9IO.FD:-8C;2AU90I.X%<H '0Y;
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MN[BUB^:08*L2FS[NX_W1QS5!(O$VE6-P+$W3B9KN7RVB7$/^F#!3"Y),3R,
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MF2;<*"<L/XB<=JGF\+6$VKW.I;I$EN5Q*%5/F/E^7N#%=ZG:!]U@.![YVZ*
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MF36$4CO#*NPDQQHP7;C&41<\=SD^]4F\%Z?-9-;W5S=73[(HXYIO++1K&VY
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M%S WDR6TA@91YD3XW(<@\':.1@CL15NRTZ"P6X6#<%GE,K GH2 ,#VX%6Z*
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MJ3[YL-@@^6J?*>W"*?K0!0F\5V[7NG6ME#++)=79MI1+#+&8,)O.X%,@X*D
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M$)1VE\QF"A-IYZ ;,8'/ QJ:GX+TW5=,2PGEN! K3M@%&SYS$O\ >4@'+'!
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M 6J*;)(D4;22,%1069F.  .IJ"&_MI[M[:*4/*D,<Y '&QRP4@]#G8WY>XH
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M)'\/:@"N?!2,ZP/%9M8"^^U&V*Y4C[(83\N,$F0[OUZU3_X0:\BTR.V@EM0
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M"H^EZ?):R6KV-LUO+M\R(Q*5?: %R,8. J@>F!Z4L>F6$2*D=E;(JE2H6)0
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M\8E60<@H1D'\JI6_B+2;JQCO+>[66*1() (U9G"S8\LE -R@Y[@=\]#7%1>
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M_M=1M_/M)1)'N*DX(*L#@@@\@CT-8"^&KC_A#KK1T9()IW+#;*&1,L#\NV-
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M73+:VGD:E,)-\?#N#$J,KC:.X8@Y.=YZ=^;MO VM>7<+>:E!,9K213\S?\?
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M@P?H3Q0!W%1QSQ3&012(YC;8^UL[6]#Z'D5S>F^&[NT\57.J7$B2K([LDHD
M?:RJ-C+Y>2!CC+D< XJK<>$IQ=74D5AI<\,FHF\:"5BJW*M$5Q)A#RK'</O
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MV\S='"J!2%*[N!QA2PSZ$BHFT+1KE$E2PM ?)\N*>*-0R)M(&Q@,@8)QCUH
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M)I]JT6U$V-"I&U#E!C'123CT[4 )JE[+8:;+=06KW<B$8B3.3E@"> 3@ DG
M)P#@$\5AOXPW7=K;VL%O<"ZC^26.9RBR>0TP5CY> "J^N[!!VXK;32+!=/>Q
M>VCEMI)&E=)5#AW9RY8Y[[B355+70$FGNX[*S$NG_N7D6V&Z(",?*"!G&Q@.
M.QQ0!A:'XJU!X-,LY[.:]NY+:WFN9UW$*9LE3\L07:,9.=N!TW$<S67C"Z^P
M::VH6$2W6H1*T"V\Q*R,9%0KRH(P'#=^ WI71_V1IIG@G_L^U\VW0)"_DKNC
M4= IQP!V JG/INC6UW9R-'#;&T>2ZC55"('8;&<G&,X<CK_%WH M:MJ/]FZ>
MURJQN^]41'9@&8D# VJS$^P4U@P>-'N3:/'IA$$D=H\SM-AHS<3-"H"[?FPR
M\YV\'UXK>31]/73%TY[6*:U!W&.90X9MVXL<]3NYSZT^/2]/BC6..QMD11&
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M:CI\-TIC_>+DB-BP!S@CD \$$<@'CI5NJ=II5E8W#S6MND3-$D.$&%5$+%5
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M6V$B:?N2*..*1'*?8BLSN7C54 +,C(#C:"4_NGC3U_1-2U+7=/NK;[*L%M)
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MS!"\KE-LH=HW^90I . 0#P1C!T++PY>P>+%U*6.U9%FN'-UYK&:5) -B%=N
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MT#S<G:?NB/'OG\* .YHKS6T^(&L(\S?V;'>VD%E=7CGS0DQ$5R\9  7:<*O
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M;S8WMIYYK>5Q&<(JMUP2",D8]3SZT =)17*2>-?](O?)TNXEMK1'+S , &6
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M144Y4+@F,$[MW&X("01G.,P1>+KB>)(XM,07[>:SVLMPT9A6-49@Y*</^\7
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M+',T3!?EPRY7@\9!S[4 =)17)7GBZ>P-V$LC=>0+N9RTPCVQ0>7N PIR3YG
M/IR>]37WB"\DM[F2TA2*""^AM1.9 78^?&CC85P 0S '.>^!Q0!T]%<Q-XQ2
M.*,K9%I)?-5%,H WK<I;J"<< LX)/8 \&J$'C*_@W03Z;)=WAGNB8K?<^R.*
M15VJ50[C\PQN"CU(H [:BN>U[5]1L=16TM8H/)?3;JZ:5G.]'C\L# P01^\Z
M'K[8P<^/QE=0VD$-SII;4))(XE2.1G5MT)EW$I&2#A6! 4\]\<@ [&BL6?7)
MUBTM;?3V^UW\9D$%S)Y/E (&8,<'YAD#&.N>F*I-XLF\R7RM*::,FZ2V\N7,
MDKP/L<%-OR@D'!!8G'3) H Z>BN>TG7KO5-::W6"T^Q"RCG\R.9RX=GD4K@H
M.A3'.""#D=AFZQXPNX=+U*6TLHT*07OV29ILDR6Q*N63;P,@D<G.!G&: .SH
MKG-8UZY\.Z99*]L;^^EC;Y/-P795R0"L?))P!\@!)[4Z7Q5';R.D\"1&.>6%
MV:;"KY<'FEB<=,<?K[4 =#17+V/BRXO[J"TCTP+<-<R0RAY618PB(Y8;HPQ^
M608!4<^W-.\.Z_>:WJLC2PI!9RZ=;7=M&) YVR-)\S<##$*N5Y QP3S0!TU%
M<@_C:58(U729'OW>139J9"\8158AL1DACO7  *G.=V.:M/XK:&6YEN+#R-.M
MKJ*UEN))L,A=$8,4QP 9$4\]2?2@#I:*Y2W\574\T<4=@3=731"*WGF$:Q[H
M#*=S!2<@*1C!Y]N:N:=XD?4=:FLDTZ=;>-Y(C<X<J'3 ()VA<$YQAB>.@H W
MZ*Y6\\9FSCN[AM/W6L0NQ$RS?/(]N&W@KCY0=C ')[9 S6I>:K=V=M8*]E$;
M^]G\B.'[0?+5MCN<OMSC:AZ*><#WH UJ*X>Y\7:I<VE_-9VD,,45A!<1DR9D
M$CRR(RX*[2/W9 /X\YP+=QXTGMV6W_L>6:^#3^9!;L\HQ$4SL*H22?,3&X*.
MN2.X!UM%96GZK/?MJ+?8ML-K,\,9$N7F9>ORX 4=,<^O3J<4^-Y/+MECTF6:
M[D2226VA\UGB"% 5(\O._P"<<,%'^UR"0#KZ*P%\22,CW!LE%I]N%C&_G_.S
M>?Y+$KMX ;)')R/3-4;GQ?,]I?/:V6$MK2YN'F\X941/)&-HVD,28\\\ 'OC
M! .MHKECXKGL9M2EU.V@CTZTOUM?M$<I)1&@60,X*]V95X/\?MDV[_7[NST_
M39DTS==7JDFWDGV"(B)I&!;:>FTCIUH WJ*Y >-Y/)BSI3"YN)(U@B61G!5X
MFE!8HC$':C @*W..<<BQ_P )<WVZSMAIDI:YC_U>6$L4OD--Y;@KM5MJXQOS
MR.,<T =/17+?\)FB6#W$EHOF1V<]R\:R-\IC95,9W(I#?,.H&/?K2W/BV>#=
MMTO?OOWL;?$CL9&0.S,P2-BHQ&<8#'/4 <T =116'I_B"2\U*.UGL)++S+99
MT%P65V)"EE V[?EW8/S9!'W<$&CQ!XB70GMAY"S^8<R*&;>J;E7< $(QEOXB
MH]^: -RBN4D\9O"UP9=-Q&HN1 PG!,C03K"0PV_("SJ0<GC.>G*?V_JL'AGQ
M+J,D-N;S3I)O*A,F8U"1JV-P4%AU/0'MQV .LHKEH_$.H6_B">UO+:(VIGAA
MWI-_J7>+=@?*-RY')..HX]*\/C&\OIK:.TL+?<]Y'"Y>:0*T3Q,X9"8P3]WT
MQZ$YR #L:*R9=4D@U^YMI,?98; 7) 7+9W,#^@Z5D1>,[B32EU!]&EA@+(QE
ME,BQ)$R,V]F,>>-N#A2HW [L9( .MHKFY/%,J7D]F+!5N_M2V]O%+,R&0-OQ
M(QV8"$(Q!7?GIP<BI-(\22ZOJ"VT=@(T2'S+B1I_N-YDL>U1M^;YHCSQP<^U
M '045RFI^)+])I;:VM4AN8;Z")(Y7(,T;R;2QRF I_O*6/T(Q3E\9 O8*;-<
MW$B13JLC,T#-*T(/";2N]3@L5R < D8H ZFBN8\*ZO?:E.ZW<WF :?;3CY /
MG=YPQX'<(OY52T;Q?>R:#:M?6L1OVL;.X4F5L7'G!N<)&2&S&YVJK<8YZX .
MTHKDHO'5N\%O(]C*K3VT=XJ;LGR6B>1FZ?PF-EQZE>FZKVG>(YKS1KW4)]-F
MMQ;1&55;>!*NS=P613['C'H30!OT5R\/BNZFDCM1I<:W\TRQQ1-=?N]K0F7+
M/LR#A2,!3SWQS5O_ (2,SZ5H]U9V@>;52JP132[%4F-I#N8!N@1N@.3CMS0!
MNT5QEIXQN9]16?[(#ITL=B"IE >%YY'CX 'SC=MSR.!D9Z5%:>,;BWLK=KE?
MM%Q+;6S#>PC3?(9R2=JDCB'L#VX')H [BBN6'BVX-U96K::J3W4?*&5\P3&%
MIA'(?+P.%QUW<@[<<U!9^++Q[6RDN+6,W=W9VDB01RXB\R9W ^8KD#"Y/!QT
M&3R0#L**Y/\ X3.7@C2P1$2+H_:/]7MN&@;9\OS_ #*2/NY'H>*MZ_XKA\/W
M<<$]J\GFHLD;*P^90W[X_P#;-,.?4<4 =#17'1>+;Q]5\Y;0/IDL-F5S* R"
M:XEB60#;\VX"-L$C Z9/4N/&=V_VF.PL;9Y8KBT5'>:01RQS7!AR#Y8YX/3<
MO.<G&" =C17-R^*98[N>S-@JW8N4MX(I)F0R;BV')*8"$*2"N[T.#Q5>#QH]
MS>P6L.DSR2?*+D1[W$69WA)!5"" T3L2Q7Y1D9/% '645R)\<JT2"'3I'G,B
M6[(&9@EP?,+QG8C-\HB))"G[R\<\:>E:[<ZI?FW.FO;(EM%-*9I-KHTF<)LV
M]MIR21VX] #;HKE;;Q-J<D8C;3K5[N2[NXH5%T43RX'9268H<-P!@ YZ\#IT
M&FWT>IZ7:7\*LL5U"DR*XP0&4$ ^_- %JBBB@ HHHH **** "BBB@ JA=Z'I
M-_%-%>:797$<\@EE2:!7$C@!0S CD@ #)["K%ZK-87"H"7,3!0.I.#7#Z-X2
MO9K2Q:^MK>WMB;9Y[/S7;S"D4@=WRHRS,Z9!_N<DT =I:Z986+!K2QMK=A$L
M(,42J1&N=J<#[HR<#H,FK'G1^?Y&[]YMWXP>F<=:XL^$M2EN+QC)!!(ZW)6[
M25B\SO*)("ZX&!'M ZGI@8!-.F\,:O+9@R26\D\J))<PF9@DCFX$LD><?<*Y
M0$CI@$8H Z^VNH+R)I+>0.BR/$2 1AD8HP_!E(_"J/\ PC6A#[9_Q)=/_P!-
M_P"/K_1D_?\ .?GX^;GGGO7*1>"]25+%6:..&*2X?R+>X $!DN#*K(S1$DA2
M%R IXP.":W]6TJ^N?$%C?V:V_P"YC9&:X;< "#]U=N0V2.0PR,@@X% %U/#F
MAQO:NFCV"M:*5MR+9,P@Y)"\<9)/3UHL_#FB:<$^Q:/86VQQ(GDVR)M<!@&&
M!UPS#/HQ]:Y?3O!M^88X=26U-L;W[1);H_R$?9FC("JBC_6$-C';))-,_P"$
M+U./3H+>.:(J%M7N8O-R+B1(Y%E+%T8$EFC;)4YV<XZT =:V@Z42CII]K%+$
MLBQ2I"@>+S,E]IQQDDD^I/-0Z-I.D0^%].TZRCBN-+BAB-OO <.JX9'Z8)R
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M<8Z \X]:?<V%G>,C75K!.R*RJ9(PQ4,,,!GL1P?458HH K#3K(*%%G;@!8T
M\L<+&=R#Z*>1Z'I5<:!HZQW$8TJR"7.#.H@7$F#N&[CG!)//>M&B@"@VAZ2Z
MW"MIEF1<D-,# O[P@Y!;CG!Y^O-+_8VE[K9O[.M-UJ +<^2O[H Y 7CCD9XJ
M]10!3DTC39H9H9-/M7BGE\Z5&A4AY./G(QRW YZ\"IH+2VM?^/>WBB^14_=H
M%^5?NCCL,G [5-10!GSZ%I%RLBSZ792K))YSAX%.Y\8W'(Y..,U?50JA5
MP .U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 9L8!\179(Z6L&/^^I:SM6\07.FZE-$EDLEM;01SS2%\-M9ROR
MCU&">>N,<=:THO\ D8KS_KU@_P#0I:P-3TZ^O?%4D.T-8SK!)(V. D9=MF?5
MGV_AFADHT+?Q5I]SXD?1(UE^T!6(DV_(Q7[P!ZY'T[&M\5Q_A_PU)#+:ZC=^
M9!>QPA&57!W,<EV;ZL3^%=@O2BY0M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 95\ =?TP
M$9'ESG_T"GZG?R6<EK#;V_GSW$@54+[0%'+,3[#\Z9>_\C!IG_7*?_V2JNI2
M/;:_:W1@DE06TB($7/[PLN![9 /-#)ZLN6>K0:A*5@AN&C!($QC(C;'H:TA7
M-:&\\.K75K%;RI999R'3 BD+<A3W4YS[5TJ]*"A:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH BN;F"SM9;JYE2&"%#))(YPJ*!
MDDGL *Y[_A8O@S_H:=(_\"T_QKHY8HYX7AFC62)U*NCC(8'J"#U%9O\ PB_A
M_P#Z 6F?^ D?^% &=_PL7P9_T-.D?^!:?XT?\+%\&?\ 0TZ1_P"!:?XUH_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*<,$)!_"O,TU[7+:S6\>[GEMIX[&W;C)AE>.)@_3HY9U/N4]Z -;_A8FI?\
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M/%'_ 'XC_P#BZ/\ A8FI?]"!XH_[\1__ !==W10!PG_"Q-2_Z$#Q1_WXC_\
MBZ/^%B:E_P!"!XH_[\1__%UW=% '"?\ "Q-2_P"A \4?]^(__BZ[B&0RP1R&
M-HRZABC]5R.A]Z?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM/\ OPO^%7** *?]D:9_T#K3_OPO^%']D:9_T#K3_OPO^%7** *?]D:9_P!
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MD:9_T#K3_OPO^%']D:9_T#K3_OPO^%7** *?]D:9_P! ZT_[\+_A1_9&F?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>bionano-nancyridgeleasee015.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0,9
M/7I0K*PRI!'J#0 M%("",@YI: "BBD!!Z'- "T44BLK#*D$>H- "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%(2 ,DX'O0 M%%% !112 @C(.: %H
MHHH **** "BBB@ HHHH *** 0<X/3K0 444C,%4LQ  Y)/:@!:*** "BBB@
MHHHH **3(! SR>E+0 4444 %%%% !1110 444A(! )Z]* %HHHH ***,C.,\
MT %%&1G&>?2@D#J<4 %%%% !1110 444@((R#F@!:*** "BBB@ HHHR,XSSZ
M4 %%%% !1110 4444 %%%% !1110 44$@=3BB@ HHHH **** "BD) &2<4M
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MRW$_DNZHVR/]RTH^?&TG"K\N<X8&@#B+K4_'GFZC]E&H>>HN=T;62>3#B91
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M_EQO]GDVA]VS:S;<(VX;<-@YXIA\3Z2+-+OSIC"[E(RMK*3)@9)4!<LN!G<
M1[T <?KNJ:QI%[-;1W<MG$TD\SW0MT+>6B6X\U@(FW#YI,X R0!D8Q4US8^(
M(=-UB&TGOU6ZCU-XXXXU!CD\W,11MN[+ MU)SGC&!6_>^(O#<ERD5R1<RQN/
M+*V4DP#E!( A5""VPAL#G )[&KJ>(])DN((8[O>TZJT;+&Q0[EW*"^-H)49
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M(N%!(W1H#NR<*.:19M<M=(\0*OF7EY:%_L#31!3-^X1P/E !'F,R\>F.H)K
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M<21K=?:S([#>TGG^?DX &"_H.E0_\(M9+JUWJ44CQSW6XOB*%L,4"%@S(6'
M'&=OMR:W** .<7P;8I9K:K=7:Q"VN+5PIC&^.8Y88"87!^Z%  QC!'%6[[PY
M;7MV;O[1<P7.V$)+$5S&8C(5(#*1D^:X.01@UL44 8S>'('GDEDN[IS));RN
MI*8:2$J5?A<Y.T CIZ 57@\'V,*Q(;F[E2#REMU=EQ D<JRJBX49&Y$!W9.
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M B@*&1AR%W-R@^\3C+8QFMNB@#CM*\&SVUY=F[N(S;S7 N2(@N]Y%N//0D[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ([K&
MC.[!549+$X %<2OQ&@ET'5=6CT_9#87(A'VJY2 2(8UD20%NFY67"]<D>^.R
MN;:&\M9K6XC$D$R-'(AZ,I&"/R-<U%X!TRRMM1@TRZOM/74)5DF,+H_"Q^7L
M D5AMQSTSGOP!0!T&F7PU/2K._6&2$7,"3"*489-R@X/N,U:K+T?0H-#@@MK
M.XN?LL%K':Q6\CAD0)G##C.XYY.>PX%:E !7%0_$C3QK=W87MNUK!;O<I]I,
MJN/W# .60?,H.X8X.>G6NUKG)/ ^BRZ9J]B\+%=6EDFN9<+YF7;=@-CH#R <
M_C0 DOCSP_%&A^TSM*XE*P+:3&7,>-X*;<J1D=0.HJIH?Q"TO4M.TR6]/V.[
MOXXY! J2R+$)&(C#R&-0I;&!G )^Z6&";>F^"M-TR2*6*65GCMYK;(CBB!64
MH6)6-%7/[M<''KG-5H_A[I43V>RZOA!;Q6D;V_F+LN/LW,+/\N<@@'Y2H.!D
M4 2/\1O"T=LERVI.()/,*/\ 9)L,$V[V^Y]U=ZY/0<^AQ.?'/A\:=)?_ &N<
MVL4C12N+.8^45 )+C9E%PRG<V!@@YJO+\/\ 2)M*@TYIKOR8;"YT]2'7=Y<Y
M4N3\OWOD&#]>#5;6OAIHVN?:1<W%ZHN9I)9%1HR,O%'&<!D(&!$N"/F!)P><
M4 :;^-_#L=[=6DFI!);596F+Q.J+Y8!<;RNTD @X!)P<TO\ PF>A![9'NIHW
MN-NU9;25"H9]BE\J/+!;@%L GIFJEY\/M&OHYH[A[IDFDN9& D YG0(^..P
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MZC#I%'+#&5V2K&Y=0V5)ZD]"..* +5EK-AJ%U);6TQ>2,$G,;*& ;:2I( 8
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ML"OEM*(Q&'^[NSM XSC(!Q0 0>+-&N;;SX;F5U)0(HMI=\F\%E*)MW," Q!
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MF:Y2!RGEK,R%&?A0<D,W&<?,>.F "M=>,+.WNY8!;7;&"_6RF)MY/O-%Y@*
M*=_88'/.>F";L?B3299+9([HM]I2-XV$3[</G9N;&%+$$ ,02>*3_A'[<ZE)
M>F>XR]TEYY65V"18O*R.,X*@9&>HXQSFG:^#--L[^VO(6D\R"-(_GCB?<$)*
MG+(64_,?ND=J -&XUW3K6_%E-.PG)52%B=E5F^ZI8#:&.. 3D\8ZBLF'QSIL
MK6,CQ7,-K=VSSB26WD!3:R+\RA3A?G^^3M'K5^X\.VUSJ;7C7%PJO+%/+;*5
M\N22/&QC\N[(PO0@':,CUKKX1LA9&T:XNGB^RRVB[F7*1.0<#"]MH )S[YH
MLS>)]'MWN%ENROV<.TC&)]N$8*^UL8;:S $+G!/-7#J=HJ6S.[Q_:03$LD;*
MQPI8Y4C*G )P<5D+X,TU)KYU:15O&=W41Q JS2"1B'V;^6'0L1S],:.K:/'J
MPMRUS<6TD#ETD@*[OF4H1\P(P0Q[9Z8H AB\4://=16\=V2\H4JQB<)\T?F
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M.3<JJH4$-"A  QUR#DU*WA&QEAN%FN+J62YM[F">9F4,XGV!VX4 $"- ,#
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M$R,F\;U4E6(PP!89QG&1ZU'-XEB@T-]4D@(CCOS9LN[.,77V??P/^!8Q[>]
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M$\C*9VCMC>Q120LJR;%\T89EQN& <=1UQQ5V_P!:L-,BB>]F,7F*7 ",YV@
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M)YK&7S6B,,3NTUJXB=)7:-02PQR1CG@@]^< &,UWXIN5BF2>> /'9R>6EJK
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M7R7WNS*77"[<D%02#C! )S3_ /A)=(VS'[7Q"0#^[?YR6V#9Q\^6^7Y<\\4
M<GIUCJ^DZ3<:F1<Q2S-Y0AMPSN29S^]<,C8PIQPC<>O&'RS>*-2\/7[O/?6L
M\>BK)&D%N%>2X)F#8)3=NPD?"@$;N@R*Z*#Q-;WFMV>GV49FCG@DG><JZA K
M;-N-N-VX$$$J1CUXJS+X@TR"2>.6=T># 96A<%LL$&SCY_F(7Y<\D#O0!E6.
MI:G)XI72S+++:+"M[]HEA",T3)L6-A@88R!WZ#@8JC)<ZO:7M_&UYJH@?5"'
ME6T\TP0&$LOE#RR""X"GAL>Q)-=#J&JV6EQQW\D7$\9W,L9$C*D;R ;<9) #
M<'&,FI4UJQ:QM+QY6ABNQF+SD*$X1G(((X^56//I0!C7%QK+Z)H%S);-]O)9
M[@"')1OLTQ!(YV_/M'U..]9TVH>);.Q)DEO9W5H)3LLQYD@:)B\28C91AP,;
MA[%AG-=(WB;2%L_M8N]]OY:2F2*)W 1EW!CM!P-O.3T'7%7+;4;6[N9[>"0R
M/ <2$(VT' . V-I/(X!XS0!QTL>LL;J!)]1DG^W7821X1^Y0P2&,QMMQC.T9
MR<'CBIH-6UB%+.V4:C-YT=ALEELFW<S$7&\[ %(3'WL=C[UNQ^*=%FBFECO0
MR1!2?W;Y;<VU=HQ\^6!7Y<\\=:=:^)-.O=2@L;9II))X7F5Q"VP!6VLK$CY6
M!!!!P01@\XH Y*.]\3VME8VT,]Z[YN!+/=V[,?-610B-MA8E"I)R,9[.,8KI
M-7O-2@U^PBM?/>VE5E>.*$D!N<,S%"NT8Z;E(_VLXJ4>)[",S"[?[.8YY8AP
M7RJ$!G.!\JC<,D\#(R:F'B+3&N9[=)I7E@#%PEO(V=K;#M(7#$-\N!DYSZ&@
M#F[/4M:U6;3UEM[N-5%KYKR69C*2F*?S6&Y>S",9Z#/O2FRO]3^&NE6EQ/J$
MEVTEDEV9H1YI_?1B4,K)RH&[)(.0,DD9SK2^++47*);Q&>%Q;D2@D?ZV5X\;
M2,@J4.1U[<8K3AUC3[B!YX;I'B2W2Y9US@1,"5;\0I- ')3:EXD0WJ6HNO-1
M+H"%K']U#MD"P&-MHW[DY(RW?[N,5T.H)J<;Z/:VM[<8>X*W=R(49R@B=N?E
MVKE@HSCO@=:EC\2Z3*;<)='_ $C:8R8G PS%4))'RAF!"DX#=LTD'B;1[EV2
M*]4D,B\HP#;WV(5)'S MP",@^M ',6^K>*&M9Y+LSQ?O8UF6*T9Y+8&0AC&#
M$ PVX[R?WLXJV;_79M56W@N+Y0TD<<7F6&(V@,(+3.Q0;7$A;Y<C[H&WG-;4
MWB73+=I6EN4$$8PT@R3O\TQ;0H&2=XV\=33V\2:0CS(]X(_)C:1RZ,J@* 6&
M2,$@$97J,\B@#E9M9\6SV$%Q]GEL_-=HW'V=BT3)&HY C<E6D\S!V\JJX(W<
MW;[5-=TNUU'6+AY98;.[C7[$D"JLL)C0,4)&XG>Y/7^#&.M:B>*[(Z3K.IM%
M.+72W97Q&V]PL:.?D(!!^;&#Z9.*LOK6D7%S%8RR!I)"A6.6!@ WWT#$C"OQ
MD*<'@'% &?J=QJ]GIVDQS7%RCLN+ZZLK7SG#B/(PFUL*6[[3V'&<U!X:M-0;
M5+W5M5CD2]FL[965HEVHWEY=4(&X@/GC)YK;DUW38M3&G/<@76X)LV-@,5W
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M@#@@].<UF^$]1UO4&N7U4(A"*?(V,K0R9;<F2B@C&.['C.<$5SEMJOB FYU
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M!5LC@$^E;T?A70(;46T>C62P!)$\OR5QMD(+C'^UM7/T'I4\>AZ7%IHTY+"
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MBGBTBS22*(0HPB'"!2H7Z!21]#B@#"N/B ;&R:>_TB2!QILFHK&+A7W1JT8
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MR1NH9'0Y# ]"#W%0VNH6MX2+>8.06!P"/NN4;\F4C\* +-%,FFC@C,DK;4!
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M7<CV;VLL,*3A6</E'3<IX[\$$>W4UFVWBV]-I=W$FG"6&!+8JZ,<GS$5BS@
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M6&T ="WEOM^GO0!CZKX<U*PT^YN;51)-,9A<*C.YE#WB/'N !)58MX( . 2
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M1^)J>B@"DNDZ>BQJMG"!&L:H @^4(VY /H>11#I&G6]I/:16<*V]QD31A>)
M1M.?7C ^G%7:* ,Q/#VD1^3LL(0823&<<KD@GGTR <=.!0/#NC@S%=.@4SG,
MA5<%OF+=1[DGZD^M:=% %&'1]-M[I+F"RABF1 BLB;< #:.!QPO ]N*'T;39
M+Y[U[&!KEP0TI09.5VY^NWY<]<<=*O44 5XK&UA#B*WC0.BQMA>JJ, ?0 FJ
MSZ#I4@8-80_-&D1PN,JOW1QZ=/I6C10!0O-%TS4+>&WN["WEA@&(D9!A!C&!
MZ<<?3B@Z+IC7#3FQ@\QT\MB$QN7;MP1T/R\?3BK]% &?<Z%I5VNVXT^WD&0<
M,@[*5'_CI(^A(J6/3+&%U>.TB5D<2*0HX8)Y>?KL^7Z5;HH I3:/IUQ80V,M
MG$UK!M\J(KPFT8&/3 J-=!TI;I+D:?;^<B[5<ID@;=G_ *"=OTXK1HH SHM
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MCC(X7 P<8)]L:%O;PVMND$$:QQ1C:J*, "I** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDLJ00O+(P6-%+,Q[ <DT^HK
MJW2[M)K:3.R:-HVQZ$8- &'IWBVTOIA:R*+:\>.)XX)'^\9(]X7., ]1[X.,
MXK7TR_CU32K2_B4JES$LH5NJY&<'W'2L"T\*SH+:>YO6>5!!)-;H (WFB0*I
M#8W 9&3]![YVM$T]M*T.QL'</)!"J.XZ,P'S$?4YH DU&_CTVV2>5797GA@
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MG,EJEV&481HV) (8\?PGK4UKXDTN[>=%N?+:&26-A*I3F/[^,]0!S]*HGP?
M()($O)EBEM?LL@VJ=P#LZG/8@NWUXJ+5_"/V^TDMH[EC'-J NFW8!C1LB900
M.=R,Z\]-W7B@#>?4[..2UC:<;[H9A4 DN..?8?,O)XY'K6?IGBK2]2T]KI9P
MC1JK2Q<LR98J. .>01QW!'6I]4T9=3NK"?SVA:TE$@,:C>>5.T-U .W!'0@D
M>F,]_"$/V2."*^N(RD$< 88^95DWX8=P>A'<4 3OXHM#>1PP)Y\<BVK),C?*
MPG>1!^7EG\ZG;Q%8Q:])I$\JQ3JL10L>'+[@![<K@9ZD\51LO!UI9+ $N9F\
MD6X&0HSY4DD@Z#N92#]!5B]\-K>ZP;UKV98G>W>2W"KM=H7+QG.,CYL$^N/K
M0!H6.JV&I/*MG<I,T6"P7T.<$>H.#@C@X/I56W\1Z9,+-6NHXYKN-)$C+ _?
M^Z"1QS@@<\XXS4&A>&X/#=K+'9".4B)8HMT:QL53.U6<#+=>I^N,YS1TSP:;
M:QL(KB]<>7%:?:88P"DDMO@H0Q&0-RC/J%'3G(!J0>)=*E:UB>[BCN+E$=(B
MP)PY(7D<<E2!ZD8JO;>+],NY+4QLRP3K,?.E4H%:.2./!!]3*.:;!X2M8(4C
M%Q,0JV:Y./\ EWF,J_F6P?:HY?"41L9H?/>?_1[R")'P@"SLKD%@,\%!@]>?
M:@#;;4K-+66Y\\&&)S&[*"V&#;2N!R3GC [U5'B/1S+;Q#4("]RJ-$,_>#L5
M4^V6!49[\=:K1^'F_P"$6M](>\D69 CS7"?\M9 P=RP[AVW9'<,:@M/!UI:6
MRP+<S, MJN2%'^HG:9>@QR7(/L* +UKXBL;[6VTRTD69TB>1W4\+M<(1[\D\
MCC*D=JD;Q!I:0-,;Q?+64Q9"D[G&<A>/F^ZW3/0^AJKI/AM=*OEN%O9IDBB>
M"&)U4"-&</C(&201C)[8[Y)I3>";>9F=KIBXNOM,:&%3$K%64_N^F2'))&,D
M ^N0#9_MS2O+\S^T+?R]Q7?O&W/E^;U_ZY_-GTYIB>(M)<PA;V/?/*88T((8
MN,$KMQD'# _0YZ<UFS^"=-N)9RSR)#-IYL3!$%5%!79YB@# ;: OH ,8JSIW
MAJ#3[B"=73S8C(28H5B#EU1<D#OA!S_3% $DGB2P+P);/YYDN/(8#*E"8W<$
M@CD$(<'H:DTS7['4[*SG25$DN0@$);+*[1"79]=AS]*R]/\ !4%C*DK7]Q/*
MLD;EY -SE$D0%CW)$A)/<CMTI^F>%5TW7K>\20M;VNG16D:D\O(N5,A&,!M@
M5<]P2.,<@%Z/Q!;M?7-M(OEB!Y59RPY"+&Q..O\ RT'3T]Z@G\7Z1;W-JDER
MBP7$4T@G8D!#$Z*RL,9&"_.<8VG--NO"L-Q/=3I>W,,MP)OFB(!0R+&#@^WE
M#\S5)O L/V/[/'J4\2O'=0S;(T =+AE9P!CY?N#!'3OF@#5'B73T\[[7,MMY
M=Q)"-YSD)C<_'11N&2>!D9/-.O\ Q#8Z9J\%A>2+"9H3(LC'CAE7'MRPYZ5G
M7G@FQN[D3LX8[YMR30I*A64J67##_8&#[G.:T=5T&#59)GEFD0RVCVIVXX5F
M#9^ORT /D\0Z1"]RDNH0H;96:4LV H4@,<]#@D XZ$C.*5=?TIIDA^VQB1TW
MA6!'&TM@Y'!V@G!YP"<5ECP59"2^(D 6Z:1\^2GF(9)!(_SXR1N'3^>!BQ+X
M4LY=<N-38JQN#OD1XE9@WE^7E7(ROR@?Y)H N3Z_I5O&KRWT2AMFWJ2V\%E
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M()##'$A$T*.3Y;%E8$C*G+=O08P>: -#3O$5CJVJ7-E92+,((8Y6E4_*=S.
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MMI>3*WE7JQW+VZ1):E#)_HAG#9W''S@1CZ\Y-1V&L^(K^UM%6YM5:XN2C3I
M7,:B!G(93@ [U Y['!YYKMZ* . 76]6U/4M'%QFV)FMI3:I;O\ZM!O9R^> '
M8I@_W>>2*FT[6/$S_8IKIXG22*PFEC6S93FX9D=<[CC9@-Z\\\5W-% '":=K
M_B2_M S_ &:&:6:WC9!$S/;%V82*R\= !@D]<DY!%7M$U#5;G7K<7]PR1O9L
M/)\G:LDB2NI8>AP%./<5UM% '$'5]4M)[J&?4#'&=3DC>>2V+?9HMC,G'HQ
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M?,0EO9_!GB^5;B6YE9IOL\RPLI<?9TVE%ZGG/3J<D=:[JB@#@IM>UC[/>7$
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M9!*D?H>:DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***AO+E;.RGNG!*PQM(0.I &?Z4 345RB^(=0ET*Z\F
MO>6EB))[GY1$LYA$NW;G)7E>1_>'N1T]O,MS;13H"%D0. ?0C- $E%8WB6\U
M'3]-2YTZ:U1O/BB<7$#2 B214R,.N,;L]\^U9T7B2\MM6O+"^@\P)<BVBNHD
M"IO^RK,04+%NS_FHR>2 #JJ*P]&\1)J=REHT3I+]ECN [X3S0RHQ*+DDJ-X!
M(R 01Z9K_P#"4BVT?[9=0[Y9-1N+*&.(8W%)I$4G/3Y8\D_7 [4 =)17.)XP
MMFN].MS:3JUZ@(5BOF1L59@&3.1]PC/KC&1DBJ_CRT2TMI?L-R\LR22-!'AI
M(UCV[@0.=_SJ-G7.?Q .MHK#U[Q(FA2(K6-Q=#[/+=2&$H-D<90,?F(R?W@P
M!Z54N_&EO8V<D]S92QR0RO'-"98]ZA I) S\W#J>/7G'&0#IZ*R;'7X+_4Y-
M/CAE6>'S?.#8_=;'"KG_ 'P=R^P/2L2W\;_9K-WU.RF5RTWD,FTB8+<"$  '
MCF2,<^I/:@#L:*PG\3P1>'/[8EM;B-?-$ A9<,7,GEC'^R20<^AS[5!%XQMG
MN=.MY+*ZBEO_ #/)#J!GRV829YZ +N!_B##% '245RMEXWAU&"%K;3;QI+EX
MUMD;:HE#H[CYB< A8V)';CKD5;N?$Z0K*BV<QN$G>V$;,H_>+;^?R<XQCY?K
M[4 ;]%<O;>,DDFT^VFT^X%S<PP2RB+#B+SF*KTZC()/H.?6I=#\13:UJS*MJ
M\%B]C'=6[2%29 [, W!.,@#@T ='17(Z7XR9K2V_M*RFCDE"L)05VLK2B+?@
M'@!F7.>QSV.+]SXCD_LG3-0LK%IDOKE(T5W"GRW)P_X@ CZT ;]%<A!XT^S0
M79U*SF'ER7AADCVD3+%<^2% SD'YXQSC/)JY>>))?^$1N]7MK9H9H6*!)XF8
M9#!<@*06'.1CK]: .CHKDT\72V-G;OJMJ?,FN&C5D3R6:/>J+)Y3G>!\PR/;
M/< S_P#"47,U[91V^E2&"XU*:P,LDJ#/E"7<P .<9B/7M^% '2T5RMEXTAGG
ML;4VUQ-+/'$TDD<> GF,0ORY)Q\N3SP#GUQ:'B5;CPIJ6L11- UI#*[12 .\
M95-V'0$8;IE21]<$&@#H**Q+7Q&ESK)T_P"Q3QKYDL*3L5VN\>"PP#D#!X)'
M8^V62^)EC6YE6PN)((K@6D<@9!YLQD6/: 3D#<V,G^Z?;(!O45SG_"86RV]P
M\MI.DEM#-)+&2I*F)PC*"#@Y)!!]/3I5?4/&AM;74GATR9FM8+N2)I'4)*UN
M<..#D#GN.Q]L@'5T5SQ\61+K TU["Y\U=JS,H#+$Y3> <=L8R>F6'OBL?&JK
M907<FD7:126@OGR\9,<!(^8_-R<'.!GH: .JHKF;CQI:P75Y;"TEFDMRH40R
M(WF$RK%C.< AF'!/UP012/XKN+8:F]WI3QQV5Q%#N652!NC1R7/10-_+=.E
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M+#<-=1X)!65BQ9@1W)=L^NXCO5VB@#.CT+38IX9HK41O"@C0HS*-H)(! .&
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MTJ>\:\EL('N&ECG,A7DR1@A&^H!(%:-% %!]%TV12KV<9!$H(([2N'D_[Z8
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M2Z1IZ1&)+.)8R8R45<#]WC9Q_L[1CZ5EZ3X0LM+D=O.EG0E66.3 4,K[PY
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M(*\8."#G!'!]1UIRZ3IZ,&6TB4B19!A< ,$V X]EX^E7** *5GI-C86SVUM
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M$DWI9QJ?W?"Y"_N\;#CID8&#[ =JCE\.Z1/=3W,MC$\TZLLC'/S!EVMQT&5
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M=?)-L#[W7;@_,6&<]0 "..=&[T"\N/">G6,\8NKFSN(92C3'+*DG3<>IV>M
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M3@QQPL8R<J/XAM?;M) )(Y#&@#N:*YCPGHVI:6]R^HSSRS.BJ[-*&CE<%B9
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MBP4_B4;\JXNT\,ZPL%N+ED:2,VH):7<0L5Z9<9]H\ ?3%7-9T+4;OQ2+^UC
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MDC2^V;C*VU8 P! =L$ \X&<#/&>E3:GX>T[5;:\AG@"B]V"Y90,R!2" <\=
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M \DD94E0C9)7<""<>HKJ** ..F\.ZC:ZQI::=Q8VAC8S-,0[9=S+N'0YW X
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MQ^^?F/!PO09&*VZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M";>XLEE CD.74JI(++VSC/<$=":H+XT:*TB2XTV?[>\B1"%2&W;HC+NRN<<
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M33+>$12B:,*O". 5!7TP&8#'J:YS1?#6L6-]I)NIIO*M;6VC'DS#9'LBV.C
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MQ'R$^?QG!RIZD<U=U72M5N-7OI;8D&:S\NSN?M!46DFQP24'7)93G!Z<_=%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !ORY_X%CD=#WH Y7P]XTUSQ5'->VBV%C;V5G;SW$$T+R/,TL?F':P==J@<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+N[G 50,DD]AB@!]%5I+^TBTYM0:X3[&(O.\X'*[,9W9'48YJ1[F&.YBMWD
MFF#-&G=@N,_ED4 2T45%+<PPS00R2!9)V*Q*?XB 6(_($_A0!+1110 4444
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M*6.>%)H9%DBD4,CH<JP/(((ZB@!]%1-<PI=QVK2 3RHTB)W*J5#'\"Z_G4M
M!1110 44R*:.;?Y;AMC%&QV(ZBB&:.XA2:%P\;C<K#H10 ^BBB@ HIHD0RF(
M.OF !BN>0#G!QZ<'\J9<W,-G:S75Q(L<$*&21VZ*H&23^% $M%0QW4,L<+AB
MOG#,:R*48\9QM;!SCMC-,BU"UFL[>[CG5K>X"&)^S[ONX^N10!9HJ.>>*UMY
M;B>18H8D+R2.<!5 R23V %24 %%%% !1110 44Q9HWF>%7!D0 LO< YQ_(T^
M@ HHIDTT<$?F2N$3(7)]2<#]2* 'T444 %%-$B&4Q!U\P ,5SR <X./3@_E1
M)(D4;22.J(HR68X _&@!U%-61'=T5U+(<, >5XSSZ422+%&TCG:B LQ] * '
M44R&:.X@CGB8-'(H=&'<$9!IL]S#:B,S2!!)(L:Y[LQP!0!+131(AE:(.ID4
M!BN>0#G!QZ'!_(T22)#$\DKJD: LS,<!0.I)H =144=S#+<301R!I82!(O\
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M(BNP*  4=N^"<_1;WPMJUYJEQ-^Z#NUP5O#<-NVR6YC1=F.-K'U]QRQKNJ*
M.,;P_JNJ2[]2CCCA>Z\UH%NF8;!:F, D ?\ +3#8_'K5[0M#OM,LKN&27)GM
M(1DS,Y,X0B1R3SR=O/?%=+10!Q \)7\5SI&R:;R+>WA5_*N &297W22$NK%M
M_ .""<$'AN*D>A:Y#J#Q+"1,(O.,XN7*73K=1R?-QA"R KW[CH!7H5% '%2>
M'=;NX<3R+'YCS&1$N6^57NXY0 P /$:L..G05-=^%;FYNKB/*_83,[0Q"9E"
MK]ECC08'HZ,<=N#UKKZ* //]&M=33QUOU"WGE\O$:S!9.#]GC#,6(VE-RL
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M(S@9)R!78:;'<6]K';3AF$,<:+,\N]Y2%&2W YSW[]>.E7** "BBB@ HHHH
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M_P!H6_8"7S+;RXT\OHI$F'W>W6@#T>/7](EF:)-1MC(I<$&0#&P*7_(.I/\
MO"K<-Y;7$]Q!#.CRV[!9D5LF,E0P!],@@_C7E^I^ O$%_9ZM:AT\N\2^(7[0
M5#O(EN(BV/\ :B?KZ^]2ZKX2\47;2&V>>"Q>>-A9I?$NB"U2/AR>2L@8\GD_
M-R: /4:KP7UI=3W$%O=0S2VS!)TCD#-$Q&0& Z''K7+>'=&UO3/$FHW-VTD]
MI+;H%>XN-\C2@*,+C "X!/(!!/!P37+P^!O&%C!>3PW=HUSJMJ6OE@9H&$WG
M^;M\S<=V5DFCW +@;>* /5Q)&96B#J9% +*#R <X)'X'\J=7!:5X?U/1_$UW
MK-MHP/VG3X(4ADU-F\IDD?<I+9S\C*1P0-I ZY/>T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !14,5U!/:+=Q2J]NZ>8LB\AEQ
MG(]L4^*6.>%)HG5XY%#(RG(8'D$4 /HHK-B\0Z+<2F*#5[&60,%*1W",P)8*
M. >[,!]2* -*BBJSZC8Q7R6,EY;I>2+N2W:51(PYY"YR1P?R- %FBBB@ HID
M4T4Z%X9$D4,R%D8$;E)!''<$$'W%/H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW\4L^G7
M4,#;)GB=8V]&((!_.K%% '#6%MJ[7^@WD-O);:9!;1&7]ZP^3R'!1D+XR'*\
M!.V=V1BNB\+02VWA32H9T:.1+6,&-A@IP,*?H./PK7HH *Y6_P! NKS^UDV$
M)=:M:7*E)=C&*,6X<Y!!!_=O[\5U5% '#1:)XA34[,27-X;.)\1F.XW&-5N9
M&^?=(-P:(Q+R'. 1@'KJW/AV6_\ %<U]<3.ED([1DC3;^\EBDE<9)&X %E/&
M,].F17244 <$GA[7X8-%C-U?MLM4^U,ET7=+G*EW):0!E.,8^8#G"\FI'\-Z
MUF2=+J]\\K-(H_M"3;YGVC=%\N[&!&2,8QV(KN:* .)FTKQ*+@FVEF$SB\59
M99\Q0AY)FB8 -DL T8P588 'RE:CM](UV&"S=1J+2I=AV@GN1Y:KA Q8B8L1
MPQ'+<YRG-=U10!7L49+;:Z2H?,<XEE\QL%R0<Y/!Z@=A@=JL444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !117.C_ (1_[9>_VC_9GVCSSG[1Y>_&!C[W- '145RE\TR>$K?^S)5B8ZE
ML3J"4"&[4=%(RNT] 1D52D\7ZC!-IUNZP-<27?V>9!!M$B_:C 70F3(X&[ #
MXXR0"#0!W%%<)+XOUA+5W:U@B\BY2QN9GCPB3#S"[_,ZC80L6W+?\M.IQ@[4
MVIZJ^EZ$T/V..[U"58YGV&:)!Y+N2NUAD908Y[]Z .AHKA[;Q=JEQ)IP9;.*
M6>.S)M&B8R3^;CS'C.[A4R2>#]TY(R#5S3];OX?!#:C<W-O=7D$A6=A$5$8$
M@#A@&."JY/;Z4 =917#WGBW57@N+C319O!!#?7 9H7<3+ T815(88W!S\W/0
M$"J^I^)=3CUJ=X3%*]B+PKIT2-YAV1YC+G=R'Z@;1UXS@T >@45Q^F>(-7U"
MXLHUETXPRRREYXT\P-&BQG "2,%8EF'WFX ..U9FE^-M4OM.ANKBXTRTCGFB
M0S21\6JM"[DN!*>"RA%)*_3H* /0Z*XNT\2ZW<26DLD%M% 5LQ-$8'WL9V92
M5);Y0,!L$$X.#5SPCXAO]<CN);V.WC"1QN8HR/,A<[MT;J'8Y& ,D*2<_**
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MA:5DP[>9PV -P(7'.,@@T =Q17*>)[S4(+ZX^P&3SX=(N9K=$&XM)N0;@O\
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M[H4CH=I'7J6Z=X@U;4-1AM89[">#[3(IO(H&V31I'$_R#?P=SLF<D97IG(H
M["BN$TOQ5KFJ6D+*MA%+/-!&04WM;EPY='19"<KM49.TDYRHQ3[3Q!K-S#;?
M;4MR9?L,P^SQR1;/,G*.#\YSPH/IR0010!W%%>?2>-=5&GQLOV#SC/)%)<X7
M[,K*BLJ!S* <[CSD'Y2-F:Z+2-:N;S7[[3[DV_[I%=%@P^P8&0[;N&R3P57(
MY!/- &_17$1^++R2PM9I+_3+=IY_+N&DA;;I_P CMLE_>#+94+D[>3TY HA\
M1^(KQK,I'9VHE%JLB2VTC,K2HQ8_?& "!P1GG!(H [>BN#C\8ZF]Y8P,UBDL
MD-F[6WE/YD[2S/'(4^;Y0JIOZ-@=3CFIM&UW4XIM)TIXQ(UZOF1S2*Q(1&?S
MMQSU \H#WD'!Q0!VU%<3KOB_5='UBXLX]/2>*++A@C9*.@6$=>K3[E/L,\4U
M]4U1-96![R&"!I;J)PR,?-=8XRH0L_RGE\ <<'@T =Q17*^%M2U'^RVAU)TE
M:WT^VN%ECA8,0Z-E2"Q+,"G48SGH*YVX\2:EK&D2RK(5\J2X1)+8;-Z_87<9
M"NXR&/\ >X('0B@#TRBN7\0:[=Z1#9K#-:VXDM993-=1LZO(@3;$ &7YGW,1
MR3\AP#V;HIU.>Y\2W4TFR<R(EO&R,1#_ *-$^W&[! 9ST R=W/.  =517GNF
M:UK+/:7XO;>[C>QTQ;@>4V':6XEC<KA\(P!^;@Y*C@=*V_#&OZAK-[=I=QVT
M:1Y_=*0)86#D;7 =CT'4A>0>,'@ Z>BBB@ HHHH **** "BBB@!&8*I9B  ,
MDGM6>?$&BBT^UG5[ 6V_R_.-RFS=C.W.<9QSBKL\;2V\D:2-$SH5$B@$J2.H
MSZ5QR>$=4LYK26WU.*:Y^W&YEGGA=U4?9C#]UI"S9P/XN_H,4 =3_:^FF[CM
M!J%H;F092$3+O88W<+G)XY^E4[3Q-IMSIL>H2SI9V[PPS![F5$P)%W*#\W!Q
MZ_AFL73O!UQ9WJ0_:E&FVS6IC!BS+*88@BG=GY1D<C!SVQFI[;P;)8QV#6FI
M*+BR6 1O+;[T/EP/"<J&!Y#D\$8..M &M?>(M+LK:]E-Y!-)9P-<2P0RJT@0
M#.=N?<=?44Y?$&FRS6ZP744\4ZRL)XI%:-?+QNRP/'6L6^\&7&HW5]+<ZP[K
M<6D]JBF)CY0E"9P"^W V< *,YY)ZTMQX+-]'>F\U'=->B?SG@A\M09(HXAM!
M8D86)3U.23TH Z.'4;&YLVO(+RWEM5!+3)*K( .N6!QQ4 UW2"MNPU6Q(N25
M@(N$_>D'!"\_-SQQWJ@OAK=X?O\ 39;A/-O"6DGC1^6VJ 2'=R<!5'WN0,<5
M#>^&+S4)9)+C4H-US EO=[+0@.B2,Z^7ESL/SD$G=V/&* -<:WI1>X0:G9%[
M8$SJ)US$ <$MS\N#QS4*^)-%:ZEMAJEIYD4"7+YF4 1L2%;.<8X_4>HK.?PB
MC+Q<1L=MX,2PDJ3<7"39.U@?EV8!!![\8IK>$YY8I(Y]4,XFLX+6=I82S.8I
M&<,"6[[V!!R>G/7(!NPZE87"(T%[;2J[!4*2J0Q*[@!@\DKS].:J#Q+HC7-M
M;QZK9R27,C10B.96W.H!*Y!Z\CCW'K5*\\,27>L/=?;PEK).+F2 0_.7$)AX
M?=P-I!QMSD=>U.M/#][;QZ2)-0@D;36VH5M2H>+R]FTC?PW?=T_V: -"#6].
MG^QH;RWCN+N)98;=YD\QE89& "<]#R,C@\U+9ZGI^HF06-];71CQO$$JOMST
MS@\9P:Y^S\&-9QVENNHAK6(6AE4P?.[VX785;=\H)1<C![\\U:T_PI!91Q1O
M<RNL=E#:_NF:$GRV9MVY&!YWGB@#1FUK1T2X$VIV(2%O+G#SIA&.1M;)X/!X
M/H:SK&[\/:,UXJ2064<+1PM-/, KCR]Z*K,WW0K' Z#G J.[\)^=:PI#>F*:
M*_GO5?:X!,IDRIV.K<"3&0PZ#MQ4%UX+DDL);2TU,VD4NQ62.-PNQ8!$%X<-
MC@$9)'8@T ;0\0:09;V(ZE;*]BRI<[Y OEE@",Y]=P_'CK3+WQ'I5BMINO8)
M'NWB2"..52THD=4#*,\KELDCL#67<>$))HYD34=@::"X0^6P*R1HL?)5U)4J
MHX&"#SGM3?\ A#766$PWL44.;5IHQ;LVYH)C*-K,Y*@ECG.[Z]<@'12ZC907
MD5G+>6\=U*,QPO*H=^O1<Y/0_D:KMK^C)#),VK6"Q1R>4[FX3"OS\I.>#P>/
M:J6J>'Y]3UJUO3J3QV\#Q/\ 9MK$%D8MD8<#G(!RIQM&,56M_"]]:66F0PZI
M;[],'E6SO9DCRMA3#CS!N;&/F! Z\<T ;3:OIB2SQ-J-HLENN^9#,H,2\<L,
M\#D=?6JPU31K&&=[>ZM69XWO3''.FZ1<$EQD@8.#SD#CK66O@U4GOF^TPRI<
M&9HUGCE8Q&5P[=)0,9'&T*>%YXY2?P?<W$#Q2ZPQ\VP>SFD$3;YMR,H+Y<A@
MN[(R-W'WN3D TT\3:8\]_;_:(UN;+?YENTJ"1@JABP!;[N&')P*;+XHTZW%X
M]RS0169<32.5P L:2$@9R>) . >?PSG7?@V2\N+LOJ*BVGDFF5%M_G222 P9
M+;N5"DG& <XYXJ6X\'QW#7FZ]8+<K,I C^Z)((X?7MY>?Q]J -N#4["Y17@O
M;:578(I253EBNX#KU(.<>E07_B#2-,6<WFHVT1M]OG*9!NCW$ 9'49W#\ZS8
MO#]S_P )7:ZE<2H\<-H!)L78LEP-RJX7)(PCN#DG[R^E+?>&)KR[U&5+]8([
MQ /*2)BOF H5D<%\,1LQ\H4D'!)P" #074-$74+B5;ZR^UBW5ICYZ[A"N6!/
M/"C>3GI\WO1+XAT:'3VOSJED;8,4$@N$VLX&=H.<%N.E8VH^#KG5;J]FNM89
MEN+6:W5!$V(_-B"' +[< @D# /."3UJ>]\*O/?7%Y;7R0RS3.Y$EOYBA6@2%
MEQN'/[L$'W(P: -.UU_2[J.(B]MXY9+<7)@DE42(A4-EESP ",GI4-WXHT:U
MAMY!J%M,;F5(H4AF1FD+2"/*C/(!/..F#61)X)FEDA$FL2/!# 88XS&WRYMS
M"<#?MQR7^[G)(SCI:O?"CW%U$\-\D4/EVD<L9M]Q86\ID3:=PVY)(/![8Q0!
MN0ZA97"S-#>6\BP,5F*2 B,CJ&P>,>]1W&KZ9:QF2XU&TAC&/FDF51R"1R3W
M )'L#5+3]!>TMM1MY;O?!>%ML42,B0A@<[0S-@G.3C ] .<TM/\ "<UO=VMS
M=ZBEQ);RQR );^6I"021 8+'G]YNSZC\@#3O?$6EV4EI$UY#)-=O$L,4<JEW
M$C!5<#/*\YR.P-2-KND+%/*VJV(CMVV3.;A,1MR,,<\'@]?2L*V\%R6@LHHM
M27[/ +3S%:WRSM;_ '2&W?*".V#]>M+IW@E+""&%KL2K;R6YB=D<OLA8LJL6
MD8=^JA1G)QZ '1S:C96[PI->6\;3_P"I5Y5!DZ?=R>>HZ>M4[7Q+HEY;6UQ!
MJMF8[IML&9E4R-D# !.2<D<>X]:-2TB6^U.PO(;I;=K5LLRHV]UR"4R& VMM
MP0RMZC! -8\W@Z[FL;*R.LE;:U/^K6%E#J)%=<XD +#;C)!'/ % &Q%XET26
MUDN1JMFL,<[6[N\RJ!(I(*\GK\I^HYZ4_4;NPBO+&.\49S)/%*Q 2(HARQ)/
M'RL:Q[OP?)< !=050EU<3Q@Q.!MF)9T;9(I;D\$$<<$'K6CJ.@M=PVRVUXUF
M]M;RPQ/&F=N] H8<]L9_K0!<36=+E@\^/4K-H=K/YBSJ5VJ0&.<] 2 ?0FK4
M<T4N_P N1'V,4;:P.UAU!]#7(3> (KNS2WN[]I-US)+.0C?O8WVEHLL[-C='
M&<DG[N*W=$TFXTBR@MGO1<A1(T\C1;6FF=]Q?.>!DM\O/4<\4 1W/B?3[:XU
M6W/FM+IEL;B957[RA=Q"D\$@%<^F]?6F3>+M%@>1&OHB8;E+6X^=1Y+LF\;L
MG@8[^N1U!K.N/ T<XGE&I7"W5R+I)Y&RRLDZD%0F["X(C(Q_SS [YJ__ ,(V
MQU"6X:[4PO?17HC\GD.D*Q$;MW((13TX.>O8 N/J&C->6,CWMD;F9#]D)F7=
M(KX^YS\P.%Z=<"K#ZGI\<1E>^MEC"ER[2J %!VDYST!X^M<]'X,:+9&FH+]G
M9;=9U:#+-Y,K2IL;=\G+8/!]L'FJ6I>#M06RD^RWHG9&401I%Y;HGVI)R=Q?
M#,-N!]WMTZT ;O\ PDFAW=VNGF_M9%N85:)_/0I.&9DVH<_,<J1@>M6KF;2+
M1[6WN9[6%X%,MO')(%*A5(+ $] N[GZUA6'A2:33U^V,EO.T<4>Q%+;1'<-*
M"26/S,"-W)YSR:V+S1Y+G7;748[H0+$FR541M\RX;Y6;=M*Y;."I(.<$9H ?
M:>(M&OH;.6WU.T87J![<&50T@/HI.<\'CL0:;;>)=$NK.*[BU6S\B60Q([3*
MH9P<%1D]?;W%9">#[SR=(@EUDM!IR6R^6L+*K^2^X' DQD@*#N#?=R-M-G\$
MM/' CWZ,D(N8MC12!7AF=7*,$D7)!7&<X(/W: .@NM6M;*_CM;EQ%OMY;@RN
MP5%5&13DD\<R#\C3H]6TV6)98]0M7C8*0ZS*00S;%YSW;Y1ZGCK5/6-$EU*Y
M2XM[][2:.VDMU95)^^\3$Y!!_P"66."#\W!!%8<WP^2XL;6WEU)]T1NC(RQG
M]Z99&E0_,Q.8W(8$DG(]Z .KEU"R@M'NYKRWCMHV*/,\H"*P;:03G (;C'KQ
M5*S\2:3=V]M-]M@A^U.Z6Z2RJK2E7*?*,_,"1QCU%0/X>8:%86$%V%N+.2.9
M9Y(MRR2*<LS(",[B6/!&"<]JSD\$R)"81J2F.>,176;;EU$SRC9\WR',C#/S
M=NF* .A;6=+5KA6U*S!MO]>#.O[KG'S<_+SQS3KC5-/M+2.[N;^UAMI,;)I)
ME5'R,C!)P> 3]*YZ/P6(DNT%U#*)6=H6GCE9HM\PE/(E ^\!@J$(*J<DCG7_
M +&=X=%6XO'GETV02-*ZY,[>2\9)YX/S[N_3\: ++:OIJ7$-NVH6BS3('BC,
MR[I%.3E1G)'!Y'H:CM-=TN^TK^U+>_MVL>\YD 5><<D]/QK$L_!C6<=I;KJ
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M=IOE59!MPSMC=O[>G-M/#5W%8K:)J,/EP78N;4M:DE?WC.0_S_/][&1M]>:
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M-B+#[>;RW%GC=]H\U?+QTSNSBN<G\$I+91P+?,C1QJJNJ$?,LXF!.U@<9&"
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M_;([/^T+3[5(,I#YR[VXSPN<GCGZ5&=>T<6\DYU:Q$,;^6\AN$VJV,[2<\'
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M6I9-2L8KZ.QDO;=+N092!I5$C#GD+G)Z'\C65IOAH6-_;WLL\<D\8FWE4?\
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MM;5=7OK7Q!+9V8B#.EFBM,&=5\QYPQVAAR @Z8SW/3&I;7FDRWZS1SVZW]U
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M6'PVTO4/[3C2[FDM)+BZN$9U"22H'R&?@88YY  S@+QB/_A(M6TI=2F*QWL
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M.0:DAUG2KF5(H-2LI9'8JB).K%F R0 #R0.: ,[1=;N]2U>^L)H(XSIY*7#
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MSQU-IK.F7L-S+;7T$D=M(T<[!QB-E."&].E,NIM.DOH$G,;26N^X5BX A*J
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M/9>IZ4 <GXG\07D$NL:;#/#&Z6+2V_DG,@8!<EB'RG7@;<$$8;/%0ZMXSO\
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MI=S.I:^C,<D\7F9^X$!_>._(P.^. ,4MUX>OM7^RKJ^IQO';L[[;. P[V*;
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M%C/"[=PZY.*[*B@#CCX':2=)YKZ.1W:4W,>R1(W\R7S#M5)!C!X^8MGK5O\
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M02^?E#8^8DL!R<Y-6[WPW-<ZR+N&\BAMFDMI)(3 2Q,+$@*VX  Y]#TKH:*
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MA)("MN&T$'T..?6I+#PV8/#]]H]W="6VN5:-$C1E6",H%V)N9C@8)'/&<#
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M. >U=A10!BZ9H][IEU<NE[#]GGG\S[.(6VH"7+;<N<%BP)Q\ORG"C)-;5%%
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M^E"S1.BNLJ,C'"L&!!/M7':EI&K7%Y?Q#49)V,5L^PPQCSD61BR<C'KP>#N
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M@)YP>*T;?PY9V]T)07,2",10[VV+L&%R,X8]^:F70[-+9+=3.(XF5HL3-F+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%FMM;22?V'%N,2S1 7*_=+$'.<9/&0!]/>FU173\&3&>8RU51:.WQ+_,?;>
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M#.YSNQ@@[N""/UJ--=UV>POKA-%11&TJ1,+A3@HS*2P^J]JIQ^+=77[,KZ5
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M:%\^7OR,=5QZ>A]*'\3ZM-J,,=KIL/DB[-N^;E&W_N@^ <XSR?RQZT/V/;\
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MCH&#/F0EPP9^>HQCWR35^^\'6$\]L\-O&T<096BFED*\XPP^;J,$?1C0G/\
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MFQ(8U7&-H4 8I#;P,'#0QD2'+@J/F/OZU+118.9]RNEE;1W37*PJ)6 7=CH
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M*C''3BG;$)R57.<]*=10%V-CCCB39&BHOHHP*=110)NX4444 %%%% !1110
M44C.J#+L%&0,DXY/ I: "BBB@ HHHH **0.K,RA@2O! /2EH **1W6-"[L%5
M1DDG  I: "BBB@ HHHSSCO0 444C.J#+,%!(&2<<DX _.@!:*** "BD9U4J&
M8 L<#)ZGTI: "BBC..M !1110 44C,J+N=@H]2<4M !110#GI0 4444 %%%
M.1D=* "BBB@ HHHH **1G5%+.P51U).!2T %%%&: "BB@'(R* "BD)"@DD #
MDDT AE#*001D$=Z %HHHH **** "BD9E12S,%4#)). !2YR,B@ HIGFQE]@D
M7?G&W/.<9Q^1!_&GT %%%&<4 %%(&4N4##< "1GD ]/Y'\J6@ HHHH ****
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M3Z4M !1110 4444 %%'6B@ HIDLL<$32S2)'&O5G; 'XFG,ZHC.[!549+$X
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M ##%#%O7'0A6Z^P."<5V]% '$61\11WEI$RW<90PJ(UB06X@^SC?D@</YNX
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M-(TI[R*V\\JZ*020J*6 +L55B%4')P#T_&J0\4VT903;)3)' 8Q9%IP[2AR
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MI)^Y+.OD-M+ #MP3^&.M '5T5A3>,-%@O)K5KDEXD9F*H2,K'YI4>IV?-_\
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MRN$$+*9 9/+)7/4!NOX>M:=MKEE=7@M(V<7):1#$R$,I0*6SZ##I_P!]#UH
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M8A7,3[XRP[X8GZ]^@QR.J:SK-@+&"75+B*)Q--),T?ER1QJ\0!*LFY\ R #
MSD>@-;4(UFWU"V013^1)=7GF01Q!%VM-(5D+!<'Y=O!P3G.2<T ;EWH-AJ5Z
MM\[2G>L6]8Y,),(V+Q[AW ))XZYP<CBFKX:T\>8I,S*YN#M,G"^><R >Q.3[
M9-<OI\?B)/['TU(;VWMTLDMYSQM ^RGD';A2)0J_>)R#Q@BG6D>MV]A;,J7Z
MH+*RBN9C"#<C#S>:!E<L1E?7@DCDY(!T?_"+:<'NBOG+'=1F.:(/\K9C$9;I
MD': .#COC/-7=0TJ#4M,;3Y7D6!EV,$(RRXQ@Y!!&*Y:(>*75)6GO5\H1-&A
M2,&53=./W@V_>\C9N Q@D]^F[KJ3:CH3+;V\WF?:X?D9<-A+A<M],*2/:@!L
MWA33IA(-UPBO+'-M63(5T01AAG/.P <YZ ]>:8?">DK EKF58OLL-HL?F]5A
M;=$W^\IR<_GFH=&36TUD/>S7,EM-]M+I(JA8MMPH@"X /,98\DYQ6.-(U66:
M.,7&IQR0ZC>R^=A3M1ED,>TE2"IW+^/''2@#JI]#MKK1AID[RO$&5]Y(W;E<
M.#TQPP'&,=L57@\*Z7;VY@1)=A5%.9"3A93*/_'F-9.ES>)9O$%N=0DEA@VQ
ML8A!F-U, W@L!A6$I;J<X  &#3KE/$ESXCO[>.]FM+<[EMF$&^/88/E;=C 8
M2DGDYXQC!S0!LV/AZRT[4#>P-.7"RJB/*2D:R.'<*.V64'].F ()_"6F3[@?
M/59/-$RI*0)EDD,C(_JNYF_ D=":YZYN?%]U:VMSBXT_[5YS-$L/FM;.!&L2
MD*"2IQ(Y[?, 2.*GU*T\1W,>II'<7A6X2]ACC4(JH-O[DJ<9!)R,D]_I@ VY
MO"MA-'/$9;H12S_:1&)<I'(7\PLH(QRQ)YR.3C%6=*T33],3_0@VW[/':Y,A
M;Y(R^!GU!=LFLS4H+J;2M#E@DU("&ZC>?:N)2FU@=RXSU(R,>]95O;Z]I-K/
MY2WTT4WVN0PKM'E,;L;"A"D\QN[8PQ(''.* -BU\%:590)';/=1/&R-%*LN'
MC*(R+CC'W'9>0<YR>>:LR>%["5;J-WNC#<LLC1><=HD!4B0?[644Y]0?4YQ]
M"CUEM7TRZU-K\9MKJ)E*_)D3'RRX X)CP<G&<>O%)<R:M:Q:_!86UTEU+?I/
M'*(25,)$*N5.""VT/@=>.!F@#;;PY:2-9&6:YD^R,7CRX'SG/S< 8/S'I@5!
M_P (?I1@EB<3N9DF21_,VLWFE"Y^7&#^Z3D8Z'N2:RX9=?CFT\-<WEPKQ2AR
M+4IY?,A1VROS$#8NT[2>#W(JGY_BJ2'3T62[@0"16G,!D,D@==K,FT,JD;N"
M !SD_=- '0OX5TKR)A<--(9TE2::67YG\T(K9/KA$ ],"K::%9Q7L5Y$94FC
MDEDRK\-YA!<$>A*J?PK$TRWU;4-8OH=9>4VGF2D6[1$(0LP,#*X 'W!R 23G
MG&*N:3)JSQZQ%.;AW5V-M/*GEAB=V%"D#&WY1G)!X(/44 6=$\/Q:-X?&E1R
ML =Y:2/@@L2?ESGA1A1G/"@5"/!^E"T^R@3B)H);>15DQYBR,6;/_ F)&, 9
MQTXK#FO_ !)-I[3I#J*/&+?$!@VM.XC?S%!P=F7V_,1C('\)S6GH[ZZ_B:\^
MWRRK;*TP6$PGRRFX>45?&,[>HR3DG(X% %VV\,:=9>2\;3 Q/*Y8O]_S,;PW
M&,':#@8QCC%0VGA32TM%^SW%TZGR6CF^T;RHBSY>T], $CW[\\U@:O!XBU&R
MUNS_ -/+2VU_&T?EJ(MN2+<1''+,N,\GJV<'%;^JV,\5UX=^SR7GD6UUMF\@
M#E3$X!< =-VT'L,D\=0 3P>';*.&Y%K/.D-T6;$;J57<V]MN0>"<\'(P<#BE
MN?"^FW6DV.F,LJ6UB ( K\J A3&3U^5B/7G(P:Y6TM?$^E:!#;6[W946MH75
MD4M"?,82J@"YX3;QR<#(YZZVIZ=J.J>#K*UFV7=RUW TAN+8[2@F!R\9QD!1
MSTSCM0!J'PQIIT^:S"2".5XI"0_S*\2HJ$'V$:^QQSUJQ/HUO<:7'8R23%8W
M61)0P$BNK;@P(&,Y]L=L8KG#I6O:3:7EMIMW-(+33<VB*B+&]PSS$@ YP%&P
M*N< ;0<U7F7Q1)ICFVOKXLEM=RQ$6X1S(JQ^2C!UR?F\SL,CCGN ;\'A33K6
M:WE@>X22(MEO-W&4&1I"&+9S\S,<]>3S5:V\%6*P3I>2SW+R/,4)D($(DF\[
MY!V.Y4/U0=!Q5*>VUV.XGC\^Y=899Q;WDENDDB*ULA#  #.)2XP,9QCI4,4_
MB>:\TT,;JTMRJ<F(R[V$S!]_R@J#&$(W;<;CGYA0!T+^&[&:W,,[32[K>2V9
MV8 E'8,W0 9R!T%0R^$-*GFN&E%P\<ZS*83,=B^<<R%1V)(SGL>F*K:?-K1T
M76ED^TR74?F?99I$V&1MI*[4(&,' [@]0:J/'XB@UK3X!>W1M1% S2M"'\QS
M(QF5]JX7Y=H&< 9XR10!M?\ "-V3P>7,\\W[F: N[ $I*%##@ ?PCM5NSTRW
ML;NZG@:0&Y*M(A;*[E14# =CM51^%<5::EXA2>2*5]1>ZCBM9[F%X4P#]I G
M$0 RR^6& ZY&,<YJT1XBNE\]8[FWFE=D$ODIYL<1OA@<@](.<'/3/6@#0?P3
M9I;)%:75U"5>V <REBD<#,R(GIC<1W]\U:'A#2U\L+]H"A0LR^<<7 $C2#S/
M7YW=NV=Q!X.*R9!XD75]0B^W74,,<;K;L+7S@R>2-KC P7$F3@G)P1C!&+X?
M6+GPG;!!=6U\]U$CMPT@B\\!G^91C,>3RN0#SR* -6UT:SL[F*XA5Q)&)PN6
MS_KI!(__ (\H^E49O"^G^3.)+BY6(SM=J#*-L,A8NSKD<<LW7(P2*Q OBJUM
MG_TB^GWAPY:.,NB)=*H* *,N8"[<YR0..U4M9C\17NAW5H1JDEO/;W:6P2)/
M-E)($8F!'R@J7QT..OS8H ZR?0[#[3:S37<RRPHT-N3*%(8J02./O8SQT[XX
MIEKX2TVREMY;8S1O$,$JP_>CS&DPPQC[SL>,8W$=.*Y_4-&U*YOY[C[/)^[B
MU+RD$2;'9O+\O((Y+?-UZXJVT^M0C4M\>I-,@5;>*%%6$1$1C<K;"=P)<D#)
MX( ^[0!T&F:+:Z0TOV5I!&Y)$;,"L>220.,XR>Y..@XI+30[:RBO5AEG\R\?
M?+,7&\G:%!'&,@ <XY[YKCI+?Q#<6)FN5OI+B32]0@2)HPR.X=O)\Q2N,LF.
MH&<<]2#>O9?$HO+T6OVT2J;C:GE+Y A\AO**''+^9LXSGELC&* +\7@FQCO%
M833BT6%$^SJY D997E)?'!!9\X &,$=#BK8\*Z>L$\"M<+%+()519,>4XD\P
M,AQD8< \DCMTXK&N?^$BLXW59[^Z\N[C9%\M=TZF)=R;U7" .2<D8XP2!TN^
M)9-;6]VZ<;M1]FS:_9XU9&N-W24D'"8QZ#!;G.* -1= LQ.D[M-),K1OYDDA
M)9HPVTG_ +[:F6WAZQL+J.ZMY+B$HFQPLI"R*&9AN'?!=SVZ\YJ*P75(=.U2
MYN7N9[EIK@V]N=B[45W$83C'*[>6SVKF#)XFN-+FCN!J:P//*J&&(&8@P(4!
MW(#L\PR D@=!G H ZJ;0-/FU5-2,TZRO()55)R$:3RC&'QW.PX_ 'M4">$=,
MB:.6-YUF5W8S!QN?>5+ C&.=B] #QQU.>=BL]:?4=*AGAOMEI(A2,1KY"Q?8
MF4DG&=_FLRXSZ<8YJ6QL-6B 66*Z9W_LQQ$T2F% K1B7:,84KAC@<CJ.U '4
MZKH%EK$@>Y,RDQ-!((I"HEB;&Y&]0<?7K@\FK,>F6L45Y&J$I=NSS GJ2H4_
M3@"N/@?Q3-#L\W4(YG\A;IGB0"*0W"!_)RN"@B\SGD8"]\U=M'UZ'4=.CG>\
MGB$]Q%(I0+F,2N(Y&<+@_($X.TG.1D\4 :T7AJPCC5&,\A5;9=SR9)$$ADCS
M]&)^HJ?2M$M='$BVC2B)ONQ,P*QC).%XSCGN36!J46KVVL:M+:OJ!CF^RLOE
M*'58@P$OEY!&\+GCKSD G%/NH=7N_!4@D>^%RMT'C*@+.T"S@KD ?>\L=,9/
M<9R* -N/1['^S8M.3)@MYDD4!\D.CB09/^\!4$OAC3YFU $S"*_219XE?"DN
MNUB.,@D>^,\XS6 UIXAL[G4KK2VN6>YGF,<,RKY9_P!%'EN<@$$R*HY/<BIC
M;ZO?> ?$%O/)<W-S/;3QV\<T!CD!,.-O(&[+9YQWP. * -RY\.:?=M.TJ.3-
M*\SX<CYFA\D_^.?KS4-SX3TV[FDEG\YW:-(T)?\ U05E==O'9D4\YZ>A(.=9
M:!J&E7]M#;77EVLTTMS/'9P+# I"QJD84[BJG:Q.#R2QXS5'2E\4W5K;)>WE
MY'))-"MT%@"M$=DAEVL5P5+; -N0,<'F@#HIO#L$AM)/M,WG688V[2$$+(0P
MWD #GYCP" >/05-=:)%>6=C!+=77F63!XKA9,2%@C(6)QR2&;/UKFK&'Q'Y=
MF+YKBZ++8S2>?%&?+DWOYP&%&,*$^G7N:JO/XL;3[>-9KU K3(]Y]G)>1]L?
MEOY6S*KDR97&,J.=I% '50^'+6WDN7@GN8_M&XL%<8#,<LPR.I/)'3D\<U7_
M .$-TAX(()$EDMH89(4B9_EPZLKGCGD.PP#CI@<##]'DU+^W-3BNS/+;@AHI
M63RT7DC8JD<XZ[@3G/.#6+ID'B.&+3F9KB%((K%&M4BC6,[B1/D!>PP>" ,4
M =#:^'K.VN([DO//<I-YWG32;F9O+,8S[!21C\>N:EO-(L;F>6[N 0S" NV_
M  @D,J?DQ)/M61J4FMCQ&$MS=B+S;;R5CC4P-%N_?F1B,A@N<<C^'&>:P=9M
M/$<_A1+6>75)Y;S3+CS5BCC+?:65 D;?+\J8W_KDYQ0!T\G@_2I;N&Y*S!XI
MO/ $G!;SS.,^WF$GC'H<X%'_  AVDK&ZQ+-$7E6?<C])06^?!XW88J>.1@'.
M!6-=/XJ:ZUKRI[B-UCG%K$L&Y",#RF1B-N[U!).2<C &-?6;*Z0Z$8KF_D2V
MO0;AX\%V0Q2*"P Y&XKG X!SVR "]'H5JFH6MZTDTDMK&8XM[#"Y&">G4CMT
M[XS44WAS2KZ*42QF6.9IF<"0X8R+L?I[?E6?X<DUM]1_XF!NRGD-]J6>-51)
M]XVB$@#*[=W/(QM[YK M(_$]EITT%BM^H0'SEFB7Y,W(/[G RW[HR$]3]W^+
MB@#M['2+:PCN%WRSO<MF:2X;<TGRA0#VQ@ 8'\R:RX/ NAVUO)!'#-MDM#:,
M3*22A8L3S_$3C)[X&>E CU.7PW8"5FNKH7T+,TD&UO*%P#DJPX(3O@'C/!I/
M#2:W',IU2:YE66SCD?SE4".;<P91M _AV\<]/K0!>LO#6GV&TQ"4L$G3<SYR
M)F5G]N2@Z=.U13>$]+GFL9668&S2%(P'X(B<.F?HPSQC/?/%8<4^N'3K(W4F
MLK(7_P")B8H$+))L;B(;>8]^.1G^'G&ZEM[?Q5<R69O;R\MV9[>.X6!8]H!M
M\RD':?\ EI@9!X[4 ;S^%]->V\C;*J^4T2E9#E09!)D>X8 TMAHL$&OWFLK*
M)7N8(HEP<\*#EL]"6^0$CLB^E<Q9W_B*74[*VEEOC=QP6#31B)/*^9F^T&0X
MX.T$@9'.,=ZCMK?7--T:"&*SNHW-I:0EX5 ="$EW9PK%@&V#'8L#D#- '32>
M$],E-R)//:.=9AY1E.R/SCF0J.Q8Y/MDXQDUNUQ=J?%3O;W4LEP)=T*O;LB"
M(@VV7)XS_K??C'UJI/-XE;3+ 6]QJD;LDGVJ6:V#.EQM3: JKS'GS.V,@<XH
M [^C/.*YCQ2?$:BV70V/F3QM$[!05B?*N'.>VU9%^KK6/>6^O7]F+N:*\@DD
M2.<K$BB:)/M0?RL@9)6+JO.2#UH [Y65L[6!P<'!Z&EKDM)LM4M->DG$EU]C
MN;V8R12*NP)Y:E7Z9!+#'7N:K26>MGQ?)K7V$?9I'>PXE/F"WV_*QCVXQYJE
M@V[.U^E ';45YKI^E:C;Z+'%H^D2V+R:5%97(9/(#W#%%,F ,Y1?,)?'.1C.
M*W;"#6M,\'7VGPVODW=D[QV@A;S!Y)(9?++ ;BJ-L&1U2@#K:*Y+34URXU6W
M$ESJ":6LLSHTT:K)(@$.Q9,KD#>9L< E0,UUM !1110 4444 -DD2&)Y9&"1
MHI9F8X  ZDU@OXQTT+"8X[R1I)HH]GV617 D!*/M(SM.T\^Q'45N3P1W-O)!
M,@>*5"CJ>X(P16+'X4M$BP;N\><-"4N'=3(@B)V*/EQ@;FZ@D[CDDT 167B[
M3FBNQ=!K5K:2ZR#"^UDAF,993C#'.S(7)R^*MP>)],N9[:"%YWFN6D58Q;OE
M2A4/NX^4#>O)P.13+CPIIES T,JRLC+<C&_IY\HE<_4.H(]/>K%CH=M8SV\Z
MR222P1RQ*S*BY$C(S9"*H_Y9KT% #KK6[&ROX[.Y>2)Y Q5WB81G"ER-^-N=
MJL>O8U"GB73Y%MRJWFZXR8D^QR[V4;<OMVYVC>O/3G'7BH;OPGIE[K)U.X$C
MRMG=&2-IS$T1YQNQL8\9QGG&>:='X;CC-HXU'4#-:AHTF,B[C$VS,9^7&W]V
MG.-W&<Y)H 0^+]%7S_\ 27_<G!_<O\Y\P1_)Q\WSD+QZCL<T^Z\26<,5[Y>\
MRVD FE$L<B*@(# ,VTX."#C!/M4</A2RMH;R&WFEBBN2V5"1-LW-N8#<AR"2
M>&W#' Q4;>#M-=%1WN&C2R^PQJ67Y(\*#\V-Q^Z.I(SSB@"/_A,;5(M2$R&*
M>S-R5\Q)%BD$.2?G"D9QR0 3UP#@TEWXNCL5U&2>WRED+ARL99G=8EC8X&W'
M_+3G)&..O.)IO"&GW#W?G373QW*S@Q&0;4,PQ(R\9!(..20.>.34]QX8TZY:
MZ,HE/VE)TD&_&1,J*^/P1<?C0!/%KUA+.EN))$G>58A$\3*VYHS(."/[H)ST
MX(ZBJ^H^*+'3XM0;9<3M8%%G6*%FPS;2!G&"<.I^A]C1%X?5/$D.KR3M+)%9
M"U!?&YSN)WM@!<@$@8 ^\U%[X8LK^\N[J>6<R7$!M_E*KY:DJ>"%R3E01N+8
MYQ@$Y %OO$UC8&594NA*EN]PJ&W<>8%7<0I(P3@]/KZ'#XO$6GR1([/+$S+;
ML4DB8,OGN8X\C'=@1[=>E5CX0TZ35)=0F>>6>9&63<5&[=&(V.0H/*@<9P#T
M S2MX4M'FMY9+N]=H5@5@74"7R9#)%OPO9B>F,YYS@8 (X_&ND_V<MY<?:;=
M&>90DEN^[;$V'? 'W1QS[XZ\5K6>J6M_<7,-LSN;9_+D;RV"[NX#$8)'M67+
MX0L)1'^^N T4LSQ,1&VQ96#.@#*1M+ 'D$CL:G;P^HU*;4(+R:*XF>+S&VK_
M *M'W;!@#(/3+;B 2!B@"V=25=9DT]DVA+87!E+<8+%<8_#.:H1>,-&GB1XI
MYG+NB(@MY-[[U9E(7&2"$8Y_V3WXJW=:-%=:FE_]HN(W\KR9(T*[)4R3M8%2
M>YZ$=:SAX,T\:+)I GN/LC[5*[8L[ " N=G/7[Q^;(!W9H NR>)-,B2Z=I9-
MMM,('(A<AI"<;%X^8Y].GTJ)?%NC/);(MTQ-QLV_NG^7<YC4-Q\I+@K@XY!J
M.[\(Z?>W%U/</,\MP8R'^3]WL8LN/E^;!)^_NXXZ<4]?"UBE];7JO()X8TC+
M;(_WBJQ9<C9\N"S?<V]?I0!>N]6M+&]M[6X,JO<,$C?RF*;CD %@, G'KZ>H
MK.3QEH\D9='N6!,83;:2DR>8&*%!M^8$*>14U_X9L=0UF'5)6E%Q#Y>T#;MR
MC%EZC(Y8YP1GOT%97AKP8VC01PW,\;QPO%)&L*!<RHK*9&.,G<&'!SC;U.:
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M9D\M&10H*E2H#R?>!/S'))YH O1>*M(GN;>"*>1S<+&T;B!]F) 2F6Q@$X.
M3G/%-;Q=HZ:=#?F:;[//N,1%NY+JHW%@,9*@=_PZ\5,/#UD&#$R%@8&SD#)A
M^YP!CZX_2J)\%::1N,LYN//:<SE8RQ9E56&TILY"K_#G(SG/- '11R)+&LD;
M!D<!E8="#T-.J&"W\@R8DD<.P(5B,)A0,+Z#C/U)J:@ HHHH **** "BBB@
MHHHH 3:N[=@;L8SCG%+110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.PB 4O\ ,R@A3M!(!.2.@JT-=TUGG1+C>\%JEY(J1LQ$3;MK  <YV-P.>.E
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M<3--!!YFXVX)_P!='M 7Y^F2:T_!^K:QKESK9N[N94BNKJVMSY<&Q0DSHI4
M[R0%&=X /O6):>)O$MG-9/+<S:OYVNW6G&UB@AC=XX5FP025&244G)'0XZT
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MBUW7?$FD7GBAXM7:>/3$M)((#;1#=YSD%<X[ 8'/?FJM]XU\2S>(9+"*&ZL
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M&[QQ)-@@DJ 244G)'3CK5*V\:>+-2M<6KQK<&V\YHBL2R@"\FC8(6.PN(XP
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M$8&]X9UD)&U>0P,H^;GD9-37/B[6F\"Q7L$Z/>?VR-.%U;1IBXC$YC\Q YV
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M*Q!^4#![#\*++QE?ZMX[OM'COOL]A<M-;6$JVV3'+!MWG<PVON/G8'./+]Z
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MZ1VRK;B#MP /D!- %R_\":CXBU,ZCKSZ>6<V\,EM;[S&8(S(6R6 )9C(>P
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M64?(Z'/4\KDD5QR^-/$H%GILUW/_ &PU\L5XD$5L5"-!+(IA=F"%#L!^8A@
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MQ@>6IQD+Z X' ]!36T^R>.6-[2W9)9!+(IC!#N,88C')^4<]>!Z59HH SO[
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M!_JII859X^_RL1D?A5B&WAM]_DPQQ[W,C[% W,>I..I/K4E% %=;"S5E9;2
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M1%DNYAB1"77S5]1NC8$=N/6KNN^.M/T.VT:\:&6>RU.0#SU!7R8\9\QE89P
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MF21AF%D=5*'_ +[# ^A'K6=)\3%@TZ/4Y]%N(]/N[6XN;";SE+3B*-I,,O\
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MESELD2C!7[@&!C.:Z*31[^\^%>O036NH&13=S:1!*SFYC3#>2.N[/)PIR<$
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M:596JE#&1# J94G)7@="><5';>&]"LKK[3:Z-I\%P8A#YL5LBML "A<@9Q@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!LC%(V949RH)"KC+>PSQ6)X<\1G7GU*&73YK&YT^X%O-'(Z
MN-Q4,,,I(/##([&MJ:,RP21K(\9=2H=,;ER.HSQFN>\/^$?^$=@@MX-;U*>"
M*5I2DPA_>%@P.\K&"V2V[).<@<T =)7'7OQ!L['Q5/H<EC.S0RK"94D0DL8?
M.!V9W;=O!;& :[&N8O/ NF7FLSZL9KF.]FN%G,L94$ 0^24!V_<9>H/?GB@#
M*A^)#W6B6.K6NAR7%O>3Q6Z>5?0L4DE*A%8!OE.7&0>1WK1D\=6L&NW.DS64
MZ36]FUP[[E*>8J+(T((/WPCJWI@T^R\$VUKH=EI,FIWUS;65Q;SV_F"%63R&
M4HN4C7(^49SD^]5[GX<:-<W,EVTUZM[)=2W+W*R_,?,5D9,8V[=C;>F<*.:
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M&5(V+*!L0 G)^\P)QWJ74? UC?ZG<ZFMY>6U_+.DZSQ%"8B(O*( 92"K+U#
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M&.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLO\ P<I_\37=T4#.$'B'XB9&? ED!_V&4_\ B:[NBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#'DU9X-:U:&9HUM;.P@N@7.W!9I]Q+=AB-?IS6=;^,'F\L2
M:<80+S[+/*[2".(E8V4Y,8;YA(,;E49!&>1G<N=&TR]NA=76GVL]QL\OS9(E
M9MG/RY(Z?,W'N?6HD\/Z-&L832K-1%)YJ 0+\K\?,..ORKS_ +(]* ,=M?U0
M^!=4U>2"WAO+<7(B6)C(I\MV4$[@.?EZ?CQG KZSXAU72]#GCBAD?4%L9[MI
M+DQQM"JD*#M7<K')!QGH.3G KIQI=@+6YMA96_V>Z9FGB\L;92WWBPZ$GOGK
M5=_#FB2010R:18O%%N\M&@4A=WWL#'&<#/T% &*WBFZM]3='@CDL8H[Z:=RV
M)%$#H,* ,'A^YY]1CE5\77DULBIHTD=W*S>6LSM&C(L>\L&= 21TQMQGOCFN
MA;2[!Y4E:RMS)&[NC&,95F^\1[GOZU!_PCNB_95M?[)LOLZOY@B\A=H;&,XQ
MUQQ].* &Z!>W5_HEE<7*?/+:0RF7(Q(S("W Z<UC-J^ICPQ>W$U_#%>V]Y-
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M<)_;7Q*_Z%#2?_!I_P#8T?VU\2O^A0TG_P &G_V- '=T5PG]M?$K_H4-)_\
M!I_]C1_;7Q*_Z%#2?_!I_P#8T =W17"?VU\2O^A0TG_P:?\ V-']M?$K_H4-
M)_\ !I_]C0!W=%<)_;7Q*_Z%#2?_  :?_8T?VU\2O^A0TG_P:?\ V- '=T5P
MG]M?$K_H4-)_\&G_ -C1_;7Q*_Z%#2?_  :?_8T =W17"?VU\2O^A0TG_P &
MG_V-']M?$K_H4-)_\&G_ -C0!W=%<)_;7Q*_Z%#2?_!I_P#8T?VU\2O^A0TG
M_P &G_V- '=T5PG]M?$K_H4-)_\ !I_]C1_;7Q*_Z%#2?_!I_P#8T =W17"?
MVU\2O^A0TG_P:?\ V-']M?$K_H4-)_\ !I_]C0!W=%<)_;7Q*_Z%#2?_  :?
M_8T?VU\2O^A0TG_P:?\ V- '=T5PG]M?$K_H4-)_\&G_ -C1_;7Q*_Z%#2?_
M  :?_8T =W17"?VU\2O^A0TG_P &G_V-']M?$K_H4-)_\&G_ -C0!W=%<)_;
M7Q*_Z%#2?_!I_P#8T?VU\2O^A0TG_P &G_V- '=T5PG]M?$K_H4-)_\ !I_]
MC1_;7Q*_Z%#2?_!I_P#8T =W17"?VU\2O^A0TG_P:?\ V-']M?$K_H4-)_\
M!I_]C0!W=%<)_;7Q*_Z%#2?_  :?_8T?VU\2O^A0TG_P:?\ V- '=T5PG]M?
M$K_H4-)_\&G_ -C1_;7Q*_Z%#2?_  :?_8T =W17"?VU\2O^A0TG_P &G_V-
M']M?$K_H4-)_\&G_ -C0!W=%<)_;7Q*_Z%#2?_!I_P#8T?VU\2O^A0TG_P &
MG_V- '=T5PG]M?$K_H4-)_\ !I_]C1_;7Q*_Z%#2?_!I_P#8T =W17"?VU\2
MO^A0TG_P:?\ V-']M?$K_H4-)_\ !I_]C0!W=%<)_;7Q*_Z%#2?_  :?_8T?
MVU\2O^A0TG_P:?\ V- '=T5PG]M?$K_H4-)_\&G_ -C1_;7Q*_Z%#2?_  :?
M_8T =W17"?VU\2O^A0TG_P &G_V-']M?$K_H4-)_\&G_ -C0!W=%<)_;7Q*_
MZ%#2?_!I_P#8T?VU\2O^A0TG_P &G_V- '=T5PG]M?$K_H4-)_\ !I_]C1_;
M7Q*_Z%#2?_!I_P#8T =W17"?VU\2O^A0TG_P:?\ V-']M?$K_H4-)_\ !I_]
MC0!W=%<)_;7Q*_Z%#2?_  :?_8T?VU\2O^A0TG_P:?\ V- '=T5PG]M?$K_H
M4-)_\&G_ -C1_;7Q*_Z%#2?_  :?_8T =W17"?VU\2O^A0TG_P &G_V-']M?
M$K_H4-)_\&G_ -C0!W=%<)_;7Q*_Z%#2?_!I_P#8T?VU\2O^A0TG_P &G_V-
M '=T5PG]M?$K_H4-)_\ !I_]C1_;7Q*_Z%#2?_!I_P#8T =W17"?VU\2O^A0
MTG_P:?\ V-']M?$K_H4-)_\ !I_]C0!W=%<)_;7Q*_Z%#2?_  :?_8T?VU\2
MO^A0TG_P:?\ V- '=T5PG]M?$K_H4-)_\&G_ -C1_;7Q*_Z%#2?_  :?_8T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>bionano-nancyridgeleasee016.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0JEF(
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MOI^8A,Y9Y1&P;: 20%DZ 9)'%1ZC\3;W2+ZZM;S3X=J6L;P3@.BO.R!S&RL
MRY4L0#@_(0>: *VH>&=7NGR?#DMZLVDSV/\ ITEHACE>3<KN(L+@#NBYX]>:
MZ35?"\]U;^$HI(8;V73;J(W<\@4EHU@D4GYN3EBIQ[UDW/Q"U2QMKB^N-.LV
MLFNK^TMS'*WF"2W$K+O!&"K"$\@\9%2VOC+Q!?#28K2ST]KB_M[BYQ.D\"A8
MA%A?G7.29#\V".!C- %&R\)ZQ'/IUH^CK%+8:I<7TNL)-&&N4?S2%7!W[F$B
M@[@ -O4\5T&M^'Y]6T3PY&UB9;BUO+26=;J1))$C4@R!G/#GUQUJ:P\8?VFW
MA62"UV0ZY;R3D.?FBVQA\>_)Q7/VWQ(U"7[++<V-M9VT]H\T+R^9MN9%\S,:
M.!M##8O#')W<=* *=UX%UYIGEBEE,)UN[N5LMT(B2)X9E20'&[)+J,;N,]..
M+EMX9UE_A)>>'VLKB/4F@CB5;AK;#$! =IBP"HVG&_YO4FNI\&ZW>>(= BU*
M\CCC:4*RHD,L> 5!Q^\ +=?O#*GL:Z"@#S4^";GP_KD6H0:8/$,$L5SY]N?)
MB$<\K1G>B.0H4JFTX)/UR:RK/P)K6G+:VG]FRW,<FG?9=4)GA,4R"!E"PLQ\
MR.0%M@/"D#)KU^B@#QJ[\%>*[W2FBDLL^7:75O;AW@6;8TMLT8DV'87Q')R.
M, 9Y-:?A_P .^(=$UVPU!]'EG@$U\6430+,BSF AI &5,Y1^$XP!QFO4J* /
M-?#GAC6;/X8ZSH-S8W$=_+I\D$0E>VV.[1N $:/G&2.9#GGKUK-U+X7ZDUO:
MBRN4-U-'.]U(88A&CFV6)%$9!&#MP6&3R3FO7** /)[7P?J/FZU#?:#?FRU"
MUAC6""YM<*!;11E?,8^9O!1@.=IQSUS3]*\.>)X?$6DZAJ5C.\4,3PDP"S#A
M?/#+YP/RYV\L8N?0YKU6B@#Q)?AIXGAT^.PM/+BMY["X:16F'[BZ=-C 8/W7
M 7.,X.X]ZW]0T+5+S5-!O[7PI-IL-DL\<]O:O9,QW"':?GRA7Y&&?O8 Z5Z=
M10!P'BO0-2NM>U.ZBT./6(=0TE;&$O+&OV60-(22'(^4[U)*Y/R].E3^"?".
MHZ%JFI76H7._>T:1_)&WG!;>%#)NQO&61AC('?%=Q10!Y)#X-\6Z;9:?-:2S
M3744&H1I!))"([1YG^1E( 8\'<<ENF..E1GP;XBTW1Y?#(T:&^T:6\CF:2TD
MC1DA*#S8D$K@J69!DYZ2-CV]?HH \JN/"GB>;Q!-X@BL+:(SM+9_8_,421V;
M0^6H+!MF RK)@<\GZ51L/ NO:2EBTNDC4C%/87$BJ\"$K';RQO$5)5259OO?
MQ!AR<5['10!Y-9^#]9TJX>ZF\/0:G!<VMS%%IZ31;; R3M(%&\@;=K*"5SC;
MP"*=!X-\16.GS:&;07:7O]F%]0$Z!(OLZQ"3<I(<_P"JXP#G(SBO5Z* //\
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MH@LOF);HDAWG@-Y3$@ D9Z5+;?#[6(/#][8W5O#>7).E"*5G4[A"8_-P6Y
M4CG&0*]9HH \SF\*ZI9>*Y=631$U"P349Y4L4DB4LCVT$:2*'(7Y3&ZX)!PW
M%8-Q\-O$::?+<V<,4>H1::T-O$LR[-LLUR9+;/H(YDP>FY1CI7M5% '"ZKHN
MH1:MHNH?V(NLP6VF26<EF9(P8I6,9WCS"%((4J2#G'K5+P+X'U70M76YU"90
MD%C:PJ$6-UD95D#*&(+J$W*!C&?>O1Z* /.=?\%WMY-XH>QLHHGOI;!K66/R
MPP\MU:4C/0C&>>N.]95WX*\0P:^UX5OM1C&IRW'VA&M/.D1K6*,$K(HC^\K+
M]T' S[UZW10!YQX[\(:MK^M_;;.!7@CT^-# QC'GLLZN8MQY0E0<,".>]4CX
M.UN?RM.734MKF+5[B_.N^;'ET<R%0 #YF[#JA!& %ZGBO5** /&[SP/KNH:#
M:65OH$6F3V&D/8R.LT1^VR,T7(P?NCRV;+X.3TZUV7B+PWJ5YX;T_0+,P7,+
MW2M>S7$:1H8E)DVLD>W(9@BX4="<UV5% 'C-SX"\636"RB*/^U--TH:=:R><
MNVZ023(RGG@-"Z'YNC >E:5CX/UE=06&32(XF75[6_&IF6,[(HXHE=% )?+%
M&7& ,-UKU2B@#S3Q'X5U:_U#Q';PZ1'<G6);=K74VEC'V-45%(()WC:59AM!
MR6[5G7OPVU.;1M8NR"^I2W5Q]EMHA$O[J2\68LSGAB50$!N!G&*]<HH \GU+
MP7K>HZE;Z@EE-Y,%O9J]K<&V62<QW4DCKNCPJ$*58%, ]#WJYHOA/Q#!XBN-
M5U&SLY(M8BN!?0A@6C.[?!OR2&VCY!MZ9_&O3** /(YOA[J<^AZ/8-ID.Q-&
MM;2\02( 9%N;=Y <'GY(WY[X^E,M_!/B>SO&N+NV&IQ6E[B%!+$9)XA;^3%,
M!)\GF)QP_4Y->OT4 >=7^@:U>?#_ $NWN=.F;6[6X>XC%F;9/)DS)L9E.(F&
MU@& ]21S4,W@2XNM1N[G4;#SX;C1E66VM)EC0WKKY<S1@XVGRT4 GCD^IKTN
MB@#S?3?"NKSCP[)JNGP.UEJ<SN94A$HMC#(L?F[/E9]S#.W/8^M9$7@'5K[P
M]_8E_87"(^I>;+([VVQ8B\QW1E/WA(#J?G).>F*]?HH \>7P/X@OI)M3\06$
MMS?7ED8[D65S$KI(DT'E;"YVGB$R8/&6(/6NR\/WOB&#P[<V-UI8;5K*SWJR
M!(XYIF+E8QC"A@ A8CY<OQ77T4 >.0_#77%LVT*]C@N--NY[6ZN)[>385E56
M29L,<[R-C9'<&I;'PIXGMKN&ZUC0H=9E\R^29?.B"2^8ENJ2'>> WE,2 "1G
MI7KU% '"W'A"\;P9X7TJ>*&^O--N;(W$C8(V1NIDP6ZC Z=2!TK'N? VNM=/
M-%++]G.NSW266Z$1+$T+JL@.-V<D#&[OTKU*B@#SO1?#5XGPPFT#5-+U!YO(
MCB>$2VJ.^%4'RVCPN 5)'F<GN368OA_Q?%:7#SZ4MW/?:3<::!'+!$T.Z5VC
M>4 A"2KY;9GD'@YKU>B@#S*+P-?K$T4]C!.5UZTN5=BAW6Z0PH[<]LHWR]3C
MI56_\'^*)=8U/68;6U+:@MY9/;K(%D6V:+9#DD[< Q1M@<CS&]Z]7HH \9L_
M ?B18!NL2H,N\B:6$2Y^PRP$GR\)MW% ,?-R2WK6ROAK6=2M MWHA@,/AJ73
M$2>6)]T_R;2-K$ '!P3C&.U>FT4 <"/ Y_MKPI=+:+%!:6P748XV54>2-0T.
MX#[VV0N01WJEXG\*ZM?ZCXEAATB.[_MD6XM=1:6,?8@B*IW G>-K N-@.2W:
MO2Z* .1\'^&;K29-9FU!@PO;ZZD6!HXB/+>5F4E@-QR".&)QZ"L*T\#ZI$^D
M" '3'AU?4+F:YM?)+I%(9O*(#!@<AU&,' /:O2Z* /*O"?A'7=$\0:;/>V5R
MT*64<$CQ/;,H<33L2^[Y@,2*?W>/TQ4^K_#Z^U74?%.H2$!Y7F?3H4" S.]D
M( 6?J%R6&TX&0":].HH \<_X0/7[*> BSFN/*ODN&N+4VJR,GV0Q;1'(/+RK
M<$D<@YZ]+4W@779M;OY8K9(;#6;MAJ*-(F3;IY;Q\ XR2)8R/1_2O6:* /&8
MO NOVVD1G^RYVU&"VLA:/#/ RQS1VOE/YBR':R9)4]\<BM"+PCJ[IXB@U72;
MRX74)1*HL9;5(R?W1W1E_P!X&#(2%8["!@CFO5J* //+GPUX@U;PCX=LKX11
M7UMJ8GN'CCA_=Q#S0&*X,9;#+D $9)Q5.Z\(:N;C4-/72HYGNM6M[V+6R\2F
M&*,Q'&WAPP$;* HV_-U'->GT4 ><^ _"&K>'M<6[U"%626REBW Q@V[&X9]A
MV\N&4JP)R1M(XS64/#?B,Z1X=LY-%O(VTFYG:1X)K1VD6028*"4LO\0SN&>>
M*];HH \KO?"6I3ZAK4<>BWJZ3>DSO$)[;SOM'FQNKP.3POR;F20XR !1I7AO
MQ/'KT%]JE@[/)IL=O(UK]E6,.))S^\#?,"%="3%@;L]17JE% 'FV@>$)1\.F
MTC6M&O);J*U$ 1I;9'.8@C")X\#'7!DY.>374>"[35K+P_Y&L1A)Q-)Y0*QB
M3RL_)YGE_)OQU*\5T-% !1110 4444 %%%% #)8TFB>*091U*L/4'K6"W@;P
MV]@MB^F(UNKP.J&1SAH4"1D'.1A5 ]^^<FNAHH QKSPKHU^EVMQ:N?M=S'=S
M,D\B,94"JCAE8%2 B],=*AN/!7A^\LYK6ZL6N(IFB>0S3R.S-']P[BV[(]<\
M]\UOT4 <\O@;PZL]S,=/9WN/.WB2XD=5\[/FE%+$(6W')4#K4<G@+P]+!;PR
M6]XZ6X=8MVHW!*JX4,F?,R5(1?E/''3DUTM% &1J'AG2-2L[.UGM2D5E_P >
MWV:5X&A&W;A6C((&WC .,55/@?P\WV=38MY5O&(XH/M$OE* I4'R]VW=@D;L
M9YZUT-% &/IGAC2](^S?8TN@+8,(5EO9I0@*A2 '<C&%&!T';%;%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!#=7"6=G/<R!BD,;2,$&20!DX'<\5SS>/_#X\X"Z
M=S%81:@0L9),4A 3'J3E>/\ :%=,0""",@]0:\XL?A-%9R6#'6'D^S7?FN#!
MCS;=3$8X#\W 4P1\]\'CF@#IKCQMHEM=ZU;23R>;HUO]HNP(R1L"[CM/\1 (
MR!TR*KK\0_#XFMH9Y;BVFGNQ9>7/ R&.4JK*&ST!#K@]/F%8EW\+&N8KAQK\
MXN[N*]BNI'AW1N+@'.U-PVX;8>I^YCC/%@?"ZQ+2VS70_LMY9I5M1#AD,L*Q
MMA]W9EW@XXZ=A0!H7?Q(\.6-M)<W$\ZQ1HKNPA)PIF>'/'^U&WX#-6Y_&ND0
MRM!$;BZN1<&W2"VA,CR,(TD)4#JH6126Z<USUA\+S;)9K<ZQ]K,"P+*7M<>=
MY=S).21N.-WF%?PSSG%,L_A8VEQ-]AUA6E6XG,0O+4RQ_9Y8XH_(<!U+;1"F
M&!'3I0!VZ:Q:/I\EV2\8B@\^6&1"LL:8)^9#R/NG\JH:3XNT_6]0-I8PWDFV
M..1YC 1&@>-9%!;L2K#BJVD>$Y=,T&32I+^*=6T]+/S_ +-MD) <%F;<2P^<
M87M@\\U'X8\#VOAV_FOGE6ZNGB@A27R]A18X$B(ZG.=F?;./>@!T/C[2I+N6
MV>UU*!X;F*UD,UJ5599"@12?4^8I^G-2S>-M+CU 6$45[<W1GF@\N"W+G=%L
MWGZ#S%Y]ZJZGX%AU5M46XNE>'4-3M;Z2)X-PVPK&IC//(81]>V[H<5E'X716
M^H6]S87&G)%;W=S<16USIWFQ()?*P% D7!7RN#_M=.* .DU7QAI6C:NFFWAN
M%D*1.TB0LT<8D<QH68=,L,5GI\2= >VEG O0$5'13;,&F5I1""G][YR!^-7+
MSP=8:CXN_MZ^Q<;+:*&*W8':KQR.X<\X;EA@$<$9KE_^%211:9/9VVIPK]IB
MB6X,MGYBRO'<B96*[QQC<A4'G(/;D ZN#QEI,VM)H\IN+6^:U^U^7<Q%-J9(
MY)X!^4G'H,UGP_$WPW/8+>I-<^4T;2*# P9MLJPX ]2[J />LW4?AC_:B,9=
M3AM93%;P@V-H841$\Y755+G >.=EZ\8SST$W_"N3%/=2P7MFZSI=)]GNK'S8
M=LUPLVUEWC( 7;U'KQC% &W_ ,)C8"_%F]IJ*3"W6YFW6Q MXV+@&3T^XWY5
M<TCQ!9ZQI!U2%+B"TV^8LES$8]R;0P<9ZK@]:Y/2OAM/I&HV=[%JEE<26]FM
MJ&O-/,KIAY6S$WFC8,2[<'=PH&35NS\ RVOAK6](&I10#5I,NMG:F*&!" KK
M'&7;:6 ;)SC+9QQB@"VGQ"T.;1['4X!>317LLD44<=NQEW1AF<%.HP%)^E7-
M,\7Z9K.HK::<EW< Q1RFX6 ^4JR1^8F6/3*D5SDWPIM+BX>.?4YYM->X>X-M
M*F7#M T+$."/]AAQP5]ZO:#X&N=&\1+JTM_I]W(;>&&1FT[;+^[B$>4<280'
M )&T^E &Q/XMTJ"QN;MGF98+TV'EI$6>2<'&Q%'+$FJ8\>Z.T:!([Y[QYWM_
ML"6K&X5T4,P*=@%93GI\PYYJA+X&U%I+DQ:W;HG]J'5K0&Q):*8GHY\S#IM+
M# "GG.>*:G@34(-4378-;@&O-/++-,]D6@=9$C0H(_,!  B3!WDY!SG- &V?
M%^E_VR^D+]I>_6S^V>2(&W%>#M /\>"#MZ\U0@^(>E7,<#0V.K.;B:2&%!9M
MND>/=O '^SM(/TJM;^ )HM=@UV37)Y-22_-W(WE 1.A3RS&$SQ\@49R>1G%1
M7?PZ:?3],MUO;*5K&\N[H"]L#-%)Y[NV"@D7[N_@YZC.* -FV\:Z3<:M_9V+
MN*0W+6BRRV[+$\RC)C#]-V >#C..*2Z\<Z%9:LFFW%Q)'.][]@!,9V^:41P"
M>P(D09]3BJ%MX(NEU;SKK5XY;!=4;55MH[38QF(P SESE03G 4?6H[_X=6VJ
M:G?W-W>EX+R>:9H1%@KO@CB&&SU4QA@<=<>F: -R;Q5I<'AF3Q [R_84)7(C
M)=F#^7@+U)+< =Z+SQ3IEGHMAJNZ6:#4&C6T6&,L\S2#<H ]P">?2L>'P)(/
M#&BZ'/K4SI87/VF:>*/RWN&!=EQR=N'8-W^Z.E#>!I$\$+X9CO;2XMXY7\MK
M^R,P6(LQ5,!U.Y=PPX(^Z.* -*W\7V=QKJ:.+'4X[IHA,3+:LJK&?XB3T&1C
MZU2'Q%T.3P__ &W M[/8B;R&>*V8E&^7&1V#;E(/?<*8_@B<6SI%K4HF;1%T
MC[1)%O?@DF4G<,L<GCUYS59?AQ';V&JV%IJTZVE^+4[)T\QHGA8<@@C(*(BX
MQQM!R>E &[IOBFTU359M.@L]06:#:)FEMBJ1,R!PK'L=K#CWJL_CK2$OFM@E
MZZB=[5+A+9C%).H.8E;H6RI'H2,9S3;+PF]EXWU'Q"L]BZWS*65[(^?'B)4V
MK-OX7* XV]_QJG;^![F&[MX7U9'T:VU)]3AM1;8E$K,SA3)NP4#L3]T'H,T
M7=,\<Z7JMU!;Q07\+SW,EI&;BV*!I45V=<G^[Y; ^^*6S\<:5J%Y#:V<5[.\
ML7G%DMR5C3S'CW,>PW1M^547^'MG<K917\T5W;6^J7>HO!+;@K+YWF80Y/\
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M9,3B;;(?, =>"N %.&Z\4 :TWCO2;:^CL[F#4(96$.[?:MB(RNR1A\?=+,I
M_"FP^/=*DL=2O'MM1@ATX[)S-:LI\S*CRP.[G<O'N*S'^&ZRZG!JC7EI%?6P
MM!;_ &>R*11>2[D@(7/#*^W&>",@U=N? YNEN(6U66."XUC^U)!#'M?A%"H&
MR<8=%?..V,#K0!-?_$'P_IVGI?S7$IMWLXKY6CB+9BD=44X'?<PXJ[+XMTB+
M3=5U#SV>VTQ5>=T7<"K1K("O][*NIKF;;X8?9_*B_MAI+> QK"DEODK&EVMR
M$)W<]-F<#@YQQBK-K\.([+POXDT*#4W\C5V;R6:+/V6,HJ*@^;Y@H4 =.,"@
M"U/\2-!MT)D2_#H9O/B^R/O@$2HSEUZ@!9$.1G@U:D\=:+'>^0&N9(1-';O=
MI;L8$E?&U&?H"=R^P+ $BLO6_A=H^K)!%"1:Q107*_=,C--+Y>)2S-EBOEC@
MYR..@IQ\"7KF>UDUF)M*N[Z/4+J 6>)'E4HQ"OOPJ,\8.-I(Y&: -"7Q[H46
MG65\TLQAO(6F0+$2RJKJC;AVPSJOUJ2'QMI,X+HMWY!O%L4G,!$<DID,>%/?
M# @_GTK'D^&T;?VZ!J;"/474VR&#(M%\[SI%'S?-N<D]L<>E-;X<R3:W-J4V
MI6\?F7=O<-#:69B24Q2^9ND'F$-(1\N\8^AH T?^%BZ#Y4D[&[2V$$UQ#</;
M,([E(@6<QG^+ !/N.1D4]OB%H M[>:*6>;[3%#) D4)+2>:SHJ@?WMT;@@XQ
MBL5_AI=7&C0Z/=:XCV-E9W%IIX6SVO'YL;1!I&WD.55B  %SU-/G^&:B\UF6
MUO+1K?4A&#9WUD9XHL%V?: ZGEW+C!&#GUH ZC4?$MGIMO8O+#>//??\>]I%
M S3-A=S93M@=<XQ5.R\;Z3J=[9VEBE[<27,7F_);-B)=[1GS,_=(96!STQ5>
M3PA>0VGA]K#6,:CHL+0)<WD!F6=60*V]0RG/RJ00W&.]0:)\.[/2M8M]3N+G
M[;<10,NYXMI\YIGF>08/&3(0%[ =30!;U#QWIFEW]]9W5KJ2/8V[74[_ &4E
M!$-WS@]P2C >I%3ZCXSTK3;QK21;J6Y62&,100EV9I5=D ]>(V_*H-?\'_VY
M<:S+]N\G^TM(&F8\K=Y?S2-OZC/^LZ<=.M8E]\*;&2:5M.>PM87GMI_LLEAY
MD):))5.Y0ZYW>;GJ,;>^: .R.LVJWVG64BRQW&H1/+#&Z8("!2P;T(W#BLN+
MQSI4FA76M&*^CL+?&)7MR/-);8!&/XCNXQ[BEU#PYJ%Q?:%?V>HV=M<Z9#)$
MP-DSQ2!P@;:HD!3[G RV,]\5@Z?\,Y+2P@T]]5MTM([Q;MWLK'R)YF7>5WR&
M1@<,RD':/N>_ !T<7C#2[B^L;2U^T7+W=K'>*T,)94A<D*[GL"0?ICG%)9>,
M=-O?#=SX@6&\BTV"W-R99H"OF1A2VY!WX%<_;_#::W?2(AJT)MM*G,EO)]C(
MNEC\QG$7FA\;"&"D%>0.V:LZ/X ?3/ >H^%C>V.R[M&M5N;:P,+9*%"\@\QM
M[<@_P]* -2/QSH4K:(J3R,VLEA:J(CGY>#O_ +N#QSWI(?'6A3QW4D<\ICM+
MY;"9S&0$=FVJV?[A;C=TK$7X9^1J,]]:ZNT<OVM;FV#P;EM\"0LH&X<-)*SG
M\![TMK\,(;'3[^R@U:>2"^T@Z=,MQ&)/G&=DHY&-I9SCWZC% &U=>.=#LM#M
M-:N)Y(]/N[G[-#,8S@G+#=[)\A.[TYI6\::8=373H(KVYN6DFC*00%MOE,J.
M3[ NO/O2ZCX2M=1TC1]+E9/LFGNI:+ROEF00O$4QGY00_OTKFM-^%LNEW.FS
MIJUK>O8O,RG4-/,Q(=T8$8D7#KY8&[G.2<4 ;P\>Z6;,W:VNI- ;D6L3K:G$
MTF]DVIZ_,I%69/&.EIX=FUQ$NY;6W9TN$2W;S8"F=X=#@KMP<YKGK;X<7=E9
MM#:ZGIL4BZ@M_'.-,/F.RR.X64B7YP-Y QMP!6W#X2,?A36=(DOS+=:O]H>X
MN_*P/,E7:2J9X &,#/;K0!%-\0=(@A$KVVI86W^U3JMFY-O"20)) /N@[6([
MX!.,5;UKQGI&@M;_ &MIW2:W>Z$D$)D585*AG;'11O7\ZS-0\$WLLEW_ &=K
M,=K'J&GQ6%\)+3S2RH&4/&=XV-AV'(8=..*B\4?#J/Q#_9Z0W<%O#9V,EDJS
MVIF95;9AT.]=LB^6,-SUZ4 =#IOB*TU74[NRM8+L_9)&BEG:$B+>N,J&[GD5
MCK\2= :VFFQ>@1JKJIMFS,IF$.4_O?O"!^-2>'/!\GA_7=1U 75I<)>R/(SM
M9D7/S;>&FWX9?ESC:.36 ?A)%'IMQ:6VIQ(;J)$N3+9^8LKI<B=&*[QQC<A
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M\T;><=CG:06Y!R...;_B3P$?$6I76H/K%Q;3F&&.S$2#; T;F0,PS\_SX/\
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M$UW!&6D$*AY ,N1D*,G[V.<=:F1UD171@R,,JRG((]10 ZBF++&TKQ+(AD0
ML@/*@],CMG!_*AY8XWC1Y$5I&VH&8 L<$X'J< GZ T /HHHH ***9%+'/&)(
MI$D0D@,C C@X//UH ?13?,3S/+WKOQNVYYQZXIU !1110 444UI$1D5G52YV
MJ"<;C@G ]> 3^% #J*** "BFI(DJ;XW5U.1E3D>E.H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&570HZAE88
M((R"*XR/PQ,;;3H?L[VP36+VYF:VD$3B)S<^6=RD'D2)P.1GZUVE% '%:7:>
M*&U?3Y=2FN%18(#)LVLA/E8E5\2 9\S)R$;^'!QG#YVU>?QE<K:"]:.WN8?F
M\\+;I&8LR*RYR2>,?*<$@C'-=E10!PFEZ?XEN3#'??;K6V>\CDE471W*GD2;
MU#^8S%?,\L<$>H %*NCZ[:65S%IL=Q%="YU"2.6><.A,@D:%AEC@99,C YSD
M=Z[JB@#B(;/Q!%;6C@ZC,RWN\V\K^6!'A 0S^>S$ [V&2P.2-N-M7M;TG4I]
M>?4+$SHT=O;K&8YM@=A.2X89^8;">#QSZXQU-% '"KIWBB1M0\VZO$DDFVCR
MV 4H;A2&1C(=N(MPP$7.><D#,\VD:Y+K=Y UQ>#3RC1P8D)5HC;[0K,9<AO,
MRV[86Z?-@G'9T4 <';Z?K\,.FPPP:E$(K>U2+==J5A=9#Y_FC>=X*8Q][C@;
M36GK.DZE-X@DU&R,Z%(+5(S'-L5RL[&0,,_,-A/!XYXYQCJ:* .'6#Q2+O5+
ME(+E%0K-!;FX#+*R3$E%+2$ /'QT0#(XXS3[?3_$ZZQI[75W<&)8H7D:(AD$
MA9FF5@9%X.0 2K8 &W!%=K10!RU_:ZY)XN29);E=.41%/)P5P-WF*P,B\GCD
MJV.,8(-8XL?&!TV.*XDO-WVC+F.8,_D^5B,?+)'\RM]\[OF;GE>!Z#10!QLM
MKX@":H"-0EO?)'V2=)T2(@1)E=F_ <R"3G'<?-BD^PZQ>:U:ZE/:WL8CNY_*
MC:X \J-HT"%E5\%=RMD<GGI79T4 <#96'B9--@^W-J<Q,T1O((I5CD8"-]YC
M?SCP9#&2 4&%.!R15LZ)??\ "#Z%9R6]TUU926SS0PW 23"D;OF# ' )/7MQ
MVKLZ* .%.AZY;07PM?M&;E=18Q&<% [7 : JI.%)4N<CUY[5O:+%J46KZL+M
M+AK9I-T$TTG7+-\JJ'8!0-N" I((R,@FMRB@#@!9^(O^$8T;3X+6]LS:1B&Z
MV,A=B(\*R[9ERH;U8=L@C-69[7Q+)K,^W[;';FUDB,T4BG>QA7:ZH9-JMOW<
M!1TY8@UVU% '#1VGBB6ZTPR?:K:!%4$1R&4AA,VXR;IAPT>S@^9MRP'(&=+7
M8M;E\0V!T^&<6L;PF25)L*5,A$JLN\#A,'.UB<\8QFNGHH XR/0;S_A76J:.
M(+L7;+<+&KW1+2$DE2K[S@'C@D=\CDTZ+2-5BUB2_LQ=PB2YB_=S7&Y3$+7:
M2XW'<0X4$G)^7@XSGL:* .7\+6VM6NF7+:O-<F<Q)E9L'$@4[V4^8^03C@;0
M,< 9-8N@VNN7UII=Y+%>O!_H=P1>7"NS2^7)YLB_,<*=T6!QSGY17H5% ' 6
M=KXG^SC[9;:C]F:ZC>6WBNP)MAA<,JN92<"78?O+D X &0=72[775\43SWDM
MTMIN;8IPT;1E5V@_O,!@<Y(3).>2"*ZJB@#B+^V\43:MJS6D=U!"]I.D)6X!
M4R9C\IERY"G'F=$7'<MP:AUG2=>:TO+&)=1N;(FY2!8[P"0EHX_*+,S@L@8S
M @D]5X( KO:* .9UFUU,VFFQP0WLD"0LL\5E.(I?,V (=Q9?E!W9&>I&01FH
M+#3_ !"FIVUU>W$[NMS&DP6;]R8OL@#D)G',_MGTX)SUM% '&:MH%Y=:MJ9B
MAN]EU/82K*MSA L<R&3 +?*P"DY ^ASQ4+Z=XG%Q9Q"XO%MXI)@KHXD8 7#&
M,OF5=P,6P?-O[Y&:[FB@#D/%VGZKJ%UY5O!=S6S0IY0MYUC1)!)ES("PW KC
M'!Z'H<&L_4-,\0ZC)K$<EM>+:R M'$MT?G9)P5V'S.-R G " 9 .2,UW]% '
M%FQ\0OJ]\_GZA#;&-Q;B/:_R&$!1\TN-XDR<E<DCEMIJZ8-7D\%B%H[J"_#]
M(Y2\C*)<C),N0&4<@29 ; .173T4 <';-X@NM=98X[R&:"6 /NN@]M"IME,B
M,-V7.XCG!YP<CFFV5CXFCTV#[<VIS@S1&\@CE6.0@1N&,;^<3@R&,D H,*<#
MDBN^HH XYM$U&XUJ&[ECN0D-U+)%FXQA&MD4;@K8/SAASGOV-5;+3_%:7D!D
MGFB\NVC$?1HLBW"LK_O ,^;DY",?NX.,@=W10!R?A:PU&TEU&YN;6]1YK>!5
M%[<K([R*K[_F#-@;C^O QQ6-'IOB&:"U>_L]2>.'45G\F*Z F2,VLB-M=I2<
M>8P_B'4X '%>BT4 </:V7BCSK 7AO&N56T#3I<*(50 ?:!(H8;G/S8(4\E2"
M,&HWL?%K6"":6X)BN4MW$<F7FMXXW F&V1"&>1E8@,#A1[@]Y10!S.HZ9>SV
MGAMY?M=U/97$;W+1R"%V_<NA8@.!]Y@2 3QG&>^.FB^([#398[![E7F5VD1I
MPP!^U!L(-PVDPEP,%><9(/-=]10!Q)TSQ"UK BSWF615:4NL<B*;I6(SO8\1
M;ADL20.>3BMZ^L+J6^TB*":Z6R@+&<I.06POR!CG<W/7U[\$UL44 <!;V'BI
M=&NOM4VH/>GRBT2$!7D!8N5;S\A6X'R[,#;\OWA3D/B*[UR_^QB[BF@N"FZ2
MX#6T:FR4A-N<L?.93NV^O/45WM% '"6UCXACL;?[5_:T\)N-T\$<RQS >40-
MKF9B5WX)&X<]!MS5B'1-134;B.-;V&*;5))I)S<[AY3VTBADRQ*D.RC@#G'4
M#CLZ* .!GL_&-UI]O+</<0S22.)XK9P6C*QJB,N)$!4LKOC=_&H(.#C>UF'5
M3+I#V@N)VCD7[0B.(D<97+.0X(P-Q PRGD$=#7044 >;-=ZE:>)].T^^GNHE
M#1/LBG )+W$PQL#C>"OEY.&V@9..:T8K#Q':Z:P<7MS)/:V_G!KL[DE\QO,*
MX=2,)MX5E!QUSG/<44 <!#I/B&.&2Z>.];4Y-'6%9!=  3(TAPPWXW$,N#R,
MYR>IK4M;;6[[68[BZ6]M;(7,LHB,ZCY0D7EA@C'C<)#C/KG@X/5T4 >?6]AX
MK3093<RZA+?_ +DM"K!5DD ??A_/W!6)7[I0#"D+C<*[NVEEE5Q+;O"R$+\S
M A^ <J0>F21S@\'CI4U% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !14<[F.WD=>JJ2/RKC;3Q9>Z=X5T[5=6MYI7OC&BJWE
M1X=X]RXVD_(6XR3E1R1@$@ [:BN5D\:%);XC2KAK>V:2,3 ,%:1'";22H4 L
M3@ACP"2!5N;Q')9R207EDJ3QK;%UCFWK^^G:(8)49QMST'7% &_17&KXSOX;
M2/S]($]W+->".&T:23,<$OEGHA.XDJ " #U)7I5N/Q#=WGB.SMH;<16#3SP,
M[."\C1ID@KCY1NZ'/..<<9 .GHKD=9\936+:K!:6<,LMK9SW$,C2/L9HMFY6
M^3&?G'"L>F#MKIH);EPRS6Z1.%4@K)O4L1R!P#@'N0,T 6**Y=M5U5?#,MYY
M]N;J"^DAD;R3M9%G,>%&[@XQR2:O:K>WPU"UL+=TM//=\7+ /D+'NX';D]^P
M/U'1]6E>UUU_#<5S:HKC=&\2ZCJ;:==R&)(;FXCMWM0G*[K43%LYSG<>G3;[
M\U:D\3.GC!M.#Q_9 #;XVG=]HV>9G/3;M^7_ 'JN6"JQDX]4KBYD=117!67C
M#4[G2])C80?VBUQ;_;B$^40R/$%*C/!83)C_ '7]*[VHKX:=!VGY_A_6@TTP
MHHHKG&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !16+XHO[S3]*BDL0QGDNH81L56;#N%. Q"YP>YJA=
M>+5TB[%A?6TSS1V!OI'+(&\M58OE1QO!4#:#@Y)!PIP =317,6WBF\N6A@71
MGCNYI&"),[Q1LBHK%@S1@G[P7&WJ#SCFHM4\82V^EW<UG9HUS%!?RH)I,+FU
ME$9S@9YSG],\YH ZRBN8F\7O;:C<VTVESM'9C%W-"'=8W$'G'!V!2N"!DD')
M'RXYJ31];O+JXU9]1CAMH[:**5(Q,&5%9"Q)? _'/3'IS0!T=%<E:^+;V_O+
M&&WT^! ^H-9W'F2R#"_9_/#)NC!/!'4#ICH=PUM5N-4&E1S6=NRS^8/.C3:\
MBQ\Y*9(4MT.#VSU.*J$>>2C>UP9KT5S'_"80J]L(D%U!-!O6>/<I+>29@&4K
MA<J,XW;N1QCFKMCK<U[9WKR6HMY[>-9 OF;P59-RG.!SV(]NIK:6%JQ5Y*W]
M6]1<R-JBN/M]>U&W6S2ZG2X-U!:S[XXPC1F29(RIZ@@[^. ?E;\)D\9;[22Y
M&FRI"618)9-Z(^Y]GS,4XQU^7=Q5O!5OLJ_3^KBYD=517-1>*9F6!Y=,,2D6
MQN TN&B,[[4 4J-V#C.<8SQDBKFMWUU#<Z78V<R0/?W#1&=DW; L;/A1T+';
MCGMD\XK&I1G3^-#3N;-%<A+XGGL_%UGI4MS#+;KLMKEQ$5)GD5F4]2 !M08[
MF8>E=?60PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 0@,"" 0>"#6=#X>T6W@,$.DV,<)#*8UMU"X(VD
M8QW''TJW>BX-C<"U(%SY3>43TWXX_7%<! +Z!;*70[?4[>X%HL>H/<V\AW2M
M+",D.,.X'G$L,@#.3@B@#N#HNEM+/*=.M"]PACF8PKF12 "&XY! '7T%1_\
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MP>=!J!M7CO&6VCAFS!.Q0PJ!@-\J[P&^Z&Z8XJHX/WK<VWE==7^5OO%S&O\
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M4T?3(P@33[50A!7$*\84J,<?W6(^A([U0\4K,VF0!$N)+8741NTMPQ=H<_,
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M1_PB'AG_ *%W2/\ P"C_ /B:V:*OZS6_G?WL+(QO^$0\,_\ 0NZ1_P" 4?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM/1_# T..6&TU;4#;O.9EA?RBL9:0R, 1&&PQ)!R2<'@@\T ;U%%% !1110
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M[8YBL_!FI7\#36_Q$\1LBRR1$DQCYD<HW\/]Y35:U\-W%Y>-:P_$CQ)YP:1
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M5_K/_10?$7_?4?\ \31_PK_6?^B@^(O^^H__ (FD!W=%<)_PK_6?^B@^(O\
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M+_OJ/_XF@#NZ*X3_ (5_K/\ T4'Q%_WU'_\ $T?\*_UG_HH/B+_OJ/\ ^)H
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MIDKVR0R33-<('416\CE5+;<O@?(,Y'S8Z'T.,H3Q5-<JB_N^?X#]UF)!X(2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 5M0L8=3TVZL+C=Y%S$T4FTX.UA@X/XU4N]!M;N]-X9)H[CS(I \;#@H
M& P"".0[ _6J_BN\N[+28GLI)TFDNX(<P+&9-K2 $+Y@VYP>]8D.MZ_IVH*F
MH1QS*MO:"='D"NAEN9(PP"@J6V["V"!E<#KP ;4/A/3K:_AO(#*DL8 /W6#@
M.SC.Y21@NW*D'GG.!5R[T>&^L(K6::X+12"6*</B1'!R&!Q[D=,$'!R*Y]_&
MMPB2R"P@=6BGD@47!W#RIEB(D^7Y22^>,XP1S277C*_MV6U324GOE:Y#I',=
MC"'9PIV]6$B]0 ,&@#HK71X+:>6=I9KB::!8)7G8,756=AG@#K(WMC [5!IO
MAVUTR>&5)[J?[/"8+99Y-P@C.,JO S]U>6R>.M:%O,\KSAUC41R;5V2;CC:I
M^88&TY)XYXP<\X$] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?VYI/_04LO\ P(3_ !K:"K0^%/[A:,I_\(Y_U&M8_P# K_ZU'_".?]1K6/\
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M?4X 'X4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\
M@J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%
MFG_H1_&?_@J_^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_
MX6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\ @J_^
MRH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H
M1_&?_@J_^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?
M^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\ @J_^RH [
MNBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?
M_@J_^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\
M9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\ @J_^RH [NBN$
M_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_
M^RH_X6:?^A'\9_\ @J_^RH [NBN$_P"%FG_H1_&?_@J_^RH_X6:?^A'\9_\
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M"/XS_P#!5_\ 94 =W17"?\+-/_0C^,__  5?_94?\+-/_0C^,_\ P5?_ &5
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M3_T(_C/_ ,%7_P!E0!W=%<)_PLT_]"/XS_\ !5_]E1_PLT_]"/XS_P#!5_\
M94 =W17"?\+-/_0C^,__  5?_94?\+-/_0C^,_\ P5?_ &5 '=T5PG_"S3_T
M(_C/_P %7_V5'_"S3_T(_C/_ ,%7_P!E0!W=%<)_PLT_]"/XS_\ !5_]E1_P
MLT_]"/XS_P#!5_\ 94 =W17"?\+-/_0C^,__  5?_94?\+-/_0C^,_\ P5?_
M &5 '=T5PG_"S3_T(_C/_P %7_V5'_"S3_T(_C/_ ,%7_P!E0!W=%<)_PLT_
M]"/XS_\ !5_]E1_PLT_]"/XS_P#!5_\ 94 =W17"?\+-/_0C^,__  5?_94?
M\+-/_0C^,_\ P5?_ &5 '=T5PG_"S3_T(_C/_P %7_V5'_"S3_T(_C/_ ,%7
M_P!E0!W=%<)_PLT_]"/XS_\ !5_]E1_PLT_]"/XS_P#!5_\ 94 =W17"?\+-
M/_0C^,__  5?_94?\+-/_0C^,_\ P5?_ &5 '=T5PG_"S3_T(_C/_P %7_V5
M=V#D T %%%% !1110!'<,4MI74X94)!_"O.])\6:G:Q6L&JW0:>+2_M+2O'\
MLXD>$1.0,<_.Z'D#*D\ @CT=F55+,0% R2>@%5TFLI_D22WDR-FU6!R,9Q^0
MZ>U '&KXUU2;3XKFWM+,E4D:4.YP^RY,'RE20,XW9RV.G/6I+GQCJ=O)%:K9
M6TMT'N1(?,6-)/*D50JEW&TD,#G+8]#G([)?L_F-"OE;T4%D&,@$G!QZ$@_D
M:<T,3XW1HV&W#*@X/K]: .6\43ZTVNV-CH\LZ2R6<\J[#&(Q(KPA6DW<E!N;
M(7GG\0V;Q%?KY=R\<*P_VA=6T21L<L(8[@Y?ZF(<#IUSVKK<#=NP,@8S2;$Q
MC:N,D].YZ_S- '%_\)-K#RV,<CV%L7NH!*VUF0QRPNX7)(P0RXSWXX'2FQ>-
M;^6"YF-G;0Q><D,;RRK^Y+3B+]X Q;C.[HO(V^]=J8HV&&C4CC@CTZ4GD0GS
M,Q)^\^_\H^;Z^M '/^$]4N+_ $^(W%U:SM)->MN27<S!+EE4H.Z!<#/;Y1WK
MI*:L:+C:BC&0,#IFLNY\/6EW<O/)<ZFK.<D1:E<1J/HJN /P%7!0;]YV^5_U
M0&M16)_PBUC_ ,_FL?\ @VN?_CE'_"+6/_/YK'_@VN?_ (Y6G+1_F?W?\$6I
MMT5FV.AVVGW'GQ7&H.V",3W\TR_]\NY'Z5I5E-13]UW_  _S&%%%%2 4444
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MHO\ XJM:.:&8*8I8Y RAU*L#E3T(]O>I,#TK?FH_RO[U_P#(BU,7_A,?"_\
MT,FC_P#@=%_\55NPUS2-5D>/3M4LKQT&YEM[A)"H]2%)Q5_ ]*,5,G2M[L7?
MU7^0:A11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QO%FFG5O"FJ6<=LEQ/)
M:RK"C ']X4(7&> >>M8^NZ-=R7<OV6UF%E$UB\<=FXB)V2R&4#!'164X/X<U
MTNI:E!I5J+B=9&5I$B58D+,S,0H  ]S52R\3:5?W:VT5R%D>))$$OR%]S2+M
M .#N!B<$8XH YJ?3?$<<T<=K)/;6[7-Y+NA4.0[7!:-F'F+D%">#D<G(SBNI
MDU2QTJ*275+Y;*-YV5&OIXT#>R'/3T!YJR-2L"TZB]MB;<A9AYJ_NR> &YX/
MUI/[3T\QV\GVZV*7)Q WFKB4^BG/S?A3C:_O; 4/^$Q\+_\ 0R:/_P"!T7_Q
M5'_"8^%_^ADT?_P.B_\ BJV%9'!*%6 )!P<\CJ*=@>E;<U#^5_>O_D1:F+_P
MF/A?_H9-'_\  Z+_ .*K81TDC62-E=& *LIR"#W!IV!Z45$W3?P)KU=_T0:A
M11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH 9*GFPO'G&Y2N?3-<[8^#K.PM=
M&B0AWL)$EFDD!=IRL#Q#EB2 "^0.0,8%=%,_E0R28SM4MCZ5REGXVB3PO#K>
MIJ@BD4.WD?*(QL#'/F%2Q&?X<D]@: $L_!<UHEG +Z)K>);,R$P'S"UMC;L;
M=\JMM&1@XRW][AA\";;"W@BO51X+>UB!5&0.T+N^X[6!YWGH<@\\UN1>(;2>
M_N[&**Y>XLR!.BQ9V;B I]PP.X8[ YQTK6H S-(TK^RXHXD6W$:1;/D1M^[<
MS'YF9B5^;@'OGGG BFUF_CFDC3PSJLJJQ D22U"N >HS,#@^X!]JV**N$E'>
M*?K?]&A&)_;FH_\ 0J:Q_P!_;3_X_1_;FH_]"IK'_?VT_P#C];=%:>UA_(O_
M ";_ #"WF9UAJ-U>3M'/HM_8J%W"2X> J3D<?NY&.?PQQUK1HHK*4E)W2M_7
MG<84445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#C];5%%9SJ.>]ODDOR"P4445 PHHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFMZ5(8@FIV3&8XC N%.\],#GFKU !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN@Y .,>U%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *>H75W:HAM-/DO"QPRI*B;??YB*Y/7
M+#5-:-RS:'=0R2VZQ1NMQ"3$ZLS!Q\W/WL$=QD=Z[BBNBAB'1=XQ5^^O^8FK
MG QZ9K,D:+=:+=_+=>>_DWD2%PJ>7&-P<$84 D?WJU]%DU;2].MM._L*Y:&'
M]VCM<Q92/)V@_,<[5P,]\5T]%:U,:ZD>645;Y_YB4;!1117$4%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<WNI"[4@;0(%CVG\#S4RIQ2NII_?_D%R_11160PHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ9C0J  Q&TY)R1T)Z$]A5BF30QW$$D,J[HY%*,N>H(P:Q_\ A$="_P"?!?\
MOX_^-:05-_&VO17_ %0M3;HK$_X1'0O^?!?^_C_XT?\ "(Z%_P ^"_\ ?Q_\
M:OEH?S/[E_\ )!J;=%5;#3[73+<P6<0BC+%BH)//X_2K58RM?3884444@"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC@DD&,JI(S["N-LO&TT6@Z?=W\$MU=WL1F6&WLG@PJHK-@.QW<L ".#D>YH
MNR^#5-I'!#J4\06*"%L#B18XW3# $9SOW>F57KTJ:R\)Q6+V[Q7<F^!U="4'
M5;80#]!N^M4[_P :"VNTF%I,FF0O/]HG8+EO*@:1E5<[@01CD=CTXS;M/%GV
MR>VMTTJ[6::9HR&*JJA55B^21D8?''<$>] &O<R7MM9)]EMTO+@85@\@B!XY
M.<'\JH?VAX@_Z -O_P"# ?\ Q%4+;Q<-2U&QM[6/8'O1%*=RR*\;032*593C
MK&.GIWS2W>N:H^LMIMFUI"?[3^R+)-"TF$^Q^?D@.N3NXZ]*UA4C%6<4_O\
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MY#?/S[C R3B@#3O[K5()E6QTV*ZC*Y+O=>60?3&TU4_M#Q!_T ;?_P & _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI>RFX7OZ#3N@HHHK(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_-&BD*K[C_JG(''WB?XC6GUB?9?^ Q_R"QV&GV=Y:M(;K5)KT,!M$D4:;?\
MOE1^M7JY?Q')J5OK5M>637#16MI+)-;QDE9EW(",=W )9>^5QW-9,=Q?WNF0
MR(EW+<_9K?35,;8E#NBR7#AB1AM@ !)&&4]ZZ%A75BJCDM?E;IY>HN:VAWU%
M97ARXN9]#@6]25+N#,$WFXW,R';N."0=P ;@D<UJUQU(<DG%]"EJ%%%%0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=U&< D D<U/7D3<G)\[NS1!1114 %%%% !1110 4444 %%%% !1110 4444
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M20HSU-6***\5MR=V:!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBL23Q=H4-_?V+WZBZL'A2YCV-E#,5$?;G)=>1G&><4 ;=%<\/&^@->
M/:K=3O(ID162TF9)7C!+I&P7;(PP?E4D\'BFV/CKP]J C:&\F1)&D5'N+2:%
M6,:LTGS.H'RA&SZ8QUH Z.D9E12S$*JC))Z 5S:^/= >&"59;YA</L@5=-N"
M\WRELHHCRR[03N QQUK7U'5;#3-(N-2OI?+LH(]\S%&)5?=0,]^F,T >4Q_$
M+6Y+'6IGN+B+[5"E]I32V9C$<7V@(44LH$G[MHFR,_?/I6SX9\1Z[=_$">RO
M+V8Z>]QJ$<23)%Y;^3*%18BJA@R@G=O/(Z=#79VVKZ#J2GR9[:6."WBFW,N$
M6*7.P@D8P=G0>@K0<V4"K,_V>-<EU<X R1DD'W&>: /,M3\5:BFD^+-1'B7[
M+J=A)=PVVE!8<(D8.Q]K*78D#?G.,'IBJ4GBGQ"CVUE<ZQ<VS_VM<6THEDM8
MKA(TA5U61VC,6226!4<J0,YKU:1=->Y8R"T:=XOFW;2S1^_<K^E5_M&B7VHO
M8[K*>[""9HB%9MN2H;_QTC\* *6O:?KM]=:1)HVKBUMX92UV"H;STV\=O_K<
MYQP*P_%'B;5=!\8,ULL4^GQ:?#)/!+(5^_<>663 /S8(Z\<5U>J:[INBZ;=7
MMU<((;1095C^9ESP!M'<]A5?4->T6R@::^>-)/L+WIA=093"@#,=O?&1QZT
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M/4CJ* )J*CAGAN8_,@ECE3.-R,&'YBI* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KS_6_AS)JFM7&JPWZ6]Q+J<-T2$)WVZI &B;U^>!6![?B:] HH X?
M3/!6HVDVDV=Q?VKZ1I-[+>VP2)A/(S>9M5R3@!?-;D=<#I4,_P .Y+O1;'3)
M[]!'"^HF5T4Y*W7F@8]U\T?7%=]10!P.H>#_ !#JMOHXOKK297TMSL5$FC65
M3$4RQ5L@\@X'''>MG4?#EQJ/A_6M./V&WEU"7>)((B ?E0;I.?F;Y2,^@7TK
MI:* /-?^%87%K?W<]G>6DMK]MAN;6QNXBT2HHFS$V.JAIRR^FT"IM4\%W\7A
MWPEHUI%9Z@=.NRTQNXLP!?)E'*9SM#,H &<<>E>B44 >6I\+-21[%#JUM)#:
M6GV=',&USFU> @D<D;FW<D\ #M71Z)X)BT+Q!9W]I#8)#'I<=E*J0;7WJ6)=
M2/[V[G// KKZ* /,'^%<\\=U%/<V!4QRQQR"W.^?S+A9M\Q/5E"[1C^\3QTK
M=\5>"6UR_2YM/L47_$JNM-/FPY*"51L9".FT@C'HS8KLJ* /,;_X5-*[BTFL
MX[4S!Q9;"D1!MDA8_+T;*DY _B/UJ2\^&E[/)>_9[ZV@@EE@F6$JS^:\; DN
MS989"C@$C(!QVKTJB@#B-3\!RWG@O3=%L[N.RNK)R4F7<X575TD4$\\I(P'O
MCTK(B^%UW;6R;;RQO)8IW$<5["SQ?9_)\F)2,_>1<G/JS=,UZ=10!YL?A2IT
MVXM3?KY\LMB!>JFV<101Q(P#=028RP[ D>E:?A[P9?:/K]IJ#S6*)%9+;3K;
MQ$><54*I /\ J\8)^4\YP1QFNVHH \RN?A/'<1W+%['[3-#>*)C!\PEFN!+&
M^>N44%<]>>.*;J?P^U3S]>U;[3!/<R6\SV4=M"$?SA,L\)/09!0*23D\DGDU
MZ?10!PUSX(N9_!V@:8K64EU87*7MP+R(R13R[7,F0/5Y"<]O>L_1/AC/I.KZ
M9=RWT-U':QP9SN1HVC##" ?P'<>">.>N:])HH X/6_AZVIW.KWL4ULEW>:A;
MW:.T?)CCC1?*9NN"R%N,X.#CBL>T^'-\OB.(".S@LK-;!TN64O(#"[NR0L3E
M0?E4Y[$>F*]4HH \OE^%$@T2QT^VFTY2FGO97#R6Q.UW92;B/'_+3Y0,GT'/
M%%U\+;RYN=0<7UBHF6\\N?R#Y\AGD61?-;/S!"NT8[?E7J%% 'GUOX$U1-:C
MU:ZN-*NIFNIYI8)K=FB02^3\T8)R'7RL GJ&[5G67PJNK*Q2/[38W$T$\+@W
M".\=TL9DXE3IG]X3WY'7T]2HH X?_A!+@>$-"T07D ?3)GD:18R%<&*9, 9X
M_P!:#^%2:+X&DT/2M6M+.>TB:]T^"V0K;@HLJ1,C2,AX;)()!ZXYKM** /+H
M?A3-):317UQ8S>9]L=4,.51YH(HU(& ,JT9.0!UXQ6MX=\(W6F>.;N]F+-I\
M%LK6P.-IN9$19G7G/2%>O=VKNZ* /,KWX6R26\L5K+IH$YOT99K8E8EN90ZR
M(!C]XB@*/YC%7Q\-;=G0W'V2XSJSW\S30AFFC,+HJ,3U(+[N>.M=]10!Q7A7
MP!%H%G=6DS6\EO=Z7;6-PD,>WS'C602.?4MY@YZ\5SUK\)M12"=;S6X[EY["
M6)\QG!N#$\$<O7H(GP1ZC->K44 >?1?#9?[2+7"Z=-9-JD6H.C6^6DVVYB9&
MSP1N.\>Y;O533OAA>6<VFB6_M)4MA9EYS"?/0VZXV1MGA&[_ %;KFO3** /+
MX/ACJ0LH([N[TNYDLXK"&V5[=BC+;/(?GR3RRR$''TJ]XI\&W_B+QMY\<=K%
M9_8;9#=S1[I(V2X:0B(@_*V .>GS>V*]"HH \RM?A6\>^.ZN+:X0W<4KNX8F
M>);CSF613QD@D9YSD^N*DOOA3;WDEY)MT\//_:&UC;@E?/"B+_OC!_/BO2:*
M //!\/;Y-3M[V.]M?-COVN6E=&8^6PB#)M/!W>5UX(X(-4E^%M^VEBR.I6L4
M4<5Q%#$D19423R-J$\%U_<D'=SAL9.*]0HH \RN?A9)?6]U]IDTY7GBO]D,<
M!\JVEG2%4:,'IM\HL3P<L<5M^)_!,OB*XA<W,(C6R6UD21"V_%Q!*3]"(2/^
M!5V5% '&2>"94\)WNDV5S!;3G4GU"PD6/Y+=O.\U!M'8="!ZFL73OA/]D2."
MZO8;VUAN;=H8YXRV((W>1T.>I9Y&/T KTVB@#S:[^&4\LMY)#/8;KJ#4[<M)
M"=T2W,A="I'=<E3[,V.M5=>^&UV-.U&[L!!/?S&[;"(%DE26)4";B1T()P3B
MO4Z* ..\!:9JVEZ;Y-U9P6D#33R2JR@33.S*5DPIVH"-P*X[+TZ5V-%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<_X4 =W17">;\5O^?;P?_P!_;G_"CS?BM_S[>#_^_MS_ (4 =W17">;\5O\
MGV\'_P#?VY_PKN(?-\B/SP@FVC?LSMW8YQGMF@!]%%% !1110 4444 %%%%
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M3V"@D#CMDXZ9-:-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG0B0AHV!\HX?I_#[^E<#!X<2Z\/1VDNAV\L=KJ=M]GEDL%ADEA\R$R.Z$<'
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MI-Q;2"W,!$=N4^W R(TC%\8;Y5*H"<_,W3- '0'P?IYT=M),UR;)@$,99?N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#!5_\ 9T?\++_ZDCQG_P""K_[.NZHH X7_ (67_P!21XS_ /!5_P#9T?\
M"R_^I(\9_P#@J_\ LZ[JB@#A?^%E_P#4D>,__!5_]G1_PLO_ *DCQG_X*O\
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M_4D>,_\ P5?_ &='_"R_^I(\9_\ @J_^SKNJ* .%_P"%E_\ 4D>,_P#P5?\
MV='_  LO_J2/&?\ X*O_ +.NZHH X7_A9?\ U)'C/_P5?_9T?\++_P"I(\9_
M^"K_ .SKNJ* .%_X67_U)'C/_P %7_V='_"R_P#J2/&?_@J_^SKNJ* .%_X6
M7_U)'C/_ ,%7_P!G1_PLO_J2/&?_ (*O_LZ[JB@#A?\ A9?_ %)'C/\ \%7_
M -G1_P ++_ZDCQG_ ."K_P"SKNJ* .%_X67_ -21XS_\%7_V='_"R_\ J2/&
M?_@J_P#LZ[JB@#A?^%E_]21XS_\ !5_]G1_PLO\ ZDCQG_X*O_LZ[JB@#A?^
M%E_]21XS_P#!5_\ 9T?\++_ZDCQG_P""K_[.NZHH X7_ (67_P!21XS_ /!5
M_P#9T?\ "R_^I(\9_P#@J_\ LZ[JB@#A?^%E_P#4D>,__!5_]G1_PLO_ *DC
MQG_X*O\ [.NZHH X7_A9?_4D>,__  5?_9T?\++_ .I(\9_^"K_[.NZHH X7
M_A9?_4D>,_\ P5?_ &='_"R_^I(\9_\ @J_^SKNJ* .%_P"%E_\ 4D>,_P#P
M5?\ V='_  LO_J2/&?\ X*O_ +.NZHH X7_A9?\ U)'C/_P5?_9T?\++_P"I
M(\9_^"K_ .SKNJ* .%_X67_U)'C/_P %7_V='_"R_P#J2/&?_@J_^SKNJ* .
M%_X67_U)'C/_ ,%7_P!G1_PLO_J2/&?_ (*O_LZ[JB@#A?\ A9?_ %)'C/\
M\%7_ -G1_P ++_ZDCQG_ ."K_P"SKNJ* .%_X67_ -21XS_\%7_V='_"R_\
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M.NZHH X7_A9?_4D>,_\ P5?_ &='_"R_^I(\9_\ @J_^SKNJ* .%_P"%E_\
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>bionano-nancyridgeleasee017.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D
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M&%C\\DC8VCUQ7J&GWT&IV$-Y;2+)#*NY64Y% %FBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAYP)&Q^F* .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:EI<:3<P&>,6ZJ'9,DCJ#BM.%8UB B"A.P7I0 ^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXU]K;&F/H@M5GWKS+YH;;C.>@ZXQ79V]O#:6T5O;1)#!$H2..-0JHH&  !T
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M^T9[^+RXTEX)V*2Q.,_X=J]7\,:(GAOPQINC))Y@LX%B,F,;F'4X[9.:UJ*
M.'\$:!J>D^)?&=W?6WE0:AJ(FM7WJ?,3!YP#QU[XKDOACX<U?PN-/M=2^'L(
MO(YGWZU]HMR\:L3SP2QP#C@]*]EHH \(C^%FKP>'=0UBVTM(O%EKKCWMB3(A
M\Z'<N%/S;<'YC@\\>]=#J_@C5/$WB'Q3/>:>;>VU30X88&>1&VW*X8*<'^%@
M.>G'6O5J* /#H/ 'BJ?P2MQJ5H9O$=[K=M=7:F5,K!%\BY.<' R>#_%7N-%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'.F:EXWO?"MO%<FZLXFDDG*CR25V;E!SDD>8N>/6NFH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA<V C1<><<3 2YY^3 QTXXZ"O8** /')O!'B&[OM9FT_0X]!@O=-NX;JUCU
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKU(X[6:9'A+B-$&]&5BK!B6V]>,#WQGLMQXDT^WVDN70Q+,S J-B-R"0Q!/
M)P 3[<BCV%2]D@NC7HJC<:HD%W';+;7$TDD9D3RE!#*,9YSQC(ZXSGC-7JS<
M6DF^HPHK.>YNX]4AA+0-'*S?NE0[T0*?G+9QUP,8_BZTC7ES%K4-I(T;1S!B
M (67: ./G)VL?]D#..>@JO9/\+BN:5%%-<N(V,8!?!VAC@$^YK,8ZBL@:C=0
M0:B\I@N/LD6X/$A12^"2AR6Z87G_ &NG%313WY:YM7:W>YC5'20(RIM;(Y7)
M.05;C//'(K5TFOZ]/\T*YHT5FVUU=W-A<.DD#.CE8IQ&?+D4 ?,%W9ZY'7G&
M>]6[*9KFQMYW #21*Y Z9(S4R@X[A<GHHHJ!A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJO0&DL+4=1+D=M._S#F5C?BFM9YIXD7YX"!)NB*@$C/!(P>/2IO+BQG8F/7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444R*:*=-\,B2)TW(
MP(_2@!]%%% !113)98X(GEED6.-%+.[G 4#DDGL* 'T444 %%%% !14<T\-M
M'YD\L<29QN=@HS]32-=6Z2>6T\0?;NVEQG'K]* ):*@BO;6=@L5S#(QXPD@)
M_P \&E6\M71G2YA94;:Q#@A3Z'WH FHJ&2[MHI$CDN(D>1_+16< LVTMM [G
M:"<>@S38KZSGE6*&Z@DD9"ZHD@)*@X) '8$@9]Z +%%5TO[.3=LNX&V#<V)
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M44 %%%% !113))8X@ID=4W,%7<<9)Z >] #Z*9YT7DB7S4\ML$/N&#GIS3Z
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ML#T%7!P7QIOT=OT8&-_PF'AC_H8](_\  Z+_ .*H_P"$P\,?]#'I'_@=%_\
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M"A;CH?XN@KN:9-,EO \TA(1%+,0"< >PYH YVRN+^PUF_%Y!>36]Q<(EM(S
M\LS9 3>0%51NW *2.H+ Y358M:;6+QK1;HYL\6$B2J((Y=LF?-4L,\[.Q[8Q
MS734QYHHFC621$,C;$#,!N;!.!ZG )_"@#CK;3];N9K>(MJMMIS72&59[H>>
M%$$N\[U8D*9/*X!Z@D8%58]/\175QHYU*&]DEB-E([+,@A3:H\[>N[E]^3D
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M5Y#,P1_)E,:W ;'$AR1'ZL2< GFJ36/BF2XU(FZO$9Y'6,1[0OEF=3&58R$
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MJQ7)VC##:<CD=.33="\0RZE/;VT]N8O-LH[F.21CNGRB%BH"!2 7P<-D$?=
M(- %0^"A]N2X^VAT+NTL4BR!6!N'G& DBC(+D9;<. <#H6GP;=/-?33:JL\M
MP$5&ECES'MD9U(Q*""-V!LV@8Z4YO&<D32>;I@5&:9+8BXR9&CN5MSO^7Y 6
MD4YRW&?3F6T\1ZC=^(;;3OL-K&H^T)='[0S%6C,6"AVC<,2CJ!SGICD T=*T
MFXTZ[N)I+[[2L\<0<O%AS(B!"Q(.,$ '&.N>:+G5-0@N7CB\/WMQ&IPLL<T
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MW6XG&<+MQM95^^#D],<T 16W@ PI<M)JK2SSH'WM  HN"Z/)(5W<J[11Y3/
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M$,>O//%1/&TLD,4R:7\@7=<;IRIC G,)V@IECE2<';QUP>*L:?X@O-2\3V\
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MGKVQCWSFMNLW1=3GU.VEDN+&2T>.38 P?#C:#N7>BL1SCE1R#UZUI4 %%%%
M!1110 4444 %9,OAG1I+*[M(].MK>.[7;.;>)4+C.><#GOU]36C<K(]K*L)0
M2LA";P=N<<9QVKAK/P3?-:F"_6S,+7+S>0KY09MA&,!44?ZP;L8]\DT =A'H
MVEQ10Q1Z;:)' Q>)%@4"-CU*C'!.32KH^F)=)=+IUHMQ&@C240KN50,!0<9
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MSVLSKYGDC='(?F;!(ZDMDD>IKGK;06O_  #!IXTZ*.5+I9Q;W0VH^RX\P_P
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MP^3+IUI)%M"[&A4C .0,8Z9)/XU=HH IW>DZ=?V\=O>6%K<01_<CEA5E7C'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***YJ#QKIOF70O-UM%'?O912['=7*%4+,0N(QYA*C<>W7G
M.EHK+\/:Q_;NC1WQA\B3S)(98MV[9)&[(PS@9Y4]JGU?45TG2+J_:-I1;QE]
MBG!;';- %VBLBRU^*:]:PO(6L[Y9%C$+L&#[D9P58=051^N/NGVRP^*=+D"?
M9;@3,X@<81PH29E"$MMP"=X(!Y/X' !M45CIXIT:19F2[+"+ .(7^8E]@V?+
M\_S_ "_+GGBEG\2Z=#IMGJ"_:9;>\F6&(Q6SELDD E<9 X/:@#7HK!LO%NFW
M,=SYTAMY+>29&1E8[A',8LJ=N&).WA<D%@.I&;-QK]I%I']HP"2X5I5MXXE7
M8[2LXC"$-C:=QP<XQSF@#5HK!3Q3;0O-!J<,EG=Q2K%Y*J9C(60NI38"6&U6
M[ _*>/54\5Z=<3O%;&20(UMB4QLL3K,5"%7Q@_>''_U\ &[16-_PE6BF*23[
M8=D>SGRG^?>VQ2G'S@MP"N1FC4?$$=MX:GURRA-Y;PQO*ZAO+8*@8MPPSN!4
MC:<'- &S166FN6\<\-I>XM[V3&8AF14+$A07 V@M@X!QGH,U5_X3+0!;0W!O
MB(9EWQR&"3!3(&_.WA,LOS=.>M &]16(WBC3S)"8WS 8KB:>20-&84AVA]RL
M,YRZ\$#C)JS#K$<^J06BQ2*MQ;//$\B,C'8ZJX*, 1C>G7KD^G(!I45EKXCT
MAI!&+Z,R%58)@YPTGE#C'_/3Y?K5+3?%]CJ5A!/'\DSF$/"^Y=OF/L!#%<,,
M@C(XR,9% '0T5SUSXQTR VCH99;:X=D\Y8)#P$+[E 7+J0IY7(QSGBM675;*
M$V@,Q<W?^H$2-)O''S?*#A>1R>!D<T 7**Q+?Q7I<]C]L;[7#!Y\D!:6TD7:
M4?8Q/R_*N?XC@>N"" LGBK2TO8;1#<S22W;6>Z*VD94E"N2"V,<;#G&<=3QS
M0!M45CZ?XAM[](0JLL]QYCPQA6<&,.RJ[,!A P&>?7'.*=;^(+1]"LM4N-\*
MW2KMB56D?>1DH%4$L1@]!V)H UJ*R$\3Z-)<6\"7H9[A4:/;&Q7#DA-S8PN2
MI !(Y&.M:] !1110 4444 %%%<POCK2S);LZ7,-K*ETS3302*4,#HC97;G;\
MY.[H ISWP =/15&'6+"?47L(Y]UPN[(V,%)7&X!L;21D9 .1GFJ4GB_0XIY(
M7O2'C9T;]Q(0-C;'.=N,*W#'HN1DC(H VZ*RI?$ND02W,<MX$-LDCR,T;! (
MQE\-C#%1U )(J(>*=,>XLX(C<R/=7#6R[;:3]VX3?\X(RHVD$$]B#TR: -JB
MN:LO&=G?:5;7<,3>=*ULLD#;E,8F<(""5&X [N1P2I'%;%IJUC?J#:7"RY@2
MX&T'_5OG:?QVMQUXH NT5S.@^-;+6["2[$$B+&D3D0?Z3Q(N0O[L$[ACE<<<
M>M:2>(M*=&D2[#1);BY:4(QC6,C<"7Q@9'.,YQVH U**R;KQ#9P:!?ZO%OEC
MLHW>2-E,;@JNXJ0P!4XQU'0@U5M/%^GRV+W-R3 $F>+]WF=6VJ&9E* Y0 \M
MT!!!QB@#H**QYO$^DQ3SP?:&DE@5F98XG;)5!(54@8+;"&V@YQS4J:]8MI%K
MJ;&>."Y"^4C0/YC%N@V %B>O0=!GIS0!IT5BVOB:QGU6]TZ3=%/;S&-<HQ$F
M(ED.#C&[#'Y<YP,U6U'QA:V=I)<6T+W BBN'D1PT+(T47F;2K+D$@CJ.A!YH
M Z.BL?5?$5IHU]:PW@989X)IC*JL^SRRF<A03C#DD] %YJS%K6GS:@;&.X#3
M\C 1MI( 8J'QM+8(. <XYH OT5C7'BC3+)IA>SB(QO(ORJS\(%+L=J\ !P3V
M YS4L_B+2K9[E9KDJ+7'G/Y3E%)*C&X#!/SKP#GF@#4HK,3Q!IKW*VXG<2L,
M[6A=<'9YFTY'#[/FV'YL<XI(O$6F3-&B32F1Y3"(C;R"16 !.Y"NY0 RG) &
M&!SR* -2BLD^)=(43DW9Q"<-^Z?YCOV?)Q\_SX7Y<\D#J:2Q\16EWH;ZM+F"
MV6>6$;@Q)V3-$/EQG+%1A<9R<<F@#7HK&D\5Z+%'$[WA42[R 87RH1@KEQMR
M@4D EL8SS6S0 4444 %%%,ED6&)Y7SM12QP"3@>PY- #Z*Q9?%FBP0+++=NB
MGS,AH) R^7C>67;E0NX$D@8!STITGB.S_MVVTF'=+-+(\;L%8+&5C+GYL;6/
M3(!R,C- &Q167/XCTFVN)H)KL(\.=Y,;;01@D;L;20""0#D#DT3>(M*MYC%)
M=@.'*-MC9@A! )8@84 L!N.!GC- &I162OB;2&>=?M@ @\T.S1LJ@Q<288C!
MVX.<$]#Z5JHP=%=<X89&1B@!:*** "BBLS4?$&EZ3.L-]=>5(RA\>6S *6V@
MD@$ 9P,GN1ZT :=%8[>*=&2".9KLA)-_6%\H$;:Y<;<H W!+8 -17GB_1[.&
M^D,TLK64<LDL<4#DD1D!PO&&()&<'C()P.: -VBL*#Q7I\FJ7%C,7MWC=5C:
M6-U#@Q"7G*@(<;OE)S\IJQ<^(;&VT)M8*W+VB[?N6[[SD@ A2 <<CGTH U:*
MPK;Q7ITNH7MG.YMGMI"H:5656 A24DD@!2%8_*3G"DU.GB;29#$JW$GF2R^2
MD9MY Y?:&QMV[A\I#9(QCGI0!K45E1^)-+FBEDAFEE6,*2([>1F96SM90%RR
MG:V&7(X/-9DWCBQAU!XQ!<36:QVS+<P0R2;VG;";0$P5P0<[L]@": .HHK)E
M\3:/ UP);P)]G#&1FC8+A6"M@XPVUF .,X)P<4[4=?L=-TZ.\G:0"5"\49A?
M>V%W'*[=R@ <D@8[XH U**R;7Q%I\]G#/),L32%59#D[7,/G;<XY^3FH5\5Z
M4RF;SS]F,<;I)Y;[G\QV1=J;<D$KP1G.>/< W**R!XGTAGM46Z9FN=OEA89#
MC<Q5=V%^3+*P^;'*GT-3SZUI]M/<12SLK6R>9,WEL5C'NP& <$'&<XYQ0!H4
M5G2Z[IL-Q]G:X+3>88O+CB=V! 4G(4'  =<MT&X9-0:)XCL];#I'NCN$+[HF
M5NBN4R&( 897G&<'@T ;%%<[#XLB9K:>:SDATZZ>1+>[9P=Q16;)4<J"J,0>
M>@R!FI?^$NTAY+5(7N)C<SB!?+MI#@E&<,1C.TJIPW0_0$@ W:*QH?$^F/\
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M0Q H&?>1O5 [#/0,Q[>E9L7PTTY+#[')JNJ3)';O;6I>2,?9D=@S;-J $G:
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MM]<N_.FN98U:#R)$14.Y=V[@L"5.>XP?3!YJLW@JV:YOKA[R65[H,I\Z*.0
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MX..AXZT <7_:/B+2K2.RAPDHGNM\ER9)(T=60PQAR&9D97)]>" 1C%7=3O\
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M<H<Y[]1@ BJ-QK7BB'3M,</ )KN*69GF@9$20;!'"<*QP<L3T)P<$8Q7>T4
M<1<^(=9.JZE!;9C@CBE*O<P%1&R2QH.0IX968@G=T#8 XJ2RU[6[S6[&+R_(
MM7BA<I=1%))5927;A2 P..,@#'/48[.B@#AM8:X_X2'41;R:A_: >U^PI$TO
MED9&_<!\FWKN)_GBJ]WKNMW;ZDD,EU;P030.LGV;#QJ+G9(,8P1L&[')QR<
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MA<@GGKWZ U5U/7=9N+/4;.V^T0W,%OJ#L\5LVY3'.H@VDC!+1$GC)/6N\HH
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MBI)8<C.05.2,DU#4=6U"QU.W>62&Y41"&W6T8Y4B)O,W=_F9QC/;'4$UW=%
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M(K":18GMR0LJPJZ$8&2"Q(Y/." .,G6DFUE]"\20-.[7EKOCM)XH=C/F!'!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK'J-G+>-9I<(UPNX&,=?
ME"%OR\Q/^^JM5YY>Z!J=VTOD6LCS0RZE&'%RT!#SR))#("/O*JXSZ%>,D8H
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MF0 P$1)'AE(R<%-PQUW'IU(!T=%</8^&]5=K=+D3P6@>#[1 ;YW,C(DHDDW
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MP]\3OXBENO"4.KVUK):M>- EL)]I($SHB.0I(_C!QGM5V72=&M[I+Z6*&*2
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M5VCEC;<&65A(Q!Z$,V&JM?6^A>)1+IURUK>M:R!WB24%X'&0#\IW(>HSP>M
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M:S"$$.J%5)(5<;P ,#@T 9$WC(W,=DVG64Y6:2S\Z639MA$T@7:1NR6QGD9
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MV[@\27DS8NYS?_V=:H4"?OX0@+/C/M@D =<5W^F:;!901.+>-+DQ(LKJ.6(
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MK4E([QQPLLAEVMYC, 4*#^'./NC%:EGHU]96OB6&S$D%S=R226EQ).9%W-&
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M[E8$@X&03C@>E:=% %(:38CR\6X_=SR7"<GB1PP9NO<.WYU#'H-E!-:R6RO
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M9"AM%*E64@LW(9_,;OW;D^M:5% &3_PC6D>;/(;3<9BQ8-(Y4;F#MM!.%W,
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M&D/]C!MW LXXHX56=U&V-@T88!OFVE01NS4O]@:<$54CEB*HZ*T4[HP#.'8
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M>2S2SN[%=V[!8G/7_#I5"]\+Z5J6FZCI\,C+'=2C[0@F=U1MXD;:A;",2<\
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M2)$241H2)%+(V2^T A2.2#GC&2 62>-;:U2X:]LI[<I>O:0@RQ?OBJEBP)<
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MWNX;Y4:6Y@(1)VG=V7;N7;N))_B<$=SUZ5*VF:<+X3M&HN7G-T,N<F01>26
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M,C9DA##:,D[2^<]?D^_Q]VG7?C&UM+J>#^S]0F\EI$+Q(FUF10[ 9<=%.><
M]!D\5-/X.T6YCE2:"X<R[O,=KN7>X90C*6W9*E5 QG'%7'T+3I'=VM\L[2.Q
MWMR74(W?NH H IVWBW2[O6UTJ!V>9CM#@KC=Y?F8QG</E.<[=O;.>*2\\6Z?
M8ZC=V4T<WFVUN]P=C1MN5=N< -N7[X^\%'4YP*N6FD:=9W[RVOF1S;5+Q+</
MM/R[ Q3=MSA<9(_A]J@CT'2)KN>^@\WSI#(C/#=R *Q(#[0&PK909Q@Y'UH
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MY"FVDF&WGK\BCGW^M5H/&<%Y-9QV5A//Y]^;*7;+$?)80F;=E7*L-H'0^O<
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M.UBID*J ^!A2!W"@5H?\)QI1M&GCCN93&)6ECA59&C6-59V)5BI $B?=)/S
M=<XT!X@L6E$2^:7-P;< )U<0^=_Z!^O% ',:=IGB"#6(IGAO5ED>W:>8W"^2
MRK;*L@9=V2Q<8!P><$'&:DTS2/$5L;*6:ZU"21$LFE66[W*7.1<Y&<$8V\=
M>5YS5B_\<(-.GNM.B5S!%=&1)2#MDBA$H&48@@AEZ$]>QK>MM<L[J_\ L,9D
M^T!I59"N-OEE02?8[T(]0PH XR3PYJTNGW:SVUZ]S/HEM%F.[VKYT;R%TP'
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M2ACM 3?GA>HSD],I?#6H';$J7\)BO;^;S1>')$A<Q%3N) ^9<CCD'/?/>T4
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MG3CCUR:Q+31O$5I]NN7B,4FJP&6<VCAI(IA+N53EES\CE"58';$,'.#7H%%
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M-Y.5S)OZ],\<8K$L;7Q$C0K>PZG)9+<2E8X;@)*,K$8RQ:4DH#YV07/5<C'
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M9<SS,$59 L8PJ*Y4[CO8G:"#D98$8Z.B@#S^]T?Q!J-IJ5K-'?'SK>Y67==
M1S.95,/E -\@"!@>%Z@')KHM;@U!;K23IZW,T<4H$L8E*J5RHW.V\,2!N/(8
M'D$9((WJ* .'L;7Q+)?3O<07$4#7%K(L<DX<+B5_-VDNQQMV= H]%'-6?"6G
MZM;ZE<7>IP7:S/8012R7,ZR"2=6D,A3#':F6&!P.> *Z^B@#SZ*V\5'2[PR0
M7Z2EX98K87&26VMO0R>=N"[MOS!AS@[=N0="\@\0FZU/R(KQHI3"P83A6"!T
M\R.+Y]N2@DPV$.3R<\CL:* .-M;;6TN;$W4.IO8B2<I&ETOFQ9D4Q><V_P"<
M!=_&6X/()Q4,EKXE2?3$B@N%$=R'ED6<;3&;DEPR[P/]5@Y*N3G VD9KN**
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M+Q-Y%XSM, Y!)?J0<Y'X=*C/A_3F;=)"TK&83L9'+;G\GR<G)Y^3C]>M:=%
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M569B8YW7?ND:0AL'D;F8X/3)'0D4^UT.SL[I[F)KCSI)1([M<.2Y"E0&R>5
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MWX'NKC1)["&\@MVN?,%P5\UP^Z(1@Y9RPP%'R@@$8!SCD Z]KZT1IE>Z@5H
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M[^:6.[2VBN+-[2?:A9I%*2*H()V_*9-P( /!&<&@#<FO;6W4M-<PQJ&"$O(
M QY Y[G(XJ'3]6L]2\U;>93)%+)$\9(WJ4D:,DC/3*G![USX\+:D;QM0EO+"
M2Z:<R&-[9C#M,*1'C=G(V9SGH2.^:O:;X;73M4CO5DC+*UZ7VQX+_:)UE&3_
M +(7;[^U %E/$FG27ZVBO-\TS6ZS&%A$TJYW('QC(VL/J".O%33:[I,$:22:
MC:A&E$ ;S01O/(7CH<5DQ^&KQ&BMGO(6TV"]DO8T$1$I9F9PA;=C 9\YQD@
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M"4"WB E_U@V#Y_KZTJVMNCHZP1!HP0A"#*@]<>E '/:)X@OM7T.\O)K:* K
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;@7-N!//"$>!RQ\EBKL !]T8Z^X'7BI3XGM9=;L]-M%>;SIGB>81L(U*Q&3
M?&UC]WC/?V--G\)6$Q#>=<*RSS3QM\C>7YIW2* RD8+<\Y(/0BIXO#EG#JJW
MZ2W&4E:=(=X\M9&38S 8SR/?KTQDY (QXILA<WT$D-TCVMTMH (&8S.8Q)A
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M/!D<N6WL3R,;B,9/7-//@ZP*2?Z3>++),TSS(ZJS;D\M@<*!@K@9QG/.<\T
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MBU/V>4F*0;_F(( YQR,XY%7=4N=1U;2?"TL,3K+?3(]Q"EW+:C!M97*ET!8
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M4MS+>/*TJO(Q6*2-5526PN?,)[@8X% %9?!%R(+G?K+2W4RQ*+J2.0R1^6)
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M+$9*AN,;\G@'+9/%FM75E>2I+8V0M[B(.756>W7[2J,)%\PG&S)+$)@ ^H(
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M2+(5B<B0O+%(2=\C'_EECDGKGMBM73]/NM/OI522)K*:2:XDRN'\QV4J!ST
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MSIR+<)<M,\D1^506B@C"-\Z$H?*))![_ '3U !UFFZ3I^F*38PA Z*N=[/\
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ML#NQUQ0!)1110 44U9(W=T5U9D.' .2IQGGTX(-#RQQE0[JI=MJ[CC)]![T
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MBI: "BF2S10*&ED2-2RH"S8!8G 'U)( ^M/H **8DT4KR)'(CM$VR0*P)1L
MX/H<$'Z$4^@ HHILDD<,9>5U1!U9C@"@!U%%-DD2*-I)'5$0%F9C@*!U)/I0
M ZB@'(R.E% !14-Q=VUHJ-<W$4(D<1H9'"[F/11GJ3Z4^6:*! \LB1J65 78
M ;F("CZDD >YH ?114,MY:P31PS7,,<LG"([@,WT!ZT 344UY(XR@=U4NVU
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M,@=?,4?-D#[C8&-N,5&-(\10:1IP22\ENOL ^W;KO,C2F2 R*C%L E%E"D$
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M[" KKT8G)QC/%/T;Q'_:-]+8SVTD4PFNEBDV_NY$AF\LX.2<@%,Y !)..AP
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M)\Q'RAF ]3@X! S0!5\,V>K()UU);Z.)[6%'6YNO,9KCY_-="K':IRF,$=.
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MB@ HHHH CN(O/MI8<[?,0KG'3(Q6)HOAK2;&VM3"S74MMLQ<-.[G<B-&.K'
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MER9]LLI,2;&(W-LR^1M!V_+G 4XHU6T\3Z@^H0_9;@13:=- R^:#'*S6XVD
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M3LC3(4E*7,7^J&[@>62 #CJ.^XU8O?\ A*9T@:"TO8W-W+*I,RY1/-7:K*'
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M0<CG&"%R,D<$9P>*S9AKUYXF@N4%Y:V&V(I%L4XPS>8K@2  D;>2&P,8P<T
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M.J&,N/,8LNX-U+'I6GX936[/2;J;4OM5S<B)6%O* "90IW!6\QL[CC^ZH[
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M.BN:\'V^LPVDIUB:X>9DCW),H^60 [RI\QL@G' VJ,<#DUTM !1110 4444
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MV966-9AO49QDD'@GCJ>>3ZU43PKI4>GRV*0R+;RI'&565@0L9R@!!R,=L>U
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MU")HVV:@"+@;C\W[L1\>GRJ!Q5?5O#NG:U;16]XDNR)&C7RY"AV,NUER/44
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M#:16>0YR(XPP0 ^HWMSUJD?!VAJB+;V2VNR-(U:V/EGY&5D.1U(*C!/J?4T
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M*.\,5XEML\O"L;C, EY^YL S[=><5:O[+Q0PO9K>\U!9/*OWAC5DV[U<?9E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV;#&4!C!;C/SCYLD=.QXU?$/B4Z)?65NB12F9XQ(C%@P5Y5CR#C Y;OUQCW
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MY6A+?NI/(>4$$C!X0<>^?:@#KJ*Y+5/%$NA^$=/OSY<]S)9B8I*6!DVQ;VY
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MYB2&^;.3DYYR>:N_:(=C/YT>U/O'<,#ZUQUEX*N;5M/1YK206Z6>ZX*GS8S
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M4[*6>TFBDMHYF1V*[5#AN>H'?G/?((SG-/L;JRO[2.]M@GER E6*@'YCS^9
M^M<NO@>>RVQVMVEY:1R03"VOT7:[1QM%AMB@8V>61P3F,?@6G@::W6PB^VQQ
MP16HCG6%"NZ5%=8W49X \TGZHGI0!U*P::@298K11;Y1'"J/*]0#VILC:7IL
M5Q<.+6W2$&XF<!5V\'+G\,\URT/@N[B$,WEZ8&A: ?8U0BWF$<<J;FXX8^:#
MT./+49/4)?>";S4+O47FGLEBN;&XM(Q'" %\Q$"Y4 <*4SR23QTQ0!ULMO97
M2V\+",^6RS0JC8(*G@C';MZ8..]5)#H2:I_9+P6@N[J(SF$P#]XH/4G&.N<
M\G!(Z&LJV\*RIXF359EM]N4D"1R,/L[+%Y>Q!M^9.IY(^\W%2W7AB[N->.LC
M4G6=+N*2&':OEB)%*%2=N[)5YCP<9<<<4 :?G:7!K<2AD%W/;%4(/RB.-ERH
M[ YE7Z\>@I1+I#W<ENR6ZW$_F!DDB"M*%VASR/F'*\]#Q7+7?@%WT?3;&W33
MMT&G3V<SR0GAY1$#,F/XAY9/."<]15^3PE*=0^U*UM(S&[4F13N59MA!!QU!
M3V^\>?4 W?LFFM<V<JB$/;%_LZHP 4D88@#C.,CVR?6ELYM+>R#6;6OV:9R!
MY>T*['@_4USDW@V<3Z0EL]G#:6*VV52(*VZ-]SD$+DAAQU&.>#NXK3>!KAM.
M6S0:=L$%S:@M&<(LK B91C_6 #&._'S#% '8QI8VH"QK;PB/H%"KMSQ^&<8_
M"J=Q+I5IJ6GV#6L7VF0226ZK$O[L+C<W^R,L.GK]:Q;[P<\EC="V^RB^FOFN
MDN9%Y0E2JEA@A\!C\K#!!/3K6EK6@R:E?)>0O;I<1V%S:QO+"'VO+Y>UL'@@
M;&R/]KZT 7+S4M/L+%I)>;81/(3'&63:N-W(X[]._/H:F#:?;W4-B/L\<[(9
M(H0 "53"Y ]L@?C7)1>"+P6EQ&]U IFCNE"J"0GF^3CL,X,39X&<]*U]?\./
MK%\EQ$\,3&PNK)I2O[R/S0NUT/JI4\9'WCSZ@&Q!;V(5GMX;<*SEV:-5Y;H3
MQWZTDOV"6R"2_9GM6PH5]I0XZ#T[?I6-I^@75K8:LJ_8;2>^CVQQ6\6Z"(B/
M8&*D#=GJ1CH .<9KDM5\(:K!$B+:K>QRO<2O#"$*DLD"B,DJ-N[RW^<*,9[9
MY /1GCT_S3.Z6WF1IL,C!<JIXQGL.M.\BS%VK^5 +D)A6VC?L]!WQ7+WG@PS
M6Y:$6PG;4I+V12-HF5E=0C-@_=#Y!P>GOD.T[P<;#7;>\W))#"L7EYE;?"4@
M\K:./F7J>2/O'@T =(MG81HD:V]LJQL=BA% 4D<X'8D$T;+ ,UUMM@RKY;2X
M7(7^Z3Z>U<]J/AW4)M5N+F*6 VKW+7NS!\PO]D-OL';'1L_ACO69IO@R^BL[
M.>2#34EB%N6L=A$,GEQ2(2_!^<F7/0X\M1SU !V<EK8R7%NSI%YL3;X1G!!"
ME<@=\*S?3-/DALWN<RQP-.T97+*"Q3N/7%<M9^"/LIMI#+;R3VXLU2;R\,HA
M9BRKW (; &>G!JUJ?AR]O_%-KJ0N+=;>!@RC8 _^KD0C(&3G?G);C&,<YH W
M98["XB<S);21APS%PI&X8 )SWZ?I56._TF>WMM48P(+H"**650K,&Z+D\\^E
M<Y%X&>S@LUMEL&6WCM0]M)'B*=XDE1F8 =_,5@<'E!FM#_A%Y$\+Z1IG^B33
M:=)%( Z8C;8>0!R5X)QUH V(HM+EMXHQ;6ZQ1R,(HY(0FUU8@E5(]0<$=>HJ
M:1+*=H)I5MY&!_<NP4G)_NG\.U<K<>!5NO-^T&UF+,Y0R1[MH:[:<]?]DA?J
M*9<>!G>XA*O"]NLEQ^XW&,1K)-YH*$ X(Z8&.@Y&* .H@GL-4C,X2.01O+!F
M1!E2KM&XY[$H1[XJ=X[5I#&Z0F20$E6 RPQ@\=^,"N4;PM<IK.G%7#6[W-S/
M>E1PZ?:&N(%/NKO^(+U<U3P[>WWBBUU-9X!;VY5U78!)PDBD9QDYWCDM@8(Q
MSF@#==;&5Q<.+=WCX$AVDK_%C/;H#4<MGI\UWYTR1/+/#Y)#'(D0'<!MZ-@D
MGVR?6N"L/!VIV^DZ4S6&G^<!9)+:!,1_NDD+/)_M$R8.,XV@\UIP>"+F!K53
M-:.JBV+2E"'M_*F:7;#Z*=VT<C '?I0!UMM)9M%$852,%=D:,FQMO/ 4@$#@
M\>U5K>#2+N""XM5MS!:S,\9APJ*X#(<XXXRW7ZU@Q>"2CQRR26[SQ"S$<A3Y
MD$-R\SX/4;E8+^'-7K;P_<VGAB]TJW-G%))-*\3K&"I5G+#<I& <';T., \]
M* -34=0TW3-.EU2^DC2U3:SS;=_<!3P"3R1BF1G1YOML:):%=Z_:<Q@*S, R
M[CC#9# YYZUEV?AF>#PHND231&3[;]I) RH7[3YVWH.W'0?2LIO 5Q'')%'=
M136Z7WGP6\N5 A\GREC)PWW<X!P> !U.: .R>"RX+Q0?("HRH^4'DCVSU-10
M2:9?"&_A-K-YT8,4X"DLA!(P>N,9_6L"#PI<P:C;A9;<Z='<)<.C[GD)6U^S
M[.>", -D\GD8[U%8>#)K335C_P! 6\ATA=.@E$(=58;P7PP_B# D<]^O< Z*
M6;3;BZM;"2.&8R1//""@9 L9121V!'F+^M-%YI-W?WFEDPR3P*LEQ"T? ##@
MG(P>!^ (SU%9/A_PQ<Z3?PW4TT1"+=#RTYQYSPL #@=/*;/ SGI5.[\%7MQ]
MLG752;F]2\BF5T7RPDRX4+A=V5V0CDGA3C&: .C6?2[B[ETS9 SI#&6C*#:R
M$N% ['!1^.U$=SI5\?LQ$#,JK<&&6/#*&)PQ5AD9*MS6%>^#O,UN*XM(K""U
M5;101%B2'R)FE(CP,8;=M/3N>>E0?\(/)]GE@8V<@GL(K21V0[@4D=^..0P?
M!_W1U[ '3S#2_*E>9;0IY&9"P4@Q#GG_ &?TJ6WDLRD+6[0;9$ BV8&Y!T ]
MA7,WW@^>]UQ[CS+2.QV/''&D(!5&@,6T@+SAOFR3TP,#',:>#[HS6C.+! BV
M@9T4EX3!(7Q%P.'Z'IC)^]F@#K1';2NSA(G8,"6 !.1T_$9_6J+ZII"31Q&2
M!FDGDMC@ A7VM(X;TR$)/J:KZ'I<VAV]II\-O;^1LD>YG0;2TA8;>.I)RV2?
M051_X1!)-1WSP64EJ-3>^*F/)D#0NF&!&,AGR#S^% '1""SC@%D(H%B*G$ 4
M!2O?Y?2B..S\L^6D'EH%4[0,*%Y ]L=1Z5R%AX'GM+NTEGGCN##;0Q^:796C
M>.'ROE&.5/)Y(^\W!S6OX>\-1Z&DD06W\F2SMX'CCCPK/&K!F([[LC\J +5E
M?:+<7"I9_9B9XDNE>- !(&+;6![G()]:T46 XC01GR2,*,?)QQQVXKCK7P*T
M=A9Q2BR$]I9VUM%(D?W3%+O+CC(+  GW[GK6CX>\,OHVIW5U*R2M(9=LP<[G
M#R%_F7&,CIG)[],XH N6FJZ'JC36<.Q@J%626W9%=$8J<;E 90V1QD GWJ^(
M+ R1$16Q>!,Q$*N8U]5]!]*YQ?!%M_9;6\I6:XDNDED>9V=#$+H3F,*Q(4$#
M!  !.,U%)X*WZEJ4SI!-#<K)Y8,K1D*\8C,9"C[N!P<\#'&1F@#IE>PVS0*D
M0B9/-D/EXC8.2"2<;23@Y_7K3;&YT^[@BFMA$%:1UC!4*2R90X'L%(^E<T?"
M%^T*/-/:3RHL'[F1,1R>7-*^UL* >)%^;;RRYQVJ&T\"S6]W82R/;2QP! 8T
M+1+$4N'F!C !_O@8R/N#DT =7YVF:7;NRM:VT/F*&V[5&]R ,X[DD5;:6- I
M>15#$!23C)/85QA\";+'RHA9&3RX]X:/"RR)<><"W'<97/)^8UH^)/#D^M>2
M8Q9D"TFM6CN%++'YFS]XF!]Y=G3C(/4=P#9M-3MKV^O;2 LSV;K',V/E#%0V
MT'N0"/S^M0V_B#2[J'SH+M7C^U?8\A6_UN<;>GZ]""#G!JK::'-IMOK1LI84
MN[Z0R13,G*MY*("_K\REOQK,L_!<NFRQQV^HO-:+):R[;A5W!H1MXV* <H$'
M//R]30!NZ7KVG:P[K93.[*@DP\+QY0D@,NX#<I(/(R.*@;Q3I*QS2^;.8HF"
M&1;65D=BXCPC!<.=Q ^7-5/#/A=_#TNX3B426L<4NYF8AT+'*EB<*0Q^7H",
M@<FJZ>&=1/A^/09;BV^PV[P^3*A=962.9' ./NMM4C(/).>.E &JGB;2Y&ME
MBDGD>Y\SRTCM968;&"/N 7*;6(!W8P:UZX^#PE=65[ILL+P3161N542321L5
MDE2122N=[#:0=WWCR>2:["@ HHHH **** (YY&BMY)$3>RJ6"[@-Q Z9/2N)
MG\7ZBKPWJ6T)C@L;J:]M&E9"AB>+(&4R7 8@= <YSC%=RZJZ,K@%2,$$<$53
M-GIUE9.%LX$MXHW!CB@!^0\LH51SG'0#F@#F-3\73-=7=C;*B;#F.XC+'[EQ
M'$ZG<@!.7(^4D#!%:%OK<]OX;DO)G66<W\]O&)-WS8N71% 123@ #IVY(ZU>
M>30X;MV\JU^T33BWE98@6,A42 .<9S@*>?:KTUG:36KV\UM ]NQ+-&Z H3G.
M2#QUY^M '*6_CF:Y-FZ6$ AEALI)0;D^8#<3-$ B[?F"E<Y)&1VI(/'%Q+'$
M386P>Y6,V^VZ+*I:81?O#L^7DYXSG!'45T::+ID>IB_%I!]I6)(D.P?NU4N1
MM_N_?;I266AZ3963V<%G;F&0;90R*QEQ_?X^;KWH Y__ (2^Z)+):*TP9;?R
M?/'E&0W?V?<&V;L=_IQC/-6]+\0:CJ.N6ML]O;16[0W/G 2EF$D,_E';\HRN
M1GG'7VYWEM+)(U5+>W5(PH4!  @4Y 'I@X(IJQZ>U\$6.V-W;J90 J[XQ(6R
MP[C<5;GO@T 8TGBB2#4I[2XM$C*74,,8,ART;OL$F=NW&>P)(/!Q4%MXKGU-
MI4M8+>-(X#*\CW')!DEC78-IW?ZHGG'W@*WVTW376<-96C+=$&;,2D3'MNX^
M;\:C2VTF9O,CMK21K-F0%(E8Q$\L!@9!.>0.N: ,KPWK=]?:6T=_#&EW#903
M^9')O#B1"03E1@Y4Y'3I7.Z=XWU.UM;9-3 N+N/3A/(JH$$_F20+#)P#@?O&
M#8'56XX%>@6ZVYB62&)461% _=[#MQP"" 1@'H>E1-%8-)Y#6T1_<%.8<KY>
M0"N<8QT^7/X4 <_+XQFM;222\TX02I;2S['EQOV2! !D9YW \C(SCWI;7Q#J
MSW"6[6EG))-J<UHA$[*$C0.V3\IYPN,=\]JU[FUT6T2R@FLK14\SRK9!;J0C
M,"3M 'RYP:F7^S8X6U/RH80Z?:'FDB\ML;?O-D @A>.>0.* .9B\73:E?1V\
M"I&BW-JPEB+%9HI3*,?.BG_EGG(X.1@U-JWB6XL_%]I:QM)_9\+QPWA%NS*7
MFR$S(!A"I\LX)&1+["M^VMM,CEE%M:01G*S.Z0!58G)#;L88]>^1GWJTT%NP
MD5HHB)3N<%1\YP!D^IP!^0H XNX\5ZL#97RVUG'"]O>R^1)=E0ZQ%,$MLX;[
MW XP<YXJU;^)+^XUR&&&-/LLD\BN+A\.H$,4@"@+_MG@DG/?TZ6?3K"X2.*>
MSMI$0Y1)(E(!SG@$>H!ITEI9R$/);P,5?S0S(#A\8W?7'&: .67QI<K:://<
M65NKWXMW:&.9W:*.9U1"3Y>WJW<C."!ZU''XOU.+3]\]I8O<@7TQ_P!)*((K
M>0(1G:?F.X>V 2?2NK?3["22!GL[9G@&(2T2DQ@8^[QQT'3TJC)_8$LL,+6]
ME*T]U(5_<JP\] =Y)QPPVGD\\4 )I6L7>JOJ#)9QQPV[B.'?*=\C;%?YAMPH
M^<#J>AKG8_B$+^*>.VL71_LQG1_,&0@A=G894C*2*(R"#R1]*[A4CC9MBJK.
M=S8&"QZ9/Z5E"^T--5.F!(5N\M#M^SD*2X\QDW[=I)'S%<Y/7% &"VO:W-<2
M1Q+:_N]5@MH@92"Z-;+(0_R^K9R![=LU+#XMO+B:'R+-3-<Q6N(9)\1QO(TX
M8@A-QQY7?KQPO.>I%I9"8W M[?S3M!D"#<=N0.?;)QZ9J&!M-EDB^SQPON#%
M'CBRH\ML$;@, @L<#.>6QWH PM1UC4+_ ,,:5=606VFO;J"*4"7[@+X8*VT]
MQC.!P>U8]UXBUL&YO+5XS%:V4DJI/+@,WGO'E@J#( 7CI[YZUWPAM_+C01Q;
M%(9%"C /7(J'R]/>::S\NV:3RAYL6U<^6Y;J/0D/]>: .<N?&5S:76I*^DM)
M;Z<C_:)(G)PRVXF.,J 0<A1SG)!QBD;Q9JHMUQH\(G8RE?,N&1&1(UDW [,\
MY*\@=,UTB:=IZ3)<I9VJRI'Y:RK$H8)C&T''3':B#3].M8A';V=K#'DD+'$J
MC+#!X [B@#.GU*6XO] 6!FBBO \[C^\HBR$/XL#_ ,!K)6]URXT>0QWYDFM]
M2FCGDA$,;M"H? 3S 5'.WKS@'GO74S65M/+:LR -:/YD.TXVG:R=/3#$8_PJ
MF=)T-%2U_LJR\N5O,"K:*4)7N<# //&??% %31-7:_U*4I)-):3:;:7T7FJ
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M:V4;,JVRNT:@E3\H0''0],4 5+W5=1M-.L'^Q6S7MW.L/E?:&$:;@QSNVY.
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MXO*Y^\(P[@X!(VD[3@$Y5N.*RV\<77D-MT^V$\?VHR":X:)<0JC'&4SDA^A
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M:XM[:XF-Q'%##!.TB+FW,N 5CW$D@#ICYLYKMAI]DMQ]H%I!Y^T+YOEC?@#
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M<7S+]@A\XW9$T6[S)O.G$JB3Y?X ,=3U[=^ZHH Y.#P>BWT;2VM@;:/4Y;[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTMD\^)]ZDN20?IFMA1@<4BAU%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!G1?\C%>?\ 7K!_Z%+7+:^ZW/B*^T]8
MB)[J*UMU;'\&YW=OP4'\<5T5Y=#3=9>YG1_LTT"1F502$96<\^@._K[5 =6T
M)KT7C31_:!'Y8<@Y"YS@>G]:=F3>QR_ARPNKSQ/!XC3;(D\!>5_,QC>20N?X
MMJE>.V*]&'2L:+7-'A0)%<1H@Z*JX'\JUXG22-70Y5AD&EJ.X^BBB@84444
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MDGF/S/@Y.3G ]!GG KHHV#H&4Y!Y!I6'<=1110,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"O?6SWEA<6T=Q+;/-&R+/"0'C)&-RY[
MCJ*XS_A7NJ?]% \3?]_8_P#XFNXEEC@B>6618XT4LSN<!0.I)["L[_A)=!_Z
M#>F_^!<?^- ',?\ "O=4_P"B@>)O^_L?_P 31_PKW5/^B@>)O^_L?_Q-=/\
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M&[E3R0HSG(Y/%:.GV$&EV$-E;*1#$N%W')/<DGU)R: ,'_A7/@O_ *%;2?\
MP%3_  H_X5SX+_Z%;2?_  %3_"NGHH YC_A7/@O_ *%;2?\ P%3_  H_X5SX
M+_Z%;2?_  %3_"NGHH YC_A7/@O_ *%;2?\ P%3_  KI8XTAB2*-0B( JJ!@
M #H*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112,P
M52S$!0,DD\"@!:*** "BD!#*&4@@C(([TM !136D171&=0SYVJ3RV.>/6G4
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M/L/LC-'>%U\_> %959L8ZGA3Z=1U[-TS5C?3:E'-;&U:RNOL^'D!WYC1PW'
MR''&3TH X=WUC0-+MT2!XI0$M2P55W-]I?<L;%6*H5Y48.U2._-6M)CUF>:#
M58+^ZN#)#812R+$H2?\ >2+,2"@/RAB>,=C6G>>+%:&<3:2DUJZ3M;[Y<B7R
M95C;>NT[1EMP/S< YP>*W=.U!;S2([B 6;N4;9';7&^,E21M#[1Z8/'!R.U
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MNQW'J/>I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF;?D%5 X;YAQU]N*?9>'[:SO%O3-<3W>Z1WFE*YD9U122% '"QH!@#@5K44
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M;Q!_T4+7/^_4/_Q-'_"#>(/^BA:Y_P!^H?\ XFNYHH X;_A!O$'_ $4+7/\
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M_"#>(/\ HH6N?]^H?_B:[FB@#AO^$&\0?]%"US_OU#_\31_P@WB#_HH6N?\
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M_P#B:[FB@#AO^$&\0?\ 10M<_P"_4/\ \31_P@WB#_HH6N?]^H?_ (FNYHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>bionano-nancyridgeleasee018.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD<@CFLQO&6@J8C_:-OY+3RV[S-*JI&\>=P8DC'W3CU^E &5#XCU66XL+=Y;
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M"6.>,&? 5"XW;BN_;C/W@O./3FA=7TUKN6U74+0W$*EY(A,N]%'4D9R ,C-
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MNW7*@L?E^;KWJG>^,[ZUU+4[. 6UPUI9SRC='L*RQ^6,-B0L5.\\[5Z<$]:
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MUWJUC=#4G2VM/)*VNUMNZ,DY&&"\Y Y4D;1@BI[?P\D&FZ'9&?>-*9&#%/\
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M<6=Q+)>M'#:3;C)$!9JZR?>XCWKM(QU<_-GB@#2'A#R88Q;7VV6**S1'DAW
MM [ON8!AG=O.>1ZU=L/#R6.H0W8N-QC-X=NS&?M$RRGG/\.W'O[54LO%#7OA
M:^U[RQ!:J&:WWQDL%50&+KD='WCJ!@#D=:N>%]7FUO1_M<XB\Q9Y8MT6-K!7
M(!&&8<@#HQ'O0!LT444 %%%% !1110 C,%4LQ  &23VJE!K6E7,R0V^IV4LK
MLRJD<ZLS$#)  /) Y-6KB+S[:6'=M\Q"N<9QD8KG+?P<EL8&CNE5HOLN&6
M_N49!W[[OP]Z -F+6+"X\G[+=0W*RS&$-!*KA6"%R#@^B].OX4@UO2#;-<C5
M+(P!_+,HN$VA\9VYSC..U<HO@R^2>VBGO9+L33,]S<KE#&HM98<C<['<3("
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M9RPQ7-W!!).VV))9 ID/HH)Y/(Z>M9D/BO29;'4[]KA8[+3I'CGN&=2N5X;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8L'FD*.Q;?N8#C/U7ISNLZIXIU.#4[W2;::V>YBM91O6VP4F6$2!@IE)*G/
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M8875G1I&"J67.0/F&3[U8_MS2/,A3^U+'?-&98E^T)ET&<LO/(X/(]* .?\
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MLRW%H@SOMR)-W..,<'GBHK;Q!IERB%KE+>5YF@$-R1')YBG!4*>IY'3/4>M
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MP\[Q*X.X#/R$X56Z<[<@T'Q1JJW6@7EQY"17]O,7";A# IDMPKR<Y)&YAD8
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M)0 /850L/$^H6.EG[=- V^/S()F5F()N/*"OE@#G<N#E0.YP,T =#)H[V_\
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M86/R"U2WP2KJ2?DW=<'."#71:OJM[8ZKI BN;<VT\4S2IY>3.RJI54.[@GG
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M4=H79LL >AW?@0#STIUQX1N[W4UN+F_@\D(RB** J%#0&(@+NQC)+9.3R!G
MH W8M7TUX7G2YA6V$:2F<L!&0Y(!W=.H-3FZL3+#"T]OYD@S"A=<L,=5'?C/
M2N<_X12\\ZUNQ=6IN;9;<+&83Y3&-9DY&<\B;(]"H/-):^"5M5C_ -)C:1!9
MX?R<8\B9I6"\\*=Y4#L/6@#I9;BSCN(X)IH%F?+1QNP#-ZD \FLW2?$6G:Q<
M*+16_?+*T4IVD2K&RJQ!4D]67@X.#TJMJ/AJ6]UEKL7,*P2R6TL@:(F13 ^\
M!&S@ G@\<9;UX-.T&;3]0TI1M:WLK>X#2 !=SR.A QUX ;/X4 6F\2:)'*JB
M\MSNN6MW<,H6.159B')Z?</XXK1,]H;E+<RP&X*EUB+#<5[D#KCWK"'A7=?"
M2:2WD@2_EO$0P\GS(W0@Y.."^0?2JVD>"SIFI6MS+<K<B%8CEC(K*Z6X@RH#
M[<$ GD$_,WJ, &[%K%E<7MU:KYA-ME)I6B(B4X4E=Y&,X9?\@X+K5].L[V&U
MN)XHVE#D,S*%!7:""2>"=Z\=ZQM4\*7&I7]_<+=6UJ+FVDA)AA8-*2 $,HW8
M;;C@X!YQD#@UKKP=J%V\UQ)>6#7$S7!</:LR*)8XT^4;\Y CZ]\D<9H Z>6_
MTVV9XI;NTB:-<LCR*I5>!R,\#D?I507^CZ;J$T;S1V]S>W00F1L>=+Y2GC)_
MN*H[#CU/.7_PA4'VCS6DBD/VAI=TD09B#:B#!/<\;L_A3K7PG-:26<JW<4CV
M]Y%<'?$3N"VHMV'7@G&X'Z#WH V+;6-(O;2*X@OK62"=O*C;>,.W]T9ZGVI3
MJ>GG5H]*5XWNO*=]BD'RU7:"&],[QCUYKFY/ SRQ6D4MQ#)% DT!CQ)&&CD=
M6S\CCYAMP>QXZ8K0TSPS-8:^+]KBW>%#=E L!$I\^593N;/(4C XZ8H N37^
MD:A%;+,=ZR7C(BD,N)H"S$M[*8B<GC@>HJ<ZQISSVR+/%*LR22QS(RM&!'@,
M=V<#[P_6LR7PO*=5U2]@OA%]J@D6W0Q!A;RR*JO)@G#9\M#C'7?_ 'JSU\#S
MM:WD4NH('N4N5R$9MIF2)<_,Q)P8\]><]J .KGN;&%"+B>W1"PB/F.H&[&0O
M/?GI[T]+BWDG>".:)I8<;XU8%DSTR.U<C>>"KK4)9;F[N[>66:65I(E66.,I
M)%%&1\KAB0(O7!#'@=M:RT2\T_4[NYMKJ!()V0^04=A]X;VY;ABHQQQGYB#T
MH LW>M6=GJ\%C+;W37,X_=LELS*0.OS 8XSS]:?8ZSI>I::M_%<0B 1AV\QE
M!B##.&Y^7CUJ2YT\W&L6%\) HM5E4IC[V\+W[8Q7-'P)ML(((KN-'B@MH_E1
MD$CPR,^6VL#R6/0Y!YYH ZN2>R2V:\EE@6!D!,S, I4]/FZ8YJM::MIU_:V[
M)+$JW.Y8HI" 7VD@X7OT[50E\.,-#L+*U>".2SN%N%5U>2-FR20=S%B/F)'/
M! /;%9EGX%-K=64LEQ%,D*1*Z 21*#',\JE%5\=7Z-D#:.O(H Z?^T;/SECC
MFCD8R&%O+8-L8*6PV.G"FFIJ.GN=Z30M$8VF,ZL#'M!P3NZ?_JK!A\(SKIMC
M8S3V<D5DS!#]G8&9#!+%^\.[DGS<G&.A]>(V\'7DEK$LNI))-$HV;XRR_+<)
M,JMDY9<(%))R>M '2_;].'DS?:[4>=A8G\Q?WF3P%/?\*DFN+2U=?/F@A>9@
MB[V"F0]@,]3[5RS^"#-!<>;<P>?/!=)E8/EC>:17R@SP!M_$\\5>\1>&YM;E
M=HKB&-9K.2RE\V(N41R"63D8;CO['MR 6K?7M+D34RKI';:8QCGF)78"!E@
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ML$CV[F1G8L?KO/Z^M94G@9Y8K6*6XADB@2> QXDC#12.K9.QQ\PVX/8\=,4
M=7'/933RV\<MN\V,RQJREL9Q\P^H(YJE-X@TZW1S+YHC2\6S#+$6#2L5';.
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M-JT%M<0111Z/)<PCD2>:-PR#[8':H[[QAJEE+)9"PMI;V*:6-F$NV)MD44@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI,,Q:Z0NO3@LF-P!]1D?KC.#@ UZ*Q;KQ3IME=75M<&=)+>/S"/*)++N525
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M\PC_ %S!G.1T.0"/2N9N9O&%U:6URWVBP-SYS/%'$)6MG C6($#.5)$K^GS
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MQ&TRS@8)!\[WX/'3.5M$U6U\!:1"OV\7,:P1WA*@W"J"!)MR.>_(R=O(R<4
M:]]HVG7>IM-<S2++=V_V:2 2[5N(UWG:5[X\QNGK44GANP>RBL+BYN9(?,#A
M))N7Q@@'CG&T'/7WZUF:'IVIR:];:EJ1N28[2:-#+M!VF=O+W #AS'L)]Q5(
M:-JDMTD?GZE&\6IW<OG97Y49)-FPD$8.Y1]>* .@?PK8/<277F72W;RK*+A9
M<.A"LH /3&UW'(/!]AB[IVCV.DDBSC* Q1PX+$_*F=O7O\QR>]<YI4GB:;7[
M9M1DFAAV1LT0@S&ZFW&\$CA6\XMWS@ #@TKZ5?6NK>)M8ALXI)G?_1=L %PX
M^SQ+\DISA=P88VGD&@#:F\.:?+##$#+$T4\MQ&\;X96D9F?KU!+G@^WH*E&A
M6(N!.4<R?:?M.2YYD\GR,_\ ?''UYKDT3Q/+:Q.%N%N%BNHTG,2^8JF>#R_O
M#/W YP1SMY&16EXLT:^O+?1Q8>9-<6$[7$<KMSO2)]FX^C-A3[,: -J'1+2'
M2[/3LRO!9M&T.]\L-A!0$]P, ?04MEI-AI/ER0@QB.W2U4N_ 12=HY[Y8UQT
M-KK5M<:GJALKQ+C5([5Y!&WS0_//\IP&)*(8E(7OSG&34DEGXFU'0F:[:<W?
MV*QVP.JB,S[@TK,%&200,X.!SB@#I/\ A%=,-M);L)FB>"XM]K2'Y8YBI=1[
M948]*LVFC6MCJ$]W TJ&9F=HM_R;VQN8#U./7')]:YB)O$\FH::LLMW!$(XO
M-)A$@:82MYX;:,!2H7:3@8.1S5RPT>[N?!5YIDTET+T33&*2ZY*R+(6B<'NH
M(1A0!>_X1#2?M=Q<%)B\Q<L/,.!OD61L?5T!_3IQ4LOAS2;Q95=&<,9P^V0\
M&4AGY'0Y4$>E<O?MXC70IM0L["\@U747EG,:$$PLJ!88V&#G(4'J%!+9ZBK%
M_P#V_IO]J/8VMTWV@7WDB% Q\]EB\EN>@XDY/'KVH VYO".FSPLDDEV9)'=Y
M9Q.1)+O0(P8CL551QC&T8JU'X?T^.176-LK.+@9<_?\ (\C\MG'UYK+TTZZW
MBNY^V32K:*[A(O)S&T>%V$/T!SG/.>3QC&,^^D\4;]3^R&]%R([S:I1/)"[3
M]F,9QR_W<]>=V?X: -RZ\-Q2Z%9:3!=3Q0VDL+I(7)<+&P( ;Z#&?SS3%\':
M2EQ;SA9_,A*-DRD[V61I0S>IWNS'UW<]!ANLV\]K#HKHMW>BTO1)*X7?(5\N
M1<D #/+#H*RF?Q)/J.IL;JZM8RDOD*MH9%"%1Y;+_M Y)&<YR,=* -*'P9IX
MM;B*<N6EU"6_W1$KM9]RX'7C8Q'U)(QQBQ!X3TRWN(I8_M&(O+(B,S%"R1B-
M&*^H4?GSV&,-KGQ05B>U@NO/>PE5(9?N12@2%)&8J VXB,;3M9<@G^*IK2/7
M+F[MXUN=3CTXW@)DG1%F,8@8L&^7A?,"]L]<<8H V=.\.Z;830W%@\JJD:1[
M5DRC[$$:D^I"@#\!GI4MWH-E=22RN98YY)DF$L<A5D=%V@K_ ,!R,=P35"*"
M[T_Q-:VMHEP=+\@J8P"(X3\[%RQ!WY)48R".#R":IWL>K133WTLDTD<6HET2
M1$*10+"V&48S]X]<Y[=* -W3]'L-(EW6P*221K#EY"2^UG?//5B9')/?-(FA
M6:7WVL>;O^TF[52YVK(8VC) ]U8\>M<-H1U3Q%'I[3ZA>>?#>++,8G1C C6C
M@$-MQ\SDG '&X#TKHO#,.J#4Y;C53=B:YL+5V5@/*639B0#' 8-V]Z -*Q\,
MZ?IL\$MIYT7DQ1P[!)E7"+M4MGN!QGC.!G.*L/HUF]Z;QD;SC.MQG<<;U0H.
M/]TFN-$/B&RTE+:%]7+H+P!E56<W&\>3DD8\L@L<_=]2.*Z/5'U(:GI8S=K:
MF-_/-DH;]]F/8&R#A,>9[>O:@!4\+:3:FW8&6.*$0KY9F(20Q']T6'<@XQZX
M&<X%/'AG2I;-88_,"+%'"CI*<J(Y-ZD'U#C/X5SGD^(;T)'<)>28F@>[29%"
M+*MW$P\K Y01AR>O 7OFELK?Q':W]E;JT]K9A]X"P[PQ-S(9 ^.@,93!. ,D
MCD4 =9#HMG!<I<(K^:DSS ER?G==K'\JKW7AW2Y1=R3JP%Q'/'*3(0-LP0/]
M,^6OTK BAU>X31Y[Q]7%Q!?*U\H50@)CE4[ !\T>XIZC!!ZY-2^)=,U"ZU'5
M1 ;UH[G38XX5CP8Q(LCEN",!L,I&>O/7% &]+X>T^:XGG>-]\[.SG>>2T2Q'
M_P <115>Y\.Z29(B[O!.TBF%Q+AMRQ[,#/!^3.1@^O45@Z@GBJ%Q;6]U=K;I
M+<*ESY(E<G]V8BP4<KS+Z#@9-:7B33-1N=7@O-/,OGP:7>K"5*[1.WE>7U[D
M@G_@- %V7P[I::@M]++,C!_-V-<$(T@B,6\CN?+X_#/O3(/!^D6]U%<1QRYC
M4!5,A*\0^3D_\ X_7J3GG]7AUG7+>[<6-V(MTZV\<T85@K6)7IUYD+#GN?2M
M7Q5+K<%C:1Z/#<F81.V^'! ==NU67!SG+=2!P>I(H T;;PS96D]M/#+<B2")
M(<F3/F(A)0-ZXW'G@^N:CM_#%I:ZSI]]#\J6-HUM%&<DG)&&)SR5&\#C_EHW
MK6'J%MXH8WLUO>WZ-Y=\\,:+'MW(P^SJ,KG!Y[\]^.*DO6\3R7MZMH;M;@FX
M" J@MQ%Y+>24)'W_ #-F<G/WL\8H V!X8MWUJ[U&XGFD\ZX6=(0Y$:,(5B!(
MS@GACGW'H#4P\.6"264D1FB:TA2W0H_WXU^ZK>N/7KR>>:Q2^O:K<G8=1L;1
M[O@[$1Q$+;W!P/-_'\*L^&H=375+FXU,W8EN+2VD*O\ ZI7V .!C@,&!X]Z
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MTN(IY8;=V@%O(3F8';L&W+ E6 (X^6K$7C+19K9YUFG5%6-@'MI$+[V*+M!
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M,@[YZ8!!R-N"43P1RA70.H8+(I5AGL0>0:PXO!VEQ0K'^^; DYW 9\QXY&X
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ML;28*=[;$.XKC!;Y<YQFI&\6:,JS,;J3$3*I(MY#O)D$8V?+\_SD+\N>H]:
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MW*H2-L@2*@^Z2-Q[<C2UG2K_ %>S\-Q3K;7$J2[[M[FS,D6?L\@+-'E<98C
M)X)%=;10!PFHSZ_/J.J6D-I<M9"UF5(Y85>,N&C\O;F, @@R<;G]\$8K<M8=
M3DTK6'NYKB2:62Y2"%D50D89Q'MP 3E=IR2>U;]% 'FMEH^MB'2M/FMK@6FD
M7-M+"Y/^M#NA^N(E\Q"#V(/:K]G=>*+^:6)CJ%I"\UO\[Q(9(@3+YJ@F)5X
MCY 8#/#'-=W10!Y^A\3:?!J\<$-PJF[>2V*1 YC:Z/FL?E)W[#E0 00> 2"*
MT]'35O[=L+B^O+Z6.2SE7'D%(RPD)7>"@*ML(Y.W)' [5UM% '&/9:E;ZY=0
M):W$EA:O-J=NT9'[R5TP(@3QG>TS\\#*5GJ?$UW:RW(BNC=VYNQ9/+'AAFV0
MIG<B9_>E@,J.F.E>AT4 <+J&I^([DSRV:WMM9/>%8Y#:'S%C^SQ[?D\MFV^;
MYF<KG( R!5_Q7>:[:Z1;_P!EQW,E\878O;QY4RA1M5E*.<$Y_NC@Y8<5U=%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6.J6<UG/>W@MY)9Y?+'ED*9B2X&Y#W)(/WADX.* +L7B>P,^H0W$@A>RD96
MRY*C;AN!QDM@#J2#C/.+#:U:MIHOH'#1><L)\P-&58R",@@C(()Z$?EUK.N?
M!6F7,NH2-)<*=0(-P 5*NP*E"05()4KQG^\0<C@78_#]JFCIIF]O*69)MR1Q
MQDLL@D'"*%ZJ!TZ>_- %:Y\8Z-;V]U,LL\WV;[ZQ6\A+8?RSMXPV&X.,X[U=
MCU[39=06Q6=Q<,=H5H74;]F_9N(P'V_-MSNQVJG+X2L9;<P^=<K^[GC#*RY7
MS91*2,C&0RC';'7-21>&H(]36]:\NI L_P!I\EBFSSO+\LOPH.2N>,XR<XH
MLW&N:=9W4MO<SM"\4;2LTD3JFU0&8AR-IP#D@'--37]/DE@B#W EG^[&UK*K
M*,XRP*Y09[M@&LZ]\%:=J&I7=[<37+-<QR1LH*?*'C"'#;=V,#(&< Y.*MIH
M#+>Q7CZK?23B/RIF81?OT#;@K )@ 9/W<'D\T /MO$ND7A AN\[C&%W1.N\2
M$A&7(&Y6(.&&0<=:1O$^CK/%";LEY" N(G(&9#&,D#"@NI7)QS]15*+P9:Q6
MZ1C4+XO"D$=O*3&6@2)MR*OR8/7!+ D^M2P>$;&"!HOM%T^X1!F=ER?+F:8'
MA>[.<^WIUH LVGB/3[K2+O5"9K>TM'F69[B%H]OE,RLV".1\I/'TX((#D\0Z
M9)<PVXFD664#:'@D7!.2 Q*@*3@X!P3VIG_"/VYT?4=+:XN&MKYIV8$KF/SB
MS.%(7IEF(SGK39/#-C)X@.LY(N&V[U,4; E00"&92RG&/ND=![Y (#XTT9K6
M*X@DN;B.66*-?*M9"<2YV/C;DH<'##(.,#GBM*YU>RM+Z.RED?[3)&TJQI$[
MG8.K':#@=N>Y ZD5FKX1LX[>&**YNHV@@M((Y%*%E%NS%#RI!)WG/&/3%7[W
M1H+Z:XE>6>-Y[1K0F)]I56[J<9#>AH K#Q3IKWEI;)]J:2YE>(?Z+(/+95#$
M2 @%."#R.ASTYIR>*='EC5X[F1][*J*MO(6DW*S*57;EE(1B& (PIYX-5;+P
M=8V/EF&XN 5N6N&PL2A]T8C9"JH %(4= #GO4">!-.BT5]*CN)8X&V#<D$ <
M!00HW"/.1G(;[P(R#UR =%>WMOIUE->7<HBMX5+R.0<*!WXJBOB/2S.D!GD2
M1QG$D$B[3M+;6)7Y6V@G:<'':G2Z4][IEY8W]T\B7#O@H IC0GY5''8 <G/.
M:K2^%;"76YM5RPFG'[Q?*C;)V;,AF0NIVXZ,!Q[G( S_ (3'1VCMY(7N9UGG
M2%?+M9"074LK8VYVD X89![5IW6J6EE<PP7#R(TS*B-Y+E-S'"@N!M4D\#)&
M36=_PBMHHB,5S=1R0BW".I4D>2&"]5(Y#L#Q],4[4_#%IJNK6VHSSSA[=HF5
M%V%<QR;P1N4E<G@[2,@ 'I0 S2O%EAJ5CY^)DE5 [P+!([8+%<KA?G&1@E0<
M=Z<GBW29+AXQ)-Y:6BW9G,#B/8Q8 9Q][*GY3SGCKD"H/!%G]F,#ZA?2*$6.
M+>8SY:"02%0-F&!(&0P/ Q3AX(TX6)LA<7/V=K06KI^[PRARZL1MQE68XQ@>
MH- %J?Q;HEM$DD]VT:N)#AH) R!"H<N-N4"[UR6P!D'I3V\4Z.EMY[W3JF7#
M*8) Z;,%BR[=RJ 5)8@ !@<\BJY\'V#69MFDE"M:W%J3&D4>5F*%CA$ R/+7
M!QZYS3=0\&:=J%XUW(\@F:623+1Q2 ;UC5EVR(PQ^Z0],\'G!Q0!/=^+-(M/
MM@,TLDEI'))(D<#G.P!F53C:6 (. <X.>G-6[/6K*_G6" S>:8EE*M;NNP'H
M&)&%/L>:J3>%["<2!WFVR/,[*& '[U-C#ITQTJ&;PS)YJW=OJEPM_':FVBG>
M.+*Y&-QVH"V.H4G;GM0!H:GKFG:.4%].T9='D 6)W^1,;F.T' &X9)X&:CF\
M2Z1;R7"2W@46\;R2.4;8 BAFPV-I(4Y(!)]JK:YX>DUK4+:3[=-;6Z6EQ;3>
M3MWN)3%Q\RD 80\C!SC%0-X(THMJ&PO&E]%)&ZK'%E-Z[6*N4WCCL6(YZ=J
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MFUA=88E" C&["H-V.6"GY<]JU+C3+>ZOHKJ;>S1V\MOMS\K+(4+9]_W8_,T
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M[B,X89Q-*)6[=F''MZU:L-%AL-2O[Y)I7DO2I=2$51@MC 51D_-C<<G '/%
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MY:?4H7"V\UUY=GL:VD\]?,CC^3]XH3=_>X4<D-BNRBUS39M3;3H[M6NE)4H
M<9"AL;L8SM(.,YP<U3'BO3(]0U&SNI1;O92%"6!(<"%9B0<8R%8G;G.%)Z4
M8/F>(--N-3N;!)[D33W!BMY8,*S"W#1MG /+KMZ@<XQFK.F7?B"[>Q26[D$,
MET_F2BV(<1K$&"MOB0#+Y&0O0XSD9KI9-5L(K>\N)+J-8;(9N7)XC&P/R?\
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M93;EY-Y7S%"?*6.0-P*\'J*T$U[3))+5$N@WVI!) X1MD@*EAAL;<[03C.<
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MC)CG<YQC=U., CGI8/%6CW$'FK<D8BCE9#&VY!(%**0!]X[UPO4YXHE\5Z'
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M*Z116X#( 2% 7N< 'G^7%5;75=:F\&W%T!_Q,$N&BB=H2=R^;M5MN%S\ISD
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M&HP 6W8V] 1GD50?Q#XD;3H%BVK-OE66[E@80M(J(45,1EMA+-U4-E"N<\D
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M% &M)X0C:+9'J5W%Q<QAE$9(BG8.Z<KZJ,'J/>K"^%[))-R23*/.:4*",#=
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MJT$W!@&J6WFA]FW=WW;?_0OE)Z \'FID\0Z3)// E_"TL <R*#DC8VUOJ02
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M(6.1GIG=SW.U>>.<.U\%:A!H^G(VI9O[=+.+?M79$D+;B%X^;DGDXR .AR2
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M5OHM\\ACC0Y#,PQD;>H(W \]CGI4>H^'K;4VU(SR2!;^R6SD"X^55,A!'O\
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ML*N&6)BR$9^Z<L>1[>@-5K?P1;6=OY=M<"-XY$>WF$";TV/N 8_QCMVX]^:
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MXBUV]T[6=.M+-&;S981(IARK(\JHV&SG*J2W XX)X.*Z>B@#B1K^O6UM->7
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M(HTD;$+&;S?)'V5L0[+I8AGYOFRC[NWW>.*ZJZTG3[VXCN+JSAFECP%=T!(
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MD@%MN 2<9'>L27Q7K</AU[HO!)<,Y$+0P[AD1%BC@D8.X8 &6.0.O->@@ #
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M^(-3O=0TN.]15%W8I*\441#1R;26+@G*KT Z\Y!YQ23^([^UO]1CD*/%;W4
M+QQ$I'"TH5MQZA@,DY&,<@XKKZ* /.Y/$&K'45OHF*/)$4BMWM7(N,74BJHY
M&UBF#SSWZ U8_P"$@UF.ZAM[5;>.)[NZ ><L1*5NW38"2<':,X'J,#"XKO*A
MM;2WL;=;>UA2&%<D(@P 2<D_B23^- '&7.M:K/9M-_:(M9(M21)X5M#FWB\Y
MD^8D\@KM.?Q'!%:/B'4-4T[6XY+-VDC&F74D=GY1(GG3:57(YR03QZ UU%%
M'-Z7K-W)IVK7$DOVV&T7=!<06Q!E_=[F4)GYB#QP1UQU!-5;'7]4G\):]?[%
MDNK(2_9&\OB7$*NIP#AOF8CY>N*ZZB@#AM:UK5]%NWB!:>67[/'YL4!)8E+A
MCL0MM&/+7//0G.3BC3+[6CJ0N5NX9H+N6VCD,<)9&W6P)D1LXV[@.WKGKQV%
M[I]IJ,:1WEO',J-O0.,[6P1D>AP2/H34T,,5O#'##&D<4:A$1!A54<  #H*
M.4L=6U*'X?6%[)<>??%8([F:2$DPY95D9E'4H"Q/TYXS4.F2ZCJOB32;JZEW
MVT,%[L(A*I+MEC1),$\$J3CU&XCAJ[2B@#@Y'U+3]5U*]7?/))J4H3*, J)9
M,R#@X*[L#GC.3U/%N;5-;CN+2RDN4>6ZL6<&WM_F28K(V64GA!A0"">>#]X&
MNQHH Y:&_P!4D\,:"UK=K)=7;QQSW+P%MH*,6.W(P01CGO\ E61J>L:_?67B
M:V5HK?R;2\$<:*?/38<1LO?YUR<^XQT->@44 <DFKW6G:K%HH1?DN4B3; P!
MM_LQ8OQP!Y@(_2LNY\7ZO!X>2=!YE^IER4M]T,S(J':C;LD$L0,#<<-TVFO0
M:* ,/1KH17VH6UQ(PEFOI3 CY^955,X]AG]:W*88HS*LI13(JE0^.0#C(SZ'
M _(4^@ HHHH **** (KF4P6LTP )C1F /? S7%7'B^]L+.*]O?LT;36=M,<;
MFBB$LNW)'5B ?49QVKNCC!ST[UF7,6EZN5M'<2,B1W*&&1D*KD[&5E(XX/0T
M <Q:>(M8_M"*[F^RM;RVVG>="K$A6GGECRA!(XRN3SG;VJ_9>(;V+P7-JEY+
M:W%U%,T3%!L2/][LR_)P%SD^PKHK.PM;"U2VMH@D2= 26.<DY)/).23D]S4X
MC0!@$4!B2P ZD]<T <=::MJ.K^)--@-Q +:![H2M;,X2Y,?E89<-T'F$%3N&
M0>N!ACZGJ%IXBU&66<RQ#4_LT40=E546Q,V",D'+=P <]\  =D1!;0[SY<44
M2DY.%5%[_04.T"E=YC!D;"[L?,V.WJ< _A0!R:^)=4SI\4XL8I;^S,T7E@R?
MO&1V5,;@P "_>(PV&'RD#,\7B&Z3PAHU_)/9R7%]Y,;W)X@C+C.YL'VQC(RQ
M XKH;:6UO$6YM]CA2T8<+TVL58?F"/PJ7R8O*,7EIY9ZIM&/RH \YU#6M9U*
MWO+VWNX[98M,9HQ$S[2QF>,R*0PR&5-RD@X!!'OHR^+M0L#JL264,D6EV\P_
M>3C>S11!PQRY<ACQ]W."#DYKMO+3&-BXQCIV]*JK<64NIS6BA6NTB#2?NR<(
M>@+8QSZ9SWQ0 0W,B6SI<O#+>Q1^9+%;^ASC )SSM(&>N#7&+X]U!- _M233
M[9PWELD<<P+,'1V(PK,?DVAF) RH8@ C%=U';0Q3S3I&!+-CS'[M@8'X#T]S
MZTJP1)G;$BY)8X4#)/4T <?+XUDM]3N899+!K>"22)_+9FD54MO/\X@9^3C;
M@#N.>U0IXSU.>VF\BWLVF@-SO=B=K"*..08"LV"?,V_>.,9_V:[&WT^TM)9Y
M8(%1YWWR-UR< ?@,*..G%.?[-:P@NL<<>0@^7 RQ"@?B<"@#E9_%4SWDEL1'
M'^_L_)6-LLT;S0HQ9@3CF0@J0#]0<B!/&M[*BF*&RD>?84C5VS;%KE(=DW7Y
MOG)X Y1A@XS77^9:)>BV_=BYD3S=NWEE4@9_ D?G4PAC!8B- 6(9B%')]30!
MSS>(KF'PQ)J$L=N+B.\-FS9(B4BX\GS#W"C[Q&?;/>L>Z\=7=M 6"Z<S1Q74
MF3(0+KR9%3;",]6W<=<$8YZUVJ3VTL\]HI5I(P#+'CH&SC/UP:KI!IL^IETC
MC:[LT$6,']VK88#'3^$&@#EI?$VH6?VF6X:.Z-O?W4:V]N-C[(X)9%5ASDG8
M,?GS4\7BC4KF>&RM3IEQ-+=)"+J)F:##6\DW0')8>6!UY# \=*ZEY;6*\BA8
MHMQ.&=!MY;: "<^P(_.I4BCC4*D:* <@*H&#ZT <Y-XFE;1-"O8Q:VK:JB.9
M+ICY4.83)@\C)XP.1Z]L&3PYKU[KLWF/;0V]L+6"4KEF??(@;&>!@?3)SVQS
MMHUK=Q.B>5+&CF-E&"%93R,>HJ8  D@#)ZF@#@KOQEJ4EG<-:O8Q/Y3S \N;
M4).D9649ZD,3VQM8<XS4Y\2:EIE_J<LJQ7MI]J>.)(RV_*V2S_)U&TE6 '/+
M9S7:>3%\_P"[3]Y]_P"4?-]?6E$:+C"*,'(P/;'\J .1T[Q-JU^UC$+>R5KF
MY*><) Z^6(O,) 1VYZKR?1O:K=[XCO(/%D>DP6D31 0F1GD5682,P)7+ _+M
M[!L\CC'.S:W5A*_E6K1[@TF JXY1MK]NS'!JTT4;.KLBEU^ZQ'(^E '$VWC+
M47LX'N8;&![J"SGCE+-Y<*SF0?/DC./+XY&2P'N;A\8;+U;,M9R3M<K$HCES
MYD9M//\ ,4=2N[*@],>]=288F0HT:%2-I4J,$>E'E1[P_EIN QNVC./2@#C]
M.\5:O/<V@NK:R$,S6V[RB^X"="P S_=(Y/<'H,<YV@>+]4GT73K=7L;RZDMK
M'_2/,9@K2[E828Y+C9NQQG)'&,GT+RT'1%XQV].E(L,2 A8T7)SPH'/K0!QE
MQXUN8]1O;6"*UN/*5O+.2F'6=(65N2<9<\[1]WC<.:M6_BB[?4;>PN&L+>7S
M)TEEE8JDOERJ@6,$\,0X/)..!SG(Z#[19#4C9 *;MHQ,RB,G"DX!8XP,E3C)
MYVG'2K)BC8@F-25;<,CH?7ZT </!XWU*?29[\V=K#$!&ZEYD+1J2VY63S,LR
MA<X^4GYAC*X/7I-#JEBXM[L@D ,\# -&2H8#D<'# X(Z$5.;: AP88R'.YLJ
M/F/J?6I H!)  ).3[T >=PZMK-CI6EW\=ZUY(VF7=Y.EVWROY?E$ !0.>H![
M;B>>E;VG>);O4/$T]@+.-;2.1HBQD42*0BL&QNR0<XQMZ8.3GCI?+3&-BX Q
MC';TJJUW8QZ@T+/&MV$CR-OS;7+!.?<HWY4 <I+XHNX?%-R^9FTO$UG$IA(B
M,T:;]V_'4LLL9&>J+4$OBC5+/48)[B6QS-86TQL][#>9)F7;$#U;# 9[D#@9
MX[SRT*[2BXSG&.]5&O+#RKFX9X]EB2)G*_ZHJNX]NRGMZT <@_BG4K0WD_F6
M[P065].EO-G?*\,TB@!O3"KQ@X%:%SXEOK;Q#9Z,QLWN)OW<NQ"!&YBDD4C+
M98?(!@#OU'2NH$<,JJX1&!!*G;V/7\Z;&UO/*[H$:2-O+9L<J>N,_C0!P]GX
MTOQI.FRS26$T[V%M<R\E6N6E<H4B /WUQSUY8# S5]_%-_###=7"6<5K+?S6
MV1EG5$E,8.W<"2Q Y4';D<'J.K$$(*$1(-A)7Y1\I/7%*8HVVYC0[3N7*C@^
MH]Z ,S6-16'3(KBVE$@-];P%HW'\5PD;#(],D$>Q%4O#VOWNJ70CNX;=$EM_
MM$7E%LJ Y0AL]>@/'J1SC)W8+6"UMU@AB5(E.0H]<YS]<\Y]:E"*O10.,<"@
M#SL>-;[[1)>@VTBM;1;;6.3_ (]VDN!'^]R0-R@\\KT(XZUL6GB>\NKJ*VN!
M8V;_ &<2L'F!,^9)$ B*L1D",,1EL;P/>NI\B+#CRDP^=WRCYL]<^M @B&S$
M2#RQA/E'R_3TH X*#Q5>WMSHT G@A4RP+)$93Y\P:T,I;W3+ =.JDY[5;TWQ
M9J#Q6+O!"UJRV\;EF8RLTEMYN<].#QTYSVQSV,:V\I\R,1/MRFY<'&TD$9]C
MD8JIJ%UIEK$UO?-&B/ \C*5/,:[58\>F]1^- &#H/B:^U[PSJ6I1-:!XX\VY
MB4D!O*#$,-Q)PQV]L[<]#5.S\0ZJ+Z&Y:>UNK:2UTT3!"0-\\\D99 "0#RI/
M7.W'%=9IVCV6E"3[(D@,@56:29Y&(48498DX'.![FK:PQ(H58T &. H['(H
MYWPOXDN]=:>2XM8H( @D0B5"R?,P*. Q.1@<D+SD8XK"L?&&HK]MF9'D^V".
MYTY+F)HD$;3"+:#CD!'A?//+MVQ7?K%&A<K&H+G+$#[WU]:4QH<913MZ<=*
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M!IOA?Q':WR//?QRP*,!7F<Y\F-HX,_[V[>_NHZTVU\,:Y%98*0><+Y;F*(S
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MS*^USCIEXRN.VY?? !+H7A^_L?$1O[J*' AN8WG$[.TY>975BI&%PJXZ]L=
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MMX;:T@65;N08VD&4@Y')Q][J<59TW0M0TC4#=PAYE"W@\E[MB&#2HT"_,2
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MLM,LM-$@L[=(1(?F5.G?@#H!R>!QS5NB@#)_X1C1/LPMO[,MQ"K;E0+@+QC
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MT:* ,T>'M(  _LZW*B(PA&7*[",$8/'(X)[BI+71]/LMGV:TCC9&9U8#+;F
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M]#T^[>YE: )/<1-&\J<$@KMSZ$XXR1TXJO%X4T2*Q2S&G0-$I#<KR2%V9/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?FLX9<-)AB @/++U^@H [^BN4N_$-Y:^#]-U"2>U^VW017>&,/"'*,Q )D4
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MH4M(,9!/(+9QD CBDD\1ZGIEO.D;Q!UEOI84N49VNW6Z<)!&=PP=N .O48&
M: ._HKAYO%NLQ:[)IGV",XN/L@E\MB/,>3=&>OW1 "[>_''2NPLIC<0,YFBE
M(ED3=$I &UR,<D\C&#[@].E %BBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "HHK:&"6>6.-5DG</*PZL0H4$_@H'X5+10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>]L+;4(5BNHMZJP=
M2"5*L.X(Y!Y/(]:L44 16UM#9VT=O;Q+%#&,*BC  J6BB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%->:7J$0>"6Y93Y),<,>S<YQ(<C]XO RW7BM!=<M&\0MHH\S[4(//W;?DQD
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M444 %%%% !1110 4444 %%%% !1110!@7^N:C9ZO+9KIUJ\*6KW0F-VP8HN
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M<C2$?*?*9OO%>/7GG//MQ6?!X/TV"S:V5IRC1M&QRJ\-)YAP  !\QZ  8[4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9M]H.F:E<">\M
M1+*%"[M[#C\#[U6_X1'0O^? ?]_7_P :VC&E;63OZ+_,6IMT5B?\(CH7_/@/
M^_K_ .-'_"(Z%_SX#_OZ_P#C3Y:'\S^Y?_)!J;=%8G_"(Z%_SX#_ +^O_C1_
MPB.A?\^ _P"_K_XT<M#^9_<O_D@U-NBL3_A$="_Y\!_W]?\ QH_X1'0O^? ?
M]_7_ ,:.6A_,_N7_ ,D&IMT5B?\ "(Z%_P ^ _[^O_C1_P (CH7_ #X#_OZ_
M^-'+0_F?W+_Y(-3;HK$_X1'0O^? ?]_7_P :?#X6T:WGCFBL@LD;!U;S'."#
MD=Z3C1Z2?W+_ .2#4V****Q&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!1U#6+'2VC6\E9#("5VQ.^<
M?[H-4O\ A+M$_P"?J3_P&E_^)K;HK6+I6]Z+OZK_ "8M3$_X2[1/^?J3_P !
MI?\ XFC_ (2[1/\ GZD_\!I?_B:VZ*KFH?RO[U_\B&IB?\)=HG_/U)_X#2__
M !-'_"7:)_S]2?\ @-+_ /$UMT4<U#^5_>O_ )$-3$_X2[1/^?J3_P !I?\
MXFC_ (2[1/\ GZD_\!I?_B:VZ*.:A_*_O7_R(:F)_P )=HG_ #]2?^ TO_Q-
M'_"7:)_S]2?^ TO_ ,36W11S4/Y7]Z_^1#4Q/^$NT3_GZD_\!I?_ (FK5AKN
MG:G.8+29WD"[B#"Z\?5@!WK1HI2E2MI%W]5_D&H4445B,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,>;Q1I%O/)#)<R"2-BK 6\AP0<'D+3/^$N
MT3_GZD_\!I?_ (FMNBME*CUB_O7_ ,B+4Q/^$NT3_GZD_P# :7_XFC_A+M$_
MY^I/_ :7_P")K;HI\U#^5_>O_D0U,3_A+M$_Y^I/_ :7_P")H_X2[1/^?J3_
M ,!I?_B:VZ*.:A_*_O7_ ,B&IB?\)=HG_/U)_P" TO\ \31_PEVB?\_4G_@-
M+_\ $UMT4<U#^5_>O_D0U,3_ (2[1/\ GZD_\!I?_B:/^$NT3_GZD_\  :7_
M .)K;HHYJ'\K^]?_ "(:F)_PEVB?\_4G_@-+_P#$UIV5[;ZA;+<6SEXF) )0
MKT]B :L45$W3:]U-?._Z(-0HHHK,84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!1U"YU&!HQ8Z?'=@@[R]QY6WT_A.:I?VAX@_
MZ %O_P"# ?\ Q%;=%:QJ12LX)_?_ )BL8G]H>(/^@!;_ /@P'_Q%']H>(/\
MH 6__@P'_P 16W15>UA_(O\ R;_,+>9B?VAX@_Z %O\ ^# ?_$4?VAX@_P"@
M!;_^# ?_ !%;=%'M8?R+_P F_P PMYF)_:'B#_H 6_\ X,!_\11_:'B#_H 6
M_P#X,!_\16W11[6'\B_\F_S"WF8G]H>(/^@!;_\ @P'_ ,11_:'B#_H 6_\
MX,!_\16W11[6'\B_\F_S"WF8G]H>(/\ H 6__@P'_P 15JPNM4GG*WNF16L6
MW(=+H2$GTQM'OS6C12E4BU902^__ #"P4445B,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,>:^UQ)Y%BT2"2,,0CF^"EAG@XV<?2F?VAX@_Z %O
M_P"# ?\ Q%;=%;*K#^1?C_F*WF8G]H>(/^@!;_\ @P'_ ,11_:'B#_H 6_\
MX,!_\16W13]K#^1?^3?YA;S,3^T/$'_0 M__  8#_P"(H_M#Q!_T +?_ ,&
M_P#B*VZ*/:P_D7_DW^86\S$_M#Q!_P! "W_\& _^(H_M#Q!_T +?_P & _\
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M  &@_P#B*VZ*/K$^R_\  8_Y!8Q/[(U?_H9KO_P&@_\ B*/[(U?_ *&:[_\
M :#_ .(K;HH^L3[+_P !C_D%C$_LC5_^AFN__ :#_P"(H_LC5_\ H9KO_P !
MH/\ XBMNBCZQ/LO_  &/^06,3^R-7_Z&:[_\!H/_ (BK5A87]K.7N=8GO$*X
M$<D,: 'URJ@__KK1HI2K2DK-+[E_D%@HHHK$84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 8\VEZI)/(\?B&YB1F)6,6\)"C/ R5SQ[TS^R-7_P"A
MFN__  &@_P#B*VZ*V5>:Z+_P%?Y"L8G]D:O_ -#-=_\ @-!_\11_9&K_ /0S
M7?\ X#0?_$5MT4_K$^R_\!C_ )!8Q/[(U?\ Z&:[_P# :#_XBC^R-7_Z&:[_
M / :#_XBMNBCZQ/LO_ 8_P"06,3^R-7_ .AFN_\ P&@_^(H_LC5_^AFN_P#P
M&@_^(K;HH^L3[+_P&/\ D%C$_LC5_P#H9KO_ ,!H/_B*/[(U?_H9KO\ \!H/
M_B*VZ*/K$^R_\!C_ )!8Q/[(U?\ Z&:[_P# :#_XBM.R@GM[98[B[>ZD!.97
M15)_!0!5BBHG5E-6=ON2_)!8****S&%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 4=0T73-5:-M0L8+DQ@A#*@;;GKBJ7_  A_
MAS_H"6/_ 'Y%7=0U>TTQHUN1<DR E?)M99NGKL4X_&J7_"5Z7_=U'_P67/\
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M_P#?D4?\)7I?]W4?_!9<_P#QNC_A*]+_ +NH_P#@LN?_ (W1_MO][\0]T/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\&/_ -KH^W^(O^@%:?\ @Q_^UT_J\^Z_\"C_ )A<VZ*Q/M_B+_H!6G_@Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]:SF2YUFYO$*X$<L42@'URB@_P#ZZF5.*5U-/[_\@N:-%%%9#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HK.O]/OKJ<26VLW-F@7'EQ11,"?7+
MJ3_^JJO]CZM_T,]]_P" ]O\ _&ZVC3BU=S2^_P#R%<VZ*Q/['U;_ *&>^_\
M >W_ /C=']CZM_T,]]_X#V__ ,;I^RA_.O\ R;_(+^1MT5B?V/JW_0SWW_@/
M;_\ QNC^Q]6_Z&>^_P# >W_^-T>RA_.O_)O\@OY&W16)_8^K?]#/??\ @/;_
M /QNC^Q]6_Z&>^_\![?_ .-T>RA_.O\ R;_(+^1MT5B?V/JW_0SWW_@/;_\
MQNC^Q]6_Z&>^_P# >W_^-T>RA_.O_)O\@OY&W16)_8^K?]#/??\ @/;_ /QN
MKNGV5W:-(;K5)[T-C:)8XUV?38H_6IE3BE=33^__ ""Y>HHHK(84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_ 9?\*/^$.\-?\ 0!T[_P !E_PI\M#^9_<O_D@U-NBL3_A#O#7_ $ =._\
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MV"\N[E?/_>PM!L)0@@8;YP"",Y([#F5/B:D<["^T.[M8(WV22^;&^TFW-PO
M.3E <^AP.>P!WM%<"GQ,>6TADC\.WQGF+^7&[!%95A\TL&8#/R@@X[COUIB?
M$BXV:E>'17;3[<VQBE63E4FB63=+@': &Y(&!QGUH ]!HJ."9+B!)8V5E=0P
M*L&'(SU%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P .K()!HMD'$7D@B(<)Y?E[?IL^7Z8':MNB@"M)I]G,ELLEM&RVKB2 %?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;LA00BCYL'.,'!Q5SQ'H>HZGJ/FVWE,I@6.&1YF1K.4.295 !R2,>GW0.A-
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M-HY2I8N$\LMA<Y&UN<\9X')H [>BN.E\,WD%Z?)M[>XTU;IY(K*2X9%0-%$
M_0\JZRG'_33(YJUH.@WVGZ[>WMY-)(96FPXF4K(KR[DRNP-E5PHRQP,@<'@
MZ>J<FJ6,5I+=/<H(8HS*Y[J@SEL=<<'\JY-/"VN#71*;Y/[.%P4\OS6S]G$O
MGJ<8QNW_ +K']SOVID_@Z^EM[M6BMI+BYTN2S\\RD,CEY".<9P0X&>V* .YD
MD2&)Y975(T!9F8X"@=23V%1QW4$MS+;I(&EB56=1V#9Q^>#6#)X;=O#_ (@T
ME!$L%Z9!:1EB5C5HE7GT^<,W'KFJ:>%[C^THM0C@@MI8S9B-4E)\M$9O-48
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M8O%$\L-[&H\Y@/GE1H%]E558<?=W' Y-2RZ%KL\]U>%+19I5NO+A>9G51(L
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MP<J1S'N3D$<XQBM9M!NU\*VME"=US;72721W,H*MMF\P1EE4 #' PN%P.N*
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MD_G4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!8,>>NT'BIW\2Z-&LK-J$6(IF@?&3B1<[EXZD;6SCI@YH U:*R(?$>G2W=U
MUQ%&(>5D,@VR)Y2R%P?[H#C)Z=/45(OB+2'\D+?1;II#%&AR&9Q@E=O7.&!^
MASTYH TZ*I1:OI\VG/J$=TALT!9ICD+C&<Y/48(((ZYXJD/%&F_VP-.DF$;O
M##+$SY'F>8\B!<$<',>.>[ =: -JBLB;Q%8*P2"03R"XB@=%X*>8Q4-SU&0>
M1P<'TJ$^*+6/1](U*>-HH=29%&3DQ[HV<9QU^[C [D4 ;M%9R:]I4DUM%'?P
M.]RBO#M;(96SM.>G.#CUP<=*=+K6FPZDNGR7D2W;$ 1$\Y.=N?3.#CUP<4 7
MZ*S$U_3YI(T@N$E+S>2WS!=IV,X.#C((4XQUZ]C3-+\0V.L7EW#92K+';1QR
M&93\K;]V/T7.>X(- &M16?'K5C/875Y;S>=':AC*$&&&%W8P<=001ZY%9UAX
MQTR\M&N)R]FHE2$"9E;>S('4*4+ G;VZ\=.E '0T5C7?B?3;>.Y\JX2XFMSA
MXD;D_.$;!Z':Q ..AX/-6/[?TK= HOX2;@XB(.0WS;1SZ%N >A/3- &C165_
MPDNC>29O[0B,2R&,R#)4,.N3C  Z$] >M.?Q#I,=Q/ ]_$LD"LT@.<*%(#<]
M."0,>IQUH TZ*R[O7K.VT1]5BW74"NL86+ 8L7";?F( (8X.<8P:<FN68>WA
MNI%M;J< K!(ZLPR2JY*DJ,D8'/)X'- &E15.RU6QU&25+.ZCF:+&\*>@)(!]
MP2",CC@^E5;7Q+I5RUG$;N)+BZBCD2$N"<.,KR..<''/.#B@#6HJI+JEE!?Q
MV4MPB7$@^1&XSP3C/3.%)QUP":K)XDT=X8I4OXF25]D9&?F. <CVP0<],$'/
M- &I166WB/1D-P'U*W7[,"92S8"@-M)ST(#$ XZ'@U#-XITQ-1L;&.=9)KN3
M9M!P8QY32Y.?]E>G7Y@: -JBLE_$VBQVWVA]0B6/S3#SD'?MW[<8SG;\W3IS
MTJ5M>TI)&1K^ %8O.8[_ )53&[);H/EY^G/2@#1HJE'J]A+9&[2Z3R%<1LYX
MVL2!@@\@Y(Z^M0RZ_IRJOE7,4S-*8@JR#.X2K$_7^Z[@$>O% &G17-CQOHVZ
M!FG,=O*;A3-*"H5H656&#VY)SV )-:VH:SIVE*C7UY% ) S)O/W@N"2/8 Y/
MH.: +U%9TNNZ7!+-%+>Q(T,+3ON. $4 LV>A !!..F11'KVERRP1K>1[KA2T
M6<@,,$\$\=%8X] 30!HT5D1^*-$E17348B&E6%>#\SE=P XYROS<=N>E2-XB
MTA%F9[^)1"RH^[(P6)"X]<D$#'4@@4 :=%8:>+-)?4X[/[5&%FABEAEW<2%W
M9 H]#N4#GNP'6KMYJJ6>IZ?8O;SL;V1HTE4#8C!'?#$G/(1N@/OB@"_165HN
MNQ:V;DP0/&D$K1%FDC;<0Q4\*Q*_=_B ZU5U'Q?I5E875Q#<)<R0%5,2$\EG
MV#G'3=P2,XP>_% &_161?>(;33YHK:X#?:I;62Z2-02"(PNX;L?[0ZTVU\4Z
M/=::E\M[&(V*J0"20Q7<% ')^7GCL">E &S15&75;:.3354F5=0D\N&2,@J?
MW;R9SGH50]/44TZYI@N)X/MD?FP*S2*.H"D!L>N"0"!T) [T :%%9\.N:;<-
M L-VCM/N*!0<_*2K9_NX((YQR".M/LM6L-2CDDL[N.5(\%F4\ $9!^A'(/0]
MJ +M%9 \4:(UOYXU*#R]ZQ@Y/+,"5 '4Y )&.N.,TS7?$=OH<4C2QEW5(RJA
ML;B\@10>I R>3C\SQ0!M452GU6TL_LZWDR0O.0%!R1DD #...2!SCDBJ_P#P
MDNB[KA3J=N#;;O.)? 3:VQLGV8@'T)&>M &K16'+XIL%DB$#">.2&:4R*P4*
M8WC0J=V,',HZ^E6VU[3%-P/M:,;=MD@0%L-G! P.2""#C.".: -&BL6'Q3I<
MVK?8!<Q!GCAD@DWY682!BN#[[>/7/%.T_P 2:=?06#-,D,]["DJ0,V2-X) )
MZ9.#CUP<=* -BBJM]J-GIL*2WDZ0H[[$+?Q-@D*!W/!XJ&/7-,EEM8X[V)VN
MU#P%3D2 @D8/3D G'7@T :%%94/B71KB*WFBU")XKE@D,BYVN20!SC')( /<
MG I'\3Z(AGW:C"/(*B0G. 2Q0<XYRP*C'4@B@#6HK-?Q!I,33++?11F&,RR%
MSM 08!;)[#<,^F1FJ<_C#1X+BV5[N,03QS-YY. AC*!E8=0</GGH 3TH WJ*
MQ];\0P:(5#VT]P?L\MTXAV_)%%MWM\Q&<;UX&2:M7VLZ=IB1O>WD4*R LI8]
M5&,M[*,C)Z#(S0!>HK$A\2VTLVMY0K;Z2VV63DECL#G"XZ ''7D@]L$M@\6Z
M7/J,=H9A'YUO!/ TGR^9YK.H7'8Y3'/4L!0!NT53M=5L+ZYFM[:ZCEEASO53
MTP2#CUP01QW&*IZ;XBM=1CGF\MX(([C[,LDKI\\F\IMP&)4[@.& /S#WP ;%
M%8DWBK2[?4X[.6YC19$9EE+?+N63RROMAN">F:?'XDT[RM]U,EL3<30*KMU\
MN0H6]ESCD\#<* -BBL^37=,BEN(I+R-7MUW2*V1@9 X]>2!QGD@=32_VUIHN
M(+<W<8FG56C0Y!(;.W/IG!P#C.#Z4 7Z*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH CN(1<6TL#$A9$*$CJ 1BN$LOA
M/I%O%;QW-S)=I";<&.2&-8Y$A5U5655 8GS#ECDG KOZ* .'3X;I#9R6EMKN
MH0P7%FMC=@+&QGA3<$&2I*L$<IN'48[\T3?##3&_M'[->7-J;^.>"?RPN&AD
MC"!#D<A2H93U!)[$UW%% '$7/PVLK^&(7MZ\LL%M)!;RQV\<1@9G1UD4*  Z
MF,8/N<UJZYX477[[3IKN_D\FREBF$2PQY,B-N#!RNY,D $ \@8XYST5% '*Z
MIX#TO5GU^6?BXUB)8FG\M2\"B,)A&(SR!DU''X'*:K8:E_:A-Q:1F(8LH0K(
M7#\*%PIR.HP>:ZZB@#-O]'35-,6QO93,@N(YF+(OS;)1(%(QC'RA?I5.?PO!
M+?\ FQ3M!:L\$DEK&BA6:%@T>#C*C(7('7:.G.=ZB@#&D\.6TOA9=!>60P+&
MJ"3 W94@@XZ'D#CI6=<>"H;B&VB-XT21.7>.&%41VWJ^[;T#?*!GDX)KJJ*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHILA98V*+N8 D+G&3Z9H IG6=+"W3'4;0+:.([D^<O[ECC ?GY3R.#ZTEKK
MFDWNH3:?:ZG9SWL!(EMXIU:1,'!RH.1@\5YFGP]\3P6-ZK7%A/)JUJIO5C4Q
M[;@7 FR26;?]^5<@+P%XK<T+P=JFF>,_[7N'6>V>YU!Q$T@_T<32!T=, 9+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(-.@"-+%,5"X&^(*L9Q_LA5 ^E,L?#&C:;=0W-G81Q2P1^5$021&O PH)P.
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MQ_C6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !16=?ZE);7*6UM;/<W#IOV A55<XRS'I^IJ&.^UAG ?2HE3NPNL
MX'TVT["N:]%<OI&M:[=7]O%>Z88H)(MS2>4R[6P#@Y/'.1ZG&>E=.*0Q:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **IZCJ"V$<?[N2:65MD<48Y8_CP![FJ8O]9/72(@
M/^OL?_$T["N;%%<I;ZYX@?4X()=)Q;/,4DE\ME*+CW./Q[]JZE22,FD,=111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M23STS75+THN4+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4#.('QB\ $@#Q%#D_P#3"7_XFNYINQ/[J_E3J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CGGCMK>2>9ML42%W;T
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M_P +C\ ?]#'#_P!^)?\ XBNVAFCN((YHFW1R*'5O4$9!I=B?W%_*G4 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IC4X/[2N[)MR/:V\=
MQ([8"[7,@'/MY;9_"HH]>TN;RO+O8V,LAB11G=N&,@CJ/O+U_O#U%5[W0YKG
M4[N\@U*6U%W:+:RB-!N 7S"K*W\+ RG\A6?!X+2 (5OW$@O!=M*D85P=L:E5
M;.5!$8!R3D$YSQ0!?'BC3I/#MYK<!DFM;02[PJX8F,D$#=@=O6HK_P 66.F:
M,U_>CR)/+DDCMGE0O($ZX*LPZD#.>I ZFI&\.J_AW4=&>Z<PW;3E7V#,8E8L
M1Z'!8_A5.]\(M?6OE-J)A+VTMI*8+=%5HW(. O(4@CJ/4]\$ &@OB33O[233
MY)/+N)/.*@D%<1,%8DC@?>'!]\TK^)]%2R-W_:,!A#[ =W5MN['_ 'S\WTYZ
M<U4F\)P32NQNI0DHNTF7 ^9+@J7 /8@HN#]:@A\'+!#"8;T0W,3M^_BMD!=2
MFPA@<@G'.>Q'3'% &UIFJ6^J6,-Q$P#201S-%N!:,.NX @>U41XD$FC3ZE#I
ME[(()9(Y(?W:NNS.YCN<#''KGD<=<7M,T]M,LH;1;AI(88(X8PR@8"+MSD=<
MXS6-)X4N9=*GL'U=BD]VUS+_ *.N) Q):-AGE22..X&#D$B@#0;75>6S2SM)
MKHW-JUV%4A65/EVC#$#)+="1T;TJ@WC:T6R^T_8+TB-)Y+E $S;I#(8Y&;YL
M$!@<;2<@&K0T6\<:H[Z@8;N[CC@BN84&Z*-%[ \ [VD/MN'I5.3P:LMC':_;
MVCC^RO93"*%5$D#$$KSG#=?FY^\>^" #1N=:DBO+R"VT^:\^RQQLYAD0'<VX
M[?G*CA0">?XUXJI!XPLKEK1X;:[:VN!;YN-JA8FG ,:L"V[)RO0$#</?!-X<
MGNM&NK22^\F:\NFGN7C7<)$)P(SG'R[ B'ID+[TX^&-]ZL[WS^4SP33PK$JK
M)+#C8P_NCA<@?W1TYR -F\6Q6MAJUS<:7?QOIB"6:#$;.4*EL@JY7H#U(Z>X
MSIZSJL>B:1<:C+!//' AD=(%!;:!DGD@< 'O^M9"^%+C^P-4TN75FE.HAQ-<
MFW7S#O!5B><$XP!V   &!BM+5=*FU7P]/I<E[Y;7$)AEG6(9*L"&P,\'F@"6
M358X]<@TIH)_,FA>99MH\O"E05SG.?F'08]ZC_MVU;4;&TA629+V)I8KF/!B
M( SC=GDD>@/OC(J.32+J76+#47U#)M87B,8A $F_;N.<\?=7Z4V?1;FXU#3;
MJ34F/V-&5E\D#S2PPQR"-N1Z=* )M+URUU:\O[>V27_0Y!&TC !9,YY7G) (
M(YQTXR.:SYO&>GQ6.JW0M[N0:=.L+1HBEY27\L,@SRI<,O..5/MFQI'ABST*
M6Z?3Y+A%GBCB5)9WE6(("%QO8^OZ51@\#6-JL*V]U=J%BBCD\R9I/-\N5)5/
MS$[>5?@8'[QJ -)/$EA-K5GI<'F2R75K]K25 #&$_AR<YRW)&!V/3BM>N?TG
MPE::1>1W$$\S%))757QA5<*JQCT5%4 "N@H **** "BBB@""]:=;&X:U4-<"
M)C$IZ%\<?KBO.;B[N!HTTFDW^IRR_P!C3/?F6>4F*X_=[.O^KDR9/E7&!GC@
M5Z;10!A:4_GZ7% @,UK*L@EN8K^20H>> ['?^((QVZ5D6\EY9>"M3N;:6^-[
M?QW%QI\,TLDTD8$?[M1O)()55;:?XF(KM** /-I+H"[F0:CJ7_".EY/)N%N9
MBQF$,>U1)G>1DR8&<;QCJ,5T[7UU-X(O-TKC5K;3RMP(\AX[CR ^.._S \>H
MKHJ8D4<6[RXU3>Q9MHQDGN?>@#SR'5-<T:SD@=C&[WJJSW,SSI!$;<,K"20@
MD,ZD?-@ Y4=B;FHZ]KWV34+-[6/SDTV2^+PK)L*>1@(K @[O.W8Q@[5[$YKN
MJ* .*U#Q-JMK/J<,8A<PW$2"5$S'!$S$$N<Y##'(( &0W(S52]UO6+I]/MIY
MX(BTMA)MMXG;[2&NL.5<'A0JJ3U&&.>"#7H%% '.:Q=K;>*]"4WTL?F.Z/ )
M"$92CX)4=<MM SW QCG,.B:A)]M\00VTTNHM'J"F-)9^50PQ9VD\!0^\8'&<
MUU-% 'G/FWEQ/<H=4N[69DO!?/)-*([?%P@AX!'EY3(!7&5)//6N@TG4I&\/
M;[BUFCLD6<270NI)&V*6^=2W[PA@,@]1D8R,&NFHH \S2\+Z;%)+J5^FFS&[
MDC$=U*TL,F(_)B:0$L6P9&VDD;B!S@5K:?>-/XEA26_N+:ZAL<:@CSMM>9D0
MX2-B5&P L6 QDXY^;';44 8'@ZZ%UH+?Z5)<F*[N8]\LA=MHF?9DGD_)MQ[8
MK?HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\\TV?6M*T5M4NKF9$N D2
MK+,]P=YD;,C"0J(AC P"1^.*]#HH \ZMO&>N7-Q:*((ED^R1RRP&+:))# TG
MEJ2V0Y?8 N#QGG-;NAZQ<7V@7]WJT\)@C0DRVFY75=@+@A22&!SC!ST[CG<;
M2=/;4!?M9PFZ!#>;MYR!M!^N.,]<<5<H X[2M1N;;P5?:A9RO<OYKR0Q32/<
M-;H2,*QR68JIW$9[E0> :AL[C4=7\1::9;E9K&VFN#'-'"52Y"I$5?KCAG=<
M\@[21UKMZ* .6M[J&?Q_-';7EP@@@=+B&6=RLTAV%=D9.T!5!RP R6QS\V.I
MHHH **** "BBB@""\N[?3[*>\NY5BMX(VEED;HJJ,DG\!7)_\+8\"?\ 0RV?
MY-_A79$!@00"#U!J/[-!_P \(_\ O@4 <C_PMCP)_P!#+9_DW^%'_"V/ G_0
MRV?Y-_A77?9H/^>$?_? H^S0?\\(_P#O@4 <C_PMCP)_T,MG^3?X4?\ "V/
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MP)_T,MG^3?X4?\+8\"?]#+9_DW^%==]F@_YX1_\ ? H^S0?\\(_^^!0!R/\
MPMCP)_T,MG^3?X4?\+8\"?\ 0RV?Y-_A77?9H/\ GA'_ -\"C[-!_P \(_\
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M G_0RV?Y-_A77?9H/^>$?_? H^S0?\\(_P#O@4 <C_PMCP)_T,MG^3?X4?\
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M^S0?\\(_^^!0!R/_  MCP)_T,MG^3?X4?\+8\"?]#+9_DW^%==]F@_YX1_\
M? H^S0?\\(_^^!0!R/\ PMCP)_T,MG^3?X4?\+8\"?\ 0RV?Y-_A77?9H/\
MGA'_ -\"C[-!_P \(_\ O@4 <C_PMCP)_P!#+9_DW^%'_"V/ G_0RV?Y-_A7
M7?9H/^>$?_? H^S0?\\(_P#O@4 <C_PMCP)_T,MG^3?X4?\ "V/ G_0RV?Y-
M_A77?9H/^>$?_? H^S0?\\(_^^!0!R/_  MCP)_T,MG^3?X4?\+8\"?]#+9_
MDW^%==]F@_YX1_\ ? H^S0?\\(_^^!0!R/\ PMCP)_T,MG^3?X4?\+8\"?\
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M_P \(_\ O@4 <C_PMCP)_P!#+9_DW^%'_"V/ G_0RV?Y-_A77?9H/^>$?_?
MH^S0?\\(_P#O@4 <C_PMCP)_T,MG^3?X4?\ "V/ G_0RV?Y-_A77?9H/^>$?
M_? H^S0?\\(_^^!0!R/_  MCP)_T,MG^3?X4?\+8\"?]#+9_DW^%==]F@_YX
M1_\ ? H^S0?\\(_^^!0!R/\ PMCP)_T,MG^3?X4?\+8\"?\ 0RV?Y-_A77?9
MH/\ GA'_ -\"C[-!_P \(_\ O@4 <C_PMCP)_P!#+9_DW^%'_"V/ G_0RV?Y
M-_A77?9H/^>$?_? H^S0?\\(_P#O@4 <C_PMCP)_T,MG^3?X4?\ "V/ G_0R
MV?Y-_A77?9H/^>$?_? H^S0?\\(_^^!0!R/_  MCP)_T,MG^3?X4?\+8\"?]
M#+9_DW^%==]F@_YX1_\ ? H^S0?\\(_^^!0!R/\ PMCP)_T,MG^3?X4?\+8\
M"?\ 0RV?Y-_A77?9H/\ GA'_ -\"C[-!_P \(_\ O@4 <C_PMCP)_P!#+9_D
MW^%'_"V/ G_0RV?Y-_A77?9H/^>$?_? H^S0?\\(_P#O@4 <C_PMCP)_T,MG
M^3?X4?\ "V/ G_0RV?Y-_A77?9H/^>$?_? H^S0?\\(_^^!0!R/_  MCP)_T
M,MG^3?X4?\+8\"?]#+9_DW^%==]F@_YX1_\ ? H^S0?\\(_^^!0!R/\ PMCP
M)_T,MG^3?X4?\+8\"?\ 0RV?Y-_A77?9H/\ GA'_ -\"C[-!_P \(_\ O@4
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MRV?Y-_A77?9H/^>$?_? H^S0?\\(_P#O@4 <C_PMCP)_T,MG^3?X4?\ "V/
MG_0RV?Y-_A77?9H/^>$?_? H^S0?\\(_^^!0!R7_  MCP)_T,MG^3?X5V0.1
MD=#47V:#_GA'_P!\"I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>bionano-nancyridgeleasee019.jpg
<TEXT>
begin 644 bionano-nancyridgeleasee019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D
M$G@"HK>[@NU9K>9)54X)1@<&@":BBHVGB258FD02-RJD\G\* )**CEGC@B,D
MSK&B]68X JG_ &[I7_01M?\ OZO^- &A15:#4+.Z.+>ZAE/HD@)JP#F@!:*9
M)+'$A>1U1!U9C@"LP^)M%$OEG5+3=Z>:* -:BHH;F&XC$D$J2(>C*V14=SJ%
MI9D"YN8H2>GF.%S^= %FBLXZ]I(_YB-K_P!_5_QJS!?VMT?]'N(I<==C@T 6
M**:SA%+,0 !DD]JY36OB1X:T/<D^H1R3#_EG&=Q_,4 =;17DJ?'*PN=3BMK;
M3G,+'YY'?&T>N,5ZCI]_!J=A#>6TBO#*NY64Y% %FBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^%EZ$H8X,,G&?=*Z3P_J\.N:+;:A#P)5!([@]P:YK7/^2FZ#_UPD_\ 0DH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?2;=I8C$Y7E#VJ]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRC$J3QD"LVXM_B#JO@2+P/)X6CM9?(CLIM5>]C:'REP-X4?,25'3W_"O8J*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+>VZ6^EM=VJHPEPZ+NW#!49<$$#G.#UK%U_Q?J&D^"O#VJ1&U%SJ4MK%-)-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %1SPK<6\D+YV2*4;'H1BI** ..L
M_AUI>FV$\4,EU?2'3GTZ 7\^Y(X6'W!M P"0,G!/%6-!\&6VF_#R+PI>.94D
MM7BNY(V(,CR9,C ]>K'!/M74T4 <E8?#O1[!XY%GO994O(;W?(ZY,D2%$X50
M,;3T '2H[CX:Z+-$J)<ZC;G;<I(T%QL:6.=S))&QQRNX\8P?>I?B3?7&F^!K
MNZMKF2VE2XM1YL;E"JFXC#<CL02#[&L;Q3X^U.RU^/3_  ]!9WJ+8B\+LRLL
M_P"\*%%?S%"8VG+?-R1Q0!T^I>$K'4M$TW2VN+N"/3GBDMI8) LBM&NU3D@C
MH?2LT_#?1E2W:"XOX+N&2:4WB2JTLK2D&3>74@Y*CMQCC%9=WXUUV'6->T](
M;#[5! \NFV[+\LRJR+N:;S-N<L04(0YP,]ZH3?$?4IK*V^Q7>EQ2KI]U>SW%
M]:O$LC0R;/)5/,^5O4[F]1F@#L)O!6F7%WJ$\DUV5U&Q6QNX?,&R5%4JK$8S
MO 8\@]^E4]-^&GAW2[R*YBBN)&CL6L2LLNX.C$EF;CESN8$^AJAI7B[7M:U#
M4&C32[&RL],M[MA=APRR30%P&;("HK#YCC./SKM[*5Y["WED>&1WB5F> YC8
MD DJ>Z^GM0!R\?PZTI-&?2GO-0EMP8F@+R)NMS$<H4(4<C_:W9[U<7P98;K5
MY[F\N);>"XMUDD=066;;OR%4#/RC& ,5J:S<36NE2RVX8RY105QD!F"DC/ P
M"3D\<<U!:Q1S6DT,[3PFVE/FE;R1N=@/WR0V,,#CCD5K&G>/._Z_JXKES3-/
MATG2;/3;8N8+2!((]YRVU%"C)]<"K58T,2#0(KB\ENU2-&N& G<.%.6VD@Y.
MT'')[436S0:#%)=27+W$$'*I<NN^0@<$@@GG@9]:?LE>U^M@N;-%16L306D,
M+R-*\:*K2,<EB!C)]S7/ZY>7=C<:C(MS(MJMFA.,?N7)DVN#CIE0"/?/&#2I
MTG4ERQ8-V.EHK%N]5FM+J*.)?-A26&"9F3D,[*!\Q8<X93@ _A4CZA>)=W!*
MP?9H;J.WQ@[VWA.<]!@N/7..U/V$M_Z_K5!<UJ*S$O+R:0RQ_9EMUN# 4D)#
M\-M+9SC.>BXY&.><4R/4;E[Y;(B'SQ,_F+M/$(&0PY[Y4?4GT-+V,@N:U%(R
M[D9<E<C&1U%<]X>N[R<P+.UR-]FLI%R4/F,<?,FWL,\@G/*\#NH4W*+DGL%S
MHJ*R8+R6WT>69P))EN)(^6.W)E*@Y.2%&?P ]JJ_;KNUU&_266&20+;*I#,(
MU+LZ[BI)V]N ><#D9XM4).]NG^:7ZA<Z"BL ZU=QK<1E8)94O!:(T*DC/EAR
MQ&??&W/7OS6GIMS/<P.;F'RY$<ITV[A@$'&21UZ']>M3.C*"NPN7**S]4$AD
MLA'/+$&G"MY9 W @G!_*H[J7S[O3G@N950W3Q2*AP&VJY(.1_>2DJ=TG?N%S
M4HK),O\ :.H211WDL,,<(9#%A27WNK$Y'.W:..G/.<BM&US]DAS.)SY:YE&/
MWG'WN..>M*4.5:[A<EHHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!#=6UM>6[V]W!%/ ^-T<J!E;G(R#QUQ51O#^C/%!$^D6#1P$M"AMD(C).25&
M..?2N?\ BD&/P_O2J.VVXM7(12QP+B,DX'/0&N;\7>,=8GU:T/A[45M--ELC
M+;W,T;(DUP)"I1@878@ #Y1M)W9S0!Z.VBZ4SW+MIED7NABX8P+F8>C\?-^-
M))H>DS6T%M+I=D\%N<PQ-;H5B/\ LC&!^%>?W?B#7HO$?B.Q75BK+:2R6DJQ
M!K>R(" "5?*WALEB&W,""?EXK)O?%WB631M&-M=W5C%,MVLE]=E"'F1@(QO6
M @H<L1\BE@.O'(!Z\UG:L9RUM"3<*$F)C'[Q0, -ZC!(Y]:ECC2*-8XT5$4!
M551@ #H *\LF\1>+&\;6MC)>P6L8^P[(V4K%=JZ@SE082S'<6 ^9-NT9'6O0
M="N3=0WK&_DO-E[-'N>W\GR\-CRP,#<%Z;N_6@";4]-.I1K']MNK91D,("HW
M@]FW*<__ %ZS8_"HAM_(BUG4XX>1Y:M$%YZ\>7BMV;R_(D\XJ(MIWEC@ 8YS
M7+>&IMH@/VBW\HV :5H)"0CC;DR9R W)].C9SCCLHRJ>S?*]%Y(EVN:#>'9'
M4JVOZNRG@@R1D'_QRAO#DKC#:]JY&0<&2/J.1_!3+*_0:'.;.XAFECGDWL@5
MBJM,V9"J^V6]Z;+J4J6L_D:FDD2RP*EXRH1EWPZ\ *<#GC'7VJ_W]VKK1VV_
MX :$W_"/3?\ 0P:Q_P!_(_\ XBH7\)1R222/J^I,\B>6[$Q$LO\ =)\OD>U/
MFU*2"VNH3>;GBNA MPS(FT% ^7.TJ.ZYV^@QFHK?4[B[LM.'V](I9;R6WD=0
MK%E7S,8R ,G:ASC!W=.137UA+F35O3ROV%H)-X-M[B7S9]3U"63&-[B%CCZF
M.E/A")BY;5=1)=Q(Y/D_,PZ,?W?)'K4HU)W@M_-U!;>$O.CW8"<E'VJ,D%06
M&3T[<8K4TZ:6XL8Y9A\YSSMV[@"0&QVR,'';-3.MB(*[EY;?\#R'9,QSX1B-
MT+HZMJ)N!_RU)BW],=?+STI(O"<D5U+<GQ'K3RR*J$L\/"@D@<1_[1J;57MU
MOY?MIBV"!/LZSS&)"VYMY#?W@-ON.,8R:I2ZI?Q"-4=+4+!&T$5Q* 925!(8
ME2S<_+A<'C/<5I&5>:TE]Z0M"\WAR1T9'U[5V5A@J9(R"/\ OBH5\(QI$D2Z
MMJ2QQ@A$!B 4'K@>7QG)J2XOYHKZ[?\ M!1%;W,$?DX3 #[0VX]>Y(Z<@]1P
M'/J$PO2OVH"<7(C%CM',>X#?TW'Y<MD' Z8X-0I5[:-?=_P//T\QZ%>'P;!;
M+(L&J:A$L@PX3R5##T.(^>M(G@V"))$AU74(MZ%&\L0C(]/]7R/8TRTU*],P
MD?41-%O0!=B ,&F:,\@=@%/'<^AQ6C87ELVLW\,=W!-(VU@ R;L\@KQUQ@=>
M153GB(WO*]O+T\A)(HP^#8XK5[?^V=4:*0@NK&':QP!]WR\= .W:IH/"WV6+
MRK?6M4ACSG;&T2C\A'3]/U!I2DTFI"1_(9[BU$0)A;@XP!N7'(PV2:-"OKBY
MGD2>\2ZQ&K$Q%616R<\@ C_=89XZFE.>(M)N6WE_P LB&Y\)1W@476KZE.$Y
M7S3$V/IF.HF\$VCQQQOJ%ZR1YV*5A(7/)P/+XKIZ*P6,K+1/\$/E1S;^#;>6
M&.&34]0>*/[B,(2J_0>7Q7001&"WCB,CR%%"[Y"-S8[G&.:DHK.I6G45I,:2
M04445D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ I'=8T9W8*JC)). !2U6U&-Y=,N
MXXU+.\+JH'<E30!6TKQ#HNN^9_9.JV5]Y6/,%M.LA7/3.#Q6E7CUKX%UVR\
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M$^K37MUK$)+WNTVT3,DD+*PAV.TVP%?E*@(#N&">2:TA6J05H2:]&*R9WO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA+INBV]M.5,X#/+L.5WNQ9L>V6.*/:3[L+$O]D:;_P! ^T_[\K_A1_9&F_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M =%P<&M.N:JXN;<-OZ\V-!11168PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9V/0 <DU1EU:,SVD<,@7S;@PN)H9%).PMM''!Z'GC&:KEC%W,G6K5H.-M/\
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M$=I67[RD;NHXP?;I7044O9Q']=K/K^"[6_(PAX> U.2[;[)*)O*:02VP8HZ
M %#GY> ..<$9J]>:?)<ZG87:3(BVI<LA0DON7;P<\?K5^BJY(D/$U&TV]E;Y
M6M^1S]MX<>WALX?M2F.P@DAMOD.?F  +<\X QQUZ\=*TK'3OL^A0:9/()!';
MB!G0;=P"[<XR<<5>HI*$5L%3$U:GQ/S_ #_S9SK>&7FLQ;SW:GR].DT^)DCQ
M\KA0789Y/RKQ]?7B2YT.\NCODNX [:?)9MMA.,N1\P^;M@<5O44>SB7]=K7O
M?\%UW.?C\-[+SSV-I,'BA2436V\AHQ@,F3QGC@YP0#6CI=A+8?;/,F203W+S
MC:A7;N[=3GIUJ_134(K5$3Q-6HN63_I&#-H%P^H2S1W<2Q27T=[M:(EMRHJ%
M<[AP0H/3O4$GA/SHKM&N5C^T+\XB0A'DWAQ(R$XSD8.,;LG/MTM%3[*+-(XV
MO&UGM;HNFQS]SX<^TVXC9;&,[RY\B QX?:%#JRL&##!YSR#CWK3LH[V*XECG
ME$MLD<:Q.RX=F .\DYYSQV'>KM%4H).Z,YXFI./++5&%#H=TFM1:A+>I+Y<L
MQ :,[MDG1<[L#;@#@<]>IJYHVGS:7HUO8/-'*UO&(T=4*Y4# R,GFM&BA02=
MT%3$U*D>63TTZ+I?_-G-Q>&[P:&NCRZA&;1EF68QP%6=9 _ )8XP7!]]M2-X
M<\VS$,L>G$ED,OEVOE^8%#8Y#9!R<@@\<^IKH**GV<31XVLW>_6^RW[_ -?H
M<^OAR47%G,]Z6EMEB47&&$I"G+*6W?,K<C#9QDGDU$OA&+^S;BP9K;RW22..
M=;<"90QR,MGG''UP*Z6BCV4>P?7J_P#-^10TZP-G'(2EHDLF-QMH/+!(&,GD
MYJOHNBG26E(E7;(J@Q1 K&&&<N%)(7.1P..*UZ*KD6GD9.O4:DK_ !6O\MCF
MY?"OGF]W7(B^U(X<0J55W+AE=ESC<,8R,;LG-2W>@7%V]S.UU$MS/);,2(R5
M587W@8SG).>?0^U;]%3[.)I]=KZ:_@O+_)?<8MGH*V>HRW %K(C7#W"LUN#*
MC/G(#YZ9)YQT.*CU70)KZ34C;W20KJ%H+:8/$7VXW89<$?WSQ]*WJ*?LXVL)
M8NLI\]]?Z?YZF'<Z%-=7%[)+-;2)=101M$\!*_NV8G^+ON..XX/-,M_#\]I-
M;S0WBNZ120.MPK2 QL^X $MGY>G).16_11[..X?7*UN6^GHNUOR,2;0&N8M:
MAGN08M2 'R)AH\1A,]<'[H/04R30)7M4"-8P7*SQ3;H;78KE#GYAG)SSWXK>
MHH]G$%BZRV?;HNB2_1&%-H$TUY<W1ND#O<PW,0$9PK1J%P>>01GTQF@:!*+B
M&X%R@E&H&^E_=DAB8S&%'/&%(YYY%;M%'LXA]<K6M?I;9;6L8VFV%_IB6=JL
MT4L DG>=O*VY#,64#YN""WH<C/3NM[HK7>KQ7XF6)XRFUT4K(%4Y*$@X96Y&
M".,FMBBCD5K"^LU.=S6[O?3>[O\ UY:'/1>')DNHF:[C-O'<7,H3RCN(F+$C
M=N[%CSBE_L"[.@QZ6;V#$*PI'+Y!R5C8,-WS=?EQQCJ37044>SB4\;6;3;VU
MV7=O\VRAIUA)97.HRR3)(+NX\\!4(V?(J8ZG/W ?QK)C\-78E>6:^@G=[>2W
M=I8"V\,P;Y@6P1QC' QTQ72T4.$63'%58MM/>W1=-#/TC33I=M) )2R-(71-
MS$1# &U2Q)QD$_C65#X9NH["V@_M!4FL[*2VMYHHL%6< ;R">VT<?4_3I:*'
M3BU8(XJK&3DGJ_\ @K\F_4YM?#,ZO+*MW$LQNHKN/$3$!T0(0V6RP(SSG.3F
MGZAX=N-0O+>Z^VI!+!"ZQM%$1MD+JX;&[D#: 0>H)KH:*7LHVL7]>K\RE?5>
M2[6,^32+:;SI98T%W-$8Y)D!&<K@X!-8&HZ%>VVA:FQF6YEDTE;)(H(&RS('
MVD<GKOZ5U]%.5.+%2QE6F][K3\.GE\C-L+%EOI]2FD#37$,<6U4*!53<1P><
MDN>OL.U8%KIMY+?2K+;*(+J2YBE1H75[>-]Q++)NV')"\*N3G))P378T4G33
ML.&+G'F??3[E9?U_P3G/^$:D_LA[,264<Q6)//BM-I8(P8;OFYSCIG R:=<>
M&Y+B:XF>X@9WOEO8U>'<@(B$15AGD%1UXP3[5T-%'LH@L;73;O\ @O+_ "1D
M0Z,\&HV-S&]M%';131M#%!L4F1E8D8/'*^^<FJT'A^Z345NY[Y)B([B(DQG<
M5E96'.[ V[0, 8Z^M=!13]G$E8NJNOELO/\ S9@VNA7=HEBZ7<)N;:S-F6,1
MVLGRX;&[J"OKSG\:ETS0CI=W;M%.&MX+&.S5&3YCL).[.<=^F*V:*%3B@EBZ
MLDTWOY+^NIG);WMWH;6]ZT/VF5&5R8<H02<93)_AQD9]>:HP^'98%M$CN@L=
MO>_:EB8,X5?+*;%);(')/MGIBM^BAP3W%'$U(W4=$^ECCM)L-0#LA@CC6YBE
M1P]NZM:AB6"ABVUADXP@ .,]JO#P[>I$PBU%(Y/[/BLU=(B""A)W?>[Y(QU'
MK71T4E2BD:SQ]64KJR^2.1N]%N[2,)$Z'SK_ .T^=' [>0?*VG(5MYSC&01U
MYXR#-;:!+=1VUQ/;V*-' UH8);8M&8@QV,JELJ<?PDGK@]*ZBBE[*-QO'U7&
MW7O_ %_7S*EHMVMQ<K,4^SAE%N FT@;1G."<C/3I].YK:=IMS82ZE(;B*0WE
MP9U C(V':JX///W1Z5J45?*CF]M+5+K:_P C.T+39-(T:VL)9DF,"[0ZIMR/
MIDU1@T&\BU1+Z2^CF=!<*"\1W%9&# 9W<;=H&  ,9[FM^BER*R78M8FIS2E?
M66^BZW_S.77PE(UA%93WJM$FE_V>2D1!/3#]3Z#BM2QTZ[@U6XO[FYAD:>"*
M%DCB*X*%SG)8]=YXK4HH5.*U0YXRM43C)[^2[W_1&5!I#)K5]?3R12QW/E%8
M_+(*&/.#G//7T%%II#0ZM?WL\D4JW,J2QJ(R#&50(.<G/ ]NM:M%/D1+Q%1W
MUW27R5O\D<LGA6[BN(IDOX0\,S.KM 2TJ-)YFR7YANP3D'CGGU!O2:->'5;V
M^6YM2;B.%%22W+>6T98JWWN>6S^ K;HJ52BC26-K2U;_  7>_P":*UI%=Q;A
M<W*3+M0)B/:V0,,2<\Y//08JS115I6.64G)W84444Q!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44C9VG;C
M..,]*Q=)O-0GOMDTL4]N+96EF0803YY6,\;DQGGGMSZ)RL[&D*3G%R3V-NBL
M'Q<X;P=J,T3@X@+QNC=^Q!%8.K,\&G^*[9BT4L=O'<1PQ.3'"N" RG@@DJ21
M@=NO)K.=3E=K?UK_ )'5A\%[:*ES6UMMYQ7_ +=^!WE%94MI:OK=I^[0K]DE
M7 Z8S&!Q]"1^)KFK-%;PWX79LEGOU#L2<L"'R#Z]!U]!3=2SM;^M/\Q4\(IQ
MYN;\/\7G_=_$[JBN=UMH+G6]#C!60"]DBF7.1_J';:?_ !T_E61J32C3]=MA
M))):6M];+;.SDE"S1[T#=<#<1[;B.U*52U]/ZM<=+!>TY?>M>SV[RY?^#Z'<
MT5RNIQ3:=K=QJ-FKR6\5M%]LLUY$D9+@LJ_WE"@^X!'I4.G/%/?Z+9YSILUG
M+<(,DK/)N7&<_>PI)P?KVH]IK:P+!7ASJ6ENWE=K?_A_DSL**Q]"FMS#?B".
MXBBBN75EF(.P@#(7!/RCM]>*Q=&22*_L[:_B6?S[60Q7T$A9+M/E.Z13R&P0
M<\CDX/:G[3;S)6$OSZ_#_E?O_G]USLJ*X?1)'EM?"MI.S?9+FSDEDR>)I@%P
M&]>"S8/7'M5F>VMK[3]0MK4WEF\>I1HLA< PR'RP1'AC\N"#CI\V*E5;JZ7]
M6N:2P*C/EE+YV_O./?R.OHKE]*OU;4KZ;48A#?V-LJW6W.TX+'>OLR@$=^W:
MJ2:CJVG6VO0/',+UK5M0M%DPQ!*X=5P3D*P&!_M"G[56N)8";DXIZJWSO;;N
ME>]^VIVM%<U$+"WN-!:)+B62XR4N(W!$V8F)\PELMQELX/3BJ>@Q#SFDGAB2
MVBU"Z5+CS2'#B;9''C^Z0Q&,GH.E'M-;"^IKE<K_ (>OGY'8T5S6K?Z3I7B*
M]YQ':R00D'IY:L2P]#O)'_ !3$5K;5=!BM<^7>0.+N$'*%!&"'(Z [L#/?=S
M3=37;^MB8X2\;\VNOX+F?^7J=117!1+CPEHSJGF2-J@4AFY<>:PP3Z8 '/H*
M=(S2>!KZ;S7\T7P(@=CNM#YJ@Q9Z\#/MAN.,5/MO+I<W_L[6W-]KEV\[=SNZ
M*Y#4I'LH%C94LS<7\,=TL$IVI 6*JV>-N[ 4D8ZGZUK2Z)I_VR61<C:BO]F5
ML1@@. VWISN/XJ#VJE-O9'/+#1@DY2WVTOV\_/\ JYLT5PEI&8O#'ARY225!
M?_9(;UPY&Y-I.3Z%F(4GJ<XK1OU^S:Q?V5LNVS;2GFEB7[L<@;"$#^$D;NG7
M;GM2572]C66!2DXJ7?IV=GU^[Y=SJJ*XKPU&+VY\BYWP(VEPAK8N2+C< 3,#
MV(/R\<YZ]JO>&;>20O'=;7?29'LXY >9.AWM[[2OX[CWHC4YK:;BK8)4N:\O
MAMT[_/O^?J=/17%>)(Y6UG5/)PNW25E,GF%6B(=_G3_: 'J.@YJ]IKQZSK-]
M]KW2VZ6UNUJDHQ\CH27Q_>)R,]MM'M/>Y; \%:E[7FTM=Z>GGY^6QT]%<9#<
M:AJ?@^&SBEN&NK@S".=&&_RD=@DF21G/[L'U#$T[4-0;5--\-WRVWF32W>R6
MWW8RPBDWQGMPR]^X%'M5;8?]GRYK.75K[K_G9_<=C17#@^;X/T^1KAY2VJ0Y
M5R<PAK@ PG//R@E#GT]*TUDNK/7]2M+"6,6ZV:3 7#$Q03%F&.O *@' ],]Z
M%5VT%+ VO:6J;6W9I?J=+16%XP'_ !2]TV2&4QD$'!!WJ.#^)J75-6-C<V5A
M:(KSSR!-N ?+78[ X)7KY9 Y'0^F*IS2=F80P\IP4H]6_E9)W_$V**YO^W-2
MBGM([NVC@5_+25U7S561I"I5BK?)D8P2",G!/%0/XGO(8IC-;HLNZ,11^7\I
M5Y0@</NVNN&!ZJ?7&>%[6)HL!5>UG\SJZ*YN36=72ZAL39(MU*9F0_*050)M
MROF<$[_[QX4G'/%^\U"]@T>UN8[4-<R[-\*$.5R,L%&1O(P>AZ GFG[1:D/"
MS7+JM?/\?30U,C.,C/I2UQ-QJ5PMU)K%HUL9DT9YW+0, ^Q\[<9!7H1R3CWK
M5N=>N(]4AAB6%X6GAAD4*Q9#(I/+9 !Z$  \=<9%2JJ-98"HK6_JW_#F^'4X
MPP.>G/6ER-VW(SUQ7&64,27NE%(T7;KEZJX4# V3\#VX%7M;>>V\1Q75IY"3
MII=RY:6,L&"O$0#@@_K0JGNWL.6"2JJFI;IO[F_\CIJ*YJ?Q%<++:F)(&CD-
MH)4 8LGG-M.3D =01C)/.0.#2MKM] =1CF2%YM/,LLJ)&P\R$)N0K\QP3G'?
M[K>E/VL2/J-7^OZ\U]Z.DI"0,9(&>E9>CWM_=ES>01I&8HY(G0@;MV<C 9N!
M@8/?/M7/N]Y=:;!)<SQ2S)KACB<QGY,3LO\ >/& ,#CCC/>AU+*]@AA'*3BY
M+2R[[W_IG:T5S$>OZ@YM[588GNI+BYA+HGRD1-@84N.3P<;NQJ]>:M=6FB6=
MR]LHN[AX8FC#!EC=R ><@'!SCD9XYIJHFKDRP=2,E%VNWW]5]VC-FBN:O-:U
M6PM8I[B&VC4RR12@C)0?P2G:QPHRNX<XSG-6H]0O;G4KFU06ABM)8H9_,!!D
M#H&++R<?>  .<X/-'M%L#PDTN:ZMZ]G;]5]YM AAD$$>HI:X_1K^XLM-TRT@
M$"Q26UU(-R$[6C<8Z$<?-T]NM6HO$-X_]F/)%&D%U#;,\JQEU620\H<-E.J[
M2002>34JJK:FD\!44FHZK7\&U^ATU%<G;:M/I]I#,T=M'9G4+FWN#'$V0WF.
M%<?-_$P (YY88JR-7U<WLEJMK#));" W&,*IW\L02_  SC@Y(--543+!33=F
MK+Y=;?G;[T='161JUYJ$-_96E@UL&N5EYG1F 95R.A'%9J:I/9O=K'%;1EM5
M:&218V.1Y(<-LW99L@#@].<<4W42=B:>$E./,GNK_C8ZC(W;<C/7%+7'3SZD
MFH6-^Z6L.I?V-<2RJ8BR@AHCLX;/!XSGUK1TZ^O+SQ$29D6U?3H)_(VDX+%\
MX.>O YQTP/>DJEW:Q<\$XPY^96M^MO\ ACH**YB]U6]T[4M=N#(DMO:6<,J0
M%2,$^9SG/'3DXZ#VK4LKZX?5KO3KCRG:"&*82Q*5!#EAM()/(V9Z]"*:FF[?
MU_6AG/"SC'GZ63_+\N9&D"&&001[4M<AI-W<Z=Y<,0@-K<ZM=VXC$9#1G?*P
M;.<$#;R,#@]:FM=<O=0MK=)4M<76ES7+#RVP'5E7'WOND,>.O'6I55-&L\#-
M2=G=?\/_ ),ZC<"<9&?2@,"2 02.OM7%+J*Z<1JD5M$'&APOY:\*"6P 3UVC
M/Y"EO!):S^(9)4M)V_T1G4PE4?D]1NSGOG/84O:E_P!GN]K]OOND^O2YVM%<
MW<ZUJ$&HW2#[,;>"^M[;;Y;;F678,YW8!!?TYQVJ:QU34;S6&@\N 6T<DZ2D
M(25VL F&W8)8$DX'&,&K]HKV,'@ZBCSW5K7_  O^7^6YO45S>H:G>:?K6J3;
MQ+:VFF+<BW"G+$&3H<\$[1SCICZTR_U[4+%;B/\ T626.VAN%D6-MF'?85(W
M>V0<^O'%)U$MRHX*I*W*UK;\;?YHZ>BLS3K^XEO]1L[KRF:T9,2QJ55E9=V"
M"3@CZ^E8R^);YK'4)E6V8PZ:+Z!U1MC??XY()4[1@X7Z4W42)C@ZDFTNEOQV
M.LI P;."#C@XKFI=?OK4WD<RV[R(;41.J,JKY[[/FY.0I&<\9]JL>'HVBU+7
MT;R]WVY23&FP',$1Z9-)5$VDOZ_JPY82482E)[?CM_\ )(WJ*YB+6=5EO((=
MUF%FOKBS!\ELKY8=@WW^?N8Q[]>U+9Z_>WT5HB+;PS264ES([J2A*L%P!D8&
M3D\G'%'M4-X&HNW]7_R9TU%<C/XFU$V4E[!';QQII<6H^5+&Q;YMV4R&']WK
MC\#5R_UN\M;F_C06Y6WFM%7<AR5E<*V?FZC.0?TH]K$?U"JG;2__  R_5'14
M5S-QK6IQW]S$AM/*BU"*T :)MQ61$8'.[J"_XX[41Z_?O]FMA#&]U)<W,!=$
M^4B(D9"EQR>#C=V-'M8["^HU+*6G]*_Y'345RE[K^KVUO<2&*TB>WTP7LD3*
M7^<%MR!@V,?+P>WO6C8SW<GBC4HGG4VT<,#)%L.5W;^AS[<\<\4*HF[(4L'.
M,7-M:+_+_-&U16(^K72Z_P#865(X'D\N*4QEU<^7NP6#?*P.?E(&0.#S63;:
MS?0:-IL5A:VJ/+:/)'&J,59U=0% W94?-G).*'42''!5))>=OQ3?Z'8T5S6H
MZUJ5E=7RJ;1HK-+9R#$V7$C%6&=W'W<@\]:G.MW']OPV:B&2VDNFMB45LH1"
M9.6)P3D$8 (P1SGBCVBV%]3J6YEVO^"?Y-&]17)Q^)-273;O49;> P06OF%5
M0C$NY@5W%L,H !W 8.:V]/N[MVF2_CCBPZB%LJ#("/[H9L'(;OSBG&HGL*KA
M*E--RMIY^G^:-&BL'7T4ZMX?R/O7S*W/4>3(V#Z\J#^%)J.MW0U)[#2X8[B:
M.W>4[B,%@0-F2RX]SSC(XH<TKW%'"RFH\KW5^R6K6_R-^BN=?7KM-0EB>**.
M/#F!F&4EVQ[B/-#84@AL@@< D9J&/Q'>D00-;XNY;H0-&\&PQ?NB_(+X;.TX
M(;'/J,%>UB6L#5:OIM?Y?\#K]VYU%%<P^NZP9#;)I\7VR*U$\B;UVL=[+@'>
M OW,G[V-PSTYT]:U"YL(H6M8?-W,?,VIYC*@!^8)N!;G&<<\]*:J)JY#PDU)
M1;5WY_U\NYI@@D@$9'44M<9)J,]KJ.HZI:&U8-8V,LG[ML2AGE&5Y!'!X)SV
MXK4DUJ<:[%9J()+:2[-JQ53E3Y)DY).,Y7H 1@CD'BDJJ-)X&:V[7_!-_F;P
M=3C# YZ<]:,C=MR,]<5QFD11I+H!6-5*WE^JX&,#=+P/:KFMR3VGB'[79^0L
M\6E7$A,L98,%>,XX(/Z\4E4]WFL5+!)5?9J7?\&U^AU%%<W<^(;B.XMO)6!H
MW:T65,,63SGV\G@#J",9)P<@#!IXUJ^CN+ZWF6%IK)GED1(V^>#9N0K\W#$G
M'X-QQ3]I$S^I5;7_ *Z?YK[SH:0D+U('UK)T74+^^ >Z@C2&2".6)U(&2V<C
M 9L@?+@\=>E85Z]W<Z/J1N9HIC#J\*0YC/R8FB]SQS_/UH=2RND.G@W*IR2D
MMTN^[M^!VE%<T=?OHV^S-%%)<'46LQ)&F%P(O,SM9NN./O>_M5Z;4+Z#PM<W
M\L4,5[!!)(4/S)N3/H>^.F>,^U-5$R)82I&U[:VMKWZ^AKTA(49) 'J:Y\SW
MO]JZ2UW'9RO+YQC:-&5D&P$8)8\GH>/RK*OM1OM7\(:O-=16_P!F_LT2*5B(
M_>E6+ $L<A<## 8.>#Q4NJD:PP,I-:Z.WXMK3OMY';45RFJ:IJ:6FIP">&.:
MUGM@LL<;#*2,N01NZ]><\CL*TO$<UY;:(DEO<+'.+BW5G"'!#2HIP,\ Y]3Q
MD>]/VBU\B/JDKP3:]YV_!/\ 5&S17.W>NWELVH.$A9+":"%TV$-,7"$E>>/O
MX YY!J]JMY=VU[ID%JT"B[G>%S+&6VXC=P1AA_<Q^-/G7]?<1]5GI?K?\%?\
MFC3W#=MR,^E+7(P:B;O5=+O[A(8YHH;Z*1QPI\MU7(/)VG:3WQFGQ^)KQ8)S
M+%"7'V01R!&5!Y[;=Q!.=H//."1V%3[6/]>ES9X"KT^?KS.)U=%<[<ZMJ\-X
MFGQP6\MVT<\JLG*L%90@(9EP2'!/)Q[YXL:U</\ V-:3O!"Q:YM=\<GS@;I4
M'!!'()R#R.*KG5GY&2PLN:*;7O?\,;5%<Q%J.IPC6I%9+IHK]8HH0N&"[(R0
MN7 . 6(7C)SZXK0CU.67PU-J,;1M,D<K#=$R@,A889"<@C;@C/7-"J)CGA)Q
ML[W3:7WJYKT5S*:_>QI=_:6M R6=O<Q-L<*#*S+M(!8MRHQC&<XI5US47@CV
MI;I*=2-DV^,D;<$AL!N#T[G\*7M8E?4:OE_2N=+17,66O:@TMJ;E;=XY9+N%
MEAC8-NA9AN&6/7:>/?K5W0M3O]22&>YMXTM[BV2>-U(SD]5P&)(P1S@?2FJB
M>Q-3!U*:;E;3S\VOT9M45@1ZW<R:['9KY#V\DLT(=%;Y610>22,G.00!CWR#
M5.U\2WZV\-S=QP2QRV%S=>7 C*P:%E&,ECG(;TX]Z7M8E+ U7_7K_DSJMP)(
MR,CM2US6E&67Q2;F8P-)/ID4A,*%1R[=R3GZUTM5&7,KF->E[*2C>^B"BBBJ
M,0HHHH **** "BBB@!&4.I5@"I&"#T(JE:Z+I5C*9;33;.WD92I:*!5)!ZC(
M'2K-R\D5K-)"GF2JC,B?WB!P*Y:+5KMM,MKI-4$RSM;K<D1J#:Y)\PD]!SA<
M$?+@FLYRBGJCJH4JM2+Y)66BZZ_=^OR.E?3[*2R6R>T@:T4!1 8P4 '0;>E.
MBLK2WC>.&VAC23[ZI& &XQSZ\5R\FIWTC6T2ZDT,<FJ26L<X6,F6+RF8'D8.
M'&W(ZX[YI+K4=0MKW4(8]3>6YMIK98+<I'^^#!=P("YP<L<@\?05/M([V-U@
MZS]WGWUZ]TNW?[NIT\&G65K&\=O:01(XVLJ1@ CT/M4?]CZ9Y,</]G6GE1-O
MC3R5VHWJ!C@UB1:K?->Q*9SY[:C)!):;5^2 ;L/TR. K;LX.['<57M=4NAHD
M=]/K$C^==?9ON1A4Q*XY8 !<KM!)SCL,FCGCV#ZK7WY]VN_6_EY/7[CHCHVE
MD*#IUH0K%U_<KPQZD<=?>I9=/LI[86TMG;R6ZG(B:,%0?ITKE+2_EO+GP]<W
M6H%&,ES"Y!0*S*< '(ZD#V]@*OZ#J-_?W:M<7, .)5GM-V7C8/\ +QM!4 9'
M).<@T1G%Z6_K0=7"UX+F<]O7>[6GW?B;%M'IOV^X:VCMA>1A4F9$ <#^$$]<
M<<5*]A:26Z6[VL+0QD%$*#"D=,#M7-7M]+::QK3VL@#YLDD<8)BC+$.^/923
MSP.IIMUK5U;+,YO";"._$*W("[G0P[B Q&WB3C)]".O4]I%;H/J=633A+HM]
M]D_UT.JAMH+>(Q00QQQDDE44 $GKQ446F6$"LL-E;QJRE2$B !4]1]*YI-5O
M!:6XGU9"O]G--]KAV%9IP<, <8(7T R<^U:E]?WT6@6-RR_9YYF@%TP&?(#$
M;SSZ9(R>G7M34XM;;&<L+6C)+F^)VW?]?UW-$:98+:+:+96XMU.Y8A$ JGU
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M2G:;7*['8RV6E6<7VB6VLX(X7,WF,BJ$8]7SV/O2M'IE_>3*T5M/<PIY4FY
MS(K?PG/8^E<O=Z[-+IVM20ZDCK%I\$\) C8!SOW <<@D*,'/7M4][J+VNJ:U
M-:3(#_H2O*N&\J-F(=\>RDGT[T>TCVT_X?\ R$L'6ZR][U?7E\O[WW_CL>3X
M?E#,8=/(B=+8ED3Y6!!1.>^2,#W&*U/*C$C2!%WN K-CD@9P"?Q/YFN+%\ML
M-5EAU!7SK5I\[%&WHRP*>V,8W<C!^7KP:LOJ]U'JD^=3)CCU=+40D1X\MHU)
M!XSPQ;!SV[T*HET_K4)X*I+:73K?M%]O,Z>ULK6R4K:VT,"GJ(D"@_E546NC
MR7LUN+:S:Y#+<2)Y:[MQSASQUZ\UCZ3JMQ=>(7M9]4CS$UPCVV4!<B3Y-HQN
MP$!SZG!Y'--UB]FL];U.6S(:YCTN,J -Q'[Q\G'? .<4^>/+>VA"PM55'!RU
M:OU[VU-JYM-'MH4CN+:SCBEG!56C4!I6. >GWCGKUJ:Y-@$BL;D0;+C]W'!(
MHVO@9P!TZ#./:N7U2\EFCN8OMAFLH;RP:.Z^4[295+C(&#@!6]MU)<74TTUD
M+B]8V\.LF."\^0%D^S/SG&TX9F7..WK2=1)V2-(X.<HJ4I=^_9-6TWUU6YU/
M]F6!38;*W*[#'CREQM/)7IT/<4HTVQ$J2BSMQ(BA$<1C*J.@!]*YN/4=72VL
M[IIY9H7GGM/EC7]YEF$$WW>,X ../F!QBNEM9X][69N?.N;=$\TD -R#@G
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MH,;'8Y4/GC&.OK@Y&>*MU(I7MN80PE><G'F^%VZ[W2_R^1UYL+,RI(;6#?&
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M",'!P?SKC--&H>1;I<)J6]=(>&8L)>9P5Z'NW7##KZU$I\K.BC0]K%N]K?\
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M0"&4GJ,'K2P7T-Q=W-LF\2VQ42!EQ]X9&/7BN+D@U&W\,:?;6MOJ$=Q%I?!
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MA6AXFF(T%)T>=/\ 2;8YB9E;:TR CY>>02,4^9./,UL3["<*JI1EI)I7]?\
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M $B_8WD.HV4-Y;EC%*NY2PP<?2K%<+8V>K0Z5;)IJ74-TNGSK,LVX)YF!Y6
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MX!.[H<XS351MVL14P<:<.9RZ)].U^_33[SH#+&&VF10V0,$\YH$L9 (D4@G
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M/I7*V6B7<4-C'>6/VB)=,AM&C\T#R98SDG.?NM\O(R?E'%3VNFZ@GB&.[DM
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MZU:HHI));#E)R=Y.X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.<;CC.:D70[,6]A%('E-@X:W>1LLF!C&>XQQ24)V6I4\1AN>3459O31:;_\
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MN.]:S:6>?=:2"6,J5&7 (R>.>"?;FF7&BVUS)=&22;R[O'VB'=\DF !R"..
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M001*<N#QSDFK=AIZ:?$L4<T\B(H1!*^[8HZ ?XG)]Z4%-63+Q$\-/FE!:O\
MS?Z6_0QK[7I7T_47%G=0Q6I='N(I4R&1E'RYSU!SR.Q]JN2:ZO\ :PT]+9V)
MN/LY;?@@^7YA;'7;CC/KQ[U(^A6TEC>V;2SF*\D:27YAG)ZX...E43HFH?VO
M+>I=M&[SHV]9CM:)=H*M'MQD@$9![Y]J3YT7%X62:M:U[;^5ONU_R(]"UB<0
MP6D\4LKRR70AF>0'=Y<K *>_3 S[5=TK5+N]\*0:I+ @N)+83;%/RDE<_@/:
MI;;0;:UEMI$EG)MGE= S#&9#E\\=R34]CID&GZ:NGQ-(]NB[%61LE5QC;GT
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MG3'&*B_X1NS-O<0M+<,+A(U<EQG,?W2,#@C ]N.E2XU.G]:&\:F%NG);6_\
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MD;=W_6W_  3;ZU3C3Y(IVU7_ *5Y^<;^AS^CR"&/18_+4HU]>QJ=S#9AIB,
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M:\NK.+6+F.+S8H&E@AAD(5PT:G#$\ Y!'IWK032;"-75+9 KH8R!GA2<E1Z
M^@Q4HL[<67V+RE-ML,?EGD;<8Q],<4U&75BG7H_\NXV_RU\^VGXE/1=3;4H9
MC)A9(I C1F)HG3Y0<,K=#R>1D$8-9R>(KMM(CU3[+$;:Y6/R!OP59Y BAO\
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MB&_2KW]F60>V9;:-3:@K"5&-@.,@8[<#CVI;O3K.^9&NK=)2BLH+?W6ZCZ'
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M74]2N(HG<:7#,4AR 3OD&"><]AN]!TJ?4I[FXBMOM=MY;0ZG;"*7;MWJ67)
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M9AUHP"V^4855<*Q[Y(P>N,,.*TO$6IW6GO&8'(C6&2281;#(H&W#A6^\HYR
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MVXQTJ36M0N_L>H6Z7[20Q06TXNHPH(+2$%<@8Q@!O7GK@UUJ1P))A$C$BC.
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M[$V\#!088R%^[E1Q3O+3>7V+N(P6QR12]E+N:/&TO^?>GZ7O;;Y?D<S-JUY
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MOI1'+>74[2FW N()(779-GDY8X[D848(P?2H6EOCJMZ&>X>!EFVNKR1F' P
M5^Z1D?*RD']:Z::3R8))1&\FQ2VQ!EFP.@'K361;JU*2(ZI*F&4DJP!'3CH:
M.31*X?6KS=1QT>GI^7];G#O)>W?ANZ,+W=S#<:"QF#[WS<,H"A<\Y.6R!QT]
M:N:VMQ=P:_;QK=R1/I<3Q( ^#)^\W!??&S*C\JZNUMHK.UBMH%*PQ*%12Q;
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ML0!$T@#')P.,YY/2JE%2W9E2K5*3:A#?7KTNOU.298U\1&XN+>XGMX;Z)?M
M"/ME,:QA&)8-M#,#A5//.>H$EKI^I)=7$K:=)%YUG<1.BNI!D+Y7DL2V03R?
M7H!72K+I;W$LZO:--$,R2 KN0#(R3VZ$?@:>VIV"P><U[;B+)&\RC&1U&<]J
MA4UNV;RQE2RC&'1+KV_I_P!:Y&H:=<7/@&33_LA>[-@(EA8KD2;,#G..#WS5
M>?1YY=79F@N$MBD#6WD&)?(*$EE.>5YP3MZ@D5O3:II]O+Y4U];1R8!V/*H/
M/3C/>HO[<TT7=W;/=PQO: -,9)%4*#[Y[=ZIQAU9G3KXA)\L>[V?6W^2^\P8
M='O!]L>XBO7NO]* DBEC19D?=M ;[V<;0,\*1Z 5<TK[5H\/DSVN\7%VJ(T:
M)&Q4H/G9 <<;<';V&<=36R^HV,8E+WENHA($A:51L)Z9YXS31J>GF-)!>VQ2
M0D(WFKAB#@X.>QX^M"A%;,)XFK434H:/R?K_ ,$H:I8&;7])O19"X2'S%=@%
MRF0-IY(X!!Z5CV^B7@L+L7$%S)>FVN(F):+RYRYRI]2> 1N^[S767-Y:V:JU
MU<0P*QPIE<+D^@S5:'5;>66X(GM?LT4<;B9;A6X8$\C^$=,'/.:)0BWJ_P"O
MZ0J6)KQII1CHNOS?ZOI^ASJZ7?6T5\MOI3;9K"V0Q[U4/*K-YF=K D[6'<;L
M8S0ND7C6R0R:?(Z+JPG"MY8 A(YX!P!R<C^=;5YKUM ]DT,UM-;S7)MY91,,
M1'8S?3^'&#BIY-<TZ.:RC^UQ-]LSY+*X*M@9ZY_#ZU/)#N;O$XG?DWUZ]%;O
MV1S\6C3JFFF32M\=IJEQ((CY9*P.)=F,G& 63CMCIQ6UJ]K--J6C30VYD$%T
MSRN"HV(8G7N>F67@>GM5R>\$-];6^8?WH<G?,%8!1G(7^+W]*+;4K"\D\NVO
M;>=]N_;%*K';TSP>E4H16E_Z1SU,16FU4<>C[[.]^OFSE;/09%N+-IM(_=BY
MO#,#Y9!B=F:,$;N1RN!V([5%#8LDN@VNHZ:UQ.-(GBEA;8S$JT(&23CN<'/&
M?K79R7EM#.D,MQ$DKXVHS@,<],#\#4#3:8UZ7>2T-U C$L2N^-1UYZ@#//UJ
M?916S_K3_(V6/K2=Y1[[7Z\WG_>_!&%I^A7 U*P;4K?SW@T^%'N2P(\]&SGK
MDGWQ3+#0KF1;&WO+<J$M98=0E+#_ $EFQ@\')Y!;)Z9]S6^^J0--:I;S6THF
ME,9_?@$84D[1_$>G'H<T_P#M73M[I]OM=R LX\Y<J!U)YZ#!_*FH0[DRQ6)?
MV=_73=?+?\$<X=%U(:+#YD2M=QRQ1RB+9NF@B.!U^7)^_@_2GG0_](TT-I\T
M]K&;DR+.8R5#\A2 0,9Z 9QQTK?75M.>*:5;^U,<(!E<3+A >A)SQ2+J^F,X
M1=0M2Q<1A1,N2Q_AZ]>1Q[T<D.X?6L1K[O?H^JM^">AREIHFK1:<L4%L]M=R
M:+]GEF,B\W QC)!))ZX;G&:M3:-(]BODV%T2]Y;2O#*8AL",-Y4+@#Y1@^M=
M.;VU6<P&YA$P&3&7&X<9Z?3FH5UC39$D>*_MI!''YK;)5;"^O7I2]E!:7&\;
MB)/F4?/9_P!6.;;19Q!"K:5OBM]7>9(<1G$+!ON@G &2#CCZ5;@M;NQUF[U
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MX)Q_=S24(/K_ %_3+EB,3!-..S7?K9KKK\/GU*_V*Y;P=/926L?VEK>5!#$
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MWGCE53@F-@V#C/;V(K/U/6X;/3KJYM7@N9+8!GB$HR!G';.._P"5'+&*O?\
MJUA.O5KS<7'5Z=>LN;\_/8U:*K)J-C) \\=Y;M$C[&=9 0&XX)]>1Q[U5FU4
MB_L(;80S0WBR%91)P"JY'0'(/UK1R2..-&;=K?TE?\C3HJCH]^VIZ3;WKQB)
MI5R4#;@.<=>*O4T[JZ)G!PDXRW04444R0HHHH **** $.<' R>V:YJVT?5X]
M!.DLUI$DS7'FS)*S,JR%V&T;1R"P[]C72L0JECG &>!DUF6OB'3+P;HIV"F
MW :2)XU,8X+ L!TR,^F:B2C?5G30E5C%\D;JZ>U[-7M^;,T>'YWM%62WA6XQ
M$KR1WLN[$>[!5B/E(+<#!&"0:!H.I>=:2FX031+&KSK(1Y@60L5=-NUN#P?E
M.23Q5V]\26=KI]Q<HLLC0QK+Y1C9696. V".G!YJ36]0EL]#>^M3M960XDC.
M2"P!&TX(.#4<L/N.I5<4Y)-6YG;6^^G?U7](I6NA7<$EC&SQ&*RNY[E9 QWR
M[_,PI&./]8<G)SM'KQ?T#3I-,TB"VG2$3HNUVB.0PR2.2 >YIZZU8NKXD<.D
MHA,31,'WD9 VD9Y'/ICGM4G]J6?]EOJ0E)M45F9PC$@+D-\N,Y&#D8[545!.
MZ9C5J8B:Y9QW:Z==7^-V<^?#FH_V7>6J/ JSQ(JPM,SQHP;+;25W*OHO(^G>
MS-I&I-<WTT8M,7%[#<!6<YV*BJ1DH=K94$$9_ \U?;Q#IJ07$SS2(MO&LL@:
M!P0C=& QDC@\CTI7U_3HXFE>615579]T+@HJ':S,",@9[FIY:?<V=;%-W<-_
M)^3_ $7F9VGZ)J%FVE[A;%;-K@MB9B6$A)7&5]^<_K5NPTRZM?"BZ;)Y)N5@
M:+*N2A)SCG&>_I5I]6LVNOL27&+AW,2D(2HDV;]N>F=O.,U1TOQ##+H]C-?R
M%;J:Q^V.(X7(VC;N(P#T+#CKS0E"+M?^M"9RQ-2/,X]4]G?[3OZ:LHOX;OIH
M)(F>VC!TZWM@5=CEXG+<C:/E.<>N.U6+O1+ZYDN[M?(6XEN+65(3(=F(7#'+
M;>IY'3L*DUWQ EIHUS/8S;KF.U%R@\EG 4YVEL= <'KZ'T-:4FK6<-U]G>4B
M3>L9(4E5=ONJ3C )XX]QZBERPVO_ %J4ZV*LI\OX/IRO_(AUBRN;^TM4A6'?
M'=0SN'<@81PQ .#GICH*S1HNI*3@6FUKZ:X8>80VQU(&&VY4\\XQD=_6R=:\
M_7;"WM)-]K.)@Y,1P2G=6Z'G(I]_JDL>N6^G0DQYA:XD<V[R9"LHVC'J"W/8
MX^E-\KU)I^WII4TEJF^OFG^15M?#US'::*KR1)):6PM+L*2RS1 #@<#^)5Z]
MF:I;;0Y(=6EFE6.:(W9NHI&GD#(2N,;/NDCD9ST/3BK-OXBTVZACE@EE=92H
MB'D.#)N7<-H(YX!/MCFG/X@TY5A82ROYRNT8C@=B=APPP!P0>H/-"5/N$JF+
M;:<7K?H^MW_G\BAKVCZAJ5S(;<VWE&*(+O<HP=)-YR0I+*1C S@')P:;=:)J
M$UU>2HMKB:^M;E<RMD+%LR#\O4[./K6K8ZQ8ZC*([65F8Q+,NZ-E#HW1E) R
M/I4=SK^G6=Q+!-)*KPF,28@<A=YPN2!C!/&:'&#UN*%7$Q:IJ&JZ6=]U_DBM
MI5LKZO>WD$A:R=]Z(R%<3$;9",^RC\6:K#Z=+)XB-ZZ0M;_91$,L=X8/N! Q
MC]:D36K%X6D5Y/EG^SE#$P?S,9V[2,]"#]*CD\1:9'%;2&:1EN8S+%L@D;<H
MQGHO&,C@\T_<2W(?UB4VU%[6V\OSTN8L7A6Y7119DPBYA@6"*X,\C^8%=6 9
M3PH.P9 SUX][>HZ/?WJ 106,'FB;SU1R&W.@4-OV9/0Y QGCGCFUIFKF6>XM
MKM]TRW4L4>R)L;%QRQ&0.O4XI+SQ/8VVGS747F3&.)9E0(PWHQP&!QR/?Z>H
MJ>6G;^NAT.KBW4M:[OY_:T_KL]C'ELKF;4)]*VVWG2Z+';.6D)53EP2/E^;
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MB#7-B;-ML!P,D_,/F_VCQ^M4]1T2[2VO)(Y!.]Q;V]L52+!01L<R#+'.-['
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M<M\J^@X]ZO-:S/=:?%)AH;93([@8#.!M48R?[S'Z@5I44*"6PI8JI+XG??\
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M9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 5="667;+'F09QQ@9X]"<U:O9=/NM)N;&_G@N3)<Q>?*B[4<--\HR.ZHHSZ
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MGBD64@;=H&WC'RC@D'.6!-5M =?-\,+D9%A<J1Z'='Q^A_(TO:W>G];?YEK
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M;$5RI+$<C)X8U?\ M]^;[ E?[3_:0B%OCY3;?WL>FW+;O7C/:A54.6 DNO\
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MZ?110%PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*#4KG4(X+BRG@^SM9"=BT))W,/E_BZ<-D>PYYJ#0-7O=8M;>8W%MN>Q2>9!
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MSM 7T^9L^NX].,6]/TP6*72M,TPN9FF?<H&"P&0,=N*:Y^;4B;PZI-0W=O\
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M%UXAG:*WO;*,FQDC23<T1.<R!75B.$VKD\]_H:N0:%]E%E)#=,+BTMC:K(R
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M Z<U)_;]F$.1()!<_9/*.T'S=N_;G.W[O/7VZ\4FH:&+^YN9C=RQ&>U^S8C
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M!O+6R:68QR3*D;,VZ-&V@C"]6[#I[U<70[(07L+K)(E\,7 DD+;_ )0N?8X
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MK98VM99%N%\S)1$0/O''((*X'^T/?%N31;*65G='.\HTBESB1DQM+#N1@?7
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M^5>OI1::'964MK)")0;:-XXMTA("N06'/7D#\J2C.][_ -:%RK87E<5'3_\
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M'&<9Y//O5M=*MDO&NE,JR/M,FV1@)"HP"P[G 'UP,TZ[TNUO;F.>=79DC>(
M.0-K@!@0/7 _*G:36IFJE",DXIVLT_5JWYF7'XH1K6[F:U.;=8781OY@VR'&
M25'\.#NQD8'&:6'6[J[U72X[=+9K6Z@GD9DGW@['105('/#9Q[X.,5:A\/64
M&3&UP&*1IN\]LXC)*=^V3]>^:E31;..:VE19$DMVD9&60C)D;<^?7) -)*IU
M?]7_ ,C253"*_+%_U&W?^;4BU/5IK&\CMHK19VDMY9P3+L'[O;D'@_WAC_)J
MHOBF-;>6>>T=$%I%=Q!7#%UD)55/3#9 '<<]:U+K2[:\N4N)?,\Q(GB4JY V
MOC=Q^ _*JR^'=."%&C=T-LMH5:1B/+7E1UZC/7K0U4OHR:<\+R)3B[]?O]>Q
M!<^(7M#<1R68-Q;RVZ.BR\%9FVJP) [YR"!TJ"XUZ]*0B"UB29=1%G,C2DKT
MSP=O<$<XXK1DT*SFBE27S7:62.220R'<S(04Y'8$ X_Q-(^@V3K*")@9+D71
M82L")!@9![<#&.E#53N5&IA%O'7_ ("\^]W]QF6^J3V.KZC'(CS6S:E% &:8
MDQ%XHR H.>-Q/<8SQ5F^U+_A'PJ3.9OM,DLB23RE$0Y&(]Y! )SQG X/(X%6
MGT&RDEED;SMTEPERW[UO]8@ 4_DHX]JGO=,M[_(G\PJ8VB95<@.C=01WZ?7T
MHY9I,3K8>4HW6EE?SLO7N4?%-S<6>B^?:S21RK<0+F/&6#2JI'/'(8U5L-7N
M84U!;E_->*]$21SNL;PHR@C>1P>Y&W)((')SC9U#3;?4[06UP'\H.KX1RO*D
M%>1Z$ _A59O#^GL2Y23SC.MP9O-;>7"[0<Y_NDC'3FB49\UT%*M05'V=1:W?
M3TZW\G]Y2/BJ+[)83_9Q&+M&*^=)L4,&"[-V,;B<X!QG%6;?7EN=2^S16LK1
M>?);F958A60')/& N05SGKCCFGIX>L$MOLRB;R"I1HS*Q5E)+;3D\C)/O5B'
M2[:WNY+B+S$,CF1D$AV%R,%MO3)_^OUH2J=6*<\)9\L7?6WZ=>G]>6'XEU27
M3=6M\W5U%;-97$CK H;#(8PK<@X WG)/'K5C^W+JPLK*WNH?M>I-9_:)A!G:
MVW .W .22>.@]QQ6K/I=M<:A%?2AVFBC:)1N.W:V-P*]#G _*JT/AZPMX[=(
M?/C^SJR1,L[;E0XRF<YV\#CMCC%)QGS-IEQK89TX0G'5;Z;[]=^WK\M:UQXC
M>">=?L),,#6^]S)M8+*< [<=0>HS^-6=+OKN[U+5H)XXA#:W(BC*L2<>6C<C
M'^T3^G;-.GT"QN&N#()?W_E^8!*PSY9RGTP:>^CVK27CAIT-V5,OES,N2  "
M,'@X51QZ4[3O_7G_ , ASPO*TE9M?_(^?^+\#0HHHK4X0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***BBN
M8)I9(HI%=XCAPO.T^A/K[4#2;U1+14%W>6]A;/<W4JQ0I]YVZ#ZTS^T;3[7%
M:^<!<2IYB1D'++Z_3I2NBE3DU=+0M45&MQ"\\D"R*98PI= >5!SC/UP?RJI%
MK.G3M L5TC?:"1"0#B0@9^4]^ :+H%3F]DR_14:W$+SR0+(K2QA2Z \J#G&?
MK@U5AUG3KB98H[N,R,[1JI.,LO51GJ1W'6BZ!4YO9/0O451_MC3A-)$;N-7C
MD$;AC@*YZ*2>,G(P.^:EN-0M;1Q'-*%<KOV@%B%_O$#H/?I1S+N/V52]N5_<
M6:*JMJ5DLMM&;F,O=#, !SY@QGY<=>.::-5L2)2+A?W3B-Q@Y#GHN.YZ<#UH
MYEW#V4_Y7]WR+E%0VUW;W<)EMY5D0$J2#T(Z@^A'I5<:SIS*["[3:D?FD\_Z
MO^^/5?<<4<R$J4VVDGH7J*J#5+)OLV)U/VH9@X/[SOQ^'/TIEOK&GW4J10W<
M;.Y957."Q7[P&>I'<=J.9=Q^RJ6ORO[B]15!];TV,MYEY$H4,V6. 0OWB#WQ
MWQTI8M8T^>X$$=RAE9S&$P0=P7<5Y[[><>E+FCW'[&I:_*_N+U%0BZ@;S]LJ
ML8#ME"\E#@-@_@0?QJN-8TYK.&\6[C:WF;9'(IW*S9Q@8[YXIW1*IS>R9>HJ
MG/JUA:R.DURB&/'F$]$ST#'HI/;/6FOK.GI)+&UTH:%PDF0?D8] 3CC.1^='
M,NXU1J/51?W%ZBJCZG91W(MWN$$A<1X/3>>0N>F['..N*M,P12S= ,FBZ)<)
M*UUN+15$:SIS627JW<36SOY:R*<@MG&..^>/K5X<C-":>P2A*/Q*P44U'21=
MR,K+ZJ<BF7-S%:0-/.Q6-<9(4GJ<#@<]33N)1;=EN2T55O-1M;"UFN+B3$4.
M/,*J6*?4#)[U:I70W%I7:T"BF[T\SR]R[\9VYYQZXIU,D***HPZO93JI21_F
MG:V :)@?,&2001QT/)XI-I%1A*2NE<O4444R0HHHH **:[I&NYV55R!EC@<\
M"H8;V">\N+5&;SK<*9%*$8#9P02,'H>GI2NBE%M-I;%BBHHKF*:6:*-B7A8)
M(-I&"0#WZ\$=*EIB::W"BFNZQHSNP5%&69C@ >IIU @HIK.B8WLJY.!DXR?2
MH;:]@NY;F.%F+VTGE2AD*[6P&[CGA@<CUI712BVFTMBQ1113)"BBFNZ1HSNR
MJBC)9C@ 4 .HHHH ***BGN8K94:9BH=UC7"DY9C@#CWH&DV[(EHHIK2(K!2P
MW$$A>Y ZX'>@5KCJ*KV=[!?VBW5NQ:)BP!*E3D$@\'GJ#3[:XBN[:.X@8M%(
MH9"5(R#['D4DTRG"4;W6VA+15>ZOK6S:%;B98VF?9&#_ !-Z#WJQ3N)Q:2;6
MX4444""BBJ[7UJE\EDTRBY=2ZQ]RHZGZ47L-1<MD6****!!1110 4444 %%%
M% !1110 457NKZVLC$+F98S,^R//\3>@]Z(KZVGNYK6.96GA ,B#JF>F?K2N
MMB_9SMS6T+%%%%,@***K0WUO/>7%I&S>=;A3(I0C ;.""1@]#T]*+C46TVEL
M6:***!!15>]OK73K9KF\F6&!2 9'X ^II)]0M+5H%FN$1KAML()YD.,X'K2N
MBU3F]4OZ19HHIJ.DB*Z,K(PR&4Y!%,@=1145M<Q7=ND\#%HW^Z2I&?P/- [.
MUR6BJ\5]!->W%FC-Y\"JTBE",!L[2"1@_=/3TJQ0G<)1<79H****!!1110 4
M444 %%%5S>P+J"6!9A</$TRKL."JD G.,<%AQUYHO8:BY;(L4576^@?4)+$,
MWVB.,2LI0@;22 0<8/(/2K%%[@XN.Z"BBB@04444 %%%% !115:ZO[>S>))6
M;?*<(B(SL>0"<*"<#(R>@S0W;<<8N3M%799HHHZ#)H$%%56U"V6ZMK?S,R7*
MEH2JDJP R?F''3WJU2NF4XN-KK<****9(4456NKZ"S>!9V93/((HR$)!8] 2
M!Q^-#=MQQBY.R5RS1137=(T+NRJHZLQP!0(=1145S<Q6D)FF;:F0O ))).
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MEEK+0RF/4E>*X1+:3?&/O1EQCC;C9T'WJDL+I3??VI<V-VI)^S65LMJ_^CP
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MYI\T>K1Z+?M/)?-=VK+;PO&7S, ^[S J]<JR@\=0U=C44LQBEA00RN)6*ED
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M2[OY0VH>9%+9M&L7FF/EAYN .&&,Y'(%%W]JEOU^U1WK31:LC(J)(8Q!_"0
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M&WYB3@G+<C)]:Z2BFJ:3N9RQM24'"RM9+[CD]0TJ\.IW;PZ>94EOK2Z2160
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %4(]/D:SG26=X[BX??)+ V"IXP%)'0  =.<>]7Z*35RHS<=BE
MJFFQZK9_99998T\Q),Q8R2K!AU![@'\*?<67VB:UD-Q,OV=]X5=N'."/FR/0
MGIBK5%'*MRE5DDDGHK_CN8L_AJWGCOXS=W2QWLRSR(I3 88^[\O'W5S]/K3Y
MO#UO*NH*MQ<1IJ$>RX1"NUB1M+@%>&(X)'Y9K7HJ>2/8T^M5OYOZT_R7W&5#
MH,-O<FX@N;F*5X5AE*E,2A1A68;<;@.XQ1::%'96^G6\-Y=>58#$2DI\PQM
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M>97]@VXMKJU%Q<K:W/FY@5P%0R9W%2!GJQ."2 3TZ4V'P_%"9&2]NMTA0O\
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M:/\ 1!1115& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% ",P12S'"@9)IEO<17=M%<P.'AE021N.C*1D'\J69#)!)&,
M LI S[BN0T[P;-9SV-S(UJUU;-; 3#.X)'!Y;J#CH3V[CK0!T]SJ5G:;A-.H
M*R11LHY*M(X1,@=,L0*MURFJ>$S?ZM?SBWL3%>M9-)(X_>$0S*[H1MY#*H[]
M0 1CFJ+^"+H7-GAX&M8)9BD*R"/R%:X:5#&3&V"%*KA=OW0 <4 =S17,:UX;
MN=2\2VFHAT>WB6(;&D"-$R2%RR'RV.6! (!3.T D@\9DO@F_:VDC^U02+%<H
MMM"QPAM$\PI&^Y'&09?[K ^6GU !W51PSQ7,*S02))$XRKH<@CV-<E#X,:.X
MMK@B RP"T6-Y&,CHD>1(H;:.&5L=!D=0*G@\,3V_@K^Q(HK*)XY%;;&2(IU6
M16(?"C&]05;AL _Q4 =!/J%O;WUM9NSFXN0S1HJ,WRKC<Q(& !N49/J*M5RF
MC^$S9:Q9ZC/!9(8$NPD,(W"#S7C95C)4< (^>!RYP,$U3U#PAJ=_J^J7)DLH
MXKNUGMU*?*S;S'MWX0'C8W)9NO '2@#MZ*X;4/"4\4\4-@D<5K=7SQ21PKA(
M[*2-6E4@8"DM%QCN_N:V]1T:>Z\16VH""SN(4B$8^T,0ULP;/F1C:06(P.J_
M='- &]6=?:W8:=<""YE=9"GF';$S!5+;020,#).!GK7*V/@>Y6&*&ZBT]8E^
MRK/'$69;HQ,Q>60%1\[9Z'/NQJ5/!$B1M@68E%LMO$^TY15G:0 '&0 A5<>W
MI0!V44R3H73=@,R_,I4Y!(/!]QU[]1Q4$FI6<5E%>&=6MIGC2.1/F#&1E5,8
M[$L.?>N=M_"]S#JL=Q<06%]#YD[;;ACFW#W$DNZ,;2"Q5U!^[]P<D4)X6GC\
M!VV@+;Z>LL#P$H"1%,(Y4<EL+D%@ASP>3U/6@#K:CAGBN$+PR)(H9D)4Y 92
M58?4$$'W%<./!%\9;-W-L(8WD;[-%+L6UW3>8/*8Q,>!@<!/NCD#@/N/ LTM
MFUI"+2UCDOK@SO"2K36D[EG0X48?[BCDC"]1T !W-%<#+X)U2Y@LGO;J"ZN<
M3&[(D\L%W*;9$8QN0RH@7("GT8=Y7\%7DEQJKRRPN;MI=LQEP61YED"NHC!.
MU1M!+M@#@ '  .UFGBMH'GGD2.)!N9W. H]2:9!>07,]S#$^Z2VD$4HP1M8J
MK@>_RNIX]:P)_"V_PKK&BQQV@BNGE:VB*_NHPW*@C''S<\#CK55O!\C:BU_$
MMI9W+W(<209+0Q?8_(V*=HX#X8#@8 /!XH ["BN0TKPY=:/X6U2U:-#<3VY4
M+!(&5V$97( C3!/XD\9)JKI?@R5OL4E[:6$-NEQ%/+91Y=&VV\D>\@J 7+.I
M((_@')- '<U&)D,[PC=O50Y^4XP20.>A/RGCJ./45Q<?@R^!G<-90W"1R&*X
MC9BUS-YRRQ23?*,;2F,9;AVQ@<%;CP;>O8S1AK:>>6WMPQDD*J;A9)Y)'(*.
M&4M-D*0>_3 - '9QS)*T@7=F-MC;E(YP#QGJ.1R.*DKB=0\(W]U)-(ZZ=>+*
MTW[BX++&K/%"@E VM\RF)\#T<_,*D/@R474ET7AFN'G8R3,[))+";/R=A< D
M9D ;C('7K0!V559M0MX-0MK%V<W%PKO&JHS?*N-Q) P!\RCGUK!7P]??\(<F
MDN+(RI.LGE !8I(UE#^6Y5%!W*-I(09R<@\Y;HOA0Z?JMG?S0V2O!%=(J1#/
MD^;*KJD9*CY5 <=OO'  .* -]]2LTGAA,ZF2:<VZA>?W@1G*G'0[5)Y_K4ZS
M(\LD0W;H\;LJ0.>F#T/X5RA\&QRZF[3V6G/9OJIOW!7)F4V\D>UUVXR'?/4Y
M&3P>#3?P;J?]DP0>9:3W445J$>:0E%DBB9"S*R,'!+=#@]\J0#0!V-[J-GIW
MV?[9<)#]HF6WBW'[\C?=4>YQ3Y[R"WGMH97VR7,ACB&"=S!6<CV^56//I6%X
ME\-77B*90+\VL$5M(L1C4,WG,1ASN!QM"C!'/S&LFX\'ZI>:C)=R-80W,C22
M&^B9C,I>U,.P?*/E5SN'S=!T!Z@'9Q7D$]S<6\;YEMRHE&#\I(R/KQ4]>?MX
M&OF@8);:9;1M<I,UC _[E@(3&<EHB,Y.[[A_/FK\?@R6.[2Z26..X29"MP6+
MRK$+3R2N_ )._P";L#UZ\4 =4EY!)>S6:/F>%$=UP>%;<%YZ?PM^53UPFG>$
M-2TUX[F"VTN&:%K9A!#*ZI*8TE1V9MF03YF>AY'/K3HO DDD=J;X64\T,5E'
MN()P(I':4#(Z.K[<=^AXH [FBN8E\/7B^$XM(A%FYCF)V2J#'Y7F%@HW(P!"
ME0,J0,8'8BC9>"KF!;"6>2VDO+2&PB2?DLGDN3+M.. RG';/0X% '7"\@-\U
MD'_TA8A*5P?NDD YZ=0:CCU*SFN8;>*=9))XY)8]G(94958Y''!=1^/M7/>%
MO#%SHE[)-<Q62[K2.V>2!B7N75F)EDRH^9MW/7GN:SG\ O)I8M/L^FQ-!:7T
M-LR X$LK1M%+]T;6&SG&2.,$T =[17,:7X;N;+Q3=ZI.Z2+*\K)*) '*N00C
M+Y>2%Q@9<]!@#MB_\(CJ&H-JS>1:VAG-_$LY9A+.)7.P/A>$&,@@GMP.: .]
M69'EDC&[='C=E2!SZ'H?PH6>)IW@61#+&H9T!Y4'."1[X/Y&N9N/!\,VIQ'[
M/9_V8ES'+]D*?+L6"6/;MQC[TBG'3@UF_P#"#WRV3Q*;+[1)IUE;27.?G=X'
MRZ$E#E'4!23GH,J10!VMY>06%J]S<OLB3&6P3U( Z>YJ>N"N/ ]W);V\2PV+
MA8PJ^?,6^RMYYD+18C ^8$+@!,!0.15SQ-H%YK.OIY%K;F/[&$%U.2#;OY@.
M^/"G+@#(Z?6@#L:9-*L$$DS[MD:EFVJ6. ,\ <GZ"N1F\'NL*NMIIUW*U_<W
M5Q#<DK'.LCR&/<VUB2@<  @CKCL:K/X(U VKVG]H1RPG33'F0MN:]\C[/YIZ
M_*4^ISS0!VTDR1(K/NPS*HVH2<DX' ''7KV[U)7)-X8O3JEW/']EBAGNK:X/
MS;Y',<J.WS; 0"JX"DL,GC:*HV_@>[^S""X6Q"@6R3LC,?MWEW"2/)*"H^<J
MK#'S<N<G% '=T5R-CX5NK'5=.GB6S$5K+<<EL[(7ED9$1"GRD*ZC*LO0C# "
MGW'A>>Y\2R7TD=F\#W(F\]R3,(_)\LP;=N-A.6/S8^8_+GF@#>M-6LKW3[>_
MBFVVUP5$+RJ8]^XX7 8 \\8]<U-:7D%[$TMN^]%EDB)P1\R,48<^C*17-OX3
MQX+T?1EM;":73S;.8Y%Q$[1D;^=IQN^;G;SGGJ:IW'@BX9+M[66V@N+I;X2R
MH"#+YMPLD88XY 4,ISG&XX!R: .QN;J"SMVN+B01Q+C<QZ#)P/U-35RZ^'+F
M/P?<Z5"L,=Q*YD5#-F-3N#8!6-=H..@3C)ZU%-X=U*^\36^KW8MUVK%^[CN,
MF HS'Y6,6Y@P(R 4SR#D4 =;17GL?@G5AIUQ&XTTW$DD4L:J56%9%1U9S&(=
MK [A\I&<?QY -:5MH&I:3K&H:LD<=Y<2&4P$3!"_F.I5''EYVK@#)=L!>!SB
M@#J+F]MK0-Y\RH1$\VW/S%$QN8#J0,C\QZTJW<+I;NI8K<8\LA"<_*6YXXX!
MZX].I%8NO>'WU35;:]BAM'>.SN;4O-PR&0)M93M.<;2,<<.>>QSHO!LEJ8DM
MA;1VR2K*T,;-&&/V62%CD#@EG4YZX&>M '822)%$\LC!8T4LS$X  ZFJD>K6
M,NC_ -K1W"O8^29_-4$C8!DG'7IVZUB1>';_ /X0Q]",MM TKF-VA PL#/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3YOWH,?FY.W9M!*$ >G<5T5C\1-$O(FF9I88A%;NN8V=W>7S/W8106+J8F!
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MR-)YF4..,, 1P>E4-.^&^AZ5*7M'NE'VJ"Y52ZD(8MQ5!QPI+NQ'JQYKL**
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M(AE3[=&A;RPA QW ;&"1W -; I%"T444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_6W_ ']7_&@9:HJK_:=A_P _UM_W]7_&K(((!!!!Z$4 +1110 4444 %%%%
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MI\"_]"U9?DW^-'_"J? O_0M67Y-_C57_ (6WX:_YX:Q_X+)O_B:/^%M^&O\
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M7Y-_C57_ (6WX:_YX:Q_X+)O_B:/^%M^&O\ GAK'_@LF_P#B: +7_"J? O\
MT+5E^3?XT?\ "J? O_0M67Y-_C57_A;?AK_GAK'_ (+)O_B:/^%M^&O^>&L?
M^"R;_P")H M?\*I\"_\ 0M67Y-_C7711)!"D,2A8T4*JCL!P!7#_ /"V_#7_
M #PUC_P63?\ Q-=Q#*L\$<R9VR*&&X8.",\B@!]%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% $<[F.WE=?O*A(_*O.T\9:Q!"L]S)$;>XCLXXY
M!&!Y<[QQNP/LX9\>A4#^(5Z.0""" 0>H-<_:ZQX9O;D:;!]G9F*8C-L0C%0"
MA!*[3PH*GN ,4 9R7^JWESIC+JLT"7.IWMF\<<41&R)[C:1N4G.(U!Y_7FJ,
MWC2\@_LQV?*(SRZ@5MRP\HSF)<D#"  .Y)Q_J_>NMDO-(M=1MK"3R8[EW9X5
M\K WL&+8;& Q&\]<GGWJDNM>%UTV]N/.LDLP@^T%H]JNC;L'!'SJWS8(R#SC
M/- %634=8NM"DGM&9IH]2N(9!"(Q*88Y9% C#_(6 5?O=0#WKH-,NXM0TJSO
M8)3+%<0I*DC+M+JR@@D=LYZ5CWEOX5CU+[)>:98_:KN0 [[#(E<Y(R^W!/7J
M:V#?65O?0::9HTN9(V>* <$HN <#T&1_D4 6J*RAXDT@SP0B^3?.J-'\IVD.
MQ5,MC W,I R>2.*GO-8L+"ZBMKBX"S2#<$"EB%SC<< [5SQDX% %ZBLA?$^C
M,EPXOEQ;_P"L^1L_>V9 QEAN^7(SSQ6E;7,=W;I/#O\ +?.-Z,AZXZ, 10!+
M16>^N:;&;P&[0M9.D=PJY)C9\;00/7(I9-:T^+3FOWGQ;+,8"P1B?,$GE[0
M,D[QC@<T 7Z*JV>HVE^B/:S>:CIO5U4[<9(ZXQD$$$=1BGI=P27DUHCYGA1'
MD7!X#9V\]/X3^5 $]%,AFBN(5EAD22-AE70Y!^AJFVMZ<FJ#36NE6[)"A"I
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M!%"9SYGG)&N'(38Q;*]B<@8/7CGZU+110 4444 %%%% !1110 4444 %%%%
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M#1],%['>C3K0748"I,(5WJ ,  XR.#CZ4LFE:=+J":A)86SWJ+M6X:)3(H]
MV,XJY10!5L=-L=,B:*PL[>UC9MS)!&$!.,9P/8#\JJ#PSH*PRPKHNG"*4AI$
M%LFUR#D$C'.#S6K10!4.EZ>VG'3FL;8V)7:;8Q+Y>,YQMQCK4/\ 8&C>7!'_
M &38[+=B\*_9UQ&Q()*C'!R!^0K1HH SQH.CK-<3#2K(2W(83N+=<RAOO!CC
MG/?/6K5I9VUA;K;VEO%;PKDB.) JC)R>![U-10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!\BCR8_P#GFG_?(H XK_A</@#_ *&.#_OS+_\ $T?\+A\ ?]#'!_WYE_\
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M<'_?F7_XFNU\F/\ YYI_WR*/)C_YYI_WR* .*_X7#X _Z&.#_OS+_P#$T?\
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MAC@_[\R__$T?\+A\ ?\ 0QP?]^9?_B:[7R8_^>:?]\BCR8_^>:?]\B@#BO\
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MC_YYI_WR* .*_P"%P^ /^AC@_P"_,O\ \31_PN'P!_T,<'_?F7_XFNU\F/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>bngo-20211231_g1.jpg
<TEXT>
begin 644 bngo-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ![ 3D# 2(  A$! Q$!_\0
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M./\ @J0N_P" NBC_ *CL7_HF:DREN?1WP-_Y(SX&_P"P)9_^B5KN:X?X'_\
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M&F;^\?SIAE/]X_G2YAV/C+_A9'[0IX UC_P3I_\ $4?\+#_:&;J-9_#2$_\
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MBT'CB20@<>9IT;?^TZ]_\+_M"Z!;^!?!-]XS35KK6=>M)=3N=4L+2-U.Z5U
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MK/<PO&_V=%88)C4*?S%.&NS(J@-:X48&4!I_VSA.Q/\ 9>(ZS?WG07D.FPW
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M$9BV_=P O'X5]/\ P4_:4BU"2#0O&%RL-XQ$=KJ;*423T64GHW^UT-?'']O
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M-M6ZV\9_X#4#:/8MUM8^OI2L/F/SF^%?[.=[X/\ !-GIFNZ+8:GJ4;.TEQY
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MBV/_ #ZQ_E2_V+8?\^L?Y4A<Q\0CX4QX_P"1<L__  $3_"G?\*H7MX<LR?\
MKT3_  K[?_L6QW?\>L?_ 'S4BZ-8[L?98\?2G8+GQ'#\*W5@5\.VH'M:)_A7
MD/P\_8^\5>%/BE<>)+M[6^TQO.*6?DDD%\[<AOEXS^E?I\FDV?\ S[1_]\U.
MFFVHZ6\?_?-%A7/C6T^%^IIC;H=F/^W2/_XFM[3_ (:ZNK G2+$?6SC_ /B:
M^LQ8VXQ^Y3\J/LT2XQ&H_"@?,>1>#='\1Z>D4998H%P!&B[5 ] !7K.FB80C
MSCEL592-5^ZH%.]*I$MW%HHHJA!24M% 'G'CK0_'4GBRSU7PT^C7-K#;/ ;7
M4FD0AF*DL&4'^Z*YA?"_Q.\YYCH7@T2NV]F^VW9R?RZ<]*]NHH]!GB4WA7XL
MZA8PZ6%\(:+IYN8YY)K9KF:5-KACL#<9X[U[3;J\<*+(_F2 89L8R?6I**!&
M#XOM;R[TBXBM)6B=T(W)U&17ROJD.I^%=0==5LKAH5./MUBI=2!_?BZCZKFO
ML5N0:YKQ+I%G-$7>VC9O4BLY1ZEQ=CS3X/ZA::A:WUS:W4,]N2H\Q'&._!]#
M]:[Z;Q'H]FO[_5;*(^AG7/Y US,?@W0UFDD72[97E.Z0J@&\CN?4UN:?X;TN
M+[EA G^Z@%0B[W&R_$#P]#TOS<$=K>"23^0JK)\2K!L_9=+U2Z/M (Q^;&NE
MAT6Q7 %LGY5HP:;:H/E@08]JH5S@F\;:Q<\6?AAP.S7-R!^B@U)%>>,;X_+:
M6-DOLKR']2*]&2VB7@(H_"I%4 # IV(YCCM+T/6IW#:C?^8O4I'&J#].?UKI
.._LA]6_.K8I:NP79__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>bngo-20211231_g2.jpg
<TEXT>
begin 644 bngo-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# ),# 2(  A$! Q$!_\0
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MP[7^/P5? >VHPG^:BE'[7FB[2&\%ZD/]VZMS_6O7_P#A'M'8Y.CZ>3[VD?\
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M^6,9']:PEN;K8YJU_:QTN/KHEQ^$JUI0_M<:3P/[$NO^_B_XUP_BC]E.[OC
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'Z***L#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>bngo-20211231_g3.jpg
<TEXT>
begin 644 bngo-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "T 5 # 2(  A$! Q$!_\0
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MB@!:*3(HR* %HI,BEH ***3(H 6BDR*6@ HHHH **** "BBB@ HHHH ****
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MK,?^V2_XTG_"MX_^@I+_ -^E_P :?]DXKR#^T\+W/UL_X7Y\./\ H=]#_P#
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M GP,S\N=*@SSG^$5Q5:,J,N6>YVTJT:T>:&QZ51116)L%%%% !1110 4444
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M&6Z2:O\ ^ G_ ->EL-)L^PZ*^/?^'I/P:_OZO_X"?_7H_P"'I7P9_OZO_P"
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M9^?S?!SPESC3-P#8W M@T^/X0^$^G]E8_%C7Z#-KG[+T(+/-X=4=R1)BHO\
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M\-K>$_\ H#ZM_P!\+_C2_P##:GA3_H#:M_WRO^-?"_\ PKSXY_\ 0H:C_P"
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M$_\ 8,A_]!%<TZ;I/E;N:J2DKH]%HHHK,04444 %%%% !1110 4444 %%%%
M'YU_#O38-9_X*9_%G3[M?,M;K0KB"5?5&6$,/RS7TEI_[*'PRU.$33^'U9]Q
M!VMUKYI\!QZE-_P4J^+L>CO&FKG0+H633?ZL3E(1&6]@V,U[;8Z!^U%::;-&
M=2\+&YRIC;8,#GG/'I3A%RV=@?H=5??LJ?#72HU:V\/[-QP1OR*BLOV5_A9>
M3%)/#8,AYSNQ7'7V@_M87F%.I^$-JG(PG_UJ9:^'OVLK/=LU+P><]RG_ -:M
MO9R_G0N?^K'H;?LB?"R3&[P]NP,?ZRHYOV3?AA8QF2+0O*8<;BV:X?\ LO\
M:V_Z"?@__OC_ .M39-%_:TN8RKZGX/"GT3_ZU/V<GM-!SG;6W[*?PUU+YAH\
M<BD_-\@#5U=O\+_"W@KP7)HVFZ/;G3HIS<I;W2"0!VXR,^W'XUY!I^A?M4V*
M$/J'A0CD_*H]/I7H^A^)M:\&^ @WQDUW1=-U.XO62"XB.R!DQE$X'WN&S6<Z
M<HV:EKZW#FUL=?:_#?PC=6T3R>%M))=067[(AY_*LC4?AWX6CU(Q0^%=%"@<
M*]G'C^55X_VE/A1"1&/'NAQB,;2INL?S%4F_:&^$K7K7,GQ$T%N.%^UBH7M>
MY6ATVF_#GPE=1MYGA'1%=>/W=FA'\JN#X8^#O^A3T?\ \ H_\*Y<?M+?"9<[
M?B#X? _Z^@*=_P -,?"G_HH7A_\ \#!56J]Q.QTW_"KO!O?PGH__ (!)_A3?
M^%5^"V.?^$3T?&1D?8D]SZ5S?_#3/PI_Z*%X?_\  L4P?M,?"TRX3X@>'R"<
M "ZW$GGCI2_>6UN3HCY2\2*MM_P4V$<7[A4T%53R^-J@$8 [8K[BL[M)&.^^
MDC'4G=D5\.ZW<Q:A_P %,(Y[>2.>&;0%>.16)#J5X(Q7V[:^;')D!,CJ/G/\
MA6<4S2RM<Z*WN%EA1HYMZG^( US7Q$E'_"+W8:5@-\>23@#Y@:Z.SDEGM@^Q
M!_L@''6N<^(BR'PU<?=5MR8^\?XAV7DU0BMK<YC\3>&%61U9DGP0?]@5/HLF
M/&?B'=*V!]GXSD+\I]/ZU#K._P#X2?PQ@?+MGW+EOF_=CJ1P/^!5/HF__A-/
M$ PI7,'!W CY3SD\'\.E/Y#MY%3PG,!9Z^//8'[?)T^@XZ5T>C$F.3,[,-W8
MUSGA623[-KQ8!C]O=@P\P#H!T(R1]*Z712SV[[BOWNRL/YU$K]@^1H-_UV;\
MJ59!Y8_>-GUI-LGM3EW[?NK^=*+?8G0./^>K5',YV@^8PYJ3]YZ+4<OF"/ *
M$YJAD$C9OE/G,H9/N]JIZI)MAU']_)L%JQ*YPJ\'GVJZRS&Z3.W!3T-4-7\S
M[/J !'_'L^.IYVGTY/TI)N^P?(^'/^"AO_)%_A@-[/\ O1C)S_R[D=?\]:^O
MOV=_^2'^"?\ L%P_^@BOD'_@H86'P9^&>XYQ* 3@CGR#U!Y'T-?7W[.__)#_
M  3_ -@N'_T$4T5]D]&HI*,TR!:*3-&: %HI,T9H 6BDS1F@!:*** "BBB@#
M\^_@[_RE0^)'OI4O\H*^_FC/F ]OK7P!\'?^4J'Q(_[!4O\ [0K] ^M2 FT?
MY-)L'I^M/VBC:*>@#-@]/UI<>E.VBC:/2BP#64,,$?K7->./#ND:]I*QZII5
MGJD<3AXX[V$2*&Z9 /?!(_&NFV"L[7H?,TYU"ECGC%"WN!YKIOPA\"74SB3P
M-H$A'<6$8Q^E;#? WX>+C/@301_VXQ_X5M6&D2R%)/-V>H Z5KQJ57#.9,='
M8=:J\OY@TZG&?\*/^'7?P-H'_@!'_A36^!OP[[>!- _\%\?^%=QM%"XHYI_S
M!:)P_P#PH[X>?]"+X?\ _ "/_"E'P-^'8^;_ (0700RMD8L8Q@C//2NYXI 1
MMXR>?Z&I<IV^($H]#\^/%UQIVA?\%)FENI(+"QAT)$!D81HH(P .>*^PX?'W
M@_H?$>E-[_;AC_T*OSM_;0\-ZSXN_;.US3= TZXU357T:$QVULH+L!G.*\PC
M_9K^,BJ-_P /M9W=\1#_ .*JZ:I_;;"7-;0_6?\ X6#X/7;M\0Z6!GG_ $T?
M_%52\>?$;PK-X:GB@\2Z4[EH\*EXIS\PR.&SC%?E0?V:_C&RX_X0#6<?]<A_
M\54B?LT_&#@_\(#K(/O$/_BJWM1[LCW^A^J6K?$/PO)XB\.LGB32MD:S>8WV
MM?DR@ Z-@<^N:=H_Q%\)Q^+M?F;Q#I20R& *3=J-Q"GN6P?PQ[U^5B_LR_%]
M>G@/6@<8_P!4/7)Q\U<OXZ\ ^+?AA'9MXLT6\T%+HL(1>#:9"!\W0G. :7[G
MNPM4/UQ\+_$#PK;V^N";Q%I>9+]V3-V!N4@8QEL_E6]H_P 2/"$,,@;Q+I(;
M.?\ C[7^K5^) U"-F!%SDC@<G\^M;7ACPSK7C358M-T&PN=3U&8$I;P#<S #
M)[^E%J#[CM4/VQ_X6=X.Y_XJ?2O_  -C_P :1?B?X-5<?\)-I/\ X&Q_XU^1
MO_#,WQ9_Z$76O^_0_P#BJ9_PS+\6?^A&UG_OV/\ &ERT.C8+VC['ZZ_\+.\&
M_P#0SZ4?^WY/\:JW7Q+\%-=0LWB332V< K?1A?Q^:OR0F_9G^+$,>3X"UO\
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M?XHXKX'_ .'JFG?]"5-_X&#_  H_X>J:?_T),W_@8/\ "ES(FS/OCBBO@?\
MX>J:=_T)$W_@8O\ A1_P]4T__H2)O_ M?\*.9!9GWQ17P/\ \/5+#_H2)_\
MP+7_  H_X>J:=_T(\_\ X%K_ (4<R"S/OBBO@?\ X>J:?_T)$W_@6O\ A0/^
M"J>GGIX'G/\ V]K_ (4<R"S/OBC-?!UI_P %1;:ZOK:W_P"$$N 9Y5C#?:@<
M9./2OK?PG\3K#Q1JT&G0O']KDMS</"K[FCP5^5N/>A-,+'=T4450C\^O@[_R
ME0^(_P#V"I?_ &A7Z!CK7Y^?!W_E*?\ $?\ [!<O\H:_02H0"T4458!1110
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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A4'!WH>;BT=1</)K_ ^W-BCFA_FD4     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
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MB3,(*0F'9,>?!2<CW+F#ZREXX3OXXIZ]WQI-4QO]X!.']G[GVV@YX468.80
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M"2G98 9\TR!=*:(3>_;LI3HF0P5/YTW,)!'MCCCIG3.LF7PQD4AD<]EJG5;
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M.H1/<E]G6"MW+G&_KI3$H_9MP'3.&0AP,@VSUN#CUED2F9VJ -%$.E)X9\A
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M:,5!+'[HZ)/V>YL_-K&=01M1)&61IR8<19$^U!.1*&TMA7H%60YC:C>4G;?
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M/M?>U1F)1.Z\ZTXNCW4]WTL9 4=9ZAP%"3MNL7/'PGTVAR#KL(F8F&AK*6,
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M.(5YP*R9XS0&92DBX"B3N/$<!9B$5$"7OOLVF\^!Y KY7*DX3-O"Z,CZW/!
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MWP%3:6EK2^EZ:WM[*(2#9.&@((X2#D>44*BSNULS,BVM;< \+IR["&'.G[V
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M9./,L5E>G[S1P)SOC1-O;G]LI^.@P6Y%3THY]Y[QD:/<^.KVOSS[(Q!+.<_
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M,XU9 _?!16<41VD*+"73,L6WV 99]W#$!TOP#@XLH 7,@@(U!6V8C%E<%*(
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MO??+;+YLV%=^_?K%QY^V36L>V(B),U3@3O'11Q\/=-GV_#VB.@I-P8V0G%[
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M@R_ ^D)526JI2 3W.]-3J8E,6EYU;FX\9S8S/3.2T."64#C,=A2,M"6.PKF
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M!QA3,!B,Q6)/CNVNOD-!04%QE';#:\R ;'SGO7>G9V>@\P=]OFP>^WQ3M/H
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M$16RDM;/""ZU=]_[ /H&LM]O4ZL)D3!'@4\&Y0BD67@FLG'_1-/T3!8%<J6
MT@'=C65':6O^70+--O!54[DLZ$V<C"\]$5!V05)!LX-PZJ.CX^F,H%7W7'W8
M0A#&F>GYZGB;@?Q:SECTEN6H9BPX"]<@",HB*2&8$EMP@Y=_]54V8^!7DQV(
MO@-=7.Y[^AF.H3$<CDAY!]D(F5E]1S, B_KC.^\YQ4UR@KDD!"1/2Z6R,[-
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M/R278SL*TUF\)*"MQ/6>M[_^"M[+\[2JXW4!T7I]HV$."S0\ T?AFL4G@?&
M] (QY:3*^_E9^>%KA\HKW00TYRBR[IEDA8-*]>C.QRY?N\IDF>\RI:^P1:]8
M%C@'^0 B8=/?U>O7MN[<$>ONAOS:NGT;YR!6SA5'OQ'!)<UJEX4;/C">3$*
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MR+2CQX_=N'</C4!P*.LT&^2\/3%,T 3U?8A'04;_ X%Y[8TW5(JD89-6E82
M&8RH;#<<S/R)^(@)TJU3DKJ(Z=CQEZQ?S0WY* E<D0=RBQ))Z1YNT.[(/!-%
M6I+D8!&'[V@[0WSVAR^(42 Z/W_OI$3=K3EH3L\81@%<R!6+HGY]?6@0HR%X
MZ=>_DC.BG5RU#) +';^LRM+YPJF%^?M;9?:4\%<79$X!FN0+1<ZHA:6$'A:*
MTZ6P88%;M)N75E<JNDC'5_M5$=I2V6@NTT\K1K%\MG$KUC2?7KUR<GZNHDNK
M^"U1X,[32XN,7P#0V<6%6_?NPM:<OWQI]>R9K];O,TO7-T6SS&1W1"P=>ZV]
MP?+KZRHOG/6,7TZD0&7PVZN?H8BAYI"?VW?NV2OXY5M5)3?.G5#O&,57/CVM
MA#R=0, ]T/[MTRNH?MR09FJ[,$W=811>\+L4I(W-,C(0S6)P^.7-6R?G%_[/
M?_[7^D8@8YXS$;X]DY&,\KK%*+Z#@VW5S*6/+__3N7.%::G"(9Q7/KO*1UV4
MKT<F&S&*DX%'CQX]=.B0! X%STKJ^/'CE@_V"G+RQ(GO0@%_^,:;7FN,0A^+
MRM,6FG1+A[W+,(G(?V2:'% GRPBDV?;.J=FL=GB@_L<K0!AX6M;;JFYE!!,:
M3)]J09)1OO?1Q0NC>W:C0E4;W@U&L81+[>L4]+7K-V'3;MZ]!Z-][M)EL$2Q
MI(!9>ML75E N]3ZP&&#[W=E3%;UMO[+LT9!UYP? G>?U]/5QLKDE 7FEDW(4
MH_AAXB-Y4=7!,,@*VOK(M5J./BAZQC#*9"$/50' #^;?A*)O 23Y3@;8$D1@
M%!OKD5]=90>9YEB/])3H8F/X;U8]Q!],(M-@DSJ)#& E$RYI\ZU5UT*FGU:,
M8HF-J#I+@>F5R7T,UGD_"E^$:G$TDYF)Z\VPN(,._^W:0ZV($1I;.XS$\)#G
M5);@;U.7M0-%5;5S3< PD4'/*M@I1C&*R#\NP2_89X8.#,@J#,E&39$9*W^[
MNK\5=8I1%+#5\MP=@&#YUA90T%.99+;;BVWF)T8RRNL6HQ!Y\\+72;XT.+05
M- XT!=WEFR30:X)16"+KZ^N&D"PM]B$\-?GGKQ6Z=(H4IV'*O%881:]YJ%E%
M8K$LJBT1P"U0+-?5>XI"RCJX ZNX7JYPDBQ:=U,ZN#- 0[JXG'?$M9&VPO5Q
M7F@H/)F[*0L@&N6\#5G14QY,/.1'XP38%8;UMO$M>]%Y6$<223T/D@-J,<BY
M&7'YKC/Z]HC)%4XRG$RF$HDD,[-2O[MF%*.85 69Z,N:3 #&H>$1-!38!+2-
M"Q\ /6,8)5LL3FA7"M/(M-IO$^'3<&CN9/.YQ942E*I?YZYSQ$=&OJ>GH7BR
MS</\ A%,F6:HM*(SPB08P"G47AH-JI]BK?2+@=8UD^FG%:/X83Z+F(4)]W3-
MGJ>F7/:#L?1VCE%(C)GU! U$)=RTRLW$+N8@LW0LBB8"4T_5</,N-[W61^(S
M0ETH9"(1OAI,F;3;CJAKC$(R*Q0ASHX*-G *21 A 7>S5]I3%QC%#R&FY2%O
M69&XT](CY6NXH0U%,LKK%J.0F"WN1U$K%:=GEDLRZ9@^LE:N\[K*(Y,-&$5^
MPI@M3TRH(N#,;BF<-$?2OBH%ZWI:810_C!.,5W09(R (VV "PG+Y=V?G.(')
MTXFT7%Z 8&(A,[*S%'=/(:R!G7QO;GYFW[[U-O5:_<8Y%;4-Q>),IQB%1*UT
M??@B<T!F#8;?L@O*6V.!1B@HEWH?6 S[G$=;1W"W(V8?+@6SESR=C]+7ERL4
M;*PG*.)*9;,LJ*//53DWD>Q'2<B9@B.$M^+9.H\ZIF<,HXSGI@!3J#R!W+ -
MVT#,!K$@>C4V,7[@\"' ?]G;8W4MW=^/Z_V'#N\>&S^UM+1[?/S \\^?7%Q,
MI=.G%A:'1W8=/'1X[?39=+H?!FYX=/3 X>>AM'@**//3G__LR^O7^(E6,OVT
M8I2(G+MV1WS"\6F?&M)%>KW@'%0S"AG=X9&9R:SN IH8L72,KYUHHG&"*J'V
M:8U"X(O:Q*#Z#.,UB\G;-NW^5M0%1FGZE,TAHA#\(C.Y[6;5V1#3';:S%W=(
MG6(4-R',_""7PO?8#^>3F3"37<8B(A>A2$9Y/6"4^_?O\Z(:UH@$XMELCEO"
MB,_&INW<TQ%Y9+(!HT@MV[2M55\Z5:>Z=0.O;VS!-L*^>2TP"F^W=+/FFS=O
MOO/N21BTH5V[#AP^#+L'^X9*"M;O[[[U[7T'#^'BO9.S_?T9V(J]^P^,C4](
MF%0:$.W@D2.C8V, +K"0^(5Y'-TSUJ9@R+R5'3CB/)@N,(HK #79"#'0_8WU
M#&<-JJ>%9RYMJT=!N=3[9'0_!:I)D-M<U-DRFH=/^FFF';\;F^6T#I\5IF5]
M>,3@U/I1/#79U?K>.<YU , 9WK5KY<S9C4JYMH/O Z%G#*/D9@1Z<\)YX"6]
MV74J+3E@>1 >]C$X),L:H76#0T,H"_P.C8P,#@_C>F37*"YPNVO/GCXY_5$Z
MS1)Z#&1"__A;NTTF7_W!:^PO;2733RM&\4,YMTSF+0T!\H3#80&Z[[Q]:0:%
M\>-B4+>QXA=]Y^M^5W4J2\?*H6EEX%)5Z_+&8.236<!92O1D2/ZZQK13Z@*C
M^!')=SS]D!FNN[8!=0M<W=E.]HW4*4;Q">P</EF(7K@:UC NR7)^4P\L<YXT
MITA&>=UB%/M6,!/?"YS'V1NZ_Z%55UWHM;SD-<$H\A/6IFYG4F..&8?T#[)1
M%R&^.RL38)MB%%>2O_6=;XL]2Z5DC;*8O53-W(47:@QEH@+,XY LPAH9'=T]
M/#PB]A/&<V07?& _97*O<Z)-4R(;)FFXZ0ZCD,HZTX+7;J(\'2[D-0.X&>5M
MMY%F4"[U/F(QU)/"8 :A?50/FV!LA5L=)?""L9[$Y%0P'\4,:46V01(1"N;,
M-F;QKW[]KRQ[_ X,#>6GBQ/9['>__THD6/?TC&&4B7QN,I?C5MFNP%'^/&>#
M!!)W<D0EM_;^V6P^E\WEH<-PA>(T-$1<H8ARS:FJH!DQ,# HQ\Q(EZ'/,4Y<
M(_#@T'#I]!DT(^975M"26%P*K%XKF7Y:,4HD>XT,CK@(H N,PA(,ZGA=H<K.
M?Y);C[J&:>?$TK$(=QX)N3(9\SGBHPL[@:+8]'=#^J%@\!5[ND/J#J/X80;R
MHPQ?ZP_0G7L\S01+N&G0H\$H!"A^?;;8A7'(64=E[9VR_ S"U-]&R"(/;KO%
M**0@3R2_=(6@)^M=N6-UU3&T762=E(+7!*,0D5B$5M/8MPS2T=\-+$\K'JQ9
MFW4]$D9S%9Y+)=E%;6%U=:Y4@D%#&^S[K_Y &',#5SS@#]D1H%B$$_N9RV>S
M8H2+S^V5J8%3.3CDR>MOR&G;K<BK[_YDW_>D;LC9*.=MJ*DP5,-!L:]U6CW@
M4VT[*$?&3#;:8(N@7.I]V(]B+1#QW([/1T!>N+M_3N=H D[V]0FFO/+950M#
MAH-^%$N_20\OWGS[IX"<WSYV#.[';[VUL%K:>V#_Y%368NF5GC&,,B4(HRAG
MNZL5:T^BO6&&!(=1AXZ3JO@K%^HR<@:A&G'I?0DT_W>?7H6VIWCFEIXIB(MS
MYR\&)=X@KY3IIQBC\,)$/;CPU/#HT S3R<SOE!@_T8EE(/M1^-08J(2]*1T1
M2\=>L]C:D'R[OLX@D;U*V/07O,(&8LA5%U674:<8I<VWQ!8I3/?T0)Q@X"PL
M/E*;F-M3IQB%U+22J.J$1$Z)\+1U& G RE5"MBZU2$9YO6$4W\28E6I5SN5!
M>P8UNN1A6T[:$XO ;\ H]BV!1'K!J0],D96R03W7A]'FB]-R9F0+C.)>+^I.
M <$A@BEIGJ&&0X)H^EB%5756;+\>6R9FDYRKXY0,8UE?L;BC))!.+X("4L69
MZKP?Q02@483XB2W=K3A@LB&VQK<BU/B6IQ;#S6>JDNW@][@(1G)\<N+ D<-S
MI:79Y>69??LFLE/]F0$4JVL;5?T5H]2][="I)=G>48I$$XEX3RW,YXJ%:+BN
MZ1G#*)#I7+'(%59"5!$EMU3LMQ6UDD4>9RJBK ]17GO&Q]&,0(U.$&/*)J]H
M%$WC>5HQ2GMB'>-F47=D9<?,[#$VER(1MA>2;<ESDAQ]UAMUBE%:D0BAISJB
M/P\V,_UN,4HKZEU^(AGE]8Q1(L2:E>MZNF;2=\HEBE$ZI%;I]5IA%+OBK3ZS
MO:/Z$C+ITE-$2WOEJ07K5^ HI!QNRR75RK[+6T[<L866GBQ-Z+@?I3UY/>NC
M,%;/@^9 <.;:$T62@5/!8@XOQ/397&YV419_,(==L-(2HRRNK> U9ADG1BR4
MEJ<*[;:[Z8R>,8PRF<_G9V;RQ>+&9JTKC^BX4C\9R)XVI5:RR)T6_3#.#\_)
M/MPHKQBC[(1ZKV-(,4:),4IW%,DH+\8H]842^0 M&#'*>GDKE4XG4\D_7_LR
M8$_-1:<8Q7H36_7M22>0[^-S,D@18Y2NJ*K;]LS,[%U:75L/M\WU=8N-E3.G
M-[8V;1/M<KAJKR5&^>[W7T$K'#7?@.Z;J7.1$D,CP]%P7=,SAE%RQ>)X-CLT
M/+QV^NQ'YV0_<D\-AUO9F-ZVR8E6LMB?Z;<=4!#GP.# Z5^\/Y'+QAAE)]1[
M'4.*,4J,4;JC2$9Y,4:I+Y3(!VC!IO1$S(H:J\G<5&&ZR)%T:?)UCE$\12?N
MJK&*-.?ED"_Z(,D7+U_ZX1NO#X_NBC%*UP3&AH='=+YS M "597L<^V<2.].
M /+;8!3VNE1T(N#*RDI?GVR0.IG+1<-U3<\>1I$S!77?7AE 3:6RN=RU.W)8
M \7+!JW;4RM9S(3G,D"M?O3ZC]&P -[/YN4 BQBC;$N]US&D&*/$&*4[BF24
M%V.4^D*)?( 63/I1%N9Y&.JM>W?1J/[TZA6&]#K$*.Q^MK:[=:4PN_[TY9^G
M<KF4'FJ!=B8JPQBC=$>;>J1S-IOC%$G9%9W;\^LF4IS/)[<5.4.15JXE1F'9
MD.87EB@W^>*T&Z8G>L8PRD0N-YF7_6:X3]&?KE^;D.-=4J^_^8;GS&.*:$@C
MM9)%&G$Z'AI2$6 D-7J,4;:EWNL84HQ18HS2'44RRHLQ2GVA1#Y "X:Z0_;"
MU]G?][<V<3L\,L($>AUB%-?DVAI=7&Q4RA^=/P=T4IR9_O+Z-4_.XUR-,4HO
M) 6G6]BCU(!1R'E0:LW,14N,@DSCLB@O/.FQKZ\/I1(-U34]8QAEJE HS,ST
M]25XO [=N4L7T^GT=U_^GJ=[/^PD ZP@79^,SD=A/\KTWN?&)L:)42:GXK&>
M'5'O=0PIQB@Q1NF.(AGEQ1BEOE B'Z %0]UQ4@^CZ<_T5W1. ]Z=6YAG&CO"
M*+["%%>MV+-R_O(EQ/G/'WX@XT?ZT=GYN4179PJV(:]G?90DU_.@.?#$892*
M['I2R1?DZ+K^S  %TAY%I(+;NK3$*)7RIN2;=K\L+I5D["B1R!7B?I0N:3(O
MTZR \TZ?>1^*0&5 J?S3AQ^DTND;MVZRLXN>;7*BE2QR7<_UV[< ^7_SR;\1
MH^3C?I2=4>]U#"G&*#%&Z8XB&>7%&*6^4"(?H 5#W;&@ZWH@'IM^=3P[69B9
M1JN/K;5.,0K)!GWP^^677R:3R<N_^IB/R,_:F=,PXS%&Z9K F&P/FTAD!@=Y
M%&#=#C3A(1[FTQ*CR/+VBG1Y(6QI94WFHP \QOTHW1(7'D/]@EW4JC+YW%?;
M 20QD<V*D/6P#I[RG<WG)J>R5-HMKQK/1]DA]5['D&*,$F.4[BB245Z,4>H+
M)?(!6C#4':75E?M;FQF>5E;(@Z6AX>$7CK_D=8Y1(CJ%+^3SLEEF8 9U*SS0
M_/Q\W(_2"R&-,M;3)QAE;EYVQ"&1?Y:"YZRN:HU10O)TSQS*S=0#Q"BZEGUY
M;54.$^)1L31)3RE-ZH&"R$, ?S\L"?Y>OWDCE4JAY C_Q;_LV4Y0AEHD,)&-
M2'2P9ZCD&S%*9N#W__X%BHEC2;+G5;F:R^5YR]/C]. J>0'Q!Z<V.!'"#0P,
M( 8YKTM/-A?OWNK"WBF0B!BCQ!@E&J0GBC%*=V3E\I PBJ\8!11@ B_<"TY_
M ZL5WN9SN>5EL0;]_6+? "B6EDI+NO/LS;OW^L4HRC[WG(:IWVJG-6*!=?]E
M?J)<KB:2R=MW[U@KG[4F\E"JPD(AF\M'TMVU%"EG/>EC4"[U/D\F1O%D@QF9
MCX)*:FYI>=LD/S:,XFF.OCM[:C(W5=&O"'4NZW\K!)F>R.7Z^OJ62LNV+0H?
M00>@3><O7\(]@$6P@8K60]%N%54>=P-'3S60VC@X-,1-VRHZB:S"G2575C>K
M'A#K_2W9A @9C$]H-*(57(R^L25SK46F=4?:X)J3</4K/=:(O9 )AA=CE!BC
M/#B*,4IW9.52?3@8Q0OZ4?HX]DW':]O!F58+MX5B 96<GGL\""L'T !S!R?]
M'/F\6$4[UU,_5)8)#,T) 9 BUD1R>J7GGSG[BW2_#*#SJ85<7"H1HW#7N*XE
MW"6O9WTT3ER?)QRC(+UV7'$;>FP8Q5<A6UPIY0KYK_6T0MLC]:DDE$IQ[U[D
M(3+3/.7D%*ULLE-9G3NR#"U=.7/VU,+BS=NW?!4[49ZP0N*.A\0HU7 .%Q18
M]K!)I^7PP%0JG<GT#PR@!0!<(GM%I].R:;3>9G1S:-DB>F" L*9?!XDR@W*+
MZW2FG_TH(M_AWO#RW=;KC!XV!1S$&"7&*-$@/5&,4;HC*Y>'A%%@X-"04WLU
M ',$1QO%"]HHWF:X%WY_/S?%YRU0A>[GEH(!3*?3L'64\/!#K;7&$T.ZO+:Z
MM+J"9B2 ""#(N [!5Y5"AOVWWOX9C"0>$:-0$]5.=YP)1A)/;_H8E$N]SQ.(
M420GM?&<T'4]7.7:WIH]3HSRP4<?'C[R?#8OV\,'0QM=%M#? $WD<KO'QQ.)
MY/=>>=FK/QT*L'UT]^C0\/!$=E+@>;$(K?OQ&Z\')Y>&PB= 02117+#DBOY>
M%=H(<81^"N"0^;.*/Q2."/[0&;4R'D1$ @V'8DL8^BM T<#PAVXW8I1>U*]'
M"CX<8Y08HT2#]$0Q1NF.K%P>$D;QM!\E)09-6U!JOG MIDPM&RT5S^*AH4/3
M*]4OIY*99]#T4C+.9&<.Z2AI09[_[LGW\.*D3NDK3A=A#/<>/MRH(*]\_S5P
M.#HVQK-B3!-[44F)IS=]#,JEWN<)Q"B><HFR1AXBAUGB[;/NL6$4R<%,)E_(
MG[]X@=UQ[1G]6R<9ZYF:0C9>_M7'!"A26IY'M''@X '%&0(@QG-3$_D\L+RO
M>6)]&.QG\L)N%4ID)-/L*1^Y_1^V\\I?[W\M JW.ND]Y 0WIU^Y-E>_@R/(>
MS7>/%'P[QB@Q1HD&Z8EBC-(=6;D\)(P"P08@X2-/,Y:Y6@VGZ\&9!>,FL+SV
MPEVF&)@7OFI*->P%D2>MJ.JOK*WFBH7)W!3Q33*9_,&;KTL\3JF6R\$JUQBC
M=$V>'AS=UY=(I=(\1;(]/3:, MD:'!ITA8RU]=-*J%SER)YBT?;1<T5J8V.#
M&EA1<)";F9Y;F#>$0;0A.A ,[T27_R#K. QD<\KL0L4_L/7NC+-JN<)9:7@Q
MF)ZFP=!@X:5AE%YTKW<*\BC&*#%&B0;IB6*,TAU9N3PDC((KM-:DT-F=JP:*
M%W!;&YMV73-Q50\6C+=X:W-] Q?KZU*;!&8S;*%M;J[7.(A052::H!D)(T.S
M*Q%K@<+8;FUMF<GU9*A"#C:)QWJZ(R^<CY+N[W^BYZ,P!REC5M*/<=[#PR:9
M!Y[/9W-UT)NC.29;/+L1)9<K%E=/K]&_ZLZ<U7X4>Z5I=AG4"]3&LEA=18E/
M?6=ANGTBDQF P>&Z'BI,+[K7.P7?CC%*C%&B07JB&*-T1U8N#PFC<':=;\:-
M[(;12Y=(M2IV,GPQH@BN<7,;<F&;L*76>!59L).?F>G7X2&"(4\GTKK! 'T\
MV1LS%\^9[8X\Y3*G>[@-# YR/DK[W'ML&$4Z##*9H/M.J4>S^X23]*/D<OEB
MD5)8#D_G8>$(5M"KS:W*P.#01'9J?G'!E?X J6B8IM D@/QA=RAO+6]-73E#
M/A*875GL*05&H2?D6Y;AZ:?;R]!#I>##,4:),4HT2$\48Y3NR,KE86$4;:15
M0B;%UK'?UPQ:Z&"^(G:,%BQ8$!0VYTQ3U :VUAI/^E$F\_F@_U@B$N6@#?2T
M>F*$LJ=#00Y?B]<>=T<>^U'Z^C*#@[.+LC5&>VJ)4;QP$Q5$@?J2& 6E$@W7
M+3$'C;\>;>Z33ZA<W6U_FDJSI[Z05!0A]+^IV#ULRNBN1SK64YLS^Q@IX"#&
M* ]47[R>;6(KBC%*=]2JSJX+U /]K6"42%GW*.<=$0P+S$L_OZXI:LPKFN@I
MW32\4<Z[)J]G?116&RJ+)Q.C /8AZ_IT70]+O#VUQ"A& *<K:ZM /7VR%_X#
MZT=YC++X6"C&*-U1P$&,41ZHOG@]V\16%&.4[JA5G5T7J >*,<JV%&.41T#2
M'>7[A>D9KCU>7%G=-LDM,8H-*)2KE:72,OM18HS2-<48I3L*.(@QR@/5%Z]G
MF]B*8HS2';6JL^L"]4 Q1MF68HSR:*CB5;-Z[G%F()B/TIY:8A0_G'.$*!:6
M@G./<X5B-%"W]!AE\;%0C%&ZHX"#&*,\4'WQ>K:)K2C&*-U1JSJ[+E /%&.4
M;2G&*(^ V(^"K)/S>@8&4.*;Y:VF,RR-VF$4$G)MJ;3,L1[4G=''W=)CE,7'
M0C%&Z8X"#F*,\D#UQ>O9)K:B&*-T1ZWJ[+I /5",4;:E&*,\&MJJE+.Y/,=Z
MEE;7MDUR.XQ"^4 $I^9F$TI3#VY=SV.4Q<=",4;IC@(.8HSR0/7%Z]DFMJ(8
MHW1'K>KLND ]4(Q1MJ48HSP: F/CDUE=>SST[NR<YVR!T93:812F^:NO_RI;
MI LEXW4]75.,4;JC@(,8HSQ0??%ZMHFM*,8HW5&K.KLN4 \48Y1M*<8HCX8V
MMC9']^SI8[=',KEM@EMB%!LBTJ0.5*K^\MKI>*RG:XHQ2G<4<!!CE >J+U[/
M-K$5Q1BE.VI59]<%ZH%BC+(MQ1CET1 80P5W:F&QHM5-<%1?:VJ)42S!%:_:
MG\EL5KW2V;,3N1S]B6!< :I)FU*C?S!RY(CFP,  I^6&FP!&<[DI59TMQ=YY
MYYV%U=532TOXA7S#O?*#'WYY[4:;6#QG-YX(N6S8D3I\U!B^T<<\+:5N_F1S
M$.E\7E6:+C@B1TTP?\L5>3^3&<@7BDC+>ED"R%,57$_)OF(?XH5Q4PN&"'VY
MZLAQFT6XS.# EE<%YO6=G F^U2SMK:P)<I+24D.]3LYXM@V/D]5&>B^.-W+$
MZ>#@_L.'%E9+<Z4EF,BW?OZSTFHP,]SVN&M/3?F$9R8C^MPT:1$B_Y%\X,[=
MUV_<6BZM0OU0?-SI>7&E](\?_'-%T\']H(QJ::R_-K(N4/*,Y/M.R,AY"#LD
M3\6)OZP,S*>5VRJ+=$DPE=+/?_^'[[W\?:I;HSOX_)'!X>&EU;7%E=63\PNX
MF%U<0C[@$2Y.O/S*IY__W@M%G1&V<N J.,D+K*I8VJ:"3$LEW.F\,>O,$[_,
M1C>'\6*ND$?1U)WV4M_A[(9O&C_I@XL7ETZ??G=^'L4-0W1R<7%^9>7ZW;O1
M<-L1M6!]?9W,**3(SRTM^O4[1]M%4Y;$MQ)DCARAISFV=N;TW[_]%G@;&ADY
M>.0(2F%QJ?3IE<^JS2!5HV!'J*KGYE3U&)WEE1+,FC&,S/0=-8=\6BQ69&;P
MY9TP:=QU#4:/JSRXP[47BJ7MU=;&5?4<>(O?U7%+3B &FD0W ZNRQZP/.2B=
M/C,YE8.%P37JNXHFJO:)\.0@N%P^E\WG<GI>CQ?N@<E#3AASFPR,$!GF+TU0
MUU0N2ZIA@J!T4+?%M;5D*@53>6IA_N777B6K0<5=%L5IY#-R6VUVXIOO%J)#
MC*V]\/AA3F9SN94SIU&_B%ZW#>^WP2A^K5!]%!O8^8?9V?ST-.0IV,@O=+ C
M$1_RX89TMS>EW<&OR:)M%-C&43<L*OZF4BG4_-QC?C*7RQ6*J73Z9^^^Y\I6
M*T>90SR\0.01;O$+)DW^ DBA(=LP;.=:,8;1W:,9.5A83PP'Z1GBK&OE4,X!
M.="39Q#C0@[W'!S4#K DP@\.#>FCH%7A%K\K'_243V]MF7+"$U_/Z#'('3E\
M&MSVZY%:&67H_OW[%J<Q8*I%HT9/AN&M906+&%C'S27+?&^[TO=#BX-KY![<
M>'9R$@:B4$ U@RS:O6=W14]]"AAH[5B49FML5TKZ,Y\9H%&>VSB+<&.S#.N/
M+-,-A:?!FS)98-<4DVF)Y2N-49DVW=^0ZLH-AIC)JB6D,89MW:6/+_.P:XA;
M6-;] VWD1$Z3'11!TA-E!P>'\%:?[D30W/7) D!N56".I-XBV_+YP4'1@@$Y
MS+:ITV\-DC<07A0F(9:IU/N__ 72#HEB/NRPL%PX C>1S0*CT%!8H5349-$F
M-,;0U$%/Q?[D\T!FL$5:W(,\A:13YW*X606**@B'[HEF]0+<RE&*O-!J[1K=
M-0S>"H5=NW>/34R@&L8/6DM2KVMW2&,,;9P;?GYQP>IIYB2K#$//K+8#(.(T
M4?Q0J:FP^_;O0Y&C9/6X8[$\$$Z:33F@O8UP#HCX\ACDBI(;LYT;[WY:4NR$
MP:/=>_;H)P;%O"23(FDB>'*<<D;D4Z2.WQJ0D^'3D$-:<I5DT:2)R8E>5-+>
MM?9A%XY6 [\+B\O@":4,F1P9'066*DP7P:I98#.G31UEQM4I2J"]CEO78E,:
M.TWXY%3VY/Q<);2Z[:DE1@EJ/JWJ^G5SXN^]^AJD"((N'0+%(EP #J9RA9D9
MP0H*%*BH^.4%?"P @#Q?T1BF8:[&)[.C>_8$P=3Q+<9 Y:<//H<+;B</S^+,
M<X@6,=R\=<?3[9/W'3P$)H=W[9(2RDD)-74L/)=#(!N-?QJWPR.[G(\BC=,3
MV2DD&3S#X=.%Z1GR(-LA:Y+%A4S6^)R25",,1+FL"@RC ]C(BXKZ\%9J+_V%
M6R]7[F^5[7I+C0A+T90JD+!Z/>=!/Z1:UY1VBC"VG3MP55:6UJO2+X',Y+=,
MSQLOC S!$,L@,PN%8C:;FYS,X@)F,3N5@PPPP_%KR!*Y2L&0@@OSDP* UM54
M+H_741"HXR M^.K8^ 3,V?VMS3???DLJ"2V1?+$P/C%A!0%GA0Y/2"!BH A1
M / AQ(:ZBE]'29$9B)#[;L0A$L9@'-+!$S()7$)$LO? @72Z_Z.+E[;*55B]
MR>R4RHRP,8X:0H4D$'(5(;NE9E$@X0_VE!_QA+0SV.B>,50V9)ML,+TN2[QN
M=$.HKW;MTH*6XC;9:^40X*OU#;N%6'[CV]]!7J%,FCJ4U]Z]^U!D.76%XC1^
MI[1DD038RI=?^P'BW*B(\/.WE7/#D$]< PI KI"'Q>?VPC$#+?F6=M>G5IJY
M/-(^O7<OS$ZZ/X.HP-+XY.2NT=W"N3K+1EY0(!NST2(4ZU^IGKMT&7*X[\#!
MBBB=U&:-K[@O\MHM-2WQ(@V@&$PTMU+IH:%A? (,0P!8XG 4AKHDUT0HD"M>
MT >%]>;;/X4E@?7>,S8.Q3Q^XK]#EF9F]HI*FB2'>J=2-Q4DL,$A<N0_2Q,9
M:!!M;&*<?:YF!,PH18Q5S6J%C57H;^GT&1-%Z;ZM!&:0SFQFHT,,<G[(@& 4
M/\1#C1]E:XH8Y:NOOF( AH'"\M/4B(HCEJ[D.^9:NEA"J^[A IDY/?.<"(]C
M$ +'"D+SMJG;C2(91WZC=BE EJ PR%J4NPE,Q/&M1G^U&],H;B2'"K[_T&$4
M/4P0DH.847"L^QA)+3;53;.*:IREAI6GHEG%W6-C>\;'(7CXI<CA6Z@3H3BT
M8Y:66H13@1EO9!7H!#8-C+WZHQ^B6 V6M:&6&,5@J1>6XF=_^ *)1^R#0\.P
MQ9!4.%0Y\,0MY'5@< @.%_#$8S@$&-DUBO"XAMZB+&<7EY;73I]:6#RUM'3X
M&]\8SV83BD;17!+<*@!66GGJI"T5NO!6@Z6U"9;.9&#]/6VC \P>._[27S?6
MBS,S*(^146&LJ1,P/#14XW#7+CA>@T]$*+UD*ZMPN "?J%2(K)$):6V!2M>&
MX.Y&#M4'_F%:X-"F!+?09+@]XV-H^HO%%,.'ZA#%"2B#Z@M2,J6/\L7G4)5F
MI=+-0RJ>@^PB.17MXK9!$^HAU2\?MF.\T$?0B>H>&N))K=4Z<ME"?E)[,J>4
M'\1 W7;;*'8*J)D 7KMC$V7MY=+!CE7I7EY9Q36*'IE):0'&%_D9'L%%6"+#
M(CPJ/Q0M*1?UAQ3!H1'^#R=/563@+#^@8[=W[MU-R%Y VN32A@[+0GTB!20-
M\[!MQ& 9R![4#(S!H8(!DPNE%7PE^&XS)[T*X)9"KDX4046(VL'31K[SXC&$
M_.#\!4^[?R"PDCI-B01VDD:M"2)4.803(1V1G)&F97\&&0A]V7_X\/S*"AS[
MD](4MD#PZM(;"FH3AQ<3VDL'/N%@UUS(U>BT.A2HA%]8);3)(,:03Y.Z1O?7
M^U_S(M*GB-_1W;N'1H8UMD*N**[QBW2L90T12KM5>)8B2VIGI-D!N5"5;*J/
MH4D1V9"$I]+OG)J%''[S.T??>.MM%'=!+490F@J @E(8&8G8-+-X86!Q$#\4
M-S */O'M%UZD<"9D764TY^FT:"),JA/S@G\I(!3WRNKI%X\=?_NG/P>'>_<?
MT*Z%(4FO%*X$<]-H3OP9#U*M-BJC75#7;]^!"N,:Y0FM^<,?OT@D10V'-16!
M#0S3!2E%9M626>^0 X@0D *:^).?_NR%XR<XQM<?-HAEB,?:*GX-"M",B*?^
M6K<T<@S6#Q5A5D^&AV! QN!C(@=;E&\M)[23R!]^T>(W'O"AR>QD[:GVHY"J
M2JET2H5-S)V)NMKG FJ3P&)K;P2XHO]$=E)_I]BR59LFAFM8JSQ'/,2@:759
M,Q<1!\X/'3D"R[.TNG;@\.&3\PLK9\["!#5*3F-QUTM1<,L(@;>^=?0%R/SY
M"Y>0$90?K8N'ZNR/7(0<DGFJ "VP6FE(+ _6>?]__B-^(9"H%A$/])&2$U$*
M1*4&S?F$HSLC:B1!G_WQ#S+6,SC GDLKE$9JB5&LI%&*&1VWKE1]8'GVW :_
MVJMKW;GLYJWK^-4P%CZA^NPVW5 J[ %V7R$U^H@GHW,>"9/JI(?*]P\?.:+^
M#6R8:XA!/6M?J2B@+BM&QO6)EU]QDQ!<-^O-KKM68H20&"03X@*QGEU<.+4P
MO[P&#%3"]?PR$-LJ'#P72LMPN%A:78'_PN+RW/SB<FD5*A0HLP-06#J__?1W
MB)]ES)E'].>YH+B"56<%O'.'3P,O[SM\\.3B/#B4<]+#:(E(K*5"<F=%F#T2
M?YG1(D.$-K+++B+F"<FD1:Z=@FCI^OH^__T?UC=J/?R;Y:U:ACLA:Q$V.K<T
M$XE7?_1CDT8T.,#V=J\W^-0_[=>^*^NE*%<\& @3!OXQ<'#AR(K% R/%1W(%
MD!IJ#24SJ3W2_)Q%Y;[>QI$./@^9?!Z6 C7-VON_@-%IE 2ZD_-SE$G*Y]S2
M(D3W^NU;5+HVCMV_ZYL;YH/"^O3JE86EQ=6S9RC_B*WQBW0$M6PPP'P#71P^
M\M^@1Y(SH;9:BMQ;-YER;:H:^EIF4CB_>?2HO1N)A*_SQ:B_\TJU?E;-WGW[
MVX2/O.N&Y'6"[:Y-'8BL"I.HM^21):#AE4B$@:<CYQ*5C7>H[LBC>I6IB[#9
M(S>,J<S7FUO4:XC]U^O!H+ U5SS>L]%BIZAJ@T?2J,,'9=\##D8+ >#[P)$C
MN\?VJ%0LTDC"X5H%K[E;7"K-+RQ!DGVU>VZK2="2 F4P?.O.;;*Q50G,E]DQ
M6&; 5M@]?.B]N5F:7_SB&@[ROW+F-&TUF/F'D^^!&?B X='=>U T@&N6+4'N
M-;K61B.AK6):'HHE\K,QV+:.GY;?OKX3WWL9":=8;I5E.D^"%J--L39PZ(8'
MNH6FP/A8#Y,T=1HC:1V;\TCB3$KOHXA-1D]P-#EI2BTQBN^TDE%-RL@Q(+Q
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M*4YM7+\*#/OI&16G?$5DIHUC/"CT>:UJ-4(M#W7(^8R8\>1/_OYM2#A?L0:
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MA<I,D/NYIH[Q6 8&ZJE/B!'-1::Q[] 9??WUU[X6$#\!4U/6&;+\D)D@7WF
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DQ44>;I<S+USLPHN8GDSZ_W:P(&K3&S+I     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985293938680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 24, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bionano Genomics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1756290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9540 Towne Centre Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">888-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,045,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,612,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#8217;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#8217;s fiscal year ended December&#160;31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001411690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNGO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNGOW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985298682776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985299425288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,571<span></span>
</td>
<td class="nump">$ 38,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">226,041<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $690,000 and $2,119,000 as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">4,934<span></span>
</td>
<td class="nump">2,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">3,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,481<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">272,414<span></span>
</td>
<td class="nump">46,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,318<span></span>
</td>
<td class="nump">4,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,691<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, related party</a></td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">26,842<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">56,160<span></span>
</td>
<td class="nump">7,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">377,100<span></span>
</td>
<td class="nump">60,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,696<span></span>
</td>
<td class="nump">2,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,694<span></span>
</td>
<td class="nump">5,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liabilities</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, related party</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">21,840<span></span>
</td>
<td class="nump">8,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">5,288<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, net of current portion, related party</a></td>
<td class="nump">3,642<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ContingentConsiderationFairValueOfContingentLiability', window );">Contingent consideration</a></td>
<td class="nump">9,066<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">39,982<span></span>
</td>
<td class="nump">25,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December&#160;31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 400,000,000 shares authorized at December&#160;31, 2021 and 2020; 289,602,000 and 189,953,000 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">553,747<span></span>
</td>
<td class="nump">178,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(216,119)<span></span>
</td>
<td class="num">(143,684)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(539)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">337,118<span></span>
</td>
<td class="nump">35,082<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 377,100<span></span>
</td>
<td class="nump">$ 60,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ContingentConsiderationFairValueOfContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Fair Value of Contingent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ContingentConsiderationFairValueOfContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295014552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 2,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">289,602,000<span></span>
</td>
<td class="nump">189,953,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">289,602,000<span></span>
</td>
<td class="nump">189,953,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985296637720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 17,981<span></span>
</td>
<td class="nump">$ 8,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">14,107<span></span>
</td>
<td class="nump">5,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">22,485<span></span>
</td>
<td class="nump">10,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">58,490<span></span>
</td>
<td class="nump">31,068<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">80,975<span></span>
</td>
<td class="nump">41,324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(77,101)<span></span>
</td>
<td class="num">(38,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(927)<span></span>
</td>
<td class="num">(2,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan', window );">Gain on forgiveness of Paycheck Protection Program Loan</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(2,076)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expenses)</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(1,051)<span></span>
</td>
<td class="num">(2,526)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(78,152)<span></span>
</td>
<td class="num">(41,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) for income taxes</a></td>
<td class="nump">5,717<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (72,435)<span></span>
</td>
<td class="num">$ (41,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">276,782<span></span>
</td>
<td class="nump">104,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 11,695<span></span>
</td>
<td class="nump">$ 6,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">10,524<span></span>
</td>
<td class="nump">4,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">6,286<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="nump">$ 3,583<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Forgiveness Of Paycheck Protection Program Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297868920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Statement) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss:</a></td>
<td class="num">$ (72,435)<span></span>
</td>
<td class="num">$ (41,106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) on investment securities</a></td>
<td class="num">(539)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (72,974)<span></span>
</td>
<td class="num">$ (41,106)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985293973000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 3,613<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 106,188<span></span>
</td>
<td class="num">$ (102,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue common stock, net of issuance costs</a></td>
<td class="nump">37,935<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">37,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issue stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issue stock for employee stock purchase plan</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodSharesCovenantWaiver', window );">Issue stock for covenant waiver (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodValueCovenantWaiver', window );">Issue stock for covenant waiver</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issue stock for warrant exercises</a></td>
<td class="nump">28,645<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">28,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issue stock for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issue stock for acquisition</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss:</a></td>
<td class="num">(41,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 35,082<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">178,747<span></span>
</td>
<td class="num">(143,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (in shares)</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">$ 602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">9,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue common stock, net of issuance costs</a></td>
<td class="nump">$ 341,023<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">341,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issue stock for employee stock purchase plan (in shares)</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issue stock for employee stock purchase plan</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issue stock for warrant exercises</a></td>
<td class="nump">9,418<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issue stock for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issue stock for acquisition</a></td>
<td class="nump">14,159<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss:</a></td>
<td class="num">(72,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (539)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 337,118<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 553,747<span></span>
</td>
<td class="num">$ (216,119)<span></span>
</td>
<td class="num">$ (539)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_StockIssuedDuringPeriodSharesCovenantWaiver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Covenant Waiver</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_StockIssuedDuringPeriodSharesCovenantWaiver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_StockIssuedDuringPeriodValueCovenantWaiver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Covenant Waiver</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_StockIssuedDuringPeriodValueCovenantWaiver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985293958216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (72,435,000)<span></span>
</td>
<td class="num">$ (41,106,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,351,000<span></span>
</td>
<td class="nump">1,479,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of financing lease right-of-use asset</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Amortization of interest on securities</a></td>
<td class="nump">329,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">1,264,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">671,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SettlementOfInterestOnDebtNoncash', window );">Settlement of interest on debt</a></td>
<td class="num">(1,235,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Benefit from deferred income taxes</a></td>
<td class="num">(5,777,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,719,000<span></span>
</td>
<td class="nump">1,554,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,809,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan', window );">Gain on forgiveness of PPP Loan</a></td>
<td class="num">(1,775,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_GainLossOnExtinguishmentOfDebtCashExpense', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,480,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_CostOfLeasedEquipmentSoldToCustomer', window );">Cost of leased equipment sold to customer</a></td>
<td class="nump">568,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClientWarrantyExchangeOfFixedAssets', window );">Client warranty exchange of fixed asset</a></td>
<td class="nump">539,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities (net of assets acquired and liabilities assumed in acquisition)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(493,000)<span></span>
</td>
<td class="nump">2,087,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(15,928,000)<span></span>
</td>
<td class="num">(4,201,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,971,000)<span></span>
</td>
<td class="num">(999,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,781,000<span></span>
</td>
<td class="num">(1,810,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and contract liabilities</a></td>
<td class="nump">3,959,000<span></span>
</td>
<td class="nump">1,483,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(71,927,000)<span></span>
</td>
<td class="num">(38,314,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_PaymentsForPropertyAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(822,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForConstructionInProcess', window );">Construction in process</a></td>
<td class="num">(638,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_PaymentsForInitialCostsOnLeases', window );">Payment of initial direct costs on lease</a></td>
<td class="num">(607,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale securities</a></td>
<td class="num">(313,392,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale and maturities of available for sale securities</a></td>
<td class="nump">86,483,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(278,062,000)<span></span>
</td>
<td class="num">(2,450,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of term-loan debt</a></td>
<td class="num">(15,000,000)<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments of financing lease liability</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ProceedsFromPayrollProtectionProgramLoan', window );">Proceeds from PPP Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,774,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from borrowing from line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">761,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of borrowing from line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,258,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock</a></td>
<td class="nump">342,711,000<span></span>
</td>
<td class="nump">39,934,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses on sale of common stock</a></td>
<td class="num">(1,704,000)<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_EmployeeStockPurchasePlanCompensationExpense', window );">Proceeds from sale of common stock under employee stock purchase plan</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant and option exercises</a></td>
<td class="nump">10,020,000<span></span>
</td>
<td class="nump">28,651,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">336,111,000<span></span>
</td>
<td class="nump">61,902,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(13,878,000)<span></span>
</td>
<td class="nump">21,138,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">38,449,000<span></span>
</td>
<td class="nump">17,311,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">24,571,000<span></span>
</td>
<td class="nump">38,449,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,910,000<span></span>
</td>
<td class="nump">1,252,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">447,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ContingentConsiderationNoncash', window );">Contingent consideration related to BioDiscovery acquisition</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities resulting from obtaining and modifying right-of-use assets</a></td>
<td class="nump">4,751,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory', window );">Transfer of instruments and servers from inventory into property and equipment, net</a></td>
<td class="nump">6,857,000<span></span>
</td>
<td class="nump">4,224,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan', window );">Forgiveness of PPP Loan</a></td>
<td class="nump">1,775,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_StockIssuedForServices', window );">Stock issued for services</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_IssueCommonStockForCovenantWaiver', window );">Issue stock for covenant waiver</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_WarrantExerciseNonCash', window );">Warrant exercise pursuant to cashless exercise</a></td>
<td class="nump">129,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,450,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of common stock issued related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition, net of cash acquired</a></td>
<td class="num">(49,086,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of common stock issued related to acquisitions</a></td>
<td class="nump">$ 14,159,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClientWarrantyExchangeOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Client Warranty Exchange of Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClientWarrantyExchangeOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ContingentConsiderationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Noncash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ContingentConsiderationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_CostOfLeasedEquipmentSoldToCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Leased Equipment Sold to Customer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_CostOfLeasedEquipmentSoldToCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_EmployeeStockPurchasePlanCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Compensation Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_EmployeeStockPurchasePlanCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_GainLossOnExtinguishmentOfDebtCashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Extinguishment of Debt, Cash Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_GainLossOnExtinguishmentOfDebtCashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Forgiveness Of Paycheck Protection Program Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_IssueCommonStockForCovenantWaiver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Common Stock For Covenant Waiver</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_IssueCommonStockForCovenantWaiver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_PaymentsForInitialCostsOnLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Initial Costs on Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_PaymentsForInitialCostsOnLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_PaymentsForPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Property and Equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_PaymentsForPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ProceedsFromPayrollProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Payroll Protection Program Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ProceedsFromPayrollProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SettlementOfInterestOnDebtNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of Interest on Debt, Noncash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SettlementOfInterestOnDebtNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_StockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_StockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer of instruments and servers to property and equipment from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_WarrantExerciseNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Exercise, Non-cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_WarrantExerciseNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297416344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#8220;Company&#8221;) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company&#8217;s mission is to transform the way the world sees the genome through optical genome mapping (&#8220;OGM&#8221;) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. (&#8220;Lineagen&#8221;) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC. (&#8220;BioDiscovery&#8221;) business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had approximately $24.6&#160;million in cash and cash equivalents, $226.0&#160;million in short term investments, and working capital of $250.6&#160;million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, and September 30, 2021. In February 2021, we applied for forgiveness of our PPP Loan of approximately $1.8 million, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. During the year ended December&#160;31, 2021, the outstanding term loan under the Innovatus LSA was paid in full, including all accrued interest, an end of term fee, and a prepayment fee for a total of $17.0 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its available cash, cash equivalents and available-for-sale securities will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months. However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#8217;s business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to additional risks and uncertainties as a result of the continued spread of COVID-19 and uncertain market conditions, which could continue to have a material impact on the Company&#8217;s business and financial results. The Company closely monitors and complies with various applicable guidelines and legal requirements in the jurisdictions in which it operates, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. If restrictions related to COVID-19 persist, the Company could see supply chain disruptions that impact its ability to produce its products and may cause the Company to make strategic determinations regarding, among other things, the cost and quality of the components and supplies it acquires. The Company&#8217;s manufacturing partners, suppliers, and customers, have implemented similar operational reductions. Despite reporting an increase in revenue for the year ended December&#160;31, 2021 when compared to the same period in 2020, the Company believes travel restrictions and overall reduced activity had a continued negative impact on the Company&#8217;s financial results. Given the continued evolution of the COVID-19 pandemic and the related complexities and uncertainties associated with the additional variants, the future effects of COVID-19 are unknown and the Company&#8217;s financial results may continue to be negatively affected in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. These negative effects could have a material impact on the Company&#8217;s operations, business, earnings, and liquidity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985300423432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions used by management include estimates of selling prices for multiple performance obligation arrangements, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used in purchase accounting and to evaluate the recoverability of long-</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lived assets and goodwill, warranty reserves, certain accrued expenses, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company&#8217;s net deferred tax assets, stock-based compensation expense, and related valuation allowances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company&#8217;s 100%-owned subsidiaries.  All intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (&#8220;Lineagen Merger Sub&#8221;), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the securityholders of Lineagen, entered into an Agreement and Plan of Merger (the &#8220;Lineagen Merger Agreement&#8221;). Pursuant to the terms and conditions of the Lineagen Merger Agreement, Lineagen Merger Sub merged with and into Lineagen (the &#8220;Lineagen Merger&#8221;) whereupon the separate corporate existence of Lineagen Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Lineagen Merger as a wholly owned subsidiary of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Starship Merger Sub I, Inc., a wholly owned subsidiary of the Company (&#8220;BioDiscovery Merger Sub I&#8221;), Starship Merger Sub II, LLC, a California limited liability company (&#8220;BioDiscovery Merger Sub II&#8221;), BioDiscovery, Inc., a California corporation (&#8220;Former BioDiscovery&#8221;), and Soheil Shams, solely in his capacity as the securityholders&#8217; representative, entered into an Agreement and Plan of Merger (the &#8220;BioDiscovery Merger Agreement&#8221;), pursuant to which the Company agreed to acquire Former BioDiscovery. Pursuant to the terms and conditions of the BioDiscovery Merger Agreement, BioDiscovery Merger Sub I merged with and into Former BioDiscovery (&#8220;BioDiscovery Merger I&#8221;), whereupon the separate corporate existence of BioDiscovery Merger Sub I ceased, with Former BioDiscovery continuing as the surviving corporation of BioDiscovery Merger I and a wholly owned subsidiary of the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately after BioDiscovery Merger I, pursuant to the terms and conditions of the BioDiscovery Merger Agreement, Former BioDiscovery merged with and into BioDiscovery Merger Sub II (&#8220;BioDiscovery Merger II&#8221;), whereupon the separate corporate existence of Former BioDiscovery ceased, with BioDiscovery Merger Sub II continuing as the surviving company of BioDiscovery Merger II and a wholly owned subsidiary of the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with BioDiscovery Merger II, BioDiscovery Merger Sub II changed its name to that of our current subsidiary, BioDiscovery, LLC.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its acquisitions of Lineagen and BioDiscovery using the acquisition method of accounting pursuant to Accounting Standards Codification Topic 805, Business Combinations ("ASC 805"). Under ASC 805, the tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the acquisition date. Any excess purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of identifiable intangible assets acquired with the assistance of independent valuations that use information and assumptions provided by the Company&#8217;s management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 805, acquisition-related transaction costs (such as advisory, legal, valuation, other professional fees) are expensed in the statements of operations in the periods incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. The Company has not experienced any losses in such accounts. The Company believes that it is not exposed to any significant credit risk on cash and cash equivalents.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221;, defines and establishes a framework for measuring fair value and expands disclosures about fair value measurements. In accordance with ASC 820, the Company has categorized its financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the company has the ability to access at the measurement date.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on quoted prices for similar attributes in active markets; quoted prices in markets where trading occurs infrequently; and inputs other than quoted prices that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income (loss). A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company maintains deposits in federally insured major financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers are located throughout the world. The Company generally does not require collateral from its customers. More information on accounts receivable is contained in the paragraph titled &#8220;Accounts Receivable&#8221; below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources of Materials and Products</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The materials and components for the Company&#8217;s product offerings are currently obtained from single or limited sources. The Company competes with other companies for production capacity, therefore, the Company is exposed to a risk of inventory being unavailable at acceptable prices, or at all, if suppliers are unable (or decide) to provide sufficient levels of materials and components and the Company is unable to identify alternative suppliers. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,624,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,894,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(690,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,119,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,934,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,775,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For &#8220;OGM&#8221; products and services, credit is extended based upon an evaluation of each customer&#8217;s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the year ended December&#160;31, 2021, the Company recorded a recovery of bad debt expense of $108,000, which </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is included in selling, general and administrative expenses. During the year ended December&#160;31, 2020, the Company recorded bad debt expense of $1.8 million which was included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company&#8217;s total accounts receivable balance. As of December&#160;31, 2021, no customers met or exceeded 10% of the Company&#8217;s total accounts receivable balance. As of December&#160;31, 2020, two customer balances represented 27.4%  of the Company&#8217;s total accounts receivable balance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net of reserve, are as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,282,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,642,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,387,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,315,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets (including Finite-Lived Intangible Assets)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and acquired finite-lived intangible assets. The Company records property and equipment at cost, and records acquired finite-lived intangible assets based on their fair values at the date of acquisition. Property and equipment generally consist of laboratory equipment, computer and office equipment, furniture and fixtures, and leasehold improvements. Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the assets (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc4OTc_81782cd1-ff67-4bc0-b19a-d3f9ef09300e">three</span> to five years, or the remaining term of the lease for leasehold improvements, whichever is shorter). Repairs and maintenance costs are charged to expense as incurred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date. Intangible assets are amortized over the estimated useful life of the asset on a basis that approximates the pattern of economic benefit. Intangible assets are reviewed for impairment if indicators of potential impairment exist. There was no indication of impairment of intangible assets for any of the periods presented.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Lineagen and BioDiscovery acquisitions the Company recorded intangible assets, which consist of trade name intangibles, customer relationship intangibles, and a developed technology intangible, which are amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is not recoverable when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recognized no impairment losses on long-lived assets. Substantially all of the Company's long-lived assets are located in the U.S.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded contingent consideration resulting from a business combination at its fair value on the acquisition date. On a quarterly basis, we revalue this obligation and record any increase or decrease in fair value as an adjustment to the consolidated statement of operations. Changes to the fair value of the contingent consideration obligation may result from changes to the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discount rate, the passage of time, changes in our estimate of the likelihood, or timing of achieving the criteria for payment of the contingent consideration.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill arises when the purchase price of an acquired business exceeds the fair value of the identifiable net assets acquired, with such excess recorded as goodwill on the balance sheet. Goodwill is not subsequently amortized. Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indications of impairment exist. Goodwill is assigned to specific reporting units for purposes of impairment assessment. The Company has determined that it has a single operating segment and a single reporting unit. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In testing goodwill for impairment, the Company will first assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the qualitative assessment indicates that it is more likely than not that the fair value of the reporting unit is less than its carrying value, then the Company will perform a quantitative impairment analysis by comparing the fair value of the reporting unit to the carrying value of the reporting unit, including goodwill. An impairment charge for goodwill is recognized for the amount by which the carrying value of the reporting unit exceeds its fair value, not to exceed the total goodwill allocated to the reporting unit. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recognized no impairment losses on goodwill.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2021, the Company determines if an arrangement is, or contains, a lease at the inception of the arrangement. Right-of-use (&#8220;ROU&#8221;) assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating leases are included in operating lease right-of-use assets and operating lease liabilities in the consolidated balance sheets, while finance leases are included in finance lease right-of-use assets and finance lease liabilities.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and liabilities are recognized at commencement based on the present value of lease payments over the lease term. The Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments. The ROU assets also include any prepaid or accrued lease payments and is adjusted for lease incentives and initial direct costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease terms may include options to extend or terminate the lease which are recognized when it is reasonably certain that the Company will exercise that option. Leases with terms of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the lease terms, or in some cases, the useful life of the underlying asset. Variable lease payments are excluded from the measurement of ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. The Company accounts for the lease and non-lease components as a single lease component for all classes of underlying assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Rent</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating leases include incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2021, the difference between rent expense and amounts paid under the lease was recorded as deferred rent in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue primarily from the sale of products and services. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a receivable when we have an unconditional right to payment, which is generally at the time of delivery of software, consumables and instruments, including any extended warranties, or at the time services are rendered. Payment terms are typically 30 days for sales to customers in the United States but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within selling, general and administrative expenses, less any amounts reimbursed by the customer, when the corresponding revenue is recognized.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded net of discounts and sales tax. The Company&#8217;s contracts typically do not provide for product returns or refunds. In general, estimates of variable consideration and constraints are not material to the Company&#8217;s financial statements. Employee sales commissions are recorded as selling, general and administrative expenses when incurred as the amortization period for such costs, if capitalized, would have been one year or less. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenue recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue consists of sales of our Saphyr system and related consumables. These products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors. In addition, the Company provides the Saphyr system to certain customers under its reagent rental program, under which the Company provides Saphyr systems to customers at no cost and the customers agree to purchase minimum quantities of consumables.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains control of the product. As such the Company's performance obligation related to product sales is satisfied at a point in time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For transfers of instruments and consumables to customers under the Company's rental reagent program, the Company allocates the total contract consideration between the instrument and the consumables based on estimates of stand-alone selling prices, and recognizes the instrument revenue evenly over the rental period, and the consumables revenue when the consumables are delivered. Rental revenue related to the reagent rental program recognized over-time totaled $0.2 million and $0.1 million during the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service and other revenue recognition </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue primarily consist of revenue from diagnostic testing services, the sale of software, and license maintenance agreements, and support, repair and maintenance services and extended warranties on Saphyr systems. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the completion of diagnostic testing services is initially recorded at the estimated consideration the Company expects to receive from contractual and non-contractual payors, and is subject to adjustment based on the amount actually collected. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results, which the Company has determined is the point at which control is transferred to the customer for revenue recognition purposes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the sale of software is recognized at the point-in-time the software license is transferred to the customer, or for hosting arrangements, on a usage basis as the customer processes the number of genetic samples purchased with the software. Revenue related to license maintenance agreements is recognized over-time based on the contract term. Revenue recognized over-time related to license maintenance agreements totaled $0.1 million during the year ended December&#160;31, 2021. There was no revenue recognized related to license maintenance agreements during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from support and maintenance contracts and extended warranties is recognized over time based on the contract term, which represents a faithful depiction of the transfer of goods and services given the stand-ready nature of the performance obligations. Service revenue related to repairs and customer sample evaluations is recognized as the services are performed based on the specific nature of the service. Warranty and maintenance revenue recognized over-time totaled $0.6 million and $0.5 million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in service and other revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was&#160;$0.8 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations, as well as obligations related to software under hosting arrangements. The Company expects to recognize approximately&#160;82.4%&#160;of this amount as revenue in 2022,&#160;13.8%&#160;in 2023, 2.3%&#160;in 2024 and 1.5% in 2025 and thereafter. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. The Company's liability for product warranties provided under its agreements with customers was $0.2 million and $0.2 million as of December&#160;31, 2021 and 2020, respectively. Warranty expense recorded in cost of goods sold totaled $0.5 million and $0.4 million during the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets primarily relate to the Company&#8217;s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheets. The Company recognized revenue of&#160;$0.4 million and $0.4 million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor Transactions </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain markets, the Company sells products and provides services to customers through distributors that specialize in life sciences products. In cases where the product is delivered to a distributor, revenue recognition generally occurs when the distributors obtains control of the product. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers and do not contain return rights. Distributor sales transactions typically differ from direct customer sales as they do not require the Company&#8217;s services to install the instrument at the end customer or perform the services for the customer that are beyond the standard warranty in the first year following the sale. These transactions are accounted for in accordance with the Company&#8217;s revenue recognition policy described herein. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue for products consists of the Company&#8217;s raw material parts costs and associated freight, shipping and handling costs, contract manufacturing costs, royalties due to third parties, salaries and other personnel costs, equipment depreciation, overhead and other direct costs related to those sales recognized as product revenue in the period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of service and other revenue consists of salaries and other personnel costs, and facility costs associated with costs related to warranties and other costs of servicing equipment at customer sites, and performance of diagnostics services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for research and product development, including acquired technology and costs incurred for technology in the development stage, are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to filing and pursuing patent applications are recorded as selling, general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards as compensation to employees and directors. Stock-based awards may include stock options, stock appreciation rights, vesting stock awards and performance share awards. These awards are accounted for as equity awards. To-date, the Company recognizes stock-based compensation expense net of actual forfeitures on a straight-line basis over the underlying award&#8217;s requisite service period, which is generally the vesting period, as measured using the award&#8217;s grant date fair value. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the impact of uncertain tax positions at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it does not have a greater than 50% likelihood of being sustained. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company chief operating decision-maker, the Chief Executive Officer, views the Company&#8217;s operations and manages its business as one operating segment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. Pre-funded warrants from the Company's follow-on offering have been treated as if they were common shares outstanding on the date of issuance.  The Company&#8217;s potentially dilutive securities which include outstanding warrants to purchase stock and outstanding stock options under the Company&#8217;s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive were as follows (in common stock equivalent shares): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,765,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,290,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,174,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,006,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,778,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,464,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued But Not Yet Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuer&#8217;s Accounting for Certain Modifications or Exchanges for Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to clarify the accounting for modifications or exchanges of equity-classified warrants. The standard is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is in the process of evaluating the expected impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2021-04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on its financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The Company&#8217;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. In February 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASC 842&#8221;) which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASC 842 establishes a right-of-use model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. ASC 842 also requires disclosures to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was adopted </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2021, as the Company lost its status as an Emerging Growth Company effective December 31, 2021, and therefore was required to adopt the standard for the year ending December 31, 2021, using the modified retrospective method. Under this transition method, the Company recognized and measured leases that existed at the adoption date in the consolidated balance sheet as of January 1, 2021. In connection with the adoption of ASC 842, the Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company also made accounting policy elections not to apply the recognition requirements under ASC 842 to any short-term leases and to account for each separate lease and associated non-lease components as a single lease component for all the Company&#8217;s leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of ASC 842 resulted in recognition of operating lease assets and liabilities of approximately $2.1 million and $2.1 million, respectively, as of January 1, 2021, related to the lease of office and laboratory space. The comparative prior period information continues to be reported under ASC 840. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. For further details, see Note 11, Commitments and Contingencies. The adoption of the new standard did not materially impact the Company&#8217;s consolidated results of operations or cash flows.</span></div>In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities From Contracts With Customers. This ASU requires an acquirer to account for revenue contracts acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. Prior to ASU 2021-08, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers and other similar contracts, at fair value on the acquisition date. The guidance is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and should be applied prospectively to business combinations occurring on or after the effective date. Early adoption is permitted. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company adopted ASU 2021-08 on October 1, 2021, and applied the ASU prospectively to its acquisition that occurred in 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985300389624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contracts with Customers</a></td>
<td class="text">Revenue from Contracts with Customers<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue by Source</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,887,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,085,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,808,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,145,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,695,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,230,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services and other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,273,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,981,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,503,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,329,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,489,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEIA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,604,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,163,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,048,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,981,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,503,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables above provide revenue from contracts with customers by source and geographic location on a disaggregated basis. North America consists of the United States and Canada. EMEIA consists of Europe, the Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia. For the years ended December&#160;31, 2021 and 2020, sales in the United States represented 46% and 42% of revenues, respectively. During the year ended December&#160;31, 2021, sales in China accounted for 11% of total revenue. No other countries represented greater than 10% of revenue during the years ended December&#160;31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297392024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Investments and Fair Value Measurements</a></td>
<td class="text">Investments and Fair Value Measurements <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are not re-measured at fair value include cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s long-term debt approximates its fair value due to the market rate of interest which was determined to be a Level 2 measurement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The carrying values of these financial instruments approximate their fair values. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis in the Consolidated Balance Sheets:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,860,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,860,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,181,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,181,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Investments:</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,041,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,041,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,126,000&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,126,000&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,066,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,066,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds are classified as cash equivalents on the balance sheet. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration liability is reassessed on a quarterly basis using the income approach. Assumptions used to estimate the acquisition date fair value of the contingent consideration include the probability of achieving certain milestones and a discount rate of 3.2%. The fair value measurement of the contingent consideration is based on significant inputs not observed in the market (Level 3 inputs). Significant inputs used in the measurement include probabilities of achieving the remaining milestones, which depend on the milestone risk profile. The change in fair value of the contingent consideration during the year ended December&#160;31, 2021 was due to the passage of time. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimated fair value of contingent consideration liability in the year ended December&#160;31, 2021 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contingent</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Consideration</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Liability</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Level 3</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Measurement)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability recorded as a result of current period acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value, recorded in selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,066,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not hold any investments as of December&#160;31, 2020. As of December&#160;31, 2021, the Company held 57 securities in an unrealized loss position for a period of less than 12 months resulting in an unrealized loss of $0.5 million included in other comprehensive income during the year ended December&#160;31, 2021. None of the Company&#8217;s available-for-sale investment securities were in a material unrealized loss position at December&#160;31, 2021. As such, the Company has not recognized any impairment in its financial statements related to its available-for-sale investment securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company received proceeds of $86.5 million relating to sales and maturities of its available for sale securities, and recognized a loss of $8,000 in other income relating to the sale of these securities. Amounts are reclassified out of accumulated other comprehensive income into earnings using the specific identification method. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized loss</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,929,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,173,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,478,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,929,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,651,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in interest income for the year ended December&#160;31, 2021 was interest income related to the Company&#8217;s available for sale securities of $0.4 million. All interest income related to the available for sale securities in 2021 related to year ended December&#160;31, 2021. All available-for-sale securities are classified as current assets, even if the maturity when acquired by the Company is greater than one year due to the ability to liquidate within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297418008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses And Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepayment to supplier</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,461,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,348,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,481,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,250,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297744008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,341,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,718,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service equipment placed at customer sites</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,556,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,267,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,674,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,390,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,366,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,072,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,456,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,318,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,910,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>For the years ended December&#160;31, 2021 and 2020, the Company recorded depreciation expense of $1.9 million and $1.4 million, respectively, which includes an allocation to cost of revenue of $0.9 million, $0.5 million, and $41,000 respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985300394664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that are subject to amortization consisted of the following at December&#160;31, 2021 and 2020:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,630,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,420,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">630,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,950,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,572,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,800,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(950,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,850,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,380,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,538,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,842,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,475,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense for intangible assets of $1.4 million and $0.1 million for the years ended December&#160;31, 2021 and 2020 respectively, in selling, general and administrative expenses. The customer relationships and trade name intangibles from the Lineagen acquisition are both being amortized on a straight-line basis over their estimated useful lives of 5 years, and have remaining amortization periods of 3.6 years. The customer relationships, developed technology and trademark intangibles from the BioDiscovery acquisition are being amortized on a straight-line basis over their estimated useful lives of 5 years, and have remaining amortization periods of 4.8 years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,676,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,676,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,676,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,571,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,243,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,842,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297423176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,529,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,251,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goods received not invoiced</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,073,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,941,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,694,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,599,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297385256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company received the PPP Loan proceeds of approximately $1.8&#160;million pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) administered by the U.S. Small Business Administration (the &#8220;SBA&#8221;).  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP Loan accrued interest at a rate of 1% per annum and was subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act. In February 2021, the Company applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. A gain on forgiveness of Paycheck Protection Program loan of $1.8&#160;million was recognized during the year ended December&#160;31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovatus LSA</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company entered into a Loan and Security Agreement (the &#8220;LSA&#8221;) by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent and the lenders listed on Schedule 1.1 thereto, including East West Bank. The LSA provided a first term loan of $17.5 million, a second term loan of $2.5 million and a third term loan of $5.0 million (collectively, the &#8220;Term Loans&#8221;) if the Company satisfied certain funding conditions. Interest on the Term Loans is due on the first of each month at a rate of 10.25% per annum in cash or a discounted rate of 7.25% in cash with 3.0% of the 10.25% per annum rate added to the principal of the loan and subject to accruing interest through the end of the interest only payment period, which ends March 1, 2022. At inception, the Company elected to pay interest in cash at a rate of 7.25% per annum and have 3.0% per annum of the interest added back to the outstanding principal. As of May 14, 2021 (the effective date of the loan payoff), the effective interest rate, including debt issuance costs, for the Term Loans was 16.7%. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA provided for prepayment fees of 3.0% of the outstanding balance of the loan if the loan is repaid on or prior to March 14, 2020, 2.0% of the amount prepaid if the prepayment occurs after March 14, 2020 but prior to March 14, 2021, 1% of the amount prepaid after March 14, 2021 but prior to March 14, 2022 and 0% of the amount prepaid if the prepayment occurs thereafter. In addition, upon the final repayment of the total amounts borrowed, the Company is required to pay an end of term fee of $0.8 million. This end of term fee was being recognized as interest expense over the term of the LSA. As of December&#160;31, 2021, the outstanding term loan with Innovatus was paid in full, including all accrued interest, the end of term fee, and a prepayment fee for a total of $17.0 million. The Company recorded a loss on debt extinguishment of $2.1 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA also provided for a revolving line of credit in an amount not to exceed $5.0 million (the &#8220;Revolver&#8221;), which was terminated effectively upon payment in full of the above term loan.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSA was collateralized by substantially all of the Company&#8217;s assets, including its intellectual property. The LSA required the Company to comply with various affirmative and negative covenants, including: (1) a liquidity covenant requiring the Company to maintain a minimum cash balance at all times in a collateral account and (2) a revenue covenant requiring the Company to meet certain minimum revenue targets measured at the end of each calendar quarter. The LSA also included certain standard events of default, and a provision that Innovatus could declare an event of default upon the occurrence of any event that it interprets as having a material adverse impact to the Company's business, operations, or condition, a material impairment on the Company's ability to pay the secured obligations under the LSA, or upon a material adverse effect on the collateral under the agreement, thereby requiring the Company to repay the loans immediately, together with a prepayment fee and other applicable fees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, in connection with the receipt of $20.0&#160;million in proceeds from the Term Loans, the Company issued to Innovatus a warrant to purchase up to 0.2 million shares of its common stock at an exercise price of $4.63 per share, which has a term of 10 years. These warrants were equity classified and their respective fair value was recorded as a discount to the debt. The warrants were exercised during the year end December 31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the LSA was amended to among other things: (i) extend the deadline for the Company to maintain its domestic depository and operating accounts with the Bank, subject to a control agreement in favor of Innovatus, to July 31, 2019 and (ii) permit the Company to incur credit card indebtedness in an amount not to exceed $0.2 million. As of September 30, 2019, the Company did not achieve the revenue covenant under the Innovatus LSA. As a result, in October 2019, the Company obtained a waiver letter from Innovatus. Pursuant to the waiver letter, Innovatus agreed to allow the Company to cure its noncompliance with the revenue covenant as of September 30, 2019 so long as the Company (i) raised at least $10&#160;million in gross proceeds from the sale of its securities in an underwritten public offering by October 31, 2019 and (ii) amended the warrant to purchase stock, issued by the Company to Innovatus in March 2019 to decrease the exercise price of the warrant from $4.63 per share to $0.48 per share. Also pursuant to the waiver letter, as consideration for the prospective breach of a liquidity covenant, the Company agreed to issue to Innovatus 0.6 million shares of the Company's common stock. As a result of the amendment and shares issued, the Company recognized $0.6 million as a debt discount, which is being amortized as interest expense over the remaining term of the LSA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company did not achieve certain financial covenants under the Innovatus LSA. As a result, in March 2020, the Company and Innovatus entered into an amendment to the Innovatus LSA (the &#8220;Second Amendment&#8221;) to, among other things: (i) waive the events of default from not achieving the specific financial covenants for the December 31, 2019 measurement date, (ii) require an immediate partial repayment of $2.1&#160;million, (iii) require an additional partial repayment of $2.9&#160;million on the earlier of completion of an Equity Event (as defined in the Second Amendment), or April 30, 2020, (iv) modify the liquidity covenant, such that the Company&#8217;s minimum cash balance shall vary based on outstanding borrowing capacity under the Revolver (provided, however, that the Company shall maintain a minimum cash balance of $2&#160;million at any given time), (v) reduce the dollar amount of certain minimum revenue covenants measured as of the end of each calendar quarter (each, a &#8220;Revenue Covenant&#8221;) and (vi) modify the terms of certain events of default. For example, the Second Amendment provides for a cure period in connection with the breach of certain minimum revenue financial covenants, as long as the Company submits an updated management plan and financial projections, which are subject to Innovatus approval, and completes a Qualified Financing Event (as defined in the Second Amendment) within 45 days of such breach. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Second Amendment, the Company was obligated to pay Innovatus a waiver fee in the amount of $0.2 million and a prepayment fee of $0.1 million, payable in cash or in shares of the Company&#8217;s common stock at the Company's election, no later than following completion of the Equity Event, as defined in the Second Amendment. As described in Note 10 below, the Company completed a follow-on public offering in April 2020 that constituted an Equity Event under the Second Amendment. A portion of the proceeds from the follow-on offering were used to pay-down $2.9&#160;million of principal balance outstanding under the Term Loans in accordance with the Second Amendment. In addition, the Company issued 0.9 million shares of its common stock to Innovatus to satisfy the $0.2 million waiver fee and the $0.1 million prepayment fee due under the Second Amendment. As a result of the amendment and shares issued, the Company recognized $0.3 million as a debt discount, which is being amortized as interest expense over the remaining term of the LSA. Also pursuant to the Second Amendment, the Company subsequently registered such shares for resale on a registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) filed with the Securities and Exchange Commission on June 22, 2020 and declared effective on July 7, 2020. The Company has not and will not receive any of the proceeds from the offering described in the Registration Statement. In connection with the Merger, the Company and Lineagen entered into a Third Amendment (the &#8220;Third Amendment&#8221;) to the Innovatus LSA. Among other things, the Third Amendment adds Lineagen as a &#8220;Borrower&#8221; under the Innovatus LSA and updates certain financial covenants in light of Lineagen becoming a wholly owned subsidiary of the Company. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company obtained a waiver from Innovatus of its previously disclosed noncompliance, as of September 30, 2020, with the revenue covenant contained in the LSA. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company was in compliance with the covenants under the Innovatus LSA. The Innovatus LSA was paid in full and terminated in 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Debt Obligations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no debt as of December&#160;31, 2021. The carrying value of the Company&#8217;s debt as of December 31, 2020 was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,981,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPP Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,775,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total principal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,756,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,430,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,326,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985300414840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity and Stock-Based Compensation</a></td>
<td class="text">Stockholders&#8217; Equity and Stock-Based Compensation<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently authorized to issue up to 400 million shares of $0.0001 par value common stock. All issued shares of common stock are entitled to vote on a 1 share/1 vote basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently authorized to issue up to 10 million shares of $0.0001 par value preferred stock. No preferred stock has been issued to date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Follow-on Public Offerings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company completed an underwritten public offering of&#160;16.9 million&#160;shares of its common stock and, to certain investors, pre-funded warrants to purchase&#160;37.7 million&#160;shares of its common stock, and accompanying common warrants to purchase up to an aggregate of&#160;54.5 million&#160;shares of its common stock. Each share of common stock and pre-funded warrant to purchase&#160;one&#160;share of common stock was sold together with a common warrant to purchase&#160;one&#160;share of common stock. The public offering price of each share of common stock and accompanying common warrant was&#160;$0.33&#160;and&#160;$0.329&#160;for each pre-funded warrant. The pre-funded warrants are immediately exercisable at a price of&#160;$0.001&#160;per share of common stock. The common warrants are immediately exercisable at a price of&#160;$0.33&#160;per share of common stock and will expire&#160;five years from the date of issuance. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The gross proceeds to the Company, before deducting offering costs of $1.6 million, were&#160;$18.0 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 12, 2021, the Company completed an underwritten public offering of 33.4 million shares of common stock, including 4.4 million shares of common stock sold pursuant to the underwriters' exercise in full of their option to purchase additional shares. The price to the public in the offering was $3.05 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $2.867 per share. The gross proceeds were&#160;approximately $101.8 million before deducting underwriting discounts and commissions and other offering expenses of $0.3 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company completed an underwritten public offering of 38.3 million shares of common stock, including 5.0 million shares of common stock sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional shares. The price to the public in the offering was $6.00 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $5.64 per share. The gross proceeds to us were&#160;approximately $230.0 million before deducting underwriting discounts and commissions and other offering expenses of $0.4 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statements; Ladenburg and Cowen At-the-Market Facilities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $125 million of the Company&#8217;s securities, including up to $40 million of common stock pursuant to an At Market Issuance Sales Agreement, with Ladenburg Thalmann &amp; Co. Inc. acting as sales agent (the &#8220;Ladenburg ATM&#8221;). During October through December 2020, the Company sold 27.0 million shares of common stock under the Ladenburg ATM at an average share price of $0.82, and received gross proceeds of approximately $22.1 million before deducting offering costs of $0.6 million. In January 2021, the Company sold an additional 6.3 million shares of common stock under the ATM at an average share price of $2.68, and received gross proceeds of approximately $16.9 million before deducting offering costs of $0.4 million. The Company terminated the Ladenburg ATM in March 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2021, the Company filed an automatically effective shelf registration statement on Form S-3 with the SEC as a &#8220;well-known seasoned issuer,&#8221; allowing for the Company to issue an indeterminate number or amount of its securities from time to time in one or more offerings. On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) which provides for the sale, in the Company&#8217;s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0 million through or to Cowen, acting as sales agent or principal (the &#8220;Cowen ATM&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company agreed to pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August and September 2021, the Company sold 2.3 million shares of common stock under the Cowen ATM at an average share price of $6.15 per share, and received gross proceeds of approximately $13.9 million before deducting offering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity for the year ended December 31, 2021 was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-  <br/>Average  <br/>Exercise  <br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-  <br/>Average  <br/>Remaining  <br/>Contractual  <br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate  <br/>Intrinsic  <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,406,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,933,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,396,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,628,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,780,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,174,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,841,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,794,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,191,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a Warrants Amendment and Agreement with certain holders of warrants that were exercisable for 3.2 million shares of common stock. The agreement reduced the exercise price of existing warrants from $0.86 per share to $0.75 per share, which were exercised following the amendment, in addition to issuing 3.2 million new warrants at an exercise price per share of $1.06 that were exercised in the year ended December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company&#8217;s board of directors (the &#8220;Board&#8221;) and its stockholders adopted the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), as a successor to and continuation of the Company&#8217;s 2006 Equity Incentive Plan (the &#8220;2006 Plan&#8221;). Under the 2018 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then its employees, directors and consultants, including employees and consultants of its affiliates. The Company has initially reserved 1.5 million shares of common stock for issuance under the 2018 Plan, which is the sum of (1) 1.0 million new shares, plus (2) the number of shares that remained available for issuance under the 2006 Plan at the time the 2018 Plan became effective, and (3) any shares subject to outstanding stock options or other stock awards that were granted under the 2006 Plan that would have otherwise returned to the 2006 Plan. In addition, the number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2019 through January 1, 2028, in an amount equal to 5% of the total number of shares of the Company&#8217;s capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board. As of December&#160;31, 2021, 6.2 million shares of common stock were authorized for future grants under the 2018 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company&#8217;s Board and its stockholders adopted the 2020 Inducement Plan and amended by the Board on October 6, 2021. Under the 2020 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then its employees, directors and consultants, including employees and consultants of its affiliates. The Company has initially reserved 2.1 million shares of common stock for issuance under the 2020 Plan. An additional 1.0 million of shares of common stock was reserved for issuance under the Inducement Plan for a total of 3.1 million shares pursuant to an amendment to the Inducement Plan approved by the board of directors on October 6, 2021. As of December&#160;31, 2021, there were approximately 0.7 million shares of common stock authorized for future grants under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity is as follows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise <br/>Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Remaining <br/>Contractual <br/>Term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate <br/>Intrinsic <br/>Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,290,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,178,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,108,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(471,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,547,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,162,000)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,765,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,891,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and exercisable at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,389,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.53&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 5.5pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,428,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock option grants during the years ended December&#160;31, 2021 and 2020 was $4.35 and $0.44, respectively. The total intrinsic value of the stock options exercised during the years ended December&#160;31, 2021 and 2020 were $2.5 million and $7,000, respectively. The contractual term of stock options granted to employees was 10 years, which is also the maximum contractual term permitted for stock options (and stock appreciation rights) issued under the 2018 Plan. Stock options generally vest or become exercisable monthly over a four-year period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock award in the amount of 5.0 million shares with a grant date fair value of $5.20 a share was granted as part of the acquisition of BioDiscovery. One-third of the Restricted Shares will vest on October 18, 2022 and one-twelfth of the Restricted Shares shall vest every three months following October 18, 2022, subject to continuous service of a key employee. The weighted average remaining contractual term for the restricted stock is 2.8 years as of December&#160;31, 2021. The fair value of the restricted stock award is based on the market value of common stock as of the date of grant and is amortized to expense over the respective vesting period or the service period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues restricted stock units (RSU) and performance stock units (PSU). The Company grants restricted stock pursuant to the 2018 Stock Plan and satisfy such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. RSUs generally vest over a two-year period with equal vesting annually. We issue PSUs for which the number of shares issuable at the end of a four-year performance period is based on our performance relative to specified revenue targets and continued employment through the vesting period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(179,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.76</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of the RSUs that vested was $0.9 million during fiscal 2021, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is 1.4 years as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock activity was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual term for the PSUs is 3.4 years as of December&#160;31, 2021</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the years ended December&#160;31, 2021 and 2020 was as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,188,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,719,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,554,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of the employee stock option grants were as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s stock options. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and lack of company-specific historical or implied volatility as a private company, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded. As a result, the Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forfeitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company reduces stock-based compensation expense for actual forfeitures during the period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized Stock-Based Compensation Expense </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the unrecognized compensation expense for all non-vested share-based awards was $59.2 million and is expected to be recognized as expense over a weighted-average period of 3.1 years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Board and the Company&#8217;s stockholders adopted the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of 0.2 million shares of common stock were initially reserved for issuance under the ESPP. In addition, the number shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2019, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through January&#160;1, 2028, by the lesser of (1) 1% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of the automatic increase, (2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares, </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (3) a lesser number of shares as determined by the Board. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, 0.2 million shares of common stock were authorized for future grants under the ESPP.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Option Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2022, the compensation committee of the Company&#8217;s board of directors granted various executive officers stock options to purchase an aggregate of 4.3 million shares of common stock at an exercise price of $2.18 a share, in each case with an effective grant date and vesting commencement date of February 15, 2022 (the &#8220;Grant Date&#8221;). These stock option grants were issued from the 2018 Stock Plan. The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of the Grant Date, such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985300414840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases approximately 35,823 square feet of office, laboratory, and manufacturing space in two buildings at our headquarters in San Diego, California, with the lease for all rented space expiring December 31, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, the Company executed a new lease for approximately 11,978 additional square feet square feet of office and laboratory space in San Diego, California that expires in January 2026.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2022, the Company executed a new lease for an additional 5,278 square feet of office and laboratory space in San Diego, California that expires in January 2026. Rent payments for the additional space are $16,000 each month through December 2022, and increases annually according to the Company&#8217;s lease agreement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, through the acquisition of Lineagen, the Company obtained a lease for approximately 9,710 square feet of office space in a Salt Lake City, Utah under a non-cancelable operating lease that expires in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance lease</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, through the acquisition of BioDiscovery, the Company obtained a finance lease of 4,786 square feet of office space in El Segundo, California that expires in February 2041.  The portion of the future payments designated as principal repayment and related interest was classified as a finance lease obligation on our consolidated balance sheets. Refer to Note 15. Related Party Transactions for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental information </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all leases, the Company has the ability to enter into renewal negotiations, prior to the lease end date, with no specific terms. At this time, it is not reasonably certain that we will extend the term of the lease and therefore the renewal period has been excluded from the aforementioned ROU asset and lease liability measurements. The leases are subject to variable charges for common area maintenance and other costs that are determined based on actual costs and includes certain lease incentives such as tenant improvement allowances. The base rent for the leases is subject to an annual increase each year. Rent expense is being recognized on a straight-line basis over the term of the lease. The Company&#8217;s estimated incremental borrowing rate of 7.1% was used in its present value calculations as the operating and finance leases do not have a stated rate and the implicit rate was not readily determinable. In determining the incremental borrowing rate, the Company considered the interest rate of the Term Loans as well as publicly available data for discount rates used by peer companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information pertaining to the Company&#8217;s leases in which the Company is lessee for the year ended December&#160;31, 2021 is as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;19.2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash lease liabilities resulting from obtaining right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,751,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of the Company&#8217;s lease cost:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,118,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total rent expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,504,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(422,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense and sublease income for the year ended December 31, 2020 reflects accounting treatment under ASC 840.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum payments under non-cancellable operating and finance leases as of December&#160;31, 2021, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,950,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,011,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,088,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,949,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,162,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,599,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,407,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,658,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,755,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,941,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASC Topic 842, future minimum rental payments under operating leases as of December&#160;31, 2020, were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ending December&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">734,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,464,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a contractual commitment with a supplier to purchase $0.3 million of products every month for an initial term of two years beginning in May 2021 until May 2023. The contract can be terminated with 90 days written notice by either party.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of the loss can be reasonably estimated. Based on the Company&#8217;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Merger Agreement related to the acquisition of BioDiscovery, the Company agreed to pay a milestone payment of $10.0 million in cash contingent on the achievement of a commercial milestone within eighteen months of the acquisition date. The Company determined the fair value of the milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The outcome of the milestone consideration is binary, meaning the milestone is either achieved or not achieved, and the only other variable factor is the timing of when the milestone is achieved. The Company determined it is highly likely that the milestone will be achieved and therefore used a 95% probability factor which is applied to the $10.0 million milestone consideration. Based on these valuation assumptions, a contingent liability of $9.0 million was recognized on the acquisition date. As of December&#160;31, 2021, the fair value of the milestone consideration was determined to be $9.1 million. The change in fair value of $0.1 million was recorded in selling, general and administrative expense in the consolidated statement of operations for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297764264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of income (loss) from continuing operations are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,356,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,191,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,152,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,077,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for domestic and foreign income taxes is as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current income tax provision (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,055,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,722,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,777,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,717,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the income tax computed at the federal statutory tax rate to the expense for income taxes are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,413,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,626,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,030,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(522,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,879,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,816,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 162(m)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(938,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,717,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2021 and 2020 are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,399,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,354,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,911,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,671,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC 842 - lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,148,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,133,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,623,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,478,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC 842 - ROU asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,504,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83,151,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,273,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has federal and state tax net operating loss carryforwards of $341.1 million and $158.4 million, respectively. The federal tax loss carryforwards include $176.8 million that do not expire but utilization is limited to 80% of the Company's taxable income in any given tax year based on current federal tax laws. The remaining federal tax loss carryforwards of $164.3 million and state tax loss carryforwards begin to expire in 2027 and 2023, respectively, unless previously utilized. As of December&#160;31, 2021, the Company also has federal and California research credit carryforwards of $6.7 million and $6.1 million, respectively. The federal research credit carryforwards begin to expire in 2027 unless previously utilized. The California research credits carry forward indefinitely. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses all available evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company has experienced net losses since inception, and the revenue and income potential of the Company&#8217;s business and market are unproven. Due to the Company&#8217;s continuing research and development ("R&amp;D") activities, the Company expects to continue to incur net losses into the foreseeable future. As such, the Company cannot conclude that it is more likely than not that its deferred tax assets will be realized. A valuation allowance of  $83.2&#160;million, and $70.3&#160;million as of December&#160;31, 2021, and 2020, respectively, has been established to offset the deferred tax assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired BioDiscovery, LLC. an entity designated for income tax purposes as a corporation in a plan of reorganization  within the meaning of Section 368(a)(1)(A) on  October 18, 2021. Under ASC 805-740, the Company recorded deferred tax liabilities of $5.8 million related to customer lists, patents/trademarks, developed technology, and fixed assets as part of the business combination. As the deferred tax liability recorded in the business combination constitutes a source of future taxable income, the Company recorded a decrease to its valuation allowance against its deferred tax assets of $5.8&#160;million as a deferred income tax benefit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating losses and R&amp;D credit carryforwards are subject to annual limitations due to ownership changes that have occurred or that could occur in the future, as required by Sections 382 and 383 of the Internal Revenue Code of 1986,as amended (the "Code"), as well as similar state and foreign provisions. These ownership changes will limit the amount of net operating losses and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change" as defined by Section 382 of the Code results from a transaction or series of </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions over a three-year period resulting in an ownership change of more than 50 percentage points of outstanding stock of a company by certain stockholders. Due to the existence of the valuation allowance, limitations created by past or future ownership changes, if any, will not impact its effective tax rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company last performed a 382 study during 2013 and since this date there have been changes in ownership that will limit the Company's ability to utilize the net operating loss and R&amp;D credit carryforwards. The Company is in the process of refreshing its 382 study but the results of that analysis are unknown as of the issuance date of these consolidated financial statements. The completion of the 382 study could result in material reductions to deferred tax assets and related valuation allowance disclosed above. However, the Company had not utilized any of the net operating losses and R&amp;D credits during the years ended December 31, 2021 and 2020.          &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, are as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,201,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,708,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions/(reductions) for tax positions - prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,119,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,201,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the benefit of uncertain tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. Due to the valuation allowance position, none of the unrecognized tax benefits, if recognized, will impact the Company`s effective tax rate. The Company does not anticipate a significant change in the unrecognized tax benefits during the next twelve months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company had no accrual of interest and penalties on the Company&#8217;s balance sheets and has not recognized any interest and penalties in the statements of operations for the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the United States, the United Kingdom and China. The Company's tax years from 2007 (inception) are subject to examination by the United States and state authorities due to the carry forward of unutilized net operating losses and R&amp;D credits.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297403400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DefinedContributionPlanDisclosuresTextBlock', window );">Employee Benefits</a></td>
<td class="text">Employee Benefits The Company has a defined contribution 401(k) plan available to eligible employees. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. The Company expensed matching contributions of $0.83&#160;million and $0.46&#160;million for the years ended December&#160;31, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DefinedContributionPlanDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DefinedContributionPlanDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297365672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lineagen Acquisition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company, Merger Sub, Lineagen, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the security-holders of Lineagen, entered into the Lineagen Merger Agreement. Pursuant to the terms and conditions of the Lineagen Merger Agreement, Merger Sub merged with and into Lineagen whereupon the separate corporate existence of Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Merger as a wholly owned subsidiary of the Company. Lineagen&#8217;s expertise in development, commercialization and reimbursement of laboratory-developed tests provides a platform for accelerating sales growth for the Company&#8217;s Saphyr system. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Lineagen Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), the shares of capital stock of Lineagen and all options of Lineagen that were issued and outstanding immediately prior to the Effective Time were automatically cancelled and extinguished without any payment with respect thereto. Certain holders of convertible notes and other indebtedness of Lineagen at the closing of the Merger (the &#8220;Closing&#8221;) received common stock of the Company. The total number of shares of the Company&#8217;s common stock issued or reserved for issuance as consideration for the Merger was 6,167,510 shares, subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen (the &#8220;Merger Shares&#8221;). 925,126 of the Merger Shares (the &#8220;Escrowed Shares&#8221;) were held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Lineagen Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also as consideration for the Merger, pursuant to the Lineagen Merger Agreement, the Company paid approximately $1.9&#160;million in cash to certain creditors and assumed certain liabilities of Lineagen totaling approximately $2.9&#160;million, reflective of the Company's preliminary estimate of the post-closing purchase price adjustment (which adjustment is subject to finalization pursuant to the terms of the Lineagen Merger Agreement).  In addition, on August 21, 2020, concurrent with the Closing, the Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to that certain Promissory Note, dated April 22, 2020, by and between Lineagen and Silicon Valley Bank (the &#8220;Lineagen PPP Loan&#8221;), issued pursuant to the CARES Act administered by the SBA. The Lineagen PPP Loan was repaid by the Company prior to maturity without penalty.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its acquisition of Lineagen using the acquisition method of accounting pursuant to ASC 805.  The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non tax deductible. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. During the fourth quarter of 2020, the Company recorded a $0.2 million adjustment to the original purchase price allocation to reduce the estimated fair value of accounts receivable, with the offsetting amount recorded to goodwill. There were no additional purchase price adjustments made during 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the purchase price for the acquisition of Lineagen:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,940,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash transferred for repayment of Lineage PPP Loan (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares common stock issued as consideration (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,167,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares of common stock returned to the Company (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(138,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price per share on closing date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Value of common stock consideration (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total purchase price (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,144,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company paid approximately $1.9&#160;million in cash to certain creditors of Lineagen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The total number of shares of the Company&#8217;s common stock issued as consideration for the Merger was 6,167,510 shares. The total number of Merger Shares was subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the common stock consideration and the total purchase price incorporated the return of 138,247 Escrowed Shares to the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price was allocated to Lineagen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">596,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">337,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,580,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,173,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,862,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,144,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">950,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">630,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,580,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $1.5&#160;million of acquisition-related transaction costs, including financial advisor fees, legal expenses and accounting fees during the year ended December&#160;31, 2020. These costs are included in the consolidated statement of operations in selling, general and administrative expense. Also, the Company reported approximately $1.5&#160;million of service revenue generated by Lineagen in its consolidated statement of operations from the date of acquisition through December&#160;31, 2020. As the Company began integrating Lineagen&#8217;s operations with its existing operations during the fourth quarter of 2020, it is not practical or meaningful to distinguish Lineagen&#8217;s expenses or net income or loss from that of the combined operations for 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioDiscovery Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company completed the acquisition of BioDiscovery, LLC., pursuant to the BioDiscovery Merger Agreement. BioDiscovery's solutions for analysis, interpretation and reporting of genomics data is expected to accelerate and broaden Bionano&#8217;s market leadership in digital cytogenetics and comprehensive genome analysis.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to BioDiscovery Merger Agreement, the Company paid upfront consideration consisting of a combination of approximately $52.3&#160;million in cash and $40.0&#160;million in shares of Company common stock. Approximately $26.0&#160;million worth of the shares of the Company&#8217;s common stock issued pursuant to the upfront consideration are subject to vesting based on continued service, subject to the terms and conditions of a stock restriction agreement. Accordingly, the restricted stock is being accounted for as compensation over the requisite service period, and is not included in the purchase price. The upfront consideration is subject to adjustment for, among other things, cash, unpaid indebtedness, unpaid transaction expenses and working capital relative to a target. Under the BioDiscovery Merger Agreement, the Company has also agreed to pay a milestone payment of $10.0&#160;million in cash based on the achievement of certain commercial milestones. Cash of $2.5&#160;million will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the BioDiscovery Merger Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its acquisition of BioDiscovery using the acquisition method of accounting pursuant to ASC 805. The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non-tax deductible. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The purchase price allocation for the acquisition of BioDiscovery is preliminary and subject to revision as additional information about the fair value of assets and liabilities becomes available. As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. Per the terms of the BioDiscovery Merger Agreement, the purchase price is still subject to adjustment for the final determination of cash, unpaid indebtedness, unpaid transaction expenses and working capital, as well for deferred and current tax assets and liabilities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the estimated purchase price for the acquisition of BioDiscovery:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,291,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated fair value of milestone consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated return of cash to buyer from escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(694,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,723,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock price per share on closing date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Value of estimated common stock consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14,159,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total estimated purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">74,756,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated purchase price was allocated to BioDiscovery&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,782,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,987,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,800,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,987,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Right-of-use liabilities (short-term and long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,987,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,777,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">74,756,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">22,800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tradename</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">26,800,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the income approach to derive the fair value of the identified intangible assets acquired. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The developed technology, customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $-1.5&#160;million of acquisition-related transaction costs, including financial advisor fees, legal expenses and accounting fees during the year ended December&#160;31, 2021. These costs are included in the consolidated statement of operations in selling, general and administrative expense. The Company reported approximately $1.1&#160;million of revenue generated by BioDiscovery in its consolidated statement of operations from the date of acquisition through December&#160;31, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company began integrating BioDiscovery&#8217;s operations with its existing operations during the fourth quarter of 2021, it is not practical or meaningful to distinguish BioDiscovery&#8217;s expenses or net income or loss from that of the combine operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro forma Financial Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company, Lineagen, and BioDiscovery as if the companies had been combined as of the beginning of the year prior to the acquisition. These amounts have been calculated after applying the Company&#8217;s accounting policies and adjusting the results of Lineagen and BioDiscovery to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied at the beginning of the year prior to the acquisition. The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisitions had taken place as of January 1, 2019 and January 1, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,<br/>(Unaudited)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,076,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,927,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80,065,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,228,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297427320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsThrough the acquisition of BioDiscovery in October 2021, the Company inherited a building lease with a landlord owned by BioDiscovery&#8217;s former Director and Chief Executive Officer, who is now the Company&#8217;s Chief Informatics Officer. The Company recorded $0.1&#160;million in finance lease costs related to this lease for the year ended December&#160;31, 2021. Refer to Note 11. Commitments and Contingencies for future commitments pertaining to this finance lease.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295619752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#8220;Company&#8221;) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company&#8217;s mission is to transform the way the world sees the genome through optical genome mapping (&#8220;OGM&#8221;) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. (&#8220;Lineagen&#8221;) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC. (&#8220;BioDiscovery&#8221;) business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. </span></div>Basis of PresentationThe consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company&#8217;s 100%-owned subsidiaries.  All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had approximately $24.6&#160;million in cash and cash equivalents, $226.0&#160;million in short term investments, and working capital of $250.6&#160;million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, and September 30, 2021. In February 2021, we applied for forgiveness of our PPP Loan of approximately $1.8 million, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. During the year ended December&#160;31, 2021, the outstanding term loan under the Innovatus LSA was paid in full, including all accrued interest, an end of term fee, and a prepayment fee for a total of $17.0 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its available cash, cash equivalents and available-for-sale securities will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months. However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#8217;s business.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions used by management include estimates of selling prices for multiple performance obligation arrangements, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used in purchase accounting and to evaluate the recoverability of long-</span></div>lived assets and goodwill, warranty reserves, certain accrued expenses, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company&#8217;s net deferred tax assets, stock-based compensation expense, and related valuation allowances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (&#8220;Lineagen Merger Sub&#8221;), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the securityholders of Lineagen, entered into an Agreement and Plan of Merger (the &#8220;Lineagen Merger Agreement&#8221;). Pursuant to the terms and conditions of the Lineagen Merger Agreement, Lineagen Merger Sub merged with and into Lineagen (the &#8220;Lineagen Merger&#8221;) whereupon the separate corporate existence of Lineagen Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Lineagen Merger as a wholly owned subsidiary of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Starship Merger Sub I, Inc., a wholly owned subsidiary of the Company (&#8220;BioDiscovery Merger Sub I&#8221;), Starship Merger Sub II, LLC, a California limited liability company (&#8220;BioDiscovery Merger Sub II&#8221;), BioDiscovery, Inc., a California corporation (&#8220;Former BioDiscovery&#8221;), and Soheil Shams, solely in his capacity as the securityholders&#8217; representative, entered into an Agreement and Plan of Merger (the &#8220;BioDiscovery Merger Agreement&#8221;), pursuant to which the Company agreed to acquire Former BioDiscovery. Pursuant to the terms and conditions of the BioDiscovery Merger Agreement, BioDiscovery Merger Sub I merged with and into Former BioDiscovery (&#8220;BioDiscovery Merger I&#8221;), whereupon the separate corporate existence of BioDiscovery Merger Sub I ceased, with Former BioDiscovery continuing as the surviving corporation of BioDiscovery Merger I and a wholly owned subsidiary of the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately after BioDiscovery Merger I, pursuant to the terms and conditions of the BioDiscovery Merger Agreement, Former BioDiscovery merged with and into BioDiscovery Merger Sub II (&#8220;BioDiscovery Merger II&#8221;), whereupon the separate corporate existence of Former BioDiscovery ceased, with BioDiscovery Merger Sub II continuing as the surviving company of BioDiscovery Merger II and a wholly owned subsidiary of the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with BioDiscovery Merger II, BioDiscovery Merger Sub II changed its name to that of our current subsidiary, BioDiscovery, LLC.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its acquisitions of Lineagen and BioDiscovery using the acquisition method of accounting pursuant to Accounting Standards Codification Topic 805, Business Combinations ("ASC 805"). Under ASC 805, the tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the acquisition date. Any excess purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of identifiable intangible assets acquired with the assistance of independent valuations that use information and assumptions provided by the Company&#8217;s management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 805, acquisition-related transaction costs (such as advisory, legal, valuation, other professional fees) are expensed in the statements of operations in the periods incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. The Company has not experienced any losses in such accounts. The Company believes that it is not exposed to any significant credit risk on cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221;, defines and establishes a framework for measuring fair value and expands disclosures about fair value measurements. In accordance with ASC 820, the Company has categorized its financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the company has the ability to access at the measurement date.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on quoted prices for similar attributes in active markets; quoted prices in markets where trading occurs infrequently; and inputs other than quoted prices that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment Securities</a></td>
<td class="text">Investment SecuritiesAll investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income (loss). A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company maintains deposits in federally insured major financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers are located throughout the world. The Company generally does not require collateral from its customers. More information on accounts receivable is contained in the paragraph titled &#8220;Accounts Receivable&#8221; below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources of Materials and Products</span></div>The materials and components for the Company&#8217;s product offerings are currently obtained from single or limited sources. The Company competes with other companies for production capacity, therefore, the Company is exposed to a risk of inventory being unavailable at acceptable prices, or at all, if suppliers are unable (or decide) to provide sufficient levels of materials and components and the Company is unable to identify alternative suppliers.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,624,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,894,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(690,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,119,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,934,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,775,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For &#8220;OGM&#8221; products and services, credit is extended based upon an evaluation of each customer&#8217;s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the year ended December&#160;31, 2021, the Company recorded a recovery of bad debt expense of $108,000, which </span></div>is included in selling, general and administrative expenses. During the year ended December&#160;31, 2020, the Company recorded bad debt expense of $1.8 million which was included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible.Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company&#8217;s total accounts receivable balance. As of December&#160;31, 2021, no customers met or exceeded 10% of the Company&#8217;s total accounts receivable balance. As of December&#160;31, 2020, two customer balances represented 27.4%  of the Company&#8217;s total accounts receivable balance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">Inventory Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets (including Finite-Lived Purchased Intangible Assets)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets (including Finite-Lived Intangible Assets)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and acquired finite-lived intangible assets. The Company records property and equipment at cost, and records acquired finite-lived intangible assets based on their fair values at the date of acquisition. Property and equipment generally consist of laboratory equipment, computer and office equipment, furniture and fixtures, and leasehold improvements. Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the assets (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc4OTc_81782cd1-ff67-4bc0-b19a-d3f9ef09300e">three</span> to five years, or the remaining term of the lease for leasehold improvements, whichever is shorter). Repairs and maintenance costs are charged to expense as incurred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date. Intangible assets are amortized over the estimated useful life of the asset on a basis that approximates the pattern of economic benefit. Intangible assets are reviewed for impairment if indicators of potential impairment exist. There was no indication of impairment of intangible assets for any of the periods presented.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Lineagen and BioDiscovery acquisitions the Company recorded intangible assets, which consist of trade name intangibles, customer relationship intangibles, and a developed technology intangible, which are amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is not recoverable when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded contingent consideration resulting from a business combination at its fair value on the acquisition date. On a quarterly basis, we revalue this obligation and record any increase or decrease in fair value as an adjustment to the consolidated statement of operations. Changes to the fair value of the contingent consideration obligation may result from changes to the </span></div>discount rate, the passage of time, changes in our estimate of the likelihood, or timing of achieving the criteria for payment of the contingent consideration.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill arises when the purchase price of an acquired business exceeds the fair value of the identifiable net assets acquired, with such excess recorded as goodwill on the balance sheet. Goodwill is not subsequently amortized. Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indications of impairment exist. Goodwill is assigned to specific reporting units for purposes of impairment assessment. The Company has determined that it has a single operating segment and a single reporting unit. </span></div>In testing goodwill for impairment, the Company will first assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the qualitative assessment indicates that it is more likely than not that the fair value of the reporting unit is less than its carrying value, then the Company will perform a quantitative impairment analysis by comparing the fair value of the reporting unit to the carrying value of the reporting unit, including goodwill. An impairment charge for goodwill is recognized for the amount by which the carrying value of the reporting unit exceeds its fair value, not to exceed the total goodwill allocated to the reporting unit.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2021, the Company determines if an arrangement is, or contains, a lease at the inception of the arrangement. Right-of-use (&#8220;ROU&#8221;) assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating leases are included in operating lease right-of-use assets and operating lease liabilities in the consolidated balance sheets, while finance leases are included in finance lease right-of-use assets and finance lease liabilities.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and liabilities are recognized at commencement based on the present value of lease payments over the lease term. The Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments. The ROU assets also include any prepaid or accrued lease payments and is adjusted for lease incentives and initial direct costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease terms may include options to extend or terminate the lease which are recognized when it is reasonably certain that the Company will exercise that option. Leases with terms of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the lease terms, or in some cases, the useful life of the underlying asset. Variable lease payments are excluded from the measurement of ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. The Company accounts for the lease and non-lease components as a single lease component for all classes of underlying assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Rent</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating leases include incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2021, the difference between rent expense and amounts paid under the lease was recorded as deferred rent in the accompanying consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue primarily from the sale of products and services. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a receivable when we have an unconditional right to payment, which is generally at the time of delivery of software, consumables and instruments, including any extended warranties, or at the time services are rendered. Payment terms are typically 30 days for sales to customers in the United States but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within selling, general and administrative expenses, less any amounts reimbursed by the customer, when the corresponding revenue is recognized.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded net of discounts and sales tax. The Company&#8217;s contracts typically do not provide for product returns or refunds. In general, estimates of variable consideration and constraints are not material to the Company&#8217;s financial statements. Employee sales commissions are recorded as selling, general and administrative expenses when incurred as the amortization period for such costs, if capitalized, would have been one year or less. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenue recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue consists of sales of our Saphyr system and related consumables. These products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors. In addition, the Company provides the Saphyr system to certain customers under its reagent rental program, under which the Company provides Saphyr systems to customers at no cost and the customers agree to purchase minimum quantities of consumables.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains control of the product. As such the Company's performance obligation related to product sales is satisfied at a point in time.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For transfers of instruments and consumables to customers under the Company's rental reagent program, the Company allocates the total contract consideration between the instrument and the consumables based on estimates of stand-alone selling prices, and recognizes the instrument revenue evenly over the rental period, and the consumables revenue when the consumables are delivered. Rental revenue related to the reagent rental program recognized over-time totaled $0.2 million and $0.1 million during the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service and other revenue recognition </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue primarily consist of revenue from diagnostic testing services, the sale of software, and license maintenance agreements, and support, repair and maintenance services and extended warranties on Saphyr systems. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the completion of diagnostic testing services is initially recorded at the estimated consideration the Company expects to receive from contractual and non-contractual payors, and is subject to adjustment based on the amount actually collected. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results, which the Company has determined is the point at which control is transferred to the customer for revenue recognition purposes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the sale of software is recognized at the point-in-time the software license is transferred to the customer, or for hosting arrangements, on a usage basis as the customer processes the number of genetic samples purchased with the software. Revenue related to license maintenance agreements is recognized over-time based on the contract term. Revenue recognized over-time related to license maintenance agreements totaled $0.1 million during the year ended December&#160;31, 2021. There was no revenue recognized related to license maintenance agreements during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from support and maintenance contracts and extended warranties is recognized over time based on the contract term, which represents a faithful depiction of the transfer of goods and services given the stand-ready nature of the performance obligations. Service revenue related to repairs and customer sample evaluations is recognized as the services are performed based on the specific nature of the service. Warranty and maintenance revenue recognized over-time totaled $0.6 million and $0.5 million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in service and other revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was&#160;$0.8 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations, as well as obligations related to software under hosting arrangements. The Company expects to recognize approximately&#160;82.4%&#160;of this amount as revenue in 2022,&#160;13.8%&#160;in 2023, 2.3%&#160;in 2024 and 1.5% in 2025 and thereafter. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. The Company's liability for product warranties provided under its agreements with customers was $0.2 million and $0.2 million as of December&#160;31, 2021 and 2020, respectively. Warranty expense recorded in cost of goods sold totaled $0.5 million and $0.4 million during the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets primarily relate to the Company&#8217;s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheets. The Company recognized revenue of&#160;$0.4 million and $0.4 million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor Transactions </span></div>In certain markets, the Company sells products and provides services to customers through distributors that specialize in life sciences products. In cases where the product is delivered to a distributor, revenue recognition generally occurs when the distributors obtains control of the product. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers and do not contain return rights. Distributor sales transactions typically differ from direct customer sales as they do not require the Company&#8217;s services to install the instrument at the end customer or perform the services for the customer that are beyond the standard warranty in the first year following the sale. These transactions are accounted for in accordance with the Company&#8217;s revenue recognition policy described herein.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue for products consists of the Company&#8217;s raw material parts costs and associated freight, shipping and handling costs, contract manufacturing costs, royalties due to third parties, salaries and other personnel costs, equipment depreciation, overhead and other direct costs related to those sales recognized as product revenue in the period. </span></div>Cost of service and other revenue consists of salaries and other personnel costs, and facility costs associated with costs related to warranties and other costs of servicing equipment at customer sites, and performance of diagnostics services.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for research and product development, including acquired technology and costs incurred for technology in the development stage, are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Costs</a></td>
<td class="text">Patent Costs Costs related to filing and pursuing patent applications are recorded as selling, general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based CompensationThe Company issues stock-based awards as compensation to employees and directors. Stock-based awards may include stock options, stock appreciation rights, vesting stock awards and performance share awards. These awards are accounted for as equity awards. To-date, the Company recognizes stock-based compensation expense net of actual forfeitures on a straight-line basis over the underlying award&#8217;s requisite service period, which is generally the vesting period, as measured using the award&#8217;s grant date fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.</span></div>The Company recognizes the impact of uncertain tax positions at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it does not have a greater than 50% likelihood of being sustained. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company chief operating decision-maker, the Chief Executive Officer, views the Company&#8217;s operations and manages its business as one operating segment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. Pre-funded warrants from the Company's follow-on offering have been treated as if they were common shares outstanding on the date of issuance.  The Company&#8217;s potentially dilutive securities which include outstanding warrants to purchase stock and outstanding stock options under the Company&#8217;s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued But Not Yet Adopted and Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued But Not Yet Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuer&#8217;s Accounting for Certain Modifications or Exchanges for Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to clarify the accounting for modifications or exchanges of equity-classified warrants. The standard is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is in the process of evaluating the expected impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU 2021-04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on its financial statements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#8217;s annual fiscal year. The Company&#8217;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. In February 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASC 842&#8221;) which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASC 842 establishes a right-of-use model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. ASC 842 also requires disclosures to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was adopted </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2021, as the Company lost its status as an Emerging Growth Company effective December 31, 2021, and therefore was required to adopt the standard for the year ending December 31, 2021, using the modified retrospective method. Under this transition method, the Company recognized and measured leases that existed at the adoption date in the consolidated balance sheet as of January 1, 2021. In connection with the adoption of ASC 842, the Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company also made accounting policy elections not to apply the recognition requirements under ASC 842 to any short-term leases and to account for each separate lease and associated non-lease components as a single lease component for all the Company&#8217;s leases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of ASC 842 resulted in recognition of operating lease assets and liabilities of approximately $2.1 million and $2.1 million, respectively, as of January 1, 2021, related to the lease of office and laboratory space. The comparative prior period information continues to be reported under ASC 840. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. For further details, see Note 11, Commitments and Contingencies. The adoption of the new standard did not materially impact the Company&#8217;s consolidated results of operations or cash flows.</span></div>In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities From Contracts With Customers. This ASU requires an acquirer to account for revenue contracts acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. Prior to ASU 2021-08, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers and other similar contracts, at fair value on the acquisition date. The guidance is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and should be applied prospectively to business combinations occurring on or after the effective date. Early adoption is permitted. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company adopted ASU 2021-08 on October 1, 2021, and applied the ASU prospectively to its acquisition that occurred in 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_CostOfGoodsAndServicesSoldPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Of Goods And Services Sold [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_CostOfGoodsAndServicesSoldPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294884168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, trade</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,624,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,894,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(690,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,119,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,934,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,775,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUtilityInventoryTextBlock', window );">Schedule of Components of Inventories</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net of reserve, are as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,282,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,642,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,387,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,315,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive were as follows (in common stock equivalent shares): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,765,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,290,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,174,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,006,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,778,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,464,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUtilityInventoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all information related to inventories for utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUtilityInventoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985300402616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue by Source</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,887,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,085,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,808,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,145,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,695,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,230,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services and other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,286,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,273,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,981,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,503,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue by Geographic Location</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,329,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,489,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEIA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,604,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,163,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,048,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">851,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,981,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,503,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985301195160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurement of Assets And Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis in the Consolidated Balance Sheets:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value and Carrying Value on Balance Sheet</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurement&#160;Category</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,860,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,860,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,181,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,181,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Investments:</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,041,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,041,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,126,000&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,126,000&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,066,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,066,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">Changes in estimated fair value of contingent consideration liability in the year ended December&#160;31, 2021 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contingent</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Consideration</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Liability</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Level 3</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Measurement)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability recorded as a result of current period acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in estimated fair value, recorded in selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,066,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial Paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Notes/Bonds</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized loss</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,929,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,173,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,478,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,929,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,651,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297761480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid expenses and other current assets consist of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepayment to supplier</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,461,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest receivable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,348,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,481,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,250,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985300410760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,341,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,718,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service equipment placed at customer sites</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,556,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,267,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,674,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,390,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,366,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,072,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,456,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,318,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,910,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985298416360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that are subject to amortization consisted of the following at December&#160;31, 2021 and 2020:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,630,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,420,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">630,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,950,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,572,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,800,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(950,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,850,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,380,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,538,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,842,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,475,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,676,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,676,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,676,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,571,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,243,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,842,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297365112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,529,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,251,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goods received not invoiced</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,073,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Insurance </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warranty liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,941,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,694,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,599,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297365672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt and Unamortized Discount Balances</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no debt as of December&#160;31, 2021. The carrying value of the Company&#8217;s debt as of December 31, 2020 was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term Loans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,981,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPP Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,775,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total principal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,756,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,430,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total carrying value of debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,326,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297866040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text">A summary of the Company&#8217;s warrant activity for the year ended December 31, 2021 was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-  <br/>Average  <br/>Exercise  <br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-  <br/>Average  <br/>Remaining  <br/>Contractual  <br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate  <br/>Intrinsic  <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,406,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,933,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,396,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,628,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,780,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,174,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,841,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,794,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,191,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,356,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.96&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under 2018 Plan and 2006 Plan</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity is as follows: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Stock under Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Exercise <br/>Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- <br/>Average <br/>Remaining <br/>Contractual <br/>Term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate <br/>Intrinsic <br/>Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,290,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,178,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,108,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(471,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,547,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,162,000)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,765,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,891,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and exercisable at December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,389,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.53&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 5.5pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,428,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(179,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.76</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of the RSUs that vested was $0.9 million during fiscal 2021, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is 1.4 years as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock activity was as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.74</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense for the years ended December&#160;31, 2021 and 2020 was as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,188,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,719,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,554,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of the employee stock option grants were as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985298478792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information pertaining to the Company&#8217;s leases in which the Company is lessee for the year ended December&#160;31, 2021 is as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments included in the measurement of lease liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;19.2 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash lease liabilities resulting from obtaining right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,751,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of the Company&#8217;s lease cost:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,118,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total rent expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,504,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(422,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,552,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense and sublease income for the year ended December 31, 2020 reflects accounting treatment under ASC 840.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum payments under non-cancellable operating and finance leases as of December&#160;31, 2021, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,950,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,011,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,088,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,949,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,162,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,599,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,407,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,658,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,755,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,941,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease, Liability, Fiscal Year Maturity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future minimum payments under non-cancellable operating and finance leases as of December&#160;31, 2021, are as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,950,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,011,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,088,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,949,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,162,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,599,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,407,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,658,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,755,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,941,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASC Topic 842, future minimum rental payments under operating leases as of December&#160;31, 2020, were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year Ending December&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">734,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,464,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297510744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of income (loss) from continuing operations are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,356,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,191,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,152,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,077,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Domestic and Foreign Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for domestic and foreign income taxes is as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current income tax provision (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,055,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,722,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,777,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,717,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the income tax computed at the federal statutory tax rate to the expense for income taxes are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,413,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,626,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,030,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(522,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,879,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,816,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 162(m)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(938,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,717,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2021 and 2020 are as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,399,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,354,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,911,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,671,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC 842 - lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,148,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,133,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,623,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,478,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC 842 - ROU asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,504,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83,151,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,273,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliations of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, are as follows: </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,201,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,708,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions/(reductions) for tax positions - prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase related to current year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,119,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,201,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985296485416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the purchase price for the acquisition of Lineagen:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,940,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash transferred for repayment of Lineage PPP Loan (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares common stock issued as consideration (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,167,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares of common stock returned to the Company (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(138,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock price per share on closing date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Value of common stock consideration (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total purchase price (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,144,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company paid approximately $1.9&#160;million in cash to certain creditors of Lineagen.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The total number of shares of the Company&#8217;s common stock issued as consideration for the Merger was 6,167,510 shares. The total number of Merger Shares was subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the common stock consideration and the total purchase price incorporated the return of 138,247 Escrowed Shares to the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the estimated purchase price for the acquisition of BioDiscovery:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,291,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated fair value of milestone consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Estimated return of cash to buyer from escrow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(694,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares common stock issued as consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,723,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock price per share on closing date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Value of estimated common stock consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14,159,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total estimated purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">74,756,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price was allocated to Lineagen&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">596,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">337,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,580,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,173,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,862,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,144,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div>The total estimated purchase price was allocated to BioDiscovery&#8217;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,782,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,987,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,800,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,987,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable and other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Right-of-use liabilities (short-term and long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,987,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,777,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">74,756,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">950,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">630,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,580,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,<br/>(Unaudited)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,076,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,927,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80,065,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,228,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair values of identifiable intangible assets acquired are as following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">22,800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tradename</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Fair value of identifiable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">26,800,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985296367448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,571<span></span>
</td>
<td class="nump">$ 38,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,041<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan', window );">Forgiveness of PPP Loan</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Forgiveness Of Paycheck Protection Program Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985296485544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable, trade</a></td>
<td class="nump">$ 5,624<span></span>
</td>
<td class="nump">$ 4,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less allowance for doubtful accounts</a></td>
<td class="num">(690)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 4,934<span></span>
</td>
<td class="nump">$ 2,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295632344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recovery of bad debt expense</a></td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,809,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Liability for product warranties</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 6,691,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">6,755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyExpense', window );">Warranty expense</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LicensingRevenueAndMaintenanceAgreements', window );">Licensing revenue and maintenance agreements</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_WarrantyAndMaintenanceRevenue', window );">Warranty and maintenance revenue</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_RentalRevenueReagentRentalProgram', window );">Rental revenue</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">82.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Performance obligation, percentage</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=bngo_TwoCustomersMember', window );">Two Customers | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LicensingRevenueAndMaintenanceAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Revenue and Maintenance Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LicensingRevenueAndMaintenanceAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_RentalRevenueReagentRentalProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental Revenue, Reagent Rental Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_RentalRevenueReagentRentalProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_WarrantyAndMaintenanceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warranty and Maintenance Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_WarrantyAndMaintenanceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3,4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1),(c)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bngo_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bngo_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294913720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 2,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">11,642<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 12,387<span></span>
</td>
<td class="nump">$ 3,315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985296592392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">22,778<span></span>
</td>
<td class="nump">20,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">12,765<span></span>
</td>
<td class="nump">5,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember', window );">Common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">4,356<span></span>
</td>
<td class="nump">15,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_UnvestedRestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">5,006<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount (in shares)</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bngo_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295541880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294058136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 17,981<span></span>
</td>
<td class="nump">$ 8,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 9,329<span></span>
</td>
<td class="nump">$ 4,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America | Revenue | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of revenue</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">EMEIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,604<span></span>
</td>
<td class="nump">$ 3,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">EMEIA | Revenue | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of revenue</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,048<span></span>
</td>
<td class="nump">$ 851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific | Revenue | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of revenue</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA | Sales Revenue, Net | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Sales Revenue, Net | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of revenue</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember', window );">Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,887<span></span>
</td>
<td class="nump">$ 3,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember', window );">Consumables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5,808<span></span>
</td>
<td class="nump">3,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11,695<span></span>
</td>
<td class="nump">6,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 6,286<span></span>
</td>
<td class="nump">$ 2,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bngo_InstrumentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bngo_ConsumableRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295971864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Financial Assets and Liabilities (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 226,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Investments | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">100,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Investments | Corporate Notes/Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">125,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">11,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Total Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Total Investments | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Total Investments | Corporate Notes/Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">11,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Total Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">226,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Total Investments | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">100,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Total Investments | Corporate Notes/Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">125,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Total Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Total Investments | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Total Investments | Corporate Notes/Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bngo_CorporateNotesAndBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bngo_CorporateNotesAndBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295610088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in an unrealized loss position | lease</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) on investment securities</a></td>
<td class="num">$ (539)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale and maturities of available for sale securities</a></td>
<td class="nump">86,483<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Loss on sale of available for sale securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure servicing liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985391940744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Contingent Consideration Liability (Details) - Contingent consideration<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Liability recorded as a result of current period acquisition</a></td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in estimated fair value, recorded in selling, general and administrative expenses</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Cash payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 9,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294956328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 1 year</a></td>
<td class="nump">$ 100,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">100,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 1 year</a></td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Due after one year through five years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=bngo_CorporateNotesAndBondsMember', window );">Corporate Notes/Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 1 year</a></td>
<td class="nump">41,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">84,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total</a></td>
<td class="nump">125,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Unrealized loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 1 year</a></td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Due after one year through five years</a></td>
<td class="num">(409)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">$ (470)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=bngo_CorporateNotesAndBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=bngo_CorporateNotesAndBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985298156136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Prepayment to supplier</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 1,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,461<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,348<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 4,481<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985296231832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 19,390<span></span>
</td>
<td class="nump">$ 12,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(9,072)<span></span>
</td>
<td class="num">(7,456)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,318<span></span>
</td>
<td class="nump">4,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,341<span></span>
</td>
<td class="nump">6,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ServiceEquipmentMember', window );">Service equipment placed at customer sites</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,556<span></span>
</td>
<td class="nump">3,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,674<span></span>
</td>
<td class="nump">$ 1,889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ServiceEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ServiceEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985298186424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ReagentRentalsMember', window );">Reagent rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ReagentRentalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bngo_ReagentRentalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297646264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Summary of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 28,380<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,538)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">26,842<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,630<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,950<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(378)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3,572<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">22,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(950)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 21,850<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297658200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember', window );">Customer Relationships, Developed Technology and Trade Names | Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember', window );">Customer Relationships, Developed Technology and Trade Names | BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297705768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Future Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 5,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">5,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">5,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">5,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">4,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 26,842<span></span>
</td>
<td class="nump">$ 1,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295570152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation expenses</a></td>
<td class="nump">$ 4,529<span></span>
</td>
<td class="nump">$ 3,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_AccruedInventoryCurrent', window );">Goods received not invoiced</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">677<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Insurance</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and royalties</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warranty liabilities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 9,694<span></span>
</td>
<td class="nump">$ 5,599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_AccruedInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Inventory, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_AccruedInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123377177&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985290183752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Mar. 02, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,076,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_WarrantsToPurchaseSharesIssued', window );">Warrants to purchase shares issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants to purchase, Fair value preferred stock (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness', window );">Maximum credit card indebtedness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_LoanUnderPaycheckProtectionProgramMember', window );">PPP Loan | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Loan proceeds received</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_TermA1LoanMember', window );">Term A-1 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_TermA2LoanMember', window );">Term A-2 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusTerm3LoanMember', window );">Innovatus Term 3 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentInterestRateCashRate', window );">Cash rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentInterestRateDiscountedCashRate', window );">Discounted cash rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">End of term charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_WarrantsToPurchaseSharesIssued', window );">Warrants to purchase shares issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants to purchase, Fair value preferred stock (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassofWarrantorRightTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross', window );">Minimum proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of outstanding term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise', window );">Default payment required upon completion of equity raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance', window );">Minimum cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod', window );">Waiver fee payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentCovenantWaiverFee', window );">Waiver fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentCovenantPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember', window );">Innovatus LSA | PIK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentInterestRateCashRate', window );">Cash rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bngo_RevolverMember', window );">Revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodOneMember', window );">Period One | Innovatus LSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodTwoMember', window );">Period Two | Innovatus LSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodThreeMember', window );">Period Three | Innovatus LSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodFourMember', window );">Period Four | Innovatus LSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Default Payment Required Upon Completion of Equity Raise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Liquidity, Minimum Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Maximum Credit Card Indebtedness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Proceeds From Sale Of Stock, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentCovenantPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentCovenantPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentCovenantWaiverFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Waiver Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentCovenantWaiverFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Waiver Fee Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentInterestRateCashRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Cash Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentInterestRateCashRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentInterestRateDiscountedCashRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Discounted Cash Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentInterestRateDiscountedCashRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPrepaymentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPrepaymentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_WarrantsToPurchaseSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_WarrantsToPurchaseSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_LoanUnderPaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_LoanUnderPaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_TermA1LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_TermA1LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_TermA2LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_TermA2LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusTerm3LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_InnovatusTerm3LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_InnovatusLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bngo_RevolverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bngo_RevolverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DebtInstrumentPaymentTermsAxis=bngo_DebtInstrumentPaymentTermsPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295048584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Debt Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal</a></td>
<td class="nump">$ 17,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(1,430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total carrying value of debt</a></td>
<td class="nump">16,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bngo_TermLoanMember', window );">Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal</a></td>
<td class="nump">15,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bngo_RevolverMember', window );">Revolver</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bngo_LoanUnderPaycheckProtectionProgramMember', window );">PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal</a></td>
<td class="nump">$ 1,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bngo_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bngo_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bngo_RevolverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bngo_RevolverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bngo_LoanUnderPaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bngo_LoanUnderPaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985283324088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Oct. 06, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Jan. 12, 2021</div></th>
<th class="th"><div>Mar. 02, 2020</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,300,000<span></span>
</td>
<td class="nump">33,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants to purchase, Fair value preferred stock (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses on sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,704<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="nump">$ 101,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="nump">$ 22,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per unit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.15<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SaleOfStockAuthorizedAmountToBeIssued', window );">Issuance and sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod', window );">Exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,794,000<span></span>
</td>
<td class="nump">104,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,547<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost related to outstanding employee options, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issue stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bngo_CowenMember', window );">Cowen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SaleOfStockValueSharesIssuedInTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_CommissionFeeMaximumPercentageOfGrossProceeds', window );">Commission fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option | Executive Officer | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bngo_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for future issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of new shares issued under plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding', window );">Incremental rate at which the shares reserved for issuance increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for future issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding', window );">Incremental rate at which the shares reserved for issuance increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested and exercisable (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="nump">0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2018 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for future issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriter Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per unit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 2.867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bngo_PreFundedWarrantMember', window );">Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants to purchase, Fair value preferred stock (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonWarrantsMember', window );">Common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants to purchase, Fair value preferred stock (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrant or right, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonStockWarrantsOriginalAgreementMember', window );">Common Stock Warrants, Original Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants to purchase, Fair value preferred stock (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonStockWarrantsAmendedAgreementMember', window );">Common Stock Warrants, Amended Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants to purchase, Fair value preferred stock (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SaleOfStockAuthorizedAmountToBeIssued', window );">Issuance and sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | 2020 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember', window );">Authorized for future stock awards, option grants, or employee stock purchase program | 2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for future issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember', window );">Authorized for future stock awards, option grants, or employee stock purchase program | 2020 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock initially reserved for future issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase in aggregate number of shares reserved for future issuance as percentage shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Exercised In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Granted In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_CommissionFeeMaximumPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission Fee, Maximum Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_CommissionFeeMaximumPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SaleOfStockAuthorizedAmountToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount To Be Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SaleOfStockAuthorizedAmountToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SaleOfStockValueSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Value, Shares Issued in Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SaleOfStockValueSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bngo_CowenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bngo_CowenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bngo_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bngo_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bngo_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bngo_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonStockWarrantsOriginalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonStockWarrantsOriginalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonStockWarrantsAmendedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bngo_CommonStockWarrantsAmendedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bngo_TwoThousandAndTwentyInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bngo_TwoThousandAndTwentyInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295675928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Warrant Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Shares of Stock under Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at January 1, 2019 (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,174<span></span>
</td>
<td class="nump">24,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod', window );">Exercised (shares)</a></td>
<td class="num">(3,200)<span></span>
</td>
<td class="num">(10,794)<span></span>
</td>
<td class="num">(104,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod', window );">Canceled (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at December 31, 2019 (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
<td class="nump">15,174<span></span>
</td>
<td class="nump">24,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding at January 1, 2019 (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod', window );">Exercised (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod', window );">Granted (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.88<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod', window );">Canceled (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.29<span></span>
</td>
<td class="nump">59.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding at December 31, 2019 (USD per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward', window );"><strong>Weighted- Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">3 years 9 months 3 days<span></span>
</td>
<td class="text">4 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,841<span></span>
</td>
<td class="nump">$ 7,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,191<span></span>
</td>
<td class="nump">56,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">$ 26,841<span></span>
</td>
<td class="nump">$ 7,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Canceled In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Canceled In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Exercised In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Granted In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294029032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Summary of Stock Option Activity Under 2018 Plan and 2006 Plan (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares of Stock under Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (shares)</a></td>
<td class="nump">5,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">9,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (shares)</a></td>
<td class="num">(1,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (shares)</a></td>
<td class="nump">12,765<span></span>
</td>
<td class="nump">5,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (shares)</a></td>
<td class="nump">3,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (USD per share)</a></td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="nump">6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (USD per share)</a></td>
<td class="nump">4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (USD per share)</a></td>
<td class="nump">4.97<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (USD per share)</a></td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward', window );"><strong>Weighted- Average Remaining Contractual Term &#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value &#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 10,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Canceled</a></td>
<td class="nump">2,547<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">7,891<span></span>
</td>
<td class="nump">$ 10,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable</a></td>
<td class="nump">$ 4,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985283292280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Total intrinsic value</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bngo_PerformanceShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985296214504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,719<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,531<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,188<span></span>
</td>
<td class="nump">$ 1,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985296503928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock-Based Compensation - Weighted-Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.20%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295843448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 21, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LesseeEstimatedIncrementalBorrowingRate', window );">Estimated incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter', window );">Contractual commitment with supplier to purchase products every quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_PurchaseObligationInitialPurchasePeriod', window );">Initial purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_PurchaseObligationContractTerminationPeriod', window );">Termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ContingentConsiderationFairValueOfContingentLiability', window );">Fair value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in estimated fair value, recorded in selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_ContingentConsiderationMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bngo_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LesseeOperatingLeaseAreaLeased', window );">Operating lease, area leased (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LesseeOperatingLeaseAreaAdded', window );">Area added (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bngo_SanDiegoCaliforniaMember', window );">San Diego, California | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LesseeOperatingLeaseAreaAdded', window );">Area added (in sq ft) | ft&#178;</a></td>
<td class="nump">5,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_OperatingLeaseMonthlyRentPayments', window );">Monthly rent payments</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bngo_SaltLakeCityUtahMember', window );">Salt Lake City, Utah</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LesseeOperatingLeaseAreaLeased', window );">Operating lease, area leased (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bngo_ElSegundoCaliforniaMember', window );">El Segundo, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_LesseeFinanceLeaseAreaLeased', window );">Finance lease, area lease (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ContingentConsiderationFairValueOfContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Fair Value of Contingent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ContingentConsiderationFairValueOfContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ContingentConsiderationMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ContingentConsiderationMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitment, Purchase of Products, Every Quarter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LesseeEstimatedIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Estimated Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LesseeEstimatedIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LesseeFinanceLeaseAreaLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Area Leased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LesseeFinanceLeaseAreaLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LesseeOperatingLeaseAreaAdded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Added</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LesseeOperatingLeaseAreaAdded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_LesseeOperatingLeaseAreaLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Leased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_LesseeOperatingLeaseAreaLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_OperatingLeaseMonthlyRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_OperatingLeaseMonthlyRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_PurchaseObligationContractTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Contract Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_PurchaseObligationContractTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_PurchaseObligationInitialPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Initial Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_PurchaseObligationInitialPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=bngo_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bngo_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bngo_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bngo_SaltLakeCityUtahMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bngo_SaltLakeCityUtahMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bngo_ElSegundoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bngo_ElSegundoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985295926200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Supplemental Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_OperatingLeasePaymentsModifiedAndUnmodified', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments of financing lease liability</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">19 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities resulting from obtaining and modifying right-of-use assets</a></td>
<td class="nump">$ 4,751<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_OperatingLeasePaymentsModifiedAndUnmodified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Payments, Modified and Unmodified</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_OperatingLeasePaymentsModifiedAndUnmodified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297644584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="nump">$ 887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total rent expense</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of financing lease right-of-use asset</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_FinanceLeaseExpense', window );">Total finance lease costs</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Gross sublease income</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(422)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,552<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_FinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_FinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297501800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">8,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">6,755<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">7,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(3,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 3,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297862424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract', window );"><strong>Total Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter', window );">2025 and thereafter</a></td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 3,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity Net [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Future Minimum Payments, Due in Four Years and Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985298423272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Domestic and Foreign Components of Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (78,356)<span></span>
</td>
<td class="num">$ (41,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (78,152)<span></span>
</td>
<td class="num">$ (41,077)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294030856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Domestic and Foreign Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax provision (benefit)</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(4,055)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(1,722)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax provision (benefit)</a></td>
<td class="num">(5,777)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (5,717)<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294955576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes at statutory rate</a></td>
<td class="num">$ (16,413)<span></span>
</td>
<td class="num">$ (8,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefits</a></td>
<td class="num">(2,030)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">12,879<span></span>
</td>
<td class="nump">9,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount', window );">Section 162(m)</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other permanent differences</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Research credits</a></td>
<td class="num">(938)<span></span>
</td>
<td class="num">(568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (5,717)<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Excessive Employee Remuneration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297505672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 81,399<span></span>
</td>
<td class="nump">$ 62,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">5,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DeferredTaxAssetsLeaseLiability', window );">ASC 842 - lease liability</a></td>
<td class="nump">2,517<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,457<span></span>
</td>
<td class="nump">2,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross</a></td>
<td class="nump">93,133<span></span>
</td>
<td class="nump">70,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DeferredTaxLiabilitiesAmortization', window );">Amortization</a></td>
<td class="num">(7,478)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_DeferredTaxLiabilitiesRightOfUseAsset', window );">ASC 842 - ROU asset</a></td>
<td class="num">(2,504)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(83,151)<span></span>
</td>
<td class="num">(70,273)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DeferredTaxLiabilitiesAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DeferredTaxLiabilitiesAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985290143256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 83,151<span></span>
</td>
<td class="nump">$ 70,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">341,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration', window );">Operating loss carryforwards that do not expire</a></td>
<td class="nump">176,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Research credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">158,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_OperatingLossCarryforwardsSubjecttoExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="nump">164,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research credit | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_OperatingLossCarryforwardsNotSubjecttoExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject to Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_OperatingLossCarryforwardsNotSubjecttoExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_OperatingLossCarryforwardsSubjecttoExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject to Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_OperatingLossCarryforwardsSubjecttoExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294968984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 4,201<span></span>
</td>
<td class="nump">$ 3,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions/(reductions) for tax positions - prior year</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year positions</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the year</a></td>
<td class="nump">$ 5,119<span></span>
</td>
<td class="nump">$ 4,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985300400856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution amount</a></td>
<td class="nump">$ 830<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985299534344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,981,000<span></span>
</td>
<td class="nump">$ 8,503,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued or reserved for issuance (in shares)</a></td>
<td class="nump">6,167,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration transferred in acquisition</a></td>
<td class="nump">$ 1,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities assumed of acquiree</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Payment to satisfy outstanding principal and accrued interest amounts</a></td>
<td class="nump">$ 1,105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Adjustment to original purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen | Escrowed Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued or reserved for issuance (in shares)</a></td>
<td class="nump">925,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued or reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessCombinationConsiderationTransferredValueOfShares', window );">Consideration transferred, value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting', window );">Value of shares subject to vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessAcquisitionMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Cash held in escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Consideration Transferred, Value Of Shares, Subject To Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessAcquisitionMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessAcquisitionMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationConsiderationTransferredValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Value Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationConsiderationTransferredValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bngo_EscrowedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bngo_EscrowedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985294983384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Acquisition Purchase Price (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 1,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Payment to satisfy outstanding principal and accrued interest amounts</a></td>
<td class="nump">$ 1,105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares of common stock issued as consideration (in shares)</a></td>
<td class="nump">6,167,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment', window );">Estimated shares of common stock to be returned to the Company (in shares)</a></td>
<td class="num">(138,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Stock price per share on Effective Date (in dollars per share)</a></td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of estimated common stock consideration</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total estimated purchase price</a></td>
<td class="nump">$ 7,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen | Escrowed Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares of common stock issued as consideration (in shares)</a></td>
<td class="nump">925,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,291,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares of common stock issued as consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,723,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Estimated fair value of milestone consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow', window );">Estimated return of cash to buyer from escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (694,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Stock price per share on Effective Date (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of estimated common stock consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,159,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total estimated purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,756,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Estimated Return of Cash to Buyer from Escrow</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bngo_EscrowedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=bngo_EscrowedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985299525928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 56,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability', window );">Right-of-use liabilities (short-term and long-term)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,862)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985297677032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Identifiable Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember', window );">Lineagen | Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">$ 26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember', window );">BioDiscovery | Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_LineagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985298525608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Pro Forma Information (Details) - BioDiscovery - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 23,076,000<span></span>
</td>
<td class="nump">$ 15,927,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80,065,000)<span></span>
</td>
<td class="num">$ (47,228,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bngo_BioDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139985298534872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_FinanceLeaseExpense', window );">Total finance lease costs</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bngo_FinanceLeaseExpense', window );">Total finance lease costs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bngo_FinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bngo_FinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bngo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>bngo-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bngo="http://bionanogenomics.com/20211231"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bngo-20211231.xsd" xlink:type="simple"/>
    <context id="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie425f0ffddbe4e4dacd9db92085c4d0d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic0f3d7dc69bc4efbb36a792b9284b7a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbc7366eda1d47268de3bcdd81337d41_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie2dd45992746482e9f54504e09c41346_I20220224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2022-02-24</instant>
        </period>
    </context>
    <context id="ifedeab9392574bbf9284ae95544b0969_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia410863cec75450bb20b01bb978eb339_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idef8a112a8af49b29859c89619c7063f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6cb6eb48fccd436d82f456c60a03129e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iab96b4f9d91c40b3bcff03e74ce07d85_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15621385cea8481886f364ad4a851311_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17c82a645e374a6bb89950a49d16c0b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0efd9aa753ee49239268311cb402902f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5c0ff63e4b1469dae81b41f649a9a94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd11d2c4283b40818c2322674b6ee110_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic96f54a37ef346c38c3fce9c1e707621_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf2232560f854d898b520b0322a5df9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25c7362828a64a8eb87f775b1491fd99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib45ae24785a44441a4802ef1030f892b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3634a0ee07e4c1fb4cb0dc6914a2405_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idaa462baf9fc4f2680655d14713bccaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida156f9281c3453e97c6d3eb9345fa03_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i110a0435adb34efbb4036d329457f22c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i515aa68d30164045bab97fec3cd86d29_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0418bf1522234b33bd7a72931d18580f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib40de96003224a488c14b76a879a457e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bngo:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i371c9488f9534e7b9b874201105a3f58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03e386398bdb44b3addd41e681970261_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibec93384d0cb4cd38ec922514c5a2307_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9a9995ad77a4d72a6747277f6afc40f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7901fe27277a43038341f30e9235fb33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72760e7d4c4d4bc29225a99c2b52e6a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia421179e929849a0811736046100d29a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02a66891cd81408b94c3dcf095dd9aa1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b2ff0a385ec4419bd63ad02cc162c4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie803dd47b1c54023ad328f5a634b77a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice0bf1763a264af2afecbaaa10564f18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7b1ff8dff57441e9939f8789ca2e6c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib55aca94255b45f7ba3ade3bbb054941_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03ac604fde724aebbc7ddc5ec7989381_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfc32dda88c8491493b3a97900889e74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if65481e6e2e34f818b1abd233bbcb586_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9baa4e36abe6400f9c053d7f3434b31f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9377784747ef4e6792d946ece3659fdb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd45b65fd98e44ee92578a3812d0ebdf_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i796761a85df6417896123b60211dc456_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4cd58ed3c4a43c7accda85e938edcc0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:InstrumentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e3054d21f6f4798b007ef1b3abea827_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac08b5e748c44125918877c58eeb2adc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bngo:ConsumableRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c68a12eca334a838f030a41e51a46b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ff8553873fd49468f9f75a5c165e98f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7c615c6f945420e93b92d85cf0b8c01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0873412be8547959d4aa0e904da5fca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89f08d0b9d254e4cb81421c9274acb67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i763f202ae44a40c09fe53b95d9006d97_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b47aea725d34079a308232d226a3001_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4169c1867a245108d470229bac5dbac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f8f8c29630a401a88a5285f57e55166_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76c0e564fd0c4699af8abe0b4a4a8f5b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i639735ace7a54defa242bf743d278ad3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iede1a65bd15f4596838c10a96b56c281_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86bea6db7f4248ed94253fad6c47e824_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i029ea0650fb04082a13c21022c54f216_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia60395f370984c03913b1237f78f5f74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie85c1983cea24f5fbb6e90a2a347fd4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie758ad97885e40af865734d6d0735fbd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i64252642d88c4f9a8cdb7a3c4abb6daa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fd395e693f843f68c015a3fb16e63e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45b6072efea34c43a77e7e2a8d672e57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fd8b99cec464ca2a5fbc78e6d86bd6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21077c1aab5d457cb1cdf940f451908e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfba7f0bab47499d9d16e7fcfea7c8e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66e1e879fb554dcaa245d830024b147c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad7080a2ac2845729f17c608390c3daf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i678854c029c5451f9cf24fe07efbf514_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b0ee927463d486baa5cba33982c2569_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic609659d259845b3a37a1bf8b59de543_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d1a6733a3f14bf2972c366549628e23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i219dd660a26b49beb67b572a81c81389_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3289f5383254228be7158bd06d11bfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a26c057095f4a36a0b30546701c58f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i467ef72acc6840729feb7f12f3a6e516_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie93e575b671b4188b8e1e04eb90b0d27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica9bc63b1b5444dea0111bbe4ec8f8bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1484c4dbff544b29b2781e84672dded_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefe2bac092bd4c778f47ddbc97f1d0c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1cf405044e174ea88a98016ca955831d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id637a744712b44988d29a346fc913709_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1ba840538fd4b0791ae9c324539369e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5544954547a5409f8662da2a285cdb1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">bngo:CorporateNotesAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i970b26562f48462b986160dadd23e2e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9431acbfefa14bc1a8c51e9791630133_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e966a20a2d94bd6ac86960b0db2e83b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7c44f25d40c4d78a5d9623e10febeb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib110b6c1e25a43b190344fed192d23fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ServiceEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cdf5494bbd9490295ca735e1ec45cfd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ServiceEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i386f22e822f8474daca8ae8933acbb26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa83cb53f8d446e58b64dd7b82b48311_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaba22332706445abbde9bbbbbea71f04_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ReagentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d2d20d9c1274e4e8d7386137b4f34ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ReagentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81e2dc0ae87648a58b8afa4c80a78bce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bngo:ReagentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a480bc32add481ea931915f5e4e20a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6af5f30224ff436d833405ae9d5be9ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6981036f191b41ae8e646c1a85e17819_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79aff88d479e4c73bf896e7479d3d66f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib45196371119428bb263f59a387de373_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic33d1be42b47486b97d23a00612757c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb5ee1e4c6bd48d2be372e02f845f9f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bngo:CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ac9d5e475ba4422a72f931d6569a467_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bngo:CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i187f2e41e0e647169625953a97e7c680_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:LoanUnderPaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i885cb3edb89544758da163ee290c2716_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:TermA1LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if8fefc0da0874a5b9ef1c40c3768d9b2_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:TermA2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9113153c66234219aee4b2506362eeb2_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusTerm3LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifc845bca945a4f5fa755dc944afdc43d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="icbd4ec7b849b4fdfb36d13c56714da97_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5e120690c77f416090e340927b324ea8_I20210514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="ifada802da30d4375a5c5a06d5d2c5ddf_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4d74e091a5294082809d17f5146d70ad_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id0d3bb253582446b9f1f1ac8c1549355_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i49e07068caf640e88b8e67d05b03a126_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bngo:DebtInstrumentPaymentTermsAxis">bngo:DebtInstrumentPaymentTermsPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib8e87945aa7f410299777da79c66a83f_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:RevolverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifb921d59feb74c7e9883ca143d13a63e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie0e9fefb7a034edb966f004c59f7d49c_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i807cfb44a24d46fe8574bed9d3d3fa46_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i3751fdde71464399810902ffa867ecde_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12947374461e4e6b9a6e0e872431a338_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i7ec81e424f424534aa64d4e480141a53_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bngo:InnovatusLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i4795567b94164ea29b5699dc096d6ebf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5821d7ac4676425ba01bdcd20c6d2f91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:RevolverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d06a7344f2e49ab9598f04154df56cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bngo:LoanUnderPaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i938f91bd8c3946d395a47bb4a55c4f39_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="id95371e1105d406580e1d89a5e055efa_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i842467c3c99147a9899c7166293dd2df_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i0733c5c486d840aa90f9b967fc4b62a4_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ic96948543913400fa1d1b0b719ebabf1_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="iad11bf28fea04b8aba14929027d8fa54_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ia66ac253e88644c8815ddb6f83187e4d_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i473f14c3b9164deeb0b53c014f09915c_D20210112-20210112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-01-12</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="i2623ef25413a4354ac9f72e113c78e64_D20210112-20210112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-12</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="i01445096e010443d97b89ad87ab3c883_I20210112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-01-12</instant>
        </period>
    </context>
    <context id="i5df53405a8de4826bff81815bde4ed6c_I20210112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-12</instant>
        </period>
    </context>
    <context id="i411e62885bec4fb3beab2f000e27b94f_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="id608a0c5267f429cb8c9e21ce9a996e7_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="ic49d68891599499b9fcf7774b2002c46_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i96499813715849179f8f5b094e5056d1_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i1d6ccdf4c05242a6877437f969ff350d_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i4d0542f51814417b825a21ad6a71dd4c_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i8c6b16906f9c47c490d636cc5dc3cd1b_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04fb2be1f6bc4a1ea3a4950d33413347_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ie9dfa5830e684b5b9aeb0425d2971c55_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ie90abf42c0fa483585e7c0ddbc44d00c_D20210323-20210323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bngo:CowenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="i3baa8f239ec74369b0750b2c579131a4_D20210801-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6575ee0a35434402aebe8d5e012a1d85_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i50bbecaae644414b92db4dfed11dc7e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i44a4af39e9424b53a07681fa1a5d8f50_D20200302-20200302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <context id="ia1a664a51c194792a34d9f22fad31cac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonStockWarrantsOriginalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f822c4990b1439daba5becfbc85c5aa_I20200302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
        </entity>
        <period>
            <instant>2020-03-02</instant>
        </period>
    </context>
    <context id="i93c22029995e4f6384a607093272bbfa_D20200302-20200302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonStockWarrantsAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <context id="iab207f0b1ddf422e9fdb826c96fbbae0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bngo:CommonStockWarrantsAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2aef460467747f28861ce3854e7c187_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i1c415e70a6a948e8b2be43920872a619_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="ic9ca65a64a4549f589630eadc720acf0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f4b74c4fd9d4e7094439d2d2c7562e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bngo:AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ea7966b68f743518a7b346891b8cfa1_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandAndTwentyInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i17c21833ff0041eaad1473112a77f0a7_D20211006-20211006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandAndTwentyInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-06</startDate>
            <endDate>2021-10-06</endDate>
        </period>
    </context>
    <context id="i4ad50c757a9743e791dd8f5af71e8e31_I20211006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandAndTwentyInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="i5e25fe9fc0eb46c29dddcb5c5cfde31d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bngo:TwoThousandAndTwentyInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bngo:AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f676ebcb6964b0db783a5db2a081ffa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8eacd11ad8142c39a3d70452a09fdda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab4219a77977404ba46cadf9c1e2d9e1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7265080c4d794589a09bd0e17f4e4a2d_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i96e920c0320b47feb8ecdd4d667557e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86da882447604a1e9e8017d09d518536_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1180bacce9964e6ab67c6cf06acfbbde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1112f0645024f47bfb4ccd3ed88f2ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a68a48ad08c4a4a90ebcf1971894c02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f80b7d6b8944158bd9c8a9940a3b414_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6166e9bcdaf64523922f223a68f2ae8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33f329ca85c24dc6ac16f2cf9b3ac9b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bngo:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fe3e09f6a3945efabf706cebdf47304_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48d32570b3e4421289d391c0f57b1c05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7cc3a87e87bc437b84ce90bf5c661e8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd34a35d15694242a41144a942e3bbd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i729c6da2107844e28908f101e5b69b18_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i6e08bcf17c014092be59db6343e02b9d_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i2390b4b66da344ecb775181baacb32dc_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i6ddb1728db3a49f8abb7b5af01e8a6e3_D20220215-20220215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="i4d5183cf0cdf481fb13cb77e135891e9_D20220215-20220215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="i826d7a082f1c44b7bf787aecb9e7c3ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb6d3ff5dfb74f5e9b0306ff18734baa_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:SanDiegoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i320f1643428144d38fdcf459b451c4a6_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:SanDiegoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i470e708352854bb7934441171219601e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:SaltLakeCityUtahMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ea6c5e3b632418db86e6b334229c600_I20211021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bngo:ElSegundoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-21</instant>
        </period>
    </context>
    <context id="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="idebec6bf5580446897b029f768bd15cf_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">bngo:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ib44b75fe239a4b60b494433a3f77f70d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99a808d515494cdbadb3da6e47f4e15c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29f75a2dd05a4220bc087386e5a5149b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4c282464a94473ba123371ddc89314a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3624ecef1ddd4361a818dfb9464218ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8898d29f877f4495ab155612c9339010_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="ic37f97c4ea0a4f4bb16de8adcef347a3_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">bngo:EscrowedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i132f0f05159f47b79fd74e910694340d_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a669e6254fb41a7804a698577b0161a_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i257cbc434ff74964959fc60f88c37154_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="ie5462c3bde0c4f4b91de75d0b7ce8831_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:LineagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i294164fc14f446a2b2e24cbae2459436_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="id7c4019bf43a47b28bc8cfe7f136b957_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i07bdd4786bb848d3aab8623ac0910407_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i974ac13511bd4accb073439efd2968a7_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bngo:BioDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="id1804c21be1e41dc94b90988721c64f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001411690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>bngo:segment</measure>
    </unit>
    <unit id="lease">
        <measure>bngo:lease</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM180L2ZyYWc6OTE3ZGRmMGY2Mjk5NGViYTg1MTZkYzgxNjliMGIwOTAvdGFibGU6OGE3OTM4MzYzY2FhNGFjOTk0MzFhNWViNjM3OWVmYzAvdGFibGVyYW5nZTo4YTc5MzgzNjNjYWE0YWM5OTQzMWE1ZWI2Mzc5ZWZjMF8zLTEtMS0xLTE_4f9dd4aa-e955-4259-acbb-5c49b7f142c3">0001411690</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM180L2ZyYWc6OTE3ZGRmMGY2Mjk5NGViYTg1MTZkYzgxNjliMGIwOTAvdGFibGU6OGE3OTM4MzYzY2FhNGFjOTk0MzFhNWViNjM3OWVmYzAvdGFibGVyYW5nZTo4YTc5MzgzNjNjYWE0YWM5OTQzMWE1ZWI2Mzc5ZWZjMF80LTEtMS0xLTE_f6cdbb06-88cb-4b6f-9207-2a7fe370baac">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM180L2ZyYWc6OTE3ZGRmMGY2Mjk5NGViYTg1MTZkYzgxNjliMGIwOTAvdGFibGU6OGE3OTM4MzYzY2FhNGFjOTk0MzFhNWViNjM3OWVmYzAvdGFibGVyYW5nZTo4YTc5MzgzNjNjYWE0YWM5OTQzMWE1ZWI2Mzc5ZWZjMF81LTEtMS0xLTE_31e3ad2d-b236-4048-bb8a-765acfb0132d">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM180L2ZyYWc6OTE3ZGRmMGY2Mjk5NGViYTg1MTZkYzgxNjliMGIwOTAvdGFibGU6OGE3OTM4MzYzY2FhNGFjOTk0MzFhNWViNjM3OWVmYzAvdGFibGVyYW5nZTo4YTc5MzgzNjNjYWE0YWM5OTQzMWE1ZWI2Mzc5ZWZjMF82LTEtMS0xLTE_0dec9f45-4b4e-42e8-aaee-3ab861924d62">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i371c9488f9534e7b9b874201105a3f58_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc4OTc_81782cd1-ff67-4bc0-b19a-d3f9ef09300e">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ibec93384d0cb4cd38ec922514c5a2307_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTk0L2ZyYWc6MjkwMzg1NjBmMzU2NGFmMWExZjU4NDg3N2I2OGQ5YTcvdGFibGU6NGNhMzFiMjBhMThhNDE1MmFjY2FmMTcxNTk5ZWU2MzUvdGFibGVyYW5nZTo0Y2EzMWIyMGExOGE0MTUyYWNjYWYxNzE1OTllZTYzNV8wLTEtMS0xLTQzNDky_52a18f3b-7164-40b0-ad75-d6cf0ae2f8d1">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ic9a9995ad77a4d72a6747277f6afc40f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTk0L2ZyYWc6MjkwMzg1NjBmMzU2NGFmMWExZjU4NDg3N2I2OGQ5YTcvdGFibGU6NGNhMzFiMjBhMThhNDE1MmFjY2FmMTcxNTk5ZWU2MzUvdGFibGVyYW5nZTo0Y2EzMWIyMGExOGE0MTUyYWNjYWYxNzE1OTllZTYzNV8xLTEtMS0xLTQzNDky_68ab19d9-bfc9-4e7a-ad16-617459f61768">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i7901fe27277a43038341f30e9235fb33_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTk0L2ZyYWc6MjkwMzg1NjBmMzU2NGFmMWExZjU4NDg3N2I2OGQ5YTcvdGFibGU6NGNhMzFiMjBhMThhNDE1MmFjY2FmMTcxNTk5ZWU2MzUvdGFibGVyYW5nZTo0Y2EzMWIyMGExOGE0MTUyYWNjYWYxNzE1OTllZTYzNV8yLTEtMS0xLTQzNDky_6b2e5881-8944-400c-9963-5b044129efb2">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i72760e7d4c4d4bc29225a99c2b52e6a4_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTk0L2ZyYWc6MjkwMzg1NjBmMzU2NGFmMWExZjU4NDg3N2I2OGQ5YTcvdGFibGU6NGNhMzFiMjBhMThhNDE1MmFjY2FmMTcxNTk5ZWU2MzUvdGFibGVyYW5nZTo0Y2EzMWIyMGExOGE0MTUyYWNjYWYxNzE1OTllZTYzNV8zLTEtMS0xLTQzNTA1_1a2e84f2-b001-4795-a1e3-db33fae07cd2">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6MDE5NmUwMDk3NTFkNGI4MTg1YmEyYzQxNTlkNWMyYzYvdGFibGVyYW5nZTowMTk2ZTAwOTc1MWQ0YjgxODViYTJjNDE1OWQ1YzJjNl8wLTAtMS0xLTEvdGV4dHJlZ2lvbjplMDkyNDNjZGMzYzk0NzBiOTdhMzY4OWQ3ZmIzYjA0ZV85_47e23ca0-79d6-4347-a539-fe971f102978">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV81NDk3NTU4MTQzMzc5_c40fe8ab-26e0-4e08-bc12-16e9d6fa45b1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV81NDk3NTU4MTQyNzc1_0b22c2cb-7b91-4ea7-bd66-b19cfa9702e8">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV81NDk3NTU4MTQyNzc1_f6d8b9e9-c8f9-49a5-adfc-ed45212ba188">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDA3_921c0877-17e4-4ecc-8fed-a9358acf9315">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDEw_3f6e0396-5c7b-4b6d-8310-3430b91c497e">001-38613</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6NTIzMTYyN2EyNzA2NDg1N2JiMzI3YzMzNDhkNWZhMDYvdGFibGVyYW5nZTo1MjMxNjI3YTI3MDY0ODU3YmIzMjdjMzM0OGQ1ZmEwNl8xLTAtMS0xLTE_779f0e7d-c20e-46e7-94a5-820cbb16887c">Bionano Genomics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8wLTAtMS0xLTE_b69aad8e-a372-4817-aa42-94e36eaca2d9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8wLTItMS0xLTE_a2d25b87-e88e-488e-8ebf-c2a5b17990e5">26-1756290</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjozN2JkYzA4MGNkMjc0MWM4OWQ3MmNhNzY5MzZlN2RjN180_23ecc9f0-c859-43a9-a6ac-760adcae2402">9540 Towne Centre Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjozN2JkYzA4MGNkMjc0MWM4OWQ3MmNhNzY5MzZlN2RjN184_7077bee8-d7cb-460e-8587-02763dee547b">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjozN2JkYzA4MGNkMjc0MWM4OWQ3MmNhNzY5MzZlN2RjN18xMw_500bbd29-b87b-41a7-9128-06528a85d3f9">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTAtMS0xLTEvdGV4dHJlZ2lvbjozN2JkYzA4MGNkMjc0MWM4OWQ3MmNhNzY5MzZlN2RjN18xNw_d94444e6-68ec-477d-8b5b-d07741c99f7c">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF8yLTItMS0xLTE_cbf503f9-5e82-4c8e-ae6c-17dc1206a144">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF80LTAtMS0xLTEvdGV4dHJlZ2lvbjozZDk0Y2MzNWZkZTg0M2ExOGMyYzk0ZTg3Mzk2Mzg2M181Nw_5ba322fb-0c7d-4090-9875-f1f1dbc7f62a">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YmJiODEyMTkxOWVjNGZkNjhmM2JmMDUyZjFmMjRjNTAvdGFibGVyYW5nZTpiYmI4MTIxOTE5ZWM0ZmQ2OGYzYmYwNTJmMWYyNGM1MF80LTAtMS0xLTEvdGV4dHJlZ2lvbjozZDk0Y2MzNWZkZTg0M2ExOGMyYzk0ZTg3Mzk2Mzg2M182MQ_decdee30-c390-4791-b5a5-dcbc9d005d9f">888-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie425f0ffddbe4e4dacd9db92085c4d0d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8xLTAtMS0xLTE_cfe78cb6-e9b3-40c9-a70f-7932f28e60fa">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie425f0ffddbe4e4dacd9db92085c4d0d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8xLTEtMS0xLTE_7598bc44-4b93-4107-8480-c6f2e3d5394d">BNGO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie425f0ffddbe4e4dacd9db92085c4d0d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8xLTItMS0xLTE_6571f48b-cc8b-40c9-8a12-f30a9177080d">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ic0f3d7dc69bc4efbb36a792b9284b7a8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8yLTAtMS0xLTE_c44036a6-3689-4df0-a4f7-bb24b87fcd5b">Warrants to purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic0f3d7dc69bc4efbb36a792b9284b7a8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8yLTEtMS0xLTE_a472f58e-d174-4f76-842c-7fc4484ff754">BNGOW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic0f3d7dc69bc4efbb36a792b9284b7a8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6YTJkNzU4ZDFiNDBkNDRlMWFlYmJmZjA1Y2MwOWJiYjgvdGFibGVyYW5nZTphMmQ3NThkMWI0MGQ0NGUxYWViYmZmMDVjYzA5YmJiOF8yLTItMS0xLTE_fb3b250e-15c9-4022-8274-b2452fb15373">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDEy_ec03460a-2ae3-4f5a-ad59-efa522b12a4c">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDA4_a9a1a61c-6e1d-4743-951a-bea446f2a1c1">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDAx_128f9add-a183-4735-8c5f-39b6ddd076a3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDEx_636de7dd-0421-4897-b7c8-79cb634573b4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6MjcyNmY2NTdlYzBiNDhiZjg5YzBhNWEwYTA3ZmIyNzAvdGFibGVyYW5nZToyNzI2ZjY1N2VjMGI0OGJmODljMGE1YTBhMDdmYjI3MF8wLTAtMS0xLTMxMTU2_99dde3c9-f69e-45d8-983a-18dd56db51ce">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6MjcyNmY2NTdlYzBiNDhiZjg5YzBhNWEwYTA3ZmIyNzAvdGFibGVyYW5nZToyNzI2ZjY1N2VjMGI0OGJmODljMGE1YTBhMDdmYjI3MF8xLTMtMS0xLTE_16ff21f8-d5bd-441f-92b3-184bcff9e934">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGFibGU6MjcyNmY2NTdlYzBiNDhiZjg5YzBhNWEwYTA3ZmIyNzAvdGFibGVyYW5nZToyNzI2ZjY1N2VjMGI0OGJmODljMGE1YTBhMDdmYjI3MF8yLTEtMS0xLTE_9db930ee-d840-440f-a317-4fa5278af2fc">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDEz_f2553d24-cba7-4445-9aa0-b72110abce35">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDA5_fcbd0def-e7df-4544-8e28-db6f5f9c2a32">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ibbc7366eda1d47268de3bcdd81337d41_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zODQ4MjkwNzAxMjI1_9337cf9f-0c54-4009-b5bc-656f5cf44fbd"
      unitRef="usd">2045466000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie2dd45992746482e9f54504e09c41346_I20220224"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zODQ4MjkwNzAxMTE3_0adc21ac-f11f-412e-bfe2-6fb8fc0bdd24"
      unitRef="shares">289612949</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xL2ZyYWc6YWY5ZTc5N2Y0NzY2NDA3Mzk5NzcyNDZlYmVmOTU3YmUvdGV4dHJlZ2lvbjphZjllNzk3ZjQ3NjY0MDczOTk3NzI0NmViZWY5NTdiZV8zNDA0_f428d142-f3c0-40db-a6ea-c50f7d92a965">Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#x2019;s 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#x2019;s fiscal year ended December&#160;31, 2021.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzAvZnJhZzphMjU3YWY4NjUzZDg0OGM2YjQwYTI3MjkwNzg4MTNhZS90YWJsZTpiZmE5YzBlODBiZDg0ODlkOWI4NWM4Nzc4NzM5MTlmOS90YWJsZXJhbmdlOmJmYTljMGU4MGJkODQ4OWQ5Yjg1Yzg3Nzg3MzkxOWY5XzEtMC0xLTEtNTMzNjYvdGV4dHJlZ2lvbjo0YjVjZGU4YmVlNTM0YjBjOWRmMjBhOTViYTJmYmJhNl81NDk3NTU4MTM4OTk3_50ea7335-af64-49c1-90f3-88be0a95acf1">243</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzMvZnJhZzo0NzdjODk2ZWM3MWU0NjJhOWRjZGUyNTg3MzI3ZDEwOC90ZXh0cmVnaW9uOjQ3N2M4OTZlYzcxZTQ2MmE5ZGNkZTI1ODczMjdkMTA4XzU0OTc1NTgxNDUzOTg_dd9249e5-ddd6-45f3-9d58-9008c2d01d86">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzMvZnJhZzo0NzdjODk2ZWM3MWU0NjJhOWRjZGUyNTg3MzI3ZDEwOC90ZXh0cmVnaW9uOjQ3N2M4OTZlYzcxZTQ2MmE5ZGNkZTI1ODczMjdkMTA4XzU0OTc1NTgxNDU0MDA_9c91e908-fce3-4649-9e99-06818e3cf91c">San Diego, CA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzUtMS0xLTEtMQ_1a1f02b7-f53f-4a67-b1b0-18b437b5c729"
      unitRef="usd">24571000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzUtMy0xLTEtMQ_784dffad-a67b-4abb-9e37-e03d05d52224"
      unitRef="usd">38449000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMS0xLTEtMjE0OTY_d3650a73-f428-4005-ab01-37e5d81d88fa"
      unitRef="usd">226041000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMy0xLTEtMjE0MTY_742e3cad-bab2-4b86-b74c-6940e65490db"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMC0xLTEtMS90ZXh0cmVnaW9uOmM0OTljNWUxZDNiZTRkZTc4NDYxNzNmNDA1ZDM2ZDJjXzM4NDgyOTA2OTczNTI_6d485b8b-5013-4de2-ab8b-0509aff8f3aa"
      unitRef="usd">690000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMC0xLTEtMS90ZXh0cmVnaW9uOmM0OTljNWUxZDNiZTRkZTc4NDYxNzNmNDA1ZDM2ZDJjXzM4NDgyOTA2OTczNDY_ed865f89-ee41-478b-b644-27093dfb5826"
      unitRef="usd">2119000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMS0xLTEtMQ_68348e81-f649-4445-a36b-7f3bed04cddf"
      unitRef="usd">4934000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzYtMy0xLTEtMQ_6c6cf906-932c-43a5-ad1b-21e874f54cb9"
      unitRef="usd">2775000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzctMS0xLTEtMQ_1bb63df4-5320-4f50-bcdf-4a6465fdea00"
      unitRef="usd">12387000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzctMy0xLTEtMQ_f55ab2d3-98cf-47fa-a4d1-268509e02b0d"
      unitRef="usd">3315000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzgtMS0xLTEtMQ_ac98ce53-25b4-4a13-833d-6c0d074d0a0c"
      unitRef="usd">4481000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzgtMy0xLTEtMQ_4594ef88-2bd6-4023-bd65-5c55804228fc"
      unitRef="usd">2250000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzktMS0xLTEtMQ_0609da75-5a60-4539-9e83-07df2150d1ce"
      unitRef="usd">272414000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzktMy0xLTEtMQ_5d863386-1fe6-45c9-bc57-d30c68d39654"
      unitRef="usd">46789000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEwLTEtMS0xLTE_304eb99b-7a41-47e1-acd4-b25247dd4a49"
      unitRef="usd">10318000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEwLTMtMS0xLTE_03e38186-d097-4744-b3fd-7cbe67029d2e"
      unitRef="usd">4910000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEyLTEtMS0xLTMzNDI0_f0d109ea-fdb0-488a-9da8-f7e55b6e0553"
      unitRef="usd">6691000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEyLTMtMS0xLTMyNzcy_12e47d72-3bdf-442f-b42d-814b2587312a"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEzLTEtMS0xLTMzNDI0_44bb6256-ecbd-4767-b9f2-2691469eb942"
      unitRef="usd">3926000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEzLTMtMS0xLTM0ODY1_3596defc-e3fe-41c3-ab27-616e4c5b6a73"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzExLTEtMS0xLTE_10eafb7d-6d4f-44cf-88cf-47a25e23ad25"
      unitRef="usd">26842000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzExLTMtMS0xLTE_1a65e9bd-b389-4323-88c2-27a3c26e0650"
      unitRef="usd">1475000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEyLTEtMS0xLTE_e78db5b9-aa7e-4552-a14a-b71866cec2b6"
      unitRef="usd">56160000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEyLTMtMS0xLTE_8b232ee1-e117-4643-a623-c00e8d72cd76"
      unitRef="usd">7173000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEzLTEtMS0xLTE_5199011c-f50d-442b-9e58-0c021c8c0706"
      unitRef="usd">749000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzEzLTMtMS0xLTE_4fb79398-f4ad-402c-85ea-b62bfc0082d5"
      unitRef="usd">103000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE0LTEtMS0xLTE_95411403-d06b-426f-b55f-08a40fe02454"
      unitRef="usd">377100000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE0LTMtMS0xLTE_fa7d81d1-838f-4fb6-91cf-667da2ee12bf"
      unitRef="usd">60450000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE3LTEtMS0xLTE_c65fef37-8893-4cb2-aa38-b0bbb1388c2f"
      unitRef="usd">9696000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE3LTMtMS0xLTE_f26bee22-0a1a-4c8c-b22e-c6a1808cf50b"
      unitRef="usd">2930000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE4LTEtMS0xLTE_fccc6491-7723-4e96-a81d-07c7fd96a2c2"
      unitRef="usd">9694000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE4LTMtMS0xLTE_1bdf9d11-b885-4721-9fa5-abe158f7dd7f"
      unitRef="usd">5599000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE5LTEtMS0xLTE_59a97c12-276a-44e4-8558-03ba5b95e01e"
      unitRef="usd">684000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzE5LTMtMS0xLTE_74b54746-7253-4c95-a2f9-0176c0dd31b8"
      unitRef="usd">416000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTEtMS0xLTMzNDM3_c0826a05-37e8-493f-82bc-a930b75666e7"
      unitRef="usd">1467000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTMtMS0xLTQzMzEx_f7a3f7f9-c9fd-415f-93b3-a4654b5d6f37"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTEtMS0xLTMzMjYy_44c5d1a2-1bdf-4eb3-a8a5-98c5fd817bf1"
      unitRef="usd">299000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTMtMS0xLTMzMjYy_2d3df1f3-12f7-43d7-9836-7b7c34fc7d57"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIxLTEtMS0xLTE_bc29b38e-6a17-4549-9adc-8c2bcf01ea7b"
      unitRef="usd">21840000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIxLTMtMS0xLTE_465bd712-3ad3-41ea-8f00-6bd4ad04f00f"
      unitRef="usd">8945000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTEtMS0xLTM2NTc1_e9650819-4000-497f-9202-9e138dc9e86e"
      unitRef="usd">5288000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTMtMS0xLTQzMzEx_2da2c34e-d4a2-4b58-8a7e-b3a6accc8081"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTEtMS0xLTM2NTc1_28a47357-c503-4997-800f-ad228e8c20e0"
      unitRef="usd">3642000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTMtMS0xLTQzMzEx_872949e2-a588-4b6b-9557-e588ce61333b"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <bngo:ContingentConsiderationFairValueOfContingentLiability
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTEtMS0xLTUzMjY0_6cdf920c-a47f-486e-815a-58c103b121eb"
      unitRef="usd">9066000</bngo:ContingentConsiderationFairValueOfContingentLiability>
    <bngo:ContingentConsiderationFairValueOfContingentLiability
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTMtMS0xLTUzMjY3_d897bfaa-bbca-4bcc-a9d6-6382e66a3e9e"
      unitRef="usd">0</bngo:ContingentConsiderationFairValueOfContingentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIyLTEtMS0xLTE_8073e0f5-bcea-4de6-b83b-15d1a4374213"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIyLTMtMS0xLTE_15e9aca7-63f2-4561-a296-5b2ffc14f1a1"
      unitRef="usd">16325000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIzLTEtMS0xLTE_764651aa-ddbf-49bb-8259-05749765220a"
      unitRef="usd">146000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzIzLTMtMS0xLTE_0d8cb8f8-5db8-4a72-962e-31ca9570be0f"
      unitRef="usd">98000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:Liabilities
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTEtMS0xLTE_f1d6c37c-7f02-4e21-8540-2baa9dc4283b"
      unitRef="usd">39982000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI1LTMtMS0xLTE_cffe0a7b-7b03-4bee-87d6-97bff7ee9748"
      unitRef="usd">25368000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzM0LTEtMS0xLTUzMjcx_827718dc-1ec4-44f8-a552-8be2b92c0826"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzM0LTMtMS0xLTUzMjcx_8693db71-e6c5-49c1-a409-d0ddb8a71f58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfMzg0ODI5MDY5NzMyNA_38652c6b-3873-4d6e-abd9-13f261a6ade9"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfMzg0ODI5MDY5NzMyNA_f0eeb0ba-36c4-4a7b-9ed8-af77f1e07de9"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfMzg0ODI5MDY5NzMyOA_ebb864f2-5de9-4ba5-a813-7705e9b36bb4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfMzg0ODI5MDY5NzMyOA_f4e852ab-88b0-4a3d-851a-3c0de7b6016e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfNTQ5NzU1ODEzOTAwMQ_59d27b54-0f33-4759-b1b3-271e18d47055"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfNTQ5NzU1ODEzOTAwMQ_7e41969e-318e-44ce-b299-c5d76ff21a8d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfNTQ5NzU1ODEzOTAwMQ_b054fc5e-f28c-498d-b3f1-1b1a747d0de1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTAtMS0xLTIzNTYwL3RleHRyZWdpb246Y2NlM2NkZjJlZWFhNGQzY2I2YzY5NzllODgyMDkwYmNfNTQ5NzU1ODEzOTAwMQ_f271d3ed-96bd-4902-99fb-ea83e582230b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTEtMS0xLTIzNTYw_8f2946c3-7cb5-46e3-af92-e5232cf52949"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI5LTMtMS0xLTIzNTYw_9f6c713e-31d9-427a-b8d7-15def6bd21d0"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzc0_115fae02-0270-42b3-8950-658783166a72"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzc0_b70b67e4-a252-4c1d-8bfc-c462f7c3dc79"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzc5_4f34b870-5cc7-49d6-a4dd-87b99776e07f"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzc5_634437bb-68b1-4695-b8bd-eb7d54fe22d9"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzg3_71265059-c854-41d5-9225-5b305a2de873"
      unitRef="shares">289602000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzg3_a6538da1-b693-4970-9c47-1ebce32d4b4b"
      unitRef="shares">289602000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzkx_9daaeb3d-3494-4fb7-be40-3ede44023d03"
      unitRef="shares">189953000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTAtMS0xLTEvdGV4dHJlZ2lvbjo3MGExMjI1ODY1M2I0M2FlOTQxM2ExODZlMGNlYTY5YV8zODQ4MjkwNjk3Mzkx_f7701f21-8cd0-42a9-8be7-47adc757ca6f"
      unitRef="shares">189953000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTEtMS0xLTE_6293e231-46f7-4ce4-86b7-0e32c6f81fdc"
      unitRef="usd">29000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzI4LTMtMS0xLTE_0ecbc6bf-d625-499f-9897-90e1bb36feea"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMwLTEtMS0xLTE_71cef66d-2536-4fe5-aac8-880c4c2b1814"
      unitRef="usd">553747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMwLTMtMS0xLTE_f06597bf-bbac-4a9c-9520-adabba5388a7"
      unitRef="usd">178747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMxLTEtMS0xLTE_6fb933fa-1a6e-4abf-b356-9d1e3d666604"
      unitRef="usd">-216119000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMxLTMtMS0xLTE_08dfec40-43e6-45ef-a580-7f824cddf927"
      unitRef="usd">-143684000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMzLTEtMS0xLTIxNTIy_1005712c-c1b8-42d5-943b-6c9f01996461"
      unitRef="usd">-539000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMzLTMtMS0xLTIxNDg1_04a83489-712d-4fcc-8ef3-e78f300f0cca"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMyLTEtMS0xLTE_53c260f9-b431-46a9-909a-ef2acaf54b76"
      unitRef="usd">337118000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMyLTMtMS0xLTE_b42ebdbd-71ad-4522-9a2d-07ae22aca43a"
      unitRef="usd">35082000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMzLTEtMS0xLTE_abf5ee74-634c-4a49-acb7-bc3051d27351"
      unitRef="usd">377100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzYvZnJhZzo5ZDFiOTZjMTI1NjA0M2NhOGJmZDg0NGI5YzkyNjdkYy90YWJsZTpkZWViODgxOGU4MDI0YzQwOTc1M2RiMWQwY2RiNmJjYy90YWJsZXJhbmdlOmRlZWI4ODE4ZTgwMjRjNDA5NzUzZGIxZDBjZGI2YmNjXzMzLTMtMS0xLTE_88b41bea-9e45-42f6-ab23-7ec345c9dd00"
      unitRef="usd">60450000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzMtMS0xLTEtMQ_d9beba78-71cc-4f04-b734-ab0046810c28"
      unitRef="usd">11695000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzMtMy0xLTEtMQ_dcbbf629-6083-4ab3-93fb-c68c0f4958be"
      unitRef="usd">6230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzQtMS0xLTEtMQ_79e3525b-e535-4a63-80fa-8bebd3ee77eb"
      unitRef="usd">6286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzQtMy0xLTEtMQ_ac42e084-a8e6-4124-9a0a-273eec4dc8f7"
      unitRef="usd">2273000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzUtMS0xLTEtMQ_1712abe4-b074-4db4-b0a9-540c2083e00e"
      unitRef="usd">17981000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzUtMy0xLTEtMQ_9c56ea91-2ee3-4fdc-94a1-1119b9aa6cd5"
      unitRef="usd">8503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzctMS0xLTEtMQ_0fc7b170-570c-47b5-af65-2d26afb1c9c7"
      unitRef="usd">10524000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzctMy0xLTEtMQ_9a8d987c-50ab-4060-8a05-8d1ee62b53fa"
      unitRef="usd">4810000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzgtMS0xLTEtMQ_2e4e5235-dd53-4b82-af55-02c76617722b"
      unitRef="usd">3583000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzgtMy0xLTEtMQ_03d00fe1-c0a0-4ee1-b316-9de9dff2acba"
      unitRef="usd">920000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzktMS0xLTEtMQ_71a73dcc-ee99-4bc2-839f-d3c0d21b4b71"
      unitRef="usd">14107000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzktMy0xLTEtMQ_2265663e-f42b-46c9-8794-906d591635ba"
      unitRef="usd">5730000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzExLTEtMS0xLTE_25fb1f95-a2e3-4c22-bdf3-5ffd5bc7d570"
      unitRef="usd">22485000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzExLTMtMS0xLTE_d173bc65-a18e-4108-9657-4242673e4a7d"
      unitRef="usd">10256000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzEyLTEtMS0xLTE_76d5966c-cbe0-4d10-9d30-e115ec705717"
      unitRef="usd">58490000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzEyLTMtMS0xLTE_1e63027d-9d3b-428d-afd7-196cb7166cf6"
      unitRef="usd">31068000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzEzLTEtMS0xLTE_c50b1a89-3f4f-493f-9fa5-e637b976078b"
      unitRef="usd">80975000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzEzLTMtMS0xLTE_10670247-76fc-48d3-8186-ea9bc280455a"
      unitRef="usd">41324000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE0LTEtMS0xLTE_14dec5b6-4bf1-4102-baae-a4f8353e519d"
      unitRef="usd">-77101000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE0LTMtMS0xLTE_a08f334f-3b45-46f7-b8a1-4ceb27f978ca"
      unitRef="usd">-38551000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE2LTEtMS0xLTIyMTI3_ba495941-1c5f-45be-aefd-822fee013045"
      unitRef="usd">236000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE2LTMtMS0xLTIyMTMz_510aaac5-b487-4c78-935c-a673b253867c"
      unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE2LTEtMS0xLTE_ebba1f30-dd7c-4ea3-8c4f-ad85f18078d0"
      unitRef="usd">927000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE2LTMtMS0xLTE_7024d21f-1ab6-4f30-a4a0-f7412e2c2d84"
      unitRef="usd">2519000</us-gaap:InterestExpense>
    <bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE4LTEtMS0xLTIxOTk0_7c77f467-d889-4401-990a-c5286f9a7683"
      unitRef="usd">1775000</bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE4LTMtMS0xLTIyMDIz_e60a874f-25f0-4a25-9acb-aed803308922"
      unitRef="usd">0</bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE3LTEtMS0xLTE_f0792a0f-529d-43d0-acce-f7665a66651b"
      unitRef="usd">-2076000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE3LTMtMS0xLTE_8f993db1-35de-4190-b43b-ab95dfa852d9"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE4LTEtMS0xLTE_6fc906a8-1564-4732-a522-716c2776c813"
      unitRef="usd">-59000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE4LTMtMS0xLTE_72a064ad-0781-46f6-bbfb-e0b9e7426e9c"
      unitRef="usd">-7000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE5LTEtMS0xLTE_31fc5b23-56bc-4d9b-8fdf-1643dac97691"
      unitRef="usd">-1051000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzE5LTMtMS0xLTE_51c6dcc6-4b16-4c8b-80cb-b6773f10735b"
      unitRef="usd">-2526000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIwLTEtMS0xLTE_1f0ad0c4-3720-4dbd-872c-dea0b9d0cb2e"
      unitRef="usd">-78152000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIwLTMtMS0xLTE_fa099939-509c-4f76-8821-c292d1809b11"
      unitRef="usd">-41077000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIxLTEtMS0xLTE_c6f33af1-f542-4c03-8e6f-5b4a83cb59c9"
      unitRef="usd">-5717000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIxLTMtMS0xLTE_98dbbb3d-25c5-4f4f-ac73-196732b7deda"
      unitRef="usd">29000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIyLTEtMS0xLTE_fc547125-81b8-480d-8fe6-3390eb2712bf"
      unitRef="usd">-72435000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIyLTMtMS0xLTE_96d30954-9c14-4684-ac30-c16b49d763d3"
      unitRef="usd">-41106000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIzLTEtMS0xLTE_9a51702a-c549-4cc8-99ab-7cfe13842636"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzIzLTMtMS0xLTE_c8f76e20-92ff-4928-a21a-9535a2ac93b8"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzI0LTEtMS0xLTE_9bb6005c-3c79-4a67-b055-ca44ae359deb"
      unitRef="shares">276782000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xMzkvZnJhZzo4ZGUzN2Q4MmIwYjQ0YjNkOGI5YzViOTg4ZjJiODk4Yy90YWJsZTpkOTE5MmE5MDQ4NGY0MDZkYWY2ZGY3ODg0YWE2ZmJhYS90YWJsZXJhbmdlOmQ5MTkyYTkwNDg0ZjQwNmRhZjZkZjc4ODRhYTZmYmFhXzI0LTMtMS0xLTE_5076a045-4e62-426a-b1f2-14ca1be899bd"
      unitRef="shares">104251000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl8yLTEtMS0xLTIxNTc0_73713bc9-603b-404d-be81-3751c0772d3c"
      unitRef="usd">-72435000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl8yLTMtMS0xLTIxNTc0_8e18be2d-0c9b-4bfe-8377-e34e92b94618"
      unitRef="usd">-41106000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl8zLTEtMS0xLTIxNTc0_4813443b-65dc-4e08-a2ea-b3c8ab7520fd"
      unitRef="usd">-539000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl8zLTMtMS0xLTIxNTc0_4e245e1f-3421-417d-98a1-3c26f62f946e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl80LTEtMS0xLTIxNTc0_36744b34-5054-40c3-aae0-476c18862dc4"
      unitRef="usd">-72974000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQ2L2ZyYWc6OTQwZmVkYTY2YTdkNDM5Yjk0NDEzMDMyYzgzODRmZDAvdGFibGU6ODFkYTQ2NmJhYTY5NDk4NTk5NjI4NDZjNzNiZmZjOWYvdGFibGVyYW5nZTo4MWRhNDY2YmFhNjk0OTg1OTk2Mjg0NmM3M2JmZmM5Zl80LTMtMS0xLTIxNTc0_2efd7fef-7b05-48ff-bcda-26ee035e8e95"
      unitRef="usd">-41106000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="idef8a112a8af49b29859c89619c7063f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTItMS0xLTE_65e65398-c048-4ffb-84a2-c8d5acd3832d"
      unitRef="shares">34274000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idef8a112a8af49b29859c89619c7063f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTQtMS0xLTE_69253a04-2fad-4a95-84c9-98907ead3134"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6cb6eb48fccd436d82f456c60a03129e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTYtMS0xLTE_55f6d3b0-8e00-4ecb-b7a7-689308740ca6"
      unitRef="usd">106188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab96b4f9d91c40b3bcff03e74ce07d85_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTgtMS0xLTE_9d8f0593-5ade-4235-a220-f48684bc87b3"
      unitRef="usd">-102578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE0LTEwLTEtMS0x_e81a9ce2-63ef-4183-8f46-1d2dad3f0188"
      unitRef="usd">3613000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE1LTItMS0xLTIyMjYw_adc8d840-a9f2-4a05-92c4-4a2839755ed0"
      unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE1LTYtMS0xLTIyMjYw_5604ec32-c4c1-4e59-9abc-0a51a136b978"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE1LTEwLTEtMS0x_35135852-360a-4572-b84e-4c488d28e326"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE2LTYtMS0xLTE_068aa3ea-e74f-40df-8f87-5211f9c09771"
      unitRef="usd">1554000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE2LTEwLTEtMS0x_1676ccdb-c2d5-44bd-a962-9d2aa4eed2ac"
      unitRef="usd">1554000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE3LTItMS0xLTIyMjYw_2ea8ba4b-c7d3-4cc2-8aaa-3dc8ec47a208"
      unitRef="shares">43921000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE3LTQtMS0xLTIyMjYw_9141c00f-b7b6-4bcd-a655-79b85e90a4f8"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE3LTYtMS0xLTE_e8aec500-be41-470c-af26-5e07891df5c3"
      unitRef="usd">37930000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE3LTEwLTEtMS0x_e6228bdb-580c-4822-93eb-6924216baafc"
      unitRef="usd">37935000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE4LTItMS0xLTE_a84bb661-cb85-45d8-8fd5-e5f5ee25d5eb"
      unitRef="shares">88000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE4LTYtMS0xLTE_19d08c6c-f2ba-46db-b669-6cab3d573466"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE4LTEwLTEtMS0x_912f0004-67f1-41a1-85c9-b66c93612423"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <bngo:StockIssuedDuringPeriodSharesCovenantWaiver
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE5LTItMS0xLTE_d507a5a4-08b0-41f5-9569-4a0cdb291e09"
      unitRef="shares">873000</bngo:StockIssuedDuringPeriodSharesCovenantWaiver>
    <bngo:StockIssuedDuringPeriodValueCovenantWaiver
      contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE5LTYtMS0xLTE_849f7695-df5a-4523-ae7f-49a980ba55e3"
      unitRef="usd">300000</bngo:StockIssuedDuringPeriodValueCovenantWaiver>
    <bngo:StockIssuedDuringPeriodValueCovenantWaiver
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE5LTEwLTEtMS0x_887687e7-5427-433b-8b0f-1891815b4105"
      unitRef="usd">300000</bngo:StockIssuedDuringPeriodValueCovenantWaiver>
    <bngo:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIwLTItMS0xLTE_f84c0730-395c-45dc-8e90-ce60a9e4baa6"
      unitRef="shares">104628000</bngo:StockIssuedDuringPeriodSharesWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIwLTQtMS0xLTE_155ee20a-3462-49d2-b658-d7cb887fd9c6"
      unitRef="usd">10000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIwLTYtMS0xLTE_5453927e-978e-407a-81e8-f5230da9c70a"
      unitRef="usd">28635000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIwLTEwLTEtMS0x_2cee4184-2063-4525-91ad-efc7adf1c0c9"
      unitRef="usd">28645000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIxLTItMS0xLTE_4dd6ff56-c0ea-4066-a15b-de7d73aab888"
      unitRef="shares">6168000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i15621385cea8481886f364ad4a851311_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIxLTQtMS0xLTE_4f6f2daf-567f-4cc5-963d-4e081fe9322d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i0072c58700d645c0b6d6e11d7442e126_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIxLTYtMS0xLTE_0ac3e7a0-6541-4b12-9d8b-dbde5ead3289"
      unitRef="usd">4099000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIxLTEwLTEtMS0x_e504b441-5a42-4b5a-a8a5-d7eecdfc5639"
      unitRef="usd">4100000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:NetIncomeLoss
      contextRef="i17c82a645e374a6bb89950a49d16c0b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIyLTgtMS0xLTIyMjYw_10334d68-f25b-45f9-a999-21341885ca43"
      unitRef="usd">-41106000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzIyLTEwLTEtMS0x_947960aa-2418-4d46-8b26-5739ea6da29b"
      unitRef="usd">-41106000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i0efd9aa753ee49239268311cb402902f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTItMS0xLTE_3ce6cc3e-078c-44f3-bbd9-9ad7106728ed"
      unitRef="shares">189953000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0efd9aa753ee49239268311cb402902f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTQtMS0xLTE_9d458d5b-bee4-4210-acf7-e3062b236ed4"
      unitRef="usd">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5c0ff63e4b1469dae81b41f649a9a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTYtMS0xLTE_d73d983c-5ac1-4813-ac9c-1858eeb3e32f"
      unitRef="usd">178747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd11d2c4283b40818c2322674b6ee110_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTgtMS0xLTE_92f15afc-e689-4ab4-a295-fbbf1632f371"
      unitRef="usd">-143684000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI0LTEwLTEtMS0x_b7054dc1-d7cf-4692-8618-c8e3496f2f09"
      unitRef="usd">35082000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI1LTItMS0xLTIyMjYx_dad36ceb-bb8f-49ba-bf48-88589515a25d"
      unitRef="shares">479000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI1LTYtMS0xLTIyMjYx_4136f230-34d5-40ec-9bc3-3a1e1a09935c"
      unitRef="usd">602000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI1LTEwLTEtMS0yMjI2MQ_e22c1034-ea0c-4b2f-8674-dc78a970644b"
      unitRef="usd">602000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI2LTYtMS0xLTIyMjYx_6c9dd461-2e9a-4927-ae42-62cf6f841436"
      unitRef="usd">9719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI2LTEwLTEtMS0yMjI2MQ_1282548d-3805-4891-8555-c30ffe1a10b7"
      unitRef="usd">9719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI3LTItMS0xLTIyMjYx_6ffed0ee-67d4-49e3-b2e9-ad466a76d799"
      unitRef="shares">80178000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI3LTQtMS0xLTIyMjYx_da3d93cf-d0d6-4e76-b652-2db1593fb5b1"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI3LTYtMS0xLTIyMjYx_fc81d2df-eba1-4b45-83ab-5de93922f35b"
      unitRef="usd">341015000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI3LTEwLTEtMS0yMjI2MQ_bcde2c07-3af1-4a09-834e-a0587649e37c"
      unitRef="usd">341023000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <bngo:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI4LTItMS0xLTIyMjYx_99adbdf0-3bf2-46d6-bf30-a59284cde256"
      unitRef="shares">10794000</bngo:StockIssuedDuringPeriodSharesWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI4LTQtMS0xLTIyMjYx_b6aba601-3f3a-4af6-add9-d6676c4e0a67"
      unitRef="usd">1000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI4LTYtMS0xLTIyMjYx_939178b6-cdaf-47d7-8663-73166de7de1f"
      unitRef="usd">9417000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <bngo:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI4LTEwLTEtMS0yMjI2MQ_2004e93a-0588-4a3d-b6b2-b3e0b52967c4"
      unitRef="usd">9418000</bngo:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI5LTItMS0xLTIyMjYx_61cda606-3e10-4f61-8809-832206d55b10"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI5LTYtMS0xLTIyMjYx_2cf947ea-3f0e-4d89-845c-5073fd324ba2"
      unitRef="usd">89000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzI5LTEwLTEtMS0yMjI2MQ_e14e25ef-082b-4249-8bb4-382a11c0f464"
      unitRef="usd">89000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzE4LTItMS0xLTUxOTQ4_befdf097-ba13-4ced-94c5-d6cf7bcfd71b"
      unitRef="shares">169000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTItMS0xLTMyOTI4_eaea050f-69f7-46ff-8fe6-f99b54962ffa"
      unitRef="shares">7729000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i110fcd468c2643d7b4e1cca41f2b60b2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTQtMS0xLTMyOTI4_1796eb28-0450-4d4e-a8c7-d6614d358b96"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="if902b72d40424734916e6ea6a4d0455f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTYtMS0xLTMyOTI4_6fc77c37-fbe8-47e4-a2d2-48d55fe10876"
      unitRef="usd">14158000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTEyLTEtMS00MzM1Mw_11539adc-77a3-4ecd-93a2-b9ef316d20a3"
      unitRef="usd">14159000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:NetIncomeLoss
      contextRef="ic96f54a37ef346c38c3fce9c1e707621_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTgtMS0xLTIyMjYx_c2532f2c-1742-4ee6-8a22-b5c2dffcd6db"
      unitRef="usd">-72435000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMwLTEwLTEtMS0yMjI2MQ_64936495-0fea-419b-814d-217e91173daf"
      unitRef="usd">-72435000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iaf2232560f854d898b520b0322a5df9d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMxLTEwLTEtMS0yMzQyMA_25ee301e-dc70-4151-b370-eba3a152d080"
      unitRef="usd">-539000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMxLTEwLTEtMS0yMjI2MQ_c020f37a-5329-4cc5-8b65-708296b49d0d"
      unitRef="usd">-539000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i25c7362828a64a8eb87f775b1491fd99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTItMS0xLTIyMjYx_aa6c52ec-2839-4e46-ba5a-c7ac8c897fa3"
      unitRef="shares">289602000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i25c7362828a64a8eb87f775b1491fd99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTQtMS0xLTIyMjYx_335f8d00-26bb-4e52-b0aa-5657dcaeacec"
      unitRef="usd">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib45ae24785a44441a4802ef1030f892b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTYtMS0xLTIyMjYx_86ab5b1a-d61f-4bbe-98fd-e6bd973e3416"
      unitRef="usd">553747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3634a0ee07e4c1fb4cb0dc6914a2405_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTgtMS0xLTIyMjYx_fd2f4976-b238-4e1e-aa65-dc77996c5b19"
      unitRef="usd">-216119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idaa462baf9fc4f2680655d14713bccaa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzMyLTEwLTEtMS0zMTc4Mg_20b29f58-bd24-4edd-a381-f0e4a6c8451d"
      unitRef="usd">-539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDIvZnJhZzo4NDRlYjQ4NjRkMTc0OTZlOGNiNDY4M2VhODkyY2Y5Yy90YWJsZTpmZDk3MmEwNzViZjA0YjdiYjE1Y2NlZWYyNDE4MmY2NS90YWJsZXJhbmdlOmZkOTcyYTA3NWJmMDRiN2JiMTVjY2VlZjI0MTgyZjY1XzM0LTEwLTEtMS0yMjI2MQ_6c69b741-a0a8-422a-b484-7e12b7a650b6"
      unitRef="usd">337118000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMtMS0xLTEtMQ_2ee88465-f785-4cee-852f-3835d043474e"
      unitRef="usd">-72435000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMtMy0xLTEtMQ_6d1579b8-6482-4214-9874-b8574e0e5928"
      unitRef="usd">-41106000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzUtMS0xLTEtMQ_ab2f90bc-685a-4650-8839-aed776e43d18"
      unitRef="usd">3351000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzUtMy0xLTEtMQ_06c320b3-5b46-44ff-a7d6-f7b20d4cf9a6"
      unitRef="usd">1479000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYtMS0xLTEtNDE0MjQ_a8ff9970-eec6-442b-9a72-c6e6d2b20a05"
      unitRef="usd">19000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYtMy0xLTEtNDE1NTI_9d6e393a-3051-4ac4-a2ea-c4c45fb47591"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AccretionExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzctMS0xLTEtNDYxNDY_ed2a649a-e3f6-4609-a6e4-9f641f97f0c2"
      unitRef="usd">329000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzctMy0xLTEtNDYxNTM_7e5d3eee-2f0f-4ee4-914d-ad9c6227a57e"
      unitRef="usd">0</us-gaap:AccretionExpense>
    <bngo:NoncashInterestExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzctMS0xLTEtMQ_de85d93f-ad41-4550-8824-6cc7737af552"
      unitRef="usd">205000</bngo:NoncashInterestExpense>
    <bngo:NoncashInterestExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzctMy0xLTEtMQ_9a1d794f-ad04-4510-b1c0-0418ef4cc6e9"
      unitRef="usd">1264000</bngo:NoncashInterestExpense>
    <bngo:NonCashLeaseExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzktMS0xLTEtNDk1OTg_d3b3a2ca-cc0a-4afa-9d25-ac24d09f1178"
      unitRef="usd">671000</bngo:NonCashLeaseExpense>
    <bngo:NonCashLeaseExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzktMy0xLTEtNDk2MDU_df0bb072-40e2-48d0-8791-a40a07e2fb06"
      unitRef="usd">0</bngo:NonCashLeaseExpense>
    <bngo:SettlementOfInterestOnDebtNoncash
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTEtMS0xLTUwMzgz_db928dbf-21d2-436f-a62d-fcd8156622d4"
      unitRef="usd">1235000</bngo:SettlementOfInterestOnDebtNoncash>
    <bngo:SettlementOfInterestOnDebtNoncash
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTMtMS0xLTUwMzkx_29bd0291-7c79-4719-ad3b-36edf1c9fba5"
      unitRef="usd">0</bngo:SettlementOfInterestOnDebtNoncash>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzExLTEtMS0xLTUyMTA0_3b015c6f-911d-4907-a37f-3d097935dfaf"
      unitRef="usd">-5777000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzExLTMtMS0xLTUyMTE4_06b18502-a5e0-475b-899a-5c83584e1382"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzgtMS0xLTEtMQ_0f639271-23ab-47ea-8d88-5c97bd929378"
      unitRef="usd">9719000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzgtMy0xLTEtMQ_9b9221c4-8549-494e-a25d-9b23b3cfc1b9"
      unitRef="usd">1554000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzktMS0xLTEtMQ_70d29687-5d87-4925-a5fd-d6ab16e13019"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzktMy0xLTEtMQ_34010c99-cc1d-4846-ba96-814ab54a3428"
      unitRef="usd">1809000</us-gaap:ProvisionForDoubtfulAccounts>
    <bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTEtMS0xLTIyNjg2_6611ac5a-0b00-47b8-9d52-643e506af1e7"
      unitRef="usd">1775000</bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTMtMS0xLTIyNjg2_7f68e830-4774-4533-89fe-d33600746657"
      unitRef="usd">0</bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <us-gaap:InventoryWriteDown
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTEtMS0xLTE_7fe74ffd-25f0-48eb-a25d-cf422afbf05f"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEwLTMtMS0xLTE_caac81d7-47ab-459e-a46c-ce8346406e23"
      unitRef="usd">126000</us-gaap:InventoryWriteDown>
    <bngo:GainLossOnExtinguishmentOfDebtCashExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzExLTEtMS0xLTE_32b0dfed-051c-461a-84f6-e5d090f8c022"
      unitRef="usd">-1480000</bngo:GainLossOnExtinguishmentOfDebtCashExpense>
    <bngo:GainLossOnExtinguishmentOfDebtCashExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzExLTMtMS0xLTE_76b82113-46b4-44ee-93d9-0e124bdae627"
      unitRef="usd">0</bngo:GainLossOnExtinguishmentOfDebtCashExpense>
    <bngo:CostOfLeasedEquipmentSoldToCustomer
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE1LTEtMS0xLTUwMTQ2_e53c64b1-a2ad-421d-8f32-69eeca116fe3"
      unitRef="usd">568000</bngo:CostOfLeasedEquipmentSoldToCustomer>
    <bngo:CostOfLeasedEquipmentSoldToCustomer
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE1LTMtMS0xLTUwMTYw_9e1bba24-1081-458a-b630-0164f6b2ea97"
      unitRef="usd">0</bngo:CostOfLeasedEquipmentSoldToCustomer>
    <bngo:ClientWarrantyExchangeOfFixedAssets
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE2LTEtMS0xLTUwMTUz_2256454d-84aa-4868-9407-d3aae3dee714"
      unitRef="usd">539000</bngo:ClientWarrantyExchangeOfFixedAssets>
    <bngo:ClientWarrantyExchangeOfFixedAssets
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE2LTMtMS0xLTUwMTY3_6f68c82f-6260-4e09-9ac3-31e0a7fe42d0"
      unitRef="usd">0</bngo:ClientWarrantyExchangeOfFixedAssets>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzEzLTEtMS0xLTQxNDEx_108530ef-55c5-4886-9537-6dfffc748e4f"
      unitRef="usd">66000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE0LTMtMS0xLTQxNTM4_62df2a67-6ef2-471b-bff3-afa8139892a0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE2LTEtMS0xLTE_dbaa89cf-85e2-4b1c-8fc4-433674e5d61c"
      unitRef="usd">493000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE2LTMtMS0xLTE_316de20a-9061-4ff3-a071-0091a7de5040"
      unitRef="usd">-2087000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE3LTEtMS0xLTE_185af922-01f0-42e8-b994-7d20d65b89c5"
      unitRef="usd">15928000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE3LTMtMS0xLTE_ab4a415e-cca7-4379-9d3c-699168cdaede"
      unitRef="usd">4201000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE4LTEtMS0xLTE_324751e4-5467-4dfb-9ef9-4323eb0f03bf"
      unitRef="usd">1971000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE4LTMtMS0xLTE_fdcb1df8-b006-4ac7-a6f9-df3138819480"
      unitRef="usd">999000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE5LTEtMS0xLTE_e835079d-65c3-4e26-ad7a-0d0eceb26bbb"
      unitRef="usd">6781000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzE5LTMtMS0xLTE_7a13bcf6-effb-44df-8716-f82042186de0"
      unitRef="usd">-1810000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIwLTEtMS0xLTE_486418a9-cf3a-4390-a907-58882bb16a42"
      unitRef="usd">3959000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIwLTMtMS0xLTE_072f256f-49c0-438d-8d81-3c4dfa522d7c"
      unitRef="usd">1483000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIxLTEtMS0xLTE_d725d1c7-55cf-4dc6-a088-082d011c4991"
      unitRef="usd">-71927000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIxLTMtMS0xLTE_9db78ea9-2816-42a8-b0d3-d8d581d99344"
      unitRef="usd">-38314000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ida156f9281c3453e97c6d3eb9345fa03_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIzLTEtMS0xLTE_3436a676-8f37-4000-8d9d-d30283492a54"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzIzLTMtMS0xLTE_cab770c5-01e9-4d3e-9888-b4272124aadf"
      unitRef="usd">2450000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTEtMS0xLTQxNDMx_2057d96d-883a-457b-8b17-c59b219188c0"
      unitRef="usd">49086000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI2LTMtMS0xLTQxNjM5_00cc9fc6-23d7-49b9-b14d-925d694bb7fc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <bngo:PaymentsForPropertyAndEquipment
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI0LTEtMS0xLTE_2339d05e-db34-409d-8719-5a4e173cca27"
      unitRef="usd">822000</bngo:PaymentsForPropertyAndEquipment>
    <bngo:PaymentsForPropertyAndEquipment
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI0LTMtMS0xLTE_168d1af5-1e5d-4417-ad7e-a5cd88ee93cc"
      unitRef="usd">0</bngo:PaymentsForPropertyAndEquipment>
    <us-gaap:PaymentsForConstructionInProcess
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMxLTEtMS0xLTQxNDQw_770ed110-76b0-49bf-959c-c0d46de534f9"
      unitRef="usd">638000</us-gaap:PaymentsForConstructionInProcess>
    <us-gaap:PaymentsForConstructionInProcess
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI4LTMtMS0xLTQxNjU0_d1033740-0edf-4a64-a599-09bc820ffe1f"
      unitRef="usd">0</us-gaap:PaymentsForConstructionInProcess>
    <bngo:PaymentsForInitialCostsOnLeases
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTEtMS0xLTQ5NzA4_2f67e64c-f9fd-4886-b68c-3fc621ec987b"
      unitRef="usd">607000</bngo:PaymentsForInitialCostsOnLeases>
    <bngo:PaymentsForInitialCostsOnLeases
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTMtMS0xLTQ5NzE1_30363296-961f-494c-a6f2-147328b4f131"
      unitRef="usd">0</bngo:PaymentsForInitialCostsOnLeases>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI2LTEtMS0xLTIyODA2_3e9412cc-f532-406d-bc35-4b3e27b3032c"
      unitRef="usd">313392000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI2LTMtMS0xLTIyODA2_6877650c-2c98-4982-80a8-29076440f898"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI3LTEtMS0xLTIyODA2_06da7171-4d71-478d-a3a2-4f6da0befea6"
      unitRef="usd">86483000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI3LTMtMS0xLTIyODA2_fe4a2cf1-4e91-4b95-b18d-c2cf37b10850"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI1LTEtMS0xLTE_5b8ef8d1-e02c-4f5f-bb7a-55db43e06e66"
      unitRef="usd">-278062000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI1LTMtMS0xLTE_1d9942f5-652c-4664-9ec6-73281a5d3f12"
      unitRef="usd">-2450000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI4LTEtMS0xLTE_39ee0f9e-b6ab-48d3-b6b0-16680f6b8d86"
      unitRef="usd">15000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI4LTMtMS0xLTE_e58bd8f4-06b3-4605-95cf-16411ba3f4fd"
      unitRef="usd">5000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM5LTEtMS0xLTQxNDQ5_caf7f563-8274-4ce4-9e11-98f398950b62"
      unitRef="usd">5000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM5LTMtMS0xLTQxNTA2_22cc8b04-36e4-4c8c-8dc2-4f14b1e34360"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <bngo:ProceedsFromPayrollProtectionProgramLoan
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTEtMS0xLTE_8e34f7ca-b834-4958-8b5a-f3ca4d6cd50d"
      unitRef="usd">0</bngo:ProceedsFromPayrollProtectionProgramLoan>
    <bngo:ProceedsFromPayrollProtectionProgramLoan
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzI5LTMtMS0xLTE_e1e7a0bb-08ad-4d3e-aa08-5ed1e56eea05"
      unitRef="usd">1774000</bngo:ProceedsFromPayrollProtectionProgramLoan>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMwLTEtMS0xLTE_98d334a2-6459-4121-9443-30a609c86745"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMwLTMtMS0xLTE_b9d6cce7-b08c-4bfa-8a63-956e6de77b03"
      unitRef="usd">761000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMxLTEtMS0xLTE_a4e210f1-c96a-4ea6-8615-b324f947bd56"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMxLTMtMS0xLTE_91679c5a-1105-4834-a0d8-09c872efa5e2"
      unitRef="usd">2258000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMyLTEtMS0xLTE_d949b846-b9b5-416a-aba4-e9316e43f532"
      unitRef="usd">342711000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMyLTMtMS0xLTE_80154ff0-e516-4912-8b43-1c0d4d8b8759"
      unitRef="usd">39934000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMzLTEtMS0xLTE_489e6b67-6e14-46ef-903f-3dbaac16d73b"
      unitRef="usd">1704000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzMzLTMtMS0xLTE_610e7fba-2d09-42ab-bead-68627ad136e0"
      unitRef="usd">2000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <bngo:EmployeeStockPurchasePlanCompensationExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM0LTEtMS0xLTE_287163c1-01a9-4b7c-b839-faeed8947a82"
      unitRef="usd">89000</bngo:EmployeeStockPurchasePlanCompensationExpense>
    <bngo:EmployeeStockPurchasePlanCompensationExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM0LTMtMS0xLTE_719349bf-72fa-45ba-a073-d902cedeb4fb"
      unitRef="usd">40000</bngo:EmployeeStockPurchasePlanCompensationExpense>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM1LTEtMS0xLTE_287bb155-dd89-4fc1-8cba-a3bfcbdd5a11"
      unitRef="usd">10020000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM1LTMtMS0xLTE_1de58107-ec6c-4dd4-bedf-88bd3032a38b"
      unitRef="usd">28651000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM2LTEtMS0xLTE_44d9a6c4-8e53-498b-95ea-d775270f0c10"
      unitRef="usd">336111000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM2LTMtMS0xLTE_ca66e273-da52-43e3-96fa-68445f472425"
      unitRef="usd">61902000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM3LTEtMS0xLTE_fdcba8fe-3159-45a2-b121-0bc594494afc"
      unitRef="usd">-13878000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM3LTMtMS0xLTE_54f5396f-e9e5-48cb-a330-fb9a61353446"
      unitRef="usd">21138000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM4LTEtMS0xLTE_d1af1fb2-9e85-4aca-bf40-cfb5d4f1cb8b"
      unitRef="usd">38449000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM4LTMtMS0xLTE_3fd55b51-e5a4-4be1-a9a8-26cbdc4cc229"
      unitRef="usd">17311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM5LTEtMS0xLTE_0197500b-f3c8-4ff2-8037-1145f601ccb1"
      unitRef="usd">24571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzM5LTMtMS0xLTE_d7183ede-3388-4577-81ac-768e9d0506c5"
      unitRef="usd">38449000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzQ2LTEtMS0xLTIyMzE1_9ab3917a-aaee-4f8e-ba60-a83ec6f3ea90"
      unitRef="usd">1910000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzQ2LTMtMS0xLTIyMzE1_2925a967-d507-4f3b-88f5-da381da5b051"
      unitRef="usd">1252000</us-gaap:InterestPaidNet>
    <us-gaap:OperatingLeasePayments
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzUwLTEtMS0xLTQzMjYw_86aa6916-6df9-48d3-840e-f37d20bcf012"
      unitRef="usd">447000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzUwLTMtMS0xLTQzMjY3_0593b5ae-e66e-4000-8e04-d271864ae8f2"
      unitRef="usd">0</us-gaap:OperatingLeasePayments>
    <us-gaap:StockIssued1
      contextRef="ida156f9281c3453e97c6d3eb9345fa03_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU1LTEtMS0xLTUxNzY3_2a767894-c385-4ba2-89b8-2cd0ddb97507"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU1LTMtMS0xLTUxNzY3_0682c87f-e3c5-40da-9c45-5bcd161c23f1"
      unitRef="usd">4100000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU2LTEtMS0xLTUxNzY3_0b5514ab-4aff-4527-9ab7-b855eeece884"
      unitRef="usd">14159000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU2LTMtMS0xLTUxNzY3_93eb9e48-cc1d-481d-9c1a-267eb2fd9318"
      unitRef="usd">0</us-gaap:StockIssued1>
    <bngo:ContingentConsiderationNoncash
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU4LTEtMS0xLTUxNzY3_f1845b5c-bec6-4efb-9097-15e43651dd13"
      unitRef="usd">9000000</bngo:ContingentConsiderationNoncash>
    <bngo:ContingentConsiderationNoncash
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU4LTMtMS0xLTUxNzY3_2cecd850-1170-473d-a0a9-002bd81ed6ec"
      unitRef="usd">0</bngo:ContingentConsiderationNoncash>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU5LTEtMS0xLTUxNzY3_90abbe17-850e-4d08-9954-ed444965359d"
      unitRef="usd">4751000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzU5LTMtMS0xLTUxNzY3_3be506e1-ce95-4221-b70a-75a03c29af13"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYwLTEtMS0xLTUxNzY3_ae8ec9b4-ce5a-45ad-9af0-d9be5b43cb93"
      unitRef="usd">6857000</bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory>
    <bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYwLTMtMS0xLTUxNzY3_3b11aaad-edf4-4d23-b365-ff53bf820c12"
      unitRef="usd">4224000</bngo:TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory>
    <bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYyLTEtMS0xLTUxNzY3_6ea99887-36c3-4738-bd06-c23c0bd94edc"
      unitRef="usd">1775000</bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYyLTMtMS0xLTUxNzY3_e5c309be-1811-403e-9de1-4a0521b34274"
      unitRef="usd">0</bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <bngo:StockIssuedForServices
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYzLTEtMS0xLTUxNzY3_5de94cd9-b069-4bb3-a3ea-65fec1f3cec8"
      unitRef="usd">15000</bngo:StockIssuedForServices>
    <bngo:StockIssuedForServices
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzYzLTMtMS0xLTUxNzY3_6fcd9756-25cd-49a2-afe9-cc416cde52a2"
      unitRef="usd">0</bngo:StockIssuedForServices>
    <bngo:IssueCommonStockForCovenantWaiver
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzY0LTEtMS0xLTUxNzY3_b3a05efc-cc71-4aa4-b3d6-ef403eef0e07"
      unitRef="usd">0</bngo:IssueCommonStockForCovenantWaiver>
    <bngo:IssueCommonStockForCovenantWaiver
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzY0LTMtMS0xLTUxNzY3_c30fed22-0970-4647-82d5-8fabe3a40471"
      unitRef="usd">300000</bngo:IssueCommonStockForCovenantWaiver>
    <bngo:WarrantExerciseNonCash
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzY1LTEtMS0xLTUxNzY3_dbc60100-13be-478d-8831-c0fe507686b6"
      unitRef="usd">129000</bngo:WarrantExerciseNonCash>
    <bngo:WarrantExerciseNonCash
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNDUvZnJhZzoxYWIwOTcyYmQzNTY0MzBjYjhhYzYzYWZmZWIxODNkNy90YWJsZTo4NjI4YmQ1N2M1ZTQ0MDc4ODk0OWJkYjJjMGYwNzlmYy90YWJsZXJhbmdlOjg2MjhiZDU3YzVlNDQwNzg4OTQ5YmRiMmMwZjA3OWZjXzY1LTMtMS0xLTUxNzY3_fbb62649-eada-4a63-bd9d-c92b4bf9038b"
      unitRef="usd">0</bngo:WarrantExerciseNonCash>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzcxMTc_8cd276d7-01eb-47bb-be2a-d06b2a5c785b">Organization and Operations&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#x201c;Company&#x201d;) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company&#x2019;s mission is to transform the way the world sees the genome through optical genome mapping (&#x201c;OGM&#x201d;) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. (&#x201c;Lineagen&#x201d;) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC. (&#x201c;BioDiscovery&#x201d;) business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had approximately $24.6&#160;million in cash and cash equivalents, $226.0&#160;million in short term investments, and working capital of $250.6&#160;million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, and September 30, 2021. In February 2021, we applied for forgiveness of our PPP Loan of approximately $1.8 million, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. During the year ended December&#160;31, 2021, the outstanding term loan under the Innovatus LSA was paid in full, including all accrued interest, an end of term fee, and a prepayment fee for a total of $17.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes its available cash, cash equivalents and available-for-sale securities will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months. However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to additional risks and uncertainties as a result of the continued spread of COVID-19 and uncertain market conditions, which could continue to have a material impact on the Company&#x2019;s business and financial results. The Company closely monitors and complies with various applicable guidelines and legal requirements in the jurisdictions in which it operates, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. If restrictions related to COVID-19 persist, the Company could see supply chain disruptions that impact its ability to produce its products and may cause the Company to make strategic determinations regarding, among other things, the cost and quality of the components and supplies it acquires. The Company&#x2019;s manufacturing partners, suppliers, and customers, have implemented similar operational reductions. Despite reporting an increase in revenue for the year ended December&#160;31, 2021 when compared to the same period in 2020, the Company believes travel restrictions and overall reduced activity had a continued negative impact on the Company&#x2019;s financial results. Given the continued evolution of the COVID-19 pandemic and the related complexities and uncertainties associated with the additional variants, the future effects of COVID-19 are unknown and the Company&#x2019;s financial results may continue to be negatively affected in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. These negative effects could have a material impact on the Company&#x2019;s operations, business, earnings, and liquidity.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzcxMTk_81b04708-28f7-43dd-a3c9-c5abaeaf3ddc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the &#x201c;Company&#x201d;) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company&#x2019;s mission is to transform the way the world sees the genome through optical genome mapping (&#x201c;OGM&#x201d;) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. (&#x201c;Lineagen&#x201d;) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, LLC. (&#x201c;BioDiscovery&#x201d;) business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. &lt;/span&gt;&lt;/div&gt;Basis of PresentationThe consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company&#x2019;s 100%-owned subsidiaries.  All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <bngo:LiquidityPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzcxMjI_256fb6ef-e755-4cec-a052-02802ec22bed">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had approximately $24.6&#160;million in cash and cash equivalents, $226.0&#160;million in short term investments, and working capital of $250.6&#160;million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, and September 30, 2021. In February 2021, we applied for forgiveness of our PPP Loan of approximately $1.8 million, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. During the year ended December&#160;31, 2021, the outstanding term loan under the Innovatus LSA was paid in full, including all accrued interest, an end of term fee, and a prepayment fee for a total of $17.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes its available cash, cash equivalents and available-for-sale securities will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months. However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;</bngo:LiquidityPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzEwOTk1MTE2NTAwNzk_5d67eb10-5e2d-4059-8d82-3cf571be3caa"
      unitRef="usd">24600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzEwOTk1MTE2NTAwNzM_0f2fc8af-8258-4aaf-a08b-4fba67ae0f1b"
      unitRef="usd">226000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <bngo:WorkingCapital
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzM4NDgyOTA3MDQ0ODk_720d2b70-5508-4036-b10e-f5f127fe767e"
      unitRef="usd">250600000</bngo:WorkingCapital>
    <bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="i515aa68d30164045bab97fec3cd86d29_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzM4NDgyOTA3MjY3NjM_f0742587-0f9d-457a-ae7c-789f38ddf5e1"
      unitRef="usd">1800000</bngo:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i0418bf1522234b33bd7a72931d18580f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTEvZnJhZzo5ZDc1ZTU3ZTQ4ZmU0YmFkYWQ0NTRiMjY1ZmE5MzFjOS90ZXh0cmVnaW9uOjlkNzVlNTdlNDhmZTRiYWRhZDQ1NGIyNjVmYTkzMWM5XzM4NDgyOTA3MjY3ODQ_0ca64ae0-ae1d-447f-9c31-0e85335ae07e"
      unitRef="usd">17000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzI4_1b08ffda-2b07-4084-9faa-255c5c324752">Summary of Significant Accounting Policies &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions used by management include estimates of selling prices for multiple performance obligation arrangements, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used in purchase accounting and to evaluate the recoverability of long-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lived assets and goodwill, warranty reserves, certain accrued expenses, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company&#x2019;s net deferred tax assets, stock-based compensation expense, and related valuation allowances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company&#x2019;s 100%-owned subsidiaries.  All intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (&#x201c;Lineagen Merger Sub&#x201d;), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the securityholders of Lineagen, entered into an Agreement and Plan of Merger (the &#x201c;Lineagen Merger Agreement&#x201d;). Pursuant to the terms and conditions of the Lineagen Merger Agreement, Lineagen Merger Sub merged with and into Lineagen (the &#x201c;Lineagen Merger&#x201d;) whereupon the separate corporate existence of Lineagen Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Lineagen Merger as a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Starship Merger Sub I, Inc., a wholly owned subsidiary of the Company (&#x201c;BioDiscovery Merger Sub I&#x201d;), Starship Merger Sub II, LLC, a California limited liability company (&#x201c;BioDiscovery Merger Sub II&#x201d;), BioDiscovery, Inc., a California corporation (&#x201c;Former BioDiscovery&#x201d;), and Soheil Shams, solely in his capacity as the securityholders&#x2019; representative, entered into an Agreement and Plan of Merger (the &#x201c;BioDiscovery Merger Agreement&#x201d;), pursuant to which the Company agreed to acquire Former BioDiscovery. Pursuant to the terms and conditions of the BioDiscovery Merger Agreement, BioDiscovery Merger Sub I merged with and into Former BioDiscovery (&#x201c;BioDiscovery Merger I&#x201d;), whereupon the separate corporate existence of BioDiscovery Merger Sub I ceased, with Former BioDiscovery continuing as the surviving corporation of BioDiscovery Merger I and a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately after BioDiscovery Merger I, pursuant to the terms and conditions of the BioDiscovery Merger Agreement, Former BioDiscovery merged with and into BioDiscovery Merger Sub II (&#x201c;BioDiscovery Merger II&#x201d;), whereupon the separate corporate existence of Former BioDiscovery ceased, with BioDiscovery Merger Sub II continuing as the surviving company of BioDiscovery Merger II and a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with BioDiscovery Merger II, BioDiscovery Merger Sub II changed its name to that of our current subsidiary, BioDiscovery, LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for its acquisitions of Lineagen and BioDiscovery using the acquisition method of accounting pursuant to Accounting Standards Codification Topic 805, Business Combinations ("ASC 805"). Under ASC 805, the tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the acquisition date. Any excess purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair value of identifiable intangible assets acquired with the assistance of independent valuations that use information and assumptions provided by the Company&#x2019;s management. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 805, acquisition-related transaction costs (such as advisory, legal, valuation, other professional fees) are expensed in the statements of operations in the periods incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. The Company has not experienced any losses in such accounts. The Company believes that it is not exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d;, defines and establishes a framework for measuring fair value and expands disclosures about fair value measurements. In accordance with ASC 820, the Company has categorized its financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Assets and liabilities whose values are based on quoted prices for similar attributes in active markets; quoted prices in markets where trading occurs infrequently; and inputs other than quoted prices that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#x2019;s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#x2019;s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income (loss). A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company maintains deposits in federally insured major financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customers are located throughout the world. The Company generally does not require collateral from its customers. More information on accounts receivable is contained in the paragraph titled &#x201c;Accounts Receivable&#x201d; below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sources of Materials and Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The materials and components for the Company&#x2019;s product offerings are currently obtained from single or limited sources. The Company competes with other companies for production capacity, therefore, the Company is exposed to a risk of inventory being unavailable at acceptable prices, or at all, if suppliers are unable (or decide) to provide sufficient levels of materials and components and the Company is unable to identify alternative suppliers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,894,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(690,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,119,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,934,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For &#x201c;OGM&#x201d; products and services, credit is extended based upon an evaluation of each customer&#x2019;s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the year ended December&#160;31, 2021, the Company recorded a recovery of bad debt expense of $108,000, which &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is included in selling, general and administrative expenses. During the year ended December&#160;31, 2020, the Company recorded bad debt expense of $1.8 million which was included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company&#x2019;s total accounts receivable balance. As of December&#160;31, 2021, no customers met or exceeded 10% of the Company&#x2019;s total accounts receivable balance. As of December&#160;31, 2020, two customer balances represented 27.4%  of the Company&#x2019;s total accounts receivable balance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories, net of reserve, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,282,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,642,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,033,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,387,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,315,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets (including Finite-Lived Intangible Assets)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment and acquired finite-lived intangible assets. The Company records property and equipment at cost, and records acquired finite-lived intangible assets based on their fair values at the date of acquisition. Property and equipment generally consist of laboratory equipment, computer and office equipment, furniture and fixtures, and leasehold improvements. Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the assets (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc4OTc_81782cd1-ff67-4bc0-b19a-d3f9ef09300e"&gt;three&lt;/span&gt; to five years, or the remaining term of the lease for leasehold improvements, whichever is shorter). Repairs and maintenance costs are charged to expense as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date. Intangible assets are amortized over the estimated useful life of the asset on a basis that approximates the pattern of economic benefit. Intangible assets are reviewed for impairment if indicators of potential impairment exist. There was no indication of impairment of intangible assets for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Lineagen and BioDiscovery acquisitions the Company recorded intangible assets, which consist of trade name intangibles, customer relationship intangibles, and a developed technology intangible, which are amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is not recoverable when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company recognized no impairment losses on long-lived assets. Substantially all of the Company's long-lived assets are located in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded contingent consideration resulting from a business combination at its fair value on the acquisition date. On a quarterly basis, we revalue this obligation and record any increase or decrease in fair value as an adjustment to the consolidated statement of operations. Changes to the fair value of the contingent consideration obligation may result from changes to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discount rate, the passage of time, changes in our estimate of the likelihood, or timing of achieving the criteria for payment of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill arises when the purchase price of an acquired business exceeds the fair value of the identifiable net assets acquired, with such excess recorded as goodwill on the balance sheet. Goodwill is not subsequently amortized. Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indications of impairment exist. Goodwill is assigned to specific reporting units for purposes of impairment assessment. The Company has determined that it has a single operating segment and a single reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In testing goodwill for impairment, the Company will first assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the qualitative assessment indicates that it is more likely than not that the fair value of the reporting unit is less than its carrying value, then the Company will perform a quantitative impairment analysis by comparing the fair value of the reporting unit to the carrying value of the reporting unit, including goodwill. An impairment charge for goodwill is recognized for the amount by which the carrying value of the reporting unit exceeds its fair value, not to exceed the total goodwill allocated to the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company recognized no impairment losses on goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2021, the Company determines if an arrangement is, or contains, a lease at the inception of the arrangement. Right-of-use (&#x201c;ROU&#x201d;) assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating leases are included in operating lease right-of-use assets and operating lease liabilities in the consolidated balance sheets, while finance leases are included in finance lease right-of-use assets and finance lease liabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and liabilities are recognized at commencement based on the present value of lease payments over the lease term. The Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments. The ROU assets also include any prepaid or accrued lease payments and is adjusted for lease incentives and initial direct costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease terms may include options to extend or terminate the lease which are recognized when it is reasonably certain that the Company will exercise that option. Leases with terms of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the lease terms, or in some cases, the useful life of the underlying asset. Variable lease payments are excluded from the measurement of ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. The Company accounts for the lease and non-lease components as a single lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Rent&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating leases include incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2021, the difference between rent expense and amounts paid under the lease was recorded as deferred rent in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates revenue primarily from the sale of products and services. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes a receivable when we have an unconditional right to payment, which is generally at the time of delivery of software, consumables and instruments, including any extended warranties, or at the time services are rendered. Payment terms are typically 30 days for sales to customers in the United States but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within selling, general and administrative expenses, less any amounts reimbursed by the customer, when the corresponding revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded net of discounts and sales tax. The Company&#x2019;s contracts typically do not provide for product returns or refunds. In general, estimates of variable consideration and constraints are not material to the Company&#x2019;s financial statements. Employee sales commissions are recorded as selling, general and administrative expenses when incurred as the amortization period for such costs, if capitalized, would have been one year or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue consists of sales of our Saphyr system and related consumables. These products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors. In addition, the Company provides the Saphyr system to certain customers under its reagent rental program, under which the Company provides Saphyr systems to customers at no cost and the customers agree to purchase minimum quantities of consumables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains control of the product. As such the Company's performance obligation related to product sales is satisfied at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For transfers of instruments and consumables to customers under the Company's rental reagent program, the Company allocates the total contract consideration between the instrument and the consumables based on estimates of stand-alone selling prices, and recognizes the instrument revenue evenly over the rental period, and the consumables revenue when the consumables are delivered. Rental revenue related to the reagent rental program recognized over-time totaled $0.2 million and $0.1 million during the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Service and other revenue recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service and other revenue primarily consist of revenue from diagnostic testing services, the sale of software, and license maintenance agreements, and support, repair and maintenance services and extended warranties on Saphyr systems. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from the completion of diagnostic testing services is initially recorded at the estimated consideration the Company expects to receive from contractual and non-contractual payors, and is subject to adjustment based on the amount actually collected. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results, which the Company has determined is the point at which control is transferred to the customer for revenue recognition purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from the sale of software is recognized at the point-in-time the software license is transferred to the customer, or for hosting arrangements, on a usage basis as the customer processes the number of genetic samples purchased with the software. Revenue related to license maintenance agreements is recognized over-time based on the contract term. Revenue recognized over-time related to license maintenance agreements totaled $0.1 million during the year ended December&#160;31, 2021. There was no revenue recognized related to license maintenance agreements during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from support and maintenance contracts and extended warranties is recognized over time based on the contract term, which represents a faithful depiction of the transfer of goods and services given the stand-ready nature of the performance obligations. Service revenue related to repairs and customer sample evaluations is recognized as the services are performed based on the specific nature of the service. Warranty and maintenance revenue recognized over-time totaled $0.6 million and $0.5 million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in service and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was&#160;$0.8 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations, as well as obligations related to software under hosting arrangements. The Company expects to recognize approximately&#160;82.4%&#160;of this amount as revenue in 2022,&#160;13.8%&#160;in 2023, 2.3%&#160;in 2024 and 1.5% in 2025 and thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. The Company's liability for product warranties provided under its agreements with customers was $0.2 million and $0.2 million as of December&#160;31, 2021 and 2020, respectively. Warranty expense recorded in cost of goods sold totaled $0.5 million and $0.4 million during the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets primarily relate to the Company&#x2019;s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheets. The Company recognized revenue of&#160;$0.4 million and $0.4 million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor Transactions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain markets, the Company sells products and provides services to customers through distributors that specialize in life sciences products. In cases where the product is delivered to a distributor, revenue recognition generally occurs when the distributors obtains control of the product. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers and do not contain return rights. Distributor sales transactions typically differ from direct customer sales as they do not require the Company&#x2019;s services to install the instrument at the end customer or perform the services for the customer that are beyond the standard warranty in the first year following the sale. These transactions are accounted for in accordance with the Company&#x2019;s revenue recognition policy described herein. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue for products consists of the Company&#x2019;s raw material parts costs and associated freight, shipping and handling costs, contract manufacturing costs, royalties due to third parties, salaries and other personnel costs, equipment depreciation, overhead and other direct costs related to those sales recognized as product revenue in the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of service and other revenue consists of salaries and other personnel costs, and facility costs associated with costs related to warranties and other costs of servicing equipment at customer sites, and performance of diagnostics services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for research and product development, including acquired technology and costs incurred for technology in the development stage, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to filing and pursuing patent applications are recorded as selling, general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues stock-based awards as compensation to employees and directors. Stock-based awards may include stock options, stock appreciation rights, vesting stock awards and performance share awards. These awards are accounted for as equity awards. To-date, the Company recognizes stock-based compensation expense net of actual forfeitures on a straight-line basis over the underlying award&#x2019;s requisite service period, which is generally the vesting period, as measured using the award&#x2019;s grant date fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the impact of uncertain tax positions at the largest amount that is &#x201c;more likely than not&#x201d; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it does not have a greater than 50% likelihood of being sustained. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company chief operating decision-maker, the Chief Executive Officer, views the Company&#x2019;s operations and manages its business as one operating segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. Pre-funded warrants from the Company's follow-on offering have been treated as if they were common shares outstanding on the date of issuance.  The Company&#x2019;s potentially dilutive securities which include outstanding warrants to purchase stock and outstanding stock options under the Company&#x2019;s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive were as follows (in common stock equivalent shares): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,765,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,174,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,006,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,778,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,464,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued But Not Yet Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuer&#x2019;s Accounting for Certain Modifications or Exchanges for Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to clarify the accounting for modifications or exchanges of equity-classified warrants. The standard is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is in the process of evaluating the expected impact of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2021-04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on its financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#x2019;s annual fiscal year. The Company&#x2019;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. In February 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, &#x201c;Leases (Topic 842)&#x201d; (&#x201c;ASC 842&#x201d;) which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASC 842 establishes a right-of-use model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. ASC 842 also requires disclosures to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on January 1, 2021, as the Company lost its status as an Emerging Growth Company effective December 31, 2021, and therefore was required to adopt the standard for the year ending December 31, 2021, using the modified retrospective method. Under this transition method, the Company recognized and measured leases that existed at the adoption date in the consolidated balance sheet as of January 1, 2021. In connection with the adoption of ASC 842, the Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company also made accounting policy elections not to apply the recognition requirements under ASC 842 to any short-term leases and to account for each separate lease and associated non-lease components as a single lease component for all the Company&#x2019;s leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption of ASC 842 resulted in recognition of operating lease assets and liabilities of approximately $2.1 million and $2.1 million, respectively, as of January 1, 2021, related to the lease of office and laboratory space. The comparative prior period information continues to be reported under ASC 840. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. For further details, see Note 11, Commitments and Contingencies. The adoption of the new standard did not materially impact the Company&#x2019;s consolidated results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities From Contracts With Customers. This ASU requires an acquirer to account for revenue contracts acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. Prior to ASU 2021-08, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers and other similar contracts, at fair value on the acquisition date. The guidance is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and should be applied prospectively to business combinations occurring on or after the effective date. Early adoption is permitted. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company adopted ASU 2021-08 on October 1, 2021, and applied the ASU prospectively to its acquisition that occurred in 2021.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzI5_aab490a6-375e-46d3-952f-4300349cd56a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions used by management include estimates of selling prices for multiple performance obligation arrangements, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used in purchase accounting and to evaluate the recoverability of long-&lt;/span&gt;&lt;/div&gt;lived assets and goodwill, warranty reserves, certain accrued expenses, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company&#x2019;s net deferred tax assets, stock-based compensation expense, and related valuation allowances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzE0_499b34cd-1d72-4472-9692-ad43df961dce">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (&#x201c;Lineagen Merger Sub&#x201d;), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the securityholders of Lineagen, entered into an Agreement and Plan of Merger (the &#x201c;Lineagen Merger Agreement&#x201d;). Pursuant to the terms and conditions of the Lineagen Merger Agreement, Lineagen Merger Sub merged with and into Lineagen (the &#x201c;Lineagen Merger&#x201d;) whereupon the separate corporate existence of Lineagen Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Lineagen Merger as a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Starship Merger Sub I, Inc., a wholly owned subsidiary of the Company (&#x201c;BioDiscovery Merger Sub I&#x201d;), Starship Merger Sub II, LLC, a California limited liability company (&#x201c;BioDiscovery Merger Sub II&#x201d;), BioDiscovery, Inc., a California corporation (&#x201c;Former BioDiscovery&#x201d;), and Soheil Shams, solely in his capacity as the securityholders&#x2019; representative, entered into an Agreement and Plan of Merger (the &#x201c;BioDiscovery Merger Agreement&#x201d;), pursuant to which the Company agreed to acquire Former BioDiscovery. Pursuant to the terms and conditions of the BioDiscovery Merger Agreement, BioDiscovery Merger Sub I merged with and into Former BioDiscovery (&#x201c;BioDiscovery Merger I&#x201d;), whereupon the separate corporate existence of BioDiscovery Merger Sub I ceased, with Former BioDiscovery continuing as the surviving corporation of BioDiscovery Merger I and a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately after BioDiscovery Merger I, pursuant to the terms and conditions of the BioDiscovery Merger Agreement, Former BioDiscovery merged with and into BioDiscovery Merger Sub II (&#x201c;BioDiscovery Merger II&#x201d;), whereupon the separate corporate existence of Former BioDiscovery ceased, with BioDiscovery Merger Sub II continuing as the surviving company of BioDiscovery Merger II and a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with BioDiscovery Merger II, BioDiscovery Merger Sub II changed its name to that of our current subsidiary, BioDiscovery, LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for its acquisitions of Lineagen and BioDiscovery using the acquisition method of accounting pursuant to Accounting Standards Codification Topic 805, Business Combinations ("ASC 805"). Under ASC 805, the tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the acquisition date. Any excess purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair value of identifiable intangible assets acquired with the assistance of independent valuations that use information and assumptions provided by the Company&#x2019;s management. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 805, acquisition-related transaction costs (such as advisory, legal, valuation, other professional fees) are expensed in the statements of operations in the periods incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzMz_4ddf1a5f-af85-41cc-bfb5-8734d801128d">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. The Company has not experienced any losses in such accounts. The Company believes that it is not exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODA_75ea9bdd-ee18-4a92-913c-75b01e5af062">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d;, defines and establishes a framework for measuring fair value and expands disclosures about fair value measurements. In accordance with ASC 820, the Company has categorized its financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Assets and liabilities whose values are based on quoted prices for similar attributes in active markets; quoted prices in markets where trading occurs infrequently; and inputs other than quoted prices that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODE_c8c5b94b-5a2e-4669-8f8f-3cdee25f233c">Investment SecuritiesAll investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#x2019;s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#x2019;s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income (loss). A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5Mjkz_ac659403-4fdf-4a06-b27c-b84576ec87b7">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company maintains deposits in federally insured major financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customers are located throughout the world. The Company generally does not require collateral from its customers. More information on accounts receivable is contained in the paragraph titled &#x201c;Accounts Receivable&#x201d; below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sources of Materials and Products&lt;/span&gt;&lt;/div&gt;The materials and components for the Company&#x2019;s product offerings are currently obtained from single or limited sources. The Company competes with other companies for production capacity, therefore, the Company is exposed to a risk of inventory being unavailable at acceptable prices, or at all, if suppliers are unable (or decide) to provide sufficient levels of materials and components and the Company is unable to identify alternative suppliers.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzIz_76762970-4cc7-449f-859b-29165df81f5c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,894,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(690,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,119,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,934,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For &#x201c;OGM&#x201d; products and services, credit is extended based upon an evaluation of each customer&#x2019;s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the year ended December&#160;31, 2021, the Company recorded a recovery of bad debt expense of $108,000, which &lt;/span&gt;&lt;/div&gt;is included in selling, general and administrative expenses. During the year ended December&#160;31, 2020, the Company recorded bad debt expense of $1.8 million which was included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible.Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company&#x2019;s total accounts receivable balance. As of December&#160;31, 2021, no customers met or exceeded 10% of the Company&#x2019;s total accounts receivable balance. As of December&#160;31, 2020, two customer balances represented 27.4%  of the Company&#x2019;s total accounts receivable balance.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyMTU5ODI_1cadc742-5831-49b7-9f57-2707f46b814c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts receivable, trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,894,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(690,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,119,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,934,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzItMS0xLTEtMjU5Njc_50f7baea-dea8-4f2f-b625-67fe95d5b07c"
      unitRef="usd">5624000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzItNC0xLTEtMjU5Njc_35e94bbf-2cad-4d93-9410-7c1ae11b29d9"
      unitRef="usd">4894000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzMtMS0xLTEtMjU5Njc_72e41804-670b-460d-a9a4-cd857dd138ce"
      unitRef="usd">690000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzMtNC0xLTEtMjU5Njc_6a67fed9-4546-4052-bf2a-31056ab45596"
      unitRef="usd">2119000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzQtMS0xLTEtMjU5Njc_cdf89c91-a871-44ee-9c34-fbc56e631be9"
      unitRef="usd">4934000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTo2NDkxNjI3YzQxN2M0MjBhYmFiMDVlODQyNWVhYTlmNC90YWJsZXJhbmdlOjY0OTE2MjdjNDE3YzQyMGFiYWIwNWU4NDI1ZWFhOWY0XzQtNC0xLTEtMjU5Njc_24c493ba-a059-4ff7-9cf0-26a1a3ba8325"
      unitRef="usd">2775000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA3MzIyMTg_6bb26943-1411-4181-bf5b-a5607c90d575"
      unitRef="usd">108000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4MTQ4NTc_ea3e4287-ca57-4ed3-ba47-ee9b94404043"
      unitRef="usd">1800000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib40de96003224a488c14b76a879a457e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA3MzIyNTc_99a623e4-5f0c-4f7a-b389-d12f01a7713a"
      unitRef="number">0.274</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzE2_2b221847-7dc9-4ac1-9301-cd66270f8d64">Inventory Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfUtilityInventoryTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzM0_13cf0ba2-1c3f-4e31-a4a6-f5ee42b4f5ca">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories, net of reserve, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,282,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,642,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,033,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,387,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,315,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUtilityInventoryTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzMtMS0xLTEtMQ_9dd3cebe-5631-42a3-9233-e3cf7aed5f79"
      unitRef="usd">745000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzMtMy0xLTEtMQ_1411f6a3-1e6e-4f65-834c-62ad81234d5a"
      unitRef="usd">2282000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzQtMS0xLTEtMQ_147f679b-dce4-4a93-9ff3-5b3f70e79077"
      unitRef="usd">11642000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzQtMy0xLTEtMQ_fc1b5a53-ce0b-4586-b6bf-270b26d4b0cf"
      unitRef="usd">1033000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzUtMS0xLTEtMQ_d2d167ed-43c6-4f23-b899-3e3b6c52d366"
      unitRef="usd">12387000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTpkY2QyOGU1Yzc5OWU0YTY1YTgxZjAwMTk2YWNlZWY3ZS90YWJsZXJhbmdlOmRjZDI4ZTVjNzk5ZTRhNjVhODFmMDAxOTZhY2VlZjdlXzUtMy0xLTEtMQ_ed9151da-0ef2-41b1-aa1a-4bbdf58f6ca7"
      unitRef="usd">3315000</us-gaap:InventoryNet>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzI0_0afd4394-2e80-499e-bb95-7fe64a471f7c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets (including Finite-Lived Intangible Assets)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment and acquired finite-lived intangible assets. The Company records property and equipment at cost, and records acquired finite-lived intangible assets based on their fair values at the date of acquisition. Property and equipment generally consist of laboratory equipment, computer and office equipment, furniture and fixtures, and leasehold improvements. Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the assets (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc4OTc_81782cd1-ff67-4bc0-b19a-d3f9ef09300e"&gt;three&lt;/span&gt; to five years, or the remaining term of the lease for leasehold improvements, whichever is shorter). Repairs and maintenance costs are charged to expense as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date. Intangible assets are amortized over the estimated useful life of the asset on a basis that approximates the pattern of economic benefit. Intangible assets are reviewed for impairment if indicators of potential impairment exist. There was no indication of impairment of intangible assets for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Lineagen and BioDiscovery acquisitions the Company recorded intangible assets, which consist of trade name intangibles, customer relationship intangibles, and a developed technology intangible, which are amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company identifies a change in the circumstances related to its long-lived assets, such as property and equipment and intangible assets (other than goodwill), that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset (other than goodwill) is not recoverable when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i03e386398bdb44b3addd41e681970261_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzc5MDM_39dd2f04-b153-4088-826a-a5b58c514272">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzg4MDE_f7ea3986-0330-41b7-bfd1-e0af9bc8fd1f">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzk3MTA_726decae-d317-47d8-beb5-04e9317ad45a"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzk3MTA_c2beb49c-7149-49d1-82a5-fde4e3a56be8"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <bngo:ContingentConsiderationPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODI_34b32e89-60c8-47ce-9830-46aee92ab719">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded contingent consideration resulting from a business combination at its fair value on the acquisition date. On a quarterly basis, we revalue this obligation and record any increase or decrease in fair value as an adjustment to the consolidated statement of operations. Changes to the fair value of the contingent consideration obligation may result from changes to the &lt;/span&gt;&lt;/div&gt;discount rate, the passage of time, changes in our estimate of the likelihood, or timing of achieving the criteria for payment of the contingent consideration.</bngo:ContingentConsiderationPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzM1_b7b54a0e-df8e-4076-8a53-235f045a2bf8">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill arises when the purchase price of an acquired business exceeds the fair value of the identifiable net assets acquired, with such excess recorded as goodwill on the balance sheet. Goodwill is not subsequently amortized. Goodwill is reviewed for impairment annually (during the fourth quarter) or more frequently if indications of impairment exist. Goodwill is assigned to specific reporting units for purposes of impairment assessment. The Company has determined that it has a single operating segment and a single reporting unit. &lt;/span&gt;&lt;/div&gt;In testing goodwill for impairment, the Company will first assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the qualitative assessment indicates that it is more likely than not that the fair value of the reporting unit is less than its carrying value, then the Company will perform a quantitative impairment analysis by comparing the fair value of the reporting unit to the carrying value of the reporting unit, including goodwill. An impairment charge for goodwill is recognized for the amount by which the carrying value of the reporting unit exceeds its fair value, not to exceed the total goodwill allocated to the reporting unit.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzExMjg4_444737b6-97f8-47d0-9e30-11433546cb82"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzExMjg4_8b20760e-7629-4465-81eb-02383f95ab8b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODM_859ee699-c9d4-46c9-b901-9414a6190ebc">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2021, the Company determines if an arrangement is, or contains, a lease at the inception of the arrangement. Right-of-use (&#x201c;ROU&#x201d;) assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Operating leases are included in operating lease right-of-use assets and operating lease liabilities in the consolidated balance sheets, while finance leases are included in finance lease right-of-use assets and finance lease liabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and liabilities are recognized at commencement based on the present value of lease payments over the lease term. The Company generally uses its incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments. The ROU assets also include any prepaid or accrued lease payments and is adjusted for lease incentives and initial direct costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease terms may include options to extend or terminate the lease which are recognized when it is reasonably certain that the Company will exercise that option. Leases with terms of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the lease terms, or in some cases, the useful life of the underlying asset. Variable lease payments are excluded from the measurement of ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. The Company accounts for the lease and non-lease components as a single lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzU0OTc1NTgyNTYwODQ_ac86089f-21f6-4f76-90e9-919a1fcbabb7">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Rent&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating leases include incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2021, the difference between rent expense and amounts paid under the lease was recorded as deferred rent in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzAw_357af272-93ee-4601-98c0-e9320734a041">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates revenue primarily from the sale of products and services. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes a receivable when we have an unconditional right to payment, which is generally at the time of delivery of software, consumables and instruments, including any extended warranties, or at the time services are rendered. Payment terms are typically 30 days for sales to customers in the United States but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within selling, general and administrative expenses, less any amounts reimbursed by the customer, when the corresponding revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded net of discounts and sales tax. The Company&#x2019;s contracts typically do not provide for product returns or refunds. In general, estimates of variable consideration and constraints are not material to the Company&#x2019;s financial statements. Employee sales commissions are recorded as selling, general and administrative expenses when incurred as the amortization period for such costs, if capitalized, would have been one year or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue consists of sales of our Saphyr system and related consumables. These products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors. In addition, the Company provides the Saphyr system to certain customers under its reagent rental program, under which the Company provides Saphyr systems to customers at no cost and the customers agree to purchase minimum quantities of consumables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains control of the product. As such the Company's performance obligation related to product sales is satisfied at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For transfers of instruments and consumables to customers under the Company's rental reagent program, the Company allocates the total contract consideration between the instrument and the consumables based on estimates of stand-alone selling prices, and recognizes the instrument revenue evenly over the rental period, and the consumables revenue when the consumables are delivered. Rental revenue related to the reagent rental program recognized over-time totaled $0.2 million and $0.1 million during the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Service and other revenue recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service and other revenue primarily consist of revenue from diagnostic testing services, the sale of software, and license maintenance agreements, and support, repair and maintenance services and extended warranties on Saphyr systems. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from the completion of diagnostic testing services is initially recorded at the estimated consideration the Company expects to receive from contractual and non-contractual payors, and is subject to adjustment based on the amount actually collected. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results, which the Company has determined is the point at which control is transferred to the customer for revenue recognition purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from the sale of software is recognized at the point-in-time the software license is transferred to the customer, or for hosting arrangements, on a usage basis as the customer processes the number of genetic samples purchased with the software. Revenue related to license maintenance agreements is recognized over-time based on the contract term. Revenue recognized over-time related to license maintenance agreements totaled $0.1 million during the year ended December&#160;31, 2021. There was no revenue recognized related to license maintenance agreements during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from support and maintenance contracts and extended warranties is recognized over time based on the contract term, which represents a faithful depiction of the transfer of goods and services given the stand-ready nature of the performance obligations. Service revenue related to repairs and customer sample evaluations is recognized as the services are performed based on the specific nature of the service. Warranty and maintenance revenue recognized over-time totaled $0.6 million and $0.5 million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in service and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was&#160;$0.8 million. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations, as well as obligations related to software under hosting arrangements. The Company expects to recognize approximately&#160;82.4%&#160;of this amount as revenue in 2022,&#160;13.8%&#160;in 2023, 2.3%&#160;in 2024 and 1.5% in 2025 and thereafter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue. The Company's liability for product warranties provided under its agreements with customers was $0.2 million and $0.2 million as of December&#160;31, 2021 and 2020, respectively. Warranty expense recorded in cost of goods sold totaled $0.5 million and $0.4 million during the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets primarily relate to the Company&#x2019;s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheets. The Company recognized revenue of&#160;$0.4 million and $0.4 million during the years ended December&#160;31, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor Transactions &lt;/span&gt;&lt;/div&gt;In certain markets, the Company sells products and provides services to customers through distributors that specialize in life sciences products. In cases where the product is delivered to a distributor, revenue recognition generally occurs when the distributors obtains control of the product. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers and do not contain return rights. Distributor sales transactions typically differ from direct customer sales as they do not require the Company&#x2019;s services to install the instrument at the end customer or perform the services for the customer that are beyond the standard warranty in the first year following the sale. These transactions are accounted for in accordance with the Company&#x2019;s revenue recognition policy described herein.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <bngo:RentalRevenueReagentRentalProgram
      contextRef="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjA0NTQ_34eb46c6-8488-4150-9530-be1c4631da21"
      unitRef="usd">200000</bngo:RentalRevenueReagentRentalProgram>
    <bngo:RentalRevenueReagentRentalProgram
      contextRef="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjA0NjI_9252ab49-de80-4386-a09e-285826074750"
      unitRef="usd">100000</bngo:RentalRevenueReagentRentalProgram>
    <bngo:LicensingRevenueAndMaintenanceAgreements
      contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NTQ3OTk_d0dc7c42-92ac-42fa-8e31-2fb39467a31f"
      unitRef="usd">100000</bngo:LicensingRevenueAndMaintenanceAgreements>
    <bngo:WarrantyAndMaintenanceRevenue
      contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjM4NDg_b0b21e5c-8abd-4d8d-bc6b-35cd3419ce35"
      unitRef="usd">600000</bngo:WarrantyAndMaintenanceRevenue>
    <bngo:WarrantyAndMaintenanceRevenue
      contextRef="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjM4NTY_3fef6ed9-b000-4944-8b86-cda30835ce9e"
      unitRef="usd">500000</bngo:WarrantyAndMaintenanceRevenue>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTkxMzU_a1dc844a-c243-4c2a-8a1e-9ed0683de9f2"
      unitRef="usd">800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="ibec93384d0cb4cd38ec922514c5a2307_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTkzNzg_49b70317-3b7d-41fb-8795-0f63902db59f"
      unitRef="number">0.824</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="ic9a9995ad77a4d72a6747277f6afc40f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTk0MTY_a59040a4-1aeb-42ec-8ce1-e7e765173189"
      unitRef="number">0.138</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i7901fe27277a43038341f30e9235fb33_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTk0Mjg_7f08622a-dc79-457c-a654-11609105fe88"
      unitRef="number">0.023</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i72760e7d4c4d4bc29225a99c2b52e6a4_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzEwOTk1MTE3NTk0NDM_66e3ccbe-65bf-41ae-a657-0517c5a4e464"
      unitRef="number">0.015</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NzcyNzM_c3f3891a-81ef-422b-8857-bc23e4dbecd2"
      unitRef="usd">200000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NzcyODE_913d98d9-2e3f-410f-bbf7-b46c3644f379"
      unitRef="usd">200000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:ProductWarrantyExpense
      contextRef="ia421179e929849a0811736046100d29a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NzczODM_b59a874b-4f02-4620-8ec9-9faa3f965754"
      unitRef="usd">500000</us-gaap:ProductWarrantyExpense>
    <us-gaap:ProductWarrantyExpense
      contextRef="i02a66891cd81408b94c3dcf095dd9aa1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NzczOTE_5282e3a0-67af-4bdb-822a-e3ae1e98a229"
      unitRef="usd">400000</us-gaap:ProductWarrantyExpense>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA3MzI5NjA_d8ef1098-8e8c-4a68-87b1-6e998eb6c6b9"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA3MzI5NjQ_f80a1948-d35b-4ca7-9f1f-af4c18c4ccaa"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <bngo:CostOfGoodsAndServicesSoldPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzEw_1af49783-f4b6-4818-b208-cf7a9c863bd5">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue for products consists of the Company&#x2019;s raw material parts costs and associated freight, shipping and handling costs, contract manufacturing costs, royalties due to third parties, salaries and other personnel costs, equipment depreciation, overhead and other direct costs related to those sales recognized as product revenue in the period. &lt;/span&gt;&lt;/div&gt;Cost of service and other revenue consists of salaries and other personnel costs, and facility costs associated with costs related to warranties and other costs of servicing equipment at customer sites, and performance of diagnostics services.</bngo:CostOfGoodsAndServicesSoldPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzAy_19fc06d7-836a-4e03-97d1-fac20b5450c8">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for research and product development, including acquired technology and costs incurred for technology in the development stage, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzAz_c1887cf3-b984-4f78-8955-7f2e0736dfe6">Patent Costs Costs related to filing and pursuing patent applications are recorded as selling, general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzE5_169152b7-5349-45b9-b478-693a1c20468f">Stock-based CompensationThe Company issues stock-based awards as compensation to employees and directors. Stock-based awards may include stock options, stock appreciation rights, vesting stock awards and performance share awards. These awards are accounted for as equity awards. To-date, the Company recognizes stock-based compensation expense net of actual forfeitures on a straight-line basis over the underlying award&#x2019;s requisite service period, which is generally the vesting period, as measured using the award&#x2019;s grant date fair value.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5Mjk2_71ed1c0d-2a26-49ae-91f3-82003f95dc6e">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;The Company recognizes the impact of uncertain tax positions at the largest amount that is &#x201c;more likely than not&#x201d; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it does not have a greater than 50% likelihood of being sustained. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzA1_705dfed4-9b2e-4391-88eb-a8860910ef7a">Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company chief operating decision-maker, the Chief Executive Officer, views the Company&#x2019;s operations and manages its business as one operating segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI0MDcx_19114d16-c064-4b56-87a5-7a4d464fcb60"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzM2_a3ce5bd2-b1c4-453f-a45f-a6a159772244">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. Pre-funded warrants from the Company's follow-on offering have been treated as if they were common shares outstanding on the date of issuance.  The Company&#x2019;s potentially dilutive securities which include outstanding warrants to purchase stock and outstanding stock options under the Company&#x2019;s equity incentive plans have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. Restricted stock is treated as outstanding for accounting purposes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5MzIw_46e020cf-eee3-4004-810e-2ecab8facc21">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive were as follows (in common stock equivalent shares): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,765,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,174,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,006,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,778,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,464,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9b2ff0a385ec4419bd63ad02cc162c4f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzItMS0xLTEtMQ_1ba661cd-3096-4f0e-ab58-8488f45c048d"
      unitRef="shares">12765000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie803dd47b1c54023ad328f5a634b77a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzItMy0xLTEtMQ_84f534d9-6bbb-454d-8e5b-ede516018c63"
      unitRef="shares">5290000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ice0bf1763a264af2afecbaaa10564f18_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzMtMS0xLTEtMQ_88765171-b14b-416d-849e-955bcf4697ce"
      unitRef="shares">4356000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib7b1ff8dff57441e9939f8789ca2e6c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzMtMy0xLTEtMQ_6721151e-6c7d-49bd-a10f-ffc687911043"
      unitRef="shares">15174000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib55aca94255b45f7ba3ade3bbb054941_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMS0xLTEtNDYyMzY_b5dbd4ee-1405-49a6-9263-0244f940cdab"
      unitRef="shares">5006000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03ac604fde724aebbc7ddc5ec7989381_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMy0xLTEtNDY1OTk_d1b36cb6-4573-4a90-8f7b-f352cfbdeec9"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idfc32dda88c8491493b3a97900889e74_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMS0xLTEtMjY2Nzk_1caa88b1-5466-44a9-8dec-e1286fb292e6"
      unitRef="shares">361000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if65481e6e2e34f818b1abd233bbcb586_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMy0xLTEtMjY2OTA_ba0a2b5b-165a-4561-aef1-195bce26f36b"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9baa4e36abe6400f9c053d7f3434b31f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzUtMS0xLTEtMzMxMzI_46dd0284-ffb3-44f0-9b61-d1ab6383cc34"
      unitRef="shares">290000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9377784747ef4e6792d946ece3659fdb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzUtMy0xLTEtNDM0NzY_f4bcfcf1-35b7-4329-8f24-99437a157240"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMS0xLTEtMQ_c5ea2c47-d439-4cb4-b221-dabbcb243eec"
      unitRef="shares">22778000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90YWJsZTowMTk4Y2I4OWRjMDI0MjE5OWJkYzcyMmE3Njk4ZmZiNi90YWJsZXJhbmdlOjAxOThjYjg5ZGMwMjQyMTk5YmRjNzIyYTc2OThmZmI2XzQtMy0xLTEtMQ_557313d4-4d51-4410-8f21-353a2c2cc5ee"
      unitRef="shares">20464000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzI5Mjk1_4c4047a1-9e73-404f-ab32-c4087a189f2e">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued But Not Yet Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuer&#x2019;s Accounting for Certain Modifications or Exchanges for Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to clarify the accounting for modifications or exchanges of equity-classified warrants. The standard is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is in the process of evaluating the expected impact of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU 2021-04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on its financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and adoption must be as of the beginning of the Company&#x2019;s annual fiscal year. The Company&#x2019;s early adoption of this accounting standard on January 1, 2021, did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. In February 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, &#x201c;Leases (Topic 842)&#x201d; (&#x201c;ASC 842&#x201d;) which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASC 842 establishes a right-of-use model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. ASC 842 also requires disclosures to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard was adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on January 1, 2021, as the Company lost its status as an Emerging Growth Company effective December 31, 2021, and therefore was required to adopt the standard for the year ending December 31, 2021, using the modified retrospective method. Under this transition method, the Company recognized and measured leases that existed at the adoption date in the consolidated balance sheet as of January 1, 2021. In connection with the adoption of ASC 842, the Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company also made accounting policy elections not to apply the recognition requirements under ASC 842 to any short-term leases and to account for each separate lease and associated non-lease components as a single lease component for all the Company&#x2019;s leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption of ASC 842 resulted in recognition of operating lease assets and liabilities of approximately $2.1 million and $2.1 million, respectively, as of January 1, 2021, related to the lease of office and laboratory space. The comparative prior period information continues to be reported under ASC 840. The adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. For further details, see Note 11, Commitments and Contingencies. The adoption of the new standard did not materially impact the Company&#x2019;s consolidated results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities From Contracts With Customers. This ASU requires an acquirer to account for revenue contracts acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. Prior to ASU 2021-08, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers and other similar contracts, at fair value on the acquisition date. The guidance is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and should be applied prospectively to business combinations occurring on or after the effective date. Early adoption is permitted. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company adopted ASU 2021-08 on October 1, 2021, and applied the ASU prospectively to its acquisition that occurred in 2021.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifd45b65fd98e44ee92578a3812d0ebdf_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjI2MTY_de6d6b67-6cac-4714-8efe-1279b52175c9"
      unitRef="usd">2100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ifd45b65fd98e44ee92578a3812d0ebdf_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNTQvZnJhZzpjZjZiNmRiYjJlODk0YmFiOWVkNzI4ODBmYWEwZDY4ZC90ZXh0cmVnaW9uOmNmNmI2ZGJiMmU4OTRiYWI5ZWQ3Mjg4MGZhYTBkNjhkXzM4NDgyOTA4NjI2MjM_7c21e2a2-80fb-4c47-acb2-ece0497821f6"
      unitRef="usd">2100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF81NDk3NTU4MTU0OTE1_746b451f-182e-4472-b08e-0d13f4c4b01d">Revenue from Contracts with Customers&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue by Source&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,887,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,085,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,808,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,695,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,230,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,286,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,273,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,503,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue by Geographic Location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,329,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,489,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;EMEIA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,604,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,163,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,048,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;851,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,503,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables above provide revenue from contracts with customers by source and geographic location on a disaggregated basis. North America consists of the United States and Canada. EMEIA consists of Europe, the Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia. For the years ended December&#160;31, 2021 and 2020, sales in the United States represented 46% and 42% of revenues, respectively. During the year ended December&#160;31, 2021, sales in China accounted for 11% of total revenue. No other countries represented greater than 10% of revenue during the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF81NDk3NTU4MTU0OTE2_677a0e00-49ad-491b-8a35-0c538a622f22">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue by Source&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,887,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,085,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,808,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,695,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,230,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,286,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,273,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,503,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue by Geographic Location&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,329,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,489,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;EMEIA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,604,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,163,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,048,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;851,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,503,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i796761a85df6417896123b60211dc456_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV8yLTEtMS0xLTQ1NTgz_ad10da36-619e-4016-a8b5-61f08bba11f1"
      unitRef="usd">5887000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4cd58ed3c4a43c7accda85e938edcc0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV8yLTMtMS0xLTQ1NTgz_6688c695-dffd-4b47-823a-b5489637c7f6"
      unitRef="usd">3085000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e3054d21f6f4798b007ef1b3abea827_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV8zLTEtMS0xLTQ1NTgz_125384a5-9c69-414a-a726-e5af0e711831"
      unitRef="usd">5808000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac08b5e748c44125918877c58eeb2adc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV8zLTMtMS0xLTQ1NTgz_507c7c59-6eb6-458a-8792-1a8392ff6d1b"
      unitRef="usd">3145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if19fb7ce82b047a9bf86be402ad9bed1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV80LTEtMS0xLTQ1NTgz_39df2fc2-8f84-4032-be5e-a495572b75cc"
      unitRef="usd">11695000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48b44bcc554b4d9c87da5e86d45608ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV80LTMtMS0xLTQ1NTgz_bad60275-cb7a-4801-9bf2-bdf92b2e66b4"
      unitRef="usd">6230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70e447b3fffd46cbbdf13752253aa376_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV81LTEtMS0xLTQ1NTgz_58e309a1-9aeb-480e-b710-46ec04f14fdc"
      unitRef="usd">6286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b5f4dcf4e43418da56ae22fc33ad970_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV81LTMtMS0xLTQ1NTgz_decb62a8-f87f-4222-b8e6-881ea44b07fd"
      unitRef="usd">2273000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV82LTEtMS0xLTQ1NTgz_73970957-14c4-4c45-9dbe-38dc7258fdee"
      unitRef="usd">17981000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6NGVhMzg3MzJmZjIyNGQwNTk5N2I2MTM0Y2MzYjYzZTkvdGFibGVyYW5nZTo0ZWEzODczMmZmMjI0ZDA1OTk3YjYxMzRjYzNiNjNlOV82LTMtMS0xLTQ1NTgz_c30bedc4-025e-4d6c-9d42-d3f4027ac293"
      unitRef="usd">8503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c68a12eca334a838f030a41e51a46b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV8zLTEtMS0xLTQ1NTgz_ffcc9409-8d7c-49ab-aa5c-bc6bd127c594"
      unitRef="usd">9329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4ff8553873fd49468f9f75a5c165e98f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV8zLTMtMS0xLTQ1NTgz_4951d867-7394-49f0-8dbc-8cad2347ff28"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7c615c6f945420e93b92d85cf0b8c01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV8zLTUtMS0xLTQ1NTgz_08ee92d1-aabe-46b0-a185-15ae5a34b21e"
      unitRef="usd">4489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic0873412be8547959d4aa0e904da5fca_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV8zLTctMS0xLTQ1NTgz_ada2a93e-0c27-401e-875d-7ea096217d51"
      unitRef="number">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89f08d0b9d254e4cb81421c9274acb67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV80LTEtMS0xLTQ1NTgz_d61873e6-6df8-4df2-97ae-2189715595ce"
      unitRef="usd">5604000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i763f202ae44a40c09fe53b95d9006d97_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV80LTMtMS0xLTQ1NTgz_1086c045-b325-4d96-bbe9-da14c19487a9"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b47aea725d34079a308232d226a3001_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV80LTUtMS0xLTQ1NTgz_9fbf9f78-e6d4-4e97-bc70-d711147b0fce"
      unitRef="usd">3163000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id4169c1867a245108d470229bac5dbac_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV80LTctMS0xLTQ1NTgz_c47e8118-6b87-44a3-8d69-7b7ce7cfda51"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f8f8c29630a401a88a5285f57e55166_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV81LTEtMS0xLTQ1NTgz_59868c7d-64f3-4cf1-86bb-b96d2f6ecddc"
      unitRef="usd">3048000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i76c0e564fd0c4699af8abe0b4a4a8f5b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV81LTMtMS0xLTQ1NTgz_5a41604c-6392-4629-bf2b-5e46731a736d"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i639735ace7a54defa242bf743d278ad3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV81LTUtMS0xLTQ1NTgz_cc6b8b81-c84b-4c40-954b-fbad881e689b"
      unitRef="usd">851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iede1a65bd15f4596838c10a96b56c281_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV81LTctMS0xLTQ1NTgz_b487c35a-ef03-44af-b0e7-e50ad87d609c"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV82LTEtMS0xLTQ1NTgz_ae2130c3-eb33-4cc2-82f7-7a2677bac73c"
      unitRef="usd">17981000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i86bea6db7f4248ed94253fad6c47e824_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV82LTMtMS0xLTQ1NTgz_1c596456-e30c-4ff5-8156-330a1496f600"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV82LTUtMS0xLTQ1NTgz_ab86dfe5-0f52-468e-a966-844fe42d4976"
      unitRef="usd">8503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i029ea0650fb04082a13c21022c54f216_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGFibGU6ZDFhMWJiNTAxNDlhNDk3MmE1YWExNzM3MjhiNWRhMWEvdGFibGVyYW5nZTpkMWExYmI1MDE0OWE0OTcyYTVhYTE3MzcyOGI1ZGExYV82LTctMS0xLTQ1NTgz_3fb05ad1-20da-450d-81ca-89cb26bf59eb"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia60395f370984c03913b1237f78f5f74_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF8zODQ4MjkwNjk4Njgw_d87b323c-fc6e-49c9-94f6-1cf16dec8277"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie85c1983cea24f5fbb6e90a2a347fd4f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF8zODQ4MjkwNjk4Njg1_47915f0d-8984-438a-bafa-f8cf819dab33"
      unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie758ad97885e40af865734d6d0735fbd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNjEyL2ZyYWc6MTUxZDdkYWNjZjBkNGRiNzgzM2FhNDcyZmQzYTkyNjQvdGV4dHJlZ2lvbjoxNTFkN2RhY2NmMGQ0ZGI3ODMzYWE0NzJmZDNhOTI2NF8zODQ4MjkwNjk4Nzgw_c4cb9411-f66f-4536-83dc-dd62c46d7c34"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzE4NTQ_292040bf-248f-430e-80fa-c51af53e9e3c">Investments and Fair Value Measurements &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that are not re-measured at fair value include cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company&#x2019;s long-term debt approximates its fair value due to the market rate of interest which was determined to be a Level 2 measurement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The carrying values of these financial instruments approximate their fair values. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis in the Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Fair Value and Carrying Value on Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurement&#160;Category&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Notes/Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,181,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,181,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Investments:&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,041,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,041,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,126,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,126,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,066,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,066,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money Market Funds are classified as cash equivalents on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the contingent consideration liability is reassessed on a quarterly basis using the income approach. Assumptions used to estimate the acquisition date fair value of the contingent consideration include the probability of achieving certain milestones and a discount rate of 3.2%. The fair value measurement of the contingent consideration is based on significant inputs not observed in the market (Level 3 inputs). Significant inputs used in the measurement include probabilities of achieving the remaining milestones, which depend on the milestone risk profile. The change in fair value of the contingent consideration during the year ended December&#160;31, 2021 was due to the passage of time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in estimated fair value of contingent consideration liability in the year ended December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Contingent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(Level 3&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Measurement)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability recorded as a result of current period acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value, recorded in selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,066,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not hold any investments as of December&#160;31, 2020. As of December&#160;31, 2021, the Company held 57 securities in an unrealized loss position for a period of less than 12 months resulting in an unrealized loss of $0.5 million included in other comprehensive income during the year ended December&#160;31, 2021. None of the Company&#x2019;s available-for-sale investment securities were in a material unrealized loss position at December&#160;31, 2021. As such, the Company has not recognized any impairment in its financial statements related to its available-for-sale investment securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company received proceeds of $86.5 million relating to sales and maturities of its available for sale securities, and recognized a loss of $8,000 in other income relating to the sale of these securities. Amounts are reclassified out of accumulated other comprehensive income into earnings using the specific identification method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate Notes/Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,929,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,478,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,929,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in interest income for the year ended December&#160;31, 2021 was interest income related to the Company&#x2019;s available for sale securities of $0.4 million. All interest income related to the available for sale securities in 2021 related to year ended December&#160;31, 2021. All available-for-sale securities are classified as current assets, even if the maturity when acquired by the Company is greater than one year due to the ability to liquidate within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzU0OTc1NTgxNDM0Mzg_0b04c908-6313-4c87-8f0c-0cef41b5e022">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis in the Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Fair Value and Carrying Value on Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurement&#160;Category&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,860,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Notes/Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,181,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,181,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Investments:&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,041,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226,041,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money Market Funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,126,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,126,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,066,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,066,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i64252642d88c4f9a8cdb7a3c4abb6daa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzQtMS0xLTEtMjM5NzY_7c2bb0b2-0ddb-4593-ada0-3296d3facad4"
      unitRef="usd">100860000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4fd395e693f843f68c015a3fb16e63e0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzQtMy0xLTEtMjM5NzY_885a4056-5ebd-418d-af36-f17b0264380e"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i45b6072efea34c43a77e7e2a8d672e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzQtNS0xLTEtMjM5NzY_91469593-abad-4787-ad7e-b7730c7e96d4"
      unitRef="usd">100860000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5fd8b99cec464ca2a5fbc78e6d86bd6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzQtNy0xLTEtMjY3ODA_34c40a7e-4fa1-4fd6-9834-c36b1695ccb7"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i21077c1aab5d457cb1cdf940f451908e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzUtMS0xLTEtMjM5NzY_93d7450b-478e-447f-a366-5bb32517c625"
      unitRef="usd">125181000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibfba7f0bab47499d9d16e7fcfea7c8e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzUtMy0xLTEtMjM5NzY_30fceb46-f9f9-4dd5-805f-d0dd3adeddee"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i66e1e879fb554dcaa245d830024b147c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzUtNS0xLTEtMjM5NzY_55d7a137-55ee-4559-a719-171db9064875"
      unitRef="usd">125181000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iad7080a2ac2845729f17c608390c3daf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzUtNy0xLTEtMjY3ODA_6bad2b9e-773c-4306-849e-332bce82d8a3"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i678854c029c5451f9cf24fe07efbf514_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzYtMS0xLTEtMjY3Njc_07741a9a-5ae0-4aa1-8af0-18953c6c90c5"
      unitRef="usd">226041000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5b0ee927463d486baa5cba33982c2569_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzYtMy0xLTEtMzE5NjE_1dd49086-2f0b-4e82-bf1a-032db20a08fd"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic609659d259845b3a37a1bf8b59de543_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzYtNS0xLTEtMjY3ODA_3b989ffa-ab90-4db2-a057-ec573b8e24f1"
      unitRef="usd">226041000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7d1a6733a3f14bf2972c366549628e23_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzYtNy0xLTEtMzE5NjE_5df88368-9019-4418-bad2-7f7d654db0c6"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i219dd660a26b49beb67b572a81c81389_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzctMS0xLTEtMjM5NzY_394af263-ea30-46ab-8197-615de88ef2f6"
      unitRef="usd">11126000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id3289f5383254228be7158bd06d11bfb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzctMy0xLTEtMjM5NzY_4e4c920f-0742-42f3-ab9b-95afa3841315"
      unitRef="usd">11126000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2a26c057095f4a36a0b30546701c58f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzctNS0xLTEtMjM5NzY_eb1cc238-b88e-438b-849e-d12d2d926afd"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i467ef72acc6840729feb7f12f3a6e516_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzctNy0xLTEtMjY3ODA_ec72e8a4-36db-4e81-9bf0-9a6d71bedb0f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ie93e575b671b4188b8e1e04eb90b0d27_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzktMS0xLTEtNDAwMzA_1a42b91a-ebc9-4e78-ba7b-a62daa6f9d50"
      unitRef="usd">9066000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ica9bc63b1b5444dea0111bbe4ec8f8bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzktMy0xLTEtNDM4ODU_39c2a61b-9cfc-4ac9-b078-82c84ef962df"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ie1484c4dbff544b29b2781e84672dded_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzktNS0xLTEtNDAwMzI_6a2f00bb-4630-48eb-86f3-ecf589037f40"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="iefe2bac092bd4c778f47ddbc97f1d0c3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTplNWYwODQxM2U0NTY0MTE2YTA3ZmMyMjY0YzFmOTg1Mi90YWJsZXJhbmdlOmU1ZjA4NDEzZTQ1NjQxMTZhMDdmYzIyNjRjMWY5ODUyXzktNy0xLTEtNDAwMzY_8a5d641f-b473-41ed-9211-ce418f80ae40"
      unitRef="usd">9066000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ServicingLiabilityMeasurementInput
      contextRef="i1cf405044e174ea88a98016ca955831d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzM4NDgyOTA3MTk0Mzk_af5c3f55-fc63-4bff-a1fa-ea9be7c75941"
      unitRef="number">0.032</us-gaap:ServicingLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzU0OTc1NTgxNjIyMDM_72e62ad1-cff4-483a-905c-ef6de3635ea7">Changes in estimated fair value of contingent consideration liability in the year ended December&#160;31, 2021 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Contingent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(Level 3&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Measurement)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Liability recorded as a result of current period acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value, recorded in selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,066,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id637a744712b44988d29a346fc913709_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzEtMS0xLTEtNDQyODc_671f4ae5-0547-42b0-929b-59457656c1a4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzItMS0xLTEtNDQyODc_acf3a380-3125-461e-a7e9-76e6605f46b9"
      unitRef="usd">9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzMtMS0xLTEtNDQyODc_d244be2c-d00e-40c1-bf32-046f44644a3b"
      unitRef="usd">66000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzQtMS0xLTEtNDQyODc_32a483ce-5ff2-42da-abbf-810a22950e7b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic1ba840538fd4b0791ae9c324539369e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0YmRmMGU5MmJjZTc0NTM5ODgxNzQzZTI5MjYwYmUwNy90YWJsZXJhbmdlOjRiZGYwZTkyYmNlNzQ1Mzk4ODE3NDNlMjkyNjBiZTA3XzUtMS0xLTEtNDQyODc_78a0fa60-997f-44b1-a56f-4dec372e4095"
      unitRef="usd">9066000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzM4NDgyOTA3MDE3OTU_72bfbea8-746d-4344-ab9f-b9b26da6d977"
      unitRef="lease">57</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzQzOTgwNDY1MjU0MDE_eec3cc45-55e4-487d-859e-22857b3b21c1"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzQzOTgwNDY1MTY2MDE_57a0146f-0c5a-4283-ab7b-10c682bbae34"
      unitRef="usd">86500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzQzOTgwNDY1MTY2MDU_64c25888-87d3-402e-8b64-513b7ed244c7"
      unitRef="usd">-8000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzU0OTc1NTgxNDM0Mzk_1a25f6ff-c966-465e-91a7-967696b2b997">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate Notes/Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,929,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,478,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,929,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzItMS0xLTEtMjM5NzY_a632546a-c9b0-48db-95be-c760facbb1e3"
      unitRef="usd">100929000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzItMy0xLTEtMjM5NzY_7c1a51a3-060f-4903-9788-1f033deae98f"
      unitRef="usd">69000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzItNS0xLTEtMjM5NzY_cef63ab4-93d8-46ec-8e96-2e36d6453b9c"
      unitRef="usd">41173000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzItNy0xLTEtMjM5NzY_58d746fd-9272-442b-99f2-467a71b4cea7"
      unitRef="usd">61000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzMtMS0xLTEtMjM5NzY_d271421d-4b5d-4548-ae3e-a2b0be1fddb8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzMtMy0xLTEtMjM5NzY_63bf73ea-f2cb-4c1b-a015-dbd363e6bf22"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzMtNS0xLTEtMjM5NzY_1183fb06-b335-41a0-a4e5-d14fd4a65a5f"
      unitRef="usd">84478000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzMtNy0xLTEtMjM5NzY_0830a2fa-f1cb-4a67-868c-f33779ff6185"
      unitRef="usd">409000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzQtMS0xLTEtMjM5NzY_790920c6-5d3a-4e1b-9356-7822e0387334"
      unitRef="usd">100929000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzQtMy0xLTEtMjM5NzY_1808398b-2e20-4835-95af-9c01c3856a3e"
      unitRef="usd">69000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzQtNS0xLTEtMjM5NzY_1818aff4-d99f-4372-acf3-762238a11e00"
      unitRef="usd">125651000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5544954547a5409f8662da2a285cdb1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90YWJsZTo0ODRiYzhkMjJiNjY0ZTI2ODIyNmYxYjA2NDc0ZGU3NS90YWJsZXJhbmdlOjQ4NGJjOGQyMmI2NjRlMjY4MjI2ZjFiMDY0NzRkZTc1XzQtNy0xLTEtMjM5NzY_c58859d9-0f2c-46ae-b48d-59e54631e6c1"
      unitRef="usd">470000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjAvZnJhZzo0Y2I1YjY0NmQ1OTY0Y2ViYWQ1NjFkMDVmMWEyNWI2OC90ZXh0cmVnaW9uOjRjYjViNjQ2ZDU5NjRjZWJhZDU2MWQwNWYxYTI1YjY4XzM4NDgyOTA3MDE3NjI_db034ce8-9e2e-4421-9394-bafd0fa9a787"
      unitRef="usd">400000</us-gaap:InvestmentIncomeInterest>
    <bngo:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90ZXh0cmVnaW9uOjBlYTQ0MjM0MGM5NzQzZjJhZWVkNzVjNDYzZmIxN2FhXzEyMQ_f02ee080-6236-46de-9b3e-150e22b5fd28">Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepayment to supplier&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,461,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,348,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,481,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bngo:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90ZXh0cmVnaW9uOjBlYTQ0MjM0MGM5NzQzZjJhZWVkNzVjNDYzZmIxN2FhXzEyMw_87b01bef-0aef-44e4-8972-e0ccf64b3b75">Prepaid expenses and other current assets consist of the following: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepayment to supplier&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,146,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,461,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,348,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,481,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:Supplies
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzEtMS0xLTEtMQ_9abd47ec-4d2c-44fb-b3cc-14ebf3c2d1ee"
      unitRef="usd">285000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzEtMy0xLTEtMjY5Mjc_82d7a32e-5eed-4655-a452-629b2c588efd"
      unitRef="usd">1146000</us-gaap:Supplies>
    <us-gaap:PrepaidInsurance
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzItMS0xLTEtMQ_301b341f-6475-49d9-b0c5-f9cd3940527d"
      unitRef="usd">1461000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzItMy0xLTEtMjY5Mjc_2ee4e4b9-8f90-4a5b-9503-8214d8928a67"
      unitRef="usd">642000</us-gaap:PrepaidInsurance>
    <us-gaap:InterestReceivableCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzMtMS0xLTEtMzM0NTE_9fce8413-bdfb-40a5-bab4-51dc0e77051f"
      unitRef="usd">387000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzMtMy0xLTEtMzM0NTc_47104577-7689-4086-89e6-2ea41573ec3d"
      unitRef="usd">0</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzMtMS0xLTEtMQ_3eba9055-2798-4c33-a689-fd222b05fd8b"
      unitRef="usd">2348000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzMtMy0xLTEtMjY5Mjc_4a1a2d65-0e1c-45e7-aca5-cd75375f8cbd"
      unitRef="usd">462000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzQtMS0xLTEtMQ_1257045e-0d50-4730-8d5b-4553ed01b72e"
      unitRef="usd">4481000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjMvZnJhZzowZWE0NDIzNDBjOTc0M2YyYWVlZDc1YzQ2M2ZiMTdhYS90YWJsZTplNTcxZTBmZmU3MTQ0ODYxOGQzODQ2ZjRmNDZlZGNhMi90YWJsZXJhbmdlOmU1NzFlMGZmZTcxNDQ4NjE4ZDM4NDZmNGY0NmVkY2EyXzQtMy0xLTEtMjY5Mjc_d84645ed-489e-4438-85b8-8bfc1857187c"
      unitRef="usd">2250000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzI3MA_44bc9d87-9865-4d8e-b7a7-ba79a91390a5">Property and Equipment, Net &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,341,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,718,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service equipment placed at customer sites&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,556,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,267,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,674,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,889,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,390,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,366,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,072,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,456,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,318,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,910,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;For the years ended December&#160;31, 2021 and 2020, the Company recorded depreciation expense of $1.9 million and $1.4 million, respectively, which includes an allocation to cost of revenue of $0.9 million, $0.5 million, and $41,000 respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzI3MQ_50bec9cf-6e9e-47a2-9cca-c4a9403eef7b">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,341,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,718,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service equipment placed at customer sites&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,556,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,267,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,674,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,889,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,390,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,366,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,072,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,456,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,318,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,910,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i970b26562f48462b986160dadd23e2e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzEtMS0xLTEtMQ_c2691198-ab33-474d-954b-e38f9291fe7e"
      unitRef="usd">819000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9431acbfefa14bc1a8c51e9791630133_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzEtMy0xLTEtMQ_b7592892-89f8-4ba8-ba08-4e32c66fa079"
      unitRef="usd">492000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0e966a20a2d94bd6ac86960b0db2e83b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzItMS0xLTEtMQ_ce5a674c-18c0-4987-a2c7-aa7b60b9c244"
      unitRef="usd">9341000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if7c44f25d40c4d78a5d9623e10febeb0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzItMy0xLTEtMQ_7ca745d9-dbf8-4814-bfbf-f65cd8d949f7"
      unitRef="usd">6718000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib110b6c1e25a43b190344fed192d23fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzMtMS0xLTEtMQ_0c590d9e-bb93-4ce4-bce3-ae2aaa8b43bb"
      unitRef="usd">6556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6cdf5494bbd9490295ca735e1ec45cfd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzMtMy0xLTEtMQ_ccfd9971-62ca-4329-8c8a-b74b60fc9cd6"
      unitRef="usd">3267000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i386f22e822f8474daca8ae8933acbb26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzQtMS0xLTEtMQ_6d8a1c43-4b85-48a1-b419-1783e2dc1b60"
      unitRef="usd">2674000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifa83cb53f8d446e58b64dd7b82b48311_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzQtMy0xLTEtMQ_02c56cfc-f317-4765-8421-25fc3c4b623e"
      unitRef="usd">1889000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzUtMS0xLTEtMQ_56768343-5b3f-4d8f-b3c8-54e6405c7970"
      unitRef="usd">19390000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzUtMy0xLTEtMQ_29b367a5-46f4-42c7-b293-33fa01f72cc3"
      unitRef="usd">12366000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzYtMS0xLTEtMQ_455c83b3-51be-48be-bbca-7fd6c9e220db"
      unitRef="usd">9072000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzYtMy0xLTEtMQ_32cf4f4f-a33c-4925-a828-d2c178bf0df3"
      unitRef="usd">7456000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzctMS0xLTEtMQ_5c1c6f39-0574-4af0-b36e-13463f861b30"
      unitRef="usd">10318000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90YWJsZToxMTUyMTEzMmJiNWY0Mjg5YmIxNWI3NTY3MTZkNzYyOC90YWJsZXJhbmdlOjExNTIxMTMyYmI1ZjQyODliYjE1Yjc1NjcxNmQ3NjI4XzctMy0xLTEtMQ_9d15a5df-8ca0-4493-899c-ad73231c9a66"
      unitRef="usd">4910000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzM4NDgyOTA2OTc2MTg_d6895309-3c7d-447a-be9e-3c1a885048a1"
      unitRef="usd">1900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzM4NDgyOTA2OTc2MjI_ca2f40ce-d80d-43e6-aac8-7215d03bfa98"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iaba22332706445abbde9bbbbbea71f04_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzM4NDgyOTA2OTc1ODE_8b988bd4-c1b0-4cb5-a906-5cfb44c275e0"
      unitRef="usd">900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7d2d20d9c1274e4e8d7386137b4f34ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzI1Mg_9f258487-af1f-4ca5-b90e-7db2b36a0fa5"
      unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i81e2dc0ae87648a58b8afa4c80a78bce_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjYvZnJhZzo4NWNlNzY3YTRlNWM0MzgxOGU3MThmOTBlNTVlZTdkMi90ZXh0cmVnaW9uOjg1Y2U3NjdhNGU1YzQzODE4ZTcxOGY5MGU1NWVlN2QyXzM4NDgyOTA2OTc1NDc_899459e8-5bc8-41a5-bf83-dfeb78fd376f"
      unitRef="usd">41000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQ4Nw_eaf154d7-cf1c-47ef-97b5-9e809e46501b">Intangible Assets, Net &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that are subject to amortization consisted of the following at December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(210,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,420,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;588,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(378,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,572,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(950,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,850,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,538,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,842,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(105,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization expense for intangible assets of $1.4 million and $0.1 million for the years ended December&#160;31, 2021 and 2020 respectively, in selling, general and administrative expenses. The customer relationships and trade name intangibles from the Lineagen acquisition are both being amortized on a straight-line basis over their estimated useful lives of 5 years, and have remaining amortization periods of 3.6 years. The customer relationships, developed technology and trademark intangibles from the BioDiscovery acquisition are being amortized on a straight-line basis over their estimated useful lives of 5 years, and have remaining amortization periods of 4.8 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense of intangible assets is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,676,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,676,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,676,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,571,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,243,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,842,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQ4OQ_a893b81f-ae70-4767-92f2-48a2bfb0a8ae">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that are subject to amortization consisted of the following at December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(210,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,420,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;588,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(378,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,572,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(950,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,850,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,538,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,842,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(105,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a480bc32add481ea931915f5e4e20a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItMi0xLTEtMjcyODM_40f463c3-3cc1-4688-ba9f-f9fa0eade8ed"
      unitRef="usd">1630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a480bc32add481ea931915f5e4e20a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItNC0xLTEtMjcyODM_1fce2b5e-3350-4c47-9649-04a7aec8f698"
      unitRef="usd">210000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0a480bc32add481ea931915f5e4e20a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItNi0xLTEtMzc5MjQ_eef564ec-f408-4b4f-8bfa-448766b6b924"
      unitRef="usd">1420000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6af5f30224ff436d833405ae9d5be9ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItOC0xLTEtMzc5NTM_9da366c9-664f-435b-8207-d641e08d022c"
      unitRef="usd">630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6af5f30224ff436d833405ae9d5be9ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItMTAtMS0xLTM3OTUz_57fc9684-ea60-4377-8ca6-b55dc20ba09f"
      unitRef="usd">42000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6af5f30224ff436d833405ae9d5be9ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzItMTItMS0xLTM3OTUz_5975e156-44c1-452b-85aa-70c47b22e30e"
      unitRef="usd">588000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6981036f191b41ae8e646c1a85e17819_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtMi0xLTEtMzQwNjY_b4bb254f-9df0-4bb4-abb6-8b9548ae41f8"
      unitRef="usd">3950000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6981036f191b41ae8e646c1a85e17819_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtNC0xLTEtMzQwNjY_114f34d3-532e-4532-84f4-b390f5c21c47"
      unitRef="usd">378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6981036f191b41ae8e646c1a85e17819_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtNi0xLTEtMzc5MjQ_f498ff85-d9da-44e3-a06c-68d7f13e1635"
      unitRef="usd">3572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i79aff88d479e4c73bf896e7479d3d66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtOC0xLTEtMzc5NTM_299fe93a-0187-47f0-ad0f-cdffa7b511ef"
      unitRef="usd">950000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i79aff88d479e4c73bf896e7479d3d66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtMTAtMS0xLTM3OTUz_858bbdf4-b703-43f9-9f92-606753ce554e"
      unitRef="usd">63000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i79aff88d479e4c73bf896e7479d3d66f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzMtMTItMS0xLTM3OTUz_f3d833eb-c7b9-45d1-8a0d-feb811c56006"
      unitRef="usd">887000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib45196371119428bb263f59a387de373_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtMi0xLTEtMzQwNjY_fe54dc25-eabc-4123-b74c-0f7da2184311"
      unitRef="usd">22800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib45196371119428bb263f59a387de373_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtNC0xLTEtMzQwNjY_1bd87950-263c-4961-8904-e10090d8cf03"
      unitRef="usd">950000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib45196371119428bb263f59a387de373_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtNi0xLTEtMzc5MjQ_5f92e00f-1362-471f-9dc8-91a857149dd9"
      unitRef="usd">21850000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic33d1be42b47486b97d23a00612757c8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtOC0xLTEtMzc5NTM_13963044-feae-4191-9eae-238c2b0fb714"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic33d1be42b47486b97d23a00612757c8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtMTAtMS0xLTM3OTUz_c547f26b-8428-4dd0-b58d-57c07eee7fbf"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic33d1be42b47486b97d23a00612757c8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtMTItMS0xLTM3OTUz_c5571e1c-99e3-447e-8cdd-580bbd889bfd"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtMi0xLTEtMjcyODM_23209874-4402-403e-9684-255cfa5deb30"
      unitRef="usd">28380000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzQtNC0xLTEtMjcyODM_42bf8ade-6599-4357-a1e7-4533ed09c3ed"
      unitRef="usd">1538000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzUtNi0xLTEtMzc5NTI_19840bf0-90d8-48b5-bdaf-fdc4421d151a"
      unitRef="usd">26842000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzUtOC0xLTEtMzc5NTM_4e0eb9cf-b26b-40be-8d2b-ed2e91e901ac"
      unitRef="usd">1580000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzUtMTAtMS0xLTM3OTUz_eecec8e4-b883-4359-a82b-75f35dfb5864"
      unitRef="usd">105000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZTo2YzYzMTgxNmE1N2Q0NDA4OWMxZWVjOTEzNDUyNTFmYi90YWJsZXJhbmdlOjZjNjMxODE2YTU3ZDQ0MDg5YzFlZWM5MTM0NTI1MWZiXzUtMTItMS0xLTM3OTUz_b16324c7-896b-47d7-82f5-f40f9c6bf8e7"
      unitRef="usd">1475000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQzOTgwNDY1MTE5Mjc_658d499e-c50c-4d0a-9888-2734c4f6d69f"
      unitRef="usd">1400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQzOTgwNDY1MTE5MzE_a5400a92-eca6-47a8-8699-6533dabab900"
      unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="icb5ee1e4c6bd48d2be372e02f845f9f7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzM4NDgyOTA2OTg1Nzc_1f8e10f1-abd8-44fe-9d6c-298de0cf1850">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="icb5ee1e4c6bd48d2be372e02f845f9f7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQzOTgwNDY1MTIwNDc_f32b670e-dcac-41f2-bb38-7f171c8cf779">P3Y7M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6ac9d5e475ba4422a72f931d6569a467_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzM4NDgyOTA2OTg1NjE_9ba06e4a-50fa-4809-8492-e94d03d53b5e">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i6ac9d5e475ba4422a72f931d6569a467_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQzOTgwNDY1MTIzMTA_1f0a8bff-cc3a-4fb0-976a-cd737e973132">P4Y9M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90ZXh0cmVnaW9uOmFmZDk5ZWVmNWI5NzQzNjc4YjgzYjczYzE2MjQ4OGVhXzQ4Ng_be50df7a-a0ec-4ab7-bb4d-cfdff51ed722">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense of intangible assets is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,676,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,676,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,676,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,571,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,243,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,842,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzEtMS0xLTEtMQ_0b1f3689-0af8-42fa-93c5-11c13797dd6a"
      unitRef="usd">5676000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzItMS0xLTEtMQ_0ad02a6c-4241-4c7d-bad8-d29818acd8bc"
      unitRef="usd">5676000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzMtMS0xLTEtMQ_785326f1-c29c-4f42-8577-238c39b41c4c"
      unitRef="usd">5676000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzQtMS0xLTEtMQ_6f08c9a0-46f6-4396-bfbe-475dbc14f270"
      unitRef="usd">5571000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzQtMS0xLTEtMzQyNTM_818b7a9e-e654-4240-9d16-b5e69812a56e"
      unitRef="usd">4243000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNjkvZnJhZzphZmQ5OWVlZjViOTc0MzY3OGI4M2I3M2MxNjI0ODhlYS90YWJsZToyNjVmOWUyNzQ5NDc0MDZjYTY3ZDJiNGEyYTgzNDI3OS90YWJsZXJhbmdlOjI2NWY5ZTI3NDk0NzQwNmNhNjdkMmI0YTJhODM0Mjc5XzUtMS0xLTEtMQ_d466d75d-a34e-4705-b9e1-91a6620154e5"
      unitRef="usd">26842000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90ZXh0cmVnaW9uOjIxOGM5MTE2NmMwZjRiOTlhZTU3NzMyZGM5OTJmMjhmXzcz_b12a722a-ae4b-4d16-b7c6-97e84689499e">Accrued Expenses &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,529,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,251,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goods received not invoiced&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,073,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;562,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Insurance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,694,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90ZXh0cmVnaW9uOjIxOGM5MTE2NmMwZjRiOTlhZTU3NzMyZGM5OTJmMjhmXzc0_e1ab2675-c843-4aaa-9763-4a8bdf444f22">Accrued Expenses &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,529,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,251,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goods received not invoiced&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,073,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;562,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Insurance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,694,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90ZXh0cmVnaW9uOjIxOGM5MTE2NmMwZjRiOTlhZTU3NzMyZGM5OTJmMjhmXzc2_2e6ccefe-0cb5-4202-a5e6-ce6ceb189207">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,529,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,251,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goods received not invoiced&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,073,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;562,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Insurance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,694,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90ZXh0cmVnaW9uOjIxOGM5MTE2NmMwZjRiOTlhZTU3NzMyZGM5OTJmMjhmXzc3_4bf48228-c03a-4558-9541-3007c18489d9">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,529,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,251,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goods received not invoiced&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,073,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;562,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Insurance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees and royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warranty liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,694,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzEtMS0xLTEtMQ_51284d93-ff25-41d1-b416-78b3c863593d"
      unitRef="usd">4529000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzEtMy0xLTEtMQ_393615b7-e2bf-4af4-b471-ba8b0add7430"
      unitRef="usd">3251000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bngo:AccruedInventoryCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzMtMS0xLTEtMQ_987942f0-e39b-4841-a1b3-4c219b20d6a2"
      unitRef="usd">1073000</bngo:AccruedInventoryCurrent>
    <bngo:AccruedInventoryCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzMtMy0xLTEtMQ_b10fdf2d-fc52-44ad-8a27-3de4af1f42d6"
      unitRef="usd">567000</bngo:AccruedInventoryCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzQtMS0xLTEtMQ_a13bac61-70af-4421-9d83-e81bb5311ba8"
      unitRef="usd">677000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzQtMy0xLTEtMQ_9e6aec31-2150-4dc6-b16a-84d5e7d5e86f"
      unitRef="usd">562000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzUtMS0xLTEtMQ_32de7254-3fd5-4929-9943-10d728121f20"
      unitRef="usd">1011000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzUtMy0xLTEtMQ_8d3eb650-79c3-45c9-8117-da00eefdf6d9"
      unitRef="usd">358000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzYtMS0xLTEtMQ_00e84062-ac05-476b-a52e-d113f76e1432"
      unitRef="usd">288000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzYtMy0xLTEtMQ_ee795122-3dda-49db-bb68-e66991536486"
      unitRef="usd">247000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzctMS0xLTEtNDg0NDM_ea441cc3-0ab7-4af0-8c3a-f5bbad245bb4"
      unitRef="usd">175000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzctMy0xLTEtNDg0NDM_996e8e63-e5af-424b-9859-410dc4208c70"
      unitRef="usd">113000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzctMS0xLTEtMQ_efaabcd4-a109-45d3-be76-327e798b7c30"
      unitRef="usd">0</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzctMy0xLTEtMQ_8398a4ad-962f-4bc1-9f55-15b13acf2f0f"
      unitRef="usd">98000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzgtMS0xLTEtMQ_333d5fa7-8606-4f4f-a111-9f3d70d6cee6"
      unitRef="usd">1941000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzgtMy0xLTEtMQ_3102a820-7ceb-4ab1-8ade-597c8f2a0a00"
      unitRef="usd">403000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzktMS0xLTEtMQ_fd4eac02-3b40-454a-aa91-fdbb0181c557"
      unitRef="usd">9694000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzIvZnJhZzoyMThjOTExNjZjMGY0Yjk5YWU1NzczMmRjOTkyZjI4Zi90YWJsZTo3OGFiMDlhNmE0MDU0ODMwYWZlOWZkNzVmYjY0MGVhYy90YWJsZXJhbmdlOjc4YWIwOWE2YTQwNTQ4MzBhZmU5ZmQ3NWZiNjQwZWFjXzktMy0xLTEtMQ_6198ec8c-672f-487f-a1e5-b9f5bd94cd36"
      unitRef="usd">5599000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzExODIz_d5621666-6201-4c48-b8b0-fe422d673962">Long-Term Debt&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Paycheck Protection Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2020, the Company received the PPP Loan proceeds of approximately $1.8&#160;million pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) administered by the U.S. Small Business Administration (the &#x201c;SBA&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PPP Loan accrued interest at a rate of 1% per annum and was subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act. In February 2021, the Company applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. A gain on forgiveness of Paycheck Protection Program loan of $1.8&#160;million was recognized during the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Innovatus LSA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, the Company entered into a Loan and Security Agreement (the &#x201c;LSA&#x201d;) by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#x201c;Innovatus&#x201d;), as collateral agent and the lenders listed on Schedule 1.1 thereto, including East West Bank. The LSA provided a first term loan of $17.5 million, a second term loan of $2.5 million and a third term loan of $5.0 million (collectively, the &#x201c;Term Loans&#x201d;) if the Company satisfied certain funding conditions. Interest on the Term Loans is due on the first of each month at a rate of 10.25% per annum in cash or a discounted rate of 7.25% in cash with 3.0% of the 10.25% per annum rate added to the principal of the loan and subject to accruing interest through the end of the interest only payment period, which ends March 1, 2022. At inception, the Company elected to pay interest in cash at a rate of 7.25% per annum and have 3.0% per annum of the interest added back to the outstanding principal. As of May 14, 2021 (the effective date of the loan payoff), the effective interest rate, including debt issuance costs, for the Term Loans was 16.7%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LSA provided for prepayment fees of 3.0% of the outstanding balance of the loan if the loan is repaid on or prior to March 14, 2020, 2.0% of the amount prepaid if the prepayment occurs after March 14, 2020 but prior to March 14, 2021, 1% of the amount prepaid after March 14, 2021 but prior to March 14, 2022 and 0% of the amount prepaid if the prepayment occurs thereafter. In addition, upon the final repayment of the total amounts borrowed, the Company is required to pay an end of term fee of $0.8 million. This end of term fee was being recognized as interest expense over the term of the LSA. As of December&#160;31, 2021, the outstanding term loan with Innovatus was paid in full, including all accrued interest, the end of term fee, and a prepayment fee for a total of $17.0 million. The Company recorded a loss on debt extinguishment of $2.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LSA also provided for a revolving line of credit in an amount not to exceed $5.0 million (the &#x201c;Revolver&#x201d;), which was terminated effectively upon payment in full of the above term loan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LSA was collateralized by substantially all of the Company&#x2019;s assets, including its intellectual property. The LSA required the Company to comply with various affirmative and negative covenants, including: (1) a liquidity covenant requiring the Company to maintain a minimum cash balance at all times in a collateral account and (2) a revenue covenant requiring the Company to meet certain minimum revenue targets measured at the end of each calendar quarter. The LSA also included certain standard events of default, and a provision that Innovatus could declare an event of default upon the occurrence of any event that it interprets as having a material adverse impact to the Company's business, operations, or condition, a material impairment on the Company's ability to pay the secured obligations under the LSA, or upon a material adverse effect on the collateral under the agreement, thereby requiring the Company to repay the loans immediately, together with a prepayment fee and other applicable fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, in connection with the receipt of $20.0&#160;million in proceeds from the Term Loans, the Company issued to Innovatus a warrant to purchase up to 0.2 million shares of its common stock at an exercise price of $4.63 per share, which has a term of 10 years. These warrants were equity classified and their respective fair value was recorded as a discount to the debt. The warrants were exercised during the year end December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the LSA was amended to among other things: (i) extend the deadline for the Company to maintain its domestic depository and operating accounts with the Bank, subject to a control agreement in favor of Innovatus, to July 31, 2019 and (ii) permit the Company to incur credit card indebtedness in an amount not to exceed $0.2 million. As of September 30, 2019, the Company did not achieve the revenue covenant under the Innovatus LSA. As a result, in October 2019, the Company obtained a waiver letter from Innovatus. Pursuant to the waiver letter, Innovatus agreed to allow the Company to cure its noncompliance with the revenue covenant as of September 30, 2019 so long as the Company (i) raised at least $10&#160;million in gross proceeds from the sale of its securities in an underwritten public offering by October 31, 2019 and (ii) amended the warrant to purchase stock, issued by the Company to Innovatus in March 2019 to decrease the exercise price of the warrant from $4.63 per share to $0.48 per share. Also pursuant to the waiver letter, as consideration for the prospective breach of a liquidity covenant, the Company agreed to issue to Innovatus 0.6 million shares of the Company's common stock. As a result of the amendment and shares issued, the Company recognized $0.6 million as a debt discount, which is being amortized as interest expense over the remaining term of the LSA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2019, the Company did not achieve certain financial covenants under the Innovatus LSA. As a result, in March 2020, the Company and Innovatus entered into an amendment to the Innovatus LSA (the &#x201c;Second Amendment&#x201d;) to, among other things: (i) waive the events of default from not achieving the specific financial covenants for the December 31, 2019 measurement date, (ii) require an immediate partial repayment of $2.1&#160;million, (iii) require an additional partial repayment of $2.9&#160;million on the earlier of completion of an Equity Event (as defined in the Second Amendment), or April 30, 2020, (iv) modify the liquidity covenant, such that the Company&#x2019;s minimum cash balance shall vary based on outstanding borrowing capacity under the Revolver (provided, however, that the Company shall maintain a minimum cash balance of $2&#160;million at any given time), (v) reduce the dollar amount of certain minimum revenue covenants measured as of the end of each calendar quarter (each, a &#x201c;Revenue Covenant&#x201d;) and (vi) modify the terms of certain events of default. For example, the Second Amendment provides for a cure period in connection with the breach of certain minimum revenue financial covenants, as long as the Company submits an updated management plan and financial projections, which are subject to Innovatus approval, and completes a Qualified Financing Event (as defined in the Second Amendment) within 45 days of such breach. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Second Amendment, the Company was obligated to pay Innovatus a waiver fee in the amount of $0.2 million and a prepayment fee of $0.1 million, payable in cash or in shares of the Company&#x2019;s common stock at the Company's election, no later than following completion of the Equity Event, as defined in the Second Amendment. As described in Note 10 below, the Company completed a follow-on public offering in April 2020 that constituted an Equity Event under the Second Amendment. A portion of the proceeds from the follow-on offering were used to pay-down $2.9&#160;million of principal balance outstanding under the Term Loans in accordance with the Second Amendment. In addition, the Company issued 0.9 million shares of its common stock to Innovatus to satisfy the $0.2 million waiver fee and the $0.1 million prepayment fee due under the Second Amendment. As a result of the amendment and shares issued, the Company recognized $0.3 million as a debt discount, which is being amortized as interest expense over the remaining term of the LSA. Also pursuant to the Second Amendment, the Company subsequently registered such shares for resale on a registration statement on Form S-3 (the &#x201c;Registration Statement&#x201d;) filed with the Securities and Exchange Commission on June 22, 2020 and declared effective on July 7, 2020. The Company has not and will not receive any of the proceeds from the offering described in the Registration Statement. In connection with the Merger, the Company and Lineagen entered into a Third Amendment (the &#x201c;Third Amendment&#x201d;) to the Innovatus LSA. Among other things, the Third Amendment adds Lineagen as a &#x201c;Borrower&#x201d; under the Innovatus LSA and updates certain financial covenants in light of Lineagen becoming a wholly owned subsidiary of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company obtained a waiver from Innovatus of its previously disclosed noncompliance, as of September 30, 2020, with the revenue covenant contained in the LSA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company was in compliance with the covenants under the Innovatus LSA. The Innovatus LSA was paid in full and terminated in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Debt Obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no debt as of December&#160;31, 2021. The carrying value of the Company&#x2019;s debt as of December 31, 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term Loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revolver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PPP Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,756,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,430,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,326,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i187f2e41e0e647169625953a97e7c680_D20200417-20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzMjg_ea895fdf-aa2d-4600-bd02-570829ff7788"
      unitRef="usd">1800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i187f2e41e0e647169625953a97e7c680_D20200417-20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzMzY_ea895fdf-aa2d-4600-bd02-570829ff7788"
      unitRef="usd">1800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i885cb3edb89544758da163ee290c2716_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzNjA_2ea7e219-8eab-4fa6-b2db-01f7fc5e2655"
      unitRef="usd">17500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if8fefc0da0874a5b9ef1c40c3768d9b2_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzNjQ_d80c1810-e1d6-4537-85e3-3748ce0fab34"
      unitRef="usd">2500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9113153c66234219aee4b2506362eeb2_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzEwOTk1MTE2NTQ0NTE_98bd4ef9-988f-4b5e-ae31-1d23edea54e3"
      unitRef="usd">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <bngo:DebtInstrumentInterestRateCashRate
      contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzNzI_b4954d2b-46f8-4ec2-85ff-3ecfc508a9b4"
      unitRef="number">0.1025</bngo:DebtInstrumentInterestRateCashRate>
    <bngo:DebtInstrumentInterestRateDiscountedCashRate
      contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzNzY_5f8f5ba3-197c-4256-b42b-8993c0bfee79"
      unitRef="number">0.0725</bngo:DebtInstrumentInterestRateDiscountedCashRate>
    <bngo:DebtInstrumentInterestRateCashRate
      contextRef="icbd4ec7b849b4fdfb36d13c56714da97_I20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzODA_82fd336f-b04e-4533-a664-b0e7c6685dbe"
      unitRef="number">0.030</bngo:DebtInstrumentInterestRateCashRate>
    <bngo:DebtInstrumentInterestRateCashRate
      contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzODQ_b4954d2b-46f8-4ec2-85ff-3ecfc508a9b4"
      unitRef="number">0.1025</bngo:DebtInstrumentInterestRateCashRate>
    <bngo:DebtInstrumentInterestRateDiscountedCashRate
      contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzODg_5f8f5ba3-197c-4256-b42b-8993c0bfee79"
      unitRef="number">0.0725</bngo:DebtInstrumentInterestRateDiscountedCashRate>
    <bngo:DebtInstrumentInterestRateCashRate
      contextRef="icbd4ec7b849b4fdfb36d13c56714da97_I20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjMzOTI_82fd336f-b04e-4533-a664-b0e7c6685dbe"
      unitRef="number">0.030</bngo:DebtInstrumentInterestRateCashRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5e120690c77f416090e340927b324ea8_I20210514"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MDQ_788edacd-22d7-47b1-b4c3-71555333a8ac"
      unitRef="number">0.167</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="ifada802da30d4375a5c5a06d5d2c5ddf_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MDA_a260859b-e777-4b24-a805-34c3de067a42"
      unitRef="number">0.030</bngo:DebtInstrumentPrepaymentFeePercent>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="i4d74e091a5294082809d17f5146d70ad_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MDg_3b8cbfe6-f904-455b-97c7-0119dcc393bf"
      unitRef="number">0.020</bngo:DebtInstrumentPrepaymentFeePercent>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="id0d3bb253582446b9f1f1ac8c1549355_D20190301-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MTI_297bea3d-cd9a-4689-b96c-18cc658874b5"
      unitRef="number">0.01</bngo:DebtInstrumentPrepaymentFeePercent>
    <bngo:DebtInstrumentPrepaymentFeePercent
      contextRef="i49e07068caf640e88b8e67d05b03a126_D20190301-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MTY_d97e5fa5-12b1-4b6f-96df-be84cbbbed16"
      unitRef="number">0</bngo:DebtInstrumentPrepaymentFeePercent>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MjA_e7675362-deaa-4d25-95d9-c4b5e99d0a88"
      unitRef="usd">800000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i0418bf1522234b33bd7a72931d18580f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0Mjg_0ca64ae0-ae1d-447f-9c31-0e85335ae07e"
      unitRef="usd">17000000.0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY4NDM_454bd8cf-a973-4fbf-a6e4-e0bfcae7484d"
      unitRef="usd">-2100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib8e87945aa7f410299777da79c66a83f_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3MjM0MzU_e6ff7173-e291-40f3-9dc9-af9d708b8026"
      unitRef="usd">5000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODgzMTY_e48f16a2-ac6a-45f7-803f-893e0e11d6b9"
      unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <bngo:WarrantsToPurchaseSharesIssued
      contextRef="ifb921d59feb74c7e9883ca143d13a63e_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1MDc_1be73538-2290-45da-964c-ad0118c9f284"
      unitRef="shares">200000</bngo:WarrantsToPurchaseSharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODgzMzE_034cb7e4-bf09-43ef-a8a9-9d1d33bb2c75"
      unitRef="usdPerShare">4.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassofWarrantorRightTerm
      contextRef="ie0e9fefb7a034edb966f004c59f7d49c_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODgzNDA_a0543dd8-6e30-4627-acbd-2ce62dc29589">P10Y</bngo:ClassofWarrantorRightTerm>
    <bngo:DebtInstrumentCovenantMaximumCreditCardIndebtedness
      contextRef="i807cfb44a24d46fe8574bed9d3d3fa46_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY2NDY_3d8dee20-d2cf-474b-b665-6617e2bae963"
      unitRef="usd">200000</bngo:DebtInstrumentCovenantMaximumCreditCardIndebtedness>
    <bngo:DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross
      contextRef="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0MTE_23240aab-27ba-49f1-8f60-227a537bb7e2"
      unitRef="usd">10000000</bngo:DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifc845bca945a4f5fa755dc944afdc43d_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0MjQ_a6d71046-07ca-4798-a496-9f00876f4022"
      unitRef="usdPerShare">4.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0MzE_45d0b345-d3e3-48cb-ba3b-d37bddd99f1b"
      unitRef="usdPerShare">0.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:WarrantsToPurchaseSharesIssued
      contextRef="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1MjI_59845969-1fdf-4c8c-b03b-9272303bc71d"
      unitRef="shares">600000</bngo:WarrantsToPurchaseSharesIssued>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ib0a8b67aedb84f3399ba4dc8abcaaef9_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1MzM_d8ba3201-5875-442a-8b39-4856e9e21ee2"
      unitRef="usd">600000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:RepaymentsOfDebt
      contextRef="i3751fdde71464399810902ffa867ecde_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0Mzg_a971c85f-1d7f-4c13-94a0-540082ea97ef"
      unitRef="usd">2100000</us-gaap:RepaymentsOfDebt>
    <bngo:DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise
      contextRef="i3751fdde71464399810902ffa867ecde_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0NTI_9c4a171f-bee1-4d70-b2db-403166755409"
      unitRef="usd">2900000</bngo:DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise>
    <bngo:DebtInstrumentCovenantLiquidityMinimumCashBalance
      contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0NjY_32718490-81e8-4197-b4af-d607540f5c84"
      unitRef="usd">2000000</bngo:DebtInstrumentCovenantLiquidityMinimumCashBalance>
    <bngo:DebtInstrumentCovenantWaiverFeePaymentPeriod
      contextRef="i3751fdde71464399810902ffa867ecde_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0ODA_611a6104-2ddf-49d3-8dd2-d2f6cf86cbd2">P45D</bngo:DebtInstrumentCovenantWaiverFeePaymentPeriod>
    <bngo:DebtInstrumentCovenantWaiverFee
      contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1NjM_f0c3c8bd-9c33-4913-998f-a5ac5213711e"
      unitRef="usd">200000</bngo:DebtInstrumentCovenantWaiverFee>
    <bngo:DebtInstrumentCovenantPrepaymentFee
      contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1NzQ_78f95f05-e70a-439b-a1b4-78c62a3ec474"
      unitRef="usd">100000</bngo:DebtInstrumentCovenantPrepaymentFee>
    <bngo:DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise
      contextRef="i12947374461e4e6b9a6e0e872431a338_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzU0OTc1NTgxODg0OTI_41564aca-e423-4660-8fd9-1ab3c2d2831a"
      unitRef="usd">2900000</bngo:DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise>
    <bngo:WarrantsToPurchaseSharesIssued
      contextRef="i7ec81e424f424534aa64d4e480141a53_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1NTA_145b467e-e0b0-4780-9abc-1100ea459438"
      unitRef="shares">900000</bngo:WarrantsToPurchaseSharesIssued>
    <bngo:DebtInstrumentCovenantWaiverFee
      contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY1OTE_f0c3c8bd-9c33-4913-998f-a5ac5213711e"
      unitRef="usd">200000</bngo:DebtInstrumentCovenantWaiverFee>
    <bngo:DebtInstrumentCovenantPrepaymentFee
      contextRef="i54d3f9a1b1cb4511975ec7c6c6ae3035_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY2MDI_78f95f05-e70a-439b-a1b4-78c62a3ec474"
      unitRef="usd">100000</bngo:DebtInstrumentCovenantPrepaymentFee>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i7ec81e424f424534aa64d4e480141a53_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzM4NDgyOTA3NDY2MTM_48861a13-3b32-456f-b92f-a4d5b5bfa35e"
      unitRef="usd">300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90ZXh0cmVnaW9uOjk3MjY1YWEyNDEyYzRhODZiMWIxNDVmYmZhZjBhYjBhXzExODI0_9c60301b-6a8d-40f4-994a-99de338163bc">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no debt as of December&#160;31, 2021. The carrying value of the Company&#x2019;s debt as of December 31, 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term Loans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,981,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revolver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PPP Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,775,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,756,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,430,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total carrying value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,326,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4795567b94164ea29b5699dc096d6ebf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzEtMy0xLTEtMQ_cf772f3b-6168-48ea-a57d-ce412508b880"
      unitRef="usd">15981000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5821d7ac4676425ba01bdcd20c6d2f91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzItMy0xLTEtMQ_8df00d84-cd7e-431e-8cfc-151f67234dac"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1d06a7344f2e49ab9598f04154df56cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzMtMy0xLTEtMQ_02580547-9805-4fcf-a15e-c733027f0d27"
      unitRef="usd">1775000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzQtMy0xLTEtMQ_b8445fb7-dfd3-4c9f-b50b-f5887aa88de7"
      unitRef="usd">17756000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzUtMy0xLTEtMQ_a1c6aca5-3be7-4c61-9f8e-ed6f07d194bf"
      unitRef="usd">1430000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzUvZnJhZzo5NzI2NWFhMjQxMmM0YTg2YjFiMTQ1ZmJmYWYwYWIwYS90YWJsZTpjZjNjYTAwYWE1MWM0YjE4Yjk2ZDBiNjdmZmE1MWNkMi90YWJsZXJhbmdlOmNmM2NhMDBhYTUxYzRiMThiOTZkMGI2N2ZmYTUxY2QyXzYtMy0xLTEtMQ_738e706b-ddfc-4a10-be80-8a4b5df29ba0"
      unitRef="usd">16326000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDIz_95fc2e48-0552-4f75-8534-8516dc31208f">Stockholders&#x2019; Equity and Stock-Based Compensation&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently authorized to issue up to 400 million shares of $0.0001 par value common stock. All issued shares of common stock are entitled to vote on a 1 share/1 vote basis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently authorized to issue up to 10 million shares of $0.0001 par value preferred stock. No preferred stock has been issued to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Follow-on Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company completed an underwritten public offering of&#160;16.9 million&#160;shares of its common stock and, to certain investors, pre-funded warrants to purchase&#160;37.7 million&#160;shares of its common stock, and accompanying common warrants to purchase up to an aggregate of&#160;54.5 million&#160;shares of its common stock. Each share of common stock and pre-funded warrant to purchase&#160;one&#160;share of common stock was sold together with a common warrant to purchase&#160;one&#160;share of common stock. The public offering price of each share of common stock and accompanying common warrant was&#160;$0.33&#160;and&#160;$0.329&#160;for each pre-funded warrant. The pre-funded warrants are immediately exercisable at a price of&#160;$0.001&#160;per share of common stock. The common warrants are immediately exercisable at a price of&#160;$0.33&#160;per share of common stock and will expire&#160;five years from the date of issuance. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The gross proceeds to the Company, before deducting offering costs of $1.6 million, were&#160;$18.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 12, 2021, the Company completed an underwritten public offering of 33.4 million shares of common stock, including 4.4 million shares of common stock sold pursuant to the underwriters' exercise in full of their option to purchase additional shares. The price to the public in the offering was $3.05 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $2.867 per share. The gross proceeds were&#160;approximately $101.8 million before deducting underwriting discounts and commissions and other offering expenses of $0.3 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company completed an underwritten public offering of 38.3 million shares of common stock, including 5.0 million shares of common stock sold pursuant to the underwriters&#x2019; exercise in full of their option to purchase additional shares. The price to the public in the offering was $6.00 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $5.64 per share. The gross proceeds to us were&#160;approximately $230.0 million before deducting underwriting discounts and commissions and other offering expenses of $0.4 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statements; Ladenburg and Cowen At-the-Market Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $125 million of the Company&#x2019;s securities, including up to $40 million of common stock pursuant to an At Market Issuance Sales Agreement, with Ladenburg Thalmann &amp;amp; Co. Inc. acting as sales agent (the &#x201c;Ladenburg ATM&#x201d;). During October through December 2020, the Company sold 27.0 million shares of common stock under the Ladenburg ATM at an average share price of $0.82, and received gross proceeds of approximately $22.1 million before deducting offering costs of $0.6 million. In January 2021, the Company sold an additional 6.3 million shares of common stock under the ATM at an average share price of $2.68, and received gross proceeds of approximately $16.9 million before deducting offering costs of $0.4 million. The Company terminated the Ladenburg ATM in March 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 19, 2021, the Company filed an automatically effective shelf registration statement on Form S-3 with the SEC as a &#x201c;well-known seasoned issuer,&#x201d; allowing for the Company to issue an indeterminate number or amount of its securities from time to time in one or more offerings. On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) which provides for the sale, in the Company&#x2019;s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0 million through or to Cowen, acting as sales agent or principal (the &#x201c;Cowen ATM&#x201d;)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company agreed to pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August and September 2021, the Company sold 2.3 million shares of common stock under the Cowen ATM at an average share price of $6.15 per share, and received gross proceeds of approximately $13.9 million before deducting offering&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; costs of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.6 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity for the year ended December 31, 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-  &lt;br/&gt;Average  &lt;br/&gt;Exercise  &lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-  &lt;br/&gt;Average  &lt;br/&gt;Remaining  &lt;br/&gt;Contractual  &lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate  &lt;br/&gt;Intrinsic  &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,406,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,933,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,396,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,628,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,780,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,174,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,841,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,794,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,191,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company entered into a Warrants Amendment and Agreement with certain holders of warrants that were exercisable for 3.2 million shares of common stock. The agreement reduced the exercise price of existing warrants from $0.86 per share to $0.75 per share, which were exercised following the amendment, in addition to issuing 3.2 million new warrants at an exercise price per share of $1.06 that were exercised in the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) and its stockholders adopted the 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), as a successor to and continuation of the Company&#x2019;s 2006 Equity Incentive Plan (the &#x201c;2006 Plan&#x201d;). Under the 2018 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then its employees, directors and consultants, including employees and consultants of its affiliates. The Company has initially reserved 1.5 million shares of common stock for issuance under the 2018 Plan, which is the sum of (1) 1.0 million new shares, plus (2) the number of shares that remained available for issuance under the 2006 Plan at the time the 2018 Plan became effective, and (3) any shares subject to outstanding stock options or other stock awards that were granted under the 2006 Plan that would have otherwise returned to the 2006 Plan. In addition, the number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2019 through January 1, 2028, in an amount equal to 5% of the total number of shares of the Company&#x2019;s capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board. As of December&#160;31, 2021, 6.2 million shares of common stock were authorized for future grants under the 2018 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company&#x2019;s Board and its stockholders adopted the 2020 Inducement Plan and amended by the Board on October 6, 2021. Under the 2020 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then its employees, directors and consultants, including employees and consultants of its affiliates. The Company has initially reserved 2.1 million shares of common stock for issuance under the 2020 Plan. An additional 1.0 million of shares of common stock was reserved for issuance under the Inducement Plan for a total of 3.1 million shares pursuant to an amendment to the Inducement Plan approved by the board of directors on October 6, 2021. As of December&#160;31, 2021, there were approximately 0.7 million shares of common stock authorized for future grants under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity is as follows: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,178,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,108,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(471,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,547,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,162,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,765,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,891,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,389,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 5.5pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,428,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock option grants during the years ended December&#160;31, 2021 and 2020 was $4.35 and $0.44, respectively. The total intrinsic value of the stock options exercised during the years ended December&#160;31, 2021 and 2020 were $2.5 million and $7,000, respectively. The contractual term of stock options granted to employees was 10 years, which is also the maximum contractual term permitted for stock options (and stock appreciation rights) issued under the 2018 Plan. Stock options generally vest or become exercisable monthly over a four-year period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A restricted stock award in the amount of 5.0 million shares with a grant date fair value of $5.20 a share was granted as part of the acquisition of BioDiscovery. One-third of the Restricted Shares will vest on October 18, 2022 and one-twelfth of the Restricted Shares shall vest every three months following October 18, 2022, subject to continuous service of a key employee. The weighted average remaining contractual term for the restricted stock is 2.8 years as of December&#160;31, 2021. The fair value of the restricted stock award is based on the market value of common stock as of the date of grant and is amortized to expense over the respective vesting period or the service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units and Performance Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues restricted stock units (RSU) and performance stock units (PSU). The Company grants restricted stock pursuant to the 2018 Stock Plan and satisfy such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. RSUs generally vest over a two-year period with equal vesting annually. We issue PSUs for which the number of shares issuable at the end of a four-year performance period is based on our performance relative to specified revenue targets and continued employment through the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;540,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(179,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of the RSUs that vested was $0.9 million during fiscal 2021, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is 1.4 years as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining contractual term for the PSUs is 3.4 years as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense for the years ended December&#160;31, 2021 and 2020 was as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,188,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,179,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,719,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,554,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of the employee stock option grants were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and lack of company-specific historical or implied volatility as a private company, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded. As a result, the Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend yield. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forfeitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company reduces stock-based compensation expense for actual forfeitures during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unrecognized Stock-Based Compensation Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the unrecognized compensation expense for all non-vested share-based awards was $59.2 million and is expected to be recognized as expense over a weighted-average period of 3.1 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Board and the Company&#x2019;s stockholders adopted the 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). A total of 0.2 million shares of common stock were initially reserved for issuance under the ESPP. In addition, the number shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year, beginning on January 1, 2019, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;through January&#160;1, 2028, by the lesser of (1) 1% of the total number of shares of the Company&#x2019;s common stock outstanding on the last day of the calendar month before the date of the automatic increase, (2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;220,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or (3) a lesser number of shares as determined by the Board. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, 0.2 million shares of common stock were authorized for future grants under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Option Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 15, 2022, the compensation committee of the Company&#x2019;s board of directors granted various executive officers stock options to purchase an aggregate of 4.3 million shares of common stock at an exercise price of $2.18 a share, in each case with an effective grant date and vesting commencement date of February 15, 2022 (the &#x201c;Grant Date&#x201d;). These stock option grants were issued from the 2018 Stock Plan. The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of the Grant Date, such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3Mzg_4f34b870-5cc7-49d6-a4dd-87b99776e07f"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3Mzg_634437bb-68b1-4695-b8bd-eb7d54fe22d9"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NDg_115fae02-0270-42b3-8950-658783166a72"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NDg_b70b67e4-a252-4c1d-8bfc-c462f7c3dc79"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NjE_ebb864f2-5de9-4ba5-a813-7705e9b36bb4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NjE_f4e852ab-88b0-4a3d-851a-3c0de7b6016e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NzE_38652c6b-3873-4d6e-abd9-13f261a6ade9"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzA3NzE_f0eeb0ba-36c4-4a7b-9ed8-af77f1e07de9"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i938f91bd8c3946d395a47bb4a55c4f39_D20200401-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM2NjM_148afc5c-8863-4fc4-947f-fed41ffc399f"
      unitRef="shares">16900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="id95371e1105d406580e1d89a5e055efa_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM3NTI_2bdc3103-ed79-4fb3-b912-8627f01b57f3"
      unitRef="shares">37700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i842467c3c99147a9899c7166293dd2df_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NTA_e276b4b1-811f-45af-8a14-c5c4c280b006"
      unitRef="shares">54500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i0733c5c486d840aa90f9b967fc4b62a4_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM5NDM_034b635c-3de7-432c-a545-b95ed1a817ab"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i0733c5c486d840aa90f9b967fc4b62a4_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTYwMjM_034b635c-3de7-432c-a545-b95ed1a817ab"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic96948543913400fa1d1b0b719ebabf1_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQxMzg_2b938e4e-5b80-439a-9406-7d10ffeefd43"
      unitRef="usdPerShare">0.33</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0733c5c486d840aa90f9b967fc4b62a4_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQxNDU_2e93cc2a-a1db-4d7c-89ba-9a54af520c24"
      unitRef="usdPerShare">0.329</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0733c5c486d840aa90f9b967fc4b62a4_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQyNDM_0e87c9cc-8f77-4b78-8407-67579c33160b"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic96948543913400fa1d1b0b719ebabf1_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQzMzU_97970199-9d05-4e68-ae18-8af278b7414b"
      unitRef="usdPerShare">0.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightExpirationPeriod
      contextRef="iad11bf28fea04b8aba14929027d8fa54_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQzODA_47bb8f5a-8aa5-48f9-810e-eb8c85db18c5">P5Y</bngo:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia66ac253e88644c8815ddb6f83187e4d_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQ2Mzk_e758d468-1119-4dc9-88ac-5fe313564177"
      unitRef="usd">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ia66ac253e88644c8815ddb6f83187e4d_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQ2NDg_cc9245a2-ae02-4e57-9e13-3f9e8583934b"
      unitRef="usd">18000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i473f14c3b9164deeb0b53c014f09915c_D20210112-20210112"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTQ3NzU_c3c25609-2611-4020-9374-cdebff935dfe"
      unitRef="shares">33400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2623ef25413a4354ac9f72e113c78e64_D20210112-20210112"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTQ3Nzk_68830804-4324-49c4-bde1-3d5a5e9d1b80"
      unitRef="shares">4400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i01445096e010443d97b89ad87ab3c883_I20210112"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQ5MzY_b8f6b884-e3cd-478c-a0fb-a1238578298f"
      unitRef="usdPerShare">3.05</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i5df53405a8de4826bff81815bde4ed6c_I20210112"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzUwNjE_e9901374-b81c-4fb7-b5d1-9fd9a1c00c35"
      unitRef="usdPerShare">2.867</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i473f14c3b9164deeb0b53c014f09915c_D20210112-20210112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzUxMTM_c7bb397c-7c07-458d-9398-87154698e74f"
      unitRef="usd">101800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i473f14c3b9164deeb0b53c014f09915c_D20210112-20210112"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTIwNzY_d2587b91-c2db-439c-a8bf-f80a4ac78a88"
      unitRef="usd">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i411e62885bec4fb3beab2f000e27b94f_D20210125-20210125"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTQ3Njc_749d20da-94e1-4997-a3e4-1ee7762bda5f"
      unitRef="shares">38300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id608a0c5267f429cb8c9e21ce9a996e7_D20210125-20210125"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTQ3NzE_58e2f0e8-45d4-48c9-85a4-5950f8c1dc01"
      unitRef="shares">5000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ic49d68891599499b9fcf7774b2002c46_I20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTU_0b592ebf-f1f0-4aad-939f-877647080fc6"
      unitRef="usdPerShare">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i96499813715849179f8f5b094e5056d1_I20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU2MjA_d2fed8c7-48af-4b9a-b1c3-b404504f4c3f"
      unitRef="usdPerShare">5.64</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i411e62885bec4fb3beab2f000e27b94f_D20210125-20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU2Nzg_94b09ee6-5d18-442a-be25-87c2f48cafd9"
      unitRef="usd">230000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic49d68891599499b9fcf7774b2002c46_I20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NTY3MDQ_1934c1b4-dbc5-4c46-9dd8-85a23cd8537e"
      unitRef="usd">400000</us-gaap:DeferredFinanceCostsNet>
    <bngo:SaleOfStockAuthorizedAmountToBeIssued
      contextRef="i1d6ccdf4c05242a6877437f969ff350d_I20200831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NDM_ad6a02d2-efd9-410e-8001-7abdea4233a2"
      unitRef="usd">125000000</bngo:SaleOfStockAuthorizedAmountToBeIssued>
    <bngo:SaleOfStockAuthorizedAmountToBeIssued
      contextRef="i4d0542f51814417b825a21ad6a71dd4c_I20200831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NDc_4842bc49-9699-4003-b1fb-960c07d1dba0"
      unitRef="usd">40000000</bngo:SaleOfStockAuthorizedAmountToBeIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8c6b16906f9c47c490d636cc5dc3cd1b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NTQ_b76a1a7b-eb73-4f8e-a023-f00bb611c8ab"
      unitRef="shares">27000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NjE_a6923b59-089a-4824-9cef-a20cdc2e22d7"
      unitRef="usdPerShare">0.82</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i8c6b16906f9c47c490d636cc5dc3cd1b_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NjU_22176445-2370-4ddd-a477-93baec341093"
      unitRef="usd">22100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1NzI_cfecbb2f-ff7b-4fc4-b5dc-4bca8fe8c5b6"
      unitRef="usd">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i04fb2be1f6bc4a1ea3a4950d33413347_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1Nzk_dc40d539-c0ee-46e9-b03a-5c3cf925dd1b"
      unitRef="shares">6300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ie9dfa5830e684b5b9aeb0425d2971c55_I20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1ODY_8eb239e8-4c41-48ed-8f52-7971b355d3c3"
      unitRef="usdPerShare">2.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i04fb2be1f6bc4a1ea3a4950d33413347_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc1OTA_7a7e71ab-c3bf-4255-842a-537788c66f9c"
      unitRef="usd">16900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ie9dfa5830e684b5b9aeb0425d2971c55_I20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTA5MDQ_a20888c7-5c28-4a32-ba40-8f61a0274913"
      unitRef="usd">400000</us-gaap:DeferredFinanceCostsNet>
    <bngo:SaleOfStockValueSharesIssuedInTransaction
      contextRef="ie90abf42c0fa483585e7c0ddbc44d00c_D20210323-20210323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NjA2OTU_f366adba-31a7-466b-9cec-3e5335d4a5e6"
      unitRef="usd">350000000</bngo:SaleOfStockValueSharesIssuedInTransaction>
    <bngo:CommissionFeeMaximumPercentageOfGrossProceeds
      contextRef="ie90abf42c0fa483585e7c0ddbc44d00c_D20210323-20210323"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgxNTk0NjU_0db049a9-584d-44a4-996f-a505666d80b7"
      unitRef="number">0.030</bngo:CommissionFeeMaximumPercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3baa8f239ec74369b0750b2c579131a4_D20210801-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2MTc_5cb63bf7-b99a-45a5-a604-744e039576db"
      unitRef="shares">2300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i6575ee0a35434402aebe8d5e012a1d85_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2MjI_65e72b56-2acc-46ec-8c23-ca14b371c50f"
      unitRef="usdPerShare">6.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i3baa8f239ec74369b0750b2c579131a4_D20210801-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2Mjk_7b22a412-7f90-4649-95f6-780895f3d76d"
      unitRef="usd">13900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6575ee0a35434402aebe8d5e012a1d85_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2NjA_b9ace35d-ec48-4d6f-8be3-602b3b855e38"
      unitRef="usd">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDI3_2ea9cf91-ecd1-43a1-ad48-92fe06221744">A summary of the Company&#x2019;s warrant activity for the year ended December 31, 2021 was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-  &lt;br/&gt;Average  &lt;br/&gt;Exercise  &lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-  &lt;br/&gt;Average  &lt;br/&gt;Remaining  &lt;br/&gt;Contractual  &lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate  &lt;br/&gt;Intrinsic  &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,406,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,933,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,396,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,628,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,780,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,174,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,841,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,794,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,191,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,356,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzUtMS0xLTEtMQ_8686dc5c-d32e-4753-85f1-71b2ae84a39b"
      unitRef="shares">24406000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzUtMy0xLTEtMQ_bf28fd40-30dd-46de-9ffb-ba5ee8c5aa7c"
      unitRef="usdPerShare">1.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
      contextRef="i50bbecaae644414b92db4dfed11dc7e6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzUtNS0xLTEtMQ_228a0666-039f-4f7f-b6ef-24c0f6dc1fe1">P4Y9M25D</bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
      contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzUtNy0xLTEtMQ_264c87ab-8f86-41ac-b8ec-1b42348899de"
      unitRef="usd">7933000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzYtMS0xLTEtMQ_e7b4db8c-39e4-49e4-8b27-379320276240"
      unitRef="shares">95396000</bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod>
    <bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzYtMy0xLTEtMQ_b2be32c3-d932-4c92-956f-1267b8e0496e"
      unitRef="usdPerShare">0.22</bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzYtNS0xLTEtMQ_e9558ab9-ea46-4635-a5ae-4b518ac22f47">P4Y3M10D</bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzctMS0xLTEtMQ_7932522f-d5cf-4bb9-98ca-4db4e98e9503"
      unitRef="shares">104628000</bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod>
    <bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzctMy0xLTEtMQ_d9fa355b-418b-4995-9849-bd999831fc09"
      unitRef="usdPerShare">0.28</bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzctNy0xLTEtMQ_4b668a8f-d142-47e4-a29f-d2c9116fc240"
      unitRef="usd">56780000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzgtMS0xLTEtMQ_fcb892b9-dc7e-46a5-957c-fcca576fba4e"
      unitRef="shares">0</bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod>
    <bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzgtMy0xLTEtMQ_8886ce82-198a-4504-bd5c-a9617c06b88a"
      unitRef="usdPerShare">59.90</bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzktMS0xLTEtMQ_6777c555-493b-4053-92dc-d3e7846510dd"
      unitRef="shares">15174000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzktMy0xLTEtMQ_bfeedf16-09a3-4f9a-9984-af2ad3921aa6"
      unitRef="usdPerShare">2.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzktNS0xLTEtMQ_803761e5-08ce-4271-8f39-f9249406e0f5">P3Y9M3D</bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzktNy0xLTEtMQ_4928bbc2-2c78-4c16-97db-9d2a9e44cd2c"
      unitRef="usd">26841000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEwLTEtMS0xLTI3NzAy_f0fc10e5-c9b7-4b90-9218-e882a083d222"
      unitRef="shares">0</bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod>
    <bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEwLTMtMS0xLTI3NzAy_45fa8ce4-c94b-4e23-b026-24f29bfe19bc"
      unitRef="usdPerShare">0</bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzExLTEtMS0xLTI3NzAy_e3cbba43-5295-43da-8200-db05dd6788c9"
      unitRef="shares">10794000</bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod>
    <bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzExLTMtMS0xLTI3NzAy_215b87cc-c7ed-4ccb-a8d3-dc7af0620835"
      unitRef="usdPerShare">0.88</bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzExLTctMS0xLTI3NzAy_cf3a4e58-bd48-43b1-9903-b8c16fcade61"
      unitRef="usd">58191000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEyLTEtMS0xLTI3NzAy_292dd2bd-7532-4add-8ad9-7706c8c3fede"
      unitRef="shares">24000</bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod>
    <bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEyLTMtMS0xLTI3NzAy_3ed271d1-4852-4444-98c5-44231455455c"
      unitRef="usdPerShare">3.29</bngo:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEzLTEtMS0xLTI3NzAy_d416e489-de72-4bd8-82f8-347f324bf45d"
      unitRef="shares">4356000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEzLTMtMS0xLTI3NzAy_baf35909-1201-4978-a62d-4278dc2a7908"
      unitRef="usdPerShare">5.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEzLTUtMS0xLTI3NzAy_ee933d67-131f-4e1a-96b1-712384554524">P1Y9M3D</bngo:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmMzc5ZTg2MWEyNTA0MzVkYjQ1NTMzMzE1NGUwODEwNS90YWJsZXJhbmdlOmYzNzllODYxYTI1MDQzNWRiNDU1MzMzMTU0ZTA4MTA1XzEzLTctMS0xLTI3NzAy_2de5b19f-140e-4b0b-8ba4-264c19e3ad80"
      unitRef="usd">785000</bngo:ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
      contextRef="i44a4af39e9424b53a07681fa1a5d8f50_D20200302-20200302"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDMyMjE_7f9d7547-fae2-4129-9115-f4e4f7318a55"
      unitRef="shares">3200000</bngo:ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia1a664a51c194792a34d9f22fad31cac_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDQwNDg_c78c65af-4765-485a-af4a-4760181eac6f"
      unitRef="usdPerShare">0.86</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6f822c4990b1439daba5becfbc85c5aa_I20200302"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDMyMzg_d2a8f9f9-b454-497f-840d-41f9ebcd8186"
      unitRef="usdPerShare">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
      contextRef="i93c22029995e4f6384a607093272bbfa_D20200302-20200302"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDMyNDU_5cd13301-9e2b-4ae4-8485-79c96e15d6f8"
      unitRef="shares">3200000</bngo:ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iab207f0b1ddf422e9fdb826c96fbbae0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgyMDMyNTY_9c98cef1-7d18-464b-85af-db100acf08ff"
      unitRef="usdPerShare">1.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic2aef460467747f28861ce3854e7c187_I20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4Xzc5MDI_04175de1-974d-4dc6-81b4-f58f2f952222"
      unitRef="shares">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i1c415e70a6a948e8b2be43920872a619_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4Xzc5ODY_f85659c8-eb41-4ef6-af3f-62b9820b6679"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <bngo:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding
      contextRef="ic9ca65a64a4549f589630eadc720acf0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4Xzg1MzI_69519a63-9f31-4669-a786-0c536d58eaaf"
      unitRef="number">0.05</bngo:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9f4b74c4fd9d4e7094439d2d2c7562e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MjEzNDY_d5707895-e48d-4c79-a0c1-678b8c4f6cbb"
      unitRef="shares">6200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3ea7966b68f743518a7b346891b8cfa1_I20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NTgxODA_e31ba8ff-f2dd-4a4e-9965-7335f5d55d26"
      unitRef="shares">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i17c21833ff0041eaad1473112a77f0a7_D20211006-20211006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NTg1MjA_a3df5b73-fa65-477f-8dec-fd2df6b36ea5"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4ad50c757a9743e791dd8f5af71e8e31_I20211006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2NTg2Njk_5e27371a-b5ca-4d1e-b0d2-c32c8a33e53d"
      unitRef="shares">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5e25fe9fc0eb46c29dddcb5c5cfde31d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3Mjk4MDg_2fb56889-89f3-43ae-9226-337076890fd0"
      unitRef="shares">700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDIw_914710b0-44f0-438c-bda8-4a4f885c74af">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity is as follows: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of Stock under Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,178,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,108,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(471,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,547,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,162,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,765,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 5.5pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,891,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,389,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 5.5pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,428,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzktMS0xLTEtMjgyMjg_31c5c24a-9ce1-4187-aaf3-1ee4dd9d4bdd"
      unitRef="shares">5290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzktMy0xLTEtMjgyMzk_ae3fd519-5e69-49af-a21d-857ce9a53c60"
      unitRef="usdPerShare">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzktNS0xLTEtMjgyNTA_1a5acb37-a532-4390-97f8-dc196c48f76d">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzktNy0xLTEtMjgyNjE_055d4397-968a-496f-8af9-8e48d376d2f2"
      unitRef="usd">10178000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzUtMS0xLTEtMQ_b6d70407-225f-48b8-a453-5b8e5ffb5dce"
      unitRef="shares">9108000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzUtMy0xLTEtMQ_3dd93d8d-1153-4cfc-af0a-b6de6c46295e"
      unitRef="usdPerShare">6.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzYtMS0xLTEtMQ_a525eb11-2e56-4142-b6e0-268bfb593b8e"
      unitRef="shares">471000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzYtMy0xLTEtMQ_f4edc393-5a6e-4810-a686-706dbb15230c"
      unitRef="usdPerShare">1.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzYtNy0xLTEtMQ_d2a3ca36-19d1-4201-ad72-6c26cd28e7db"
      unitRef="usd">2547000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzctMS0xLTEtMQ_88331313-a95e-4062-a83d-9172f62454a5"
      unitRef="shares">1162000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzctMy0xLTEtMQ_d12c9177-7856-4ce1-8ea4-e79b4e0d403e"
      unitRef="usdPerShare">4.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzgtMS0xLTEtMQ_b8326172-d4ce-4e91-b8c6-80ba6cf0d1c5"
      unitRef="shares">12765000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzgtMy0xLTEtMQ_b8d59f82-6e6b-4c4a-8124-7794172628a6"
      unitRef="usdPerShare">4.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzEzLTUtMS0xLTMyMDUx_c830180c-9403-4ca0-afe9-af23a7c246d7">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzgtNy0xLTEtMQ_56a640b6-fc00-4315-be36-973b36eb936d"
      unitRef="usd">7891000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzExLTEtMS0xLTE_ee0e345f-6ac6-4dc3-9e48-9d46769a6c98"
      unitRef="shares">3389000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzExLTMtMS0xLTE_8b002701-a3d0-44b4-9a38-893a3d496604"
      unitRef="usdPerShare">3.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzExLTUtMS0xLTE_8275a453-d911-4725-a062-973db6c90884">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTozNGFhMjIzY2Y0ZDU0NzJhOTYwOWUxOTlkMGNlNWRiOS90YWJsZXJhbmdlOjM0YWEyMjNjZjRkNTQ3MmE5NjA5ZTE5OWQwY2U1ZGI5XzExLTctMS0xLTE_5f07f4c7-d076-491c-96c1-2f84d3523ad5"
      unitRef="usd">4428000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i4f676ebcb6964b0db783a5db2a081ffa_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc3MDM_7589da46-bf03-4c3c-b4b1-9b1ea930a843"
      unitRef="usdPerShare">4.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="ic8eacd11ad8142c39a3d70452a09fdda_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc2OTk_53884071-bb6b-4bab-8ee2-b7fbb69e571a"
      unitRef="usdPerShare">0.44</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzYwNDczMTQwMDMxOTA_ffd5b27e-d63a-4234-b017-e9e9c211769f"
      unitRef="usd">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzQzOTgwNDY1NjE0Nzg_0f93dbf4-20b2-4dea-9706-940ac4b7bb2d"
      unitRef="usd">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i4f676ebcb6964b0db783a5db2a081ffa_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzkxMTA_dad85022-e26e-4e53-8589-563ecfbe73cb">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iab4219a77977404ba46cadf9c1e2d9e1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDE3_151c073d-5cb3-4ca3-8394-53ca482df749">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7265080c4d794589a09bd0e17f4e4a2d_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3Mzc4OTQ_ad67ab99-0203-412f-8648-5b795dc59b15"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7265080c4d794589a09bd0e17f4e4a2d_D20211001-20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3Mzc5MDI_0e982174-922d-4781-a612-850b69949084"
      unitRef="usdPerShare">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i96e920c0320b47feb8ecdd4d667557e4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEwOTk1MTE2Nzg0Nzg_2963e44b-8863-40af-96d4-10ef04507ee4">P2Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgxNzE4NDM_93400e7d-8217-4e1c-b9f7-604529824eda">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgxNzk3NDI_b52c82e3-8e14-4816-af36-0699b31475ea">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzU0OTc1NTgxNzE4MDU_32cf5a7c-1721-4d0e-b6e1-7cb7e6aecd08">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;540,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(179,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of the RSUs that vested was $0.9 million during fiscal 2021, determined as of the date of vesting. The weighted average remaining contractual term for the RSUs is 1.4 years as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Grant Date Fair Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 5.5pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1180bacce9964e6ab67c6cf06acfbbde_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzEtMS0xLTEtMzI1MTE_a93d16ab-bb2a-4ec9-8595-5ba3d3d13fd1"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1180bacce9964e6ab67c6cf06acfbbde_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzEtMy0xLTEtNDM4NTc_bae861e8-8598-4ab0-9a5f-4e8ba7693050"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzItMS0xLTEtMzI1MTE_bd6fa1a9-780b-47c8-9a5e-f32f159ca4cf"
      unitRef="shares">540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib1112f0645024f47bfb4ccd3ed88f2ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzItMy0xLTEtMzI1MjU_6b27506e-9fa3-403c-bd05-9257ce458c48"
      unitRef="usdPerShare">4.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzMtMS0xLTEtMzI1MTE_3152abe3-f650-4e5e-ae5f-acdf0c7848de"
      unitRef="shares">179000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib1112f0645024f47bfb4ccd3ed88f2ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzMtMy0xLTEtMzI1MjU_c5d2ba28-b83a-414b-a87b-dd6b07598cd8"
      unitRef="usdPerShare">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzQtMS0xLTEtMzI1MTE_38a7744a-fa49-4e87-aae1-9462abd2c9b0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib1112f0645024f47bfb4ccd3ed88f2ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzQtMy0xLTEtNDM4NTc_f18a7673-d684-4de5-afaa-158da9b28341"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9a68a48ad08c4a4a90ebcf1971894c02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzUtMS0xLTEtMzI1MTE_27a0d617-9b27-4e44-a3d8-de28fb0ac568"
      unitRef="shares">361000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9a68a48ad08c4a4a90ebcf1971894c02_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpjZmNmOTQ1NjA5ZjY0NzM2YWQ3OThlNTU1YjI1MjBmMC90YWJsZXJhbmdlOmNmY2Y5NDU2MDlmNjQ3MzZhZDc5OGU1NTViMjUyMGYwXzUtMy0xLTEtMzI1MjU_74ac4c6d-0b5b-4aa0-931c-cc975f284051"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MjExNjU_49d2fad9-a031-44f0-b968-0cfb87388e36"
      unitRef="usd">900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i86da882447604a1e9e8017d09d518536_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzAwMDA_547cd33b-45e6-40c3-915b-cbd378789897">P1Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3f80b7d6b8944158bd9c8a9940a3b414_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzEtMS0xLTEtMzI1NDI_ffd09e62-d1c0-4b45-98e9-d38240ed09e4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3f80b7d6b8944158bd9c8a9940a3b414_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzEtMy0xLTEtNDM4OTQ_2b5afdad-2509-4a72-accc-7fcb11f6e07e"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzItMS0xLTEtMzI1NDI_3e3f72f4-748b-4c65-a9f5-da85246db0d9"
      unitRef="shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6166e9bcdaf64523922f223a68f2ae8a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzItMy0xLTEtMzI1NDg_d87e28df-769e-429e-b149-c9b69ddc780f"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzMtMS0xLTEtMzI1NDI_6f80a4a0-6129-4893-a8d7-d317a113340f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6166e9bcdaf64523922f223a68f2ae8a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzMtMy0xLTEtNDM4OTQ_d09b1e1c-7031-4d9b-b49f-9839cd8916fb"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzQtMS0xLTEtMzI1NDI_998c1915-0568-4203-beb4-ccc29442d3f0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6166e9bcdaf64523922f223a68f2ae8a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzQtMy0xLTEtNDM4OTQ_0256b01c-2a33-4728-911d-4e9f251632c0"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i33f329ca85c24dc6ac16f2cf9b3ac9b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzUtMS0xLTEtMzI1NDI_bf239dfe-abf8-417a-8298-79a2aef71f54"
      unitRef="shares">290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i33f329ca85c24dc6ac16f2cf9b3ac9b1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTplNjdmODkxYTI2NTg0ZDIwOGRhODZiNDlkYjgxYzk3MC90YWJsZXJhbmdlOmU2N2Y4OTFhMjY1ODRkMjA4ZGE4NmI0OWRiODFjOTcwXzUtMy0xLTEtMzI1NDg_f4397ae0-ccaf-4f88-b8be-9cd453f18fc5"
      unitRef="usdPerShare">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i36e6dc56ca5d42bf9a548b37a5d7c942_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MzAxMTc_56c6f067-4ff3-4804-aee6-feda599f3de1">P3Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDI2_a663ba6c-9c17-4630-84b9-629ec79d6c76">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense for the years ended December&#160;31, 2021 and 2020 was as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,188,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,179,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,719,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,554,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3fe3e09f6a3945efabf706cebdf47304_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzItMS0xLTEtMQ_2a366ab6-72c7-41e8-8768-8bb9f6048885"
      unitRef="usd">3531000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48d32570b3e4421289d391c0f57b1c05_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzItMy0xLTEtMQ_879082e6-12d9-4c00-bdd1-4f01ff0f4abe"
      unitRef="usd">375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7cc3a87e87bc437b84ce90bf5c661e8d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzMtMS0xLTEtMQ_6f8b8482-841d-4874-896f-850b5c20b52d"
      unitRef="usd">6188000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd34a35d15694242a41144a942e3bbd5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzMtMy0xLTEtMQ_592ef53d-c278-43d7-b5c7-85720e037ba8"
      unitRef="usd">1179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzQtMS0xLTEtMQ_1a36c7d8-0851-4dea-b9a9-541bf54da961"
      unitRef="usd">9719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpiMzRhMzRiNmJmNWU0ODcxYTYzYjhjODkxYzE0MTZhYy90YWJsZXJhbmdlOmIzNGEzNGI2YmY1ZTQ4NzFhNjNiOGM4OTFjMTQxNmFjXzQtMy0xLTEtMQ_44e761a8-2efa-4bf2-b12f-bf62719eaa82"
      unitRef="usd">1554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzEyMDIy_dc9ddc85-7de6-4f78-a6ea-2b5d5293d5ae">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of the employee stock option grants were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzMtMS0xLTEtMQ_1db27584-690a-40b2-b280-d377618fc0e8"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzMtMy0xLTEtMQ_387950a7-0127-4e91-9381-caf496323ee9"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzQtMS0xLTEtMQ_88eefc49-5c52-4bb0-8924-7a19a0fa5148"
      unitRef="number">0.762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzQtMy0xLTEtMQ_900260cf-eb95-4420-9312-68ad7005c4ca"
      unitRef="number">0.770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzUtMS0xLTEtMQ_ffd2fbb8-353e-4f94-b408-771a90cee213">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzUtMy0xLTEtMQ_6cb6a0fc-140e-4044-a801-f09a45b10f7a">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzYtMS0xLTEtMQ_90047a46-4c9f-4100-8a1c-29e8f15bed27"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90YWJsZTpmNTdjMmE0ODRiMDU0NmQ0YTc1ZTU4MmQwYTc1NTdmYy90YWJsZXJhbmdlOmY1N2MyYTQ4NGIwNTQ2ZDRhNzVlNTgyZDBhNzU1N2ZjXzYtMy0xLTEtMQ_a369c91f-71b1-4237-9f71-0244d1f96db7"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MTc3Mjk_08c1dc75-3f5d-4d63-8887-3ccc8d0a54d9"
      unitRef="usd">59200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3MjEzMDg_ff691230-3111-435d-9e1c-da1ea2ec2313">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i729c6da2107844e28908f101e5b69b18_I20180831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzExMzk1_becba571-e283-4cfb-b96e-be326adbef04"
      unitRef="shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <bngo:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding
      contextRef="i6e08bcf17c014092be59db6343e02b9d_D20180801-20180831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzExNjk4_e5fa7d52-ab62-4067-9092-afbcd2e384b0"
      unitRef="number">0.01</bngo:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2390b4b66da344ecb775181baacb32dc_I20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzExODU4_3b06f75a-f6ab-4d6a-a951-0fe6be46f3b1"
      unitRef="shares">220000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzExOTQx_b5593d14-ad03-4e7a-af50-c6c490dc07a5"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6ddb1728db3a49f8abb7b5af01e8a6e3_D20220215-20220215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3NDQ5MzI_e5c8ee0b-e457-4d9b-a215-9699badc717e"
      unitRef="shares">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6ddb1728db3a49f8abb7b5af01e8a6e3_D20220215-20220215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzM4NDgyOTA3NDc1MjM_2cd72693-b140-4c79-ad91-3a382d41e491"
      unitRef="usdPerShare">2.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4d5183cf0cdf481fb13cb77e135891e9_D20220215-20220215"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xNzgvZnJhZzo0MmQwYzMyZWI2Zjk0YjBhYjhlYjVmNjk5ZDVmZDYxOC90ZXh0cmVnaW9uOjQyZDBjMzJlYjZmOTRiMGFiOGViNWY2OTlkNWZkNjE4XzYwNDczMTQwMDMxMjI_22d5cc4a-2b2f-4baa-a694-1ce8c8a451b9">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzI4NjM_b0ddf761-67fe-494c-8b62-c0125845d29e">Commitments and Contingencies &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases approximately 35,823 square feet of office, laboratory, and manufacturing space in two buildings at our headquarters in San Diego, California, with the lease for all rented space expiring December 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2021, the Company executed a new lease for approximately 11,978 additional square feet square feet of office and laboratory space in San Diego, California that expires in January 2026.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2022, the Company executed a new lease for an additional 5,278 square feet of office and laboratory space in San Diego, California that expires in January 2026. Rent payments for the additional space are $16,000 each month through December 2022, and increases annually according to the Company&#x2019;s lease agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, through the acquisition of Lineagen, the Company obtained a lease for approximately 9,710 square feet of office space in a Salt Lake City, Utah under a non-cancelable operating lease that expires in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Finance lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, through the acquisition of BioDiscovery, the Company obtained a finance lease of 4,786 square feet of office space in El Segundo, California that expires in February 2041.  The portion of the future payments designated as principal repayment and related interest was classified as a finance lease obligation on our consolidated balance sheets. Refer to Note 15. Related Party Transactions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all leases, the Company has the ability to enter into renewal negotiations, prior to the lease end date, with no specific terms. At this time, it is not reasonably certain that we will extend the term of the lease and therefore the renewal period has been excluded from the aforementioned ROU asset and lease liability measurements. The leases are subject to variable charges for common area maintenance and other costs that are determined based on actual costs and includes certain lease incentives such as tenant improvement allowances. The base rent for the leases is subject to an annual increase each year. Rent expense is being recognized on a straight-line basis over the term of the lease. The Company&#x2019;s estimated incremental borrowing rate of 7.1% was used in its present value calculations as the operating and finance leases do not have a stated rate and the implicit rate was not readily determinable. In determining the incremental borrowing rate, the Company considered the interest rate of the Term Loans as well as publicly available data for discount rates used by peer companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental information pertaining to the Company&#x2019;s leases in which the Company is lessee for the year ended December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash payments included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;19.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncash lease liabilities resulting from obtaining right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,751,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of the Company&#x2019;s lease cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,118,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,504,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(422,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,552,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense and sublease income for the year ended December 31, 2020 reflects accounting treatment under ASC 840.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future minimum payments under non-cancellable operating and finance leases as of December&#160;31, 2021, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,881,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;322,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,011,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,088,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,949,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,162,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,407,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,658,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,755,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the adoption of ASC Topic 842, future minimum rental payments under operating leases as of December&#160;31, 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year Ending December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;734,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;666,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,464,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a contractual commitment with a supplier to purchase $0.3 million of products every month for an initial term of two years beginning in May 2021 until May 2023. The contract can be terminated with 90 days written notice by either party.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount of the loss can be reasonably estimated. Based on the Company&#x2019;s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Merger Agreement related to the acquisition of BioDiscovery, the Company agreed to pay a milestone payment of $10.0 million in cash contingent on the achievement of a commercial milestone within eighteen months of the acquisition date. The Company determined the fair value of the milestone consideration using a scenario-based technique, as the trigger for payment is event driven. The outcome of the milestone consideration is binary, meaning the milestone is either achieved or not achieved, and the only other variable factor is the timing of when the milestone is achieved. The Company determined it is highly likely that the milestone will be achieved and therefore used a 95% probability factor which is applied to the $10.0 million milestone consideration. Based on these valuation assumptions, a contingent liability of $9.0 million was recognized on the acquisition date. As of December&#160;31, 2021, the fair value of the milestone consideration was determined to be $9.1 million. The change in fair value of $0.1 million was recorded in selling, general and administrative expense in the consolidated statement of operations for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <bngo:LesseeOperatingLeaseAreaLeased
      contextRef="i826d7a082f1c44b7bf787aecb9e7c3ce_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTE1Mzg_f4a8745e-26a1-4d9c-a305-2121b2a4b810"
      unitRef="sqft">35823</bngo:LesseeOperatingLeaseAreaLeased>
    <bngo:LesseeOperatingLeaseAreaAdded
      contextRef="i826d7a082f1c44b7bf787aecb9e7c3ce_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1NDA0MDM_f62faffa-7f44-4c91-844b-26c53b687731"
      unitRef="sqft">11978</bngo:LesseeOperatingLeaseAreaAdded>
    <bngo:LesseeOperatingLeaseAreaAdded
      contextRef="ieb6d3ff5dfb74f5e9b0306ff18734baa_I20220131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1NDA0MTM_288ba825-bb96-4e73-86fa-a5cdbcec5ea2"
      unitRef="sqft">5278</bngo:LesseeOperatingLeaseAreaAdded>
    <bngo:OperatingLeaseMonthlyRentPayments
      contextRef="i320f1643428144d38fdcf459b451c4a6_D20220131-20220131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3Mjk2ODc_b355d2ed-1784-41ba-8da1-f67bd9c4688e"
      unitRef="usd">16000</bngo:OperatingLeaseMonthlyRentPayments>
    <bngo:LesseeOperatingLeaseAreaLeased
      contextRef="i470e708352854bb7934441171219601e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1NDEwMTg_dc3692a8-779b-4102-9c1b-2a48bd68b2fb"
      unitRef="sqft">9710</bngo:LesseeOperatingLeaseAreaLeased>
    <bngo:LesseeFinanceLeaseAreaLeased
      contextRef="i4ea6c5e3b632418db86e6b334229c600_I20211021"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTE1NjM_f769d3c3-7f46-41cc-9911-af18f50ef103"
      unitRef="sqft">4786</bngo:LesseeFinanceLeaseAreaLeased>
    <bngo:LesseeEstimatedIncrementalBorrowingRate
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1MzI1NzE_78f5ad52-76ef-42e1-a399-41abeb2b77e6"
      unitRef="number">0.071</bngo:LesseeEstimatedIncrementalBorrowingRate>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzI4NjY_28aa4b51-7ab5-45b3-ad0c-ebb09605e5f6">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental information pertaining to the Company&#x2019;s leases in which the Company is lessee for the year ended December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash payments included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;19.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncash lease liabilities resulting from obtaining right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,751,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of the Company&#x2019;s lease cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,118,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,504,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(422,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,552,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense and sublease income for the year ended December 31, 2020 reflects accounting treatment under ASC 840.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <bngo:OperatingLeasePaymentsModifiedAndUnmodified
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzEtNS0xLTEtMzUxOTA_9c8b25c1-1c33-4fc6-8ded-504c38c86af5"
      unitRef="usd">447000</bngo:OperatingLeasePaymentsModifiedAndUnmodified>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzItNS0xLTEtMzUxOTA_c164a5a1-5e06-4d27-ac33-408771fbff33"
      unitRef="usd">47000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzMtNS0xLTEtNDA0NDE_806f07d7-c4d1-4585-8313-508e0ceacd4d"
      unitRef="usd">5000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzQtNS0xLTEtMzUxOTA_4061f5ac-ba13-45c4-842e-a52644d8426d">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzUtNS0xLTEtMzUxOTA_2f53d161-087e-4087-8d73-c025f5d2a2cf">P19Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzItNS0xLTEtMQ_2d32badc-257a-47f2-9afc-4c5fb2dd9f7c"
      unitRef="number">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzMtNS0xLTEtMQ_08e22e7d-f16f-4579-b6dd-0f2162dd7562"
      unitRef="number">0.071</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTozMGQ1YTQ5OTNjNzI0NDNlODczMWQwOTg1YTA2MTNiMS90YWJsZXJhbmdlOjMwZDVhNDk5M2M3MjQ0M2U4NzMxZDA5ODVhMDYxM2IxXzUtNS0xLTEtMQ_395c014a-4b76-4b09-b470-6b97d150557e"
      unitRef="usd">4751000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzMtMS0xLTEtMzUyNjU_97030b97-0360-4d92-8dba-6df9c8e046ec"
      unitRef="usd">1118000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzMtMy0xLTEtMzUyNjU_66c4bbf7-e519-4c66-adc4-d2e1e28674ac"
      unitRef="usd">887000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzQtMS0xLTEtMzUyNjU_e3105880-e431-4f3a-b4d2-75ad5dffe538"
      unitRef="usd">386000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzQtMy0xLTEtMzUyNjU_ebef8f6f-c12c-49e7-a615-4b193b072e1b"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzUtMS0xLTEtMzUyNjU_4af6243d-c5bb-4465-ad60-f19053b9ce71"
      unitRef="usd">1504000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzUtMy0xLTEtMzUyNjU_2e2c8bb4-548a-41bf-b914-b0c5f311e175"
      unitRef="usd">887000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzctMS0xLTEtMzUyNjU_f64aa9a1-e34b-4bc6-8a24-879bf4553714"
      unitRef="usd">19000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzctMy0xLTEtMzUyNjU_4d626b16-f845-4620-84e4-498c92dda016"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzgtMS0xLTEtMzUyNjU_afc4e935-4a0e-4040-ac8c-a8e7640fa228"
      unitRef="usd">47000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzgtMy0xLTEtMzUyNjU_4e8813b3-aebf-4a05-9b6f-56af4a49499c"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <bngo:FinanceLeaseExpense
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzktMS0xLTEtMzUyNjU_4eec1c0c-bcc7-43a8-b35a-411fe1ca2991"
      unitRef="usd">66000</bngo:FinanceLeaseExpense>
    <bngo:FinanceLeaseExpense
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzktMy0xLTEtMzUyNjU_f450849f-edd6-42f7-af8e-d0afa89d0335"
      unitRef="usd">0</bngo:FinanceLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzExLTEtMS0xLTM1Mjcy_23b7dd7c-7581-49d0-9a98-b4c8d793a4d7"
      unitRef="usd">18000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzExLTMtMS0xLTM1Mjcy_803920ff-be22-4c76-ad6d-1b6b06452a22"
      unitRef="usd">422000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzEyLTEtMS0xLTQzNzQx_c1ba19d7-ce52-4c86-ad1d-ef2ce9e5a1ca"
      unitRef="usd">1552000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpmM2FmMDg2ZmM5NWQ0OGRkOTcwMDM5NzYxNzk1YzM2NS90YWJsZXJhbmdlOmYzYWYwODZmYzk1ZDQ4ZGQ5NzAwMzk3NjE3OTVjMzY1XzEyLTMtMS0xLTQzNzQx_5196c681-72a5-4723-b153-fe215319cc8f"
      unitRef="usd">465000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzU0OTc1NTgxNjAzMzU_7feeef88-e318-4138-9904-200f0ad1af00">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future minimum payments under non-cancellable operating and finance leases as of December&#160;31, 2021, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,881,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;322,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,011,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,088,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,949,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,162,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,407,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,658,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,755,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzU0OTc1NTgxNjAzMzU_d31869d5-f7c3-4723-b6a3-cc3475e2dd4e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future minimum payments under non-cancellable operating and finance leases as of December&#160;31, 2021, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,881,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;322,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,011,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,088,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;338,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,949,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,162,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,407,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,658,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,755,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzEtMS0xLTEtMzUzNzc_b8f00238-60aa-49b7-ac90-d82f1174b21b"
      unitRef="usd">1881000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzEtMy0xLTEtMzUzOTc_09763be1-a593-4484-b2de-b75f6901d68e"
      unitRef="usd">314000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzItMS0xLTEtMzUzNzc_01e75dde-aafa-49c9-8800-834882e7d9bb"
      unitRef="usd">1950000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzItMy0xLTEtMzUzOTc_9bf2062d-4d0b-4618-b796-6f119fc61173"
      unitRef="usd">322000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzMtMS0xLTEtMzUzNzc_7808020f-44df-4bb4-bb08-ac46e371cb3e"
      unitRef="usd">2011000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzMtMy0xLTEtMzUzOTc_c42ede60-7c9d-40c6-b557-02e70eac4d00"
      unitRef="usd">330000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzQtMS0xLTEtMzUzNzc_05a04f58-afbb-4bbb-9cea-7a59b5badc4f"
      unitRef="usd">2088000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzQtMy0xLTEtMzUzOTc_0ac904c0-9a0a-4caa-a1bd-de1ca12849a1"
      unitRef="usd">338000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzUtMS0xLTEtMzUzNzc_226a9ac6-d871-4249-b0f7-25c4d2f8acf3"
      unitRef="usd">232000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzUtMy0xLTEtMzUzOTc_3ff4de88-d9c6-494c-b86b-46295041d2e3"
      unitRef="usd">346000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzYtMS0xLTEtMzUzNzc_72be6bc3-45e3-45ba-b9c4-5c024a990340"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzYtMy0xLTEtMzUzOTc_dc889080-9c85-4f89-a27d-b8abdd9003a3"
      unitRef="usd">5949000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzctMS0xLTEtNDM2Mjg_39c0c893-40d6-41de-b4b9-92a1368a67fe"
      unitRef="usd">8162000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzctMy0xLTEtNDM2MzE_bdaf9eba-c667-4563-b862-79fb6f4fcfe8"
      unitRef="usd">7599000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzgtMS0xLTEtMzUzODg_f3562685-1585-482e-8d9c-c2a1b3839ed8"
      unitRef="usd">1407000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzgtMy0xLTEtMzUzODg_78055325-01ac-41cf-b5dd-d1e95f89ada3"
      unitRef="usd">3658000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzktMS0xLTEtNDM2Mjg_f925e995-ea07-4c25-87cd-c67aa6058b14"
      unitRef="usd">6755000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZToxMGIzMmE5OGQyOTI0NWM4ODRhMGFlZTA3YTMyY2I4My90YWJsZXJhbmdlOjEwYjMyYTk4ZDI5MjQ1Yzg4NGEwYWVlMDdhMzJjYjgzXzktMy0xLTEtNDM2MzE_61db2e83-54db-4d2c-9cd5-6849d8d933f1"
      unitRef="usd">3941000</us-gaap:FinanceLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzU0OTc1NTgxNjk1NDg_0fef1046-d517-4888-b796-b55250d639c3">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the adoption of ASC Topic 842, future minimum rental payments under operating leases as of December&#160;31, 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year Ending December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;734,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;666,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,464,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzEtNS0xLTEtNDk4OTc_d1fe34cc-28ab-4612-a477-ab0a2666f0a6"
      unitRef="usd">734000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzItNS0xLTEtNDk4OTc_a58feb50-6848-4971-bfe1-8c30315fa772"
      unitRef="usd">639000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzMtNS0xLTEtNDk4OTc_27d137f0-19c9-4a3e-b64a-dc21314c03d8"
      unitRef="usd">666000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzQtNS0xLTEtNDk4OTc_242dd01b-2dc1-44c5-a050-342b4f29e9f6"
      unitRef="usd">696000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <bngo:OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzUtNS0xLTEtNDk4OTc_acc0140a-7571-4e37-81dd-ea4e7658f838"
      unitRef="usd">729000</bngo:OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90YWJsZTpjMGYxZWNmMzY4OTE0ZTNmYmYxY2QxYjE3NDc3YTBmYi90YWJsZXJhbmdlOmMwZjFlY2YzNjg5MTRlM2ZiZjFjZDFiMTc0NzdhMGZiXzYtNS0xLTEtNDk5Mzg_734f6c4e-c07a-40fe-96a1-d403c1a14cd7"
      unitRef="usd">3464000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <bngo:ContractualCommitmentPurchaseOfProductsEveryQuarter
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MDEzMDY_4378d9c8-8cfa-481a-bb0b-6c6f09970848"
      unitRef="usd">300000</bngo:ContractualCommitmentPurchaseOfProductsEveryQuarter>
    <bngo:PurchaseObligationInitialPurchasePeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzE5NTE_d0f27164-ae08-4a4f-81ae-a9b0972e5238">P2Y</bngo:PurchaseObligationInitialPurchasePeriod>
    <bngo:PurchaseObligationContractTerminationPeriod
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzIwMTU_3e2f1d3a-cf82-4992-a7e0-57c1fe5cee70">P90D</bngo:PurchaseObligationContractTerminationPeriod>
    <bngo:ContingentConsiderationMilestonePayment
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTUyMTY_86f0dffe-e1c1-449e-bb78-74dddb12b8eb"
      unitRef="usd">10000000</bngo:ContingentConsiderationMilestonePayment>
    <bngo:ContingentConsiderationMilestonePayment
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTUyMzE_86f0dffe-e1c1-449e-bb78-74dddb12b8eb"
      unitRef="usd">10000000</bngo:ContingentConsiderationMilestonePayment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idebec6bf5580446897b029f768bd15cf_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTUyNDY_d6018568-c509-40f1-af97-be8039c22668"
      unitRef="usd">9000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <bngo:ContingentConsiderationFairValueOfContingentLiability
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzQzOTgwNDY1MzI1Nzg_52bba8db-d188-427e-a05f-7255617db5b9"
      unitRef="usd">9100000</bngo:ContingentConsiderationFairValueOfContingentLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i05172e87df1541b6abebf75d4d8bb195_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODEvZnJhZzozZTA5MGMyNzk0NDk0ZmE1OWM3ZTYxYzc4OTRjNWIxZC90ZXh0cmVnaW9uOjNlMDkwYzI3OTQ0OTRmYTU5YzdlNjFjNzg5NGM1YjFkXzM4NDgyOTA3MTUyMDE_358b1c77-287a-4317-a3a1-250529fc205f"
      unitRef="usd">100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTU_d2af6c27-6499-474c-acec-2564773ce5eb">Income Taxes&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of income (loss) from continuing operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78,356,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,191,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78,152,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,077,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for domestic and foreign income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,055,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,722,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,777,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,717,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliations of the income tax computed at the federal statutory tax rate to the expense for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,413,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,626,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,030,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(522,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,879,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,816,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Section 162(m)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;966,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(165,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(938,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(568,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,717,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets at December&#160;31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,399,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,354,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,911,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,671,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ASC 842 - lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93,133,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,623,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,478,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(350,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ASC 842 - ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,504,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83,151,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70,273,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has federal and state tax net operating loss carryforwards of $341.1 million and $158.4 million, respectively. The federal tax loss carryforwards include $176.8 million that do not expire but utilization is limited to 80% of the Company's taxable income in any given tax year based on current federal tax laws. The remaining federal tax loss carryforwards of $164.3 million and state tax loss carryforwards begin to expire in 2027 and 2023, respectively, unless previously utilized. As of December&#160;31, 2021, the Company also has federal and California research credit carryforwards of $6.7 million and $6.1 million, respectively. The federal research credit carryforwards begin to expire in 2027 unless previously utilized. The California research credits carry forward indefinitely. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assesses all available evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company has experienced net losses since inception, and the revenue and income potential of the Company&#x2019;s business and market are unproven. Due to the Company&#x2019;s continuing research and development ("R&amp;amp;D") activities, the Company expects to continue to incur net losses into the foreseeable future. As such, the Company cannot conclude that it is more likely than not that its deferred tax assets will be realized. A valuation allowance of  $83.2&#160;million, and $70.3&#160;million as of December&#160;31, 2021, and 2020, respectively, has been established to offset the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired BioDiscovery, LLC. an entity designated for income tax purposes as a corporation in a plan of reorganization  within the meaning of Section 368(a)(1)(A) on  October 18, 2021. Under ASC 805-740, the Company recorded deferred tax liabilities of $5.8 million related to customer lists, patents/trademarks, developed technology, and fixed assets as part of the business combination. As the deferred tax liability recorded in the business combination constitutes a source of future taxable income, the Company recorded a decrease to its valuation allowance against its deferred tax assets of $5.8&#160;million as a deferred income tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the net operating losses and R&amp;amp;D credit carryforwards are subject to annual limitations due to ownership changes that have occurred or that could occur in the future, as required by Sections 382 and 383 of the Internal Revenue Code of 1986,as amended (the "Code"), as well as similar state and foreign provisions. These ownership changes will limit the amount of net operating losses and R&amp;amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change" as defined by Section 382 of the Code results from a transaction or series of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transactions over a three-year period resulting in an ownership change of more than 50 percentage points of outstanding stock of a company by certain stockholders. Due to the existence of the valuation allowance, limitations created by past or future ownership changes, if any, will not impact its effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company last performed a 382 study during 2013 and since this date there have been changes in ownership that will limit the Company's ability to utilize the net operating loss and R&amp;amp;D credit carryforwards. The Company is in the process of refreshing its 382 study but the results of that analysis are unknown as of the issuance date of these consolidated financial statements. The completion of the 382 study could result in material reductions to deferred tax assets and related valuation allowance disclosed above. However, the Company had not utilized any of the net operating losses and R&amp;amp;D credits during the years ended December 31, 2021 and 2020.          &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliations of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,201,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,708,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions/(reductions) for tax positions - prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;687,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,119,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,201,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the benefit of uncertain tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. Due to the valuation allowance position, none of the unrecognized tax benefits, if recognized, will impact the Company`s effective tax rate. The Company does not anticipate a significant change in the unrecognized tax benefits during the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company had no accrual of interest and penalties on the Company&#x2019;s balance sheets and has not recognized any interest and penalties in the statements of operations for the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation in the United States, the United Kingdom and China. The Company's tax years from 2007 (inception) are subject to examination by the United States and state authorities due to the carry forward of unutilized net operating losses and R&amp;amp;D credits.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTc_3c9fbd8a-86bc-4587-9dd4-8d6dfd409b7a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of income (loss) from continuing operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78,356,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,191,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78,152,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,077,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzItMS0xLTEtMQ_23012f79-e97f-4cc1-8c2e-4dd9c2fb3e36"
      unitRef="usd">-78356000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzItMy0xLTEtMQ_70fc7f58-cab2-4be1-b326-e93cd2eeebab"
      unitRef="usd">-41191000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzMtMS0xLTEtMQ_27175a9f-fdaf-4b7d-9439-b2cf4ce2cffe"
      unitRef="usd">204000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzMtMy0xLTEtMQ_c684c1e4-b961-4853-ae41-0f59f139909f"
      unitRef="usd">114000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzQtMS0xLTEtMQ_727ad42c-3f07-4cdc-839a-8c5f0a728d6a"
      unitRef="usd">-78152000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpiZWQ3NDlhM2RjMTI0MjlkOTA5ZDQ2NzZkMTRjY2JlMS90YWJsZXJhbmdlOmJlZDc0OWEzZGMxMjQyOWQ5MDlkNDY3NmQxNGNjYmUxXzQtMy0xLTEtMQ_30b25395-5684-4d02-b646-d0edd8f64000"
      unitRef="usd">-41077000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTE_65270edc-dc40-448b-987d-102b037afef4">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for domestic and foreign income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,055,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,722,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,777,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,717,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzMtMS0xLTEtNDIyMTc_2db49419-1d89-4d80-a537-45907406056e"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzMtMy0xLTEtNDIyMTc_f0fd505f-d546-46ae-8d34-64112646190d"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzMtMS0xLTEtMQ_7c24f773-e07d-46b4-8ecb-124079040b0f"
      unitRef="usd">39000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzMtMy0xLTEtMQ_f37dae88-4bc0-416b-be44-d955156670e5"
      unitRef="usd">24000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzQtMS0xLTEtMQ_3769b693-26ee-4445-acc2-8f5a14657504"
      unitRef="usd">21000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzQtMy0xLTEtMQ_e1d5dc31-b6de-45db-93c7-c1eeae27fcd2"
      unitRef="usd">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzUtMS0xLTEtMQ_c9819a64-54d0-48a3-9bdd-1372db25575a"
      unitRef="usd">60000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzUtMy0xLTEtMQ_0503c990-3ab8-4106-9e48-e9417a6a339d"
      unitRef="usd">29000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzgtMS0xLTEtNDgwMzI_e58bc81e-2eb4-4e6a-8f71-3bb616d00ec9"
      unitRef="usd">-4055000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzgtMy0xLTEtNDgwNDA_10899e96-2dd0-467a-a6ec-b52e0c25ec15"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzktMS0xLTEtNDgwNDA_1c48f5b7-4f98-4887-8f08-9a3f22a3678c"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzktMy0xLTEtNDgwNDA_e458bf52-07e6-47df-97c1-3030147d70e1"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzEwLTEtMS0xLTQ4MDQw_b67d0109-66e8-44c8-8e38-f61ebc752dde"
      unitRef="usd">-1722000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzEwLTMtMS0xLTQ4MDQw_0d531fa1-d1ff-4959-8400-f21835439b27"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzExLTEtMS0xLTQ4MDUw_5c562408-c1de-438d-9015-1a74fecd95a3"
      unitRef="usd">-5777000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzExLTMtMS0xLTQ4MDUx_d136c7b7-c212-4edd-b5cd-7a18af7f2cf8"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzEyLTEtMS0xLTQ4MDUw_c48138ec-8afd-43e9-a76c-e0641d72a057"
      unitRef="usd">-5717000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpmNmJmMzJiMmNlMDI0NzUwYTBhYjM1MDEyMmMwY2U5MS90YWJsZXJhbmdlOmY2YmYzMmIyY2UwMjQ3NTBhMGFiMzUwMTIyYzBjZTkxXzEyLTMtMS0xLTQ4MDUx_407bd351-8c58-4138-aa6a-faf39738a254"
      unitRef="usd">29000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTg_fde17efa-a640-41a2-b973-f20543522965">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliations of the income tax computed at the federal statutory tax rate to the expense for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,413,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,626,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,030,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(522,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,879,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,816,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Section 162(m)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;966,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(165,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(938,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(568,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,717,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzItMS0xLTEtMQ_722c6f2d-851b-49ad-916a-b47c57a9fd41"
      unitRef="usd">-16413000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzItMy0xLTEtMQ_1585f368-52b1-49f7-ad5e-58f263977429"
      unitRef="usd">-8626000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzMtMS0xLTEtMQ_11d472af-f9d8-4f07-8399-95bfe91eea81"
      unitRef="usd">-2030000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzMtMy0xLTEtMQ_38a34f29-1445-4c8f-ba46-19f96284a8a5"
      unitRef="usd">-522000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzQtMS0xLTEtMQ_ee474f93-3e2e-4e71-94f7-55a8c9329ee0"
      unitRef="usd">12879000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzQtMy0xLTEtMQ_ffb9748e-0cb7-4907-9a0c-7f6e22d27d30"
      unitRef="usd">9816000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <bngo:EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzUtMS0xLTEtNTM1ODI_36fa3645-55e2-412d-b3d0-861d115de21e"
      unitRef="usd">966000</bngo:EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount>
    <bngo:EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzUtMy0xLTEtNTM1ODk_1eac48c2-97e0-470a-964b-663e97aec9aa"
      unitRef="usd">0</bngo:EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzUtMS0xLTEtMQ_14cc1080-a2b9-4675-9a76-093129f71468"
      unitRef="usd">-165000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzUtMy0xLTEtMQ_12f9f20e-5766-4b30-93e3-3e34e131b4b0"
      unitRef="usd">-67000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzYtMS0xLTEtMQ_8388ce7e-0b59-4bae-a046-a7814798fefd"
      unitRef="usd">938000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzYtMy0xLTEtMQ_53694a21-cf06-473d-ae5b-a9eddf4c22dc"
      unitRef="usd">568000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzctMS0xLTEtMQ_7a77aba8-3adf-4baa-8d2b-de174122c860"
      unitRef="usd">-16000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzctMS0xLTEtMQ_ba5b443a-ba99-402e-987e-d1601bc5d0e4"
      unitRef="usd">-16000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzctMy0xLTEtMQ_30509249-a5bd-48f7-986e-c2676195f327"
      unitRef="usd">-4000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzgtMS0xLTEtMQ_503c3d8d-457f-49dd-84b3-1c9d971844cd"
      unitRef="usd">-5717000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTpkN2E3ZDY4ZjNjOWM0M2VlYjExNjMyYWU3NzkyODUzMC90YWJsZXJhbmdlOmQ3YTdkNjhmM2M5YzQzZWViMTE2MzJhZTc3OTI4NTMwXzgtMy0xLTEtMQ_77e075d9-6b03-42de-a615-205abb925b05"
      unitRef="usd">29000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTk_d3d0b31b-29c5-494d-9cf8-878e10a5444c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets at December&#160;31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,399,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,354,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,911,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,671,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ASC 842 - lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93,133,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,623,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,478,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(350,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ASC 842 - ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,504,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83,151,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 5.5pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70,273,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 5.5pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzMtMS0xLTEtMQ_3de95228-cd38-4bce-8b64-44c82f55f994"
      unitRef="usd">81399000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzMtMy0xLTEtMQ_d2b57344-b24b-4fde-bb68-ed8c1570a361"
      unitRef="usd">62354000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzQtMS0xLTEtMQ_adbb60f8-65d6-4d38-a48f-fb845a922eb5"
      unitRef="usd">6911000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzQtMy0xLTEtMQ_f16cc741-524e-4da2-bf1a-6b87cf51df9a"
      unitRef="usd">5671000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzUtMS0xLTEtNDgxNzM_5b895349-9d99-47ed-b418-40b55c6a5baf"
      unitRef="usd">849000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzUtMy0xLTEtNDgxODU_056a9a16-ae38-49af-943a-c1a9440fe531"
      unitRef="usd">450000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <bngo:DeferredTaxAssetsLeaseLiability
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzYtMS0xLTEtNDgxNzk_00e2ae43-a409-430c-b08f-1be709b76e5a"
      unitRef="usd">2517000</bngo:DeferredTaxAssetsLeaseLiability>
    <bngo:DeferredTaxAssetsLeaseLiability
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzYtMy0xLTEtNDgxNzk_310e1ad4-7006-4bc8-995f-17c8ba4168e8"
      unitRef="usd">0</bngo:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzUtMS0xLTEtMQ_47982230-4847-422e-9ea7-493b73f9bc0a"
      unitRef="usd">1457000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzUtMy0xLTEtMQ_a17fb5b5-7fad-45ea-8efa-accbb7411dc6"
      unitRef="usd">2148000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzYtMS0xLTEtMQ_30fc090e-1be6-4dc9-a755-d9cff58e8410"
      unitRef="usd">93133000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzYtMy0xLTEtMQ_ef0a9422-a287-47ab-9d50-10c53be91f8e"
      unitRef="usd">70623000</us-gaap:DeferredTaxAssetsGross>
    <bngo:DeferredTaxLiabilitiesAmortization
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzEwLTEtMS0xLTQ4MjAx_22664231-3145-46d0-ab01-2713a5081141"
      unitRef="usd">7478000</bngo:DeferredTaxLiabilitiesAmortization>
    <bngo:DeferredTaxLiabilitiesAmortization
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzEwLTMtMS0xLTQ4MjAx_3a094d45-53e0-4c26-943d-8f448ca22ab6"
      unitRef="usd">350000</bngo:DeferredTaxLiabilitiesAmortization>
    <bngo:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzExLTEtMS0xLTQ4MjAx_cadd0896-ceca-4735-872f-7391557a12e1"
      unitRef="usd">2504000</bngo:DeferredTaxLiabilitiesRightOfUseAsset>
    <bngo:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzExLTMtMS0xLTQ4MjAx_d79061e3-6bc1-47de-850e-ca0755e2d4e3"
      unitRef="usd">0</bngo:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzEyLTEtMS0xLTQ4MjAx_95c01804-1bc4-4429-98aa-2511c401f049"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzEyLTMtMS0xLTQ4MjAx_d99e4bfd-f03d-482b-9ed3-edb19e7b10f9"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzctMS0xLTEtMQ_569098e7-646c-43c5-8ad9-7ac02ca1ef4c"
      unitRef="usd">83151000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzctMy0xLTEtMQ_caa8c856-83b7-4447-9335-03f9acaf89f4"
      unitRef="usd">70273000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzgtMS0xLTEtMQ_2ff73e90-e7ad-4d94-99ce-dc201a0e615f"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTo0NmQ0ZWQyZjYyOTM0MTg4YWQ4MjFkOTQxZjEwNDFmMy90YWJsZXJhbmdlOjQ2ZDRlZDJmNjI5MzQxODhhZDgyMWQ5NDFmMTA0MWYzXzgtMy0xLTEtMQ_830673b8-c2d7-4121-8927-b8c9c6a327a7"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib44b75fe239a4b60b494433a3f77f70d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQxOTA_9a825737-946f-4c03-ab8c-a692a4d622df"
      unitRef="usd">341100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i99a808d515494cdbadb3da6e47f4e15c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQzMzI_45cca2dd-6db7-4a6e-9ce8-c233ff238d82"
      unitRef="usd">158400000</us-gaap:OperatingLossCarryforwards>
    <bngo:OperatingLossCarryforwardsNotSubjecttoExpiration
      contextRef="ib44b75fe239a4b60b494433a3f77f70d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQzNDg_e6f08e95-368d-4e26-afbe-98588f08cd38"
      unitRef="usd">176800000</bngo:OperatingLossCarryforwardsNotSubjecttoExpiration>
    <bngo:OperatingLossCarryforwardsSubjecttoExpiration
      contextRef="i99a808d515494cdbadb3da6e47f4e15c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQ1ODg_62eb401e-9d35-44c2-a76a-155b22deb85b"
      unitRef="usd">164300000</bngo:OperatingLossCarryforwardsSubjecttoExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i29f75a2dd05a4220bc087386e5a5149b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQ3MTU_60090ac3-8dfb-46d8-ab70-b8cd8fbcfa7d"
      unitRef="usd">6700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic4c282464a94473ba123371ddc89314a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDQ3MjI_26e37b31-f1b8-4d3a-87f7-9605a194cf3e"
      unitRef="usd">6100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzE3MzA_6045e6a5-86fd-4d8c-bb99-5a0e01a0ad67"
      unitRef="usd">83200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzE3Mzc_64491bce-5a88-4a6f-a26f-e0f41f4becb0"
      unitRef="usd">70300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i3624ecef1ddd4361a818dfb9464218ce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzM4NDgyOTA3MDUzOTY_e3d3880f-2ffe-4238-a644-d15addf5c544"
      unitRef="usd">5800000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYwNDczMTM5NjEzMzY_4a7056bb-1327-482a-bbee-e698be7e83d9"
      unitRef="usd">-5800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90ZXh0cmVnaW9uOjkyNmQ5M2E3NmY2ODQ3MjhiNzY5ZjViNzVlYzU5NmFkXzYxNTM_13f01e5b-259b-4a32-943e-a449b49d5e5c">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliations of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,201,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,708,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions/(reductions) for tax positions - prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase related to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;687,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,119,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,201,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzItMS0xLTEtMQ_1dd35e20-2312-4127-b372-6acff23cdfc4"
      unitRef="usd">4201000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzItMy0xLTEtMQ_d329b009-0aba-4ed0-b1f9-b56a1b143a91"
      unitRef="usd">3708000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzMtMS0xLTEtMQ_eb6b7764-78aa-4deb-a83a-9c60e1281238"
      unitRef="usd">231000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzMtMy0xLTEtMQ_b047c830-e076-4c6c-a249-99eb48d8065f"
      unitRef="usd">53000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzQtMS0xLTEtMQ_be9a59fc-1219-4783-88a9-5fdd7a6c015c"
      unitRef="usd">687000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzQtMy0xLTEtMQ_4571715f-4173-40a8-beb3-ac1acc87680c"
      unitRef="usd">440000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ifedeab9392574bbf9284ae95544b0969_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzUtMS0xLTEtMQ_3e6b9ebb-0097-4a0c-8e61-93b5e6b1cf23"
      unitRef="usd">5119000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODQvZnJhZzo5MjZkOTNhNzZmNjg0NzI4Yjc2OWY1Yjc1ZWM1OTZhZC90YWJsZTplMWVkZTM2Mzk5NjI0NmI3YjA5NWRhYWE5MDUxNzJjMi90YWJsZXJhbmdlOmUxZWRlMzYzOTk2MjQ2YjdiMDk1ZGFhYTkwNTE3MmMyXzUtMy0xLTEtMQ_906d7828-542a-40e0-90ef-c567bc324043"
      unitRef="usd">4201000</us-gaap:UnrecognizedTaxBenefits>
    <bngo:DefinedContributionPlanDisclosuresTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODcvZnJhZzo5NGVmMDU4NDgzYWU0ZjkzODI5ZjllYTBjZGZkYzI5ZC90ZXh0cmVnaW9uOjk0ZWYwNTg0ODNhZTRmOTM4MjlmOWVhMGNkZmRjMjlkXzQ2OA_a23376a0-12af-4ea2-ac65-1eb8c1953675">Employee Benefits The Company has a defined contribution 401(k) plan available to eligible employees. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. The Company expensed matching contributions of $0.83&#160;million and $0.46&#160;million for the years ended December&#160;31, 2021 and 2020, respectively.</bngo:DefinedContributionPlanDisclosuresTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODcvZnJhZzo5NGVmMDU4NDgzYWU0ZjkzODI5ZjllYTBjZGZkYzI5ZC90ZXh0cmVnaW9uOjk0ZWYwNTg0ODNhZTRmOTM4MjlmOWVhMGNkZmRjMjlkXzEwOTk1MTE2MjgyOTk_bf0d8cd2-8ce7-4b5a-9304-f8f8578912b8"
      unitRef="usd">830000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ia410863cec75450bb20b01bb978eb339_D20200101-20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xODcvZnJhZzo5NGVmMDU4NDgzYWU0ZjkzODI5ZjllYTBjZGZkYzI5ZC90ZXh0cmVnaW9uOjk0ZWYwNTg0ODNhZTRmOTM4MjlmOWVhMGNkZmRjMjlkXzEwOTk1MTE2MjgzMDY_c52e8406-bf6a-46b9-b654-ac662a35e2c8"
      unitRef="usd">460000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzczNjk_ce4ec5bf-f402-4cfb-abee-274572846aa4">Acquisitions&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lineagen Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company, Merger Sub, Lineagen, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the security-holders of Lineagen, entered into the Lineagen Merger Agreement. Pursuant to the terms and conditions of the Lineagen Merger Agreement, Merger Sub merged with and into Lineagen whereupon the separate corporate existence of Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Merger as a wholly owned subsidiary of the Company. Lineagen&#x2019;s expertise in development, commercialization and reimbursement of laboratory-developed tests provides a platform for accelerating sales growth for the Company&#x2019;s Saphyr system. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Lineagen Merger Agreement, at the effective time of the Merger (the &#x201c;Effective Time&#x201d;), the shares of capital stock of Lineagen and all options of Lineagen that were issued and outstanding immediately prior to the Effective Time were automatically cancelled and extinguished without any payment with respect thereto. Certain holders of convertible notes and other indebtedness of Lineagen at the closing of the Merger (the &#x201c;Closing&#x201d;) received common stock of the Company. The total number of shares of the Company&#x2019;s common stock issued or reserved for issuance as consideration for the Merger was 6,167,510 shares, subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen (the &#x201c;Merger Shares&#x201d;). 925,126 of the Merger Shares (the &#x201c;Escrowed Shares&#x201d;) were held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the Lineagen Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also as consideration for the Merger, pursuant to the Lineagen Merger Agreement, the Company paid approximately $1.9&#160;million in cash to certain creditors and assumed certain liabilities of Lineagen totaling approximately $2.9&#160;million, reflective of the Company's preliminary estimate of the post-closing purchase price adjustment (which adjustment is subject to finalization pursuant to the terms of the Lineagen Merger Agreement).  In addition, on August 21, 2020, concurrent with the Closing, the Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to that certain Promissory Note, dated April 22, 2020, by and between Lineagen and Silicon Valley Bank (the &#x201c;Lineagen PPP Loan&#x201d;), issued pursuant to the CARES Act administered by the SBA. The Lineagen PPP Loan was repaid by the Company prior to maturity without penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for its acquisition of Lineagen using the acquisition method of accounting pursuant to ASC 805.  The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non tax deductible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. During the fourth quarter of 2020, the Company recorded a $0.2 million adjustment to the original purchase price allocation to reduce the estimated fair value of accounts receivable, with the offsetting amount recorded to goodwill. There were no additional purchase price adjustments made during 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the purchase price for the acquisition of Lineagen:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,940,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash transferred for repayment of Lineage PPP Loan (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,105,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares common stock issued as consideration (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,167,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares of common stock returned to the Company (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(138,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock price per share on closing date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Value of common stock consideration (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total purchase price (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) The Company paid approximately $1.9&#160;million in cash to certain creditors of Lineagen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) The Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c) The total number of shares of the Company&#x2019;s common stock issued as consideration for the Merger was 6,167,510 shares. The total number of Merger Shares was subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the common stock consideration and the total purchase price incorporated the return of 138,247 Escrowed Shares to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase price was allocated to Lineagen&#x2019;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;337,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;209,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;111,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2,862,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of identifiable intangible assets acquired are as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized approximately $1.5&#160;million of acquisition-related transaction costs, including financial advisor fees, legal expenses and accounting fees during the year ended December&#160;31, 2020. These costs are included in the consolidated statement of operations in selling, general and administrative expense. Also, the Company reported approximately $1.5&#160;million of service revenue generated by Lineagen in its consolidated statement of operations from the date of acquisition through December&#160;31, 2020. As the Company began integrating Lineagen&#x2019;s operations with its existing operations during the fourth quarter of 2020, it is not practical or meaningful to distinguish Lineagen&#x2019;s expenses or net income or loss from that of the combined operations for 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BioDiscovery Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company completed the acquisition of BioDiscovery, LLC., pursuant to the BioDiscovery Merger Agreement. BioDiscovery's solutions for analysis, interpretation and reporting of genomics data is expected to accelerate and broaden Bionano&#x2019;s market leadership in digital cytogenetics and comprehensive genome analysis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to BioDiscovery Merger Agreement, the Company paid upfront consideration consisting of a combination of approximately $52.3&#160;million in cash and $40.0&#160;million in shares of Company common stock. Approximately $26.0&#160;million worth of the shares of the Company&#x2019;s common stock issued pursuant to the upfront consideration are subject to vesting based on continued service, subject to the terms and conditions of a stock restriction agreement. Accordingly, the restricted stock is being accounted for as compensation over the requisite service period, and is not included in the purchase price. The upfront consideration is subject to adjustment for, among other things, cash, unpaid indebtedness, unpaid transaction expenses and working capital relative to a target. Under the BioDiscovery Merger Agreement, the Company has also agreed to pay a milestone payment of $10.0&#160;million in cash based on the achievement of certain commercial milestones. Cash of $2.5&#160;million will be held in an escrow fund for purposes of satisfying any post-closing purchase price adjustments and indemnification claims under the BioDiscovery Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for its acquisition of BioDiscovery using the acquisition method of accounting pursuant to ASC 805. The tangible and identifiable intangible assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date, and the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed was recorded to goodwill. Goodwill relates to the expected synergies from combining the operations of the companies. The acquisition was structured as a stock sale and therefore goodwill is non-tax deductible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The purchase price allocation for the acquisition of BioDiscovery is preliminary and subject to revision as additional information about the fair value of assets and liabilities becomes available. As permitted under ASC 805, the Company is allowed a measurement period, which may not exceed one year, in which to complete its accounting for the acquisition. Per the terms of the BioDiscovery Merger Agreement, the purchase price is still subject to adjustment for the final determination of cash, unpaid indebtedness, unpaid transaction expenses and working capital, as well for deferred and current tax assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the estimated purchase price for the acquisition of BioDiscovery:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,291,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Estimated fair value of milestone consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Estimated return of cash to buyer from escrow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(694,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,723,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Stock price per share on closing date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Value of estimated common stock consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;14,159,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total estimated purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;74,756,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated purchase price was allocated to BioDiscovery&#x2019;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,205,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,782,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,987,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,987,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Right-of-use liabilities (short-term and long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,987,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,777,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;74,756,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of identifiable intangible assets acquired are as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;22,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tradename&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Fair value of identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;26,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the income approach to derive the fair value of the identified intangible assets acquired. This approach calculates fair value by estimating future cash flows attributable to the assets and then discounting these cash flows to a present value using a risk-adjusted discount rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The developed technology, customer relationships and trade name intangibles are both being amortized on a straight-line basis over their estimated useful lives of five years. Straight-line amortization was determined to be materially consistent with the pattern of expected use of the intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized approximately $-1.5&#160;million of acquisition-related transaction costs, including financial advisor fees, legal expenses and accounting fees during the year ended December&#160;31, 2021. These costs are included in the consolidated statement of operations in selling, general and administrative expense. The Company reported approximately $1.1&#160;million of revenue generated by BioDiscovery in its consolidated statement of operations from the date of acquisition through December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company began integrating BioDiscovery&#x2019;s operations with its existing operations during the fourth quarter of 2021, it is not practical or meaningful to distinguish BioDiscovery&#x2019;s expenses or net income or loss from that of the combine operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pro forma Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company, Lineagen, and BioDiscovery as if the companies had been combined as of the beginning of the year prior to the acquisition. These amounts have been calculated after applying the Company&#x2019;s accounting policies and adjusting the results of Lineagen and BioDiscovery to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied at the beginning of the year prior to the acquisition. The following unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisitions had taken place as of January 1, 2019 and January 1, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;br/&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,076,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,927,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(80,065,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,228,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgyMDE5MTk_50d5410e-b5d7-441b-9a0c-470ee1e0f0ed"
      unitRef="shares">6167510</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ic37f97c4ea0a4f4bb16de8adcef347a3_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQzOTgwNDY1NzI0MzY_bba8d763-25ee-477a-b6c2-10e92283fdf8"
      unitRef="shares">925126</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgyMDE5MzA_3a76afbc-033f-44cc-b42d-fc400bb4a204"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgyMDE5NDQ_e49aa9ba-3bc3-4c3f-b620-c3c43202022f"
      unitRef="usd">2900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgyMDE5NTg_ab36651c-1a7b-46fc-86d4-5c2e0c336ba7"
      unitRef="usd">1100000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
      contextRef="i132f0f05159f47b79fd74e910694340d_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQzOTgwNDY1NzI5MjM_5feba808-d493-49ed-8f21-899c376c0abe"
      unitRef="usd">200000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzczNjQ_4af8e24b-f03c-4473-ab0d-3e0c6e10a261">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the purchase price for the acquisition of Lineagen:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,940,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash transferred for repayment of Lineage PPP Loan (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,105,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares common stock issued as consideration (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,167,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares of common stock returned to the Company (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(138,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock price per share on closing date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Value of common stock consideration (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total purchase price (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) The Company paid approximately $1.9&#160;million in cash to certain creditors of Lineagen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) The Company paid approximately $1.1&#160;million to satisfy all outstanding principal and accrued interest amounts due pursuant to the Lineagen PPP Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c) The total number of shares of the Company&#x2019;s common stock issued as consideration for the Merger was 6,167,510 shares. The total number of Merger Shares was subject to adjustment for cash, accounts receivable, unpaid indebtedness, unpaid transaction expenses and certain other liabilities of Lineagen. The value of the common stock consideration and the total purchase price incorporated the return of 138,247 Escrowed Shares to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the estimated purchase price for the acquisition of BioDiscovery:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,291,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Estimated fair value of milestone consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Estimated return of cash to buyer from escrow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(694,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares common stock issued as consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,723,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Stock price per share on closing date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Value of estimated common stock consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;14,159,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total estimated purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;74,756,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzAtMi0xLTEtMQ_fbaa27c1-e1d7-49cd-8469-6b42baebde46"
      unitRef="usd">1940000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzEtMi0xLTEtMQ_244972ec-a6ad-46e4-84dc-c4b7ae65ed40"
      unitRef="usd">1105000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzItMi0xLTEtMQ_4c4b542a-2bc9-45e4-89aa-d6dec648e5e7"
      unitRef="shares">6167510</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzMtMi0xLTEtMQ_61ad9d01-dc5f-4a2b-99ce-751ad20ea67b"
      unitRef="shares">138247</bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzQtMi0xLTEtMQ_b5f4631a-56a1-481e-b8ce-f4aef4bb8c01"
      unitRef="usdPerShare">0.68</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzUtMi0xLTEtMQ_3df159eb-f91a-4717-82da-d2a54d15216e"
      unitRef="usd">4100000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1OTc5NzJlMWYwY2M0NWZmOTY4NGYwMjA5MzJmMWRlNi90YWJsZXJhbmdlOjU5Nzk3MmUxZjBjYzQ1ZmY5Njg0ZjAyMDkzMmYxZGU2XzYtMi0xLTEtMQ_b9d14da9-729b-4ebb-bb9f-7b85e55eaeeb"
      unitRef="usd">7144000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQzMTY_366f378a-f563-43bb-9ea6-9a6e379a0356"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQzOTY_93bfee4b-1f07-40e6-b11b-1f82a70d35c9"
      unitRef="usd">1100000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzQ2MzM_9d3190cd-05d3-4d5c-89d1-d78b9d63fbc0"
      unitRef="shares">6167510</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzUxMzk_ae71303c-5271-4c28-abb5-b42af709373b"
      unitRef="shares">138247</bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzczNjU_71c67f7c-1ca6-4fc9-9aa4-6ae4dc624617">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase price was allocated to Lineagen&#x2019;s tangible and identifiable intangible assets acquired and liabilities assumed on based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;337,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;209,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;111,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2,862,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The total estimated purchase price was allocated to BioDiscovery&#x2019;s tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded as goodwill, as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,205,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,782,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,987,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,987,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounts payable and other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Right-of-use liabilities (short-term and long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,987,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,777,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;74,756,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzAtMi0xLTEtMQ_f12b383c-d68a-41fe-ba84-de48a854bce6"
      unitRef="usd">596000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzEtMi0xLTEtMQ_887e7f70-2b64-464c-bc43-c1309a06eab6"
      unitRef="usd">337000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzItMi0xLTEtMQ_7965b304-890e-48d0-976f-96375b944c4b"
      unitRef="usd">209000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzMtMi0xLTEtMQ_335b9dd0-664c-44f6-b9c6-be50a04dabf4"
      unitRef="usd">111000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzQtMi0xLTEtMQ_08f418a7-0ac6-4f76-a100-ae589f0dc5ad"
      unitRef="usd">1580000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzUtMi0xLTEtMQ_b0e27398-e2c6-4ee4-80c6-0900b1583e5a"
      unitRef="usd">7173000</us-gaap:Goodwill>
    <bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzYtMi0xLTEtMQ_8cd75bb0-c2c2-476e-b990-fa66c89d67c0"
      unitRef="usd">2862000</bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyZWQ2ZWYzOTVmMzI0ZmM4YWJjYjlhOGU1M2M4NDhiMC90YWJsZXJhbmdlOjJlZDZlZjM5NWYzMjRmYzhhYmNiOWE4ZTUzYzg0OGIwXzctMi0xLTEtMQ_dc7624e1-07bc-4c2e-8263-6b1724f00a2d"
      unitRef="usd">7144000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzczNjY_25bc7320-d2bb-4c75-b135-2e9d68e15c9d">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of identifiable intangible assets acquired are as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;950,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;630,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,580,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i257cbc434ff74964959fc60f88c37154_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyNWUwOGExZDExNDg0YjQ0YjFlMjY1ZDdjMGY5MDRiMy90YWJsZXJhbmdlOjI1ZTA4YTFkMTE0ODRiNDRiMWUyNjVkN2MwZjkwNGIzXzAtMi0xLTEtMQ_4e50920e-2a84-415a-9ffc-f691428178a7"
      unitRef="usd">950000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie5462c3bde0c4f4b91de75d0b7ce8831_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyNWUwOGExZDExNDg0YjQ0YjFlMjY1ZDdjMGY5MDRiMy90YWJsZXJhbmdlOjI1ZTA4YTFkMTE0ODRiNDRiMWUyNjVkN2MwZjkwNGIzXzEtMi0xLTEtMQ_3e7b487e-46ed-43a4-89e8-0aaeab2f1768"
      unitRef="usd">630000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4a669e6254fb41a7804a698577b0161a_I20200821"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZToyNWUwOGExZDExNDg0YjQ0YjFlMjY1ZDdjMGY5MDRiMy90YWJsZXJhbmdlOjI1ZTA4YTFkMTE0ODRiNDRiMWUyNjVkN2MwZjkwNGIzXzItMi0xLTEtMQ_38ec9a10-1e96-439d-86cf-017d93d9e426"
      unitRef="usd">1580000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8898d29f877f4495ab155612c9339010_D20200821-20200821"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU3MjU_ae4f638f-eb24-43a1-8e2a-44bcdb3cb9f5">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU4OTY_0f326282-75a1-440c-9dbb-c7bfe250a82a"
      unitRef="usd">1500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i4fdfce4ac4554fadac3393d171eb3796_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgxNDYzMTE_9d0ef9d0-3f7e-430e-870e-e9ae89bb0e6e"
      unitRef="usd">1500000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzU5NDc_7681f567-a42b-4753-a8f9-882d7941983e"
      unitRef="usd">52300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <bngo:BusinessCombinationConsiderationTransferredValueOfShares
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzYwNDQ_581c53af-f9c7-4d9a-b76b-dad9adbf7f59"
      unitRef="usd">40000000</bngo:BusinessCombinationConsiderationTransferredValueOfShares>
    <bngo:BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzYwNjE_6306306d-5792-4724-ab5f-9a0c7b46b538"
      unitRef="usd">26000000</bngo:BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting>
    <bngo:BusinessAcquisitionMilestonePayment
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzYwNzg_53093781-9fa1-4c55-a25d-7a1dbf3ca02c"
      unitRef="usd">10000000</bngo:BusinessAcquisitionMilestonePayment>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzEwOTk1MTE2NzYwOTc_0abb3a7f-ee65-4c0b-bf97-e42d576edc30"
      unitRef="usd">2500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzAtMi0xLTEtMzQzOTc_1c8a37d1-5e7c-416d-b3ac-2745375dee6d"
      unitRef="usd">52291000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzMtMi0xLTEtMzQ0Mzg_8e093da1-4d50-4fde-818d-d682aa9455b0"
      unitRef="usd">9000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <bngo:BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzQtMi0xLTEtNDg4ODM_ad11e13a-d517-45a8-bff1-c58e60e6c972"
      unitRef="usd">694000</bngo:BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzQtMi0xLTEtNTM4MDU_20df15a6-c8d9-4573-a353-41e93540a819"
      unitRef="shares">2723000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzItMi0xLTEtMzQ0MTM_af491e22-7fe4-4462-a19c-8f29c6f89dfa"
      unitRef="usdPerShare">5.20</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzMtMi0xLTEtMzQ0MTk_baf0e9ad-060b-4a5d-ac2b-0c56bb351d6e"
      unitRef="usd">14159000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7ab42905ccb04e29a735491e624912a6_D20211001-20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MTUxMGI5NGFjOGQ0ZGQ5OWE3NTYxMmM4M2IyMTk4OC90YWJsZXJhbmdlOjUxNTEwYjk0YWM4ZDRkZDk5YTc1NjEyYzgzYjIxOTg4XzYtMi0xLTEtNDM5ODY_fa723e4d-46fc-48ad-9d57-0d6693e7c5ac"
      unitRef="usd">74756000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzAtMi0xLTEtMzQ0ODI_84201405-b7eb-4710-9406-40836ea690bf"
      unitRef="usd">3205000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzEtMi0xLTEtMzQ0ODI_9298b819-0a89-45d4-a65e-60b0bea1c9c9"
      unitRef="usd">1782000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzItMi0xLTEtMzQ0ODI_9d566d0f-69ae-45e9-884b-7487283aa293"
      unitRef="usd">3987000</bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzQtMi0xLTEtMzQ0ODI_c0ef3e07-73a2-40a9-83b7-6edbeba20c96"
      unitRef="usd">213000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzUtMi0xLTEtMzQ0ODI_3cd0f959-c1a3-46eb-8698-bd7d39be2384"
      unitRef="usd">26800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzYtMi0xLTEtMzQ0ODI_fb36e2be-23a0-426c-8cdc-52ba219aa8a1"
      unitRef="usd">48987000</us-gaap:Goodwill>
    <bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzctMi0xLTEtMzQ0ODI_557b7660-9437-43b9-b89c-26d01a4fdc02"
      unitRef="usd">193000</bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities>
    <bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzgtMi0xLTEtMzQ0ODI_e39787c4-58e2-4905-acf1-aa9f28269f0b"
      unitRef="usd">3987000</bngo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzgtMi0xLTEtNTM0MjY_4f03fc1c-da83-4fac-b733-2410abe7fc8c"
      unitRef="usd">5777000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzktMi0xLTEtMzQ0ODI_0aa6657e-ae7d-4075-b7c4-2c84c4879a09"
      unitRef="usd">261000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo1MGVkYzg0ZTczNGY0MjIzOTIzMGY2NGRiNzI0YTRjNS90YWJsZXJhbmdlOjUwZWRjODRlNzM0ZjQyMjM5MjMwZjY0ZGI3MjRhNGM1XzEwLTItMS0xLTQzOTkw_627ce96e-38a7-4d11-95ef-af4f6d0c437b"
      unitRef="usd">74756000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgxODcyMzk_a7263bd4-fe3c-4490-9d4d-452c4944ba80">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair values of identifiable intangible assets acquired are as following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;22,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tradename&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Fair value of identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;26,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id7c4019bf43a47b28bc8cfe7f136b957_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo5NDgxMDc5MTI5Yjc0NDk4OWZhNTNlZDE5NDlkY2JmOC90YWJsZXJhbmdlOjk0ODEwNzkxMjliNzQ0OTg5ZmE1M2VkMTk0OWRjYmY4XzAtMi0xLTEtMzQ1MzM_01fd070c-a51d-4f27-9298-8fc2e48901ae"
      unitRef="usd">3000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i07bdd4786bb848d3aab8623ac0910407_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo5NDgxMDc5MTI5Yjc0NDk4OWZhNTNlZDE5NDlkY2JmOC90YWJsZXJhbmdlOjk0ODEwNzkxMjliNzQ0OTg5ZmE1M2VkMTk0OWRjYmY4XzEtMi0xLTEtMzQ1NDc_dcb5db06-784e-4737-8378-43cfdbcdce4c"
      unitRef="usd">22800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i974ac13511bd4accb073439efd2968a7_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo5NDgxMDc5MTI5Yjc0NDk4OWZhNTNlZDE5NDlkY2JmOC90YWJsZXJhbmdlOjk0ODEwNzkxMjliNzQ0OTg5ZmE1M2VkMTk0OWRjYmY4XzItMi0xLTEtMzQ1NDA_7914cc9d-9888-4432-a260-fccb3a6e5800"
      unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i294164fc14f446a2b2e24cbae2459436_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo5NDgxMDc5MTI5Yjc0NDk4OWZhNTNlZDE5NDlkY2JmOC90YWJsZXJhbmdlOjk0ODEwNzkxMjliNzQ0OTg5ZmE1M2VkMTk0OWRjYmY4XzMtMi0xLTEtNDM5NzQ_f189a7fb-f408-4498-8e94-26327781e433"
      unitRef="usd">26800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzU0OTc1NTgxODcyMjg_3c629789-0970-4f1d-8e48-221b2be83973">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzM4NDgyOTA3MjM1MjE_2ba82e96-f97e-49eb-81ab-29f87a49c673"
      unitRef="usd">1500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzM4NDgyOTA3MjM4NTE_3ae2dd90-33a6-4436-b484-a1ab5ff35ac4"
      unitRef="usd">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90ZXh0cmVnaW9uOjFmOGU4MmEzMmJlMTRiZmJhZmU3MGViMWFhN2UxNjVkXzYwNDczMTQwMjgzNjQ_c0077ad7-f85e-4735-a905-514de0c43886">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;br/&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,076,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,927,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(80,065,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,228,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzItMi0xLTEtNDkyNjE_fdd938f8-2d28-4cce-95b8-d8ddd32b2a89"
      unitRef="usd">23076000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzItNC0xLTEtNDkyNjc_04b60a62-3f02-4b14-88a0-9e26de78fc2d"
      unitRef="usd">15927000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzMtMi0xLTEtNDkyNjE_e290c59c-23db-486a-b09e-4e0878c64932"
      unitRef="usd">-80065000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzMtNC0xLTEtNDkyNjc_1a06a8ef-299c-41f0-871b-ba45bc00e435"
      unitRef="usd">-47228000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzQtMi0xLTEtNDkyNjE_309a4543-9822-479c-8ef2-ad7fd8467343"
      unitRef="usdPerShare">-0.28</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i110a0435adb34efbb4036d329457f22c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzQtMi0xLTEtNDkyNjE_54f7dd85-097a-4c94-a345-a4a0f8d35634"
      unitRef="usdPerShare">-0.28</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzQtNC0xLTEtNDkyNjc_508e5633-6687-4757-903c-f17bf9c95acb"
      unitRef="usdPerShare">-0.43</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i1535deb62b8a46f78cca75ccb040cfde_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18xOTAvZnJhZzoxZjhlODJhMzJiZTE0YmZiYWZlNzBlYjFhYTdlMTY1ZC90YWJsZTo2OTBkZjJjNTYzYWM0ZWI3OTk4NmY5NGYyZGJkNjU1Zi90YWJsZXJhbmdlOjY5MGRmMmM1NjNhYzRlYjc5OTg2Zjk0ZjJkYmQ2NTVmXzQtNC0xLTEtNDkyNjc_ca1f8a65-9ffe-4d01-8d4f-35021456a50f"
      unitRef="usdPerShare">-0.43</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTM5L2ZyYWc6M2ZlMjM4Zjc3NDg3NDgwMDk4MGUzYzgwYjA2ODQ1NjcvdGV4dHJlZ2lvbjozZmUyMzhmNzc0ODc0ODAwOTgwZTNjODBiMDY4NDU2N181NDk3NTU4MTQwNTQ5_cf263a1f-42cb-4df2-b241-5b1adb8b9f26">Related Party TransactionsThrough the acquisition of BioDiscovery in October 2021, the Company inherited a building lease with a landlord owned by BioDiscovery&#x2019;s former Director and Chief Executive Officer, who is now the Company&#x2019;s Chief Informatics Officer. The Company recorded $0.1&#160;million in finance lease costs related to this lease for the year ended December&#160;31, 2021. Refer to Note 11. Commitments and Contingencies for future commitments pertaining to this finance lease.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <bngo:FinanceLeaseExpense
      contextRef="id1804c21be1e41dc94b90988721c64f1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQzYmFkZTAwMjM3YjRlOGNiM2MyNGMzMGVhMWNkNmQzL3NlYzo0M2JhZGUwMDIzN2I0ZThjYjNjMjRjMzBlYTFjZDZkM18yNTM5L2ZyYWc6M2ZlMjM4Zjc3NDg3NDgwMDk4MGUzYzgwYjA2ODQ1NjcvdGV4dHJlZ2lvbjozZmUyMzhmNzc0ODc0ODAwOTgwZTNjODBiMDY4NDU2N18zODQ4MjkwNjk4ODkw_d4e26c22-00a3-4b1e-a98c-2eb0e17a7a7c"
      unitRef="usd">100000</bngo:FinanceLeaseExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>125
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M 'Y?"]@_MS?F#[ISU^5_4$L#!!0    ( $Z"851HB>/ZE0(  (X&   8
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MQ84YCF<>&?1ZIGI34PY$\P=(M2WI=_)X:;MKLHV<WUNQL)U*?G>KH<;8LK[
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MB>L*2SZQ@N&92-!KI*X@/E\3Y/L_]I6/)NT'.$Y*!I7I'1WSRA;-=P'L?>K
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MGA-CA0ZRAF/"TP6JNJ[[?3OL]G9E&+(;ZJ)#5H:E\'_XLS<DE*/N'.#H8(]
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ME00HV73<\$,J*'F5&$@8UX6Q.@D-%T[APL:D1HADG[MS75EYR;?P^D$(<2B
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M<JE"D-)&L@5-9;SE92VT1.G&;=2J6/P:UDED2X>/<UF#1/.DGP;>!3@=L?@
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M5?9?()7>8.':6WR'')F\^,K?DLQ/JF@[HK^VE\J$LJA+N6ZS1A4 :D1MP#!
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MI<G9^2ABMETGK8.F"2.\-D@+(9@5;6"P/H'B&V/PX/@&_4Z?_P902P,$%
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M'HJTVFV2HY!BYD,9%%JR<F887V =M3/5CNY!]3;M+> US=Q$'!K@U!BF4/5
MQ? H-67)Z!,+4[9/RH$MR7QD!2"*:+ C$- KPRV9(UJWP_(2/NV=TE]D/\CU
MC @4'.!Z\J37\,@CN\4,,B%I-;_Y#M'JG")"ZGVH?0 4)]D6CH"5P+3^L3^S
M!W3F$=BDP)\XC@&SDXC1EN@ 61)] G$D^;Q1Z_"AP(4:J)@?_JTXGS\GEVH<
M4%)YE5;%,U-UEQU*(P1.Y9(:75TC'7 B221("07W][I6CCTY*(T*SL"LV?GB
M>0"!:EKU6PZFX4>J(]+1:;N7=@W#8I&D]K$D-;(XX(*AD%2+H4S]%74ZL\\
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MV =?TO6FI@=G;U[MY%I=J_KK[JK$MS.W2I)N55ZE12Y*M7I]<A']_'9"XWG
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M])5KV+:TUYP D8TV8Y"N .?>G66O&$Q.Q$8XVDGEIL%F=>5 <ATGT6;*K:M
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MXGSPAY[@4X)PW$G2((?)/>,4AU&7@T(W)TD[DAH)P]XM@4_%<GG.9<CCB^X
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MWYZ*;6VWAG,%_^!4/-E(RK!(;$L(@556&;N254/8=]JO*;NAR$9)IE),:KK
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M=0CBX3L9WC7XH364E<#BB7NOID<:G+J;X_,$=QHT585<W!%A75$E7%6L::=
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MN/64F2;/=E;*:O7,G]-ZFPS/QN_>C$Z33UHJ%=9(E?OCR>GQ,:_'$&V'PCI
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M1Q#B0V:I +,NR$.P=K4GVNQ O$?J>"O-3%L#UWYI9=TX;K-S<(NB4!P/!VG
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MOJ&B0<=MX/!!:(^VS4A;-$YK)L"F1>.T;$=O(<A@SJR2:_9!9)C$*=AL(20
M-[\T-BC6Z;RV?_WF6[]#&G]7USG\-S$2^66Q0>:71GM]Z *8)A@P+?SUJ5)W
M08<+8Q]H+::%-SO)'*'?);!L7="A\:(N;#;)QGP"WDP[0Z+@=)8-:>.\-X1
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M0U]QD% Q&+_9"KG%B! ;A/.*D#'#R+9Y2\Q_8\/FC,=OZW%,MQ'&$408XNG
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MEKZ'4#L%.E\KJI]VX1QT7UC3_P!02P,$%     @ 3H)A5 P.[F/@ @  5 8
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M*+.;16FTO[B1VQ+]13R?UF(+MX#?ZY6E4]RC%+("[:31S,)F%BW2LV7FXT/
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MIO'%A$JHN[W5,59M_*Y8*DL-[\F*5CUJIT#G*Z7LCG$.AC\/\_\!4$L#!!0
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M[M(>O[U';OG1TF.L\-QN3M:L9.>Y0"X=H4B%UY"VDYA@Y2687E4IY/OPT._
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M'SOR4:L>_G#/?:4R:JGTHZA_D+ZVT8DHADT4P\[S,(>5)K<<MW-I2DL>[M"
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M(."0:QN!FM\>5L"Y#61D_!EC>E-*2SRT7Z+?N=I-+3NJ8(7\)RMTO?2N/%)
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MB\4%_OR#]BNZVBG>_];O^^?_ U!+ P04    " !.@F%47X[<U%4#  !X"0
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M(D>$ E/K)!C][7"&0C@EXOBG%@V:-9WA\?=!_<X[3\ZLF,&9$G_SS&['P3"
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M;,G,.'JNU-$O42OBH[LC?G-$N(O(R:)?:=P<'\CKJ).\V(SPZ [+46_\U6[
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M$#E!*#"U#H'1WQ+'*(0#(AEO:\R@H72.V^L-^JV/G6*9,8-C)7[SS.:#H!=
MAG-6"?ND5C]Q'4_'X:5*&/\+J[5M%$!:&:N*M3,I*+BL_]G[.@];#G'K@$.\
M=HB][IK(JYPPRX9]K5:@G36AN84/U7N3."[=HTRMIEM.?G9X)Y=H+&79&F R
M@UO&-;PP42$\(#.5QOKN&XR5M%PN:.>6AF>HF4_L/6<S+KC]@-,)6L:%.?MJ
MGGXQ/P$NX5>N*D-\IA]:BL)I"=.UXE&M.#Z@N!7# V'G!K[+#+.O "&%W^0@
MWN1@%!]%G&!Z >W6.<11W'J>3N#TY.P(;+M);=O#M@_ ?J;R'$9,,)DB3'VC
M_="J*BDYYW#+)9US)F!JF?6YAC$K7:(,_+DG1+BC8_/WB)[+1L^EUW-Y0,\(
M%UQ*HJ4R]FKVY;Z&Z'@(U]#+8=0/EWM8.PUKYRCK9W5H3)6F%P-&I48[0XT#
M:DY5KK6+NT3-%=VF;Q4WW*5@G\":+=D2>!5%!S0FC<;DJ,9QSJA275U2+W!J
M=1(Y=Z^WK%^O44X6-%"$?SHJ;2IIX;N&9=2:W%A7XDL$?*>9:7!O<2<[^I-D
MO_INH[Y[7#TS.93LPS?J/LKN#N6!?/4:QMY11FJ\_Y11;Z>,KJ*=.,.ML56@
M7OCA;&A<5-+6$ZPY;>;_33WV/LWKC\<#TU3<!@3.R36ZZ!*UK@=RO;&J]$-P
MIBR-5+_,Z1N&VAG0_5PIN]DX@N:K./P'4$L#!!0    ( $Z"853'3B%,$P,
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M]1P='AR]1G%UR%7<?A6W;V&#%M@93Q(02TH86I ,1 =DKX+L6<A>"^3K"^H
M#"K H)/C!4B)5$Q2A-$S$+'O\@J$OD4P+_!Q@CUOZ ]'[N,>S_W*<[_3\URG
MGZP5",13L+XU#\'S38S6^A'9E;VY+&##!AUO/Y.P8A)V,KGABK!]GL(=3UV!
M1Y6[J#.'C8IFNI0[DCBH$ <?3N)@)Y;CL"608>5V^'\R.'QK!K%72XSWOAR6
M=F\*'#<4#?_C:8N,"Z( _> *I#OE.\+S&KG6#.Q_S@O'M6;@WH?+HX1H7E.
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MMQSA3&LT^BU\M--V!&=9QEQG*(>)J.;+]>GU& UE7+^Q(9]OQO#ZU1MX!4S
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M\ZY2K1==T^PFBF]MWUEQI;N8'5;Z/P/"&.C]->?J=6):V?#GRO\ 4$L#!!0
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MU1U;/R[59Q!P+5#].6/RI:$OVO;#:OP?4$L#!!0    ( $Z"853H@9B,OP8
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MV^@7V>+58NZ)H&<L^A$&<GT\F Y00%<DC>0M>_I"BP5Y.I[/(I']CYZ*L=8
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MO('T[T570K<+@^A7?G8\91$C%VBP\.=*1'7'8+*NQ%(7)J*O[80B@S6 JJ]
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M$O;39=6Z R X30C.J*LJ*[J$_7QYW,,#@+BM0/RC7BZ.#:R<BF9A/\]VM?,
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M'H#[2R'TZXGY8E)^M!O_"U!+ P04    " !.@F%4L*"6,RP#  "H"0  &0
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M!B(2F$IAF%A2$3.JX13NRJ+@U(X3#M>BVC<V_\<S:@CC^@0GW=_-X/CH!(Z
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M+%QE74B#==I]9OB4HLI.P/%42K-I6 ?-XVS\!U!+ P04    " !.@F%4/_@
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MB>H @>L =7_%F#P.] )E3SG^"U!+ P04    " !.@F%4T/W ^44#  "\"0
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M%)55,YHU&R.W]73S) W.2O6RP'$6E!7 \[64YFUC!Z9N0)[]#U!+ P04
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M5.STZSND9,7QUEQL<CCS^-YP---?2_6B,P!#-CD7>N!EQA2WOJ^3#'*J6[(
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ME-#QSY^[.NP!AN<' %D'R-X"1@< >0?(@]"869"UX,B+L35;9KTWL?E%J$U
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M,-DW:)4O6NJ%\BBY^DH53BZ6R;>*"JHG38 ;\ Y3#K[@O"* ;<$G7.[H4TX
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MF WZ^9IS]30QS6+YYV#R#U!+ P04    " !.@F%46%[!SJ<"   V!P  &0
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MN49K9:ZM!=$DF4JQ0])F&S:[<+-Q:-,-Y?9?O-?2G%*#T\E5]EQ11>U(%;I
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M?EG;P8_:)=CS2BG:!JY _U>2_P)02P,$%     @ 3H)A5*X @)U$ P  \A0
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M_YU4CY=SR^WRU^773KQ?K*XXU_<5P_-?4$L#!!0    ( $Z"850L 6<[&P(
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M2P$"% ,4    " !.@F%4X!C8E.T    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !.@F%4F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( $Z"852\/AEQ$P<  "<>   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !.@F%4[.M7<A4"  !@!0
M&               @(%5#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ 3H)A5!AQ" &Y!@  7AP  !@              ("!H!$  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $Z"852R8B^$#P,
M ( *   8              " @8\8  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !.@F%46 4MS6L%  "#%0  &               @('4
M&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 3H)A5&B)
MX_J5 @  C@8  !@              ("!=2$  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( $Z"853-E:M8;@8  )\>   8
M  " @4 D  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !.
M@F%4"M.K)E@*  #*,   &               @('D*@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ 3H)A5)XYR)!A"0  GQ8  !@
M         ("!<C4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( $Z"850;^(V,("@  -6%   9              " @0D_  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 3H)A5.,N()36 P  !0D
M !D              ("!8&<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !.@F%4#9:P^:P*   F'@  &0              @(%M:P
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $Z"850<-CJ2
MCP(  -\%   9              " @5!V  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ 3H)A5 ) 15>] @  %08  !D
M ("!%GD  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !.
M@F%4&#N!+!P$   H"@  &0              @($*?   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $Z"851 ?*'[P@(  .T%   9
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M970R,"YX;6Q02P$"% ,4    " !.@F%4BE\.I=4"  !#!@  &0
M    @($ O@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M $Z"853HP@YV&A   /<W   9              " @0S!  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ 3H)A5,WLO:[: @  408  !D
M             ("!7=$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !.@F%4MHH/6!<N  #!G   &0              @(%NU   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $Z"8524.Q')[ ,
M &T)   9              " @;P" 0!X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ 3H)A5 P.[F/@ @  5 8  !D              ("!
MWP8! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !.@F%4
M*O(#%;($   )#   &0              @('V"0$ >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( $Z"852(+L(NG0(  ,H%   9
M      " @=\. 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ 3H)A5,S/M>'- @  #@8  !D              ("!LQ$! 'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !.@F%4NLQR3VL#  !("
M&0              @(&W% $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( $Z"852#Z4CJTP(  /$%   9              " @5D8 0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 3H)A5&T  3>V
M @  P@4  !D              ("!8QL! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !.@F%4HL'5TQT&   4$0  &0
M@(%0'@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( $Z"
M850T_B!0<@4  !80   9              " @:0D 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ 3H)A5(!ZF9[Q!0  51   !D
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M=#,Y+GAM;%!+ 0(4 Q0    ( $Z"852#Z\W/70(  ,L%   9
M  " @>9# 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M3H)A5/$].LZG P  3 \  !D              ("!>D8! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " !.@F%4*ING\HT"   @"P  &0
M            @(%82@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( $Z"850L'A%MM@0  &\8   9              " @1Q- 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 3H)A5,Q&X]G&!
M^Q\  !D              ("!"5(! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " !.@F%47X[<U%4#  !X"0  &0              @($&
M5P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( $Z"850H
M<LS4\ (  "$'   9              " @9): 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ 3H)A5,=.(4P3 P  !PL  !D
M     ("!N5T! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $Z"852_/$J/. ,  $D,   9              "
M@:AM 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ 3H)A
M5$]4$M]S @  Q08  !D              ("!%W$! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " !.@F%4WN.)'1$#  !D"0  &0
M        @('!<P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( $Z"853H@9B,OP8  #(B   9              " @0EW 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 3H)A5&X=>AZ[ @  9 @
M !D              ("!_WT! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " !.@F%4ZCAD?C@,  #71P  &0              @('Q@ $
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( $Z"852;!4C@
M<00  %@1   9              " @6"- 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ 3H)A5)@?XH%R!   M1   !D
M ("!")(! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !.
M@F%4-^(("&\$  "($P  &0              @(&QE@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( $Z"851H!X&B] (  .T(   9
M          " @5>; 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#
M%     @ 3H)A5%?$O(FQ @  KP<  !D              ("!@IX! 'AL+W=O
M<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " !.@F%4/FG;P=8$  #
M$P  &0              @(%JH0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM
M;%!+ 0(4 Q0    ( $Z"852PH)8S+ ,  *@)   9              " @7>F
M 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ 3H)A5#_X
M )LO P  N D  !D              ("!VJD! 'AL+W=O<FMS:&5E=',O<VAE
M970V-2YX;6Q02P$"% ,4    " !.@F%4N( <RFX#  "\#   &0
M    @(% K0$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M $Z"852BR_WC=@(  $8&   9              " @>6P 0!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ 3H)A5(,-QXN. @  :P8  !D
M             ("!DK,! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " !.@F%4XFS5=14#  !?"@  &0              @(%7M@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( $Z"8530_<#Y10,
M +P)   9              " @:.Y 0!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ 3H)A5$R#<.9G P  + L  !D              ("!
M'[T! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !.@F%4
ME5ZY;:P#  "##0  &0              @(&]P $ >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( $Z"852F^099]0(  )P'   9
M      " @:#$ 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ 3H)A5.(%5H%! @  '@4  !D              ("!S,<! 'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !.@F%4<#O_>Y$$  !/$@
M&0              @(%$R@$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( $Z"851TL<.3# 0  *0.   9              " @0S/ 0!X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ 3H)A5&\RG!4Z
M!   ?Q   !D              ("!3],! 'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    " !.@F%4TCI@80\#   H#   &0
M@(' UP$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( $Z"
M85187L'.IP(  #8'   9              " @0;; 0!X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ 3H)A5%06 +IB @  5@8  !D
M         ("!Y-T! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
M    " !.@F%4K@" G40#  #R%   #0              @ %]X $ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( $Z"8527BKL<P    !,"   +
M  "  >SC 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $Z"850$WI7-X04  /LT
M   /              "  =7D 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !.@F%4M,4*KF@"  !'+P  &@              @ 'CZ@$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !.@F%4+ %G.QL"   .+@
M$P              @ &#[0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..6 !8 !\8  #/[P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>227</ContextCount>
  <ElementCount>581</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Statement)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Statement)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Revenue from Contracts with Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenuefromContractswithCustomers</Role>
      <ShortName>Revenue from Contracts with Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements</Role>
      <ShortName>Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Stockholders??? Equity and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2154112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2162113 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2164114 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2171115 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Revenue from Contracts with Customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenuefromContractswithCustomersTables</Role>
      <ShortName>Revenue from Contracts with Customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/RevenuefromContractswithCustomers</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/IntangibleAssetsNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/AccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2336308 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/LongTermDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2340309 - Disclosure - Stockholders??? Equity and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2355311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2365312 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/Acquisitions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/OrganizationandOperationsDetails</Role>
      <ShortName>Organization and Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/OrganizationandOperations</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Revenue from Contracts with Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails</Role>
      <ShortName>Revenue from Contracts with Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/RevenuefromContractswithCustomersTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Investments and Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Investments and Fair Value Measurements - Contingent Consideration Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Contingent Consideration Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails</Role>
      <ShortName>Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Intangible Assets, Net - Future Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Future Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Long-Term Debt - Schedule of Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Summary of Stock Option Activity Under 2018 Plan and 2006 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Summary of Stock Option Activity Under 2018 Plan and 2006 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Stockholders??? Equity and Stock-Based Compensation - Weighted-Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stockholders??? Equity and Stock-Based Compensation - Weighted-Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Commitments and Contingencies - Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Commitments and Contingencies - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Income Taxes - Domestic and Foreign Components of Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails</Role>
      <ShortName>Income Taxes - Domestic and Foreign Components of Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Income Taxes - Provision for Domestic and Foreign Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Domestic and Foreign Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2459435 - Disclosure - Income Taxes - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2460436 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2461437 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2463438 - Disclosure - Employee Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/EmployeeBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employee Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2466439 - Disclosure - Acquisitions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2467440 - Disclosure - Acquisitions - Acquisition Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails</Role>
      <ShortName>Acquisitions - Acquisition Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2468441 - Disclosure - Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2469442 - Disclosure - Acquisitions - Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Acquisitions - Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2470443 - Disclosure - Acquisitions - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails</Role>
      <ShortName>Acquisitions - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bngo-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2472444 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bionanogenomics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bionanogenomics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="bngo-20211231.htm">bngo-20211231.htm</File>
    <File>bionano-nancyridgeleasee.htm</File>
    <File>bngo-1038_bionanoxcommerci.htm</File>
    <File>bngo-20211231.xsd</File>
    <File>bngo-20211231_cal.xml</File>
    <File>bngo-20211231_def.xml</File>
    <File>bngo-20211231_lab.xml</File>
    <File>bngo-20211231_pre.xml</File>
    <File>bngo-ex1034_bionanoxkeyemp.htm</File>
    <File>bngo-ex1035_bionanoxstockr.htm</File>
    <File>bngo-ex1036_bionanoxemploy.htm</File>
    <File>bngo-ex1039_bionanoxfiftha.htm</File>
    <File>bngo-ex107_bionanoxnonxemp.htm</File>
    <File>bngo-ex211_bionanoxsubsidi.htm</File>
    <File>bngo-ex311x20211231.htm</File>
    <File>bngo-ex312x20211231.htm</File>
    <File>bngo-ex321x20211231.htm</File>
    <File>bngo-ex322x20211231.htm</File>
    <File>exhibit231-bdoauditorconse.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bngo-20211231_g1.jpg</File>
    <File>bngo-20211231_g2.jpg</File>
    <File>bngo-20211231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="868">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>131
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bngo-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "contextCount": 227,
   "dts": {
    "calculationLink": {
     "local": [
      "bngo-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bngo-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bngo-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bngo-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bngo-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bngo-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 741,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 5,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 9
   },
   "keyCustom": 84,
   "keyStandard": 497,
   "memberCustom": 38,
   "memberStandard": 49,
   "nsprefix": "bngo",
   "nsuri": "http://bionanogenomics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://bionanogenomics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://bionanogenomics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Revenue from Contracts with Customers",
     "role": "http://bionanogenomics.com/role/RevenuefromContractswithCustomers",
     "shortName": "Revenue from Contracts with Customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Investments and Fair Value Measurements",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements",
     "shortName": "Investments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bngo:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bngo:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Property and Equipment, Net",
     "role": "http://bionanogenomics.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - Intangible Assets, Net",
     "role": "http://bionanogenomics.com/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Accrued Expenses",
     "role": "http://bionanogenomics.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Long-Term Debt",
     "role": "http://bionanogenomics.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Commitments and Contingencies",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://bionanogenomics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154112 - Disclosure - Income Taxes",
     "role": "http://bionanogenomics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bngo:DefinedContributionPlanDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162113 - Disclosure - Employee Benefits",
     "role": "http://bionanogenomics.com/role/EmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bngo:DefinedContributionPlanDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164114 - Disclosure - Acquisitions",
     "role": "http://bionanogenomics.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171115 - Disclosure - Related Party Transactions",
     "role": "http://bionanogenomics.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Revenue from Contracts with Customers (Tables)",
     "role": "http://bionanogenomics.com/role/RevenuefromContractswithCustomersTables",
     "shortName": "Revenue from Contracts with Customers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Investments and Fair Value Measurements (Tables)",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables",
     "shortName": "Investments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://bionanogenomics.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://bionanogenomics.com/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://bionanogenomics.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336308 - Disclosure - Long-Term Debt (Tables)",
     "role": "http://bionanogenomics.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340309 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation (Tables)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355311 - Disclosure - Income Taxes (Tables)",
     "role": "http://bionanogenomics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365312 - Disclosure - Acquisitions (Tables)",
     "role": "http://bionanogenomics.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Operations (Details)",
     "role": "http://bionanogenomics.com/role/OrganizationandOperationsDetails",
     "shortName": "Organization and Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bngo:LiquidityPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "bngo:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)",
     "role": "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUtilityInventoryTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details)",
     "role": "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUtilityInventoryTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)",
     "role": "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails",
     "shortName": "Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Revenue from Contracts with Customers (Details)",
     "role": "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
     "shortName": "Revenue from Contracts with Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i86bea6db7f4248ed94253fad6c47e824_D20210101-20211231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ie93e575b671b4188b8e1e04eb90b0d27_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails",
     "shortName": "Investments and Fair Value Measurements - Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ie93e575b671b4188b8e1e04eb90b0d27_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Investments and Fair Value Measurements - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Investments and Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "id637a744712b44988d29a346fc913709_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Investments and Fair Value Measurements - Contingent Consideration Liability (Details)",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
     "shortName": "Investments and Fair Value Measurements - Contingent Consideration Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "id637a744712b44988d29a346fc913709_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)",
     "role": "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
     "shortName": "Investments and Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i1d4ba587a7c34d8f86d1fb3e8ff7778b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, net (Details)",
     "role": "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Intangible Assets, Net - Summary of Intangible Assets (Details)",
     "role": "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Intangible Assets, Net - Future Amortization of Intangible Assets (Details)",
     "role": "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Future Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "role": "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifb921d59feb74c7e9883ca143d13a63e_I20190331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "bngo:WarrantsToPurchaseSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Long-Term Debt - Schedule of Debt Obligations (Details)",
     "role": "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails",
     "shortName": "Long-Term Debt - Schedule of Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i411e62885bec4fb3beab2f000e27b94f_D20210125-20210125",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Warrant Activity (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "bngo:ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Summary of Stock Option Activity Under 2018 Plan and 2006 Plan (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Summary of Stock Option Activity Under 2018 Plan and 2006 Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Statement)",
     "role": "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Statement)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i1180bacce9964e6ab67c6cf06acfbbde_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Restricted Stock and Performance Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i86da882447604a1e9e8017d09d518536_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Stockholders\u2019 Equity and Stock-Based Compensation - Weighted-Average Assumptions (Details)",
     "role": "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails",
     "shortName": "Stockholders\u2019 Equity and Stock-Based Compensation - Weighted-Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "bngo:LesseeEstimatedIncrementalBorrowingRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "bngo:LesseeEstimatedIncrementalBorrowingRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bngo:OperatingLeasePaymentsModifiedAndUnmodified",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Commitments and Contingencies - Supplemental Information (Details)",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails",
     "shortName": "Commitments and Contingencies - Supplemental Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bngo:OperatingLeasePaymentsModifiedAndUnmodified",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Commitments and Contingencies - Lease Cost (Details)",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails",
     "shortName": "Commitments and Contingencies - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Undiscounted Future Non-Cancellable Lease Payments Under Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases (Details)",
     "role": "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Income Taxes - Domestic and Foreign Components of Income (Loss) (Details)",
     "role": "http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails",
     "shortName": "Income Taxes - Domestic and Foreign Components of Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Income Taxes - Provision for Domestic and Foreign Income Taxes (Details)",
     "role": "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Domestic and Foreign Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "idef8a112a8af49b29859c89619c7063f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "idef8a112a8af49b29859c89619c7063f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459435 - Disclosure - Income Taxes - Deferred Tax Assets (Details)",
     "role": "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460436 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i3624ecef1ddd4361a818dfb9464218ce_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifeb35d83105d4a66b9c5f6f5ad1651e4_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461437 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "role": "http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i43b9ee19b62a4ebbbb91daf83affcfc5_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463438 - Disclosure - Employee Benefits - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/EmployeeBenefitsAdditionalInformationDetails",
     "shortName": "Employee Benefits - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466439 - Disclosure - Acquisitions - Additional Information (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
     "shortName": "Acquisitions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i8898d29f877f4495ab155612c9339010_D20200821-20200821",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i8898d29f877f4495ab155612c9339010_D20200821-20200821",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467440 - Disclosure - Acquisitions - Acquisition Purchase Price (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
     "shortName": "Acquisitions - Acquisition Purchase Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i8898d29f877f4495ab155612c9339010_D20200821-20200821",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bngo:BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "ifedeab9392574bbf9284ae95544b0969_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468441 - Disclosure - Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Fair Value of Tangible and Identifiable Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i294164fc14f446a2b2e24cbae2459436_I20211031",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i4a669e6254fb41a7804a698577b0161a_I20200821",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469442 - Disclosure - Acquisitions - Identifiable Intangible Assets (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
     "shortName": "Acquisitions - Identifiable Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i257cbc434ff74964959fc60f88c37154_I20200821",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i110a0435adb34efbb4036d329457f22c_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470443 - Disclosure - Acquisitions - Pro Forma Information (Details)",
     "role": "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails",
     "shortName": "Acquisitions - Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i110a0435adb34efbb4036d329457f22c_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bngo:FinanceLeaseExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472444 - Disclosure - Related Party Transactions (Details)",
     "role": "http://bionanogenomics.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "id1804c21be1e41dc94b90988721c64f1_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "bngo:FinanceLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Operations",
     "role": "http://bionanogenomics.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bngo-20211231.htm",
      "contextRef": "i6ae26446637a47d8ad2937ba20b3b797_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 95,
   "tag": {
    "bngo_AccruedInventoryCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Inventory, Current",
        "label": "Accrued Inventory, Current",
        "terseLabel": "Goods received not invoiced"
       }
      }
     },
     "localname": "AccruedInventoryCurrent",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in aggregate number of shares reserved for future issuance as percentage shares outstanding.",
        "label": "Annual Increase In Aggregate Number Of Shares Reserved For Future Issuance As Percentage Shares Outstanding",
        "terseLabel": "Incremental rate at which the shares reserved for issuance increase"
       }
      }
     },
     "localname": "AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://bionanogenomics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "bngo_AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorized for future stock awards, option grants, or employee stock purchase program.",
        "label": "Authorized For Future Stock Awards Option Grants Or Employee Stock Purchase Program [Member]",
        "terseLabel": "Authorized for future stock awards, option grants, or employee stock purchase program"
       }
      }
     },
     "localname": "AuthorizedForFutureStockAwardsOptionGrantsOrEmployeeStockPurchaseProgramMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_BioDiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioDiscovery",
        "label": "BioDiscovery [Member]",
        "terseLabel": "BioDiscovery"
       }
      }
     },
     "localname": "BioDiscoveryMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Consideration Transferred, Value Of Shares, Subject To Vesting",
        "label": "Business Acquisition, Consideration Transferred, Value Of Shares, Subject To Vesting",
        "terseLabel": "Value of shares subject to vesting"
       }
      }
     },
     "localname": "BusinessAcquisitionConsiderationTransferredValueOfSharesSubjectToVesting",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment",
        "label": "Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares, Incomplete Accounting, Adjustment",
        "negatedTerseLabel": "Estimated shares of common stock to be returned to the Company (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfSharesIncompleteAccountingAdjustment",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_BusinessAcquisitionMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Milestone Payment",
        "label": "Business Acquisition, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "BusinessAcquisitionMilestonePayment",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationConsiderationTransferredValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Value Of Shares",
        "label": "Business Combination, Consideration Transferred, Value Of Shares",
        "terseLabel": "Consideration transferred, value of common stock"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredValueOfShares",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Estimated Return of Cash to Buyer from Escrow",
        "label": "Business Combination, Estimated Return of Cash to Buyer from Escrow",
        "negatedLabel": "Estimated return of cash to buyer from escrow"
       }
      }
     },
     "localname": "BusinessCombinationEstimatedReturnOfCashToBuyerFromEscrow",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable and Other Accrued Liabilities",
        "negatedTerseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Liability",
        "negatedTerseLabel": "Right-of-use liabilities (short-term and long-term)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseLiability",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]",
        "label": "Class Of Warrant Or Right, Aggregate Intrinsic Value Of Warrants Or Rights [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRightsAbstract",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Canceled In Period",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Canceled In Period",
        "terseLabel": "Canceled (USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCanceledInPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Exercised In Period",
        "terseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Granted In Period",
        "terseLabel": "Exercised (USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bngo_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights [Roll Forward]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsRollForward",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Expiration Period",
        "label": "Class Of Warrant Or Right, Expiration Period",
        "terseLabel": "Class of warrant or right, expiration period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Canceled In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Canceled In Period",
        "negatedTerseLabel": "Canceled (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Exercised In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Exercised In Period",
        "negatedTerseLabel": "Exercised (shares)",
        "terseLabel": "Exercised (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Securities Granted In Period",
        "label": "Class Of Warrant Or Right, Number Of Securities Granted In Period",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_ClassOfWarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "label": "Class Of Warrant Or Right, Outstanding [Roll Forward]",
        "terseLabel": "Shares of Stock under Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingRollForward",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Granted In Period Of Warrants Or Rights",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights",
        "label": "Class Of Warrant Or Right, Weighted- Average Remaining Contractual Term Of Warrants Or Rights",
        "verboseLabel": "Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]",
        "label": "Class Of Warrant Or Right, Weighted-Average Remaining Contractual Term Of Warrants Or Rights [Roll Forward]",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRightsRollForward",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_ClassofWarrantorRightTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Term",
        "label": "Class of Warrant or Right, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "ClassofWarrantorRightTerm",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ClientWarrantyExchangeOfFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client Warranty Exchange of Fixed Assets",
        "label": "Client Warranty Exchange of Fixed Assets",
        "terseLabel": "Client warranty exchange of fixed asset"
       }
      }
     },
     "localname": "ClientWarrantyExchangeOfFixedAssets",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_CommissionFeeMaximumPercentageOfGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission Fee, Maximum Percentage Of Gross Proceeds",
        "label": "Commission Fee, Maximum Percentage Of Gross Proceeds",
        "terseLabel": "Commission fee"
       }
      }
     },
     "localname": "CommissionFeeMaximumPercentageOfGrossProceeds",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_CommonStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock option member.",
        "label": "Common Stock Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "CommonStockOptionMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CommonStockWarrantsAmendedAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants, Amended Agreement [Member]",
        "label": "Common Stock Warrants, Amended Agreement [Member]",
        "terseLabel": "Common Stock Warrants, Amended Agreement"
       }
      }
     },
     "localname": "CommonStockWarrantsAmendedAgreementMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CommonStockWarrantsOriginalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants, Original Agreement [Member]",
        "label": "Common Stock Warrants, Original Agreement [Member]",
        "terseLabel": "Common Stock Warrants, Original Agreement"
       }
      }
     },
     "localname": "CommonStockWarrantsOriginalAgreementMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CommonWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common warrants.",
        "label": "Common Warrants [Member]",
        "terseLabel": "Common warrants"
       }
      }
     },
     "localname": "CommonWarrantsMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ComputerAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer and office equipment.",
        "label": "Computer And Office Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipmentMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ConsumableRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumable Revenue [Member]",
        "label": "Consumable Revenue [Member]",
        "terseLabel": "Consumables"
       }
      }
     },
     "localname": "ConsumableRevenueMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ContingentConsiderationFairValueOfContingentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Fair Value of Contingent Liability",
        "label": "Contingent Consideration, Fair Value of Contingent Liability",
        "terseLabel": "Fair value of consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationFairValueOfContingentLiability",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Liability",
        "label": "Contingent Consideration Liability [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ContingentConsiderationMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Milestone Payment",
        "label": "Contingent Consideration, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "ContingentConsiderationMilestonePayment",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ContingentConsiderationNoncash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Noncash",
        "label": "Contingent Consideration, Noncash",
        "terseLabel": "Contingent consideration related to BioDiscovery acquisition"
       }
      }
     },
     "localname": "ContingentConsiderationNoncash",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration",
        "label": "Contingent Consideration [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bngo_ContractualCommitmentPurchaseOfProductsEveryQuarter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Commitment, Purchase of Products, Every Quarter",
        "label": "Contractual Commitment, Purchase of Products, Every Quarter",
        "terseLabel": "Contractual commitment with supplier to purchase products every quarter"
       }
      }
     },
     "localname": "ContractualCommitmentPurchaseOfProductsEveryQuarter",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_CorporateNotesAndBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Notes And Bonds",
        "label": "Corporate Notes And Bonds [Member]",
        "terseLabel": "Corporate Notes/Bonds"
       }
      }
     },
     "localname": "CorporateNotesAndBondsMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CostOfGoodsAndServicesSoldPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Goods And Services Sold [Policy Text Block]",
        "label": "Cost Of Goods And Services Sold [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldPolicyTextBlock",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bngo_CostOfLeasedEquipmentSoldToCustomer": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Leased Equipment Sold to Customer",
        "label": "Cost of Leased Equipment Sold to Customer",
        "terseLabel": "Cost of leased equipment sold to customer"
       }
      }
     },
     "localname": "CostOfLeasedEquipmentSoldToCustomer",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_CowenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen",
        "label": "Cowen [Member]",
        "terseLabel": "Cowen"
       }
      }
     },
     "localname": "CowenMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Relationships, Developed Technology and Trade Names",
        "label": "Customer Relationships, Developed Technology and Trade Names [Member]",
        "terseLabel": "Customer Relationships, Developed Technology and Trade Names"
       }
      }
     },
     "localname": "CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Default Payment Required Upon Completion of Equity Raise",
        "label": "Debt Instrument, Covenant, Default Payment Required Upon Completion of Equity Raise",
        "terseLabel": "Default payment required upon completion of equity raise"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDefaultPaymentRequiredUponCompletionofEquityRaise",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtInstrumentCovenantLiquidityMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Liquidity, Minimum Cash Balance",
        "label": "Debt Instrument, Covenant, Liquidity, Minimum Cash Balance",
        "terseLabel": "Minimum cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLiquidityMinimumCashBalance",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtInstrumentCovenantMaximumCreditCardIndebtedness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Maximum Credit Card Indebtedness",
        "label": "Debt Instrument, Covenant, Maximum Credit Card Indebtedness",
        "terseLabel": "Maximum credit card indebtedness"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMaximumCreditCardIndebtedness",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Minimum Proceeds From Sale Of Stock, Gross",
        "label": "Debt Instrument, Covenant, Minimum Proceeds From Sale Of Stock, Gross",
        "terseLabel": "Minimum proceeds"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumProceedsFromSaleOfStockGross",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtInstrumentCovenantPrepaymentFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Prepayment Fee",
        "label": "Debt Instrument, Covenant, Prepayment Fee",
        "terseLabel": "Prepayment fee"
       }
      }
     },
     "localname": "DebtInstrumentCovenantPrepaymentFee",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtInstrumentCovenantWaiverFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Waiver Fee",
        "label": "Debt Instrument, Covenant, Waiver Fee",
        "terseLabel": "Waiver fee"
       }
      }
     },
     "localname": "DebtInstrumentCovenantWaiverFee",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DebtInstrumentCovenantWaiverFeePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Waiver Fee Payment Period",
        "label": "Debt Instrument, Covenant, Waiver Fee Payment Period",
        "terseLabel": "Waiver fee payment period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantWaiverFeePaymentPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_DebtInstrumentInterestRateCashRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Cash Rate",
        "label": "Debt Instrument, Interest Rate, Cash Rate",
        "terseLabel": "Cash rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateCashRate",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_DebtInstrumentInterestRateDiscountedCashRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Discounted Cash Rate",
        "label": "Debt Instrument, Interest Rate, Discounted Cash Rate",
        "terseLabel": "Discounted cash rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDiscountedCashRate",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_DebtInstrumentPaymentTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms [Axis]",
        "label": "Debt Instrument, Payment Terms [Axis]",
        "terseLabel": "Debt Instrument, Payment Terms"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsAxis",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_DebtInstrumentPaymentTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Debt Instrument, Payment Terms [Axis]",
        "label": "Debt Instrument, Payment Terms [Domain]",
        "terseLabel": "Debt Instrument, Payment Terms"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsDomain",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPaymentTermsPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms, Period Four [Member]",
        "label": "Debt Instrument, Payment Terms, Period Four [Member]",
        "terseLabel": "Period Four"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsPeriodFourMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPaymentTermsPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms, Period One [Member]",
        "label": "Debt Instrument, Payment Terms, Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsPeriodOneMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPaymentTermsPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms, Period Three [Member]",
        "label": "Debt Instrument, Payment Terms, Period Three [Member]",
        "terseLabel": "Period Three"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsPeriodThreeMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPaymentTermsPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Terms, Period Two [Member]",
        "label": "Debt Instrument, Payment Terms, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTermsPeriodTwoMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_DebtInstrumentPrepaymentFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment fee percent.",
        "label": "Debt Instrument Prepayment Fee Percent",
        "terseLabel": "Prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercent",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "ASC 842 - lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DeferredTaxLiabilitiesAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Amortization",
        "label": "Deferred Tax Liabilities, Amortization",
        "negatedTerseLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAmortization",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-of-Use Asset",
        "label": "Deferred Tax Liabilities, Right-of-Use Asset",
        "negatedTerseLabel": "ASC 842 - ROU asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_DefinedContributionPlanDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan disclosures.",
        "label": "Defined Contribution Plan Disclosures [Text Block]",
        "terseLabel": "Employee Benefits"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosuresTextBlock",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bngo_EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Excessive Employee Remuneration, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Excessive Employee Remuneration, Amount",
        "terseLabel": "Section 162(m)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExcessiveEmployeeRemunerationAmount",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_ElSegundoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "El Segundo, California",
        "label": "El Segundo, California [Member]",
        "terseLabel": "El Segundo, California"
       }
      }
     },
     "localname": "ElSegundoCaliforniaMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_EmployeeStockPurchasePlanCompensationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Compensation Expense",
        "label": "Employee Stock Purchase Plan, Compensation Expense",
        "terseLabel": "Proceeds from sale of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanCompensationExpense",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_EscrowedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Escrowed Shares",
        "label": "Escrowed Shares [Member]",
        "terseLabel": "Escrowed Shares"
       }
      }
     },
     "localname": "EscrowedSharesMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_FinanceLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Expense",
        "label": "Finance Lease, Expense",
        "terseLabel": "Total finance lease costs",
        "totalLabel": "Total finance lease costs"
       }
      }
     },
     "localname": "FinanceLeaseExpense",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails",
      "http://bionanogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_GainLossOnExtinguishmentOfDebtCashExpense": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Extinguishment of Debt, Cash Expense",
        "label": "Gain (Loss) on Extinguishment of Debt, Cash Expense",
        "negatedLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfDebtCashExpense",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_GainLossOnForgivenessOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Forgiveness Of Paycheck Protection Program Loan",
        "label": "Gain (Loss) On Forgiveness Of Paycheck Protection Program Loan",
        "negatedTerseLabel": "Gain on forgiveness of PPP Loan",
        "terseLabel": "Gain on forgiveness of Paycheck Protection Program Loan",
        "verboseLabel": "Forgiveness of PPP Loan"
       }
      }
     },
     "localname": "GainLossOnForgivenessOfPaycheckProtectionProgramLoan",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_InnovatusLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Loan Agreement [Member]",
        "label": "Innovatus Loan Agreement [Member]",
        "terseLabel": "Innovatus LSA"
       }
      }
     },
     "localname": "InnovatusLoanAgreementMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_InnovatusTerm3LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Term 3 Loan [Member]",
        "label": "Innovatus Term 3 Loan [Member]",
        "terseLabel": "Innovatus Term 3 Loan"
       }
      }
     },
     "localname": "InnovatusTerm3LoanMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_InstrumentRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument Revenue [Member]",
        "label": "Instrument Revenue [Member]",
        "terseLabel": "Instruments"
       }
      }
     },
     "localname": "InstrumentRevenueMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_IssueCommonStockForCovenantWaiver": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Common Stock For Covenant Waiver",
        "label": "Issue Common Stock For Covenant Waiver",
        "terseLabel": "Issue stock for covenant waiver"
       }
      }
     },
     "localname": "IssueCommonStockForCovenantWaiver",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_LesseeEstimatedIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Estimated Incremental Borrowing Rate",
        "label": "Lessee, Estimated Incremental Borrowing Rate",
        "terseLabel": "Estimated incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeEstimatedIncrementalBorrowingRate",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bngo_LesseeFinanceLeaseAreaLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Area Leased",
        "label": "Lessee, Finance Lease, Area Leased",
        "terseLabel": "Finance lease, area lease (in sq ft)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseAreaLeased",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bngo_LesseeOperatingLeaseAreaAdded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Added",
        "label": "Lessee, Operating Lease, Area Added",
        "terseLabel": "Area added (in sq ft)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaAdded",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bngo_LesseeOperatingLeaseAreaLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Leased",
        "label": "Lessee, Operating Lease, Area Leased",
        "terseLabel": "Operating lease, area leased (in sq ft)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaLeased",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bngo_LicensingRevenueAndMaintenanceAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Revenue and Maintenance Agreements",
        "label": "Licensing Revenue and Maintenance Agreements",
        "terseLabel": "Licensing revenue and maintenance agreements"
       }
      }
     },
     "localname": "LicensingRevenueAndMaintenanceAgreements",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_LineagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lineagen",
        "label": "Lineagen [Member]",
        "terseLabel": "Lineagen"
       }
      }
     },
     "localname": "LineagenMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity",
        "label": "Liquidity [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bngo_LoanUnderPaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Under Paycheck Protection Program [Member]",
        "label": "Loan Under Paycheck Protection Program [Member]",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "LoanUnderPaycheckProtectionProgramMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Lease Expense",
        "label": "Non-cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_NoncashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Interest Expense",
        "label": "Noncash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NoncashInterestExpense",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_OperatingLeaseMonthlyRentPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Rent Payments",
        "label": "Operating Lease, Monthly Rent Payments",
        "terseLabel": "Monthly rent payments"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyRentPayments",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_OperatingLeasePaymentsModifiedAndUnmodified": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Payments, Modified and Unmodified",
        "label": "Operating Lease, Payments, Modified and Unmodified",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePaymentsModifiedAndUnmodified",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity Net [Abstract]",
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity Net [Abstract]",
        "terseLabel": "Total Payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueFiscalYearMaturityNetAbstract",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Future Minimum Payments, Due in Four Years and Thereafter",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years and Thereafter",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYearsAndThereafter",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_OperatingLossCarryforwardsNotSubjecttoExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Subject to Expiration",
        "label": "Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards that do not expire"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjecttoExpiration",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_OperatingLossCarryforwardsSubjecttoExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Subject to Expiration",
        "label": "Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjecttoExpiration",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_PaymentsForInitialCostsOnLeases": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Initial Costs on Leases",
        "label": "Payments for Initial Costs on Leases",
        "negatedTerseLabel": "Payment of initial direct costs on lease"
       }
      }
     },
     "localname": "PaymentsForInitialCostsOnLeases",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_PaymentsForPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Property and Equipment",
        "label": "Payments for Property and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsForPropertyAndEquipment",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_PerformanceShareUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Units (PSUs)",
        "label": "Performance Share Units (PSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceShareUnitsPSUsMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrant [Member]",
        "label": "Pre-Funded Warrant [Member]",
        "terseLabel": "Pre-Funded Warrant"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bngo_ProceedsFromPayrollProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Payroll Protection Program Loan",
        "label": "Proceeds from Payroll Protection Program Loan",
        "terseLabel": "Proceeds from PPP Loan"
       }
      }
     },
     "localname": "ProceedsFromPayrollProtectionProgramLoan",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_PurchaseObligationContractTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Contract Termination Period",
        "label": "Purchase Obligation, Contract Termination Period",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "PurchaseObligationContractTerminationPeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_PurchaseObligationInitialPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Initial Purchase Period",
        "label": "Purchase Obligation, Initial Purchase Period",
        "terseLabel": "Initial purchase period"
       }
      }
     },
     "localname": "PurchaseObligationInitialPurchasePeriod",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bngo_ReagentRentalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reagent Rentals [Member]",
        "label": "Reagent Rentals [Member]",
        "terseLabel": "Reagent rentals"
       }
      }
     },
     "localname": "ReagentRentalsMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_RentalRevenueReagentRentalProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Revenue, Reagent Rental Program",
        "label": "Rental Revenue, Reagent Rental Program",
        "terseLabel": "Rental revenue"
       }
      }
     },
     "localname": "RentalRevenueReagentRentalProgram",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_RevolverMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolver [Member]",
        "label": "Revolver [Member]",
        "terseLabel": "Revolver"
       }
      }
     },
     "localname": "RevolverMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_SaleOfStockAuthorizedAmountToBeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Authorized Amount To Be Issued",
        "label": "Sale Of Stock, Authorized Amount To Be Issued",
        "terseLabel": "Issuance and sale of stock"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedAmountToBeIssued",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_SaleOfStockValueSharesIssuedInTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Value, Shares Issued in Transaction",
        "label": "Sale of Stock, Value, Shares Issued in Transaction",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockValueSharesIssuedInTransaction",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_SaltLakeCityUtahMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salt Lake City, Utah",
        "label": "Salt Lake City, Utah [Member]",
        "terseLabel": "Salt Lake City, Utah"
       }
      }
     },
     "localname": "SaltLakeCityUtahMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_SanDiegoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego, California",
        "label": "San Diego, California [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoCaliforniaMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_ServiceEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service equipment placed at customer sites.",
        "label": "Service Equipment [Member]",
        "terseLabel": "Service equipment placed at customer sites"
       }
      }
     },
     "localname": "ServiceEquipmentMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_SettlementOfInterestOnDebtNoncash": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of Interest on Debt, Noncash",
        "label": "Settlement of Interest on Debt, Noncash",
        "negatedTerseLabel": "Settlement of interest on debt"
       }
      }
     },
     "localname": "SettlementOfInterestOnDebtNoncash",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Contractual Term [Roll Forward]",
        "terseLabel": "Weighted- Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageContractualTermRollForward",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_StockIssuedDuringPeriodSharesCovenantWaiver": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Covenant Waiver",
        "label": "Stock Issued During Period, Shares, Covenant Waiver",
        "terseLabel": "Issue stock for covenant waiver (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCovenantWaiver",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Stock warrant exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_StockIssuedDuringPeriodValueCovenantWaiver": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Covenant Waiver",
        "label": "Stock Issued During Period, Value, Covenant Waiver",
        "terseLabel": "Issue stock for covenant waiver"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCovenantWaiver",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Issue stock for warrant exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_StockIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued For Services",
        "label": "Stock Issued For Services",
        "terseLabel": "Stock issued for services"
       }
      }
     },
     "localname": "StockIssuedForServices",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bngo_TermA1LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A-1 Loan [Member]",
        "label": "Term A-1 Loan [Member]",
        "terseLabel": "Term A-1 Loan"
       }
      }
     },
     "localname": "TermA1LoanMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TermA2LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A-2 Loan [Member]",
        "label": "Term A-2 Loan [Member]",
        "terseLabel": "Term A-2 Loan"
       }
      }
     },
     "localname": "TermA2LoanMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loans"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer of instruments and servers to property and equipment from inventory.",
        "label": "Transfer Of Instruments And Servers To Property And Equipment From Inventory",
        "terseLabel": "Transfer of instruments and servers from inventory into property and equipment, net"
       }
      }
     },
     "localname": "TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_TwoCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Customers",
        "label": "Two Customers [Member]",
        "terseLabel": "Two Customers"
       }
      }
     },
     "localname": "TwoCustomersMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TwoThousandAndTwentyInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Twenty Inducement Plan",
        "label": "Two Thousand and Twenty Inducement Plan [Member]",
        "terseLabel": "2020 Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyInducementPlanMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen equity incentive plan.",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_UnvestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock",
        "label": "Unvested Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "localname": "UnvestedRestrictedStockMember",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bngo_WarrantExerciseNonCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Exercise, Non-cash",
        "label": "Warrant Exercise, Non-cash",
        "terseLabel": "Warrant exercise pursuant to cashless exercise"
       }
      }
     },
     "localname": "WarrantExerciseNonCash",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_WarrantsToPurchaseSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase shares issued.",
        "label": "Warrants To Purchase Shares Issued",
        "terseLabel": "Warrants to purchase shares issued (shares)"
       }
      }
     },
     "localname": "WarrantsToPurchaseSharesIssued",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bngo_WarrantyAndMaintenanceRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty and Maintenance Revenue",
        "label": "Warranty and Maintenance Revenue",
        "terseLabel": "Warranty and maintenance revenue"
       }
      }
     },
     "localname": "WarrantyAndMaintenanceRevenue",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bngo_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://bionanogenomics.com/20211231",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r397",
      "r577",
      "r578",
      "r581",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r62",
      "r64",
      "r127",
      "r128",
      "r306",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r196",
      "r378",
      "r383",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r305",
      "r335",
      "r400",
      "r402",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r618",
      "r668",
      "r672",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r305",
      "r335",
      "r400",
      "r402",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r618",
      "r668",
      "r672",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r196",
      "r378",
      "r383",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r193",
      "r378",
      "r381",
      "r621",
      "r667",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r193",
      "r378",
      "r381",
      "r621",
      "r667",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r305",
      "r335",
      "r389",
      "r400",
      "r402",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r618",
      "r668",
      "r672",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r305",
      "r335",
      "r389",
      "r400",
      "r402",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r618",
      "r668",
      "r672",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r63",
      "r64",
      "r127",
      "r128",
      "r306",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r194",
      "r195",
      "r378",
      "r382",
      "r670",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r194",
      "r195",
      "r378",
      "r382",
      "r670",
      "r695",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r197",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44",
      "r586"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, trade"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r26",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $690,000 and $2,119,000 as of December 31, 2021 and 2020, respectively",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r276",
      "r277",
      "r278"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Accretion Expense",
        "terseLabel": "Amortization of interest on securities"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r49"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails",
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r49"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees and royalties"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r270"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r68",
      "r69",
      "r70",
      "r657",
      "r677",
      "r678"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r67",
      "r70",
      "r77",
      "r78",
      "r79",
      "r131",
      "r132",
      "r133",
      "r515",
      "r673",
      "r674",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Intangible assets useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r435",
      "r436",
      "r437",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r403",
      "r405",
      "r441",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r405",
      "r432",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r33",
      "r201",
      "r223"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Less allowance for doubtful accounts",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recovery of bad debt expense"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r107",
      "r254",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r122",
      "r176",
      "r185",
      "r191",
      "r221",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r511",
      "r516",
      "r538",
      "r584",
      "r586",
      "r638",
      "r655"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r61",
      "r122",
      "r221",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r511",
      "r516",
      "r538",
      "r584",
      "r586"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r208",
      "r231"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r209",
      "r210",
      "r649"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r207",
      "r231"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r406",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r399",
      "r401",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails",
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Cash held in escrow"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of shares issued or reserved for issuance (in shares)",
        "verboseLabel": "Shares of common stock issued as consideration (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Stock price per share on Effective Date (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r500",
      "r501",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total estimated purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r500",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Value of estimated common stock consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r498",
      "r500",
      "r501",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liabilities assumed of acquiree"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r106",
      "r508"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r499",
      "r502",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent liability",
        "verboseLabel": "Estimated fair value of milestone consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred",
        "terseLabel": "Adjustment to original purchase price"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "negatedTerseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r491",
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r491",
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r40",
      "r109"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r103",
      "r109",
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r103",
      "r539"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activity"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r119",
      "r122",
      "r143",
      "r144",
      "r145",
      "r147",
      "r149",
      "r154",
      "r155",
      "r156",
      "r221",
      "r291",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r333",
      "r334",
      "r338",
      "r342",
      "r538",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r357",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Outstanding at December 31, 2019 (USD per share)",
        "periodStartLabel": "Outstanding at January 1, 2019 (USD per share)",
        "terseLabel": "Warrants to purchase, Fair value preferred stock (USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of securities called by each warrant (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding at December 31, 2019 (shares)",
        "periodStartLabel": "Outstanding at January 1, 2019 (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r53",
      "r283",
      "r643",
      "r661"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock initially reserved for future issuance (shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r131",
      "r132",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://bionanogenomics.com/role/Cover",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25",
      "r586"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 400,000,000 shares authorized at December\u00a031, 2021 and 2020; 289,602,000 and 189,953,000 shares issued and outstanding at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r72",
      "r74",
      "r75",
      "r83",
      "r646",
      "r663"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r196",
      "r536",
      "r537",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r196",
      "r536",
      "r537",
      "r679",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r196",
      "r536",
      "r537",
      "r679",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r159",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r164",
      "r165",
      "r196",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of revenue",
        "verboseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r196",
      "r536",
      "r537",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r87",
      "r621"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Cost of revenue:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r467",
      "r475"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r467"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r467",
      "r475",
      "r477"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax provision (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r467",
      "r475"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r162",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r121",
      "r129",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r323",
      "r324",
      "r325",
      "r326",
      "r551",
      "r639",
      "r641",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r320",
      "r641",
      "r654"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Total principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r302",
      "r323",
      "r324",
      "r549",
      "r551",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan face value"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r51",
      "r322",
      "r549",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r52",
      "r121",
      "r129",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r323",
      "r324",
      "r325",
      "r326",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r52",
      "r121",
      "r129",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r323",
      "r324",
      "r325",
      "r326",
      "r350",
      "r353",
      "r354",
      "r355",
      "r548",
      "r549",
      "r551",
      "r552",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r309",
      "r548",
      "r552"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "auth_ref": [
      "r548",
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Current",
        "verboseLabel": "End of term charge"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r216",
      "r235",
      "r238"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "negatedTerseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r216",
      "r235",
      "r238"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "negatedTerseLabel": "Less than 1 year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Gain (Loss)",
        "negatedTerseLabel": "Loss on sale of available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r214",
      "r232"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r215",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Rent"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r468",
      "r475"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r43",
      "r309",
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r468",
      "r475"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r123",
      "r468",
      "r475",
      "r476",
      "r477"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Benefit from deferred income taxes",
        "totalLabel": "Total deferred income tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r457",
      "r640",
      "r653"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Long-term contract liabilities"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r463",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/EmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r107",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r107",
      "r174"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "EMEIA"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost related to outstanding employee options, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r77",
      "r78",
      "r79",
      "r131",
      "r132",
      "r133",
      "r135",
      "r140",
      "r142",
      "r153",
      "r222",
      "r349",
      "r356",
      "r435",
      "r436",
      "r437",
      "r471",
      "r472",
      "r522",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r673",
      "r674",
      "r675",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r529",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r524",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r524",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r311",
      "r323",
      "r324",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r525",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r524",
      "r525",
      "r527",
      "r528",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r311",
      "r390",
      "r391",
      "r396",
      "r398",
      "r525",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r311",
      "r323",
      "r324",
      "r390",
      "r391",
      "r396",
      "r398",
      "r525",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r311",
      "r323",
      "r324",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r525",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in estimated fair value, recorded in selling, general and administrative expenses"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Liability recorded as a result of current period acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r311",
      "r323",
      "r324",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r531",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r558",
      "r564",
      "r574"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "bngo_FinanceLeaseExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r561",
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Lease"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r557",
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liability, related party"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Finance Lease, Liability, Fiscal Year Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liability, net of current portion, related party"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r560",
      "r568"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Principal payments of financing lease liability",
        "terseLabel": "Principal payments of financing lease liability"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets, related party"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r558",
      "r564",
      "r574"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "bngo_FinanceLeaseExpense",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of financing lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r571",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r570",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r217",
      "r218",
      "r219",
      "r224",
      "r227",
      "r228",
      "r229",
      "r230",
      "r234",
      "r236",
      "r237",
      "r238",
      "r319",
      "r347",
      "r521",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r255",
      "r257",
      "r261",
      "r264",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r261",
      "r623"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r261",
      "r622"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetFutureAmortizationofIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r107",
      "r327",
      "r328"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r163",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r247",
      "r249",
      "r586",
      "r637"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r107",
      "r248",
      "r250",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAmortizedCostandUnrealizedGainsLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r107",
      "r267",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r266",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets (including Finite-Lived Purchased Intangible Assets)"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r124",
      "r478"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r176",
      "r184",
      "r187",
      "r190",
      "r192",
      "r636",
      "r644",
      "r648",
      "r665"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r124",
      "r478"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesDomesticandForeignComponentsofIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r273",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r449",
      "r455",
      "r462",
      "r473",
      "r479",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r126",
      "r141",
      "r142",
      "r175",
      "r447",
      "r474",
      "r480",
      "r666"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit (provision) for income taxes",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
      "http://bionanogenomics.com/role/IncomeTaxesProvisionforDomesticandForeignIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r445",
      "r446",
      "r455",
      "r456",
      "r461",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income taxes at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedTerseLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities (net of assets acquired and liabilities assumed in acquisition)"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r253",
      "r259"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r80",
      "r173",
      "r547",
      "r550",
      "r647"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r101",
      "r104",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r49"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r242"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r58",
      "r586"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r59",
      "r117",
      "r152",
      "r239",
      "r241",
      "r243",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r36",
      "r37",
      "r242"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory impairment"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r89",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r220",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Total Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r572",
      "r574"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r48",
      "r122",
      "r186",
      "r221",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r512",
      "r516",
      "r517",
      "r538",
      "r584",
      "r585"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r122",
      "r221",
      "r538",
      "r586",
      "r642",
      "r659"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r50",
      "r122",
      "r221",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r512",
      "r516",
      "r517",
      "r538",
      "r584",
      "r585",
      "r586"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Term loan facility available"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r20",
      "r310",
      "r321",
      "r323",
      "r324",
      "r641",
      "r656"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total carrying value of debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-term Purchase Commitment [Line Items]",
        "terseLabel": "Long-term Purchase Commitment [Line Items]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table]",
        "terseLabel": "Long-term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r52",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/LongTermDebtScheduleofDebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r103",
      "r105",
      "r108"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r71",
      "r73",
      "r79",
      "r82",
      "r108",
      "r122",
      "r134",
      "r136",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r146",
      "r176",
      "r184",
      "r187",
      "r190",
      "r192",
      "r221",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r523",
      "r538",
      "r645",
      "r662"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Loss:"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued But Not Yet Adopted and Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r176",
      "r184",
      "r187",
      "r190",
      "r192"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r565",
      "r574"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "totalLabel": "Total rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSummaryofUndiscountedFutureNonCancellableLeasePaymentsUnderLeasesDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r562",
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r571",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r570",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r553",
      "r554"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r553",
      "r554"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r553",
      "r554"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r553",
      "r554"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r553",
      "r554"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsRequiredunderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r49"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r60",
      "r586"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r65",
      "r66",
      "r68"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized (loss) on investment securities",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLossStatement",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expenses)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriter Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "PIK"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForConstructionInProcess": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.",
        "label": "Payments for Construction in Process",
        "negatedTerseLabel": "Construction in process"
       }
      }
     },
     "localname": "PaymentsForConstructionInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Offering expenses on sale of common stock",
        "terseLabel": "Offering expenses on sale of common stock"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r92",
      "r94",
      "r206"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchase of available for sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r95",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash consideration transferred in acquisition",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r406",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r24",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r24",
      "r586"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December\u00a031, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r9",
      "r244",
      "r246"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from borrowing from line of credit"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Loan proceeds received"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r92",
      "r93",
      "r206"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sale and maturities of available for sale securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrant and option exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Service and other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r49",
      "r285",
      "r286"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Warranty liabilities"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyExpense": {
     "auth_ref": [
      "r106",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.",
        "label": "Product Warranty Expense",
        "terseLabel": "Warranty expense"
       }
      }
     },
     "localname": "ProductWarrantyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r71",
      "r73",
      "r79",
      "r102",
      "r122",
      "r134",
      "r141",
      "r142",
      "r176",
      "r184",
      "r187",
      "r190",
      "r192",
      "r221",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r510",
      "r513",
      "r514",
      "r518",
      "r519",
      "r523",
      "r538",
      "r648"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r269"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r271",
      "r586",
      "r650",
      "r660"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r85",
      "r225"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debt expense",
        "verboseLabel": "Bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r200",
      "r203",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r397",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r397",
      "r577",
      "r581",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r575",
      "r576",
      "r578",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayment of outstanding term loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r99",
      "r121"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedTerseLabel": "Repayments of borrowing from line of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayment of term-loan debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails",
      "http://bionanogenomics.com/role/OrganizationandOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherDebt": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other.",
        "label": "Repayments of Other Debt",
        "terseLabel": "Payment to satisfy outstanding principal and accrued interest amounts"
       }
      }
     },
     "localname": "RepaymentsOfOtherDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r443",
      "r620",
      "r713"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research credit"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Issuance of common stock due to the vesting of restricted stock units, net of shares withheld to cover taxes (in shares)"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r356",
      "r438",
      "r586",
      "r658",
      "r676",
      "r678"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r131",
      "r132",
      "r133",
      "r135",
      "r140",
      "r142",
      "r222",
      "r435",
      "r436",
      "r437",
      "r471",
      "r472",
      "r522",
      "r673",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r170",
      "r171",
      "r183",
      "r188",
      "r189",
      "r193",
      "r194",
      "r196",
      "r377",
      "r378",
      "r621"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r164",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r380",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue from Contracts with Customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r569",
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities resulting from obtaining and modifying right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesSupplementalInformationDetails",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r164",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RevenuefromContractswithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossPerShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsAcquisitionPurchasePriceDetails",
      "http://bionanogenomics.com/role/AcquisitionsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/AcquisitionsFairValueofTangibleandIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/AcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision for Domestic and Foreign Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt and Unamortized Discount Balances"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r405",
      "r431",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Recognized Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurement of Assets And Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r255",
      "r260",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Domestic and Foreign Components of Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
      "http://bionanogenomics.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r579",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r406",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r411",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under 2018 Plan and 2006 Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r54",
      "r119",
      "r154",
      "r155",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r342",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r357",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r454",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUtilityInventoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all information related to inventories for utilities.",
        "label": "Schedule of Utility Inventory [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories"
       }
      }
     },
     "localname": "ScheduleOfUtilityInventoryTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ServicingLiabilityMeasurementInput": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure servicing liability.",
        "label": "Servicing Liability, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "ServicingLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Canceled",
        "verboseLabel": "Intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r413",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (shares)",
        "periodStartLabel": "Beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares of Stock under Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (USD per share)",
        "periodStartLabel": "Beginning balance (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of new shares issued under plan (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r406",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Total intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationRestrictedStockandPerformanceStockActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r426",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and exercisable (USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Offering price per unit (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r116",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandardProductWarrantyAccrual": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.",
        "label": "Standard Product Warranty Accrual",
        "terseLabel": "Liability for product warranties"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r119",
      "r122",
      "r143",
      "r144",
      "r145",
      "r147",
      "r149",
      "r154",
      "r155",
      "r156",
      "r221",
      "r291",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r333",
      "r334",
      "r338",
      "r342",
      "r349",
      "r538",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r56",
      "r77",
      "r78",
      "r79",
      "r131",
      "r132",
      "r133",
      "r135",
      "r140",
      "r142",
      "r153",
      "r222",
      "r349",
      "r356",
      "r435",
      "r436",
      "r437",
      "r471",
      "r472",
      "r522",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r673",
      "r674",
      "r675",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r153",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r112",
      "r113",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Fair value of common stock issued related to acquisitions"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r24",
      "r25",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issue stock for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issue stock for employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issue stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (shares)",
        "verboseLabel": "Stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationSummaryofStockOptionActivityUnder2018Planand2006PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r56",
      "r349",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issue stock for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issue stock for employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r349",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issue common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r349",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r30",
      "r31",
      "r122",
      "r202",
      "r221",
      "r538",
      "r586"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets",
      "http://bionanogenomics.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r334",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r356",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity and Stock-Based Compensation"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r567",
      "r574"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Gross sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r546",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r546",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r546",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/StockholdersEquityandStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r7",
      "r9",
      "r245",
      "r246"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Supplies",
        "terseLabel": "Prepayment to supplier"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/AcquisitionsIdentifiableIntangibleAssetsDetails",
      "http://bionanogenomics.com/role/IntangibleAssetsNetSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r217",
      "r218",
      "r219",
      "r319",
      "r347",
      "r521",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsAdditionalInformationDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsContingentConsiderationLiabilityDetails",
      "http://bionanogenomics.com/role/InvestmentsandFairValueMeasurementsFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r444",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions/(reductions) for tax positions - prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r157",
      "r158",
      "r160",
      "r161",
      "r166",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r566",
      "r574"
     ],
     "calculation": {
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://bionanogenomics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123377177&loc=d3e11281-110244"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12524-110249"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3,4))",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1),(c)(5)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r714": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r715": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r716": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r717": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r718": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r719": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r720": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r721": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r722": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r723": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r724": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r725": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r726": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r727": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r728": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r729": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r730": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>132
<FILENAME>0001411690-22-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001411690-22-000007-xbrl.zip
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M-7SVV?/GS[.WN%_9!]RP[,V;5^'-7=>T\FKZWO>\P=G?RKK95LO.?[(,@SR
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MF/3&<W(CD1HAC.U$>%G&(KQI/U^$D]&Y3X2;2W;/O3#9B_Z(6JPDA*-IL[N
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MB[82P\W2N<1SP3&J^T$XCJ,W[J+#^6H\OAP/?3?YL2CFRV$SY=:_<W2VB&U
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M7C!@/SM=P,/5*4<!^C(\X8.DX8VEQSZ<. +->M:I)#CMO'YMI_,3(5OB5$'
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M$6(YB++<6 O&XHLB9W1UR.[KLE]1Q$^]F<H36Q=5KAL.+*M)U.KE2 MW',N
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M.L!]S-08ZB79X%HSA&94;2-U=>H%*#V_]2"-;(.F]<\5$V^)/&\VP$53#^2
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ME0*%.PO26\21H8CX-8*(I+G8#UJT#+D@OVIA>F&Z(8F?B SJ6A31 +4Q<UZ
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M)RV,+Y,&5?/AUKI9&W<!QA/9(_$ +;,[M$'59!'6CD ;-'(-MNYENLV<E5
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M+[)5C$A<S90'#X:8,[:%L7L5I8D,.+3R612;V+_^K%"+Y]\?:O'B:T(M7O1
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M*T;BUFBH!FEML&0A(BY1/)'A'ND0?]'/13.:8CST<PW&)LG/.+S"0.%1.3
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MY2IC:49G)SE4YOG.3?OC>6%@\M['&/"T4N&=&V+W8;$>$# 8Z%F5!(0X+NU
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M<C4A5=.WC3Q$_WE[>O 1_OM^?GST[_\+4$L#!!0    ( $Z"851Y' .7"ID
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M6T\AGJ39.JE0XG<:F2HDC<3_'7UGT39+B5^1L^?V-77:$:-2J48(,;R65?S
M ?5-%@4#TP2S[!BM',4%NZ+'A_8WH0-YDOQV4U8<W\M6X&9^*I>8D.K^-:#?
MN6A P5T7^A(=7[+,UAP)G2'>8>A\FHLC@7C]XM_@E#Q^8H'QD576EEU3IY$+
M&UQ-O-UOWEXE?8FAW"8>&4Y30G4F[,CN[Y)#F,U0Y3S!>3^ I,>]11_9Q#/9
M:<[+!0$]^I/D3=.+1I*=@W=D^2T%(^'+MWA2UJ.'NG!CP88 Q5O=4A_F9=U'
M2OFEGLL]7E>.QN;@K]Q*#MB=5'=WDUG;P!6=PWVMZ:0MP%K!LYL7LQ8#NYK:
MC1)-B=S>\ZRMULF[!I[5=9I(2I.[FW)^4^!K%V4+%F\S!Y/?IP(O>U!<0<Z)
MKGR:@'*J&DP8="(._C64+1Q(6(A;M%W@NO<MG,?.I(SA GF%]NW)*3HB%'.G
MN%(SPZRZSXD7<J'JI("K '?)A;9+T*4<4U\T%?Q<<PE^L#"OK&TSSKV[G$;9
MT34H$/'2HJN8)JMJ6,[@CRE.'RTNT-8?JP)D8(7;1)_<%!G_!XBSOJSH'S2T
MK&R]6,,_=NNN+Y9^]7[Y^]E+OVY5DU&:+V^:%L1C-RQ7((26*_CO<@$/7+,T
M)4%*(9=N ,\#1LL@ A%J7B[SERC'T-^ ),.Q='T[S'N[B*G/8< 3KAOP;Q"Q
MP+-PH\?CTV%H)Z?5<XO&SQO0*'4#$6$*QW&!.9.,#)P[> <+^D4SU+E+;<"T
MDME05AP/;<(Y)$?&5OI)ON4RHV[<>M)1&^"=PWP9;&''Z^7&ZIZ:-R2#\0@B
M3N,F^W?6YLW0@:Z[+:I.A[5L0!;#[5@,]76)SZ33AP<:-,]< !F8L(*C@M'U
MKI?KM"AR,M.K[(ZR-!F\KGZ$.J0J*6F')Y674X[AFD]?AT^7Y;.'%>W&!>7I
MX$/:=3U)\(E;=]$>RZR"$<]Y@6$P65G9K ]I3CC&.%;W=G9LT\3*FQ0'XT%Y
MI]_^"*]H,(LP@[//&T@3:0M,(I$NH['!-O1X0R1;EUE+UJ6C LV>XM^7JQY!
M50OX+3QR7I3P6YANE$MS=@AL><=VE-@*O*B<SIIC4 )G6V>4\^,45H\R3U<P
MW))T:MG@ERD.I4?]V67+ HV;:$6*3ZNB1ML$DX+1>G;^B&8JBR2V<%0>)R\T
MOTI'BH:+ D'WED_O40G??"HI0O]%.,IP=*U,P2_SC8\OHEX<.HNR='E3^)RA
M;GL@J&6]=STY\Z:EE?*W6E?Y_D4.4[?F>#5NO++PC(;T1W'>=+WF)WD;9"KD
M':F,%WDU=JLT]XFG$<\927'OJ UU=D>:9T'[A9-J,3N Y_<-+0^M\2O)SF>D
MAE39B+2![?[^1]Y%_#WJ\/I? X7.EXBR FDT%"I+X N@!$#28ER-A;057/PL
M.17RP%E6?VR'53]?XQV:%P4CS*:&<J@NV#[P5"_=H=RC61?9('RS9T5'0JJ$
MOR..KRKR:[X8 60PUI1TR]8L!.DQ<NGA S"PK)H"K10X7P0:#U$/?,I1]ET/
M%5U%D4;PU[+&5?,VS)E_\GN6'31 IZ5I;G>8'/26FBAD B#0YY2*-O,CE;<"
ML5[R/-L";8F[K+,VS$ER&:A0)],81"+K.2!>HF$[5J7)70GB9C6$9@%(IR9'
MW<$3EE^@]S@S8E&NY-FR0 L1OX8K_JKLLEE9E8A03LY@A@W?YJZ$,Y.UM.8H
MO3-<:I053K(Y>8;C/.J"!.CSQ\>I8$+Q86=57[0R./CKAQY?N$XN8$% ?,H'
M1UGG3)7(GGYZE!T?<Q&  YIJ20 /Y@2]U_/8ET3]#H\N<8O1,59?E,RZFX)T
MCJ!::&FF#P0?(#(52H**XG?_379Q2O:]52\+@KH$ZU/6H+YS*D63.$4V=_=#
MKM J@[LSB,\^"@+4[)+ :%$AHS+&,W2QV& <^OL46&JQD;3-RMF#7?,P$3]1
M4V9^(C+K*5;6C5-KFVKM9DW?-\L?'ON?9#-0UD,__LD]A6W\?V]:??(JNRX>
MS=HB^_B(EO.'K+H#L^A/#ZT*W&\]W?<[Y3+_]-?80%5#E-RN>XS1>PR]Z.PU
MFUP4LM"=?!53T)FMFYWKT!BDJQD]_C-:?'*!-X@=$BVH0/@"SL$;OL8P1"/&
MM AV"SE4 *2!KN"?G>9Q-JY#3>*#2.*#6%$9/1)!,.C_^=^???LC?%$M\E1M
M>;#: H_X%^>27@XS$.]T )R%7M8@&22$@_A-DL"KFW6',8M B^D@/M0EZ-1M
M0_%(Y&Q58J+P'-<7I@=BQH<HU+KV46*!;59<02 +U7DWZZYI/\;>SU<U0W>]
M;@@&N?1165.& (IS+H$HBL30O":6B<^:LQ0B=4_75J0X1\7K\E\#VR?Q43$1
MKDYBS_! NI*#?-Z+]88Q&\X*IN&68%QDJ @<&ZIOMT7.KO+JZ@9T(H<8X?IM
MF2J;!3)1<W4J5,!/I%P@O$(<B@E?3<JS #]998K<=1]?=Y-"!5["!2RR/&'S
M@X^;>[YX=QYBBYY=YX)<UL,307:J7G6LFB.YHZ_#^R02D]9'<RFP1Q0RY'#[
M*F,1K0'Z>>%J+4T(/E@%,F9J<0@36%;$.S>;%\7*=WIS,,;H')1+EBY8P#=W
MPFSJU+'!*]O:;=Y['*Z+13<;= H?]34YH\$*8@ 1A3OFE7H'?NZ=B :K'E\\
M^HF86W)":4/!H"LPYDKXZZRM2A_NE*.8TV8X50++CA&RJK@F"W1 "_K?1;0*
M<#B:H;>0V$TK\77]Z9T%V>P8S\>VJZNF^G\JG8[H)1G8]M=8,5LO*>D'*[O,
M:BY)[HJR6\(C ]?JF/1>'1C2=&]0/&T]=L')IE*WF3,?W/5++;(Y*"7 F!D&
M6DP>,I)2XK>13=T%SJ?#3O=R_3'\23<F3 B6%-%)IR[T*2G=TV?/8%R*ZA<?
M5]4ER@44K5G7U&#+@-_0@V<^&WHR;,2E=?&<<#UP!2_ 2VHI@L##G645V5OP
M!!*AJ[; KV%PP5A=64^S1G\<98NY99]1 7 06_;<S-"E-L6)*UWE2P$F5[-$
MHP:^MH!?E+((.@68=UOX+0K.TT3QR[3>P.1T6(,1B3*?8C,Z!OX5Z)BF?;B.
M,9;[-AWC A;WW!"G%M!'5[.?]$,P>7:>,?3*T>2"KH1?3AN^G7A+H)&S_);-
M>?SR8JCS3K1##G8R>2F\$NY<INSHTDT9,%LVRC#H&,QU\-E[MFA6X(];'<BA
M6CD;"PY033Y7,RGV9LA%I!%A*!;'K_42"V=R!Y+#G1V7S$<\5BF(=K6ZRN5L
M:+M"!XG7#._Y M$-,SC+7:2HW8%E2IVMYU43 M,GM6D/5#.!&?VFZ?% H$^3
MJ]#(9J ]V!<RQ0-P^>>@4_!+&XUM%Q3"$!E%_4@I] WYF[=-!6<L0R:'H49_
M$6TT/OY8!;?!8W0>Y9:WBAT*.W5=M&%*.K3Z40NPQ==0+18B2G+Q0E%>4##+
M_Y/FTY5<>TV?-6WHT$4J@!1IJHEPCJ7>6KN9SU91HI#TJ:>Q4<C73;SC0<1U
M-!KK-_;91_F1Y*+[8D4A3@F8UB#JN@Z+51%B4I7N(#L/B=S7;?*,)D^9$PH<
M%'VQQ3CH6:?=U6$JR*T W!"CUNBN43YGVUT[S%OTY/,6RHY?NP']ZJ.M<DV^
MZ" V)T[PDL617SG9X,*#]8 .&6D+KH=$J;M".PM,VIZ.(]Q?2ECCK5G"1@]M
MZ .D"=K0]DD*I_)T##:$TC8?BY:4:0>7M%N0<5)4BU%ZG*QL]#@"P-O(P#[R
M5!%HMU&Y*%P@L7 )JV(@*I0S)I4>(%1\&KD3E#[8Q?5MV39BIL-E77F41!SZ
MVQA.$S?^G@3(L6(OBA(O.-S7&6<K[HWLHY)0!&(FG$5T[<OZ%@P(9[)VN$%Y
M@:EO+VMDP=7Q#A$)//BLZP:D=$.AX$(C/#8R)'&  EJB*"O%N^E1)&#F\V$%
MJ[2.-PT&GA\;VQ5^1LXOJ7TT!\#R[G#==?3V.(RS%9R5T9,E:X8VYE%QS+_;
M#GK$5!D.PT%BG!'KECT';Z\3E5*YP("-$;I8QACI*."$Q3$L/ND6-\#([H+!
M4?*G-A>%I"_-$9>F:5D[JBT3+A5-7D+0I;CG >($<S.ZOP;QE&V!D5[XR*T/
M:6X0*:!]QL.NFWB4G.FAA0O':ZR8:/WU1L D;II:+$WG*MD[@]%E/'?KZ,0Y
M? @?NRFL3GS"&W.->,/97L8C,L]6^D8CW>Q T*"I*F_'2!#R4/7D9RT,WU5/
M>COP'3F3;^]JM+Q@,=^R[.CWHCD-/*DT$D;!+C93_,1'D!ND&$@HVT!0,T[?
M@P=E#<B N,"G@9SO*M*TP86@?(6L0RRTZ&(RIG'"A)T5HT@V2@\O^S7I!)<4
MDPZ'>2B??N'-W\P>=*CK\5D+,!ZT(/NZAB,(=II$_#U<5FU9EN)D2DL2)@"P
M^0M\>O+T4'?[LR+X'RB2OQ#FZR&^BXM.HFUF844@/36ELO(0_-BJLY%(C9U1
M5@,GIL91%-O%<"GG]T"LPO^5F%>)E6=D[A^9(K*3Y\<GR3NAFY(!K5TT3G\_
M)9G]/(2=2 M^PN%TCL?.TT)@0) L<XJ1QE@"[PM1?"A;+P7MPNG!.HHGQ8B(
M2G (" &#[]T@IMNL\$KF:B*SP52#I3I)?AY:-#%3C60782#<SAXM6S)'36&3
MTY0-_1G<,F(N<J ].^](F4K* ZLOR"F4TX31%A?BG9H@'Q0)IKJ!H/Q@7Q6$
MQV'*BF=[T9247CW0]3C=VXH@Q!D1A7N1F\@BMFSJ @.Y@23Q6"&?A=[*D@G.
M,X/U-*X?\Q<<T\7 H(*KLZ,+NH=E5SB.)7(ZU(.Y%Z7^CC7!/L.0+)/G&8;&
M(\7D3@^HE=L@< B66I7=+08^U"Z.A @M^!Y1K':I0R%(OHA0M[E@SXX\Y%13
M]I0A76$(N^_CXIICRETWB'J%<R_T>,@ IOGK4I/6S-CG[IH6*'@MCY5;/@A9
M%QFF]/Y G/Z?@CB]N\&04=Y45=:2,TZA9D+84&8);9JROFTPU4A @C8\V1C*
MS=!"R7H7L^5_S]?&[B4@9=D/Z.<D=QD9O2-PQP2N@W.%C*G8&-M[KUDE'*SP
MM<383H%=R>GG:F_/QXAE=IC#A8M=@768*;^>&Q>8TRT-BYDE*2%KH%WUL)QQ
MIIA2M&A14HP2'P+&=20GW%,I(N,5F22TLCQO<61AF3D;D2;[!A/M)%:ZJK)Y
MX4OWR$(D$YNK+1K^W[SHRFM*=WG0 ES_.0H638MG3JBYE?*K9/:"L#R8.@]<
M&[>U8[ #)=U<!-PDXFE&;->WQ776YERP-7H ;$O3=H4N)&XU$=$AK!=7BHO=
M)L\O?2]-\A;N<^K1LR5A>_6!.F].(/GDKM\>%)AE1W%;:;S 4?ZL,P"\# EC
M.G=ZW8\I?C^03__G)\]Q!RR0&!_T&G?FY0W( H][PN"ZICE7'+O&O54 ,RZ]
M,)R^%TP<XB1P]/.LNRD+OWRT!NXH=HPNF15<)%3D4NF-0YG/VP'^0!F0.0U'
MDB@@<%O07NZ1BZ+@3%-3Y_:7I<-]T"F!3PRT\\+YH/C,]TB7_D[HTI.K[).&
MN'EEM=Y1#UUC7"S0E,X!U&&2B]4=:G#ZV>>M>MLYB1L17>W%>KH(SWL GXM"
M"^&],;"^"70='0<.MFN&Q<R6/>Z\P;HEN'IX7K'<&X\[)?S07T;0]G6&HB"*
M2U^* ,<8BU<#^$<M@\=,(0E6A\20/PH-K\3 #837H*B<;C/C76#M1HD!;5_*
M9CX_S%/]?"\>:NS%[=\ER'D@'-A1SQ3-A,*1KHD-,N6%<NY2_C:1+U]D\%AT
M("(>\/LB;18RY^!_>/;>:\6EKV"3FN;Q0U)K5W I'N.N$-U(= H4IQ+[RZ!;
M\;:,9NJ(];Q5A+^3JYU5H%#S-=D6J@'Q%^]9:Y%1HKH+OR/WCK5@ZI*88BYY
M1![)@B6BA#1-A;7H,N:JE&QGJD@B9.;H2*'DV1*3[;Z65-8! 8"<VRIK"M"I
M*:#85 O-'"1)S-JVV[!>4P<C$HZ3$%.?1?_74&B- 5=M\I*+&+-',\0OHKIN
M*#XXM6,BBLA EFT*:V.#TQ9!HVML)TA%EMNJK<)IIGQSXGD%?%0Z-\-B/S7-
M)G%<(#V1(<H$-MU#J6WJ:8MZ:@2(="9>N%,BO+6*3*>8FVF+[%>&_-%K9N25
M-\&7C**X]*10GH&0S+6EQS[.J?<+UU9XT(<'%I*AC4T<C4%=:!UP^.MNF%7N
M4U YX"<4Q29PM<//Z<2G5]*QVE.IJLO9$F0Z=@X4&5XD_QSR:ZX&ET$.QK?S
M*WV'>T)H(]Z<F.[%W%"+SK17,S-+1<Q$3657B3F/W*$-:II\%:2!4,;("@OU
M<GF#G6>/6T!1GKHG9'$^S(L\$@9Z!;@B8^L]R(P1$UY]#F5MVL$9P2PSKHQI
MI8K;#)C8<WR[!;L<,-&)U3@)#]5$3NQC4:PVW$T,/U"I. H"5'U2!J<'!<RV
MWUA /@T$))]#WUVA#;#W$X+(C0_TV] *R/8>24US(:HY)^A-I 0IV["SQ'V2
M9\9%IV5>M"X>?5-4;&"V0\<7@T12Z>H^? NI0K6J7ADY"_*Y.(<NH1@9"P=I
M8+[8BX'YX7"78R_H"5R/O=O8@D>?0L9Q$8#:EEYIIFIG<=2 R@#I.2Z^9<J2
MN.R6JTI04_2-%,Y0=:G&W9@C<HPU5P@]Q^233267:"ZKB\C%3VAQ<WX@E>;+
MG9B=Q'_"!&-94@]E9ZK"X9=YV8%XFCF(*O,_H:F;D<4IMBN61N":@M&!.FOE
MEJS55G4E>KQO/9+R>@ !Q$H(I6N-17T%\>2M,5A\'=>QX.Q);A,-$[+W1<QT
M$IIEY'&YS"KXCUG9YD@E6G8W*?L2J[ZLM,0M4!%#;7;)I;S)PJVD+@RE9N&#
M1"/;D99PJD[>GI6(P9 ,/O(VJ"D3'(Y2+$%/@8=2^+H5I"29<]LH>^1\+@M4
MDE2ZW[0&V>V8O7H#N554IE8>!9;!$@U)<'%R\%J:Y42YH'="M&S8@ 9DT2*E
M)T[&MU:%DF;7Q21>"5N'9-=4*L#H>FEA,%<E$ZH#;S JXRKSZC<RB!JJR"=_
M5J83&K5^QPY51.\E.SI!('&@D5 LVM@+K %-.!+O'_ R2I%#\I)OP=[ @6B,
M[F$YE&1SXMQ\@8:[NRY(UAF^9N=UL019,L\MT=YA9AQKE2U5"BO+.R(^9:@^
M?D 1*U"XPP*S=1@E KT)*AP+:?H6QDJG@K,KI(8J=@2DR&'F2GLXDP]&PDQ=
M!W*QV"Q0!YP9>9098E;$*H"Z<L>U>:L&G63VKLKZG^ 8X':(\%N!<U[.D7*V
MZD%3=MFBZ"GX=@>#H@I7\F]\G8]J&5.G@A4#PNS&#@KZ!7TC$1Q<4EO-GV1#
M?]-P_1#7XR'S(%>P,D^VCM>'SKP<5Q4</A%<M?F:1P9ZGURAM>% C#A5AUY#
M=C!0!$_@A)IV?3)%D].%"B9U%52P^KZ(*DUNUGG;S+-VQL4;!;K\Q;!,DVNP
M+? D!NIVWJ*R:DH?J>-#AY;+^I'^@R@MD=28U97&%T;645%?9ZS!:+:(6<=%
MX\1N;"6P\O0Y<XQ@A,(+5WMR)11$(BXO)9+#"G<UE/Q^41RE7!9B 4M)V-&8
MC4F"H\=\[G%J&^MI]R#/''K*+M0>)9F167C'.=3G>?L2C@N[^#<61#-D!^WG
M:P+>)!B6)1,^JS_*-<;G<-R#198'?J;Z=9%Y$\)-)1_G^B=.$#L6CA F4V\&
M0RXL8Z-B+#ZK&&'#-Z5B\E$R'[P3'W%QD4BT_&($+1(7@>G/?$?I5GED;BC+
M)2XA9V&?Q'' C=/<, VD7-Q0!>G6A'$%:MO.3*]/A604&)FA2D"I?%G'M*Q$
MGACX9-X/FRJ71Q37=>.X:B6)R/[P6B@ZVS57=0YP"I;X+Z^2C/<4+;OMC5!C
M8@EC=9PQ&;M'[CW:C&:0?,;1O%D1$T]3,T\ZO -E_ K_=5TA-TK1ST^.M>P4
MA3J(J:Y@+P3YZW&F;L"!)T:NQ\#4"ZQ_@ZK5+6(H59\I%I_LUGO"C$_HT>^R
M06M5;DL>,J;DVK+[R TCX*SZJ*)+':'KQ2\(]:-7G9JPF2Y3Q)WVT>0)7S=2
M#90[812B"U&;Z# 6P[:L+#QB*.!F">MKN9B@IR(PLH-28Y6$?4$"LH#()M$L
MNP8V@M5*V>H)BA!-4L[5 Z03Q='I6+(>X>["F)I;E'06",G6Y,98\#$A@7BV
MZ..&[+!*?40X_A:Y"4#F9(Q)ZHX#5YT3%8XG,<Y6'Z97-MN+5_9JX%MU45,1
MA8;+]P%2<8D:K ON2-UA/;K)=TBV!$4G"+Y;;8LPK6-NF,E/OI\P72)*6T3G
MIF+\HOTU:T:\Q&%9,^BW6W0)R$*CNR\"7-,+6PC@1L$:@[M#CPB?\SD7^P&%
M42R&M51)2>5(J,,\5VNUC6+;8EYEY=(#^?)F3C ^\<D4X'R3!:78@9V@"S"Q
M;5_Y<N[,HO,%]VAK"=U[3U7Z>6_EP^/_A"3.PC#[!NI4N7/=JJPJ]GC%KX_N
M7SI] 2T?1W\#MO@U5VMI;Q@JUP<+@$#S77'GN#?8Q!$DFQ!!IQ/$M@YG8DFG
MMY@R[*0A 0][NEK0WX1*4WAEJX0]TM#P8WI#(OV,.+P)4E01I(<3C_0H-A1]
MLR^RTX:5@]^&]L["YTHHQ)T1QP?'9ARTR0Q5(A!3K;@V&L<B;HD4/M-<JUJ-
M+!R9.B\0CP5'A_ 9 BCE<CS$M5>WW+EG^A#-:.>162_F8+H'S3*C4(<'<KDT
ME(E^'*2@R?<G:"[@:"YK9V_M6]B4,IQU2KV%")2<)^2P./*_WI.=%'"-FS5!
MHBNBU^,K*WY\I;^0IDXW6;LDH+NOA!7[F&(!TO*),6@+*D@+C&LVHO%5I:/@
M21UZI!,-V3DX&X6[P/CG[UDTMV.:%7HBA,EDTLL!_TR@66R#1_>4JI/^TZMS
MS]WXHU#HZQ8*[70S.%Q[-&*-%H$\)C7$Q@O.OQW5?\?1%_J"7)5E>>W9U#>=
M+E_SZ?LWTDW*_YG-T=WT.L-;#;D@PB=5Q/%)K*(MKG:W #/YO,27TFU0DJTZ
MNBY:E/K0PH37S'" /!'$9D@\Z/BV'/UZP)>5J@N<6KKY5,">0DKE94HV@S<Q
M^,R;,-W0WI:"^]L10?5%Y?:T GG3A&38<SPC)LPJIA\7Y]"Z4H2.:U6:D.$M
M/,OZ2X50*_!L*[M!?+JG O6I$LL&Y9S8HH#C;4'QJ!1K!3UTU(-Q<SI(<Z+8
MDSD!Z[9_<^+\GF9X*T/"\6W0:(&8>8?YG/[B..S*:R.)(N,D-5CWP$XA(GQX
MG+-/Z&,Q478U1$(206=]A#P=*H0"8:,$\P2_I7=,IZWH:]00D9&D@6AW'!JQ
MA/;,?*U&\-M"A;VT;0*UTF$\\QIN+/O^+6%ZJ!R[[#"RBL3%+AUFS3J*W>K"
M*2YI2D%0XT1<K;L; 1T%G:,VA:=W5RL')>$/4=(L]B!I+NQF=%+1Z/;A,V=!
M'TXX),4YA-D/.0&5Z-$#ZX.)^$ ";;[PI7;!N0[R<P@&(%L+;#\4!XA@Z'+N
M+C?)B,HW72)QDQ+AP3+ :U2&JHW&'R0==VC,YJ6;MKWSS=@DK4S7WK1>6T6M
MUSB9>SPF#BTU3LFERO>QWM&45LI^$5)1--RZ5UN_",* ;0.&&5#%D79_8 2?
ME79NFIE6-436T(C:D_@KT<HWD?&,M-6(JYJ2R>Y+7%!#H(><.XG,LQ;SB<.H
MKY4YDK>LTEQL*SC,Y5<'N>TFCZ[W9_E<&<']=K4GX^=B4^;=-5>/6Q]^?W(*
M]N+QJ/1F.L(6]F4@GH+K+.Y]Y"KACMR%FQMS7A :&%7E'&+ -NR/G&U)N:MR
M%]\L0K"A.UC67+=(]73,LTG-S<AQ9".@\TVIIGD4V.?P:_?BY F&[O YAA/P
MZ;%-(J<3W>.454"P;L03;\AB[1H4&S,F?DLIP.4#QYB\;YCZV 2B$;!"N[.Q
MF=U(/OZ>=6R$2%YZ/^"<EN1+<Q^F)IZ83[%KAZK3)R*PZ RB84>%Z# %7^@'
M;_GSZ>/'*=P@,7:IF18,]YI<=\0_3"3@G!YS74.>3G8-\6X@G#S?&E;T"=V4
M]KZ$EMV>,=@:64&D%G&J]81O3DZE@B]DE&$?0/JH<4VV<881%\<(@DZ+DDWT
M0+$ EU%+E=ZUC-JZK$T[H=,Q^U'V2\%-1-PRL,Z^L8_:VJPP@T9]]Z^Q.SU3
MS8 ^QX&*.P!-9$^IC)=;LU">"DG_P!:@7)&B/YP\B\Y?7-OH5FU$U?M[+J4W
M*?SP<;EP=9:NO81=]/MDB"OP<W)9>M(@/\IM5E8HF3=WQS1'-DA&3SR12V.G
M5\^%97R$=+0\_GY%ERJ@=(VNIT_8FZMRB ;/B\_,;O* S)%;K)>[-30XP%#0
MYDKX#3U1G:8DJQ\A[13>H+;#3$>2*::7:\W2,$^Z4](YM== "IH6,5R;6E!X
M:EFR3% L<W:Y)68FK% JLL$'K%TR.N1U#/B>X" 7DD9SF&R?H'*1I4H8K0B5
M)V5UTF>!J:7L?!0>S513#/SD3/CHRR1!:BYE$Q)TPI$1HH?_0#IL@L'V)-K#
M!S8&BVK7TDD93XC+SM'S$QB"C<X0%*-=W'NFO*),/^LIIKN=Z%(P0EAN0<5Z
MV66P2#ZZ9(%('I>X$BS/8BK(?11/KU[[R4CBL<B/]:/^AM1B+777TFH3TY\&
M+U0J!/HN:[G[.,T1(0I2>=C UFT!"! &%Y3)P(W*#)7"3<C5'-RLS>L&)Z3\
M6* 8>"!RRUHXOGZ$*A[Q>IN2SQB8*6&!3HI3X)4K F*N&JQ]@"6!GZZ8*Z*-
M:8P3CI)2G%"*4KC^0<RB95/!'7W^_8_.ZJ;;.(#-'3ZQ01(WSADNB4:BA#>X
M+L(6GH6/C*M(#U/O?=[63#L&'FD;8?5YU;\4S?E#8HX3T:*OOBX2J'M-V8TO
M4?JQ8WEC$!3T#OG3QXJ ]VIL$[D*92@Y/VF#:=JS,]6[0?$,[CH'HJ6E,BLC
M\LG2F K"J1)R?U9AZ?B9N,Y=V-#IN+E$SZ8N5@H N\5UHZ('HTL\\81O-"\9
MXROC=;GH9>D.><S 9E2-A(&RY+9L*N>F;;1GJ I\AZC4RD:ECIDP=&":0PI=
MLRF TAIV69BT!(8N8]9H<]%)_EZA=5AOMZ&ZQ;M8\Y$EJ.J3X[=AJTF!TUC?
M-5K!<4%%/%*#$ZPRTW;,K&L;HADFJA5&7FEHI6 V_1:[P#BV(BEF!#,P@U\6
M1;\'H7'TZ^6KRR\:K9T6$UZ51_:A"STX S';R/%UB"KQVSU 0'[U<%-6B>\+
M9&N *_^AYYS7A:D0Z?@[5RT2\/Y<?I(^GW#!38YG\]+^@43;9YW*M_MAP(F<
MI+<^^7^@Y3S[(5D G? W9N7:2PW/I<^<B)NBO85!C)I^9R=/DB.G\X]3^,-3
M_(,:*_ 7#&@=_;X $_SZ6WQ!9 Z;(P/?^#XY>N4*!%\53"G#@T%!=/J,!U@L
MI33MH8$AQZ/FL\Z3HA!S8]*,<X)XM/@TKX8.'3\J*:X;:;R(<9/6U33)F(WP
M1//TNFER-GM28S-R3HFH=(ZB,@3:L9!ES9F6'(7BOCTBV;72H,AJ@4GC!VJE
M,@\-!G&,<<.ECGF)83)*6&M[>8NHG!A57<CR2'R:1J"9RGNQ!*GP!Y1<\BU
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M8QB6DHX>OD,13;7SDP*5779!8V6I<_89JC%.EQ:7QT""00!,/G3664I/K4[
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M+J65(TPWY\-(+#9-CIRN&24)$1A\@].1##Z-9XKC+KY_RU75K$E@F4[;)(W
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M$?GN06B85YICP]SF2>3 P)4)TR0+44OT>-6F4N_TT6&GQ[_?2_O&R=;BA[I
MGY?\[7=T/#[(==D3#EI2L,Y!HWP"B$,^48?1BM62\'K'6GLC6C*$4:,:TY_U
M]Q1J2Y\;^+6))5+"$WEM62*]B(AYO9.9"]J,_WMB#B=A\!&UZV)M@H[*_B]\
M=9K+W_T%TO9>PP"LP>W72[_C\.%5 Y,_T.NQ'T!S?#UHA:R0_2]P0S[3;:!/
MQKV,Y8(P)>X?=^3_0DBTW!%;HGS@M^(+ZHPMM^0NLY%JK+R]+2QKB0!PA$'
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M'0#,0=] H/C@AH?,34+CDINBLE5H4X5B70G#SEH;[HX.&[\1&1[+9NB(^3.
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MBW;0T0E0)XQ..CN/*05\NW8JJ'+@2[MC03^2^4!(!=TAU]K=.6K>@TJ.+G$
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MPDW1?*@KL!,XC<HZ;/,'+\U9=.JW:+U->RTUR0QBC+A@&;;1*C7&*$A"\(X
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M-"[ME1=SBPTH.)/!*:FXUX$QN]CZM%5N[19#)=KJZ(L['&>_LT3K>>O<+G+
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M3ECHOWQU3J,'M,K=P^*\<5#6+\%9\@#+O6DG?3TXV[.I4,#@N[ABP(G@CDH
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ML(Z'G@F5HU_#.E^T$@FM0(9@]7,Y=<)8.VB"?T_3;N!3(Y[]%\J?)T#@JU*
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M/(.9\;2/5WQ4YX=X<W>W@ 3A/(P5V'J@ :S:E/4.56,QT[N(Z6G7%3IZ3^R
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M=!&.4"&@+20W3A'E#:(NSTC7L;=]^%TG1>LHP)[#L:8KZ,]"GN_I$:[+C(!
M.T5K:5SOUJE"OC&>!)_I/[=@EE=I(QQ/F=^'W*"?4Z63*N8) O:ZF"<7#IO@
M%ON Y]RP%YV5''63,]"5H_&AO&=;9MP]'#G[CH^*W/ZA)R-KJ-DU25EXHJ $
M@C![HN.I""0-&N +<?9S[G52GC=0B]U)S&_;M+'B72KH0%N9&08".-PV><J+
MT*R5Y?._%="#\Z+'-7>GX3/EFD-B2]BL;M)F!KY5;&<KY2@Q!*D#]70S, Q!
M80!/T(^GO=U[[R7=QHE\#S,XAT <NKX5!H_R!S.%]W-)=%*J\\'4G_]E T,V
MQSO"=O0N"BX&T_DHF@7OHFET_#'X,!B]C_"+T3281K.+:#C'#Z:CM^_FLV ^
M">;3T> L@"O_<CG]&(S&P6#\,1C 59-Q,)D&%]/),(I.1N.W\-W[R=E[_(N>
M,YU<1-/Y1[QH,!W-\//)Y3R8G,+7HUDP>#N-HO-H/._GJ'52PC(HK[+:VK(3
M#E!VLJL-5L$@@?-JLEG*^M4\?:.1:)DDDEJUZD8[M)G,XUQ1K)76[Z;V;7;;
M>WIO]@%^1@B*W_9VC]^?'<RFK.K):WYM(]CS[OSWOB8Z$X__HG%=QTAM[KL3
MO30-+SM!NC$+MN ,1!-^";=:Q"OA)@%KP4%9W'2#04\KES'J//=9UMZTU^Q]
M;;O&CA4L&).:DX(W''C"<--:7%]RBH>FC)X'.I@A0T^<9W D>#8<S-9[[9/N
MC]1)O[&#&$7#&3=ESG&2A18UL$SK0,MKA>F3(H,EDQ4_)V@<'L+=)1<H$[)(
MDL3,1C6$%EP7Y2J#%F:?X @_+)(T^.__.'SU^L>7+_=?'@;PL"K]Q]/H_5ZC
MEV0)'WC3+H:QEUOJU5XPRS"S1(#WS&J'D+M^CY4 (Q$\&YP,]BAQEJ[Q9 ZM
M)JZ2IAJGT)"UX7!"F\SXF1+8@2;H[OC$+KD[D?R@F(&I;:&D"@ZH/\S*R\NM
MAC;2=4P"S(E%3*EG52YAD5W5<_=1[&M@HFJ$-.[5)<@P'IQPX.^*BE"Q<;;G
M=X54#)[(JACX3W4UX\W3M]]#D,6]G(EGT6R&Q_WQ28!_1E'P;O ^"H:#:71Z
M>7;V,9A&@Q/Z>AJ]'T4?HA..!9Q%@UE$GT>#X;M@'DW/Z5\7T\G[T0PC#</)
M>#X8C>$'&+<8C4/Z_O@CA1JBOT?#2PY(G+HWG+V;?)#0QFA\.IF>1_SP]Y.S
M2[C=]"/>=A:-YWC1-)I/6B,D%*B +P9S>"A=&LQ'YY'[(/B#VQ"=A'P!O,&L
MT1KH!'C>^7DT'8X&TAFSR7AP?":O?GH:#>>7@SF%8Z#%<VP9=</E]&("=X#[
M;??PA]'\G49N*%Y#L9?H?#2+9D\P\J\/1K[#_9_C;( ISO[R> )##J.,DW>@
MH;AI1--K?,*?P,0['YQ$NDB(T,Q,/YQ\9T$TF^-T&\"<@@_U/CCGQQ^#X^GD
MKQ%,M9G.JK/H+?QF=GEZ.AJ.HO'P8R@?\<P-\;?SP=]Y4?WM$JZ(FFL K\#E
M,1V,9Q)#A)M_>#>"53^:0Z/.H#TS?QGBNKF<OL6]8M(#,I3V\3G<#V Q_A5L
MP?O1D%;J<'()W7"VU7^X=._OI8ZW]O87/-J'T<$M.!A<8&AW.L*9@R]Q>38?
MC#E6S+LZO>)H_!YFU^BM;F=PY<G([M'.'A7,!B/W>KP&=N[+,_QP>':)4_AR
M#E-^'AQ#)X[.1W,[%_A6D]ELA-LHKPCN_W>#_QM,3R:7,YBQQS#/L9]Y<_Z_
MR9B"T7X[^+O9?'H)F_ 4!@HWX+?3T?QCV/X"TPG\@:^*<6YH-MQR]G$VC\YG
M;)SH=I>C^>!X=#;".+C_O  ,DNSA8MMGO.>?P-M==CX+=M,NKKTT)#O_)G'I
MIH+8<3?R#8E"7)(80\7B4**#?E4P>#0K55D>T:28*XMK*E[Y/<W8UD]J.CH8
M<X6^W7/HQ3Q>5^D/^L>/&.+.X[L?,JIG>TX_^E'N)3;N)73A)SSH+.+\.1PH
M;E8_U.DOM7PM=N?[@_T#-CTU-+).],%BE?;Y"%<GV]]]]V;_^X/=7Q_L'^[\
M[G>Z[9^IR=QLZ)AJ':_^YT\O_M3HNSR]KN%GT!L!&'HXK>EDE.^QY]N^7J/7
MN[KYX6C]2W (W^+_W^P?0:=2+W*'XLV;G<S]^UCKX,!RG^+<K7D;.DVO]H.C
M-V%P='#XRLP]Z=!?WU<$QWWJ3-.9OW$&?DV],A'>#3H35O3?8%; )7DPNXV7
MU6-,LC]L?_V^\^C!O=%NAM[@@8KOR(]\C5W\6-X===ZQ%D$]:O3P@!6NR(V+
M9H/@F,GPS\Z&C8/8XTWQKVDHV_OS^)%ER@XT\(-^[*Y<SK_YE;/B)*NX-B8,
M1JO%?LO\^89,QQAQC!<,D^4Q<3?",+BX/7FR'K^MR[ZAV33'JC?ND\GG55H^
M39V=_7,!AU4L\JF_U;DR2)*2Q;J=,-V3]?YU'1B\/GP9C/>#DV)SD\=5,*OW
M@PAVI/1FLTJ*,!@.@N\/CKY[^6T;NWF:I^O;8L5+\%FP][0__2L=] W-E--X
M0;GCIYGRJSKH&YHIT3+.\JZ,V-?8,]_0W#A-4;0Q#T8GP=@IPGJ:'U_J'9DC
M#3C!X?><A+FOZQ1#L+OSOCBS#K#G_O20<?H-#WOP2'JMH7[Y,R64^I7R'4_F
MHZ$$=>:W:<7":4QO65QC):PI=$.0$^+QJ/0,*SM*1SH=85=Y_%E8SI)-59?(
MD)HF%8JQ(V:#"N12%H/.<Z<*#9YT5VSHB9LZRQVU*&2 ,ZI0T"QNYD-5VUX>
M' 3CX+C$)AWGGY(PF&VP!=\?'(3!VSQ=)7&>LH<-??&BEQEYX]?A2@N>'1V^
MV M>O7G]_,WKUZ_W@]/X%_Q<N+OMEZ\.7_7R;1!K^?V/,'CK.^:@.3HX. R>
M!\=W#QQ4G$NYDJ ) =N#N>K=G105 =/R"1+U*R!1.[OQ<>80D4D.DI]@A\&-
MYUFU]UN'_W':/1-,L@ GM.ZNC\OTA"#5CX\Q/T==[N"PD1+N4<<<,UG-L11
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M*8,9!)^=%8/#[),/_>,LEKU.]JE7'A>G)L^K>][T3B[*XN!PD!%$R)V+Y:M
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MR)=!SQVOGQ?]E;5)DS>]3J?7K2Z,^OGCY;W=7TW=U2AJ04R'(O72.Z&M8Z
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M>$3EIWW2%4IO3.#\1,2^HT;6$G730!U=HNZ[:FXM43<-U+$EZKZKAM<2==-
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M2"T2O)6.2'EDM2><!>:LPHQ@EP[I,\Z*NO@U7X'WA+";C<WU150S4M ('9K
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M3'IOG09#U"-'ES">4T-P">.;,,8N,L018P%+%E+1-ZT0%F!K<*XH]O-O5-P
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ML[UWV4,-\N?A_KN/9XV-K<LFV4+[K<.CO:/F4>-HYZAQ^;J]UWI[M+^Q?]S
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MGOCT%6&K\DHD%MWDY[S*"5GETW^-1YEW\-"GY\3U;G=HVCOAI%<.5K*J+M8
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MLZ+=GOP$U)_\FCJX\7/BGVXX&%6)&[$;$&U$)[@\8HI^ :+%0.-0=JJ?888
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M,3TOUI=;.5:_?#B3\9+8(G<\8I%MBA]7M6#RDR/;PE62G0 M^0Q%0] +XN2
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M>HR;,M)YALC7-D;7F(>QP!PQ9"W+//&X]*-DA9;J*M:HMM.0V+QK$8\BN0G
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M=_V>M';,_T7]DTB&[-V+]KI(3'M\H98]*$4S[!:\J*QM6NTU8NS=KJ8@ 8"
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MW7U+J:*.Q=I%=9'2-1-*C2\<-CZ<,TQVN]J8'\V-VYVI'@D$@!Z0<:Y6OWY
MQMV-L3P@X^XE,JX4<[?=3OY$BI@?/I!>/R9Z'_WIA_/'H8BZ6O6[CCDP.#&[
M'2!L&A:Y@6R_#QE5('#TF12*&0'>]]"U2NQ^0^YKN >FB^E5QP71EIB\?/XN
M)(]#-9XUP%)(BH:1J]X<7"U]UFK:HC/\5+QY_0;'GW]Y_EQ-*)9QH$PKJ6#P
MS)R,!6Z.WG_K8FMUQ7TYUT+CU$I(:,8U!*6&U=&,($![M5SXR_QWO<,6DO<S
MKT"_3%VN2UZ> \.&<OO1[M#*KLQ9Q<IU<,3%HF1!G,7!1@5<,F>Q[U@\*I8&
M2Y.'+K%NFD$?3M_7F3VL^4+2<#+!=(;: ZN[!0 KL)T8:0TX;&@MA%&&0J&L
M!J*[*AW"U2R&2FT35CG0V5'?3V?6]F4R^\A!LV)H$4$0]'B;(&-+NU2=8'&7
M&<6#HW_1%J2.BH44^H)I-M'R Z@>/#>T&4-:.=J5F),UUXW3/WOYXC1,G3,0
M%]E[=JR'#LP)>(LM!!WNT-+-HSB)29WSW%R(TU^&'7-JK TQM!_?K.7.>++G
M#G:]#T49MSBO.U5/XW*U@.Q5IC>K8O8P!&(RZI5HGXV<RL3 SOLC&QZ!Y\\=
M NW)N1"JO[(RQ*NJ'P!%2"IOU66IE9D"1GBE#0K2LBQ4FZ?]*QUF&^NK\@J\
M53N..B<1V%!=EP+8\AG'-CC--B5^A@+_Z3Q!>H?20B_]VJEC8Z4<L,'PK&>]
M'V>%(_QU>]&2D>_1Z6NCI:M;K5<??^&E?&&:ZBQ>\ K*B(:!CR?M'XKOCZO$
MEEJ_J_%4MAU/V"' ',;[/GC_!<,%EF2-D)*H&FJ/!#%"<._.$91R,1>%W0=J
MAN^K%A10+7/<"!3JI57JM0797+9UU>IB:R@P;,!-0A7%SU:<@&<O-Z2%I6GH
M/>6@8YXXC2%HCKDN';W(MM_A@FW*#6T)G1+RU\GE5>A-'^*?]=8OI.6@)19Y
MJ\;COW.&D$_\^*;PGS5AF9B5X]K/> I3!:4%W?TP@\%HJ^U6)7&8J=1$]1?*
M.*LR)":]P^"HO,3P4N2I*/I*K1Z-1C$ST/-49]8;I$WK,U.!IR4( Q$4'&H<
M882L,*9W &6H5<E]!#\8E512T:J1_9W+:5]!=I8SZV15"UI>67#=(GZL@34B
MTCW:-M5D3GZ0%MK*Y5!N'$9HINT6>I!]KK25%,Q#6-Y'Z[([LI8Y9FNQS"(>
MH6YH&JM;P-K\@<0J6!ZMUIXSLR$[X-Y:7QK'0L\$-#M?ZEFC-67G#40N64DY
M^(2TM2\/+!J(6"5QQ)XT89.L8/R:/(.,3 53-LBG1OF\^C>O) [UY#"?FW*"
MD*E>EZ/+U&4V"?99+ET>;_IFCV7X<06^ST[N6WGO6;P:7QN35G\G;\-/5+1)
MMEMK@+7B*5)X_H8YAO!DM1(?NIO_?_\R:R[:([2#/'GZ[.3_OS@Y_O/ZXE_@
MX![Z* ^NRD?K#]_9"RUTBF"A* MR.]A[.03]V.*(ST[DAP@Z_I;1Z[QGW1_^
MXR[N\VTWF(<\E!!6629VRQ:]L&GC+<) $&[\'9G>OAG=H!$D\T!6ZY8Z/=<G
M^U@VT!BX1J]S8BL698F42LQRFXO@2;?TO8M0%KC#<G)CN<ABP?Z+YD,@K?,1
M\"FD84B*5<&H_FV]T![@;K\)[O:S04$MG5-^7B3;+L[ L#)T1L,@+;8*4-;^
MAKV]USH2_O-E7H(4RSDSCI@'1/OO*'9G6<GPY\>I)Y3:6LX,1:D:=4IH681X
M[P"[_[?(U]1CPJ2#B>W,<S[\P/29@M!(;$?^&GBD<KM>PM_I-D>L\-*XABP?
M__4G6,H;JO*U<M.>?/7DPX2>AXSM 2G\>\KPN3.PZ4W;;SZO&+^UE/BX8VJ4
MM6D*WDK"Y>+>KA7P^O67_ZK8,$\+@#B@4 )JX@2SN!].PARE1/5VM;YL9]84
MO2Z']^6J*B:/3E^^?!P1LZ0@8\ LX;W*B '!],?5?/7RS>F=C(K_=N/_1<"0
M_!:OYE:+_^EAB__I/HO_JZ]_F\%_\L77!PS^?SJ<QC</.(V[,98'G,:]Q&DD
MRC$"[#1DI_F7HZSZ6*WY3:QK(0@^;;6$^-\<M66#J!3>:Q9^K%L-GFIB7VZV
M53&_!)*M+HN.(<BD%L5[*1E>#\328K)=%\::A#XA71N39EIJ%B<0X \8WM'N
M\)"D$^??::-U:JP2#H7 +#(P-FOCX=8:0?XCK:,[^'(?9<Q8F2,%"I7P+>>Z
M]&^K.E74 $MHM =34\'5TCXKFO)6C.G6BB0K %!A:52K,O2!VK=^1/&"-5L+
MDAWMT*,J>8&!6',(BTN0S(#+PZCKK,3?-=6NVQBC$?K:O=(4W;V]M!9J^GQ)
M'HF4Z[RG"["5'8'%_2RSLD\W1DM*$P8WK5)4-F(HS:T'F(5]0B&3C'O#FNJ,
M3BA##'A2,<U3'8#4DRLVL!K=S;3A;[>5SBZK]9V<TL?J,TS@W_[7R==??!=[
MD[B#J=N\+N;OBPMC0]]#+8"SD2H%JS)Y(5;Y)L@TOK6::@,2+S?!TFEQ!MC?
M"7?1MB?6AXO:+B<X>:HL+:EBB? WRIA\ZYE^855N-)U$YBOD2_%RO 9OH1=\
MV=8+ICXLG:%*&, #,/$/H"?VBEZ=[-2+P<6)V+0U.-<N.DQ'@4D]TN> %FFS
M@6+6.2^OA3=9)RVZ3!;DH-;<5,T6Y8PML%Y(7LD/YV!K+98AFZOER,K.[1\P
M%9DV7Y#U-:9>_B?72/;(BW44S11GF7#A.5^>ZJIE/53R,E$B5U77-BNC.^9R
M!EG0(L+D]0G[CKP'Z<_^NEI"-;#'(#4:Z\HVUM5& Q;/T2GGYT-K$Q^*[5MI
M4E4SFP?7,U"+9%*3WVW3F#J+A>.\%A-"ME3E-WNN?KFSJSN*B_A$!>=9(+5)
MWG3EVBN!E-CAOW"R[^(\;\5_.#J"<\(TQ,+XXINGWW%^&7G%>\S1J[^LR\=%
M:(;'.W*.,C@D#O0"M"917OXF$B<2UA5'M/Y,2N2.UC&25.G7GU_]::J\*\SZ
MEH?Z-QA:A&,B7E,,M!7M+Y)IQ-H<;>77:*6(5?NF56D47 2?2Z-?U"TF@\J=
M#&/<NJ,!*LDN>7U<P4J<\Q#/O&$G5.40/*"+L89L'%AJ>ZB5QJV'SD@^;GF^
M7@_>4,RM)XA3[:'_@#3&U[W?6!O8Z545:SJ.QB5>794+;]*UGXW,R,I@_6$:
M19T+6JSY=JZ>\?EPQ9X!@4W>)DN[14Z>3$20.1*LG5TZNH+963'8D?-S%*%Z
MWG^N';(."6C*^T/[ER$^3FM3];VQL2CKSY0XY(U],*5E01-%/IGARA>9[@BP
M75>QVE,?.ZO;=G$W%?FMQR'HKZBN=H1XK!'V*(T@%>>;0A%*%)BPS2Y]D027
MEMH:6:UR1XJF&?F+,9S03=UL"C*OP'\(]"\9:4DF^1%Z A=#"Z*5S53''SED
M5 $'@MT$$"N.#&@F6C(R@.!U-8,!(([O94L*X@1IR5:;%]:(+P %#Z;R #)G
M(Q?YCU$J3R:H_ELD[I056#DOWCV5MO>&H4]O3BVJ?$[ DIH,7+YS5LT^>O[R
M_#%^-M7P2<*R,95=:<2;5U:-JS*A]6%:/J>R"7(^:D.FNE4!=\Z I'W"'%:7
M2_KQ1$8$C1B#.0:V.@JOB$Q#<JA49R$'0=D%-2YDNQ6/H"N=@H=]']G7Q^7Q
MJZ/(^)1/93K95F6]V./M?.5'!?[]R9-]#)6;4=\S\?@1NQUM1C2;<>CRZ$UB
M;- CRX(5:8"",%<R'T4X87;/3N.FI&QQ#L&3BV$\&A2S:L^8F+0T^DM$(C2;
MLTO-J1IA=,);\TB".:ZX63+5*0IN1W%X8^9:"0CTCI87'%VC9UK2%S'T0I2C
MK46N"2&WDD$%(AIVQS1'\BZ>Z4]U!7;J)_YGFNI05NC9X:S0L[TXL&^>_$8<
MV+.O/AD']OD5+<.*2<N@V,$S4"=%]-8 _C0R%B31X(",U9JG!=!=I:+(+5B*
M:( U2)Z.*8_LGDR*3LA/I,<G"TACI,I8C=^-F9R""ZT<[X'7'!S:J%=J@C\/
M^L>RJ;05S\PJW>((TX"OEGVW]7V\14.18-RV \Q3^>+RGM/F0&;6C/LK9$M_
ML(U"S)&OJW5) ]D[!D 54A-RG9RM@#IN#^4J#&N$#LNF'_I<2-)6 RA [+1%
M[51;+2V\57W9\6YYE5U6RG55RQZ5RHR*&_::51$EZ0,H@G)EK^NV6@1[CN%T
M]KI/:BC832U4W PW:+)_N@SQMP\9XKLQEH<,\;W,$.]5K:&A2.C437T86Q)R
MI-8R,/<+>^TR"C4[-2]T@,;" XY1@4#^Y+0X@^%Q/%[+:OH#!)TY!1F[( ^A
MK(:)02O5B81L;4[?.S1T@R==L"P4+1Y<G< ?<P^O8RQ/,)L"ZCU868EG=,;$
M<4E.+#2Y43LF\ /:E7545^_++/5OWLX2%/K>DTAV<[[):;?Q)@^C['^5EO_U
ML:I,>ULB=3RWYCJ\J]VL, OI3Q8?[9.:P^FHV)\W=DQ!)_%E)$TJ!.32_(G)
MH,70Y/KW[!T%MZ'@QCQ*8+2HK7.@.F@]RN<-E K\WG51A0)WF#WH6Z2I?*1^
M0GM+D*.+P%QH4%:C1'WDZM'":5 &M,/"C,BLF"$KY;R3#MN-\IJ4'MY6$LWB
MP#7,_@7Y>[,*Z83>KS?3VJ/8_N=I4@!+AFBMJOB8^NJZ#C&:4,!'ASFINO:>
MDMB00#]FF -M001Z:WMB,FTF/>4*6K>L2??*MZ16+:>\(HM6UI,SR$/;S ,:
M0BS1NR@,GXI4^ ?C\4O*6*D994Z:D]=SGI8]IJR:H-!,&#[D4_^F-5AP-A0T
M)(([0:(2D;.4)$8$Q%3_B*N$">Q1_6Y:1GUO5O='-*0]WY3KYQ\F;U[^>JXA
M6E2MIR2="0^I%FC56PL+L#3+RJ.:! O0W\SQ-AWS^XF?M9T&7;*7^>W^K>T.
MH=SDT8__Y_QQ8%K9V[XL6\1'K+@@:YX"^4O^]V-=77E8QAPQ%[5:0?C-#@ N
MA4[I_9/+7V0@.V)Y3=*L\D/>1D\I!_>*:U8[V&P2X%#1@_@RUD0'@DE6GX.Z
M\+)M%ZF4WD,!_&%=O1%SK<X6,3#ZFA"N\8VX? 07.!DJN(@9JM*(8:DTOF7U
M5[1D 1'X$H0', W71;_J :F9E^O+0I:LV%QN"7A8EK..7[&?W3]9?//3!Y6Q
MD$30GE:3KYYX3 K*[^2$:RN6J/_ SC@LIYB/DH7L 3QE,F8%8@)@?:GYC+$%
MP:L*C6V*&@W4(:[F8SA5PDKY# *KVZ+M ?W\S?7X7]RG>OQ76L[\FM2N0P._
MY]Z)U.E<S->%<9>^,KX-UA;I?VO6++3Q]!)N',Y [62T7N:!F7DW-GX[)LC&
M)8%?''\QF2EZ!,7;3Y\\_7**7+5B,?(O/WUZ_'7XLHBY?/D)XKEK6%N-FIJT
MH)FY*YIF(*-8>RUR2EL)=8#?_NL]5)^CRG*&H %PSGHZ8"="@;V3,G85>:/W
M\^8YT4)7/O2[_+W<HD-UOHTX@M4B>*T'V._[M"06K37@!U2;P;YYL,/"9ZT;
M;@.2L?#V28'5*[*[I!S_9-?W-D23]Z (.P!Z"9(N#WP_@O(X.?I$I;XKUN6@
M. K65I26R@]M 7&;\MK+FQ,?0-NDK0?,74##8M0M@"R(L50/8]IEZ3D<](6J
M5A7[_R8->L%QB/^P[ASH/[<JK>%6%QO19>92'YH<$QY7LB'8QC$'/IE,@A:#
M(T78_RL9P;@9\MZ9'T_.TJ>EM&Q<%"(A&[M0E!G*U(W1279EK&B/W=$G>3OL
MM#_[LFI"CY=#_:Z'/A3UCKGQDU-Q//F1L@"VPO)"<\V10$%)ZFH820A7J@$:
MHDZ[\:S09N>FWMV'"7 M<^I'H0897EVB;= $_^Q#5W5G"+%HUS;U..0O=7E1
MS+=YCXS0Z9(A!@C,2H,%Q6;<>W8*K-A\M*6](D+CO?_ ^O"9[P<0)#BYEG8>
MC4*@?7G&(=,1;C T3K@[-\.+9N_XE%S-7#\Y=V!Y0*>\..'*:_(JI(3,4X&:
M4,K*<?&<-R Z< ^D?>+U_$\GE^UUR70'5$566^::V]1H16;;3(DB W9(=[[>
MZ1R/(J09NO1I2D45715,.=-3,(YCZ_<14#3R'6L_BD-]W0/3]*QT&E8"SWKK
M9 "%/;^DF5G$.R<J/7*T96W$[M+)^9?_N'\._8YR9K#,JM:BT[7OE.!22[6V
M"0IV\4*;H7@[.6U]1,(I3:HE_FHD_.L1NC.""X .+SJY5S9[>%Q.%!$IBLA2
M6DG;CQUW;-,BJ)H .4VLTS'L,L4\/3YQ1^\>>FLON-R50W4W6>GQI&<(-9F_
MYC_W+F=D.^Y S-YIEO&J;(92/62"9E-2'B7V-/!],(Z'/A!.1K))JQA+?,M<
M%.FO&VQY_^CV-K=2X--'#MA60YN".M^SMRW]WU^KI$$B<_DX^5H+D;WT6"Z'
MX>+"TTW)>"P(\$F#2473AS)Z_Y,D$+%YZ,D21?_DR0.4ZVZ,Y0'*=2^A7&-%
M%Q5-;.EA?3=@)+K&7AS6=./;_H#2 _#'"7\7 8VC?BX:6<C72U3354HN#S(W
MJM_QXR(F2TL90SVJE;7>2QLM:UA9W70EPKJV/HZ*CU[#/O-,/6RQQ!#;L86J
MDO%V^!Q&Y;T&;?PBA )Q9RN<6I[9]+53AP2SD+<OEAI]W31&K'32YG0\0C&3
MCJ]-"VSZQTX.KQ@&\Q+<MTI)Q ,[G_>B89FE>6L1(^]EPZMB&YJ-KM&<$(DY
MK=@)>0/R;/O?K6RS; J8CB$DF'BM4RV98GR)#4;XK4FY4-#6B#40+ZUZK6;5
M'-?Q! 01F(MV;"_!#D%FDD!Y'4V(;'?8Q*1=#U;;V\MREPT+"F2]9VV7_6E6
MM>O+HEL5.[TY60_Z%[2IV$16&1;*-G,-V]R[4_(ZX8S?8^.[HK(.-_0*]IT@
M4T=%<X-&N\%VLQ*3:Q'/H[IMWUOSI(VUH/&^4][/.B>.F8BS]%Z_!'X:=MJT
M?I1D.=<#?%UVJMJ*SMH<(SV_+*K-I7/:(P(;0MZ]M5Y4-J#6J=@-+#AA_T_M
MF*CG):X4HZE.Q21:0>8$5G:GQ8^'WF"$VHW!GM\.&RQ @D1;E  Y&G\&:$ @
MZC6)WL?J/TD7L7-CZN#%* 0ID7:A1PZFF\;TG^Y3:/-@C""WW!0]:5R4AQZ!
MK:EMP($%<N&SHN\_ZYOAU2H=$G.2RUSI.5.5NT_3X/2$54M$!?0=\%"0< \<
M3OF FH5>E<JPGR*46E7D-^K^D$)(A?+/P\(<>\LA:/Y^T^9M5-&>Z4(F8-L/
M/8N4H.Y7N:DTVBX^/717BX)7&P$WNFI$1-ENQ8$Z?8;GL:<&LT %1%0<2K"!
M:EN8CO4E=41D/C_K%[YECF)&5@NB#[Q]K+FK57-9&O73@9/J[YWNGZBYP3[7
M0P=[5 ;F7>P@;AOERL&%8=5>"+QG7Y43UN.$>\,,5>,:XDLV/I4'AOV#M& A
M[%IEND8VP3,*X3"'C6FY#FS!=L,"RK*Q:2NE38%KKFCP*^W1AX[MHN29<O#*
MT42,%[?**0^F6R73/89-ONMFR]B0K1@+K^F3^5T,U8)7.=5"_ 6EFX5@G&[-
MNO^U]E93IK.FA#6CL6!DBN::"9)MR56MKM&V'0QA/EA;/LN7:6=@V;A!WZ-<
M=,V-B[.[*GHQ6+;JXW['6X.&?38]5R5LFF>9(*1,7(E?X9XVHT)!&BH]\VV@
MY@.2F*<3.M<Z1X=.*0D??ZC4:QN_MVCU#;UVD):;1_6PYU(5![L>9F+5R*H7
M5T6E2;Q>!&^>M*-.'FRZK=\Y$ RHNV'G6Y1(P 5V4_?%.$V@#(;\\??/8')O
M+NW.J*$A60A>D-3W[T$?N*X:+"&:VRC95D1\Y 'AD%;/K.7(7-*ICDL2HVYQ
MIM]B[MKB_ Q"!Q@RD?TB(NAOW,0T_O2 .S(UAR7^.VOS=8&KU"F] HZA3R\>
M[^>CAO2<B1L#.B3M+UG$TO ,_O"!)D4??([_'@"8>QZ^+.OQ?2?[4&B'D3_)
M7)LPOY_;GJT5IY.?B^X*3H[W23^?7[:M_/W5\\DI&T/(?IPIU.*,$;<IV.S8
M9WKG:9.7;2^_NM":T3/D]6=5,?FUJ5A5(!:=O^7V1Z'YNGPHJUBO+ZMB&G\:
M>[O_5+8B\P5(($Z'"U3$)._:\_!??-]^5J#?N37E^%X6#-,\-)CIY$W9B8W]
M0[W"H-]TQ0>QF+R)_'3R$]:P(:4S]C;K._\VB,2K^?,6M&BUUZG%[\L$_E3T
ML&PPCG0.8<CAR]1R.@&,JVGZ;2UOEV4XAP.0_?IML9BUP^+P#BAI2%&_3P8#
MV_'[BD 1"H0FS?;E)SX2Z_CU?<(Z,G'IG:SNH[)5\*HGC5G"I8Z#8^1&C>C"
M-;>'$&W4837VE]Q)^S81JSN//6,,^H$83=#?J5(/1>,73*;09^'-IQ7H1.YT
M0*"3 !<$+ ;1K<#4N#5#F]>+6ETEPA:]9L2M9]K6' ?WF[*+)&LM'.%1]S 9
M]SHV%]ZF"6Y&V;RT\@'^^'GA+<^S@J9BDX"R0$T!Q#^@3[$/]>'F#7M0D0D@
MS"HKR+8F+NQ&M3G*6F3_Y#;?YNB8SPF.F4Q>K]78&;&C[72E" L4<6C> LB#
M_K> TA!=Z)*^&/N[3: 62U:W$9^D0U7MNBR[HZX$*@2I 7H#SNO&& EYDL3X
M4G9HLD"3+'8F&[*L-.YKD>6%8CX]-DV\-J(91;^Q:(N5U<$U5]:-&MV]+)2(
M7C3'$\(YKXIZ8)F"9T^#.^3!@="IWF Q,<R5(RK<.^K9)WNMTH28A/CYSDG'
MMNV(*^?!#JJ:174A+_QKZ0@]UILJ.B>1UT?)8ELU52KSCH-4KCMG\3ZO&N/?
MW3?BV+FL-W)PC*NPOL#[-M^B!WVY6RIK/"@*%U"O .@D,Y> 3*G6D%ZZL2E*
M_<!:TK)?MU6O$0 E"(=#*G^S=N#H#HSVYL T]4Q]/>CGSPT_M)@OJZ0II'9B
M,L=OJNK3.'7VH):LH>MG5JRC<HI1]REO08L)(@V6TO >J&R'^CD*H.:,%2,%
MX87*<Z(414-H&6$DWQ #BRU1>^9</1@8E(4"/<5W'[J$"RL\6CMCD?IQ;8U9
M,8=95RV<0?VB6".D$_BF=Y#+>Y7###%*>VY$.&9]<S7@VC-ZO<:=H%T;AL;^
M" 0V:;DP?=5E7&>@+1E'[]1"Y\5QHN@>[0X;@_7X;U2Y+4Q!U!K$(J68A>V-
M6B(BXLDOHMD_M=5C^L)U+>Y5FMA)A74L6-@#@UQ7REF>(2$-A-M%L!Y#>]FM
M.,K;JC6_"]R]P<K^YP,4G3P BN[&6!X 19\"*'JP0_X>=LBI. >U F)G8A;C
MRJE6LZ'K5:&[(6]I-@VKHUEN$?JAY\@5Q%R&:J',@[@81>\O01%)O]%M7-3G
MEYLL_/$98UC&.43Z39FQW&^D13JRID0A!>"@?E8QB7U".,TT &NF^QW@RGF4
M4(VH;.:18"EU$<=K:13N>.LVHY-P-TG! -'CZLIY-U0;9W8\X94?FB"RW6?%
M'$ /?S!Q:*>APH__ . <,*)*2S!(6(:2YI!,9#,@8_?85VQEY66W36_?\JNY
M(>^_Z(I5'SE<M&)+TY)B;<&4H+_6)F*9BVZA%##KXLK;JFP-K  N+RMXSJ13
MI7*;"G "B-H=/YNI@&,%(H"<6U/0,B\6R"P&!F$*D\E2$!O;UFLY1S1HF*R2
M 3V7.:+8D;V='DK$/JMN/!\8?5! ?K0ZF0=W"0^.FZBZG'1M5FY;JQ^B$<NN
M$,^^>"(2"9J(9-L1V! %_/E[$1L^K&&Y+?DL4EM[618;=9.(CO)"B@6F[O6H
M4 [LLU(N2D-$)D59[+U:)=W$%N!$E+/U],G)$^W2NHEG*EEQ^!, AQU/WI9S
MPE@T/\^^:'4Z8M,?Z;CQ9G 6-'G9F5:NEIK<G+KKP0W*HG &>#S2-D\[FQ<F
M\.UT<O+5B8'9TB/-+FWFEF7L5$:GI]K19$W=+X;H4G%2MG14,I?UFK-1C7C;
M3B4=02S7&&FR,@CNGG6C;B:5X7)@YCB3;W^<7XI*(KF_-A?%*$ZNP)XJ0[,J
M-\$:0"7N5/$'11]Y*,7$U)P)0J&,!W9)#3+PH4,7<H?$7@R]NGWQ.WN8J$(5
MIT:NB9DEH#'4^9.W4#L)/_2U_MQALGA$JJ9IKQ@45F;L2)"R/Z'VF2S*8*;%
MV$<QG[>K54N>QI0[M&PN\?\1B[A3FRZF&$!4*5FW\<O&,,Y(D06ZTV$M-M3"
MK$\D1K.JM@[I#\1C M((QM+0S2^A:5 ;ZR<]U5I&=]+?, ]%WL& NB+%-XOD
M%#G8>85<!G:[YL.J=F%FY*IX7V8 *.-U#/.!ZHS]BRRGO! %CVZK0#@TK76@
MTUK]#VN'F[HTI3R4#+,MM10<DI615XR ^EKSO%2>704IYJ7'22H:'X8F4#'0
M9MJ87?3* F_5JH;08-,[),5&=<H!%--/_'<TV ]Q(J1\Q:>J=Y.'.OMFUJ?T
M;]465'6H9I,8#L9]7G:A(:,2'NL#=\   >I&%OK8>\4)AT9L"T^^G/PT6_/Q
M<GX4TTQQMRT9C5_;NJ*5B?SXFZ=/LA^KDW1S0U4F:] #"QU5BYU^K \V^V>]
M,-X4W4;L4K7+'9EYY)BW@&IS:'PD6HD5_P&U@NRE^_Z>9OFLM\L/P=5-"ICD
MY381VEJ<>-;>C28CNW$@DTM&)-9P&-CJ!YWU6A<..$F0QH @PI[E2[ /'6CQ
M?WD5(,?(S+Y\_BYT,OKU^/PXA1[R,R[QVE+48-[I ^X[_.:W L"^>'*? &#G
MH3!'F>&P+?<.#71*JSZ$+9Z=3*D&C8(\B(;L=+&B!2(W8DEM>?+ETXP/%;09
M!?&<6GF4ND0K7R#O[)A^05D7P73I"-718X,7E3"D+]&DRZGU1('+XI:>=M//
M$MR*7K>RW+U6%>'2C%.34[E<Y@PJ=3NG:RPO_T6&>#DYE2_+PZ:3'\1I65L'
MX[/+JBG0(:4/W<SRF7'1JCX\3JX;?.E2U-E?!CFP!ET^EVU_7I47K04:C2=+
M[)I5RTO2;F8W+W'&]H[DWDG?GTIEV<A< C<)"^O\9HLJ.FWNU4WC?>$BZ()D
M$N8PMP"UWV@G>^VL/DISZV^T7K/S:JR:45YC\& PM!]9I<&&BONO0Z7F]%L)
M'WJ-SC_>1C7EAA(KJ[A C\!J-LB]'"Z2T[XJCMX42D(GOH1CD.219%[5'FY&
MM9E4$1W>X_.D!09=D/!:W8=Q25M@ +FJBJQR<#Q<'X6',WBRII/_+&31IY-S
M&=SEY+]:>=P4D*.+0LZYG,%3V"FR3_+7%PA[*%J:7SY=8O#LT5<&KR-[J^5=
M[$T@6Y-_)4^TO[P0NVH;_G5^78I5&?[)\5GY@GX>1WH/Q8TM1MNZS-7J[4?3
M( VER"<C0L&.LC:*3 9LZ)?(DY.HI[5,C=$S^DXQ_$:OM@^086N"FHSPQCO'
MAN48BK:1Q0",I;/&')P/:?YX0A3>PI257R3\,>L<'6$3?-/$T7]]ZT"(70N/
M)W6T&XJ6*$&MZX6(:E8ETZ,B5[_VYO)Y?ZRWCH:0X?T:$?7&\""1DIJQ0Z]P
MR2MS$%1/*+O$"$Y^=P]E=AP4R;IIIJ*%F:IED%S]T\F93$(N#M1GD+*W5S,K
MD8NP79<M<5A$SJ!\$7R@=;FX*&/6*@>OIT$!O-G\]EL-I?+ R-G,I1O8K61H
M%EYZDHQUY-98#3(.R])+K1$<4B_&0P;JZHQZ.2A\U8Z9W3VQX^+H9"2'@69>
M'&UL!918?L[,/-MB-CR+O55+Q?X2&LB+[2NP_(N6=036*S /(FF@K^HF[?7]
MK,*+*8[$>'';7C72-#?K@\MI%[[5F0)8%SC\]-ZC0;=LVXWF8VXPY%+/,VL\
MLP> YGK2[1"_3HWJ(RV4WEMF3F5Z/#D-;KE9%>,<"V[JC/XP0SC+6]64T0E$
M@\$F)__.+"&ZCM5B(0?A!\*Z&S..U,1$Q_1D$[S2I2_]6S1F*DP!K 5&J\)F
M8=8V(=@8#P"Z!$#W] % =S?&\@"@NY>,7*]C4IKV9$+BC;B]V19BS)1J$,R=
M,T$)!=0=^\N +!AHE;2*5U%$3NR:I:K5$%%[WSH6)TT;@VL?JG#8\4P;PUNR
M.%@4,<0:.N>MRW9M-8!JJ[7=1=%8GW1Q-!&-B=Q'T:, +\C ED B%FMY8@E#
MQ:M]K-F?I3""'2WV OY/!BGF1M+KV7KG'5VV"$YDYL0XW08?53'W0[-12+4N
M#1.59FFC9"24DAO=:"@F]\57(AD0W%BTO"!=>MF%5=:U5;:84EM<:J@DFOJ+
M=DXW.Y9R%M8S'E J\N/:TXXGWY?:C2K@/):R2VT7BFTFLT%L6)G:=EZKAY;)
MP31Q!?D5S16Q%(IVKU^%R!.B@Z/!V4/X4%8(3Q 3I*S6&XT!A92I];Z"7=V*
MPB?95U.1^7QR\A2]K3>7]S1R$^.:(883VE RI@\C.B T1/9Z$8NB20,\X8]'
M:L*);\*<TI/O9,X:P.6_3[YS7[U=E/4-L=;#$=; VJP'/@2'XRSRX*@\@4D'
M@D"<W,T)1-H97# EU%+6J1QFF$8+]UNT])B1C-XHVY^-(?I*FVU</*Q:ZC?'
M50UHEQZ\*PZ=L0('_>/(4S-4S*R$TF@[FGC):V)331V=>^/YM_0,U/B&H8UX
MKKR+E$Y?XRH+10"G\PY[G>(TO9,H5"P7[0_@4 1BC"JR\D) 6:LK9^X9*R/;
MBM 4C?:UAT<(14*6-^]WA6>>GC_7(!?-;  8.)U?GC_?U[OJ(Y-.S^Y8TND3
M.;Y?)*'.>Z>=7H]CM<2U- -NAJ%3<&(>L UUEB4S/\F7NV,9%7$!3O6S\VBD
M1]?Z5 ([DQ\;O0]D#AQ,=>Q=#X$;4Q-:RY'CR:^@)HH( WJ-3,+JV:FW?NOL
M(.^H 7DA>_$6>[*E;MON5\V_GAN0Q3F,W!P3%VQQ0]#]F.0=\BJ_R*=>@67X
MF6::1_@5*J'T1V:6E3+5=EN682P>,0^*URVC-'NC+YKMQMLWEVV_YQGB/C,
M]"F>[%V5\0RKR3X&+G763,=R5'W:[<5H^-!BNG<C^7CR<VC"H&M/HD34<V@C
MW3[!V$.<-Q5S^D4L\ Z:.Y-]2NTU^:62T&T&4N -E0$PC1;..$ 7K?(D30-3
M6V#"F_/!,]S(W0H@X'?Y*I1D9E,'0J\B4>J()I3]O+02;9;K(RK:6.%C$INW
M!Z+$@IUJ(DM)U3$R%)Y+]\*-VR!KN#R;ELT#&7$%$PATC5U+++KP1L4<ELME
MV?!%0*>$@OS8CC5R,]Q1H?W$>^8L@1_>Q>G<#',PNW>W/8!V<!2%M?>RR81T
M0W"\_)MU-=_%EBC7>YC+*&8+=-54OHD,"YH]MUJZ2[:@41=NKX^XA[08R%S(
M99AB?RO4X&Z*Y*VV0LCC:J=P<.LMK#5BZ$,34?4\_!5=QVB3ASM3_A$(^N)7
M4:-@[W XRDCY^&:Q\GN VVR83[E27__T*D+A16TS#*Z&/<"<;9P!&K+^=;LJ
MDRD1?,J_]<-,[X7CR6D-7+&HF7$X.E4PIKQG"?!VBFM!_[P!(G=70<GK#%!6
M9L(9!@2Y):J21"0@H/5$C:KT!OU05&\7+/77;R<-W%3YQM\KFAA#D3\;F/AM
MMJ6#T25$UW/_/IG2]W_ZIB@]3KA&5:U;;DM1RI%*:MF&Z\&0Q8[.)47(+DE5
M;"(64V]XFL)5?239U5Q6]%14FUQ#,]#;!L$VD">EY>HBR>$]/)?P0_/[.YZ6
M_"*?D;ZVGXLQ9[D[LA&4S2(Q=N5?1^WRB/'#=/\0"$/$1K_.]G1- +Z;ZWA@
MZZFAWY?E6D[J$B6"8HK/W\=6W#Y8@+K%$E[!:!*CLQO6WK)&[=&\0=A=VJ!/
MO,M?928HP2IZ$.[BW&Z]% X;U)2PC:F.A%.=YC5,@=7.0C!ZK+1&%HQQYEG<
MPD%=JSHS.Q3%:6X6_$/(Q[D5;=S%J=PJ#DL@$BS6A'8&1]"VL0XEE8_ E=XZ
M?Z'HA%7QWOL*#K-*KI4-L@J&2/?"1_6MO(N<WE5])6: NA$LL:0HK;LR"X[W
M($;4X+J,(DW8.LU.T75@IL83$M4V(MOI&7TWIA6GU]$V#AD*A7P](=!?QK"$
M75/Y2]T/MV;6:==0/3.[K70S"F8CBE0Z&V3J\0A;)4:$/2:_+K9'2>>M7SZ<
MA2I]WR>'>!QK:PIU&5D;H+-*L D)_/![.*Q-6F'$O#F]17^R^'*6F='1D#3^
M )F1F$4;Q!F/ GC>UGRTN0Y--K?2HBAK<:79%:#MJHNJL=R$=1QP.B58;:A9
M #4 :FA1/:;6I4:O/[;U(%$L9"+2MHVW$=Q%D %#6&H!6?-$O5EU+T-K>T5V
M@!,I3)9]-WU=M70K#1NPBLN8EP")4GE088X%1=EA@NB)4-Y)X,PG:M%WWG]-
MQ/2E%ZML)^>&.KJ+,[Q1N?K9>HEVN"2$=>*'WNL)(\@=6+$<X-9V_ID5JVA?
M72\V:>B\G6]"WPC'^F:(I QM[>]'SPWEODB4@MP  P^(?DD#4^NAZX=R<O;R
MQ2D=P6C@QT[P#L:7T3W@9A+<S+,'W,S=&,L#;N9>XF9^9'8GH9%V_+:7[[H=
M">WU4GX.1X,.<R4_Z[8YJCBF8,VD2HR@<66D*6?ET2DWFD WJQ?6 .S;E\_?
M63D?G!J (:SDFCF(@-/1)+F-85F7'XQEB('S!1<XR0_S%D@Z-B&$U:,B]HBF
MR1]H< WK!:$ 27B%MF:H^M+[\GARL%9M7_QUM#ZR-I:]WQY<'BP-!NRP8 3?
MZBP>G/V2KP01!K)3#9W">5>QD4R& 9")JCE,T#^X%XU=J VY=W@KEB)C!Y>S
MTS=:UR7WU)'=4Q8=-INP*Z[51>"3LG$I2]*.Z]&50*K&&CPT$3?7*/>8BT$;
M;&<5\! -O5(C90[W5>3&VR"(^_$#HEY#P,]F9"E79>=$)2IH\F=YSIVT]&ZT
MZ_ZKW$Y.42-Q=Y/NGVBIO@3!E>Q+F)75>@"H7^:=)N[D=&\KS/C/HAEP\I\^
M>?(%!9.&5&F@:J0.=/Z%SW\Z,7-P9V6FAY>&/PH?'$_>P-@L-*YXZ%FEPM'(
M]QW[F\.0)<T9>B"QSX'V!=+?'^ITEF25TF9&L:ED%RL>U.52_;0)Z0>@,!M'
M"=:%07\4=A?ZTAD.<$IJ!_ QN(_C3-G6?<\H?]V#3H [:.$3M?W=C)A]#/-@
M*Y?-A:_2NM@F4L%J/-)Q^:[QUBP; I^691G@$]7B:*FU$1=IAD4# UT9,I-=
MNRTTW;XN*KXQOFTQ>(<M-O<L>?$X:M$2'X&PCZ"Q;.BD;-'G(_6]#4PP\0TE
M,H_XTZ/JL79-AS."6'\R#TO5Z$P\'\GHDK:*4^3A[,B6I PQ_Z8,;>"745X)
M!(MHG5TEA4<_J@X,J&ZO?_N LLZ:X=#<-B"]67TA;8EYF@)U#1-@]KJ%3_5H
MMCT:_RT]\:'0/?NB%[\SCT9(2$EN<44&;[-^5=.)_*VJK0/!)I"M:3L"++W"
M87=&$76&:T1QL:N(!$:8*4J)ZA)567<T4W)KW2E-(EN=??=B7<?=U$6UGHEM
MLO=VB#(9L"+)-7+'V ]&@4,F<#$!=HV9S;B>:%&8YPIW1\3F>-=B> *TC*S7
MO,QSD#8T[W$X@7<>R,'W/+!::@;;OM>5T%S(MLV)R(-Y^=434?);C2!^S!B=
M'$OQWQRQ/<(/G--TCB:2ZJ"[*4^?:&G%-?& TZODUD;\7+;J7D,Z0QN_YH*H
MXI#!/PBLT2P'+CI+L_>;G2)^NU+[([JFT,&*'G@WAG&:M*>_!8-DTR9G4>^\
M9-E'/W!Q'9<'[+3Y'./8#KS)W&6UKA "AJ[^,+=&E+R+UFA(E;V,]IH?VC[_
M"<O55]#S0'D@(-HB8K\ES 1'$9 0Q:T9VLEXA^4IWR9G=]>(\2%@4$%C+""R
MBV0(ZY%E6\0;\!UM$)Q=$,,51GULHUJ02Z];6)JAF*P&]1;U"8LCJ@;\'-^
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M#]#@")9(&W;[6/MYL5RBTB8M%4:;A?76P,?3+![6E>NR\'*"JB=S2&=4ZJ%
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ML^/131O&;GX?Q[B-(O)W[16WF&XV$'(H5Y_9!_%SYLW04*EB2;QBZ6=;[^[
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MN]ED+T/3G9SM;17/W##RZ/, &7:"D6C'3R@>RC95FP(#;6-?5<])#@Z[S<;
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MS6=V(4/I;G<B-1KH2;X R] 8L<[E[:+(WLO)D(683G[=%*25SPL4#+J0/(*
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MS=S_M0\+\5FX-7R.UN?X$#>I7+6L674@(C?.7@W2*$S/*:JM7M(W9W$@.M=
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M#?G#*=*O-S-1'56DTM=Z[]F;%F7 &!DL-'>6BI4N@F?$.\5<E9'J_(1Z=M@
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M6TS9I3"=8\\H&I 4Y^HV'#\FTZ.$75P@RN?:'S\"A]O\O(.GL[H5O9$*EW:
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MIT?!)TMA)5),Z>M_']DR?:.F5;H.TD#KRT4N[1D4%0N%OW;L@/'2?43^3)1
M=[SMOX&B>8?I2_!%^DG^'I;7C :*F[VU46)=P.21>$@!E:\:':57)&I(S:6
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MYPPLVGJY&;$+(K=L>O8B.&>'3;U/&3S;HPX26T+B72'P<-EP2H_NFLH46_-
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M$0A#F%8W7S5--1,-8TXBT:Q652V5/EY".NB4WP4.FMI\E=7"_&B>!K0F^&>
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MQ=2HXDJC+6Q><F@H*3N03:ZAA)O/'B$5@ V4=@(20KPT3FL,"6]#/J]DJ*C
MM0I']#)8:.*\!\SI@K6@0X3)#?S#(8^ )[07[28$P!TF:I4>X@/D4IK(U[>
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M&$?(>UR9_:>T[I2P/,PWXGWF\@?\"T1"]M7]0_V?!PCZ[ @(>AC/<@0$/4I
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MZ>:>FO2_-@O1]SB>Q+^D'&HD=D'Q=Y+3A-KIX,ERXO_'!L68MTQR? #ZZI[
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M]4"!T^E2\R]&T5X;I<G& 7OQ-O*EVCK@,3_Z!,PIO%:BWPG9X"-/<"?M.2
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M0QWS5C/?M.QO9LODCHR:2LOY39V^F-ZO%UF)=/5EK4*]_I1&)357NC?N/LO
M\-,4@$]Q+WXXL>0'(#4'_/Z[QE5)%,T6'5,TY0\@=7GY+T>\J*=:Y)K73@U?
M=NOG: (C&<*9[@I=QHQU[P$6Q)K5@$[;(FM6MBP7^= 9*7H^AB/LK7?VY52I
M9=^3;1%>J"'P,>;]P4TYD)P.G2/C'TMV902F%/"WTKK;Z[1+Y'(&?S[\@L6
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MC:REB[1:B#)35OQJ=B'R3RJ:<D&B*2D\33<Z08 , O3[$P3H:3S+"0+T+"%
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M7,H< !BWI;1W23EXD:6[KM*,T2E;=JK"1V*$0FYY16'G#BWCV\%QZ%,H =F
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M)//!#Y<US.CAE0TQ7T?]$,N?GQ;_1S"H%<TBCM18.67^-<XI'_$A.6&=UA.
ML9LV?1D)Q_3LA9VYHK0+\M)5=2N\IKZ@<.KK*BA#*N^T'C[">J"5H/%/0 ?&
MJNOA^(<K,%9>8>/GA:U__+IP_>S:)P?LL5N"W>=Y0(&?'"5F)+2,%K5*2&V@
M$J1GD^$HT%%YVO>/N^^YQV39NE/+F$;7@CZ\-04%CVZ5KFJ7TF.4]GJU9@!
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M8]/ZR5XXO4BZK^A^4M09J98ELY#1TQD0-K^(@2.D6ZSE[C$,7#I.J5)T6\E
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MEG$J:'::"IKU&$M30;.1%32@UL98I0<NXSO-ID'A+=)R>(L=H34'RBB=:,J
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M.5")XMNRSJO2 E68? 52-<B(108+BC(6:*<D6A@GAXEQ/2.][(NV2L-^V8/
MZ#?&E-+: K^L:3'9E8:CU!])W8G9JR!>>/$[J%05!5!FBI 2Z&HY1:+Y3[!N
M;D:J4 72.'ACQ=4$6S-.QEC,B>5:Z*'WI&PG55L$!:4T@IAMFV&D9OTZ+@>(
M9L#"T=9U'B+M1I)O1UNSSXY_-F(3-R U$IGV-PZKTF5@[S)S+?B,<U"Z&L;^
MC#K$CWP-B.TV&%4MW4J+C!#+P)A9@6E+SS#+&5E>3_VUNH%<-8ZMOG(8^TJ5
M\JEB<"0\5%0WH])4T"7%(LYF9,)1$>B_";U*7F:*1D1+C>D&+RGR345,E66M
MGO-!W0FNZ!K#Z%;*]I2,QQF>&(%IOI-@.4D-6\P1-D[)M6Q26]KN-:BI[INK
MU_I 19@XD=BE#+_<-\=;SZ6,J-1N0%L01I\!,(072.+.8F#UIH1'A?R?V)7E
M'/Q,,[:'U+BB>\,U%MMURG1P98H($*ER7U I1(!3M>*+Y3)]'9"M.1(6F;7N
M4R/\U:6:?8$Y.E4# )]QQPPT%*) "],-0 #L5;Q;,?RQ<2C/U7C"E5E\05/]
MGRW)Y0YZ"R,Y3 1MBH?NNP/7TQ28.MBC$M>>2^WKU 66("K9W7-.OKN>=MB.
MTC"K8/6"[+ON(;*L8'3A9 NCQR^O<&6W*5Q9C[$TA2L;6;CR>\GET\R K)&D
M\H!H_B0"6',]..HXML:]O3T(4T*B>ZX"'"0JFPF$S5PI?*6[I"H)(U24C5ZG
M4];1QW"78W\Y3B4D@7.OI+*RMDW<CDHF2UF\J527OZRCU;:B>7Q>P)PIT2V
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M,:WWGS)#Q=:3%.P\!FIF4M$BA52A#%=3XO*M<?6<2+].UC32\XC2D\]0Q98
M;HM%8,*Z]&D&67:FJZ.Y-![97*R)0FB %C;L3.S$8B.P)XNT8J86@EBFRPE.
MF]]LSNF3GE-!\<2J%\,<9CH0[N('I-O"96RCF#C8_Y,B5YK@1C&?GP8>4E\Q
MZTW>@26GTMV:-QKCJ?:5S?E_^O-O3KQ 4)28UA*G?6:6%]2M^7$X0AL%\#2;
MZJ"U6EP>MPR@Q-U:&YCD&QI%XQ6J@V8C'U.3*]<96X3VK7M@,J?8(S:<Z$I*
MZRJ<Z!N7X;ID7,-258UTVB?]?D%TATI7/#N(QT0>7E>VLW2J-!S\SP]+Y-8/
M#@]^6,OUK,^G?J ^AP\"K0N:_Z+*+'JI8%D9.VP=I67%_/$55<8AGH5,+[/3
MPQP?!4!UUK($!8#7XPTAT4=*.[K8=XBM"676JW+A$_P'78)Q7PKSITGA$MX2
MA!I#2N./IQJ+,<L)NG@=U_S.EL\L3_I?9)UG5M66*R?NFC)DUR! "%T=6)9N
M0G[04"*00GO/[\"G8^^[JIQVWTL#CEUJD,J X++MYO_8WMW>W4>-^$;UT@*N
MO__\C_9>ZQ6#T'7:#'V-X'/N;[8/=F=_TNG23SK;WFO=^X[PKM2*D1N!FR"(
MW8B*%H>SD\#AZG)4BI^#>;4U" BY6UZ]UW6>0=S:SM=H<C*MO4/[Q0VM8D#C
MDBDBZL]JB*UF7Q176V*\"7X/_S 'U!;%E/F5;S&4-8R*O@L_(*WSM*@&2$$S
M_VI@1ZX #4@13!/IVI06!A>CA>H?I/\4_PU#*L9J!GO&X,7K0A;,IQ19QDDV
M+O3551N(TAQEBF,IXJT=Q3%>_Q\4LY/S3:B?)>SJOS2FVB/F7D0U25\@V&6$
MG.-1YYFF/V$N2MOR<JUB%"\#VR,<,JX\61Q^PO9%O8F<T$WD\S$WUV*Y&M1]
M%^#(LH+KZ@W9R&:3'G&3M*]3HIU(K6E+Z4L-<8:5F7TLMVR2"(^[2[H_8&"S
M2!8%WD*692X'%',O--OT-!J/(913M)FXXV8H:+@)MA5FBK";,59DB._ALBH!
M4)EO.13S3'!_BP@*\+\3],Z#OH*/^@@Y52(D$VN.&^/MPQPJ#GM=EC"UI<N:
M8Q_<4>,RFA3PE*#2\N-[3'>!RESJPIV@V'P1?'G]*WM-_\IZC*7I7UFE?Z6Y
M'+Y-6-II;)F3+:8:Y.":G7%#28=,9[T"[+2QQKQ']?L.WHOXA+;/I8)@&F09
M-K<*?">BVIL*-,0"@"%22)=8+K!X)-]*AEN3I(_Q([G#0+421GXRU/2G=XZO
M,3F>2*HDXF.[G!XN9GS_&ZO2TFM?!I/1-+7\K2R1YU^/8=A$KJ4[PAII>&IO
MKH_0R*G!KH47%QCS HF11KBL('*2M/'I'COV%<:.:6V!]"1YTK=4!F!>-YOS
MJ ?)@?H9(-M3K@%!OJ@I,QPB@D.?LUIQ(-!B$SA%21RKIG;K<<,C>0FX ^'-
M<\48YN;N(EPA#<SAV;R8+I9M=NPQSU<<)]@HRS<4&I<.T7+0_W<19AI C(KF
M$O//+$=\E&LX>1H %AO6?>]S E+@854#'U2$)IE@BIL2#&'.;VHV?PTVO]*V
M[R*[LBKE-$^:W.:C9F,>V9G 9W PDM;?<LKK"D98=F5YJYN3\V3>7NK@V!D&
M%2GR<J*S)=1+J=[B6#"E6X,FX?:X-Q^7(!+2IL66Q H*6UL!WGB:(];R+)!?
MLU>/79X0@$.F[8]F]1]Y]9V Z5@I9OY&PQY!>C--W_I9XSUKTEU3"4BV'[*X
M3J6*Q-1"<?6(8(\;Y.:IPRFB>_A*2,2- #QFXR4MN;G:S+V54OT6[&$/6ZZM
M/2\Y;\'^X#-[0Q=EK*ZY:1O9"<8@&0.+RX%M>(,TN VBTDM,A+0WK9.;1A">
M+J\N%:X(\!.8@Z^[]$V"N]FAQ]35Q \;N87;6ALC9"JQ'C?NPJ/'Q;*L$!+(
M(;@!/6+\DOVP.JW9DD?<$JY,G:W-+@6FJ,*=:>PKM)G-7CVFMUVJ1I_=M&8S
MGL8&0.A]A..F5@?PIS&\W^S%H^9;3,PV=OJW0N8RCG2'1[,IC[DIX-($FKC#
M; E;PU.#$XK-.;!I@Z3"F]?LU"/NE'1!) P)PC@^I8H-N?(_QM04=9F;8(>F
MNP+MES87T".?+XW=87K*9WLFA-#1A0=@_ ZWVKJ2_IH#\3O[#-W%MEQM=2,!
MW]YV=W+4V-$$?E0VRS2/\N$8\!ZVRUPW<!Z/O5E"NN1-$MP K$BDEE AC'+(
MO)I=><1=B8,<Z=$Q<QD@YRR='S(EL7\8_JJ8K1OA<Z*PCRSAX4T8$0-R!O]2
MDY#:902(.99_V#-X?/&OT]=;[4/DTLJIAR)C0O,4B=R5P#-^IO*0'(8 6G8$
MXL!P& U4RV.'#>D>U5@DJ6T@'Y<XS^H;R#</YJ%*ZRQ0!A+/ANM=E):A--0?
M#0EC<JBX\+"O7/(I$_#V"!@PS9'A+$B]GYS^+O<KY99!G]NII0&MW$&FVT"Q
MIQYVY6>?$7+4UPE,'X<Q(+!]-=9H#?@("9:4X (HP4:_389P13*T!1YI?CY7
M,J#!DZ0$L)2;K%LM)(A%L3$3V_9^39- %Z4(IQ)W0)98+W0BR!+G.:L\!S?!
MKX$JT5G\NN$9[K-)@"K+"?+UHP 1=+A.T=H%A&7AK(QN^$,H<>%PL#LX3)#_
M5%X9)@,:DD XH$59SI&8*07:%90&D,P9%RR>,%5(R-[20S@/UNMB84H,'4,/
MLVH,B,[E0920L?-VIEJ*9@JOJ^:UM5]CK%6S#/X,%UE6]+(\T!06F;2^!"!'
M6  O"4-;EVLFC11BL0&(@.<1!:.EH*_G*JLA5"1M54.GN(XZ:46X'\L)2@PD
M#@^[2PWNM.]K<)H![& FB^00(Y,]#,L-1XB$%:%*SH-L$/S;.Y82S3.25E__
MF7<;Z7PL?8E!?IF_Q"^OG72_:2==C[$T[:2KM).NC4%V452:V['@)**PW(18
MV=%00.R9V:RI,=&B$#X:.#=D":;*X"E5&7L1L\@H6E9U&LIJKH(D0$KSHR+6
MNCE/80V&2I,-9#H.%<1L8+MF)EDG2&B55C!+"1V*?LKW.FR,EX&$9,.I!\HA
M'!=CY\9SHY$+M3_576GU[T9+ O=[I;$$YGV]<&!-&%SL8S9B_BLKKS)C?;5:
M#H37.E[$"V71H:#RA7!>@;4"MC$9R4>P#I'7Z1!J6LO7?"7G2:XML5O%5S81
MRV)".;=R=$G+)%+T[MTQ_9X_$S![=#&Z+0)R !EGA@O)?PZPB1C1BM6 @=H4
MC4GOB1X"_G=IPVJ YP:><.3T%&*TX4\J&V?VWA"(:]KSLI#!0^>?$T),#UBL
MY!OOY'<?"C@SN[N[K9^"GW_J_&P6\DQ>^RO,X#W-X(,5SPT$A+N(O=^"&/'V
MO#9#[;6-?66$A'9>SI2@2^>T2^CQA+'@S40A>5W&]%NX5(;UCBDO&)/P;K%@
MM$,BU0"]4Y6)!-M!5("G@33D:Y#%<0_^U3GD\X ;;:;+9Z2][1U%R,IR/<+3
M0>[GW&D9PW.1+O-%^6)1*C%?BG;4:E8>XJJU6MDU^P!Z<3B4*T*7F\9TFG@S
M9E;*<;8<?#Z^/>#!V][OL.;86Y5C[S\6SB)P)CV+NO=!#"G80NW_PF TF3#.
M)/M<3(=F"2[HBP[(-:^@LWZPRGTP)5 S(()D3GA[, ;\49QXU[ E<!"5FOO$
M$LF@+(R9SVF-N,!%9>Y+T'):BX559O; BPL2$NH(E +0<&P)7DJW41WLK\6A
MK!%;W[.H3&7_>_:;H,:*/@F MA5JOT;FA-"9#]6 X]>I0M)K<6DSS 667&M$
M5N-V'3X?AN.>WT'M_SA!N;II4=TPE!&>!>;+0.&3>VGR1:5@.081UB7101P'
M7_@NMS$LG1ZC(FHDAZ5GIQ+;HC=54?3+JU#U]0.S)C#K5#(LID7:5NEJVDVT
MUT!5#I0M\B88552.,A7]51=:B:O)J7]7)L=UY#S@:KV69J!_;99/.&HCI*LE
M!>B,6\#@^[,8#;[3Y9TXV7G?=N5SX@+D-IDJ&ZI81*MN24R9_W MC:$5HQ*_
MBPJ/%3(A3((0D4Y08\8#GK3E2[$,QPAK8K\E0-ZZ+Y2C"9MWLY=7 N&4@Y2C
MJ+0JQ#6$32MZXG/FC5<%GR?T24PO4EE/IXK.B0B4"@A&(M/0(&X&W+=0X"RP
M7V%I="1N1D)EIYS7\CQ$5\"^L5*N3,6^&?Y7@7*A2T0'$Y$ZFLXWF)"!QHPM
MBT 9G=I<1;E$Q3/D97#'G(#70L6S<*%S%)E$#7_'5'%>,2$.EQI =+\N0.@;
M3+:",=[R5&A__-*_\*)B0WGJAMI W3NNEXYLSQGJ0"$T2ZHBA6Q3E8L:KHLH
M_-/V#7ITK\,_*F#:I<G*G0@#@G>$YL<S]Z0;/&=UQ<%W8OI%R/GU/'8KJJ0+
M*M, *P D."H7[3)NMX&%0)JPH-3C#E*"H4-J=G8#ZT:\' L)>6'RTJ\E \:L
M,&,,:L,['8O0K3_ S4IN@F@]E_S.\ Q,7MS1! T;NC++IW'W+[-K+[B%\ NP
M4K%HQZJZ'M@A\" XE1CH66)CDB*G  :7 C.H!*O0*TI"E5X^0V3,ZH@AZ_5.
ML8=@'C2S4:500'[G2[0TJ,AIA#-KY'L!-CP9I 7FI;P.8CG]F(U/^H5X.(D=
MAVXG!C/E&OF]L72=_I9E)?(:2:<GZ02-&,71*$YR28)'V(YNQ':CMN6"S+8B
MSA(X;%3GYL ^4/53 B_DUR!R1V9@SQPKC.XJ=''P#4.E(@J,A:+$>FQBBJV)
M.;:X?-ID/=?Q7-PK9Z,=4^-2F3+=F=I<5AWV@N*>.A/\FV4W"E!M<T"4OTO+
MZ#[ R8M%@@]*&<JP;SKVR)I'C'^&>HA1K.S](&9SR0W+JO0KEA*!OLT75<)@
M9\0-X1C;8K;SVS&29$;KD"R9!UJ_45-4:+/?ICS7TI*^RUHDHG1[.1"*OM[N
M2JJ.[W*'ON3D*Q?>@_% 6=WV87>'J2A1J6!J5@PR]XOLR5X&:2^ +=NZ^!JI
M*3U Q\S3PN*S6T1P>#P[\TQK4?-[&2SIM 1-14UN"4:IC5G4B+\0+[/+R,7I
MNGL8_')"C.&:@4H%^]QC@E[TDB<* Q8!ORE#HPQO&P;7UC$?AP*0PC84E^*B
M QUP!2LNU)D*C [4O$8O+FC:29 :X\Q^E8('IL(X(&O0AL!*715DU. >244*
MN@C]OIKDFFI!>1^W+[>]D]45#"Z'Y40<$BEB>3%PIFC65WY;ISY84EB<&#U9
M+YA-.9-84#H#U-E86?Q,QT##8P_76I;5-C+,GTN0<A%*I+Z*.). EBP*?;M*
M98,&IB+Q2[(LQ+GB 1RP0;UY*N:-J( I^(<>:04;H.VV=<+BEHX><6P,)$QX
M2Y2VV,N?XK+>JN!++/0/M=N@XILP36(VJ>=MB8X_8SP W&%#TPYF7H$6)"*W
M.9%!4P-"=G,QH:L-9\/X-P*C33OLY/CJ7NQJ4F/X5*=&4PE[A<#K+YB]GC1:
M4C?2)$C!1G'"^J"A\9=@#Y%(YR-],CNM=M=[DX*&ODU2,%,O)^"LH3!&$J$5
M)42A*8F$&86GUZQ<EDXGDPS#"0*58&#O.E771LD,"BXDNBJ#W-J4WET_I21
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M^0.IT\%#'?Z78NS,S;+#.[]/$TEG*?GVGJZ#Y8>_79X<VZBGT\0;%'#HG*K
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MKLV161@$#W=?RHCR$RR.!XV/"5$*<7 I=SVKX,R^&S2J7HE@T4$NG'&II*H
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M!8B,%U(DG"8<5/:]S'):N6O<6+<(JR/-=3W3B!/#<[2I(HM0GSN4I#8K8I]
M? E%+%QO<W("9$ZFF(HLGS,'(HI6D:NV*\N^1,,O=LCCQV98Z$7%HL@IZNA&
M.&<,HAFTH)E#2::U1<?CUCOX@#JFX4&Z-'1N+9!@#=@D.VQW/ B(M187O'9,
MKNQI5!7V432>:YWLLPP3&ZQ[[_,U9:QU1]=3MPHQ*F$"1KG^E\_F10WIL.]
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M7."# [G*=NN"G*M?9=UVC2.]X"HSIR*;=:G0N=R?<XV4SB#[7G6Q1Z/#6(W
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MP>&&@__Y88F2@7;GAZ8X9?W+.IKBE$>_K>:8B2&H[ %J7U2<Q\$$+VWO@\K
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M7Q\@Q&N%^56_%.?HE>'53"&/ 1LZ/Q6,>_/S+X_(^OJM"6*7>,X]MO9;\87
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M&.LC)#G/@9'$ )3B5"D1%*-*MDC.3HYJT8V'J&ZV&IZJOW/E.9A7VFH1.43
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M;RF@-)KGFC$,I/'8*%S4LDM*= 5&*]/%;3GG?-Z%2]Z%C2N[D"OBC$# <\L
M518!3:$"#CIGI!8H,'GK+JS:\5GI9[SV@_#KK9U,<Q/+4KK5NO;WR8/'GP?I
MS>^1+ ;T B+_U!_[\FM%&]MZ[5]WG0J??/_KH>[[4JS [>8?5T^'Z6B*G?A)
M]UO]K\.4XU:$1\Z^/1N!#TS!V!@?&7%..[L__B)?.O[_?;G8^^9.#:9\%S<[
M<;S'>T=_QN?^<=C\&-<-Q\]?[L9G=CIQC!>-S>,?\7FA<7D 6YO;K+&97HOK
MN+%/)&?8<@.(%-&N=-P#;9P"B 3,D>;:>74WV[AU7SW&8YKWU2O95P%Z;Z#1
M@/!$KY/G0GD7.780(B /1;&OX+L(D.@&>G/E%RE-MO8]R?NWVJU[<9#VP>!Y
MMF&QYP8;9\/#7C\"MLN.KU79FZV-?6^,Y#1@P.(F!-2D%DP2$2 $9%X9PHVA
M=V#>+?ML*<=HWF<KO,\"]9)A;8"4!D8,) Y(AB(D6NB\,!RB5((%%07D;O39
M7L?!T=ZKZ>F&*)Q>%=JJVX/!V=5MFN/+*[%#FSN?T_>@^-V7K;2NG_>9<E@8
M1@$,)+(_P10PR!" !?)(.AH!D54*"5MGP\$P;OEH?>4]MAI[3'B*(M%*X4[2
M TJM!P8K!2QS@H> D9;NX7MLB:PN[[&5VV,&,AHL\R!@:0%5T@%# @+(("VH
M</&\197:8_F87*7M%>)YZ$@4CN+&Q>V5RNBI8(#7DG@F,2:I"7RW]W,"=W^*
MURYV2*W7K_5F>%33@Y1$N>FM/S&^/[K3)ZA>2UNQH(+I;)WZ>UW[>XZD7EHL
MWZ)>%]ZHK-"EUY :*?2^#%A1;J.1;@T#E'L"=)0<\ P3; -+96FJF.^=TR"J
M&;26E?<YJD:-E5<%;@4BR01P"E L-##2B909[4,\4C%RL(K*^ZQWQM6[7TSQ
M'KUN)2X71T/)-T#EUE29D.:M[^[C/]3]OTB.<>>[.>J1QL>M\\;1=B3!N_%[
MM^.X_^BT=CZ?-_#6>6MSK]/X&-=E9Y?M_B,O6YN?:>/H^$?SZ)@T+BW<1X@%
M[2-)AEC J.Z& *D8!)Q)$?<"YUK@E[U3S-MIA;:3$=!PX2G0F&% +7) FF"!
MI1P'88FSXE%7B?67\IO/[;Y\O[."6Y+MTT"HD1'<F+4"T%1X2E,7]Z4P2@G!
M/13AQ?Q->7NM^O;BA%(BC %<&A2-7<4B7S8.>",<H\%C["+B4?C$F\/ASQQ)
M+Q9L<6T+W^J3SWNXBGOX@.P+A#F#3 $K&044.084Q@PP0R#3V'DI2'4@\B9_
M?-Y:%=U:FC,BG4; <)7JR<=S6%DJ /+&>H(=-30UYY.JSN'-";[7X?$%PRCR
M9ES9S7A\OJ^<UG$G.$"HBC@7C #&4PA(Q"I*(28./@+GEK6U\CFZ:OLK" %1
M2"4,K$O.%*U2BEHT.H2.AB\35O-H:J (=HJ1AW'!\15C@KZ%.\:?\L+4OF9P
MZN/3OOO.Q1.N&]]&.<ARKAOG=/F&ZXJLOV65C]_:YU@1'^41+:_4E-QZ"B2/
MN XCN; \2!2<C?Q"5:P(9*[C6LVKQJRXSU,9?FL?>FLL-P$XCE,VK0I 226
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MD+'@=2%OCJI[7'V8^ZO5:L;6O4&L*/W*.&-%%;!B+B$!"JYA:N7B.0;1!-3
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ME\WVWLG>4>O;[O@S_\3O8MV]G1YM?/MRV-R,WW7RQV$S?D]KYP"U=HYQX^@
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M-096.J:M(Y)@M[9.:!W?D@/RY.++KS 1Y(WG@JQ6.L@#LD%*P[<Y:VAD!66
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M4\0&X*#C@'K!4P=0#+ SB"D2##,HZG=6[5>MVL\:Z9-5>TFJ?<51&*Q$#KL
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M6#Y/SJS*OHLWPC(>J-*9<SQ!FQMSVGQ\OH^5<1!'EB&L4( *I(".I@0@W+N
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M5!!.DX PQT]I&A!*>2!2;6+*@*2&0YHM+V7Y-&CJ6C./)KG@>;D)UXQOU+L
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MF- %FLK3]"RN-27Y(Y^\S$LU@?&<WQ,M>;2>AIN 5Q!005D4"RTC9JR4C$9
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M)61>U-4SW \=27A\*#"7EX/UMYSA#A,%CN%=0'=]?/%<KF&E!PPF17[D F8
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MTFM56GCX/;I%&L$]6A1?-P;DWH(X;T'<.529BB6P&Q*+$//8$TXRFUD2*6V
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M6+^JVWFTF_]\=[VU'.\>?(CW7[X^#)30*F4AB;,H((S+E' ;IR1,:6I9(K.
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MT]H4L-92$B8B$/#W+ IC9)YI&C\1K'6T]=\NXN<11^S.E5G^-C58A:R*P,>
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MJS).8*PAKJDVF+52N+S^<F*G9X!7PZIS)CZR-@<!;,RJTA9=\#FO["<(Q\Z
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MS'<DQF,\/O /42L("\25A&UX];^LZI;4$F*S623<<\XP(/526SZ5F97YI '
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M_E5;UHN:-F6NRN3AXP39LK3(-)<ATSAD[\F$XRI5>NU6<S#O!*I/?B*82%3
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MSB73B/'2BK&4@015Z&B%X-Z95"?:*X8QY9;PPC7;\O+)\KP30PA?&,(*)$2
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MF$[$"*P';&;@.;03F:(1TZ2Y2":M1L@%/<A/T(OA"D+TL=@ \"]AN/#4'\H
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M_55&BG$FFX\2?VY)G[8ZG>X7.P"(_^N?EX_Q>:[$TZTIK! S#T^EV'X-(UV
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M,2?:)2(HI8P[QEQ05E'#2"!::)Q6'J2X2O[_'H^LOYMVNH-)+Z=&WB?R?GB
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MKQK1^?ZB<_'F0.@("ATU&.L WJC.L5YA.1)&X*0]"6#UGKT05\3W[NR-CNL
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M+I(D@1A:$BVSW(!3QT!PX<]BPPQ,&B+S\(+T^2!XCH-@!GD<(^(R&N0PLTB
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M>TG^<_%AL/T/_OK7WIO!]OL#+;4,N>%P8#0BK@1#6B2"%''41LTM,WE/@F^
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MO0!S<7@0J-7))(,<%[GOJTI(<QP :I*)S@=-M,Q2H,054K!1G1VUP!#.&BC
MDM1MM[MG&38RJMBQ[=L LUAE$E.$!02HU>\/\Z=N9\H,\Q2$Q!@C  LEN)=6
M8H4-HXH"2;?W8LKNU([X9S=D0,,/A ^$,4R0B=0A<)\XR)D62!EO9"0B ")<
M8\@Z0-LF]L=F"K5HJ::P!#;K3L;)4:P28%((B5,:30I.4PE#3,[9B)O8]4.(
MR][^ 4B%]C$1I +1B$L.#EFV5<&!]VY]PCJE'$?"*XS3$E<N1+Q@4 [M 3D/
M\,KJ7?;-Q^B%E"L^;PW@=G[.+U$K_1)@3[IZ\W_#UN"\VNIX0-S6EUB]:]O.
M8WRXZURLE\-#&$*5'VK.QRJI*>JW?N6ZMA>RPH=6+_I!%SRG7_+G\@<H_NWW
M_';YF?SVK^)VM0 ^"@<>.UHV=$\'(^Y[^>3-7;5\++\ZOO)&9>%"57\(WGV_
M#WY9=OPZH9IUK/,@5ST!&"=YHWO"QV;ON5E] %'N3<>=WYQW1$_L>768<:9^
MX@H>% ;2WQC]:D]/8<Y:]>A*W #> E,[ (S*,U(^M?Q*@=)^>;XNW*U76<#E
MT"^VO -BU0I# $8@!3 'F2,>Q4Z9]7ARVNZ>QP@WF2[6:);ZP_8@XV%F![X]
M+,DPD\\O?BC/9!E!2JTV##_V:W]F_-A'L!@M&&/+MMOG>?BQ]P4&?SN"X:F-
MB4O,I5)<):JU)#XR+7A4GFB5C0'16,\;@ZV=MTOFH/A=_^29>V5/LQX7V]/_
M>S2NM]W>V^%@V(M;0(1R#FE#*U;;"2]@7 >8$R5"!"JA.!#5X"72Q'&4A$XT
M&4%+[1NRN8*Q7NT3EWA*:[0&(!PK=*OFN:U^>;T_/,F7^(7\ZY:213PG(BIL
MI35<1YV[LX,71+%6U$I22EEFR2J;8#<2L2)0OULP=5D%8J=?5/IEIAB'Q<'_
M_7SZD7?V/+_T,BMM+8E9\!I6>[WX[;[>/TA:2&&\1M%Q@GA,$OQFEI"DSFB*
MG93*%&IR-9.M!6.C.FT/P6#1?Q6)ZA2'(PO52$(+E^F5_4S +_O%MMJ3R-]*
M21V9B,R/\PL#L,;S,ER!FPVB4\64 (#!T&P4</V%9>-X/KYO?^B.X>V,Z-V9
M[,0Y(U+!&&KX'QF3D1&8T*_#VEE:.;[Z4]UA.P!8@[4K%SK+5+X7 0KST\*]
MY[ZS"<9QXC=NK)ZO18V>0/]UJEV=P=I4=C@ TE+BYF WP!#U(BA,!9?[TX(1
M[YU7I(3#+(! UH). #Z9264VJ+970F2S'\ZDDABX4Z\[/#R:?YWJVA&&_Y]T
MAV"AX_^!U<Q/?2F8U(^[:*:,MU)8R2UX\ 9 T$B&HPU>T<*4KSGV, ,FQ1%^
MV8$QMK=&C[[5F6Q139SAJVW7RSZ 2.8P]C#6'YU+@1R!!Z(_'7H<DNV+K0-I
M!#%6,F02 _20TB"KM$38"R:#T-%:<&R63=?_C,GCH O\8:7@KZ*6ON8;8\6=
M4>5N[1&!ISJH K#$T04F4@TZ-#@"L #%J1$D@ Q,A'^B*!,EV<AP8*LVL%\8
MV-+X0AS$_Y^]-^]I+$G6A[^*Q=QY-2.1=.Y+S4](=$.5&(U-TPW=0_V#<@53
MQF9LTQ1\^C?RG&/PQEH&#!S=.S2%C\^6$4\\$1E+_[1 ,7=9G*\@YFN-C>+>
MYWMCJX\-"27N%/<\!1. I&'#<VR1!NJ5D#2R6S9J14W8GDGFF[RU>72YL[?!
MFB=;5RVPGD$HK+01*'*=FQPHD'_L"9)*.PTK)[US*^OR\1L:I<D!N3SN]<'#
M+!$_%:M4&J+!/-A_'_X^Q6 :\_Y-L97SYCW]J=W4:S K$.,A+OSL^RB^542@
MIP HX^ ..*(9K605 YIPJ^%<M5N]2+>:1:N,E$[JI#@31%OE&)?:$ " 9$FU
M]0-K?C=(/]GEF20R&]>(48/X?!#?NMC9^T::>UNTM7?T?6=SXS RXJQ."24:
M ,0MC\@8*9!B3"01A BT&-=!%N>!5VH(?.'&!P!>\TB_6WE*-&,I8<P)4*U
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MP[,ZE?Y<_UL<WGP5G*G3;%;*KPQ&9RM,"OQ>&IBL=MDI/.WUA\"4RHC#]RQ
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M\\LR@3,@7BV@7KND2.\_.<"MJR8]^'.7[>P==UI[^^3@9)LT3WX^;?XR528
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M9 @)B$>3J""24?]07?Y@^25U >_S,@^6&#7>:N$I#UY:#_25^F0<LQYX;EW
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M-6-QU;?O.<#\N&=_+UC]7$SLECS!&J07!]+[XQ3,&TV,E1P)'L QU)8AXT)
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MHXM#;K-R-51Y"JB"ISU,2O!/E'!/),CC'<#.*@H)37S72]+(96&,:3ZOI.'
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MY)AZ=<D1M^7_ZF=<:81E\%F!JO '6IYV05-/AM:2F)/7$J6 %ESRK%\"OA'
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M\T)*";YC:GHJ?YYFY7 N^8DF OS?.>$IC/8][USQ8;[QKTG+ V:GN#OS-J,
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M2V-DD,#-5#Z-9N*&@HAJ(+Q"5P!> ZXVM6&53Y%'K9OK:28YK(!RN)39P/+
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M/I\^DV\-L-RBS%2SW];V\$GLX0'<<_O'L4=5Z@8\)#)6"=C#R"?<#WS"7)W
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M>J 5UY96'HFO,VXJ9' 0R#</RXR$]C.,\R!@Z:#C=$"2S('<;8?)X"8X97[
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MKDP#W7]GH(S_A47L2M ZAZM?[;R7.:G6<$5'GV"7$U"T+F(&]!Q<CGPN7N.
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M&CU!%?5"[N9!'!VU :P-X),8P, /E!:A)V+.PC2*I>11@!G:C,I4:6, :6D
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M&/(;I" H.!O:F=,39]9:V:>/9W""]<#2-.1F*L\&ZL1< &M<6+Z2 @)W@$2
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MQ8N)0A1&:Y!8'6VSG_YE5I6$A $#S2GJC_'0.JM*F;_*.[OHEA[0)\95-E#
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M[I?(74^[T*;X$HX'C0R3HY')T>CG=W6K:I]NIM)O5;-K"XQF-BS9]?FX5%?
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MZ;5(<(X_&#(OI)$?C,BP3[V]I+ ]W>/?*0K#*KE=%]N78%6T*& TXC36HZ'
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M+@H>!F:O-<B]#A&;XO ;FN-@@1RL-AF??[(L8!.9+R@++;\ /4'!6% ;L%"
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M816GF8#7$HBM/.8#U_*SH:U$U7'*U>C)H&@"%3FXCXI48=IO".>8PS>RPR#
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M*@)0ZL=45Z@BSS"K"ZV]YE\)^H>*SB_'?*"!,\-S]/FG?P-02P,$%     @
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MU:P0L?E6N\J#K]J*$8]=9MMT4VD[^X_1>4$7:82/&5Q8M2]) 7Q&1G!ISF-
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M'ZH&N4+7GOW7^6RQV(RY1&V\\Q)RMJ2OM>00T9&5)WP0+D7&>9\NJ_?C&E(
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MY)2+H.'2SLEH 68-(07:5IDT40?&#(_''?,*U[!LWT:<N:6FJ)5H6G;-VT1
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M!)]\ :ETSMD6*T6?BO[[<1VZH:Z?OI[JF\/6+JMB.0U;I]KY5'+P(C"P2>;
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MB_,@QZ=Z6]9(9F-$,/4J-J;K]1<"O(BKILK%VZQ#L7W"MD<9WE8'>>Q_==*
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M$F7N=;2V9'J??.A!1WH0W'-/0#B+-B1N')YS2DP**D8?<X)Z+^_BZ!55?*L
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M\\$X &CB>IX=\8JBJ<-***L-LGBZ+JDL4EC;7OY1ZWY%!NL!5;^-=!O<S<Z
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M+ IT#YK09A6B1[,*5=/FO3JK%531N&S.^V$7I_ZE5 2>0NV8+"SWI>[KI/N
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MS5NTO>GGP?!R6I?C.IDF)V"*&Q*Y#R69)A!KF2!,&F^HY]2*-N%-&P)\\M$
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M;1LUUJYO<,NC?O>E"&9V7":H26"U+5>N)4DS,>*8XZ7H)(]92^TM?>@4:-T
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MT%DE']H4Z:^#_U!76Z="WNV5_E@NM?:>^L>Q'XY?^?$T#X99+Y/7Z/]SBB(
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M.L!O,,FURFWBI)]F7^ZFG-E&%PVX\D#(X-S#%#'*B 8/6#1S),M O$8WT]#
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M4S?-TI!-D,1Y-)8EA$#<I'*)MI$RFZAJE/6P ;AC'8S5)\1JQE513,NU:QG
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MC94H"?\"5UJ% G")NQ!C!M&(*ILB/-3U1&.R-%'(8[F$6#FEG[]?5W9/4=,
M#*652XZ4!4<<"XXPX:U.'"CC;2+!-P!WK(N)-J38=)G:43F'W,QN%7[?!&+3
M&X<-0![G\J"Z@C<ET)[:.1*1LC+.4</P#7+X+N%&39RFB#<$:@7E^$ZUJ09S
M- (]<$[_&/BSC5+J)T=??KD:PQ"AO<NY&^$:X/SHSCD5K8G$>V\1G-+$VU12
M?K6+TF<-B\<A*P]0UX_TB$SD774S:"78VD?F;WU8A*.BMQ2L)6!D(A*].Q*
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M5EF7)ILO87NIZ[#;W@W0W_SE]1G9!G#;%KC8#O#1>@2U(<#F1*NFO4= NN0
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M7BL#R106JFW$$B&*IF)+%GA G1.O%25MWD;>Q_+<'<6>I-R@X]1=1+>;LW7
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MA@ZO(!VBS>+94^&)D,=03-A%U@T8\,=DCNEJAKG"6MU2B;&0/5D5.N4"2ID
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M^D7/@\F"0A$# ^T<K2!E3KZ^=!!94G0G"EMBFRO@U :3#<F$Q\>8[:"1YS(
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M&FCPTNL7+#@C; 3QQ7R.BWFM_;ENAGIY.?VS-FX99>5C*%81?Y<]>0A=2-Y
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M4G:LXLQU8'L"F4-F/GA,C2=9=\?Z8Q)K'T4UZ!FZ\\L KU,Q@F4HY%Z"*G5
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MW)KC=+,>T>RT_-3P:]7A7$KGYR\3CO8)(=F)1M472  _2?812WYA$>D^+0H
M^<FMNF9^*I!M0@4^Y,!NFQYK/Q7"8L"$5?A 0$@(2Y=KNFJ@Y3ONK6]S&,EJ
MNZ8$^7F#EWZW3"NT 7Z>HJN^9OQ[)3N0H8^6<+K)M[!LL-=V7.OI:DP*^WF'
MDN^"1*LX1Y&T4FM4GP'*'-YTZ./3B?PTVYGF]<B ,EI=,2/WZLYW/3GFGC,
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MZ>^-@Y5(ZQI)?=&W:0P9Z:EXM%9)!>:RP(3D>)(I^0.-4E9!__5(]#<L( [
MJB%>,-J4M1 F:;PC26Y[DF/WO0O-!6BDN\L<^OTGN= .?H"BG,VD L\1]0+N
M%#QI+=&"C#D:6A:"I2+G76-_PY^HPDA<)V;HD^3 DQ=:TSQP0UPG\I])G>O0
MZUJ#8:35Y1V0]$YV$B+ZT6BUUD8!I^-:\"),%*/7'Q-<N_!Q=!^6'AF3.Q"P
MX*=O_CJP\>!8X0*22UAVO>1=W2%LQ81++18/3@L)OK^\?)#^M^K%4LQ@.J2G
MH%XVU"^*"C"6TXR]G[(P.,G3>NTYE$T'3!%M1]FPEY?SWER??1_Z@!&6?N)5
M];Q# Y+/.T!["P4D/7O<(-8,0P5.K??Z+6R L5.7Q0:;<J;M''J^3IP#7-!Q
M&ON(3[PN-/M7HF-PVS<(6<4-B0V>XK[N@C\ZN#K^)E_;TQ)0>):5,W,6WYZ"
M9^D\.)YY&OWF.+I3\$U2VI=BA*73M, ,(G$?RD"@\1U?O,ID=E*XLK5Q8 !V
M85=>X?4CKJX(5FU<#%LH+[)1,B6;F\NS]>)GNF>B+]Z$MU\+,EZHW1OL^J);
M%JV.UVZY, LW.8J7/(9P$K4WW/?;E+5FW^JK\5$F$$AP!H(-#\%ZX>FM<#/%
M+D4$?:/1[:T%'[>ZNL3'[FZA,C\KJE_]HT&278)_(L#G!L1GUZ][)$=KPSN
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M<TOKWUW=)'+/^]Z^(<KPR"AU;'R"1I^;__IM87'I.W/]Y\8F:XN]O?.+"P2
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MZ(5DP-PFK[P]RD?K!X-QJXTX1W:)C0T\IB$ _-%)]5;ESEU!M2X_?6?N- L
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M]*E'NQ_H8X;*T#$T?-V2AI>^=L%W2Y.@9]AT8E1+_FFA_/I1L'_&VG%6PO6
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MCD2T4G9B2:8P07)5B+S,9#!;[Q82Q2$UZ:=#TPFG/^J;3C09B99?QYS!;OE
M%B0J!/L54N:ZKOKA1B2+]YY49%T@2JV[$/>SD[<_.NP*^0LL+G>-T#*)WYMW
M4?*#@J;"PHG>KH>EN^]8?>DZ\ZNP]2[H 6Z>'N$%?7B[E(HK+';UUU@.'@.#
M;KK'^JQ(CZSUTE)BS-I+W3*(LYES.#%BAZNT#KD4SG(;W:IR\DH[);6_O^5F
MI(C@7OY.*1$LRE!;Q0XG,'O*@/@5@ ,GU22^6OS0-+MA$+CSC*!.Z!""34@4
M=0;/+'F]A@/$8&@#BNB%'.\\F)M,Q:&&"+K0D,_M#'37E='+"2U@/1*![O%3
ME?6>,&MZNFF\X\V> &NYNX211DX/'5N[S\R!Y9UKTE="';"_2'^ 3R$%R]CT
M=^8$E6$NZ)ODL<A:7?K!EOL4GZ,N19HGI])L<B"0GGHZS"]CZ^>$2W::KQVC
M:\MILAX=<?F6&SW#BNV8ZV"M=Y!EWIHAXEP$$H)0:WV"+.';C#(V#1%36/=V
ME9:6YD"0]])T5G_]D:-'\6=*+W922/5SX;[#LI5A_!B#5SFSUCA?_A+302RM
M?QBQ_>>&A0@O!.UR (2W#7R[OXR]])L9!ZBIA*8XP+&('"3R^\ 'NZ%;]&JS
MAK# 73QP6@/4OJJ'_1#6OP-1T!>/I(\V# (TJAQ87B"EM!*)Y$=#'6 $6)(B
ME"$?>O4^ZN,@ZXWFM& ?CV7U[A1,;6:L^8AN6*F4XIH[RXM]!O>CBH;L6QXL
MC_MMB A,"?\3Y!'6"[N9&'O&5835_>T0GO[")=MRE&U&A;=]N$VL>'F>< 1J
M$*U]'61YMNS$1JKCOO=1GZ]YA9YQ*#O,XGO=D#\"#X-;2_ /,U"TEB<IEX-]
M=A8N?Y\<Y>( >QMY5DD5', #W-@^+, !WKI@&:+$4ZQS;:R W)D/$E"!66I3
M3;!CH9_R?:6F4U/7,G.)I7 K9NDX"]FW"XW@BKA+Y\L90_M?WB]>%,499T?M
MT?COR=CJ*"8=%%OIU<Z$5#/KT@T7",W.A4)C@@X_Y=Q$L'M[.IS ^2Q:L\T]
M"VSDSTQ_?I] 4BJ!7S%7EX4N&)L/.5*?6M&V/SS1 GYSQEI<#G^AM^66;^P=
MII635[%)H+JP?%I^S <1L>!6Q<<4F7WI=QA;[=;G\VD]IV*<!FJ9N@KB9*7L
M]^PD6-K5W-I2-&S[U)%W+H%K8<QSKFYG\BBBKZ\=R&1[7R9%DGWV& QHJ_.G
MK:MR@.["SX@A"V<RWDW[,I4(>Q/E*PT^\6#FU/3(ET8BI#52E-HJ7RKX[4NE
M<(#W', 'SQ"$L# 2 N=L+K6#/J>?-E7EC=+RVK&,+G9:1J?1CQO=(^\S:\^?
MGMRB?TT5J]O(X^" IY%KAH5H+JDZSW(&T@^KMC0Y#VU[Q.^GJ;700'4URIO&
ME5I$;69$A@N,LUX;&"9-,S /2DE\D(!NO<5-X\[ (P^[3^Y7.K+M4KW5(<RM
MB!:/P]=B4I]4E8GY7@U<(XNR=@3Z2GZC^"HGGW4D-D9F-KW7QD02I>.L-8Y3
MSJ-5%/;T-<1-V%'9N8;H8R?<&SXJ7-0HR?_8L"QE1O;$WRL,Z=$DG&ASCI59
MN)AURW7"\WH_OC93\+S)L,>]Z\:!U/4;GJ9+!6&4N##RM WBWC0A+*W(A=@Q
M(IA\A+@-(J 8#.YTQ.LU:'EPE R27&D'[)Q(_D>VZK+4%OG6:1EQB$N9P>@1
MR(XH[)X)G5@A7+H4^L"@-3< I'5BA<#IK""0 W#7'2!V8H3-RRWO*V*VI0'[
MRR2"J;GJP\[.B=F&UG2EPC(6NM=4YI?402G;):C_N?CM(Q>KQHH_F<DN5B5H
M=*7W2=%^E05((\&*]T#LK> =&7(EO$'C]LJ'DT:C'08^5%V]=FE3XZQA "O<
M ]VRMS @NZS<T<TDUG<6O,_CTO/5S)2EM.Z6>T&W(>$,L'&G*/:'F<<'U#M^
MYC:%P** ,:5&@K;_NEW9+D,ZO+TO6/O8'I^ IRP+2KCC5L<$PF:P5\KPX2Y]
MC[&M'1_X^Z ?QUAYG8RNPS\0L&G&TKBSM)!Y;:(*/Q3[XB_LJ)WA S(L:;E9
M1-6ENGI08,-23Q]3FXM]M#!N2TO[XCA';;U '-EM^9R:>SU$8Y>>UI$#0[T]
M>A1'9:9.Y3D^+/Z&B/Z7PUQMT?$K1<G&>]<6RTG#\V^PZ2=(O88F86#/%5:^
MO=%$W+!.J)?.MX4SYYG$6?AZ]LC%ZV+8J0+; +U^U-/:U,3UC(=6S9,"-"')
MU*Q')_NJ;*8T(RP_]>?/)OA&6K%9SW@+)"IJ2/R9WA^;-3Z:+U1;'K?5!K7F
M&;<W@0W%U/PIKY5QMNJNQ;>$N$CL:!9YR1B6%9WG )]EO[6R/L7WL%9))/+O
M6 ,+_BW6") >@:-9X9'5F1&W8OU5-HW&$L*Z%$W;>GI&BLFL1PCRX0"]^S'L
M33;&H8GMKU[D'&R4CC)O3P6<5+5,/+D\7[3(_;[H^7,3Q+.\.+K(RCT^9EJ5
MI+YTMPKV;'V*PA<2N&@W8>LL^@ZXVIH#+ BQ>>:LN7TQXQU7%3,+L9XYGGG/
M17H-L$XN(38?HG3B3NWE<3PN(L[HT:;&B<UL64MX-YMJEY&O<$;QT**;A(I?
M"K!>O8->].S"FX40C-:90*%S4]%GR\H5?5ZRMM-V=OU0ING<V;ZU[IX[)O>J
M[I>1R(?1D*019HV*@>Q_1L3O#5=>OA%R^[!]I;?=7S\N-9BZ=;]>@B]TYM>#
M-7%0X,B7?GX8,(71W9 \;;'LSD$42Z8!EAKT1>]7F<Q<YLW^"W&CG"I%L.TA
M$G980!Q+U119PWT22<4R1B*%\0]EZP5:#?94C#T2+XO. +/RKZ57;3ME@&J-
MDW'QZI=AH5-R/R8("\M>5SYZR6V+R@Y +(CTED)?#V-@Q&<L%M<H<6PA\A'0
M%R4Z9[B?75S:HGNTLTC;PF[%T_Q&=Y/P6[D?>[[O8*?"FFHQ2/53FCY$W\P!
MQE[/O 9]WR9KEV =.0#E F1P8X$N]H0OF -88%AVUO2IKWBA%DK^6-C7CS85
MGK3\H#SL@49*<;3#A!'"2^,]%=XLZH%9;03I=DK$%JSL(2SM]MPVYE<L]'JX
MZ]9[ SAR]DDA'56S%/2P]DV&<L<'D^+@F+72#<W;8C%W6HN\^K%?<8(-8PO$
M*W2QQX\:+PA9],=\5?WES$]K^$RT5Y]OIH>&!*&<^!%H9VMPS7_909U* J R
MRKT;OF,MTLM&I[-KQ(-T4@0PNL<";GL1ISX)VV)=".ITGIH/:XS19U^=7"^1
M;Y@/W:DX*5OOC$W">W( "?WM(II\]/T)\GH(=BZ%"W$/>,[&/!4/2#BDD-E:
MZ!OD7GNX)T;[7,D07\V43=>53;F5/ $'>':3<Z6?,V-_H@8PD..PV!2L%KH'
M <CN2)XWAC)'?[J -18O.,#H59"*BR?3OH](@]/&W>3%-F27\S-IW\G(V*0;
M7.Q%/G I.:PCW&_8,$=B[5WD0\!':RZ&2;2DOR[#2;#0/6>+@Q(M]J5QE[6'
MLXC>K$?/UCR@=R+!AMS='&!8(QJ<M@M_0\#0I>,IG]T=*Y/FYTN:'Y?B]712
MD#-\\%>P K&D0H4#:*D&Y*P95>T,VE>$0)L:RQRJ'Y:ZAH75BE?Q]S/$? Q.
MY-U?>=GR:;_]JAZUKX(AQ#K%5/ADRK#-/)^DO.^FMZ&%T>/ "37?4P;G>O36
M^1<6QGQE'"$C6G^G1=>;1;\+?W68XK==,1J_\$MN9[#!W()E'Q4^"=[%SLN@
MX##< P<'B6&]!*J5I)8(WQ?J*ND#+(\4RV;S!,'14%1M#$557=Z\]/25%+^[
MD6H::1??/\X)E7,:L%D!HPZ1[B"V.)MZDRUH XY>0- ]%AF!;$&MOXU<&I]I
M+<:J_)-*$AR]B!1#&-JJ!1:^]X!,VP?6Q%Z2]AA!.R U#&WU-(HA@4"Z+Z5_
M9W63+;",G)03\HU"X][6JG^P O^P^OV:!Q;*R\O(X$_C  /]_TG60MCJA20C
MI(*M^E"&^*W$J-S$N=K05PJ7J!U59;3,KW,HM'>;5ULEZ),P.*BOQDS5E]IP
MC@N1--][\[J5\=FX5E(8>2D)=9\#K DE<P!/AVG9.5QF)C\X@< 6<:3FE5%?
MBB ;J6T6-D;;W;8R1@/64D/5<NB2LSPWPJ<U3*H[>3"G M' 4$[G2FZ_ >\^
M-#"R#_RH^LF$\H5GQMK&>5'(''5W'+%)E#5&AW]-5G9UPV?1"=IEN7$**:=Z
M1<!I[?7/RCJ[J:94G#[</E+:G4B3L2[ML*XN3;]",8_HNRQ^O^?=;JG1'@S-
M6GVS>44I[4>R[,+D8#&F$QVP?>E#*)+_>J8\6%(?MRN#8H#"1L\V)JO ALQ"
MGVZ0_"O5) Q5,3S"U"8PF?8$0G?584<HQ"+(BPYZF*D:%UN_\ ,"$D)5=:P?
M&A([KIH7;ZL/GJRJ8]];H?O0YVHC/?F_E4]A5AI[OC&NO'O9UR@2:?A4:A[+
M1SR,X89^--NWV6N!WD5217<\&WL#9OH3;NSOQQ1C8W99YLWA,A <4WV,%8!A
MM&@=39ZI!.=_:B)O3NI;XK_#6SMV-N#4KN F+1PT-2<\IN67"D>B(-1:GPVJ
M^M-DPI%#ZSB3G/D/PZ?B/T4S,O:40^K(,0MT$'<1CG56;B_TQ/7JACS2<'8-
M?6,F>9)?,%I$VF!/,]:G\,:<+63Y1OCAE;#&+O=H#6O=RY\-XN3R$^==+LZW
MWJ/2P\>ON@G+G9@W/3A 1EOZ\]0I:X2[A=W6.M?!-5FQF'IY^[9!V0.M_,]?
M#)2,$P_Z=S^Y\S!5R\P80#\N.<M]B0,DGHX+47FN+4EC>[5/7'(!@ZQM<IAS
M,.VY6(-)S=P6+V;>@E4 $H2DF/*T.ZX&IW0T^N)WOMIU\@*W35KHU IB[BR_
MCM.BWK4*<24GSG1V3DDQYFCJN%1FW7M' W*2@KVCPT#/KW76[,7Y>3T3>L5B
MET,*X1)]K8"V>-SW5/V/L<E!DT:+2FY[,ZVE=ZZ?0GINSX!EDP\\+DFZ5E3&
M;A 1"5\>P!1Z3K@K%Q&FQA9CGV"1W(_>/:8;%2AO66JTL]AITU2!0"RXDW2>
M T0601[P;7>8@:>1]D&Y;^ 6#B!=Z?LJB/155W'7EJH739WR+MF_ '4A?@6A
MR>VTN/D\U"YJW>(\0M?]:O)\BQ[.?1AQU#GB%J3P4X?UN\#:[DHMI%8SX@"A
MNI #4G/5'&&J,*"\541U.]K4?$Y&E2H;K$G6?;IA]0M'6VT5!=MD.("B-PX*
M&8G 3@MA%U^24$CY_>URU0WZ688'2Y5:2WZO.5X<5)K\<3R.EO/L.Z'*M,(4
ML0<G6H[ZXL$$)'OR'$06UM^!+$QNGYOJT]_-W"^??Q[/,AO7'7R0[=L,3281
M=OZ^=)AZ@%U$['++3;>F.# 1%BJE7.9I[CC-OAD5!RM64#(9W"CF3$&U&RUS
M_N-^='/PF*4RST?M^W='8BT<042H7IM/=8X-YQM8*I]DU R:8<4R"HG!S0&H
M+:8L@X!:[ J"L1I2*]5A\9$^;$\=E@19@[]W0#'RS_/DLICM+1++ %^+^QME
M*CA:D"$GA^U-V2;YLZ"&3-G*?AP223]%7X2EG"P%B4T#58XL6ZZ5O=A<A>;R
M#4+LW"BJ?H]E'(YV]J&E=)\S^\FP[W:*^'B&;4#/'"ZOAKR?* XUKX5 \E39
M2BN*#VES4:&"KY#V[,%7/%P)7(H_YS[FL= 2P@][.TVZ[KV3;&K.2_AN\#:D
MT_K$H>(7[#>@V\.X6%@'E/;:LKX6N/SED9F/DI^]<*QI=Q52/T2Z0W.DM2$2
M[C@.),A!B;I?6\3.'SL=O#U234FSWOT*K\D\J4=[>L 8MV]5(BFNF0S=4(\%
MIX_X<  "N#K3C$#0:GHQ)M.EQ/!93NLJJ>NPZE)<>F8R%18$J1B&:!\X0H(_
MGWL("T:.K4PQ_;[ZQZVZ]AK,K8Q%Z1U/8W4BZ>+N%>B]F4YK85]]1K86K/US
MADP[C3NL,*MX0/Q;VWW? +;/"M^36"L]%\B]&J29&Z!J8*WV5>:(U'EO#:\R
MX9MK)RGB*<HF@^0#^M?V1+"+5DV[#&5F'^S+'8JF#]<]_97=Z_])5C$G>I)L
M'+@I_HV?M.3[*S%W=?4U%!0-YI:6QY)KU:-#NI^-B7(S:WH.][<$*W2OM[V[
M>/]%^HNRX=:R4P^DY#P)SNJ,;X8E36O%3%6618(YX@3"K_@6U_U9K_!]V#%B
M)P= [UP+C4+2V)DL]SH5$H*!(FR@M,\$X5?N,,_)D??DKS7D):79'?!&SMEW
M5/0%AL-[L'8/ZS0'R)(\R^IAJ8*4)\2=)%9CZAV&5(Y5AK;QK1W$9E"" TR?
MZ.(?XU]ZJ3M/IN\,@63.LHK9JES4+H<B\GP#?:L_LO3^%\3;R-*[65H.7P,Y
M0(K,[WL62\BF"[4C]XPRSGZ'',D9$<@/BB(O*WE[P-Q@S=.1XLROAX:<X<T6
MYA<8&%K.V4-#BK^$8ZY]L[?S+1/G+A_?.M="_$P0Z/+;35=_W.\[KB&L!2?O
MY;UX]2K%B:Q5N9.ISCI9WOT\%<,[NSE1[=V5HX<WAV3F$I^S9"!\81 1;G4F
MEW?Y1C_!*S "?WX)LC=_=?ZUX2*0JA=8OO&Y.\ZGHC1V22;*\VM\&:_S(^._
M0EH1'"$X)RFWLWWAIB+Y$^EX=JE_1=0-_6#R%2Q?L0=3K:?(;&D:WX=40RN"
MB-V0CWV.B,HXF;R@'-3#TN(/ Z>EO,&%^\^)S54B2.RR(+$94O,E5M_$ [3J
MD8B63) %)Z40NR4B^Z2YCI!+7C5E!Y NM9;*K>7$HS),D:A3>R!(%[XC/;+^
M*YY\>9'O+0=X9%?. 3X$SG?93,@<T7>&Y?#5.;";/4*1",MY_!;EPQ]17D?I
MG0W0JD,6>D*00Z+6,SQSW8P#B+P;_=%O]PIA<?'SRRB7>+$K03G$IBI1OU0[
M$IO^FZ!@=)'!.P".<']^'Z6GA/7:\17AD410T$K7',"L_B@\1_R>L?EMN9FD
M^6U-A0AQH34UE7&C']\+4;7='T7+(_JXU:+='+A+/;-+M/[E2MZO?=#FU7.^
M#9]>5%-,6-OOYV#WSI6<9MRON*9,8T"K"?>+-&'ZF#R(^S-LMD3>QZF"Y>0D
MPRA[K@PG\#K1-N,4Z ]NM[8ROOWP6QP<3&(OJ1(09%6.54N(NF"B=/;:9E6&
MS8SG<^XHE?_QCN+T_0=02P,$%     @ 3H)A5'CN'?'C7 $ 'JT. !4   !B
M;F=O+3(P,C$Q,C,Q7VQA8BYX;6S<O7MOY#B6)_K_?@K>GHM%%6!6Z4%)9,_.
M+)RO7F.RRHG,K*Y=%"X"?-J:#H?<4H0S/9_^DGK$P_$B%92LV@:ZTIF6Q'-^
ME'X\/#R/__$_OS_,P9,LJ[Q8_-M?PI^"OP"YX(7(%W?_]I??OGZ ^"__\]__
MVW_['_\/A/_[S>>/X%W!5P]RL01O2TF74H!O^?(>_"YD]0^@RN(!_%Z4_\B?
M*(3_7M_TMGA\+O.[^R6(@BAZ^=ORKS(6+)4BA)@A"1&+(D@XPA!'(8HRDL8I
MIE=W?XWB4,1$(ACQ(( HBE-]6<!ABKBB.-,/$;Q^Z#Q?_..OYC^,5A)HY195
M_==_^\O]<OGXUY]__O;MVT_?63G_J2CO?HZ"(/ZYN_HO[>7?]Z[_%M=7AX20
MG^O?KB^M\D,7ZL>&/__O7SY^X??R@<)\42WI@IL!JORO5?V/'PM.ES7F9^4"
M1Z\P?X/=9=#\$PPC&(<_?:_$7_[]OP'0P%$6<_E9*F#^_.WSS=$AR<_FBI\7
M\L[,["=9YH7XLJ3E\B-E<JZEKY^V?'Z4__:7*G]XG,ONW^Y+J0X_=EZ6.T\U
M4A(C99@:*?_EV& _7R"^)WF7^[)Z$*Y6]U=?,I["]%=OXG[5_""'%WAKF(M%
M;EZH]PLQUKN['NIBT8>7V-=K42SI?(378C/,ELAS\P\?]4_M,.9!)\BT'J>E
M[BU1Y?>E7 C9L.7.HT$N_NTO^J<96]P5L^O5\KXH\_^2XD-1?E@M5Z7\LBSX
M/ZZ_T5)4MX^&RO]6TL6RNBW?:^V+9]E<\&E5\GO-SI_*XJZD#[_(!R;+690J
MAA5G,..<0I0@"IDB,4QY'/,L8%D2Q+/E^G.8R07\[4LG>2W>8++]Q0'/Y1%>
M*&55Z&=O5M2'^:%E4J^09DW%/R_H@ZP>:7N#5M 8'XW._[[1#JBB!*K6#U1&
M?D!K#:] 4>L([FHE]5]+(%L]VPL?6TW!8Z/J__AY@^2X,S^?\GS.1YM*K1EH
M5 .UZ*!1#C3:@48]<%N"3L'VLDY%T.H(_FBT_/]>;T9%:Q'7YMQ49W9'R#_9
MQ_K3T;DM^(XF<V-3%^5+] L^)/K-\F8&T,M7%(918W[_RQ!#_KSW9E^7'02T
MY&=>A/:*GWFA]R*/2[CSM9N]V^!8+8O!/X;F3="J_D6_64*6>D][ +8U(:PJ
M>$?IXTP_BTLIJ@\:AM]I:89]_UV6/*]D-2,T(X(2HK>GYC\1EY!@EL(H9I(&
M"4M8$-FLUC:#36WY[61M-O??&FD!78CN.Y:=Y'8,; 7XZ472-XP#KWJ["+:"
M@O=G8;,F-Q<\-L9XI56IP5"T8K4V[7-^-C3VLYPOJ^Y?:F*#0=AZ%O[%:L!1
MN,I%]8Y\G.[IQR9?5H]Z U2OM_.WM+K_,"^^W2STBOA0K[_7K%J6E"]G+ DI
M8T$,>9R&$ F.(8W3&&9!0JB(,!8H<R$6RW&GQC';8@.15WQ>5,9N*!3@6@N@
MM!H@W^CAQC2VDV%'.@- /##_[*!K1 9&9K E-/BC$_NX&>W,1HY >24FV[%'
MY2A'0%[2E>OM;LQ5E<O9K_HENE6_T/\LRK<K;8H_R/)=\4#SQ0Q'* D(22'.
M,(=(A@(2E(0P2@2-,B+#.*4V/'5RE*FQ4B<=^*.1SW*+>1K)TR3C#9^!*<4>
M&FO:L%+]%$GH!VP1A/[;2W(X/<(H5&"E9/?AVUWL]IDW&R_.RY44-XLG329%
M^?QV59;ZIUG$0J%BE&K,L(*((@5)J&(8*!5)'"51E%A9(Z<&F=I'_K>BT)9Y
M*;G,GZ0 BV*I#8VG(N=2N'B4CB!JX^R['*>AO7:-A& MXA5HA?2 D(OS['*D
MQO*"N2/FZ,DZ#<5IE]21>T?T+9V6?M=)=.;:?ONS][1<Y(N[ZI,LO]S34GXJ
MYCE__BJ_+]]H*?\Q2VB*$QHKF&%F]F59#*D0"/(@HC%!/.'*R>%S9KRID>*O
M<@D^%E4%M+R@%MAMQW4.7KN=ED?0!F;(3M(-7E>@D1;\T?YIQ :UW!ZW6)8(
M>=U:G1MSU"V5)0 OMU*VM_4CEY:BONA51EXOA GTF7^EW]]_?Y2+2KZ1"ZGR
MY8QE >(DC* *%88(2P8921 4>E]%B4(BX4ZN'ZM1IT8TM;2U,]F\[',WEK'#
MV8YKO*,W^ :LEA=L *Q%!EIFT H-?FC%_M$?X3C!Y)5V[$8>E7R<P'A)06XW
M]_1"&VY[0RLIWA8/YKF-H\AXNN]J1]*;Y\TEG^BS^:?Z\.W]/U?Y\OEF42W+
MVERN;I?WLOQZ3Q?-J5SU=UDMC5'61#[-@B@@BLH(AI)*J&DMAIAG$E*EMY,A
MC8A*V6POQNN\JW4D^:V^:[N .)_?^&<YET8S\$.^ )51M#K^*;_N"V#I.I_2
M?([D>S?Z0%9/X[;28$MKP)[!]G6MYDU$S!5HE =;VH-:?;#4^K?Q,M45:"
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MG=PA6#QFO*V!O4X[>P*'VUZG)%+7QWM=;^.K";6[62S+?%'EO+$0$YQ@0DD
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MU;89DHD(4(H(#*0V#A&C#%*5<D@)%A11$21AY.)5?CG U%S*M7S 7.%& 7O
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M%*JBA$;5NJ)_(SPPTE^M\_WT;^8UR[55H;YHJTE;]>MTP'<U<3:S7T?(:V!
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MTO:LE!S2"!%(I;9T>1;I_UO9LX[C3HTE=F)8.]FO0"<]6(OOG&9E-0NGF61
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MC<RP%AILI&[*;U07-)ZSF@$[HO6-Z\ TZ@/2/O5+K#'R7<CD_,!C5S2QAN)
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MWBLZO=85U,KN%GSL%!Z@"?- 4S),!V??PKY.^^>!(#_:.WJH\7H<,+W)"].
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M_W!3,^\;:1L3?]>V<@O(1F+[!F^&P)MYT_[@'-BV;Y'\K4&RD378"NN54<$
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MGP=[4 E&I-0> \E]=NY11G3; OV^T!U8GA;:T7DD/]^+A9#%JIHEB.<XR4,
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MZ5Y-VC<=9H[/ " /;%P.ZD>_=W JL1OFQ[M@5_)A"D<-H!JL8K1O[)N5BAH
MTE<C:G*[XP9N/E_^I<?YO"P_+M=T)=?S-N94?1=,%*\Z6[HCL YCY<# &(*4
MZ*)W9<\ 3:4$:9@E.:-Q0IA=LTB;T2=GR3KAZ]1.WHH?D%9^RWV;U3S$7*0H
M2S$@G%, 8_51()AD(&<2,1D)&$6XZQITJYG8[R T\%S\4I\>W&Y"#+?10[WN
MPV^B:QF#K9!J%=E#^T,I>+$*] 9K"/9W%^#\;J"M)!AW^^P"SM'FV>DA#NW7
M/\R54_<@_R Z<63U4-9+VZ>?HF1%);Z5!1.;/U;M7ZOOR_E<R:6326:4,L91
MA$&2Y!& A&% 1<X!1T+&(D]X'!GMKWT(,[45J<N? 9O4LTZ7H%;&HG'YM=/4
M;Q#'!G_H(P^M2? @@U;<X*%L'.^[@PG8N:;:7%0%?VJU@E8OP[)-+[-DT8=^
MQ-D:J6']2+-FU^7>$\S-VJ>?6"]H4=PN9U[&&&5U\XE&M]AY?:;;?NO+XE6]
MV<OR[8^R6(F/R[\6LRB2E%&F%K-0Q.I_U(J&*85 4IRF*8="AIG-INIXB*FM
M4QL)@^+YA13E<Y^S: JCF0M^'3@#KR-;7&KI %?B^7.BSZONU5,^,<RH[O!Y
M-0]]WIXKO;5$TG1>\V6U+L4V[XS*$&<IX2"D60Y@QG2'HS0'41XKYY9PJ+M#
M7M?7Z,2P4S,"=2>0ADSV^N9$IV V,PC^P1O82)QJ$Q1L10[^'":WSPJFH3OU
MG!KZUNUV>N PZ)G3=[>;,?HNJI7R9M1VL*9(;5/O*4L%IF$,)(MTNYN4 ,)I
M"L(T)8+&!"([VW-RE*F9FJV0#3NOG;DY#:29=;D:GH&-R2$R Y0K]$+@U5"<
M'FE4N]"K[*$9Z+_8(;;VB[(JY$DLVE<TCA,F\D@"A&FB6R;$@#(H@, D% DF
M#.9&Q%DGGCVU+[R3SB)V<@"60<#*'8*!O^).L,M?[T48+")"[G",%."Y^%+8
MA69.Z]L;:3FX9;S R6E9]^(@9R[QT1RK^KQ>*4_FUV)1/*^?VUK0ZN-:?%D\
M*KS$?PI25C,"0T@EYP!S 95Y(@E 2# @HE!&28XRGE@5&#C(,#4SIMZ@Y)HN
M3V; F[DN \,YL$D\Z Y5W06- D&K05?FK_Z@E B*15"K$=1Z#-5 R@K$ 9M+
MF<EQP\935D#U-Z6R>Y1]+O 7)LO[-2_4>W"_6BF/KE[4/L_)TXRBC HA<K7#
MD@3 2%! 4P9!&!(B"4IPA(RX^OJ'F9H-^_+A\_>@%378D370PIHG O?@VF^_
M_*$U=+37"2BK+.#+.#@G ?<\>K0<X,OJ[:8 &USM2%?&?@B^GHL'>9H H][=
MM5P7FL:B(<[0+8^;WSW6A*2;N&5*8 PAYH"+$.DF6"E /&(@IF%".>.198V4
M7_&F9FXZ[70N\2;_H4M_V-%"+_'OYX3]5P#4+4JZJB7OJ<]XM:/PZY(+RT;(
MGF?>S#&[W7P.;!!WI[*'D:D)5&V8ES8J[LWVG[66P]2Y#S,!?JF3_(HX+@G2
M(/ >T1D-,XK;"O*M7#(A>/59@5$S5"]T%L)'05<S$4(H4Y@!(3)=AI\D@$9J
M<=#-Z2.:\)CD5JO!^:&F9ME_69)%\-**JWF51?':TTK/%E@S8^L'KH$-9R=D
MH#^FH!-3FU$MJ#_#=QD,KT:L9[A1#=)EM0^-B\$=#N']VB0U1/8?UZ6F!*DY
M-6MFM"YCJ4MDXC-$!<RH;IZ*$MUK)^4 $\E &C*"&<F2)#?:?=H//35#4LO=
M-%FM<]7_:O/]1"NP8?J!PQP8'"H,ANS0SEH-9]LBHY&\93K?]#[=Y$QNY!\,
M:(MCB\$ '^E4PR_P=D<@3MCUGI#8/7&\ Q0G3??.5]R>X*NBXH!*\[O0K4Z4
M$)K\I21LM2;S1U$^UQ2;@G]9-,(=9[[.<B)$3G@$J$"A\C\A BC.,<AB+-5<
MAAQA?%V]A2]1I[;LM )?F\[O;28-%J/)S,_ BU=/ZO]Q#<U&X6!'XT"K'+0Z
M!U\679>/DZ4"DWD%KJWWN,6K</MJD%%?"0_E(KYGR;Z8Q)L$-RXU\8WDY4(4
M[R,ZT@(L5@4OYNM5\2I^$TSY+ZM"5%_5]],V <Q#F$C!$\UF0@#,>0XP@Q+P
M5$+.,BB3A%@Q 5P8<&J+^ZZ\P5;@NT"+[-B!\2+H9B$KGU .O Y?B:)]';DA
M-'Y+QR\-.FZUN"$$1P7BIO<Y-JD74I2ET(VDE 5<-'1MC^1GVVOVO5@(6:QF
M/$E8F JD=B.I3JG(&" QS0 BH<@ARDE*C78C=L-.S?BTTEIVI#=#V,S&^,=M
M8$O3"1RT$G?$CTKFH!4Z>->*[;'%M!U.?EO5FPT];L-Z*SB.VM;;W>T281>K
MU;QN9O(@N\ZQ#PL=M_^J%"35CUG"<X8IDB#6_;Q@E-<Y]13(F,<HP1DB<=0Q
M[SR:!M<OC6KT'>WS[3R.D7JQD5L?-15=V^3E(N!]QTXNL)L$TKV@.%+P? ^Y
M+SO(:7GK;E):8J\0VH3(?4(Y5EC\2D@M ^&F"/4'OR\^9<2 MZE&^T%NX[OL
M,VO;7#WM8LYPR.(0Y@@P)C6KKH@!H4D(4D9H1-,\EUEBFDJ[\]RI.79=-JB6
MS3Q5=A>H?D-YA?I#[P1--+?*?3VAIW.RZ^ZS1LMN/:' ;CKKJ3_;?V0?EJ^B
MO*=5'5PR>'OVKI_0^U/+%?S92>8A9G!66^>W:/]IH[U')Y78?9-.7^#:4::J
MFTRT/GDUDW&"HY0PP"%1#G,896K'+C.0I3GD*&09)F*VTIVFS7;LAP-8F?#-
M,,.]B'73[&"Y*3\2K9RVS6(.8#3;EE\#SN ?:-4VA/ET"1&'7C"GU?;< .9@
MD)&[OIQ6\;C5RYGK'$L;E-M>NW?M846=U'#_LZAFD#.6$/4AJ^VP^JXQ%H!@
M% ,69TF4$Q3*S*IZ\^Q(4_/1FH-"G:+>$"9H&2T#_>=1-?O,O6 U]/=N!9-]
M#OXE"/RFTY\=;=S,^$M*'R6Y7[SA.J*K70ZG;^7R\[)\)E_%:MML9<9QB A.
M8Y"3C /(1 1HPA"@*$TQ8R)'L73ANKHX\M3,ANXL9-_.R1QH,\LQ"'P#6Y(-
MX=6.T'>!DCJHQ:Y[-NVU<?+/>F4,UR#$5Y='OPGWE3$HY^BOS!_@$,K_)*5@
MJTWGIT?R\[NRA=^%5K*8%W4T\M-/IL10UWQZ?IDOWX1.MU@O1-,9^/Y9DU_/
MHA!QP:$ &"81@)IT'T,)02[3D")*22J,&O;Z%&IJMNTWK=1R$419_.[9L"VF
MUTDR.!ZX ?0#V\6-1KMGF5JI8%\K36?<ZA5TB@6[FM4=8=:F%*Q>)\[B4.(&
M$SC2T<5X$VEWR.$9\=ZC$%]CC7=@XAF=O6,5W\]VC.61ZH?N%ZO^\TFMU*]D
MKJE3#KNH"Y@0'@FU+&+=D"%!$&"28 !1*DF<I9!"JTQ HU&GM@)J:9MNQ_J'
M';DMPWY&B!O& GWC.'3 X!R$XS2OMX++;V#1:.1QHXTV8!R%(*UN=C1-IW*G
M']:K:J7>H&+Q-(L0UKVP,L##4(<GHQ00BC.0AU$,11Y+&J:SESIY^K<5*5>&
MMNG"L#:?T^'@PWU9.P(&9!7\?V2Q)N5;$-T%<1CAX%VE"1!ZMLUN,R"R/$US
M3@'#H28N8!1@+C7[*%?_)],DPUD[ Y\6AEW*_./?#3T:^A\%JPD7@V1@_ U7
M"8^(CA51[BITEIL*G1V!/:X(AM#X70PN#3KN.F (P=$28'J?F_77W?Z$V.?Y
M^Z4@5+G&J[??U0A5W;A,\,9';O>:)"($QS $!*820((XP%$N !.Q3/*0)AQF
M%JF;5PEC]%F-G]&I=?EWW91EK4O8NHQ..\/D-CEFUFHXK$<B:J[E5_9JGYWT
M+M@H<1?LJM%N^+UMZ[W@Z-7>N4DRJA&\"JQ#RWC=PQSBX%\6B^4K6:TK3:=T
M_U2*^CRP9?O&$24B3"&0$5%[=Y@D .4T!CE,XUQ(M747YAPQ?2--;;^^D37X
MY;=[B[AG+YH&46A?& ULIW;@T21<&T%=".9[(;.(__J";J2@KCN$=D%:$UAZ
M(Z^]#Q@OG&JBQUZ,U.@&.X-9K5[*V8?[&642(BAUM !" ".U;-&(,<#B5(I8
M**\Q,@IIML^;FO'[0.:%7):+@IA]QATL_?;-0=FA-XSWOWSY_/#]ZY?S%M[X
M6SO0KB<'6%_9^#_ZI_J#JS^V[@FC?%('XG8?SN&O77M8MH<2]^O5CV6I')<Z
M=XU(SIA$,2 11P"F3.K64ASDC*4AI"S/0Z-V,_W#3.UCVCFRV\CIE!1X!E6S
MC='U6 WN4=C#Y-#AL@\%SUTN3PXU<J?+/G6/NUWV7NUF"CX7"\UMN;^-V6FR
M<"_5-ZA;+'PN7L4LC'!(11*#C N]W9 ,8,83D/.(QBS-4Q@9;3><1I^:X7C\
M(4I!M(1V=L(.<C/S,1B0 UN55NX34935,J B^$8*?A?4(->=70(MOS][XP2;
M5S-D)\&HULD)G$.CY?80E]9Y=5QF=[A[]776/_ 9YPF/PYP (3 #D(084)T(
M*..08$3#,(U3\T9Z/2--S49UW]>\^;Z($K3Y.7A7+(+J'X'L(<NP!-D@>N(+
MNI&BO ?62<O:_&S#"=G_8EITZ_.$W5B]^]PQM.SJ9X!+?X^_O@>,V/'/0(_]
M_G\F-[BV,Q O:N5M:]#N%_QAI9R=>S7>JOJP+DOU^LQ"D<HP9110G"N;BF(!
M2)IA0&0>QAA&(616NT6#,:=F75N1-R6B=?;34HL=L$;B@-3RV_8\N(Q^C#A,
M$NUZLY0"&'.%/A$"Q!%#4A\]2I;:5.7Z1G^L0EW_R)HYW)[Q&GA!ZU[4CBA+
MOZ>UP$$C\5W0RNRSU80Q0)Y[3EP>=^3F$\9 ''>A,+_5<?M/BK(F-&\>^JM:
M/-:EX ^+[YHA4).>OR=54?V^6-)*E*^Z9<Z7Q<MZM9_)O,UL19B&&8\08$F:
M 1@Q A!&$8A@1N,$\3C/C!SM@>2;V@*BU>LX_QL-@TY%37RT43*HM=2I!5L]
M@UK1@PH#RTB$Y]DWC%7<;DZ'CF;XGLY!NZ -- ]^PR.>91PW@#(,P$<AEH&&
MN2:@7)#YET6U*NN=9GT,PA'$H> YD#&DNEDX!HB1'(2ZPVXF<YAE5MN%,^-,
MSL)W8@9;.9U.E\[A:A,?O@JM42+!=D YQGO/PC! 9/=XK!O$<,\J?#I:>_YR
M;V03NJYD]=81#E9-EYV'LFZUINS3U[5. FD[.[9_G0G"LRCF!- PB@"DD $:
M*^BQI%D2PB1,>'0E$X6#6%,S.(V,.LN^J4H(BJ;1U+(,U+^4_5<_ZQYJ1==D
ML X$NQ0P>)I6)BC'"46 Y[G:,F1"+0PT82!/PYB*%-*8I[-74=+E="=V5[SA
MIK:13D\M6SX_*^^PZ8C73C"IU*\75<';"M*;3ZS9RC3^9 V\D)UF.VETVM+:
M?ME\E9U:=\'VTVU4&Y0&Y0J0A^9(<1'MU@0J5\!IP*YRS=,=^\<P5JJG=$>V
MA=C$1R.(8)3*%&#*H7+D]0D 9RG(L<"Y<N0%)%8=',Z.-+65M174D1#R/*!Y
M3O(8AQCD5"?51#D". VI^E8@C$E&HY1$-J%\/X!.,X!_'D6SU<8+-@,O(-U[
MMB/D /'YBTCX;:%S=K1Q>^=<4OJH:<[%&]S,ZW?Q*A9KH=M+=XW!_BA6/SZL
ME4OW+,I//]E\K>LL=4A'_1]_)#]GRDCD$BH[D2J0 11$F6"8AT RB2,>AU3]
MR\;P.L@P-9/<</66C2)VEL1E!LQLS,"X#FQ]6NF;3O2=_,%?2H&@TZ"F,6IT
M"#HE=&*P/^-T!81>S9:+'*,:M"N .C1UUSSJNI9A.J6Y#EVK'[K?M6>>'Y;/
M^K\-)=*"MQV"JMK1?:\3778OT-3),ZG\)Y8+#AC1WE2,,X )@4!RRG$L4TI2
M[M)@S*>04S.C-:LLH%I4'5K8R.K6G\SK=)J9W%M/TL V>=/[K*Z^:#,V],^;
M/[1**C]Q1XLZS:-3]*X)*K2SO'>9UM9_Q[0AYF*0_FI>!;U)-[8AH#[7NVV0
ML1SRO76+HNTIA>Z L2"+U1^D>!7E9R%F,@YQ"G,=1V9,><M0K0,9E !%-$8Y
MY3S!1N>-)H--S9XW@@52&/K$1H#V6V+?, UN4>EJYZ!1V\U&V+N@!>^S5_ L
M\KP]@CA2JO=U8-IE>QNBTYOP?>D9X^5\&VJSE_9M>H_'>L"SI#\4AR@2.01$
M( @@# 5 <0I!AG,I61JE!$$'1B8K(8P^B']-)B:[R;#)!/&)[:TK!<?@6W)"
M;?A"P6GP*SF!8U0HZ)E/J9?=;G.(MNF-_H',YX*_?_M$V(_]:V<QSU#.\AR0
M6&  I<P X1$!(<LRC$*NO$RKYDE72S0U%W0G#64C?<!J\0/Z%@BE0/!72P/I
MD3_3:A+-#.:H4S.P$>UAX-Q)/MA.V(?-A&FUCNX:F*K3!>3AN3RMI+H]V:<+
MB$9LH$X/=N6K44ZN>H'>U")15#\$__MRR:NO8O4@OS<Y;=4,98+Q+ L!9AD"
M$",)"*58)Y2E!+.48VG5I\I@S*G9W$[2X$F+:DM><QEB,WOI&;B!+>)&VKI2
MN8&O%OBN;DNES&$GM$^6&V.$/%/>7!YW9/X;8R".R7#,;W5T$IN#_@WK3AOD
M;*.:^HBL6*R+Q5-+!;I<5)LNS!G%$<J3$+ 8A0#&80(0@Q306&1)$O-08#OO
MT%F4J9FH5I-_MW3UW*?"T,<;!>"AG;NVY'R'J:NK]WW7:O*WNV"K3+#5QFO?
M;7^@^G7FW,49UXN[&K8C]^WZ)[J9T*ZQ47V^_/"B']W2QH8Q@GDJ0Y D"0,P
MC]7^&8L,T) G,HIAED)H8R'/CC0U ]C(9F?^SL-H9MV\@#.P\=H]G&[IH8)[
MO85X$LV90B.W1_)=8W2\6J'SHXUJ9"XJ?6A#+M_@[0SW5_*S>%X_?R@%5]:)
ME/S+@JL+!==)\;.()!%)<[6[B_4^+\*Z'W$6 Y'E.)$"B3"/KSS7[15@:@:E
M%39@M;0!4^(&Q8Z\5Q]B]D^'\ZFP-Y!O=U+<0=_H$&@E@B_C07_UF;*W*;C]
M.;/S5/@X?3;"T>%$NO^YMSZE-M+:X.3:[#D.JTO',OEY67XKE\JW7;W=+[@N
MI7K1OY_Q..21Y *(E"0 4I0H'S1/080T$;9N@1G1[O#:8"VY,)S#,?7 *\<W
M]: ?I&HJ2E]:D>N<0=$);6'!+J%ML%#X0' D/JU6TKJ2^MLN=)\&@,["T'N$
M<"2C?@V4=L;;$)M>0WWI&>,994-M]@RPZ3UVQI:+8O:Q?5F^+-0T/C>$,KHR
M=99#F<L$JXU^FB/=7#A71E:W\90LH@1!)G-FXJ[W#3(UE[R3,]@1M&5R,B1]
MZ86TWY+Z FIHM]H%(^/OW02$G@X@ZO9Z1_\/J'\$S8^U$>A]\"@?OXEJW4=O
M=*UC:*^N2-^$V1G*8Q)R!A):=PZ/$X!1'((\XRE+(,IP:'7ZNO_XJ7W@+9F#
M0=#<!#O#()XS(@-_R>9@V(?F3NKL-QZW/\2X0;B3ZAU%WDY?=27?Y_NWS8__
MNQ"E>M"/MU_$J])7DXK%1,2(( )DJKYD**#:&A&4@32.:!)BA"0Q6K7MAIW:
M9[ZE<PPVPM:>Z=?[_^/&X6:&OIE!\(_IP(;B&CC=R2V-T!F&L[)_Z-M041K!
M<99ATNQN-]/4\E8VOLK+>O6H'O-Q^4R*Q2R+":498R"M<[M"HIG?! ,<,\SC
M6(0)2VS,T?FAIF:"=B1M"6*UK'96IP=8,TOC!ZZ!K<MII((_&T$]6I;+:'BU
M)CW#C6I!+JM]:#4,[G!-!VV*:;X+)HJ:S[8C 4IYGB&><R!2I/R6!&* ,@8!
MSO)$Y(C&J<SLDD#/C#0U.['AE2LWDMKF?Y[#U,Q&>$%J8!.Q 6DKY #$2A>1
M\)S3>6ZTD3,Y+RA]G+]YZ0:'$Y^O2EA2_>B>W>8YS2*8912E"9 HRY7[H#P'
MDH4($)S%'.&0Y,2\%/ST&%.S!TI*H,7<%!YVK'46QQ)GT#0XR+D>HX$M02O@
MEH[SDR]T+,YJKD=II",::[3LSF7Z<>@]CCESZWBG,/VR[QV^7+C4S15J4S87
M3[\LJ^H#*<LWN2S_(B6OFK,"&F4PQ%AW/L<<P#2/ 64( PD%2R.19'%BU8_E
MPGA3,X,;<0,M;[ GL-V)C"G@9MZ21Q@'MI17(6CM.QGBXM6#NC3FJ'Z4(0"'
MWI3I;</TB-[T*N:IC'":$9 F- *016K[A20&C!(LTSQ)$Y<>'Y<'GIK946]:
MYK<GM.=VT/^RG:!OT /ZINV?I]GY^=JFSU?V>]Y2DM'5MOKX_I44<VWM/B_+
MWXC:3S9U+<MU]?NB%&1>_%-P;1Z_+1M.=4W0\OB#+*+X5W7ECVK&8(HE(A)0
MF:8 9CP"2" &XD0D5"0"RCAU(+/Q*Z71%WL;MIM@I>0,HN!-S:XM<Z37B32S
MD3>8EQ$SUK>:W04;W8#R"D!%ZK#71K]@JV#CXW4J*B.\G=4X:/3TR1,Y!/Z>
M&2*]BC@R-^00\!ZS0@XRBCM-1+5ZWI0Z=EOM6<2B/(=8@A@EL>Y*F@(B4P9R
M&(:(A+E$*;+EAC@UT-3\T$W IJC%M&>$.(FFZ8' ]1@-?A[0B=C63-]M0EQ^
MR1[Z</#.\'!RL-%I'?I4/L7ET'N](X%#W22K+EALRV498Q0SF("4,IV,' F
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M7!%H^8<)]IO#-EC(WT"$FP7^S>'I"_];/.7*#(BM89TIY"&B6( XD\IV\5P
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M"VH>_UK.$HE%0C3)@52;>IA#!@B$'$@82DY2*7)D96><I)B:^5$O8&)]8N\
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M9/!.-&+:6M +*)L92'_(#6S_&LAV)0V^M/BUPIZ'S[X]H!$J?ML#]@\Y;GM
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MV<2C)'UM^GA%Z5^@-6HU^EWKKY]+W0>*;_WYER\8$"3TOC)._:E:.9961;C
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M>FLG$/O)KL)XXD>:XW2[&^%.KC-C7R[WQ_#=@*VO78IRX\,-L$Z:WV[ L]J
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MD(I[+NS/HEN6,D\T+J"T^R-L8PE((3D4"'/,2)F6V$NK_2IL1R31G9T6VH"
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M\RKBX]#FU+AZSTZP-=1+"<D'<#>.#0QC9/H<A*!_H7=W3,)6>'=H=]S2[NY
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M7*@O:EUG;\\DU4F>92DL>69K\-(44BH*2'@B$Y8F)2[\:.5,0U/CD]HXFQ
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M)[8^G$X@$3F'6!1%PBVQ9\R'OB^V.#5.WA8>W[/X!G0V@S\:JST/KB[C[L;
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M0)1YWO->1CSQV'B$=][F S[K^9@?74DUG[UK^[@Y1WB_E._8QA870"1!MJX
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MZ-_GR_GCT^/76M&R;:+ZL%K?_5!K9E7PZAI=U5$H=VJVE*G*!50$F_UEFM@
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M" E^;\4<T7*YAL2XCI67.IO6=_**RB?ND=>>GRX1R9>M-J^^RO;OU8(2@:A
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M4D9"J"QJS!.)LI#%CI4!G85PF933U <T8H*UD1.(1LX;;DT&# R/4T*(2*!
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M-,V&BU!Q6RS#&":8*M+C>0II%B4PC>-(,%V+3EB=\??V,C=JJP4%C8AW[0_
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MAD3"(4U3JDB5*7IE2,"$QV&<RIA@[E96<2Z:S8VUOXFE,!'..A\A7R^7M*R
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M<R,M?5H/EFNZ K*1'- ?M%CJH"[7<V:'(; ]@?8#K/>SZ96)<JP%!ZWDNMR
MD1WLA >M]&,>7;MC-O*AMH, $Q]WNT-S>A ^H(UAG/:W]4JHMLM_BLVG[8JW
M>;$(QF%,([5M#F(,4:"V<SD37),9$GF4L9PZQ;&=[V9N/&6D!+68P,CIQDX7
MP+3CH=LA\LPXI^AX."/O1V%4#KG0U:1LT:_N,2]<>7H8 [2;N??KYUQ94?I$
MZ)M@ZZ>5CK3]S)4%5<B"[NJ<-%M '7S;N:^[KU/+ZG./)LW,#[K4>\9%E.
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MJW,C3GU<7E2;0N>*^)O";ELVEQ-:6,N+FD/8^IEQ,!@37,L,P,%ZSI[5N\]
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MN3%](VY3_F[9"GP'5L*DAF_3C+RLR[J0<RF65,^=%UIN7MV.LZX-A=T)U(@
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MA2Z.E^6Z/@ZGD&)"($]IG+"4Q(ET.NAQZ'MNA-"(#HSLH"N\&RNXP&]'%YY
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MX_OI[*=ON%Q-%_-_^QO_._O;3SA/BSR=?_ZWO_WVZ0VXO_V/?_]O_^U?_R^
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M;)&N_=*LRG9Q\2]G(>*L^^XDXW32?>J+N%HO0UI/A#6Q\))!IRA!:1*AY[9
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MI$@;QU$S#$$4SUG8%5GUT#M_!W7'-F1^L5J1<"]X95)J0GD"J64$Y66!(+,
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MF7P_F1%0)BR>+&_2K>J>'J9N6%>\9T#<GEO>KW9&A+AS1X\GK@4G^7@,@OP
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M,-U=O'73E/+DK/$I@?&V]BBG4S8:YL$QB\)B+>QJ$\/N1=ZPE[2-(-:_8D:
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M-@T#OFZ["+SMKM&FW_#]+%R4,"F,1M8WO)I[62MI*:9FGH&4.KB,3)M&H#R
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M6(MKZQB]7"1$4:KS8T71VB;&&QW3S2X7CWX NSDRK516)8;@6*@VPY)0/(O
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M)1G;YLI^0$HGN)L4(<LQU=4!WOZ^7.#WRS2*-Q>+?,6%4X5$P)'VKB.O*F$
M3^(!YXR+R;* P_HU[I[%\B@]G7@A/2%O!,5U +^;_7-3ZLP<IEPR)/0U;![(
M&*K3 U74T3B7F6DTC?XA+=-V&&AN.AXH_.[@\SJ<XZ?E:OY?&Q5=S0.P(A9F
M/#!3(FT(62#PHB$+IR(ZF90-1X#38[1->Y\>JOUGP72P*CH U^OEER^XJJED
M[\/7Z\9 ,D?K;0GD_"='DJ&;WKOL(0:!*I=B16H3!WZ4G)X@=+C.'Y0_'JJ
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M.CA,#W8#F;,D4-KE!H4"Y0+QRY@%Z:(P*A;$W+@'>\MG_&ES]@ZZ[(^IV)Z
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MG+:+]J8N=7PTVOY(5)1NHP=//BQS5VA; V=I,^T0P3$50/E<&%.:8Q[6</$
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M^SUM&-HFCEJ=?&)U[G6@RZ(0(YX9T)[^](E+;MITAWB2I&GQ,YK2'P3FQ]!
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MBD3B<01[I;4&G]""RQF9<EJ*U";M\ X9TZ;MMS);]I=T!S!YHIZFQC\_;7;
M^J?OCY<FW+"]R/<V8_(\T5&*8)QW4(O*(- !"YAEC)G<2"?:O*&WX&;:^_$
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M/ 15(]9>T1KBG$%BDF597,1&,XR'4GI.706/@6-3#7: T/O+;0_N3 ["1E;
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MP=S$N-Z5JY>\QK)<X=T+Z9_U9I[(M/N1OC__N-C*_@[[P1<FM)$0BZP1>FO
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MXU@^@>GK39',F0B8+#EU(DD(.G!(Z)G40A9Q?G&OZS3\';?,3ZW26W'H9(I
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MTA@:Z!1(]=,5WEAMS*M$!I4$SXVK"06:5H:KXK(E>:9B9FVB\"^2-JVU.PH
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MRT?G42DNE9J;7=OA*&,21%^'EA3GC1!)Y]3&DV_+U[2U/\VPWA$8SN3F8.R
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M><\LLI=?MA^RSB=0U$3('=F/.P-?C^->VR5#/MS\XP+S+"MTQ0D'R1CBMO@
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M[-?P^7865;*U K= TC9!3:^$X(2 ;*R6*$K4C<8S#R1TVJ.P&6#V!^;1VNL
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M0D8F2D7FID^T)!DK3AGO69NA2@>1V_G6-@1;N^.8K=37@;>P'VO;6(I07KI
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M.BD*N<[R431T1T+&$P_O9]<Y7G7+$>78_J+A^@?U0R0B__?_^/]02P,$%
M  @ 3H)A5+ ,,F@./0  ?:T! !X   !B;F=O+65X,3 S-%]B:6]N86YO>&ME
M>65M<"YH=&WM?6MSVT:V[??[*W"<.SG2%"7KY7<F5;1$VSS7EEP2DTP^G6H"
M31(Q"#!XB.;\^KM?W6B ("TEB@@Q.E5G8I$$T.C'?JZ]]@__=79Q.OCU<\^;
MY-/(^_S3VX_]4^_)WM.GOQR?/GUZ-CCS/@P^??1.]@\.O4&JXBS,PR16T=.G
MO?,GWI-)GL]>/WTZG\_WY\?[23I^.KA\BK<Z>1HE2:;W@SQX\N,/^ G\KU;!
MC__GA__:V_/.$K^8ZCCW_%2K7 =>D87QV/LET-D7;V]/?G6:S!9I.)[DWM'!
MT9'W2Y)^":\5?Y^'>:1_-/?YX2G__<-3>L@/PR18_/A#$%Y[8?"O)^'AB?_R
M^.CYBY.3D^')H=;JN3\<OE3X3STZ.CG\WT,8Y%/X.5^3Y8M(_^O)-(SW)AJ?
M__KEB_W#HUG^9AX&^>3UX<'!/YY4?IKKK_F>BL)Q_)H&#-^.$G@]^=I/HB1]
M_=T!_=\;_&9OI*9AM'C]WX-PJC/O7,^]RV2JXO_N9##)>YE.PQ'_, O_HU\?
M'L+#Z<\Y#^@%W"<*8VT&R$/J?9V$PS#W#@_VCT]^>(H7-+S7BL'"K*4_WO:B
MO^X-3QK?\/3B_%W_K'<^Z'<_MF"L=,?780X/\V\P^MY7[1=X@+R?=9K!?ZNO
ML+P#53J&33A,\CR9OCXZ@<<Z[^;#QM?IIK;:I\\?+W[]!"OA==]?]GKXKY4+
M4GT/.DG.>_Q69'DX6O!'81S :[T^?C[;U!8;3,+,,Z_2MJG=Q(1X._E$_]4S
MLO(D-<_1]]^]/#HZ>-,=IUJC J"_#]]L<IIV/=@W4Q5H3\6!1V<3%%L8YXDW
M7-!G0YW/M8Z]MZA"X\1[K^-D&OI9Q^O'_GZ+I_DTF<Y4O&C%).-$7B7P8>1=
M3=0T\W9:.64BZJ]U&R9MWQO UI)5I!FTP_-4JKT);-4P5B/8LAX,*M(^?A4M
MO%2/=(K;&#:QRKS6;M#/*LU#G;5@KCLTO:#%PNLP*%2T/(FJO5/8AA.^_P>M
MB U:0SR,0/M)JM"Z>UV $9/BKY[\>-D[[0^Z'Z^VPS8Z36*_@+T<Y["OYV$^
M(9&@K5F+>S_0$0B/=.$E(_@6=*)5TAWZM54FSUZ]\:YRE6:3<.9]TND8I,]5
M,?3ZK _A)'FG, NC)(U#!7(IG<G\TF.4-Y^ J%KL)?,8SE96#+,P"!4_UXBZ
M'=G<[3IQ[KMN\JC):=]=LQ2P%A\_GM:6(@JG(3KM4:B&813F"UB<AS+?+9IP
M, //PLQ/\+!\<\N3<=C*V;W28#"D[9G6NH'80:5[!1(JA9T*(@-$,QD*AR_>
M>)=ZENH,1)-"@Z=#QA#I$8Q&D>F>3U3N^3K-51B7DHP>\CE2,0H;V5X[J-OA
MRT ''6^:!.$HQ'\E*<BFV2RBZ^#0C-)DZN7P^F@.T'_AQLJ'M0Y4[&N6JF$.
MQI9.<?"M77=Y;3LG;=@!'6]6I%FA8 0PN_-)Z$\\WI]>-@%C#%PPF.O?BQ#-
M,?#*''W4P;^G&@:!:ZK@G_1ZY?J2^.#E81,/GL#W7O/4>0@/S8KTFDQM\@%!
M5FJKO;PF[>6,JM42]?OO#I\?O&F%1"6SFT[Z#.Q8,XD9G$</Y2LN?8[A:^6C
M-(4%@U,X0R.&G1Y9XCX?-UXO% &PK5&]E9N@SRM*FZ.V%VIJD[ZL?.;<-RM@
MB\@.:_,*MT-?\MKFR5C#ZJ25F>VW7D!F+9A .!Y@0N!$D5*A/0LBYS?P\TD+
MP1=^ BXKGHW,RW3N@06":H@OJDOZ/^JBM<R9&52<DVI81 R$S-/3690LZ <8
M)2'/CLP$.V$J\HJ93*\?)93($OGCB)P,+\CQ;I3O6C6S7FU0)&U$9^C1B ,S
M*.:,FI 'GL%=\>- C\)X]?TW&V-<LT?;=G9[=JYQ9ELX81N/*/9Y X+1$_KA
MC#;UK;>[%R1>G.1T;'2G%BW@O3]1L 9Q(IO?V]'7.O;"$5C(\%4&1P/^Y/B#
M#G8[? W>$@R](4;A\##&58L*+'+\;S(B,UN-1N##PBBS7;35X<=6"' L+]8A
MJ1WG8_=V<7D[_)CMOLQ]"GP<IA[X&3-S?)U'LEE*;TFYRHP&,01YJ7@>K=39
M&JE;SEV@,[#$80TR,(W(^Y%9A \2/RR#/?"LZ]#7)/;*T#7L*O":8&E AZ6:
M/+0& ?YU!@/5</..EWV![8$.(84M0@W_'"K_RSA-"HPHP?]_B9-YI(.QK#WL
M1]Q1N(O@&;BEP[C01F?J>*S&O%?=<=E'EZ.N*]_5VM8] 5NRXN6"F?7&E)@V
M0H$U;-WO69Y]\)'U+'<5\CU/:TLCS%N6?N_'N(S@#6N)?,G&@,74XP3WPJ7V
M45?RDD^+O  +#/VY,--F&X"2 ,7$2DB10<0I+C[5(Q2Q)-/'2<+G_EI%A1I&
MNOILEO227.J@FZ=9I? &CO28$CQ#%!]P:]Q@:(2-P+-/YMGWWSU[^>8VBS)3
M =Y]+](CV 8W6*:]>UFG9@OI</]^#)#&XU"9J:,7^R^>X3R4P(F'F,!J6F#<
M!!M;W\/6+/#1_A$M\ !!?AM=VP8M/TL8%%E&&$\GH1YY_1CDS!3DB)]Y%V#Q
M^1Q-K(0<:T[X)@V$C6ZUH_9M-5B*S>ZT@6R(Y3RJW6ECM(#9"*HZK&PTTZ^L
MT5K ?R.Z8Q@;IZR>=]C<&Z^S<*XT^93>R2871"R(%J.T<,NV(C:P+5+IN'52
MZ:Q 2[0E&E $3)"0M $O&_6=AQ\9QQ=L8I\C&B# XG'FQ1H^S2C-E7HJN XS
M,KI!_<' P)>VNJ] I0@';8B% 7!)DWM(J5D,Q<:H9]$0-V$#$&X6G&+5,\)"
M5BGFCH3$_8DX!@%--!KS4[5HR-D.*48!NY9A779.EJ<GU3-0WD;#\PC*WS0;
M!JM/D*P%.0?FS5ZG.J+\]<KR!#EP!^4E:I@E49&OON3^_=[F_798G0KW?R>I
M&<P,ML[>,-7JRQ[E\UZK:*X6V9/;EG.L+(1XZ)+LGC3G+239YP1T6R@.^^<T
M\750I)L6;0,;CB(SB\\5V."(BC+@;2<B4%K\8TPRQP93L)16$J3!S'WG68J1
M<HP.ZBP'*1AFDR5, O[P^^].7KPA">I Y\3U>)NH-$#9<1:F8",E&'=NK7E"
M@VV#?4*8'!-^'K,M["?3:9CG6N,\ISH9[8.:X/#D-:YBZ9TM6^-!"+9WRDHB
MX>1@2$&L$<Q/7FJB^NJMV XKUKI'^Q(&^ %^/DR2+TOYDM+>3Y-H:XRP9ZT3
M71\3G\3"9F753W&$=I$KCLATF8>9EE D[,)Y"OH^'G? H"%,&_X<_80E,\68
M;X1_,7D+)]62@304W!28,N;7+NZI+O?RQFV<D,&3X=AZD7>EQ^#G)1T7]=BN
M9.LL3:Y#@O1-DCG(@HT"'3ML\[H:HMD\E;5R%A"_2=6UQ@C %%&E*0P//V5[
M-Y(]G8GHBL7E7BF\C&%^*SGSH +<1^T+<'^\^+7[<? KXUS/+\[W3B\^?>X-
M^H/^Q7GYX=7%QSX6'>"GCX'P.]@'[0N$?TP6*LH7FPX$4$)648X=;/<,!(H1
MER9:5C5F' V%>3:-*;H&);46A55'[2Z%(_1UDNN&>XP*M-5-/$''&O:@R>K!
MZ','%B 668)A"!*>1K:B$9\F,X2 88TGZK(0!R7ZT$ 8EA\N\02&C]6"^-YY
MDJ.<!3= LHMNNG/Y#<'?F&$4-\]9&;NP!)E_+XDY5XK37$2Y9#.'Y"\X3@6%
M8))T4:I\O)^@W0G\BJ,N8REI"!?A<N4Z-DMH8Q>K0ALI?*5"G!WSTZ'Q6P+K
MM]1ASQ2+,4] 0 ^G7(L8O/PLB<%AX@*DB8Z";8DX'K4P#U(:=+((B*\6Q!>>
MW;I=@']KV#>PIOL;3"=@J/3;LJ1NW;AGC4SHS+RU% UT"*J$H/*T-A$=V<L1
MA381><9_=<C3-'$WE#;7(&L8OI):V4.XHQAE6\5BPRAC #9GIMEES=4XB4/8
ML[Z-)YJ!(Y3-"#=R<$$2$. ,_AJ%,4BF4$6> 3Z@".[P &A\OKD-")8L(;$M
MT'<R.,-L]>N1O<AK7C$85T5NJ^B[KH7"4?V,@:\.=93,-\G!L+M9U7HQ!_7$
M8:>%"SR$R89U'<&T$O X6DC</ #M%@<9U3I( 8J#NDID'Q/*4.(#N Y!F/FI
MIF4+8W=G!MH/\0F\DZAF>8;A;L+<F5]U< W%!P71GL_)+?0)97STCUVS[DF1
M6\4&^BME$)^O9NB"P<PF_A<JN*%=6-:[T3Y*8MKXTP3QUA&,@"_&C5.]002'
M B8!T8)>K 25G7'-%VHP_=6',8[YW!9#</W0^4E5<-.+!*N&\[L'_]CSDP*/
M+DQ_^D6;T M!66'6X"@4F(/U,"2-*04)&4D><]][1\. EY47JI?)MA(2;8]J
M"PH:N%!+BFP$64MB&G81_A&"Z2$2C 4P>[F.3%LMT/))FA3CZN8C.3W56*%%
M-J,<(K0>,_-'1.%;EJK&TL.P8A+;,T?#)<M&!JD#&=/66##MRYF>"AK0J'*V
M4#8,(_JSUDDI<!B$O%(--V02&M5OQQ.8^QH]S_&F.&:C'B2P\OF 9>Q(4"4D
MO!<:11'B(4F86;0[5]V!<X8_ ^,IQG\D)@%K7(&.3(%&O#8*=R[9[5"E9(I'
M;\_^BWT;4D5P4/5TR)E4>E\'05ZU>N1%9A.56;RY:ZR  PG6QXQ<+WC;8J3\
MG%>+\*8D\*7&1UQ$BMF7'I1)2XO.H")$..H1>3P%VW*LHUUWF#:EZVHUW+IF
M2FEVP&_HGGTKM?S0XW7'[8O747CN_(HB<=[%.Z_W[][I3X/^S[W'L-P=+'?[
MPG)O4:1<J4BE&P[-N44VDM]1KF\)IBD.-:.AFE0-2/8"EOH_8)2DZ-2"X/B_
MQT?/.C!8M.R]A59IF_/+Y>2W(\M,OA',.]J&H%4HF(@9%F*O(620)-0HC@5:
M#B%2J!H7!(H"]9'J<0'OXPU#>)C^@O%51;9!5M%I34A.L_J49%[L>U=H=3I3
MY,024_2Y-)=%T"48V !7B-8;-L%RQ0ULGE!H$HZ?/]L+, <%OJ1<LS4"IGW1
MN#/KL>,2ODWB8L.(F2Z+CBR!#>N$$^HX=ZZ((48%=(AAI^@X4&G#%FL,=VO8
M'Z$ !<%*U"S"@LID^"J;>$.<$>%E\'+8;>";JRGZZF1[S? &B*5?E*&*DP..
M52R;XO &\9[0757D98ME(+Y_.Z0?3EA0*:>U$PM;( 0CV\%8<;C3)![<;,HX
MP4JO=G(\?G;&^1['V8:9E[CQ:E 96P>!-I4 <E[G$UTM<Z;ZZJGF [[TJJ0M
M'F&J-O#Q@&&J&YHR-#7&(9;SHQ:0>NL1J!*NNBS%-OZ0!!N[UD*) 69*R#8+
M!=38. WIUR!]K.HP^WP96XDA;S"D2'61229[S=$K! *T)>8U100/I-""54AF
MF*X*F\(4PR^FE$_EN,;20$S D9F$_*BP26!0DD:5TOO5PYT<1:#WYPD"JPR'
MI8.ML<':%T_L?9WI&(R!2QU.AT6:;9S\K.KNT?%(S=B<K4CF/7TG"70G[*7Y
MG2J(/V3Z-' P\ET:XY4";+ L%9T:)G 9.59D6+ M3RQ'2M: @<0RF,F"2>C<
M.W8A\NF%FL&/:H:(C!0#C$2CAO% B?M9X6!?+TX\)"1))655/6+6*IW"E$\<
MFQ6_Y,\0K%*>.7O;N4YEPH17SJD'>2<0&'6=A($!B 1),40Z5.&1^)HSQA@#
MAQ37:YB;S#J&;KU)(Z*$HH^Y^BIN)!/.+5,^T?12F@^'9(OL#EYUS8ST4:-B
M5NP24= %KF5 XS]\]?(YQWV9\+#%)C$.N15V&9<L:7'JRU" ,!$4LCMRAV:*
M2$G 5<]Q<T=JCE.?A3 ZV*2&$*?"U]W*%7!W5AM6@G@9P%;8;5#JR9 \D*I4
M6I8C-05/ FFQ)(X"Z4[#TL@53H8"<'."J0,3$.[R]L)+:K*F8F35BU+0:,*L
M.:9]P+0*LSQ5L@&EC($D#U,KPFM/0\(KT.[%9U7F!3S%(L?Q(\D3U5HX$W$&
MMA5E=8X/*X90=0KH(SL#+%%9@LY59E^?WA@7O6)<VJFR$T"%T9C\%9-+\FR*
MSYMSM=TW([("W1TC.29<<OU[@9^4-NY.>,V#X-9&:$DVZL)&R>[R6SGB/ I_
M1_EALET6N< A/98P0QWK4;@MG ''+:QI.Z5)SVR2.<Y:4">R;++YSMCL04_U
M=:CG.I L0+20;.>"F9JP3U>VBKVXR<JK102W9M>UKQRI5X;G!^KKIDLHN["=
M&J.IE5U'^&J3RF@4=-:!=Z2<#YL!QI@NW(P)&KJ"V': /N6<R->9D'8B'H=Z
M<I3%3$-MFIY@P#*UL.)ZW&Q;MO#SUFWAMZR:VD5LT/EV6LW:]$YI*)F D9A
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M&NE-,I,/*X\-?L#T(SI'M1PZQXAT?Q%+I1)B%PHTQ&K=!<'H[!@$FVTV1-$
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M=?CFLO>IB\KG$D-QG[OO>QX23IVC$NI^_/BK]['W;N"]_=@]_W_KF[;4WO/
MROV&/?>W/O:'JX\]#C<,_O4D/#SQ7QX?/7]Q<G(R/#G46CWWA\.7"O^I1T<G
MA_][\N3/BXH76]F7N'FK]\^]7_J#\][5E??+A]YE[^+=9NGK71IZ\D$L046=
M<<QZ@U1K,0I31%EB5M+8ZS<6/0=U._WHV=$-3^EM[G2/2WM\C(W5+CY][I[_
MNKX#6)M?X"V*VO,+[WWO_.)3__2J Q+X]#Y6M7K9R8O]331C?7:\?W!R\D=Z
ML1X^VW]V^/S.>[&^!)?LY<E?T(O5P_\>[[]X4964J[OYW;-HXLU8ZXAZXP:%
M#^+M*":2T?]ZE_M>+PV_>!^2: J_['B?)_MG^Y47O^'Z'N#[/UD[67*,L)_;
M 1XSCZKG///&#W$NS]64VR[>[TP^Q*D:('"5Y\KS/G-]ED#AOM7XU)F\FLE\
M>,+2^JXFM/+3+91L9RK7-Y5M<ER-F[$E)_8"/%4L*7[9\8X.G$;"M^Y0>4^6
MY&WO].AP-M8"7!G../ X&,KAP'&MI['[5T2C'EW,1Q>S!8*A/;Y>[]^]TY\&
M_9][=^>N;K>/!U>^>G7W/M[)_HN#U9=^T\=[ON66@NLG-;8BO_G,;)/+\ZVI
MV("%_N@4/#H%#]8I>+37_Q)[_>9II!=M2R.A_=Z:_&COWQ_Z;_L#KTNO ?]_
M>G'^KG^&R='N1Z]__N[B\A.A=:@+1/_\9TZ;7GG=JZO^^W/L^>IUWU_V>F[W
MU\<-;CM([ZU)A3X=)L$"_C/)I]&/_Q]02P,$%     @ 3H)A5"#2+8GK-
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MV(6/Z;:UXHY,IBT:3CD_DDSYJT?4!-<8_@?S6J[F2GU*0?6@4YI;<[0E!?0
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M78]EY$P(SM"8^ARB,$P/4FV$B4I3RA!5(Y+QJ#88UN9)8E@Q4%L5+CR(Y<%
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M;"^V.)Y1I1B4&4K,>%O$1U&YN%*!YI<5[9SM+-2[VG"HL>9+VT5N5@CBHT-
M=)OB*TU7)%\L+>3)/;_./8\A3B2O% 4\$$?0P.M$@% SKU!I/\6J>CMYS%FN
MH5M_DQLP'&/;\6L_P4X=NK.$*6SD:B=Z4GF)>UMUO&2G'P_CK4QMN)L8;]-V
MK:I APCJB#@U@8*+"MM2?RUDO.<J#-,!5E?X!,+R.(FGHC?VK^%ZEL&,Q.GI
M>8T,O:D,=?%^:3H>UG*$9IG0MD(L;<)E.$VJHYZX,)7;WH4CFUHQ*)7SY2^;
M1D]:J]%L"]NS%">R^KF;FX/5;CE/$[(?Z2:,FNWE[>5'"M6\L9\NP<AT-+O;
M5$C<7Y[)XSGQE2G1<].)SQN*G,!V;/; EW77"W2UF]P(O"2WK<@ X9!M<EH[
M1F KLNO6:HS\:H7LN"CPEXCJV%2)ZVM;7E88OCPV6U*,]\+D5J-_59P<O_[R
MLO&:"R5_:+8IT=SD\YXWWWF83HZ5D#LVT_O4>]L7;TZ;G3_@U?T[A<FM=%.4
MN#U^9L?3\6K'$\Y6!7]_IO;W=W>/_-V7HX/A\& 4' W\HZ-1PS_V!\<#>30:
M_.O@V5]W5A'('Z>GBO/,EW^V.UB5I4,%J[E:2S%QC ),J3%&L$@(='SVS#JB
MV:BG62^1/>"Z6&YS$&,-/@Y+O16)^%&P*E<]5\'JOG\^0>;6D*G6(=HT6#:!
M"N?-+G#)S1IERL+6UW'8)ZS!GV]0M.F<B7=>Y^Q#N]7#JFFM9;)\,R#7BS$+
M?G63L\5-'*W0@L63=ZCB\C25K\POKP.53D-__DI%!$]ZZ761OZ):0$T0AWZH
MB2/12;ZMV?CA8?WEWDODY!E,-0O,AS63KQ.3?YX%)?=VZT<'+U;>WJTW5K^Z
M9MCC%_7&X?ZMAGU.4^9I V!2T.3__FS_V0)\7^U-OXK&-!/X_W[]Q4+L.D)_
M"4SQ=$-2R)MY\=!J$#R2U9$3,Z6?HEL77J*^H'5A D_6Q/FX?E(O+/R6^[N+
MZW^V%ECZ&&%_D%T\9MB3707"K/@APK+C3R3ARH^%Y$,$51\;!S"LA#A/)(:2
M:7M;:ZSD2'AL>0 9_&PT4L,\T]T%WH+VV=#4^GL!M/ H??(Y$?7OP'#^VKV?
M71IX O7F];M'9/'9O5T*6Z_]KM/L7W0]MKIA7=75#<^VOX=]Z,7F[$,_%_9O
M4BGE%G</42G]3GI6X\7A9O2LW?KQ;N.;]*Q&_7C_=@K1G?0L4/R.;J>^/>E9
M^>INMZ35-N_=I5SJ^HO#Z6++0K[XXV%#>.9J:;T8;H7H89^D"\1[DQK:3[ +
MN7YWFSWX!EWA9V.W3Z!9^MGDL@.,9C\Y+.Z(/C\+6*I9KE+@/XI4^-O?_D9A
M!]]KO>(6_YXHS1,:/:'1$QH]H=$#12,/R\85I9ZJ8]1M,.'F?YLU_&R69ORD
MN YJ8R)9Q']P5/6PMKM[5#MX\?(V]/$GW^>?!/T?V7(>^L\GC]T&/7:-W:J%
M=!\53;/WM"&-6[FZO'^^;[]I]T7SEAD)59J[Z>QUO(_Y9=XI__E-WJ_U,?=D
MZ+[W19:?F'\Y_YB:T*\UL;>[U[AW.G^[.9Y(S$Z<.(GB?:P+.4OF%9E@V_0J
M[V(-T)D4/2YQ_LVU???M.=!9=COWDF9WN]6=7<(4:N*B+XX/]G8;._"UO<>Q
MLJY<*Y)[H<ZSO*":):8T!-&#.P!@0XL[]0/34^D= )K:LMRUAOJ&IHZ5>[A5
MF*ZLY'^=^G/=X\OT*4AKA?*)A=TQ=&+I8+;B@-(<&R^/CVI4C<JTKH$A3"T=
M%8G+)$XQ\9<2!_V4Z^U&*6?-4[%\/N&IKHJ$':K$EJ(J/?;K(U\E H#Z1698
MIF1F.X2EI Z*0*;#1 VP)AG5VX]U#Q7L?S;#NK"^"G3V=)R:M[A\$U<SP^1-
MA64X)WD3 .S 8XKL+Z10&JH)T#!5>\AP]>*UP/"&G;V[H,=114YV.>]NU.]'
MG[X=_OY8'?]V$$&LB0#;:R*-A]B#)Y7#68(U*;CN:RUO[L!(ZAS FDV+AY-(
M$3MSZ2>$FJ9J*:">-.02?N=N(!,?*U,E\JYX=>_YY;?;QMS[O]D-O:O1YLYZ
M8F5WH,>HVC.HVB%4?=J33>Z)&Z_PM <_(X/YP7"ON!*Q:G5]AU6N/2PM/P09
M%/@I,574N^]6K+\*H"F7.?:>I+ 2*8S[NF&U)>KSE1::&9NJ*T:8TAE3KIGF
M7_>R ,SXO,422NS(&"ZZLU\_+@G!'OBI9!IP3Z6Y;@?U>W*YW@X-M;+'35LF
M6% UBX=?Q!;N^KW6-+33HQ%O7].0G96;/;FZD"$ [0W@FA_%:,/ KBB@];>C
M81TT$G$""'B-19Z!YTPUVQ%;E00I%Q>K DCO4OIK0UQC_XEKE' -/I7B6F)5
M<ZSE-I()-2,M&O4V 3*QUHEP/[M9PJ[*B[1]&[MZ< ;N<L0YJ*^43G.40A)J
MQ ]=52TW+\(#6<+=Q72(^D:9Z>IIC^)D)!5US5%+!BP1Q))KOMNN9O"*+B>;
MVW*=>I%4Y!PMM-2+![OQPH3C@.0S6!!;81.5?L$KSK<I82UE4Z[O]#R] CA2
M(58:YDX%&*N+7H=/E+H$/U>:_0WB<I\L1".ZHXFYV HD5T $=#$-21)YZ2>V
MJ30AEWLDT35A.DVH:(V!?_/[M,E=(>_&_I;:WMX\KRRJ<OSO0;+(_<=!PXZ>
M:%@)#7,]D+IADLM.34EG)ZYULW)!V:&ZGPG=\ZDZV"QQ6J=I8/=O/[$Q.*8=
M'+.91 XE++(46U0TY&(_IAO3\-\SQ=#1&OZ)2K&,?3+/M?L60 ;0+%)^4;^O
MK-E$5S&O@I*/FZ#E6 P#<&M_"^P_I49S[ER5M]5(9)Q<^I'ZC\]61]W@26&3
M@V)KLM&*J K3CVO_Z'C+WZZ+=[ZB?D,A1E)0_(%N.F'0P$&1O+>V-9:9HO!#
M?XI;H*UFUXJ;6@"ZQ9<P6VZ[Y?;2-?WI 00WS//PJ"Y$3TI[NSL+<85[N[LO
M=@Y>UC::J$&3V-,.@OJ;NMC;?[%::]")^X;CVLS]0>@/OY14RM!7D")19*T.
M/3W<Y0H!ZQGZ_B(_;QPO\G.\\KWY^5']1KJ[MX[N;L(\?6/4\MY:#Q*@];]G
M<:9TY",(L'Q#MRW"YK9TO:FO___]70'S"TU;O*TWY@4=0&7/V=EU!&=OK*;8
ME1NC;/U+61.!LF=G2[D?T\2DGU ?1'$.ZL>:*NJ/'UWNJ>W 7T,770J?&@S\
MS)NSO\G-61F6XI[-R2S,%(?IH;ATF\/Y,V_H/<G$5=W0363MW$L*PO&M))V#
MXX/#G<.#QO'.WLO=E_6K@R)@OD^#[]($FYNRE^Y8[:P*'K4[QE.3.#W"OO7%
M"$[;>VE59@.('5BCE1_4,:!F4!PO%3B>'T78Y4^'4<,#(+=GLR0B2SRV)4(K
M@@^B^*X(8/=T,SJW'8TUCA9,J-A+=1A/Y^:JG;<?IK'5$4;P)96.<Q5A"@#0
MX=O7XWC"<1?&]D_J+CR!T=2FQ6]!B4W=,?2#IGN.':6D/Y.)D%VI6-^6M.\=
M+-+VO7WW$M?+.CS8&)I]Q';Q68*M-N;Q+$EKW\JS*K6N'QK9UCA87CE?^_%9
M<6M:$W%D]+I&0W>CJ4^L[U&SOOT%DT/."7],(93;V+W7'?.NU[_H=D3/ZWYL
MM[ IU_]>>+V^=[+1ZBY/N9.5\BX]Y4Y6Q(&UM@OCFHS.M3F#&_7*5"ED;Q65
M\0&:*D%[_P<_\"=W332M2F*%%PW#&+O(34.@DM@:+@I C<E;QUE58W9'#"K/
M.D5=*5CRCJP(&5X9#?L  =U$34T::*.NZ&AT\&<H,VI,CN"'N?F3*8(KE>%H
M1^<IXF9$5S*,I[(NSGF[G&[%[)&<&K8'-R>H<"I0$:D!O9]\,=H;??AZ+!TO
M)O?P15V5<FS+?%8/$>I]T+:_H'(FT-DJ)MAL'-5A5-< +U.%/6%O;]I_TDB?
M--+*:Z2;9"0S)Y'B+Q2,65<5Y\>,\Z28KU+,GP_B8 [_C;-)^/O_ 5!+ P04
M    " !.@F%40KXEHN@[  #A$P( '@   &)N9V\M97@Q,#,V7V)I;VYA;F]X
M96UP;&]Y+FAT;>U]:W/;.-;F]_T5W/1.O_9;BF+YECCI297C*&F]F]@IVST]
M\VD+(B$)'8K4\&)%\^OW7  0O,BQ$R>F;$[5="R)%^  ./?SG-_^]]NSD\M_
M?1IZLVP>>I_^>/-A=.(]>?KLV9][)\^>O;U\Z_U^^?&#M]_?&7B7B8A2E:DX
M$N&S9\/3)]Z3698M7CY[MEPN^\N]?IQ,GUV>/\-'[3\+XSB5_2 +GKS^#;^!
M_TH1O/Y?O_WOIT^]M[&?SV64>7XB128#+T]5-/7^#&3ZV7OZ5%]U$B]6B9K.
M,F]W9W?7^S-./JLKP;]G*@OE:_.<WY[QY]^>T4M^&\?!ZO5O@;KR5/#W)TH$
M+_9\N;_WXFA_=W]O9_)B/]@YV#G8&P\.Q<'^^.C_#6"0S^!ROB?-5J'\^Y.Y
MBI[.)+[_Y?/=1?9JJ8)L]G*PL_.W)Z7K,ODE>RI"-8U>TFCAUTD,<],_^W$8
M)R]_V:'_O<)?GD[$7(6KE_]UJ>8R]4[ETCN/YR+ZKUX*%'Z:RD1-^,)4_4?"
M&^'E]'&I1P//"54DS>AX2,,O,S56F3?8Z>\=_O8,;S"3JD]-)%.8718O7@YP
M:LX4?""G3"IS& O_\S2)\RAXJJ<SH?^]^O[)#6XVN8^?/IS]Z^/P]-([?G\^
M'.)?Y3G>;'9_Y6FF)BO^2D4!3/;E[G[_8%%=M9\XX_W&&5_.5/KK+X/#G5=F
MGBU=$!YD;55:14P>XU8VD_=+4GK52Y7!9O1O0.1??WFQNPNTG292(INCSX/[
MWA#-)-[V5.K-12 ]$04>,1'@ZRK*8D].)M+/U!7\E'KQQ/N?/)+>8+^';'W@
M;>JJ#.VLWH((:_72]+SQBI9E++.EE%&+^<J;T=GI\>D9C_#]\/3LX^CDHN>-
M3D]:2=K^QF[?DWB^$-&JU?N6]FPKM^FY\F<B";R+F5HL5JVDGK>U61MR^$7Z
M.?+35F_)OG<YDYX^/+0_[;@]D4AO!F)/16("XL^#084L(L*5E\B)3% D@D $
M,;BA7..32#(ETS8O48]6!71[=:6"7(1UVHM-I7RKN77_6^RQ-EJ;/+Y ^G$B
MT-OQ$@8B$[P*^/[P9'1Y_.'BH=N>!8L+9*H2>+1(TSP1D2]1@P?NA5_$OB(*
MT8F#=UTI7Y*&7_!$%7EQ N3#HY?(3,#G$J,?/'^5>O++ @8JX>$]+_VLPC"%
M0SQ6H4)> \JKI0>]Z',4+T,93*4^Z:FWA%O0?P3O\&%R*LHE_HVCE-%43,EX
M*HW+OKH8=437PVZ<I_1<>%) WBZ\*/,F<9+-<#H9&.:>-<F^:==OSDXH%M+L
M Z#K6#(=@+KS11BOS([06Z9I683ORT6FK^?5^(GTWC0N\TA<7*,(%SU5,&]F
M(WH?P=++:8P[YUSZ*"=Y@\SS#,2YMTCBN4JEV317,A)1EM+!!^X"0IY5,-Z%
M\"@OAF<FWC2.F7U<B3 7XU"6W]VC-VOUIH=^"PG;D3<O[/=03DF3&".YX-&X
M'5&5F("*%R]!'SIX\:JV6"TC=UGK<4:9$3G,,(E=XQ!#L4CE2_/'JT"EBU"L
M7JJ('DTWO=+[<!QG63Q_"7OLU94$$OHBU+N1=B'_7#C0^SOL1,\2^']@WJQ_
M[M-/S[*@_MMN_VCG<.VO._W!VM]^_E./=OHO7KRXT6.?$1V8%D#N%)CHWY_L
M/?GJQEF( +?HR]W%%V]09@*AG-268JZ"()1W'IWXZN;;VZMO/DV2'SA;8(T_
M?*HUODY3'?1_^C1KS.;GAP&:;))[,CV*0_6,N-3U\O/PZ^)S_T7_Z%[E9S/Q
M!_U!*RU!/NOK_MM*?]XEAH];2<Q^@]&RB#D.[Z4ST$I0/SF9*3GQWF 87::I
M=S:9@%&3U!3S-!__)?W,&$?W9NRT]D#MMG(/;.*!@JW52EJR Q=W/I\.=W_;
M\S1%MP4;J.4P'UL5?)EU->3P;TB/5!%EL\#=8/""(DW^DJ6"LW2!#XEUY&U?
MVR@;&SS"U6VS+W*[[WD/GE?MM9+T&\BKWN9H]+>2FH[TUUPGB(D%+60"0GKN
MX5?&APG,R<]2+TZ0K473U(LD?)N*9(7?B>!*I63I@_2'@8FIM*(_1YT F-W8
M*!!EQ8&NRV8BHQ!7!.\E9XCQ  /'(QZ'=UC5!)[0K)1H%IK[,^V9"8C\Z$V9
MBY4W2>*YEP$-24G!?\?D:X;CR0$<2Y Z;1*Y ,7%:#?\^N*:9J7HX>LT^ZW<
MV1O()S[%("25]CQ^2F)?!GG26L9Q:?WSI-HD,B1'9SI3"Y,'Y/H\"UMB&E_)
M! _;>%75CRB':*4/ND.,10*<A\(H,D636Z4S::]TF,BOO^P_?T7\R7YMC9HW
M,294P.%\JQ)0EN(DW5CUB*;2:OVH1Q)!A_>FK+7Z\7RNLDQ*7)Y$QI.^-])A
MGBM<_,)BK"O.@0(U.6'FC4].*$0$HF4"A,L*\5!=]#6[:,T6&=)VA@'^#I>/
MX_ASKUF!1\T\B<.'S]H/6KF[-I"U?XA]XHZMI&??^R,*48-RV37I3DN52AV,
M@N.V3$#UBJ8]T*@2"EW!Y6BIU?0DHSSB!38 [L3L4Y 6_\Z5SI@Q5R_R),U%
MI/6KLES(&L]K3!I7BF.[$!$P=CF->]X)'#1X8*3:FH?3O J+)+Y2@0QZWBQ>
M D=,6KE7>JRGNW*W6:O6*^PL._Z2B"N)KHPY*-(B@>'AMZRFA_J(I)JS1^S1
M6,_;C3%19\-,L]>_C=%%7_NM"T=VX<@N''EGX<C=1Q2._'#VK^,/O_YR</3*
M.ST[?7IR]O'3\')T.3H[+;Z\./LPPB0^_+8+6OYT36NW"UK>G=*Z$F'6SNH#
M=,Y1RI^@],X$] !0)HP.97.TM*;:D!):>"[*;H1>W2,JK^),-CQCDJ-#P[@?
M923A^)CD+AA0YB29:OLS1D\HZ4)&54)/1Q*#"LQE;:C0*AR45HI-0FS]Y=JK
M25E]CRR,NMN%4>^*E(6)%<5D>"W0_//50F1D\E5U;OPL,X7>LSY/Z[[KIYJ7
MXNT-SGW5L'!//MF\J2&*\,F6Z5&2.AS<.*G0"1@-.15#BH1@;0A_ZI$/S,0L
MD#-< 5_@_.3$\@G*.(^0#Y6,)8Q+!*#_I)*=:9F8QI&"4^K;"(09N,H*<XA<
M;\!3T@4, 3Y-5 1<1(G0,[FJ:-7W>  T/M\\!IA.BJ&5!.MK5;9B6T^EZZ='
MIAIOB9*MMB[0H[V"\"T.^1C878@!GM3; CX>R DEV(YE&"];>5RV6[G9^][9
M$H0/>]Z=343+ SMA @M!J!KA2@?F I!=40"K ]O+6\Z4/W.V7A#KG3\#8WU]
MF-N%KC [_"5' :[D6C +;3KO%+>(<1J'>5:_Y<9J\W$"N_NFX!:W8]V#BA+M
M_'>6F*$M@*)/QXD4GY]28=Y+$2[%*GUR*[2/M3Z+;Q#B;4O$U_YR//V!2OU$
M$K-0D<L/ ^DKW*7,O["*#G@L[%NJ\3%7]9!S:%>EB+QL2=Y#++_PMG;_MFVX
M39QG:28XOQYTN(2+AGRQ0&<<4"7V/^,7S/N2A:Z08.X51\1NYW$B/3^$$?#-
MR*[*#PB!%<-!PNHD+Q(,6^.E<(@2UOCD%Q_&.&5ID8]#Y:.W*Q'!36_B&AC>
MAWA0G\(G6, <I09_"SOALS1!"3RQ6'( K!A.$SP?=R0&P74P16<(];UW-""8
MMIY:67GL>085PC!G'6CRYE+@ZA"5@*0+G>B'5,0/"E17+3=8[+%;SY$DZ\5(
M-H/M.2T3GZ3C7 9*)*15ZTV4HOM8_QUR$! ?9C1A##+%D;F !TNY 'J(,M C
M>OA*<I>_<T>D/-%%0$8=9"6XK>F\WZOZ%MR$:QO7ZG@-<?=&W:[G2<6)..N5
M2(XC1!&FSR3(:(7/?"3EO"),ZUG O%#C#K$^BCB5,._H4=466.EX&6CF$?X1
MFWR@0 ?\>YH$$LM D8?/XC"@*U%]ZO$.]..GY8]1FH<@3#*22W,Y'W.*#\W<
M*5$M*]=Z2HN92&U!JZL3!_(*E-P%1=-@WOE$^!FO&U6B$5_'3W"I]AI0T-H&
MTVRRE"Z43 68)<#=0LIPR-ED8,6N".3Q*DHGF:KIT16-7;*;Q;E'X:,3C.1S
M?9VN?;TVYZEEIZ0K5>MB0UULZ,?'AO8>46R(@D&G%\<<#<(E/GO'_P[_.3SY
MXW+TCV$7#OKINMM>%PZZ,^@TU&4N1"B2MH:$7%P1G8DD7*<JV,0XAY3F8)**
M0.O,85O_!RS#!+VYH,K\G[W=G1X,%IT+WDJ*9',S18LU:WF^*'EU8+G0K ?U
MF )EF R$^C#GWNN,,=1$47''"@34]E>DLH$>G,AI#A/E91HK>*/\'*[X(UR&
MAD]:4M.;ZJC,]J'$T57?NT#?@4/%(HT9E.>$\EHGVO"AD( (></ +JJ#D<#N
M4Z1@Z\RTO<.#IX'00YRHU-=W/W3?Q%X7P+NSVB+K3\7-^2:.\K;6"QPSNTUC
M.*V.%[A:0LR()VC[DO<2CH2, I$TG*JZTP).I82SH'01$EC]DME^4**2+]*9
M-T92\9D77@;'2H)!/4?O*EG0"WP EBFO"@_S_@Z[F.NN%9A!]-3/DX3R"1P9
ML[%R ZG3<HF!="97>GT]8.<H>26=PA0.J?I@,2!$F)M=,8T1 &C#P"P_.1-X
MCQ-H]5KI:/;ZVAU6W0)I:IPU8UC.)#D.BW,^PRH^R9RD1@,KB:=P:40<0V.%
M38#M, )3<<3Q0MKF[$Q#,#$2ZT*Q2*>H 2M_BJZ&+6?9C!EJO0H)HUJ@9Q";
M(]U%AS<='D1U+Q:UKL*TX(7D3+3,RPS397=SD/5PQ1SWLO9IU@9B8BJ,5NF'
M>6!R]H&A&K9+\ZM&=-AO2/-G H'2@L.2P<-73+J@R5TA]WQ9R @$X;E4\W&>
MI)+[:+20N&6[D?A 8@;MG#EB+O2;2$&/P.-:Y/[Q9$M%+A'H Z:6@:R9QJ",
M3N/#?$4*8/8J93#ULH<\190Z_<9BI"3K3+D;9R/;;$AB<(ZRE"\6H9)<[R,6
MF'^88!0%X5LP;I[ID(;E@G9Z4>R!,*6$0Q%5>8E5U>9 \IFCR.&/_!T6$17,
MQ3YV*1--L(3YF%.#_4[7ZHFK6 4F'3*(\S'H?P:#\TO&]8,8$Z&010-M4FLJ
MNC7>C?F3%%C)Q!=M6/KQ7.J:\A*Z#9&74A9P2&4 CIVC8T.6$<:Q,<Q_CF6.
M.2YH0),8'+TXY @7O!27:5.519Q0N_4/QA>0VD50.!8T=&.N=U9FCR&+;G0C
M97@P0K'$%4L5C XV.#><\+9\!X![$Q>NMF=;O8H$@@G*V':#UA2/2:\O<\,Z
M_ZIH4,0(5S4V&.BN3\P%7::(^43WRQ![0 "US2M&^Q/OJS"ZDBI;+9)'U133
MCS"P#@JL2K-$: AY71]-;(\1YF'N<T7)@[3]\5TEXH 1EF<X": #%W$[U'@+
M&BQ&R[6O:U#2.<O$H*\L+9BG,P]?BM02@N9N)E]6YBWE+"D()0GSB;2*JW,:
M!!]=YVZ[C2:D=;L;2$?Q<0?(?^?X36%3;*DK9R3<1@S5]T:YW"AE[)C&TA4M
MH?HW\B.35& SPMBX88XUEI&<J >?Z+_788O<6722-E%JTY>BM,WUZ'4]V7<&
M;1E<(J^47,I QW#"E<Z>63&$.#;_0T90+T[663-5U;KBFWSXQZO#=[@K:[>(
M]5R*+ZW%[#F&<]/HP"X=+ZI5,P&S1M%E_6".W/)AX\,8DY4;H4,S2E>_.2G!
M!;'TSRF97)R[2_U4"G2(L31];M#9R\ZJ&>:Y53R(]U>G8&[Y6D. [U_FF]4R
M[%8R/3:C9F$S&.9A*P_V!C+,-ZS!MI515B*+O:^G"E@?@P-A169EJ"VJ10@V
MD;&>L.M,V8*M%%YJ#=_P7WR/_HH?1"!8">IT;$N0X60U'^.AJ&L^K"!A%\TK
MH4+C#VM2AJ0E ;SKLS2E8_0ZDT?=@+WRT$[\\U;NT T\\;_#,0E Q- 6_(=H
M-1[6=8D%$ZK^58$WXPGIIB\\'VM>?(U9I-]P2FOFBHPP%_]QGLNC=9M_"+IC
MMG( FENUMRX*A9E<CE<B-)HL U1N(6>O8R5N-V:[3$$"9&3_>O&"]U^, 22?
MZDY@!)3%Z)1 <G4<%S"6C6"3#CD1*M$%*-3*2)KDM4 G1]([*59A*@4WQ.E]
MMF@MQ]%^=X05QUBD7K!*O(G'S\X/+(CEZNU)G'-RE%Y@PHR/<]MYKH85P)4\
M2SC<JZ<3W$U%!>U!44)[[1#P[52=Q#MCHI*47:/HB%$(64"8T).U /<<B\'T
M!:=$USP5&>._,<9)+O(04RI26.-0)W!>20X(.EY9L$X3F$VJOGA;>X?;?.-:
M>N"!(IM'4UM/JHY/BVR< KX,I6#.:4G!J_+DW9W!"X]9D#>*D*XX\T^HLFW@
MD<%QM_K N/%3WEJ:#PKKJS!8Q$X:N-Z!-OFH2=QCD7#HN""XEYM)]PVXFTE1
M3<YO)=Y8^$QXX7F,Q.R++)WKF7TIB^@ZAV3KEJ6KJ^OJZKJZNA^H_M)4]Q]1
M7=WE\/SCZ+2#4[P?0VN_JY^[RY95)KFY$KQHQ:B_TJ'Y)C@2F"EL<JF=4*S3
MNJJ:CL(9>];I83*X.<F2(!?PJRBVW]A49LX]P?R)4('Z1*I:SU&]B@R3HOE<
M<Q_=;W2-/#_J'[3SQ'9G]L>?6=J7)R)/VXH#XR8UXSFTA_!Z:)C&>*^=*Q(A
MD"':^&3@&QP0.(;:U^"D[A[#F_4/:"T[I.0"C1K@O\Y'U%:8]HZZ]PEK=QMO
M%/[-[S"X829133=_HKQFB_VD?5Y\1W^-N=(0T"T#JS4CRZ^_;5/81E>5^>/9
M!HK,& 378V$=I?G>6M[K FR7!Q0N&NM8=#W4I38C:0PG'HO$ZA5G#SQ LM\=
MYA]TF.T&:R5]76?F+8YN'=3MUHIYO@#Z[.WP0F*@5[^G04=X5.>PJRC\ ><0
M]]Y;*1"O-:&M%"*PW5ML0(J(^VT%J+G=&61))W),JR2'7.B>YT+\T<ESE>*&
M,L-K:%7'WMY^^*>R*RSX,=+Q8YYAZ+;0_[2-IMO*M9+JMSV7=:^6*RWI- IO
MSH0HXI!% [T*3=A03JMZ;AE!B'D!(;)3:1GB;F+P&Q$[2^8M/4?<KA7("W.0
MVWYJNWJ%.X,T=O+]:<<ZY[B51+[13KY!G*6U[I>#SFM[9Z!8UV@[_582V1LU
M:6U?B;2X @C[)202H:IOKP#V&K1.!$YTO;ED\;E?V"?#/!(7G*;HS^EB+6(!
MD.\G.24K!EX>Y5B99]-F;;H[X\Q8\)J2J]=U!'.R8J*SY;6K6']+8KA\@\87
MI*X0F'A3 1AT,06;8"2+G#$6P6#V3O*$',SQ&%B-AA0H(4LXL.AKB-;H,.L9
MQ&WA]N"U4!Z@8B$8P19U"[,7VI]+V(;UUY:2E:R2D-9VUS4&P*,KI]HKDV(3
MRZE:+/,Z+^4=$?-/JC(0&OK_3^UU?Q_'@7?.KO16#+Z9WM\K_1SS2_>:6!>L
M1>*4&JTMZY1:*P_AVV,MQ,X*MM^K)I1^A]#81(GP<)A1YZJ]0V94!/UTK, Y
M8:VD<_][E?#K(KTUOE.AB :JC S_\D4)?"Z%TX0J?BH70G<K<SU+!MV1<LD7
MB9R!;4_,36"F!CT:5#2IF]'XH5#SU#J+,#Z*+*/JXM)5^!L+2W;.,VXUII7'
M(#^X571J"@FQ!3P.MD8J*?6&-QTW-+X&;VG_P./Z2A(Y#2#%COT4V%(<@5ER
M*>\$33&N>2#8NR+(T%#3B/8:%\-LT>TXEI1:%U,Y0Z M-Q?6R;S!CW.$<*B\
MA 7OAD'QFBF]E2+ BUJ]WXC"44G]H0HGQIHMITT:F_SZI,D?DR0UV-GO[[15
M2VBUHZZ5^L %,*N$&,<GQI5I)0'[(*K360%]HSDRR<>BEM!&9^H<UNT3<5L/
M%6=8&,Y/8)-?O*VBF+$,F%?EY9O&-&L;HM5<D^%T05K>E0W4;O;69I],*]E;
MR\%L/JW!@498=Q?5@MP8\.IP!=]3Q;-F>7 K3F'AS:0(0?'SL4(:6X,6U18G
M<902'@;J?6?S2(USX(=Y@&TUSD'-BWSJU(G\ZMC/-/SQP::QK9.S-^?M!LEU
MY,1-+(!F1Y=MU*IS]524YLRMM5LIT0#8<J[R.3O7D#)E$6EWR<0-@= NJP^-
MJ5$6@D5?!OEE@9:H3722(D$ <]I'6P81]I8"<T.M6B:TEIK8 P,HU>H=R8C%
MO&S6FJ0EJ+ CM@8K/"F"43#7\1DB4.\IOHCSUQR0'!TVQ+O<1D%Q4H4.KN>*
M(Y1S'$T1G] =@-G8_-X>V[*HO7@\6@*_^+8TFQ9[0KOTN#LBYGM0#1(1>H7"
MJY4%2KAIJ<9P1ZDV;=9R-[.N^;+<=H(,U*)N3HM!$N,HB9,XU'TK0*"F,J!F
M0NAHG!K!3E=15T/K:33/M.$G;L%!JD&>+.)4ZAJ\<H@JD1.9<#HB(I41T]3Z
M0>JTE&=7-7<U8OSUHB]'R3VN80]M2>!@]\!JGR@(*GU/$%_'548#2=Y\-S#H
MJCJV?5/:6P.UTF/I!.?4%Q&.W 0 *U,S3OY%C#U(%.5H,UX]DGD"*@=HO@+7
M(^7NDPL9P2RP^XJ>8H$026$\I[[9/)OJFW4:2VFI=Y\/#FTR:3Z&YWB_,XTN
M--@1Z-K&YY?(J4B"4#>@K[?6JJG\S<H^S=]&*T +RW63>M +<<IE^I0U3-+E
M$,U)BJ#2FE4K=J$ I0Y!]3#[55!K X,2Q0T3#.Q2@Q8$NV624XZ\;MWB.]X<
M#2EEBD_*BSBA'C.PW/2.GHMZY2P//+;2?)3]VM9?5)P\)"#0*U.AHZXFNE&!
M2JP+:>U4W"K79=ECVZ@FZ;4J%'6[:MR *-+'B/SV9>VH'/9J?GQE#Y@V!!IN
M,+%:?,E*7!#V4:7EAIK/98!=-D*N#9Z48V:F>)>"&S9 H6F46AEJH5 -Z0GY
MR0FJ7X-:[9.WOE!%G9+A]?43CKIY9X'P=HO'-CN!UOT7.3ZL<+%/[/X@,,WU
M73C*2.8V2W!-.V*7">@O^!GTEKBYMX#N3FR?Z:_\$,P)DZ?1\V;Q$L>M!0\9
MY/5Y%-D<*5@A05X@E-&[%XGB-,T&:TNS%!.NXL-@F#'G9M)D3.,8Y8+[F5&[
MECD;V#IT6'X9Z@S&^BZWR2K/RZ9]VJZ#Y>I%%XB-5Z_<L@C=E4U.C"[U9K.J
ML3I8]3LBY7$!3/@6*_H8]J:5U"U:^UUG5Y1#TIQM4*F%*GZ>2X&JXE<BUH\N
M@WF_3(HN@_DN.==&^A$VS.5=+UEIA\=[W:A;(!Z:=P5S3F23.JYC2L#),C6:
M$&*(<V_M]0UKF[4EXU4@%4;GM:$'P^F9BTED\WD<F/Z!TJ?TR'*+;YT8AIED
M(H(GAQB32O'^P,V5T_S>Z)4:6Q_[PQ;%[;I_:\4RQKLL6'X%RYG=)8HR,GQ)
MS;I)G;YBJ.GB.API:)9W]5KSQG4&OZ% SP:TNL/\D_CH=>=F>#_GQD"QF,T/
M&TXLA$_E?(O9*D6\"'P4]>H,>TX.ID6"'U-W/ JJHE,&;Q !N0TI&0!,$U @
MX4?7WA$>K#9VN ST6Y2@Q%"P?1J:R?0<3RO^1#J;'2GE"C@9T=@& TN2TXGP
MLSC!>+"F)^4VK^M=Q@VQ-;R[<>95 >]O1-1J"A88N6@L9VC3SV#E$/Y[L.M
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M"C8(N6ZT.]FFYN!N31:))*!\0O %4SF\IHS]Q[AKVGG@3^,,5XTJOG4B]]<
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M6=CW3O%=ZWF! =\AT!I3JT&H*S!O;'^"I8HWQL4A-*PU;T+;CY4O?NIX163
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MB;7&T@09'L KI)](*EH.XVBJ<^Q('RWIP/7D0WP6"'L->()71S9UZ9HA'D]
M%5;4YY<\+? V4&%\E;&2XSK"M4[B#+L/3XU2U+G=E$?X64YC,G2;2$> =<'7
M2%>,JU?SP5\S!0=PD (Q'#<.8C^W?8/\>*$X$Z;X6I>M4VI$=8Z=*M.I,ITJ
MTZDR@\?4:OCX[3^&YY>CB]'I>P,"@]T7.MWE_@!@*,.!/&3L1+U.) I'>KI*
M".5-8#YDYJ%/@LJUBPP%^05$N8; KQ20@R@%(JMT!G9^D"?-*HB3(*$]K[;Z
MH>13O=_LAULFR6C?;Z%D:&=F*UU=VSV#GY-25T?MWX8_IB)2_Q&<$^Y$ZRKK
M=(T2!OLN1XR@14[[@-X38($%PP2(@!A8:CHH",RC 55O'N,[L<.URF1"!?_D
M[)))9'Q?<!4F7:7NVU.=6&4<O3<8H/;1S84_ [HDNH;SW[E:,*AT6J  %H#-
MNC\*JM9ZR]>W=430!<6+%\KGDU.*"F;BLXS,"]!YQMG]]<>5D*_M/&^A#2\6
M4B1]%Y,2YC#6Y32I1F(,I4B-T6%*#CA;I;@/'8-%_(.R(4REI5LK4"R[;XT5
MN_)D!;BQ6,.FP'+J@2D0AO&2%OHVC4.5 _+D$X@$322"0T(C*N\EH[G?8N5,
M *YI=;!!::4-3F<#=#9 9P-T-L#KP>/JIOYV^/%T]&YTTG54OQ>N?N'4 Z[%
M9R!!.9;&K180FO0\4A,CK;5F,1=?U#R?-Z(_.)J'%81O5O BUB:.<5>&K/",
M(C_& BQAT *,1Y)R),44^W5,G.'VNFHANYY'7;70]Q^*W#:2"50"IP.QT7&3
MQJ B@U6! ?TT3P@Z=!&C)QMU9O)-:\]N^738$EI[$-[$&%PW3=XF&A]]3J>%
M\PBG<1QX$X'/' LT*RCR#D<!$U;(F:Q]XJ'.<8)+MIS4$:W#<O4_=V!DNRQU
M!D"P,@L\U9+2"80NWYS!C^E,+;9YUI&&88UB+\3DQHFXBCG'@(J:+%?0B6UL
M#AI=718)#DP]5NV9K#?*91GLEC=-X_FZ]SWSZR]'@U?GPX_'*-+.O;-WWJ?C
M]T,/>T><HF@[_O#A7]Z'X;M+[\V'X]/_"Y?O-2G3:\Y4G3*:1R%;>'*3VQX=
M)QSLM(@5MBW+ZE1[7$>7I\,+'4+^\_?A^?#L72N=3CVWJQ6[$2Q(9;7EAW7H
M4)'T1"58*X79>L;D[DSMFYG:^SO]%X<'ZRSMZRW;O<,7=V\3'_2?'^Y^TV._
M,MCGM[*T*RQUP&K]-]II.VBE.2]OQ3,:70I'#\C(?H,2^?2,#]K[X>G9Q]')
M10^D]<D->G]?)V[OX8SN[NY_BS?L>?_P</]''*:CO3L_^2]>] _V;_;8QW9&
M*Q,]^B'S/+Q+/G+W3BP^$??DFGRSHKK8G^BSN]?I_G1/[#W/=O_YJY3^ZYWW
MO6&B/GN_Q^$<KJP+BN_8Z'?!'3:#GM^[>[1$1<? 3O\YL'6/\) \,_9-HD9E
M1_6\3PPBHLOE3H9GFZ>-[!Q^DS8R&/2??V-P[GJE8O\'A/Q>[/</;OC83AWI
MU)&?RE/>"L*(Z!22G[2?;V$5WX>)_9.6IMG*'OYS>/+'Y>@?PR9=J764U=+1
MN+PW7;DHJ:[*QYB.=S%3B\7JZYKKS:GU,/2PKY"G[3K7-WJ 0.<ZW#_:%!<0
MZ%P'-_,I=SI7IW-U.M=FZ%R;,-N/8N5AGYO=G=W!=PJ'+HA_RR#^H$5!_)L2
MY][#^\-__CYZ,[K4/;8W,<=F7?_0TW>CMYA/<_R!)S<Z?7=V_I%R1RL=Q4>G
M_^#$&]-J_.)B]/[T(WRG/[\_'P[QXZV2<+I#VG1(=]<?TF?C.%C!/[-L'K[^
M_U!+ P04    " !.@F%4KG6QN+HK  #,-@$ '@   &)N9V\M97@Q,#,Y7V)I
M;VYA;F]X9FEF=&AA+FAT;>U]:U/;2-KH]_,K^LW,.TNJA+&YD\Q.E6-,XCT$
M*&!F]GS:DJ6VW1-9\NH"\?SZ\URZI98L$Y,!9 92-9. K5;WT\_]^O/_')_W
MKO_?15],TFD@+G[]<#KHB3>;6UN_[_2VMHZOC\6GZ\^G8K?5[HCKV T3E:HH
M=(.MK?[9&_%FDJ:S=UM;M[>WK=N=5A2/MZXOMW"IW:T@BA+9\E/_S2\_XV_@
M_]+U?_D_/__/YJ8XCKQL*L-4>+%T4^F++%'A6/SNR^2+V-S4W^I%LWFLQI-4
M;+>WM\7O4?Q%W;C\>:K20/YBUOEYBW_^>8M>\O,P\N>__.RK&Z'\?[Y1\M#W
M]N1N^\@;[NSN'0V///>H/=K?:W=&G?:1O_V?#FQR"[[.SR3I/)#_?#-5X>9$
MXOO?'6S/TO>WRD\G[SKM]O^^*7TOE5_333=0X_ =[18^'45P-OVQ%P51_.Z'
M-OUYCY]LCMRI"N;O_M&-E1O\PTD KIN)C-6(/T[4GQ+> Z^D'V_U'N#I0(72
M[(DWTO\Z44.5BDZ[M7/T\Q8^8(ZR<"!KHQX 3<9/NM.3P<GU)]']W#\[AO^N
MRWM=89=PJ_$OJSSU1Y:D:C1_3[]2H0^+O-O9GSW6O>S6GO;ZT^!*5(XL-M*)
M%#_]L+/[WISCZ<#?!3KQF58>[]7UL* 3OQ4J$5/7E\(-?4$7"W2OPC02;B*B
MD7V[-5L;T9\'WYIX>FC\RPTS-YZ+SK9#?,T1PSG!9"C36RG#1]U2/6X,+G\;
MG/5%OWMU_;%[W1?G)R>#7E\,Q.EISVD 1*XXEH%[Z\92!&JJ4$#4_@F4.U2!
M2N?"BZ8S-YP[8@)HY8X N83G!@$\V!"YG<*-POK^TP//H1,31CW]L3\,SL^Z
M9^?B8__L_/.@=^6(P5FOU0 0A'LG,WF4ES9 *89.7L1AO2B>1;&+&NCZ$/JU
M#-TFA&JK=-X5]*'[JE$-J(B7_=[@NGMZ]="GFKF^#_;%9B!'K J^_X:ZN/GD
M^F+W49ED/;A_^J&SWWZ_^/^G1V8C+<4&Z())YGDR2:(8M$-4$('0DU2 GG@-
MVO,@OH&GP30D>8\*REL2=4R& E6&F1NG2B;X1#IQP<:4<>K"4H%T$RE\LC=S
M)6P?E3!4Q6XGRIOH[TQ@%T-4Q6:QO%%1E@2@H:'^#$^BLB9.5 Q;RE5J?-6I
MM?J5G*5R.@3>U&G3^CL@C^"W7@0[+9[26\E@]0Y];0^_=CU1\>*WCJ6G5SRB
MKQZ)C9]^.-S>?MS;6L+RRCMLPJ" DW?>\\W#;419G$X60'8BAS%?\AYIVAVQ
M =L*I)>J&QF KMB@-4;8TI0EUA+B(HN3S&7,13#0?AR1TR%2 -&"3X3'Q)7,
M7$\*+XMC '* 2G>(A(6>&W<VBZ.O:@J AP]V]IS#[1V!7W.'@13)?S,DS)&4
M::,V\'FLQBIT W$1RZE*9-*8+>S+Q(O5$, +@+[*P,1)@%>T":$[>WLB"NE:
M.@^XP?W6W@H[?#^+V,?W+@;5$BGE?1K-0"#2TS? 2A7H6UIT#@%!<($WOR0-
M< $Q"B(0$M&(0#7,5(!"7@211^0/G/]H;[<MKJ-;%!B BX""QS&<R!%7;BB.
ME1Q'CNC!4491'"K7H&9#7)4V^T&?HF&>2AA)"*D1<40"[]L WW]. -]?"X"W
M7J"V^^%%:[M:G**,C>5_,]!N4<RBJHHWQP$6(VR7B=@]9_O@</TDK&8<>VW1
M_SK#<!'PCRL\26.2=CD#*S%<E,/)!#@7/O#T<--A',;(;@.R=,--4]>; "*B
M8R6-WH(!A.C("B"":T%Y(DE!:)MKD/00XND,MD1X:LPF_&ZN7:I$W*H@0+##
MXCZOG\!7\]L"/3VZI<]E/.4WH?%$Q)$\.,=L+GA4CPUGY[\[XOI3_[)_<G[9
M;\)["N8RP#M1OF1_FZ$9=QC=2& [GDK=(-%&,YC$Z40A,QL![H3 MI 7J=#X
MZS12J9!-KFF69H!&'JR$?+!ZNX;GY4_1YQ$\&8L;-\B(WY4VQ\O"IJ2:I?3M
M)!N-E*=@+W/<.6\3-X4KH@7O?0FCVT#Z8^E;5H_M2!C'4B)38%1,?OIA[_#!
MO6TE2;VWNXZ2>O#DDOI]67]IMW9S%<:7GO;_OLL (#';'G4R!V^R/QJQK2^.
M 0<;"$*(1\47RDE8.WSIMI;I6>B]NP9N#A05$\$NU15 $+L!,HCIE+@)_#[W
MUQUPT!2]7VNCX)01K4&O3K$1"JDOA7)YP\P^C51W\%E?CH@!J]#V#O&U#(FU
MQ^P<&L71]$YW#S%J0$P0Y;"ASI&SW=FO_R:\J\X14JNKX8?[SG[[X.ZEV(+5
M*]C6'JH=3X\[NQVGTWY(E\ZJ?*@62"2U96YRW(4O1)6 7R^0GWU8RL^>^A[O
M$H$8!IXCVE]$"= P7EH#$4DA!J-<F7*(SV.,!ED%(-$M6 I))&]D[ C/#<,H
M!383 !.*Q2S?-6+A<KE0N*+QFS&P(GB'7)'-B020'KZ?3H@_X"?PG4&KRTJM
MPSIL$41@;H?;!(YW$RD?WXA_$R6%\ -_(]<>AY(24@)[GP4,DBQ(V5N6)+B2
M[T[=,1#5I^B686*<[/9K]7K%*GK)N\4GVV6KP21_6^1Y62RR,%76D?0%)94;
M^O[7\S< SG %(]=+$3G\.9T)-P!? XW=$D!#"<JW(^173\Y2-C95@6/H0NL<
MO <EW55!%A/@DZ@.K>"-8.#&:IBEYH80H"XC 84:];^!+>J;V  Q%V0D+FY5
M.HFRE+.1V"#"Q_47F?H*E[Z6FIBO"J(S3?%V8=>4GY2;V615VPCWEN1PN))J
M!*CA2SF%96K@YY2-[?P)> <FR=*K1QG\;B9C>'#JHHY5>VS<RLR=$SG M<>\
MRT*WP#A;\:+;* LP<G0C.7AJ &VNX^Z#%30#=T0'XA_S._81RAL)ZCE7V? /
MP&+CF4 F,(Y@P\Y?!QY?%!P&KZ+@9?I-P($1%NYL%B@/S^>(#?<MRP-TY\VR
ME%,:HYDQG.F-1NT SGJC/%!Q "WQ.L ,-N2<)?+;I)7?$KQW:+\WCFZ4SR<"
M7DN0=RF*;G:^?,T"U$@[3&*IF )&#VE7?H[]61A*7!,5<8K+:W.?$6[#TQM:
M;D[3XA7$Q'.3IA][ (Y@;A]!CI!?TQDPP2^0< 1\YA8I"UVG*F9TQBN-0H)/
MX60*JQQ=:SS?9HO+'4SKX5NG==ZA"T9Y#^#Y?MA3/G^71],^C^V#UO[1W3Z/
M#VZB/'$) &K"KR$&86$WY(P[Y]31$&[3-1^" !'%=G-^M^!.KFA ^%A.RS7/
MWZ%_/*[3[D&B<GNM@[U:W(>UM*G&CPWA^#+>Q,05=Y;(=^8?[WV5S$ @OE,A
M71 ]]'[JQ@#4S6&4IM'T74W$GE[('^MZEL-.:[=#)2TI[#[US8MUM4N+/MI*
M_<7/=K9;G?V#I1^W6YVEGS6S[,[^_DK+;A$D&!H [P30ZY]O=MY4KH0NLHUI
M$2 W S /#+GISS%MHNYCC0COMF=?1:>, YQRN7!GT>Q)HP^?X1L3TO'(70?T
M=@$+17DJNX'?2P4-Z"B7J/@"5,05.U1.HBA]./!0%=D#P\^(UC4!8,'02V![
MX93707G9V6Z4T'#)>C@L$V;;+,O,[QA[MQ<$7 /YY#\^O6ZTTVJW*V68:\D/
M7J_Y+UUS9\\YW-FMO^N7SL1VD(MM[[YRL>>+WCNMSNXK%_O;7W-GW]D[V&X=
M;;]RL2IHMO>0B^WLOW*QYXO>.ZWMPU<N]K>_YLZ!L]/IM [K)-9J7$S[R^ZX
MU;\MG]LY0#ZW>[@ZGVL$6*\D\A<YX>[.?3GA7[_G5UZY=HC0.70Z[9W6WE)>
MN46!A*<M1GKHA9X&E&=1BH'Q)'7#/%F"T^,33/#( HKG6Y$K'8G']/;8C>>4
M2!%$7'JB0U\JH5P<%8IC.7*S(*6">"L;4Z<M<?RVL]OJO!44%;33-$MAM$K>
MAXMI&6XJ34K'#F>" "W)T'=C,<U]_];&=3Z+.Q['<HR>;W<:9?S\C[L'SEY[
MN]5NBPW5DBWQ8^X9P?027N]MPX5^W2'5("SZG)\.6?+J2A.^Y'JD)>"WRE]6
M2^-: _@21I4#14\/WA:%IBE3YP;WDR=H$3%A#ACE;:5J*H6?Q0;"&.=R*+-D
M 54T&:GI5/JZI&DHO8B>YU2WF3M'E@FOOK;2I8I\*IW4L[BRLG<*WW)SHB^R
M\BCA#$-P+ETX[3XJ$N#^D>C"&))JB2-FI;I^8"=<EH4+P&+N+:>Z"4R=2>>P
MY?.P%(PIF(;+V[6 5+UE;KX W^8=6*6+E*98%.UX46**?"9N/);)\CQBN]WB
M8B'ZL@:,1E,I'G&'H%!DZ?)''DMV'*R65*RB,S>,Q$<91E/EP;T-0J^UN:1<
M??/JNB_:0/^;>2K3YEYW9UE63^>G'W8/WG?X+ZR5V#R?S3;;N[L[!]NK)#4\
MI"*T&C@ZJVSKF[J"_?])7*@-8[DYC*7[99.Z1;US@UMWGI2QX3LZ?:ZXG756
M8)*9]-1(R2)5CID%\X!83K%I#JH?9497X3&2DP\3*MTC7F<6:HDNK)-DWJ26
MPYCE"DZ)K_,\8&N4D8K*%:W/):":C?+*ZZ%N-IZG-FBD.*$V@>V.7+6+.*)L
MW5XN!^ WH!RF</'NUR::L(#@.]%ZV(QEF:XUHS*EY2G8%:V+&YGZUD/P5:7S
M?KFRJJJ+Z]0X5L8QQ:V2.G<UP702P/5O 0TI)<[PU5RJ&^IZAIQJ[LB^?QHR
M>X@$T34EO-^>!=UU"XT,S$90Y !WCB7I2.M4N]1( FLO"HL^5D0"B]4&6+0P
MST5:KGM5B-JN;DBR*1G%G2/GJ$,V,#:&RXL(N P=OU2HV7:'A>HM8?NYA+<X
ME$CJ$QGXU1SW*BF;PJ;=UDZ9F$67O@GKF-YG"^^CNIQ2:>>/AX?.]LZ^/LJ/
MG?:A RP%?FP];C'@>A+^;R^D;<U].<U@BCH@&8=4K+$V76!6XCN-2;?UK'A=
M7L&_3K?7,_U"[JP8;42UM-H[J1"-+&[O]*V222J1(O+!RJU96C3%H?I^7"WA
MUMZF'HLJ&/$I(CP'3#8M, A:\ N"EW%04]5I49J1&)T5VZ7:/B723+DRD-\0
MI+J6C5_AJIB64A;1YQ6:;F(JQ^17W QV3LV+T\@==*L2N5B;M2(QWI=BGCTQ
M/H_R<XWQMAAHA/**]J6ZS4].4J9\\%&V=<]RO 8ZI[.3>^&25BBF6F(LEGT^
MC?5+$Q^::(Y5*NRN]$U[B=T<?WOZ@LGGH1=?N/&71^XM6@^<1FSJ:D <E0<3
M["X8!G*4YOC%20. *;?8UE%:C1J.CEQBJ?MWM6ZJ5--S__J\)->Q:_#M;Y!Q
M7W@FW-".WVUW0'-$33*^D>CVIYW"W]A- YZ4Y*#D6![L,XZR\:3.^\D143VE
MPS&Z)JVE'R[<(.EB3P^315'L %L))KQUBN B8.'O0N7F]:@#!74$Q%O@#A0)
M<$MTV6+OJ<JYJ-%J N?_P_6L-(URQRD,QU%CDOQQJVU" >-\\XCK:02*<I:J
M0/U)[\$MC'5_S!M9<N2\3*GQ*C:6-#0\/A.GJHF6ZI;URAIT;E)R#.+6C6-J
MV4F=/$*I*,"O'PEUEZ((>V\BQ?LJ!EX5P;\D:-_17 *_0FLSQ ^G/,X";5):
M9!:KT%,S8#]4>,RM:,KS&AJ=\",N>*Q(8XV,P5P.%+6*!C;D@GHN=<.48\/=
M?''F:A:.E_4AB+PO\,L+&6/_K<8Z)AZ?-=W\&>&&:$6QZ!F!(S%C"!7-BE%)
MDC%+QN__VKIJB6OT@V? ]<\)G_'YDRB&EX2B"Y(0B*"'RDT4B(WSDVYO6>Z1
M)@H+B>9XE=2]#/.(2K<*5M?QV6+44+<K LT),QG@#*4X>UV[IT49B.$]13*P
MZ-9L9S5E,XP>Q@JLFA!3CY3=D^F%RJ?G$5\_ENC9H "QMLD;4?]-X GE>L^H
ML-5A1GDNJE:#+PD]D;0H'_)2CK+$#8Q2#!BNY9"OSX@3H8#R<!FPMGEN)CP=
M8D>SF.0(Z&4>);RQ1OT$O<*?-O;\[U>EJ98*/O;/^I?=TP9M[1?4%?5YQ(C8
M5D;^D#.@9OS2U[G$+>7680],3/]FED7Z"._8M+LL-1TTG?EPC'+D<^*>Z;R_
M0ASE[XN,SR-&TB>1);HF7M<0(I8:(H()!IB$$9*)U#*U'#/,9U+7]G3$C&Y0
M64%!]29N.,8('Z:3TX1$U"2-UZ/LZ["6:+&#R.H9"H+<<D0!&/%_N5I:"7"2
M;IW'/^%XOU(I#*SAJ=C+IG@*=.TPT9GNHM6"&-U6-R^+<>S()B:X1[<N-;DD
MS]DD"OQ*Z%-K^(F"FW)![_ BRNK&5!I\TXW4YC(&1HN3YE'1(OFUFL9'B=B<
MXE?V(69A@*T]=0*O1U9@J;OQ*U/H/0NFT,,Z*AFC4P2;%1Z]%\=JC(%$<44F
M?18WE!X[J&:]H=B17Z67:2W<LW;N"#)*;6W= TK(6[.ZV&&9NSWR(0%A'3$Q
MC:_-M(<0\":%]:D!,'9S-8VD*0G"S;&9VT^6NC<#,7E2^M0"&#^93:(T&L?N
M;*(\AW]*D&EX3N%P\J)937:?25]0:-K[F4>GA6-()%83 HVH0S'<(UUH2Q?^
M\-19W>DVS^)PA:^O5&'#;[N],IXS+_+)Z_/X:\H,0HJG7!MT<7SBB']=]#\Z
MXN/@1(Q4<%<PNS/:/3KP'R'V^?38F%^8W$P,4;PU%Z<'9A6YF=B^V>K.',L1
M.1!U#1-CL,X:0A1#-PRL;LQ5?8D.N]C26%<^ .G&I$EJ+'Z)#/7X63#48UTJ
MBQ5]S7#.+O>G]A.[IH#$N0H5=?SVW!GQ@X R")*:1M6(<W4C6*K./6*,4^F&
MN@Z@NDQ2&>"B]0;XS9RF814)6:6WO73=H?\L4+V;@2#"].VF%(2B9MT59M0;
M36,S\@RG5Z@ $\P]/:X=134'@)*)FI$P5D0HLUAASGDT,A6N@)E3HU> *0+2
M%V?&:?Y-W+R$ZB:1Z;OV84>Y2%.?D&!()C2IPL?Y["X#^T^6TEH1TG1J\O]+
M&\))$A*H=93''<CJF-M#$ZOZU5"QT46N>/N9FB0L]()2Q<YK&G,]CIX\"R*V
MAB'WL*D)>76Z/+E!1_@P=C7@/.*FQOK8T^+M'0-9!J(7^9BBW-D_, 7(1SN'
MSD(N)NK?QA*VYXVQ-$,UF, R1JU,Y<=E9\)=H-GH=:]F;\6&)<&^O<6]O=;>
M]H;[=F/G[=O*^<H=-N H1C>L777QG-JN3RIS3#&BAJ9ZM67^WN%[CFMW5SDE
MNELT<'3!$0]"F=DC67W)L3Z)0TQ(<Z[]*J7$ZN(G*N/7$SYS[9E-LC@C>&Q2
M%3Z&*6EO2C-4<A2YJ.UP&Q*Z96PT0)H06DKC2?%+X4>2.YSHX1UXMW P^\+U
M-JK;=31[-X-"$,Y<#HGU\I1'@+H-_(4&'+X"OL Y7Q0!QH$KQ-53/9@)LXBB
M83Y<>=5]Y)*FF!B#PB1*]3@7Z]>CVC>3B5*,?=81Y^JW\FX2;%2RWL>#4P.=
MUVR"VY22,:XD]%)^%"+#U T)/!J'RX<T25GYA!_"62GS9>C[K]T:7KLU6."X
M_[:>>[.&)0K.DZHS-M$:OQ@V5D&JG;I?3+ZMJ<\I!C51\0.[+VY4%!C/^:C$
MW<6WN#M*"6U+&D[8XF*DU\*=VOOZ^"S4SRZPXCB4\^0?XD0VY&J^KFDA8OP=
M8)7-M/O.DE)NL>N1S*6C&R01:2_SQ=EZ+]&+\>E98."'./H"5G@SKCKL(AE(
M+8@/RZB';@U$']VJ@[7ZPGPQFADPUF@<PGLK^GX>#F!#8,C'!(T\ MX\!F.
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M%['!1>G-(=-:#!3/6T\4#>KU'#FL5"1 Z4X-OCUBO-S=TNZW,@M</7<NG]S
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MN<#?$9X$)AB.X5_YQZ!JJ60B[5_QU&#A1R ^'! OJ*NA9X)G+XV"B-H&W-!
M)/C"+:!W=&O_)L -T@08B2,_8O21<:M,^'DV(3F6I2"A$26";#K$LHBB[PW\
M=@)L>ZY?%42NSV*(.RLDW(NY+)2:PP; ;JS2"K'#YP6@?9,X0/VGE-(-J( $
M)7"A*4VGKY+>W6I(F?;6C^)Z^>Z;!+=6%ZCY*P*,2;"L@N2Z*!*-"Q:CGL1D
M?N\OTSC6!*5[>+B^1J/F@ UJ;&D$HSU92,N8$A5J0:;9X6+'L6&F NK 91KK
MFF[DY8%R>&@\1*VM4,BW"!N3M\I]78P,Y?XLYJ?:O6)/?E :3$,PW<R(=J<[
M&5DX11)Y!PZ0 +"2! OEJ6@>&]&89GAVHZ5B/$BQC<1J-E.9<<UGI$$7+--U
M'SPW,4?.E]%,O=+)"1>=\LA,&HXYKS\S-KT,3=:LK+:C2[+QF+NRQ](T7$-3
MI6B\GL E)"-B 7/=6ITGFN73_'A*)PTRY#'@I>&#BV.Y=2=X/4&1V_GXIC>.
M=EPL',/@ !B7,VSB Q>1I2!D_S1MH+.0O$1P3-O"R&%&C Q;]^"'&Y;S@S0K
MG(AP%J5XZ?D<2#V+3(XCDK#Y[+9:Y$.8T913:MZ++;H63D!CSQ#-$6 A)IT!
M#]ON. *C"$TR(=Q<UR#:<:/<Q\%IKT-)$V%X*&<4:02K(.X(* 8;5Z'!&6$[
MQ861>J[QY>@+PS3YN7&<42-91J7D/IW^7G:'[^5C9\]I)N%0(L$P 2]@585R
M3'MAH!PS.-7FO[#:<O5?% RT<"A1_\BB(5=IWL2"NL5:6M[H<80C[LHN"C_R
M,M8/N/=FPHIV,<K0-.BBU@&\4A5':=6$='/]HEMB&K @J]R%49"K+S7'"B+S
MDS5)$;5U;JK[6[=7TM'?UG0GQ8]G1</EO"_9B.>@D+X?1N'FHKBVY;16J12
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MP0D@%!^$;!KQZST;8QZ&! 1E_)89Q'+!AUBD*-9R!&HN5_(!%&$\@JL08+$
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MX^G9^=LO0?^Q4)HERV_D^XM"JH+BOEH0G0*1\$?!)-@\4*!)(J1.">/DLLB
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MZEG9TS>?LI706A0#^_D(6>$T[?3W1]ZLW*NU?HBKOP3C?P%02P$"% ,4
M" !.@F%4M'J-([>M  !7A ( '               @ $     8FEO;F%N;RUN
M86YC>7)I9&=E;&5A<V5E+FAT;5!+ 0(4 Q0    ( $Z"851Y' .7"ID  .LV
M P >              "  ?&M  !B;F=O+3$P,SA?8FEO;F%N;WAC;VUM97)C
M:2YH=&U02P$"% ,4    " !.@F%4_Y;!WHY-! "*Y20 $0
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M              "  6B3!@!B;F=O+3(P,C$Q,C,Q7V<R+FIP9U!+ 0(4 Q0
M   ( $Z"850?AZ&2G2   )XC   4              "  96@!@!B;F=O+3(P
M,C$Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( $Z"851X[AWQXUP! !ZM#@ 5
M          "  63!!@!B;F=O+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" !.@F%4Q3K-X%+2  !]R@D %0              @ %Z'@@ 8FYG;RTR,#(Q
M,3(S,5]P<F4N>&UL4$L! A0#%     @ 3H)A5+ ,,F@./0  ?:T! !X
M         ( !__ ( &)N9V\M97@Q,#,T7V)I;VYA;F]X:V5Y96UP+FAT;5!+
M 0(4 Q0    ( $Z"850@TBV)ZS0  +^% 0 >              "  4DN"0!B
M;F=O+65X,3 S-5]B:6]N86YO>'-T;V-K<BYH=&U02P$"% ,4    " !.@F%4
M0KXEHN@[  #A$P( '@              @ %P8PD 8FYG;RUE>#$P,S9?8FEO
M;F%N;WAE;7!L;WDN:'1M4$L! A0#%     @ 3H)A5*YUL;BZ*P  S#8! !X
M             ( !E)\) &)N9V\M97@Q,#,Y7V)I;VYA;F]X9FEF=&AA+FAT
M;5!+ 0(4 Q0    ( $Z"850V)(IWWPH  (!E   >              "  8K+
M"0!B;F=O+65X,3 W7V)I;VYA;F]X;F]N>&5M<"YH=&U02P$"% ,4    " !.
M@F%4)VOG@XX"   4"@  '@              @ &EU@D 8FYG;RUE>#(Q,5]B
M:6]N86YO>'-U8G-I9&DN:'1M4$L! A0#%     @ 3H)A5/RUIN\9"    B8
M !<              ( !;]D) &)N9V\M97@S,3%X,C R,3$R,S$N:'1M4$L!
M A0#%     @ 3H)A5.@;D+(T"   ZR4  !<              ( !O>$) &)N
M9V\M97@S,3)X,C R,3$R,S$N:'1M4$L! A0#%     @ 3H)A5)?/+B@I!@
M>QT  !<              ( !)NH) &)N9V\M97@S,C%X,C R,3$R,S$N:'1M
M4$L! A0#%     @ 3H)A5!X ISP2!@  C!T  !<              ( !A/ )
M &)N9V\M97@S,C)X,C R,3$R,S$N:'1M4$L! A0#%     @ 3H)A5(X/RG0V
M P  ;0@  !X              ( !R_8) &5X:&EB:70R,S$M8F1O875D:71O
@<F-O;G-E+FAT;5!+!08     %@ 6  X&   ]^@D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
